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Molecular typing – Part 1
P509 One platform and multiple assay formats: mass spectrometry
for molecular typing of the Mycobacterium tuberculosis
complex
C. Honisch °, S. Niemann, M. Mosko, C. Arnold, S. Gharbia (San
Diego, US; Borstel, DE; London, UK)
Objectives: The analysis of nucleic acids by mass spectrometry (MS) has
evolved to a user friendly technology for characterising DNA, and RNA
in clinical research and molecular medicine. Recently, the technology has
become a versatile tool for microbial identiﬁcation utilising comparative
sequence analysis as shown for 16S based typing of mycobacteria [1].
Here, we present examples for the development of MS speciﬁc
assays for molecular typing of the M. tuberculosis Complex including
spoligotyping and antibiotic resistance identiﬁcation, which is essential
for epidemiological analysis. One technology, the MassARRAY®
platform can be used with different assay formats and typing schemes
to obtain results from species to strain identiﬁcation in an automated
fashion.
Methods: Nucleic acid analysis by MS is based on PCR ampliﬁcations
using unique primer sets.
Traditional spoligotyping detects the presence or absence of 43 different
spacer sequences. For MS 43 spacer oligonucleotide probes were
designed and the presence of a spacer is detected by base extension
(TypePLEX™).
Resistance regions are ampliﬁed by PCR with a tagged primer system
in multiplex followed by in vitro transcription of both DNA strands.
Subsequent endonuclease digests of the RNA transcripts at the bases
cytosine and uracil result in four mixtures of RNA cleavage products
(iSEQ™). Resistance is identiﬁed by correlating acquired spectra with
theoretical peak patterns predicted for in silico cleavages of sequences
contained in a reference database. Microheterogeneities are identiﬁed
and deliver new resistance types.
Results: Over 200 characterised strains from different reference centres
representing the major M. tuberculosis Complex lineages were run over
the established spoligotyping and resistance assays. Results were in
concordance with traditional spoligotyping and dideoxy sequencing data.
Advantages of the MS approach are the homogeneous assay formats
without any clean-up steps, semi-automated processing, the time-to
result with a throughput of 192 samples in 8 hours for spoligotyping
and plexing capabilities for comparative sequence analysis of multiple
genomic regions in one reaction.
Conclusion: Mass spectrometry speciﬁc assay formats for genotyping
and comparative sequence analysis generate highly accurate qualitative
and quantitative data and provide a toolbox for molecular typing of
microbes and viruses.
Reference(s)
[1] Lefmann, M. et al. (2004). J Clin Microbiol 42(1): 339−46.
P510 Application of MALDI-TOF mass spectrometry for
Helicobacter pylori study
E. Ilina °, V. Vereshchagin, M. Serebryakova, V. Chelysheva,
A. Borovskaya, K. Momynaliev, T. Maier, M. Kostrzewa, V. Govorun
(Moscow, RU; Bremen, DE)
Objectives: The applicability of MALDI TOF mass spectrometry
techniques for investigation of a highly variable bacterium such as
Helicobacter pylori was studied.
Methods: H. pylori were grown on Columbia agar plates (BioMerieux,
France) at 37ºC and 5% CO2 for 48 hours. Fresh bacterial colonies
were transferred into 300ml of water. After precipitation with ethanol
(900ml) and centrifugation the pellet was suspended in 20mL of 50%
acetonitrile, 35% formic acid, and analyzed in a microﬂexTM (Bruker
Daltonics, Germany) using a saturated solution of a-CHCA as matrix.
Spectra analysis and species identiﬁcation was done using ﬂexAnalysis
2.4 and MALDI Biotyper 2.0 software (Bruker Daltonics, Germany).
Mass spectra of protein fragmentation were obtained by an Ultraﬂex
II MALDI-TOF/TOF mass spectrometer (Bruker Daltonics, Germany)
equipped with Smart BeamTM laser.
Results: 17 clinical strains as well as two laboratory strains of H. pylori
were analyzed by MALDI TOF MS. Mass spectra collected were found
containing 7−13 signiﬁcant peaks per sample, and only ﬁve protein
signals were identical for more than 70% of strains. Four of them
were matched to ribosomal proteins. The ﬁfth reproducible peak with
m/z 6948 was assigned to histidine-rich metal binding polypeptide
by MS/MS. In spite of evident intra species protein heterogeneity of
H. pylori the mass spectra collected for a particular strain under the
several cultivations were reproducible. Moreover, all clinical strains
were perfectly identiﬁed as H. pylori by MALDI Biotyper 2.0 software
using a database containing mass spectra from different bacterial strains
(n = 3290) including H. pylori 26695 and J99.
Conclusion: MALDI TOF MS ﬁngerprinting is a suitable tool for
H. pylori species identiﬁcation and typing and could help in better
understanding of transmission pathways of this bacterium.
P511 Helicobacter pylori genotypes in different ethnic groups
resident in Tehran, Iran
H. Dabiri °, Y. Yamaoka, F. Jafari, K. Baghai, L. Shokrzadeh,
M. Bolﬁon, M. Rezadehbashi, A. Mirsalehian, P. Maleknejad, H. Zojaji,
M.R. Zali (Tehran, IR; Houston, US)
Objectives: There is a geographic variation in Helicobacter pylori
genotypes. cagA and cagE, oipA and vacA genotypes of H. pylori are
associated with peptic ulcer disease (PUD). This study compared the
distribution of these genotypes in major ethnic groups residing in Tehran,
Iran and their association with clinical outcomes.
Methods: H. pylori infected patients proven by culture were recruited
prospectively. DNA was extracted from isolated H. pylori and PCR was
carried out to determine the cagA, cagE and oipA status and vacA alleles.
Results: A total of 124 patients living in Tehran were enrolled in this
study. The ethnic distribution was 74 Persian, 33 Turkish and other
ethnics including 7 Kurdish, 5 Lurs, 3 Afghani and 2 Arab patients.
The predominant vacA signal region genotype was s1 among isolates
from all ethnics. The vacA middle region genotype m2 was predominant
in Persian and Turks. Of the Persian, Turkish and other ethnic isolates,
64.9%, 72.7% and 70.5%, respectively, were cagA positive, and 47%,
30% and 76.5%, respectively, were cagE positive. The oipA gene was
present in 51.4% of Persian, 33.3% of Turks and 70.5 of others ethnics
isolates.
Conclusion: There is difference in the H. pylori strains among the
ethnic groups in Iran. However, there was no signiﬁcant association
between cagA, cagE and oipA status or vacA genotypes and clinical
outcomes in Iranian patients irrespective of ethnic groups. None of these
markers were helpful in predicting the clinical presentation of a H. pylori
infection in Iran.
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P512 The number of Helicobacter pylori CagA EPIYA C tyrosine
phosphorylation motifs is associated with histological
features of chronic gastritis
R.M. Ferreira °, J.C. Machado, F. Carneiro, C. Figueiredo (Porto, PT)
Background and Aims: H. pylori strains containing CagA are more
virulent than CagA-negative strains and are associated with increased
gastric carcinoma risk. CagA may undergo phosphorylation on tyrosine
residues within Glu-Pro-Ile-Tyr-Ala (EPIYA) motifs, present in the
C-terminus. In Western strains EPIYA motifs are classiﬁed as EPIYA-A,
-B, and -C. The number of EPIYA C motifs inﬂuence the level of
CagA tyrosine phosphorylation, the degree of SHP-2 binding, and the
magnitude of cytoskeleton changes induced by H. pylori. The aim of
this study was to characterise H. pylori CagA EPIYA motifs in strains
infecting Portuguese patients in order to explore their relationship with
the histopathological features of chronic gastritis.
Materials and Methods: 117 H. pylori-infected patients with
chronic gastritis were studied. H. pylori density, chronic inﬂammation,
polymorphonuclear activity, epithelial damage, glandular atrophy, and
intestinal metaplasia were scored according to the Sydney system. One
biopsy specimen from the antrum was used for DNA isolation and
H. pylori genotyping. The presence of cagA was determined by PCR
and reverse hybridisation. The number and type of EPIYA motifs were
determined by PCR using primers ﬂanking the EPIYA-coding regions.
Results: H. pylori cagA-positive strains were present in 55 of the
117 patients (47.0%). In cagA-positive cases, the number of EPIYA C
motifs ranged from 0 to 3: 11 cases (20.0%) had 0, 33 cases (60.0%)
had 1, 9 cases (16.4%) had 2, and 2 cases (3.6%) had 3 EPIYA C motifs.
The presence of cagA and the number of cagA EPIYA C motifs were
associated with more severe chronic inﬂammation in the corpus, and
higher grade of polymorphonuclear activity and presence of epithelial
damage in both corpus and antrum. The magnitude of risk for gastric
atrophy and intestinal metaplasia increased with increasing number of
EPIYA C motifs: the odds ratio for atrophy was 5.4 (95% CI, 1.6−18)
in individuals infected with strains <2 EPIYA C motifs, and was 12.1
(95% CI, 2.5−57) in individuals infected with strains with  2 EPIYA C
motifs.
Conclusions: H. pylori cagA-positive strains and strains with  2
CagA EPIYA C motifs are associated with more severe histopathological
features of the gastric mucosa, gastric atrophy and intestinal metaplasia.
The characterisation of the CagA EPIYA-containing region may be
important in more clearly deﬁning risk for gastric pre-malignant and
malignant H. pylori-associated diseases.
P513 Helicobacter pylori vacA intermediate region i1 strains are
associated with more severe histological features of chronic
gastritis and increased gastric carcinoma risk in Portugal
R.M. Ferreira °, F. Carneiro, D. Letley, J.C. Atherton, C. Figueiredo
(Porto, PT; Nottingham, UK)
Background and Aims: H. pylori vacA gene is present in all strains
and is polymorphic at the s and m regions. Functionally, s1/m1 strains
cause more extensive vacuolation and in a wider range of cell lines
than s1/m2 strains, and s2/m2 strains are non-vacuolating. Clinically,
s1/m1 strains are associated with gastric atrophy, intestinal metaplasia
and gastric carcinoma. Recently, a new polymorphic region within vacA
designated intermediate (i) region, was described as a major determinant
of vacA toxicity, and i1 strains were associated with gastric carcinoma.
The aim of this study was to characterise the i-region in strains infecting
Portuguese patients in order to explore the relationship between i-region
genotypes and the histological features of gastritis, and the risk for gastric
carcinoma.
Materials and Methods: 154 H. pylori-infected patients were studied,
106 with chronic gastritis and 48 with gastric carcinoma. Histological
parameters were scored according to the Sydney system. DNA isolated
from gastric specimens was used directly for PCR. Genotypes were
determined by reverse hybridisation on a line probe assay for vacA s
and m regions, and by type-speciﬁc PCR for vacA i region.
Results: vacA i region was successfully genotyped in 97.4% strains.
53 (35.3%) cases were multiple for vacA s, m, or i regions. In the
97 cases of single vacA genotypes, 42 (43.3%) were s1/m1, 45 (46.4%)
were s2/m2, and 10 (10.3%) were s1/m2. In agreement with previous
descriptions, s1/m1 strains were predominantly i1 (41/42) and only one
s1/i2/m1 strain was found. Also, the great majority of s2/m2 strains were
i2 (44/45) and a single s1/i2/m1 strain was found. s1/m2 strains were
genotyped as i1 (9/10) or i2 (1/10).
In chronic gastritis patients, vacA i1 strains were signiﬁcantly
associated with higher degrees of corpus chronic inﬂammation and
polymorphonuclear activity (P = 0.0006 and P = 0.002, respectively).
vacA i1 strains were also associated with the presence of corpus and
antral epithelial damage (both P< 0.0001), and with glandular atrophy
and intestinal metaplasia (P = 0.0016 and P = 0.0043, respectively). No
associations were observed between i region genotypes and H. pylori
colonisation density. vacA s1, m1, and i1 strains were strongly associated
with gastric carcinoma (all P< 0.0001).
Conclusions: H. pylori vacA i1 strains are associated with more severe
histological features of chronic gastritis and increased gastric carcinoma
risk in the Portuguese population.
P514 Evaluation of use of multiple locus variable number tandem
repeat analysis for typing of Pseudomonas aeruginosa
J. Turton °, S. Turton, S. Yarde, M. Kaufmann, T. Pitt (London, UK)
Objectives: To establish and evaluate a method using Variable Number
Tandem Repeat (VNTR) loci suitable for routine typing of Pseudomonas
aeruginosa in a reference laboratory.
Methods: PCR ampliﬁcation of up to 12 VNTR loci was carried
out on a panel of isolates previously characterised by pulsed-ﬁeld
gel electrophoresis (PFGE) and on serotype reference strains. Repeat
numbers at targets with small repeat units were determined using
ﬂuorescent forward primers and sizing on a sequencer. Repeat numbers
at the remaining loci were determined by agarose gel electrophoresis. A
scheme using eight loci was adopted and tested on a further 100 isolates,
also typed by PFGE.
Results: The twelve loci initially used were reduced to eight, with no
loss of discrimination, at least among the 40 isolates originally tested. Of
the 28 PFGE types represented by the 77 isolates in the panel, 27 were
successfully distinguished by their repeat numbers at loci 172, 211, 214,
217, 222, 207 and 209. The Liverpool and Midlands 1 strains, isolated
from multiple patients with cystic ﬁbrosis (CF), could be identiﬁed
unambiguously by their characteristic VNTR proﬁles at the 7 loci. This
was also the case for other CF associated strains. There was some
variation in repeat numbers at two of the 7 loci among isolates of clone C
from different patients, but, otherwise, with the odd exception only,
repeat numbers were consistent among representatives of a single PFGE
type. The method successfully distinguished all 17 serotype reference
strains, none of the proﬁles of which matched one another, or any of the
panel or routine isolates tested. Repeat numbers at the eighth locus (61)
could provide discrimination within a PFGE type. Representatives from
outbreaks, received within a short space of time, all shared the same
number of repeats at this locus. In contrast, isolates of the Liverpool
strain from CF patients showed variation in repeat number at this locus,
even among isolates from the same centre. Agreement with PFGE was
good for the further 100 isolates tested, but in two instances, the VNTR
analysis failed to distinguish pairs of isolates that were distinct by PFGE,
except at locus 61.
Conclusion: In the vast majority of cases, VNTR analysis at these
eight loci provided discrimination at a level similar to that afforded by
PFGE, with most strains being identiﬁed unambiguously. Results could
be obtained within a day, leading to signiﬁcant improvements in reporting
times.
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P515 Comparison of opr sequences for the characterisation of
clinical isolates of Pseudomonas aeruginosa
L. Yearwood °, J. Turton, R. Pike, J.P. Pirnay, T.L. Pitt (London, UK;
Brussels, BE)
Objectives: Allelic variation has been described in the genes encoding
the outer membrane proteins of P. aeruginosa (Pirnay et al. 2002). OprD,
oprI, and oprL show potential for use in the epidemiological typing of
strains. We determined the partial oprD, oprI and oprL sequences on a set
of epidemiologically diverse clinical isolates of P. aeruginosa, some from
cystic ﬁbrosis (CF) patients that had previously been characterised by
pulsed-ﬁeld gel electrophoresis (PFGE). We also explored associations
of oprD sequence variation and predicted structure with imipenem
susceptibility of the isolates.
Methods: OprI and oprL and partial oprD (corresponding to nt 701–
1269 of the coding sequence of PA01) sequences of 30 isolates
of P. aeruginosa representing 26 distinct PFGE proﬁle types were
determined and aligned. Clustering of each gene was displayed in an
UPGMA dendrogram. The MICs of imipenem for the isolates was
determined by agar dilution.
Results: Both oprI and oprL sequences showed little variation and
did not deﬁne clear groupings within the panel. For oprD sequences
the isolates fell into 2 clear sequence type groups, one of which was
further divided into 2 subgroups (1A and 1B). Isolates with the same
PFGE type invariably belonged to the same oprD sequence type group.
Ten of the 12 isolates from CF patients, including those belonging to
lineages affecting multiple centres, fell in subgroup 1A. Each group
included some representatives with various sequence disruptions, such
as stop codons (3 isolates), frameshift mutations (2), deletions (2) and
an insertion sequence (ISPa20). Those with these disruptions exhibited
imipenem resistance (MIC 16mg/L).
Conclusion: OprD sequences of P. aeruginosa fall into 2 distinct
phylogenetic groups with those from CF patients mainly clustering
into a single group. Disruptions in the sequence were common and
sometimes extreme and were associated with imipenem resistance.
Sequence differences between the two groups can be exploited for strain
characterisation and may provide insights into the relationships between
strains.
P516 Molecular epidemiology of Pseudomonas aeruginosa in
intensive care units over a 10-year period (1998–2007)
M. Cuttelod °, L. Senn, V. Terletskiy, I. Nahimana, C. Petignat,
P. Eggimann, J. Bille, A. Wenger, G. Zanetti, D.S. Blanc (Lausanne, CH)
Background: P. aeruginosa is one of the leading nosocomial pathogens
in ICUs. The source of this microorganism can be either endogenous
(digestive ﬂora) or exogenous (other patients, the contaminated
environment such as sinks or taps). The proportion of cases due to
transmission (patient-to-patient or from the environment) in this setting
is still debated, and is important for implementing appropriate control
measures.
Objectives: To determine the relative importance of exogenous versus
endogenous sources of P. aeruginosa in ICU patients over 10 years.
Methods: Molecular typing was performed on all P. aeruginosa isolates
obtained from routine swabs of the inner part of the ICU taps. It was
compared with typing of P. aeruginosa isolated in clinical specimens
of ICU patients in 1998, 2000, 2003, 2004, and 2007. This allowed
the division of patients with clinical specimens yielding P. aeruginosa
(thereafter: cases) into 3 categories:
1. Cases with isolate identical to one found in taps
2. Cases with isolate identical to one of at least another case, but not
found in taps
3. Cases with isolate of a unique genotype
Results: Results are presented in the table. The number of cases in
category 1 was high in 1998 and decreased signiﬁcantly thereafter,
presumably as a result of enhanced control measures since 1999.
The highest numbers of cases in category 2 were found in 1998 and
2003, 2 years for which the hypothesis of patient-to-patient transmission
within this category was supported by plausible epidemiological links in
61% and 85%, respectively, of the cases who shared a common genotype,
and by lower ﬁgures after enforcement of infection control practice in the
following years. In the 3 other study years, a plausible epidemiological
link was only found in 23 to 25% of cases.
The number of cases in category 3 (unique genotype) remained stable
over the years, suggesting that endogenous source was constant during
this period of time.
Conclusion: Molecular typing of P. aeruginosa in ICU patients allows
to better understand the epidemiology in this setting and to evaluate
the impact of control measures. Cases of endogenous source appear to
remain stable over the years.
Table: Molecular epidemiology of P. aeruginosa cases in ICUs between
1998 and 2007
1998 2000 2003 2004 2007
No. of ICU admissions 2367 2446 2400 2554 2675
No. of cases 142 74 85 83 87
No. of cases/1000 admissions 60 30.3 35.4 32.5 32.5
Cat. 1 23.7 7.0 0.4 1.6 2.6
Cat. 2 16.5 6.5 11.3 8.2 10.1
Cat. 3 15.6 13.1 16.7 16.8 17.9
Not typed 4.2 3.7 7.1 5.9 1.9
P517 Assessing clonal relatedness of Pseudomonas aeruginosa
isolates: MLVA should be preferred over MLST and PFGE
R. van Mansfeld °, M.J.M. Bonten, R. Willem (Utrecht, NL)
Objectives: Pulsed-ﬁeld gel electrophoresis (PFGE) is generally
considered the gold standard for typing of Pseudomonas aeruginosa.
The last decade PCR and sequence-based molecular typing techniques
have been developed, like multiple-locus-variable number tandem repeat
analysis (MLVA) and multi-locus-sequence typing (MLST), which are
faster, easier to interpret, better reproducible among laboratories, and
that generate unambiguous typing data. To investigate whether MLVA
and MLST can replace PFGE for genotyping we typed 32 strains with
each method and compared typing results.
Methods: 32 P. aeruginosa strains, derived from sputum samples of
Dutch CF patients, were typed by PFGE, MLST and MLVA. MLST
was based on the scheme designed by Curran et al (JCM, 2004) and
the MLVA typing method was an adjustment of the Vu-Thien scheme
(JCM, 2007), using only 9 of the original 15 VNTR (variable number
of tandem repeats) loci. The discriminating ability of these methods was
determined as well as the congruence among the different techniques
by using the Adjusted Rand Index (aRI) and Wallace coefﬁcient (Wc).
MLST, MLVA and PFGE types were compared. Clonal clusters were
deﬁned as isolates with PFGE banding pattern similarity of >80% or
with MLST and MLVA proﬁles with a maximum of one locus difference.
Results: In the set of 32 isolates PFGE, MLVA, and MLST distinguished
28, 27, and 21 types, respectively and 21, 21, and 20 clonal clusters.
All three methods have Discriminatory Indices (DI) with overlapping
95% conﬁdence intervals (CI) of 98.8 (CI 97.4−1.0), 98.0 (CI 95.9−1.0)
and 95.2 (CI 91.4−98.9) for PFGE, MLVA and MLST, respectively.
Congruence testing between the methods, at the level of clonal clusters,
showed an aRI of 0.97 for PFGE vs. MLVA and 0.94 for PFGE vs. MLST.
Wc between PFGE and MLVA is 0.97 both ways. Wc between PFGE
and MLST was also 0.97, while MLST had a slightly lower prediction
of partition by PFGE of 92% (Wc 0.92).
Conclusion: Discriminatory Indices between these typing methods are
similar and congruence as measured by aRI and Wc is very high between
all methods. MLVA and MLST are comparable typing techniques with
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respect to portability and ease of interpretation. This is a huge advantage
compared to PFGE. In this study MLVA is slightly more congruent
to PFGE than MLST. And, MLVA is cheaper as it does not require
sequencing. Therefore, we suggest MLVA as ﬁrst choice typing method
for characterising clonal relatedness of P. aeruginosa isolates.
P518 MLST reveals a polyclonal structure of Pseudomonas
aeruginosa from initial and early colonisation stages in cystic
ﬁbrosis patients
A. Fernandez-Olmos °, R. del Campo, A. Lamas, P. Ruiz Garbajosa,
L. Maiz, F. Baquero, R. Canto´n (Madrid, ES)
Objectives: MLST typing schemes have been scarcely apply to
Pseudomonas aeruginosa isolates from cystic ﬁbrosis (CF) patients. The
aim of this study was to assess the population structure of P. aeruginosa
isolates from initial and early colonisation stages in CF patients followed
by our CF-Unit from 1994 to 2007.
Methods: Twenty-four P. aeruginosa isolates (20 ﬁrst P. aeruginosa
isolate in the patient, four 2nd-4th isolate), from 21 CF patients (median
age 9 years, range 0−34) were typed by SpeI-PFGE and MLST (Curran et
al. 2004, http://pubmlst.org/paeruginosa) using the housekeeping genes
acsA, aroE, guaA, mutL, nuoD, ppsA and trpE. Median follow-up period
of these patients were 6.9 years (range 1−14). The eBURST algorithm
(http://pubmlst.org/analysis/) was used for phylogenetic analysis.
Results: SpeI-PFGE identiﬁed unique patterns (n = 21) from 19 unrelated
patients with single isolates, and from the other two patients with
multiple isolates (two and three, respectively, collected separately from
more than two years). However, PFGE proﬁles with 6 bands of difference
were observed in two pairs of unrelated patients. Moreover, 20 different
sequence types (STs) were identiﬁed within studied isolates. Within four
isolates with PFGE proﬁles with 6 bands of differences, two STs were
identiﬁed. A group of 3 patients carried single locus variants.
Conclusions: Unlike other studies, a polyclonal structure of P. aerug-
inosa from initial and early colonisation stages in CF patients were
observed with no previously identiﬁed epidemic clones. Moreover, the
ﬁnding of different genotypes in the same patient during a long term
follow-up period suggests ephemeral persistence of initial colonising
strains.
P519 The applicability of three different methods for the
molecular typing of Pseudomonas aeruginosa
C. Ratkai, S. Quinteira, F. Grosso, E. Nagy °, L. Peixe (Szeged, HU;
Porto, PT)
Objectives: Pseudomonas aeruginosa is a Gram-negative rod causing
serious infections, often isolated from nosocomial outbreaks. Several
methods have been developed for the typing to determine the relatedness
of these nosocomial pathogens, such as serotyping, ribotyping, or PCR
based methods. For epidemiologists a reliable, cheap and rapid typing
method is essential for measuring the effectiveness of the infection
controll, and in case of the increasing number of resistant P. aeruginosa
isolates, the ability to decide if it is due to patient-to-patient transmission.
Methods: During the period of 2004 to 2008 we isolated 25 carbapenem
resistant non-mucoid P. aeruginosa isolates from different non-cystic
ﬁbrosis patients, hospitalised in nine different hospital wards of South-
Hungary, and 18 P. aeruginosa isolates from cystic ﬁbrosis patients.
We compared different typing methods for these P. aeruginosa isolates,
namely pulse-ﬁeld gel-electrophoresis (PFGE), which is considered to
be the “gold-standard” method for molecular typing of P. aeruginosa;
multilocus sequence typing (MLST), which is based on the allelic
differences in certain housekeeping genes; and the DiversiLab typing
system (BioMe´rieux), which is based on repetitive element-based PCR
(rep-PCR).
Results: In case of the carbapenem-resistant isolates we determined
eleven different pulso-types with the PFGE, and twelve different types
with the rep-PCR. Contradictory results were obtained in case of three
of the 25 (12%) isolates with these two typing mehods. Twenty-one of
the 25 isolates were members of three different outbreaks observed in
the intensive care unit, and according to the MLST analysis they belong
to different clonal complexes. In case of the strains isolated from cystic
ﬁbrosis patinets 10 pulso-types and 12 different types with the rep-PCR
were determined. Contradictory results were obtained in case of seven
of the 18 (39%) isolates with these two typing mehods. According to
the MLST analysis, these strains are singletons.
Conclusion: Our experiences suggest, that the PFGE had a high
discriminatory power, but it is limited by the technical complexity,
expense and time. Only the MLST method provides data about the
clonal relationship of the isolates, but it is not applicable in case of local
outbreaks. Rep-PCR is suitable as a rapid epidemiological surveillance
tool, however, mainly in case of strains from cystic ﬁbrosis patients, it
proved to be too discriminating.
P520 Molecular characterisation of Candida parapsilosis, Candida
orthopsilosis and Candida metapsilosis clinical isolates in a
tertiary-care hospital
M. de Toro, M.J. Torres, M. Ruiz, J. Aznar ° (Seville, ES)
Objective: To describe the prevalence of the recently renamed species
Candida orthopsilosis and Candida metapsilosis in candidaemia and
identiﬁed them in isolates recovered from different body sites.
Methods: Fifty-six clinical isolates recovered from blood cultures
obtained from patients with candidaemia (study period 2003–2008), and
74 isolates from a variety of sources from some in-hospital and outpatient
were studied. These isolates were previously identiﬁed as Candida
parapsilosis by conventional laboratory tests. Molecular characterisation
of the clinical isolates was performed by RAPD test using the primer
RPO2 (5′-GCGATCCCCA-3′), and by BanI digestion proﬁle analysis of
a fragment of the secondary alcohol dehydrogenase gene. C. parapsilosis
ATCC 22019, C. orthopsilosis ATCC 96139 and C. metapsilosis ATCC
96144 were also included as reference strains.
Results: Between 2003 and 2008, a total of 381 cases of candidaemia
were detected in our hospital, and 95 (24.9%) of them corresponded
to C. parapsilosis. Based on molecular criteria, 10 of the 130 studied
isolates were identiﬁed as C. orthopsilosis (6 of them were bloodstream
strains and 4 of them were from other sources), and 1 as C. metapsilosis
(recovered from a skin sample). The remaining 119 isolates were
identiﬁed as C. parapsilosis. Based on these results, C. orthopsilosis
accounted for 7.7% (10/130) of all strains studied, but accounted for
10.7% (6/56) of the C. parapsilosis bloodstream strains and for 5.4%
(4/74) of the strains from other sources. C. metapsilosis accounted for
0.77% (1/130).
Conclusions: The prevalence of the recently described specie C. or-
thopsilosis in candidaemia is signiﬁcant and its characterisation can
be recommended. Further studies are needed to establish the clinical
signiﬁcance of C. metapsilosis isolates in our area.
P521 A new method PCR MP for Candida albicans strains
genotyping
B. Krawczyk, J. Leibner-Ciszak, A. Mielech °, A. Sledzinska, A. Samet,
J. Kur (Gdansk, PL)
Objectives: Infections with Candida albicans strains can be a serious
medical problem. It is necessary to establish the genetic relatedness
of clinical isolates. The aim of this study was the elaboration of a
new PCR MP method for genetic typing of Candida albicans strains,
designed for epidemiological studies. The principle of the method is
to use low denaturation temperatures during the ligation mediated PCR
(LM PCR). The optimisation of the method has been carried out using
different restriction enzymes and denaturation temperature. We evaluated
the typeability and discriminatory power of this technique in comparison
to RAPD and REA-PFGE. We also validated the reproducibility of the
PCR MP method.
Methods: A total of 123 Candida albicans strains (including 7 reference,
11 clinical unrelated, and 105 isolates from different geographic origins
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and patients of two hospitals in Poland) were examined. Typing of
candidal strains to determine their genetic relatedness has been done
by PCR MP, REA-PFGE and RAPD methods.
Results: The genotyping results of the PCR MP were compared with
results from macrorestriction analysis of the chromosomal DNA by
pulsed-ﬁeld gel electrophoresis (REA-PFGE) and RAPD techniques.
Digestion of the chromosomal DNA with the SmaI endonuclease
and separation of the fragments by PFGE revealed 26 unique types.
Application of RAPD resulted in recognition of 25 types. Strains were
grouped into 27 types using PCR MP.
Conclusion: Data presented here show for the ﬁrst time the evaluation
of PCR MP technique for candidial strains differentiation. The results
showed that the PCR MP technique has at least the same discriminatory
power as REA-PFGE and RAPD. We propose that PCR MP can be used
as an alternative technique in large-scale hospital studies of intra-species
genetic relatedness of Candida albicans strains.
P522 Mutilocus sequence typing of sequential Candida albicans
isolates from patients with persistent or recurrent fungaemia
D.A. da Matta, A.S.A. Melo °, T. Guimaraes, M.E. Brandt, T.J. Lott,
A.L. Colombo (Sao Paulo, BR; Atlanta, US)
Multilocus sequence typing (MLST) is a useful tool in understanding
the phylogenetics and epidemiology of Candida albicans strains from
invasive candidiasis.
Objective: Our goal was to determine whether indistinguishable or
different strains were responsible for persistent or recurrent fungaemia
by performing MLST and ABC typing, which is based in the presence or
absence of an intron in the 26S rDNA region, on sequential C. albicans
isolates from the same patient.
Methods: We applied MLST to 21 C. albicans strains from 8 patients
with persistent or recurrent candidaemia collected during a multicentre
surveillance study in 4 public tertiary care hospitals in Brazil. Persistent
candidaemia was deﬁned as two or more blood cultures positive for
C. albicans on 2 or more separate days. Recurrent candidaemia was
deﬁned as an episode of candidaemia occurring at least 1 month after
the apparent complete resolution of an infectious episode caused by the
same Candida species.
Results: All the patients’ strains but one showed the same MLST diploid
sequence type (DST), ABC type and susceptibility proﬁle to antifungals
in the ﬁrst and second samples. One patient with 7 samples collected
sequentially over 10 days showed 3 distinct strains, well discriminated
by MLST. The ﬁrst four samples were indistinguishable, the ﬁfth and
sixth were also indistinguishable but different from the ﬁrst four and
the seventh collected sample. Signiﬁcantly, the seventh strain recovered
was the only C. albicans clade 2 isolate found in our total collection
involving 61 patients (data not shown), although clade 2 is commonly
found worldwide.
Conclusions: To the best of our knowledge, this is the ﬁrst study
describing a blood stream infection with 3 distinct C. albicans strains in
the same patient within a short period of time.
P523 An optimised RAPD protocol for rapid genotyping and local
epidemiological mapping of Clostridium difﬁcile
L. Green °, J. Rollason, T. Worthington, A.C. Hilton, P.A. Lambert
(Birmingham, UK)
Objectives: To develop an optimised Random Ampliﬁed Polymorphic
DNA (RAPD) PCR protocol for rapid and reproducible discriminatory
typing and local epidemiological mapping of Clostridium difﬁcile.
Methods: Two 10-bp primers were selected and used in separate
ampliﬁcation reactions to determine their ability to discriminate
between different PCR ribotypes of C. difﬁcile. Concentrations of
deoxyribonucleotide triphosphates (dNTPs), primer and template DNA
were titrated to determine optimal concentrations for reproducible and
discriminatory ampliﬁcation. Concentration of Magnesium Chloride
(MgCl2), Potassium Chloride (KCl) and pH of the reaction buffer were
also optimised. The ampliﬁcation cycles used were as follows: 5 cycles
of 4.5 minutes (94ºC), 30 seconds (94ºC), 2 minutes (20ºC) and 1 minute
(72ºC) followed by 30 cycles of 30 seconds (94ºC), 30 seconds (30ºC)
and 1 minute (72ºC). Ampliﬁed products were size separated on a
2% agarose gel in 1×TAE running buffer (40mM Tris-HCl, 1mM
EDTA, 0.1% (v/v) glacial acetic acid, pH 8). Following electrophoresis,
amplicons were detected by Ethidium Bromide staining and viewed
under UV light. Following RAPD optimisation, both primers were used
to type a panel of control PCR ribotypes (001, 002, 005, 014, 015, 017,
023, 027, 064, 078, and 106); clinical isolates known to belong to the
same ribotype were also tested. DNA preparations from selected isolates
were prepared in duplicate for ampliﬁcation in the same cycling reaction
and at widely different times to determine reproducibility.
Results: The parameter having the greatest inﬂuence on the discrimina-
tory capacity and reproducibility of RAPD was the reaction buffer; KCl
having the greatest effect. The optimised RAPD protocol generated a
unique proﬁle for each distinct ribotype tested and clustered identical
ribotypes together. Proﬁles were reproducible when generated from
independently prepared reactions using different batches of reagents.
Conclusion: RAPD, when optimised effectively, has the ability to
produce reproducible and stable ampliﬁcation proﬁles. When applied to
isolates which had been characterised previously by PCR Ribotyping
RAPD demonstrated the same discriminatory capacity; isolates with
unique ribotypes had unique RAPD types and those indistinguishable
by ribotyping were also grouped together by RAPD. Optimised RAPD
offers a rapid and cost-effective method for the epidemiological typing
of C. difﬁcile.
P524 Genotypic characterisation of binary-toxin-producing
Clostridium difﬁcile strains
M. Marı´n °, A. Martı´n, L. Alcala´, T. Pe´laez, E. Domı´nguez,
M. Sa´nchez-Somolinos, R. Insa, P. Catala´n, E. Bouza (Madrid, ES)
Background: Clostridium difﬁcile (CD) is an important cause of
communitary and nosocomial diarrhoea. In recent years, epidemic strains
belonging to the 027 and 078 ribotypes have emerged. Both ribotypes
are characterised by binary toxin production and deletions of tcdC gene
(negative regulator of toxin production), the latter possibly related to
increased toxin production.
Objective: To genotype the binary-toxin-positive CD strains (bin+)
circulating in our hospital during the year 2007.
Methods: CD strains were cultured and identiﬁed by conventional
microbiological methods. Toxins A and B were detected in isolates
using an immunochromatographic method (ImmunoCard, Meridian
Bioscience). DNA was obtained from pure cultures using Chelex resin
(Instagene matrix, BioRad). The tcdA gene (toxin A), tcdB gene
(toxin B), and binary-toxin genes cdtA and cdtB were detected by PCR
following methods previously described (Kato, 1991; Wolfhagen, 1994;
and Stubbs, 2000, respectively). Bin + isolates were characterised by
PCR-ribotyping (Bidet et al. 2000). Phylogenetic analysis of ribotyping
proﬁles was conducted using Bionumerics software 5.0. The tcdC gene
was ampliﬁed by PCR using the method described by Spigaglia and
Mastrantonio (2002), sequenced by the Big Dye Terminator method,
and detected in an AbiPrism 3100 automatic DNA sequencer (Applied
Biosystems Inc.). Sequences were aligned using BioEdit software
(http://www.mbio.ncsu.edu/bioedit/bioedit.html).
Results: Seven hundred and forty three CD toxigenic strains were
isolated from patients with CD associated diarrhoea during 2007. Eighty-
eight isolates were bin + (62 patients) and all were also tox A+B+. The
isolates were from 8 different ribotypes. Most CD isolates belonged to
ribotype 078 (63 isolates from 45 patients). Only 6 isolates (2 patients)
belonged to ribotype 027. The analysis of the tcdC gene revealed
deletions of 18 bp in 10 isolates (2 different ribotypes), 36 bp in 5 isolates
(2 different ribotypes), 39 bp in 69 isolates (2 different ribotypes), and
54 bp in 6 isolates (only 1 ribotype).
Conclusions: Twelve percent of our CD toxigenic isolates had binary-
toxin genes. Ribotype 078 is a frequent cause of diarrhoea in our patients,
representing 8% of toxigenic CD isolated at our institution during 2007.
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In our study, epidemic strains of ribotype 027 were detected in only
2 patients. All the bin + CD detected had deletions in the tcdC gene.
P525 Co-existence of multiple MLVA sub-types of Clostridium
difﬁcile PCR-ribotype 027 strains within faecal specimens
H.E. Tanner °, K.J. Hardy, P.M. Hawkey (Birmingham, UK)
Objectives: Multiple Locus Variable Number Tandem Repeat Analysis
(MLVA) for the nosocomial pathogen C. difﬁcile has previously been
shown to be capable of sub-dividing isolates of the epidemic strain
PCR-ribotype 027. The aim of the study was to investigate whether
MLVA typing could identify different subtypes of ribotype 027 within
individual faeces specimens from cases of C. difﬁcile infection (CDI)
and to determine the impact this may have on the utility of MLVA as a
typing method for outbreak situations.
Methods: Five isolates of PCR-ribotype 027 C. difﬁcile were cultured
from each of 39 faeces specimens from patients with CDI and typed
with MLVA.
Results: Twenty two specimens tested contained at least two different,
but closely related, MLVA proﬁles. Five specimens yielded isolates with
MLVA proﬁles over ﬁve summed tandem repeats different from other
isolates from the same specimen.
Conclusion: These observations agree with previously published studies
using different typing methods showing that multiple types of C. difﬁcile
can co-exist in a single faeces specimen. These differences may have the
potential to obscure epidemiological links between cases of CDI.
P526 First nationwide estimates on incidence and case fatality of
Clostridium difﬁcile-associated infections
O. Lyytika¨inen °, M. Snellman, S. Kotila, S. Ibrahem,
A. Virolainen-Julkunen (Helsinki, FI)
Objectives: In 2008, C. difﬁcile were included in the national
surveillance, and clinical microbiology laboratories were asked to send
C. difﬁcile isolates from severe cases and persistent outbreaks to the
reference laboratory for genotyping. We analyzed the ﬁrst 9-month
surveillance data to assess the incidence and case fatality of CDI, and
to detect regional differences in CDI epidemiology.
Methods: All laboratories reported all C. difﬁcile ﬁndings (positive
culture and/or toxin production) from stools to the National Infectious
Disease Register. Each notiﬁcation included specimen date, each
individual’s national identity code, date of birth, sex, and place of
residence. Within this information and a 3-month time interval, multiple
notiﬁcations of the same person were merged as a single episode. The
dates of deaths were obtained from the Population Information System.
An episode of CDI was deﬁned as detection of C. difﬁcile toxin from
stools of persons aged >2 years from January 1, 2008 to September
30, 2008. PCR ribotyping was performed according to the protocol
of the Anaerobe Reference Unit in Cardiff, using the Cardiff-ECDC
collection of different C. difﬁcile PCR ribotypes as reference. When a
local outbreak was suspected, also pulsed-ﬁeld gel electrophoresis was
performed.
Results: In total, 4571 episodes of CDI among 4411 individuals were
identiﬁed; 3169 (69%) occurred in persons aged >64 years and 2707
(59%) in females. The overall incidence was 11.5 per 10,000 population
(range by regions, 5.5−19.4). The incidence increased by age and was
highest in persons aged >84 years (128.2). Of the CDI episodes, 202
(4.4%; range by regions, 0−8.9%) lead to death within 7 days and 526
(11.5%; range by regions, 0−16.2%) within 30 days. The 7- (7.4%) and
30-day (20.8%) case fatality was highest in persons aged >84 years. In
total, 223 (5%) isolates from 12/20 regions were sent for genotyping:
108 (48%) were of PCR ribotype 027, 28 (13%) of 001, and 10 (4%)
of 002; among the rest of the isolates, some 30 distinct PCR ribotype
proﬁles were identiﬁed, including 023, 045 and 078. The isolates of
PCR ribotype 027 came from 6/12 regions. The non-027 ribotypes were
equally common among severe cases as the 027.
Conclusions: Our study showed the ﬁrst nationwide population-based
estimates on incidence and case fatality of CDI. The major regional
variations may be due to differences in diagnostic activity or spread of
hypervirulent PCR ribotypes.
P527 A rapid and simple identiﬁcation of Clostridium difﬁcile
PCR ribotype 027 by loop-mediated isothermal ampliﬁcation
method
H. Kato °, Y. Ito, Y. Arakawa (Tokyo, Gifu, JP)
Objectives: A number of outbreaks caused by Clostridium difﬁcile PCR
ribotype 027 have been documented in North America and Europe.
The emerging strain was reported to cause more severe disease. Earlier
recognition of PCR ribotype 027 might be beneﬁcial in countries where
the type is epidemic as well as in countries where the type is not currently
predominant. We established and evaluated a loop-mediated isothermal
ampliﬁcation (LAMP) method for identiﬁcation of PCR ribotype 027.
Methods: A total of 85 C. difﬁcile isolates recovered from symptomatic
patients admitted to hospitals in Japan were used. The collection of
PCR ribotype 027 isolates for the previous collaborative typing study
(Killgore G. et al 2008. J Clin Microbiol) was also included. Isolates
were analyzed by two typing systems, PCR ribotyping and surface layer
protein A gene (slpA) sequence typing. Four primers derived from the
sequence of the slpA gene of PCR ribotype 027 were used for the LAMP
assay to identify PCR ribotype 027. The increased turbidity of ampliﬁed
products was monitored by a real-time turbidimeter.
Results: The 85 isolates tested were typed into 18 PCR ribotypes
including PCR ribotype 027. The isolates representing the 18 PCR
ribotypes were tested for slpA of PCR ribotype 027 by LAMP. The
slpA gene of PCR ribotype 027 was detected by LAMP in all PCR
ribotype 027 isolates examined; no ampliﬁcation products were obtained
in isolates belonging to other PCR ribotypes. DNA was extracted directly
from a stool specimen of a patient who suffered from pseudomembranous
colitis caused by PCR ribotype 027 strain. In addition, the stool specimen
of this patient was cultured in cooked meat medium overnight, followed
by the DNA extraction by a simple boiling method. The slpA sequence
of PCR ribotype 027 was detected by LAMP in the both DNA extracts.
Conclusion: The LAMP assay detecting the slpA sequence of PCR
ribotype 027 appears to be a valuable tool for the rapid identiﬁcation
of this type. This method could be feasible to detect PCR ribotype 027
C. difﬁcile in stool specimens.
P528 Comparison of molecular and susceptibility characteristics
of CA-MRSA and HA-MRSA among hospital-admitted
patients in two main cities of Iran: 1-year study
M. Moghadami °, M. Mardani, M. Amini (Shiraz, Tehran, IR)
Objective: Methicillin-resistant Staphylococcus aureus (MRSA) has
traditionally been considered a health care-associated pathogen in
patients with established risk factors. However, MRSA has emerged in
patients without established risk factors.
To characterise epidemiological and microbiological characteristics of
community-associated MRSA (CA-MRSA) cases compared with health
care-associated MRSA (HA-MRSA) cases in our country this survey
was done.
Method: Prospective cohort study was done for patients with MRSA
infection identiﬁed at 4 medical universities’ hospitals in Tehran
(capital of Iran) and main hospital in Shiraz (main city in South of
Iran) from December, 2007 through September, 2008, comparing CA-
MRSA with HA-MRSA cases. Clinical infections associated with either
community-associated or health care-associated MRSA, microbiological
characteristics of the MRSA isolates including susceptibility testing
(MIC Determination by broth method for clindamycin, rifampin,
doxycyclin, trimethoprim-sulfamethoxol, tetracycline, ciproﬂoxacin),
and staphylococcal SCCmec genes type was done (by multiplex PCR)
were determined.
Molecular typing – Part 1 S113
Results: Of 109 documented MRSA infections, 15 (12%) were
community-associated and 94 (85%) were health care-associated. The
staphylococcal cassette chromosome mec (SCCmec) types and antimi-
crobial susceptibility patterns of all MRSA strains were determined.
Although community-associated MRSA isolates were more likely to
be susceptible to antimicrobial classes, most community-associated
infections were initially treated with antimicrobials to which the isolate
was nonsusceptible. Most frequent SCCmec in our hospitals was
SCCmec-I (56.9%) and least one was SCCmec-III (10.1%) and relevant
SCCmec with community was type IV.
CA-MRSA strain were signiﬁcantly more susceptible to above antibiotics
in comparison to HA-MRSA (OR, 5.2; CI, 4.83−5.94) but overall
we have very high index of resistance for MRSA as our most
sensitive antibiotic was Trimethoprim-Sulfamethaxozol with 42%
susceptibility (Table).
Resistance proﬁle of MRSA strains according to epidemiological
classiﬁcation of MRSA
Antimicrobial agent Number (%)
HA-MRSA CA-MRSA Total P-value
Ciproﬂoxacin 68 (72) 5 (33) 73 (67) 0.003
Cotrimoxazole 60 (63) 4 (26) 64 (58) 0.007
Clindamycin 73 (77) 8 (53) 81 (74) 0.045
Rifampin 63 (67) 5 (33) 68 (62) 0.012
Tetracycline 78 (83) 6 (40) 84 (77) 0.00
Erythromycin 73 (77) 9 (40) 79 (72) 0.002
Doxycycline 58 (90) 4 (57) 62 (87) 0.011
Conclusions: Our study, as we know, was ﬁrst study in Iran about
differentiation of different characteristic of CA-MRSA and HA-
MRSA. We have very resistant MRSA in our hospitals and this is
troublesome for care of patient’s most important point in for control of
emerging infections is supervision in antibiotic use by infectious control
committees.
Also we found as other studies difference in origin of CA-MRSA and
HA-MRSA.
P529 Phenotypic and molecular characterisation of methicillin-
resistant Staphylococcus aureus isolated from clinical samples
in northern Chile
J. Gahona, J. Araya, J. Silva ° (Antofagasta, CL)
Objectives: Methicillin-resistant Staphylococcus aureus is a signiﬁcant
problem in healthcare settings around the world. The aim of this work
was to study the phenotypic and molecular characteristics of methicillin
resistant Staphylococcus aureus (MRSA) isolated from clinical samples
in the north of Chile.
Methods: A total of 76 MRSA strains from skin and tissues infections
samples isolated in Health Centers of Antofagasta, Chile (2007),
were included in this study. The S. aureus strains were identiﬁed
by biochemical tests, API Staph and typed by Phene-Plates. The
susceptibility to antimicrobial drugs was determined by a dilution
technique agar, the presence of beta-lactamase by phenotypic and
molecular methods, and detection of mec and luk genes by PCR. Also,
the presence of plasmids was investigated by gel electrophoresis and
genotypes by PFGE.
Results: More of 80% of the assayed MRSA strains exhibited high
resistance to ampicillin, penicillin, eritromycin, claritromycin, amikacine
and ciproﬂoxacin; moderate resistance to cotrimoxazole (18.5%) and
tetracycline (4.2%); and 100% of susceptibility to rifampin and
vancomycin. Around 90% of the strains were resistant to methicillin
and the 79% presented beta-lactamase. The Ph-phene method identiﬁed
7 biochemical phenotypes and the antibiotic resistance patterns shown 5
different antibiotypes. More of 60% of the strains exhibited multiple
resistance to 9 or more antimicrobials. Different genotypes were
identiﬁed by PFGE and one genotype was dominant. A plasmid of 7 kb
in 8 MRSA strains, also two of them presented a plasmid of 20 kb.
The PCR analysis revealed the presence of mecA gen in 97.3%, mecR1
MS gen in 52.6%, mecR1 PB gen in 36.8%, and mecI in 55.2% of the
MRSA strains, and also in 44.5% of the strains was detected the luk
gene. However, the mecA gen was found in 6 methicillin susceptible
strains. In two MRSA strains, it was not possible to detect the presence
of the mecA gen.
Conclusions: MRSA strains are present in a high percentage in Health
Centers of Antofagasta Chile, the strains exhibited multiple resistance
to antibiotics and presence of plasmids. Also, the MRSA strains
presented beta-lactamase, mec and luk genes in prevalent phenotypes and
genotypes of MRSA strains. These ﬁndings can contribute to understand
and control the MRSA strains circulating in the Health Centers of
Antofagasta.
P530 Molecular characterisation of methicillin-resistant Staphylo-
coccus aureus isolates in a tertiary hospital in Madrid (Spain)
A. Garcı´a-Can˜as °, A. Vindel, P. Garcı´a-Hierro, P. Trincado, T. Boquete,
C. Ballesteros, V. Bautista, J.I. Alos (Getafe, Madrid, ES)
Objectives: The aim of this study was to determine which clones of
methicillin-resistant Staphylococcus aureus (MRSA) are circulating in
our hospital and to analyse the genetic relationships of these strains.
Methods: We studied a total of 52 MRSA strains isolated from clinical
samples of 52 hospitalised adult patients (10 patients were admitted to
the medical/surgical intensive care unit, ICU, and 4 to the burn ICU)
during 2007 at the Department of Microbiology of Getafe University
Hospital in Madrid. The sources of the isolates were nares (65%),
oropharyngeal (15%), rectal (7%) and wound (13%) swabs. The 52
MRSA were characterised by phage typing using the 23 phages of the
Basic International Set at 100 RTD and 1,000 RTD, pulsed-ﬁeld gel
electrophoresis (PFGE) following SmaI digestion of chromosomal DNA
as described by Cuevas et al. (Clin Microbiol Infect 2007;13: 250–256)
and SCCmec typing wich was performed using several multiplex PCR
strategies [1−3].
Results: Of the 52 MRSA isolates, 33 (63%) belonged to phage group III
and 5 (10%) belonged to phage group III and also were lysed by
phage 81. The rest (14 strains) were non-typeable. Genotyping by PFGE
showed that the majority of the strains belonged to the clones E-7
(16 isolates, 31%) and E-8 (14 isolates, 27%) with the next subtypes:
5 strains belonged to E-7a, 8 to E-7b, 3 to E-7c, 8 to E-8a, 5 to E-8b and
1 to E-8c. We observed two isolates belonging to E-11, one to E-13 and
one to E-20. The remaining 18 MRSA belonged to sporadic clones but
3 of these strains presented the same PFGE pattern and were isolated
from 3 different patients who were admitted to the burn ICU at the same
time.
SCCmecIV accounted for 46 (88%) of the isolates (76% IVa, 22% IVc
and 2% IVh). The remaining 6 strains (12%) carried SCCmecI and all
were sporadic clones.
Conclusions: The majority of the strains showed the most common
PFGE types present throughout Spain (E-7 and E-8). The genotypes E7,
E8, E11 and E20 belong to the clonal group 5 (paediatric clon). We also
found one strain with the PFGE proﬁle E-13 (SCCmecIVh) belonging
to the EMRSA-15 clone which is epidemic in the United Kingdom. It
is important to note that we observed an outbreak in the burn ICU of a
sporadic clone carried SCCmecIVa.
Reference(s)
[1] Milheirico et al. J Antimcrob Chemother 2007 Jul; 60(1): 42−8
[2] Milheirico et al. Antimicrob Agents Chemother 2007 Sep; 51(9):
3374−7
[3] Oliveira et al. Antimicrob Agents Chemother 2002 Jul; 46(7):
2155−61.
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P531 Molecular and phenotypic characters of methicillin-resistant
Staphylococcus aureus bloodstream isolates from Taiwan
W.Y. Wang °, J.J. Lu, G.W.S. Tsai (Miao-Li, Taichung, Taipei, TW)
Objectives: Staphylococcus aureus is a major pathogen responsible
for bacteraemia and sepsis with extremely high mortality. Methicillin-
resistant S. aureus (MRSA) has emerged since 1960 s and increased to
more than 70% in Taiwan. Limited MRSA clones circulating worldwide
have been identiﬁed We intend to illustrate the molecular and phenotypic
characters of MRSA blood stream isolates from Taiwan.
Methods: MRSA isolates from patients with bacteraemia were retrieved
from database of the Surveillance of Multicenter Antimicrobial Resis-
tance in Taiwan (SMART). Antibiotic susceptibility tests were performed
with disc diffusion and inducible macrolide-lincosamide-streptogramin
resistance (MLSBi) were validated with D test. Molecular types of
MRSA blood stream isolates were assigned by PCR-based typing
methods of accessory gene regulator (agr), staphylococcal cassette chro-
mosome mecA (SCCmec), direct repeat units (DRUs), and multilocus
sequence typing (MLST). Gene encoding Panton-Valentine leukocidin
(pvl) was also ampliﬁed by PCR and identiﬁed by electrophoresis.
Results: Totally 160 non-duplicate MRSA blood stream isolates were
selected from database of 9 medical centres. All isolates were identiﬁed
as MRSA with presence of mecA. There were 6 (3.8%), 117 (73.1%),
22 (13.8%), 1 (0.6%), 11 (6.9%), and 3 (1.9%) isolates assigned as
SCCmec type II, III, IV, V, VT, and non-typabe strains, respectively.
Most MRSA isolates (150, 93.8%) belonged to agr type I and the other
10 isolates belonged to agr type II (6.2%). Signiﬁcant association was
found between 4 DRUs copies number with agr type II (6/10, p< 0.001),
14 DRUs copies number with SCCmec III (75/76, p< 0.001), and 9
DRUs copies number with SCCmec IV (18/22, p< 0.001). There were 13
(8.1%) isolates assigned as positive MLSBi phenotype and no signiﬁcant
association of MLSBi with SCCmec type or DRUs copies number
(p = 0.10) was noted. Forty-one MRSA isolates were typed with MLST
and 3 major clusters were identiﬁed (9 with ST59 and 1 with ST338, 17
with ST239 and 6 with ST241, and 6 with ST5). Only 14 isolates (8.8%)
were positive for pvl and were signiﬁcantly associated with SCCmec VT
(11 isolates, p< 0.001). Resistance to 4 or more antibiotics was noted
mostly in SCCmec III but rarely in SCCmec IV and VT.
Conclusions: Two major clones of SCCmecIII-ST239-agrI-DRUs14
and SCCmecIV-ST59-agrI-DRUs9 were predominant in MRSA blood
isolates from Taiwan. MLSBi and pvl gene were not prevalent in MRSA
blood isolates.
P532 Epidemiological typing of methicillin-resistant Staphylococcus
aureus isolates from India and Pakistan
S. Shabir, K. Hardy °, W. Abassi, C. McMurray, S. Malik, P. Hawkey
(Birmingham, UK; Islamabad, PK)
Objectives: To gain a greater understanding of the epidemiology of
MRSA in the subcontinental regions of India and Pakistan.
Methods: Sixty MRSA isolates were obtained from three regions;
Pakistan (2) and India (1). All isolates were conﬁrmed as MRSA using
biochemical tests and typed using a range of genotypic methods. Detailed
epidemiological relationships were identiﬁed using pulsed ﬁeld gel
electrophoresis (PFGE) and staphylococcal interspersed repeats (SIRU),
whilst the overall global epidemiology was studied using the restriction
modiﬁcation (RM) method and multi locus sequence typing (MLST).
Results: All isolates were typable by PFGE, SIRU and RM assignment.
57/60 isolates were all closely related, all belonging to CC8, differing
at only one locus using SIRU and clustering within 67% relatedness
by PFGE. Within CC8, SIRU typing sub-divided the isolates into
12 different proﬁles all of which were closely related. Two of the SIRU
proﬁles were present in isolates from both India and Pakistan, whilst
nine were distinct to Pakistan and one to India. If the strict criterion
of one band difference was applied to the PFGE proﬁles a total of
24 different types were identiﬁed within the CC8 isolates. Unlike the
SIRU proﬁles where the same proﬁles were present in both Pakistani and
Indian isolates, all PFGE proﬁles were distinct between the two countries.
MLST typing of ten CC8 strains with diverse SIRU and PFGE patterns
revealed eight belonged to ST239, one to ST113 and ST8 respectively.
The 3 isolates with a different clonal complex all belonged to CC30 and
were all from the same hospital in Pakistan.
Conclusion: Epidemiological typing of strains from three distinct
locations in India and Pakistan reveals that ST239 is the predominant ST
type and could be presumed to have been present for some time. SIRU
and PFGE differentiated within ST239 demonstrating their utility and the
importance of using epidemiological typing methods with a high degree
of discrimination when investigating clusters and outbreaks within these
countries.
P533 The clonal structure of PFGE non-typeable methicillin-
resistant Staphylococcus aureus in the Netherlands
X.W. Huijsdens °, T. Bosch, M.G. van Santen-Verheuvel, E. Spalburg,
M. Heck, G.N. Pluister, M. van Luit, A. Haenen, A.J. de Neeling
(Bilthoven, NL)
Objectives: In the Netherlands, the National Institute for Public Health
and the Environment (RIVM) serves as the national reference centre for
surveillance of MRSA. Recently, animals such as pigs and calves were
identiﬁed as possible MRSA reservoirs. MRSA isolates (either human
or animal), referred to as NT-MRSA, related to livestock belong to a
relatively new CA-MRSA clonal lineage, ST398. The present study gives
an overview of the human NT-MRSA isolates in the Netherlands in 2007.
Methods: The molecular characteristics of NT-MRSA and the clonal
structure of the isolates was determined by Panton-Valentine leukocidin
(PVL) PCR, staphylococcal protein A (spa) typing, staphylococcal
cassette chromosome mec (SCCmec) typing, and multilocus sequence
typing (MLST). For the SCCmec typing the multiplex PCR method of
Kondo et al. was used.
Results: In 2007, a total of 793 human MRSA isolates were non-typeable
by PFGE. Three isolates were PVL positive. Spa typing revealed 27 dif-
ferent spa types, all related to each other. The two most prevalent spa
types were t011 and t108. SCCmec typing results of 300 NT-MRSA iso-
lates showed SCCmec type IV, type V, and unknown type(s). Surprisingly,
all isolates with spa type t108 were either SCCmec type V or could not
be typed, no SCCmec type IV was found. One isolate per spa type was
subjected to MLST. All isolates belonged to the ST398 clonal lineage.
Conclusion: The clonal lineage ST398 is not speciﬁcally found in
pigs anymore, but has also been found in other animals, serving as
MRSA reservoirs. Whether the number of NT-MRSA will increase even
further remains to be seen. Surprisingly, independent of the host (animal
or human) the typing results of NT-MRSA isolates showed the same
clonal origin.
P534 dru-typing.org: an Internet resource for the sequence-based
typing of methicillin-resistant Staphylococcus aureus
analysing the hypervariable mec-associated direct repeat unit
R.V. Goering ° (Omaha, US)
Objectives: Variable-number tandem repeat (VNTR) sequences have
found important use in the epidemiological typing of problem bacterial
pathogens. With Staphylococcus aureus, sequence analysis of the
polymorphic X region of the protein A gene (spa), coupled with a
uniform system of nomenclature, has resulted in a robust method for
epidemiological analysis. In methicillin-resistant Staphylococcus aureus
(MRSA), the direct-repeat unit (dru) VNTR region adjacent to IS431
in SCCmec has also proved useful in the epidemiological analysis
of highly uniform epidemic strains (e.g., EMRSA15 and -16) and in
tracking the horizontal movement of SCCmec. Recently, more efﬁcient
use of dru typing has been facilitated by a proposed uniform system of
nomenclature (Goering et al., 2008; Clin. Microbiol. Infect. 14:964−69).
However, optimum use of this typing approach requires a convenient
means where newly generated data can be cataloged and compared in
an internationally shared database.
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Methods: The establishment of a new Internet-accessible database freely
available at http://www.dru-typing.org/search.php.
Results: Based on the newly published nomenclature, the dru-typing.org
website allows investigators to enter user generated 40-bp repeat
sequences which are then searched against the current database of
dru repeats and identiﬁed, if known. Speciﬁc combinations of repeats
may also be queried against the database and, if recognized, the
resulting dru type will be identiﬁed. New dru repeat and/or dru type
chromatograms can be submitted online for veriﬁcation and inclusion
into the database. At present, the growing database contains 51 different
dru-repeat sequences and 137 dru types which can be downloaded for
off-line reference.
Conclusions: Dru-typing.org represents the ﬁrst freely-available
Internet-accessible database for collecting and harmonising dru-repeat
and dru-type sequences. The website provides an interface which should
assist in standardising and facilitating the use of dru typing as a tool in
the epidemiological and evolutionary analysis of MRSA strains.
P535 Stability of spa types from multiple MRSA isolates from the
same persons
K. Boye °, S. Rohde, H. Westh (Copenhagen, DK)
Objectives: Sequencing of the repeat region of the Staphylococcus
protein A gene (spa) has since 2003 been used in our department to
monitor outbreaks of MRSA, follow routes of transmission and study
the evolutionary relationship of MRSA. This typing system works well
on the MRSA population in Copenhagen (Bartels et al. 2007). The aim
of this study was to examine how often and how fast the spa region of
MRSA changes, both over time and from different body sites.
Methods: All MRSA isolates including duplicate isolates from the same
person, from 2004−7, in Copenhagen, were spa typed by PCR and
sequencing as previously described (Bartels et al. 2007).
Results: From 2004–2007 we received between two and 35 individual
MRSA samples from 335 individuals, a total of 1598 MRSA including
1263 duplicate isolates. 36% of the persons had two MRSA samples,
31% had more than ﬁve. One person contributed with 35 MRSA isolates.
66 spa types and 24 NTs were found in the 1598 isolates. spa types
occurred between one and 737 times (t024; 46% of all isolates). 41% of
the spa types were only seen one or two times.
26 persons (8%) exhibited more than one spa type. Seventeen (5%) had
MRSA with spa types that could evolve from each other, most often
by deletion or duplication of repeats. Nine had more than one MRSA
judged by the presence of very different spa types where the variation
could not be explained by mutational changes. No more than two spa
types were retrieved from one person. In eight of the 17 cases, both spa
types were found at the same time. In nine cases a period between 1
and 20 months passed between the occurrences of the two types (median
10 months). Often the most common spa type was recorded both before
and after the less common one.
Conclusions: The spa-repeat region is very stable over time. Only in
5% of the 335 persons actual evolution/change of spa type was found.
It did not seem to be a process af one spa type replacing another but
more likely the co-existence of spa type variants with a common origin.
Reference(s)
Bartels MD, Boye K, Rhod Larsen A, Skov R, Westh H (2007): Emerg
Infect Dis.13:1533−40.
P536 Clonal enrichment of integrated resistance plasmid-
containing Staphylococcus aureus in a burn centre associated
with persistent carriage among healthcare workers
M. Kooistra-Smid °, E. van Zanten, M.K. Nieuwenhuis, W.J.B. van
Wamel, S.V. Snijders, N. Lemmens-den Toom, W.H.M. Vogels,
G.I.J.M. Beerthuizen, A. van Belkum, H.A. Verbrugh (Groningen,
Rotterdam, NL)
Objectives: Burn wound surfaces are generally infected by S. aureus,
but the reservoirs and transmission routes remain to be elucidated.
The genetic population structure of serial S. aureus isolates obtained
from patients and healthcare workers (HCWs) in a burn centre was
investigated. We assessed the frequency of auto- versus exo-infection and
established a model describing import and local persistence of S. aureus
clones.
Methods: Three populations of S. aureus isolates were collected (2001–
2005) and typed by PFGE. Population I comprised 375 strains from
HCWs, Population II harboured 586 nosocomially acquired strains from
burn wounds. Population III involved 202 strains from patients at
admission. Comparative genome hybridisation (CGH) was performed
for endemic versus incidental S. aureus strains.
Results: The diversity index for Population III was signiﬁcantly higher
than those for Populations I and II. Three PFGE-types were clearly
endemic among HCWs and nosocomially acquired S. aureus strains.
CGH revealed that endemic strains possessed an integrated plasmid
encoding resistance to heavy metals.
Conclusion: Genetic diversity for S. aureus strains circulating in the
burn centre was lower than that of strains in the open community.
Apparently, endemic S. aureus clones have a superior potential to
colonise burns which may be associated with their heavy metal resistance
in an environment where silver and cerium containing antibiotics are the
most used.
P537 Spa versus phage typing – utility for analysing diverse MSSA
in the UK
M.J. Ellington °, S. Hashim, M. Ganner, B.D. Cookson, A.M. Kearns
(London, UK)
Objectives: For more than 30 years phage typing has been used to type
S. aureus. The method assays the pattern of phenotypic susceptibility
to a panel of S. aureus bacteriophages. In recent years genotypic, DNA
sequence based, spa typing has been adopted internationally. We aimed to
determine the correlation between spa typing and phage typing amongst
genetically diverse, disease associated, MSSA from around the UK.
Methods: Diverse S. aureus isolates (n = 170) from around England,
Wales and Northern Ireland, referred to the national Staphylococcus
Reference Unit from September 2006/7 were selected for testing based
upon their phage type at 100 x routine test dilution (RTD) and their toxin
gene proﬁle. Additional phage typing was carried at routine test dilution
(RTD) and DNA sequencing of spa amplicons was performed according
to Harmsen et al (2003). Phage types were assigned into groups II,
group 95, group 94/96 and mixed according to their phage susceptibility
proﬁles. Data was collated and analysed using BioNumerics software.
Results: The spa type correlated phage type for 132/170 (78%) S. aureus
isolates, and in 81% of cases individual spa types mapped to a single
phage-type. Phage-type could be correlated with spa inferred MLST
clonal complexes for 157/170 isolates, with at least 15 CCs represented
amongst the isolates. Isolates from phage group II belonged to CCs 15
or 121 in 79% of cases, 93% of phage group 94/96 isolates were CC25
or 152 and 10/11 (91%) phage type 95 isolates were CC45. Isolates
belonging to the “mixed” phage-type group were more genetically
diverse and comprised isolates from at least 8 different CCs including
CC1, 5, 8, 12, 30 and 59. Amongst 28 isolates that were non-phage
typeable, nine had spa types related to CC22 isolates of the same lineage
as the dominant MRSA strain in the UK (EMRSA-15). The remaining
19 non-phage typeable isolates were genetically diverse suggested by spa
typing and belonged to at least 8 different CC’s.
Conclusions: Amongst MSSA found in the UK, spa typing accurately
predicted phage-type in over three quarters of a panel of 170 diverse
isolates, and was able to predict the genetic relatedness and diversity
amongst phage non-typeable isolates. Marked associations between some
phage groups and MLST CCs was noted (CC15 and 121 with group II)
indicating the broad comparability of spa data with previously collected
phage data, for some phage groups at least.
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P538 Staphylococcus aureus genotypes in patients with cystic
ﬁbrosis
K. Semczuk °, K. Dzierzanowska-Fangrat, H. Dmenska,
D. Dzierzanowska (Warsaw, PL)
Objectives: The aims of this study were to determine: (a) identity of
S. aureus strains isolated from airways of cystic ﬁbrosis (CF) patients;
(b) S. aureus genotype typical for CF patients; (c) duration of airways
colonisation.
Methods: From 1998 through 2005 sputum and throat swabs were
collected 2−3 times a year from 33 CF patients (age range 6 months –
17 years). A total of 392 specimens were obtained (mean 12/patient).
Identiﬁcation and susceptibility testing were performed using standard
procedures. PFGE method with digestion with SmaI RE was used for
genotyping. Restriction proﬁles were analysed using Molecular Analyst
Fingerprinting Plus Programme.
Results: A total of 297 S. aureus isolates (mean 9/patient) that belonged
to 76 different genotypes were collected. Majority, i.e. 58 PFGE types
showed a tendency for persistent colonisation (3−8 years). Only 6% of
strains were isolated on a single occasion. In 27% of patients isolated
strains were identical during the whole study period. 12% of patients
were simultaneously colonised by 2 or 3 genotypes of S. aureus with
a predominance of a single genotype. In 9% of children a long-lasting
single genotype was replaced overtime by another persistent genotype. In
the remaining 52% of patients various S. aureus genotypes were isolated
on subsequent visits. MRSA strains were found in 9% of children. These
isolates belonged to 3 genotypes showing different susceptibility proﬁles.
Conclusions: The airways of CF patients can be simultaneously
colonised by a few genetically and phenotypically divergent S. aureus
strains capable of long-lasting persistence. No S. aureus genotype typical
for CF patients was found.
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P539 Measuring human immunodeﬁciency virus type 1 RNA
loads in dried blood spot specimens using NucliSENS EasyQ
HIV-1 v2.0
P. van Deursen °, A. Verhoeven, P. de Bie, L. Bertens, J. de Jong
(Boxtel, NL)
Background: The amount of HIV-1 RNA measured in plasma is one
of the key parameters for monitoring anti-viral treatment responses in
HIV-1 infected individuals. Accurate viral load measurement depends
strongly on sample stability. In remote areas, sample collection sites can
be located far from test sites, meaning that sample stability and thereby
accurate measurement of the clinical state of the treated individual is at
risk. To circumvent this possible risk, dried blood spot testing is proposed
as alternative for plasma testing. The NucliSENS easyQ HIV-1 v2.0 (in
development, bioMe´rieux) supports plasma and dried blood testing.
Objectives: The aim of this study is to establish the analytical sensitivity
and the linear range of quantiﬁcation for HIV-1 RNA detection in dried
blood spot specimens using NucliSENS EasyQ HIV-1 v2.0.
Methods: EDTA whole blood samples obtained from HIV-1 RNA
negative individuals were spiked with different amounts of HIV-1 (range
0−70,000,000 VQA copies/ml). Spots of 50ml were made on paper
(ProteinsaverTM 903® Card, Whatman) and dried 3−24 hours. Next, two
spots (0.1ml blood) were extracted with the NucliSENS EasyMAG and
analyzed with NucliSENS EasyQ HIV-1 v2.0 (including three batches) to
determine analytical sensitivity by applying Probit analyses, and accuracy
of quantiﬁcation as compared to 0.1ml plasma specimen processed in
parallel. In addition, robustness testing was performed with an HIV-1
input concentration three times above the established limit of detection
using three NucliSENS EasyMAG instruments, and on each instrument
129 samples were processed.
Results: The analytical sensitivity (95% detection rate) was 71 and
26 VQA copies/extraction for dried blood spot and plasma samples,
respectively. Excellent linear correlation (y = 1.00x − 0.05 with R2 = 0.99,
range 70−7,000,000 VQA copies/extraction) was found between DBS
and plasma measurements, for all three batches included. Robustness
testing at an HIV-1 RNA input concentration of 218 VQA copies resulted
in 100% detection, supporting the limit of detection as indicated above.
Conclusions: In this study, NucliSENS EasyQ HIV-1 v2.0 was
successfully validated for DBS specimen types, resulting in an analytical
sensitivity of 71 copies, and accurate quantiﬁcation in the range
70−7,000,000 copies. Next, additional clinical studies are required to
evaluate the new method for monitoring anti-viral therapy responses in
HIV-1 infected individuals.
P540 Measuring HIV-1 RNA stability in dried blood spot
specimens using NucliSENS EasyQ HIV-1 v2.0
P. van Deursen °, A. Verhoeven, P. de Bie, J. de Jong (Boxtel, NL)
Background: The amount of HIV-1 RNA measured in plasma is one
of the key parameters for monitoring anti-viral treatment responses in
HIV-1 infected individuals. Accurate viral load measurement depends
strongly on sample stability. In remote areas, sample collection sites can
be located far from test sites, meaning that sample stability and thereby
accurate measurement of the clinical state of the treated individual is at
risk. To circumvent this possible risk, dried blood spot (DBS) testing is
proposed as alternative for plasma testing.
Objectives: The aim of this study is to determine HIV-1 RNA stability
in DBS using different storage conditions.
Methods: A total of 5, 10, 4 and 5 EDTA whole blood samples obtained
from HIV-1 RNA negative individuals were spiked with HIV-1 RNA:
0 VQA cps/ml, 700 VQA cps/ml, 21,000 VQA cps/ml and 70,000 VQA
cps/ml, respectively. For these samples, 50ml spots were made on paper
(ProteinsaverTM 903® Card, Whatman) and dried 3−48 hours. Next
samples were stored at different temperatures (−20ºC, 5ºC, RT, 37ºC,
and 55ºC). Samples stored at 37ºC were subjected ﬁrst to shipment
simulation; 5 days 37ºC (of which 8 hours high humidity at 37ºC and
8 hours high humidity at 55ºC), 3 days 5ºC, 5 days −20ºC, 3 days
5ºC, and subsequently 5 days 37ºC (of which 8 hours high humidity at
37ºC and 8 hours high humidity at 55ºC). High humidity conditions were
tested at 37ºC and 55ºC. After storage HIV-1 RNA levels were measured
using two spots (0.1ml blood) and NucliSENS EasyQ HIV-1 v2.0.
Results: For the high input samples no or limited reduction in HIV-1
RNA levels (0.30 log10) was observed for all conditions tested with
one exception (6 weeks 37ºC at high humidity). For the low input
sample (70 VQA copies/extraction) the detection rate was 80% for
all conditions tested, with an overall detection rate of 244/250 (97.6%).
Sample stability was demonstrated for a period of 9 weeks at 37ºC (with
and without including shipment simulation), 3 weeks high humidity at
37ºC, 1 week high humidity at 55ºC, 3 weeks 4ºC, 1 week −20ºC, and
5 months room temperature.
Conclusion: HIV-1 RNA stability in DBS was demonstrated for several
conditions including 5 months room temperature, shipment simulation,
and storage at 37ºC for 9 weeks. Instability was observed after 6 weeks
37ºC high humidity. The results support the use of DBS specimen for
accurate viral load measurements after transport and storage when taken
these limitations into account.
P541 Multicentre evaluation of the Versant® HIV-1 RNA 1.0
Assay (kPCR) with the Versant™ kPCR molecular system
P. Taylor °, H. Mistry, P. Nutter, J. Yao, D. Schmidt, J. Kathrotiya,
J. Turczyn, L. Fisher, D. Maghakian (London, UK; Rochester, Berkeley,
US)
Objectives: The Siemens VERSANT®a HIV-1 RNA 1.0 Assay (kPCR)b
is a reverse transcription kinetic polymerase chain reaction (kPCR)
method for quantifying human immunodeﬁciency virus type 1 (HIV-1)
RNA in human plasma, using the VERSANT kPCR Molecular
System – a semi-automated system combining a fully automated sample
preparation module and a fully automated ampliﬁcation and detection
module. This study examined the performance characteristics of the
assay, and a method comparison was conducted between the VERSANT
HIV-1 RNA 1.0 Assay (kPCR) and the Abbott RealTime® HIV-1 assay.
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Methods: Assay performance characteristics were evaluated at three
laboratory sites, with each site using two VERSANT HIV-1 RNA 1.0
Assay (kPCR) kit lots and two instrument systems. Plasma samples
from 1,055 HIV-1 seronegative individuals were tested to assess assay
speciﬁcity. A 13-member dilution panel prepared from high titer HIV-1
8E5/LAV viral stock was used to determine precision, linearity, accuracy,
quantiﬁcation range and analytical sensitivity: panel members had HIV-1
RNA concentrations ranging from 10 to >11,000,000 copies/mL. The
method comparison between the VERSANT HIV-1 RNA 1.0 Assay
(kPCR) and the Abbott RealTime HIV-1 assay was conducted using
189 HIV-1 RNA-positive plasma samples that included HIV-1 Group M
subtypes A, B, C, D, F, G, H; circulating recombinant forms AE and AG;
and Group O variants. All samples possessed HIV-1 viral loads within
the common assay range of 75 to 10,000,000 copies/mL.
Results: The overall assay speciﬁcity was 99.7%. The limit of detection
(LoD) was 37 copies/mL: the lower limit of quantitation (LLoQ) was 37
copies/mL and the upper limit of quantitation (ULoQ) was 11,000,000
copies/mL. On average the VERSANT HIV-1 RNA 1.0 Assay (kPCR)
generated values that were 0.21 log copies/mL lower than the Abbott
RealTime HIV-1 assay. The Deming regression slope (ﬁtting VERSANT
log quantitation versus Abbott log quantitation) was 1.07.
Conclusions: The VERSANT HIV-1 RNA 1.0 Assay (kPCR) using the
VERSANT kPCR Molecular System is a reliable and accurate assay
for the quantiﬁcation of HIV-1 RNA in plasma from HIV-1 infected
individuals.
aVERSANT is a registered trademark of Siemens and all other
trademarks are the property of their respective owners.
bCE marked in Europe; not available in the US.
P542 Comparison of commonly used real-time PCR methods to
detect and quantify HIV-1 proviral DNA in infected patients
G. Rozera °, I. Abbate, A. Bruselles, B. Bartolini, G. D’Ofﬁzi,
E. Nicastri, C. Tommasi, M. Capobianchi (Rome, IT)
Objectives: Different PCR methods have been widely used to quantify
cell associated HIV-1 DNA. The clinical use of HIV-1 DNA may
be limited by the lack of an international standard to calibrate the
different methods. In addition, genetic variability of HIV-1 subtypes may
profoundly inﬂuence the accuracy of the assays. The aim of the study
was to evaluate three non commercial commonly used Real-time PCR to
quantify proviral HIV DNA in lymphomonocytes from infected patients.
Methods: Parallel evaluation with 3 assays to quantify HIV-1
DNA targeting pol, gag and LTR regions was performed in 93
lymphomonocytes from 43 patients. All the patients harboured HIV-1 B
subtype and were in the chronic phase. Twenty-three patients were
successfully treated with HAART and underwent CD4-guided treatment
interruption; the remaining 20 patients included subjects with virological
failure because of multiple-drugs resistant HIV strains. An additional
real-time PCR targeting a cellular gene (hTERT) was done to refer
the HIV-1 DNA copies to 1 million lymphomonocytes. Full-length
sequencing of the virus present in a representative patient was performed
by massive parallel pyrosequencing (GS-FLX platform, Roche).
Results: A statistically signiﬁcant difference between the mean values
of HIV-1 DNA in clinical samples obtained by pol, gag and LTR real-
time PCR was observed. Only the LTR-targeting PCR was able to detect
HIV-1 DNA in all the samples from all the patients, with a number
of copies always at least 1 Log higher than that obtained by the two
other methods. A stronger correlation between viraemia (HIV-1 RNA)
and proviral load was found when HIV-1 DNA was measured with LTR
real-time PCR as compared to pol real-time PCR, while the correlation
was not signiﬁcant with gag real-time PCR. Full-length sequencing of the
virus, present in a representative patient, clearly showed the simultaneous
presence of multiple mismatches in the primers and probes of pol real-
time PCR. Conversely, only 1 mismatch was observed in one of the
primers of gag real-time PCR.
Conclusions: The data strongly suggest that HIV-1 DNA quantiﬁcation
may be very different, depending on the genome target region. The
possible use of HIV-1 DNA as a marker to predict disease progression
and treatment outcome in infected patients depends on standardisation
of the laboratory methods to minimise variability in genome recognition
by the different molecular tools.
P543 HIV and HBV mutations in co-infected patients treated with
lamivudine
L. Manolescu °, C. Sultana, A. Temereanca, C. Vagu, C. Grancea,
S. Ruta (Bucharest, RO)
Objective: Hepatitis B virus (HBV) mutations conveying resistance
to antiviral drugs are a major problem in the treatment of chronic
hepatitis B. Information available on the prevalence and distribution
of distinct HBV variants in HIV positive patients is scarce. Our aim
was to investigate the frequency of mutations and variables potentially
associated with an increased risk of liver disease evolution in HIV/HBV
co infected individuals that have fail antiretroviral treatment.
Methods: For HBV genotype was determined using commercial Line
Probe Assay (Innogenetics) and detection of hepatitis B virus mutations
conveying resistance to lamivudine (LAM) was performed with INNO-
LiPA HBV DR v2 (Innogenetics NV, Ghent, Belgium).
For HIV we sequenced the HIV pol gene with Trugene genotyping
kits (Bayer Diagnostics Inc.), and for HIV subtyping purposes, all the
nucleotide sequences were submitted to the Stanford database.
Results: We evaluated 9 patients, aged 20±1 years, HIV-HBV co-
infected that have been treated with antiretroviral therapy including
LAM for an average of 3.8±3years. HIV and HBV were parenterally
acquired during childhood. The patients had no clinical signs of hepatitis.
Median CD4 count was 143.6cells/mmc (range 8–490); median HIV
ARN was 380278.5 copies/ml plasma (range 38000–1020000). We found
a positive correlation between HBV-DNA and HIV-RNA in plasma
(r = 0.6, p< 0.001). All patients were infected with the HIV F1 subtype,
while HBV genotype was A. Patients had no HDV co-infection.
Analysing resistance to LAM in HIV viral strain we noticed that
6 patients had a high degree of resistance. The most common mutation
in the RT gene was M184V/I that causes high-level in vitro resistance to
LAM, but also confers a diminished HIV replicative ﬁtness, associated
with type 2 TAMs: D67N, K70R, T215F, and K219Q/E.
In HBV viral strain the most frequent mutation were: 11-L180/A181 in
8 patients; 18 M204 in 7 patients; 26-N236 in 7 patients; 15M180/A181
in 4 patients; 20-V204 in 4 patients; 20-V204 in 3 patients; 12L181/T181
in 2 patients. 55.5% of the patients were HBeAg positive with
signiﬁcantly more frequent LAM resistance mutations.
Conclusions: Comparing the frequency of mutations conveying resis-
tance to LAM in 2 different viruses reveals a greater variety in HBV
than HIV viral strain in spite of the absence of clinical signs of hepatitis
and virologic failure toward HIV treatment. The presence of HBeAg
may be a determinant of LAM resistant mutants.
P544 Human papillomavirus prevalence and type distribution in
women before the introduction of vaccination in Italy
L. Barzon, V. Militello, S. Pagni, C. Mengoli, G. Palu` ° (Padua, IT)
Objective: Knowledge about the prevalence of human papillomavirus
(HPV) on a population level is important to assess the potential impact
of HPV vaccines. Aim of this study was to determine the baseline
prevalence and type-speciﬁc distribution of HPV in women from the
Northeast of Italy prior to the introduction of HPV vaccination.
Methods: Population-based study of prevalent type-speciﬁc HPV
infection in consecutive women undergoing HPV testing at our
Institution for cervical cancer screening program or opportunistic
screening in the 5 year period from January 2004 to December 2008.
HPV DNA was detected in cervical samples by MY09/MY11 and
GP5+/GP6+-based PCR and genotyped by sequencing.
Results: Cervical samples from 2,978 women were analyzed:
1,153 (38.7%) tested positive for HPV DNA, 200 of which could
not be genotyped because of the presence of multiple infections or
low HPV DNA load. In the remaining samples, sequencing allowed to
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identify 52 different HPV types, among which HPV-16 was by far the
most commonly detected (6.2% of all specimens), followed by HPV-6
(2.6%) and HPV-66, HPV-58, and HPV-53 (2.3% each). HPV-18 was
detected in 0.6% of samples and HPV-11 in 0.3%. Overall, high-risk
HPV types accounted for 42.6% of detected HPVs, probably high-
risk HPVs for 16.6%, low-risk HPVs for 22.2%, and undetermined-risk
HPVs for 18.6%. Pap cytology results were available for a subgroup
of 1,088 women: 31% with a negative Pap test, 27% with ASC-US,
39% with LSIL, and 2% with HSIL or ASC-H. Prevalence of HPV
DNA detection increased with severity of cytology, from 39% in negative
samples to 100% in HSIL. HPV-16 and/or HPV-18 were present in 7%
of normal cytology samples, in 5.7% of ASC-US, in 6.3% of LSIL, and
in 27% of HSIL/ASC-H. Among high-risk HPVs, HPV-58 and HPV-31
were the most commonly identiﬁed types in high-grade lesions, besides
HPV-16. Classiﬁcation of HPVs into species showed that species 9 was
the most represented (37% overall; 56% in HSIL), followed by species
3 (19%) and 6 (16%). Species 7, which includes HPV-18 and HPV-45
among other HPVs, was poorly represented in our population.
Conclusions: These data provide knowledge about the prevalence and
type distribution of HPV in the Northeast of Italy and indicate that
HPV-16/18 VLP vaccination is expected to reduce the burden of HSIL.
Development of enhanced VLP vaccines with larger type coverage
should take into consideration HPV epidemiological data.
P545 Prevalence and type speciﬁc papillomavirus load in female
anal infection
A. Pierangeli °, C. Scagnolari, A.M. Degener, M.L. Ferreri, M. Bucci,
E. Riva, M. Indinnimeo, A. Fiore, G. D’Ettorre, V. Vullo, G. Antonelli
(Rome, IT)
Objectives: HPV persistence and progression has been recognized as
strongly associated to anal as well as to cervical carcinoma; however,
epidemiologic data have shown no reduction in the incidence of anal
cancer so far, probably due to an increase in high-risk sexual behaviours.
Besides high-risk groups, HPV infection in the anal canal occurs in
immuno-competent individuals even in the absence of anal intercourse.
To date, the role of HPV-type speciﬁc infection in anal lesions in women
have been addressed in a few studies. Hence, the aim of this study was to
monitor female anal infection, in terms of prevalence of HPV genotypes
and type-speciﬁc viral load.
Methods: The presence of speciﬁc HPV genotypes in anal and cervical
brushings was determined by two different PCR assays followed by
sequencing, a method that allows the identiﬁcation of a wide range of
HPV types. Type-speciﬁc viral load was measured using a quantitative
real-time PCR ﬂuorogenic assay with TaqMan probes and primers
designed for 14 HPV genotypes in the E6 genomic region.
Results: Anal brushings were collected from 12 HIV-positive and 40
HIV-negative women attending a proctology clinic. The prevalence of
high-risk HPVs in anal samples were higher than in cervical samples
(67% vs. 25%). HPV genotypes detected in anal samples were: HPV 16
(4 cases), HPV 6 (3 cases), HPV 31 and HPV 53 (2 cases each), and
HPVs 62, 66, 74 and 84 (1 case each). Considering the women for whom
anal and cervical cells were concurrently obtained, anal HPV was more
common than cervical HPV in HIV-positive (63% vs. 37%) women;
conversely, only about 10% of HIV-negative women harboured anal HPV
infection vs. 37% of cervical HPV infection. The simultaneous presence
of the same genotype occurred only in 2 out of 8 HPV positive women
with both anal and cervical samples. The analysis of the association
between grade of lesions, immune status and HPV load is in progress.
Conclusion: Our study conﬁrmed the high prevalence of HPV anal
infection in HIV-positive female patients. The distribution of high-risk
HPVs in anal samples supported the need to develop HPV screening
programs in anal brushings.
P546 Inter-laboratory reproducibility and precision of the Roche
prototype Cobas® 4800 human papillomavirus test
A. Johnson °, P. Halfon, H. Khiri, D. Riggio, M.T. Sandri, M. Krevolin
(Pleasanton, US; Marseille, FR; Milan, IT)
Background: The prototype cobas® 4800 is a highly automated system
that performs sample preparation, real-time HR-HPV ampliﬁcation and
simultaneous detection of 12 HR-HPV genotypes in a single pool, with
separate detection of HPV16, HPV18, as well as the human beta globin
gene, all in single tube. Reproducible run to run and system to system
performance is demonstrated using a multi-level PreservCyt panel with
HPV high risk genotypes 16 and 18.
Methods: A six level reproducibility panel was prepared in PreservCyt
media containing puriﬁed plasmid DNA with the cloned HPV genotype
39 target site, SiHa cells (HPV genotype 16), HeLa cells (HPV genotype
18) and HCT-15 cells (source for the Beta-globin gene). The panel levels
ranged from zero to titers seen in HPV-infected clinical specimens. Each
of the three study sites performed multiple panel runs on the cobas
4800 system, where each run totaled 84 assays (14 replicates of each
of 6 levels) plus a set of positive and negative controls. Reproducibility
and precision were assessed with a linear mixed effects model, while
sensitivity to the HPV titer was assessed using binomial regression.
Results: Comparable quality and technical precision were observed
among all three participating laboratories for clinically relevant
concentrations of HPV. For all runs, the positive and negative controls
for the plate (one of each per plate) produced the correct results. No
false positives were observed in any replicate.
Conclusion: The prototype cobas® 4800 HPV test system shows good
between-lab reproducibility and within-run precision for both HPV16
and HPV18.
P547 Epstein-Barr virus 30 bp deletion variant of LMP-1 gene in
paediatric liver transplant recipients and its association with
clinical course
B. Kasztelewicz °, M. Nowak, I. Jankowska, J. Pawlowska, P. Kalicinski,
M. Pronicki, K. Dzierzanowska-Fangrat (Warsaw, PL)
Objectives: Paediatric liver transplant (LTx) patients (pts) are at partic-
ular risk for developing EBV related post-transplant lymphoproliferative
disorders (PTLD) following administration of immunosuppressive
therapy. LMP-1 is the main oncogene of Epstein-Barr virus. Wild type
(wt) and 30 bp deletion variants of LMP-1 gene (30 del LMP-1) have
been shown to differ in their molecular and biological properties (the
latter being considered as more tumorigenic and less immunogenic).
The aim of the study was to evaluate the relationship between these
two LMP-1 variants and EBV DNA loads, response to reduction of
immunosuppression (RIS), and PTLD development in paediatric LTx
pts.
Methods: 67 pts after LTx were included in this study. Median
age at LTx was 1.25 y (0.2−14.3 ys). The study involved 6 pts
with histologically conﬁrmed PTLD. Primary immunosuppression was
tacrolimus (FK-506) plus mycophenolate mofetil (MMF) in 24 pts, FK-
506 plus prednisone in 30 pts, 13 pts followed others schemes of IS
according to established protocol for paediatric LTx. LMP-1 variants
were detected in blood of 65 EBV DNA positive pts by PCR using
primers ﬂanking the site of characteristic 30 bp deletion. 40 pts have
had EBV DNA load monitored using real-time quantitative PCR method.
The results were reported as EBV DNA copies/ug PBMC DNA. High
viral load pts (HVL pt; EBV DNA >2000 copies) received RIS with
antiviral medications.
Results: The wt LMP-1 was detected in 52/65 (80%) pts, including
4 PTLD pts, whilst 30 del LMP-1 variant was detected in blood of
11/65 (17%) pts, including 2 PTLD pts. Both wt and 30-del LMP-1
were detected in blood of 2 (3%) pts. 13/40 pts had low viral load
(median 675 copies). 27/40 pts received RIS plus antivirals due to high
EBV DNA load (median = 40 421 copies). Statistical analysis showed
no signiﬁcant difference between LMP-1 variants and EBV DNA load
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(Mann-Whitney test, p = 0.56) and no correlation between LMP-1 variant
and PTLD development (Chi square, p = 0.62). Interestingly, signiﬁcantly
slower decrease in EBV DNA load in response to RIS was found in pts
with 30 del LMP-1 variant (Mann-Whitney test, p = 0.016; median 15.05
vs. 2.87 months for pts with 30 del and wt LMP-1, respectively).
Conclusion: The presence of 30 bp deleted LMP-1 variant, may
determine outcome of EBV infected immune-suppressed paediatric LTx
pts, such as response to treatment.
P548 Novel mutation (A427S) in the CMV UL97 gene associated
with resistance to ganciclovir
A. Anton, V. Dimova, T. Pumarola, C. Cervera, L. Linares, A. Moreno,
F. Cofan, M.T. Jimenez de Anta, M.A. Marcos ° (Barcelona, ES)
Introduction: Cytomegalovirus (CMV) infection is the leading viral
cause of morbidity and mortality in kidney transplant recipients.
Mutations in the CMV UL97 gene product, which confer ganciclovir
(GCV) resistance, are well known but some unusual sequence changes
observed in specimens from treated subjects remain uncharacterised.
Patient and Methods: We report a male who underwent a kidney
transplant (D+/R+) and where we detected on posttransplant day 111
a CMV resistant strain to GCV, after treatment for 5 weeks. The
patient was monitored for CMV infection after transplantation by CMV
antigenaemia and viral load. When antiviral resistance was suspected,
mutation screening by PCR sequencing of CMV UL97 and UL54 was
performed from plasma samples. The ampliﬁed regions included almost
all of the known resistance mutations. Derived sequences of each isolate
were aligned with the strain AD169 reference sequence and amino acid
differences were compared with previously published.
Results and Conclusions: Nucleotide sequence of the UL54 and UL97
of the clinical isolate showed 5 amino acid substitutions (N685S, S655L,
N898D, S897L and A885T) in UL54, which were polymorphisms as
already described, and 5 mutations (A427S, C428M, I429H, D430A,
Y432N) in UL97. To our knowledge these mutations in UL97 of
unknown signiﬁcance have not been described yet. The codon 427 is
outside the region with well-known mutations (codons 460, 520, and
590–607) related to GCV resistance. A change in the codon 427 (A427V)
was already reported and phenotyped in a BAC recombination system
as GCV sensitive (Martin M et al, 2006). In case we had been able
to isolate this strain, the sensitivity test to GCV by phenotyping assay
would have been interesting. As we did not detect these UL97 mutations
from samples collected just in the beginning of the GCV treatment,
we think that these may be associated with resistance to GCV. The
antiviral treatment in this patient was changed to foscarnet with good
virological response. Deﬁnitive conclusions about the role that such
mutations play would require a marker transfer of the mutated UL97
region in a known susceptible CMV strain and the corresponding IC50
value by recombinant phenotyping to know their role in drug resistance.
P549 Development of a quantitative real-time HHV-6-PCR:
comparison of the results to qualitative “in-house” PCR
and commercial quantitative PCR Argene CMV, HHV6,7,8
R-geneTM kit
R. Loginov °, L. Mannonen, T. Karlsson, M. Lappalainen,
I. Lautenschlager (Helsinki, FI)
Objectives: Human herpesvirus 6 (HHV-6) is a ubiquitous virus.
Primary HHV-6 infection occurs early in childhood causing exanthema
subitum. Neurological symptoms are sometimes seen. The virus may
also reactivate later, especially in immunosuppressed tranplant patients.
The objective of this study was to develop a quantitative assay for the
detection of HHV-6 genome.
Methods: The quantitative real-time HHV-6 PCR assay was developed
using TaqMan chemistry and two automated sample preparation systems
MagNa Pure LC and EasyMag. The assay ampliﬁes a sequence of viral
U67 gene detecting both HHV-6A and HHV-6B variants. The designed
assay was compared to in house qualitative HHV-6 PCR test and to com-
mercial quantitative Argene CMV, HHV6,7,8 R-gene kit. The clinical
material of 127 whole blood specimens and 57 cerebrospinal ﬂuid spec-
imens, mostly from paediatric patients, were tested using these two quan-
titative real-time PCR methods and the qualitative PCR test in parallel.
Results: From the whole blood samples 50 were positive and 77 were
negative and from cerebrospinal ﬂuid samples 12 were positive and 45
were negative by the qualitative “in house” HHV-6 PCR test. When the
qualitative “in-house” HHV-6 PCR test was used as a “golden standard”
the sensitivities of the quantitative HHV-6 PCR tests for whole blood
samples were 86% for “in-house” TaqMan test and 76% for Argene’s
test and speciﬁcities were 96% and 92% respectively. For cerebrospinal
ﬂuid samples the sensitivities were 92% for “in-house” TaqMan test and
80% for Argene’s test and speciﬁcities were 98% and 82% respectively.
The samples that were in disagreement between the 3 tests contained
very low levels of HHV-6 DNA. The reproducibility of the “in-house”
TaqMan test (including DNA isolation) was good: CV% 25.5 (n = 5,
mean value 23000 copies/ml) and comparable to that of Argene’s test:
CV% 18 (n = 5, mean value 10800 copies/ml). The correlation of viral
loads between two quantitative tests was good (R = 0.95).
Conclusions: The “in-house” quantitative HHV-6 real-time TaqMan
assay correlated well with the in house qualitative PCR test and
commercial quantitative Argene CMV, HHV-6,7,8 R-Gene test. The
newly developed test can be used for the diagnosis of HHV-6 infection
in whole blood and cerebrospinal ﬂuid, as well as monitoring of viral
load in whole blood.
P550 Quantiﬁcation and typing of herpes simplex virus type 1
and 2 in cerebrospinal ﬂuid by Taqman and Sybergreen
real-time PCR assays for HSV encephalitis diagnosis
A. Pivert, H. Le Guillou-Guillemette, A. Ducancelle, F. Lunel-Fabiani °
(Angers, FR)
Objectives: Different methods are currently available to detect Herpes
Simplex Virus (HSV) in various clinical samples (cerebrospinal ﬂuid
(CSF), mucocutaneous samples). The real time PCR is now considered as
a reference for the diagnosis of encephalitis, due to the poor sensitivity of
the viral detection by the culture of CSF. Our objective was to provide a
useful strategy for the diagnosis of HSV encephalitis in a routine labora-
tory. These assays allow quantiﬁcation and genotyping of the viral strain.
Methods: Two new real time PCR based-assays were developed to
quantify and genotype the HSV DNA in CSF samples. The ﬁrst assay
was based on Taqman® technology with primers and probe deﬁned in
the polymerase HSV gene. We used as quantiﬁed standard a plasmid
containing the target sequence within the HSV polymerase gene. This
standard was used to generate a standard curve. A PCR targeting the
GAPDH gene was simultaneously performed and used as an internal
control. HSV strain was retrospectively genotyped with an original real
time PCR assay using SYBR®-Green technology (samples conserved at
−20ºC). Two pairs of primers allowing the ampliﬁcation of a 142pb
(HSV1) and a 82pb (HSV2) targeting two adjoining regions in the
polymerase gene were used. The perfect complementarity in the 3′ end
of the primer and the template was needed to initiate the transcription.
Discrimination of the two HSV genotypes was ﬁnally performed by the
analysis of the melting curves: each PCR product provided a speciﬁc
melting temperature (84.75ºC and 84.75ºC respectively). To assess these
methods, we screened 708 CSF samples collected in patients with a
suspicion of HSV encephalitis, between 2003 and 2007.
Results: Among them, we detected and/or quantiﬁed HSV in 20 samples
(3%) from 12 patients. The mean viral load, calculated with the
ﬁrst positive sample of each patient, was 5.66 log cop/ml (2.65
to 10 log cop/ml). Genotyping PCR was performed in 11 patients:
7 encephalitis were caused by HSV 1 and 2 by HSV 2. Two patients’
samples were not detectable with this assay: a problem of sample
conservation was suspected. CSF sample of the last positive patient was
no longer available.
Conclusion: Our assays allowed rapid quantiﬁcation and genotyping
of the circulating HSV if present in CSF. These parameters may be
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essential for the follow-up of treatment by acyclovir, and to understand
the pathogenesis of the infection.
P551 Interest of the PCR in the diagnosis of herpes simplex virus
oesophagitis
N. Leveque °, E. Frobert, R. Guedec, A. Lukaszewiez, H. Brixi
Benmansour, L. Andre´oletti, V. Brodard, M.D. Diebold (Reims, Lyon, FR)
Objective: Type 1 Herpes Simplex virus is the second infectious
aetiological cause of oesophagitis after Candida albicans. HSV1
oesophagitis generally occurs in immunocompromised patient causing
odynophagia, retrosternal pain or dysphagia. Its current diagnosis
consists in the histological examination of oesophageal lesions sampled
during the endoscopy. The potential advantage of the HSV1 speciﬁc PCR
assay in the diagnosis strategy of the herpetic oesophagitis remains to
be assessed.
Patients and Methods: Nineteen biopsies demonstrating an evocative
histological aspect of herpetic oesophagitis (presence of plurinuclear
squamous cells with vitreous aspect of the nuclei) conﬁrmed by speciﬁc
immunohistochemical assay using an anti-HSV1 antibody (Dako®), and
seventeen biopsies of oesophagitis without any histological proof of
herpetic infection were retrospectively selected. After the dewaxing
phase, DNA was extracted using DNA Blood kit (Qiagen®) and was
then quantiﬁed using a spectrophotometer. A qualitative GAPDH DNA
PCR was performed in order to check the good quality of the DNA
extracts and the absence of PCR inhibitors before testing the samples
by “Herpes consensus” kit (Arge`ne®) for a qualitative detection of HSV
DNA. For each HSV1 positive sample, HSV1 viral load levels were
measured by in-house real time PCR system and expressed by the results
were expressed as the number of HSV DNA copies/mg of extracted DNA
(Frobert and Al, Antiviral Res., 2008).
Results: Eighteen of the nineteen HSV1 oesophagitis histologically
proven were conﬁrmed by the HSV1 speciﬁc PCR displaying a number
of genomic DNA copies ranging from 11 to 3.42×106 per mg of extracted
DNA. Two negative biopsies by histological examination were tested
positive by PCR. Their measured viral loads were respectively of 197
and 146 copies/mg of extracted DNA.
Conclusion: These preliminary data indicated a good correlation
between the histological and the virological molecular diagnosis of
HSV1-induced oesophagitis. The quantiﬁcation of HSV1-DNA in
oesophageal biopsies with a histological positive diagnosis may allow
establishing a viral load threshold, estimated here at 1000 copies of
genome/mg of extracted DNA, beyond which an aetiological diagnosis
of herpetic oesophagitis could be performed even in the absence of
histological evidence. However, the threshold of HSV-DNA load levels
remains to be assessed in further larger prospective studies.
P552 Evaluation of real-time PCR in the detection and
management of herpes viruses infections in ulcerative colitis
and oesophagitis
M. Pape °, K. Mandraveli, S. Dionysopoulou, D. Papadopoulou,
O. Giouleme, A. Gatzarou, F. Frantzidou (Thessaloniki, GR)
Objective: The aim of this study was to evaluate the advantages of
Real-time PCR for early detection and management of virus infection
of the herpes group (CMV/EBV/HSV) in ulcerative colitis (UC) and
oesophagitis (ES).
Methods: 10 patients were included in this study: 8 patients, (7 men/1
woman) with UC (treated with steroids) and 2 patients with ES (1 man
with a pre-existing history of ES/1 woman with no previous history
of upper gastrointestinal complaints) admitted to the gastroenterology
clinics of AHEPA University Hospital. Endoscopic examination was
performed either at the time of admission or during follow up. Biopsy
specimens obtained from the identiﬁed ulcers were submitted for
histological evaluation for observation of viral inclusions (VI) and
processed with Real-time PCR to detect CMV/HSV (artus LC, QIAGEN)
and EBV (LC EBV, Roche) viral load. Whole blood specimens were
processed with Real-time PCR for the referring viruses and sera were
tested for anti-CMV/EBV/HSV IgG/IgM antibodies using the ELISA
assay.
Results: Serological tests exlcuded primary infection or reactivation. In
blood specimens no CMV, EBV or HSV viral load was detected. CMV
and EBV DNA was detected only in tissue samples (5/8 UC, 2/2 ES).
The virus combinations in UC were: EBV [1 man – 6.9×101 copies/ml,
VI(+)], CMV [1 man – 1.2×105 copies/ml, VI(−)], EBV+CMV [1 man –
3.3×105 + 3.1×106 copies/ml VI(−)/1 man – 2.2×101 + 4.9×103
copies/ml VI (+)/1 woman 2.4×104 + 1.1×103 copies/ml VI(+)]. In two
patients no viral load or viral inclusions were detected. In one patient,
although the histological examination showed speciﬁc features of virus
infection, including inclusions, hyperchromaticity and atypical mitoses
no viral load was detected. The results in ES were: EBV [1 man –
2.5×103 copies/ml (VI+) – 1 woman – 1.6×103 copies/ml (VI+)]The
patients were started on antiviral treatment with good resolution of
the symptomatology. Follow-up endoscopic examination showed a clear
improvement. PCR on biopsy materials was once more performed, but
no viral genome could be detected.
Conclusions: This study emphasizes the possible role of herpes
viruses in the pathogenesis or in reactivation of ulcerative colitis and
oesophagitis. The perfomance of two different diagnostic techniques
(histological examination/PCR) seems to optimise the speciﬁc diagnosis
and leads to an appropriate therapy.
P553 The role of microRNAs in hantavirus infections
J. Klein °, P. Sætrom, M. Berdal (Trondheim, NO)
Members of the genus hantavirus (Family Bunyaviridae) cause serious
and often fatal human diseases, as haemorrhagic fever with renal
syndrome (HFRS) in Eurasia and hantavirus pulmonary syndrome (HPS)
in America. Furthermore, in Fennoscandinavia, Puumala virus (PUUV)
causes nephropathia epidemica (NE), a mild form of HFRS.
No approved vaccine exists and therapy of hantavirus infections is mainly
supportive. Except for ribavirin, which causes adverse side-effects, no
potential antiviral drug has been reported to show efﬁcacy in animal
models. Thus, the development of new therapy approaches is important.
In recent years microRNAs, single stranded short RNA molecules that
silence the expression of genes, have demonstrated their potential in
ﬁghting virus infections in eukaryotic cells.
We use PUUV as a model to elucidate the role of microRNAs in
hantavirus infections to identify potential therapeutic targets. Already
before the discovery of the miRNA pathway in 2001, it has been shown
that plants use RNA interference as antiviral defence. Even if miRNAs
are mainly involved in the natural regulation of gene expression in
vertebrates, they play although a role in antiviral defence, viral tropism,
latency and virus induced oncogenesis. Methods
miRNAs aberrantly expressed during viral infection.
a. Global expression analysis is performed using microarry technology
and validated by real time PCR.
b. Bioinformatics tools are used to identify potential targets for
aberrantly expressed miRNAs and are validated in infection assays
by over-expressing or depleting miRNAs.
We will present the results of this work during the meeting.
P554 Hantaviruses in Microtus fortis and Microtus maximowiczii
in far-eastern Russia
L. Yashina, N. Zdanovskaya °, L. Ivanov, R. Slonova, G. Kompanets,
J. Hay, R. Yanagihara (Koltsovo, Khabarovsk, Vladivostok, RU; Buffalo,
Honolulu, US)
Background: The reed vole Microtus fortis has the highest prevalence
of hantaviral antigen among rodent species in the Far East of Russia.
Previous studies demonstrated two distinct hantaviruses, Khabarovsk
virus (KHAV) and Vladivostok virus (VLAV), in M. fortis. Since each
genotype of rodent-borne hantavirus appears to be primarily associated
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with one speciﬁc rodent host, there may be another principal host of
KHAV or VLAV.
Methods: Microtus-associated hantaviruses circulating in Khabarovsk,
Amursk and Primorsky regions of far-eastern Russia were analyzed
by RT-PCR. Taxonomic identiﬁcation of rodent hosts was based on
phylogenetic analysis of partial cytochrome b gene.
Results: Of 17 hantavirus antigen- or antibody-positive Microtus sp.,
partial L-, M- and S-segment sequences were detected by RT-PCR in four
M. fortis and in four M. maximowiczii. Hantavirus sequences recovered
from M. maximowiczii captured in the Amursk region and from M. fortis
captured in the Amursk and Primorsky regions resembled KHAV and
VLAV, resepectively. Alignment and comparison of nucleotide sequences
showed an intra-strain difference up to 14% for KHAV and up to 9% for
VLAV. Phylogenetic analysis, based on partial M-segment sequences,
showed that hantavirus sequences ampliﬁed from M. maximowiczii
clustered with KHAV Mf43 and Topografov virus (TOPV) carried by
Lemmus sibiricus. Also, the hantavirus detected in M. fortis clustered
with VLAV.
Conclusions: Our data demonstrate the co-circulation of KHAV and
VLAV in the Amursk region of far-eastern Russia. Also, our results
indicate thatM. maximowiczii is the reservoir host of KHAV and conﬁrm
that M. fortis is the natural host of VLAV.
P555 Seewis virus: genetic diversity of a soricid-born hantavirus
in Siberia, Russia
L. Yashina °, S. Abramov, V. Gutorov, T. Dupal, G. Danchinova,
V. Panov, J. Hay, R. Yanagihara (Koltsovo, Novosibirsk, Irkutsk, RU;
Buffalo, Honolulu, US)
Background: Hantaviral antigens were reported more than 20 years ago
in tissues of the Eurasian common shrew (Sorex araneus), medium shrew
(S. caecutiens) and pygmy shrew (S. minutus), captured in European and
Siberian Russia. Recently, a phylogenetically distinct hantavirus, named
Seewis virus (SWSV), has been identiﬁed in Sorex araneus captured
in Switzerland, Hungary and Finland. The Eurasian common shrew is
among the most widely dispersed small mammals species in Eurasia,
spanning from Europe to Siberia.
Methods: To further clarify the geographic distribution and genetic
diversity of SWSV and other hantaviruses harboured by shrews, lung
tissues from 29 Sorex araneus, 11 S. tundrensis, six S. minutus and six
Sorex sp., captured throughout Western and Eastern Siberia (Teletskoye
Lake, Karasuk, Irkutsk and Novosibirsk) in 2007–2008, were analyzed
by RT-PCR. To verify the taxonomic identity of the hantavirus-infected
shrews, the cytochrome b gene of mtDNA was ampliﬁed by PCR.
Results: Hantavirus L- and S-segment sequences were detected in seven
S. araneus, two S. tundrensis, and one S. daphaenodon. Overall, the
sequences appeared to be genetic variants of SWSV, differing from the
prototype mp70 strain from Switzerland by 16−20% at the nucleotide
level and 0−2% at the amino acid level. Alignment and comparison of
nucleotide and amino acid sequences showed an intra-strain difference of
1−9% and 0−2% for the L-segment and 0−8% and 2% for the S-segment,
respectively. Phylogenetic analysis, based on 353- and 837-nucleotides
of the L and S segments, showed geographic-speciﬁc clustering of
SWSV strains. At the same time, at one of the sites SWSV strains
from S. araneus showed two separate lineages within the SWSV group.
Conclusions: The detection of SWSV in S. araneus, S. tundrensis and
S. daphaenodon in widely separated geographic localities in Siberia
demonstrates the vast distribution of SWSV among different but closely
related Sorex species. Whether this is a consequence of cross-species
virus transmission or co-divergence is unclear. Also, to what extent other
sympatric shrews are infected with SWSV warrants further investigation.
P556 One tube RT-PCR for Chikungunya and Dengue, including
Dengue serotype, with bead-bound probes in a liquid array
detected on a Luminex instrument
M. Inoue, T. Barkham °, L.C. Ng (Singapore, SG)
Objective: In Singapore dengue is endemic while chikungunya (CK)
is emerging. Repeated imported cases led in several outbreaks and
over 650 notiﬁed cases in 2008. The two illnesses are difﬁcult to
distinguish clinically. Dengue’s primary vector is Aedes aegypti, a
mosquito species that prefers to dwell indoors. CK can be spread by
Ae. aegypti and Ae. albopictus. The latter prefers to dwell outdoors so
control strategies differ. To support outbreak control with directed vector
control management it is desirable to look for CK in clinically compatible
cases. We evaluated a multiplex RT-PCR assay that detects both viruses,
and also the dengue serotype, in one tube.
Methods: RNA extracted with the EasyMag system from sera submitted
for clinical PCR were retrieved from frozen storage and re-tested with
the test RT-PCR system. RT-PCR in one tube was performed with the
Qiagen one step RT-PCR reagent. PCR products were detected on a
Luminex instrument after hybridisation with bead bound probes speciﬁc
for CK and the four Dengue serotypes. Results were compared with
the routine singleplex Dengue (SYBR green method on a Light Cycler)
and CK (Taqman probe on a Lightcycler) RT-PCR methods. A blinded
series with two sera of each serotype were prepared from cultured dengue
viruses and used to assess serotype speciﬁcity.
Results: Of 65 CK samples, the test system correctly identiﬁed 63: two
were reported as ‘nil’ and had ct values of 39 with the Taqman singleplex
assay. Of 14 Dengue samples, the test system correctly identiﬁed 14.
Of 115 ‘Nil’ samples, the test system correctly identiﬁed 113 as ‘nil’
but detected two as CK. These came from patients with clinically or
laboratory deﬁned CK. All 8 of the ‘blinded’ series were correctly
serotyped to Dengue serotypes 1, 2, 3 or 4.
Conclusion: The multiplex test system’s performance was equivalent
to the existing singleplex methods and contributed extra information in
terms of the dengue serotype data. The cost, including labour, was half
that of running the two separate existing assays for the two target viruses.
The run time is half a working day. In areas where both of these viruses
circulate combined assays that perform as well as this system may be
a sensible step forwards in routine diagnostics and reveal CK in cases
when it may not have been clinically suspected.
P557 Limited yield of multiplex PCR in adults with acute
pneumonia
T. Barkham ° (Singapore, SG)
Objectives: Most inpatients with a pneumonic illness are cared for in
an open ward and do not have the causative organism identiﬁed. Our
experience with SARS, in which diagnostic PCR tests were negative
in early disease, showed how isolation facilities could be quickly
overwhelmed if all possible cases were isolated. In these circumstances
the ability to conﬁrm an alternative diagnosis would be helpful for
guiding infection control decisions. Multiplex PCR was perceived as
a potentially useful tool in this respect. In order to establish systems and
to evaluate their value we introduced multiplex PCR assays for adult
patients with a pneumonic illness in routine non-outbreak related care
in a 1200 bed hospital.
Methods: A respiratory multiplex PCR service was made available to
‘Infection’ specialists. Samples included combined nose/throat swabs,
sputa and bronchial washes. Nucleic acids were extracted with an
EasyMag instrument, tested with Resplex I and II kits (Genaco, now
Qiagen) with Luminex detection and reported on the same day.
Results: Of 652 samples tested over 16 months from May 2006,
312 did and 340 did not have a target detected in them. Of all
652, Streptococcus pneumoniae was detected in 10%, Haemophilus
inﬂuenzae 9%, Mycoplasma pneumoniae 1.8%, Inﬂuenza A 13%,
Inﬂuenza B 9.6%, Rhinoviruses 4.3%, Coxsackie/Enteroviruses 4.3%,
human Metapneumovirus 2%, Parainﬂuenzavirus 2%, RSV 1% and
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Adenovirus 0.5%. More than one target was detected in 49 samples;
47 had mixed bacterial and viral targets detected.
Conclusion: Although a target was detected in 48% of samples, the
potential utility of the data to direct infection control activities was
much less as the presence of many of the targets was felt either to
be insufﬁcient to explain the symptoms as a sole pathogen or, especially
in the case of bacteria, possibly a reﬂection of carriage. Existing simpler
and cheaper PCR systems could detect Inﬂuenza whilst the detection of
S. pneumoniae and H. inﬂuenzae with culture and urinary antigen tests
are more likely to reﬂect real disease. The yield of multiplex PCR in
the adult inpatient population studied was disappointing, leaving at least
52% without a speciﬁc diagnosis. It is hard to justify the cost in routine
care. It might be of greater value in paediatric and outpatient populations
and in an outbreak situation when a more heterogeneous group might
present for ‘assessment of fever’.
P558 Genetic diversity of human rabies virus isolated during
2000–2008 in Morocco
A. Faouzi °, L. Anga, H. Amarouch, J. Nourlil (Casablanca, MA)
Objective: Rabies is an acute, progressive and fatal disease caused by
an RNA virus of the Lyssavirus genus of the Rhabdoviridae family. The
World Health Organization (WHO) estimates that rabies is related to
the death of approximately 55,000 people per year. In Morocco human
mortality due to rabies is estimated to be 20 deaths yearly. The aim of
the present study was to determine the genetic diversity using sequence
analysis of rabies strains isolated from humans in the Pasteur Institute
of Morocco during 9 years.
Methods: Since 2000, 70 post-mortem brain samples from suspected
rabid humans were collected from different areas of Morocco. Rabies
virus was isolated from all samples and RT-PCR was used to amplify a
1300 nucleotide segment of the Nucleoprotein gene. Segment sequencing
data was used for phylogenetic analysis.
Results: Comparisons of Nucleotide homology and phylogenetic tree
analysis based on this sequence indicated that all the rabies virus isolates
from Morocco belonged to genotype 1. Our result demonstrated a
low diversity between different strains with high nucleotide homologies
(99.1–100%).
Conclusions: Data presented in this study demonstrate the importance of
molecular protocol for diagnosis suspected rabid humans and to evaluate
the genetic diversity of strains circulating in our country. This study
showed that rabies virus isolates from Morocco have a close genetic
relationship.
P559 Molecular identiﬁcation of viral pathogens using
PCR/ESI-MS
L. Blyn °, R. Ranken, R. Lovari, H. Matthews, D. Toleno, R. Housley,
R. Melton, F. Li, T. Hall, D. Ecker, R. Sampath (Carlsbad, US)
Objective: Unacceptably high mortality rates and excessive costs
associated with viral infections of sterile sites can be attributed
in part, to delayed pathogen identiﬁcation, which is dependent on
traditional and relatively insensitive culture based methods. A rapid
and reliable diagnostic test that allows for accurate identiﬁcation of
infected patients, and informed early therapeutic interventions based on
pathogen characteristics could signiﬁcantly reduce morbidity, mortality
and medical costs. We propose to use the PCR/ESI-MS technology for
broad-based identiﬁcation of viral pathogens commonly associated with
viral meningitides, encephalitis, sepsis or fever of unknown origin.
Methods: We have developed a PCR/ESI-MS based assay to rapidly
detect and identify important viral pathogens associated with sterile sites.
Viruses targeted in this assay include all species from the following
genera: Adenovirus, Alphavirus, Enterovirus, Flavivirus, Herpesvirus
and Human Parvovirus B19. Validation studies were performed using
representative viral isolates from each target group to establish assay
limits of detection (LOD), sensitivity and speciﬁcity. This was followed
by a retrospective study using 54 blinded clinical specimens (CSF, urine,
plasma) obtained from ViraCor.
Results: Viral isolates were spiked into human plasma obtained from
healthy volunteers to determine assay analytical performance metrics.
Target LOD ranged from 15–125 copies for the different viral species
spiked. Analytical sensitivities and speciﬁcities were determined using
5×LOD of target viruses and showed 100% concordance. Blinded viral
specimens from ViraCor were tested using PCR/ESI-MS and detections
were compared to speciﬁc agent qPCR results from ViraCor. Of the 54
samples tested, 8 were not tested at ViraCor and 4 were not targeted
by the PCR-ESI/MS assay. 41 of the remaining 42 showed concordance
(98% correctness of ID) between the two assays.
Conclusion: The PCR/ESI-MS technology is a high throughput assay
system useful for rapid detection and identiﬁcation of broad range of
viral pathogens from a variety of clinical specimen.
Viral infections: diagnostic and clinical
ﬁndings
P560 Fulminant deaths caused by Crimean-Congo haemorrhagic
fever in Iran
S. Chinikar °, A. Ghalyanchi Langeroudi, R. Mirahmadi, S.M. Ghaiasi,
M.M. Goya, M.R. Shirzadi, M. Moradi, N. Afzali, T. Jalali, M. Zeinali,
M. Bouloy (Tehran, IR; Paris, FR)
Objectives: Crimean-Congo Haemorrhagic Fever (CCHF) disease is one
of the most important infectious diseases in Iran. This arboviral disease is
common between humans and livestock with a mortality rate around 50%
whose agent is a virus of the genus Nairovirus and family Bunyaviridae
which is transmitted from infected livestock to humans by the bite of
Hyalomma ticks or directly between humans. CCHF has been reported
from Africa, Eastern Europe, Asia and the Middle East. In addition
to clinical signs, the diagnosis of the disease is based on ﬁnding anti-
CCHF antibodies (IgM and IgG) and a fragment of the viral genome by
molecular analysis (RT-PCR) in the patient’s sera. In 1999, some cases
of clinical ﬁndings have been reported from some provinces of Iran,
especially the Chahar Mahal – Bakhtiari and according to the studies
of the laboratory of Arboviruses and Viral Haemorrhagic Fevers of the
Pasteur Institute of Iran (National Reference Lab), the disease is endemic
in Iran.
Methods: From 1999 to 2007, 207 sera of human dead cases suspected
for CCHF have been sent for diagnosis to the Arbovirus Lab from all
around the country, all have been analyzed for the presence of speciﬁc
antibodies (IgM) against CCHF by ELISA and of the virus genome by
RT-PCR.
Results: 64 sera were studied in 207 human dead cases infected by
CCHF. In those cases with a molecular diagnostic positive response,
in 67.2% of the cases no antibody against CCHF was observed. On
the other hand in 9.4% only antibody response without viral genome
presence has been observed. In 23.4% of the patients, both criteria of
antibody response and molecular diagnosis have been found positive.
Discussion: The results of this study indicate that in a high proportion
of fulminant deaths due to CCHF no immunological response has been
observed and this can corroborate the virulence of the disease and the
resulting mortality rate.
In this regard, for a better analysis of the pathogenicity of the disease,
the determination of mediators in the serum (Such as Interleukins . . . )
and also the genetical study of intervening factors in the pathogenicity
are underway in the different research projects of the laboratory.
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P561 Comparative study between the new VIDAS® EBV tests and
Liason for the detection of Epstein-Barr virus VCA IgM,
VCA/EA IgG and EBNA IgG antibodies in human serum
samples
P. Desmottes °, A. Foussadier, L. Allard (Marcy-l’E´toile, FR)
Objectives: The VIDAS EBV reagents currently under development are
aimed to detect immunoglobulins against Viral Capside Antigen (VCA),
Early Antigen (EA) and Epstein-Barr nuclear antigen (EBNA). The
aim of the study was to evaluate the results obtained by the 3 new
automated VIDAS VCA IgM, VIDAS VCA/EA IgG and VIDAS EBNA
IgG comparatively to the 4 corresponding tests available on LIAISON
instrument (DiaSorin). Results concordance between techniques was
determined for each kit, and a comparison of the methods was carried
on acute EBV infection panels.
Methods: VIDAS EBV VCA/EA IgG and EBNA IgG reagents use
speciﬁc EBV peptides coated on the solid phase to capture viral antigen
immunoglobulins. The peptide-EBV IgG antibody complexes are later
revealed using an anti-human IgG conjugated to Alkalin Phosphatase.
VIDAS EBV VCA IgM is based on immunocapture of serum VCA IgM.
Concordance study:
– 564 samples including 93 EBV primary infection (pi), 299 EBV past
infection (PI) and 172 EBV negative serum (NS) were tested with
both VIDAS and LIAISON VCA IgM kits.
– 338 samples including 45 EBV pi, 93 EBV PI and 200 EBV NS
were tested with VIDAS VCA/EA IgG and compared to the combined
results of LIAISON VCA and EA IgG kits.
– 483 samples including 64 EBV pi, 281 EBV PI and 138 EBV NS
were tested with both VIDAS and LIAISON EBNA IgG kits.
The equivocal results of both methods were excluded for the concordance
calculation.
Acute EBV infection panels:
– 149 samples from 24 acute EBV infection panels were tested with the
3 kits of each manufacturer.
Results: Concordance between VIDAS and LIAISON were found to
be 95%, 97% and 99% for VCA IgM, VCA/EA IgG and EBNA IgG,
respectively. Equivocal results rate was observed at 7.4% for LIAISON
EBNA IgG, while VIDAS EBNA IgG yielded 2%, only.
Acute EBV infection panels testing showed:
– better sensitivity for VIDAS VCA IgM compared to LIAISON VCA
IgM.
– VIDAS VCA/EA performed equally to LIAISON VCA and EA IgG,
– odd reactivity of LIAISON EBNA IgG in early samples of 7 EBV
panels out of 24.
Conclusions: The concordance between the new VIDAS EBV reagents
and the corresponding LIAISON reagents was higher than 95%, but
LIAISON EBNA IgG showed a signiﬁcant rate of equivocal results.
Comparison of the results of the 2 methods on acute EBV infection
panels highlighted better performance for VIDAS VCA IgM and EBNA
IgG than the respective LIAISON reagents.
P562 RIDA®QUICK Norovirus: a new dimension for norovirus
detection
F. Apostel °, D. Dressler, H. Leidinger, R. Fischer, P. Sander
(Darmstadt, DE)
Objectives: Noroviruses are commonly associated with large outbreaks
in recreational or institutional settings. They are highly infective, thus the
rapid and reliable detection of the noroviruses in compromised specimens
is of great importance for the hygiene management.
Current approaches such as the PCR detection of the viral genome and
the use of sensitive ELISA test kits still require several hours to conﬁrm
a suspicion of norovirus infection. Due to the nature of the noroviruses
both screening methods require constant monitoring and development.
We here describe the development of an assay format that will detect
norovirus in less than 20 minutes. The RIDA®QUICK Norovirus Assay
is a ﬂow through enzyme linked immunoassay based solely on the use
of virus speciﬁc but genotype cross-reactive monoclonal antibodies for
the detection of norovirus.
Methods and Results: Monoclonal antibodies raised against VLPs
or against capsid protein preparations of noroviruses from various
genogroups and -types are bound to a ﬁlter membrane. Stool sample
dilutions are applied to the membrane and subsequently treated with
conjugate, washing buffer and substrate. Results can be obtained after
15 minutes. Signal detection is accomplished by visual reading. First
study results run with 113 stool samples using predeﬁned samples
form the outbreak season 2007/2008 rendered a sensitivity 86%
and a speciﬁcity of 94.6% using real-time RT-PCR as reference.
Reproducibility was assessed testing 5 stool samples in three independent
laboratories on three consecutive days. The results showed 100%
agreement. No cross-reactivity with the usual causes for gastroenteritis
was observed as well as no interference with substances commonly used
to treat the symptoms of gastrointestinal diseases. The overall results
obtained with the RIDA®QUICK Norovirus are in excellent agreement
with those obtained using the well established RIDASCREEN®
Norovirus ELISA assay.
Conclusions: The RIDA®QUICK Norovirus detection assay opens a
new dimension for the quick and reliable analysis of compromised
specimen. Its value for a possible prevention of outbreaks in settings
where timely reaction are required is certainly indisputable.
P563 First PCR-based detection of a central nervous system
infection by Toscana virus in Piedmont region (north-western
Italy)
P. Ravanini °, M. Bandi, M.G. Crobu, F. Fila, E. Gobbato, A. Godino,
A.M. Nicosia, V. Quaglia, O. Bargiacchi, D. Brustia, P.L. Garavelli
(Novara, IT)
Objective: Toscana Virus (TOSV) is an arthropod-borne virus trans-
mitted by sandﬂies (Phlebotomus species). It was ﬁrstly isolated in
1971 in central Italy, and it is a member of genus Phlebovirus (family
Bunyaviridae).
TOSV can cause acute aseptic meningitis and meningoencephalitis, and
in some areas of central Italy it is the main cause of these pathologies.
The virus is widely spread in central and southern Italy, in Spain, in
southern France and in Portugal. Despite the increasing evidence of its
importance, the reports of TOSV infections in northern Italy remain
sporadic.
In September 2008, during a summer stay in Italy, a 61-year-old man
from England was admitted to our hospital with severe headache, fever,
and mental confusion. The examination of the cerebrospinal ﬂuid (CSF)
revealed a lymphocytic meningitis.
To determine the possible viral cause of the meningitis, speciﬁc nucleic
acid ampliﬁcations (PCR) for Herpes viruses, Entroviruses, and TOSV
were performed.
Methods: Viral nucleic acids in the CSF from the patient were extracted
with Extragen kit (Nanogen, Italy), and nested rt-PCR for TOSV was
performed using the Toscana Virus Oligomix Alert Kit (Nanogen, Italy),
that ampliﬁes a 310-bp speciﬁc fragment in the S segment of TOSV
genome.
Results: The PCRs for Herpes viruses and Enteroviruses resulted
negative, while the rt-PCR for TOSV resulted strongly positive. The
antibiotic and antiviral therapy was discontinued, and the patient
recovered rapidly within a few days.
Conclusions: This is the ﬁrst report of a rtPCR-based diagnosis of
neuroinvasive infection caused by TOSV in Piedmont region (NW Italy)
(precedent reports are only serologic).
Few physicians in northern Italy are aware of the potential role of TOSV
to cause CNS infections, and for this reason the number of TOSV
infections could be greatly underestimated.
It is therefore important to include TOSV in the differential diagnosis
of all cases of aseptic meningitis and meningo-encephalitis, especially
during last summer months, also in northern Italy.
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P564 Impact of rapid enterovirus molecular diagnosis in the
management of aseptic meningitis in children
M.I. Quiles-Melero, M. Lorenzo, F. Gomez, P. Garcia,
M.P. Romero-Gomez ° (Madrid, ES)
Introduction: Enteroviruses (EV) are the main aetiological agents of
aseptic meningitis. EV may cause up to 90% of aseptic meningitis cases
for which an aetiology is identiﬁed.
Objectives: The aim of the study was to evaluate the impact of EV-PCR
testing on diagnosis and clinical management of children with suspicious
of aseptic meningitis.
Methods: PCR had been performed in 165 children of children with non-
speciﬁc febrile illness by a commercially available reverse transcription
based PCR (GeneXpert Dx system (Cepheid, Sunnyvale, CA) according
to the manufacturer’s instructions.
Clinical, laboratory data and initial treatment were recorded for all
patients. The turnaround time of tests and the length of hospital stay
were analyzed.
Results: 165 patients with fever syndrome and/or suspected aseptic
meningitis were attended in emergency room of a children’s hospital,
alone 2008. RT-PCR was performes in all of them. Forty ﬁve (27.87%)
had a CSF EV-PCR positive result. Fourteen (26.84%) of CSF samples
had no pleocytosis. All of them were patiens <3.6 months (median
1.27 months; range: 0.0−3.6 months). The turnaround time of tests
for RT-PCR ranged from 0.16 to 2 days (mean time; 1.2 days). EV-
negative patients received intravenous antibiotics in 97 cases (81.01%)
while only 26 patients (57.57%) with EV-positive patients received
antibiotic therapy. A positive EV-PCR result was associated with more
rapid hospital discharge (median EV-PCR-to-discharge time; 3.05 days)
compared with a negative result (median EV-PCR-to-discharge time;
4.44 days).
Conclusion: Rapid reporting of PCR results have a signiﬁcant impact
in the management and treatment of patients with EV meningitis.
P565 Efﬁcacy of a direct immunoﬂuorrescence assay versus shell
vial culture in the detection of herpesvirus 1 and 2, and
varicellazoster in skin infections
J. Reina °, V. Plasencia (Palma de Mallorca, ES)
Objectives: To prospectively evaluate the efﬁcacy of a direct immunoﬂu-
orescence assay (DFA) versus the shell-vial culture in the detection of
herpesvirus 1 and 2 (HSV-1 and HSV-2) and varizellazoster virus (VZV)
in skin infections.
Methods: The different skin samples were send to the vitrology
laboratory in a virus liquid transpotrt medium (MTV, Vircell). For
performance of the DFA, 200ml per slide, were cytocentrifuged
(Cytospin 3, Shandon Scientiﬁc, England) on 3 slides at 700 rpm for
10 min. After air drying the slides were ﬁxed with acetone at −20ºC
for 10 min, and then stained with ﬂuorescein-labeled mouse monoclonal
antibodies to HSV-1 and HSV-2 (Syva MicroTrack HSV1/HSV2, USA)
and to VZV following manufacturer’s instructions. The sample was
considered adequate for the DFA if the total number of epithelial cells
present was >25 per slide. A sample was considered positive if at
least 2 epithelial cells with speciﬁc ﬂuorescence were detected. The
samples were inoculated into shell-vials of the Vero and MRC-5 cell
lines (Vircell, Granada, Spain). The vials were incubated at 36ºC and
stained with the same monoclonal antibodies used in the DFA.
Results: In the 2000–2008 study period we analyzed 468 skin samples.
372 (79.4%) were considered adequate. Of them the DFA was positive in
136 (36.7%) samples and the shell-vial culture in 106 (28.4%) samples.
The DFA detected the HSV-1 in 65 (17.4%) samples, the HSV-2 in
29 (7.7%), and the VZV in 42 (11.2%). The shell-vial culture was
positive for HSV-1 in 57 (15.3%) samples, for HSV-2 in 21 (5.6%),
and for VZV in 28 (7.5%). Using the DFA as a reference method, the
shell-vial culture has an overall sensitivility of 77.9% for the HSV-1,
87.6% for the HSV-2, and 66.6% for VZV. In the 205 skin samples with
a clinical suspicion of HSV-1 infection, 65 (31.7%) were positive, with
suspicion of HSV-2 infection, 29 (23.3%), and with the suspicion of
VZV infection, 42 (31.8%). We not isolated in the shell-vial culture a
herpesvirus not previously detected in the DFA. The turnaround time for
the herpesvirus isolation in the shell-vial culture was 1.7 days, and for
the VZV of 4.5 days. The turnaround time for the DFA was 2.7 hours.
Conclusion: The DFA is a sensitive, rapid and easy alternative to
the shell-vial culture in the detection of herpesvirus in skin samples.
The shell-vial could be the reference method yet, but the molecular
techniques have more sensitivity and speciﬁcity than the cell culture.
P566 Epidemiological and virological study of aseptic meningitis
caused by enterovirus in children
M. Lorenzo, M.I. Quiles-Melero, P. Garcia, F. Gomez,
M.P. Romero-Gomez ° (Madrid, ES)
Introduction: Enteroviruses (EV) are the main aetiological agents of
aseptic meningitis. EV may cause up to 90% of aseptic meningitis cases
for which an aetiology is identiﬁed.
Objectives: To evaluate incidence, clinical characteristics and manage-
ment of children with aseptic meningitis caused by enterovirus.
Methods: A retrospective study was conducted to determine the
epidemiological, clinical, and laboratory characteristics of our patients
with aseptic meningitis. The microbiologycal diagnostics was performed
by RT-PCR (GeneXpert Dx system (Cepheid, Sunnyvale, CA) and/or
viral culture by shell vial method, in CSF.
Results: 2005 CSF samples, received between January 2004 and
December 2008, which corresponded to patients with a fever syndrome
and/or clinical suspicion of meningitis. 134 CSF (6.68%) were found
positive for EV by a RT-PCR or viral culture. A total of 131 children,
median age 2.4 years, were evaluate. The study population included
children <1 month to 14 years of age and was divided in 4 age groups:
<1 year (64.7%), 1−5 years (16.5%), 6−12 years (16.5%), >12 years
(2.3%).
Most cases occurred during summer (48%) and autumn (16%). The most
frequent symptoms were fever (58%), headache (19%), vomiting (19%)
and neck stiffness (16.7%).
The mean CSF cell count was 78/mm3, and polymorphonuclear cells
were predominant in 52.3% of the cases. 28 (21.3%) of CSF samples
had no pleocytosis.
EV RNA was detected in 57 of 131 (43.5%) samples and EV were
isolated in the culture by the shell vial method in 74 (56.5%) of children
studied. Detection times of culture by the shell vial method ranged from
3 to 5 days (mean time, 3.1 days) and from 0.16 to 2 days for for RT-PCR
(mean time, 1.2 days).
Conclusion: PCR reduce the detection times and length of hospitalisa-
tion and plays an important role in the diagnosis and management of
children with aseptic meningitis.
Rapid detection and characterisation of EV meningitis is essential in
making decisions for patient management and treatment.
P567 Multi-centre evaluation of the CMV IgG assay on the Family
of Access immunoassay systems from Beckman Coulter
L. Grangeot-Keros, N. Gaidot, M. Rawlins, O. Flecheux, J. Ritchie,
C. Darte, F. Bouniort °, M. Olson (Clamart, FR; Salt Lake City,
US; Marnes-la-coquette, FR; Atlanta, US; Marseille, FR; Nyon, CH;
Chaska, US)
Background: The human cytomegalovirus (CMV) is a member of the
Herpesviridae family. CMV is transmitted person-to-person via close
non-sexual contact, sexual activity, breastfeeding, blood transfusions, and
organ transplantation. CMV infection is a serious concern for women of
child-bearing age, because it is a leading cause of hearing and vision
loss, as well as mental retardation among congenitally-infected children.
Serological conﬁrmation of antibodies to CMV is indicative of exposure
to the virus and is the principle means of diagnosis and follow-up.
The Access® CMV IgG assay is a two-step immunoenzymatic (“sand-
wich”) assay based on paramagnetic particle, solid phase technology and
chemiluminescent signal detection.
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Objectives and Methodology: Access CMV IgG assay reproducibility
was evaluated at three centres, using a panel of eight samples with
varying degrees of reactivity and two controls. Five replicates of each
sample were analyzed each day for seven days. Concordance (percent
agreement) with the bioMerieux VIDAS™ and the Abbott AxSYM™
assays was evaluated at one site. Two hundred and ﬁfty-eight de-
identiﬁed residual non-selected samples were analyzed from pregnant
subjects as well as male and female subjects who had CMV IgG testing
ordered. The platform utilised was the Access® 2 Immunoassay System.
Similar performance has been demonstrated on the UniCel® DxI 800
Access Immunoassay System.
Results: At the cut-off (15AU/mL), within site total %CV ranged from
6% to 8%. The overall agreement of the Access CMV IgG assay to the
VIDAS CMV IgG assay was
99% (95% CI, 97% to 100%). The overall agreement of the Access
CMV IgG assay to the AxSYM CMV IgG assay was 100% (95% CI,
98% to 100%).
Conclusion: The Access CMV IgG assay provides excellent concor-
dance with the comparison methods. The assay can aid in the diagnosis
of CMV infection and may be used to assess the serological status of
pregnant women with the advantage of a rapid, automated, random-
access immunoassay system.
P568 Toscana virus: serosurvey study in domestic animals within
Granada province (southern Spain)
J.M. Navarro-Marı´, B. Palop-Borra´s, M. Pe´rez-Ruiz °,
S. Sanbonmatsu-Ga´mez, J.M. Mayor, M.C. Acedo-Sa´nchez,
M. Jime´nez-Valera (Granada, ES)
Objectives: Toscana virus (TOSV) is the main arbovirus involved in viral
meningitis within the Mediterranean basin. Infected individuals acquire
the virus through the bite of a sandﬂy, Phlebotomus spp. The vector
circulates during the summer, coinciding with the pick of incidence
of TOSV meningitis, mainly localised in rural areas. TOSV has been
detected in pools of sandﬂies, but it remains unknown if there are animal
reservoirs able to maintain the virus through the cold months of the year,
when the vector is not circulating. We conducted a serosurvey study of
TOSV in domestic animals within Granada province (south of Spain) to
evaluate the prevalence of anti-TOSV antibodies in this population.
Methods: Serum samples from the following domestic animals were
processed for the investigation of anti-TOSV IgG antibodies from
September 2006 to April 2007: cats, dogs and horses (provided by
a veterinary laboratory in Granada city), and goats, sheep, cows and
pigs (provided by the Regional Laboratory of Production and Animal
Health, Santa Fe, Granada, Spain). The investigation of anti-TOSV IgG
antibodies was carried out by indirect ﬂuorescence assay (IFA), using
Vero cells infected with a Spanish strain of TOSV as the antigen source,
and speciﬁc antisera from each animal species.
Results: A total of 1,186 serum samples were investigated by IFA, and
429 (36.2%) were positive: 138 of 286 dogs (48.3%); 127 of 213 cats
(59.6%); 9 of 14 horses (64.3%); 27 of 151 cows (17.9%); 43 of
243 goats (17.7%); 74 of 229 sheep (32.3%); and 11 of 50 pigs (22%).
Conclusion: These results show that an important percentage of the
domestic animals have been infected by TOSV. Further studies are being
conducted to evaluate the role of some of these animals as possible
reservoirs of TOSV.
P569 Diagnosis of primary rubella infection in 122 adults in
Cosenza, Italy and neonatal follow-up
C. Giraldi °, F. Greco, R. Tenuta, F. Orrico (Cosenza, IT)
Objectives: Italy introduced MMR vaccine in 1999, recommending
its use in all newborns. Two studies (in 1996 and 2004) found a
10−12% prevalence of seronegativity in women aged 15−39 years, and
a 2007 Italian multicentre study found a 65.4% seroprevalence of anti-
rubella IgG. In Calabria, occasional infectious episodes after June 2007
culminated in a rubella epidemic in summer 2008.
Methods: Between June 2007 and August 2008, we saw 122
asymptomatic patients (47 males, 75 females, including 20 pregnant
women; mean age 21 years, range 5−65) unvaccinated against rubella,
who reported evanescent fever, lymphadenopathy, rash (generally
regressing from day 2) and joint pain. Biochemical tests revealed normal
PCR, ESR, haemochrome; slightly altered transaminases; high LDH.
Sera were screened for anti-rubella IgG and IgM by CLIA (LIAISON®,
Diasorin Saluggia, Italy) and MEIA (Architect®, Abbott, Germany), and
IgG avidity was tested at baseline, and 1 and 2 months after infection.
Differential diagnoses included EBV, HHV6, parvovirus B19, Coxsackie
and echovirus. Whole blood and urine samples from 8 newborns at
birth were tested for speciﬁc IgG and IgM, and rubella RNA (Nanogen
Advanced Diagnostics, Milan).
Results: The diagnosis was based on IgG/IgM seroconversion and/or
conﬁrmed speciﬁc IgM and low IgG avidity. Eleven pregnant women
infected at 4−12 gestational weeks (gw) underwent voluntary abortions;
nine refused prenatal investigation. Four of the eight tested newborns
(whose mothers were infected at 15−32 gw) were positive for speciﬁc
IgM antibodies and rubella RNA in serum and urine (3 asymptomatic; 1
with transitory jaundice, hepatosplenomegaly and high ALT); 4 were
negative for both and presumably uninfected. In the newborns and
pregnant women, CLIA was more sensitive than MEIA in assaying IgM,
thus allowing better deﬁnition of acute rubella infection.
Conclusion: The infection in Calabria involved many pregnant women
and could have had serious effects on newborns. Our preliminary data
show that IgM rapidly decreased, and were absent in 61% two months
after the acute phase; IgG avidity rapidly matured in 31% over the same
time, and partially matured in the rest. Women should be screened for
rubella in the ﬁrst 8 weeks of pregnancy as delayed testing does not
exclude early maternal infection. Biomolecular and serological tests at
birth are useful in identifying infected newborns.
P570 The infection of macrophages by enveloped virus
N. Plekhova °, L. Somova, N. Krylova, G. Leonova, G. Companets,
R. Slonova, E. Pustovalov (Vladivostok, RU)
It was eexperimentally evidenced that macrophages play the important
role in resistance to viral infection. In this study, we tested the
ultrastructure of infected RNA enveloped (Hantavirus, HV, caused
haemorrhagic fever with renal syndrome, and Tick Borne encephalitis
virus, TBEV) viruses primary macrophages of mice and monocytes.
The estimate of dynamic accumulation of a viral antigen in cells was
made: an indirect method of ﬂuorescent antibodies, the detection of virus
RNA was performed with the help of PCR. The deﬁnition of TBEV
infectious titer was performed on cytopathogenic action on cell culture
of SKEC and HV on Vero cells. For the detection of plasma membrane
components, a monolayer of infected macrophages was ﬁxed during 1 h
in combined composite containing 0.075% ruthenic red. The dehydration
of samples was performed in ethanol solution of increasing density and
embedded in epon-araldite. The ultrathin sections were prepared in a
plane parallel to the cell monolayer.
The viruses adhesion on the cells surface and penetration with
reproduction in macrophages from virus-included liquid was determined.
The entry and exit of viral particles were realised by local destruction of
cells plasmalemma. The type of macrophage infection was autonomous,
because the activity of TBEV and HV genome and reproduction of
viruses were in cell cytoplasm.
The appearance of virus-inducted structures was indicated in determinate
region of cell cytoplasm − fabrics of viral synthesis. The most intensive
formation of viroplasts, polyribosomal ﬁlaments and microﬁbrils were
identiﬁed after 9 hours post-infection by TBEV, and near its the virions
formation were determined. The viruses RNA was bound with ribosomes
that expressed in form of polyribosomal ﬁlaments.
In macrophages infected by HV were detected formation three types of
viroplasts in cytoplasm: (1) the compactness viroplasts; (2) viroplasts
forming from the ﬁrst and surrounding by two-layer membrane,
(3) lamellar and tube structures. The synthesis of virus nucleoproteins
was localised on the surface of ﬁrst and second type viroplasts, then the
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envelope protein formed in lamellar and tube structures. The results of
ultrastructure study were indicated that the places of HV components
synthesis had different localisation. In infection by TBEV macrophages
we did not observed the similar delimitations of virus component
synthesis places.
P571 Genotype of varicella zoster virus isolated from Korean
elderly patients with herpes zoster
Y.J. Choi °, K.H. Kim, M.D. Oh (Koyangshi, Seoul, KR)
Objectives: Herpes zoster develops via reactivation of the latent varicella
zoster virus (VZV) in neuronal ganglia as host immunity declines. In
Korea, the seroprevalence of VZV IgG is high about 80−95%, and
there is a high probability for immunosuppressed patients to develop
herpes zoster. As the elderly population increases and the number of
immunosuppresed patient increases, we also expect increases in herpes
zoster cases. The objective of this study was to evaluate the infection
rate of the VZV and to evaluate the lifetime prevalence of herpes zoster.
Also, to isolate the varicella zoster virus and to determine the genotype
of the VZV isolated from elderly patients in Korea.
Method: Serum IgG antibody titer were measured in 399 patients
visiting National Cancer Center for diagnostic checkups. Lifetime
prevalence of herpes zoster was evaluated through a survey on history
of herpes zoster with 2054 participants visiting National Cancer Center
for diagnostic checkups. VZV was isolated by cell culture technique
using MRC-5 cells. To determine the genotype, ORF 22, 38, 54, 62
were ampliﬁed by PCR, and after digestion of the PCR products with
enzymes pstI, bglI and smaI, restriction-fragment-length-polymorphism
was analysed. The ampliﬁed ORF 22 PCR product were sequenced and
checked for single nucleotide polymorphisms. For the determination of
VZV genotype, genotype classiﬁcation by Loparev was used.
Results: The overall seroprevalence of VZV IgG in adults were
93.9% (375/399); 91.4% (85/93) for ages 30−39, 92.5% (98/106) for
ages 40−49, 97% (97/100) for ages 50−59 and 95% (95/100) for
ages 60−69. The overall lifetime prevalence of herpes zoster was
13.7% (282/2054).
Of the patients with herpes zoster, 17.7% (50/282) of patients
experienced postherpetic neuralgia for more than 1 month duration.
The genotype of the isolates of VZV were all of J genotype; 21 (95.4%)
isolates were all pstI+, bglI+, smaI-, and 1 (4.5%) isolate was pstI− bglI+
smaI− (pOka) genotype.
Conclusion: The seroprevalece of VZV IgG ntibody was high and it
was 93.9% in adults. The ifetime prevalence of herpes zoster was 13.7%.
The genotype of VZV isolated from adults over 60 years old were all of
J genotype.
P572 Prevalence of human papillomavirus types in women with nor-
mal citology, atypical squamous cells of unknown signiﬁcance
and cervical intraepithelial neoplasia 1 in Madrid, Spain
J.M. Sanchez Calvo °, M. Rodriguez Dominguez, J. Chacon de Antonio,
I.R. Sanz Gonzalez de Suso, M.L. De La Morena Serrano, M.L. Mateos
Lindemann (Madrid, ES)
Objectives: The presence of certain high-risk human papallomavirus
(HR-HPV) types is related with higher rates of persistence of infection
in cervix and with more severe lesions leading to carcinogenesis.
Our objective was to study the prevalence of HR-HPV types in
women with normal cytology, atypical squamous cells of unknown
signiﬁcance (ASCUS), cervical intraepithelial neoplasia (CIN)-1, and
their geographical distribution in order to monitor all women with HR-
HPV to prevent cervical carcinoma.
Methods: A total of 351 women attended at the Gynaecology Unit were
studied for a period of two years (04/30/06−04/30/08). The presence
of HPV was investigated in cervical samples by a hybrid capture test
(DIGENE, Gaithersburg, USA). All positive HR-HPV specimens were
studied by PCR (Linear Array, ROCHE DIAGNOSTICS) for genotyping.
Citology and/or cervical biopsy results were available from all patients.
Results: The most prevalent HR-HPV types in patients with normal
cytology were HPV-16 (18.8%), HPV-31 (15.4%), HPV-51 (11.4%),
HPV-52 (10.7%), HPV-53 (8.7%) and HPV-56 (10.7%). In ASCUS and
CIN-1 specimens, respectively, the most prevalent HR-HPV types found
were HPV-16 (35.7%, 17.6%), HPV-31 (14.3%, 16%), HPV-51 (28.6%,
17.6%), HPV-52 (14.3%, 11.7%), HPV-53 (7.1%, 17%), HPV-56 (28.6%,
12.2%). Multiple infections ranged from 50 to 62.8% in normal, ASCUS
and CIN-1 specimens. However, multiple infections were not associated
with more severe lesions.
Conclusions: HPV-16 was the most frequent type followed by HPV-
31, 51, 52, 53 and 56. Epidemiology studies have demonstrated that
HPV-16 was the type most frequently found in all countries. The other
HR-HPV types differed in the different geographical areas. More studies
are needed to observe if this pattern of prevalence is changed with the
administration of vaccine.
P573 Human herpesvirus 8 infection in central Tunisia:
seroprevalence among different groups
N. Hannachi, N. Ben Frdj, J. Boukadida ° (Sousse, TN)
Objectives: The epidemiology and modes of transmission of human
herpesvirus 8 (HHV-8) in Tunisia are still unclear. The aim of this study
is to evaluate seroprevalence of HHV8 infection in different population
groups.
Methods: Sera from 220 children and adults were tested: 50 healthy
children, 50 blood donors, 50 patients with multiple transfusions
(22 multi-transfused thalassaemic children and 28 polytransfused adults)
and 70 subjects with sexual risk of exposure (50 HIV-positive and
20 HIV-negative). Serological analysis was performed by using an
immunoﬂuorescence assay able to detect anti-latent and anti-lytic HHV-8
antibodies.
Results: The seroprevalence of HHV8 was found to be 12 and 14% in
healthy children and blood donors respectively. There was no difference
between men and women or age group (p> 0.05). A signiﬁcantly higher
prevalence of HHV-8 infection was found among polytransfused patients:
60% in children and 53.5% in adults (p< 0.05). Rates of seropositivity
were signiﬁcantly higher than healthy subjects in patients with sexual
risk: 54% in HIV infected patients and 65% in HIV-negative persons
(p< 0.05). Among sexually exposed subjects, non association was found
between HHV8 and HIV infections.
Conclusion: HHV8 infection is of intermediate endemicity in our region.
Non-sexual transmission of HHV8 is operating in our geographical
setting and saliva may be a potential source of HHV8 spreading in
the general population. The lower prevalence of HHV8 than other
herpesviruses in our country suggests a recent introduction of the virus
or a lower transmissibility. There is an evidence of an increased risk of
infection with multiple transfusions and sexual behaviour.
P574 Variant GII.4 noroviruses in Italian children
S. Ramirez, S. De Grazia, C. Colomba, A. Cascio °, P. Aiello, V. Rotolo,
G.M. Giammanco (Palermo, Messina, IT)
Objectives: Among human noroviruses (NoVs), a few genogroup II
strains of genotype 4 (GII.4) are dominant worldwide. GII.4 NoVs
evolve rapidly and in 2006 two new epidemic variants have been
identiﬁed. To investigate the circulation of GII.4 NoV variants in Italy a
sequence analysis was performed on NoV strains obtained from children
hospitalised for sporadic viral gastroenteritis in Palermo.
Methods: A total of 465 faecal specimens were collected from children
(<5 years) hospitalised from January 2005 to December 2006. The
presence of NoVs was detected by RT-PCR using primers JV12/JV13,
targeting the region A of the RNA-dependent RNA-polymerase (RdRp)
gene. NoV strains were genotyped by RdRp restriction fragment length
polymorphism (RFLP) with XmnI, BstXI and sequence analysis of
region A and of the ORF1/ORF2 junction region obtained with primer
pair GIISKR/GIIFBN1−2−3. Phylogenetic analysis including isolates
from the 2002–2004 surveillance was carried out using the software
MEGA version 4.
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Results: Viral gastroenteritis surveillance resulted in the detection of
NoV strains in 20.9% of the patients admitted to hospital. RFLP and
sequence analysis of the RdRp gene allowed to successfully characterise
59 NoV strains. Eighty-one % of the strains were characterised as
GII.4, 14% as GIIb/Hilversum and 5% as GI.1. Phylogenetic analysis of
region A and of the ORF1/ORF2 overlapping region of the GII.4 strains
recovered in Palermo in the years 2002–2006 revealed the sequential
emergence of four variants, GII.4 2002, 2004, 2006a and 2006b. The
variant GII.4 2006a was detected in June and July, 2006, while the variant
2006b ﬁrst appeared in August, 2006, becoming predominant thereafter.
Conclusion: The high detection rate of GII.4 NoVs in Italian
children with gastroenteritis conﬁrms their prominent role as human
enteropathogens. At least four distinct GII.4 NoV variants appeared
in Palermo in the last years and their dynamics of replacement and
circulation in 2005–2006 appear to have matched the temporal pattern
observed in Europe during the same period.
P575 Symptomatic Parvovirus B19 infection in immunocompetent
adults. Epidemiological, diagnostic, and clinical issues
R. Manfredi °, G. Marinacci (Bologna, IT)
Introduction: Parvoviridae are part of air-, parenteral- and perinatal-
transmitted ubiquitous viruses, whose associated signs and symptoms
strongly depend on patient’s age and immune defence.
Methods: All cases of symptomatic Parvovirus B19 infection in
otherwise healthy adults which came to our attention since spring 2006
were prospectively investigated and followed-up.
Results: In a 19-month period, 10 patients (7 females-3 males), with a
mean age of 39.8 (range 27−46) years with a symptomatic Parvovirus
B19 infection were recorded. Intrafamiliar exposure and occupational
(health care) exposure were identiﬁed in 2 cases each. Clinical signs
and symptoms included fever (100%), arthralgia (90%), followed
by headache (80%), anaemia (70%), and rash. A mild-to-moderate
myelosuppression of all hematological lines characterised 7 cases, while
increased serum transaminases were associated in 60% of patients. Three
patients were hospitalised (mean 10.8 days of admission), and 4 more
cases were followed on Day-Hospital basis (for a median 95-day period);
in 3 patients treatment with i.v. high-dosage human immunoglobulins
was performed. Elevated levels of speciﬁc serum anti-Parvovirus B19
IgM antibodies were detected in all cases. In a 33-year-old female a
severe anaemia and a persisting headache, vomiting, and neck stiffness,
led to RBC transfusion and a diagnosis of meningoencephalitis, with
positive search of IgM antibodies and Parvovirus B19 viraemia (detected
by RT-PCR) in the cerebrospional ﬂuid which lasted 3 months, despite
treatment with i.v. serum immunoglobulins.
Conclusions: Parvovirus B19 infection may play a signiﬁcant role also in
the adult, immunocompetent subject, and the disease sometimes is not
mild and self-limiting, requiring admission and/or frequent outpatient
interventions in a signiﬁcant number of cases. The causes supporting
a persistant infection in immunocompetent subjects have not been
investigated to date, as well as the pathogenesis of myelosuppression
and severe artrhalgia. Symptomatic Parvovirus B19 infection is still
an underestimated condition, and therapeutic perspectives are extremely
limited.
P576 Epidemiological and clinical characteristics of human par-
vovirus B19 infections during 2006–2008 in northern Greece
M. Exindari, D. Chatzidimitriou °, A. Melidou, G. Gioula,
E. Diza-Mataftsi (Thessaloniki, GR)
Objectives: Parvovirus B19 infects children and adults causing erythema
infectiosum, polyarthritis, aplastic crisis in patients with chronic
haemolytic anaemia, rash, fever, and foetal anaemia-related disease or
foetal death.
The aim of this effort was to study acute human parvovirus B19
infections during the years 2006–2008 in northern Greece on their
epidemiological and clinical aspect.
Methods: Specimens were obtained from 56 patients suspected for acute
h. parvovirus B19 infection (17 in 2006, 29 in 2007, and 10 in 2008).
27 of them belonged to children (1 day – 15 years old) and 29 to adults
(17−65 years old). The infection was proved by PCR amplifying a 227 bp
DNA segment, part of the viral gene VP1, in whole blood and in two
cases in pleural ﬂuid. Detection of speciﬁc IgM antibodies in the patients’
blood serum was performed by ELISA.
Results: 19 out of the 56 specimens were found to be positive by
PCR (33.9%): 3/17 (17.6%) in 2006, and 16/29 (55.2%) in 2007,
p = 0.03. Speciﬁc IgM antibodies were detected in all 19 positive patients.
10 positive specimens belonged to children and 9 to adults, p = 0.64.
Children presented with haematological disorders, mainly types of
anaemia (six cases), hydrothorax/ascites (two cases), arthritis (one
case), and liver transplant rejection (one case). Adults presented with
pregnancy complications (two cases), arthralgia/arthritis (three cases),
febrile syndromes (three cases, two of them on SLE and one on chronic
haemoglobinopathy background), and atypical rash (one case).
Conclusions: An annual variation in the circulation of h. parvovirus
B19 was observed, presenting a statistically signiﬁcant increase of acute
infections during 2007 in northern Greece.
Children and adults were equally affected, however differences in clinical
manifestations were observed between them, with haematological
dysfunctions predominant in childhood.
P577 Distribution of genotypes of human papilloma virus in
women from different countries
M.E. Alvarez-Argu¨elles °, S. Melon, L. Villa, A. Palacio, J.A. Boga,
M. Junquera, P. Mejuto, M. De On˜a (Oviedo, ES)
The aim of this study was to determine the distribution of genotypes of
HPV in women from different countries attending a consultation as part
of an STI control program and screening of HPV infection.
Patients and Methods: Between 2000 and 2007 are being studied
2067 samples brushed endocervical of 1201 women (average age
28.9±7.8 years, range 18−75) from: Brazil 472 (817 samples), 360
rest of Latin America (648 samples), 248 were born in Spain
(382 samples), 67 from Eastern Europe (128 samples) and 54 sub-
Saharan Africa (92 samples). HPV detection was performed using a
PCR fragments compared to L1 and E6/E7. The positive samples were
characterised using hybridisation with probes labeled with 32P for
6/11/16/18/31/33/45/58 genotypes.
Results: HPV was found in 148 (31.3%) women in Brazil, 96 (27%) of
Latin America, in 75 (30%) of Spain, 20 (29.8%) from Eastern Europe
and 11 (20.4%) from Africa.
The distribution of genotypes (in percentage) is found in the table.
The percentage of vaccine genotypes (HR and BR) ranged between 42
and 73%. The HPV 16 and 18 ranged between 40 and 52% of all high-
risk genotypes (Africa not included).
Conclusions:
– The prevalence of HPV infection was similar in all groups.
– The 16 genotype was distributed equally in all countries included in
this study.
– The 18 genotype was less common in Spanish women.
– The genotype was detected in only 45 women in Latin America.
– The high-risk genotypes vaccine account for half of oncogenic
genotypes detected.
VPH6 VPH11 VPH16 VPH18 VPH31 VPH33 VPH45 VPH58 VPHNT Coinfection
Brazil 8.78 11.49 25.68 9.46 14.86 6.76 2.03 10.81 37.16 18.92
Latin America 11.46 9.38 13.54 8.33 10.42 7.29 1.04 10.42 53.13 7.29
Spain 30.67 17.33 24 1.33 12 2.67 0 8 34.67 12
Eastern Europe 30 10 15 5 5 15 0 10 40 25
Africa 9.09 9.09 27.27 9.09 9.09 0 0 0 45.45 9.09
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P578 Seroepidemiology of Varicella zoster virus infections in
Greek adults during a two-year period
P. Karabogia-Karaﬁllidis °, M. Katramadou, E. Marinopoulou,
E. Petrou, A. Kefalakis, H. Malamou-Lada (Athens, GR)
Introduction: Varicella zoster virus (VZV) is a human alphaherpes
virus, which causes varicella (chickenpox) and herpes zoster (HZ,
shingles). Varicella is a common illness of early childhood that
occurs during primary infection. Zoster usually occurs in adults or
immunocompromised patients. It is caused by reactivation of the virus
in latency after the primary infection in cells of the dorsal root or cranial
nerve sensory ganglia.
Objectives: The aim of this study was to determine the current status
of VZV immunity and to estimate the incidence of varicella and HZ in
hospitalised adults over the years 2007–2008.
Methods: A total of 918 serum samples from adult patients
(17−65 years old), hospitalised in several clinics of the General Hospital
“G. Gennimatas”, were examined during a two year period. The sera
were tested for speciﬁc IgG, IgM and IgA class antibodies by an enzyme-
linked immunosorbent assay (VIR-ELISA-ALPHADIA-BELGIUM).
Results: The seroprevelance for IgG, IgA and IgM was 81.5% (748/918),
2.17% (20/918) and 0.98% (9/918) respectively. The susceptibility rate
for VZV was found to be high, 18.5% (270/918). VZV infection
was clinically conﬁrmed in 19 patients (2.9%, 19/918). The incidence
for varicella was 0.76% (7/918) and for zoster 1.3% (12/918). IgM
antibodies were detected in all patients with varicella and in 2 patients
with HZ. The remaining 10 patients with HZ developed only IgG and
IgA antibodies.
Conclusions: During the acute phase of HZ infection, IgA antibodies
are usually developed, while IgM antibodies are often absent. Although
varicella and HZ infections occurred in a small number of adults
(2.09%), the risk of primary infection remains high, due to the high
sensitivity rate (18.5%) to the virus.
P579 Clinical and genetic analysis of human bocavirus in children
with lower respiratory tract infection in Taiwan
J.H. Lin, S.C. Chiu, Y.C. Lin, H.l. Chen, K.H. Lin, H.S. Wu, H.F. Liu °
(Taipei, Pingtung, Kaohsiung, Tamshui, TW)
Objectives: Human bocavirus (HBoV) has a potential role in the
development of acute respiratory disease in children. Recently, the
prevalence of this virus has been studied worldwide. We conducted the
ﬁrst clinical and molecular study at the Centers for Diseases Control,
Taiwan, to investigate the genomic and epidemiological proﬁles of HBoV
infection in Taiwan.
Methods: Throat swabs or nasopharyngeal aspirates were obtained
from paediatric hospitalised patients with acute lower respiratory tract
infection. Specimens that were negative for other respiratory viruses by
molecular screening were examined for HBoV. Complete viral genome
was amplifyed and sequenced to re-construct their phylogenetic trees.
Results: HBoV was detected in 30 (5.6%) of 531, of these positive cases
56.67% at the age less than 2 years old. Sequences comparison showed
highly conserved and similarity with Taiwan HBoV among different
isolates with 2 groups of HBoV co-circulated. There is no genotypic
difference between the strains from Taiwan and other countries. Split
decomposition tree and BootScan showed a possible recombination of
different HBoV strains.
Conclusion: HBoV might have circulated in Taiwan for a certain
period and is involved in the aetiological agents responsible for lower
respiratory tract infection in children. Evolutionary networks suggest that
HBoV might have an opportunity for interbreeding of virus and genetic
recombinant among the different genes.
P580 Activation of interferon response in human PBMC by avian
inﬂuenza H5N1 virus
E. Lalle °, C. Castilletti, L. Bordi, R. Chiappini, M.R. Capobianchi
(Rome, IT)
Objectives: The severe complications of HPAI H5N1 strongly suggest
a key role for over-exuberant immune response pathogenesis
Higher plasma levels of chemokines and proinﬂammatory cytokines have
been observed in patients with H5N1 virus infection.
The aim of our study was to compare the capability of H5N1 and
H3N2 viruses to induce IFN-a and -g and to activate the IFN stimulated
genes in human PBMC from healthy donors. Moreover we analysed the
differential modulation of a broad range of TLRs pathway’s genes.
Methods: Normal PBMC were exposed to both viruses at different
MOI. IFN-a and -g induction was measured both at mRNA level and
cytokines release; IFN stimulated genes (PKR, MxA, 2′−5′ OAS) were
also analysed. The proﬁle of expression of TLR signalling pathway
related genes was studied by a Real-Time PCR array.
Results: The amount of H5N1 RNA was signiﬁcantly lower than that
of H3N2 after 1 hour of adsorption. The results indicate that H5N1
is able to induce more efﬁciently IFN-a and -g mRNA as compared
to H3N2. Interestingly, released IFN was observed at 3 hours only in
PBMC induced by H5N1, and not by H3N2. The induction of a set of
genes involved in the innate immune response, was detected at 3 h.p.i.
in PBMC exposed to H5N1, and not to H3N2, however, at later times,
the extent of activation of these genes was similar. TLR array analysis
suggests a different mechanism of INF induction for H5N1 and H3N2
Conclusion
Conclusion: HPAI H5N1 is able to stimulate, in a dose- and time-
dependent manner a coordinate induction of IFN-a and -g in normal
PBMC. Type I and II IFN response to H5N1 is more rapid and intense
as compared to H3N2. A more rapid response is also observed for IFN-
activated genes, but the overall extent is not different from H3N2. The
different kinetics are not accounted for by differences in cell bound viral
RNA. The IFN induction mechanisms may be different from those based
on interaction of viral RNA with TLR or with other cellular receptors.
Different kinetics of IFN response may have pathogenic signiﬁcance.
P581 Protein C, protein S levels and other haematologic parameters
in patients with Crimean-Congo haemorrhagic fever
Z. O¨zkurt °, S. Erol, A. Kadanal, K. O¨zden (Erzurum, TR)
Objectives: Crimean Congo haemorrhagic fever (CCHF) may be fatal
viral haemorrhagic fever. Massive bleeding is the most frequent cause of
death in patients with CCHF. Coagulopathy and DIC is the main cause
of bleeding in CCHF and other viral haemorrhagic fevers. This study is
conducted with prospectively to investigate which parameters disordered
in coagulation cascade.
Methods: Fifty CCHF patients hospitalised at Ataturk University
Medical School, Department of Clinical Bacteriology and Infectious
Diseases enrolled the study. Protein C, Protein S, Factor VIII, PT, aPTT,
INR, D-dimer, ﬁbrinojen levels were investigated in these patients.
Results: Some pathologic changes were detected in levels of measured
parameters. The most important changes were detected d-dimer values,
and the values were increased in 48 (96%) of patients. Second important
changes were detected protein S values; there were protein S deﬁciency
in 27 (54%) patients with CCHF. Both protein C and Protein S deﬁciency
were found 8 (16%) patients. In all patients have protein C deﬁciency,
protein S levels also decreased. Decreased protein C and S levels at on
admission improved (returned to normal) later period of the diseases.
Results are shown in Table 1.
Table 1. Haematologic parameters in patients with Crimean Congo Haemorrhagic fever
n: 50 Protein C Protein S Factor VIII Fibrinogen D-dimer PT aPTT INR
Normal, n (%) 42 (84) 23 (46) 48 (96) 40 (80) 2 (4) 42 (88) 39 (78) 40 (80)
High/Prolonged, n (%) – – – 2 (4) 48 (96) 8 (16) 11 (22) 10 (20)
Low, n (%) 8 (16) 27 (54) 2 (4) 8 (16) – – – –
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Conclusion: Protein C and protein S consumption may be increased
and/or syhnthesis may be decreased in CCHF. Pathologic changes in
these haematologic parameters and others should be investigated to
explain the pathogenesis of the disease and therapy.
P582 Analysis of the importance of nuclear export of the
inﬂuenza A virus NS1 protein for viral replication
J. Tynell °, K. Melen, I. Julkunen (Helsinki, FI)
Objectives: The NS1 protein of inﬂuenza A virus is a multifunctional
protein responsible for the inhibition of host cell immune responses.
Through its action in the nucleus and the cytoplasm NS1 functions to
shut down host cell interferon production and to limit the effects of
interferon-inducible antiviral proteins. To study the importance of the
intracellular localisation of NS1 we created a recombinant inﬂuenza A
virus of the strain A/Udorn/72 bearing a mutation to inactivate the
nuclear export signal (NES) of NS1.
Methods: The recombinant virus was created using a 12 plasmid
transfection system. The intracellular localisation of NS1 was visualised
by immunoﬂuorescence microscopy. The growth properties of the virus
were analyzed by measuring its growth kinetics on MDCK cells at
different multiplicity of infection (MOI) values. The cytokine production
of infected A549 cells was measured by ELISA.
Results: The mutated NS1 localised and remained in the nucleus even
at late stages of infection. The recombinant virus replicated to titers 10-
fold lower compared to the wild type virus and was not able to inhibit
the production of interferon-alpha or interferon-beta by the host cell.
Conclusion: The nuclear export of NS1 appears to be important for
the replication of inﬂuenza A virus and for its ability to inhibit host
cell interferon production, although the exact cytoplasmic role of NS1
responsible for the observation cannot be elucidated from these results.
The possibility of other properties of NS1 besides the NES being affected
by the induced mutation also cannot be ruled out.
P583 Prevalence of human papillomavirus types in women with
cervical intraepithelial neoplasia in Madrid, Spain
J.M. Sanchez Calvo °, M. Rodriguez Dominguez, J. Chacon de
Antonio, I.R. Sanz Gonzalez de Suso, E. Diaz Gonzalez, M.L. Mateos
Lindemann (Madrid, ES)
Objectives: Infection with high-risk human papillomavirus (HR-HPV)
types is the main cause of cervical cancer. Prior to vaccination, it
is important to deﬁne the prevalence of HR-HPV in each geographic
area. Our objective was to study the prevalence of HR-HPV types in
our country in patients with CIN2+ results in cervical samples and
investigate the relationship between HPV types and histological data
to ascertain whether HPV types differ geographically.
Methods: A total of 458 women attended at the Gynaecology Unit at our
hospital were studied for a period of two years (04/30/06−04/30/08). The
presence of HPV was investigated in cervical samples by a hybrid capture
test (DIGENE, Gaithersburg, USA). All positive HR-HPV specimens
were studied by PCR (Linear Array, ROCHE DIAGNOSTICS) for
genotyping. Cytology and/or cervical biopsy results were available from
all patients.
Results: This study included 149 women with normal cytology, 14
atypical squamous cells of unknown signiﬁcance (ASCUS), 188 cervical
intraepithelial neoplasia (CIN)-1, 57 CIN-2, 34 CIN-3 and 16 with
cancer. The most prevalent HPV types in CIN2+ were HPV-16, 18,
31, 33, 51, 52, 56 and 58. HPV-16 was implicated in CIN-2 (56.1%),
in CIN-3 (47.1%) and in cervical carcinoma in situ (CIS) (87.5%).
Multiple infections in CIS specimens, comprising more than 2 HPV
types, were found in 31.3% of patients. HPV-16 was present in all
multiple infections. However, the presence of more than 1 HR-HPV
type was not associated with an increased risk of high grade lesions.
Conclusions: HPV-16 was the most common type in patients with
CIN2+ results. Consistent with other authors, also in Spain, HPV-16
and HPV-18 were the two most common types found in CIN2+ lesions.
Interestingly, in our study HPV-18 caused only 7.5% of CIN2+, in
contrast with the fraction attributable to HPV-16 (58%). In our study,
the prevalence of HPV-16 in CIS was higher (87.5%) than in other
studies performed in other countries (50−55%). Regional variation in the
distribution of HR-HPV types should be considered to design screening
tests and vaccination programs.
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P584 Tuberculous meningitis in adults: evaluation of 38 cases
A.S. Inal °, B. Kurtaran, A. Candevir, Y. Tasova, H.S.Z. Aksu (Adana, TR)
Objective: Tuberculous meningitis (TM) as a marker of uncontrolled
of tuberculosis in population is still a health problem in developing
countries. The aim of this study is to determine epidemiologic,
diagnostic, clinical features and outcome of TM in adults who were
admitted in Cukurova University Hospital.
Methods: Thirty-eight patients treated in Infectious Diseases Depart-
ment between January 1995 and December 2004 were investigated
retrospectively.
Results: Of patients, 20 were male (52.6), and 18 (47.4) were female.
Mean age of the cases was 29 (min 15, max 60, SD ±13). Diagnosis
was conﬁrmed by microbiological evidence (culture, polymerase chain
reaction or acid fast stain positivity) in 15 cases (39.5%), by
histopathological, radiological and clinical ﬁndings in 13 (34.2%), and
through response to therapy in 10 (26.3%) of patients. Mycobacterium
tuberculosis (MT) was recovered from clinical samples in 10 patients
(26.3%), wheras acid fast stain positive only in 4 (10.5%) patients. Drug
resistance were detected for 2 isolates from CSF (One resistant to both
isoniazid and rifampicin, and another resistant to both ethambutol and
rifampicin). Both patients who has resistant MT were recovered with
sequela. The initial examination of cerebrospinal ﬂuid (CSF) showed cell
counts ranging from 10 to 1530 with mean cell count 263/mm3, mean
protein level 227mg/dl (min 16, max 700), mean lactate 6.4mmol/L
(min 2.2-max 11.3). Three (7.9%) of the patients were classiﬁed as
stage I, 15 (39.5%) as stage II, and 20 (52.6%) as stage III according
to their clinical ﬁndings. Overall, 5 (13.2%) of the patients had a full
recovery, 25 (56.7%) had recovery with sequela and 8 (21.1%) fatal cases
were observed. All deaths were associated with stage III. No patient had
HIV infection and in 33 (86.8%) of the patients there were no evidence
of underlying pathology. Three patient had diabetes melitus, one has
Crohn disease and one was pregnant. All of the patients received four
major antituberculous drug regimen for 3−4 months and then INH and
RMP plus steroid around 4 weeks, except ones with resistant MT. The
mean duration of therapy was 12 months. Hydrocephalus was evident in
16 patient (42.1%), and 5 (13.2%) of them required ventriculo-peritoneal
shunt.
Conclusion: TM is still an important health problem with high mortality
and cost and severe sequela even in adults in developing countries.
Clinicians must be aware and administer promp terapy to reduce
complications.
P585 Genitourinary tuberculosis: a 12-year experience
D. Staios, A. Skolarikos, E.M. Fakiri, G. Alevizatos, M.A. Ntrivala °,
C. Deliveliotis, E. Papafrangas (Athens, Marousi, GR)
Background: We present our experience with genitouritary tuberculosis
(GUTB).
Methods: We reviewed the medical records of patients who have been
treated for GUTB. The epidemiology, clinical presentation, diagnosis,
treatment and long-term follow-up are presented.
Results: 27 males and 8 females were treated for GUTB in our hospital.
19 patients were admitted for pulmonary infection, 10 patients for upper
tract dilation and LUTS, 4 patients for fever of unknown origin, one
patient with painful testicle and one patient for haematuria. Urine culture
in liquid media (Mycobacteria Growth Indicator Tube; MGlT) was
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positive in 27 patients at a mean time of 12.1 days, while culture in solid
media (Lowenstein-Jensen medium; LJ) was positive in 23 patients at a
mean time of 26 days. Acid-fast stain (Ziehl-Neelsen; ZN) was positive
in only 9 patients raising the positive predictive value (PPV) of MGIT, LJ
and ZN in 90%, 63% and 25%, respectively. Mono-resistance was noted
in 4 isolates (isoniazid, streptomycin, pyrazinamide), poly-resistance in
2 isolates (isoniazid/streptomycin; isoniazid/pyrazinamide/ethambutol)
and multi-resistance in one isolate.
Urological intervention (14 double-J stents; 2 nephrostomy tube, 1
nephrectomy) was needed in 17 patients at presentation. All patients
were treated for a period of 9 months with the exception of one patient
who was treated for 12 months. The mean follow-up was 44.3 months
(range 5–146). During follow-up two patients died because of sepsis
secondary to urinary tract manipulation. No other complication was
noted and the urinary tract system was normal in 24 patients at the
last evaluation.
Conclusions: GUTB has a wide spectrum of clinical and radiological
ﬁndings. A high clinical suspicion is warranted for diagnosis. MGlT
shows the highest PPV among the diagnostic studies. The incidence of
mono-resistance or multi-resistance to ﬁrst-line anti-tuberculosis agents
still remains relatively low. Complications secondary to the infection
or its treatment are rare and most of the patients are cured following
appropriate treatment.
P586 Pulmonary Mycobacterium simiae disease in Iran’s national
referral centre for tuberculosis
P. Baghaei Shiva ° (Tehran, IR)
Background: Various types of non-tuberculosis Mycobacterium (NTM)
can affect human and can cause either symptomatic or asymptomatic
infection. In this particular study, we intend to determine the clinical,
radiological, and treatment of M. simiae in patients in our referral centre
in Iran.
Methods: This retrospective study is conducted at Masih Daneshvari
Hospital, a TB referral hospital in Iran. All patients presenting to our
centre between 2002–2008 with conﬁrmed infection with M. Simiae
are included in the study. For all patients, smear and culture for AFB
and drug susceptibility testing were performed. Also, PCR, identiﬁcation
methods for NTM, and high-resolution CT scan were carried out as well.
All patients with conﬁrmed M. simiae diseases were treated according
to ATS recommendations.
Results: Totally, 14 cases of M. simiae were identiﬁed in our centre.
Eight were female, all but one were Iranians, and the mean age of the
patients was 53±17.76 years. Just one patient was HIV positive.
The most frequent symptoms were cough (100%), Fever (92.9%), weight
loss (85.7%). 57% of the patients had nodular lesions. As well, each
bronchiectasis or cavitation was present in 50%. All patients were
resistant to all ﬁrst-line drugs. 12 patients reached cure and two patients
failed the treatment. There was no recurrence of the disease by any of
the patients after undergoing treatment.
Conclusion: M. simiae may present with clinical and radiological
manifestations consistent with tuberculosis, and be resistant to anti-TB
agents. NTM such asM. simiae should be sought to shorten the period of
treatment, lessen the adverse effects, and reach a more efﬁcient treatment.
P587 Tuberculosis in the oral cavity: a systematic review of the
published evidence
A. Kechagia, O. Kakisi °, I. Kakisis, M. Falagas (Manchester, Athens, GR)
Objectives: The incidence of oral tuberculosis, observed mainly
secondary to pulmonary infection has been diminished to less than
1% following the succesful implementation of antituberculous drug
therapy. The recent outbreaks however, combined with emerging
resistance in antituberculous medication warrant an increased suspicion
of mycobacterial involvement for persistent or atypical lesions of the
oral cavity.
Methods: We sought to review the published reports of mycobacterial
infection of the oral cavity in the literature from 1950 until today and
analyze the reported ﬁndings.
Results: Oral tuberculosis infection appears in all regions of the oral
cavity (soft and hard palate, uvula, buccal mucosa, gingivae, lips, tongue,
maxilla and mandible) more often in males than in females (age mean
37 yrs), predominantly in the form of ulcerative lesions covered with
slough and elevated margins, but also as swellings, nodules, pappulae
or granulomatous plaques. A large proportion of patients have had
multiple prior failures to treat by conventional antibiotics and/or steroid
treatment. Diagnostic investigation is important and microbiological
staining and/or culture has always been the golden standard for oral
Mycobacterium tuberculosis showing however varying sensitivities in
oral tissues. The importance of PCR detection is manifest and discussed.
Oral tuberculosis is found secondary to a pulmonary lesion in 42% of
the cases, to extrapulmonary TB in 3.5% and in all the remaining cases
is found primary. Antituberculous treatment shows effectiveness in (%)
of cases, while 3/144 deaths are documented due to the spread of the
mycobacterial infection in sites such as the meninges, or due to extensive
pulmonary (miliary) disease.
Conclusions: The investigation for a mycobacterial infection in oral
cavity lesions should be intense in the dental ofﬁce due to the re-
emergence of the disease and the importance for infection control.
Half of the times oral tuberculosis leads to the diagnosis of pulmonary
tuberculosis with signiﬁcant beneﬁt for the patients. A conventional
X-ray and biopsy is imperative, rapid microbiological identiﬁcation and
drug susceptibility required and awareness warranted.
P588 A new approach to tuberculous meningitis in Spain
V. Moreno °, E. Valencia, G. Ramirez-Olivencia, J. Gonza´lez Lahoz
(Madrid, ES)
Objectives: Tuberculosis (TB) is an increasing health problem in Spain
due to immigrants and patients HIV+. Tuberculous meningitis (TM)
is one of the most important manifestations and our objective was to
analyse the characteristics and evolution of a group of Spanish and non-
Spanish patients with TM.
Methods: We reviewed the clinical history of 25 patients with TM
hospitalised (2002–2008). Statistical study was done by SPSS 13.0. A
comparative study was performed of variables related to nationality.
Results: TB was only meningeal in 17 patients and disseminated with
meningeal localisation in 8. In 10 cases there was a previous episode
of TB and 20 (12 Spanish and 8 immigrants) were HIV+ (80%). Mean
age was 43 years, 13 were men (52%) and 14 were Spanish (56%). The
other were from Equatorial Guinea (20%), Ecuador (12%), Nigeria (8%)
and Peru (4%). Fever and headache were the most frequent symptoms
(96%), 17 patients (68%) had confusion and 14 were disorientated.
The most important criteria for TM diagnosis were cerebrospinal ﬂuid
biochemical alterations with elevated cells (mean: 298 cells/mm3, all
cases lymphocytes), elevated protein level (mean: 171mg/dl), decreased
glucose level (mean: 34mg/dl) and elevated adenosine deaminase level
(mean: 15 IU/L). Koch bacilli grew in sputum in 16%, in urine in 20%
and in spinal ﬂuid in 8%. All cases were sensible TB. 21 (84%) patients
were treated with 4 drugs and 15 (60%) received dexamethasone. One
year after treatment 17 patients were cured, 4 were dead (16%) and 4 left
pursuit without ﬁnishing the treatment. Three subjects cured with major
sequels. The use of dexamethasone did not inﬂuence evolution. Spanish
patients were men most frequent than immigrants (71% vs 27%), heavy
alcohol drinkers (50% vs 9%), smokers (79% vs 18%), intravenous drug
users (71% vs 0%) and had more disseminated tuberculosis (43% vs
18%). None of immigrants patients had culture positive, all were treated
with 4 anti-tuberculous drugs and there was no differences between
clinical manifestations, presence of HIV infection, cerebrospinal ﬂuid
biochemical alterations or evolution.
Conclusions: TM is a very important health problem with an elevated
number of sequels and mortality. Half of our patients were immigrants
and 80% were co infected with HIV. The clinical and evolutionary
characteristics of immigrants were comparable to Spanish patients but
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their demographic, microbiological ant treatment characteristics were
different.
P589 Human pulmonary tuberculosis due to Mycobacterium
microti: description of 6 recent cases in France
S. Godreuil ° (Montpellier, FR)
Objectives: Mycobacterium microti belongs to Mycobacterium tubercu-
losis complex (MTBC). Although it was considered for a long time as
nonpathogenic for humans, the ﬁrst human tuberculosis due toM. microti
has been reported in 1998. Here, we report the clinical, microbiological
and molecular characteristics of 6 human pulmonary tuberculosis due to
M. microti in France.
Methods: We carried out a retrospective study of cases diagnosed
between 2000 and 2007. The isolation of M. microti was performed
by culture from respiratory samples and the isolates were identiﬁed
as M. microti by the following molecular methods: (i) GenoType My-
cobacterium AS (Hain, Lifescience, Germany), (ii) a spoligotyping, and
(iii) speciﬁc signature at gyrB gene determined by sequencing.
Results: Out of the 6 patients (4 males and 2 females), 5 patients (83%)
were born in France and 1 patient was native of Senegal and was living in
France since 1990. Three patients had underlying conditions such as HIV
infection (n = 1), diabetes mellitus (n = 2). For 6 patients, any notion of
tuberculosis in childhood or in the entourage has been found. No patient
was exposed to pets specially cats or small rodents. The median time
between the onset of clinical symptoms and the diagnosis of tuberculosis
was 10.2 weeks (range, 16−72 weeks). The presenting symptoms were
productive cough (6 patients), night sweats (2 patients), thoracic pain
(1 patient) and there was no fever or haemoptysis. Chest radiographs
revealed cavitating pulmonary lesions in 5 patients and bilateral disease
in 2 patients. For the 6 patients, sputum microscopic examination showed
acid-fast bacilli. The cultures were positive in an average time of 48 days.
Spoligotyping revealed the llama spoligotype for 5 isolates and a new
pattern for 1 isolate. Drug susceptibility testing revealed sensitivity to
isoniazid, rifampin, ethambutol and streptomycin. Treatment regimens
are categorised into two groups; 3 patients were treated with tri-therapy
(rifampin, isoniazid, and pyrazinamid), 3 with tri-therapy regimen plus
ethambutol. Treatment period ranged from 6 to 12 months. The 6 patients
had favourable outcomes.
Conclusion: The prevalence and clinical importance of M. microti have
been previously underestimated. Further studies based on molecular
methods are needed to better understand the epidemiology and the
transmission of this pathogen to humans.
P590 Risk factors of paradoxical response in HIV-negative patients
with peripheral lymph node tuberculosis
O.H. Cho, J.H. Woo °, S. Choi, S.O. Lee, Y.S. Kim, J.M. Kim,
M.W. Kang, S.H. Kim (Seoul, KR)
Objectives: The paradoxical response (PR) of lymph node tuberculosis
(TB) during anti-tuberculosis therapy was well-known phenomenon in
non-HIV infected patients as well as in HIV-infected patients. But data
on risk factors are limited.
The aim of this study is to elucidate the clinical characteristics and risk
factors for PR of peripheral lymph node TB in non-HIV infected patients
Methods: The medical records were reviewed between Jan 1997 and
Aug 2007 on non-HIV infected patients who were >16 years of age
with peripheral lymph node TB at a 2,200-bed tertiary teaching hospital.
Patients were classiﬁed as having conﬁrmed TB if clinical specimens
were positive forM. tuberculosis on culture, acid-fast bacilli (AFB) stain,
or M. tuberculosis PCR. Patients were classiﬁed as having probable TB
if the histologic ﬁnding of biopsy tissue showing necrotising granuloma
and successful response to anti-tuberculosis therapy. PR was deﬁned
as the clinical or radiological worsening of pre-existing TB lesions
or the development of new lesions in patients who had received anti-
tuberculosis therapy for at least 2 weeks.
Results: A total of 300 non-HIV-infected patients with peripheral
lymph node TB were enrolled. The mean age (+standard deviation)
of the patients was 37.9 (+13.9) years and 232 (77%) were female.
Of these, 267 patients (89%) had cervical lymphadenitis. By clinical
categories, 234 patients (78%) were classiﬁed as conﬁrmed TB, and
the remaining 66 (22%) as probable TB. Necrotising granuloma, AFB
stain, TB PCR, and cultures for M. tuberculosis were positive in 192
of 300 (64%), 106 of 300 (35%), 156 of 188 (83%), and 42 of 141
(30%), respectively. The PR occurred in 61 (20%, 95% CI 16.2% to
25.3%) of 300 patients, the median onset time of PR was 7 weeks
(interquartile range, 4−12 weeks). Thirty-one patients (53%) were closely
observed with anti-TB medications only, 16 (26%) had surgical lymph
node excision, 10 (16%) had ﬁne-needle aspiration performed, and
2 (3%) received corticosteroid therapy. The young age (OR 0.96), male
sex (OR 2.7), large nodes (OR 1.3), the presence of local tenderness
(OR 2.9), and prior treatment of active TB (OR 2.4) were independent
risk factors for PR in a logistic regression analysis.
Conclusion: The PR was common, occurring in one-ﬁfth of patients.
The risk factors of the PR were young age, large nodes, the presence of
local tenderness, and prior treatment of active TB in non-HIV patients
with peripheral lymph node TB.
P591 Mycobacterium marinum infection in a striped bass farm in
northern Italy
E. Bozzetta, K. Varello °, I. Giorgi, M. Fioravanti, M. Pezzolato,
R. Zanoni, M. Prearo (Turin, Bologna, IT)
Objectives: Striped bass (a hybrid of Morone spp.) is an economically
and recreationally important farmed ﬁsh in US. In Italy this species is not
highly valued, but recently its farming is becoming more popular with the
Italian consumers. Mycobacterial infection in wild and farmed Morone
spp. are often reported in US and other countries, Mycobacterium
marinum, M. shottii and M. pseudoshottii being the species most
frequently isolated. To date, few cases of mycobacterial infections were
described in ﬁsh reared for human consumption in Italy. Here we describe
an episode of M. marinum infection in a striped bass farm located in
Northern Italy.
Methods: A striped bass was reported to the ﬁsh disease laboratory
following the detection of yellow-brown nodules on the gills. The mi-
croscopic identiﬁcation of multiple mycobacterial granulomas suggested
further investigations in the ﬁsh rearing
Forty ﬁshes were randomly selected sacriﬁced and necropsied in order to
investigate the presence of the infection and to identify the mycobacterial
species involved. At necropsy samples of gills, liver, spleen, kidney,
skin and muscle were collected for histological examination and
parasitological, virological and bacteriological investigations.
Results: At gross examination ulcerative cutaneous lesions, yellow mu-
cus with red nodules on the gills, splenomegaly and miliary granuloma-
tous lesions in liver, kidney and spleen were observed in all animals. Mi-
croscopically, granulomas presented a central eosinophilic area (necrosis)
surrounded by inﬂammatory cells and enclosed by a thin capsule. The
nodules resulted positive at Ziehl-Neelsen staining, displaying a variable
amount of acid-fast bacilli. From all the tissues, with the exception of the
muscle, photochromogenic colonies were identiﬁed; the puriﬁed isolates
were phenotypically and biochemically characterised as M. marinum.
Parasitological and virological investigations resulted negative.
Conclusions: This episode suggests that striped bass can represent a
reservoir of mycobacterial infection in Italian rearings too. It is important
to emphasize that, although granulomatous lesions could be observed
in various organs, the mycobacterial infection was not responsible for
mortality in the farm. Due to the low death rate observed, the risk of
human exposure to the infection by manipulation and consumption of
the contaminated ﬁsh belonging to this species has not to be disregarded.
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P592 Particularities of tuberculosis in teenagers horizontally
infected with HIV-1 during infancy
A. Cupsa °, F. Dumitrescu, L. Giubelan, I. Niculescu, A. Romanescu,
C. Miu, A. Rosca (Craiova, RO)
Background: Historically, Romania cumulates, worldwide, the largest
number of horizontally HIV-1 infections in children. Meanwhile, the
southern part of the country (Oltenia province) registers the highest
incidence of tuberculosis (TB) from Europe (about 160.5/100000
inhabitants). Contextually, HIV infected teenagers have a high risk of
tuberculosis – from exogenous sources or endogenous reactivation.
Objectives: To evaluate the incidence, clinical and evolutive aspects
as well as immunological and virusological characteristics in teenagers
having both TB and HIV-1 infection horizontally transmitted.
Methods: retrospectively study (01.01.2002−31.12.2007); we have
evaluated 415 teenagers (born1988 and 1989), horizontally infected with
HIV-1 during their infancy, under surveillance of Regional Center for
Evaluation and Monitoring of HIV/AIDS Infection, Craiova, Oltenia
province, Romania. TB workup was based on epidemiological, clinical,
imaging (X-ray, CT scans), microbiological (smears, culture) and
immunological (Quantiferon TB, PPD skin test) data.
Results: 76 (18.3%) patients (Ps), HIV infected teenagers (male/female
= 41/35) have been diagnosed with TB. Exogenous sources have
been identiﬁed in 9 cases (11.8%) vs 67 Ps (88.2%) having probably
an endogenous reactivation of a latent infection. Clinically we have
encountered: pulmonary TB – 48 cases (63.2%), non-pulmonary TB –
19 cases (25%) and mixture – 9 (11.8%) cases. 20 Ps (26.3%) had
a bacteriological conﬁrmation of tuberculosis. The average CD4 count
has been 185.2±171.1 cells/mm3 while the average viral load has been
5.6±5.4 log copies/ml. Relatively to antiretroviral treatment (ART): 23 Ps
(30.2%) was naive before TB diagnosis (19 of them newly diagnosed
as HIV infected) while 53 Ps followed ART (average 2.7 regimens/Ps,
28 of them – 36.8% – being multiexperienced). All Ps received ART,
anti-bacillary treatment, pathogenic and supportive care. 21 Ps (27.7%)
recorded a complete recovery, 20 Ps (26.3%) registered relapses, 4 Ps
(5.3%) had an inﬂammatory reconstitution syndrome and 3 Ps (3.9%)
remained with sequelae. We have recorded 28 deceases (36.8%).
Conclusion: The incidence of TB among HIV infected teenagers is high
in the Oltenia province; pulmonary TB is the most frequent clinical type;
TB occurs regardless of the CD4 count or viral load level; evolution of
TB is severe in Ps having advanced HIV infection, with multiple ART
regimens, even with a proper tuberculostatics treatment.
P593 Non-tuberculous Mycobacteria: incidence and clinical
signiﬁcance
M.W. Kang °, Y.J. Kim, Y.H. Jeon, S.I. Kim, S.H. Wie, Y.R. Kim (Seoul,
KR)
Objectives: There is geographic variability in the prevalence of
mycobacterial species. However there have been only a few incidence
data for nontuberculous mycobacteria (NTM) in Asian countries. Also
clinical signiﬁcance of NTM infection is still unclear. To describe the
incidence and clinical signiﬁcance of NTM infection in a single centre
of Korea.
Methods: Between January 2004 and December 2007, we analyzed a
total of 19,593 clinical samples from 10,057 patients who were requested
for mycobacterial cultures. NTM species were identiﬁed by using PCR-
restriction fragment length polymorphism methods (PRA).
Result: A total of 160 specimens (94 sputum, 55 bronchial washing,
5 peritoneal dialysate, 4 pus, 1 lymph node, 1 bone marrow) from
100 patients (50 male, 50 female) were culture-positive for NTM. The
mean age of the patients was 60.6±12.8-years old. Among a total of
100 patients with culture-positive for NTM, 47 cases had COPD, 40
previous tuberculosis history, 10 malignancy, 9 autoimmune disease, and
3 HIV-infected. The most frequently isolated organisms were M. avium
complex (n = 86, 53.8%), followed by M. abscessus (n = 48, 30%),
M. fortuitum complex (n = 9, 5.6%), M. gordonae (n = 4, 2.5%), and
unclassiﬁed (n = 13, 8.1%), Forty-seven patients with NTM infection (43
pulmonary disease, 2 peritonitis, 2 disseminated disease) received anti-
NTM treatment. Two patients were reactivated NTM after treatment.
Only 49 cases (30.6%) were smear-positive for acid-fast bacilli (AFB)
by microscopy.
Conclusion: The common species of NTM in our centre were different
from other countries. In our centre, the incidence of NTM disease
using PRA demonstrated in 47% of patients with culture-positive for
NTM. The sensitivity of AFB-smear for NTM infection was relatively
low, therefore culture for NTM should be considered in patients with
suspicion of mycobacterial infection but negative AFB-smear result.
P594 Prevalence of Mycobacterium tuberculosis drug resistance in
a Spanish teaching hospital during a six-year period
S. Agudo °, D. Domingo, M.J. Moreno, M.C. Martı´nez, M. Lo´pez-Brea
(Madrid, ES)
Objective: An increase in Mycobacterium tuberculosis drug resistance
has been registered in the last few years in industrialised parts of
the world. Rapid detection of M. tuberculosis strains resistant to
antituberculosis drugs is probably the most important factor to minimise
the spread of contagion. The aim of this study is to evaluate the drug
resistance of culture positive cases of pulmonary and extra-pulmonary
tuberculosis during a six year period in a Spanish teaching hospital.
Methods: 343 strains ofMycobacterium tuberculosis were obtained from
samples, received at the Microbiology Department (Hospital Universi-
tario de la Princesa, Madrid) from January 2003 to December 2008.
Samples were collected by standard procedures. They were examined
by auramine stain and inoculated on Lowenstein Jensen (LJ) media and
BACTEC MGIT 960 system.
All of the strains were identiﬁed as belonging to M. tuberculosis
Complex by combining DNA-probe hybridisation (AccuProbe M. tu-
berculosis; Gen-Probe, San Diego, Calif). In vitro drug susceptibility
tests against the ﬁrst line drugs (Isoniazid, Streptomycin, Rifampicin,
Ethambutol and Pyrazinamide) were performed by BACTEC MGIT 960
SIRE and PZA (Becton Dickinson).
Results: A total of 77.56% strains were susceptible to the ﬁve ﬁrst line
essential drugs. Drug resistance rates of 7.28% was detected against
isoniazid, 10.20% against Streptomycin, 2.33% against Rifampicin,
0.96% against Ethambutol and 2.88% to Pyrazinamide. Multidrug
resistance (MDR: Resistance to both isoniazid and Rifampicin) was seen
in 8 (2.43%) of the isolates. 3 (0.87%) isolates were found to be resistant
to all drugs tested. 3 out of 8 MDR M. tuberculosis isolates were from
patients who had immigrated to Spain and only one patient was infected
by the human immunodeﬁciency virus. The resistance to both Isoniazid
and Rifampicin decreased from 3.77% in the period of 2003–2004 to
2.35% 2007–2008.
Conclusion: Ethambutol and Streptomycin were the most and the less
active drugs, respectively. According to our work, resistance to Isoniazid
and Rifampicin is low in our area, specially in the last years. All
reasonable efforts to prevent the spread of MDR tuberculosis must be
made and maintained. It requires an efﬁciently working anti-tuberculosis
programme to prevent resistance.
P595 Mycobacterium genavense infections: a French national
multi-centre retrospective study from 1996 to 2007
P. Charles °, O. Lortholary, A. Dechartres, F. Doustdar, M. Lecuit,
J.P. Viard, M.C. Gutierrez (Paris, FR)
Objectives: To describe Mycobacterium genavense infections in the
era of highly active antiretroviral therapy (HAART) and to provide a
molecular overview of this mycobacteria using a multigenic approach.
Methods: A retrospective national survey was conducted in France.
Patients with M. genavense infection diagnosed from 1996 to 2007
in a national reference laboratory were identiﬁed and their clinical,
biological and microbiological data were collected with a standardised
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form. The mycobacterial DNA was sequenced to identify potential
sequence variants within the ARNr16 s, hsp65 and rpoB genes.
Results: Twenty ﬁve cases ofM. genavense were identiﬁed in 15 centres.
Twenty patients were AIDS patients, 3 had a solid transplantation and
2 had a sarcoidosis. Sixteen patients (64%) were male, mean age was
42 years (SD=10) and the median CD4 count was 13/mm3. Twenty
four patients had a disseminated infection with fever (75%, n = 18),
weight loss (79%, n = 19), abdominal adenopathies (62.5%, n = 15),
abdominal pain (71%, n = 17), diarrhoea (62.5%, n = 15), splenomegaly
(71%, n = 17), hepatomegaly (62.5%, n = 15). M. genavense was isolated
in the adenopathies (n = 13), digestive biopsies (n = 9), blood (n = 6),
sputum (n = 3), stools (n = 3), bone marrow (n = 5). Eleven patients (44%)
died, 8 (32%) were cured and 6 (24%) had chronic symptoms. The one-
year, three-year and ﬁve-year survival rates were respectively 72%, 59%
and 53%. Four sequence variants of M. genavense were identiﬁed within
the hsp65 gene.
Conclusion: The prognosis of M. genavense infection has dramatically
improved with HAART. We identiﬁed a genetic polymorphism of the
mycobacteria useful to improve the molecular diagnosis of the infection.
P596 Extensively drug-resistant tuberculosis in patients recently
immigrated from Eastern Europe. Microbiological,
therapeutic, and public health features
R. Manfredi °, L. Calza (Bologna, IT)
Introduction: MDR-XDR TB is a worldwide emergency. The increased
number of patients (p) immigrating from countries where health care
systems could not ensure adequate drug delivery and monitoring is a
major concern in Europe.
Methods and Results: During the 2nd half of y 2006 and the 1st
half of y 2007 a 30-y-old male from Moldova and a 24-y-old female
from Ukraine underwent very prolonged hospitalisations due to XDR
TB. The 1st p, with TB known since 6 y developed MDR-XDR due to
frequent treatment discontinuations. On the ground of in vitro sensitivity
assays, cycloserine, para-aminosalycilic acid, capreomycin, ethionamide,
and linezolid were added, obtaining clinical-microbiological cure after
9 mo of hospitalisation. Three mo after discharge, our p maintained an
effective 6-drug regimen on Day-Hospital basis, but 3 mo later another
5-mo hospitalisation was needed after retrieval of a positive sputum. An
outpatient treatment was conducted on Day-Hospital basis for 3 mo, but
positive sputum prompted a third admission lasting since 3 mo. Our
2nd p who came to Italy with a MDR TB, had an unfavourable course,
and was tested in vitro for 2nd choice drugs, which suggested a cy-
closerine, para-aminosalycilic acid, capreomycin, ethionamide, and mox-
iﬂoxacin adjunct, and achieved clinical-bacteriological cure and hospital
discharge after 5 mo, despite a concurrent chronic hepatitis C which ham-
pered liver tolerability. During the subsequent 3-mo Day-Hospital follow-
up, a 5-drug association ensured a temporary cure, but 4 mo later another
3-mo admission was needed due to repeated positive sputum searches.
Conclusions: The management of the emerging MDR-XDR TB
encompasses elevated clinical suspicion, diagnostic accuracy, availability
of susceptibility assays of 2nd-3rd line anti-TB drugs, and adequate
isolation and public health issues, when prolonged hospitalisations
or protected discharges are needed. The frequent involvement of
foreign immigrants is burdened by further social-economic, cultural,
and administrative problems. The easy development of life-threatening,
contagious MDR-XDR TB in health care contexts where low-cost
anti-TB drugs are not always available, is in contrast with the huge
danger and the exceedingly high costs of these episodes which need
prolonged hospitalisation-isolation, and enormous technologic and health
care efforts. A systematic planning of the most adequate management-
prophylactic measures aimed at containing-preventing XDR TB in the
next future is needed.
P597 Signiﬁcant re-emerging of tuberculosis in Italy. Relationship
with potential risk factors, and comparison between native
residents and foreign immigrants
R. Manfredi °, S. Sabbatani, L. Calza (Bologna, IT)
Introduction: Tuberculosis (T) is burdened by increasing morbidity-
mortality rates, due to changes of epidemiologic scenario, and diffusion
of resistant strains. The recent, profound modiﬁcations occurred among
predisposing factors (increase mean patient [p] age, concurrent diseases,
iatrogenic immunosuppression, alcoholism, drug addiction, migration,
and HIV pandemic), played a key role in this process.
Methods: Among the 182 consecutive p hospitalised due to T since
1996, we compared the 101 p from Italy with the 81 immigrants from
extra-European and/or developing countries, in relation of a number of
risk factors, including HIV infection.
Results: Compared with immigrants, Italian p had a higher fre-
quency of HIV-AIDS (33.7%; p< 0.001), and a predominant pleuro-
pulmonary involvement versus lymph node and/or disseminated T among
HIV-infected p versus non-HIV-infected ones (p< 0.01). Moreover,
Italians had a greater mean age (p< 0.001), and an increased frequency
and a broader spectrum of predisposing conditions (positive history,
chronic lung, heart, liver, kidney disease, diabetes mellitus, malignancies,
and collagen vascular disease; p< 0.02), while foreigners had a lower
frequency of more generic supporting factors (low income, economic-
social problems, cigarette smoking, and alcohol-drug abuse; p< 0.03
versus natives). Our decade experience shed light on two different
patterns of T. Local p are predominatly represented by elderly with
frequent concurrent disorders and speciﬁc T risk factors, a more frequent
HIV infection, and a predominant involvement of sites other than
pulmonary ones, while immigrants are represented by otherwise healthy
younger p, who develop prevalent lung localisations.
Conclusions: The clinicians awareness of T needs increased attention, in
order to obtain a rapid diagnosis and treatment, and reduce transmission
risks. The progressive integration of immigrants with local population
may lead to increased risks of T dissemination, especially among the
local, more vulnerable and older p population.
P598 Trends of tuberculin skin test positivity rate among children
6−14 years old in Attica, Greece
M. Dandoulakis °, N. Roussos, D. Karageorgopoulos,
N. Yatromanolakis, M. Falagas (Athens, GR)
Objective: The rising incidence of tuberculosis in developed countries
is partly associated with immigration from high-prevalence countries. In
Greece, a steep rise in foreign-born immigrants has been observed over
the past 2 decades. We sought to estimate the prevalence and temporal
trends of tuberculin skin test (TST) positivity rate among schoolchildren,
in a sub-urban area of Attica, Greece.
Methods: We retrospectively analyzed the TST positivity rate (forearm
volar surface induration >10mm) of schoolchildren, in the catchment
area of the public primary health-care centre of Vari, over a 16-year
period (from 1990–2005). TSTs were performed in the context of a
national, government-directed TB screening program.
Results: A total of 11,105 records of TSTs performed in children,
aged 6−14 years, were retrieved. These tests referred to 7,920 and
2,969 BCG unvaccinated and vaccinated children, respectively, as well
as 120 children who had close contact with a TB-conﬁrmed case, and 6
children with known active or latent TB. The TST positivity rate among
BCG unvaccinated children was 2.0% over the whole study period; this
ﬁgure declined in the second compared to the ﬁrst half of the study
period (1.4% vs. 2.4%, p< 0.001). The TST positivity rate among BCG
vaccinated children was 63.6%, and appeared to gradually decline after
vaccination.
Conclusion: The gradual decline in the TST positivity rate among BCG
unvaccinated schoolchildren, despite the substantial rise in the number
of immigrants in Greece, over our study period, may, at least in part, be
attributed to relevant national screening and prevention measures.
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P599 Comparison of smear positive pulmonary tuberculosis in
young adult and elderly patients
R. Qasemibarqi ° (Qazvin, IR)
Background: Pulmonary tuberculosis remains a signiﬁcant clinical
and public health problem in the elderly population. To describe age-
related differences in disease manifestations, a comparison of the clinical
features and radiographic ﬁndings in cases of smear positive pulmonary
tuberculosis among 324 patients was performed.
Design: Between January 1997 and December 2006 all patients with
smear positive Pulmonary tuberculosis diagnosed at the Department
of Medicine, Bo Ali Sina of Qazvine Hospital and ﬁve district health
centres were recruited into the study. The following data were collected:
presenting symptoms, radiographic appearance and sputum results for
acid-fast bacilli. The patients were divided into two groups (254 young
adult lower of 60 years and 70 elderly equal or higher of 60 years) and
differences in presentation of the two groups were analyzed.
Results: Prior to treatment, symptoms occurring with a higher frequency
in elderly patients included fever nightly sweating, dyspnea and
haemoptysis (p less than 0.05).
Symptoms occurring with equal frequency in both young adult and
elderly patients included coughing, production of sputum and weight
loss.
Elderly patients had signiﬁcantly higher incidences of negative reactions
to the PPD test (p less than 0.05). Radiographic ﬁndings revealed that
upper lung ﬁeld inﬁltrates were still common in both groups, but the
elderly had more lower lobe lung ﬁeld involvement, and frequent cavitary
lesions than younger patients (p less than 0.05).
Discussion: Since there were non-speciﬁc clinical features, false negative
skin test and complex radiographic manifestations, tuberculosis was
frequently not suspected in the differential diagnosis, especially among
elderly patients with multiple medical problems. We suggest that
physicians need to have a high level of suspicion and awareness of
varied manifestations for tuberculosis, especially in elderly patients.
P600 Application of the optimal 24 MIRU-VNTR loci set for
Mycobacterium tuberculosis strains improves the correlation
between strain typing and epidemiological data
J.T. Evans °, B. Taylor, D. Estephane, S. Gardiner, E.G. Smith,
P.M. Hawkey (Birmingham, UK)
Objectives: The utility of DNA ﬁngerprinting of M. tuberculosis strains
and its ability to direct and focus cluster investigation has been greatly
enhanced by the use of MIRU-VNTR typing. An enhanced, optimal
set of 24 MIRU-VNTR loci that offers greater discrimination over the
original 12 MIRU-VNTR loci and aims to improve the concordance of
strain typing data with epidemiological data has been published. In the
Midlands region of the UK, all M. tuberculosis isolates are typed using
the original 12 MIRU-VNTR loci and 5 ETR loci. The aim of this study
was to evaluate the public health applicability, utility, and performance of
optimal MIRU-VNTR loci set in discriminating clusters deﬁned by the
original MIRU-VNTR loci that have varying levels of epidemiological
links.
Methods: Six clusters containing 71 M. tuberculosis strains typed using
the original MIRU-VNTR loci set were selected for further analysis by
the optimal MIRU-VNTR loci set. Epidemiological links within each
of the 6 clusters were investigated retrospectively and these strains were
selected for further analysis by the optimal MIRU-VNTR loci set as they
contained a range of cases with varying levels of epidemiological links
ranging from none found to deﬁnitive. MIRU-VNTR analysis was carried
out by PCR using previously published oligonucleotides and fragment
sizing by agarose gel electrophoresis.
Results: Using the original set of MIRU-VNTR loci the degree of
concordance between molecular data and epidemiological data was 61%.
Analysis using the additional 9 loci required to complete the optimal set
of MIRU-VNTR loci increased the level of concordance to 93%.
Conclusion: The optimal set of M. tuberculosis MIRU-VNTR loci
greatly increases the concordance between strain typing and epidemi-
ological data. This further enhances the utility of MIRU-VNTR loci in
DNA ﬁngerprinting of M. tuberculosis strains as clusters identiﬁed by
the original MIRU-VNTR loci set but with no apparent epidemiological
links are differentiated into epidemiological relevant sub-groups whereas
epidemiological relevant clusters are not signiﬁcantly split by the optimal
MIRU-VNTR loci set.
P601 Comparison of Mycobacterium tuberculosis strains prevalent
in the Indian Sub-continent and the UK
H.E. Smith, J.T. Evans °, E.G. Smith, R. Webber, D.A. Lammas,
P.M. Hawkey (Birmingham, UK)
Objectives: Previous studies have reported the predominance of
“ancient” strains in the Indian Sub-Continent (ISC) which may represent
a focus of past evolution within M. tuberculosis. The study presented
here analysed prevalent strains originating from the ISC and present in
the Midlands, UK to compare predominant strains in the two regions.
Methods: From 4,345 M. tuberculosis isolates typed in the Midlands
region of the UK, a collection of 100 prevalent representative MIRU-
VNTR proﬁles associated with patients originating from the Indian Sub-
Continent were selected for further analysis by gyrA-katG SNP analysis,
RD1 and TbD1 deletion analysis, and spoligotyping. These strains were
selected by using OriginsInfo software which analyses given and family
names and assigns a global cultural, ethnic, and linguistic origin. SNP,
RD1, and TbD1 analysis were carried out using previously published
protocols using agarose gel electrophoresis. Spoligotyping was carried
out using a previously published protocol for analysis on a Luminex
system. Spoligotyping results were compared against a global database
(spoldb4).
Results: When compared against spoldb4, 69/100 strains had deﬁned
known spoligotypes. Deﬁned spoligotypes identiﬁed were the Central
Asian Strain (n = 40, East-African Indian (n = 8), T (n = 8), Haarlem
(n = 4), Beijing (n = 3), and AFRI/S/U/X (n = 6). Strains with unde-
ﬁned spoligotypes included probable CAS (n = 19), Haarlem (n = 3),
LAM (n = 3), EAI (n = 2), X (n = 1), and indeterminate (n = 2).
12/100 strains possessed the TbD1 region, with all 100 strains containing
the RD1 region, 76/100 strains were in PGG1, 18/100 were in PGG2,
with 6/100 in PGG3. Extrapolating this data to the UK collection of
4,345 strains typed, there are 2,357 isolates originating from Southern
Asia. 427/2,357 (18%) isolates are M24 = 2 or greater (ancient). A
minimum of 935/2,357 (40%) strains may be members of the CAS family
with 933/935 being modern (M24<2 repeats).
Conclusion: Previous studies have indicated that M. tuberculosis strains
present in the Indian Sub-Continent are predominantly ancient. Our study
of isolates in the UK originating from the ISC show that this population
is predominantly modern due to the predominance of the CAS family
and not the EAI family as has been reported in the ISC. This difference in
prevalent strains may be due to speciﬁc strain importation from speciﬁc
areas of the ISC and subsequent clonal expansion within the Midlands.
P602 Novel mutations outside rifampin resistance determining
region associated with rifampicin resistance inMycobacterium
tuberculosis
K.H.G. Siu °, W.C. Yam (Hong Kong, HK)
Background:More than 90% of rifampicin resistance inMycobacterium
tuberculosis was shown to be caused by mutations inside the 81-bp
rifampin resistance determining region (RRDR) located in the centre
of the rpoB gene. The association of mutations outside RRDR with
rifampicin resistance in M. tuberculosis has not been fully elucidated.
Objective: To identify the novel mutations associated with rifampicin
resistance in M. tuberculosis.
Methods: A collection of 50 clinical isolates of rifampicin-resistant
M. tuberculosis were sequenced for the whole rpoB gene. The
rpoB genes of the isolates with novel mutations were cloned into
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a mycobacterial expression vector pVV16 and were transformed into
M. smegmatis MC2155 for rifampicin minimal inhibition concentration
(MIC) study.
Results: PCR-sequencing of rpoB gene revealed that mutations inside
RRDR occurred in 49/50 rifampicin-resistant isolates with the most
common changes in codons S450L (45%), H445D (17%) and L452P
(9%). Two novel mutations, I488V and I491F, were identiﬁed. The
former one is hard to elucidate as the isolate also harboured the hotspot
mutation, S450L. The isolate with I491F does not habour any mutation
in other region of rpoB. Transformation of the mutated rpoB gene into
Mycobacterium smegmatis MC2155 rendered an increase in MIC from
32 ug/ml to 128 ug/ml. By homology, codon 491 in M. tuberculosis
rpoB corresponds to Escherichia coli rpoB codon 572, which lies
within the cluster II and is known to be a hotspot mutation site for
rifampicin resistance in E. coli although it has not yet been reported for
M. tuberculosis.
Conclusion: Result indicates that the codon 491 is probably another
rifampcin-resistant determinant site for M. tuberculosis. Appropriate
molecular tests should be able to detect this mutation in addition to
RRDR for early and reliable prediction of rifampicin susceptibility in
clinical M. tuberculosis samples or isolates.
P603 High-resolution melting analysis for rapid detection
of rifampin and isoniazid resistance in Mycobacterium
tuberculosis clinical isolates
G.E. Choi °, E.J. Song, S.H. Hwang, H.H. Kim, E.Y. Lee, C.L. Chang
(Busan, KR)
Objectives: Rapid detection of drug-resistant tuberculosis improves
therapy and transmission control. We used high-resolution melting
(HRM) curve analysis, which detects single nucleotide polymorphisms,
to identify rpoB, katG and inhA mutations responsible for rifampin (RIF)
and isonizid (INH) resistance.
Methods: Total 161 clinical isolates that included 65 INH-resistant (R),
61 RIF-R, and 76 dual-susceptible (S) strains were tested. The PCR
primers ampliﬁed the region containing codons 510–528 of rpoB, codon
315 of katG, and nucleotide substitution C209T in inhA. The melting
curves were obtained with ﬂuorescence of Eva Green dye by using
Corbett Life Science Rotor-GeneTM 6000 instrument. All R strains and
randomly selected 40 S strains were subjected to DNA sequence analysis.
Results: All 96 INH-S strains showed unique melting curves in the katG
and inhA PCR (speciﬁcity 100%). Sixty-two INH-R strains had melting
curves different from wild-type strains. Sequence analysis showed 48
katG S315T and 22 inhA C209T mutations. Three INH-R strains showed
wild-type melting curves (sensitivity 95.4%). All 100 RIF-S isolates
displayed a single peak in rpoB PCR (speciﬁcity 100%). Among 61 RIF-
R strains, 53 had distinct mutant-type melting curves, demonstrating the
D526Y mutation in 8 and the S531L mutation in 44. Three strains with
D516Y mutations exhibited melting curves similar to the wild type, but
a difference plot curve demonstrated a distinction. The remaining strains
had 1 D516V and 4 H526D mutations in rpoB (sensitivity 91.8%).
Conclusion: An HRM analysis is rapid and detects RIF- or INH-R
M. tuberculosis with high sensitivity and speciﬁcity.
P604 Characterisation of pncA mutations in Mycobacterium
tuberculosis clinical isolates from South Korea
Y.K. Cheah, Y.J. Yun, H.Y. Kim, H.J. Kim, S.H. Lee, Y.H. Maeng,
Y.R. Kim, K.H. Lee °, Y.H. Kook (Selangor, MY; Seoul, Jeju, KR)
Objective:Tuberculosis (TB) is a major public health problem in many
parts of the world. 2 billion people-one third of the world’s population-
are infected with the TB. One in 10 of those people will develop active
TB. Pyrazinamide (PZA) is one of the most important and an effective
ﬁrst-line drug for the treatment of TB together with Rifampin (RIF).
It is a prodrug that requires conversion into its active form, pyrazinoic
acid, by the bacterial enzyme pyrazinamidase (PZase), which is encoded
by the pncA. Therefore, the purpose of this study was to characterise
the pncA mutations of Mycobacterium tuberculosis clinical isolates in
South Korea.
Methods: DNA of specimens or Mycobacterium tuberculosis clinical
isolates was obtained from 93 Korean patients who were clinically
diagnosed with TB (Table 1). Mutations of the pncA in Mycobacterium
tuberculosis clinical isolates in this study were identiﬁed by comparison
with the pncA of the type strain M. tuberculosis H37Rv by using
PCR-sequencing or PCR-plasmid TA cloning-sequencing method.
Ampliﬁcations were carried out with a GeneAmp PCR system 9600
thermocycler (Perkin-Elmer Corp., Foster City Calif). The pncA
amplicons were subjected to a sequencing reaction by using a 373
Automatic sequencer and a BigDye Terminator Cycle Sequencing kit
(PE Applied Biosystems, Warrington, United Kingdom). Sequences
obtained were analyzed with BioEdit software (version 5.0.9.1; T. A.
Hall Software). Speciﬁc mutations will be categorised and cross-checked
with the clinical data available.
Types of clinical specimens in this study
Clinical specimens No. (%) of samples
Sputum 36 (38.7%)
Cultures 27 (29.0%)
Tissue 11 (11.8%)
Pus 3 (3.2%)
Bronchial wash 3 (3.2%)
Bone 2 (2.2%)
Pleural 2 (2.2%)
Cerebrospinal ﬂuid 1 (1.1%)
Others 8 (8.6%)
Total 93 (100%)
Results: Generally, 37.6% (35/93) had mutations in the pncA, including
substitution, deletion and insertion as demonstrated in Figure 1.
Conclusions: Our results showed that the pncA mutation proﬁle in
South Korea. We found the pncA mutation rate 36.3% (16/44) and
38.8% (19/49) of M. tuberculosis clinical isolates in Jeju, which is
located at south west from main land and other cities respectively. Also,
this study is more signiﬁcant of the pncA mutations in Mycobacterium
tuberculosis incidence in South Korea compared to the previous
published papers. Because this study is recently investigated and included
Jeju clinical isolates which has never reported, while the last papers were
published in 2001 year.
Figure 1. Frequency and types of pncA mutation in South Korea.
P605 Mutations associated with resistance to second-line drugs
in Mycobacterium tuberculosis clinical isolates from Lisbon,
Portugal
J. Perdiga˜o °, A. Ferreira, A. Malaquias, R. Macedo, L. Brum,
I. Portugal (Lisbon, PT)
Objectives: Multidrug resistance (MDR) constitutes a serious problem
to tuberculosis (TB) control program in Portugal. An even more serious
threat is the one posed by the high rate of extensive drug-resistant TB
(XDR-TB). Our laboratory has already shown that high rates of this
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form of TB exist in Lisbon. Given the fact that MDR-TB and XDR-
TB are currently associated with a limited number of genetic clusters,
mainly Lisboa family clusters, the diversity of genetic polymorphisms
conferring resistance to second-line drugs is also probably limited. In this
study we intended to characterise the genetic polymorphisms associated
with resistance to second-line injectable drugs and to assess the clinical
isolates clonality.
Methods: We have analyzed 19 MDR-TB strains resistant to one or
more second-line injectable drugs, collected from several hospital units
across Lisbon Health Region during the year of 2005. All isolates were
typed by Mycobacterial Interspersed Repetitive Units (MIRU-VNTR)
and, screened for mutations in tlyA and rrs genes.
Results: Three different mutations were identiﬁed on tlyA gene and
another three at rrs gene. Overall, 9 isolates had mutations in tlyA
gene and 8 isolates had mutations in rrs gene; two isolates didn’t have
any mutation in either gene. The most frequent mutations found were
A1401G in rrs gene (6/19) and 755InsGT in tlyA gene (6/19). We also
veriﬁed that there was no overlapping of mutations from different genes.
The genotyping analysis revealed that the isolates could be distributed
through two different MIRU-VNTR genetic clusters: Lisboa3 and Q1.
Cluster Q1 contained all clinical isolates bearing the A1401G mutation
in rrs gene, while Lisboa 3 cluster contained all isolates that had the
755InsGT mutation in tlyA gene.
Conclusion: We have identiﬁed several mutations that might be
associated with resistance to different but related second-line drugs:
kanamycin, amikacin and capreomycin. The two most prevalent
mutations were associated with different genetic clusters, which suggests
recent transmission and, ultimately, that XDR-TB transmission is taking
place. The most prevalent mutations associated with injectable second-
line drugs have therefore been deﬁned, which opens the way for
molecular detection of resistance to second-line drugs in the region.
P606 Characterisation of gidB gene in streptomycin-resistant
Mycobacterium tuberculosis isolates in Lisbon health region
J. Perdiga˜o °, A. Sabino, C. Milho, R. Macedo, L. Brum, I. Portugal
(Lisbon, PT)
Objectives: Streptomycin (STP) was the ﬁrst antibacillary drug intro-
duced in the treatment of tuberculosis in 1944. With the development
of further antibacillary drugs, streptomycin has become less used.
Development of STP-resistance is usually explained by the acquisition
of mutations in rpsL gene or in the rrs gene. Our laboratory regularly
isolates STP-resistant strains without any mutation in the referred genes.
Recently, mutations occurring in a rRNA methyltransferase (encoded by
gidB gene) were shown to be involved in the acquisition and resistance to
STP. In this study, we examined the gidB gene of STP-resistant isolates
in search of mutations that may explain the acquisition and STP low-level
resistance on these strains.
Methods:We have analyzed by sequencing and/or endonuclease analysis
the gidB gene of 57 STP-resistant clinical isolates and 30 STP-
susceptible clinical isolates, recovered in 2005 and 2006 from different
hospital units. The entire rpsL ORF of all isolates was ampliﬁed and
screened for mutations by endonuclease and sequencing analysis. All
clinical isolates were also genotyped by MIRU-VNTR.
Results: The gidB gene of 19 STP-resistant isolates was sequenced and
two missense mutations, A80P and F12L, were found in 5 and 1 out of
19 isolates, respectively. We have found that these gidB mutations were
only present in isolates without rpsL mutations. The remaining isolates
were screened by endonuclease analysis for mutations A80P and K43R
in gidB and rpsL genes, respectively. Overall, mutation A80P in gidB
gene was found in 10/57 STP-resistant isolates; 11/14 STP-susceptible
multidrug resistant isolates; and, none of 16 pansusceptible isolates.
GidB mutation A80P was also associated with MIRU-VNTR genetic
cluster Q1, although an independent occurrence has been identiﬁed.
Conclusion: We conclude that gidB mutations may in fact explain
the high number of STP-resistant strains with no mutation in rpsL
or rrs, isolated in our laboratory. These mutations probably confer
STP low-level resistance that may pass undetected in regular drug
susceptibity testing. The independent occurrrence suggests however, that
the acquisition of such mutations present an adaptative advantage.
P607 Structural and biochemical study of new KatG mutations
found in clinical strains of Mycobacterium tuberculosis
resistant to isoniazid
F. Brossier °, M. Boudinet, W. Sougakoff (Paris, FR)
Objectives: Resistance to isoniazid (INH) is mainly due to acquisition
of mutations in the KatG protein (the catalase-peroxidase), particularly
in position 315 (Ser315Thr). In previous studies, we evaluated
the performance of a diagnostic strip, MTBDRplus, enabling rapid
identiﬁcation of S315T in strains of M. tuberculosis resistant to INH.
In the course of this study, we identiﬁed new mutations in KatG, the
role of which has never been characterised before. For these mutations,
structural and biochemical studies have been undertaken to establish their
contribution in resistance to INH.
Methods: katG genes coding for the wild-type protein and six new
mutants A162E, D189G, H270R, Q461P, G494D and F658V have been
included. Expression and puriﬁcation of KatG in Escherichia coli was
carried out by cloning the katG genes in the pET30 expression vector.
The crystal structure of the M. tuberculosis KatG protein (Zhao X et al.,
code-PDB 2CCA) was used to model the position and the consequences
of the new mutations in the KatG protein.
Results: The KatG protein contains a covalently bound heme surrounded
by a proximal and a distal pocket. Of all the mutations studied, H270R,
which was identiﬁed in a clinical strain of high level of INH resistance
(INH-R), appears to be of great interest since H270 is part of the
proximal pocket and is covalently linked to the heme. Thus, H270R
causes loss of the covalent bond linking the heme and, consequently, of
the catalytic activity of KatG. The mutation A162E, linked to a high level
of INH-R, is located in a alpha-helix situated close to the distal pocket
and creates steric hindrance in this region. Two others mutations (F658,
Q461P), found in strains showing a low level of INH-R, are located
in alpha-helices positioned far from the heme. F658V leads to steric
hindrance, while Q461P likely contributes to the destabilisation of the
alpha-helix secondary structure. Finally, D189G and G494D, conferring
low and high-level of INH-R, respectively, modify the pattern of ionic
interactions in regions located far from the heme pocket, and their role
in the KatG protein is less obvious.
Conclusions: These results shed light on the importance of KatG
mutations other than S315T in resistance to INH and will be integrated in
a global strategy involving molecular modeling and biochemical studies
to increase our ability to predict resistance to INH, a goal particularly
important to improve the treatment of TB patients.
P608 Binding domain of the TMC207 in subunit C of
mycobacterial ATP synthase
E. Segala °, A. Nevejans-Chauffour, V. Jarlier, W. Sougakoff, S. Petrella
(Paris, FR)
Objectives: In mycobacteria, the subunit c of ATP synthase, encoded by
atpE, has been identiﬁed as being the target of the new anti-tuberculosis
drug R207910 (TMC207) (Andries, Science, 2005). Here, we report on
the in vitro isolation of reference strain (H37Rv) and clinical strains
of Mycobacterium tuberculosis mutants resistant to TMC207 and the
characterisation of amino acid substitutions in AtpE. We also evaluated
the level of resistance conferred by these mutations in Mycobacterium
smegmatis and we generated a model for the structure of the ring of c
subunits in M. tuberculosis to predict the role of these residues in the
binding of the drug by docking experiments.
Methods: Mutants were obtained by selection on 7H11 + OADC agar
medium containing TMC207 at various concentrations. Mutations in
the atpE gene were identiﬁed by PCR and sequencing. The plasmid
pLYG204 was used to complement M. smegmatis mc2155 with atpE
gene carrying the mutations identiﬁed in the resistant strains. The 3D
model was made using data from the crystal structure of the c ring of
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Ilyobacter tartaricus (Meier, Science, 2005) and Autodock was used for
docking experiments.
Results: Only the mutation A63P previously identiﬁed for M. tuberculo-
sis was found in the mutants selected from H37Rv whereas we identiﬁed
the mutations D32G, L59V, E61D, A63P and I66M in the mutants
selected from clinical strains. Thanks to the model of the structure of the
c ring of M. tuberculosis we can see that the 4 amino acids implicated in
the resistance to TMC207 are all in the close vicinity of E61 implicated
in the transfer of proton and also in the resistance, and they form a
putative binding pocket where the bulky brome atom of the drug is deeply
accommodate. We also highlighted another major interaction between
the drug and the c ring which is the presence of H-bonds between
residues D32, E61 and TMC207. Accordingly, complementation studies
in M. smegmatis revealed that amino acids substitutions D32G/V and
E61D efﬁciently increase the level of resistance to TMC207.
Conclusion: Our objectives are to deﬁne, in as much detail as possible,
the binding site of TMC207. To achieve this goal, we have developed
an efﬁcient tool combining complementation assays and molecular
modelling. Our initial results show that amino acids D32, L59, E61,
A63 and I66 make a deep binding pocket where the brome atom can
accommodate and the binding of TMC207 is also stabilised by H-bonds
with residues D32 and E61.
P609 Molecular epidemiology and antimicrobial susceptibility of
Mycobacterium abscessus isolated from patients with cystic
ﬁbrosis
C.A. Burnham °, W.M. Dunne (St. Louis, US)
Objective: Mycobacterium abscessus is a rapidly growing mycobac-
terium that is ubiquitous in the environment. While M. abscessus is
commonly associated with skin and soft tissue infections, it is also
capable of colonising and causing disease in the respiratory tract. One
group with a propensity for colonisation with M. abscessus is patients
with cystic ﬁbrosis (CF). The objective of this study was to determine
if CF patients infected with M. abscessus harbour the same strain over
time, as well as to determine if patients cared for at the same centre share
strains. The antimicrobial susceptibility proﬁle of the isolates was also
obtained to determine if chronic colonisation was related to resistance
to typical antimicrobial regimens for this organism.
Methods: Mycobacterium abscessus from CF patients who had the
organism isolated from at least 3 separate respiratory cultures collected
from 2004 to 2007 were included, corresponding to 35 isolates from
9 patients. The organisms were cultured according to standard protocols
in the Barnes-Jewish Hospital Mycobacteriology laboratory. DNA was
extracted and strains were compared using repetitive sequence PCR
(REP-PCR). Diversilab Bacterial Barcodes software was used to compare
banding patterns and determine the similarity index (SI) between the
isolates. Antimicrobial susceptibility testing was performed using a Trek
Diagnostics Sensititre broth microdilution panel for rapidly growing
mycobacteria in accordance with NCCLS document M24-A.
Table 1. Summary of antimicrobial susceptibility testing results
Interpretation Antimicrobial agent
CLA LZD TOB FOX AMI SMX DOX CIP
Susceptible (n) 35 21 5 6 26 0 4 1
Intermediate (n) 0 11 14 19 3 0 5 1
Resistant (n) 0 12 16 9 6 35 26 33
Results: The REP-PCR analysis of sequential strains isolated from
individual patients showed a high degree of similarity, suggesting that
once the organism is acquired, a patient remains colonised by a single
clone, rather than clearing the organism and subsequently becoming
infected with a different strain. The M. abscessus isolated from 3 of
the patients had unique REP-PCR patterns, but there were 3 separate
sets of 2 patients with shared patterns (SI> 95%). The results of the
antimicrobial susceptibility testing are in Table 1. Of note, all of the
35 isolates tested were susceptible to clarithromycin.
Conclusions: The results of this study suggest that CF patients from
which M. abscessus is repeatedly isolated are chronically colonised
with a single clone. In vitro susceptibility may not correlate with
clinical response as all isolates tested in our study are susceptible to
clarithromycin, the antimicrobial agent of choice, yet the patients in our
study do not eradicate the organism.
P610 Genetic characteristics of Mycobacterium tuberculosis strains,
isolated among Moscow residents
M. Afanasev °, E. Ilina, T. Smirnova, E. Larionova, A. Kuzmin,
S. Andreevskaya, L. Chernousova, V. Govorun (Moscow, RU)
Objectives:Moscow is the largest city of Russia with intensive migration
ﬂow (including peoples from Former Soviet Union (FSU) countries).
High TB morbidity and increasing numbers of multidrug-resistance
(MDR) in Russia and FSU countries call an attention to the effective
preventive, prophylaxis and surveillance measures, aimed to prevent and
avoid M. tuberculosis transmission and MDR spread in the community.
The purposes of this study were to evaluate epidemiological diversity
and MDR spreading among M. tuberculosis strains, circulated among
Moscow residents.
Methods: M. tuberculosis strains (n = 115) have been randomly selected
from sputum of epidemiologically unrelated TB patients, which were
Moscow residents. Species identiﬁcation and drug susceptibility testing
to main antituberculosis drugs – rifampicin (RIF) and isoniazid (INH) –
were performed according to the WHO recommendation protocols.
Standard procedures of spoligotyping and 24-loci VNTR typing were
carried out as described previously. For detect speciﬁc antimicrobial
resistance SNPs minisequencing reaction followed by matrix-assisted
laser desorption ionisation time-of-ﬂight mass spectrometry (MALDI-
TOF MS) of the reaction products was used.
Results: Among 115 M. tuberculosis strains 76 (66.0%) were identiﬁed
as MDR, 20 (17.4%) were susceptible to RIF and INH, and 1 (0.9%)
and 18 (15.7%) were resistant either to RIF or INH, respectively.
Mutations in the RRDR of the rpoB gene were detected in 64 (64/77;
83.1%) RIF resistant strains. The Ser531Leu substitution was prevalent
among them (49/64; 76.5%). Aberrations in the Ser315 codon of katG
and/or in the inhA promoter region were found in 79 (84.0%) of 94
INH-resistant strains.
Strains belonged to the Beijing family were prevalent – 66.0% (76/115),
the other two large families (LAM and T) occurred rarer (10.4% and
8.7%, respectively). Seventy one different VNTR proﬁles were identiﬁed.
Tree main 24-loci VNTR clusters included 34 (34/115; 29.5%) strains
belonged to Beijing family. MDR-phenotype revealed more frequently
among Beijing strains (59/76; 77.6%), than among other strains (17/39;
43.6%) (c-square = 13.3; p = 0.0003).
Conclusion: Obviously, Beijing family plays a signiﬁcant role in the
spread of MDR TB in the Moscow. Spoligotyping and 24-loci VNTR
typing combination demonstrate sufﬁcient discrimination power and may
be useful for TB monitoring in Moscow region.
P611 Detection of efﬂux pump genes among clinical isolates of
non-pigmented rapidly growing mycobacteria and their
relationship with phenotypic resistance
J. Esteban °, N.Z. Martı´n-de-Hijas, A. Ortiz-Pe´rez, I. Gadea,
R. Ferna´ndez-Roblas (Madrid, ES)
Objectives: To detect the presence of previously described efﬂux pumps
genes (lfrA for quinolones and tap for tetracyclines) among clinical
isolates of non-pigmented rapidly growing mycobacteria (NPRGM), and
to correlate its presence with the in vitro susceptibility results.
Methods: In vitro susceptibility of clinical isolates of NPRGM was
studied using the reference microdilution technique. Breakpoints to
determine susceptibility of the strains were those described by the CLSI.
Tested antibiotics were Doxicycline (DOX), Tigecycline (TGC) and
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Ciproﬂoxacin (CIP). Gene detection was performed by PCR analysis
using primers designed for each gene. Accuracy of detection was
conﬁrmed by sequencing of the ampliﬁed products. We use as controls
the type strains of M. smegmatis (for lfrA) and M. fortuitum (for tap).
Results: 166 clinical isolates of NPRGM were included in the study
(9 Mycobacterium abscessus, 30 M. chelonae, 89 M. fortuitum, 5
M. mageritense, 7 M. mucogenicum, 22 M. peregrinum, 2 M. alvei,
1 M. septicum and 1 M. porcinum). Only 4 strains were positive for
lfrA (2 M. chelonae, 1 M. fortuitum and 1 M. mucogenicum). Two of
these strains (1 M. chelonae and M. mucogenicum) were resistant to
ciproﬂoxacin (MIC: 4mg/L), while the other two were susceptible (MIC:
0.12mg/L). For tap, 109 strains were positive: 3 M. abscessus (33.3%),
12 M. chelonae (40%), 75 M. fortuitum (84.3%), 2 M. mageritense
(40%), 15 M. peregrinum (68.2%), 1 M. alvei and 1 M. porcinum. The
results of MIC90 (mg/L) and non-susceptible percentages against DOX
and TGC for each subgroup are shown in the table for strains with
5 isolates (NS: non-susceptible).
No strain ofM. mucogenicum was tap positive. One strain ofM. alvei and
the strain of M. porcinum were also tap positive. No differences between
tap positive and tap negative strains were observed for resistance against
DOX (Fisher’s exact test, p = 0.055).
Conclusions: lfrA efﬂux pump is rare among clinical strains of NPRG.
On the contrary, tap gene is common among these mycobacteria,
although its relationship with DOX resistance is not clear, and it has
no effect on susceptibility against TGC.
Species tap+ tap−
MIC90 DOX % DOX NS
strains
MIC90 TGC MIC90 DOX % DOX NS
strains
MIC90 TGC
M. abscessus >64 0 1 >64 100 0.5
M. chelonae 32 41.7 0.25 64 77.8 0.5
M. fortuitum 64 68 0.25 64 64.3 0.5
M. mageritense 8 50 0.12 16 66.7 0.06
M. mucogenicum – – – 64 57.1 0.5
M. peregrinum 32 53.3 0.06 64 100 0.12
All strains 64 63.3 0.25 64 77.2 0.5
P612 Incidence, clinical and epidemiological risk factors, and
outcome of drug-induced hepatitis due to anti-tuberculous
agents in new TB cases
P. Baghaei Shiva ° (Tehran, IR)
Background: Drug-induced hepatitis (DIH) is an important issue in TB
treatment. We intend to assess the incidence, risk factors and outcome
of hepatitis due to anti-TB drugs.
Methods: The study is carried out at the national TB referral centre
2006–2008 including all documented new case TB patients. All patients
received standard anti-TB treatment. If DIH occurred, all drugs were
discontinued; and re-initiated after LFT normalisation in a stepwise way.
Results: Of total 761 patients 99 (13.0%) patients developed drug-
induced hepatitis during anti-Tb treatment. There was no difference in
sex, nationality, smoking or opium use history between in Hepatitis group
and the control group (P value >0.05).
DIH was signiﬁcantly higher in patients aged above 65 years. (p = 0.019).
The mean duration of DIH from the beginning of treatment was
17.53±19.42 days (Median = 12; 1–125 days). Also, the mean of the
time elapsed from DIH till the LFT normalisation was 10.26±5.95
(Median = 9; 0−32 days).
Anorexia, nausea, vomiting, abdominal pain, jaundice, diarrhoea,
decreased level of consciousness, and fever were signiﬁcantly higher
in DIH patients.
13 (13.4%) of the patients in DIH group died while death occurred
just in 21 (3.2%) of cases in the control group. (p< 0.001, 95% CI =
2.26−9.70, odds ratio = 4.7).
After adjusting with logistic regression, all of the anticipated factors
retained the statistical signiﬁcance.
Conclusion: Our study indicated that DIH most often occurs during the
ﬁrst two weeks of anti-TB treatment. DIH development is associated
with old age, certain clinical manifestations, and higher death rates.
P613 Evaluation of VersaTREK® system for isolation and
susceptibility testing of Mycobacterium tuberculosis
M. Espasa °, P. Ferreros, M. Torra, V. LaBombardi, D. Fontanals
(Sabadell, ES; New York, US)
The increasing number of new tuberculosis cases and emergence of drug
resistant strains of M. tuberculosis (MTB) is of public health concern. To
adequately address this threat requires reliable microbiological methods
to both isolate this organism and perform susceptibility testing. The
VersaTREK®(TREK) system detects positive cultures by measuring
changes in gas pressure whereas the BacT/ALERT 3D®(BioMe´rieux)
system detects pH changes.
Objective: To evaluate the VersaTREK®(VTK) system and compare it
to the Bact-Alert 3D®(BA) system for the isolation of mycobacteria from
clinical specimens and for susceptibility testing of MTB.
Methods: For a period of two months all samples received in the
Microbiology Laboratory of Hospital Parc Taulı´ (Sabadell, Spain)
requiring mycobacteria culture were processed on BA and VTK
systems. The samples were decontaminated, inoculated into each vial
and incubated for 42 days following standardised methods. Cultures
conﬁrmed to contain acid-fast bacteria growth were identiﬁed from
bottles using Mycobacteria Genotype CM kit®(Hain).
Susceptibility testing was performed in both systems on non-duplicate
MTB isolates from the processed samples and a group of archived
drug-resistant MTB. Isoniazid (H), rifampin (R), streptomycin (S),
ethambutol (E) and pyrazinamide (Z) were tested following standardised
protocols. An additional 10 WHO National Reference Laboratory strains
were tested in the VTK system.
Table 1. Susceptibility testing results comparing BacT/ALERT-3D® and
VersaTREK® systems
Drug and result category No. of isolates by result category
and system used
BacT/ALERT-3D® VersaTREK®
Isoniazid (Low − 0.1 ug/mL) 22 22
Susceptible 9 9
Resistant 13 13
Isoniazid (High − 0.4 ug/mL) Not tested 22
Resistant 11
Rifampin (1 ug/mL) 22 22
Susceptible 21 21
Resistant 1 1
Ethambutol (Low − 5 ug/mL) 22 22
Susceptible 21 20
Resistant 1 2
Ethambutol (High − 8 ug/mL) Not tested 22
Resistant 2
Streptomycin (Low − 2 ug/mL) 22a 22
Susceptible 21 21
Resistant 1 1
Streptomycin (High − 8 ug/mL) Not tested 21
Resistant 1
Pyrazinamide (300 ug/mL) 22b 22
Susceptible 21 21
Resistant 1 1
a1 ug/mL; b100 ug/mL.
Results:
a. Isolation. During this two month period, 327 specimens were received
for mycobacterial culture. Of these 28 (8.6%) were positive. Twenty-
ﬁve MTB and one M. intracellulare were isolated in both systems.
The average time to detection was 8 days in both VTK and BA. In
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addition, one isolate each of M. xenopi and M. scrofulaceum were
isolated only in VTK. The VTK had 4 (1.2%) false positive cultures
while the BA system recorded 28 (8.6%). The contamination rate was
3.7% in both systems.
b. Susceptibility testing. A total of 22 MTB isolates were studied.
Brieﬂy, the correlation was 100% for both systems for H and R
resistant strains. Detailed results on Table 1. The VTK allowed
obtaining two points of MICs for H, E and S.
The result of the WHO quality control strains showed a good
performance of VTK system.
Conclusion: The VTK system isolated two additional strains of
mycobacteria and had a lower false positive rate than the BA system
and proved to be a reliable system for the isolation of mycobacteria and
susceptibility testing of MTB.
Clinical epidemiology of nosocomial
infections
P614 Do splenectomized patients for trauma suffer from more
early postoperative infections?
I. Pen˜uela °, J. Palomino, M.D. Rinco´n, J.M. Domı´nguez, F. Murillo,
J. Pacho´n (Seville, ES)
Objectives: Little is known about the effect of splenectomy for trauma
on early postoperative infections. The purpose of this study was to
determine if splenectomy increases the early mortality and postoperative
infections in trauma patients.
Methods: We review all trauma patients undergoing splenectomy from
January 2006 through December 2007. Each splenectomy patient (SP)
was matched with two trauma patients without splenectomy (WSP) based
on age, gender, injury severity score (ISS), and hospitalisation date,
by using a design of matched cohort study. The primary outcome was
the appearance of an infectious complication (pneumonia, bacteraemia,
and urinary tract infection [ITU]), and the secundary outcome was in-
hospital mortality, both during the ﬁrst 30 days. Statistical analysis was
performed using SPSS 16 version. The log-rank test was used to compare
the mortality, and timing of apparition of infections.
Results: There were 20 SP and they were matched to 40 WSP.
SP and WSP were similar regarding age (33.6±11.2 vs 33.6±10.7;
p = 0.95), male gender (100% vs 100%) and ISS (26 [20−31.2] vs 25.5
[19.2−29]; p = 0.84). Pneumococcal 23-v (mean = 0.44 days after) and
Hib (mean = 0.50 days after) vaccines was administrated to 85% and
65% SP, respectively. SP developed pneumonia (15% vs 27.5%; p = 0.34;
RR= 0.58 [0.19−1.69]), bacteraemia (10% vs 7.5%; p = 1.00; RR= 1.22
[0.39−3.81]) and ITU (0% vs 12.5%; p = 0.15). Isolated microorganisms
in SP with pneumonia were Gram-negative bacilli 2, unknown 1, and
in WSP S. aureus 3, Acinetobacter spp 2, others 4, and unknown 2. In
SP with bacteraemia P. mirabilis 1 and S. saprophyticus 1, and in WSP
S. epidermidis 2 and S. aureus 1. There were no ITU in SP. In WSP with
ITU, Gram-negative agents 4. The mortality rate in SP was 10% vs 5%
in WSP (p = 0.59; RR= 2.11 [0.27−16.21]). Statistical differences were
no found in survival curves as for time to appearance of death (log-rank
1.38; p = 0.24), pneumonia (log-rank 1.16; p = 0.28), and bacteraemia
(log-rank 0.24; p = 0.62) in SP vs WSP during the ﬁrst 30 days.
Conclusion: In patients vaccinated with pneumococcal and Hib vaccines
and an ISS mean score of 26, SP for trauma is not associated with an
signiﬁcant increase of postoperative infections (pneumonia, bacteraemia)
neither higher mortality than WSP.
P615 Early intravenous to oral antibiotic switch therapy is
effective in the treatment of infected total hip replacement
E. Darley °, G. Bannister, A. Blom, A.P. MacGowan, S. Jacobson,
W. Alfouzan (Bristol, UK)
Objective: To determine outcomes for an antibiotic regimen using
early switch to oral antibiotic (AB) for treatment of infected total hip
replacements (THR) treated by either 1-stage or 2-stage procedures.
Methods: Cases of infected THR were identiﬁed from the microbiology
records held on all orthopaedic infections in a 24 month period in
North Bristol NHS Trust. Diagnosis was made by microbiological culture
of theatre specimens and ﬁndings at operation. The total number of
THR operations was also determined. Data on organisms cultured and
AB treatment regimens were recorded from orthopaedic cases notes,
microbiology patient and pathology computer records. AB treatment
regimens were tailored for each patient by a medical microbiologist,
according to culture and sensitivity results and history of previous
THR infection. A standard approach of 10−14 days intravenous (iv)
AB followed by a switch to oral ABs either for 6−8 weeks until 2nd
stage re-implantation or for 6−26 weeks following a 1 stage procedure,
was used. The exact date of oral switch and ultimate AB duration was
determined by clinical resolution and the CRP. Outcome was recorded
as no microbiological or clinical evidence of relapse of infection, relapse
after completing AB course, or unknown.
Results: In 24 months 1854 THR elective operations were performed,
1% for infected THR. 19 patients underwent 2-stage THR, 17/19 were
treated with 14 days iv ABs followed by oral ABs for 4−8 weeks.
2/19 patients were treated with iv ABs for the whole duration, 1 for a
resistant pseudomonas and 1 patient with co-morbidities who remained
in hospital. None of the 19 patients have relapsed. 6 patients underwent
1-stage THR, 4 had 2 weeks iv then 6−26 weeks oral ABs, with no
relapse. Case notes are unavailable for the other 2 patients, neither
has represented to this hospital Trust for further treatment. Follow up
duration for all cases, to date, is 12−24 months.
Conclusions: 17/17 patients treated for infected THR with 2-stage
replacement and an AB regimen incorporating early switch from iv
to oral ABs have had to date a successful outcome. Early oral AB
switch therapy is effective and has an important role enabling patients
to return to independence after revision surgery and avoid complications
of prolonged iv access.
P616 Do cardiac centres in the United Kingdom have a standard
policy for antibiotic prophylaxis in cardiac surgery? First
clinical audit in last 10 years
A. Guleri, S. Hosmane °, J. Zacharias (Blackpool, UK)
Objectives: Antibiotic prophylaxis (AP) is known to reduce surgical site
infections [SSI] post cardiac surgery. There appears to be variation in the
choice of antibiotic/s, dose and duration between surgeons and across
centres. Preliminary to drafting AP guidelines for surgery, Microbiology
and cardiac surgery at Lancashire cardiac centre, Blackpool carried out
this audit of practice across all cardiac centres in England.
Method: An online questionnaire was sent to consultant surgeons in
all the 36 cardiac surgery units in England. 26 responses obtained
representing all geographical regions of the country.
Results: All centres use prophylactic antibiotic/s. 50% [13/26] use
a combination of two antibiotics while the rest use a single agent.
92.3% [12/13] use cefuroxime as a single agent and 7.8% [1/13] use
ﬂucloxacillin. Different combinations of seven antimicrobial agents used
in 50% centres include cefuroxime [73.1%], ﬂucloxacillin [23.1%],
gentamicin [19.2%], vancomycin [15.4%], and Teicoplanin [11.5%]. The
antibiotic/s are administered at induction of general anaesthesia (73.1%),
just before the skin incision (19.2%) or along with the premedication in
the ward (7.7%). Duration of use – Over 24 hrs (76.9%); more than
24 hrs (19.3%) and as a single dose (3.8%). The trust policy addressing
prophylactic antibiotic in cardiac surgery is followed by 88.5% [23/26].
The policy formulation has contribution from cardiac surgeons (95.7%),
microbiologists (87%), infectious disease consultant (26.1%), cardiac
anaesthetists (21.7%) and pharmacists (4.3%). The estimated sternal
wound infection rates were <1% in 7 (26.9%), 1−3% in 18 (69.2%)
and >3% in only 1 (3.8%) centres. As per 24/26 responses on MRSA
infections per month, it is <1% in 21 (87.5%) and >1% in 3 (12.5%).
The clostridium difﬁcile infection rates per month (23/26 responses) are
<1% in 14 (60.9%) and >1% in 9 (39.1%).
Conclusions: There is evidence of reduction in rates of SSIs with use
of antibiotic prophylaxis in cardiac surgery. However, there is paucity
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of randomised controlled studies comparing choice of agents, single or
combination of agents, duration of use (single dose, <24 h or <48 h) and
rates of infections. This clinical audit has revealed variation in practice
across cardiac centres in England and lack of correlation to SSIs. The
results of this national audit of practice, recent NICE guidance on SSIs
and local HCAI data will help frame revised trust guidance on antibiotic
prophylaxis in surgery.
Figure: Prophylactic antibiotic usage in cardiac surgery.
P617 Rapamycin, used in the prevention of in-stent restenosis, has
antichlamydia-activity
Y. Yan °, S. Silvennoinen-Kassinen, M. Leinonen, P. Saikku (Oulu, FI)
Objective: Rapamycin coated eluting-stents have been used recently in
humans to reduce the risk of in-stent restenosis [1]. Serological study
suggested that C. pneumoniae could play a role in the pathogenesis of
restenosis [2]. Here we examined the effect of rapamycin on the growth
of C. pneumoniae in vitro.
Methods: C. pneumoniae CWL029 or C. trachomatis L2 were
inoculated onto the HL cell monolayers by centrifuge. Infected HL cells
were incubated for 48 h (C. trachomatis) or 72 h (C. pneumoniae) at
35ºC and 5% CO2. During the incubation, 23, 11 or 7 ug/ml rapamycin
was present in the culture medium continuously or for 8-hour periods:
0−8, 8−16, 16−24, or 24−32 h. C. pneumoniae infected cells cultured
with 0, 11, 7 or 3.5 ug/ml rapamycin respectively were repassaged to
fresh HL cell monolayers with centrifuge and incubated for another 72 h.
The infected cells from both passages were checked by a ﬂuorescent
microscope or an electron microscope.
Figure 1. Antimicrobial consumption trends in DDD per 100 bed-days,
Colombia, 2002–2007.
Results: The growth of both C. trachomatis and C. pneumoniae was
inhibited by 74−94% when 23 ug/ml rapamycin was present during
0−8 h and 8−16 h after inoculation, but effect on C. pneumoniae lost
after 24 hours although still effective on C. trachomatis (p< 0.01).
Other concentrations were not effective. Continuous presence of 11
and 7 ug/ml rapamycin inhibited the growth of C. pneumoniae by 80%
(p< 0.01) and 27% (p< 0.05) respectively, but 3.5 ug/ml rapamycin had
no signiﬁcant effect. The diameter of the inclusions decreased from
12.6+1.75 um in controls (a.) to 3.4+1.3 um in those under inﬂuence of
23 ug/ml rapamycin during 8−16 h, or continuously presented 11 ug/ml
rapamycin (b.) in which there are fewer chlamydial particles and fewer
matured EBs(b.). 11 ug/ml rapamycin presented in ﬁrst passage caused
the reduction of the growth of C. pneumoniae to 57% at ﬁrst passage
and to 24% at second passage (p< 0.05).
Conclusion: It has been shown that roxithromycin prevents restenosis in
patients with high C. pneumoniae antibody titres [3] suggesting that
antibiotics effective against chlamydia might have beneﬁcial effects.
We showed here that rapamycin exhibits antichlamydial activity on
C. pneumoniae in HL cell cultures. Thus, the beneﬁcial effects of
rapamycin in the prevention of in-stent restenosis might partly be
explained by its antichlamydial properties.
Reference(s)
[1] Eisenberg M J et al 2006 Am J Cardiol 98:375–382.
[2] Hayashida K et al 2002 Heart Vessels 16:137–145.
[3] Neumann F et al 2001 Lancet 357:2085–2089.
P618 Characterisation of LD- and EVD-associated
meningitis/ventriculitis in neurosurgical patients
S. Scheithauer °, U. Bu¨rgel, H. Schulze-Steinen, H. Haefner, S. Lemmen
(Aachen, DE)
Objectives: Data on drain-related infection rates [IR] are rare.
To determine IR and to characterise patients with drain associated
infections [DAI] and identify possible risk factors, we conducted a
prospective surveillance study at the neurosurgical ICU of the University
Hospital Aachen.
Methods: All patients admitted between January and December 2007
were enrolled. DAI including symptoms and laboratory results, kind and
duration of drainage utilisation [DU], acute and underlying diseases,
therapy and outcome were recorded.
Results: During 4086 patient-days (375 patients) and 2290 drainage-
days [DD] (496 LD-days, 1794 EVD-days) in 149 patients 28 cases
of meningitis (12 with LD, 15 with EVD, one with both) occurred.
Thus resulting in an overall IR of 12.23/1000 DD, 26.21/1000 LD-
days and 8.92/1000 EVD-days, respectively. In 19/28 (68%) infections
a pathogen could be detected, in 16/28 (57%) cases the clinical criteria
for a drainage associated infections were fulﬁlled. Coagulase-negative
staphylococci were the main pathogen (8/19 culture positive cases;
42%). Decreased glucose level (CSF) was the most common laboratory
parameter (21/28; 75%).
Figure 1. Incidence of LD- and EVD-associated meningitis.
Meningitis was more often in patients with SAB ºV (6/28; 21%;
OR: 6.33), ICB following trauma (3/28; 11%; OR: 3.5), in those
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with diabetes mellitus (5/28; 18%; OR: 3.1) or neoplasm (10/28;
36%; OR: inﬁnity) and in patients with LD versus EVD (OR: 2.06).
Association with SABºV (p = 0.005) and neoplasm (p = 0.000) were
highly signiﬁcant.
The average of DU was 8.6 (median: 6) days for LD and 15.0
(median: 14) days for EVD, respectively. For correlation of incidence
of meningitis and duration of LD and EVD see ﬁgure 1.
Conclusions: Benchmarking/Comparison of these results with earlier
studies is difﬁcult since different surveillance parameters and case
deﬁnitions were used in previous investigations. This study represents
provides data on drain-associated meningitis rates in combination with
identifying associations and/or possible risk factors. Moreover the
reliability of various clinical and laboratory parameters commonly used
was evaluated.
P619 Ventricular assist device-related infections
A. Gkouziouta °, P. Sﬁrakis, L. Louca, S. Adamopoulos, V. Voudris,
G. Saroglou, P. Alivizatos (Athens, GR)
Objectives: Heart failure remains a leading cause of death in developed
countries despite medical management. Heart transplantation (HTx),
a proven lifesaving intervention, is limited by donor availability.
Ventricular assist devices (VADs) provide temporary support for patients
with severe heart failure until transplantation or more seldom myocardial
recovery. Assist devices may be used permanently for those ineligible for
transplantation having demonstrated a survival beneﬁt and an improved
quality of life. Infection, in 18%-59% of cases, may involve any
component of the device causing substantial mortality and morbidity.
Methods:We retrospectively reviewed the medical records of 39 patients
with implantable VAD at the Onassis Cardiac Surgery Centre supported
longer than 72 hours, from February 2003 through September 2008.
Infection types included primary bacteraemia, septicaemia, endocarditis,
pocket, driveline and exit site infection.
Results: In 39 patients supported with VAD, 9 developed 14 VAD related
infections. Primary bacteraemia in 4 patients, VAD endocarditis in 3,
while driveline and exit site infection occurred in 7 patients. Duration of
VAD support was longer in infected patients (2648 days) vs. uninfected
ones (1500 days). Pathogens identiﬁed: Staphylococcus epidermidis (4),
Pseudomonas aeruginosa (4), Klebsiella pneumoniae (2), Acinetobacter
baumannii (2), Proteus mirabilis (1) and Candida parapsilosis (1)
were also identiﬁed. Five patients were successfully treated with
i.v. antibiotic usage. Four patients were urgently transplanted due to
septicaemia from multi antibiotic resistant nosocomial pathogens not
responding to antibiotic treatment. One patient died from polymicrobial
bacteraemia with Klebsiella pneumoniae, Stenotrophomonas maltophilia
and Candida albicans. We were unable to transplant him due to lack of
donor heart.
Conclusions: Infection remains the most common complication for VAD
application. Development of appropriate strategies is essential such as
continuous clinical surveillance, continuous patient clinical surveillance
and infection control preventive measures are essential in a HT-VAD unit
to prevent and manage device related infections in the MDR pathogen
era.
P620 Risk factors for colonisation by colistin-resistant Klebsiella
pneumoniae in critically ill patients
F. Kontopidou, D. Plachouras, G. Koukos, E. Papadomichelakis,
I. Galani °, A. Antoniadou, G. Poulakou, A. Armaganidis,
H. Giamarellou (Athens, GR)
Introduction: Emergence of colistin resistant Gram-negative bacteria,
and especially strains of Klebsiella pneumoniae, in the ICU severely
limits our treatment choices in critically ill patients. The aim of this
study was to investigate the risk factors for colonisation by such strains.
Methods: The study was performed in a 12-bed University General
ICU from November 2003 to December 2006. Empirical antimicrobial
treatment was guided by weekly active surveillance of patients’ ﬂoras.
All specimens were cultured in MacConkey agar plates containing
antibiotics in order to focus on resistant pathogen detection. Colistin
resistance was deﬁned by Etest according to BSAC breakpoints
(>4mg/L). Demographic and clinical data of the patients were recorded.
Risk factors for colonisation by CRKP were assessed by univariate and
logistic regression analysis.
Results: 150 patients (mean age 65.1 years) with mean APACHEIII
score (SD) 18.7 (7.8) and mean days of hospitalisation (SD) 76.0 (54.0)
were included in the study. 29 (19.3%) patients were colonised with
CRKP. Among these patients seven (24%) developed an infection by
CRKP with fatal outcome in six of them. The median number of
hospitalisation days was 64.5 in the group colonised with colistin
resistant isolates compared to 34 days in the non-colonised group (p
0.01). Mean APACHEIII score was 19.6 and 18.4 respectively (NS) in
the two groups. Administration of colistin was signiﬁcantly associated
with colonisation by CRKP strains (p 0.001). The median duration of
colistin treatment was 23.0 and 14.7 days among patients colonised
and not colonised with CRKP respectively (p NS). Among the patients
with CRKP 26 (89.7%) had previously received colistin. 15 (16.1%)
of patients who had received piperacillin/tazobactam were colonised
by CRKP compared to 14 (24.6%) of patients who had not received
this combination (p NS). In the multivariate analysis model the only
signiﬁcant risk factors for colonisation with colRKP were administration
of colistin (p 0.005, OR 6.7) and piperacillin/tazobactam (p 0.017,
OR 0.32).
Conclusions: Colistin use is the only signiﬁcant risk factor associated
with the emergence of resistant Klebsiella pneumoniae strains,
jeopardising treatment choices in the ICU. Unnecessary or prolonged
administration of colistin should be avoided.
P621 Nationwide investigation into the prevalence of nosocomial
infections in Belgium
B. Gordts °, F. Vrijens, G. Peeters, F. Hulstaert, M. Huybrechts,
P. Jordens, Y. Glupczynski (Bruges, Brussels, Aalst, Yvoir, BE)
Objectives: Since the prevalence of nosocomial infections (NI) in
Belgium had not been determined nationwide since 1984, the Federal
Ministry mandated the Belgian Healthcare Knowledge Center to set up
a national study in 2007 in order to estimate the actual burden of NI in
Belgium.
Methods: A point prevalence study (PPS) was conducted in collabora-
tion with the Federal and regional platforms for hospital hygiene during
a 4 week period (Oct 15 – Nov 11, 2007), involving 17,343 patients from
56% of all Belgian acute care hospitals excluding long stay psychiatric
care and day care. A speciﬁc software comprising an expert system
establishing the diagnosis of NI according to the CDC-deﬁnitions was
developed in order to enable bed-side registration of symptoms instead
of diagnoses. NI appearing after discharge were not studied.
Prevalence of nosocomial infections registered in the Belgian national surveillance study 2007
Bed category Prevalence of
patients with NI
Type of NI Prevalence Proportion
of all NI
Adult ICU 25.3% Urinary tract 1.69% 23.9%
Neonatal ICU 12.6% Lower respiratory tract 1.42% 20.1%
Chronic care 7.6% Surgical site 1.04% 14.6%
Geriatric 7.4% Bloodstream 0.96% 13.6%
Surgical 5.9% Gastrointestinal 0.88% 12.5%
Non-intensive neonatal 5.6% Ear, Eye, Mouth 0.18% 2.6%
Medical 5.2% Bone and Joint 0.15% 2.1%
Paediatric 2.7% Upper respiratory tract 0.11% 1.5%
Psychiatric 1.7% Reproductive tract 0.07% 1.0%
Maternity 1.0% Central Nervous System 0.05% 0.7%
All 6.2% Cardiovascular system 0.04% 0.6%
Results: After correction for sampling ratio in different hospitals, the
prevalence of patients infected nationwide was 6.2% (CI95% 5.9−6.5)
and the prevalence of NI is 7.1% (CI95% 6.7−7.4). Break-downs
according to bed-category and type of NI are shown in the table.
Surgical site represented 38.7% of NI in patients in surgical wards.
Infections of the urinary, bloodstream and lower pulmonary tract
accounted for 23.6%, 22.8% and 20.4% of NI resp. in patients in medical
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wards. In adult IC units, pneumonia and septicaemia represented resp.
51% and 20% of NI.
The annual number of patients suffering from a NI in Belgium was
derived from the results of the PPS, and estimated to be between 103,000
and 116,000 or 0.97 to 1.10% of the Belgian population.
Conclusion: For the ﬁrst time in 25 years, a national study determined
the burden of NI to patients and society as comparable to neighbouring
countries. The use of an IT expert system facilitated participation and
ensured higher standardisation.
P622 National investigation into the infection control practices in
surgery in Belgium
B. Gordts °, A. Lenez, B. Heyneman, M. Costerson behalf of the
Belgian Federal Platform for Hospital Hygiene and BAPCOC
Objectives: Belgian regulations compel acute care hospitals to have local
regulations on infection control (IC) in operating suites (OS). However,
since no national minimal IC standards exist, the federal platform for
hospital hygiene (FPHH) suspected a different approach in Belgian
hospitals. In order to evaluate the present IC practices in our country,
the FPHH performed a national survey evaluating the extent to which
internationally suggested IC precautions are actually deﬁned, carried out
and monitored in Belgian OS.
Methods: A working party of the FPHH established an inventory of
essential IC precautions prescribed in national guidelines in France, the
Netherlands and the United States and grouped the series into different
categories: architecture/structure, cleaning, per-operative procedures,
sterilisation, logistic activities and surveillance of postoperative wound
infections (POWI). A questionnaire was sent to all Belgian acute care
hospitals, examining the local implementation of – and compliance
with – each IC measure.
Results: In this national survey, 92 acute care hospitals (81%) provided
data on 168 OS. Compliance with basic IC measures like closing
doors during surgery, awaiting wound closure before clearing the OR,
wearing gloves and masks, antimicrobial prophylaxis and even standard
precautions was widely variable. In many hospitals, several essential IC
measures were not incorporated in local regulations and in spite of this,
compliance is average or low and systematic monitoring almost non-
existent.
Although many hospitals formerly claimed to perform POWI surveil-
lance, the survey demonstrates that standardised surveillance projects
with follow-up and feedback to surgeons is generally lacking.
Conclusions: This investigation conﬁrms the extensive variability of IC
practices in Belgian OS, both with respect to standards described in
local operating procedures as to actual compliance with local and/or
internationally prescribed IC measures. National IC standards for OS
are urgently needed, truly implemented and ofﬁcially monited. The
variability in approach of IC and the extensive lack of POWI surveillance
projects demonstrate the necessity for Belgian IC professionals to
practice process surveillance in OS rather than outcome surveillance.
P623 Evaluating the impact of the National Resource of Infection
Control
G. Madle, S. Wiseman, P. Kostkova °, G. Jawaheer (London, UK)
Objectives: The National Resource for Infection Control (NRIC) became
a member of the International Federation of Infection Control in 2008 to
support a growing number of international users. The need to evaluate
the impact of NRIC on professionals in the infection prevention and
control ﬁeld is essential to identify how successful it is and where future
investment can be targeted and an impact evaluation was undertaken
in Spring 2008. Participants were recruited by an advert on the NRIC
website, through the NRIC mailing list (approximately 1800 members)
and via the Infection Prevention Society (IPS) website forums and
contacts.
Methods: The impact evaluation was conducted using the Impact-ED
model for digital library evaluation. This provides a set of criteria around
which questionnaires and interviews are designed to collect appropriate
data.
Results: 65 NRIC users signed up for the impact evaluation. Of these
32 completed pre and post visit questionnaires of which 72 sets were
matched for analysis. On arriving at the NRIC library participants were
asked to login with a unique username and password for the purposes of
tracking their activity during the study period. NRIC had an impact on
user knowledge in 52.8% of visits. Most visits were to seek evidence to
either support existing knowledge or practice (n = 28) or extend existing
knowledge (n = 9). Other reasons included seeking general information
about a subject (n = 10), looking for new resources or news (n = 14),
looking for training information or educational materials (n = 4) or
searching for speciﬁc documents (n = 4). Reasons for no impact were
that not enough information was found or the user couldn’t access the
document. NRIC has a positive impact in many areas of user work
including policy development, training and education, implementing
changes in practice and business case or proposal preparation (See Fig).
Conclusion: This study has shown that NRIC is a popular, easy to use,
library that is having a positive impact on user knowledge and work.
However, further sustained investment is required if NRIC is to fulﬁl its
potential as a one-stop resource in the infection prevention and control
community. Raising awareness is key to encouraging the involvement of
this community in developing NRIC and ensuring that any development
is in-line with user needs.
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P624 Review of methods of national prevalence surveys of
healthcare-associated infections in 17 European countries
C. Suetens °, A. Ammon, K. Weist, L. Sodano, D.L. Monnet (Stockholm,
SE)
Objectives: In order to prepare a common protocol for a EU-wide
point prevalence survey (PPS) of healthcare-associated infections (NI)
in 2010–2011, a methodological analysis of current national protocols
in 17 European countries was carried out.
Methods: Methodological data were extracted from papers, full reports
or protocols published in international or national scientiﬁc journals,
on the internet or from copies obtained from national PPS coordinating
centres when not available elsewhere. Keywords used for MEDLINE and
Google searches were: prevalence combined with nosocomial, hospital,
hospital-acquired and healthcare-associated infections.
Results: The percentage prevalence of HCAI varied from 3.5% to 9.9%.
The main differences are summarised in table 1. The ﬁrst difference
concerns the use of different case deﬁnitions. Secondly, all criteria of the
case deﬁnition had to be present on the day of the survey in some studies
while in others criteria were looked at for the entire infection episode.
The strict application of the criteria was either controlled, e.g. during
analysis, or left to the investigators’ judgment. Third, included infection
types were sometimes limited to the major types only (urinary tract,
bloodstream, lower respiratory tract, surgical site infections). Fourth,
speciﬁc infection types included different subtypes (e.g. exclusion of
asymptomatic bacteriuria). Fifth, infections acquired in other hospitals
were sometimes included. Finally, large differences existed regarding
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the workload (patient-based data for all patients, for infected patients
only, or aggregated infection and denominator data), type of risk factors,
exclusion or not of speciﬁc types of departments (e.g. paediatrics), types
of hospitals (e.g. long-term care), types of patients (e.g. minimum length
of stay), type of investigators (internal vs external) and their training,
case ﬁnding methods, the use of data sources such as a pharmacy or
microbiology database and the type of microbiological data collected
during the PPS.
Conclusions: The European Centre for Disease Prevention and Control
(ECDC) plans an EU-wide PPS of NI in order to obtain nationwide
data on all types of NI from all EU Member States. The current review
however shows that most MS may have to adapt their current national
protocol in order to comply with an EU-agreed method including at least
common case deﬁnitions, comparable case ascertainment and a minimal
common dataset for stratiﬁed comparisons.
Methodological difference % Countriesa
Case deﬁnitions
Diagnostic related groups 11.8% LV, SE
CDC, modiﬁed 11.8% FR, NL
CDC, unmodiﬁed 76.5% Other
Imported HCAI includedb 47.1% DK, ES, FI, FR, IE, NL, SE, UK
Included infections
All infections 52.9% BE, GR, IT, LT, LV, NL, PT, SE, SI
Only main infection types 11.8% NO, DK
Exclusion of secondary bloodstream infections 23.5% UK, IE, FI, DE
Exclusion of asymptomatic bacteriuria 11.8% ES, FR
Data collection type/workload
Aggregated numerator and denominator 11.8% NO, DK
Patient-based numerator and aggregated denominator 11.8% SE, LV
Patient-based numerator and denominator 76.5% Other
Exclusion of speciﬁc patients or specialties 17.6% FR, NL, FI
aBE: Belgium, DE: Germany, DK: Denmark, ES: Spain, FI: Finland, FR: France, GR: Greece, IE: Ireland, IT: Italy,
LT: Lithuania, LV: Latvia, NL: Netherlands, NO: Norway, PT: Portugal, SE: Sweden. SI: Slovenia, UK: United
Kingdom; references: see review in ECDC Annual Epidemiological Report on Communicable Diseases 2008
available from http//ecdc.europa.eu, except Belgian PPS available from www.kce.fgov.be.
bNot always included in main HCAI prevalence result; UK, IL: only if re-admission from same hospital.
P625 A national point prevalence measurement of healthcare-
associated infections in somatic care in Sweden, 2008
M. Erntell °, B. Isaksson, E. Melander, M. Prag, I. Qvarfordt, D. Stro¨m,
A. Tammelin, S. Wallin, S. Wetterbrandt, I. Zetterqvist, Swedish Study
Group for Healthcare-Associated Infections
Objectives: The objective was to perform a nation wide web-based
point prevalence measurement (PPM) of healthcare associated infections
(HAI) and risk factors. The PPM is part of the national patient safety
initiative and will be performed twice during 2009.
Method: A national cross sectional PPM of HAI was performed within
a two-week period in November 2008. Demographic data, ﬁve deﬁned
risk factors for HAI and antibiotic therapy for all admitted patients
was recorded by the staff of each ward. HAI was recorded in relation
to 18 pre-deﬁned diagnosis groups. Type of HAI was referred to as
postoperative, device or drug related, and others.
Results: 101 hospitals included 22,746 patients, close to all admitted
patients in Sweden. 20,131 were admitted in somatic wards. 1,203
were children and 54% women. 52.1% were admitted to specialities
of internal medicine, 18.2% to surgery and 10.4% to orthopedics.
2,227 patients with 2,385 diagnoses of HAI were recorded. The most
frequent HAI diagnoses were infections of the lower urinary tract, 20.5%
(68% device related), skin and soft tissues 16.5%, lower respiratory tract
14%, fever 7.7%, septicaemia 6%, contagious gastrointestinal infections
5.9%. The overall HAI prevalence was 11.1%. Large variations of HAI
were observed between different hospitals; tertiary hospitals 7.4−19.8%,
secondary hospitals 6.2−15.1% and primary hospitals 2.8−23.8%. The
risk factors for HAI was central venous lines, present in 12.8% of all
patients, catheter a´ demeur in 21.9%, immuno-suppression in 8.4%,
surgery 30.8%, mechanical ventilation 2.1%. 4.4% of the patients were
treated in an ICU. 32.7% were treated with antibiotics and 9.7% were
treated for HAI, corresponding to 89% of all HAI.
Conclusions: The PPM method was successfully introduced including
almost all patients in Swedish hospitals. The results give us speciﬁc
knowledge of HAI including the role of the risk factors. The facilitation
of the national patient safety initiative is important as well as the
tutorial aspects of self-assessment of HAI. Local results are available
for immediate analysis.
P626 Epidemiology and outcome of C. difﬁcile infection in a large
UK teaching hospital
H. White, D. Bell, J. Reid, C. Walker, M. Wiselka ° (Leicester, UK)
Objectives: C. difﬁcile infection is an important healthcare associated
infection. University Hospitals of Leicester (UHL) experienced a
signiﬁcant increase in cases over the three years until 2006, coinciding
with the introduction of the ribotype 027 strain. A C. difﬁcile cohort
isolation ward was opened in April 2007. The aims of this study were
to review the epidemiology and outcome of infected patients and the
impact of the Isolation Unit.
Methods: Clinical information on cases of C. difﬁcile infection was
collected prospectively using a standard clinical proforma. A total of
492 outcome forms were completed between October 2006 and March
2008. Patients were managed according to an agreed protocol during this
period.
Results: The median age of patients with C. difﬁcile infection was
77 years. 70% were admitted from their own homes. In 81.6% of cases
this was their ﬁrst admission with C. difﬁcile, but 18.6% of patients were
admitted with recurrent disease. In hospital mortality was 38% and mean
length of stay was 40 days. 73% of those discharged returned to their
own home. 30% of patients were on a proton-pump inhibitor at the time
of diagnosis of C. difﬁcile and 87% had received antibiotics within the
last 2 months.
Initial treatment with 10 days of oral metronidazole led to resolution
of diarrhoea in only 34% of cases. Subsequent treatment with oral
vancomycin (125mg four times daily) led to resolution in a further
51%. Approaches used to treat those patients who did not resolve
after metronidazole/vancomycin included pulsed therapy and intracolonic
vancomycin.
The opening of the C. difﬁcile Unit resulted in an 80% reduction of new
cases of C. difﬁcile infection identiﬁed in the Hospital Trust. Patients
admitted to the Unit had signiﬁcantly lower mortality and length of stay.
Conclusions: This is one of the largest prospective studies of the
outcome of C. difﬁcile infection and highlights the impact of infection
and associated in-hospital mortality. The outcome of metronidazole
treatment was disappointing with vancomycin appearing to lead to
resolution in a greater proportion of cases. There is currently no
consensus on treatment of C. difﬁcile infection which is recalcitrant to
metronidazole and vancomycin therapy. The opening of the cohort ward
and other measures implemented by the Trust resulted in a dramatic
and sustained fall in the incidence of C. difﬁcile with a signiﬁcant
improvement in clinical outcome.
P627 English voluntary surveillance scheme for Clostridium
difﬁcile infections: seasonal variation by age group
(January 2000 – December 2008)
A. Pearson °, R. Guy, R. Blackburn, R. Mandalia, J. Davies, M. Murray,
M. Painter, S. Batley, B. Duerden, J. Giltrow, M. Fleming (London, UK)
Objectives: This paper describes apparent age variation in seasonality of
C. difﬁcile infection (CDI) in hospital and community associated cases
in England.
Methods: Data on CDI reported by National Health Service (NHS)
laboratories in England are collected by both voluntary and mandatory
reporting schemes. This paper analyses reports sent to the voluntary
surveillance scheme for the period January 2000 to December 2008. The
reports are from specimens taken from patients in healthcare facilities
and the community. The dataset includes patient sex, soundex, age and
specimen date.
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301,797 cases of CDI where the patient’s age was known were reported
(January 2000 to September 2008). Patient age at the time of diagnosis
was used to stratify age groups as: 2−14 years, 15−44 years, 45−64 years
and 75 years. Data on patients aged less than 2 years of age were
excluded from the analysis (1,720 reports). Also excluded from the
analysis were specimens without age data (5,726 cases) and reports stated
as toxin negative (4,723 cases).
Results: There was a four fold rise in reported CDI in the 75 years and
over age group between 2004 and 2007, followed by a reduction in 2008.
Marked seasonality with peaks in the January to March (Quarter1) from
2004 to 2007, is predominately seen within the oldest age and 65−74
groups (30% of annual cases occurring in this quarter). Regular seasonal
patterns are not discernable in the younger age groups (2−14, 15−44 and
45−64 years). CDI in 2008 shows rapidly decreasing counts and lacks a
peak in the ﬁrst quarter of the year, which may be due to a mild winter.
There is marked variation between regions: Q1 peaks have been sustained
high since 2004 for the 75 years age group in the South Western,
North Eastern, East of England and Yorkshire and Humberside Regions
of England. These differences may be due to one or more of a number of
reasons: variable ascertainment, epidemiology effect of different strain
types and the consequent variation of associated risk factors.
Conclusions: There is no current explanation of the seasonality seen in
the ﬁrst six months of the year. Further investigation of the association
of antibiotic usage linkage and strain typing data is required to test the
hypothesis that pneumonia diagnosis and treatment with broad spectrum
antibiotics could explain this seasonality.
P628 A case-control study during an outbreak of Clostridium
difﬁcile infections due to PCR ribotypes 027 and 017
occurring simultaneously in one hospital in the Netherlands
A. Goorhuis °, S.B. Debast, J.C. Dutilh, C. van Kinschot,
D.W. Notermans, C. Harmanus, E.C. Hagen, E.J. Kuijper (Leiden,
Amersfoort, Utrecht, Bilthoven, NL)
Objectives: Outbreaks of Clostridium difﬁcile infection (CDI) due to
PCR ribotype 027 (type 027) are emerging worldwide, whereas some
European countries report an increase of toxin A negative PCR ribotype
017 (type 017). We encountered a unique outbreak due to types 027 and
type 017 occurring simultaneously in a 1100 bed teaching hospital in
The Netherlands.
Methods: From May 2005 through January 2007, an outbreak of CDI
occurred with a peak incidence of 85 per 10,000 admissions. A case
control study was performed with two different control groups. Risk
factors and outcome parameters were compared in multivariable analysis,
using age, sex, medical specialty, co-morbidity score and concomitant
use of drugs and antibiotics as co-variates. All isolates from CDI patients
were investigated by PCR-ribotyping and multi locus variable number
of tandem repeat analysis (MLVA).
Results: During the study period, 168 patients were included, 57 (34%)
of whom had CDI with type 017, 46 (27%) with type 027, and 65 (39%)
with other types. Controls consisted of 77 non-CDI diarrhoeal patients
and 162 patients without diarrhoea. Independent risk factors for CDI
were nasogastric intubation (OR 2.7), recent admission (OR 2.1), use
of second generation cephalosporins (OR 12), clindamycin (OR 11) and
antifungal agents (OR 8.1). Individual comparison of CDI due to types
017 and 027 with CDI due to other types, identiﬁed age above 65 years as
risk factors for types 017 and 027 (OR 4.6 and 6.1, respectively) and use
of macrolides (OR 9.4), clindamycin (OR 2.3) and immunosuppressive
agents (OR 5.0) as risk factors for type 017. Patients with type 027 used
signiﬁcantly less clindamycin (OR 0.3). The overall mortality at 1 year
follow-up was signiﬁcantly higher among CDI patients, compared to
both patients with non-CDI diarrhoeal and non-diarrhoeal patients (38%,
29% and 20%, respectively). The overall mortality among patients with
types 017 and 027 was higher when compared to patients with other
types (46%, 49% and 23%, respectively). MLVA showed clonal spread
of types 017 and 027 throughout the hospital, where clones could persist
on wards for more than a year, despite thorough disinfection.
Conclusions: In this unique outbreak in one hospital, distinct risk
factors were found for types 017 and 027, which were associated with
a signiﬁcantly higher one-year overall mortality than that of patients
with other types and controls. MLVA showed persistence of clones over
prolonged periods of time.
P629 Surveillance of nosocomial pneumonia and bloodstream
infection in patients with acute leukaemia
C. Kiefer, D. Luft, R. Babikir, H. Bertz, W. Kern, A. Widmer,
M. Dettenkofer ° (Freiburg, DE; Basel, CH)
Objectives: We prospectively determined rates and incidence densities
of nosocomial pneumonia and bloodstream infections (BSI) that
occurred during neutropenia in patients with acute leukaemia (acute
myeloid leukaemia [AML] and acute lymphatic leukaemia [ALL])
undergoing chemotherapy. The infection rates were compared to those
of haematopoetic stem cell transplant (HSCT) patients.
Methods: CDC deﬁnitions for laboratory-conﬁrmed bloodstream infec-
tion were used to deﬁne BSI, CDC adapted criteria to deﬁne pneumonia
in neutropenic patients [for detailed information see http://www.nrz-
hygiene.de/surveillance/onko.htm]. Data of six participating centres were
entered into the ONKO-KISS_AL database, an extension established in
2005 of the well introduced ongoing multicentre infection surveillance
project in haematopoetic stem cell transplant patients (ONKO-KISS:
German Surveillance Programme for nosocomial infections in haema-
tology patients) and analyzed.
Results: From 01/2005−06/2008 data on 1,012 consecutive patients
(range 47 to 225 per centre), age 16 years, was provided with a mean
duration of neutropenia of 16 days (range 2 to 106) resulting in a total
of 16,262 neutropenic days. Mean duration of neutropenia was 17.3 days
in AML patients and 12.3 days in ALL patients, respectively. The
overall rate of BSI in acute leukaemia patients was 15% (in allogeneic
HSCT patients: 16.5%), the BSI incidence density was 9.3 (8.6) per
1,000 neutropenic days. The overall pneumonia rate in acute leukaemia
patients was 8.6% (in allogeneic HSCT patients: 11.4%), the pneumonia
incidence density was 5.3 (6.0) per 1,000 neutropenic days. For detailed
results see table. BSI was more frequent in female patients (17.7% vs.
12.9% in males, incidence density 10.3 vs. 8.5). Pathogens isolated from
blood cultures were Gram-positive cocci in 59.5% (most frequently:
coagulase negative staphylococci 36%, enterococci 15%, streptococci
5%), Gram-negative rods in 37% (E. coli 20%, Pseudomonas aeruginosa
6%) and Candida spp. in 3.5%.
Therapy Bloodstream infection Pneumonia
groups No. of
patients
Rate
(%)
Incidence
densitya
Rate
(%)
Incidence
densitya
AML ALL AML ALL AML ALL AML ALL AML ALL
All 768 244 16.0 11.9 9.3 9.7 9.1 7.0 5.3 5.7
Standard 345 161 15.1 11.2 8.3 10.2 9.3 2.5 5.1 2.3
Extended 100 47 18.0 4.3 13.2 3.5 5.0 10.6 3.7 8.7
Relapse 25 4 28.0 n/ab 12.9 n/ab 28.0 n/ab 12.9 n/ab
>60 years 291 32 15.5 28.1 9.1 15.0 7.9 25.0 4.6 13.3
aNo. of infections/1,000 neutropenic days. bn/a.: not applicable due to small group
size.
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Conclusions: The ONKO-KISS_AL infection rates and incidence
densities appear similar to those in patients with allogeneic bone marrow
or peripheral blood stem cell transplantation derived from ONKO-KISS.
With ongoing surveillance, variation among centres stratiﬁed for case-
mix can be estimated and correlated with infection control and antibiotic
policy practices.
P630 Incidence of infections in burn centres in France
C. Vinsonneau °, F. Ravat, R. Le Floch, P. Ainaud, M. Bertin-Maghit,
H. Carsin, G. Perro, on behalf of SFETB
Objectives: Infections in burn patients are the leading cause of delayed
death. To improve the prognosis of burns, prevention of infectious
disease is mandatory, but large epidemiological study are lacking in
our French population. This study aims to assess the incidence and
characteristics of infections in this population.
Methods: Non-interventional study, epidemiological, longitudinal, con-
ducted among 15 burn centres in France and held a period of three
months from July to September 2006. Only new episodes of infection
occurring during this period have been taken into account. Among the
784 patients admitted during the study period in participating centres,
348 had a burn centre stay strictly included within the range of the
observation time.
Results: The characteristics of the whole population are (median,
IQR): age 35 y.o [16−52], sex ratio (M/F) 7/10, Total Burn Surface
Area (TBSA) 10% [5−20]. 24% are younger than 15 y.o and 15%
have a TBSA> 30%. The overall incidence of infected patients is
19% (N= 784) and 48.3% for burns over 30% (N= 120). The overall
incidence of infections is 32.7%. The density of incidence of infected
patients is 1.7 episodes/100 patient-days and density incidence of
infections is 2.0 episodes/100 patient-days. The site of infection and
their relative rate are burn wound (32%), lung (32%), urine (17%)
and bacteraemia (14.6%). Multi-site infections represent 14.6% of all
cases. Gram-negative pathogens are the leading strains (72%) with
Pseudomonas aeruginosa (28%), Proteus (18%), E. coli (16%), Serratia
(11%), Klebsiella (4%). Gram positive pathogens represent 55% of all
infections with Staphylococcus aureus (32%) and Enterococci (9%).
Yeasts represent about 5%. Strains antibiotic susceptibility analysis
shows that 27% of them are multi-resistant. Overall mortality is 5%.
Conclusion: Infections acquired in burn centres are frequent and most of
the patients experience several episodes. Burn wound and lungs mostly
affected and micro-organisms have not infrequently a multi-resistant
phenotype.
P631 Are Staphylococcus epidermidis infections nosocomial
infections?
M. Hercun, W. Solbach, J.K.M. Knobloch ° (Lubeck, DE)
Objective: Staphylococcus epidermidis strains causing catheter-
associated infections display a high prevalence of the icaADBC gene
cluster required for PIA-dependent bioﬁlm formation as well as the
mecA gene mediating methicillin resistance. In contrast, commensal
isolates from healthy individuals display low prevalences for icaADBC
and mecA suggesting a possible transmission of icaADBC and mecA-
positive strains in hospitals.
Methods: We investigated the prevalence icaADBC and mecA in
S. epidermidis strains from hospital environments (H-SE, n = 164) and
non-hospital public environments (P-SE, n = 130). The clonal relation of
representative icaADBC and/or mecA positive isolates was determined
by MLST using the eBURST algorithm for analysis.
Results: Similar prevalence of icaADBC was observed in H-SE (20.7%)
and P-SE (20.0%). In H-SE a signiﬁcant higher prevalence of mecA
(17.7%) was observed compared to P-SE (6.2%). Thereby, 13 of 34
icaADBC-positive H-SE were also positive for mecA (38.2%), whereas
only 3 of 26 icaADBC-positive P-SE were mecA-positive (11.5%),
indicating that the observed linkage of icaADBC and mecA in infection
associated S. epidermidis is characteristic for hospital associated strains.
Analysis of the clonal relation revealed also signiﬁcant differences. 32
of 50 H-SE clustered in one clonal complex with MLST ST6 as primary
founder and STs ST2 and ST5 as predominant clones, corresponding
to the epidemiology evaluated in different studies for S. epidermidis
isolates causing foreign body-associated infections. In contrast, only 10
of 30 P-SE were associated with this cluster and 18 isolated displayed
MLST STs characterised as singletons. Interestingly, 6 H-SE with ST2
were mecA-positive, whereas the only P-SE with ST2 was icaADBC-
positive and mecA-negative. All 7 H-SE of ST5 were icaADBC-negative
and mecA-positive. In contrast, one of two P-SE with ST5 displayed a
icaADBC-positive and mecA-negative genotype.
Results: Summarising the epidemiological data as well as the clonal
relation of the investigated isolates it could be suggested that hospital
speciﬁc environmental S. epidermidis clones exist which might be a
source for transmission to patients with subsequent infection. Thereby,
the linkage of icaADBC and mecA could result in the selection of
bioﬁlm-positive strains by antibiotic treatment.
P632 Results of the ﬁrst national prevalence study on
hospital-acquired infections in the Netherlands
T.I.I. van der Kooi °, J. Mannie¨n, J.C. Wille, B.H.B. van Benthem
(Bilthoven, Utrecht, NL)
Objective: A national prevalence survey was set up to acquire national
estimates of the prevalence of hospital-acquired infections (HAI), to offer
leads for further research or interventions and to improve benchmarking
possibilities.
Methods: In March 2007 the ﬁrst Dutch national point prevalence study
on HAI was organised. This study, set up by the PREZIES-network
(network for “prevention of nosocomial infections through surveillance”)
and other working parties is repeated in March and October of each year.
Infections are recorded according to a uniform protocol, using the CDC
criteria with minor adaptations.
Results: In March 2007 30 hospitals participated, in October 2007 12
and in March 2008 29: in total 37 different institutions of the total of
96 Dutch hospitals.
The prevalence of HAI in 21,370 patients was 7.2% (95% conﬁdence
interval (CI) 6.9−7.6%). Of the patients 6.3% was infected. Table 1
shows the prevalence of all and the major infection types. Surgical site
and symptomatic urinary tract infections occurred most frequently.
Mean % (range)
All patients non-ICU ICU
SSI (n = 7712) 4.8 (1.9−14.3) 4.5 (1.5−14.3) 8.1 (0.0−60.0)
Pneumonia 1.1 (0.0−3.4) 0.6 (0.0−3.0) 9.5 (0.0−36.4)
Primary sepsis 0.5 (0.0−2.5) 0.4 (0.0−2.0) 2.4 (0.0−21.4)
Symptomatic urinary tract infection 1.7 (0.0−6.5) 1.7 (0.0−6.9) 2.1 (0.0−18.2)
All infection types 7.2 (2.2−15.4) 6.3 (1.5−15.3) 25.1 (0.0–100)
Of the patients with a urinary catheter on the survey day 3.6% (range
0.0−13.3%) had a symptomatic urinary tract infection. The percentage
ventilated patients with pneumonia was 14.9% (range 0.0–100.0%).
Secondary and primary sepsis, gastro-intestinal and skin infections
occurred in 0.3−0.5% of the patients.
The use of urinary catheters on the survey day varied between 13.2 and
30.7%. Antibiotic use ranged from 22.0 to 42.9%. Of the patients with
HAI 71.9% received antibiotics at the survey day and of those without
28.7%. At admission 3.6% of the patients had a HAI, 65.5% of which
were acquired in the same hospital.
Multivariate regression, accounting for clustering per hospital (Proc
Genmod in SAS) showed an increased risk for age (Odds ratio
1.1 (CI 1.0−1.1) per 10 years increase), specialism (anaesthesiology,
surgery (not plastic surgery), traumatology, haematology compared to
cardiology, dermatology, ENT, paediatrics, obstetrics & gynaecology
and ophthalmology 1.7 (1.4−2.1)), surgery 1.3 (1.1−1.4), central venous
catheter 1.8 (1.4−2.2), peripheral catheter 1.4 (1.3−1.6), invasive
ventilation 1.7 (1.3−2.3), urinary catheter 1.7 (1.5−2.0) and length
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of stay (2 weeks 4.9 (3.8−6.2), 3 weeks 9.8 (7.5−12.8), 4 weeks
13.4 (10.5−17.0), 5 weeks 16.1 (12.7−20.3)).
Conclusions: The prevalence of hospital-acquired infections varies
considerably between hospitals. These differences can partly be
explained by differences in patient population.
General surveillance
P633 National network set-up for monitoring micro-organisms
resistance to anti-infectives in a developing country: case of
the Ivory Coast
N. Guessennd °, V. Gbonon, D. Ouattara, B. Tiecoura, A. Achy-Brou,
M. Dosso, on behalf of the ORMI-CI
Created in June 2000 under ONERBA (France) sponsorship, the
Observatory of the Resistance of the Micro-organisms in Ivory Coast
(ORMICI) set up a national network of sentinels laboratories for the
monitoring of bacterial resistances to antibiotics. Since June 2006,
ORMICI had become the National Reference Center for the monitoring
of bacterial resistances in Ivory Coast.
Objectives:
– Standardising the methods of susceptibility tests and improving quality
of information and the conditions of their collecting.
– Collecting information concerning micro-organisms resistances to
anti-infectious evolution in Ivory Coast in order to analyze and diffuse
them to the medicals authorities, scientist societies and professionals
of health.
– Training the prescribers and sensitising the population.
– Comparing the national data with those obtained in the other countries
of the sub region.
Methods: The epidemiologic strategy of bacterial resistance monitoring
is based on the choice of sentinel laboratories which can provide
information in the Community and in Hospital. The activities were based
on:
• network organisation and working,
• capacities reinforcement of the CNR and its network laboratories,
• network animation and management,
• strains stocks constitution.
CNR collects laboratories strains with epidemiologic information.
Quality control is insured by the reference laboratory of antibiotics
resistance study group of the International Network of the Pasteur
Institutes.
Results: The network includes height public laboratories of various
levels in the medical pyramid and nine private laboratories.
A national campaign of sensitising to the right prescription of antibiotics
was organised in collaboration with the General Mutual Insurance
Company of Ivory Coast.
Several scientiﬁc workshops bringing together the professionals of the
environment and those of human and animal health were organised.
A regional course in susceptibility tests standardisation, ﬁnanced by
Pasteur Institute of Paris, has taken place in April 2008 in Abidjan.
Information reports on the resistance levels were published.
ARV resistance training intended for the prescribers has taken place in
December 2008.
Conclusion: ORMICI was restructured in 2008 with the working out of a
schedule and a charter for a better national establishment. The setting in
of this network is a real experiment to be shared with the other countries
of our sub-region in order to federate a West African network.
P634 Seven years of SARI (Surveillance of Antimicrobial Use and
Antimicrobial Resistance in Intensive Care Units; 2001–2007
E. Meyer °, P. Gastmeier, B. Schroeren-Boersch, F. Schwab (Berlin, DE)
Objectives: To analyse data of SARI (Surveillance of Antimicrobial Use
and Antimicrobial Resistance in Intensive Care Units from 2001–2007
and to look for temporal changes.
Methods: Prospective unit and laboratory based surveillance in 49
German ICUs from 2001–2007. The data were calculated on proportions
of non-duplicate resistant isolates (RP), resistance densities (RD; i.e.
the number of resistant isolates of a species per 1000 patient days)
and antimicrobial usage density (AD) expressed as daily deﬁned doses
(DDD) and normalised per 1000 patient-days (pd). Linear trends were
calculated using linear regression analysis with monthly data.
Results: Total mean antibiotic use (without sulbactam) stayed stable
over time. AD was 1180 in 2001 and 1236 in 2007. Carbapenem use
almost doubled to an AD of 134 in 2007. Signiﬁcant increased were
also calculated for quinolones (AD of 168 in 2007) and 3rd and 4th
generation cephalosporin (3/4GC) use (AD of 124 in 2007). The most
prominent decrease faced aminoglycoside use (AD was 86 in 2001 and
29 in 2007).
RRs were as follows in 2001 and 2007: MRSA 26 and 21%, VRE
0.6 and 1.7%, 3GC resistant E. coli 1.2 and 11.2% and 3GC resistant
K. pneumoniae 3.8 and 10.5%.
The burden of resistance or the RDs did not change for MRSA
but increased signiﬁcantly for VRE and 3GC resistant E. coli and
K. pneumoniae. RD of MRSA was 4.5 in 2007, of VRE 0.3 and of 3GC
resistant E. coli and K. pneumoniae 2.2 resistant pathogens/1000 pd.
Conclusion: Total antibiotic use did not change over time with 1.2 DDD
per patient per ICU day. However, there was a signiﬁcant increase in
the use of broad spectrum antibiotics like carbapenems. The burden of
MRSA did not change in contrast to an increase in the burden of 3GCR
E. coli and K. pneumoniae in German ICUs. In the face of resistant
pathogens we ﬁnd it better to describe and compare the burden of
resistance and the magnitude of the public health problem by resistance
densities besides resistance proportions.
P635 Inadequate drugs for the treatment of infections with Gram-
positive pathogens using the EPICENTER Network data
B. Grabein, M. Hoeck, H.M. Just, I. Schwede, B. Wiedemann ° (Munich,
Berlin, Nuremberg, Frankfurt-Oder, Schaalby, DE)
Objectives: Surveillance data must help to identify drugs, which are
obsolete for the empirical treatment of infections, because of resistance
development. We analysed a one year period of the EPICENTER
Network data to select drugs, which are useful for the treatment for
infections with Gram positive pathogens.
Methods: At present 4 laboratories participate in the network using
the automated BD PHOENIX system. The BD EPICENTER Data
Management System is used for the evaluation of the data in the
laboratory and for the transfer of the data to the concentrator for
evaluation of the data with stratiﬁcation by material, source, medical
discipline, time, patient and others. Copy strains are excluded. Quality
control is mandatory. Antibiotics with a rate of more than 35% resistance
for a species were regarded as obsolete for empirical treatment.
Results: We analysed 1532 Enterococcus faecalis-, 638 Enterococcus
faecium-, 3759 Staphylococcus aureus-, and 1718 Staphylococcus
epidermidis-strains (see table). Blank ﬁelds indicate a drug–bug
combination which is generally regarded as obsolete and was not
tested or documented, R = intrinsic resistance. The isolates were
from all specimen types. Analysing the data by specimen types,
urine-, blood-, or pulmonary tract-isolates, the general outcome for
the drug–bug combinations in question is similar. Enterococi and
Staphylococci show different susceptibility proﬁles. Only teicoplanin,
vancomycin, rifampicin, and fosfomycin are active on all tested Gram
positive pathogens, but the last two mentioned drugs are only for
use in combinations. Aminoglycosides are active only on S. aureus.
Surprisingly, even at high concentrations activity of aminoglycosides is
low for the Enterococci. All quinolones seem to be of little value, even
Moxiﬂoxacin shows acceptable results only with S. aureus.
Conclusion: Resistance %ages seen in the data of the EPICENTER
Network indicate that an empirical treatment of Gram positive infections
is even more difﬁcult than with Gram negative ones and classical drugs
like clindamycin and macrolides show doubtful results and should not be
used without microbiological data of the patient. The only drugs which
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still appear of some value are teicoplanin and vancomycin, however even
with these drugs we must be prepared for the worst.
Antimicrobial Antibiotic resistance of Gram-positive isolates
E. faecalis E. faecium S. aureus S. epidermidis
Gentamicin 100.0% 100.0% 5.00% 45.40%
Gentamicin-Syn 33.10% 43.90%
Streptomycin-Syn 44.00% 77.20%
Amoxicillin/Clavulanic acid 0.90% 81.30% 32% 62.80%
Ampicillin 0.90% 87.10% 79.20%
Cefazolin 32% 62.20%
Cefoxitin 32.00% 73.00%
Imipenem 0.60% 95.20% 32% 84.70%
Meropenem 7.70% 91.70% 32.10% 73.40%
Oxacillin 100.00% 100.00% 32.00% 73.40%
Penicillin G 0.00% 0.00% 76.40% 85.10%
Trimeth/Sulfa 100.00% 100.00% 1.60% 33.60%
Fosfomycin w/G6P 0.40% 4.10% 0.80% 24.30%
Fusidic acid 1.40% 21.00%
Teicoplanin 0.10% 3.30% 0% 0%
Vancomycin 0.20% 3.30% 0% 0%
Clindamycin 98.70% 95.90% 24.10% 49.40%
Erythromycin 50.50% 90.40% 30.90% 71.80%
Mupirocin high level 1.40% 4.80%
Ciproﬂoxacin 45.40% 86.30% 36.20% 61.20%
Levoﬂoxacin 39.70% 84.60% 35.70% 55.00%
Moxiﬂoxacin 36.00% 85.20% 30.80% 36.50%
Oﬂoxacin 45.10% 51.10%
Rifampin 1.60% 8.10%
Tetracycline 75.10% 31.00% 4.80% 12.60%
P636 Ten-year trend in aminoglycoside resistance from a worldwide
collection of Gram-negative pathogens (1998–2007)
D. Biedenbach, R. Jones °, G. Miller, E. Armstrong (North Liberty,
San Francisco, US)
Objectives: To assess resistance (R) trends to aminoglycosides (AG) over
ten years from a global sample of Gram-negative (GN) pathogens. This
study determined the R rates of gentamicin (GEN), tobramycin (TOB)
and amikacin (AMK) against nine common GN species groups from
medical centres in North America (NA), Latin America (LA), Europe
(EU) and Asia-Paciﬁc (APAC).
Methods: Non-duplicate isolates from bloodstream and respiratory
tract infections were collected from 38 countries between 1998–2000
(27,491 strains) and 2005–2007 (30,430 strains) via the SENTRY
Program. Organisms included E. coli (EC), Klebsiella spp. (KBS),
Enterobacter spp. (EBS), Citrobacter spp. (CBS), Serratia spp. (SER),
P. mirabilis (PM), Indole + Proteae (IPP), P. aeruginosa (PSA) and
Acinetobacter spp. (ACB). Susceptibility (S) testing was performed by
two central monitoring laboratories using CLSI methods (M7-A7, M100-
S18) and concurrent quality control testing.
Results: With the exception of KBS in EU, R to GEN increased in
all regions for the three most prevalent Enterobacteriaceae (listed ﬁrst
in the Table). Nearly all pathogens in NA showed increased GEN
R rates (0.6−11.1%) during the last surveillance period (2005–2007),
while signiﬁcant variations were noted in other regions. The dramatic
increase in GEN-R for nearly all species in APAC countries was due to
strains sampled from countries not included in the earliest sample (e.g.
India and Indonesia). Between 60−70% of the ACB were R to GEN
in regions outside of NA, with the USA rate approaching 43% in the
most recent years. R to all three AG agents for each of these pathogens
was generally <1% among enteric pathogens from NA. However, much
higher GEN/TOB/AMK-R rates were observed in other geographic areas
for the most common Enterobacteriaceae, highest in LA 1.4−17.1%
during both time periods. R to all three AG ranged from 3.1% (NA)
to 25.3% (LA) for the PSA isolates collected during 2005–2007.
Conclusions: Signiﬁcant geographic variability in AG S was observed in
the analysis of this large sample of GN pathogens with highest R rates in
LA and APAC. Although the AG-R-mechanisms associated with these
isolates were not assessed (companion abstract) it appears that a new
generation of AG compounds would be a valuable therapeutic alternative
to GEN, TOB and AMK for GN infections.
Table
Organism % GEN R
1998−2000 (27,491 isolates)/2005−2007 (30,430 isolates)
NA LA EU APAC
EC 3.2/9.3 10.4/15.4 6.4/7.8 15.5/43.1
KBS 3.9/7.9 30.5/38.4 20.9/12.3 12.0/37.6
EBS 5.8/8.7 21.2/29.9 9.7/10.1 12.8/30.4
CBS 3.2/3.8 26.5/12.5 14.1/5.0 5.4/28.4
SER 2.7/3.9 26.0/20.6 14.8/8.9 22.8/13.2
PM 6.4/6.3 36.1/28.1 20.2/11.0 6.2/21.5
IPP 11.5/12.4 20.5/43.9 15.9/12.0 21.5/24.3
PSA 14.7/12.6 38.6/36.7 30.0/22.6 15.7/33.6
ACB 31.6/42.7 65.6/67.9 69.2/63.0 35.3/60.0
aIsolates were non-S to GEN.
P637 Klebsiella pneumoniae 2002–2007: multi-class resistance
and changing patterns of resistance to carbapenems and
third-generation cephalosporins
R.M. Mera °, L.A. Miller, H. Amrine-Madsen, D.F. Sahm (Durham,
Upper Providence, Hendon, US)
Objectives: To describe the changes over time of K. pneumoniae
resistance to several antimicrobial classes in a statistical model that
adequately adjusts for changes over time and the effect of several risk
factors.
Methods: The surveillance study consisted of 186,819 US isolates
from the TSN Network® surveillance database (Euroﬁns Medinet) for
the period 2002–2007. Covariates available for analysis were time,
age, sex, state, location (Ward or ICU) and source (blood, sputum,
etc). Antimicrobial classes considered in the model were carbapenems,
3rd generation cephalosporins, aminoglycosides and ﬂuoroquinolones.
Multi-class or multiple resistance was deﬁned as non susceptibility
to three or more antimicrobial classes. Odds of resistance and 95%
conﬁdence intervals around rates were obtained using a logistic
regression model.
Results: Non susceptibility to carbapenems was not observed in this
data set in 2002 but reached 3% for Meropenem in 2007. 3rd Generation
cephalosporins such as Ceftazidime showed a continuous increase from
8.9% in 2002 to 14.2% in 2007, with 70% of the latter being multiply
resistant compared to 50% in 2002 (p< 0.001). Levoﬂoxacin resistance
had a similar increase from 7.6% in 2002 to 14.5% in 2007, with
69% of the latter also being multiply resistant. Although there is a
tendency toward a plateau for aminoglycosides, such as Gentamicin
and Amikacin, multiple resistance has increased 2.9 fold (2.7−3.2)
in ﬁve years of surveillance from 3.9% in 2002 to 10.7% in 2007.
A multivariate model for multiple resistance has it increasing 2.1%
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(0.5−3.7%) every year (p = 0.001), with a 2.4% (0.8−3.4%) signiﬁcant
difference between ICU and Ward independent of time. Subjects under
18 years had a signiﬁcantly lower rate (7.8%, 7.4−8.2%) in 2007 than
those over 65 years old (11.2%, 10.9−11.6%).
Conclusion: K. pneumoniae non susceptibility to several antimicrobial
classes has shown a marked increase during the surveillance period.
Resistance to three or more antimicrobial classes has been ampliﬁed
despite relatively low levels of carbapenem resistance and a plateau in
aminoglycoside resistance.
P638 Susceptibility of baseline Pseudomonas aeruginosa and
Acinetobacter baumannii to doripenem and other antibiotics
from six doripenem phase 3 clinical trials
K. Kaniga, R. Redman, I. Friedland, A. Quintana ° (Raritan, US)
Background: In 6 worldwide phase 3 clinical trials of doripenem
(DOR), the principal baseline non-fermenter isolates obtained were
P. aeruginosa and A. baumannii. The distribution and susceptibilities of
these pathogens to DOR and other antibiotics in regions where phase 3
DOR clinical trials occurred are reported.
Methods: The distribution of non-fermenters in 6 multinational
trials of complicated intra-abdominal infections, complicated urinary
tract infections including pyelonephritis, and nosocomial pneumonia
(including ventilator-associated pneumonia) in North America (NA),
South America (SA), Europe (EU), and Australia and South Africa
(AU/SA) was calculated. The minimum inhibitory concentrations (MICs)
for P. aeruginosa and A. baumannii isolates were generated utilising
Clinical and Laboratory Standards Institute broth microdilution methods.
Results: The distribution of baseline non-fermenters were as follows:
for P. aeruginosa, 27% (59/219) were from NA, 35% (77/219) were
from SA, 35% (76/219) were from EU, and 3% (7/219) were from
AU/SA. For A. baumannii, 29% (18/63) were from NA, 32% (20/63)
were from SA, 29% (18/63) were from EU, and 11% (7/63) were from
AU/SA. Overall, for all non-fermenters, DOR MIC50 and MIC90 were
0.5 and 16mg/L, respectively, vs 1 and 32mg/L for imipenem (IMI).
For P. aeruginosa, DOR MIC50 and MIC90 were 0.5 and 4mg/L,
respectively, vs 1 and 16mg/L for IMI. When DOR MIC was 4mg/L
(n = 12), 25% of P. aeruginosa had IMI MIC 4mg/L. For A. baumannii,
DOR MIC50 and MIC90 were 1 and 32mg/L vs 0.5 and 32mg/L for
IMI, respectively.
Conclusion: In all regions, IMI MIC50 and MIC90 were generally
double the DOR MIC50 and MIC90. Carbapenems had high MIC90
(32−64mg/L) against A. baumannii across regions. While IMI MIC90
varied from 4−16mg/L across regions, DOR MIC90 for P. aeruginosa
varied little (2−4mg/L).
P639 Antimicrobial resistance surveillance in Korea in 2007:
increasing prevalence of vancomycin-resistant E. faecium,
cefotaxime- and cefoxitin-resistant K. pneumoniae, and
imipenem-resistant P. aeruginosa and Acinetobacter spp.
K.W. Lee, M. Lee, J. Lee, K.H. Roh, S.J. Kim, C.H. Lee, J.J. Kim,
D. Yong, S.H. Jeong, Y. Chong °on behalf of the KONSAR Group
Objectives: Surveillance of antimicrobial resistance in Korea has been
increasingly important with wide dissemination of bacteria resistant
to clinically useful antimicrobial agents. Two surveillance methods
have been used for the KONSAR (Korean Nationwide Surveillance
of Antimicrobial Resistance) program: (1) analysis of routine test data
generated by the participating hospitals; (2) and collection and testing
susceptibility of problem organisms by the coordinating laboratory. Aims
of this study were to determine trends of resistance and emergence of
new resistance.
Methods: Antimicrobial susceptibility test data generated in 2007 by
40 hospitals and one commercial laboratory (C-Lab) participating the
KONSAR program were analyzed. The susceptibility was tested by
either the CLSI disc diffusion method or commercial microbroth dilution
methods.
Results: Of the 131,365 isolates, the ranks in decreasing order were:
E. coli, S. aureus, P. aeruginosa (PAE), K. pneumoniae (KPN),
coagulase-negative staphylococci (CNS), E. faecalis, Acinetobacter spp.
(ACI), and E. faecium (EFM). Resistance rates at hospitals and at a
C-Lab, which tested isolates mostly from small hospitals and clinics, are
shown below. Comparison to the previous data in 2003 and 2005 showed
that oxacillin-resistant (R) staphylococci, continued to be very prevalent
at hospitals, whereas, it increased at the C-Lab. Increase of vancomycin-
R EFM was signiﬁcant at C-Lab. Further increases of cefotaxime-R
E. coli (20%) and KPN (45%), and cefoxitin-R KPN (35%) at the
C-Lab were new problems found. Imipenem-R rates of PAE and ACI
were similar or even higher at the C-Lab.
Conclusion: Resistance of frequently isolated organisms continued to
be prevalent or further increased. Recent efforts by the Health Insurance
Review Agency Korea did not result in reduction of resistance, although
signiﬁcant reduction of inappropriate antimicrobials use had been
reported. Further study is required to determine the genetic mechanisms
of cephalosporin-R E. coli and KPN and of imipenem-R PAE and ACI.
Organisms Hospitals Commercial Lab
2003 2005 2007 2003 2005 2007
Oxacillin-R S. aureus 68 59 64 55 53 63
Oxacillin-R CoNS 73 70 64 69 53 70
Vancomycin-R E. faecalis 1 2 1 0 0 1
Vancomycin-R E. faecium 20 20 21 7 12 17
Cefotaxime-R E. coli 11 12 11 12 12 20
Cefotaxime-R K. pneumoniae 20 25 25 18 39 45
Cefoxitin-R E. coli 10 8 6 6 8 11
Cefoxitin-R K. pneumoniae 23 24 21 18 33 35
Imipenem-R P. aeruginosa 20 19 21 17 19 29
Imipenem-R Acinetobacter spp. 13 16 22 5 9 20
P640 Susceptibility to levoﬂoxacin-centred ﬂuoroquinolones and
other antibiotics of 19 species, 12,919 clinical isolates
collected from 72 centres in Japan, 2007
K. Yamaguchi °, A. Ohno, Y. Ishii (Tokyo, JP)
Objectives: A detailed knowledge of the susceptibility to antimicrobial
agents is important to facilitate the development of effective strategies
to combat the growing problem of resistance. We have done a
nationwide and longitudinal surveillance study to monitor resistance
trends to levoﬂoxacin-centred ﬂuoroquinolones (FQs) in addition to
other antimicrobial agents since 1994. In the present study, we analyzed
the surveillance results from major bacterial species collected in Japan
during 2007.
Methods: A total of 12,919 clinical isolates in 19 species were
collected from 72 centres (the Levoﬂoxacin Surveillance group) during
2007 in Japan. The activity of 30 antimicrobial agents against these
clinical isolates was determined using the broth microdilution method
recommended by the CLSI.
Results: The common respiratory pathogens, Streptococcus pneumo-
niae, Streptococcus pyogenes, Haemophilus inﬂuenzae, and Moraxella
catarrhalis showed a high “Susceptible” rate of 98% or more to FQs. The
prevalence of macrolide resistance in S. pyogenes has been increasing
from 2% to 25% during 1994–2007. The isolation rate of beta lactamase
non-producing ampicillin-resistant H. inﬂuenzae was approximately eight
times as large as those of western countries due to the high usage
level of the third generation oral cephems in Japan compared with
the United State or Europe. Most strains of Enterobacteriaceae were
also susceptible to FQs. The resistance rate of Escherichia coli to FQs
has however been rapidly increasing from 2% to 25% since we started
our surveillance in 1994. The FQs-resistant rate in methicillin-resistant
Staphylococcus aureus (MRSA) was approximately 90% except for
sitaﬂoxacin while FQs-resistance rate in methicillin-susceptibl S. aureus
was around 5%. In Pseudomonas aeruginosa clinical isolates, 25−30%
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from UTI and 10−20% of from RTI were resistant to FQs. Carbapenem-
resistant Acinetobacter spp. 16 isolates (A. baumannii 14, A. lwofﬁi 1,
A. haemolyticus 1) were found in 598 isolates and these resistant isolates
were focused in some particular facility.
Conclusion: It was conﬁrmed that FQs including Levoﬂoxacin have
still strong activity against the common respiratory pathogens and
Enterobacteriaceae except for E. coli. Increase of macrolide resistance
was remarkable in A group streptococci. Outbreak of carbapenem-
resistant A. baumannii began to show a sign in Japan.
P641 Molecular characterisation of ﬂuoroquinolone resistance
in Streptococcus pneumoniae, Streptococcus pyogenes,
Haemophilus inﬂuenzae and Escherichia coli clinical isolates
collected from 72 centres in Japan, 2007
A. Ohno °, Y. Ishii, K. Yamaguchi (Tokyo, JP)
Objectives: A detailed knowledge of the susceptibility to antimicrobial
agents is important to facilitate the development of effective strategies
to combat the growing problem of resistance. In this light, the molecular
characterisation of ﬂuoroquinolone resistance in Streptococcus pneumo-
niae, Streptococcus pyogenes, Haemophilus inﬂuenzae and Escherichia
coli based on surveillance data conducted during 2007 in Japan to mon-
itor the appearance of resistance to ﬂuoroquinolones (FQs) was studied.
Methods: QRDR mutations of levoﬂoxacin-resistant Streptococcus
pneumoniae 474 isolates, Streptococcus pyogenes 8 isolates and
Haemophilus inﬂuenzae 9 isolates, and 101 isolates of Escherichia coli
with decreased susceptibility to ﬂuoroquinolones were determined by
PCR and direct DNA sequencing method.
Results: S. pneumoniae isolate with levoﬂoxacin MIC 16 mg/mL
possesed 3 points mutation. Two points mutation was shown in all with
MIC 4mg/mL and 8mg/mL. In levoﬂoxacin-susceptible isolates, 2 points
mutation was detected in 4 of 384 isolates with MIC 1 mg/mL and 5 of
69 isolates with MIC 0.5 mg/mL.
S. pyogenes with MIC of 4mg/mL were found in 8 of 509 isolates.
Two points mutation was detected in 4 of 8 isolates and 3 of them
showed MIC 16mg/mL and 1 isolate was 8mg/mL. One point mutation
was also found in 2 isolates with 4mg/mL and 1 isolate with 8mg/mL.
In E. coli, 8 of 9 isolates with MIC 1mg/mL and 18 of 28 isolates with
MIC 0.5mg/mL had 2 points mutation or more. Most of rest isolates
were all 1 point mutation. Two points mutation were also shown in 26
of 47 isolates with MIC 0.25 mg/mL and 12 of 17 isolates with MIC
0.12mg/mL (other isolates did not have mutation). In H. inﬂuenzae, only
1 isolate showed levoﬂoxacin-resistance (MIC 8mg/mL) and this isolate
had 3 points mutation. Two points mutation was detected in 1 isolates
with MIC 2mg/mL and 4 of 6 isolates with 0.5 mg/mL.
Conclusion: Quinolone-resistance was very few in S. pneumoniae,
S. pyogenes and H. inﬂuenzae clinical isolates in 2007. Nevertheless,
raise of MIC value was associated with the increase of numbers of
mutation point in QRDRs. The rate of ﬂuoroquinolone-resistance in
E. coli has increased rapidly worldwide. Most resistant-strain have
mutation of 4 positions or more (data not shown). Even in susceptible
isolates with MIC ranged from 1 to 0.12mg/mL, most isolates had at least
1 point mutation, and it may relate to the increase of resistant isolate.
P642 Antimicrobial resistance and in vitro bioﬁlm-forming ability
of Pseudomonas aeruginosa isolates from veterinary origin
M. Oliveira °, S. Santos, A. Leita˜o, D. De Vos, J-P. Pirnay, C. Lobo
Vilela (Lisbon, Sintra, PT; Brussels, BE)
Objectives: Pseudomonas aeruginosa is an important human oppor-
tunistic pathogen, but is also relevant for animals. Treatment options
are declining, due to massive antibiotic use. Antimicrobial resistance
mechanisms include intrinsic low cell wall permeability, acquired beta-
lactamases and aminoglycoside-modifying enzymes and efﬂux pumps,
and may be further enhanced by bioﬁlm production. We aimed to
investigate the relation between antimicrobial resistance and bioﬁlm
formation in P. aeruginosa from veterinary origin.
Methods: Antimicrobial resistance of P. aeruginosa animal isolates from
house pets, farm and zoo animals (n = 34), with clinical signs of infec-
tion, previously characterised by fAFLP ﬁngerprinting, was evaluated by
the disk diffusion method (CLSI) for 21 antimicrobial compounds, used
in the treatment of human and veterinary infections. Bioﬁlm formation
was evaluated by Fluorescent In Situ Hybridisation (FISH), applied at
different incubation times (24 h, 48 h, 72 h), and the relation between
results was estimated using the Wilcoxon Signed Ranks Test.
Results: Antimicrobial resistance was similar among all isolates,
showing high resistance to most drugs. None of the isolates
was susceptible to all antimicrobials, while the majority possessed
multi-resistance proﬁle (97%). Resistance percentages were: amoxi-
cillin/clavulanic acid, ampicillin, cephalexin, cephotaxim, nalidixic acid,
penicillin G, tetracycline, 100%; chloramphenicol, 97.96%; sulphame-
toxazole/trimethroprim, 97.06%; streptomycin, 88.24%; enroﬂoxacin
(ENR), 61.76%; carbenicillin (CAR), 67.65%; gentamicin (GEN),
47.06%; cephoperazone (CFP), 44.12%; amikacin, 32.35%; piperacillin,
29.41%; oﬂoxacin, 23.53%; ciproﬂoxacin, 17.65%; ceftazidime, 11.76%;
imipinem, tobramicin, 5.88%. About 18% of the isolates produced
bioﬁlm at 24 h. This percentage signiﬁcantly increased with time. A
signiﬁcant relation (p< 0.05) was found between bioﬁlm production
at 72 h and antimicrobial resistance to most drugs (80.95%), with the
exception for CAR, CFP, ENR and GEN.
Conclusion: Most of our isolates are multidrug resistant, while
antimicrobial resistance increases with bioﬁlm formation, especially
for CAZ, CL, IPM, NA, PRL, TE and TOB. Monitoring antibiotic
resistance of P. aeruginosa from animal origin provides information on
the antibiotic resistance prevalence outside human isolates. It contributes
to a better understanding of drug resistance evolution and the potential
resistance transmission to humans.
P643 Surveying aminoglycoside resistance mechanisms: a tool for
the development of neoglycosides
E. Armstrong °, D. Biedenbach, R. Jones, G. Miller (South San
Francisco, North Liberty, US)
Objectives: To support the development of neoglycosides, the next
generation of aminoglycosides (AG) with an improved antibacterial
spectrum, we conducted a survey of AG resistance mechanisms (AGRM)
among selected clinical isolates. These data will be used to determine
the spectrum of activity required of new compounds to overcome these
mechanisms.
Methods: AGRM were surveyed using isolates of diverse geographic
origin from the SENTRY 2005 and 2007 collections. Enterobacteriaceae,
Pseudomonas aeruginosa and Acinetobacter baumannii from Europe and
North/South America were chosen from the 2005 SENTRY Program
collection based on established amikacin (A), gentamicin (G) and
tobramycin (T) MICs. They were selected such that resistance rates to
these AGs in the test population matched those in the entire collection.
MICs of 9 AGs were determined for 406 strains and the resulting
antibiogram was used to characterise the AGRM. Phenotypes for 6
common AGRM were conﬁrmed by PCR (89 strains). Our study of
the 2007 SENTRY Program collection focused on multidrug resistant
(MDR) Gram-negatives from Europe, North/South America, and Asia.
MDR was deﬁned by resistance to representatives of 3 drug classes; an
aminoglycoside (A, G, or T), a ﬂuoroquinolone (ciproﬂoxacin), and a
third generation cephalosporin (ceftazidime or ceftriaxone). The strains
selected for study were again representative of resistance rates to A, G,
and T within this population. MICs of 9 AGs were determined for 302
strains and the resulting antibiogram used for AGRM characterisation.
AGRM ﬁndings were compared to a published survey conducted between
1988 and 1993 (CID 1997;24:S46).
Results: The incidence of combined AGRM remained high and consisted
of G and T modifying enzymes (AAC(3)-I, AAC(3)-II and ANT(2′′)-I)
occurring with the T-, netilmicin- (N) and A-modifying enzyme
AAC(6′)-I. The GTNA-resistance phenotype that results from these
combinations also continues to occur as a result of permeability/efﬂux
and now due to ribosomal methyltransferases (RMT). In all 3 studies the
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kanamycin-/neomycin-resistance phenotype caused by APH(3′)-I/II was
not evaluated.
Conclusions: These results demonstrate that while the overall prevalence
may be increasing (companion abstract by Biedenbach et al), the distribu-
tion of AGRM amongst AG-resistant isolates worldwide remained stable
during the past 20 years. New agents that evade these AGRM, such as
neoglycosides, are needed.
AGRM Phenotype Percentage of AG-R isolates with given AGRMa
CID 1988–1993
n = 10,181
SENTRY 2005
n = 406
SENTRY 2007
n = 302
Alone Comb. Alone Comb. Alone Comb.
AAC(3)-I G 1.2 8.3 0.7 12.1 0.3 6.3
AAC(3)-II GTN 20.9 17.5 12.3 23.7 23.2 15.2
AAC(3)-IV GTN 1.7 0 0.7 2.0 0.3 1.0
AAC(2′)-I GTN 2.1 1.1 0 0 0 0
AAC(6′)-I TNA 10.4 21.8 8.6 25.9 9.6 19.2
AAC(6′)-II GT 3.6 3.0 7.4 2.7 1.7 4.0
ANT(2′′)-I GT 7.2 4.3 15.0 7.4 2.7 4.6
APH(3′)-VI A 0.1 3.4 1.0 4.7 1.0 9.3
Perm/Efﬂux GTNA 7.6 7.4 2.0 6.4 12.9 11.3
RMT GTNA 0 0 5.2 0.2 15.6 NDb
Total 54.8 66.8 52.9 85.1 67.3 70.9
aComb. = AGRM present in combination with one other or more AGRM.
bND = No data.
P644 Antibiotic susceptibility of Bacteroides clinical isolates in
Europe, 2007−2008
E. Nagy °, E. Urba´n, C.E. Nord, on behalf of ESGARAB
Objective: Bacteroides strains are the most frequently isolated anaerobic
bacteria causing serious infections alone or in mixed cultures. Due
to several special resistance mechanisms antibiotic resistance occurs
among these bacteria, which may lead to treatment failure using empiric
antibiotic therapy. The aim of this study was to evaluate the antibiotic
susceptibilities of recent clinical isolates of Bacteroides strains collected
from different European countries and to follow changes in this respect
in Europe.
Methods: Consecutive, recent clinical isolates were collected from
serious infections. Altogether 824 isolates from 13 countries were
involved in this study belonging to different species of Bacteroides.
Antibiotic susceptibilities were measured by agar-dilution method
using Brucella agar (BBL Microbiology Systems, USA) supplemented
with 5mg haemin and 1mg vitamin K per ml and 5% leaked
sheep blood. MIC values of ampicillin, amoxicillin-clavulanic acid,
piperacillin-tazobactam, cefoxitin, imipenem, clindamycin, metronida-
zole, moxiﬂoxacin and tigecyclin were measured. Overall resistance
rates and frequency of multi-resistant isolates were evaluated. EUCAST
breakpoints were used for all antibiotics where available.
Results: High level resistance rates were found for ampicillin,
only <0.7% of the isolates had an MIC lower than the resistance break-
point. Amoxicillin-clavulanic acid as well as piperacillin-tazobactam
were active against 89.6% and 89.9% of the isolates, respectively.
Most of the isolates (84.6%) had an MIC> 4mg/l for cefoxitin and
clindamycin resistance was quite frequent in some countries. Altogether
31.3% of the isolates had a clindamycin MIC higher than the resistance
breakpoint. Imipenem, metronidazole and tigecyclin were the most active
anti-anaerobic drugs against Bacteroides strains in this study. Only 0.8%,
0.2% (according to the EUCAST breakpoint) and 1.7% (according to the
CLSI breakpoint) of the strains were resistant, respectively. Moxiﬂoxacin
activity was inﬂuenced by the country where the strains were isolates.
The overall resistance to moxiﬂoxacin was 15% according to the CLSI
breakpoint.
Conclusion: As in many countries resistance determination of anaerobic
bacteria is not always carried out in the routine laboratories, it is
mandatory to follow the resistance status of these important pathogens
on the European level in the future as well.
P645 Molecular analysis of recent cephamycin and
carbapenem-resistant Bacteroides isolates
J. Soki °, E. Urban, G. Terhes, E. Nagyon behalf of ESGARAB
Objectives: Our aim was to investigate the cephamycin and carbapenem
resistance mechanisms of recently isolated clinical Bacteroides strains
whether there is a change with respect to the well-known resistance
genes (cfxA, cﬁA) and the mode of modulation of their expression
by insertion sequence (IS) elements. We put a special attention to
examination of strains displaying heterogenous resistance phenotypes
for these two groups of antibiotics.
Methods: For cefoxitin resistance 165 B. fragilis group strains were
included that were isolated in Hungary in 2007–2008. For carbapenem
resistance out of the 474 strains from the recent ESGARAB study
investigating the antimicrobial susceptibility of Bacteroides strains,
12 isolates were examined that exhibited imipenem MICs 4mg/l.
Antibiotic susceptibilities were measured by agar dilution or Etests. The
detection of resistance genes and regulatory elements were carried out by
PCR. In interesting cases, regulatory regions were subjected to nucleotide
sequencing.
Results: Of the 165 Hungarian Bacteroides isolates from 2007–2008, 25
exhibited very high level resistance (256mg/l) to cefoxitin or heteroge-
nous resistance with resistant colonies at the 256mg/l cefoxitin MIC
value using Etests. Out of the 25 strains, 16 were cfxA-positive. Compar-
ision of the the regulatory region of cfxA genes of strains from a previous
study that included cfxA-positive strains from a random collection with
that of from this study demonstrated that the latter strains harboured
mutations (mainly insertions of ISBf8 or deletions) in this region more
frequently. Mutations involved disruption of an abortive phage-infection
gene uniformly found in the random cfxA-positive strains.
Out of the 12 Bacteroides strains with imipenem MICs 4mg/l 6 were
resitant (MIC 16mg/l) of wich 5 were cﬁA-positive. Among these
latter strains 4 harboured IS elements (2 IS614-like and 2 IS1187) in
the regulatory regions of the cﬁA genes and 1 did not but displayed a
heterogenous resistance phenotype using Etests.
Conclusion: The main type of activation of the cﬁA gene was achieved
by IS elements but a heteroresistant and a cﬁA-negative strain also
occurred. For cefoxitin heteroresistance mutations at the 3′ end of the
resistance element were very frequent. These mutations may be linked
to the recently discovered ampliﬁcation of the cfxA gene among Bac-
teroides strains and probably to their cefoxitin heteroresistant phenotype.
P646 Antimicrobial susceptibility of food-borne bacteria
(Salmonella, Campylobacter) from cattle, pigs and chickens
(2002–2004) recovered from 8 EU countries (EASSA
programme)
A. de Jong °, S.A. Simjee, A. Wheadon, P. Butty, K. Godinho, U. Klein,
H. Marion, T. Shryock, K. Smets, V. Thomas, M. Valle´ (Brussels, BE;
Edinburgh, UK)
Objective: Nontyphoidal Salmonella and Campylobacter are a major
cause of food-borne illness. For severe illness, ﬂuoroquinolones and
3rd generation cephalosporins for salmonellosis; and macrolides for
campylobacteriosis are the treatment of ﬁrst choice in the EU.
Antimicrobial susceptibility to human-use antibiotics was investigated
among Salmonella spp., and C. jejuni and C. coli from healthy cattle
(Ca); pigs (P); and chickens (Ch) at slaughter across the EU.
Methods: Colon or caecal content was randomly collected at 4
abattoirs/country (n = 5 per host). Each herd/ﬂock was sampled once.
Salmonella and Campylobacter were isolated using standard methods.
Susceptibility testing was done by agar dilution (CLSI, M31-A2) in
a central laboratory. Clinical resistance per drug/organism/country was
based on the recommendations of CLSI (M45-A; M100-S17); decreased
susceptibility (DS) was based on epidemiological cut-off values as
deﬁned by EFSA (2007).
Results: In total 406 Salmonella (Ca, n = 24; P, n = 271; Ch,
n = 111) comprising 37 serovars were recovered. Clinical resistance to
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ciproﬂoxacin (CIP) was absent but DS to CIP was 10%, mainly S.
Enteritidis from Spain. Cefotaxime (CTX) resistance was absent. DS to
CTX was 2%. Gentamicin (G) resistance did not exceed 1%. In contrast,
resistance to ampicillin, chloramphenicol, tetracycline (T), sulﬁsoxazole
and trimethoprim/sulfamethoxazole amounted to 23, 18, 53, 41 and 15%.
Totally, 512 C. jejuni (Ca = 258; P = 11; Ch = 243) and 1064 C. coli
(Ca = 131; P = 752; Ch = 181) were recovered. Mean resistance (%) for
C. jejuni (Ca; P; Ch) was: CIP 11, 9, 33; erythromycin (E) 0, 0, 0;
G 0, 0, 0; nalidixic acid (NA) 18, 9, 35; T 29, 0, 87. Resistance to CIP
for Ch isolates varied per country from 12 to 82%. DS to CIP did not
exceed 1%; DS to E was 2%. In the case of C. coli, a much less frequent
pathogen for humans, resistance (%) was: CIP 28, 34, 57; E 8, 33, 16;
G 2, 5, 2; NA 34, 36, 57; T 57, 69, 80, respectively. E resistance was
notably observed in porcine isolates from France and Spain.
Conclusions: This pan-EU survey, with uniform methodology, shows
that clinical resistance among Salmonella from food animals to CIP
or CTX, essential drugs for treating salmonellosis in humans, was
zero. DS to both drugs was low. For most older drugs, notably higher
rates of clinical resistance were assessed in Salmonella. Signiﬁcantly,
erythromycin resistance in C. jejuni, the major human pathogen of
Campylobacter spp., was absent.
P647 Antimicrobial susceptibility of commensal bacteria
(Escherichia coli, Enterococcus) from cattle, pigs and
chickens (2002–2004) recovered from 8 EU countries (EASSA
programme)
S.A. Simjee °, A. de Jong, T. Shryock, P. Butty, K. Godinho, U. Klein,
H. Marion, K. Smets, V. Thomas, M. Valle´, A. Wheadon (Brussels,
BE; Edinburgh, UK)
Objectives: Antimicrobial susceptibility to human-use antibiotics was
studied for commensal E. coli (Ec), and E. faecium and E. faecalis (Ent)
from healthy food animals at slaughter across the EU.
Methods: Colon or caecal content was randomly collected at 4 abattoirs
per country (n = 5/host). Each herd/ﬂock was sampled once. Ec and Ent
were isolated using standard methods. Susceptibility testing was done by
agar dilution (CLSI, M31-A2) against 9 (Ec) and 5 (Ent) antibiotics in
a central laboratory. Clinical resistance (CLSI, M100-S17) was assessed
per drug/organism/country; decreased susceptibility (DS) was based on
epidemiological cut-off values as deﬁned by EFSA (2008).
Results: In total 3005 Ec were recovered (cattle (Ca) n = 991, pigs (P)
n = 1015, chickens (Ch) n = 999). Mean resistance (%) for Ec for each
respective animal host was: ampicillin (A) 7, 32, 51; cefepime 0, 0, 0;
cefotaxime 0, 0, 0.4; ciproﬂoxacin 1.3, 0.3, 6; chloramphenicol 3, 18,
14; colistin 0, 0.3, 0; gentamicin (G) 1.8, 1.5, 3.4; tetracycline 13, 68,
67; and trimethoprim/sulfamethoxazole 6, 42, 47. DS was particularly
apparent for ciproﬂoxacin (28% for Ch; 2−4% for Ca and P), whereas the
corresponding ﬁgures for cefotaxime were 3 and 0.2−0.5%. In case of
A and G, DS was negligible. For Ec, Italy (Ca), Spain (P, Ch), and Nether-
lands and Germany (Ch) generally showed the highest resistance; Den-
mark (P) showed the lowest. In total 1124 Ent isolates were recovered,
comprising 975 E. faecium and 149 E. faecalis. All Ent were susceptible
to linezolid. For E. faecium resistances to A, G and vancomycin (V) were
1−2%, whereas resistance to quinupristin/dalfopristin (Q/D) amounted
to 31−33% for all 3 hosts. DS of E. faecium was only considerable for
Q/D (31%). Though low prevalence of E. faecalis limited conclusions,
particularly in Ch (n = 14), resistance to A and V was absent; G resistance
was low in Ca and P (0−8%), and intrinsic resistance to Q/D was noted
(71 and 98%, respectively). DS was usually negligible.
Conclusions: This pan-EU survey, with standardised methods, shows
that antimicrobial resistance among enteric commensal bacteria at
slaughter was variable. For Ec, prevalence of resistance varied for
older drugs and between countries but resistance to newer medically
important antibiotics was absent or very low. With respect to Ent,
quinupristin/dalfopristin resistance rates varied for E. faecium, but
resistance was absent or very low for other drugs including linezolid
and vancomycin.
P648 Antibiotic susceptibility of invasive Neisseria meningitidis
isolates from 1995 to 2008 in Sweden – the meningococcal
population remains susceptible
S. Thulin Hedberg °, P. Olce´n, H. Fredlund, M. Unemo (Orebro, SE)
Objectives: The aims of the present study were to describe the antibiotic
susceptibility of all Swedish invasive Neisseria meningitidis isolates from
1995 to 2008 and to identify any longitudinal trends in the susceptibility
and/or resistance.
Methods: All N. meningitidis isolates cultured in Sweden between
1995 and 2008 were included in the study (n = 717). The isolates were
serogroup B (n = 391; 55%), C (n = 204), Y (n = 79), W-135 (n = 33),
non-groupable (NG; n = 5), 29E (n = 2), A (n = 1), X (n = 1), and
Z (n = 1). The minimum inhibitory concentrations (MICs) of penicillin
G, penicillin V, cefotaxime, chloramphenicol, ciproﬂoxacin, rifampicin,
and sulfadiazine were determined using the Etest method on Mueller-
Hinton agar supplemented with 5% heated (“chocolated”) horse blood.
All isolates were also tested for beta-lactamase production.
Results: All isolates were fully susceptible to cefotaxime (MIC
0.12mg/l) and ciproﬂoxacin (MIC 0.03mg/l). No isolate was resistant
to penicillin G (MIC> 1mg/l) but in total 9% displayed reduced sus-
ceptibility (MIC> 0.094mg/l), 59% of these isolates were serogroup B.
The proportion of isolates with reduced susceptibility varied from
4% (in 1999) to 18% (in 2004). In 2008, only 5% of the isolates
displayed reduced susceptibility. For penicillin V, during the years the
susceptibility patterns were similar. However, in total 2% (0%-5%
during the years) were resistant (MIC> 1mg/l), and 50% of these were
serogroup B. In 2008, no isolate was resistant. All isolates, except
one serogroup B isolate from 2001 (MIC= 0.38mg/l), were fully sus-
ceptible to rifampicin (MIC 0.25mg/l). Concerning chloramphenicol,
resistance (MIC> 4mg/l) was observed in one isolate (serogroup B from
1996) and two isolates (one serogroup C from 2000 and one serogroup B
from 2003) displayed reduced susceptibility (MIC> 2mg/l). All the
remaining isolates (99.6%) were fully susceptible. The percentage of
sulfadiazine resistance varied between 52% and 81% over the years.
Conclusions: The Swedish population of invasive N. meningitidis
isolates is still highly susceptible to the antibiotics used, both for
prophylaxis and treatment. For penicillin G, in occasional years an
increase of isolates with reduced susceptibility could be observed, but
there was no obvious longitudinal trend towards a less susceptible
population for penicillin G or any of the other antibiotics.
From concept to lab: preclinical vaccine
development
P649 The immunogenicity and protective immunity for a novel ge-
netic vaccine against Mycobacterium tuberculosis with recom-
binant Plasmid expressing antigen Ag85A fused to cytokine
L. Bao °, Y. Xie, W. Chen (Chengdu, CN)
Objective: BCG provides dissatisfactory protection against tuberculosis.
Although DNA vaccines encoding Ag85A can induce strong immune
response in vivo, the relatively low protective immune efﬁcacy may limit
its practical use. The cytokine gene adjuvant can improve the efﬁcacy
of DNA vaccine. So we constructed the recombinant plasmid to express
Ag85A fused to murine GM-CSF and detected its immunogenicity and
protective immunity to Mycobacterium tuberculosis. Our objective is to
improve the immunogenicity and protective efﬁcacy of DNA vaccine
against tuberculosis.
Methods: Ag85A gene was ampliﬁed from M. tuberculosis H37Rv
and the cDNAs encoding GM-CSF were ampliﬁed from murine
spleen-derived RNA. The recombinant plasmid pBK-GM/85A was
constructed and the DNA vaccines were administered into mice to assess
humoral and cellular responses. Serum antigen-speciﬁc antibodies were
determined by ELISA. Lymphocyte proliferation assays and Cytokine
assay were conducted for determination of cellular immune response.
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The vaccinated mice were injectedM. tuberculosis H37Rv and the mice’s
organs were homogenised to determine the number of CFUs.
Results: COS7 cells transfected with pBK-GM/85A and pBK-85A
expressed 52 KD and 36KD protein respectively. The antibody titers of
pBK-GM/85A were higher than that of pBK-85A in immunised mice.
Both the recombinant plasmid induced signiﬁcantly higher lymphoprolif-
eration than the control. The pBK-GM/85A was more potent than pBK-
85A in the elevated stimulation index. The production of IFN-g with
pBK-GM/85A was much higher than that with pBK-85A. Immunisation
with pBK-GM/85A enhanced the amount of speciﬁc lysis compared to
pBK-85A as the detection of CTL activity. As Protection against My-
cobacterium tuberculosis challenge, vaccination with recombinant plas-
mid pBK-GM/85A or pBK-85A was capable of reducing signiﬁcantly the
number of CFU in the lungs compared with the control. pBK-GM/85A
reduced the number of CFU more potently than pBK-85A (p< 0.05).
Conclusion: The protective efﬁcacy for pBK-GM/85A was higher than
that of pBK-85A in immunised mice. The results indicate that GM-
CSF can potently enhance the immunogenicity and protective efﬁcacy
of M. tuberculosis DNA vaccine.
P650 IgA levels in lung and serum after oral immunisation with
BCG encapsulated in alginate microspheres
M. Hosseini °, S. Ajdari, A. Adli Moghadam (Tehran, IR)
Introduction: BCG is the only available vaccine for prevention of
tuberculosis. In tuberculosis induction of concurrent mucosal and
systemic immunity protective against both pulmonary infection and
systemic disease progression is desired. BCG is currently administered
parenterally, which primarily stimulates systemic immune responses.
Mucosal administration of vaccine offers the ability to trigger both
mucosal and systemic immune responses.
Materials and Methods: In the present study, BALB/c mice were
vaccinated orally with BCG encapsulated in alginate microspheres,
then IgG and IgA levels in sera and lung homogenates, and DTH
response were compared with those of mice vaccinated with free BCG
by subcutaneous route.
Results: Mice immunised with encapsulated BCG and those immunised
subcutaneously with BCG developed comparable DTH responses.
IgA level in lung homogenate was signiﬁcantly higher in the group
immunised with encapsulated BCG than the group immunised with BCG
subcutaneously. IgG level in lung homogenate was similar between two
vaccinated groups. Serum IgG level was signiﬁcantly higher in the group
subcutaneously immunised than the group orally immunised with BCG,
however immunisation with BCG either orally or subcutaneously produce
similar level of IgA in serum.
Conclusion: Our data indicate that oral administration of BCG in
alginate microspheres results in both systemic and mucosal immune
responses.
P651 Protection of BALB/c mice against Brucella abortus 544
challenge by vaccination with combination of human
serum albumin CL7/L12 recombinant fusion protein and
lipopolysaccharide
I. Pakzad °, A. Rezaee, M.J. Rasaee, A. Zavaran hosseini, B. Tabbaraee
(Ilam, Tehran, IR)
Objectives: The immunogenic Brucella abortus ribosomal protein
L7/L12 and LPS are promising candidate antigens for the development of
subunit vaccines against brucellosis. This study was aimed to evaluate the
protection of combination of recombinant HSA-L7/L12 fusion protein
with LPS in Balb/c mouse.
Methods: The ampliﬁed L7/L12 gene was cloned in pYHSA5 vector
then pYHSA5-L7/L12 construct was transformed in Saccharomyces
cerevisiae and expressed protein from supernatant was puriﬁed by
afﬁnity chromatography column. LPS was extracted by n-butanol,
puriﬁed by ultracentrifugation. Balb/c mouses were immunised in 9
groups with PBS, HSA, tHSA_L7/L12, L7/L12, LPS, LPS+HSA,
LPS+tHSA_L7/L12, LPS+L7/L12, B. abortus S19. ELISA, LTT tests
and challenging two weeks after last injection were carried out. Bacterial
count of spleen of immunised Balb/c mouse was done four weeks after
challenging with virulent strain B. abortus 544.
Results: In ELISA test the speciﬁc antibodies of tHSA-L7/L12 exhibited
a dominance of immunoglobulin IgG1 over G2a (IgG2a). LPS-HSA and
tHSA-L7/L12-LPS produced a signiﬁcantly higher antibody titer than
LPS alone and L7/L12-LPS (P< 0.05). The predominant IgG subtype
for LPS and L7/L12-LPS were IgG3. However, tHSA-L7/L12-LPS and
LPS-HAS elicited predominantly IgG1 and IgG3 subtypes.
In addition, the tHSA-L7/L12 fusion protein and L7/L12 elicited a
strong T-cell proliferative response upon restimulation in vitro with
recombinant tHSA-L7/L12 and L7/L12, suggesting the induction of a
cellular immunity response in vivo. However, There was no signiﬁcant
difference proliferative response in L/L12 and tHSA-L7/L12 fusion
protein (P> 0.05). The combination of tHSA-L7/L12 fusion protein
with LPS and B. abortus S19 induce higher level of protection against
challenge with the virulent strain B. abortus 544 in BALB/c mice than
other groups (p 0.005).
Table 1. Protection of mice against challenge with B. abortus 544 after
immunisation with various vaccines
Vaccine LogCFU/spleen, mean±SD Log protection p value
PBS 4.96±0.23 0.00 >0.05
HSA 4.86±0.26 0.1 >0.05
L7/L12 3.75±0.27 1.2 <0.05
HSA-LPS 3.91±0.16 1.0 <0.05
LPS 4.271±0.02 0.7 <0.05
HSA-L7/12+LPS 3.01±0.14 1.9 <0.05
L7/L12+LPS 3.45±0.15 1.5 <0.05
S19 2.14±0.18 2.82 <0.01
Conclusions: The combination of tHSA-L7/L12 fusion protein with LPS
had higher protective ability than LPS and fusion protein distinctly.
P652 Evaluation of antibody response to group 2 outer membrane
proteins of Brucella abortus S99 in animal model
S.D. Siadat °, S. Karami, B. Tabaraiee, D. Norouzian, M. Nejati,
M. Aghasadeghi, S.M. Sadat, M. Kheirandish, M. Zangeneh, A. Sharifat
Salmani, A. Moshiri, H. Ahmadi, J. Izadi Mobarakeh (Tehran, IR)
Objective: Outer membrane proteins of Brucella are considered as po-
tential immunogens to develop a Brucellosis subunit vaccine. Although
the antigen that dominates the humoral response in brucellosis is the
lipopolysaccharide, outer membrane proteins would be characterised and
evaluated since they are T-dependent antigens. In this study, Group 2 of
OMPs or Porins of Brucella abortus S99 was initially extracted through
an optimised method. Following the immunisation of animal models
with extracted Porins, antibody response against these OMPs analyzed
by ELISA method to determine anti-Brucella IgG titer in the sera of
immunised animals.
Methods: Cells were suspended at 10mM tris buffer, and 1mg
each of DNase and was added per 100ml. Samples were centrifuged
twice to remove unbroken cells. Supernatants were submitted to
ultracentrifugation to pellet the crude membranes. Detergent extraction
of cytoplasmic membranes was performed by using sodium N-lauroyl
sarcosinate. Resultant insoluble material was dialyzed against tris buffer.
In order to isolate the peptidoglycan from outer membrane proteins,
lysozyme (1mg/50mg of membrane protein) was added. Samples
were ﬁnally ultracentrifuged and supernatants were kept at 4ºC. After
biochemical evaluations of the extracted sample, animal models were
immunised intramuscularly with B. abortus Porins and hyper immune
sera of immunised animals collected. Animal models were immunised
in three different patterns: (1) B. abortus Porins, (2) B. abortus Porins in
combination with B. abortus LPS, (3) B. abortus Porins in combination
with Complete Freund’s adjuvant. Finally, titer of the elicited speciﬁc
anti-Brucella IgG assayed by ELISA method in the sera of immunised
animals and titers expressed in OD units.
ESBLs in hospitals, nursing homes and the community S153
Results: Among the three different compounds applied to promote
humoral immune responses in the animal models, B. abortus Porins
in combination with B. abortus S99 LPS have been the most potent
immunogen that signiﬁcantly elicited the highest IgG titer against
B. abortus (P< 0.05). The difference between IgG titer following the
immunisation with B. abortus Porins and B. abortus Porins + Complete
Freund’s adjuvant has not been signiﬁcant (P> 0.05).
Conclusion: The application of both B. abortus Porins and B. abortus
LPS would be a promising aspect to design a human brucellosis subunit
vaccine since Porins are able to promote T-dependent and Cell mediated
responses while the highest titers of anti-Brucella IgG antibodies are
directed against LPS.
P653 Serological evaluation of Brucella abortus S99
lipopolysaccharide extracted by an optimised method to be
applied as a part of a candidate vaccine
A. Sharifat Salmani °, S.D. Siadat, M. Fallahian, H. Ahmadi,
D. Norouzian, M. Aghasadeghi, J. Izadi Mobarakeh, M. Nejati,
K. Parivar, T. Nejadsattari, P. Yaghmaie (Tehran, IR)
Objective: Brucellosis is a globally found infectious disease and there
is no licensed vaccine against human brucellosis. Brucellae can cause
abortion in cattle and a debilitating fever (undulant fever) that may
persist intermittently for years in humans. Lipopolysaccharide (LPS)
is one of the main virulence factors and LPS-deﬁcient strains have
less virulence and intra-cellular survival potency. Wild type Brucellae
mainly express smooth LPS (S-LPS) which is the main antigenic
and immunogenic structure on the surface of smooth strains of this
microorganism. A protective level of anti-Brucella IgG and IgM would
be efﬁcient to inhibit the primary infection and decrease the rate of
infected Polymorphonuclears and macrophages.
Methods: Following the extraction of B. abortus S99 LPS by an opti-
mised method based on hot phenol-water extraction, biological and bio-
chemical evaluations of the extracted samples, animal models immunised
intramuscularly with boosters in 14 and 28 days after the ﬁrst injection.
The animals were bled on the days 0 (before any immunisation and as
the negative control), 14 (before the ﬁrst booster injection), 28 (before
the second booster injection) and 42 (two weeks after the second booster
injection). The immune sera were separated, pooled and kept in −20ºC.
Presence of anti-Brucella antibodiesin the sera of immunised animals
demonstrated by Rose Bengal test (RBT), Serum agglutination test
(tube agglutination and rapid slide agglutination) and Agarose Gel
Immunodiffusion (AGID).
Results: Sera of immunised animals have been reported positive by RBT
as a result of B. abortus LPS immunogenicity which we extracted through
our optimised method. The highest titer of anti-Brucella antibodies
detected two weeks after the third immunisation (assayed by tube
agglutination and rapid slide agglutination tests). All of the collected
serum samples of immunised animals reacted speciﬁcally with the LPS
of B. abortus and precipitation lines between B. abortus LPS and immune
sera appeared after 30 minutes.
Conclusion: This modiﬁed extracted LPS of B. abortus S99 has
efﬁciently promoted the synthesis of high levels of anti-Brucella
antibodies. Furthermore, elicited antibodies reacted speciﬁcally with
the extracted LPS (demonstrated by AGID). Potency of this structure
to induce high titers of speciﬁc antibodies against Brucella suggests
the possible application of this component as a part of a sub-unit or
conjugated vaccine for human brucellosis.
P654 Construction of mutant pneumolysin pNK14 based DNA
vaccine against Streptococcus pneumoniae
D. Bansal °, R. Verma, A. Kapil, J.C. Samantharay, B.K. Das (New
Delhi, IN)
Objectives:
a. PCR ampliﬁcation of wild Ply gene (1432 bp);
b. Cloning of wild ply gene into pGEM-T Easy vector;
c. Site directed mutagenesis of wild ply-pGEM-T construct;
d. Construction of a pneumolysin DNA vaccine using pNK14 vector.
Methods: Wild type ply gene was PCR ampliﬁed and subjected to
TA cloning using pGEM-T Easy Vector (3015 bp) and construct after
sequence conﬁrmation was subjected to deletion at A¨146AA to generate
a nontoxic mutant construct. This mutant was sub-cloned in pET28a
(Prokaryotic expression vector) for recombinant protein production and
pNK14 for in-vitro expression evaluation in 293 HEK cell lines in tissue
culture.
Results:
a. PCR ampliﬁcation of wild ply gene: Streptococcus pneumoniae Rx1
strain was ampliﬁed with primer having restriction enzyme sites for
BamH1 and Acc65I.
b. Cloning of wild ply gene into pGEM-T Easy vector: Ampliﬁed ply
was cloned into p-GEMT Easy vector and construct obtained was
conﬁrmed by the single (EcoR1, Pst1, & Apo1) and double enzyme
restriction digestions (BamH1 & Acc65I) and ﬁnal conﬁrmation by
sequencing.
c. Site directed mutagenesis (A¨146AA deletion): ply-pGEM-T construct
containing mutation is denatured, primer annealed and pfu turbo
polymerase extend and incorporate mutagenic primers resulting in
nicked strands. DpnI enzyme digest the methylated non-mutated
parental DNA template and ﬁnal conﬁrmation of deletion is conﬁrmed
by mutant gene sequencing.
d. Sub-Cloning of MPly in pNK14 Vector: Mply-pGEMT and pNK14
vector was double digested mixed and ligated using T4 DNA ligase.
The recombinant clones were conﬁrmed by double digestion and
sequencing. Similarly Mply-pGEMT was sub-cloned in pET28a
vector. Double Digestion of pET28ply and pNK14ply using Not I
and BamH I is shown in graphics.
Conclusion: Pneumolysin is produced by virtually all identiﬁed strains
of S. pneumoniae. As pneumolysin is highly toxic, a nontoxic form of
pneumolysin would be more desirable starting point in terms of vaccine
production. Mutant Ply is prepared to generate non toxic ply which
could be used for the DNA vaccine preparation. DNA Vaccine Mply-tPA
pNK14 DNA is based on ply gene fused with a signal peptide sequence
tPA (tPA-ply) from pNK14 vector used for construct preparation which
may induce predominantly Th2 type of protective immune response
against Streptococcus pneumoniae when induced in BALB/c mice.
Secreted pneumolysin may induce predominantly antibody mediated
protection.
ESBLs in hospitals, nursing homes and the
community
P655 First results of the new Dutch Infectious Diseases Surveillance
Information System-Antimicrobial Resistance (ISIS-AR).
Epidemiology of extended-spectrum beta-lactamases in the
Netherlands
M. Leverstein-van Hall °, J. Muilwijk, E. Boel, J. Marcelis, R. Vreede,
W. Dorigo-Zetsma, N. van de Sande-Bruinsma (Bilthoven, Utrecht,
Tilburg, Delft, Hilversum, NL)
Objectives: ISIS-AR was initiated medio 2007 in response to the
widespread concerns about rising antimicrobial resistance in the
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Netherlands and the lack of consistent long-term surveillance covering
all clinical relevant pathogens. ISIS-AR is a combined effort of the
RIVM-Centre for Infectious Disease Control, the Dutch Working Party
on antibiotic policy and the Dutch Society for Medical Microbiology.
It consists of a laboratory based surveillance system that collects the
epidemiological and susceptibility data for each isolate present in the
laboratory information system of a clinical microbiological laboratory
(CML) on a monthly basis. In 2008, the ﬁrst 8 CMLs were connected
to ISIS-AR covering 34 pathogens. The aim of this study was to
determine the prevalence and susceptibility patterns of Escherichia coli
(EC) and Klebsiella pneumoniae (KP) isolates (intermediate) resistant
(I/R) to 3 d generation cephalosporins (CEPH3) in 1) nosocomial
blood isolates, and 2) urine isolates from the hospital (HOSP), out-
patient-departments (OPD), long-term care facilities (LTCF) and general
practioners (GP).
Methods: Data of the ﬁrst isolate per species per patient collected from
Jan-Oct 2008 were analysed.
Results: The prevalence of blood isolates I/R to CEPH3 was 5.3%
among 588 EC and 7.9% among 114 KP (2007 EARSS: Dutch data: EC
4.2%, KP 6.9%). An ESBL conﬁrmation test was performed in 74.1%
of the EC of which 78% were positive and 4.0% indeterminate. All of
the 5 (56%) KP tested were positive.
The prevalence of urine isolates I/R to CEPH3 was 3.2% among 14,986
EC and 2.8% among 2,057 KP. For EC the prevalence was 4.2% in HOSP,
3.7% in OPD, 5.7% in LTCF, and 2.4% in GP. For KP the prevalence
was 5.6%, 1.1%, 4.0% and 1.7% resp.
ESBL positive EC were R/I to ciproﬂoxacin in 57%, aminoglycosides in
44%, cotrimoxazole in 71%. Co-resistance to these 3 antibiotics existed
in 30%.
ESBL positive EC and KP urine isolates from GP were R/I to norﬂoxacin
in 61%, cotrimoxazole in 70% and nitrofurantoin in 22%. Co-resistance
to the ﬁrst 2 antibiotics existed in 46% and to all 3 in 7%.
Conclusions: This ﬁrst analysis of the ISIS-AR database shows that
(1) the Dutch ESBL prevalence rates are increasing, (2) ESBLs have
entered the community and LTCFs, (3) oral treatment of urinary
tract infections with ESBL positive EC or KP in the community is
compromised, (4) other resistance mechanisms than the classical ESBLs
probably play a role in the decreased susceptibly to CEPH3 as well.
P656 High prevalence of extended-spectrum b-lactamase
production in Enterobacter spp. bloodculture isolates in the
Netherlands
J. Cohen Stuart °, N. Al Naiemi, A. Fluit, N. Arents, B.M. Diederen,
S. Thijsen, B. Vlaminckx, J. Mouton, M. Leverstein-van Hall (Utrecht,
Amsterdam, Veldhoven, Haarlem, Nieuwegein, Nijmegen, NL)
Objective: In 2008 a guideline of the Dutch Society for Medical
Microbiology for screening and conﬁrmation of ESBLs in Enterobac-
teriaceae was issued. An optional recommendation in the guideline was
to screen Enterobacter spp. for ESBLs (i.e. MIC> 1mg/L for cefotaxime
and/or ceftazidime) and to perform a conﬁrmation test with cefepime ±
clavulanic acid. Dutch microbiologists questioned this recommendation
because no data were available indicating that Enterobacter spp. might
be an important source for ESBLs.
The aim of this study was to determine the prevalence of ESBLs
in Enterobacter spp. causing invasive infections and to obtain their
susceptibility patterns.
Methods: Enterobacter cloacae and Enterobacter Aerogenes bloodcul-
ture isolates obtained in 2006 and 2007 in 12 hospitals throughout The
Netherlands were collected (one isolate per patient). Susceptibly testing
for 22 antimicrobial agents using broth microdilution (18) or Etest (4)
was performed on all isolates as well as the ESBL conﬁrmation Etest
with cefepime/cefepime + clavulanic acid. EUCAST breakpoints were
used.
Results: 272 isolates were obtained (83.5% E. cloacae). Of the total
collection of 272 isolates 41.5% (113) was positive in the screentest of
which 30% was positive in the conﬁrmation test, reﬂecting an ESBL
prevalence of 12.9% (35/272), ranging from 0% to 33% per hospital.
E. cloacae isolates were ESBL positive in 14.5% and E. Aerogenes in
4.4%. The conﬁrmation test was indeterminate in 2.9% (8/272) of the
isolates. Molecular analysis of ESBL genes is pending.
Susceptibilty rates in ESBL positive versus ESBL negative isolates were
as follows: for meropenem 97% vs 97%, respectively; for imipenem 91%
vs 95% (NS); for ertapenem 43% vs 86% (p< 0.001); for cotrimoxazole
43% vs 93% (p< 0.001); for ciproﬂoxacin 20% vs 91% (p< 0.001);
for tobramycin 20% vs 95% (p< 0.001); for amikacin 77% vs 97%
(p< 0.001); for tigecyclin 40% vs 28% (NS) and for colistin 69% vs
69% (NS).
Conclusions: The prevalence of ESBL in Enterobacter spp. bloodculture
isolates was 12.9%, showing that Enterobacter spp. are an important
reservoir for ESBLs in the nosocomial setting. For optimal infection
control, detection of ESBLs in Enterobacter spp. should be common
practice in clinical microbiology laboratories. Phenotypic ESBL
production in Enterobacter spp. is associated with increased resistance
to ertapenem, ciproﬂoxacin, tobramycin, amikacin and cotrimoxazole.
P657 Acquisition of cephalosporin-resistant Enterobacteriaceae
in relation to global exposure to antibiotic b-lactams in ten
intensive care units of Paris metropolitan area
A. Thie´baut °, C. Berne`de-Bauduin, G. Arlet, A. Andremont, J.P. Sollet,
D. Guillemot, B. Schlemmeron behalf of the ColoRea Group
Background: Nosocomial infections due to third-generation cephalo-
sporin-resistant Enterobacteriaceae (CRE) have become a major public
health threat, in particular in intensive care units (ICU). The inﬂuence
of beta-lactam exposure on CRE acquisition and selection still remains
in debate.
Objectives: To investigate the dynamics of incident gut colonisation with
CRE in combination with b-lactam use in ICU patients, we focused
on the ecological link between global beta-lactam exposure of the
population hospitalised in each unit and the incidence of CRE acquisition
in previously “naive” patients.
Methods: A prospective cohort study was conducted in 10 ICUs
of Paris metropolitan area, in France, between November 2005 and
February 2006 (ColoRea study). All patients admitted during the
study period were followed-up until discharge. Rectal swabs were
collected at admission, twice weekly thereafter, before b-lactam
prescription and before discharge. Specimens were inoculated on agar
supplemented with ceftazidime 2mg/L and cefotaxime 2mg/L. CRE
were deﬁned as isolates growing on the selective media showing
decreased susceptibility to ceftazidime (diameter 17mm, according
to Clinical and Laboratory Standards Institute 2008) or to cefotaxime
(diameter 22mm), or producing extended-spectrum b-lactamase (Etest
ESBL strip containing cefepime-clavulanate). Patients were informed
about the study goals.
Results: In total, 917 patients provided 3,443 swab specimens (median,
3.2 per patient-week of follow-up). Of these, 109 (12%) were colonised
with CRE at their ﬁrst specimen collection (obtained within 48 hours of
admission for 95%), including 48 with an ESBL-producing phenotype.
Of the remaining 808 naive patients, 115 (14%) acquired CRE during
their follow-up (incidence rates ranging from 10 to 23 per 1000 patient-
days in the 10 ICUs), including 39 with an ESBL-producing phenotype.
A majority of patients (73%) had received b-lactams at least once, with
deﬁned daily doses ranging from 428 to 1003 per 1000 patient-days in the
10 ICUs. Correlations between antibiotic pressure at the ICU level and
CRE acquisition rate among naive patients were 0.27 for all antibiotics
and CRE, 0.34 for b-lactam and all CRE, 0.40 for b-lactam and ESBL-
producing CRE, and −0.14 for b-lactam and non-ESBL-producing CRE.
Conclusion: Global antibiotic exposure may play a role in CRE
acquisition among ICU patients, which needs to be disentangled from
individual exposure.
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P658 Cross-contamination does not explain the increase in
ESBL-producing isolates in intensive care units in a French
university hospital
V. Leﬂon-Guibout, F. Bert, S. Pease, C. Paugam-Burtz, N. Claudel,
M.H. Nicolas-Chanoine ° (Clichy, FR)
Objectives: To determine if the ESBL-producing enterobacteriaceae
increase (attack rate, 3.7% in 2007 vs 7.7% in 2008) in 2 ICUs (33
beds) of our hospital was essentially related to cross-contamination.
Methods: For the 2 ICUs in which active surveillance of ESBL
digestive carriage (rectal swab at admission and once a week:
1700 screenings/year) and precaution barriers have been implemented
for several years, faecal or clinical ESBL-positive isolates (one
isolate/species/patient) were identiﬁed (API System) and typed (ERIC-2
PCR method) from 1 May to 30 November 2008.
Results: Over the study period, of the 72 ESBL-producing isolates
from 57 patients (41 colonised and 16 infected), 27 (37.5%) were
E. coli, 21 (29%) K. pneumoniae, 17 (23.5%) E. cloacae and 7 (10%)
others. The rate of ESBL-positive isolates detected at admission was
globally 37% (n = 27) with 60% for E. coli, 38% for K. pneumoniae
and 12% for E. cloacae. Typing showed that 29 (64%) of the 45
remaining presumably ICU-acquired isolates had a unique ERIC-2 PCR
proﬁle ruling out cross-contamination. The 16 remaining isolates from
16 patients showed ERIC-2 PCR proﬁles shared with imported or another
acquired isolates suggesting cross-contamination. Thus, 2 proﬁles were
found for E. cloacae with 2 isolates each, 2 proﬁles for 9 K. pneumoniae
with 5 and 4 isolates, respectively, 1 proﬁle for 2 E. coli and 1 proﬁle
for 2 K. oxytoca, including an imported isolate. However, 2 proﬁles (1
for E. cloacae and 1 for K. pneumoniae) were found in the isolates from
patients without overlapping ICU stay, excluding cross-contamination.
Overall, 11 (19%) of the 57 patients with an ESBL-positive isolate
acquired the isolate from another concomitantly hospitalised patient.
Conclusion: This study highlights the complex epidemiology of ESBL-
producing isolates in our ICUs. ESBL-positive isolates of different
species were present at the same time. One third of them was imported
with an importation rate higher for E. coli than for the other species.
Cross-contamination occurred but did not account for the majority of
ESBL-positive isolates detected after 48 h hospitalisation in our ICUs
where precaution barriers are systematically applied to the patients
with ESBL-positive isolates. A signiﬁcant number of isolates that were
not imported and not transmitted, emerged during ICU stay suggesting
ESBL-positive isolate digestive carriage at such a low level that they
were not detectable at admission.
P659 Factors associated with colonisation with extended-spectrum
beta-lactamase-producing enterobacteria in newborns
hospitalised at the neonatal intensive care unit
V. Strenger °, V. Dosch, G. Feierl, A. Grisold, G. Zarfel, B. Resch,
B. Urlesberger, W. Mu¨ller (Graz, AT)
Objectives: Colonisation and infection with extended-spectrum beta-
lactamase producing enterobacteriaceae (ESBL-E.) are a growing
problem in Neonatal Intensive Care Units (NICU). Preterm low
birthweight, prolonged mechanical ventilation, invasive devices and prior
use of third generation cephalosporines were reported to be risk factors
for colonisation and/or infection with ESBL-E. In the last years several
outbreaks of ESBL-E. colonisation occurred at our NICU.
Methods: We retrospectively analyzed risk factors associated with
colonisation with ESBL-E. in newborns hospitalised at the NICU from
Jan. 2005 to Jul. 2008. Patients were screened routinely at least twice a
week for ESBL-E. in stool.
Fisher’s exact test and Mann-Whitney-U test (SPSS for Windows) were
used for statistical analysis.
Results: 69 (5.9%) out of 1164 patients have been colonised with ESBL
producing Klebsiella pneumoniae (n = 51), Klebsiella oxytoca (n = 11),
Serratia marcescens (n = 6) and E. coli (n = 1). For details see Table 1.
Cefuroxime/ampicillin were used as ﬁrst line antibiotic regimen. Third
generation cephalosporines were not used during the observation period.
Conclusion: ESBL gene expression might be induced under therapy
with second generation cephalosporines.
Factors associated with more severe illness (including lower gestational
age and birth weight and more invasive therapeutic procedures) leading
to longer stay at the NICU were signiﬁcantly associated with colonisation
with ESBL-E. Longer hospital stay increases the risk of patient-to-patient
transmission.
Table 1
ESBL
non-colonised
patients
ESBL
colonised
patients
p-value
n = 1095 (94.1%) n = 69 (5.9%) p-value
number (%) Fisher’s exact test
Female gender 506 (46.2) 36 (52.2) n.s.
Cesarean section 712 (65.0) 55(79.7) 0.013
Apgar 1 <9 563 (51.4) 57 (82.6) <0.001
Apgar 5 <10 555 (50.7) 54 (78.3) <0.001
Apgar 10 <10 427 (39.0) 49 (71.0) <0.001
Respirator therapy 366 (33.4) 44 (63.8) <0.001
CPAP therapy 353 (32.2) 37 (53.6) 0.001
CVC 70 (6.4) 12 (17.4) 0.002
median (range) Mann-Whitney-U
Gestational age 35 (23−43) weeks 31 (24−40) weeks <0.001
Birth weight 2365 (400–5215) g 1415 (540–3834) g <0.001
Respirator days 0 (0−66) 3 (0−36) <0.001
CPAP days 0 (0−63) 1 (0−86) <0.001
CVC days 0 (0−37) 0 (0−28) <0.001
Stay 15 (1–198) days 48 (3–194) days <0.001
Clean stay 15 (1–198) days 22 (1–194) days 0.005
CVC: central venous catheter; Clean stay: stay before/without ESBL colonisation.
P660 Bacteraemia by extended-spectrum beta-lactamase-producing
Escherichia coli as a complication after endoscopic retrograde
cholangiopancreatography
A. Rodriguez-Guardado °, P. Alonso, F. Perez, A. Fleites, M. Lantero,
J. Carto´n (Oviedo, ES)
Background: The present was performed to describe the characteris-
tics of bacteraemias by Extended-spectrum beta-lactamase-producing
Escherichia coli following cholangiopancreatography and the methods
of prevention and treatment of the same.
Methods: Thirteen different episodes of bacteraemia by Extended-
spectrum beta-lactamase-producing Escherichia coli were retrospectively
studied in patients submitted to endoscopic cholangiopancreatogra-
phy (ERCP) from 2006–2008. All the patients received antimicro-
bial prophylaxis with piperacillin-tazobactan (4.5 gr/8 hours during
24 hours).
Results: Thirteen patients (3.6% of the patients undergoing ERCP)
presented episodes of bacteraemias by the microorganism in the 48 hours
following the procedure. 53.6% were male, mean age 70 years, limits
44−85). A biliar prosthesis was put during the procedure in eight patients.
All the patients presented obstructive disease in the form of calculi
or neoplasms at the level of the biliary tree. All the patients showed
typical clinical manifestations of cholangitis. One patient (7.7%) died as
a consequence of bacteraemia and a hepatic abscess was developed in
other case. The prosthesis was removal on trhee cases.
Conclusions: Bacteraemia by Extended-spectrum beta-lactamase-
producing Escherichia coli following ERCP is more frequent in patients
with obstructive disease of the biliary tract and has an important
additional morbimortality. The use of drugs with an betalactamase-
inhibitor as preendoscopic prophylaxis probably should be considered
as predisposing factors.
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P661 ESBL E. coli bacteraemia: clinical inﬂuence at a
university-afﬁliated hospital
A.M. Garcia-Hernandez, J. Gomez-Gomez, E. Garcia-Vazquez,
A. Hernandez-Torres °, J. Ruiz, R. Ban˜os, M. Canteras, J.A. Herrero,
M. Valdes (Murcia, ES)
Objectives: Incidence of ESBL E. coli bacteraemia (ESB) has
progresively increased but its repercusion in mortality and mortality is
not clearly known. The aim of this study was to evaluate epidemiological
and clinical aspects in a cohort of patients with ESB.
Patients and Methods: Observational and comparative study of a cohort
of non-paediatric patients with ESB admitted at a university afﬁliated
hospital. Data collection from clinical records has been done according to
a standard protocol. We analysed epidemiological, clinical, microbiolog-
ical and laboratory data from January 2006 through May 2007. Patients
with ESB were identiﬁed by review of results of blood cultures from the
hospital microbiology laboratory. E. coli isolation, identiﬁcation and sen-
sitivity test (VITEK-2; Biomerieux, France) were performed by standard
criteria. Mortality was assessed till 30 days after diagnosis of ESB.
Results: 150 patients with E. coli bacteraemia were studied; prevalence
of ESB was 17% (n = 26; 12 female). Mean age was 57 years (range
14−94); 14 cases were considered nosocomial (53.8%) with a previous
hospital stay of 12 days; 18 cases (69%) were patients in Medical
Wards, 6 (23%) in Surgical Wards and 2 (7.7%) in ICU. A predisposing
factor was identiﬁed in 19 patients (73%): previous antibiotic treatment
(9), previous hospitalitation (8), urinary catheter (8), surgical catheters
(5) and post-surgical period (5). An underline condition was present
in 22 patients (84.6%): cancer (11), obstructive uropathy (6), diabetes
(5). Charlson comorbility index was >3 in 15 cases (57.6%). Acute
severity of illness at onset according to Winston criteria was “critical”
in 11 patients, “poor” in 9 and “fair” in 6. Origen of ESB was urinary
in 9 cases (34.6%), abdominal in 5 (19%) and unknown in 12 (46%);
11 patients (42%) developed complications (renal failure, 10; shock, 7;
respiratory distress, 3; and intravascular disseminated coagulation, 2).
Empirical antibiotic treatment was wrong in 50%. Mean hospital stay
was 20 days and mortality rate 64%.
Conclusions: Knowledge about risk factors and clinical aspects of ESB
is necessary to improve empirical treatmets and dicreased associated
mortality and morbility.
P662 In vitro activity of beta-lactam antibiotics against
CTX-M-producing E. coli
M. Ta¨rnberg °, A˚. O¨stholm Balkhed, H. Hanberger, A. Ha¨llgren,
H.J. Monstein, L.E. Nilsson (Linko¨ping, SE)
Objectives: Multi-resistance is an increasing problem and it has been
discussed that a beta-lactam antibiotic might be an option in the treatment
of infections caused by multi-resistant ESBL-producing E. coli if the
minimal inhibitory concentration (MIC) is low. Thus, the objective
of this study was to investigate the activity of different beta-lactam
antibiotics against CTX-M producing Escherichia coli in the County
of O¨stergo¨tland, Sweden.
Method: From 2002 to 2007, 95% of the clinical isolates of E. coli
with ESBL-phenotype carried CTX-M-genes. One-hundred eighty-seven
of these isolates were further analysed. PCR-ampliﬁcation of CTX-
M genes and DNA-sequencing of PCR-amplicons were performed.
MIC for amoxicillin-clavulanic acid, aztreonam, cefepime, cefotaxime,
ceftazidime, ceftibuten, ertapenem, imipenem, mecillinam, meropenem,
piperacillin-tazobactam and temocillin were determined using Etest.
The susceptibility was determined according to the breakpoints of the
European Committee on Antimicrobial Susceptibility Testing. MIC50
and MIC90 were calculated.
Results: One-hundred thirty-two isolates belonged to CTX-M group 1
and 55 isolates to CTX-M group 9. Susceptibility of E. coli from
CTX-M group 1 and 9 are shown in the table. Isolates with CTX-
M group 9 enzymes showed higher susceptibility to the beta-lactam
antibiotics tested than isolates belonging to CTX-M group 1. More
than 90% of the isolates belonging to CTX-M group 9 was susceptible
for amoxicillin-clavulanic acid, ceftazidime, ceftibuten, piperacillin-
tazobactam and temocillin. The isolates belonging to both CTX-
M-groups showed high susceptibility (92.5%) to mecillinam. All
isolates were susceptible to imipenem and meropenem and 98.4%
to ertapenem.
Conclusions: This study show signiﬁcant difference in susceptibility to
different beta-lactam antibiotics among the CTX-M producing E. coli
isolates and a signiﬁcant difference for many antibiotics tested between
the CTX-M producing groups 1 and 9. The good in vitro activity of other
beta-lactam antibiotics than carbapenems against CTX-M-producing
E. coli indicate that clinical studies are warranted to examine these beta-
lactam antibiotics potential role in the treatment of infections caused by
multiresistant ESBL-producing E. coli.
Antibiotic MIC range (mg/l) MIC50 (mg/l) MIC90 (mg/l) Susceptibility (%)
Amoxicillin-clavulanic acid 4−16 8 16 84.5
Aztreonam 0.5−>128 16 128 5.3
Cefepime 0.125−>128 4 32 5.3
Cefotaxime 2−>128 32 >128 0
Ceftazidime 0.125−>128 4 16 33.7
Ceftibuten 0.125−>128 4 16 34.8
Ertapenem 0.008−2 0.032 0.25 98.5
Imipenem 0.125−1 0.25 0.25 100
Meropenem 0.008–025 0.008−0.25 0.064 100
Mecillinam 0.125−>128 0.125−>128 8 92.5
Piperacillin-tazobactam 0.125−>128 0.125−>128 16 86.1
Temocillin 1−32 8 16 81.8
P663 In vitro activity of 13 antibiotics against CTX-M
ESBL-positive and -negative clinically signiﬁcant Escherichia
coli isolates from 8 major hospitals in Kuwait
G. Al Hashem, N.A. Al Sweih, W. Jamal, V.O. Rotimi ° (Safat, KW)
Objective: The objective was to evaluate the antibiotic susceptibility
of Escherichia coli, an important community and hospital pathogen,
isolated from 8 Kuwait hospitals.
Methods: A total of 846 consecutive clinically signiﬁcant strains of
E. coli were studied during a one-year period. In vitro activity of
13 antibiotics against the isolates was determined by Etest. ESBL-
production was assessed by ESBL-Etest method and conﬁrmed by PCR
technique. PCR amplicons positive for blaCTX-M were sequenced.
Results: About 69% of the E. coli isolates were highly non-susceptible
to ampicillin with MIC90 of 256 mg/ml. Resistance to the 3rd generation
cephalosporins ranged from 7.5% in Maternity hospital (MH) to 29%
in Ibn Sina hospital (ISH); ciproﬂoxacin resistance rates ranged from
14% and 40%, respectively. Carbapenems and amikacin demonstrated
excellent activities. Prevalence of ESBL-producing E. coli varied
from hospital to hospital, with highest rate (32%) from ISH and
lowest (4%) from Mubarak hospital and MH. MIC90 of cefotaxime,
ceftazidime, cefepime and ciproﬂoxacin were >256, 64, >256 and
>32mg/ml, respectively for CTX-M-positive isolates versus 0.5, 1, 025
and 0.125mg/ml for CTX-M-negative strains. Frequencies of CTX-M-
positive isolates in cefotaxime MIC range of 1−2, 3−8, 9−16 and
>16mg/ml were 0, 4, 15 and 81%, respectively.
Conclusion: The prevalence of E. coli resistant to the 3rd generation
cephalosporins and ciproﬂoxacin is at an unacceptable level. This is
compounded by a high incidence of CTX-M ESBL-producing strains in
almost all hospitals in Kuwait.
P664 Are CTX-M beta-lactamases associated with poorer
clinical outcomes in bloodstream infections caused by
ESBL-producing E. coli?
U.I. Wu °, H.M. Chang, C.J. Yang, J.L. Wang, W.C. Chen, Y.C. Chen,
S.C. Chang (Taipei, TW)
Objectives: The CTX-M-type ESBLs have recently undergone a rapid
and global spread in Enterobacteriaceae. However, the clinical impact of
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this epidemiologic change has not been well elucidated. We conducted
a retrospective study to evaluate the differences of characteristics and
clinical outcomes in patients with bloodstream infection caused by ESBL
E. coli harbouring with or without CTX-M enzymes.
Methods: From July 1, 2005 to June 30, 2007, patients older than
16 years with at least one positive blood culture of ESBL-producing
E. coli were reviewed. ESBL production was screened and conﬁrmed
in accordance with CLSI standards. CTX-M b-lactamases were detected
through multiplex PCR.
Results: During this 2-year study period, a total of 60 patients
diagnosed of having ESBL E. coli bacteraemia were included in our
analysis. CTX-M b-lactamases were detected in 41 blood culture isolates
through multiplex PCR. Univariate analysis showed those subjects
harbouring CTX-M enzymes were less frequently associated with renal
failure [OR: 0.149, p = 0.007], ICU hospitalisation [OR= 0.23, p = 0.04],
carriage of nasogastric tubes [OR: 0.29, p-0.035] and central venous
catheters [OR: 0.266, p = 0.025]. In multiple analyses, renal failure was
the only independent risk factor of acquiring non-CTX-M type ESBLs.
The most commonly identiﬁed primary infection site was urinary tract
in both groups. Although the early and late mortality rates did not differ
signiﬁcantly in these two groups of patients, those harbouring CTX-M
enzymes seemed to have lower disease severity in terms of requirement
of mechanical ventilation and development of septic shock at onset of
bacteraemia. Five patients were identiﬁed as having strictly community-
acquired infection and all of them had CTX-M b-lactamases detected in
the blood isolates. All of these 5 patients survived despite 2 of them had
received inadequate empirical antimicrobial treatment.
Conclusion: CTX-M enzymes have emerged as the predominant type
of ESBLs in E. coli bloodstream isolates in many parts of the world
including Taiwan. Comparisons among bloodstream infections caused
by ESBL-producing E. coli showed CTX-M b-lactamases were not
associated with poorer clinical outcomes.
P665 Multidrug resistance of Klebsiella pneumoniae isolates in a
teaching hospital
S. Vamvacopoulou °, E. Petinaki, C. Bartzavali, A. Damani,
I. Spiliopoulou, E.D. Anastassiou, M. Christoﬁdou (Patras, Larissa, GR)
Objective: Klebsiella pneumoniae is emerging as an important noso-
comial pathogen due to rapidly increasing resistance to all currently
available antibiotics. The aim of this study was to deﬁne the susceptibility
proﬁle of multidrug resistant (MDR) K. pneumoniae nosocomial isolates
to antibiotics, including tigecycline (TIG), during the last three years in
Patras University Hospital.
Methods: From September 2005 to October 2008, a total of 216 K. pneu-
moniae isolates were collected from inpatients hospitalised in ICU (125),
in Internal Medicine units (48) and in Surgical Wards (43), one isolate
per patient. Isolates were recovered from cultures of clinically signiﬁcant
specimens (102 blood, 76 pus, 24 urine and 14 BAL). Identiﬁcation was
performed by biochemical tests. Antimicrobial susceptibility was carried
out by disk diffusion method, according to CLSI criteria, for amoxicillin-
clavulanic acid (AMC), cefoxitin (FOX), ceftriaxone (CRO), ceftazidime
(CAZ), imipenem (IMP), aztreonam (AZT), gentamicin (GM), netilmicin
(NET), amikacin (AN), ciproﬂoxacin (CIP) and by E-Test strips (AB
Biodisk) for TIG. MIC breakpoint of susceptibility to TIG is equal or less
than 2 microg/mL. IMP-resistant isolates were examined by E-Test (AB
Biodisk) for detection of metallo-beta-lactamases (MBL). In addition
the genes encoding MBL (vim, imp) were detected by PCR following
by sequencing.
Results: Resistance rate to lactams was as high as 99%, 94%, 100%,
97%, 94% and 79% to AMC, FOX, CRO, CAZ, AZT and IMP,
respectively, 87% to AN and CIP, and 91% to NET and 61% to GM.
Among 216 MDR isolates, 49% were resistant to all aforementioned
antibiotics. Among IMP-resistant strains, 150 (88%) were MBL (+)
according to E-Test results, whereas, in 164 (96%) were found to carry
the vim-1 gene. Among MDR isolates 90% were susceptible to TIG
(MIC 0.25−2). On beginning the study, 5% of 28 MDR isolates were
intermediately sensitive to TIG (MIC 3), 7% of 77 the next year and
12% of 111 on 2008. Two resistant strains to TIG with MIC 19 were
found during the last month of the study.
Conclusions: A total of 107 (49%) MDR K. pneumoniae were resistant
to all commonly used antimicrobials. The presence of vim-1 gene (96%)
in MDR isolates make IMP not useful in empiric therapy. The only
active agent towards such strains remains TIG (90%), although 9% were
intermediately sensitive isolates according to our results. However TIG
must cautiously be used, since resistant strains have already emerged.
P666 Escherichia coli and other Enterobacteriaceae. Antimicrobial
susceptibility trends in a four-year prospective surveillance
hospital monitoring
R. Manfredi °, A. Nanetti (Bologna, IT)
Introduction: The changed rate of drug resistance among Enterobacte-
riaceae is a relevant issue, especially in hospital facilities. A prospective
microbiological surveillance based on a continued monitoring of in vitro
antimicrobial susceptibility rates, is ongoing at our General Hospital,
since the year 2004.
Materials and Methods: The temporal variations of in vitro
antimicrobial sensitivity trends were updated quarterly for all suitable
Enterobacteriaceae strains, followed from year 2004 to year 2007. The
same pathogen cultured more than once from the same patient within
one month, has been considered one time only.
Results: Among overall Escherichia coli isolates (4,413 strains tested
on the whole), imipenem and colistin maintained a full (100%) in vitro
activity, followed by amikacin (97.3−99.5% of tested strains), nitrofuran-
toin (89.2−94.8%), piperacillin-tazobactam (89.0−93−9%), gentamicin
(81.9−89.4%), ceftazidime (78.3−89.5%), cefotaxime (78.0−89.8%),
and ciproﬂoxacin (63.8−73.9%). When considering Enterobacteriaceae
other than Escherichia coli, imipenem and colistin remained 100%
active, followed by amikacin (94.9−97−2%), piperacillin-tazobactam
(78.4−86%), cotrimoxazole (72.1−78.0%), gentamicin (74.0−77.3%),
norﬂoxacin (66.4−76.2%), ceftazidime (62.7−69−7%), and cefotaxime
(62.3−69.0%). The emerging spread of enlarged-spectrum beta-
lactamase production signiﬁcantly reduced the activity of third-
generation cephalosporins over time (from a mean of 89.7% of
susceptible Escherichia coli strains in the year 2004, to 78.1% in
the year 2007; p< 0.001; and from a mean of 69.7% of sensitive
Enterobacteriaceae strains in the year 2004, to 62.4% in the year 2007;
p< 0.03). Also ﬂuoroquinolones and protected beta-lactams suffered
from a drop of their in vitro sensitivity rates (p< 0.02 to p< 0.005).
Conclusions: A long-term prospective bacteriological monitoring of
antimicrobial susceptibility rates of relevant hospital-related microor-
ganisms like Enterobacteriaceae is of paramount importance, to plan
antibiotic treatment and prophylaxis schedules, in common, local clinical
settings. Despite a maintained activity of carbapanems the old colistin,
a signiﬁcant trend toward increased resistance rates was found over
a four-year observation period, with extended-spectrum beta-lactamase
secretion playing a major role.
P667 Temporary changes in the frequency of extended espectrum
beta lactamase producing Escherichia coli and Klebsiella
pneumoniae in Colombia, 2002–2008
A. Meneses, G. Buitrago, J. Cortes °, A. Leal, J. Castillo, C. Alvarez
(Bogota, CO)
Objective: To describe the trend in time of the frequency of E. coli and
K. pneumoniae isolates with extended beta lactamase (ESBL) production
in colombian thrid level hospitals.
Methods: A time series analysis of E. coli and K. pneumoniae ESBL
producers, obtained in clinical samples from hospitalised patients in 9
third level hospitals in 2 cities in Colombia (Bogota and Ibague) between
january 2002 and june 2008. All the isolates had an ESBL conﬁrmed
by use of automated microbiological Vitek system (Lyon, Biomerieux).
Data was systematised with Whonet 5.4®. Isolates were characterised
according to ward type (ICU vs. non ICU) and sample type. Monthly
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information (78 consecutive periods) was analysed with time series
methodology (Box Jenkins) for each microorganism according to its
localisation. With the best model, forecasts were realised for the next
12 months with conﬁdence intervals of 95% by means of Statgraphics
Centurio´n XV® software.
Figure 1. Time series and forecasting for ESBL-producing Enterobacte-
riaceae. GREBO 2002–2008.
Results: 14055 E. coli isolates and 4627 K. pneumoniae isolates were
analysed. Global frequency of ESBL production was 6.9% (n = 976)
for E. coli (samples were most frequently obtained from urine 48.5%,
secretions 14.3%, blood 8.2%, faeces 6.9% and dialytic ﬂuid 4.8%).
ESBL were found in 27.81% (n = 1287) of K. pneumoniae isolates
(obtained in 29% from urine, 22% from blood, 11.7% form secretions
8.4% from catheters and 7% from faeces). Annual frequency for ESBL
in E. coli from the years 2002, 2003, 2004, 2005, 2006, 2007 and the
ﬁrst semester of 2008 were 8.1%, 9.1%, 6.7%, 7.1%, 6.1%, 6.3% and
7.4%, respectively. ESBL was found in K. pneumoniae, for the same
years, with a frequency of 39.3%, 34.8%, 28.6%, 33.6%, 27.0%, 22.5%
and 18.1%, respectively. Time series models and the forecast for the next
12 months is showed in the ﬁgure 1.
Conclusions: There is trend for a lower rate of ESBL isolates among
K. pneumoniae in ICU and non ICU samples. The frequency of ESBL
producers in E. coli has remained stable and there is slight increase
for the last 18 months in non-ICU wards. The forecast for the latter is
remain in a similar level.
P668 Dynamics of extended-spectrum b-lactamases in Escherichia
coli and Klebsiella pneumoniae: a mathematical model
K.R. Philipsen °, M.C.J. Bootsma, M.A. Leverstein-van Hall, J. Cohen
Stuart, M.J.M. Bonten (Lyngby, DK; Utrecht, NL)
Objectives: The prevalence of infections caused by extended-spectrum
b-lactamases (ESBL) producing bacteria, associated with increased
mortality, length of stay and costs, is rapidly increasing. Here we aim
1) to elucidate the dynamics of spread of ESBL and 2) to estimate the
expected equilibrium prevalence of ESBL+ Escherichia coli (EC) and
Klebsiella pneumoniae (KP) in a single hospital and its catchment area.
Methods: We use a deterministic mathematical model with 3 hospital
compartments distinguished by the risk for patients to acquire
ESBL: Intensive Care Units (ICUs), high-risk non-ICU wards (e.g.,
haematology) and low-risk wards. Outside the hospital 3 patient
groups are distinguished based upon their hospitalisation rates (data
University Medical Center Utrecht (UMCU)). EC and KP can be
ESBL + or −. Assuming each individual carries EC, we distinguish
6 intestinal colonisation states, EC−, EC−/KP−, EC−/KP+, EC+,
EC+/KP−, EC+/KP+. Within the hospital, patients can acquire ESBL
bacteria by cross transmission or by conjugation, when a patient is
already colonised with a ESBL+ KP or EC. Within the hospital patients
remain ESBL+ and after discharge lose ESBL+ strains after a mean of
90 days and do not acquire ESBLs. The nosocomial ESBL prevalence
data used are deduced from the Dutch EARSS data (2000–2008) and
UMCU (1996–2008) with a percentage of ESBL+ blood cultures in
2007 of 7% and 4% for KP and EC.
Results: Model simulation results ﬁt well with observed prevalence
rates in recent years. Inside and outside the hospital the prevalence of
ESBL+ carriership is for 2008 estimated to be 7% and 2.5%, respectively,
for KP and 4.5% and 0.3%, respectively, for EC. Without changes in
infection control measures, an equilibrium prevalence will be reached
after 7 years. Equilibrium prevalence in ICUs will be 11% for patients
colonised with EC+ and 8% for those colonised with both “KP+ and
EC+”, respectively. The equilibrium prevalence will be highest (19%)
for both ESBL+ species in the high risk wards, because of the highest
readmission rates of chronically ill patients. Conjugation between EC
and KP contributes to 14% of the acquisition of KP+.
Conclusions: A multi-compartment deterministic model ﬁtted to the
observed increase in ESBL prevalence in the last 10 years, predicts that,
in the absence of interventions, the number of patients per year with
KP+ and EC+ will increase 116% and 67%, respectively, within the
next 7 years.
P669 Faecal colonisation with extended-spectrum b-lactamase
producing Enterobacteriaceae among patients in nine
Swedish nursing homes
M. Andersson °, H. Andersson, B. Fossum, M. Kalin, C. Lindholm,
A˚. O¨rtqvist, C.G. Giske, A. Iversen (Stockholm, SE)
Objectives: Extended-spectrum b-lactamase producing Enterobacteri-
aceae (ESBL-EB) have increased during the last years also in low-
prevalence countries like Sweden, and mandatory laboratory reporting
has been introduced on a national level. Little is known about the
population prevalence of ESBL-EB in Sweden, and information is also
largely lacking on source of the isolates (community vs hospital). The
objectives of this study was to investigate the prevalence of ESBL-EB
among the total population of elderly patients living in nursing homes
in Solna County, north of Stockholm, Sweden.
Methods: Faecal swabs from 495 elderly living in nine nursing homes
were collected during a ﬁve week period in October and November
2008 and sent for cultivation at Karolinska University Laboratory. Faecal
swabs were cultured on selective chromID ESBL plates (bioMe´rieux).
Species determination was performed with in-house biochemical tests
and presence of ESBL was investigated with disks (Becton Dickinson)
or Etests (bioMe´rieux). ESBL-producing isolates were epidemiologically
characterised using pulsed-ﬁeld gel electrophoresis (PFGE) when several
cases were detected in the same nursing homes. A previously described
real-time probe based PCR was used for typing of blaCTX-M to the
phylogenetic subgroups.
Results: Fifteen of the 495 elderly living in seven of the nine
nursing homes were ESBL positive (3%). The majority of the elderly
were colonised with Escherichia coli (14/15), followed by Klebsiella
pneumoniae that was found in two patients, one of which was co-
colonised with E. coli, K. pneumoniae and Citrobacter koseri. PFGE
patterns on XbaI digested DNA was analysed for eleven E. coli isolates
from elderly living in four nursing homes with several cases. In two
of the homes a close correlation was found between the isolates,
indicating transmission between patients. PCR typing of blaCTX-M
among E. coli showed that 11 belonged to CTX-M-1 subgroup, one to
CTX-M-9 subgroup, and two isolates were blaCTX-M negative. Among
K. pneumoniae and C. koseri all isolates were blaCTX-M negative.
Conclusion: To our knowledge this is the ﬁrst population based
prevalence study of ESBL-carriage in Scandinavia. In the study
population 3% were colonised with ESBL-producing Enterobacteriaceae.
Only a few examples of possible local transmission were documented.
P670 Epidemiology and clinical features of infections caused by
extended-spectrum b-lactamase-producing Gram-negative
urinary pathogens in non-hospitalised patients
A. Vanegas °, P. Merino, J. Pe´rez, FJ. Candel, JJ. Picazo (Madrid, ES)
Objective: Infections due to extended-spectrum b-lactamase (ESBL)-
producing by Gram-negative urinary pathogens in nonhospitalised
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patients and their clinical relevance have constantly emerged during
the past years. Therefore, the epidemiology data and antimicrobial
susceptibility tests would contribute to enhance knowledge from these
pathogens. The aim of this study was to describe the epidemiology
and clinical features of patients with urinary tract infection caused by
Enterobacteriaceae ESBL and its antimicrobial susceptibility.
Methods: A retrospective descriptive study was carried out. Enterobacte-
riaceae ESBL strains isolated from patients with urinary tract infections
(UTI) in outpatient clinics from primary care services and the emergency
department from Hospital Clinico San Carlos were used as target group
between January of 2007 and August of 2008. Clinical protocols and
epidemiology data from patient’s medical history were collected.
Results: A total of 185 ESBL strains were isolated from patients with
UTI. 140 (75%) Escherichia coli and 39 (21%) Klebsiella pneumoniae.
62% were females and 37% males. The median age of patients with
E. coli and K. pneumoniae was 69 and 60 years respectively (P< 0.009).
56% were from outpatients and 43% from emergency room patients.
From 60 patients (32%) without a previous hospital admission 55 (39%)
were diagnosed with UTI ocassionated by E. coli and 4 (10%) by
K. pneumoniae (P< 0.001). The most frequent features associated to
infection by E. coli and K. pneumoniae were to use betalactamics or
quinolones antibiotics in the previous 3 months 55% and 66% (P = 0.27),
comorbility 50% and 74% (P = 0.10), recurrent urinary tract infections
44% and 53% (P = 0.36), urinary abnormalities 36% and 56% (P = 0.28),
hospitalisation in the last 3 months 33% and 66% (P< 0.001), and renal
transplant 5% and 38% (P< 0.001) respectively. Resistance to quinolones
in E. Coli and K. pneumoniae were 54% and 61% respectively, and to
aminoglycosides 39% and 59%. Fosfomycin-resistance were detected in
17% and 38% respectively.
Conclusions: Elderly patients, comorbility, renal transplant, prior use to
betalactamics or quinolones and previous patient hospitalisation were the
most frequent characteristics associated with UTI. Antibiotic resistance
such in quinolones and aminoglycosides has to be considered in advance
as well as the epidemiological data from patients before establishing an
accurate treatment.
P671 Community-onset urinary tract infections caused by
ESBL-producing Enterobacteriaceae
O. Zarkotou °, A. Giannouli, I. Kristo, G. Altouvas, V. Mamali,
S. Drimis, G. Chrysos, D. Voutsinas, S. Pournaras, K. Digalaki (Athens,
Larissa, GR)
Objectives: ESBL-producing Enterobacteriaceae (ESBLE), especially
E. coli, are increasingly identiﬁed in community patients mainly with
urinary tract infections (UTI). We deﬁned the prevalence of community-
onset versus hospital-acquired UTI caused by ESBLE. The clinical data
of patients with community onset UTI caused by ESBLE were reviewed.
Methods: A total of 1169 single-patient isolates, recovered from urine
cultures of 776 hospitalised patients and 393 outpatients during 2008,
were studied. The bacterial species studied were E. coli, K. pneumoniae
and P. mirabilis. The identiﬁcation, MIC determination and screening
for ESBLs were performed by the Vitek 2 compact automated
system. CLSI approved conﬁrmatory test (combined disk test) was also
applied. Clinical isolates co-expressing carbapenemase phenotypes were
excluded. All community strains were tested by PCR. The demographic
and clinical characteristics of patients were evaluated using medical
records.
Results: 83 patients (7.1%) harboured uropathogenic ESBLE. Species
distribution was: E. coli 66, 7.2%; K. pneumoniae 14, 11.7%;
P. mirabilis 3, 2.3%. Hospital-acquired infections were considered
in 24 patients. Healthcare-associated infections were identiﬁed in
13 patients (outpatients under haemodialysis or chemotherapy, surgery,
prior hospitalisation the past one month). The criteria for community-
onset infection were met in 46 patients (55.4%). Female gender was
prevalent (33/46). Mean age was 74.9 y (range 27−91 y). Regarding
E. coli isolates 36/66 (54.5%) were characterised as community-acquired
and resistant rates to quinolones and cotrimoxazole were 79% and
67% respectively, whereas all ESBL-producing P. mirabilis isolates
were hospital-acquired. Predominance of community-onset infections
was noted for K. pneumoniae (10/14). The rate of ESBLE among patients
with community-onset UTI was 7.4% (46/624): E. coli 7% (36/510) and
K. pneumoniae 18.5% (10/54). The proportion of ESBLE among hospital
and healthcare-associated UTI was 7.4% (37/499). PCR identiﬁed 33/36
community E. coli isolates as carrying blaCTX-M gene.
Conclusions: The rate of uropathogens expressing ESBL was similar in
community and hospital-acquired strains. This indicates a change in the
epidemiology of ESBLE, with a rather high proportion of community
isolates to express ESBL, especially CTX-M. It is suggested that
empirical administration of beta-lactams for community UTIs should
be done with caution in high risk patients.
P672 Emergence of community-onset extended-spectrum b-
lactamases-producing Escherichia coli in acute pyelonephritis
in Korean hospitals
J.W. Chung °, S.H. Choi, S.M. Moon, M.S. Lee (Seoul, KR)
Background: Extended-spectrum b-lactamases (ESBL) produced by
Gram-negative bacteria is a growing threat in hospital-acquired infections
worldwide. Recently, a few studies have reported the dissemination
of ESBL producers throughout the community. We report several
cases of community-onset ESBL-producing Escherichia coli in acute
pyelonephritis (APN) from the Korean hospitals.
Methods: The cases of community-onset APN caused by ESBL
producers were collected from 3 secondary or tertiary care hospitals
in Seoul, Korea. They were regarded as community-onset when they
presented community-acquired infections (developed within 48 hours
of hospital admission), no hospitalisation in the last one year, no
transfer from other hospitals, no stay in nursing home, no urinary
device and no antimicrobial treatment in the previous 6 months. Species
identiﬁcation and antibiotic susceptibility test were performed with
VITEK II automated system and ESBL production conﬁrmed by double
disk synergy test. Furthermore, characterisation of ESBL encoding genes
is being performed and the results will be presented later.
Results: From January 2007 to December 2008, there were 8 cases
of community-onset APN, caused by ESBL-producing E. coli, in the
hospitals. All cases developed in women with median age of 61 years
(ranged from 36 to 79 years). Any serious underlying disease or condition
was not found, except diabetes mellitus in two patients. Antimicrobial
resistance to amikacin (none of 8), gentamicin (2 of 8), trimethoprim-
sulfamethoxazole (2 of 8) and tobramycin (1 of 8) were not observed
frequently. However, resistance to ciproﬂoxacin was observed in 4 of
8 cases (50%), one of whom died during inappropriate empirical therapy
with ciproﬂoxacin and ceftriaxone.
Conclusion: Our study suggests that APN caused by community-
onset ESBL-producing E. coli may develop in women without serious
underlying diseases or risk factors for hospital acquisition of ESBL-
producing Gram-negative bacteria. The emergence of community-
onset infections caused by ESBL-producing pathogens will make the
empirical therapy difﬁcult in Korea, where ciproﬂoxacin or ceftriaxone
is recommended for empirical therapy for APN. Close observation
will be needed for the emergence of ESBL-producing organism in the
community.
P673 Faecal carriage and household transmission of CTX-M
producing Escherichia coli
W.U. Lo °, P.L. Ho, K.H. Chow (Hong Kong, HK)
Background: Escherichia coli that produce CTX-M type extended-
spectrum b-lactamases (ESBLs) have emerged as signiﬁcant pathogens
worldwide and increasingly found from patients with community-onset
infections.
Objective: To investigate the epidemiology of faecal colonisation by
CTX-M producing E. coli among thirty families and to assess the extent
of transmission within family members.
S160 19th ECCMID, Posters
Methods: Selective media (MacConkey agar with ceftazidime or
cefotaxime at 2mg/L) were used for screening faecal samples from the
family members. Colonies of E. coli were picked for susceptibility test
and molecular studies by PCR, sequencing and PFGE.
Results: CTX-M-producing E. coli isolates were found in at least one
member in 20 (67%) of the 30 families and 43 (34%) of 127 participants.
Faecal prevalence was similar among children and adults (37% vs.
33%, respectively). Six different CTX-M enzymes were found. CTX-
M-14 accounted for 61% of all CTX-M producers. Of the 20 families
with CTX-M type ESBL carriers, thirteen families had >1 carriers and
7 families had at least 2 members carrying the same CTX-M allele.
However, pulse ﬁeld gel electrophoresis (PFGE) showed that most CTX-
M producers within families were not clonally related.
Conclusion: Our result demonstrates that the faecal carriage of CTX-
M-producing E. coli is strikingly high in Hong Kong community, in
comparison with other areas. Nonetheless, household transmission do
not seem to play a major role in their dissemination.
P674 Molecular ﬁngerprinting of faecal isolates of E. coli with and
without ESBL-phenotype in patients with intra-abdominal
infections
M. Ta¨rnberg °, A˚. O¨stholm Balkhed, H. Hanberger, L.E. Nilsson,
H.J. Monstein (Linko¨ping, SE)
Objectives: To investigate clonal relatedness of faecal isolates of E. coli
with and without ESBL-phenotype from 9 patients with intra abdominal
infections, sampled before, during and after antibiotic treatment.
Method: From the 9 patients 76 faecal isolates of E. coli with different
antibiograms, with and without ESBL-phenotype were isolated. All
isolates with different antibiograms at each sampling time were further
analysed. MIC-determination of the isolates were made for 16 antibiotics
representing common prophylactic agents, treatment options and last
line treatment of multi drug resistant isolates. The isolates were
subjected to PCR-ampliﬁcation and DNA-sequencing for detection of
genes belonging to the CTX-M and SHV-families. All isolates were
ﬁngerprinted four times using a semi automated approach and the
GTG-5-PCR method. Fingerprinting data and MICs were evaluated and
isolates clustered using the bioinformatics software BioNumerics.
Results: Each patient was sampled 3−12 times during a period of
10−64 days. From each patient 2−17 isolates were detected. 43 of the
76 isolates had an ESBL-phenotype. Multi resistant isolates (i.e. resistant
for 3 or more of b-lactam antibiotics, aminoglycosides, trimethoprim-
sulfa and/or ciproﬂoxacin) were isolated from 2 patients. CTX-M genes
belonging to group 1 were found in 3 patients and group 9 in 2 patients.
SHV genes were found in one patient (SHV-1-like). Each patient’s E. coli
were divided in 1−7 ﬁngerprinting patterns when subjected to semi-
automatic GTG-5-PCR. No pattern of an isolate was 100% identical
to any pattern from a different patient. In 2 patients the isolates with
ESBL-phenotype differed completley from isolates without ESBL, but in
the remaining 7 patients ESBL-phenotypes shared ﬁngerprinting pattern
with isolates without ESBL.
Conclusion: This study shows that it is possible with the GTG-5-PCR
method to detect each patient’s clones of E. coli since no patients had
100% identical clones. However it was not always possible to detect
E. coli with ESBL genes among the other faecal isolates of E. coli with
different antibiograms within the same patient. This indicate that most
patients have several clonal related faecal isolates of E. coli with and
without ESBL-genes and ESBL-phenotype with different antibiograms.
P675 Extended-spectrum beta-lactamase-producing
Enterobacteriaceae: recent evolution and clinical
impact in a large tertiary-care Italian hospital
A. Bartoloni °, E. Mantengoli, A. Cavallo, D. Cecconi, P. Pecile,
L. Attala, P. Nicoletti, F. Paradisi, R. Cauda, G.M. Rossolini (Florence,
Siena, Rome, IT)
Objectives: The extended-spectrum beta-lactamases (ESBLs)-producing
Enterobacteriaceae represent a major public-health concern. Epidemi-
ology of ESBLs has recently undergone a remarkable evolution in
several settings, mostly due to the massive diffusion of CTX-M-type
enzymes vs. the older TEM- and SHV-type ESBLs. In Italy, a large
multicentre, prospective, cohort study is ongoing to assess the molecular
epidemiology, clinical impact, treatment outcome and risk factors for
infections caused by ESBL-producing Enterobacteriaceae. We report the
preliminary results from one of the study centres, where a major evolu-
tion of the ESBL epidemiology has been observed in the past few years.
Methods: ESBL screening was carried out using modiﬁed cefotaxime
and ceftazidime breakpoints, as recommended by the CLSI. ESBL
production was conﬁrmed using the combination disk test, based on
CLSI methodology. ESBL determinants were investigated by PCR and
sequencing. Patients with ESBL infections and matched controls were
prospectively enrolled in the study. Data on risk factors, therapy and
outcome were collected in an electronic database.
Results: 65 cases of infections caused by ESBL-producers observed
at Florence University Hospital were studied during a 12-month period
(July 2007-June 2008). The most prevalent ESBL-positive species was
Escherichia coli (77%), followed by Klebsiella pneumoniae (12%).
CTX-M-type enzymes accounted for 74% of the ESBL producers. The
ESBL epidemiology was found to be profoundly changed in comparison
with that observed in 2003, in the same centre, during a nationwide
survey (E. coli and CTX-M-type enzymes accounted for 15% and 1% of
the ESBL producers, respectively). Isolates were mostly from urinary and
lower respiratory tract infections. Almost half (43%) of infections were
from internal medicine/geriatrics wards. Previous hospitalisation and
presence of urinary catheter were associated with infection with ESBLs
producing Enterobacteriaceae. Empirical treatment resulted appropriate
according to in-vitro susceptibility testing in 69% of the cases.
Inappropriate therapy was mainly (88%) based on ﬂuoroquinolones.
Conclusion: A recent and massive dissemination of CTX-M-producing
E. coli modiﬁed remarkably the ESBL epidemiology in this hospital
setting. Similar strains now pose a major clinical challenge.
Acknowledgements: Study supported by a research grant from Merck
Sharp & Dohme.
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P676 Multiresistant urinary tract isolates of Escherichia coli: is it
an issue in the empiric management of acute uncomplicated
cystitis?
I. Katsarolis °, G. Poulakou, S. Athanasia, P. Panagopoulos,
F. Kontopidou, J. Kremastinou, E. Karaiskos, D. Voutsinas, L. Zarkotou,
G. Koratzanis, M. Kanellopoulou, P. Gavra, G. Adamis, E. Vagiakou,
E. Vogiatzi, P. Perdikaki, C. Panou, L. Kalovolou, M. Psychogiou,
N. Lambri, C. Birbilis, C. Kalyvas, G. Daikos, G. Veliotis,
K. Kanellakopoulou, H. Giamarellou
on behalf of the Collaborative Study Group for the Antibiotic
Resistance in Community-acquired Urinary Tract Infections
Objectives: To assess the prevalence of multiresistance (multiR) among
E. coli strains isolated from patients with community-acquired urinary
tract infections (UTI).
Methods: Escherichia coli strains were isolated from outpatients >16 ys
referred for urine culture. Resistance (%R) was deﬁned by disk diffusion
according to CLSI 2006. A questionnaire accompanied each sample, in
order to differentiate acute uncomplicated cystitis cases (AUC). MultiR
was deﬁned as R to 3 or more agents among ampicillin (AMP),
cephalothin (CEP), nitrofurantoin (FUR), cotrimoxazole (COT) and
nalidixic acid (NAL). R to amoxicillin-clavulanate (AMC), cefuroxime
axetil (CXM), mecillinam (MEC), fosfomycin (FOS) and ciproﬂoxacin
(CIP) was also deﬁned. Risk factors for multiR strains isolation were
processed by univariate analysis and parameters with P< 0.1 were
entered in a multivariate logistic regression stepwise model. Odds ratio
(OR) and 95% conﬁdence intervals (95%CI) were calculated. A P value
0.05 was considered as statistically signiﬁcant.
Results: From Feb 2005-Mar 2006 and a total of 1545 E. coli strains,
731 cases of AUC were identiﬁed. %R rates in AUC were: AMP 25.5,
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CEP 6.7, FUR 4.6, COT 18.4, NAL 5.9, CIP 1.8, AMC 2, CXM 1.6,
MEC 2.7 and FOS 0.8. Of these isolates, 6% were multiR (44/731). The
predominant multiR phenotype included R to AMP-COT-NAL (12/44,
27.3%). Among multiR isolates, %R rates were: AMP 97.7, COT 77.3,
CEP 63.6, NAL 61.4, FUR 31.8, CIP 22.7, CXM 22.7, AMC 20.5,
MEC 9.5 and FOS 4.5. Use of ﬂuoroquinolones in the previous 3 months
(OR 3.66, 95%CI 1.82−7.37, P< 0.001) and age >65 ys (OR 2.22,
95%CI 1.46−3.39, P< 0.001) were signiﬁcantly associated with multiR
E. coli isolation in the multivariate analysis (model variables: UTI
history, antibiotic use in the previous 3 months, hospital admission,
diabetes mellitus, age).
Conclusions: Prevalence rates of E. coli urinary isolates multiR are
signiﬁcant and call for continuous surveillance, especially among elderly
patients. For AUC empiric treatment, increased COT %R undermine its
use as ﬁrst-line agent. Although CIP exhibits low %R, caution in ﬂuoro-
quinolone use as ﬁrst-line for the empiric AUC treatment is prompted by:
(a) increased NAL %R, (b) quinolone-resistant strains being frequently
multiresistant, and (c) ﬂuoroquinolone use association with multiR
E. coli isolation. Mecillinam, fosfomycin and nitrofurantoin could serve
as ﬁrst-line choices, in the context of ﬂuoroquinolone-sparing regimens.
P677 The effect of sewage treatment on antibiotic resistance of
enterobacteria
M. O¨sterblad °, A. Hakanen, J. Jalava, P. Huovinen (Turku, FI)
Objective: Wastewater can potentially spread resistant bacteria. Most of
the bacteria are removed from the puriﬁed wastewater, but some are still
released. Studies on the effect of puriﬁcation on resistance are conﬂict-
ing. Treatment methods have also changed. We sampled sewage plants of
different sizes, all using biological-chemical treatment. Resistance levels
of Enterobacteriaceae in raw sewage and efﬂux were compared.
Methods: Wastewater samples were collected in Southwestern Finland
in December 2001 – June 2002. The samples were suitably diluted and
plated in duplicate onto Rambach agar without antibiotics, and with
100mg/l trimethoprim, 8mg/l tetracycline, 25mg/l streptomycin, 20mg/l
nalidixic acid, and 1mg/l ciproﬂoxacin. All blue colonies were counted
on plates with a suitable density of growth. The CFU/ml on antibiotic
plates was compared to the CFU/ml without antibiotics. Samples with
<90CFU/ml were excluded.
Results: 23 sample pairs (raw and treated sewage) from 20 treatment
plants were included. Treatment removed on average 98% of enterobacte-
ria, but of those left, a larger percentage were resistant, for all antibiotics
but ciproﬂoxacin (Table). One CTX-M-carrying E. coli was found; the
oldest detected in Finland so far (in inﬂux wastewater from Turku City,
December 2001).
Conclusion: Sewage treatment, although removing most of the bacteria,
can increase the frequency of resistant bacteria. Studying wastewater can
also work as an early warning system, enabling the detection of emerging
resistance in faecal bacteria.
Resistance percentages of Enterobacteriaceae in raw and puriﬁed wastewater
Percent resistant
Trimethoprim Tetracycline Ciproﬂoxacin Nalidixic
acid
Streptomycin
Inﬂuent 7.4 7.1 0.6 5.4 5.5
Efﬂuent 11.5 15.2 0.7 7.5 8.8
P678 Surveillance of antibiotic resistance in urinary coliforms in
Greater Lincolnshire, U.K. and the potential for temocillin,
ertapenem and mecillinam usage
A.F. Vicca °, P. Cowling, C.A.J. Brightman, E.R. Youngs, B. Stoddart,
K.W. Loudon (Lincolnshire, UK)
Objective: Surveillance of antibiotic sensitivity patterns in resistant
urinary coliforms for a large, rural population over a recent six month
period.
Method: Lincolnshire is England’s second largest county with an area of
>500 hectares and a largely rural population of >1 million. It is covered
by a single-managed microbiology service which uses U.K. Health
Protection Agency national standard operating procedures, disc diffusion
sensitivity testing to BSAC standards and collects sensitivity data on one
IT database. This was interrogated for all urinary coliforms from hospital
and community patients that required second line sensitivity testing over
the period of March to August 2008 and sensitivities of these isolates to
16 routinely tested antibiotics were recorded.
Results: Of 16,944 urinary coliform isolates from hospitals and
community tested March-August 2008, 806 (4.8%) were multi-resistant
requiring second line sensitivity tests. Percentage sensitivities against
16 antibiotics are shown in the ﬁgure (AMC = amoxicillin clavulanate;
AMX = amoxicillin; ATM = aztreonam; CAZ = ceftazidime; CFX =
cefalexin; CIP = ciproﬂoxacin; CPO = cefpodoxime; CTX = cefotaxime;
CXM = cefuroxime; ERT = ertapenem; GEN = gentamicin; MEC =
mecillinam; NIT = nitrofurantoin; TAZ = piperacillin-tazobactam;
TEM = temocillin; TMP = trimethoprim). Sensitivity to temocillin,
ertapenem and mecillinam was 95.8%, 95.4% and 83.6% for all multi-
resistant isolates, 92.7%, 90.6% and 83.3% for all gentamicin resistant
isolates (n = 96), 93.5%, 95.7% and 92.4% for all ciproﬂoxacin resistant
isolates (n = 184). 108 (0.6% of total isolates, 13.4% of resistant isolates)
were extended spectrum beta lactamase (ESBL) producers and 32 (0.2%
of total, 4.0% of resistant) were Enterobacter, Citrobacter, Morganella,
or Serratia genera. Sensitivities against these four genera and ESBLs
were highest (>95%) for temocillin, ertapenem and mecillinam.
Number resistant coliforms tested
Conclusion: In our large, predominantly rural, population, temocillin
and ertapenem show the lowest resistance rates of 16 antibiotics
routinely tested in resistant urinary coliforms. For ESBL producers
and Enterobacter, Citrobacter, Morganella, Serratia genera, temocillin,
ertapenem and mecillinam have very low resistance rates. Mecillinam is
available as an oral preparation but sensitivity testing in ESBLs may be
unreliable. Temocillin and ertapenem are good options for the treatment
of antibiotic multi-resistant urinary pathogens in hospital patients.
P679 Anti-pseudomonal activity of piperacillin/tazobactam: more
than a decade of experience from the SENTRY Antimicrobial
Surveillance Program (1997–2007)
R. Jones °, H. Sader, M. Stillwell, P. Rhomberg (North Liberty, US)
Objectives: To summarise the susceptibility rate (% susceptible [S])
experience for piperacillin/tazobactam (P/T) tested against Pseudomonas
aeruginosa isolates from the Asia-Paciﬁc (APAC), Europe (EU), Latin
America (LA) and North America (NA) for 1997–2007. All testing was
by reference CLSI (2006) methods and interpreted by contemporary
CLSI and USA-FDA breakpoint criteria (2008).
Methods: A total of 25,460 P. aeruginosa were tested originating from
APAC (4,441), EU (7,695), LA (4,277) and NA (9,047); >110 medical
centres/year and samples averaging >30 nations/year. CLSI M7-A7
(2006) and M100-S18 (2008) methods and categorical criteria were ap-
plied and all quality control results were within published limits. For this
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analysis results from 1997–2007, 1997–1999, 2005–2007, APAC, EU,
LA and NA were assessed against several broad-spectrum beta-lactams
(cefepime [CPM]), ceftazidime [CAZ], imipenem [IMP], meropenem
[MER], and piperacillin alone [PIP]; total of 12 agents overall.
Results: Using CLSI P. aeruginosa breakpoints (64mg/L), P/T had
the broadest coverage (% S) in two regions (EU, LA) and overall at
83.6% followed by MER (83.0%) 7> IMP (79.7%) > PIP (79.5%) >
CPM (77.5%) > CAZ (75.8%). Other non-beta-lactam activity results (%
S) were ciproﬂoxacin at only 71.5%, but tobramycin and polymyxin B
had higher S rates (81.0 and 99.5%, respectively). Trends toward P/T
resistance (R) were noted between 1997–1999 and 2000–2007 in APAC
(−11.6% S), NA (−4.0%) and EU (−2.3%). LA S rates were lowest
but actually increased over time by +2.9%; current rate 79.4% S. For
beta-lactamase inhibitor combinations S rates were higher for P/T when
compared to PIP alone in all regions (+2.6 to 7.1%), greatest for
LA isolates. In contrast, ticarcillin/clavulanate S rates were lower than
ticarcillin tested alone in NA (−1.5%; antagonism) and this agent only
inhibited 70.3% of isolates worldwide.
Table
Beta-lactam % susceptible by region (no. tested)
APAC (4,441) EU (7,695) LA (4,277) NA (9,047) All (25,460)
P/T 82.9 83.0 74.8 88.7 83.6
MER 83.5 81.5 71.6 89.4 83.0
IMP 80.4 78.0 68.7 85.9 79.7
PIP 79.3 78.4 67.7 86.1 79.5
CPM 77.0 77.1 64.6 84.0 77.5
CAZ 74.7 75.9 62.8 82.4 75.8
Conclusions: P/T remained the most active beta-lactam tested in vitro
against clinical isolates of P. aeruginosa found in the SENTRY Program
(1997–2007). Trends toward slightly decreased S were noted in all
regions over the decade, except LA; only polymyxins had S rates
at >90%. R surveillance programs should be sustained to document
emerging patterns of old and newer agents for difﬁcult to treat pathogens
such as P. aeruginosa.
P680 ECO-SENS II: antimicrobial susceptibility in Escherichia
coli from community acquired urinary tract infections in
Austria, Greece, Portugal, Sweden and United Kingdom
H. Ode´n °, G. Kahlmeter (Va¨xjo¨, SE)
Objectives: The original ECO-SENS international survey of prevalence
of pathogens and antimicrobial resistance in uncomplicated urinary
tract infections in women was performed in 1999 to 2000 (Journal
of Antimicrobial Chemotherapy 46 S1:15−22 (2000) and 51:69−76
(2003)). To compare resistance development over time, the ECO-SENS
II, performed in 2007–2008, determined the antimicrobial susceptibility
from similarly acquired E. coli in 5 of the countries.
Method: Five European countries (see title) where chosen to represent
different areas of Europe. The aim was to collect 200 E. coli from each
country. Susceptibility tests were performed in accordance with SRGA
recommendations (www.srga.org) on 14 antimicrobials.
Table 1. Resistance among E. coli from urinary tract infections in ﬁve European countries in 2008 compared to
resistant rate in the ﬁrst ECO·SENS-study in 2000
Country Rate for ECO·SENS II (for ECO·SENS I), %
AMP AMC MEC TRI SUL TSU NIT NA CIP GEN FOS CDR CTX CAZ
Austria 30.0 10.0 0 16.4 20.9 14.5 0.9 9.1 4.5 1.8 0.9 4.5 2.7 2.7
(17.5) (2.4) (1.6) (9.5) (25.4) (9.5) (0.8) (2.4) (0) (0.8) (0) (0.8) (NT) (NT)
Greece 25.8 4.2 1.4 18.8 23.0 17.8 0 13.1 5.6 0.9 2.8 1.4 1.4 0.5
(22.0) (0.8) (0.8) (13.6) (19.7) (11.4) (3.0) (6.8) (1.5) (0.8) (1.5) (3.0) (NT) (NT)
Portugal 35.0 4.9 0 17.6 31.4 16.7 0 13.7 6.9 2.9 0.9 0 0 0
(45.3) (9.3) (2.3) (26.7) (44.2) (26.7) (5.8) (11.6) (5.8) (3.5) (0) (2.3) (NT) (NT)
Sweden 21.0 2.4 0.5 16.1 22.4 16.1 0 6.3 2.4 1.5 1.0 1.5 1.5 1.0
(15.5) (5.7) (1.6) (8.8) (16.6) (8.3) (0) (2.6) (0) (0) (0.5) (5.2) (NT) (NT)
UK 31.9 2.0 1.0 15.2 26.5 14.7 0 7.4 1.0 0.5 0.5 1.5 0.5 0.5
(37.2) (2.8) (1.7) (13.3) (37.7) (12.2) (0) (2.2) (0.6) (0) (0) (1.7) (NT) (NT)
Total
(n = 834)
27.8 4.1 0.7 14.6 20.9 16.1 0.1 9.6 3.7 2.6 1.3 1.7 1.2 0.8
Results: To date 834 E. coli have been studied (at least 150 per country).
The results are summarised in Table 1. Among those we found six E. coli
to be ESBL producers, as compared to none in the ﬁrst ECO-SENS
survey. In 37 of 60 instances, resistance rates were higher in 2008 than
in 2000. In ﬁve countries ciproﬂoxacin resistance and in 4 trimethoprim
resistance had increased. Resistance to pivmecillinam, nitrofurantoin and
fosfomycin was low in all countries.
Conclusion: Antimicrobial resistance in community acquired E. coli
continues to increase. This was especially true for ﬂuoroquinolone
and trimethoprim resistance. However, resistance to pivmecillinam,
nitrofurantoin and fosfomycin was low in all countries and had with
few exceptions not increased between 2000 and 2008.
Both ECO-SENS surveys were sponsored by LEO Pharma, Ballerup,
Denmark.
P681 Catheter-associated urinary tract infections in a geriatric
ward
P. Lanzafame, P. Dallape`, L. Scartezzini, M. Monterosso, I. Caola °,
E. Baldantoni (Trento, IT)
Objectives: Catheter-associated urinary tract infections (CA-UTIs) in
the elderly represent the most common nosocomial infections; about 15
to 30% of hospitalised elderly patients with acute conditions usually
undergo urinary catheterisation. This study was done to describe the
incidence of catheter-related infections, the risk factors associated with
the duration of catheterism and the microbiological pathogens involved.
Methods: An active surveillance system of nosocomial infections
associated with CA-UTIs in patients hospitalised in the geriatric ward
of a country hospital (720 beds) was carried out from January 2006
to December 2007, and a study of prevalence was made in July
2008. The surveillance was based on CDC’s Guideline for prevention
of Catheter-associated Urinary Tract Infections. Standard clinical and
microbiological criteria were used to deﬁne colonisation and infection.
Results: A total of 122 patients, negative for bacteriuria, underwent
urinary catheterism during the observation phase. The incidence rate/100
catheter days was 7.09% for 57 cases of infections. The average days
of catheterisation was 6.6 days. We calculated the average catheter-
days of the infections for each year of the study; the results were
10.28 and 17.42, with a signiﬁcant correlation between the infection
and the catheter days. The percentage of catheterisation was 12.88%.
The study of prevalence made in July 2008 conﬁrmed the previous data:
the prevalence rate of infections/catheter-days was 8.3%, the percentage
of patients undergoing urinary catheter was 25%. The bacterial aetiology
of CA-UTIs generally involved a single uropathogen, mainly E. Coli, but
several other bacterial pathogens and yeasts were detected: P. mirabilis,
K. pneumoniae, E. faecalis, Citrobacter spp., P. stuartii, M. morganii,
and Candida spp.
Conclusions: Urinary catheters are used frequently in elderly popu-
lations. The infection rate is about 7−8% per day. Escherichia coli
remains the most common infecting organism, but a wide variety of
other organisms may be isolated, including yeast species. The duration
of catheterism is a conﬁrmed risk factor for developing CA-UTIs.
P682 Detection and management of catheter-associated urinary
tract infections: an audit of clinical practice in a district
general hospital
G. Pollara °, A. Sivananthan, A. Schwenk, Z. Adhami (London, UK)
Objectives: Urinary catheters introduce a portal for invasion by
infectious organisms, resulting in catheter associated urinary tract
infections (CAUTI), the source of 8% of hospital acquired bacteraemia.
North Middlesex University Hospital, London, UK guidelines on
managing CAUTI indicated the need for catheter change and sensitivity-
guided antibiotic usage, but did not focus on distinguishing between
asymptomatic bacteriuria and septic patients. Thus, a clinical audit was
carried out to identify clinical parameters involved in the detection
and management of microbiologically conﬁrmed catheter associated
bacteriuria.
Methods: Patients were identiﬁed from catheter specimen urine (CSU)
that had grown a single organism >105 cfu/ml. Their medical records
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were then analysed to assess the parameters being audited: the indication
for CSU collection (clinical suspicion, costovertebral tenderness or
fever), change of catheter (+/− antibiotic prophylaxis) and antibiotic
usage. Overall 41 patient records were collected over a 2 month period.
30/41 patients were female and the median age was 75 (range 38−98).
Results: Only 13/41 (32%) of samples originated from patients with pos-
sible symptomatic UTI. While 21/41 (52%) of catheters were removed,
this occurred only in 6/13 (46%) of patients where symptomatic infection
was suspected. Furthermore, 15 catheters were removed when not
clinically indicated, and 6 of these were replaced, potentially introducing
a second bacteraemic event. Of the 21 removed catheters, only 9 patients
(43%) received gentamicin prophylaxis. With regards to treatment of
suspected CAUTI, of the 20 patients that received antibiotics, only
8 (40%) had a clinical indication for doing so at the time of sample
collection. Furthermore, there was no association between catheter
removals and administration of antibiotics to treat a suspected UTI.
Conclusion: The variability in clinical practice identiﬁed by this audit
have resulted in new hospital guidelines, specifying clear indications
for CSU collection (fevers, localising tenderness, rigors) and gentamicin
prophylaxis (history of CAUTI following catheter manipulation, recent
catheterisation following urinary tract instrumentation, neutropaenia).
An education programme has been rolled out to reinforce these new
guidelines, prior to a comprehensive re-audit. This audit may serve as a
template for other hospitals to compare local practice in the management
of CAUTI to evidence based standards.
P683 Changing trends in community urinary tract infections in
South Manchester
R. Roy °, N. Doshi, M. Cullen, C. Thornhill, M. Birch (Manchester, UK)
Objectives: Urinary Tract Infections (UTIs) are the second most
common clinical indication for empirical antibiotic treatment in primary
and secondary care. Many different antibiotic resistance mechanisms
are present, but the mechanism of extended-spectrum beta-lactamase
(ESBL) production is of particular interest. Periodic assessment of the
causative organisms for UTIs allows clinicians to keep a track of species
and any changes in the trends of bacterial susceptibility. We aimed
to look at the patterns of organisms and antibiotic sensitivities for all
urinary isolates from patients in the South Manchester community, over
a four year period (2004–2007).
Methods: Data was collected retrospectively from the microbiology
laboratory database (Telepath) at our hospital. Analysis of the positive
isolates received over the four year period was performed using
Microsoft Excel.
Results: The majority (>80%) of bacterial species responsible for UTIs
were Gram-negative. The approximate ratio of 5.4:1 between Gram-
negative and Gram-positive species was maintained for the entire period.
For each year the main Gram-negative species were enterobacteriaceae,
while enterococci were the most common Gram-positive species. Overall
antibiotic sensitivity has declined. Trimethoprim (6% decrease) and
ciproﬂoxacin (5% decrease) have shown the largest reduction followed
by amoxicillin, cephalexin and piv-mecillinam with decreases of 2−3%
each. Sensitivity to nitrofurantoin has remained largely unchanged. The
proportion of UTIs due to ESBL producers has increased annually,
showing a more than threefold increase from 2004−07. The majority
of ESBL producers are Escherichia coli. Sensitivity to nitrofurantoin
and piv-mecillinam has remained high (around 90%) with no notable
change for carbapenems.
Conclusions: During the period 2004−07, there has been an increase
in antibiotic resistance to the ﬁrst line antibiotics used by general
practitioners to treat urinary tract infections in South Manchester. There
has been an increase in ESBL incidence which may be direct result of
antibiotic use or a spillover of nosocomial organisms into the community.
Prudent antibiotic prescribing is generally recommended to combat
increasing antibiotic resistance. The increased use of nitrofurantoin and
piv-mecillinam as empiric agents for community UTI may be considered.
It is worth expanding the scope of the study to include data from 2008.
We hope to include these data in any future presentations.
P684 Persistence of Escherichia coli clones in recurrent urinary
tract infections
L. Skjøt-Rasmussen °, A.M. Hammerum, C.H. Lester, L. Jakobsen,
P. Larsen, N. Frimodt-Møller (Copenhagen, Køge, DK)
Objectives: Escherichia coli is the most frequent causative agent of
recurrent urinary tract infections (rUTI). Relatively few studies have
investigated the characteristics of E. coli strains causing rUTI, and
differing views prevail as to whether rUTIs are primarily due to either
reinfection with new strains or bacterial persistence or reinfection
with the originally infecting strain. In the present study, E. coli
isolates obtained from cases of rUTI were characterised with respect
to antimicrobial resistance, phylogenetic group, virulence genes (VGs)
and Pulsed Field Gel Electrophoresis (PFGE) typing.
Methods: From December 2005 through the beginning of April 2006,
131 E. coli urine isolates from Danish patients with UTI were collected
at a general practice in Køge, Denmark. Of these, 41 isolates were from
the same 13 patients (2−7 isolates per patient). The 41 isolates from
cases of rUTI were investigated by three multiplex PCR reactions for
their phylogenetic background (A, B1, B2, D, non-typeable) and presence
of eight VGs (kpsM II, iutA, papA, papC, hlyD, sfaS, focG, afa), PFGE-
typing with XbaI restriction enzyme was performed, and MIC-values to
eight antimicrobial agents (ciproﬂoxacin, nitrofurantoin, trimethoprim,
sulfamethoxazole, ampicillin, chloramphenicol, tetracycline, and gen-
tamicin) were determined.
Results: In ten out of the 13 patients with rUTI, index isolate and recur-
rences had similar PFGE patterns and belonged to the same phylogenetic
groups, while in the remaining three patients they varied. Also, in these
ten patients very high similarity of virulence gene proﬁles and antimicro-
bial resistance proﬁles among the individual isolates from the same pa-
tients was observed. In one patient, from whom four episodes of UTI was
observed, the isolated strain changed from ciproﬂoxacin susceptible (iso-
late no. 1 and 2) to ciproﬂoxacin resistant (isolate no. 3) after treatment
of the second UTI episode with ciproﬂoxacin. The isolate again turned
ciproﬂoxacin susceptible for the fourth UTI episode (isolate no. 4).
Conclusion: Our study shows that episodes of rUTI are frequently
attributable to bacterial persistence or reinfection with the originally
infecting E. coli, i.e. one persisting clone. This may imply either an
external reservoir (vaginal or rectal) for rUTI or the possible intracellular
persistence of E. coli strains in the bladder epithelium.
P685 Antibiotics versus placebo in the treatment of women
with uncomplicated cystitis: a meta-analysis of randomised
controlled trials
M. Falagas, I. Kotsantis, E. Vouloumanou, P. Rafailidis ° (Athens, GR)
Objective: Acute uncomplicated cystitis is one of most common bacte-
rial infections in women and is conventionally treated with antibiotics.
However, emergence of resistant uropathogens forces physicians to
reconsider the prescription of antibiotics for acute uncomplicated cystitis
in non-pregnant young women. We aimed to evaluate the effectiveness
of antibiotics in the treatment of acute uncomplicated cystitis.
Methods: We searched PubMed, the Cochrane Central Register of
Controlled Trials and Scopus database.
Results: Five randomised controlled trials (RCTs) involving non-
pregnant, non-immunocompromised adult women with clinically and
microbiologically documented acute uncomplicated cystitis were in-
cluded. Clinical success was signiﬁcantly more likely in women
treated with antibiotics versus those treated with placebo [4 RCTs,
1062 patients, random effects model (REM), odds ratio (OR) = 4.81,
95% conﬁdence intervals (CI) = 2.51−9.21]. Antibiotics were also
superior to placebo, regarding cure (4 RCTs, 1062 patients, REM,
OR= 4.67, 95%CI = 2.34−9.35); microbiological eradication at the
end of treatment (3 RCTs, 967 patients, REM, OR= 10.67, 95%CI =
2.96−38.43); after the end of treatment (3 RCTs, 738 patients, REM,
OR= 5.38, 95%CI = 1.63−17.77), and microbiological reinfection or
relapse (5 RCTs, 843 patients, REM, OR= 0.27, 95%CI = 0.13−0.55).
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However, adverse events were more likely to occur in antibiotic-treated
patients versus placebo-treated women (4 RCTs, 1068 patients, REM,
OR= 1.64, 95%CI = 1.10−2.44). No difference was found between the
compared treatment arms regarding study withdrawals from adverse
events, the development of pyelonephritis and emergence of resistance.
Conclusion: Antibiotics are superior to placebo regarding both
clinical and microbiological success in adult non-pregnant women with
microbiologically conﬁrmed acute uncomplicated cystitis. However, they
are associated with more adverse events.
P686 An analysis of isolation of Mycoplasma hominis and
Ureaplasma urealyticum from genital tract specimens of
women receiving care at a general hospital serving rural
population in Greece
A. Bakossi °, E. Pitsouni, P. Holevas, E. Stamata, M. Falagas (Tripolis,
Athens, GR)
Objective: Mycoplasma hominis and Ureaplasma urealyticum are
among the most common microorganisms isolated from the genital tract
of sexually active women. Furthermore, some experts perform screening
for M. hominis and U. urealyticum in asymptomatic pregnant women
with a history of preterm delivery.
Methods: We performed an analysis of microbiological data to evaluate
the frequency of M. hominis and U. urealyticum isolation from genital
ﬂuid specimens of sexually active women, most of whom were pregnant,
who received care at a general hospital of a small city in Greece serving
mainly rural population. We retrospectively collected and analyzed
the ﬁndings of the microbiological testing of cervical swab samples
obtained from 796 young adult women (18−40 years old) receiving
outpatient or inpatient care at the General Hospital of Tripolis, Tripolis,
Greece (01/01/2001−01/01/2005) focusing on potential infection with
M. hominis and/or U. urealyticum.
Results: The overall frequency of isolation of M. hominis and U. ure-
alyticum in pregnant women (n = 528) was 2% and 14%, respectively.
The overall frequency of isolation of M. hominis and U. urealyticum in
non-pregnant women (n = 268) was 9% and 46%, respectively.
Discussion: Our study enriches the relevant literature, since it provides
data regarding the frequency of isolation of these important genital
pathogens for a tertiary centre in a small city in Greece serving rural
population. The observed frequencies of M. hominis and U. urealyticum
isolation are within the range of the ﬁgures reported in studies performed
in various parts of the world.
P687 Symptomatic women with non-gonococcal, non-chlamydial
cervicitis show a high incidence of Mycoplasma genitalium
in Greece
I. Karanikolas, S. Baka °, S. Demeridou, G. Kaparos, P. Salomidou,
V. Genimata, G. Arsenis, E. Kouskouni (Athens, GR)
Objectives: The purpose of the present prospective study was to assess
the incidence of Mycoplasma genitalium (M. genitalium) in a cohort
of reproductive age women presenting with signs and symptoms of
cervicitis since, to our knowledge, has not been previously reported in
a Greek population.
Methods: Between March 2007 and March 2008 women of reproductive
age presenting with signs and symptoms of cervicitis were invited to
participate in the study. Eligible for our study were 150 women with
nongonococcal, nonchlamydial cervicitis which previously presented
at different hospitals and private practices with the same symptoms
and did not receive therapy for mycoplasmas. In order to identify
aerobic microorganisms cervical specimens collected from all study
participants were inoculated on blood agar, MacConkey agar, Chapman
and Sabouraud agar followed by incubation at 37ºC for 24 hours, whereas
anaerobic cultures were carried out on Wilkins-Chalgren agar at 37ºC for
48 hours. The isolated strains were identiﬁed using the automated system
VITEK 2 (BioMerieux, France). For the identiﬁcation of Ureaplasma
urealyticum and Mycoplasma hominis we used Mycoplasma IST 2
(BioMerieux, France). Samples were tested for M. genitalium using
the hyplex® STD ID (BAG Health Care GmbH, Lich, Germany), a
multiplex – PCR-ELISA system. Statistical analysis was performed using
student t-test and chi-square test.
Results: M. genitalium was detected in 27 (18%) of the 150 women
tested. Data regarding women tested positive for M. genitalium was
compared to women who tested negative. The two groups did not
differ in age (p = 0.85), in the number of children (p = 0.09) and in
number of sexual partners (p = 0.64). Interestingly, a higher proportion
of women not using condoms had M. genitalium isolated from their
cervices (p = 0.021). Pruritus, in contrast to other symptoms, was more
frequently associated with M. genitalium cervicitis (p = 0.05) while
dyspareunia was signiﬁcantly increased in the control group (p = 0.05)
where other pathogens except M. genitalium where isolated. In 9 patients
M. genitalium was the only pathogen isolated while in 12 cases
was isolated together with Ureaplasma urealyticum. Finally, 6 patients
presented with infection by all 3 mycoplasmas tested.
Conclusions: Symptomatic women harbour M. genitalium in their lower
genital tract. Rapid detection by means of a multiplex – PCR-ELISA
system is useful for a prompt and correct management of these women.
P688 Anorectal Chlamydia trachomatis infections in Swiss
HIV-infected homosexual men
T. Dang °, K. Jaton, M. Flepp, H. Kovari, J.M. Evison, J. Fehr,
P. Schmid, E. Bofﬁ El Amari, M. Odorico, P. Tarr, G. Greub (Lausanne,
Zurich, Berne, Basel, St. Gallen, Geneva, Lugano, Bruderholz, CH)
Objectives: Since 2003, anorectal lymphogranuloma venereum (LGV)
and non-LGV Chlamydia trachomatis infections are re-emerging among
homosexual men in developed countries. We prospectively assessed
the prevalence and risk factors for these infections in HIV-infected
homosexual men in a large cohort, the Swiss HIV Cohort Study (SHCS).
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Methods: Male homosexual SHCS participants who reported unpro-
tected receptive anal sex and/or symptoms of proctitis during a visit
at one of the SHCS centres from April 2007 to March 2008 were
eligible. Those enrolled consented to complete a questionnaire and to
have an anal swab screened for C. trachomatis DNA by real-time TaqMan
PCR. Positive samples were genotyped by ompA gene ampliﬁcation
and sequencing. Demographic, immunologic and virological data were
retrieved from the SHCS database.
Results: 149 men were enrolled. 2 were excluded who did not fulﬁll
inclusion criteria, leaving a total of 147 anal swabs from 147 men.
The prevalence of anorectal C. trachomatis infection was 10.9% (95%
conﬁdence interval [CI] 6.2%-17.6%). Of the 16 C. trachomatis-positive
swabs, one LGV was identiﬁed from a man presenting with a 7 day
history of rectal discharge, tenesmus, and bloody stools. The remaining
serotypes were G (n = 5), J (4), E (2) and D (1). Serotype could
not be determined in 3 samples. 5/16 men with versus 54/131 men
without anorectal C. trachomatis-infection had detectable HIV viraemia
>40 copies/ml. In both anorectal Chlamydia-positive and negative
groups, 19% of men reported symptoms of proctitis. Having had more
than 20 sex partners within the last 2 years was the only identiﬁed risk
factor for anorectal C. trachomatis infection (odds ratio 5.6, 95% CI
1.87−17.09). Neither infrequent use of condom with occasional partners,
nor other risk factors for sexually transmitted infections (STIs), such
as drug use, alcohol misuse, ﬁsting, anal toy use or rimming, were
associated with anorectal chlamydial infection.
Conclusion: In this HIV-infected population at high risk for STIs, the
prevalence of anorectal chlamydial infection is moderate compared to
other STIs and we found no evidence of an ongoing LGV outbreak.
Nevertheless, since chlamydial infections are commonly asymptomatic
and since the risk of transmission of other STIs is high, screening for
anorectal C. trachomatis infection should be added to the other routine
screening of homosexual men who report unprotected receptive anal sex.
P689 Characteristics of patients infected with Mycoplasma genital-
ium in an STI outpatient clinic, Rotterdam, the Netherlands
J. Ossewaarde, E. Lanjouw, L. Roorda, O. Pontesilli °, W. van der
Meijden (Rotterdam, NL)
Objectives: Emerging STIs are a continuing challenge for diagnosis.
Known diseases emerge with new clinical presentations, like LGV in
MSM, while diagnosis of others, like M. genitalium (Mg), becomes
possible through new PCR technology.
Methods: Standard STI care was provided for all patients attending the
STI-outpatient clinic. From January until June 2008, 1362 consecutive
specimens submitted for Chlamydia trachomatis testing were collected
and used for Mg DNA detection by real-time PCR. DNA was isolated
from all specimens using NucliSENS reagents and easyMAG equipment.
Primers and probe were previously validated (Jensen et al., 2004). When
the Mg Ct value was >35, specimens were completely retested. Addition
of phocine herpes virus (phHV) to the clinical specimens was used as an
internal control for lysis and ampliﬁcation. A phHV Ct value of >35.7
(historical mean plus 1.5×SD) was regarded as inhibition.
Results: One hundred ﬁfteen specimens (8.4%) had a phHV Ct value
>35.7 and Mg Ct value of >50 and were regarded as not suitable for PCR
diagnosis. Of these specimens, 85 were self-collected vaginal swabs, 15
were cervical/urethral swabs, and four were urines. Of the remaining
specimens, six had a Mg Ct value of >35, but were negative upon
retesting. Thirty-two specimens had a Mg Ct value of >35 and were again
positive on retesting. Thirty-ﬁve specimens had a Mg Ct value between
25 and 35. These 67 specimens (4.9%) were regarded as positive: one
throat specimen, ﬁve penile swabs, seven cervical/urethral swabs, 10
rectal swabs, 21 urines, and 23 vaginal swabs. From 42 Mg positive
patients (21 males and 21 females; age 18 to 62 years) further data
were available. Twenty-ﬁve (60%) had no concurrent STI and 21 (50%)
no history of other STIs. Twenty-nine (69%) reported no symptoms
and 10 (24%) one or more symptom, two of which had another STI
compatible with those symptoms. Thirty-three (79%) reported vaginal
sex only, seven (17%) anal sex only, and one both types. In all but one
case the sex was unprotected.
Conclusion: Mg is an emerging pathogen, that is claiming its place. In
this study we have shown that the incidence of infections is at least 4%.
Only one in every three patients will report symptoms. All infections
are the outcome of unprotected sex. Thus, in empiric syndromic therapy
the physician should take the possibility of an infection with Mg into
account, especially when standard therapy for Chlamydia trachomatis
fails to cure the symptoms.
P690 Micro-organisms isolated from male urethral exudates
during an 8-year period in a Spanish teaching hospital
M.C. Martı´nez °, D. Domingo, S. Agudo, M.J. Moreno, M. Lopez-Brea
(Madrid, ES)
Aim: The main aim of this study was to describe the microorganisms
isolated from male urethral exudates, from 2000 to 2008 at the
Microbiology Department of La Princesa University Hospital in Madrid.
Methods: Eight hundred and eighty six samples obtained from
urethral exudates from men with symptoms of urethritis were collected
by standard procedures. They were examined by Gram stain and
inoculated on blood agar medium, chocolate agar medium and modiﬁed
Thayer-Martin medium and incubated at 37ºC in O2, and 10%
CO2 until 48 hours. Subsequently, they were identiﬁed by API NH
(BioMerieux), by MicroScan (Dade Behring), CHROMagar Candida
(Becton Dickinson/BBL) and Auxacolor.
Results: A total of 290 samples (32.73%) were considered of
microbiological value and informed to the clinician. According to
the positive samples, the percentage of isolated microorganisms were
as follows:14.45% of Neisseria gonorrhoeae, 4.17% of Haemophilus
parainﬂuenzae (groups II and III), 5.64% of Gram-positive cocci, 4.74%
of Gram-negative rods and 3.72% of Candida sp.
The average age for each group of microorganism isolated was: 33.78 for
N. gonorrhoeae, 32.65 for H. parainﬂuenzae, 49.18 for Gram-positive
cocci, 67.88 for Gram-negative rods and 66.10 for Candida sp.
The resistance rate of N. gonorrhoeae to the antimicrobian agents
studied, increased considerably during the period.
Conclusions: According to positive cultures, the most prevalent mi-
croorganism isolated from urethral exudates was Neisseriae gonorrhoeae,
followed by Gram-positive cocci, Gram-negative rods, Haemophilus
parainﬂuenzae and ﬁnally Candida sp. By age group, Neisseria
gonorrhoeae and H. parainﬂuenzae were more prevalent in young adults,
Gram-positive cocci had a scattered distribution and Gram-negative rods
and Candida sp. were isolated more frequently in elderly. The high rates
of resistance of N. gonorrhoeae may difﬁcult the treatment of gonococcal
infection in the next years.
P691 Seroepidemiological survey of viral hepatitis, HIV, syphilis
and herpes simplex virus in a Portuguese correctional facility
N. Marques °, R. Margalho, M.J. Melo, F. Coelho, J. Oliveira, V. Silva,
J. Saraiva da Cunha, J. Lemos da Silva, A. Melic¸o-Silvestre (Coimbra,
PT)
Objectives and Methods: Prison inmates are reported to have higher
rates of transmissible infectious diseases, particularly blood-borne virus
and sexually transmitted infections than the general population. This
cross-sectional study conducted during December 2007 to January 2008
and March to June 2008 was aimed to determine the seroprevalence for
viral hepatitis (HAV, HBV, HCV), human immunodeﬁciency virus (HIV),
syphilis and herpes simplex virus (HSV-1 and HSV-2) in prison inmates
of a regional Portuguese prison. The following serological techniques
were used: CMIA (“chemiluminescent microparticle immunoassay”) for
viral hepatitis and HIV (conﬁrmed by “western blot”); RPR (“rapid
plasma reagin”) and TPPA (“Treponema pallidum particle agglutination
assay”) for syphilis and ELISA (“enzyme-linked immunosorbent assay”)
for HSV.
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Results: During the study periods, 151 (71.6%) of 211 male inmates
accepted to be screened for the mentioned infectious diseases. The
mean age was 34.1±10.8 [19−75] years. Anti-HAV was positive in
69.5% (n = 105). The rate of anti-HCV+ was 34.4% (n = 52). One (0.7%)
person had HBs Ag and 29 (19.2%) had past HBV infection (anti-
HBc + anti-HBs). Nonimmune inmates for HBV were 40.4% (n = 61).
Syphilis was diagnosed in 6.0% (n = 9). The rate of HIV infection
was 6.6% (n = 10; all HIV-1). The majority (n = 8) of HIV-infected
inmates were co-infected with HCV. The seropositivity of HSV-2 (most
common cause of genital ulceration) was 19.9% (n = 30) and of HSV-
1 was 82.1% (n = 124). Alcohol dependence was reported by 26.5%
(n = 40). Excluding tobacco and prescription medication, 73.5% (n = 111)
reported drug use in prison. The most commonly used drugs were:
cannabis (100%; n = 111) followed by heroin (56.7%;n = 63). Methadone
maintenance treatment was reported by 12.6% (n = 19). In prison, 43%
(n = 65) had received a tattoo and 3.3% (n = 5) a piercing.
Conclusions: The rate of HCV antibody was noteworthy. Vaccination
for HBV should be offered for nonimmunes. HIV infection rate (6.6%)
in Coimbra’s Regional Prison is at least 13 to 22 times greater than in
general population. As the inmate‘s return to community increases the
risk of disease exposure for the general population, early detection and
counselling is urgently needed for prisoners.
This study was sponsored by a grant of Portuguese Society of Clinical
Microbiology and Infectious Diseases – Abbott Virology.
P692 Prevalence of syphilis in volunteer blood donors in a deﬁned
area of northern Greece: a retrospective study (1998–2008)
A. Karantani °, A. Ioakimidou, A. Michailidou, S. Georgousi,
A. Chatzimichailidou (Giannitsa, GR)
Objectives: Syphilis is a sexually transmitted disease caused by
Treponema pallidum. Transfusion syphilis was once a serious problem
but nowadays cases are very rare in the Western World due to the parallel
decline of the prevalence of the disease. In Greece, blood donors are
being routinely screened for syphilis by non-treponemal serological tests
such as rapid plasma reagin (RPR). The aim of this retrospective study
was to determine the prevalence of syphilis among the healthy blood
donors of the City of Giannitsa of Northern Greece during a ten-year
period of time.
Methods: During the last decade (October 1998 to October 2008)
sera from 25551 consecutive blood donors were screened for syphilis
using a comercial non-treponemal serological test, the rapid plasma
reagin-RPR (Omega Diagnostics, Scotland, United Kingdom). The RPR-
positive samples were further examined by speciﬁc treponemal tests in
a reference laboratory. The speciﬁc treponemal tests that were used
were the Treponema pallidum haemagglutination test (THPA) and the
ﬂuorescent treponemal antibody absorbtion test (FTA-ABS).
Results: During the study only one serum sample was found RPR-
positive. The diagnosis of syphilis was conﬁrmed by both THPA and
FTA-ABS tests. The blood donor was male without clinical symptoms
and the diagnosis of “syphilis incognito” was made.
Conclusions: Although the practically zero prevalence of syphilis among
the healthy blood donors of our area indicates that syphilis is not a major
problem for transfusion medicine, the case of syphilis described above
should keep alert the Blood Services of our area, especially when fresh
blood components are needed.
P693 Rising rates of syphilis in Bilbao health area between 2001
and 2007
P. Liendo, G. Ezpeleta, M. Perez, V. Esteban, R. Cisterna ° (Bilbao, ES)
Introduction: The epidemiology of sexually transmitted infections (STI)
is clearly related to many socio-cultural factors and major changes in
STD epidemiology have been noted since the onset of the HAART
therapy. A dramatic increase in frequency of different STIs was noted
in Bilbao over the past six years.
Aim: The aim of this study is to describe the syphilis cases identiﬁed at
the Serology Laboratory at Basurto Hospital (SLBH) between 2001 and
2007 in Bilbao health area.
Material and Methods: All serological specimens for syphilis testing
between 2001 to 2007 from different medical providers located in
Bilbao health area were included in this study. We used an ELISA IgG
assay for syphilis serological screening and in positive cases a RPR
and FTA syphilis conﬁrmatory test was performed. All early syphilis
cases (primary, secondary, and early latent syphilis) are interviewed
by STI specialists regarding history of symptoms, demographics, risk
behaviours, and partner contact information for case ﬁnding and partner
notiﬁcation. We used standard CDC contact periods as the time period
of interest when interviewing patients.
We used Fisher’s Exact test to compare categorical variables and
Wilcoxon rank sum test to examine differences in the number of sexual
partners reported by patients. We also calculated rates of early and latent
syphilis cases and trends in numbers of persons tested and diagnosed
through screening and partner notiﬁcation from 2001 to 2007.
Results: Early syphilis cases increased continuously from 2001 to 2007
with 87% occurring among men who have sex with men (MSM).
Ninety ﬁve percent of cases were men and the average age were bigger
than the age recorded in women cases. Four percent of patients were
diagnosed of HIV infection in the same STI episode. Despite public
awareness campaigns, increased publicly ﬁnanced syphilis screening
among MSM and intensiﬁed partner notiﬁcation efforts, the prevalence
of early syphilis cases among screened populations was low (13%) and
most (67.9%) of syphilis cases were diagnosed after seeking care for
symptoms.
The proportion of cases diagnosed through screening and partner
notiﬁcation did not signiﬁcantly change during the evaluation period,
but early syphilis incidence among MSM more than doubled between
2004 and 2007.
Conclusions: New, innovative approaches to syphilis control are needed.
P694 A multi-centre prospective study of risk factors for
Jarisch-Herxheimer reactions after penicillin therapy among
persons with syphilis
C.J. Yang °, H.C. Lee, C.H. Liao, W.H. Sheng, Y.C. Lo, W.C. Ko,
C.H. Wu, W.C. Liu, P.Y. Wu, C.C. Hung, S.C. Chang (Taipei, Tainan, TW)
Objectives: Risk factors for development of Jarisch-Herxheimer (JH)
reactions are rarely investigated in persons with syphilis who received
penicillin therapy according to treatment guidelines for syphilis. This
study aimed to investigate the factors associated with JH reactions among
persons with syphilis after receipt of standard penicillin therapy.
Methods: Between January 1, 2007 and December 31, 2008, persons
diagnosed as having syphilis were enrolled in this observational study.
Diagnosis of syphilis was made by elevation of Venereal Disease
Research Laboratory (VDRL) titers followed by conﬁrmation with
Treponema pallidum haemagglutination antibody (TPHA) assays. Those
blood specimens tested positive for anti-HIV antibody would be
conﬁrmed by Western-Blot. Penicillin was given for those persons with
syphilis by following the treatment guidelines. The persons receiving
penicillin were contacted by cell phone to inquire reactions following
receipt of standard penicillin treatment. The JH reactions were deﬁned
as fever and/or exacerbation of skin maculopapular rash within 24 hours
of receipt of penicillin therapy.
Results: During the 2-year study period, 125 HIV-infected persons and
61 HIV-uninfected persons who received penicillin for syphilis were
enrolled. JH reactions developed in 28% (35/125) of the former group
and 13.1% (8/61) of the latter group. In univariate analysis, we found
that persons with non-latent (primary or secondary) stage of syphilis,
higher VDRL titers (1:32), and having HIV infection were more likely
to develop JH reactions than those with latent syphilis, lower VDRL
titers and without HIV infection, respectively (all comparisons, p< 0.05).
In multivariate logistic regression analysis, we found that non-latent
stage was the only independent factor that was associated with the
development of JH reactions, with an odds ratio of 5.72 (95% conﬁdence
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interval, 2.66−12.3), while HIV infection was of borderline statistical
signiﬁcance in association with JH reaction (OR 2.30, 95% CI 0.87−6.06,
and p = 0.09).
Conclusion: Non-latent syphilis was associated with higher risk for
JH reactions in persons who received penicillin therapy according to
treatment guidelines. A larger sample size of subjects is needed to
conﬁrm if HIV infection is an independent factor for development of
JH reaction.
P695 Evaluation of Chlamydia trachomatis and Neisseria
gonorrhoeae infections in patients visiting gynaecology
department of hospitals in Delhi using an in-house PCR
assay and ELISA-based method of detection
A. Patel °, D. Sachdev, P. Sachdeva, D. Saluja (New Delhi, IN)
Infection by Chlamydia trachomatis (CT) and Neisseria gonorrhoeae
(NG) is asymptomatic especially in women. Although completely curable
by antibiotic, undetected infections by CT and NG can lead to various
complications and transmission of infection. In developing countries,
STI laboratories are limited or absent. An early, affordable and rapid
diagnosis will be a valuable tool for control of NG and CT. We have
developed and evaluated an in house PCR and ELISA assays for CT and
NG detection and show high prevalence of infections in females.
Objectives:
1. To develop sensitive, rapid and point of care test for diagnosis of CT
and NG and its evaluation.
2. To study the prevalence of infection in females from low resource
income.
Methodology:
1. For in house PCR assay unique gene sequences of CT and NG, were
ampliﬁed from gDNA isolated from endocervical swabs of about
200 patients aging 15−42. Molecular beacons were used to increase
the sensitivity of PCR.
2. Proteins unique to CT and NG were cloned and puriﬁed. Sera of
patients was tested for antibodies against these proteins in ELISA
format.
3. Sensitivity and speciﬁcity were calculated using commercial kit as
gold standard.
Results: Out of 200 patients 41 patients were positive for CT (21%)
and 53 were positive for NG (27%) and 38 were co infected (19%), with
high prevalence in females with history of ectopic pregnancy and primary
infertility. Using Roche Amplicor Micro well plate test as gold standard,
the sensitivity and speciﬁcity of the in-house PCR assay was found to
be 93% and 97.45%, for CT, while it was 88% and 82% respectively
for NG. Use of molecular probes further increased the sensitivity of
the assay and reduced the time for analysis making it a rapid point of
care test. An ELISA based detection assay was also developed using
puriﬁed proteins of NG and CT cloned in bacterial expression vector.
Serum samples of the patients and healthy volunteers were checked for
determining the speciﬁcity and sensitivity and validated by PCR assay
of endocervical swabs.
Conclusion: Our results show high prevalence of infection of NG
and CT in young females from low resource setting. The in house
developed PCR and ELISA are highly sensitive and cost effective
method for the diagnosis of NG and CT and can provide an alternative
diagnostic method for management of genital infection in India and other
developing countries.
P696 Azithromycin-resistant Neisseria gonorrhoeae strains recently
isolated in Italy
S. Starnino, P. Stefanelli °
on behalf of the Italian Neisseria gonorrhoeae Study Group
Objectives: Azithromycin (AZM) is not routinely used to treat
gonorrhoea in our country but it is widely employed to treat Chlamydia
co-infection, as recommended by the CDC guidelines for treatment of
sexually transmitted diseases. In this study, AZM susceptibility of 219
gonococcal strains, during the evaluation of the prevalence of antibiotic
resistance in Italy from January 2007 through June 2008 and the asso-
ciated patient demographics and clinical characteristics, were assessed.
Methods: Minimum inhibitory concentrations (MICs) of azithromycin
(AZM), ciproﬂoxacin (CIP), ceftriaxone (CRO), penicillin (PEN), and
tetracycline (TET) were determined by E-test method. The AZM
resistant strains (MIC 1mg/L) were genetically analyzed by Neisseria
gonorrhoeae Multi Antigen Sequence Typing (NG-MAST) and Pulsed
Field Gel Electrophoresis (PFGE).
Results: A total of 22 AZM gonococci resistant strains were found
among 219 collected in the study period. Five of the 22 strains showed a
high level of AZM resistance with MIC values of 128 or 256mg/L. Two
of the latter showed a multidrug resistance phenotype. In particular, one
strain was resistant to CIP (8mg/L), PEN (32mg/L) and TET (128mg/L)
and the other to CIP (12mg/L) and TET (256mg/L). All the strains
were fully susceptible to ceftriaxone. Moreover, the resistant strains were
mainly (17 out of 22) isolated among men having sex with men (MSM),
Italians and resident in Rome. Among all the resistant strains NG-MAST
analysis revealed the presence of 14 different Sequence Types (STs).
PFGE showed the presence of 4 clusters among strains isolated from
patients with similar epidemiological characteristics.
Conclusions: This is the ﬁrst report describing azithromycin resistant
N. gonorrhoeae strains in Italy. Interestingly, a high level of resistance
was detected for 5 of the 22 AZM resistant gonococci. Genetic
relatedness was found among some resistant strains. This study
represents a reference point for future surveillance in Italy and suggests
the need to add azithromycin in the antibiotic susceptibility panel for
gonococcus to monitor the drug’s efﬁcacy with particular regard to
people at high risk for sexually transmitted infections.
P697 Multiple mutations and change in conformation of Mtr efﬂux
pump leading to penicillin resistance in Neisseria gonorrhoeae
D. Sachdev °, P. Sachdeva, M. Bala, J. Zack, A. Patel, D. Saluja (New
Delhi, IN)
Neisseria gonorrhoeae, (NG), facultative intracellular pathogen causes,
gonorrhoea, a sexually transmitted disease. Strains resistant to penicillin,
a common drug used in developing countries for its treatment, have
become prevalent world wide. This is attributed to presence of beta-
lactamase encoding plasmids (PPNG strains) or active removal of
the drug due to increased expression of the MtrCDE efﬂux pump
(chromosomal mediated resistance). The expression of efﬂux pump is
negatively controlled by MtrR protein. Mutations in MtrR or in the
promoter region of Mtr operon lead to increased expression of the efﬂux
pump (MtrCDE). This leads to increased drug resistance among NG
strains. Mutations in MtrE have also been shown to be associated with
increased resistance towards hydrophobic drugs.
Objectives:
a. Analysis of mutations in MtrR and MtrE genes of penicillin resistant
clinical isolates.
b. Structure analysis of MtrE and MtrR in context of mutations.
Methodology:
a. PCR ampliﬁcation and sequencing of the amplicons of MtrR and
MtrE genes from penicillin resistant clinical isolates.
b. Mutation analysis of amplicons using BLAST and ClustalW.
c. Structure analysis of MtrE and MtrR using Insight II program.
Results: Mutations were found in helix turn helix motif of MtrR (L33V,
G45D) and in its C′ terminal (Y105H) region. Mutant MtrR protein
shows reduced binding afﬁnity to its promoter leading to increased ex-
pression of MtrCDE efﬂux pump thereby causing resistance to penicillin
and other hydrophobic drugs. Analysis of nucleotide sequence of MtrE
also showed distinct mutations (I429S, K165E, K191R, and R285G) in
different clinical isolates with K191R as the most frequent mutation
observed. Strains with mutations in both MtrR and in MtrE showed
higher MIC values (16 to 22 microgram/ml). PPNG strains with mutant
MtrR or MtrE had even higher MIC for penicillin (32 microgram/ml).
In-silico modeling of MtrE protein indicates that mutations (K191R and
R285G) in MtrE distorts hydrogen bonding and thus results in structural
changes which may be responsible for altering efﬂux activity.
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Conclusion: Mutations at multiple loci act in synergism with each other
to confer high penicillin resistance to NG strains.
P698 Screening of macrolide resistance locus in Treponema
pallidum subsp. pallidum in the Czech Republic
P. Matejkova´ °, M. Flasarova´, H. Za´koucka´, M. Borek, S. Kremenova´,
P. Arenberger, V. Woznicova´, G.M. Weinstock, D. Smajs (Brno, Prague,
CZ; St. Louis, US)
Objectives: Due to alergies to penicillin, macrolide regimens are
frequently applied in the treatment of syphilis. Unlike penicillin,
macrolide treatment represents a risk of treatment failure due to
chromosomally encoded resistance in Treponema pallidum subspecies
pallidum. A2058G mutation in the 23S rDNA locus was described to
cause erythromycin resistance in syphilis. Molecular detection of syphilis
represents the only available test to reveal macrolide resistance in clinical
isolates, because T. pallidum can not be cultured in vitro. Our aim was
to assess the incidence of this mutation among clinical isolates in the
Czech Republic.
Methods: Primary screening of clinical specimen included nested PCR
detection of two T. pallidum speciﬁc loci (tmpC, polA). In PCR positive
samples, 23S rDNA was ampliﬁed. Nested PCR protocol to detect
23S rRNA gene was developed and direct Sanger sequencing of PCR
products was applied to detect mutations in corresponding part of the
23S rRNA gene.
Results: The set of 28 clinical isolates with detectable genetic material
were collected from 22 patients in the Czech Republic in the time period
2005–2008. 14 patients (63.6%) were infected with macrolide sensitive
strains of T. pallidum. Four patients (18.2%) were diagnosed with a strain
bearing the A2058G transition and four patients (18.2%) with a strain
bearing the A2059G mutation (spiramycin treatment failure was reported
in one of these patients). There was a complete concordance of multiple
samples collected from the same patient.
Conclusions: Screening of clinical samples revealed a novel mutation
at the position 2059 of the T. pallidum 23S rRNA gene. This mutation
causes macrolide resistance in several other bacteria.
Our results show that macrolide resistant isolates of T. pallidum bearing
A2058G and A2059G mutations are relatively abundant in the Czech
Republic, possibly causing macrolide treatment failures in penicillin
alergic patients.
This work was supported by the grants from the Internal Grant Agency
of the Ministry of Health of the Czech Republic (NR/8967−4/2006) and
from the Grant Agency of the Czech Republic (310/07/0321).
P699 Prevalence and antimicrobial susceptibilities of genital
mycoplasmas in outpatients with clinical urogenital infections
in Korea
H.J. Kim °, J.H. Lee, N.Y. Lee (Seoul, KR)
Objectives: The aim of present study was to evaluate the occurrence
of Ureaplasma urealyticum and Mycoplasma hominis in patients
with clinical urogenital infections and to determine the antimicrobial
susceptibilities for the most suitable treatment strategy.
Methods: 963 vaginal or urethral swabs were collected from 535
outpatient women and 255 urethral swabs were collected from 239 men.
The identiﬁcation of the genital mycoplasmas as well as the antimicrobial
testing were performed using A7 Mycoplasma agar plates (bioMerieux,
Marcy l’Etoile, France) and the Mycoplasma IST 2 commercial Kit
(bioMerieux, Marcy l’Etoile, France).
Results: Of the 294 positive specimens from women, 263 (89.5%)
and 7 (2.4%) were positive for U. urealyticum and M. hominis as a
single pathogen, respectively. Both urogenital mycoplasmas were grown
in 5.4%. The majority of U. urealyticum isolated were susceptible to
tetracycline, doxycycline and azithromycin (89.4%, 95.8% and 92.0%,
respectively), while ciproﬂoxacin and oﬂoxacin proved to be inactive
against most of the strains. All of the M. hominis isolates were
completely susceptible to doxycycline and about half of the isolates were
susceptible to ciproﬂoxacin, oﬂoxacin, erythromycin, azithromycin and
clarithromycin. Of the mixed isolates of U. urealyticum and M. hominis,
68.8% were susceptible to doxycycline. 18 positive specimens were
obtained from men and only U. urealyticum strains were isolated, the
susceptibilities of them resembled those of U. urealyticum from women.
All of the strains of mycoplasma were 100% susceptible to pristinamycin.
In every positive specimen the colonies of U. urealyticum or M. hominis
were observed on A7 agar plate by direct microscopy.
Conclusions: Of the patients with suspected urogenital infections
U. urealyticum orM. hominis were isolated in 33.5% of women and 7.5%
of men. In the evaluation of antibiotic susceptibility, the higher resistance
was obtained against oﬂoxacin and ciproﬂoxacin by U. urealyticum, and
against erythromycin, azithromycin and clarithromycin by M. hominis.
Mixed infection of U. urealyticum and M. hominis had higher resistance
to most antibiotics. The present results suggested that doxycycline would
be the ﬁrst choice when empirical treatment is necessary in our hospital.
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P700 Evaluation of EDTA and dipicolinic acid, with and without the
addition of zinc, in the detection of metallo-beta-lactamases
M. O¨sterblad °, P. Huovinen, J. Jalava (Turku, FI)
Objectives: Carbapenem-resistant Gram-negative bacteria carrying
transferable resistance genes are spreading worldwide, and to stop local
epidemics we must be able to detect them. Phenotypic detection of
carbapenemases belonging to the metallo-beta-lactamases (MBL) is
problematic. We compared the performance of the enzyme inhibitors
EDTA and DPA in different combinations with imipenem (IMI),
meropenem (MRP) and ceftazidime (CAZ).
Methods: We tested 16 strains with known MBLs (11 VIM, 3 IMP,
1 GIM, 1 SPM), 27 with known serine beta-lactamases including
TEM, SHV, CTX-M and GES, of which 16 were ESBLs, and 2 KPC
carbapenemases, 24 IMI-resistant Pseudomonas aeruginosa strains with
unknown resistance mechanisms, and 16 IMI-resistant Acinetobacter
baumannii strains with different OXA-genes.
Conﬂuent suspensions were plated onto Mueller-Hinton II agar with or
without the addition of 70mg/l of ZnSO4x7H2O. Five Rosco tablets
(CAZ, DPA, MRP, IMI+EDTA, IMI) were placed in a row, at a distance
of 10mm edge-to-edge to the next. A CAZ+DPA tablet was placed
separately. IMI+EDTA zone diameters >4mm compared to IMI zones,
and CAZ+DPA vs. CAZ were read as positive, as recommended by the
manufacturer. Synergy (keyhole zones) between tablets (CAZ and DPA,
DPA and MRP, MRP and EDTA, IMI and EDTA) was noted. Hydrolysis
of IMI was measured spectrophotometrically for the P. aeruginosa and
A. baumannii strains. MBL genes were screened by PCR.
Detection of metallo-betalactamases: zone diameter differences between
imipenem vs. imipenem+EDTA, and ceftazidime vs. ceftazidime+DPA.
Results: IMI+EDTA zone mm differences detected all 16 known MBL
strains, EDTA synergy only 9, CAZ+DPA zone mm differences detected
13, and DPA synergy 12. Zinc addition lowered the sensitivity of all
methods, due to smaller zones. The serine beta-lactamases were generally
interpreted as negative; DPA+zinc was worst with 4 false positive. The
P. aeruginosa strains (no MBL genes found) tested false positive in
10/24 cases both by EDTA and DPA; addition of zinc lowered the number
of false positives (4/7). The P. aeruginosa mm differences overlapped
with those of the MBL strains (Figure). IMI was hydrolysed well by 1
strain and weakly by 5. The A. baumannii strains were false positive in
6/16 cases by EDTA; addition of zinc increased this to 11/16. With DPA
there were no false positives; addition of zinc gave 1.
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Conclusion: Zone mm difference comparison of IMI and IMI+EDTA
was found to be the most sensitive method. Sensitivity of DPA was low
due to the small CAZ zones of MBL strains. Zinc improved only the
P. aeruginosa results.
P701 Evaluation of drug-drug interaction study of zaboﬂoxacin in
vivo
S.K. Ku, S.K. Seong °, S.H. Lee, D.R. Choi, J. Rock, J.M. Ryu
(Gyeongsan, Anyang, KR; San Diego, US)
Objectives: Zaboﬂoxacin, a new ﬂuoroquinolone (FQ) antibiotic in a
phase II study for community-acquired pneumonia (CAP), has a broad
spectrum and a great potential against Gram-positive bacteria including
S. pneumoniae and some quinolone resistant bacteria. Although FQs are
associated with a low incidence of CNS disorders, they may occasionally
induced convulsive seizures, especially in patients receiving FQs
in combination with non-steroidal anti-inﬂammtory drugs (NSAIDs),
epileptic seizures in patients receiving both FQs and theophylline, and
prolongation of prothrombin time (PT) due to a possible interaction
between many FQs and warfarin. The purpose of this study was to
investigate drug-drug interactions between zaboﬂoxacin and NSAIDs,
theophylline and warfarin.
Methods: Zaboﬂoxacin and other FQs [gatiﬂoxacin (gati), levoﬂoxacin
(levo), ciproﬂoxacin (cipro)] were administered once orally to ICR mice
at doses of 1000mg/kg (n = 6 or n = 7) with pretreatment of NSAIDs
(fenbufen, BPAA, indomethacin, aspirin and celecoxib), theophylline
and warfarin (once orally, 400 or 200mg/kg). Mice receiving FQs with
NSAIDs and theophylline were monitored for neurotoxic signs, such as
tonic extensor, convulsion and mortality within 2 hours after the FQs
dose. Mortality within a day was also monitored. In mice pretreated
with wafarin, the PT was determined at 24 hrs after FQ dosing.
Results: Gati, levo and cipro showed relatively severe neurotoxic signs
when administered with NSAIDs and theophylline. In addition, these
FQs demonstrated a signiﬁcant prolongation of PT compared to that of
vehicle control groups. No neurotoxic signs and prolongation of PT were
observed in zaboﬂoxacin-dose groups.
Conclusion: Zaboﬂoxacin demonstrated a favourable drug-drug interac-
tion proﬁle compared to other FQs in ICR mouse when given to ICR
mice pretreated with NSAIDs (fenbufen, BPAA, indomethacin, aspirin
and celecoxib), theophylline and warfarin at doses of 200 and 400mg/kg.
P702 In vitro antibacterial and anti-pathogenic activity of
colistin, azithromycin and their combinations against
colistin-susceptible and -resistant Pseudomonas aeruginosa
C.H. Tan °, J. Li, L. Turnbull, C.B. Whitchurch, J.D. Turnidge,
R.L. Nation (Melbourne, AU)
Objectives: Infections caused by multidrug-resistant Pseudomonas
aeruginosa (PA) have become a critical challenge and colistin (COL) is
often used as ‘salvage’ therapy. The pathogenicity of PA is attributable
to the arsenal of pathogenic factors, e.g. quorum sensing, bioﬁlm and
pyocyanin production. Azithromycin (AZM), has been shown to have
beneﬁcial effects on these factors but PA is resistant to AZM. The study
evaluated COL and AZM, both alone and in combination, in regard to
antibacterial activity and effects on pathogenic factors.
Methods: COL susceptible PAO1 and 3 clinical isolates (COLS,
MIC 2mg/L) and 4 COL resistant isolates (COLR, MIC 8–128mg/L)
were studied; all had AZM MICs> 128mg/L. Studies were performed
in 96-well plates. Multiples of the COL MIC up to their respective
MICs were used for COLS. For COLR, 2, 4, 8mg/L COL were
used (all clinically relevant). Clinically achievable 0.125, 0.25, 0.5,
1, 2mg/L AZM were used. Untreated controls were included. Assays
were conducted at 24 h or 48 h depending on the isolate. Antibacterial
effect was measured by viable counting. Synergy was regarded
as fractional inhibitory concentrations  0.5. Analytical methods
based on LCMS and HPLC were developed to assay the quorum
sensing molecule N-3-oxododecanoyl-homoserine lactone (C12-HSL)
and pyocyanin, respectively (limits of quantiﬁcation 0.5mg/L and
0.2mg/L, respectively). Bioﬁlm was assayed using crystal violet.
Results: Synergy was bidirectional. A marked synergy was observed
against COLR, e.g. decreasing the AZM MIC from >128mg/L to 2mg/L
and COL MIC from 128mg/L to 4mg/L. Combinations had greater
antibacterial activity, relative to COL and AZM alone, against COLR.
For all isolates, sub-MIC AZM substantially reduced, in a concentration-
dependent manner, the production of C12-HSL and pyocyanin (up to
>90% reduction), an effect COL enhanced. COL at the MIC reduced by
>90% the amount of bioﬁlm formed by COLS; AZM effect was minimal.
In general, COLR formed relatively poorly-stained bioﬁlms; clinically
relevant, but sub-MIC, concentrations of COL were without effect while
1mg/L and/or 2mg/L AZM usually increased bioﬁlm formation. The
effects of combinations on bioﬁlm formation were variable across strains.
Conclusions: The ﬁndings showed the potential beneﬁts of combining
COL and AZM, particularly against COL^R. The effects on key
pathogenic factors provide potentially important infection management
strategies.
P703 Interactions between linezolid and a carbapenem on
methicillin-resistant Staphylococcus aureus
J.M. Sahuquillo-Arce °, E. Colombo, A. Valentin, J. Garcia,
M. Gobernado (Valencia, ES)
Objectives:Methicillin-resistant Staphylococcus aureus (MRSA) is both
a therapeutic and epidemiologic challenge. Eradication from an infection
site might require the use of potent antibiotics or the combination of
different ones. In this study we analyse the performance of linezolid in
combination with two carbapenems on two different clones of MRSA
from our hospital, by means of a variation of the microdilution dynamic
checkerboard (MDCh), that is, time-kill curves (TKC) in a microdilution
fashion.
Methods:MICs for both MRSA clones were calculated by microdilution
in cation-adjusted Muller-Hinton broth. MDCh for meropemem and
ertapenem were evaluated at concentrations ranging from 1/1024 to
1× MIC, combined with linezolid at 1 and 4× MIC in 200-microliter
96-well microtitre plates. Microtitre TKC were performed for 1×MIC
of linezolid plus 1/32× MIC of each carbapenem (a different microtitre
plate was seeded for each CFU/ml counting time). MRSA viable cells
were counted at 0 and 24 hrs for the MDCh and at 0, 6 and 24 hrs for
micro TKC, by seeding 100 microlitres of each well on blood agar plates
at 10-fold serial dilutions.
Results: Linezolid alone showed its maximum bacteriostatic effect at
4−8× MIC. MDCh showed a synergistic effect for the combination of
1× MIC of linezolid plus both carbapemens at concentrations ranging
from 1/64 to 1/8× MIC. No synergy was observed in any of the
combinations of linezolid at 4× MIC, moreover, a tendency towards
antagonism was seen the higher the amount of carbapenem present
in the combination. Discrepancies have been reported when different
methods are employed, but micro TKC yielded similar results for the
combinations carried out, without disagreement with the other two
procedures, as for the MICs or the ﬁnal effect.
Conclusions: Linezolid at 1× MIC in combination with a carbapenem
under their MIC exhibited a synergistic effect on MRSA. This was not
seen with higher concentrations of linezolid. Our work hypothesis for
future studies is that linezolid at low concentrations allows some bacterial
growth, but restrains mecA by means of inhibiting PBP2′ formation, this
lets carbapenems to act on the cell wall formation. Higher amounts of
linezolid block bacterial metabolisms, thus, no synergy can be seen.
On the other hand, micro TKC has proven to be material and time saving,
and an easy and cheap procedure for basic research on drugs interaction,
as well as teaching. It also offers the possibility for automation.
P704 In vitro synergistic activity of ceftriaxone, rifampicin and
doxycycline against Brucella melitensis isolates by E-Test
C. Bulut, M.A. Yetkin, F. Erdem, F. Ergin, C.A. Hatipoglu °, S. Kinikli,
A.P. Demiro¨z (Ankara, TR)
Objectives: Brucellosis is a zoonotic disease seen world-wide including
Turkey. Ceftriaxone is used as a treatment option in neurobrucellosis
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cases in our country. In our study in vitro synergistic activities of
ceftriaxone doxycycline and rifampicin were investigated.
Methods: In vitro activities of antimicrobial agent combinations
were tested against Brucella melitensis strains isolated from 18 pa-
tients treated at Infectious Diseases and Clinical Microbiology
Department of Ankara Research and Training Hospital. In vitro
effectiveness of ceftriaxone-doxycycline, rifampicin-doxycycline and
ceftriaxone-rifampicin combinations were tested by E test method.
The fractional inhibitory concentration (FIC) index was calculated as
FIC = /MICA-B/MICA+/MICB-A/MICB. The interactivity of in vitro
combinations was evaluated as synergism, additive, indifference and
antagonism depending on the conclusions of FIC index calculated for
each strain.
Results: The MIC50 and MIC90 of isolates to ceftriaxone doxycycline
and rifampicin were 0.5mg/ml and 0.75mg/ml, 0.064mg/ml and
0.125mg/ml and 0.19mg/ml and 0.38mg/ml, respectively. Synergism was
found in 14 strains (78%) with ceftriaxone-doxycycline combination and
additive effect was detected in other 4 strain. Whereas only in one strain
(6%) synergistic effect was seen between rifampicin and ceftriaxone
combination. Additive and indifference effects were detected six and
ten strains, respectively. Antagonism was found with this combination
in one strain. With rifampicin-doxycycline combination, in 12 strains
(67%) synergism, in ﬁve strains additive and in one strain indifference
were found.
Conclusion: In our study, all Brucella isolates showed susceptibility
to all the antibiotics tested. The results of this in vitro study suggest
combination of ceftriaxone and doxycyclin as a therapeutic alternative
for neurobrucellosis.
P705 In vitro activity of polymyxin B and rifampicin in
combination against pandrug-resistant Acinetobacter spp.
T.P. Lim °, W. Lee, T.Y. Tan, S. Sasikala, T.T. Tan, L.Y. Hsu, A. Kwa
(Singapore, SG)
Objectives: Outbreaks of pandrug-resistant (PDR) Acinetobacter
spp.(As) have emerged in Singapore. Combination therapy may be
the only viable option until new antibiotics become available. While
polymyxin B (PB) may remain a viable treatment option, heteroresistance
has become a major problem. We evaluate if combination therapy with
PB is warranted and the efﬁcacy of PB and rifampicin (R) combined
against PDR As isolated from our local hospitals, when combination
therapy is needed.
Methods: 361 As isolates from all public hospitals in Singapore were
collected from 2006−07 over 2 months each year and studied. MICs
were determined according to CLSI guidelines and 29 PDR As isolates
were identiﬁed. Emergence of resistance studies (ERS) were performed
with approximately 105 CFU/ml at baseline against 3 isolates (selected
based on the unique genotype that represents the PDR As population)
with PB alone and in escalating concentrations. Serial samples were
obtained over 5 days to determine total and resistant bacteria load.
Resistant sub-population was detected using media plates supplemented
with PB at 3× MIC. (TKS) Time-kill studies (same baseline as ERS)
were performed with the maximum, clinically achievable, unbound
concentration (mcg/ml) of PB (2) and R (2) alone and in combination
against the 29 PDR As isolates.
Results: All 29 PDR As isolates were susceptible to PB
(MICs 1−2mg/L) and resistant to all antibiotic classes whereas R MICs
ranged from 2−16mg/L. In ERS, a signiﬁcant reduction in bacteria
burden was seen for PB (1, 2, 4mg/L). However regrowth was seen at
24 h due to selective amplication of a resistant sub-population(s) for all
3 PB regimens. Repeat MIC testing of the resistant isolates conﬁrms PB
resistance (MICs 32–128mg/L). In TKS screening, PB was bactericidal
after 2 h for all isolates; however, regrowth occurred within 24 hr. R was
bacteriostatic with regrowth by 24 h in all isolates. PB+R achieved
>99% kill from baseline in 16 out of 29 isolates with no regrowth at 24 h.
Conclusions: We have shown that our PDR As has the propensity
to exhibit heteroresistance, and combination therapy with PB is
needed. These ﬁndings demonstrate that in vitro synergy of antibiotic
combinations in PDR As may be strain dependant. PB and R may be
a potential antibiotic combination as a pre-emptive therapy for PDR As
infections and warrants further investigations.
P706 Activity of vancomycin and daptomycin alone and in
combination with gentamycin against Enterococcus faecalis:
interaction studies using a calorimetry assay
G. Munoz °, I. Majic, A. Steinhuber, A. Trampuz (Barcelona, ES;
Basel, CH)
Objectives: Severe enterococcal infections and the antimicrobial
resistance are increasing. Treatment options of these infections are
limited. Vancomycin (VAN) and daptomycin (DAP) are active against
enterococci, but the synergistic effect of gentamicin (GEN) is unclear.
Calorimetry is a highly sensitive method for measurement of heat
production generated by microbial growth. We determined the inhibition
of heat production of Enterococcus faecalis ATCC 10433 incubated with
VAN or DAP alone or in combination with GEN.
Methods: The MIC values of VAN, DAP and GEN were determined
by a gradient strip test (E-Test). Subinhibitory concentrations between
0.062× and 0.5× the MIC were tested. For calorimetry, 4ml-glass
ampoules were ﬁlled with 3ml of TSB containing the respective
antibiotic(s) and 0.1ml saline containing 5×105 cfu/ml of the test strain.
Heat generation of bacterial culture without antibiotic was used as
control. Ampoules were air-tightly sealed and heat production of the
growing cultures at 37ºC was measured continuously in a TAM III 48-
channel batch microcalorimeter (TA Instruments, Newcastle, USA) over
6 h. The peak heat ﬂow (in microWatt) with antibiotic(s) was recorded
and compared with the peak without antibiotic(s). Experiments were
performed in triplicate.
Results: The MIC values were 2 ug/ml for VAN, 1 ug/ml for DAP and
8 ug/ml for GEN. Calorimetry without antibiotics (control) showed a
peak of 305±15 microWatt (100%). When used alone (at 0.5× and
0.2× MIC), DAP inhibited growth-related heat production more
efﬁciently than VAN (59% vs. 88% an 75% vs. 98%, respectively).
The addition of GEN at low concentrations (0.125× and 0.062× MIC)
showed an additional effect on growth-related heat production, whereas
GEN alone at these concentration has no measurable effect on the heat-
ﬂow curve (data not shown).
Conclusions: Using E. faecalis ATCC 10433 as test strain, the
calorimetric assay showed that DAP alone was more active against VAN
alone at the same subinhibtory concentration. The addition of GEN at
low concentrations (0.125× MIC) augmented the anti-enterococcal
activity, whereas GEN alone showed no antimicrobial effect at these
concentrations. Calorimetry has the potential for a rapid and accurate
evaluation of antimicrobial activity and their combinations.
DAP
(×MIC)
GEN
(×MIC)
Peak heat ﬂow VAN
(×MIC)
GEN
(×MIC)
Peak heat ﬂow
0 0 100% 0 0 100%
0.5 0 59% 0.5 0 88%
0.5 0.125 54% 0.5 0.5 66%
0.5 0.062 58% 0.5 0.25 84%
0.25 0 75% 0.25 0 98%
0.25 0.125 72% 0.25 0.5 89%
0.25 0.062 74% 0.25 0.25 99%
P707 Evaluation of the in vitro activity of tigecycline alone and
in combination with rifampicin against multidrug-resistant
Gram-negative bacilli
F. Mzali °, V. Dubois, C. Vidaillac, A. Hoursiangou, C. Quentin
(Bordeaux, FR)
Objectives: The in vitro activity of tigecycline (TIG) was evaluated
against a collection of 107 Multi-drug resistant (MDR) Gram-negative
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bacteria isolated from patients. TIG in vitro activity was compared to
those of tetracycline (TET), doxycycline (DOX) and minocycline (MIN)
and the antimicrobial activity of TIG combined with rifampicin (RIF)
was assessed.
Methods: 107 genetically characterised non related MDR clinical
strains were used in this study (77 Enterobacteriaceae, 18 Pseudomonas
aeruginosa and 12 Acinetobacter baumannii). All isolates harboured
various antibiotic resistant determinants singly or in combination (ESBls,
carbapenemases, chromosomal and plasmid mediated AmpCs). The
MIC of TET, DOX, MIN, TIG and RIF were determined by an agar
dilution method. The activity of TIG combined with RIF was tested
by the checkerboard method. The effect of the drug combination
(TIG + RIF) was estimated at the point of maximal effectiveness by
the fractional inhibitory concentration (FIC) interpreted as follows:
synergy (FIC 0.5), addition (0.5< FIC 1), indifference (1FIC< 2)
and antagonism (FIC 2). PCR using described primers was carried out
to characterise the tetracycline resistance genes present in the strains.
Results: Regression curves between MIC values and zone diameters
showed a good correlation: TET (r = 0.967), DOX (r = 0.930), TIG
(r = 0.949) and MIN (r = 0.871). Based on MIC values, TIG showed
a better in vitro activity than the other tetracyclines (MIC range of
0.015−16mg/L). However, TIG as expected, proved to be less active
against P. aeruginosa strains. The combination of TIG+RIF was in most
cases additive, often synergistic and occasionally indifferent but never
antagonistic. All strains were susceptible to TIG in the presence of
concentration of RIF achievable in vivo except for the P. aeruginosa
strains for which the combination was principally synergistic, but
at concentrations of RIF of 4mg/L and of TIG> 2mg/L which are
higher than the recommended breakpoint. PCR showed the concomitant
presence in the strains of various tetracycline resistance genes.
Conclusions: The results demonstrate the need to test for TIG on MDR
clinical isolates. The excellent in vitro activity of TIG conﬁrmed its
clinical utility against these pathogens. Moreover, combination of TIG
with RIF must be encouraged in order to increase its efﬁciency for
the treatment of infections caused by MDR organisms and prevent the
emergence of resistant mutants.
P708 Mutant prevention concentration of tigecycline and
vancomycin against contemporary clinical isolates of
Clostridium difﬁcile
J. Blondeau °, B. Barks, S. Borsos, S. Sanche (Saskatoon, CA)
Objectives: Clostridium difﬁcile is an important cause of hospital
acquired diarrhoea (CDAD) and is the causative agent of pseudomem-
branous colitis. Numerous different classes of antibacterial agents have
been associated with CDAD, however, in many instances the mechanism
of the association remains unknown. We performed mutant prevention
concentration (MPC) testing of CD isolates (collected September-
December 2008) against tigecycline (TIG) and vancomycin (VAN).
Methods: Minimum inhibitory concentration (MIC) testing was based
on current Clinical and Laboratory Standards Institute procedure
by E-test using 105 cfu/ml on Brucella agar containing 5% sheep
blood. Following incubation (anaerobic), the lowest drug concentration
preventing growth was the MIC. For mutant prevention concentration
(MPC) testing, 109 CFUs were applied to Tryptic soy agar plates
(TSA) containing 5% sheep red blood cells containing doubling drug
dilutions and following incubation (anaerobic), the lowest concentration
preventing growth was the MPC.
Results: For clinical isolates, MIC values (mg/L) for TIG ranged from
0.047 to 0.064 (4 strains). The MIC values (mg/L) for VAN were 0.25 to
0.38 0.5. The MIC values for ATCC strain 9689 were 0.094 (TIG) and
0.5 (VAN). The MPC values (mg/L) were as follows: TIG – 0.063 for
all strains; VAN – 2 to 4. MPC values for ATCC 9689 were 0.125 and
2mg/L respectively. MIC and MPC values for Tig against ciproﬂoxacin
resistant strain (MIC32mg/L) were 0.047−0.094 and 0.063mg/L
respectively; 0.38−1.5 and 2-mg/L respective for vancomycin.
Conclusions: TIG was highly active in vitro against contemporary CD
isolates with MIC and MPC values 0.125mg/L. VAN MPC values
ranged from 2−4mg/L. TIG showed a low propensity to selection for
CD subpopulations with high MPC values. TIG may be useful for therapy
in patients with CDAD.
P709 Comparative minimum inhibitory concentration and mutant
prevention concentration values of cethromycin, azithromycin,
clarithromycin, erythromycin and telithromycin against
clinical isolates of Streptococcus pneumoniae
J. Blondeau °, S. Borsos (Saskatoon, CA)
Objective: Cethromycin (CET) is a ketolide antimicrobial agent with
reported low minimum inhibitory concentration (MIC) values against
macrolide susceptible and resistant pneumococcal strains, however,
limited data exists on MPC activity. The mutant prevention concentration
(MPC) deﬁnes the drug concentration necessary to block the growth of
the least susceptible cell present in bacterial population 109 CFUs. We
compared MIC and MPC values for CET against macrolide susceptible
and resistant Streptococcus pneumoniae (SP).
Methods: For MIC testing, the recommended Clinical and Laboratory
Standards Institute procedure was followed utilising 105 cfu/ml tested
against doubling drug dilutions in Todd-Hewitt broth with incubation at
35−37 degrees Celsius in 5% CO2 for 18−24 hours. For MPC testing,
109 CFUs were added to drug containing agar plates (tryptic soy agar
with 5% sheep red blood cells). Inoculated plates were incubated as
described for 24−48 hours and screened for growth. The lowest drug
concentration preventing growth was the MIC or MPC depending on
method.
Results: For 26 clinical isolates, MIC50/90 values for CET, azithromycin
(AZ), clarithromycin (CL), erythromycin (ER), telithromycin (TEL)
respectively were 0.004/0.008, 0.125/0.25, 0.031/0.063, 0.063/0.063,
0.008/0.016; MPC50/90 values respectively were 0.063/0.125, 1/8,
0.125/4, 0.25/1, 0.031/0.063. CET MPC values ranged from 0.002−0.125
for 10/11 strains with elevated MPC values to AZ. One strain with a
MPC to AZ of 128mg/L had a CET MPC of 2mg/L and TEL MPC
of 0.063mg/L.
Conclusion: CET had low MIC (MIC90 0.008mg/L) and MPC (MPC90
0.125) values against macrolide susceptible and resistant SP. CET
MPC90 value against AZ resistant isolates was 0.063mg/L. CET and
TEL had comparable MPC90 values (0.125 vs 0.063mg/L). CET
demonstrates a low propensity to select for ketolide resistant SP and
may be useful for therapy against macrolide resistant strains.
P710 Comparison of modiﬁed microbroth dilution to agar dilution
for determining the mutant prevention concentration
of gatiﬂoxacin and moxiﬂoxacin against Streptococcus
pneumoniae ATCC 49619
C. Hesje, J. Blondeau ° (Saskatoon, CA)
Objectives: The current method (agar dilution) for mutant prevention
concentration (MPC) testing of Streptococcus pneumoniae (SP) is
technically more demanding than minimum inhibitory concentration
(MIC) testing as subculturing to liquid media, subsequent incubation
and then centrifugation are required to achieve organism densities
necessary for the assay. This adds 2 days to obtaining a result. We
compared a modiﬁed microbroth dilution method to agar dilution for
determining MPC values for SP ATCC 49619 against gatiﬂoxacin (Gfx)
and moxiﬂoxacin (Mfx).
Methods: For mutant prevention concentration (MPC) testing, 109
CFUs of SP ATCC 49619 were inoculated to drug containing agar plates
and incubated under ideal conditions (5% CO2 at 35−37 Degree Celsius)
for 24−48 hours. For the modiﬁed microbroth dilution, 101-107 cfu/ml
were added to microtiter wells containing media and doubling drug
dilutions. Following incubation under ideal conditions, the lowest drug
concentration preventing growth was recorded as the MPC.
Results:MPC values for Gfx and Mfx by agar dilution was 0.5mg/L. For
Gfx, MIC (MPC) values for the 101-104 cfu/ml inocula was 0.125mg/L,
0.25mg/L for the 105-106 cfu/ml inocula and 0.5mg/L for the
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107 cfu/ml inocula. For Mfx, MIC (MPC) values were 0.063−0.125mg/L
for 101-104 cfu/ml, 0.125mg/L for 105 cfu/ml, 0.25mg/L for 106 cfu/ml
and 0.5mg/L for 107 cfu/ml. These values were reproducible when the
assays were repeated severe times.
Conclusion: Using a modiﬁed microbroth dilution method gave MPC
results that were consistent with the established agar dilution method
for testing SP ATCC 49619 against Gfx and Mfx. This observation may
have important implications for the advancement of MPC susceptibility
testing and may facilitate the introduction of this testing to a larger
number of clinical laboratories.
Toxoplasmosis and borreliosis: diagnostic
and clinical problems
P711 Evaluation of enzygnost IgA conjugate in combination with
the kit Enzygnost Toxoplasmosis IgG (Siemens Healthcare
Diagnostics) for the detection of IgA anti-Toxoplasma gondii
in human serum samples
A. Marangoni °, A. Moroni, S. Accardo, R. Cevenini (Bologna, IT)
Objectives: Laboratory diagnosis of Toxoplasmosis is mainly based
on serological methods, particularly important in the most challenging
situations, as diagnosis of primary infection during pregnancy and
diagnosis of congenital infection. Tests for the detection of IgA
antibodies are especially important in the newborns, because they are
more sensitive than IgM conventional methods. The purpose of this study
was to evaluate diagnostic performances of Enzygnost system for IgA
detection, achieved by using Enzygnost Anti-human IgA/POD Conjugate
in combination with Enzygnost Toxoplasmosis IgG (Siemens Healthcare
Diagnostics Products GmbH, Marburg, Germany).
Methods: A retrospective study was performed with 591 serum
samples submitted to the Microbiology Laboratory of S. Orsola
Hospital in Bologna for Toxoplasmosis screening. All the sera were
tested by Enzygnost Toxoplasmosis IgG, Enzygnost Toxoplasmosis
IgM and Enzygnost system for IgA (Siemens Healthcare Diagnostics).
Border-Line or positive IgM results were conﬁrmed by Vidas Toxo
IgM (bioMerieux, Marcy l’Etoile, France). Finally, IgG Avidity was
performed by Vidas Toxo IgG Avidity (bioMerieux, Marcy l’Etoile,
France) and LDBio Toxoplasma WB IgG/IgM (LDBio Diagnostics,
Lyon, France).
Moreover, a second study was performed with 172 selected sera in order
to compare results obtained by Enzygnost system for IgA with those
obtained by Enzywell Toxoplasma IgA (Diesse, Monteriggioni, Siena,
Italy).
Results: Retrospective study. 453/591 samples were negative, 53 were
Border-Line and 85 were positive when tested by Enzygnost system for
IgA. 3 babies were correctly diagnosed as infected infants because of the
presence of IgA antibodies at birth. These newborns had negative IgM
results in both conventional methods used, whereas comparative WB
conﬁrmed the infection because of the different immunological proﬁles
between maternal and newborn samples.
Comparative study. Results obtained by the two methods are summarised
in Table 1. They showed a concordance of 93%.
Table 1. Enzygnost system for IgA anti-Toxoplasma and Enzywell Toxoplasma IgA reactivities in relation to the
four groups of subjects tested for the comparative study
Study groupa No. of
samples
Number of reactive samples when tested by
Enzygnost and Enzywell, respectively (%)
% Concordance
+ and + − and − + and − − and +
Pregnant women 57 41 (71.3) 8 (14.0) 7 (12.3) 1 (1.8) 86.0
Infants 32 0 (0) 32 (100) 0 (0) 0 (0) 100
HIV positive 26 3 (11.5) 22 (84.6) 0 (0) 1 (3.8) 96.2
Healthy blood donors 57 0 (0) 54 (94.7) 0 (0) 3 (5.3) 94.7
Total 172 44 (25.6) 116 (67.4) 7 (4.1) 5 (2.3) 93.0
a Immunological situation of the patients:
• All the pregnant women had low Avidity and IgM positive results;
• No infants born to mothers with primary infection during their pregnancies were infected by Congenital
Toxoplasmosis (all of them turned to be seronegative within 1 year of age);
• All HIV positive patients had positive IgG results. The 3 patients with IgA positive results by both methods were
also IgM positive;
• The healthy blood donors were selected to be IgG and IgM seronegative for Toxoplasmosis.
Conclusion: Enzygnost system for IgA anti-Toxoplasma showed very
good diagnostic performances: in the retrospective study it allowed the
correct identiﬁcation of three infected newborns and in the comparative
study it showed a higher speciﬁcity than Enzywell Toxoplasma IgA, since
no sera from healthy blood donors were scored reactive. We conclude
that its good performances and its suitability for automation make it an
ideal screening test.
P712 Congenital toxoplasmosis in the Netherlands
L.M. Kortbeek °, Y. van Duynhoven, C. Nijhuis, A. Havelaar,
A. Hofhuis (Bilthoven, NL)
Introduction: Congenital Toxoplasma (CT) infection may occur after
primary Toxoplasma infection during pregnancy and can cause severe
complications. The information available on the incidence of CT in the
Netherlands are old data from a regional study in 1987 (Toxoplasma
Intervention Prevention (TIP) study). In order to get more recent
information on the incidence of CT in the Netherlands we conducted
a study in neonates and used this to recalculate the burden of disease of
CT in Daily Adjusted Life Years (DALY’s).
Methods: A random sample of dried blood spot ﬁlter paper cards from
newborns born in 2006 in the Netherlands were tested for Toxoplasma
gondii-speciﬁc IgM antibodies, using Wallac AutoDELFIA Neonatal
Toxoplasma Screening kits and conﬁrmed by a modiﬁed immunosorbent
agglutination assay (ISAGA bioMe´rieux) for Toxoplasma speciﬁc IgM
antibodies.
Results: Approximately 185,000 neonates were born in the Netherlands
in 2006 and a random sample of 10,008 cards was tested. Thirty-two
samples (0.32%) tested positive in the screening assay, eighteen samples
were conﬁrmed IgM positive, resulting in an observed birth incidence of
1.8 per 1000 live born children in the Netherlands in 2006. Accounting
for 99.9% speciﬁcity and 77.7% sensitivity, the adjusted incidence would
be 2.0 per 1000. This means that 388 infected children were born in
2006. Although regional differences were not statistically signiﬁcant,
the incidence of congenital toxoplasmosis appeared to be higher in the
South-East and West than in the North-East of the Netherlands. The
most likely burden of disease is 2227 DALYs with a range of 818–6713
DALYs. In the previous calculations using the incidence of the Dutch
TIP study of 1987 this was 620 (range 220–1900) DALYs.
Conclusion: The incidence of congenital toxoplasmosis in the Nether-
lands is much higher than previously reported with 2 infected children
per 1000 live born. This is ten times higher than in Denmark (0.2 per
1000, Schmidt2006) and 20 times higher than in Ireland (1 per 10,000;
Philip Mayne, personal communication) using the same methods. There
is no screening program in the Netherlands and most children will be
born asymptomatic and therefore will not be detected or treated.
After recalculation of the DALY’s of toxoplasmosis, the burden of
disease of congenital toxoplasmosis in the Netherlands is high and if
combined with acquired toxoplasmosis it will be even higher, indicating
its signiﬁcance as a zoonotic pathogen.
P713 Binding properties of decorin-binding proteins from three
different Borrelia genospecies
J. Neuvonen °, M.K. Viljanen, J. Hyto¨nen (Turku, FI)
Objectives: Lyme borreliosis (LB) is a tick born infectious disease
which is caused by Borrelia burgdorferi sensu lato bacteria. There are
three major Borrelia genospecies, B. burgdorferi sensu stricto (Bbss),
B. garinii (Bg) and B. afzelii (Ba), which are known to cause disease in
humans. Borrelia has several surface proteins which mediate attachment
to different tissues and molecules in the tick or mammalian host. Decorin
binding proteins (Dbps) A and B (DbpA and B) are two adhesins of
Borrelia that are expressed during mammalian infection. They mediate
bacterial attachment to proteoglycan decorin which is closely associated
with collagen ﬁbers in the extracellular matrix. Decorin is widely
expressed throughout the body, and highest concentrations are detected
in the skin and joints. Different Borrelia genospecies have different
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tissue tropism. Bbss causes most of the Lyme arthritis cases, while Bg
is associated with neuroborreliosis and Ba with chronic skin disorders.
Decorin binding proteins of these three genospecies differ in their amino
acid sequence, but little attention has been paid to the potential difference
in their biological activity.
Methods: We have constructed three recombinant Borrelia strains
through cloning of dbpAB operons from Bbss, Bg and Ba to the non-
infective Bbss B313 strain, which lacks several major surface proteins
including DbpA and B. dbpAB operon was PCR ampliﬁed from genomic
DNA of Bbss N40, Bg SBK40 and Ba A91 strains, cloned to pBSV2
shuttle vector, and electroporated into B313. The binding of biotinylated
decorin to the recombinant Borrelia strains was studied by Western blot
and dot blot assays. In cell adhesion studies, the binding of ﬂuorescent
recombinant Borrelia strains to ﬁbroblasts was studied using confocal
microscopy. Also, we have expressed individual recombinant DbpA
and B of the three genospecies in E. coli.
Results: The strains expressing Dbps from Bbss and Bg bound to decorin
and decorin expressing ﬁbroblasts, while the strain with Dbps from Ba
showed only little adherence to decorin and ﬁbroblasts. Analysis of
the binding properties of the individual Dbps expressed in E. coli is
underway.
Conclusions: DbpA and/or DbpB from Bbss and Bg mediate adherence
of the recombinant bacteria to puriﬁed decorin and to cells expressing
decorin. In contrast, the Dbps from Ba do not have this activity.
P714 Patients after proven neuroborreliosis – how severe is the
persisting neuropsychological damage?
H. Schmidt °, C. Schmidt-Samoa, M. Djukic, K. Neubieser, P. Dechent,
M. Knauth, R. Nau, N. von Steinbu¨chel, H. Eiffert (Gottingen, DE)
Objectives: Next to neurological sequelae such as persisting facial palsy
or radicular symptoms, patients after Neuroborreliosis (NB) often report
cognitive disturbances even if they had received an early and state-of-
the-art antibiotic treatment. In this study, we evaluate for the ﬁrst time
in Europe the frequency and extent of these deﬁcits in a sufﬁciently
powered study.
Methods: 54 patients who had been treated during the last ten
years in the Go¨ttingen University hospital for proven Neuroborreliosis
received an extensive standardised neurological examination, a three-
hours neuropsychological work-up covering all important cognitive
domains, quality of life questionnaires, questionnaires for psychological
symptom-load, and a 3-Tesla MR-Scan with a 3D-T1 sequence to
measure the brain volume. The MRI examinations were analyzed for
atrophy using the FSL-SIENAX software package. All results were
compared with an age-, education- and gender-adapted group of 33
neurologically healthy control persons.
Results: Patients after NB showed more often pathological ﬁndings
in the neurological examination (mean+SD Scripps Neurological rating
scale 97.2+4.5 vs. 99.4+1.7, p< 0.01) but these neurological deﬁcits
were in general mild and only rarely disabling. Considering the cognitive
functions, z-values were statistically lower in the NB group only in
the domain of non-verbal learning/memory (mean+SD: −0.13+0.41 vs.
0.13+0.57, p = 0.02) and in the domain of frontal executive functions
(mean+SD: −0.28+0.61 vs. 0.09+0.63; p< 0.01). However, in the
examined domains, the difference of the frequencies of pathological
results never reached signiﬁcance. Quality of life scale values and
the load of psychological symptoms as measured with the SCL 90-R
questionnaire were also comparable with the control group. The total
brain volume and the volumes of peripheral grey matter, total grey
matter, total white matter and ventricular volume were not different when
compared with the control group.
Conclusion: Statistically, Neuroborreliosis may lead to measurable
neurological and to some extent also to neuropsychological sequelae.
In most of the patients, however, these deﬁcits are subtle and do not
affect the quality of life on the long run. Alike, in our population, brain
atrophy is rather the exception than the rule in patients after proven
Neuroborreliosis.
P715 Molecular analysis of Borrelia spirochetes detected in Ixodes
granulatus ticks removed from rodents in Taiwan
C.M. Shih °, L.L. Chao (Taipei, TW)
Objectives: To identify the genetic identity of Borrelia spirochetes
detected in Ixodes granulatus ticks removed from rodents in Taiwan.
Methods: A general survey was conducted to collect adult I. granulatus
ticks removed from trapped rodents in Taiwan. Total genomic DNA was
extracted from individual tick specimen by using DNeasy Tissue Kit
(Qiagen). The genetic identity of Borrelia spirochetes were determined
by analysing the gene sequences ampliﬁed by a genospecies-speciﬁc
polymerase chain reaction (PCR) assay based on the 5S-23S intergenic
spacer amplicon gene of Borrelia spirochetes. Aligned sequences were
analyzed by neighbour-joining (NJ) compared with maximum parsimony
(MP) methods to estimate the phylogenetic relationships of these
detected spirochetes.
Results: A total of 162 adult I. granulatus ticks were examined and
tested by PCR assay and Borrelia spirochetes were detected in 71 adult
ticks. Phylogenetic analysis reveals that all these detected spirochetes
constitute two major separate clades from other Borrelia genospecies
in both NJ and MP methods. Within the clades, 8 strains of Borrelia
spirochetes detected in adult I. granulatus ticks were closely related to
the genospecies of B. burgdorferi sensu stricto and 26 strains of detected
spirochetes were closely related to B. valaisiana.
Conclusion: Our results describe the ﬁrst detection of B. burgdorferi
sensu stricto and B. valaisiana-related spirochetes in adult I. granulatus
ticks collected in Taiwan. The genetic identity of these spirochetes
was conﬁrmed by analysing sequence homology of 5S-23S intergenic
spacer gene. Further investigations on Borrelia spirochetes detected in
patients, other ticks, and reservoir hosts would beneﬁcial to the better
understanding of genetic diversity of Borrelia spirochetes in Taiwan.
P716 Performance of four commercial immunoblots for serological
conﬁrmation of Lyme borreliosis in Rhone-Alpes (France)
K. Barrial °, C. Roure-Sobas, A. Carricajo, S. Tigaud (Lyon,
Saint-Etienne, FR)
Objectives: Immunoblot (IB) is usually used to conﬁrm antibodies speci-
ﬁcity after a screening positive Lyme test. Many blots are commercially
available but of our knowledge no evaluation has compared the results
obtained by the different tests. This study aimed to analyse detection of
immune response by four different serological conﬁrmation tests.
Methods: The present study compared four IB IgG and IgM tests:
Europe Line® (Virotech, Ingen), Ecoblot® (Virotech, Meridian), EU
Lyme WB® (MarDx, Trinity Biotech) and Recomblot® (Mikrogen,
Diasorin). From May and December 2007, we tested the sera from 42
well-deﬁned patients at different stages of Lyme borreliosis (clinical
and serological ﬁndings), 10 patients with an indeterminate status and
33 non conﬁrmed diagnosis. All sera were positive or equivocal on
screening Enzygmost® (Dade-Berhing) test for borrelial IgG and/or IgM
antibodies. Reactivity of VlsE (IgG) and OspC (IgM) were especially
studied. Technical criterias were also evaluated such as automated use,
simplicity of reading, and cost of use.
Results: Presence of borrelial IgG antibodies in patients sera was
established in 68.2% (n = 58), 76.5% (n = 65), 60% (n = 51) and 60%
(n = 51) for Europe Line®, Ecoblot®, EU Lyme WB® and Recomblot®
respectively. Borrelial IgM antibodies were found in 52.9% (n = 45),
42.4% (n = 36), 78.8% (n = 67) and 55.3% (n = 47) respectively. Among
42 conﬁrmed Lyme borreliosis (LB) patients, concordant results for IgG
were found in 59.5% (n = 25), 64.3% (n = 27), 54.8% (n = 23) and 66.7%
(n = 28) with Europe Line®, Ecoblot®, EU Lyme WB® and Recomblot®
respectively. Likewise, we obtained for IgM 59.0% (n = 25), 54.7%
(n = 23), 69% (n = 29) and 71.4% (n = 30). The diagnosis sensitivity
evaluated for Europe Line®, Ecoblot®, EU Lyme WB® and Recomblot®
were 59.5%, 64.3%, 54.8%, 66.7% for IgG respectively and 59.%,
54.8%, 69%, 71.4% for IgM antibodies respectively.
Conclusion: LB diagnosis remained difﬁcult. IB results should be
interpreted carefully always in relation to the clinical ﬁndings.
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Discrepancies in ﬁnding obtained on identical sera indicate the need for
standardisation of the serological methods for conﬁrmation LB infection.
A good conﬁrmatory test requires a high speciﬁcity evaluated among the
population followed.
Immunology, host defences and
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P717 The polycyclic aromatic hydrocarbons modify response of
lung epithelial cells to Aspergillus fumigatus spores, in vitro
A. Czarny °, E. Zaczynska, U. Nawrot, K. Wlodarczyk, A. Janicka,
W. Walkowiak (Wroclaw, PL)
Objective: Epidemiologic studies have shown association between
elevated levels of polycyclic aromatic hydrocarbons (PAHs) in air and
increased incidence of pulmonary infections, especially in patients sus-
ceptible to infection. We investigated inﬂuence of PAHs extracted from
diesel exhaust on activation of signal transducer and activator of tran-
scription STAT-1 and STAT-3 factors in lung epithelial cells infected with
Aspergillus fumigatus spores, in vitro. The STAT-1 and 3 proteins are ac-
tivated in response to microbial infections through respectively cytokine
receptors and regulate production of inﬂammatory mediators. Interferons
are activators of STAT-1, and interleukin-6 is a STAT-3 activator.
Methods: In our experiments human epithelial cells A549 were
preincubated for 24 hours, with non-toxic concentration of PAHs,
subsequently were treated with Aspergillus fumigatus spores for 24,
48 and 7 days. The activation of STATs were determined by an
immunocytochemical method. The cells expressing STAT in the nucleus
were labelled as STAT(+) cells. The activation of STAT system in A549
cells was expressed as the percentage of STAT(+) cells; the ratio of
STAT(+) to STAT(−) cells.
Results: The PAHs solution contents 51% fenantrene 30% acenaphtene
9% ﬂuorene and acenaphtene, ﬂuoranthene 5% weakly activated of
STATs in lung epithelial A549 cells. The STAT-1 and 3 activation
in A549 cells incubated with the Aspergillus fumigatus spores was
signiﬁcantly higher than in cells treated with PAHs only or control
cells. In the cells stimulated simultaneously with PAHs and spores
the activation of these transcription factors were higher than in cells
incubated with fungal spores only, but not statistically signiﬁcant.
Conclusion: These preliminary results demonstrate that PAHs may cause
lung epithelial dysfunction and enhance inﬂammatory reaction to fungal
antigens. The prolonged higher level of inﬂammatory mediators may
contribute to the increased risk of degeneration pulmonary cells.
P718 Echinaceae purpureae herba inhibits adhesion and invasion
of Streptococcus pyogenes adhering to and invading human
mucosal epithelial cells
A. Conrad °, I. Engels, U. Frank (Freiburg, DE)
Objective: Streptococcus pyogenes is an important bacterial pathogen,
causing infections of the respiratory and other organ systems in
susceptible hosts. S. pyogenes infection is initiated by adhesion to
and invasion of mucosal epithelial cells. An in-vitro model system for
bacterial adhesion and invasion of respiratory epithelial cells was used to
investigate the inﬂuence of a phytotherapeutic preparation containing the
pressed juice of purple coneﬂower herb (Echinaceae purpureae herba;
Echinacin® Liquidum, Madaus GmbH, Cologne, Germany) as active
agent on S. pyogenes epithelial cell adhesion and invasion.
Methods: Adhesion of S. pyogenes to human epithelial HEp-2 cells
was determined by a ﬂow cytometric assay. S. pyogenes (DSM 2071)
was stained with Calcein-AM and adhesion kinetics were determined by
incubating bacteria and epithelial cells for 30 min, 60 min, 120 min, and
180 min, respectively. For cell invasion, HEp-2 cell monolayers were
infected with S. pyogenes (DSM 2071). After co-incubation for 30 min,
60 min, 120 min, and 180 min invasion of HEp-2 cells was analyzed
by a penicillin/gentamicin-protection assay. The phyto-lyophilisate was
applied at concentrations of 0, 10, 100, and 1,000 microg/mL.
Results: The administration of 1,000 microg/mL of the Echinaceae-
preparation reduced S. pyogenes adhesion to epithelial cells on average
by 18.3% at 0 min, 19.2% at 30 min, 22.6% at 60min, 23.5% at 120 min,
and 21.8% at 180 min (n = 10; p< 0.001, repeated measures ANOVA).
HEp-2 cell invasion was decreased by 22.9% at 30 min, 38.6% at 60 min,
40.2% at 120 min, and 44.8% at 180 min respectively (n = 11; p = 0.008,
repeated measures ANOVA).
Conclusions: The Echinaceae purpureae herba preparation reduced
signiﬁcantly S. pyogenes adhesion and invasion of human epithelial cells.
Our results hold signiﬁcant potential for these preparations as therapeutic
agents for the prophylaxis of streptococcal infection.
P719 Potentially probiotic bacteria induce inﬂammasome activation
and cytokine production in human monocyte-derived
macrophages
S. Latvala °, M. Miettinen, R. Kekkonen, R. Korpela, I. Julkunen
(Helsinki, FI)
Objectives: In the present study, we have analyzed the ability of
eleven potentially probiotic bacteria to activate human monocyte-derived
macrophages (MO) and induce their cytokine gene expression. Our aim
was to analyze whether there are signiﬁcant differences in the ability
of these bacteria to activate macrophage inﬂammasome-induced IL-1b
production, and whether suppressor of cytokine signaling (SOCS3)-
mediated negative feed-back systems are also operative.
Methods: MOs obtained from buffy coats and differentiated in vitro
with GM-CSF were stimulated with probiotic bacteria. After bacterial
stimulation the cell culture supernatants were collected and cytokine
levels were determined by ELISA. The kinetics of mRNA expression of
cytokine genes and the involvement of SOCS3 in MO responses were
analyzed by qRT-PCR.
Results: Most bacteria induced cytokine production in a dose-
dependent manner. However, certain differences in the ability of these
bacteria to induce MO cytokine responses were found. All bacteria
induced pro-inﬂammatory cytokines (TNF-a, IL-1b, IL-6) indicating
that macrophage inﬂammasome system was activated. In addition,
some bacteria also induced anti-inﬂammatory (IL-10) and Th1 (IFN-
g) cytokines. Biﬁdobacterium, Streptococcus, and Lactobacillus-strains
were good inducers of IL-6, IL-10, and TNF-a, while Leuconostoc
mesenteroides ssp. cremoris and Propionibacterium freudenreichii ssp.
shermanii were relatively poor inducers of cytokine gene expression.
In addition to activating cytokine production all studied bacteria were
also able to induce SOCS3 gene expression, which likely leads negative
feed back of extensive cytokine production in bacteria stimulated
macrophages. SOCS3 gene expression was induced directly by bacterial
stimulation as well as indirectly via IL-10 produced by macrophages.
Conclusion:Most probiotic bacteria activate macrophage inﬂammasome
system leading to IL-1b secretion. In addition, other pro-inﬂammatory
Th1 type cytokines and anti-inﬂammatory IL-10 were also efﬁciently
induced in cells stimulated with these bacteria. All bacteria were also
able to induce SOCS3 expression, which is likely to shut off enhanced
cytokine gene expression. These results show that macrophages respond
very strongly to bacterial stimulation even in the case of non-pathogenic
bacteria and the responses vary between different bacterial strains.
P720 Toll-like receptor ligand induced synergistic interferon gene
expression in human monocyte-derived dendritic cells
S.M. Ma¨kela¨ °, P. O¨sterlund, T.E. Pietila¨, I. Julkunen (Helsinki, FI)
Objectives: Toll-like receptors (TLRs) are pattern-recognition receptors
of the innate immune system that recognize various pathogen-associated
molecules. TLR ligands are potent vaccine adjuvants and binding of
ligands to different TLRs can induce a synergistic production of pro-
inﬂammatory cytokines. In the present study, we have analyzed dendritic
cell (DC) interferon (IFN) responses to the stimulation with two TLR
ligands simultaneously.
Methods: Monocytes from healthy blood donors were differentiated
into DCs in the presence of granulocyte-macrophage colony stimulating
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factor and interleukin 4. DCs were stimulated with TLR3 ligand polyI:C,
TLR4 ligand LPS and TLR7/8 ligand R848 alone or in a combination
of two. RNA was isolated for semi quantitative RT-PCR analysis.
DNA binding assay was used to study TLR ligand induced binding
of transcription factors to the IFN-lambda 1 promoter IFN stimulated
response element (ISRE).
Results: Stimulation of DCs with polyI:C or LPS alone induced mRNA
expression of IFN-b, IFN-l1 and IFN-l 2/3, whereas R848 alone was
ineffective. However, simultaneous stimulation with R848 together with
polyI:C led to a synergistic IFN-a, -b, -l 1 and -l 2/3mRNA expression
already in 3 h and the synergistic effect was sustained in the later time
points. Interestingly, R848 combined with LPS induced synergistic IFN
mRNA expression only at the later time points, when the IFN expression
induced with LPS alone had declined. To clarify the mechanisms behind
the synergistic effect, DNA binding assay was used to study LPS
or/and R848 induced binding of IFN regulatory factor (IRF) and signal
transducer and activator of transcription (STAT) transcription factors to
the IFN-l 1 promoter ISRE site. LPS and/or R848 stimulation induced
the binding of IRF1, IRF7 and IRF8 to the ISRE site while IRF4 and
IRF5 were bound constitutively. Only LPS was able to induce binding
of STAT1 and STAT2 to the ISRE site.
Conclusion: This data suggest that TLR3 or TLR4 ligand combined
with TLR7/8 ligand induces synergistic and sustained IFN expression
in human monocyte derived DCs. However, there might be differences
in the pathways driving the synergistic IFN response, as its kinetics and
magnitude varied between the two ligand combinations. Understanding
the molecular mechanisms behind the synergistic IFN response is needed
when designing better vaccine adjuvants or DC-based therapies.
P721 Detection of HIV-speciﬁc cytotoxic T-lymphocytes using
viral delivery system
Y. Zeng, K.C.W. Chan, C.S. Chan, F. Ng, K.H. Wong, B. Zheng ° (Hong
Kong, CN)
Objective: Although methods for the detection of HIV speciﬁc cytotoxic
T lymphocytes (CTL) have been established, i.e. ﬂow cytometry,
Tetramer and Elispot using speciﬁc CTL peptides, their applications
are still limited because: (I) the patients’ HLA-I subtypes must be
determined; (II) only a few HLA-I HIV speciﬁc peptides have been
identiﬁed; and (III) HLA typing and synthesis of speciﬁc peptides are
expensive. Thus, this study aims to develop a new technique for detection
of HIV speciﬁc CTL.
Methods: Recombinant adeno-associated virus (rAAV) expressing HIV
antigens gp120, gp41 and gag were constructed. HIV antigen-speciﬁc
CTLs were detected in 10 HIV patients with HLA-I subtype A2 (HLA-
A2) by a standard method of ﬂow cytometry for detection of intracellular
IFN-gusing HLA-A2-restricted HIV-1 CTL speciﬁc peptides (gp120
194–202, gp41 741–749 and gag 77−85) and the new technique using
rAAV infected autologous B cells or dendritic cells (DC) as stimulator.
The results obtained from these 2 methods were compared.
Results: Frequency of CD3+/CD8+/IFN-g+ cells was lower in the test
using rAAV infected B cells than in the standard method using HIV
speciﬁc CTL peptides. It might be due to the infection rate of rAAV was
less than 3% in B cells. However, frequencies of CD3+/CD8+/IFN-g+
cells were similar when compared results between the tests using rAAV
infected DC or puriﬁed rAAV infected B cells for the stimulation and
those tested by the standard method.
Conclusion: Theoretically, this may be used for detection of HIV speciﬁc
CTL, but the infection rate of rAAV in B cells should be improved.
Alternately, the other viral delivery system which has higher infection
rate for B cells, such as lentivirus, may be used.
This study was suported in part by AIDS Trust Fund, Hong Kong.
P722 Neuropeptide S receptor 1 variation is associated with
Chlamydia pneumoniae seropositivity in Finnish military
conscripts
T. Lajunen, A. Rantala °, R. Juvonen, T. Laitinen, M. Leinonen, J. Kere,
P. Saikku (Oulu, Helsinki, FI; Stockholm, SE)
Objectives: Chlamydia pneumoniae is a common Gram-negative
respiratory pathogen that has been suggested to associate e.g. with
asthma. Neuropeptide S receptor 1 (NPSR1, GPR154, GPRA) is a
susceptibility gene for asthma and related phenotypes. NPSR1 is
expressed in macrophages, and lipopolysaccharide (LPS) stimulation has
been suggested to affect NPSR1 expression. Our aim was to study if
NPSR1 polymorphisms associate with C. pneumoniae seropositivity.
Results: NPSR1 haplotypes H1 (frequency = 0.34) and H2 (frequency =
0.25) were associated with high C. pneumoniae IgG and/or IgA antibod-
ies (IgG titre  128 and/or IgA titre 40) both at entry (n = 144, 16%)
and at end (n = 91/790, 12%) of the service. In a haplotype speciﬁc logis-
tic regression analysis, H2 was found to be a risk haplotype, OR= 1.46
and p = 0.010 at arrival, and OR= 1.45 and p = 0.037 at leave, whereas
H1 was found to be a protective haplotype, OR= 0.74 and p = 0.036 at
arrival, and OR= 0.61 and p = 0.005 at leave. The analyses were adjusted
for asthma, duration of the service, and intake group. No association was
seen between NPSR1 haplotypes and asthma, or the presence of C. pneu-
moniae IgM and/or IgG or IgA seroconversions during the service.
Methods: Our study population consisted of 226 asthmatic and 659 non-
asthmatic men from two intake groups who were at military service in
the Kainuu Brigade between July 2004 and January 2006. Serum samples
were obtained at the beginning and at the end of the service, and during
infection episodes. Serum C. pneumoniae IgG, IgA, and IgM antibodies
were measured by a microimmunoﬂuoressence method. Seven tagging
single nucleotide polymorphisms in the conserved haplotype block of
NPSR1 were genotyped on a MALDI-TOF platform. Statistical analysis
was performed with PLINK software version 1.01.
Conclusion: Variation in NPSR1 gene may affect the susceptibility
to C. pneumoniae infection. Association was observed between the
haplotypes and high IgG and/or IgA antibody levels both at entry
and at leave of the service, but not for markers of acute infection.
This may imply that NPSR1 plays a role especially in persistent
C. pneumoniae infection. No association was seen between NPSR1
variation and asthma, possibly since there are no severe asthma cases in
our study population. Further studies are needed to address the question
if C. pneumoniae infection modulates the effect of NPSR1 variation on
asthma susceptibility.
P723 IgG-antibody response against Clostridium difﬁcile antigens,
PCR-ribotype and relapse of C. difﬁcile-infection
M.P. Bauer °, I.R. Poxton, K. Adamowicz, E.J. Kuijper, J.T. van Dissel
(Leiden, NL; Edinburgh, UK)
Objectives: To investigate the IgG antibody response against C. difﬁcile
antigens in patients with C. difﬁcile infection (CDI), and establish the
correlation with infecting PCR-ribotype and previous episodes as well
as future relapse of CDI.
Methods: In sera of patients with toxin assay-positive and culture-proven
CDI who had completed 10 days of antibiotic therapy for CDI, IgG titres
against EDTA extracts (cell surface molecules), guanidine hydrochloride
extracts (surface-layer proteins) and culture supernatant (crude toxin)
of ribotypes 001 and 027, and against lipoteichoic acid of ribotype
001, were determined by enzyme-linked immunosorbent assay (optical
density [OD]). By multivariate analysis, we correlated the IgG titres with
infecting ribotype (027 versus other), prior CDI episodes (ﬁrst versus
>1 prior episodes) and future relapse within a 60-day follow-up period.
Results: Patients suffering CDI caused by ribotype 027 had higher ODs
against EDTA extracts and crude toxins of both ribotypes as compared
with patients with CDI caused by other ribotypes. IgG antibody titres
against antigens from ribotype 001 were higher than those against
antigens from ribotype 027. Against EDTA extracts and crude toxins
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of ribotype 27, the difference in ODs between those infected by O27
versus other ribotypes reached a level of signiﬁcance. In all patients,
ODs in ELISA measuring antibody titres against surface-layer proteins
were low. Of note, IgG antibody titres were not inﬂuenced by number
of prior CDI episodes nor a predictor for future relapse.
Conclusion: Patients infected by C. difﬁcile ribotype 027 have higher
ODs, reﬂecting a higher concentration or higher afﬁnity in the IgG-
ELISA, against cell surface molecules and crude toxins as compared
with patients infected by other ribotypes. IgG titres were not correlated
with number of prior episodes, nor were they a predictor for future
relapse.
P724 The association of mannose-binding lectin with elevated
body mass index
A. Rantala °, T. Lajunen, J. Korvuo, P. Vikatmaa, P. Saikku,
M. Leinonen (Oulu, Helsinki, FI)
Objectives: In previous studies obesity has been linked to inﬂammatory
pathways. Mannose-binding lectin (MBL) is an important serum protein
involved in innate immune defence system. MBL deﬁciency and MBL2
gene polymorphisms have been associated with decreased defence
response and recurrent infections which may be associated to low-
grade inﬂammation. A recent study found that MBL was associated
with insulin resistance and obesity. Our aim was to study the association
of serum MBL levels and MBL2 gene polymorphisms with overweight
and obesity in patients with cardiovascular diseases.
Methods: Six single nucleotide polymorphisms in the promoter region
(alleles H/L, X/Y and P/Q) and exon 1 region (variant alleles D, B and
C and wild-type allele A) of the MBL2 gene were genotyped by a real-
time PCR and serum MBL concentrations were measured by commercial
ELISA test in 174 patients with symptomatic carotid stenosis, abdominal
aortic aneurysm or occlusive aortic disease. Information about BMI and
hypercholesterolaemia was available. SPSS 15.0 was used for statistical
analysis.
Results: BMI was divided into three groups: normal weight
(BMI< 25.0), overweight (BMI 25.0−29.9) and obese (BMI 30.0).
MBL2 exon 1 variant allele genotypes (A/O or O/O, where O indicates
any of the variant alleles D, B or C) were more common among combined
overweight and obese group (BMI  25.0) than among the normal
weight group (38% vs. 20%; p = 0.021) and the risk was up to 2.4-
fold (95% CI: 1.1−4.9) when adjusted for age, gender and the disease
group. Also a borderline signiﬁcant association was seen between the
three BMI groups (20% vs. 38% vs. 35%; p = 0.066). In addition,
exon 1 variant genotypes and possibly also an MBL level below the
median concentration associated with hypercholesterolaemia (p = 0.008
and 0.071, respectively). MBL2 promoter polymorphisms were not
associated with BMI or hypercholesterolaemia.
Conclusions: In this study, MBL2 structural variant genotypes
signiﬁcantly associated with BMI of 25 and hypercholesterolaemia
which both are also connected to overweight. Since exon 1 variant alleles
are strongly associated with MBL deﬁciency and recurrent infections in
several studies, the theory on the link between obesity, MBL, infections
and inﬂammation seems possible. However, an association between MBL
levels and BMI was not detected here. Further studies are needed to
replicate these ﬁndings.
P725 A SNP in IFNGR1 promoter is correlated to the susceptibility
to chronic HBV infection in Chinese population
Y. Zeng °, J. Zhou, D.Q. Chen, V.K.M. Poon, F. Ng, K.Y. Yuen,
B.J. Zheng (Hong Kong, HK)
Objectives: The antiviral mechanism stimulated by interferon-gamma
is found to be crucial for clearance of hepatitis B virus (HBV) in
vivo. The antiviral signaling transduction is triggered by the speciﬁc
binding between interferon-gamma and its receptor IFNGR1 (interferon-
gamma receptor 1). Interferon-gamma signaling transduction pathway
is directly controlled by the IFNGR1 expression level. In our study,
single nucleotide polymorphisms (SNPs) in the IFNGR1 gene and the
correlation between the SNPs and susceptibility to chronic HBV in
Chinese were investigated.
Methods: Blood samples of 983 Chinese, including 361 chronic hepati-
tis B patients, 366 healthy individuals, and 256 hepatitis B spontaneously
recovered patients, were collected. Seven SNPs (−611A/G, −56C/T,
40G/A, 95C/T, 130A/G, 20685A/G, 21227T/C) in IFNGR1 gene were
identiﬁed by restriction fragment-length polymorphism (RFLP) assays.
The transcription levels of different SNPs variants were compared by
luciferase assays.
Results: −56C and −56T allele were found to be correlated to HBV
clearance and persistence. In luciferase assays, the transcription level
of IFNGR1 promoter with the −56C is signiﬁcantly higher than that
with −56T.
Conclusion: −56C/T SNP in IFNGR1 promoter region is associated with
susceptibility to chronic HBV in Chinese population.
P726 Comparison of two Mycobacterium bovis Bacillus
Calmette-Guerin preparations used for immunotherapy of
human superﬁcial bladder cancer
W. Janaszek-Seydlitz °, M. Rutka, B. Bucholc (Warsaw, PL)
Objectives: Aim of present study was comparison of safety and
immunoactivity of two Bacillus Calmette-Guerin (BCG) preparations
used in Poland for bladder cancer immunotherapy.
Methods: BCG preparations. Onco – Tice (Organon Teknika, The
Netherlands) preparation (Tice substrain), Onko BCG 50 (Biomed
Lublin, Poland) preparation (Brazylian Moreau substrain).
Bladder cancer cell line. T24, a transitional cell of bladder cancer cell
line of human origin.
Viability and thermostability. Classical technique for the determination
of the number of CFU and thermostability of BCG preparations on a
solid Ogawa medium have been used
Multiplation BCG in spleen of mice. Residual virulence of compared
BCG substrains was evaluated on Balb/c mice injected intravenously.
Attachment of BCG to bladder cancer cells. Cancer cells T24 were
cultured together with BCG preparations. After 1, 2, 3, 4, 5 and 6 days
of culture the total number of cancer cells and number of cancer cells
with attached BCG were counted.
Cytostatic effect of BCG. Antitumour activity was based on luminomet-
ric measuring of the ATP activity of viable cancer cells in suspension
with or without presence of BCG preparations.
Results: Both BCG preparations showed the high number of viable
culture forming units and good thermostability The peak of bacillus
multiplication in mice spleen was observed 2 weeks after i.v. injection
of BCG dosage. It was 1.8×106 CFU/spleen in mice vaccinated with
Tice BCG and 1.1×106 CFU/spleen in mice vaccinated with Moreau
BCG substrain.
The peak of attachment of BCG to T24 tumour cells occurred after
2 days of cultivation. The maximal percentage of the tumour cells with
attached BCG was 56% for Onko BCG50 and 51.4% for Onco-Tice.
BCG-inhibited T24 cell growth was dependent on concentration of BCG
and time of cultivation. Both BCG substrains had similar proﬁle of
inhibitory effects.
Conclusion: Preparations Onco-Tice and Onko BCG 50 used for
immunotherapy of superﬁcial bladder cancer have been showed similar
residual virulence and very similar viability and thermostability.
– The higher percentage of tumour cells with attached BCG showed the
cultures with Onko BCG (Moreau).
– Both preparations showed similar proﬁle of cytostatic activity.
P727 Moxiﬂoxacin decreases neutrophilic inﬂammation in the
LPS-treated ferret airway
B.K. Rubin, M. Pearce ° (Winston-Salem, US)
Objectives: Quinolone antibiotics concentrate in inﬂammatory cells and
may be immunomodulatory. We hypothesised that oral moxiﬂoxacin
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could ameliorate neutrophil-induced airway inﬂammation in ferret
tracheae exposed to bacterial endotoxin (LPS).
Methods: Ferrets (N = 32) were anaesthetised and intubated with an
endotracheal tube coated with 10mg of LPS for 30 minutes per day
for 5 days. Starting at day 4 and continuing for ﬁve days, moxiﬂoxacin
10mg/kg was administered to 24 animals by nasogastric tube and saline
control to 8. On day 9 and again on day 11, twelve moxiﬂoxacin-treated
ferrets and four control animals were sacriﬁced and the trachea excised.
Mucociliary transport was measured by timing the movement of charcoal
ash across a 3mm segment of trachea. Attached mucin (ng/mg tissue)
and lysozyme as well as secretion over 1 hour were measured in an
additional tracheal segment. The integrity of the ciliated epithelium and
inﬁltration of the epithelium by neutrophils were determined by light
microscopy after haematoxylin and eosin plus Alcian blue/PAS staining.
Results: LPS-induced neutrophilic inﬂammation was associated with
dose-dependent histological evidence of airway damage There was
signiﬁcantly less neutrophil accumulation (Figure, P< 0.03) and a trend
toward decreased mucin secretion (P = 0.07) in the moxiﬂoxacin-treated
animals.
Conclusion: Topically applied LPS induces neutrophil inﬂux in the
ferret trachea and is associated with mucin hypersecretion and epithelial
metaplasia. These changes can be ameliorated by 5 days of moxiﬂoxacin
treatment.
P728 Adenosine A2A receptor agonist (2-chloroadenosine)
treatment modulates pro-inﬂammatory immune response
during the course of Klebsiella pneumoniae B5055-induced
acute lung infection in BALB/c mice
V. Kumar °, S. Chhibber (Chandigarh, IN)
Objective: Present study has been designed to evaluate the anti-
inﬂammatory and immunomodulatory effect of adenosine A2 receptor
analog called 2-chloroadenosine (2-CADO) in Klebsiella pneumoniae
B5055 induced acute lung infection in mice.
Methods: The animals were divided into 2 groups: a. control and b.
2-Chloroadenosine (2-CADO) treated. Acute lung infection in mice
was induced by directly instilling the selected dose (104 cfu) of
bacteria intranasally. Histoptahological examination of lungs was done
for assessing neutrophil inﬁltration and degree of lung inﬂammation.
Besides that other inﬂammatory parameters myeloperoxidase (MPO),
malondialdehyde (MDA), nitric oxide (NO), TNF-a, IL-1a and IL-10
levels were also estimated in lung homogenate. The 2-chloroadenosine
was administered intravenously at a dose of 10 mg/kg/day.
Results: The lungs of control group animals on histopathological
examination revealed the profound neutrophil inﬁltration into the lung
alveoli. TNF-a, IL-1a, MPO, MDA and NO were also signiﬁcantly
(p< 0.05) increased. However, intravenous treatment of animals with
2-CADO (10mg/kg/day) signiﬁcantly (p< 0.05) decreased the neutrophil
inﬁltration into the lung alveoli without lowering the bacterial count in
lungs. A signiﬁcant (p< 0.05) decrease in TNF-a, IL-1a, MPO, MDA
and NO along with elevation of IL-10 levels in lung homogenate of mice
was observed upon treatment with 2-CADO.
Conclusion: A2A receptor agonist (2-CADO) protected acute lung
inﬂammation via acting as an immunomodulatory agents in acute lung
infection.
P729 Interaction with complement factor H and C4b-binding
protein contributes to the serum resistance of an anaerobic
pathogen, Fusobacterium necrophorum
N. Friberg °, P. Carlson, S. Meri, H. Jarva (Helsinki, FI)
Background: Anaerobic bacteria are part of our environment and
ﬂora. They usually become invasive and pathogenic only under special
conditions e.g. tissue hypoxia, concomitant infection or neoplasia.
F. necrophorum is an exception and can on its own be pathogenic.
This strictly anaerobic Gram-negative rod is involved in local and
invasive diseases such as the life-threatening Lemierre’s syndrome.
This syndrome, characterised by sore throat, septicaemia, jugular vein
thrombosis and disseminated infection, affects mainly otherwise healthy
young adults. In order to cause disease, F. necrophorum must evade
innate immune responses. Innate immunity is the ﬁrst-line of defence
against microorganisms. An important and efﬁcient part of the innate
immunity is the complement (C) system.
Objectives: The aim of our study was to understand how F. necrophorum
avoids C activation and whether it binds C inhibitors such as factor H
(FH) (inhibitor of alternative pathway) and C4b binding protein (C4BP)
(inhibitor of the classical and lectin pathways).
Methods: We collected twelve F. necrophorum strains isolated from
patients with sepsis. To study the serum resistance, strains were incubated
in 75% serum and grown under anaerobic conditions. To detect binding
of C inhibitors, we used radiolabeled proteins and ﬂow cytometry.
Results: All strains were resistant to serum killing after a one-hour incu-
bation. All strains bound FH, except strain 12. FH-binding was ionic in
nature, speciﬁc and occurred via sites on both the N- and C-terminus. All
strains bound C4BP. The interaction between F. necrophorum and C4BP
was hydrophobic and speciﬁc in nature. Bound complement inhibitors
remained functionally active as a cofactor for factor I in the cleavage of
C3b for FH and C4b for C4BP. Strain 12 did not bind FH and bound
less C4BP than the other strains. Its survival in normal human serum
was impaired after 3.5 hours incubation compared to the other strains.
Interestingly, patients with the most severe symptoms carried strains
with the strongest ability to bind FH and C4BP. The carrier of strain 12
had not developed a typical Lemierre’s syndrome. This suggests that the
binding of C inhibitors contributes to the virulence and the survival of
F. necrophorum in the human host.
Conclusions: We show for the ﬁrst time that an anaerobic bacterium is
able to bind the C inhibitors FH and C4BP to evade C attack.
P730 Action of bacterial extracts from Aggregatibacter
actinomycetemcomitans in the production of IL-6 and IL-8
by human gingival ﬁbroblasts
O. Gonzalez, N. Roa, C. Valdivieso, F. Gamboa ° (Bogota, CO)
Objective: Periodontal disease is refers to a pathological response that
cause inﬂammation and loss of supporting structures of the teeth.
Aggregatibacter actinomycetemcomitans is a Gram-negative bacillus
associated to aggressive forms of periodontitis. This microorganism
express a cytolethal distending toxin (Cdt), which induces cell
cycle arrest and modulates cytokine synthesis. The aim of this
study was to evaluate the action of two bacterial extracts from
A. actinomycetemcomitans (Cdt mutant and wild-type strains) in the
production of IL-6 and IL-8 by human gingival ﬁbroblasts (HGF).
Methods: The supernatants from HGF primary cell cultures were ex-
posed to either wild type A. actinomycetemcomitans or Cdt mutant strain
bacterial extracts. The IL-6 and IL-8 production was determined by using
a cytometric bead array human inﬂammation kit (Becton-Dickinson).
Results: There were not signiﬁcant differences in IL-6 and IL-8
levels produced by HGF challenged with wild type or Cdt mutant
bacterial extracts. However, when response to lipopolysaccharide
was not controlled by preincubation of HGF with antibodies anti-
CD14 and anti-TLR4 before bacterial challenge, IL-8 production was
signiﬁcantly reduced in HGF stimulated with Cdt mutant but not with
A. actinomycetemcomitans wild type strain.
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Conclusion: These results suggest that Cdt does no affect directly the
IL-6 and IL-8 production by HGF in vitro. Nevertheless, a potential
indirect immunostimulatory role of Cdt in HGF may be associated
with other A. actinomycetemcomitans bacterial components such as
lipopolysaccharide, which has to be studied.
P732 Smoking status interacts in the association between
mannose-binding lectin serum levels and carriage of
respiratory bacteria
U. Jounio °, A. Rantala, A. Bloigu, R. Juvonen, T. Lajunen,
S. Silvennoinen-Kassinen, A. Peitso, O. Vainio, T. Harju, A. Saukkoriipi,
M. Leinonen (Oulu, Kajaani, Lahti, FI)
Objective: It is known that carriage of respiratory bacteria is a major
factor in the transmission of the infection and in some cases the invasion
can lead to respiratory or even systemic disease. Mannose-binding lectin
(MBL) is an important molecule of innate immunity: it acts as an opsonin
and stimulates the complement lectin pathway. The MBL insufﬁciency
has been associated with increased susceptibility to common respiratory
infections as well as invasive infections. We studied the association
of smoking and MBL concentrations with oropharyngeal carriage of
S. pneumoniae, N. meningitidis, H. inﬂuenzae, M. catarrhalis and beta-
haemolytic streptococci in young men with and without asthma.
Methods: We measured MBL concentrations by a commercial ELISA
test in 518 military conscripts (127 asthmatics and 391 controls)
of Kajaani garrison. Oropharyngeal swabs were collected from study
participants at the beginning, at the end of the military service and during
all infectious episodes requiring consultation by the physician. The
isolates were cultured and identiﬁed using generally accepted methods.
SPSS 15 was used for statistical analysis.
Results: The carriage rate of beta-haemolytic streptococci (P< 0.001),
S. pneumoniae (P = 0.002) and N. meningitidis (P = 0.005) throughout
the military service was signiﬁcantly higher among smoking military
conscripts than in non-smokers. In non-smokers, under median MBL
level proved to be a signiﬁcant risk factor for the carriage of beta-
haemolytic streptococci (OR= 2.0; 95% CI 1.2−3.2), N. meningitidis
(OR= 1.9; 95% CI 1.0−3.5) and a borderline signiﬁcant risk factor for
the carriage of S. pneumoniae (OR= 1.5; 95% CI 0.9−2.5). Same kind
of association was not found in the smokers.
Conclusions: Non-smoking conscripts with low MBL concentration
are prone to acquisition of oropharyngeal carriage of beta-haemolytic
streptococci, N. meningitidis and S. pneumoniae during military service.
P733 Regulation of immuno-pathological response in mouse lungs
by TGF-b1 after inﬂuenza A virus infection
M. Khanna °, V. Srivastava, V. Vijayan, R. Kulshrestha (New Delhi, IN)
TGF-b is a potent immunomodulator and regulates the inﬂammatory
process in a complex biphasic fashion. The immune response to
inﬂuenza A virus is characterised by an inﬂux of both macrophages
and lymphocytes into the lungs of the infected host. We hypothesize
that the TGF-b negatively regulates the inﬂammatory response by
regulating lymphocyte inﬂux to the airway and further modulating
release of proinﬂammatory and anti-inﬂammatory cytokines. Eight-
week-old BALB/c mice were intranasally instilled with inﬂuenza A virus
(A/Udorn/317/72/H3N2), 4.1×103 PFU of virus in 50ml of allantoic
ﬂuid or mock infected 50 ml of allantoic ﬂuid. rTGF-b1 administered to
mice by giving intravenous injection of rTGF-b1, 0.5mg/Kg body weight
of mouse. The mice were euthanised on days 3, 5 and 7 postinfection
for the analysis of parameters. We observed an increase of lymphocyte
count both on 3rd and 5th day p.i however administration of rTGF-b1
with virus reduced the lymphocyte count. Lungs of mice showed clear
progression of the inﬂammation, signiﬁcant alveolitis, with necrosis of
epithelial cells. The alveoli, interstitial septa and perivascular spaces were
extensively inﬁltrated by a mixture of inﬂammatory cells on 3rd, 5th
and 7th days after inﬂuenza virus infection. An increase of INF-g level
observed 3rd day of post infection however IL-10 level was maximum on
7th day and INF-g level reduced to basal level on 7th day. Simultaneous
administration of rTGF-b1 with virus instillation inhibited release of
INF-g level on third day and increased level of IL-10 level seventh day.
rTGF-b1 acts as an immunomodulatory cytokine and inhibits lymphocyte
inﬂux after virus infection and lymphocyte activation. It modulates the
inﬂammatory process by inhibiting INF-g a proinﬂammatory cytokine
and increased release of IL-10, which is an anti-inﬂammatory cytokine.
rTGF-b1 affects recruitment of inﬂammatory cells at the site of
inﬂammation by inhibiting lymphocyte invasion and interfering cytokines
mediated inﬂammatory cascade by less involvement of lungs.
P734 Relevance of procalcitonin level on the serum
lipopolysaccharide concentrations in intensive care unit
bacteraemic and non-bacteraemic patients
A. Foca, M.C. Liberto, A. Giancotti, M.C. Pulicari, A. Quirino,
A.G. Lamberti, R. Puccio, V. Tancre`, E. Zicca, A. Carrabba,
P. Mastroroberto, A. Renzulli, S. Caroleo, B. Amantea, G. Matera °
(Catanzaro, IT)
Objectives: Procalcitonin (PCT), in addition to being a pivotal
marker of sepsis severity, has been reported to be a mediator
of the systemic inﬂammatory response associated to life-threatening
infection. Concentration of PCT increases in serum samples of septic
shock patients until immunoparalysis. In experimental animals, co-
administration of PCT with bacterial lipopolysaccharide (LPS) increased
lethality, while immunoneutralisation of PCT produced encouraging
results for sepsis therapy. The aim of the study was to investigate the
changes in the PCT, LPS and IL-10, as well as their relationship with
severity of the clinical conditions among ICU patients stratiﬁed based
on blood culture positivity.
Methods: The serum level of PCT was tested by Enzyme Linked
Fluorescent Antibody (ELFA) procedure (Vidas B.R.A.H.M.S., PCT
BioMerieux, Italy), LPS concentration by Limulus Amoebocyte Lysate
(LAL) test (QCL-1000, Cambrex, Walkersville, USA), IL-10 was
evaluated by ELISA (Bender MedSystems GmbH, Vienna, Austria) in
samples obtained at the time of the blood culture (BacT/ALERT 3D,
BioMerieux, Italy) and at different periods thereafter.
Results: In blood cultures positive patients, LPS concentrations at the
zenit of PCT levels were signiﬁcantly (P< 0.05) increased in comparison
to LPS evaluated at the nadir of PCT concentration. On the contrary
among blood culture negative patients, when PCT peaked the LPS levels
were found signiﬁcantly (P< 0.05) lower than LPS concentrations at the
minimum of PCT levels. SOFA score and serum IL-10 were higher
among bacteraemic patients versus culture negative subjects.
Conclusion: LPS was found a reliable marker of sepsis severity
in the culture positive patients if evaluated together with PCT. The
paradoxical feature, of a quite high LPS level when PCT was very low
in nonbacteraemic subjects, deserves further investigations.
Pathogenesis of infections caused by
Gram-positive bacteria
P735 Role of rsbU and Staphyloxanthin in intracellular growth
of Staphylococcus aureus in human phagocytic cells (THP-1
macrophages)
A. Olivier, S. Lemaire, F. Van Bambeke, P. Tulkens °, E. Oldﬁeld
(Brussels, BE; Urbana, IL, US)
Background and Aims: S. aureus intracellular survival is critical
for persistence of infection. rsbU expression stimulates the production
of Staphyloxanthin (SFX), a yellow pigment that protects S. aureus
against oxidant damage (Science [Wash.] 2008; 319:1391–1394). We
have examined the role of rsbU and SFX in phagocytosis and growth of
S. aureus in phagocytic cells.
Methods: Bacteria: strain 8325−4 (natural deletion in rsbU) and SH1000
(isogenic rsbU+ construct); USA300. Cells: THP-1 macrophages
cultured and infected as previously described (AAC 2008; 52:2797–805).
Impairment of SFX synthesis: BPH-652 (3-phenoxy-alpha-phosphono-
benzenebutanesulfonic acid [dehydrosqualene inhibitor]).
Pathogenesis of infections caused by Gram-positive bacteria S179
Results: 8325−4 produced no SFX whereas SH1000 and USA300
were pigmented. BPH-652 impaired pigmentation of both SH1000 and
USA300 at 1mM in MH broth. The ﬁgure shows (A) that SH1000 was
more resistant to inactivation by hydrogen peroxide; (B) that intracellular
growth SH1000 and USA300 were more intense than that of 8325−4,
and that addition of BPH (100mM 48 h prior to phagocytosis [broth]
and during intracellular growth [culture medium]) reduced their growth
to the level of that of 8325−4.
Conclusion: rsbU functionality and SFX production is an important
factor in promoting intracellular growth of S. aureus in macrophages.
This effect may be due to SFX-mediated resistance to oxidative
stress. Inhibition of SFX synthesis may help in controlling intracellular
S. aureus infection.
P736 Staphylococcus aureus secretes two homologues Fc gamma
receptor antagonists
A.M. Stemerding °, A. Kuipers, A.Y.L. Weersink, J.G.J. van de Winkel,
K. van Kessel, J. van Strijp (Utrecht, NL)
Objectives: Fc gamma receptors (FcgR) play an essential role in
the speciﬁc cellular defence against invading pathogenic bacteria, like
Staphylococcus aureus (S. aureus). They are expressed on phagocytes
and initiate phagocytosis in response to immunoglobulin G (IgG) coated
on the bacterial surface. S. aureus evolved several mechanisms to evade
host immunity. However, staphylococcal evasion molecules targeting
FcgR have not been described yet. Our goal was to investigate whether
S. aureus secretes any FcgR antagonists.
Methods: Culture supernatants of various clinical and laboratory
S. aureus strains were screened for their ability to inhibit speciﬁc
FcgR staining on phagocytes, analyzed by ﬂow cytometry. An
inhibitory protein was puriﬁed from one of the effective staphylococcal
supernatants using dye-ligand afﬁnity chromatography, gel ﬁltration, and
FcgR coated magnetic beads. Subsequently the puriﬁed protein was
identiﬁed by mass spectrometry. To determine its FcgR modulating
capabilities recombinant protein was generated. Direct binding of the
inhibitor to the different FcgR subclasses, its ability to block FcgR-IgG
interaction and its effect on FcgR mediated phagocytosis and intracellular
killing were analysed using FACS and ELISA.
Results: S. aureus is able to evade FcgR mediated immunity by secreting
two potent FcgR antagonists, FLIPr and its homologue FLIPr-like. Both
proteins bind to FcgR and block FcgR-IgG interaction. They inhibit
FcgR mediated phagocytosis and intracellular killing of S. aureus.
Conclusions: Our ﬁndings increase the insight into the immune escape
mechanisms of S. aureus, and furthermore might lead to the development
of novel therapeutic agents in FcgR mediated diseases, like allergy and
autoimmunity.
P737 Biocide exposure activates sae promoter activity in Staphylo-
coccus aureus strain Newman and increases cellular invasion
D. Scha¨fer, T.T. Lam, T. Geiger, M. Mainiero, A. Bosserhoff,
M. Hussain, M. Bischoff, M. Frosch, S. Engelmann, C. Wolz, J. Reidl,
B. Sinha ° (Wurzburg, Tubingen, Heidelberg, Munster, Homburg-Saar,
Greifswald, DE; Graz, AT)
Objectives: Staphylococcus aureus has a high potential to cope with
changing environmental conditions like heat, pH and chemicals. This
is mostly due to its large number of global regulators such as the
sae (S. aureus exoprotein expression) regulon, a two-component-like
signalling system. Therefore we tested the ability of S. aureus strain
Newman to react to sub-lethal concentrations of the commonly used
biocide Perform® (Schu¨lke & Mayr) and its major components.
Methods: Changes after exposure to Perform and its components were
monitored by real-time RT-PCR, promoter activity assay, SDS-PAGE,
bioﬁlm assay and invasion assays (ﬂow cytometric and lysostaphin
protection).
Results: Perform or its component SDS induced a similarly altered
protein pattern compared to untreated controls, as determined by SDS-
PAGE. Most prominently, augmented bands were found for adhesins like
Eap and Efb, which are known to be regulated by the sae regulon. Up-
regulation of eap and sae (compared to 16S-rRNA) was conﬁrmed by
rtRT-PCR. A promoter activity assay of the sae promoter P1 showed an
up to 140% increased P1 activity by treatment with Perform and SDS.
In addition, S. aureus strain Newman exposed to Perform, but not SDS,
showed a stronger bioﬁlm formation. Perform and SDS enhanced cellular
invasiveness to 250% and 320% of untreated controls, respectively.
Increased invasiveness of Perform- and SDS-treated strain Newman was
dependent on Eap and the sae regulon, but independent of agr, sarA
and FnBPs, as determined by isogenic mutants. A sigB mutant had the
tendency to further enhance cellular invasiveness.
Conclusion: Exposure of S. aureus strain Newman to sub-lethal con-
centrations of Perform or its component SDS activates the sae promoter
P1 resulting in increased cellular invasiveness. By contrast, bioﬁlm
formation was only enhanced by Perform, but not by SDS. Changes in
the protein expression pattern, including up-regulation of Eap, under the
control of the sae regulon may account at least partially for these effects.
P738 Phenotype-speciﬁc small non-protein-coding RNAs of
Staphylococcus aureus
L.F. Abu-Qatouseh, S.V. Chinni, T.S. Rozhdestvensky, J. Seggewiss,
R.A. Proctor, G. Peters, J. Brosius, C. von Eiff, K. Becker ° (Mu¨nster,
DE; Madison, US)
Objectives: The formation of phenotypic variants of Staphylococcus
aureus, in particular of the small-colony variant (SCV) phenotype, is only
partially understood. Non-protein-coding RNA (npcRNA) genes have
been found to act as key regulatory players in response to environmental
changes and host signals. So far, only few npcRNAs have been described
in Gram-positive bacteria including staphylococci.
Methods: Since growth rate speciﬁc-expression was observed for
bacterial npcRNA, we performed identiﬁcation of npcRNA candidates
using total RNA of S. aureus isolated from different growth stages
of an isogenic clinical strain pair displaying the normal and the SCV
phenotype. Total RNA was extracted and size-fractionated (from 10 to
500 nt) and two separate cDNA libraries were constructed. A total
of 10,000 cDNA clones were randomly sequenced and analysed by
BLASTN database search. Northern blot analyses were applied for
conformation of the expression of novel npcRNAs candidates.
Results: Overall, 183 putative candidates for novel npcRNAs were
identiﬁed. The expression of 34 of the identiﬁed npcRNAs was
experimentally validated and conﬁrmed by Northern blot analyses.
Growth phase speciﬁc regulation was detected for 23 npcRNAs. Of
particular interest, S. aureus phenotype-speciﬁc expression of six
npcRNAs was found: Whereas ﬁve of the identiﬁed novel npcRNAs were
speciﬁcally expressed only in the normal phenotype, expression of one of
the novel npcRNA candidates was restricted to the SCV phenotype. Most
of the novel npcRNAs were stage speciﬁc-regulated in SCVs with the
majority being down regulated at the late growth of SCVs. In addition,
several of the newly identiﬁed S. aureus npcRNAs exhibited relationship
to S. aureus pathogenicity. Some of the experimentally veriﬁed npcRNAs
were originated from pathogenicity islands indicating a putative role in
the regulation of S. aureus virulence.
Conclusion: For the ﬁrst time, a classiﬁcation of npcRNAs based on
their differential expression between the normal and the SCV phenotype
of S. aureus was established. Thus, a role of npcRNAs in the regulation
of the divergent phenotype-associated behaviour of S. aureus in the
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host environment might be assumed. Further studies are warranted to
elucidate the potential functions of the novel npcRNAs and their impact
on the pathogenesis of S. aureus infections.
P739 Holo- and apo-transferrins interfere with adherence to
abiotic surfaces and with adhesion/invasion to HeLa cells in
staphylococci
A. Cellini °, C. Avanzolini, G.L. Scoarughi, R. Papa, E. Mileto,
C. Farina, M. Artini, L. Selan (Rome, Lucca, IT)
Objectives: Staphylococcus aureus and Staphylococcus epidermidis are
the major cause of infections associated with implanted medical devices,
such as intravascular catheters, prosthetic heart valves and orthopaedic
devices. Colonisation on abiotic and biotic surfaces is often sustained by
bioﬁlm forming strains. Human natural defences can interfere with this
virulence factor. In these experiments we investigated the effect of human
apo-transferrin (apo-TF, the iron-free form of an iron-binding serum
glycoprotein) and holo-transferrin (holo-TF, the iron-saturated form) on
bioﬁlm formation by S. aureus and S. epidermidis. For S. aureus the
effect of apo-TF and holo-TF on the adhesion/invasion ability on human
cell lines was also studied.
Methods: We used two S. epidermidis strains (1 clinical isolate
and ATCC35984 strain) and two S. aureus strains (1 clinical
isolate and ATCC6538P strain). Apo-TF and holo-TF were used at
concentrations starting from physiological (3−4mg/ml) up to non-
bacteriostatic and non-bactericidal. Bacterial bioﬁlm formation was
assessed by Christensen assay. S. aureus adhesion and invasion assays
were performed in HeLa cell lines. Bacterial invasion was determined
by numbering viable bacteria resistant to gentamicin treatment 1 h after
infection. Bacterial adhesion was calculated as difference between total
bacterial count and bacterial invasion count, 1 h after infection.
Results: Both transferrins (TFs) do not possess bacteriostatic and
bactericidal effects. A strong reduction in bioﬁlm formation with both
TFs was obtained. In particular, the reduction in bioﬁlm formation
was higher with holo-TF rather than obtained with apo-TF. Both TFs
exerted a signiﬁcant reduction of S. aureus adhesion to and invasion of
HeLa cells. SDS-PAGE and zymogram analyses are ongoing in order to
compare surface protein proﬁles of treated and non treated samples.
Conclusion: Our results suggest that both forms of TF could be used
for antibacterial adjuvant therapy in infection sustained by staphylococci
to strongly reduce their virulence related to adhesion and invasion.
P740 Beta-lactams targeting septum formation increase Panton-
Valentine leukocidin expression by Staphylococcus aureus
O. Dumitrescu °, C. Badiou, Y. Benito, M. Bes, J. Etienne,
F. Vandenesch, G. Lina (Lyon, FR)
Objectives: S. aureus is a human pathogen producing a high number
of virulence factors, one of them being the Panton-Valentine leukocidin
(PVL) which is responsible of cutaneous abscesses but also of severe
necrotising pneumonia. Previous reports showed that PVL expression
may be modulated in vitro by beta-lactams such as oxacillin which
increase PVL release when used at sub-inhibitory concentrations. In
this work we studied the effect of several beta-lactam antibiotics of
PVL release and we explored the mechanisms by which these antibiotics
modulate PVL expression.
Methods and Results: We assayed for PVL production (by ELISA
speciﬁc quantiﬁcation and mRNA expression) of a PVL positive
reference strain cultured in presence of sub-inhibitory concentrations of
several beta-lactams. The beta-lactam tested were oxacillin (non-selective
beta-lactam), but also four molecules having speciﬁc afﬁnity for each one
of the four penicillin binding proteins (PBP) of S. aureus: imipenem
(PBP1 selective), cefotaxim (PBP2 selective), cefaclor (PBP3 selective)
and cefoxitin (PBP4 selective).
We obtained increased PVL release in the culture supernatant (2 to
3 fold) as well as increased PVLmRNA expression of the cellular pellet
(20 to 50 fold) when cultures where treated with either oxacillin or
imipenem but not with cefotaxim, cefaclor or cefoxitin.
Imipenem targets speciﬁcally PBP1, therefore we explored PBP1
depletion effect on the modulation of PVL expression by using a
Cadmium inducible pbp1 antisense RNA. We observed that bacteria
cultured in presence of Cadmium expressed high level of pbp1 antisense
RNA (up to 150 fold when compared to bacteria cultured without
Cadmium) and also increased PVLmRNA (20 to 25 fold when compared
to bacteria cultured without Cadmium).
Discussion and Conclusion: In this work we conﬁrmed that beta-
lactams, at sub-inhibitory concentrations, may modulate PVL expression
by S. aureus. We showed for the ﬁrst time that not all beta-lactams
have the ability to modulate PVL release; only those inhibiting PBP1
lead to increased PVL expression. Moreover, we showed that PBP1
depletion induces PVL expression. PBP1 being an essential enzyme
of the cell wall septum formation, our observations support the fact
that antibiotics, by blocking the septum formation, might increase PVL
expression. Based on our data, further studies are needed in order to
clarify the mechanisms by which septum formation arrest may induce
increased virulence in S. aureus.
P741 Sialic acid: a preventable signal for pneumococcal bioﬁlm,
colonisation and invasion of the host
C. Trappetti, A. Kadioglu, M. Carter, F. Iannelli, G. Pozzi, P.W. Andrew,
M.R. Oggioni ° (Siena, IT; Leicester, UK)
Objectives: The correlation between carbohydrate availability, pneu-
mococcal bioﬁlm, nasopharyngeal colonisation and invasion has been
analysed in order to investigate possible signals changing the host
microbe equilibrium.
Methods: A series of sugars were used to evaluate their impact on
extent of pneumococcal bioﬁlm formation in a mirotiter bioﬁlm assay
and in a carriage model in mice. Speciﬁcity of effects was controlled by
competition experiments using structural sugar analogues both in the in
vitro and in vivo assays.
Results: Out of a series of sugars only sialic acid (N-acetylneuraminic
acid) enhanced pneumococcal bioﬁlm formation in vitro, at concentra-
tions similar to those of free sialic acid in human saliva. In a carriage
model in mice intranasal inoculation of sialic acid signiﬁcantly increased
pneumococcal nasopharyngeal counts and instigated the translocation
of pneumococci to the lungs. Both sialic acid dependent phenotypes
could be competed by neuraminidase inhibitors DANA, zanamivir and
oseltamivir.
Conclusions: The link between levels of free sialic acid on mucosae,
colonisation and initiation of invasive disease shows how a host-
derived molecule can inﬂuence a colonising microbe and highlights
a molecular mechanism which explains the epidemiologic correlation
between respiratory infections by neuraminidase bearing viruses and
bacterial pneumonia. The data provide a new paradigm for the role of a
host compound in infectious disease pointing to new treatment strategies.
P742 Cell replacement therapy for brain damage after bacterial
meningitis: neuronal stem/progenitor cells migrate,
differentiate and integrate in organotypic hippocampal slices
injured after challenge with Streptococcus pneumoniae
S. Hofer °, G. Grandgirard, K. Oberson, A. Ducray, H.R. Widmer,
S.L. Leib (Berne, CH)
Objectives: Bacterial meningitis (BM) causes life-long disabilities in up
to 50% of the survivors. The underlying brain injury prominently affects
the hippocampus, a brain region involved in learning and memory func-
tion. Hippocampal injury is characterised by apoptosis of immature neu-
rons in the subgranular zone of the dentate gyrus (DG). Stem/progenitor
cells are promising candidates for cell replacement therapies aimed
at improving neurofunctional outcome after bacterial meningitis. Here,
hippocampal slice cultures were challenged with live Streptococcus
pneumoniae (SP) to induce apoptosis of immature neurons and subse-
quently neuronal stem/progenitor cells were evaluated for their potential
to survive, differentiate and integrate in the injured hippocampus in vitro.
Methods: An in vitro system combining long-term organotypic
hippocampal slice cultures from postnatal rats with embryonic
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stem/progenitor cells from the subventricular zone was established. To
induce apoptosis of developing neurons in the hippocampus, the brain
damage pattern characteristic for BM, the slices were kept in partially
nutrient-deprived medium and were exposed to live SP together with the
antibiotics penicillin and streptomycin to cause bacterial killing and lysis.
Stem/progenitor cells expressing green ﬂuorescence protein (GFP) were
expanded as neurospheres. Cells were then grafted into the hilus region
of the DG in injured hippocampal slice cultures after challenge with SP
and in control slices. The survival and integration of grafted cells was
examined on cryosections of the slice cultures and the differentiation
stage was assessed by immunohistochemistry.
Results: Histomorphologic analysis revealed neurite outgrowth and
migration of subventricular derived stem/progenitor cells into the
DG of hippocampal slices 7 days after engraftment. GFP-expressing
neurosphere cells were able to differentiate and to mature into neurons.
Conclusion: Grafted embryonic derived stem/progenitor cells survive,
migrate, differentiate and integrate into injured hippocampal slices with
apoptotic cell damage due to challenge with SP. The transplantation
of neurosphere derived stem/progenitor cells may hold promise for
regenerative therapies aimed at repair of brain damage in patients
suffering from neurofunctional sequelae after bacterial meningitis.
P743 Differential expression of enterococcal virulence-related
genes: clinical versus food strains
A.R. Carlos °, T. Semedo-Lemsaddek, M.T. Barreto Crespo, R. Tenreiro
(Lisbon, Oeiras, PT)
Objectives: Enterococci are Gram-positive bacteria that have been
associated both with health and illness. Understanding how these
microorganisms become pathogens and the characteristics involved in
such process might help preventing more severe diseases. In the present
investigation the differential expression of eight virulence-related genes
(cylM, cylB, cylA, cylI, agg, esp, efaAfm and efaAfs) was assessed
for six clinical, eight food and two reference enterococci. Expression
analysis was performed after enterococcal growth in media simulating
infection sites (serum, BHI and urine) and environmental colonisation
(skim milk). The effect of different temperatures (30 and 37ºC),
osmolarities (0%, 2.5%, 5.0% and 6.5%) and pH values (6.0, 7.0 and
7.4) on gene expression was also assessed.
Methods: For all strains and conditions gene expression analysis was
accomplished using Reverse-Transcriptase PCR followed by agarose gel
electrophoresis. The expression of all virulence genes was normalised
using the housekeeping genes 16S rDNA and rpoA.
Results: The expression level of the virulence-related genes analysed
varied signiﬁcantly considering all the conditions assayed (P< 0.05).
Serum was one of the media that highly promoted an increase in gene
expression. Skim milk was also found to stimulate gene expression, but
to a lesser extent. Osmolarity showed a small effect on the expression of
virulence-related genes while both pH and temperature appear to be im-
portant cues for gene expression with pH 6.0 and 37ºC greatly stimulat-
ing gene expression. While some of the strains under analysis appear to
activate gene expression only in response to a particular condition, such
as the clinical strain MMH594, other strains, (e.g. LN11, a food strain),
appear to activate their expression machinery regardless the growth
environment. However, no signiﬁcant differences were detected when
comparing the expression proﬁles of clinical and food strains (P> 0.05).
Conclusion: The expression proﬁles obtained in the present investigation
were found to be environmental and strain-dependent, since no constant
response was observed neither for clinical nor for food enterococci.
These results reinforce the need for a careful evaluation regarding the
pathogenic potential of enterococcal strains.
P744 Comparison effect of vitamin C vaginal tablet with metronida-
zole vaginal gel treatment and relapse of bacterial vaginosis
Z. Abbaspoor ° (Ahwaz, IR)
Introduction: Bacterial vaginosis is the common cause of abnormal
vaginal discharge among women of reproductive ages.
Objective: This is a randomised clinical trial study to compare the
effect of vitamin C vaginal tablet with metronidazol gel in treatment
of symptomatic bacterial Vaginosis.
Methods: After conﬁrmed diagnosis of bacterial vaginosis to Amsel
criteria (at least 3 out of the 4 characteristic symptoms discharge,
ﬁshy odour, vaginal pH 4.5, and presence >20% of clue cell), 60
non pregnant women of 15−45 years of reproductive ages enrolled in
randomised clinical study. The women were randomly assigned to receive
either 250mg vaginal tablet vitamin C once daily for 6 days (n = 30) or
vaginal gel 0.75% metronidazol 5 gr once daily for 5 days (n = 30). The
two groups resulted comparable for demographics, history and baseline
clinical picture. Participants were evaluated in two follow-up visits (after
treatment and two week after treatment). Therapeutic success was deﬁned
as the presence of less than three of Amsels criteria.
Results: At the ﬁrst follow-up visit, 23 (76.7%) of women in vitamin C
group and 24 (80%) in metro gel group were cured (P = 0.7). At second
follow-up visit two women (9.5%) in vitamin C group and one (5%)
in metro gel group bacterial vaginosis was relapse (P = 0.999). Three
women in vitamin C group and four in metro gel group were reported
occasional burring and itching during product use.
Conclusion: Vitamin C vaginal tablet 250mg has effectiveness as
metronidazol vaginal gel for treatment of bacterial vaginosis.
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P745 Non-compliance with guidelines for surgical antibiotic
prophylaxis and the risk of surgical site infection: results
from the INCISO Surveillance Network
K.Y. Miliani °, F. L’He´riteau, P. Astagneauon behalf of the INCISO
Network Study Group
Objectives: Antibiotic prophylaxis reduces the incidence of surgical site
infection (SSI) for many procedures. Nonetheless, these medications are
not always given appropriately. The aim of this study was to describe
practices of surgical antibiotic prophylaxis (SAP) and to determine
whether the risk of SSI vary according to these practices.
Methods: Data were collected during a 7-year surveillance period
(2001 to 2007) from the INCISO surveillance network based on
volunteer participation of surgery wards in Northern France. Major
aspects of SAP were evaluated including antibiotic agent choice, timing
administration of ﬁrst dose, total SAP duration and compliance to
standard guidelines. The study focused on a few standard procedures
in digestive, orthopaedic, gynaecological and cardiovascular surgery,
for which a SAP is usually recommended. Univariate and multivariate
logistic regression analyses were carried out to identify SAP-, patient-,
and procedure-speciﬁc factors associated with SSI.
Results: Of 8029 surgical procedures which were assessed for
compliance to guidelines, 7330 (91.3%) received SAP and 184 (2.6%)
developed SSIs. Among patients receiving SAP, 83.3% received
appropriate antibiotic agent and 82.6% had an optimal timing of
administration. SAP was considered to be appropriate in 35.0%,
unnecessarily prolonged in 45.2%, and shorter than recommended in
19.8% (e.g. when a single dose was administered instead of several for
a longer surgical procedure). After adjustment for surgical speciality,
NNIS risk index, age, and pre-operative hospital stay in the multivariate
analysis, the risk of SSI increased signiﬁcantly if SAP was shorter
than recommended (OR= 1.8, 95% Conﬁdence Interval: 1.2−2.8). Non
signiﬁcant relationships were observed between SSI and the other SAP
parameters.
Conclusions: Inappropriate SAP duration was the most signiﬁcant
non-compliant practice associated with an increased SSI risk after
some standard procedures. Information towards practitioners should be
reinforced based on standard guidelines.
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P746 Community and non-community-acquired bacteraemia:
correlation between empiric antimicrobial therapy and
susceptibility of micro-organisms isolated during 2007 in the
Ile de France Microbiologists Network
H. Porcheret °, D. Barraud, M. Bingen, T. Rabenja, Y. Costa,
V. Este`ve, F. Faibis, M.C. Demachy, A. Scanvic, E. Valle´e, Y. Pe´an
(Aulnay-sous-Bois, Gonesse, Lagny, Orsay, Meaux, Argenteuil,
Saint-Germain-en-Laye, Paris, FR)
Objectives: The aim of the study was to analyze the antimicrobial
therapy administrated before the ﬁrst positive blood culture result and
the antibiotic susceptibility of the isolates
Methods: During 2007 in the 8 hospitals of the Ile de France network,
empiric antimicrobial therapy was reported for all patients with a positive
blood culture. Antibiotic susceptibility was determined according to the
recommendations of the French Microbiology Society. The therapy was
deﬁned as “appropriate” if the patient received at least one antibiotic
the micro-organism was susceptible to. This deﬁnition was not based
on clinical efﬁcacy. The bacteraemia was community acquired or not
according to clinical and anamnestic features.
Results: On the 2013 bacteraemia, 58.3% were community-acquired and
41.7% were non-community-acquired infections. Antimicrobial therapy
was appropriate in 1286 (64%) cases, inappropriate in 266 (13%),
and no antibiotic was administrated in 461 (23%). In these ﬁrst
two cases, large spectrum antibiotics were most frequently used:
third generation cephalosporins (25%), aminoglycosides (13−19%),
ﬂuoroquinolones (15−16%). Therapy was more frequently appropriate
if the bacteraemia was community-acquired, was monomicrobial
(Streptococci, Pneumococcus, or Escherichia coli), was associated with
urinary or respiratory tract infection and if it occurred in paediatrics
or maternity patients. Among non-community-acquired bacteraemia,
appropriate therapy rate was almost the same for mono or polymicrobial
bacteraemia, higher for Enterobacteriaceae and Streptococci and lower
for Pseudomonas aeruginosa and Staphylococci bacteraemia.
Conclusions: Empiric antimicrobial therapy before blood cultures results
was not prescribed in 23% of episodes. Those patients might have nor
sepsis nor severe clinical features. Therapy of non-community-acquired
bacteraemia might require multidisciplinary approach, while national
recommendations were enough to take care of patients with community
bacteraemia.
P747 Efﬁcacy of tigecycline versus ceftriaxone and metronidazole
for complicated intra-abdominal infections: Americas
study 400
S. Towﬁgh, J. Pasternak, A. Poirier, H. Leister, T. Babinchak °on behalf
of the 400 Study Group
Background: Tigecycline (TGC) has demonstrated clinical efﬁcacy and
safety versus imipenem-cilastatin in previous clinical trials in subjects
with complicated intra-abdominal infections. The current study was a
multicentre, open label, randomised, comparative study of tigecycline
versus ceftriaxone (CTX) plus metronidazole (MET) for the treatment
of hospitalised subjects with complicated intra-abdominal infections
conducted in 6 countries in North, Central and South America.
Methods: Subjects meeting the deﬁnition of complicated intra-
abdominal infection (i.e. local or systemic infections secondary to a
physical perforation in the gastrointestinal tract or via a necrotic gut wall
into the peritoneal space, leading to abscess formation or peritonitis) and
requiring surgery or a percutaneous drainage procedure in addition to
intravenous antibiotics were randomised to receive TGC 100mg loading
dose followed by 50mg q 12 hours or CTX 2 grams once daily, plus
MET 1 gram to 2 grams daily, for a minimum of 4 days and not more
than 14 days. Patients were stratiﬁed at randomisation for APACHE II
scores 10 or >10. Subjects were not allowed to receive oral therapy.
The primary efﬁcacy endpoint was the clinical response in the clinically
evaluable (CE) population at the test of cure (TOC) assessment up to
21 days after the last dose of test article.
Results: For the CE population, clinical cure rates were 70.4% (133/189)
for TGC versus 74.3% (139/187) for CTX plus MET (95% CI
−13.1, 5.1; p = 0.009 for non-inferiority). Clinical response for subjects
with APACHE II scores >10 were 56.8% (21/37) for TGC versus
58.3% (21/36) for CTX plus MET. Microbiologic efﬁcacy was similar
between the two treatment arms with 68.1% (94/138) of TGC treated
organisms and 71.5% (98/137) of CTX plus MET treated organisms
considered eradicated at the TOC. The most frequently reported adverse
events (AE) were nausea 38.6% and vomiting 23.3% in the TGC subjects
and 28.6% and 18.2%, respectively, in the CTX plus MET subjects.
Overall discontinuation rates due to AE were slightly higher in TGC
subjects than comparator subjects, 8.9% and 4.8%, respectively.
Conclusion: Tigecycline monotherapy was found to be non-inferior to
a combination regimen of CTX plus MET in subjects with complicated
intra-abdominal infections.
P748 Tigecycline use in nosocomial osteomyelitis
L. Michelim °, A. Falavigna, J. Fracasso, P. Garrido, F. Morsch,
P. Zimello (Caxias do Sul, BR)
Objective: New antimicrobial agents are urgently needed for clinical use
due to the increasing prevalence and spread of multidrug-resistant bac-
teria. Speciﬁcally, multidrug resistant Gram-negative bacteria containing
expanded spectrum b-lactamases (ESBL), commonly found in hospitals,
has severely limited the number of antimicrobial agents available for use.
Tigecycline is a ﬁrst-in-class glycilcycline antibiotic, and is indicated
for the treatment of complicated skin and intra-abdominal infections
caused by susceptible microorganisms. In osteomyelitis, this antibiotic
is not indicated nor has such use been systematically evaluated in human
studies. The authors describe 10 cases of osteomyelitis that tigecycline
has been used to treat multidrug-resistant bacteria.
Methods: Report of 10 cases of nosocomial osteomyelitis due to ESBL
Escherichia coli and Klebsiella pneumoniae infection. In all cases,
the diagnosis had been done based on the clinical ﬁndings, imaging
procedures and data from laboratory tests: leukocytosis, elevations in
the erythrocyte sedimentation rate, and C-reactive protein level. Blood
cultures were negative, but bone cultures were positive in six samples
for ESBL E. coli (three from lumbar spinal column biopsy and three
from sacrum biopsy) and four samples of K. Pneumoniae (two from
tibia biopsy and two from femur biopsy). All 10 patients had allergic
reactions due to the use of carbapenens, and treatments were changed to
tigecycline intravenous (100mg initial dose, then 50mg every 12 hours).
Results: In the ﬁrst week of treatment, clinical and laboratorial improve
were evident. After 14 days of treatment, all the patients had negative
bone cultures. The use of tigecycline was extended for more 46 days to
complete treatment.
Conclusion: Although tigecycline is not indicated for the treatment of
osteomyelitis and the duration of therapy is for a maximum of 28 days,
the authors report ten cases of successful use for a longer period in
osteomyelitis. We suggest that this antibiotic can be an option for ESBL
treatment in patients that carbapenens can not be use.
P749 Macrolide use in intensive care units
E. Meyer °, P. Gastmeier, B. Schroeren-Boersch, F. Schwab (Berlin, DE)
Objectives: To analyse macrolide use in German intensive care units
(ICUs) participating in the SARI (Surveillance of Antimicrobial Use
and Antimicrobial Resistance in Intensive Care Units).
Methods: Prospective unit based surveillance in 43 German ICUs from
2006 to 2007 (16 interdisciplinary, 9 medical and 18 surgical ICUs).
Monthly data on antimicrobial use were obtained from the computerised
pharmacy database. Consumption i.e. antimicrobial usage density (AD)
was expressed as daily deﬁned doses (DDD) and normalised per
1000 patient-days (pd).
Results: In 2006 and 2007, 43 ICUs reported data on 361,824 pd
and the pooled mean antibiotic consumption of 1213 DDD/1000 pd
without sulbactam. The median macrolide use was 102 (range 2–157)
in interdisciplinary ICUs, 99 in medical ICUs (range 47–345) and 40
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in surgical ICUs (range 1–150). Median erythromycin use accounted for
52% of total macrolide use in interdisciplinary ICUs, 26% in medical,
but 80% in surgical ICUs. The median percentage of macrolides on total
antibiotic use was 9% (range 0−13) in interdisciplinary, 7% (range 4−24)
in medical and 3% (range 0−12) in surgical ICUs.
Conclusion: Erythromycin is not only used as an antibiotic but
also as a systemic acting prokinetic drug e.g. to treat postoperative
adynamic ileus in patients undergoing abdominal surgery. However,
recent Cochrane reports stated that erythromycin showed “homogenous
and consistent absence of effect” as prokinetic drug. Therefore, it seems
most worthwhile to revise the indication of erythromycin use especially
in surgical ICUs all the more macrolide use accounted considerably to
total antibiotic use in surgical ICUs (up to 12%). Furthermore, macrolide
use is a known risk factor for MRSA.
P750 Intravenous fosfomycin for the treatment of nosocomial
infections due to carbapenem-resistant Klebsiella pneumoniae
in critically ill patients. A prospective evaluation
A. Michalopoulos, S. Virtzili, P. Rafailidis, G.H. Halevelakis,
M. Falagas ° (Athens, GR)
Objective: Nowadays ICU-acquired infections due to MDR Gram-
negative pathogens remain a serious problem in critically ill patients. We
examined the safety and effectiveness of fosfomycin in adult patients
with ICU acquired infections due to carbapenem-resistant Klebsiella
pneumoniae (K. pneumoniae).
Methods: To assess the safety and effectiveness of intravenous
fosfomycin as an adjunctive to the intravenous antimicrobial therapy for
the treatment of life-threatening infections due to carbapenem-resistant
K. pneumoniae, we prospectively examined all patients, who received
intravenous fosfomycin.
Results: Fosfomycin was administered intravenously in 10 critically ill
patients of mean age 67.3±15.2 years old (6 females) for treatment of
hospital-acquired infections due to carbapenem-resistant K. pneumoniae.
Mean APACHE II score on ICU admission was 23.1. Fosfomycin (2−4 gr.
every 6 hours) was administered in combination with colistin in 6 pa-
tients, or gentamicin in 3 patients. Patients received fosfomycin for bac-
teraemia (n = 2), VAP and bacteraemia (n = 2), VAP plus urine tract infec-
tion (UTI) (n = 2), UTI (n = 2), bacteraemia and wound infection (n = 1),
and wound infection (n = 1). The median time for the development of
infection due to carbapenem-resistant K. pneumoniae was 29.5 days
following admission to the hospital. The majority of patients developed
multiple nosocomial infections mainly due to MDR Gram negative
bacteria prior to this episode. The mean (± SD) duration of treatment
was 14 (±5.6 days. All patients had good bacteriological and clinical
outcome of infection. All-cause hospital mortality was 2/10 (20%);
both patients died later on because of septic shock of other cause and
multiple organ failure. Patients had prolonged ICU length of stay (median
LOS = 34 days) and hospital stay (median LOS = 87.5 days). No patient
developed adverse events related to the administration of fosfomycin.
Conclusion: Intravenous fosfomycin may be a beneﬁcial and safe
adjunctive treatment in the management of life-threatening ICU-acquired
infections due to carbapenem-resistant K. pneumoniae in critically ill
patients.
P751 Relationship between piperacillin-tazobactam consumption
and bacterial resistance in Colombian hospitals. A time-series
analysis, 2004–2007
G. Buitrago, C.A. Alvarez, A.L. Leal, J.S. Castillo, J. Martinez,
R. Sanchez, J.A. Cortes °, A. Jimenez, O. Chaves, A.F. Meneses
(Bogota, Cucuta, CO)
Objectives: Determine the relationship between the piperacillin-
tazobactam (TZP) consumption and resistance of Pseudomonas aerug-
inosa and Klebsiella pneumoniae to this antibiotic in three high
complexity hospitals from Colombia.
Methods: Ecological time series study to relate the effect of TZP
consumption in P. aeruginosa and K. pneumoniae resistance. Monthly
hospital consumption of TZP was collected in three hospitals of two
cities in Colombia (Bogota and Cucuta). Antibiotic consumption was
grouped as the number of deﬁned daily doses (DDD) per 100 bed-
days (World Health Organization) each month between January 2004
and December 2007 (48 periods). P. aeruginosa and K. pneumoniae
resistance to TZP was determined as the proportion of resistant isolates
reported by hospital laboratory, data was analyzed in Whonet 5.4®
(Geneva, WHO). Resistance proportions were translated to odds and log
transformed (ln[R/(1 − R)]). Univariate monthly series per hospital were
performed for consumption and resistance (ARIMA – Box Jenkins).
The relationship between both variables was explored using transfer
function models per institution. All time series analysis were done in
SCA (Villa Park, USA).
Results: Average monthly consumption of TZP was 1.36 DDD per
100 bed-days. In the three hospitals there was an upward trend in
TZP consumption for study period. There was an absolute increase of
0.56, 1.81 and 3.33 DDD per 100 bed-days for each hospital. Monthly
average resistance proportion in each hospital was 13.9, 19 and 36.8% for
K. pneumoniae and 4.7, 24.4 and 37.1% for P. aeruginosa. Univariate
consumption analysis shows an increase. Transfer function in the six
models evidence consistency between the statistical association of TZP
consumption and the expression of resistance to this antibiotic for
K. pneumoniae and P. aeruginosa (Figure 1).
Conclusions: There is consistent relationship between TZP consumption
and resistance of K. pneumoniae and P. aeruginosa to this drug. TZP
consumption can explain until 20% of resistance found in P. aeruginosa
and 12% in K. pneumoniae. Remaining unexplained resistance can be
related to other uncontrolled factors not considered in the models.
P752 Surveillance of antimicrobial consumption patterns in high
complexity hospitals in Colombia, 2002–2007
G. Buitrago, J.S. Castillo, A.L. Leal, C.A. Alvarez, J.A. Cortes °,
A.F. Meneses (Bogota, CO)
Objectives: Describe novel information about antimicrobial consump-
tion patterns in a reference hospital wide network in Colombia
Methods: Surveillance of antimicrobial consumption prescribed in
hospitals (intravenous indications) of ten wide used antibiotics in
the country, from january 2002 to december 2007. The follow-
ing antimicrobials were studied: amikacin, ampicillin/sulbactam, ce-
fepime, ceftazidime, ceftriaxone, ciproﬂoxacin, clindamycin, imipenem,
meropenem, oxacillin, piperacillin/tazobactam, vancomycin. Ten refer-
ence hospitals from ﬁve most important cities in the country including
capital city reported antimicrobial consumption in milligrams from
pharmacy registers, prescribed drugs were grouped as the number
of deﬁned daily doses (DDD) per 100 bed-days (World Health
Organization). Information in DDD per 100 bed-days was monthly
grouped. All descriptive analysis were performed, we describe temporal
patterns using time series analysis of median consumption for each
month (72 periods).
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Results: ten hospitals at the end of the observation period notiﬁed an-
timicrobial consumption information. There is an important decrease in
general use of ciproﬂoxacin and the reject of ceftazidime use from 2004.
An upward trend can be observed and predicted for ampicillin/sulbactam,
ceftriaxone, meropenem, piperacillin/tazobactam and vancomycin. The
rising in meropenem use is set in contrast with imipenem steady trend.
Trends of some antibiotics are shown graphically in Figure 1.
Conclusions: antimicrobial consumption surveillance is a main step in
antimicrobial stewardship programs design. The Nosocomial antibiotic
use patterns could be reﬂecting the effect of rational use strategies in
studied hospitals, microbiological proﬁles and antimicrobial availability
conditions. This ﬁrst report of antimicrobial consumption in hospitals
in our country establishes the need for further research in the
antimicrobial use and the relationship with antimicrobial resistance and
the identiﬁcation of determinants to direct control strategies.
Figure 1. Antimicrobial consumption trends in DDD per 100 bed-days.
Colombia, 2002–2007.
P753 Need for dose adjustment in hospitalised patients using
intravenous antibiotics in a university hospital
J.A. Cortes °, J.Y. Rodriguez (Bogota, CO)
Objective: To evaluate the need for dose change of antibiotics among
hospitalised patients according to pharmacodynamic targets.
Methods: Antibiotic use for IV administration was reviewed in every
admitted patient to a new universitary hospital. In those in which
serum creatinine levels were available the creatinine clearance (CrCl)
was calculated, as was the need for dose adjustment. Therapeutic
objectives were determined according to pharmacodynamic (PD) targets
(beta/lactams time>MIC: penicillins >50%, cephalosporins >65%,
carbapenems >40%; quinolones AUC/MIC> 100; aminoglucosides
Cmax/MIC> 10). MIC90 for the most frequently found microorganisms
(example: S. pneumoniae for community pneumonia) were used in the
PK&PD calculations. In those not reaching a PD target, the percentage
of dose increase was also calculated.
Results: During the two ﬁrst months of the new universitary hospital,
234 antibiotic formulations were reviewed, for 117 hospitalised patients,
55.2% of them were women. The mean age was 64.5 years-old (range
16−95). The most frequent diagnosis were urinary tract infection
(30.7%), followed by skin and soft tissue infections (20.3%), community
acquired pneumonia (17.7%) and COPD exacerbations (10.8%). 71.3%
of the patients with antibiotic formulations had a creatinine level and
CrCl was calculated. The mean CrCl was 65.6ml/min (range 10–127).
10.7% of the patients had a CrCl lower than 30ml/min and 28.1% had
a CrCl lower than 50ml/min.
Conclusions: Dose adjustments for renal impairment is frequently
required, specially among older patients. Stewardship programs for
correct antibiotic use might contribute to a better administration of IV
antibiotics in older patients, specially if PD targets are used.
Antibiotic N % reaching
PD target
% of dose reduction
(range)
% of dose increase
(range)
Ampicillin/sulbactam 120 93.3 71 (9−97) 52 (3−84)
Cephalotin 36 27.7 18 (3−28) 147 (7–404)
Oxacillin 16 86.6 79 (10−81) 2768 (66–5470)
Piperacillin/tazobactam 10 80 36 (19−62) 13 (2−24)
Ciproﬂoxacin 9 0 0 261 (50–513)
Ceftriaxone 8 100 70 (0−90) 0
Meropenem 3 100 60 (30−78) 0
Aminoglycosides 3 100 50 (22−70) 0
P754 Ten years of antibiotic consumption in ambulatory care:
trends in prescribing practice and antibiotic resistance in
Austria
S. Metz-Gercek °, A. Maieron, R. Straub , P. Wieninger, P. Apfalter,
H. Mittermayer (Linz, AT)
Objectives: The primary aims of this study were to determine (i) the
quantity and pattern of antibiotic use in Austria between 1998 and
2007, (ii) to analyze antibiotic resistance rates in relation to antibiotic
consumption in important clinical situations in order to provide data for
empiric therapeutic regimens in key indications.
Methods: Consumption data and resistance data were obtained via
the Austrian European Antimicrobial Resistance Surveillance System
(EARSS) and the European Surveillance on Antimicrobial Consumption
(ESAC). The Anatomical therapeutical chemical (ATC) classiﬁcation and
the deﬁned daily dose (DDD) measurement units were assigned to the
data. DDDs and the number of packages (PID) were used to calculate the
amount of antibiotic consumption. Antibiotic resistance was expressed
in resistance rates being the percentage of resistant isolates compared to
all isolates of one bacterial species.
Results: The overall antibiotic consumption measured in DIDs showed
an increase of 10% between 1998 and 2007 whereas in PIDs a
decrease of 3% was found. The consumption for substances within
the drug utilisation 90% segment measured in PID increased for
ciproﬂoxacin (+118.9), clindamycin (+76.3), amoxicillin/clavulanic acid
(+61.9%), cefpodoxim (+31.6), azithromycin (+24.7) and decreased for
erythromycin (−79.5%), trimethoprim (−56.1%), norﬂoxacin (−48.8%),
doxycycline (−44.6), cefaclor (−35.1%), penicillin [(−34.0%), (pen)]
amoxicillin (−22.5), minocycline (−21.9%) and clarithromycin (−9.9%).
Since 2001, an increase in the percentage of resistant invasive E. coli
isolates for aminopenicillins (from 35%-53%), ﬂuoroquinolones (from
7%-25.5%) and 3rd generation cephalosporins (from 0%-8.8%) was
observed. The percentage of pneumococcal isolates (spn) non- or
intermediate susceptible to pen remained stable over the years at around
5%. In macrolides the rate of resistant isolates increased from 5% to
12.8% with a peak in 2005 at 14.7%.
Conclusions: The Austrian resistance data do not explain the change in
prescribing practice. The increased use of ciproﬂoxacin has most likely
contributed to rising resistance rates in E. coli. Because of very low levels
of resistance against penicillin in spn there is no need for the application
of broadspectrum pen, pen combination products (amoxicillin/clavulanic
acid), third generation cephalosporins as well as new ﬂuoroquinolones
for the treatment of community acquired pneumonia in ambulatory care
patients.
P755 Theory of planned behaviour and its use in antibiotic
prescribing in a hospital setting
P. Cortoos °, W.E. Peetermans, B. Schreurs, K. De Witte, G. Laekeman
(Leuven, BE)
Background and Objective: In order to understand barriers against
antibiotic guideline use, qualitative methods have proven to be efﬁcient.
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However, they do not provide quantitative data allowing to track the most
inﬂuential problems. The Theory of Planned Behaviour (TBP) describes
the inﬂuence and relative importance of barriers on intention and
behaviour. In this model, intention is moderated by Attitude against the
behaviour, how it is perceived by others (Subjective Norm (SN)) and the
ability to perform the behaviour (Perceived Behavioural Control (PBC)).
We present the development and testing of a TBP-based questionnaire
aimed to improve use of antibiotic guidelines.
Design: Barriers against guideline use were identiﬁed by focus group
discussion (Cortoos, 2008) and were sorted in 3 categories: Attitude
(What do you believe are the (dis)advantages of using AB guidelines?);
SN (Are there any individuals or groups that would (dis)approve your
AB guideline use?); PBC (What factors enable/prevent using the AB
guidelines?). Sorting was done by 2 independent researchers. Within
each category, barriers with highest quotation frequency were used
for the questionnaire (Francis, 2004). Every category was completed
with 4−6 generic questions, directly measuring the speciﬁc category. To
test the inﬂuence of habit, a 12-item questionnaire was also included
(Verplanken, 2003). Intention towards improved guideline use was
measured with 3 generic questions. Actual use of antibiotic guidelines
(behaviour) was measured on a scale between 0 and 10. All other
questions used a 7-point Likert scale. The questionnaire was piloted
within a paediatric department among 10 randomly selected physicians
with various experience and professional status.
Setting: tertiary care university hospital. This study is part of a larger
project on guideline compliance.
Results: No major remarks were made on the questionnaire. A limited
multivariate analysis showed a good ﬁt (R2 = 0.865; P< 0.001) with
signiﬁcant inﬂuence of habit (P< 0.001) on intended use of antibiotic
guidelines with a smaller inﬂuence of PBC (P = 0.014). SN and Attitude
were not signiﬁcant.
Conclusions: As a result of this pilot study, the questionnaire will be
used on a larger scale in different hospitals. Preliminary analysis shows
a major inﬂuence of habit on intended use of antibiotic guidelines
combined with a modest inﬂuence of external factors. Attitude and
supervisors or peers appear to be of low inﬂuence.
P756 Inﬂuence of a restriction model on the rational use of
antibiotics in a large, secondary care hospital
A.M. van den Abeele, M. Baert, D. Rijckaert, D. Ommeslag ° (Ghent, BE)
Objectives: Judicious use of antibiotics for resistant Gram positive
organisms is difﬁcult to organise. We present 5-year data (2003–2007)
concerning therapeutic indications, posology, monitoring and side effects
of vancomycin (VAN) and linezolid.(LZD)
Methods: Sint-Lucas hospital (816 beds) has a multidisciplinary,
antibiotic restriction model in use, organised by the local antibiotic
management team (AMT). For over 5 years, selective delivery of VAN
and LZD by hospital pharmacy is possible only after clinical and
microbiological consultation, available on daily base and combined
with (daily) therapeutic monitoring and dose adjustments. Methicillin-
resistant Staphylococcus aureus (MRSA) or coagulase negative staphy-
lococci (MRSE) infections are predominantly caused by catheter-related
(CVC) or neutropenic septic episodes, osteomyelitis, postoperative
meningitis and endocarditis. These infections are registered continuously
and matched with usage of VAN and LZD.
Results: Over 80% of all patients have documented MRSA/MRSE
infection. Over 5 years the number of treated patients with VAN is stable
(n=±100/year). Underdosing of VAN is frequent only in haemodialysis
patients. Overdosing with serious side effects seldom occurs.
Consumption of LZD is growing (n = 5 in 2003 to n = 45 in 2007). Over
65% of LZD treated patients have received VAN ﬁrst, in 20% LZD was
ﬁrst choice because of renal insufﬁciency or CVC problems. Duration
of treatment with LZD in different indications was not standardised with
treatment times between 5 and 70 days.
Conclusions: The concept of a restriction model for antibiotics has
been a major factor in reducing antibiotic pressure and total cost in
the hospital. Continuous registration and antibiotic stewardship by AMT
helps to achieve therapeutic levels of VAN and minimises side effects of
VAN and LZD in the individual patient. It also contributes to tailor local
therapeutic guidelines. Duration of treatment for several indications has
to be improved.
P757 Prevalence of antibiotic use in hospitals in Cyprus
E. Kritsotakis, E. Vounou, M. Kontou, P. Papakyriakou,
M. Koliou-Mazeri, I. Dimitriadis, A. Gikas ° (Heraklion, GR; Limassol,
Nicosia, Pafos, Larnaca, CY)
Objectives: There are few data on antibiotic prescribing within Cypriot
hospitals. This study, set out as part of a larger study of nosocomial
infections, aimed to obtain main indicators of hospital antibiotic use in
Cyprus.
Methods: A point prevalence survey was conducted in the 5 public
hospitals of Cyprus in November 2006. The survey included all
inpatients older than 1 year who, on the study day, had been present for
at least 24 hours in the hospital. Data collected for all patients included
demographics, antibiotics for systemic use received on the survey day
and duration of prescription.
Results: On the survey day, 345 out of the 705 screened patients
(48.9%) were receiving antibiotics (interhospital range: 38.8−53.3%),
of whom 115 patients (33.3%) were receiving combination therapy.
The highest prevalence of antibiotic use was observed in surgical
wards (59.9%), followed by paediatric wards (54.2%), intensive care
units (50%), medical wards (42.8%), and gynaecology-obstetrics wards
(20.6%). A total of 176 patients (51.0%) received empirical treatment;
119 patients (34.5%) received surgical prophylaxis, and 30 patients
(8.7%) received antibiotics for bacteriologically documented infection.
For 20 patients (5.8%), no justiﬁcation for antibiotic use was provided.
Of the patients who received perioperative prophylaxis, 82 patients
(68.9%) had undergone surgical operations classiﬁed as “clean”. The
median duration of perioperative prophylaxis was 3 days (interhospital
range: 2.0−3.5 days). Out of the total 468 antibiotics prescribed, the
most commonly used classes included third generation cephalosporins
(23.5%), second generation cephalosporins (17.9%), imidazoles (11.5%),
ﬂuoroquinolones (10.3%), carbapenems (8.1%), macrolides (5.3%), and
glycopeptides (5.1%).
Conclusion: A high prevalence of hospital antibiotic use was found in
Cyprus, compared to the prevalence seen in other European countries.
The frequent use of combination therapy and broad spectrum antibiotics,
their use in clean surgery and the extended duration of surgical
prophylaxis observed in this study, are indicative of the potential for
limiting and improving prescribing. Study data emphasize the need to
develop effective antibiotic surveillance and management programmes
in Cypriot hospitals.
P758 Antimicrobial prescribing awareness campaign in the
emergency department
S. Foley °, F. Fitzpatrick, B. Masake, E. Smyth, H. Humphreys (Dublin,
IE)
Background and Objectives: Antibiotics are frequently prescribed in
the Emergency Department (ED) and continued for the duration of a
patient’s admission. Doctors in the ED change every 6 months and
frequently come from other hospitals. A September 2007 audit revealed
that ED doctors prescribed the majority (68.6%) of antibiotics, 44%
did not comply with hospital prescribing guidelines and microbiological
investigations were not sent in 24% patients. As the initial prescription
and investigations can affect a patient’s outcome, a hospital wide
programme was commenced targeting prescribers, speciﬁcally in ED.
Methods: A ‘quick reference’ antimicrobial prescribing guide was
created, distributed to all doctors and placed on the hospital intranet
homepage. Antimicrobial prescribing awareness education sessions were
held for ED doctors. Weekly ﬁve minute educational sessions were
performed by the microbiology team at medical grand rounds. An
antimicrobial restriction list was put in place. The ED audit was repeated
in September 2008.
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Results: Ninety-ﬁve medical patients, (age range: 19−92 years)
were prescribed 126 antimicrobials in the ED in September 2008.
The most commonly prescribed antibiotics were co-amoxiclav (56),
clarithromycin (24) and piperacillin-tazobactam (13). 63.5% (80/126)
of prescriptions were appropriate. The referral of microbiological
investigations also increased to 81.1% (77/95 patients). Attendance at
the weekly microbiology sessions has been good and feedback positive.
Conclusions: Antimicrobial prescribing in the ED improved following
the introduction of education sessions and the ‘quick reference’
antimicrobial guide. The weekly ﬁve-minute antimicrobial information
sessions were particularly successful in targeting one ‘key message’,
however it was important to also target the ED speciﬁcally with education
sessions due to staff rotas making attendance at medical rounds difﬁcult.
As doctors in the ED continue to change, educational sessions are
ongoing, the antimicrobial guide will be reviewed in July 2009 and
compliance re-audited in September 2009.
P759 A one-day prevalence study: the evaluation of antibiotic use
and cost in a training hospital
A. Inan °, D.O. Ozturk, N. Ceran, S. Senbayrak, I. Erdem, P. Goktas
(Istanbul, Tekirdag, TR)
Purpose: Rational antimicrobial use is important not only for the
effectiveness of the treatment but also to prevent spread of antimicrobial
resistance and to decrease unwanted side effects and high costs.
The aim of this study was to determine the usage patterns of antibiotics
and cost of antibiotic therapy in hospitalised patients.
Methods: This one-day, cross-sectional study was conducted in
Haydarpasa Numune Hospital, a 750-bed training and research hospital
in Istanbul. On December 30, 2008 each hospitalised patient on medical
and surgical wards was visited particularly by an infectious diseaes
specialist, and in the patients who received antibiotic, data concerning
patient and antibiotic therapy were recorded. Statistical analysis was
made Fisher’s exact test and the cost of antibiotic therapy was calculated
as United States Dollars.
Results: On the study day 542 inpatients were evaluated. Antibiotic
usage rate was 40.4% in all hospitalised patients and it was 36.9% and
44.3% in the patients on the surgical and medical wards, respectively
(p> 0.001). The most frequently used antibiotic was ampicillin–
sulbactam in medical wards and cefazolin in surgical wards. The total
empirical antibiotic use was more frequent (48.4%) than prophylactic
(29.6%) and speciﬁc (based on culture result, 21.9%) use. The 23% of
the antibiotic use in inappropriate and these prescribed antibiotics don’t
need Infectious Disease Specialist’s approval. The total one-day cost of
antibiotic therapy in our hospital was 5496 dollars, the mean daily cost
per patient was 2.3 dollars for prophylaxis, 15.3 dollars for community
acquired infections and 99.5 dollars for hospital infections.
Table 1. Antibiotic usage rates in Haydarpasa Numune Teaching Hospital
Medical wards Surgical wards Total
n % n % n %
Ampicillin-sulbactam 57 19.3 58 16.0 115 17.5
Cefazolin 6 2.0 122 33.7 128 19.4
Ceftriaxone and cefotaxime 41 13.9 44 12.1 85 12.9
Ceftazidime 5 1.7 − 5 0.7
Cefoperazone-sulbactam 22 7.4 4 1.1 26 3.9
Piperacillin-tazobactam 46 15.6 28 7.7 74 11.2
Imipenem/cilastatin and meropenem 41 13.9 14 3.8 55 8.3
Teicoplanin and vancomycin 25 8.4 15 4.1 40 6.0
Linezolid 4 1.3 2 0.5 6 0.9
Gentamicin and amikacin 8 2.7 23 6.3 31 4.7
Ciproﬂoxacin and levoﬂoxacin 11 3.7 4 1.1 15 2.2
Metronidazole 13 4.4 44 12.1 57 8.6
Clarithromycin 5 1.7 – 5 0.7
Other antibiotics 11 3.7 4 1.1 15 2.2
Total 295 100.0 362 100.0 657 100.0
Conclusion: This study showed that the antibiotic usage rate was 40.4,
inaproppriate usage rate was 23%, the total one-day cost of antibiotic
therapy was 5496 dollars, and the total daily cost for hospital infection
was 3583 dollars in our hospital. The antibiotic cost of hospital infections
is an important part of extra costs that should be reduced providing effec-
tive infections control strategies and rational antibiotic usage in hospitals.
P760 Antibiotic consumption in Lithuanian general and nursing
hospitals and inﬂuencing factors
A. Palekauskaite °, A. Berzanskyte, R. Valinteliene (Vilnius, LT)
Background: Surveillance of antibiotic consumption and investigation
of inﬂuencing it factors in hospitals is important tool of resistance
control. In Lithuania only preliminary crude data on total consumption
are available with limited information from hospitals. The main aim
of our study was to determine antibiotic consumption and inﬂuencing
factors in general and nursing hospitals.
Methods: Data on the consumption of antimicrobial agents for systemic
use (ATC group J01) in 2007 and data on the inﬂuencing factors were
collected by questionnaires sent to all general (66) and nursing (50)
hospitals (response rate respectively – 71.2% and 82.7%). The ABC
Calc from the WHO, version 3, was used to calculate the number of
DDD/100 bed days of purchased antibiotics. Frequencies of existing
inﬂuencing factors were used for comparison analysis. Differences
between compared hospitals’ groups were accepted as statistically
signiﬁcant, when P< 0.05, counting Pearson’s c2 or Fisher’s exact test
for proportions.
Results: There was huge variation of antibiotic consumption (ranging
from 11.5 tol 79.5 in general and from 0 to 26.6 DDD/100-bed
days in nursing hospitals) and their structure between hospitals. The
total antibiotic consumption was 40.6 DDD/100-bed days in general
hospitals with three most used groups: penicillins (18.7 DDD/100-
bed days), aminoglycosides (5.8) and cephalosporines (6.0). Antibiotic
consumption in nursing hospitals was 9.7 DDD/100-bed days. The most
used were penicillins (6.2 DDD/100-bed days), tetracyclines (1.5) and
aminoglycosides (1.1). Only 25.5% of general and 2.1% of nursing
hospitals have regulations on antibiotic prescribing. 44.7% of general
and 16.7% of nursing hospitals have infection control specialists. None
of the hospitals performs antibiotic consumption surveillance. In nursing
hospitals higher antibiotic consumption was conditioned by lectures
about antibiotic use organised by pharmaceutical companies. In general
and nursing hospitals lower antibiotic consumption was conditioned by
lectures given by universities.
Conclusions: The study revealed that antibiotic consumption in Lithua-
nian hospitals is not high. Big variations and expected misjudgment
due to antibiotics purchased by patients themselves conﬁrmed that the
surveillance of antibiotic consumption should be stimulated in hospitals.
Importance of some inﬂuencing factors indicated the need to revise
regulations and audit procedures.
P761 Sustained favourable impact of an antibiotic management
programme on the prescription of ﬂuoroquinolones in a
tertiary hospital after 4 years
M. Lafaurie °, C. Jansen, M. He´bert, B. Didry, J.L. Donay, S. Touratier
(Paris, FR)
Objectives: The increase of bacterial resistance and of ﬂuoroquinolones
(FQ) consumption led us to set up an action plan in order to improve
the use of FQ.
Methods: The impact of the programme was evaluated by comparing
results of on a given day audits on FQ prescriptions, done in all
wards of our institution (medicine, surgery and ICU) in 12/2005 (ie
before implementation of the action), in 01/2007 and in 12/2008. Global
antibiotics and FQ consumption in our hospital were also compared
throughout the intervention. Main points of the action led by the
antimicrobial stewardship programme team were as follows: feedback
to the prescribers of the ﬁrst and second one day audits, redaction and
diffusion to all prescribers of a pocket-size leaﬂet of recommendations
on FQ utilisation, direct daily educational interaction with the prescribers
for antibiotic prescriptions, with emphasis on FQ use.
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Results: The prevalence of FQ prescriptions among hospitalised patients
were 9.7% in the 1st audit, 6.2% in the 2nd in 2007 and 4.2% in the
3rd in 2008. FQ were prescribed in patients treated for hematologic or
solid tumours in 43%, 60% and 56.5% of cases in 2005, 2007 and 2008
respectively. FQ were prescribed in an empirical situation in 74% of cases
in 2005, 50% in 2007 and 62.5% in 2008. The use of the intravenous
(IV) route decreased from 45% in 2005 to 27% in 2007 and 34.8% in
2008 and was deemed not justiﬁed in 27% of IV prescriptions in 2005,
37.5% in 2007 and in 25% of cases in 2008. The unit dose of FQ was
appropriate in 90% of prescriptions in the 3 audits and the frequencies
of administration were appropriate in 92, 93 and 95% of prescriptions
in 2005, 2007 and 2008 respectively.
Consumption of FQ in the hospital decreased from 145 deﬁned daily
dose per 1000 patient-days (DDD/1000 PD) in 2005 to 101 DDD/1000
PD and 95 DDD/1000 PD in 2007 and 2008 respectively (−34.5%
between 2005 and 2008). Global institutional antibiotics consumption
decreased by 18% between 2005 and 2008.
Conclusion: The intervention by the antimicrobial stewardship team
contributed to the dramatic and sustained decrease in the consumption
of FQ. The use of FQ in empirical treatments had also decreased but
still remains high. The appropriateness of the route of administration
(oral administration when possible) and of the unit dose could also
be optimised. The results should be maintained and the quality of
prescriptions reinforced.
P762 Failure of a restriction list-based antibiotic policy to reduce
the consumption of two antibiotics recently added to this list
C. Loupa, I. Tzannou, V. Tsolaki, E. Katsiki-Divari, P. Anapliotis,
K.I. Karnezi, M. Tsakoniatis, M. Lelekis ° (Athens, GR)
Background and Objectives: According to an antibiotic restriction
policy implemented in Hellenic hospitals since late 80 s, all potent antibi-
otics (3rd and 4th generation cephalosporins, aztreonam, carbapenems,
quinolones and glycopeptides and more recently linezolid, daptomycin
and tigecycline) are included in a restriction list and can be dispensed by
the hospital pharmacy only if the treating doctor ﬁlls in a speciﬁc form.
However, ticarcillin–clavulanate (t/c) and piperacillin–tazobactam (p/t)
were added to this list long after their introduction to the market and
after a very successful course in Hellenic hospitals (at least for the latter).
Our purpose was to study the impact of this kind of restriction policy
on the consumption of t/c and p/t in our 300-bed hospital.
Methods: We retrospectively studied t/c and p/t consumption in our
hospital by month from January 2007 to August 2008. We used data
from the pharmacy computer. Antibiotic use was calculated in DDDs
per 1000 patient days (ABC Calc 3.0_b). The values before and after
restriction implementation (mid-June 2007) were studied with linear
regression analysis (SPSS 11.5) for possible trend.
Results: P/t consumption was 15.4, 28.1, 19.1, 19.5, 18.3, 26.8 DDDs
per 1000 patient days for the months January 2007 to June 2007 and
18.1, 21.6, 15.6, 29.1, 34.9, 29.8, 16.8, 21.5, 14.1, 27.8, 25.0, 15.1,
18.1, 12.7 for the months July 2007 to August 2008, respectively, and
no statistical trend was found. The values for t/c consumption were 3.1,
1.6, 3.3, 0.3, 3.5, 0.3 (January to June 2007) and 6.1, 2.4, 8.1, 0, 4.4, 4.1,
6.8, 9.1, 1.7, 1.0, 4.4, 8.6, 5.2, 3.9 for the 14 months after restriction and
again no trend was found. Furthermore, the mean per month consumption
for p/t was 20.1 and 21.6 DDDs per 1000 patient days before and after
restriction implementation respectively, and that of t/c 2.4 and 4.7 DDDs
per 1000 patient days respectively.
Conclusions: The addition of t/c and p/t to the antibiotic restriction
list failed to reduce their consumption in our hospital during the study
period. Besides it is worth noting that, almost two decades after the
introduction of the above mentioned restriction policy in the Hellenic
hospitals, no formal audit has ever been performed. Perhaps it is time
for us to revise our antibiotic policy.
P763 Antibiotic therapy in critically ill patients: rates of empiric
appropriate or adequate therapy and subsequent adaptation
of therapy in daily practice
D. Vogelaers, D. De Bels, F. Foreˆt, S. Cran, E. Gilbert, K. Schoonheydt,
S. Blot °for the Anthicus Study Investigators
Objectives: To investigate rates of empiric appropriate or adequate
antibiotic therapy and subsequent adaptation of therapy in ICU patients
with severe nosocomial infections.
Methods: A prospective, observational multicentre study was performed
(Januari to December 2007) in which ICU patients with nosocomial
infection were included. Appropriate therapy was deﬁned as in vitro
susceptibility of the causative pathogen and clinical response to
the antibiotic agent. In non-microbiologically documented infections,
empiric therapy was considered adequate in case of favourable clinical
response within 5 days of therapy.
Figure: Rates of empiric appropriate or adequate therapy in ICU patients
with nosocomial infections.
Results: 171 patients from 28 centres were included (62% male;
mean age 67 years, interquartile range (IQR) 55−76; mean APACHE
II score 20, IQR 15−24). Patients had pneumonia (n = 131, 68
ventilator-associated), intra-abdominal infection (n = 23), bacteraemia
(n = 16) or sinusitis (n = 1). 115 infections were ICU-acquired (67%).
In 130 infections a causative pathogen was isolated (76%). Gram-
negative aetiology was most prevalent (n = 92; 75%) with Pseudomonas
aeruginosa (n = 28), Escherichia coli (n = 26) and Enterobacter aero-
genes (n = 21) being most common. In 51% of infections (n = 64)
multidrug resistant (MDR) bacteria were involved (ESBL, MDR
nonfermenting Gram-negatives, or MRSA). Appropriateness/adequacy
of empiric therapy and subsequent rates of adaptation are shown in
the ﬁgure. In 106 patients empiric therapy was adapted, in 60 cases
following initial inappropriate/inadequate therapy, in 46 patients in order
to ﬁne tune empiric therapy. Rates of empiric appropriate/adequate
therapy were highest with use of meropenem, either in mono (89%)
or combination therapy (90%). These rates didn’t change when
only patients with particular risk factors for MDR involvement
(prior hospitalisation or antibiotic exposure) were taken into account.
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Combinations mainly based on piperacillin-tazobactam, amoxicillin-
clavulanate, cephalosporins, quinolones or glycopeptides never reached
rates of appropriate/adequate therapy in excess of 60%. Surprisingly,
these rates did not increase considerably for patients without MDR risk
factors only.
Conclusion: In this prospective study reﬂecting real life practice in ICU
patients with nosocomial infections, the rate of appropriate or adequate
empiric therapy was 64%. Empiric ﬁrst-line use of meropenem allowed
for the highest rates of appropriate or adequate therapy, irrespective of
presence of risk factors for MDR involvement.
P764 Staphylococcus aureus bloodstream infection management
indicators as quality indicators for hospital antibiotic
stewardship: feasibility study by the ABS International
Quality Indicators (ABS QI) team
W.V. Kern °, S. Metz-Gercek, F. Buyle, V. Jindrak, A. Lechner,
H. Mittermayer, H. Seifert, A. Wechsler-Fo¨rdo¨s, C. Wenisch,
T. Zupanc-Leijko, R. Mechtler, M. Struelens and the ABS QI Team
Objectives: The ABS QI team has developed a set of structural and
process QIs as tools for evaluating hospital antibiotic stewardship
programmes and auditing key treatment and prophylactic practices. Indi-
cators related to the management of Staphylococcus aureus bloodstream
infection (SAB) (echocardiography, intravascular (iv) catheter/device
removal, effective therapy) were tested for feasibility, reliability and
potential sensitivity to improvement in pilot hospitals.
Methods: Pilot hospitals participated in a review of all consecutive
SAB cases admitted in 2007 and identiﬁed by microbiology laboratory
databases. Three indicators (%age of patients [pts] with community-onset
SAB who had echocardiography performed within 10 days after SAB
onset [ECHO],%age of pts who had their iv catheter/device present at
SAB onset removed within 10 days after SAB onset [CATH-EX],%age
of pts with MS-SAB with a duration of iv betalactam therapy of >10 days
within the ﬁrst 14 days after onset [BL-THER]) were assessed including
data availability, reliability (tested on 25% of CRFs) and workload of QI
measurement.
Results: A total of 494 SAB cases from 9 hospitals in 5 countries (3 in
AT, 2 in BE, 2 in DE, 1 in CZ, 1 in SLO) were assessed. 60% of the pts
were male (range between hospitals, 36−70%). The mean age was 62 yrs
(58−70 yrs). 240 cases were community onset (49%; 19−96%), 320 had
an iv device in place at SAB onset (65%; 28−77%), and 429 were MS-
SAB (87%; 67–100%). 11% of the pts died within 14 days after SAB
onset. Reliability was excellent (kappa> 0.8) for the 3 QIs. The estimated
median workload was 26min per case assessment. Availability was 97%,
89%, and 87% for ECHO, CATH-EX, and BL-THER, respectively. In
an intention-to-treat-analysis, QI values were: ECHO, 60% (9−75%);
CATH-EX, 64% (30−78%); BL-THER, 60% (38−74%), respectively. As
expected, per protocol QI values (excluding missing data and cases non-
evaluable for other reasons) were slightly higher: ECHO, 62% (10−75%);
CATH-EX, 72% (47−90%); BL-THER, 69% (44−82%), respectively.
51% of the echocardiographies, and 83% of the device removals were
performed within 3 days after onset.
Conclusions: The data demonstrate that these QIs can be reliably used
across European acute care hospitals to retrospectively assess clinical
compliance with recommended SAB management standards. Substantial
inter-hospital variation in practice indicate that these indicators may be
useful targets for quality of care improvement.
P765 Adequacy of antimicrobial treatment and outcome of Staphy-
lococcus aureus bacteraemia in nine European countries
H.S.M. Ammerlaan °, M. Antonelli, C. Brun-Buisson, S. Harbarth,
J.A.J.W. Kluytmans, H. Seifert, A. Torres, M.J.M. Bontenon behalf
of the SEPIA Study Group
Objective: Inadequate empirical antibiotic therapy of S. aureus
bacteraemia [SAB] has been associated with increased mortality and
longer hospital stay. We aimed (1) to quantify inadequate empirical
treatment in hospitalised patients with SAB in a representative sample of
hospitals in nine West-European countries (Denmark, France, Germany,
Italy, Netherlands, Spain, Sweden, Switzerland, UK); (2) to identify
hospital-, patient- and microorganism-speciﬁc characteristics associated
with inadequate treatment; and (3) to identify variables associated with
30-day mortality.
Methods: In a retrospective cohort study all adult patients with
community- or hospital-acquired monobacterial SAB (methicillin-
susceptible [MSSA] or -resistant S. aureus [MRSA]), admitted to 60
randomly selected hospitals between 1 November and 31 December
2007, were eligible. Adequate antimicrobial therapy was deﬁned as
intravenous administration (with few exceptions depending on severity
of illness and primary site of infection) of at least one antibiotic to
which the isolate expressed in vitro susceptibility, that started (or was
adequately adapted) within two days of the index blood culture or within
one day if the patient had severe sepsis or septic shock. Quality of data
was validated through checking of recorded data in 10% of randomly
chosen case record forms in 31% of the participating hospitals.
Results: 334 SAB episodes (257 MSSA and 77 MRSA) were included.
Ninety-ﬁve patients (28.4%) received inadequate empirical therapy
(21.4% for MSSA and 51.9% for MRSA). Both length of stay (in days)
before SAB and methicillin resistance were associated with inadequate
therapy with adjusted odds ratios of 1.01 (1.00 to 1.02) and 3.7 (2.1
to 6.4), respectively. Age (1.06 (1.03−1.10)), Charlson comorbidity
score (2.1 (1.2−3.6)), severe sepsis or septic shock at time of SAB
(2.7 (1.5−4.8)) and ICU stay at time of SAB (2.9 (1.5−5.6)), but not
inadequate treatment (0.7 (0.4−1.3)) were associated with increased 30-
day mortality. Based on the validity check 97% of eligible SABs had
been included and 94% of the checked items were in accordance with
patient source records.
Conclusion: In a representative sample of 60 hospitals in 9 West-
European hospitals 28.4% of patients with SAB received inadequate
empirical therapy, which was strongly associated with infection caused
by MRSA. In this study inadequate treatment or SAB due to MRSA
(compared to MSSA) were not associated with higher 30-day mortality.
Table 1. Univariate and multivariate analysis for the outcome of 30-day all cause mortality
Variable Alive Death (all
causes)
Univariate Multivariate
n = 254 n = 80 OR (95%CI) p-value OR (95%CI) p-value
Teaching (vs non-teaching) hospital (%) 197 (77.6) 55 (68.8) 0.64
(0.37−1.11)
0.11
Age, median (IQR) 66.0
(54−76.0)
74.5
(62.5−83)
1.04
(1.02−1.05)
<0.001 1.06
(1.03−1.10)
0.001
Male (vs female) (%) 170 (66.9) 54 (67.5) 1.03
(0.60−1.75)
0.93
Adapted Charlson comorbidity score,
median (IQR)
3.0 (0−5) 4.0 (2−6) 1.18
(1.07−1.30)
0.001 2.09
(1.21−3.63)
0.008
Immunocompromised (vs
non-immunocompromised) (%)
32 (12.6) 8 (10.0) 0.77
(0.34−1.75)
0.53
Secondary (vs primary) bacteraemia (%) 94 (37.0) 28 (35.0) 0.92
(0.54−1.55)
0.75
Length of stay before onset of SAB,
median (IQR)
2.0 (0−10) 2.0
(0−9.5)
1.00
(0.98−1.01)
0.67
Severe sepsis or septic shock (vs sepsis)
at onset of SAB (%)
77 (30.3) 49 (61.3) 3.63
(2.15−6.13)
<0.001 2.68
(1.52−4.75)
0.001
ICU (vs non-ICU) at onset of SAB (%) 44 (17.3) 29 (36.3) 2.71
(1.55−4.75)
<0.001 2.89
(1.48−5.64)
0.002
Inadequate (vs adequate) initial treatment
(%)
75 (29.5) 20 (21.1) 0.80
(0.45−1.41)
0.48 0.69
(0.36−1.32)
0.26
MRSA (vs MSSA) (%) 57 (22.4) 20 (25.0) 1.15
(0.64−2.07)
0.64 0.98
(0.50−1.94)
0.95
Age Adapted Charlson comorbidity score 1.002
(1.001−1.004)
<0.001 0.99
(0.98−0.999)
0.03
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P766 Clinical experience with daptomycin in Europe
A. Gonzalez-Ruiz, S. Daugelat °, A. Beiras-Fernandez, H. Lehmkuhl,
P. Gargalianos-Kakolyris, Z. Dailiana, A. Galloway, V.J. Gonza´lez
Ramallo, P. Dohmen, A. Skoutelis, R.A. Seaton, B. Almirante,
G. Dogan, H.J. Thurston, R. Chaves (Dartford, UK; Basel, CH;
Munich, Berlin, DE; Athens, Larissa, GR; Newcastle-upon-Tyne, UK;
Madrid, ES; Glasgow, UK; Barcelona, ES; Bad Oeynhausen, DE)
Objective: To describe the clinical experience with daptomycin (DAP)
in Europe since marketing authorisation in January 2006.
Methods: The European Cubicin® Outcomes Registry and Experience
(EU-CORESM) is a retrospective, non-interventional records review
evaluating outcomes of patients (pts) receiving DAP. Investigators
collected demographic, antibiotic, microbiological and clinical data
from Jan 2006 to Sep 2008 from 118 institutions in nine European
countries. Pts with multiple infection types were categorised by severity
of infection (in order of decreasing severity: endocarditis, osteomyelitis,
bacteraemia, other [foreign body, septic arthritis, pyelonephritis/UTI,
necrotising fasciitis], complicated skin and soft tissue infection [cSSTI],
uncomplicated skin and soft tissue infection [uSSTI]). Outcomes were
assessed by investigators using standard deﬁnitions.
Results: A total of 1127 pts were enrolled in EU-CORESM in the data
reporting period. Of the pts in the safety population (n = 1127), 64%
were male, 46% were aged 65 years, 14% had CrCl <30ml/min
and 9% were on dialysis at the initiation of DAP therapy; 77% of
pts were hospitalised prior to DAP therapy. The majority (89%) had
signiﬁcant underlying disease, including hypertension (30%), diabetes
mellitus (26%) and chronic renal failure (13%). Primary infections
included cSSTI (33%), bacteraemia (22%), endocarditis (12%), uSSTI
(11%), foreign body/prosthesis (8%) and osteomyelitis (6%). Clinical
outcomes were success, deﬁned as ‘cure plus improved’ (79%), failure
(8%) and non-evaluable (13%). DAP was used as second-line therapy
in 70% of pts, most frequently following therapy with glycopeptides
(28%). DAP was given empirically in 53% of pts and methicillin-resistant
Staphylococcus aureus infection was suspected in 29% of pts. Cultures
were obtained in 91% of pts: the most frequently isolated pathogen
was S. aureus of which 52% had conﬁrmed methicillin resistance. The
initial dose of DAP was 6mg/kg in most pts (47%), whereas 32% of
pts received 4mg/kg and 20% received other doses. Outpatient DAP
therapy was received by 14% of pts, whereas the majority were treated
in hospital, where DAP was used with concomitant antibiotics in 67%
of pts.
Conclusions: DAP was used to treat a range of infections, most
frequently cSSTIs, with a large proportion of pts aged 65 years and
with signiﬁcant comorbidities. DAP was frequently used as second-line
therapy, achieving an overall success rate of 79%.
P767 Patient factors impacting the transition from inpatient to
outpatient daptomycin treatment
K. Lamp °, B. Donovan, M. Yoon, K. Lindﬁeld (Lexington, US)
Objectives: Outpatient parenteral antimicrobial therapy (OPAT) has
increased dramatically over the past decade for multiple reasons.
Recommendations for the clinical characteristics of patients appropriate
for OPAT are largely based on expert opinion. Daptomycin has several
characteristics that support OPAT (once daily administration, 30 minute
infusion, well tolerated). This pilot study investigated patient factors
associated with a transition to OPAT for daptomycin.
Methods: Patients (pts) were randomly selected from years 2005 and
2006 of Cubicin Outcomes Registry and Experience (CORE) program
data, which is an observational, multicentre, retrospective study that
describes the clinical use of daptomycin. This pilot study examined
the differences between: those remaining as inpatients (IP) and those
that began therapy as outpatients or transitioned from IP to OPAT (OP).
Additional clinical data was collected for IP at the time daptomycin was
initiated and for OP at the time OPAT was initiated or considered.
Results: Sixty endocarditis, bacteraemia and skin and soft-tissue
infection pts (20 IP, 40 OP) were randomly selected. The infection
types by IP and OP, respectively, were; endocarditis (5, 25%; 5, 13%),
bacteraemia (9, 45%; 18, 45%), and skin (6, 30%; 17, 43%). One
difference was found in underlying diseases, the IP group had a higher
rate of cerebrovascular disease (15% vs 0%, P = 0.03). The factors
present in higher rates of IP pts were: abnormal respiratory status (45%
vs 10%; P = 0.02); abnormal chest x-ray (55% vs 15%, P = 0.005);
and a white blood cell (WBC) count >10,000/mm3 (75% vs 13%,
P< 0.001). Additionally, the IP group had a signiﬁcantly higher median
SAP (simpliﬁed acute physiology) score; 26 vs 16, P = 0.001. The
primary contributors to the higher SAP score in IP pts were: age, systolic
blood pressure, serum urea nitrogen, and type of admission. Thirty-
seven of the 40 (93%) OP pts completed their daptomycin therapy in
the OPAT setting. Three pts who transitioned to OPAT subsequently
were readmitted to receive daptomycin as an IP; however, all 3 required
inpatient treatment for a noninfectious underlying disease.
Conclusions: Of the factors investigated, abnormal respiratory status and
elevated WBC were associated with pts remaining in the IP setting to
receive daptomycin. A high percentage of pts who began or transitioned
to OPAT daptomycin therapy were able to complete their daptomycin
therapy in that setting.
P768 Outpatient parenteral teicoplanin treatment in staphylococcal
prosthesis infections
S. Sapmaz-Karabag, V. Avkan-Oguz °, N. Yapar (Izmir, TR)
Objectives: Isolation of the methicillin-resistant staphylococci from
orthopedic joint prosthesis infections are on increase. Patients usually
require intravenous antibiotic therapy and are treated while being
hospitalised for long terms. In this study we aimed to investigate the
results of the outpatient parenteral teicoplanin treatment for shortening
the length of stay.
Methods: Fourteen patients between the time interval January 2006
and December 2007 retrosepectively and 18 patients between January
and December 2008 prospectively were included in the study. The
inclusion criterion was isolation of more than one staphylococcus on
the patients’ microbiological culture taken during the prosthesis removal
operation. Teicoplanin treatment (1×800mg/day) was given to all cases.
Inﬂammation parameters in the operation area and ESR, WBC, platelet
counts, CRP valuations were followed up weekly.
Results: Of the patients, 20 were female (62.5%), 12 male (37.5%)
and mean age was 65.72±10.87 (43−83). Twenty of the prosthesis
(62.5%) were located in knee, 10 (31.3%) in hip and 2 (6.3%) in
shoulder. Methicillin resistant coagulase negative staphylococcus (75%)
was the most common strain with 24 patients and the second was
methicillin resistant Staphylococcus aureus (15.6%) with 5 patients.
Methicillin susceptible coagulase negative staphylococci were diagnosed
in 2 (6.3%) patients. Only one patient was diagnosed to have Methicillin
susceptible S. aureus (3.1%). No one had thrombocytopenia during
the follow-up. Further radiological investigations were followed by
surgical debridement in 8 cases that did not have a satisfying CRP
decrease. Twenty three patients (71.9%) both clinically and laboratory
responded the treatment, and new joint prostheses were placed. Five
patients (15.6%) underwent surgical debridement. In 3 patients (9.4%)
the treatment agent (teicoplanin) was changed and surgical debridement
was performed. In one patient (3.1%) the treatment agent was changed
because of the isolation a pathogen other than staphylococci. Performing
surgical debridement and teicoplanin treatment succeeded in 87.5% of
the cases, without performing surgical debridement the percentage of the
treatment success rate was 71.9%.
Conclusion: As we did not observe any side effects and the success of
treatment is high; the outpatient parenteral teicoplanin treatment can be
an appropriate choice for the joint prosthesis infections.
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P769 Impact of nasal methicillin-resistant Staphylococcus aureus
surveillance culture results on subsequent antibiotic
prescribing patterns
J. Ruhe °, B. Kreiswirth, D. Perlman, D. Mildvan, B. Koll (New York,
Newark, US)
Objectives: Few data exist on whether the results of routine nasal MRSA
surveillance culture (SC) may inﬂuence subsequent physician antibiotic
prescribing patterns, especially with regard to the potential overuse of
vancomycin.
Methods: Medical records were reviewed on all hospitalised patients
(pts) with positive routine nasal MRSA SC between November 2007
and February 2008 (= cases). Zero time (ZT) was deﬁned as the day the
ﬁrst nasal SC was performed. Data on antimicrobial agents administered
between 3 days and 12 weeks after ZT were recorded. Pts with negative
nasal staphylococcal cultures (= controls) were matched in a 1:1 ratio
to case pts according to age, hospital ward at ZT, and length of
hospital stay after ZT. Pts with active MRSA infections around ZT were
excluded. MRSA isolates were characterised by multilocus sequence
typing (MLST) and spa typing.
Results: Cases (n = 115) and controls (n = 115) did not differ signiﬁcantly
with regard to a variety of variables including sex, number of days in the
intensive care unit, Charlson comorbidity score, and subsequent therapy
with b-lactams or ﬂuoroquinolones (P> 0.05 on bivariate analysis).
However, cases were more likely to develop MRSA complications within
the observation period (8% versus 2%; P = 0.03). The mean duration
of subsequent vancomycin exposure was 2.4 days (95% CI, 1.4−3.5)
among cases and 0.7 days (95% CI, 0.4−1.1) among controls (P = 0.03).
On multivariate analysis, a positive MRSA SC remained an independent
predictor of subsequent vancomycin exposure (P = 0.037). 39 (45%) of
86 tested isolates belonged to clones that cause community-associated
MRSA infections (MLST type CC8 and spa types 1or 7, respectively).
Conclusion: Pts identiﬁed as MRSA carriers were more likely
to receive vancomycin within the subsequent 12 weeks than non-
carriers, independent of other clinical characteristics such as infectious
complications.
P770 Cost-effectiveness of daptomycin in hospitalised patients
with cSSTI caused by Gram-positive organisms
N. Muszbek °, I.M. Gould, R.E. Brown, M.M. Balp (London, Aberdeen,
UK; Bethesda, US; Basel, CH)
Objectives: Mortality associated with complicated skin and soft tissue
infections (cSSTIs) due to MRSA infections has been increasing in the
UK creating signiﬁcant economic and humanistic burden. Daptomycin is
a new, cyclic lipopeptide antibiotic for the treatment of cSSTI caused by
Gram positive bacteria. Two randomised controlled trial showed similar
overall clinical success rates for daptomycin vs. SSP or vancomycin
(83.4% vs. 84.2%). However, 63% of patients successfully treated with
iv daptomycin, required only 4−7 days of therapy, compared with 33%
of comparator-treated patients (p< 0.0001). The aim of this study was to
assess the cost-effectiveness and budget impact of daptomycin compared
to vancomycin in hospitalised cSSTI patients with suspected MRSA
infections.
Methods: A cost-minimisation model was developed from the perspec-
tive of the UK NHS (Figure 1), as due to the non-inferiority, similar
efﬁcacy was assumed between comparators. Only direct medical costs
were considered. The outcomes assessed were total healthcare costs
of treatment, including inpatient, laboratory tests, outpatient and drug
costs. Resource use was collected based on information from a physician
survey. Unit costs were extracted from publicly available databases.
Probabilities and incidence of cSSTI were from a systematic literature
review.
The time horizon was from hospital admission until resolution (i.e., less
than a year), so no discounting was required. Uncertainty was explored
in one-way sensitivity analyses and presented using a tornado diagram.
Results: Daily drug costs were £62.00 and £32.22 for daptomycin and
vancomycin respectively. This cost differential was offset by the lower
weekly monitoring costs (£39.42 vs. £114.07) and shorter hospitalisation
for daptomycin. Total healthcare costs per patient were £3,756 and
£3,841 respectively, resulting in £85 saving per person with daptomycin
treatment. The main cost driver was hospitalisation, which was
responsible for 84−85% of the total costs, while drug costs amounted to
9−12%. The introduction of daptomycin was estimated to save £110,491
in the ﬁrst and £244,064 in the ﬁfth year after the introduction of
daptomycin as empiric therapy. The results were most sensitive to length
of treatment with vancomycin, the number of days until ﬁrst assessment
of treatment failure and success rate with MRSA-induced infection.
Conclusion: Treatment of cSSTI with daptomycin is at least as effective
as and less costly than vancomycin.
P771 Utility of unique procalcitonin dosage in patients with acute
exacerbation of chronic obstructive pulmonary disease in
emergency wards
L. Blairon, M.A. de Villenfagne, H. Dahma, P. Mols, A. Dediste °,
O. Vandenberg (Brussels, BE)
Objectives: Some authors showed that procalcitonin (PCT) was able
to distinguish patients with a bacterial aetiology of acute exacerbation
(AE) of chronic obstructive pulmonary disease (COPD), resulting in a
signiﬁcant decrease in inappropriate antibiotics use. We tried to evaluate
the ability of PCT to work in emergency conditions in this indication,
and we compared the effect of a PCT-guided treatment vs the clinician’s
intention to treat on the adequacy of the treatment.
Methods: We enrolled consecutive patients with AE-COPD in a six-
month prospective, double-blind observational study. Every patient
underwent a chest radiography and a supplemental blood puncture for
differed dosage of PCT. PCT serum levels were assessed in batch
with Vidas® B.R.A.H.M.S PCT (bioMe´rieux). Bacterial aetiology was
suspected in the presence of suggestive clinical symptoms and either
signiﬁcant positive bacterial culture of sputum, or a positive atypical
bacterial serology.
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Results: Among 54 enrolled patients (median age 69.4; 95% CI
64.5−73.3), 17 had a bacterial infection (BI), 26 an atypical-bacterial
infection (AI), 4 a proven viral infection (VI), 3 an isolated radiological
focus (IRF), and 15 were considered as non-infected (NI). Some patients
had mixed infections (BI+AI, or AI+VI). Median PCT serum levels
(95% CI) were 0.05 ng/mL (0.05−0.53) in BI, 0.065 ng/mL (0.05−0.13)
in AI, and 0.05 (0.05−0.10) in NI. In patients with isolated VI or
IRF, median PCT values were both 0.05 ng/mL (CI non-applicable).
Differences in PCT values among all these patients groups, and between
infected vs non infected were both non signiﬁcant (P = 0.39 and P = 0.21
respectively). Sensitivity and speciﬁcity of PCT were 46.2% and 73.3%.
Antibiotic use should have been 8 on 39 infected patients in a simulation
model of a PCT-guided treatment, and was 37/39 in standard conditions
(OR= 12.5; 95% CI 4.86−32.20; P< 0.0005). Inadequacy of treatment
was 9/39 in standard conditions and should have been 32/39 with the
PCT-guided model (OR= 15.2; 95% CI 5.04−46.0; P = 0.0059).
Conclusions: Bacterial aetiology of AE-COPD is difﬁcult to prove in
absence of evidence-based guidelines. Although PCT had been shown
by some authors to reduce the antibiotics use, our experience showed
that PCT could not be used safely in an emergency setting following
the previously published recommendations in order to decide which AE-
COPD patient should receive antibiotics.
P772 Surveillance of antimicrobial use in Belgian hospitals
S. Vaerenberg °, E. Hendrickx, B. Catry (Brussels, BE)
Objectives: To develop an easy to use and standardised method to
monitor antimicrobial use in Belgian acute and long term (minimum
150 beds) care facilities, as part of a national programme to foster
prudent antimicrobial use. This will allow individual hospitals to
compare their own use with the national mean (benchmarking) and to
analyse trends over time.
Methods: In Belgium, all antimicrobials for systemic use are reimbursed
by the National Institute for Health Insurance and Disability and are
identiﬁed by an unique Tariﬁcation Unit Code (TUC). An electronic list
of TUCs to monitor was deﬁned and a secured web-based data upload
module was created. Hospitals extract past calendar year data from
their pharmacy database and upload them together with denominator
data (bed days, admissions). Data are stored in a national database
and the web module gives an immediate feedback of the numbers of
DDD (Deﬁned Daily Dose) used per 1000 bed days for each ATC
code (Anatomical Therapeutical Classiﬁcation, WHO, version 2008).
The following drugs are monitored: antimicrobials for gastro-intestinal
use (ATC-group A07A), antibiotics, antifungals and antimycotics for
systemic use (D01BA, J01, J02&P01AB), and tuberculostatics (J04A).
Table 1. Overview of DDD/1000 bed days in participating hospitals
Class ATC 2006 (N= 24) 2007 (N= 46)
mean range mean range
Beta-lactam antibacterials, penicillins J01C 235 168–375 253 85–380
Other beta-lactam antibacterials J01D 111 48–175 116 14–230
Quinolone antibacterials J01M 65 8–102 69 7–115
Other antibacterialsa J01X 36 13−61 38 10−81
Antimycotics for systemic use J02A 26 0−72 35 0–111
Macrolides, lincosemides and streptogramins J01F 24 9−38 26 5−64
Aminoglycoside antibacterials J01G 15 3−38 15 1−38
Drugs for treatment of tuberculosis J04A 12 0–132b 11 0–110b
Sulfonamides and trimethoprim J01E 9 1−22 9 1−29
Intestinal antiinfectives A07A 4 0−21 3 0−14
Agents against amoebiasis and other protozoal diseases P01A 3 0−7 4 0−10
Tetracyclines J01A 3 1−13 4 1−44
Antifungals for systemic use D01B 1 0−6 1 0−6
Amphenicols J01B 0 0−1 0 0−2
Total 545 344–827 583 225–929
aGlycopeptide antibacterials, polymyxins, steroid antibacterials, imidazole derivatives, nitrofuran derivates and
others.
bHospital specialised in HIV.
Results: A total of 24 and 46 of the intended 37 and 61 hospitals
participated in 2007 and 2008 (data for 2006 and 2007), respectively.
The mean antimicrobial use was 545 (min 344, max 827) DDD/1000
bed days in 2006 and 583 (min 225, max 929) DDD/1000 bed days
in 2007 (Table 1). Nineteen hospitals participated both in 2006 and
2007 and for these a small increase in antimicrobial use was seen.
Especially beta-lactam antibacterials (J01C) and antimycotics (J02A)
contributed to this effect. For 2007, the most frequently used molecules
were ‘amoxicillin and enzyme inhibitor’, cefazolin and ciproﬂoxacin (70,
31 and 30 DDD/1000 bed days, respectively).
Conclusion: The web module allowed to collect standardised data from
different hospitals. The participation rates (65% in 2007 and 75% in
2008) demonstrate that this surveillance system is feasible for Belgian
hospitals after a relatively short time of notiﬁcation. Antimicrobial use
could be compared between hospitals and between years. Further data
collection will also enable analysis of trends and incorporation of more
indicators will further increase the usefulness of this web module as a
tool to guide antibiotic policy in hospitals.
P773 Improving patient safety in Europe. Standards and
performance indicators in healthcare-associated infection
and antimicrobial stewardship
B. Cookson °, D. Mackenzie, A.P. Coutinho, A. Gilsdorf, I. Russell,
J. Fabry (London, UK; Copenhagen, DK; Lyon, FR)
Objectives: To achieve a consensus on Standards and Performance
Indicators (SPI) to assess Healthcare Associated Infection (HCAI)
prevention and control programmes and antimicrobial stewardship
(AMS) in European countries and to try and produce a reduced set
of SPI (RSSPI).
Methods: We used several sources to draft HCAI/AMS SPI and used a
novel Likert spreadsheet approach from an EU project (HARMONY)
to assess consensus and analyse responses from 29 of 33 European
countries approached. Since the 2008 ECCMID, these have been ﬁnalised
interactively. Several countries and ECDC wanted to develop an RSSPI
and we used the same approach to do this.
Results: National and local SPI had been developed in ﬁve groups with
144 statements. Despite the high consensus achieved in the ﬁrst round
there were many comments received and the advisory group agreed 64
modiﬁcations to the SPI (and recommended practices) to further increase
their acceptance. The second round of interactions and consensus
conference in May 2008 showed we had effectively addressed the issues.
Four ways of publishing surveillance data were proposed to circumvent
the differences in attitudes in several countries. Stafﬁng and isolation
requirements need further consensus work in Europe. 13 international
and 13 national RSSPI were all felt to be important by the 24 responding
countries. For example “Recording training at staff induction”, the lowest
scored national indicator, had an average priority of 7.52 (out of 13), with
three responses placing it in the top three and six in the top ﬁve. The
modal prioritisation for eight of the national indicators and six of the in-
ternational indicators was of the highest possible. It was thought to be im-
portant to develop and agree a validation process for SPI/RSSPI and that
there should be a core group of SPI which could be repeated regularly,
with others that could be reviewed over time and perhaps even changed?
Conclusions: We believe this to be the most rigorous consensus ever
attempted in the ﬁeld and it is reassuring to see the level of agreement
realised. The methods used have again shown their ability to rapidly
establish a consensus in a multi-faceted landscape. It is anticipated that
others will ﬁnd their use as productive. We have also developed a RSSPI
which will be explored further with ECDC in the coming years.
P774 Linezolid for patients with neutropenia: can bacteriostatic
agents be used in this patient population?
P. Rafailidis °, V. Kouranos, C. Christodoulou, M. Falagas (Athens, GR)
Objective: A long held doctrine is that bactericidal antibiotics are
required for infections in neutropenic patients. We sought to review the
available data concerning the clinical use of linezolid, a bacteriostatic
antibiotic, in the treatment of infections in neutropenic patients.
Methods: We evaluated the available published evidence (PubMed)
regarding the role of linezolid, a bacteriostatic antibiotic, in neutropenic
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patients with Staphylococcus aureus, Enterococcus faecalis, or Entero-
coccus faecium infection.
Results: We retrieved three non-comparative studies, two comparative
studies [one of them is a double blind randomised controlled trial (RCT)],
two retrospective studies and eight case reports that focused on the use of
linezolid for Gram-positive bacterial infections in neutropenic patients.
Linezolid was administered to 438 neutropenic patients, mainly on a
compassionate-use basis, as other antibiotics failed to cure the infection
or were associated with signiﬁcant adverse events. In total, 62 out of
438 (14.1%) neutropenic patients that received linezolid died during
therapy. In the only RCT that compared linezolid to vancomycin in the
treatment of Gram-positive infections in neutropenic patients, mortality
was 5.6% versus 7.6%, respectively (p = 0.4).
Conclusion: The available evidence suggests that linezolid is successful
in a signiﬁcant proportion of neutropenic patients with infection, despite
the fact that it is a bacteriostatic agent. Such data seem to justify further
studies regarding the role of bacteriostatic agents, including linezolid, in
this patient population.
P775 What determines regional differences in outpatient
antimicrobial consumption in the Russian Federation?
A. Fokin °, S. Ratchina, S. Kozlov, I. Gudkov, A. Ishmukhametov,
M. Denisova (Smolensk, Moscow, RU)
Objectives: We aimed our study to compare outpatient antimicrobial
consumption (AC) in different regions of Russian Federation (RF) and
investigate socio-economic determinants of AC.
Methods: AC data in ATC class J01 were obtained by RGC in 2004–
2006 during pharmacy audit in 11 regions of RF and expressed as
number of DDD per 1000 inhabitants per day (DID) (ATC-DDD
Index, 2007). Demography and socioeconomic indexes: population,
population density (v2), urban sector weight, men/women ratio, age
structure, natural increase and marriage (v9) rates, economically active
population weight, economic activity level, unemployment rate, average
per capita population monetary income (v13), average monthly nominal
accrued salary for working in economics (v14), average rate of monthly
pension assigned (v15), pensioners quantity, population with monetary
incomes lower living-wage weight (v17), medical institutions quantity,
hospital beds quantity (v19), hospital beds quantity/1000 inhabitants
(inh), number of inh/hospital bed, out-patients’ clinics visits/day (v22),
out-patients’ clinics visits/day/10000 inh, physicians quantity (v24),
physicians quantity/10000 inh, number of inh/physician, nurses quantity,
nurses quantity/10000 inh, number of inh/nurse, morbidity, some in-
fectious and parasitic diseases morbidity, retailment turnover, retailment
turnover per capita, gross regional product per capita were taken from RF
Federal agency of state statistics report. To assess correlation of variables
multiple regression analysis was performed using SAS (program package
SAS Institute, USA, version 8.02 for Windows XP).
Results: AC in 11 regions of RF in 2004–2006 is presented in Table.
Region AC (DID)
2004 2005 2006
Voronezhskaya oblast 11.08 12.9 12.23
Krasnodarskii kray 8.62 7.08 6.08
Krasnoyarskii kray 7.16 9.59 9.62
Nizhegorodskaya oblast 8.09 8.59 8.37
Novosibirskaya oblast 10.04 12.24 12.43
Omskaya oblast 6.40 7.29 7.26
Bashkortostan 9.74 11.06 11.88
Tatarstan 8.92 9.92 10.45
Rostovskaya oblast 4.94 7.12 6.93
Samarskaya oblast 8.55 7.76 8.38
Sverdlovskaya oblast 7.94 7.38 7.19
After multiple regression analysis carrying out we deﬁned dependence
model: DID = 93.905 − 0.15*v2 − 3.8311*v9 − 9.3132*ln(v13) −
11.1692*ln(v14) + 0.0154*v15–− 0.3549*v17 − 0.6319*v19 −
0.1126*v22 + 48.0576*ln(v24) (R2 = 0.849, adjusted R2 = 0.789).
Conclusion: Regions differed signiﬁcantly in level of AC in study
period. Some variables – v15 and v24 exerted positive inﬂuence on
AC, some – v2, v9, v13, v14, v17, v19 and v22 – negative one.
P776 A survey on current antibiotic prescribing attitude of
primary care physicians in Greece
A. Antoniadou °, G.M. Gourgoulis, E. Giannitsioti, I. Katsarolis,
G. Poulakou, V. Sakka, M. Droggiti, K. Varveraki, H. Mbasianou,
A. Maragkos, D. Kavatha, D. Plachouras, H. Giamarellou (Athens, GR)
Objectives: Greece is the leading country in antibiotic consumption in
Europe in the outpatient setting. A public survey conducted in Greece
a few years ago indicated that more than 75% of antibiotics used in
the community were prescribed by primary care physicians (PCPs). A
survey was performed to investigate the prescribing attitude in clinical
practice among PCPs.
Methods: An anonymous questionnaire was mailed or dispensed during
the annual meetings of paediatricians, internists, pneumonologists and
general practitioners (GPs), addressing indications of antibiotic use,
antibiotic choices and factors affecting prescribing.
Results: 1416 questionnaires were ﬁnally collected at a national scale
during winter 2007–2008 (from 230 paediatricians, 178 pneumonolo-
gists, 232 GPs and 776 internists). GPs were mostly working for
the state (78%), practicing in rural areas (80%), while the rest were
mostly private practice phycisians working in urban areas (65−85%).
The commonest indication for antibiotic use was respiratory tract
infections (70−90%), including primarily exudative tonsillitis, COPD
exacerbations and pneumonia in adults, and prolonged nasal purulent
discharge along with otitis media in children. Antibiotics most commonly
prescribed were macrolides, second generation cephalosporins and
amoxicillin or amox/clav. Antibiotic choices followed guidelines for
acute cystitis, tonsillitis and otitis media, but were inappropriate in
pneumoniae (40%) and COPD (30%) and overused in acute diarrhoea
(33−40%), patients with indwelling urinary catheters (40−60%) and
patients with viral symptoms (50%). Eighty ﬁve percent admitted
prescribing retrospectively antibiotics to their patients which had been
already self-administered and >50% included pharmaceutical reps in
their sources of new information.
Conclusions: Campaigns for the prudent use of antibiotics should aim at
PCPs. New information, education and guidance should be continuously
offered.
P777 Public campaigns to improve outpatient antibiotic use in
high-income countries
B. Huttner °, S. Harbarthon behalf of the CHAMP Consortium
Objective: Public campaigns have attempted to educate the public
regarding prudent outpatient antibiotic use. We reviewed characteristics
and outcomes of these campaigns as part of an international collaborative
project.
Methods: Through Medline, internet searches and contact with expert
informants, we identiﬁed public campaigns aimed at improving antibiotic
use conducted on a national or regional level in high-income countries
between 1990 and 2007. Campaign managers were contacted to obtain
unpublished information. Randomised trials and campaigns carried out
on a community level were excluded. Analyses were performed using a
mixed approach (quantitative and qualitative methods).
Results: We retrieved information on 16 national campaigns and 6
regional campaigns (16 in Europe, 3 in North America, 2 in Oceania
and 1 in Israel). All but 4 campaigns were conducted over more
than 1 year (range, 1−13 y) and 12 campaigns were still ongoing in
2007. Most campaigns (n = 17) were organised by health authorities
and publicly funded. Two national campaigns were funded by the
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pharmaceutical industry. All campaigns focused on upper respiratory
tract infections and used similar key messages. All but one campaign
targeted physicians and the public in parallel, with an emphasis on
parents of young children (n = 17). Interventions were multifaceted
and varied in intensity. Distribution of information material was the
most common intervention (n = 22). Twelve campaigns used television
and 2 campaigns used intensive academic detailing for physicians.
Nine campaigns observed a reduction in antibiotic prescriptions and 2
campaigns in self reported antibiotic use. The impact on antimicrobial
resistance was difﬁcult to evaluate because of poor data availability and
the concomitant introduction of the pneumococcal conjugate vaccine in
several countries. Potential adverse outcomes and sustained effects have
not been evaluated systematically.
Conclusions: Antibiotic campaigns are widely used and some have
resulted in a reduction in antibiotic use, although a clear cause-effect
relationship is difﬁcult to establish. The lack of detailed evaluation,
the multifaceted approach and the differences in healthcare systems
make identifying the most effective interventions a challenge. Although
the impact on antibiotic resistance is difﬁcult to assess at the current
moment, policy makers and epidemiologists can use our ﬁndings to
develop initiatives suited to different country settings.
P778 Linezolid versus vancomycin health and economic outcomes:
a retrospective database study of 11,018 infection-related
hospitalisation treatment episodes
C.D. Mullins, V.D. Hsu °, A. Shorr, C.E. Cooke, A. Shelbaya,
E.N. Perencevich (Baltimore, Washington, New York, US)
Objectives: Vancomycin has been the standard drug for infections
with speciﬁc aetiologies, including methicillin-resistant Staphylococcus
aureus, but there is increasing evidence from large comparator controlled
trials that linezolid may have clinical advantages over vancomycin.
The objectives of this study were to examine the likelihood of repeat
hospitalisation and to compare the post-index hospitalisation costs of a
cohort of discharged patients who were treated for their infection with
either linezolid or vancomycin.
Methods: Data came from 3 separate administrative claims databases.
Adult non-Medicare patients were required to be on either vancomycin or
linezolid and treated for an identiﬁable infection. The index date reﬂects
the date that the index drug was dispensed. Patients were excluded if
they were not continuously enrolled for at least 6 months following
index. Analyses were adjusted for comorbidities, age, sex and geography,
as well as the index infection. Adjusted odds ratios were calculated to
determine the relative impact of linezolid versus vancomycin on the
likelihood of a repeat hospitalisation following initiation of treatment.
Results: The proportion of patients with re-hospitalisation following
their index date was 26.1% in the linezolid group (759/2907) and
33.4% (2706/8111) in the vancomycin group. The relative odds of a
post-index hospitalisation in the adjusted logistic regressions ranged from
0.830 to 0.839. Furthermore, the post-index costs were statistically lower
for patients on linezolid compared to those on vancomycin.
Conclusion: The unadjusted likelihood of a post-index re-hospitalisation
was 7% lower in absolute terms or 22% lower in relative terms for those
on linezolid versus vancomycin. The adjusted rates, controlling for the
index infection, comorbidities, age, sex, and geography found relative
reductions in the range of 16% to 17%. Linezolid was also associated
with lower post index adjusted and unadjusted costs.
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P779 Testing for Clostridium difﬁcile infection
J. Swindells °, N. Brenwald, N. Reading, B. Oppenheim (Birmingham,
UK)
Objectives: Recently concerns have been raised regarding the reliability
of many of the methods that are currently utilised by laboratories for the
diagnosis of Clostridium difﬁcile infection (CDI). In addition, several
new alternatives have become available, including the development of
polymerase chain reaction (PCR) tests. We sought to compare the
performance of four rapid tests against the gold standards of cytotoxicity
assay and culture.
Methods: To date 71 consecutive diarrhoeal specimens taken from
inpatients aged over 65 have been analyzed using the following
rapid tests: VIDAS® Clostridium difﬁcile A& B (bioMerieux) enzyme
immunoassay (VIDAS EIA), Xpert™ C. difﬁcile PCR (Cepheid),
Gene Ohm™ PCR (BD Diagnostics) and C. DIFF QUIK CHEK
COMPLETE™ (TechLab). The latter of these tests independently detects
both glutamate dehydrogenase antigen (GDH) and C. difﬁcile toxin
(CDT). The stool samples were cultured for growth of C. difﬁcile
according to standard methods. Cytotoxicity assay was undertaken using
Monkey African Green Kidney ‘Vero’ cells on each stool sample and
any positive culture isolates.
Results: C. difﬁcile was cultured from 14% of specimens. The C.
DIFF QUIK CHEK COMPLETE™ GDH component identiﬁed all of
these, with a sensitivity of 100% and speciﬁcity of 98.4%. The stool
cytotoxicity assay was positive for 10% of specimens, giving calculated
sensitivities of 100% for each of the PCR tests compared to 71.4% for
both the C. DIFF QUIK CHEK COMPLETE™ CDT component and
VIDAS EIA (see table).
Test under evaluation Gold standard used for
comparison
Sens
(%)
Spec
(%)
PPV
(%)
NPV
(%)
C. DIFF QUIK CHEK COMPLETE™
GDH antigen C. difﬁcile culture 100 98.4 90.9 100
C. difﬁcile toxin Stool cytotoxicity assay 71.4 100 100 97.0
VIDAS® Clostridium difﬁcile A&B Stool cytotoxicity assay 71.4 100 100 97.0
Xpert™ C. difﬁcile PCR Stool cytotoxicity assay 100 96.9 77.8 100
Gene Ohm™ PCR Stool cytotoxicity assay 100 98.4 87.5 100
Sens = sensitivity; Spec = speciﬁcity; PPV = positive predictive value; NPV = negative predictive value.
GDH = glutamate dehydrogenase.
Conclusions: The C. DIFF QUIK CHEK COMPLETE™ GDH
component and both of the PCR tests studied all have very high
sensitivities and can therefore be relied upon for the exclusion of CDI.
Since the PCR tests detect the presence of genetic material encoding
for CDT, false positive results due to non-toxigenic organisms are
eliminated. Furthermore, the Xpert™ C. difﬁcile test can indicate the
presence of an 027 ribotype. A small number of samples were positive by
PCR but had negative stool cytotoxicity assay results, possibly reﬂecting
faecal carriage of C. difﬁcile organisms with repressed toxin production.
The signiﬁcance of this observation warrants further study.
P780 Determining hypervirulent markers for Clostridium difﬁcile
by array comparative genomic hybridisation
G. Marsden °, I. Davis, V. Wright, J. Hinds, E. Kuijper, N. Minton
(Nottingham, London, UK; Leiden, NL)
Objectives: The aim of the study was to use a comparative genomic
approach for the identiﬁcation of hypervirulent markers in Clostridium
difﬁcile.
Methods: A high density oligonucleotide microarray was designed
to the Clostridium difﬁcile 630 sequence and constructed by Oxford
Gene Technology (UK). Extra probes were also designed to regions
of divergence in the un-annotated sequences of two PCR ribotypes
O27 strains, C. difﬁcile R20291 (WTSI, UK) and QCD-32 g58 (McGill
University, Canada) when compared to C. difﬁcile 630 and regions of
interest, such as the agr operon. A set of 34 clinical strains comprised
of the most commonly represented PCR ribotypes throughout Europe,
including type O27 was hybridised to the microarray. These included 21
ribotype 027 strains originating from Europe, the USA and Canada, and 7
strains representing the subtypes of ribotype 001. Strains representing the
new emerging ribotype 078 have also been hybridised to the microarray.
Analysis of the microarray data was performed using GeneSpring GX
v7.3 (Agilent, USA).
Results: Microarray analysis revealed distinct regions of divergence
amongst the strains analysed in comparison to C. difﬁcile 630 across all
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PCR ribotypes tested. Comparison of O27 strains from North America
showed genetic differences or divergence from R20291 speciﬁc probes,
yet probes designed speciﬁcally to the Canadian strain QCD-32 g58
appear to hybridise consistently to all European O27 strains.
Conclusion: Array comparative genomic hybridisation (aCGH) success-
fully identiﬁed regions of divergence that could be used as markers for
O27 strains as well as markers for C. difﬁcile 630.
P781 Toxin genes (tdcA, tdcB, cdtA and cdtB) of
Clostridium difﬁcile strains isolated from patients with
C. difﬁcile-associated diarrhoea in Turkey
U. Deniz, N. Ulger Toprak °, B. Aksu, G. Soyletir (Istanbul, TR)
Background: Clostridium difﬁcile is the causative agent of a spectrum of
gastrointestinal syndromes in humans ranging from diarrhoea to severe
life-threatening colitis. Pathogenesis primarily involves the action of two
large clostridial cytotoxins, toxin A and toxin B, which are encoded by
the tcdA and tcdB genes, respectively. Reports on toxin A variant strains
(tcdA negative, tcdB positive), and the recent emergence of the epidemic
binary toxin positive C. difﬁcile strains in Europe, USA and Canada
lead to important changes in epidemiology of C. difﬁcile-associated
diarrhoea (CDAD).
Objective: This study investigated the toxin genes of C. difﬁcile
strains isolated from hospitalised patients with antibiotic-associated
diarrhoea (AAD).
Methods: In the period of September 2006-March 2008, the stool
samples from 633 patients with nosocomial AAD at Marmara University
Hospital were analyzed for C. difﬁcile by cultivation, toxin A/B
immunoenzymatic detection (ImmunoCard Toxins A&B, Meridian
Diagnostics, Inc., Ohio, USA). In addition, culture ﬁltrates of the isolates
were also screened for the toxin A/B by immunoassay test. Genes for
toxin A (tcdA), toxin B (tcdB), binary toxin (cdtA and cdtB) were
determined by PCR.
Results: Fifty stool specimens yielded C. difﬁcile on culture; while
only 30 of these were positive by toxin immunoassay test. However; an
additional 6 samples which were negative by direct toxin test were found
to be toxin positive when assay was performed on culture ﬁltrates of the
C. difﬁcile isolates, giving a sensitivity for direct toxin assay as 88%.
The toxin A and toxin B genes were detected in all strains (n: 36) isolated
from samples that were toxin positive either directly or from culture
ﬁltrates. There were neither variant strains (tcdA-negative and tcdB-
positive) nor binary toxin gene positive isolates among tested bacteria.
Conclusion: Our ﬁndings form a database about toxin genes of
C. difﬁcile in hospitalised patients with AAD in Turkey, where
molecular investigation of toxin-producing C. difﬁcile strains has not
been performed so far. Despite absence of isolates producing new toxin
variants or binary toxin in this study, it seems to be important to monitor
the isolates for the emergence of those strains which still cannot be
detected by commercially available tests, in order to control and prevent
the outbreaks.
P782 Proof of antigenetic diversity among the cytotoxins TcdB and
use of novel monoclonal antibodies to diagnose Clostridium
difﬁcile ribotype strains
V. Braun, K. Gisch, S. Zedler, J. Trumpler, C. von Eichel-Streiber °
(Mainz, DE)
During recent years several outbreaks of Clostridium difﬁcile infection
have been related to single ribotypes like 017 and 027. Ideally it should
become possible to detect endemic ribotypes with a quick bedside test.
The aim of the current study was to prepare TcdB of different C. difﬁcile
strains and to use the polypeptides for immunisation and lateron
induction of hybridoma cells that could be used to differentiate the most
prominent C. difﬁcile ribotypes mainly according to their variant TcdB
molecules. TcdB was isolated from standard strain C. difﬁcile VPI10463,
of the ribotype 017 strain 1470 and of ribotype 027 strain LUNC4. The
toxins were inactivated and used for immunisation of mice. Thus app 30
novel monoclonal antibodies were generated Testing was done by ELISA,
Western blotting and to mAbs were identiﬁed that differentiate between
different toxins. The monoclonal antibodies obtained could be classiﬁed
into three major groups. The ﬁrst group called pan-TcdB speciﬁc mAbs
represents antibodies that recognize all TcdB molecules that we have
in hand. A second group of antibodies (TcdB-027 speciﬁc) recognize
TcdB of ribotype 027 but not of ribotype 001. The third group contains
antibodies that react ribotype 001 TcdB but not TcdB-027 (TcdB-001
speciﬁc). Combinations of these antibodies were tested for their potential
to diagnose 027 versus 017 or 001 ribotype infections.
Our experiments demonstrate that not every monoclonal reacts with all
TcdB molecule of all different strains. Only a fraction of mAbs is pan-
TcdB-speciﬁc. Lack of pan-TcdB speciﬁcity might be an obstacles of
some commercial tests with deﬁcits in sensitivity. Further our results
prove that monoclonal antibodies can be generated that differentiate
between a ribotype 027 infection versus infections with other ribotypes.
In collaboration with an accompanying company a prototype test was
developed that allows the diagnosis of a ribotype 027 infection within
less than 20 min.
Our data demonstrate that immunogenic testing will become an
appropriate approach for quick diagnosis of the most abundant endemic
C. difﬁcile strains. Testing on the most abundant European ribotypes will
be presented and the use of such testing for diagnosis of CDI will be
discussed.
Acknowledgement: This work was support as part of the EACCAD
FP6 European grant coordinated by Dr. Ed Kuijper (Leiden University
Medical Centre)
P783 Evaluation of a combined toxinA/B PCR for the detection
of Clostridium difﬁcile in a general hospital
L. Smeets °, I. Pollard, P. van Wunnik, E. van der Vorm,
M. Kooistra-Smid, R. de Boer (Delft, Groningen, NL)
Objective: To evaluate a combined (duplex) real-time PCR for the
detection of the Clostridium difﬁcile toxin A and toxin B for the detection
of C. difﬁcile associated diarrhoea (CDAD) in a general hospital.
Methods: Stool samples for C. difﬁcile were ﬁrst tested with a
cytotoxicity test on Human embryonic lung (HEL) cell culture (CTA)
and if positive the faeces were cultured for C. difﬁcile. All stool samples
were stored at −80ºC and screened retrospectively with PCR. DNA
extraction was performed with the Xtractor Gene (Corbett Robotics)
and PCR on both the tcdA and tcdB genes was performed on an ABI
prism 7500 thermocycler. If the PCR was inhibited, extraction and PCR
were repeated after 1:5 dilution of the sample in saline. If the three tests
(CTA, culture, and PCR) yielded discrepant results, the combination
of two independent results was considered to be the consensus gold
standard. If only two independent results were available, the sample was
withdrawn from the study.
Results: In total 143 samples were tested with CTA and PCR (Table 1).
Of 15 samples that were positive in both the CTA and culture, 12 were
also PCR positive. Of the 15 samples that were CTA positive but culture
negative, none were PCR positive. These samples were thus regarded
true negatives. Of the 113 samples that were CTA negative, 110 were
also PCR negative and 3 PCR positive. One of these was also positive
in subsequent culture from the frozen faeces and thus considered to be
a true positive. This patient had an earlier faecal sample that was CTA
positive, indicating that a toxigenic strain was present. The remaining
two CTA negative, PCR positive samples were not available for culture.
One of these patients had repeatedly negative CTA tests.
Table 1. Results of CTA, PCR and (if available) culture of all 143 samples
CTA− a (113) CTA+/culture+ (15) CTA+/culture− (15)
PCR 110 negative, 3 positiveb 3 negative, 12 positive 15 negative
aCulture not performed. b1/3 culture positive, 2/3 not available for further analysis.
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Altogether, for 141 samples a consensus result could be obtained
(Table 2). The sensitivity of the PCR was 81.3%, the speciﬁcity 100%.
For CTA these ﬁgures are 93.8% and 88.0%, respectively.
Table 2. CTA and PCR results compared with the consensus gold standard
Negatives (125) Positives (16)
CTA 110 negative (speciﬁcity 88%) 15 positive (sensitivity 93.8%)
PCR 125 negative (speciﬁcity 100%) 13 positive (sensitivity 81.3%)
Conclusion: In comparison to the CTA test on Hel-cells, the combined
tcdA/tcdB PCR for C. difﬁcile has a higher speciﬁcity but lower
sensitivity. Theoretically, the presence of tcdA/tcdB is no evidence
for actual toxin production. In our 143 samples however, only two
potentially contained non-toxigenic strains. The presence of the toxin
genes (as detected by PCR) therefore appears to be a reliable indicator
for C. difﬁcile toxin production.
P784 Rapid detection of Clostridium difﬁcile in faeces by real-time
PCR
K. Egli, S. Peter-Getzlaff, M. Altwegg ° (Lucerne, Zurich, CH)
Objectives: Traditional methods for the detection of C. difﬁcile consist of
immunoassays (sometimes believed to lack sufﬁcient sensitivity), culture
on selective medium, and traditional “gold standard” tissue culture
cytotoxicity methods, which are difﬁcult to perform and require several
days to yield results. Our study was aimed at determining whether a
commercial and a home-brew real-time PCR are suitable for the rapid
detection of C. difﬁcile in faecal specimens.
Methods: As part of an ongoing study for determining the performance
of culture, cell culture cytotoxicity and three immunological toxin tests,
a subset of 133 unformed stool specimens from patients with suspected
CDAD was also analyzed by the BD GeneOhm™ Cdiff Assay (BD-PCR)
consisting of a rapid, glass bead-based DNA preparation without further
puriﬁcation followed by real-time ampliﬁcation of part of the toxin B
gene on a SmartCycler II. The same extract was simultaneously analyzed
with a home-brew duplex PCR detecting both toxin A and B genes
using the 5′ exonuclease format on a LightCycler 480 (BA-PCR). The
performance of PCR was compared to the ‘gold standard’ (cell culture
cytoxicity, with culture as reference for the resolution of discrepant
results). 131 specimens were also analyzed by commercial and home-
brew PCR after extraction/puriﬁcation of DNA from specimens with the
easyMAG system.
Results: DNA preparation according to the BD GeneOhm™ Cdiff Assay
(N= 133) resulted in inhibition of 3 (2.3%) and 11 (8.3%) of specimens
with BD- and BA-PCR, respectively. Sensitivity/speciﬁcity for not
inhibited specimens was 95.7%/96.4% for BD-PCR, 95.1%/97.5% for
BA-PCR, and 89.1%/98.8% for cell culture cytotoxicity. After easyMAG
extraction (N= 131), 2 (1.5%) and 1 (0.8%) of specimens showed
inhibition in BD- and BA-PCR, respectively. Sensitivity/speciﬁcity for
not inhibited specimens was 100%/97.5% for BD-PCR, 97.6%/96.3%
for BA-PCR, and 89.8%/100% for cell culture cytotoxicity.
Conclusions: Both PCR assays are more sensitive than and almost as
speciﬁc as cell culture cytoxicity und thus provide simple and rapid
stool tests that allow same-day identiﬁcation of toxigenic C. difﬁcile.
DNA puriﬁcation slightly increases the performance of the commercial
assay and is a must for our home-brew PCR in order to avoid too many
non valid results due to inhibition.
P785 A two-step glutamate dehydrogenase antigen: real-time
polymerase chain reaction assay for detection of toxigenic
Clostridium difﬁcile
S. Goldenberg °, P. Cliff, G. French (London, UK)
Objectives: Most diagnostic laboratories in the UK and Europe use
one of several commercially available Enzyme Immunoassays (EIA) to
diagnose Clostridium difﬁcile infection (CDI). These assays detect toxins
A/B but suffer from having a poor sensitivity compared to Cytotoxin
assay (CTN) which is considered the gold standard). We evaluated a
new two-step algorithm which utilises the common antigen Glutamate
Dehydrogenase (GDH) as a screening step, followed by conﬁrmation
using real time PCR for detection of the toxin B gene (tcdB).
Methods: 500 consecutive diarroeal stool samples were tested using the
two-step protocol and compared to testing by a commercially available
EIA, according to manufacturers instructions. To conﬁrm the true status
of the sample, toxigenic culture was also performed at the same time as
the other tests.
Results: Of 500 specimens tested, 399 (79.8%) were negative for GDH
and EIA. 80% of samples were GDH positive and went on to have RT-
PCR performed. Among the 16 samples that were EIA positive, 13 were
also GDH positive, RT-PCR positive, were isolated in culture and were
shown to be producing toxin. Two samples were GDH positive but RT-
PCR negative. C. difﬁcile was cultured from one of these samples and
was shown to produce toxin.
Of the 484 samples that were EIA negative 85 (17%) were GDH positive.
23 of these samples were RT-PCR positive and organism was cultured
from 21 of these. Toxin production was demonstrated in 20 samples that
were cultured and were considered true positives.
Among the 62 samples that were GDH positive and RT-PCR negative,
organism could not be cultured in 58. Organism was cultured from
the remaining 4 samples, and only one of these demonstrated toxin
production and was considered to be true positives. Toxin production
could not be demonstrated in the other three samples and were considered
to be non-toxigenic.
Comparing EIA to toxigenic culture sensitivity and speciﬁcity were
found to be 40% and 99.6% respectively. (PPV=87.5% NPV=95.6%).
Comparing the two-step algorithm to toxigenic culture demonstrated a
sensitivity and speciﬁcity of 94.3% and 100% respectively (PPV=100%
NPV=99.5%).
Discussion: The two-step algorithm was found to be more expensive than
the EIA assay (an additional cost of £GBP 8000 based on 5800 samples
tested per year). However the two step algorithm enabled negative
samples to be rapidly excluded and led to markedly fewer false negatives
whilst causing minimal diagnostic delay.
P786 Analysis of Clostridium difﬁcile binary toxin gene expression
D.S. Metcalf °, J.S. Weese (Guelph, CA)
Objective: The major Clostridium difﬁcile toxins, TcdA and TcdB, are
well characterised virulence factors, however many toxigenic strains also
possess cdtAB genes encoding a binary toxin. The role of the binary
toxin is currently poorly understood as is its regulation of expression. The
objective of this research was to characterise the expression of cdtA, and
the upstream putative regulator, cdtR. In addition, complete sequencing
of the cdtAB locus is being performed to evaluate inter-strain variability
and identify other potential regulators of binary toxin gene expression.
Methods: Eleven cdtAB positive C. difﬁcile isolates from 9 different
ribotypes were evaluated. RNA was isolated from exponential and
stationary phases of growth, reverse-transcribed, and real-time PCR was
used to compare expression of cdtA and cdtR, using rpoA as a reference
gene. Testing was performed in triplicate and 24 primer pairs were
designed and used to sequence the complete ~6.5 kb binary toxin locus
of all 11 strains.
Results: There was a signiﬁcant difference in expression of both cdtA
and cdtR between exponential and stationary phases (P< 0.05), with
signiﬁcantly higher expression in stationary phase. There was not a
statistically signiﬁcant correlation between cdtA and cdtR, however
that may be a limitation of statistical power. There was no association
between the level of expression of either gene and ribotype or toxinotype
(P> 0.05). Although the CDT locus is mostly conserved, several
polymorphisms are present in both the promoter regions and open
reading frames.
Conclusions: Higher levels of expression of cdtA and its regulator
in stationary phase compared to exponential phase is consistent with
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the expression of tcdA and tcdB, suggesting common regulatory
mechanisms. The wide range of expression levels between strains
suggests a high level of heterogeneity even within C. difﬁcile ribotypes.
Heterogeneity is also observed in comparison of the CDT locus. The
weak correlation between cdtA and its putative regulator cdtR suggest
that while cdtR may have a regulatory role, other factors are probably
also involved in cdtA expression. Further study of this, and the inﬂuence
of exogenous factors such as antimicrobial exposure, is ongoing.
P787 Preliminary molecular evaluation of the toxigenicity of
Clostridium difﬁcile strains isolated from dogs in the area of
Parma (Italy)
M.C. Ossiprandi °, L. Zerbini (Parma, IT)
Objectives: Clostridium difﬁcile has been associated with canine acute
and chronic large and small bowel diarrhoea, as well with acute
haemorrhagic diarrhoeal syndrome. Reports have documented a variable
carriage rate of C. difﬁcile ranging from 0−40% in diarrhoeic and non-
diarrhoeic dogs.
The purpose of this study was to evaluate the molecular characteristics
of C. difﬁcile strains isolated from diarrhoeic and non-diarrhoeic dogs
by using PCR toxin gene proﬁle.
Methods: Faecal samples were collected from 95 diarrhoeic and non-
diarrhoeic dogs, tested for the presence of C. difﬁcile toxins A/B with
a commercially human EIA (Remel), and cultured onto pre-reduced
selective medium before and/or after thermal shock.
Preliminary identiﬁcation of C. difﬁcile was based on lack aerotolerance,
colony appearance, odour, and cellular morphology following Gram
staining. Species identities were conﬁrmed through a rapid latex slide
agglutination test (Oxoid) and Rapid ID32A (bioMe´rieux). All C. difﬁcile
isolates were PCR-screened for the presence of tcdA/tcdB and cdtA/cdtB
genes, as previously described by Spigaglia and Mastrantonio (2002) and
Stubbs (2000), respectively. Toxigenic strains were tested for in vitro
toxin production by EIA.
Results: C. difﬁcile strains were isolated from 10 of 95 canine faecal
specimens (10.5%). Eight of the samples (80%) belonged to diarrhoeic
dogs: 4 dogs were subjected to antibiotic treatment and the enteritis
followed the therapy, 1 with megaoesophagus was treated for enteritis
and C. perfringens was also isolated, 3 were not treated.
The majority of C. difﬁcile isolates (6/10, 60%) were toxigenic
(tcdA+/tcdB+) and possessed ctdA and ctdB genes. All faecal samples
tested by EIA were negative. On the contrary, all PCR-positive strains
were positive for in vitro toxin production.
Conclusion: The results of this study suggest that commercially human
EIA is inadequate for the diagnosis of canine C. difﬁcile-associated
diarrhoea when tested on faecal specimens, but it may be useful when
used on toxigenic isolates. Moreover, based on our results, the isolation
rates of C. difﬁcile from diarrhoeic dogs (80.0%) and non-diarrhoeic
dogs (20.0%) were statistically different. This is in disagreement with
previous reports in which signiﬁcant differences were not found in the
isolation rates between the 2 groups. Probably, antibiotic administration
caused the overgrowth of C. difﬁcile in intestine of the dogs, predisposing
the animals to enteritis.
P788 Comparison of a multiplex real-time PCR and the cell
cytotoxicity neutralisation assay for the diagnosis of
Clostridium difﬁcile infections
H. Huang, A. Weintraub, H. Fang, C.E. Nord ° (Stockholm, SE)
Objectives: Clostridium difﬁcile infection (CDI) is the major cause of
healthcare-associated diarrhoea. Recently, a new virulent C. difﬁcile
strain 027 causing outbreaks has emerged and was associated with
increased morbidity and mortality. Therefore, rapid and accurate
microbiological diagnosis is urgently needed. Toxigenic C. difﬁcile
detection by cell cytotoxicity neutralisation assay (CCNA) is considered
to be the “gold standard”. However, this assay is time consuming,
labour-intensive and requires facilities for cell culture. Toxin enzyme
immunoassays are more rapid but are associated with widely varying
sensitivity and speciﬁcity, making its reliability questionable for an
accurate diagnosis of CDI. The purpose of this investigation was to
evaluate the use of Xpert® C. difﬁcile (Cepheid, Sunnyvale, CA) real-
time multiplex polymerase chain reaction (PCR) assay as a diagnostic
test for the detection of toxigenic C. difﬁcile strains and presumptive
ribotype 027.
Methods: A total of 125 unrepeated strains and 220 unformed fresh
stools for C. difﬁcile test were determined by CCNA. For the stool
specimens, toxigenic cultures were performed additionally. All strains
were typed by PCR-ribotyping. Concurrently, the Xpert® C. difﬁcile
Assay was also performed to identify toxin B (tcd B), binary toxin (ctd
A/B), and the tcdC deletion nt 117 (ribotype 027). The sensitivity and
speciﬁcity of the Xpert® C. difﬁcile Assay were determined related to
CCNA and strain typing on the isolates.
Results: Of 125 strains, 17 (13.6%) were negative with both PCR and
CCNA while 107 (85.6%) were positive with both assays yielding 100%
sensitivity and 94.4% speciﬁcity. Of 220 stool specimens, 172 (78.2%)
were negative with both PCR and CCNA, while 17 (7.7%) were positive
with both assays yielding 97.1% sensitivity and 92.4% speciﬁcity. No
ribotype 027 strain was found.
Conclusions: The Xpert® C. difﬁcile Assay offers sensitivity and
speciﬁcity that is comparable to the CCNA reference method. With
the results available within one hour, it provides prompt and precise
laboratory diagnosis and enables rapid and effective management of
Clostridium difﬁcile infections.
P789 Real-time PCR assays for the simultaneous detection of gyrA
and gyrB mutations in Clostridium difﬁcile isolates
P. Spigaglia °, A. Carattoli, F. Barbanti, P. Mastrantonio (Rome, IT)
Objectives: Recent studies have demonstrated the involvement of
ﬂuoroquinolone (FQ) resistant Clostridium difﬁcile strains in C. difﬁcile
infections (CDI). In particular, recent severe outbreaks were caused
by the hypervirulent C. difﬁcile PCR-ribotype 027/toxinotype III, a
FQ resistant clone. In toxigenic strains, resistance to FQs is mainly
associated with the amino acid change Thr to Ile in position 82 of GyrA
and more rarely with the substitution Asp to Asn or Val in position 426
of GyrB. In this study, we developed two sets of primers and probes to
be used in two single Real-Time PCR assays or in a multiplex assay for
the detection of these substitutions.
Methods: Real-Time PCR assays were developed on the LightCycler
Real-Time PCR platform (Roche Diagnostics). Single and multiplex
assays were performed with the same reaction conditions. To distinguish
between ﬂuorescence emitted by each hybridisation probe set, two probes
were labelled with a different ﬂuorophore (LC-Red705 for gyrA and LC-
Red640 for gyrB) and read in two different channels. The results were
compared with MIC values obtained by the E-test and by sequencing
the ampliﬁed genes.
Results: 17 toxigenic and 2 non toxigenic FQ resistant C. difﬁcile strains
isolated during the European prospective study performed in 2005 were
used as representative of the different alleles of gyrA and gyrB currently
known. Reference strain 630, susceptible to FQs, was used as control.
Thirteen toxigenic strains showed the substitution in GyrA82 and 4
strains a substitution in GyrB426. The two non toxigenic isolates showed
the substitution Arg to Lys in position 427 of GyrB (GyrB427). All
strains with the substitution in GyrA82 showed a Tm of 52ºC, compared
to a Tm of 59ºC of the wild type. Strains with the substitution Asp to
Asn in GyrB426 showed a Tm of 53ºC, strains with the substitution
Asp to Val in GyrB426 a Tm of 54ºC and the wild type and the strains
with a change in GyrB427 a Tm of 59ºC. A gyrB allele characterised
by 3 silent mutations not involved in resistance showed a Tm of 50ºC.
The results were easy to interpret and always in agreement with those
obtained by E-test and by sequencing.
Conclusion: These molecular assays for screening of gyrA and gyrB
mutations are a reliable method for genetic detection of resistance to FQs
in C. difﬁcile, particularly in a setting where the use of these antibiotics
may facilitate the dissemination of hypervirulent C. difﬁcile strains.
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P790 ST17 within CC17-E. faecium serves as substrate for
sporadic acquisition of vancomycin resistance determinants
despite dominance of ST18 among ampicillin resistant clones
(Madrid, Spain)
P. Ruiz-Garbajosa °, G. Ca´rdenas, R. Canto´n, F. Baquero, T.M. Coque
(Madrid, ES; Quito, EC)
Objectives: Ampicillin-resistant E. faecium (AREfm) is associated with
the expansion of a genetic lineage designated CC17. This CC grouped
hospital-related isolates including most of the vancomycin resistant
E. faecium (VREfm) causing hospital outbreaks. AREFm isolates have
been suggested to serve as substrates for the emergence of VREFm.
The aim of this study is to describe the population structure of VREfm
isolates recovered in a setting with a low incidence of vancomycin
resistance but a high incidence of ampicillin resistance and to analyze
the corresponding glycopeptide resistance elements.
Methods: Eleven VREfm strains (8 VanB and 3 VanA) recovered at
the Ramo´n y Cajal University Hospital (Madrid, Spain) (1996–2006)
were studied. VREfm features were compared with a characterised
collection of AREfm isolated from blood cultures (n = 124) (1995–2008).
VREfm strains were typed by MLST. The structural analysis of Tn1546
(vanA) and Tn1547(vanB) was assessed by a vanRSHAXYZ (11 kb) and
vanRSYWHBX (6Kb) Long-PCR and PCR products were digested with
ClaI y BspHI/DraI respectively.
Results: Vancomycin resistance among E. faecium invasive and non-
invasive isolates was 0.8% (15/1782) (1996–2006). In 11 years, VREfm
were recovered from 15 patients (5 with VanA and 10 with VanB)
admitted at surgery (40%) and medical (33%) wards and ICUs (27%).
In 6/15 patients (40%) isolates were recovered from invasive samples (5
blood, 1 peritoneal ﬂuid). All VREfm isolates were resistant to ampicillin
and ciproﬂoxacin. By MLST, VREFm isolates were mainly grouped
into ST17 (2 VanA and 5 VanB) and sporadically into ST16 (1 VanB),
ST18 (2 VanB) and ST265 (1 VanA) all belonging to CC17. Among
vancomycin susceptible-AREfm blood isolates, ST18 (n = 62, 50%) was
the most frequently found following by ST16 (n = 17, 14%) and ST17
(n = 17, 14%). Tn1546 and Tn1547 restriction proﬁles were identical in
all VREfm strains and they corresponded with the complete backbone
for these elements.
Conclusions: In our setting, VREfm strains were sporadically present.
Vancomycin resistant determinants were infrequently acquired by
endemic and persistent CC17-AREfm clones. Although endemicity of
AREfm-ST18, vancomycin resistance appeared more frequently linked
with ST17, suggesting differences in the ability for the acquisition or in
the stability of these resistant determinants among endemic STs.
P791 Vancomycin-resistant Enterococcus in Canada: results from
the Canadian Nosocomial Infection Surveillance Program,
1999–2007
J. Embil, D. Gravel, L. Johnston, A. Simor, A. Matlow, M. Mulvey,
D. Ormiston, G. Taylor ° (Winnipeg, Ottawa, Halifax, Toronto,
Edmonton, CA)
Objective: Surveillance is one component of a strategy to identify
and limit the spread of Vancomycin Resistant Enterococci (VRE) in
hospitals. The objective of our National surveillance system is to provide
a Canadian benchmark rate for VRE.
Methods: The Canadian Nosocomial Infection surveillance Program
(CNISP) is comprised of 48 University-afﬁliated hospitals, including
8 paediatric stand-alone facilities in 9 Canadian provinces. Since 1999
surveillance for VRE has been ongoing. Cases of VRE are deﬁned as
inpatients from which Enterococcus faecium or Enterococcus faecalis
having a minimum inhibitory concentration of vancomycin of 8mg/mL
is isolated from a clinical or screening specimen. Infection was deﬁned
as the presence of an illness that met standard infection surveillance
deﬁnitions. Colonisation was deﬁned as the presence of VRE in surgical
wounds, urine, stool (rectum), or other body sites in an individual not
manifesting clinical signs and/or symptoms. To be deﬁned as health-
care associated, there had to be no evidence that the organism was likely
present at the time of admission.
Results: From 1999 to 2007, the rate of VRE increased from 0.37 to 2.48
cases per 1,000 admission s (do you mean, admissions). The increase
in the rate was due primarily to an increase in VRE colonisation, from
0.34 to 2.74 cases per 1,000 admissions (p< 0.0.001). The rate of VRE
infection increased from 0.02 to 0.08 cases per 1,000 admissions. The
overall incidence of VRE increased from 1.20 per 1,000 admissions in
2006 to 2.48 per 1000 admissions in 2007 (p< 0.0001), with increases
seen in all regions of Canada. Most cases of VRE (82%) were health
care-associated and were acquired in the reporting CNISP hospital.
Overall, only 2% were community-acquired.
Conclusion: Although the incidence rate of VRE carriage in Canada is
increasing, it remains low. There was a signiﬁcant increase in the rate
of VRE reported to CNISP in 2007, which more than doubled in a year.
The number of cases of VRE acquired in the reporting CNISP hospitals
increased in 2007 by 6%; whereas there was a decrease in the number
of community-associated VRE of 6%.
P792 A probiotic approach to combat multiresistant enterococci:
a cross-over clinical trial on the effect of probiotics on noso-
comial spread of ampicillin-resistant Enterococcus faecium
M. de Regt °, T. Hopmans, R. Willems, M. Bonten (Utrecht, NL)
Background: Colonisation and infection rates with ampicillin-resistant
Enterococcus faecium (ARE) have increased in our hospital. We assessed
whether oral probiotics (microbial food supplements that improve
intestinal colonisation resistance) decreased the risk of acquisition of
intestinal ARE-colonisation in hospitalised patients (pts).
Methods: In a prospective cohort study with cross-over design all
eligible pts (length of stay [LOS] >48 h) on two wards where
ARE-colonisation is endemic (gastro/nephrology [ward1] and geri-
atrics [ward2]), were offered a multispecies probiotic product (5
gram;109 cfu/g) 2×/day until discharge (4.5 months, probiotic period)
or not (4.5 months, control period). During the entire study, all pts were
screened for perianal ARE-carriage <48 h after admission, 2×/week and
<48 h before discharge. Data were analysed with a Cox proportional
hazards model with time-dependent covariates. Colonisation pressure
(daily proportion of pts colonised with ARE), antibiotics (AB) with
intestinal activity (subdivided in 2 classes according to activity against
ARE), a post-antibiotic effect of 3 days (assuming the intestinal ﬂora
needs time to restore after stopping AB), treatment in isolation, age and
medical specialty were analysed as potential confounders. AB active
against ARE included piperacillin(/tazobactam) and oral vancomycin.
Results: During the study (267 days on ward1 and 296 days on ward2)
852 pts had a LOS> 48 h. 563 (66%) were screened on admission, of
which 127 (23%) were colonised with ARE. In all, 1987 cultures were
obtained and, on average, daily colonisation status was known for 69%
of the pts. Of all pts at risk for ARE-acquisition (n = 436), 110 (25%)
used probiotics during (part of) their stay and 92 (21%) acquired ARE-
colonisation: 28 (25%) of the 110 that used probiotics and 64 (20%)
of 326 control pts. After adjustment for colonisation pressure (hazard
ratio (HR) 1.76 [95%CI 0.3−10.3]), AB inactive against ARE (HR=4.61
[95%CI 2.8−7.6]) and the post-antibiotic effect (HR= 5.25 [95%CI:
1.9−14.3]), the HR for probiotics was 0.53 (95%CI: 0.2−1.8). There
was an interaction between probiotics and AB inactive against ARE: the
combined use was associated with the highest risk of ARE-acquisition
(HR=8.31 [95%CI 4.2−16.5]).
Conclusion: In the absence of antibiotic use, probiotics tend to have a
protective effect on ARE-acquisition in hospitalised pts. In pts using AB
inactive against ARE, probiotics increase the hazard of acquisition from
4.61 to 8.31.
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P793 Molecular epidemiology of Staphylococcus aureus among
asymptomatic carriers from Saxony
S. Monecke °, C. Luedicke, R. Ehricht (Dresden, Jena, DE)
Objectives: The objective was to characterise the colonising Staphylo-
coccus aureus population among asymptomatic carriers from Saxony to
provide data for comparisons to isolates from deﬁned clinical conditions.
Methods: Diagnostic microarrays were used in order to extensively
characterise 155 S. aureus isolates obtained from asymptomatic carriers
(admission screening of trauma and neurosurgical patients, nasal swabs
from junior medical students and from workers of a biomedical facility).
Results: Some superantigens proved to be very common. Toxic shock
syndrome toxin (tst1) was detected in 14.8% of these 155 isolates. The
enterotoxin cluster egc comprising of seg, sei, sem, sen, seo, and seu
was very common (45.2%). Enterotoxin A (sea) was found in 17.4%.
Enterotoxins D, J and R (sed, sej, ser) were always detected together in
15.5%. Enterotoxin genes C (sec) and L (sel) also occurred together in
12.3%. The genes encoding Panton-Valentine leukocidin (lukS-PV and
lukF-PV) were found only once, in a CC30 MSSA isolate. This virtual
absence of PVL in asymptomatic carriers emphasizes its pathogenetic
signiﬁcance in patients with skin and soft tissue infections.
Three isolates (1.9%) were MRSA. Most isolates (71.6%) harboured
the beta lactamase gene blaZ, while other resistance genes were found
only sporadically. The 155 isolates typed in this study belonged to
twenty different clonal complexes (CC). The most common CC was
CC8 (18.7%). It was followed by CC15 (16.8%), CC30 (16.1%) and
CC45 (9.0%).
Discussion: These data might provide an insight into pathogenesis,
especially with regard to the different epidemiology of superantigens
and PVL. In a previous study (Monecke & Ehricht, 2007) PVL was
found in 30% of abscess isolates, but it was present in only 0.6% of
asymptomatic carriers. This emphasizes its pathogenetic signiﬁcance in
patients with skin and soft tissue infections. Contrastingly, there was
virtually no difference between abscess and carrier isolates with regard
to abundances of superantigens including tst1.
Prevalence data on surface antigens, such as capsules, could be helpful
for the design of a future vaccine.
P794 Experience with polymerase chain reaction-based methicillin-
resistant Staphylococcus aureus screening in paediatrics
M. Patel °, J. Gray, H.L. Turner, J. Room, N.M. Dyer, S. Bullingham
(Birmingham, UK)
Objectives: In England Department of Health Operational Guidance
requires only that paediatric admissions in high-risk groups need to be
screened. Our objective was to identify high-risk patients group based
on previous 10-years experience of methicillin resistant Staphylococcus
aureus (MRSA) in our hospital and investigate accuracy of polymerase
chain reaction (PCR) based screening in high-risk patient group who
might beneﬁt from rapid availability of results.
Methods: In the 10-year period April 1998 to March 2007 MRSA was
detected in 405 in-patients at Birmingham Children’s Hospital. A high
proportion (20%) of the patients was from paediatric intensive care unit
(PICU). PCR based screening was introduced for all admissions to PICU.
A pair of nasal swabs was collected at the time of admission to the PICU.
First swab was used for PCR using GeneXpert Dx system (Cepheid).
The second swab was cultured on MRSA selective medium and then
was placed in an MRSA enrichment broth and sub cultured onto MRSA
selective medium after overnight incubation. The accuracy of PCR was
determined by comparing PCR results with direct and enrichment culture
of the nasal swab or any other clinical specimen growing MRSA at the
same time.
Results: In two months period 203 specimens were processed from 180
patients. Thirteen nasal swabs were found to be positive by either PCR
or culture. The sensitivity, speciﬁcity, positive predictive value (PPV),
negative predictive value (NPV) and accuracy of PCR when compared
with culture results of screen specimens or clinical specimens was 88.9%,
97.9%, 66.7%, 99.5% and 97.5%, respectively (Table 1). We reviewed
four PCR positive and culture negative cases. Two were direct hospital
admissions from home with no known risk factors for MRSA and the
other two were hospitalised and the positive result coincided with a
culture conformed case on the same unit.
Results: See table 1.
Table 1
MRSA results Culture positive Culture negative Total
PCR positive 8 4 12
PCR negative 1 190 191
Total 9 194 203
Conclusion: In our study prevalence of culture conﬁrmed MRSA in
PICU patients was 5%. These data suggests that PCR may be more
sensitive than direct culture. Signiﬁcance of PCR positive and culture
negative result is currently uncertain. Our preliminary data suggests that
at least some of these results are true positives. We are now screening
all PCR positive patients using swabs from multiple body sites to try to
conﬁrm patient’s MRSA status.
P795 Development and implementation of a 4-plex real time-PCR
assay for screening and detection of methicillin-resistant and
methicillin-sensitive Staphylococcus aureus
S. Kolman, Y. Ben-Nissan, A. Kilman, C. Arieli, Y. Paitan ° (Kfar
Saba, IL)
Objectives: To develop a new real time-PCR (QR-PCR) assay for
methicillin-resistant and methicillin-sensitive Staphylococcus aureus
(MRSA, MSSA) detection with high and clinically satisfactory
diagnostic values (Sensitivity, Speciﬁcity, PPV, NPV) and to implement
it in a cost-effective, logistically feasible protocol in our infection control
program.
Methods: We developed a 4-plex QR-PCR assay enabling detection of
MRSA and MSSA overcoming most problems found in previously pub-
lished assays and in commercial MRSA kits. The assay simultaneously
detects in one PCR tube, a PCR internal control (inhibition and reagents
integrity), the mecA gene, a S. aureus-speciﬁc gene and SCCmec:orfX
region types 1 to 5. The assay was validated using 150 known staphy-
lococcal strains. Analytical speciﬁcity was analyzed using 83 different
bacterial and fungal species. Analytical sensitivity, direct swab sensitivity
and detection of MRSA and MSSA in mixed population were evaluated.
All samples were analyzed for mixed population and by conventional
identiﬁcation methods. The assay was implemented in our infection
control program in a cost-effective, logistically feasible protocol.
Results: Validation with 150 known staphylococcal strains reviled
100% concordance with microbiological analysis. No cross reaction
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was observed to 83 different bacterial species (analytical speciﬁcity).
The limit of detection was 20CFU/PCR reaction for MRSA and
2CFU/PCR for MSSA (analytical sensitivity). Direct swab sensitivity
was 3000CFU/ml for MRSA and 300CFU/ml for MSSA corresponding
to 150CFU/swab or 20−25CFU/PCR reaction for MRSA and to
15CFU/swab or 2−4CFU/PCR reaction for MSSA. No meaningful
redaction was found in mixed population analysis.
During 2 years, out of 39,120 samples, we applied the assay on 4,482
samples suspected to contain staphylococci or S. aureus in 504 runs
(2500 samples after exclusion of patient’s duplicates). All calculated
diagnostic values are >95−99% for MRSA detection and >91−99%
for MSSA (Table 1). For logistical and economical reasons PCR is
performed from colonies and results are available at the next day. Results
are available in less then 3 hours if direct swab PCR is performed.
Conclusion: Our assay demonstrates very high diagnostics values,
analytical sensitivity and speciﬁcity; suitable for direct swab analysis and
can be incorporated into infection control programs in a cost-effective,
logistically feasible protocol which will be presented.
P796 Identiﬁcation, cloning and characterisation of ScaD, a novel
antigen from Staphylococcus aureus
M.R. Pourmand °, S. Menbari, S. Foster (Tehran, IR; Shefﬁeld, UK)
Objectives: Staphylococcus aureus and Staphylococcus epidermidis are
major human pathogens of increasing importance due to the spread of
antibiotic resistance. Novel potential targets for therapeutic antibodies are
products of staphylococcal genes expressed during human infection. Sca
gene family has been identiﬁed in both S. aureus and S. epidermidis with
a highly conserved 110 amino acid C-terminal domain. ScaD is a novel
protein demonstrating a strong identity with staphyloxanthin biosynthesis
protein. In this study, puriﬁed recombinant protein was screened and
analysed with patient sera.
Methods: ScaD has likely signal peptide, therefore for overexpression,
the mature form of ScaD was produced. Restriction map of the scaD
locus was created. It was found that NdeI and XhoI do not cut within the
gene and so could be used for cloning. The pET21a(+) system was used
for cloning and overexpression of the protein. The puriﬁed PCR fragment
was digested with NdeI and XhoI, and ligated into pET21a(+), which
had also been digested with the same enzymes. The recombinant plasmid
was transformed into the expression host strain, E. coli BL21(DE3). The
patient sera were collected form Tehran university of medical sciences
hospitals.
Results: The mature Staphylococcus aureus ScaD was cloned and
overexpressed successfully. Expression product of scaD exhibited a
molecular weight by SDS-PAGE analysis comparable with a theoretical
estimation. The soluble protein was tagged with 6xHIS allowing
puriﬁcation. SDS-PAGE and Western-blot analysis using patient sera
demonstrated reactivity of the puriﬁed recombinant protein with patient
sera.
Conclusion: ScaD belongs to the Sca protein family with a highly
conserved C-terminal domain. Further studies to determine the role of
the conserved ScaD domain in ligand binding and demonstration of
conserved epitopes may establish the domain as a credible target for
vaccination.
P797 Evaluation of eSwab® for surveillance of MRSA by Xpert
MRSA® and culture on pooled samples
K. Martens, H. De Beenhouwer, J. Frans °, A. Van den Abeele,
R. Cartuyvels, G. Coppens on behalf of the Bilulu Study Group
Objectives: The Xpert MRSA® assay (Cepheid), which runs exclusively
on the GeneXpert® system (Cepheid), is a FDA approved molecular test
to screen for MRSA. It has previously been validated on nose, throat
and perineum samples taken by a double Copan swab® (Copan). This
study evaluates, in a multi-centre setting, the use of pooled eSwab®
liquid transport medium (Copan) from nose, throat and perineum (NTP)
as input sample for the Xpert MRSA® assay in comparison to standard
culture technique from the same medium.
Methods: High-risk patients (n = 159) were sampled from July untill
September 2008 in 5 Belgian hospitals. Separate nasal, throat and
perineum swabs were collected using the eSwab®.
Four hundred microL of each eSwab® liquid medium from a NTP set was
pooled to a ﬁnal volume of 1200 microL. For the molecular test using
the Xpert MRSA® assay, 150 microL of pooled sample was added to the
lysis buffer provided in the kit. Further testing was performed according
to the manufacturer’s instructions. Another 500 microL of pooled sample
was transferred to 4mL of TSB and incubated for 18−24 h at 35ºC.
Ten microL of this enriched culture was transferred to a MRSA-ID®
plate (bioMe´rieux) and screened for the presence of MRSA after 24 and
48 hours.
Results: Twenty nine (18.2%) samples were MRSA positive on culture.
Of these 28 (96.6%) were Xpert MRSA® positive, while 1 (3.4%)
tested negative. Of the 130 culture negative samples, Xpert MRSA® was
negative in 125 (96.2%) but positive in 5 (3.8%) samples. Sensitivity
and speciﬁcity of the Xpert MRSA® assay was 96.6% and 96.2%,
respectively. The positive predictive value (PPV) was 84.8% and the
negative predictive value (NPV) was 99.2%. No invalid results were
observed for the Xpert MRSA® assay.
Conclusion: The results of Xpert MRSA® on eSwab® liquid transport
medium pooled from NTP are comparable to the results previously
obtained with the double Copan swab®, but fewer invalid results were
obtained with eSwab®. The high NPV (99.2%) makes it suitable to rule
out MRSA. However, due to the lower PPV (84.8%), positive Xpert
MRSA® results need conﬁrmation by culture. For culture, the same
eSwab ﬂuid can be used, reducing the risk of sampling bias.
Pooled eSwab® liquid medium from NTP is an adequate matrix for rapid
MRSA screening by the Xpert MRSA® assay with culture conﬁrmation
possibility without extra sampling.
Table 1: Overview of the results performed on the GeneXpert® system
and eSwab® culture method
eSwab® culture + eSwab® culture − Total
GeneXpert® + 28 5 33
GeneXpert® − 1 125 126
Total 29 130 159
P798 Sequence-based characterisation of the agrD gene and
the hld gene in Staphylococcus epidermidis isolated from
prosthetic joint infections
B. Hellmark °, B. So¨derquist, M. Unemo, A˚. Nilsdotter-Augustinsson
(Orebro, Linkoping, SE)
Objectives: Staphylococcus epidermidis is a commensal that comprises
a substantial part of the normal human skin ﬂora. Nevertheless, this
bacterium has emerged as the most important pathogen in infections
related to implanted foreign body materials, especially prosthetic joint
infections (PJIs).
A regulatory gene-complex, called accessory gene regulator (agr), has
a major role in the regulation of different virulence factors and it has
been found to be polymorphic. It consists of four genes; agrA, agrB,
agrC, and agrD. By sequencing of the agrD gene, three different agr
types have been described and there seems to be a correlation between
agr type and the virulence of the bacteria.
One of the regulated virulence factors is the delta toxin, which is encoded
by the hld gene. The hld gene is located in close proximity of the agr
complex.
The aim of this study was to sequence the agrD gene and the hld gene
in S. epidermidis isolated from PJIs, and compare the sequences with
the agrD gene and the hld gene in commensal S. epidermidis.
Methods: Thirty-three S. epidermidis isolates obtained during revision
surgery due to PJIs were analyzed. Twenty-four commensal S. epider-
midis isolates from 24 healthy individuals were used as controls, 12 from
skin and 12 from nares. Sequencing of the agr complex and the hld gene
was used.
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Results: Among the 33 isolates from PJIs all three agr types were
identiﬁed; 18 isolates displayed agr type 1, two type 2, and 13 type
3. Among the 24 commensal isolates 10 isolates comprised agr type
1, three type 2, and seven type 3. Furthermore, two isolates displayed
an AgrD amino acid sequence that was similar to agr type 2 but had
one and two amino acid alterations, respectively. Two isolates were not
possible to type due to lack of PCR amplicons.
In nearly all evaluated PJI (33/33; 100%) and commensal (21/22; 96%)
isolates, the hld gene was present and encoded identical amino acid
sequence. Accordingly, one commensal isolate displayed a one amino
acid alteration and in two commensal isolates the presence of the hld
gene could not be evaluated due to lack of PCR amplicons.
Conclusions: Regarding the correlation between agr type and origin of
isolates there was no statistically signiﬁcant difference; type 1 was the
most common type in isolates from both PJIs and the commensals. In
addition, no difference in prevalence of the hld gene between the two
groups of isolates was found.
P799 Genotypic characterisation of Helicobacter pylori isolates
from southern Poland
E. Karczewska, I. Wojtas, A. Budak °, E. Sito, M. Zwolinska-Wcislo
(Cracow, PL)
Objectives: The high level of Helicobacter pylori infection in Poland
(about 60%) may constitute a risk factor of still high morbidity rate on
gastroduodenal diseases in this country. H. pylori strains that possess the
vacA s1/m1 (or s1/m2) cagA-positive genotypes have been associated
with more severe clinical outcomes. The aim of the present study was
to determine the prevalence of the cagA gene and the vacA alleles in
H. pylori strains isolated from dyspeptic patients and to investigate the
correlation of the vacA genotypes with cagA status as well as the relation
between the cagA and vacA genotypes and different clinical outcomes.
Methods: The vacA (s1, s2, m1, m2) and cagA genotypes of 46 H. pylori
isolates from patients in the southern part of Poland were characterised
by PCR. The prevalence of the different cagA and vacA genotypes in
two clinical groups, peptic ulcer disease (PUD) and non ulcer dyspepsia
(NUD) was compared and the correlation between the distinct genotypes
and clinical outcomes was statistically examined.
Results: Thirty (65%) H. pylori strains were identiﬁed as cagA-positive.
The three of four possible combinations of the vacA signal (s) and middle
(m) regions were identiﬁed in this population and the most frequent
genotypes were s1/m1 and s1/m2 (both 37%). The s2/m2 genotype was
strongly associated with the cagA-negative strains (p< 0.001). The pres-
ence of the vacA s1 genotype correlated with the cagA-positive isolates
(p< 0.001) and the m2 isolates were associated with the cagA-negative
strains (p = 0.012). There were no statistically signiﬁcant differences
in the prevalence of the cagA and vacA genotypes in the groups of
patients with PUD and NUD, but considering these groups separately the
presence of the s1 allele was signiﬁcantly associated with PUD as well
as with NUD (p< 0.001, p = 0.007, respectively), the m2 allele − with
NUD (p = 0.027) but not with PUD (p = 0.064). The cagA gene displayed
an association with PUD (p< 0.001) in contrast to NUD (p = 0.2).
Conclusion: Our study demonstrates that individuals infected with
H. pylori strains that carry the vacA s1 cagA-positive genotypes are
associated with increased risk of PUD, compared to those infected with
the vacA s2 cagA-negative strains. It can mean that some non ulcer
dyspepsia patients with the vacA s1 cagA-positive strains will be at risk
of developing PUD in the future.
P800 Identiﬁcation of sialic acid biosynthesis and transferase locus
in human and canine Helicobacter bizzozeronii strains
M. Rossi °, T. Raitila, M. Ha¨nninen (Helsinki, FI)
Helicobacter bizzozeronii is a canine gastric species belonging to the
“Helicobacter heilmannii” Type 2. “H. heilmannii” comprises at least
ﬁve different Helicobacter species observed occasionally (0.17−2.3%) in
gastric biopsies of human patients with upper gastrointestinal symptoms.
These organisms are difﬁcult to cultivate in vitro and H. bizzozeronii
is the only “H. heilmannii” species isolated from human. Up to now,
only two human H. bizzozeronii strains are available, one isolated
from a Danish patient and the other from a Finnish one. The genome
of H. bizzozeronii CCUG 35545T was sequenced using the 454-
pyrosequencing technology. Preliminary gene prediction and homology
searches for each contig larger than 1000 kb were carried out. A cluster of
ﬁve predicted genes, 4899 bp in total length, presenting high homology
to genes involved in the synthesis of sialylated lipopolysaccharade outer
core in Campylobacter jejuni (neuB, neuC, neuA and two copies of
cstII) were identiﬁed. The G+C% of this island was equal to the genome
average value of 46% and showed identical synteny and high levels of
homology to a cluster of genes located downstream of the fragmented
vacA locus of Helicobacter acinonychis strain Sheeba. Homopolymeric
runs of 15 residues of cytosine and 15 of guanine were detected upstream
and downstream of the ﬁrst cstII homologue suggesting a potential site
of phase-variation in H. bizzozeronii. A PCR primer set was designed
in order to amplify the spanning region between neuA and the ﬁrst cstII
homologues of four canine and two human strains. No fragments were
ampliﬁed from the Finnish human strain and from one canine isolate,
indicating either the absence of the island or a change in the synteny.
The 354 bp fragments of the Danish human strain and of one canine
strain showed the expected repeat of cytosine and 96.5% of identity
with the sequence of H. bizzozeronii CCUG 35545T, whereas two canine
strains lacked in the poly-C stretches and showed less identity with the
type strain (92.4% and 94.6%). Further characterisation of the entire
fragment is still in process. The role of this island in H. bizzozeronii
lipopolysaccharade biosynthesis or protein glycosylation as well as the
function of the high plasticity observed among human and dog strains
in the host adaptation are the aims of our further studies.
P801 Helicobacter pylori and Candida albicans: interrelation
and genetic features of micro-organisms in patients with
duodenal ulcer
N. Baryshnikova, E. Tkachenko, Y. Uspenskiy, A. Suvorov ° (St.
Petersburg, RU)
Objective: There are a lot of the evidences supporting the direct
correlation between the presence of Helicobacter pylori (HP) in a
stomach and Candida albicans (CA) in colon (Zaharchenko M.M., 2003,
Baryshnikova N.V., 2006). There were researches in which yeast (ﬁngi)
are considered as HP carriers (Siavoshi F et al., 2005). The aims of
research are revealing interrelation between the presence of HP and
CA in stomach mucosa and investigating the genetic features of these
microorganisms in patients with duodenal ulcer (DU).
Materials and Methods: 27 DU patients were included in this research.
All patients were treated with standard eradication therapy (omeprasole,
amoxicillin, claritromicin) during 10 days. An antifungal treatment was
not appointed. Before and after therapy polymerase chain reaction (PCR)
in biopsy material of stomach mucosa was performed for all patients.
Several genes of pathogenecity island (PAI) of HP (ureC, cagA, cagC,
cagA, cagH) and genes of CA (sap2 − secreted aspartic proteinases,
hwp1 − hyphal wall protein 1, alp7 − agglutinin like protein 7) were
studied.
Results: It was determinated, that at all DU patients carried both CA and
HP before treatment. The HP genes encoding for PAI were determinated
quite often: cagA − at 88.9%, cagC − at 77.8%, cagE − at 77.8%, cagH −
at 77.8% of patients. The combination of all four above-named genes
was found in 92.6% of cases. CA genes sap2 and alp7 were determinated
in 100% of patients, gene hwp1 − in 51.9%. After the anti-HP-therapy
the percentage of determinating of hwp1 gene decreased by 25%. To
other CA genes frequency didn’t change. The proportion of successful
HP eradication was 66.7%, and in this group of patients the gene hwp1
of CA was identiﬁed by PCR-method in 44.4% of cases before treatment
and only in 22.2% − after therapy (p< 0.05).
Conclusions: Highly virulent strains of Helicobacter pylori can be
often associated with carriage of Candida albicans. Anti-HP-therapy can
signiﬁcantly decrease the carriage of CA in stomach mucosa. Possibility
mechanisms of this phenomenon in discussed.
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P802 Comparasion of Genotype® HelicoDR with real-time PCR
to identify clarithromycin resitance in Helicobacter pylori
S. Agudo °, T. Alarco´n, P. Urruzuno, A. Somodevilla, M. Lo´pez-Brea
(Madrid, ES)
Objective: Clarithromycin is one of the most important antibiotics
for Helicobacter pylori treatment and it is an important factor of
eradication failure. The early detection of resistance is important in
the treatment of H. pylori. The aim of this study was to evaluate
two commercially available kits: the MutaREAL® H. pylori Real Time
PCR Kit (MutaREAL Immundiagnostik), and a assay based on DNA
hybridisation technology on nitrocellulose strips, Genotype® HelicoDR
(Hain, Diagnostika, Nehren, Germany) for detection of point mutations
in the 23S rRNA genes responsible for H. pylori clarithromycin
resistance in gastric biopsies.
Methods: 49 biopsies for H. pylori were obtained from patients with
gastric symptoms, received at the Department of Microbiology from
December 2007 to May 2008. Standard microbiological procedures were
used for H. pylori culture. Clarithromycin resistance was determined
by E-test. DNA extraction was carried out by the NucliSens easyMAG
platform with the NucliSens magnetic extraction reagents (bioMe´rieux)
according to the manufacturer instructions. MutaREAL® Helicobacter
pylori Real Time PCR Kit and Genotype® HelicoDR was used
to clarithromycin resistance in H. pylori following manufacturer
recommendations.
Results: All biopsies showed a positive result with the MutaREAL®
kit and Gentotype® HelicoDR. 24 out of 49 showed clarithromycin
resitance by E-test. The Real time PCR detected clarithromycin
resistance in 21 cases with a sensitivity and especiﬁcity 87.5% and
92%, respectively, compared with phenotypical methods. The Genotype®
HelicoDR detected resistance in 27 cases: 20 biopsies had one point of
mutation, 2 biopsies had two points of mutation and 5 biopsies showed
hetero-resistance with a wild type and mutated strain. The sensitivity and
speciﬁcity were 100% and 96%, respectively. The mutation A2143G was
detected in all specimens, and the mutation A2142C in two biopsies with
two points of mutation.
Conclusions: MutaREAL® Kit and Genotype®HelicoDR were able to
detect clarithromycin susceptibility with high sensitivity and speciﬁcity
and are quicker than culture. Genotype®HelicoDR had better sensitivity
and speciﬁcity and it was possible to detect the type of mutation and
hetero-resitance strains. Real Time PCR is suitable to be done in 1 hour
after DNA extraction.
P803 Development of a new test, GenoType® HelicoDR, for molec-
ular detection of antibiotic resistance in Helicobacter pylori
E. Cambau °, V. Allerheiligen, C. Corbel, L. Deforges, F. Megraud
(Paris, Bordeaux, FR; Nehren, DE)
Objectives: Eradication rate of Helicobacter pylori by standard therapy
is decreasing due to an increase in antibiotic resistance. Our aim was to
provide a new molecular test to facilitate detection of this resistance.
Methods: A panel of 126 H. pylori strains was studied for phenotypic
(MIC) and genotypic resistance to clarithromycin (rrl mutation) and
levoﬂoxacin (gyrA mutation). Genotype correlated to phenotype at the
rate of 97% for clarithromycin and 100% for levoﬂoxacin. On the basis
of the panel test sequencing results and literature data, we developed a
genotyping test using the DNA Strip technology. Oligonucleotide probes
were wild-type sequences or sequences of the most prevalent mutations.
Twenty Helicobacter species other than H. pylori were tested to assess
analytical speciﬁcity. Clinical strains (n = 64) and H. pylori positive
gastric biopsies (n = 109) were tested blindly with the new molecular
test GenoType® HelicoDR.
Results: The presence of mutations or the absence of hybridisation with
wild-type sequences was predictive in rrl, for clarithromycin resistance
in 85 cases (mostly the A2147G mutation), and in gyrA for levoﬂoxacin
resistance in 53 cases (mutations at codons 87 or 91). Sensitivity,
speciﬁcity, and positive and negative predictive values for detecting
resistance were 95.5%, 96.5%, 98%, and 96.5% for clarithromycin,
respectively, and 87%, 99%, 98% and 93% for levoﬂoxacin, respectively.
Concordance score was 0.97 for clarithromycin and 0.95 for levoﬂoxacin.
Genotyping showed a mix of genotypes reﬂecting a co-infection in 31%
of strains and 35% of biopsies.
Conclusion: GenoType® HelicoDR is an efﬁcient method to detect
mutations predictive of antibiotic resistance in H. pylori when applied
to strains or directly to gastric biopsies.
P804 Analysis of 3′ end variable region of cagA in Helicobacter
pylori isolated from Iranian dyspeptic patients
L. Shokrzadeh °, K. Baghai, N. Sahebekhtiari, H. Dabiri, F. Jafari,
A. Tahami, A. Alizadeh, H. Zojaji, M.R. Zali (Tehran, IR)
Objective: CagA protein, encoded by the cagA, is the best studied
virulence factors of H. pylori. CagA is mainly tyrosine-phosphorylated
at Glu-Pro-Ile-Tyr-Ala (EPIYA) motifs. The aim of the present study was
to investigate the structures of the 3′ region of the cagA gene, number
and type of EPIYA motifs in Iranian H. pylori isolates.
Methods: A total of 190 gastric biopsies from patients with dyspeptic
symptoms who were qualiﬁed for endoscopies of upper gastrointestinal
tract from February 2007 to February 2008 were included in this
study. Samples were cultured by standard methods and genomic DNA
was extracted by using the QIAamp tissue DNA extraction kit. After
conﬁrming isolates with glmM followed by amplifying cagA gene, we
examined 92 cagA gene-positive H. pylori isolates. The entire 3′ end
variable region of the cagA gene was ampliﬁed by PCR followed by
sequencing.
Results: Out of 92 H. pylori cagA-positive isolates, the EPIYA motif
was present in 86 strains with three copies, 3 strains with four copies,
and 3 strains with two copies. Sequence analysis of the entire 3′ end
PCR products showed three types of primary gene structure depending
on the type and number of repeats: EPIYA-ABC, EPIYA-ABCC and
EPIYA-AB. We found no strains within our population harbouring the
Eastern type of EPIYA-D.
Conclusion: Studies of the structure of the 3′ region of the cagA
gene of H. pylori isolates in Iran as an East country showed that
this region of cagA differs markedly from Eastern isolates. On the
other hand, alignments of deduced amino acid showed that the type
of Iranian isolates can be related to Western types rather than Eastern
types. Differences in cagA 3′ region can be useful for molecular
epidemiological studies and it may provide a marker for differences in
virulence among cagA-positive H. pylori strains.
P805 Frequency of vacA, cagA and babA2 virulence markers in
Helicobacter pylori strains isolated from Mexican patients
with chronic gastritis
G.L. Paniagua, E. Monroy °, R. Rodriguez, C. Rodriguez, S. Arroniz,
J.L. Corte´s, A. Camacho, E. Negrete, S. Vaca Pacheco (Tlalnepantla, MX)
Objective: Helicobacter pylori has been strongly associated with chronic
gastritis, peptic and duodenal ulcers, and is a risk factor for gastric
cancer. Three major virulence factors of H. pylori have been described:
the vacuolating toxin (VacA), the cytotoxin-associated gene product
(CagA) and the adhesion protein BabA2. Since considerable geographic
diversity in the prevalence of H. pylori virulence factors has been
reported, the aim of this work was to establish the H. pylori and vacA,
cagA and babA2 gene status in one hundred adult patients, from a
marginal urban area of Mexico, with chronic gastritis.
Methods: H. pylori was identiﬁed in cultures of gastric biopsies by
nested PCR. vacA and cagA genes were detected by multiplex PCR,
whereas babA2 gene was identiﬁed by conventional PCR.
Results: H. pylori-positive biopsies were 81%. All H. pylori strains were
vacA+; 38.3% were cagA+; 21% were cagA+ babA2+ and 6.2% were
babA2+. Mexican strains examined possessed the vacA s1, m1 (40.7%),
s1, m2 (28.4%), s2, m1 (16%) and s2, m2 (14.8%) genotypes.
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Conclusion: These results show that the Mexican patients suffering
chronic gastritis we have studied had a high incidence of infection by
H. pylori. Most H. pylori strains examined may be considered as highly
virulent since sixty six percent of them possessed two or three of the
virulence markers analyzed, with s1, m1 as the most frequent alleles of
vacA.
Acknowledgements: Project supported by PAPIIT IN216508, DGAPA,
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P806 EUCAST breakpoints in automated susceptibility testing of
Gram-negative bacteria − BD Phoenix validated
R. Smyth °, S. Bengtsson, G. Kahlmeter, G. Babini, E. Montrucchio
(Va¨xjo¨, SE; Buccinasco, IT)
Objectives: To evaluate the performance of the BD Phoenix AST System
for susceptibility testing of Gram negative clinical isolates and their SIR-
category interpretation using breakpoints from the European Committee
on Antimicrobial Susceptibility Testing (EUCAST).
Methods: 242 Gram negatives, both stored strains and fresh isolates,
were tested in parallel using BD Phoenix (PHX) and the Swedish
Reference Group for Antibiotics (SRGA) disc diffusion method. The
PHX panels, speciﬁcally manufactured for this study, were NMIC/ID-73,
containing amikacin (AN), amoxicillin/clavulanate (AXC), aztreonam
(ATM), cefepime (FEP), cefotaxime (CTX), ceftazidime (CAZ),
cefuroxime (CXM), ciproﬂoxacin (CIP), colistin (CL), gentamicin (GM),
imipenem (IPM), meropenem (MEM), moxiﬂoxacin (MXF), nalidixic
acid (NA), piperacillin (PIP), piperacillin/tazobactam (TZP), tobramycin
(NN), trimethoprim (TMP) and trimethoprim/sulphamethoxazole (SXT),
each in an appropriate range of doubling dilutions. Category (SIR)
interpretations of MIC results from PHX and inhibition zone results from
disc diffusion were in line with EUCAST breakpoints. Discrepancies
were resolved by retesting and then if necessary by MIC determination
using E-test. Reference strains E. coli ATCC 25922, P. aeruginosa ATCC
27853 and K. pneumoniae ATCC 700603 were included for QC on each
day of testing.
Results: The results are summarised in the table. Overall category
agreement was 98.8% for 3444 tests. A variety of ESBL producers,
30 strains in all, were tested. PHX detected all but one, a CTX-M
14 conferring low-level resistance (CTX MIC 2mg/L.) Among the 36
strains of P. aeruginosa, 7 major errors (ME) were seen for FEP, one
ME for IPM and two minor errors (mE) for CIP and MEM. For E. coli,
one ME for AXC and SXT, one mE for each of CTX, TZP, CAZ, GM
and NN, one very major error (VME) for NA.
Conclusion: This ﬁrst evaluation of EUCAST breakpoints in an
automated system for Gram negative bacteria indicates PHX to be a
reliable tool.
Organism group CA ﬁrst test CA ﬁnal test Total tests
n % n % (n)
P. aeruginosa 305 94.1 314 96.9 324
ESBL 443 92.3 463 96.5 480
Esch. coli 937 97.6 952 99.2 960
K. pneumoniae 652 98.8 660 100.0 660
K. oxytoca 176 97.8 180 100.0 180
P. mirabilis 321 97.3 328 99.4 330
M. morganii 176 97.8 179 99.4 180
E. cloacae 172 95.6 177 98.3 180
E. aerogenes 147 98.0 149 99.3 150
Total 3329 96.7 3402 98.8 3444
P807 EUCAST breakpoints in automated susceptibility testing of
Gram-positive bacteria − BD Phoenix validated
R. Smyth °, S. Bengtsson, G. Kahlmeter, G. Babini, E. Montrucchio
(Va¨xjo¨, SE; Buccinasco, IT)
Objectives: To evaluate the performance of BD Phoenix AST System
for susceptibility testing of Gram positive clinical isolates and their SIR-
category interpretation using breakpoints from the European Committee
on Antimicrobial Susceptibility Testing (EUCAST).
Methods: 280 clinical isolates of known identity comprising 114
staphylococci, 25 enterococci and 141 streptococci, both stored strains
and fresh isolates, were tested in parallel using BD Phoenix (PHX) and
the Swedish Reference Group for Antibiotics (SRGA) disc diffusion
method.
The PHX panels, speciﬁcally manufactured for this study were
PMIC/ID-66, containing ampicillin, cefoxitin, ciproﬂoxacin, clin-
damycin, daptomycin, erythromycin, fusidic acid, gentamicin, imipenem,
linezolid, moxiﬂoxacin, nitrofurantoin, oxacillin, penicillin, quinupristin-
dalfopristin, rifampicin, teicoplanin, tetracycline and vancomycin,
each in an appropriate range of doubling dilutions. Category (SIR)
interpretations of MIC results from PHX and inhibition zone results from
disc diffusion were in line with EUCAST breakpoints. Discrepancies
were resolved by retesting and then if necessary by MIC determination
using E-test. Reference strains E. faecalis ATCC 29212, S. pneumoniae
ATCC 49619 and S. aureus ATCC 29213 were included for QC on each
day of testing.
Results: The results are summarised in the table. Overall category
agreement was 99.4% for 2540 tests. Of note, all MRSA and MSSA
strains were correctly identiﬁed as such with both cefoxitin and oxacillin.
Among the enterococci, 12 VRE strains were correctly designated, as
were 11 strains displaying gentamicin HLR. Inducible MLSB resistance
was present in 8 strains of staphylococci, reported clindamycin R by
disc testing and clindamycin S by PHX. However, PHX advises a test
for inducible resistance, in line with EUCAST Expert Rule 11.3.
Conclusion: This is the ﬁrst evaluation of EUCAST breakpoints for
Gram positive organisms in an automated system and the results indicate
PHX to be a reliable tool.
Organism group CA ﬁrst test CA ﬁnal test Total tests
n % n % (n)
MRSA 414 98.6 418 99.5 420
MSSA 888 99.1 893 99.7 896
CoNS 353 98.1 353 98.1 360
S. lugdunensis 108 100.0 108 100.0 108
Str. pneumoniae 256 99.2 258 100.0 258
Str. pyogenes 244 99.6 244 99.6 245
Str. agalactiae 244 99.5 244 99.5 245
E. faecalis 141 100.0 141 100.0 141
E. faecium 109 97.3 109 97.3 112
Total 2513 98.9 2524 99.4 2540
P808 A new European standard method for disc diffusion
antimicrobial susceptibility testing on Mueller–Hinton agar:
a preliminary report
E. Matuschek °, R. Smyth, G. Kahlmeter (Va¨xjo¨, SE)
Objective: There are several methods available for antimicrobial
susceptibility testing in Europe, but no European standard disc diffusion
method. The European Committee on Antimicrobial Susceptibility
Testing (EUCAST) was recently tasked with developing a European disc
diffusion method calibrated against the recently harmonised European
MIC breakpoints. This should preferably be achieved in 2009. This poster
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describes the basic details of the proposed new European method and
presents tables of target zone diameters and ranges for quality control
strains. Where relevant, the EUCAST and Clinical and Laboratory
Standards Institute (CLSI) methods are compared.
Methods: The method is based on two media, Mueller-Hinton agar
(MHA) without supplements (medium A) for non-fastidious organisms
and MHA with 5% horse blood and 20mg b-NAD/L (medium B) for
streptococci, Haemophilus and other fastidious organisms. Medium A
was incubated in air 18±2 h and medium B in 5% CO2 for 18±2 h.
The inoculum suspension was 1 to 2 ×108 CFU/mL, corresponding to
McFarland 0.5 for all organisms except for S. pneumoniae (McF 1.0). For
non-fastidious organisms the EUCAST and CLSI methods are in almost
all respects identical. The EUCAST method does, however, suggest
a common medium for fastidious organisms, while the CLSI method
requires two different media for these organisms. In the present study,
inhibition zone diameters were obtained with the EUCAST disc diffusion
test for a large number of agents, for several quality control strains and
on ﬁve batches of MHA from three producers.
Results: All microorganisms tested showed satisfactory growth after
16−20 hours on the ﬁve tested batches of medium. Disc diffusion testing
for a battery of antimicrobial agents resulted in reproducible inhibition
zone sizes (mean ± <3mm). All inhibition zone diameters were within
the CLSI ranges for organisms where comparison could be made.
Compared to the corresponding CLSI target values for E. coli ATCC
25922, mean values of inhibition zone sizes were  1mm and 2mm
for 21 and 28 of 29 antimicrobials, respectively. For S. aureus ATCC
25923, the corresponding ﬁgures were 27 and 30 of 31, respectively.
Conclusion: A new European standard method for antimicrobial
susceptibility testing is being developed by EUCAST. Preliminary results
show that non-supplemented MHA and MHA with 5% horse blood and
20mg b-NAD/L can be used for non-fastidious and fastidious organisms,
respectively.
P809 Comparison of results from testing sensitivity to amoxicillin/
clavulanate with CLSI versus EUCAST interpretation
M. Hoeck °, B. Wiedemann (Berlin, Schaalby, DE)
Objectives: Methods and interpretation criteria for susceptibility testing
with amoxicillin/clavulanate differ markedly for CLSI and EUCAST
method. By using both methods in parallel we wanted to analyse the
difference in the results.
Methods: In one laboratory of the EPICENTER network both CLSI
and EUCAST combination types of amoxicillin/clavulanate were
used in parallel to determine the MICs for E. coli and Klebsiella
pneumoniae with the BD PHOENIX system. The CLSI combination
of amoxicillin/clavulanate was tested at the concentrations 2/1, 4/2, 8/4,
and 16/8. The concentration of EUCAST combination were 1/2, 2/2, 4/2,
and 8/2. The criteria for interpretation were for CLSI: S 8, R 32, for
EUCAST: S 8, R 16. In addition we used the DIN breakpoints S 2,
R 16, because EUCAST does not recommend a ﬁxed “S” breakpoint
because of the different possibilities for dosing and application.
E. coli Klebsiella pneumoniae
CLSI EUCAST DIN CLSI EUCAST DIN
% Resistant 6.7 39.8 39.8 9.5 20.9 20.9
% Sensitive 77. 2 5.00 85.1 58.4
Results: 16963 E. coli – and 5037 K. pneumoniae – isolates were
tested between 2003 and 2008 and included in the analysis The
MIC distributions with both methods have different shapes. While the
EUCAST method gives a bimodal distribution with the resistant strains
 16mg/L, the CLSI method gives more or less a unimodal distribution
for E. coli and Klebsiella. The relative interpretive results are given in the
table. Most striking is the difference in the number of resistant strains for
E. coli: 6.7 for the CLSI method versus nearly 40% with the EUCAST
method. In addition, for scientiﬁc interest, we interpreted the results of
the CLSI combination with EUCAST criteria and vice versa what is
obsolete in the daily practice but unfortunately in few laboratories is
still common practice. The differences were less evident.
Conclusion: Microbiologists and clinicians should be aware of the
differences in the methods and interpretation of test results the comb
of the combination of amoxicillin with clavulanate. We believe the
EUCAST method to be more on the safe side.
P810 Comparison of the M.I.C.Evaluator™ (Oxoid M.I.C.E)
and ETest® (AB Biodisk − BioMe´rieux) for antimicrobial
susceptibility testing of anaerobic bacterial species
L.A. Turnbull °, C. Brosnikoff, R. Rennie (Edmonton, CA)
Objective: Historically only one gradient end point product has been
available for the routine antimicrobial susceptibility testing of common
aerobic and anaerobic bacteria.
This study was developed to compare a new agar gradient end point
system (M.I.C.ETM-Oxoid; Thermo Fisher Scientiﬁc). For routine
testing, such devices are important for anaerobes that cannot be tested
on automated systems.
Methods: A total of 102 recently isolated strains comprising of
28 species of anaerobes were tested. Four agents were tested;
amoxicillin-clavulanate (AMC), imipenem (IPM), metronidazole (MTZ)
and penicillin (P) (low and high concentration strips). Agar dilution tests
were also performed on brucella agar supplemented with 5% laked sheep
blood, haemin, and vitamin K according to CLSI guidelines. ETest was
also tested. Strips for each agent were added to the plates according to
manufacturers’ instructions and the plates were incubated for 24−72 h
at 350C in an anaerobic atmosphere. Inhibition for each strip was read
at the point where the elliptical zone intersected with the strip. Quality
control strains for these tests were Bacteroides fragilis ATCC®25285TM,
and Bacteroides thetaiotaomicron ATCC®29741TM. Performance was
evaluated using FDA criteria.
Results: All quality control results for all tests were within CLSI
published ranges. For clinical strains, agreement between M.I.C.E and
ETest was excellent. Essential and categorical agreement (EA & CA)
between the two devices was 98% and 100% respectively for P, MTZ and
IPM. For AMC, EA was lower (90%) but CA was 95%. Agar dilution
results for clinical isolates did not correlate well with either M.I.C.E
or ETest. Essential agreements were less than 90% for all four agents.
Using agar dilution as a standard, there were 14% very major errors
for MTZ, and 9% for P. There were less than 1% major or very major
errors for AMC and IPM when M.I.C.E and ETest were compared to
agar dilution.
Conclusions: M.I.C.E and ETest results for 102 clinical strains of
anaerobes were in essential and categorical agreement. Quality control
results with the strip tests and for agar dilution were in range, but there
were differences between clinical isolates when the strips were compared
to agar dilution. The consistency between M.I.C.E and ETest results for
these clinical strains suggests that this methodology provides an easy,
rapid and reproducible means of determining antimicrobial susceptibility
for most anaerobe species.
P811 Comparative evaluation of four commercial methods for
antimicrobial susceptibility testing of a collection of 96
Aeromonas clinical isolates
B. Lamy °, H. Marchandin, I. Verdier, J.W. Decousser, E. Lecaillon,
S. Tigaud, H. De Montclos, A. Kodjo, F. Laurent (Se`te, Montpellier,
Bourg-en-Bresse, Paris, Perpignan, Lyon, Marcy-l’E´toile, FR)
Commercial systems offer the possibility to evaluate susceptibility of
Aeromonas strains, although this has never been extensively evaluated.
Objectives: To evaluate accuracies of 4 commercial methods for
antimicrobial susceptibility testing for 96 clinical Aeromonas strains.
Methods: Antimicrobial susceptibility testing with API ATB G-strips
(A) (API, bioMe´rieux, France), AST NO52 card (B) (VITEK2,
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bioMe´rieux, France), NC47 panel (C) (Walk/Away, Siemens, USA)
and disk diffusion method (D) (Biorad, USA) was carried out
according to the CA-SFM guidelines on 96 Aeromonas clinical strains.
Testing was performed after control of each system. Results were
compared to MIC-based categorisation determined with the agar dilution
method (MIC-agar), used as gold standard. Antimicrobial drugs tested
were: amoxicillin (AMX), co-amoxiclav (AMC), ticarcillin (TIC),
ticarcillin+clavulanic acid (TCC), piperacillin (PIP), cefalothin (CFT),
cefotaxim (CTX), cefepim (FEP), imipenem (IPM), nalidixic acid
(NAL), oﬂoxacin (OFX), ciproﬂoxacin (CIP), cotrimoxazole (SXT),
gentamicin (GEN), tobramicin (TOB), amikacin (AMK). Very major
error (VME) and major error (ME) rates were determined only when
denominators (numbers of true-R and of true-S, respectively) were 
20.
Results: Categorical agreement levels were 82−98%, 78−98%, 82−95%,
79–100% with A, B, C, D, respectively for all antibiotics except
for AMC, TCC and TIC, for which categorical agreement levels
were lower: 42−75%, 6−59%, 20−64%, 4−73% with A, B, C, D,
respectively. Concerning discrepancies, VME rates were acceptable
(1.5%, according to the CLSI guidelines), except for: AMX (C: 3%);
AMC (A: 11%; B: 48%; C: 3%; D: 13%;); TIC (A: 8%; B: 15%; C:
15%); TCC (A: 10%; B: 52%; C: 42%; D: 10%); CFT (A: 1.7%; B:
5%; C: 8%; D: 5%). ME rates were acceptable (3%, CLSI guidelines),
except for: TIC (A: 28%; D: 24%), TCC (A: 33%), PIP (A: 4%), IPM (A:
5%; C: 8%), GEN (C: 3.1%), AMK (A: 3.1%), CIP (C: 3.1%). Essential
agreement for MIC-based methods and scatterplots of MIC-agar versus
zone diameter for the disk diffusion method were also determined.
Conclusion: Antimicrobial susceptibility testing systems were reliable
in predicting Aeromonas susceptibility to AMX, CTX, FEP, GEN, TOB,
AMK, CIP, OFX, NAL, but were unreliable in predicting susceptibility to
AMC, TCC, TIC, CFT, IPM and such results should not be transmitted
to clinician without control. Users should be aware of these limitations
and improvement should be considered.
P812 Appropriate Muller-Hinton agar is crucial for the
performance of metallo-b-lactamase E-test
N. Al Naiemi °, Y.J. Debets-Ossenkopp, P.S. Lee, P. Savelkoul,
C. Vandenbroucke-Grauls (Amsterdam, NL)
Objectives: Metallo-b-lactamases (MBLs)-producing bacteria form a
real challenge to routine microbiology laboratories, as there are no
standardised methods for detection of these multiresistant isolates.
During an MBL prevalence study performed at our hospital, we noticed
that 6 of 9 positive MBL E-test results were false positive. We
investigated whether this high percentage of false positive results was
due to the use of inappropriate Muller-Hinton (MH) agar.
Methods: The presence of carbapenemases was assessed by PCR with
primers for blaIMP, blaVIM, blaGIM, and blaSPM, and by cloning and
sequencing. The performance of MBL E-test was evaluated with different
MH agars (Becton Dickinson, bioMerieux, Difco, Oxoid) with the 9
phenotypic MBL-positive Pseudomonas isolates from the prevalence
study.
Results: Of the 9 phenotypically MBL-positive strains (E-test with Difco
MH agar), three isolates were conﬁrmed MBL-positive by PCR and
sequencing. The three MBL-producing isolates were detected correctly
with E-test performed on all MH agars except on bioMerieux MH agar,
with which two were missed (both VIM-2 producers). While the 6 MBL-
negative isolates were detected correctly with bioMerieux MH agar, the
number of false positive E-tests on other MH agars was the following:
Becton Dickinson MH:1; Oxoid: 2; and Difco:6.
Conclusions: These data showed that appropriate MH agar is crucial
for the performance of MBL E-test and emphasized the necessity for
standard guidelines for detection of these multiresistant bacterial strains.
P813 False susceptibility to amikacin by VITEK 2 in Acinetobacter
baumannii harbouring armA
S.K. Jung °, J.K. Yu, K.G. Park, K. Han, Y.J. Park, S.Y. Kim, Y. Arakawa
(Seoul, KR; Tokyo, JP)
Objectives: Amikacin (AN) is the most active aminoglycoside for
treatment of infections caused by Acinetobacter baumannii. The VITEK
2 (bioMe´rieux Inc., Hazelwood, MO) automated system recommends an
alternative susceptibility testing prior to reporting of AN susceptibility
result for A. baumannii. We accidently found an A. baumannii isolate
which was susceptible to AN by VITEK 2, but showed resistance by
disk diffusion test and agar dilution MIC test.
Methods: On June 2008, we performed a disk diffusion test for an
A. baumannii isolate which was susceptible to AN by VITEK 2. AN
MIC was determined by agar dilution method according to the CLSI
guideline and presence of 16S rRNA methylase genes were investigated
by PCR. Also, we tested the AN susceptibility of Serratia marcescens
isolate harbouring armA and its transconjugant (E. coli J53 harbouring
armA) by VITEK 2, disk diffusion test and agar dilution method. To
check the purity, we picked a single colony from the A. baumannii and
E. coli transconjugant into MH broth, and repeated the disk diffusion
test. In addition, to investigate whether this phenomenon is associated
with induction, we assayed the resistant subpopulations directly for AN
susceptibility.
Results: A. baumannii showed susceptibility to AN by VITEK 2
but revealed resistance (double zone of inhibition) by disk diffusion
test. AN MIC was >512mg/ml and it harboured armA. In cases of
S. marcescens harbouring armA and its transconjugant (E. coli J53
harbouring armA), S. marcescens showed resistantance to AN but its
transconjugant showed susceptibility to AN by VITEK 2. By disk
diffusion test, the S. marcescens and its transconjugant revealed complete
resistance and resistance with double zone of inhibition, respectively.
Both A. baumannii and E. coli showed same phenomenon with a
single colony. However, the AN MICs of the two isolates were both
very high (>512mg/ml). The direct susceptibility testing of resistant
subpopulations after exposure showed identical double zone of inhibition,
suggesting it was not caused by induction.
Conclusions: VITEK 2 automated system can exhibit very major error
for both A. baumannii and E. coli harbouring armA. Considering
widespread dissemination of armA, further study is needed to investigate
the mechanism and frequency of this phenomenon in 16S rRNA
methylase-producing Gram-negative bacteria.
P814 Disc diffusion test results after 6 hours in major pathogens
from blood cultures
M. Sundqvist °, S. Bengtsson, R. Smyth, G. Kahlmeter (Va¨xjo¨, SE)
Objectives: Standard empirical therapy of severe bacterial infections
usually includes a b-lactam antibiotic. The increasing resistance to these
agents has forced many countries to make changes in the empirical
treatment schedules often resulting in less efﬁcient treatment. In an area
with relatively low frequency of septicaemia caused by b-lactam-resistant
bacteria rapid and reliable phenotypic susceptibility testing would be of
great importance to avoid inappropriate and/or less effective treatment
regimens.
Methods: A susceptibility test based on disc diffusion on Mueller-
Hinton agar supplemented with 5% horse blood and 20mg/L of NAD
and incubation at 35º in CO2 was developed and wild-type distributions
for major b-lactam drugs determined. Zone diameters were measured
after 6 h.
Two reference strains (ATCC 25922 and ATCC 29213) and sets of
wildtype S. aureus (n = 33) and E. coli (n = 17) and well characterised
isolates of MRSA (n = 20) and ESBL-producing E. coli (n = 20) were
used to deﬁne wild-type and non-wild type zone diameter distributions
for a limited set of b-lactam drugs. Inocula corresponding to viable
counts of type strains in BacT/Alert (bioMe´rieux) blood culture bottles
following 0−20 h post signal for positivity were investigated.
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Results: Reference strains and all clinical isolates grew sufﬁciently after
6 h. Zone diameters were reproducible (to within ± 2mm for the blood
culture bottle inocula (0.4−0.6 McF)). The method could distinguish
between micro-organisms without and with resistance mechanisms, eg.
methicillin-resistance using cefoxitin (10mg) and ESBL-detection using
both cefotaxime (5mg) and ceftazidime (10mg).
Conclusion: The described phenotypic method for rapid susceptibility
testing can exclude the presence of important b-lactam resistance
mechanisms in S. aureus and E. coli after 6 hours incubation using
direct inoculation from blood culture bottles. This prevents the use of
suboptimal therapy in patients with severe infections and a premature
switch to empirical therapy with “rescue” drugs.
Zone (mm) after 6 h incubation
n ceftazidime cefotaxime cefoxitin
ATCC 25922 9 23−25 23−26 nd
E. coli non-ESBL 17 21−24 21−25 nd
E. coli ESBL 20 6−24 6−19 nd
ATCC 29213 9 nd nd 19−20
MSSA 33 nd nd 17−20
MRSA 20 nd nd 6−17
P815 Evaluation of direct susceptibility proﬁle testing by disk
diffusion on respiratory tract samples
A. Piette °, G. Verschraegen, G. Claeys (Ghent, BE)
Objectives: To compare direct susceptibility proﬁle testing (DSPT),
using a disk diffusion technology, on respiratory tract samples, with
standard susceptibility testing (SST).
Methods: Respiratory tract samples, showing mainly staphylococci or
Gram negative rods (GNR) on Gram stain, were directly swabbed onto
Mueller-Hinton agar and paper disks for antibiotics active either against
staphylococci or against Gram negative rods were applied. Standard
culture was done on the samples and a standard disk diffusion test was
performed on colonies grown overnight. A total of 208 samples, mainly
from intensive care patients were analyzed.
Results: In 34/208 (16%) samples, culture showed no growth or growth
of commensal ﬂora. In 133/208 (64%) samples only one potentially
pathogenic organism was recovered in culture, 5 of them concerned a
pathogen unable to grow on Mueller Hinton agar. Of the remaining
128, 89 yielded GNR and 39 Staphylococcus aureus. DSPT was
not interpretable in 12% of all possible micro-organism antibiotic
combinations. Among the 1184 interpretable micro-organism-antibiotic
combinations, there was a total agreement between DSPT and SST of
98.2%. The percentages of very major, major and minor errors were
respectively 0.00%, 0.11% and 1.71% for GNR and 0.66%, 0.98%
and 0.00% for staphylococci. In 41/208 (20%) samples more than
one potentially pathogenic organism was recovered in culture. The
combination of several GNR in culture occurred in 20 samples, the
combination of one or more GNR and S. aureus in 21 samples. In the
ﬁrst combination 80% of all possible micro-organism combinations were
interpretable; in the second combination only 42% (DSPT was only
used for staphylococci or GNR). Results of DSPT were compared to the
cumulative susceptibility of all pathogens. Among the 354 interpretable
micro-organism-antibiotic combinations, the percentages of major and
minor errors were respectively 1.46% and 4.39% for the combination
of GNR and 2.01% and 2.01% for the combination of GNR and
staphylococci. No very major errors were found. Even with incomplete
or complex proﬁles, results of direct testing were useful in suggesting
adequate antibiotic treatment.
Conclusion: Direct susceptibility proﬁle testing on respiratory tract
samples is potentially very useful in the management of critically ill
patients, as results are obtained 24 hours earlier than conventional testing.
However, additional conventional testing remains necessary.
P816 Determination of provisional British Society for Antimicrobial
Chemotherapy zone breakpoints for 10-mg doripenem discs
R. Hope °, T. Parsons, M. Warner, D. James, D.M. Livermore (London,
UK)
Objectives: Doripenem is a new carbapenem, recently licensed in
the EU. A 10-IFN-ug doripenem disc has been proposed for routine
susceptibility testing. We determined provisional zone breakpoints for
these discs in the BSAC disc method.
Method: Isolates (n 800) were from the BSAC bacteraemia survey
(2005–2006), supplemented with additional isolates with doripenem
MICs outside the wild type distribution from other ARMRL survey
collections and reference submission, care was taken to, whenever pos-
sible, select isolates with MICs straddling breakpoints. Zones and agar
dilution MICs were determined by BSAC methods, and reviewed against
European Committee on Antimicrobial Susceptibility Testing/European
Medicines Agency (EUCAST/EMEA) MIC breakpoints of S 1mg/L
and R> 1mg/L for streptococci, and S 1mg/L and R> 4mg/L
for staphylococci, enterococci, Enterobacteriaceae, Acinetobacter spp.
and Pseudomonas spp. Error minimisation was used to derive the
breakpoints.
Results: Corresponding zone breakpoints for, IFN-a/IFN-b-haemolytic
streptococci, and S. pneumoniae were S 23mm, R 22mm; for
S. aureus and coagulase-negative staphylococci S 32mm, R 27mm,
(though, non-susceptibility to doripenem here is best inferred from
methicillin resistance); for Enterococcus spp., S 22mm, R 18mm;
Enterobacteriaceae, S 24mm, R 18mm; Acinetobacter, S 24mm,
R 17mm and Pseudomonas S 32mm, R 24mm.
Conclusion: The 10-IFN-ug doripenem discs effectively differentiated
between S/I/R for most bacterial groups. For streptococci where there are
currently few or no doripenem non-susceptible isolates reported, MIC
determination (e.g. by Etest) should be performed on isolates producing
zones close to the susceptible breakpoint.
P817 Calculation and validation of a discriminating disc content
for colistin
H.B. Drugeon °, A. Michaud-Nerard (Nantes, Beaucouze, FR)
Objectives: Colistin (a polymyxin E) displays activity mainly against
Gram negatives: Enterobacteriaceae (except for Serratia, Proteus,
Providencia), Pseudomonas and Acinetobacter. This is a voluminous
cyclic polypeptide with a lipidic chain of high molecular weight (1200
Da). This structure involves agar diffusion problems of the molecule
and thus interferes with the diffusion methods. Several disk contents are
recommended: 50mg by the CA-SFM (Antibiogram Committee from
the French Microbiology Society), 25 mg by the BSAC and 10 mg by the
CLSI.
Methods: In this study, by using Vesterdal formula which connects the
Log (MIC) with the square of the inhibition zone radius, a discriminating
charge was calculated then validated by the diffusion method. In
total, 250 strains were used: 130 clinical isolates (19 A. baumannii,
18 C. freundii, 20 E. cloacae, 21 E. coli, 19 K. pneumoniae, 33
P. aeruginosa), 120 mutant strains of reduced susceptibility obtained by
the method of the antibiotic continuous gradient. MICs were determined
by the agar dilution method. The parameter (1/4DT) [D: diffusion
coefﬁcient; T: critical time] was calculated for all the strains by using 7
disc contents (2.5, 5, 10, 20, 30, 40, 50 mg)
Results: Values of 1/4DT ranged from 0.019 to 0.114 with a median
= 0.059, corresponding to a diffusion coefﬁcient 3 times slower than
those of b-lactams and ﬂuoroquinolones. The contents equal or superior
to 5mg were not discriminating.
Conclusion: We recommend 2.5mg content with S (susceptible; MIC 
2mg/l), presence of an inhibition zone and R (resistant; MIC> 2mg/l),
absence of an inhibition zone.
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P818 Impact of different EUCAST and CLSI interpretive
breakpoints on antimicrobial susceptibility of Pseudomonas
aeruginosa − SMART 2007
R. Badal °, S. Bouchillon, S. Hawser, D. Hoban, A. Johnson,
M. Hackel, J. Johnson (Schaumburg, US)
Objectives: CLSI guidelines are used in many countries; however, in
Europe EUCAST breakpoints (BPs) are primarily used. Since EUCAST
BPs often differ from CLSI’s, we evaluated the impact on reported
susceptibility of P. aeruginosa of using EUCAST vs. CLSI BPs for
selected anti-pseudomonal agents.
Methods: Investigators in 93 hospitals in 33 countries in Europe,
North and South America, Asia/Paciﬁc, Middle East, and Africa
collected up to 100 consecutive Gram-negative isolates from intra-
abdominal infections in 2007; 654 of the organisms were P. aeruginosa.
Minimum inhibitory concentrations (MICs) were determined by broth
microdilution following CLSI methods, and results for drugs commonly
used to treat P. aeruginosa were interpreted using both CLSI and
EUCAST BPs.
Results: See the table.
Drug S/I/R* Breakpoint % S/I/R* P (%S)
CLSI EUCAST CLSI EUCAST
Amikacin 16/32/64 8/16/32 87/4/9 74/12/14 0.0001
Cefepime 8/16/32 8/–/16 75/10/15 75/–/25 1
Ceftazidime 8/16/32 8/–/16 74/6/20 74/–/26 1
Ciproﬂoxacin 1/2/4 0.5/1/2 72/4/24 69/3/28 0.2
Imipenem 4/8/16 4/8/16 73/8/19 73/8/19 1
Levoﬂoxacin 2/4/8 1/2/4 72/4/24 65/6/29 0.007
Piperacillin-tazobactam 64/–/128 16/–/32 85/–/15 76/–/24 0.0001
*S = susceptible, I = intermediate, R = resistant.
Conclusions:
• The tendency of EUCAST BPs to be one doubling dilution lower than
CLSI’s caused reductions in %S with 4 drugs (amikacin, ciproﬂoxacin,
levoﬂoxacin, and pip-tazo), the other 3 drugs evaluated (cefepime,
ceftazidime, and imipenem) had equivalent %S since the S BP was
the same in both guidelines.
• The largest decreases in %S were seen with amikacin and piperacillin-
tazobactam: 13 and 9%, respectively.
• Absence of an “I” category in EUCAST for 3 drugs (amikacin,
cefepime, and pip-tazo) would result in reported resistance rates to
be 6−10% higher than in countries using CLSI BPs.
• Using EUCAST guidelines, none of the study drugs achieved %S
higher than 76%; even using CLSI only 2 drugs (amikacin and pip-
tazo) were above 80%. If 90% or even 80% susceptible is considered
to be a minimum indication of a drug’s utility for empiric therapy,
the list of agents remaining active in vitro against P. aeruginosa is
limited.
P819 Computerised antibiotic susceptibility prediction: accounting
for prior knowledge and cross-resistance
S. Andreassen °, A. Zalounina, G. Kariv, L. Leibovici, M. Paul
(Aalborg, DK; Petah Tiqva, IL)
Objectives: To develop an automated method for estimation of a broad
range of antibiotic susceptibilities given a restricted antibiogram.
Methods: Amended susceptibility for a non-tested antibiotic was
determined using the probability of it being sensitive (S) to this antibiotic
a priori; available susceptibility results for all antibiotics in the antibi-
ogram and cross-resistance, expressed as the conditional probability of
resistance for non-tested antibiotics given the tested antibiotics. The
method was derived using a bacteraemia database of 3347 clinically
signiﬁcant isolates (CSI) collected between 2002–2004 and validated on
a bacteraemia database of 4848 CSI between 2006–2008, both at Rabin
Medical Center, Israel. The Brier score (BS) was used to measure the
accuracy of the predicted amended susceptibilities. This score measures
the distance between the predicted susceptibility and the actual outcome
(0% indicates perfect agreement and 100% complete deviation).
Results: The table exempliﬁes how the susceptibility of Acinetobacter
to imipenem is amended. The knowledge that Acinetobacter is sensitive
to amikacin and meropenem increases the odds for imipenem=S by odds
ratios (OR) of 5.8 and 21.5, respectively. Resistance (R) to minocycline
reduces the odds by an OR of 0.47. The remaining antibiotics carry
insigniﬁcant ORs (p0.10). In the proposed method the biggest OR
(21.5) is then multiplied by the smallest OR (0.47) and the a priori
odds for imipenem=S (56/44 = 1.27) is multiplied by that product.
The resulting amended probability for imipenem=S is 93%. Across all
pathogen/antibiotic combinations in the derivation DB, the BS for a priori
susceptibilities was 39%, reduced to 25% for amended susceptibilities.
For the validation DB, the BS for a priori susceptibilities was 41%,
reduced to 29% for amended susceptibilities, indicating that there is a
signiﬁcant advantage to the amendment (p< 10−99).
Conclusion: Amended susceptibilities can be used to guide the
prescription of antibiotics not included in the antibiogram. This
is necessary to allow for a restricted antibiotic panel testing in
the laboratory, to assist clinicians and to improve the management
of polymicrobial infections. The computerised algorithm will be
incorporated into the TREAT computerised decision support system for
antibiotic treatment.
Susceptibility of Acinetobacter spp.
% a priori coverage Susceptibility Odds for S
p 0.10
Odds for R
p 0.10
penbriti 3 R
pipera 11 R
keﬂin 2 R
cefuroxi 4 R
ceftazid 17 R
ceftriax 3 R
genta 25 R
tobra 34 R
amikacin 30 S 5.8
chloram 17
septrin 14 R
oﬂo 15 R
aztreona 3 R
colistin 98 S
tetra 10 R
augmenti 5 R
cipro 15 R
minocycline 52 R 0.47
tazocin 14 R
cefepime 18 R
unasyn 87
ertapenem 14
imipenem 56
meropenem 57 S 21.5
P820 Assessment of Microscan® rapid ID-AST versus conventional
panels for Gram-negative bacteria
M. Zoppelletto °, M. Gaino, A. Gardumi, P. Lanzafame, P. Ober
(Trento, IT)
Objectives: The new rapid MicroScan® Synergies NEG BP Combo
Panel 7 (SI+NBPC7) for Gram-negative bacteria was assessed for the
ability in bacteria identiﬁcation (ID) and antibiotic susceptibility testing
(AST) compared to Microscan® conventional panel. The new system
combines early MIC results with the capability of holding and reading
panels incrementally for up to 18 hours.
Methods: The accuracy of the new system SI+NBPC7 was evaluated
by comparing the performance of the new system to Microscan®
NEG33 and NUC37 panels. A combination of 50 fresh and 29
stock Enterobacteriaceae and Pseudomonas aeruginosa isolates was
tested, comprising ESBLs, b-lactamases AmpC-like and carbapenemasis
producers.
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Results: For the organisms tested, rapid results were available from 4.5
to 18 hours, with 75% of the results ﬁnal at 8 hours and more than 90%
of the ID complete by 2.5 hours. Performance results indicated that the
essential agreement (major and minor errors) between the test system
and the reference method was greater than 95% for all the antibiotics
tested. 18 (1.03%) very major errors were noted in the performance
of these drugs: ampicillin (3/79), trimethoprim/sulfa methoxazole
(3/79), levoﬂoxacin (2/79), ciproﬂoxacin (2/79), gentamicin (1/79),
cefuroxime (2/79), imipenem (1/79), meropenem (1/79), tobramycin
(2/79), amikacin (1/79). 44 (2.53%) minor errors in AST was observed:
piperacillin/tazobactam (4/79), cefepime (4/79), gentamicin (3/79),
tobramycin (7/79), amoxicillin/K clavulanate (4/79), ceftazidime (7/79),
meropenem (2/79), amikacin (1/79), cefotaxime (1/79), imipenem (1/79),
levoﬂoxacin (1/79), cefazolin (6/79), ciproﬂoxacin (1/79), ampicillin
(1/79), nitrofurantoin (1/79). The errors in ID was 10/79 (12.65%).
Conclusions: This study showed that the new MicroScan® rapid
panel SI+NBPC7 for Gram-negative bacteria provides rapid, accurate
results for ID and against all antimicrobial agents when compared to
conventional panels. The new panels are very useful to decrease time of
microbiology tests keeping high quality levels.
P821 Use of a chromogenic media to detect enteric carriage of
multidrug-esistant Acinetobacter baumannii in critically ill
patients
N. Gordon °, D. Wareham (London, UK)
Objectives: Multi-drug resistant A. baumannii (MDRAB) has emerged
as an important nosocomial pathogen in the critically ill. The organism
is difﬁcult to eradicate from the environment and many centres have
experienced ongoing outbreaks despite heightened infection control
procedures. Selective decontamination of the gut (SDD) has been used
to reduce nosocomial infections with some of the Enterobacteriaceae,
as intestinal colonisation is an important process in pathogenesis. In
order to determine whether SDD might be a sensible approach for the
prevention of A. baumannii infection we evaluated a novel chromogenic
medium for the detection of MDRAB in enteric samples from patients
in intensive care (ITU).
Methods: 48 stool samples and 23 perineal swabs obtained from ITU
patients were plated on to Chromagar Acinetobacter (CAAB) and then
inoculated into peptone broths. The agar plates were examined after
24 hrs for the growth of aqua blue colonies indicative of A. baumannii.
The broths were incubated for 24 hrs and then used as a PCR template in
an MDRAB speciﬁc (OXA-51, 23, 24 and 58) PCR. These results were
compared with those obtained using the solid media. The clonal complex
of all strains recovered on CAAB was determined using a multiplex
sequence (csuE, blaoxa-51, ompA) based typing scheme.
Results: 34 samples were culture positive for MRAB compared with
32 positive by PCR. 27 patients were known to be colonised at the
time of sampling but in 7 individuals the organism had not been found
in previous cultures of clinical specimens. There was a signiﬁcant
correlation between colonisation elsewhere and stool carriage (p< 0.05).
All isolates were found to be members of European Clone II.
Conclusion: CAAB appears to be a useful media for screening for the
carriage of MDRAB. It compares favourably with molecular methods
and is able to isolate common epidemic clones. The study also conﬁrms
the human gut as an important reservoir of MDRAB in critically ill
patients and raises the possibility of SDD as an additional measure in
outbreak management.
P822 Evaluation of direct E-test on lower respiratory tract samples
using a chromogenic agar medium: a rapid procedure for
antimicrobial susceptibility testing
E. Cercenado °, M. Marin, R. Insa, P. Martin-Rabadan, M. Rivera,
E. Bouza (Madrid, ES)
Objectives: We have previously demonstrated the accuracy of direct
Etest (DET) on lower respiratory tract (LRT) samples from ICU patients
as a rapid procedure for antimicrobial susceptibility testing (Cercenado et
al., Diagn. Microbiol. Infect. Dis. 2007; 58:211) which may be crucial for
modifying therapeutic regimens. In this study we evaluate a modiﬁcation
of this technique using a chromogenic agar medium in order to generate
rapid susceptibility results and organism identiﬁcation.
Methods: Over a period of 6 months we received 272 LRT samples
from ICU patients. Samples were processed by DET onto chromogenic
Mueller-Hinton agar (IZASA, Spain) as well as by the standard quan-
titative culture followed by identiﬁcation and susceptibility testing by
microbroth dilution method (MBD). Oxacillin, piperacillin/tazobactam,
cefepime, imipenem, ciproﬂoxacin, and amikacin were the antimicrobials
evaluated.
Results: A total of 143 LRT samples (94 monomicrobial and
49 polymicrobial) yielded signiﬁcant counts in the MBD with
microorganisms able to grow on chromogenic agar (Haemophilus spp.,
S. pneumoniae and M. catarrhalis were excluded from the analysis).
Microorganisms isolated (n = 192) were: S. aureus (54), P. aeruginosa
(44), A. baumannii (24), S. maltophilia (15), E. coli (14), Klebsiella spp.
(14), P. mirabilis (11), and other Enterobacteriaceae (16). Overall, 92.7%
of the isolates were recovered by the DET-chromogenic at 18 h, and 100%
at 24 h (12 S. maltophilia isolates). Among the 731 microorganism-
antibiotic combinations evaluated, there was a total agreement with
the MBD in 94.9%. There were 5 very major errors (0.68%) (all
in polymicrobial cultures), 29 major (3.9%) (9 with imipenem and
A. baumannii), and 4 minor (0.5%). Discrepancies corresponded to 20
monomicrobial and 18 polymicrobial cultures, and the majority occurred
with imipenem (14.4%) and cefepime (5.6%). The chromogenic medium
allowed identiﬁcation by colours and facilitated readings especially in
polymicrobial cultures.
Conclusions: DET on respiratory samples is a reliable and clinically
useful technique that provides same day susceptibility results (18−24 h)
comparable to these obtained by MBD. The use of chromogenic agar
medium constitutes an improvement that facilitates readings and allows
concomitant identiﬁcation of the pathogen involved.
P823 Evaluation of VITEK 2 for identiﬁcation of enterococci and
detection of vancomycin resistance
H. Adler °, S. Oezcan, S. Sax, R. Frei (Basel, CH)
Objective: To evaluate the VITEK 2 (bioMerieux, Marcy l’Etoile,
France) for the identiﬁcation of Enterococcus faecalis, E. faecium,
E. gallinarum and E. casseliﬂavus and for the detection of vancomycin
resistance.
Methods: We examined a total of 83 enterococcal isolates. Isolates
comprised 26 E. faecium and 24 E. faecalis, 26 of them with acquired
vancomycin resistance (VanA, VanB). Additionally, 33 isolates with
natural vancomycin resistance (22 E. gallinarum, 11 E. casseliﬂavus)
were tested. Isolates were identiﬁded with the VITEK 2 colorimetric GP
card. For susceptibility testing the antimicrobial susceptibility testing
card P 534 was used. MICs were interpreted using the breakpoints
recommended by the CLSI. Identiﬁcation and vancomycin resistance
were molecularly conﬁrmed with the GenoType Enterococcus test (Hain
Lifescience, Nehren, Germany) as gold standard.
Results: All isolates of E. faecalis and E. faecium were correctly
identiﬁed as were 20 of 22 isolates of E. gallinarum and 7 of 11 isolates
of E. casseliﬂavus. In 6 isolates Vitek 2 could not differentiate between
E. gallinarum and E. casseliﬂavus. Vitek 2 results of susceptibility
testing are presented in table 1. Vancomycin resistance was detected
in all isolates carrying a vanA or vanB gene, thus the test was 100%
sensitive for acquired vancomycin resistance. Teicoplanin resistance was
missed in one isolate of vanA, consequently the isolate resembled a VanB
phenotype. Sensitivity for natural vancomycin resistance (VanC) was
91%. Of the isolates with vanC, 48% had a MIC of 32mg/l (resistant),
thus resembling a VanB phenotype.
Conclusions: VITEK 2 is an excellent tool for the identiﬁcation of
E. faecalis and E. faecium (100% correct identiﬁcations). The system
was less able to differentiate between E. gallinarum and E. casseliﬂavus
(82% correct identiﬁcation, 18% low discrimination). However, since
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both species have natural resistance to vancomycin, the clinical
signiﬁcance of separating them is minimal. VITEK 2 is a useful means
for the detection of vancomycin resistance in enterococci. However, both
identiﬁcation and susceptibility testing should be performed in order
not to miss natural vancomycin resistance and to discriminate between
natural and acquired vancomycin resistance.
Table 1.
Organism (no.) Susceptibilities as determined by Vitek 2
Vancomycin Teicoplanin
S I R S I R
vanA VRE (12) 0 2 10 1 0 11
vanB VRE (13) 0 1 12 13 0 0
vanA+vanB VRE (1) 0 0 1 1 0 0
vanC1 VRE (22) 0 7 15 0 0 0
vanC2 VRE (11) 3 7 1 0 0 0
VSE (24) 24 0 0 24 0 0
S sensitive, I intermediate, R resistant.
VRE vancomycin resistant Enterocccus, VSE vancomycin susceptible
Enterococcus.
P824 Comparison of the impact of direct plating versus a short or
overnight pre-enrichment on detection of methicillin-resistant
Staphylococcus aureus from clinical specimens
L. Van Heirstraeten °, J. Cortin˜as Abrahantes, C. Lammens,
A. Lee, S. Harbarth, G. Molenberghs, M. Aerts, H. Goossens,
S. Malhotra-Kumar on behalf of the MOSAR WP2 Study Group
Objectives: Rapid detection of methicillin-resistant Staphylococcus
aureus (MRSA) from screening cultures is crucial for effective infection
control. While an overnight pre-enrichment (On-En) can increase
chances of MRSA detection, time to result is 48 hrs. A short, 4-hour
pre-enrichment (Short-En) would enable next day results, however its
advantage over direct plating (DP) is not known. We compared the
impact of DP to plating after Short-En or ON-En on MRSA detection
from screening samples.
Methods: Fifty two nasal and groin swabs from 25 patients previously
identiﬁed as MRSA carriers were collected in BHI + glycerol.
10ml sample was spiral plated directly on a chromogenic medium,
CHROMagar MRSA (BD, Belgium) or on mannitol-salt agar with
4mg/ml cefoxitin (MSAC), or added to enrichment broth (Tryptone soya
broth with 2.5% salt, 20mg/ml aztreonam, and 3.5mg/ml cefoxitin). 10ml
of enrichment broth was spiral plated on CHROMagar and on MSAC
after a Short-En and ON-En. Colony counts were done for agar cultures
after overnight incubation, and putative MRSA colonies conﬁrmed by
standard tests. Non-parametric comparisons were made using Friedman’s
test. Differences in readings (MRSA positive/negative) at the three time-
points were modelled using a logistic approach. Generalised estimating
equation was used to account for repeated measures over time and the
Score test to assess differences between the three time-points.
Results: Of the 52 samples, 9 were negative for MRSA at all three time-
points. Plate readings for MRSA positivity after DP or Short-En did not
differ signiﬁcantly (P = 0.317), and showed clear differences after ON-
En in comparison to DP or Short-En (P = 0.002 and 0.004, respectively).
Two MRSA negative samples gave positive results after ON-En (4%
misclassiﬁcation error). Colony counts differed signiﬁcantly between
DP (mean CFUs/ml: 3.91×104, 95%CI: ±9.66×102), Short-En (mean
CFUs/ml: 6.79×104, 95%CI: ±1.22×103), and ON-En (mean CFUs/ml:
2.31×105, 95%CI: ±1.16×103) (Friedman’s chi-square = 53.91, degrees
of freedom = 2, P = 1.964e-12) (Figure). Of the 52 samples, 60% (n = 30)
showed similar colony counts after DP and Short-En, 23% after DP and
ON-En, and 31% after Short-En and ON-En.
Conclusions: A Short-En does not offer a signiﬁcant increase in
MRSA detection in comparison to DP and cannot replace an overnight
enrichment at least when culture-based methods are used for downstream
processing.
Figure: Colony count proﬁles and trend after DP, Short-En, and ON-En.
P825 Performance of Oxoid Brilliance MRSA, a new chromogenic
medium
E.J.M. Verkade °, S. Elberts, C.J.M.M. Verhulst, J.A.J.W. Kluytmans
(Breda, NL)
Objectives: To assess the in vitro sensitivity and speciﬁcity of Oxoid
Brilliance MRSA for the detection of MRSA.
Methods: A collection consisting of 235 methicillin-resistant Staphylo-
coccus aureus (MRSA) strains, 284 methicillin-susceptible Staphylococ-
cus aureus (MSSA) strains, and 265 coagulase-negative staphylococci
(CNS) was used. Identiﬁcation of strains as S. aureus and as being
methicillin resistant had been performed by duplex PCR for the mecA
gene and the coagulase gene. Strains were selected on the basis of their
different phage types. The isolates were inoculated onto agar plates to
obtain fresh growth. From the resulting cultures, a suspension with a
0.5 McFarland standard was made, and subsequently, 10 microliter was
streaked onto an Oxoid Brilliance MRSA plate. The plates were read
after 20 hours of incubation at 35ºC. Growth of colonies showing blue
coloration was considered to be positive (indicating MRSA). No growth
or colonies with colours other than blue were considered negative. The
procedure was performed as recommended by the manufacturer.
Results: Twenty-nine MRSA strains gave discordant results, and a PCR
for the mecA gene was performed on these isolates. A total of 28 (97%)
of the MRSA strains had a negative result with the mecA PCR. These
strains were removed from the analysis, according to the protocol of the
study. The results obtained with Oxoid Brilliance MRSA are shown in
Table 1. The sensitivity was 99.6% and the speciﬁcity was 97.4%.
Conclusion: Oxoid Brilliance MRSA can detect a large number
of different MRSA strains and is a sensitive and speciﬁc tool for
differentiation between CNS/MSSA and MRSA in vitro.
Table 1. Results for Oxoid Brilliance MRSA medium after 20 hours of
incubation
Isolate No. of strains with a positive
test result/total no. of strains (%)
MSSA 5/284 (1.8)
CoNS 9/265 (3.4)
Total (CoNS + MSSA) 14/549 (2.6)
MRSA 234/235 (99.6)
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P826 Performance of three methods for determining the
susceptibility to daptomycin and three other antimicrobials
of Enterococcus spp.
F. Lo´pez-Fabal °, A. Burillo, Y. Gil, J.L. Go´mez-Garce´s (Madrid, ES)
Objectives: To compare the E-test, an automated test (Wider) and broth
microdilution (as the reference test) used to determine the susceptibility
of clinical isolates of Enterococcus spp. to vancomycin, teicoplanin,
linezolid and daptomycin.
Methods: Microorganisms were isolated from clinical specimens
obtained from patients in three hospitals in south Madrid. 100 strains
identiﬁed in 2007 using standard procedures were included. For quality
control, we used Enterococcus faecalis ATCC 29212. The broth
microdilution method conducted according to CLSI guidelines was used
as the reference method. For daptomycin, the medium was enriched with
calcium cations to achieve a ﬁnal concentration of 50mg/L.
Results: All isolates were tested using the three methods and results
compared to those obtained using the broth microdilution method as
reference. The MICs of the control strains were within their known
ranges. The table shows the results obtained using the two methods
compared to the reference method.
Conclusions: Our ﬁndings indicate that both the E-test and Wider tests
are reliable methods for routine microbiology laboratory practice to de-
termine the antimicrobial susceptibility of enterococci isolated from clin-
ical samples. These two techniques, however, often provide discrepant
results when determining the MICs of daptomycin and vancomycin for
Enterococcus spp. Nevertheless, this high rate of disagreement in no case
translated to any type of interpretative error in the categorical comparison
of test results with the reference results. The most likely explanation for
this is the need to adjust the calcium cation concentration of the medium
used when testing daptomycin, the impaired diffusion in agar media of
both agents or use of an insufﬁcient inoculum size. Thus, when faced
with a serious enterococcal infection, a second MIC determination for
daptomycin and vancomycin should be undertaken using a reference
method such as the broth microdilution technique.
Percentage strains with a MIC
−2 dilutions −1 dilutions 0 +1 dilutions  2 dilutions
E-test Wider E-test Wider E-test Wider E-test Wider E-test Wider
VAN 0 2 3.1 1 60.2 64.3 20.4 14.3 15.3 17.4
TEC 3.1 1 2 3.1 40.8 91.8 47.9 1 5.1 2
LZD 0 0 9.2 18.4 77.6 68.4 11.2 11.2 2 1
DAP 2 0 14.3 13.3 39.8 32.7 29.6 33.7 13.2 19.4
P827 Performance of three methods for determining the
susceptibility to daptomycin and three other antimicrobials
of methicillin-resistant Staphylococcus aureus and
methicillin-resistant coagulase negative Staphylococcus spp.
F. Lo´pez-Fabal, A. Burillo, Y. Gil, J.L. Go´mez-Garce´s ° (Madrid, ES)
Objectives: To compare the E-test, an automated test (Wider) and broth
microdilution (as the reference test), to determine the susceptibility to
vancomycin, teicoplanin, linezolid and daptomycin of clinical isolates
of methicillin resistant Staphylococcus aureus (MRSA) and methicillin
resistant coagulase negative Staphylococcus spp. (MRCNS)
Methods: The microorganisms included were isolated from clinical
specimens from patients of three hospitals in south Madrid. Selection was
based on their resistance to methicillin. 60 MRSA and 60 MRCNS strains
identiﬁed in 2007 using standard procedures were included. As a quality
control we used S. aureus ATCC 29213. As the reference method we
conducted the broth microdilution method according to CLSI guidelines.
For daptomycin the culture medium was enriched with calcium cations
to achieve a ﬁnal concentration of 50mg/L. Isolates were classiﬁed as
susceptible, intermediate or resistant according to CLSI criteria for each
antimicrobial and microorganism.
Results: All isolates were tested using the methods described above and
the results compared to those obtained using the broth microdilution
method as the reference. The MICs of the control strain were within
their known ranges. All the Staphylococcus spp. scored as susceptible to
the four antibiotics. The table shows the results obtained using the other
two methods compared to the reference method.
Conclusions: Our ﬁndings indicate that both the E-test and Wider tests
are reliable methods for routine microbiology laboratory use to determine
the antimicrobial susceptibility of staphylococci isolated from clinical
samples.
Percentage strains with a MIC
−2 dilutions −1 dilutions 0 +1 dilutions  2 dilutions
MRSA MRCNS MRSA MRCNS MRSA MRCNS MRSA MRCNS MRSA MRCNS
E-test
VAN 0 0 0 10.2 40 71.2 53.3 18.6 6.7 0
TEC 0 1.7 3.3 22 20 40.7 70 30.5 6.7 5.1
LZD 8.4 15.3 31.7 32.2 53.3 50.8 5 0 1.7 1.7
DAP 0 3.4 28.3 16.9 46.7 54.2 23.3 23.7 1.7 1.7
Wider
VAN 0 1.7 20 18.6 58.3 69.5 20 10.2 1.7 0
TEC 0 10.2 0 28.8 100 54.2 0 6.8 0 0
LZD 0 0 13.3 22 75 61 8.3 15.3 3.4 0
DAP 0 0 10 3.4 76.7 96.6 13.3 0 0 0
P828 An update to a comparison of E-test and agar dilution MICs
for European anaerobes − a multi-year analysis
M. Hackel, S. Bouchillon, B. Johnson, D. Hoban, M. Renteria, J. Johnson,
R. Badal °, S. Hawser, M. Dowzicky (Schaumburg, Collegeville, US)
Background: The Tigecycline Evaluation and Surveillance Trial (TEST)
program is a global surveillance study designed to monitor activity of
tigecycline (TIG) and comparators [clindamycin, penicillin (P), cefoxitin
(CFX), metronidazole, pip/tazo (PT), meropenem (MER)]. This report
compares Etest results from each site to agar dilution at a central lab.
Methods: 17 labs in Europe collected 2,040 anaerobic isolates between
2007–2008. MICs were determined locally by Etest, and at a central lab
by agar dilution. %S by each method was compared using EUCAST
breakpoints.
Results: The table lists the 3 drug/organism combinations tested that had
>10% difference in % Susceptible (S) between agar dilution and Etest.
All drugs not listed had %S by Etest and agar dilution within 10% of each
other. Among individual species with n10, however, there were 24/119
drug/organism combinations where %S by Etest differed by 10% from
the agar dilution result. In 21 of those cases Etest %S was lower than
agar dilution.
Conclusions: Despite inherent difﬁculties often experienced with
performing anaerobe susceptibility tests, in this study Etest results from
17 diverse labs across Europe yielded %S values broadly comparable to
those obtained by a single reference lab using agar dilution. However, use
of Etest in some speciﬁc drug/bug combinations such as Bacteroides spp.
vs. CFX and PT, and Clostridium spp. vs. meropenem, may under-report
susceptibility. Tigecycline Etest and agar dilution % S were comparable
for all organisms tested.
Organism group N Drug Agar Dil. %S Etest %S
Anaerococcus spp. 45 P 68.2 90.2
Bacteroides spp. 430 CFX 85.5 57.8
Clostridium spp. 239 MER 100 89.5
P829 Are erythromycin and ciproﬂoxacin broth microdilution
breakpoints for Campylobacter sp. suitable to categorise
minimum inhibitory concentrations obtained by Epsilon test?
T. Pe´rez Pomata °, O. Stelmakh, F. Lo´pez Fabal, J.L. Go´mez Garce´s
(Mo´stoles, ES)
Objectives: The Epsilon test (Etest) is a simple method to determine
minimum inhibitory concentrations (MICs). The aim of the present
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work was to assess the suitability of Clinical Laboratory Standards
Institute (CLSI) broth microdilution (BMD) breakpoints to categorise
MICs obtained by Etest.
Method: The strains were ATCC 33560 and 59 Campylobacter sp
clinical isolates selected among the 331 obtained from stools of patients
with diarrhoea between february 2007 and september 2008.
Categorisation of clinical isolates was accomplished through disk
diffusion; CLSI (M-45, 2006) guidelines were followed; plates were
incubated 24 hours at 42ºC. Etest was performed according to
manufacturer instructions; clinical isolates were incubated 24 hours at
42ºC; all were tested twice. Every reading was performed by the same
observer.
ATCC 33560 was evaluated 25 times; two plates were prepared daily,
one of them was incubated 48 hours at 37ºC and the other 24 hours at
42ºC.
Results: According to disk diffusion categorisation 55 clinical isolates
were susceptible to erythromycin and 24 to ciproﬂoxacin. Strains with
erythromycin inhibition diameters below 6mm had MICs >256mg/l
while those with zones broader than 6mm had MICs  4mg/l; there
were not strains with MICs between 8 and 256mg/l. Ciproﬂoxacin
resistant isolates according to CLSI disk diffusion criteria had MICs
>32mg/l, and MICs of susceptible ones were  0.5mg/l; we did not
ﬁnd strains with MICs between 1 and 32mg/l. Ten ciproﬂoxacin and
22 erythromycin MICs interseries discrepancies were found; none of
them entailed category changes according to CLSI BMD susceptibility
criteria. When CLSI BMD breakpoints were employed to categorise
MICs obtained by Etest, agreement with disk diffusion was complete.
Etest incubated at 37ºC yielded two ATCC erythromycin MIC values
one dilution over the upper limit established by CLSI for BMD and this
was the case with nine ciproﬂoxacin and three erythromycin MICs when
plates were incubated at 42ºC.
Conclusion: Our data indicate that CLSI interpretive criteria for BMD
could be tentatively applicable to MICs obtained by Etest. Incubation at
37ºC for 48 hours seems to provide more accurate results. Correlation
between Etest and CLSI BMD standard method must be established to
conﬁrm our results; studies including a greater number of erythromycin
resistant strains would be of special interest.
P830 Molecular genetic analysis of 23S RNA mutations associated
with clarythromycin resistance in Helicobacter pylori strains
isolated in St. Petersburg, Russia
E.A. Tarasova °, M.A. Suvorova, A.V. Svarval, R.S. Ferman,
A.B. Zhebrun, A.N. Suvorov (St. Petersburg, RU)
Objectives: Resistance to antibiotics quite often interferes with effective
eradication of Helicobacter pylori. It is known that resistance to
clarythromicin which interferes with ribosomal synthesis can be achieved
by point mutations in 23S ribosomal RNA. Most of the claR mutations
described in the scientiﬁc literature are the transitions of adenine to
guanine in the positions A2142G or A2143G. Recently other mutations
of such kind have been described (Garrido L, 2007; Toracchio S, 2004;
Umegaki N, 2000). After the analysis of H. pylori clinical strains
collection isolated in St. Petersburg we have determined that most
common claR mutations were A2142G, A2143G and T2717C. All these
mutations are possible to determine by PCR with the following restriction
analysis. However, in some cases of claR strains those mutations were
not found.
The aim of present work was to analyze the structure of mutations in
23S RNA in H. pylori strains isolated in St. Petersburg, Russia.
Materials and Methods: 20 patients with chronic gastritis associated
with H. pylori infection were selected. Clarythromicin resistance of the
strains was tested by the disk diffusion method. Region corresponding
to 23S RNA was ampliﬁed by PCR, digested with MboII, BsaI and HhaI
and subjected to DNA sequencing.
Results: The presence of H. pylori among the group of patients under
study was determined by urease test and by PCR employing the primers
corresponding to several H. pylori genes (UreC, UreI, CagA). 7 strains
under study were found to be resistant to clarythromicin and 4 out of 7
were resistant to digestion with MboII, BsaI and HhaI, which suggested
the absence of mutations A2142G, A2143G and T2717C. After DNA
sequencing it was determined that the rest of the strains carried different
claR mutations: T2182C, C2195T or C2288T. Mutation T2182C have
been described previously (Khan R, 2004; Kim, 2002; Posteraro R, 2006;
Chihu L, 2005) but mutations C2195T and C2288T were found only
together with A2142G or A2143G (Posteraro P, 2006; Pimbara E, 2007).
Conclusions:Molecular study of the structure of clarythromicin resistant
23S RNA mutations in St. Petersburg Russia allowed determining the
broad spectrum of mutations some of which were determined for the
ﬁrst time. This fact leads to conclusion that commonly used for such
diagnostics PCR with the following restriction analysis might be not
appropriate for determining clarythromicin resistant H. pylori strains in
Russia.
P831 Use of peptide nucleic acid probes as a new method for the
detection of clarithromycin resistance in Helicobacter pylori
strains
L. Cerqueira °, N.F. Azevedo, N. Guimara˜es, C. Figueiredo, C.W. Keevil,
M.J. Vieira (Braga, Porto, PT; Southampton, UK)
Objectives: The treatment of patients infected with H. pylori is being
seriously compromised due to increased antibiotic resistance patterns
(e.g. amoxicillin, clarithromycin and metrodinazole). For that reason, the
purpose of this study was to develop a fast and more efﬁcient method
to test clarithromycin resistance in clinical samples using ﬂuorescence
in situ hybridisation (FISH).
Methods: There are several phenotypic, cultivation-dependent methods
able to identify the clarithromycin resistance in H. pylori strains, but
they are all fastidious and growth is time-consuming. Three mutations
in the 23S rRNA of H. pylori are strongly associated with clarithromycin
resistance. In these mutations, an adenine is replaced by a guanine
at positions 2142 and 2143, or by a cytosine at position 2142.
Hence, we developed a set of peptide nucleic acid (PNA) probes for
the identiﬁcation of target sequences for the different clarithromycin
resistance polymorphisms. PNA molecules are DNA synthetic mimics
with a non-charged backbone, due to their chemical conﬁguration. As
such, they present a lack of electrostatic repulsion, resulting in improved
thermal stability compared with DNA/DNA duplexes.
Results: After probe design, an optimisation of the hybridisation
conditions, like temperature, pH, ionic strength and formamide
concentrations, was performed. To ensure speciﬁcity and sensitivity,
probes have been tested against resistant and susceptible strains of
H. pylori.
Conclusions: This novel PNA FISH method will facilitate a more prompt
(<3 h) diagnosis of H. pylori clarithromycin resistance in clinical samples
such as gastric biopsies, thus allowing a more rational patient treatment.
P832 Evaluation of the Vitek 2 YST and AST-YS01 card for
the identiﬁcation and antifungal susceptibility testing of
Candida spp.
S. Nys °, S. Vijgen, K. Magerman, A. Boel, R. Cartuyvels (Hasselt,
Aalst, BE)
Objectives: The YST and AST-YS01 cards for Vitek 2 were evaluated
for their accuracy and rapidity to identify yeasts and to perform
susceptibility testing for ﬂuconazole (FLU), voriconazole (VO) and
amphotericin B (AMB) respectively.
Methods: A total of 69 yeast strains were tested (Candida glabrata
n = 29, Candida albicans n = 22, other Candida species n = 18). All
strains were clinical isolates from unrelated patients.
Each yeast strain was tested with Vitek 2 (bioMe´rieux), using the YST
and AST-YS01 cards, according to the manufacturer’s instruction.
Results of identiﬁcation and susceptibility testing with Vitek 2 YST
and AST-YS01 cards were compared to results of previous biochemical
identiﬁcation, conﬁrmed by ITS2 fragment length determination on
CEQ8000 (Beckman Coulter), and susceptibility testing results with
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micro-broth dilution according to CLSI guidelines. MIC results were
categorised according to CLSI breakpoints (document M27-A3/S3).
All strains were also sent to the Belgium Reference Laboratory for
conﬁrmation of identiﬁcation and susceptibility testing.
Results: Three strains (4%) were falsly identiﬁed with Vitek 2 YST: 1
C. albicans was misidentiﬁed as C. glabrata and 2 C. glabrata strains
were misidentiﬁed as C. albicans and Rhodotorula glutinis respectively.
Vitek 2 did not determine any MIC values for 2 C. glabrata strains
(3%) due to an insufﬁcient growth in the control well. For Rhodotorula
glutinis the Vitek 2 expert system has no interpretation criteria. These 3
strains were excluded from further analysis.
MIC values for AMB and VO of all C. albicans isolates were comparable
to the reference method. The MIC value of FLU obtained with the Vitek
2 was different for 2 strains (9%), leading to a minor error for 1 strain
(4.5%).
For C. glabrata, there was an essential agreement of 56%, 78% and 89%
for FLU, VO and AMB respectively, leading to 8 (30%) minor errors for
FLU, 1 (4%) minor and 1 (4%) major error for VO. For other Candida
species an essential agreement of 94% and 88% was found for VO and
AMB respectively without any errors. For FLU this was 82%, with one
(6%) very major error.
Conclusions: The Vitek 2 YST card is a simple and fast method for
a reliable identiﬁcation of Candida species. Performance of the new
Vitek 2 AST-YS01 card for susceptibility testing seems to be species
dependent. For C. glabrata, the AST-YS01 is rather unreliable, especially
for ﬂuconazole. For other Candida species this method is fairly consistent
for VO and AMB.
P833 Evaluation of the VITEK® 2 system for the susceptibility
testing of Candida species and Stephanoascus ciferii with
caspofungin, micafungin and posaconazole
J. Slaughter °, K. Engelhard, M. Dante, A. Fothergill, D. McCarthy
(Hazelwood, San Antonio, US)
Objective: The VITEK 2 System provides rapid, automated identiﬁ-
cation and susceptibility testing of yeast isolates. With the increasing
prevalence of antifungal resistance, the ability to quickly and easily
perform susceptibility testing with available antifungals is becoming
more important. The purpose of this study was to determine whether
caspofungin (CAS), micafungin (MCF) and posaconazole (POS) could
be incorporated into the current VITEK 2 system menu for automated
susceptibility testing of yeast.
Methods: Over 450 isolates were tested in VITEK 2 IUO cards
containing varying concentrations of CAS, MCF and POS. All of
these strains were either Candida species or Stephanoascus ciferii. All
strains were tested with all three antifungals using both IUO cards
and a reference method. The reference method for all three was broth
microdilution, which was performed according to Clinical Laboratory
Standards Institute (CLSI) standards. Growth data were collected from
the VITEK 2 cards and compared to the reference results. Analyses were
then developed using these data.
Development results: Overall category agreement (CA) for CAS
was 98.9%(449/454). Overall essential agreement (EA) was 99.6%
(452/454). Overall category agreement (CA) for MCF was 99.6%
(452/454). Overall essential agreement (EA) was 98.7% (448/454).
Overall category agreement (CA) for POS was 95.4% (433/454). Overall
essential agreement (EA) was 94.9% (431/454).
Conclusion: These development data indicate that the VITEK 2 can
accurately detect resistance to CAS, MCF and POS in Candida species
and in Stephanoascus ciferii.
P834 Resistance to trimethoprim-sulfamethoxazole and
Tropheryma whipplei
F. Fenollar °, J.M. Rolain, L. Alric, T. Papo, M.P. Chauveheid, D. Van
de Beek, D. Raoult (Marseille, Toulouse, Paris, FR; Amsterdam, NL)
Objectives: Whipple’s disease (WD) is a chronic infection caused by
Tropheryma whipplei and was fatal before the advent of antibiotics. A
one-year treatment of oral trimethoprim-sulfamethoxazole is commonly
used. The recent advances in culture of T. whipplei has allowed for
full genome sequencing and antibiotic susceptibility testing, which
has demonstrated resistance of T. whipplei to trimethoprim. Several
mutations in the folpP gene that encodes dihydropteroate synthase, the
target of sulfonamides, has been reported by our team for one patient
with clinically acquired resistance to trimethoprim-sulfamethoxazole,
whereas no mutations were observed in 19 strains from patients
without any evidence of clinical failure or relapse. Herein, we conﬁrm,
complete these data and propose a strategy in order to improve the
management of WD.
Methods: Three new patients who experienced clinically acquired
resistance to trimethoprim-sulfamethoxazole during treatment were
reported as well as one patient with biological failure. Sixty-two folP
sequences from DNA samples of 59 WD patients were also obtained.
Primers were designed according to the two available complete genomes
of T. whipplei to frame the 801-bp folP. The nucleotide and amino acid
sequences obtained were compared using the CLUSTALW program.
Results: The three new patients who experienced clinically acquired
resistance to trimethoprim-sulfamethoxazole during treatment, were all
veriﬁed by positive PCR analysis. The patient with biological failure
only showed positive PCR. From the sixty-two sequences, eight different
amino acid sequence types were found. Among the detected amino
acid changes, two positions (N4S and S232F) signiﬁcantly predicted
secondary failure (in four out of ﬁve cases). The sensitivity of the N4S
substitution to predict resistance before treatment was 50%, with 98%
speciﬁcity, a positive predictive value (PPV) of 75%, and a negative
predictive value (NPV) of 94.4%. The sensitivity of the S234F change to
predict failure before treatment was 66.7%, with a speciﬁcity of 96.4%,
PPV of 50%, and a NPV of 98.2%. Besides, new mutations appeared
in two out of three amino acid sequences with previous N4S or S234F
changes.
Conclusion: We suggest that these mutations (N4S and S232F) should
be detected at the time of the WD diagnosis by sequencing folP in order
to avoid sulfamethoxazole monotherapy.
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P835 Plasmid analysis of ampicillin-resistant and ampicillin-
susceptible Enterococcus faecium causing bacteraemia in a
Spanish university hospital (1995–2008)
A. Tedim Pedrosa °, A.R. Freitas, P. Ruiz-Garbajosa, F. Baquero,
T.M. Coque (Madrid, ES; Porto, PT)
Objectives: Ampicillin-resistant Enterococcus faecium (AREfm), which
are mainly associated with CC17, has increasingly been reported in
European hospitals in the last decade. They have been suggested as
the substrate for vancomycin resistance in this species although little is
known about their content on mobile genetic elements. We analyzed the
plasmid diversity of AREfm and ampicillin-susceptible (ASEfm) isolates
in an area with a high rate of AREfm but low rate of vancomycin-
resistant (VR) Efm.
Methods: We studied 72 Efm (52 AREfm and 20 ASEfm) causing
bacteraemia (1995–2008). Antibiotic susceptibility was determined by
CLSI microdilution. Clonality was established by PFGE-SmaI and
MLST. PPlasmid characterisation included determination of size and
content (S1-PFGE), and identiﬁcation of 27 relaxases (rel), 13 rep
initiation proteins (rep) and 5 toxin-antitoxin systems (TA) by PCR and
sequencing.
Results: AREfm isolates were classiﬁed in 30 PFGE-types and 10
STs belonging to CC17 (ST18 was predominant; 64%) and CC9 (2%).
ASEfm isolates were clonally heterogeneous, being identiﬁed as 11
STs clustering into CC1, CC9, CC17, CC22 and CC94. A great
diversity of plasmid size (25–440 kb) and content (1−4/cell) being
megaplasmids higher than 200 kb predominant. AREfm/ASEfm isolates
harboured plasmids containing relaxases from pEF1 (87%/65%), pCIZ2
(83%/20%), pAD1 (25%/20%) or pRUM (14%/0%); rep proteins from
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pRUM (69%/5%), pCIZ2 (40%/20%) or pRE25 (21%/10%); and Axe-
Txe (73%/5%). Relaxases from plasmids pHTb and pRE25, as well as
rep proteins from Inc18, pHTB and pAD1 plasmids were rare (all <5%).
Conclusions: AREfm were enriched in sequences associated with
antibiotic resistances. Some sequences commonly present among VREfm
CC17 were also found among most AREfm (from pRUM, pEF1
and pCIZ2 plasmids) while others (from Inc18 and pHTB plasmids)
were scarcely observed in VSEfm. Endemic AREfm clones carrying
a diversity of plasmids may supply a substrate for the acquisition of
vancomycin resistance in our area.
P836 Dominance of ampicillin-resistant vancomicin-susceptible
Enterococcus faecium-CC17 causing bacteraemia over a
14-year period in a university hospital, Spain
P. Ruiz-Garbajosa °, L. Derdoy, E. Loza, F. Baquero, R. Canto´n,
T.M. Coque (Madrid, ES; Buenos Aires, AR)
Background: Bacteraemia caused by ampicillin-resistant E. faecium
(AREfm) has been increasingly reported in European hospitals due
to the expansion of Clonal Complex-CC17. This was ﬁrstly observed
in USA, preceding the emergence of vancomycin-resistant E. faecium
(VREfm). CC17 is associated with ampicillin resistance and the presence
of virulence/epidemicity markers esp and hyl and is enrichment in IS
elements, specially IS16. The aim of this study was to analyze the
population structure of Efm causing bacteraemia in an area with a high
rate of AREfm but low rate of VREfm during 14 years (1995–2008)
and to investigate the presence of genetic determinants associated with
CC17 epidemicity.
Methods: 167 Efm isolates (124 AREfm and 43 ASEfm) (167
patients) recovered from blood cultures (1995–2008) were studied.
Susceptibility was determined by CLSI microdilution. Clonal relatedness
was established by PFGE-SmaI and one representative isolate from each
PFGE type was analyzed by MLST. esp and hyl genes, IS16, were
detected by PCR.
Results: Ampicillin resistance among E. faecium isolates increased from
42% in 1995 to 100% in 2008. A low rate of VREfm (3.6%; 6/167)
among bacteraemic isolates was observed during all the studied period,
with no trend to increase. By PFGE, 64 (21 AREfm, 43 ASEFm)
types were identiﬁed. By MLST AREfm and ASEfm isolates were
grouped into 11 STs and 40 STs respectively. Among AREfm, ST18
(62/124; 50%), ST17 (17/124; 14%) and ST16 (17/124; 14%) appeared
as endemic and persistent STs during 14 years, whereas ST203 emerged
more recently (2006) compromising 40% (16/41) of AREfm isolates
recovering between 2006–2008. esp and hyl determinants were detected
in 56% (69/124) and 45% (56/124) of AREfm isolates respectively.
Within speciﬁc STs, ST16 showed the highest rate of isolates harbouring
esp (94%) and hyl (82%) genes. None of the ASEfm isolates ampliﬁed
esp and hyl genes. Presence of IS16 was investigated in a subset of
isolates (AREfm, n = 92 and ASEfm, n = 20). IS16 was detected in 91%
of AREfm population whereas was absent among ASEfm isolates.
Conclusions: An increased prevalence of AREfm isolates causing
bacteraemia along 14 years associated with a dominance and persistence
of related CC17 STs. These STs, enriched in IS16 element and esp
and hyl virulence/epidemicity markers that might contribute to hospital
adaptation when compared with non-CC17 STs, might supply a substrate
for the emergence of vancomycin resistance in our country.
P837 High-density faecal colonisation by Enterococcus faecium in
patients harbouring CC17
P. Ruiz-Garbajosa °, M. de Regt, M. Bonten, T. Coque, R. del Campo,
R. Canto´n, F. Baquero, H. Harmsen, R. Willems (Madrid, ES; Utrecht,
Groningen, NL)
Objective: To quantify the proportions of E. faecium (Efm) and
E. faecalis (Efc) in faecal samples recovered from CC17-Ampicillin-
Resistant Efm (AREfm)-colonised [AREfm(+)] and non-colonised
[AREfm(−)] patients.
Methods: A faecal sample was recovered from 16 patients admitted
in the Haematology and Gastroenterology/Nephrology ward at the
Univ. Medical Center (Utrecht, The Netherlands) and this was used
for bacterial quantiﬁcation (July-Sept 2007). For each faecal sample
ARE colonisation was conﬁrmed using Enterococcosel Agar plates
supplemented with ampicillin (16mg/L). Presence of CC17 was
determined by MLVA. The total number of Efc and Efm of each faecal
sample were enumerated by Fluorescent In Situ Hybridisation (FISH)
using speciﬁc probes (Waar et al. 2005) and compared with the total
amount of cells (per gram wet weight) in the sample.
Results: 8/16 patients were AREfm(+) (mean age 64±10.1; 7 male)
and 8/16 were AREfm(−) (mean age 49.6±19.4; 5 male) with a
similar length of stay (22.5 and 20.5 days, respectively). Mean total
number of cells was 8.6×109 and 1.5×1010 cell/g for AREfm(+) and
(−) patients, respectively. Efm was undetectable among all AREfm(−)
patients, whereas very high numbers of Efm were observed in all
AREfm(+) patients (2.3×108, ranging 0.5%-7% of the total number
of cells). 5/8 AREfm(+) patients presented a mean of 3×106 cells
for Efc (ranging 0.01−0.52%) and in one AREfm(−) patient, Efc
represented 5% of the total number of cells (1.3×108). In the rest
of patients Efc fell under the detection limit (105) [3 AREfm(+)
and 7 AREfm(−) patients]. All AREfm(+) patients received antibiotic
treatment, most of them in combination [3rd gen. cephalosporins (4
patients); amoxicillin-clavulanate (3 patients); gentamicin (2 patients);
carbapenems ciproﬂoxacin and metronidazol (1 patient)], whereas only
one AREfm(−) patient received amoxicillin-clavulanate, gentamicin and
ciproﬂoxacin.
Conclusions: This study demonstrated a higher Efm cell density than
that of Efc in faeces from patients colonised with CC17-AREfm,
while in non-CC17 colonised patients Efm are below the detection
limit. High Efm densities could facilitate host-to-host transmission and
hospital environmental contamination. Antibiotic-mediated increased
Efm density and the ecological shift in the Efc:Efm normal ratio in
the intestinal compartment might contribute to the current increasing
proportion of Efm-CC17 in bacteraemic episodes.
P838 A nationwide outbreak of vancomycin-resistant enterococci
in Sweden, 2007–2008
T. So¨derblom °, I. Ho¨keberg, G. Hedin, O. Aspevall, J. Smedjega˚rd,
D. Heimer, M. Erntell, K. Kidd-Ljunggren, S. Sylvan, A˚. Melhus,
B. Olsson-Liljequist, K. Tegmark-Wisell, J. Struwe (Solna, Huddinge,
Va¨stera˚s, Halmstad, Uppsala, SE)
Objectives and Background: The aim is to describe an ongoing
nationwide outbreak of vancomycinresistant enterococci, vancomycin-
resistant enterococci (VRE). The outbreak was ﬁrst recognised in
Stockholm county in October 2007 and has subsequently been reported
from Va¨stmanland, Uppsala and Halland counties.
Vancomycin-resistant Enterococcus faecium and Enterococcus faecalis
(VRE) infection and carriage have been mandatory notiﬁable in Sweden
according to the Communicable Diseases Act since 2000. Around 20−50
cases were reported annually between 2000–2006.
Methods: Analysis of all VRE-cases reported in the national web-
based surveillance system SmiNet2. Genotyping and pulsed-ﬁeld gel
elecrophoresis (PFGE) performed at local laboratories and at the Swedish
Institute for Infectious Disease Control, respectively.
Results: During the period July 1 2007 to December 11 2008 altogether
618 reports of VRE were received. 437 of the notiﬁcations came from
Stockholm, 74 from Halland, 72 from Va¨stmanland, 13 from Uppsala
and 22 from another 8 counties throughout Sweden. The median age of
the cases was 70 years. 486/618 of the cases were detected in faecal
screening samples. Blood-stream infection was reported in 12 cases.
E. faecium with gene vanB (EfmB) was found in 465 cases and
E. faecium with vanA in 90 cases. The remaining isolates have not
yet been fully typed. PFGE has shown that virtually all EfmB isolates
analysed until now belong to the same clone.
Conclusion: A nationwide outbreak of E. faecium with vanB traced
back to August 2007 is ongoing in Sweden. The reasons for the extensive
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dissemination in the country and in the affected counties, respectively, are
still unclear but under investigation. A national group has been formed
to discuss strategies to prevent further spread of VRE and laboratory
coordination of typing.
P839 Isolation of glycopeptides-resistant enterococci from stool
and blood samples of hospitalised patients during a
three-year period
E. Vagiakou, M. Orfanidou °, A. Vyrla, K. Savvidou, E. Tsianou,
H. Malamou-Lada (Athens, GR)
Objectives: The isolation of glycopeptide resistant enterococci from
stool and blood cultures of hospitalised patients and their antibiotic
resistance in a tertiary hospital in Greece during three years period
(27/11/05−30/09/08).
Methods: During the study period 5047 stool samples were examined
in our laboratory for GRE carriage and 15232 blood cultures for
investigation of bacteraemia. Enterococci were isolated on esculin azide
agar with 6mg/ml vancomycin and were identiﬁed by the automated
system Vitek II (bioMerieux). The susceptibility was tested by disk
diffusion agar method (Kirby–Bauer) and the MICs were determined
by Vitek II system and E-test (AB, Biodisk, Solna).
Results: GRE strains were isolated in 631/5047 stool specimens (12.5%)
and in 36/2483 patients with positive blood cultures (1.4%). Especially,
610 strains E. faecium (610/631, 97%) and 21 E. faecalis (21/631, 3%)
were isolated from stool cultures and 31 strains E. faecium (31/36, 86%)
and 5 E. faecalis (5/36, 14%) from blood cultures. The distribution per
clinic of GRE strains from faeces was as followed: Haematology ward
177 strains (177/631 28%), Intensive Care Unit (ICU) 53 (53/631, 8.4%),
Nephrology ward 60 (60/631, 9.5%) Internal Medicine department
243 (243/631, 38.5%), Plastic-Burn Unit (PBU) 70 (70/631, 11%),
Vascular Surgery department 2 (2/631, 0.3%) and Surgical department 25
(25/631, 4%). The distribution of GRE strains in the bacteraemia cases
was: Haematology ward 5, Gastroenterology ward 3, ICU 12, Internal
Medicine department 6, PBU 9, Vascular Surgery department 1. Six
cases of GRE bacteraemia coexisted with GRE carriage; 2 from patients
of ICU, 1 from Vascular Surgery department, 1 from Haematology ward,
1 from PBU and 1 from Gastroenterology ward. All isolated GRE strains
from blood cultures and stool cultures were multi-drug resistant and
sensitive to Linezolid.
Conclusions: The enteric carriage of GRE was approximately 13%.
Most of the GRE strains were identiﬁed as E. faecium. Most of the
strains, both from stool and blood cultures, were isolated in Haematology
ward and Internal Medicine department. In six cases GRE carriage led
to bacteraemia. Antibiotic policy and strict enteric precautions should be
implemented to restrict GRE carriage. As the risk of GRE bacteraemia
exists the epidemiological surveillance is necessary especially for
immunocompromised patients.
P840 International spread of vancomycin-resistant Enterococcus
faecium (CC17, CC5) and Enterococcus faecalis CC2 among
animals and humans
A.R. Freitas °, C. Novais, R.M. Silva, T.M. Coque, L. Peixe (Porto, PT)
Objectives: Spread of vancomycin resistance among enterococci (VRE)
by clonal expansion or by horizontal transfer has been described in
both hospital and community settings. However, transmission between
animals and humans has been scarcely demonstrated, probably due to
the apparent host speciﬁcity observed for enterococcal clonal complexes
and for some genetic elements. We analysed a collection of wide
disseminated VRE from humans and swine in order to assess possible
routes of genetic exchange and transmission.
Methods: We characterised 6 E. faecium (VREfm) and 1 E. faecalis
(VREfc) from swine, the only expressing resistance to glycopeptides
among 473 collected from piggeries in different regions of Portugal
(2006−07). Epidemic clinical isolates from European hospitals were
included for comparison. Susceptibility proﬁle, resistance and virulence
genes (PCR), clonality (PFGE, MLST), transferability (ﬁlter mating)
and Tn1546 (PCR overlapping, I-CeuI-hybridisation) were characterised.
Plasmid analysis included determination of size and content (S1-
nuclease) and comparison of ClaI-RFLP patterns.
Results: We identiﬁed two VREfm and one VREfc PFGE types
persistently recovered from humans and also observed in swine. One
VREfm (ST132-CC17) was collected from swine (n = 1) and hospitalised
patients (n = 2) in Portugal (PT), all sharing similar antibiotic resistance
and virulence proﬁles, and a 70 kb plasmid with the same RFLP proﬁle.
The other VREfm (CC5) was a clone widespread among swine from
4 EU nations (Portugal, Spain, Italy, Denmark) since 1997 and also
identiﬁed from 3 patients of different PT hospitals (2002). All CC5
isolates (ST5, ST6, ST185) contained the variant D of Tn1546 type
located in a 150 kb plasmid. The VREfc (CC2, ST6) is the epidemic
multidrug-resistant clone “B”, widely disseminated in PT, Spanish and
Italian hospitals since 1993 and now recovered from swine. VanA
plasmids from clinical isolates showed variable sizes and RFLP patterns,
though an identical 100 kb plasmid was observed in the PT swine isolate
and in one clinical isolate from Spain (Tn1546 type A; same RFLP).
Conclusions: We described VREfm and VREfc identical strains within
major enterococcal CCs from swine and humans, stressing out the role
of animals as reservoir of VRE involved in human infections. This is
the ﬁrst report documenting the presence of CC2 Efc strains outside the
hospital setting and identical VanA plasmids in swine and humans from
different countries.
P841 Plasmid analysis of vancomycin-resistant Enterococcus
faecium isolates from hospitals and aquatic environments in
Portugal (1996–2008)
A.R. Freitas °, C. Novais, M.V. Francia, L. Peixe, T.M. Coque (Porto,
PT; Santander, Madrid, ES)
Objectives: Vancomycin resistant (VR) enterococci constitute one of
the most common nosocomial pathogens nowadays and they are mostly
identiﬁed as CC17-E. faecium (Efm). VR among Efm isolates is
frequently transferable by conjugation although little is known about the
molecular epidemiology of their transferable plasmids. Plasmid diversity
among VREfm from Portuguese hospitals was analyzed in order to better
understand the plasmid ecology and the dramatic recent spread of VRE
in our country.
Methods: We analysed 75 VREfm-vanA mostly belonging to CC17
(43 PFGE types; 18 Tn1546 types) from hospitalised patients in
6 hospitals of different cities (n = 62) and from hospital waste
waters and contaminated river samples (n = 13) (1996–2008). Plasmid
characterisation included determination of size and content, comparison
of EcoRI/ClaI-RFLP patterns, and identiﬁcation of 27 relaxases (rel), 13
rep initiator proteins (rep) and 5 toxin-antitoxin systems (TA) by PCR,
hybridisation and sequencing.
Results: A high diversity of plasmid content was observed (1−6/cell,
2–350 kb). All Tn1546 types, mostly containing ISEf1 or IS1216, were
located on plasmids of variable size (30–250 kb; 95% conjugative). We
identiﬁed 24 RFLP plasmid patterns with overrepresentation of 2 proﬁles
corresponding to plasmids types of 60 kb and 90 kb, the most dissemi-
nated among hospitals and environment which were persistently recov-
ered for long periods of time. All isolates harboured plasmids with simi-
lar content: relaxases from pEF1 (100%), pCIZ2 (80%) or pHTB (33%);
rep proteins from pRUM (88%), pCIZ2 (65%), pRE25 (64%), Inc18 and
pHTB (36% each), pEFNP1 (33%); Axe-Txe (16%) or omega-epsilon-
zeta systems (14%). Relaxases from pAD1 (8%) and pRUM (4%), as
well as rep proteins from pAD1 (7%) and pDT1 (4%), were rarely de-
tected. VanA-plasmids were predominantly derivatives of pEF1 plasmid
containing rel-pEF1, mostly associated with rep-pRUM and eventually
with rep from pRE25 and/or Inc18. pHTB-like plasmids which have been
involved in the spread of VRE in Japan and USA, were rarely detected
among 60 kb-plasmids and were not associated with Tn1546.
Conclusions: VREfm isolates recovered from Portuguese hospitals and
aquatic environments contained plasmids with similar gene content over
years, which indicate a high plasmid genetic stability among VRE in
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our area. The conjugative plasmids driving the spread of vancomycin
resistance in our area are mosaics including mainly sequences from pEF1
and pRUM.
P842 Impact of reduction of environmental and equipments
positive cultures for VRE on the rates of infection due to
VRE in an intensive care unit at a teaching hospital in Brazil
M. Perugini, S. Nomi, G. Lopes, I. van der Heijden, A. Mostachio,
S. Costa ° (Londrina, Sao Paulo, BR)
A variety of measures have been used to reduce VRE rates, the optimal
approach however, is not well deﬁned.
Objectives: The aim of this study was to evaluate the impact of a
multidisciplinary process to monitor healthcare work (HCW) compliance
with standard and contact precautions and the role of environment and
equipments on the transmission of VRE.
Material: This study consisted of four periods baseline, pre, intervention
and pos-intervention period. Chi-square test was used to compare data
pre and pos intervention and Chi-square test for linear trend was used
to evaluate the distribution of VRE and use of glycopeptides during the
study period, the level of p< 0.05 was signiﬁcant. PFGE was performed.
Results: E. faecium was the most frequent species isolated being
responsible for 71% of positives cultures. Forty-six infection were
documented, bloodstream infection 17 (47%) was the most frequent site.
The educational intervention was given to 136 HCW. 706 opportunities
were evaluated, the compliance with standard and contact precautions did
not improve comparing pre and pos-intervention period. However, the
proportion of environmental and equipments positive cultures decreased
signiﬁcantly comparing pre- (23.2%) and post-intervention (2.4%) period
(p< 0.001) and was associated with decrease of VRE infection per
1,000 pts-day (p = 0.004). The use of vancomycin (DDD) did not change
signiﬁcantly over the study period (p = 0.97) and the use of teicoplanin
increased (p< 0.001). Ninety percent of E. faecium belong to the same
type.
Conclusions: In the present study, reduction of proportion of positive
environmental and equipments cultures was associated with decreased
of rates of VRE infections.
P843 Vancomycin-resistant enterococci infection outbreak in the
intensive care unit
D. Spanogiannis, M. Kalaitzopoulou, E. Kakasi, E. Mastrogiannidou,
A. Vasiliadou, A. Papa, E. Kosmidou ° (Thessaloniki, GR)
Objectives: Vancomycin Resistance Enterococcus Faecium (VREF) is
becoming a signiﬁcant pathogen in the Intensive Care Units (ICU)
patients. In this study we present a VREF infection outbreak in the
ICU of our hospital.
Methods: Two patients had documented both infection and colonisation.
VRE was isolated in blood and stool culture of the ﬁrst patient and in
wound and stool culture of the second one. Screening of the rest of
ICU patients by stool culture revealed one carrier. Phenotypic control
and MIC’s determination were performed by VITEK system (broth
microdilution panels). Additionally MIC’s were conﬁrmed with E-test
according to CLSI standards. Multiplex PCR was used for the detection
of rrs and ddl genes. Also special primers for VanA, VanB, VanC1,
Vanc2/C3 genes were used.
Results: Strains were identiﬁed as Enterococci faecium by both
phenotypic and genetic methods. Resistance to vancomycin and
teicoplanin was detected in all strains. MIC’s determination by VITEK
was 32mg/ml for both glycopeptides. E-test revealed vancomycin’s
MIC> 256mg/ml and teicoplanin’s MIC=32mg/ml in all strains. All
strains were susceptible to linezolid. Molecular method (PCR) detected
VanA gene in both two patients and in the carrier too.
Conclusion: The results indicated potential survival of strains in the
hospital environment and possible transmission among the hospitalised
patients.
The outbreak may be controlled by continuous implementation of an
infection control program including improved hand-washing facilities.
P844 Typing of vancomycin-resistant enterococci from Danish
hospitals
C.H. Lester °, S.S. Olsen, H.C. Schønheyder, D.S. Hansen, M. Tvede,
T.G. Jensen, J.O. Jarløv, A. Friis-Møller, K. Truberg Jensen,
J.J. Christensen, A.M. Hammerum (Copenhagen, Aalborg, Hillerød,
Odense, Herlev, Hvidovre, Esbjerg, DK)
Objectives: Vancomycin-resistant enterococci (VRE) are reported to
increase in numbers in European hospitals. Vancomycin resistance can
be encoded by seven different genes but only vanA and to a lesser
extent vanB are widely prevalent among clinical isolates of enterococci.
The E. faecium clonal complex 17 (CC17) has been associated with
nosocomial outbreaks in ﬁve continents. The aim of the present study
was to elucidate the molecular epidemiology of VRE in Denmark.
Methods: From January 2005 through October 2008, 61 vancomycin
resistant enterococcal isolates causing invasive as well as non-invasive
infections were referred by seven of the 15 Danish departments of
clinical microbiology to Statens Serum Institut. All isolates were
identiﬁed to species level by PCR, MICs of vancomycin were determined
(Trek Diagnostic Systems, UK), and the presence of vanA, vanB and
vanC genes were detected by PCR. Multi locus sequence typing (MLST)
was performed on the vancomycin-resistant E. faecium isolates.
Results: The collection consisted of 45 E. faecium and 16 E. faecalis
isolates which originated from 12 different hospitals. Thirty three of 45
E. faecium isolates were vanA positive and the remaining 12 isolates
were vanB positive. All but one of the E. faecalis isolates contained the
vanB gene (n = 15) and the remaining isolate contained the vanA gene.
MLST of the 45 E. faecium isolates revealed 10 different sequence types
(ST). The STs were ST18 (n = 21), ST203 (n = 8), ST78 (n = 3), ST192
(n = 3), ST412 (n = 3), ST16 (n = 2), ST17 (n = 2), ST65 (n = 1), ST80
(n = 1), and ST306 (n = 1). Forty four (98%) of the 45 tested isolates
belonged to CC17. The 45 E. faecium isolates originated from nine
different hospitals. Each hospital was mainly dominated by one speciﬁc
ST; however, ST18 was present in three of the nine hospitals.
Conclusion: The vanA gene was the most common in E. faecium
isolates whereas vanB was predominant in E. faecalis isolates. Most
of the vancomycin-resistant E. faecium isolates belonged to the hospital-
acquired clonal complex 17.
P845 Vancomycin-resistant enterococci in haematopoietic stem cell
transplant recipients
P.M. Rath °, R. Trenschel (Essen, DE)
Objective: Vancomycin-resistant enterococci (VRE) are emerging
pathogens. There are no data on the prevalence in pre-treated patients
with haematological malignancies admitted to a BMT unit. Therefore,
the prevalence of VRE was determined by using perianal swabs and the
clonality of isolates was studied. In addition, follow up isolates were
compared with those of the perianal swabs.
Materials: 137 patients were screened for VRE at admission by
using perianal swabs cultured on chromogenic agar (Oxoid). Species
identiﬁcation and detection of van A, van B and esp was performed by
PCR. Perianal isolates and isolates detected during the hospital stay in
routine cultures were genetically compared by PFGE (Sma I).
Results: VRE were detected in the perianal swabs of 18/137 patients
(13%). All isolates were identiﬁed as E. faecium with van A. Esp was
detected in 10 isolates. In seven patients VRE were also detected in
other materials during the hospital stay (throat 1 pt., urine 4 pts., central
venious catheter (cvc) 2 pts., blood culture 1 pt.). PFGE analysis revealed
25 different genotypes in total. In two patients identical isolates were
cultured from perianal swabs. Comparing the isolates of the perianal
swabs and those of other samples showed that two patients had an
identical isolate in urine (1 pt.), and on a cvc (1 pt.), respectively. In
one patient with a positive blood culture the isolate was different to that
of the perianal swab. Regarding overall survival and treatment related
mortality, clinical outcome of VRE carriers was similar non-carriers.
Conclusion: In this study 13% of BMT patients were colonised with
VRE but invasive infections were rare (1 patient). The epidemiology was
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polyclonal. In ﬁve of seven patients with the additional detection of VRE
in other materials than perianal swabs, different genotypes were found.
P846 In vitro antimicrobial sensitivity trends of enterococci isolated
at an Italian teaching hospital. A 2004–2007 prospective
report including over 2,700 examined microbial strains
R. Manfredi °, A. Nanetti (Bologna, IT)
Introduction: The increasing temporal trend of antimicrobial resistance
among Gram-positive cocci (including Enterococci) is of concern,
especially among inpatients.
Materials and Methods: The temporal trend of the in vitro antibiotic
susceptibility rates was examined for all Enterococcus faecalis and
Enterococcus faecium strains, isolated at our General Teaching Hospital
during the years 2004–2007. The same pathogen isolated more than once
from the same patient within one month, has been considered once.
Results: Among Enterococcus faecalis isolates (2,736 strains tested
on the whole), the greater activity rate was achieved by linezolid
(100% of tested strains), followed by teicoplanin (97.9–100% of
strains), nitrofurantoin (96.4−98.3%), vancomycin (81.0–100%), ampi-
cillin (90.2−91.9%), penicillin (88.8−91.5%), while irregular variations
of sensitivity occurred over time for gentamicin (>60% of tested
strains), streptomycin (>70% of strains), and tetracyclines (<20% of
strains). When considering Enterococcus faecium strains (626 overall
isolates), only linezolid maintained a 100% in vitro activity, followed by
teicoplanin (87.7–100% of tested strains), vancomycin (78.4−86.2% of
strains), tetracyclines (56.8−81%), and gentamicin (59.1−71.0%), while
unpredictable efﬁcacy was shown by streptomycin (27.6−69.8% of tested
strains). Sixty-six strains of vancomycin-resistant Enterococcal strains
were detected, with a clearly increased trend from 2004 (7 cases) to
2007 (21 cases) (p< 0.001). An increased in vitro resistance rate was also
detected for tetracyclines, during the four-year study period (p< 0.01).
Conclusions: A prospective surveillance monitoring of the in vitro
antimicrobial sensitivity ﬁgures of Enterococci as relevant hospital
pathogens, plays an useful role to target antimicrobial treatment and
prophylaxis strategies, on local and regional basis. The emerging of
resistance to the reference compounds, and that of vancomycin-resistant
organisms in particular, may be also well assessed on these temporal
basis, in order to addresss the clinical choice according to the local
epidemiology and antimicrobial testing features.
P847 Prevalence of vancomycin-resistant enterococci in presistance
patients who referred to a paediatric hospital, Tehran, Iran
M. Navidinia °, S. Rafeii Tabatabaii, F. Fallah, A. Karimi, M. Malekan,
M. Hadipour Jahromi, Z. Gholi Nja (Tehran, IR)
Introduction: Vancomycin is one of the most effective antibiotics against
the Gram positive cocci. Prevalence of resistance between enterococci
and its simple spread way to other Gram positive cocci such as staphylo-
cocci and streptococci have led to serious problems for in-bed patients.
It could be suggested that frequency of resistant enterococci indicate a
reliable pattern of antibiotic susceptibility. Result in saving time and cost.
Objectives:
1. Prevalence of vancomycin resistant enterococci in Mofeed children
hospital and Ali Asghar hospital
2. Antibiotic resistance patterns in enterococci
3. How is the vancomycin resistance between enterococci isolated from
patient’s stool samples
4. Pattern of antibiotic resistance of enterococci against other antibiotics
5. Determination of vancomycin resistance and its relation to effective
antibiotics for anaerobic bacteria
6. Prevalence of vancomycin resistance in enterococci isolated from
stool samples from distinct wards in hospitals.
Method: Stool Sampling was performed on in-bed patients in distinct
wards in hospital including GI and infectious of Mofeed hospital
and chemotherapy in Aliasghar hospital. Stool culture was done once
introduce to laboratory 48 hours after patient’s admittance. Specimens
were cultured on media such as Enterococcocel agar and Bile Esculin
agar. And then some speciﬁc tests were performed for their conﬁrmation
such as PYR test, growth in 15ºC and 45ºC in Mueller Hinton agar.
Growth in 6.5% NaCl. E-test was performed on VRE strains. Selected
antibiotics for E-test were included cephotetan, rifampicin, gentamycin,
ciproﬂoxacin, ceftriaxon, oxacilin, cefotaxim, amikacin, clindamycin,
chloramphenicol, imipenem. Susceptibility level was reported on the
basis of NCCLS charts.
Results: In this research, we examine stool samples of 64 patients
who had one or two samples. 13 percent of enterococci were resistant.
Antibiotic pattern was cefotetan 60%, rifampicin 36%, gentamycin 36%,
ciproﬂoxacin 32%, tetracycline 53%, ceftriaxone 86%, oxacillin 65%,
cefotaxime 76%, amikacin 48%, clindamycin 23%, chloramphenicol
24%, imipenem 25%.
Conclusion: Antibiotic resistance in enterococci is increasing even
vancomycin which is the ﬁrst choice for enterococcal infections
treatment, it could be suggested before effective treatment, disc diffusion
test and E-test should be done.
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P848 Nosocomial outbreak of an extended-spectrum b-lactamase
producing Klebsiella pneumoniae strain on a medical
intensive care unit
R. Laffer °, M. Michot, M. Buehlmann, C. Mohr, T. Bregenzer,
H. Fankhauser (Aarau, CH)
Objectives: The incidence of extended spectrum b-lactamase producing
(ESBL) bacteria is increasing. Isolation precautions are recommended
to prevent transmission. Delayed diagnosis of ESBL colonisation may
increase the risk for nosocomial outbreaks. We report an outbreak
of ESBL producing Klebsiella pneumoniae (ESBL-KP) on a 10-bed
medical intensive care unit (ICU) and surveillance and infection control
measures taken to interrupt transmission.
Methods: All infected or colonised patients were isolated and cohorted
if possible. Hand hygiene was reinforced and surveillance cultures were
performed (rectal swabs every 2nd day in all patients who stayed at the
ICU for 24 hours, environmental sampling from computer keyboards,
telephone receiver, water tap, rinsing tank and the lavatory). The number
of beds was reduced to a ﬁxed key according to the available staff.
Results: The ﬁrst patients were diagnosed on July 8th. Three additional
patients were diagnosed on July 16th. The time between screening and
isolation was 3 days according to the time needed for microbiological
identiﬁcation. Hand hygiene promotion was reinforced on July 11th.
Surveillance cultures were initiated and environmental screening was
performed when 4 additional patients were diagnosed with ESBL-KP on
July 23rd. ESBL-KP was also cultured from two rinsing tanks. Water
taps, rinsing tanks and lavatories were rinsed with sodium hypochlorite.
On August 23rd, 2 newly colonised patients were identiﬁed. Intensiﬁed
investigations could not detect further potential sources of ESBL-KP.
There were no further ESBL-KP isolated after August 23rd. In total, 12
patients were affected. 7/12 patients died.
Conclusion: The source of our ESBL outbreak could not be identiﬁed.
Standard hygiene precautions and a high level of awareness for hygiene
issues reduced the risk of, and subsequently interrupted transmission.
Such measures are particularly important since the population at risk
has a poor prognosis, supposably because of comorbidity but probably
due to infectious complications too. The role of environmental or staff
screening should be investigated.
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P849 Food-borne nosocomial outbreak due to ESBL-producing
Klebsiella pneumoniae (SHV-38). Epidemiology and
successful control
E. Calbo °, M. Riera, N. Freixas, C. Nicolas, O. Monistrol,
M. Xercavins, J.M. Nava, J. Vila, J. Garau (Terrassa, Barcelona, ES)
Objective: Nosocomial outbreaks of food-borne ESBL producing
K. pneumoniae (ESBL-KP) have not been reported. We describe the
epidemiology and control of an outbreak.
Methods: After the identiﬁcation of 2 infected patients with ESBL-
KP in a medical ward of a 500-bed acute care teaching hospital,
an epidemiological investigation was performed. That included: a
systematic faecal sampling in patients of medical, surgical and critical
care units, hospital kitchen environmental surfaces and food stuff
cultures, and faecal samples of health care workers and food handlers.
Characterisation of the ESBL was performed by PCR and sequencing
whereas the epidemiological relationship of the isolates was carried out
by PFGE.
Results: From June-October 2008, 153 colonised/infected patients
were identiﬁed; 32 patients were infected (21%) [UTI (25), SSI (5),
pneumonia (1) and primary bacteraemia (1)].
Given the fact of the high prevalence of faecal colonisation (up to 37%
in some wards), the rapidity of its spread, the early colonisation soon
after admission, and the lack of carriers among health care workers
investigations were directed to the hospital kitchen and food chain.
In the kitchen, up to 35% of studied surfaces or foods were contaminated.
Six out 44 (14%) of asymptomatic food handlers were found to be
faecal carriers. One of the kitchen washing rooms was found to be
persistently colonised and justiﬁed the persistence of the outbreak over
time. Phenotypic and genotypic analysis of all isolates showed that all
strains were identical and that the outbreak represented the spread of a
single clone of SHV-38 producing KP.
Contact isolation measures were immediately applied on colonised/
infected patients. A protocol for routine detection and isolation of
patients with faecal colonisation was implemented. A proactive campaign
to reinforce hand hygiene practices and structural and functional cleaning
measures in the kitchen area were carried out. Once the source had been
identiﬁed and we learned that the food was the vehicle of the massive
colonisation of inpatients, isolation practices for colonised patients were
abandoned. No restrictions in the use of antimicrobials were needed to
control the outbreak. No new cases of nosocomial colonisation/infection
were identiﬁed after October 2008.
Conclusions: To our knowledge this is the ﬁrst reported outbreak that
provides some evidence that food can be a transmission vector for ESBL-
producing-KP in the nosocomial setting.
P850 Environmental contamination in the rooms of
ESBL-colonised patients
H. von Baum °, S. Jung, A. Moericke (Ulm, DE)
Objectives: The presence of ESBL positive enterobacteria in the rooms
of ESBL colonised patients and its relationship to the contamination of
healthcare workers’ (HCW) gloves and clothing was examined.
Methods: 12 standardised environmental samples from patients’ rooms
as well as samples from the gloved hands and clothing of HCW
were examined. Samples were incubated for 48 h at 37ºC. Species
identiﬁcation of Gram negative bacteria was performed using the API 20
E® (bioMerieux). Conﬁrmation of ESBL positive isolates was done by
standardised susceptibility testing. All ESBL positive isolates were either
E. coli or K. pneumoniae. All environmental ESBL isolates as well as
the corresponding patients’ isolates were genotyped using pulsed-ﬁeld-
gel-electrophoresis (PFGE) after digestion with the restriction enzyme
Xba1.
Results: ESBL positive enterobacteria were present in the rooms of only
8 of 36 patients colonised with ESBL positive enterobacteria (22%).
Contamination of HCWs’ gloved hands and/or clothing was identiﬁed in
4 of 65 nurses (6%); 1 of 8 physicians (13%) and 1 of 76 medical
students (1.3%). Contamination of physiotherapists, members of the
housekeeping staff or visitors could not be found. In only 1 patient
more than one ESBL strain was present.
Conclusion: Healthcare workers must be aware that contamination of
their gloved hands and clothing whilst caring for an ESBL colonised
patient is possible. In contrast to the ﬁndings for MRSA colonised
patients (i) the environment of ESBL-colonised patients is less frequently
contaminated, (ii) the contamination occurs usually only in close
proximity of the patient and (iii) in the majority of cases the strains from
the environment are identical with the clinical isolates of the patients’.
P851 Transmission rate of Enterobacteriaceae producing
extended-spectrum b-lactamase to hospital contacts and
household members in a Swiss university hospital
B.Y. Betsch °, S. Droz, K. Mu¨hlemann (Berne, CH)
Objective: Gram-negative bacteria with extended-spectrum b-lactamase
(ESBL) production are spreading rapidly world-wide. We studied the
transmission rate of ESBL germs from index patients with ESBL
carriage to hospital room mates and household members.
Methods: Patients with ESBL carriage newly detected during diagnostic
work-up for infection were recruited prospectively at the University
Hospital Bern during the time period May 7 to December 13 2008.
Hospital contacts were deﬁned as room-mates of the index for 48 hours.
Screening was performed weekly for the duration of contact and
continued for another 2 weeks after separation of the index patient.
Screenings were stopped after 2 negative results. Screening included
faecal samples for all contacts and respiratory tract sample in patients
with intubation or tracheostoma, dermal swab in case of skin lesions and
any bodily ﬂuid drained by a catheter. Faecal samples were collected from
household contacts in a 3-monthly interval until both index and contacts
screened negative. Stool samples were analyzed with 3 different ESBL
selective culture media: ChromID ESBL agar (Biome´rieux®) and ESBL
agar (AES™), a bi-plate with 2 selective media (MacConkey agar plus
Ceftazidim and Drigalski agar plus Cefotaxim).
Results: A total of 37 index patients, 24 (65%) inpatients and 13 (35%)
outpatients were analyzed. The ESBL-species detected was E. coli,
K. oxytoca and K. pneumoniae in 58%, 29% and 13% for inpatients
and 77%, 15% and 8% for outpatients. Faecal colonisation was detected
in 75% of inpatients and in 54% of outpatients. The screening was
not interpretable due to antibiotic treatment in 4 index cases and faecal
screening was missing in 4 cases. Household screening was performed
for 27 members of 16 households. ESBL carriage was detected in 5
households (with 7 members). 3 of these 5 households were of South-
Asian ethnicity. Faecal ESBL carriage in index patients was 80% in the
5 households with ESBL-transmission and 55% in the 11 households
without transmission.
Conclusions: The rate of faecal colonisation with ESBL tends to
be higher for hospitalised patients than for outpatients (75% vs.
54%). Inhospital patient-to-patient transmission rates may be lower than
transmission rates within households and may correlate with faecal
carriage in the index patients.
P852 Skin colonisation with extended-spectrum b-lactamase
producing Enterobacteriaceae
M. Buehlmann °, R. Laffer, H. Fankhauser, T. Bregenzer (Aarau, CH)
Objectives: Extended-spectrum b-lactamase producing Enterobacteri-
aceae (ESBL) are emerging worldwide. ESBL carriers are an important
source of ESBL spread and no effective decolonisation is available.
Screening for ESBL has been performed by rectal and urine sampling.
Skin colonisation of ESBL has not been studied. The aim of this study
was to determine the rate of inguinal colonisation in ESBL carriers.
Methods: From November 2006 to November 2008 all newly detected
ESBL carriers at the Cantonal Hospital of Aarau, Switzerland, were
screened by rectal, bilateral inguinal swabs and uricult. ESBL was mainly
diagnosed in clinical samples, six patients were screened for ESBL
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during a limited outbreak of K. pneumoniae ESBL on the intensive care
unit involving 14 individuals. Laboratory diagnosis of ESBL was made
according to the guidelines of the Clinical Laboratory Standard Institute
(CLSI); cefpodoxime, ceftriaxone, ceftazidime were used for screening.
Since July 2008, a chromogenic medium (chromID ESBL, Biome´rieux,
France) has been used for rapid identiﬁcation of ESBL. If screening was
positive, conﬁrmation was performed by E-test strips.
Results: Within the study period 65 ESBL carriers with a mean age of
58 years were identiﬁed. Of those 46% (30/65) were males and 80%
(52/65) were hospitalised at the time of ESBL diagnosis. E. coli and
K. pneumoniae were the most common ESBL types (51% and 47%,
respectively), 4 patients were colonised with two different ESBL strains.
Inguinal colonisation was found in 64%, rectal colonisation in 70% and
urine colonisation in 75% of patients. Inguinal colonisation was more
common in hospitalised than in outpatients (73% vs. 25%, OR 8.4,
1.4−47, p = 0.013). In one patient inguinal swabs were the only samples
positive for ESBL.
Conclusion: Inguinal colonisation is common in ESBL carriers. Skin
colonisation may be important for nosocomial ESBL transmission.
Future decolonisation attempts should include treatment of skin
colonisation with antiseptic soaps.
P853 The extended antibiogram, a useful tool for typing of ESBL
producing E. coli
A. Porczak °, M. Sundqvist, G. Kahlmeter (Va¨xjo¨, SE)
Objective: Outbreaks of extended-spectrum b-lactamase (ESBL) pro-
ducing E. coli are becoming an everyday problem for local microbiology
laboratories and infection control personnel. A simple and rapid method
to suggest or exclude epidemiological relationship is therefore needed.
Two phenotypic methods can be used without specialised competence
in molecular biology. The PhenePlate™-system utilises the dynamics
of eleven biochemical reactions over 48 h. The extended antibiogram,
in this study comprising 32 antibiotic discs, compares inhibition zone
diameters between isolates following overnight incubation.
Method: A collection of 51 ESBL producing E. coli isolates, including
6 and 9 isolates from two different outbreaks were analysed using
PhenePlate™-system and the extended antibiogram. E. coli ATCC
25922, E. coli ATCC 35218 and K. pneumoniae ATCC 700603 were used
as control strains in all systems. Susceptibility testing was performed
using 32 antibiotic discs on IsoSensitest agar (Oxoid, Basingstoke,
UK). All zone diameters (mm) were registered and antibiograms based
on zone diameter values constructed. The PhenePlate™-system was
used according to the manufacturers description. Cluster analyses were
performed using the PhPWin 4.2 software utilising pairwise comparision
statistics.
Results: Both methods identiﬁed the outbreak related isolates. Both
methods identiﬁed three distinct clusters. One of the reported outbreaks
turned out to consist of two separate outbreaks. The three clusters were
veriﬁed using PFGE. Neither of the two methods showed unexpected
clusters in isolates that were expected to be non-related. However,
both methods did occasionally include single isolates unrelated to the
outbreak, in the three outbreak clusters.
Conclusion: The extended antibiogram and the PhenePlate™-system
performed equally well in identifying and excluding outbreaks of ESBL-
producing E. coli. The extended antibiogram was fast, simple and easy
to standardise and we suggest that it can give early and rapid support in
outbreak investigation.
P854 The prevalences and risk factors of nosocomial infections
caused by extended-spectrum b-lactamase-producing
Escherichia coli and Klebsiella pneumoniae in Thailand
N. Hiransuthikul °, P. Saonuam, C. Suankratay, K. Malathum,
S. Danchaivijitr (Bangkok, TH)
Background: Extended-spectrum b-lactamase (ESBL)-producing Es-
cherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae)
have been increasingly reported as causative pathogens of nosocomial
infection (NI) in Thailand.
Objectives: To determine the prevalences and risk factors of NI caused
by ESBL-producing E. coli and K. pneumoniae in Thailand.
Methods: The cohort study and nested case-control study were
conducted at 6 regional hospitals and 6 provincial hospitals in Thailand
during 1 July 2007 to 31 December 2007. We collected the data of all
NIs and those caused by ESBL-producing E. coli and K. pneumoniae.
Nested case-control study were done by using 131 matched pairs of
NIs caused by ESBL-producing and non ESBL-producing E. coli and
110 matched pairs of NIs caused by ESBL-producing and non ESBL-
producing K. pneumoniae. The hospital where data were collected and
the organism were selected as matching criteria.
Results: The prevalences of NIs caused by ESBL-producing E. coli
and K. pneumoniae were 59.8% and 59.3%. For subjects with NIs
caused by ESBL-producing E. coli, the mean age was 61.3 years
old with 54% female. The three most common sites of infection
were urinary tract (45.0%), surgical site (22.9%), and respiratory
tract (17.6%). For subjects with NIs caused by ESBL-producing
K. pneumoniae, the mean age was 58.0 years old with 36% female.
The three most common sites of infection were respiratory tract
(66.4%), urinary tract (16.4%), and surgical site (10.0%). By multivariate
analysis, the previous use of third-generation cephalosporin was a
signiﬁcant risk factors associated with NIs caused by ESBL-producing
E. coli (OR= 5.55, 95% CI=2.73−11.29, p-value <0.001) while the
previous use of third-generation cephalosporin and aminoglycoside were
signiﬁcant risk factors associated with NIs caused by ESBL-producing
K. pneumoniae (OR= 3.95, 95%CI=1.94−8.04, p-value <0.001, and
OR= 6.85, 95%CI=1.86−25.21, p-value=0.004)
Conclusion: Infections caused by ESBL-producing E. coli and
K. pneumoniae were common in Thailand. The previous use of third-
generation cephalosporin was a predictor of NIs caused by each
organism, while previous use of aminoglycoside was also associated
with NIs caused by ESBL-producing K. pneumoniae. Appropriate
use of third-generation cephalosporin and aminoglycoside should be
implemented to reduce the burden of NIs caused by these pathogens.
P855 Report of an outbreak of carbon dioxide dependent
methicillin-resistant Staphylococcus aureus on a hospital ward
C.L. Hamson °, K.E. Walton, J. Collins, L. Wilson, J.D. Perry,
I. Al-Zahrani, C.R. Harwood (Newcastle-upon-Tyne, UK)
Objective: To investigate and control an outbreak of carbon dioxide
(CO2) dependent meticillin resistant Staphylococcus aureus (MRSA) in
a regional liver unit (RLU).
Methods: On 15th March 2008 a liver transplant recipient was screened
for MRSA on admission to the critical care unit from the RLU. Small
poorly-growing green colonies were isolated from a nasal swab on
chromogenic MRSA identiﬁcation media (chromID MRSA, bioMe´rieux)
after 24 hours aerobic incubation. They were slide-coagulase positive
(Slidex Staph-Plus reagent, bioMe´rieux). The strain repeatedly failed to
grow after 24 and 48 hours aerobic incubation on Isosensitest agar (IST,
Oxoid) or 5% horse blood agar (BA, TSC) for susceptibility testing.
When subcultured onto BA and incubated overnight at 37oC in 5% CO2,
however, a heavy growth of an isolate with colonial morphology typical
of S.aur was seen. Susceptibility testing performed on IST according
to British Society for Antimicrobial Chemotherapy guidelines but in
CO2 enriched atmospheric conditions (5% CO2) conﬁrmed that this
was meticillin resistant S.aur (MRSA), also resistant to erythromycin,
clindamycin, moxiﬂoxacin and trimethoprim.
A possible outbreak was suspected as the medical microbiology/infection
control teams were aware of another liver transplant recipient on the
RLU who was found, in February 2008, to be colonised/infected with
a strain of MRSA that grew much better in 5% CO2 than aerobically.
All patients and staff on the RLU were screened for carriage of CO2
dependent MRSA using MRSA ID media in 5% CO2. A deep clean of
the ward was carried out and infection prevention and control practices
were reinforced.
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Results: Four further cases (3 patients, 1 staff member) were found
to be colonised at one or more sites by a CO2 dependent strain of
MRSA. Ongoing targeted screening revealed a seventh case ﬁve weeks
after the initial outbreak. This patient was admitted to the RLU during
March 2008 but had been discharged two days prior to recognition of
the outbreak and screening swabs were found to be positive when he
was readmitted to the RLU in May.
Molecular analysis conﬁrmed that all strains were identical: EMRSA-15
(ST22-SCCmecIV).
Conclusions: To our knowledge we report the ﬁrst outbreak of CO2
dependent MRSA. Similar outbreaks may be missed if screening swabs
are processed by conventional methods. Establishing the local prevalence
of CO2 dependent MRSA is necessary to determine whether targeted
screening is required.
P856 An outbreak of multidrug-resistant Pseudomonas
aeruginosa sepsis after endoscopic retrograde
cholangiopancreaticography
J. Kovaleva °, N.E.L. Meessen, F.T.M. Peters, M.H. Been, R.P. Borgers,
J.E. Degener (Groningen, NL)
Objective: Endoscopes, including duodenoscopes, are the medical
devices frequently associated with outbreaks of nosocomial infections.
We investigated an outbreak of multidrug-resistant Pseudomonas
aeruginosa sepsis affecting 3 patients after endoscopic retrograde
cholangiopancreaticography (ERCP) during a 4 months period, from July
to October 2008.
Methods: Outbreak investigation included microbiological testing of
the implicated endoscope and environmental sampling from the washer
disinfectors, the connecting tubes and the environmental surfaces in
the endoscopy centre. Specimens for culture were obtained from the
biopsy/suction and the water/air channels of the implicated endoscope
with a retrograde technique. The available P. aeruginosa epidemic
strains underwent molecular typing by repetitive-DNA-sequence-based
polymerase chain reaction (rep-PCR). Results of recent surveillance
cultures from endoscopes and medical records of all patients who
underwent ERCP with the implicated endoscope were reviewed.
Results: During a 4 months period, from July to October 2008, 3 in
total patients developed sepsis with multidrug-resistant P. aeruginosa
after undergoing an ERCP procedure. Our registration system enabled
us to retrieve one of three endoscopes daily in use as the possible source
of infection. This ERCP scope demonstrated the contamination with
P. aeruginosa in 2 surveillance samples in July and September and in 3
consecutive cultures in October 2008. All of the environmental samples
and recent surveillance cultures from endoscopes were negative for
P. aeruginosa. Other 33 patients treated with this endoscope had neither
symptoms of infection nor positive blood cultures. Rep-PCR of the
P. aeruginosa isolates demonstrated matching patterns (95% similarity)
and conﬁrmed that this microorganism was transmitted from patient to
patient by one endoscope. The implicated ERCP scope was removed
from service and underwent gas sterilisation with ethylene oxide.
Conclusion: This P. aeruginosa outbreak was caused by patient-to-
patient transmission and infection from a common source, i.e. the
ﬂexible ERCP endoscope. Our microbiological surveillance protocol
with routine culturing of endoscopes was helpful in detection of the
source of contamination. However, the current surveillance system could
not prevent the serious infections in three patients and probable numerous
cross-contaminations in other persons, who underwent ERCP with this
particular endoscope.
P857 Investigation of nosocomial outbreak of multiresistant
Acinetobacter spp. at a Korean hospital
K. Lee, E.S. Park, M.S. Kim, E. Koh, J.Y. Choi, D. Yong, S.H. Jeong,
J.M. Kim, Y. Chong ° (Seoul, KR)
Objectives: Acinetobacter spp. are important nosocomial pathogens
with increasing resistance to multiple antimicrobial agents in Korea:
Acinetobacter spp. had been the 6th or 7th most frequently isolated
species, and imipenem resistance rate was 16% at a university hospital
in 2007. In September 2008, laboratory data at the hospital showed
sudden increase of Acinetobacter spp. isolation. Aim of this study was
to determine the source of the spread and to devise measures to control
the outbreak.
Methods: Samples taken from instruments and fomites in ICUs as
well as from ICU nurses were cultured to ﬁnd source of Acinetobacter
infection. Antimicrobial susceptibility was determined by the CLSI
disk method. PFGE patterns of SmaI-restricted genomic DNA of the
isolates from environment and patients were compared to determine the
relatedness of the isolates.
Results: Analysis of routine test data showed the number of
Acinetobacter isolates signiﬁcantly increased from 44 in January to 160
in September, 2008. Most of the isolates were from ICU patients. Among
the 160 isolates in September, 70 (43.8%) were from sputum and other
respiratory-related specimens. Resistance rates to relatively more active
antimicrobial agents, imipenem, amikacin, and levoﬂoxacin were 40.0%,
46.8%, and 52.5%, respectively. To investigate the source of spread,
samples were taken from the environment of ICUs in October. Of the
105 samples, 31 (29.5%) yielded Acinetobacter spp. Among these, 28
(90.3%) were from respiratory-related instruments.
Additional samples with positive cultures were: 3 of 24 humidity jar
of individual patients, and 3 of 44 hands of ICU nurses. Isolates with
multiresistance to all 13 antimicrobial agents tested were randomly
selected and used to compare PFGE patterns of SmaI-restricted genomic
DNA. An identical pattern (A1) was observed in 12 (42.9%) of 28 patient
isolates, and 11 (39.3%) of 28 environment isolates. Intensive cleaning
of respiratory equipments and fomites in the ICUs with antiseptic
solutions, and enforcing hand washing resulted in a slight decrease of
Acinetobacter isolation to 137 in November.
Conclusion: Source of outbreak of Acinetobacter spp. was mostly
respiratory-related instruments in ICUs. Multiresistance may also aided
the spread. Control of Acinetobacter was only partially successful
when judged immediately after the enforced intervention, suggesting
requirement of continued efforts.
P858 Outbreak of Burkholderia cepacia in two German university
hospitals caused by contaminated prefabricated washcloths
M. Martin °, B. Christiansen, I. Chaberny, F. Mattner (Lubeck, Kiel,
Hanover, DE)
Introduction: We investigated an outbreak with B. cepacia in seven
different intensive care units (ICU) of two German university hospitals
started in the mid of July 2008. The two university hospitals in the North
of Germany merged in 2003. Each hospital has its own infection control
team (ICT).
Methods: Cases were deﬁned as microbiologic detection of B. cepacia
in any material sent to the laboratory. Patients charts were reviewed.
Mineral water, different alcohol-free mouthwashs, surfaces of patients
environments and moist prefabricated washcloths were investigated for
B. cepacia. To prove clonal identity of B. cepacia strains pulsed-ﬁeld
gel electrophoresis (PFGE, SpeI digest) was performed.
Results: In total 41 cases were diagnosed with B. cepacia in 7 ICUs
and 2 wards of two hospitals. 30 were positive in respiratory specimens,
6 in wound (2 tracheostoma) swabs, one each in vaginal or lip swab,
one each in urine, pleural effusion or blood culture. 32 patients were
intubated and at least 8 patients had a ventilator-associated pneumonia
due to B. cepacia. One patient suffered an infection of a pacer cable
insertion site. 8 patients died, one probably related to B. cepacia
infection. Environmental research was started especially looking for
liquid and moist equipments. B. cepacia was found in opened and closed
packages of moist prefabricated washcloths. After recognition of the
source German health care authorities were informed and a Europe-wide
alarm (RAPEX) was given through the systems to prevent infections in
other hospitals. PFGE proved the identical clone in clinical specimens
and washcloths of both hospitals. After elimination of the washcloths in
both university hospitals no more cases occurred.
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Conclusion: Contaminated moist prefabricated washcloths were identi-
ﬁed as cause of a B. cepacia outbreak on seven ICUs of two German
hospitals. For critical ill patients it should be carefully reconsidered what
kind of care products are used. In case of infections due to contaminated
drugs, medical products or cosmetics the immediate information of
health care authorities is required to prevent further cases in other
hospitals. To spread the information different international alarm systems
are established. In Germany, in case of cosmetics the Bundesamt fu¨r
Verbraucherschutz und Lebensmittelsicherheit is the authority which has
to be informed and initiates a Europe-wide warning over the alarm
system called RAPEX.
P859 Tap water as a potential source of nosocomial Pseudomonas
aeruginosa infections in an intensive care unit
Z. Barna °, K. Antmann, J. Pa´szti, M. Ne´meth, R. Ba´nﬁ, M. Vargha
(Budapest, HU)
Pseudomonas aeruginosa is a frequent cause of nosocomial infections in
intensive care units. The water distribution system, tap and shower points
of use may often serve as reservoirs for pseudomonads. If tap water is
identiﬁed as the source of infections, appropriate preventive measures
can be employed to reduce infection rates.
Aim of the present study was to assess the effect of point-of-use ﬁlters
on
1. Pseudomonas aeruginosa counts in tap water
2. incidence of Pseudomonas spp. infections in an ICU
3. clinical and environmental Pseudomonas spp. strains, in order to
provide evidence for water-related infection.
The study was carried out in a 12 bed intensive care unit of a Hungarian
hospital. Point-of-use ﬁlters (Pall Medical) were applied to all water
outlets for 2× 2 weeks. Tap water was sampled weekly before, during
and after the use of the ﬁlters. Pseudomonas aeruginosa was enumerated
according to ISO 12780 standard. Environmental Ps. aeruginosa strains
were isolated from tap water and compared to clinical isolates by serol-
ogy, phage and antibiotic resistance proﬁle, pyocin production pattern
and total genome restriction pulse ﬁeld gel electrophoresis (PFGE).
Three of ﬁve tap outlets were found to be initially colonised by
Ps. aeruginosa (1–300CFU/L). Application of the point-of-use ﬁlters
eliminated Ps. aeruginosa as well as other waterborne bacteria from
the tap water during the two weeks of usage (as speciﬁed by the
manufacturer). After the removal of the ﬁlters, Pseudomonas spp. counts
within the water samples returned to the levels initially detected.
There were no new clinical cases of Pseudomonas infections identiﬁed
during the use of the ﬁlters, whereas an average of 6 cases/month was
recorded during the preceding 2 years.
Clinical (13) and environmental (101) strains were collected and
identiﬁed in the study period. Environmental isolates clustered into
two groups by all of the employed typing methods; serotypes O1
and O17 were discerned. All strains (including clinical isolated) had
identical antibiotic resistance proﬁle, all were sensitive to b-lactames.
PFGE proﬁles of the clinical isolates showed high similarity to the
environmental strains.
In conclusion, typing results supported the hypothesis that tap water
and/or taps are likely reservoirs of infective strains. Point-of-use
ﬁlters were found to be effective means for the infection control of
pseudomonads.
P860 Prevalence and antibiotic resistance of Stenotrophomonas
maltophilia in the water supply of a haematology ward
C.L. Wright °, K.G. Kerr, L. Newton, A.M. Snelling (Bradford,
Harrogate, UK)
Objectives: Stenotrophomonas maltophilia is emerging as a signiﬁcant
opportunistic nosocomial pathogen. Patients undergoing therapy for
haematological malignancy are at particular risk. Antimicrobial therapy
of infection is often complicated as isolates may manifest multi-drug
resistance. Outbreaks of S. maltophilia have been linked to water sources
in hospitals, but little is known about the prevalence and antimicrobial
resistance patterns of the bacterium in potable or bathing water. We
investigated the longitudinal prevalence of S. maltophilia in the water
distribution system of a haematology ward and the antibiotic resistance
characteristics of isolates.
Methods:Water samples (100ml) and swabs were taken from the outlets
of a 14 bed (12 patient rooms) haematology unit. Samples were collected
bi weekly from each tap or shower in the patient rooms, the kitchen
taps supplying cleaning and drinking water, and 2 handwash stations,
totalling 38 outlets. Membrane ﬁltrates of water were incubated for
48 h on R2A agar. Isolates were subcultured on vancomycin-imipenem-
amphotericin B agar for selection of S. maltophilia. Identity was con-
ﬁrmed by species speciﬁc 23S rRNA-PCR. Susceptibility to a panel of 9
common anti-pseudomonal drugs was investigated using disc diffusion.
Results: Over 19 weeks, 647 water samples and 332 outlet swabs
were collected. Of these, 74 water samples (11.4%) and 25 swabs
(7.5%) yielded S. maltophilia. Outlets in 10/12 patient rooms yielded
S. maltophilia on at least one occasion, but the kitchen and hand-
wash stations were consistently negative. The most persistent source
of S. maltophilia was showers in patient rooms. There were only
2 weeks when the pathogen was not isolated. Of the 90 isolates
examined, none were resistant to minocycline or levoﬂoxacin (using
CLSI breakpoints for Stenotrophomonas). Using BSAC breakpoints for
Pseudomonas, 5.6% were resistant to colistin, 25.6% to ceftazidime, 30%
to ciproﬂoxacin, 46.7% to amikacin, 62.9% to piperacillin/tazobactam,
72.2% to gentamicin and 94.4% to aztreonam. Only 4 isolates were
sensitive to all 9 drugs, while 59 (65.6%) were resistant to 3. Nine
isolates were resistant to 6 drugs.
Conclusions: Hospital water can act as a reservoir for S. maltophilia,
and some of these environmental isolates are highly multi-drug resistant.
This should be taken into account when developing infection control
strategies for preventing sporadic infections or outbreaks amongst high-
risk patients.
P861 Prevalence of Legionella spp. in water systems in German
hospitals
E.B. Kruse °, S. Schulz-Stuebner (Freiburg, DE)
Objectives: Although there is mandatory testing of drinking water for
Legionella in German hospitals, the actual prevalence of Legionella
contamination in the hospital setting remains unclear. In this study, we
investigated the prevalence of Legionella in water systems in hospitals
in Germany in order to determine the risk of exposure and the efﬁcacy
of disinfection measures.
Methods: In a nationwide survey, 77 random hospitals were asked
to report the results of their last water sampling and, if Legionella
was found, the control sampling six months later, and the measures
of disinfection and/or patient protection which were taken.
Results: Twenty-eight hospitals with 78 to 477 beds answered the
questionnaire. At the ﬁrst sampling, a mean of 9.4 (1−34) samples were
taken per hospital. Two hospitals were free of Legionella. Twenty-six
hospitals had at least one positive sample. Overall, 94 of 260 samples
(36.2%) were tested positive. Rates were signiﬁcantly higher in smaller
hospitals (<200 beds) with 56 (50.5%) positive samples out of 111, than
in larger ones with 38 (25.5%) positive samples out of 149 (p = 0.0001).
Seven (27%) institutions used water ﬁlters or restricted the use of tap
water for patients at risk. Twenty hospitals (77%) applied at least one
additional disinfection measure (see table 1). At the control sampling,
one of 14 samples taken at the two previously negative hospitals was
positive (7.1%). At the hospitals who had taken additional disinfection
measures, 80 of 204 samples were positive for Legionella (39.2%).
In hospitals without additional measures, 11 of 47 samples (23.4%)
were tested positive. Together, Legionella was found in 92 of 265
water samples (34.7%). There was no statistically signiﬁcant difference
between the ﬁrst and second sampling (p = 0.73).
Conclusion: This survey shows that Legionella can be found in nearly
all hospital water systems at times. Even radical disinfection measures
were not generally effective in reducing the Legionella burden. Therefore
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restrictive use of tap water for immunocompromised patients and those
with swallowing problems remains essential. To achieve a more precise
estimate of the epidemiological situation in hospital water systems the
results of expensive mandatory water tests should be collected and
evaluated in a nationwide database instead of vanishing in the archives
of local health authorities.
Table 1. Overview of positive samples and measures taken at different
hospitals
Hosp First sample Measures taken Second sample p
(pos/total) a b c d e (pos/total)
1 2/9 yes yes 2/9 1.0
2 1/3 yes 1/1 0.4
3 3/3 yes 1/1 n/a
4 12/12 yes yes yes 6/6 n/a
5 0/4 0/6 n/a
6 4/7 0/10 0.04
7 1/4 0/6 0.33
8 2/2 0/2 0.14
9 2/10 yes yes yes 2/4 0.28
10 1/12 yes 0/17 0.37
11 1/1 1/1 1.0
12 5/6 yes 15/21 0.56
13 1/13 yes yes 0/13 0.48
14 5/11 yes 4/9 0.96
15 5/12 yes 3/12 0.39
16 3/18 yes yes yes yes n/a n/a
17 18/32 yes 20/32 0.61
18 8/34 yes 9/36 0.89
19 2/5 yes yes yes 1/11 0.17
20 2/6 yes yes yes yes 0/6 0.24
21 1/9 6/9 0.03
22 1/5 yes 1/4 0.86
23 0/7 1/8 0.52
24 4/4 yes yes yes yes 6/6 n/a
25 2/2 yes yes 6/6 n/a
26 4/9 yes 2/9 0.32
27 2/16 1/16 0.55
28 2/4 4/4 0.21
Total 94/260 92/265 0.73
Measures: (a) Technical check of the water system; (b) periodical heating
of complete system; (c) constant increase of temperature above 60ºC;
(d) single heating cycle of complete system plus ﬂushing of all taps;
(e) addition of chlorine or chlorine dioxide. n/a, not available. All
p-values calculated with Student’s t-test.
P862 Distribution of environmental L. pneumophila sg.1 strains
with heterogeneous chlorine-susceptibility patterns inside
hospital plumbing system
B. Casini, A. Baggiani, F. Torracca, F. Battisti, P. Valentini,
G. Privitera ° (Pisa, IT)
Objectives: To describe the distribution of Legionella strains and their
evolution during the application of a ﬁve-year Water Safety Plan (WSP)
in a university hospital based on a disinfection-ﬁltration strategy.
Methods: Between March 2002 and June 2008, 224 out of 698 water
samples were positive for Legionella spp.; 91 strains were selected
on temporal and spatial criteria and were analysed applying both
the comparison of the nucleotide sequences of six genes by SBT
or the comparison of the genomic proﬁle by PFGE. The chlorine-
susceptibility of representative isolates was assessed according to the
BS EN 1040:1997. Feasibility of a rapid assessment of chlorine-
susceptibility using quantitative ATP detection was also evaluated.
Results: The majority of the isolates belonged to Legionella pneu-
mophila serogroup 1. Molecular typing indicated the presence of three
prevalent types of L. pneumophila Wadsworth (Type 1: 28/91. Type 2:
51/91. Type 3: 2/91) with different chlorine susceptibility. Type 1 and
2 were pre-existing chlorination, Type 1 being initially predominating,
while Type 2 became widespread over the years. Type 3 was isolated
only occasionally. Type 2 was fully susceptible to chlorine, while Type 1
and 3 were chlorine-tolerant. Following exposure to chlorine, ATP levels
correlated well with the measured number of viable cells of the three
Types, but the luminescence signals were signiﬁcantly decreased only
for Type 2, compared to untreated controls.
The WSP allowed to control the spread of Legionella spp. in the
hospital water distribution system by the adoption of an integrated
disinfection-ﬁltration strategy, presumably due to the application of ﬁlters
at those points-of-use where Type 1 persisted despite chlorination. The
predominance of Type 2 in the last period of environmental monitoring
could be explained either by the inability to obtain effective chlorine
concentration at every point of use or by the emergence of a resistant
Type 2 phenotype.
Conclusion: Standard environmental surveillance methods may not be
sufﬁcient to choose the most effective and efﬁcient water safety plan, and
should at least in some instances be accompanied by in vitro evaluation
of the susceptibility of the environmental isolates to the sanitising agent
considered.
P863 Use of soda fountains in hospitals: four-year surveillance of
daily routine
D. Luft, A. Conrad, R. Babikir, A. Neuwo¨hner, R. Scholz,
M. Schuhmacher, M. Dettenkofer ° (Freiburg, DE)
Objectives: Soda fountains (cooled and carbonated water produced
directly from the hospital tap water supply) are a convenient way to
provide patients, employees and visitors with drinking water. Use of
such devices can reduce required storage space, waste and transport-
related emissions compared to the classical supply with bottled mineral
water. However, microbial contamination of water from soda fountains
can occur and may pose a threat to immunocompromised patients. Fifty-
one soda fountains are currently in use at the University Medical Center
Freiburg and under continuous surveillance regarding microbial water
quality.
Methods: Water samples were obtained routinely after installation of
new soda fountains and twice a year thereafter. Microbiological results
were evaluated according to the German drinking water regulation
(GDWR). If the acceptable number of colony forming units (CFU) was
exceeded (>100CFU/ml at 22ºC; >20CFU/ml at 36ºC), water analysis
was repeated with a new sample. If a second sample was still positive,
or if pathogenic bacteria or high colony counts were detected in the 1st
sample, the fountain was put out of service until a negative sample was
obtained after mandated maintenance and disinfection.
Results: From 2004 to 2008, 358 water samples from 51 different soda
fountains were analysed. The mean number of samples per fountain
was 7 (1−15). 309 samples (86%) met the criteria of the GDWR, the
remaining 49 (14%) did not. Of the latter, 43 samples (88%) exceeded
the acceptable number of CFU, 5 samples (10%) were positive for
coliform bacteria (3) or P. aeruginosa (2), 1 sample (2%) was both
positive for coliforms and had excessive CFU counts. No enterococci or
E. coli were found. Additionally (not contained in GDWR) we identiﬁed
A. baumannii (2 samples), S. maltophilia (2) and yeast (1). The rate of
non-conform samples dropped steadily from 25% (16 out of 64) in 2004
to 3% (2 out of 77) in 2008.
Conclusions: State-of-the-art soda fountains are a feasible alternative
or addition to bottled mineral water. However, standard cleaning,
disinfection and maintenance procedures should be implemented to
ensure safe operation. Continuous surveillance should be performed to
identify deﬁcient fountains. Use of these devices in high-risk areas is
not recommended since pathogens found in our samples may endanger
immunocompromised patients. Replacing charcoal ﬁlters with particle
ﬁlters may have contributed to the decrease of non-conform samples.
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P864 Evaluation of bacterial contamination of patients using
ocular drops
M. Mehdinejad °, M. Feghhi, A.Z. Mahmoudabadi (Ahvaz, IR)
Objectives: The aim of the present study was to investigate the incidence
of bacterial contaminations of in-use eye drop products in the teaching
department of ophthalmology, Imam Khomeini Hospital, Ahvaz, Iran.
Methods: Two hundred and eighty seven eye drop bottles were randomly
collected at the end of day 1, day 2, day 3, day 4 and day 7 of use.
The eye drop residues, swabs from internal caps and droppers were
inoculated onto MacConkey agar and blood agar. The identiﬁcation of
the recovered organisms was accomplished using standard microbial
identiﬁcation techniques.
Results: The incidence of microbial contamination of in-use eye
drop products was 17.8%, with the highest rate (24.6%) and the
lowest rate (9.0%) noted with day 1 and day 3 samples, respectively.
The most contaminated part of the eye drop products was the caps
(45.9%) followed by droppers (41.0%) and residual contents (13.1%).
Considering mendicants contents, those with pilocarpine (41.7%) had the
highest rate of contamination followed by atropine (31.8%), tropicamide
(28.6%) and betamethasone (23.3%).
Conclusion: Our study revealed the potential risk of contamination
of in-use eye drop products in hospitals, but we did not ﬁnd a direct
relationship between usage duration and contamination rate.
P865 Horizontal transmission of group B streptococci in a
neonatal intensive care unit
A. Marigliano °, S. Savini, E. Manso, P. Barbadoro (Ancona, IT)
Group B Streptococcus (GBS) is a leading cause of life-threatening
infections (pneumonia, septicaemia, meningitis) in newborn infants and
it can result in death or long-term disabilities. Early onset disease
occurs within the ﬁrst week of life, with most cases appearing within
72 hours and it is normally related to vaginal carriage in the mother
and subsequent vertical transmission during birth. The cause of late
onset disease, occurring after the ﬁrst week of life, remains unclear:
pathogens may have originated from the maternal genital tract (vertically
transmitted), but also may come from contacts with human carriers or
nosocomial sources after birth (horizontally transmitted).
During a 20 days period (4−23 May 2008), two preterm newborn infants
(case nº2 and case nº3) developed late-onset neonatal GBS infection
while hospitalised by the Neonatal Intensive Care Unit (NICU) of the
Maternity Hospital “G.Salesi”, Ancona, Italy. The onset of these two
cases was preceded by a case of early-onset GBS neonatal disease
occurred in a baby hospitalised in the same ward with a culture proven
GBS sepsis (case nº1 − supposed index case).
Objective: to assess the possible cross contamination within the NICU
Methods: to deﬁne the clonal relatedness of the three GBS strains
isolated from the blood of the three babies with GBS sepsis, we
used pulsed-ﬁeld gel electrophoresis (PFGE): DNA was extracted and
digested with 40U of SmaI, the PFGE proﬁles of the isolates were
compared according to Tenover et al.’s criteria.
Results: The PFGE proﬁles of the isolates of cases nº2 and nº3 are
indistinguishable from each other, so that we can assume that these
strains are genetically and epidemiologically related. Further, we can
say that these strains are closely related to the supposed index case (case
nº1).
Conclusions: Even if it is not frequently reported, horizontal transmis-
sion of GBS can represent an actual risk for babies during hospitalisation.
These ﬁndings suggest us to perform further studies for identiﬁcation and
assessment of unexpected GBS infection cases.
P866 Faecal carriage of carbapenem resistance in Hong Kong
J. Ling, K.T. Wong, T. Ling ° (Hong Kong, HK)
Objectives: To document the prevalence of carbapenem-resistant
organisms in stool samples in Hong Kong.
Methods: All stool samples from patients of seven hospitals in Hong
Kong sent for routine bacterial culture during January to August 2008
were tested. Approximately 500mg of an undiluted stool sample were
spread onto a MacConkey agar plate and an imipenem disk (10mg)
was placed onto the primary inoculum. The agar plates were incubated
at 35ºC for 24 hours. Colonies growing around the imipenem disk were
picked and their susceptibility to imipenem was tested by a disk diffusion
method according to the Clinical and Laboratory Standards Institute
(CLSI). Microorganisms that were resistant were identiﬁed by the API
system. The minimal inhibitory concentration (MIC) of imipenem was
determined by a microbroth dilution method (CLSI). Escherichia coli
ATCC 25922 was used as a negative control and a clinical strain
previously conﬁrmed to be imipenem-resistant was used as a positive
control.
Results: A total of 3,138 stool samples from 2,894 patients were
examined. The age of the patients ranged from 1 day to 102 years and
the male to female ratio was 1:1.15.
A total of 53 (2%) strains that were imipenem-resistant and belonging
to six species were obtained with 37 (70% of the 53) being
Stenotrophomnas maltophilia. The others were Klebsiella pneumo-
niae (1), Acinetobacter baumannii (9), Pseudomonas aeruginosa (3),
Cedecea lapagei (2) and Aeromonas hydrophila (1). The MICs of
imipenem to these strains were 16–128mg/ml.
The K. pneumoniae strain was isolated from a patient who had an
imipenem-sensitive K. pneumoniae strain isolated from the sputum
previously. The A. baumannii strains were from long-term hospitalised
patients who had been on various b-lactams. The two Pseudomonas
aeruginosa strains were from patients who also had the strains in their
sputum or bile and had been on antibiotics that included b-lactams and
aminoglycosides. The Aeromonas hydrophila strain was from a patient
in the surgical ward after undergoing elective surgery. Both the two
Cedecea lapagei strains were from patients who were recently admitted
into the hospital.
Conclusions: Carriage of carbapenem-resistant organisms was uncom-
mon in Hong Kong. Continuous surveillance to monitor the development
of carbapenem-resistance especially in naturally carbapenem-susceptible
organisms should be carried out to prevent spread of the resistance.
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P867 Evaluation of a sonication protocol for the detection of
bacteria in retrieved osteosynthesis implants
J. Esteban °, J. Cordero-Ampuero, H. Adames, N.Z. Martı´n-de-Hijas,
A. Ortiz-Perez, R. Ferna´ndez-Roblas, E. Sandoval, E. Go´mez-Barrena
(Madrid, ES)
Objectives: To evaluate the usefulness of a sonication protocol to
detect the presence of bacteria in retrieved osteosynthesis implants from
patients with and without clinical infection.
Methods: A sonication protocol previously developed by us was used
in the experiment (Esteban J et al. J Clin Microbiol 2008; 46: 488–
492). The protocol includes both low-power sonication during 5 minutes,
centrifugation, the use of a broad spectrum of culture media (including
speciﬁc media for fungi and mycobacteria), and quantitative evaluation
of the results. Osteosynthesis implants were processed within 24 hours
from surgical removal. Clinical diagnosis of infection was performed
according internationally accepted schemes.
Results: Between July 2006 and November-2008, 63 samples from 47
patients (1.34 samples/patient) were processed. Samples included nails
(23 samples), plates (10 samples), groups of screws (19 samples) and
other osteosynthesis material (11 samples). 15 patients (21 samples) had
a clinical diagnosis of infection. Among these cases, 17 samples gave
positive results (77.3%). Bacteria isolated from these cases included
9 strains of S. aureus, 3 S. epidermidis, 2 Enterococcus sp., 2
S. intermedius, 1 S. maltophilia, 1 P. stuartii, 1 P. prevotii, and 3
cases with mixed anaerobic bacteria (>3 different species/sample). 8
cases had >1 isolates. Among the clinically non-infected patients (42
samples), 11 samples from 10 patients gave positive results (26.2%).
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Isolates included 1 Burkholderia sp., 2 M. fortuitum, 2 P. acnes (from
the same patient), 1 R. pickettii, 1 S. paucimobilis, 2 S. epidermidis, 2
S. aureus, 1 C. parapsilosis and 1 Micrococcus sp. Two samples had
>1 isolates. The average colony count was 69,927.08CFU/ml for the
samples from clinically infected patients (range: 50–100,000CFU/ml)
and 36,473.08CFU/ml for clinically non-infected patients (range: 50–
100,000CFU/ml), a statistically signiﬁcant difference (Student’s T,
p = 0.02).
Conclusions: The presented sonication protocol is a valuable tool
for the isolation of bacteria from retrieved osteosynthesis implants.
Patients without clinical infection can show higher counts of potentially
pathogenic bacteria, although the average count is signiﬁcatively lower
than the average count of the patients with clinical infection. The clinical
signiﬁcance of low pathogenic organisms is doubtful, but they may not be
considered as colonisation or contamination without further evaluations.
P868 Using of sonication of bone or removed orthopaedic
prostheses for diagnosis of infection after surgery
G. Ersoz °, M. Uguz, V. Oztuna (Mersin, TR)
Objectives: Culturing of samples of bone or removed orthopaedic
material is the standard method used for the microbiologic diagnosis
of osteomyelitis.. Yet, this method is neither sensitive nor speciﬁc.
Microorganisms are typically present in a bioﬁlm on the surface of
the prosthesis or bone. Trampoz et al recommended culture of samples
obtained by sonication of prostheses to dislodge from bioﬁlm or bone
surface. We hypothesized that using sonication for culturing of samples
obtained from bone or removed orthopaedic material would be more
sensitive for the microbiologic diagnosis of osteomyelitis.
Methods: Patients with osteomyelitis diagnosed clinically and/or
radiologically and underwent orthopaedic surgery for revisions or
resections were included in the study. We performed a prospective trial
to compare culturing of samples that were obtained peroperatively by
sonication of bone and/or prostheses with conventional culture of tissue.
Results: Fourteen patients (9 male and 5 female) were included. We
cultured ten bone samples, one bone graft and three prosthetic materials.
With the use of conventional microbiologic procedure, we deﬁned
osteomyelitis in four (28.6%) patients. With sonication, the ﬂuid cultures
were positive in ten patients (71.4%) (P = 0.031). Means of the colony
count numbers before and after sonication were 1000.00±1664.10 and
32357.29±35334.76 (P = 0.004), respectively. Counts as colony-forming
units (CFUs) and bacterial identiﬁcations were shown in the Table.
Before sonication, only one colony of methicillin-resistant coagulase-
negative staphylococci was isolated from one patient and evaluated as
contamination. But after sonication 50000CFUs of the same strain were
obtained from the same sample. All cases were cured successfully.
Table: CFU counts and bacterial identiﬁcations of isolates
Case no. Before sonication After sonication
1 3000CFUs Pseudomonas aeruginosa 50,000CFUs Pseudomonas aeruginosa
2 No growth 5000CFUs MSSA*
3 No growth 8000CFUs MSSA
4 40,000CFUs MRSA 100,000CFUs MRSA**
5 No growth No growth
6 1CFU MRCNS 50,000CFUs MRCNS***
7 30,000CFUs Pseudomonas aeruginosa 80,000CFUs Pseudomonas aeruginosa
8 No growth 30,000CFUs non-fermentative bacilli
9 40,000CFUs MRSA 70,000CFUs MRSA
10 No growth No growth
11 No growth No growth
12 No growth No growth
13 No growth 6000CFUs Pseudomonas aeruginosa and
Enterobacter spp.
14 No growth 2CFUs MRCNS
*Methicillin-sensitive Staphylococcus aureus.
**Methicillin-resistant Staphylococcus aureus.
***Methicillin-resistant coagulase-negative staphylococci.
Conclusions: For a better evaluation and approach to the diagnosis
of osteomyelitis, data should include clinical, microbiologic, and tissue
histopathological ﬁndings. Using of sonication technique for isolation of
agents of osteomyelitis from bone or other specimens that were obtained
peroperatively was more effective than conventional microbiological
methods.
P869 Sonication cultures of explanted components under supposed
prosthetic or implant infection
J. Holinka °, M. Pfeiffer, R. Kotz, A. Hirschl, W. Graninger, E. Presterl
(Vienna, AT)
Objectives: Microbial bioﬁlms growing adherently on prosthetic
surfaces may inhibit the detection of the pathogens causing prosthetic
joint infections. To evaluate the usefulness of sonication cultures in our
patients with prosthetic joint infections we investigated this promising
method, and compared the results to those of periprosthetic tissue
cultures and histology.
Methods: The sonication cultures of the explanted prosthesis were
cultured according to the protocol by Trampuz et al. in the New England
Journal of Medicin and using the routine method incubating the aspirated
pus and periprosthetic material in brain-heart-infusion broth without
sonication. To assess the most frequently affected component of the
prosthesis all components were “sono-cultured” separately. The diagnosis
of infection was based on the presence of bacteria or leucocytes in pus
or tissue plus local signs and symptoms and/or systemic markers of
inﬂammation (fever, leucocytosis, increased C-reactive protein)
Results:We investigated 60 patients with 41 septically and 19 aseptically
explanted components of total knee (n = 24), hip (n = 21) tumour (n = 6)
and shoulder (n = 2) endoprosthesis, as well as osteosynthetic material
(n = 6) and spinal instrumentation (n = 1). The most frequently affected
component of the hip prosthesis was the inlay and the cup with each 89%,
of the knee prosthesis was the polyethylen-inlay with 56%, of the tumour
prosthesis was the femur component with 43%, of the shoulder prosthesis
was the sphere and stem with 100%, of the osteosynthesis material were
the plate and screws with each 50% and of the spine instrumentation
were the rod and the screws each with 50%. From all detected pathogens
in sonication cultures the most frequently were Staphylococcus aureus
(29%), Staphylococcus epidermidis (25%) and Corynebacteria (7%).
The sensitivity of sonication cultures and periprosthetic tissue cultures
was 85% and 72% (p< 0.001) without preoperative antibiotic therapy
compared with histological analysis of 100% sensitivity. The speciﬁcity
was 89% for sonication cultures, 95% for periprosthetic tissue cultures
and 100% for histological analysis.
Conclusion: Our results of separating the explanted components for
sonication culture proved the detection of valid pathogens for every kind
of endoprosthesis or implants and supplied further information for the
focus of infection.
P870 Percutaneous bedside bone biopsy coupled with gallium
SPECT-CT in suspected diabetic foot osteitis: a pilot study
E. Aslangul °, J. M’Bemba, N. Caillat-Vigneron, S. Coignard,
A. Braun-Mauger, A. Sola, C. Boitard, C. Le Jeunne (Paris, FR)
Objectives: Diagnosing diabetic osteitis might be difﬁcult as it shares
with osteoarthropathy the same clinical and radiological inﬂammatory
features. We have evaluated the association of gallium SPECT-CTs and
percutaneous bone biopsies to diagnose osteitis in a diabetic foot clinic.
Methods: In a pilot prospective monocentric study, all patients suspected
of foot osteitis underwent a gallium SPECT-CT scan (Single Photon
Emission Computed Tomography-Computer Tomography), to precisely
spot the suspected infection, and apercutaneous bone biopsy performed
during the consultation.
Results: From may 2007 to november 2008, 36 diabetic patients
suspected of osteitis (because of chronic foot ulcer) were enrolled.
They all had a gallium SPECT-CT scan to detect an inﬂammatory bone
lesion in regard of the skin ulceration evocative of osteitis. Five patients
(14%) did not demonstrate any inﬂammatory bone ﬁxation, so therefore
no biopsy was performed. The other 31 patients demonstrated a bone
gallium ﬁxation next to the chronic skin ulcer. A bone punction with
a Mallarme´ needle was performed. Bone aspiration was inoculated in
Bactec® haemoculture aerobic and anaerobic bottles.
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Three out of 36 punctions were excluded because antibiotics were
started before the punction. Fourteen punctions (42%) were negative
with a good 3 months outcome without antibiotics. Nineteen punctions
(58%) were positive: one Streptococcus, twelve coagulase negative
Staphylococcus and six Staphylococcus aureus (three MRSA). All
cultures were monomicrobic and positive within the ﬁrst 24 hours. All
patients with positive bone cultures received antibiotics adapted to the
sensitivity for 8 weeks (including oﬂoxacin, rifampicin, linezolid), and
were evaluated at least three months after. They all were improved with
no local inﬂammatory signs, nor tomographic spoting when available.
Conclusion: The coupled procedure, gallium SPECT-CT scan-bone
aspiration with Mallarme´ needle is efﬁcient to diagnose bone osteitis in
diabetic feet. Gallium SPECT-CT scan provides a functional and exact
imaging of bone inﬂammation when punction isolates the responsible
micro-organism in case of infection. The main interest remains a bedside
procedure after imaging. Coagulase negative Staphylococcus seems to be
the most frequent germ found in diabetic osteitis.
P871 Comparison of Copan eSwab with Copan Venturi
Transystem for the quantative survival of Escherichia coli,
Streptococcus agalactiae and Candida albicans
S. Nys °, S. Vijgen, K. Magerman, R. Cartuyvels (Hasselt, BE)
Objectives: Swab transport systems should preserve the viability
and stability of microorganisms in clinical specimens throughout the
transport and storage process. In this study, eSwab, a new nylon-ﬂocked
swab in modiﬁed liquid Amies transport medium specially designed
to optimise specimen collection and to minimise entrapment of the
microorganisms, was compared with an Amies agar swab system for
the quantitative survival of Escherichia coli, Streptococcus agalactiae
and Candida albicans.
Methods: The quantitative elution method, as described in the CLSI
document M40-A, was used to evaluate the performance of the eSwab
(Copan, 480CE) and the Copan Venturi Transystem (CVT, Copan,
108C.USE) in the maintenance of E. coli (ATTC 25922), S. agalactiae
(ATCC 13813) and C. albicans (ATCC 90028) after 0, 6, 24 and
48 hours preservation at 4ºC. Also different concentrations of E. coli
and S. agalactiae (9:1, 7:3, 5:5, 3:7 and 1:9) were tested.
Results: The average colony forming unit count was for both E. coli
and S. agalactiae more than one log higher for the eSwab as compared
to the CVT after 6 to 48 hours at 4ºC. The recuperation when using
the eSwab resulted in a similar colony count compared to the control
experiment.
For the combinations of E. coli and S. agalactiae, the eSwab performed
overall better compared to the CVT. In the 9:1 ratio after 24 hours at 4ºC
no S. agalactiae could be cultured from the CVT, whereas the colony
count for the eSwab remained stable throughout the experiment (0 to
48 hours at 4ºC). E. coli colony counts were for the eSwab also ~1 log
higher for all time points tested. For the E. coli and S. agalactiae ratio
of 1:9 similar results were found as for both strains separately.
For C. albicans no signiﬁcant differences in the performance of both
transport systems were detected. The colony counts of both systems
were also similar to that of the control experiment.
Conclusion: The eSwab transport system showed overall a similar
or even better recovery of all microorganisms tested. Furthermore,
preservation of the eSwab for 48 hours at 4ºC had no inﬂuence on the
results of the colony counts. Also, E. coli showed hardly any proliferation
after 48 hours conservation in the eSwab transport system.
P872 Copan ESwab, the ﬁrst liquid-based microbiology device,
preserves microbial viability up to 96/120 hours
A. Giambra °, S. Castriciano, R. Paroni (Brescia, IT)
Objectives: Although it is recommended that swabs specimens should be
processed soon after collection, delays are occurring due to microbiology
laboratory consolidation. Specimens transport to centralised laboratories
results in long storage times, samples accumulation and increasing
workload. Therefore the use of a preservation medium that supports
microbial viability for prolonged storage time is necessary. ESwab (ES),
a high release ﬂocked swab combined with one ml of liquid Amies
medium, is the ﬁrst liquid based microbiology (LBM) collection and
preservation system that provides a homogeneous specimen suspension
and allows multiple testing from the same original sample. The objective
of the study was to compare the ability of ES to Amies Agar Gel
Transystem (TS) to maintain the viability of a panel of microorganisms
for an extended period of time.
Method: A panel of ATCC microorganism strains, representative
of different body sites infections, was tested. P. anaerobius (PA),
S. pneumoniae (SP), B. fragilis (BF), H. inﬂuenzae (HI) were selected for
the respiratory system; VRE for the gastrointestinal system; S. pyogenes
(SPY), P. acnes (PAC) for the skin membrane system; C. albicans
(CA), for the genital tract system; MRSA for multi-site infections.
Each strain was serially titrated and each swab was loaded with 100uL
inoculum, to obtain 300–500CFU from each time zero (T0) plate. After
inoculation, the swabs were held at room temperature (RT) for the ﬁrst
24 h, refrigerated for the following 72/96 h and plated every 24 h.
Results: Colonies count was recorded for each strain for all storage
times. HI in ES was viable up to 120 h but negative in TS. SP, BF, SPY,
PA and PAC were stable at 120 h in ES; one log reduction was found
for SP at 48 h, for BF, SPY and PA at 96 h in TS. CA, MRSA and VRE
were stable up to 120 h in both devices, but TS had one log reduction.
Testing of additional 10 microorganisms is in progress and results will
be reported later.
In some cases at T0, recovery rate of ES was up to 20% higher than TS.
Conclusion: ES was superior to TS in maintaining bacterial viability
for longer time and had a higher colonies count than the TS. The ES
with its ability to maintain the original microbial load up to 96/120 h
can be used for the collection of clinical specimens that require longer
processing time, multiple testing and results conﬁrmations.
P873 Gram-stain by a new specimen collection system: ESwab
C. Fontana °, M. Favaro, D. Limongi, J. Pivonkova, C. Favalli (Rome, IT)
Objectives: The ﬁrst step in routine microbiology laboratory procedures
is the collection and safe transportation of swab samples. This can be
accomplished using the Copan ESwab Collection and Transport System
which incorporates a ﬂocked swab with a tube of modiﬁed Liquid Amies
transporting medium. Aim of the present study was to compare the Gram
stain exam results of smears prepared from clinical specimens collected
and transported in the ESwab with those obtained using Amies Agar Gel
without charcoal Transystem.
Methods: A total of 80 samples (32 vaginal swabs, 27 cervical swabs,
11 urethral swabs and 10 wound swabs) were collected and examined
by Gram-stain. Two swabs were collected from each patient, one using
the conventional Amies Gel WO/C Transystem (Copan Italia), the other
using ESwab (Copan Italia). Once a swab sample is collected, it was
placed immediately into the ESwab transport tube and transported
directly to the laboratory. For each specimen two set of slides were
prepared: the ﬁrst using 100 microliters of Amies medium, the second
using 50 microliters. Both ESwab-slides were Gram stained using an
automated Gram stainer. The microscopic examination results of the
ESwab-slides were compared with those obtained by the observation of
the slides (one for each sample collected) prepared directly at the time
of the sample collection (using Transystem).
Results: Microscopic examination of 240 slides from 80 different
specimens evidenced that the quality of smear preparation from
ESwab-slides are superior to that obtained from conventional specimen
collection system. Particularly, those prepared using 100 microliters of
ESwab medium evidenced more details either concerning the amount of
cellular elements (epithelial cell and leucocytes as well as red blood cells
and clue cells) or bacteria/fungi elements. Moreover the slides prepared
from ESwab exhibits a very good preservation of cellular elements. The
micro-organism elements that are more frequently observed in ESwab
slide and not in traditional slide are: yeasts, Gram-negative bacilli and
Gram-positive diplococci.
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Conclusion: The ﬂocked swab of the ESwab kit demonstrated superior
absorption and release abilities of sampled material in the medium
as evidenced by the signiﬁcantly higher counts of cellular as well
as microbial elements evidenced on the slide preparations. Herein
microscopic exam performed using ESwab, especially when preparing
the slides with 100 microl, shows excellent results.
P874 Evaluation of Sysmex UF1000i, a novel high-performance
and high-throughput third-generation ﬂow-cytometry
screening method for the exclusion of urinary tract infection
R. De Rosa, M. Avolio, S. Grosso, G. Bruschetta, A. Camporese °
(Pordenone, IT)
Objectives: Urinary tract infections (UTI) are the infectious diseases
with the highest incidence in the hospital and community population.
Although the incidence of UTI is high, a large proportion of the samples
tested by a routine microbiology laboratory will show no evidence of
infection with up of the 80% of the specimens with negative results for
urine culture. Therefore a rapid and reliable screening method is useful
to screen out negative samples, reducing unnecessary testing.
Methods: The Sysmex UF-1000i is a fully automated third-generation
ﬂow cytometry analyzer now able to better determine bacterial values
with the development of a reagent system which exclusively stains
bacteria. Our study investigated 1,298 urine samples collected from
inpatients and outpatients and compared Sysmex UF1000i with standard
urine culture tested on Cled and CNA agar plated by means of
10microliter loop.
Results: The results obtained are very interesting, especially if UF1000i
is used as a screening method for negative urine samples, and
comparable to data obtained from culture examination. Considering
together bacteria/yeasts and/or leukocyte count (>200 bacteria, >30
yeasts and/or >100 leukocytes/microliter) in comparison with the
standard culture method, diagnostic performances for Sysmex UF-1000i
were: sensitivity 98.7, speciﬁcity 76.9, negative predictive value 99.5,
positive predictive value 59.7.
Conclusion: The results of the present study allowed us to improve the
efﬁciency and effectiveness of the whole diagnostic process on urine
samples submitted for microbiological investigation. The high negative
predictive value (99.5) and the low percentage of false negatives (less
than 0.3% of the total samples analyzed), both absolutely fundamental
to guarantee the diagnostic efﬁcacy of the screening process, allow us to
claim that the Sysmex UF-1000i is able to reach the diagnostic excellence
that we set out to obtain. From the management point of view, one of the
most interesting features that we have experienced with Sysmex UF1000i
is its major contribution to improving the global turn around time, as
57.5% of samples can be reported as negatives within a few minutes of
the sample admission, and can be sent to the Laboratory Information
System for validation and subsequent immediate reporting in case of
negative results. For physicians this should mean prompt reporting of
normal samples and improvement in the quality of patient care.
P875 The Sysmex UF-1000i ﬂow cytometer as a means of reducing
urine cultures
J.L. Dı´az de Tuesta, D. Sua´rez °, J. Sa´nchez, Y. Martı´n, R. Cisterna
(Bilbao, ES)
Objectives: The gold standard method for diagnosis of urinary tract
infection is semiquantitative urine culture, although fewer than 30
percent of urine samples sent to the laboratory are proven positive. Thus,
a rapid screening method is required to reduce these time-consuming and
expensive procedures. The aim of this study was to evaluate the Sysmex
UF-1000i ﬂow cytometer (Sysmex Corporation, Kobe, Japan) as a means
of reducing the number of urine samples requiring culture.
Methods: A total of 786 urine samples from general practice patients and
represented all age groups were collected and analyzed for white blood
cells (WBC) and bacteria by the UF1000i ﬂow cytometer (Sysmex).
Semiquantitative culture was performed on a culture plate of Chromagar
Orientation medium (Becton Dickinson) using a standard 1 uL loop
and incubated overnight at 37ºC in air. Culture results were reported
as no growth; urine contaminated if there were 3 or more kinds of
colonies without a dominant species; and were considered positive if they
contained 105 or 104 to <105 colony-forming units/mL (cfu/mL) of an
urinary pathogen of pure culture, if two or more potentially pathological
bacterial species were isolated when the individual counts were 104 cfu,
or when the count for one organism was  104 cfu/mL and it was clearly
predominant. The microorganisms isolated were identiﬁed and antibiotic
sensitivities were determined.
Results: Table 1 shows the results of the Sysmex UF-1000i ﬂow
cytometer test using 20 WBC/ul and 25 bacteria/ul count as the cutt-
off compared with bacterial culture.
Table 1.
Culture positive/sysmex positive 149
Culture negative/sysmex positive 339
Culture positive/sysmex negative 10
Culture negative/sysmex negative 288
Sensitivity 94
Speciﬁcity 46
Positive predictive value 30
Negative predictive value 96
Urine samples selected for culture (%) 488 (62%)
Conclusions:
1. These cutt-off values for bacteria and WBC give an acceptable
Negative Predictive value (96%) and allow for the reporting of
negative results without culture being performed, reducing the urine
cultures by 38%.
2. This reduces the turnaround times for these samples from 24 h to
same-day reporting.
3. A result extremely pathological of the cytometer in a sample with
a bacterial culture negative suggests a repetition of the analysis or
an enlargement of the study towards other feasible pathogens no
detectable through standard bacterial culture.
P876 Evaluation of three diagnosis models for differentiating
bacterial from viral meningitis
V. Cocquerelle, C. Fossard, L. Souply, L. Croce, B. Jaulhac,
F. Schramm, J.P. Gut, S. Faﬁ-Kremer, P. Riegel ° (Strasbourg, FR)
Objective: Evaluation of diagnosis models for differentiating bacterial
meningitis (BM) from viral meningitis (VM): three models in a
population of children and one model in a population of adult patients.
Methods: Retrospective study design. Analysis of a consecutive series
of 102 patients (42 adult patients and 60 children under 15 y) with a
diagnosis of community-acquired meningitis in the period from 2006
to November 2008. The diagnosis was based on direct Gram stain,
cerebrospinal ﬂuid (CSF) culture, blood culture, CSF antigen or CSF
PCR for BM and on CSF PCR for VM. For adults, we evaluated the Hoen
model or pABM (Hoen et al. EJCMID. 1995: 252−4). For children, this
pABM model was also proposed (Jaeger et al. EJCMID. 2000. 418−21)
and we evaluated it in comparison with the “Bacterial Meningitis Score”
(Nigrovic et al. JAMA. 2007. 52−60) and with the De Cauwer score (De
Cauwer et al. Eur. J. Emerg. Med. 2007. 343−7)
Results and Conclusions: For adults, the pathogens were N. meningitidis
(n = 11), S. pneumoniae (15), L. monocytogenes (3), H. inﬂuenzae (1),
enterovirus (5) and other virus (22). For children, the pathogens were
N. meningitidis (8), S. pneumoniae (2), enterovirus (29) and other
virus (3).
Routine analyses cannot be used alone to distinguish between BM and
VM: CRP> 4mg/l (Sensitivity for adults/children: 100/99, Speciﬁcity
for adults/children:33/22), CSF protein >0.45 g/l (Se:97/80 Sp:32/75),
CSF leucocytes >10/mm3 with >50% of PMN (Se:83/90, Sp:100/62),
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ratio CSF glucose/serum glucose <0.5 (Se:93/60, Sp:79/93). All the
cases but one exhibited at least one abnormal result for theses analyses.
Use of the pABM in adults can distinguish 19 of 25 patients with VM
from BM and allowed to predict BM with 100% accuracy (true positives)
and 24% false positives (Se: 100%, Sp: 76%). In contrast, the pABM
used in the population of children exhibited only 80% speciﬁcity (2 false
negatives in patients of 2 and 3 y). The sensitivity of the BMS and the De
Cauwer score for cases of BM in children was 100% and the speciﬁcity
was 62.5% and 47%, respectively. It is noteworthy that one case of BM
was detected by assigning the BMS on the basis of a positive Gram stain
alone. The pABM is quite reliable for differentiating between BM and
VM in adults but not in children. The BMS and the De Cauwer score
could be an accurate decision-making tool, ensuring 100% accuracy and
limiting the treatment with antibiotics in our population of children.
P877 BacT/Alert automated blood culture system for culturing
sterile body ﬂuids and deep site abscesses
A. Christidou °, Z. Gkiti, S. Kanaki, S. Maraki (Heraklion, GR)
Objectives: This study compared the BacT/Alert automated blood
culture system (Biomerieux) with the conventional culture method for
recovery of microorganisms from sterile body ﬂuids and deep site
abscesses.
Material and Methods: Sterile body ﬂuids (pleural, peritoneal,
synovial, CSF), or deep site abscesses were cultured using both methods
(BacT/Alert system and conventional method). For BacT/Alert system,
a pair of an aerobic and an anaerobic bottle was used. For conventional
method, the specimens were centrifuged at 3000rpm for 15min and
inoculated on blood agar and chocolate agar plates, and in Schaedler
broth.
Results: A total of 225 specimens (41 peritoneal, 34 pleural, 25 synovial,
1 cerebrospinal ﬂuids, and 124 deep site abscesses) were cultured and
137 pathogens were recovered from 104 specimens. Among the 104
positive specimens, microbial growth was detected with both methods
in 71 (68%) specimens, with only the BacT/Alert system in 29 (28%),
and with only conventional method in 4 (4%). Of the 137 isolates, 71
(52%) were recovered by both methods, 50 (36%) by BacT/Alert only,
and 16 (12%) by conventional method only.
Polymicrobial growth was detected in 21 specimens and 59 strains
were isolated from these specimens. Among them, 21 (36%) were
detected by both methods, 26 (44%) by BacT/Alert only, and 12
(20%) by conventional method only. Regarding the isolates, 21% (4/15)
of S. aureus, 30% (11/37) of coagulase negative staphylococci, 31%
(5/16) of enterococci, 68% (13/19) of streptococci, 31% (9/29) of
Gram negative bacteria, and 57% (4/7) of anaerobes were detected by
BacT/Alert system only, versus 0%, 5% (2/37), 12.5% (2/16), 10.5%
(2/19), 21% (6/29), and 29% (2/7) respectevely, that were detected by
conventional method only.
Conclusion: BacT/Alert blood culture system was more sensitive
than conventional method for detecting bacterial growth and recovery
of pathogens, especially in staphylococcal, streptococcal species, and
anaerobic bacteria.
BacT/Alert system alone, or in combination with conventional method
can successfully be used in culturing sterile body ﬂuids and deep site
abscesses.
P878 Liquid-based microbiology and automation: a new frontier
in the management of bacteriology laboratory
V. Grazioli °, A. Leuci, L. Deﬂorio (Milan, IT)
Objective: Bacteriology specimens have been historically inoculated
and streaked manually onto agar media. Some systems to perform
these tasks automatically are now available on the market. These
automations can process only liquid specimens. Copan Italia (Copan)
has developed a range of collection and transport devices that provide
the lab (and automation) with a liquid specimen − a new approach
called Liquid Based Microbiology (LBM). An automation called “Walk
Away Specimen Processor” (WASP, Copan) performs the inoculation and
streaking from a variety of bacteriology specimens (swabs, urine, faeces,
etc.), fully managing the opening/recapping of containers and plates-
labelling. Our laboratory is beta-testing site for the WASP and the LBM
range. We evaluated the quality of the culture results, when processed by
the WASP and manually; we report our experience in using the machine.
Methods: Six months prior the implementation of WASP we adopted
in our routine ESwab and Uriswab (both from Copan), replacing
the traditional collection and transport systems for vaginal swabs
(Transystem with gel) and urine (vacuum tubes with preservative).
ESwab comprises a ﬂocked swab and a tube with liquid Amies medium,
while Uriswab is a container incorporating a sponge bonded with
preservatives and a tube; both devices allow manual as well as automatic
processing from just one specimen collected.
WASP was installed on 29/10/2008 and used to process vaginal swabs
and urine. For one month clinical specimens were processed manually
and automatically, and results compared, for 832 ESwabs and 1,378
Uriswabs. WASP was evaluated in terms of throughput, reliability,
reproducibility; consistency with the results from manual processing was
analysed.
Results: The quality of the plates processed automatically is equivalent
or superior to those obtained manually. For vaginal swabs a signiﬁcant
improvement of isolation rate was found on the samples processed by
WASP: its quality of streaking is highly consistent and facilitates plate-
reading and subsequent tasks. The machine did not show failures and is
very easy to use. WASP full management of the process is faster than
operators and guarantees full traceability.
Conclusions: WASP fully processes bacteriology specimens with
minimal intervention from operators. The quality and consistency of
results using the automation is valuable. Lab technicians have more time
to perform other important tasks, generating signiﬁcant savings.
P879 Identiﬁcation of clinical isolates of Bacteroides by matrix-
assisted laser desorption/ionisation mass spectrometry
E. Urban, M. Kostrzewa, T. Maier, G. Terhes, E. Nagy ° on behalf
of ESGARAB
Objectives: Members of Bacteroides genus, are important anaerobic
pathogens causing sever mixed infections including peritonitis and
sepsis. Their correct identiﬁcation is necessary as resistance to different
anti-anaerobic drugs may differ according to the species. As phenotypic
identiﬁcation of anaerobes is difﬁcult, a new approach, the matrix-
assisted laser desorption/ionisation mass spectrometry (MALDI-TOF
MS) method was evaluated.
Methods: 424 clinical isolates of Bacteroides genus, collected from
8 European countries for antibiotic resistance determination, were
identiﬁed by MALDI-TOF MS using the Microﬂex LT instrument
and the data processing was performed by the BiotyperTM 2.0
software (Bruker Daltonics, Germany). Mass spectra of each isolate
were compared with the mass spectra of 3260 references available.
The phenotypic identiﬁcation for 277 isolates was carried out by
classical biochemical tests and by rapid ID32A(ATB) and API20(ANA)
(BioMerieux) and was used as reference. 16S rRNA gene sequencing
was carried out for a selection of the strains which gave discrepant
results and for all those which gave inconclusive identiﬁcation with the
MALDI-TOF. The spectra of sequenced species missing from the data
base were added and used for the further identiﬁcation. For 147 isolates
the phenotypic identiﬁcation was carried out only on the genus level and
species identiﬁcation was carried out by MALDI-TOF.
Results: During the ﬁrst part of the study out of 277 isolates 270 (97.5%)
were unequivocally identiﬁed [log(score) 2.0]. Of the 23 isolates
whose MALDI-TOF species identiﬁcation differed from the phenotypic
identiﬁcation 11, were sequenced The sequencing data conﬁrmed the
MALDI-TOF result in 10 cases, for one isolate the sequencing did not
lead to species determination. Sequencing those 7 isolates, which gave
inconclusive identiﬁcation with MALDI-TOF, revealed species missing
from the present data base, such as P. distasonis, and P. goldsteinii. In the
second part of the study 147 Bacteroides isolates were identiﬁed blindly
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by MALDI-TOF. 145 could be identiﬁed on species level using the
extended database. There were only 2 isolates, which gave inconclusive
identiﬁcation.
Conclusion: MALDI-TOF MS represents a promising tool for rapid
identiﬁcation of Bacteroides strains including newly recognised species
and the discriminatory power and identiﬁcation accuracy of its proved
superior to biochemical testing for B. thetaiotaomicron, B. ovatus and
B. uniformis.
P880 Identiﬁcation of members of the Bacteroides fragilis group
by mass-spectrometric discrimination
R. Schaumann °, K. Losensky, C.S. Stingu, G.H. Genzel,
W. Schellenberger, A.C. Rodloff, K. Eschrich (Leipzig, DE)
Objectives: A major part of the human colonic ﬂora consists of the
Bacteroides fragilis group. Members of the B. fragilis group, in particular
B. fragilis, are frequently involved in anaerobic or mixed aerobic
and anaerobic infections, such as intra-abdominal, gynaecological, and
bloodstream infections. These infections are responsible for high rates
of morbidity and mortality. The aim of the present study was to evaluate
the use of matrix-assisted laser desorption ionisation time-of-ﬂight mass
spectrometry (MALDI-TOF-MS) to identify members of the B. fragilis
group.
Methods: A total of 78 cultivated strains of the B. fragilis group
(B. caccae n = 9, B. distasonis n = 5, B. eggerthii n = 2, B. fragilis n = 10,
B. merdae n = 1, B. ovatus n = 10, B. stercoris n = 10, B. thetaiotaomicron
n = 10, B. uniformis n = 11, and B. vulgatus n = 10), including reference
strains and clinical isolates, were analyzed by MALDI-TOF-MS in
combination with methods of multivariate statistical analysis. The strains
were identiﬁed previously by biochemical reactions.
Results: The MALDI-TOF-MS analysis was able to discriminate rapidly
between the different members of the B. fragilis group and showed
identical and typical patterns on species level.
Conclusion: The results of the present study showed that MALDI-TOF-
MS might be used as a rapid method for identiﬁcation of cultivated
strains of the B. fragilis group. Thus, the MALDI-TOF-MS can serve as
a valuable tool for laboratory diagnosis of infections due to strains of
the B. fragilis group.
P881 Matrix-assisted laser desorption ionisation time of ﬂight
mass spectrometry is superior to biochemical identiﬁcation
in clinically important Staphylococcus species
F. Szabados °, M. Kaase, S. Gatermann (Bochum, DE)
Objectives: Recently Matrix assisted laser desorption ionisation time of
ﬂight mass spectrometry (MALDI-TOF MS) was introduced as a new
method for bacterial differentiation. The bacterial proteom in the range of
2 kDa to 20 kDa was measured and compared to a database (Biotyper 2.0,
Bruker). This method is straightforward, faster and cheaper compared
to other methods of bacterial differentiation. Nevertheless, the database
for the protein-proﬁles was not validated sufﬁciently, only little data was
published concerning clinical important strains.
The aim of this study was to evaluate the value of this new
differentiation-method, compared to the automated biochemical differ-
entiation (Vitek2-system, Biomerieux).
Staphylococcus lugdunensis is an uncommon species of coagulase-
negative Staphylococcus (CoNS) and can cause serious invasive
infections such as osteomyelitis and infective endocarditis just as
S. aureus. Biochemical identiﬁcation of Staphylococcus lugdunensis is
challanging, because some strains morphologically resemble S. aureus,
and further tests are required (e.a. ornithin decarboxylase [ODC],
pyrrolidonyl arylamidase [PYR]).
Methods: The species differentiation of 215 clinical isolates of S. aureus
(70 methicillin suseptible and 105 methicillin resistant, 39 methicillin
suseptible and pantone valentine leukocidin toxine (PVL) positive
S. aureus isolates) and 110 clinical isolates of S. lugdunensis were
re-examined with MALDI-TOF-MS and results were compared to a
combined gold-standard (automated biochemical differentiation (Vitek2-
system bioMerieux) and sodA sequencing for equivocal results).
Results: Bacterial differentiation of clinical important staphylococcus
isolates using MALDI-TOF MS is not only superior to biochemical
differentiation regarding analytical speciﬁcity, but also time to result
was reduced signiﬁcantly.
Conclusion: Bacterial differentiation of staphylococci using MALDI-
TOF MS technology is superior to biochemical tests. Further tests
have to show analytical equivalence of this database to molecular
biological methods. MALDI-TOF MS technology could be an excellent
compensation for the time consuming and expensive gold-standard
(sodA-sequencing, rpoB-sequencing or 16S sequencing).
P882 Identiﬁcation of bacteria and yeast by matrix-assisted
laser ionisation/desorption time-of-ﬂight mass spectrometry
(MALDI-TOF MS) in routine laboratory setting
S.Q. van Veen °, E.C.J. Claas, P. Dofferhoff, W.F. Rijnsburger,
A. Vredeveld, B. Theelen, E.J. Kuijper (Leiden, Utrecht, NL)
Objectives: Application of MALDI-TOF for microbial identiﬁcation and
comparison with standard biochemical and molecular identiﬁcation in a
routine laboratory
Methods: Ten clinical isolates were selected to test different sample
preparation methods: direct application, ethanol (75%) ﬁxation or
extraction (ethanol, formic acid, acetonitrile). Inﬂuences of various
culture media (blood-, chocolate-, CLED- and Sabouraoud’s agar) and
incubation conditions (time, O2 or CO2 concentrations and temperature)
were tested. Thirdly, 189 clinical isolates (30 different genera and 74
species) cultured at regular base in our laboratory, were identiﬁed by
both MALDI-TOF (duplicates) and routine identiﬁcation methods such
as VITEK-II, API and standard biochemical tests. Discrepancies were
further analyzed by molecular sequencing of 16S genes.
Results: Gram-negatives (n = 5) were correctly identiﬁed irrespective of
sample preparation method used, Gram-positives (n = 4) required direct
or extraction method and were poorly identiﬁed by ethanol ﬁxation, and
yeast (n = 1) required extraction. Culture medium as well as overnight,
4−8, 48 or 72 hours of incubation had no inﬂuence on accuracy of
identiﬁcation. There was no inﬂuence of incubation with O2 or CO2
nor of incubation temperature (4, 30 or 35 degrees Celsius). Of 189
clinical isolates, 179 (94.7%) were correctly identiﬁed to the genus level
by MALDI-TOF. Furthermore, 152 isolates (80.4%) had correct species
identiﬁcation. Four isolates (2.1%) could not be identiﬁed by MALDI-
TOF and six isolates (3.2%) had no uniform species identiﬁcation
between duplicates (Klebsiella planticola or K. oxytoca). There were no
incorrect identiﬁcations to the genus level. Nine (4.8%) had correct genus
identiﬁcation, but were misidentiﬁed by MALDI-TOF with a genetically
related species (Citrobacter koseri or C. murliniae), as determined by
16S analysis. Gram-positive cocci were most difﬁcult to identify to
species level with only 51 (69.9%) of 73 correct species identiﬁcations.
Yeast yielded most correct species (n = 7) identiﬁcations: 18 out of 19
(94.7%) strains.
Conclusion: MALDI-TOF MS can be applied easily without need
for special sample preparations, speciﬁc culture medium or incubation
conditions. Microbial identiﬁcation by MALDI-TOF has high accuracy
to genus level and acceptable accuracy to species level. Incorrect
identiﬁcations were rare and occurred only at the level of closely related
species, not at genus level.
P883 The performance of matrix-assisted laser desorption/
ionisation time of ﬂight mass spectrometry in the identiﬁca-
tion of Enterococcus faecalis and E. faecium in clinical isolates
G.H. Genzel °, R. Schaumann, W. Schellenberger, A.C. Rodloff,
K. Eschrich (Leipzig, DE)
Objectives: Enterococci are part of the human physiological intestinal
ﬂora, but gained an increasing relevance as a pathogen. Enteroccus
faecalis or E. faecium, the two species most frequently associated with
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human infections, demand a rapid identiﬁcation and could serve as a ﬁrst
hint towards an effective antibiotic therapy. We investigated the ability
of MALDI-TOF MS to distinguish the two species.
Methods: To create a reference mass spectra database, 10 strains of
E. faecalis and E. faecium including reference strains and clinical
isolates were used, respectively. The strains were identiﬁed previously
as E. faecalis and E. faecium by biochemical reactions. MICs were
determined by broth microdilution test. Subsequently, all strains were
analyzed by MALDI-TOF-MS. Peak lists derived from the mass spectra
were analyzed by different methods of multivariate statistical analysis.
For classiﬁcation of E. faecalis and E. faecium support vector machine
algorithms turned out to be most powerful. Thereafter, clinical isolates
of E. faecalis (n = 72) and E. faecium (n = 28) were analyzed by the
blindfolded MALDI-TOF-MS investigator.
Results: A reliable reference spectra database for the following
investigations was established with 10 strains of E. faecalis and
E. faecium, respectively. From the 100 blindfolded tested strains, the
system was able to distinguish 98 strains correctly, only 2 were
misidentiﬁed. All results were reproducible.
Conclusion: MALDI-TOF-MS has a excellent ability to distinguish
rapidly between E. faecalis and E. faecium and can therefore serve as a
valuable tool for laboratory diagnosis of Enterococci caused infection.
P884 MALDI-TOF MS-based identiﬁcation versus biochemical
test systems: a representative study with clinical
Enterobacteriaceae isolates
S. Engels-Schwarzlose, S. Burak °, M. Erhard, I. Streit, A. Gehrt
(Dusseldorf, Potsdam, DE)
Objectives: The identiﬁcation of pathogenic microorganisms in a clinical
laboratory is commonly based on species-speciﬁc biochemical growth
and reaction patterns. In contrast, Matrix-Assisted Laser Desorption
Ionisation/Time-of-Flight Mass Spectrometry (MALDI-TOF MS) offers
a new and promising approach to rapid identiﬁcation. To establish
this method in a routine laboratory, an evaluation study focused
on Enterobaceriaceae was performed. We compared the biochemical
identiﬁcation results of clinical Enterobacteriaceae isolates with the
results obtained by MALDI-TOF MS.
Methods: 816 Enterobacteriaceae isolates with at least 90% probability
of biochemical identiﬁcation by Phoenix (BD, Germany) or Micronaut
E (Merlin, Germany) were analysed by MALDI-TOF MS. Small
amounts of intact cells of a single colony were directly applied
onto the target plate, mixed with matrix solution and air dried.
Mass spectra were acquired using an AXIMA-LNR mass spectrometer
(Shimadzu, Germany) and analysed by the SARAMIS database tool
(AnagnosTec, Germany). In case of divergent results, biochemical and
MS identiﬁcation were repeated. If divergence continued, 16S rRNA
sequencing was performed.
Results: Concordant results of both identiﬁcation systems were obtained
with 686 strains (84.1%). 46 strains (5.6%) had divergent results of
MALDI-TOF MS and biochemical identiﬁcation. Further experiments
showed false biochemical identiﬁcation of 45 strains in the ﬁrst analysis
and still eight in the second one. Only one strain was misidentiﬁed in
the ﬁrst and second MS analysis. 10.3% (4.9%) of the isolates could
not be identiﬁed in the ﬁrst (second) analysis by MALDI-TOF MS. The
discrepancies between the ﬁrst and the second experiment seem to be
correlated with handling inaccuracies of both methods.
Conclusion: The great advantage of MALDI-TOF MS/SARAMIS
identiﬁcation of Enterobacteriaceae is the high validity with an error
ratio of only 0.12%. The proven robustness of the new method offers
the opportunity to facilitate the identiﬁcation of Enterobacteriaceae in
routine laboratories with high sample throughputs. The only incorrect
result in this study was corrected by database revision. Due to further
development of the SARAMIS database we expect signiﬁcantly higher
identiﬁcation ratios in the future. MALDI-TOF MS/SARAMIS is a new
and easily manageable technique of identiﬁcation of Enterobacteriaceae
with very high reliability.
P885 Development of an analytical method based on protein
proﬁling for the rapid identiﬁcation of Aspergillus spp. from
clinical samples by MALDI-TOF-MS Biotyper
L. Putignani °, L. Mancinelli, L. Dimiziani, C. Russo, L. Coltella,
T. Maier, D. Menichella (Rome, Macerata, IT; Leipzig, DE)
Objectives: Invasive mould infections are becoming more frequent,
resulting in signiﬁcant morbidity and mortality in children. Paediatric
populations are currently at high risk for fungal opportunistic infections
due to the high impact of changes in medical practice, intensive care and
organ transplantation practises. In our study, we enlarged the library of
the MALDI-ToF MS (Matrix-assisted laser description ionisation-time
of ﬂight-mass spectrometry) Biotyper with the aim to exploit proteome
proﬁling of Aspergillus spp. to provide an advanced and reliable method
for the identiﬁcation of Aspergillus species from clinical specimens.
Methods: Reference and clinical strains of ten Aspergillus species
were both purchased from the culture collection Centraalbureau voor
Schimmelcultures (CBS) and collected in our diagnostic unit to select
the most representative species isolated from clinical specimens. Medium
growth conditions and protein extraction protocols were optimised to
produce suitable template for MALDI-ToF MS analysis. Replicates
for each spectrum were collected for each species and analysed for
reproducibility. Finally eight overlapping spectra were selected for each
species and evaluated for variance by principal component clustering
and dendrogram analysis (PCA). Selected spectra were uploaded into
the library of the MALDI TOF-MS and added to the pre-existents to
perform identiﬁcation of fungal clinical specimens.
Results: The reference spectra of the Aspergillus species showed typical
MALDI-TOF-MS spectra with peaks between m/z 2000 and up to about
m/z 16,000. On visual inspection, the similarity of spectra produced by
different Aspergillus species could be recognized. Obvious differences
between spectra produced by the diverse species were also easily noticed.
The reproducibility of the method was proved by the high similarity
and PCA outcome of spectra belonging to the same species. Enlarged
dataset provided high matching scores (2.3−3.0 range) for Aspergillus
spp. identiﬁcation from clinical testing samples.
Conclusion: New proteome proﬁling-based assays for detection of
mould fungi may be an optimal diagnostic approach to overcome current
culture-based methods, encompass multiple fungal genera, and for being
applied to a variety of specimen types. In our experience, MALDI-ToF is
currently under setting and may represent a new frontier for the fast and
reliable management of fungal infections in paediatric high risk patients.
P886 Comparison of BioTyper and VITEK2 in identiﬁcation of
bacteria
E. Kalogeropoulou °, W. Solbach, J. Knobloch (Lubeck, DE)
Objective: MALDI-TOF mass spectrometry (MS) is a simple and
fast diagnostic method for the identiﬁcation and classiﬁcation of
microorganisms. We evaluated the performance of the BioTyperTM
system using two different sample preparations (direct smear and
Ethanol-formic acid extraction; EFAE) in comparison to the biochemical
identiﬁcation system VITEK2, for bacteria of the clinical microbiology
routine.
Methods: In a two-month period 1098 aerobical grown bacterial isolates
were obtained from clinical microbiology routine. Strains were cultured
on Columbia Blood agar (BioMerieux) and were tested by VITEK2 and
the two above mentioned applications of MALDI-TOF MS using the
BioTyperTM system in parallel. The results of MS identiﬁcation were
classiﬁed as “species identiﬁcation” (A) “genus identiﬁcation” (B) or
“no reliable identiﬁcation” (C) as given by the automated BioTyperTM
identiﬁcation system and were compared with the results of VITEK2.
Results: 6 (0.5%) were not identiﬁed by VITEK2. 32 (2.9%) displayed
discrepancy regarding the results of the two methods respectively
(PCR/Sequencing will be performed for these 38 isolates). The
classiﬁcation of direct smear/EFAE results (S/E) in A, B and C among the
most frequently Gram(+) and Gram(−) isolated species is the following:
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Staphylococcus aureus (n = 260, 24.5%): A (188/124), B (64/34),
C (8/88). Staphylococcus epidermidis (n = 67, 6.3%): A (44/25),
B (17/23), C (6/19). Enterococcus faecium (n = 42), 4%): A (31/34),
B (4/3), C (7/6). Enterococcus faecalis (n = 33, 3.1%) A (21/22),
B (10/6), C (2/5). Escherichia coli (n = 176, 16.6%): A (128/98),
B (24/10), C (24/65). Enterobacter cloacae (n = 55, 5.1%): A (40/10),
B (8/7), C (7/38). Klebsiella pneumoniae (n = 40, 3.8%): A (29/20),
B (4/8), C (9/11). Pseudomonas aeruginosa (n = 99, 9.3%): A (55/45),
B (18/21), C (26/33). Acinetobacter baumannii (n = 24, 2.3%): A (11/13),
B (3/2), C (10/9). Stenotrophomonas maltophilia (n = 24, 2.3): A (6/7),
B (7/4), C (11/13). Despite the classiﬁcation by the system all results
classiﬁed in B displayed the correct species and not only the genus.
Conclusions: Discrepancy of bacteria identiﬁcation between VITEK2
and MALDI-TOF is rare (2.9%). The incidence of no reliable
identiﬁcation regarding direct smear and EFAE preparations of the
samples is 15.5% and 31.7% respectively. However, only 3.9% of
samples remained without identiﬁcation by applying both direct smear
and EFAE. Modiﬁcation of the software will result in a higher number
of correct species identiﬁcation.
P887 New automated solution for plate streaking: comparative
evaluation of the PREVI Isola in a microbiology lab
G. Funke, T. Kunert, B. Barth, C. Fulchiron, G. Bossy ° (Ravensburg,
DE; La Balme-les-Grottes, FR)
Objectives: The study was performed in our routine clinical microbi-
ology laboratory to evaluate the PREVI Isola system in terms of time
saving and quality of the results compared to the routine manual method.
Methods: A total of 536 urine specimens, 385 faecal specimens, 137
wound swabs, 48 ENT swabs were included in the present study.
These samples were processed with the PREVI Isola and the current
manual method used in our laboratory.
The PREVI Isola is a new automated system able to perform the
inoculation and streaking of Prepoured Media (PPM) with liquid
microbiological samples.
According to the specimen type and data previously introduced in the
system, the instrument selects the media to inoculate, applies a radial
inoculum onto the agar plate, and performs circular streaking with a
disposable applicator.
The quality of the automated streaking (AS) was described as lower,
equivalent or higher to the manual streaking using two criteria:
a. Isolates must reﬂect the specimen’s microbiological status (polymi-
crobial sample, presence of pathogen),
b. Isolates must present enough isolated colonies to allow the required
identiﬁcation and susceptibility tests to be performed afterwards.
The time measurement was performed by two persons to record all the
steps needed from collection to plates streaking for the management of
urine samples for both methods.
Results: For urine samples, regarding the number of isolated, further
processable colonies, the PREVI Isola was superior to the manual
method.
For the faeces, the PREVI Isola was more sensitive than the manual
method by detecting 120 isolated colonies vs. 98 on Leifson agar and
77 vs. 66 on SS-agar, respectively.
For wound swabs, the PREVI Isola allowed a faster processing of the
cultured material than the manual method.
For both totally independently processed wound and ENT swabs, the
PREVI Isola was superior to the manual method in a relatively narrow
range from 54.5% to 66.7% for the main growth media and allowed a
faster processing of the cultured material than manual method.
The time measurement showed a saving time of up to 57% with PREVI
Isola compared to the manual method for the streaking of urines.
Conclusion: The PREVI Isola system seems to produce a higher number
of colonies suitable for further characterisation than the manual streaking
method. Further evaluations in clinical laboratories with larger numbers
of clinical specimens in order to prove the suitability of this new system
are needed.
P888 Usefulness and reproducibility of sputum Gram stain in
LRTIs
D. Papaventsis °, H. Moraitou, M. Makarona, S. Niki, F. Havouti,
S. Mytas, A. Georgousi, V. Spyropoulos (Athens, GR)
Objectives: Sputum Gram stain examination is a controversial rapid
diagnostic method for the presumptive identiﬁcation of pathogens
causing lower respiratory tract infections (LRTIs). The purpose of this
study was to evaluate the usefulness and reproducibility of sputum Gram
stain for diagnosis of community and hospital-acquired LRTIs.
Methods: One thousand eight hundred adult patients (1148 males, 652
females, mean age 64) hospitalised for pneumonia at Sotiria General
Hospital, Athens, Greece, were enrolled in the study. Two hundred
ﬁfty coded slides were randomly selected and prepared after sputum
homogenisation and Gram stain, and three experienced microbiologists
evaluated sputum quality. Samples of good quality were assessed for
a predominant morphotype. The sensitivity, speciﬁcity, positive and
negative predictive values of Gram stain compared to culture was
calculated. Intra-observer variation was assessed using the kappa statistic
(k).
Results: One hundred seventy slides (68%) were of good quality
and 150 (60%) showed a predominant morphotype. The calculated
sensitivity, speciﬁcity, positive and negative predictive value were very
similar between different observers; for Gram-positive cocci 64%, 42%,
41%, 64%, respectively; and for Gram-negative bacilli 44%, 78%,
87%, 30%, respectively. The sensitivity and speciﬁcity of the Gram-
positive diplococci identiﬁcation in the sputum culture of S. pneumoniae
were 35% and 96%, respectively, and the sensitivity and speciﬁcity of
the Gram negative coccobacilli identiﬁcation in the sputum culture of
H. inﬂuenzae were 16% and 96%, respectively. Inter-observer agreement
for the identiﬁcation of infected samples was good (k=0.65−0.75 for
squamous epithelial cells; k= 0.50−0.60 for neutrophils). Prediction of
Gram positive cocci infection showed the greatest agreement between
observers (k=0.45−0.85).
Conclusion: Sputum Gram stain has been proven useful in guiding
microbiological diagnosis of pneumonia in 60% of cases. Speciﬁcity
of Gram-negative bacilli, Gram-positive diplococci, and Gram-negative
coccobacilli identiﬁcation was very high. Sputum Gram slide interpre-
tation was reproducible and predictive of a positive culture.
P889 Performance of the PREVI™ colour Gram automated
staining system
H. de Montclos °, I. Verdier (Bourg-en-Bresse, FR)
Gram stain is a critical stage of the microbiological diagnosis. Even
though it is usually carried out manually, automation has become an
alternative. Bacteriologists used to the manual method may, however,
consider that automation allows to subtly adapt the decolorisation step
to the thickness of the smear.
Objectives: A study was performed to evaluate the performance of the
PREVI™ Color Gram system on pure strains and biological samples in
comparison with the manual staining method. This new system ensures
an automatic Gram staining of slides disposed on a carrousel. Dyes are
sprayed on slides during rotation.
Methods: Manual and automatic stainings were carried out in parallel.
Manual Gram stain was performed according to the conventional
procedure. The Gram staining on PREVI Color Gram system was
performed using the Decolorizer 2 and 3 programs. Slides were then
mixed and read by a trained bacteriologist not knowing the bacterial
identity and the staining type carried out on each slide.
The ﬁrst part of the study consisted of the staining of 40 reference
strains. Results were considered to be concordant when morphology,
arrangement and Gram reaction of bacteria were identical. The second
part of the study included 107 clinical specimens from various origins.
Smears were randomly attributed to the manual or the 2 automated
protocols. Preparations were considered to be concordant when the main
bacterial populations were found in equivalent proportions.
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Results: 321 preparations were compared, 8 of them were declared non
concordant, but not signiﬁcant as real discrepancies. These discrepancies
involved 4 samples and were due to:
a. insufﬁcient decolorisation by the manual technique,
b. washing out of the smear during manual staining,
c. difference in thickness of the smears in the case of a very mucoid
expectoration, and
d. staining problem which could not be allocated to one or the other of
the techniques.
The 2 automated protocols gave the same results.
The PREVI Color GRAM using the Decolorizer 3 provided 100% and
98% agreement with the manual method for reference strains and clinical
samples respectively. Discrepancies analysis was never in discredit of the
automatic technique.
Conclusion: Even using a manual standardised protocol, signiﬁcant
staining differences may persist between operators. The PREVI
Color GRAM system provides distinct and reproducible results, thus
contributing to stain standardisation, besides saving dyes and technician
time.
P890 The PREVI Isola system for automated streaking of patient
materials
E.A.E. Verhoef-Verhage °, A.P.J. van Boxtel, M. van de Wijdeven
(Utrecht, NL)
Introduction: The aim of this study was to assess the value of the PREVI
Isola (bioMerieux) in the routine diagnostic laboratory, combined with
a preliminary cost-beneﬁt analysis. This system uses a fully automated
technology that is able to process any material from patients (liquid
format) automatically. Different tube sizes can be used to collect patient’s
material and they can be loaded into the PREVI Isola. Disposable tips
and applicators inoculate different agar plates automatically. A touch
screen interfaces with a software program that contains the information
which plates should be inoculated for each clinical sample. The PREVI
Isola was introduced in our laboratory in December 2008 (Saltro) and
we decided to evaluate the technique by ﬁrst studying urine samples.
Methods: From 100 different patients with urinary tract infections, urine
samples (with a positive native slide) were processed manually and by
the PREVI Isola.
Results: After overnight incubation, all samples could be evaluated.
No signiﬁcant differences in bacterial count between both methods
could be detected. With PREVI Isola, individual colonies were easier to
distinguish than after manual inoculation. In general, colonies (especially
Proteus spp.) could be easier differentiated than after manual processing.
This new system is labour saving: only the samples need to be placed
in the machine. Inoculation and streaking are done automatically. We
estimated that for every 100 urine samples 1 h of manual work could be
saved.
Conclusions: PREVI Isola is a new technology that leads to better
readable results for urine samples. It saves labour time and therefore
costs. Because individual colonies were more frequently observed, sub
culturing and therefore identiﬁcation and susceptibility testing can in
some cases be done sooner. Also by introducing elective agar plates,
identiﬁcation could be done 24 hrs earlier. Further studies are needed
with different materials to obtain a deﬁnitive analysis of this method.
P891 Correlation of Sedimax® (Menarini) versus reverse light
microscopy for the examination of urine sediment
H. Devos, I. Mermans, H. Goossens, M. Ieven ° (Edegem, BE)
Objective: Automated analysis of insoluble urine components can
reduce the workload and hands on time of conventional microscopic
examination of urine sediment. Urinary ﬂow cytometry and automated
microscopic pattern recognition are two new techniques. The objective of
this study was to compare the reversed light microscopy (RLM) method
with the Sedimax® (Menarini), a fully automated urine analyser.
Method: Routine urine examination is done by RLM after sedimentation
of 60ml of sample in a multiwell plate. Leucocytes and erythocytes
are quantiﬁed. Bacteria, cellular and other elements are identiﬁed
qualitatively. Quantitative culture is performed on a Cystine-Lactose-
Electrolyte-Deﬁcient (CLED) plate. The Sedimax® was used according
to the instructions of the manufacturer. Both methods were compared on
782 consecutive routine samples during a 3 weeks period. All samples
were examined within 30 minutes by the two methods. Results for
leucocytes and erythrocytes were divided into classes based on their
number. A difference of one class was deﬁned as a minor deviation,
a difference of more than one class as a major deviation. A positive
signiﬁcant culture of >100CFU/ml was used as gold standard to evaluate
the Sedimax® and RLM interpretation of bacteruria.
Results: 698/782 (89.3%) urine specimens could be evaluated. Due
to some technical problems 4.1% of the samples were not examined
correctly by the Sedimax® and 7.5% of samples did not contain enough
urine.
Concordance for leuco- and erythrocytes between both methods was
respectively 73.1 and 82.8%; 26.9% of the urine samples showed major
disconcordances for white blood cells and 17.2% for red blood cells. In
most cases this is due to misinterpretation by the Sedimax® of other
elements present in the urine such as clumbed cells, amorph sediment,
crystals, epithelial cells. Using the manufacturer’s criteria for bacteruria,
concordance between the two methods was almost 73%. The Sedimax®
produced 4.3% false negative results and 26.1% false positives. This
may be caused by a too low cut off value for bacteria in the Sedimax®.
Instead the RLM reports only 5.9% false negative and 4% false positive
results.
Conclusion: In its current version, Sedimax® is not superior to our RLM
method in workload and hands on time.
Given the high number of disconcordance of white and red blood
cells, the Sedimax® can not be used in our laboratory without further
adjustments.
P892 In vitro effects of iodinated contrast agents on bacterial
growth
M.J. Bruins °, J.H. Zwiers, C.C.P.M. Verheyen, M.J.H.M. Wolfhagen
(Zwolle, NL)
Objectives: Injection of iodinated arthrographic contrast medium in
(artiﬁcial) joints (puncture arthrography) is used to diagnose infection or
aseptic loosening of arthroplasties. During this procedure synovial ﬂuid
is aspirated and submitted to the microbiology laboratory for culture.
Inevitably, contrast medium will be mixed into the sample. The fact
that iodine is used as a disinfectant has led to the assumption that
this will adversely affect culture results. Despite previous reports on
contrast media inhibiting bacterial growth, the role of iodine herein is
questionable. Contrary to free iodine, iodine in a bound state is not
bactericidal. Moreover, currently used media are iso-osmolar. In this
study, we assessed in vitro bacteriostatic and bactericidal properties of
iodinated contrast media.
Methods: The inﬂuence of three currently used media (Omnipaque®,
Visipaque®, Xenetix®) and two older media (Hexabrix®, Telebrix®)
on the growth of pathogens commonly isolated in prosthetic infections
was studied using well-deﬁned strains of Bacillus cereus, Candida
albicans (C. albicans), Corynebacterium jeikeium, Enterococcus faecalis
(E. faecalis), Escherichia coli (E. coli), Propionibacterium acnes,
Pseudomonas aeruginosa (P. aeruginosa), Staphylococcus aureus,
Staphylococcus epidermidis and Streptococcus pyogenes. Inhibition was
determined using a disk diffusion technique and a time-killing curve
method in which high (5×108 CFU/ml) and low (5×103 CFU/ml) inocula
were tested respectively. Colony counts were performed of freshly
prepared suspensions in contrast medium and a saline control and after
2 and 24 hours of incubation at 35ºC.
Results:With disk diffusion testing we found no inﬂuence on the growth
of micro-organisms of any of the media. In the high inoculum tests the
only, non-signiﬁcant, growth inhibition occurred with the combination
of Telebrix® and E. coli (1 log10, P = 0.07). In the low inoculum tests
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both E. coli and P. aeruginosa were inhibited by Telebrix® but not by
any other medium. For all other combinations there was no inhibition
compared to the saline control, except for some media and E. faecalis
and C. albicans. In these cases however, the percentage surviving cells
was always higher than 30%.
Conclusion: The effect of the dated medium Telebrix® on E. coli
and P. aeruginosa seems consistent with previous reports. There is no
evidence that currently used iodinated contrast media impede detection
of micro-organisms in synovial ﬂuid.
P893 Fever of unknown origin: differential diagnosis between
infectious and non-infectious causes
S.P. Efstathiou, A.V. Pefanis °, A.G. Tsiakou, I.I. Skeva, D.I. Tsioulos,
A.D. Achimastos, T.D. Mountokalakis (Athens, GR)
Objective: The aims of the present study were (a) to develop a simple
and reliable diagnostic model that could aid physicians to discriminate
between infectious and non-infectious causes of fever of unknown origin
(FUO), and (b) to evaluate the performance of the derived tool in an
independent database of subjects with FUO.
Methods: Participants were patients with classical FUO fulﬁlling the
modiﬁed criteria of Durack and Street. Data were prospectively gathered
in two distinct, observational phases: an internal developmental study
(from 1992 to 2000) and an external validation study (from 2001
to 2007). In the internal phase, 33 variables regarding each patient’s
demographic characteristics, history, symptoms, signs, and laboratory
proﬁle were recorded and considered in a logistic regression analysis
using the diagnosis of infection as dependent variable. In the external
phase, the model derived on the basis of the independent predictors of
diagnosis of infection was applied on the next consecutive subjects with
FUO and the respective discriminatory capacity was calculated.
Results: Data from 112 hospitalised individuals (mean age
56.5±11.2 years, 55% males, fever duration before admission
32.1±11.9 days) were analyzed in the internal study. The ﬁnal diagnoses
included infections, malignancies, non-infectious inﬂammatory diseases,
and miscellaneous conditions in 30.4%, 10.7%, 33% and 5.4% of
subjects, whereas 20.5% of cases remained undiagnosed. C-reactive
protein >60mg/L (odds ratio 6.0 [95% conﬁdence intervals 2.5, 9.8]),
eosinophils <40/mm3 (4.1 [2.0, 7.3]) and ferritin <500mg/L (2.5 [1.3,
5.2]) were independently associated with diagnosis of infection. Among
the 100 patients of the external study, the presence of  2 of the
above factors predicted infection with sensitivity, speciﬁcity, and positive
and negative predictive values of 91.4%, 92.3%, 86.5%, and 95.2%,
respectively. Thus, the overall discriminatory capacity of the model −
when the cut-off of 2 factors was used − corresponded to an area under
the curve (AUC) of 0.92 (95%CI 0.85, 0.98; p< 0.001), whereas the
respective AUC values of its three components were 0.75 for C-reactive
protein [95%CI 0.65, 0.86], 0.70 for eosinopenia [0.59, 0.80], and 0.68
for ferritin [0.57, 0.78]).
Conclusions: The combination of C-reactive protein, ferritin and
eosinophil count may be useful in discriminating infectious from non-
infectious causes in patients hospitalised for classical FUO.
P894 The diagnostic accuracy of endotracheal aspiration
and bronchoalveolar lavage in the diagnosis of
ventilator-associated pneumonia
H. Gedik °, M. Yahyaoglu, M. Fincanci (Istanbul, TR)
Objective: To assess the diagnostic accuracy of endotracheal aspiration
(ETA) and mini-non-bronchoscopic, protected bronchial lavage (mini-
BAL) in the established clinical diagnosis of VAP.
Design: Prospective observational study using ETA and mini-BAL
collected within 24 h.
Setting: This prospective study was conducted in a 11adult-bed surgical
ICU between August 2004 and August 2005.
Patients: Thirty-one patients hospitalised for more than 72 h, who were
mechanically ventilated and had a new or progressive lung inﬁltrate plus
at least two of the three clinical criteria for VAP
Interventions: Diagnostic threshold for ETA was considered
100,000 cfu/ml and for mini-BAL 1000 cfu/ml.
Results: Quantitative cultures of ETA and mini-BAL cultures yielded
negative results for 23.2% of patients with clinically suspected VAP. The
agreement between the microbiological results obtained from the two
techniques was assessed according to the statistical methods (p: 0.005,
kappa: 0.804). Existence of leukocytes and bacteria in ETA samples were
correlated with culture results (p: 0.001; kappa: 0.395) and in mini-BAL
samples, as well (p: 0.003, kappa: 0.460).
Conclusions: Clinical and radiological diagnosis of VAP without
microbiological cultures may be misleading. Quantitative cultures of
ETA and mini-BAL were in agreement in our study. Also quantitative
culture of ETA may be adequate for routine diagnosis of VAP. Gram
staining of ETA and mini-BAL samples could provide important clues
for early and appropriate antimicrobial treatment.
P895 Utility of alveolar and ascitic sTREM-1 to diagnose aetiology
of acute respiratory distress syndrome
P. Ramı´rez °, V. Marti, P. Kot, R. Martinez, V. Sainz, D. Gomez
(Valencia, ES)
Critical care patients with abdominal pathologies often developed an
acute respiratory distress syndrome (ARDS). ARDS can be due to the
abdominal pathology or can be caused by a nosocomial pulmonary
infection. Soluble triggering receptor expressed on myeloid cells 1
(sTREM-1) has shown to be of utility in diagnosing pulmonary
infections. Our objective was to asses the utility of sTREM-1 in the
aetiological diagnosis of ARDS in critical care patients with abdominal
pathology.
Methods: On the ﬁrst 4 days of ARDS we analysed alveolar and
peritoneal ﬂuid: microbiological and cytological analysis and sTREM-1
by an ELISA method. Clinical and laboratory tests were performed to
complete diagnosis. Statistical analysis included U Mann-Whitney test.
Results: We included 21 patients. Mean age was 48 years (DE 17)
and 68% were men. Mean APACHE II was 19 points (DE 6) on ICU
admission day and SOFA value on the day on evaluation was 13 points
(DE 3). The most frequent abdominal pathologies were: spontaneous
bacterial peritonitis (27%), enteritis (23%) and pancreatitis (14%). In
41% of the patients a pulmonary infection was diagnosed, in 27% an
abdominal infection was diagnosed, in 27% both infections coexisted
and in 5% no focus could be identiﬁed. Mean alveolar sTREM-1 was
1713 pg/ml, 1512 pg/ml if an abdominal infection existed and 2027 pg/ml
if a pulmonary infection was diagnosed. Mean peritoneal sTREM-1 was
1424 pg/ml, 2198 pg/ml if an abdominal infection existed and 1275 pg/ml
if a pulmonary infection was diagnosed. To distinguish between the
absence and presence of an abdominal infection peritoneal sTREM-
1 (p< 0.001) and serum procalcitonin (p 0.18) were of utility. To
distinguish between the absence and presence of a pulmonary infection
alveolar sTREM-1 (p 0.019) was of utility. A ratio alveolar sTREM-
1/peritoneal sTREM-1 >1 strongly indicated a pulmonary infection
(sensibility 63%, speciﬁcity 100%) whereas a ratio <2 strongly indicated
an abdominal infection (sensibility 89%, speciﬁcity 83%).
Conclusions: In a critical care patient the compartmentalisation of the
inﬂammatory response in the initial infectious focus is not the regular
performance. However, sTREM-1 keeps certain capacity to indicate
the infectious origin. To establish the aetiology of ARDS could have
important treatment implications, meanly the indication of surgery if an
abdominal infection is diagnosed.
P896 Procalcitonine in abdominal surgery: is there an economical
interest?
F. Meurant, P. Geukens ° (Luxembourg, LU)
Objectives: Sepsis and severe infections are common causes of
morbidity and mortality in intensive care units. The abuse of antibiotics
is known to promote pathogens resistance and increase long term co-
morbidity. Procalcitonine (PCT) could indicate the right time to introduce
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antibiotics in patients but is still an expensive laboratory test. We attempt
to evaluate beneﬁts of using this biological marker and its economical
interest in daily antibiotic therapy.
Methods: 66 patients who had an elective non-complicated chole-
cystectomy and who developed criterias of systemic inﬂammatory
response (Temperature >38ºC or <36ºC, WBC count >12,000/mm3
or <4000/mm3, or >10% immature (band)), without positive bacterial
culture, were randomised prospectively in our ICU directly after the
surgical procedure. Each patient received one shot of Amoxicillin–
Clavulanic Acid (2 g) during surgery. In the control group (Gc: n = 33)
the antibiotic therapy was stopped right after the surgery, compared to
the study group (Gs: n = 33) where the antibiotics were given during
2 days. Serum PCT levels were measured each day in the two groups.
Samples of blood, mid stream and lung expectoration cultures were also
taken every day. Antibiotic costs, were compared between groups. For
statistical analysis a Shapiro–Wilk test, Wilcox and a student T-test were
used.
Results: Demographic data were comparable in terms of gender, age,
SAPS and operating time (mean 1 h25+/-15min). During the ﬁrst 2 days
in the Gc 8 patients developed infections compared to 7 in the Gs
(p = 1). PCT increased signiﬁcantly in all of the 15 patients (p< 0.05).
For 6 patients in Gc, a bacterial identiﬁcation allowed to guide a
cheaper antibiotic choice compared to the Gs (p< 0.01) where empirical
antibiotherapy appeared to be more expensive.
Conclusion: It is not the systematical prolonged antibiotherapy after
elective surgery who can protect against infections. This attitude avoids
the beneﬁt of bacterial identiﬁcation and so far has an economical bad
impact on the choice of antibiotherapy. PCT could help to choose which
patient would beneﬁt from prolonged post-surgery antibiotics.
P897 Plasma procalcitonin levels in clinically stable patients with
cystic ﬁbrosis
A.P. Watt °, J. Courtney, J.S. Elborn (Belfast, UK)
Objective: Chronic bacterial infection is a major cause of morbidity
and mortality in Cystic Fibrosis (CF). The identiﬁcation of inﬂammatory
biomarkers which correlate with lung injury and infection may be useful
in monitoring progressive pulmonary disease. Blood procalcitonin (PCT)
levels are raised in bacterial infections and remain low in viral infections
and non-speciﬁc inﬂammatory diseases. To date, no studies have been
published evaluating PCT levels in CF; the objective of this study is to
establish baseline plasma PCT and examine the possible role of PCT as
a biomarker useful in rationalisation of antibiotic therapy in CF.
Methods: BRAHMS PCT immunoluminometric kit was used to measure
PCT in 163 retrospective anonymised plasma samples. 85 plasma
samples were from patients with CF who had no history in the
previous four weeks of hospitalisation for an acute exacerbation and/or
intravenous antibiotics. 78 samples were from non CF individuals.
Retrospective data on C-reactive protein (CRP) and alpha 1 antitrypsin
for the two groups studied were compared using the non-parametric
Mann Whitney U test.
Results: No signiﬁcant difference in the levels of plasma PCT
were observed between the two groups – CF samples (Mean±SEM,
0.14±0.05 ng/ml), and 78 control samples (0.16±0.01 ng/ml). AAT
was signiﬁcantly higher in patients with CF (1.69±0.05 g/L) compared
to Controls (1.38±0.03 g/L, p< 0.001), whilst CRP was signiﬁcantly
higher in the CF group (13.02±1.39mg/L) compared to controls
(5.4±0.45mg/L, p< 0.001). No correlation was observed between PCT
and CRP or AAT. No signiﬁcant difference in PCT levels was observed
between those patients with CF infected with P. aeruginosa (n = 47,
0.16 ng/ml) and those infected with B. cepacia (n = 18, 0.16 ng/ml).
Conclusions: This pilot study reports no signiﬁcant difference in the
levels of plasma PCT in clinically stable patients with CF compared to
healthy controls even when CRP and AAT are signiﬁcantly elevated. The
low levels of PCT observed may reﬂect on the compartmentalisation of
infection within the lungs. Further work is required to investigate PCT
levels during pulmonary exacerbations.
P898 Changes in platelet sizes as indicators for clinical outcome
of bacteraemia
T. Kitazawa °, Y. Yoshino, K. Tatsuno, Y. Ota, K. Koike (Tokyo, JP)
Objectives: Systemic infections such as bacteraemia induce acute phase
responses, leading to multiple alterations including the haematostatic
system. It has been reported in many studies that thrombocytopenia is
observed during sepsis. However, little is known about changes in platelet
sizes in the course of sepsis and association between the changes and
the outcome of sepsis. The aim of this study is to elucidate whether the
changes or the levels of platelet sizes were associated with the prognosis
of bacteraemia.
Methods: From April 2003 to March 2006, all the patients aged 
20 years whose blood cultures were positive at the University of Tokyo
Hospital were enrolled in this study. We selected 350 patients whose
mean platelet volumes (MPV) were tested during the three periods;
the ﬁrst period, between 30 days and 7 days before the onset of
bacteraemia, the second period,  1 day from the onset, and the third
period, 3 to 5 days from the onset. A retrospective chart review was
performed to collect demographics. The end point was deﬁned as 30-day
mortality.
Results: Average MPV at the ﬁrst period were 7.33±0.90 fL, and
increased to 7.66±1.06 fL at the second period and 7.89±1.21 fL at
the third period, respectively, with statistical signiﬁcance (p< 0.001).
There were no differences in average MPV at the three points between
in non-survivors (n = 25) and in survivors (n = 325). However, the levels
of average MPV increase between the ﬁrst and the second periods were
signiﬁcantly smaller in non-survivors than those in survivors (0.00±0.55
vs 0.35±0.74, p = 0.006). While, those between the second and the third
periods were signiﬁcantly larger in non-survivors than those in survivors
(0.74±0.70 vs 0.19±1.18, p = 0.03). Using the changes of MPV in the
two intervals, the area under the receiver operating characteristic curves
was 0.71.
Conclusion: Changes in MPV during early time of bacteraemia serve
as prognostic indicators for bacteraemia.
P899 Lymphocytopenia and neutrophil/lymphocyte count ratio
predict bacteraemia better than conventional parameters in
an emergency care unit
C. de Jager °, R.B. Mathoera, J. de Jongh-Leuvenink, P. van Wijk,
T. van der Poll, P.C. Wever (’s-Hertogenbosch, Amsterdam, NL)
Objectives: Prediction of bacteraemia is essential in clinical decision-
making. Absolute lymphocytopenia (lymphocyte count <1.0×109/L)
has been reported as predictor of bacteraemia in medical emergencies.
Likewise, the ratio of neutrophil and lymphocyte counts (NLCR,
normal value 0.4−7.5) has been shown a simple promising method to
evaluate the extent of stress or systemic inﬂammation in critically ill
patients. We studied the association between several routine chemical and
haematological infection markers and bacteraemia in patients presenting
to the emergency care unit of the Jeroen Bosch Hospital, an 800-bed
teaching hospital in the Netherlands.
Methods: During a seven month period one ore more blood cultures
were obtained from 746 adult patients. Contaminated blood cultures were
excluded (n = 29) as well as positive blood cultures from patients with
chemotherapy, haematological diseases, glucocorticoids use (n = 14) or
patients with incomplete data (n = 12). C-reactive protein (CRP) level,
white blood cell (WBC), neutrophil and lymphocyte counts and the
NLCR were compared upon admission between patients with positive
blood cultures (n = 92, 64% Gram-negative bacteria versus 36% Gram-
positive) and age and gender matched control patients with negative
blood cultures. SPSS 15 was used to evaluate differences between cases
and controls.
Results: Paired Student’s t-tests revealed signiﬁcant differences in CRP
level, lymphocyte count and NLCR between patients with positive and
negative blood cultures. Area under the receiver operating characteristic
curve was highest for the NLCR.
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Conclusion: In the setting of an emergency care unit, lymphocytopenia
and, even more, the NLCR, is more predictive of bacteraemia than
routine parameters like CRP, WBC or neutrophil count.
Table 1. Predicting bacteraemia using conventional parameters (CRP,
WBC and neutrophil count), lymphocytopenia and the neutrophil/
lymphocyte count ratio
Parameter, mean±SD Cases, n = 92 Controls, n = 92 ROC area
CRP 176±138mg/L 116±103mg/L 0.62
WBC count 13.6±6.6×109/L 12.9±5.2×109/L 0.53
Neutrophil count 12.1±6.1×109/L 10.7±5.1×109/L 0.58
Lymphocyte count 0.8±0.5×109/L 1.2±0.7×109/L 0.73
NLCR 20.9±13.3 13.2±14.1 0.74
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P900 Development of PCR Electrospray ionisation mass spectrom-
etry for identiﬁcation of clinically relevant fungi and yeast
T. Hall °, M. Frinder, R. Ranken, D. Rubiro-Aparicio, S. Manalili,
D. Ecker, R. Sampath (Carlsbad, US)
Background: Diagnosis of candidaemia typically relies upon blood cul-
tures, which often require several days for correct species identiﬁcation.
Diagnosis of invasive fungal infection (IFI) relies upon a consensus of
clinical and laboratory criteria with certainty ranging from deﬁnite to
probable or possible. Because deﬁnite diagnosis requires visualisation of
the organism in tissue, the majority of patients with IFI fall into the prob-
able or possible categories. We investigated the hypothesis that a single
molecular assay based upon broad PCR ampliﬁcation followed by mass
spectrometry could be used to identify a wide variety of fungi and yeast.
Methods: Four broad-range PCR primers were selected within the
5.8S and 26S rRNAs for detection of fungi such that the product
base compositions could be used to directly identify species or narrow
possibilities to a range of species. Additional twelve primer pairs were
designed to identify speciﬁc groups by virtue of product ampliﬁcation
and identify species by virtue of product base compositions. Automated
PCR/Electrospray ionisation mass spectrometry and data analysis provide
base composition signatures that identify clinically-relevant species of
fungi and yeast.
Results: An assay has been deﬁned to target a range of fungi and yeast
that consists of 16 primer pairs, allowing 6 samples to be run on a 96-well
plate. The assay broadly detects fungi and yeast, and identiﬁes members
of Candida spp. (speciating C. albicans, C. tropicalis, C. glabrata,
C. parapsilosis, and C. krusei), Aspergillus spp., Cryptococcus neofor-
mans, Mucorales, Coccidioides immitis/posadasii, Ajellomyces spp. and,
Fusarium spp. A collection of clinically-relevant isolates consisting of
25 Aspergillus spp. isolates, 58 Candida spp. isolates, 13 Cryptococcus
spp. isolates, 10Mucor/Rhizopus isolates, 5 Saccharomycete isolates and
9 Sordariomycete isolates have been tested and correctly identiﬁed with
automated data analysis. Assay limits of detection were determined using
quantitated C. albicans and C. glabrata isolates obtained from ATCC.
Both species were detected at 30−60 genome copies/PCR.
Conclusion: PCR/ESI-MS is a novel approach to fungal diagnostics
with potential for rapid identiﬁcation of a broad variety of fungal or
yeast pathogens in a single assay.
P901 Detection of candidaemia in patients with and without
underlying haematological disease
M.C. Arendrup °, O.J. Bergmann, L. Larsson, H.V. Nielsen, J.O. Jarløv,
B. Christensson (Copenhagen, DK; Lund, SE)
Objectives: The diagnosis of candidaemia remains difﬁcult despite the
development of new diagnostic tools. We here compare the diagnostic
potential of three different blood culture systems, D/L arabinitol, antigen,
and antibody detection.
Methods: 114 episodes in 93 patients with either underlying haema-
tological disease and fever without response to antibacterial treatment
or documented systemic Candida infection were enrolled prospectively.
A pro forma was provided to gather clinical and para-clinical information
on all patients. Blood culture (BC) was done using a conventional
blood culture (2 aerobic and 2 anaerobic bottles), a fungal blood culture
(Mycosis bottle, BACTEC), and the Isolator 10 lysis centrifugation blood
sample (Isolator 10, Wampole). Surveillance cultures from oropharynx,
urine, and faeces were performed. The D/L arabinitol ratio in serum and
urine was determined by gas chromatography (Larsson L, 1994). Antigen
(Ag) was detected by the CandTec Kit (Ramco Laboratories Inc., Vernn,
Houston, USA) and by using the Platelia Candida Ag ELISA kit (Bio-
Rad, France) and anti-Mannan antibody (Ab) was detected using Platelia
Candida AB/AC/AK kit (Bio-Rad, France).
Results: The 114 episodes were classiﬁed as proven invasive candidiasis
(24), probable (14), possible (52), or unlikely (24). Candidaemia
involved C. albicans (17 episodes), C. albicans + C. glabrata (3
episodes), C. tropicalis (1 episode), and yeast not identiﬁed (1 episode).
The mycosis bottle was the only BC positive in 2 episodes and
the conventional blood culture the only BC positive in 1 episode.
Evaluating only the proven and unlikely episodes sensitivity (sens)
and speciﬁcity (spec) of the indirect tests were as follows Mannan
Ag & anti-Mannan Ab: 83.3%, 78.3%; D/L arabinitol ratio in serum:
41.7%, 86.4%; CandTec Candida Ag: 66.6%, 70.8%. By lowering
the cut off values to Mannan Ag: 0.10 ng/ml and anti-Mannan Ab: 4
AU/ml the values were: sens 100%, spec 73.9%, PPV 80% and NPV
100%, and by applying the D/L arabinitol ratio to only patients with
haematological neutropenia the values were: sens 75%, spec 90.5%,
PPV 60%, and NPV 95%.
Conclusion: The fungal blood culture bottle slightly improved the
detection of candidaemia. Among the indirect tests the combined use of
Mannan Ag and anti-Mannan Ab showed the best performance especially
when cut offs were lowered. D/L arabinitol ratio seemed useful in the
setting of haematological underlying disease and neutropenia.
P902 Candida mannan and anti-mannan in the diagnosis of
invasive candidal infections in neutropenic patients
M. Ellis °, B. al-Ramadi, R. Bernsen, J. Kristensen, H. Alizadeh,
U. Hedstrom (Al Ain, AE)
Objective: Antifungal (AF) therapy given to all pts with febrile
neutropenia (FN) is costly and toxic. Beta-D-glucan assay is fungal-
non-speciﬁc; galactomannan is useful only for aspergillosis. This study
focused on serial assay of mannan (M) and mannan-antibodies (MA) to
diagnose invasive candidiasis (IC) in pts with FN, hence to aid selection
of pts for AF. Previous experience with this assay has been limited to
non-neutropenic pts, based on retrospective infrequent sampling.
Methods: 100 patients with acute leukaemia undergoing chemotherapy
complicated by FN, given liposomal amphotericin B, were studied
prospectively with clinical, microbiological (blood culture), and ra-
diological (CT scans chest, liver, spleen, sinuses) evaluations for
the development of IC, based on revised EORTC/MSG diagnostic
criteria. M + MA were measured daily using Platelia Candida-
speciﬁc antigen/antibody ELISA kits (Bio-Rad). Diagnostic cut-offs were
determined using ROC curves.
Results: 12 of 86 (14%) eligible pts had IC [C. albicans candidaemia
(1), C. tropicalis candidaemia (4), hepatosplenic candidiasis (7)], 24 had
invasive mould, 50 persistent FN. These last 2 groups served as the
comparison group.
Cut-offs were 0.25 ng/ml and 2.5AU/ml for M and MA, lower than
manufacturer’s recommendations. All pts with IC developed  1 +ve
diagnostic M or MA during persistent FN (FIG1). Optimal overall
performance occurred when 2 consecutive positive tests for both M and
MA were used. Sensitivity, speciﬁcity, PPV and NPV [95%CI] were
0.73[0.39−0.94], 0.80 [0.69−0.89], 0.36[0.17−0.59], 0.95[0.86−0.99]
respectively.
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A positive correlation (r = 0.28, p = 0.01) was seen with previously
determined beta-D-glucan (BDG) concentrations in these pts.
The ﬁrst +ve M test occurred at a mean ±s.d. of 8.8 ±8.5 (2 to 23) days
prior to clinical/mycological diagnosis of IC.
High MA concentrations were delayed until leucopenia resolved.
The candidal colonisation index (CCI) was 0.5 in 60% of the
comparison group.
Conclusions: Using institution-based cut off values, early serial
determination of combined M+MA is useful to diagnose IC in FN
pts. Low PPV may reﬂect low prevalence of IC, whilst the high NPV
conﬁdently excludes IC. Negative M+MA tests in the presence of +ve
BDG test indicates IC rather than mould. Speciﬁcity may be low as a
result of subclinical candida infection in the comparator group (high
CCI). This assay could be used as part of a broad fungal diagnostic
strategy aimed at tailoring AF.
Figure: Serial course antigen and antibody pt#12.
P903 Adherence of Candida albicans on FEP (polymer of
tetraﬂuoroethylene and hexaﬂoropropylene) catheter and
polyurethane catheter in an in vitro dynamic adhesion model
D. Jin °, M. Hui, C.Y. Chan (Hong Kong, HK)
Objectives: To investigate adherence features of Candida albicans in a
dynamic adhesion model and to evaluate the impact of different catheter
material on Candida albicans adhesion.
Methods: We designed an in vitro dynamic adhesion model to test the
adherence features of Candid albicans to catheters of different material
(Figure). Yeast-peptone-dextrose (YPD) broth was used as the ﬂow
medium. The ﬂow rate was kept at 90ml/min to mimic the average
ﬂow rate of human venous blood. FEP and polyurethane catheters were
placed inside the glass tube. Candida albicans SC5314 at an initial
concentration of 105 cell/ml was used. The whole model was maintained
at 37ºC. When Candida albicans SC5314 growth reached mid-log phase
(6 h), FEP and polyurethane catheters (both 2 cm long, outer diameter =
1.3mm) were picked up and gently washed thrice with 1ml phosphate
buffered saline (PBS). This is followed by sonication in 1ml PBS
solutions at a frequency of 37kHz at 4ºC. The sonication procedure
consisted of a 3min sonication followed by 10 s vortexing, this was
repeated thrice. After sonication, PBS solutions were used for viable
count to calculate adherent cell number on the surface of catheters.
Catheters were cultured in YPD broth to check whether sonication
process was complete or not. Adherence features of different catheter
materials were presented as the number of colony forming units (CFU).
The experiment was done in duplicates. Two independent experiments
were performed.
Results: At mid-log phase (6 h, concentration of cell suspen-
sion was (5.0±1.18)×106 cell/ml), the adherent cell number on
FEP and polyurethane catheters were (8.25±0.62)×103 CFU and
(5.62±0.93)×104 CFU respectively (P< 0.05). The results of viable
count of YPD broth immersing catheters were zero, showing sonication
process is complete.
Conclusion: FEP catheter and polyurethane catheter have different
adhesion features for Candida albicans SC5314 under dynamic
environments. Polyurethane catheter has stronger adhesion to Candida
albicans SC5314.
Figure: An in vitro dynamic adhesion model.
P904 Evaluation of commercial phenotypic identiﬁcation systems
for the characterisation of common and rare yeast pathogens
J. Meletiadis °, M. Arabatzis, K. Tsiveriotis, M. Bobola, L. Zerva,
A. Velegraki (Athens, GR)
Objectives: Yeasts are commonly implicated in superﬁcial skin and
mucosal infections in the community as well as in invasive infections
in immunocompromised and seriously ill patients. Their identiﬁcation to
species level can have consequences for the diagnosis, epidemiology
and treatment choice. Various automated systems are commercially
available but few have been systematically tested with strains identiﬁed
by molecular methods. The aim of the study was the evaluation of three
main automated yeast identiﬁcation systems, using for the ﬁrst time local
clinical strains.
Methods: 93 clinical isolates (comprising 24 species) were identiﬁed
by the VITEK 2 system, Auxacolor KAI API ID32C. The results
were compared to the reference identiﬁcation method that employed
sequencing of ribosomal regions.
Results: From the 61 strains belonging to the clinically most common
species C. albicans, C. parapsilosis, C. tropicalis, C. glabrata,
C. lusitaniae and C. krusei, Auxacolor correctly identiﬁed 95.1% of
the strains, VITEK 2 90.2% and API ID32C 86.9%. From the 32 strains
of rare species, the corresponding percentages were 43.8% (Auxacolor),
71.9% (VITEK 2) and 87.5% (API ID32C).
Conclusion: Auxacolor seems to be an excellent tool for screening
common yeasts in the clinical laboratory. Rapid and fully automated
identiﬁcation was achieved by VITEK 2 (18 h versus 48−96 h for
Auxacolor and API ID32C respectively). Generally, API ID32C and
VITEK 2 were equally effective. No system could identify all
uncommon, clinically relevant, non-C. albicans species. Consequently,
these strains should be polyphasically identiﬁed by a combination of
biochemical, physiological, morphological and genomic studies.
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P905 Anti-aspergillus antibodies and galactomannan antigen
detection for serodiagnosis of aspergillosis
N. Tsagarakis °, N. Kentrou, V. Margariti, A. Malgarinou, S. Maurea,
I. Tsagarakis, E. Anastasakou (Athens, GR)
Objectives: The development of minimally invasive diagnostic methods
is a major advance in the early diagnosis of aspergillosis. Clinically
relevant antigens have been adapted for use in immunoassays for the
detection of speciﬁc antibodies of Aspergillus fumigatus, while the
detection of circulating galactomannan antigen is a useful tool for
serodiagnosis of aspergillosis. The aim of this study was to investigate
the concordance of anti-aspergillus antibodies and galactomannan
detection in cases suspicious for Aspergillus fumigatus infection.
Methods: Sera from patients hospitalised in our hospital during the
period 1/1/2007 – 1/12/2008 with clinical suspicion of aspergillo-
sis, were examined for detection of anti-Aspergillus antibodies, by
SERION ELISA classic Aspergillus IgG/IgM/IgA indirect enzyme-
linked immunosorbent assays. All positive sera were processed for the
detection of galactomannan (GM) by the Platelia Aspergillus EIA (Bio-
Rad), a sandwich immunocapture ELISA, according to manufacturer’s
instructions. All patients were investigated for diagnostic purposes, so
they were examined for the ﬁrst time.
Results: Among 1288 sera tested, 139 (10.8%) were positive for the
detection of IgM antibody, 1070 (83.1%) were negative and 79 (6.1%)
were determined to the gray zone. For the detection of IgG and
IgA antibody, the results were: 111 (8.6%) and 80 (6.2%) positive,
1119 (86.9%) and 1168 (90.7%) negative, while 58 (4.5%) and 40 (3.1%)
belonged to the gray zone, respectively. All anti-Aspergillus antibody
positive sera were also tested for the detection of galactomannan (GM),
so 35 patients were found positive. Among these patients 28 (80%) were
hospitalised in Pneumonological Departments, 4 (11.4%) in Departments
of Internal Medicine, and 3 (8.6%) in ICUs. Moreover, 16 (45.7%)
patients were simultaneously positive for GM and IgM, 5 (14.3%) for
GM, IgM and IgA, 3 (8.6%) for GM, IgG and IgA, 3 (8.6%) for GM, IgG
and IgM, 3 (8.6%) for GM, IgG, IgA and IgM. Also, 3 (8.6%) patients
were simultaneously positive for GM and IgA only and 2 (5.7%) for GM
and IgG.
Conclusions: The low concordance of anti-Aspergillus antibodies and
galactomannan antigen detection, but also the different types of anti-
bodies simultaneously detected with circulating galactomannan antigen,
suggest that the combined examination increase the sensitivity and
speciﬁcity of both tests, avoiding the cross-reactivity of galactomannan
and the false-positive results of antibodies.
P906 Galactomannan as a prognostic marker for poor outcome
of invasive pulmonary mould infection in patients with
haematological malignancies
M. Weisser °, L. Bla¨ttler, L. Elzi, I. Steffen, F. Gambazzi, C. Orasch,
M. Stern, C. Arber, D. Heim, B. Khanlari, A. Conen, A. Gratwohl,
U. Flu¨ckiger (Basel, CH)
Objectives: Little is known on prognostic factors for outcome of invasive
mould infections in patients with haematological malignancies. Besides
new prophylactic regimes, knowledge of predictors for therapy failure
might improve outcome.
Methods:We analyzed cases of proven and probable invasive pulmonary
mould infection in patients with haematological malignancies treated in
a tertiary-care hospital from 2002–2008 with the aim to investigate risk
factors for poor outcome.
Results: In 34 patients with probable (n = 18) and proven (n = 16)
invasive pulmonary mould infection a galactomannan value of 
0.5 ng/mL at the time of diagnosis was an independent risk factor of
poor outcome at 6 months after diagnosis (HR 1.24, 95%CI 1.09−1.52,
p 0.023). Age, gender, underlying disease, transplantation, use of
steroids, duration of neutropenia, CT ﬁndings, surgery and antifungal
treatment had no signiﬁcant inﬂuence on the outcome. Under an
antimould treatment (and thoracic surgery in 16 patients) a radiological
resolution was seen in 20 patients (59%) after a median of 80 days. Cure
at 6 months was reached in 24 patients (70.6%). Overall 23 patients
(67.6%) died during the follow up. Three patients died of a mould
infection corresponding to an attributable mortality of 8.8%.
Conclusion: The level of galactomannan at diagnosis of the fungal
infection is predictive for poor outcome.
Figure 1. Kaplan-Meier curve of treatment failure within 6 months
after diagnosis of invasive mould infection according to the initial
galactomannan (GM) value.
P907 Evaluation of serum Aspergillus galactomannan in
haematological patients
R. Banon °, R. Rojas, M. Causse, J. Serrano (Cordoba, ES)
Introduction: The incidence of invasive aspergillosis (IA) is signiﬁ-
cantly high in haematological patients. Nevertheless this fungal infection
is characterised by a high mortality rate in these high risk patients. An
early instituted antifungal therapy should improve the patient prognosis.
However, IA is always difﬁcult to diagnose. Major criteria for IA
suspicion are essentially based on a set of arguments such as abnormal
chest computed tomography scan, and the detection of circulating
galactomannan (GM).
Objective: Our study evaluated the efﬁciency for IA diagnosis of the
Platelia Aspergillus test routinely performed in a prospective serological
survey of haematological patients.
Material and Methods: From June, 2002 to June, 2008, 5397 serum
samples from 383 patients from haematological department of Co´rdoba
University Hospital that were at risk for IA were tested in a routine
screening program, including two blood samples obtained per week.
Patients were classiﬁed according to IA diagnosis criteria of European
Organization for Research and Treatment of Cancer/Mycosis Study
Group (EORTC/MSG) with three levels of certainty: proven, probable,
and possible. Proven IA was difﬁcult to establish because tissue samples
were not systematically taken, not even the cultures are requested, and
autopsy was never performed. Excluding the galactomannan antigen as
microbiological criterion, we have considered 34 patients to be probable
or possible IA. The detection of GM by the Platelia Aspergillus test
(Bio-Rad, Marnes-la-Coquette, France) was carried out according to the
manufacturer’s instructions. We consider as reactive to the GM antigen,
that one with two or more positive samples (index 0.5 or major) in the
length of one week.
Results: Of all the patients studied, only 36 cases were reactives to the
GM antigen. The patient’s proportion considered probable or possible IA
that obtained a positive result in the diagnostic test was 61.8%, whereas
the probability of a patient without IA to get a negative result was 95.7%.
The probability of suffering IA if a positive result is obtained in the test
was 58.3% and the probability of not suffering IA if a negative result is
obtained was 96.3%.
Conclusion: Employment of the GM test, in a population of high risk,
to detect patients with minor risk of suffering IA, allows to avoid
unnecessary treatments in these setting. Consequently we think that it is
a useful test for the control of haematologic patients.
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P908 Immune evasion of Aspergillus fumigatus by secreted
proteases can be undermined by application of amino acids
G. Rambach °, D. Dum, I. Mohsenipour, C. Lass-Flo¨rl, R. Wu¨rzner,
C. Speth (Innsbruck, AT)
Objectives: The high lethality of cerebral aspergillosis delivers evidence
for efﬁcient immune evasion mechanisms of Aspergillus. An important
target for evasion mechanisms is the complement system as a key player
of innate immunity in the CNS. As our studies indicate that secreted
fungal proteases can degrade complement proteins we aim to target these
proteolytic enzymes by new therapeutic approaches.
Methods: Aspergillus spp was grown in medium or cerebrospinal ﬂuid
(CSF). Different supplements were used to study their inﬂuence on
protease secretion. The degradation of soluble immune proteins was
investigated by Western Blot, cellular expression of surface proteins was
quantiﬁed by FACS. Fungal opsonisation and subsequent phagocytosis
by primary microglia was examined by immunoﬂuorescence.
Results:When cultivated in CSF pathogenic Aspergillus species secreted
proteolytic enzymes that are able to degrade a broad spectrum of
complement factors of all three activation pathways. Besides soluble
complement proteins, also complement receptor CR3 (CD11b/CD18)
and MHC molecules on membranes of immune cells were affected.
The consequences were striking: any new opsonisation of fungal hyphae
was markedly reduced by CSF/Aspergillus supernatant, and complement
factor C3 already bound to the surface was removed. In consequence
microglial cells showed less phagocytic activity compared to conidia
opsonised in CSF without fungal growth.
In order to prevent the secretion of fungal proteases, different
supplements were tested. While sugars, phosphate and iron compounds
showed no effect, various nitrogen sources were able to suppress the
proteolytic activity. Amino acids as endogenous substances were of
particular interest and turned out to be very effective; the number of the
nitrogen atoms within the molecule seems to be crucial for the relevant
concentration. Glutamine and arginine appear as the most promising
candidates for a future therapeutic use as they are present in the brain
and act in comparatively low concentrations.
Conclusions: The degradation of complement and surface-bound
molecules of immune cells by secreted proteases turned out to be
an important mechanism for immune evasion in cerebral aspergillosis.
Inhibition or suppression of these proteases are promising approaches
for supportive therapeutic approaches in the future.
P909 Cumulative sums test for monitoring the incidence of
invasive nosocomial aspergillosis
J. Menotti, R. Porcher, P. Ribaud, C. Lacroix, V. Jolivet, F. Derouin °
(Paris, FR)
Objective: A close epidemiological surveillance of invasive aspergillosis
(IA) is required in hospitals in charge of severely immunocompromised
patients. In order to provide a statistically-based evaluation of IA
incidence over time, we applied the Cumulative Sums (CUSUM)
methodology, which was developed for quality control and has already
been applied for the surveillance of hospital-acquired infections.
Methods: Cases of IA were prospectively recorded during a 5-years
period and incidence rates were analyzed by CUSUM. Fungal monitoring
of the environment (air and surfaces) was performed once every 3 weeks
in haematology wards. The risk related to construction or renovation
works was scored using a semi-quantitative scale with 4 levels of risk
according to the type and location of works. Relationships between
incidence rates, fungal contamination in haematology wards and risk-
scores of works were tested by using time series methods.
Results: Between Jan 2002 and Dec 2006, 122 cases of probable or
proven cases of IA were diagnosed; 41 cases had a previous history
of aspergillosis and/or signs of aspergillosis at entry and the 81 other
cases were called “nosocomial IA” (NIA) since hospital acquisition of
infection could not be ruled out.
CUSUM analysis of NIA incidence showed no signiﬁcant deviation from
the expected monthly number of cases between Jan 2002 and Aug 2005.
On Sept 2005, the CUSUM crossed the decision limit, i.e. identiﬁed
a signiﬁcant increase in risk of NIA as compared to the reference
period (i.e. before Dec 2004). Up to April 2006 the Learning Curve
CUSUM stayed over its limit, supporting an ongoing outbreak, then it
showed a signiﬁcant decrease on May 2006. Follow-up from May 2006
indicated no out-of-control situation, thus supporting a return to the
baseline situation.
In the haematology wards, several signiﬁcant links were found between
the incidence of NIA and the degree of fungal contamination by
Aspergillus or other fungi of several sites of each ward, especially
the contamination of sites other than patient rooms. No signiﬁcant
relationship was found between NIA incidence and the construction or
renovation works.
Conclusions: The CUSUM test is well suited for real-time monitoring
of NIA, early identiﬁcation of an ongoing uncontrolled process and
assessment of the efﬁcacy of control procedures. Fungal contamination,
mainly in unprotected common sites of the wards might indicate a higher
risk of NIA.
P910 Usefulness of real-time PCR at mt LSU rRNA for the
identiﬁcation of Pneumocystis jirovecii colonisation
E. Campano °, R. Morilla, V. Friaza, N. Respaldiza, M.A. Montes-Cano,
I. Martin-Garrido, F.J. Medrano, J.M. Varela, E. Caldero´n, C. de
la Horra (Seville, ES)
Background: The accepted current diagnostic standard for P. jirovecii
infection is the demonstration of the microorganism in sputum or
bronchoalveolar lavage (BAL) samples using conventional stain or
polymerase chain reaction (PCR). Besides oropharingeal washes (OWs)
are used to detect P. jirovecii colonisation by nested PCR in general
population. Several studies have evaluated the use of Real time PCR to
detect the MSG genes of P. jirovecii.
The efﬁcacy of this assay at mt LSU rRNA gene of Pneumocystis to
detect the colonisation status is was not being proved.
Objective: To evaluate the usefulness of Real time PCR versus nested
PCR using to detect P. jirovecii colonisation.
Methods: A total of 100 OWs specimens which included 23 samples
colonised where P. jirovecii status was deﬁned as samples identiﬁed
by nested PCR at mt LSU rRNA gene at least twice in independent
separate DNA extraction for each case. These samples were matched by
colonisation status with 68 negative samples. Three controls colonised
OW samples previously evaluated were also included. Nested PCR was
performed using the consensus primers pAZ102-E and -H, and -X and
-Y as internal primers. This protocol was adapted to a Real time PCR
assay using only the pAZ102 -X and -Y primers.
Results: The data shows that mt LSU rRNA gene of P. jirovecii was
detected by nested PCR in the three controls to 1:125 dilution of DNA
target, and using real time PCR we are able to amplify to a 1:200
dilution. Among samples in study, twenty-three standard OW samples
were positive for Pneumocystis using both methods, nested real time
PCR. Likewise 64 samples were negative by both assays. Nine samples
were positive using real time and in only one of the DNA extraction by
nested. Finally 4 samples were only positives by real time PCR.. The
concordance of results was 100% respect to the positive samples and
94.9% respect to negative standard samples. Besides a 9% of samples
were considered as indeterminate. The results show for the real time PCR
respect to nested PCR a sensitivity of 100% and a speciﬁcity of 94.11%
for the detection of P. jirovecii colonisation. The positive predictive value
was 85.4% and the negative predictive value was 100%.
Conclusions: Real time PCR at the mt LSU rRNA gene may be a useful
method because of its high sensitivity and negative predictive value this
technique may be a valuable alternative to detect Pneumocystis specially
when a large number of samples need to be analised.
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P911 Hyper-pigmentation of blastospores in contrast to
basidiospores of pathogenic cryptococci upon induction to
ultraviolet radiation of near solar spectra
P. Yegneswaran Prakash °, P. Sugandhi Rao (Manipal, IN)
Objectives: To understand the effects of Ultra violet radiation exposure
for controlled time intervals in the induction of hyper pigmentation in
blastospores and basidiospores of pathogenic cryptococci.
Methods: A total of 15 strains isolated from clinical and environmental
sources, representing the 5 serotypes and 3 varieties along with Crypto-
coccus neoformans 32045 from American Type Culture Collection and
Cryptococcus albidus and Cryptococcus laurentii from environmental
sources were used in the study. The blastospores were grown on
sabourauds dextrose agar media and the basidiospores were using
ﬁlamentation agar. Both the harvested blastospores and basidiospores
were suspended in the deﬁned minimal media with melanin precursors
in the form of L-dopa. Blastospores and basidiospores were spread on
to agarose sheet of 0.22mm thickness and subsequently exposed to
315–400 nanometer wavelength mimicking solar rays with a control on
exposure set for 10, 20, 40, 60 minute intervals. The copper sulﬁde silver
staining was employed to record the hyper pigmentation after exposure
to ultra violet rays subsequently data analyses performed by a Student t
test using Statistical Package for Social Sciences version 11.0 software.
Results: The survivability of blastospores and basidiospores for shorter
time period 10 to 20 minutes were in comparable limits. Longer
exposure times 60 minutes were documented to be detrimental for
both blastospores and basidiospores. At an optimal exposure of
40 minutes there was a statistically appreciable difference in the hyper
pigmentation properties of blastospores P< 0.005. The Cryptococcus
neoformans variety gatti blastospores was observed to be hyper
pigmented compared to Cryptococcus neoformans variety grubii and
Cryptococcus neoformans variety neoformans.
Conclusion: Radiation induced melanoprotective activity may play a role
in the prolonged senescence and enhanced environmental survivability
of the soil saprophyte like cryptococcus. The quest for melanin
substrates might account for the central nervous system predilection
of this basidiomycete in an infected host and hyper pigmentation
the Cryptococcus neoformans variety gatti blastospores points to
the increased virulence and and its ability to infect an apparently
immunocompetent host.
P912 Fungal metabolites can fuel an underlying HIV infection
C. Speth °, G. Rambach, M. Hagleitner, I. Mohsenipour, R. Wu¨rzner,
C. Lass-Flo¨rl (Innsbruck, AT)
Objective: Invasive aspergillosis is a dangerous and highly lethal
opportunistic infection in immunosuppressed HIV-infected patients.
Nothing is known about a putative cross-effect between fungal and
viral infection. A deeper insight into pathogenic mechanisms is urgently
needed for an adaptation of antiviral therapy in the case of invasive
aspergillosis. Therefore we studied whether fungal metabolites inﬂuence
HIV replication and thus contribute to a progression to AIDS.
Methods: HeLa cells transfected with the HIV promoter, primary
microglia, M8166 lymphocytes and THP-1 monocytes were pre-
incubated with puriﬁed fungal metabolites followed by infection with
HIV. Viral replication was analysed by quantiﬁcation of promoter activity
and by quantiﬁcation of p24 in the culture supernatants. Toxicity and
cell activation was controlled by measuring mitochondrial activity (MTS
test).
Results: Subtoxic concentrations of the fungal metabolites gliotoxin
and citrinin, known to be produced by pathogenic Aspergillus
species markedly stimulated the cellular activity. Furthermore the two
compounds both strongly enhanced HIV infection of HeLa cells as
shown by the increased numbers of infected cells and of generated
syncytia. The viral load in the culture supernatants was ampliﬁed
after pre-incubation with gliotoxin or citrinin compared to mock-treated
control cells. A similar effect of gliotoxin was visible for the infection
and the production of progenitor virus with T-cells, monocytes and
primary microglia. Other fungal metabolites like patulin, fumitremorgin
or verruculogen were proven to be ineffective and did not inﬂuence viral
infection and replication.
Conclusions: The fungal metabolites gliotoxin and citrinin boost and
fuel the HIV infection of those cell types which represent viral targets in
the patient, with a subsequent stimulation of progenitor virus production.
Thus an opportunistic fungal infection of HIV-infected individuals
should not only be treated with antimycotic drugs but also result in
adaptation or initiation of antiviral therapy. Further knowledge in the
pathogenic mechanisms of gliotoxin and citrinin might help to neutralise
to metabolite-induced escalation of virus production and thereby inhibit
disease progression in the patients.
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P913 Zinc: a modulator of inﬂuenza A virus induced programmed
cell death
V. Srivastava °, M. Khanna (Lucknow, New Delhi, IN)
Objective: Programmed cell death (apoptosis) is a hallmark event ob-
served upon infection with many viral pathogens, including Inﬂuenza A
virus. Zinc is known as a potent inhibitor of programmed cell death.
However, the effect of zinc on inﬂuenza A virus induced apoptotic death
is not well established.
Methods: HeLa cells were infected with a cell adapted pathogenic
strain of Inﬂuenza A (/Udorn/317/72H3N2) virus. Infected and mock-
infected cells were treated with 0.1, 0.15 and 0.20mM zinc at
various time intervals. DNA fragmentation and Caspase-3 activity was
examined at various time periods. The morphological changes and
ultrastructural changes were studied staining with Haematoxylin–Eosin
and Transmission Electron Microscopy (TEM) respectively. Annexin V
assay was carried out for analysis of phosphatidylserine externalisation.
Phagocytic index was determined by incubating infected cells with
adherant mouse peritoneal macrophages.
Results: DNA fragmentation was observed in virus infected cells by
24 hours post infection. Caspase-3 activity was maximum at 4 hours
post-infection after that it reached to plateau. It was observed that when
the infected HeLa cells were incubated with adherent macrophages,
efﬁcient phagocytosis occurred and the release of virus into the culture
medium was completely inhibited. Furthermore, TEM analysis detected
phagosome-like structures within macrophages, which coexisted with the
peak of phosphatidylserine externalisation i.e. 9−12 hours. Treatment of
cells with 0.15mM concentration of zinc inhibited DNA fragmentation
till 8 hours of post infection and caspase 3 activity was decreased
signiﬁcantly up to 2 hr post infection
Conclusion: These results suggest that the inﬂuenza A virus induces
apoptosis in cell culture; thus apoptosis may represent general mecha-
nism of cell death in infected host cells. Zinc has its inhibitory effect on
caspase 3 and endonucleases both. Therefore, zinc modulated apoptosis
in a time and dose dependent manner by inhibiting executioners caspase3
and endonucleases.
P914 Analysis of microRNA expression in cytological cervical
samples and correlation with HPV infection
V. Militello, E. Peta, M. Trevisan, S. Pagni, L. Barzon, G. Palu` °
(Padua, IT)
Objectives:MicroRNAs play an important role in carcinogenesis. Recent
studies have shown abnormal microRNA expression in cervical cancer
cell lines carrying human papilloma virus (HPV) infection and suggested
abnormal expression was related to HPV-16 E6 oncogene.
Methods: Cervical swabs from 40 females (age range: 17−56 years;
mean age: 34.5 years) with negative Pap test were analyzed for
the presence of HPV DNA by PCR and HPV-positive samples were
genotyped by sequencing of the HPV L1 gene. Moreover, the expression
proﬁle of 20 microRNAs, which were selected because reported to
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be abnormally expressed in cervical carcinoma cell lines or because
correlated with tumorigenesis and P53 activity, was investigated in all
samples by real-time PCR using TaqMan®MicroRNA Assays (Applied
Biosistems). The expression levels of each miRNA was calculated by
the 2-DDCt method against two different housekeeping snRNAs.
Results: Out of 40 samples, 10 were HPV-negative, 10 had low-
risk HPVs and 20 had high-risk HPVs, including 13 samples with
HPV-16. Analysis of microRNA expression showed that let-7a/b/c,
miR-21, miR-210 and miR-34a were abundantly expressed in all
cervical samples. the microRNAs let-7a, let-7c, and miR-34b/c were
frequently underexpressed, while miR-126, miR-143, and miR-368 were
overexpressed in samples positive for HPV-16 and for other high-risk
HPV types as compared with HPV-negative samples or with low-risk
HPVs.
Conclusion: The results of this study provide new information on
HPV-related carcinogenesis and potential new diagnostic markers. The
abnormally expressed microRNAs are involved in pathways that are
altered in HPV-related carcinogenesis: in fact, underexpression of miR-
34b/c might be the consequence of P53 downregulation by E6; let-7a and
let-7c downregulation could contribute to the effect of E6 on cell growth
induction; overexpression of miR-126 and miR-143 could cooperate with
E6 to inhibit expression of the their target genes encoding PDZ domain-
containing proteins involved in the regulation of cell polarity.
P915 The pathogenesis of a novel enterovirus serotype EV-94
T. Smura °, P. Ylipaasto, M. Roivainen (Helsinki, FI)
Objectives: Enterovirus 94 (EV-94) is a recently described enterovirus
serotype that is, together with EV-68 and EV-70, a member of Human
enterovirus D species. EV94 was found during poliovirus surveillance
from waste water in Egypt and from acute ﬂaccid paralysis patients
in the Democratic Republic of Congo. The seroprevalence studies in
the Finnish population have revealed a high prevalence of EV-94 over
past two decades. In this work, we studied the ability of EV-94, to
infect, replicate and inﬂict damage in cellular models of tissues that are
considered to play essential role in enterovirus induced diseases. These
models include human leukocytic cell lines, human primary endothelial
cells and human primary pancreatic islets.
Results: EV-94 was able to infect, form infectious progeny and inﬂict
cell death in cellular models of tissues that are considered to be of
importance in the pathogenesis of enteroviruses, including leukocyte
lines with granulocytic, monocytic, B-cell or T-cell characteristics,
human primary endothelial cells and pancreatic islets. Moreover this
virus is able to inﬂict damage on pancreatic islet beta-cells.
Conclusion: These results provide in vitro evidence, that EV94 might be
a potent pathogen and should be considered as a potentially diabetogenic
enterovirus serotype.
P916 Prevalence of EBV and CMV in tonsils among patients with
recurrent tonsillitis and tonsillar hypertrophy in Greece
E. Tigiroglou °, D. Klapsa, A. Damani, A. Liakopoulos, C. Skoulakis,
E. Petinaki (Larissa, Volos, GR)
Objective: To compare the prevalence of EBV and CMV in tonsils
between patients with recurrent tonsillitis and tonsillar hypertrophy.
Methods: A total of 194 patients, who underwent a total or partial
tonsillectomy were included. The patients were categorised into two
groups: a recurrent tonsillitis group (Group I, 105 patients) and a tonsillar
hypertrophy group (Group II, 89 patients). The tonsillar tissues extracted
during surgery were immediately transferred in sterile dry containers,
and they were shipped to the laboratory immediately. Pieces of tonsillar
tissue from each patient were chosen for simultaneous extraction of
DNA, using the commercial kits (Invitrogen) according to manufacturers
instructions. The detection of EBV and CMV was performed by Real-
time PCR (Nanogen Advanced Diagnostics). The association between
the two disease group (recurrent tonsillitis and tonsillar hypertrophy) was
tested using the Fisher’s exact test. A result was considered signiﬁcant
when P< 0.05.
Results: Sixty two specimens were found to be positive for the presence
of EBV-DNA (32.98%). No signiﬁcant difference was found concerning
the presence of EBV-DNA between the two groups studied; 32.91% in
patients with recurrent tonsillitis versus 26.47% in patients with tonsillar
hypertrophy. On the other hand, CMV was not detected in any specimen.
Conclusions: The high prevalence of EBV among patients with recurrent
tonsillitis and tonsillar hypertrophy verify that the tonsils are a potential
reservoir for EBV infections.
P917 SEC14 is required for secretion of the fungal invasin,
phospholipase B1, and virulence of the AIDS-related
pathogen, Cryptococcus neoformans
M. Chayakulkeeree °, T. Sorrell, C. Wilson, J. Djordjevic (Sydney, AU)
Objectives: Yeast SEC14 genes encode phosphatidylinositol transfer
proteins that link phospholipid turnover with export of secretory
vesicles from the Golgi complex by undeﬁned mechanism(s). In both
Saccharomyces cerevisiae and Candida albicans, Sec14 protein is
essential for growth, hindering delineation of its role in secretion. The
aim here is to investigate the role of Sec14 in secretion of the fungal
invasin, phospholipase B1 (Plb1), and in virulence of the model fungal
pathogen, C. neoformans.
Methods: The coding region of the putative SEC14 gene and two
homologues, SFH1 and SFH5, were disrupted in C. neoformans creating
the strains d-sec14, d-sfh1 and d-sfh5. Plb1 protein/activity was assessed
by western blotting with an anti-Plb1 peptide antibody/radiometric
enzyme assay. Cryptococcal virulence was investigated in a mouse model
of cryptococcosis and in a macrophage killing assay.
Results: Similar to wild type (WT), all mutants grew at 37 degree
Celsius and produced melanin. Only d-sec14 exhibited a cell wall
defect and secreted less total protein and almost no Plb1, indicative
of a secretion block, and these phenotypes were also observed for a
phospholipase C1 (PLC1) deletion strain [1]. As Plb1 is anchored to
membranes and cell wall prior to secretion, Plb1 associated with these
fractions was assessed by western blotting to determine the site of the
secretion block in d-sec14. Results conﬁrmed that, compared with WT,
mature fully-glycosylated Plb1 (120 kDa) had reduced association with
cell walls and, together with a smaller 40 kDa form, accumulated in
the membrane fraction. As this fraction potentially contains plasma
membrane (PM) and Golgi-associated Plb1, the origin of the secretion
block could be either Golgi or PM. However, the presence of potentially
degraded Plb1 suggests that the block occurs at the Golgi. Finally,
d-sec14 was hypovirulent in mice and exhibited reduced survival in the
presence of a macrophage cell line (J774.1). All d-sec14 phenotypes
were restored by genetic reconstitution with either an intact SEC14 or a
SFH1 gene which share 86% amino acid identity.
Conclusion: SEC14 regulates secretion of the fungal invasin, Plb1,
maintains cell wall integrity, and is a novel virulence determinant in
C. neoformans, highlighting it as a potential antifungal drug target.
Investigation into whether SEC14 and PLC1 co-ordinately regulate
secretion of virulence determinants is underway.
Reference(s)
[1] Chayakulkeeree et al. Mol Microbiol 2008;69:809−26.
P918 Antifungal activity of human beta-defensins 1, 2 and 3
against ﬁlamentous fungi
E. Kazakos °, T. Stefanidou, K. Manolopoulos, O. Vasilaki,
E. Protonotariou, F. Frantzidou-Adamopoulou (Thessaloniki, GR)
Objectives: In the present study we demonstrate the potent antifungal
properties of human beta defensins (hbD1, hbD2 & hbD3) against
representative clinical isolates of ﬁlamentous fungi.
Methods: Defensins. Recombinant peptides of hbD1, hbD2 & hbD3
were purchased from Peprotech EC, UK. Lyophilised peptides were
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reconstituted in 0.1% acetic acid and stored in working aliquots ranging
from 1 to 0.002mg/ml.
Fungal strains & AFST. The ﬁlamentous fungi used in this study
were Aspergillus fumigatus, Aspergillus niger, Aspergillus nidulans and
Aspergillus terreus, deriving from suspected cases of invasive mycotic
infections. Presumptive species identiﬁcation was done microscopically
by the lactophenol blue method and further validated by determining
their carbon assimilation proﬁles using the ID32C system (Biome´rieux,
Marcy d’E´toile). Routine antifungal susceptibility testing (AFST) for
itraconazole, ﬂuconazole, voriconazole, posaconazole, caspofungin and
amphotericin B were performed by means of E-test (AB Biome´rieux)
according to the manufacturers’ instructions.
Antifungal defensin assay. Minimum Fungicidal Concentrations (MFC)
of hbD1, hbD2 & hbD3 were determined by the microdilution assay as
described elsewhere. Brieﬂy, fungal spores were harvested from mature
colonies grown on SDA agar at 30C and resuspended in 10mM sodium
phosphate Buffer (PB) to obtain a ﬁnal concentration of 106 cells/ml.
Aliquots of diluted cells were exposed to varying concentrations of
defensins for 24 h at 30C in sterile 96-well microtitre plates and growth
inhibition was assessed by measuring culture absorbance at 595nm using
a microplate reader. Cell suspensions in buffer alone and/or acetic acid
served as negative controls.
Results: Inhibition of fungal growth was evident with all three defensins
tested and was accompanied by fungicidal effects as demonstrated by
re-inoculation of the fungi to SDA plates. Among those tested, hbD3
appears to have the strongest potency as compared to those of hbD1&2.
Conclusions: In recent years, intensive work on defensins has expanded
our knowledge on innate defence mechanisms and may provide us
novel therapeutic options for combating serious and emerging infections
as invasive mycoses. The present study, provides a ﬁrst indication
of speciﬁc antifungal activity of those endogenous peptides against
clinically important ﬁlamentous fungi and highlights the need for further
analysis of their mode of action.
P919 Formation of stomathopathies in correlation with presence
of Candida and Lactobacillus strains
M. Brzychczy-Wloch °, M. Lacki, S. Majewski, P. Heczko (Cracow, PL)
Objectives:
1. To identify species composition of Candida and Lactobacillus strains
isolated from patients with a total lack of dentition using a plate
dental prosthesis.
2. To indicate the reciprocal relationship between the presence of
Candida and Lactobacillus and the formation of stomatopathies.
Methods: The study was performed on a group of 100 persons living
in the South-Eastern region of Poland. Inclusion criteria were total lack
of dentition and using a plate dental prosthesis during a min. 6 months
period. Group I (n = 53) were patients with inﬂammation of the mucous
membrane of the prosthetic base, Group II (n = 47) were patients without
stomatopathy. We collected palate swabs. The materials were cultured on
Sabouraud and MRS agar. The Candida and Lactobacillus strains were
identiﬁed using phenotypic methods (API20C AUX, API50CHL). The
identiﬁcation of Lactobacillus was conﬁrmed by PCR.
Results:
1. Higher percentage of positive cultures of yeast-like fungi in patients
with stomatopathies (67%) was statistically signiﬁcant (p< 0.0001)
in relation to patients without stomatopathies (28%).
2. Between isolated yeast-like fungi strains, Candida albicans species
dominated in patients with (87%) or without stomatopathy (67%).
3. The differences in composition and number of Lactobacillus
species in both examined groups were found. From patients with
stomatopathies ten different species of Lactobacillus genus were
isolated: L. fermentum 32%, L. salivarius 21%, L. rhamnosus
12%, L. brevis 10%, L. acidophilus 7%, L. para paracasei 7%,
L. cellobiosus 5%, L. plantarum 2%, L. delb. lactis 2%, Lc. lact.
lact. 2%; whereas from patients without stomatopathies ﬁve species
were isolated: L. fermentum 39%, L. plantarum 34%, L. para
paracasei 17%, L. rhamnosus 5%, L. salivarius term. 5%.
4. A signiﬁcant correlation between the presence of L. plantarum strains
and the lack of stomatopathy was conﬁrmed (p = 0.0012).
Conclusions: Stomatopathies are patological lesions which give
characteristic symptoms and these are triggered by using a plate
dental prosthesis and appearance of yeast-like fungi. Our results
conﬁrm signiﬁcant inﬂuence of mycotic infection on induction of
the stomatopathies. Moreover, a statistically signiﬁcant correlation was
demonstrated between the presence of L. plantarum and lack of
stomatopathies. The following step which should be undertaken is to
conﬁrm these results in a clinical trial with administering the probiotic
strains representing these species of bacteria.
P920 Mapping the host response to cerebral aspergillosis by
integrative transcriptome analysis
S. Zimmerli °, M. Wittwer, R. Zulliger, S. Leib (Berne, CH)
Objectives: Cerebral aspergillosis is fraught with a mortality exceeding
90%. Prerequisite for therapeutic advance is the knowledge of the
pathophysiologic processes underlying the disease. Setting the global
gene expression proﬁle in the context of biological meta-data resources
permits to unravel the complex pathological processes that determine the
outcome of cerebral aspergillosis.
Methods: Gene expression was assessed in an infant rat model of
experimental cerebral aspergillosis at 6 h, 72 h and 120 h after infection
using the Affymetrix GeneChip® Rat Genome 230 2.0 arrays. The
signiﬁcance of transcriptomic changes was calculated with moderate
Bayesian t-statistics using R. Data annotation was performed by software
packages provided by the R based Bioconductor project.
Results: Of the 31,000 genes represented on the chip approximately
18,000 were expressed and detected on the chip in both control and
infected animals. After statistical testing with the consideration of a
false discovery rate (Benjamini-Hochberg p0.05), approx. 1550 genes
were found to be signiﬁcantly regulated at 72 h after infection and
approx. 600 genes at 120 h after infection. According to data clustering
and GO annotation most of the differentially expressed genes are
related to the immune system and inﬂammatory host response. The
ﬁndings validate gene microarray as an appropriate tool to decipher
complex regulatory pathways in aspergillosis. Nevertheless, there were
a considerable number of genes with unknown functions or not yet
established connections to infection or neuronal tissue.
Conclusion: The results expand the current knowledge of pathways
leading to neuronal injury in cerebral aspergillosis by integrating
differential gene expression data in the context of biological research
databases. This approach is a promising strategy to identify new targets
for further study and, hopefully, therapy.
P921 Sero-prevalence of Rift Valley fever in south-western Saudi
Arabia and study of risk factors
T. Alazraqi °, A. Mahfouz, A. Mekki (Abha, SA)
Seroepidemiological studies are valuable tools to identify the state of
immunity among the general population to Rift Valley Fever (RVF) in
the affected zones.
The objectives of the present research were to study the seroepidemiol-
ogy of RVF infection in Jizan, Aseer and Al Qunfuda regions (Southwest
Of Saudi Arabia), potential risk factors leading to the infection and to
elucidate the predisposing factors of developing severe RFV disease
requiring hospitalisation.
Through a series of ﬁeld trips, (during the period September 2007–
June 2008) to the centres selected for the present study (Jizan, Abu-
Areesh, Al-Arda, Samtah, Beesh, Al-Birk, Al Gahma, Muhayeel, Al-
Majardah and Al-Qunfuda) a random sample of individuals attending the
outpatients’ clinics for any reasons were included. All abattoir workers
in those regions were also enrolled.
Through questionnaire interviews, data were collected.
In vitro resistance of Gram-positive cocci S239
Blood samples were taken and tested for RVF-speciﬁc IgG and IgM
utilising commercially available enzyme-linked immunosorbent assays
(ELISAs).
Out of 2,322 persons included in the study, only 137 were positive
for RVF-speciﬁc IgG thus giving an overall prevalence of 6.0%. On
the other hand, none of the study samples were found to be sero-
positive to RVF-speciﬁc IgM. The highest prevalence of sero positive
RVF IgG was observed in Al Birk of Aseer region (13.3%) followed
by Al-Arda of Jizan Region (11.8%), where the ﬁrst animal deaths were
reported during 2000–2001 outbreak. The study revealed zero prevalence
of speciﬁc IgM and IgG among pre-school children born after the 2000–
2001 outbreak. Using multivariate binary logistic regression analysis
to identify potential risk factors associated with seropositive RVF IgG,
the following signiﬁcant risk factors were identiﬁed; lacking electricity,
having animals in the house, history of slaughtering animals, contact
with or transporting aborted animals.
The study included a retrospective cohort of 61 cases with severe RVF
infection hospitalised in Aseer Central Hospital during the outbreak of
2000–2001. Results revealed that prior hepatic (HBV, HCV) and renal
involvement on admission were strong predictors of poor outcome.
In conclusion, the study documented a seroprevalence of 6% of RVF-
speciﬁc IgG among the general population and the lack of recent RVF
activity among humans in th study areas, the major risk factors were
contact with animals especially aborted animals.
In vitro resistance of Gram-positive cocci
P922 Identiﬁcation by genomic and genetic analysis of two
new genes playing a key role in glycopeptide intermediate
resistance
A. Renzoni ° (Geneva, CH)
Endogenous, low-level glycopeptide resistance in Staphylococcus aureus
results from multi-factorial genetic changes. Comparative genomic
hybridisation analysis revealed the speciﬁc deletion of a 1.8 kb
segment, encompassing two adjacent open reading frames (ORFs) of
unknown function, in a teicoplanin-susceptible revertant (strain 14−4rev)
compared to its isogenic, teicoplanin-resistant parental strain 14−4.
This provocative ﬁnding prompted us to perform a detailed genetic
analysis of the contribution of this genomic segment to glycopeptide
resistance. Despite repeated efforts in our laboratory, 14−4 and 14−4rev
have proven refractory to most genetic manipulations. To circumvent
this difﬁculty, we evaluated the contribution of both putative ORFs
(designated as teicoplanin resistance factor trfA and trfB) on teicoplanin
resistance in a different, genetically tractable background. Genetic
analysis showed that single or double trfA and/or trfB mutations
abolished teicoplanin resistance in two independent teicoplanin-resistant
derivatives of NCTC8325 strain ISP794, generated by two-step passages
with the drug. The frequency of teicoplanin-resistant mutants was
markedly decreased by the absence of trfAB in the teicoplanin-
susceptible ISP794 background. Nevertheless, a low rate of teicoplanin-
resistant mutants was selected from ISPtrfAB, thus indicating an
additional contribution of trfAB-independent pathways in emergence of
low-level glycopeptide resistance. Further experiments performed with
the clinical GISA isolate NRS3 indicated that trfAB mutation could
affect not only teicoplanin, but also vancomycin and oxacillin resistance.
In conclusion, our study demonstrates the key role of two novel loci in
S. aureus endogenous, low-level glycopeptide resistance, whose precise
molecular functions warrants further investigation.
P923 The regulatory mechanisms of macrolide-lincosamide-
streptogramin B resistance in methicillin-resistant
Staphylococcus aureus
K.E. Szymanek °, A. Mlynarczyk, G. Mlynarczyk (Warsaw, PL)
Objective: The cross resistance to macrolide, lincosamide and
streptogramin B (MLS-B) in Staphylococcus aureus, depending on
dimethylation of adenine A2058 in V domain of 23S rRNA, is mediated
by the presence of the ermA, ermC, or rarely ermB or ermF methylases
genes. The expression of the MLS-B resistance phenotype needs an
induction or proceeds constitutively. The regulation of expression occurs
on the level of initiation of translation. In the case of ermA, important
role acts the ermAR fragment, located downstream of the regulated ermA
gene, which can form a hairpin secondary structure. Mutations in ermAR
can lead to constitutive phenotype. The aim of the work was the attempt
to resolve mechanism of development of constitutively resistant mutants
among strains harbouring inductive ermA gene.
Methods: 94 MRSA strains were examined for the inductive of
resistance by disc diffusion method according to CLSI recommendations.
In all these strains the presence of ermA, ermB, ermC and msrA/B genes
was checked with PCR technique. To the further investigations strains
with inducible phenotype of MLS-B resistance and possessing ermA as
the only determinant of macrolide resistance were chosen. Spontaneous
mutants constitutively resistant were obtained in the BHI-agar with
16mg/l of lincomycin. Mutants were examined for the regulatory region
ermAR, using PCR with primers surrounding 574 bp fragment.
Results: Among investigated MRSA, 21 strains with inducible MLS-B
resistance and possessing ermA as the only determinant of macrolide
resistance were found. The constitutive MLS-B resistant mutants were
obtained from each of the parent isolate, with an average frequency 10−8.
Several mutants of each parent strain (total number 93) were taken to the
ampliﬁcation of ermAR fragment. The obtained products were in wide
range of size (500–2000 bp). The most frequent (59.1%) was 574 bp
fragment, which was the same length as the wild product. The other
products contained some 20- and 80-bp deletions (31.2%) and smaller
(10-, 25-bp) or larger (1400 bp) insertions (9.7%). For several mutants
more than one product was obtained.
Conclusions: The constitutive mechanism of MLS-B resistance may
be procured as an effect of various mechanisms: point mutations or
insertions, duplications or deletions some larger fragments of DNA.
These changes prevent the ermAR cistron from forming the hairpin
structure, which make the ermA RBS region constitutively available to
the ribosome.
P924 A ﬂuorescent multicolour multiplex real-time PCR protocol
for the simultaneous detection of SCCmec types I to V in
methicillin-resistant Staphylococcus aureus
H. Valvatne, M.I.A. Rijnders, A. Budimir, M.L. Boumans, P.S. Beisser °,
E.E. Stobberingh, R.H. Deurenberg (Maastricht, NL; Zagreb, HR)
Objectives: MLST, Spa typing and MLVA are well established methods
for molecular typing of Staphylococcus aureus isolates. Yet, these
methods are restricted to targeting core genomic elements. It has become
increasingly clear that mobile element typing is a valuable addition to
the molecular epidemiology of S. aureus infections. The most valued
mobile target for typing to date is the methicillin resistance gene-bearing
staphylococcal chromosome cassette (SCCmec).
Methods: A multiplex real-time PCR was developed for identiﬁcation
of the abundant SCCmec types I to V. The assay was evaluated on 212
clinical methicillin-resistant Staphylococcus aureus isolates from various
lineages.
Results: When comparing the assay with established SCCmec typing
methods, the correct SCCmec type was identiﬁed in 210 of 212 (99%)
isolates.
Conclusion: When combined with core genome typing, this real-time
PCR assay provides a versatile means for SCCmec typing both on local
outbreak scale, and for high throughput epidemiological studies.
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P925 Molecular characteristic of Staphylococcus aureus associated
with bacteraemia in Poland during 2005
M. Orczykowska-Kotyna, A. Luczak-Kadlubowska, N. Marszalek,
A. Kozinska °, J. Empel, W. Hryniewicz (Warsaw, PL)
Objectives: The objective of the study was characteristics of
bacteraemia-associated methicillin-susceptible (MSSA) and methicillin-
resistant S. aureus (MRSA).
Methods: Between January and May 2005 a total of 915 S. aureus
isolates were recovered from 39 hospitals located in different areas of
Poland. Clinical strains were isolated from the following specimens:
wound, blood, respiratory tract, bone and joint, urine, and cerebrospinal
ﬂuid. Further phenotypic and molecular investigations were performed
on blood culture isolates only (n = 146). All isolates were characterised
by an RM PCR based test and analyzed by spa typing. MRSA isolates
were conﬁrmed by PCR for mecA. Selected MRSA and MSSA isolates
(nontypeable by both spa and RM tests) were typed by the MLST
method. The presence of luk-PV genes was detected by PCR.
Results: Among the 108 MSSA over 50 different spa types were
identiﬁed. The most common spa types were t084 (10.2%), t127 (8.3%),
t091 (5.5%), t008 (3.7%), and t012 (2.7%). The all spa types were
clustered into 10 different clonal complexes (CCs), four singletons, and
10 spa types that were excluded from the analysis, because the spa locus
was less than ﬁve spa repeats in length. Up to 30% of the MSSA had a
background observed in four major international MRSA lineages: CC5,
CC8, CC30, and CC45. Several MSSA lineages were observed that were
not associated with MRSA, such as: CC1, CC7, CC12, CC15, CC25,
and CC51. In contrast, simultaneously circulating MRSA strains (n = 38)
belonged to 10 different spa types and were classiﬁed to three CCs: CC8,
CC5, and CC45. One MRSA isolate with spa type t437 was nontypeable
by RM testing. It was classiﬁed to CC59 (ST338-Vclone) according to
MLST. PVL coding genes were detected among MSSA of CC15 and
MRSA of CC59, which is a common CA-MRSA lineage worldwide.
Conclusion: MRSA strains belonging to CC8 were predominant
among isolates associated with bacteraemia during the study period.
In contrast, among MSSA isolates, strains belonging to CC15 (ST15)
were predominant. MSSA were more diverse genotypically, including
representatives of four major MRSA clonal complexes (CC5, CC8,
CC30, and CC45). PVL, detected in only two isolates, did not seem to be
an important factor in the pathogenesis of staphylococcal bacteraemia.
P926 Molecular characteristics of PVL-positive community
acquired methicillin-resistant Staphylococcus aureus strains
isolated in the Czech Republic
M. Fridrichova´ ° (Prague, CZ)
Objectives: Community-acquired MRSA (CA-MRSA) strains producing
Panton-Valentine leucocidin (PVL) have a propensity to cause skin and
soft tissue infections of considerable severity. The aim of the study was
to describe the presence and the clonality of CA-MRSA PVL positive
isolates collected in our laboratory in past three years.
Methods: Forty nine national microbiology laboratories participating in
the European Antimicrobial Resistance Surveillance System (EARSS)
submitted MRSA isolates (n = 879) collected from individual patients in
2006 to 2008 to the National Institute of Public Health. The strains
were identiﬁed by conventional phenotyping methods, the resistance
to oxacillin was conﬁrmed using chromogenic screening plate (Oxoid
Chromogenic MRSA Agar) and by PCR detection of mecA gene. The
presence of PVL encoding genes was performed by PCR. 24 PVL
positive MRSA isolates were further characterised by SCCmec typing,
S. aureus protein A (spa) sequencing and MLST. Antimicrobial suscep-
tibility testing was determined by microdilution method recommended
by the Clinical and Laboratory Standards Institute (CLSI).
Results: Altogether 24 (2.7%) of 879 MRSA strains had the genes
encoding PVL. The strains were collected mainly from skin lesions
(19 isolates), 4 strains were recovered from blood, and one strain was
isolated from nose. The type IV of SCCmec cassette was the most
predominant among isolates (n = 16), remaining strains possessed type V
(n = 4), type II (n = 2 and type VI (n = 1); one strain was untypeable.
Spa typing and MLST typing was highly congruent. Molecular typing
revealed the presence of 4 clonal groups, 5 strains were singletons. The
most prevalent ST’s and spa types were as follows: ST 8, spa type t008
(n = 8); ST 5, spa type t002 (n = 3); ST 80, spa type t044 (n = 3) and ST
88, spa types t186 and t690 (n = 2).
Conclusion: Our survey revealed the presence of CA-MRSA PVL
positive strains in the Czech Republic. The most prevalent type identiﬁed
in set of Czech strains showed sequence and spa type usually associated
with USA300 clone. The other clonal lineages previously reported in
CA-MRSA strains have been also observed.
This work was supported by a research grant from the Internal Grant
Agency, Ministry of Health (CZ), IGA 9642−4.
P927 Emergence of “animal” MRSA ST398 as coloniser and as
infectious agent in humans
C. Cuny, B. Strommenger, W. Witte ° (Wernigerode, DE)
Objective: To assess the frequency of colonisation by of humans
professionally exposed to MRSA ST398 and of their family members.
Methods: Investigation of nasal swabs from famers and veterinarians
as well as of their family members, typing by means of spa-typing and
grouping of SCCmec elements.
Results: In 32 farms in all Germany: 73 (54.4%) humans from 134
humans exposed to MRSA colonised pigs and 7 (5.4%) of their
nonexposed family members carried MRSAST398.
In 24 families with veterinarians exposed to MRSA positive pigs 28
(57%) from 49 were positive for MRSA ST398 and this was also found in
3 (4.7%) of their nonexposed family members. The frequency of MRSA
ST398 among all MRSA from various kinds of infections in humans
sent to The German Reference Center for Staphylococci for typing was
0.3% with two cases of septicaemia included besides infections of skin
and soft tissue which needed surgical intervention.
Conclusion: As shown in a number of studies in other European
countries MRSA ST398 is a frequent nasal coloniser of humans exposed
to colonised animals. It is obviously also able to spread to contact
persons, in one case emerging during this study the patient died after
wound infection and septicaemia. In general MRSA ST398 is still rare
among MRSA from infections in humans.
P928 Detection of cfr-carrying Staphylococcus spp. Isolates in
Blood Cultures from a Spanish site during a phase 3 clinical
trial of topical administration of omiganan 1% gel
R. Mendes °, M. Sanchez, L. Deshpande, M. de la Torres, R. Jones
(North Liberty, US; Madrid, ES)
Objectives: Central venous catheter related infections (CRI) are often
caused by skin ﬂora. Prevention of catheter colonisation by skin ﬂora
and local catheter site care are crucial steps for controlling CRI.
Omiganan, a topical cationic peptide, is being studied for this indication
in a large, multicentre phase 3 trial. We report detection of cfr-
carrying staphylococci from a patient during the trial. Experiments were
conducted to evaluate potential in vivo cfr transfer.
Methods: Staphylococcus spp. isolates were tested for susceptibility
by CLSI broth microdilution methods. Identiﬁcation was performed by
Vitek 2. Isolates displaying linezolid MIC at 4mg/L were screened for
mutations at the 23S rRNA, L4 and L22 genes, followed by sequencing
and for cfr. Primers targeting the sequences previously detected in the
cfr-carrying plasmid pSCFS3 were used to PCR map the cfr surrounding
region. Gene location was accessed by Southern blot and hybridisation.
S. aureus isolate was submitted for spa and MLST typing.
Results: A 77 y/o male patient was hospitalised in the ICU due
to respiratory failure. Patient received broad-spectrum antimicrobial
therapy, including linezolid. One S. epidermidis and one S. aureus
were recovered on the hospital day 23 and 26 from catheter and
peripheral drawn blood specimens, respectively. Isolates were susceptible
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to omiganan (MIC, 8 and 32mg/L) and resistant to mupirocin, neomycin,
ciproﬂoxacin, erythromycin, gentamicin and oxacillin. Both strains were
resistant to chloramphenicol, clindamycin, linezolid, retapamulin and
quinupristin/dalfopristin, consistent with cfr. Ribosomal target mutations
were not detected. Plasmid analysis identiﬁed two bands in each isolate
of c.a. 160- and 250-, and 145- and 190-kb. Hybridisation signals with a
cfr-probe were noted from the 250-kb and 190-kb bands. PCR mapping
identiﬁed delta tnpB downstream of the cfr in the S. epidermidis. Both
isolates did not possess the istAS and istBS structures associated with
the cfr mobility.
Conclusion: cfr were embedded in different size plasmids and
both genes showed distinct surrounding sequences, suggesting diverse
acquisition events. This report highlights the ability of staphylococci
to acquire multidrug resistance and the potential for cfr dissemination,
representing a serious threat against current Gram-positive agents. The
MIC values for these isolates were well below the concentration of
omiganan 1% gel (10,000mg/L) used in this trial.
P929 Non-mutational cfr-mediated linezolid resistance
Staphylococcus epidermidis isolates
F. Campanile °, D. Bongiorno, S. Borbone, G. Mongelli, M. Baldi,
R. Provenzani, S. Stefani (Catania, Palermo, IT)
Objectives: The mechanism of cfr-mediated resistance to linezolid
involves the methylation of A2503 in the 23S rRNA of the large
ribosomal subunit. This methylation affects the binding of at least three
antimicrobial classes (phenicols, lincosamides, and streptogramin A),
leading to a multi-drug resistant phenotype. The aim of our study was to
investigate the rapid spread of S. epidermidis strains sharing high level
resistance to linezolid.
Methods: The activity of linezolid and other comparator agents was
evaluated against 18 clinical S. epidermidis isolates recovered during
2007–2008, from the ICU of the Hospital Villa Soﬁa in Palermo, by
broth dilution (MICs) and E-test methods. Mutations in the domain V
of the 23S rRNA or cfr-mediated linezolid resistance were conﬁrmed by
PCR and sequencing assays. Macrorestriction analysis was performed
by PFGE.
Results: The 18 clinical S. epidermidis, isolated from 14 patients, were
methicillin-resistant, MDR and showed linezolid MIC values ranging
from 16mg/L to 256mg/L, not related to the G2576T mutation of 23S
rRNA. They all belonged to similar PFGE subtypes (A1-A3) and only
8 strains showed the cfr gene. The presence of this methylase conferred
full resistance to linezolid (MIC 256mg/L) and related drugs. The
cfr gene was localised on the pSCFS-like elements, down-stream of the
IS21–558 insertion sequence that is involved in its mobilisation.
Conclusion: Even if cfr-mediated linezolid resistance among clinical
isolates is rare, here we demonstrate the cfr gene acquisition by 8 S. epi-
dermidis strains of human origin and their rapid spread among patients
of the same ICU, independently from the linezolid use. Non-mutational
resistance to oxazolidinones, due to the cfr gene, has recently been
reported in veterinary isolates of staphylococci, ﬁrst described in S. sciuri
and immediately detected in many other Staphylococcus spp. of animal
origin, carried by pSCFS-like elements. The recent acquisition of the cfr
gene by S. aureus and S. epidermidis human isolates has been described
in only three cases, localised either on plasmids or a chromosome.
P930 A C2534T mutation in the 23S rRNA gene responsible for line-
zolid resistance in a clinical Staphylococcus epidermidis isolate
A. Liakopoulos °, C. Neocleous, M. Kanellopoulou, N. Skarmoutsou,
M. Martsoukou, E. Papafragas, E. Petinaki (Larissa, Athens, GR)
Objective: In the present study the mechanism of resistance of a clinical
S. epidermidis isolate, expressing resistance to linezolid (MIC: 12mg/L)
was investigated.
Methods: In September 2008, a S. epidermidis exhibiting resistance to
linezolid was isolated from blood cultures of a patient hospitalised in
the Intensive Care Unit at “Sismanoglion” General Hospital of Athens,
after ten days exposure to linezolid. The identiﬁcation of the isolate to
species level was performed by conventional and molecular methods.
Susceptibility testing for various antimicrobial agents was performed by
disc diffusion using CLSI criteria, while, the determination of MICs
to oxacillin, vancomycin, teicoplanin, and linezolid, was assessed by
CLSI micro-dilution method and by E-test. After extraction of bacterial
DNA, the isolate was ﬁrstly tested for the presence of the most common
mechanisms: for the presence of G2576T mutation by PCR followed by
NheI digestion, and for the presence of the cfr gene by PCR. In addition,
the detection of some mutations in the region V of 23S rRNA and on
ribosomal protein L4 and L22 genes was performed by PCR followed
by sequencing analysis.
Results: According to disk diffusion test results, S. epidermidis was
resistant to oxacillin, cefoxitin, tobramycin, gentamicin, ciproﬂoxacin,
oﬂoxacin, fucidic acid, erythromycin and clindamycin, intermediate
resistant to linezolid and susceptible to vancomycin, teicoplanin,
tetracycline, daptomycin and tigecycline. The MICs to linezolid,
oxacillin, vancomycin and teicoplanin were 12, 32, 1 and 1mg/L
respectively. The isolate did not carry the G2576T mutation, neither
the cfr gene and any mutations on ribosomal protein L4 and L22 genes.
Analysis of 23S rRNA DNA sequences showed that, our isolate had two
out six copies of 23S rRNA gene (the rrlA and rrlC) that carried the
C2534T mutation. To conﬁrm that this mutation involved to the linezolid
expression, a total of 20 S. epidermidis isolates, genetically unrelated
and linezolid susceptible were also tested for the presence of the C2534T
mutation; none of them was found to contain one or more mutated alleles.
Conclusions: A new mutation, the C2534T, of the domain V of 23S
rRNA, was identiﬁed in a clinical linezolid-resistant S. epidermidis.
This ﬁnding emphasizes that Gram-positive cocci under the pressure
of linezolid had the possibility to develop various ribosomal mutations,
other than the G2576T.
P931 Continuous increase of antibiotic resistance among
non-vaccine type Streptococcus pneumoniae in the era of
7-valent conjugate pneumococcal vaccine
S. Nunes °, R. Sa´-Lea˜o, A.S. Simo˜es, N. Fraza˜o, A. Tavares, H. de
Lencastre (Oeiras, PT)
Objectives: We have been monitoring changes in the Streptococcus
pneumoniae population inhabiting the nasopharynx (NP) of young
children (up to 6 years) following introduction of the seven-valent
pneumococcal conjugate vaccine (PCV7) in 2001. In 2006 and 2007
approximately 60% of the target population had received PCV7. Here
we describe the most recent data obtained in Oeiras, Portugal in 2007.
Methods: Data on antimicrobial consumption and NP samples were
obtained and pneumococci were isolated by routine methods. Antibiotic
susceptibility testing and serotyping were performed.
Results: Of 538 children, 19% had taken antibiotics in the month
preceding sampling and 334 (62%) were colonised with pneumococci.
Eighty-six percent of the isolates were non-vaccine type (NVT) a value
comparable to what was observed in 2006. However, the proportion of
NVT resistant to at least one antibiotic increased signiﬁcantly from
27% in 2006 to 37% in 2007. Furthermore, this increasing trend has
been continuously observed since introduction of PCV7 when this rate
among NVT was 16%. In particular, intermediate resistance to penicillin
(0.12MIC1 ug/mL) increased from 6% in 2001 to 18% in 2006 and
23% in 2007. Resistance to penicillin among NVT was found in 1.4%
of the isolates only. Resistance to macrolides (mainly MLSB phenotype)
increased from 9% in 2001 to 22% in 2006 and 28% in 2007. Multidrug
resistance in 2007 reached 26% of the NVT. In 2007 the most frequently
NVT serotypes associated with resistance were 19A, 6C, 15A and 11A.
Conclusions: The relative proportion of NVT among the total
pneumococcal population did not change from 2006 to 2007. However,
rates of resistance to antibiotics continue to increase among NVT
and apparently a plateau has not yet been reached. The data suggests
that antibiotic pressure in this population is very high. Continuous
surveillance is needed as well intervention strategies aimed to decrease
antibiotic consumption.
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P932 Adult invasive pneumococcal disease in North-Rhine
Westphalia, Germany, 2003–2006: serotype distribution
before recommendation of general pneumococcal conjugate
vaccination for children <2 years of age
M. Imo¨hl °, R.R. Reinert, M. van der Linden (Aachen, DE; Paris, FR)
Objectives: This study was performed to analyse the current epidemi-
ology of invasive S. pneumoniae isolates in adults before the general
recommendation for vaccination of German children <2 years with the
pneumococcal conjugate vaccine was issued at the end of July 2006.
Methods: A population and laboratory based surveillance study of adult
(16 years and above) invasive pneumococcal disease was conducted in
North-Rhine Westphalia, Germany’s most populous federal state, with
approximately 18 million inhabitants. Species conﬁrmation was done by
optochin testing, bile solubility and serotyping.
Results: Invasive isolates were obtained from 519 adult patients from
2003 to 2006. The leading serotypes were serotypes 14 (14.3%), 7F
(9.4%), 3 (9.2%), 4 (8.7%) and 1 (8.1%). Serotype coverage for the
7-valent conjugate vaccine was 43.9%. For the 10-valent and 13-
valent vaccines (in development) the coverages were 61.8% and 76.7%,
respectively. The 23-valent polysaccharide vaccine had a coverage of
91.1%. Penicillin G resistance was observed in 5% of meningitis
cases. In the non-meningitis group only intermediate resistant strains
were detected (0.4%). Cefotaxime intermediate resistance occurred in
meningitis (1.7%) and non meningitis cases (0.4%). Nonsusceptibility
rates (intermediate resistance and resistance) were 16.2% for macrolides,
10.9% for trimethoprim-sulfamethoxazole (SXT), 5.0% for tetracycline,
3.9% for clindamycin and 0.4% for levoﬂoxacin. All isolates were
susceptible to amoxicillin (non meningitis) and telithromycin.
Conclusions: The present study describes the current status of IPD
in adults in North-Rhine Westphalia, Germany, and may serve as a
basis for the interpretation of potential changes concerning effects of
pneumococcal childhood vaccination programmes on IPD in adults,
especially on serotype distribution, resulting coverages of current
vaccines and vaccines in development as well as their potential effects
on antibiotic resistance of S. pneumoniae.
P933 Serotypes evolution in Streptococcus pneumoniae strains
isolated from respiratory tract infections in adults in France
from 2001/02 to 2006/07
H.B. Drugeon °, E. Leput (Nantes, Beaucouze, FR)
Objectives: To describe changes in serotypes of Streptococcus
pneumoniae (SP) strains isolated in respiratory tract infections (RTIs)
in adults in France between 2001/02 and 2006/07
Methods: Since 2001/02, a French survey evaluates each year (from
October to March) the susceptibility of SP isolated from RTIs in adults
to usually prescribed antibiotics. Serotypes were determined by Quellung
test in 657 strains isolated in 31 laboratories in 2001/02 and by PCR
in 1002 strains from 42 laboratories in 2006/07. Antibiotics MICs were
determined by microdilution.
Results: In 2001/02, 46 serotypes or groups of serotypes were identiﬁed
whereas in 2006/07, 29 serotypes or groups of serotypes were identiﬁed
and 11% of strains were not determined even possessing the capsular
gene. In 2001/02, 8 serotypes had frequencies above 5% (3, 6A, 6B,
9V, 14, 19A, 19F, 23F) vs. 6 serotypes (3, 6A, 14, 19A, 19F, 23F) in
2006/07. Between the two periods, the frequency of 23F has decreased
from 17.05 to 6.1% and the frequencies of 2 serotypes (11A and 35B)
have increased and were higher than 3% in 2006/07. Between 2001/02
and 2006/07, intermediate resistance to penicillin was observed in 14
and 14 serotypes and high resistance in 9 and 15 serotypes respectively.
Regarding amoxicillin, intermediate resistance was observed 9 and 13
serotypes and high resistance in 6 and 9 serotypes respectively. Vis-a`-
vis the macrolides, a mechanism of resistance was found in 21 and 19
serotypes respectively.
Conclusion: Frequencies of some epidemic and vaccine serotypes (6B,
9V, 23F) signiﬁcantly decreased. The resistance to b-lactams (low and
high level) spreads and was observed in a greater number of serotypes
in 2006/07. The mechanisms of resistance to macrolides were largely
present amongst numerous serotypes but their number decreased slightly.
P934 The serine threonine kinase StkP of Streptococcus
pneumoniae contributes independently from pbp genes to
penicillin susceptibility
R. Dias °, D. Fe´lix, M. Canic¸a, M. Trombe (Lisbon, PT; Toulouse, FR)
Objectives: The PBPs are the major targets for penicillin in Streptococ-
cus pneumoniae. The serine/threonine kinase StkP of S. pneumoniae was
described to be one target of the phosphoglucosamine mutase GlmM
involved in peptidoglycan biosynthesis, being implicated in b-lactams
susceptibility. In order to further elucidate the association of StkP in
S. pneumoniae in susceptibility to b-lactams, mutational analysis was
undertaken as well as the analysis of genetic diversity of StkP and PBPs
of a sample of clinical strains.
Methods: A set of isogenic mutants was constructed in RX derivatives
with different combinations of PBP and StkP alleles. The conservation
of StkP and PBPs was assessed for 50 strains randomly selected between
1994 and 2005 in various areas of Portugal. Half of the isolates
were non-susceptible to penicillin (minimal inhibitory concentration,
MIC> 0.1mg/L). These isolates were compared to seven reference
strains. The MIC of penicillin G was determined by agar dilution
method according to Clinical and Laboratory Standards Institute. Genetic
polymorphism of penA, pbpX and pbp1A genes was investigated by
restriction fragment length polymorphism analysis, and by nucleotide
sequencing. The average evolutionary divergence of StkP within
penicillin susceptibility was estimated by the Poisson Correction method
and the Maximum Composite Likelihood method for the amino acid and
nucleotide substitutions, respectively. To further understanding the role
of each founded StkP amino acid mutations, a 3D-model of the kinase
domain of the StkP protein was used.
Results: Deletion replacement mutation in stkP conferred hypersensi-
tivity to penicillin G and was epistatic on mutations in PBP2X, PBP2B
and PBP1A from the resistant 9V clinical isolate URA1258. Genetic
analysis of 55 clinical isolates allowed identifying 11 StkP alleles with
regard to the reference R6 allele. Four alleles (StkP alleles: 3, 7, 10
and 11) were only found in sensitive strains. Nevertheless, these strains
showed PBP proﬁles characteristic of sensitive strains, suggesting that
MICs were determined by their PBPs rather than mutations in StkP.
Conclusions: These ﬁndings reveals that StkP is involved in the bacterial
response to penicillin and suggests that StkP activity allows bacteria to
bypass cell wall injury due to penicillin up to a critical concentration
independently of PBPs for a given strain. It is also suggested strong
functional conservation of StkP among clinical isolates.
P935 Characterisation of genetic elements carrying mef other than
mef(A) in Streptococcus pyogenes
M. Del Grosso °, G. Barbabella, R. Camilli, J. Blackman Northwood,
D.J. Farrell, A. Pantosti (Rome, IT; Cambridgeshire, UK; Toronto, CA)
Objectives: In Streptococcus pyogenes, erythromycin (ERY) resistance
due to efﬂux is mainly associated with the mef(A) subclass of the mef
gene, that is carried by a conjugative transposon/prophage. The aim
of this study was to characterise the genetic elements carrying mef
subclasses other than mef(A), in selected S. pyogenes isolates.
Methods: From a global collection of clinical isolates of S. pyogenes, 10
isolates carrying mef other than mef(A) were selected: 4 were resistant
to ERY and tetracycline (TET), 5 to ERY and chloramphenicol (CHL),
and 1 to ERY, TET and CHL. PCR assays were performed to detect
the resistance genes and to deﬁne the possible linkage among them. To
verify the presence of composite genetic elements previously described
in other bacterial species, PCR mapping was performed.
Results: The 4 ERY-TET resistant isolates carried mef(E), rarely reported
in S. pyogenes, and tet(M). The 5 ERY-CHL resistant isolates carried
mef(I), a mef subclass recently described, and catQ. The ERY-TET-
CHL resistant isolate carried a novel subclass of mef, tet(M), and catQ.
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Physical linkage among the resistance genes was observed. Analysis
of the 10 isolates by PCR mapping, indicated the presence of genetic
elements, or part of them, harbouring the resistance genes. In the 4
mef(E)/tet(M)-positive isolates, mef(E) was carried by a typical mega
element that was found inserted in orf6 of Tn916, showing the genetic
organisation of Tn2009 described in Streptococcus pneumoniae. In all
the mef(I)/catQ-positive isolates the linkage between mef(I) and catQ
was observed. PCR mapping indicated the same structure of the IQ
element described in the 5216IQ complex of S. pneumoniae. The novel
mef/tet(M)/catQ-positive isolate showed the same genetic structure of
the 5216IQ complex with the exception of a ca. 4 kb-deletion.
Conclusion: This study showed the presence in S. pyogenes of two
composite elements, Tn2009 and the 5216IQ complex, that have not been
reported before. These ﬁndings enlarge the number of genetic elements
and resistance modules shared between S. pyogenes and S. pneumoniae.
P936 Tn1806, the erm(TR)-carrying genetic element of
Streptococcus pneumoniae
R. Camilli °, R.J.P. Bonnal, M. Del Grosso, M. Iacono, E. Rizzi,
F. Iannelli, G. De Bellis, M.R. Oggioni, A. Pantosti (Rome, Milan,
Siena, IT)
Objectives: Tn1806 is the ﬁrst erm(TR)-carrying genetic element
reported in a clinical isolate of Streptococcus pneumoniae (strain AP200)
and to date has been only partially characterised. In the context of a
whole genome sequencing project of the pneumococcal AP200 strain,
the complete nucleotide sequence of Tn1806 has been obtained. Aim of
this study is to give a fully characterisation of Tn1806.
Methods: The Tn1806 sequence was obtained by high-density
pyrosequencing and comparative analysis was carried out using the
BLAST algorithm.
Results: Tn1806 is 52,457 kb in size and comprises 49 ORFs. Tn1806
is inserted into the hsdM chromosomal gene coding for a restriction
modiﬁcation methyltransferase. At the insertion sites a duplication of the
target sequence for integration of the element has been observed. In the
region ﬂanking erm(TR), Tn1806 carries other antibiotic resistance genes
such as the tetronasin efﬂux pumps and a spectinomycin fosfotransferase.
Comparative nucleotide analysis conﬁrmed similarity of Tn1806 with
ICE10750 RD-2, the Streptococcus pyogenes erm(TR)-carrying element.
Tn1806 is approximately 4 kb larger in size than ICE10750 RD-2 due to
the presence of additional regions such as 3 ORFs found also in RD1,
a chimeric element of S. pyogenes MGAS6180. Comparative analysis
detected an element similar to Tn1806 in Finegoldia magna, an anaerobic
Gram-positive coccus. The F. magna element shares high nucleotide sim-
ilarity over a region of about 23 kb but lacks the region carrying erm(TR)
and the other antibiotic resistance genes, which is replaced by a different
sequence of similar size. A large region similar to Tn1806, has been
found also in the incomplete genome of Ureaplasma urealyticum ATCC
33175. Tn1806, ICE10750 RD-2 and the F. magna element share a sim-
ilar backbone structure, with some insertion/deletion or replacement of
modules that confer element-speciﬁc features. Most of the unique mod-
ules differing Tn1806/ICE10750 RD-2 from the F. magna element car-
ried genes related to drug resistance such as those conferring resistance
to erytromycin, tetronasin and spectinomycin in Tn1806 and ICE10750
RD-2 or a series of ABC multidrug resistance efﬂux pumps in F. magna.
Conclusions: The common backbone structure shared by Tn1806,
ICE10750 RD-2 and the F. magna element could represent a broad-host-
range element able to incorporate resistance genes, thus contributing to
the diffusion of multiple drug resistance.
P937 Tigecycline activity against macrolide resistance in
Streptococcus pneumoniae mediated by mefE and ermB
determinants: a global analysis 2008
D. Hoban, M. Renteria, J. Johnson, R. Badal, S. Hawser °, M. Hackel,
S. Bouchillon, B. Johnson, M. Dowzicky (Schaumburg, Collegeville, US)
Background: Macrolide resistance in S. pneumoniae (MRSP) has
increased steadily in the last decade. Two important determinants in
MRSP are the mefE (clindamycin-resistant, macrolide-resistant) and
ermB (clindamycin-resistant, macrolide-resistant) genes. This report
evaluates tigecycline and comparator drug activity from a global
population of MRSP in clinical isolates collected in the T.E.S.T. program
during the years 2004 to 2008.
Methods: 1,962 S. pneumoniae clinical isolates were collected from 163
investigative sites in 31 countries and tested for erythromycin resistance.
Clinical isolates were identiﬁed to the species level at each participating
site and conﬁrmed by the central laboratory. Minimum Inhibitory
Concentrations (MICs) were determined by a reference laboratory using
broth microdilution panels and interpreted according to CLSI guidelines.
Results: Summary data for the 557/1962 (28.4%) MRSP strains
categorised by ermB and mefE determinants are presented in the table.
Conclusions: Tigecycline demonstrated the lowest MIC50 and MIC90 in
vitro values of all study drugs against macrolide-resistant S. pneumoniae
with ermB determinants and was equivalent to clindamycin against
mefE determinants. Tigecycline in vitro activity suggests that tigecycline
may be effective against this important clinical pathogen and resistant
phenotype.
Drug ermB (n = 254) mefE (n = 244)
MIC50 MIC90 % Sus % Res MIC50 MIC90 % Sus % Res
Tigecycline 0.03 0.12 na na 0.03 0.12 na na
AmoxClav 0.5 4 71.3 9.8 0.25 2 92.2 1.6
Cefdinir >2 >2 39.8 59.1 1 >2 46.3 46.3
Ceftriaxone 0.5 1 87.8 3.5 0.25 1 92.2 1.2
Cefuroxime 4 8 38.2 59.1 1 8 48 49.6
Clindamycin >64 >64 0 100 0.06 0.12 100 0
Erythromycin >64 >64 0 100 16 64 0 100
Levoﬂoxacin 0.5 1 99.2 0.4 0.5 1 99.2 0.8
Linezolid =0.5 1 100 0 =0.5 1 100 0
Minocycline 4 8 3.9 1.6 =0.25 4 5.7 0.4
Penicillin 1 4 23.6 40.9 0.25 2 27 25.4
Trimeth Sulfa 4 >4 27.2 59.1 4 >4 30.3 54.1
P938 In vitro activity of garenoxacin against clinical isolates of
levoﬂoxacin-resistant Streptococcus pneumoniae with amino
acid substitutions in QRDRs of gyrase and topoisomerase IV
M. Takahata °, Y. Furuya, H. Yamada, Y. Fukuda, J. Mitsuyama
(Toyama, JP)
Objectives: Fluoroquinolone-resistant S. pneumoniae are increasing
rapidly throughout the world. In vitro activities of garenoxacin (GRN),
a des-ﬂuoro (6)-quinolone, were evaluated against clinical isolates of
S. pneumoniae resistant to levoﬂoxacin (LVX), characterised genetically.
Methods: Quinolone resistant-determining regions (QRDR) of gyrA,
gyrB, parC and parE of 19 LVX-resistant strains, isolated from adult
patients in Japan, were analyzed by PCR-based sequencing. MICs of
GRN and other ﬂuoroquinolones were determined by a microdilution
broth method. The 50% inhibitory concentrations (IC50 s) against
supercoiling activity of DNA gyrase and decatenation activity of
topoisomerase IV (Topo IV) of LVX-resistant S. pneumoniae D-3668
(GyrA: S81F, ParC: S79F, GyrB, ParE: no mutation) were measured
referring to previously described methods.
Results: MICs of GRN against LVX-resistant S. pneumoniae (LVX MIC
range, 8−32mg/L) were 0.125 to 1mg/L, 16- to 256-fold lower than
those of LVX, and 4- to 16-fold lower than those of moxiﬂoxacin (MXF,
MIC range, 0.5−8mg/L). Seventeen of 19 strains had single or double
amino acid (Aa) substitutions in the QRDR of GyrA, which included
D80A, S81Y/F, E85G and S114G. In GyrB, 2 of 19 strains had a single
Aa substitution (D435N/E or E474K). Fourteen of 19 strains had single
or double Aa substitutions in ParC, which included S79Y/F, D83N/Y,
N91D and K137N. In ParE, 14 of 19 strains had single or double Aa
substitutions (D435N, I460V and E474K). Even if there was a mutation
of S81Y/F in GyrA, GRN showed potent antibacterial activity if ParC
did not have a mutation such as S79Y/F. The IC50 s of GRN against
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supercoiling activity of DNA gyrase and decatenation activity of Topo IV
of LVX-resistant S. pneumoniae D-3668 were 357mg/L and 3.76mg/L,
respectively. GRN showed 3.6- and 1.7-fold (gyrase), 11.0- and 2.7-fold
(Topo IV) more potent inhibitory activity against the two target enzymes
than of LVX and MXF, respectively.
Conclusions: GRN showed more potent in vitro antibacterial activity
against LVX-resistant S. pneumoniae than MXF. The potent activity of
GRN against the LVX-resistant strain was based on potent inhibitory
activity against the target enzymes.
P939 Epidemiological analysis of pneumococcal carriage in
Hungarian children from a day-care centre
O. Dobay °, A. To´thpa´l, S. Kardos, E. Hajdu´, E. Nagy, S. Amyes,
K. Nagy (Budapest, Szeged, HU; Edinburgh, UK)
Objectives: The carriage of Streptococcus pneumoniae (pneumococci)
plays a major role in the transmission of bacteria to sensitive individuals.
The carriage rate can reach 50–100% in small children, especially
attending day-care centres. Prevenar was proven also to have an effect
on the carriage. As this vaccine became widely available in Hungary
for children <2 y in Oct 2008, it was important to examine the
carriage of pneumococcal strains before the vaccination programme was
implemented.
Methods: Thirty-four pneumococcal isolates were collected from the
nasal passages of children attending a day-care centre in Szeged,
Hungary. The species identity of all strains was conﬁrmed by the
presence of the lytA gene. Their antibiotic sensitivity was determined
by E-test, applying the EUCAST breakpoints. Serotyping was done by
the combination of the conventional method (with antisera) and a PCR-
based method. The genetic relatedness of the strains was examined by
PFGE.
Results: We could serotype 25 out of the 34 strains (=73.5%). The
detected serotypes were (n): 14 (6), 6A (6), 3 (3), 13 (2), 18C (2), 9L, N
(2), 9V (1), 19A (1), 19F (1), 15A (1). None of the strains were resistant
(R) to penicillin (pen), the highest MICs (0.5−0.75mg/L) were detected
in sero 14 isolates. Serotypes 6A and 19 also fell in the pen I category.
All isolates were sensitive (S) to levoﬂoxacin. Seven strains showed high-
level R to erythromycin (ery), these were of different serotypes, and 4
carried the erm(B) gene. Five strains were R to ery (6−24mg/L), but S
to clindamycin (M type), all these were of sero 14, identical by PFGE
and had the mef gene. One single sero 14 strain was S to everything, and
shared PFGE identity with one sero 13 strains. The six sero 6A strains
formed 2 PFGE clones, mirroring the different pen and ery MICs.
Conclusions: It is surprising to observe the absence of the usually
frequent serotype 23F among the carried strains, and the presence of
the rather rare serotype 13. Based on our data, and taking certain cross-
protections into account, Prevenar (serotypes 4, 6B, 9V, 14, 18C, 19F,
23F) would cover 18 out of the 25 isolates (72.0%), or 52.9%, if we
relate it to all 34 strains. The presence of a mef+ serotype 14 clone (very
probably the England 14−9 PMEN clone) was observed. An interesting
serotype switch was detected between sero 14 and 13. This study involves
only a small number of isolates; however, this is the ﬁrst study on
pneumococcal carriage in Hungary.
P940 Analysis of alterations in the leader sequence of the erm(B)
gene of different species of viridans group streptococci
expressing MLSB resistance phenotype
I. Rodriguez-Avial °, C. Rodrı´guez-Avial, E. Culebras, J. Picazo
(Madrid, ES)
Objectives: The main methylase conferring MLSB resistance among
viridans group streptococci (VGS) is encoded by the erm (B) gene. To
determine the sequence of the erm (B) regulatory region, we analyzed
the leader sequence of the gene in different VGS species and in
S. bovis showing cMLSB and iMLSB phenotypes. A telithromycin-
resistant S. bovis isolate was also included.
Methods: From 1998 to 2006 223 VGS and S. bovis were isolated from
blood in our institution. Erythromycin resistance was observed in 104
strains; 62 displayed cMLSB and 5 iMLSB phenotype. Sixteen strains
were selected: 5 S. anginosus, 4 S. mitis, 3 S. costellatus, 2 S. bovis, and 1
S. salivarius cMLSB phenotype, 1 S. bovis iMLSB and 1 S. bovis cMLSB
showing telithomycin resistance (MIC=4mg/l). The erm(B) upstream
region of these isolates was ampliﬁed from chromosomal DNA. The
DNA sequences and the deduced amino acid sequences were compared
to the upstream erm (B) region found in Tn1545 (accession no. X53632).
Results: Three different point mutations were detected in the leader
peptide region compared to Tn1545: A138T was detected in 1 S. mitis
cMLSB isolate resulting in N8Y substitution, G186A in 2 S. anginosus,
1 S. mitis and 1 S. bovis cMLSB isolates resulting in A25T substitution
and in the telithromycin-resistant S. bovis isolate, G186A was detected
resulting in a stop codon and a shorter leader peptide (16 amino acids)
compared to Tn1545 (27 amino acids). A 24 pb duplication at the
beginning (position 333) of the ORF of the erm (B) was also observed
in the telithromicin resistant S. bovis strain. No mutations were detected
in the remaining strains included.
Conclusions: Some of the mutations presented in this study are likely not
involved in resistance and may represent heterogeneity in the erm (B) and
its leader sequence among viridans group streptococci and Streptococcus
bovis. However a shorter leader peptide and duplication in the ORF of
the erm (B) gene were detected in a telithromycin resistant S. bovis strain
and could be implicated in the ketolide resistance.
P941 Rapid decrease in the prevalence of macrolide-resistant
group A streptococci in Spain
J. Valverde, J. Ferna´ndez, L. Molina, C. Campelo, I. Buhigas,
A. Delgado-Iribarren ° (Madrid, ES)
Objectives: To study the antimicrobial susceptibility and prevalence of
the different phenotypes of macrolide resistance in group A streptococci
(GAS) isolated in Madrid, (Spain in) 2002–2007.
Introduction: The increase of the resistance and the changes in
the implied mechanisms reduce the effectiveness of macrolides and
clindamycin as an alternative treatment for GAS infections.
Methods: A total of 2380 isolates of Streptococcus pyogenes collected
in the years 2002–2007 in Madrid, Spain were used. Antimicrobial sus-
ceptibility testing was performed using the agar diffusion method. Discs
containing erythromycin and clindamycin were used to recognize the
phenotypes of macrolide-lincosamide-streptogramin (MLS) resistance.
Results: Evolution of antimicrobial resistance is shown in ﬁgure 1.
Although the overall level of macrolide resistance has remained stable
in Spain (15−20%) in previous years, a rapid inversion in the dominant
phenotypes has been noted, with a sharp decrease in the MLS(B)
phenotype paralleled by an increase in the M phenotype in the last
years. In our study the peak was reached in 2004 showing 39% of
the isolates resistance to erythromycin (81.9% M phenotype), with a
continuous decrease since then to reach a minimum in 2008 (8.2%),
although keeping the predominance of the M phenotype isolates (80.2%).
Figure 1. Resistance to macrolides and lincosamides in Streptococcus
pyogenes.
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Conclusions: We have found a dramatic decrease of erythromycin
resistance to GAS during the last years; this may be explained because of
changes in the distribution of M phenotype in the community, due to the
appearance of new epidemic clones as has been described recently. [1]
Reference(s)
[1] Oliver MA, Garcı´a-Delafuente C, Cano ME, Pe´rez-Herna´ndez F,
Martı´nez-Martı´nez L, Albertı´ S. Rapid decrease in the prevalence of
macrolide-resistant group A streptococci due to the appearance of
two epidemic clones in Cantabria (Spain). J Antimicrob Chemother.
2007 Aug;60(2):450−2. Epub 2007 May 31.
P942 Bacteriophage-mediated transfer of erythromycin and
tetracycline resistance genes among group A streptococci
L.A. Vitali °, M.C. Di Luca, S. D’Ercole, D. Petrelli, M. Prenna,
S. Ripa (Camerino, IT)
Objectives: In Streptococcus pyogenes (Group A Streptococcus,
GAS), genes conferring efﬂux-mediated erythromycin (ERY) resistance
(mefA/msr) are carried by functional prophages and may be associated
with the tetracycline (TET) resistance determinant tetO.
We sought to demonstrate the “ex vivo” lysogenic transfer of ERY and
TET resistance genes among GAS.
Methods: Forty-one ERY-susceptible GAS clinical isolates belonging to
12 different M-serotypes were used as recipients. The strain K56 (M-
serotype 12) was used as a standard indicator to prepare lawns and as
a model recipient, while the ERY- and TET-resistant strain m46 (M-
serotype 4) was used as the donor of the tetO-mefA phage (phi-m46).
The donor was induced with 0.2mg/L mitomycin C. The culture
supernatant was ﬁltered, treated with DNAse/RNAse, concentrated
by PEG/NaCl precipitation, and then added to cultures of the
recipient strains. After incubation, these mixtures were either added to
supplemented molten top agar and poured over BHI agar plates for
the visualisation and counting of plaques or plated on BHI agar plus
erythromycin for the selection of ERY-resistant lysogenic clones.
PCR was used to check for the emm-type, mefA, and tetO genes before
and after lysogenic transfer experiments, and to detect phi-m46 DNA in
the supernatant of induced donor cultures.
Results: The reference strain K56 and 85.4% (n = 35) of the clinical
isolates acquired ERY/TET resistance when infected with puriﬁed phi-
m46. All the M1 (n = 7), M12 (n = 6), M75 (n = 2), M18 (n = 1), M94
(n = 1) and a fraction of the M3 (5/7), M4 (1/3), M5 (1/2), M6
(4/7) strains were lysogenised and converted to the ERY/TET resistant
phenotype. No lysogenic clones were isolated in the case of the M77,
M78 and M89 recipients. Only M12 strains and the totality of them were
phi-m46-sensitive.
Conclusions: The erythromycin and tetracycline resistance determinants
carried by phage-m46 can be efﬁciently transferred from a GAS strain to
another by transduction. This is the ﬁrst direct demonstration of phage-
mediated horizontal resistance gene transfer in S. pyogenes. In the set of
strains analyzed, an M-serotype dependent barrier to lysogenic transfer
was not observed. The exclusive lysis susceptibility of the M12 strains
indicates that GAS with this serotype may represent the main responsible
for the spread of this phage and the associated antibiotic resistance genes
in S. pyogenes global population.
P943 Amoxicillin resistance of oral streptococci in healthy patients
undergoing tooth extraction
C. Plainvert °, K. Yasukawa, A. Ergani, J. Azerad, H. Chardin,
A. Bouvet (Paris, FR)
Background: Reduced susceptibility to penicillin is commonly observed
in oral streptococci from patients exposed to recurrent courses of
antibiotics, but little is known about the susceptibility to penicillins of
the commensal oral ﬂora in healthy adults.
Objectives: The aims of this study were (i) to evaluate the presence of
oral streptococci with reduced susceptibility to amoxicillin (ii) to identify
to the species level the resistant isolates using phenotypic and genomic
methods, and (iii) to follow up the evolution of the susceptibilities after
amoxicillin therapy.
Methods: Thirty three healthy patients undergoing tooth extraction
were randomly assigned in a double blind control study to a 7-day
amoxicillin treatment or a 3-day amoxicillin + 4-day placebo treatment.
The patients treated with any antibiotic in the 45 days before were
excluded. Post-operative follow up was done 7 and 30 days after tooth
extraction. Oral streptococcal ﬂora was quantiﬁed on selective Columbia
blood agar supplemented with 0mg/L, 0.5mg/L, 2mg/L or 16mg/L
of amoxicillin. MICs were determined on streptococci by E-test®
(Biomerieux). Amoxicillin-intermediate and resistant (amoxicillin-I and
-R) strains were deﬁned according to the recommendations of the
CA-SFM. Identiﬁcations were ﬁrst determined by metabolic characters
obtained on rapid ID32 STREP® gallery (Biomerieux). Final speciation
was then determined by sequence analysis of the 16S rRNA and the
sodA genes.
Results: A total of 43 amoxicillin-R (MIC> 16mg/L) and 70
amoxicillin-I (0.5<MIC 16mg/L) streptococcal strains were isolated.
Most of the resistant strains were Streptococcus oralis, others were
Streptococcus mitis, Streptococcus sanguinis, Streptococcus australis,
Streptococcus parasanguinis or Streptococcus infantis.
Two and 28 patients were respectively colonised by amoxicillin-R or
-I streptococci before treatment. Among the 22 patients followed up
after treatment, all but two were colonised by amoxicillin-I and two by
amoxicillin-R streptococci, irrespective of the duration of the amoxicillin
course.
Conclusion: These results demonstrate both the presence of resistant oral
streptococci in the commensal ﬂora of healthy patients and their rapid
selection by amoxicillin treatment. Given the role of oral streptococci
in the acquisition of b-lactam resistance by virulent pneumococci, this
study leads to promote short antibiotic course and to survey the antibiotic
resistance among oral ﬂora.
P944 Rapid detection of G2576T mutation conferring linezolid
resistance in enterococci
N. Bourgeois-Nicolaos, E. Salomon, K. Benzekri, M.J. Butel,
F. Doucet-Populaire ° (Paris, FR)
Objectives: Resistance to linezolid has been described in clinical
enterococci isolates and is mediated by a single nucleotide polymorphism
(SNP) of guanine to thymidine at bp 2576 (G2576T) in the multiple rrl
genes encoding 23S rRNA synthesis. The proportion of rrl genes with
this SNP correlates with the level of resistance to linezolid. A rapid test
based on Allele Speciﬁc PCR (AS-PCR) was designed to detect the SNP
at position 2576 of the 23S rRNA genes of Enterococcus.
Methods: The assay was evaluated on 52 enterococcal isolates
(Enterococcus faecalis (n = 40) or Enterococcus faecium (n = 12)) and
4 non enterococcal isolates. Thirty isolates were susceptible to linezolid
(MIC of linezolid <4mg/L); 26 isolates were linezolid resistant (MIC of
linezolid >4mg/L) known to contain by sequencing analysis either the
G2576T SNP (n = 23) or the G2505A SNP (n = 3).
Real time PCR was performed using a speciﬁc primer in which the
second nucleotide from the 3′ end was designed to match site of the
point mutation (T) and the second nucleotide was designed to produce a
mismatch in order to yield AS-PCR ampliﬁcation. DNA melting analysis
with ﬂuorescent SYBR Green afforded detection of the PCR products
on a Smart Cycler®.
Results: Perfect correlation was obtained between AS-PCR and
reference sequencing method. All non enterococcal isolates, linezolid
susceptible enterococcal isolates and linezolid resistant isolates con-
taining a mutation at position 2505 were negative with our AS-PCR
assay. The G2576T mutation responsible to linezolid resistance could be
detected successfully by this method in enterococcal isolates. A good
correlation was also found between linezolid MICs and the number of
rrl genes carrying G2576T mutation.
Conclusion: The real-rime AS-PCR assay for detection of G2576T
mutation in Enterococcus allows an easy and rapid detection of linezolid
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resistant strains of E. faecalis and E. faecium. This method is even able
to identify a single mutated rrl gene witch is known to increase the
selection of linezolid resistant enterococci under linezolid pressure.
P945 Outbreak of multiple clones of linezolid- and vancomycin-
resistant enterococci in the intensive care unit of a Greek
university hospital
E. Ntokou °, C. Stathopoulos, A. Ikonomidis, D. Makris, E. Zakynthinos,
A. Tsakris, A. Maniatis, S. Pournaras (Larissa, Athens, GR)
Objectives: Linezolid is often used for the treatment of infections
due to vancomycin-resistant enterococci. During the last few years,
linezolid-resistant enterococci are sporadically isolated from several
hospitals where linezolid is overused. The current study investigated
the dissemination and the resistance mechanisms of linezolid-resistant
Enterococcus faecium and faecalis isolates causing an outbreak in a
Greek University Hospital.
Methods: During the period January 2007 and December 2008, 23
linezolid-resistant E. faecium and faecalis clinical isolates were recovered
from 14 patients hospitalised in the intensive-care unit (ICU) of the
University Hospital of Larissa, Greece. Isolates were screened by PCR
using four overlapping sets of primers amplifying the total domain V of
the 23S rRNA subunit, to detect mutations on the peptidyl-transferase
centre of the bacterial ribosome. Sequencing of the PCR products
revealed the mutations conferring linezolid resistance. The number of
mutated copies was estimated from the presence and relative size of two
different peaks in the mutated nucleotide position. The isolates were
also screened by pulsed-ﬁeld gel electrophoresis (PFGE) to determine
the clonal clusters.
Results: Nine patients yielded linezolid-resistant E. faecium and ﬁve
E. faecalis isolates. These isolates were multidrug resistant and recovered
from bacteraemias in eight and from less signiﬁcantly sites in the
remaining six patients. The linezolid MIC’s of the 23 isolates varied
from 24 to >256mg/ml, while 11 isolates (47.8%) were co-resistant
to vancomycin and 12 of 23 (52.1%) to teicoplanin. All of the
isolates carried the commonly detected mutation G2576T. The amount
of the mutated copies ranged from two to six and correlated with
the linezolid MICs. PFGE revealed multiple unrelated electrophoretic
patterns indicating a multiclonal outbreak. Resistance was correlated
with prolonged linezolid treatment in 11 patients, while three patients
had not received linezolid.
Conclusions: Both E. faecium and faecalis have developed linezolid-
resistance in the ICU of our hospital. Most of the isolates belonged to
unrelated clones, indicating that linezolid resistance was not related to
patient-to-patient transmission and is probably endemic in our institution.
Rational use of linezolid and intensive infection control measures are
required to restrict further isolations of these difﬁcult to treat pathogens.
P946 Clonal spread of penicillin-resistant ampicillin-susceptible En-
terococcus faecalis among bloodstream infections in Denmark
H.C. Schønheyder °, J. Larsen, L. Guardabassi (Aalborg, Frederiksberg,
DK)
Objective: Penicillin resistance has remained rare in E. faecalis despite
being frequent in E. faecium. In the last few years we have noted
the emergence of penicillin-resistant ampicillin-susceptible E. faecalis
(PRASEF) among blood culture isolates in North Denmark Region. The
objective of this study was to elucidate the molecular epidemiology of
PRASEF.
Methods: We identiﬁed 44 patients with E. faecalis bacteraemia in
2007 through a regional microbiology information system; clinical and
epidemiological data were obtained from a regional bacteraemia register.
Antibiotic susceptibility was determined by Etest using the Clinical and
Laboratory Standard Institute (CLSI) breakpoints. We used nitroceﬁn
disks to test for b-lactamase activity (Oxoid, UK). A total of 20 PRASEF
isolates and 13 random penicillin-susceptible isolates were genotyped by
gdh sequence analysis, and isolates displaying allele type 12 were further
analyzed by multi-locus sequence typing (MLST). Isolates belonging to
the predominant sequence type (ST) were characterised by pulsed-ﬁeld
gel electrophoresis (PFGE).
Results: We recorded 20 cases of PRASEF bacteraemia, 15 of which
were nosocomial. At the time of diagnosis patients were admitted to
7 hospitals with different types of infection (Table). PRASEF isolates
had penicillin MICs 16mg/mL and ampicillin MICs 4mg/mL. No
b-lactamase activity was detected. Two PRASEF isolates were resistant
to imipenem (MICs 16mg/ml). High-level resistance to gentamicin was
common (17/20 isolates). All isolates were susceptible to vancomycin.
Seventeen PRASEF isolates belonged to gdh allele type 12 and ST6. The
three remaining PRASEF and all penicillin-susceptible isolates were not
related to ST6. The seventeen ST6 isolates were genetically related as
shown by PFGE (5 band differences).
Conclusion: The emergence of PRASEF in North Denmark Region is
mainly due to clonal spread of a speciﬁc lineage (ST6) that has acquired
this atypical penicillin resistance phenotype. It is generally assumed
that penicillin and ampicillin resistance are linked in enterococci, but
the emergence of PRASEF underpins that this is not necessarily true.
PRASEF constitutes a challenge to current guidelines for susceptibility
testing and treatment of E. faecalis infections.
Origins, resistance phenotypes and genotypes of 20 penicillin-resistant ampicillin-susceptible Enterococcus faecalis
(PRASEF) isolates from blood cultures in North Denmark Region.
Strain ID Site of infection Origina Hospital MIC (mg/ml) Sequence
type
PFGE
AMP PEN IPM GEN VAN gdh MLST
B63792 Urinary tract NH 8 1.5 >32 6 >1024 4 12 6 A1
B37814 Undetermined N 8 1.5 >32 8 >1024 3 12 6 A1
B71580 Hepato-biliary-pancreatic tract HC 8 1.5 >32 8 >1024 4 12 6 A1
B33621 Urinary tract N 7 1 16 8 1024 3 12 6 A1
B135456 Urinary tract N 6 4 >32 8 96 2 12 6 A1
B69486 Aortic vascular prosthesis C 4 1.5 >32 6 >1024 3 12 6 A1
B15725 Undetermined N 8 1.5 32 32 >1024 3 12 6 A2
B98380 Undetermined C 1 3 16 4 >1024 2 12 6 A2
B37093 Undetermined N 8 1 >32 4 >1024 3 12 6 A3
B72715 Urinary tract N 4 2 >32 6 1024 3 12 6 A3
B54027 IV catheter N 8 3 >32 6 >1024 3 12 6 A4
B147794 Diabetic gangrene N 8 0.75 >32 4 >1024 2 12 6 A4
B33672 Perirenal abscess N 3 1 32 4 1024 3 12 6 A4
B110274 Undetermined N 8 3 >32 4 >1024 3 12 6 A5
B85040 Urinary tract HC 8 1.5 16 4 >1024 3 12 6 A6
B67010 Endocarditis N 8 1.5 >32 8 >1024 3 12 6 A7
B37957 Surgical site infection N 8 1.5 >32 6 >1024 3 12 6 A8
B84847 Hepato-biliary-pancreatic tract N 5 1.5 >32 2 16 3 2 23 NTb
B56765 Undetermined N 8 4 >32 32 >1024 4 4 28 NTb
B16457 Undetermined N 8 4 32 8 96 4 New New NTb
aN, nosocomial; C, community-acquired; HC, health care-related.
bNT, not typed by pulsed-ﬁeld gel electrophoresis (PFGE).
P947 Spread of EfcTn1 in enterococci from different ecological
niches
C. Novais °, A.R. Freitas, F. Baquero, L.V. Peixe, T.M. Coque (Porto,
PT; Madrid, ES)
Objectives: Conjugative transposons (CTn) have contributed to the
spread of tetracycline (Te) resistance and have been associated with tetM
and rarely with tetS. The latter was recently described in EfcTn1 from an
E. faecium (Efm) of a primate. We evaluated the frequency of EfcTn1
in enterococci from different settings and characterised its molecular
structure.
Methods: Enterococci (n = 616) from several Portuguese sources
(animals or animal environment-260, healthy human (HH)-125,
sewage/river-54, clinical samples (CS)-102 from 1999–2006) and 97
enterococci representative of HiRECC nosocomial strains from other 19
countries of 5 continents (1986–2006) were screened for the presence
of tet genes (M, O, L, S, K), integrases, excisionases, transposases or
relaxases of CTn from Gram positives (EfcTn1, Tn916, Tn5397, Tn5398,
CW459TetM or Tn5386) associated with resistance to tetracycline and/or
erythromycin. Positive samples for int/xisEfCtn1 were ampliﬁed with
tetSFW-IntRVEfcTn1 and orf20 Tn916/orf14 Tn916/orf13Tn916-tetSRV
(long-PCRs). PCR products were digested and RFLP patterns were
compared (TaqaI/AluI). One representative E. faecalis (Efc) was partially
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sequenced. Antibiotic susceptibility test was done by disc diffusion/agar
dilution and clonality by PFGE.
Results: int/xisEfCtn1 were detected in 7 Efc (5-HH; 2-USA CS) and in
2 Efm (same clone; 2 piggeries). All but 2 (HH-TeI) were TeR. tetS, tetM
and tetL were ampliﬁed in all, 6 and 1 isolates, respectively. RFLP proﬁle
of tetSFW-IntRVEfcTn1 (~4 kb) was the same in all isolates. Sequencing
of one Efc revealed the organisation previously described to EfcTn1 with
int/xisEfCtn1 followed by 4 orf showing >50% of aminoacidic similarity
with orf8, orf7, orf9, orf6 of Tn916 and tetS. Ampliﬁcation of Tn916
sequences as orf13, orf14 or orf20 (relaxase) and tetSRV was negative.
Seven of the enterococci also harboured Tn916 (n = 5), Tn917 (n = 4),
Tn5398 (n = 4) or CW459tetM (n = 1). Transconjugants contained Tns
other than EfcTn1 supporting the low frequency rate of transposition
previously described.
Conclusions: EfcTn1 is described for the ﬁrst time in different ecological
niches and seem to be more widespread than initially expected. Isolates
from different settings showed a similar structure between tetS and the
integrase suggesting genetic stability in this area.
P948 Portuguese healthy human volunteers are reservoirs of
conjugative transposons associated with tetracycline and/or
erythromycin resistance
C. Novais °, A.R. Freitas, C. Barros, F. Baquero, L.V. Peixe, T.M. Coque
(Porto, PT; Madrid, ES)
Objectives: Conjugative transposons (CTn) have contributed to the
spread of tetracycline (Te) and erythromycin (Er) resistance and they
might inﬂuence the adaptation of enterococci to different environments.
Diversity of Gram positive CTn was analyzed among enterococci from
Portuguese healthy human volunteers (HV).
Methods: We studied 125 enterococci (61 E. faecalis-Ef, 51 E. faecium-
Efm, 13 Enterococcus spp-Ep) from the faeces of 80 HV obtained in
the Centre and North of Portugal in 2001. Resistance to Te and Er was
observed in 74% of the isolates studied each. Resistance genes were
analyzed by PCR (tetM, tetO, tetL, tetS, tetK, ermB). The presence of
known Gram positive CTn and other Tn frequently associated with them
was screened by a multiplex PCRs for detecting integrases, excisionases,
transposases and relaxases of Tn916, Tn917, Tn5397, Tn5398, EfcTn1,
CW459TetM, or Tn5386.
Results: Tet genes were found among isolates resistant (n = 93),
moderately resistant (n = 8) or susceptible (n = 24) to Te. We found
tetM, tetL and tetS among Ef (75%, 26%, 7%), Efm (69%,
45%, 0%) and Ep (62%, 33%, 0%). Occurrence of int/xisTn916,
tnpA/tnpRTn917, orf298Tn5398 or int/xisEfCtn1 was higher for Efc
than for Efm or Ep (69%/25%/46%; 15%/8%/0%; 52%/25%/46%;
8%/0%/0% respectively). tndXTn5397 was more common among Efm
(18%) than Efc (2%). IntCW459tetM was detected for the ﬁrst
time in enterococci and was observed in 4 Ep, 3 Ef and 1 Efm.
Among isolates harbouring CTn, 57% presented one and 43% two
or more of these genetic elements (int/xisTn916+orf298Tn5398−24%;
int/xisTn916+tnpA/tnpRTn917−6%; int/xisTn916+tnpA/tnpRTn917+
orf298Tn5398−3%; int/xisTn916+tnpA/tnpRTn917+orf298Tn5398+
int/xisEfCtn1−2%; 8 other combinations with 1 isolate each).
Conclusion: Portuguese HV are important reservoirs of Gram positive
Tns associated with Te and Er resistance. Some Clostridium sp typical
genetic elements were isolated for the ﬁrst time in enterococci from
this setting (CW459tetM, Tn5398) and their high occurrence suggest
frequent mobilisation among different bacterial genera.
P949 Characterisation of Gram-positive conjugative transposons
among international epidemic vancomycin-resistant isolates
of Enterococcus faecalis and Enterococcus faecium
C. Novais °, A.R. Freitas, M.V. Francia, L.V. Peixe, F. Baquero,
T.M. Coque (Porto, PT; Santander, Madrid, ES)
Objectives: Conjugative transposons (CTn) contributed to the spread
of antibiotic resistance in enterococci (tetracycline, TeR, erythromycin-
ErR and vancomycin-VcR). Diversity of all known Gram positive CTns
was analyzed by a multiplex PCR in clinical vancomycin-resistant
enterococcal strains causing hospital outbreaks in different continents.
Methods: We studied 63 E. faecium (Efm) and 32 E. faecalis (Efc)
isolates from different patients of 20 countries (Portugal, Spain, France,
Italy, UK, Poland, Germany Hungary, Cyprus, Greece, Serbia, Norway,
Netherlands, Denmark, USA, Chile, Brasil, Argentina, Australia,
Singapore) collected from 1986 to 2006. They are representative isolates
causing well characterised clinical outbreaks isolates, most of them
belonging to High Risk Clonal Complexes (HiRCC) of Efc (CC2, CC9,
CC87) and Efm (CC17). All but two isolates (Efm) were resistant to
vancomycin (vanA-68%; vanB-25%, vanG-1%). Characterisation of tet
(tetM, tetO, tetL, tetS, tetK) and ermB genes was performed by PCR.
The presence of integrases/excisionases from Gram positive CTns or
other Tn associated to them (Tn916, Tn917 Tn5397, Tn5398, EfcTn1,
CW459TetM, Tn5386) was screened by multiplex PCR assays and
further sequencing. Speciﬁcity of the method was proved by using
speciﬁc control strains and sequencing PCR products.
Results:We identify tetM, tetL and tetS in Efc (69%, 41%, 9%) and Efm
(38%, 21%, 0%). ermB was also detected in Efc (100%) and Efm (87%).
Occurrence of int/xisTn916/Tn1545, orf298Tn5398, tnpA/tnpRTn917
was higher among Efc [47%-10 countries (c), 72%-6c, 44%-6c] than
Efm (13%-7c, 18%-6c, 13%-4c). Conversely, IntCW459tetM was more
common among Efm than Efc (30%-8c and 19%-4c, respectively).
tndXTn5397 was only detected in 2 Efm and 1 Efc from Spain and
Portugal and int/xisEfCtn1 in two Efc strains from USA. A high rate of
isolates (35%) presented more than one Tn.
Conclusion: A diversity of Gram positive CTns was observed among
nosocomial epidemic strains of enterococci from different continents.
Beside antibiotic resistance dissemination, CTn might be involved in
recombinatorial events and/or spread of other genetic elements favouring
the maintenance of HiRECC strains in the hospital setting. This is the
ﬁrst description of IntCW459tetM in enterococci, and of int/xisEfCtn1
among enterococcal strains associated with the hospital environment.
P950 Prospective study of Corynebacteria other than
Corynebacterium diphtheriae in clinical specimens:
identiﬁcation, clinical relevance and antibiotic susceptibility
A. Ferjani, S. Mhalla, M. Marzouk, N. Hannachi, J. Boukadida °
(Sousse, TN)
Objectives: Corynebacteria other than Corynebacterium diphtheriae
have increasingly been reported as opportunistic pathogens in noso-
comial infections. Moreover, new species isolated from humans have
recently been described. The purpose of this study was to evaluate
the distribution of corynebacteria species other than Corynebacterium
diphtheriae, using currently available identiﬁcation methods. The clinical
relevance of the isolates was assessed and the antibiotic susceptibility
was determined.
Materials and Methods: The isolates were collected over a period
of 2 years (January 2007 to December 2008), from different human
specimens coming from different departments. Strains were identiﬁed
according to metabolic and biochemical characters (Api Coryne,
BioMe´rieux). Antimicrobial susceptibility tests were carried out by
MIC determination using the E-test (AB BIODISK). The susceptibility
breakpoint concentrations were as recommended by the Clinical and
Laboratory Standards Institute (CLSI).
Results: During the period of study, 33 strains were collected
and included in this study. C. striatum and C. macginleyi were
mainly isolated, 39.4% and 33.3% respectively. The majority of
isolates came from hospitalised patients (79%), essentially from ORL
department. six patients (18%) had less than 15 years, 7 (21.1%) were
immunocompromised and the sex ratio was of 0.4.
Of the 33 strains, 8 (24.2%) came from ear infection specimens, 6 (18%)
from biomaterials essentially from thorax drains (3/6) and 6 (18%) from
wound cultures. Urinary tract specimens represented 4 (12%) and lower
respiratory tract specimens 3 (9%).
The high rate of resistance with high MICs was showed for penicillins
(42%), erythromycin (60%) and clindamycin (60%). Thirty-three percent
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(11 isolates) were resistant to ﬂuoroquinolones and 36% to cotrimoxazole
(12 strains). No resistance was noted to glycopeptides and generally the
activity of teicoplanin was superior (MIC lower) to that of vancomycin.
Among the 13 multiresistant strains (39%), 7 (53%) were C. macginleyi,
4 (30%) were C. striatum and one strain of each was C. jeikeium and
C. pseudodiphtericum.
Conclusion: Corynebacteria other than Corynebacterium diphtheriae
are a non exceptional cause of human infections, implicated essentially
in ear and wound infections. C. striatum and C. macginleyi were
mainly isolated. High levels of resistance were noted for penicillins,
erythromycin and clindamycin.
Glycopeptides are the antibiotics of choice.
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P951 Management of infective endocarditis: clinical experience
with outpatient parenteral antibiotic therapy
J. Larioza °, L. Heung, A. Girard, R.B. Brown (Springﬁeld, US)
Objective: To describe our experience in treating infective endocarditis
(IE) with outpatient parenteral antibiotic therapy (OPAT), and to identify
new groups of patients with IE who may qualify for OPAT.
Methods: Following institutional review board approval, patients
discharged from Baystate Medical Centre with IE documented by
modiﬁed Duke criteria treated with OPAT were identiﬁed. Data obtained
included organisms implicated, endothelial surface involvement, emer-
gent surgical intervention, indications of clinical stability, percentage
of total therapy rendered after hospitalisation, and one year follow-
up. Pairwise comparisons of clinical groups were conducted using
the Wilcoxon rank-sum test. For these comparisons, medians are
reported. Analyses were performed using Stata (version 10.1, College
Station, TX).
Results: Forty-three patients met criteria. Thirty-ﬁve percent were
infected with Staphylococci; 40% harboured streptococci or Enterococci.
Native valves and left-sided valves each constituted approximately 75%
of total. All patients received  4 weeks of therapy, with  66% of total
treatment rendered after hospital discharge. The table provides further
pathogen-speciﬁc data. A median of 7 days of haemodynamic stability
and negative blood cultures occurred prior to discharge. After one year,
no patients died from IE. Twenty-three percent were hospitalised during
OPAT from intravenous catheter, antibiotic, or other complications, none
for direct complications of IE.
Conclusions: Outpatient parenteral antibiotic therapy for infective
endocarditis can be safely utilised, and at least 66% of care can be given
in this manner. Our investigation provides enhanced data for employing
OPAT for IE caused by Staphylococci and left-sided cardiac infections,
and also provides favourable outcome data one year after treatment.
Distribution of patients by infecting organism, infected endothelial surface, requirement for surgery, total treatment
duration and OPAT
Infecting organism Number
of patients
(N = 43)
% Left-sided
disease
(N= 33)
% Required
emergent
surgery
(N= 12)
Duration of
treatment
(weeks)
% OPAT
Viridans streptococci 8 (7/8) 88 (3/8) 38 4 72
Enterococcus faecalis 5 (5/5) 100 (2/5) 40 6 80
Methicillin susceptible Staphylococcus aureus 9 (5/9) 56 (1/9) 11 4 68a
Methicillin resistant Staphylococcus aureus 1 (0/1) 0 (0/1) 0 6 90
Staphylococcus non aureus 5 (4/5) 80 (2/5) 40 5 80
Culture negative 9 (7/9) 78 (2/9) 22 5 74
Other streptococci 4 (3/4) 75 (1/4) 25 4 75
HACEK 1 (1/1) 100 (1/1) 100 4 68
Proteus mirabilis 1 (1/1) 100 (0/1) 0 6 66
a1 patient lost to follow-up.
P952 Outcome of empiric versus targeted antibiotic therapy in
infective endocarditis, Medellin, Colombia. Study of 120
cases over a 20-year period
C. Bustamante, S.M. Gil, G.M. Montoya, M. Zuluaga, N. Lopez,
G. Franco, J.C. Gonzalez ° (Medellin, CO)
Objectives: Despite current medical developments, mortality of infective
endocarditis (IE) reaches 25% and without treatment, IE can be lethal.
Although one of the most crucial factors to improve the outcome is the
use of targeted antibiotic regimen guided by bacteriological results, the
microbiologic diagnosis is not always possible and empiric treatment is
required. The outcome differences between both approaches are not yet
extensively evaluated in Latin America. The aim of this study was to
compare the outcome (complications and death) between patients with
proven diagnosis of EI according to Duke Criteria that received targeted
or empiric antibiotic therapy.
Methods: Retrospective evaluation of medical records of hospitalised
patients attended between 1988 and 2008 in a 140 bed specialised
cardiovascular clinic, was performed. The epidemiological features and
clinical outcome were assessed in both groups. The statistical analysis
included Pearson’s square Chi test.
Results: In 20 years, 120 adult patients fulﬁlled IE Duke criteria. 96
(80%) received targeted antibiotic therapy and 24 (20%) received empiric
treatment according to American Heart Association (AHA) guidelines,
adapted to known local antibiotic resistance proﬁles. 28 (23.3%) patients
had a valvular prosthesis, among them 24 received targeted treatment
and 4 empiric treatment. Surgery was also needed in 56 patients of
targeted treatment group and 19 of empiric treatment group (57.7%
and 79.3%, respectively). Overall, no differences in hospital mortality
(targeted treatment 19.6% vs. empiric treatment 20.8%) or complications
(arrhythmias, abscesses, rupture of tendinous cords, valvular perforation
or prolapse, acute cardiac failure, acute renal failure, sepsis, need of
valvular surgery, surgical reintervention) were observed between empiric
versus targeted treatment.
Conclusions: Interestingly, no differences in mortality and complications
were found between targeted and empiric treatment. It could be explained
by a close adherence to antibiotic guidelines and the knowledge of
nosocomial infections proﬁle. Remarkable, most IE cases were targeted
treated indicating accurate microbiological methods and no previous use
of antibiotics. Since the mortality and complications of empiric treatment
cases were similar to targeted treatment, we emphasize the importance of
following antibiotic guidelines and the determination of epidemiological
patterns in each centre.
P953 Epidemiology, clinical and microbiological features of
infectious endocarditis: a review of 54 cases
D. Kofteridis, M. Christofaki °, A. Valachis, C. Mattheou, D. Dimopoulou,
I. Aristeidou, A. Christidou, G. Samonis (Heraklion Crete, GR)
Objectives: The purpose of the study was to investigate the aetiology,
risk factors, clinical features and outcome of infective endocarditis (IE)
in the area of Crete.
Methods: The medical records of all patients hospitalised at the
University Hospital of Heraklion, Crete, Greece, diagnosed with IE from
1993 to 2007 were retrospectively reviewed. All patients who met the
modiﬁed Duke criteria for deﬁnite IE, were included.
Results: Fifty four cases of deﬁnite IE occurring in the same number of
patients were evaluated. The median age of patients was 60 years (range
46−74). There were 35 males (64%). Transthoracic echocardiography
(TTE) was performed in 37 patients (68%), and transoesophageal (TEE)
in 19 (35%). Findings consistent with endocarditis were found in 32
(86%) out of 37 TTE and in 16 (84%) out of 19 TEE. Most cases
[41 patients (76%)] were native valve IE. Predisposing conditions
were evident in 40 patients (74%) and included prosthetic valve [13
patients (24%)], injected drug use [1 (1.8%)], mitral valve prolapse
[6 (11%)], poor dental hygiene [3 (5%)], diabetes [10 (18.5%)] and
HIV infection[1 (1.8%)]. The mitral valve was affected in 26 patients
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(48%), the aortic in 22 (40%), while 6 (11%) had both valves affected.
Blood cultures were negative in 8 cases (15%). The leading causative
microorganism was S. aureus isolated in 15 cases (28%), followed by
coagulase-negative staphylococci in 12 (22%), viridans streptococci in
9 (16.6%) and E. faecalis in 5 (9%). A number of rare and difﬁcult
to treat microorganisms had been identiﬁed such as G. morbillorum
in 2 (4%) cases, S. lugdunensis in 2 (4%), Brucella spp in 1 (2%),
and S. pneumoniae in 1 (2%). One patient had positive serologic test
for C. burnettii (2%). All patients received antimicrobial treatment on
empirical basis, which was proven appropriate in 43 patients (93%)
based on the results of blood cultures. Seven patients (12%) had surgical
treatment. In-hospital mortality reached 15% (8 patients).
Conclusions: Staphylococcus and Streptococcus spp remained the most
common aetiologic agents of IE. However, the presence of uncommon
and/or difﬁcult to treat pathogens raise concern that appropriate
prophylaxis and empirical treatment may be more complicated than
believed in the past. Furthermore serology for C. burnettii should be
included in the diagnostic work-up in endemic areas.
P954 120 blood cultures negatives endocarditis in southern Spain
A. Plata °, J.M. Reguera, R. Ivanova, M. Nourredine, J. Ruiz, J. de la
Torre, F. Martı´nez-Marcos, J.M. Lomas, J. Galvez, C. Hidalgo-Tenorio,
J. Fajardo, A. de Alarco´n on behalf of the Andalusian Group for
the Study of Cardiovascular Infections
Objectives: To know the clinical features and possible aetiologic agents
of the blood culture negative endocarditis (BCNE).
Methods: Descriptive cross sectional study in a serie of patients with
Infectious Endocarditis (IE) diagnosed from 1986 to 2007 in seven
second and tertiary hospitals in the south of Spain.
Results: 120 (14.8%) of 359 cases of IE included were categorised as
BCNE affecting in 71.7% and 28.3% to native and prosthetic valves
respectively. The mean age was 60 + 12 years. Seventy eight (62.5%)
patients were male. The most affected valve was aortic in 49.2%, mitral
in 35%. An nosocomial endocarditis was found in 8.3% and previous
manipulation in 26 cases (21.6%). The clinical symptons until diagnosis
were 68±126 days. The symptons were fever (93.1%), new murmur
(67.5%), chills (45%), splenomegaly (45%) and hepatomegaly (45%). In
14.2% we detected vascular phenomena and immunological phenomena
were present in 15%.
Antibiotics were used previously in 67 (55.8%) patients, serologic test
were positive in 24 cases (20%) and valvular cultures in 12 (10%). In 83
cases (69.2%) we didn’t ﬁnd germen, in 19 (15.8%) Coxiella burnettii,
in 4 (3.3%) Brucella, in 4 (3.3%) Fungus, in 2 (1.7%) S. coagulase
negative, in 2 (1.7%) S. aureus, in 1 (0.8%) Bartonella and in 1 (0.8%)
Mycoplasma.
Transthoracic echocardiogram (TTE) alone was performed in 45.5%,
Transoesophageal echocardiogram (TEE) in 4.2% and TTE + TEE in
45.8%. The TEE was diagnostic in 85% and the TEE only in 69%.
Complications seen in Echo or Surgery were valvular rupture (12.6%)
and abscess (10%).
Surgery (60%) was undertaken in 49.2% during the hospital admission
and in 10.8% cases later. Congestive heart failure was the main reason
for surgery (67%), valvular disfunction (20%), sepsis (9%) and abscess
(2%). The global mortality ratio was 20%.
Conclusions: 1) Antibiotics taken before a IE diagnosed is the main
factor for the negativity of the blood culture. 2) Serologic tests
for Brucella, C. burnettii and Bartonella might be considered in
BCNE mainly in endemic areas. 3) The histologic and microbiologic
examination of the valves after the surgery is so much important
to identify the aetiologic agent. 4) Molecular techniques may be an
interesting alternative diagnostic test for IE caused by bacteria that
usually give a negative blood culture. 5) Negatives blood cultures
endocarditis presents a high surgery percentage with similar mortality
than positives blood culture endocarditis.
P955 Brucellosis as an aetiology for culture-negative endocarditis
in endemic regions
Maryam Keshtkar-Jahromi °, M.A. Boroumand, S. Gholamin,
S.M. Razavi, M.J. Hashemi, M. Hekmat, M. Shahzamani,
A. Salehiomran, B. Haghighat, Marzieh Keshtkar-Jahromi (Tehran, IR)
Background: Brucellosis is an orally transmitted bacterial through
unpasteurised milk products manifesting with fever, chills, bone pain,
fatigue and myalgia. Although it has been eradicated in some countries,
it is still endemic in other regions. If left untreated or partially treated,
complications may occur. Endocarditis is the most fatal complication. In
this study we evaluated brucellosis as an aetiology for endocarditis in
Iran as an endemic region.
Method: 572 cases deﬁned as endocarditis (Duke Criteria) (1991–2008)
in 3 referral heart surgery centres were retrospectively evaluated. 365
out of 577 were culture negative based on routine culture media after
48 hrs. 11 (3%) culture negative cases were proved as brucellosis by
serology or blood culture after 2−3 wks. Patients were followed for
clinical, serological ﬁndings and outcomes as measures.
Results: Brucellosis was the aetiology for endocarditis in 1.9% totally
and 3% in culture negative cases. Fever (100%), Chills (90.9%) for more
than one year were the most common complaint. Aortic (54.5%) and
Mitral valve (36.3%) were the most commonly involved valves. Valsalva
sinus was involved in one case. Operation in addition to antibiotic
therapy was performed in 10 cases out of 11 (90.9%). The complications
observed in these patients are renal failure, back pain, arthritis and
CNS involvement. Blood culture was positive in 4 patients (36.36%). 6
patients survived and 5 patient died before, during or early after surgery.
2 patient developed brucella prosthetic valve endocarditis 2 years after
surgery. Aortic root aneurysm was observed in one case as a complica-
tion for brucella endocarditis 16 years after primary surgical treatment.
Conclusion: Brucellosis should be considered in culture negative
endocarditis in endemic regions. It is associated with high mortality
(45%). Serologic and speciﬁc culture media for isolating the organism
should be ordered in case.
P956 Infective endocarditis: Czech experience. Results of a
multi-centre incidence study
J. Benes °, O. Dzupova, R. Baloun (Prague, CZ)
Objectives: Infective endocarditis (IE) seems to be changing and trans-
forming into civilisation disease. We were interested in characteristics
of the disease in our central European postcommunistic country.
Methods: A multicentre prospective observational study was carried out
in 29 regional hospitals. The hospitals take care of 3,934,000 inhabitants
what is 37.7% of the whole population of the Czech Republic. All the
IE cases that occurred in the particular regions within one year period
(February 2007–January 2008) were reported.
Results: In the monitored period, 124 cases of IE were reported,
this implies the average annual incidence of 3.15 cases per 100 000
inhabitants. The patient’s age range was 19−98 yrs; median 63 yrs.
Men/women ratio was 91:33. One hundred and seven patients fulﬁlled
criteria of “deﬁnite IE” according to the revised Duke criteria (Li, 2000).
Only 74 pts (60%) were admitted in departments of cardiology/internal
medicine initially. The others were admitted in ID departments (16
pts, 13%), neurology (15 pts, 12%), surgery (6 pts, 5%), or another
departments.
There were 18 prosthetic valve endocarditis and 16 pacemaker
endocarditis. Seven patients were intravenous drug addicts. Aortic valve
was involved in 49 pts (40%), mitral valve in 43 pts (35%), both aortic
+ mitral in 6 pts (5%), tricuspid in 10 pts (8%). Other localisation
or multiple site involvement was found in 14 pts (12%). Aetiological
agent was Staphylococcus aureus in 36 pts (29%), coagulase-negative
staphylococci 13 pts (10%), streptococci in 17 pts (13%), enterococci in
10 pts (8%), other bacteria in 8 pts (7%). No fungal agent was found.
The aetiology was not established in 40 pts (32%); twenty-six of them
were given antibiotics before collecting blood cultures.
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Heart surgery was carried out in 33 pts (27%) before ﬁnishing antibiotic
treatment. Thirty-one patients died due to endocarditis (25%).
Conclusion: The ascertained incidence of IE is lower than expected,
probably because of insufﬁcient availability of good echocardiography
in several hospitals. We conﬁrmed the new trends in IE characteristics:
raising men/women ratio, raising frequency of aortic valve involvement,
prevailing staphylococcal aetiology. High rate of culture-negative
endocarditis (CNE) documents incorrect antibiotics prescription habits.
We feel that most CNE cases were caused by antibiotic-sensitive
streptococci.
P957 The incidence of sepsis in a large Dutch University hospital:
CRP and the SIRS criteria
T.T.N. Le °, H.J. van Leeuwen, E.E. Mattsson, J.A.G. van Strijp,
J. Verhoef (Utrecht, Arnhem, NL)
Objectives: In 1991, consensus guidelines were established for diagnosis
of sepsis. Sepsis is deﬁned as an infection with symptoms of systemic
inﬂammatory response syndrome (SIRS). This sepsis deﬁnition was
reviewed in 2001 and has been found to be sufﬁcient only with
the addition of more possible symptoms and signs of SIRS and
biomarkers like C-reactive protein (CRP), although it was premature
to use biomarkers to diagnose sepsis. We conducted a prospective,
observational study on the epidemiology of sepsis at the University
Medical Center Utrecht. We evaluated the value of CRP in addition
to the SIRS criteria to differentiate sepsis from SIRS or seriously ill
patients.
Methods: At the University Medical Center Utrecht, all patients from
whom blood cultures were drawn were evaluated between October 2004
till September 2005 for having sepsis. All patients with a possible
infection and who met 2 of the SIRS criteria or patients who did
not met the SIRS criteria but who were seriously ill (altered mental
status, organ failure, hypotension) were enrolled in the study. Sepsis and
SIRS patients (seriously ill patients without infection) were divided into
three groups: patients without organ failure, patients with organ failure
and patients with shock. SIRS and sepsis patients in the same category
were compared with respect to the SIRS criteria and CRP. Area under the
curve (AUC) in ROC curves were calculated (AUC> 0.8 was considered
discriminatory).
Results: 6203 blood cultures were drawn from 2197 patients. Based
on the above mentioned criteria 2025 episodes in 1676 possible sepsis
patients were identiﬁed after a ﬁrst evaluation. After a further second
evaluation of these episodes with knowledge of the culture results and
clinical course 998 patients with deﬁnitive sepsis and 408 patients
without infection were identiﬁed.
Respiratory rate was not measured in 1973 episodes and was therefore
not evaluated.
In patients without organ failure CRP gave an AUC of only 0.558. No
additional differential effect was observed with addition of any of the
SIRS criteria.
In patients with organ failure CRP combined with temperature yielded
an AUC of 0.601.
In patients with shock CRP with any of the SIRS criteria did not
signiﬁcantly differentiate between septic shock and shock patients.
Conclusion: Temperature, heart rate, white blood cell count and CRP did
not discriminate sufﬁciently between sepsis patients and comparatively
ill patients without infection.
P958 The effect of bacteraemia on the immune response and
outcome of patients with severe sepsis
L. Leonidou °, A. Mouzaki, A. Georgakopoulou, V. Kyriazopoulou,
H.P. Bassaris, C.A. Gogos (Patras, GR)
Objectives: The aim of the present study was to examine the levels of
pro and anti-inﬂammatory cytokines and outcome in patients with severe
sepsis and bacteraemia.
Patients and Methods: The study included 56 patients with severe
sepsis. The patients were divided into two groups according to the
presence or absence of positive blood cultures: patients with bacteraemia
(group B, n = 17) and non-bacteraemic patients (group NB, n = 39).
Severe sepsis was deﬁned as the presence of conﬁrmed infection and 2
of the following criteria: (a) a temperature >38ºC or <36ºC, (b) heart rate
>90 beats/min, (c) respiratory rate of >20 breaths/min, (d) WBC
>12,000 or <4,000 cells/mm3 plus at least one organ dysfunction
indicated by the following: (a) hypotension, (b) PaO2 <75mmHg
without evidence of primary respiratory tract disease, (c) pH< 7.3 or
a base deﬁcit of >5meq/liter, (d) urine output <30ml/h, (e) liver
dysfunction, (f) acute alteration of mental status, or (g) DIC. The severity
of sepsis was classiﬁed by the sepsis-related organ failure assessment
score (SOFA). Levels of the pro-inﬂammatory cytokines TNF-a and
1L-6 and anti-inﬂammatory cytokine IL-10, as well as TGF-b1 were
measured within 24 hours after admission (mean±SEM, pg/ml).
Results: The most common pathogen was E. coli (5/17, 29.4%).
Other pathogens isolated were: S. aureus (3/17), P. aeruginosa (2/17),
Enterococcus spp. (1/13), E. cloacae (1/13), S. pneumoniae (2/13),
S. viridans (1/17), S. epidermidis (2/17). Six out of 17 patients (35.2%)
with bacteraemia and 10 out of 45 (22.2%) patients without bacteraemia
died (difference not signiﬁcant). Group B had similar levels of IL-6
with group A (121.3±32.9 vs 108.4.4±13.9, p = 0.9) and similar levels
of IL-10 (10.2±4.2 vs 33.1±12.1, p = 0.7). There was no difference in
TGF-b (22.7±3.2 vs 21.6±1.9, p = 0.4) and TNF-a levels (44.4±10.9 vs
34.1±5.1, p = 0.3) between the two groups. Patients of both groups had
a similar SOFA score (4.4±1.0 vs 3.4±0.5) and CRP levels (14.8±2.4
vs 15.2±1.7, p = 0.8). Patients with bacteraemia stayed more days in
hospital than patients without. (Length of hospital stay (LOS): 12.5±
2.9 vs 7.7±0.8 days, p = 0.03)
Conclusion: Patients with severe sepsis and bacteraemia do not seem
to have a different immune proﬁle than patients without bacteraemia.
Bacteraemia seems to inﬂuence LOS but not the ﬁnal outcome.
P959 Analysis of immune competent cells following major and
minor visceral surgery provides insight into origin of
postoperative sepsis
P. Koerner °, A. Westerholt, K. Cziupka, S. Diedrich, W. Kessler,
T. Traeger, C.D. Heidecke, S. Maier (Greifswald, DE)
Objectives: Abdominal surgery is frequently followed by immune
dysfunction which usually lasts for several days. Septic complications
in this stadium of postoperative immune dysfunction result in increased
mortality. Consequently we previously categorised sepsis into type A
(spontaneously acquired) and type B, which is acquired postoperatively
and associated with a higher mortality rate.
Methods: We analyzed expression of HLA-DR on monocytes of 118
patients by ﬂow cytometry prior to and 24, 48 and 72 hours after surgery.
For statistical analysis we used Mann-Whitney-Test, p was considered
signiﬁcant if <0.05.
Results: We hereby describe a signiﬁcant reduced HLA-DR expression
on monocytes following major surgery compared to minor surgery.
Both groups differ from extent of trauma, blood loss and duration
of operation. 24 h postoperatively, we detected decreased expression
of HLA-DR on circulating monocytes and therefore reduced immune
function (p< 0.0005) following major compared to minor surgery. These
differences were constant over a period of three days. We observed a
signiﬁcant reduction of HLA-DR expression if the operation required
more than 2.5 hours.
Furthermore we analysed HLA-DR expression in correlation with the
incidence of postoperative sepsis. We compared monocytes of patients
with severe postoperative sepsis to monocytes of a non-complicated
postoperative progress. No differences concerning pre-operative HLA-
DR expression could be displayed between both groups. 24 hours after
surgery both levels decreased to 25% of initial value. Monocytes of
patients with an uncomplicated postoperative course showed regeneration
of HLA-DR levels within the ﬁrst three days. In contrast, patients
with septic complications had prolonged suppressed levels of HLA-
DR expression resulting in signiﬁcant differences between both groups
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48 hours postoperatively (p< 0.005) and even more 72 h postoperatively
(p< 0.0005).
Conclusion: We describe a direct correlation between dimension of
previous surgical trauma and immune dysfunction in the postoperative
course. Major, especially protracted surgery results in signiﬁcant
suppression of immune function when compared to minor surgery.
Consequently the incidence of postoperative severe sepsis is presumably
increased following major compared to minor surgical procedure, which
has to be considered right from the planning stage of extensive
operations.
P960 Prognostic factors of community-acquired severe sepsis and
septic shock
A. Artero, R. Zaragoza °, J. Camarena, S. Sancho, R. Gonza´lez,
J. Nogueira (Valencia, ES)
Objective: We sought to determine the independent risk factors on
mortality in community acquired bacteraemic patients with severe sepsis
and septic shock.
Methods: A single-site prospective cohort study in a medical-surgical
ICU in an academic tertiary
care centre. Seventy patients with community acquired bacteraemic
severe sepsis and septic shock were identiﬁed. Clinical, microbiologic
and laboratory parameters were compared between hospital survivors
and hospital deaths.
Results: The global mortality rate was 50%, 52.8% in septic shock
and 41.2% in severe sepsis. One o more comorbidities was present in
64.3% of patients. The most commonly identiﬁed bloodstream pathogen
was Escherichia coli (24.3%). Gram-positive microorganisms were
isolated in 51.4% of blood cultures. The proportion of patients receiving
inadequate antimicrobial treatment was 7.1%. By univariate analysis,
age, APACHE II score, 3 or more organ dysfunctions, and albumin, but
neither inadequate empirical antimicrobial treatment nor microbiologic
characteristics nor site of infection, differed signiﬁcantly between
survivors and non-survivors. APACHE II (OR: 1.19; 95%CI: 1.08−1.31)
and albumin (OR: 0.13; 95%CI: 0.04−0.44) were independent risk
factors associated with global mortality in logistic regression analysis.
Conclusions: APACHE II score and low levels of albumin were
independently associated with increased mortality. Our results support
that inadequate empirical antimicrobial treatment is not a signiﬁcant
factor to outcome in community acquired severe sepsis and septic shock
in standard clinical setting.
P961 Risk factors for and prognosis of sepsis secondary to severe
or complicated pyelonephritis
N.N. Macias ° (Malaga, ES)
Objectives: The aim was to identify the possible risk factors associated
with and the prognosis of severe sepsis in patients with severe or
complicated pyelonephritis.
Methods: Retrospective, descriptive study including 1101 patients older
than 14 years with severe or complicated pyelonephritis were admitted
in Internal Medicine or Infectious Diseases wards of a tertiary hospital
between January 1997 and December 2007, Three hundred and one of
them (28.1%) developed severe sepsis according to International Sepsis
Deﬁnitions Conference criteria. All patients were treated and followed
homogenously according to a previously deﬁned protocol. Demographic,
clinical, analytical, microbiological and sonographic variables were
compared between patients with and without severe sepsis.
Results: Of the 1001 patients, 335 (30.4%) were men and 766 (69.6%)
women. The mean age was 55.6±20.0 years (range, 14−97 years). Five
hundred and eighty eight patients had one or more structural or functional
urinary tract disorders. In multvariate analysis, male sex (OR: 1.03;
CI95%: 1.02−1.04), recent urinary instrumentation (OR: 3.64; CI95%:
1.74−7.63), nosocomial acquisition, thrombocytopenia (OR: 2.57;
CI95%: 1.66−3.96), creatinine (OR: 1.41; CI95%: 1.21−1.66), age
(OR: 1.66; CI95%: 1.15−2.39), positive blood cultures (OR: 6.34;
CI95%: 3.6−11), and grade III/IV sonographic ectasia (OR: 1.94;
CI95%: 1.38−3.06) were associated to severe sepsis.
Mortality was 19.4% and 1.3% in patients with and without severe sepsis
p< 0.0001.
Conclusions: The incidence of severe sepsis in complicated or severe
pyelonephritis is high. There are demographic, clinical, analytical,
microbiological and sonographic data independently associated with
urinary severe sepsis. Patients with complicated pyelonephritis and
severe sepsis have a considerable attributable mortality.
P962 Streptococcus milleri group sepsis: abdominal infections and
macrolide resistance
T. Tarukawa °, A. Yoshida, H. Yoshida, K. Okuzumi, Y. Okamoto,
H. Suzuki, Y. Yamamoto, A. Hishinuma, T. Ieiri (Mibu, JP; Boston, US)
Objectives: We analyzed S. milleri group (S. intermedius, S. anginosus
and S. constellatus) sepsis/bacteraemia cases in terms of clinical
presentations and antimicrobial susceptibilities in Japan between January
2004 and March 2008. This analysis focused on the gastrointestinal
and hapatobiliary system as a portal of entry of S. milleri group.
Whereas S. milleri group is considered to be pathogens mainly in
respiratory infections, the pathogenesis of S. milleri bacteraemia is not
fully understood.
Methods: Clinical and demographic data were obtained from 15 patients
in our 1300-bed tertiary hospital. Antimicrobial susceptibility testing
was based on the CLSI criteria. Macrolide/lincomycin resistance related
genes, ermB, ermTR, mefA and linB, were analyzed with PCR.
Results: Fifteen patients (aged 3−91 [mean 60 years]) had male prepon-
derance (male: female = 12:3). As underlying conditions, 7 (46.7%)
had hepatobiliary or digestive diseases such as cholangiocarcinoma,
hepaticolithiasis, and 5 (33.3%) respiratory diseases including lung
carcinoma, and 5 (33.3%) receiving chemotherapies against malignancy.
As associated sites of infection, 5 (33.3%) were hepatobiliary, 4 (26.7%)
gastrointestinal tract, 4 (26.7%) lung, respectively. In susceptibility
testing, 5 isolates (33.3%) were resistant to erythromycin, and 2 (13.3%)
to clindamycin. ErmB gene and mefA gene were detected in 2 (13.3%)
and 3 (20.0%) isolates, respectively. None of the patients, however, had
a history of long-term administration of macrolides or clindamycin.
Conclusion: The pathogenesis of S. milleri bacteraemia implicated
retrograde bile duct infection and bacterial translocation from the gut
to peritoneum. Macrolide-resistant S. milleri can cause bacteraemia in
patients with no prior long-term macrolide use.
P963 A circulating factor of patients with septic shock stimulates
release of angiopoietin-2 by human monocytes
H. Kranidioti, A. Kotsaki, M. Mouktaroudi, D. Plachouras, A. Savva,
E.J. Giamarellos-Bourboulis ° (Athens, GR)
Objectives: Angiopoietin (Ang)-2 was shown to circulate in high levels
in the serum of patients with septic shock (Orfanos S, et al. Crit Care
Med 2007; 35: 199). The present study attempted to unravel the existence
of any factor in serum stimulating the production of Ang-2 by human
monocytes.
Methods: Peripheral blood mononuclear cells (PBMCs) were isolated
from 14 healthy volunteers after gradient centrifugation over Ficoll.
Serum was sampled from four patients with sepsis and 10 patients with
septic shock on day 1 of diagnosis (ACCP/SCCM 1992). PBMCs were
stimulated for 24 hours at a density of 5×106/ml with 50% of patients’
serum in the absence or presence of 10 ng/ml of lipopolysaccharide
(LPS) of Escherichia coli O155:H5, of 3 microM of the MAP
kinase inhibitor SB203580 and of 1 microg/ml of E. coli TLR-4
antagonist (aTLR4). Ang-2 was estimated in supernatants by an enzyme
immunoassay after adjustment for serum levels. Then 1×106/ml of
PBMCs were stimulated for four hours either with medium or serum of
patients with septic shock or with 10 ng/ml of LPS. RNA was extracted
after trizol and chloroform treatment and cDNA was synthesized.
Expression of Ang-2 was estimated by real time-PCR against the
expression of b-2-microglobulin as a reference gene.
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Results: Ang-2 production after cell stimulation is shown in Figure 1
(results as means ± SE, pg/ml). Median rate of Ang-2 gene expression
after serum stimulation was 13.7; that after LPS stimulation was 5.9.
Conclusions: A circulating factor exists in serum of patients with
septic syndrome stimulating release of Ang-2 by human PBMCs. Its
concentrations are greater in septic shock than in sepsis. Release is
antagonised by LPS and the MAP kinase pathway and is mediated, at
least in part, by stimulation of gene expression.
P964 The use of the Pneumoslide test in blood cultures and its
relation to capsular serotype
W.W. Chan °, M. Lovgren, G.J. Tyrrell (Edmonton, CA)
Objectives: The BBL Pneumoslide is an agglutination test for the rapid
identiﬁcation of Streptococcus pneumoniae, consisting of latex beads
coated with polyvalent antisera which reacts with pneumococcal capsular
antigens. When used directly on positive blood cultures, it can yield
an rapid diagnosis of pneumococcal bacteraemia, but the data on its
performance in this setting is limited. Because it is based on antibodies
targeting the capsular antigen, it is likely that test sensitivity would differ
between serotypes. Our objective was to assess its performance in blood
cultures at our centre, and evaluate the variation between serotypes.
Methods: A retrospective review was conducted of the blood cultures
processed at the Department of Medical Microbiology, at the University
of Alberta Hospital over an 18-month period. All blood cultures ﬂagged
as positive by the Bactec 9240 system and shown to be Gram-positive
cocci in chains/pairs were tested with the Pneumoslide. Identiﬁcation
was conﬁrmed using routine biochemical methods, including optochin
susceptibility and bile solubility. Capsular serotyping was done by the
Quellung method.
Results: 41,528 blood cultures were reviewed, with 3038 positives, and
290 yielding a Gram stain of Gram-positive cocci arranged in pairs or
chains. Of these, 73 were ultimately identiﬁed as S. pneumoniae, and
55 were positive by the Pneumoslide assay. The 217 that were Gram-
positive cocci other than S. pneumoniae registered 3 positive results. This
corresponded with a sensitivity of 75.3% and a speciﬁcity of 98.6%,
corresponding with a positive-predictive value of 94.8% and a negative-
predictive value of 92.2%. When analyzed by serotypes, certain serotypes
(7F, 15B, 33A, 38) were negative every time. The Pneumoslide was
50% accurate for serotypes 5 and 12F, 86% accurate for 22F, and 100%
accurate for the remainder of the serotypes isolated from positive blood
cultures.
Conclusion: The Pneumoslide test, when used directly on positive blood
cultures, is useful in the rapid diagnosis of Streptococcus pneumoniae.
It has a high speciﬁcity, with somewhat lower sensitivity, correlating
with good positive and negative predictive values. Sensitivity varies by
capsular serotype, and thus the local epidemiology of S. pneumoniae
will alter the utility of the test.
P965 Sentinel survey of typhoid prevalence among febrile patients
attending clinics in Bushenyi district of Uganda
E. Agwu °, L. Wambua, L. Titus (Ishaka, UG)
Background/Objective: Recent country data on the geographical
distribution of typhoid indicates that western districts of Uganda were
among the most affected. We therefore surveyed the prevalence of
typhoid among febrile patients attending clinics in Bushenyi district and
suggested intervention strategies to clamp down typhoid cases.
Methods: Six hundred and eighty seven blood samples were collected
aseptically and analyzed using standard Widal serological Slide
agglutination and tube dilution of somatic and ﬂagella antigens of
Salmonella enterica serotype Typhi. Chi-square test (p = 0.05; 0.01) was
used to test for statistical signiﬁcance of age, sex, socio-economic status
and monthly distribution of typhoid in Bushenyi.
Results: Among the males surveyed between sentinel centres, age group
10−19 years had the highest typhoid prevalence of 28.6% (Comboni) and
36.6% (BMC), while age group 20−29 years had 24.6% (IAH) highest
typhoid prevalence. Among the females surveyed age group 10−19 years
had the highest typhoid prevalence of 33.8% (Comboni) and 32.8%
(BMC), while age group 20−29 years had 24.3% (IAH) highest typhoid
prevalence. Typhoid was more prevalent in the low class group and
lowest in the high class group across the sentinel centres. It appears that
typhoid prevalence is uniformly distributed from January to December.
Conclusions: Typhoid is highly prevalent among febrile patients
attending clinics in Bushenyi. Typhoid prevalence was signiﬁcantly
(p< 0.05 & p< 0.01) dependent on age and sex, not socio-economic
status and season. Hygiene education and monitoring of the street-food
trade is recommended typhoid control measure.
P966 Validation of a new stratiﬁcation score to predict infection
due to antibiotic-resistant bacteria
M. Salvado´ °, E. Calbo, M. Riera, M. Salamero, N. Freixas,
M. Xercavins, M. Rodriguez-Carballeira, J. Garau (Terrassa, ES)
Introduction: Relation with health care system has been associated with
a higher risk for resistant pathogens (RP) and a greater mortality than
community acquired infections; however not all component criteria for
HCAP convey a similar risk for resistance. Recently, a new score to
determine which patients with pneumonia were more likely to be infected
by RP has been published.
Objective: To validate this score system in a cohort of patients with
health care associated bacteraemia (HCAB).
Material and Methods: From Jan 2006 to Oct 2008, consecutive
adult patients with HCAB were identiﬁed through the records of the
Clinical Microbiology Laboratory in a 500-bed acute care hospital.
Deﬁnition of HCAB included: residence in a nursing home in the
previous month, hospitalisation in an acute care hospital for 48 h or
longer in the 90 days before, haemodialysis treatment 30 days before
admission or receive IV therapy, wound care, enteral nutrition, indwelling
urinary catheter manipulation or health care at home in the 30 days
before the HCAB. This scoring system used assesses 4, 3, 2 and 1
points to recent hospitalisation, nursing home residence, haemodialysis
and intensive care unit (ICU) admission, respectively. Patients with
a higher score were more likely to have resistant pathogens. RP
included MRSA, Extended Spectrum b-Lactamases (ESBL) producing
Enterobacteriaceae, P. aeruginosa and other non fermenting Gram
negative rods, as described previously in the referred score.
Results: Among a cohort of 321 HCAB patients, RP were recovered in
42 (13%) [8 MRSA, 11 ESBL, 22 P. aeruginosa and 1 Acinetobacter].
The prevalence of RP ranged from 10% to 13% and was not signiﬁcantly
different in those with previous hospitalisation, on haemodialysis or ICU
admission; patients coming from a nursing home were more likely to
have RP (21% vs. 10%, p = 0.007). Among patients with fewer than
3 points the prevalence of RP was 10%, 11.5% in those with a score
ranging from 3 to 5 and more than 37.5% in those >6 (p< 0.001). The
sensibility and speciﬁcity of a score >6 was 21.4% and 95%, respectively.
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Conclusions: Residence in a nursing home is associated with HCAB
due to resistant pathogens. The sensitivity of the new scoring system
used is very low in areas where the prevalence of RP is low and is not
a good tool to predict infection by RP in these areas.
ESBLs, AmpCs & others in
Enterobacteriaceae: genes, plasmids &
clones – part 1
P967 Spanish nationwide study on Klebsiella pneumoniae
producing extended-spectrum b-lactamases (GEIH-BLEE
2006). Emergence of CTX-M-15
C. Ruiz de Alegrı´a °, M.E. Cano, M.A. Dı´az, E. Roma´n, J.R. Herna´ndez-
Bello, J. Rodrı´guez-Ban˜o, A´. Pascual, L. Martı´nez-Martı´nez and GEIH
Objectives: To study the susceptibility testing and types of extended-
spectrum b-lactamases (ESBL) in clinical isolates of K. pneumoniae
collected in a nationwide study performed in Spain in 2006.
Methods: Consecutive K. pneumoniae with an ESBL-production
phenotype obtained from diagnostic clinical samples (1 per patient) in
44 centres representing all regions in Spain were included. Identiﬁcation
was conﬁrmed by API 20E. Susceptibility to b-lactams and conﬁrmation
of ESBL production were performed with ESBL-Plus panels (Dade, Mi-
croscan), and susceptibility to other agents by standardised microdilution
(CLSI guidelines). Resistance was deﬁned with EUCAST breakpoints.
Clonal relationship was performed by Rep-PCR and, for some isolates,
with pulsed-ﬁeld gel electrophoresis. Beta-lactamase genes were charac-
terised by PCR in parental strains (representative of clonal groups and
resistance phenotypes) and in ESBL-producing transconjugants selected
with E. coli J53 Azide-Resistant and cefotaxime (2mg/l) or ampicillin
(100mg/l). Speciﬁc primers for TEM, SHV and CTX-M were used;
when CTX-M genes were detected a second PCR for speciﬁc groups
was performed. ESBL-encoding genes were identiﬁed by sequencing.
Results: One hundred and sixty isolates (78 clones) were isolated
from 31 centres (1 to 16 isolates and 1 to 9 clones per cen-
tre). Percentages of resistance (all isolates) were: 0% (imipenem,
meropenem), 2% (amikacin), 5% (ertapenem), 9% (tigecyclcine),
50% (Piperacillin/Tazobactam, gentamicin), 62% (ciproﬂoxacin), 66%
(cotrimoxazole), 68% (tobramycin) and 96% (Amoxicillin-clavulanate).
In 114 parental strains evaluated, amplicons for CTX-M, SHV and TEM
were obtained in 80 (70%), 107 (94%) and 55 (48%) isolates. SHV and
TEM genes were only sequenced in transconjugants. ESBL identiﬁed
in 78 transconjugants included CTX-M (71%), SHV (26%) and TEM
(6%). CTX-M-15 and SHV-12 were identiﬁed in 18 and 14 of 31 centres,
respectively, and both enzymes in 6 centres.
Conclusion: K. pneumoniae producing ESBL are widespread in Spain.
CTX-M-15 and to a much lesser extent SHV-12 were the more common
enzymes found in this study.
P968 Diversity of extended-spectrum b-lactamases in Escherichia
coli: second nationwide study in Spain (GEIH-BLEE 2006)
J.R. Herna´ndez-Bello, M.A. Dı´az, L. Serrano, J. Calvo,
J. Rodrı´guez-Ban˜o °, L. Martı´nez-Martı´nez, A. Pascual and GEIH
Objectives: To describe the diversity of extended-spectrum b-lactamases
(ESBL) types and susceptibility pattern in clinical isolates of E. coli
obtained in a nationwide study performed in Spain (2006).
Methods: Forty-four hospitals representing all regions of Spain
participated in the study. All consecutive clinical isolates (1/patient)
with a phenotype compatible with ESBL production from February-
March 2006 were included. Identiﬁcation was conﬁrmed by API
system (bioMerieux). ESBL production was conﬁrmed by microdilution
using ESBL-Plus panels (Dade, Microscan). In a selection of strains,
susceptibility to antimicrobials and ESBL conﬁrmation was performed
by microdilution (or diffusion) according to CLSI guidelines. ESBL
encoding genes were characterised by PCR. Final identiﬁcation of ESBL-
encoding genes was performed by sequencing.
Results: The total number of ESBL-producing E. coli isolated were
1,021; 257 isolates were selected and used for further analysis. Two
hundred and sixty-four ESBLs were identiﬁed among the 257 E. coli
selected strains, distributed as follows: CTX-M (73%), SHV (26%),
and TEM (1%). Sequence analysis of 249 ESBL selected genes in
E. coli yielded: CTX-M-14 (116 isolates), CTX-M-28 (43), CTX-M-
9 (21), CTX-M-32 (5), CTX-M-27 (1), CTX-M-1 (2), CTX-M-22
(1), CTX-M-79 (1), SHV-12 (56), TEM-52 (2), and TEM-4 (1). The
most active antimicrobial agents were tigecycline and carbapenems
(100% of isolates were susceptible), followed by amikacin (98.1%),
fosfomycin (93.7%), piperacillin/tazobactam (87%), gentamicin (78.4%)
and amoxicillin/clavulanate (66.9%). Only 30.1% of strains were
susceptible to ciproﬂoxacin.
Conclusions: There was a great diversity in ESBL types among clinical
isolates of E. coli in Spain in 2006, CTX-M being the most prevalent
family and CTX-M-14 the most frequent enzyme.
P969 Emergence of Escherichia coli producing CTX-M-15 in
Seville: epidemiological and clinical features
J. Rodrı´guez-Ban˜o °, M.D. Navarro, P. Egea, L. Serrano-Rocha,
L.C. Go´mez, M. de Cueto, Y. Doi, D.L. Paterson, L. Lo´pez-Cerero,
A. Pascual (Seville, ES; Pittsburgh, US; Brisbane, AU)
Objectives: Escherichia coli clonal group ST 131 producing CTX-M-15
has emerged worldwide. Until recently, CTX-M-14 was the predominant
enzyme produced by extended-spectrum b-lactamase-producing E. coli
(ESBLEC) in Spain. We detected the emergence of CTX-M-15-
producing isolates in our area (North of Seville, Spain) in 2006. We
describe the clinical and epidemiological features of this cases in
comparison with those producing CTX-M-14.
Methods: Prospective cohort of patients colonised or infected by ES-
BLEC in our area from September 2006 to March 2007. Epidemiological
and clinical data were collected from all patients. We compared the
features of patients with CTX-M-14 and CTX-M-15-producing isolates
using the chi squared or the Mann-Whitney U tests. ESBL production
was studied by PCR and sequencing; clonal relationship was studied by
PFGE.
Results: There were 79 cases of colonisation/infection caused by
ESBLEC during the study period. The ESBL was CTX-M-15 in
17 (21%) (data were available in 16) and CTX-M-14 in 24 (30%).
Among CTX-M-15 producers, acquisition was nosocomial in 8 (50%),
healthcare-associated in 2 (12%) and strict community in 6 (37%); 11
patients had urinary tract infections (68%), and 4 patients (25%) were
bacteraemic. Although 11 patients had clonally related isolates, we could
not ﬁnd evident epidemiological link between them, except for 2 patients
who were admitted to the same ward. Nosocomial acquisition was more
frequent in CTX-M-15 producers than in CTX-M-14 (50% vs 21%,
p = 0.05); also, COPD and haematologic cancer were somehow more
frequent, although not signiﬁcantly (31% vs 8%, p = 0.09). We found no
other differences in predisposing factors or clinical features.
Conclusions: We describe the emergence of clonally-related CTX-M-
15-producing E. coli in Seville. Although acquisition of these isolates
was more frequently nosocomial than CTX-M-14-producers, there was
no clear evidence of nosocomial transmission in most cases. Patients
with these isolates more frequently had some underlying conditions and
nosocomial infections.
P970 Emergence of CTX-M-15-producing Escherichia coli isolates
in Seville, Spain
L. Lo´pez-Cerero °, P. Egea, D. Navarro, J. Blanco, A. Mora, M. Blanco,
J. Rodrı´guez-Ban˜o, Y. Doi, D. Paterson, A. Pascual (Seville, Lugo,
ES; Pittsburgh, US)
Introduction: Recently, a virulent ciproﬂoxacin-resistant CTX-M-15-
producing E. coli clone (O25b:H4-ST131) has globally disseminated.
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This clonal group belongs to phylogenetic B2 group and it shares several
plasmidic multirresistant determinants as aac (6′)-Ib-cr and blaOXA-1.
The detection of an emerging clone is the ﬁrst step to the design of
prevention and possible intervention strategies. The aim of this study is
to characterise the CTX-M-15-producing strains among ESBL-producers
E. coli isolated in our area.
Methods: Two collections of clinical ESBL-producing E. coli isolates
were analyzed: 54 were obtained between June 2005-August 2006 and
80 between September 2006-Marh 2007; and 67 strains isolated from
raw poultry meat were also included. Identiﬁcation and antimicrobial
susceptibility were performed by standard methods. ESBL production
was tested by the double-disk method and characterisation was carried
out by PCR with speciﬁc primers for bla-genes and sequencing. Presence
of aac-(6′)-Ib-cr and blaOXA-1 were screened by PCR and sequencing.
Isolates were serotyped, compared by XbaI PFGE and phylogroups were
assigned by mutiplex PCR.
Results: A total of 21 CTX-M-15 isolates were detected. An increase
of clinical CTX-M-15-producing strains was observed from 4% in
the ﬁrst period to 24% in the second period and they were obtained
from urine (71%), blood (24%) and pleural effusion (5%). Two (3%)
food ESBL-producers were positive for this enzyme. All the isolates
were resistant to ciproﬂoxacin, 74% to co-trimoxazole, and 79% to
tobramycin. Twelve (57%) strains belonged to clone O25b:H4-ST131
(B2 phylogenetic group). One cluster (>85% similarity) was identiﬁed
by PFGE containing 11 isolates O25b:H4-ST131 which was positive for
aac-(6′)-Ib-cr and blaOXA-1. Four of six strains belonged to phylogenetic
A group were included in the same cluster by PFGE (2 clinical isolates
and 2 food isolates).
Conclusions: The increase of CTX-M-15-producing E. coli isolates
observed recently in our area is mainly due to clone O25b:H4-ST131.
Furthermore, we also detected spread of this enzyme among clonal
E. coli isolates of phylogenetic group A from both food producing
animals and humans.
P971 Outbreak of Klebsiella oxytoca strains harbouring
blaCTX-M-15, blaOXA-1, qnrS1 and two copies of
aac(6′)-Ib-cr genes in a paediatric intensive care unit
E. Ruiz °, A. Rezusta, L. Vinue, A. Vindel, Y. Saenz, M.L. Monforte,
V. Estepa, F. Ruiz-Larrea, M.J. Revillo, C. Torres (Logrono, Zaragoza,
Madrid, ES)
Objective: To analyse an outbreak of broad-spectrum cephalosporin-
resistant K. oxytoca strains in a paediatric intensive care unit and to
determine their resistance genes
Methods: Eleven K. oxytoca isolates were recovered from clinical
specimens (haemoculture, bronchial aspirate, conjunctive secretions)
from 5 patients during a 5-month period (2006–2007). Antibiotic
susceptibility patterns were determined using Microscan® system and by
agar dilution method. The screening of ESBL production was checked
by the double disk test (CLSI). Isolates were typed by PFGE with XbaI.
The presence of b-lactamase genes, qnr, qepA, aac(6′)-Ib-cr, aac(3)-II
and tet genes and their genetic environments were analysed by PCR
and sequencing. Amino acid changes in GyrA and ParC proteins were
studied by PCR and sequencing.
Results: All K. oxytoca isolates presented a multiresistance phenotype
that included resistance to ciproﬂoxacin, trimethoprim, sulfamethoxa-
zole, gentamicin, tobramycin, and tetracycline, in addition to b-lactams,
and ESBL-production was identiﬁed in all cases. The MIC of cefotaxime,
ceftazidime, nalidixic acid, ciproﬂoxacin, levoﬂoxacin, gentamicin,
amikacin and tobramycin were of 64, 32, 8−16, 4−8, 2, 128, 8, and
64mg/L, respectively. All isolates showed an indistinguishable or closely
related pattern by PFGE. The gene encoding CTX-M-15 was found in all
isolates, being this gene surrounded by ISEcp1 and orf477. All isolates
harboured blaOXA-1, qnrS1, aac(3)-II and tet(A) genes. In addition, they
contained two copies of aac(6′)-Ib-cr gene, one of them included in the
aac(3′)-II-IS26-aac(6′)-Ib-cr-blaOXA-1 structure, and the other one in
the aac(6′)-Ib-cr-IS26-intI1 structure, being this last one non previously
reported. The M157L amino acid change was identiﬁed in ParC protein
in all isolates, although the wild sequence was obtained for GyrA. All
patients survived and the outbreak was ﬁnally controlled after special
control measures.
Conclusion: This report emphasizes the importance of blaCTX-M-15-
containing K. oxytoca as nosocomial pathogens in intensive care unit
outbreaks, and the coexistence with genes associated with quinolone
(aac(6′)-Ib-cr, and qnrS1) or aminoglycoside resistance (aac(3)-II,
aac(6′)-Ib-cr). Two copies of aac(6′)-Ib-cr genes were identiﬁed in our
strains, one of them with a new genetic environment.
P972 Shift in ESBL-types produced by Enterobacteriaceae in a
Portuguese hospital
E. Machado, T. Gonc¸alves °, R. Silva, T. Coque, L. Peixe (Porto, PT;
Madrid, ES)
Objectives: Shifts in ESBL-epidemiology might impose new therapeutic
and infection control approaches, justifying their periodic surveillance.
In a previous survey (2003−05) performed in a tertiary care Portuguese
hospital, Hospital S. Teoto´nio, a low incidence of ESBLs (only TEM
variants -10, -24 and -116) mainly associated with E. aerogenes epidemic
clones was described. In this work we report the recent changes in ESBL-
types occurred in this institution.
Methods: A total of 1486 Enterobacteriaceae were isolated during one
year-period (2006−07). Species identiﬁcation and susceptibility testing
were performed by standard methods. ESBL characterisation included
synergy test and identiﬁcation of known bla genes (blaTEM/SHV/CTX-
M) by PCR and sequencing. Presence of the recently described qepA
gene was also searched by PCR.
Results: ESBL production was observed in 5% (81/1486) of the
isolates. ESBL-producers were identiﬁed as E. coli (n = 48), E. cloacae
(n = 14), K. pneumoniae (n = 10), K. oxytoca (n = 4), M. morganii (n = 2),
E. asburiae (n = 1), S. marcescens (n = 1), and. P. mirabilis (n = 1).
Co-resistance to non-b-lactams was frequently observed, mainly to
tetracyclines (78%), kanamycin (78%), tobramycin (70%), gentamicin
(70%), streptomycin (60%), ciproﬂoxacin (60%), and sulfonamides
(58%). qepA genes were absent. Nine ESBL-types were observed, being
identiﬁed as TEM (-10, -52, -57, -116) (19/81, 23%), SHV (-12, -64)
(18/81, 22%) or CTX-M (-14, -15, -32) (38/81, 47%). The most common
ESBL types were CTX-M-15 (35/81, 43%), recovered from E. coli
and SHV-12 (15/81, 19%) from E. coli, K. pneumoniae, K. oxytoca
and E. cloacae. Both ESBL-types were consistently recovered during
the studied period from the Medicine Service, although they were also
detected in other hospital wards. All CTX-M-15-producers harboured
blaOXA-1 and/or blaTEM-1/-116.
Conclusion: A rapid increase and diversiﬁcation of ESBL-types and
-producing species was observed in this hospital, being especially
prevalent CTX-M-15 and SHV-12 producers. Dissemination of epidemic
clones and plasmids carrying these ESBLs also conferring resistance to
other antibiotics seems to have contributed to this shift.
P973 The molecular epidemiology of the ESBL enzyme, CTX-M
in Enterobacteriaceae surveyed in north London
C. Ling, N. Smoktunowicz °, I. Balakrishnan, B.M. Charalambous
(London, UK)
Objective: ESBLs have become widespread in hospitals and in
communities. The CTX-M genotypes in particular have spread and
diversiﬁed rapidly. Over 50 CTX-M b-lactamases are recognised, which
divide into ﬁve clusters, CTX-M1, 2, 8, 9, 25 based on sequence
homology. In the UK, over 90% of ESBLs have been sown to belong to
group 1 CTX-M, with CTX-M15 predominating.
The aim of this study was to investigate the molecular epidemiology and
prevalence of CTX-Ms in Enterobacteriaceae collected in the Royal Free
Hospital and adjacent surgeries in north London.
Methods: Clinical isolates of Enterobacteriaceae were collected from
June until August, 2008. CTX-M genes were detected by PCR using
two sets of primers to differentiate CTX-M1, 3, 10, 11, 12, 15, 55,
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23, 28, 29, 29, 30 (“M3 like”) from “M14 like” (M9, 13, 14, 16, 17,
18, 19, 21, 24, 27) (Chia JH et al 2005 J Clin Micro 43: 4486−91).
Amplicons of 479 base pairs indicated the presence of CTX-M3-like
alleles and 355 bp indicated CTX-M14-like alleles. Amplicons were then
sequenced with another set of primers, CTX-F and CTX-R1, which
corresponded to nucleotide positions −19 to +2 and +894 to +877 on
CTX-M3 plasmid, respectively (Chia, JH et al, 2005 J. Clin. Micro.
43:4486−91). Data analysis was performed using Bionumerics© software
and results were compared using the BLAST nucleotide database and
Clustal W2 alignment programme for DNA.
Results: Twenty nine isolates were CTX-M producers, with CTX-M15
the most prevalent (Table 1). CTX-M15/28 varies from CTX-M15 by
only two nucleotide positions and has no impact on resistance phenotype.
Conclusions: Antibiotic sensitivity and ESBL detection methodologies
currently in use do not distinguish the ESBL genotype. The genotype has
implications for susceptibility to other antibiotics, such as gentamicin
and piperacillin-tazobactam. The ability to rapidly type ESBLs could
also inform infection control practises, particularly when investigating an
outbreak. Adaptation of this rapid molecular method in to routine clinical
diagnostics is planned. Rapid and accurate screening would greatly
beneﬁt patients as it would optimise the effectiveness and timeliness
of treatment. Optimal antibiotic treatment would also reduce the further
development of antibiotic resistance.
Table 1. Prevalence of CTX-M expressing ESBL organisms
Strain No. of CTX-M +ve Total (%)
strains (%) M14 (%) M15 (%) M15/28 (%)
E. coli 124 (62.0) 3 (2.4) 12 (9.7) 4 (3.2) 19 (15.3)
K. pneumoniae 29 (14.5) 1 (3.45) 4 (13.8) 1 (3.45) 6 (20.7)
E. cloacae 10 (5.0) 0 (0) 1 (10.0) 1 (10.0) 2 (20.0)
Others 37 (18.5) 1 (2.7) 1 (2.7) 0 (0) 2 (5.4)
Total 200 5 (2.5) 18 (9.0) 6 (3.0) 29 (14.5)
P974 Epidemiology of ESBL-producing Enterobacteriaceae in
Belgian hospitals: results of nationwide study in 2008
Y. Glupczynski °, C. Berhin, P. Bogaerts, C. Bauraing,
H. Rodriguez-Villalobos, A. Deplano, R. De Mendonca, M.J. Struelens
on behalf of the Belgian Infection Control Society
Objectives: As part of national two-yearly surveillance, we assessed the
species distribution and characterisation of the different types of ESBLs
among broad-spectrum cephalosporin-resistant Enterobacteriaceae iso-
lates prospectively collected in Belgian hospitals during the ﬁrst trimester
of 2008.
Methods: Maximum 10 consecutive, unduplicated clinical Enterobacte-
riaceae isolates resistant to 3rd and/or 4th generation cephalosporins were
collected in each participating centre and sent to a reference laboratory
for central testing.
All strains were conﬁrmed as ESBLE by double combination disk
synergy test and in the presence of boronic acid 400mg disks for AmpC
hyperproducers. ESBLs were characterised by PCR-sequencing assay
targeting the blaTEM, blaSHV, blaOXA and blaCTX-M. Genes encoding
the major plasmid-mediated AmpC b-lactamases and carbapenemases
were also sought by PCR-sequencing.
Results: 91 hospitals (43 in Flanders, 31 in Wallonia and 17 in Brussels)
sent 733 isolates (401 conﬁrmed as ESBLE) originating from patients
(mean age 71 years; range 0−98 yrs) hospitalised in medical (55%),
surgical units (21%) or ICU (20%). ESBLE were mainly isolated from
urinary (53%) and respiratory tract (20%), wound swabs (12%) and
blood (4%). E. coli, E. aerogenes, K. pneumoniae and E. cloacae
represented 56, 21, 9 and 8% of the ESBLE, respectively. 48% of
all ESBLE were considered as community-acquired (CA) (73% of
E. coli isolates). Majority of ESBL types were CTX-Ms (53%) (with
predominance of CTX-M-15 [77%]), TEM (31%; TEM-24, TEM-52)
and SHV (12%; SHV-4, SHV-12). Among ESBLE, co-resistance to
ciproﬂoxacin, cotrimoxazole and aminoglycosides was 79, 70 and 51%
respectively. CMY and DHA-like ampC were detected in E. coli (6%)
and in K. pneumoniae (10%). No carbapenemase was detected in this
survey. Spread of CTX-M-15 E. coli, K. pneumoniae and SHV-12/CTX-
M-9 co-producing E. cloacae occurred in several hospitals.
Conclusions: In comparison to a previous study carried out in 2006,
we observed a marked increase in CA CTX-Ms producing E. coli and a
parallel decrease of the TEM-24 E. aerogenes Belgian epidemic clone.
The emergence of isolates simultaneously containing ESBLs, AmpC and
resistance mechanisms to ﬂuoroquinolones and aminoglycosides is of
concern and highlights the need for further surveillance at national level
in Belgium.
P975 Clonal dissemination of CTX-M-15 producing E. coli in
Belgium: a multi-centre surveillance study
H. Rodriguez-Villalobos °, P. Bogaerts, C. Berhin, R. De Mendonc¸a,
A. Deplano, C. Bauraing, M.J. Struelens, Y. Glupczynski (Brussels,
Yvoir, BE)
Objectives: CTX-M ESBL-producing strains of E. coli are expanding
world wide. As part of a national surveillance project, we analysed the
diversity of extended spectrum-B-lactamases (ESBL), resistance genes,
genetic environment, clonality and phylogenetic background of ESBL-
producing E. coli (ESBLEC) isolated in Belgian hospitals.
Methods: A total of 132 unduplicated clinical ESBLEC isolates
collected between 01/2006 and 06/2006 in 40 (maximum of 5 strains
per centre) were sent to a reference laboratory. The presence of ESBL
was conﬁrmed by double combination disk test (DDT) and/or by ESBL
E-tests (cefotaxime and ceftazidime + clavulanic acid). ESBL were
characterised by isoelectric focusing and PCR-sequencing assay targeting
blaTEM, blaSHV, blaCTX-M and blaOXA. The genetic environment
of ESBL genes was analysed by PCR mapping and DNA sequencing.
Phylogenetic group were assigned by multiplex PCR targeting chuA,
yjaA, svg genes and the TSPE4C2 element. Clonality was assessed by
PFGE.
Results: ESBL-EC isolates harboured TEM alone (n = 68), CTX-
M+TEM (n = 49), CTX-M alone (n = 10), SHV alone (n = 3), CTX-
M+SHV (n = 1), TEM+SHV (n = 1). DNA sequencing of CTX-M-EC
revealed CTX-M1 group in 44 isolates (including 33 CTX-M-15, 10
CTX-M-1 and 1 CTX-M-3) and CTX-M-2 or CTX-M-9 group in 8 and
5 isolates. Among CTX-M-producing E. coli, 82% harboured TEM-1
and 57% OXA-30 enzymes, whereas co-production of SHV was rare
(2%). CTX-M producing strains belonged to phylogroups B2 (67%), A
(21%), D (7%) and B1 (5%). PFGE showed 25 genotypes in CTX-M-
producing E. coli. Majority (27/33) of CTX-M-15 isolates belonged to a
major PFGE type found in 18 centres (1 to 4 isolates/centre) suggesting
clonal spread of CTX-M-15 in Belgium. ISEcp1 and IS26 was found
upstream to CTX-M-15 in 29 and 4 isolates respectively and uptstream
to CTX-M-1 in 6 and 4 isolates, respectively. None of these IS could
be found upstream to CTX-M-3. Orf513 transposition element was only
detected upstream to CTX-M-2.
Conclusion: This study showed that CTX-M producing E. coli strains
are widely distributed in Belgian hospitals. Molecular analysis indicates
this derives from both gene dissemination (CTX-M-2 and CTX-M-9) and
epidemic spread of CTX-M-15 producing clone in approximately half
of these centres. Further study is in progress to establish the relationship
of this epidemic strain to the international O25:H4-ST131 clone.
P976 Predominance of virulent CTX-M producing strains in
extended spectrum B-lactamase producing E. coli in a
Belgian university hospital
A. Cardentey-Reyes, H. Rodriguez-Villalobos °, R. De Mendonc¸a,
M.J. Struelens (Brussels, BE)
Objectives: The spread of CTX-M producing E. coli (CTX-M-EC) is of
public health concern. We analysed the molecular epidemiology and the
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phylogenetic background of CTX-M-EC strains over a period of 8 years
in a University hospital in Belgium.
Methods: In 2000–2007, E. coli clinical isolates were screened for
ESBL production and conﬁrmed by double-disk synergy test and/or
combined-disks. ESBL producing E. coli isolates (n = 288) from blood
(n = 23), urine (n = 117) and rectal swabs (n = 148) were included in
this study. ESBLs were characterised by multiplex PCR for bla genes
of the SHV, TEM and CTX-M family, CTX-M group determination
and DNA sequencing. Phylotyping was performed by multiplex PCR
targeting chuA, yjaA, svg genes and the TSPE4C2 element. PCR. ESBL-
EC (n = 112) strains were tested for MIC of 12 antimicrobials by agar
dilution. The genetic environment of CTX-M-1 group was analysed by
PCR mapping and DNA sequencing.
Results: ESBL-EC strains harboured CTX-M (57%) TEM (37%) or
SHV enzymes 10%. The proportion of CTX-M enzymes increased from
25% in 2000 to 69% in 2004 and levelled off in the last 4 years. Among
CTX-M-EC, CTX-M group 1 was predominant followed by group 2
(75 and 16% of CTX-M enzymes, respectively). The proportion of
group 1 increased (30%in 2000 to 90% in 2001). CTX-M group 1 was
ﬂanked by a truncate ISEcp1 and orf477 transposition elements in 91%
of isolates. CTX-M producing strains belonged to phylogenetic groups
B2 (59%), and A (22%), B1 (10%) and D (9%). The proportion of
phylogroup B2 in rectal swabs isolates was similar to those from blood
or urine. In ESBL-EC, meropenem, amikacin and temocillin were the
most active antibiotics in vitro with MIC90 of 0.06mg/mL, 8mg/mL and
16mg/mL respectively. Co-resistance to ciproﬂoxacin, cotrimoxazole and
tobramycin was 54, 58 and 48% respectively.
Conclusions: In our hospital, CTX-M enzymes were the most frequent
ESBL among EC in recent years. CTX-M of group 1 was predominant
(75%) and appeared located within the same element of transposition
as CTX-M-15. The majority of CTX-M producing isolates belong to
virulent phylogroup B2. Contrary to previous reports this phylogroup
was as frequent in rectal isolates as in urine or blood isolates. Those
data document an important reservoir of ESBL genes among virulent
E. coli strains at this hospital.
P977 Polyclonal spread of extended-spectrum b-lactamase produc-
ing Enterobacter cloacae at a Belgian university hospital
T.D. Huang °, P. Bogaerts, C. Bauraing, G. Wauters, M. Janssens,
J. Van Broeck, Y. Glupczynski (Brussels, Yvoir, BE)
Objectives: Nosocomial outbreaks caused by extended-spectrum
b-lactamase-producing Enterobacter cloacae (ESBL-EC) have recently
been reported in several countries worldwide. We describe here the
clinical, epidemiological and microbiological characteristics of ESBL-
EC isolates recovered at a large Belgian university hospital.
Methods: We performed a prospective surveillance of all hospitalised
patients with infection or colonisation by an ESBL-EC strain. Production
of ESBL was determined by decreased susceptibility or resistance
to expanded-spectrum cephalosporins (Ceph-R) with the BD Phoenix
System and by combination disc method using Rosco tablets. ESBL
types were further characterised by multiplex PCR targeting the TEM,
SHV, CTX-M coding genes families and amplicons were sequenced. All
isolates were identiﬁed up to the subspecies level within the E. cloacae
complex and the clonal relatedness of the strains was determined by
PFGE using Xba1 restriction enzyme.
Results: From Oct. 2006 to Sept. 2007, 98 of 396 E. cloacae isolates
were identiﬁed as Ceph-R. 25 of these strains (26%) were ESBL-positive;
6 isolates expressing SHV-5/-12 and 16 other harbouring CTX-M (13
CTX-M-9 and 3 CTX-M-2) alone (6) or in association with SHV-5/-
12 (10). Most ESBL-EC displayed associated resistance to quinolones
and to aminoglycosides. The ESBL positive isolates were identiﬁed into
four subspecies including 12 Enterobacter hormaechei subsp. oharae, 6
E. hormaechei subsp. steigerwaltii, 2 E. hormaechei subsp. hormaechei
and 7 E. cloacae sensu stricto. PFGE disclosed at least 20 different
patterns. Medical records of the 25 patients revealed 15 admissions to
an intensive care unit (ICU) prior to the isolation of the strains, 11
infections and 6 deaths (including 4 attributable).
Conclusion: ESBL-EC have clearly emerged in our hospital (6.3%
of all E. cloacae isolates compared to 3.7% and 2.6% during the
same period one and two years before). Clinical epidemiological
data, phenotypic identiﬁcation to subspecies and molecular typing all
suggested a polyclonal dissemination with possible horizontal gene
transfer originating from strains that were predominantly recovered
from patients hospitalised in ICUs. Continuous active surveillance is
warranted in microbiology laboratories for the early detection of ESBLs
and the prevention of outbreak in infrequent ESBL-producing species
such as E. cloacae.
P978 Epidemiology of ESBL producing Klebsiella pneumoniae
isolates from a paediatric hospital
D. Dzierzanowska °, W. Kaminska, K. Semczuk, D. Borowiec,
J.A. Patzer (Warsaw, PL)
Objective: The extended-spectrum b-lactamases (ESBLs) are the main
mechanism of resistance to oxyimino-b-lactams among Gram-negative
clinical isolates, especially in K. pneumoniae, an organism responsible
for community- and hospital acquired infections. During 2004–2007,
in the Childrens Memorial Health Institute (CMHI) the frequency
of K. pneumoniae among Gram-negative isolates from blood varied
between 15−28%, but the frequency of ESBLs reached 37% in 2006 and
decreased to 16% in 2007. The aim of this study was the epidemiologic
analysis of K. pneumoniae isolates producing ESBLs obtained from
hospitalised children in the period 2004–2007.
Methods: 62 clinical isolates of K. pneumoniae producing ESBL were
obtained from CMHI. MICs of selected b-lactams were determined
by the agar dilution method agar as recommended by CLSI. PCR
analysis was performed using primers speciﬁc for blaCTX-M, blaSHV
and blaTEM. Sequencing was carried out using ABI PRISM 310 DNA
sequencer and analyzed using CLC Free Workbench 4.0 and Finch TV
Program. Genotyping was done using PFGE.
Results:. All 62 K. pneumoniae ESBL+ isolates gave a positive result
for blaCTX-M genes. Among them 51 had the identical sequence typical
for CTX-M-3 enzyme and eleven had CTX-M-15 enzyme. The MIC90
values for ceftazidime and ceftazidime plus clavulanate were equal to
64mg/L and 4mg/L, respectively. The MIC90 values for cefotaxime
and cefotaxime plus clavulanate was equal to 128mg/L and 4mg/L
respectively. Majority of K. pneumoniae strains produced additionally
TEM enzymes (37) and/or SHV enzymes (20). TEM-47, TEM-48, TEM-
86, TEM-130, TEM-132, SHV-1 and SHV-5 enzymes were detected.
PFGE analysis showed that only 37% of K. pneumoniae strains were
clonal. The presence of ﬁve clones with 100% identity and two clones
with 90% and 87% identity, respectively, were found.
Conclusion: Epidemiological analysis of K. pneumoniae ESBL produc-
ing clinical isolates showed that they produced CTX-M enzymes and
majority of them additionally TEM and/or SHV. Only 37% of them
showed clonal relationship.
P979 Emergence of ESBL-producing Escherichia coli and
Klebsiella spieces isolates in Lithuania
V. Seputiene °, M. Linkevicius, A. Vitkauskiene, A. Pavilonis,
E. Suziedeliene (Vilnius, Kaunas, LT)
Objectives: the main purpose of the study was to investigate the
frequency of ESBL-producing E. coli and Klebsiella clinical isolates
in Lithuania and to determine the types of ESBL encoded.
Methods: the antibiotic susceptibility of 221 nonduplicate clinical
isolates, including 124 E. coli, 86 K. pneumoniae and 11 K. oxytoca
collected in three regional hospitals during the period 2007–2008 was
determined by using Sensititre plates (GN1F). The isolates with reduced
susceptibility to oxyimino-cephalosporins were examined for ESBL
production using Conﬁrmatory MIC plates (ESB1F, Sensititre). ESBL
producers were analyzed by PCR to detect the ctx-M, shv, oxa genes.
ESBL type was determined by nucleotide sequencing (CTX-M) and NheI
restriction typing (SHV-ESBL).
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Results: phenotypic analysis revealed the presence of ESBLs in 32
isolates of E. coli (25.8%), 63 isolates of K. pneumoniae (73.2%)
and 5 isolates of K. oxytoca (45.5%). E. coli isolates were found to
carry SHV-ESBL (N= 1), CTX-M-1 (N= 3), CTX-M-3 (N= 4), CTX-
M-15 (N= 13), CTX-M-14 (N= 3) and a novel variant of CTX-M-
2 designated CTX-M-2a (Ala208Thr) (N = 6). K. pneumoniae isolates
were found to carry SHV-ESBL (N= 25), CTX-M-3 (N= 5), CTX-M-15
(N= 21), CTX-M-2 (N= 5), CTX-M-2a (N= 13). K. oxytoca – CTX-M-
15 (N= 2), CTX-M-2 (N= 1), CTX-M-2a (N= 1). Two K. pneumoniae
isolates coexpressed SHV-ESBL together with CTX-M-15 and one
isolate together with CTX-M-3. All E. coli and majority of Klebsiella
producing CTX-M-15 were found to carry OXA-1 type b-lactamase. All
E. coli and Klebsiella isolates producing CTX-M-2 and CTX-M-2a were
OXA-2 type b-lactamase positive. The majority of Klebsiella and E. coli
ESBL producers were multidrug resistant expressing resistance to two
or more non-b-lactam antibiotics. The common resistance proﬁle for
K. pneumoniae CTX-M-15 producers was CIP GEN TOB NIT (N= 16)
and for E. coli CTX-M-15 producers GAT CIP TOB (N= 13) with
additional GEN resistance being expressed in 11, SXT − in 8 isolates.
Klebsiella spp and E. coli isolates expressing CTX-M-2, CTX-M-2a,
CTX-M-3 and SHV-ESBL were mainly GEN TOB resistant. CTX-M-14
producing E. coli isolates were not resistant to non-b-lactam antibiotics
GAT CIP GEN TOB AMI NIT SXT.
Conclusion: the ﬁrst survey revealed the high frequency of ESBL pro-
ducing E. coli and Klebsiella clinical isolates and a high predominance
of SHV-ESBL, CTX-M-15, CTX-M-2a in K. pneumoniae and CTX-M-
15, CTX-M-2a in E. coli isolates in Lithuania.
P980 Dissemination of ST274 Klebsiella pneumoniae epidemic
clone adapted to the newborn and adult hospital settings
by producing SHV-2a or CTX-M-15 type extended spectrum
b-lactamases
A´. To´th °, I. Damjanova, E´. Kenesei, M. Ko¨halmi, S. Kocsis, P. Sza´ntai,
M. Fu¨zi, J. Pa´szti (Budapest, Va´c, HU)
Objective: To investigate the molecular epidemiology and genetic
features of extended-spectrum b-lactamase (ESBL) producing K. pneu-
moniae epidemic clone (KP-EC) with unusual resistance pattern isolated
from multiple nosocomial outbreaks and sporadic cases between 2006
and 2008 in Hungary.
Methods: As result of continuous monitoring of ESBL-producing KP-
ECs 28 isolates collected from 5 healthcare facilities submitted to the
National Center for Epidemiology were selected for macrorestriction
proﬁle analysis by PFGE. Of these 12 strains were isolated from adult
inpatients (including 5 invasive samples from one nosocomial outbreak)
in 2 healthcare facilities and 16 strains were isolated from newborns
(including 12 invasive samples from two nosocomial outbreaks) in
4 healthcare facilities. The MIC values were determined by agar
dilution technique for the following antibiotics: ceftazidime, cefotaxime,
gentamicin, amikacin and ciproﬂoxacin. Furthermore molecular typing
was performed by PCR and sequencing of several antibiotic resistance
genes, plazmid proﬁle analysis, transfer of resistance determinants and
multilocus sequence typing (MLST).
Results: All isolates showed moderate resistance to ciproﬂoxacin (MICs
ranged from 0.5mg/L to 8mg/L). The MICs for ceftazidime proved 64–
128mg/L in the “adult isolates” and 8mg/L in the “newborn isolates”.
PFGE revealed the existence of only one genetic cluster deﬁned as EC
IV. PstI digestion of plasmid DNA from transconjugants/transformants
revealed two highly diverse restriction patterns corresponding to “adult”
and “newborn isolates”. Sequence analysis of b-lactamase genes from
plasmids of 15 selected isolates detected blaSHV-2a in strains isolated
exclusively from newborns and blaCTX-M-15 in strains isolated
exclusively from adult inpatients. MLST established that strains of the
PFGE cluster belonged to a novel sequence type ST274.
Conclusion: ESBL-producing K. pneumoniae isolates belonging to the
novel sequence type ST 274 adapted to the newborn and adult hospital
settings in Hungary by acquiring SHV-2a or CTX-M-15 type enzymes,
respectively. Thus, new strategy for exceptional adaptation to different
hospital settings was found in KP population.
P981 Identiﬁcation of PER-1, CTX-M-3, CTX-M-15, SHV-2,
TEM-3 and TEM-15 extended-spectrum b-lactamases in
chromosomal AmpC-producing Enterobacteriaceae isolates
from cancer patients in Bulgaria
S. Sabtcheva °, T. Kantardjiev, V. Borissova, M. Kaku (Soﬁa, BG;
Sendai, JP)
Objective: To characterise extended-spectrum b-lactamase (ESBL)
genes present in chromosomal AmpC-producing enterobacterial isolates
recovered in a Bulgarian cancer hospital.
Methods: Screening for genes encoding ESBLs (blaPER-1, blaTEM,
blaSHV, blaCTX-M, blaVEB-1 and blaGES-1) was carried out by
PCR ampliﬁcation with speciﬁc primers in 37 non-duplicate, clinically
relevant ESBL-producing isolates including 19 Citrobacter freundii, 9
Enterobacter cloacae, 5 Serratia marcescens, 2 Enterobacter aerogenes,
1 Morganella morganii and 1 Providencia rettgeri. For isolates with
PCR-positive results, sequencing was performed. Susceptibility to
antimicrobials was determined by standard disk diffusion or Etest
procedures.
Results: The 37 chromosomal AmpC-producing Enterobacteriaceae
were found to coproduce the following ESBLs: 14 (37.8%) CTX-M-3,
nine (24.3%) TEM-3, eight (21.6%) SHV-2, four (10.8%) CTX-M-15,
one (2.7%) TEM-15 and one (2.7%) PER-1. Sixteen isolates (43.2%)
also carried blaTEM-1, and one of them carried blaSHV-1 as well. In
vitro, all isolates were susceptible to imipenem. Susceptibility to other
drugs was as follows: 78% for ciproﬂoxacin, 43% for amikacin and 32%
for gentamicin. Associated resistance to amikacin and ciproﬂoxacin was
observed most frequently among CTX-M-positive isolates.
Conclusions: The most prevalent ESBLs were CTX-M enzymes (CTX-
M-3 and CTX-M-15) followed by TEM-3 and SHV-2. This is the ﬁrst
report of TEM-15 and PER-1-producing Enterobacteriaceae in Bulgaria.
P982 Prevalence of CTX-M producing Klebsiella pneumoniae in
hospitals versus community
Z. Bosˇnjak °, B. Bedenic, A. Budimir, I. Marekovic, N. Beader,
J. Vranesˇ, S. Kalenic on behalf of the Committee for Surveillance
of Bacterial Resistance to Antibiotics in Republic of Croatia
Objectives: This study was conducted to detect and analyze the presence
of extended-spectrum b-lactamase (ESBL)-producing Klebsiella pneu-
moniae within clinical isolates of both community- and hospital-based
patients in Croatia and to characterise bla genes in these isolates.
Methods: 648 consecutive non-duplicate K. pneumoniae isolates from
26 laboratories in 21 Croatian cities were collected from October 2006 to
January 2007. 128 K. pneumoniae isolates were selected for further study
on the basis of positive double disc diffusion test for ESBL production.
After determination of minimal inihibitory concentration (MIC), transfer
of bla genes was performed by conjugation assay with E. coli J62−2
(RifR) (NCTC 50170) as the recipient. PCR was used to detect alleles
encoding CTX-M enzymes. 33 producers were compared by analysis of
banding patterns generated by pusled-ﬁeld gel electrophoresis (PFGE)
of Xba I-digested genomic DNA.
Results: Percentage of ESBL-positive isolates from hospitals was 56,
and 44% originated from community. CTX-M was detected in 33
(25.8%) isolates. 16 hospital acquired isolates were CTX-M positive
(22.2%) and 17 CTX-M positive community isolates were detected
(30.4%). Pulsed-ﬁeld gel electrophoresis analysis demonstrated three
major similarity groups according to Tenover criteria, each in different
geographical region.
Conclusions: According to our results (25.8%) of ESBL isolates were
CTX-M positive. PFGE analysis revealed three major similarity groups
which have shown speciﬁc geographical distribution. CTX-M positive
K. pneumoniae strains will be further characterised using multiplex PCR
and sequencing.
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P983 Antimicrobial susceptibility testing of extended-spectrum
b-lactamase producing Enterobacteriaceae isolated from
Macau, China
T. Ling °, J. Lei, C.C. Lee, K.T. Wong, K.V. Koon (Hong Kong, HK;
Macau, MO)
Objective: ESBLs emerged in the 1980 s and now have been reported
throughout the world. The consequences of ESBL-mediated resistance
in the clinical setting can be tremendous and lethal. This is the ﬁrst
study that we present antibiotic susceptibility proﬁle, prevalence rate
and genotypes of ESBL producers in Macau.
Materials and Methods: The MICs of amikacin (AMK), ciproﬂoxacin
(CFX), piperacillin-tazobactam (PTZ) and imipenem (IMP) were
determined using GNS-121 and 137 cards loaded to the VITEK system
following the CLSI recommendations. ESBL production was determined
by a 5mm increase in zone diameter for either ceftazidime or cefotaxime
in combination with clavulanate versus its zone size when tested alone.
The ESBL enzymes were characterised by multiplex PCR according
to the method of Colom which detects and discriminates between
blaSHV, blaTEM and blaOXA-1 PCR amplicons of 392, 516 and
619 bp respectively. CTX-M type ESBL enzymes were characterised
by multiplex PCR according to the method of Xu which detects and
discrimates between CTX-M-gp 1, CTX-M-gp 2, CTX-M-gp 8, 25/26,
and CTX-M-gp 9 of 260, 341, 207 and 293 bp respectively.
Results: A total of 697 clinical Enterobacteriaceae isolates were
collected during Oct 2007 to Jul 2008 in CHCSJ and the results
showed that 26.9% of E. coli and 21.6% of Klebsiella spp. were ESBL
producers. The resistance rate of ESBL producing organisms to AMK,
PTZ and CFX were 3.8%, 8.2% and 71.4% respectively. All strains
were sensitive to IMP. Among 150 ESBL producing E. coli, 59.3%
were producing TEM-type, 6.7% OXA-type; 4% TEM+OXA-type and
30.0% did not produce TEM, SHV or OXA-type enzymes. Among 30
ESBL Klebsiella spp., 26.7% SHV-type, 16.7% TEM-type and 1 OXA-
type. 30% SHV+OXA-type, 2 produced TEM+SHV-type and 5 did not
produce TEM, SHV or OXA-type enzyme. In this study, E. coli (90%)
and Klebsiella spp. (80.0%) were producing CTX-M-type ESBL. Among
E. coli, 59.3% CTX-M-gp 9 type, 28.0% CTX-M-gp1 type and 4 both
CTX-M-gp 9 type and CTX-M-gp1 type. Among Klebsiella spp., 63.3%
CTX-M-gp 9 type, 16.7% CTX-M-gp1 type ESBL.
Conclusion: ESBL producing rate of E. coli and Klebsiella spp. were
26.9%; and 21.6% respectively. All ESBL producers remain sensitive to
IMP; however, there was a high resistance rate of more than 70% to
CFX. CTX-M is the predominant type of enzymes found in both ESBL
producing E. coli and Klebsiella spp.
P984 Molecular characterisation and epidemiology of
Enterobacteriaceae isolates other than Escherichia coli and
Klebsiella spp. that are non-susceptible to extended-spectrum
cephalosporins in Thailand
P. Kiratisin °, A. Henprasert (Bangkok, TH)
Objectives: To (1) characterise b-lactam resistant genes, (2) survey
the susceptibilities to antimicrobial agents and (3) demonstrate
molecular epidemiology of extended-spectrum cephalosporin-resistant
Enterobacteriaceae other than Escherichia coli and Klebsiella spp.
(EOTEK) in Thailand.
Methods: Non-duplicate clinical isolates of EOTEK were collected at
Siriraj Hospital, a 2200-bed university hospital in Bangkok (Thailand)
during October 2006-March 2007. Antimicrobial susceptibilities were
tested by disc diffusion and E-test® methods. Isolates resistant to
an extended-spectrum cephalosporin were tested for ESBL production
based on the CLSI phenotypic method, and were detected for ESBL
genes by PCR. AmpC gene detection was performed for isolates that
were present with ESBL genes but negative for ESBL test. All PCR
products were sequenced to identify their molecular types. Pulsed-
ﬁeld gel electrophoresis (PFGE) analysis was used to demonstrate their
genetic relationships.
Results: A total of 143 out of 598 isolates (23.9%) of EOTEK
were not susceptible to extended-spectrum cephalosporin(s), including
Enterobacter (n = 91), Salmonella (n = 20), Proteus (n = 11), Citrobacter
(n = 9), Serratia (n = 6), Providencia (n = 4) and Morganella (n = 2).
ESBL genes were detected in 142 isolates (99.3%) and included CTX-
M-15 (53.5%), TEM-116 (43.7%), CTX-M-55 (16.9%), VEB-1 (16.2%),
CTX-M-3 (14.8%), SHV-12 (13.4%), CTX-M-40 (2.1%) and SHV-2a
(0.7%). Only 100 isolates (70.4%) of ESBL gene-carrying isolates
were positive for ESBL test. Among 42 ESBL phenotype-negative
isolates that harboured ESBL genes, 34 isolates (81%) also possessed
AmpC gene(s). The MIC90 (ug/mL) of ESBL gene-carrying isolates
against cefotaxime, ceftriaxone, ceftazidime, ciproﬂoxacin, imipenem,
meropenem, ertapenem and doripenem were >256, >256, >256, >32,
1.5, 0.5, 6 and 0.19, respectively. 20.4% of isolates were shown to be
non-susceptible to ertapenem. PFGE analysis demonstrated that multiple
clones were present.
Conclusion: We found that ESBL genes, particularly CTX-M-15, were
very common among cephalosporin-resistant EOTEK. However, the
phenotypic detection of ESBL suggested by the CLSI was not efﬁcient,
probably due to the high prevalence of AmpC production among
these isolates. We ﬁrst report the detection of TEM-116 in Thailand.
Susceptibility to ertapenem was noticeably reduced as compared to other
carbapenems. Based on the PFGE analysis, most of these isolates had
no clonal relationship.
P985 Rampant resistance to b-lactam antibiotics in previously sus-
ceptible Enterobacteriaceae: the Kwazulu-Natal experience
S. Essack °, U. Govinden, C. Mocktar, U. Ramgulam (Durban, ZA)
Objectives: Molecular mechanisms of resistance were investigated in
Escherichia coli, Salmonella spp. and Proteus mirabilis, enterobacteri-
aceae previously fully susceptible to all b-lactam antibiotics ranging from
penicillins to carbapenems.
Methods: E. coli and P. mirabilis were obtained from a multi-
centre surveillance study instituted in 16 hospitals at 3 progressive
levels of health care (district, regional, and tertiary) where microbi-
ology laboratories collected 100 consecutive, non-repetitive isolates.
Salmonella spp. were obtained from a collection of putative extended-
spectrum b-lactamase-producers from a tertiary hospital. Representatives
of particular resistance phenotypes determined by susceptibility testing
using the CLSI Kirby Bauer disc diffusion method were subjected
to isoelectric focusing, plasmid proﬁle analyses and detection of
b-lactamase genes by PCR and sequencing.
Results: Sequencing evidenced TEM-145 and TEM-146, new inhibitor-
resistant b-lactamase genes and CMY-20, a new plasmid-mediated
AmpC-type b-lactamase gene, in addition to the OXA-1, TEM-55, SHV-
2, CTX-M1 and TEM-1 genes in the 38 E. coli isolates. TEM-1, SHV-
1 and TEM-53 were found in the 29 P. mirabilis isolates while 41
Salmonella spp. expressed one/more of the SHV-2 SHV-12, TEM-63,
TEM-116, TEM-131, CTX-M-3, CTX-M-15, CTX-M-37, CMY-2 and
OXA-1 b-lactamase genes. Diverse b-lactamase genes and/or enzyme
combinations and plasmid proﬁles indicated extensive mobilisation of
resistance genes.
Conclusions: The complex and diverse patterns of b-lactamase genes
suggest an epidemiology where b-lactamase production has become
endemic, and where evolution is generating a wide range of enzyme
combinations complicating patient management and rendering useless a
once highly efﬁcacious antibiotic armamentarium in a public healthcare
system dependent on syndromic management and empirical therapy.
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P986 Medical intervention at immigrant camps in Greece
O. Adrami °, A. Spilioti, I. Keramidas, T. Sideroglou, T. Papadimitriou,
I. Pierroutsakos (Athens, GR)
Objectives: Registration and evaluation of typical medical screening of
migrating populations, with emphasis on epidemic infectious diseases,
at camps where illegally arrived immigrants, at ﬁrst stay.
Methods: The staff of the Ofﬁce for Mobile Populations of the HCDCP
conducts medical intervention regarding health inspection of illegally
arrived persons in Greece, in speciﬁc places where these persons are
kept temporarily after they are arrested. The typical screening of the
intervention involves physical examination, obtaining the immigrant’s
medical and social history. Information is registered in the data base of
the HCDCP. Data analysis is based on descriptive statistics.
Results: The screening conducted on 4505 persons (4020 male, 485
female) during the period of 09/01/2007–22/12/2007. Mean age was
24.21 years (± 8). In reference with the declared countries of origin,
1123 (24.92%) immigrants were from Afghanistan, 1180 (26.2%) from
Iraq, 338 (7.50%) from Pakistan, 626 (13.9%) persons were from
Palestine, 706 (15.67%) from Somalia and 532 (11.80%) from other
countries (India, Bangladesh etc). Health problems were detected at
1029 (22.84%) cases. 365 (8.1%) cases of dermatological diseases,
310 (6.89%) cases of respiratory diseases, 120 (2.66%) cases of
gastrointestinal system diseases, 77 (1.71%) cases of myoskeletal system
diseases, 61 (1.35%) cases of urinary system diseases, 23 (0.51%) cases
of cardiovascular system diseases and 73 (1.62) cases of other systems
were registered. 53 (1.18%) persons were referred for further clinical
assessment by specialists, 40 persons (0.89%) for laboratory tests and
treatment was given to 438 of them (9.72%).
Conclusions: In case of mass arrival of immigrants, the aim is the safe
treatment of them with respect to international humanitarian principles.
Main priority is the immediate intervention, so the state mechanism
for immediate interference is activated, if cases of emergence infectious
diseases are detected.
P987 Protocol for congenital Chagas disease control in Florence,
Italy
M. Strohmeyer, S. Gabrielli, F. Bartalesi, C. Truppa, K.H. Aiello,
M. Di Tommaso, G. Cancrini, A. Bartoloni ° (Florence, Rome, IT)
Objectives: Chagas disease causes high morbidity in many Latin
American countries. Maternal-fetal transmission of Trypanosoma cruzi
occurs in 2−12% of pregnant infected mothers. Early treatment of
infected infants attains a nearly 100% eradication rate. In August 2008,
the Tuscany Reference Centre for Tropical Diseases implemented a
protocol for the screening of congenital Chagas disease at the main
public maternity hospital (Careggi Hospital) of Florence, Italy.
Methods: The programme consists of: 1) screening of pregnant
women coming from endemic areas for seroreactivity to T. cruzi,
by using an immunochromatographic assay (ICT)(Chagas Quick Test,
Cypress Diagnostics, Belgium) and conventional T. cruzi IgG ELISA
test (CHAGAS IgG ELISA, Nova Tec, Germany), 2) serological
(ICT plus ELISA) and parasitological (microscopic examination and
nested polymerase chain reaction-PCR with primers TCZ1/TCZ2 and
TCZ3/TCZ4, followed by sequencing) evaluation of infants born to
T. cruzi-infected women, 3) treatment of infected infants. Infants are
considered infected in case of microscopic detection of T. cruzi, or PCR
positivity in at least two different samples, or seropositivity at 8 months
of age.
Results: From 1/8 to 31/12/2008, 35 pregnant women were screened
(mean age 31 years, limits 14−40). The countries of origin were: Peru
(17), Brazil (6), Argentina (3), Bolivia (2), Colombia (2), El Salvador (2),
Chile (1), Costa Rica (1) and Venezuela (1). All except one mother tested
negative. The seroreactive mother, aged 29 years, came from Bolivia. The
further evaluation of her infant is ongoing. The parasitological evaluation
at 1 month of age was negative.
Conclusions: In Europe, the presence of immigrants from endemic
areas makes possible the appearance of congenital infection in newborns
of mothers living with chronic Chagas disease. To increase the early
detection of congenitally infected infants and thus facilitate their early
treatment, surveillance of pregnant women from endemic areas is
recommended. Furthermore, the detection of a maternal Chagas infection
should lead to extend the screening to other family members.
P988 Travel-associated enteric fever: a review of demographics,
clinical features, laboratory ﬁndings, treatment and outcomes
in a UK district general hospital
V. Sreeharan °, M. Laundy (Oxford, Slough, UK)
Objectives: To identify the demographics, clinical and laboratory
features of enteric fever in a UK hospital over a 5 year period, and
to review the management and outcomes of these cases.
Methods: This is a retrospective study of 41 blood culture conﬁrmed
cases of Salmonella typhi and Salmonella paratyphi between 2003
and 2008 with available medical notes. Patient demographics, clinical
features, treatment and outcomes were obtained from the notes, and
laboratory data from the hospital database.
Results: Demographics: Ages ranged from 3 years to 66 years
(median 21 years), male:female (60%:40%), and all had a history
of recent travel (55% India, 30% Pakistan, 5% Sri Lanka). Clinical
features: Onset of symptoms occurred whilst abroad in 37% and on
return to the UK in 63% (median duration on arrival was 10 days).
Symptoms included fever (100% with 78% rigors), gastrointestinal (90%
with 68% diarrhoea, 63% nausea/vomiting, 46% abdominal pain, 7%
constipation), non-speciﬁc features (93% including malaise, anorexia,
fatigue, myalgia, headache, dizziness) and cough (24%). Signs included
fever (93%), gastrointestinal (51% with 44% abdominal tenderness,
15% hepatomegaly and 10% splenomegaly), bradycardia (5%) and rose
spots (2%). Laboratory ﬁndings: Raised C-reactive protein (100%) and
raised alanine transaminase (88%) were the most consistent ﬁndings.
The blood culture organism was S typhi (39%), S paratyphi A (59%)
and S paratyphi B (2%), with the proportion of S paratyphi A cases
increasing over the study period. 54% were ciproﬂoxacin resistant with
the proportion of resistant cases increasing over time. Treatment and
outcomes: 93% received appropriate antibiotics, with no known negative
outcomes for those who did not. There was 1 severe case of enteric
colitis, 1 case of known relapse and no known mortality. Time to
defervescence was variable (1−16 days, median 4 days) and length of
stay varied from 1−18 days (median 6 days).
Conclusion: A diagnosis of enteric fever must always be considered in
patients with fever and a recent travel history. Clinicians in areas with
a high proportion of patients from South Asia should be particularly
familiar with the diagnostic features and the high levels of ciproﬂoxacin
resistance.
P989 Effective tick removal with a ﬁshing line knot
G. Ghirga °, P. Ghirga (Civitavecchia, IT)
Objective: The Centers for Disease Control recommends tick removal
using a pair of ﬁne-tipped tweezers to ﬁrmly grasp the tick very close
to the skin and with a steady motion, pulling the tick’s body away.
Unfortunately, this method carries a high risk of crushing tick’s body
(thorax, head) particularly for tiny species. This may force infective
body ﬂuids through the tick’s mouthparts into the wound site.
We report the results of an open study aimed to investigate if ticks
attached to human skin can be effectively removed by tightening a knot
of a ﬁshing line around the tick’s mouthparts.
Methods: Ten ambulatory children between the age of 4 and 13 entered
the study. Seventeen ticks attached to children’s skin were removed by
two physicians, a paediatrician and a dermatologist, tightening a knot
of a ﬁshing line around the tick’s mouthparts. Technique: Use a 20 cm
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ﬁshing line, diameter 0.4mm or thinner. Slowly tie a simple knot around
the tick’s head. If the line is pressed against the skin while being gently
pulled, the knot will tighten around the tick’s mouthparts. Pull the ends
of the line slowly and steadily until the tick can be eased out of the skin.
Avoid tightening the knot sharply, as this may tear the mouthparts from
the body of the tick, leaving them embedded into the skin.
Results: All ticks detached as the knot was tightened. Once the
ticks were removed they were placed in 70% ethanol for microscopic
evaluation of the mouthparts. The ticks were all less than 0.5mm. Twelve
ticks were completely removed. The remaining have the mouthparts
almost completely removed. All ticks were alive. On follow up no patient
showed sign of local infection or rickettsiosis.
Conclusions: Tick removal by tightening a knot of a ﬁshing line around
the tick’s mouthparts appears to have a high success rate however areas
covered with hairs may make this method difﬁcult to apply. It seems
particularly indicated for removal of tiny species.
A 2mm tick struggling to free from ﬁshing wire node after it has been
removed from the thigh of an infant.
P990 Phylogenomic and subproteomic approaches to gain
new insights into the mitochondrion features of the
Cryptosporidium parvum parasite
L. Putignani °, A. Petrucca, P. Jedelsky, F. Del Chierico, C. Russo,
L. Mancinelli, J. Wastling, J. Tachezy, D. Menichella (Rome, Chieti,
IT; Prague, CZ; Liverpool, UK)
Objectives: Cryptosporidium spp. is a protozoan parasite that causes
widespread diarrhoeal disease in humans and other animals and is
responsible for large waterborne outbreaks of cryptosporidiosis. Unlike
many organisms belonging to the phylum Apicomplexa, such as
Plasmodium spp. and Toxoplasma gondii, there is no clinically proven
drug treatment against this parasite. In our study an analysis of the
mitochondrial proteome of C. parvum, performed by exploiting genomic
and proteomic approaches, has allowed us to infer preliminary metabolic
maps and hypothesize evolutionary implications.
Methods: Genomic entries from C. parvum genome project (Abraham-
sen et al., Science 304 5669: 441−5) were analysed for EC and GO
classiﬁcation, leader peptide signals and transmembrane regions and
matched against CryptoDB annotations (http://cryptodb.org/cryptodb/) to
provide an updated list of mitochondrial ORF and peptides. Organellar
proteomics was performed on: i) mitochondrial fractions, from
oocysts/sporozoites, by using 1D-PAGE LC/MS-MS; ii) mitochondrial
and mitochondrial/reticulum endoplasmaticum fractions, from puriﬁed
sporozoites (DEAE cellulose/pH gradient), by using iTRAQ quantitative
labelling and RP-HPLC/MS-MS. Phylogenomics was performed by
using ClustalW, Phylip 3.6 and MEGA 3 softwares.
Results: Genomic and subproteome analyses have identiﬁed mitochon-
drial related peptides from which metabolic pathways associated to
a modiﬁed oxidative phosphorylation system (OXPHOS) have been
inferred. In particular, the mitochondrial NADH dehydrogenase and the
alternative oxidase associated to the OXPHOS, the pyridine nucleotide
transhydrogenase related to the inner membrane electron transport, the
superoxide dismutase involved in the reactive oxygen species (ROS)
scavenging system, and proteins implicated in the importing processes
have been characterised. Phylogenomics analyses of the loci have
provided inference for evolutionary strategies developed by C. parvum
to adapt its mitochondrial metabolism to low oxygen conditions typical
of the host gastrointestinal tract.
Conclusion: Our data aim to provide new insights into the metabolism
of C. parvum, describing peculiar biochemical pathway of the proteome
network, suggesting new ideas for the adaptation evolutionary strategies
of the parasite and new potential drug targets. However, to gain further
advances into the metabolism of C. parvum we need to persist with the
development of more precise sub-proteome studies.
P991 Alpha-tocopherol transfer protein gene disruption confers
resistance to protozoan infections
M. Herbas °, X. Xuan, H. Arai, H. Suzuki (Obihiro, JP)
Objective: The nutritional status of the host inﬂuences susceptibility or
resistance against protozoan infection. Micronutrient deﬁciency, such as
vitamin E might play a protective role against infection. Mice deﬁcient in
alpha-tocopherol transfer protein (alpha-TTP), with undetectable levels
of vitamin E in circulation, were used as a model to analyze the effect
of vitamin E deﬁciency on the outcome of protozoan infections, in order
to propose a new strategy for the prevention and control of protozoan
infections by modiﬁcation of the nutritional status of the host.
Methods: alpha-TTP knockout mice were infected with Plasmodium
berghei or Trypanosoma congolense at lethal doses, and their survival
rates and parasitaemia were recorded. DNA damage of parasites was
evaluated by means of comet assay and anti-8-OHdG test and antioxidant
defence system in parasites was examined by monitoring the mRNA
expression of antioxidative stress enzymes by real time quantitative PCR.
Results: alpha-TTP knockout mice infected with P. berghei or
T. congolense survived signiﬁcantly longer than the wild type mice
(p< 0.05). The percentage of parasitaemia in alpha-TTP knockout mice
infected with P. berghei, remained at very low levels during the acute
phase of infection. Whereas, parasite density in the knockout mice
infected with T. congolense remained at very low levels compared
to wild type mice (p< 0.01). Comet assay revealed clear comet
tails in the parasites infecting alpha-TTP knockout mice, such tails
were not observed in parasites infecting the wild type mice. In
addition, anti-8-OHdG test revealed a positive reaction in the parasites
infecting the alpha-TTP knockout mice. Furthermore, mRNA expression
of antioxidative stress enzymes from parasites infecting alpha-TTP
knockout mice were signiﬁcantly up-regulated after infection (p< 0.05).
Expression levels were signiﬁcantly higher in parasites infecting
knockout mice as compared to parasites infecting wild type mice
(p< 0.05).
Conclusion: Inhibition of alpha-TTP confers resistance to the de-
velopment of protozoan infections, and this resistance is induced by
oxidative damage of the parasites due to vitamin E deﬁciency in
the circulation of the host. Inhibition of alpha-TTP activity might be
an interesting alternative for the control, prevention and treatment of
protozoan infections.
P992 Iron supplementation for children in malaria-endemic areas:
systematic review and meta-analysis
J.U. Ojukwu, J. Okebe, D. Yahav, M. Paul ° on behalf of the Cochrane
Infectious Diseases Group
Objectives: Iron supplementation has been claimed to increase the risk
for malaria among children living in malaria-endemic areas. We assessed
the effect of iron on malaria and malaria-related adverse events, including
deaths.
Methods: Cochrane systematic review and meta-analysis of individually
and cluster randomised-controlled trials conducted in hypoendemic
to holoendemic malaria regions. Trials comparing orally administered
iron+/-folic-acid vs. placebo or no treatment for children <18 years
old were included. Iron fortiﬁcation was excluded. Antimalarials
and/or antiparasitics could be administered to either group. Additional
micronutrients could be administered only equally to both groups. The
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primary outcomes were malaria-related events and deaths. Secondary
outcomes included haemoglobin, anaemia, other infections, growth,
hospitalisations and clinic visits. Pooled relative risks or absolute mean
differences are presented with 95% conﬁdence intervals. Adjusted
analyses were obtained or computed for cluster-randomised trials.
Results: Sixty-four trials compared iron vs. placebo for prevention or
treatment of anaemia. Iron supplementation did not increase the risk
for clinical malaria 1.03 [0.96−1.12], 13 trials, 21,105 children. The
risk was similar among non-anaemic children. The risk for malaria
parasitaemia was higher with iron, 1.13 [1.01−1.26], but there was no
difference in adequately concealed trials. Iron supplementation increased
haemoglobin by about 1 gr/dL in malaria hyperendemic settings, with
signiﬁcant heterogeneity. Lower haemoglobin at baseline was associated
with signiﬁcantly higher effects and co-supplementation with zinc or
antiparasitics with smaller effects. Malaria endemicity did not affect
results. Other secondary outcomes were not affected, but for increased
risk for diarrhoea with zinc co-supplementation and fewer clinic visits
with iron. Iron with antimalarial vs. placebo (4 trials) decreased malaria,
hospital admissions and anaemia. Iron vs. placebo given for treatment
of malaria (3 trials) did not increase risk for parasitological failure (0.98
[0.69, 1.39]). There was no increased risk for death across all trials
comparing iron vs. placebo, 1.06 [0.69−1.62], 12 trials, 20,712 children.
Conclusions: Considering the overall evidence, iron does not increase
the risk for clinical malaria or death. Recommendations regarding iron
supplementation for children living in malaria-endemic areas should
consider these results.
P993 Uncovering the secrets of East African relapsing fever
S. Cutler ° (London, UK)
Objectives: To gain further insights into the relationship between the
louse-borne Borrelia recurrentis and its tick-borne counterpart, Borrelia
duttonii.
Relapsing fever, caused by spirochaetes belonging to the genus Borrelia,
were once a worldwide epidemic disease. Despite a global reduction,
disease remains a signiﬁcant burden in several African nations. Indeed,
tick-borne relapsing fever (TBRF) is usually listed within the top 10
causes of mortality in children under ﬁve in Tanzania. In Ethiopia, louse-
borne relapsing fever (LBRF) is also within the top 10 causes of hospital
admission, associated with signiﬁcant morbidity and mortality.
Methods: The recent publication of full genome sequences for
B. recurrentis and B. duttonii relapsing fever spriochaetes has provided
opportunity to gain insights into the relationship of these organisms,
with B. recurrentis appearing as a louse-borne derivative of the tick-
borne B. duttonii. Furthermore, several intriguing features were noted
for B. recurrentis such as the apparent truncation of recA and smf genes
together with a frame shift in mutS, possibly hastening the evolution of
this spirochaete. We explored whether these observations were a feature
of more than the single isolate for which the genome has been sequenced
and whether this could have been introduced through selective pressures
of in vitro cultivation. Both questions were assessed using analysis
of spirochaetal DNA directly in patient serum samples, thus avoiding
selective pressures through in vitro cultivation. Furthermore, we have
explored the phylogenetic relationship among these spirochaetes from
both Tanzania and Ethiopia through sequencing an intragenic spacer
region (IGS).
Results: The clustering of IGS types previously observed for these
species using cultivated spirochaetes and those detected among arthropod
vectors was conﬁrmed using 123 sera from patients form Ethiopia and
Tanzania. Similarly, the geographical demarcation of these spirochaetes
was called into question, with the ﬁnding of IGS types resembling
B. crocidurae normally found in Western Africa. Interestingly, the novel
spirochaete described in tick samples was not detected in any human
samples calling into question its human pathogenic potential.
Conclusions: We were able to conﬁrm the apparent damage to DNA
repair genes directly in situ within LBRF patient clinical material. The
apparent phylogenetic overlap between LBRF and TBRF spirochaetes
was also conﬁrmed.
P994 Entamoeba histolytica or dispar through PCR and Elisa II?
Y.A. O¨ner °, E. Okaygu¨n (Istanbul, TR)
Objectives: Amebic infections are serious parasite diseases that cause
invasion and damage in organs such as liver, lungs and brain
besides intestinal colonisation. For many years diagnosis of amebiasis
was conﬁrmed by microscopic identiﬁcation of E. histolytica cysts
and trophozoites in stool. But then, it was realised that there are
nonpathogenic Entamoeba species (E. dispar) in a similar morphological
structure with E. histolytica, so ELISA and PCR are used for diagnosis
more often nowadays. In our study, we used a multiplex PCR method
to distinguish E. histolytica and E. dispar and compare the results with
the ones of ELISA and microscopy.
Methods: Eighty-three stool samples sent to the Microbiology and
Clinical Microbiology Department which were determined to have
Entamoeba cysts were taken into our study group. Adhesin was examined
in our study group through Teclab E. Histolytica II ELISA kit. Parasite
DNA was investigated through multiplex PCR method, using primers
speciﬁc to E. histolytica (EhP1 and EhP2) and E. Dispar (EdP1 and
EdP2).
Results: 40 out of 83 microscopy-positive stool samples were positive
after applying the Techlab E. histolytica II ELISA kit and E. histolytica
DNA was positive in 48 samples through PCR-method.
Conclusion: It was impossible to distinguish the pathogen (E. histolyt-
ica) and non-pathogen (E. dispar) Entamoeba species through direct
stool microscopy. PCR-method has not been in common practice due
to its high cost and the requirement of experienced staff. ELISA II kit
determining E. histolytica adhesin should be preferred due to its high
sensitivity-speciﬁcity and low cost and ease of use.
P995 Real-time characterisation of cytoadhesion of Plasmodium
falciparum by using a novel biosensor technology (thickness
shear mode)
D. Ko¨mpf °, S. Kleiner, R. Fendel, J. Held, S. Tschan, E. Bo¨ttger,
B. Mordmu¨ller, A. Renz, H. Northoff, F.K. Gehring (Tubingen, DE)
Objective: A medically relevant phenomenon of malaria tropica
(P. falciparum) is that late so-called signet-ring-stages cannot be detected
in the peripheral blood. These stages adhere to endothelial cells of
postcapillary venules by receptor-ligand binding and thereby escape from
clearance in the spleen. In this work it is planned to investigate to which
point of time infected erythrocytes, expressing Plasmodium falciparum
erythrocyte membrane protein 1 (PfEMP1) on their surface, bind to
ligands of endothelial cells. Measurement will be done ﬁrst-time by
Thickness Shear Mode (= TSM).
Methods: The innovative TSM-method is based on the principle that
binding of particles or cells onto the surface of the quartz alters its
resonant frequency. In relation to malaria research we are able to realise
experiments with human whole blood over a period of 48 hours in the
platform. This is an essential precondition for experiments with infected
erythrocytes. Aim of this project is the optimisation and development of
a novel sensitive measurement of the binding behaviour of signet-ring-
stages to endothelial cells. Previous methods depend on a pure optic
registration of bound erythrocytes in cell culture with the disadvantage
that these methods are not accurate enough for a clear deﬁnition of
binding times. Furthermore they are very time-expensive. By analysing
and interpreting the signals obtained by TSM, information on mass and
physical behaviour of the attached objects can be gained. This means that
quick, reproducible and automated tests can be run which is a signiﬁcant
advantage over conventional methods.
Results: At present, immobilisation of the ligands CD36 and CSA is
ﬁnished. Coating of the quartz’s surface with these ligands was proven
by both immunoﬂuorescence and TSM measurements. Furthermore we
could detect adherence of late trophozoites and schizonts to both ligands
by use of TSM. Adequate controls with uninfected red blood cells have
been carried out parallel where no binding effect could be demonstrated.
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Conclusions: The innovative TSM-method can give new insights into
the adherence procedure of P. falciparum, so this could provide possible
points of attack for the use of drugs against this dangerous infectious
disease.
P996 Cytoadherence and genotype of Plasmodium falciparum
strains from symptomatic children in Franceville,
south-eastern Gabon
F. Toure Ndouo ° (Franceville, GA)
Background: Plasmodium falciparum causes severe clinical manifes-
tations by sequestering parasitised red blood cells (PRBC) in the
microvasculature of major organs such as the brain. This sequestration
results from PRBC adherence to vascular endothelial cells via
erythrocyte membrane protein 1, a variant parasite surface antigen.
Objective: To determine whether P. falciparum multiple genotype
infection (MGI) is associated with stronger PRBC cytoadherence and
greater clinical severity.
Methods: Nested PCR was used to genotype P. falciparum isolates
from symptomatic children and to distinguish between single genotype
infection (SGI) and MGI. PRBC cytoadhesion was studied with cultured
human lung endothelial cells (HLEC).
Results: Analysis of two highly polymorphic regions of the merozoite
surface antigen (MSP)1 and (MSP)2 genes and a dimorphic region of
the erythrocyte binding antigen (EBA-175) gene showed that respectively
21.4% and 78.6% of the 42 children had SGI and MGI. It also showed
that 37 (89%) of the 42 PRBC samples expressed MSP1 allelic family
K1. Cytoadherence values ranged from 58 to 1811 PRBC/mm2 of HLEC
monolayer in SGI and from 5 to 5744 PRBC/mm2 in MGI. MGI was not
associated with higher cytoadherence values or with more severe malaria.
Conclusions: These results suggested that infection of the same
individual by multiple clones of P. falciparum does not signiﬁcantly
inﬂuence PRBC cytoadherence or disease severity and conﬁrmed the
predominance of the MSP1 K1.
P997 Analysis of pathogenicity of Plasmodium falciparum ﬁeld
isolates using a coculture model of human endothelial
cells/P. falciparum
F. Toure Ndouo ° (Franceville, GA)
Plasmodium falciparum infection can lead to a life threatening disease.
However, the pathogenetic mechanisms of severe manifestations are not
fully understood. Here we investigated whether P. falciparum-parasitised
red blood cells (PRBC) with clinical malaria can induce endothelial
cell (EC) apoptosis in vitro. In all 45 subjects tested, PRBC that cyto-
adhered to HLEC could be found albeit to a variable degree. In contrast,
PRBC that induce HLEC apoptosis was found only in 9 subjects.
Interestingly, apoptosis was signiﬁcantly associated to the presence of
neurological signs (P = 0.02) but there was no signiﬁcant association
between apoptosis and the severe malaria clinical status as a whole
(uncomplicated versus severe malaria; P = 0.11). The intensity of apop-
tosis was variable and was linked to parasite load (Spearman rho=0.41,
P = 0.005). The degree of cytoadherence was higher among individuals
with apoptosis (median, 25%-75% interquartile interval: 937, 610–1811
PRBC/mm2HLEC) than individuals without apoptosis (median, 25%-
75% interquartile interval: 437, 130–830.5 PRBC/mm2HLEC). This
difference was signiﬁcant (Mann-Whithney U test, P = 0.017), however,
the correlation between the degree of cytoadherence and the capacity to
induce apoptosis was not signiﬁcant (rho= 0.14, P = 0.37) suggesting a
qualitative rather than a quantitative relationship.
PRBC single (SGI) and multiple genotype infections (MGI) were
determined using nested polymerase chain reaction targeting two highly
polymorphic regions of the merozoite surface antigen 1 and 2 and a
dimorphic region of the erythrocyte binding antigen 175 loci. The results
demonstrated that infection of the same individual by multiple clones
of P. falciparum does not signiﬁcantly inﬂuence PRBC cytoadherence
or apoptosis induction in HLEC. However, MGI is inversely correlated
with in vivo synchronisation.
Analysis of the whole transcriptome from apoptogenic versus non
apoptogenic P. falciparum revealed 59 genes putatively associated
with the induction of EC apoptosis. Finally, silencing of parasite
gene expression with speciﬁc double-stranded RNA was performed on
8 selected genes; 5 of these, termed “Plasmodium apoptosis-linked
pathogenicity factors” (PALPFs), were found to be linked to parasite
apoptogenicity. Strategies of using these new pathogenicity factors as
anti malaria drugs or vaccine targets will be discussed.
P998 Coagulation abnormalities in imported malaria-clinical and
laboratory ﬁndings
J. Nikolic, G. Stevanovic, M. Pelemis, M. Pavlovic ° (Belgrade, RS)
Objectives: Evaluation of coagulation proﬁle, through assessment of
clinical and laboratory indicators, in patients with imported malaria. The
association with disease severity and prognosis was determined through
comparison with parasitaemia, disease severity and manifest bleeding.
Methods: A retrospective case-control study included 81 travelers from
endemic regions, diagnosed and treated for malaria in Institute for
Infectious and tropical diseases, Belgrade, Serbia, from January 1998.
to January 2008.
Results: Age, sex, use of prophylaxis, previous immunity and species
of Plasmodium, did not have a signiﬁcant effect on coagulation proﬁle
(p> 0.05). Only two patients (2.5%) had bleeding manifestations-
paetechial haemorrhage and splenic infarction, but there was no evidence
of disseminated intravascular coagulation (DIC). Laboratory ﬁndings
included signiﬁcant thrombocytopenia, prolonged prothrombin time and
activated thromboplastin time with D-dimer elevation (p< 0.05). There
were no signiﬁcant changes in antithrombin III levels or ﬁbrinogen
(p> 0.05). Severe malaria was associated with thrombocytopenia, which
was reversible after 5 days of antimalarial therapy. There was a
positive correlation between parasitaemia and levels of D-dimer and
antithrombin III, while thrombocyte count was in negative correlation
with parasitaemia (p< 0.05).
Conclusion: Although hypercoagulability is often observed in malaria,
bleeding manifestations and need for supportive therapy are uncommon.
P999 Awareness, possession and use of insecticide-treated net for
prevention of malaria in children under ﬁve in Abeokuta,
Nigeria
O.A. Idowu °, S.O. Sam-Wobo, A.S. Oluwole, A.S. Adediran (Abeokuta,
NG)
A survey was carried out to assess awareness, possession and use of
Insecticide Treated Net (ITN) by mothers in preventing malaria among
children under-ﬁve. Malaria though was considered dangerous by almost
all respondents (98.5%); the level of awareness of ITN as a malaria
preventive tool was 75.1% while possession was 45%. Awareness and
possession of ITN were positively and signiﬁcantly inﬂuenced by high
educational qualiﬁcation of mothers and attendance of a public hospital
for antenatal care. Hospitals were identiﬁed as the major source of
awareness among respondents; Women that delivered their babies in
Traditional birth home displayed least awareness (38.6%) and recorded
low possession (10%). There was no signiﬁcant relationship between
ITN usage, birth order and age of child. Heat experienced while sleeping
under ITN and problem of how to hang the net were major limitations
identiﬁed in the use of ITN. The need to involve women receiving
antenatal care outside the hospital in malaria control intervention is
hereby recommended.
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P1000 Survey through questionnaires in Madagascar: preliminary
study on possible risk-cofactors during childhood in the
transmission route of human herpes virus-8 with promoter
blood sucking arthropods
R. Romano °, L. Mannocci, F. Tabacchi, G.M. Paganotti, M. Coluzzi
(Rome, IT)
Objectives: The Human herpesvirus-8 (HHV-8) infection occurs mainly
in Africa with an high level in paediatric age and this suggest the
existence of an alternative way of transmission beside the sexual
intercourse. The presence of HHV-8 in saliva of seropositive subjects
led to consider this ﬂuid as the source of infection. Our study is
based on the hypothesis of “promoter arthropod”, according to this
the promoter arthropods play a role in the transmission of virus when
mother’s saliva is used to relieve itching and scratching on the bite
site of children. Our aim, as in other surveys in sub-Saharan African
countries is to observe the presence of possible risk-cofactors related to
the virus infection route such as: (i) use of traditional methods based on
saliva and premasticated herbs used on children’s skin to relieve itching,
(ii) the local inﬂammatory reaction related to child’s hypersensitivity
response to the bite and (iii) systemic symptoms such as fever.
Methods: We carried out survey with questionnaires directed at 224
children (age 5−13) interviewed at schools in four villages located in a
south-eastern area of Madagascar.
Results: Questionnaires revealed the following frequencies: use of
traditional methods 3.6% (respectively saliva 2.2% and herbs 1.3%),
fever after bite 54.9%, skin irritation 63.8%, swelling 32.1% and skin
mark 64.7%, lasting of skin boring: <3 days 46.4%, 3−7 days 15.2% and
>7 days 6.2%. The association between traditional methods and fever
is slightly signiﬁcant (p< 0.038), the variable fever shows statistically
signiﬁcant direct relationship with the presence of skin mark (p< 0.004)
and with the lasting of skin boring time >7 days (p< 0.001).
Conclusion: Analysis of data shows that skin reaction and fever are
possible risk-cofactors in the transmission route of HHV-8. Further
surveys on the presence of HHV-8 DNA virus in mother’s saliva will
be important to conﬁrm our hypothesis that blood sucking promoter
arthropods are involved in the transmission of virus. This could be an
attempt to control HHV-8 transmission addressed to a cohort of HHV-
8 seropositive mothers to make them aware on the risks of the use of
saliva to relieve insect bites, and on the far safer habit to protect children
against arthropod bites with insecticide treated nets (ITNs), repellents or
anti-histaminic products to relieve the itching.
P1001 Entomological survey of plebotomine sand ﬂies in a focus
of visceral leishmaniasis in a regional centre of Portugal
(Coimbra municipality)
M. Pereira °, O. Afonso, M. Machado, M.C. Sousa (Coimbra, Lisbon, PT)
Leishmaniasis, zoonoses caused by protozoans of the genus Leishmania,
has been the object of considerable attention of both human and
veterinary medicine. Leishmania parasites are transmitted by female sand
ﬂies of the genus Phlebotomus in the Old Word and Lutzomyia in the
New Word. P. ariasi and P. perniciosus species are the biologic vectors
of leishmaniasis canine in the Mediterranean basin include Portugal.
An entomological survey of plebotomine sand ﬂies was conducted in a
focus area of canine leishmaniasis, in Coimbra municipality of Portugal.
Standardised sampling with Centers for Disese Control (CDC) light traps
was employed to determined monthly trends is species composition,
density and sex ratio. A total of 992 sandﬂies (569 males and 353
females) were collected from June 2008 to October 2008. Four species
representing two genera were identiﬁed: three Phlebotomus species
(P. perniciosus, P. ariasi and P. sergenti) and one Sergentomyia species.
Phlebotomus perniciosus was the predominant species, comprised 69%
of the sand ﬂy population, followed by P. ariasi (23.4%), S. minuta
(7.3%) and P. sergenti (0.3%). A population peak (August) was observed
for P. perniciosus, suggesting a uni-modal annual pattern. Considering
the high density of P. perniciosus and P. ariasi, the area of Coimbra
should be considered as a potential focus of L. infantum. Abundance was
greatest in non urban areas and in the yard (68% of the phlebotomines
captured), in the vicinity of households. This is the ﬁrst description of
plebotomine sand ﬂies species in the municipality of Coimbra, in region
centre of Portugal.
P1002 Brucella melitensis endocarditis accompanied with Candida
albicans in a patient with prosthetic valve
A.Y. Tezer Tekce, A. Erbay °, A.R. Erbay, H. Cabadak, S. Sen (Ankara,
TR)
Objectives: Although the incidence of Brucella and Candida endocardi-
tis is low, their courses are associated with high mortality rates. We report
a patient with prosthetic valve who had Brucella melitensis endocarditis
accompanied with Candida albicans, successfully treated with medical
and surgical intervention.
Case report: A 27-year-old male was admitted with a history of fatigue,
loss of appetite and fever. He had mechanical aortic and mitral valve
replacement ﬁfteen years ago. He had a history of consumption of
unpasteurised dairy products.
Physical examination revealed a temperature of 37.5ºC, hep-
atosplenomegaly and in cardiac examination a grade 3/6 aortic diastolic
murmur was detected. In laboratory examination; WBC: 9100/mm3,
haemoglobin: 7.4 g/dl, ESR: 84mm/h, CRP: 56.4mg/dl and serum
Brucella agglutination titre was 1/80.
Transthoracic echocardiography demonstrated minimal mitral and
tricuspid regurgitation in addition to moderate aortic regurgitation. Two
vegetations with 1×0.4 cm and 1×0.5 cm diameters were detected on
the ventricular side of aortic valve leaﬂet.
Vancomycin plus gentamicin therapy was initiated empirically. At day
5th, Brucella melitensis was isolated from the cultures of blood.
The antibiotic treatment was switched to rifampicin (600mg/d p.o.),
doxycycline (100mg p.o., bid) and trimethoprim-sulfamethoxazole
(TMP-SMZ; 160mg TMP and 800mg SMZ p.o., bid). At day 14th, the
patient required mechanical ventilation support due to respiratory failure.
At day 30th, the patient still had mechanical ventilation support and fever
plus leucocytosis developed. From the repeated blood cultures Candida
albicans was isolated. Caspofungin was added to the treatment. At day
43th, he underwent aortic valve replacement because of unresponsiveness
to medical treatment, aortic valve dysfunction and left ventricular failure.
Cultures of the excised aortic valve yielded C. albicans.
During postoperative course no surgical complication occurred and
the rifampicin, doxycycline, TMP-SMZ and caspofungin treatment
was administered until discharge. The patient recovered fully without
sequelae and discharged at day 94th. The triple antibiotic regimen for
brucellosis was continued for 3 months after the discharge.
Conclusion: In prosthetic valve endocarditis due to Brucella melitensis
and Candida albicans, surgical replacement of the vegetated valve, and
postoperative treatment with appropriate antibiotics, is the best options
for curing this disease.
P1003 Trypanosoma cruzi infection diagnosis in a Spanish health
department during 2008
M.J. Gimenez °, E. Calabuig, A. Gil, M.D. Gomez, J. Lopez Aldeguer,
M. Gobernado (Valencia, ES)
Objective: Chagas’ disease is a vector-borne disease endemic in
Latin America. In Europe, where the triatomine vector is not present,
transmission of Trypanosoma cruzi infection can be either mother-to-
child or through organ transplant or blood transfusion; early diagnosis
and treatment could avoid it. Since January 2008, T. cruzi infection
screening must be done to all Latin American pregnant women by order
in council at the Valencian region (Spain).
The aim of this study was to describe the main features of the newly
diagnosed patients with Chagas’ disease in our Health Department during
2008.
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Methods: A descriptive study was conducted through all 2008. 645
sera from 627 patients from the 7th Health Departament in Valencia
were sent to our tertiary referral hospital Microbiology laboratory (La
Fe University Hospital) for Chagas’ disease screening. The samples were
tested for anti-Trypanosoma cruzi antibodies (IgG) using 2 different
enzyme-linked immunosorbent assays (ELISA). Positive sera were then
conﬁrmed with an immunoﬂuorescent assay (IFA) and a particle gel
immuno assay.
Results: Out of 627 patients, 9 were Spanish citizens who had previously
been in Southamerica; their median age was 38 (range 25−67) years old
and 55.5% were women.
618 patients had Latin American origin; grouped by age, 85 (13.8%)
were less than 15 years old, 71 (83.5%) being newborns in Spain from
Latin American mother. 533 patients were older than 14 (range 15−64;
median age 28 years old) of whom 93.1% were women. Most patients
were pregnant women (80.7%). The most frequent countries of origin
were Bolivia (35.5%), Ecuador (32.1%) and Colombia (14.1%).
All non-neonatal patients with positive T. cruzi serology (n = 49; 8.8%)
were from Latin America (68.2% from Bolivia); 28 were pregnant
women (57.1%).
Out of all children born to Latin American women, 23.3% (n = 17) had
positive T. cruzi serology at birth which corresponded to 6.5% (n = 28)
of the total of pregnant women studied.
Conclusions: Prevalence of Chagas’ infection is high in pregnant women
from Bolivia. Screening should be carried out in pregnant women from
Latin America in our country for follow-up and early treatment of
infected children. The introduction of screening programmes is important
to determine the relevance of the disease in fertile women and to interrupt
vertical transmission, but adult men should not be forgotten.
P1004 Visceral leishmaniasis in Serbia − treatment problems
G. Stevanovic °, M. Pelemis, Z. Dakic, M. Pavlovic, L. Lavadinovic,
J. Poluga (Belgrade, RS)
Visceral leismaniasis is parasitic diseases caused by Leishmania
donovani (L. infantum, L. chagasi). Reservoirs of the parasites in Serbia
region are mostly dogs and rodents. Vector of transmission is sand ﬂies.
Illness was sporadically occurred in the southern regions of Serbia.
Methods: During 2001–2008 periods in our department we treated 25
patients safer from visceral leismaniasis. Diagnosis was established by
serological methods (Leishmania dipstick rapid test Diasys Europe),
and deﬁnitive diagnosis was done by microscopic examination of bone
marrow smears.
Results: In endemic regions of Serbia and Montenegro, 18 patients were
lived, others were been during summer period in these regions. No one
was traveled out of Europe. All the patients were adults, average age
of 40.24 (range from 22−78) years, 17 of them was mails and 8 were
females. Medium duration of the illness before treatment was longer
then 4 mounts. Most of them had fever, anaemia or pancytopenia and
enlargement of liver and spleen.
As a primary therapy we used antimony (Glukantime®) in the doses of
20mg/kg during 21−28 days in 23 of our patients. In one patient we
used Pentostam®.
In two patients we used liposomal amphotericin B (Ambisome®), as a
ﬁrst choice therapy. And they were cured.
Good outcome we have in 17 patients, initial treated with antimony.
But in 5 patients in spite of therapy clinical, ﬁndings were present.
Spelnohepatomegaly was persisted, with pancytopenia.
In patients with persistent ﬁndings of parasites we repeated therapy with
antimony compounds. One of patient had good outcome, but other 4
needed amphothericin B. All of them were treated during 15−28 days,
given intravenously for a total dose of 20mg/kg. After two courses of
amphothericin B therapy, only two patients had persisted clinical ﬁndings
longer then 6 months. These two patients were treated with liposomal
amphotericin B (Ambisome®) in daily dose of 2mg/kg during 5 days.
Resolution of the symptoms was achieved during ﬁrst month after the
therapy.
Conclusion: Unresponsiveness to antimony therapy is becoming
problem in Asia. In former Yugoslavia, we did not have such problems,
few years ago. Now it became increasing problem and amphothericin B
of different formulation will became a drug for primary therapy. Other
drugs such as miltefosine were not present on Serbian market. Favourite
outcome was achieved by use of liposomal amphothericin B.
P1006 Cystic echinococcosis: decreasing prevalence in Central
Greece
I. Varbobitis °, G. Pappas, D. Karageorgopoulos, I. Anagnostopoulos,
M. Falagas (Athens, Ioannina, Trikala, GR)
Objectives: Cystic echinococcosis (CE) remains an endemic parasitosis
worldwide, with Greece traditionally considered as one of the endemic
European countries. We sought to evaluate prevalence trends of CE in a
hyper-endemic for zoonoses area of Central Greece, as detected through
abdominal ultrasound.
Methods: Abdominal ultrasound records of patients tested at the
Radiology Department of the General Hospital of Trikala, Thessaly, in
Central Greece, for the period 2001–2008 were evaluated. The presence
of simple hepatic cysts and liver haemangiomas was studied in parallel.
Results: Of the 47045 total ultrasound tests performed in the period
2001–2008, a total of 189 tests revealed abdominal hydatid disease,
representing 153 individuals with cystic echinococcosis, indicating
prevalence below 4 per 1000. Prevalence of haemangiomas reached 5 per
1000, and that of simple hepatic cysts 13 per 1000. Dividing the study
period in two sub-periods (2001–2004 and 2005–2008), a statistically
signiﬁcant trend towards decreasing annual incidence was noted for
abdominal CE.
Conclusion: The prefecture of Thessaly in Central Greece is hyper-
endemic for numerous zoonoses, CE included, due to its population
characteristics (rural orientation, agricultural basis of the economy).
Despite a generally high prevalence, a statistically signiﬁcant decreasing
trend in annual incidence was noted during the second half of the study
period. In conclusion, the implementation of a national campaign for
control of cystic echinococcal disease in both animals and human (started
in Greece in 1984), has led to decreasing annual detection rates of CE
in Central Greece.
P1007 The prognostic and diagnostic value of Western Blot test
in cystic echinococcosis
P. Yuksel °, M. Aslan, B. Kocazeybek, G.M. Saglam, E. Polat, H. Cakan,
K. Zengin, S. Arikan, G. Adas, S. Saribas, H. Uysal, Y.A. Oner,
R. Caliskan, M. Torun (Istanbul, TR)
Aim: Cystic echinococcosis (CE) is a zoonosis and surgery is the
treatment of choise and in certain cases supply complete cure.
Surgery have problems like the inadequate cyst removal and relapses
from ruptured and ‘new’ cysts not previously detected. The pre and
post-surgical follow-up (PS) of hydatidosis performed by indirect
haemagglutination (IHA), ELISA and Western Blot IgG (WB) tests. The
antibodies can be detected for longer years and the usefullness of ELISA
and IHA methods are limited for PS. We aimed to show the antigenic
patterns of operated (OP) and non-operated patients with hydatid cysts
(NOP) and also evaluate the importance of the antigenic differences
for the PS of the patients. We also aimed to detect the speciﬁcity of
Echinococcus granulosus WB kit.
Method: A total of 80 patients, 25 NOP, 33 OP and 22 healty controls
(HC) with no known chronic disease were included. ELISA method was
used. Cystic hydatid IgG antibodies were detected positive in serum
samples of the all patients and no positivity for IgG antibodies were
detected in serum samples of the HC. The antibodies against to the
non speciﬁc p39, p24/26 kDa (genus speciﬁc but cross reactive with
other species), p16/18 and p7 antigens speciﬁc for E. granulosus were
investigated with WB (Euroimmun Labordiagnostica, Germany) kit.
Serum samples with antibodies against to the p39 were considered
negative and serum samples with antibodies against to the p7 were
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considered positive. Serum samples which have a weak bands for p16/18
ve p24/26 were considered negative, on the other hand the serum samples
with strong bands for the same antigens were considered as suspicious
and need to follow up.
Results: Antibodies against to the p7 antigen were detected in 24 (96%)
of NOP and 18 (54.5%) of OP. No antibody was detected against to the
p7, p16/18 and p24/26 antigens. It was detected a statistically higher
signiﬁcant difference between OP and NOP for p7 antigen (p< 0.01).
The calculation of sensitivity and speciﬁcity of diagnostic Western Blot
IgG kit were performed with serum samples of 25 NOP and 22 HC. The
sensitivity and speciﬁcty of the WB test kit were calculated as 96% and
100%, respectively.
Conclusion: As a result of we suggest that antibodies against p7 antigens
can be used for the diagnosis and PS of the patients with hydatid cysts
because of the presence of antibodies against p7 antigens in serum
samples of NOP and the decrease of antibodies against p7 antigens in
the serum samples of OP.
P1008 Evolutive pattern of trichinellosis in patients of a Roma
community
I. Marincu °, L. Negrutiu, I. Iacobiciu, A.M. Neghina, C. Oancea,
R. Neghina (Timisoara, RO)
Objectives: Trichinellosis remains a major public health issue in
Romania because of diagnostic difﬁculties and multiple complications.
The present study aims to conduct a retrospective investigation of the
evolutive and clinical pattern of trichinellosis in a group of patients
belonging to the rromi community.
Methods: The authors have retrospectively analyzed the hospital records
of 88 Rromi patients (48 males, 40 females) inhabitants of 3 endemic
areas for trichinellosis in Timis county, Romania, and hospitalised in
the Clinic of Infectious Diseases from Timisoara during the period
2002–2007. The positive diagnosis was based on epidemiological
elements (the onset of infection following consumption of pork
infested with Trichinella spiralis), clinical elements (fever, headache,
repeated chills, nausea, diarrhoea, facial or periorbital edema, myalgia)
and laboratory tests (erythrocyte sedimentation rate, ﬁbrinogen, IgM
Ab anti-Trichinella, leucocyte value, eosinophil value, serum protein
electrophoresis). The statistical processing of data was done using the
Epi Info 5 program.
Results: Of the study group 31 patients (35.27%) were inhabitants of
2 rural areas (26 patients from Iecea Mare, 5 from Padureni) and 57
patients (64.77%) lived in urban areas (Timisoara). The clinico-biological
pattern presented as follows: 86 patients (97.72%) had dispeptic digestive
syndrome, 70 patients (79.54%) had fever over 38ºC, 55 patients
(62.50%) presented periorbital edema, 22 patients (25.00%) had non-
speciﬁc eruptions, 18 patients (20.45%) had pulmonary involvement,
and 5 patients (5.68%) had myocarditis. According to the severity of the
disease 23 patients (26.13%) presented asymptomatic clinical forms, 25
patients (28.40%) had mild forms, 35 patients (39.77%) had moderately
severe forms and 5 patients (5.68%) had severe clinical forms. The
source of trichinellosis was the consumption of infested pork, without
prior veterinary inspection. Winter was the season with most cases
(70.45%). All patients had a favourable outcome following treatment
with albendazole (Zentel) or mebendazole (Vermox) for 7−10 days.
Conclusions: Trichinellosis is a widely spread zoonosis among the
members of gipsy communities that consume pork in poor hygenic
conditions. The study of evolutive and clinical pattern of trichinellosis in
a population at risk increases the awareness regarding the implementation
of efﬁcient prophylaxis and proper treatment.
P1009 A Romanian winter outbreak of trichinellosis due to
consumption of pork contaminated with Trichinella spiralis
R. Neghina °, A.-M. Neghina, C. Merkler, I. Marincu, R. Moldovan,
I. Iacobiciu (Timisoara, RO)
Objectives: Extensive characterisation of a trichinellosis epidemic in a
Romanian endemic region due to consumption of contaminated pork.
Methods: In January 2008, an outbreak of trichinellosis due to
consumption of infected pork involved 15 people in localities Carpinis
and Peciu Nou. The epidemiological investigation performed by the
Department of Public Health in Timis County and the medical records of
the patients hospitalised at Victor Babes Hospital of Infectious Disease
in Timisoara were the main sources for data collection. Identiﬁcation of
Trichinella sp larvae at species level was performed by Multiplex PCR at
Istituto Superiore di Sanita, Rome, Italy (CRLP code 223/08) following
the isolation of the larvae from an infected meat sample by artiﬁcial
digestion.
Results: All 15 cases consumed pork from the same backyard pig
which was slaughtered in a household without veterinary inspection of
the meat. The infective species was Trichinella spiralis. Five patients
presented clinical forms of the disease and were hospitalised. The
following considerations include only the hospitalised cases. All cases
were serologically conﬁrmed (IgG antibodies against Trichinella in a
positive titer). The mean age of the trichinellosis patients was 33.4 years
(range 22−53). The symptomatology occured 17 days following the
consumption of the infected meat and all patients presented headache,
eyelid and lower limb oedema, myalgia, fever, diarhhoea and nausea.
The eosinophil values ranged between 5.5% and 52%. The outcome
of the hospitalised patients was favourable under treatment with
Albendazole, Dexamethasone and Calcium lactate. The nonhospitalised
patients consulted an infectiologist and were ambulatory treated with
Albendazole for 7 days.
Conclusion: Even if the current European regulations aim at ensuring
that only meat that has been certiﬁed trichinella-free after systematic
control may be consumed, the people who slaughter backyard pigs
are not always aware about this issue. Trichinellosis outbreaks, as
an important public health concern, reinforce the need to urgently
implement veterinary and educational programs. Identiﬁcation of
Trichinella spiralis species is in accordance with the ﬁndings of other
Romanian studies and strengthens the supposition that it is the most
frequently spread of the species in our country.
P1010 Expression of K2S form of human tissue plasminogen
activator in trypanosomatid protozoan Leishmania tarentolae
R. Nazari °, N. Davoudi (Qom, Tehran, IR)
Objective: Tissue plasminogen activator protein (t-PA) is one of
the most important thrombolytic agents for treating of cardiovascular
obstructions such as stroke and efforts is currently focused to improve
the t-PA molecule and thereby its pharmacokinetic properties. K2S is
a derivative t-PA that has a longer half-life and greater resistance to
inhibitor than the natural t-PA molecule. The Leishmania tarentolae
expression system represent the combination of easy handling known
from bacterial expression systems with the potential of an eukaryotic
protein expression/folding/modiﬁcation system. The aim of this research
is cloning and expression of K2S form of the t-PA cDNA in eukaryotic
system L. tarentolae.
Methods: cDNA of t-PA was made by RT-PCR from human blood
cells. PCR with speciﬁc primers for producing truncated form of t-PA
(K2S) were used. For introducing the K2S form of t-PA in Leishmania
tarentolae cells, we constructed plasmid pFXmlsap1.4hyg-K2S. After
development of construct, electroporation was done on L. tarentolae
cells for transfecting developed construct. Western blot analysis and
zymography analysis for evaluation of expression and biological activity
of recombinant K2S was performed.
Results: The construct (pFXmlsap1.4hyg-K2S) were conﬁrmed by
restriction analysis and PCR. After electroporation and screening of cells,
diagnostic PCR analysis showed integration of K2S expression cassette
in 18 SSurRNA (18 s) gene. We replaced the native signal sequence
of t-PA gene with a signal sequence derived from the secreted acid
phosphatase of L. mexicana. This study revealed that using Leishmania
derived signal sequence yielded secretion of recombinant K2S form
from transformed L. tarentolae. Then production of recombinant
K2S was conﬁrmed by Western blot analysis on supernatant of
transformed L. tarentolae culture. Performance of zymography analysis
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on supernatant of transformed Leishmania culture showed clear zone
as a result of K2S function. The test conﬁrmed serine protease activity
and natural biological activity of recombinant K2S. Thus we showed
heterologus proteins as complex as K2S produced in an active form in
leishmania tarentolae.
Infections in animal models
P1011 Identiﬁcation of pertinent indicators of virulence in a
mouse model of Acinetobacter baumannii pneumonia
M. Eveillard °, M. Kempf, C. Soltner, M.L. Joly-Guillou (Angers, FR)
Objectives: Animal models have been developed to study Acinetobacter
baumannii (Ab) pathogenesis which is still poorly understood. Our
objective was to identify patient indicators of virulence in a mouse model
of Ab pneumonia.
Methods: Five bacterial strains isolated from patients with nosocomial
infections (AB-M, SAN, AYE, AB-NM, CIP 53.77) were used. These
strains were inoculated by intra-tracheal instillation of 5×106 CFU
in C3H/HeN mice rendered transiently neutropenic. Each strain was
inoculated in 40 mice separated in 2 groups: one group to assess
spontaneous outcome and another group to assess virulence according
to the weight and a clinical score (CS) built on the basis of mice
mobility, the development of conjunctivitis, and the aspect of hair.
Mice were followed during 7 days. Concurrently, bacterial counts in
lungs were performed. Inﬂammatory response was assessed by the
dosage of MIP-2 and TNF-a in lungs. To identify pertinent indicators
of virulence, correlations with mortality were studied for bacterial
counts, CS, maximal loss of weight (MLOW), and concentrations of
pro-inﬂammatory mediators. Correlations were studied by Spearman
correlation coefﬁcient (r) analysis and the Fisher F-test.
Results: Strain SAN was highly virulent (78.9% mortality), strain AB-
M intermediately virulent (48.4% mortality), and the 3 others were more
weakly virulent (24.0%, 18.8% and 13.0% for strains AYE, AB-NM and
CIP 53.77 respectively). Bacterial counts in lungs, clinical score, MLOW
and concentrations of pro-inﬂammatory mediators varied according to
strains. There was a signiﬁcant correlation between our CS and mortality
(r = 0.85; P< 0.05), whereas there was not any between the MLOW
and mortality (r = 0.33), and between the bacterial counts in lungs and
mortality (r = 0.56). Whereas variations of concentrations by strains were
much stronger with TNF-a than for MIP-2, there was a strong and
signiﬁcant correlation between MIP-2 dosages and mortality (r = 0.97;
P< 0.005) and there was not any signiﬁcant correlation between TNF-a
dosage and mortality (r = 0.67).
Conclusion: Pertinent indicators of pathogenesis like the CS or MIP-
2 concentrations could be useful in combination with mortality or in
replacement of mortality to differentiate low and highly virulent strains
in future studies. If these indicators had been used in replacement of
mortality in our experimental design, half of mice (n = 100) would have
not been used.
P1012 Caenorhabditis elegans-based analysis for the host-pathogen
interaction of Salmonella enterica subsp. enterica serovars
isolated from indigenous vegetables and poultry meat in
Malaysia
C.H. Khoo, Y.K. Cheah °, J.H. Sim, L.H. Lee, N.Z. Awang Salleh,
S. Mohd Sidik, S. Radu, S. Sukardi (Selangor, Petaling Jaya, MY)
Caenorhabditis elegans (C. elegans) have been widely used to study
infections with promising results. Moreover, as its genome is surprisingly
similar to that of humans (40% homologous), C. elegans becomes
suitable as a simple host model.
Objectives: The increase of Salmonella enterica (S. enterica) occurrence
in local indigenous vegetables and poultry meat can be potential health
hazards. This study aimed to investigate the pathogenicity and persistent
infection of various serovars S. enterica using C. elegans as a simple
host model.
Methods: A total of S. enterica isolates (including 2 reference strains
and 6 food sources) associated with 4 different serovars were tested. All
S. enterica isolates were detected of virulence determinant by multiplex
PCR. The virulence of S. enterica isolates in the C. elegans host model
was evaluated by measuring the survival rate of worms fed on pure
cultures of these isolates. Each assay was repeated 3 times for statistical
analysis.
Results: Each S. enterica isolates under this study was found to possess
up to 95% virulence genes. Result showed that different serovar have
different mortality rate. The pathogenic S. enterica kills C. elegans faster
than E. coli OPO50, which is the standard laboratory food strain. The
time required for 50% C. elegans to die (TD50), which ranged from 3 to
4 days after ingesting various serovars of S. enterica compared to 17 days
after ingesting the positive control strain E. coli OPO50. S. enterica
shows similar persistency after 4 days of the infection which correlated
to their TD50. Results from this study also revealed that the ability of
S. enterica in killing of C. elegans correlates with its accumulation in
intestine of the nematodes to achieve full pathogenicity.
Conclusion: The ﬁndings demonstrated that the virulence factors
essential to mammalian pathogenesis also required for full pathogenicity
in C. elegans.
P1013 A gut colonisation model to study bacteriophages/bacteria
relationships in vivo
D. Maura °, L. du Merle, C. Le Bougue´nec, L. Debarbieux (Paris, FR)
Objective: In order to study relationships between an established
bacterial community and its speciﬁc bacteriophages, we developped an
animal model using an enteroaggregative Escherichia coli strain known
to persist in the mice gut for several weeks.
Methods: 7 week-old BALB/c mice were treated by streptomycin during
24 hours to eliminate most of intestinal facultative aerobic bacteria. The
enteroaggregative E. coli nº55989 strain (isolated from stools of a patient
who presented persistent diarrhoea) was administered by oral gavage and
the level of colonisation was followed by examination of the digestive
tract over time. Bacteriophages were administered to the animals through
drinking water during 24 hours.
Results: We ﬁrst showed that gut colonisation with the strain 55989 was
established within a few hours in the large intestine, and also interestingly
in the small intestine which is quite rare for E. coli strains.
New phages speciﬁc of the E. coli 55898 strain were isolated from
Paris sewage water. A set of 3 phages were selected based on their host
spectrum against a panel of 7 different E. coli strains. Interestingly each
of the three phages belongs to a different family of the Caudovirales
order.
A phage treatment (cocktail of the three phages) was given for 24 hours
to 2 groups of animals: the ﬁrst one was previously colonised by the
E. coli strain and the second one was not. We ﬁrst observed in mice
faeces that phages remained for more than 18 days in the colonised
group instead of 3 days in the control group suggesting that phages are
able to multiply in vivo.
Then, we determined the bacterial content of the digestive tract at the
end of the 24 h-phage treatment. We observed that the amount of bacteria
remained stable in the large intestine but was signiﬁcantly reduced in the
small intestine.
Conclusions: This work allowed us to establish the conditions necessary
to monitor phages/bacteria interactions in vivo when bacteria are part of a
complex and stable community. These results suggest that the 3 phages
are able to multiply in vivo and can clear partially the E. coli strain
from the small intestine. These observations are of a particular interest
in terms of phage therapy.
P1014 Physical activity affects the risk of respiratory
pneumococcal infection
M. Pannacci °, V. Lucini, A. Caronno, F. Scaglione (Milan, IT)
Objectives: Many data shows that respiratory tract infection (RTI)
represent one of the most common diseases spread among athletes,
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whose frequency is about 7 times greater than a control subjects. A “J”-
shaped model has been proposed to describe the relationship between
physical activity and risk of RTI. Some observations in athletes lead to
the hypothesis that moderate exercise will protect from infections while
strenuous exercise will increase the susceptibility to RTI. However this
hypothesis is not yet fully studied in validated experimental models.
The purpose of this work was to evaluate the susceptibility to RTI in a
model of experimental infection in mice subjected to different degrees
of physical stress.
Methods: A validated experimental model of physical stress in that mice
Balb/c were subjected to swimming for 1 h/day for 4 weeks, was used in
this study. After the 1st (moderate) and 4th (chronic) week of exercise
the animals were infected intranasally by inhalation with 1×108 CFU
of S. pneumoniae ATCC49619 virulent for mice. The level of infection
was evaluated 48 hours after induction; lungs were taken for histological
analysis and bacterial count.
Results: All controls and all chronic stressed mice resulted infected.
However the pneumonia was markedly extended in the stressed group
compared to controls. The bacterial size was signiﬁcantly higher
(p< 0.001) in the chronic stressed animals vs controls (4×106 ±
2.5 CFU/lung vs 3×104 ± 2CFU/lung). In contrast, 30% of mice
subjected to moderate exercise resulted infected only. The bacterial size
was 2×104 ± 1.4 CFU/lung.
Conclusions: Data obtained experimentally conﬁrmed that a prolonged
strenuous exercise increases susceptibility as well as the severity of RTI;
in contrast the moderate exercise results protective. The molecular basis
of this phenomenon are still unknown. A key concept is that exercise
has a direct effects on the immune system, leading to a change in
innate response; recently it is becoming clear that moderate exercise
may activate the innate immunological response while in intense and
prolonged exercise the immunological response seems to be impaired to
preserve immunity tolerance. Further research is warranted to address
the molecular and cellular mechanisms of these observed effects.
P1015 Anti-inﬂammatory effect of adjuvant glycerol in
experimental pneumococcal meningitis
C. Blaser °, M. Klein, M. Wittwer, A. Buehlmann, K. Oberson,
U. Koedel, S.L. Leib a EMESG collaborative study
Objectives: A recent clinical study demonstrated beneﬁcial effects
of adjuvant glycerol in children suffering from bacterial meningitis.
The study demonstrates a signiﬁcant reduction of severe neurological
sequelae by glycerol. A collaborative study by the EMESG was initiated
to investigate the mechanisms underlying the beneﬁcial effect of glycerol
in experimental pneumococcal meningitis.
Methods: Infant rats and adult mice were infected intracisternally with
sterile saline containing Streptococcus pneumoniae. At 18 h and 24 h af-
ter infection, all animals received ceftriaxone (100mg/kg). Furthermore,
they were treated with glycerol or placebo (carboxymethylcellulosis)
starting from 18 h after infection. At 40 h after infection, animals
were evaluated clinically. In infant rats, the brain was dissected to
determine histomorphology and tissue density as an index of brain
edema. Furthermore, concentrations of matrixmetalloproteinase (MMP)-
2 and MMP-9 as well as activity of myeloperoxidase (MPO) were
assessed in the cerebrospinal ﬂuid (CSF) obtained at 24 h and 40 h
after infection. In adult mice, hearing thresholds were determined using
auditory brainstem potentials. Then, animals were sacriﬁced. Mouse
temporal bones were dissected and evaluated for histomorphology.
Results: In the infant rat model, glycerol reduced MPO-activity at 24 h
after infection and lowered the concentration of MMP-9 in the CSF
at 40 h after infection. Hearing thresholds and histomorphology of the
inner ear showed no signiﬁcant differences between glycerol and placebo
treated mice.
Conclusions: The reduced activity of MPO in the early phase indicates
that less inﬂammatory cells (i.e. neutrophils) invaded the CSF. MMP-2
and particularly MMP-9 were shown to contribute to the development of
brain injury in bacterial meningitis. Thus, the decrease of MMP-9 at 40 h
after infection suggests a potential neuroprotective effect, possibly as a
result of the reduction of pleocytosis. However, these effects of glycerol
were not strong enough to translate into signiﬁcant improvements in the
infant rat and adult mouse model of pneumococcal meningitis.
P1016 Efﬁcacy of garenoxacin in a skin infection model caused by
methicillin-resistant Staphylococcus aureus in diabetic mice
M. Takahata °, K. Hashimoto-Hasegawa, Y. Fukuda, Y. Ito, Y. Sugiura,
K. Kizawa, I. Nozawa, J. Mitsuyama (Toyama, JP)
Objectives: Garenoxacin (GRN), a des-ﬂuoro (6)-quinolone, exhibits
potent antibacterial activity against S. aureus, including MRSA, which
causes severe skin infection in diabetic patients. We established a skin
infection model with MRSA in diabetic mice and compared the efﬁcacy
of GRN to levoﬂoxacin (LVX) and moxiﬂoxacin (MXF).
Methods: Male C57BLKS/J Iar-+Leprdb/+Leprdb mice were used as
type II diabetic mice. After shaving the hair on an area of the thigh under
anaesthesia, mice were infected by placing a 5 ul droplet containing ca.
105 CFU of MRSA F-3410 (MIC: GRN 0.0313mg/L, LVX 0.25mg/L,
MXF 0.0625mg/L) on the thigh skin. Five mg/kg of each quinolone
was administered orally once at 2 h after infection. Twenty-four h
after infection, skin tissue was removed, and the viable cell count in
skin was measured. At the same time, after ﬁxation and staining with
haematoxylin-eosin, histopathological observation was performed. The
drug concentrations in thigh skin of mice infected with MRSA F-3410
were also measured by HPLC with a single oral dose of 20mg/kg,
and pharmacokinetic evaluations were performed by non-compartment
analysis.
Results: The viable cell count in the skin (Log10CFU/skin) of the
GRN-treated group (3.41±0.51) was signiﬁcantly less than LVX-
(6.18±0.39*), MXF- (4.44±0.31*) and non-treated (6.34±0.40*)
groups, (N = 10, Mean ± S.D., *: p< 0.001 vs. GRN). In the non-treated
group, 24 h after infection, inﬁltration of inﬂammatory cells surrounding
bacterial colonies reached the subcutaneous adipose tissue. After GRN
treatment, although cell debris derived from inﬂammatory cells persisted
on the skin surface, the inﬂammatory reaction was very slight. The
AUCinf of GRN in the thigh skin at 20mg/kg was 11.4 ug Eh/g (N= 3,
Mean) and the AUC/MIC ratio was 364, which was more than ten times
greater than with LVX. The greater AUC/MIC ratio of GRN reﬂected
its favourable therapeutic effect.
Conclusions: GRN is considered a valuable quinolone in the treatment
of skin infections caused by S. aureus, including MRSA in diabetes.
P1017 Beneﬁcial effects of erythropoietin in experimental
pneumococcal meningitis
D. Grandgirard °, A. Bu¨hlmann, K. Oberson, S.L. Leib (Berne, CH)
Objectives: Up to half of patients surviving pneumococcal meningitis
suffer from neurologic sequelae including hearing loss and learning
difﬁculties. In experimental pneumococcal meningitis, these functional
deﬁcits are associated with loss of neurons in the cochlea and the
dente gyrus of the hippocampus for hearing loss and learning deﬁcits,
respectively. Erythropoietin (EPO) is neuroprotective in other paradigms
of brain injury. Here, the effects of EPO on hearing loss and hippocampal
neurogenesis were evaluated in an infant rat model of pneumococcal
meningitis.
Material and Methods: Pneumococcal meningitis was induced in
11 day old Wistar rats by intracisternal injection of Streptococcus
pneumoniae. Control littermates were injected with sterile saline.
Eighteen hours after infection, antibiotic therapy (ceftriaxone, 100mg/kg
s.c. bid) was initiated. Animals were randomised for treatment with EPO
(500 U/30 g, i.p) or an identical volume (150 microL) of saline daily
for 5 consecutive days after infection. In order to quantitatively assess
neurogenesis by measuring cell proliferation, bromodeoxyuridine (BrdU,
50mg/kg, i.p) was administrated for 3 consecutive days, directly after
the infection or 3 weeks later. Hearing capacity was tested in both ears
by assessing auditory brainstem response 3 weeks after infection and
animals were sacriﬁced subsequently for histomorphometry of the brain
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and inner ear. BrdU cell density was determined in the dentate gyrus of
the hippocampus.
Results: Hearing loss due to pneumococcal meningitis assessed 3 weeks
after infection was signiﬁcantly attenuated upon EPO treatment. While
hearing threshold in infected, saline treated, animals was 81.1±17.1
decibels (dB, n = 26), this threshold was reduced to 69.8±20.6 dB in
infected, EPO-treated animals (p = 0.04, t-test). In the hippocampus, EPO
signiﬁcantly (p = 0.04, t-test) increased neurogenesis. The rate of cell
proliferation in the dentate gyrus 3 weeks after infection was 262±123
BrdU positive cells/mm2, (n = 5) in infected animals treated with EPO
vs 148±21 cells/mm2 (n = 7) in infected animals treated with saline.
Conclusion: In experimental pneumococcal meningitis EPO attenuates
hearing loss and increases cell proliferation in the neurogenic zone of
the hippocampus. This pleiotropic effect may be due to a neuroprotective
effect during the acute disease or increased cell regeneration in the inner
ear and the hippocampus during the recovery phase.
P1018 First experiences with N-chlorotaurine in a swine
bronchopulmonary infection model
A. Pinna °, R. Geiger, M. Schwienbacher, H.J. Steiner, B. Treml,
W. Gottardi, C. Sergi, A. Lo¨ckinger, M. Nagl (Innsbruck, AT)
Objectives: N-chlorotaurine (NCT), a new endogenous antiseptic, can
be applied topically to different body regions. Recently we demonstrated
the tolerability of inhalative NCT in the pig model.
In present studies NCT is investigated in a pig bronchopulmonary
infection model.
Methods: In a pilot study anaesthetized pigs were infected by instillation
of Streptococcus pyogenes through a catheter placed to the carina
via the ventilation tube. An hour later, test solutions of 1% NCT
(n = 6) and 0.9% saline solution as a control (n = 6), respectively, were
inhaled. Applications were performed every hour within four hours, i.e.
4 inhalations in total, with 5ml each. Lung function, blood oxygenation,
and circulation were monitored. One hour after the last dosing the
animals were euthanised, and bronchial alveolar lavage samples for
bacterial cultures and lung samples for histology were removed.
Results: Tolerability of 1% NCT was very good, there were no hints for
toxic side effects. Bronchial alveolar lavages revealed a higher bacterial
count in the control (saline) pigs compared to NCT treated animals.
Because of high standard deviations and the limited number of animals,
this result was not yet signiﬁcant. The same is true for oxygenation
parameters where the values seemed to be better in the test group, too.
Lung histology showed bacterial infection and inﬂammation as expected.
Conclusion: The good tolerability of inhalative NCT is conﬁrmed also in
the infection model. There are ﬁrst hints for efﬁcacy, which encourages
further investigations.
Acknowledgements: This study is supported by the Austrian Science
Fund, grant no. L313-B13.
P1019 Viral RNA replication is associated with changes in
selenium in target organs of Coxsackie virus B3 infection
Y. Molin °, P. Frisk, N.G. Ilba¨ck (Uppsala, SE)
Objectives: Selenium has been found to reduce replication of several
viruses, both in vitro and in vivo, but it is unknown whether viral
replication affects the host’s selenium balance in target organs of the
infection. Further, studies of sequential changes in viral replication in
target organs of infection are sparse.
Methods: In this study Balb/c mice were infected with Coxsackie virus
B3 (CVB3) and sequential changes in viral replication (as determined
by RT-PCR) were related to changes in selenium concentration (as
determined by ICP-MS) on days 3, 5 and 7 of the infection in serum,
heart, lung, liver, pancreas, kidney, spleen, intestine and brain.
Results: After an initial viral peak on day 3, viral load drastically
decreased in all organs, i.e. by >99% (serum), 97% (lung), 98% (liver),
60% (pancreas), 95% (kidney) and 93% (spleen), except in the heart,
intestine and brain, where viral load in fact tended to increase after day 3.
Selenium decreased in all organs except the heart. Moreover, selenium
was negatively correlated to viral load in serum, liver, pancreas and
intestine.
Conclusion: These ﬁndings give evidence that selenium is directly
involved in the replication of CVB3.
P1020 In vitro proﬁling of pramiconazole against a panel
of moulds and yeasts and in vivo activity against
Microsporum canis and Candida albicans
K. de Wit °, A. Matheeussen, E. Be´ne´re´, G. Van Minnebruggen, P. Cos,
L. Maes (Antwerp, Geel, BE)
Objectives: In vitro and in vivo evaluation of a novel triazole antifungal,
pramiconazole, (Stiefel Laboratories Inc., formerly Barrier Therapeutics
Inc.) in comparison to two leading dermatomycological reference
compounds itraconazole and terbinaﬁne.
Methods: The in vitro susceptibility (IC50-values) of several moulds
and yeasts was evaluated in a microplate assay within the dose range
64−0.03125 micromolar, adopting two-fold dilution series. In each
plate, positive, negative and reference controls were included. The dye
resazurin was used as viability indicator, allowing spectro-photometric
reading. Next, the clinical efﬁcacy of pramiconazole was evaluated
after topical and oral administration in the guinea pig model with
Microsporum canis and the rat vulvovaginal model with Candida
albicans. To our knowledge, pramiconazole had never been tested in the
latter model. In both models, drug formulations were PEG400 for oral
dosing and a mixture of PEG400 + PEG1500 for topical application. Skin
lesions were scored using a semi-quantitative scoring system based on
severity and lesion size. Intravaginal infection burdens were determined
by plate-counting vaginal swabs taken at different days post-infection.
Results: Pramiconazole exhibited good in vitro activity against the
dermatophytes M. canis (IC50 0.17±0.02 micromolar), Trichophyton
rubrum (IC50 0.25±0.18 micromolar) and T. mentagrophytes (IC50
0.08±0.10 micromolar) and against the yeasts C. albicans (IC50
0.03±0.01 micromolar) and C. parapsilosis (IC50 0.85±0.78 micromo-
lar). In addition, high potency was present against Cryptococcus neo-
formans (IC50 0.20±0.33 micromolar). In contrast to itraconazole and
terbinaﬁne, no activity was observed against Sporothrix schenckii and
Aspergillus fumigatus (IC50> 64 micromolar). In both animal models,
pramiconazole was comparable or slightly better than itraconazole and
clearly superior to terbinaﬁne. In the vulvovaginal C. albicans model,
superior activity of pramiconazole to ﬂuconazole was also found.
Conclusion: Pramiconazole is a promising new triazole antifungal show-
ing comparable in vitro potency to terbinaﬁne against dermatophytes.
Pramiconazole was associated with faster healing of skin lesions and
faster clearance of C. albicans vaginal infection than comparator drugs,
suggesting a more advantageous pharmacokinetic proﬁle.
P1021 Reduction in serum lipid parameters by incorporation of
Lactobacillus plantarum A7, native strain in mice diet
H. Fazeli °, J. Moshtaghian, M. Mirlohi, M. Shirzadi (Isfahan, IR)
Objectives: Yearly many deaths occurred because of coronary heart
disease and there is relationship between hyperlipidaemia and its
incidence. Drugs used for reduction of cholesterol and other serum
lipids have very adverse effects and imposed very expenses to patients.
Therefore new ways presented for reduction of serum lipids such as
lactic acid bacteria. Researches shows a variable range of cholesterol
lowering effects for speciﬁc strains of lactic acid bacteria and routine
use of them still is not complete and need more research to elucidating
the geographical events on usefulness of them. So the aim of this study
was to assess the effects of native L. plantarum strain on mice blood
lipid proﬁle, when it introduced in their daily diets and compromised it
with other probiotics.
Methods: Lactobacillus spp isolated from faecal samples of 11 infants
3−21 month. More identiﬁcation performed by PCR and probiotic
aspects deﬁned. Lactobacillus plantarum A7 due to its superior bile
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resistance among several Lactobacillus spp was selected for evaluation
of its effect on cholesterol reduction. 16 Male Balb/c mice weighing 25
to 30 g were fed with a high cholesterol regimen diet. After 14 days,
serum of all samples analyzed for lipid parameters. In the next fourteen
days mice randomly divided to two groups, one received 10 8CFU/ml
of lactobacillus plantarum by gavage and second don’t received any
bacteria. Then again serum lipid parameters measured.
Results: In treated group pre intervention means of Cholesterol,
triglyceride, HDL and LDL was 101.3, 105.1, 40.9 and 35.6 respectively.
According to statical analysis no signiﬁcance differences obtained
between Treated and Control groups (P= 0.87). After intervention
in treated group mean of Cholesterol, triglyceride, HDL and LDL
was 92, 97.7, 46 and 30.4 respectively. In control group mean of
Cholesterol, triglyceride, HDL and LDL was 106.3, 146.6, 39.1and 42.4
respectively. Comparison of lipid proﬁle in treated and control group
showed cholesterol, triglyceride and LDL had reduced in treated group
signiﬁcantly (p = 0.029, p< 0.001, p = 0.015 respectively) but for HDL
this difference not signiﬁcant (p = 0.19).
Conclusion: Our results showed oral administration of L. plantarum A7
lowered harmful serum lipids without any pathogenic side effects. The
results of this study and comparison of it with others showed in use
of probiotics and its biological products geographical aspects must be
considered.
P1022 24-nor-ursodeoxycholic acid as novel therapeutic strategy
for inﬂammation-induced liver ﬁbrosis in a murine model
of Schistosoma mansoni infection
M. Sombetzki °, M. Lo¨bermann, P. Fickert, A. Fuchsbichler, C. Langner,
J. Gumhold, D. Silbert, D. Riebold, M. Holtfreter, H. Nizze, M. Trauner,
E.C. Reisinger (Rostock, DE; Graz, AT)
Objectives: Vigorous granulomatous and ﬁbrosing reactions to parasite
eggs specify the pathological picture of Schistosoma mansoni infection
as one the leading causes of liver ﬁbrosis and portal hypertension.
Current antihelmintic therapy is ineffective once hepatic ﬁbrosis is
established. The aim of our study was to test 24-nor-ursodeoxycholic
acid (norUDCA) as a novel therapeutic strategy for liver ﬁbrosis since it
is known to have great anti-inﬂammatory and/or anti-ﬁbrotic effects in
a mouse model of biliary ﬁbrosis.
Methods: Adult NMRI mice were infected with 50 S. mansoni cercariae.
Hepatic ﬁbrosis was studied at two time points (8, 24 weeks post
infection, pi). To test effects of bile acids, mice received a 0.5% bile acid
diet (norUDCA and UDCA) for 4 weeks. Effects on liver histopathology
(sirius red, a-smooth muscle actin, a-SMA; keratin 19, K19), serum liver
biochemistry and inﬂammation (CD4, CD11b) as well as expression
of ﬁbrosis-related genes (TNF-a, IFN-g, iNOS, TGF-b, col1a2) were
compared to untreated controls.
Results: S. mansoni infected mice showed a time-dependent increase in
total hepatic hydroxyproline content (7-fold, 24 weeks after infection,
p< 0.05). No changes in serum liver parameters were detectable.
Expression levels of ﬁbrosis-related genes (col1a2, TGF-b1, iNOS)
were elevated during infection, peaking around 8 weeks. Dysbalance
of mRNA expression of matrixmetalloproteinase-2 (MMP-2) and tissue
inhibitor of matrixmetalloproteinase-1 (TIMP-1) was established after
8 weeks (12-fold and 38-fold increase, respectively, p< 0.05). Bile-
duct proliferation became prominent after 24 weeks. NorUDCA but
not UDCA reduced hydroxyproline content and a-SMA expression (1.5-
fold and 2-fold, respectively, p< 0.05). Liver histopathology revealed
a reduction in hepatic ﬁbrosis and granuloma size (33% compared to
untreated controls, p< 0.05). IHCs showed a decrease in inﬂammatory
cell count. In contrast, conventional UDCA did not improve liver
histology.
Conclusions: This study demonstrates (i) a time-dependent development
of non-cholestatic liver ﬁbrosis in S. mansoni infected mice, (ii) anti-
inﬂammatory properties of norUDCA and (iii) beneﬁcial effects of
norUDCA on granuloma size and hepatic ﬁbrosis, therefore qualifying
norUDCA as a promising drug for the treatment of non-biliary liver
ﬁbrosis.
P1023 Vancomycin versus linezolid in the therapy of experimental
methicillin-resistant Staphylococcus aureus meningitis
S. Calik, T. Turhan, T. Yurtseven, O. Sipahi °, C. Buke (Izmir, TR)
Objectives: The aim of this study was to compare the antibacterial
efﬁcacy of vancomycin and linezolid in a rabbit model of methicillin-
resistant Staphylococcus aureus (MRSA) meningitis.
Methods: New Zealand white rabbits weighing 2−2.5 kg were anaes-
thetized by ketamine (35mg/kg) and xylazine (5mg/kg) before each
intraventricular intervention including induction of meningitis and CSF
sampling. Meningitis was induced by intracisternal inoculation of MRSA
(ATCC 43300) strain. After 16 h incubation time and development of
meningitis, rabbits were seperated into three groups. Group 1 was given
vancomycin 20mg/kg every 12 h, Group 2 was given linezolid 20mg
kg every 12 h, and Group 3 was control. Cerebrospinal ﬂuid bacterial
counts were measured at 16 and 40 h. Bacterial concentrations in CSF
were measured at 16th, 40th h. of the study by plating undiluted and
serial 10-fold and 100-fold dilutions of CSF (10mL) on 5% sheep blood
agar and incubated at 37ºC for 24 h. Bacterial response was evaluated
in three categories; full response, sterilisation of CSF; partial response,
any decrease in bacterial count; and bacteriological failure, a stable or
increased bacterial count. Data were evaluated by SPSS 11.0 package
program using Mann-Whitney U test, Kruskal Wallis test and Fisher’s
c2 test. A p-value less than 0.05 was considered signiﬁcant. The study
was approved by the local ethical commitee on animal studies.
Results: At the beginning of the study, 45 rabbits were inoculated with
bacteria, of which 33 were alive at the end of 16 h. Bacterial counts were
similar in all groups at 16 h. At 40 h bacterial counts were similar in
vancomycin and linezolid groups (p> 0.05), and both counts were lower
than control group (see table, p< 0.05). During the study, mortality was
similar among three groups (2/11 in gr. 1, 6/11 in gr. 2 and 5/11 in
gr. 3, p: 0.192). At the end of the study, rates of full (2/11 in gr. 1,
2/11 in gr. 2), partial (5/11 in gr. 1, 1/11 in gr. 2) and full or partial
bacteriological response (7/11 in gr. 1, 3/11 in gr. 2) were similar in
two treatment groups (p> 0.05). The decrease in bacterial counts in
vancomycin and linezolid groups at 40 h was also similar (−2.860±4.495
versus −0.724±4.360 log10CFU/ml, P> 0.05).
Conclusions: These results suggest that linezolid is not inferior to
vancomycin in the treatment of MRSA meningitis in experimental rabbit
model. Additional data should conﬁrm in advance of clinical trials to
assess efﬁcacy in humans.
Group Bacterial count (log10 CFU/mL)
16 h 40 h
Vancomycin 4.33±1.42 3.09±2.05
Linezolid 3.43±0.91 2.22±2.08
Control 3.85±0.26 5.14±0.99
P1024 Dalbavancin and rifampin against methicillin-resistant
Staphylococcus aureus in an experimental foreign-body
infection
D. Baldoni °, A-K. John, S. Aeppli, E. Angevaare, Z. Rajacic,
W. Zimmerli, A. Trampuz (Basel, CH)
Objectives: Implant-associated infection is a devastating complication
caused by bioﬁlms adhering to surface of devices. We investigated
the in-vitro susceptibility, pharmacokinetics and treatment efﬁcacy of
dalbavancin (DAL), alone and in combination with rifampin (RIF) in a
foreign-body MRSA infection model.
Methods: MRSA (ATCC 43300) MIC and MBC was determined
by macrodilution method. Time-kill curves were determined in the
logarithmic and stationary growth-phase during 48 h. Tween 80 (ﬁnal
concentration 0.002%) was added to all solutions in glass tubes. A
S270 19th ECCMID, Posters
guinea pig infection model with subcutaneously implanted Teﬂon cages
was used. DAL concentrations were determined in sterile cages after
a single dose of 10, 20 and 40mg/kg i.p. Cage-associated infection
was established by percutaneous injection of MRSA (5×106 CFU/cage).
3 days after infection, i.p. treatment was started (3 animals/treatment
regimen): DAL 40mg/kg single dose, RIF 12.5mg/kg/12 h × 4 days
and their combination. Bacterial titer in cage ﬂuid was determined 5
and 9 days after treatment start. Then were animals sacriﬁced and cages
cultured in TSB for 48 h. Cure rate (%) is the proportion of cage cultures
without MRSA. Positive cage cultures were tested for development of
RIF resistance.
Results: DAL MIC was 0.06 ug/ml and MBC was >20 ug/ml. Time-kill
curve studies showed a reduction of bacterial load >99.9% after 48 h
with DAL concentrations 5mg/mL in logarithmic and 0.157mg/mL
in stationary growth. After single dose of 10, 20 and 40mg/kg DAL,
in cage ﬂuid Cmax was 4.6, 18.2 and 34.9 ug/ml at 10−12 h; AUC
was 150, 926, 3018mg/h/ml, respectively. Bacterial counts in cage ﬂuid
at start of treatment ranged from 7.0−7.3 log cfu/ml. Addition of RIF
signiﬁcantly improved the efﬁcacy of DAL on planktonic bacteria in
cage ﬂuid during (p = 0.06) and after treatment (p< 0.001) (Figure).
The cure rate with DAL alone was 8%, which was improved in
combination with RIF to 33% (p< 0.05), which did not differ from
the RIF monotherapy, but reduced the frequency of RIF resistant cage
cultures from 38% to 25%.
Conclusions: DAL alone reduced 0.5−1.1 log cfu/ml MRSA in cage
ﬂuid and had a cure rate of 8%. DAL combined with RIF reduced
>5 log cfu/ml MRSA in cage ﬂuid and achieved a 33% cure rate. The
combination DAL plus RIF deserves further studies to determine the
optimal dosing for implant-associated MRSA infections are needed.
P1025 Antibacterial activity of NXL103 (linopristine-ﬂopristine)
against intracellular Staphylococcus aureus and efﬁcacy
following per oral administration in murine models of
systemic infection
J. Pace °, P. Levasseur, A.M. Girard, L. Lavallade (Romainville, FR)
Objectives: NXL103 (linopristine-ﬂopristine) is an oral streptogramin
which was recently evaluated in a Phase II clinical trial. Activity has
been observed against a wide variety of Gram-positive pathogens as well
as Haemophilus inﬂuenzae and Moraxella catarrhalis. We here report
in vitro antibacterial activity against intracellular Staphylococcus aureus
(SA) and in vivo efﬁcacy in murine infection models.
Methods: SA strains were opsonised in medium 199 containing 10%
guinea-pig serum and incubated with J774 macrophages followed by
inactivation of extracellular bacteria, and incubation with antibiotic
(2−8×MIC; 1−4 h). Surviving intracellular bacteria were released by
sonication and enumerated by plate counting. Septicaemia was estab-
lished in ICO:OF1 mice by intraperitoneal injection of approximately
7×105 CFU in 7.5% mucin suspension following growth in BHI
broth. Efﬁcacy in the murine thigh model was evaluated following
injection of the right thigh muscle with 3×107 CFU of bacteria.
Antibiotics were administered either orally (p.o.) or subcutaneously
(s.c.) at 1 and 6 h post-infection, and the 50% effective dose (ED50)
was determined.
Results: NXL103 reduced susceptible SA counts from 1.25 to 1.96 log10
within 4 h at concentrations from 1× to 8× MIC. Counts of two
intracellular MLSB-constitutitively resistant SA strains were reduced by
1.41 to 1.58 log10 when infected macrophages were treated with 8×MIC.
This antibacterial effect of NXL103 was superior to that observed
with clarithromycin or vancomycin. In the murine models of systemic
bacterial infection, the NXL103 ED50 (p.o.) ranged from 20−60mg/kg
for the methicillin-susceptible and methicillin-resistant MLSB strains
tested. Oxacillin and clarithromyin activities (p.o.) were similar or
inferior to NXL103 depending on the strain susceptibility, and the
vancomycin ED50 (s.c.) was 2.2−2.4mg/kg for treatment of septicaemia,
and 17−70mg/kg in the thigh model.
Conclusion: NXL103 kills intracellular bacteria in infected macrophages
in vitro and is efﬁcacious against S. aureus, including drug-resistant
strains, following oral administration to infected mice.
P1026 Efﬁcacy of vancomycin, linezolid, and cotrimoxazole in the
treatment of an experimental pneumonia model caused by
methicillin-resistant Staphylococcus aureus
F. Docobo-Pe´rez °, R. Lo´pez-Rojas, J. Domı´nguez-Herrera, M.E. Pacho´n-
Iba´n˜ez, M.E. Jime´nez-Mejı´as, C. Pichardo, J. Pacho´n (Seville, ES)
Objective: Previous studies have shown the suboptimal activity of
vancomycin (VAN) in the treatment of severe infections caused
by methicillin-resistant Staphylococcus aureus (MRSA) strains with
MIC> 1mg/L. Also, the efﬁcacy of linezolid (LZD) in clinical MRSA
pneumonia appears to be higher than that obtained with VAN. Moreover,
there are controversial results about the efﬁcacy of cotrimoxazole (COT)
in the treatment of severe infections caused by MRSA. The aim of the
study is to compare the efﬁcacy of VAN, LZD, and COT, in a murine
pneumonia model, caused by MRSA.
Methods: MIC of VAN, LZD, and COT were determined for 2
clinical MRSA strains (MRSA30 and MRSA33). The bactericidal
activity (time-kill curves; 1, 2 and 4×MIC) were studied for both
strains. In vivo: pneumonia model in neutropenic C57BL/6 mice
(cyclophosphamide 150mg/kg) was used, with an intratracheal inoculum
of 8−9 Log10 cfu/mL.
Pharmacokinetic/pharmacodynamic (PK/PD) parameters (Cmax [mg/L];
AUC [mg.h/L]; t1/2 [h]; t>MIC [h]; AUC/MIC) were determined
in serum after a single dose of 30mg/kg and 110mg/Kg of VAN,
30mg/Kg of LZD, and 10/50mg/Kg of COT on uninfected mice. For
the experimental pneumonia, mice were randomly grouped in untreated
(CON), VAN (30mg/kg) and VAN (110mg/kg) every 6 hours, LZD
(30mg/Kg) every 6 hours, and COT (10/50mg/Kg) every 4 hours.
Analyzed variables (after 72 h treatment): bacterial lung concentration
(Log10 cfu/g), negative blood cultures (%), survival (%). Statistical
analysis: ANOVA, post hoc test, and Chi-square tests.
Results:MIC (mg/L) for MRSA30 and MRSA33 were: VAN=1, LZD=4,
and COT=0.13. Bactericidal activity (3× Log10 in bacterial reduction):
MRSA30, VAN (2×MIC, 4×MIC); MRSA33, COT (4×MIC), VAN
(4×MIC). PK (Cmax, AUC; t1/2): VAN (30mg/kg) 35.54, 35.08, 0.42;
VAN (110mg/kg) 97.79, 111.36, 0.57; LZD (30mg/kg) 25.31, 36.22,
0.93; COT (10/50mg/kg) 1.89, 1.87, 1.69. PD (t>MIC; AUC/MIC):
VAN (30mg/kg) 1.85, 35.08; VAN (110mg/kg) 3.9, 111.36; LZD
(30mg/kg) 2.72, 9.06; COT (10/50mg/kg) 1.45, 14.38.
Conclusions: Overall, linezolid was the most efﬁcacious antimicrobial
treatment in the experimental pneumonia caused by MRSA. In order to
reach an optimal activity, vancomycin needs a high dose to obtain an
AUC/MIC0−24 h ratio above 400, when its MIC is 1mg/L. The results
showed that cotrimoxazole is as efﬁcacious as vancomycin at high dose,
which suggests that it could be used as therapeutical alternative in the
pneumonia caused by MRSA.
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Group Doses
(mg/kg)
No. Log cfu/g lung
(mean±SD)
Negative
blood culture
(%)
Survival
(%)
MRSA30
CON – 14 8.93±0.78 3 (21.4) 12 (85.7)
VAN 30 14 6.67±3.01 9 (64.3)a 13 (92.9)
110 13 3.25±1.59a,b 13 (100)a,b 10 (76.9)
LZD 30 16 2.87±1.86a,b 15 (93.8)a 16 (100)
COT 10/50 15 3.18±2.04a,b 15 (100)a,b 15 (100)
MRSA33
CON – 15 8.62±0.72 6 (40) 10 (66.7)
VAN 30 15 5.76±2.43a 10 (66.7) 15 (100)a
110 16 3.97±1.52 16 (100)a,b 12 (75)
LZD 30 15 1.59±1.40a,b,c,d 14 (93.3)a 15 (100)a
COT 10/50 15 3.08±2.49a 13 (86.7)a 15 (100)a
a p< 0.05 respect CON; b p< 0.05 respect VAN (30mg/kg); c p< 0.05
respect VAN (110mg/kg); d p< 0.05 respect COT.
P1027 Attenuation of bacteraemia by treatment with serotype-
speciﬁc antibodies diminishes hippocampal neural apoptosis
during experimental pneumococcal meningitis
C. Østergaard °, S. Leib, I. Rowland, C. Brandt on behalf of the EMESG
Objectives: Bacteraemia and systemic complications contribute to the
development of brain damage and may be directly responsible for up to
half of all fatal cases of pneumococcal meningitis.
Methods: Using an adult rat pneumococcal meningitis model, the impact
of accompanying bacteraemia on the development of hippocampal
injury was studied in the following groups: Meningitis controls (n = 11),
meningitis with early onset bacteraemia from concomitant iv infusion of
pneumococci (n = 9), meningitis with attenuated bacteraemia resulting
from iv injection of serotype-speciﬁc pneumococcal antibodies (n = 10),
and uninfected controls (n = 6).
Results: Degree of hippocampal neural apoptosis is shown in the
Figure. Pneumococcal meningitis resulted in signiﬁcantly higher degree
of neural apoptosis 0.22 (0.18−0.35) as compared to uninfected controls
(0.02 (0.00−0.02), P = 0.0003). Among meningitis groups, attenuation
of bacteraemia by antibody treatment resulted in signiﬁcantly reduced
apoptosis (0.08 (0.02−0.20), P = 0.01).
Conclusion: Our results suggests that accompanying bacteraemia
has a signiﬁcant role in development of hippocampal injury during
pneumococcal meningitis.
P1028 Efﬁcacy of oritavancin in the rat haematogenous pneumonia
model
V. Ostiguy, I. Fadhil, M. Malouin, C. Cadieux, N. Goyette, S. Fournier,
T.R. Parr Jr., D. Lehoux ° (Saint-Laurent, CA)
Objectives: Oritavancin (ORI) is a semi-synthetic lipoglycopeptide with
bactericidal activity against Gram-positive cocci including methicillin-
resistant Staphylococcus aureus (MRSA) and vancomycin (VAN)-
resistant S. aureus. ORI was highly active in the mouse pneumonia model
of Streptococcus pneumoniae infection. Here, we have simulated blood-
borne staphylococcal pneumonia and have investigated the efﬁcacy of
ORI in the rat haematogenous (HP) model of infection caused by MRSA.
Methods: Infection was established in CD rats (n = 5/group) by injecting
1.2×107 colony-forming units (CFU)/mL of MRSA strain NRS123
(USA 400) (ORI MIC= 0.06mg/L) enmeshed in 0.08% agar beads
(as described by Sawaı¨ et al., 1997; Infect. Immun 65:466). The rat
HP model was established by injecting 0.5mL of agar beads bacteria
suspension intravenously (i.v.). To assess the efﬁcacy of ORI at 50mg/kg
i.v., the rats were treated from Day 1 to Day 6 PI once daily. The
ORI treatment was compared to VAN (100mg/kg, subcutaneous (s.c.)),
daptomycin (DAP) (50mg/kg, s.c.) and nafcillin (NAF) (150mg/kg, s.c.,
twice daily). The lungs and spleen of the infected rats were harvested on
day 1 and day 6 or 7 post-infection (PI) and homogenised to determine
the bacterial burden. The bacterial densities were expressed in mean Log
CFU/organ ± standard deviation and the statistical calculations were
performed according to the Kruskal-Wallis and Mann-Whitney U tests
by using StatsDirect software. P-values below 0.05 were considered
signiﬁcant.
Results: The rat HP infection was successfully established and stable
over 7 days. On day 6 PI, 5.41±0.91 Log CFU were recovered in
lungs, while 1.94±0.25 Log CFU/spleen were recovered showing that
the MRSA concentrates and remains in the lungs. ORI regimen showed
efﬁcacy in the rat HP model. All treatments (except NAF) decreased
signiﬁcantly the CFU counts in lungs compared to untreated. MRSA
densities on day 7 PI were 7.68±0.42, 4.10 ± 0.59, 5.26±0.65,
6.39±0.43 and 7.32±0.47 Log CFU/lung for untreated, ORI, DAP, VAN
and NAF, respectively; p = 0.008, except NAF. The ORI regimen also
signiﬁcantly decreased bacterial densities compared to other comparators
(p 0.036 for ORI vs DAP, VAN and NAF).
Conclusion: ORI was efﬁcacious in the rat HP model. Moreover, ORI
had greater efﬁcacy than all the comparators as tested. These results
suggest that ORI might be useful for the treatment of human blood-
borne pneumonia infections.
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P1029 Investigation of carbapenem heteroresistance among
susceptible Acinetobacter baumannii
E. Neou °, A. Ikonomidis, A. Katsiaﬂaka, A. Vasdeki, A. Maniatis,
A. Tsakris, S. Pournaras (Larissa, Athens, GR)
Objectives: Carbapenem heteroresistance in Acinetobacter baumannii
has been described previously and might threaten carbapenem activity.
The present study aimed to investigate the heteroresistant phenotype
among apparently susceptible A. baumannii, against which carbapenems
may be used and heterogeneity might affect treatment outcome.
Methods: Fourteen carbapenem-susceptible A. baumannii clinical
isolates were recovered during a six-month period. Carbapenem MICs
were tested by agar dilution. Pulsed-ﬁeld gel electrophoresis for
clonality and PCR for known carbapenemase-genes were performed.
Heteroresistant subpopulations were revealed by population analyses and
carbapenem MICs of the subpopulations were estimated after subcultures
in drug-free medium, to investigate the heteroresistance stability. Time-
killing studies utilising meropenem at 4mg/L were also performed.
Results: Imipenem and meropenem MICs of the native isolates
ranged from <0.25 to 6mg/L and <0.25 to 4mg/L, respectively.
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The isolates belonged to nine genotypes carrying solely the intrinsic
blaOXA-51 gene. Population analysis assays for imipenem had colonies
grown in concentrations from 8 to 24mg/L for half of the isolates,
whereas the rest remained within the susceptible range. Imipenem-
heteroresistant colonies returned to carbapenem susceptibility after
subcultures in drug-free medium. Population analyses for meropenem
revealed colonies grown from 8 to 32mg/L for all isolates except one
(AB13). These colonies retained elevated meropenem but not imipenem
MICs after subcultures in drug-free medium. In time-killing assays using
meropenem, four isolates (incl. AB13) were killed in a time-dependent
manner, while in ten isolates the initial bactericidal effect was followed
by substantial re-growth after 9 to 12 hours (three isolates) or 24 h (seven
isolates) of incubation. Six of the fourteen patients were treated with
meropenem and in ﬁve patients (three of whom died due to A. baumannii
bacteraemia), whose isolates had signiﬁcant re-growth in time-killing,
meropenem treatment was not efﬁcient. Notably, the patient successfully
treated by meropenem was infected from an isolate sufﬁciently killed in
vitro.
Conclusion: Our ﬁndings indicate that meropenem susceptible A. bau-
mannii have the potential to produce heteroresistant subpopulations
under meropenem pressure. Should these subpopulations be selected
under inappropriate meropenem treatment they may subsequently affect
patient outcome.
P1030 In vitro activities of various antimicrobials alone and in
combination with imipenem against carbapenem-resistant
Acinetobacter baumannii blood isolates
W.H. Sheng ° (Taipei, TW)
The prevalence of carbapenem-resistant Acinetobacter baumannii
(CRAB) related infections continue to increase, however, therapeutic
options for the treatment of infections with CRAB have limited. In
this study, in vitro synergism using checkerboard titration and time-
kill method among amikacin, ciproﬂoxacin, colistin (polymyxin E),
sulbactam and tigecycline alone and in combination with imipenem
were investigated among 15 epidemiologically different CRAB blood
isolates. THP-1 cells were added as antimicrobial-phagocyte synergistic
model. Colistin (MIC90: 1 mg/mL, susceptible 95.8%) and tigecycline
(MIC90: 2mg/mL, susceptible 91.7%) were the most two active agents
against CRAB, followed by minocycline (susceptible 87.5%), amikacin
(58.3) and sulbactam (susceptible 47.7%). In checkerboard titration,
synergism existed with imipenem while combined with all test agents,
including colistin (33.3%), tigecycline (33.3%), amikacin (26.7%),
sulbactam (26.7%) and ciproﬂoxacin (13.3%). In time kill method,
antimicrobial synergy and bactericidal effects were found in amikacin
(66.7% and 53.3%), ciproﬂoxacin (33.3% and 40%), colistin (80%
and 73.3%), tigecycline (66.7% and 40%), and sulbactam (53.3%
and 46.7%) while combined with impenem, respectively. The results
of antimicrobial synergistic effects were not affected by existing of
phagocytes (THP-1 cells). Of six CRAB isolates with high minimal
inhibitory concentration (MIC) of imipenem (>32mg/mL), none had
antimicrobial synergy by checkerboard titration. In summary, our results
demonstrate synergism between imipenem in combination with various
antimicrobial agents, such as colistin, tigecycline, amikacin, sulbactam
and ciproﬂoxacin, against A. baumannii isolates with low or intermediate
resistance to carbapenem. For those serious infections caused by
highly imipenem-resistant A. baumannii (MIC> 32mg/mL), newer
antimicrobial combination, such as amikacin, colistin and tigecycline
should be considered. Surveillance of carbapenem resistance and known
the susceptibilities of prevalent A. baumannii strains, might provide
the information to develop an appropriate empirical therapy for CRAB
infections.
P1031 Multidrug-resistant Acinetobacter: is colistin still effective?
O. Koseoglu Eser, A. Ergin ° (Ankara, TR)
Objectives: Acinetobacter is a primary nosocomial pathogen causing
ventilator-associated pneumonia, meningitis, endocarditis and sepsis,
especially in intensive care units (ICUs). The study was performed
to investigate the antibiotic susceptibility and metallo-b-lactamase
production of Acinetobacter isolates in patients hospitalised in Hacettepe
University Adult Hospital, Turkey in a one year period.
Methods: The microorganisms have been isolated from clinical speci-
mens of patients with respiratory and bloodstream infections. In vitro
activity of imipenem (IMP), meropenem (MER), ceftazidime (CAZ),
ciproﬂoxacin (CIP) and aztreonam (AZT) in clinical Acinetobacter
species isolated was evaluated by microdilution test. Each isolate was
also tested for metallo-b-lactamase (MBL) production by using IMP
and EDTA combined disk diffusion test. Antimicrobial susceptibility
testing was performed in MDR isolates for colistin by microdilution, and
for amikacin (AN), piperacillin-tazobactam (PIP-TAZ), cefepime (FEP),
ceftriaxone (CRO), tetracycline (TET), trimetoprim-sulfomethoxazole
(SXT), mezlocillin (MEZ) by disk diffusion method. All antimicrobial
susceptibility tests were done according to CLSI guidelines.
Results: Among nonduplicate 124 isolates, 72 were Acinetobacter
baumannii, 52 were A. lwofﬁi. Forty ﬁve (36.3%) of isolates were from
patients in ICUs. MIC50 and MIC90 (mg/ml) values of isolates were
found 32 and 128 (IMP), 16 and 32 (MER), 128 and 256 (CIP), 64 and
256 (CAZ), 128 and 256 (AZT), respectively. Only forty three (34.7%)
isolates were susceptible to IMP. Sixty four (51.6%) were positive for
IMP-EDTA combined disk test. Overall, 51 (%41) Acinetobacter spp.
were found to be resistant to  3 antibiotics belonging to different
antimicrobial classes and deﬁned as MDR. Colistin MIC50 and MIC90
values were 2 and 8 and resistance were found 27.5% in MDR isolates.
The resistance rates for AN, PIP-TAZ, FEP, CRO, TET, SXT and MEZ
were 80.4, 98.0, 92.2, 100.0, 100.0, 86.3, 86.3% respectively.
Conclusions: The rate of resistance against antimicrobial agents tested
was high in our isolates. Colistin was the only active drug in high
resistant isolates. Although there is a need for new drug development
against multidrug resistant Acinetobacter isolates, the study suggests
that colistin may still be an alternative therapeutic option in MDR
Acinetobacter isolates.
P1032 The role of the MDR efﬂux pumps of Gram-negative rods
in removing “non-antibiotic” drugs
A.E. Laudy °, E. Rurarz, S. Tyski (Warsaw, PL)
A potential role of non-antibiotics in the treatment of multidrug-resistant
Gram-negative infections has been investigated recently. In the case
of some medicines like antipsychotic or cardiovascular drugs, a direct
antibacterial activity was shown. Moreover, phenothiazines inhibit efﬂux
pumps in Gram-positive bacteria. On the other hand, salicylate is the
natural substrate for the efﬂux pumps in some Gram-negative rods eg.
Burkholderia cenocepacia and can induce efﬂux-mediated resistance.
In our study, the activity of 10 non-antibiotic drugs and their 6 active
substances was evaluated against non-fermentative Gram-negative rods
and Enterobacteriaceae (12 standard and 59 clinical isolates) in the
presence and absence of pump inhibitors (Phe-Arg-b-naphthylamide or
reserpine). Inﬂuence of analyzed drugs on activity of efﬂux pumps in
Gram-negative rods was studied by changing the strain susceptibility to
nalidixic acid in the presence of tested medicines and +/− pump inhibitor.
Results: The highest activity of alendronate and drugs possessing
this active substance (Osalen®, Rekostin®) was shown (MIC 100–
800mg/L) for majority of strains. Only B. cepacia and Acinetobacter
baumannii were resistant. Also drug Amitryptylinum® (containing
amitryptyline) was very active (MIC 200–800mg/L) against rods,
except B. cepacia and P. aeruginosa. Moreover, the decrease of
MIC values (4−64-fold) of some active substances (drugs) like
alendronate (Osalen®, Rekostin®), ticlopidine (Ticlo®, Apo-Clodin®)
and drugs as Amitryptylinum® and Niglostin® in the presence of
Phe-Arg-b-naphthylamide (but not reserpine) was obtained for E. coli,
Klebsiella pneumoniae, P. aeruginosa, Stenotrophomonas maltophilia
and A. baumannii. Generally, in the presence of drugs as Osalen®,
Apo-Clodin®, Amitryptylinum® and Niglostin® the change of strains
sensitivity to nalidixic acid was not observed. Only for 3 A. baumannii
strains and one E. coli the decrease of nalidixic acid MIC in the presence
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of Osalen® was noted. It appeared that Phe-Arg-b-naphthylamide
affected the susceptibility of majority of tested strains to nalidixic acid
and +/− non-antibiotics drugs.
Conclusions: Some drugs containing as an active substance: alendronate,
ticlopidine, amitriptyline and ribavirin substance showed a direct
antimicrobial activity. Moreover, these drugs are also substrates for the
efﬂux pumps in some Gram-negative rods. Unlike salicylate, these drugs
do not induce efﬂux-mediated resistance to nalidixic acid.
P1033 Comparative susceptibility of European Gram-negative
pathogens to ceftobiprole, ceftazidime and cefepime
H. Seifert, M. Dryden, A. Quintana, J. Laeuffer, P. Okolo, I. Morrissey °
(Cologne, DE; Winchester, UK; Raritan, US; Baar, CH; Fordham, UK)
Objectives: Ceftobiprole (BPR) is a novel cephalosporin with
bactericidal activity against both Gram-positive and Gram-negative
bacteria, including activity against methicillin resistant S. aureus
(MRSA). The Ceftobiprole Local Antibiotic Susceptibility Surveillance
Study (CLASS) compared the susceptibility of common pathogens
causing serious infections in hospitalised patients. Here we report the
comparative activity of BPR, ceftazidime (CAZ) and cefepime (CFP)
against Gram-negative pathogens (GNP).
Methods: 1,271 GNPs (including 366 E. coli, 299 P. aeruginosa,
237 Klebsiella spp., 223 Enterobacter spp. and 140 H. inﬂuenzae
were collected from 32 centres in Austria, Germany, Ireland, Poland,
Switzerland and UK during 2008 from hospitalised patients with cSSTI,
blood stream infections or nosocomial pneumonia including VAP. MICs
were determined at each centre using Etest methodology.
Results: Against all GNPs combined, all three agents had an MIC90
of 4mg/L but BPR had the lowest MIC50 of 0.06mg/L compared
with 0.125mg/L for CFP and 0.25mg/L for CAZ. Against E. coli,
H. inﬂuenzae and Klebsiella spp., BPR had a lower MIC90 than
CAZ and CFP (0.125, 0.5 and 0.25mg/L vs. E. coli; 0.125, 0.25 and
0.25mg/L vs. H. inﬂuenzae; 0.125, 1 and 0.25mg/L vs. Klebsiella
spp. respectively). Against Enterobacter spp., BPR had a lower MIC90
(4mg/L) than CAZ (128mg/L) but two-fold higher than CFP (2mg/L).
Against P. aeruginosa, BPR, CAZ and CFP MIC90 were 16mg/L,
8mg/L and 8mg/L respectively.
Conclusion: BPR showed activity comparable to CFP but generally more
active than CAZ against a range of GNPs.
P1034 Comparative susceptibility of European Gram-negative
rods to doripenem, imipenem and meropenem
R. Mutters, M. Morgan, P. Nordmann, A. Quintana, J.M. Laeuffer,
D. Cooper, I. Morrissey ° (Marburg, DE; Exeter, UK; Le
Kremlin-Biceˆtre, FR; Raritan, US; Baar, CH; Fordham, UK)
Objective: Doripenem (DPM) is a new carbapenem recently introduced
into Europe. The Comparative Activity of Carbapenem Testing Study
(COMPACT) compares the susceptibility of common Gram-negative
rods (GNR) causing serious infections in hospitalised patients to DPM,
imipenem (IMP) and meropenem (MPM).
Methods: 1,162 GNPs (542 Pseudomonas spp, 504 Enterobacteriaceae
and 111 other GNRs were collected from 21 centres in France,
Germany, Ireland and UK during 2008. DPM, IMP and MPM MICs
were determined using Etest methodology and susceptibility interpreted
according to CLSI break points for IMP and MPM, and FDA break
points for DPM.
Results: The MIC90 against all isolates was 2, 4 and 32mg/L for DPM,
MPM and IMP. Enterobacteriaceae (43% E. coli, 22% Klebsiella spp.,
13% E. cloacae) were highly susceptible to all 3 carbapenems with
MIC90 of 0.125mg/L for DPM & MPM but 0.5mg/L for IPM. DPM
had the lowest MIC90 against Psuedomonas spp. at 8mg/L with MPM at
16mg/L and IPM at  64mg/L. Resistance to DPM, IMP and MPM was
seen in 7.3%, 11.8% and 6.8% of all isolates respectively and resistance
to DPM (10.9%) and MPM (9.8%) in Pseudomonas spp. was similar
and approximately half that for IMP (19.2%).
Conclusion: DPM showed excellent activity against GNRs being
generally more active than IMP and at least as good as MPM. Against
Pseudomonas spp., DPM was more active than both IMP and MPM, and
DPM/MPM resistance in Pseudomonas spp. was similar and lower than
that for IMP.
P1035 Temocillin in vitro activity against ESBL- and AmpC
producing Gram-negative bacteria isolated in tertiary-care
hospital
L. Naumiuk °, A. Samet (Gdansk, PL)
Objectives: The aim of the study was to determine temocillin
in vitro activity against ESBL- and derepressed AmpC-producing
Enterobacteriaceae isolated in tertiary care hospital in Poland
Methods: Fifty Enterobacteriaceae isolates from 2008 from which 31
produced ESBL and 19 produced derepressed AmpC enzyme were
selected for temocillin activity determination. Modiﬁed double disk test
(DDT) was done with cefepime, cefotaxime and amoxicillin+clavulanic
acid disks for ESBL detection. Derepressed AmpC isolates were
selected based on negative result in DDT, resistance to cefotaxime and
ceftazidime and susceptibility to cefepime. Disk diffusion method with
30 ug temocillin (Neosensitabs, Rosco) was used and inhibition zones
were recorded.
Results: There were 22 Enterobacter cloacae (16 AmpC), 12 ESBL
E. coli, 7 ESBL Klebsiella spp., 4 Proteus mirabilis (3 ESBL),
4 Citrobacter freundii (2AmpC) and 1 ESBL Serratia marcescens.
In AmpC producers there were only 2 resistant isolates within 10
nonsusceptible ones (mainly E. cloacae). In ESBL producers only one
isolate was nonsusceptible and none resistant. Bacteria were isolated
from respiratory specimens (19) followed by soft tissues (13) and
faeces/rectum (7). Only 6 were from urine.
Conclusion: Temocillin was highly active in vitro against our ESBL
and derepressed AmpC Enterobacteriaceae. Nonsusceptibility occured
mainly in AmpC E. cloacae and resistance in AmpC E. cloacae only.
Temocillin remains an interesting alternative in treating multidrug-
resistant Enterobacteriaceae infections in our setting.
P1036 Trends in susceptibility of Gram-negative pathogens
isolated from intra-abdominal infections in North America
from 2003 to 2007 − the SMART Study
R. Badal °, S. Bouchillon, D. Hoban, A. Johnson, M. Hackel,
J. Johnson, G. Bochicchio (Schaumburg, Baltimore, US)
Objectives: The Study for Monitoring Antimicrobial Resistance Trends
(SMART) program has been monitoring the activity of ertapenem,
amikacin, cefepime, cefoxitin, ceftazidime, ceftriaxone, ciproﬂoxacin,
imipenem, levoﬂoxacin, and piperacillin/tazobactam against Gram-
negative bacteria isolated from intra-abdominal infections (IAI) since
2003. This report compares susceptibility levels in 2003 vs 2007 for key
IAI pathogens in North America.
Methods: 7−13 labs in the U.S. collected 100 consecutive Gram-
negative isolates from IAI each year. MICs were determined by broth
microdilution following CLSI guidelines, and % susceptible (%S) rates
in 2003 and 2007 were compared for species with >20 strains per year.
2003/2007 n’s of E. coli, K. pneumoniae, E. cloacae, and P. aeruginosa
were 427/224, 147/75, 80/31, and 161/64, respectively.
Results: 30/36 drug/bug combinations analyzed showed decreased %S
from 2003 to 2007, but only 4/36 (E. coli vs. ciproﬂoxacin and
levoﬂoxacin, K. pneumoniae vs ceftazidime, and P. aeruginosa vs.
imipenem) were statistically signiﬁcant (p< 0.05). Average change and
range of changes in %S for all drugs for E. coli, K. pneumoniae,
E. cloacae, and P. aeruginosa were −3.1% (+1% to −9%), −5.1% (−1% to
−8%), −0.4% (+6% to −11%), and −7.1% (−3% to −12%), respectively.
Conclusions:
• Although all species showed trends of decreasing susceptibility to
most drugs, relatively small n’s precluded establishment of signiﬁcance
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in all cases except ciproﬂoxacin and levoﬂoxacin vs. E. coli,
ceftazidime vs. K. pneumoniae, and imipenem vs. P. aeruginosa.
• In vitro activity of ertapenem has not changed signiﬁcantly against
Gram-negative IAI pathogens in North America from 2003 to 2007.
P1037 Trends in susceptibility of Gram-negative pathogens
isolated from intra-abdominal infections in Europe from
2003 to 2007 − the SMART Study
R. Badal, S. Bouchillon, D. Hoban, A. Johnson, M. Hackel,
J. Johnson °, R. Canton (Schaumburg, US; Madrid, ES)
Objectives: The Study for Monitoring Antimicrobial Resistance Trends
(SMART) program has been monitoring the activity of ertapenem,
amikacin, cefepime, cefoxitin, ceftazidime, ceftriaxone, ciproﬂoxacin,
imipenem, levoﬂoxacin, and piperacillin/tazobactam against Gram-
negative bacteria from intra-abdominal infections (IAI) since 2003. This
report compares 2003 to 2007 susceptibility levels for key IAI pathogens
in Europe (EU).
Methods: 28−31 labs in EU collected 100 consecutive Gram-negative
isolates from IAI each year from 2003 to 2007. MICs were determined
by broth microdilution following EUCAST guidelines, and % susceptible
(%S) rates in 2003 were compared to %S in 2007 for species with >30
strains per year. 2003/2007 n’s of E. coli, K. pneumoniae, K. oxytoca,
E. cloacae, E. aerogenes, C. freundii, M. morganii, P. mirabilis, and
P. aeruginosa were 1011/1291, 189/256, 112/124, 125/166, 40/39, 55/92,
57/53, 90/129, and 200/223, respectively.
Results: 59/87 drug/bug combinations showed %S decreases (7
signiﬁcant, p< 0.05) from 2003 to 2007; 20/87 increased %S (1
signiﬁcant, p = 0.0235); 8/87 had no change. Average changes were
−1.8% (E. coli), −2.7% (K. pneumoniae), +2.5% (K. oxytoca),
−5.6% (E. cloacae), −0.9 (E. aerogenes), −4.4% (C. freundii), −5.2%
(M. morganii), −4.1% (P. mirabilis), and −2.9% (P. aeruginosa).%S
changes of ertapenem ranged from +1% (E. coli) to −9% (C. freundii).
Conclusions:
• Although most species showed a general decline in %S vs. study
drugs, only 7 drug/bug combinations were statistically signiﬁcant; 4
of those were for E. coli, against which ertapenem and imipenem
remained 99% effective.
• SMART study drugs showed far less change in %S from 2003 to 2007
in EU than other regions of the world.
P1038 In vitro susceptibility of quinolone-resistant Escherichia
coli isolates with and without producing extended-spectrum
b-lactamase to fosfomycin trometamol
N. Ceran, R. Adaleti, Y. Nakipoglu, S. Tasdemir, C. Tasdemir, A. Inan °,
S. Aksaray (Istanbul, TR)
Objectives: The frequency of extended-spectrum-b-lactamase (ESBL)-
producing E. coli strains has been increased in Turkey, and all of these
isolates are recovered from outpatients with uncomplicated Urinary Tract
Infections (UTIs). It is common to ﬁnd that the same plasmid coding for
ESBL is also contains genes conferring resistance to several groups of
antimicrobial agents, such as aminoglycosides and cotrimoxazole. The
concurrence of quinolone resistance, particularly in ESBL-producing
strains, is frequent, there being few alternatives for the appropriate
oral treatment of uncomplicated UTIs caused by ESBL-producing
microorganisms. The aim of this study was to evaluate and compare the
efﬁcacy of Fosfomycin trometamol (FMT) in the treatment of quinolone
resistant E. coli with and without ESBL.
Methods: One-hundred and twenty ﬁve of quinolones resistant E. coli
strains isolated from urine of outpatients (68 strains) and hospitalised
patients (57 strains) were screened for the presence of ESBL by double
disk synergy test and the susceptibility of the strains to FMT was
performed by disk diffusion methods. Clinical Laboratory Standard
Institute (CLSI) criteria was considered in both methods.
Results: Twenty-eight (41.2%) of outpatients and 35 (61.4%) of
hospitalised patients isolates, a total of 63 (50.4%) strains were revealed
ESBL. All of the ESBL negative isolates were sensitive to FMT. Only
two ESBL producing E. coli strains (3.2%) isolated from urine of
hospitalised patients were found to be resistant to FMT.
Conclusion: The high efﬁcacy of FMT against all tested ESBL positive
and negative quinolone resistant E. coli, in addition to low side effects
and pharmacokinetic properties, FMT could be a useful alternative for
single-dose therapy of uncomplicated UTIs, especially in regions with
high quinolone resistance E. coli infections.
P1039 In vitro activity of fosfomycin against multidrug-resistant
Enterobacteriaceae isolates from a Belgian hospital
A. Jeurissen °, J.P. Ursi, J. Van Schaeren (Wilrijk, BE)
Objectives: Fosfomycin, a phosphonic acid derivative, has a broad-
spectrum activity against Gram-positive and Gram-negative bacteria. It
inhibits an early step in bacterial cell wall synthesis and it has mainly
been used in the treatment of urinary tract infections. In this study
we aimed to evaluate the in vitro activity of fosfomycin against multi-
drug resistant (MDR) Enterobacter spp. and against extended spectrum
b-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp..
Methods: Between May 2007 and August 2008 all ESBL-producing
E. coli (n = 22), ESBL-producing Klebsiella spp. (n = 12) and MDR
Enterobacter spp. (n = 25) were collected consecutively from inpatients
with a documented infection. Accepted collection sources were blood,
respiratory tract samples, urine, and wound specimen. Bacterial
identiﬁcation and susceptibility testing was performed using Vitek 2
system (Vitek 2, Biome´rieux, Durham, NC, USA). ESBL production
was conﬁrmed by a double disk test, as recommended by the Clinical
and Laboratory Standards Institute (CLSI). MDR Enterobacter spp.
were deﬁned as those strains that were nonsusceptible to at least
3 out of 6 of the following antibiotics: temocillin, aminoglycosides,
piperacillin/tazobactam, meropenem, cotrimoxazol, and quinolones. The
minimal inhibitory concentration (MIC) of fosfomycin was determined
by the E-test, according to the manufacturer’s instructions (AB Biodisk,
Solna Sweden). Results were interpreted according to the CLSI for
Enterobacteriaceae: susceptible  64mg/ml, resistant  256mg/ml.
Quality control was performed by testing susceptibility of E. coli ATCC
25922 and Pseudomonas aeruginosa ATCC 27853.
Results: The ESBL-producing E. coli strains exhibited the greatest
susceptibility to fosfomycin. MIC range was 0.25 to 1024 with MIC50
of 3mg/ml and MIC90 of 16mg/ml. Subsequently, the ESBL-producing
Klebsiella spp. strains had a MIC range of 1.5 to 96mg/ml, with MIC50
of 16mg/ml and MIC90 of 48 mg/ml. The MDR Enterobacter spp. were
the least susceptible to fosfomycin, having MICs distributions across a
range of 0.19 to 1024mg/ml, with MIC50 of 48mg/ml and MIC90 of
64mg/ml.
Conclusion: Using the breakpoint of 64mg/ml, 96% of the ESBL-
producing E. coli, 92% of the ESBL-produding Klebsiella spp., and
88% of the MDR Enterobacter spp. would be regarded as susceptible.
Our data suggest good in vitro activity of fosfomycin against MDR
Enterobacteriaceae.
P1040 In vitro activity of ertapenem in comparison with imipenem
against Enterobacteriaceae in Turkey
G. Altinkanat, B. Mete, D. O¨gu¨nc¸, C. O¨zakin, B. Su¨merkan, O¨. Ergo¨nu¨l,
G. So¨yletir, V. Korten ° (Istanbul, Antalya, Bursa, Kayseri, TR)
Objectives: To evaluate the in vitro activity of ertapenem against E. coli,
Klebsiella spp. and Enterobacter spp. in the ﬁrst year of its launch in
Turkey.
Methods: A total of 416 non-duplicate clinical isolates of ESBL positive
E. coli, ESBL positive Klebsiella spp. and Enterobacter spp. isolated
during 2006 to 2008 from 5 University hospitals were included in
the study. Antimicrobial susceptibilities of ertapenem and imipenem
were determined by E-test method according to the CLSI breakpoints.
ESBL production was conﬁrmed at the coordinating centre by CLSI
disk method by using both ceftazidime and cefotaxime with and without
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clavulanate. A difference of 5mm between the zone diameters of either
of the cephalosporin disks and their respective cephalosporin/clavulanate
disk is taken to be phenotypic conﬁrmation of ESBL production. Isolates
with a carbapenem MIC of  1mg/ml were screened for carbapenemases
by the modiﬁed Hodge test and PCR for OXA-48, VIM, IMP and KPC
genes.
Results: The in vitro activity of ertapenem was as follows (Table 1).
The body sites of infections were bloodstream (34%), urinary tract
(34%), skin and soft tissue (11%), lower respiratory tract (8%) and others
(13%). MIC50 of ertapenem were lower than imipenem for all species,
about two to ﬁve fold more active than imipenem. Despite this good
activity, the MICs of ertapenem for ESBL-producing Enterobacteriaceae
with reduced sensitivity to carbapenems were higher than imipenem.
Imipenem was active (MICs <2mg/L) in 10 of 12 ertapenem non-
susceptible isolates. No isolate was imipenem resistant and ertapenem
susceptible. The modiﬁed Hodge test was positive in 9 of 23 isolates with
reduced carbapenem susceptibility. Eight OXA-48 and 1 VIM genes were
found in 9 isolates, all of them were the modiﬁed Hodge test positive
isolates. No IMP or KPC was found.
Conclusion: The susceptibility of ertapenem was 1−2% less than
imipenem in ESBL producing Enterobacteriaceae. Isolates with putative
carbapenemases were rarely encountered. The rest of the isolates with
reduced sensitivity to carbapenems most likely have ESBLs or AmpC
enzymes plus impermeability and/or increased efﬂux.
Table 1. In vitro activities of ertapenem and imipenem against Enterobacteriaceae
in Turkey
MIC50 MIC90 Range Susceptibility
(%)
E. coli ESBL(+), n = 166
Ertapenem 0.064 0.25 0.012−24 99
Imipenem 0.19 0.25 0.125−1.5 100
Klebsiella spp. ESBL(+), n = 162
Ertapenem 0.094 0.38 0.008−32 97
Imipenem 0.19 0.25 0.125−32 99
Enterobacter spp., n = 88
Ertapenem 0.047 0.5 0.008−32 97
Imipenem 0.25 0.38 0.125−32 99
P1041 Colistin resistance in multidrug-resistant Gram-negative
bacteria
V. Papaioannou °, S. Tsiplakou, A. Stylianakis, P. Petraki,
D. Paraskevopoulou, F. Zoumpouloglou, E. Pantazis, A. Koutsoukou
(Athens, GR)
Objectives: Colistin is considered as a last-resort therapeutic option for
Gram-negative bacteria. The aim of the present study was to examine
the susceptibility pattern of Acinetobacter baumannii, Pseudomonas
aeruginosa, and Klebsiella pneumoniae to colistin.
Methods: During a three-year period from 01/11/05 to 31/10/08 a
total of 1836 strains of Acinetobacter baumannii, 1772 strains of
Pseudomonas aeruginosa and 1245 strains of Klebsiella pneumoniae
were tested for susceptibility to colistin among other agents. Isolates
were recovered from blood cultures, catheters, pus, bronchial secretions
and urine samples. Susceptibility testing of colistin was performed via
the Vitek II system (Biomerieux, France) and conﬁrmed through E-test
strips (AB Biodisc, Sweden), according to the CLSI guidelines.
Results: Acinetobacter baumannii was resistant to colistin up to 1.5%
(1.1% for the ﬁrst twelvemonth, 2.3% for the second and 1.22% for the
third one). Klebsiella pneumoniae isolates showed resistance to colistin
at 16% (20% for the ﬁrst twelvemonth, 12.6% for the second and 14.7
for the third one). Pseudomonas aeruginosa’s resistance to colistin was
at 4.8% (8.2% for the ﬁrst twelvemonth, 4.9% for the second and
1.3% for the third one). Colistin resistant strains were also resistant
to most other antimicrobial agents, namely b-lactams, quinolones and
aminoglycosides.
Conclusion: Multidrug resistant bacteria showed resistance even to
colistin, although this is a rare phenomenon. Klebsiella pneumoniae
displayed the highest rates of resistance. There was no statistically
signiﬁcant difference in resistance across periods. Colistin may be
effective for infections caused by multidrug resistant Gram negative
bacteria, but precautions should be taken to restrict unnecessary usage
in order to avoid increased resistance in the future.
P1042 Molecular mechanisms of resistance to rifaximin in “in
vitro” selected enterotoxigenic and enteroaggregative
Escherichia coli mutants
M.J. Pons °, L. Mensa, J. Vila, J. Gasco´n, J. Ruiz (Barcelona, ES)
Objective: The main aim of this study was to analyse the ole of efﬂux
pump and point mutations in the rpoB gene in the development of
rifaximin (Rfx) resistance in Escherichia coli.
Methods: Bacterial strains: Parental E. coli (2 enterotoxigenic and 2
enteroaggregative) were isolated from patients with traveller’s diarrhoea
in the Hospital Clı´nic of Barcelona. Fifteen Rfx resistant mutants were
selected after growing four E. coli clinical isolates in media containing
Rfx.
Efﬂux pump: Susceptibility to Rfx was determined by agar dilution
method, both in absence and presence of Phe-Arg-beta;-naphthylamide
(PAbetaN), an efﬂux pump inhibitor.
Mutations in the rpoB gene were determined by PCR ampliﬁcation of
fragment of 848 pb, using the following primers and conditions: 5′ -AAG
CTC ATC GAT ATC CGT AAC G-3′ and 5′-GCT TAT CAG CAC GCA
GAG TCG GAA-3′, 30 cycles to 94ºC during 30′′, 60ºC during 30′′ and
72ºC during 30′′, ﬁnal elongation 72ºC during 10′). The PCR product
was recovered using a commercial kit and sequenced.
Results: The results obtained show that the two analyzed mechanisms
are implicated in the Rfx resistance. Amino acid substitutions at positions
516 and 526 of the beta-subunit of RNA polymerases, previously
described in rifampicin resistance, were the most frequently obtained.
Additionally new undescribed point mutations (512, 525 and 574) were
found, although the results suggests that some of them (512, 525) do not
play a relevant role (Table).
Strain Initial MIC Inhibitor effect Amino acids
position change
23233 parental 16 – – –
19769 parental 16 – – –
19768 parental 32 – – –
21835 parental 4 – – –
19768−32* 128 8× – –
19768−64* >128 16× 526 H→N
19768–128* >128 – 516 D→N
19769−16* >128 16× 525 T→R
19769−64* >128 – 516 D→N
19769−32* >128 8× 525 T→R
19769–128* >128 16× 512 S→ F
21835−16* >128 8× – –
21835−32* >128 4× 574 S→Y
21835−64* >128 – 516 D→G
21835–128* >128 – 526 H→L
23233−16* >128 4× 516 D→G
23233−32* >128 4× 516 D→G
23233−64* >128 4× 516 D→N
23233–128* >128 4× 516 D→G
*Antimicrobial concentration in which strains were isolated.
Except in four strains, PAbetaN presented an inhibitory effect, decreasing
the MIC of rfx from 4 to 16 fold. However, this decrease in the Rfx
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MIC could not explain the total resistance levels (because parental MIC
was lower). In 6 mutants the efﬂux pump was able to explain the total
resistance, in 4 mutants only were observed mutations in the rpoB gene,
while a the remaining mutants the resistance would be explained by the
addition of two mechanisms.
Conclusions: All mutants strains presents at least one mechanisms of
Rfx resistance, both mutations studied in the rpoB gene and PAbetaN
inhibible efﬂux pump contribute for the Rfx resistance (together or not).
The possible role of others mechanisms of resistance (such as alterations
in the expression levels of porins) may not be ruled out.
P1043 In vitro activity of azithromycin against qnr carrying
Salmonella enterica
M. Lindgren °, P. Kotilainen, P. Huovinen, A. Siitonen, A.J. Hakanen
(Turku, Helsinki, FI)
Objectives: Reduced ﬂuoroquinolone susceptibility among salmonellas
has increased worldwide. We have previously described a novel
population of Salmonella enterica showing reduced susceptibility to
ciproﬂoxacin (MIC 0.125mg/ml) but being susceptible or only low-
level resistant to nalidixic acid (MIC 32mg/ml). Ciproﬂoxacin is a
ﬁrst-line drug to treat Salmonella infections. However, when infection
is caused by reduced ﬂuoroquinolone susceptible isolates, treatment
failures may occur and therefore alternative antibiotics are needed. The
aim of our study was to investigate whether azithromycin is effective
against reduced ﬂuoroquinolone susceptible isolates and qnr carrying
isolates of S. enterica.
Methods: 599 S. enterica isolates collected from Finnish travellers
returning from abroad between 2003 and 2008 were enrolled in this
study. 46 of these isolates belonged to the qnr-phenotype and were
collected from travellers returning from Southeast Asia. The MICs of the
isolates to ciproﬂoxacin, nalidixic acid and azithromycin were tested by
the standard agar dilution method according to the CLSI guidelines. The
susceptibility data were analysed by using the WHONET 5.4 computer
program.
Results: Azithromycin resistance (MIC 32mg/ml) was detected in 17
(2.8%) and high-level resistance (MIC 128mg/ml) in 8 (1.3%) of the
collected isolates. Among the qnr-phenotype, azithromycin resistance
was detected in 6 out of 46 (13.0%) isolates and high-level resistance
in 1 (2.2%) isolate. Those azithromycin resistant isolates were collected
between 2003 and 2004 and they belonged to the S. Stanley serovar. In
the whole population, azithromycin resistance was the most abundant (5
isolates) in 2003 and 2004; thereafter, resistance decreased temporarily
but has now increased again. Azithromycin resistance was detected in
different serovars, S. Stanley being the most common one.
Conclusion: We show in this study that azithromycin resistance is
uncommon among the whole Salmonella population. Resistance is
uncommon also among the qnr carrying isolates. Moreover, azithromycin
resistance has not been detected during the last four years. Thus,
azithromycin might be a good treatment alternative for patients with
reduced ﬂuoroquinolone resistant isolates although highly azithromycin
resistant isolates do occur.
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P1044 Clinical and analytical studies of a real-time PCR assay for
the detection of toxigenic Clostridium difﬁcile
E. Ziegler, E. Tyler, S. Visuri ° (Waukesha, US)
Objectives: Clostridium difﬁcile (C. diff) is a common cause of
nosocomial diarrhoea and if left untreated can lead to complications such
as colitis and toxic megacolon. The prevalence of C. diff infection (CDI)
has been escalating, leading to increased patient care costs, morbidity,
and mortality. The surge in infection rates and the emergence of a
hypervirulent strain (NAP1) has underscored the need for a fast, speciﬁc,
and sensitive alternative to currently available assays. A Real-Time PCR
assay for the detection of C. diff was developed and prospectively tested
at three clinical sites.
Methods: Prodesse’s ProGastro Cd assay, targeting the toxin B gene
(tcdB) consists of a three-step process including Stool Clariﬁcation, nu-
cleic acid extraction on the NucliSENS easyMAG, and Real-Time PCR
on the Cepheid SmartCycler II. Analytical sensitivity was determined
by testing serially diluted titered strains of C. diff spiked into liquid
stool samples. Analytical speciﬁcity was assessed by testing a panel of
microorganisms that cause similar disease states or are commonly present
in stool. To evaluate clinical performance, a prospective multicentre
clinical trial was performed comparing ProGastro Cd to the Tissue
Culture Cytotoxin Neutralisation Assay (CTA). Discrepant results were
resolved via a combination of sequencing, culture, and EIA analyses.
Results: The ProGastro Cd Assay has a limit of detection of
1×103 CFU/mL of bacteria in clinical matrix and is able to detect from 5
to 5×109 copies/reaction of the positive control. None of the organisms
included in the speciﬁcity panel were reactive with the assay. From
sample preparation to result, the assay can be performed in as little
as three hours. Pooled results from the clinical trial on 771 samples
yielded a clinical sensitivity of 91.7% and a speciﬁcity of 94.7%. After
discrepant analysis, the clinical sensitivity and speciﬁcity increased to
96.2% and 99.8%, respectively. There were no inhibited samples in the
trial.
Conclusions: The ProGastro Cd assay is fast, sensitive and speciﬁc for
detection of toxigenic C. diff. This assay provides results faster than
CTA and more accurate than other available diagnostic tests and will be
a useful assay to aid in the diagnosis of CDI.
ProGastro Cd assay Clinical Truth*
Positive Negative Total
Positive 102 1 103 Sensitivity 96.2% (90.7−98.5%) 95%CI
Negative 4 664 668 Speciﬁcity 99.8% (99.2–100%) 95%CI
Total 106 665 771
*Numbers recalculated after completion of Discrepant Analysis.
P1045 Real-time PCR assays for the detection of Clostridium
difﬁcile ribotype 017 and 027 strains
M. Reijans °, B. Mulders, E. Kuijper, M. Rupnik, G. Simons
(Maastricht, Leiden, NL; Maribor, SI)
Objective: Clostridium difﬁcile is the causative agent of antibiotic-
associated diarrhoea and pseudomembranous colitis. Clinical and
epidemiological data suggests that there is an increase in severity,
frequency and relapse of C. difﬁcile-associated infections (CDI) in
Europe and North America due to hypervirulent PCR ribotype 027
strains. Recently, outbreaks due to the emerging PCR ribotype 017 have
also been noticed. Real-time PCR assays for speciﬁc identiﬁcation of
these two new emerging ribotypes were developed. Each PCR ribotype
speciﬁc probe was combined with an universal C. difﬁcile probe in a
duplex realtime PCR.
Method: A set of 34 C. difﬁcile strains belonging to 9 different PCR
ribotypes (ribotypes 001, 002, 012, 014, 017, 020, 027, 078, 126) which
are frequently found in Europe, was screened by Ampliﬁed Fragment
Length Polymorphism (AFLP). Ribotype speciﬁc AFLP fragments were
excised and sequenced. BLAST analyses with these sequences were
performed on the genome of C. difﬁcile strain 630 and ﬂanking primers
were designed to amplify speciﬁc fragments of various PCR ribotypes.
These PCR fragments were sequenced and compared with each other to
identify ribotype speciﬁc polymorphisms. The speciﬁc polymorphisms
for ribotype 017 and 027 were used to develop two realtime PCR assays
in which the ribotype speciﬁc probes were combined with an universal
C. difﬁcile probe.
Results: The AFLP screening of 34 C. difﬁcile strains resulted in the
isolation and sequencing of 24 PCR ribotype speciﬁc AFLP fragments.
In total, 43 ribotype speciﬁc polymorphisms were identiﬁed. Speciﬁc
Molecular Beacon probes for PCR ribotype 017 and 027 were designed.
In addition, a C. difﬁcile universal Molecular Beacon probe was designed
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directed against the triose phosphate isomerase gene. Subsequently, the
sensitivity and speciﬁcity of duplex realtime PCR assays combining a
ribotype speciﬁc probe and a C. difﬁcile universal probe were validated
on 36 additional C. difﬁcile strains and in agreement with the PCR
ribotypes
Conclusions: We developed two duplex realtime PCR assays for the
detection of emerging C. difﬁcile ribotypes 017 and 027 strains combined
with a C. difﬁcile universal probe. The assays allows a rapid detection
of C. difﬁcile and speciﬁc identiﬁcation of ribotypes 017 or 027.
P1046 Optimisation and validation of an in-house-developed
real-time PCR for detection of toxinogenic Clostridium
difﬁcile strains in human faeces
D. Bakker °, I. Sanders, J. Corver, E. Kuijper (Leiden, NL)
Background: In most laboratories there is a need for a more rapid
and sensitive diagnostic test to diagnose Clostridium difﬁcile infection.
Previously we have developed a real-time toxin B PCR (toxB PCR) with
a sensitivity of 103-105 CFU/g faeces. The aim of this study was to
increase the sensitivity and perform a retrospective study to validate the
optimised toxB PCR.
Methods: To determine the sensitivity of the different combinations
of pre-treatment techniques and DNA extraction methods, we spiked
C. difﬁcile in pooled C. difﬁcile negative faeces in tenfold dilutions
series from 101 to 107 CFU/g faeces. To increase the sensitivity of
the toxB PCR we optimised primer, probe and magnesium chloride
concentrations and tried different mastermixes. Ninety-four different
reference C. difﬁcile ribotypes were tested in the optimised toxB PCR to
validate it. The retrospective study included 101 stored positive faeces
samples (deﬁned as enzyme-linked ﬂuorescent immunoassay (ELFA) and
cytotoxicity assay (n = 40) or culture (n = 61) positive) and 64 stored
negative faeces samples (deﬁned as ELFA and cytotoxicity assay (n = 53)
or culture (n = 11) negative).
Results: The combination Stool Transport and Recovery buffer (Roche)
pre-treatment and automatic DNA extraction (Roche) had the best
sensitivity of 103 CFU/g faeces. The optimalisation of the toxB PCR
resulted in the use of a new mastermix (Hotstar, QIAgen) and by new
optimal concentrations of primer, probe and magnesium chloride. All
tested C. difﬁcile PCR ribotypes were detected by the optimised toxB
PCR. The retrospective study revealed that all 40 ELFA/cytotoxicity
positive faecal samples were detected. Six ELFA/cytotoxicity negative
faecal samples were positive in the toxB PCR. All culture negative faecal
samples were negative in the optimised toxB PCR. The optimised toxB
PCR detected 59 of the culture positive faecal samples. Discrepancies
in the retrospective study were analyzed by reculturing faeces samples
and retesting DNA samples by toxB PCR. We were able to culture
toxinogenic C. difﬁcile in 5 ELFA/cytotoxicity negative/toxB positive
samples. One culture positive/toxB negative was conﬁrmed positive.
Conclusion: All tested PCR ribotypes were detected by the optimised
toxB PCR. The optimised toxB PCR has a comparable sensitivity as the
culturing method. Using culturing and ELFA/cytotoxicity as standard
the sensitivity, speciﬁcity, PPV and the NPV of the modiﬁed PCR was
respectively 98%, 91%, 94% and 96%.
P1047 Evaluation of commercial toxin detection and two nucleic
acid ampliﬁcation tests for the routine detection of
Clostridium difﬁcile infection
S. d’Arc °, C. Thomas, K. Bamford (London, UK)
Objective: Identiﬁcation of toxigenic C. difﬁcile by cell cytotoxicity
assay (CCAT) (gold standard) is only 70−80% as sensitive compared with
culture. Enzyme immunoassay (EIA) (sensitivity 90% verses CCAT)
may be less sensitive compared to culture. We aimed to compare the
sensitivity and speciﬁcity of the Premier toxin A & B, and two nucleic
acid ampliﬁcation (NAAT) platforms, Xpert™ and PROGASTRO™ in
detecting toxigenic C. difﬁcile with culture. In addition the NAATs were
assessed for their ability to make a presumptive identiﬁcation of the
highly pathogenic ribotype 027 strain.
Methods: 147 stool samples submitted to the diagnostic laboratories
at Hammersmith Hospital for C. difﬁcile testing were studied. Culture
was performed using alcohol shock followed by isolation on C. difﬁcile
selective media (Oxoid). All tests were performed according to the
manufacturer’s instructions. The PROGASTRO™ extraction was carried
out using the QIAamp DNA stool mini kit (QIAGEN) and realtime PCR
was performed on a RotorGene 6000 (n = 92). Ribotyping was carried
out according to published guidelines.
Results: C. difﬁcile was isolated from 19 of the 147 samples, 18/19
were toxigenic: toxin B gene (tcdB) positive by NAAT or toxin A or B
positive in EIA. The Xpert™ system was also able to detect the gene for
binary toxin (cdt) and a deletion at position 117 of the regulatory gene
TcdC, which if both are present alongside toxin B provides a presumptive
identiﬁcation of ribotype 027. Of the conﬁrmed Xpert™ positives 1/19
(6%) was a presumptive ribotype 027, this was conﬁrmed by Ribotyping.
22% were binary and toxin B positive, a feature of ribotype 078 and
72% only toxin B positive. Table 1 summarises the results of each assay.
Of the toxin detecting assays the EIA had lowest sensitivity (36.8%) but
highest speciﬁcity (99.2%). The Xpert™ provided the highest sensitivity
of 94.7% with a speciﬁcity of 95.3%.
Table 1. Comparison of C. difﬁcile EIA and RT-PCR with culture positive
and toxin positive resultsa
Assay Result Comparison to culture positive +
toxin positive results
No. of
specimens
Sens Spec PPV NPV
Pos Neg (%) (%) (%) (%)
Premier toxins A&B Positive 7 1 36.8 99.2 87.5 91.4
Negative 12 127
Xpert™ Positive 18 6 94.7 95.3 75.0 99.2
Negative 1 122
PROGASTRO™ Positive 11 4 91.7 95.0 73.3 98.7
Negative 1 76
a Pos = positive, Neg = negative, Sens = sensitivity, Spec = speciﬁcity,
PPV = positive predictive value, NPV = negative predictive value.
Conclusion: Both NAAT methods produced sensitivity rates signiﬁcantly
higher than the EIA assay but in terms of ease of use and turnaround
time the Xpert™ was superior. The Xpert™ is also able to differentiate
ribotype 027 from non 027 strains, while the PROGASTRO™ only
detects toxin B. Based on this work NAATs should be used for detection
of toxigenic C. difﬁcile in routine clinical samples. The addition of a
method for rapid identiﬁcation of type 027 is useful.
P1048 A MLPA-oligochromatographic multiplex assay for
identiﬁcation of the toxin genotype and the hypervirulent
ribotype 027 of Clostridium difﬁcile
B. Durenne, T. Laurent, T. Leclipteux, M. Reijans, G. Simons,
E. Kuijper, M. Rupnik, P. Mertens ° (Gembloux, BE; Maastricht,
Leiden, NL; Maribor, SI)
Objective: Clostridium difﬁcile is responsible for intestinal infections
after disturbance of normal gut ﬂora. Enterotoxin A (TcdA) and
cytotoxin B (TcdB) are the main virulence factors but binary toxin
CDT could also play a role in pathogenicity. Besides sporadic infections,
C. difﬁcile is responsible of nosocomial antibiotic-associated diarrhoea,
a major epidemiological concern, particularly since recent outbreaks due
to hypervirulent NAP1/027 type. Fast identiﬁcation of toxinogenic strain
and ribotype 027 is crucial for both patient care and disease control.
Multiplex ligation-dependent probe ampliﬁcation (MLPA) that allows
multiple target identiﬁcation in one reaction and oligochromatography
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(OC) that offers a fast and efﬁcient detection of MLPA product are
ideal for developing such an assay. We describe here a MLPA-OC assay
applied on C. difﬁcile toxin genes and ribotype O27 identiﬁcation.
Method: Probes targeting different toxin genes as well as 027
speciﬁc probes were recently identiﬁed and adapted in a MLPA assay.
Oligochromatographic strips were designed with I) 6 immobilised probes
capturing speciﬁcally each MLPA product (tcdA, tcdB, cdtA, cdtB, 027
and tpi as marker of C. difﬁcile) and II) a colloidal gold-probe conjugate,
hybridising with all MLPA products, and allowing the detection with
naked eye.
Results: Proof-of-principle of MLPA-OC was assessed using genomic
DNA extracted from culture of C. difﬁcile of 6 different ribotypes
including 027. Culture supernatant (24 h and 48 h) of 5 strains were
also tested successfully even without DNA extraction step. No cross-
reactivity was observed with DNA extracted from negative faecal sample.
DNA extracted from human faecal sample spiked with genomic DNA of
C. difﬁcile 027 shows that human DNA and/or stool specimen have an
inhibitory effect on MLPA-OC. The total procedure (from faecal sample
extraction to result) takes only 4 h30 but overnight hybridisation during
MLPA step increases the intensity of the signal.
Conclusions: We developed a MLPA-OC targeting the toxin genes of
C. difﬁcile (tcdA, tcdB, cdtA, cdtB) in addition to a 027 speciﬁc marker.
The epidemiological interest of the test relies on its easiness: one assay
to detect 6 targets and only a cycler and a heating block are necessary
for the entire procedure. The use of MLPA-OC as a diagnostic tool will
require further optimisation of the extraction procedure, an improvement
of the analytical sensitivity and a shorter protocol.
P1049 Evaluation of a rapid molecular-based method,
BD GeneOhm Cdiff Assay™ for the detection of
toxin-producing C. difﬁcile in faecal specimens
G. Terhes °, E. Urba´n, E. Nacsa, E. Nagy (Szeged, HU)
Objectives: Since 2002, the emergence and epidemics of hypervirulent
C. difﬁcile PCR ribotype 027, the raising morbidity and mortality
rates, and the increasing number of recurrency and therapeutic failures
have highlighted the necessity of a rapid and reliable method for
the detection of toxin-positive strains in faecal specimens. The BD
GeneOhm Cdiff Assay™ is a qualitative RT-PCR performed on the
Cepheid SmartCycler® (Cepheid, Sunnyvale, CA) for the detection of
tcdB gene. Our aims were to compare the results given by BD GeneOhm
Cdiff Assay™ to the result of cytotoxicity tissue culture assay and
a commercially available ELFA test for the direct detection of toxin
A and B from faecal supernatant and to make an accurate assessment of
the cost/beneﬁt of this molecular method.
Methods: During two-month period 447 liquid to soft stool specimens
were collected from both inpatients and outpatients in various
departments of Szent-Gyo¨rgyi Albert Medical Center (Szeged, Hungary).
These samples were tested with VIDAS® Toxin A and B (BioMerieux,
France) and cytotoxicity assay, and simultaneously BD GeneOhm Cdiff
Assay™ was also set up in every case. The stool samples were plated on
the surface of Clostridium difﬁcile agar base (Oxoid, Basingstoke, UK)
for culture.
Results: 8.3% of the examined 447 samples proved to be positive by
BD GeneOhm Cdiff Assay™, while the prevalence of positive specimens
was only 6.7% and 5.1% using cytotoxicity assay and VIDAS® Toxin
A and B (BioMerieux, France), respectively. 5.4% of the tested samples
were positive with both molecular method and cytotoxicity assay. Testing
consecutive samples from three patients showed that the presence of
toxin-producing strain could be detected earlier using molecular method,
when the toxin titre was under the detection level.
Conclusions: The laboratory standard to set up accurate diagnosis of
CDAD is the simultaneous use of cytotoxicity assay or EIA for toxin
detection and selective culture of C. difﬁcile, which is enough labour
intensive and time consuming, mainly if the toxin detection directly from
stool sample is negative and the culture is positive; repeated testing on
the presence of toxins from broth culture is necessary to clarify the
toxinogenic status of the isolated strain. BD GeneOhm Cdiff Assay™
provides more reliable results than other toxin detection tests during
a short period of time, which is very important from therapeutic and
infection control points of view.
P1050 Rapid oligochromatographic assay for the detection of
group B Streptococcus in vaginal samples
J.A. Carrillo, C. Rolda´n, J. Gasso´, J. Mendoza, J. Rojas,
A.G. Camacho ° (Santa Fe, Jae´n, ES)
Objectives: To evaluate a rapid and simple new commercial assay
(SpeedOligo GBS, Vircell) for the detection of group B Streptococcus
(GBS) based on a PCR plus a rapid test device that provides results in
less than one hour.
Methods: 235 double vaginal swabs were assayed. Bacteriological
culture was carried out on Granada medium and Columbia blood sheep
agar. Sterile swabs were artiﬁcially inoculated with GBS suspensions in
order to determine the analytical sensitivity of the technique. DNA was
extracted by direct heating and a fragment of cfb gene was ampliﬁed.
Amplicons were detected by means of a dipstick in a 5 minutes
hybridisation step: two complementary probes, one conjugated to gold
particles and the other immobilised onto the membrane were used. The
reaction was visually read. Discrepant results were reanalyzed by a qPCR
based on sip gene.
Results: Culture was positive in 72 samples, 67 also positive by
SpeedOligo GBS (93% sensitive vs. culture). The ﬁve false negative
results corresponded to samples with <5 colonies in culture; SpeedOligo
was able to detect the strains of these ﬁve samples when run on bacterial
suspensions prepared from the agar plate. 13 additional samples were
only detected by SpeedOligo GBS (92% speciﬁc vs. culture). 11 of
these were conﬁrmed by qPCR on a second target, giving SpeedOligo
a ﬁnal 99% speciﬁcity while an 87% sensitivity was calculated for
culture. The analytical sensitivity of SpeedOligo was established in
225 microorganisms per swab, corresponding to 4 microorganisms per
reaction.
Conclusion: SpeedOligo GBS proved to be a rapid, sensitive and speciﬁc
assay for the detection of GBS colonisation, based on nucleic acid
ampliﬁcation techniques. The few false negative results were probably
due to the low colonisation level of the patients, but the technique was
able to detect the strains isolated from them. Some culture negative
samples could be detected with the new assay and conﬁrmed by an
alternative qPCR test.
P1051 Characterisation of human herpes viruses and enteroviruses
using a microarray technology: CLART® Entherpex
N. Manjo´n, A. Macias °, R. Benito, J. Gomez, M. Romero on behalf
of Spanish Investigators Group
Introduction: The Herpesviridae family viruses are widely spread
among human population and they have the ability to establish
lifelong latent infection. In immunocompetent individuals, the virus
reactivation is usually harmless and unnoticeable. Human herpesviruses
and enteroviruses are the major causative agents of the central nervous
system (CNS) viral infections. The similar clinical signs provoked by
these viruses make the diagnosis difﬁcult and it is necessary to use
diagnostic methods that allow multiple, sensitive, and rapid identiﬁcation
of these viruses.
Objective: To develop a high sensitivity and speciﬁcity system for
simultaneous detection of Human Herpesviruses (HSV-1, HSV-2, VZV,
CMV, EBV, HHV-6, HHV-7 and HHV-8) and Enteroviruses (Echoviruses,
Poliovirus, Cosxackievirus), called CLART® Entherpex.
Method: Virus detection is performed via multiplex RT-PCR for
ampliﬁcation, and a new technology platform based on low-density
micro-arrays (ArrayTube) for visualisation. This technology allows
simultaneous detection of viruses and any necessary control in order to
guarantee the reliability of the results obtained. In order to determine the
diagnostic parameters of the kit, a comparative evaluation of CLART®
Entherpex against clinical diagnostic’s current methods (Herplex, PCR
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real time, PCR quantitative & Immunohistochemical) was made. A total
of 256 clinical specimens were tested (whole blood, plasma, biopsy,
cerebrospinal ﬂuid, swab) being a true positive result judged according
to the concordance between both methods. All the discrepancies were
validated with sequencing, homemade PCR and nested-PCR.
Results: 100% analytical sensitivity was obtained in the detection of 14
recombinant plasmids between 10 and 1000 copies. It was observed
that there were no cases of unspeciﬁc detection of viruses, which
mean a 100% analytical speciﬁcity. About the diagnostic sensitivity and
speciﬁcity, the behaviour of each virus after the validation of 256 clinical
specimens showed that most of viruses have sensitivity higher than 90%,
and speciﬁcity higher than 97%.
Conclusion: CLART® Entherpex is useful in the clinical setting
for rapid screening and detection of a Human Herpesviruses and
Enteroviruses based on the following facts: (i) excellent speciﬁcities
and sensitivities; (ii) rapid and automatic procedure; (iii) simultaneous
detection allowing the recognition of co-infections.
P1052 Spectrum of pathogens in surgically treated infective
endocarditis patients
T. Freiberger, E. Nemcova °, B. Zaloudikova, B. Krulova, J. Pol,
Z. Sorm, M. Kolek, K. Novotna, P. Nemec (Brno, Hradec Kralove,
Ostrava, Prague, CZ)
Objectives: To characterise a spectrum of pathogens in Czech patients
with infective endocarditis (IE) requiring surgical treatment.
Methods: Pathogens were detected in tissue heart valve samples from
106 IE patients surgically treated in four centres in the Czech Republic
from 1.1.2006 to 31.12.2008, using 16S rRNA broad-range PCR
followed by direct sequencing. The results were available within 24 hours
in a routine clinical setting.
Results: Staphylococcus spp. were found in 51 cases (48.1%),
Streptococcus spp. in 33 cases (31.1%) and Enterococcus faecalis in
7 cases (6.6%). Staphylococci were represented by S. aureus in 35 and
coagulase-negative staphylococci in 16 cases, streptococci by S. pyogenes
(1), S. agalactiae (5), S. anginosus group (8), S. mitis (4), S. mutans
(2), S. sanguinis (2), S. gallolyticus (2), S. infantarius (1), S. suis (1),
S. cristatus (1) and non-speciﬁed streptococci (6). Remaining cases
included Bartonella quintana (2), Bartonella sp. (2), Cardiobacterium
sp. (2), Haemophilus sp. (1), Gemella haemolysans (1), Lactococcus
garviae (1), Corynebacterium simulans (1), Propionibacterium acnes
(1), Tropheryma whipplei (1), Proteus sp. (1), Pseudomonas aeruginosa
(1), and Enterobacteriaceae (1).
Conclusion: Staphylococcus spp., Streptococcus spp. and Enterococcus
faecalis were responsible for vast majority of IE cases requiring surgical
treatment (85.8%). Broad-range 16S rRNA PCR followed by direct
sequencing was shown as a power, rapid and very useful tool for
identiﬁcation of causative agens of IE from tissue samples to the species
level, including differentiation of streptococci and detection of rare
pathogens.
P1053 Use of a new and simple microarray assay (Prove-it™
Sepsis) for rapid identiﬁcation of bacteria involved in bone
and joint infections directly from clinical samples
E. Allais, S. Boisset, A-M. Freydiere, Y. Benito, T. Ferry, S. Lustig,
F. Vandenesch, F. Laurent ° (Lyon, FR)
Objectives: The microbiological diagnosis of bone and joint infections
(BJIs) currently relies on standard cultures, which are time consuming
and are subject to false negative results in case of fastidious organisms
and previous antibiotic therapy. Prove-itTM Sepsis (Mobidiag®) is a new
commercial PCR and microarray assay that rapidly and reliably identiﬁes
more than 50 bacterial species present in positive blood cultures in less
than 3 hours. The aim of our study was to evaluate the performance of
this assay for the detection and identiﬁcation of bacteria directly from
BJI clinical samples compared to conventional culture and universal 16S
rDNA PCR.
Methods: We selected 59 clinical samples (33 articular ﬂuids and 26
biopsies), for which a microbiological diagnosis and identiﬁcation had
been established previously either by culture (C+) or PCR only (C-
/PCR+). All these positive samples were chosen within the spectrum
of bacteria included in the microarrays. Ten negative clinical samples
(C-/PCR-) were also included. DNA was extracted with the automated
MagNa Pure System (Roche) and the Prove-itTM assay was performed
according to the manufacturer’s protocol initially dedicated to blood
culture. A human b-globin PCR was used to control DNA extraction
and absence of inhibitors.
Results:
• C−/PCR− (n = 10): all samples were negative by using Prove-ItTM
assay,
• C+ (n = 10): 7 samples were positive with concordant identiﬁcation,
whereas 3 remained negative (S. epidermidis, S. aureus, and mixed
culture S. aureus+P. acnes),
• C−/PCR+ (n = 49):
– 34 samples (69.4%) were positive with concordant identiﬁcation
with the following bacteria: S. aureus (n = 10), S. epidermidis
(n = 10), S. pyogenes (n = 3), S. agalactiae (n = 3), S. dysgalactiae
(n = 3), K. pneumoniae (n = 3), S. marcescens (n = 1) P. aeruginosa
(n = 1),
– 1 sample was positive indicating a mixture of 4 species, of which
only one was identiﬁed by universal 16S PCR,
– 14 samples were negative which corresponded to the following
diagnoses by 16S rDNA PCR: 4 belonging to Staphylococcus sp, 7
to Streptococcus sp, 2 Enterobacteriaceae and 1 anaerobe.
Conclusion: These promising preliminary results indicate that this new
microarray method allows a rapid and reliable detection of bacteria
involved in BJIs. Providing additional probes relevant in BJIs (such as
Kingella kingae, Propionibacterium acnes) being included in the array,
it could replace conventional 16S rDNA PCR for clinical samples from
patient suspect of BJIs.
P1054 Detection of OXA carbapenemase production in clinical
samples by the Hyplex®CarbOxa ID multiplex PCR-ELISA
system
E. Kraniotaki, E. Platsouka °, E. Perivolioti, M. Nepka, Z.. Psaroudaki,
O. Paniara (Athens, GR)
Objective: During the last decade, nosocomial outbreaks of multidrug-
resistant strains of Acinetobacter baumannii, especially among immuno-
compromised patients in intensive care units (ICUs), have been reported
in diverse geographical areas. Moreover, the recent development of
Acinetobacter strains producing the class D carbapenemases (mainly
oxacillinases), is of great concern for the international community, since
carbapenems were often used to treat infections caused by multiresistant
A. baumannii isolates. Hyplex®CarbOxa ID multiplex PCR-ELISA
(BAG Health Care, Germany) is a new diagnostic method for the direct
detection of OXA-carbapenemases genes in clinical specimens.
Methods: The hyplex®CarbOxa ID method involves ampliﬁcation of
genes for the identiﬁcation of A. baumannii and the blaOXA-23,
blaOXA-40 and blaOXA-58 gene families, by multiplex PCR and
hybridisation of the PCR products to speciﬁc oligonucleotide probes
in an ELISA-based system. The method was tested in 105 samples from
different patients (30 positive blood cultures, 30 urine samples, 8 pus
swabs and 37 bronchial secretions), obtained during September 2007
in Evangelismos, Athens hospital. Results were compared to those of a
blaOXA PCR screening of the tested isolates.
Results: Twenty-seven out of the 105 samples (20 bronchial secretions
and 7 blood cultures) were positive by the hyplex®CarbOxa ID. In
details, all 27 samples were positive with the A. baumannii speciﬁc
and the blaOXA-58 family speciﬁc probes. The A. baumannii isolates
were imipenem and meropenem resistant. By PCR, blaOXA-58 carrying
A. baumannii isolates were detected from all the above hyplex-positive
samples. None of the blaOXA-58 carrying A. baumannii isolates
were identiﬁed in any of the hyplex-negative samples. Sensitivity and
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speciﬁcity of the hyplex®CarbOxa ID method for blood culture and
bronchial secretions samples were 100%.
Conclusions: The hyplex®CarbOxa ID test can be reliably applied for
the rapid detection of blaOXA carriage by A. baumannii isolates in
positive blood cultures and bronchial secretions in this setting. However,
the efﬁciency of the test should also be evaluated in other clinical
specimens, since it has the potentials of a useful diagnostic tool.
P1055 Identiﬁcation of TEM-type extended-spectrum b-lactamases
genes based on real-time PCR and pyrosequencing
T. Naas °, N. Merad, P. Nordmann (Le Kremlin-Biceˆtre, FR)
Objectives: Extended-spectrum b-lactamases (ESBLs) are increasingly
prevalent worldwide being mostly CTX-M, TEM and SHV enzymes.
Positive PCR results are sufﬁcient to indicate the presence of a CTX-
M-type ESBL, whereas sequencing is required for TEM-enzymes, since
broad-spectrum (TEM-1/2) enzymes are highly prevalent. Therefore, a
fast real-time PCR ampliﬁcation, using TEM-speciﬁc primers coupled
to real-time pyrosequencing was developed.
Method: A fast real-time PCR ampliﬁcation based on a LightCycler
2.0 ampliﬁcation system (Roche Diagnostic), using primers speciﬁc for
the blaTEM alleles coupled to pyrosequencing (Biotage) was developed.
Ten well-characterised TEM producers, representing various TEM alleles
(TEM-1, different TEM-ESBLs and combinations of TEM-1/TEM-
ESBLs) were used as controls. This high throughput technique has been
evaluated by screening 20 ESBL producing E. coli isolates recovered
from the Biceˆtre hospital (France) in 2007. Bacterial DNA was extracted
by boiling and using QiAmp Viral RNA extraction kit (Qiagen).
The presence of ESBLs were conﬁrmed by standard microbiological
techniques (disk diffusion antibiogram, synergy testing) and by standard
PCR followed by sequencing.
Results: A 400-bp DNA fragment was ampliﬁed containing the four
known positions (104, 164, 238–240) conferring an ESBL-phenotype.
Ten well characterised ESBLs and broad-spectrum TEM-enzymes were
unambiguously identiﬁed by pyrosequencing the four DNA regions of
15 bp responsible for extension of the proﬁle. With one Light Cycler PCR
reaction (20ml), the four regions could be sequenced. Furthermore, the
PCR was very sensitive, since 102–103 copies of blaTEM genes could
be reproducibly detected. When bacterial isolates contained both TEM-
1 and a TEM-ESBL derivative, pyrosequencing could easily distinguish
between the two variants, and unambiguously indicate the presence of
an ESBL. This high throughput technique has identiﬁed two TEM-
ESBLs among the 20 clinical ESBL-producing E. coli isolates tested. All
contained in addition a broad spectrum TEM-1-like variant. The other
18 ESBLs were of CTXM-type.
Conclusions: The combination of real-time PCR with pyrosequencing
represents a powerful tool for epidemiological studies of TEM-producers.
This assay is of high throughput since up to 96 bacterial isolates may be
screened in less than 3 h. Furthermore, it allows to detect TEM-ESBLs
even in presence of TEM-1/2 enzymes.
P1056 Multiplex real-time PCR detection of plasmid-mediated
AmpC
A. Motakeﬁ °, K. Tegmark-Wisell, L. Elfstro¨m, M. Walder, C.G. Giske
(Solna, Malmo¨, SE)
Objectives: Plasmid-mediated AmpC (pAmpC) confer resistance to
penicillins, cephamycins, oxyimino-cephalosporins and monobactams,
and are currently being detected in Escherichia coli, Klebsiella spp.,
Salmonella spp. and Proteus mirabilis. E. coli has a chromosomal AmpC
which can be hyper-produced, making it phenotypically difﬁcult to
discern from plasmid-mediated AmpC. Infection with AmpC producing
bacteria is of great concern since treatment options are limited,
and detection of such enzymes is consequently of epidemiological
importance. All AmpC enzymes are inhibited by cloxacillin and boronic
acid and can thus be detected by synergy disc diffusion test. Phenotypic
tests speciﬁc for pAmpC are however lacking. Detection of pAmpC
therefore requires genetic methods such as PCR. b-lactamases of the
pAmpC type can be divided into six subgroups based on nucleic acid
identity; CIT, MOX, FOX, ACC, DHA and EBC.
Methods: We optimised a currently available conventional multiplex
PCR to a real-time SYBRGreen PCR method. New primers for the ACC
subgroup were designed to include detection of more recently described
variants. The six primer pairs were divided in two triplex reactions,
and PCR-products were separated through melting point analysis. The
same temperature proﬁle was used for both reactions, enabling common
cycling.
A collection of 43 phenotypically determined (cloxacillin synergy test)
AmpC producing E. coli (n = 38) and P. mirabilis (n = 5) from Ska˚ne
County, Sweden, was studied for the presence of pAmpC. Genes detected
in the PCR were analysed by sequence analysis for determination of the
exact genotype.
Results: The real-time PCR method detected 12/38 E. coli producing
pAmpC of the CIT subtype. Amongst the P. mirabilis isolates 4/5
were producers of the CIT subtype. Sequence analysis is ongoing to
determine the exact genotypes, as well as epidemiological typing and
plasmid replicon typing. The novel assay was less laborious compared
to the conventional multiplex-PCR protocol currently in use. The PCR
reaction was also faster, the run time being less than two hours including
detection.
Conclusion: The real-time PCR method for pAmpC detection is a fast
and simple screening method that gives information on the presence,
as well as subtype of pAmpC. The SYBRGreen detection assay is
relatively inexpensive, making it feasible also in a low income setting.
The epidemiology of pAmpC in Sweden will be studied during 2009
using this methodology.
P1057 Rapid detection and identiﬁcation of zygomycetes in clinical
samples using high-resolution melt analysis
K. Hrncirova °, M. Lengerova, I. Kocmanova, Z. Racil, B. Weinbergerova,
P. Volfova, D. Dvorakova, S. Pospisilova, J. Mayer (Brno, CZ)
Objectives: Invasive fungal infections are life-threatening complication
in haematooncological patients. Recent studies have shown an increasing
incidence of rare fungal infections as zygomycoses. For successful
treatment rapid and accurate diagnostic methods are needed and
molecular diagnostics is very helpful.
Methods: DNA from clinical samples and zygomycete strains was
isolated with ZR Fungal/Bacterial DNA Kit (Zymo Research), from
tissue samples with DNeasy Blood & Tissue Kit (Qiagen). For DNA
detection we adopted previously published qualitative semi-nested PCR
method for detection of Zygomycetes targeting 18S region of ribosomal
DNA. We modiﬁed it for use as semi-nested real-time PCR with
EvaGreen intercalation dye followed by species identiﬁcation using High
Resolution Melt (HRM) analysis on Rotorgene 6000 (Cotbett Research).
Figure 1. High Resolution Melt (HRM) analysis. +C: positive control.
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Results: We tested 83 samples from 53 haemato-oncological patients
in risk of fungal infection: infected tissue (n = 7), sputum (n = 4), BAL
(n = 49), peripheral blood (n = 19, 16 were taken concurrently with BAL
samples) and positive culture isolates (n = 4). 7 tissue samples, 1 sputum
sample, 16 BAL samples, 2 blood samples and all culture isolates
were PCR positive. In 17 samples we were able to directly determine
zygomycete species (Absidia spp. (n = 4), Rhizomucor spp. (n = 5),
Rhizopus oryzae (n = 4) and Rhizopus microsporus (n = 4)) using HRM
analysis and comparison with HRM curves of zygomycete reference
strains, other 13 samples need to be sequenced to clarify obtained data.
Conclusion: Presented assay enables inexpensive, fast and reliable
detection of zygomycetes in clinical samples (see Figure 1). HRM
analysis of PCR products ampliﬁed with zygomycetes-speciﬁc primers
allows determining of a broad spectrum of zygomycetes species (e.g.
Rhizopus spp., Mucor spp., Rhizomucor spp., Cunninghamella spp. and
Absidia spp.) in one reaction. Compared to qualitative semi-nested PCR
it does not require gel electrophoresis and time consuming sequencing
of all PCR positive samples.
P1058 Genotypic analysis of human Echinococcus granulosus
strains in Turkey
S. Ergin °, S. Saribas, P. Yuksel, K. Zengin, K. Midilli, G. Adas,
S. Arikan, M. Aslan, H. Uysal, R. Caliskan, A. Oner, O. Kucukbasmaci,
A. Kaygusuz, M. Torun, B. Kocazeybek (Istanbul, TR)
Objective: Echinococcus granulosus is the causative agent of hydatid
cyst disease with considerable impacts on human/animal health and
economy. Although cystic hydatid disease continues to be endemic in
our country, molecular epidemiologic data regarding the genotypes of
E. granulosus strains infecting human beings are limited. The aim of
this study was the molecular characterisation of E. granulosus strains
obtained from human.
Methods: Between March-December 2008 cyst contents of 21 patients
were collected during the to surgery in the surgery departments of
different hospitals in Istanbul. The samples were checked for the
presence of protoscoleces microscopically and were preserved in 70%
ethanol at −20ºC. Genomic DNA was extracted using a commercial
DNA extraction kit (Nucleospin tissue kit, Macherey Nagel, Germany).
A 446 bp. long part of mitochondrial c oxidase subunit 1 (CO1) gene
of Echinococcus granulosus was ampliﬁed with PCR. PCR products
were puriﬁed and sequnced in both directions with an automated DNA
sequencer (ABI®, 310).
Results: Phylogenetic analysis showed that 16 of 21 human cysts
belonged to the G1 genotype (common sheep strain) of E. granulosus.
The sheep strain (G1 genotype) of E. granulosus was to be the
predominant genotype present in humans in the study. This is the
ﬁrst molecular analysis performed on exclusively human strains of
E. granulosus in our country.
Conclusion: According to the results of our study in our country, the
E. granulosus strains of both human and animal origins belong tho the
same genotype.
P1059 Seroreactivity of dense granule recombinant antigens in
toxoplasmosis
L. Holec-Gsior °, D. Lautenbach, M. Bronk, J. Kur (Gdansk, PL)
Objectives: Toxoplasma gondii is an ubiquitous parasite that infects
a broad range of hosts, including man and domestic animals.
Toxoplasmosis in immunocompetent adults is usually asymptomatic. In
contrast, primary infection during pregnancy can be transmitted to the
fetus throughout the placenta, causing spontaneous abortion or severe
fetal abnormalities. This fact emphasizes the importance of being able to
make an accurate distinction between primary infection and reactivation.
Among the available commercial diagnostic tests, serology is commonly
used. The speciﬁcity and sensitivity of these serological methods depend
mostly on diagnostic antigen(s) used. Most of these commercial kits use a
native parasite antigen prepared from tachyzoites. Recombinant proteins
would be alternative sources of antigens. An advantage would be the
reduced test costs due to the lower costs of production and puriﬁcation
of recombinant antigens. In the present study, we have evaluated the
usefulness of the T. gondii eight dense granule recombinant antigens
(GRA) in diagnostic tests.
Methods: The gra genes were prepared by PCR ampliﬁcation using the
total tachyzoite DNA from RH T. gondii strain as a template. The PCR
products were cloned into pUET1 vector, which appended six histidine
codons to the 3′ and 5′ ends. The recombinant antigens were produced
in the form of fusion proteins in Escherichia coli expression system
and were puriﬁed by a one-step metal afﬁnity chromatography. The
immunoreactivity of the puriﬁed antigens was conﬁrmed by ELISA with
sera from patients with acute and chronic infection.
Results: Analysis of the results showed, that the sensitivity of in-house
IgG rec-ELISA test performed with particular recombinant antigens or
their mixture was 24% to 100% depending on the antigen used and
the groups of examined sera. Speciﬁcity of IgG rec-ELISA was 100%.
Moreover, r-GRA2, r-GRA7 and r-GRA8 proteins were much more
correlated with acute toxoplasmosis than the chronic one, while r-GRA1
and r-GRA6 antigens detect antibodies in both groups of examined sera
with the same sensitivity.
Conclusion: The applied expression systems allow for production of
immunologically active T. gondii GRA recombinant proteins. These
antigens are useful for serodiagnosis of toxoplasmosis and in the near
future can replace the crude Toxoplasma antigens.
P1060 A real-time PCR for the detection of Plasmodium ovale
variant strains
A. Calderaro °, G. Piccolo, C. Gorrini, S. Peruzzi, C. Chezzi, G. Dettori
(Parma, IT)
Objectives: Malaria is the most frequent imported parasitic infection
in Italy, mainly from Africa. Molecular assays based on 18S-rDNA
developed by several researchers, including us, revealed that recently
the prevalence of P. ovale (Po) infections was higher than previously
thought and allowed to demonstrate that most prevalent malaria cases in
our area as well as in Italy were due to P. falciparum (Pf), followed by
Po and P. vivax (Pv). Sequence variations in 18S-rDNA lead to describe
a classic and a variant type of Po (vtPo); therefore primers and probe
speciﬁc for classic type of Po (ctPo) can fail in identiﬁcation of vtPo.
In this study, a new primer and probe for the identiﬁcation of vtPo were
described in order to accurately and promptly diagnose cases of imported
malaria.
Methods: A new Rt-PCR assay to identify vtPo was developed using
a new (OVA-Fv) and a previously described (OVA-R) primer with a
new probe speciﬁc for vtPo (OVA-v) in a variant Rt-PCR (Rtv-PCR)
assay. This assay was comparatively evaluated with the classic Rt-PCR
assay (Rtc-PCR) to identify Po testing 24 selected blood samples from
24 patients with malaria. Some samples were also pre-ampliﬁed by a
genus-speciﬁc conventional PCR (primers rPLU1-rPLU5) before testing
with Rt-PCR assays.
Results: Among the 24 samples resulted positive for Po 15 were ctPo and
9 vtPo. Fourteen samples were Po positive by Rtc-PCR and 6 samples
were Po positive by Rtv-PCR. Two samples resulting indeterminate by
Rtc-PCR and Rtv-PCR, respectively, were positive by the same assays
after pre-ampliﬁcation. Two samples negative by both Rt-PCR assays
resulted positive by Rtv-PCR after pre-ampliﬁcation. No signal was
detected by Rtv-PCR assay testing DNA from 4 Pf, 2 Pv and 5 Pm
positive samples.
Conclusion: The present study reports that some cases of malaria
by vtPo (9 of 24 in our experience) could not be diagnosed by
both microscopy and Rtc-PCR based on 18S-rDNA. The use of Rtc-
and Rtv-PCR to accurately identify Po strains can improve sensitivity
of diagnostic assays, especially in case of malaria by Po, usually
occurring with low parasitaemia as was particularly in 4 of 24 samples
which needed a pre-ampliﬁcation. The association of microscopic and
molecular assays demonstrated to be essential for a rapid and accurate
diagnosis of imported malaria in our area and allowed to administer
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a prompt and targeted therapy with positive impact on the clinical
management of the patients.
P1061 Detection of aetiology of peritonitis in peritoneal dialysis
patients by PCR
M. Suvorova °, A. Zemchenkov, P. Garosimchuk, V. Edelshtein,
A. Sabodash, E. Tarasova (St. Petersburg, RU)
Introduction: Peritoneal dialysis becomes the method of choice for
the patients with renal dysfunctions worldwide. This type of procedure
allows people to live their ordinary life without staying in the hospital.
The main setback of this procedure is an infection which causes
peritonitis statistically once in 18 months (Kavanagh D.2004. According
to the literature the most common bacterial pathogens causing peritonitis
are: E. coli, S. aureus, S. epidermidis and C. albicans. Routinely in
identiﬁcation of the pathogen is done by bacteriological analysis with the
following selection of antibiotics. However, quite often bacteriological
method fails and in clinical practice wide spectrum antibiotics are used
(Vancomycin, Amikacin) which is often ineffective and harmful for the
normal microﬂora. The aim of present study was to identify the presence
of bacterial pathogens in peritoneal ﬂuids by PCR.
Materials and Methods: 20 patients with peritonitis after dialysis
with negative bacteriological results have been selected for the study.
Peritoneal ﬂuid from the patients was used for DNA isolation with the
following PCR. Material was primerility tested for the bacterial content
using Universal primers for bacterial rRNA.
Positive samples were studied by the speciﬁc primers to S. aureus S. pyo-
genes, S. agalactiae, E. faecium, E. faecalis, E. coli, S. pneumoniae,
S. mutans, S. sobrinus, C. albicans.
PCR negative samples were tested for the presence of: C. trachomatis,
Ureaplasma urealyticum, M. hominis and M. genitalium.
Results: After the preliminary study with universal primers 11 samples
out of 20 were tested as positive for bacterial DNA. 9 samples were
negative. Among the positive samples 6 contained the mixture of
E. faecium and S. mutans. All the enterococcal strains carried sets of
putative virulence genes efaA, asa1, gelE. 3 samples carried S. mutans
strains with the putative virulence genes PA, PGP, PGPK. Only one
sample carried S. aureus and one was positive for E. faecalis. In order
to discover the cause of infection among the rest of the patients have
been tested with DNA primers to Chlamydia and Mycoplasma. Three
additional samples were tested positive with these primers.
Conclusions: So called aseptic cases of peritonitis are in reality quite
often caused by bacterial infections missed by the classical cultural study.
Chlamydia, Mycoplasma and S. mutans might be the cause of infection
which is important for the proper choice antibiotic therapy.
P1062 Comparative analysis of serum proteomes to discover
biomarker for scrub typhus
C.S. Lee °, H.N. Kim, Y.G. Kwak (Jeonju, KR)
Objective: Proteomics has the potential to identify noble biomarkers
from pathologic tissue, biologic ﬂuids and sera. In the present study, in
order to ﬁnd an easier and simpler diagnostic method and to ﬁnd the
pathogenic proteins of scrub typhus, the sera of patients were analyzed
by proteomics techniques.
Methods: The 2-dimensional electrophoresis patterns of sera from acute
febrile patients, pre-therapy and post-therapy of scrub typhus patients
and normal subjects were compared. The differentially expressed spots
were identiﬁed by matrix-assisted laser desorption/ionisation time-of-
ﬂight mass spectrometry.
Results: A total of 2,000 to 2,300 spots of protein of 130 g
were observed when staining was done with routine silver staining
procedures. The gender and age of the samples were matched as
much as possible because human samples are rather notorious for
their individual variations in the proteins’ expression level. We found
twenty one proteins that were signiﬁcantly and consistently different
on 2-DE gels between the sera from the negative, pre- and post-
therapy patients and the sera from the normal subjects. Thirteen
proteins among them were up-regulated in the pre-therapy scrub typhus
patients, whereas eight proteins were down-regulated. The results
of the MALDI-TOF MS unequivocally indicated that the identities
of the up-regulated spots were PRO2044, PRO2675, apolipoprotein
E, albumin-like protein, glutathione peroxidase, WFDC5, ﬁbrinogen
gamma, seren/cystein proteinase inhibitor clade G member 1 splice
variant 2, complement factor B, alpha-1-B glycoprotein; the identities
of the down-regulated spots were proapolipoprotein, immunoglobulin
G1 Fc fragment, transferrin, Ig mu chain C region.
Conclusion: The proteins obtained with this proteomic analysis will
be very useful in understanding the pathophysiology of scrub typhus.
These proteins will also be useful in ﬁnding candidates as diagnostic
biomarkers and new therapeutic targets for the treatment of scrub typhus.
P1063 Molecular proﬁle of rotavirus in children hospitalised with
acute gastroenteritis in Norway, 2006–2008
K.M. Vainio °, S.A. Nordbø, G. Størvold, G. Njølstad, H. Døllner,
C. Midgaard, F.J. Bosse, A.G.W. Rognlien, A. Rojahn, K.O. Wathne,
E. Flem (Oslo, Trondheim, Bergen, NO)
Objectives: Development of new rotavirus vaccines calls for the
epidemiologic and molecular data on rotavirus diarrhoea to inform
the policy decision on introduction of these vaccines into the national
immunisation program. In order to explore the distribution of rotavirus
strains in Norway, we conducted extensive strain surveillance among
children <5 years of age hospitalised with acute gastroenteritis in three
large hospitals during two consecutive rotavirus seasons in 2006–2008.
Methods: A stool sample was collected from each enrolled child during
hospital stay. All samples were initially screened for rotavirus antigen by
ELISA (DAKO Diagnostics). A subset of samples was also tested using
a rapid immunochromatographic test (BioMerieux). Rotavirus G and P
genotyping was performed using RT-PCR.
Results: Totally 311 stool samples were collected from enrolled children
during the study period. Rotavirus was detected in 190 (63%) samples
by ELISA and in 219 (72.3%) samples by RT-PCR. Only 2 (1%) ELISA-
positive samples were RT-PCR negative. In a subset of 84 samples tested
by both ELISA, rapid immunochromatographic test and RT-PCR, the
rotavirus detection rates were 67%, 60% and 87%, respectively.
Rotavirus G and P typing was performed on 219 RT-PCR-positive
samples. The predominant G1 type was detected in 116 samples,
accounting for 51% and 55% of strains during the ﬁrst and second
surveillance years, respectively. The second most frequently identiﬁed
genotypes were G3 and G9, detected in 7.5% and 18.3% in 2006–
2007 and 20.2% and 14.1% during 2007–2008, respectively. P[8] was
identiﬁed in 188 samples (86%). The prevalence of common G and P
combinations was >80% during the two consecutive surveillance years,
and the G1P[8] genotype combination was identiﬁed in 49% of samples.
No unusual rotavirus strains were detected, and only four samples
contained mixed infections.
Conclusion: Rotaviruses responsible for severe gastroenteritis leading
to hospitalisations in children <5 years in Norway include only globally
common G and P genotypes. The observed geographical and seasonal
variation in the distribution of rotavirus genotypes shows that further
rotavirus strain surveillance in Norway is critical to monitor changes
in circulating genotypes and determine how effective available vaccines
may be in reducing severe rotavirus disease in Norwegian children.
P1064 Comparison of two matrix-assisted laser desorption
ionisation-time of ﬂight mass spectrometry systems for rapid
identiﬁcation of bacteria and yeasts in a clinical laboratory
O. Dubuis °, R. Vital, C. Noppen, E.H. Viollier (Basel, CH)
Introduction: Matrix-Assisted Laser Desorption Ionisation-Time of
Flight Mass Spectrometry (MALDI-TOF MS) allows an identiﬁcation of
bacteria and yeasts within minutes generating species and genus speciﬁc
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mass peaks corresponding to ribosomal proteins. The aim of this study
was to compare two commercially available MALDI-TOF MS systems
in a multi-user setting of a routine microbiology laboratory.
Methods: 245 bacterial and 34 yeast isolates were tested with:
Microﬂex LT MALDI TOF System/Biotyper 2.0 SR1 software (Bruker
Daltonics, D-Bremen) and Axima Assurance (Shimadzu, CH-Reinach)
along with Saramis software (Anagnostec, D-Potsdam). Depending on
the pathogen direct smear of colonies onto the target plate or extraction
protocols were applied according to the manufacturer’s instruction.
Conventional identiﬁcation was used as reference. It was performed with
commercial systems, mainly Vitek 2 and API Systems (BioMe´rieux,
F-Marcy l’E´toile).
For isolates with inconclusive biochemical identiﬁcation or discrepant
results sequencing of the 16SrRNA was performed.
Results: Correct identiﬁcation for Axima/Saramis (AS) and Mi-
croﬂex/Biotyper (MB) at species level (S) or genus only level (G) were
as follows:
Enterobacteriaceae (n = 76): AS 62 (82%) S, 5 (7%) G; MB 59 (78%)
S, 8 (11%) G
Nonfermenters (n = 23): AS 17 (73%) S, 2 (9%) G; MB 13 (57%) S, 5
(22%) G
Staphylococci (n = 16): AS 10 (63%) S, 2 (16%) G; MB 12 (75%) S, 2
(16%) G
Enterococci (n = 13): AS 9 (69%) S, 2 (15%) G; MB 11 (85%) S
Streptococci (n = 32): AS 18 (56%) S, 5 (16%) G; MB 22 (69%) S, 6
(19%) G
Campylobacter jejuni/coli (n = 23): AS 20 (87%) S, 1 (4%) G, MB 23
(100%) S
Other bacteria (anaerobes, fastidious Gram neg. rods, Gram pos. rods)
(n = 62): AS 17 (27%) S, 11 (18%) G; MB 28 (45%) S, 12 (19%) G
Yeasts (n = 34): AS 29 (85%) S; MB 29 (85%) S, 1 (3%) G.
Conclusions: Both MALDI-TOF MS systems were rapid and accurate
for the identiﬁcation of the most frequently cultured bacteria and yeasts.
Quality of results improved with time over the four weeks period of
the evaluation. This shows that training skills are essential for sample
preparation and particularly for applying the material on the target plates.
In a clinical laboratory setting MALDI-TOF MS has the potential to
replace conventional identiﬁcation for the majority of bacteria and yeasts.
P1065 Bacterial species identiﬁcation directly from urine samples
by MALDI-TOF MS ﬁngerprinting
A. Borovskaya °, E. Ilina, V. Govorun, O. Morozova, J. Ditmarova,
A. Kruglov, T. Maier, M. Kostrzewa (Moscow, RU; Bremen, DE)
Objectives: The potential of MALDI-TOF MS to rapidly identify and
distinguish various bacteria has been demonstrated in recent studies.
Examination of biological ﬂuids plays a certain role in clinical tests and
recently several studies have addressed the issue of urine proteome. Urine
represents the most easily attainable specimen and therefore one of the
most usable in clinical diagnostics. Thus the application of MALDI-TOF
MS ﬁngerprinting through urine seems feeding in clinical laboratory
diagnosis.
Methods: Fresh urine (15ml) was centrifuged at 2500 rpm for
20 minutes at 37ºC. The supernatant was removed. Suitable for mass
spectrometry water (1ml) was added to the sediment, resuspended
thoroughly and heated at 37ºC for 20 minutes, followed by a further
centrifugation step. Then 300ml of water was added to the sediment.
After precipitation with ethanol (900ml) and centrifugation, the pellet
was suspended in 10mL of pure acetonitrile, 10ml 70% formic acid,
and analyzed in a microﬂexTM (Bruker Daltonics, Germany). All
clinical urine specimens were tested in parallel by both traditional
microbiological methods according to standard laboratory protocols
(WHO, ASM) and MALDI TOF MS combined with pattern recognition
analysis (MALDI Biotyper 2.0; Bruker Daltonics, Germany).
Results: Overall, 200 urine samples from individual patients were
studied. For 179/200 specimens (89.5%) the testing data were identical
by both standard laboratory methods and MALDI Biotyper. In other
cases discordance between the MALDI Biotyper and bacteriological
testing was found. For 4 specimens (3.8%) the presence of bacteria
was revealed by both methods, but the species ID were different.
The correctness of MALDI identiﬁcation was conﬁrmed by 16S rRNA
sequencing. Five samples were successfully tested by MALDI Biotyper
that was conﬁrmed by sequencing too while bacteriological tests did fail
(no growth). For 12 samples (6%) MALDI-TOF MS analysis gave no
identiﬁcation results. The most cases of failure were closely associated
with the titre of microorganism in original urine. Clinical signiﬁcant titre
of microbes is more then 104–105CFU/ml that is congruent with the
sensitivity threshold of direct bacterial proﬁling.
Conclusion: The MALDI-TOF MS direct bacterial ﬁngerprinting from
urine samples looks very attractive for species identiﬁcation avoiding the
step of cultivation.
P1066 Dermaﬁnder: a new approach for fast and sensitive
detection of dermatophyte skin infections
G. Dingemans °, T.M. Iglesias Herna´ndez, M.T. Illnait-Zaragozi,
M. Reijans, G. Simons, I. Curfs-Breuker, J.F. Meis (Maastricht,
Nijmegen, NL; Havana, CU)
Objective: Superﬁcial dermatophytosis is the most common fungal
infection in humans. Dermatophytes are keratinophilic fungi which are
able to infect keratinised tissue. Diagnosis of dermatophytosis is based on
microscopic observation of fungal structures in KOH threated skin scales
plus culturing and identiﬁcation of the causative species. However, direct
microscopy lacks speciﬁcity and culturing is slow because it requires
generally 2−4 weeks. To address this we have developed a molecular
test, the DermaFinder. The DermaFinder assay is able to detect the major
8 pathogenic dermatophytes in a single reaction.
Method: The DermaFinder is based on the MultiFinder technology
which enables simultaneous ampliﬁcation of up to 40 fragments. Primers
and probes were designed based upon unique AFLP markers. The assay
includes two probes targeting 2 dermatophytes species; Trichophyton
rubrum combined with T. soudanense and Microsporum canis combined
with Microsporum audouinii. The DermaFinder can detect four single
dermatophytes: T. mentagrophytes, T. violaceum, T. tonsurans and
Epidermophyton ﬂoccosum. In addition, the assay includes also one
probe which detects all members of the Trichophyton genus.
Results: A set of skin samples (232) from sporters with athlete’s foot
were used to validate the DermaFinder assay. Results where compared
with microscopy, KOH/blankophor and culture and showed a good
correlation. A speciﬁc dermatophyte real-time assay was used to test
the discrepancies. In most cases the real-time PCR conﬁrmed the
DermaFinder results. In total 38% (87) of the athlete’s were suffering
from a dermatophytosis. Moreover, the DermaFinder assay was able to
detect an additional 25% (36) of pathogenic dermatophytes in culture
negative samples.
Conclusion: The DermaFinder is able to detect the major 8 pathogenic
dermatophytes in clinical specimens and proved to be more sensitive
and speciﬁc than culture and direct microscopy. Earlier therapy and
information on the source of infection is possible with this test.
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P1067 Long-term effects of the pneumococcal conjugate vaccine
on antimicrobial resistance in children
R.M. Mera °, L.A. Miller, H. Amrine-Madsen, D.F. Sahm (Durham,
Upper Providence, Hendon, US)
Objectives: To model the changes in S. pneumoniae resistance to several
antimicrobial classes ﬁve years before and six years after the introduction
of the conjugate pneumococcal vaccine in the US.
Methods: A total of 129,562 isolates from the TSN Network®
surveillance database (Euroﬁns Medinet) during the period 1996 to 2007,
as well as age, specimen source, inpatient or outpatient status and US
census region were available for analysis. To appropriately model the rise,
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drop and subsequent rebound in antimicrobial resistance, cubic splines
were utilised in a logistic regression model. Multi-drug resistance was
considered as full resistance to two or more antimicrobial classes.
Results: In children less than ﬁve years old, antimicrobial resistance
continuously increased from 1996 to reach its peak between 2000 and
2001. 2001 rates were 48.8% for TMP/SMX, 44.9% for erythromycin,
32% for penicillin, 24.9% for tetracycline, 7.0% for ceftriaxone, and
29.5% for multiple resistance. All antimicrobial classes subsequently
experienced a steep drop in resistance before leveling off between
2003 and 2004. Levels in 2004 were 35.3% for TMP/SMX, 38.1%
for erythromycin, 21.1% for penicillin, 19% for tetracycline, 2.6% for
ceftriaxone and 22.1% for multiple resistance. A rebound was also
experienced in every class, with 2007 levels near or above the 2001
peaks. Resistance rates for 2007 were 41.1% for TMP/SMX, 45.7%
for erythromycin, 27.6% for penicillin, 30.4% for tetracycline, 3.1% for
ceftriaxone, and 27.9% for multiple resistance. Similar changes were
observed by source of the isolate, with blood/CSF isolates having lower
peaks and rebounds, and otitis media isolates showing very steep changes
over time. Similar changes were also observed by inpatient/outpatient
status and in different regions of the country, with larger variations
among the regions that started with higher levels.
Conclusion: Most antimicrobial classes experienced a signiﬁcant drop
in resistance after the introduction of the pneumococcal vaccine in
2001. This effect reached its maximum in 2004 with a subsequent and
signiﬁcant rebound by 2007. The same pattern is seen regardless of
specimen source, US census region or inpatient/outpatient status, and
may be due to the fact that the vaccine serotypes were the most frequent
and most resistant in 2001. As they were replaced by non vaccine
serotypes, resistance declined initially but later increased as the non-
vaccine serotypes acquired resistance.
Resistance prevalence (%) in <5 year olds.
P1068 MIC distribution and efﬂux of 4 respiratory
ﬂuoroquinolones (GEM, GRN, MXF, LVX) towards
S. pneumoniae isolated from patients with conﬁrmed CAP
in a country with large ﬂuoroquinolone use (Belgium)
A. Lismond °, S. Carbonnelle, F. Van Bambeke, P. Tulkens (Brussels, BE)
Background: Belgium is a country with one the largest ﬂuoroquinolones
use in Europe (2.36 DDD per 1,000 inhabitants and per day in
ambulatory care, based on 2006 ESAC data [http://www.esac.ua.ac.be]).
We have examined the MIC distribution and the inﬂuence of reserpine
(efﬂux inhibitor) of MXF and LVX (in clinical use since >6 years)
in comparison with GEM and GRN (not yet approved) towards
S. pneumoniae (SP) isolated from patient with conﬁrmed CAP.
Methods: 134 SP ﬁrst isolates were collected over the 2004–2008 period
from patients received from the community into hospital (6 institutions)
and for whom clinical data were consistent with a diagnostic of CAP.
MICs were determined by semi-geometric microdilution in CAMH broth
+ 2.5% lysed horse blood, with or without reserpine (R; 10mg/L).
Susceptibility was assessed according to EUCAST breakpoints for MXF
and LVX.
Results: MIC50 and MIC90 of GEM and GRN were much lower than
those of MXF and LVX. Efﬂux (as detected by R) was demonstrated (i)
for GEM only (and for a small proportion of isolates) if using a 2-fold
dilution increase criterion; (ii) for MXF, GRN and for GEM (affecting
almost all isolates for GEM) if using a 1-fold dilution increase criterion.
Conclusions: MICs of LVX in this collection support the “high dose”
recommendation on which LVX EUCAST breakpoint is based (geom.
mean more than 3-fold larger than what was reported in the study
that established the usefulness of the 500mg dose [0.25mg/L; Preston
et al., JAMA 1998;279:125−9]). MXF MICs remain under EUCAST
breakpoint and similar to pre-marketing surveys in Germany (MIC90
= 0.25mg/L [Reinert et al. JAC 1998;42:803−6]. Efﬂux is evident for
GEM (in the absence of speciﬁc selection pressure) and likely for MXF
and GRN (but with minor impact on MIC values).
FQ MIC distribution EUCAST Efﬂux
geom. mean MIC90 Bkpt %S max % Efﬂux for
−R +R −R +R −R +R (dil×) 1 dilº 2 dilº
LVX 0.83 0.71 1 1 2 97.8 98.5 1 3.7 0
MXF 0.16 0.14 0.25 0.25 0.5 98.5 98.5 1 27.6 0
GRN 0.04 0.03 0.06 0.06 2 19.4 0.7
GEM 0.03 0.01 0.06 0.03 3 83.6 17.2
P1069 Penicillin resistance in Scottish invasive Streptococcus
pneumoniae isolates, between 1999 and 2007
B.J. Cooke °, A. Smith, M. Diggle, K. Lamb, C. Robertson,
D. Inverarity, J. Jeffries, G. Edwards, T. Mitchell, S. Clarke,
J. McMenamin (Glasgow, Airdrie, Southampton, UK)
Objectives: Streptococcus pneumoniae remains a major cause of
bacteraemia and meningitis, and treatment may be complicated by non-
susceptibility to penicillin. This study aims to identify trends in penicillin
non-susceptibility rates in invasive S. pneumoniae in Scotland, and
to determine if any serogroups/types are particularly associated with
resistance.
Method: Data on invasive isolates of S. pneumoniae were obtained
from Health Protection Scotland, and the Scottish Meningococcus and
Pneumococcus Reference Laboratory. Antibiotic susceptibility data and
serotypes for invasive isolates (identiﬁed from blood, CSF, or other
normally sterile sites), between 1999 and 2007 were analysed.
Results: 4727 isolates were suitable for inclusion. Of these, 148 (3.13%),
were of intermediate penicillin sensitivity (MIC = 0.12−1mg/ml), and
7 (0.15%), were penicillin resistant, (MIC > 1mg/ml). This is an
increase from a previous Scottish study, which found 105 penicillin
intermediate-susceptible isolates (1.85%), and only 2 penicillin-resistant
isolates (0.04%), from the 5659 isolates collected between 1988 and 1999
(p = 0.00032). The highest recorded penicillin MIC was 16mg/ml. Ten
serogroups were identiﬁed among the non-susceptible isolates (1, 3, 6, 8,
9, 14, 19, 23, 35, 38), of which 5 serogroups (accounting for 14 (9.5%) of
the non-susceptible isolates), are not covered by the 7-valent conjugate
pneumococcal vaccine introduced into the UK in 2006. Seven of the
non-susceptible isolates not covered by the vaccine (50%), were isolated
in 2007 after the introduction of the vaccine. In total 4531 (95.8%) of
the isolates were from blood, and of these, 143 (3.1%) showed reduced
sensitivity to penicillin.
Due to poor drug penetration into the CSF, clinical treatment failure of
pneumococcal meningitis with penicillin may be seen with MIC 0.12.
Interestingly, 171 (3.6%) of these isolates were from CSF, and 6, (3.5%),
were non-susceptible to penicillin. Five serogroups/types were identiﬁed,
of which one (serotype 3), is not covered by the 7-valent conjugate
vaccine. Three sequence types were identiﬁed (156, 442 and 180).
Conclusion: The rate of penicillin non-susceptibility amongst invasive
S. pneumoniae isolates submitted between 1999 and 2007 has increased
from 1.89% to 3.28% (p = 0.000004). Ten serogroups/types account for
the penicillin non-susceptible isolates, and 5 of these are not covered by
the conjugate pneumococcal vaccine currently used in the UK.
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P1070 Regional variations in penicillin resistance rates against
Streptococcus pneumoniae: The United States, 2008
B. Johnson, D. Hoban, M. Renteria, J. Johnson °, R. Badal, S. Hawser,
M. Hackel, S. Bouchillon, M. Dowzicky (Schaumburg, Collegeville, US)
Background: The percentage rates of penicillin-resistant (PenR)
S. pneumoniae (SPN) varies by country and region. Earlier studies
have documented U.S. regional variations in PenR SPN. The purpose
of this study was to determine changes in regional variations, if any, of
PenR and PenNS strains of SPN, and the current activity of tigecycline
(TIG), amoxicillin-clavulanic acid (AC), ceftriaxone (CFX), levoﬂoxacin
(LEV), linezolid (LNZ) and vancomycin (VAN) to pen-resistant isolates.
Methods: 2,443 clinically relevant isolates of SPN were collected from
patients in 193 hospitals from 2004–2008. MIC’s to all agents tested
were determined by broth microdilution and interpreted following CLSI
guidelines. Regions are deﬁned by the CDC.
Results: PenNS rate was 42.4% for all regions varying from a high
of 60.3% (East South Central) to a low of 32.3% (Paciﬁc and New
England). PenR decreased in all regions but one (New England) with a
corresponding increase in PenI rates in most regions. Regional changes
from a 1999–2000 study to 2004–2008 study are noted. Tigecycline and
vancomycin had the lowest MIC90 s (mcg/mL) against PenR SPN at 0.5
followed by LEV and LNZ at 1 and CFX and AC at 2 and 8, respectively.
Conclusions: PenNS for SPN has remained essentially constant since
1999, but PenR has generally shifted from Paciﬁc regions eastward.
VAN, LNZ, LEV and TIG MIC90 values remain unaffected by pen
phenotypes.
Regions Pen I+R 1999–2000,% Pen I+R 2004–2008,% Net Gain (Loss),%
n = 4,751 n = 1,694
East South Central 53.3 60.3 7.0
South Atlantic 47.9 47.9 0
West North Central 37.1 45.7 8.6
West South Central 47.5 45.1 (2.4)
Middle Atlantic 36.9 39.7 2.8
East North Central 38.7 39.6 0.9
Mountain 41.1 36.3 (4.8)
Paciﬁc 34.6 32.3 (2.3)
New England 26.1 32.3 6.2
All Regions 41.0 42.4 1.4
P1071 Trends in antimicrobial resistance in Streptococcus
pneumoniae, Canada, 1993–2008
K. Green °, A. McGeer, A. Plevneshi, S. Pong-Porter, D. Low on behalf
of the Canadian Bacterial Surveillance Network (CBSN)
Objectives: To monitor trends in antimicrobial resistance in Canadian
isolates of Streptococci pneumoniae (SPN).
Methods: The Canadian Bacterial Surveillance Network (CBSN) is a
collaborative network of microbiology laboratories from across Canada
that has been monitoring resistance trends in Canadian isolates of SPN
since 1993. Participating laboratories submit bacterial isolates to a
central laboratory for standardised antimicrobial susceptibility testing
performed according to CLSI protocols.
Results: Of the 31,064 SPN isolates submitted and tested between
1993 and July of 2008, 37% were from blood/CSF, 41% from sputum,
22% from other sites. The trends in antimicrobial susceptibility are
expressed below as percentage resistant. Macrolide resistance and
tetracycline resistance have both increased slightly between 2006 and
2007 (19.3 vs 22.4 and 11.2 vs 13.1 respectively). Preliminary results
from 2008 suggest a decreasing or stable trend in 2008. Resistance to
ﬂuoroquinolones declined slightly since 2006 (in 2007: Cip 1.7%; Levo
0.8%; Moxi 0.5%) but has increased slightly in all but moxiﬂoxacin in
2008 (Cip 2.2%; Levo 1.6%; Moxi 0.7%). Penicillin resistance decreased
in 2007 from to 6.2% in 2006 to 4.1%, P = 0.009), but appears to be
increasing slightly again in 2008 (6%). Ceftriaxone resistance (meningeal
breakpoint MIC 2) increased to 3.3% in 2008 from 2.9%. Amoxicillin
resistance continues to increase to 1.9% in 2008.
Conclusions: Preliminary data from 2008 suggest modest increases
in resistance to penicillin, amoxicillin, ceftriaxone, ciproﬂoxacin and
levoﬂoxacin above the rates seen in 2007. Conversely, there appears to be
decreased resistance to macrolides, tetracyclines and trimethoprim/sulfa.
’93 ’94 ’95 ’96 ’97 ’98 ’99 ’00 ’01 ’02 ’03 ’04 ’05 ’06 ’07 ’08
5.7 8.1 8.8 11.9 13.6 15.0 13.4 12.3 14.4 15.1 14.9 14.8 15.3 15.4 17.2 16.0
PenR 0.9 1.3 2.2 4.1 6.6 5.7 5.9 5.9 6.8 6.5 6.2 5.4 4.8 6.2 4.6 6.0
AmoxR 0 0 0 0 0.1 0.1 0.2 0.1 0.5 0.6 1.1 1.1 1.1 1.4 1.6 1.9
Eryth R 1.9 3.4 3.2 4.8 6.8 10.5 9.8 11.2 12.8 14.0 15.9 18.0 19.1 19.3 22.4 21.2
ClindaR 0 1.7 1.3 2.4 3.6 5.1 4.4 5.5 5.8 6.5 7.4 8.1 8.2 8.6 9.6 7.9
T/SR 3.8 4.7 9.7 12.7 14.6 12.3 12.0 11.3 11.9 13.1 13.3 13.5 12.2 11.7 11.9 10.9
Tet R 1.4 2.3 3.4 2.5 6.4 9.1 7.1 5.5 9.1 9.6 9.7 10.9 10.4 11.2 13.1 9.2
Ceftrx R(M) 0 0.2 0.1 0.7 1.3 2.5 1.5 2.0 2.4 1.5 1.8 2.5 1.9 3.7 2.9 3.3
Ceftrx R(NM) 0 0.04 0 0.2 0.1 0.1 0.3 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.3 0.2
CiproR 0.5 0.8 0.7 0.8 1.8 1.8 1.6 1.4 2.1 2.6 1.7 2.0 2.4 2.7 2.0 2.2
LevoR 0 0.4 0.1 0.2 0.5 0.3 0.4 0.9 1.2 1.8 1.2 1.5 1.5 1.7 1.2 1.6
Moxi R NT NT 0 0 0.3 0.2 0.2 0.4 0.4 0.3 0.4 0.6 0.7 0.9 0.7 0.7
P1072 Resistance and resistance mechanisms in S. pneumoniae in
the Netherlands the Duem3 study
J.W. Mouton °, H. de Valk, S. Meijers, C. Klaassen and the Duem
Study Group
Objectives: In 1999, 2001−2, 2003 and 2005 we performed surveys
in The Netherlands (NL) to monitor antimicrobial resistance in
S. pneumoniae.(SP) We then found increasing prevalence of macrolide
resistance but virtually no resistance to quinolones. We here report the
survey in 2007.
Methods: 26 laboratories equally distributed throughout NL participated
in the study. Each lab was asked to collect up to 25 pneumococcal
strains of consecutive samples. Only blood or sputum (including lavage)
was allowed. Identiﬁcation was done by participating laboratories using
their own standard identiﬁcation technique; in any case bile solubility
was required. MIC’s were determined using the Etest on site for
Levoﬂoxacin (Le), Moxiﬂoxacin (Mo), Penicillin (Pe), Amoxicillin
(Am), Clarithromycin (Cl), Cefotaxim (Ce), Cotrimoxazole (Ct) and
Doxycyclin (Do); control ATCC strains were included. Data were entered
using a web-based system. Afterwards, strains were collected by the
central lab for further analysis. Identiﬁcation conﬁrmation of all SP was
performed by bile solubility testing and also by LytA PCR for resistant
strains. Resistance genes were identiﬁed using validated PCR-based
methods for all strains with a MIC of >1mg/L for Le, and >0.5mg/L
for Cl. EUCAST susceptibility criteria were used.
Results: 583 strains were tested, of which 542 were available and
conﬁrmed SP after reidentiﬁcation. MIC90 s in mg/L were 0.125 (Mo),
1 (Le); 0.023 (Pe), 0.047 (Ce), 1.5 (Cl), 0.38 (Do), 0.25 (St) and 0.023
(Am). Of the Cl resistant strains, slightly less than half were due to the
ermB type and 41% due to efﬂux (mefA and mefE) showing a similar
pattern as earlier surveys. 0.6% was Le R with a double mutation.
Conclusions: Over the years − during 5 surveys − macrolides showed
a consistent and signiﬁcant shift to higher MIC90 values. For the
ﬁrst time more than 10% of strains are now R for Clarithromycin,
values that may prohibit blind prescribing of macrolides. In contrast, no
signiﬁcant increase in resistance was observed for b-lactams, quinolones,
doxycyclin and cotrimoxazole.
P1073 Macrolide resistance in Streptococcus pneumoniae from the
T.E.S.T. Program in Europe: a multi-year analysis
M. Renteria, J. Johnson °, R. Badal, S. Hawser, M. Hackel, S. Bouchillon,
B. Johnson, D. Hoban, M. Dowzicky (Schaumburg, Collegeville, US)
Background: Even with decreases in antibiotic consumption, non-
b-lactam resistant rates against S. pneumoniae are on the rise. The
Tigecycline Evaluation Surveillance Trial (T.E.S.T.) program is an
ongoing global surveillance designed to follow trends in antimicrobial
activity. This report evaluates tigecycline activity in Europe against
macrolide-resistant S. pneumoniae during the years of 2004 to 2008.
Methods: 459 clinical isolates were collected from 61 investigative sites
from 19 countries in the Europe. Clinical isolates were identiﬁed to
the species level at each participating site and conﬁrmed by the central
laboratory. Minimum Inhibitory Concentrations (MICs) were determined
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by the local laboratory using supplied broth microdilution panels and
interpreted according to EUCAST guidelines.
Results: Summary data for the 121 (26.5%) macrolide-resistant strains
are presented in the table.
Conclusions: Tigecycline demonstrated the lowest MIC50 and MIC90 in
vitro values of all study drugs against macrolide-resistant S. pneumoniae.
Tigecycline in vitro activity suggests that tigecycline would be effective
against this important clinical pathogen and resistant phenotype.
Drug Macrolide-resistant S. pneumoniae (n = 121)
MIC50 MIC90 % Susceptible % Resistant
Tigecycline 0.03 0.12 na na
AmoxClav =0.03 2 97.5 0.8
Cefdinir 0.25 >2 62.8 36.4
Ceftriaxone 0.06 1 86 0
Cefuroxime 0.25 8 63.6 34.7
Erythromycin 64 >64 0 100
Levoﬂoxacin 0.5 1 100 0
Linezolid =0.5 1 100 0
Minocycline 2 8 33.9 62
Moxiﬂoxacin 0.12 0.25 98.3 1.7
Penicillin 0.12 2 47.9 13.2
TrimethSulfa 0.5 >4 62 31.4
na = breakpoints not deﬁned.
P1074 Macrolide resistance in Streptococcus pneumoniae in the
United States and Canada, 2004–2008
J. Johnson, R. Badal °, S. Hawser, M. Hackel, S. Bouchillon, B. Johnson,
D. Hoban, M. Renteria, M. Dowzicky (Schaumburg, Collegeville, US)
Background: Even with decreases in antibiotic consumption in Canada,
non-b-lactam resistant rates against S. pneumoniae are on the rise.
The Tigecycline Evaluation Surveillance Trial (T.E.S.T.) program is an
ongoing global surveillance designed to follow trends in antimicrobial
activity. This report evaluates tigecycline activity in United States and
Canada against macrolide-resistant S. pneumoniae during the time from
2004 to 2008.
Methods: 1,256 clinical isolates were collected from 178 investigative
sites in the United States and Canada. Clinical isolates were identiﬁed to
the species level at each participating site and conﬁrmed by the central
laboratory. Minimum Inhibitory Concentrations (MICs) were determined
by the local laboratory using supplied broth microdilution panels and
interpreted according to CLSI guidelines.
Results: Summary data for the 371 (29.5%) macrolide-resistant strains
are presented in the table.
Drug Macrolide-resistant S. pneumoniae (n = 371)
MIC50 MIC90 % Susceptible % Resistant
Tigecycline 0.03 0.12 na na
AmoxClav 0.5 4 78.7 7.3
Erythromycin 64 >64 0 100
Cefdinir 2 >2 40.2 54.7
Ceftriaxone 0.25 1 90.3 3
Cefuroxime 2 8 39.4 57.4
Levoﬂoxacin 0.5 1 98.7 1.1
Moxiﬂoxacin 0.12 0.25 98.9 1.1
Linezolid =0.5 1 100 0
Minocycline 0.5 8 0.5 0.5
Penicillin 0.5 4 18.9 37.5
TrimethSulfa 4 >4 24 62.8
na = breakpoints not deﬁned.
Conclusions: Tigecycline demonstrated the lowest MIC50 and MIC90 in
vitro values of all study drugs against macrolide-resistant S. pneumoniae.
Tigecycline in vitro activity suggests that tigecycline may be effective
against this important clinical pathogen and resistant phenotype.
P1075 Trends of antimicrobial resistance among staphylococci and
enterococci in Germany
M. Kresken °, B. Ko¨rber-Irrgang, G. Peters, E. Leitner, C. von Eiff
(Rheinbach, Mu¨nster, DE)
Objectives: Tigecycline, which has been shown to have potent activity
against a wide range of bacteria including multi-resistant pathogens such
as MRSA and VRE, has been introduced in Germany in May 2006.
The German Tigecycline Evaluation Surveillance Trial (G-TEST) is an
ongoing surveillance programme comprising 15 laboratories monitoring
the susceptibility of bacterial pathogens to tigecycline. The objective
of this study was to compare the in vitro activities of tigecycline and
other drugs against isolates of S. aureus, S. epidermidis, E. faecalis
and E. faecium obtained in 2005 (prior to the introduction) with those
recovered in 2007 (one year after the introduction).
Methods: A total of 1,506 isolates (610 S. aureus, of which 309 were
MRSA, 310 S. epidermidis, 299 E. faecalis, 287 E. faecium) collected
in 2005 (n = 765) and 2007 (n = 741) were included. Agents tested
were tigecycline, doxycycline, oxacillin, amoxicillin-clavulanic acid,
moxiﬂoxacin, gentamicin, linezolid, vancomycin and others. MICs were
determined by the broth microdilution method according to the standard
of the guideline EN ISO 20776−1 in a central laboratory and interpreted
by EUCAST criteria. Changes in resistance over time were assessed.
Results: Comparing data of 2005 and 2007, rates of resistance (%)
were as follows: MSSA − tigecycline 0/0, doxycycline 3/3, moxiﬂoxacin
14/12, gentamicin 7/8, linezolid 0/0, vancomycin 0/0; MRSA −
tigecycline 0/0, doxycycline 6/4, moxiﬂoxacin 91/95, gentamicin 23/13,
linezolid 0/0, vancomycin 0/0; S. epidermidis − oxacillin 83/83,
tigecycline 0/0, doxycycline 10/9, moxiﬂoxacin 42/52, gentamicin 65/56,
linezolid 0/0, vancomycin 0/0; E. faecalis − tigecycline 0/0, amoxicillin-
clavulanic acid 0/1, high-level (HL) gentamicin 38/39, linezolid 0/0,
vancomycin 0/0; E. faecium − tigecycline 0/0, amoxicillin-clavulanic
acid 92/93, HL gentamicin 43/37, linezolid 1/0, vancomycin 10/18.
MIC90 values of tigecycline remained unchanged with0.125, 0.25, 0.5,
0.125 and 0.125mg/L for MSSA, MRSA, S. epidermidis, E. faecalis
and E. faecium, respectively.
Conclusion: The in vitro activity of tigecycline against staphylococci
and enterococci did not change compared to pre-marketing baseline
values. In contrast, susceptibility to gentamicin increased among MRSA,
while susceptibility to vancomycin decreased signiﬁcantly among
E. faecium isolates.
P1076 Susceptibility of Staphylococcus aureus nosocomial isolates
in Russia: ﬁve-year trends
A. Dekhnich °, A. Nikulin, N. Ivanchik, O. Kretchikova, R. Kozlov
(Smolensk, RU)
Objectives: To evaluate antimicrobial susceptibility trends in nosocomial
S. aureus isolates in different regions of Russia.
Methods: A total of 1456 clinical strains were collected during
multicentre studies (24 cities, 29 centres) in two time periods: 2001–
2002 and 2006–2007. Susceptibility testing to 13 antimicrobials was
performed by CLSI agar dilution method. CLSI 2008 criteria were
used for the interpretation of susceptibility testing results (with the
exception of fusidic acid, for which the criterion of French Society for
Microbiology was applied).
Results: Overall, 41.7% of strains were MRSA. Oxacillin resistance
rates increased from 33.4% in 2001–2002 to 54.4% in 2006–2007. The
MIC and resistance rates to other non-b-lactam antibiotics are presented
in the Table.
Conclusion: Linezolid, vancomycin, mupirocin, trimethoprim/sulfa-
methoxazole and fusidic acid retained high in vitro activity against
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nosocomial S. aureus strains in Russia. Resistance to ﬂuoroquinolones,
lincosamides, macrolides, aminoglycosides, tetracyclines, fusidic acid,
rifampicin and chloramphenicol substantially increased during ﬁve years
period.
Antibiotic 2001–2002 (n = 879) 2006–2007 (n = 577)
MIC50
(mg/l)
MIC90
(mg/l)
I+R
(%)
MIC50
(mg/l)
MIC90
(mg/l)
I+R
(%)
Chloramphenicol 8 128 42.9 64 64 57.0
Ciproﬂoxacin 0.5 4 13.0 16 64 54.4
Clindamycin 0.125 256 27.1 0.06 512 43.0
Erythromycin 0.5 256 39.5 1 512 50.8
Fusidic acid 0.125 0.25 0.0 0.06 0.06 2.4
Gentamicin 0.5 256 30.6 64 256 53.2
Levoﬂoxacin 0.25 1 9.0 4 16 52.8
Linezolid 2 2 0.0 1 2 0.0
Mupirocin 0.25 0.25 0.3 0.125 0.25 0.9
Rifampicin 0.03 0.03 6.9 0.015 256 24.8
Tetracycline 0.5 128 37.0 0.5 64 41.9
Co-trimoxazole* 0.125 0.5 0.8 0.06 0.25 0.17
Vancomycin 1 1 0.0 1 1 0.0
*MIC values are indicated for trimethoprim.
P1077 Susceptibility of Staphylococcus aureus in community
settings: ﬁrst Russian surveillance
A. Nikulin, A. Dekhnich °, N. Ivanchik, R. Kozlov (Smolensk, RU)
Objectives: To evaluate antimicrobial susceptibility of community-onset
strains of S. aureus in different regions of Russia.
Methods: A total of 417 clinical community-onset S. aureus strains were
collected from 12 cities during multicentre study. Susceptibility testing to
15 antimicrobials was performed by CLSI agar dilution method. CLSI
2008 criteria were used for the interpretation of susceptibility testing
results (with the exception of fusidic acid, for which the criterion of
French Society for Microbiology was applied).
Results: Only 3.8% of strains were resistant to oxacillin. In general,
all tested antibimisrobials revealed good activity against MSSA.
At the same time MRSA strains were much less susceptible than
MSSA to ﬂuoroquinolones, macrolides, lincosamides, tetracyclines,
aminoglycosides and chloramphenicol. Overall MICs and resistance rates
of tested strains are presented in the Table.
Antibiotic MIC50 MIC90 S (%) I (%) R (%)
Chloramphenicol 8 64 73.6 0 26.4
Ciproﬂoxacin 0.5 1 93.3 1.9 4.8
Clindamycin 0.06 0.125 95.4 0 4.6
Erythromycin 0.25 512 81.8 1.0 17.2
Fusidic acid 0.06 0.125 100 0 0
Gentamicin 0.5 1 96.3 0 3.8
Levoﬂoxacin 0.125 0.25 96.2 0 3.8
Linezolid 2 2 100 0 0
Mupirocin 0.125 0.25 100 0 0
Netilmicin 0.25 0.5 99.5 0.2 0.3
Oxacillin 0.5 0.5 96.2 0 3.8
Rifampicin 0.015 0.015 98.8 0 1.2
Tetracycline 0.5 32 84.4 0.2 15.3
Co-trimoxazole* 0.06 0.06 100 0 0
Vancomycin 1 1 100 0 0
*MIC values are indicated for trimethoprim.
Conclusion: Overall resistance rates in S. aureus, including MRSA
incidence, in the community settings are relatively low in Russia. It
is necessary to perform further investigation to assess the dynamics and
epidemiology of resistance.
P1078 Community-associated methicillin resistant Staphylococcus
aureus: a retrospective epidemiological study of cases
reported in Canton Ticino, Switzerland, between 2002 and
2008
A. Parini, V. Gaia, O. Petrini, C. Balmelli, E. Bernasconi ° (Lugano,
Bellinzona, CH)
Objectives: To characterise the clinical and microbiological epidemiol-
ogy of community-associated methicillin resistant Staphylococcus aureus
(CA-MRSA) in Southern Switzerland (Canton Ticino).
Methods: We analyzed all cases of MRSA reported to the Can-
tonal Institute of Microbiology in Bellinzona between 1.1.2002 and
31.12.2008. CA-MRSA were deﬁned on the basis of their susceptibility
to ciproﬂoxacin; resistance to gentamycin, tetracycline or to the
combination of sulfamethoxazole and trimethoprim (SMX/TMP); and
production of Panton-Valentine leukocidin (PVL). The CA-MRSA
strains were analyzed by spa-typing and for the presence of the cassette
chromosome (SCCmec) alleles IV and V. An epidemiological deﬁnition
for CA-MRSA (CDC criteria) was also used if epidemiological and
clinical data were available.
Results: During the study period 1793 MRSA strains were isolated.
250 (13.9%) were classiﬁed as CA-MRSA. The number of CA-
MRSA isolates per year remained virtually unchanged (average: 35).
Ciproﬂoxacin-resistant strains decreased over time from 69.7% in 2002
to 36.1% in 2008, while resistance to tetracycline and SMX/TMP tended
to increase (tetracycline: 15.1% in 2002, 27.8% in 2008; SMX/TMP:
9.1% in 2002, 27.8% in 2008). Resistance to gentamycin appeared to
decline (70% in 2002 vs. 25% in 2008). In the preliminary analysis,
CA-MRSA carriers deﬁned by epidemiological criteria were typically
young (median age 32.5, range 20−52), predominantly female (62.5%),
and without signiﬁcant co-morbidities. Patients presented with skin,
soft tissue or ocular infections; no case of necrotising pneumonia was
observed. 83.3% of the CA-MRSA with available epidemiological and
clinical information were PVL positive.
Conclusions: In Southern Switzerland the number of newly identiﬁed
CA-MRSA strains per year has remained unchanged over the last 5 years.
The isolates were mostly sensitive to several classes of antibiotics, but
we observed an increase of CA-MRSA strains resistant to tetracycline
and SMX/TMP. On the contrary, there was a decrease in the resistance
to ciproﬂoxacin and gentamycin.
New antimicrobials against Gram-positives
P1079 Comparison of bacterial membrane active novel porphyrin
and metalloporphyrin antimicrobials
N. Ooi °, K. Miller, W. Rhys-Williams, W. Love, I. Chopra (Leeds,
Brighton, UK)
Objectives: XF-70, XF-73 and DPD-207 are novel porphyrin drug
candidates which display rapid bactericidal activity against S. aureus.
It has previously been demonstrated that the lethal anti-staphylococcal
activity of XF-73 (a non-metalloporphyrin) is due to its rapid effects on
the integrity of the cytoplasmic membrane. This study sought to compare
and contrast the mode of action of XF-73 with XF-70 (a further non-
metallo porphyrin) and DPD-207 (an iron metalloporphyrin).
Methods: The integrity of the S. aureus cytoplasmic membrane after
exposure to lethal concentrations of XF-70, XF-73 and DPD-207 and
control agents was determined using a range of techniques. Membrane
potential was measured using a DiSC3(5) ﬂuorimetric assay, leakage
of intracellular potassium and magnesium was determined by atomic
absorption spectroscopy and a luciferin/luciferase assay was used to
quantify the leakage of intracellular ATP. The morphology of cells after
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exposure to antimicrobial agents was examined by scanning electron
microscopy.
Results: Each of the porphyrins caused rapid and virtually complete
loss of ATP and potassium from the cell within 5 minutes of exposing
S. aureus to lethal concentrations of the agents. XF-70 and XF-73 had
more pronounced initial effects on the membrane potential than DPD-
207. In contrast, DPD-207 promoted greater leakage of magnesium
than XF-70 or XF-73. Pre-treatment of bacteria with the ionophore
valinomycin (which dissipates the membrane potential) delayed the
release of ATP by XF-70, but valinomycin had little effect on the
kinetics of ATP release mediated by XF-73 and DPD-207. The gross
morphological appearance of S. aureus exposed to the porphyrin agents
was unaffected compared to drug-free controls.
Conclusion: The anti-staphylococcal activity of the metallo- and
nonmetalloporphyrins studied here can be attributed to their effects on
the integrity of the cytoplasmic membrane and leakage of potassium
and ATP appear to be particularly good correlates of membrane damage
and bactericidal activity. However the insertion of these agents into
the staphylococcal membrane may differ based upon the apparent
requirement of a membrane potential for the binding of XF-70 and
differences in the ability of the porphyrins to dissipate the membrane
potential and release magnesium.
P1080 In vitro activity of delaﬂoxacin against methicillin-resistant
Staphylococcus aureus from the United States, Europe and
Asia
E. Burak °, S. Hopkins, C. Pillar, L. Lawrence (New Haven, Chantilly,
US)
Objectives: Delaﬂoxacin (DFX) is an investigational ﬂuoroquinolone
with excellent activity against a variety of Gram-positive bacteria,
including quinolone-resistant methicillin-resistant Staphylococcus aureus
(MRSA). We evaluated the in vitro activity of DFX against MRSA
from the United States (US), Europe, and Asia. The collection included
prevalent clones of MRSA (e.g. USA100 and USA300) as well as isolates
with reduced susceptibility to glycopeptides.
Methods: Minimum inhibitory concentration (MIC) values were
determined by broth microdilution according to CLSI methodology.
Comparator agents included levoﬂoxacin (LVX), linezolid (LNZ),
daptomycin (DAP), vancomycin (VAN), oxacillin (OXA), clindamycin
(CLI), erythromycin (ERY), and tigecycline (TIG).
Results: MIC values (mcg/mL) are presented below. MIC50/MIC90
values for DFX were 0.12/0.25mcg/mL against strains from Europe
(n = 387), 0.12/2mcg/mL against strains from Asia (n = 97) and
0.12/1mcg/mL against strains from the US (n = 477). In comparison,
LFX was at least 16-fold less active than DFX against these
geographically grouped strains. Against 16 genetically characterised
strains of MRSA, including USA100, USA300, and strains with reduced
susceptibility to VAN, MIC50/MIC90 values for DFX and LVX were
0.004/0.25mcg/mL and 0.5/16mcg/mL, respectively.
Agent Number of strains MIC range MIC50 MIC90
DFX 961 0.004−16 0.12 0.5
LVX 961 0.03−>32 8 >32
LNZ 961 0.25−2 1 1
DAP 946 0.25−4 1 1
VAN 961 0.25−2 0.5 0.5
CLI 961 0.03−>8 0.12 >8
ERY 961 0.12−>16 >16 >16
TIG 961 0.015−0.5 0.06 0.12
OXA 961 4−>8 >8 >8
Conclusions: DFX was more potent than LVX against MRSA, regardless
of geographic region. The activity of DFX was largely consistent across
regions, although isolates with higher DFX MIC values were more
frequently encountered in Asia. Against characterised epidemic MRSA
isolates, including 2 strains with reduced susceptibility to VAN, DFX
maintained potent activity superior to that of levoﬂoxacin.
P1081 A novel antibacterial protein which shows rapid bactericidal
activity against MRSA in the presence of other antibiotics
S. Mushtaq, D. Livermore, A. Wilkinson, H. Fairhead ° (London,
Cambridge, UK)
Objectives: SASP are small acid-soluble spore proteins which, when
expressed in vegetative bacteria, are rapidly bactericidal. SASP bind
to bacterial DNA in a non-sequence-speciﬁc manner and inhibit DNA
replication and transcription. SASPject technology consists of using
speciﬁcally tailored delivery vectors to deliver SASP genes to selected
target bacteria. In practice, antibiotics are sometimes co-administered
and Phico’s S. aureus speciﬁc SASPject, PT1.2, could be suitable for
such use, particularly where efﬁcacy against MRSA is required. To
assess whether SASP efﬁcacy is compromised in the presence of other
antibiotics, time-kill assays were conducted with PT1.2 in combination
with 5 separate antibiotics at various concentrations.
Methods: Dilutions of an overnight culture of EMRSA 15 (CC22
SCCmecIV) (107 cfu/ml ﬁnal concentration) were incubated with
PT1.2 (1.5×108 pfu/ml ﬁnal concentration) in Luria-Bertani broth
supplemented with calcium, together with each of vancomycin (Van),
tetracycline (Tet), linezolid (Lin), ciproﬂoxacin (Cip) or rifampicin (Rif)
at 0.1, 0.3, 1 or 3×MIC. Controls comprised each antibiotic alone and
PT1.2 alone. The cultures were incubated at 37ºC and samples were
taken at 0, 0.25, 0.5, 1, 2, 6 and 24 hours to assess cell viability.
Results: SASP was rapidly bactericidal against MRSA, causing a 4-
log10 drop in viability within 15 minutes. The rate and extent of kill was
equal in all cultures containing PT1.2, showing that Van, Tet, Lin, Cip
and Rif, between 0.1 and 3×MIC did not affect the efﬁcacy of SASP
against MRSA.
Conclusions: SASP is equally effective in the absence or presence
of antibiotics with varying mechanisms of action, covering inhibition
of cell wall biosynthesis (Van), protein synthesis (Tet, Lin), mRNA
synthesis (Rif), and DNA replication (Cip). Thus PT1.2 could be used in
combination with these (or potentially other) antibiotics, or when other
antibiotics are present, without affecting efﬁcacy.
P1082 Studies on resistance development to LTX-109, a novel
antimicrobial peptide
I. Morrissey °, A. Fugelli, W. Stensen, J.S. Svendsen (Fordham, UK;
Tromso, NO)
Objectives: LTX-109 (LTX) is a novel broad-spectrum antimicrobial
peptide currently being developed as a topical agent for the treatment of
skin infections. In vitro studies have shown LTX activity is unaffected
by resistance to established antibiotics. We assessed in vitro resistance
development using LTX
Methods: Resistance to LTX was compared with fusidic acid (FUS), a
commonly used topical antibacterial agent using the following S. aureus
strains: ATCC 29213 − susceptible reference strain; ATCC 433300 −
methicillin-resistant; Mu50 − vancomycin-intermediate; VRS1 − fully
vancomycin-resistant and GP06 − teicoplanin-intermediate. Spontaneous
resistance to LTX was assessed by subculture on agar plates in the
presence of 2×, 4× and 8× MIC using 1mL suspensions of bacteria at
~1010 per mL. Selection and ampliﬁcation of resistance was determined
by 14 serial passages in a macrobroth culture containing 0.5×MIC.
Results: Using selection on agar no resistant mutants were obtained
with LTX. In contrast, each experiment using FUS resulted in conﬂuent
growth. Raised MICs were conﬁrmed on each occasion by sub-
culturing onto selective plates containing FUS at the original selecting
concentration.
During serial passage, fusidic acid MIC increased sharply. In stark
contrast, LTX showed little change in MIC over the 14 passages (P0
to P14, see Table).
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Strain MIC (mg/L)
FUS LTX
P0 P14 P0 P14
29213 0.06 512 2 4
433300 0.06 64 2 4
VRS1 0.06 32 1 8
Mu50 0.03 16 1 2
GP06 1 128 2 8
These data concur with the spontaneous resistance results indicating that
resistance to LTX109 is not observed using either method of analysis.
Conclusion: LTX109 may be a valuable new agent for treating S. aureus
infections, with a low propensity for resistance development in vitro.
Further studies are warranted.
P1083 Speciﬁc anti-staphylococcal activity of AFN-1252, a novel
fatty acid synthesis inhibitor
N. Kaplan °, J.A. Karlowsky, G.G. Zhanel, D. Sweeney, G. Zurenko,
B. Hafkin (Toronto, Winnipeg, CA; Kalamazoo, US)
Objectives: AFN-1252, a new molecular entity and lead clinical
candidate, is a potent inhibitor of staphylococcal FabI (enoyl-ACP
reductase [ENR]), an essential enzyme in bacterial fatty acid synthesis.
AFN-1252 is currently in Phase 1 studies as an oral, speciﬁc-spectrum
anti-staphylococcal antibiotic. Due to AFN-1252’s speciﬁcity for FabI,
it is expected that bacterial species possessing alternate ENR forms will
not be susceptible to its inhibition. To further assess the AFN-1252
spectrum, a phylogenetic analysis of bacterial ENR was performed and
in vitro activities against staphylococci, and other aerobic and anaerobic
bacteria were determined.
Methods: Phylogenetic trees were constructed with PHYLIP 3.52 using
protein sequences from the NCBI Refseq database. Bacterial strains for
susceptibility testing included 3,333 recent clinical isolates from 12
Canadian medical centres and characterised VISA and VRSA strains
from NARSA. MICs were determined using CLSI methods.
Results: Four distinct bacterial ENR isozymes (FabI, FabL, FabV, FabK)
were delineated by phylogenetic analyses. Of the 123 representative
aerobic and anaerobic species analyzed, only 44 species had FabI only.
For species that had FabI only, the FabI amino acid sequence identity was
divergent compared to Staphylococcus spp. Other species had alternate
or more than one form of ENR. AFN-1252 showed highly potent
activity (MIC90 of 0.016 ug/ml) against all staphylococci including both
susceptible and all drug resistant strains (e.g. MRSA, MRSE, VISA), but
poor or no activity against all other aerobic and anaerobic Gram-negative
and -positive species tested.
Conclusions: AFN-1252 showed a highly potent and selective spectrum
of anti-staphylococcal activity. Species non-susceptible to AFN-1252 had
either a non-FabI ENR enzyme, multiple ENR forms or an essential FabI
that was highly divergent from the Staphylococcus spp. enzyme. The
AFN-1252 speciﬁc-spectrum highlights the lack of resistance selection of
AFN-1252 within the normal bacterial ﬂora. The apparent lack of activity
against common gut and skin ﬂora also highlights its potential safety
beneﬁts including fewer adverse effects due to antimicrobial therapy
such as diarrhoea, antibiotic induced colitis, C. difﬁcile infections and
candidiasis. These data support the continued development of AFN-1252
as a safe, targeted, oral therapy against staphylococcal infections.
P1084 In vitro activity of AFN-1252 against MRSA in mouse and
human serum
N. Kaplan °, R. Hinshaw, G. Zurenko, B. Hafkin (Toronto, CA;
Kalamazoo, US)
Objectives: AFN-1252, a new molecular entity and lead clinical
candidate, is a potent inhibitor of staphylococcal FabI (enoyl-ACP
reductase), an essential enzyme in bacterial fatty acid synthesis. AFN-
1252 is currently in Phase 1 studies as an oral, speciﬁc-spectrum anti-
staphylococcal antibiotic. Previous AFN-1252 in vitro human plasma
protein binding studies showed values ranging from 89% to 98% using
ultraﬁltration or equilibrium dialysis methods. To better deﬁne human
PK/PD targets, including desired free AFN-1252 plasma concentrations,
the effects of mouse and human serum on in vitro killing activity of
AFN-1252 were determined.
Methods: Staphylococcus aureus 1659 (HA-MRSA) was used as test
organism. Pooled mouse and human sera were both decomplemented
by heat inactivation and ﬁlter-sterilised. Time-kill experiments using
standard techniques were conducted in Mueller Hinton Broth diluted
(v/v) with 0%, 25%, 50%, 75% or 90% serum. AFN-1252 was tested at
concentrations ranging from 4 to 64 times the MIC. Plots of the change
in log CFU/ml (compared to time 0) versus AFN-1252 concentration at
various time points were ﬁtted using inhibitory effect models. Apparent
plasma protein binding values were calculated from the ratios of AFN-
1252 concentrations required to achieve deﬁned levels of bacterial killing
in serum versus no-serum controls.
Results: The maximum serum concentration that supported adequate
bacterial growth and killing effects was 75%. Under these conditions
AFN-1252 showed apparent human plasma protein binding values of
92.5%, 93.8% and 94.4% at the 0 log kill (stasis), −1 log kill and
−1.5 log kill (compared to time 0) points, respectively. The apparent
mouse plasma protein binding values were very similar to the human
values.
Conclusions: An apparent plasma protein binding value of approxi-
mately 95% was determined in both mouse and human serum. The
time-kill experiments in mouse and human serum greatly assisted in
deﬁning a free drug concentration required to achieve bacterial killing
in serum and provide a viable alternative to in vitro analytical methods. In
addition these data suggest that AFN-1252 PK/PD parameters (expressed
as total drug concentrations) derived from mouse infection models may
be directly applicable to human infections.
P1085 MUT056399: a novel antibacterial against methicillin-
resistant staphylococci
S. Escaich °, F. Moreau, E. Malacain, S. Floquet, A. Walton,
V. Sam-Sambo, V. Vongsouthi, L. Durant, C. Soulama, F. Faivre,
Y. Bonvin, M. Oxoby, V. Gerusz (Romainville, FR)
Objectives: MUT056399 is a novel antimicrobial agent targeting the
essential enzyme FabI which catalyzes the ﬁnal step of bacterial fatty acid
elongation cycle. In this study, the biochemical activity of MUT056399
is presented along with its in vitro antibacterial activity.
Methods: IC50 s were measured on puriﬁed FabI of Staphylococcus
aureus. MIC testing and time-kill studies were performed according to
CLSI methodologies. Cytotoxicity was measured using the HepG2 cell
viability assay.
Results: MUT056399 is a highly potent slow binding inhibitor of
FabI of S. aureus with an IC50 of 13nM. MUT056399 displayed an
antibacterial spectrum consistent with speciﬁc FabI inhibition: a high
potency against methicillin susceptible and resistant staphylococci (mode
MIC 0.06mg/ml), an intermediate activity against Escherichia coli,
and no activity against FabK containing bacteria (streptococci and
enterococci). The MIC of MUT056399 on agar medium against 10
S. aureus strains was not signiﬁcantly inﬂuenced by pH, divalent cations,
NaCl and incubation temperature. It was only slightly inﬂuenced by
inoculum size (2-fold when raised from 104 to 106 CFU/spot). Time
kill studies showed a time-dependent mechanism of killing and a slow
bactericidal effect for S. aureus ATCC 29213. Frequency of resistance
was 2.5×10−9 at 4×MIC. MUT056399 did not show any cytotoxicity
for eukaryotic cells up to 32 mg/ml.
Conclusion: MUT056399 is a highly potent antistaphylococcal agent
with a new mechanism of action targeting FabI. It was particularly
active against methicillin susceptible and resistant S. aureus strains with
stable MICs among testing conditions, a slow bactericidal activity, low
frequency of resistance at 4×MIC, and no cytotoxicity up to 32 mg/ml.
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These properties support MUT056399 as a very promising new chemical
entity for clinical development as a new drug to treat staphylococcal
infections.
P1086 Farnesol as a prospective antimicrobial agent against
Staphylococcus epidermidis
F. Gomes °, N. Cerca, P. Teixeira, R. Oliveira (Braga, PT)
Objectives: Staphylococcus epidermidis is now among the most
important pathogenic agents responsible for bloodstream nosocomial
infections and for bioﬁlm formation on indwelling medical devices.
Its increasing resistance to common antibiotics is a challenge for the
development of new antimicrobial agents. Accordingly, the goal of this
study was to evaluate the effect of farnesol, a natural sesquiterpenoid,
on Staphylococcus epidermidis bioﬁlm cells and compare this one with
the effect of vancomycin, one of the most frequently used antibiotics
to treat resistant nosocomial infections. Another aim of this work was
to determine if subjecting S. epidermidis cells to farnesol they acquire
resistance.
Methods: A 24 h kinetic study was performed using vancomycin at the
peak serum concentration (40mg/L) and farnesol at concentrations of 30,
100, 200 and 300 microM. The growth inhibition effect of farnesol and
vancomycin on bioﬁlm cells of S. epidermidis was assessed by XTT (the
reduction of this tetrazolium salt is a measure of cellular activity and is
easily assessed by colorimetry) and Crystal Violet, which measures total
biomass of bioﬁlm. The bioﬁlm cells were analysed by confocal laser
scanning microscopy after being stained with Live/Dead. Resistance to
farnesol and vancomycin was tested growing S. epidermidis planktonic
cells in sub-inhibitory concentrations of farnesol and vancomycin
and then subjecting these cells to inhibitory concentrations of both
antimicrobial agents during 24 hours. After that, cellular activity was
assessed by XTT. This was repeated for 5 consecutive days.
Results: Both tested agents act at the cell wall level, vancomycin inhibits
the biosynthesis of bacterial cell wall, while farnesol is considered to
disrupt the normal barrier function of the cell membrane. Interestingly,
farnesol at a concentration higher than 200 microM displayed the same
or higher effectiveness of vancomycin at peak serum concentration. In
fact, the response of the strains tested was very similar for both farnesol
(>200microM) and vancomycin. Regarding cells resistance to farnesol,
the results point out to a slight increase of tolerance but not to an acquired
resistance, because the percentage of inhibition was steady along the
time.
Conclusions: Overall, the results indicate a potential antibacterial effect
of farnesol against S. epidermidis, and therefore the possible action of
this molecule on the prevention of S. epidermidis related infections.
P1087 The potential of the breakdown products of casein by
Lactococcus lactis strain 146 as an inhibitory therapeutic
agent(s) for MRSA
M. Al-Mahrous °, M. Alqamber, J. Burnie, M. Upton, J. Tagg
(Manchester, UK; Dunedin, NZ)
Objective: lactococci possess a proteolytic system that can release free
amino acids, peptides and oligopeptides from casein (milk protein). The
proteolysis involves the action of cell wall-associated peptidases (CWAP)
and subsequent hydrolysis is carried out by several enzymes found in
the cell envelope; which can eventually be taken up by the bacteria. This
fermentation process results in milk diaries ﬂavour and proteinacious
end-products. The objective of the current study was to investigate the
end-products of casein degradation by Lactococcus lactis strain 146, as
inhibitory agents for MRSA.
Methods:
1. Investigation of the end-products of L. lactis strain 146 was
performed using plate-diffusion method from casein-containing
minimum essential media (MEM).
2. Casein-free MEM was used as a negative control for the inhibitory
end-products, on which alternative growth factors were included.
3. Puriﬁcation and/or concentration of the end-products in broth
supernatants was carried out using ammonium-sulphate precipitation,
XAD-2 resin separation, cation-exchange; then C18 reverse-phase
chromatography.
4. MALDI TOF/TOF mass-spectrometry (MS) was used for mass
analysis.
5. A range of published and/or designed primers was used for PCR of
gene(s) responsible for the synthesis of CWAP in strain 146.
6. The gene was cloned using T-tailed vector; and then sequenced.
Results: Supernatant from casein-containing media displayed activity
against MRSA, but not the casein-free media. The reversed-phase HPLC
proﬁle of the processed active fractions revealed several peptide species
(Fig. 1). In addition, determining the mass of the peptides with MS
showed that they were seized in a window of 0.9 and 5 kD. Among
the tested primers, BG95/146CEP–invlwoer1; BG97/146CEP–invlwoer1;
BG95/4CA showed positivity with strain 146 on PCR. However, cloning
was successful; the sequence data of the vector still needs further
analysis.
Conclusion: The effect of the breakdown-products of casein by L. lactis
strain 146 against MRSA suggests the potency of these peptides as future
therapeutic agents for treating highly drug-resistant Staphylococcus
aureus, on which the cloned vector or the sue of strain 146 can be
a powerful biological tool for the breakdown of casein by its CWAP. Up
to our knowledge, this is the ﬁrst study that discusses casein breakdown
products by L. lactis and their activity against staphylococci.
Figure 1. Detection of peptide species of casein breakdown products by
Lactococcus lactis strain 146 using mass spectrometry. Resulting amino
acids were detected on a time-of-ﬂight (TOF) mass spectrometer with
matrix-assisted-laser-desorption ionisation (MALDI).
P1088 The potential of the naturally produced inhibitory
substance (A345) as a potential therapeutic agent for
treating Staphylococcus aureus
M. Al-Mahrous °, J. Burnie, J. Tagg, M. Upton (Manchester, UK;
Dunedin, NZ)
Objectives: In recent years, there has been much focus on a promising
class of bacteriocins known as lantibiotics. The most prominent
representative of lantibiotics, nisin, has already a long history of use
in the protection of foodstuffs. Lantibiotics have also been considered
for application in humans; however they have not yet been used in the
setting of chemotherapy on the same scale as traditional antibiotics.
We here investigate the cationic peptide antibiotic (A345) as a future
opportunity for treating staphylococcal infections.
Methods: 1. Investigation of S. aureus strain A345 was performed using
simultaneous and deferred-antagonism against MRSA.
3. Puriﬁcation and/or concentration of free inhibitors in broth
supernatants was carried out using ammonium-sulphate precipitation,
Sep-Pak® cartridge, Speed-Vac®, Cation-exchange; then C18 reverse-
phase chromatography.
6. MALDI TOF/TOF was used for mass analysis.
7. Electron microscopy was used for ultra-structure diagnosis.
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8. Biological activities were tested using spot-on-loan assay.
Results: The biological activity of A345 is heat-stable and displaying
speciﬁcity for the closely-related S. aureus.
The high ammonium-sulphate saturation (more than 80%) needed for
precipitating A345 suggests its small mass. The cationic-exchange
chromatography (pH 5.2) and the late elution from C18 column suggest
the cationic nature of A345. MALDI TOF/TOF showed 4 species and
sized the mass in a window between 1500.2 and 3200.7 Da. This suggests
further puriﬁcation using high resolution HPLC to eliminate, if any,
unrelated species.
The Electron microscopy diagnosis reveals a clear damage in the cell
wall (Figure 1).
Figure 1. Thin section of EMRSA-15 strain A208 cell wall after
incubation with the inhibitory substance A345 for 24 h at 37ºC. An
example of a ruptured wall is seen.
Conclusion: 1. The biological activity of the highly-puriﬁed extract of
the heat-stable small mass inhibitory agent A345, which shows speciﬁc
inhibitory activity against Epidemic MRSA-15 and strains of MSSA,
suggests its nature as a bacteriocin, possibly of Class-I.
3. The cationic-exchange separation and late elution of A345 from C18
reverse-phase column suggest that it is a hydrophobic in nature.
4. Based on the electron microscopy diagnosis, A345 shows obvious
damage to the protective cell wall of the sensitive indicators. This
postulates the binding of the hydrophobic A345 to negatively-charged
lipid-II in the cell-membrane resulting in its lysis.
6. A345 could have potential as topical therapeutic agents for treating
highly drug-resistant staphylococcal infections.
P1089 The safety of multiple ascending oral doses of TR-701, a
novel oxazolidinone prodrug antibiotic
P. Bien, P. Prokocimer °, K.A. Munoz, J. Bohn (San Diego, Madison, US)
Objectives: TR-701, a novel oxazolidinone prodrug antibiotic of the
microbiologically-active moiety TR-700 is primarily active against
Gram-positive organisms. A randomised, double-blind, placebo- and
active-controlled, 21-day oral dose study of TR-701 was performed.
Methods: 40 healthy male and female subjects were enrolled in cohorts
of 10 subjects each (8 active and 2 placebo), and received 21-days of
single oral doses of 200, 300, or 400mg TR-701, or 600mg linezolid
twice-daily. Both drugs were administered under fasting conditions.
Safety was assessed via adverse events (AEs), physical examination,
ECG and laboratory evaluations. Reporting of AEs was solicited
proactively in subjects conﬁned for 25 days.
Results: 135 treatment-emergent AEs were reported by 26 subjects
as indicated below. The most common AEs reported following
administration of TR-701 were nausea and headache (5 subjects each
[20.8%]), and stomach discomfort (4 subjects [16.7%]). No clinically
signiﬁcant changes or ﬁndings were noted in vital sign measurements,
physical examinations, or 12-lead ECGs. However, there were clinically
signiﬁcant values and changes in some laboratory evaluations. 4 subjects
were discontinued due to laboratory AEs: 2 subjects (1 receiving 400mg
TR-701 and 1 receiving linezolid) had decreased reticulocytes, 1 subject
receiving 400mg TR-701 had a low WBC count present at baseline
which further decreased, and 1 subject receiving 200mg TR-701 had
elevated liver ALT values (5 times ULN). There were no deaths or SAEs
reported.
Conclusions: Multiple doses of 200mg or 300mg TR-701 through
21 days were well-tolerated. Multiple doses of 400mg TR-701 presented
a slightly higher incidence of AEs. TR-701 400mg QD and linezolid
600mg BID presented comparable effects on haematologic parameters.
Summary of subjects with adverse events after multiple ascending oral doses of TR-701
Number of Subjects (%)
Placebo TR-701 QD Linezolid
200mg 300mg 400mg 600mg
BID
n= 8 n = 8 n = 8 n = 8 n = 8
Any AE within 21 days 5 (62.5) 5 (62.5) 5 (62.5) 7 (87.5) 4 (50)
Mild 5 (62.5) 5 (62.5) 5 (62.5) 7 (87.5) 4 (50)
Moderate 1 (12.5) – 2 (25) 3 (37.5) 1 (12.5)
Severe – – – – –
Treatment-related AEs
during 21 days of drug administration 4 (50) 4 (50) 4 (50) 7 (87.5) 4 (50)
during the ﬁrst 7 days of drug administration 2 (25) – 1 (12.5) 5 (62.5) 2 (25)
AEs leading to study discontinuation – 1 (12.5) – 2 (25) 1 (12.5)
Serious AEs – – – – –
P1090 The safety of single ascending oral doses of TR-701, a novel
oxazolidinone prodrug antibiotic
P. Bien, K.A. Munoz, P. Prokocimer °, J. Bohn (San Diego, Madison, US)
Objectives: The prodrug TR-701 is a novel oxazolidinone prodrug
antibiotic that is rapidly converted in vivo by blood and tissue
phosphatases, to the microbiologically-active molecule TR-700. TR-
700 is active against Gram-positive bacteria, including methicillin-
resistant Staphylococcus aureus (MRSA) and vancomycin-resistant
enterococci (VRE). A randomised, double-blind, placebo-controlled,
single ascending oral dose study was performed to assess the safety,
tolerability, and PK of TR-701 in healthy adult subjects.
Methods: 40 healthy male and female subjects were enrolled in this
double-blind, sequential-dose escalation study. Cohorts of 8 subjects (6
active and 2 placebo) received a single dose of 200, 400, 600, 800, or
1200mg oral TR-701 after a 10-hr fast. Safety was assessed via adverse
events, physical examination, ECG and laboratory evaluations. Adverse
events (AEs) were solicited proactively by asking multiple “how do you
feel?” questions.
Summary of subjects with adverse events after single ascending oral doses of TR-701
Number of Subjects with AEs (%)a
Placebo TR-701
200mg 400mg 600mg 800mg 1200mg Overall
n = 10 n = 6 n = 6 n = 6 n = 6 n = 6 n = 30
Any AEb 0 4 (66.7) 2 (33.3) 3 (50.0) 1 (16.7) 3 (50.0) 13 (43.3)
Treatment-related AEs 0 3 (50.0) 0 3 (50.0) 1 (16.7) 3 (50.0) 10 (33.3)
aEach subject with any AE(s) is counted once.
bAll events were reported as “mild”.
Results: 28 treatment-emergent AEs were reported by 13 subjects
receiving TR-701 and no AEs were reported by subjects receiving
placebo. 19 AEs were considered treatment-related. All AEs were
considered “mild” in severity. There were no apparent dose-related trends
in AE reporting. Similar numbers of AEs were reported in each cohort
with the greatest number occurring following administration of 200mg
TR-701. AEs reported in at least 2 subjects receiving TR-701 were:
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nausea (3 subjects [10.0%]), dizziness, diarrhoea, and nasal congestion
(2 subjects each [6.7%]). There were no deaths, Serious AEs, or
discontinuations due to AEs. No clinically signiﬁcant changes or ﬁndings
were noted in clinical laboratory evaluations, vital sign measurements,
physical examinations, or 12-lead ECGs. Overall, changes in safety
evaluations were unremarkable.
Conclusions: TR-701 is safe and well tolerated in healthy volunteers at
single doses up to 1200mg.
P1091 Effects of food on the pharmacokinetics of TR-701, a novel
oxazolidinone prodrug antibiotic, in healthy adult subjects
K.A. Munoz, P. Bien, P. Prokocimer °, M. Berry, C. Bethune (San
Diego, Madison, US)
Objectives: TR-701 is a novel oxazolidinone prodrug antibiotic that
is rapidly converted in vivo to the microbiologically-active molecule
TR-700. TR-700 is active against Gram-positive bacteria, including
methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-
resistant enterococci (VRE). A randomised, open label, 2-sequence,
2-period, 2-treatment crossover, single oral dose study was performed
to evaluate the safety, tolerability, and effect of food on the
pharmacokinetics (PK) of TR-701 in 12 healthy adult subjects.
Methods: Subjects received a single oral dose of 600mg TR-701 after
a 10-hr fast or after eating a high-fat breakfast preceded by a 10-hr fast.
Results: TR-701 was rapidly and extensively converted to TR-700. In
the fed state, the mean TR-700 Cmax was signiﬁcantly (26%) lower than
that observed in the fasted state. A 6-hour delay in TR-700 median Tmax
was observed in the fed compared to the fasted state. The mean TR-700
AUC0-t and AUC0-inf values in the fed state were similar (within 2%) to
the corresponding values in the fasted state. TR-701 600mg was well-
tolerated and no signiﬁcant clinical or laboratory abnormalities were
reported. 8 mild AEs were reported by 6 subjects, with 5 reported in
the fed state and 3 reported in the fasted state. Two treatment-related
AEs, gastro-oesophageal reﬂux disease (fed) and insomnia (fasted), were
reported by a single subject each. There were no apparent trends in
AEs and no AE was reported more than once. No clinically signiﬁcant
changes or ﬁndings were noted from clinical laboratory evaluations,
vital sign measurements, physical examinations, or 12-lead ECGs. There
were no SAEs or deaths during this study and no AE led to study
discontinuation.
Conclusions: Single oral doses of 600mg TR-701 administered in the
fed and fasted state were well tolerated. Administration of TR-701
after a high-fat meal increased Tmax and decreased Cmax, but did
not affect the extent of TR-700 exposure (AUC). Since AUC is the
main PK/pharmacodynamic (PD) driver of efﬁcacy for oxazolidinones,
the present study provides evidence that TR-701 can be administered
regardless of the timing of meals.
P1092 TR-700, a novel methyltetrazolyl-oxazolidinone, accumulates
extensively within human macrophages cells and shows
activity towards intraphagocytic linezolid-sensitive and
linezolid-resistant S. aureus
S. Lemaire °, K. Kosowska-Shick, P. Appelbaum, F. Van Bambeke,
P. Tulkens (Brussels, BE; Hershey, US)
Background: Treatment of intracellular infections requires that antibi-
otics reach their intracellular target and express activity therein. Linezolid
accumulates poorly within cells, and shows only modest intracellular
activity against S. aureus or S. epidermidis (Barcia-Macay et al, AAC,
2006; Pascual et al, AAC, 2002). The aim of this study was to examine
the cellular pharmacokinetic properties and intracellular activity of TR-
700 towards S. aureus, in light of the higher lipophilicity and intrinsic
activity of this molecule vs linezolid.
Methods: Human THP-1 macrophages were used throughout this study.
Accumulation of both oxazolidinones was measured by microbiological
assay, using S. aureus ATCC 25923 as test organism. The phenotypes
of the strains used are shown in Table 1. MICs were determined
in MHB. Intracellular activity was determined over a large range of
extracellular concentrations (typically 0.01 to 100-fold the MIC to obtain
full description of concentration-effect relationships) against bacteria
phagocytised by human THP-1 macrophages (see details in Barcia-
Macay et al, AAC, 2006). Results are expressed here as (i) bacteriostatic
concentration (SC), and (b) maximal effect (Emax) at 24 h compared to
time 0 h (post-phagocytosis) as calculated from the Hill functions ﬁtted
to the data by non-linear regression.
Results: TR-700 accumulated quickly and extensively in macrophages,
within 15 minutes reaching an apparent cellular to extracellular
concentration ratio of about 13 vs 1−2 for linezolid. MICs in broth
(mg/L) and intracellular activities are shown in Table 1.
Organisms Linezolid TR-700
MIC intracell. activity MIC intracell. activity
(broth) SCa Emaxb (broth) SCa Emaxb
ATCC 25923 2 ~4.5 −0.4±0.1 0.25 ~1.0 −0.6±0.1
SA 238 c 2 ~5.8 −0.3±0.1 0.25−0.5 ~0.5 −0.7±0.1
SA 238 c 16 >100* +0.2±0.1 1 ~1.0 −0.6±0.1
CM-05 d 8 ~21.3 −0.5±0.3 0.25−0.5 ~0.7 −0.6±0.1
aExtracellular antibiotic concentration (mg/L) yielding no apparent
change in cfu after 24 h compared to post-phagocytosis inoculum.
bMaximal decrease in intracellular cfu (log scale) compared to the post-
phagocytosis inoculum.
cStrains selected in the laboratory, dlinezolid-resistant MRSA clinical
isolate carrying the cfr methyltransferase gene.
*Bacterial growth in all conditions.
Conclusions: Compared to linezolid, TR-700 shows increased potency
(lower bacteriostatic concentrations) towards intraphagocytic S. aureus
(unaffected by resistance of the strain to linezolid), probably in relation
with its extensive accumulation within cells and its higher intrinsic
activity (lower MIC values).
P1093 Ceftaroline activity tested against common organisms
causing skin and skin-structure infections in European
medical centres during 2008
R. Jones, G. Moet, H. Sader ° (North Liberty, US)
Objectives: To assess the activity of ceftaroline and comparator agents
tested against SSSI pathogens. Ceftaroline is the bioactive metabolite of
ceftaroline fosamil, a N-phosphonoamino water-soluble cephalosporin
prodrug. Ceftaroline is active against methicillin-resistant S. aureus
(MRSA) and other resistant pathogens and is under evaluation for
treatment of skin and skin-structure infections (SSSI) in clinical trials.
Methods: Unique (1 per patient) clinically signiﬁcant isolates of
S. aureus (2168), b-haemolytic streptococci (BHS; 172), viridians
group streptococci (VGS; 86), and E. faecalis (409) were consecutively
collected from 24 medical centres in 10 European (EU) countries,
Turkey and Israel in 2008. The strains were tested for susceptibility (S)
by the CLSI broth microdilution method (M7-A7; M100-S18) against
ceftaroline and numerous antimicrobials currently available for SSSI
treatment.
Results: 25.4% of S. aureus isolates were MRSA. Ceftaroline was
very active against methicillin-susceptible S. aureus (MSSA; MIC90,
0.25mg/L) and MRSA (MIC90, 2mg/L). Against MSSA, ceftaroline was
16-, eight- and four-fold more potent than ceftriaxone (CRO), linezolid
(LZD) and vancomycin (VAN), respectively. The highest ceftaroline
MIC among MSSA was 1mg/L, and 90.9 and 99.8% of strains were
inhibited at 0.25 and 0.5mg/L, respectively. Among MRSA, 97.8%
of strains were inhibited at 2mg/L of ceftaroline. All MRSA strains with
ceftaroline MICs of >2mg/L (12 strains at 4mg/L) were found in Greece
(2 centres). MRSA showed high rates of resistance (R) to levoﬂoxacin
(LEV; 84.4%) and clindamycin (CLI; 35.1%). Only 85.8% of MRSA
strains were quinupristin/dalfopristin-S. Against BHS, ceftaroline was
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64- and 32-fold more potent than LZD and VAN, respectively, and all
strains were inhibited at 0.06mg/L of ceftaroline. VGS were very S
to ceftaroline, while 79.1 and 90.7% of strains were S to penicillin and
CRO, respectively. More than 90% of E. faecalis, including all VAN-R
isolates (VRE) were inhibited by 8mg/L of ceftaroline. Four of 5 VRE
were from Greece.
Conclusions: Ceftaroline demonstrated broad-spectrum and high activity
against the most common SSSI Gram-positive pathogens, including
MRSA, isolated in EU medical centres in 2008. This favourable
antimicrobial proﬁle demonstrates that ceftaroline is a promising anti-
MRSA therapeutic option in the treatment of SSSI.
Organism (no.) MIC90 (mg/L)/% Susceptible
Ceftaroline CRO LEV CLI LZD VAN
MSSA (1617) 0.25/NA 4/99.8 0.5/94.6 0.25/98.0 2/100.0 1/100.0
MRSA (551) 2/NA >32/0.0 >4/14.5 >2/64.3 2/100.0 1/100.0
BHS (172) 0.015/NA 0.25/100.0 0.25/100.0 1/90.7 1/100.0 0.5/100.0
VGS (86) 0.25/NA 0.5/90.7 0.25/97.7 2/88.4 1/100.0 0.5/100.0
E. faecalis (409) 8/NA >32/NA >2/71.4 >4/NA 2/100.0 2/98.8
NA = not assigned.
P1094 Antimicrobial activity of ceftaroline against bacteria
isolated in 2008 from community-acquired respiratory
tract infections in European hospitals, including
methicillin-resistant Staphylococcus aureus
H. Sader °, P. Rhomberg, R. Jones (North Liberty, US)
Objectives: To evaluate the potency and spectrum of ceftaroline
tested against community-acquired respiratory tract infection (CARTI)
pathogens. Ceftaroline, currently in phase III clinical development,
is a novel N-phosphono prodrug cephalosporin that has high afﬁnity
for S. aureus PBP 2a and demonstrated bactericidal activity against
methicillin-resistant S. aureus (MRSA) and other pathogens responsible
for CARTI.
Methods: CARTI isolates (717) were consecutively collected in 2008
from 24 hospitals located in 10 European countries (EU), Turkey, and
Israel. S. aureus isolates were obtained from patients with pneumonia
occurring less than 72 hours after hospitalisation. Susceptibility (S)
was tested by CLSI broth microdilution method against ceftaroline and
various antimicrobials used to treat CARTI.
Results: The potency of ceftaroline against 3 common pathogens
associated with CARTI is summarised in the Table.
Organism (no. tested) Cumulative % inhibited at ceftaroline MIC (mg/L) of:
0.008 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4
PEN-S SPN* (328) 85.1 97.0 98.5 99.7 99.7 100.0 – – – –
PEN-intermediate SPN* (41) 4.9 19.5 53.7 87.8 97.6 100.0 – – – –
PEN-R SPN* (78) 0.0 1.3 2.6 6.4 71.8 98.7 100.0 – – –
Beta-lactamase-neg HI (170) 86.5 99.4 99.4 100.0 – – – – – –
Beta-lactamase-pos HI (29) 65.5 96.6 100.0 – – – – – – –
MSSA (47) 0.0 0.0 0.0 0.0 0.0 85.1 100.0 – – –
MRSA (24) 0.0 0.0 0.0 0.0 0.0 0.0 29.2 75.0 91.7 100.0
*Penicillin breakpoints of 0.06 and 2mg/L were applied.
Against S. pneumoniae (SPN), the activity of ceftaroline (MIC50/90,
0.008/0.12mg/L) was eight-, 16-, and 64-fold more potent than
ceftriaxone (MIC50/90, 0.25/1mg/L), amoxicillin/clavulanate (A/C;
MIC50/90, 1/2mg/L), and cefuroxime (MIC50/90, 1/8mg/L),
respectively. Penicillin (PEN) resistance (R) was high among SPN;
only 73.4% and 92.0% of strains were inhibited at 0.06 and
2mg/L, respectively, whereas A/C inhibited 93.3% of strains at
2mg/L. R was also high among the SPN isolates for erythromycin
(33.6%), azithromycin (33.1%), tetracycline (27.5%), clindamycin
(21.7%), and trimethoprim/sulfamethoxazole (17.0%). Ceftaroline was
very active against H. inﬂuenzae (HI; MIC50/90, 0.008/0.015mg/L),
and its activity was not adversely affected by b-lactamase production.
Ceftaroline (MIC50/90, 0.25/0.5mg/L) was eight- to 16-fold more potent
than ceftriaxone (MIC50 and MIC90, 4mg/L) and cefepime (MIC50/90,
2/4mg/L) against methicillin-susceptible S. aureus (MSSA). The highest
ceftaroline MIC value among MRSA was 4mg/L (only 2 strains), and
75.0% of all isolates were inhibited at 1mg/L of ceftaroline. All non-
MRSA Gram-positive cocci were ceftaroline susceptible at 0.5mg/L.
Conclusions: Bacterial pathogens recently collected (2008) from CARTI
in EU medical centres were very S to ceftaroline, including community-
acquired MRSA, PEN-R SPN, and other R strains. This favourable
antimicrobial proﬁle places ceftaroline as a promising and potentially
effective therapeutic option in the treatment of CARTI in the EU.
P1095 Spectrum and potency of ceftobiprole against leading
North American pathogens producing community- and
hospital-acquired pneumonia (2005–2007)
H. Sader °, P. Rhomberg, M. Janechek, R. Jones (North Liberty, US)
Objectives: To establish ceftobiprole (BPR;an investigational parenteral
cephalosporin in regulatory review for community- [CA] and hospital-
acquired [HA] respiratory tract pathogens) potency and spectrum. BPR is
active against MRSA and other Gram-positive and -negative pathogens,
making it an attractive candidate for broad-spectrum therapy. Results
assessing potency of BPR against commonly occurring CA- and HA-
pneumonia pathogens in North America (NA) are presented.
Methods: A total of 5,108 non-duplicate isolates causing clinically-
signiﬁcant CA- and HA-pneumonia infections were collected from
over 25 medical centres in NA participating in a BPR surveillance
program (2005–2007). Susceptibility (S) testing was performed using
CLSI methods (M7-A7, 2006) by the central monitoring laboratory.
Results: BPR inhibited the CA-RTI pathogens HI and SPN at 0.25
and 1mg/L, respectively. Overall SA strains had MIC90 at 2mg/L,
however the MIC90 for oxacillin (OXA)-S strains was 4-fold lower
(0.5mg/L). Coverage against Gram-negative bacilli causing HA-RTI
showed EC was nearly identical for the three agents (Table; 97−98%
inhibited at 4mg/L). Whereas FEP provided enhanced coverage against
KSP (90% at 8mg/L vs. 83% for BPR and 88% for CAZ), BPR and
FEP were superior to CAZ against ESP. Against PSA, BPR was equal in
potency to FEP (MIC90, 8mg/L) and two-fold more potent than CAZ,
although the % inhibited for these agents at 2/4/8mg/L was similar
(67−92/60−90/66−87%, respectively).
Conclusions: BPR is a new b-lactam with antimicrobial activity against
pathogens causing CA- and HA-pneumonia, similar to that of extended-
spectrum cephems but including MRSA. These characteristics warrant
continued evaluation of BPR as empiric therapy for treating bacterial
pneumonia.
Organism (no. tested) BPR MIC (mg/L) Cum. % inhibited at MIC (mg/L)
50% 90% 0.25 0.5 1 2 4 8
Community-acquired
H. inﬂuenzae (HI; 883) 0.06 0.06 100.0 – – – – –
S. pneumoniae (SPN; 1912) 0.06 0.5 88.9 98.5 100.0 – – –
Hospital-acquired
S. aureus (SA; 938) 0.5 2 26.7 54.2 89.3 100.0 – –
P. aeruginosa (PSA; 492) 4 >8 1.2 5.7 25.0 45.1 60.2 77.9
Klebsiella spp. (KSP; 228) 0.06 >8 75.9 77.6 79.4 80.3 81.1 82.5
Enterobacter spp. (EBS; 155) 0.06 8 75.5 78.1 80.7 85.8 89.7 91.6
Acinetobacter spp. (ASP; 122) >8 >8 10.7 21.3 30.3 33.6 36.1 36.1
P1096 Antimicrobial activity of ceftobiprole, a novel anti-
methicillin-resistant S. aureus cephalosporin, tested against
skin and skin-structure infection pathogens (North America)
R. Jones °, H. Sader, M. Janechek, P. Rhomberg (North Liberty, US)
Objectives: To establish ceftobiprole (BPR) activity for this investiga-
tional parenteral cephalosporin under regulatory review for complicated
skin and skin structure infections (SSSI). BPR is active against MRSA
and other Gram-positive and -negative pathogens, making it an attractive
candidate for broad-spectrum therapy. Results assessing potency of BPR
against commonly occurring SSSI pathogens in North America (NA) are
presented.
Methods: Non-duplicate clinically-signiﬁcant SSSI isolates (1,466) were
collected from over 25 medical centres in NA participating in a BPR
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surveillance program (2005–2007). Identiﬁcations were conﬁrmed by
the central monitoring laboratory and all isolates were susceptibility (S)
tested using CLSI methods.
Results: BPR inhibited all SA, EF and BHS at 2, 1 and 0.12mg/L,
respectively. MIC90 values for oxacillin (OXA)-R SA strains were two-
fold higher than for OXA-S strains (1 versus 0.5mg/L). Coverage against
EC was nearly identical for the three agents (Table; 97−98% inhibited
at 4mg/L). Whereas FEP provided enhanced coverage against KSP
(90% at 8mg/L vs. 83% for BPR and 88% for CAZ), BPR and FEP
were superior to CAZ against ESP. Against PSA, BPR was equal in
potency to FEP (MIC90, 8mg/L) and two-fold more potent than CAZ,
although the % inhibited for these agents at 2/4/8mg/L was similar
(67−92/60−90/66−87%, respectively).
Conclusions: BPR is a new b-lactam with recognized activity against
NA SSSI pathogens, similar to that of extended-spectrum cephems but
including MRSA. These characteristics warrant continued evaluation of
BPR as empiric therapy for SSSI, including Gram-negative pathogens.
Species (no. tested) MIC90 in mg/L (% at 2/4/8mg/L)
BPR CROa or CAZb FEP
S. aureus (SA; 896) 1 (100/–/–) >32 (15/49/51)a >16 (40/57/76)
P. aeruginosa (PSA; 100) 8 (67/79/92) >16 (66/83/87)b 8 (60/76/90)
E. coli (EC; 99) 0.06 (96/97/97) 1 (97/98/98)b 0.25 (98/98/98)
E. faecalis (EF; 60) 1 (100/–/–) – –
Beta-haemolytic streptococcus (BHS, 52) 0.06 (100/–/–) 0.25 (100/–/–)a 0.12 (100/–/–)
Enterobacter spp. (ESP, 54) 8 (83/89/93) >16 (63/65/70)b 4 (89/96/98)
Klebsiella spp. (KSP; 42) >8 (83/83/83) >16 (86/88/88)b 2 (90/90/90)
P. mirabilis (31) 0.06 (100/–/–) 1 (97/100/–)b 0.12 (100/–/–)
CRO = ceftriaxone, CAZ = ceftazidime, FEP = cefepime.
P1097 In vitro activity of ceftobiprole against a group of
well-characterised staphylococci
S. Borbone °, F. Campanile, D. Bongiorno, S. Jeddari, C. Scuderi,
S. Stefani (Catania, IT)
Objectives: In an effort to test the in vitro activity proﬁle and the
antibacterial spectrum of ceftobiprole, a new cephalosporin particularly
active against MRSA due to its high afﬁnity to PBP2a, we examined
the susceptibilities of a group of well-characterised HA-MRSA, CA-
MRSA, MSSA and CoNS isolates, responsible for documented cases of
staphylococcal disease, in Italy.
Methods: MICs and MBCs were determined for ceftobiprole (BPR) and
the main anti Gram-positive antimicrobials (vancomycin, teicoplanin,
daptomycin, linezolid, synercid, and tigecycline) against 117 isolates
of Staphylococcus spp.: 50 MRSA strains representative of the major
epidemic clones (4 Archaic, 8 Iberian, 12 Italian, 4 Brazilian, 6 Rome,
7 sporadic, and 16 GS-MRSA stains); 8 CA-MRSA; 26 MSSA 20
MRCoNS, and 6 control strains.
Results: Ceftobiprole had a MIC90 value of 4mg/L against the MDR
Iberian, Rome and Italian clones; 2mg/L against the Brazilian clone and
the CoNS strains, while it was active at concentrations below 2mg/L
against the Archaic and GS-MRSA clones, the CA-MRSA strains and
all the sporadic and MSSA isolates included in the study. In vitro activity
of ceftobiprole is comparable to those of vancomycin (MIC90 2mg/L),
teicoplanin (MIC90 8mg/L) and linezolid (MIC90 2mg/L); good activity
was demonstrated by daptomycin (1mg/L), synercid (1mg/L), and
tigecycline (0.5mg/L). Almost all strains showed MBC values similar or
one-fold higher than their MIC values, except for few strains belonging
to the Iberian, Rome, Brazilian and Italian clones, which paradoxically
survived at higher concentrations of BPR.
Conclusion: Ceftobiprole is a very active bactericidal compound against
multi-drug resistant hospital associated epidemic clones, and is also
very active against emerging community-acquired strains possessing a
complex virulence make-up. Clinical studies will conﬁrm its usefulness
in the treatment of infections sustained by multi-resistant microrganisms.
P1098 Efﬁcacy and pharmacodynamic evaluation of CEM-101, a
novel macrolide, in murine infection models
T.M. Murphy °, M. Gaffney, S. Little, R. Wu, A.M. Slee, C. Ong,
P. Fernandes (Waltham, Winter Park, Chapel Hill, US)
Objectives: To evaluate the in vivo efﬁcacy of CEM-101 against Gram
positive pathogens including community associated MRSA.
Methods: Efﬁcacy was evaluated in both a subcutaneous abscess model
as well as neutropenic thigh infection model. Abscesses were induced
in CD-1 female mice by s.c. injection of S. pneumoniae or S. pyogenes
mixed with cytodex beads, CEM-101 or comparator test articles were
administered as a single oral dose two hours post infection with
bioburden levels assessed at 48 hours post infection. In addition, the
neutropenic thigh infection model was utilised to determine target organ
efﬁcacy after a single oral dose. CD-1 female mice were rendered
neutropenic with cyclophosphamide pre-treatment. Mice were infected
with S. pneumoniae (SPN) or S. aureus via IM injection into the right
thigh. At 1.5 hours post infection, mice received treatment via oral
gavage with CEM-101 ranging from 1 to 25mg/kg. CFUs/gram of
thigh were determined at initiation of treatment and at 24 hour post
start of treatment. Subsequently, for a preliminary evaluation of PK-
PD relationship, mice, infected with SPN, were treated with 4 doses of
CEM-101 fractionated into 1, 2, 3, or 4 doses over a 24 hour period.
Single dose plasma PK was also performed.
Results: In the abscess, a 10mg/Kg QD dose of CEM-101 demonstrated
a 2.3 log10 decrease while clarithromycin only achieved a 0.9 log10
reduction from untreated mice against SPN. Similarly, a 2.9 log10
decrease was observed for CEM-101 against S. pyogenes; while
clarithromycin demonstrated only a 0.59 log10 reduction. In the thigh
model, CEM-101 demonstrated efﬁcacy after a single oral dose against
both susceptible and MRSA isolates. Evaluation of PK-PD demonstrated
concentration dependent killing with increased bacterial reduction for the
single oral dose over the fractionated cohorts. The effect of CEM-101 on
bacterial burden was combined with free drug concentrations to predict
the most likely PK-PD parameter. Cmax/MIC was the best predictor of
in vivo efﬁcacy with an r2=0.83.
Conclusions: CEM-101 demonstrated signiﬁcant in vivo activity in a
subcutaneous abscess and neutropenic thigh infection model. Preliminary
PK-PD suggests concentration dependent killing with Cmax/MIC being
the best predictor of efﬁcacy against this isolate.
P1099 Comparative activities of the novel ketolide CEM-101 and
telithromycin towards towards Streptococcus pneumoniae
resistant to macrolides from patients with conﬁrmed
community-acquired pneumonia
A. Lismond °, F. Van Bambeke, P. Tulkens (Brussels, BE)
Background and Aims: CEM-101) is a new macrolide-ketolide in
development with activity against macrolides (ML)-resistant isolates.
After 400mg qD, it yields an AUC24 h similar to that of telithromycin
800mg qD and shows similar protein binding properties in human serum
(about 15% free drug). Belgium is a country with high resistance of
Streptococcus pneumoniae (SP) to ML (>35% for clarithromycin). Our
aim was to compare the activity of CEM-101 to that of telithromycin
(TEL) against ML-resistant strains of SP obtained from patients with
conﬁrmed CAP.
Methods: 29 ﬁrst ML-R isolates (based on clarithromycin MICs
determination; 19 MLSB, 10 M-phenotype based on erythromycin
and clindamycin resistance dissociation) were selected (for which 6
were TEL-I and 7 TEL-R based on EUCAST breakpoints [S 0.25 −
R> 0.5]). MICs were determined by geometric microdilution in CAMH
broth + 2.5% lysed horse blood according to CLSI, using SP ATCC-
49619 as a control.
Results: ATCC-49619 MICs were 0.008mg/L for TEL and CEM-101.
Data for ML-resistant isolates are shown in the Table.
Conclusions: In this Belgian collection of S. pneumoniae resistant to
macrolides and isolated from conﬁrmed CAP, CEM-101 shows globally
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lower MICs compared to TEL, especially with respect to TEL-I and
TEL-R isolates. CEM-101 has therefore the potential to stand as an
alternative to telithromycin in areas with high ML resistance and
emerging resistance to TEL.
Phenotype* No. TEL CEM-101
range geom. mean MIC90 range geom. mean MIC90
TEL-S 16 0.008−0.25 0.021 0.25 0.008−0.063 0.022 0.063
TEL-I 6 0.5−0.5 0.5 0.5 0.063−0.5 0.223 0.5
TEL-R 7 1−3 1.426 3.0 0.5−1.0 0.906 1.0
*MLSb for 7/16 of TEL-S, 5/6 of TEL-I, and 7/7 of TEL-R isolates
(S/I/R are deﬁned based on EUCAST breakpoints (S 0.25 − R> 0.5).
P1100 Antimicrobial characterisation of CEM-101: activity against
staphylococci, b-haemolytic and viridans group streptococci
R. Jones °, H. Sader, D. Biedenbach (North Liberty, US)
Objectives: To address therapy of MLSB-resistant (R) species, CEM-
101 (a new macrolide-ketolide), was developed with enhanced potency
against wildtype (WT) respiratory tract (RTI) and cutaneous (SSSI)
pathogens. Results of CEM-101 susceptibility (S) testing against 452
staphylococci and selected streptococci are described here.
Methods: A collection of 2006–2007 clinical isolates were S tested
by CLSI methods (M7-A7) with associated interpretive criteria (M100-
S18) and supplements (2−5% LHB) for streptococcal tests. CEM-101,
telithromycin (TEL) and 10 comparators were used versus 201 S. aureus
(75 WT-MRSA, 75 WT-MSSA, 30 CA-MRSA, 17 VISA or hVISA, 7
VRSA), 100 coagulase-negative staphylococci (CoNS; 10 species), 100
b-haemolytic (BHS; 30 group A, 31 group B, 14 group C, 9 group F, 16
group G) and 51 viridans group streptococci (VGS; 5 species), see Table.
Results: MSSA strains were slightly more CEM-101-S (MIC50,
0.06mg/L) that MRSA or CA-MRSA strains (MIC50, 0.12mg/L). VISA,
hVISA and VRSA were generally more refractory to CEM-101 and TEL.
CEM-101 was 2-fold more potent than TEL against all staphylococci.
Streptococci were very S to CEM-101 (MIC90, 0.03−0.06mg/L) and
TEL was 4-fold less active with non-S isolates of BHS observed. ERY-R
staphylococci remained CEM-101-S except for TEL- and clindamycin
(CC)-R isolates, but all BHS and VGS were S to CEM-101.
Conclusions: CEM-101, a novel macrolide-ketolide, was potent against
all staphylococci (MIC50, 0.06mg/L), except CC-R strains; and inhibited
all streptococci at 0.12mg/L. The activity was greater than TEL by 2-
to 4-fold. CEM-101 warrants further development for RTI and SSSI
indications.
Organisms (no.) CEM-101 MIC (mg/L) Telithromycin MIC (mg/L)
50% 90% Range 50% 90% Range
MSSA (75) 0.06 0.12 0.03−>16 0.12 0.25 0 06−>16
MRSA (75) 0.12 >16 0.03−>16 0.25 >16 0.06−>16
CA-MRSA (30) 0.12 0.12 0.06−0.12 0.25 0.25 0.12−0.5
VISA, hVISA (14) >16 >16 0.06−>16 >16 >16 0.25−>16
VRSA (7) >16 – 0.12−>16 >16 – 0.12−>16
CoNS (100) 0.06 >16 0.03−16 0.12 >16 0.03−>16
BHS (100) 0.015 0.03 0.008−0.12 0.03 0.12 0.008−2
VGS (51) 0.008 0.06 0.008−0.12 0.015 0.25 0.008−0.5
P1101 Activity of CEM-101 tested against emerging
telithromycin-resistant b-haemolytic streptococci
R. Jones °, L. Woosley, G. Moet, P. Rhomberg (North Liberty, US)
Objectives: To assess CEM-101, a macrolide-ketolide in early pre-
clinical development, potency against strains observed to be resistant
(R) to other agents in the same class. Reports have documented ketolide-
R (telithromycin [TEL]) species worldwide, most recently S. pyogenes
from Europe. CEM-101 was tested against a collection of 43 TEL-R
b-haemolytic streptococci (BHS).
Methods: A total of 53 (1.3%) BHS were identiﬁed among 3,958 in the
SENTRY Antimicrobial Surveillance Program (2003–2006) that were
TEL-R (MIC, 2mg/L). 43 strains (36 group A, 1 group C, 6 group G)
were available for testing, from 20 hospitals in Europe (31 strains), North
America (11) and Latin America (1). Susceptibility (S) testing used CLSI
broth microdilution methods and 3 strains were erythromycin (ERY)-
R, clindamycin (CC)-S requiring D-test. Nine comparison agents were
tested (4 in Table).
Table. MIC distributions for CEM-101 as MLSb-ketolide comparisons
agents
Antimicrobial Occurrences at MIC (mg/L):
0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 >4
CEM-101 4 0 1 18 10 6 4 0 0 0
Telithromycin 0 0 0 0 0 0 0 8 16 19
Erythromycin 0 0 0 0 0 0 0 0 – 43
Clindamycin – – – – 2 1 0 0 – 40
Q/Da – – – – 37 6 0 0 – 0
aQ/D = quinupristin/dalfopristin.
Results: The potency of CEM-101 against each BHS serogroup was
the same with an overall MIC50 and MIC90 of 0.12 and 0.5mg/L,
respectively. CEM-101 activity was 32-fold (MIC50 comparisons)
greater than TEL. All strains were ERY-R, but quinupristin/dalfopristin
(Q/D) was 100% S. Three CC-S strains (S. pyogenes) were D-test (+)
and 2 had (+) induction of CEM-101. The S rates for other comparators
were: penicillin, tetracycline, ceftriaxone, amoxicillin/clavulanate, and
levoﬂoxacin (100.0%); and tetracycline (46.8%).
Conclusions: CEM-101 remained active against all TEL-R (MIC,
2mg/L) BHS with all MICs at 1mg/L (MIC50, 0.12mg/L). Highest
occurrence of TEL-R strains was in Europe (greatest in Italy). CEM-101
warrants further development for infections caused by BHS.
P1102 Antibacterial activity of NXL103 (linopristine-ﬂopristine),
in vitro post-antibiotic effect, and spontaneous frequency
of resistance
J. Pace °, P. Levasseur, A.M. Girard, L. Lavallade, I. Morrissey
(Romainville, FR; London, UK)
Objectives: NXL103 (linopristine-ﬂopristine) is an oral streptogramin
which was recently evaluated in a Phase II clinical trial. Susceptibility
of both community- (CA-MRSA) and hospital-associated (HA-MRSA)
methicillin-resistant Staphylococcus aureus was evaluated against 160
clinical isolates and in vitro post-antibiotic effect (PAE) and spontaneous
frequency of resistance have also been evaluated with selected strains.
Methods: Minimal inhibitory concentrations (MIC) were determined
by CLSI broth microdilution method. In vitro post-antibiotic effect
(PAE) was determined by incubating bacteria for 2 hours with antibiotic
followed by dilution and incubation in antibiotic-free pre-warmed
medium with bacterial enumeration on agar medium (37ºC, 48 hours).
PAE was deﬁned as the difference in time required for antibiotic-treated
bacteria to increase by 1-log10 versus bacteria not exposed to antibiotic.
Spontaneous frequency of resistance was determined by plating bacteria
on brain-heart agar containing 2, 4, or 8×MIC of antibiotic (37ºC,
48−72 hours). MICs of mutant and parent strains were subsequently
conﬁrmed.
Results: NXL103 MICs ranged from 0.06−0.5mg/L. NXL103 MIC90
was 0.25mg/L for CA-MRSA and 0.5mg/L for HA-MRSA. NXL103
was active against erythromycin A-resistant bacteria with MICs 2−4
fold lower than for linezolid, daptomycin, vancomycin, and quinupristin/
dalfopristin. The PAE of NXL103 for S. aureus AS5155 and DEL4811
were 2 and 2.1 hours, respectively. First-step mutants of S. aureus
ATCC 25923 were isolated at frequencies of 4.1×10−9 to 1.8×10−10 at
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concentrations of 2 and 4×MIC (MIC increased from 0.25 to 2−4mg/L).
No mutants were isolated at 8×MIC (2mg/L) (frequency <2.9×10−10).
MICs of the mutants were similarly increased to pristinamycin and
erythromycin A but not to peﬂoxacin, chloramphenicol or tetracycline.
No mutants of S. aureus AS5155 were isolated at concentrations of 2,
4, or 8×MIC (1, 2, and 4mg/L, respectively) (frequency <3.1×10−10).
Conclusion: NXL103 exerts antibacterial activity against both
community- and hospital-acquired MRSA. An in vitro post-antibiotic
effect of 2.0−2.1 h is observed as well as a low spontaneous frequency
of resistance, ﬁndings which support additional clinical evaluation of
this compound for complicated skin and skin structure infections.
P1103 Characterisation of resistance following serial passage
of Staphylococcus aureus in the presence of the novel
oxazolidinone TR-700 and linezolid
J. Locke °, K. Shaw (San Diego, US)
Objectives: To characterise the potential for Staphylococcus aureus to
develop resistance over time to TR-700 (the active moiety of the novel
oxazolidinone phosphate prodrug TR-701) and linezolid (LZD) through
serial passage, and to elucidate the underlying resistance mechanisms.
Methods: S. aureus strains ATCC 29213 (MSSA), ATCC 33591
(MRSA), and CM-05 (cfr+, LZD-resistant MRSA (LMRSA)) were
cultured at 37ºC on Mueller-Hinton agar (MHA) or in liquid broth
(MHB). MIC values were determined via microdilution in accordance
with CLSI guidelines. Serial passage experiments were carried out by
plating ~1×108 CFU on TR-700 and LZD antibiotic gradient plates.
Following a 48 h incubation, the leading edge of growth was streaked into
MHB without antibiotics and grown overnight for the subsequent passage
plating. 23S rRNA mutations were determined through sequencing the
domain V region of all 23S rRNA gene copies for each strain.
Results: After 20 serial passages, TR-700-passaged MRSA 33591 had
an MIC increase from 0.25 to 0.5 ug/mL, but MSSA 29213 and LMRSA
CM-05 TR-700 MIC values did not change. LZD resistance for MSSA
29213 and MRSA 33591 increased from 2 to 32 ug/mL and 0.5 to
4 ug/mL, respectively, while remaining unchanged for LMRSA CM-
05. 23S rRNA domain V sequencing of passage 20 cultures revealed
mutations only in strains with elevated MIC levels. MRSA 33591
passaged in TR-700 possessed a novel dual T2571C/G2576T mutation
in 2 of the 23S rRNA genes. LZD-passaged MSSA 29213 had 3 copies
of the G2447T mutation and LZD-passaged MRSA 33591 had 2 copies
of the G2576T mutation.
Conclusion: The ability to evolve antibiotic resistance over time and the
underlying resistance mechanisms are important measures in assessing
the risk of emerging resistance for an antibiotic compound. Through
serial passage we have shown that S. aureus has a very limited ability
to develop elevated levels of resistance to TR-700. Further analysis of
the novel coupled T2571C/G2576T mutations found in TR-700-passaged
MRSA 33591 may shed light on the low frequency of resistance to TR-
700.
P1104 Characterisation of the novel oxazolidinone TR-700 and
linezolid spontaneous mutation frequencies and resistance
mechanisms in Staphylococcus aureus
J. Locke °, K. Shaw (San Diego, US)
Objectives: To compare the spontaneous mutation frequencies of 3
Staphylococcus aureus strains against TR-700 (the active moiety of the
novel oxazolidinone phosphate prodrug TR-701) and linezolid (LZD),
and to elucidate the underlying resistance mechanisms.
Methods: S. aureus strains ATCC 29213 (MSSA), ATCC 33591
(MRSA), and CM-05 (cfr+, LZD-resistant MRSA (LMRSA)) were
cultured at 37ºC on Mueller-Hinton agar (MHA) or in liquid
broth (MHB). MIC values were determined via microdilution in
accordance with CLSI guidelines. Spontaneous mutation frequencies
were determined through plating of ~1×1010 CFU on large-format
(245×245mm) MHA plates containing 2×MIC of TR-700 or LZD. 23S
rRNA mutations were determined through sequencing the domain V
region of all 23S rRNA gene copies for each strain.
Results: Spontaneous mutation frequencies for MSSA 29213 and
MRSA 33591 to TR-700 and LZD at 2×MIC were <1.2×10−10 and
<2.0×10−10, respectively. These values are 16-fold lower than the
corresponding LZD spontaneous mutation frequencies for both strains.
No spontaneous mutants for LMRSA CM-05 were generated for either
compound at 2×MIC. MIC values of TR-700 and LZD spontaneous
mutants were 2 to 4-fold greater than the MSSA 29213 and MRSA
33591 wild type control MICs. MIC values for TR-700 were signiﬁcantly
lower than LZD for all of the mutant strains. The only 23S rRNA
mutation detected for TR-700 was T2500A. Mutations for LZD included
G2447T and T2500A. Some of the TR-700 and LZD-resistant mutants
did not have any mutations in the 23S rRNA domain V region and are
undergoing further rRNA sequence analysis.
Conclusion: Spontaneous mutation frequencies and the underlying
resistance mechanisms are important parameters for evaluating the
clinical utility of an antibiotic compound. We have demonstrated that
spontaneous 23S rRNA mutations conferring resistance to TR-700 occur
over an order of magnitude less frequently in S. aureus than those
conferring resistance to LZD. Furthermore, for both of the 23S rRNA
mutations reported here, TR-700 maintains a 4-fold or greater MIC
advantage over LZD. Our analyses of these properties for TR-700 support
the continued clinical development of TR-701.
P1105 Enzymatic inhibition of Streptococcus pneumoniae PBP 2x
transpeptidase activity by ceftaroline
A. Zervosen, J.M. Frere °, A. Zapun (Lie`ge, BE; Grenoble, FR)
Background: Ceftaroline (CPT) is a novel, parenteral, broad-spectrum
cephalosporin exhibiting bactericidal activity against Gram-positive or-
ganisms, including methicillin-resistant Staphylococcus aureus (MRSA)
and multidrug-resistant Streptococcus pneumoniae (MDRSP), as well
as common Gram-negative pathogens. CPT is currently in phase 3
development. In order to understand the antipneumococcal activities
of CPT, enzymatic inhibition studies were performed to examine the
acylation of pneumococcal penicillin-binding protein 2x (PBP2x) by
CPT.
Methods: This enzyme kinetic study was carried out with puriﬁed
pneumococcal PBP2x from a penicillin-sensitive S. pneumoniae (PSSP)
PBP2x R6 isolate and a penicillin-resistant S. pneumoniae (PRSP)
PBP2x 5204 isolate. The acylation is characterised by the second
order rate constant k2/K. k2/K was determined by observing the
competitive interaction between the reporter substrate, a thioester (S2d)
and the inactivator CPT. Comparators, whose activity against PBP2x
have been well characterised previously, included penicillin G (PEN)
and cefotaxime (CTX).
Results: The inactivation of PBP2x by CPT was extremely rapid, making
it impossible to study the kinetic parameters by classical methods.
A k2/K-value of 106M−1 s−1 was determined for PSSP by using the
equation of a second-order reaction with equimolar concentrations of
PBP2x and CPT. The k2/K-value for PRSP was >2300M−1 s−1 for CPT,
which was signiﬁcantly higher than that of PEN (104 M−1 s−1) or CTX
(85 M−1 s−1). The relative inhibitory activities of these drugs against
PBP2x correlated with their MICs against the organisms.
Conclusions: CPT is a potent inhibitor of S. pneumoniae PBP2x and
has excellent bactericidal activity against PRSP, in part through rapidly
forming an inhibitory acyl enzyme intermediate with target PBP2x. CPT
offers promise for the treatment of respiratory tract infections caused by
drug-resistant pneumococci.
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P1106 Efﬁcacy of a new quinolone (UB-8902) in an experimental
murine pneumonia model caused by Acinetobacter
baumannii resistant to ciproﬂoxacin
R. Lo´pez-Rojas °, J. Sa´nchez-Ce´spedes, F. Docobo-Pe´rez,
J. Domı´nguez-Herrera, J. Vila, J. Pacho´n (Seville, Barcelona, ES)
Objective: The new quinolone UB-8902 derived from ciproﬂoxacin
showed good in vitro activity, low toxicity parameters, and efﬁcacy in
a non-discriminative murine model of sepsis caused by Acinetobacter
baumannii resistant to ciproﬂoxacin (ECCMID 08, poster nº P551). The
aim of the present work is to determine its pharmacokinetic proﬁle, and
evaluate its efﬁcacy against A. baumannii in a discriminative murine
model of pneumonia.
Methods: We used two A. baumannii strains (Ab58 and Ab33). The
antibiotics studied were ciproﬂoxacin (CIP), moxiﬂoxacin (MOX), and
the new generated quinolone UB-8902 (UB). Animals used were
immunocompetent C57BL/6 female mice.
Serum pharmacokinetic/pharmacodynamic (PK/PD) parameters [Cmax
(mg/L), AUC (mg*h/L), T1/2 (h); AUC/MIC; T>MIC (h)] were
calculated administering single doses of 20mg/kg/ip of UB, CIP and
MOX to groups of 21 uninfected animals. To study the in vivo
efﬁcacy of UB, a 72 h murine pneumonia model was performed;
bacteria were inoculated intratracheally (8.72±0.11 log10 cfu/mL for
Ab58, and 8.44±0.10 log10 cfu/mL for Ab33), and groups of 15 mice
were randomly ascribed to non treated (control), and treated with
20mg/kg of UB, CIP, or MOX every 8 hours. Analyzed variables:
bacterial lung concentration (Log10 cfu/g), negative blood cultures (%),
and mortality (%). Statistical analysis: ANOVA, post hoc test, and Chi-
square tests.
Results: MICs (mg/L): Ab58, UB=0.03, CIP=0.25, MOX=0.016; Ab33,
UB=0.5, CIP=8, MOX=1. PK parameters for UB, CIP, and MOX,
respectively, were: Cmax (mg/L), 7.91, 11.57, and 6.84; AUC (mg*h/L),
3.28, 8.79, and 3.56; T1/2 (h), 0.23, 0.27, and 0.34. PD parameters for
Ab58 (UB, CIP, and MOX): AUC/MIC were 109.18, 35.16, and 222.71;
T>MIC (h) were 0.94, 1.40, and 1.47. PD parameters for Ab33 (UB,
CIP, and MOX): AUC/MIC were 6.55, 1.10, and 3.56; T>MIC (h) were
0.89, 0.73, and 1.14. Results of the pneumonia model are in the table.
Conclusions: The new quinolone UB-8902 is efﬁcacious in an
experimental pneumonia model caused by A. baumannii. This efﬁcacy
is also shown against the resistant ciproﬂoxacin strain.
Treatment Ab58 Ab33
AUC/MIC
0−24 h
Bacterial lung
concentration
(log10 cfu/g)
Sterile
blood
cultures
(%)
Mortality
(%)
AUC/MIC
0−24 h
Bacterial lung
concentration
(log10 cfu/g)
Sterile
blood
cultures
(%)
Mortality
(%)
Control – 8.86±0.94 26.6% 80% – 8.12±1.09 18.8% 68.8%
UB 327.54 4.24±2.49* 86.7%* 53.3% 19.65 3.97±3.32* 81.3%* 37.5%
CIP 105.48 2.67±2.83* 80.0%* 26.6%* 3.30 6.57±1.99 60.0%* 66.7%
MOX 668.13 2.98±2.42* 86.7%* 33.3%* 10.68 4.64±2.26* 76.5%* 47.1%
*p< 0.05 respect to control group.
P1107 Activity of PZ-601 (SMP-601) against Enterobacteriaceae
with AmpC, ESBLs and carbapenemases
S. Mushtaq, M. Warner, D.M. Livermore ° (London, UK)
Background: PZ-601 (SMP-601) is a novel 1 b-methyl carbapenem,
active vs. methicillin-resistant staphylococci and enterococci, including
Enterococcus faecium, also vs. Enterobacteriaceae. We investigated how
its anti-enterobacterial activity was affected by b-lactamases, alone or
combined with porin loss.
Methods: AmpC expression mutants, transconjugants/transformants and
clinical isolates were used, with MICs determined by the CLSI agar
method.
Results: Among Enterobacter and Citrobacter freundii mutant series
inducible, derepressed and basal AmpC were associated with MICs
of 0.5−2mg/L, 4−16mg/L and 0.06−0.25mg/L respectively, meaning
that either inducible or (more so) derepressed AmpC expression gave
some protection. Similar patterns arose for Serratia and Morganella
spp., though the degree of protection was less. The chromosomal
Class A b-lactamase of Proteus vulgaris did not protect, however
expressed. None of the classical and extended-spectrum TEM, SHV
or CTX-M enzymes transferred into Escherichia coli protected, with
PZ-601 MICs consistently <1mg/L for transconjugants. Among OXA
enzyme, only OXA-3 protected, raising the PZ-601 MIC to 8mg/L
whilst not affecting MICs of other carbapenems. NMC-A, KPC and
IMP carbapenemases conferred resistance, with MICs 16–128mg/L. The
modal MIC of PZ-601 for ESBL-positive clinical E. coli was 0.5mg/L
(range 0.25−8mg/L) whilst that for strains with high-level AmpC was
2mg/L (range 1−16mg/L). The mode for ertapenem-susceptible ESBL-
positive Klebsiella spp. was 2mg/L (range 0.25−8mg/L), with little
change for ertapenem-resistant produces lacking porins. The mode MIC
for ESBL-positive Enterobacter spp. was 8mg/L (range 1−32mg/L);
that for AmpC-derepressed Enterobacter was 8mg/L (range 4−16mg/L)
rising to 16mg/L (range 16−>128mg/L) where porin loss and ertapenem
resistance was also present.
Conclusions: PZ-601 seems highly stable to ESBLs, which were poor
at conferring resistance even when combined with impermeability
Resistance was seen in AmpC-producing Enterobacteriaceae, particularly
Enterobacter spp. and was increased if AmpC expression was dere-
pressed and coupled with impermeability. Carbapenemases conferred
resistance.
P1108 Efﬁcacy and safety of doripenem versus comparators in
subjects with Acinetobacter baumannii: integrated analysis
of six phase III clinical studies
J. Peterson, Z. Qin, A. Fisher, S. Nicholson, J. Laeuffer ° (Raritan,
US; Baar, CH)
Objectives: With some strains of A. baumannii resistant to nearly all
antibacterials it is important to evaluate available agents for treatment
of infections due to this pathogen. Doripenem (DORI) is a carbapenem
with activity against Gram-negative bacteria, including A. baumannii.
The goal of this analysis is to present the clinical effectiveness of DORI
vs. comparators (COMP) in the treatment of infections associated with
A. baumannii.
Methods: An analysis was conducted on a subset of subjects with
A. baumannii isolated at study entry and included in the mITT population
from 6 studies [complicated urinary tract infection (cUTI, 2 studies),
complicated intra-abdominal infection (cIAI, 2 studies), nosocomial
pneumonia (NP, 1 study) and ventilator-associated pneumonia (VAP,
1 study)]. Clinical success at test-of-cure (TOC) was determined for
subjects by disease, and the pooled differences in success rates for DORI
vs. COMP agents (imipenem [IMI], meropenem [MER], levoﬂoxacin
[LVX], piperacillin/tazobactam [PIP/TAZO]) across the studies also were
determined.
Results: 44/1406 (3.1%) DORI-treated and 31/1043 (3.0%) COMP-
treated mITT subjects had A. baumannii. At TOC, 61.4%(27/44) of
DORI-treated subjects were clinical successes vs. 35.5% (11/31) of
COMP-treated subjects (weighted difference 25.9; 95% CI 3.7%, 48.0%).
17 subjects in each group received adjunctive amikacin, gentamicin,
ciproﬂoxacin, or tobramycin with clinical success in 47.1%(8/17) of
DORI vs. 23.5% (4/17) of COMP (p = 0.282) subjects that received
adjunctive therapy. Pooled clinical success rates for each disease were
as follows: cUTI, 100%(11/11) DORI vs. 0%(0/1) LVX; cIAI, 100%
(2/2) DORI vs. 100% (3/3) MER; NP/VAP, 45.2% (14/31) DORI vs.
29.6% (8/27) (IMI and PIP/TAZO). Adverse events were reported in 36
(78.3%) DORI and in 29 (85.3%) COMP-treated subjects.
Conclusion: The pooled difference in clinical success rates favoured
DORI regardless of comparator agent suggesting DORI may be an
effective alternative for the treatment of infections caused by susceptible
strains of A. baumannii.
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P1109 Doripenem clinical and microbiologic outcomes by
baseline susceptibility for Pseudomonas aeruginosa and
Acinetobacter baumannii from 5 phase 3 clinical trials
K. Kaniga, R. Redman, N. Ketter, O. Umeh, S.Y. Tong, M. Lee,
I. Friedland, A. Quintana ° (Raritan, US)
Background: Effective treatment options for infections caused by
P. aeruginosa and A. baumannii are limited. A promising alternative to
current agents could be doripenem (DOR), a new carbapenem approved
for the treatment of adults with complicated intra-abdominal (cIAI) and
urinary tract infections (cUTI) in the United States, and cIAI, cUTI, and
nosocomial pneumonia (NP) in Europe.
Methods: Per-pathogen clinical cure (CC) and microbiologic cure
(MC) rates for P. aeruginosa and A. baumannii from 5 phase 3
clinical trials were assessed. Rates for all isolates and for the subset
susceptible to the study drug received were compared between DOR
and pooled comparator agents in subjects who were microbiologically
evaluable (ME) at the test of cure (TOC) visit as well as those in the
microbiological modiﬁed intent-to-treat (mMITT) population.
Results: CC rates for all P. aeruginosa and A. baumannii isolates
combined in the ME at TOC were signiﬁcantly higher for DOR vs
pooled comparators (84.2% vs 60.0%; 95% conﬁdence interval [CI]
11.0−37.3) and for the subset of isolates with DOR minimum inhibitory
concentrations (MICs) 4mg/L vs susceptible comparators (85.6%
vs 67.6%; 95% CI 4.1−31.9). CC rates for all P. aeruginosa were
also signiﬁcantly higher for DOR vs pooled comparators (83.8% vs
60.3%; 95% CI 8.7−38.3) and for isolates with DOR MIC 4mg/L
vs susceptible comparators (83.6% vs 66.7%; 95% CI 1.5−32.7). MC
rates for all P. aeruginosa and A. baumannii combined were signiﬁcantly
higher for DOR vs comparators (81.2% vs 66.3%; 95% CI 1.7−28.1) and
numerically higher for isolates with DOR MIC 4mg/L vs susceptible
comparators (81.4% vs 67.6%; 95% CI −0.5–28.2)]. Parallel results
occurred in the mMITT population.
Conclusion: DOR was clinically and microbiologically more effective
than the pooled comparators in patients infected with P. aeruginosa and
A. baumannii causing cIAI, cUTI, and NP even when the pathogens were
susceptible to the comparator drugs received.
P1110 Resistance development studies with the novel siderophore
monobactam BAL30072
M. Page °, C. Mu¨ller, B. Hofer, E. Desarbre (Basel, CH)
Objective: Multi-resistant clinical isolates of Gram-negative bacilli were
investigated for their propensity to develop resistance to the novel
monobactam antibiotic BAL30072.
Methods: Isolates of Pseudomonas aeruginosa, Acinetobacter spp.,
Stenotrophomonas maltophilia, Enterobacter cloacae and Klebsiella
pneumoniae were examined for their propensity to spontaneously acquire
resistance to BAL30072, and selected comparators, either after single-
step selection or through repeated passaging in cultures with increasing
concentrations of test substance.
Results: The single step resistance frequencies were in the range
10−10 to 10−8 for BAL30072 against strains of Enterobacteriaceae
and Acinetobacter spp. The frequency of appearance of spontaneous
resistance to ceftazidime or meropenem in susceptible strains was
between 10−9 and 10−6. Subpopulations with elevated MICs against
BAL30072 were identiﬁed in all P. aeruginosa strains, with incidence
between 10−9 and 10−6. Subpopulations resistant to ceftazidime or
meropenem were also detected at an incidence between 10−7 and 10−4.
Repeated passaging in cultures containing BAL30072 yielded strains
with <4-fold elevated MIC after 5−20 passages. Strains with <4-fold
elevated MIC towards cefepime of meropenem appeared within 3−5
passages under the same conditions.
Conclusions: Low frequencies of spontaneous resistance to BAL30072
were observed and it was more difﬁcult to select for resistant mutants
in serial passage than it was for cefepime or meropenem.
P1111 Bactericidal effect of the novel siderophore monobactam
BAL30072
M. Page °, C. Mu¨ller, B. Hofer, E. Desarbre (Basel, CH)
Objective: BAL30072 is a novel monobactam antibiotic with potent in-
vitro activity against Gram-negative non-fermentative bacilli. We have
investigated the in-vitro time-kill kinetics of BAL30072 using a selection
of multi-resistant bacteria.
Methods: MICs were determined by standard broth micro-dilution
methods. A preliminary MBC was determined by plating out clear wells
from the MIC determination and counting colonies after 24 and 48 h
incubation. Time-kill studies were done in standard growth medium with
an inoculum of approximately 106 cfu/ml. Serial dilutions were taken at
0, 3, 6 and 24 h after inoculation.
Results: The MBC of BAL30072 was 1−4×MIC against most strains
of Enterobacteriaceae and Acinetobacter spp. tested. The MBC could
be up to 16×MIC against some strains of Pseudomonas aeruginosa
that were tested. Against the same strains the MBCs of cefepime and
meropenem were 1−4×MIC for susceptible strains of Enterobacteriaceae
and 4−>32×MIC for susceptible strains of Acinetobacter spp. and
P. aeruginosa. Time-kill analysis demonstrated that BAL30072 decreased
the cfu count by 3 orders of magnitude within 24 h at 4×MIC against
Enterobacteriaceae, Acinetobacter and at 8×MIC for P. aeruginosa. The
kill kinetics were dependent on inoculum density and were faster for an
inoculum of 5×104 cfu/ml than for an inoculum of 107 cfu/ml. The initial
kill kinetics typically depended on the concentration of BAL30072.
Conclusions: BAL30072 has marked bactericidal activity against a
range of multi-resistant Gram-negative bacteria, including carbapenem-
resistant strains.
P1112 In vitro activity of a new siderophore monobactam BAL
30072 against ESBL-producing Enterobacteriaceae and
clinical isolates of Enterobacter cloacae
K. Bowker °, T. Walsh, A.P. MacGowan (Bristol, Cardiff, UK)
Objectives: BAL 30072 (BAL) is a new siderophore monobactam with
in vitro activity against many multiresistant aerobic Gram negative
rods including Acinetobacter spp and Pseudomonas aeruginosa. In this
study, we assessed the potency of BAL against clinical strains of ESBL
producing Enterobacteriaceae and Enterobacter cloacae (Ent.cloacae) as
wild type Enterobacter spp may have aztreonam MIC of >8mg/L.
Methods: 148 strains were tested. 51 ESBL producers, E. coli n = 34;
K. pneumoniae n = 10; Ent.aerogenes n = 7; and 97 clinical isolates of
Ent.cloacae. Five antimicrobials were used, BAL; meropenem (MERO);
ceftazidime (CTAZ); piperacillin-tazobactam (P/T); cefepime (CFEP).
MICs were determined by CLSI methods but Muller-Hinton agar
supplemented with 2.2 dipyridyl was used for BAL to induce iron
transport.
Results: MICs, range, MIC50, MIC90 (mg/L) are shown in the table.
BAL MER CTAZ P/T CFEP
ESBL producers
E. coli range 0.03−64 0.008−0.06 2−64 4−64 0.12−64
MIC50 1 0.015 16 32 8
MIC90 2 0.03 32 64 32
K. pneumoniae range 0.06−64 0.015−0.06 2−64 32−64 0.25−8
MIC50 64 0.015 64 32 2
MIC90 64 0.06 64 64 8
Ent. aerogenes range 0.06−64 0.015−0.06 0.12−64 4−64 0.03−8
MIC50 0.5 0.03 32 32 0.25
Clinical strains
Ent. cloacae range 0.008−64 0.008−0.25 0.12−64 1−64 0.015−16
MIC50 2 0.015 4 16 0.12
MIC90 64 0.06 64 64 4
Conclusions: MERO was the most potent b-lactam against these ESBL
producers, and Ent.cloacae. BAL shows in vitro activity against the
majority of ESBL producers and also clinical strains of Ent.cloacae.
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P1113 Pharmacokinetics, pharmacodynamics and safety proﬁle of a
fully human IgM anti-Pseudomonas aeruginosa serotype O11
monoclonal antibody KBPA 101 in healthy volunteers
H. Lazar °, M.P. Horn, A.W. Zuercher, M.A. Imboden, P. Durrer,
M. Seiberling, R. Pokorny, C. Hammer, A.B. Lang (Berne, Lausanne,
Allschwil, Geneva, CH)
Objectives: To obtain pharmacokinetics, pharmacodynamics and safety
data after ﬁrst administration of KBPA 101, in humans.
Methods: In a double blind, dose escalation study, 32 subjects were
randomised in 4 groups to receive a single intravenous infusion of
KBPA 101: 0.1, 0.4, 1.2 or 4mg/kg body weight (in each group
6 subjects received KBPA 101 and 2 placebo). Plasma samples for
pharmacokinetics were taken pre-dose and at different times up to
14 days after start of dosing. Blood samples for analysis of antibodies
to KBPA 101 were obtained at screening and on days 7 and 14. Blood
samples for assessment of C-reactive protein (CRP), tumour necrosis
factor alpha (TNF-a), interleukin-8 (IL-8), and total complement activity
(TCA) were obtained at pre-dose, and at different times up to 48 hours
after infusion.
Results: Plasma concentrations of KBPA 101 showed a mean maximum
concentration of 1877, 7571, 24923 and 83197 ng/mL following doses of
0.1, 0.4, 1.2, and 4.0mg/kg body weight, respectively. Mean elimination
half life ranged from 70 to 95 hours. Mean volume of distribution was
between 4.76 and 5.47 litres. Clearance ranged between 0.039 and 0.120
L/hr. KBPA 101 exhibited linear kinetics across all doses. No anti-KBPA
antibodies were detected. No clinically signiﬁcant variation was observed
in CRP, TNF-a, IL-8, and TCA. No serious adverse events were observed
and none of the subjects discontinued due to an adverse event. Eight out
of 32 subjects reported nine adverse events (7 mild and 2 moderate).
Seven subjects who received KBPA 101 had 7 adverse events (6 mild,
1 moderate) and one subject on placebo had 2 adverse events (1 mild,
1 moderate). Three subjects reported 3 adverse events (all mild) related
to KBPA 101 (feeling of pressure in head, pressure at heart site and
headache). All adverse events resolved without sequelae. There was no
increase in the incidence of adverse events with increasing dose.
Conclusion: The fully human IgM anti-Pseudomonas aeruginosa
monoclonal antibody KBPA 101 was well tolerated over the entire
dose range, no serious adverse events were observed, no clinically
signiﬁcant variation was observed in any inﬂammatory markers and its
pharmacokinetic proﬁle was similar to a native IgM.
P1114 Developing DNA-based therapies to tackle antibiotic
resistance
J. Moore °, M. McArthur, M.J. Bibb (Norwich, UK)
Background: With the prevalence of antibiotic resistance amongst
pathogenic bacteria increasing, alternative therapies to combat bacterial
infection are required. We are developing a novel approach to combat
the spread of antibiotic resistance in pathogenic bacteria: Transcription
Factor Decoys (TFDs). TFDs are short stretches of DNA that contain
the binding site for a targeted transcription factor; when introduced into
cells in sufﬁcient number TFDs sequester the transcription factors and so
prevent them from binding their genomic targets within promoters, with
a concomitant modiﬁcation of gene expression. As such TFDs represent
a universal genetic tool capable of altering prokaryotic phenotypes
Objectives:
1. To develop this technology further so it can be used against a range
of clinically relevant bacteria.
2. Development of the methods of transfection.
3. Identiﬁcation of new TFD targets.
Methods: The effectiveness of the TFDs and transfection method
assessed by bacterial growth rate TFDs created by PCR
Results:
1. E. coli grown with TFDs display reduced growth.
2. S. aureus grown with TFDs display reduced growth and in some cases
viability was below detectable levels.
3. TFDs can be used to sensitising M. smegmatis to antibiotics.
Conclusions: As such TFDs represent a universal genetic tool capable of
altering prokaryotic phenotypes which we have now applied to sensitising
previously resistant pathogenic bacteria to antibiotics.
P1115 SASP: A novel antibacterial protein with potential to limit
the spread of antibiotic resistance
S. Holme, A. Wilkinson, H. Fairhead ° (Cambridge, UK)
Objectives: Antibiotic resistance spread by mobile genetic elements
is of signiﬁcant clinical importance. An antibacterial agent that can
also inactivate such elements and prevent their spread between bacteria
could provide profound clinical beneﬁt. Novel antibacterial protein,
SASP, binds to all bacterial DNA in a non sequence-speciﬁc manner
halting DNA replication and gene transcription. It is rapidly bactericidal.
SASPject is a novel technology using modiﬁed bacteriophages to deliver
SASP genes to target pathogens. SASPject PT1.2 delivers SASP genes
to S. aureus, including MRSA. The ability of SASP to limit the transfer
of plasmid-derived antibiotic resistance by rendering plasmid DNA
unusable by other bacteria was assessed and compared to ciproﬂoxacin
(Cip), a DNA gyrase inhibitor.
Methods:
1. The effect of puriﬁed SASP on the transfer of antibiotic re-
sistance: E. coli/S. aureus shuttle plasmid pSM198 (ampicillin
(Amp)/tetracycline (Tet) resistant) was incubated with puriﬁed SASP
at ratios between 0:1 to 10:1 SASP:DNA. DNA from each reaction
was precipitated and used to transform competent S. aureus.
Transformants were enumerated after 16 h incubation at 37ºC on
Luria-Bertani (LB) agar plates containing Tet (0.01mg/ml).
2. The effect of PT1.2-delivered SASP vs Cip on the transfer of
antibiotic resistance: A culture (3×108 cfu) of S. aureus carrying
pSM198 was infected with 6×108 pfu PT1.2 or its Wild Type
parental phage, or treated with Cip (1 or 4×MIC). After 45min
incubation, collected cells were lysed. Lysate (5 microlitres) was
used to transform E. coli. Transformants were enumerated after 16 h
incubation at 37ºC on LB agar plates containing Amp (0.1mg/ml).
Results:
1. As SASP:DNA ratios increase, the number of transformed Tet
resistant S. aureus cells decrease − up to 99% fewer compared with
the control.
2. Lysate of PT1.2 infected cells produced 90% fewer Amp resistant
E. coli transformants than lysate of parental phage, or Cip treated
cells.
Conclusion: SASP’s unique antibacterial mode of action also gives it
potential to reduce the spread of plasmid-derived antibiotic resistance
from targeted pathogens, potentially generating signiﬁcant clinical
beneﬁts.
P1116 In vitro susceptibility of Campylobacter jejuni to organic
acids and monoacylglycerols
Z. Molatova °, E. Skrivanova, M. Marounek, P. Brezina (Prague, Zlin, CZ)
Objective: Antimicrobial resistance among foodborne pathogens has
been recognized as an important emerging public health problem.
Campylobacter is one of the most common causes of foodborne diseases,
moreover increasing its antimicrobial resistance has been reported.
Therefore, it is important to develop means to control the transmission
of Campylobacter jejuni from food to humans. Organic acids, used for
decades as food and feed preservatives, continue to be the alternative
of choice. The aim of the present study was to evaluate antimicrobial
activity of 19 organic acids and two monoacylglycerols against C. jejuni
by the SYBR Green based real-time PCR.
Methods: Susceptibility of C. jejuni CCM 6214 (ATCC 33560) to 19
organic acids (acetic, propionic, butyric, caproic, caprylic, capric, lauric,
myristic, palmitic, stearic, oleic, sorbic, fumaric, succinic, benzoic,
phenylacetic, lactic, malic and citric) and two monoacylglycerols
(monocaprylin a monocaprin) was determined in cultures grown on
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glutamic acid. The antimicrobial activity was measured at two pH
regimes (5.5 and 6.5) and was expressed as IC50, i.e. as the concentration
of a tested acid that causes a 50% reduction of bacterial growth, in
comparison with control (untreated) cultures. Effect of most effective
organic acids on strain C. jejuni CCM 6214 was studied by transmission
electron microscopy.
Results: Caprylic acid followed by capric and lauric acid (i.e. straight-
chain fatty acids with 8 to 12 carbon atoms, respectively), were found
to be the most active in inhibiting the growth of C. jejuni (IC50
<0.1mg/mL). Antimicrobial activity of organic acids tested was pH-
dependent, being more pronounced at lower pH. The results of the
present study show that antimicrobial activity of other organic acid
against C. jejuni is variable and supplementation of feeds with some
acids would not present any protection.
Conclusion: Obtained results demonstrate the potential use of medium-
chain fatty acids against Campylobacter jejuni at concentration feasible
in vivo.
Acknowledgments: This study was supported by the Grant Agency of
the Czech Republic (grant no. 525/08/H060) and by the Ministry of
Agriculture of the Czech Republic (project MZe 0002701404).
P1117 A note on the effect of medium-chain fatty acids on
arcobacters
E. Skrivanova °, M. Matenova, Z. Molatova, M. Marounek (Prague, CZ)
Objectives: The genus Arcobacter, formerly known as aerotolerant
Campylobacter, is included in the family Campylobacteraceae. Up to the
present time, six species have been characterised within the Arcobacter
genus. Out of six Arcobacter species, four are considered as emerging
foodborne pathogens: Arcobacter butzleri, A. skirowii, A. cryaerophilus
and A. cibarius. The clinical signiﬁcance of these organisms to humans
is limited. However, three species, A. butzleri, A. cryaerophilus and
A. skirrowii have been found to be associated with human diarrhoeal
illness. A. butzleri is the fourth most common Campylobacter-like
organism isolated from the stool of human patients in Belgium and
France. The association of Arcobacter spp. with human gastroenteric
illness has also been reported in other countries. Infection may occur
by handling or consumption of contaminated water and food of animal
origin. The highest prevalence was found in poultry, followed by pork
ad beef. The study aims to evaluate the effect of medium chain fatty
acids on three predominant arcobacters, A. butzleri, A. cryaerophilus
and A. skirrowii.
Methods: Antibacterial activity of medium chain fatty acids (C6−C12)
was tested in vitro by the real-time PCR method, using speciﬁc primers.
Data were analyzed by the comparative Ct method. Positive control
(untreated cultures of arcobacters) was used as the calibrator to express
the relative fold-induction (2(-ºCt)) for each sample.
Results: All arcobacters showed a very high sensitivity to all medium
chain fatty acids tested. The IC50 values ranged from 0.1 to 1mg/ml.
The most sensitive was A. skirrowii, followed by A. cryaerophilus. The
strongest antibacterial activity was observed in lauric acid (C12).
Conclusion: Our results showed that medium chain fatty acids have
a strong potential as alternative antibacterial agents in combating with
arcobacters.
Acknowledgements: The study was supported by the Ministry of
Agriculture of the Czech Republic (project MZe 0002701404).
P1118 Antimicrobial and anti-pathogenic features of some new
oxepins
M. Bucur, L.G. Marutescu, M.C. Chiﬁriuc, C. Bleotu, C. Limban °,
A.V. Missir, I. Chirita, G.M. Nitulescu, D.C. Nuta, C. Badiceanu,
V. Nesrin, V. Lazar (Bucharest, RO)
Objectives: The aim of the present study was to evaluate some newly
synthesized new oxepins for their antimicrobial and anti-pathogenic
features, respectively.
Methods: Sixteen new oxepins derivatives were synthesized in a several
stages synthesis and the new compounds were characterised by their
physicochemical properties and the chemical structures and purity were
conﬁrmed by elemental analysis and spectral studies (IR, 1H-NMR, 13C-
NMR). The original compounds were solubilised in dimethylsulfoxide
(DMSO) and screened for their in vitro antimicrobial activity against
Gram-positive, Gram-negative bacteria and fungal strains, using both
reference and clinical, multidrug resistant strains, using the qualitative
adapted diffusion method and the quantitative assay of the antimicrobial
activity performed by nutrient broth microdilution method in order
to establish the minimal inhibitory concentration. The subinhibitory
concentrations of the tested substances were investigated for their
inﬂuence on the adherence capacity to the cellular substrate represented
by HeLa cells and to inert substrata quantiﬁed by slime test and on
the expression of soluble enzymatic virulence factors (haemolysins and
other pore-forming toxins, proteases activity, DNA-se and siderophores
production).
Results: Our results showed that the new compounds did not exhibit
signiﬁcant antimicrobial activity (MIC values >1mg/ml). In exchange,
they interferred with the expression of different virulence factors
implicated in the pathogenicity of these opportunistic strains. All
analyzed compounds decreased the ability of the tested microbial strains
to adhere both to the cellular and inert substrata and also induced changes
in the adherence patterns. Concerning the soluble virulence factors,
the tested compounds induced decreases of various degrees (%) in the
expression of haemolysins (28.5−86%), lipase (100−28.5%), lecithinase
(17−67%), gelatinase (0−71.5%), caseinase (0−45%), DN-ase (0−53%)
and siderophores production (13–100%).
Conclusion: The present study proved that the new oxepins, in the
absence of a signiﬁcant antimicrobial activity, attenuated the virulence
of different microbial strains, by inhibiting the expression of adhesion
molecules and secretion of soluble, enzymatic factors thus altering the
success of these pathogens in the colonisation of a sensitive host and the
development of an infectious process.
P1119 In vitro antifungal activity of corifungin, a new water-soluble
polyene, against sensitive and resistant Candida species
J. Vazquez °, D. Boikov, D. Vager, J. Tunac (Detroit, Mountainview, US)
Objective: The antifungal activity of a new water soluble polyene,
corifungin, was evaluated against clinical strains of Candida species.
Methods: In vitro evaluation of corifungin was performed and compared
to amphotericin B deoxycholate (AmB) against 35 different strains of
Candida which included C. albicans (5), C. krusei (5), C. tropicalis (5),
C. lusitaniae (5), C. glabrata (5), C. dubliniensis (5). This included
several C. glabrata strains with multi-drug resistance patterns. In-vitro
evaluation was performed using the CLSI standards and read at 48 hrs.
Results: The mean minimal inhibitory concentration (MIC) of corifungin
and AmB for C. albicans was 0.5mg/ml and 0.5mg/ml, respectively, for
C. tropicalis 0.5 and 1mg/ml, for C. dubliniensis 0.125 and 0.5mg/ml,
for C. parapsilosis 0.5 and 1mg/ml, for C. lusitaniae 0.5 and 1.0mg/ml,
for C. krusei 2 and 1mg/ml, and for C. glabrata 0.5 and 1.0mg/ml,
respectively.
Conclusion: The results indicate that corifungin demonstrated excellent
in vitro antifungal activity with low MICs against the most common
Candida species, with slightly less activity against C. krusei. In addition,
corifungin also demonstrated good activity against the several multi-
azole resistant C. glabrata species. Corifungin appears to be an excellent
candidate for the treatment of candidal infections.
P1120 Intracellular activity of anidulafungin against Candida spp.
S. Ballesta °, I. Garcı´a, A. Pascual (Seville, ES)
Objectives: Anidulafungin is a new echinocandin antifungal agent. It has
fungicidal activity against many Candida spp., including ﬂuconazole-
resistant, and fungistatic activity against other yeast and moulds such
as Aspergillus spp. The intracellular activity of anidulafungin against
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Candida albicans (susceptible and resistant to ﬂuconazole strains) and
Candida krusei inhuman polymorphonuclear leukocytes (PMNs) has
been evaluated.
Methods: C. albicans (two isogenic strains; ﬂuconazole susceptible and
resistant) and C. krusei were used for killing assays. Susceptibility
studies were determined by microdilution according to CLSI, M27-
A2. To evaluated the intracellular activity, PMNs and opsonised yeasts
(PMN/yeast; 1/10) were incubated for 30min at 37ºC. Extracellular
yeasts were removed by differential centrifugation and PMN containing
intracellular yeasts are incubated in RPMI for three hours in the presence
of different extracellular concentrations of anidulafungin. Afterwards,
cells are disrupted by osmotic shock and intracellular survival is
determined by pour plating method (CFU counted onto Saboureaud
Agar). The data were expressed as percentages of Candida surviving
compared with levels in controls (without antifungal agent).
Results: At all extracellular concentrations evaluated (1, 5 and 10mg/L),
anidulafungin reduced signiﬁcantly the surviving intracellular Candida
krusei (percentage of surviving Candida compared to the control: 52+-
12, 38+-5 and 32+-8 respectively). At extracellular concentrations of 5
and 10mg/L, anidulafungin also showed signiﬁcant intracellular activity
against both strains of Candida albicans (ﬂuconazole susceptible and
resistant).
Conclusions: At extracellular concentrations higher than 1mg/L,
anidulafungin showed signiﬁcant intracellular activity against Candida
albicans and Candida krusei.
P1121 Activity of N-chlorotaurine against protozoa
U. Fu¨rnkranz, J. Walochnik, M. Nagl ° (Vienna, Innsbruck, AT)
Objectives: N-chlorotaurine (NCT), a long-lived oxidant produced by
human leukocytes, can be synthesized chemically as sodium salt and
is presently investigated as an antiseptic. It is a mild active chlorine
compound and very well tolerated at different body sites. The aim of
the present study was to investigate its activity against protozoa which
might come into question for topical treatment.
Methods: Promastigotes and amastigotes of Leishmania infantum and
L. donovani, Trichomonas vaginalis, and trophozoites and cysts of
Acanthamoeba were suspended in NCT solutions, and after different
incubation times the killing of parasites was evaluated using trypan blue
staining and microscopy.
Results: Viability of all tested protozoa was reduced by NCT. Times
needed for complete killing by a concentration 1% NCT (55mM) were
approximately 2 h for leishmaniae, 1 h for acanthamoebae, and 15min
for trichomonads. Inactivation of parasites was still observed at tenfold
lower NCT-concentrations. A delay of excystation of amoebae could
also be detected. However, cysts could only be inactivated completely
by addition of ammonium chloride to NCT, which enhanced the activity
against all tested parasites signiﬁcantly.
Conclusion: NCT demonstrated broad-spectrum activity against proto-
zoa and it may be considered for topical treatment of such infections. The
booster effect by ammonium chloride can be explained by formation of
monochloramine which penetrates pathogens better because of its higher
lipophilicity.
P1122 Drug inhibition of HDAC activity: effect on the parasite
Toxoplasma gondii and chemotherapy perspectives
D. Maubon, A. Bougdour, Y.S. Wong, M.A. Hakimi, H. Pelloux °
(Grenoble, FR)
Toxoplasmosis is one of the most common parasitic diseases. The
intracellular parasite T. gondii belongs to the Apicomplex family, as
Plasmodium species, with which it shares lots of molecular similarities.
T. gondii life cycle is complex and characterised by the interconversion
phenomenon, which is the ability of the parasite to differentiate from a
tachyzoite form to a cystic structure. Cysts are mostly asymptomatic in
healthy people, but if reactivating, could be potentially life threatening in
immunocompromised patients. It has been established that the epigenetic
machinery of T. gondii is a major tool in the control of gene transcription
and more precisely that acetylation of histones plays a substantial role
in parasite interconversion.
Objectives: As a tool to clarify the role of epigenetic mechanisms in
T. gondii, we used histone deacetylase inhibitors (HDACi) and observed
the phenotypic and molecular consequences on the parasite. Potential
therapeutic effect, on both tachyzoites and cyst forms was also evaluated.
Methods: In vitro studies were conducted with different T. gondii strains.
Different HDACi belonging to the hydroxamic family (TSA, Scriptaid)
or to the tetrapeptid cyclic family (Apicidin, DrugA, HC Toxin) were
tested. Other drugs were also newly synthesized to further understand
the mechanism of action and to optimise the anti-parasitic effect. Ex-
vivo cysts were also treated with DrugA, than reinjected in mice to study
their infective power.
Results: Interfering on histone deacetylase(s) dramatically changed
parasite phenotype, pushing it through bradyzoite conversion but also
interrupting its proliferation. Only drugs belonging to the cyclic
tetrapeptide family of HDACi showed signiﬁcant efﬁciency without
disrupting human host cells. Ex vivo cysts treated for 7 days with DrugA
appeared morphologically normal, but were unable to infect mice as
serology remained negative and as no cyst were detected in mice brains
6 weeks after infection.
Conclusions: Using HDACi as a chemical knock-out of hdac(s) on
T. gondii, made us sight the importance of histone acetylation and
epigenetic control of gene transcription in the natural course of
parasite being. It also brought consistent results in growth inhibition
of tachyzoites and in blocking the infective power of cysts, which are
necessary to disease transmission. These results are promising in ﬁnding
new therapeutic agents or molecular targets in toxoplasmosis and other
apicomplex infection.
P1123 Mechanism of action of Melaleuca alternifolia (tea tree) oil
on inﬂuenza A/PR/8 virus replication
B. Bisignano °, R. Timpanaro, A. Garozzo, A. Stivala, G. Tempera,
A. Castro (Catania, IT)
Objectives: Our previous study demonstrated that the Melaleuca
alternifolia (Tea Tree) Oil (TTO) had an interesting antiviral activity
against Inﬂuenza A/PR/8 virus subtype H1N1 in MDCK cells.
When we tested TTO and some of its components we found the TTO,
the terpinen-4-ol, the terpinolene, the alfa-terpineol to have an inhibitory
effect on Inﬂuenza virus replication at doses below the cytotoxic dose;
the terpinene-4-ol was the main active component.
Studies on time of addition experiments suggested that the TTO exerts an
interference with an early step of the viral replicative cycle of Inﬂuenza
virus.
The aim of this study was to investigate the effect of TTO on viral
attachment and on acidiﬁcation of endosomal/lysosomal compartments
of living cultured cells.
Methods: The inhibition of attachment was studied by the infective
centre assay and the effects of the TTO on acidiﬁcation of lysosomes
were tested by vital staining with acridine orange using Baﬁlomycin A1
as positive control. MDCK colture cells, stained with acridine orange,
were examined by a ﬂuorescence light mycroscopy or quantiﬁed in
RFUs (relative ﬂuorescence units) using a ﬂuorimeter Wallac Victor 2
multilabel counter.
Results: The inﬂuence of the TTO on the virus adsorption step, studied
by the infective centre assays, indicated that TTO did not interfere with
cellular attachment of virus.
When MDCK cells were stained with acridine orange, nuclei and the
cytoplasms showed green ﬂuorescence, whereas orange ﬂuorescence
was observed in a granular pattern in the cytoplasm, due to acidiﬁed
lysosomes. Treatment of cells with 0.01% (v/v) and 0.005% (v/v) of
TTO at 37ºC for 2 h before staining caused complete disappearance
of the orange ﬂuorescence, whereas the green ﬂuorescence remained.
This results was conﬁrmed by measuring the ﬂuorescence intensity
by ﬂuorometry, indicating that TTO clearly inhibited acridine orange
accumulation in acid cytoplasmic vescicles.
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Conclusion: These data suggest that TTO interferes with an early
step of Inﬂuenza virus replicative cycle, after viral adsorption. Our
results indicated that this compound could inhibit viral uncoating by
an interference with acidiﬁcation of intralysosomal compartment.
P1124 Bio-informatic prediction of herpes simplex virus type 1
latency-associated transcript microRNA and their mRNA
neurotransmitter targets
W. Kwanhian, W. Namwat, V. Lulitanond ° (Khon Kaen, TH)
In herpes simplex virus type 1 (HSV-1) latent infection, no viral
gene is transcribed, except the latency-associated transcript (LAT) gene.
Although LAT is able to transcribe to mRNA and accumulates at high
copy number in the nuclei of latently infected cells, its protein product
is not found. Previous studies showed that HSV-1 LAT expression in
sensory neuron affected the level of certain neuropeptide expressions,
especially substance P (SP) and calcitonin-gene related peptides (CGRP)
genes, but its mechanism is still unclear. Recently, HSV-1 LAT derived
microRNAs (miRNAs) have been proposed for the regulation of both
viral and host genes expression. For these reasons, we speculate that
HSV-1 LAT-miRNA might regulate SP and CGRP expression by using
its miRNA property.
Objective: To predict miRNAs generated from HSV-1 LAT mRNA
precursor and to characterise their mRNA neurotransmitter targets by
bioinformatic approaches.
Methods: The web-based programs, Bayes-SVM-MiRNA web
server version 1 (http://wotan.wistar.upenn.edu/BayesSVMmiRNAﬁnd/),
was used to predict miRNAs generated from HSV-1 LAT
mRNA and the RNAhybrid program (http://bibiserv.techfak.uni-
bielefeld.de/rnahybrid/submission.html) was used to locate the binding
site of SP and CGRP mRNA targets and their binding activities.
Results: Two HSV-1 LAT miRNA (V1-miRNA and V2-LAT-miRNA)
with the size of 21 nucleotides were predicted from Bayes-SVM-MiRNA
program. After deﬁning targets of HSV-1 LAT miRNAs in Tac 1 (SP
gene) and CGRP mRNAs to RNA hybrid program, it was found that V1-
miRNA and V2-LAT-miRNA are able to bind to internal site of target
mRNAs at highest negative MFE (minimum free energy) of −28.4 and
−32.4 kcal/mol, respectively.
Conclusion: In order to save time and resources before implementation
of any experimental works, we have used the web-based program
to predict HSV-1 LAT miRNAs and their neurotransmitter targets.
The results are encouraging for further veriﬁcation by experimental
approaches in order to elucidate the biological role of HSV-1 LAT.
P1125 In vitro activity of ﬁve antimicrobial peptides against
colistin-susceptible and resistant Acinetobacter spp.
X. Vila °, S. Marti, E. Giralt, J. Vila (Barcelona, ES)
Objective: To test the activity of ﬁve antimicrobial peptides (AMPs)
against Acinetobacter baumannii, Acinetobacter genospecies 3 and
Acinetobacter genospecies 13, which were susceptible and resistant to
colistin.
Methods: Three Acinetobacter clinical isolates, belonging to A. bau-
mannii, Acinetobacter. genospecies 3 and Acinetobnacter. genospecies
13 were chosen to perform this study. The A. baumannii ATCC 19606
was also included. Colistin-resistant mutants of the above mentioned
strains were selected by serial passages from each strain in subinhibitory
concentrations of colistin. The MICs of magainin II, cecropin P1,
buforin, indolicidin, a-defensin for colistin-suspectible and resistant
Acinetobacter spp. were determined with a microdilution assay using
both cation-supplemented and unsupplemented Muller-Hinton broth.
Results: The results of the MICs using both media were similar with
only slight differences. All colistin-resistant Acinetobacter spp. mutants
showed a MIC of colistin of 256mg/L. The AMPs could be distributed
in three groups according to their activity: i. Magainin II, a-defensin, and
buforin did not show activity against colistin-susceptible and -resistant
Acinetobacter spp. (MIC> 32mg/L for both colistin-susceptible and
-resistant). ii. Cecropin P1 showed similar activity as colistin (MIC of
0.5mg/l for the susceptible strain and of >32mg/L for the resistant
strain) and iii. Indolicidin showed a good activity for both colistin-
susceptible and -resistant Acinetobacter spp. (MICs of 1−2mg/ml for
both susceptible and resistant Acinetobacter spp.). Indolicidin presented
the same activity against all three Acinetobacter spp..
Conclusions: Indolicidin shows good activity against colistin-susceptible
and -resistant Acinetobacter species, suggesting a different mechanism
of resistance than that for colistin. This peptide may be a potential drug
for treatment of panresistant A. baumannii infections.
P1126 Squalamine, a new antibiotic extracted from marine
environment
K. Alhanout ° (Marseille, FR)
Objectives: Extensive use of antibiotics has raised a serious public
health problem due to infections caused by multidrug-resistant bacterial
pathogens. Consequently, there is a pressing need to develop new
antibiotics to keep pace with bacterial resistance. Recently, a new
aminosterol called squalamine [1] has been isolated from tissues of
the dogﬁsh shark, Squalus acanthias. This unusual natural product
has attracted considerable interest because of its potent antimicrobial
activities against a broad spectrum of microorganisms. [1]
Squalamine
Methods: The feasibility of obtaining large quantities of this steroidal
antibiotic, from natural sources or by synthesis, appears questionable.
In order to understand the structure-activity relatationships of such
compounds, we have recently developed the synthesis [2] of a structural
analogue of squalamine [2] mimicking not only its structure but also its
antimicrobial properties.
Results: We have envisioned the possibility that these derivatives might
be able to disrupt the organisation of the Gram-negative bacterial mem-
branes. The antibacterial action manifested via permeabilisation of the
outer membrane of Escherichia coli bacteria has been demonstrated. [3]
On the other hand, a different mechanism of action of such derivatives
towards Gram-positive bacteria has been determined by electron
microscopy analysis and membrane depolarisation measurements and
will be discussed.
Conclusion: Squalamine is a membrane-active molecule that targets
the membrane integrity and consequently, its activity and mechanism
of action corelates with the membrane lipid composition.
Reference(s)
[1] Brunel, J.M.; Salmi, C.; Loncle, C.; Vidal, N.; Letourneux, Y. Curr
Cancer Drug Targets 2005, 5, 267–272.
[2] Loncle, C., Salmi, C., Letourneux, Y., Brunel, J. M. Tetrahedron
2007, 63, 12968–2974.
[3] Salmi, C.; Loncle, C.; Vidal, N.; Letourneux, Y.; Fantini, J.; Maresca,
M.; Taı¨eb, N.; Page`s, J. M.; Brunel, J. M. Plos One 2008, 3(7), e2765.
P1127 Large antibacterial activity spectrum of aminosterols
derivatives towards multidrug-resistant Gram-negative and
Gram-positive bacteria from patients with cystic ﬁbrosis
K. Alhanout ° (Marseille, FR)
Objectives: Resistance to antibiotics is a life-threatening danger with
more severe impacts on fragilised populations like cystic ﬁbrosis (CF)
patients [1]. Squalamine and AminoSterol Derivatives (ASDs) have
demonstrated interesting antimicrobial activities against several bacterial
and fungal reference strains 2, 3. However, when it comes to resistant
clinical strains the challenge is evidently more difﬁcult.
Methods: Antimicrobial activities of squalamine [1] and a synthesized
aminosterol [2] against multidrug-resistant bacterial and fungal clinical
strains were investigated. 135 bacterial isolates were recovered from
sputa of CF patients and 70 fungal strains composed of 50 ﬁlamentous
fungi isolated from sputa of patients with respiratory disorders (including
CF) and 20 non-ﬁlamentous bloodstream isolates.
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Results: In the case of Gram-negative bacteria, MICs ranged from 2 to
128mg/L. Mucoidity of P. aeruginosa strains and resistance to colistin
correlated signiﬁcantly with high MIC values. In contrast, compounds
1−2 appeared very active against various Gram-positive bacteria with
highest MIC value of 4mg/L. Concerning the antifungal activity,
compound 2 appeared more active than squalamine against tested
fungal strains as reﬂected by MIC values (1−4mg/L vs. 8−32mg/L,
respectively).
Conclusions: In spite of correlating with colistin in activity against
Gram-negative bacteria, tested compounds demonstrated surprising
higher antibacterial effect against Gram-positive isolates naturally
resistant to colistin indicating probably the presence of different
mechanism of action against both group of bacteria. On the other
hand, the antifungal activity was notably enhanced by modifying the
aminosterol structure. Taken together, our results indicate that ASDs
possess a broad antimicrobial spectrum against various bacterial and
fungal clinical strains.
Reference(s)
[1] Govan JR, Nelson JW. J R Soc Med 1993; 86 Suppl 20: 11−8.
[2] Salmi C, Brunel JM. Expert Opin Investig Drugs 2007; 16: 1143−57.
[3] Brunel JM, Salmi C, Loncle C, et al. Curr Cancer Drug Targets
2005; 5: 267−72.
Update on pneumococcal vaccines: 7, 10, 13
or 23?
P1128 Assessment of all-cause pneumonia admissions before
introduction of the pneumococcal conjugate vaccine in
Switzerland
B.Y. Betsch °, K. Mu¨hlemann (Berne, CH)
Objective: To describe the baseline epidemiology of hospitalised
pneumonia before the introduction of the 7-valent pneumococcal
conjugate vaccine in Switzerland in 2006.
Methods: National hospitalisation data were obtained from the Federal
Institute of Statistics for the years 1998–2006 including the primary
diagnosis (ﬁrst-listed; International Classiﬁcation of Diseases), up to 7
additional diagnoses, and other parameters characterising hospitalisation.
Community acquired pneumonia (CAP) was deﬁned by a primary
diagnosis of pneumonia or meningitis/septicaemia plus a code for
pneumonia. Pneumococcal CAP (SpnCAP) was deﬁned as CAP with a
pneumococcal disease code. Hospitalisation rates for CAP and SpnCAP
were calculated by segmented regression analysis.
Results: There were 122,572 hospitalisations for CAP (annual average
15,322). SpnCAP was coded in 5.1% of CAP. CAP hospitalisation rates
showed a rising trend between 1998 and 2001 probably due to a reporting
bias. Thereafter, annual CAP (SpnCAP) rates per 105 populations were
stable at an average of 425 (21). Rates varied by age group with highest
rates among the <2 years olds 362 (14) and the >80 years olds 1525
(64). Males predominated (57%) especially in the <2 years olds (58%),
and the elderly (60%). Ethnicity was Swiss in 84% of CAP cases, but
this proportion was lower for <2 years olds (73%) and increased with
age to reach 90% in the elderly. Average hospital stay was 13 days, but
stay was shortest for the younger age groups and increased with age from
6.1 days in the <2 years olds to 17 days in the >80 years olds. Case
fatality rate was 7.4% overall with most (88%) fatal cases occurring in
the elderly. Admission to intensive care treatment was needed in 6.2%
of CAP.
Conclusion: Data for the pre-vaccine years 2002 to 2005 serve as
baseline for evaluating the impact of conjugated pneumococcal vaccines.
P1129 Invasive pneumococcal disease among adults in Germany
after the start of the National Immunisation Programme
for the 7-valent pneumococcal conjugate vaccine in children
M. van der Linden, R.R. Reinert, M. Imo¨hl ° (Aachen, DE; Paris, FR)
Objectives: Streptococcus pneumoniae is a leading cause of pneumonia,
sepsis and meningitis in Germany and disproportionately affects young
children and the elderly. In July 2006 a general recommendation the
vaccination with a 7-valent pneumococcal conjugate vaccine (PCV7) for
all children up to the age of 24 months was made by the German Health
authorities and the vaccination program was started in January 2007 in
all federal countries with the exception of Saxony where vaccination
started one year earlier. In this paper we present the effects of routine
vaccination of young children with PCV7 on the rates of IPD in the
adult population (indirect or herd immunity effect).
Methods: The National Reference Center for Streptococci has monitored
the epidemiology of invasive pneumococcal disease (IPD) in adults
in Germany since 1992. Cases of IPD in adults are reported by
a laboratory-based surveillance system including 265 laboratories
throughout Germany. For three federal states (North Rhine-Westphalia,
since 2001, Saxony and Bavaria, since 2006) a population-based
surveillance has been conducted. The present analysis includes cases
from 2002 to 2009. In January 2007 a nationwide web-based surveillance
system was introduced. Species conﬁrmation was done by optochin
testing and bile solubility testing. All isolates were serotyped using the
Neufeld Quellung reaction.
Results: Due to enhanced surveillance the number of reported cases
increased from 421 in the pneumococcal season 2003–2004 to 1761 in
2007–2008. Since reporting of IPD is not mandatory in Germany the
calculation of incidences is not possible. However, a reduction of the
percentage of IPD cases caused by vaccine serotypes should indicate a
vaccination effect.
From 2002 to 2006 the percentage of vaccine type IPD in adults in
Germany has varied between 42.9% and 48.5%. In 2007–2008 this
percentage has dropped to 33.4. In the three populations based studies
we made similar observations. The 13-valent pneumococcal conjugate
vaccine (in development) would have covered 72.9% of IPD in adults in
2007–2008 in Germany.
Conclusions: The introduction of routine childhood immunisation with
PCV7 in Germany has led to a strong reduction of IPD in children in
Germany. The results presented here show a reduction in the percentage
of IPD cases in adults caused by vaccine serotypes. This might indicate
a herd-immunity effect.
P1130 Effectiveness of heptavalent pneumococcal conjugate
vaccination on invasive pneumococcal disease one year
after the introduction in the Danish childhood vaccination
programme
Z.B. Harboe °, P. Valentiner-Branth, T.L. Benﬁeld, J.J. Christensen,
M. Howitz, P. Andersen, K.A. Krogfelt, S. Glismann, L. Lambertsen,
H.B. Konradsen (Copenhagen, DK)
Objective: On 1 October 2007, the heptavalent pneumococcal conjugate
vaccine (PCV7) was introduced in the Danish childhood vaccination
program. Vaccination was offered to all children born after 1 April 2006,
at 3, 5, and 12 months of age (mo.) (2+1 schedule). A catch-up program
of two doses was offered to children between 12−17mo. We evaluated
the effectiveness of PCV7 on invasive pneumococcal disease (IPD) one
year after PCV7 introduction.
Methods: Prospective cohort study including nation-wide laboratory
surveillance data on IPD and data on PCV7 coverage from the Danish
Childhood Vaccination Registry. The pre-PCV7 period was deﬁned as
2000–2007. The effectiveness of PCV7 was estimated for 2008 based
on IPD data from 1 January to 15 December 2008. PCV7 coverage
was estimated per 1 June 2008. For children aged 0−2mo. at PCV7
implementation, 94% had received at least one dose and 74% at least
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two doses. In the catch-up program, 86% of children between 3−14mo.
and 57% between 15−16mo. received at least one dose.
Results: In 2008, 840 IPD cases were registered vs. an annual average
of 1048 cases in the pre-PCV7 period. 90% were bacteraemia cases.
The overall incidence of IPD declined from a mean of 19.4 to 15.3 per
100,000 comparing pre- and post-PCV7. In children <2 years (y), the
mean incidence declined signiﬁcantly from 54 to 23 per 100,000 in the
pre- and post-PCV7 (p< 0.005). In children <2 y, the mean incidence of
IPD caused by vaccine serotypes decreased from 36 to 8 per 100,000.
The most prevalent serotype in post-PCV7 was 7F (32%), all other
serotypes accounted for less than 6% of cases. In pre-PCV7 period,
the most prevalent serotypes were 14 (21%), 6B (20%), 7F (9%), 6A
(8%), 19F and 23F (7%). In children between 2−5 y, the overall incidence
slightly increased from 8.6 to 11.8 per 100,000. The incidence tended to
decline in all other age groups: from 2.5 to 1.2 per 100,000 in persons
between 5−18 y, from 7 to 5.8 per 100,000 in persons between 18−50 y,
from 23.4 to 17.5 per 100,000 in persons between 50−64 y, and from
65.4 to 52.9 per 100,000 in persons older than 65 y comparing pre- and
post-PCV7.
Conclusion: After the universal introduction of PCV7 in Denmark, we
observed a decline in the overall incidence of IPD that was statistically
signiﬁcant in children younger than 2 years. In children younger than
2 years, serotype 7F was the dominant serotype in the post-PCV7 period.
PCV7 coverage in children younger than 2 years was high.
P1131 Serotype distribution of Streptococcus pneumoniae isolated
from patients with invasive pneumococcal disease
A.W. Rosingh, E. Canton, G. Fagundez, F. Gonzalez, M. Gobernado °
on behalf of the MIVA Network
Objective: To describe the serotype distribution of S. pneumoniae
associated with invasive pneumococcal disease in patients in the Valencia
Community (5.9 million inhabitants), Spain, after introduction of the 7
valent pneumococcal conjugate vaccine (PCV7).
Methods: We serotyped S. pneumoniae isolated from blood, spinal ﬂuid
(CSF) and sterile liquid cultures collected during the year 2007 in
patients who were diagnosed with invasive pneumococcal disease in any
of the 19 participating hospitals. Serotyping was performed by antiserum
agglutination (Denka Seiken, Tokyo Japan). If necessary more detailed
serotyping was done by the Quelling reaction (Staten Serum Institute).
Results: We serotyped 363 isolates of S. pneumoniae from 363 patients
(blood cultures, CSF and sterile ﬂuids). The serotypes in order of
frequency were: 19A (10.8%), 1 (10.8%), 14 (10.2%), 8 (8.6%), 7
(7.7%), 3 (6.9%), 4 (4.4%), 7F (3.6%), 6A (3.9%), 22(2.8%). These
serotypes represent a total of 69.9% of the total number of isolates that
were serotyped. The other serotypes counted for percentages of less than
2.5%.
Conclusions: Of the serotypes isolated in this study, only 21.5% are
included in the PCV7-vaccine. Continued surveillance is needed to guide
development of future formulations of conjugate vaccines and to monitor
the effects of continued vaccine use.
PS: Data used from the Surveillance Network of the Valencia Community
(MIVA network). Public Health Department, Conselleria de Sanitat
P1132 Clinical and economic impact of a 10-valent pneumococcal
(Pnc)-non-typable Haemophilus inﬂuenzae (NTHi)-protein D
conjugate vaccine (PHiD-CV) on the overall disease burden
in Finland
S. Bergius °, S. Torvinen, T. Puumalainen (Espoo, FI)
Objective: To estimate the total impact of infant vaccination with a
7-valent pneumococcal vaccine (PCV-7), a 10-valent PHiD-CV or a no-
vaccination strategy across all ages in Finland.
Methods: The total vaccine impact is assessed with a 1-year,
cross-sectional, overall population-based model at vaccine steady-state
condition selecting local epidemiological and unit cost data. Direct
vaccine effect is estimated as reduction in incidence and clinical
outcomes associated with invasive diseases (ID) such as meningitis and
bacteraemia, with community-acquired pneumonia (CAP) and with acute
otitis media (AOM). Indirect vaccine effect of herd protection (HP)
across the whole population, cross-protection and serotype replacement
in IPD are also evaluated with the model. To obtain Finnish-speciﬁc
vaccine effect results in IPD, local serotype distribution in ID of
Streptococcus pneumoniae is multiplied by the serotype speciﬁc vaccine
efﬁcacy (VE). For CAP, an average vaccine efﬁcacy for hospitalised and
ambulatory pneumonia is used. Total VE in AOM is estimated as VE
against vaccine serotypes, non-vaccine serotypes and NTHi. Vaccine cost
is assumed to be equivalent for both vaccines.
Results: Compared with no-vaccination PHiD-CV is predicted to reduce
IPD by 350 cases, pneumonia by 400 cases, tympanostomies by 7200
events and otitis by 77800 GP visits per year across the whole population
once vaccine steady-state has been reached. Compared with PCV-
7, PHiD-CV is predicted to prevent additionally 60 IPD cases, 65
pneumonias, 4300 tympanostomies and 45800 otitis GP visits per year.
PHiD-CV vaccination is expected to result in cost savings compared with
PCV-7 (10M€ in direct costs and 4M€ in productivity costs). Sensitivity
analysis shows that the VE against tympanostomy and the cause of
AOM have the greatest impact on the cost results. Using probabilistic
sensitivity analysis the results indicate that vaccination with PHiD-CV
is reaching cost-savings compared with PCV-7 in 97% of the iterations.
Conclusion: Pnc and NTHi cause a signiﬁcant disease burden in
Finland. Especially the societal costs for pneumonia and otitis media
are substantial. However this disease burden can be reduced with
pneumococcal vaccination. PHiD-CV vaccination is expected to lead
to cost-savings compared with PCV-7 when the vaccination cost is the
same. If HP occurs in pneumonia cost-savings with the PHiD-CV vaccine
are projected to be even greater.
Cost-savings with PHiD-CV compound compared with PCV-7 by clinical
outcome.
P1133 Serologic responses to revaccination with 23-valent pneu-
mococcal polysaccharide vaccine among patients with HIV
infection who received highly active antiretroviral therapy
C.C. Hung, S.Y. Chang, C.T. Su, C.L. Lu °, Y.Y. Chen, S.F. Chang,
C.Y. Yang, W.C. Liu, C.H. Wu, S.C. Chang (Taipei, TW)
Background: Revaccination with pneumococcal polysaccharide vaccine
(PPV) is recommended to HIV-infected patients who are vaccinated
ﬁve years earlier. Data of serologic responses to revaccination with 23-
valent PPV among HIV-infected patients who continued to receive highly
active antiretroviral therapy (HAART) with favourable immunologic and
virologic responses are sparse.
Methods: Antibody responses to three pneumococcal capsular polysac-
charides (serotypes 14, 19F, and 23F) that are prevalent in Taiwan were
assessed among 129 HIV-infected patients who received revaccination
with 23-valent PPV following primary vaccination using 23-valent PPV
5 years earlier. Three groups of patients were included according to
baseline CD4+ counts when primary vaccination was administered:
group 1, CD4+ <200 cells/mL (n = 55); group 2, CD4+, 200 to 349
cells/mL (n = 37); and group 3, CD4+ 350 cells/mL (n = 37). The
proportions of responders who achieved increases of antibody titers
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by 2-fold from baselines when revaccination was administered were
compared among the three groups of patients at 12th month of
revaccination.
Results: At revaccination, patients of group 1 had a lower median CD4
count than those of the other two groups (325 vs.487 and 615 cells/mL,
P< 0.05), while the percentage of undetectable HIV RNA load (<400
copies/ml by RT-PCR) was similar among the three groups (overall,
88.4%). Increases of CD4 count (overall, 27 cells/mL) and virologic
responses to HAART (overall, 86.1%achieving undetectable HIV RNA
load) 12 months after revaccination were similar among the three groups.
At 12th month of revaccination, the overall proportion of responders to
either one of the three serotype was 37.3% (38.2%, 40.0%, and 33.3%
for groups 1, 2, and 3, respectively), while it was 23.7% to serotype 14,
12.5% to serotype 19F, and 14.8% to serotype 23F.
Conclusions: Five years following primary pneumococcal vaccination
using 23-valent PPV, more than one third of the patients who continued
to receive HAART responded to revaccination with 23-valent PPV at
12th month.
P1134 Antibody response to pneumococcal conjugate vaccination
followed by pneumococcal polysaccharide vaccine in heart
and lung transplant patients: a pilot study
R. Gattringer, V. Plunger, W. Po¨ppl, P. Jaksch, S. Ro¨dler, W. Graninger,
H. Burgmann ° (Vienna, AT)
Objective: Steptococcus pneumoniae is a major cause of infections
like pneumonia, and bacteraemia in transplant patients. At the time
vaccination with the 23-valent pneumococcal polysaccharide vaccine
(PPV23) is recommended for adult transplant patients.
However, the use of immunosuppressive medications may impair these
patients‘ response to this polysaccharide vaccine. To enhance the im-
munogenicity of pneumococcal polysaccharides conjugate pneumococcal
vaccines (PCV7) have been developed.
Therefore we conducted this pilot study to get an idea how effective the
antibody production can be boostered by a pneumococcal polysaccharid
vaccine after a prime-boost with a pneumococcal conjugate vaccine in
heart and lung transplant patients.
Methods: 23 solid organ transplant adult patients visiting our outpatient
clinic were enrolled in the study. 10 patients were in the lung
transplant (LTX)- 13 in the heart transplant (HTX) group. All received
an intradeltoid injection with 0.5ml of a single lot of the 7-valent
pneumococcal conjugate vaccine Prevenar® (Wyeth Pharma, GmbH).
8 weeks after the ﬁrst application patients were vaccinated with
the 23-valent polysaccharide vaccine (Pneumo 23 Vaccine Merieux®)
which contains 23 serotypes. Blood samples for determination of
pneumococcal antibodies were taken prior to each vaccination and
8 weeks afterwards. Serotype-speciﬁc IgG antibody concentrations to
pneumococcal serotypes 4, 6B, 9V, 14, 18C, 19F and 23F were
measured with a reference ELISA according to the WHO (World Health
Organisation) protocol.
Results: Baseline anticapsular IgG concentrations were similar in both
groups of patients. All HTX patients had an adequate antibody response,
deﬁned as a two-fold increase in speciﬁc IgG antibody titres, to the prime
boost vaccination with PCV. However, the only difference to the LTX
group was that these patients had no two fold increase in serotype 14 at
week 8.
In week 8 patients were vaccinated with PPV23. None of the patients
had a relevant increase in antibody titers measured at week 16.
Conclusion: PCV is immunogenic in adult heart- and lung transplant
recipients. The patients however did not seem to beneﬁt from a second
PPV23 dose after a short time interval of 2 months. Thus, the optimal
vaccine regime against pneumococcal disease has to be evaluated in
further studies.
P1135 Circulating Streptococcus pneumoniae-speciﬁc effector
B cells in humans in pneumococcal pneumonia and after
pneumococcal polysaccharide vaccination
L.M. Pakarinen °, N.V. Palkola, S.H. Pakkanen, N. Rossi, R. Puohiniemi,
J.M. Kantele, A. Kantele (Helsinki, Jyva¨skyla¨, Turku, FI)
Objectives: Streptococcus pneumoniae is the leading cause of pneu-
monia in all age groups. Pneumococcal vaccines are known to confer
protection against an invasive pneumococcal infection. The protective
immune mechanisms in lower respiratory tract are poorly characterised.
Antigen encounter at mucosal sites is generally regarded to be followed
by circulation of activated lymphocytes via lymphatics and blood back to
the mucosal sites. Similarly, it has been suggested that antigen encounter
in the lung would be followed by a transient appearance of activated
antigen-speciﬁc effector lymphocytes in the circulation. The homing
receptors (HR) enabling homing of circulating lymphocytes in the lung
tissue are not yet known.
Methods: In the present study, patients with pneumococcal pneumonia
and healthy volunteers immunised with pneumococcal polysaccharide
vaccine were studied for circulating Streptococcus pneumoniae-speciﬁc
antibody-secreting cells (ASC) appearing in the circulation. These cells
were characterised for secretion of pathogen-speciﬁc antibodies using
ELISPOT.
Results: In the pneumonia patients, the number of pathogen-speciﬁc
ASC was 182/106 PBMC with IgG and in vaccinees 528/106 PBMC
with IgA as the predominating Ig-isotype.
Conclusions: The present study shows that in pneumonia in humans
pathogen-speciﬁc ASC appear in the circulation in humans, conﬁrming
the circulation of pulmonar lymphocytes in humans. The data also
show differences in the in the Ig-distribution of these cells after natural
infection and pneumococcal vaccination.
P1136 Outpatient-based pneumococcal vaccine campaign and
survey on perceptions about pneumococcal vaccination in
patients and doctors
J.Y. Song, H.J. Cheong, J. Lee, W.S. Choi, Y.M. Jo, M.J. Kim, J.Y. Heo,
J.Y. Noh, W.J. Kim ° (Seoul, KR)
Background: Despite the high morbidity and mortality of invasive
pneumococcal diseases, vaccination rates have generally remained
suboptimal around the world. In South Korea, only 0.6% of high-risk
patients replied that they were encouraged to get the pneumococcal
vaccine according to the nation-wide survey.
Methods: A cross sectional, community-based survey conducted to
assess perceptions about pneumococcal vaccine at a local public health
centre. In a tertiary teaching hospital, outpatient-based pneumococcal
vaccine campaign was performed for the elderly and individuals with
chronic medical conditions from May to July of 2007. Pneumococcal
vaccine coverage rate among those high risk outpatients was assessed,
and questionnaires were administered to assess perceptions on pneu-
mococcal vaccination for the medical doctors and patients at pre- and
post-campaign periods.
Results: Community based survey revealed that only 38 (7.6%) of
500 respondents have been informed of pneumococcal vaccine ever
before, and none of them was vaccinated previously. When it came
to the coverage rates of pneumococcal vaccine before and after the
hospital campaign, annual rate was increased from 3.39% to 5.91%.
The increments of pneumococcal vaccine coverage rate were statistically
signiﬁcant in patients with either chronic lung disease or chronic
renal disease, while those among patients with diabetes, malignancy or
chronic liver diseases were unremarkable. The most common reason
for vaccination was “doctor’s advice” (53.3%). As for the interrupting
factors of vaccination, about 75% of high risk patients were not aware of
pneumococcal vaccine itself, and that was the most important barrier to
vaccination. Secondly, doctor’s negative attitude was another important
cause of non-vaccination.
Conclusions: In conclusion, the levels of perception and immunisation
rate for the pneumococcal disease were quite low in South Korea.
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Annual outpatient-based campaign around early inﬂuenza season would
be efﬁcient to improve pneumococcal vaccine coverage rate. Doctor’s
advice was the most important encouraging factor of vaccination, but
government and health department should make efforts to improve
patients’ perceptions on pneumococcal disease and vaccination.
Hand hygiene
P1137 20,000 hand-hygiene observations on 60 wards in 16 acute
trusts: dispelling hand-hygiene myths? Or reporting a
national change in practice?
C. Fuller °, R. Slade, S. Besser, J. Savage, B. Cookson, A. Charlett,
J. McAteer, S. Michie, S. Stone (London, UK)
Background: Hand hygiene observation (HHO) is the gold-standard
for measuring hand-hygiene compliance (HHC). Although published
datasets are often small, past literature shows that compliance is poor
(25−40%), is worse pre-patient-contact, in high risk clinical activities
and falls as the number of hand-hygiene opportunities rises, and stafﬁng
levels fall. That of doctors is worse than nurses’.
Objective: Given the recent emphasis on hand-hygiene in the NHS,
we re-examined these ﬁndings during the baseline phase of a national
stepped wedge randomised controlled trial of an intervention to improve
hand-hygiene, the FIT study.
Methods: From October 2006-April 2008, 670 hours of HHO (19755
observations) were undertaken an hour at a time, 6-weekly, on 60 wards
in 16 NHS Trusts, for the baseline and early intervention phases of
the trial, using a standardised reliable and sensitive tool, the Hand-
Hygiene Observation Tool [1] (www.npsa.nhs.uk/cleanyourhands). Data
were collected on stafﬁng levels, numbers of hand-hygiene opportunities
and whether they were high/low risk, pre-/post-contact. Analysis was by
descriptive statistics and Spearman rank correlations.
Results: Overall HHC was much higher at 71% than commonly reported,
even during the prolonged baseline phase of the trial. There was no
difference between doctors and nurses (73% HHC) or high and low risk
activities (68%). Although the study conﬁrmed an inverse relationship
between compliance & patient:nurse ratio (r = −0.19, p = 0.007) it showed
compliance rose with the number of hand-hygiene opportunities per
patient (r = 0.208, p = 0.000)
Conclusions: This is the largest data set of hand-hygiene observations
in the literature. Analysis shows much better hand-hygiene behaviour
than previously reported. Potential explanations of this are the larger and
arguably more representative data set and/or the use of a more rigorously
standardised measure of compliance. However, we think the difference
is most likely to be due to a signiﬁcant improvement in hand-hygiene
behaviour in the UK, reﬂecting a major change in NHS culture.
Reference(s)
[1] McAteer J et al, Development of an observational measure
of healthcare worker hand-hygiene behaviour: the hand-hygiene
observation tool (HHOT), Journal of Hospital Infection 2008;
68:222–229.
P1138 Production of the WHO-recommended alcohol-based
handrub formulations in 11 different sites worldwide
B. Allegranzi °, E. Mathai, S. Bagheri Nejad, S. Dharan, W. Grifﬁths,
P. Bonnabry, J. Storr, N. Damani, D. Pittet (Geneva, CH; Portadown,
UK)
Objective: Availability of alcohol-based handrub formulations (ABHF)
at the point of care is an essential element of the WHO multimodal hand
hygiene (HH) improvement strategy. Tools were developed by WHO to
help healthcare settings to make this system change, including a guide
to the local production of 2 formulations. We evaluated the feasibility,
quality control, and local production costs in different sites worldwide.
Methods: A survey was conducted in July-September 2008 to gather
data on the WHO-recommended ABHF local production in 11 sites
testing the WHO strategy in Bangladesh, Costa Rica, Egypt, Hong Kong
SAR, Kenya, Mali, Mongolia, Pakistan (2 sites), Saudi Arabia, and
Spain. Questions related to equipment used, staff involved in production,
sourcing and cost of ingredients, quality control of the ﬁnal product,
adequacy of facility for preparation and storage, and distribution and
end use; open-ended questions on lessons learnt were also included.
Quality checks by gas chromatography and the titrimetric method were
performed on the ﬁnal products.
Results: All sites completed the survey. Apart from Bangladesh and
Pakistan, all sites manufactured the ABHF based on ethanol. In 7
hospitals, local production was carried out successfully at the pharmacy.
In Bangladesh, Costa Rica, Hong Kong SAR and Saudi Arabia,
ABHF was produced by a pharmaceutical company for distribution
to several facilities across the country. Production volumes varied
signiﬁcantly according to local needs (10–600,000 litres/month). In a few
cases, difﬁculties arose for the local procurement of some ingredients
and dispensers. Facilities for production and storage were considered
adequate in all sites but two (Mali and Pakistan); the ABHF was shown
to be stable, even at tropical temperatures (up to 19 months). Quality
checks on samples from 7 sites yielded optimal results. Good tolerability
and acceptability by healthcare workers were reported. Cost assessment
was conducted in 5 sites and ranged between US$0.30−0.50 per 100ml.
Conclusion: Local production of the WHO-recommended ABHF is
feasible in different settings worldwide, despite some procurement
obstacles. The ﬁnal product was well-tolerated and very inexpensive
compared to marketed formulations. After a test phase, 5 countries have
decided to scale-up to national production. Local production is a very
promising approach to make ABHF available in many more settings,
especially those with limited resources.
P1139 Successful implementation of the WHO multimodal hand
hygiene improvement strategy and tools: a survey of 230
hospitals worldwide
B. Allegranzi °, S. Bagheri Nejad, H. Sax, E. Mathai, H. Richet,
D. Pittet (Geneva, CH)
Objective: In 2006, the WHO multimodal hand hygiene (HH)
improvement strategy and more than 40 implementation tools were
made available to any healthcare setting (HCS) worldwide following
web registration. We evaluated the use of the strategy and tools and
their usefulness and importance for HH improvement and impact on HH
practices.
Methods: In January 2008, all registered HCS (n = 329) were invited
to complete an online form requesting general information with speciﬁc
questions about progress with the WHO strategy and tool implemen-
tation. HCS at advanced/semi-advanced stages of implementation and
having used most of the WHO tools were selected for a semi-structured
interview with the project co-ordinators including both open and closed
(7-point Likert scale) questions on the WHO strategy elements and tools.
The objective was to receive feedback on the advantages and drawbacks
of the strategy implementation, feasibility of the local production of
the WHO alcohol-based handrub formulations (ABHF), and the validity
and obstacles encountered in the use of the tools. Co-ordinators were
also requested to send available data on key indicators such as HH
compliance.
Results: A total of 114 responses to the web survey were received from
both single hospitals and HCS networks. Among the advanced/semi-
advanced sites, 47 co-ordinators were selected for interview, representing
230 hospitals from Egypt, France, Italy, Malta, Malaysia, Mongolia,
Spain, and Viet Nam. The strategy was considered comprehensive, very
detailed, and a successful model for other interventions by all co-
ordinators; some parts were recommended for simpliﬁcation. Median
scores attributed to the WHO strategy elements and principal tools are
shown in the table according to their ranked importance to achieve HH
improvement. ABHF local production, in place in ﬁve sites, was reported
to be feasible at very low cost and the product was well accepted by
healthcare workers. Co-ordinators from some hospital networks (Italy,
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France, Spain) reported data on HH compliance and showed an average
increase of 21% after implementation.
Conclusion: The WHO strategy and tools were implemented au-
tonomously and without WHO support in many HCS worldwide. As
reﬂected by the high scores attributed by co-ordinators, their use was
considered to be very helpful and essential to improve HH. Very useful
feedback on local adaptation and suggestions for improvement was
obtained through this evaluation.
Table
Median score
(range)*
Strategy element
System change (ABHF, clean water and soap availability) 7 (4−7)
Staff education 7 (5−7)
Observation and feedback 7 (4−7)
Reminders 6 (3−7)
Promotion of a patient safety climate 6 (2−7)
Main tools
Guide to implementation 6 (4−7)
Guide to local production 6 (6−6)
Educational tools 7 (6−7)
Manual for observers 7 (1−7)
WHO posters 6 (5−7)
*7-point Likert scale.
P1140 Impact of a campaign to improve hand hygiene in
healthcare workers
O. Monistrol, L. Lo´pez-Yeste, E. Calbo °, N. Freixas, M. Riera, R. Font,
C. Nicola´s, M. Xercavins, J. Garau (Terrassa, ES)
Objectives: To compare Health Care Workers (HCW)’s hands contam-
ination and risk factors for before and after the implementation of
a multimodal strategy to improve hand hygiene (HH) compliance in
medical wards in an acute care university hospital.
Methods: A multimodal program to improve HH was conducted in
October 2007. A total of 104 out of 132 HCW in medical wards
were included and cultured in PRE (April to May 2007) and 89 in
POST campaign periods (November to December); 89 hand paired
samples of the same HCW were included. Cultures of the dominant
hand were performed immediately preceding a patient care action during
daily hospital practice. Hands were sampled by a glove juice method.
Microorganisms identiﬁed were classiﬁed as resident ﬂora, transient,
and total ﬂora (the sum of both). Data collected included: gender,
professional category, skin condition, presence and number of rings,
ﬁngernail length, number of assigned patients, hours of work before
sampling, self reported time of most recent hand washing episode
and product used. Hand’s bacterial loads were evaluated by comparing
median values in each period.
Results: A total of 89 paired hands were cultured in both periods. 82%
were female, 28% physicians, 38% nurses and 34% others. Resident
ﬂora was detected in 92.1% hands vs. 70.8% (p = 0.001) and transient
ﬂora in 96.6% vs. 75.3% (p< 0.001) in PRE and POST periods.
The hand median cfu counts decreased from 2782 (range 1–13747) to
1065 (range 0–13682) (p< 0.001), resident ﬂora from 970 (range 0–
12855) to 23 (range 0–13600) (p< 0.001), and transient ﬂora from 10
(range 0–4935) to 2 (range 0–7323) (p< 0.001). Median cfu counts of
Gram negative bacilli were 205.5 (range 0–4924) vs. 25.57 (range 0–831)
(p< 0.001) in PRE and POST periods, respectively. No other signiﬁcant
differences were detected in transient ﬂora.
In the POST intervention a lower number of rings (p< 0.001), shorter
ﬁngernail length (p = 0.008), shorter time of most recent hand washing
(p = 0.007), and a most frequent use of alcohol solutions instead of soap
(p< 0.001) were documented.
For the risk factors study a total of 193 sampled hands were included.
In the linear regression model taking total ﬂora as dependent variable,
a longer time of most recent hand washing was associated with higher
contamination rates (Beta=0.3, p = 0.005).
Conclusions: A HH multimodal strategy decreased the number of risk
factors and the level of HCW hands contamination during daily hospital
practice.
P1141 Impact of monitoring hand hygiene compliance during
entire care episodes for measurement of compliance rates
and interpretation of comparisons
M. Eveillard °, H. Hitoto, F. Raymond, A. Kouatchet, L. Dube´,
V. Guilloteau, M.T. Pradelle, P. Brunel, A. Mercat, M.L. Joly-Guillou
(Angers, FR)
Objective: Monitoring of hand hygiene (HH) practices and performance
feedback represent one of the components which should be included in
multimodal strategies implemented to improve compliance. Our objective
was to assess the importance of monitoring HH compliance during series
of successive contacts with patients or surroundings for measurement and
interpretation of the compliance rates.
Methods: A direct observational study of HH compliance was performed
in 4 intensive care units (ICUs) and 4 healthcare settings with non-
intensive care wards (NICWs) (acute-care geriatric wards, rehabilitation
units, and long-term care facilities). HH opportunities were (i) before
patient contact, (ii) before aseptic task, (iii) after body ﬂuid exposure risk,
(iv) after patient contact, (v) and after contact with patient surroundings.
To assess the impact of monitoring HH compliance during entire care
episodes, HH opportunities were differentiated in 2 categories: extra-
series opportunities (ESO) (before or after a single contact, and before
the ﬁrst contact or after the last contact of a series of successive contacts)
or as intra-series opportunities (ISO) (from the opportunity following
the ﬁrst contact to the opportunity preceding the last in the same series).
Comparisons of compliance rates were performed with the chi-square
test.
Results: In all, 1663 opportunities of HH were observed (903 in ICUs
and 760 in NICWs). Among them, the proportion of ISO was 46.0% in
ICUs and 22.9% in NICWs. The overall compliance was signiﬁcantly
higher in NICWs than in ICUs (61.2% vs. 47.5%, P< 10−6). The
compliance of HH was signiﬁcantly higher for ESO than for ISO (67.7%
vs. 28.5%, P< 10−6). The compliance in ISO was signiﬁcantly higher in
ICUs (32.2% vs. 19.0%, P< 0.005). If the distribution of categories of
HH opportunities observed in NICWs had been the same as in ICUs, the
overall HH compliance would have been 46.4% in NICWs (vs. 47.5%
in ICUs). Therefore, there would have not been any difference between
the 2 categories of wards.
Conclusion: Monitoring compliance of HH during entire care episodes
in series of successive contacts is necessary to avoid a strong
overestimation of the overall compliance rates. Concurrently, comparison
of compliance data between wards or healthcare settings should take into
account the proportion of ISO (i.e. the proportion of series of successive
contacts among all contacts and the lengths of those series) included in
the evaluation study.
P1142 Comparison of hand hygiene practices between physicians
and nurses
E. Hakko °, I. Deger, S. Civil, K. Rasa, M. Cakmakci (Kocaeli, TR)
Objective: This observational study was aimed to determine hand
hygiene practices of healthcare workers with a special interest on the
comparison of compliances of physicians and nurses.
Methods: Compliance, deﬁned as hand washing/disinfection in the
required setting, was directly observed by deﬁned personnel in hospital
wide during three months. The observed health care workers were not
aware of this observation.
Results: A total of 661 hand hygiene opportunities were observed in 239
healthcare workers (109 physicians and 130 nurses). Mean compliance
ratio was 80% and the ratios were 67.9% and 89.9% in physicians and
nurses, respectively. According to these results compliance to good hand
hygiene practice was calculated to be signiﬁcantly lower in physicians
compared to nurses (p = 0.0001).
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Also, compliance to good hand hygiene practice varied at different
settings. The compliance ratios before invasive procedures were 42% and
79%; after the invasive procedures were 85% and 87%; before gloving
were 30% and 22%; and after taking of gloves were 77% and 87%
in physicians and nurses respectively. Also compliance to good hand
hygiene practice ratio while passing from one patient to another was
42% and 91% and after physical examination of the patient was 46%
and 100% in physicians and nurses, respectively.
Conclusion: We found that the compliance to hand hygiene practices is
lower in physicians when compared to nurses. This study also showed
us that the weakest site of compliance is before putting on gloves which
is valid for both physicians and nurses. Therefore, by this study we not
only observed the present level of hand hygiene awareness and practices
but also deﬁned the sites where we could make improvements. These
ﬁndings also encouraged us to perform these kinds of observational
studies to tailor our future education programmes.
P1143 Impact of teaching activities on compliance with hand
disinfection of physicians and nurses
Y. Flammer °, H. Giger, C. Ruef (Zurich, CH)
Objective: To investigate the impact of teaching interventions on the
compliance with hand disinfection (HD-C) of physicians and nurses and
on the consumption of alcohol based hand rub (AbHR).
Methods: The study was carried out on two intervention (IW) and one
control ward (CW). AbHR consumption was measured weekly for six
weeks. During weeks one and six, hand disinfection (HD) performance
was directly observed on IW and CW. During weeks two to ﬁve,
nurses and physicians attended teaching sessions on IW (nurses: 3 to 5
sessions [20 minutes each]/week, physicians: 1−2 sessions [10 minutes,
general discussion of nosocomial infections, importance of HD/week]),
whereas no teaching was offered to the CW. Teaching of nurses included
visualising the efﬁcacy of HD by ultraviolet light, education of 6
indications of HD, analysing daily activities for indications of HD,
discussion of cases of nosocomial infections, reporting results of hand
cultures of health care workers and the results of weekly consumption
of AbHR.
Results: Compliance rates on IW are shown in the table.
Indications Compliance with hand disinfection (%)
Nurses Physicians
Baseline After
intervention
p Baseline After
intervention
p
All indicationsa 75.9c 85.3d <0.01 68.75c 63.9d n.s.
Before patient contact 66.2 78.3 0.17 48.3 56.5 n.s.
Before invasive procedure 73.7 83.8 0.16 50 20 n.s.
After patient contact 92.9 95.8 n.s.b 83.8 82.6 n.s.
After contact with body secretions 69.4 86.9 <0.05 100 100 n.s.
After object 75 82.6 n.s. 50 25 n.s.
Between patients 84.2 83.3 n.s. 88.8 80 n.s.
a417 observations during baseline period (week 1), 347 observations after intervention (week 6).
bn.s. = not signiﬁcant; cdifference not signiﬁcant; d p= 0.0004.
The overall HD-C of nurses was signiﬁcantly improved despite an
already relatively high baseline rate. HD-C on CW remained unchanged.
After intervention nurses showed a signiﬁcant improvement in HD
after contact with body secretions and a trend towards signiﬁcant
improvement before patient contact and before invasive procedures.
Overall compliance as well as compliance with individual indications
of HD remained unchanged among physicians. While there was no
signiﬁcant difference between nurses and physicians regarding overall
HD-C at baseline, overall compliance as well as compliance before
invasive procedures and after contact with objects near patients was
signiﬁcantly higher among nurses than physicians. AbHR consumption
was increased on IW-A from a mean of 59ml/patient day at baseline up
to a mean of 74ml/patient day, on IW-B from 64ml/patient day up to
84ml/patient day. AbHR consumption remained unchanged on CW.
Conclusion: Overall HD-C of nurses and AbHR consumption was
improved by teaching, resulting in a compliance rate of >75% in all
6 indications. For selective indications HD-C of physicians was high.
The teaching approach used in this study was successful in nurses but
failed among physicians. Detailed analysis of the impact of teaching
interventions on HD-C in individual indications and professions may
help to deﬁne the goals and content of future intervention strategies.
P1144 Short training sessions on hand hygiene, bed occupancy
rates and nosocomial methicillin-resistant Staphylococcus
aureus – a time-series approach at a German university
medical centre
K. Kaier °, A. Conrad, R. Babikir, U. Frank, M. Dettenkofer (Freiburg,
DE)
Objective: Programmes to improve hand hygiene have shown to reduce
nosocomial spread of and infections with methicillin-resistant S. aureus
(MRSA). Furthermore, bed occupancy rates are suggested to be linked to
nosocomial MRSA transmission. The aim of our study was to identify the
impact of short hand hygiene training sessions (STS)and bed occupancy
rates on the incidence of nosocomial MRSA.
Methods: A multivariate time series approach (01/2003–07/2008)using
autoregressive moving average (ARMA) modelling was carried out at
University Medical Center Freiburg, a 1600 bed tertiary care hospital.
The monthly incidence of nosocomial MRSA cases (patients infected or
colonised with MRSA that turned positive more than 48 h after admission
per 1,000 patient days) was applied as the dependent variable. Bed
occupancy rates of general wards and ICUs were expressed as percentage
of time that beds were occupied. Data on use of alcohol-based hand rub
(ABHR) was calculated in litres per 1,000 patient days. In addition,
two hand hygiene campaigns focussing on STS were evaluated. The
ﬁrst was conducted from 09/2004 until 05/2005 (32 STS on ICUs and
haematology wards). The second took place from 09/2006 until 12/2006
(17 STS on ICUs and general wards). STS included information on hand
hygiene, tips on improved hand hygiene and self evaluation of hand
disinfection technique by use of a UV-lamp. To analyse the effect of
STS, dummy variables were created (0 and 1 representing pre-campaign
and post-campaign periods, respectively).
Results: For the study period, a mean incidence of 0.15 nosocomial
MRSA cases per 1,000 patient days was identiﬁed. The mean percentage
of time that beds were occupied was 78% in general wards and 81% on
ICUs. The mean use of ABHR was 55.3 litres per 1,000 patient days.
Temporal increases in bed occupancy rates in general wards and ICUs
were followed by increases in the incidence of MRSA (p = 0.001 and
p< 0.001, respectively). Additionally, increased use of ABHR led to
a decrease in MRSA incidence (p = 0.025) and both hand disinfection
campaigns reduced the MRSA incidence (p = 0.038 and p< 0.001).
Conclusions: Our model shows that STS selectively performed in high
risk areas proved to be effective in preventing nosocomial MRSA while
high bed occupancy rates showed to have an effect on the incidence of
nosocomial MRSA.
P1145 e-Bug: using games to teach young children about microbes,
hygiene and appropriate antibiotic use
D. Farrell °, P. Kostkova, C. McNulty, D. Lecky (London, Gloucester, UK)
Background: e-Bug is a DG SANCO funded antibiotic and hygiene
teaching resource aiming to reinforces an awareness of microbes, hand
and respiratory hygiene and the beneﬁts of prudent antibiotics use among
junior and senior school children across Europe. Education packs used
at schools are complemented by web-based interactive games teaching
the key learning outcomes of the e-Bug project. We have developed a
platform game for 9−11 year old children that is fast and engaging and
which uses the game mechanics to teach concepts to the player. This
talk will demonstrate the game and discuss preliminary evaluation data
which shows the relative success of different aspects of the design.
Methods: The game is broken into stages. Each stage focuses on one
set of learning outcomes (for example “introduction to microbes”).
Within each stage, the games rules and mechanics implement an abstract
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understanding of each learning outcome. For example, the player throws
soap to wash away bad microbes. Before and after each stage, the player
takes part in a quiz show game. The questions are identical each time
so that knowledge and attitude changes can be assessed. By doing this,
we are able to identify the relative successes of each stage of the game
and as a result, change any stages which are not successful.
Design Evaluation and Results: The play experience of the game has
been evaluated with schools in the UK. Changes have been made to
make the game easier to understand (instructions were initially given
too fast) and to control (in initial versions jumping was very difﬁcult).
The knowledge and attitude change is currently being evaluated with
UK schools and initial results will be presented at ECCMID.
Conclusions: Following the initial evaluation, the game will be modiﬁed
as required and a fuller evaluation will be carried out in the UK,
France and the Czech Republic. The ﬁnal version of the game will be
implemented in 9 European countries following translation.
Figure: e-Bug screenshot.
P1146 Association between the amount of hand antiseptics used
and hospital-acquired infections in a Danish hospital
S. Laustsen °, B. Kristensen, A.M. Thulstrup, J.K. Møller, B.M. Bibby
(Aarhus, DK)
Objective: To investigate the association between the amount of hand
antiseptics used and hospital acquired septicaemias
Methods: A time series incidence study (ecological) was carried out
between January 2004 and March 2008 in all wards (n = 31) at Aarhus
University Hospital, Skejby, Denmark. Different data sources were
combined. Information of the monthly amount of hand antiseptics used
was collected from the hospital purchasing database system, while data
on bed days and time of admission were compiled from the hospital
administrative data system. Data on continuous cases of bacteraemia
were collected from the laboratory information system in Department
of Clinical Microbiology (n = 400). A Danish version of the Centers for
Disease Control’s deﬁnitions of hospital acquired infections was used.
The unique Danish civil registration number was used to identify patients
with septicaemias. We used a vector auto regression model with the
amount of hand antiseptics used and the number of septicaemias in the
preceding two months (two monthly lags). The logarithm to the number
of months since December 2003 was included as an exogenous variable
to consider any trend over time.
Results: The use of hand antiseptics increased signiﬁcantly from 27.3 L
per 1000 bed days in the ﬁrst quarter of 2004 to 81.5 L hand antiseptics
per 1000 bed days in the ﬁrst quarter of 2008 (p< 0.0001). There was
no signiﬁcant trend in the monthly number of septicaemias per 1000
bed days (p = 0.79). We found no signiﬁcant association between the
monthly use of hand antiseptics per 1000 bed days and the monthly
cases of septicaemias per 1000 bed days (p = 0.72).
Conclusion: There was no association between the approximately 3-fold
increase in the amount of hand antiseptics used and the incidence of
septicaemias during the study period. Hand antiseptics used seem not to
be an indicator for hospital acquired septicaemias.
P1147 Surgical hand antisepsis in practice − what surgeons do
and want
A. Conrad °, W. Ba¨tz, M. Bussmann, R. Babikir, R. Scholz,
M. Dettenkofer (Freiburg, DE)
Objective: Surgical hand antisepsis (SHA) is important to prevent
surgical site infections. In 2007 a new guideline was released in Germany
(www.rki.de) recommending the use of alcoholic hand rubs for SHA
which are licensed for a short application time of 60−90 seconds (EN
12791) and reduced routine hand washing with water and soap prior to
SHA. The objective of this survey was to assess the practice of SHA at
a tertiary care teaching hospital on the basis of existing local guidelines
before revision.
Methods: A structured questionnaire was distributed to all departments
that conduct surgeries. Additionally, observations were performed in
different departments in order to assess the current practice of SHA.
Results: 278 questionnaires were completed, most of them by surgeons
(54.7%) and operating theatre staff (37.4%). Knowledge of SHA was
mainly acquired during schooling (74.1% of respondents). However, the
local guidelines were only known to 56.5%. 43.2% stated to wash hands
with water and soap prior to every surgical intervention, 56.1% just in
case of soiling. In compliance with the valid guideline, 83.1% of the
respondents stated to apply the disinfectant 3 minutes, 6.8% less and
7.9% longer than 3 minutes. 71.2% reported to rub the disinfectant until
the skin has dried after disinfection, while 23.1% let the skin air-dry.
80.6% of the respondents quoted that time pressure is a major obstacle in
performing proper SHA and 58.6% complained about dry skin correlated
with routine SHA. A reduction of the application time (90 seconds)
would be appreciated by 70.5%. In 47 observations incorrect disinfection
technique was identiﬁed in 19.1%. In 12.7% of the observations, the
disinfectant was not rubbed up to the elbow crease but limited to
the forearms or hands. The application time was 3 minutes in 41.3%,
less than 3 minutes in 13% and longer in 34.8%. A timer to control
application time was used in only 21.4%; there was no timer available
at all in 33.3% of the observations and none of the available timers had
the ability to be adjusted for 90 seconds.
Conclusions: This survey identiﬁed limitations regarding the current
practice of SHA. Because of time pressure the majority of theatre staff
would appreciate the introduction of a shortened SHA. To guarantee high
standards, the infrastructure of SHA has to be optimised e.g. suitable
timers, skin friendly disinfectants with short application time (EN 12791)
and staff training according to revised guidelines.
P1148 Evaluation of in vitro bactericidal activity of Hibi Gel
Hand Rub+, Hibi Liquid Hand Rub+ and Hibiscrub hand
disinfectants on multidrug-resistant bacterial pathogens
C. Nonhoff °, S. El Hassouni, M. Struelens (Brussels, BE)
Objectives: To evaluate the in-vitro activity of a novel gel formulation of
hand rub disinfectant (Hibi Gel Hand Rub+) in comparison with liquid
hand rub formulation (Hibi Liquid Hand Rub+) and antimicrobial soap
hand wash formulation (Hibiscrub®) on clinical isolates of antibiotic-
resistant bacteria and Candida albicans.
Methods: Testing of bactericidal activity was performed by using
the quantitative suspension test method, according to the European
Standard EN 1276. The dilution-neutralisation method was used
to test Hibi Liquid Hand Rub+ and Hibi Gel Hand Rub+ and
the membrane ﬁltration method was used to test Hibiscrub. A
collection of clinically relevant strains was selected with a special
emphasis on multidrug resistant bacterial pathogens related to recent
epidemics of healthcare associated (HA) infections and included HA-
methicillin-resistant Staphylococcus aureus (MRSA) strains (n = 5),
vancomycin-resistant (VRSA) and -intermediate (VISA) MRSA strains
(n = 2), vancomycin-resistant Enterococcus spp (VRE) strains (n = 3),
metallo-b-lactamase (MBL)-producing Pseudomonas aeruginosa (n = 2),
a multidrug, carbapenem-resistant (MDR) Acinetobacter baumannii
strain (n = 1) and extended-spectrum-b-lactamase (ESBL)-producing
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Enterobacteriaceae strains (n = 6). One C. albicans isolate was also
tested.
Results: Hibi Gel Hand Rub+ and Hibi Liquid Hand Rub+ both
demonstrated a reduction factor (RF)> 5 within 15 s against all test
bacteria and Candida strains with no growth detected on plates after
any reaction time. The Hibiscrub disinfectant soap formulation showed
a slower killing activity on Gram-positive strains and Candida. Effective
bactericidal activity (RF> 5) of Hibiscrub was only achieved after 1 to
3min of reaction time with some MRSA, VISA and VR-E. faecium
strains and effective fungicidal activity against C. albicans was noted
only after 3min. All three products were highly bactericidal against
the multidrug resistant strains of Enterobacteriaceae and non-fermenter
Gram-negative rods.
Conclusion: Hibi Liquid and Gel Hand Rub+ disinfectants showed
equivalent in vitro bactericidal activity. Both met the requirements of
the European Standard in terms of time-dependent microbial reduction
factor. Equally rapid killing was observed with clinically relevant
antibiotic-resistant strains and quality control bacterial strains.
P1149 Study of effectiveness and antimicrobial activity of an
alcohol-free, non-rinse antiseptic developed for skin
disinfection in emergency situations
O. Lozhkina °, A. Savinov, A. Aﬁnogenova, G. Aﬁnogenov (St.
Petersburg, RU)
Objectives: After an emergency, it can be difﬁcult to ﬁnd running
water. However it is still important to clean your hands to avoid illness.
The aim of this study was to investigate effectiveness and biocidal
activity of an alcohol-free, nonrinse antiseptic combination containing
as active substances polyhexamethyleneguanidine phosphate (0.8%) and
quaternary ammonium compounds (0.35%) and to show its advantages
in respect to alcohol-based formulations for hygienic skin disinfection
in emergency situations.
Methods: The effectiveness of the formulation and its sustained effect
were tested by the swab method in a cross-over design with 40
volunteers in 5 hospitals in St. Petersburg. Biocidal activity was tested
against Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia
coli, Candida albicans, Mycobacterium B5 and Hepatitis B virus using
standard cambric test-objects method.
Results: The level of natural microﬂora decreased for 98.5 at hygienic
hand treatment with 2ml of the formulation and for 98.8 at hygienic hand
treatment with 3ml of the formulation. The time of treatment was at least
1 minute in both cases. It was also demonstrated that the combination
had a 100% 3-hours long sustained effect and was bactericidal against
S. aureus, E. coli, Ps. aeruginosa and virulicidal against Hepatitis B
virus in 15 seconds, fungicidal against C. albicans and tuberculocidal
against Mycobacterium B5 in 1 minute and virulicidal against Polyovirus
type 1 in 3 minutes.
Conclusion: The present formulation demonstrated a wide spectrum
of antimicrobial activity and excellent acceptance. Due to its unique
properties, it meets all regulatory requirements for multipurpose skin
sanitizers. On the contrast to the alcohol-based skin antiseptics, it is
non-ﬂammable, doesn’t have any skin irritating effect even at a frequent
use and has a 3 hours-long sustained effect. It is powerful to prevent
spreading of infection among people in emergency conditions when clean
water is anavailable.
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P1150 Nasal and throat swab cultures for the assessment of
S. aureus colonisation and carriage in the Tromsø Staph
and Skin Study. A validation study including standard
screening methods and molecular typing
B. Haldorsen °, K. Olsen, J. Ericson Sollid, H. Husom Haukland,
A. Sundsfjord, G. Skov Simonsen, S. Breivik, G. Larsen, A.S. Furberg
(Tromsø, NO)
Objective: More detailed epidemiological evidence about persistent
Staphylococcus aureus carriage and its determinants are needed. In
this perspective, adequate differentiation between persistent and non-or-
intermittent carriage is a prerequisite. Isolation of S. aureus in repeated
cultures is generally used to deﬁne persistent carriage. Our aim was
to assess the intra-method reliability of nasal and throat swab cultures
performed by two technicians, and to assess the inter-method reliability
of two methods which both measure S. aureus carriage but with different
time intervals between repeated nasal and throat swab cultures.
Methods: A validation study was performed autumn 2007 among 58
women and 50 men in The Tromsø Staph and Skin Study (TSSS), a
large population-based study including 3,996 participants. Mean age
was 60 years. A ﬁrst set of repeated nasal and throat swab cultures was
performed according to the TSSS protocol (culture 1 & 2; time interval
between cultures; mean=14.3 days; standard deviation, SD=7.3 days),
and a second set of repeated cultures was performed with one-week
interval according to ‘the culture rule’ developed by Nouwen et al.
(culture 3 & 4). Culture 2 and 3 were taken on the same day by two
technicians about 60 minutes apart. All specimens were cultured within
24 hours on chromID S. aureus agar plates. Among 25 participants,
S. aureus was identiﬁed in all 4 nasal cultures. All 100 S. aureus isolates
from these chronic nasal carriers were spa typed according to Ridom
StaphType 1.5 software.
Results: The inter-rater reliability was excellent for nasal culture (culture
1 vs 2; simple ú = 0.94; 95% conﬁdence interval, 95%CI=0.87−1.00)
and good for throat culture (simple ú = 0.44; 95%CI=0.21−0.67). The
inter-method reliability was excellent for nasal carriage (culture 1 & 2
vs 3 & 4; weighted ú = 0.85; 95%CI=0.77−0.92) and good for throat
carriage (weighted ú = 0.44; 95%CI=0.27−0.62). Among the chronic
nasal carriers, all but one individual had S. aureus isolates that could
be typed. In 18 carriers all 4 isolates were of identical spa types, 3
carriers had genetically closely related isolates, while 3 carriers had two
non-related S. aureus types.
Conclusion: We conﬁrm by standard screening methods and advanced
molecular methods that nasal culture is a highly reliable and robust test
for S. aureus colonisation and carriage. Throat culture has low reliability,
and its role in research and clinics is highly questionable.
P1151 Improvement of a latex agglutination assay for speciﬁc
detection of Panton-Valentine leukocidin
K. Oishi °, T. Baba, Y. Nakatomi, S. Satoh, F. Gondaira, T. Ito,
K. Hiramatsu (Tokyo, JP)
Objectives: Panton-Valentine Leukocidin (PVL) consists of two
components, LukS-PV and LukF-PV, which are secreted by some
Staphylococcus aureus strains. Clinical isolates harbouring PVL gene
are considered to be associated with severe soft-tissue infections and
fatal necrotic pneumonia, and such cases are increasingly reported in
communities.
Currently, PCR is widely used for PVL gene detection, but is often
inconvenient and not easy to perform. In recent years we have reported
the development of a simple Reverse Passive Latex Agglutination
(RPLA) method, by using the anti-PVL speciﬁc polyclonal antibodies. Its
performance correlated extremely well to PVL gene presence. However,
it was difﬁcult to prepare these speciﬁc antibodies and therefore we
made improvements resulting in a new RPLA reagent with monoclonal
antibodies, which are comparatively easier to produce.
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Methods: We prepared recombinant proteins, PVL and the homologues
(gamma-haemolysin, PVL variant). We produced some ascites containing
anti-PVL monoclonal antibodies and selected speciﬁc clones that
recognized PVL without cross-reacting with the homologues, by using
the recombinants. Antibody-sensitised latex was prepared by coating
polystyrene beads with an optimum concentration of the speciﬁc
antibody.
We collected 64 S. aureus clinical and laboratory strains, with or without
PVL gene as conﬁrmed by PCR method. Each strain was cultured in
3mL of medium for 18 hours at 37ºC with continuous shaking. The
culture supernatant was used for the RPLA assay.
In this assay, 25 uL of the culture supernatant was serially diluted with
reaction buffer from 1:2 to 1:128 in 96 well V-bottom microtitre plates
and 25 uL of the sensitised latex suspension was added to each well,
and mixed by agitation. In order to obtain an agglutination reaction, the
plate was kept overnight at room temperature under moist conditions
to prevent the plate from drying out. Thereafter, the end point of
agglutination was determined visually.
Results: Thirty-ﬁve isolates carrying PVL gene were found to produce
the PVL toxin, on the other hand, all of the 29 isolates without PVL
gene were negative. The minimum detection level of PVL by the RPLA
assay was approximately 1 nanogram per ml.
Conclusion: PVL expression from S. aureus isolates tested by the new
RPLA assay correlated extremely well to PVL gene presence. Hence
this assay might be a simple and useful method for the detection of PVL
toxin from S. aureus isolates.
P1152 Could the Streptococcus pneumoniae
immunochromatographic test applied to nasopharyngeal
aspirate be useful for diagnosing pneumococcal pneumonia?
S. Athlin °, K. Stra˚lin (Orebro, SE)
Objectives: In order to facilitate early diagnosis of community-
acquired pneumonia (CAP) caused by Streptococcus pneumoniae we
evaluated the rapid immunochromatographic membrane test (Binax
NOW Streptococcus pneumoniae kit; ICT) on nasopharyngeal aspirates
(NpAs). The test is validated on urine and cerebrospinal ﬂuid according
to the manufacturer.
Methods: In this prospective study samples were collected from
193 adults hospitalised for CAP and 64 adults with no infection as
controls. ICT was applied to NpAs, which had been collected with
an electronic suction device. Blood culture, urinary antigen test and
culture from representative sputum were used as reference standard to
identify pneumococcal aetiology. If S. pneumoniae was detected with at
least one of the reference methods the patient was considered having
pneumococcal pneumonia. The reference standard was negative if none
of these methods turned out positive. In order to identify atypical
aetiology, PCR was applied to respiratory tract samples for detection of
Mycoplasma pneumoniae and Chlamydophila pneumoniae respectively,
and to urinary antigen test for detection of Legionella pneumophila.
Results: The test was positive for S. pneumoniae on NpAs in 86 patients
(45%) with pneumonia and in three controls (4.7%). As comparison
the test was positive on urine samples in 45 patients (23%) with
pneumonia and in one control (1.6%). In 61 patients with pneumonia and
positive reference standard the ICT was positive on NpAs in 49 cases.
Furthermore, the test was positive in 37 of 132 cases with negative
reference standard. Thus, the sensitivity was 80% and the speciﬁcity
was 72%. If cultures on NpAs were added to the reference standard,
the sensitivity was 81% (59/73) and speciﬁcity 78% (93/120). Atypical
bacteria were detected in 20 patients with pneumonia, of which two
patients (10%) were tested ICT positive in NpAs. In this study 98
patients were treated with penicillin G, penicillin V or amoxicillin as
monotherapy. Among 41 patients with positive ICT and 57 patients with
negative ICT 36 patients (88%) and 38 patients (67%) respectively were
cured with no change of antibiotic regime.
Conclusion: The relative high sensitivity in combination with the low
number of positive cases among controls and patients with atypical
aetiology indicate that ICT applied to NpA could be useful for diagnosing
pneumococcal pneumonia. A positive ICT result supports early treatment
with penicillin among patients with CAP.
P1153 Rapid diagnosis by antigen detection for group B
Streptococcus carriage in pregnant women
A. Raglio °, M. Arosio, A. Grigis, M. Peretto, D. Fanti, M.A. Latino,
A. Goglio (Bergamo, Turin, Milan, IT)
Objectives: In 2002, the Centers for Disease Control and Prevention
(CDC) recommended that all pregnant women be screened for carriage
of group B Streptococcus (GBS) at between 35 and 37 weeks of gestation
by pre-enrichment overnight in Todd-Hewitt broth followed by subculture
on a blood agar plate. Not all women, however, perform the test during
pregnancy. Rapid methods are available for screening at the time of
birth. The purpose of our study was to evaluate the performance of an
immunochromatographic test to detect GBS antigen in pregnant women
24 hours before standard culture method.
Methods: Between 1 May and 30 September 2008, 176 pregnant women
were monitored, antenatally or at delivery, by placing 142 vaginal and
153 rectal swab specimens into Todd-Hewitt broth with nalidixic acid
and colistin (Biomerieux). After overnight incubation, the broth was
subcultured onto ChromId Agar strepto B (Biomerieux) and the detection
of GBS antigen was performed directly from the enrichment broth,
according to the kit procedure (Bionexia GBS). The discordant results
were analyzed by a real-time PCR, GeneXpert GBS assay (Cepheid).
Results: We examined 176 pregnant women, 63 positive and 113
negative for GBS culture. Antigen conﬁrmed all the culture positive
results. Among 113 negative cultures, 9 cases were positive by antigen.
Taking as reference the culture, antigen showed 100% sensitivity, 92.1%
speciﬁcity, NPV 100% and PPN 87.5%.
We tested by PCR 7 samples with discordant results: 4 resulted positive
and 3 negative.
Conclusions: The detection of GBS antigen by immunochromatographic
test (Bionexia GBS) allowed to identify all the positive cases and showed
a NPV of 100%. PCR results suggested that the immunochromatographic
test may be more sensitive than culture and allowed to a speciﬁcity
increase. The reading of antigen was always easy, only in 6 cases with
the growth of 3−4 GBS colonies onto Agar ChromId strepto B, the
colorimetric reaction of sample-line resulted weak and this could lead
to equivocal interpretation. GBS antigen detection was rapid, reliable,
easy-to-perform and able to identify all the colonised pregnant women
already within 24 hours after sample collection.
P1154 Evaluation of three media (BD Granada®, Chrom ID® and
Strepto B®) for screening of recto-vaginal colonisation by
group B Streptococcus in pregnant women and determination
of the prevalence of non-haemolytic group B Streptococcus
I. Mansoor °, S. Dubois, M. Bachelart, C. Leroy (Tournai, BE)
Objectives: The CDC recommend screening of all pregnant women
between 35 and 37 week of gestation for group B streptococci (GBS)
by use of selective broths and subculture on sheep blood media. In
Belgium Lim broths are subcultured on Granada® (GRA) media which
have the pitfall that non haemolytic group B streptococci (NHGBS) will
be missed as the orange red carotenoid pigment is linked with the gene
producing b haemolysis. The Chrom ID Strepto B® (CIDSB) has the
advantage of detecting all GBS but needs ancillary conﬁrmation tests.
In this study the detection rates of GBS for Granada®, Chrom ID® and
Strepto B® (SBA); the prevalence of NHGBS and labour intensiveness
were evaluated.
Methods: 427 specimens (majority (95%) recto-vaginal swabs) received
over a 3-month period were included. Swabs were placed in Lim
broths, incubated for 16−24 h at 35ºC and 10ml aliquots of broths were
subcultured onto GRA, CIDSB and SBA. CIDSB was incubated in air
while GRA and SBA anaerobically and plates were read after 24−48 h. In
case of discordant results 10ml of broths were inoculated onto Columbia
sheep blood agars (CSBA) which were incubated in 5% CO2 for 24 h
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at 35ºC. Identiﬁcation of GBS were based on colony morphology, Gram
staining, catalase reaction and latex agglutination tests (DiaMondiaL
Strep Kit®) for all probable GBS grown on the CIDSB and CSBA.
All discordant results were conﬁrmed by latex tests and Api® 20 strep
and statistical signiﬁcance (p< 0.05) for the differences in recovery rates
was obtained by using the McNemar’s test.
Results: GBS were recovered from 98 specimens. The yields for GRA,
CIDSA and SBA after 24(48)h of incubation were 91(91); 92(97) and
80(87) and overall sensitivities(speciﬁcities) of 92.9(100); 99.0(94.5)
and 88.8(100)% were observed. No signiﬁcant difference was observed
between the GRA and either CIDSA or SBA but CIDSA performed
better than SBA (p< 0.01). The positive predictive values for GRA and
SBA were 100% and 95.8(84.3)% for CIDSA after 24(48 h) incubation.
The prevalence of GBS and NHGBS in the study population was 23%
and 1% respectively.
Conclusion: The better yield of the Granada® medium compared to the
Strepto B® agar could be due to a better stability of the orange pigment.
The ChromID® could be a good alternative since it would detect non
haemolytic group B streptococci but it is more labour intensive as
colonies are smaller, not well isolated and all typical colonies of GBS
should be conﬁrmed by latex tests.
P1155 Legionella pneumophila endocarditis: a diagnostic challenge
E. Verhoye °, A. Boel, K. Van Vaerenbergh, H. De Beenhouwer (Aalst, BE)
Background: Only seven cases of prosthetic valve endocarditis (PVE)
due to Legionella pneumophila are documented in literature. Laboratory
diagnosis is hampered by the fact that detection of Legionella sp. in
commercial automated blood culture systems might be inadequate due
to insufﬁcient growth. Legionella serology can offer a meaningful aid
to this diagnostic challenge and is categorised by the modiﬁed Duke
criteria as a minor criterion.
Case report: A year post aortic valve replacement for suspected
but culture negative endocarditis, a 75 year old man was transferred
to our hospital. He suffered from episodes of relapsing fever in
spite of several therapies with different antibiotic combinations. Trans-
oesophageal echocardiography showed vegetations on the aortic valve.
Despite prolonged incubation (14 days) multiple blood cultures remained
negative. The prosthetic aortic valve was replaced and sent for culture to
the microbiology laboratory. After six days of incubation, the culture of
the valve showed rare, slow growing colonies of Gram negative bacilli on
chocolate agar medium. Nested PCR with 16SrDNA primers followed by
sequencing and BLAST analysis identiﬁed L. pneumophila both directly
from the aortic valve tissue and from the bacterial growth. This was
conﬁrmed by typing (serotype 1) and by real time Legionella sp.-speciﬁc
PCR. The Binax NOW Legionella urinary antigen assay repeatedly tested
negative. No Legionella sp. was detected in tracheal aspirates by molec-
ular diagnostics. Legionella Ab titers (IFA) were very high (>1/5000).
Retrospective analysis on serum, taken ﬁve months earlier, showed the
same high titer. In that period, spleen infarcts and a cerebrovascular
accident were reported. After the aetiological diagnosis of Legionella
endocarditis was made claritromycin was started intravenously and
initially the patient showed a good recuperation. Unfortunately, 20 days
postoperatively the man died of a neurological event.
Conclusion: We present a case of blood culture negative PVE, caused
by L. pneumophila serotype 1. Legionella urinary antigen assay was
negative but the aetiologic diagnosis was made after elective surgery
by culture and PCR on the prosthetic valve. Legionella Ab titers were
strongly elevated, highlighting the importance of serologic testing in case
of blood culture negative cases of endocarditis.
P1156 Evaluation of the Oxoid Xpect™ Legionella test kit for detec-
tion of Legionella pneumophila serogroup 1 antigen in urine
J.P. Bruin, E. Scopes, M.F. Peeters, E.P.F. IJzerman, B.M.W. Diederen °
(Haarlem, Tilburg, NL; Basingstoke, UK)
Objectives: We evaluated a new immunochromatographic assay (the
Oxoid Xpect™ Legionella urinary antigen test) for its ability to detect
Legionella pneumophila serogroup 1 antigen in urine.
Methods: The Xpect™ Legionella urinary antigen test (Thermo Fisher
Scientiﬁc) was evaluated against the BinaxNOW® Legionella urinary
antigen test (Inverness Medical Professional Diagnostics, Scarborough,
ME) using frozen urine samples. Urine samples were collected by
the laboratory for Medical Microbiology and Immunology, located at
the St. Elisabeth Hospital, Tilburg and the Regional Laboratory of
Public Health, Haarlem, The Netherlands between 1999 and 2005, and
stored at −70ºC until processing was performed. Eighty-six Legionella-
positive urine samples, previously conﬁrmed by seroconversion in an
IgM and/or IgG assay (SERION classic ELISA), and/or positive culture
or Legionella speciﬁc PCR on a lower respiratory tract sample were
included in the study. Another 87 urine samples from patients with
respiratory infections other than Legionella (mainly community-acquired
pneumonia from Streptococcus pneumoniae) were also incorporated.
All Legionella positive and negative urine samples were read at 15
and 60 minutes. To determine the optimum incubation time regarding
performance, a subset of the Legionella positive samples (n = 54) were
also read at 30 and 45min.
Results: Sensitivity was 83% after 15min incubation, 87% after 30min
and 89% after 45 and 60min incubation of the Xpect™ test. Speciﬁcity
was 100% after 15 and 45min incubation but 98% after 60min
incubation due to two false positive results from the Xpect™ test.
Sensitivity of the NOW® test was 85% after 15min incubation and
94% after 30, 45 and 60min incubation. Speciﬁcity was 100% after
both 15 and 60min incubation. In comparison with the BinaxNOW test
a calculated agreement of 96% and 97% (after 15 and 60 minutes of
incubation respectively) for the Oxoid Xpect compared to BinaxNow
was found.
Conclusion: The study provided data showing that the Oxoid Xpect™
Test has a high degree of sensitivity and speciﬁcity, with a sensitivity
that increased with incubation time. By evaluating the four different
read-time points we showed that reading the Xpect™ test after 45min
incubation returned results that gave optimal performance and this has
now been adopted in the manufacturers instructions for use.
P1157 Mycoplasma hominis: an incidental but signiﬁcant ﬁnding
by routine bacteriological culture
J.B. Gertsen °, H.C. Schønheyder (Aalborg, DK)
Objectives: M. hominis is part of the normal mucosal ﬂora and is
primarily associated with infections in the genitourinary tract. Most
infections occur following delivery or genitourinary instrumentation,
but are also seen in immunocompromised patients. We present 4 cases
diagnosed by routine bacteriological culture during a 4-year period.
Methods: Dpt. of Clinical Microbiology, Aalborg Hospital serves a
population of 0.5 mio. Aerobic bacteriologic cultures are routinely
carried out on 5% horse blood agar and chocolate agar (SSI Diagnostika,
DK) at 35 ºC in 5% CO2. The ﬁnding of translucent, pinpoint colonies
after 96–120 h of incubation raises the suspicion of M. hominis; support
for the diagnosis is provided by Gram stain failing to reveal a distinctive
micromorphology and growth of similar colonies on subculture. In the
four cases a deﬁnitive identiﬁcation was obtained by PCR performed at
Statens Serum Institut, Copenhagen (by courtesy to Jørgen Skov).
Results: The four patients were immunocompetent women (23−56 years
of age) without signiﬁcant comorbidity (Table). In all patientsM. hominis
were obtained in pure culture. At the time of diagnosis three patients
had abscesses in the genitourinary tract or endometritis. M. hominis
infection was preceded by one instance of either caesarean section,
vaginal hysterectomy, or a complicated vaginal delivery. The fourth
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patient was admitted at term with PROM and signs of chorioamnionitis
and developed endometritis postpartum. The patients did not respond to
surgical drainage of the abscesses (if present) and prolonged empirical
intravenous therapy with a b-lactam antibiotic and metronidazole
(median 9 days). The tentative diagnosis of M. hominis prompted a
change of antibiotic therapy to either moxiﬂoxacin or clindamycin which
was followed by resolution of symptoms and normalisation of CRP
(median 9 days).
Conclusion: M. hominis is a rare ﬁnding by prolonged incubation of
conventional blood agar. A pathogenic role of M. hominis was supported
by the lack of clinical response to surgical drainage and prolonged
empirical antibiotic therapy. This experience raises the pertinent question
whether M. hominis infections are overlooked particularly in obstetric
and gynaecological patients subsequent to vaginal birth/caesarean section
or genitourinary procedures.
Four female patients with an incidental ﬁnding of M. hominis by routine bacteriological culture.
Patient Age Primary procedure M. hominis isolated
from
Empirical therapy Susceptibility and therapy
1 23 Acute caesarean
section (PROM and
chorioamnionitis)
Cervix
Placenta
Ampicillin &
metronidazole
(6 days)
Clindamycin: S
Tetracycline: S
2 31 Elective caesarean
section
Intraperitoneal abscess
Surgical site infection
Cefuroxime &
metronidazole
(8 days)
MIC moxiﬂoxacin:
0.047mg/mL
MIC ciproﬂoxacin:
0.094mg/mL
Tetracycline: S
Clindamycin: R
3 35 Vaginal delivery
(complicated by uterine
perforation)
Peritoneal ﬂuid Ampicillin (8 d) →
Cefuroxime (13 d) &
metronidazole (21 d)
Tetracycline: S
4 56 Vaginal hysterectomy
(metrorrhagia)
Vaginal abscess
Renal abscess
Ampicillin &
gentamicin &
metronidazole
(10 days)
MIC moxiﬂoxacin:
0.023mg/mL
MIC ciproﬂoxacin:
0.094mg/mL
Tetracycline: S
Clindamycin: S
P1158 The comparation of the fresh and lyophilised horse serum
fertility: the effect on Mycoplasma hominis growth
T. Pljesa °, G. Dakic, M. Svabic-Vlahovic (Belgrade, RS)
Objectives: Bacteriological diagnosis of human mycoplasma infections
is complicated regarding special nutritive requirements and cultivating
conditions these bacteria have. A necessary component for mycoplasma
growth is the fresh horse serum, the source of cholesterol, but its
important ﬂaw is that it can be easily contaminated and has a
poor stability. The aim of this study was to establish the procedure
for preparing long lasting, in house made media for isolation and
identiﬁcation of M. hominis, as commercial media are not easy available
to many laboratories in developing countries or countries in transition.
Methods: Each of the 32 M. hominis strains were inoculated into
Hayﬂick broth with reconstituted lyophilised horse serum (L1) and into
Hayﬂick broth containing fresh horse serum (F). The individual bacterial
cultures were then inoculated onto Hayﬂick agar containing the same
lyophilised horse serum and the Hayﬂick agar prepared with the fresh
horse serum. After the incubation, the colony count was performed and
the bacterial growth was evaluated using the following scale: sign 0: no
growth, 1: good growth (1−10 colonies) and 2: excellent growth (more
than 10 colonies). The same procedure was performed: a) 3 months later
using the lyophilised horse sera stored for 6 months at 5±3ºC (L2) and
b) 6 months later, using the lyophilised horse sera stored for 9 months
at 5±3ºC (L3) for preparation of Hayﬂick broth and Hayﬂick agar.
Results: No bacterial growth was observed for 5 strains cultivated with
L1, 5 strains cultivated with L2, 7 strains cultivated with L3 and 5 strains
cultivated with F. Sign 1 was reported for 15 strains cultivated with L1,
17 strains cultivated with L2, 18 strains cultivated with L3 and 16 strains
cultivated with F. Sign 3 was assigned to 12 strains cultivated with L1,
10 strains cultivated with L2, 7 strains cultivated with L3 and 11 strains
cultivated with F. The comparison of bacterial growth reported for each
strain cultivated with L1, L2, L3 and F revealed no statisticaly signiﬁcant
difference between them (p 0.724552581, c-2 test.
Conclusions: Our results suggest that the fertility of in house lyophilised
horse serum is comparable to the fertility of the fresh horse serum,
and it remains unchanged for 9 months stored at 5±3ºC. Therefore, we
suggest lyophilised horse sera to be used instead of fresh horse sera
for the preparation of Hayﬂick broth and Hayﬂick agar in a case of
unavailability of commercial media.
P1159 Biotyping of Brucella melitensis using Fourier transform
infrared spectroscopy
M.A. Miguel Go´mez, A. Ordun˜a Domingo, M.P. Gutie´rrez Rodrı´guez,
F.J. Marı´n Gil, S. Garcı´a de Cruz, S. Gonza´lez Cabrero, F. Menegotto,
A. Cubero Rivas, M.A. Bratos Pe´rez ° (Santa Cruz de Tenerife,
Valladolid, ES)
Introduction: The characterisation of biovar of B. melitensis, the most
important species of the genus Brucella that produces man’s disease,
has important epidemiological implications. Spectroscopy measures
the interaction between electromagnetic radiation and material. When
infrared radiation comes into contact with material, the energy is
transferred to the atoms, ions and molecules causing tiny vibration-
rotation movements in the bonds of the compounds. The inclusion of
the Fourier mathematical function and subsequent use of computers for
instrument control and processing, storage and visualisation of data has
improved this technique.
Objective: This study has been aimed at characterising the different
biotypes of B. melitensis using Fourier transform infrared spectroscopy
(FTIR)
Methods: Strains type B. melitensis biotypes 1, 2 and 3 were studied.
The clinical strains of B. melitensis, six corresponding to biotype 1, one
of biotype 2 and ﬁve of biotype 3 were biotyped following classical
methods. After killing bacteria by formaldehyde the sediment obtained
by centrifugation was washed three times with distilled water, and ﬁnally
was lyophilised. The dry sediment was mixed homogeneously with KBr
to obtain a pellet from which the corresponding infrared reading was
taken. The equipment used was a Spectrophotometer Cygmus 100 FT-
IR Spectrometer with an MTC detector and the computer software used
was Win FIRST v2.0 (Mattson Instruments Inc, USA). The spectrum
was recorded between 4000 and 400 cm−1. The statistical analysis was
performed using the SPSS v12.0 statistical package.
Results: Using the second derivative spectral data from the B. melitensis
strains and speciﬁcally with the wavenumbers of the peaks selected for
their greater variability, a table was drawn up to facilitate comparison.
Those with the greatest variation were found to be those situated
around the following wavenumbers: 770, 860, 890, 944, 1523, 1684 and
1743 cm−1. Factorial analysis was applied to the table. When applying
factorial analysis to biotypes of B. melitensis we found that two factors
account for 75% of the variance and with three the ﬁgure reaches 89%.
Figure 1 shows the three-dimensional distribution of the factorial scores
of the B. melitensis strains.
Figure 1. Distribution of Brucella melitensis biotypes.
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Conclusion: FTIR may be useful in the characterisation of biotypes of
B. melitensis.
Acknowledgement: This work was partially supported by Red Tema´tica
de Investigacio´n en Brucelosis, ref. 2003/0204.
P1160 Performance of the BioPlex 2200 Syphilis IgM automated
bead immunoassay system
T.D. Ly °, C. Marcenaro, M. Dautigny, A. Ebel, L. Guis (Ivry-sur-Seine,
FR)
Background: BioPlex 2200 Syphilis IgM (Bio-Rad) is a fully automated,
recombinant proteins TpN47 and TpN17 based immunoassay utilising
multiplex ﬂow technology. In this study, the performance of this new
assay was compared to that of SYPHILICHECK IgM Capture (All Diag)
using native antigens of Treponema pallidum.
Methods: 745 unselected serum specimens submitted for syphilis
serology were screened with conventional tests: VDRL (Venereal
Disease Research Laboratory) and TPHA (Treponema pallidum
haemagglutination assay) or FTA-ABS (ﬂuorescent treponemal antibody
absorption). Whenever one assay was reactive, BioPlex 2200 Syphilis
IgM and SYPHILICHECK IgM Capture were performed and IgM Line
Immunoblot (Virotech) was used for conﬁrmation.
Results: The results are illustrated in Tables I−III. BioPlex 2200 Syphilis
IgM had an overall agreement of 88.3% versus SYPHILICHECK IgM
Capture with negative agreement of 89.4% and positive agreement of
84.7%. BioPlex 2200 Syphilis IgM had an overall agreement of 92.5%
versus Immunoblot, with a negative agreement of 98.3% and positive
agreement of 87.1% respectively. SYPHILICHECK IgM Capture versus
Immunoblot agreement was 65.5% overall, 66.5% positive, and 50%
negative. Low negative agreements were due to 52 and 75 samples
that were positive and equivocal respectively by SYPHILICHECK IgM
Capture and negative by Immunoblot.
Conclusion: BioPlex 2200 Syphilis IgM, the ﬁrst fully-automated
Syphilis IgM assay based on the use of recombinant proteins, showed
better performance in comparison to SYPHILICHECK IgM Capture
using native antigens microplate ELISA assay. The speciﬁcity of BioPlex
2200 Syphilis IgM is superior to that of SYPHILICHECK IgM Capture,
based on the Immunoblot results obtained for the discrepant samples.
The BioPlex 2200 Syphilis IgM compared with IgM Line Immunoblot
had an overall agreement of 92.5%; whereas, the SyphiliCheck IgM
Capture compared to the IgM Line Immunoblot overall agreement was
only 65.5%.
Table I. BioPlex 2200 Syphilis IgM vs SYPHILICHECK IgM Capture
BioPlex 2200 SYPHILICHECK IgM Capture
Syphilis IgM Positive Equivocal Negative Total
Positive 122 17 22 161
Equivocal 4 2 0 6
Negative 53 79 446 578
Total 179 98 468 745
Table II: BioPlex 2200 Syphilis IgM vs Immunoblot
BioPlex 2200 Immunoblot
Syphilis IgM Positive Equivocal Negative Total
Positive 108 37 16 161
Equivocal 2 2 2 6
Negative 2 17 114 133
Total 112 56 132 300
Table III: SYPHILICHECK IgM Capture vs Immunoblot
SYPHILICHECK Immunoblot
IgM Capture Positive Equivocal Negative Total
Positive 103 24 52 179
Equivocal 4 19 75 98
Negative 5 13 5 23
Total 112 56 132 300
P1161 Comparative evaluation of IMMULITE® 2000 syphilis
screen assay and bioelisa Syphilis 3.0 assay for determination
of antibodies to Treponema pallidum in pregnancy samples
A. Donkers ° (Rotterdam, NL)
This is a comparison study between IMMULITE 2000® Syphilis Screen
versus bioelisa SYPHILIS 3.0 for the detection of total antibodies
speciﬁc for Treponema pallidum. IMMULITE 2000® Syphilis Screen
uses one major Treponema pallidum recombinant antigen (p17). bioelisa
SYPHILIS 3.0 uses three major Treponema pallidum recombinant
antigens (p15, p17 and p47). All samples were tested on recomBlot
Treponema IgG/IgM for conﬁrmation.
Objective: To evaluate the performance of IMMULITE® 2000 Syphilis
Screen assay versus bioelisa SYPHILIS 3.0.
Methods: A total of 681 pregnancy specimens were tested by
IMMULITE 2000® Syphilis Screen, bioelisa SYPHILIS 3.0 and
recomBlot Treponema IgG/IgM. IMMULITE® 2000 Syphilis Screen is
a fully automated one-step chemiluminescent immunoassay. Puriﬁed p17
Treponema pallidum recombinant antigen were used in both capture and
detection phase. Patient sample and the reagent are incubated together
with the coated beads for 30 minutes. bioelisa SYPHILIS 3.0 is a two-
step enzyme immunoassay (EIA). Puriﬁed p15, p17 and p47 Treponema
pallidum recombinant antigen were used in both capture and detection
phase. Total incubation time is 2 hours. recomBlot Treponema IgG/IgM
is a western blot kit that separate detection of IgG and IgM antibodies
using pathogen speciﬁc Treponema antigens Tp47, Tp17, and Tp15 as
well as TmpA.
Results: An overall agreement for IMMULITE 2000® Syphilis Screen
versus bioelisa SYPHILIS 3.0 was 99%. The relative sensitivity,
speciﬁcity, and agreement for the IMMULITE 2000® Syphilis Screen
assay against recomBlot Treponema IgG/IgM were 100%, 99.4% and
99.4% respectively; the relative sensitivity, speciﬁcity, and agreement
for bioelisa SYPHILIS 3.0 assay aginst recomBlot Treponema IgG/IgM
were 92%, 99.8% and 99.6% respectively.
Conclusions: Although IMMULITE® 2000 Syphilis Screen uses a single
p17 antigen, it is more sensitive than the bioelisa SYPHILIS 3.0 using
three recombinant antigens (p15, p17 and p47). IMMULITE® 2000
Syphilis Screen shown to be a highly speciﬁc and sensitive method in
syphilis screening and it can be considered as alternative to other ELISA
tests.
P1162 Development of recombinant Helicobacter pylori CagA pro-
tein fragments for antibody production and characterisation
A. Klimovich °, L. Terekhina, I. Gryazeva, M. Samoylovich, A. Suvorov,
V. Klimovich (St. Petersburg, RU)
Objective: Helicobacter pylori strains expressing cytotoxic CagA
protein are proved to be most virulent and oncogenic. Therefore in
clinical diagnostics it is necessary not only to detect the Helicobacter
infection but to discriminate CagA-positive and -negative pathogen
strains as well. The immunodiagnostics seem to be a good addition or
even alternative to the commonly used molecular genetics methods, but
lack characterised and standardised reagents. The aim of the work was to
produce recombinant fragments of CagA protein, create and characterise
monoclonal antibodies (MAbs) against CagA.
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Methods: To develop Escherichia coli strains, producing recombinant
CagA fragments (rCagA), 4 DNA overlapping fragments of cagA-gene
were ampliﬁed and cloned into expression vectors. The N-terminally
His6-tagged recombinant proteins were expressed in E. coli upon IPTG
induction and puriﬁed by means of afﬁnity chromatography on Ni-
NTA. The pure protein samples were used for F1(SJLxBALB/c) mice
immunisation. The splenocytes of immunised animals were hybridised
with myeloma cells to produce hybridoma lines. Hybriodoma screening
and MAbs characterisation were performed by means of ELISA and
Western-blot, with rCagA and H. pylori strains protein extracts being
used as antigens.
Results: Four E. coli strains expressing recombinant CagA fragments of
75, 65, 44, 39 kDa with N-terminal His6-tag were constructed. More
than 20 hybridoma cell lines were obtained and proved to produce
antibodies against CagA. Four MAbs had the highest afﬁnity and to
recognized different isolated linear epitopes on rCagA, with one epitope
being localised inside the variable region of CagA. Two of four MAbs
were shown to bind full-length CagA protein (>120 kDa) in samples
from H. pylori strains. The efﬁcacy of discrimination between CagA-
positive and -negative H. pylori strains by means of these MAbs turned
out to be comparable with that of commonly used PCR-diagnostics. A
sandwich-ELISA system was constructed for quantitative detection of
CagA protein in biological samples and estimated the sensitivity of this
assay.
Conclusion: The obtained 4 recombinant CagA fragments may be used
further as standardised antigen reagents for epidemiological screening of
H. pylori infection and for vaccination results estimation. MAbs against
CagA can be used for detection of infections with the most virulent
CagA-expressing Helicobacter and for research purposes as well.
P1163 Evaluation of a monoclonal-based antigen in stool enzyme
immunoassay for diagnosis of Helicobacter pylori infection
in Spanish children
S. Agudo °, T. Alarco´n, P. Urruzuno, A´. Somodevilla, M. Lo´pez-Brea
(Madrid, ES)
Objectives: Helicobacter pylori infection can be diagnosed by invasive
and no invasive methods. Invasive tests, including culture, histology and
rapid urease, it is necessary to do a endoscopy to obtain biopsies of the
gastric mucosa and non invasive techniques such as the urea breath test,
serology or detection of H. pylori antigen in stool specimen (HpSA). In
this study, we use a H. pylori stool antigen test as non-invasive diagnostic
methods and we compared with diagnosis based on endoscopic biopsy-
based methods (culture and urease test).
Methods: 50 samples of biopsies obtained from paediatric pacients with
gastric symptoms before initiation of any therapy against H. pylori,
received at the Department of Microbiology (Hospital Universitario
de La Princesa, Madrid) from January 2006 to November 2008,
were cultured according to standard microbiological procedures and all
colonies suggestive of H. pylori were tested by Gram-strain, oxidase and
urease tests to conﬁrm the identiﬁcacion. Children also donated a sample
of stool. Stool specimens from these patients were examined by rapid
STRIP HpSA. (Pylori-Strip, Coris, Bioconcept), what are commercially
available enzyme-linked immunosorbent assay based technology. The
sensitivity and speciﬁcity were calculated for no invasive test used in
this study.
Results: For these 50 children, 40 (80%) were diagnosed as positive and
10 (20%) were diagnosed negative for H. pylori infection by the gold
standard methods (culture and urease). Whereas 37 (74.5%) were positive
and 13 (26%) were diagnosed negative by the rapid STRIP HpSA test.
The sensitivity and speciﬁcity were 92.5% and 100%, respectively.
Conclusion: Stool antigen test had high sensitive and speciﬁc for
diagnostic of H. pylori. The non invasive test could be used as a routine
diagnostic tool in the microbiology laboratory for assenssing clinical
signiﬁcance and eradication control of H. pylori, because it is more
comfortable for the patients, especially for children and it is possible
to obtain results rapidly without the need for sophisticated laboratory
equipment.
P1164 Comparison of 6 rapid assays for detection of Helicobacter
pylori antigen in stool in children with recurrent abdominal
pain − preliminary data
L. Blairon, H. Souayah, C. Moens, A. Dediste °, O. Vandenberg
(Brussels, BE)
Objective: Some authors demonstrated a relationship between H. pylori
(Hp) infection and recurrent abdominal pain (RAP) in children. The
diagnosis of Hp infection can be assessed by either invasive (upper
gastrointestinal endoscopy with histopathology and culture), or non
invasive, but slow and expansive methods (C13-urea breath test, UBT).
A few years ago, a cost-effective and rapid Hp stool antigen (HpSA)
detection assay (ImmunoCard STAT, Meridian) was put on the market
with a reported sensitivity and speciﬁcity up to 90%. Since a few
months, other new HpSA assays are available. In this prospective
study, we compare the performances of those new assays with these
of ImmunoCard STAT and of a gold standard method in children with
RAP.
Methods: We included every consecutive children consulting with RAP.
All patients underwent either an UBT or an endoscopy, and a stool
collection for HpSA detection with ImmunoCard STAT, Rapid Hp StAR
(Oxoid), Medcard Pylori (Medimar), Pylori Strip (Coris BioConcept),
H. Pylori Antigen Test (Cortez Diagnostics), and H. Pylori Stool Card
(Dima). All HpSA tests were performed in routine conditions.
Results: 25 paediatric patients (15 boys and 10 girls) with RAP and
either an endoscopy or an UBT were enrolled in 9 months. The median
age was 8.7 (extremes: 9.6m to 14.9 y; 95% CI 6.02−10.56). UBT was
positive in 10/18 cases (55.6%); histopathology was suggestive of an
Hp infection in 8/19 patients (42.1%). Overall, the prevalence of Hp
infection was 52.0% (13/25). The performances of the different assays
are shown in the table.
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Sensitivity 76.9% 76.9% 84.6% 61.5% 76.9% 38.5%
Speciﬁcity 92.3% 84.6% 88.5% 100.0% 84.6% 100.0%
PPV 83.3% 71.4% 78.6% 100.0% 71.4% 100.0%
NPV 88.9% 88.0% 92.0% 83.9% 88.0% 76.5%
Conclusion: Although the majority of authors reported very good
performances of HpSA in children, we observed, in routine conditions,
a median sensitivity and speciﬁcity of 76.9% and 90.4% respectively,
with a high variability between the different available kits. Furthermore,
the previously only available ImmunoCard STAT showed the lower
sensitivity. However, the present data are preliminary and the comparison
will be continued with a larger number of patients.
P1165 Diagnosis of Helicobacter pylori infection in Indonesian
children: comparison of Helicobacter pylori stool antigen
with enzyme-immunoassay and a new rapid test
D. Prasetyo °, H.J. Gerritsen, P. Mertens, V. Labrune, T. Leclipteux,
E.J. Kuijper (Bandung, ID; Leiden, NL; Gembloux, BE)
Aims: To determine the prevalence of Helicobacter pylori (H. pylori)
infection in symptomatic children and to compare a new developed
rapid Helicobacter pylori Stool Antigen (HpSA) test with a conventional
Enzyme-Immunoassay (EIA).
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Methods: A cross sectional study was carried out among 102 high school
children (12−18 years) with chronic abdominal pain (without diarhhoea
or fever) living in Bandung, West Java Indonesia. All faeces samples
were tested by a rapid test (Coris BioConcept, Gembloux Belgium) and
by a conventional EIA (Ampliﬁed IDEIA Hp StAR, OXOID, United
Kingdom). The principle of the rapid test is based on the homogeneous
membrane system technology with latex microspheres and two different
antibodies directed against H. pylori. If a sample contains H. pylori
antigen, the complex formed of H. pylori antigen and conjugate remains
bound to the monoclonal antibody adsorbed to the nitrocellulose and
a red line develops. The result is visible within ten minutes. A stored
collection of 32 faeces samples tested positive for H. pylori by HpSA
(EIA, Ampliﬁed IDEIA Hp StAR, OXOID, United Kingdom) was
retested with both assays and also included in the analysis.
Result: The overall prevalence of H. pylori infection among Indonesian
children was 3% by EIA. There was an excellent correlation of rapid
test results with EIA, except for 3 weak positive EIA samples that were
negative by rapid test. Nevertheless, retesting by EIA of these three
discrepant samples led to negative results. Of 32 stored faeces samples
at the LUMC which were previously EIA positive tested, 25 were positive
by EIA and 26 were positive by rapid test. Of 6 discrepant samples with
the previous test results, all had low OD values at the ﬁrst occasion and
tested negative by repeated EIA. One sample was weak positive by EIA,
also positive by rapid test but negative by repeated EIA. Including the
results of the repeated test, the sensitivity, speciﬁcity, positive predictive
value and negative predictive value of the rapid test were 96%, 98.2%,
92.3% and 99.1%, respectively.
Conclusion: The results demonstrate that the prevalence of H. pylori
infection among symptomatic Indonesian children is very low and that
new developed rapid test had an excellent performance.
P1166 The importance of stool antigen test for the diagnosis of
Helicobacter pylori infection and eradication follow-up
E. Demiray Gu¨rbu¨z, M. Soytu¨rk, O¨. Yilmaz °, N. Bekmen, M. Gu¨venir,
H. Ellidokuz, D. Do¨lek, I. Simsek (Izmir, TR)
Objective: To compare the diagnostic accuracy of stool antigen test
with urine antibody tests and serology, and to assess the eradication of
H. pylori infection in adult patients with dyspepsia.
Methods: Fifty-one patients out of110(15 males, 36 females; mean
age, 46.6±9.9 years) with dyspepsia referred to upper endoscopy and
resulted with positive RUT, histopathological examination and UBT
for H. pylori infection,were included between April 2006-July 2007.
Patients were treated by clarithromycin,amoxicillin andPPI.Urine,stool
and serum specimens from these patients were examined and evaluated
pre-treatment,at6thweek and at6thmonth after eradication therapy by
URINELISA (Otsuka Pharmacautical, Japan), Rapid Hp StAR (Oxoid)
and H. pylori IgA/IgG ELISA (BIOHIT, Finland), respectively.
Results: 51(100.0%) were diagnosed as H. pylori positive by the gold
standard methods. In pre-treatment, 36 (70.6%) and48 (94.1%) were
H. pylori positive by URINELISA according to the kit’s cut off (OD
1)value and new cut off (OD 0.397)value deﬁned by ROC analysis,
respectively.51 (100.0%) were H. pylori positive by the stool antigen
(Rapid Hp StAR) test and 48 (94.1%) were positive by H. pylori IgA/IgG
ELISA.In 6th week, 19(37.3%) were diagnosed as H. pylori positive
by UBT, 32 (62.7%) patients were succesfully treated. 25 (49.1%) and
37 (72.6%) were positive by OD 1 and OD 0.397 URINELISA.The
sensitivity, speciﬁcity, PPVand NPVwere 52.6%, 79.0%; 53.1%, 31.3%;
40.0%, 40.6% and 65.4%, 37.3% respectively (K 0.054) (K 0.086).
22 (43.1%) were positive by the Rapid Hp StAR test. The sensitivity,
speciﬁcity, PPVand NPV were 79.0%, 78.1%, 68.2% and 86.2%,
respectively(K 0.553). 43 (84.3%) were positive by H. pylori IgA/IgG
ELISA. The sensitivity, speciﬁcity, PPV and NPV were 89.5%, 18.8%;
39.5%, 75.0%, respectively (K 0.065). In 6th month, 15 (29.4%) and 24
(47.1%) were positive by OD 1 and OD 0.397 URINELISA, 20 (39.2%)
were positive by the Rapid Hp StAR test and 34 (66.7%) were positive by
H. pylori IgA/IgG ELISA.We also compared all results in pre-treatment,
6thweek and 6thmonth after eradication therapy by Cochran analysis.
Conclusion: We concluded that stool antigen test was more convenient
to use for the diagnosis of H. pylori infection, treatment success of
eradication therapy and also follow-up at 6 months. Also, we suggested
that 6thmonth results may indicate more reliable treatment success
instead of 6 weeks’ follow-up results and may conﬁrm the efﬁcacy of
OD 0.397 URINELISA results with the Rapid Hp StAR stool antigen
test at 6thmonth besides pre-treatment.
P1167 A two step algorithm, toxin immunoassay and stool culture,
for the diagnosis of C. difﬁcile infection where TcdA-TcdB+
variant strains are prevalent
B.M. Shin °, S.J. Yoo, J.G. Songer (Sanggye, KR; Tucson, US)
Objective: Clostridium difﬁcile infection is mediated by two toxins,
enterotoxin A (TcdA) and cytotoxin B (TcdB), and efﬁcient and
effective toxin identiﬁcation is an important part of diagnosis. Enzyme
immunoassay (EIA) to detect glutamate dehydrogenase (GDH), EIA or a
cytotoxicity assay to detect TcdA and/or TcdB, and bacteriologic culture
have advantages and disadvantages. TcdA-TcdB+ strains have become
more prevalent worldwide, so a two-step algorithm, including toxin EIA
and C. difﬁcile culture, may be an effective alternative to improve the
sensitivity and speciﬁcity of detection of toxigenic C. difﬁcile.
Methods: Stool specimens (n = 1596) were examined for TcdA and
TcdB via an enzyme-linked ﬂuorescent immunoassay (ELFA, VIDAS
CDAB, Bio-Merieux sa, Marcy-l’Etoile, France) and were also cultured
for C. difﬁcile. We ampliﬁed tcdA and tcdB from 419 C. difﬁcile isolates
and compared the results to those obtained with the two-step algorithm.
Results: The concordance rate between CDAB ELFA and C. difﬁcile
culture was 84.3% (1345/1596). The sensitivity and speciﬁcity of the
CDAB ELFA, using culture and PCR for tcdA and tcdB as the standard,
were 61.0% (205/336) and 94.7% (1193/1260), respectively. However,
use of the two-step algorithm (CDAB ELFA and bacteriologic culture)
increased sensitivity and speciﬁcity to 95.5% and 97.5%, respectively.
Among culture positive cases, 20.5% (86/419) would have been missed if
EIA for TcdA only had been used, and 20.5% (69/336) of PCR positive
strains would have been missed had we not performed toxigenic culture.
Conclusion: We recommended the two-step algorithm, using EIA to
detect TcdA and TcdB and bacteriologic culture to detect C. difﬁcile,
as a practical method whereby the routine microbiology laboratory
can conﬁrm or rule out C. difﬁcile infection. The method is reliable,
conservative of time, and has good positive and negative predictable
values, especially in areas where variant (TcdA-TcdB+) strains of
C. difﬁcile are prevalent.
P1168 Comparison of two immunoassays for diagnosis of
Clostridium difﬁcile toxin A and toxin B
B.M. Shin °, H.J. Oh, S.J. Yoo (Seoul, KR)
Objective: Enzyme immunoassay (EIA) capable of detecting both
toxin A and toxin B is strongly recommended for the diagnosis of
Clostridium difﬁcile associated disease in microbiology laboratories for
detection of variant (toxin A-/toxin B+) strains of C. difﬁcile. Therefore,
we evaluated two different EIAs for the diagnosis of C. difﬁcile toxin
A/B.
Methods: We performed bacteriologic culture for C. difﬁcile and
examined for toxin A and toxin B using enzyme linked ﬂuorescent
immunoassay (ELFA; VIDAS CDAB, Bio-Merieux sa, France) and
ELISA (C.DIFFICILE TOX A/B II, TECHLAB, USA) with a total of
228 stool specimens. We performed toxin A and B genes PCRs from
117 C. difﬁcile isolates and compared the results with those obtained
with the two different EIAs.
Results: The concordance rate between ELFA and ELISA was 83.3%
(190/228). The sensitivity and speciﬁcity of the ELFA and ELISA,
using culture and PCR for toxin A and B gene as the standard,
were 65.0%/72.1% and 71.8%/70.3%, respectively. Positive and negative
predictive values were 78.4%/69.6% in ELFA and 71.8%/70.3% in
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ELISA, respectively (P value >0.05). No differences were observed in
results from ELFA and ELISA with variant strain of C. difﬁcile.
Conclusions: The sensitivity of the ELISA was slightly higher than that
of ELFA for toxin A and toxin B, but speciﬁcity and positive predictive
value of the ELFA were rather higher than those of the ELISA although
no statistical differences were observed. Bacteriologic culture and PCR
assay for toxin gene are recommended for negative cases in both EIAs.
P1169 Evaluation of two algorithms using GDH and toxin A&B
enzyme immunoassays for rapid diagnosis of Clostridium
difﬁcile infection
J. Van Broeck °, J. Verhaegen, S. D’hollanders, C. Hubert, S. Resseler,
M. Delmee (Brussels, Leuven, BE)
Introduction: With toxigenic culture (TC) as gold standard, we
evaluated the performances of two sets of GDH and toxin A&B enzyme
immunoassays (EIA) for the rapid screening of Clostridium difﬁcile
infection (CDI) on stool specimens. A three-step protocol (1/ GDH,
2/ tox A&B if GDH positive, 3/ toxigenic culture (TC) if tox A&B
negative) was compared to a two-step one (1/ GDH + tox A&B, 2/ TC
if not both positive or both negative).
Materials and Methods: Stools were from inpatients older than 2 years,
suffering from diarrhoea. The ﬁrst set included TOX A/B Quik Chek and
C.Diff Quik Chek (GDH) (Techlab, Blacksburg VA USA), the second set
Immunocard toxin A&B and Immunocard C. difﬁcile (GDH) (Meridian
Cincinnati, Ohio USA).
A stool-cytotoxin assay (CTA) was performed with MRC5 cells. Cultures
were performed on CCFA. In case of positive culture and negative CTA,
colonies were tested for ‘in vitro’ toxin production (TC).
Results: A total of 295 stool specimens collected over a 9 months
period in 2008 were tested. Twenty-eight samples were shown to contain
toxigenic C. difﬁcile by CTA and/or toxigenic culture (prevalence: 9.5%).
The sensitivity, speciﬁcity, PPV and NPV of the GDH assays C.diff Quik
Chek and Immunocard C. difﬁcile were respectively: 89.3%, 90.3%, 49%
and 98.8% and 71.4%, 94.8%, 58.8% and 96.9%. Those of Tox A/B Quik
Chek and Immunocard A&B were respectively: 53.6%, 99.6%, 93.8%
and 95.3% and 57.1%, 99.6%, 94.1% and 95.7%. Only one specimen
gave a positive tox A&B with a negative GDH. A combined positive
result of both GDH and toxins A&B was observed in 16 cases with both
sets giving a PPV of 93.8%.
Conclusion: A two-step protocol where both GDH and toxins A&B are
performed on all specimens offers no marked advantage over a three-
step protocol. The latter allows the rapid result of more than 90% of the
negative and more than 50% of the positive specimens with excellent
NPV and PPV. Toxigenic culture is required for the remaining specimens.
P1170 Evaluation of the performance of chromIDTM Vibrio, a
new chromogenic medium for isolation and presumptive
identiﬁcation of Vibrio cholerae and Vibrio parahaemolyticus
from clinical specimens
R. Eddabra °, J.M. Scheftel, Y. Piemont (Strasbourg, FR)
Objective: The aim of this study was to evaluate the performance of the
chromIDTM Vibrio agar (bioMe´rieux, France), a chromogenic medium
for the detection of Vibrio cholerae (Vc) and Vibrio parahaemolyticus
(Vp) and other Vibrio spp. in stool and swab specimens in comparison
with TCBS medium (Bio-Rad, France).
Methods: A total of 91 samples including 30 fresh stool specimens
(28 coming from Abidjan) were tested, and 61 artiﬁcially contaminated
samples were inoculated with 10−3 dilutions of Vc and Vp. All samples
were seeded on both media: the TCBS and the chromID Vibrio media
directly and after enrichment step in alkaline peptone water (Bio-Rad).
All bacterial strains that yielded a potentially signiﬁcant growth were
observed for colony colour and size and identiﬁed using VITEK 2 GN®
cards (bioMe´rieux) or/and API ID 32E (bioMe´rieux).
Results: Out of 91 samples studied, 34 were positive to Vc including
14 from fresh stool specimens, 20 from artiﬁcial contaminations and 30
were positive to Vp only from artiﬁcial contaminations. The sensitivity
for isolation of Vc in fresh stool specimens was identical for both media:
78.6%, 100% before and after enrichment respectively. However, positive
test with chromID Vibrio concluded more rapidly to the presence of Vc.
In the case of artiﬁcial contaminations, sensitivity of chromID Vibrio
was more important than TCBS after enrichment for Vc and for Vp
before and after enrichment. In fresh stool specimens, the speciﬁcity of
chromID Vibrio for screening Vc was signiﬁcantly higher than TCBS
(100%, 100% compared to 54.6%, 45.5% before and after enrichment,
respectively), and remains important on both media for Vp (100%
chromID Vibrio; 96% TCBS).
Conclusion: The overall sensitivity of chromID Vibrio and TCBS
appeared similar for fresh stool and artiﬁcial contamination. However,
chromID Vibrio medium was more speciﬁc for Vc in fresh stool
specimens and presented some advantages in terms of rapidity to identify
strains with morphologically typical colonies.
P1171 Enhancement of motility ability of viable thermophilic
Campylobacter in viscous condition
S.P. Voravuthikunchai °, S. Wisessombat (Hatyai, Songkla, TH)
Objectives: A novel apparatus has been developed for the detection of
the four thermophilic Campylobacter commonly associated with human
gastroenteritis including C. jejuni, C. coli, C. lari, and C. upsaliensis.
It was found that the apparatus could detect more positive samples than
did the conventional culture method. However, this apparatus for the
isolation of Campylobacter from contaminated chicken products require
enrichment for 18 h. In this communication, the effects of chemotaxis
on motility ability of viable Campylobacter to pass through a 0.45mm
pore size ﬁlter in viscous condition were investigated.
Methods: Reference strains including C. jejuni ATCC 33291, C. coli
MUMT 18407, C. lari ATCC 43675, and C. upsaliensis DMST 19055
were used for the validation of the developed method. The initial
numbers of artiﬁcially-inoculated viable cells per g of chicken meat
was approximately 10−104. The constituents of mucin and bile (1:1)
were obtained from bovine gallbladder from freshly slaughtered. Sodium
citrate and constituents of mucin and bile were added into a soft-
agar-coated membrane ﬁlter and incubated at both 37ºC and 42ºC for
24 h. Drop plate method was used to determine numbers of viable
Campylobacter at 6, 12, 18, and 24 h.
Results: Campylobacter moved through the soft-agar-coated ﬁlter at
both 37ºC and 42ºC. After 6 h, constituents of mucin and bile at
concentrations of 1, 5, and 10% demonstrated signiﬁcant increase in
numbers of viable cells (p< 0.05). The numbers of the organisms at
42ºC were higher than those at 37ºC. Following the inoculation of
Campylobacter (104 cfu/g), the numbers of cells at 42ºC was 104 cfu/ml
and 10 cfu/ml, at 37ºC after 6 h inoculation. The highest concentration of
the cells reached 109 cfu/ml at 42ºC and 107 cfu/ml at 37ºC, after 24 h
inoculation. When the inoculation was 10 cfu/g, the numbers of cells
at 42ºC was 103 cfu/ml and 102 cfu/ml, at 37ºC after 6 h inoculation.
The numbers of cells at 42ºC was 106 cfu/ml and 104 cfu/ml, at 37ºC
after 24 h inoculation. However, there was no correlation between
concentration and chemotactic effects of viable Campylobacter. In
contrast, no signiﬁcant differences were observed in 0.001−0.1M of
sodium citrate after 24 h incubation.
Conclusion: These results are useful for food manufactures. Fur-
thermore, pathogen identiﬁcation can provide important epidemiologic
information that can aid in preventing further spread of the disease.
P1172 Monitoring the evolution of brucellosis by using four
common serological tests
C. Poulopoulou, A. Lazaridou, I. Sotiropoulou, E. Korou, K. Kopsari,
D. Gianneli °, K. Digalaki (Athens, GR)
Objectives: Brucellosis is an endemic disease in Greece. In chronic
courses and relapses of the disease the clinical manifestations pose
diagnostic difﬁculties. The aim of the study was the estimation of the
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serological ﬁndings of patients presented in hospital with complications
of the disease, in a three-year period.
Methods: The serological records of 17 patients hospitalised from 2005–
2007 with atypical symptoms of brucellosis, were reviewed. Blood
cultures failed to detect Brucella melitensis in 15 out of 17 patients.
The methods used were: Standard tube agglutination (STA) test, Rose
Bengal (RB) agglutination test, Elisa IgG, IgM test, Immunocapture-
agglutination test (Brucella capt).
Results: The serological titers of 3 patients were not correlated
with active disease (STA  80U, RB negative, Elisa IgM< 15U/ml,
IgG 20−50U/ml, Brucellacapt 160). In the remaining 14 patients the
serological titers of speciﬁc IgM antibodies (IgM Elisa) were negative
and the speciﬁc IgG antibodies(IgG Elisa) were positive (80–210U/ml).
These patients also had Brucellacapt test positive (ranged from 640 up
to10240 U), while in 7/14 and in 10/14 patients STA test and RB test
were respectively positive.
Conclusion: The diagnosis of chronic brucellosis is mainly based on
serological ﬁndings. However STA and RB screening agglutination tests
don’t reach the best detection performance. Brucellacapt and Elisa IgG
tests are reliable methods for the diagnosis of long evolution brucellosis.
The combination of more than two methods establishes more accurate
diagnosis.
P1173 Relationship between Guillain-Barre´ syndrome and Coxiella
burnettii infection
M.T. Fraile °, J.L. Ramos, M.D. Ocete, J. Parra, M.A. Cervello,
A. Medina, A. Ten, C. Gimeno (Valencia, ES)
Objectives: Several bacterial and viral agents have been implicated
in the pathogenesis of the Guillain-Barre´ syndrome, an acquired
inmunomediated disorder. In the Coxiella burnettii infection, focal
neurological symptoms are rarely observed. Neurological symptoms of
acute Q Fever consist of meningitis or meningo-encephalitis.
We review and evaluate two cases of Q Fever with neurological
symptoms, diagnosed in our centre.
Methods: One patient, a 31-year old man, developed progressive
mononeuritis multiplex involving the right arm and both legs. In the
ﬁrst stadium of the illness showed hyperreﬂexia.
The other patien was a 51 year old man that presented a ataxia
ophthalmoplexia, arreﬂexia in the legs and hyporreﬂexia in the arms.
In both cases we asked for electrocardiograph and electromyogram
thoracic radiological studies and serological determinations of virus and
bacterias.
Results: The ﬁrst patient was diagnosed of myelitis, and the second of
Miller-Fisher syndrome. In both of them, serological procedures showed
Coxiella burnettii phase II antibodies levels >1:2.048 for IgG and >1:32
for IgM. In one patient we underwent a lumbar puncture for cerebrospinal
ﬂuid analysis and we found a Coxiella burnettii IgG antibodies of 1:32
and high levels of proteins.
Fourteen days doxyciclin treatment (200mg. daily) induced a rapid
decreasing of antibodies levels, with a rapid recovery of the most of
neurological symptoms.
Conclusion: Coxiella burnettii should therefore be added to the list of
microorganisms capable of inducing the Guillaim-Barre´ syndrome.
Serological testing should be performed in cases of meningoencephalitis,
lynphocytic meningitis, and peripheral neuropathy including Guillain-
Barre´ syndrome and myelitis.
P1174 Clinical signiﬁcance of (1.3)-b-d-glucan detection in
Pneumocystis jirovecii pneumonia
V. Del Bono °, A. Mularoni, E. Furfaro, M.R. De Rito, E. Blasi,
E. Delﬁno, E. Nicco, C. Bernardini, F. Miletich, C. Viscoli (Genoa, IT)
Objectives: To evaluate the clinical usefulness of Fungitell test
(Associates of Cape Cod, Inc., Cape Cod, MA) − an immunological assay
detecting (1.3)-b-d-glucan (BG) − as a diagnostic aid in Pneumocystis
jirovecii pneumonia (PCP) diagnosis.
Methods: We studied prospectively the clinical application of Fungitell
in PCP presumptive diagnosis, in patients not able to undergoing invasive
diagnostic tests.
Patients were grouped as follows:
– presumptive PCP – as deﬁned in 1993 revised case deﬁnition of AIDS
– fulﬁlling the following clinical characteristics: a) recent history of
dyspnoea on exertion or non-productive cough; b) arterial PO2 <70;
c) chest X-ray ﬁnding of bilateral interstitial inﬁltrate; d) no evidence
of bacterial pneumonia. All the said clinical ﬁndings had to be in
association with at least one of the following risk factors: HIV disease
with <200 CD4 cells/mmc; full-dose corticosteroid treatment for
>8 weeks; haematologic malignancy treated with drugs affecting the
cellular immune response.
– non-PCP pneumonia
– healthy volunteers.
BG assay was performed according to manufacturer’s instructions. The
reportable range was 31–500 pg/ml. Cut-off value was 80 pg/ml.
Results: Thirty-ﬁve patients, 14 with presumptive PCP, 10 with non-PCP
pneumonia and 11 healthy volunteers, were included in the study. 7 out
of 14 PCP were HIV-positive, while 7 had other risk factors. All but two
(both HIV-positive) had a favourable clinical course with full response
to PCP therapy. 14/14 PCP patients were BG positive, 8/9 non-PCP
pneumonia were BG negative, all healthy volunteers were negative.
Based on these results, sensitivity and speciﬁcity were 100% and 95%,
respectively.
Conclusions: BG assay turned out to be very useful in strengthening
the clinical suspicion of PCP. We did not ﬁnd any false negative result,
making the BG negative predictive value equal to 100%. We had a false
positive only − not conﬁrmed in a second sample taken 48 hours apart −
in a patient with risk factors for PCP but diagnosed as having a non-
PCP pneumonia. Therefore, we think Fungitell may be a useful aid for
diagnosing PCP in patients not able to undergoing invasive diagnosis.
Blood cultures
P1175 S. aureus bloodstream infection and time-to-positivity
Y. Martin, J.A. Alava, M.J. Unzaga, C. Ezpeleta, C. Busto, R. Cisterna °
(Bilbao, ES)
Objective: The aim to this study is to asses if the time to positivity (TTP)
in blood culture of S. aureus bacteraemia correlates with the source of
infection and the outcome of the patient.
Methods: We performed a prospective, observational study involving
patients who had S. aureus bacteraemia between November 2003 and
July 2008. When multiple cultures were positive only the shortest TTP
was selected for the analysis.
Results: A total of 461 episodes of S. aureus bacteraemia were reported
from 347 patients with ages between 0−92 years (median age, 67 years).
329 were methicillin sensible S. aureus (MSSA) and 132 were methicillin
resistant S. aureus (MRSA). The mean age of this last group was higher
(P= 0.029). The source of infection was identiﬁed in 414 bacteraemias.
The most frequent source of bloodstream infection was catheter related
102 (24.6%), primary bacteraemias 77 (18.6%), skin and soft tissues
infection 63 (15.2%), respiratory 37 (8.9%), urinary tract 34 (8.2%),
surgical wound 16 (3.9%) and 8 (1.9%) gastrointestinal, other sources
of bacteraemias were 77 (18.6%). Catheter related bacteraemia was the
most common source of infection in both cases MRSA (21.9%) and
MSSA infection (25.7%).
The TTP was 13.18 h (range from 51 minutes to 30.58 hours). The
median time of MSSA (12.78 h) was shorter than MRSA (15.02 h)
although this difference was not signiﬁcant (P = 0.08). The TTP was
signiﬁcantly shorter from patients with endocarditis (6.62 h) compared
with the rest of sources (15.2 h) (P = 0.0001). However, in patients with
catheter related infection compared with the rest of sources the TTP
was shorter but not statistically signiﬁcant (P = 0.064). If the TTP is
divided into two groups, early TTP (<12 h), this group is associated with
endocarditis (median time 5.2 h), catheter related (8.94 h), respiratory
(8.11 h) and urinary (8 h). The overall mortality rate was 20.6%: MRSA
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19.3% and MSSA 21.1%. The sources with higher mortality were
gastrointestinal tract 50%, respiratory 48.6%, other bacteraemias named
group 26%, primary 20.8% and catheter related 12.7%.
Conclusions: Patients in the group of MRSA bacteraemia are older
than patients in MSSA group. Our data support the relationship of TTP
with endocarditis and catheter related infection. Growth of S. aureus
within 12 hours after the initiation of incubation may identify patients
with a high likelihood of endocarditis, catheter infection and possible
complications.
P1176 Evaluation of an agglutination method (Dryspot Pneumo®,
Oxoid) for the direct detection of S. pneumoniae in blood
cultures
S. Vazquez, S. Rey-Cao, C. Flecha, I. Wilhelmi-de Cal °
(Legane´s-Madrid, ES)
Objectives: Evaluate the agglutination method Dryspot Pneumo (DS)
(OXOID) in daily routine for the direct detection of Streptococcus
pneumoniae in blood cultures with the aim of reducing the time for
diagnosis by 24 hours.
Methods: Within the period of October 1st 2007 and the 15th of
December 2008, we studied 84 positive blood cultures for which was
observed microscopically Gram positive coccid in pairs or short chains.
From the positive blood culture, we extracted a volume of 2ml that
was subsequently centrifuged at 2200 rpm for 10 minutes. The test was
done using the supernatant, following the manufacturer’s instructions.
The results were considered positives when on the sample test site
we could observe agglutination whereas the site with non sensitised
reagent (control) remained with no agglutination. Indeterminate result
was deﬁned as when an agglutination could be observed in both sample
and control site. Culture on plated media was used as the reference
method. We determined the sensitivity, the speciﬁcity, the positive
predictive value (PPV) and the negative predictive value (NPV) based
on the standard statistical formulas.
Results: From the 34 conﬁrmed cultures positives for S. pneumoniae, the
DS test was found to be positive in 29 cases (85.3%). The DS test was
found to be negative in all of the 50 conﬁrmed cultures with an isolate
other than S. pneumoniae (15 Enterococcus sp, 3 S. pyogenes, 1 S. bovis,
1 S. agalactiae and 30 S. viridans). No indeterminate result was found.
The sensitivity, speciﬁcity, PPV and NPV were 85.3%, 100%, 100% and
90.9% respectively. The false negative strains of S. pneumoniae were
found to be of different serotypes.
Conclusions: In our study, the use of the Dryspot Pneumo directly from
positive blood cultures with a Gram stain showing pairs or short chains
Gram positive coccid reduced the TAT for a diagnosis by 24 hrs when
the result of the test was positive. We consider the Dryspot Pneumo to
be a valuable tool for the rapid detection of S. pneumoniae in blood
cultures.
P1177 Comparison of VersaTREK 528 and BACTEC 9240
continuous monitoring blood culturing systems for the
detection of clinical isolates in a seeded study
K. Doing °, M. Fogler (Bangor, US)
Objectives: Continuous monitoring blood culture systems are used in
many clinical laboratories. We evaluated the VersaTREK 528 (VT)
and BACTEC 9240 (BD) blood culture systems in a seeded study
comparing time to detection (TTD) and media type for the recovery
of Staphylococcus aureus (20 strains) Streptococcus pneumoniae (20
strains), beta streptococci (25 strains), Neisseria meningitidis (13
strains), and Haemophilus inﬂuenzae (20 strains). ATCC strains were
included as controls.
Methods: BACTEC Plus, Lytic, and PedsPlus media were compared to
VT standard aerobic and anaerobic media (80 and 40mL bottles). Bottles
were supplemented with 100 or 500 uL of human blood and inoculated
with either 1×101 or 1×104 cfu/mL of bacteria (21 bottles per isolate);
colony counts were performed from each dilution. Bottles were incubated
in appropriate instruments with the TTD and media type recorded for
each isolate. Subcultures were performed from positive bottles to ensure
purity and from negative bottles after 5 days of incubation.
Results: Both systems recovered all challenge isolates, with minor
differences between TTD and media noted. Isolates of H. inﬂuenzae and
N. meningitidis were recovered from all aerobic media, but most failed
to grow in anaerobic and all lytic media. Streptococci were detected
in both systems but had a shorter TTD using BD lytic media. No
differences were noted in the TTD of staphylococci. As expected, a
higher inoculum shortened the TTD in both systems; however, volume
of blood supplementation had no apparent impact.
Conclusions: We used a controlled inoculum to approximate the
microbial load in bacteraemic patients and compared the TTD using
VT standard media to BD high volume blood culture media. Optimal
performance of the BD system required use of three different media,
while the VT showed equivalent recovery using their standard two
bottle media formulations. Indeed, the VT system is uniquely approved
in the U.S. to culture low blood volumes facilitating routine use of
both aerobic and anaerobic media for adult and paediatric patients. In
addition, differences in instrument and media costs are signiﬁcant; BD
high volume resin and lytic media cost as much as 45% more than
standard VT media with comparable performance. The VT system has
also been cleared for body ﬂuid and platelet culturing, and the same
instrument can be used to culture mycobacteria, making this the most
cost effective and versatile of the two instruments.
P1178 Time to positivity in monomicrobial and polimicrobial
fungal blood cultures
L. Naumiuk °, B. Rybak, A. Samet (Gdansk, PL)
Objectives:The aim of the study was to assess time to positivity (TTP)
in positive fungal blood cultures who grew fungi alone or mixed with
bacteria.
Methods: We analysed retrospectively positive fungal blood culture
bottles (Bact/Alert, bioMerieux) and their TTP in tertiary care hospital
from the beginning of 2007 to the end of 2008. Positive blood
culture bottles were routinely subcultured on Columbia blood agar,
Columbia CNA, MacConkey and Sabouraud agar according to results of
microscopical examination. Microbial species were identiﬁed by classical
methods and Vitek2 cards (bioMerieux). For statistical analysis Statistica
software (Statsoft) was used.
Results: 139 positive culture bottles for fungi (18 from catheters)
were identiﬁed from 58 patients. All grew yeasts except 3 which grew
Aspergillus sp. Nearly 67% of the positive bottles belonged to FAN
aerobic type. 110 bottles (79%) were monomicrobial and 29 (21%)
were polymicrobial with different bacteria species recovered. Eight
positive polimicrobial bottles belonged to FAN anaerobic, 19 to FAN
aerobic and 2 to FAN paediatric types. The mean and median TTP for
mono and polymicrobial culture were 40.8 h, 31.1 h and 21.9 h, 16.9 h
respectively (Test U Mann-Whitney p< 0.005). In the polymicrobial
group the median TTP of cultures which grew fungi and Gram negative
and positive bacteria (n = 4) was 8.2 h and cultures with fungi and
Gram positive bacteria (n = 24) had the median TTP of 19.7 h. In
monomicrobial group TTP was the lowest for Candida parapsilosis
followed by C. krusei, C. albicans and C. glabrata taking into account
the most frequent species only.
Conclusion: In our study we identiﬁed 21% of positve blood cultures
bottles which grew fungi and bacteria. TTP was half as low in
the polymicrobial fungal cultures compared to monomicrobial fungal
cultures. It seems that bacterial overgrowth allowed faster identiﬁcation
of fungi in blood cultures and did not interfere with fungal growth. Our
ﬁndings also stress the need of positive blood culture bottles subculture
on media which can differentiate fungi in bacterial suspension.
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P1179 A comparison of the yield and speed of BACTEC Plus
Aerobic/F and Peds Plus/F blood culture bottles
H.L. Nielsen °, J. Prag (Aalborg, Viborg, DK)
Objectives: To examine the beneﬁt of adding BACTEC Peds Plus/F
bottle with 40ml ﬂuid to a standard blood culture set consisting of a Plus
Aerobic/F and a Plus Anaerobic/F blood culture bottle, both with 25ml
ﬂuid. The paediatric bottle is supplemented with animal tissue digest
(0.1% W/V) and has less sodium polyanethole-sulfonate (0.02% W/V
contra 0.05 in Plus Aerobic/F) and recent studies suggest that ordinary
blood cultures only occasionally detect fastidious microorganism like
Helicobacter spp. The aim of the study was to compare the yield and
speed of Plus Aerobic/F with the Peds Plus/F bottle.
Methods: During a one year period from June 2007 to July 2008 all
blood cultures drawn at Viborg Hospital, Denmark, were performed using
a BACTEC 9240 automated blood culture system. Blood from patients
with suspected septicaemia were drawn inoculated in the Plus Aerobic/F,
Plus Anaerobic/F and Peds Plus/F blood culture bottles and incubated
for 144 hours.
Results: The department received 7500 blood culture sets consisting of
all three bottles. Each bottle respectively contained a median volume of
blood of 8.5ml, 8.5ml and 3.5ml in the Aerobic, Anaerobic and Peds. A
total of 668 bacterial isolates were recovered per set, and of these were
491 (6.5%) of clinical importance. Of these were 279 (57%) isolates
found in both Aerobic and Peds, 74 (15%) from Aerobic only, and 29
(6%) from Plus only corresponding to 2.5 times more blood volume
drawn in the aerobic bottle. When bottles were positive the median time
to detection were 15.6 hours for the Aerobic and 14.6 for the Peds bottle
(P< 0.001).
Conclusion: Compared to the Plus Aerobic/F bottle, the Peds Plus/F
bottle was not superior in recovering ordinary or fastidious microorgan-
isms. However, it detected bacteria one hour before. Addition of a third
Aerobic bottle with 8−10ml blood to the standard Aerobic/Anaerobic
blood culture set would probably increase the detection rate of pathogenic
bacteria by 1% of the total number of blood culture sets taken. The cost
of a third vial will be around 400€ a year and then more expenses for
identiﬁcation etc.
Table 1. Comparative times to detection in Plus Aerobic/F and Peds Plus/F blood culture bottles when both bottles
were positive
Microorganism(s) No. of isolates Time to detection (h), median (range) P value
Plus Aerobic/F Peds Plus/F
Staphylococcus aureus 50 16.7 (8.9–119) 16.6 (7.9–114.3) NSa
Coagulase-negative staphylococcib 27 25.5 (9.4−54.6) 21 (12.3−58.3) 0.001
Enterococcus spp.c 26 15.6 (8.2−40.2) 14.7 (7.5–115) NS
Streptococcus spp.d 44 11.9 (3.2−61) 11.5 (4.7−45.6) NS
Gram-positive bacillie 2 28.7 (23.1−34.2) 37.3 (32.3−42.2) NS
Escherichia coli 71 14.1 (1.8−66.8) 12.6 (4.3–123.8) NS
Klebsiella spp.f 20 13.8 (4.9−50) 13.1 (3.7−66.5) NS
Other Enterobacteriaceaeg 17 15.6 (4−86) 13.7 (4.3–130) 0.006
Pseudomonas aeruginosa 4 16.2 (13.1−24) 15 (12.1−24) NS
Other Gram-negative bacteriah 7 19 (12.5−38.8) 19 (12.5−40.8) NS
Candida spp.i 11 49 (21.1−93.5) 67 (22.6–138.6) 0.002
Total 279 15.6 (1.8–119) 14.6 (3.7–138.6) <0.001
a NS, not signiﬁcant (P > 0.05).
b Includes 15 Staphylococcus epidermidis, 6 Staphylococcus hominis, 1 Staphylococcus capitis, 2 Staphylococcus
lugdunensis, 3 Staphylococcus warneri and 4 coagulase-negative staphylococci.
c Includes 18 Enterococcus faecalis, 6 Enterococcus faecium and 2 Enterococcus casseliﬂavus.
d Includes 2 Group-A beta-haemolytic Streptococcus (HS), 2 Group-C HS, 3 Group-G HS, 25 S. pneumoniae,
2 non-HS, 4 S. gordonii, 2 S. anginosus, 1 S. constellatus, 1 S. dys. equisimilis, 1 S. sanguinis and 1 S. gallolyticus.
e Includes 1 Corynebacterium spp. and 1 Corynebacterium group G.
f Includes 14 Klebsiella pneumoniae, 5 Klebsiella oxytoca and 1 Klebsiella ornithinolytica.
g Includes 4 Enterobacter cloacae, 1 Enterobacteriaceae, 4 Proteus mirabilis, 1 Salmonella enteritidis, 1 Salmonella
typhimurium, 1 Salmonella dublin, 1 Salmonella wirschow, 3 Serratia marcescens and 1 Citrobacter braakii.
h Includes 1 Capnocytophaga spp., 2 Neisseria meningitidis group B, 1 Haemophilus parainﬂuenzae, 1 caps.
H. inﬂuenzae, 1 Morganella morganii and 1 Pasteurella multocida.
i Includes 8 Candida albicans, 1 Candida lusitaniae and 1 Candida krusei.
P1180 The clinical impact of pre-incubation of blood cultures at
37ºC
L. van der Velden °, P. Sturm (Nijmegen, NL)
Objectives: Most laboratories do not provide a 24 hour service.
Therefore, blood cultures collected outside ofﬁce hours are often held
at room temperature until incubation at 37ºC in the laboratory. The
impact of pre-incubation of blood cultures at 37ºC (i.e. holding blood
cultures at 37ºC instead of room temperature prior to incubation in the
automated blood culture system in the laboratory) on turnaround time
and antimicrobial management was investigated.
Methods: The study was conducted in a 950-bed tertiary-care, university
teaching hospital in Nijmegen, the Netherlands. During a 6 month period,
blood cultures collected at the emergency department outside laboratory
ofﬁce hours were held in a 37ºC incubator until transportation to the
laboratory. On arrival at the laboratory, Gram stain and subcultures on
chocolate agar were made from the vials before they were entered into the
Bactec culture system. Times of collection, incubation in the laboratory,
and availability of positive Gram stain and culture results were recorded.
Gram stain and culture results were reported to the clinician as soon as
these were available and antimicrobial therapy was recorded. The results
of the study period were compared to the data of one year earlier when
all blood cultures collected at the emergency department were stored at
room temperature.
Results: During the study period 82 bacteraemias were detected in
79 patients, during the same period one year earlier 70 bacteraemias
were detected in 68 patients. With pre-incubation, blood cultures turned
positive on the day of collection, one day, two days, and more than two
days after collection in 12%, 70%, 11%, and 7%, respectively, compared
to 1%, 43%, 46% and 10%, respectively, without pre-incubation. The
mean turnaround time was signiﬁcantly shorter with preincubation at
37ºC in blood cultures that were more than 8 hours in transport (24 hours
versus 40 hours). In 31% of the patients with a bacteraemia the Gram
stain results from blood cultures resulted in changes in antimicrobial
management.
Conclusion: Pre-incubation of blood cultures at 37ºC resulted in a
signiﬁcant reduction of the turnaround time. Early positive blood culture
results contributed importantly to appropriate antimicrobial management.
March-Sept 2006
Pre-incubation 37ºC
March-Sept 2005
Room temperature
ED visits with BC obtained 969 885
BC bottles collected 3222 (3.33/visit) 3012 (3.40/visit)
BC bottles stored at 37ºC/room temp. 2060/1162 0/3012
Transport time per ED visit
Unknown (no collection time) 192 (20%) 286 (32%)
8 hours 211 (27%) 161 (27%)
9−16 hours 269 (35%) 189 (32%)
16−24 hours 264 (34%) 152 (25%)
>24 hours 33 (4%) 97 (16%)
ED visits with positive BC 103 (11%) 106 (12%)
Mean turnaround time (h) 24 36
Day of consultation
Unknown (no collection time) 21 (20%) 36 (34%)
D0 D1 D2 >D2 D0 D1 D2 >D2
8 hours 4 18 3 2 1 15 2 1
9−16 hours 6 21 3 2 11 13 4
16−24 hours 16 3 2 3 16 2
>24 hours 2 1 1
Total 12% 70% 11% 7% 1% 43% 46% 10%
Impact Gram stain BC on antimicrobial therapy
Initiation of appropriate therapy 21%
Streamlining of therapy 10%
ED = Emergency Department, BC = Blood Culture, Transport time = time between BC collection and incubation
in the laboratory. Turnaround time = the time between BC collection and Gram stain results of a positive BC. Day
of consultation = the day BC turns positive, D0 = the day BC was collected. D1 = 1 day after BC collection. D2 =
2 days after BC collection. >D2 = more than 2 days after BC collection.
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P1181 Evaluation of the new BACTEC FX instrument and a new
modiﬁed BACTEC Plus Aerobic medium
P. Beaty ° (Sparks, US)
Objective: Modiﬁcations to the BACTEC™ Blood culture system are
being implemented to improve the system interface (the new BACTEC
FX™ instrument) and consistent product performance (a modiﬁed
BACTEC Aerobic Plus™). The objective of this study is to critically
assess these changes to conﬁrm that the BACTEC system meets expected
product performance criteria.
Methods: A multivariate study including instruments (BACTEC 9000
and FX), media (all BACTEC Blood culture media), blood volumes,
microbial detection limits (inocula ranging from 1 to 100CFU) and
organisms diversity (a diverse set of >35 species of bacteria, yeast and
fungi) was performed. The experimental design was a paired study with
each variable tested in triplicate. Nonparametric statistical methods were
used to analyze recovery (McNemar Test) and median time to detection
(TTD) differences (Wilcoxon Test) between the test and control systems.
Results: A total of >1800 test sets are compared for recovery and TTD
in the BACTEC FX and BACTEC 9240 systems. A median time to
detection difference of 24 minutes was observed (the BACTEC 9240 was
earlier) with a 95% conﬁdence interval of 18 to 27 minutes. Differences
in median time to detection for any given organism varied from 50 to
90 minutes, however, the majority of pairs detected within 30 minutes of
the each other. There was no signiﬁcant difference in recovery between
the two instruments. A total of 473 compliant sets were used to compare
the modiﬁed Aerobic Plus to the traditional Aerobic Plus medium. The
median time to detection difference was 21 minutes earlier in the new
formulation with an interval range of 12 to 33 minutes. Yeasts (Candida
albicans, Candida glabrata and Cryptococcus neoformans) in particular
detected earlier in the modiﬁed formulation (a median TTD difference
of 3.5 hours (range of 2 to 11 hours). A signiﬁcant difference in recovery
(detection within 5 days) was observed in the new formulation with these
yeast (P = 0.0001).
Conclusion: The BACTEC is historically a high sensitivity blood
culture system with a demonstrated rapid time to detection. This study
demonstrates that the BACTEC FX is equivalent to the BACTEC 9240
for growth and detection of microorganisms and that the modiﬁed
Aerobic Plus is equivalent to the traditional formulation with the
exception of a signiﬁcant increase in recovery and a decrease in time to
detection of yeast.
P1182 Using digital tinctorial properties to rapidly distinguish
Pseudomonas aeruginosa from other Gram-negative
bacteria in bacteraemic patients
V. Nilaratanakul °, U. Rirerm, T. Chatsuwan, W. Kulwichit (Bangkok, TH)
Objectives: Proper and timely administration of antimicrobials in
bacteraemic patients is crucial. P. aeruginosa demands a distinct empiric
antimicrobial coverage. In this pilot study, we sought to determine
staining characteristics and a rapid method to aid clinicians in making an
initial antimicrobial choice upon positive signals from automated blood
culture bottles.
Methods: P. aeruginosa, Escherichia coli and Klebsiella pneumoniae
(ATCC strains 27853, 25922„ and 27736, respectively) were smeared
on surface of the slide that was divided into 4 quarters, each isolate
per quarter, as controls to be compared with a positive haemoculture
isolate that would be smeared on the remaining quarter. A standard
Gram’s staining was performed. 2 microscopic pictures of each quarter
were digitally taken. 5 bacilli were then randomly selected from each
picture for analysis. Maximal digital colour value of each bacterium was
recorded under Adobe Photoshop CS3.
Results: 30 consecutive haemocultures, 6 of P. aeruginosa, 7 of
E. coli, 5 of K. pneumoniae, 1 of mixed E. coli-K. pneumoniae, 5
of Acinetobacter baumannii and 6 of other Gram negative bacteria
(Burkholderia cepacia, Enterobacter cloacae, salmonella gr.B, Serratia
marcescens, Stenotrophomonas maltophilia and Moraxella sp.) were
subsequently identiﬁed. 1200 bacilli, 900 from 3 controlled isolates
and 300 from 30 patients’ positive haemocultures, were selected. The
mean value of bacterium colour for P. aeruginosa from clinical isolates
were signiﬁcantly different from E. coli, K. pneumoniae, E. cloacae,
Salmonella gr.B and S. marcescens (p< 0.001). 30 bacilli from 3
controlled isolates in each slide were selected for logistic regression
analysis to predict whether each bacillus from patient’s haemoculture in
the same slide was P. aeruginosa or not. Variables were width, length
and colour of each bacillus. The predicted result was shown in Table 1.
In P. aeruginosa group at least 3 of 10 bacilli in pictures from patient’s
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haemoculture were correctly identiﬁed. Incorrect predictions were seen
in pseudomonas-related species (B. cepacia, S. maltophilia), Moraxella
sp., E. coli and A. baumannii. Moraxella sp. and A. baumannii, however,
can be distinguished by their diplococcal morphology.
Conclusion: Our study demonstrates a potential utility of digital
tinctorial measurement as a diagnostic aid to guide appropriate empiric
antimicrobials. Further analysis on more bacterial genera and from more
specimens are needed.
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P1183 Approaching zero rates bloodstream infections in a tertiary
care neonatal intensive care unit: a multifaceted approach
H.H. Balkhy °, S. AlSaif, A. El-Saed, R. Dichinee, Z. Memish (Riyadh, SA)
Objective: To identify the trend of healthcare associated bloodstream
infection (BSIs) and central line-associated (CLA) BSIs among a cohort
of neonates admitted to the neonatal intensive care unit (NICU) and to
describe the intervention program aiming to reduce the rate of infections
in the NICU.
Methods: A Prospective cohort study was conducted between January
2006 and December 2007 in a level II/III NICU at King Fahad National
Guard Hospital (KFNGH). All neonates admitted to the NICU were
followed to identify BSIs and CLA-BSIs rates/1000 central line days,
central line utilisation ratios (UR) and risk factors for BSIs. Only
laboratory conﬁrmed CLA-BSIs were considered in the study and the
National Healthcare Safety Network (NHSN) deﬁnition was used for
that purpose. The Hand Hygiene (HH) awareness campaign and other
infection control measures were studied in relation to the trend of BSIs.
Results: A total of 102 neonates out of 838 followed (12.2%) had BSIs,
of those 40 (4.8%) fulﬁlled the criteria for CLA-BSI. There was a
decreasing trend of CLA-BSI rate with 3 consecutive months of zero
BSIs towards the end of the study. The initiation of the HH campaign
coincided with the downtrend of CLA-BSI rate. Out of the many risk
factors identiﬁed in univariate analysis including decreased gestational
age, decreased birth weight, using multiple CL and using umbilical
catheter, prolonged CL duration was the only CLA-BSI independent
risk factor.
Conclusions:We are reporting a successful case of reducing CLA-BSI in
a once risky NICU associated with better enforcement of HH guidelines
and other infection control measures.
P1184 Inter-unit comparisons of intensive care unit-acquired
catheter-associated bloodstream infection rates in Cyprus
and Greece
E. Kritsotakis, D. Bagatzouni, M. Alexandrou, V. Zinieri,
M. Roumbelaki, I. Dimitriadis, A. Gikas ° (Heraklion, GR; Nicosia,
Limassol, Pafos, Larnaca, CY)
Objective: Surveillance of intensive care unit (ICU) acquired infections
has become an integral part of infection control programmes in several
countries, and outcome and process indicators are increasingly used in
benchmarking the quality of medical care. The objective of this study
was to implement a standardised protocol for the surveillance of ICU-
acquired bloodstream infections and assess its usefulness in a network
of hospitals in Cyprus and Greece.
Methods: The study was conducted in the medical-surgical ICUs of 4
public hospitals in Cyprus and 5 public hospitals in the region of Crete
in Greece. All patients admitted to the ICUs during an 11-month period
were actively monitored for central line-associated bloodstream infection
(CL-BSI) until their discharge or death. The US National Nosocomial
Infections Surveillance system’s methods were applied. For inter-unit
comparisons, the central line (CL) use ratio [(number of CL days)/
(number of patient-days)] was utilised as a process indicator and the
CL-BSI rate [(number of primary CL-BSIs)/(number of CL-days)×1000]
was used as an outcome indicator.
Results: During the study period, a total of 3941 patients were admitted
to the study ICUs, for a mean length of stay of 5.8 days. A total of 233
primary BSIs were recorded, of which 91.8% were associated with the
use of CL. Overall CL-BSI rates were high in both regions: 14.6 and
18.6 cases per 1000 CL-days in Cretan and Cypriot ICUs, respectively.
CL-BSI rates varied widely among participating units, ranging from 3.7
to 22.9 cases per 1000 CL-days. CL use ratios also had signiﬁcant inter-
unit variation, ranging from 0.12 to 0.96. A simultaneous analysis of
the two indicators is shown in the Figure. Two units (CY-1 and CR-
1) were identiﬁed as having both measurements high (above the mean
values represented by the solid lines), suggesting that these units need
to review their practices for appropriate use of CL. One unit (CY-2) had
a high CL-BSI rate despite its low CL utilisation ratio, suggesting that
the unit needs to review CL insertion and maintenance practices.
Conclusion: ICU-acquired bloodstream infections constitute a major
problem in the two study regions. Simultaneous analysis of CL-BSI rates
and CL-use ratios was useful for identifying initial targets for corrective
interventions to improve CL management practices and reduce infection
rates in the ICUs studied.
P1185 Risk factors for catheter-related colonisation and catheter-
related bloodstream infection in chronic haemodialysis
patients with cuffed tunneled central venous catheters
A. Aguinaga °, J.L. del Pozo, N. Garcı´a-Ferna´ndez, A. Serrera,
M. Alonso, F. Guille´n-Grima, J. Leiva (Pamplona, ES)
Objectives: Catheter-related bacteraemia is a major cause of morbidity
and mortality among catheter dependent haemodialysis patients. The
aim of this study was to analyse risk factors for catheter colonisation
(CC) and catheter related bloodstream infection (CRBI) in chronic
haemodialysis patients with cuffed long term tunneled central venous
catheters.
Methods: From July 2003 to January 2006, we conducted a prospective
study to detect CC, and establish a pre-emptive therapy based in catheter
antibiotic lock in order to prevent development of CRBI in haemodialysis
patients. Risk factors for CC and CRBI in 35 patients with 45 catheters
were assessed. Patient demographic and clinical characteristics and
catheter characteristics were assessed for theirs relationship to CC and
CRBI in haemodialysis patients. These characteristics were analyzed by
Kaplan-Meier survival curves. Statistical differences between survival
curves were determinated by the log rank test. A multivariate Cox’s
proportional hazards model was applied testing in the model those
variables that obtained p values lower than 0.1 in the log rank test to
assess the independent risk factors for CC and CRBI.
Results: As risk factors for CC were identiﬁed: diabetes mellitus
(Hazard ratio (HR)=17.55, 95% CI, 2.91–105.99, p = 0.002), obesity
(HR=13.01, 95% CI, 1.99−85.22, p = 0.007), previous CRBI episodes
in the same catheter (HR=11.77, 95% CI, 1.27–108.62, p = 0.030) and
duration of catheter use (HR=4.46, 95% CI, 1.16−17.18, p = 0.030).
S. aureus nasal carriage (HR=9.23, 95% CI, 1.22−69.62, P = 0.031),
obesity (HR=4.27, 95% CI, 1.06−17.14, P = 0.040), early detection of CC
(HR=3.72, 95% CI, 0.99−13.87, P = 0.050) and duration of catheter use
(HR=3.57, 95% CI, 1.52−8.36, P = 0.003) were identiﬁed as risk factors
for CRBI. S. aureus nasal carriage was risk factor in CRBI episodes
caused by S. aureus (‘c2’ = 5.585, P = 0.018) and was not risk factor
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in CRBI episodes caused by other organisms different than S. aureus
(‘c2’ = 1.150, P = 0.284).
Conclusions: Diabetes mellitus was the most important risk factor for
CC. S. aureus nasal carriage was the most important risk factor to
S. aureus CRBI. Obesity and early diagnosis of CC were independent
factors associated with high risk of CRBI. Obesity and duration of
catheterisation were common factors that increased risk of CC and CRBI.
Possible preventive actions can be made according to these risk factors.
P1186 30-day mortality in methicillin-resistant Staphylococcus
aureus nd methicillin-sensitive Staphylococcus aureus blood-
stream infection in a Leicester cohort of patients; Panton-
Valentine leukocidin gene prevalence in the same cohort
S. Sharma °, D. Jenkins (Leicester, UK)
Objectives: To compare predictors for outcomes in patients with MRSA
and MSSA bacteraemia; determine the frequency of the Panton-Valentine
leukocidin (PVL) gene in Staph aureus bloodstream infections in
Leicester and ascertain any association with clinical disease.
Methods: Retrospective clinical data was collected from case records
and computerised laboratory records from August 2005 to January 2006.
All positive staphylococcal blood cultures were identiﬁed in this period
but any repeat staphylococcal positive cultures on the same patient were
rejected. Data were collected on: age, gender, speciality, date of positive
blood culture, MRSA colonisation, source, sepsis score, co-morbidities,
30 day mortality/survival, length of hospital stay, antibiotic treatment
and antibiotic susceptibility. PCR was used to detect the PVL gene in
the retrieved bacterial isolates.
Results: There were 120 cases Staph aureus bacteraemia, (58 (48%)
MRSA, 62 (52%) MSSA). 30 day mortality was 31/62 (50%) in the
MRSA group, 13/58 (22%) in the MSSA group: c2 = 9.82, p = 0.002.
Univariate analysis identiﬁed differences in mean age (t = 4.71, p = 0.000,
CI: 8.9−21.8), higher mean sepsis score (t = 5.68, p = 0.000, CI:
7.46−15.2), previous colonisation with MRSA (c2 = 9.73, p = 0.008),
quinolone resistance (c2 = 10.23, p = 0.05) and underlying co-morbidities
(t = 2.1, p = 0.035, CI: 0.03−0.8) as statistically signiﬁcantly associated
with 30 day mortality. The source of staphylococcal bloodstream
infection, gender, speciality and length of stay prior to positivity were
not identiﬁed as associations. The signiﬁcant associations were analysed
by backward step logistic regression: meticillin resistance, p = 0.042,
quinolone resistance, p = 0.014 and higher mean sepsis score, p = 0.000
were independent predictors of mortality. 107 of the samples were tested
by PCR for the PVL gene: 2 positive = 0.02%, 1 MSSA and 1 MRSA,
both associated with skin/soft tissue infection and both patients died.
Conclusions: Meticillin resistance, higher sepsis score and quinolone
resistance were independent predictors of mortality in staphylococcal
bloodstream infections. The PVL gene was present in only 0.02% of the
population but the sample size was too small to attach any statistical
signiﬁcance.
P1187 Risk factors for methicillin resistance and factors associated
with in-hospital mortality during Staphylococcus aureus
blood stream infection: an observational study
M. Revest, P. Tattevin °, P.Y. Donnio, F. Fily, A. Cady, C. Arvieux,
Y. Le Tulzo, C. Michelet (Rennes, FR)
Objective: Staphylococcus aureus is one of the most common aetiologies
of bloodstream infection (BSI) and has emerged as the leading cause
of infective endocarditis. Previous studies provided conﬂicting data
regarding risk factors for methicillin-resistance and its impact on
prognosis during S. aureus BSI.
Methods: The study took place in a 1950-bed tertiary referral medical
centre in Rennes, Western France. All adult patients with S. aureus
BSI diagnosed from 1/1/2006 to 12/31/2006 were included. Standardised
instrument was used for clinical data extraction from medical records.
The study was approved by Pontchaillou institutional review board.
Statistical analysis was performed using SPSS 15.0 software.
Results: The incidence of S. aureus BSI was 1.5/1000 admissions, which
represented 15% of all BSI. Of 122 patients diagnosed with S. aureus BSI
over the study period, data were available for 106 (87%). Male/female
ratio was 70/36, mean age was 65 years. Seventy-one patients (67%)
had been admitted during the previous year, and 24 (23%) had received
systemic antibiotics over the last 3 months. Eleven patients (10%) had
deﬁnite infective endocarditis according to Duke criteria. BSI source was
assumed to be an intravenous catheter for 27 patients (25%), skin or soft
tissue infection for 19 patients (18%), and was unknown for 23 patients
(22%). BSI was classiﬁed as nosocomial for 73 patients (69%). Criteria
for septic shock and severe sepsis were present for, respectively, 27 (25%)
and 25 (24%) patients. On admission, the only signiﬁcant difference
between methicillin-resistant (n = 18) and methicillin-susceptible (n = 88)
S. aureus BSI was the presence of foreign device (P< 0.001). In-hospital
mortality was 22% for methicillin-susceptible and 33% for methicillin-
resistant S. aureus BSI (P=NS). On univariate analysis, Charlson index
3 (odds ratio 3.24 [1.85−5.66]), septic shock (OR 2.38 [1.26−4.46]),
and serum creatinin >120micromol/L (OR 1.74 [1.12−2.71]) were
associated with mortality (P< 0.05). Only Charlson index  3 remained
predictive of mortality on multivariate analysis (OR 2.07 [1.80−2.85];
P = 0.001).
Conclusion: Co-morbidities, as reﬂected by Charlson index, and
infection severity, as reﬂected by sepsis stage, are the most potent
prognosis factors during S. aureus BSI.
P1188 Risk factors and outcome of carbapenem resistant
Gram-negative bacteraemia in critically ill patients
M. Pratikaki, E. Platsouka °, C. Routsi, C. Sotiropoulou, C. Roussos,
O. Paniara (Athens, GR)
Objective: To analyze the risk factors involved in the development of
carbapenem resistant Gram-negative bacteraemia (GNB) and to evaluate
the outcome of infected critically ill patients.
Methods: All patients admitted to the 25-bed multidisciplinary ICU
of Evangelismos Hospital in Athens, during a 18-month period, who
developed a nosocomial GNB were studied prospectively.
Results: Of 855 consecutively admitted ICU patients, with >48 h
ICU stay, 84 who developed carbapenem susceptible GNB were
compared to 85 patients with carbapenem resistant GNB. The lungs
were the main source of infection in both groups. The main resistant
pathogens were Acinetobacter baumannii 32(37.6%) and Pseudomonas
aeruginosa 31(36.5%). Patients infected with carbapenem resistant
isolates developed ventilator-associated pneumonia more often than
those with susceptible 60% vs. 34.5%, respectively, p< 0.001. Also they
had a longer ICU stay (30 vs. 22.5 days, median value, p = 0.035), a
longer ICU stay prior to bacteraemia onset (14 vs. 11 days, median
value, p = 0.026), prolonged previous use of carbapenems (10 vs. 3 days,
median value, p< 0.001) and of colistin (1 vs. 0 days, median value),
p< 0.001). Mortality, although higher in patients with carbapenem
resistant GNB, compared to those with carbapenem-susceptible (48.2%
vs. 45.2%) was not statistically signiﬁcant. By multivariate analysis,
SOFA score on GNB onset (OR, 1.44; 95% CI 1.26−1.66, p< 0.001) and
the total number of intravascular devices (OR, 2.45; 95% CI 1.16−5.15,
p = 0.019) independently affected the outcome. Among the 84 patients
with carbapenem susceptible pathogens, SOFA score on bacteraemia
day (OR, 1.39; 95% CI 1.16−1.69, p 0.001) and serum albumin
level on bacteraemia day (OR, 0.31; 95% CI 0.11−0.88, p = 0.029)
were independent factors for mortality. Among the 85 patients with
carbapenem resistant GNB, SOFA score on bacteraemia day (OR, 1.46;
95% CI 1.17−1.83, p= 0.001), total number of intravascular devices (OR,
4.59; 95% CI 1.38−15.27, p = 0.013) and the presence of candidaemia
(OR, 7.32; 95% CI 1.12−47.99, p = 0.038) were independently associated
with mortality.
Conclusions: In critically ill patients, long ICU stay and prolonged
previous use of carbapenems and colistin predispose to carbapenem-
resistant GNB. Mortality rate was higher among patients with car-
bapenem resistant GNB, compared to those with carbapenem susceptible,
but not statistically signiﬁcant.
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P1189 Nosocomial bacteraemia due to Gram-negative bacilli: risk
factors for mortality
M.G. Go¨zel, A. Erbay °, H. Bodur, S.S. Eren, N. Balaban (Ankara, TR)
Objectives: To evaluate the clinical outcomes of the patients with Gram-
negative bacteraemia and to identify the risk factors for mortality.
Methods: A prospective observational study was performed in the 1196-
bed Ankara Numune Education and Research Hospital. The patients with
nosocomial Gram-negative bacteraemia were included in the study from
July 2006 to June 2008. Bacteraemia was considered to be nosocomial
when it was diagnosed at least 48 h after hospital admission. Gram-
negative bacteraemia was deﬁned as the presence of Gram-negative
bacteria in the blood, documented by at least 1 positive hemoculture.
Antibiotic therapy was considered to be appropriate if the drugs used
had in vitro activity against the isolated strain.
Results: Among the 253 cases (mean age, 54.5±20 years old; M:F,
159:94) of Gram-negative bacteraemia included in the study, the
most frequently detected microorganisms were Escherichia coli (n = 96,
37.9%), Acinetobacter spp. (n = 54, 21.33%), Pseudomonas aeruginosa
(n = 41, 16.2%), Klebsiella spp. (n = 39, 15.4%), Enterobacter spp.
(n = 9, 3.5%) and S. maltophilia (n = 6, 2.3%). The mean duration of
hospital stay until Gram-negative bacteraemia was 19±17 (range 3−82)
days. Mortality rates at 14 days and at 30 days after the bacteraemia
were, respectively, 28.5% and 38.4%. Univariate analysis revealed that
the risk factors for mortality at day 14 included: higher age, higher
APACHE II scores, intensive care unit stay, mechanical ventilation
support, existence of arterial line and central venous catheter, receiving
TPN, hypotension, hypothermia, coma, elevated levels of urea, and
in vitro resistance to amikacin and carbapenems. Antibiotic treatment
was inappropriate in 33 (13%) patients. Mortality rate was 72.7%
in patients receiving inappropriate antibiotic treatment and 32.3% in
patients receiving appropriate antibiotic treatment (p< 0.001) at day 14.
Independent risk factors for mortality were having an APACHE II score
over 20 (OR: 3.18, CI: 1.9−5.2, p = 0.001), receiving ICU care (OR:
5.43, CI: 1.7−17.4, p = 0.004), inappropriate antibiotic treatment (OR:
2.38, CI: 1.2−4.7, p = 0.013), receiving TPN (OR: 3.96, CI: 1.8−8.9,
p = 0.001), coma (OR: 3.7, CI: 1.4−9.6, p = 0.007) at day 14 in logistic
regression model.
Conclusion: Awareness of mortality risk factors is important for the
prognosis. Appropriate antibiotic treatment could be decrease deaths
associated with Gram-negative bacteraemia.
P1190 Nosocomial versus community-acquired bloodstream
infections in hospitalised patients
M. Kati, M. Kompoti °, S. Drimis, O. Zarkotou, C. Kopsari,
K. Digalaki, D. Voutsinas (Athens, GR)
Objective: The aim of our study was to compare characteristics and
outcome in medical patients with nosocomial and community-acquired
bloodstream infections (BSI).
Patients-methods: A retrospective cohort study of patients with BSI
who were admitted in a medical department of a tertiary hospital. All
patients with at least one positive blood culture during hospitalisation
were included in the study. Patient records were reviewed and data
were extracted, including: age, gender, comorbidities, hospital day
of positive blood cultures, isolated pathogens, C-reactive protein,
erythrocyte sedimentation rate, white blood cell count and maximum
body temperature on days of positive blood culture, length of stay (LOS)
and hospital outcome. Data were analyzed with Student’s t-test and
logistic regression setting statistical signiﬁcance at p< 0.05.
Results: One hundred twenty-ﬁve patients (72 males and 53 females)
with BSI were included in our study. According to standard criteria, 96
patients had community-acquired and 29 nosocomial BSI. Patients with
nosocomial BSI were signiﬁcantly older than patients with community
acquired BSI (mean age±SD 79.2±7.0 vs. 72.1±15.8, respectively,
p = 0.001). Patients with community acquired BSI had a marginally
higher erythrocyte sedimentation rate (ESR) and a marginally higher
white blood cell count (WBC) compared with patients with nosocomial
BSI (ESR: 86.1±31.0 vs. 72.8±33.4, respectively, p = 0.049; WBC:
16.1±8.3 vs. 13.0±5.3×103 cells/mm3, respectively, p = 0.059). Gram-
positive microorganisms predominated in nosocomial BSIs (72.4%) and
Gram-negative in community-acquired BSIs (54.2%), p = 0.024. LOS
differed signiﬁcantly in the two groups (17.0±11.2 in the nosocomial
BSI group vs. 10.6±10.2 days in the community-acquired BSI group,
p = 0.009). Mortality adjusted for age, sex and comorbidities did not
differ signiﬁcantly in the two groups of patients.
Conclusions: In our patient sample, nosocomial BSIs were associated
with older age, a more prolonged hospital stay and a higher rate
of Gram-positive microorganisms, compared with community-acquired
BSIs. However, mortality did not differ signiﬁcantly in the two groups.
P1191 Incidence, clinical, microbiological features and outcome of
bloodstream infections in patients undergoing haemodialysis
D. Kofteridis, M. Fysaraki, A. Valachis, M. Christofaki °, I. Aristeidou,
C. Mattheou, E. Daphnis, G. Samonis (Heraklion Crete, GR)
Objectives: To determine the incidence, risk factors, clinical features and
outcome of bloodstream infections in patients undergoing haemodialysis.
Materials and Methods: The records of all patients who had undergone
haemodialysis at the University Hospital of Heraklion, from 1999 to 2005
were retrospectively reviewed. Multivariate analysis was used to identify
risk factors among patients developing dialysis-associated bacteraemia.
Results: One hundred forty eight bacteraemic episodes, occurring in 102
patients, were identiﬁed. Their median age was 70 years (range 20−90).
There were 53 (52%) women. The bloodstream infection rate was 0.52
per 1000 patient-days. Of the 148 episodes, 34 occurred in patients with
permanent ﬁstulae (0.18/1000 patient-days); 19 in patients with grafts
(0.39/1000 patient-days); 28 in patients with permanent tunnelled central
catheters (1.03/1000 patient-days); and 67 in those with temporary-
catheter (3.18/1000 patient-days). The relative risk for bloodstream
infection of patients having artero-venous graft access was 1.84 (p=.029),
for those with permanent central venous catheter 4.85 (p< 0.001), and
for those with temporary catheter 14.88 (p< 0.001). Forty one episodes
(28%) were catheter related. Gram positive bacteria were responsible
for 96 episodes (65%), with S. aureus (53 out of 96; 55%) being the
most frequent, followed by S. epidermidis (25 out of 96; 26%). Gram-
negative organisms were responsible for 36 episodes (23%), with E. coli
(14 out of 36; 39%) being the most frequent. In 14 episodes (9.5%) the
infection was polymicrobial. Diabetes (p = 0.005), low serum albumin
(p = 0.040) and low haemoglobin (p = 0.005) were signiﬁcant risk factors
for bacteraemia. Eighteen patients (18%) died during hospitalisation.
Multivariate logistic regression analysis has shown that septic shock
(p< 0.001) and polymicrobial infection (p=.041) were associated with
in-hospital mortality. Mortality was not associated with the type of
microorganisms involved.
Conclusion: The risk of bloodstream infection in patients undergoing
haemodialysis is related to the type of catheter and vascular access.
Presence of septic shock and polymicrobial infections predispose to
unfavourable outcome.
P1192 Nosocomial bloodstream infections in neurosurgical
patients. A 5-year study
P. Tsitsopoulos, E. Iosiﬁdis °, C. Antachopoulos, I. Anagnostopoulos,
M. Tsivitanidou, E. Roilides, P. Tsitsopoulos (Thessaloniki, GR)
Objectives: Nosocomial infections are a common, serious problem in
neurosurgical patients. Nosocomial blood stream infections (NBSI) are
associated with increased morbidity and mortality. We analyzed NBSI
in neurosurgical patients in a single centre over a ﬁve-year period.
Methods: A retrospective study was conducted in a 24-bed neurosurgical
department between 2002–2006. Medical records and postoperative
courses of 3318 patients involved in 1772 neurosurgical procedures were
reviewed to determine the prevalence and characteristics of NBSI, the
identity of isolated organisms, and the antimicrobial drug resistance of
selected pathogens. Chi-square test was used for statistical analysis.
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Results: Overall NBSI frequency was 3% (102/3318 patients) [24/1546
(1.5%) in non-operated patients and 78/1772 (4.4%) in operated patients
(p< 0.0001)]. The median age of patients was 52.4 years (range 17−85)
and the median length of stay was 39.4 days (range 5–195). The primary
diagnosis was head trauma in 39% of cases followed by intracerebral
haemorrhage (22%) and brain tumour (17%). Neurosurgical procedures
were elective in 1144 and emergency in 628 patients. Central venous
catheter was present in 63 of 102 patients with NBSI (61.7%). The
most frequently isolated organism was Klebsiella pneumoniae (KP,
32 isolates; 22.2%) followed by Pseudomonas aeruginosa (PA, 24
isolates; 16.9%), Acinetobacter baumannii (AB, 15 isolates; 10.5%),
Enterococcus faecium (EF, 15 isolates; 10.5%) and Staphylococcus
aureus (SA, 14 isolates; 9.8%). Resistance rates of KP and PA were
94 and 67% to ceftazidime, 56 and 71% to piperacillin/tazobactam,
17 and 63% to imipenem, 84 and 92% to gentamicin, 50 and 83% to
ciproﬂoxacin, respectively. All AB isolates were resistant to ceftazidime
and ciproﬂoxacin, whereas 66.6% were resistant to imipenem and 53%
to gentamicin. There was no vancomycin-resistant EF, but 64.2% of SA
were methicillin-resistant. In patients with NBSI mortality rate was 49%
(50/102), in contrast to 5.4% (175/3216) found in those without NBSI
(p< 0.0001).
Conclusion: NBSI constitute a serious problem in neurosurgical patients,
especially postoperatively, with high frequency and mortality. The
predominant organisms in our institution are multidrug-resistant Gram-
negative bacteria. Understanding the patterns of neurosurgical NBSI may
help to optimise infection control interventions as well as antimicrobial
use.
P1193 Enterococcal bacteraemia in a Swiss tertiary-care hospital:
epidemiologic risk factors and outcome
U. von Both °, R. Walti, C. Ruef (Zurich, CH)
Objectives: A retrospective study of enterococcal bacteraemia (EB)
cases was conducted to analyze potential epidemiologic risk factors and
clinical outcome with special focus on immunocompromised hosts.
Methods: Retrospective epidemiologic data for patients developing EB
during 2006 and 2007 was collected in a 950-bed university hospital.
Electronic clinical records of 104 patients (mean age 55.2 years, 67
males) were reviewed. Demographic, clinical, microbiological data as
well as data regarding antibiotic treatment and subsequent outcome were
determined.
Results: Mean length of stay (LOS) was 54 days with mean LOS of
22.6 days prior to development of EB. 64 cases of polymicrobial and 40
cases of monomicrobial culture results were detected showing E. faecalis
in 49, E. faecium in 43 and non-speciﬁed enterococcal species in 12
patients. Univariate analysis showed signiﬁcant association of isolation
of E. faecium with prior antibiotic treatment (p = 0.001), organ transplant
(p = 0.002) and ICU stay (p = 0.044). Multivariate analysis identiﬁed prior
ﬂuoroquinolone treatment and organ transplantation as independent risk
factors for development of E. faecium bacteraemia, while ICU stay and
underlying haematologic malignancies were strongly associated (table).
Patients with E. faecium bacteraemia showed signiﬁcant association with
higher mortality (p = 0.026; OR 4.73, CI95 1.2−18.6) and complication
rates (p = 0.004; OR 3.86, CI95 1.5−9.8). Primary bacteraemia was
observed in >60% of cases while in the subgroup of transplant recipients
(n = 18) surgical site infections (22.2% versus 5.8%, p = 0.024, OR
4.63, CI95 1.1−19.4) and intraabdominal infections (22.2% versus
5.8%, p = 0.024, OR 4.63, CI951.1−19.4) were signiﬁcantly more
often identiﬁed as origin of EB than in non-transplant patients.
Transplant patients showed E. faecium in 68% (vs 28% in non-transplant
patients), longer hospitalisation periods and favourable outcome despite
immunesuppression (cure rate 94.4% versus 76.7% in non-transplant
patients, p = 0.093).
Conclusions: Prior antibiotic treatment in general and exposure to
ﬂuoroquinolones in particular as well as ICU stay are signiﬁcant risk
factors for development of E. faecium bacteraemia. Organ transplant
recipients are more likely to develop EB due to surgical site or
intraabdominal infections. Patients with E. faecium bacteraemia show
higher mortality and complication rates compared to E. faecalis
infections.
Table. Multivariate analysis of potential risk factors for development of E. faecium bacteraemia
Risk factor Odds ratio p-value 95% conﬁdence interval
ICU stay 2.66 0.097 0.84–8.46
Haematologic malignancy 4.50 0.062 0.93−21.81
Organ transplant 6.06 0.016 1.39–26.39
Dialysis 2.08 0.276 0.56–7.75
Prior ﬂuoroquinolone treatment 8.13 0.008 1.75−37.77
Prior piperacillin-tazobactam treatment 1.30 0.702 0.35–4.78
Prior glycopeptide treatment 1.82 0.424 0.42–7.89
P1194 Growth inhibition of micro-organisms involved in
catheter-related infections by an antimicrobial transparent
IV dressing containing chlorhexidine gluconate
D.L. Schwab, L.K. Olson, M.E. Palka-Santini ° (St. Paul, US; Neuss, DE)
Introduction: Infections associated with intravascular devices represent
10 to 20% of all nosocomial infections and are mostly caused by
microorganisms belonging to the skin ﬂora. Antiseptic agents are used
to disinfect the skin prior to catheter insertion, to reduce the risk of
device colonisation by the skin microorganisms. Nevertheless, the skin
ﬂora will rebound over time and will be able to colonise on average
13% of the inserted vascular devices. Transparent IV dressings allowing
continuous observation of the insertion sites and early recognition of
signs of infections, and antimicrobial dressings, suppressing skin ﬂora
re-growth, are valuable elements for best practices in IV management.
This study is part of the efﬁcacy evaluation performed with a novel
dressing, the 3M™ Tegaderm™ CHG (Chlorhexidine Gluconate) IV
Dressing, which combines both transparency and antimicrobial activity.
Objective: Demonstrate antimicrobial activity of Tegaderm™ CHG gel
pad against bacteria commonly associated with CA-infections by an in
vitro assessment of growth inhibition.
Methods: Cell suspensions (approximately 108 cfu/mL) were prepared
from overnight growth plates of 12 bacterial strains and two yeasts
(Table 1). The suspensions were streaked in three directions over the
surface of a Mueller-Hinton (MH) agar plate with a sterile swab to obtain
uniform growth. Pre-cut 24mm disks from Tegaderm™ CHG dressings
were placed gel side down onto the agar surfaces. Duplicate samples
were prepared for each microorganism. After overnight incubation at
35ºC, the diameter of the zone of inhibition was measured.
Table 1. Strains of tested microorganisms and zones of growth inhibition
Organisms Millimetres
(mm)
of zone
beyond
dressing
Staphylococcus epidermidis MRSE ATCC 51625 8.7
MRSE nasal isolate #492 8.6
Staphylococcus aureus MRSA/GRSA ATCC 33592 7.3
MRSA nasal isolate #849 5.7
Pseudomonas aeruginosa ATCC 27853 4.5
Enterococcus faecium VRE ATCC 700221 7.1
MDR ATCC 51559 7.9
Enterococcus faecalis VRE wound isolate #23 4.3
Klebsiella pneumoniae ATCC 13883 4.4
ATCC 23357 3.6
Acinetobacter baumannii wound isolate #12-4 4.6
Enterobacter cloacae ATCC 35549 4.3
Candida albicans ATCC 10231 7.3
ATCC 58716 4.9
Results: Growth inhibition around the Tegaderm™ CHG gel pad
samples was observed in all MH-agar plates, varying from a minimum
to 3.6 and 4.4mm for 2 strains of Klebsiella pneumoniae to a maximum
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of 8.6 and 8.7mm for 2 strains of Staphylococcus epidermidis (Table 1).
Antimicrobial activity was observed also against methicillin resistant
staphylococci and vancomycin resistant enterococci and Staphylococcus
aureus.
Conclusion: The Tegaderm CHG gel pad showed activity against all 14
tested strains of microorganisms.
ESBLs, AmpCs & others in
Enterobacteriaceae: genes, plasmids &
clones – part 2
P1195 Heterogeneous population structure by MLST of extended
spectrum b-lactamase producing Klebsiella pneumoniae
isolates
A. Valverde °, T.M. Coque, L. Martinez-Martinez, F. Baquero, R. Canton
(Madrid, Santander, ES)
Objective: Klebsiella pneumoniae isolates represent an important
reservoir of extended spectrum b-lactamases (ESBLs) both in the
hospital and in the community settings. Population structure studies in
this species using an MLST typing scheme remain scarce, including
the relationship with the production of ESBLs. This was analyzed in a
collection of ESBL-K. pneumoniae recovered in our institution (1989–
2005).
Methods: 19 K. pneumoniae previously characterised (PCR, sequencing,
PFGE and phylogroups) non-related isolates, expressing the most
representative ESBLs (SHV-12, TEM-4, CTX-M-10 and CTX-M-15)
and were selected to perform MLST analysis (Diancourt et al. JCM
2005;43:4178−82). Allele sequences and sequence types (STs) were
assigned at www.pasteur.fr/recherche/genopole/PF8/mlst/.
Results: Characteristics of ESBL producing K. pneumoniae isolates and
MLST typing results are shown in Table 1. All isolates have different
PFGE pulsotypes and belonged to the phylogroup KpI. MLST showed
a high diversity, with no clear association of speciﬁc sequence types
(STs) and ESBLs. This was only observed in the case of TEM-4
producing isolates, most of them belonging to ST14, previously found in
K. pneumoniae isolates causing mastitis in dairy cows (Paulin-Courlin et
al, J. Dairy Sci 2007; 90:3681−9). It is noteworthy the presence of ST15
in an isolate harbouring CTX-M-15, recently described as an epidemic
clone in Hungary (Damjanova et al, JAC 2008;62:978−85).
Conclusions: ESBL producing K. pneumoniae isolates showed a
heterogeneous population structure without a clear relationship among
STs and ESBL-types. Identiﬁed STs in our collection were previously
described in animals or associated with clinical epidemic clones.
ST ESBL (no. isolates) Year Sample
ST13 CTX-M-15 2005 Urine
ST14 CTX-M-10 1990 BAS
TEM-4 1997 Blood
SHV-12 2004 Urine
TEM-4 (3) 1995–1999 Sputum, BAS (2)
ST15 CTX-M-15 2002 Urine
ST16 CTX-M-15 (2) 2004 Urine
ST20 CTX-M-10 (2) 2000–2001 Sputum, Urine
ST23 CTX-M-10 2000 Urine
ST34 CTX-M-10 2003 Respiratory
ST37 SHV-12 2003 Catheter
ST39 TEM-4 2001 BAS
SHV-12 2003 Urine
ST101 SHV-12 2005 Blood
ST111 CTX-M-10 1993 Blood
P1196 Ciproﬂoxacin-resistant and CTX-M-15-producing
Escherichia coli from extra-intestinal infections in Italy
M. Cerquetti °, M. Giufre`, A. Garcı`a-Ferna´ndez, M. Accogli, D. Fortini,
I. Luzzi, A. Carattoli (Rome, IT)
Objectives: The increasing resistance to ﬂuoroquinolone in Escherichia
coli is a major problem worldwide and the association with extended
spectrum b-lactamase (ESBL) is of particular concern. This study
investigated the molecular basis of resistance and phylogenetic
relationship among ciproﬂoxacin-resistant E. coli strains isolated from
human extra-intestinal infections occurring in hospital and community
in Rome, Italy.
Methods: 64 ciproﬂoxacin-resistant strains isolated from urinary
or bloodstream infections were examined for several gene markers
including plasmid-mediated quinolone resistance genes (qnrA, qnrB,
qnrS, and aac(6′)-Ib) and b-lactamase-encoding genes (blaCTX-M,
blaSHV, blaTEM and blaOXA) by PCR and sequencing. Eighteen strains
were positive for at least one of these markers and they were further
investigated by analysis of the mutations in the quinolone resistance-
determining region (QRDR) of gyrA, gyrB and parC genes, plasmid
transferability, PCR-based replicon typing, Southern blot analysis,
phylogenetic grouping, PFGE and MLST.
Results: 15/64 ciproﬂoxacin-resistant strains (23%) were found to be
ESBL producers, and all except one were positive to the blaCTX-M15
gene, the remaining isolate harboured blaSHV-12. Most of the CTX-
M15-producers also carried the blaOXA (85%), the aac(6′)-Ib-cr (78.6%)
and belong to the ST131 type (71%). The blaCTX-M15 gene was
located on plasmids of the IncF group, but notably, in one isolate it was
integrated within the chromosome. ST131 appeared strictly associated
with the following amino acid substitutions in the topoisomerase genes:
Ser83Leu and Asp87Asn in gyrA; Ser80Ile and Glu84Val in parC. The
remaining blaCTX-M15-positive strains all carried IncF plasmids but
they belonged to the ST12, ST167, ST410 and ST405, demonstrating
later transfer of this gene among different E. coli types. One ST131
isolate was positive for the blaSHV-12 gene. Two of 64 strains (3.1%),
ESBL-negative, possessed both qnrB1 and aac(6′)-Ib-cr genes located
on an IncHI2 plasmid and belonged to ST648.
Conclusion: The epidemic E. coli clone ST131 carrying the IncF-
plasmid mediated blaCTX-M15 gene is prevalent among our isolates
collected from urinary and bloodstream infections occurring in both
hospitals and community. This clone combines high ciproﬂoxacin-
resistance (MIC32mcg/ml) and ESBL production and is of particular
concern for the treatment of human extra-intestinal infections.
P1197 Replicon typing of plasmids from Klebsiella pneumoniae
and Escherichia coli clinical isolates producing CTX-M-15
extended-spectrum B-lactamase
C. Caneiras, F. Nunes, L. Lito, J. Melo Cristino, M. Salgado,
A. Duarte ° (Lisbon, PT)
Objectives: The aim of this study was to investigate the relatedness of
replicons involved in the emergence and spread of Klebsiella pneumoniae
and Escherichia coli carrying the blaCTX-M-15 gene.
Methods: E. coli (n = 30) and K. pneumoniae (n = 16) representative
clinical isolates producing CTX-M-15 extended-spectrum b-lactamases
(ESBLs) were collected between 2001 and 2007 in a Hospital Santa
Maria, in Lisboa. Plasmid replicons were determined using the PCR-
based replicon typing scheme described by Carattoli et al (2005) with
speciﬁc primers for 18 plasmid replicons.
Results: Among the E. coli isolates the most frequent plasmid
incompatibility group was Inc F 73.3% (22/30) with FI A and FI B
replicons found on two and four isolates, respectively. Several other
combinations involving F replicon were found, namely A/C, I1, N and
Y plasmid replicons. In K. pneumoniae clinical isolates were found only
the IncHI1 plasmid incompatibility group (10/16, 62.5%). The remaining
6 isolates were negative for all the replicons tested.
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Conclusions: In E. coli isolates the bla CTX-M-15 genes are carried by
plasmid incompatibility group Inc F. Overall, it is important to note a
high degree of variability in plasmid proﬁles observed among 30 E. coli
isolates, with 13 different combinations. In 16 K. pneumoniae CTX-M-
15 ESBL carried the IncHI1 replicons and none belonged to the IncF
group. Despite the critical role of plasmids in horizontal gene transfer,
this study has suggested that the bla CTX-M-15 genes cannot be readily
transmitted from E. coli to K. pneumoniae.
P1198 CTX-M-15 ﬂanked by ISEcp1 and orf477 is the most
frequent ESBL type in E. coli and K. pneumoniae from
Bochum, Germany
M. Kaase °, Y. Peters, F. Szabados, A. Anders, T. Sakinc, S. Gatermann
(Bochum, DE)
Objectives: Therapeutic options in enterobacteriaceae are limited due
to an increasing prevalence of extended-spectrum b-lactamases (ESBL).
A worldwide increase of CTX-M b-lactamases has been described and
the insertion element ISEcp1 plays a role in the dissemination of those
b-lactamases. However little is known about the molecular epidemiology
of ESBL in Germany.
Methods: From January 2006 to April 2007 E. coli (n = 102) and
K. pneumoniae (n = 75) ESBL isolates were collected from two hospitals.
ESBL types were determined by PCR and sequencing. PCRs for ISEcp1
and orf477 ﬂanking CTX-M genes were performed as described before.
Results: 59.8% of all E. coli ESBL isolates carried CTX-M-15, 19.6%
CTX-M-1, 8.8% CTX-M-14. In K. pneumoniae ESBL isolates CTX-M-
15 was found in 49.3% and CTX-M-1 in 45.3%. The remaining isolates
carried either CTX-M-3, CTX-M-9, SHV-12 or SHV-28.
ISEcp1 upstream of CTX-M was found in 91.8% and 35.1% of CTX-
M-15 and CTX-M-1 genes, respectively. orf477 downstream of CTX-
M was found in 98% and 59.2% of CTX-M-15 and CTX-M-1 genes,
respectively.
Conclusion: ESBLs of the CTX-M-1 cluster, especially CTX-M-15,
were the most frequent types in our area similar as in some but not all
European countries. The high prevalence of ISEcp1 upstream of CTX-M
emphasizes its role in the dissemination of this resistance gene.
P1199 Diversity of CTX-M gene environments in Escherichia coli
and Klebsiella pneumoniae nosocomial strains isolated from
Russia
N. Fursova °, S. Pryamchuk, I. Abaev, N. Shishkova, E. Pecherskikh,
A. Kruglov, S. Sidorenko, E. Svetoch, L. Weigel, J. Rasheed (Obolensk,
Moscow, RU; Atlanta, US)
Objectives: Characterisation of the genetic environment ﬂanking
blaCTX-M gene subtypes [blaCTX-M-1 (n = 50, 64%), blaCTX-M-9
(n = 24, 30%), blaCTX-M-2 (n = 5, 6%)] that had been identiﬁed in
Escherichia coli (n = 54) and Klebsiella pneumoniae (n = 25) strains
isolated in Russia from 2003 to 2007.
Methods: PCR mapping, PCR-RFLP, and DNA sequencing were used
for detection, localisation, and identiﬁcation of blaCTX-M genes and
their surrounding regions. Speciﬁc primers for detection of mobile
genetic elements ISEcp1, IS26, IS903, ORF513, ORF477, and mucA
were previously described (Eckert C. et al., 2006).
Results: Variability found in the genetic environment surrounding
blaCTX-M genes included rearrangements of ISEcp1 mobile element
upstream of blaCTX-M, short speciﬁc nucleotide sequences between
ISEcp1 and blaCTX-M, and variations in the downstream ﬂanking
region. ISEcp1 mobile element (intact or partially truncated) was
identiﬁed upstream of blaCTX-M in nearly all bacterial isolates under
study. Another mobile element, ORF513, was found in only one strain
(Fig. 1). Intact ISEcp1 was found in 39 strains; deletion of tnpA or
other modiﬁcations in the 5′ ﬂanking region in 17 strains; insertions
of other IS elements into ISEcp1 (IS26, IS10, IS1, or resolvase Tn3)
in 19 strains. Short nucleotide sequence insertions between ISEcp1 and
blaCTX-M were found to be, generally, subtype-speciﬁc: 127 bp − for
blaCTX-M-1 in K. pneumoniae; 48 bp − for blaCTX-M-1 in E. coli;
42 bp − for blaCTX-M-9; and 19 bp − for blaCTX-M-2. Three E. coli
strains, however, were exceptions in that they contained 127 bp (n = 2),
and 45 bp (n = 1) insertions. IS903 (intact or partially truncated) in the
downstream region ﬂanking blaCTX-M-9 was found in all bacterial
isolates containing this subtype. ORF477 and mucA sequences were
detected downstream of blaCTX-M-1 genes in nine isolates (Fig. 1).
Conclusion: The genetic environment of blaCTX-M genes was found
to differ among CTX-M subgroups and bacterial genera suggesting
differences in the mechanism of gene transmission. The presence of
various mobile elements, such as IS elements, in the regions surrounding
blaCTX M genes is likely key in evolution mechanisms of antibiotic
resistance.
Acknowledgements: This study was done within the framework of the
ISTS#2913/BTEP#62 Project.
Figure 1. Genetic environments of blaCTX-M genes (blaCTX-M-1, -9,
and -2 subgroups) − location of rearrangements in different strains.
P1200 Characterisation of IncHI2 plasmids carrying
extended-spectrum b-lactamase genes
A. Garcı´a-Ferna´ndez °, A. Carattoli (Rome, IT)
Objectives: IncHI2 plasmids promoted the successful spread of
extended-spectrum b-lactamases (ESBL) such as CTX-M-9 and CTX-
M-2 among Enterobacteriaceae of animal and human origin. Two major
IncHI2 scaffolds have been identiﬁed: R478 (BX664015) originated
from a clinical isolate of Serratia marcescens but largely prevailing in
Escherichia coli in Europe and pAPEC-O1-R (DQ517526), prevalent in
avian pathogenic and commensal E. coli strains in the USA, but also
detected in Salmonella in Europe. Both R478 and pAPEC-O1-R did not
carry ESBL genes. This study describes a characterisation of IncHI2
backbone among epidemic plasmids prevailing worldwide and carrying
ESBL and plasmid-mediated quinolone resistance (PMQR) genes.
Methods: Twenty-one IncHI2 plasmids from Escherichia coli, En-
terobacter spp, Citrobacter freundii and Salmonella spp. of human
and animal origin, from 8 different countries, were analysed and
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compared. Most of these plasmids were associated to the international
spread of ESBL and PMQR and carried the blaCTX-M-2, blaCTX-
M-9, blaSHV-12, blaLAP-2 and qnrS genes. These plasmids are very
difﬁcult to analyze by standard methods, being >250 kb in size, thus
the characterisation was performed by allelic variation analysis and
Southern blot hybridisation performed on total DNA restricted with
EcoRI or PstI. Allelic studies were performed on the smr0017 and
smr0199 genes, showing sequence heterogeneity between R478 and
pAPEC-O1-R. smr0017 belongs to the plasmid partitioning cluster and
smr0199 encodes a bundle-forming pilus biogenesis protein. R478 and
pAPEC-O1-R scaffolds were designated as sequence types (ST) ST1 and
ST2, respectively.
Results: All IncHI2 plasmids carrying blaCTX-M-9 and blaSHV-12,
despite their origin, source and country of isolation were ST1 and R478
derivatives, while those carrying blaCTX-M-2, blaLAP-2 and qnrS genes
were ST2 and pAPEC-O1-R derivatives.
Conclusion: blaCTX-M-2 and blaCTX-M-9 genes demonstrated suc-
cessful dissemination among different enterobacterial species from both
animal and human sources in very distant geographical regions, through
the epidemic spread of two major IncHI2 plasmid variants. This result
is of concern since these successful, epidemic plasmids could promote
in the next future and with the same efﬁciency, the worldwide spread
of other resistance genes, suggesting the necessity of monitoring their
diffusion in Enterobacteriaceae.
P1201 Dispersal and persistence of TEM-4 in Spain:
a plasmid-clone paradigm
A˜. Novais °, R. Canto´n, A. Valverde, F. Baquero, T.M. Coque (Madrid, ES)
Objectives: Opposite to other TEM-extended-spectrum b-lactamases,
TEM-4 has a local distribution, being mainly recovered in Spain. The
aim of this study was to characterise at molecular level plasmids and
genetic elements involved in its spread and persistence.
Methods: Fifty TEM-4-producing Enterobacteriaceae isolates [32
K. pneumoniae (KP), 17 E. coli (EC) and 1 C. freundii (CF)] from
ﬁfty patients (1989–2004) were studied. Clonal analysis included PFGE-
patterns and EC phylogroups. Antibiotic susceptibility patterns and
conjugal transfer were studied. Location of blaTEM-4 was searched
by hybridisation of genomic DNA (I-CeuI) with blaTEM-4/16S rDNA
probes. Plasmid content was determined by using S1 nuclease (Barton’s
method) and its characterisation included Inc group identiﬁcation (PCR,
sequencing and hybridisation), HpaI-RFLP, and screening for colicins
(cbi, cma y cvaC). The presence of class 1 integrons, Tn402 (orf5,
IS1326, IS1353, IS6100) and mer-transposon derivative sequences (tnp,
merA) in representative isolates was investigated by PCR. The linkage
of blaTEM-4 with Tn3 sequences was also assessed by PCR.
Results: Seventeen PFGE-types (9 EC, 7 KP and 1 CF) were identiﬁed.
EC isolates belonged to phylogroups A (n = 3), D (n = 4) and B2
(n = 2). Conjugative transfer was successful in 94% of the cases, with
most transconjugants showing resistance to gentamicin and tobramycin.
blaTEM-4 was located in different plasmid RFLP-types (35–120 kb):
i) pRYC106 (IncFII-80 kb, reppC15−1a, cbi +), identiﬁed in a D-EC
epidemic clone (1989–1997); ii) pRYCE11 (80−90 kb, untypeable), an
epidemic plasmid recovered from KP (n = 7 clones, 1995–2004) and
B2-EC (n = 2 clones, 1991–1999); iii) pRYC107 (35 kb, untypeable),
isolated in 3 EC clones (1991–1999); iv) pRYC108 (80 kb-IncI1, repR64
sequence), detected in 2 EC clones (2000−01); and v) 2 IncI1-like
plasmids (50–120 kb). Tn3-like sequences were identiﬁed in all plasmid
types. Class 1 integrons containing aadA1 cassette were occasionally
detected and associated with the presence of orf5, IS1326 and/or IS6100,
and presumptively linked to left (tnpR-tnpM) and right (merA, IRt) arms
of mercurial Tn.
Conclusion: The spread of blaTEM-4 in our geographic area seems to
be due to both epidemic clones and highly related plasmids, containing
genetic platforms able to facilitate either bla dispersion (Tn3) or
plasmid persistence (Tn402 and mercurial Tn derivatives) by different
recombinatorial events.
P1202 Updated epidemiology of extended spectrum b-lactamase
producing Enterobacter isolates in a university hospital in
Madrid, Spain (2001–2007)
R. Paniagua °, A. Valverde, F. Baquero, T.M. Coque, R. Canto´n
(Madrid, ES)
Objective: To further analyze extended spectrum b-lactamases (ESBLs)
producing Enterobacter cloacae (ENC) and Enterobacter aerogenes
(ENA) isolates recovered in our institution from 2001 to 2007 and
to compare current situation with that previously found (1989–2000,
Canto´n et al. JCM 2002;40:1237−43)
Methods: All Enterobacter (EN) isolates recovered during the studied
period were screened for ESBLs. One ESBL-isolate per patient were
selected for clonal typing (XbaI-PFGE), ESBL characterisation (PCR,
sequencing) and conjugation assays.
Results: A total of 54 of 2792 EN (1.9%) isolates were ESBL
producers: 18 ENC (0.8%) and 36 ENA (6.4%). These ﬁgures were
higher (p< 0.01) than those previously found. Isolates were recovered
from 50 patients (30% medical wards, 28% ICU, 18% surgical wards,
and 24% outpatients). Differences between both species were found:
i) a high proportion (43.8%) of ENC were obtained from outpatients,
which contrast with previous situation, whereas 85.3% of ENA isolates
had a nosocomial origin; ii) a polyclonal structure was observed in
ENC (16 clones/16 isolates) whereas different clusters grouped ENA
isolates (9 clones/34 isolates) with three major related clones, including
the TEM-24 European epidemic clone; iii) in ENC, an increasing
complexity of ESBLs (SHV-12, CTX-M-9 group, CTX-M-10 and CTX-
M-15) were identiﬁed whereas ENA harboured TEM-24 and only in one
case a TEM-4. Transference of ESBL-coding plasmids was achieved in
56.2% of studied cases (9/16); iv) co-resistance was higher than in the
previous period. Seventy-ﬁve percent of ENC isolates were co-resistant
to sulphonamide; 68.8% to tetracycline, trimethoprim and nalidixic ac.;
62.5% to ciproﬂoxacin; and 87.5% to one or more aminoglycosides. All
ENA clones (n = 9) were resistant to kanamycin, 88.9% to sulfonamide,
tetracycline, trimethoprim, nalidixic ac., ciproﬂoxacin and tobramycin,
and 77.8% to amikacin.
Conclusions: Prevalence of ESBL-EN was lower than that in
Escherichia coli or Klebsiella pneumoniae. Unlike previous situation,
ENC isolates were polyclonal with a diverse enzyme production and
mainly associated with the community. Similar to that previously
reported, ENA, essentially the TEM-24 epidemic clone, were recovered
in the nosocomial setting. High co-resistance rates to aminoglycosides
and ﬂuoroquinoles could facilitate the maintenance and dissemination of
ESBL producing EN isolates and the corresponding resistance genes.
P1203 First identiﬁcation in Italy of contemporary presence of
qnrB9 element and blaTEM-116 ESBL-gene in Citrobacter
freundii environmental strain
C. Forcella, M. Perilli, C. Pellegrini, M.M. Tavı`o-Perez, S. Rainaldi,
P. Bellio, C. Di Lisio, B. Segatore, G. Amicosante, G. Celenza °
(L’Aquila, IT; Gran Canaria, ES)
Objectives: Bacteria resistant to antibiotics and disinfectants have been
detected in environmental compartments such as waste water, surface
water, ground water, sediments and soils; resistant bacteria may be
released directly into waste water systems from hospitalised and non-
hospitalised patients. The aim of this study was to monitor the antibiotic
resistance in the municipal sewage of a small city, in an Italian region.
Methods: 0.1mL of the samples, collected during the period January-
May 2008 from waste water of a urban sewage plant of the L’Aquila
city (Italy), were diluted in sterile saline solution and plated on Nutrient
Agar or MacConkey plates supplemented with nalidixic acid (6mg/L)
in order to select for potential resistance to quinolones. Genomic DNA
was extracted from the strain according to the standard procedure. The
blaTEM-like and qnr gene were sequenced on both strands according
to the dideoxy-chain termination method by using an ABI-PRISM
310 (Applied Biosystem, Monza, Italy) automatic sequencer. MICs
ESBLs, AmpCs & others in Enterobacteriaceae: genes, plasmids & clones – part 2 S329
were determined by the conventional macrodilution broth procedure,
according to the CLSI guidelines.
Results: Citrobacter freundii AQ/1, selected for resistance to nalidixic
acid, showed a large plasmid named plCHIGR sized more than 100
Kb and carrying both qnrB9 and blaTEM-116 gene. The plasmid was
inserted by transformation into E. coli HB101 and resistance to nalidixic
acid and ceftazidime was co-transferred.
MIC values were evaluated for C. freundii AQ/1 in comparison
with E. coli HB101(plCHIGR) and E. coli recipient cells. Both
C. freundii AQ/1 and E. coli HB101(plCHIGR) were resistant to
penicillin, cephalosporins (i.e. ceftazidime, MIC> 64mg/L; cefotaxime
MIC> 128mg/L) and aztreonam (MIC> 64mg/L), nalidixic acid
(MIC> 64mg/L). Clavulanic acid is unable to restore the susceptibility
of amoxicillin while tazobactam lowered the MIC value of piperacillin
from 256mg/L to 8mg/L. Concerning levoﬂoxacin and ciproﬂoxacin
molecules we observed the MIC values for C. freundii AQ/1 and E. coli
HB101(plCHIGR) of 0.25 and 0.5mg/L, respectively.
Conclusion: Our ﬁnding suggests how qnr elements and blaESBLs
genes are easily co-transferred among Enterobacteriaceae in different
environments.
P1204 First report of TEM-52 b-lactamase in Proteus mirabilis
strains from Croatia
S. Sardelic, B. Bedenic °, D. Sijak, C. Colinon, S. Kalenic (Split,
Zagreb, HR; Villeurbanne, FR)
Objectives: Recently an increased frequency of extended-spectrum
b-lactamase (ESBL) positive P. mirabilis isolates was observed in
University Hospital Split. The aim of this study was the molecular
characterisation of ESBLs in P. mirabilis strains in University Hospital
Split.
Material and Methods: Seven P. mirabilis strains with reduced
susceptibility to ceftazidime were isolated from different clinical samples
(mostly wound swabs) during 2007 and 2008 in University Hospital Split.
ESBLs were detected by double disk synergy test. Minimum inhibitory
concentrations (MICs) of wide range of antibiotics were determined
by a twofold microdilution technique according to CLSI. Conjugation
experiments were set up employing E. coli A15 R- strain free of
plasmids and resistant to rifampicin. The presence of blaESBL genes was
determined by polymerase chain reaction (PCR) with primers speciﬁc
for TEM, SHV and CTX-M b-lactamases. Plasmids were extracted by
alkaline lysis methods. Genotyping of P. mirabilis strains was performed
by pulsed-ﬁeld gel electrophoresis (PFGE).
Results: ESBLs were detected in all strains by double-disk synergy
test. All strains were resistant to amoxycillin, gentamicin and
ciproﬂoxacin, but susceptible to combination of ceftazidime with
clavulanic acid, piperacillin/tazobactam, aztreonam, cefoxitin, imipenem
and meropenem. Cephalosporins showed variable degrees of resistance;
cefotaxime and ceftriaxone MICs varied between 32 and 256mg/L,
while ceftazidime MICs were slightly lower (16–256mg/L). Cefepime
had better activity with MICs varying between 8 and 64mg/L.
Three strains transferred resistance to E. coli recipient. The resistance
to chloramphenicol, gentamicin and tetracycline was cotransferred
alongside with ceftazidime resistance from two strains whereas sulpha-
metoxazole/trimethoprim resistance was transferable from one strain. A
plasmid of approximately 70 kb was isolated from three representative
strains.
All seven strains yielded an amplicon of 853 bp with primers speciﬁc
for TEM b-lactamases. Sequencing of blaTEM genes revealed TEM-52
b-lactamase. All strains have shown to possess identical PFGE patterns.
Conclusions: This is the ﬁrst report of TEM-52 b-lactamase from
Croatia. The fact that the strains were clonally related and showed similar
resistance phenotypes points out that there is endemic and epidemic
spread of TEM-52 producing P. mirabilis causing nosocomial infections
in University hospital Split.
P1205 SHV-112: a novel extended-spectrum b-lactamases produced
by Klebsiella pneumoniae strains isolated in Kuwait
A. Dashti °, M. Jadaon, F. Habeeb, E. Udo (Sulabikhat, KW)
Introduction: Extended-spectrum b-lactamases (ESBL) are plasmid
mediated enzymes produced by some Enterobacteriaceae to resist
b-lactam antibiotics. The number of new mutations among the ESBLs
are increasing. A total of >100 mutations have been reported in the
genes encoding the SHV enzymes. We hereby report a novel mutation
in genes for SHV enzymes in clinical isolates of Klebsiella pneumoniae.
Materials and Methods: A total of 22 K. pneumoniae isolates obtained
from a Kuwaiti hospital were studied. Antibiotic susceptibility testing
was performed disk diffusion method. ESBL production was detected
using AST-N020 card in the Vitek system and conﬁrmed by ESBL Etest
strips (AB Biodisk). PCR was used to amplify the SHV-genes. The
ampliﬁed products were sequenced by the Big Dye terminator using
an automated DNA sequencer (AB13100) to establish its relationship
with previously reported SHV genes
Results: All the isolates were ESBL-positive and were resistant to
ceftazidime, and ceftazidime with clavulanic acid. PCR ampliﬁcation
yielded a product of 308 kb corresponding to the expected size of SHV
gene. DNA sequencing of the SHV gene in 4 isolates yielded identical
results. They revealed a mutation at position 253 from A to G resulting in
a change from Aspartic acid (AAT) to Aspertine (GAT) at position 815
of the enzyme (A815G). It was assigned the unique number SHV-112,
with a GeneBank accession number EU477409.
Conclusion: Further studies are required to assess the prevalence of
A815G mutation in SHV ESBL-producing K. pneumoniae isolated in
Kuwait and elsewhere.
P1206 Novel PER-variant b-lactamase identiﬁed in Providencia
rettgeri strain from the United States: report from the
SENTRY Antimicrobial Surveillance Program
M. Castanheira °, L. Deshpande, M. Loeffelholz, R. Jones (North
Liberty, Galeston, US)
Objective: To characterise the genetic determinant responsible for the
ESBL phenotype in a Providencia rettgeri bacteraemia isolate collected
in a hospital in Galveston, Texas, USA.
Methods: During 2007, 283 (10% of all isolates) Enterobacteriaceae
isolates from SENTRY Program USA medical sites displayed elevated
cephalosporin MIC values (2mg/L) by reference broth microdilution
method. ESBL phenotypes were conﬁrmed using Etest strips containing
cefepime with and without clavulanate. ESBL genes were ampliﬁed in
a multiplex PCR approach using generic primers for genes encoding
PER, VEB, GES, OXA-2 and OXA-10. TEM- and SHV-encoding
genes were also ampliﬁed and sequenced. Primers comprising the open
reading frame of blaPER were used to amplify the entire gene and
amplicons were cloned into TOPO and transformed in an E. coli host for
sequencing. Conjugation experiments were carried out and selected on
media containing 500mg/L of streptomycin and 8mg/L of ceftazidime.
Results: P. rettgeri isolate 25–3141A was recovered in February/2007
from a bloodculture of a 65 years/old male patient hospitalised in a
Texas hospital. The patient that was an inmate of the Texas State Prison
for several years prior to admittission for evaluation of pneumonia.
He was brieﬂy hospitalised a month early with diagnosis of HCV
cirrhosis and ascites, when he received only one day of cefotaxime.
The P. rettgeri isolate demonstrated elevated cefepime MIC (4mg/L) and
positive ESBL conﬁrmatory test. Isolate 25–3141A also showed elevated
MIC values against ﬂuoroquinolone, trimethoprim/sulfamethoxazole and
tetracycline. blaPER amplicons were detected in the multiplex PCR.
Recombinant plasmids carrying the entire b-lactamase encoding gene
were sequenced and the analysis of the derived aminoacid sequence
showed one aminoacid alteration compared to PER-1 structure (E33G).
This isolate also harboured blaTEM-1 Conjugation failed to yield
colonies showing resistance to cephalosporins.
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Conclusions: ESBLs, other than SHV and TEM, are becoming more
common in the USA with recent reports of CTX-M-producing strains in
several medical centres. In this study, we described a novel PER enzyme
detected in a P. rettgeri that showed a single aminoacid difference
compared to PER-1. The diversity in the b-lactamase types detected
among USA isolates is rapidly increasing, changing the ESBL treatment
scenario in this country.
P1207 Variability of determinants conferring extended-spectrum
b-lactamase resistance in German Salmonella enterica
serovar Paratyphi B d-tartrate + (S. ser. Java) isolates
B. Ruiz del Castillo, I. Rodrı´guez, S. Jahn, J. Beutlich, W. Barownick,
A. Schroeter, R. Helmuth, B. Guerra ° (Santander, Oviedo, ES; Berlin,
DE)
Objective: Molecular characterisation of antimicrobial resistance (R) in
Salmonella (S.) Paratyphi B dT+ isolates showing ESBLs or AmpC
phenotype originating from foods and animals in Germany.
Methods: Among the S. enterica isolates from animal and food
origin (2003–2008) obtained in the National Reference Laboratory for
Salmonella (NRL-Salm) strain collection (Berlin), all epidemiologically
unrelated S. Paratyphi B dT+ isolates showing a MIC for ceftiofur
4mg/L, were selected. A total of 12 isolates, came from six German
regions, and originated from foods (8 from chicken meat, 1 minced meat,
and 1 from spices) and animals (2 from broilers). Their susceptibility to
17 antimicrobial agents (including the b-lactams ampicillin and ceftiofur,
and amoxycillin/clavulanic acid) by broth microdilution, and for an
additional panel of 12 b-lactams, by disc-diffusion was tested. Molecular
methods as PCR ampliﬁcations/sequencing, isoelectric focusing, PFGE
with XbaI, plasmid proﬁle analysis and Southern-hybridisation were
used to characterise the resistance determinants and epidemiological
relationship.
Results: All S. Paratyphi isolates shared a common XbaI-PFGE pattern.
They showed different resistance phenotypes, and plasmid proﬁles, but
all of them were multiresistant (more than four resistance determinants)
and harboured a 2300 bp/dfrA1-sat1-aadA1 class 2 integron. Six isolates
carried also class 1 integrons (3 different variable regions). ESBLs
were present in all isolates, whereas AmpC were found in only one
of them. Four isolates carried blaCTX-M1 and 3 blaCTX-M2 genes,
located on self-transferable plasmids from different sizes (80–100 kb),
mainly from incompatibility group IncI1. TEM-1 variants were found in
5 isolates: 3 with blaTEM-52 and 2 with blaTEM-20 genes, also located
on IncI1 plasmids. One of the blaCTX-M2 isolates also carried an AmpC
blaACC1 gene. No qnrA, B, or S genes were detected.
Conclusions: Our results show that a wide spread S. Paratyphi B
dT(+) German clone previously described (Miko et al., JCM 2002),
in which a class 2 integron is chromosomally located, has evolved to
cephalosporin resistance by acquisition of plasmids containing different
ESBL-encoding genes. Like in other middle European countries in
Germany an increase in the number of 3rd generation cephalosporins
and ﬂuoroquinolone resistant in S. Paratyphi B dT+ isolates, specially
originating from foods of avian origin, could be observed.
P1208 Prevalence of extended-spectrum b-lactamases in
Escherichia coli obtained from faecal samples of captive
ostrich in Portugal
C. Carneiro, S. Somalo, L. Vinue, E. Ruiz, J. Rodrigues, G. Igrejas,
P. Poeta, C. Torres ° (Vila Real, PT; Logrono, ES)
Objectives: To determine the prevalence of ESBLs in E. coli isolates
obtained from faecal samples of captive ostrich from the Alentejo
(Portugal), and to study the presence of other resistance genes, integrons,
virulence factors and phylogenetic groups.
Methods: 54 faecal samples of captive ostrich were obtained and
inoculated in Levine agar plates supplemented with cefotaxime (2mg/L),
and were incubated 24 h at 37ºC; one colony per sample with E. coli
morphology was identiﬁed. Antibiotic susceptibility testing for 13
antibiotics was performed by disk-diffusion agar, and screening for
ESBL production was performed (CLSI). The presence of genes
encoding TEM, SHV, OXA, CTX-M and CMY b-lactamases, as well as
other resistance genes (tetA, tetB, cmlA, sul1), and the characterisation
of class 1 and 2 integrons was carried out by PCR and sequencing.
Virulence genes (ﬁmA, cnf1, papC, papGIII and aer) and characterisation
of phylogenetic groups was determined by PCR. Clonal relationship
among ESBL-positive isolates was studied by PFGE.
Results: ESBL-positive E. coli isolates were detected in 3 of the
54 analysed samples (5.6%), and the following b-lactamases were
identiﬁed: CTX-M14 + TEM-1 (2 isolates), and CTX-M14 + TEM-
52 (1 isolate). The blaCTX-M14 gene was surrounded by ISEcp1 and
IS903 in all cases. The three ESBL-positive isolates showed unrelated
PFGE patterns, and harboured the tetA and sul1 genes (encoding
tetracycline and sulphametoxazole resistance), as well as the aer and
ﬁmA virulence genes, being the three isolates of the B1 phylogroup.
They showed resisstance to nalidixic-acid, ciproﬂoxacin, tetracycline,
and streptomycin, in addition to b-lactams, and two of them also to
chloramphenicol or trimethoprim-sulphametoxazole. Class 1 integrons
were identiﬁed in the three ESBL-positive E. coli isolates with the
following gene cassette arrangements in their variable region: aadA1
(2 isolates), and dfrA1+aadA1 (1 isolate).
Conclusion: The intestinal tract of captive ostrich may be a reservoir
of ESBL-positive E. coli isolates. CTX-M-14, frequently detected in
clinical human isolates in Portugal and Spain, especially detected in
these animals, together with TEM-52.
P1209 Comparative assessment of extended-spectrum b-lactamase-
producing Escherichia coli contamination in different food
supplies
P. Egea °, L. Lo´pez-Cerero, J. Rodrı´guez-Ban˜o, M.D. Navarro,
A. Pascual (Seville, ES)
Introduction: The spread of extended spectrum b-lactamases-producing
E. coli (ESBLEC) in the community setting is an emerging health
problem. ESBLEC has been found in livestock faeces and raw meat,
especially poultry, suggesting that contaminated food could contribute
to the dissemination of resistant Enterobacteriaceae in the community.
High ESBLEC contaminated poultry carcasses (>95% of samples) have
been detected in our area, however, few current data regarding of
contamination rate of other poultry products are available.
Objective: This study aimed to compare the contamination rate with
ESBLEC in different poultry products and salads and characterise the
isolates.
Material and Methods: Shells from 72 prepackaged and non-packaged
chicken eggs, 32 salads, and 30 samples of cooked chicken and 6
samples of pet food made of chicken meat were analyzed. Egg shells
were sampled by shaking incubation in buffered peptone water and food
samples were homogenised with Stomacher blender in deﬁned volumes
of peptone broth. Lactose-positive bacterial quantiﬁcation was done by
plate counts on MacConkey agar. After overnight incubation, broths were
platted onto MacConkey agar supplemented with 1mg/l cefotaxime or
ceftazidime. Presumptive E. coli colonies were identiﬁed by standards
methods. ESBL production was determined by the double disk diffusion
method and further characterisation was carried out by pI, PCR with
speciﬁc primers for bla-genes and sequencing. Phylogenetic group was
assigned by multiplex PCR.
Results: One (3%) SHV-12-producing E. coli strain was detected in
one salad sample. This strain belonged to B1 phylogenetic group.
No ESBLEC were found in cooked poultry, pet food or eggs shells.
A high lactose-positive bacteria contamination (>3Log10 CFU/ml) was
exhibited in 9.4% samples of salads, 33% of pet food and 6.7% of
cooked chicken but not in shells eggs.
Conclusions: Raw meat may contain ESBLEC, but the effects of
treatment process such cooking or dehydrating could reduce the risk
of transmission as well as the washing shells or sanitation procedures
in the case of hens eggs. Nevertheless, fresh vegetable food can be
contaminated with ESBLEC during meal preparation.
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P1210 Prevalence of antimicrobial resistance and antimicrobial
resistance genes among Escherichia coli from healthy
volunteers and patients with urinary tract infection
S. Garlick, R. John, A. Lovering, A.P. MacGowan, M. Gal, V.I. Enne °
(Bristol, UK)
Objective: To investigate the reservoir of antibiotic resistance in
commensal Escherichia coli from healthy community volunteers and
how this impacts on the prevalence of antibiotic resistance in E. coli
associated with urinary tract infection.
Methods: 295 E. coli isolated from healthy community volunteers
and 295 E. coli isolated from clinical urine samples from the
South West region of England were studied. Their susceptibility
to amoxicillin, cephalexin, ciproﬂoxacin, co-amoxiclav, ertapenem,
gentamicin, meropenem, nitrofurantoin, tetracycline and trimethoprim
was determined by agar dilution. The presence of the blaTEM, blaCTX-
M-1 group, blaCTX-M-2 group, blaOXA-1 group, blaVIM, aac6′-Ib-cr,
tet(A) and tet(B) genes was determined by PCR. Statistical analysis was
carried out by the chi-squared test.
Results: Isolates from urinary tract infections were more antibiotic
resistant with 58.6% being resistant to at least one antibiotic and 24.7%
being multi-resistant, compared to 43.4% and 9.8% for isolates from
healthy volunteers. Resistance to individual agents varied between 0.3%-
49.8% for urinary isolates compared to 2.4%-32.9% for commensal
isolates (Table).
Among commensal isolates the frequencies of blaTEM was 19.3%, the
frequency of blaOXA-1 was 0.3%, the frequency of tet(A) was 8.1%, the
frequency of tet(B) was 5.8% and the frequency of aac6′-Ib-cr was 0.3%.
blaVIM and blaCTX-M were not detected. Among urinary isolates the
frequency of blaTEM was 24.9%, the frequency of blaOXA-1 was 2.5%,
the frequency of blaCTX-M-1 was 0.8%, the frequency of tet(A) was
9.1%, the frequency of tet(B) was 14.1% and the frequency of aac6′-Ib-cr
was 1.0%. blaVIM and blaCTX-M-2 were not detected.
Conclusions: The prevalence of antimicrobial resistance and resistance
genes among commensal E. coli isolates was lower than in urinary
isolates, but still signiﬁcant, suggesting such isolates may act as a
reservoir of resistance. The occurrence of ertapenem resistance among
commensal isolates is of concern.
Antimicrobial Resistance (%) among E. coli c2 p value
commensal (n = 295) urinary (n = 295)
Amoxicillin 32.9 49.8 <0.001
Cephalexin 4.7 5.1 0.850
Ciproﬂoxacin 2.7 8.8 0.001
Co-amoxiclav 4.4 5.4 0.568
Ertapenem 2.4 0.3 0.075
Gentamicin 3.4 7.8 0.020
Meropenem 0.0 0.0 1.000
Nitrofurantoin 2.7 5.1 0.136
Tetracycline 18.0 32.5 <0.001
Trimethoprim 15.3 30.5 <0.001
P1211 Evaluation of the frequency antibiotic resistance genes by
Identibac TubeArray in CTX-M ESBL E. coli of veterinary
origin
H. Cockrem, H. Wearing, L. Randall, C. Teale, N. Coldham °
(Addlestone, UK)
Objectives: Extended spectrum b lactamases are important in both
human and veterinary medicine as they inactivate front line third
generation cephalosporin antibiotics. The CTX-M ESBLs are carried
and transferred on plasmids which may also contain other antibiotic
resistance genes. The ﬁrst veterinary isolation of CTX-M producing
E. coli in the U.K. was from a large dairy farm in 2004 (Liebana et
al., 2006). The objective of this study was to determine the frequency
of other antibiotic resistance genes in CTX-M bearing E. coli.
Methods: A panel of 157 CTX-M ESBL E. coli of veterinary origin
was analysed by Identibac ArrayTube for the detection of antimicrobial
resistance genes in Gram-negative bacteria. The panel of E. coli included
isolates from 54 different locations, and where appropriate, pulse ﬁeld
gel electrophoresis was used to select individual clones for analysis.
The ArrayTube includes genes encoding resistance to aminoglycosides,
trimethoprim, sulphonamides, tetracyclines, and b-lactams including the
extended spectrum b-lactamases (Batchelor et al., 2008).
Results: Most of the CTX-M genes (68.2%) hybridised with the group1
probe. The most frequently occurring genes found in the CTX-M ESBL
E. coli isolates were TEM-1 (65.6%), tetA (61.1%), strB (59.9%)
and sul2 (59.2%). The frequency of other antibiotic resistance genes
occurring with CTX-M group1, TEM-1, tetA, strB and sul2 are provided
in table 1.
Conclusion: CTX-M ESBL E. coli frequently carried other antibiotic
resistance genes, particularly those providing reduced susceptibility to
other b-lactams, tetracycline, streptomycin and sulphonamides. These
were easily and rapidly detected using the Identibac ArrayTube. Further
studies with transconjugants or transformants will be used to investigate
gene linkage and provide a better understanding of the epidemiology of
different isolates.
Table 1. Frequency of other antibiotic resistance genes occurring with CTX-M
group 1, TEM-1, tetA, strB and sul2
TEM-1 tetA strB sul2
strB (72.1%) TEM-1 (70.8%) TEM-1 (79.8%) strB (77.4%)
CTX-M1* (70.2%) CTX-M1 (69.8%) sul2 (76.6%) TEM-1 (75.3%)
sul2 (67.3%) sul2 (66.7%) CTX-M1 (65.9%) CTX-M1 (68.8%)
tetA (65.4%) aadA1 (65.6%) sul1 (64.9%) tetA (68.8%)
tetB (60.6%) intl1 (61.5%) tetA (62.8%) sul1 (66.7%)
aadA1 (58.7%) strB (61.5%) tetB (61.7%) tetB (64.5%)
sul1 (56.7%) sul1 (53.1%) aadA1 (58.5%) intl1 (62.4%)
*CTX-M1 probe hybridises with CTM-M group 1 genes including
blaCTX-M1,3,10,12,15,22,23,28 and FEC-1.
Intl1 indicates class 1 integrase.
P1212 Characterisation of CTX-M-positive isolates of Enterobac-
teriaceae using real-time PCR and melting curve analysis
M. Chroma´ °, L. Cekanova´, M. Kola´r, T. Stosova´, P. Sauer (Olomouc, CZ)
Objectives: Bacterial resistance to b-lactam antibiotics due to extended-
spectrum b-lactamase (ESBL) production is an increasing global
problem. CTX-M enzymes represent a group of ESBL, often found in
various isolates of enterobacteria.
Methods: During one-year period between may 2007 and 2008, rectal
swabs were collected from healthy community objects living in the
Olomouc Region and from patiens hospitalised in the University Hospital
Olomouc, Czech republic. The rectal swabs were inoculated onto
the chromID ESBL selective medium. Phenotypic detection of ESBL
was performed using a modiﬁed double-disk synergy test (mDDST).
Molecular-genetic methods like real-time PCR with melting curve
analysis, restriction fragment analysis and direct sequencing were used
to conﬁrm the phenotypic determination.
Results: A total of 579 rectal swabs from community objects were
investigated. According to the positive grow on chrom ID ESBL medium
and positive mDDST 7 ESBL-positive isolates of Escherichia coli were
obtained. The same approach was used for 546 rectal swabs from
hospitalised patients whereas 14 isolates of the family Enterobacteriaceae
producing ESBL were acquired (E. coli-8 isolates, Klebsiella pneumo-
niae-3, Enterobacter aerogenes-1, Citrobacter freundii-2). The presence
of blaCTX-M gene was detected in all ESBL-positive strains using real-
time PCR technique. By use of differences between restriction patterns
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and melting temperatures of the ampliﬁed products, the clusters of CTX-
M enzymes (CTX-M-1 and CTX-M-9) were identiﬁed among clinical
isolates. CTX-M-15 was the most widespread ESBL.
Conclusion: From collected data results that the occurrence of ESBL-
positive bacteria in the gastrointestinal tract was conﬁrmed in 1.2% of
subjects in the community and in 2.5% of hospitalised patients. Using
molecular genetic methods the appearance of CTX-M-15, CTX-M-9 like
and CTX-M-1 types b-lactamases was approved.
The study was supported by the grants MSM6198959223, Czech
Republic and IGA 9950−3.
P1213 Identiﬁcation of a chromosomal class A b-lactamase from
Serratia rubidaea
T. Naas °, A. Ergani, J. Didi, S. Lima, P. Nordmann (Le Kremlin-Biceˆtre,
FR)
Background:Within the Enterobacteriaceae species, strains of the genus
Serratia are frequently identiﬁed in human nosocomial infections. Ser-
ratia marcescens and the Serratia liquefaciens complex are responsible
of the majority of Serratia human infections. Human infections due
to S. rubidaea are associated with the consumption of contaminated
coconuts or vegetable salads. S. rubidaea has also been shown to cause
sepsis and other infections in outpatients and hospitalisated patients.
Serratia spp. may be a source of difﬁcult to treat infections since many
of these strains are resistant to b-lactams mediated by the production of
chromosomally-encoded b-lactamases, of either Class C (AmpC-type of
S. marcescens), class A (FONA of S. fonticola) or class B (Sfh-I of an
environmental S. fonticola). Here, we describe a novel b-lactamase from
S. rubidaea.
Method: The b-lactamase from S. rubidaea CIP 103234T was cloned,
sequenced and expressed in E. coli. The genetic location of the gene
was determined and the enzymatic properties of puriﬁed b-lactamase
analyzed.
Results: On a routine antibiogram S. rubidaea CIP 103234T reference
strain displayed a weak narrow-spectrum b-lactam-resistant phenotype
(reduced susceptibility to amoxicillin and ticarcillin, which was
recovered by clavulanic acid). It encoded a clavulanic-acid inhibited
Ambler class A b-lactamase, RUB-1, with a pI value of 6.0 and a
molecular mass of ca. 29 kDa. RUB-1 had the highest percent identity
with GIL-1, PLA-1, ORN-1, TEM-1, and SHV-1, 74%, 74%, 73%,
73% and 70% amino acid sequence identity, respectively. The substrate
proﬁle of the puriﬁed RUB-1 was similar to that of b-lactamases TEM-
1, SHV-1 and GIL-1. The kinetic properties conﬁrmed the penicilinase
behaviour of the enzyme. The blaRUB-1 gene was chromosomally-
located as revealed by I-CeuI-experiments and no gene homologous to
ampR regulatory genes was found upstream of blaRUB-1 gene, which ﬁts
the non-inducibility of b-lactamase expression in S. rubidaea. 5′RACE
analysis revealed promoter sequences that diverge from E. coli consensus
sequence, thus explaining the low-level of expression in S. rubidaea.
Conclusions: This work further illustrates the heterogeneity of
b-lactamases in Serratia spp. that may reﬂect a greater than expected
variability of Serratia species.
P1214 Biochemical study of a new b-lactamase inhibitor enzyme
(SHV-84) produced by a clinical Escherichia coli strain
V. Manageiro °, E. Ferreira, M. Canic¸a (Lisbon, PT)
Objectives: Inhibitor resistant (IR) b-lactamases are mostly derived
from parental TEM by point mutations in the corresponding coding
gene. IR-SHV b-lactamases have been identiﬁed, mainly in Klebsiella
pneumoniae strains. The aim of this study was the phenotypic, molecular
and biochemical characterisation of a new IR-SHV enzyme − SHV-84 −
produced by a clinical Escherichia coli strain.
Methods: E. coli INSRA4590 was isolated from a patient hospitalised
in 1999 at a Portuguese hospital. Antimicrobial susceptibility was
determined by an agar dilution method. b-lactamase encoding genes
were screened by PCR and identiﬁed by nucleotide sequencing, using
speciﬁc primers. Transformant E. coli DH5a harbouring the recombinant
SHV-encoding plasmid was obtained by electroporation. SHV-84 was
extracted from an overnight culture and puriﬁed by ion exchange and
gel ﬁltration. The kinetic constants were obtained by a computerised
microacidimetric method. Isoelectric point of the b-lactamase was
estimated by isoelectrofocusing.
Results: E. coli INSRA4590 was highly resistant to the penicillins tested
(MICs of 512 to >4096mg/L) and susceptible to cephalosporins and
monobactam. This strain was resistant to the amoxicillin plus clavulanic
acid combination (MIC of 64mg/L), but remained susceptible to the
piperaciclin plus tazobactam (MIC of 4mg/L). The SHV-84-producing
clone exhibited a b-lactam resistance phenotype similar to the clinical
strain. Both produced an enzyme of pI of 7.4. The blaSHV-84 gene
differed from blaSHV-1 by two point mutations that lead to the amino
acid substitution Lys234Arg. SHV-84 showed a lower afﬁnity (Km, 64 to
101 uM) for penicillins and cephalotin (Km 169 uM) than that of SHV-1
(Km, 11 to 31 uM and 40 uM, respectively). No hydrolysis was detected
against extended-spectrum cephalosporins. The IC50 for SHV-84 was
2.21 uM for clavulanic acid, 13-fold higher than for SHV-1 (0.17 uM).
Conclusion: In this study we have characterised a new enzyme, SHV-
84, that exhibits an unusual resistant proﬁle to the amoxicillin-clavulanic
acid combination. Unlike SHV-72, another IR-SHV harbouring the
Lys234Arg amino acid substitution, SHV-84 has a lower afﬁnity to
penicillins than SHV-1 and a decreased catalytic activity for these
antibiotics. On the other hand, the SHV-84 is less susceptible to
clavulanic acid than SHV-72. In conclusion, this study underlines the
role of the Lys234Arg substitution in the resistance to clavulanic acid.
P1215 Sporadic occurrence of CMY-2 producing multidrug-
resistant Escherichia coli of clonal complex (CC)48, CC38
and CC131 in Norway, 2003–2007. Indications for globally
disseminated clones?
U. Naseer °, B. Haldorsen, G.S. Simonsen, A. Sundsfjord (Tromsø, NO)
Objectives: The spread of plasmid-mediated AmpC b-lactamases
(PABLs) among Escherichia coli worldwide is worrisome. Population
analysis of PABL-producing E. coli are lacking. In this study we
collected clinical isolates of E. coli with reduced susceptibility to
oxyimino-cephalosporins without clavulanic acid synergy (n = 402)
from Norwegian diagnostic laboratories in 2003–2007 for molecular
characterisation.
Methods: Isolates with a positive boronic acid test (n = 276) were
examined for plasmid-mediated ampC-genes using multiplex-PCR.
Positive isolates (n = 38) were further examined by blaampC sequence
typing, antimicrobial susceptibility testing for b-lactam and non-b-lactam
antibiotics by Etest and Vitek2, respectively. Moreover, characterisation
of the genetic environment of blaampC, phylogenetic grouping, XbaI-
PFGE, MLST, plasmid proﬁling, PCR based replicon typing and plasmid
transfer was performed.
Results: PABL-positive isolates (n = 38) were typed as blaCMY-2
(n = 35), blaCMY-7 (n = 1) and blaDHA-1 (n = 2), from out- (n = 23)
and in-patients (n = 15) expressing moderate to high MICs for all
b-lactam substrates, except cefepime and carbapenems. All isolates
were co-resistant to trimethoprim-sulphamethoxazole and 58% expressed
multidrug-resistance. Thirty-two (91%) blaCMY-2 and one blaCMY-7
were linked to ISEcp1 upstream and one blaDHA-1 (50%) was linked
to qacED1sul1 upstream and downstream. Twenty isolates (53%) were
of putative virulent phylogenetic groups B2 and D. Thirty-three XbaI-
PFGE-types including three small clusters were observed. Twenty-ﬁve
sequence types (STs) were identiﬁed. The dominant STs were related
to clonal complex (CC) 38 (n = 7), CC448 (n = 5) and CC131 (n = 4).
Plasmid proﬁling revealed 1−4 plasmids of 50–250 kb per isolate and
11 different replicons in 37/38 isolates. BlaCMY-2 was seen carried
on transferable multiple-replicon plasmids dominated by I1 (n = 12),
FII (n = 10) and A/C (n = 7). Interestingly, Southern blot hybridisation
indicated chromosomal integration of blaCMY-2 in 9 isolates belonging
to CC448 and CC38.
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Conclusion: CMY-2 is the dominant PABL among Norwegian E. coli
isolates. It is strongly associated with ISEcp1 upstream and identiﬁed
on multiple-replicon IncI1, IncA/C or IncFII transferable plasmids. The
occurrence of PABLs in Norway is sporadic and is probably linked to
globally dispersed uropathogenic strains of CC38, CC448 and ST-131 of
which the latter has been associated with the spread of CTX-M-15.
P1216 Acquisition of a plasmid carrying blaCMY-2 by the
established blaOXA-30-producing Salmonella Typhimurium
Iberian clone
P. Antunes °, L. Peixe (Porto, PT)
Objectives: Multidrug-resistant (MDR) Salmonella is emerging world-
wide, with increasing involvement of particular clones in human
infections. Given the importance of cephalosporins in therapeutics,
our goal was to characterise mobile genetic elements associated to
b-lactams resistance in a predominant MDR Salmonella Typhimurium
clone causing foodborne infections in Portugal and Spain over years.
Methods: We analysed 46 blaOXA-30-producing Salmonella Ty-
phimurium isolates belonging to a previously described Iberian clone
obtained from human clinical infections, food products and environment
in different regions of Portugal (2002–2008). The isolates were examined
for susceptibility to antimicrobial agents and b-lactamase production.
Detection of resistance genes and integrases was done by PCR. Class
1 integrons were characterised by PCR, RFLP (TaqI) and sequencing.
Clonality was established by PFGE (XbaI). Plasmid analysis included
conjugation assays, extraction of DNA and sequencing, determination of
size (S1-PFGE) and content (incompatibility groups by rep-PCR typing,
hybridisation and sequencing). Location of integron and b-lactamase was
performed by hybridisation of I-CeuI/S1-PFGE.
Results: The isolates were MDR (predominant phenotype: amoxicillin,
chloramphenicol, streptomycin, sulfamethoxazole and tetracycline) and
harboured tetB, catA1, sul1, sul2 and blaOXA-30. The integron-borne
OXA-30 b-lactamase was located on a conjugative plasmid classiﬁed
as IncFIIA (140Kb), a common replicon among Salmonella virulence
plasmids. Recently, in 2008, we identiﬁed from a hospitalised patient
with gastrointestinal infection a clinical isolate also carrying the
blaCMY-2 gene that was responsible for resistance to most of the large
spectrum b-lactams, with exception for cefepime and carbapenems. The
blaCMY-2 gene was located on a conjugative IncI1 plasmid of 75 kb and
analysis of its genetic environment revealed blaCMY-2-blc-sugE genes
downstream of a post-segregational killing system (pnd genes).
Conclusion: We described for the ﬁrst time in Portugal the acquisition
of a resistance plasmid carrying blaCMY-2 gene by a established MDR
blaOXA-30-producing Salmonella Typhimurium clone, conferring resis-
tance to therapeutically important broad-spectrum b-lactams. Moreover,
the ﬁnding of blaCMY-2 gene in a conjugative plasmid IncI1 with a
maintenance system is worrisome as persistence of this b-lactamase and
its emergence in other Salmonella strains could be anticipated.
P1217 Prevalence of ampC b-lactamase genes in Enterobacteriaceae
clinical isolates from Aveiro, Portugal
S. Ferreira °, A. Paradela, J. Velez, E. Ramalheira, T. Walsh, S. Mendo
(Aveiro, PT; Cardiff, UK)
Objectives: AmpC b-lactamases are enzymes that confer resistance to
most b-lactams except carbapenems, thus are clinically relevant. The
general mechanism for overexpression of chromosomally encoded AmpC
b-lactamases is well known, however little is known about the occurrence
of plasmid-borne ampC genes. In the present study, we investigated the
prevalence of these plasmid encoded genes in clinical isolates collected
in Aveiro, Portugal.
Methods: Clinical isolates of Escherichia coli (n = 30), Citrobacter
freundii (n = 6) and Klebsiella peneumoniae (n = 50) were collected from
different inpatients at the Hospital Infante D. Pedro EPE, Aveiro. Strains
were selected based on a cefoxitin MIC >16 ug/ml and were tested with
Etest (CN/CNI) (AB Biodisk) AmpC strips, according to manufacturer’s
instructions. ampC gene families and respective genetic environment
were detected by PCR and ampliﬁed products were sequenced and
compared with others deposited in the GenBank, by standard methods.
Results: Two different types of ampC genes were found, blaDHA-1-like
in 5 K. pneumoniae and blaCMY-2-like in 6 C. freundii. As expected, all
the blaCMY-2-like genes were linked to ISEcp1. blaDHA-1 genes have
been found between ISCR1 and 3-CS2 of class 1 integrons in regions
of variable length that may include qnrB.
Conclusions: Two different types of plasmid borne ampC genes were
found among the population studied however, these results can only
explain a small proportion of cefoxitin resistant phenotypes. blaCMY-
2-like and blaDHA-1-like genes appeared in genetic contexts similar to
those described by other authors. AmpC producers are a major concern
in nosocomial infections and should be monitored by surveillance
studies. These data highlights the importance of the identiﬁcation of
microorganisms producing plasmid encoded AmpC b-lactamases.
P1218 First detection of plasmid-mediated AmpC-type ACC-4
b-lactamase from Proteus mirabilis in Hungary
I. Damjanova °, A´. To´th, G. Kardos, P. Sza´ntai, P. Orosi, K. Bo¨ro¨cz
(Budapest, Debrecen, HU)
Objectives: In August 2007 two clinical isolates of Proteus mirabilis
showed 3rd generation cephalosprins resistance were isolated at an
university teaching hospital and submitted to the National Center
for Epidemiology to determine the mechanism of their resistance.
Characterisation of these strains was performed.
Methods: The two clinical isolates were identiﬁed using the Micro-
naut E system (Genzyme Virotech GmbH). The MICs of ceftazidime,
cefotaxime, cefepime, cefoxitin, imipenem, gentamicin, amikacin and
ciproﬂoxacin were determined by the E-test (AB Biodisk). The
phenotypic investigations of mechanism of resistance to cephalosporins
were performed by ESBL combined disk test (MAST) and AmpC
disk test. The isolates were examined for the presence of bla SHV,
blaTEM, blaCTX-M, blaMOX, blaCMY, blaLAT, blaBIL, blaDHA,
blaACC, blaMIR, blaACT, blaFOX by PCR and the ampliﬁed genes were
sequenced. Conjugation and plasmid curing experiments were carried
out also. Furthermore typing with pulsed ﬁeld gel electrophoresis was
performed.
Results: The isolates were highly resistant to ceftazidime (>256mg/L),
cefotaxime (64mg/L), gentamicin (128mg/L), amikacin (>256mg/L)
and ciproﬂoxacin (>32mg/L) and moderately resistant to cefoxitin
(16−32mg/L). The ESBL combined disk test did not showed synergy
between clavulanic acid and indicator cephalosporins, while the AmpC
disk test proved to be positive.
According to the PFGE analysis the strains showed identical macrore-
striction proﬁles. The strains carried a large non-transferable plasmid
of app. 140 kb in size which was cured from their host. The plasmid
cured strains became susceptible to ceftazidime (0.25mg/L), cefotaxime
(0.032mg/L), gentamicin (1mg/L) and amikacin (4mg/L). By PCR
screening, the strains were found to be positive for blaACC and blaTEM.
Sequence analysis of b-lactamase genes detected blaACC-4 and blaTEM-
1 in both isolates.
Conclusion: To our best knowledge this is the ﬁrst report of plasmid-
mediated AmpC-type b-lactamase in Hungary and blaACC-4 in Europe
as well as the ﬁrst blaACC in Proteus mirabilis.
P1219 A complex outbreak of multiresistant Enterobacteriaceae
producing the acquired AmpC-type b-lactamase FOX-7 in
a neonatal intensive care unit setting
F. Montagnani, F. Arena, T. Giani, A. Zanchi, M.M. D’Andrea,
S. Cresti, G. Zanelli, C. Cellesi, G.M. Rossolini ° (Siena, IT)
Background: Enterobacteriaceae are a leading cause of infections in
neonatal intensive care units (NICUs). Plasmid-encoded AmpC-type
b-lactamases (pACBLs) are resistance determinants of increasing clinical
relevance in Enterobacteriaceae. Production of these enzymes is tipically
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associated to resistance or reduced susceptibility to third-generation
cephalosporins and penicillin plus b-lactamase inhibitor combinations,
and can also result in reduced susceptibility to carbapenems in presence
of decreased outer membrane permeability. In this work we report on a
long-lasting and complex outbreak caused by multidrug-resistant (MDR)
Enterobacteriaceae producing the FOX-7 pACBL in an NICU setting.
Methods: Antimicrobial susceptibility was determined by disk diffusion
and broth dilution methods. Clonal relatedness was investigated by PFGE
of XbaI-digested genomic DNA. b-lactamase genes were investigated by
PCR and sequencing.
Results: MDR enterobacteria of various species (mostly Klebsiella
pneumoniae but also Klebsiella oxytoca and Pantoea agglomerans)
resistant to third-generation cephalosporins but not producing extended-
spectrum b-lactamases (ESBLs) were isolated from NICU patients of
Sienna University Hospital from January to November 2008. Overall,
the outbreak involved 27 patients, yielding 23 non replicate isolates of
K. pneumoniae, 2 of K. oxytoca and 2 of P. agglomerans. Molecular
analysis showed carriage of the FOX-7 pACBL gene in all the 27 isolates.
PFGE genotyping showed a multiclonal nature of the K. pneumoniae
isolates (three different clones). A similar outbreak had been reported in
the same NICU during 2003–2004. Analysis of representative isolates
(three K. pneumoniae and one K. oxytoca) from that episode conﬁrmed
the presence of the FOX-7 pACBL but revealed clonal diversity
compared with the 2008 isolates.
Conclusions: Sporadic cases and outbreaks of pACBL-producing
Enterobacteriaceae have been reported in various settings. To our
best knowledge, this is the ﬁrst description of a large, complex
(multiclonal and heterospeciﬁc) and prolonged outbreak of pACBL-
producing enterobacteria in an NICU setting, which underscores the
potential relevance of these emerging resistance determinants also in this
peculiar setting. Plasmid spread (under investigation) apparently played
a dominant role in evolution of the outbreak.
P1220 Phenotypic and genotypic analysis of a novel
extended-spectrum b-lactamase phenotype (cefepimease)
F. Boyle °, D. Morris, S. Kariuki, G. Revathi, M. Cormican (Galway,
IE; Nairobi, KE)
Objectives: To characterise an unusual ESBL phenotype (“ce-
fepimease”) observed in 18 isolates of S. Typhimurium. The phenotype
is characterised by high cefepime MIC (relative to other cephalosporins)
that is markedly reduced by clavulanic acid.
Methods: Antimicrobial susceptibility testing against 21 antimicrobial
agents was performed by CLSI disk diffusion methods. Isolates were
evaluated for the presence of Class I and Class II integrons and
for 31 b-lactamase encoding genes by PCR using speciﬁc primers.
Sequencing of amplicons was performed in both directions using primers
homologous to those used for PCR. Isoelectric focusing (IEF) was
performed using previously reported protocols. An association between
blaOXA-1 and Insertion Sequence Common Region I (ISCR1), IS1,
IS26, ISEcp1 was investigated by PCR. Cloning of OXA into the
pBK-CMV vector and subsequent transformation into XL1 cells was
performed. Plasmid extraction was performed by an alkaline lysis
method. Transfer of cefepime resistance was attempted using solid, liquid
and ﬁlter mating methods with E. coli J53 AzR as recipient. Typing was
carried out by PFGE (using XbaI and Bln1) and VNTR.
Results: All isolates were multidrug resistant with 4 antibiograms
observed. PFGE using Xba1 and Bln1 and VNTR analysis identiﬁed
14, 8 and 13 proﬁles respectively. Each isolate harboured 2 to 5
plasmids ranging 8.6 kb to 135 kb. blaTEM-1 and blaOXA-1 were the
only b-lactamase encoding genes identiﬁed and b-lactamase enzymes of
corresponding isoelectric point’s (pI’s) of 5.2 and 7.2 were observed in
all 18 isolates. Class 1 integrons of 800 bp or 2000 bp were observed in
all isolates. Class II integrons were not detected. A link between OXA-1
and ISCR1 was observed in all isolates. Transfer of cefepime resistance
by conjugation was not achieved. Cloning of blaOXA-1 into pBK-CMV
and transformation into XL1 cells did not result in expression of the
‘cefepimase’ phenotype.
Conclusions: This unusual phenotype of resistance is present in a
genetically diverse group of S. Typhimurium. The identiﬁed bla genes do
not account for the observed phenotype. OXA-1 effectively hydrolyses
cefepime but is not markedly inhibited by clavulanic acid and transfer of
the blaOXA-1 gene into E. coli did result in the “cefepimase” phenotype.
The genetic basis for the resistance is not yet fully characterised but may
be related to expression of OXA-1 in the speciﬁc genetic context of these
strains.
Central nervous system infections
P1221 Implementation of adjunctive dexamethasone improves
outcome in pneumococcal meningitis
M.C. Brouwer °, J. de Gans, S.G.B. Heckenberg, L. Spanjaard, D. van
de Beek (Amsterdam, NL)
Objective: We compared clinical characteristics and outcome in adults
with community-acquired pneumococcal meningitis before and after the
introduction of adjunctive dexamethasone (DXM) therapy.
Methods: We compared two Dutch prospective nationwide cohort
studies on community-acquired pneumococcal meningitis. We selected
patients with cerebrospinal ﬂuid (CSF) culture proven meningitis: 352
consecutive patients were enrolled in the period 1998–2002 before
routine DXM therapy was introduced, and 279 patients were enrolled in
the period 2006–2008 after guidelines recommended routine use of DXM
in the Netherlands. Outcome was graded with the Glasgow Outcome
Scale and a score of 4 or less was considered unfavourable.
Results: Baseline characteristics were similar between both cohorts:
mean age was 58 and 59 years for cohort I and II, respectively
(p = 0.74); median score on Glasgow Coma Scale 10 and 10 (p = 0.73);
hemiparesis 12% and 12% (p = 0.57); heart rate 100 and 100 (p = 0.71);
and median thrombocytes count 199 and 197 per L (p = 0.97). DXM was
administered in 59 (17%) patients in cohort I and in 252 (92%) patients
in cohort II (p< 0.001). DXM was started with or before the ﬁrst dose
of antibiotics in 1% and 82% respectively (p< 0.001). In cohort II, 217
(80%) received a 4 day regimen of DXM started before or with ﬁrst
dose of antibiotics as recommended in the guidelines. The proportions
of patients with systemic complications were similar between cohorts
(38% vs 42%; p = 0.29), whereas neurologic complications were less
likely to occur in cohort II (78% vs 68%; p = 0.03). The proportions of
patients with unfavourable outcome (50% vs 39%; P = 0.005), hearing
loss (22% vs 11%; p< 0.001), or death (30% vs 22%; p = 0.02) were
signiﬁcantly smaller in cohort II as compared to cohort I.
Conclusion: 1) Adjunctive dexamethasone has been implemented for
pneumococcal meningitis in the Netherlands. 2) Implementation of
adjunctive dexamethasone had improved outcome in pneumococcal
meningitis.
P1222 Central nervous system involvement is common in acute
Puumala virus infection
S-M. Ma¨ho¨nen °, T. Sironen, O. Vapalahti, E. Pa¨a¨kko¨, A. Karttunen,
N. Hautala, V. Glumoff, O. Vainio, H. Kauma, A. Vaheri, A. Plyusnin,
T. Hautala (Oulu, Helsinki, FI)
Objectives: Puumala virus (PUUV) causes a haemorrhagic fever with
renal syndrome called nephropathia epidemica (NE). Recent case reports
and retrospective studies have revealed a potential connection between
acute NE and central nervous system (CNS) complications. Viral
meningitis, encephalitis, cerebral haemorrhage and hypophyseal injury,
for example, have been reported. Based on these recent observations,
our goal was to explore the frequency and nature of such complications
prospectively in patients with acute NE.
Methods: 58 patients with serologically proven acute NE volunteered
for the study at Oulu University Hospital during 2005–2007 (approval by
ethical committee of the Oulu University Hospital). CNS symptoms were
recorded and urine, blood, and cerebrospinal ﬂuid (CSF, 42 patients)
samples were collected. The patients underwent magnetic resonance
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imaging (MRI) of the brain (41 patients), electroencephalography (EEG,
33 patients), and examination by an ophthalmologist. The blood, CSF,
and urine samples were analyzed for PUUV using reverse-transcription
PCR (RT-PCR). The CSF samples were analyzed for white blood cell
count, glucose, and protein level.
Results: Majority of the patients (50 patients, 86.2%) suffered from
symptoms typical of CNS involvement (headache, vomiting, and
dizziness). MRI of brain showed abnormalities of any degree in 23 of
41 patients and seven of them involved hypophysis. We received 42 CSF
samples and 21 of them had abnormal protein level, and/or white blood
cell count. The PCR reaction was positive for PUUV in one CSF sample
only. The EEG ﬁndings were normal in all patients.
Conclusion: CNS-related symptoms such as headache, dizziness and
vomiting were common ﬁndings in acute NE. A high number of ﬁndings
in brain MRI were recorded and their clinical signiﬁcance requires
further evaluation. Signs of inﬂammation were common in the CSF
although only one CSF sample was positive for PUUV. Because of severe
thrombocytopenia, the samples were most likely collected too late during
the course of the illness to recover PUUV from the CSF. Based on our
results, we conclude that acute NE caused by PUUV affects the CNS
commonly.
P1223 In vitro comparison of bacterial permeability of different
epidural catheter ﬁlters
A. Sener °, Y. Erkin, A. Tasdogen, E. Dokumaci, Z. Elar (Izmir,
Canakkale, TR)
Objectives: The rate of infection occurrence is approximately 5.4%
during epidural analgesia/anaesthesia administration. Requirement for
bacteria ﬁlters to reduce the infection risk is one of the most debated
topics. Conﬂicting results have been reported for the effectiveness of
different ﬁlters for short and long term use with the epidural catheters.
Methods: We aimed to compare the effectiveness of different ﬁlters
(Portex™, Rusch™) in ﬁltering bacteria Staphylococcus aureus (ATCC
25923) and Pseudomonas aeruginosa (ATCC 27853) using Patient
Controlled Analgesia (PCA) pump in an in vitro model and Scanning
Electron Microscope (SEM) was used to prove ﬁltration of bacteria.
Bacteria suspensions (0.5 McF of S. aureus and P. aeruginosa) are
prepared in 250mL isotonic NaCl. Two different bacteria suspensions
and control groups (sterile 250mL isotonic NaCl) are ﬁltered using 2
different types of ﬁlters (n = 60) for 48 hours at a infusion rate of 5mL/h
by using PCA pump and collected in a sterile bottle. Bacterial colonies
were counted from the samples taken from the bottles (n = 60) and
ﬁlters (n = 60). The results were compared with Mann-Whitney U test.
A p value of <0.05 is accepted signiﬁcant.
Results: Structures of the membranes in the ﬁlters and bacterial
adherence were investigated using SEM and recorded. We observed that
the structure of Rusch™ ﬁlters were ﬁbrous and scattered, Portex™
ﬁlters were granular and compact. According to colony numbers counted
from the bottles that represents the epidural space in clinics we
established that Portex™ ﬁlters are 18 times more effective than Rusch™
ﬁlters (p = 0.0001). The presence of some bacteria in the solutions in the
bottles shows that neither of them were 100% safe.
Conclusion: As a conclusion; although they are not completely
conﬁdential the ﬁlters can be used as a barrier to prevent occurrence
of infection. We think that all the ﬁlters should be compared with a
similar methodology before they are used in routine clinical practice.
P1224 High doses of cefotaxime for cephalosporin-resistant
pneumococcal meningitis in adults. A 19-year experience
I. Cabello °, C. Cabellos, F. Tubau, R. Verdaguer, J. Lin˜ares, F. Gudiol,
P. Viladrich (L’Hospitalet de Llobregat, ES)
Objective: To evaluate the efﬁcacy of high-dose cefotaxime (CTX) in the
therapy of cephalosporin-resistant pneumococcal meningitis in adults.
Methods: Patients with suspected pneumococcal meningitis were
empirically treated in the emergency room with both high-dose CTX
(300–350mg/kg/day − maximum 24 g/day) and adjuvant therapy with
dexamethasone, manitol and phenytoin. Once the S. pneumoniae
susceptibility was known, high-dose CTX schedule was kept if a CTX
resistant strain (MIC 1mcg/mL) was isolated, or was changed to
ceftriaxone (4 g a day) in susceptible cases (MIC< 1mcg/mL). MICs
were determined by microdilution method and conﬁrmed by E-test
when available. Cases with negative cultures because of previous
b-lactamic antibiotic therapy but CSF positive antigen were considered
as susceptible and treated with ceftriaxone. The duration of antibiotic
therapy was 10 days.
Results: Between 1990 and 2008, 93 patients (58 M/35 F), mean age
62.2±15.3 (23−88), with ultimately proved pneumococcal meningitis by
positive CSF culture or positive CSF pneumococcal antigen (BINAX),
were empirically treated with high-dose CTX. 79 cases (85%) resulted
CTX-susceptible and 14 (15%) CTX-resistant − 12 cases MIC 1mcg/mL
(85.7%) and 2 cases 2mcg/mL (14.2%). High-dose CTX therapy was
kept in all CTX-resistant cases and in 4 CTX-susceptible cases with
MICs of 0.5mcg/mL. Early adjuvant therapy was similar in both groups.
Among CTX resistant cases, one case was considered a clinical but not
bacteriological failure in the ﬁfth day and then treated and cured by
adding vancomycin without sequelae. Mortality was 5 patients (35%),
all of them were patients with strains with MIC 1mcg/mL, 2 cases due
to early neurological complications and 3 cases due to late complications
after ﬁnishing meningitis therapy. Sequelae were present in 1 case and
there were no relapses. No adverse events attributable to high-dose CTX
were observed − except for phlebitis in 2 cases (14%). In no cases
intolerance caused any change in therapy.
Conclusion: High-dose cefotaxime constitutes an appropriate and safe
therapy for the majority of cases of adult pneumococcal meningitis due to
S. pneumoniae with MIC up to 2mcg/mL. However, a close surveillance
should be always taken and vancomycin should be added in case of no
rapid improvement.
P1225 Models of predicting the risk of brain herniation in
bacterial meningitis
C.N. Meyer, S. Augustesen ° (Roskilde, Holbæk, DK)
Objectives: The purpose of our study was to evaluate models predicting
a risk of brain herniation among patients with veriﬁed acute bacterial
meningitis. These models are used in daily practise to indicate when to
do a head CT scanning before lumbar puncture; ideally thus preventing
brain herniation caused by accelerated brain shift following the spinal
tap.
Methods: The predictive models originated from North-American,
British, and the Dutch guidelines (Tunkel-AR 2004, BIS algoritme
2004 (similar to Fitch-MT 2007), van Crevel-H 2002). On a national
basis, unselected patients with microbiologically and clinically veriﬁed
acute bacterial meningitis from 47 hospitals during 2 years (n = 320)
were included. Survival data and clinical data from the medical records
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were evaluated retrospectively. Two-tailed p< 0.05 indicated a signiﬁcant
difference.
Results: In 5 patients, brain herniation occurred. Among the 316 patients
with available sufﬁcient clinical data, 85% fulﬁlled the North-American
model for early CT-scanning (before lumbar puncture), but in practice
only 19% (52/269) fulﬁlling the criteria were handled accordingly. The
British model was fulﬁlled by 33% of the patients, but only 32% of
these (35/111) were handled accordingly. And very similar numbers were
found in the Dutch model (31% and 34% of these, respectively).
Antibiotics were given before lumbar puncture in 30% (6/20) of patients
suspected of meningitis, who were sent to early (before lumbar puncture)
CT scanning.
Conclusions: According to North-American guidelines, most of the
patients with meningitis should have had a CT-scan done before lumbar
puncture, though according to Dutch or British guidelines this was
recommended in much fewer patients. In a majority of suspected
meningitis patients, timely therapy before early CT-scan was not given.
Unnecessary CT scanning may still delay relevant treatment and thus
have detrimental effect in acute bacterial meningitis.
P1226 Brain herniation and the use of CT-scanning in acute
bacterial meningitis
C.N. Meyer °, S. Augustesen (Roskilde, Holbæk, DK)
Objectives: The purpose of our study was to evaluate the circumstances
surrounding brain herniation among patients with veriﬁed acute bacterial
meningitis, to analyse the use of early (before lumbar puncture) head
CT-scanning, and to evaluate whether the guidelines concerning early
initiation of therapy (before CT-scanning) were followed.
Methods: On a national basis, unselected patients with microbiologically
and clinically veriﬁed acute bacterial meningitis from 47 hospitals during
2 years (n = 320) were included. Survival data and clinical data from
the medical records were evaluated retrospectively. Two-tailed p< 0.05
indicated a signiﬁcant difference.
Results: Among 320 patients with acute bacterial meningitis, a total
of 161 CT-scans were performed, 57 CT scans were done before
lumbar puncture, and initial considerations of bacterial meningitis were
documented in 20 of these. In the other 37 cases, only other diagnostic
considerations than meningitis were documented. Five of 320 patients
(1.6%) had brain herniation. Brain herniation occurred after spinal tap
in 2 patients with no signs of brain shift on the recent CT-scan, and in
3 patients who had lumbar puncture done before the accomplishment
of a CT scan which showed signs of incarceration in 2 cases. In 4
of the 5 patients, cerebral oedema was described, and 1 CT scan was
described as normal. Though, cerebral oedema was described in 14 other
patient without brain herniation (speciﬁcity [52−14]/52=0.73). In the
20 early CT patients suspected of meningitis, antibiotic therapy was
given before CT-scan or lumbar puncture in 30% (6/20). Median time
from admission to ﬁrst relevant antibiotic dose given among the early
CT scanned patients (225 minutes) differed signiﬁcantly from the never
scanned patients (75 minutes, p< 0.001).
Conclusions: Brain herniation could not safely be predicted by CT-
scanning alone, as the sensitivity was rather low (2/5). The ﬁnding
of cerebral oedema may be seen as a radiological red ﬂag for brain
herniation with a rather low speciﬁcity (0.73). When bacterial meningitis
was suspected, the clinical guidelines were not followed satisfactorily
concerning swiftly administration of therapy without awaiting the result
of the CT scan.
P1227 Laboratory predictors of meningitis in scrub typhus
D.M. Kim ° (Gwang-Joo, KR)
Background: Scrub typhus is a febrile illness caused by Orientia
tsutsugamushi. We experienced cases of scrub typhus accompanying
meningitis, one of the rare but life-threatening complications, and
attempted to ﬁnd out laboratory predictors of the meningitis.
Methods: One hundred and ﬁfty patients who were diagnosed with scrub
typhus at Chosun University Hospital between 2004 and 2006 were
included in this study. We performed CSF analysis on scrub typhus
patients with altered mentation and severe headache, and divided the
patients into the meningitis and non-meningitis groups.
Results: Altered mentation (58.3%) and nuchal rigidity (61.5%)
occurred more frequently in the meningitis group than in the non-
meningitis group (p< 0.01). Albumin concentration was lower in the
meningitis group (3.24 g/dL ±0.45) than in the non-meningitis group
(3.6 g/dL ±0.6) (p = 0.029). No other signiﬁcant laboratory ﬁndings were
not found.
Conclusions: These results suggest that serum albumin level in scrub
typhus patients with nuchal rigidity and altered mentation may be a
simple and useful predictor of meningitis.
P1228 Meningococcal meningitis: a review of laboratory features
during an 8-year period in a general hospital
P. Giannopoulou, N. Charalambaki, I. Grafakos, A. Kyraysa,
G. Tzanakaki, J. Kremastinou, E. Trikka-Graphakos ° (Athens, GR)
Objectives: The aim of the study was to evaluate retrospectively the
laboratory features of suspected meningococcal meningitis in patients
admitted to our hospital.
Methods: During a 8-year period (2001–2008) in total 1342 CSF
specimens from 957 patients were analyzed. Acute meningococcal
meningitis has being diagnosed in 29 patients (17 children, 12 adults).
The diagnosis was established on CSF cytochemical characteristics,
positive Gram stain, CRP of blood, CSF and blood culture, detection
of antigens and multiplex PCR for CSF and blood samples. The
antimicrobial sensitivity was determined by MIC (E-test AB Biodisk,
Sweden). PCR and E-test were determined by the National Meningitis
Reference Laboratory.
Results: From the 29 patients with positive CSF samples by PCR, 12
were positive by CSF culture too, while 17 patients were CSF culture
negative. 25/29 were PCR positive in both CSF and peripheral blood
samples. 22/29 strains, half of them concerning adults, were classiﬁed
as serogroup B, with B:4P.1.14 as the predominant phenotype. Two of
the 29 were classiﬁed as serogroup C, 1/29 as serogroup A (polyvalent
group) and 4/29 as non-groupable. About 1/3 of the patients had also
positive blood culture. All strains were sensitive to penicillin, rifampicin,
cefaclor, ciproﬂoxacin, ceftriaxone and chloramphenicol.
Conclusions:
1. Bacteriological culture remains a useful tool in the diagnosis of
bacterial meningitis, the detection of Neisseria meningitidis and for
the determination of susceptibility patterns.
2. However, multiplex PCR is particulary useful in patients who
are culture(−) and/or microscopy(−), due to their prior antibiotic
treatment.
3. A dramatic decrease in serogroup C is observed in Greece, prior to
the introduction of the vaccine in 2000.
4. Serogroup B is still predominant, with an emerging shift to adult
population.
P1229 Listeria monocytogenes meningitis: clinical characteristics
and outcomes
O. Dzupova °, J. Benes, S. Polivkova (Prague, CZ)
Objectives: Listeria monocytogenes is an important cause of acute
bacterial meningitis. Compromised cellular immunity and elderly are
considered the most important predisposing factors. Listeria meningitis
is supposed to have some distinct clinical and laboratory characteristics
in comparison to meningitis caused by other bacteria. The aim of our
study was to ﬁnd out the frequency and to evaluate predisposing factors,
clinical and laboratory features and outcome of Listeria meningitis.
Methods: A longitudinal prospective study of adult patients with
community-acquired acute bacterial meningitis was carried out at the
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Infectious Diseases Department of the University Hospital Bulovka in
Prague, Czech Republic, in years 1997–2008.
Results: Twenty-six patients with L. monocytogenes meningitis were
hospitalised, what is 7.5% of the total of 348 adult patients with
community-acquired bacterial meningitis hospitalised within 12 years.
They were 12 women and 14 men with the median age of 63 years,
range 26−80 years. In all patients L. monocytogenes was identiﬁed
by culture: CSF was positive in 21 pts, blood in 11 pts and
autopsy meningeal tissue sample in 1 patient. Predisposing factors
were major immunocompromise (HIV, leukaemia, lymphoma, long-term
corticosteroids) in 9 pts (35%), age higher than 60 years in 17 pts
(65%), minor immunocompromise (diabetes, alcoholic liver disease,
autoimmunity) in 14 pts (54%) and arteriosclerosis in 16 patients (62%).
All patients presented with fever, 88% with disturbed consciousness,
79% with headache, 69% with positive meningeal signs, but only
25% with vomiting and 16% with seizures. The median count of CSF
polymorphonuclears was 790/cmm and lymphocytes 182/cmm, protein
level 2.7 g/L and glucose ratio 0.25. Mononuclear cell predominance was
present in 19% of patients. Fifteen patients (58%) recovered with no or
mild sequelae, 6 pts (23%) with moderate sequelae, 1 patient (4%) with
severe sequelae and 4 pts (15%) died.
Conclusion: Besides major immunocompromise and elderly also
minor immunocompromise and arteriosclerosis should be considered as
predisposing factors for L. monocytogenes meningitis in adults. While
there are no prominent differences in clinical manifestation and outcome
between Listeria meningitis and other bacterial meningitis in adults,
in laboratory parameters CSF leukocytes tend to be lower in Listeria
meningitis.
Pathogenesis of infections caused by
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P1230 Fibronectin stimulates Escherichia coli phagocytosis by
microglial cells
S. Ribes °, S. Ebert, T. Regen, N. Adam, S. Bunkowski, U.K. Hanisch,
S. Hammerschmidt, R. Nau (Gottingen, Greifswald, DE)
Objectives: Infections caused by Escherichia coli are common in the
clinical setting and are still associated with high rates of mortality and
long term sequelae despite antimicrobial therapy. Parenchymal microglia
are one of the effective defence systems in the brain to remove invading
bacteria contributing to the resistance of the brain. Microglia express
Toll-like receptors (TLRs) that recognize invading pathogens as well
as endogenous proteins at non-physiological concentrations such as
ﬁbronectin (Fn). Here, we hypothesized that the endogenous TLR4 ligand
Fn might protect immunocompromised patients against infections by
increasing the ability of microglial cells to phagocytose E. coli.
Methods: Primary cultures of mouse microglia were exposed to
increasing concentrations of Fn (10, 50 or 100mg/l) for 24 h. A control
group of unstimulated cells was included in all experiments. After
stimulation, supernatants were collected and stored at −80ºC until
measurement of cyto-/chemokine levels. Then, microglial cultures were
challenged with either live E. coli DH5alpha or E. coli K1 at a ratio
of 100 bacteria per cell. Phagocytosis was left to proceed for 30 and
90min at 37ºC. For phagocytosis inhibition studies, cytochalasin D (CD)
was used at 10 microM. After bacterial exposure, microglial cultures
were washed and incubated in medium containing gentamicin (200mg/l)
for 1 h to kill extracellular bacteria. Thereafter, cells were washed and
lysed with distilled water. Viable intracellular bacteria were enumerated
by quantitative plating of serial 10-fold dilutions. ANOVA (followed
by Bonferroni’s multiple comparisons test) was performed to analyse
differences between groups (n 12); p< 0.05 was considered statistically
signiﬁcant.
Results: The supernatants of unstimulated cells were devoid of
measurable amounts of cyto-/chemokines. Unstimulated microglia
ingested bacteria at a low rate. The endogenous TLR4-ligand Fn
stimulated murine microglial cultures in a dose-dependent manner
to secrete pro-inﬂammatory compounds and increase their ability to
phagocytose E. coli DH5alpha (p< 0.05 after 30 and 90min) and E. coli
K1 (p< 0.05 after 90min). CD blocked the entry of E. coli strains
by 90%.
Conclusion: Fibronectin stimulates microglia to phagocytose bacteria
in a dose-dependent manner. This approach could improve the brain
resistance of immunocompromised patients against infections caused by
E. coli.
P1231 A recombination hotspot with several genomic islands and
a high number of putative pili operons in the chromosome
of an epidemic Enterobacter hormaechei
A. Paauw, M.A. Leverstein-van Hall °, J. Verhoef, A.C. Fluit (Utrecht, NL)
Introduction: A multidrug-resistant Enterobacter hormaechei strain
(EHOS) caused a nationwide outbreak in The Netherlands. Previous
studies showed that this EHOS contained a High Pathogenicity Island
(HPI), encoding a highly efﬁcient iron uptake system and a conjugative
plasmid with multiple resistance genes. It was also shown that the
multidrug resistance phenotype was not enough to cause the strain
to become highly epidemic. To identify other features that may have
contributed to the epidemic behaviour of the EHOS the chromosome
of the EHOS was sequenced. In addition the mobility of the HPI was
investigated.
Methods: DNA of a representative isolate was sequenced using 454
pyrophosphate sequencing technology with 24-fold coverage by Roche
Applied Sciences. Resulting reads were assembled in contigs using the
454 Newbler assembler. By PCR and Sanger sequencing the number
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of contigs was reduced. The remaining contigs were concatenated
with a recognition sequence between the contigs. The concatenated
genome sequence was annoted by the JCVI Annotation Service.
Overrepresentation of each cluster of orthologous groups (COG) in the
EHOS was determined by comparing the COG distribution of the EHOS
with the COG distribution of 10 other Enterobacteriaceae.
The possibility of excision and circularisation of the HPI was investigated
by PCR using primers at sites ﬂanking all attO repeats. Obtained products
were sequenced.
Results: The chromosome consisted of approx. 4,857 kb with a GC
content of 55.4% and 4,645 open reading frames (orfs) were deﬁned.
A relatively high number of these orfs encoded proteins supposedly
involved in cell wall/membrane biogenesis (5.1%) and cell motility
(2.9%). The EHOS contained 18 operons putatively encoding 15 different
pili and one type of ﬂagella. Based on the presence of attO repeats, 5
genomic islands located next to each other were identiﬁed of which
one contained the HPI. The function of the other genomic islands is
unknown or speculative. The genomic islands could be excised from the
chromosome in different combinations demonstrating the plasticity of
this region and therefore designated a recombination hotspot (RHS).
Conclusions: The genome of the EHOS contained 1) operons that
putatively encoded 15 different pili and 2) a RHS that contained 5
genomic islands, one containing the HPI. The pili, the RHS, and the
HPI are likely important factors in niche adaptation which may have
contributed to the epidemic behaviour of the EHOS.
P1232 The siderophore yersiniabactin produced by the
high-pathogenicity island of Enterobacteriaceae reduces the
oxidative stress response of polymorphonuclear leukocytes
A. Paauw, M.A. Leverstein-van Hall °, J. Verhoef, A.C. Fluit (Utrecht, NL)
Introduction: Yersinia spp. or Escherichia coli containing the High
Pathogenicity Island (HPI) are more virulent than strains lacking the
HPI. The siderophore yersiniabactin encoded by the HPI facilitates iron
uptake, which is essential for bacterial growth. The genetic composition
of the HPI may vary between isolates. An HPI was detected in a
multidrug-resistant Enterobacter hormaechei outbreak strain (EHOS)
that caused invasive infections in over 100 patients throughout The
Netherlands.
The aim of this study was to test the hypothesis that yersiniabactin
inhibits the innate immune system at the site of infection as a result of the
competitive binding for iron between yersiniabactin, produced by HPI-
positive bacteria and lactoferrin (LF), produced by polymorphonuclear
leukocytes (PMNs). PMNs require LF-bound iron to form radicals
and peroxides to kill phagocytosed pathogens. Furthermore the genetic
structure of the EHOS-HPI was characterised.
Methods: An HPI-knockout, unable to produce yersiniabactin, was
created. Growth experiments with different iron sources were performed
using the HPI-knockout and the wild-type strain. The reactive oxygen
species (ROS) response of stimulated PMNs incubated with and without
yersiniabactin was measured with luminol. The HPI structure was
determined by PCR.
Results: Growth experiments with the EHOS and the HPI-knockout
showed that the production of yersiniabactin improved the ability
of the EHOS to obtain iron from saturated LF in an iron-depleted
environment. The use of hemin or transferrin as main iron source did not
result in growth differences. A yersiniabactin concentration dependent
reduction of the ROS response of PMNs was observed. Iron-saturated
yersiniabactin showed no reduced ROS response. The reduction of the
ROS response by yersiniabactin was less in the presence of increased
LF or transferrin concentrations.
The HPI of the EHOS had a 3′-end that was identical to the ICE of E. coli
ECO31 (HPI-ICEEc1), with the exception that in the EHOS the 3′-end
lacked the tnpA gene. This new variant was designated HPI-ICEEh1.
Conclusions: The results support the hypothesis that expression of the
HPI inhibits the innate immune system by reducing the availability of
iron for the PMN as a result of the competitive binding for iron by the
HPI-encoded yersiniabactin and host-encoded LF at the site of infection.
The EHOS contained a new variant of the HPI, designated HPI-ICEEh1,
which showed a high similarity to HPI-ICEEc1.
P1233 The genotoxin producing E. coli in the intestinal microbiota;
a new view on commensalism
F.L. Nowrouzian ° (Gothenburg, SE)
Objective: The gut microbiota contains a large amount of bioactive
substances and it is likely that intestinal microbiota plays a role in the
pathogenesis of bowel diseases that may be contributing to the increased
risk of cancer development. E. coli is a ubiquitous member of the gut
microbiota and segregates into four major phylogenetic groups, termed
A, B1, D and B2.
Group B2 strains cause the most extra-intestinal infections, and have an
increased capacity to persist in the colonic microbiota. Virulence factor
genes may be located in particular regions on the bacterial chromosome
termed pathogenicity islands such as the pks island carried by certain
phylogenetic B2 E. coli strains. Contact with E. coli strains expressing
the pks island causes DNA double-strand breaks leading to the cell death.
We have studied whether the pks island is of ecological importance for
E. coli in the intestinal microbiota, and/or is increased in strains capable
of long-term persistence.
Methods: E. coli strains sampled from colonic microbiota of 70 Swedish
infants was followed longitudinally over the ﬁrst year of life. Overall,
143 E. coli strains of which 57 resident strains persisting in the intestine
for at least three weeks and 16 transient strains were screened for the
carriage of the pks island using a duplex PCR assay (polymerase chain
reaction). These strains were previously tested for the phlygenetic origin.
Results: Totally, thirty ﬁve percent of E. coli strains (50/143) carried the
pks island of which all belonged to the phylogenetic group B2. In fact,
more than two-thirds of B2 E. coli strains (50/70) were positive for the
pks island. Among strains resident in the microﬂora, 46% carried the
pks island, while this was true for 19% of the transient strains (p = 0.08).
Conclusion: A majority of group B2 strains from intestinal microbiota
of Swedish infants carried the pks island. There was no signiﬁcant
difference concerning the carriage of the pks island between resident
and transient strains. Thus, it indicates that this bacterial trait carried
exclusively by group B2 E. coli strains does not contribute to their strong
colonising capacity in the human colon and it may not be regarded
as a ﬁtness island, on the contrary it is more likely to be an actual
pathogenicity island.
P1234 The inﬂuence of some probiotic cultures supernatants on
the growth rate and virulence expression of several selected
enteroaggregative E. coli clinical strains
V. Lazar, Y. Miyazaki, T. Hanawa, M.C. Chiﬁriuc, L.M. Ditu,
L. Marutescu °, C. Bleotu, S. Kamiya (Bucharest, RO; Tokyo, JP)
Purpose: To investigate the in vitro antimicrobial activity of three lactic
acid bacterial (LAB) strains supernatants obtained from cultures of
Biﬁdobacterium breve, Enterococcus faecium and Lactobacillus casei
of human/animal origin against enteroaggregative Escherichia coli
(EAggEC) strains isolated from diarrhoeal stools.
Material and Methods: The qualitative and quantitative study of
the inﬂuence of LAB supernatants on the adherence capacity of the
pathogenic EAggEC strains to the cellular substratum was performed
by Cravioto adapted method, in 2 variants: the simultaneous addition
of LAB supernatants and the microbial suspensions on the cellular
substratum and respectively, the addition of the LAB supernatants
after 2 hrs incubation of microbial strains and the cellular substratum.
The inﬂuence of LAB supernatants on bioﬁlm development on inert
substratum was assessed by the rapid microtiter plate method. The
cytotoxicity of the tested supernatants was assessed using a Cell
Counting kit.
Results: Our in vitro studies are demonstrating that the selected
supernatants, when added simultaneously are generally opposing to the
adherence to the cellular substratum by the enteroaggregative strains
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(10–1000 fold decrease of the viable cells and adherence indexes).
When added after the preadherence period, the supernatants dit not
change the adherence indexes of the EAggEC strains, but induced
slight changes in the adherence pattern, reducing the frequency and
size of bacterial aggregates. Only in few cases, the bacterial growth
rate was slightly increased or sustained by the probiotic supernatants; a
possible explanation could be the fact that in this study there were used
supernatants of 24 hrs fresh cultures, which are probably still containing
some nutrients and probably also other growth factors, not only inhibitory
substances, for the assay of antimicrobial activities of the probiotic
supernatants, 48 hrs cultures being more appropriate.
Conclusion: Our results are demonstrating that soluble probiotic
metabolites acumulated in culture supernatants may interfere with the
ﬁrst step of adherence and colonisation of the cellular and inert substrata
by EAggEC strains, probably by the cross-talk between probiotic soluble
molecules and quorum-sensing mediators of opportunistic strains; so
they could be used mainly in the prophylaxis, but even in the treatment
of gastro-intestinal chronic disorders, as an alternative or in association
with antibiotics.
P1235 Low virulence associated with ﬂuoroquinolone resistance
of uropathogenic Escherichia coli strains
J. Vranes °, I. Herljevic, M. Senjug, I. Butic, M. Anusic, T. Marijan,
V. Leskovar, A. Mlinaric-Dzepina (Zagreb, HR)
Objectives: Escherichia coli is the most frequent cause of urinary tract
infections (UTIs), and particular virulence characteristics are associated
with ability of strain to cause uncomplicated UTI. The aim of this study
was the characterisation of virulence characteristics of E. coli strains
isolated from urine of outpatients in Zagreb region, in dependence to
ﬂouroquinolone
sensitivity.
Materials and Methods: During the ﬁve-month study period a total of
2, 451 E. coli strains were isolated from urine of nonhospitalised patients
with signiﬁcant bacteriuria. A total of 60 ﬂuoroquinolone-resistant (FR)
and a total of 60 ﬂuoroquinolone-sensitive (FS) E. coli strains were
randomly collected and characterised. Susceptibility to antibiotics was
determined by disk-diffusion and broth microdilution method according
to NCCLS (National Committee for Clinical Laboratory Standards). For
each strain O-serogroup, adhesion type, production of haemolysin, and
the serum sensitivity were examined. Bacterial susceptibility to serum
killing was measured by assessing regrowth after incubation in serum,
the adhesins were determined by haemagglutination and inhibition of
haemagglutination, and serotyping was performed on glass slides.
Results: The range of minimal inhibitory concentrations of ciproﬂoxacin
was 8−64mg/L in the resistant group of strains. All FR strains
were co-resistant to amoxycillin, most (39) were co-resistant to
trimethoprim/sulfametoxazole, and 20 out of 60 strains were co-resistant
to aminoglycosides. Investigated virulence factors were signiﬁcantly less
frequent among resistant isolates. UTI-associated antigens were less
prevalent in FR strains than in FS strains with a high frequency of
strains with incomplete O-antigen in the resistant group in contrast
to the sensitive group of strains (p< 0.01). Haemolysin production
and adhesins expression were less prevalent in FR strains than in FS
strains as well (p< 0.01), and in 38 (63.3%) and 39 (65%) of resistant
strains adhesions and haemolysin were not detected, respectively. The
prevalence of serum-resistant strains was signiﬁcantly higher in FS group
of strains, as compared to strains isolated in FR group (p< 0.01), which
is in accordance with higher virulence and invasive potential of these
strains.
Conclusion: These results suggest the association of ﬂuoroquinolone
resistance and a decrease in the expression of virulence factors in
uropathogenic community-acquired E. coli.
P1236 Endemic clone Escherichia coli harbouring ECP common
pillus versus an outbreak clone in a patient from a hospital,
Lisbon
F. Nunes °, T. Amores, L. Lito, J. Melo Cristino, M. Jose Salgado,
M. Santos, A. Duarte (Lisbon, PT)
Objectives: The aim of this study was to compare an endemic
Escherichia coli producing CTX-M-15 extended-spectrum b-lactamases
(ESBL) with an outbreak clone E. coli producing AmpC b-lactamase,
which is maintained during only one month.
Methods: Four Escherichia coli isolates were identiﬁed in a period of
three years, from an old patient hospitalised twice times at Hospital
Santa Maria in Lisboa. The ﬁrst one collected in August 2001 from
urine, two isolates from urine and blood in April 2004 and the fourth
isolate was identiﬁed from urine one week later. Antibiotic resistance
proﬁles were determined by disc diffusion method, according to Clinical
and Laboratory Standards Institute (CLSI) and the b-lactamase genes
were identiﬁed with speciﬁc primers and sequencing. RAPD M13 DNA
ﬁngerprint and phylogenetic group was determined in order to obtain
genetic proﬁles. PCR reaction was also performed to detected genes
encoding virulence factors, including adhesins of type P (papC), 1 (ﬁmH)
and S. ﬁmbriae (sfaS), cytotoxic necrotising factor-1 (cnf-1), siderophore
biosynthesis protein (iucC), a-haemolysin (hlyA), uropathogenic speciﬁc
protein (usp) and also a subunit of ECP common pillus (ecpA).
Results: All three isolates identiﬁed from urine in August 2001 and three
years later from urine and blood in 12 April 2004 were ESBL producing
strains (CTX-M-15), exhibit the M13 ﬁngerprinting proﬁle 1, the most
prevalent in this hospital, belonged to the phylogenetic group B2,
typically associated with virulence strains, and harbour ﬁmH, iucC and
ecpA genes. The fourth isolate, an outbreak strain identiﬁed from urine
eight days after (20 April 2004), exhibit a distinct genetic proﬁle. This
strain harboured a different b-lactamase, the cephalosporinase AmpC,
exhibited the M13 ﬁngerprinting proﬁle XY, included in phylogenetic
group B1, usually associated with commensal strains and the virulence
genes were not detected including the subunit of ECP common pillus
(ecpA).
Conclusions: The endemic clone E. coli producing CTX-M-15 was
prevalent in Hospital since 2001 until present. ECP common pillus allows
the human intestine colonisation and it might confer an evolutionary
advantage, contributing to maintenance and higher prevalence of this
clone during three years in this patient compared with outbreak clone
E. coli producing AmpC b-lactamase, which was detected in four wards,
only during one month, in this hospital.
P1237 Potential role of Escherichia coli common pilus in
persistence of clinical isolates producing extended-spectrum
b-lactamase from bacteraemia and urinary tract infection
C. Caneiras, F. Nunes, J. Pissarra °, L. Lito, J. Melo Cristino, M. Jose
Salgado, A. Duarte (Lisbon, PT)
Objectives: The aim of this study was to investigate the role of E. coli
common pilus (EcpA) in extraintestinal E. coli producing extended-
spectrum b-lactamases that carrying virulence factors and are responsible
by bacteraemia and urinary tract infection (UTI).
Methods: E. coli clinical isolates identiﬁed from urine (n = 103) and
blood (n = 70) were collected between 2001 and 2007 at Hospital Santa
Maria, in Lisboa. In this study were included 26 simultaneous clinical
isolates recovered from 12 patients with both urine and blood sample
RAPD M13 DNA ﬁngerprint and phylogenetic group was determined
in order to obtain genetic proﬁles. PCR reaction was also performed to
detect a subunit of ECP common pillus (ecpA). The Fisher’s exact test
was used for categorical variables, P< 0.05 statistically signiﬁcant.
Results: The majority E. coli strains belonged to the phylogenetic
group B2 (62.5% urine Vs 65.7% blood) and group D (17.5% urine Vs
18.5% blood). Surprisingly was the fact that equal frequency (p< 0.8036,
95IC0, 6663−1.836) was detected to commensal phylogenetic group A
(15.0% urine Vs 12.8% blood), usually associated with low invasive
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capacity compared with virulence group D The B1 phylogenetic group
represent only 5% and 2.8% of urine and blood isolates, respectively.
RAPD M13 proﬁle showed a predominant clone among the E. coli
isolates (57.8%, pattern 1) while 42% were distributed among 5 patterns
(patterns 2 to 6). Within predominant and persistent (2002–2007) clone
1 the phylogenetic group B2 was prevalent although co-exist with
phylogenetic group A. Among the 2 to 6 RAPD patterns all phylogenetic
groups were represented. In 91.1% (41/45) of blood isolates were
detected the ecpA gene. The four isolates that lacked the EcpA adherence
factor were from non frequent clonal proﬁles. Also all the 26 isolates
recovered from 12 patients with UTI and bacteriaemia showed the ecpA
gene.
Conclusions: Bacteraemia and ITU are usually associated with virulent
extra-intestinal phylogenetic group B2 although this study demonstrated
high frequency of commensal phylogenetic group A in both urine and
blood isolates, suggesting that the gastrointestinal tract can be a relevant
primary source for UTI and bacteraemia. Pathogenic E. coli strains may
provide to use EcpA to mimic commensal E. coli and confer themselves
an ecological advantage for host colonisation and evasion of the immune
system.
P1238 Inﬂuence of glycosaminoglycans on Proteus mirabilis-
induced urolithiasis
A. Torzewska °, A. Rozalski (Lodz, PL)
Objectives: Infection stones account for 10−15% of all urinary stones
and represent a signiﬁcant health problem due to their high rate
of recurrence and renal tissue damage. These stones occur as a
consequence of urinary tract infection by urease-producing bacteria
such as Proteus mirabilis. Ammonia, produced by the enzymatic
hydrolysis of urea, elevates urine pH causing a supersaturation and
a crystallisation of magnesium and calcium ions as the struvite
(ammonium magnesium phosphate) and the apatite (calcium phosphate),
respectively. Macroorganisms have natural mechanisms of defence
including a presence of crystallisation inhibitors in urine. The goal of this
study was to establish a role of urinary glycosaminoglycans in struvite
urolithiasis as potential inhibitors of this process.
Methods: We used P. mirabilis strain which has been isolated from
a human renal stone. The in vitro models were provided to analyse
crystallisation and adhesion of crystals to the normal human urothelium
(Hu 609, HCV 29 and HRPTEC lines). In these models synthetic
urine was also used with or without glycosaminoglycans (GAG −
chondroitin sulfates, heparin sulfate and hyaluronic acid). Crystal
formation was examined by phase-contrast microscopy and by particle
analysis with Coulter Counter. Crystal adhesion intensity was analysed
using radioactive isotope of calcium.
Results: It was found that in the presence of all tested glycosamino-
glycans crystallisation occurred. None of the substances tested had any
signiﬁcant inhibitory effect on crystal growth. In fact, crystallisation was
enhanced in the presence of chondroitin sulfate C. It was also found that
addition of this glycosaminoglycan caused agglomeration of crystals.
Similar inﬂuence of these compounds was shown in case of crystals
adherence. Chondroitin sulfate C (ChSC) and A (ChSA) signiﬁcantly
increased crystals binding to epithelium.
Conclusion: Urinary glycosaminoglycans had no inhibitory effect on
infection-induced crystallisation. Our results showed that ChSC and
CHSA promoted crystal growth and the retention of crystals in the
urinary tract which increased the formation of urinary stones.
This work was supported by grant of Ministry of Science and Higher
Education N401 038 32/0868 (Poland)
P1239 Heat shock-induced phage shock protein A increases
Salmonella typhimurium virulence in BALB/c mice
N. Ordouzadeh °, A. Shoae Hassani (Tehran, Fars, IR)
Objectives: Salmonella typhimurium is an intracellular pathogen that
bring about thousands reported cases of acute gastroenteritis and
diarrhoea each year. Although many successful physiological and genetic
approaches have been taken to conclude the key virulence determinants
encoded by this organism, the totally number of uncharacterised reading
frames observed within the S. typhimurium genome suggests that many
virulence factors remain to be discovered. This study was conducted to
evaluate the role of heat induced phage shock protein A (PspA), in the
pathogenicity of S. typhimurium.
Methods: Salmonella typhimurium strain ATCC 14028 (PTCC 1186)
was obtained from Persian Type Culture Collection in Tehran, Iran. It
was routinely cultured on Trypticase soy agar (TSA, Difco, France).
Nine aliquot tubes (10ml) of working cultures (108 CFU/ml) were heat
stressed by immersion (3 cm above medium level in bottle) at 40ºC,
45ºC, 50ºC, 55ºC, 60ºC, 65ºC and 70ºC temperature controlled water
bath gently. The stress proteins that detected on SDS polyacrylamide
gel electrophoresis were identiﬁed speciﬁcally by immunoblotting with
polyclonal antibody against PspA. Site directed mutagenesis took place
for deletion pspA in control cells.
Results: Lethal dose of untreated Salmonella typhimurium for 50% of
female 6−8 weeks old Balb/c mice inoculated orally was 6×103 CFU. At
the point of 65ºC; stressed bacteria that has produced PspA were more
virulent (16 folds greater) to female 6−8 weeks old Balb/c mice.
Conclusion: Correspondency between decrease in LD50 and increasing
in PspA during heat stress and lower pathogenicity in non-producing
PspA cells that produced by site directed mutagenesis represents PspA
as an important virulence factor in heat stressed S. typhimurium.
A sixteen-fold difference between LD50 s of PspA producing and non-
producing Salmonella typhimurium cells to Balb/c mice.
P1240 Vibrio species utilise Acanthamoeba castellanii as an
environmental host
H. Abd °, A. Saeed, G. Sandstro¨m (Solna/Stockholm, SE)
Objectives: Vibrio is a genus of Gram-negative bacteria found in water
and it may be carried by sea living animals. The genus comprises nearly
70 species. Vibrio cholerae O1 and V. cholerae O139 produce cholera
toxin and cause cholera. V. cholerae non-O1/O139 strains and other
vibrio species such as V. parahaemolyticus, V. vulniﬁcus and V. mimicus
can cause gastroenteritis, open wounds infection, and septicaemia. The
prevalence rate of infections caused by vibrios increases globally. The
combination of increased water temperature and salinity may contribute
to increased association rates of the bacteria with sea living animals
or protozoa. Our recent studies have shown that Vibrio cholerae O1
and O139 have the ability to grow and survive in the aquatic free-
living amoeba Acanthamoeba castellanii. The aim of the current study
was to highlight interaction of different vibrio clinical isolates with
A. castellanii. Vibrio species were isolated from Bangladesh, India and
Sweden and they included V. cholerae O1, V. cholerae O139 MO10,
V. cholerae O139 SG24, V. mimicus and V. vulniﬁcus.
Methods: Acanthamoeba castellanii and Vibrio strains were alone
and co-cultivated for two weeks. Gentamicin assay was used to kill
extracellular vibrios as well as to examine ability of amoeba to
protect intracellular vibrios from antibiotic killing. Interaction between
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microorganisms was studied by viable count, necrosis assay, ﬂuorescence
microscopy, electron microscopy and statistical analysis.
Results: The results showed that Acanthamoeba castellanii grew in the
presence of Vibrio species and the amoeba numbers enhanced during 2
weeks.
Growth of the bacterial strains was enhanced signiﬁcantly in the presence
of A. castellanii compared to alone cultivated bacteria, which died within
few days.
The examined vibrio species grew intracellularly to 104–106 CFU/ml in
A. castellanii and the intracellular bacteria survived for >2 weeks.
Electron microscopy showed that the intracellular localisation of the
bacteria was in vacuoles of the trophozoites a few hours after co-
cultivation. Multiplication of bacterial cells occurred in the cytoplasm
of trophozoites one day after co-cultivation and the bacteria were found
in the cysts of A. castellanii 6 and 7 days after co-cultivation.
Conclusions: Vibrio cholerae, V. mimicus and V. vulniﬁcus grew and
survived in A. castellanii disclosing the role of acanthamoebae as
environmental hosts for Vibrio species.
P1242 In vitro study of dendritic cells maturation induced by
Helicobacter pylori strains: evaluation of the inﬂammatory
response and immunological consequences
I. Kaafarany, C. Staedel, V. Pitard, P. Blanco, J. Ferrand, F. Darfeuille,
J.F. Moreau, F. Me´graud, P. Lehours ° (Bordeaux, FR)
Objectives: Gastric MALT lymphoma corresponds to B lymphocyte
proliferation, which is organised in a lymphoid structure in the gastric
mucosa and directly linked to gastric Helicobacter pylori infection.
In this context, our aim is to investigate the role of dendritic cells
(DC) in response to H. pylori, by studying both cytokine production
and microRNAs (miRNAs) expression in well characterised ex vivo
activation conditions.
Methods: Human DCs were matured in the presence of IL-4 and GM-
CSF, and thereafter co-cultured for 48 h in the presence of H. pylori
strains isolated from either low grade gastric MALT lymphoma or
duodenal ulcer patients, at a multiplicity of infection of 10. DC surface
maturation markers (CD40, CD80, CD83, CD86, CD1a, CD197, HLA-
DR) were determined by ﬂow cytometry, and secreted cytokines by
antibody array and ELISA. The ability of H. pylori-activated DCs
to induce allogenic T lymphocyte proliferation was measured by
bromodeoxyuridine incorporation and CD3 expression, both by ﬂow
cytometry analysis. DC expression of several miRNAs was determined
on total RNAs by quantitative RT-PCR.
Results: Four gastric MALT lymphoma and 4 duodenal ulcer H. pylori
strains were tested on DCs. A signiﬁcant expression was obtained for
each maturation markers molecules. All H. pylori strains were able to
induce the production of several chemokines such as ENA-78, MIP1-
delta, MCP-1, GRO, GRO-alpha, as well as the cytokines GM-CSF,
TNF-a, IL-6, IL-7 and IL-10. A tendency was observed for IL-10 and
IL-23 to be more induced by gastric MALT lymphoma strains than by
duodenal ulcer strains. High induction of miR-155, miR-146 was also
observed, whatever the H. pylori strain. Finally, H. pylori-activated DCs
were able to induce a signiﬁcant T lymphocyte proliferation.
Conclusion: Our results show that H. pylori was able to activate DCs
ex vivo, thereby promoting T lymphocyte proliferation. We show for the
ﬁrst time that H. pylori is able to strongly induce several miRNAs that
have been implied in pathologies such as lymphoma and cancers. This
work constitutes the basis of further investigations determining whether
H. pylori gastric MALT lymphoma strains orientate the proinﬂammatory
response in a proﬁle favourable to B lymphocyte proliferation.
P1243 Relationship between prevalence of peptic ulcer and
cagA/iceA genotypes of Helicobacter pylori
I. Alipourfard °, S. Mahmoodi (Tehran, IR)
Objectives: To determine the prevalence of cagA/iceA genotypes
Helicobacter pylori (H. pylori) isolated from a group of Iranian patients
with gastric complaints, and to ﬁnd out any signiﬁcant correlation
between these strains and severe gastric clinical outcomes such as peptic
ulcer and gastric cancer in Iranien population.
Methods: A total of 918 gastric biopsies from 306 patients who
presented with symptoms suggestive of chronic gastritis, peptic ulcer
disease, or gastric carcinoma were taken from big and main hospitals in
the northern region of Tehran from March 2007 to September 2008. We
cultured the samples for H. pylori and then polymerase chain reaction
(PCR) was carried out to check for the presence or absence of cagA
gene the status of iceA genotypes.
Results: Among the 306 suspected to be infected with H. pylori by
means of clinical features and endoscopic ﬁndings; 70 patients (23%)
were positive using culture technique. Also use of PCR for determine of
the cagA gene in these samples showed the relation of the presence of
cagA and the development of cases of gastritis and ulcer was statistically
signiﬁcant (p = 0.0001). Furthermore, this study revealed that 98.2%
of ulcer cases were infected with iceA1 with a statistically signiﬁcant
correlation (p = 0.0001), while 92.5% of gastritis and 88.1% of normal
were infected with iceA2 (p = 0.0001). Moreover cagA+/iceA1 combined
genotypes was statistically correlated with peptic ulcer (100%) but not
cagA−/iceA1 (0%;p = 0.0001).
Conclusion: Certain H. pylori genotypes were more virulent than others.
Multiple clinical implications based on these ﬁnding might be studied
further.
P1244 Helicobacter pylori genetic variability and multi-drug
resistance in a case of gastric cancer
R. Grande °, M. Di Giulio, E. Di Campli, S. Di Bartolomeo, L. Cellini
(Chieti, IT)
Objective: Helicobacter pylori is involved in chronic gastritis, gastro-
duodenal ulcers, gastric cancer and MALT lymphoma development. The
virulence genes vacA, iceA and cagA play a key role in the onset
of the infection. In particular, H. pylori strains possessing the cagA
gene with repeated sequences containing EPIYA motifs are associated
to severe gastroduodenal diseases. We report a case of a patient
colonised by H. pylori and affected by gastric cancer. Multiple H. pylori
strains, possessing the main virulence factors and displaying a different
antimicrobial susceptibility pattern were harboured in the same host.
Methods: A 68 years old female patient, identiﬁed among a group
of individuals subjected to upper gastrointestinal (GI) endoscopy for
gastrointestinal compliances and previously subjected to an anti-H. pylori
therapy, was examined in this study. Two biopsies, collected from the
antrum, were analyzed for: H. pylori culture, genetic variability through
Ampliﬁed Fragment Polymorphism (AFLP); vacA, iceA, cagA virulence
status by PCR; antimicrobial susceptibility (CMI) towards the antibiotics
commonly used in anti-H. pylori therapy and for hystopathological
examination. A total of 20 clones were analyzed.
Results: The patient with gastric cancer showed a mixed infection with
the presence of at least 3 different strains. The clones isolated possessed
the main virulence factors (vacA s1m1, iceA1, cagA EPIYA P1P2P3P3)
and a pattern of multi-drug resistances were evidenced in the different
clones.
Conclusion: The data obtained in this study conﬁrm the correlation
between the severity of the disease and the presence of a greater number
of cagA EPIYA motifs. In particular, the presence of multiple H. pylori
strains colonising the same patient, with the main virulence factors and
different multi-drug resistance among isolates, point out the role of
genetic variability generating, in time, more virulent and adapted strains.
All these data emphasize the need for a careful H. pylori antimicrobial
surveillance to improve management of H. pylori infection.
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P1245 Circulating plasmablasts with reactivity against individuals’
own intestinal microbiota in patients with acute appendicitis
S. Pakkanen °, N. Palkola, N. Rossi, R. Puohiniemi, J. Kantele,
A. Kantele (Helsinki, Jyvskyla¨, Turku, FI)
Objectives: The microbes found in inﬂamed appendix belong to the
normal microﬂora of the intestine, but they appear to become causative
microbes in appendicitis. We wanted to see what kind of an immune
response is mounted against these microbes. We looked for microbe-
speciﬁc circulating plasmablasts in patients with appendicitis.
Methods: 13 patients with acute appendicitis were investigated.
Microbes were cultured from each patient’s own inﬂamed appendix
samples. Peripheral blood mononuclear cells (PBMC) were isolated and
microbe-speciﬁc ASC were enumerated using ELISPOT, where cells are
secreting antibodies in microtiter plate wells coated with bacteria isolated
from each patient’s own inﬂamed appendix after appendicectomy.
Results: In patients with appendicitis, 1−4 microbe strains were isolated
from the inﬂamed appendix. Microbe-speciﬁc antibody-secreting cells
appeared in the circulation in all patients with appendicitis. In most
cases the response was dominated by IgA-ASC. In polymicrobial cases,
the magnitude of the response varied between the pathogens.
Conclusions: Microbe-speciﬁc antibody-secreting cells appear in the
circulation in patients with appendicitis. This immune response is
dominated by the mucosal Ig-isotype, IgA. Variations in the magnitude of
the response between pathogens may reﬂect different clinical signiﬁcance
of the microbes.
P1246 Cloning and characterisation of EngA, a GTP-binding
protein from Mycobacterium tuberculosis H37Rv
M. Laxman Singh °, R. Laxman Singh (New Delhi, IN)
Guanine nucleotides are critical elements and key signaling molecules.
Many members of G protein family bind and hydrolyze such nucleotides,
particularly GTP, and regulate the intracellular level of GTP and GDP.
The structure and sequence motifs of the GTPase are highly conserved
in all organisms ranging from prokaryotes to eukaryotes. These proteins
act as molecular switches and modulate between GTP bind (active)
and GDP bind (inactive) conformations. These proteins are known to
play diverse roles in the life cycle of both prokaryotes and eukaryotes.
Comparative genomic approach was used to predict homologs of GTPase
in Mycobacterium genome. Amino acid sequence alignment of EngA of
M. tuberculosis H37Rv with three other homologous bacterial proteins
have shown that EngA of M. tuberculosis H37Rv has signiﬁcant
homology with EngA of other bacteria and DXXG motif, which is
a characteristic feature of all known GTPases is also conserved in
the EngA of M. tuberculosis H37Rv. In the present study, EngA of
M. tuberculosis H37Rv was cloned and expressed in E. coli, Puriﬁed
protein showed GTP binding and hydrolysing activity. This study,
conﬁrmed that newly cloned and expressed homologs not only had
G protein functionality but that known key residues in well-established
G proteins were also key residues in the homologs, thus indicating
that these homologues are indeed G proteins as well. Studies are in
progress to understand the physiological signiﬁcance of these proteins
in M. tuberculosis H37Rv.
Gastrointestinal infections
P1247 One-year perspective study on prevalence and
characterisation of diarrhoeagenic Escherichia coli isolated
from children, beef and cattle in Tehran, Iran
F. Jafari °, M. Tajbakhsh, P. Torabi, M. Azizmi-Rad, M. Arabshahi,
H. Dabiri, Z. Nochi, A. Dezfolian, M.M. Aslani, L. Kashi, M.R. Zali
(Tehran, Ghom, IR)
Objective: Several routes exist for human infection with Diarrhoeagenic
Escherichia coli (DEC) and Meat and it’s products remains a main
sources. The purpose of this study was to investigate the prevalence
of ﬁve important categories of DEC in Cattle faeces, Beef and children
with acute diarrhoea in Tehran, Iran.
Method: From November 2007 to 2008, four hundred and sixty six
samples, including 222
Cattle faeces collected from healthy cattle (1−3, 4−6 and >6 months) in
farm, 104 beef samples at the slaughterhouses and 140 stool specimens
from children (Age categories: 0−6, 7−12, 13−24 and 25−60 months)
with diarrhoea, who reffered to Tehran children’s hospital were tested.
All samples were investigated and identiﬁed for DEC and their virulence
genes (stx1, stx2, eae, Lt, St, ial, ipaH, bfp, ttc, O157, H7, SOD and
a-hly genes) by Conventional and Molecular techniques.
Result:A total of 270 (58%) of 466, one hundred and sixty seven (75.2%)
of 222 faecal samples which, collected from healthy cattle in farm, 81
(77.8%) of 104 beef samples at the slaughterhouses and 13 (9.2%) of
140 stool specimens from children with diarrhoea were positive for the
stx genes (STEC). Of the 270 STEC isolates, 15% harboured the stx1
gene, 23% harboured the stx2 gene and 62% carried both stx1 and stx2
genes. The eae gene, was signiﬁcantly associated with the stx1 and stx2
genes in Meat samples (38%) and Cattle faeces (51%). 98 of 167 STEC
positive, which were detected from animal faeces were carried eae gen
(58.7%). Enteropathogenic E. coli (EPEC) strain was isolated from 23%
of bovine faeces, 19% of beef samples, and 14.1% of stool specimens of
children. A PCR indicated that 6.8%, 5%, 14%, 10.7% and 13.6% strains
carried the a-hly, lt/st, ipaH, ial and Pcvd432 genes in stool specimens
of children respectively. SOD gene was positive in 18.6%, 17.3% and
37.43% of STEC strains, wich are detected from Children, Meat and
Cattle faeces respectively. Bloody diarrhoea was observed in 30.7% of
children’s stool.
Conclusion: The Result showed the most common DEC in children was
Enteropathogenic E. coli (14.1%) and STEC was isolated from large
number of the Meat samples (77.8%). Since the STEC are spread only
via faecal excretion, at present it is most important to reduce the faecal
shedding and to avoid faecal contamination of food of animal origin. In
detail prophylactic hygienic measures concerning the Farm management,
the Feeding hygiene, the Meat hygiene as well as Food hygiene are need.
P1248 Bacterial causes of gastroenteritis in the Netherlands:
ten-year trends
A. Ott °, B. Kesztyu¨s, R. De Boer (Groningen, NL)
Objectives: To study the epidemiology and time-trends of bacterial
gastroenteritis.
Methods: Analyses of all routine stool cultures performed from 1997 up
to 2006 in a laboratory covering a catchment population of almost one
million persons. Antibiotic sensitivity of detected pathogens was tested
according to NCCLS criteria.
Results: A total of 105,179 stool samples were cultured. Of these 9.7%
was positive with Campylobacter, Salmonella, Shighella or Yersinia
species, or Escherichia coli O157. Of all positives 12.6% appeared to
be (a) repeat culture(s). Campylobacter and Salmonella species were
the most prevalent pathogens, found in 5.7% and 3.8%, respectively. In
0.9% of the positive specimens more than one pathogen was detected.
Women sent in more samples than men (56% versus 44% of total), but
men were more often positive than women (11.2% versus 8.6%). The
highest proportion of positive cultures was found in age-category 10 to
20 years (14.7%), the lowest in under 1 and over 80 years (5.6% and
3.8%, respectively). February was the month with lowest and August
with highest number of positive cultures (465 and 1402, respectively).
Over time, the number of samples for culture remained constant. There
was a clear trend of decreasing incidence of Salmonella, from 457
newly positive persons in 1997 to 221 in 2006. The decrease was most
pronounced in age group zero to ﬁve: 154 new cases in 1997 to 51
in 2006. In Campylobacter species a trend was observed of increasing
ﬂuoroquinolone resistance: from 25% in 1997 to 47% in 2006.
Conclusion: Salmonella infections are gradually decreasing, particularly
in the under-ﬁve population. In 10 years time Campylobacter
ﬂuoroquinolone resistance doubled to almost half of all isolates.
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P1249 Analysis of the gut microbiota of irritable bowel syndrome
patients and healthy volunteers using selective media and
Real-Time PCR
V. Vankerckhoven °, C. Lammens, S. Chapelle, A. Vanderstraeten,
N. Hens, G. Molenberghs, H. Goossens (Wilrijk, Hasselt, BE)
Objectives: It has been hypothesized that disturbances in the intestinal
ﬂora could be a factor in the onset and persistence of IBS complaints.
The aim of the study was to analyse the faecal ﬂora of IBS patients and
healthy volunteers and to investigate differences in its composition.
Methods: Faecal samples were collected from IBS patients (n = 55)
fulﬁlling the Rome II criteria and age and gender-matched healthy
volunteers (n = 30). Microbial populations (Bacteroides, anaerobes,
biﬁdobacteria, coliforms, clostridia, and lactobacilli) were enumerated
using selective and differential media. Total bacterial counts were
performed using DAPI for 28 volunteers and 26 IBS patients to date.
Bacterial DNA was analysed by quantitative RT-PCR for the detection of
biﬁdobacteria, Clostridium coccoides and Clostridium leptum of 22 IBS
patients and all healthy volunteers. Statistical analysis was performed
using an unpaired T-test in case of normal distribution or Kruskal-Wallis.
P< 0.05 was considered statistically signiﬁcant.
Results: Large inter-individual variations in the composition of the
faecal ﬂora were observed in both groups. Total bacterial counts were
>1010 cfu/g faeces in most samples. The largest populations were
composed of strict anaerobes, biﬁdobacteria and Bacteroides, followed
by clostridia. Lactobacilli were found at an intermediate level. Total
bacterial counts were signiﬁcantly higher for IBS patients than for
healthy volunteers (P = 0.002). Also, signiﬁcantly higher amounts of
lactobacilli were observed in IBS patients than in healthy volunteers
(P = 0.03). In contrast, healthy volunteers had signiﬁcantly higher
amounts of anaerobes (P = 0.04) and biﬁdobacteria (P< 0.001) than IBS
patients.
Using RT-PCR, no statistically signiﬁcant differences were seen between
healthy volunteers and IBS patients, although the latter showed a trend
for lower amounts of biﬁdobacteria than healthy volunteers (P = 0.05).
This ﬁnding could be further conﬁrmed by analysing a larger number of
IBS patients.
Conclusions: The dominant microbial populations in the faeces of both
healthy volunteers and IBS patients were similar. Both quantitative
plating and Real-Time PCR results indicate the presence of quantitative
alterations in the gut microbiota of IBS patients. The combination of both
quantitative plating and quantitative Real-Time PCR provides a targeted
approach to enumerate and identify bacterial populations and enables us
a better understanding of the GI tract ﬂora.
P1250 Irritable bowel syndrome among a cohort of European
travellers to low income destinations
R. Pitzurra, A. Tschopp, C. Hatz °, R. Steffen, M. Mu¨tsch (Zurich, CH)
Objectives: To determine the risk of irritable bowel syndrome (IBS)
among European travelers to low income countries and to investigate
classic traveller’s diarrhoea (TD) and other potential risk factors.
Methods: Adult travellers consulting our travel clinic for pre-travel
health advice were invited to participate in a cohort study before
leaving to a high risk TD destination for a maximum of 8 weeks
between July 2006 and January 2008. Participants were investigated
about demographics, travel and health characteristics by means of
questionnaires pre-travel (Q1), immediate post-travel (Q2) and 6-months
post-travel (Q3). Exclusion criteria included pre-existing functional
gastrointestinal disorders and antibiotic prophylaxis. IBS and related
symptoms were assessed pre-travel and 6-months post-travel according
to Rome III criteria.
Results: Among 3,100 travellers enrolled (Q1), 2,800 (90.3%) concluded
Q2 and 2,440 (78.7%) were eligible for the ﬁnal analysis. Classic TD was
reported by 837 returning travellers (34.3%). Symptoms compatible with
IBS were recorded in Q3 in 31 (1.3%) travellers and a 2-weeks-of-stay
incidence of 0.9% was estimated. In a preliminary multivariate analysis
classic TD was an independent risk factor of IBS (RR 4.8, 95%CI
2.2−10.4). Additionally, age, newcomers to tropics and subtropics and
reported consumption of potentially contaminated food and beverages
signiﬁcantly increased the risk of IBS. No signiﬁcant difference was
found for gender, travel duration, travel destination and education.
Conclusions: The incidence of travel-related IBS in Europeans is lower
than the one in other populations.
P1251 Randomised health-point surveillance of human
gastro-intestinal parasites among patients attending a
teaching hospital in Ishaka, Uganda
E. Agwu °, G. Tananyen (Ishaka, UG)
Background/Objective: The upsurge of: poverty; shortage of clean
drinking water; poor nutrition, health education, health-facilities,
personal and environmental hygiene in sub-Saharan Africa has raised
infection due to human gastro-intestinal parasite to a public health
dimension. This study was designed to determine the prevalence of
intestinal parasites among patients attending KIU-TH Ishaka, Bushenyi,
Uganda.
Materials and Methods: Standard parasitological methods were used
under aseptic conditions to screen stool samples for intestinal parasites.
Seventy six (26 males and 50 female) out patients diagnosed with
lower abdominal pain and gastro-intestinal discomfort at KIU-TH were
recruited for this investigation. Patients on anti parasitic agents were
excluded. Chi square was used to test for statistical signiﬁcance of result
obtained. (p = 0.05).
Results: The overall prevalence of parasites was 52 (68.4%). The most
prevalent parasites were Entamoeba histolytica 17 (22.4%) followed
by Entamoeba coli 11 (14.5%) and Ascaris lumbricoides 7 (9.2%).
Giardia lamblia 2 (2.6%) and Trichomonas hominis 2 (2.6%) were
equally prevalent while the observed 7.9% co-infection of Ascaris
spp and E. histolytica was the highest co-infection rate followed by
3.9% co-infection of Ascaris lumbricoides and Giardia lamblia, 2.6%
Trichomonas hominis and Ascaris lumbricoides. There was similar
male/female prevalence ratio (69.2%: 68.0%) of intestinal parasites. Most
patients above 10 years were peasant farmers. The highest age speciﬁc
prevalence (89.5%) was observed among age group 21−30 years. This
was followed by 81.8% of patients, 41−50 years of age; 80.0% in age
group 11−20 years; 61.5% in age group 31−40 years; 60.0% in age group
51−60 years and 50.0% in age group >60 years. There were statistical
signiﬁcant differences (p< 0.05) when occupation, sex and age groups
were tested depicting their role in the epidemiology of parasitic infections
in the studied population.
Conclusion: Intestinal parasites were highly prevalent (68.4%) and
Ascaris spp and Entamoeba histolytica occurring both as single
and mixed infection are the most predominant parasites causing
lower abdominal pain and intestinal discomfort in Bushenyi. Parasitic
prevalence were signiﬁcantly (p< 0.05) dependent on age, occupation
and sex. More studies are needed to determine prevalence in different
age and occupational settings. Intervention strategies are paramount in
reducing infection to barest minimum.
P1252 The cost-effectiveness of hospital closure to control
norovirus outbreaks
Z. Sadique °, B. Lopman, B. Cooper, J. Edmunds (London, UK)
Objective: To estimate the cost and cost effectiveness of hospital ward
closure policy to control norovirus outbreak in the UK hospitals.
Methods: Intensive gastroenteritis surveillance data has been used to
investigate the transmission of norovirus within the hospital. On the
basis of the parameters from transmission model an epidemiological
model was constructed to ﬁnd out the outbreak of norovirus in a
hospital environment. Economic analysis was based on the outcome of
the epidemiological model. This analysis measured the costs and beneﬁts
of hospital closure, where the policy intervention was to close a ward
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when there is a outbreak. The closure policy was varied between 1, 3,
and 5 days since ﬁrst notiﬁcation of outbreak.
Results: Uncontrolled norovirus outbreaks are estimated to cost an
acute hospital around £0.12 million yearly. The cost of intervention,
i.e., closing wards to new admissions varies between £0.5 million to
£0.9 million depending on the effectiveness of closure in controlling
within hospital transmission of infection, and also when ward closure is
put into place.
Conclusion: Ward closure helps to avoid signiﬁcant amount of clinical
cases. Closure of wards reduces cases by around 50%, which has
important implication for both hospital and patient in terms of saving
resources.
P1253 Real-time comparison of Listeria monocytogenes PFGE
proﬁles of human and food isolates for enhanced
epidemiological investigation of listeriosis
S. Lukinmaa °, L. Rantala, M. Kuusi, T. Johansson, A. Siitonen
(Helsinki, FI)
Objectives: In Finland, the number of Listeria monocytogenes cases has
varied from 20 to 50 with an average incidence of 7 cases per million
inhabitants annually. In the Enteric Bacteria Laboratory of the former
National Public Health Institute (KTL), now the National Institute for
Health and Welfare (THL), all human L. monocytogenes isolates have
been PFGE- (pulsed-ﬁeld gel electrophoresis) typed since 1990 and small
infection clusters are detected every year. However, in most of the cases
the source of infection has remained unclear for several reasons and
a press release was usually given to inform consumers to avoid risk
products. In Finland, certain PFGE types have been strongly connected
with vacuum-packed ﬁshery products and, therefore, intensiﬁed hygiene
measures have been implemented in ﬁshery establishments. As well,
in early 2008, the Finnish Food Safety Authority Evira started a one
year national monitoring programme focusing on vacuum-packed ﬁshery
products at the retail level. Furthermore, to enhance the detection
of infection clusters and rapid tracing of the source of infection,
THL and Evira started a real-time comparison of PFGE proﬁles of
L. monocytogenes isolates from humans and foodstuffs.
Methods: All PFGE proﬁles of human isolates and those associated with
Evira’s national survey as well as those from ofﬁcial control samples
sent by the regional food control laboratories to Evira are included in
the comparison study. The AscI-PFGE typing is carried out using the
PulseNet protocol.
Results: During January–September 2008 among 32 human and 331
food isolates (from 166 samples), 12 and 42 different PFGE types were
found, respectively. Seven of the human PFGE types were simultaneously
detected in food, mainly in ﬁshery products. PFGE type 7, which caused
an infection cluster of ﬁve cases in August–September, was not isolated
from food during this study period. Of the human PFGE types found,
four have not been discovered in food.
Conclusion: The laboratory-based surveillance and comparison of the
PFGE proﬁles will be continued to gain more knowledge of the real-time
biodiversity of infective L. monocytogenes population in foodstuffs. The
data produced will enhance the epidemiological investigations to ﬁnd
out the sources of infection clusters. Supposedly, ﬁsh is one of the main
sources, however, the epidemiological links are missing. Furthermore,
our data also showed that certain types have only been detected in human
samples.
P1254 The prevalence of diseases associated with Helicobacter
pylori in St. Petersburg, Russia at present
R. Ferman, A. Zhebrun, O. Balabash, A. Svarval ° (St. Petersburg, RU)
Helicobacter pylori infection is a matter of pressing concern of the
Russian Public Health
In 2008 we conducted serological tests of 463 individuals including
129 children and adolescents aged 0−19 and 334 adults aged
20−82. The screening of patients with chronic gastritis, chronic
gastoduodenitis, peptic ulcer, malignant neoplasms in gastrointestinal
track and individuals without clinical manifestations of Helicobacter
pylori infection was carried out.
Methods: IgG screening for H. pylori and Cag A H. pylori antibodies
was performed using ELISA method.
Results: The results of the screening showed that 48 examined children
and adolescents (37.21%) and 164 examined adults (49.10%) possessed
antibodies for toxin-associated protein Cag A H. pylori. Antibodies for
bacterial H. pylori antigen were discovered in the screening of 45.74% of
the examined children and adolescents and of 66.51% of adult patients.
Thus, up to 20% of non-toxigenic strains of H. pylori are circulating
among the population and play a role in the development of diseases.
We can conclude that the lowest rate of infected individuals (25%) is
deﬁned in the age group 0−5 years old, whereas for 6−12 years old group
this rate is 35%, and the adolescents’ group aged 13−19 showed 50%
rate of the infection. The infection rate among adults is maximum in the
20−29 y.o. group and in 30−39 y.o. group which is correspondingly equal
to 52.27% and 54.83%. The number of H. pylori infected individuals is
decreasing to some extent with age − the infection rate goes down to
49.08% for individuals over 50 years old. Therefore, adolescents and
young people can be considered to be the main risk group for the
prevalence of H. pylori infection and diseases associated with it, i.e.
the inverted character of age-dependent dynamics of H. pylori infection
was identiﬁed.
Conclusions: Contemporary epidemic situation regarding H. pylori
infection can be characterised by high circulation rate of this pathogen
microorganism and by no evidence of the infection rate decrease among
young generations, in other words, the conducted study did not show
any signs of so-called “cohort effect” that have been observed in some
countries in Western Europe and North America. The ﬁndings correlate
with an increase of the diseases associated with H. pylori among
children and adolescents. Further consideration of these peculiarities of
the contemporary epidemic situation is necessary.
P1255 Gene mutations of 23S rRNA and rdxA deletion associated
with clarithromycin & metronidazole resistance in
Helicobacter pylori strains isolated from UAE patients
M. Alfaresi °, W. Altayyari, A. Elkouch (Abudhabi, Alain, AE)
Objective: To determine the prevalence of antibiotic resistance genes
(mutation in 23S rRNA gene in clarithromycin, and deletion in RdxA
gene in metronidazole) among H. pylori strains isolated from U.A.E
patients by using molecular methods PCR and Sequencing.
Methods: DNA was extraxted from antral gastric biopsy samples from
90 dyspeptic patients. Primary screening for H. pylori were done by Clo
test at endoscopy department in Zayed Military Hospital (ZMH). All
samples were conﬁrmed for positive H. pylori by PCR. Mutations of
the corresponding gene were studied by PCR and sequencing technique.
DNA sequence editing and analysis were performed by ClustalX, version
2.
Results: Out of 90 biopsy samples 26 were positive for H. pylori by PCR
were as 22 by clotest. Resistance to clarithromycin and metronidazole
was detected in 9 (34.6%) and 3 (11.5%) of strains, respectively. Of the
clarithromycin resistant strains, 22.22% had the A2142G mutation in the
23S rRNA gene, 55.56% A2143G, and 11.11% A2143C and 11.11%
of highly changed in sequence. Of the metronidazole resistant strains,
deletion in rdxA gene was detected in 3 strains which were negative for
Clo test.
Conclusion: A signiﬁcant proportion of gastric mucosal biopsies
obtained in the UAE is positive for Genes associated with Clarithromycin
and Metronidazole resistance(mainly in Clarithromycin). A2143G
remains the most prevalent point mutation involved, thus suggesting that
new therapeutic strategies are needed.
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P1256 Resistance to antibiotics of Helicobacter pylori strains from
patients after treatment failure
M.T. Mascellino °, M. Margani, M.P. Hassemer, A. Oliva (Rome, IT)
Objectives: Aim of our work was to evaluate the “in vitro” resistance
of Helicobacter pylori (Hp) in patients who underwent from 2 to 9
empiric therapy cycles after a wash-out period of at least 4 weeks with
no antibiotic and anti-reﬂux therapy.
Methods: The population consisted of 25 out-patients, in whom at least
two eradication regimens for Hp infection had failed. Due to the different
distribution of the microrganism in the stomach, biopsy specimens were
drawn from different sites (antrum, fundus, corpus) and inoculated on
Pylori Selective agar. The bacteria identiﬁcation was performed by
oxydase, urease and catalase tests. Antibiotic susceptibility was tested
by Kirby-Bauer and E-test for metronidazole (MZ), levoﬂoxacin (LEV),
tetracycline (TE), claritromycin (CLA) and amoxicillin (AMX).
Results: From a total of 75 specimens (3 for each patient), 32 strains
of Hp were isolated in 14 subjects out of 25 (56%) (3 antritis and 11
pangastritis). CLA and MZ showed the highest resistance: 56.26% (18
strains) and 71.87% (23 strains) respectively. Resistance to both AMX
and LEV was found in 18.76% (6 strains); resistance to TE corresponded
to 15.62% (5 strains) but with a higher number of intermediate (9.38%).
No discrepancies between the two methods used were observed except
for MZ concerning 2 strains that showed resistance only by E-test. Out
of the 11 patients with pangastritis, 81.8% (9/11) showed a concomitant
colonisation of the 3 gastric regions. The resistance to the same antibiotic
from each gastric region resulted to be different in 2 subjects.
Conclusion: The presence of mutant resistant bacteria can be due to the
prolonged and continuous exposure to antimicrobial agents during the
infection with consequent treatment failure or to the use of excessively
low doses of antibiotics during the initial treatment. K-B and E-test
provide comparable results for Hp when testing for the antibiotics tested
with reduced reliability for MZ. In fact the E-test may over-estimate
MZ-resistance because of the presence of intermediate MIC levels. Dual
resistance to both MZ and CLA was found in 16 patients (64%). LEV
appears a promising alternative for Hp refractory infections. A distinct
pattern of antibiotic sensitivity of isolates belonging to different districts
of the stomach (heteroresistance) was noticed in 22.2% of cases. The
presence in the same patient of Hp strains either S or R to various
antimicrobial agents, may interfere with the outcome of the therapy.
Table 1. Distribution of MICs (mcg/ml) and sensitivity, intermediate and resistance values for 32 Helicobacter
pylori isolates from 25 patients under consideration.
Antibiotic 0.5 0.5−15 2−3.5 4−7.5 8−32 48–128 256 MIC
cut-off
S, % (N) I, % (N) R, % (N)
MZ 0 2 4 3 16 4 3 8 21.88 (7) 6.25 (2) 71.87 (23)
CLA 6 8 6 4 4 3 1 2 40.62 (13) 3.12 (1) 56.26 (18)
TE 10 9 8 3 2 0 0 4 75.00 (24) 9.38 (3) 15.62 (5)
AMX 16 10 3 3 0 0 0 2 78.12 (25) 3.12 (1) 18.76 (6)
LEV 8 10 4 4 3 3 0 8 81.24 (26) 0 (0) 18.76 (6)
Legenda: MZ = Metronidazole; TE = Tetracycline; LEV = Levoﬂoxacin; CLA = Clarithromycin; AMX =
Amoxicillin.
P1257 Different strains of pathogenic Yersinia enterocolitica dis-
tributed among wild boars and domestic pigs in Switzerland
M. Fredriksson-Ahomaa °, S. Wacheck, R. Bonke, M. Koenig, A. Stolle,
R. Stephan (Oberschleissheim, DE; Geneva, Zurich, CH)
Objectives: Domestic pigs are an important reservoir of human
pathogenic Yersinia enterocolitica in many countries including Switzer-
land. In the past years, wild boar population has increased considerable
in Europe and at the same time outdoor rearing of domestic pigs
has become more popular. High density of wild boars and increasing
number of outdoor pigs increase the risk of transmission of zoonoses
between wild boars and domestic pigs. The aim of this study was to
compare pathogenic Y. enterocolitica strains isolated from wild boars
and domestic pigs in Switzerland.
Methods: Fourteen pathogenic Y. enterocolitica strains from wild boars
were compared with 78 strains from domestic pigs. The wild boar
strains were isolated from tonsils of 14 out of 153 (9%) animals shot in
Switzerland between October 2007 and March 2008. The domestic pig
strains were isolated from tonsils of 72 out of 212 (34%) pigs at slaughter
in Switzerland during February and March 2006. The strains were bio-
and serotyped. The presence of several virulence genes (ail, yst, hreP,
virF and yadA) were studied by PCR and the genotype was studied by
PFGE using NotI, ApaI and XhoI enzymes. Additionally, antimicrobial
resistance analysis against 16 antimicrobial agents was performed with
disc-diffusion test.
Results: No bioserotype dominated among wild boar strains but
bioserotype 4/O:3 dominated (91%) among domestic pig strains.
The wild boar strains belonging to human pathogenic bioserotypes
carried all virulence genes studied. Some (25%) of the domestic pig
strains belonging to bioserotyep 4/O:3 were negative for plasmid-
borne virulence genes. All wild boar strains were resistant to
amoxicillin/clavulanic acid but all domestic pig strains of bioserotypes
4/O:3 and 2/O:9 were sensitive. All wild boar strains were sensitive to
sulphametoxazol, trimethoprim and trimethoprim/sulfamethoxazole but
some (4) of the domestic pig strains showed resistance. All genotypes of
wild boar strains differed from domestic pig strains. Especially strains
belonging to bioserotype 4/O:3 were clearly different with all three
enzymes.
Conclusions: Distribution of human pathogenic bioserotypes and
resistance to amoxicillin/clavulanic acid among wild boar strains was
different from domestic pig strains. Furthermore, all genotypes of wild
boar strains differed from domestic pig strains, which indicates that wild
boars and domestic pigs so far are reservoirs for different strains of
human pathogenic Y. enterocolitica.
P1258 Is Clostridium difﬁcile 027 more virulent than other
ribotypes? Report of the ﬁrst outbreak of Clostridium
difﬁcile ribotype 027 in East of England: correlation of
outbreak and non-outbreak ribotypes with severity of disease
N. Elumogo °, T. Hegarty, G. Vautier, T. Chinniah, L. Hawtin,
L. Warner, B. Rechel (Gorleston, Beccles, UK)
Objective: James Paget University Hospital (JPUH) is a 550 bedded
medium-sized acute General Hospital in the coastal town of Great
Yarmouth, East of England serving a population of approximately
225,000 people which increases signiﬁcantly during the holiday seasons.
We report an outbreak of Clostridium difﬁcile 027 Infection, the ﬁrst in
the East of England. The outbreak occurred between December 2006 and
14th April 2007 and affected 221patients. We correlate clinical severity
of disease and outcome with ribotypes.
Method: The outbreak was recognised due to rising numbers of cases
and rapidly progressive clinical disease. Fifty six patients were diagnosed
in the community and 165 patients were in or associated with the
JPUH. Control measures were formulated using the Clostridium difﬁcile
associated disease (CDAD) acronym by the ﬁrst author:
• Contact precautions and isolation in a dedicated ward
• Disinfection and cleaning with hypochlorite
• Antibiotic Prudence (restriction of quinolones, cephalosporins and
clindamycin)
• Decontamination of hands with soap & water
Results: Pre-outbreak typing (Jan and Feb 2006) showed 80% ribotype
001, 10% ribotype 106 and 10% ribotype 72, none was ribotype 027.
Outbreak strains (Jan 2006 to April 2006) showed 85% ribotype 027,
15% were made up of 6 different ribotypes. Complications and mortality
among cases of ribotype 027 were signiﬁcantly more than for non
027 strains. There was increased admission in to Intensive care unit,
7 colectomies, 35% all cause mortality and 10% attributable mortality.
Post outbreak typing showed greater diversity (11 different types)
conﬁrming cases were no longer linked. Although ribotype 027 persisted
at 40% clinical severity and mortality had reduced substantially due to
heightened awareness and prompt treatment.
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Conclusion: An outbreak of C. difﬁcile ribotype 027 occurred in JPUH.
Ribotyping undertaken before, during and after the outbreak provided
robust evidence of the exact time of introduction of ribotype 027 in to
the hospital (Summer/Autumn 2006). The availability of ribotype data
allowed us to correlate clinical severity, complications and outcome with
ribotypes. To our knowledge this is the ﬁrst report from the UK that is
able to document this correlation. We conclude that prompt diagnosis,
treatment and community follow up are crucial in reducing complications
and mortality from C. difﬁcile irrespective of the ribotype.
Figure: Clostridium difﬁcile episodes − December 2006 to December
2007.
P1259 In vitro and in vivo comparison of Clostridium difﬁcile PCR
ribotype 027 and non 027 strains
K. Truusalu °, I. Smidt, P. Hu¨tt, S. Ko˜ljalg, R.H. Mikelsaar, P. Naaber,
E. Sepp, J. Stsepetova, M. Mikelsaar (Tartu, EE)
Objectives: To compare C. difﬁcile strains of PCR ribotype 027 and
VPI 10463 in vitro and their ability to cause infection in Syrian golden
hamster model.
Methods: C. difﬁcile reference strain VPI 10463 (ATCC 43255) and
clinical strain M 13042 (PCR ribotype 027) were tested for toxicity genes
using PCR. Antagonistic activity of 14 different human lactobacilli was
assessed in vitro against the two C. difﬁcile strains by streak line method
and spot agar test. In hamster model ampicillin (60mg/kg) administration
(on day −1) was followed by inoculation with 106 vegetative cells of
C. difﬁcile (on day 0). Five hamsters were infected with VPI 10463 and
5 with C. difﬁcile 027 strains. Quantitative cultures from heart blood,
liver, spleen, small and large intestines were performed at autopsy and
histological samples were taken on day 5.
Results: Both C. difﬁcile strains harboured full set of toxin genes (A,
B, C, D, E, cdd-3, cdu-2). The inhibition zone of lactobacilli against
VPI 10463 was 0−4 (median 0.65) mm and against C. difﬁcile 027
strain 0−5 (median 2.5) mm by streak line method. Similarly, in spot
agar test C. difﬁcile 027 demonstrated higher sensitivity (median score
3 vs. 2). All hamsters from VPI 10463 group died within 48 hours,
while in C. difﬁcile 027 group two animals died within 48 h, two
within 96 h and one survived until day 5 (mortality 100% vs. 80%,
respectively). The caecal median counts of C. difﬁcile, anaerobes and
lactobacilli did not differ signiﬁcantly in VPI 10463 and C. difﬁcile 027
groups (C. difﬁcile 7.0 log CFU/g vs. 6.0 log CFU/g; anaerobes 7.5 log
CFU/g vs. 8.9 log CFU/g; lactobacilli 7.8 log CFU/g vs. 7.0 log CFU/g,
respectively). C. difﬁcile was not detected in the small intestine of the
survived hamster, in caecum the counts of C. difﬁcile and lactobacilli
were 5 log CFU/g and the count of anaerobes was 9.3 log CFU/g. In
caecum no relationship was found between the counts of C. difﬁcile,
lactobacilli and anaerobes. The main ﬁnding of histological evaluation
was hyperaemia and haemorrhages in different organs.
Conclusion: In Syrian golden hamster model the reference VPI strain
caused more rapid lethal infection as compared to the C. difﬁcile 027
strain. This could be associated with higher sensitivity of C. difﬁcile 027
strain to protective lactobacilli.
P1260 Germinate to exterminate: Susceptibility of germinating
spores of Clostridium difﬁcile ribotype 027 to desiccation
and aerobic conditions
C.J. Lowden °, L.J. Wheeldon, P.A. Lambert, D.L. Rathbone,
T. Worthington (Birmingham, UK)
Objectives: The effect of desiccation and aerobic conditions on dormant
and germinating spores of C. difﬁcile ribotype 027 in the presence and
absence of a soil load was investigated.
Methods: A controlled carrier test system was designed comprising
inoculation of stainless steel disks (1 cm2) with a spore suspension of
C. difﬁcile ribotype 027 followed immediately by the addition of 2% w/v
sodium taurocholate in thioglycollate medium. Control disks contained
spore suspensions only, without the addition of germinant. Spore
suspensions were allowed to dry on carrier disks in aerobic conditions
over the course of the experiment, (to simulate a clinical setting),
and were compared to spore suspensions which were kept hydrated.
To simulate a faecally contaminated environment, the experiment was
repeated in the presence of a soil load comprising 5% w/v tryptone, 5%
w/v bovine serum albumin, 0.4% w/v mucin in sterile 0.9% w/v saline.
Results: Germinating spores showed a 3 log (99.9%) reduction in
viability within 5 hours and up to a 4 log (99.99%) reduction over
24 hours when allowed to dry in aerobic conditions in both the presence
and absence of a soil load. Germinating spores which were kept hydrated
showed less than a 1 log reduction after 5 hours in aerobic conditions
in the presence and absence of a soil load, and up to a 3 log reduction
after 24 hours in the presence and absence of a soil load. There was no
log reduction in viability of dormant C. difﬁcile spores after 24 hours
exposure to room air in either hydrated or dried conditions, with or
without soil loading.
Conclusion: Spores of C. difﬁcile 027 exposed to an appropriate
germination solution become rapidly susceptible to desiccation and
aerobic conditions in the presence and absence of a soil load. Dormant
spores remain resistant to desiccation and aerobic conditions. Use of a
germination solution in the clinical setting may provide a novel strategy
(“germinate to exterminate”), in addition to current infection control
procedures, for controlling C. difﬁcile. Further studies are warranted.
P1261 Toxigenicity and resistance to antibiotics of Clostridium
difﬁcile strains isolated from patients of a tertiary hospital
in Greece during a six-year period
M. Orfanidou °, E. Vagiakou, E. Petrou, K. Savvidou,
P. Karabogia-Karaﬁllidis, H. Malamou-Lada (Athens, GR)
Objectives: To investigate the toxigenicity and the resistance to
antibiotics of Cd strains isolated from hospitalised patients suffering
from Cd associated diarrhoea, in a tertiary hospital in Athens, Greece,
during a six year period (3/02−3/08)
Methods: During the study period 4363 diarrhoeic stool samples were
examined for Cd using cycloserine-cefoxitin-fructose agar with 5%
egg yolk and cycloserine-cefoxitin blood agar (BD). The strains were
identiﬁed by rapid ANA II (Remel, Lenexa) and latex test (Culturette,
BD). Toxin A was detected by an ELISA (Vidas, bioMerieux) and a
chromatographic assay (ColorPac, BD). Both toxins A&B were detected
by an EIA (Premier Toxins A&B, Meridian) and a chromatographic
assay (Immunocard Toxins A&B, Meridian). Antibiotic susceptibility
testing was performed by E-test (AB Biodisk, Solna) according to the
manufacturer’s recommendations and CLSI’s breakpoints
Results: Cd strains were isolated in 362/4363 (8.3%) stool specimens.
Strains A+B+ were detected in 264/362 (72.9%), A-B+ in 50/362
(13.8%) and strains A-B- were found to be 48/362 (13.3%). The
resistance rate of the isolated Cd strains to penicillin was 81.2%,
clindamycin 58.4%, tetracycline 32.4%, while no resistance was
observed to metronidazole, vancomycin and piperacillin/tazobactam,
although one strain presented to vancomycin a high level MIC 4 mg/ml.
Especially for meropenem the resistance rate was 7.7%, while 258 strains
were tested also to ertapenem and were found to be resistant 22.3% of
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them. The resistance rate of moxiﬂoxacin and erythromycin for 268 Cd
strains was found to be 35.4% and 43.4%, respectively. Linezolid was
tested in 291 strains and all were found susceptible, while 14 strains
were also found fully susceptible to daptomycin and tigecycline. All
strains A-B+ producers were found resistant to penicillin, clindamycin
and erythromycin
Conclusions: Cd strains A+B+ were the most prevalent but there was
an increase of the A-B+ strains, as well as of non toxigenic strains.
The resistance rate to penicillin and carbapenems was high, while no
resistance was observed to metronidazole, vancomycin and linezolid
P1262 Resistance of Clostridium difﬁcile to antibiotics in a teaching
hospital in Madrid: current situation
C. Bernaola, J. Perez °, E. Amor, C. Betriu, J. Picazo (Madrid, ES)
Objectives: Metronidazole and vancomycin are the drugs of choice for
treatment of Clostridium difﬁcile (CD)-associated disease. In Spain, there
have been reports of resistance of CD to metronidazole and intermediate
resistance to vancomycin. This study aims to determine the frequency
of these resistant isolates in our hospital.
Methods: We studied the sensitivity of 100 non duplicate toxigenic
strains of CD obtained between October 2007 and October 2008
against 14 antimicrobial drugs using the microdilution method according
to CSLI guidelines. We compared the results with those from a
similar study carried out 10 years ago. We also studied sensitivity
to metronidazole, vancomycin, daptomycin, and tigecycline using the
E-test.
Results: We found 2 isolates with an MIC of 16mg/L (2%) by both
methods. All the isolates were uniformly sensitive to vancomycin,
amoxicillin-clavulanic acid, piperacillin, and piperacillin-tazobactam.
Resistance to amoxicillin, imipenem, tetracycline, and clindamycin was
greater than in the previous study. Moxiﬂoxacin showed 40% resistance.
Both tigecycline and daptomycin showed good activity, although
that of tigecycline was superior (MIC50/MIC90, 0.06/0.12mg/L and
0.25/1mg/L, respectively).
Conclusion: The ﬁnding in our hospital of 2 strains with an MIC of
16mg/L to metronidazole conﬁrms the need for surveillance of resistance
by CD to antibiotics – especially to the drugs of choice – reported in
other Spanish hospitals. Alternative drugs should be studied.
P1263 Selection and persistence of erythromycin-resistant
Campylobacter coli strains at a pig farm during and after
tylosin treatment
P. Juntunen °, H. Heiska, A.L. Myllyniemi, M.L. Ha¨nninen (Helsinki, FI)
Objectives: The use of antimicrobials in production animals is a
major cause of antimicrobial resistance in Campylobacter strains.
Erythromycin, a macrolide group antimicrobial agent, is one of the
drugs of choice for the treatment of human campylobacteriosis. Tylosin
is a macrolide group antimicrobial agent used to treat Lawsonia
intracellularis infections in pigs. Our aim was to study selection of
antimicrobial resistant Campylobacter coli strains at a farm where pigs
are treated with tylosin and persistence of the resistant strains after the
treatment.
Methods: Samples were collected from a Finnish pig farm during
the treatment of weaned pigs with tylosin between October 2007
and February 2008 (a total of 125 samples from both treated and
untreated pigs). Forty eight samples were taken a half year after the
ending of the administration of tylosin for weaned pigs in October
2008. Campylobacter were recovered by selective enrichment as well
as on CCDA selective medium. One to six Campylobacter colonies
were identiﬁed from each positive sample (390 colonies in total), and
antimicrobial susceptibility to seven antimicrobial agents (erythromycin,
ciproﬂoxacin, tetracycline, streptomycin, gentamicin, nalidixid acid and
ampicillin) was determined from one colony of every positive sample
with a microbroth dilution method (VetMIC). In addition, molecular
epidemiology of the isolates was followed by PFGE (digestion with
SmaI).
Results: Of the 173 samples, 145 (83.8%) were Campylobacter positive
and of these 145 susceptibility tested isolates, 123 (84.8%) were C. coli
and 22 (15.2%) were C. jejuni. All C. coli isolates from the animals
not treated with tylosin (n = 33) were susceptible to erythromycin. Of
the C. coli isolates collected from the weaned pigs treated with tylosin
for four days or longer (n = 49), 49% were resistant to erythromycin
(MIC 32mg/l). A half year after the ending of the administration of
tylosin, 17.0% of the C. coli isolates were resistant to erythromycin.
Conclusion: Tylosin treatment of pigs selected C. coli strains which
were resistant to erythromycin. These resistant strains seemed also to
persist at the pig farm.
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P1264 Syphilis has no virological-immunological interference with
the course of HIV disease
R. Manfredi °, L. Calza (Bologna, IT)
Introduction: The reciprocal inﬂuence of HIV infection and syphilis are
not completely understood.
Patients and Methods: After the recent evidences of a recrudescence
of sexually-transmitted diseases (STD) during HIV infection, since the
year 2001 we carried out an observational study on a cohort of over
1000 HIV-infected patients (p). Fifty-4 p (36 homo-bisexuals and 18
heterosexuals, aged 23−58 years) were identiﬁed as novel cases of
syphilis (S) (secondary S in 39 cases, primary or latent disease in the
remaining episodes).
Results: All p were assessed and treated based on standardised protocols,
and followed for the 12−24 subsequent months. Immunological data
including at least 6 months preceding S and at least 9 months following S
were available. All p save six took HAART, according to current
international recommendations. During the over-18-month observation
period, no statistically signiﬁcant trend of laboratory parameters of HIV
disease was seen in our HIV-infected p co-infected with S.
Discussion: Although interactions between S and HIV were not deeply
investigated until now, the HIV-related quantitative and functional
damage of cell-mediated immunity could modify the course of S.
Concurrently, during S an impairment of cellular migration and
clearance, and cytokine network, were documented, together with an
increased lymphoid cell apoptosis. However, it remains difﬁcult that a
non-opportunistic disease like S may trigger pathogenetic mechanisms
capable of infuencing signiﬁcantly the HIV disease course, especially
when an effective HAART treatment concurs. While we agree with the
concerns related to STD in p with HIV or exposed to HIV, differently
from literature data (Buchacz K, AIDS 2004;18:2075), in our experience
syphilis does not seem to modify the laboratory course of HIV infection.
Although health care givers should take into consideration all suspected
STD in HIV-infected p, only prospective case-control studies may
answer questions associated with the potential existence of bidirectional
pathogenetic-clinical interactions between S and HIV infection.
P1265 Misquantiﬁcations of HIV RNA level in plasma from
a cohort of 100 HIV-1 newly-diagnosed individuals
in Marseilles, south-eastern France, as assessed by an
“alternative” PCR assay
P. Colson °, J. Convert, A. Motte, C. Tamalet (Marseille, FR)
Objectives: Accurate measurements of plasma HIV-1 RNA (VL) is
essential for successful clinical management in HIV-1-infected patients.
However, the high level of HIV-1 diversity worldwide is an ongoing
challenge for primers/probes-based tests, with potential failures of VL
measurement. Therefore, objective assessments of the proportion of
underquantiﬁed VL with current commercial real-time PCR assays are
needed in unsorted clinical cohorts. We aimed at assessing the proportion
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of severe (>1 Log) VL underquantiﬁcation using our routine commercial
assay among patients in whom HIV infection was newly-diagnosed.
Methods: 100 patients in whom HIV infection was newly-diagnosed
in 2006 were studied. Comparative analysis was performed between VL
measured, in the setting of the baseline evaluation panel of HIV infection,
with the gag-based commercial Cobas Ampliprep/TaqMan Roche assay
used in our routine clinical setting and the ANRS AC11/Biocentric LTR-
based Generic HIV viral load assay. Detection thresholds for Roche and
ANRS/Biocentric assays were 1.6 and 2.4 Log copies/mL, respectively.
In case of VL difference >0.5 Log, VL was retested using both assays
on at least one plasma sample. HIV-1 pol sequences were obtained from
plasma by direct sequencing with in house protocols. HIV-1 subtype was
determined using phylogenetic analysis and the NCBI genotyping tool.
Results: 57% of patients were male. Mean age was 42±12 years.
Mean CD4-cell count was 409±308/mm3. Mean VL was 4.1±1.3 Log
copies/ml using Roche assay and 4.5±1.3 using ANRS/Biocentric assay.
Mean ANRS/Biocentric VL − Roche VL difference was 0.1±0.7 Log.
When excluding plasma samples with VL around or below the detection
threshold of the ANRS/Biocentric assay, 3 serum samples showed an
ANRS/Biocentric VL − Roche VL difference >1.0 Log (2.7, 1.4, and
1.0 Log). HIV from these 3 plasma samples was classiﬁed subtype B in
one case, CRF-02AG in another case, and could not be ampliﬁed in the
third case. One plasma sample showed a Roche VL − ANRS/Biocentric
VL difference of 1.0 Log. HIV-1 in this case was classiﬁed subtype G.
Conclusion: Severe underquantiﬁcation of VL using our routine
commercialised assay might involve 3% of patients at time of baseline
assessment. The present data question the need for systematic VL ﬁrst
measurement using two different assays. Furthermore, they emphasize
the need to set-up reference VL quantiﬁcation panels in order to test
available VL assays.
P1266 Performance of the BED-CEIA in population infected with
HIV-1 recombinant viruses CRF06 cpx and CRF06A
K. Huik °, R. Avi, M. Sadam, T. Karki, K. Denks, T. Krispin, V. Ustina,
K. Ru¨u¨tel, A. Uusku¨la, G. Murphy, I. Lutsar (Tartu, Tallinn, EE;
London, UK)
Objectives: The Calypte HIV-1 BED Incidence EIA (BED-CEIA) was
developed to overcome the HIV subtype dependence associated with
many of the assays used in the identiﬁcation of recent HIV infection.
Indirectly, the assay determines the proportion of HIV-1 speciﬁc IgG
to the total human IgG and has been used in populations containing
subtypes B, D, E and C. However, the use of this assay in populations
infected with recombinant viruses has not been described. To evaluate
the assay performance in a population infected with HIV-1 recombinant
viruses CRF06 cpx and CRF06A and to determine the prevalence of
recent infections among newly diagnosed subjects.
Methods: The blood sera were collected in subjects with the ﬁrst
positive HIV test but unknown negative test in the past (group A;
n = 122), in those with the history of positive HIV test of more than
6 months ago (group B; n = 65) and in subjects with ﬁrst positive
HIV test and known HIV negative test within last 3 months (group C;
n = 6); all nave to antiretroviral agents. The BED-CEIA was performed
as per manufacturers instructions with the optical density (OD) values
of test specimens normalised by a ratio using a calibrator to minimise
interrun variation. As per instructions samples were tested in singleton
but those with a normalised OD (ODn) 1.2 were re-tested in triplicate
and the median values were used for evaluation. An ODn value <0.8
was considered to indicate recent infection. The receiver operating
curve (ROC) was constructed using ODn data of group B and C. The
performance of curve was considered fair if the AUCROC value was
between 0.7 and 0.8.
Results: The mean SD ODn values in subgroup A, B and C were 0.70
0.69, 0.86 0.68, and 0.32 0.19, respectively. A total of 87/122 (71%)
subjects in group A, 31/65 (48%) in group B and all 6 in group C
were categorised into recent infections. The calculated sensitivity and
speciﬁcity with the NPV and PPV were 100% and 52%, 100% and
16%, respectively. The ROC curve constructed using ODn values of
subgroup B and C showed an AUCROC value of 0.77 SD 0.08. No
correlation between viral load and ODn value was observed.
Conclusion: In subjects infected with CRF06 cpx or CRF06A viruses the
BED-CEIA has good sensitivity but lacks required speciﬁcity. Whether
the poor speciﬁcity of the assay is due to the viral subtype or associated
with the frequent reinfections commonly seen in IDUs, or another reason
remains to be identiﬁed in future trials.
P1267 Study on the genotypic resistance of HIV-1 in blood mono-
cytes, CD4 T cells and plasma of HIV-infected individuals
O. Turriziani °, A. Boni, M. Bucci, F. Falasca, F. Graziano, P. Maida,
I. Mezzaroma, W. Leti, A. Fantauzzi, G. D’Ettorre, V. Vullo, G. Antonelli
(Rome, IT)
Objective: Reservoirs of HIV-1 are a major obstacle to virus eradication
and can potentially compromise the success of therapy. Then there is a
need to fully understand the molecular nature of the virus population
that persist in cellular reservoirs. This study was aimed to characterise
the patterns of resistance of HIV-1 in CD14+ monocyte, CD4+ T cells
and plasma.
Methods: Plasma, CD14+ monocyte and CD4+ T cells were collected
from 8 treatment-naive individuals and 33 treated-patients; of the latter,
10 showed undectable levels of viraemia and 23 were on virological
failure. CD14+ monocyte and CD4+ T cells were isolated using magnetic
beads for positive selection (Miltenyi Biotec). Genotyping of the reverse
transcriptase (RT) and protease gene (pro) of HIV-1 was performed using
ﬂuorescent dideoxy-terminator method (TRUGENE HIV-1-Siemens
Heathcare Diagnostics). HIV drug resistance was deﬁned according to
the HIV-1 genotypic resistance interpretation algorithm of the GUIDE
LINESTM RULE 12.0-BAYER.
Results: Comparison of the amino acid sequence of the RT and pro genes
in cell-associated variants of HIV-1 with that of the plasma revealed that
in 18 of the 23 “failing” patients (78%) drug resistance mutations were
distributed differently from one compartment to another. In only one
patient both HIV-1 in monocytes and in CD4+ T cells showed the same
pattern of mutations of the virus detected in circulating virus.
As far as concern the group of virological suppress patients, sequence
analysis was performed only on cell-associated virus, since all
individuals showed undectable level of HIV-RNA (<50 copies/ml). The
results obtained revealed that, in 80% of samples, the HIV drug resistant
variant harboured in blood monocytes was different from that archived
in CD4+T cells.
Only sequences of drug-sensitive virus were found in both compartments
of treatment-naive subjects.
Conclusions: Circulating monocytes may harbour a viral dominant
population different from the viruses circulating in the blood and
archived in other cellular compartments. HIV-infected monocytes can
be an indirect source of HIV-1 by carrying virus and differentiating
into tissue macrophage where HIV may productively replicate. Hence,
blood monocytes might serve as an indirect source of drug-resistant viral
variant.
P1268 Clinical and virological correlates of HIV-1 central nervous
system disease
E. Wey °, A. Geretti (London, UK)
Objectives: To categorise and investigate the compartmentalisation of
HIV-1 in plasma and CSF with respect to genetic divergence in a cohort
of HIV-1 infected patients with varying neurological symptoms and
signs.
Methods: A search was peformed using the WinPath system for
CSF/Plasma samples which had been received from HIV positive patients
from February 2001-September 2007. 111 CSF samples were identiﬁed
from 64 patients. For this cohort, data pertaining to CSF Microbiology,
CSF Virology, Virological and cellular correlates of HIV disease, arv
and clinical history were obtained. Viral loads in CSF and Plasma
were measured using the Abbott Realtime instrument. The use of the
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Abbott RealTime assay for the quantiﬁcation of HIV-1 viral load in
CSF, was validated using a series of dilutions of HIV-1 RNA made
from a standard solution in either negative human plasma or negative
human CSF. Patients were classiﬁed into subgroups according to log
differences between CSF and plasma viral loads and detectability in
CSF versus plasma and CSF. In order to establish whether variations
in HIV-1 RNA levels or resistance genotypes in CSF were inﬂuenced
by the variations in the therapeutic levels of antiretroviral medication
in CSF and Plasma, samples were sent for Therapeutic Drug Level
Monitoring. RNA was extracted using a Biomerieux automated extractor
(easyMAG). ViroSeqTM HIV-1 Genotyping System was used to identify
mutations in the protease and reverse transcriptase (RT) regions of the
pol gene of HIV-1, and sequencing of products was performed using a
3100 Genetic Analyser Instrument. Phylogenetic analysis was performed
using MEGA4 software.
Results: We have categorised a cohort of 64 patients in which 5 patients
demonstrated a 1 log10 difference in HIV-1 RNA viral load between
CSF and Plasma, and 5 patients demonstrated 0.5 log10 difference in
HIV-1 RNA viral load between CSF and Plasma whilst on HAART. 2
Patients demonstrated identical genotypic resistance proﬁles in plasma
and CSF with no signiﬁcant compartmental phylogenetic divergence.
Data for TDM/sequencing of V3 loop of the gp120 protein pending.
(data expected late jan 2009).
Conclusions: An important feature of CNS HIV-1 infection is that its
cumulative viral populations can diverge from those in the plasma. Issues
pertaining to HAART penetration into the CNS, and bioavailability in
CSF need to be considered when interpreting genotypic resistance in
both plasma and CSF compartments. Tdm/v3loop data pending.
P1269 Impact of HLA and related polymorphisms in the control
of HIV infection in long-term non-progressors and Elite
controllers
M. Salgado °, A. Simo´n, J.L. Vicario, S. Rodriguez-Novoa, M. Lopez,
V. Soriano, B. Rodes (Madrid, ES)
Background: The multifactorial mechanisms by which some HIV+
individuals control infection (long term non-progressors, LTNP) are
becoming more complex; in addition to viral and immunological factors,
the host genetic background plays an important role in this control.
Among the LTNP, a small group of patients “elite controllers” control
viral replication. Little is known about this subset, and data emerging
on it could further HIV pathogenesis research.
Methods: 52 HIV+ naive patients with different degrees of progression
and viral load (VL) were analyzed, of them 34 were LTNP from the
HCIII cohort (mean infection: 18.62 years; mean CD4: 657 cells/ul) and
18 were progressors. Several host genes were analyzed in DNA from
PBMCs: CCR5 and HLA were typed by PCR. HLAC rs9264942 and
HCP5 rs2395029 polymorphisms and quantiﬁcation of CCL3L1 gene
copy number were determined using real time PCR. Chi-square and
descriptive statistical analysis were performed.
Results: Mean VL in LTNP was 2.76 log cop/mL, of them 13 (38%)
had undetectable VL for more than 10 years and were considered elite
controllers (EC). Mean VL in progressors was 4.16 log cop/mL, none
was EC. No signiﬁcant differences were observed in the frequency of
CCR5delta32 nor CCL3L1 copy number in LTNP and progressors (17 vs
8%; 1.17 vs 1.27, respectively), however EC showed a tendency of having
lower CCL3L1 copy number. As expected, HLAB5701 and 2705 were
more frequent in LTNP. In addition, HLACw1203 was also associated
with LTNP and only a slight association was observed in the group of
EC and HLA-Cw0701/02.
HCP5 protective SNP was present in heterozygosis in all HLAB5701
positive patients and associated with LTNP (p = 0.021). No association
was observed between EC and presence of HCP5 SNP. As for rs9264942
SNP, differences between progressors and LTNP were seen when
present in homozygosis (41 vs 15%, p = 0.043, respectively) but not in
heterozygosis. No association with EC was observed. This SNP strongly
associated with HLACw04 and Cw07 (p< 0.0005).
Conclusion: HLA plays an important role in HIV infection control
in our group of patients due to HLA-B5701, 2705 and HLACw1203
genotypes were associated with non-progression. The presence of HLA-
C rs9264942 SNP was more related with progression indicating a
possible direct interaction with viral replication other than CTL response.
Finally, no signiﬁcant differences in host genetics have been detected
between EC and viraemic LTNP.
HLA Prog (%) LTNP (%) P value
HLA B*5701 0/16 (0) 8/29 (28) 0.04
HLA B*2705 0/16 (0) 7/29 (24) 0.04
HLA Cw0401 5/16 (31) 7/30 (23) 0.73
HLA Cw0701 5/16 (31) 6/30 (20) 0.48
HLA Cw1203 0/16 (0) 8/30 (27) 0.04
P1270 Knowledge on sexually transmitted infections of
HIV-infected patients
G. Orlando °, M. Campaniello, R. Beretta, M.M. Fasolo, A.M. Bardzki,
L. Molinari, T.S. Citriniti, G. Borreggio, M. Pellegrini, G. Rizzardini
(Milan, IT)
Objective: To verify knowledge about Sexually Transmitted Infections
(STI) among HIV infected outpatients attending a Department of
Infectious Diseases.
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Methods: Cross-sectional survey with a multiple choice questionnaire to
HIV infected outpatients attending L. Sacco University Hospital, Milan
(Italy) between Feb-Apr 2008. Scores assigned: +1 point for each correct
and −1 for each incorrect answer. Unpaired t test and one way Anova
(p< 0.05 considered as signiﬁcative) were used to compare scores among
groups.
Results: 428 patient (310 M, 113 F, 5 na) aged 44.6 y (±9.7) accepted
to participate. They were Italian (91.2%), single (70.2%), with high
level education (86.5%) who acquired HIV infection by sexual exposure
(68.1%), with a mean antiretrovirals treatment period of 8.9±6.0 y, most
of them actually on treatment (75%); mean self reported CD4 cells were
535.2/mL (±260) and HIV RNA log10 2.11 (±0.9).
Clinical, immunological and epidemiological knowledge about HIV
infection was high, while the knowledge about other STIs is less
widespread. Syphilis is reported as an STI by 91.1% of respondents
but only 20.6−29.9% can associate STIs with late complications like
sterility or cancer; only 48.6% is able to correctly deﬁne gonorrhoea;
HSV, HPV, NGU, Trichomoniasis are recognized as STI by a very low
percentage of patients.
As primary prevention of HIV/STI condom use is considered useful by
94.2% while monogamy by 33.4% of the patients. Knowledge about
vaccine primary prevention is complex and hard to deﬁne: HBV vaccine
is reported by 61.2%, HAV by 39%, HPV by 22.2%; but vaccine for
HCV (25%), HIV (7.2%), syphilis (7.9%), HSV (4%) and gonorrhoea
(3.3%) are reported too.
Older ages (>60 y), lower education level (primary vs secondary school
or university), unemployment (vs employment) and suppressed viraemia
(HIVRNA log10 <50 copies/mL) are signiﬁcantly associated to lower
scores. No signiﬁcant association were observed for sex, nationality,
marital status, years of antiretroviral treatment and CD4.
Most of the patients (71.7%) declared to need more information
especially on HPV associated diseases, other speciﬁc STIs, HIV, safe
behaviours and vaccine prevention.
Conclusions: Most of HIV positive experienced outpatients had
adequate knowledge and appropriate behaviours on HIV infections
probably for the high counselling pressure by infectious diseases
specialists of the Department. More efforts must be done to extend the
body of knowledge also on other STIs.
Figure: Scores of knowledge on HIV/STIs according to age, years on
antiretroviral treatment, CD4+ cells and HIV viraemia.
P1271 Prevalence of HIV-infection in Saudi Arabia
A. Alothman °, K. Altalhi, A. Al Saedy (Riyadh, SA)
Background: Human immunodeﬁciency virus infection affects all
societies, including the very conservative society. In the beginning
of acquired immunodeﬁciency syndrome (AIDS) era the number of
HIV-positive in Saudi Arabia was estimated by UNAIDS with prevalence
of 0.2%.
Methods: Obtaining the correct data from the AIDS program at Saudi
Ministry of Health according to the annual report of HIV-positive
patients.
Results: Between 1984 and 2001, 6046 were found to be HIV-positive,
1285 were Saudis averaging 76 new cases per year. The reported number
from the Saudi MOH was 8919 total persons who were HIV-positive at
the end of 2004. saudis were 2005 cases. The rate of annual incidence
of HIV-infection in Saudis was ranging 229–342 cases per year on
2001–2006. Between 2001 and 2006 the mean annual incidence of
HIV-infection in Saudis was 275 cases per year. The last 6 years the
new HIV infection in Saudis was 1748 cases only between early 2002
and end of 2007. The total number of HIV-positive Saudis on early
2008 was 3033 persons. The calculated HIV-infection prevalence would
be 0.02% in Saudi Arabia.
Conclusion: Reporting of HIV-infections in Saudi Arabia is better now
compared to the beginning of AIDS era “early 80’s”.
The last 6 years showed signiﬁcant increase in the number of
HIV-infected people in Saudi Arabia (1748 cases). This increase in
number should be dealt with seriously.
P1272 Mother-to-child transmission of HIV: a Portuguese
retrospective study
M. Caetano, A. Horta, O. Vasconcelos, A.P. Tavares °, R. Sarmento
e Castro (Coimbra, Porto, PT)
Objectives: Mother-to-child transmission of HIV is the most important
type of HIV infection in childhood. We analysed if the use of
antiretroviral (ARV) drugs reduced the mother-to-child transmission of
HIV and compared the results with other studies done before.
Methods: HIV infected pregnant women and their newborns, born
during from January 1992 through December 2005, followed at Hospital
Joaquim Urbano were included. Demographic, maternal, obstetric,
clinical, therapeutical data were collected retrospectively for the mother-
child pairs.
Results: Of the 158 mother-child pairs, 150 were enrolled. HIV1
was present in 94.7% mothers, HIV1+2 in 2−0% and HIV2 in 3.3%.
Heterosexual acquisition of infection was registered more often (56.7%)
than injecting drug use (39.3%). Diagnosis of HIV infection was
mainly during pregnancy (42.7%)and most mothers were asymptomatic.
Transmitter mothers knew their HIV status mainly during delivery
(57.1%) or after birth (28.6%) (p< 0.001) and arrived later at health care
system (p = 0.048). Their average CD4 cell count was lower and their
HIV level was higher. The use of ARV during pregnancy (OR:55.5) and
in the three parts (OR:58.5) were associated with a lower transmission
of HIV when compared to the absence of ARV (p< 0.001). Infected
children weight less (73.8% were <2500 g) (p = 0.045) and most of them
were born vaginally (N = 13/14). Vaginal delivery and breastfeed were
associated to HIV transmission (p< 0.001 e p< 0.05, respectively). The
rate of transmission was 9.3%. This rate has decreased through the study
years [<1994: 25%, 1994–1998: 4%, >1998: 6.8%] and after 1998 only
three mothers didn’t use ARV − two infected newborns. After delivery,
mothers stopped the use of ARV and their RNA-HIV levels had rised.
Conclusions:We found that an early diagnosis of HIV infection in young
and pregnant women, an early follow-up by the health system, the use
of antiretroviral drugs in pregnancy, intrapartum and in the newborn,
caesarean section and exclusion of breastfeed of the child were associated
with a reduction of mother-to-child HIV transmission. The low birth
weight of the newborn was found to be a factor of bad prognosis for HIV
infection. Our results suggest that the use of ARV drugs in pregnancy,
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intrapartum and in the newborn is very important and that, statistically,
reduces mother-to-child transmission of HIV. These results were similar
to other studies done before.
P1273 Kinetics of expression of activation markers in HIV-infected
adults: one-year follow-up
Z. Bartovska °, O. Beran, H. Rozsypal, M. Holub (Prague, CZ)
Objectives: HIV infection is associated with chronic immune activation
that includes changes of CD38, CD28 and HLA-DR expression on
CD8+ T cells, expression of CD154 on CD4+ T cells and CD38 and
CD27 on B lymphocytes. These changes are considered as adverse
prognostic factors and correlate with the progression of HIV infection.
The aim of the study was to analyse the kinetics of expression of
these parameters during a year follow-up and to assess the effect of
antiretroviral therapy (ART).
Methods: 48 HIV+ patients were enrolled in this prospective study
including 29 patients on ART (group A), 8 patients prior to ART
introduction (group B) and 11 patients without therapy (group C).
The control group consisted of 34 HIV- individuals. The following
parameters were analysed at the baseline and after 12 months: CD4+
and CD8+ T cell count, B lymphocyte count, HIV-1 viral load (VL) and
expression of non-speciﬁc activation markers. Immunophenotyping was
done using monoclonal Ab and ﬂow cytometry analysis.
Results: We observed signiﬁcantly higher percentages of CD8+CD38+,
CD8+CD28-, CD8+HLA-DR+ and CD4+CD154+ T lymphocytes in
all groups of HIV+ patients compared to healthy controls. The same
trend was found in comparison of non treated HIV+ patients with
patients on ART, however only mean ﬂuorescence intensity (MFI)
of CD8+HLA-DR+ differed signiﬁcantly. We observed a signiﬁcant
decrease of expression of CD154 on CD4+ T cells over the study period
in all groups. In group B, CD27 expression on B cells was also decreased.
Despite higher VL in group C compared to groups A and B after
12 months, the lack of correlation was found between the expression
of non-speciﬁc activation markers and VL.
Conclusion: Our data suggest persistent T cell activation is present in
all HIV+ groups when compared to healthy controls. The expression of
activation markers on CD8+ T cells in HIV+ patients is not signiﬁcantly
inﬂuenced by ART despite the suppressive effect of ART on VL. The
observed kinetics of CD154 expression on CD4+ T cells indicates that
this marker is the most sensitive for monitoring of chronic immune
activation.
Acknowledgement: The study was supported by the grants GAUK Nr.
18/06 and GACR Nr. 310/05/H533.
P1274 Differential risk of lipoathrophy and mitochondrial toxicity
among non-Caucasian patients treated at an AIDS centre,
Jerusalem
H. Elinav °, A. Keidar, M. Hausi-Bashan, D. Nolan, S. Herrmann,
E. Hammond, S. Maayan (Jerusalem, IL; Perth, AU)
Objectives: The choice of NRTI therapy as the optimal backbone for the
treatment of HIV patients and carriers is no longer driven exclusively
by the differential efﬁcacy of these drugs. Drug toxicity has became a
major parameter when antiretroviral regimen is prescribed.
Lipo-atrophy is one of the chronic side-effects which is clinically
manifested as progressive loss of the subcutaneous fat tissue causing
signiﬁcant cosmetic disﬁguration. Nolan et al has previously described
the effect of different NRTIs upon adipose tissue of Caucasian patients
by quantitative measurement of mitochondrial DNA depletion per gram
of adipose tissue. The toxicity was most pronounced with Stavudine.
Substantial reduction of mitochondrial DNA was also demonstrated in
patients treated with Zidovudine.
Since drug toxicity might be related to genetic and ethnic background,
these results may not be applicable to other ethnic groups such as African
patients. More over, Stavudine is widely used in Subsaharan Africa as
part of First-Line regimen, as recommended by WHO.
Aims: Cross sectional evaluation of mitochondrial toxicity as induced by
Thymidine analogues and non-Thymidine analogues in fatty tissues of
non-Caucasian HIV+ Patients volunteers treated at the Hadassah AIDS
Center.
Methods: Non-Caucasian HIV carrier and Patients treated more than
6 months with Stavudine/Zidovudine or Abacvir/Tenofovir underwent fat
tissue biopsy from the iliac crest. Samples were analyses in the Centre
for Clinical Immunology and Biomedical Statistics (CCIBS), Royal Perth
Hospital, Australia for mitochondrial DNA content per adipocytes.
Results: 11 non-Caucasion HIV patients underwent subcutaneous fat
biopsy. All the patients has been exposed to at least one Thymidine
analogue (Zidovudine-11, Stavudine-2, Diadosine-3). Mean exposure
was 50.1 months (3–132 months). The log10mean mitochondrial DNA
content was 2.6 copies/cell (SD 0.4) similar to Caucasian HIV patients
treated with Thymidine analogs-2.65 copies/cell (SD 0.36) and much
lower than the log10 mitochondrial DNA content in Caucasian HIV
patients treated with non-Thymidine analogs-3.05 copies/cell (SD 0.37)
and Caucasian HIV naive patients 2.99 copies/cell (SD 0.41).
Conclusions: In non-Caucasian HIV patients, Thymidine analogues are
as mitochondrial-toxic as in Caucasian patients. This data suggest that
Stavudine may need to be dropped as a ﬁrst line ART regimen in sub-
Saharan Africa, as has been done in the West.
P1275 HLA-B*5701 screening to avoid hypersensitivity to abacavir
F. Dutly, E. Saller ° (Zurich, CH)
Objectives: Abacavir is a highly effective reverse transcriptase inhibitor
with activity against the human immunodeﬁciency virus (HIV). However,
during the ﬁrst 6 weeks of treatment up to 8% of patients develop
an immunologically mediated hypersensitivity reaction (HSR) with
severe symptoms, which reverse only after immediate and permanent
discontinuation of abacavir. In 2002, two independent research groups
described for the ﬁrst time a correlation between hypersensitivity to
abacavir and carriage of the major histocompatibility complex class I
allele HLA-B*5701. The aim of this study was to develop a diagnostic
test, which permits accurate screening of the HLA-B locus.
Methods: Two primer pairs were designed to speciﬁcally am-
plify the HLA-B*57 gene locus. One pair ampliﬁed the entire
HLA-B*57 exon 3 while the other one ampliﬁed part of exon
2. Subsequently, the amplicons were sequenced and the geno-
type determined by comparison with the sequences available on
http://www.ncbi.nlm.nih.gov/projects/gv/mhc/main.fcgi?cmd=init.
Results: The chosen primer pairs were 100% speciﬁc allowing
discrimination between the HLA-B*57 positive and negative alleles.
The HLA-B*57 positive probes were puriﬁed and further analyzed by
sequencing. The exon 3 sequence was able to recognize the following
HLA-B*57 alleles: 0102, 0103, 02, 0301, 0302, 04, 05, 06, 07, 09, 11,
12, 13 and 14. The sequence from exon 2 allowed discrimination between
HLA-B*5710, HLA-B*5712, HLA-B5715 and HLA-B5716. However,
this method allowed no discrimination between HLA-B*570101 and
HLA-B*5708, which differ only at the very 3′-end of exon 2.
Conclusion: The hypersensitivity reaction to abacavir associates with
the locus HLA-B*5701. We developed a diagnostic test, which allows
screening of the HLA-B locus through gene sequencing. The advantage
of our assay is that we sequence nearly the entire HLA-B*57 gene and
thus identify the majority of its alleles.
P1276 A comparative study of the renal functions in HIV-infected
patients treated with or without tenofovir disoproxil
fumarate
K. Woratanarat °, C. Suankratay (Bangkok, TH)
Objectives: No prospective controlled study evaluating all renal
functions in patients receiving tenofovir disoproxil fumarate (TDF)
compared with those receiving other nucleoside analogues has been done.
Our study aimed to compare the incidence of all renal dysfunctions in
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patients receiving TDF and zidovudine (AZT) at King Chulalongkorn
Memorial Hospital, Bangkok, Thailand.
Methods: A prospective controlled study evaluating renal functions
including creatinine clearance (CrCl) and all tubular functions was
conducted in HIV-infected patients receiving either TDF- or AZT-
containing HAART regimen from February to December 2008.
Results: Of 29 patients, there were 21 and 8 patients with male to female
ratio of 13:8 and 1:1 in the TDF and AZT group. Coadministration
with non-nucleoside reverse transcriptase inhibitor or protease inhibitor
was noted in 18 (85.7%) and 3 (14.3%) patients in the TDF group,
and 7 (87.5%) and 1 (12.5%) patients in the AZT group, respectively.
Except for the higher mean CD4 cell count in the TDF group than the
AZT group (365.76 and 194.13 cells/mm3, p = 0.011), there were no
signiﬁcant differences in other baseline characteristics. Among the TDF
group, the CrCl at baseline, 3 months, or 6 months of treatment was
not signiﬁcantly different. Among the AZT group, there were also no
signiﬁcant differences in the CrCl at baseline, 3 months, and 6 months.
At 3 months of treatment, the mean change of CrCl from the baseline
(delta CrCl) (-0.5876mL/min/1.73m2 and +5.45mL/min/1.73m2 in
the TDF and AZT group, respectively) between the 2 groups was
not statistically different. The delta CrCl at 6 months of treatment
between the 2 groups was not different (+2.209mL/min/1.73m2 and
+2.225mL/min/1.73m2 in the TDF and AZT group, respectively). Both
CrCl and delta CrCl between the 2 groups were still not different even
the calculation was based on MDRD Study Equation and Cockroft-Gault
formula. Ammonium chloride loading test to assess the proximal tubular
function showed no abnormalities in the 2 groups. Diabetes insipidus,
acute renal failure, and Fanconi syndrome were not observed during the
study.
Conclusion: To the best of our knowledge, this is the ﬁrst prospective
controlled study comparing all renal functions in HIV-infected patients
receiving TDF or AZT. No differences in the incidence of renal failure
and renal tubular dysfunction between the 2 groups. However, we need
to conﬁrm our observation with longer period of treatment.
P1277 Use of tenofovir disoproxil fumarate and monitoring
of renal function among HIV-1 infected patients in a
resource-limited setting
P. Doungchalermwong, S. Sungkanuparph °, S. Watcharananan,
K. Malathum (Bangkok, TH)
Objectives: Tenofovir disoproxil fumarate (TDF) has recently been
available in Asia and renal dysfunction in patients receiving TDF has
been reported. This study was aimed to evaluate the use of TDF and
the monitoring of renal function among HIV-1 infected patients in a
resource-limited setting.
Methods: We evaluated the use of TDF in a cohort of HIV-1
infected patients who were initiated TDF either in antiretroviral-naive
or -experienced patients. Reasons for using TDF were determined and
methods and compliance of monitoring for renal function were assessed.
Estimated creatinine clearance (CrCl) by Cockcroft-Gault calculation
was used.
Results: We studied 205 patients with a mean (SD) age of 44.3 (9.4)
years and 64% male. Mean (SD) body weight was 58.5 (10.5) kgs.
Median (IQR) CD4 cell count were 389 (289–514) cells/mm3. Of all,
22% had HBV co-infection and 8% had HCV co-infection. Prior to
initiation of TDF, serum creatinine (Cr) and urinalysis were tested in
183 (89%) and 44 (21%) patients, respectively. At baseline, mean (SD)
CrCl was 85.7 (23.3) ml/min and only 1% of patients had Cr> 1.5md/dl;
4% of patients had proteinuria. Reasons for initiation of TDF included
lipodystrophy from d4T and/or AZT (51%), regimen simpliﬁcation
(20%), HBV co-infection (13%), virologic failure (10%), and adverse
events from other NRTIs (6%). Regarding antiretroviral regimens, 71%
of patients used TDF in NNRTI-based regimens while the others used
in PI-based regimens. Lamivudine was the most common NRTI used
together with TDF (86%). After initiation of TDF, 58% of patients
had been followed up for serum Cr at a median (IQR) duration of
4 (2−7) months after initiation of TDF; mean (SD) CrCl was 82.7
(25.3) ml/min and 3% of patients had Cr> 1.5md/dl. Both CrCl and
Cr were not signiﬁcantly different from baseline (p> 0.05). From linear
regression, only baseline Cr was associated with CrCl at follow-up after
TDF initiation (b = 0.844, p< 0.001). Other factors including age, gender,
weight, plasma glucose, and concomitant PI use were not associated with
CrCl after TDF initiation (p> 0.05).
Conclusion: In resource-limited setting, TDF is commonly used for
substitution of d4T or AZT secondary to lipodystrophy. It appears that
assessment of renal function prior to initiation of TDF and monitoring
of renal function after initiation of TDF are inadequate. Baseline Cr is
a good predictor for CrCl change after initiation of TDF; it should not
be omitted in resource-limited setting.
P1278 Long-term risk of pneumocystosis after earlier
discontinuation of prophylaxis among HIV-infected patients
receiving highly active antiretroviral therapy
C.Y. Cheng °, M.Y. Chen, S.M. Hsieh, W.H. Sheng, H.Y. Sun, W.C. Liu,
C.C. Hung, S.C. Chang (Taipei, TW)
Background: Primary or secondary prophylaxis for pneumocystosis
can be safely discontinued in HIV-infected patients when their
CD4 counts increase to 200 cells/mL after receiving highly active
antiretroviral therapy (HAART). However, a substantial proportion of
the patients may have to discontinue prophylaxis earlier due to adverse
effects of antimicrobial prophylaxis. Long-term risk of pneumocystosis
after discontinuation of primary or secondary prophylaxis among
HIV-infected patients before CD4 counts increase to 200 cells/mL after
HAART is rarely investigated.
Methods: Between 1 April, 1997 and 30 September, 2007, 660
HIV-infected patients who had baseline CD4 counts <200 cells/mL
and had been followed up for more than 3 months after HAART were
enrolled in a prospective observational study to examine the incidence
rates of pneumocystosis when primary or secondary prophylaxis for
pneumocystosis was discontinued before CD4 counts increased to 200
cells/mL after HAART.
Results: Of 521 patients who did not initiate any antimicrobial
prophylaxis (n = 165) or discontinued primary or secondary prophylaxis
for pneumocystosis before CD4 counts increased to 200 cells/mL
(n = 356) after HAART, 21 cases of pneumocystosis developed after a
total observation duration of 1810 persons-years [PY], with an incidence
rate of 1.16 per 100 PY (95% conﬁdence interval [CI], 0.71, 1.77).
Of 139 patients who continued primary or secondary prophylaxis until
CD4 counts increased to 200 cells/mL after HAART, 3 cases of
pneumocystosis developed after a total observation duration of 445
PY, with an incidence rate of 0.66 per 100 PY (95% CI, 0.13, 1.93).
Compared with the latter group of patients, the risk ratio of developing
pneumocystosis and all-cause bacterial infections for the former group
after earlier discontinuation of antimicrobial prophylaxis was 1.765 (95%
CI, 0.5238, 5.886) and 1.58 (95% CI, 0.9859, 2.533), respectively.
Conclusions: Long-term risk of pneumocystosis was low among
HIV-infected patients who discontinued primary or secondary prophy-
laxis before CD4 increased to 200 cells/mL after receipt of HAART
with favourable virologic and immunological responses.
P1279 Serological screening of Chagas’ disease in HIV-positive
immigrants proceeding from endemic areas in Spain
A. Rodrı´guez-Guardado °, V. Asensi, M. Rodrı´guez Pe´rez, P. Mejuto,
P. Alonso, J.A. Carto´n (Oviedo, ES)
Background: Chagas’ disease is an opportunistic infection in the setting
of HIV/AIDS. The arrival of HIV positive immigrant proceeding from
endemic areas to non-endemic countries makes possible the detection of
Chagas’ disease in this group of patients. We describe the results of a
screening program conducted in HIV + immigrant population coming
from endemic areas.
Methods: We determined anti-T. cruzi antibodies in all HIV patients
proceeding from endemic areas in follow-up at the Infectious Disease
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Unit of Hosp. Central of Asturias, during 2007. The ID-Chagas antibody
test (Particle Gel Immuno Assay − PaGIA, DiaMed-ID-) was used
as screening assay. The positive cases were conﬁrmed with a second
ELISA (Total Ag) and a nested PCR. In all the conﬁrmed cases a
protocol that included a clinical-epidemiological evaluation, chest X ray,
EKG, oesophagogastroscopy, barium enema, and echocardiography was
applied.
Results: We screened 19 HIV positive immigrants (mean age 36 years).
The procedence countries were: Brazil and Ecuador (26% each),
Colombia (21%), Paraguay, Uruguay, Argentina, Dominican Republic
and Bolivia (5.2% cases each). Two patients (10.5%) had positive
antibody test for Chagas’ disease, that was conﬁrmed in both cases. PCR
was positive in both cases. Direct microscopic examination of blood was
negative in both. The positive patients were a man coming from Bolivia
and a woman from Paraguay. Both lived in houses where the reproduction
of triatomine bugs is possible. Both were on HAART with CD4 of
348 and 456 CD4+ cells/mm3 and with HIV-1 RNA <10 copies/ml.
Both patients were asymptomatic and had normal additional studies for
Chagas’ disease.
Conclusions: The overlap of HIV and T. cruzi infection occurs not only
in endemic areas but also in non-endemic areas of North America and
Europe where the diagnosis may be even more difﬁcult. It is necessary
the realisation of screening programs in this group of population for the
early diagnostic of Chagas’ disease.
P1280 Similar aortic stiffness but decreased wave reﬂections in
human immunodeﬁciency virus-infected naive patients.
The role of subclinical inﬂammation
H. Sambatakou ° (Athens, GR)
Background: The pathogenesis of increased cardiovascular risk in
human immunodeﬁciency virus (HIV) infected patients and the role of
HIV infection, per se, as a risk factor for accelerated arteriosclerosis
remains questionable. Our aim was to investigate the impact of HIV
infection on vascular properties along with markers of subclinical
inﬂammation in HIV naive (untreated) patients.
Methods: We studied 55 HIV-infected naive patients but without AIDS
(aged 33 years, 52 males, 30 smokers) and 31 healthy individuals
matched for age, sex and smoking status. Aortic augmentation index
(AIx) and augmented pressure (AP) were assessed using applanation
tonometry of the radial artery. Carotid femoral pulse wave velocity
(PWV) was estimated by means of an automated method (Complior
SP). Moreover, in all subjects venous blood samples were drawn for
estimation of high-sensitivity C-reactive protein (hs-CRP), interleukin-6
(IL-6).
Results: HIV patients compared to controls had lower diastolic brachial
blood pressure (BP) (by 4.8mmHg, p = 0.003), higher brachial pulse
pressure (by 3.7mmHg, p = 0.045), decreased aortic systolic and diastolic
BP (by 4.6mmHg, p = 0.049, and by 5.7mmHg, p = 0.017), while there
was no difference in aortic pulse pressure and PWV values. In addition,
heart rate was increased (by 6.4 bpm, p = 0.012) and AIx along with
AP were decreased (by 6.4%, p = 0.048 and by 3.3mmHg, p = 0.010)
in subjects with HIV infection. HIV-infected patients compared with
controls had signiﬁcantly increased values of log hs-CRP (p = 0.007)
and log IL-6 (p = 0.048).
Conclusions: HIV infected naive patients without AIDS compared with
controls are characterised by similar values of large artery stiffness and
decreased wave reﬂections. Peripheral vasodilatation is suggested to be
the predominant mechanism, induced probably by the chronic subclinical
inﬂammation as reﬂected by increased inﬂammatory markers in this
setting. These ﬁndings provide further insight into the pathogenesis of
HIV-related cardiovascular risk.
P1281 Parvovirus B19 and Erythrovirus type 2 and 3
infections are infrequent in HIV-infected patients with
CD4 <500 cells/mm3 and chronic anaemia
T. Ferry, B. Hirschel, T. Dang °, P. Meylan, A. Rauch, R. Weber,
L. Elzi, E. Bernasconi, P. Vernazza, A. Calmy on behalf of the Swiss
HIV Cohort Study
Background: Eryhthroviruses, Parvovirus B19 (PVB19) and the newly
described Erythrovirus genotype 2 and 3, mainly target human erythroid
progenitors. The pattern of clinical disease due to PVB19 infection is
strongly inﬂuenced by the haematologic and immunologic status of the
host. In immunosuppressed patients, a reactivation of PVB19 may occur
and may lead to severe acute or chronic anaemia and zidovudine (AZT)
intolerance. The pathogenic role of newly described Erythroviruses is
unknown.
Objectives: We aimed at screening for Erythrovirus replication in a
large cohort of HIV-infected patients presenting with CD4 cell count
<500 cells/mm3 and chronic anaemia to test if patients with HIV
infection were at risk for symptomatic parvovirus infection.
Methods: Patients included in the Swiss HIV Cohort study from 1998
to 2007 were selected according to the following criteria: (i) persistent
anaemia (haemoglobin [Hb] level below 10.5 g/dL during at least three
months) (ii) CD4 cell count <500 cells/mm3 during the episode of
anaemia and (iii) availability of at least one frozen serum or plasma
sample during the period of anaemia. Detection and quantiﬁcation of
Erythroviruses was performed with a real-time PCR targeting the VP1
gene, a well conserved region of the Erythrovirus genomes.
Results: 428 patients were included in the study (median age 44 years,
female sex 61%, intravenous drug user 36%, median CD4 cell count 187
cells/mm3, median Hb level 9.5 g/dL, AZT exposure 41%); circulating
Erythrovirus DNA was detected in 16 of them. Viral load ranged from
18 to 6820 copies/mL and was low (<500 copies/mL) in 13 patients. No
differences were noticed after comparison of patients with or without
Erythrovirus replication with regards to route of transmission, CD4 cell
count and AZT exposure.
Conclusion: Erythroviruses infections appear to be an infrequent ﬁnding
in HIV-infected patients presenting with low CD4 cell count and chronic
anaemia, despite the use of an ultrasensitive PCR technique
P1282 Non-AIDS deﬁning malignancies in the era of combined
antiretroviral therapy
R. Manfredi ° (Bologna, IT)
Introduction: The introduction of combined antiretroviral therapy
(cART) since the year 1996, contributed to a rapid, signiﬁcant drop
of frequency of all AIDS-deﬁning opportunistic infections and some
selected AIDS-related tumours (like Kaposi’sarcoma) with a consequent,
remarkable reduction of both morbidity and mortality rates associated
with these disease complications.
Patients and Methods: Our cohort of over 1700 HIV-infected patients
followed in two connected outpatient centres by the same physician staff
were prospectively followed since the year 2000 (8 years), with special
interest focused on the diagnosis, treatment and outcome of non-AIDS
related malignancies.
Results: Among haematological malignancies other than non-Hodgkin’s
lymphoma and primary central nervous system lymphoma, we observed
three cases of acute myelogenic leukaemia and 2 episodes of Hodgkin’s
lymphoma. A greater number of solid tumours involved different organs
and sites: laryngeal cancer (5 cases, with 3 episodes of papillomatous
laryngeal cancer), rhinopharyngeal squamous carcinoma (2 cases),
adenocarcinoma of the lung (3 cases), gastric adenocarcinoma (2
episodes), oesophageal carcinoma (one patient), prostate cancer (3
cases), bladder adnocarcinoma (2 episodes) pancreatic adenocarcinoma
(one case), and pheochromocytoma (one episode). Some of these
malignancies have been reported with extremely rare frequency until
now (usually as single-case anecdotal reports), in particular before
the cART era. The patient’s age ranged from 34 to 67 years, the
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mortality rate of these last 23 episodes was very elevated (78.3%),
and occurred 4−38 months after diagnosis, despite appropriate surgical
and/or cytotoxic chemotherapy.
Discussion: The signiﬁcantly increased life expectancy of HIV infected
patients in the cART era was characterised by a proportionally increase
of non-AIDS-deﬁning tumours, which may depend on the advanced
mean patients’ age, their prolonged exposure to risk factor, the
persisting functional immune system imbalance, and probably some
direct oncogenic property of HIV itself, even when a “quantitative”
recovery of CD4+ lymphocyte count has been achieved thanks to cART.
The differential diagnosis of non-AIDS-associated tumours may be
delayed by the low clinical suspicion, and their frequency to mimick
and/or overlap infectious complications. Further epidemiological and
clinical investigation is strongly warranted to increase the awareness
of this emerging phenomenon.
P1283 Long-term effects of occult hepatitis B virus infection in
human immunodeﬁciency virus infected patients
J. Chen °, H.Z. Lu, J.X. Ma, Z.Y. Wang, R.F. Zhang, Y.F. Zheng
(Shanghai, CN)
Objective: To determine the clinical signiﬁcance of occult hepatitis B
virus (HBV) infection in human immunodeﬁciency virus (HIV)-infected
patients.
Methods: We performed a retrospective cohort study among HBV sur-
face antigen negative, hepatitis C virus antibody negative, HIV-infected
patients. Their serum samples obtained before the beginning of highly
active antiretroviral treatment (HAART) were used to amplify surface
protein region of HBV previously. Patients with HBV DNA positive
were classiﬁed as occult HBV co-infection. Hepatic transaminase levels
and CD4 T cell counts were collected at 0.5 or 3-month intervals from
the beginning of HAART. The incident rate of hepatic ﬂare was assessed
by the chi-square test or Fisher’s exact test. A P value less than 0.05 was
considered to be statistically signiﬁcant.
Results: 11 and 21 patients enrolled as occult HBV co-infection
group and HIV mono-infection group respectively were followed up for
21.9±6.7 months. CD4 T cell count increased 178.9±22.1 cell/mm3 and
146.6±21.9 cell/mm3 in occult HBV co-infected group and HIV-mono-
infected group after one year of HAART, respectively. And there was
no signiﬁcant difference between these two groups (P = 0.35). During
follow up, 72.7% (8/11) patients occurred at least once hepatic ﬂare in
the occult HBV co-infection group, it was not statistically different when
compared to 52.4% (11/21) patients in the HIV mono-infected group.
However, when excluding the ﬁrst 3 months of HAART period during
which hepatic ﬂare occurred frequently because of antiviral drug side
effects and immune restoration syndrome, this event was more frequent
in occult HBV co-infected group than in HIV mono-infected group
(63.6% versus 22.7%, P = 0.02).
Conclusions: Occult HBV infection had no impact on response to
HAART regarding immune recovery in HIV/AIDS patients. However, it
can increase the incidence of hepatic ﬂare in HIV/AIDS patients. Future
studies should determine whether occult HBV infection is associated
with other clinically important outcomes, particularly hepatocellular
carcinoma.
P1284 Non-vaccine HPV types are frequent in HIV-positive subjects
K. Protopapas °, S. Tsiodras, K. Chranioti, A. Papadopoulos,
A. Antoniadou, V. Sakka, L. Galani, P. Panagopoulos, J. Georgoulakis,
D. Kavatha, G. Koukos, I. Katsarolis, A. Spathis, P. Karakitsos,
H. Giamarellou (Athens, GR)
Introduction: We examined anal HPV infection in a cohort of HIV
infected patients and correlated cytological ﬁndings with molecular
ﬁndings and immunological parameters.
Methods: Prospective follow-up with Thin prep anal smear testing is
performed in all patients of an tertiary care centre HIV clinic. Clinical
arrays are used to identify HPV infection. Univariate and multivariate
analysis was used to identify associations between HPV detection and
demographics, cytological changes and immunological parameters.
Results: 105 pts [92.3% male, median age 38 yrs (IQR: 30.3−44.8)] with
a median duration of HIV infection of 3 yrs (IQR: 1−7.8 yrs) have been
examined. Mean value of current CD4 was 419/mm3 (IQR: 284.5–593.8)
and of current HIV viral load was 364.5 c/mL (IQR: non detected-9880
c/mL, 48/105 <50 c/mL). Cytological changes were detected in 61.5%
of the population. AIN1, AIN2, and AIN3 were diagnosed in 3.7%, 1.2%
and 2.5% of the population respectively. HPV was detected with clinical
arrays in 92.4% of the population (69.2% low risk types, 83.3% high
risk types, 59.1% mixed low and high risk types). Most frequent types
detected were HPV types 6 (40%), 53 (39%), 51 (28.5%), 11 (25.7%), 66
(22.8%), 70 (21%), eae 18 (19%). Diagnosis of a cytological lesion were
associated with HPV detection (p = 0.01). HPV positivity was associated
with decreasing age (p = 0.02), n of sexual partners (p = 0.045), and lower
CD4 counts (p = 0.02).
Conclusions: HPV infection was prevalent in this patient cohort. Non
vaccine HPV types predominated. Immunological correlates of HIV
infection appear to be important in the evolution of anal cytological
changes. Prospective follow-up of HIV pts with HPV is necessary for
the prevention of perianal malignancies.
P1285 The association between changes in depression and
adherence to highly active antiretroviral therapy among
adult HIV-infected patients in Thailand
N. Hiransuthikul °, N. Buathong, S. Tangwongchai, C. Komoltri
(Bangkok, TH)
Background: Non-adherence to highly active antiretroviral therapy
(HAART) leads to development of HIV resistance mutation and
treatment failure. Depression is a common psychological disorder among
HIV-infected patients.
Objectives: To evaluate the association of depression and cofactors with
adherence to HAART in Thai adult HIV-infected patients and to assess
the temporal association between changes in depression and adherence
to HAART.
Material and Method: A concurrent cohort study was conducted at
King Chulalongkorn Memorial hospital from October 2007 to April
2008. A total of 379 HIV-infected patients were recruited. Participants
completed seven questionnaires regarding to demographic and patients’
medication characteristics, adherence to HAART, depression status,
cognitive function, alcohol use disorder, HIV social support and
HIV-related physical symptoms.
Results: The rates of non-adherence to HAART among studied
participants at week 4, 8 and 12 were 34.6, 19.9 and 24.1 percents.
The prevalences of depression at baseline, week 4, 8 and 12 were 33.3,
32.2, 23.8 and 27.9 percents respectively. In longitudinal multivariate
analysis, statistically signiﬁcant factors associated with non-adherence
were depression (mild; adjusted OR= 16.03, 95%CI = 6.73−38.17,
moderate to severe; adjusted OR= 7.40, 95%CI = 3.10−17.64), alcohol
use disorder (adjusted OR= 4.85, 95%CI = 1.75−13.46), physician’s
not reminding the patients for adherence to HAART during clinic
visit (adjusted OR= 9.72, 95%CI = 2.99−31.61), no past history
of opportunistic infection (adjusted OR= 2.19, 95%CI = 1.08−4.46)
and using herb(adjusted OR= 3.08, 95%CI = 1.09−8.67). Changes in
depression were signiﬁcantly associated with non-adherence to HAART
(mild; OR= 3.71, 95%CI = 1.86−7.37, moderate to severe; OR= 7.20,
95%CI = 2.74−18.94).
Conclusion: Depression was common among HIV-infected patients and
was a signiﬁcant predictor to non-adherence to HAART. Physicians who
provide HAART should screen and look for depression in HIV-infected
patients and regularly emphasize the goal of HAART and the importance
of adherence to the patients.
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P1286 Non-invasive assessment of liver ﬁbrosis by measurement
of stiffness in HIV-infected patients. The signiﬁcance of the
metabolic syndrome
H. Sambatakou ° (Athens, GR)
Background/aims: There is emerging evidence that severe liver disease
may develop in HIV patients. The aetiology is multifactorial and not
completely understood, but associations with viral hepatitis co-infection,
fatty liver or HAART exposure, especially to didanosine, have been
suggested. In this study we estimated the prevalence of liver ﬁbrosis
with transient elastography and determined its predictors in a cohort of
HIV patients.
Methods: We included 133 HIV patients, including 8 HIV seropositive
patients with HBV or HCV co-infection, who are followed in our unit.
Liver ﬁbrosis was evaluated with transient elastography (Fibroscan) and a
liver stiffness of >7.4 kPa was considered to deﬁne presence of ﬁbrosis.
All patients also underwent liver ultrasonography for the detection of
fatty liver. Detailed epidemiological, anthropometrical and laboratory
data, including CD4 counts and HIV RNA levels, were recorded. Insulin
resistance was assessed by the HOMA index.
Results: Patients characteristics were: males 91%, mean age 39 years,
mean BMI 24.5 kg/m2. In total, 26 (19.5%) patients had ﬁbrosis and
65 (49%) ultrasonographic evidence of fatty liver. Ninety-two (69%)
patients had received anti-HIV treatment for a median duration of
three years. In univariate analysis, presence of ﬁbrosis was associated
with increasing age (P = 0.006) and BMI (P = 0.026), high levels
of ALT (P = 0.043) and GGT (P = 0.014), presence of hypertension
(P = 0.011), abnormal waist circumference (P = 0.009) presence of
metabolic syndrome (P = 0.007) and viral hepatitis co-infection. No
association was noted between ﬁbrosis and fatty liver, insulin resistance,
treatment regimens or treatment duration. In multivariate analysis, the
only factors independently associated with ﬁbrosis were metabolic
syndrome (OR 5.675, 95% CI 1.253−25.705; P = 0.024), increasing
age (OR 1.059, 95% CI 1.001−1.121; P = 0.048) and HBV or HCV
co-infection. In the subgroup of 53 patients without ultrasonographic
evidence of fatty liver, 7 had elastographic evidence of ﬁbrosis, but no
predictive factor could be found.
Conclusions: Liver ﬁbrosis may be found in approximately one ﬁfth of
HIV-patients and is independently associated with presence of metabolic
syndrome, increasing age and HBV or HCV co-infection. Therefore,
such patients may be beneﬁt from therapeutic intervention aiming to the
management of metabolic syndrome parameters.
P1287 Erectile dysfunction in HIV+ male patients
I. Katsarolis °, K. Protopapas, P. Panagopoulos, G. Poulakou, V. Sakka,
L. Galani, D. Kavatha, A. Papadopoulos, A. Antoniadou (Athens, GR)
Objectives: To assess the prevalence of ED and to identify potential risk
factors in a HIV(+) male population.
Methods: For a 3 month period, the “International Index for Erectile
Function” questionnaire (IIEF) was distributed to HIV+ male pts
attending the outpatient clinic for regular follow-up. Pts with recent
HAART initiation (<6mos), recent hospital admission (<1mo) and
recent HIV diagnosis (<1 y) were excluded. For each pt, ED was
assessed by the IIEF score. Demographic information, clinical data
(HAART history, comorbidities) and lab data were recorded (CD4
count, viral load expressed as logVL, thyroid function tests, FSH/LH,
prolactin and testosterone serum levels, lipid proﬁle). Mann-Whitney
and Kruskal-WallisH tests were applied for quantitative data and chi-
square test for qualitative data. Variables with P value <0.1 were entered
in a multivariate logistic regression stepwise model, calculating odds
ratios(OR), 95% conﬁdence intervals(95%CI). P values 0.05 were
considered as statistically signiﬁcant. Informed consent was obtained
from each patient enrolled.
Results: Fifty pts were originally enrolled, and 47 provided a properly
ﬁlled questionnaire. Mean pt age(±SD) was 39±11.2 ys with mean
CD4 count(±SD) 518±13.7 cells/mm3 and logVL(±SD) 2.7±1.2.
Thirteen pts were not actively on HAART (23.6%). Half of the pts
had undetectable viral load (logVL 1.7). No pt had a history of
hypertension, coronary heart disease or psychiatric illness. Smoking
was reported in 30%. In 21/47 pts (44.7%) ED of any degree was
revealed. Prevalence of ED was 21% for pts <35 ys, 55% for those
36−50 ys and 75% for pts >50 ys. Risk factors identiﬁed by univariate
analysis were age (P = 0.009), nadir CD4 count (P = 0.017), history of
AIDS (P = 0.023), more than one HAART regimens (P = 0.023) and
actively receiving a PI-based regimen (P = 0.021). No difference was
identiﬁed in the other haematological and biochemical parameters tested.
From the multivariate analysis, age (for pts <35 ys, OR 0.104, 95%CI
0.020−0.537, P = 0.007) and nadir CD4 count (for <200 cells/mm3
OR 22.121, 95%CI 1.212–403.728, P = 0.037) displayed signiﬁcant
association with the presence of ED.
Conclusions: ED is prevalent among HIV+ male pts, presenting at an
earlier age than the general population. Pts with lower nadir CD4 counts
and age >35 years present more frequently with ED. A larger number
of pts will help elucidate other possible risk factors associated with the
presence of ED in HIV+ pts.
P1288 Soluble urokinase-type plasminogen activator receptor
levels predict mortality in HIV+ patients
H. Elinav °, D. Wolday, J. Eugen-Olsen, T. Bdolah-Abram, D. Chason,
O. Naor, S. Maayan (Jerusalem, IL; Addis Ababa, ET; Copenhagen, DK)
Background: Urokinase-type plasminogen activator (u-PA) is a protein
that converts plasminogen to plasmin that is elevated in multiple
inﬂammatory processes. Its soluble receptor, su-PAR (soluble urokinase-
type plasminogen activator receptor), is a secreted surface protein
expressed on macrophages, neutrophils and endothelial cells. High serum
suPAR level has been previously suggested to predict poor outcome in
malaria, pneumococcal pneumonia, streptococcal infections, tuberculosis
and HIV.
Aims: Evaluation of the correlation between suPAR levels, CD4, viral
load (VL) and death in untreated HIV patients, as means of simplifying
the laboratory follow-up in HIV.
Methods: suPAR, viral load and CD4 levels were determined in serum
samples of 146 untreated Ethiopian HIV+ patients (the ENARP cohort)
that were followed between to 1997–2005 in Addis Abebe.
Results: No signiﬁcant correlation was found between suPAR levels and
parallel CD4 or VL in each time point of follow up. Baseline suPAR
or suPAR change during the ﬁrst year did not predict CD4 or viral load
changes during the ﬁrst year or the ﬁrst three year of follow up.
The baseline suPAR of patients that died during the follow up, was
not signiﬁcantly different from the baseline suPAR level of patients that
survived during the follow up p= 0.451, but the last suPAR measurement
before death was signiﬁcantly higher than the last suPAR measurement
of patients that did not die 5.6 vs 3.6 p = 0.001.
The last suPAR measurement was found to be a predictive parameter of
death using Logistic regression model (p = 0.003)
Conclusions: Serum suPAR levels cannot be used as a laboratory marker
replacing VL or CD4 since there is no correlation between suPAR levels
and these important and predictive parameters, but a dramatic increase
during the follow up in suPAR can indicate an impending death.
P1289 Response to anti-retroviral treatment at an AIDS
centre, Jerusalem: comparison between Ethiopian and
non-Ethiopian HIV+ patients
H. Elinav °, Z. Grossman, T. Bdolah-Abraham, T. Goslitzer,
M. Housi-Bashan, S. Maayan (Jerusalem, Tel Hashomer, IL)
Objectives: Until 2007, 4999 HIV patients were reported by the
Israel Ministry of Health, 2167 of whom (43.3%) originated from
countries endemic to HIV, mainly Ethiopia. In this study we aimed to
retrospectively compare disease, treatment and resistance patterns among
Ethiopian immigrants vs. non-Ethiopian patients treated at a regional
AIDS centre.
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Methods: Medical ﬁles of 134 patients who started anti-retroviral
treatment (ART) during 1995–2006 were reviewed. CD4 & viral load
at presentation, start of treatment and every 6 months thereafter were
recorded as well as dates of ﬁrst undetectable viral load and date of
escape from Rx. Prevalence and pattern of resistance was analyzed.
Response to ART was evaluated using repeated measure analysis, T-Test
and Mann Whitney test.
Results: Eighty-one (60.4%) of the participants were Ethiopian
immigrants, 53 (39.6%) were non-Ethiopians. Median follow-up time
was 5.5 years. After 9 years of treatment mean CD4 count in the
Ethiopian group(408.3±190.1 cells/ml) was lower than that in non-
Ethiopians (616.8±391.4; p = 0.125). Exposure to NNRTI’s and PI’s was
comparable in the two patient groups. More Ethiopians were given D4T
while more non-Ethiopian were given DDC. The prevalence of primary
resistance mutations was similar in both groups (25.9% Ethiopian
vs. 30.2% non-Ethiopian, p = 0.8). Analysing as group mutations, the
prevalence of non-TAMs (M184V K65R L74V), TAMs (M41L, D67N
K70R, L210W T215F) and PI mutations (D30N, L90M, M46I) was
similar among Ethiopians & non Ethiopians. The prevalence of NNRTI
mutations (K103N, Y188L, V106M, L100I) was higher in the Ethiopian
group (42.9% vs 17.6% p= 0.096).
Conclusions: Ethiopian and non-Ethiopian HIV/AIDS patients treated
in Israel, respond similarly to antiretroviral treatment, despite minor
differences in patterns of HIV mutation. Overcoming cultural, language
and adherence difﬁculties in treatment of this patient group may be
partially attributed to case manager involvement, improving patient
compliance and understanding.
P1290 Immunological and virological outcome of a double-boosted
HIV protease inhibitor salvage regimen
L. Belarbi °, C. Delaugerre, A. Krivine, S. Rouanet, J.P. Morini,
S. Grabar, V. Julien, J.M. Treluyer, D. Salmon, J. Viard, O. Launay
(Paris, FR)
Objectives: Double boosted protease inhibitor (PI) combinations have
been used as part of salvage regimen for HIV-infected patients. We
conducted a retrospective study to assess the immunological and
virological outcome of this strategy in a clinical setting.
Methods: All patients followed in two French hospitals and receiving
a double PI regimen as part of HAART salvage regimen between 2002
and 2006 were included in the study. Double PI regimen was chosen
according to genotypic resistance. CD4 T cell count and HIV-1 RNA
viral load (VL) were monitored. Intention to continue treatment analysis
was performed.
Results: Seventy-three highly pre-treated patients initiating a double
boosted PI regimen (lopinavir/ritonavir(r)+amprenavir: n = 35, ampre-
navir+saquinavir/r: n = 16, saquinavir+nelﬁnavir/r: n= 5, others: n = 11)
were included. Enfuvirtide was co-prescribed in 4 cases. Baseline median
CD4 count and VL were 207/mm3 [interquartile range IQR: 114–318]
and 4.3 log10 copies/ml [IQR: 3.1−5.0], respectively. Patients had a
median of 9.2 years (IQR: 6.8−10.8) of previous treatment and had
received a median of 9 antiretroviral drugs (IQR: 6−11) and 2 PI (IQR:
2−4). Median number of total and major IAS PI resistance mutations
were 7 (IQR: 3−10) and 2 (IQR: 0−3), respectively. Median follow-
up was 18.2 months (IQR: 9.6−26.4); 6 and 4 patients interrupted the
double boosted PI regimen before 6 months and 12 months, respectively
for virological failure (n = 5) and toxicity (n = 5). No severe adverse event
was observed. Kaplan-Meier 6-month and 12-month probabilities of
viral suppression (VL< 50 copies/ml) were 46.2% (95%CI = 35.5−58.5)
and 64.6% (95%CI = 53.3−75.8). Kaplan–Meier 6-month and 12-month
probabilities of an increase of CD4 cell count  100 cells/mm3 were
39.9% (95%CI = 29.5−52.4) and 53.8% (95%CI = 42.1−66.3).
Conclusions: Double boosted PI combinations were well tolerated
and resulted in signiﬁcant CD4 rise and VL decline in highly pre-
treated patients. This strategy may be an alternative for those patients
with limited therapeutic options in resource-poor settings, where new
expensive antiretroviral classes are not currently available.
P1291 HIV/AIDS epidemics development of pregnant woman in
Ukraine
A. Fedchuk °, L. Mudrik, V. Lozitsky, L. Schitikova, T. Gridina,
V. Odinec, L. Kotlyk, V. Lysetskaya (Odessa, UA)
Ukraine appears to be at the centre of the HIV-epidemic in Europe, with
twice as many newly registered HIV cases as in Western Europe and 14
times as many as in Central Europe. In 2008 approximately 1.46% of
the total adult population was estimated to be HIV positive − 440,000.
In Ukraine, the rate of HIV-infected dissemination among pregnant
women is one of the highest in Europe. This parameter equals to 0.45%
of all pregnant women in 2008, while it was only 0.002% in 1995.
The increase in the number of the HIV-infected women is of additional
concern because of the risk of vertical transmission from mothers to their
children. In Ukraine 86% of the patients of reproductive age who are
being treated are women. It is worth mentioning that daily 10 children are
born to HIV-infected mothers in the south of Ukraine. Early diagnosis,
treatment and behaviour counseling is crucial to avoid transmission and
limit the damaging effects of the disease.
The studies performed by Ukraine explorers show us that about 12%–
38% HIV-infected mothers became informed on their positive status only
at the birth-houses. Odesa region is at the ﬁrst place among other regions
of Ukraine as to the level of HIV/AIDS infection cases and at the third
as to the infected pregnant women In the case of the serum-positive
response, the infected woman needs the information on the probability
of infecting the child during birth and how to avoid transmission after
delivery. In addition, the provision of such information in time could
decrease the number of HIV-infected who obtain anti-retroviral therapy
which will help diminish vertical HIV transfer from mother to child.
Ukraine have entered the seven countries’ circle and are attempting
to provide access to antiretroviral therapy for HIV-positive pregnant
women. This effort is beginning to reduce the number of HIV-positive
newborns. During last 10 years HIV infected pregnant women number
increased by 17% (from 28% to 45%).
Permanently increases the number of children born by HIV-infected
mothers. However, the level of the anti-retroviral therapy provided to
HIV-positive pregnant women was equal only to 11%. Anti-retroviral
therapy applied timely allowed to diminish the newborns HIV infection
from 30% to 9%. As the result, more than 1295 previously infected
children were qualiﬁed as healthy.
P1292 Ortotopic liver transplantation in HIV-infected patients.
Outcome of a single-centre cohort of 21 patients
M. Montejo °, M. Gastaca, J.R. Fernandez, M. Testillano, A. Valdivieso,
J. Bustamante, J. Gonzalez, P. Ruiz, M.J. Suarez, A. Ventoso, J. Ortiz
de Urbina (Bilbao, ES)
Objectives: To present the outcomes of the HIV-infected patients treated
with orthotopic liver transplantation (OLT) in our institution.
Methods: HIV-infected patients treated with OLT in our institution
were prospectively studied. Our inclusion criteria for OLT were as
follows: (1) criteria for liver disease was the same to non-HIV patients;
(2) patients with previous HIV C events were not accepted except
some OIs (TB, Can, PCP); (3) Pre-OLT CD4 count >100 cells/mm3;
(4) RNA HIV-1 viral load BDL on antiretroviral therapy (ART) or, if
detectable, post-OLT suppression predicted; (5) No heroin or cocaine
use for >2 years and no alcohol use for >6 months.
Results: From September 03 to December 08, 22 OLT with deceased
donors were performed in 21 HIV-infected patients. Fifteen were male
(71.4%) with a mean age of 44 years (range 33−60). HIV risk factor was
former i.v. drug abuse in 17 patients, transfusion in 2, sexual in 1 and
haemophilia in 1. The aetiology of liver disease was HCV infection in 14
patients, HCV/HBV coinfection in 6 and cryptogenic in 1. Nine patients
were HCV genotype 1/4 and 7 were genotype 2/3. Eight patients had a
hepatocellular carcinoma. Mean MELD score was 12 (r 6−22). Pre-OLT
antiretroviral treatment (ART) was based on efavirenz in 6 patients, on
PI in 5 patients and on NRTIs in 9 cases. One patient had no ART.
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Mean follow-up was 34 months (r 1−63). After transplantation ART was
re-started at day 17 as average (r 7−52) and currently ART is based on
efavirenz in 15 patients, on PI in 2 and on NRTIs in 3 patients. Post-OLT
mean CD4 count was 371 cell/mm3 (r 22–667) and plasma HIV-1 RNA
was <200 copies/ml in 87% patients. Acute cellular rejection rate was
19%. One patient was retransplanted on day 6 due to a graft massive
necrosis. One patient died on day 6 due to an upper gastrointestinal
haemorrhage. Late mortality (>6 months) occurred in 4 patients: HCV
recurrence in 2 and de novo tumour in other 2. Eight patients have
been treated with Peg-Inf plus ribavirin and 5 achieved sustained viral
response. Two patients developed opportunistic infections after OLT:
gastrointestinal CMV at month 4 and pulmonary tuberculosis at month
8.
Conclusions: Liver transplantation in HIV-infected patients have a good
mid term survival. HIV infection can be adequately controlled after OLT.
In our experience, mortality after OLT in HIV-infected patients was
mainly related to HCV recurrence and de novo tumours.
P1293 Genetic proﬁles of HIV-1 populations in patients on failing
abacavir/lamivudine/zidovudine
S. Hong °, Z. Camacho (Durham, US)
Objectives: To understand evolution pathway of multi-drug resistant
HIV-1 virus under drug selection pressure.
Methods: Plasma from baseline and at different intervals post treatment
failure was used for RT-PCR from seven patients. To better represent
viral quasispecies, the partial pol gene were ampliﬁed and cloned in ﬁve
independent reactions. Multiple clones (9−49) were sequenced for each
timepoint.
Results: Drug resistant mutations were detected in ﬁve patients post
treatment failure. Phylogenetic analysis showed that viral sequence at
different timepoint clustered separately by forming independent lineages.
The genetic diversity was decreased from 1.6% to 0.6% in treatment
failure viral populations, while non-synonymous/synonymous mutation
ratios increased from 0.067 to 0.118, respectively. In one patient, a
baseline subcluster was identiﬁed M184V mutation but could not be
separated from post treatment population phylogenetically. No known
drug resistance mutations were detected in two other patients and
phylogenetic analysis showed very homogenous viral population between
baseline and treatment failure viruses.
Conclusions: These data suggests that the HIV-1 virus population
changed dynamics under continual drug selection pressure. The virus
population clustered in a timepoint-speciﬁc manner with genetic diversity
decreased consistently.
P1294 Discordant genotypic interpretation and phenotypic role of
protease mutations in HIV-1 subtypes B and G
A. Santos, A. Abecasis, A.M. Vandamme, R. Camacho, M. Soares °
(Rio de Janeiro, BR; Leuven, BE; Lisbon, PT)
HIV-1 group M is classiﬁed into nine different subtypes. Antiretroviral
(ARV) drugs have been developed for subtype B, and the response of
non-B subtypes in terms of susceptibility and the acquisition of drug
resistance when facing those drugs is largely unknown. In this study, we
wanted to address differences in the impact of protease inhibitor-selected
mutations in subtypes B and G. ARV-treated, HIV-positive patients
regularly followed at the Hospital de Egas Moniz, in Lisbon, Portugal,
were examined for the presence of PI-associated primary mutations
(301 of subtype B and 184 of subtype G), and for the selection of
those mutations over time of protease inhibitor exposure. Forty-three
subtype G patients were phenotyped for susceptibility to all available
PI through VIRCO’s Antivirogram®, and compared to a similar dataset
of subtype B patients. Mutation I54V/L was selected by nelﬁnavir in
subtype G isolates, a mutation not previously described for that drug in
subtype B. L90M was associated with a lower reduction in susceptibility
of subtype G to nelﬁnavir when compared with subtype B, and with
no reduced susceptibility to saquinavir. This was compensated by the
acquisition of M89I in subtype G. L90M did not reduce susceptibility of
subtype G to saquinavir, contrarily to subtype B. Likewise, the pattern
I54V/L-L90M did not reduce susceptibility of subtype G to indinavir and
saquinavir. Indinavir-associated mutations M46I/L, I84V and V82A/F/T
developed earlier in subtype B across length of exposure to that drug
when compared to subtype G counterparts. Our results provide proof
of principle and support the growing evidence that subtype-speciﬁc
responses to ARV exist. Data presented here highlights inconsistencies
in current genotyping interpretation algorithms inadequately applied to
all HIV-1 subtypes.
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P1295 Efﬁcacy of voriconazole against three clinical Aspergillus
fumigatus isolates with mutations in the cyp51A gene
E. Mavridou °, J.W. Mouton, E. Mellado, W.J.G. Melchers, P.E. Verweij
(Nijmegen, NL)
Objective: Azole resistance in Aspergillus fumigatus (Af) has been
associated with substitutions in the cyp51A gene. These substitutions
cause different susceptibility proﬁles and it is unclear if the in vitro
activity corresponds with in vivo efﬁcacy. We investigated the correlation
between in vitro activity of voriconazole (VCZ) and in vivo survival of
clinical Af isolates with L98H, G54W, and M220I substitutions.
Methods: In vitro activity of VCZ was determined based on the CLSI
M-38A method. A total of 16 groups (n = 11/group) of CD-1 mice, were
randomised into 4 groups for the 4 different Af isolates and were infected
i.v. through the lateral tail vein. Oral therapy with VCZ at 80, 40, and
10mg/kg once daily was begun 24 hours post challenge for 14 days.
Control groups received saline orally. Mortality data was analyzed by
the long rank test. Survival was determined daily until day 14. Results
were analyzed by survival curve analysis and plotting dose/MIC against
survival and ﬁtting the Hill equation with variable slope (HEVS) using
Graphpad Prism 5.0.
Results: The MICs of VCZ were: 0.25mg/L (WT and M220I),
0.125mg/L (G54W) and 2mg/L (L98H). The median survival time for
the control groups for all strains was 2−3 days. VCZ treatment improved
survival of the L98H M220I and G54W groups compared to controls
(p< 0.001). However, compared to WT and M220I, the dose-response
curve of mice infected with the G54W and L98H isolates were shifted to
the right indicating that a higher dose was required to achieve maximum
response against these strains (R2 of 0.5034, EC50 of 58, 71, Hillslope
of 1, 338). While the 40mg/kg dose revealed 100% survival against the
M220I, G54W and WT isolates, only 50% survival rate could be reached
against the L98H. There was an excellent correlation between MIC and
in vivo efﬁcacy of VCZ.
Conclusions: VCZ showed good efﬁcacy in mice infected with all
the 4 isolates when the administered daily dosage exceeded 10mg/kg.
Compared to the other 3 isolates, a twofold increase of VCZ dosage was
required for mice infected with L98H to achieve the same maximum
response. The in vivo efﬁcacy of VCZ corresponded with the MICs.
P1296 Development of azole resistance in a clinical A. fumigatus
isolate with no mutations in the cyp51A gene
M.C. Arendrup °, K.L. Mortensen, W. Melchers, N. Frimodt-Møller,
H. Khan, P. Verweij (Copenhagen, Esbjerg, DK; Nijmegen, NL)
Objectives: A. fumigatus triazole clinical resistance has been linked
to cyp51A mutations with or without a concomitant tandem repeat
in the gene promoter. We report the isolation over a 2.5 year period
of 4 sequential A. fumigatus isolates from a CGD patient eventually
failing azole and echinocandin combination therapy. The isolates were
investigated phenotypically and genotypically and the in vivo efﬁcacy of
antifungal drugs was evaluated.
Methods: Susceptibility testing was performed using the EUCAST
E.DEF 9.1 microdilution method for conidia-forming moulds. The entire
coding region of the cyp51A gene from a susceptible and resistant
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A. fumigatus isolate was sequenced. Genotyping was performed using
microsatellite typing. The in vivo efﬁcacy of antifungal agents was
investigated in an immunosuppressed haematogenous model using NRMI
mice weighing 26−30 gram. The mice received intraperitoneal injection
of 200mg/kg cyclophosphamide, day −3 and 100mg/kg day 0 to
obtain prolonged neutropenia. Mice were inoculated i.v. with 0.2ml
of a105CFU suspension day 0 and subsequently treated once daily at
days 1−4 and 7−10 with either saline (control), anidulafungin (AND)
12mg/kg, posaconazole (POS) 20mg/kg, or both. Kidney burden and
mortality were evaluated day 4, 8 and 11 of mice in groups of 6 or 10.
The experiments were approved by the Danish Animal Experimentation
Committee under the Ministry of Justice (number 2004/561–835).
Results: The POS MICs of the 4 consecutive isolates were 0.125 mg/ml,
0.125mg/ml, 0.5mg/ml, and 1mg/ml, respectively. Caspofungin and
AND MICs were stable (range 0.25−0.5 and 0.5−1 mg/ml, respectively).
Genotyping showed the isolates were genetically identical and thus of
clonal origin and sequencing of the Cyp51 genes revealed no mutations
in the hot spots of the gene or its promoter. In the animal model
AND alone and AND-POS combination therapy signiﬁcantly reduced
mortality (P< 0.0001) and kidney burden day 8 (P = 0.0121 and 0.0167,
respectively) while POS monotherapy did not (P = 0.0856 comparing
mortality and P = 0.1167 comparing kidney burden to control group).
Conclusion: This A. fumigatus isolate obtained from a patient failing
2 years of caspofungin+voriconazole combination treatment followed
by 2 months of POS+caspofungin treatment showed POS resistance in
the mouse model despite not possessing previously described resistance
mechanisms. AND alone or in combination with POS was effective
against azole resistant aspergillosis.
P1297 Is Aspergillus nidulans susceptible to all antifungal agents?
In vitro activity of an updated panel of antifungal agents
against 63 clinical isolates
T. Pela´ez °, J. Guinea, B. Gama, R. Flores, S. Recio,
M. Torres-Narbona, P. Mun˜oz, E. Bouza (Madrid, ES)
Background: Aspergillus nidulans is an infrequent but potential cause
of invasive aspergillosis. However, its in vitro antifungal susceptibility
proﬁle has been poorly evaluated. We studied the antifungal susceptibility
of an updated panel of 8 antifungal drugs against 63 clinical strains of
A. nidulans collected in our hospital since 1997.
Methods: The strains were from respiratory samples (n = 55), superﬁcial
samples (n = 5), and other samples (n = 3) and were identiﬁed
according to morphological characteristics. Antifungal susceptibility
to amphotericin B, terbinaﬁne, caspofungin, micafungin, itraconazole,
voriconazole, posaconazole and isavuconazole was obtained following
the CLSI M38-A procedure and the results analyzed using the t test and
Pearson correlation coefﬁcient (PC).
Results: The antifungal susceptibility (MIC50, MIC90, geometric mean
and ranges, in mg/mL) was as follows: amphotericin B (4/4/3.3/1−8),
terbinaﬁne (0.062/0.125/0.09/0.031−1), caspofungin (0.125/0.25/0.38/
0.062−8), micafungin (0.062/0.062/0.065/0.062−0.125), itraconazole
(1/2/1.036/0.25−4), voriconazole (0.5/2/0.61/0.062−2), posaconazole
(0.5/1/0.54/0.25−1) and isavuconazole (0.25/1/0.46/0.062−1). Ampho-
tericin B showed the lowest activity (52.3% of strains with MICs
 4mg/mL) (P< 0.001). In contrast, terbinaﬁne showed good ac-
tivity (98.4% of strains with MICs  0.25mg/mL). Micafungin
showed higher activity than caspofungin (P = 0.027). Of the azole
derivatives, isavuconazole proved to be the most active agent (all
strains with MICs  1mg/mL) (P = 0.05), followed by posaconazole,
and voriconazole. Itraconazole showed the lowest activity (20.7%
of strains MICs  2mg/mL) (P< 0.001). We observed a statisti-
cally signiﬁcant correlation (P< 0.001) in terms of activity between
pairs of agents as follows: isavuconazole–posaconazole (PC=0.639),
isavuconazole–voriconazole (PC=0.864), isavuconazole–itraconazole
(PC=0.648), voriconazole–posaconazole (PC=0.786), voriconazole–
itraconazole (PC=0.810), itraconazole–posaconazole (PC=0.654) and
caspofungin–micafungin (PC=0.410).
Conclusions: Amphotericin B showed lower antifungal activity against
A. nidulans than the other agents. In contrast, terbinaﬁne, the
echinocandins, and the new triazoles had good antifungal activity against
A. nidulans. Positive correlations between the MICs of the four azoles
and between the MICs of micafungin and caspofungin were found.
J. Guinea (FIS CM05/00171) and M. Torres-Narbona (CM08/00277)
are contracted by FIS.
P1298 In vitro antifungal activity of isavuconazole against 345
mucorales isolates, collected at eight study centres worldwide
P. Verweij °, G. Gonzalez, N.P. Wiederhold, C. Lass-Flo¨rl, P. Warn,
M. Heep, M.A. Ghannoum, J. Guinea (Nijmegen, NL; Nuevo Leo´n,
MX; San Antonio, US; Innsbruck, AT; Manchester, UK; Basel, CH;
Cleveland, US; Madrid, ES)
Objective: Although mucormycosis (infections due to Absidia, Mucor,
Rhizomucor and Rhizopus spp.) are relatively uncommon, they are
associated with high mortality and current treatment options are limited.
Isavuconazole (ISA) is a novel broad-spectrum azole with excellent
bioavailability, currently in late-stage clinical development for the
treatment of invasive aspergillosis and candidiasis. The objective of this
study was to collate data from independent in-vitro studies evaluating
the antifungal activity of ISA against a large and diverse collection of
mucorales clinical isolates (n = 345), collected and tested at eight study
centres in Europe, Mexico and North America.
Methods: Each study centre undertook MIC susceptibility testing of
isolates collected at their institution, according to EUCAST (1 centre)
or CLSI (7 centres) guidelines. The 345 isolates comprised: 80 Absidia
spp. (49 A. corymbifera; 31 unspeciﬁed), 18 Cunninghamella spp. (3
C. bertholletiae; 15 unspeciﬁed), 77 Mucor spp. (19 M. circinelloides; 2
M. ramosissimus; 1 M. rouxianus; 55 unspeciﬁed), 29 Rhizomucor spp.
(11 R. pusillus; 18 unspeciﬁed), 139 Rhizopus spp. (28 R. arrhizus; 44
R. microsporus; 15 R. oryzae; 52 unspeciﬁed) and 2 Syncephalastrum
spp. Additional tests (E-test, hyphal growth inhibition) were conducted
at some laboratories.
Results: Across all study centres and following 24 h incubation (48 h
by EUCAST methodology), ISA exhibited MIC50 values of 1 to 4mg/L
and MIC90 values of 4 to 16mg/L against the ﬁve genera. Regardless of
genera tested, there were noticeable differences in the MIC distributions
obtained from each study centre. These differences could not be
ascribed to differences in inoculum and/or endpoint determinations. MIC
distributions using EUCAST methodology fell within the MIC ranges for
study centres using CLSI methodology. All MICs were higher following
48 h incubation. MICs of ISA against hyphae were similar to those
obtained against the standard conidial suspension. The E-test tended
to generate higher MICs.
Conclusions: Laboratory variation in the ISA MICs obtained was found.
ISA possessed at least moderate in vitro antifungal activity against
Mucorales. If ISA is conﬁrmed to yield high levels in serum and
relevant tissues it could have a role in the prevention and treatment
of mucormycosis.
P1299 In vitro combination of amphotericin B or posaconazole
with cyclosporine A against zygomycetes
E. Dannaoui °, P. Schwarz, O. Lortholary (Paris, FR)
Objectives: to evaluate the in vitro interaction between antifungals and
cyclosporine A, a calcineurin inhibitor, against Zygomycetes.
Methods: ten isolates of Zygomycetes (3 Rhizopus oryzae, 2Mycocladus
corymbifer (formerly Absidia corymbifera), 2 Mucor circinelloides, 2
Rhizopus microsporus var. rhizopodiformis, and 1 Rhizomucor pusillus)
were used. RPMI agar plates containing predeﬁned concentrations of
cyclosporine A were inoculated with a spore suspension by swabbing
the agar surface The concentration of cyclosporine A incorporated
in the agar plates was two-fold lower than the Minimum Inhibitory
Concentrations (MIC) for isolates inhibited by <8mg/l, or 16mg/l
for isolates which were not inhibited by 8mg/l of cyclosporine A.
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Amphotericin B or posaconazole Etest strips were applied on the agar
surface and MIC of antifungals were determined after 24 h of incubation
at 35ºC.
Results: A decrease of 2 dilutions of the MIC of the antifungal,
suggesting synergy, was observed for 50% of the isolates for the
combination of amphotericin B with cyclosporin A, and for 60% of
the isolates for the combination of posaconazole with cyclosporin A.
Antagonism was never observed.
Conclusion: For most isolates of zygomycetes, the calcineurin inhibitor
cyclosporine A enhanced the antifungal activity of either amphotericin B
or posaconazole. These preliminary results should be conﬁrmed in
vivo in an animal model. Positive interactions between antifungals and
immunosuppressive drugs may have clinical implications for treatment
of solid organ transplant patients with zygomycosis.
Isolate MIC (mg/1) of the
drugs alone
Concentration (mg/l) of
CyA in plates
MIC (mg/l) of the drugs in
combination with CyA
AMB PSZ AMB PSZ
R. oryzae IP 1443.83 ND 1 16 ND 1
R. oryzae IP 4.77 >32 >32 0.5 >32 2
R. oryzae CNR 03.918 >32 2 16 0.09 0.5
R. microsporus AZN 1185 0.5 >32 0.5 0.5 >32
R. microsporus IP 676.72 2 2 0.25 1.5 2
M. circinnelloides CNR 03.154 0.5 3 2 0.06 1
M. circinnelloides CNR 03.371 0.38 >32 2 0.03 16
Rh. pusillus IP 3.77 0.38 0.19 0.125 0.25 0.125
A. corymbifera IP 1280.81 2 0.25 16 0.125 0.03
A. corymbifera IP 1279.81 ND 0.5 16 ND 0.06
CyA: cyclosporine A; AMB: amphotericin B; PSZ: posaconazole. ND: Not done.
P1300 Molecular mechanisms of azole resistance in Candida
glabrata clinical isolates from Slovakia
S. Borecka, N. Berila, V. Dzugasova, J. Bojnansky, J. Subik °
(Bratislava, SK)
Objectives: The aim of this study was to investigate the molecular
mechanisms involved in a decreased susceptibility to azole antifungals
in unmatched C. glabrata clinical isolates recovered from different
patients treated in two university hospitals in Slovakia. The attention was
also paid to cell surface hydrophobicity and in vitro bioﬁlm formation
associated with virulence of fungal pathogens.
Methods: Drug susceptibilities were determined by microbroth dilution
method in 96-well plates according to the proposed CLSI (formerly
NCCLS), M27-A standard guidelines and by E-test assay. PCR was
carried out with a high-ﬁdelity KOD Hot Star DNA polymerase
(Sigma-Aldrich, St. Louis, USA). The DNA sequence was determined
with the ABI Prism 3100 DNA sequencer. The quantitative real time
PCR was carried out in the 7900 HT Fast Real-Time PCR System
(Applied Biosystems, Foster City, USA). Cell surface hydrophobicity
was measured by the water-octane two phases assay. Bioﬁlm formation
was quantiﬁed biochemically as XTT reduction.
Results: Molecular mechanisms of resistance to azole antifungals
were investigated in ten unmatched C. glabrata clinical isolates.
Overexpression of the CgPDR1 gene encoding the main multidrug
resistance transcription factor and its target genes CgCDR1 and CgCDR2
coding for drug efﬂux transporters was observed in six ﬂuconazole
resistant isolates. Sequence analysis of the PCR ampliﬁed DNA
fragments of their CgPDR1 gene identiﬁed the L347F and H576Y
amino acid substitutions in CgPdr1p in one and ﬁve clinical isolates,
respectively. Sequencing of the CgERG11 gene encoding 14C-lanosterol
demethylase and analysis of its expression identiﬁed the E502V amino
acid substitution in ﬁve of ten isolates and showed no upregulation of
this gene in any clinical isolates. No signiﬁcant association was observed
among the drug susceptibility proﬁles, mechanisms of azole resistance
and the cell surface hydrophobicity correlating with the ability of isolates
to form bioﬁlm.
Conclusion: The results demonstrate that decreased susceptibilities of
C. glabrata clinical isolates to azole antifungals are associated with
upregulation of drug efﬂux transporter genes due to novel gain-of-
function mutations in gene encoding CgPdr1p transcription factor.
P1301 Parallel-resistance of azoles and echinocandines and their
cross-resistance to ﬂucytosine and amphotericin B in
clinical yeast isolates
A. Schmalreck, K. Becker, W. Fegeler ° (Munich, Munster, DE)
Objectives: To evaluate the parallel-resistance (PR) of azoles (AZs)
(ﬂuconazole, FL; itraconazole, IT; voriconazole, VO; posaconazole, PO)
and echinocandines (ECs) (caspofungin, CA; anidulafungin, AN) and
their cross-resistance (CR) to ﬂucytosine (FC) and amphotericin B (AM),
the minimum inhibitory concentrations (MICs) of 1,355 clinical yeast
isolates (CYIs) were analyzed by susceptibility pattern analysis (SPA).
Methods: Testing of CYIs was performed by Etest®-strips on modiﬁed
RPMI agar with 2% glucose and 0.5mg methylene blue/L. All
antifungal agents (AFAs) were tested in parallel from the same inoculum
(105 cfu/ml). SPAs of the individual susceptibility results for each AFA
in each isolate were performed and the results were aligned to individual
susceptibility patterns (SPs).
Results: The CYIs comprised 9 genera: Candida (1266/93.4%, compris-
ing 749 C. albicans, 358 C. glabrata, 88 C. tropicalis, 49 C. parapsilosis
and 22 isolates of other species), Clavispora (11/0.8%), Magnu-
siomyces (8/0.6%), Filobasidiella (2/0.2%), Issatchenkia (29/2.0%),
Kluyveromyces (15/1.1%), Pichia (10/0.7%), Saccharomyces (13/0.9%),
and Trichosporon (1/0.1%). The percentage of resistant isolates differed
considerably depending on the AFA and on the MIC-reading time (24 h
vs. 48 h): FC, 8.6 vs. 11; AM, 0.6 vs. 4.9; FL, 5.9 vs. 19.4; IT, 27.7 vs.
33.5; VO, 2.2 vs. 6.5; PO, 15.1 vs. 27.6; CA, 1.6 vs. 3.5; AN, 3.1 vs. 4.8.
The species-speciﬁc resistance rates (RRs) demonstrated large variations
showing RRs for ECs of C. dubliniensis, C. parapsilosis, and Pichia from
10% to 85% and RRs for AZs of C. glabrata, Issatchenkia, and Pichia
from 20% to 90%. CR of the AZs and ECs tested to FC and AM was
not found in any isolate, even after 48 h of incubation. According to
24 h vs. 48 h incubation, 28 vs. 79 isolates showed complete PR to AZs
(C. glabrata, 25 vs. 53; C. albicans, 2 vs. 23) and 776 (57.3%) vs. 681
(50.3%) strains exhibited susceptibility to all antifungals tested. PR with
ECs was recorded in 18 (1.3%) vs. 29 (2.1%) of the strains.
Conclusion: The MIC differences and the one-sided PR of the
azoles underline the importance of analysing the routine-results with
different comparative analysing tools. Susceptibility determination of
AFA was found to be strongly species- and endpoint-reading dependent.
Consequently, species-speciﬁc breakpoints for these agents should be
established in order to achieve reliable in vitro results and qualiﬁed
therapy recommendations.
P1302 Varying interactions between voriconazole and ampho-
tericin B against Candida spp. in an in vitro kinetic model
A. Lignell °, E. Lo¨wdin, O. Cars, J. Sjo¨lin (Uppsala, SE)
Objectives: An antagonistic effect of voriconazole (VRC) on the
fungicidal activity of sequential doses of amphotericin B (AMB) against
Candida albicans (CA) has previously been demonstrated. It may be
speculated that this is an effect only seen in strains that are susceptible
to VRC. The aim of the present study was to investigate, in an in vitro
kinetic model, whether a similar inhibitory effect was seen between
VRC and AMB against CA with reduced susceptibility and known
mechanisms of resistance against VRC, and against Candida glabrata
(CG) and Candida krusei (CK) with varying susceptibility to VRC.
Methods: Four strains of CA and two strains each of CG and CK were
tested. To a starting inoculum of 104 CFU/mL of yeast in sterile RPMI
1640, antifungal agents (VRC: 5.0mg/L, AMB: 2.5mg/L) were added
and placed at 35 degrees Celsius. Antifungal containing medium was
eliminated from the culture vessel and replaced by fresh medium with a
peristaltic pump at a ﬂow-rate adjusted to obtain a 6-h half-life of VRC.
A computer controlled dosing pump compensated for the 7-h half-life
of AMB. Repeated sampling for viable counts was made. Fungal killing
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was deﬁned as the difference in log10CFU/mL before and 6 h after
administration of AMB. Fungicidal activity was deﬁned as a reduction
in CFU/mL of >3 log10.
Results: Against CA, the regimens with AMB and simultaneous AMB
+ VRC resulted in a fungicidal activity within 1.5 h. When CA was
exposed to VRC for 24 h before administration of AMB, fungal killing
were reduced in three out of four strains. Fungal killing (standard error in
brackets) were 2.0 (0.3), 2.6 (0.4), 4.8 (1.1), and 0.3 (0.1) log10CFU/mL
(MIC: 2, 8, 8, and 256mg/L, mechanism of resistance: efﬂux pumps
CDR1, CDR1, MDR1 and uncharacterised, respectively).
Against CG and CK, AMB alone resulted in fungicidal activity within
1.5−6 h. Simultaneous AMB + VRC decelerated the fungicidal killing
rate. When CG and CK were exposed to VRC for 24 h before AMB,
fungal killing were reduced in all strains. The numbers were 1.3 (0.1),
0.7 (0.3), 0.4 (0.2) and 1.7 (0.4) log10CFU/mL (MIC: 0.5, 4 (CG), 0.5,
4 (CK) mg/L, respectively).
Conclusion: An inhibition of the fungicidal activity of AMB by VRC
against CA was seen despite reduced VRC susceptibility. The interaction
seems more dependent on the type of resistance mechanism rather than
the MIC-level. Furthermore, a reduction of the fungicidal activity of
AMB by VRC was demonstrated against strains of CG and CK.
P1303 Assessment of the in vitro pharmacodynamic activity of
echinocandins against Candida parapsilosis
C. Big, J. Vazquez ° (Ann Arbor, Detroit, US)
Objectives: Echinocandins have become commonly used antifungals in
the management of invasive candidiasis despite the fact that the reported
MICs of C. parapsilosis (Cp) for echinocandins are much higher than
the MICs of other Candida spp. The main objective was to evaluate the
in-vitro pharmacodynamic activity of echinocandins against Cp.
Methods: 12 Cp isolates recovered from the bloodstream of different
patients were evaluated. MIC/MFC and Time Kill Assays (TKA) were
done for Cfgn, Anidulafungin (Afgn), Fluconazole (FLZ), Voriconazole
(VCZ), and AmB, using CLSI methodology.
Results: TKA of Cfgn, Afgn, VCZ, and AmB using Cfgn-susceptible
and -resistant strains revealed no fungicidal activity at 0.5 and 2× the
MIC for Cfgn and Afgn, when compared to control strains of C. albicans
(Ca) and C. glabrata (Cg). However, at 4× and 8× the MIC, both Cfgn
and Afgn demonstrated fungicidal activity at the 6 and 8 hr time points.
In contrast, both Cfgn and Afgn demonstrated fungicidal activity against
Ca and Cg at 0.5 and 2×MIC at the 6 and 4 hr intervals, respectively.
Conclusions: Cfgn and Afgn demonstrated concentration-dependent
activity, which was either fungistatic or fungicidal, depending on the
Candida spp. evaluated and the concentration used. Excellent fungicidal
activity was achieved with Cfgn and Afgn at 4× and 8× MIC against
different strains of Cp. However, when compared to the activity displayed
against Ca and Cg, the efﬁcacy was inferior. The echinocandins as used
today may not be the best options in the management of candidaemia
due to Candida parapsilosis.
P1304 Antifungal susceptibility of Candida parapsilosis
bloodstream isolates during the last decade
A. Spiliopoulou °, S. Vamvacopoulou, L. Pikoula, C. Bartzavali,
E.D. Anastassiou, M. Christoﬁdou (Patras, GR)
Objectives: Non albicans Candida species have emerged as important
nosocomial pathogens as the epidemiology of candidaemia has changed
over the years. Among 245 Candida bloodstream isolates, antifungal
susceptibility data of 34 cases attributed to Candida parapsilosis is
presented.
Methods: A ten year surveillance of bloodstream infection (BSI)
caused by C. parapsilosis was carried out in the Microbiology
Laboratory of University Hospital of Patras. Gram stain of material
from positive blood culture vials (Bact/Alert, Organon Teknika) was
examined microscopically for yeasts, whereas, another portion was
subcultured on Sabouraud dextrose agar (SDA, Difco, USA). All SDA
plates were incubated at 35ºC for 72 h and yeast-like colonies were
isolated. Germ tubes formation is indicative of C. albicans, whereas,
germ tubes negative Candida isolates were identiﬁed by API 20 AUX
(Biomerieux), an assimilation test of carbohydrates. Susceptibility testing
(MIC) to antifungal agents was carried out by E-Test (AB Biodisk).
MIC was evaluated according to CLSI criteria for amphotericin B (AP),
5-ﬂucytocine (FC), ﬂuconazole (FL), ketoconazole (KE), itraconazole
(IT), voriconazole (VO), posaconazole (POS) and caspofungin (CS).
Results: C. parapsilosis was the most frequent non-albicans candida
species (14%), isolated from BSI. Fifteen candidaemia cases (44%)
due to C. parapsilosis were identiﬁed in Neonatal Intensive Care Unit
(NICU), thirteen cases (38%) in Internal Medicine Ward, Haematology-
Oncology Unit and Transplantation Center, ﬁve cases in Surgical Wards
(General Surgery Units and Orthopedics), whereas, only one case was
identiﬁed in adult ICU. Susceptibility data showed that all C. parapsilosis
isolates were sensitive to AP, FC, VO, POS and CS. In terms of resistance
to other azoles, four isolates were resistant to FL, two to KE and one
to IT.
Conclusions: Almost half (44%) of C. parapsilosis isolates were
identiﬁed in NICU, where C. parapsilosis is the most common (25%)
Candida non albicans causing BSI.
In Surgical Wards and in adult ICU, the incidence of C. parapsilosis
BSI is rather low. Parenteral alimentation and the widespread use of
central venous catheters in low birth-weight infants have been linked to
C. parapsilosis infections.
Among azoles, the highest degree of resistance was observed to FL
(12%) and KE (6%), whereas POS and VO were active against all isolates
tested. No resistance was found to AP, FC and CS.
P1305 In vitro susceptibility of clinical isolates of Saccharomyces
cerevisiae
A. Gomez-Lopez °, G. Isla, I. Cuesta, J.L. Rodriguez-Tudela,
M. Cuenca-Estrella (Majadahonda, ES)
Background: The incidence of opportunistic invasive fungal infections
has increased dramatically in recent years. Saccharomyces cerevisiae, a
yeast used in food industry and as a probiotic, is increasingly reported
as aetiologic agent of human infections, and considered as a possible
emerging pathogen. We have reviewed the antifungal susceptibility
proﬁle of a collection of clinical isolates of S. cerevisiae in order to
give any insight on the management of this emerging infection.
Methods: A total of 57 isolates received in our institution over
a period of 11 years (1997 to 2007) was evaluated. The isolates
were identiﬁed by routine morphological and physiological tests.
MICs of amphotericin B (AMB), ﬂuconazole (FLC), itraconazole
(ITC), voriconazole (VRC), ravuconazole (RVC), posaconazole (POS),
caspofungin (CAS), micafungin (MCF) and anidulanfungin (AND) were
determined according to the recommendations proposed by the European
Committee on Antifungal Susceptibility Testing for fermentative yeast
(EUCAST-deﬁnitive document).
Results: Most of the 57 strains were isolated from vaginal exudates
(15/57, 26.3%), oropharyngeal exudates (11/57, 19.3%), blood (8/57,
14.0%), and biopsy specimens (7/57, 12.3%). A slight increase in the
number of S. cerevisiae strains received was detected in the last years
(1.31% to 3.36% from 1997 to 2007). The majority of the strains (54/55,
98.1%) were considered susceptible in vitro to AMB (tentative MIC
breakpoint MIC 1mg/L). However different rates of susceptibility to
azoles have been reported: High MICs of FLC (>4mg/L) were detected
in 35% of the strains. Whereas, elevated MICs of ITC, VRC, RVC and
POS (MICs >1mg/L) were detected in 18.5%, 7.8%, 2.4% and 5.3.%
of the strains respectively. In addition, echinocandins demonstrated great
activity against most of the strains. (GM for CAS, MCF and AND were
respectively 0.36, 0.04 and 0.08mg/L)
Conclusions: This species seems to be an emerging pathogen and should
not be dismissed as a non-pathogenic microorganism when recovered
from clinical sources. AMB, new azoles and echinocandins showed good
in vitro activity against this fungus.
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P1306 Antifungal susceptibility of 205 Candida yeast isolated
during systemic candidiasis. Comparison of the Vitek 2
system with E-Test and CLSI broth microdilution methods
N. Bourgeois °, L. Dehandschoewercker, S. Bertout, P. Rispail,
L. Lachaud (Nıˆmes, FR)
Objectives: The objective of this study was to evaluate a new
automatised antifungal susceptibility test system (AST-YS01 Vitek 2
cards, Biomerieux) (VK2). It was compared with the Etest procedure
and the CLSI reference broth microdilution method. For this purpose,
205 clinical isolates of Candida spp were tested with amphotericin B,
ﬂuconazole and voriconazole.
Methods: The CLSI and the Etests MICs were determined at 24 and
48 hours of incubation at 35ºC. The amphotericin B MIC was determined
as the lowest concentration inhibiting any growth. The azole MICs
were read as the lowest concentrations producing 50% (CLSI) and 80%
(Etest) reduction of growth. The MICs with the VK2 cards were noticed
spectrophotometrically after variable incubation time, depending on the
growth control. All the methods were validated each time with quality
control strains. Interpretative breakpoints available for ﬂuconazole and
voriconazole were used to calculate categorical agreement percentages.
Results: Essential agreement (EA) between the VK2 and CLSI method
was excellent. For VK2 and etest, EA depended on Candida species
and molecule tested. The interpretation for susceptibility to ﬂuconazole
at 48 hours end point with the three methods was fully concordant in
all the Candida albicans isolates: 98.8% were susceptibles (S), and
only 1 isolate was resistant (R). For Candida glabrata, only 17.86%
of the isolates were given the same interpretation for ﬂuconazole with
the three methods (7S, 2R, 1SDD). Categorical agreement was 78.6%
between the VK2 and CLSI method, while only 23.2% between VK2 and
Etest method. A cross-resistance for voriconazole was noticed in 12.5%,
10.6% and 51.8% with VK2, CLSI and Etest methods respectively.
All of the Candida parapsilosis (n = 22), Candida tropicalis (n = 17), and
Candida lusitaniae (n = 2) were found S for ﬂuconazole and voriconazole
with the three methods. It is noteworthy that none of the Candida
krusei was found R to ﬂuconazole with VK2 system, and that the MIC
corresponded to a susceptible value for 6/14 isolates. Nevertheless, the
VK2 expert does correct the interpretation to resistant. For amphotericin
B, a MIC  1 was globally found for 201 (VK2), 190 (CLSI), and 202
(etest) isolates. One Candida glabrata isolate had a MIC  2 in the
three methods.
Conclusion: The AST-YS01 Vitek 2 cards system (Biomerieux) is a
reliable and practical automatised antifungal susceptibility test.
P1307 Comparison of the Vitek AST-YS01 card with CLSI broth
microdilution reference method for testing ﬂuconazole and
voriconazole against C. neoformans
A.I. Aller °, C. Castro, A. Romero, M.T. Gonza´lez, R. Claro,
E. Martı´n-Mazuelos (Seville, ES)
Objective: The purpose of this study was to compare the results obtained
by the reference microdilution method (MDM) with those obtained
with the comercial method AST-YS01card (YS01) for antifungal
susceptibility testing of C. neoformans to ﬂuconazole (FZ) and
voriconazole (VZ)
Materials and Methods: We have studied retrospectively 89 clinical
isolates of C. neoformans.
The susceptibility to two azoles was performed by the MDM according
to the CLSI guidelines (M27-A2 document) modiﬁed by Ghannoum
et al (J. Clin. Microbiol. 1992; 30:2881−86). The MICs were read
at 48−72 h. of incubation. The YS01 was performed according to the
manufacturer’s instructions. The inoculum suspensions of C. neoformans
isolates matched the turbidity of nº2 McFarland standard. The MICs were
read at 24−48 h. of incubation.
The interpretative criteria for VZ were those published by the CLSI (Doc-
ument M27-A3 and M27-S3). For FZ the isolates with MIC16mg/L
were considered resistant and the isolates with MIC< 8mg/L were
considered susceptible, as suggested previously by Aller A.I. et al
(Antimicrob Agents Chemother 2000; 44: 1544−48). C. krusei ATCC
6258, C. parapsilosis ATCC 22019, C. neoformans 90112 and
C. neoformans 90113 were included as control strains.
Results: For FZ 23 isolates of C. neoformans (25.8%) failed to grow
in the Vitek 2 system at 24 h. and they needed to be read after 24 h.
of incubation (mean time of 28 h. with a range from 25 to 32 h.). The
overall essential agreement (EA) between the two methods was of 97.7%
to FZ. For VZ only 12 isolates grew well in the YS01 (13.5%), making
it impossible to obtain results. The cathegorical agreement between both
methods for FZ is summarised in table 1. YS01 was not able to identify
the C. neoformans isolates resistant to FZ (2/4, 50%).
Table 1
MIC (category), no. (%) CA (%) Errors, no. (%)
S R Very major Major Minor
Vitek: 86 (96.6)
CLSI: 85 (95.5)
Vitek: 3 (3.3)
CLSI: 4 (4.4)
96.6 2 (2.24) 1 (1.12) –
Conclusions:
1. These data suggest the potential value of YS01for determining the
MICs of FZ to susceptible C. neoformans isolates.
2. YST01 failed to recognize the FZ resistant C. neoformans isolates.
3. According to our study, YS01 is not a reliable method for
susceptibility testing of C. neoformans to VZ.
4. Further studies including a higher number of strains resistant to both
antifungal agents are necessary.
P1308 Does minimum inhibitory concentration of echinocandins
impact clinical outcome? First European case of
breakthrough Candida glabrata candidaemia successfully
treated with micafungin
A. Guleri °, C. Moore, S. Pettit, K. Woodrow, E. Trautt (Blackpool,
Manchester, UK)
Introduction: The echinocandins are the ﬁrst new class of antifungals
that target the fungal cell wall by blocking b-1.3-d-glucan synthase.
Literature reports an uncertain correlation between clinical failure and
elevated MIC values for the echinocandins. We present the 1st case in
Europe successfully treated with micafungin for repeated breakthrough
Candida glabrata candidaemia during caspofungin therapy.
Case study: A 16-year old male (weight 50 kg) was admitted
in July 2008 with 4-day history of lower abdominal pain. An
emergency laparotomy revealed large perforation of mid-sigmoid colon
and extensive faecal contamination of peritoneum. He underwent
Hartmann’s procedure and abdominal closure with drainage. Patient
developed wound infection and CT-diagnosed pelvic collection. Fol-
lowing dehiscence of abdominal wound he subsequently developed an
enterocutaneous ﬁstula. This is draining several litres of efﬂuent a day
through a closed sealed transparent dressing into a large bag. He was
treated with total parenteral nutrition his transfer to specialist hospital in
October 2008.
During 3-months of hospital stay the patient had 5-central line,
2-peripherally inserted central catheter [PICC] and 2-Hickman
line changes following repeated candidaemia. The patient had
9-candidaemias with C. tropicalis [between Jul 30 and Aug 20] treated
Fluconazole (400mg/d) followed by caspofungin (50mg/d). This was
followed by 7-candidaemias with C. glabrata [between Sept 19 and Oct
4]while he was treated with Caspofungin [50mg/d]. Patient received
his last hickman line under cover of caspofungin and voriconazole in
combination and then changed to micafungin (100mg/d). Taurolidine −
4% citrate line lock used in the new hickman line. Micafungin was used
for 2-weeks & taurolidine line lock for 12-days and then stopped. The
patient [hickman line − now 45-days] is on TPN without further infection
episodes.
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The 7-isolates of C. glabrata were tested in-house [Fluconazole
MIC 8mg/L] and at Mycology Regional Laboratory, Wythenshawe
hospital [MIC − Micafungin (<0.015mg/L); Caspofungin (0.5mg/L);
Voriconazole (0.125−0.5mg/L); Fluconazole (8mg/L) and Amphotericin
(0.06mg/L)].
Discussion: Uncertain correlation between higher MIC and successful
clinical outcome with C. parapsilosis is reported. Therapeutic failure
with casofungin in a susceptible C. glabrata strain is of concern. Mi-
cafungin, newest of echinocandins, has lower MICs against C. glabrata
and offered clinical success.
P1309 Caspofungin non-susceptible Candida spp. isolates in cancer
patients
D. Kofteridis °, R. Lewis, D. Kontoyiannis (Heraklion, GR; Houston, US)
Objectives: Caspofungin (CAS) has emerged as one of the main choices
for primary treatment of candidiasis. Despite extensive use, resistance
(R) to CAS and cross resistance among the other echinocandins is
considered rare in the clinic.
Materials and Methods:We reviewed the in vitro susceptibilities (CLSI
method) of 650 Candida species associated with candidaemia or non-
candemic invasive candidiasis episodes in 582 hospitalised cancer pts at
MDACC (2005–2008). We retrospectively reviewed the characteristics of
the candidiasis episodes caused by CAS-R- Candida species (MIC> 2).
Results:We identiﬁed 7 caspofungin-resistant Candida spp isolates (1%)
obtained from 7 patients (median age 56 years, range 17−87; 57% were
males). All patients had haematological malignancy and 4 had received
CAS in the previous 3 months. Neutropenia, and prior corticosteroid
treatment were seen in 5 (71%) and 6 (86%) pts respectively. Six of
7 (86%) of CAS-R Candidiasis episodes were breakthrough infection
to systemic antifungals. Five (71%) of CAS-R-Candida isolates were
isolated from blood and 1 each from pelvic abscess the urine (in a pt with
nephrolithiasis). Candida tropicalis in 3 (43%) was the most common
Candida spp isolated. One isolate (C. glabrata) had multi-resistance to
azoles, amphotericin B and echinocandins. All 7 pts responded to change
of antifungal therapy (catheter was removed in all 5 candidemic pts).
Conclusion: CAS-R candidiasis appears rare, even in a pt population
where there is extensive CAS use. Prospective surveillance studies are
needed.
P1310 Pharmacokinetics of caspofungin in patients with
candidaemia
S. Garazzino °, L. Baietto, F. De Rosa, A. D’Avolio, M. Michelazzo,
G. Di Perri (Turin, IT)
Objectives: The knowledge of pharmacokinetic/pharmacodynamic
(PK/PD) properties of antifungals and the role of therapeutic drug
monitoring (TDM) in the clinical setting are still limited. Caspofungin
is an antifungal belonging to the class of echinocandins and is
approved as ﬁrst line treatment for invasive candidiasis. Caspofungin
displays a concentration-dependent activity and the AUC/MIC has been
demonstrated to be the PD parameter linked with efﬁcacy in the
murine model. Aim of our study was to measure caspofungin plasmatic
parameters in patients with candidaemia.
Methods: We studied non-obese adult patients with candidaemia treated
with iv caspofungin at the recommended dosage. Plasma samples for PK
measurements were collected at the steady state condition, immediately
before caspofungin infusion and 1, 2, 5, 9 and 24 hours after the
daily dose. Caspofungin plasma concentrations were determined using
a fully validated HPLC-UV method. Pharmacokinetics parameters were
obtained using WinNonlin software. Cmax/MIC and AUC/MIC were
calculated considering the highest MIC reported for susceptible strains.
Results: Twelve patients (9 males, 3 females) were evaluated. Five pa-
tients were liver transplant recipients, 5 had haematologic malignancies
and 2 had AIDS. Five out of 12 patients were infected by Candida
non-albicans strains. All Candida isolates were sensitive to caspofungin
according to the CLSI breakpoints (MIC< 2mcg/ml). Mean+SD Cmax,
Cmin and AUC were respectively 8.36+2.18mg/L, 1.98+0.87mg/L and
80.45+28.84 h*mg/L. Mean plasma half-life was 15.5+4.7 hours and the
mean plasma volume of distribution at steady state was 8.63+1.98 L/kg.
Considering a MIC= 2mcg/ml, mean Cmax/MIC and AUC/MIC resulted
respectively 4.18 and 40.2.
Conclusion: Caspofungin PK values measured in our patients were
similar to those reported in healthy men, conﬁrming a prolonged half-
life and a high volume of distribution. Moreover, our data highlight
that the Cmax/MIC and AUC/MIC ratios may be acceptable even with
MIC values equal to the higher value of in vitro sensitivity. Such PK
parameters are clearly higher with clinical isolates of Candida with MIC
lower than 2mcg/ml. The role of TDM of caspofungin in the human
clinical setting needs further studies.
P1311 Pneumocystis jirovecii dihydropteroate synthase gene
mutations and sulfa resistance
V. Friaza °, R. Morilla, S. Gutierrez-Rivero, N. Respaldiza, E. Campano,
M.A. Montes-Cano, F.J. Medrano, J.M. Varela, E. Caldero´n, C. de
la Horra (Seville, ES)
Background: Sulfa drugs, trimethoprim-sulfamethoxazole and dapsone,
are mainstays for prophylaxis and treatment of Pneumocystis pneumonia
(PcP), a life-threatening disease in immunosuppressed patients. The
inability to culture Pneumocystis has led to develop molecular
techniques based on identiﬁcation of punctual mutations on the
Dihidropteroate Synthase gene (DHPS) that cause sulfa resistance in
other microorganisms. A key issue is whether the emergence of DHPS
mutations is result of transmission between patients or arises from
selection by the pressure of sulfa drugs, two possibilities are not
mutually exclusive. The role of Pneumocystis colonised subjects in
transmission of DHPS mutations still unknown. The aim is to provide
epidemiological data of P. jirovecii DHPS mutations among PcP patients
and immunocompetent colonised subjects.
Methods: The study included 47 PcP patients and 75 Pneumocystis
colonised subjects during 2001–2007 identiﬁed by nested PCR at
mtLSUrRNA gene. DHPS mutations were studied by Restriction
Fragment Length Polymorphism using Acc I and Hae III at nucleotide
positions 165 and 171 respectively.
Results: The analysis showed a 19.7% prevalence of DHPS gene
mutations in the overall population. All possible polymorphisms
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described were identiﬁed. There were not difference between the
frequency of DHPS mutations in PcP patients and colonised subjects
(23.4% vs 17.3%; p = 0.75). A trend towards decreased frequency was
observed during this period (31.3% of DHPS-mutations during 2001 to
11.6% at 2007).
Conclusions: Similar DHPS pattern was observed in PcP patients
and immunocompetent colonised subjects suggests that both group
could share a common transmission cycles of mutated strains, and
arise question about the role that colonised subjects could represent
as reservoir for DHPS mutations with ability to transmit them to
immunocompromised hosts susceptible to PCP.
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P1312 A new real-time PCR assay for the direct detection
of Chlamydia trachomatis, Neisseria gonorrhoeae and
Mycoplasma genitalium
G. Clarebout °, C. Bordet, C. Calie, O. Pradillon, L. Monfort,
P. Sednaoui (Marnes-la-Coquette, Paris, FR)
Objective: Bio-Rad has developed a new Real Time PCR assay for the
direct detection of Chlamydia trachomatis (CT), Neisseria gonorrhoeae
(NG) and Mycoplasma genitalium (MG) from DNA extracts of First
Void Urine (FVU) or vaginal, urethral, cervical and rectal swabs samples
resuspended into a transport medium.
This study was conducted in order to (1) evaluate the clinical
performances of this new assay versus Roche COBAS TaqMan CT and
Amplicor NG tests; (2) prove the interest of MG screening.
Methods: The study took place at Institute Alfred Fournier (IAF) Paris,
France, a STI-specialised medical centre. The reference assays were
Roche Cobas TaqMan48 for CT, Roche Cobas Amplicor and culture
for NG and an in-house PCR for MG. For the reference and Bio-Rad
assays, DNA was extracted with a manual extraction method, provided
in the kit.
Results: 276 samples were tested with the Bio-Rad and the reference
assay, including 137 FVU and 139 swab specimens (4 urethral, 114
cervical, 20 rectal and 1 throat).
CT: 51 samples were positive with both techniques. The clinical
sensitivity and speciﬁcity of the Bio-Rad assay were 100% versus the
reference test.
NG: 36 of 36 positive samples were in agreement with the three
techniques. 3 Bio-Rad False Positive (FP) samples were detected
resulting to 100% sensitivity and 98.7% speciﬁcity compared to Roche
techniques. These 3 Bio-Rad FP samples contained N. meningitidis
and came from 3 male patients. IAF consulting population is mainly
constituted of homosexually active men with cross-contaminations.
MG: 12 samples were found positive with the Bio-Rad test, among
them only 8 were concordant with the reference in-house test. The
4 discordant Bio-Rad extracts were re-evaluated with a third PCR
technique, conﬁrming their positivity.
Among the 12 positive samples, 6 were co-infected with either CT or
NG and 6 were CT or NG negative including 3 samples from patients
with clinical signs (uretritis and cervicitis).
Conclusion: The Bio-Rad test presents performances similar to Roche
tests for the detection of CT and NG. Moreover, this study points out the
importance of routine testing for MG, a pathogen too often left untreated
because undetected, particularly in patients co-infected with CT or NG.
P1313 Evaluation of a commercial assay for fast and efﬁcient
detection of Chlamydia trachomatis-DNA in clinical
specimens with a rapid PCR-based dipstick assay
M. Weizenegger °, J. Bartel (Heidelberg, DE)
Objectives: The purpose of this study was to evaluate the new molecular
dipstick assay GenoQuick® CT (Hain Lifescience, Nehren, Germany)
and a fast and cost effective DNA isolation system (GenoLyse®) for
the direct and speciﬁc detection of Chlamydia trachomatis in urine and
cervical swabs.
Methods: 88 urines and 69 swabs (VIDAS Chlamydia, BioMe´rieux,
Nu¨rtingen, Germany) were analysed with the GenoLyse®-DNA-isolation
kit and the GenoQuick® CT assay. Results were compared to
data received from the COBAS TaqMan® CT (Roche Diagnostics,
Mannheim, Germany).
Swabs were washed out in 1ml of sterile saline. Either 500ml urine or
saline was transferred in to a tube and centrifuged. The supernatant was
discarded and the pellet resuspended in 100ml of lysis reagent. After a
5min heating step in boiling water 100ml of neutralistion reagent was
added. PCR was performed in a ﬁnal volume of 50ml containing 5ml of
the DNA-solution and 1 U HotStar-Taq (Qiagen, Hilden, Germany).
10ml of the PCR-ampliﬁcation mix was analysed with a PCR-dipstick in
100ml running buffer in a deep well micro titer plate. The stick contains
3 lines for wild type detection, ampliﬁcation control and run control and
were evaluated after 10min by eye.
Samples were analysed in parallel with DNA-isolates derived from
an automated DNA isolation system (Chemagic MSM I, Chemagen,
Baesweiler, Germany) and ampliﬁed with the Roche COBAS TaqMan
48.
Results: The GQ CT assay showed for urine specimens sensitivity,
speciﬁcity, positive predictive and a negative predictive value of 100%,
98.5, 95.2 and 100% and for cervical swabs of 100%, 96.3%, 75.0%,
and 100% compared to the COBAS® TaqMan® CT results.
Conclusions: The GenoQuick CT dipstick assay for the direct detection
of Chlamydia trachomatis is proved to be rapid, sensitive and speciﬁc.
The turnaround time is approximately 4 hours. In opposite to other assays
no cost intensive equipment is needed.
P1314 Chlamydia trachomatis detected in a Croatian national
public health institute between 2004–2008
A. Babic-Erceg °, S. Ljubin Sternak, G. Vojnovic, N. Bauk (Zagreb, HR)
Objectives: Chlamydia trachomatis is a pathogen of global public
health signiﬁcance. Its infection is one of the most important sexually
transmited diseases.
The diagnosis relies entirely on laboratory techniques. Chlamydial
research has been guided and determined by developments in diagnostic
technology.
Materials and Methods: Sample collection: Cervical and urethral
swabs were transported in 2-SP transport medium, and ﬁrst-voided urine
specimens, sperm specimens and expressed prostatic secretions (EPS) in
the sterile containers.
Two methods were used:
1. Isolation on McCoy cells (ECACC, UK) with detection by group
speciﬁc monoclonal antibodies (Bio-Rad).
2. Nucleic acid ampliﬁcation tests (NAATs)
a. PCR Cobas Amlicor CT/NG method (Roche Diagnostics)
b. Real time PCR (TaqMan technology, ABI 7500, Applied Biosystems)
using probe and primers retrieved from the database at the National
Center for Biotechnology Information (www.ncbi.nlm.nih.gov/blast).
DNA extraction was preformed with Amplicor CT/NG specimen
preparation kit (Roche) for swabs and QIAamp Blood mini Kit (Qiagen)
for other specimens.
Results: In a four year period, total of 41902 specimens from outpatients
(36615 female, 4477 male) were examined by cell culture method
(N= 27919) and by one of the NAATs (N= 13173). There were 33173
cervical swabs, 5924 urethral swabs (3107 female, 2817 male), 541
urine samples (335 female, 206 male), 640 sperm specimens and 814
EPS. The overall prevalence of C. trachomatis infection was 1.59%
(667/41902). There were 511/33173 (1.5%) positive cervical swabs,
84/2817 (2.9%) male urethral swabs, 35/3107 (1.1%) female urethral
swabs, 10/206 (4.8%) male urine samples, 4/335 (1.2%) female urine
samples, 4/640 (0.6%) sperm specimens and 19/814 (2.3%) EPS. There
was no inhibition in NAATs.
Conclusion: Our results in a four year period show low prevalence of
C. trachomatis infection. There is lower prevalence in female population
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than in male. It is also lower when using cell culture instead of PCR.
There is an absolute need for testing sperm samples by PCR because of
its toxicity to culture cells.
P1315 A molecular assay detecting quinolone resistance in
Neisseria gonorrhoeae: treatment with ciproﬂoxacin can
still be an option
R. Nijhuis °, B. Slotboom, T. van Zwet (Velp, NL)
Objectives: In the Netherlands, resistance of ciproﬂoxacin in Neisseria
gonorrhoeae (quinolone resistant Neisseria gonorrhoeae (QRNG)) has
increased rapidly in recent years to about 30%. As a consequence
guidelines for the initial treatment of this infection have been altered.
In the majority of cases, where no susceptibility pattern is available,
intramuscular cefotaxim is now regarded the ﬁrst option.
To make a more speciﬁc approach possible for the individual patient, we
wanted to implement a polymerase chain reaction (PCR) detecting these
QRNG.
Methods: Using a Real Time PCR (JCM 2004:42; 3281–3283) targeting
the intact gyrA and parC quinolone resistance-determining regions
(QRDRs), we aimed to detect whether the Neisseria gonorrhoeae is
susceptible, intermediate or resistant to ciproﬂoxacin. This method is a
good model for resistance detection using nucleic acid ampliﬁcation
tests since the QRNG resistance mechanisms are based on stepwise
accumulation of point mutations. In this PCR, a signal for gyrA as
well as for parC should indicate susceptibility, a signal for gyrA or
parC an intermediate susceptible strain, whereas no signal should signify
resistance.
Performance of this assay was tested using 63 isolates with a known
susceptibility. Susceptibility was tested using disk diffusion according
to the Dutch CRG guidelines (S: 36mm; I: 35−30mm; R: <30mm).
A total of 26 susceptible, 6 intermediate and 31 resistant isolates were
evaluated. In case of discrepant results, E-testing was performed (S:
MIC 0.06; I: MIC 0.12–0.5; R: MIC 1.0).
Results: Of the 26 susceptible isolates, 24 gave a signal with both
gyrA and the parC genes. In the remaining two only parC gene was
detected. E-testing of these two isolates revealed one susceptible and
one intermediate strain. In the 6 intermediate isolates and the 31 resistant
isolates, a 100% correlation with the traditional culture method was seen.
Conclusion: This PCR real time assay has the potential to differentiate
between susceptible and non-susceptible isolates of Neisseria gonor-
rhoeae without using culture methods. This informs the clinician whether
treatment with ciproﬂoxacin instead of a third generation cephalosporin
is still an option.
P1316 Metagenomic assessment of sputum microbiota from
patients with chronic pulmonary diseases
V. Friaza, C. de la Horra, G. Ayala, L. Ma´iz, J. Dapena, R. Canton,
E. Calderon, R. del Campo ° (Seville, Madrid, ES)
Objective: To identify the main features of microbiota associated with
cystic ﬁbrosis (CF) and bronchiectasis, two models of chronic lung
diseases, using a non-culture microbiological approach.
Methods: Sputum samples (one per patient) were collected from
15 CF-patients and from 15 patients with non-CF bronchiectasis. All
patients presented a stable clinical status without acute exacerbations.
Total DNA from each sputum sample was obtained manually using
a phenol/chloroform protocol and diluted up to 50 ng/ml. PCR-DGGE
technique was performed in all samples using universal primers for
Bacterial Domain based on 16S rRNA conserved regions. Amplicons
were separated in vertical electrophoresis polyacrylamide gels (8%) at
60ºC; with a urea-formamide denaturating gel gradient of 30−45%. Gels
were visualised with ethidium bromide; common and unique bands were
excised, re-ampliﬁed and sequenced in order to assign bacterial species
identiﬁcation. Similarities among the electrophoretic band patterns were
analyzed using the Phoretrix 5.0 software® and dendrograms were
constructed based on the Dice coefﬁcient.
Results: All CF-patient samples presented a marked band of
Pseudomonas aeruginosa, which was undetectable in those patients
with bronchiectasis. On the other hand, several band patterns were
common to both groups. As expected, different species corresponded
to bacteria habitually found in sputum samples (Haemophilus in-
ﬂuenzae, Stenotrophomonas maltophilia, Moraxella spp., Actinomyces
odontolyticus.) although several sequences corresponded to uncultured
bacterium related with Streptococcus, Actinobacterium or Neisseria
groups. Interestingly, environmental organisms such as Pseudomonas
synxantha, Ochrobactrum anthropi, Rothia amarae, Rothia mucilaginosa,
Phycicoccus dokdonensis, or Arthrobacter spp. were detected.
Conclusion: Metagenomic tools are useful to identify the microbiota
present in patients with chronic pulmonary diseases. Moreover, we were
able to detect uncultured and environmental bacteria in sputa from
CF and non-CF bronchiectasis patients that have not been previously
described in this type of samples.
P1317 Use of novel electrochemical labels in a highly sensitive,
multiplex detection method for use in a rapid point-of-care
molecular assay
M. Green °, D. Pearce, A. Dixon, T. Jenkins, C. Frost (Trowbridge,
Bath, UK)
Objectives: To demonstrate the advantages of novel ferrocene-based
electrochemical labels used in a highly sensitive multiplex assay for
Chlamydia trachomatis, compatible with a rapid point-of care diagnostic
platform. To show how a range of electrochemical labels with different
oxidation potentials can be used in a multiplex assay for C. trachomatis,
Neisseria gonorrhoeae and an internal control.
Methods: A Chlamydia trachomatis speciﬁc PCR primer set was
used to asymmetrically amplify target DNA extracted from Elementary
Bodies (EB). A single-stranded DNA probe was synthesized with the
electrochemical label linked to the 5′ base via the terminal phosphate
group. This probe was hybridised to the C. trachomatis amplicon, then
incubated in the presence of a double-stranded DNA speciﬁc exonuclease
(T7 exonuclease). The released label was measured by performing a
voltammetric scan on the samples using screen printed carbon electrodes.
The C. trachomatis assay (above) was run in a multiplex assay with
Neisseria gonorrhoeae and an internal control, using speciﬁc primers and
probes for each target. An electrochemical label, with a unique oxidation
potential, was coupled to each probe, these were then hybridised
and incubated with the exonuclease in the multiplex mix. A single
voltammetric scan was performed using screen printed carbon electrodes.
Table 1. Results for PCR with electrochemical end-point detection of a dilution
series of Chlamydia trachomatis Elementary Bodies and DNA from common cross-
reactants
Sample Oxidation
potential
(mV)
Mean electrochemical
measurement (nA)
Standard
deviation
%CV
1000 CtEB* 192 216.33 11.02 5.1
100 CtEB* 198 109.47 25.17 23.0
10 CtEB* 198 65.07 4.66 7.2
1 CtEB* 201 54.97 25.29 46.0†
No DNA/EB Control − 0 − −
E. coli − 0 − −
Strep. agalactiae − 0 − −
Candida albicans − 0 − −
N. gonorrhoeae − 0 − −
E. faecalis − 0 − −
S. aureus − 0 − −
Lactobacillus sp. − 0 − −
T. vaginalis − 0 − −
Human − 0 − −
*CtEB = Chlamydia trachomatis Elementary Bodies; †Higher %CV due to
sampling at low level dilutions.
Results: The C. trachomatis molecular assay has been demonstrated
to show a limit of detection down to a single EB. Negative controls
(no EBs and non-target DNA), showed no voltammetric measurement
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above baseline level (see data). The assay was performed on all 15
C. trachomatis serovars and demonstrated 100% speciﬁcity against a
panel of 90 possible cross-reactants.
The multiplex electrochemical assay using C. trachomatis, N. gonor-
rhoeae and internal control provided discrete voltammetric signals at
the 3 oxidation potentials for the electrochemical labels, when measured
using a single voltammetric scan. Removal of an individual target from
the multiplex assay, resulted in removal of the voltammetric peak at the
associated oxidation potential.
Conclusions: The electrochemical detection method demonstrates a high
level of sensitivity in a C. trachomatis assay and has shown to be
capable of providing a multiplex platform for a diagnostic test panel.
The methods and materials used in these tests were directly compatible
with a rapid point-of-care platform.
P1318 MALDI-TOF MS based identiﬁcation of Staphylococcus
hominis using the BioTyperTM software
J.K.M. Knobloch °, I. Machova, W. Solbach, P. Petras (Lubeck, DE;
Prague, CZ)
Objective: Staphylococcus hominis strains are one of the major
staphylococcal species inhabitating the skin of humans. Staphylococcus
hominis is subdivided in the subsp. hominis and novobiosepticus.
Staphylococcus hominis subsp. novobiosepticus is a multiresistant
pathogen occuring with increasing frequency in human clinical material
like aetiological agent of nosocomial infections. Most commercial
identiﬁcation systems are not able to differentiate these subspecies. We
evaluated the performance of the BioTyperTM software for MALDI-TOF
MS based bacterial identiﬁcation for the differentiation of the S. hominis
subspecies.
Methods: 20 isolates of S. hominis subsp. hominis and 22 isolates
of S. hominis subsp. novobiosepticus from different years and origins
were analysed by MALDI-TOF mass spectroscopy using direct smear
and Ethanol-formic acid extraction (EFAE) for sample preparation.
The resulting mass spectra were automatically analyzed using the
BioTyperTM database. Currently, the database has 6 entrances for
S. hominis (3 subsp. hominis, 1 subsp. novobiosepticus, and 2 type strains
without subspecies designation).
Results: All 42 strains were correctly identiﬁed as S. hominis on
the species level with high score values (>2.3) independent of the
preparation method. In the majority of strains the highest similarity
was calculated to one of the S. hominis reference strains without subsp.
designation (32 by direct smear and 40 by EFAE). A correct classiﬁcation
of the subsp. was only observed in 4 strains by direct smear and
2 strains by EFAE. Using direct smear as preparation method a bias
in the identiﬁcation towards S. hominis subsp. hominis was observed
independent of the respective subspecies. Using EFAE as preparation
method a bias towards S. hominis subsp. novobiosepticus become evident
(second best similarity for 36/42 strains).
Conclusions: The BioTyperTM system for MALDI-TOF based bacterial
identiﬁcation is highly accurate in the species identiﬁcation of S. hominis
even in a simple direct smear preparation on the target plate.
Subsp. identiﬁed by the BioTyperTM database should currently not be
reported without further biochemical analysis. More Database entrances
and further bioinformatic processing are required to differentiate the
S. hominis subsp. by the BioTyperTM software.
P1319 Mutation induction characteristics and parameters of
antibiotic stress
A.T. Wong °, M.L. Chin, W.C. Chan, M.L. Ling (Hong Kong, HK)
Objectives: The term “Adaptive Mutation” describes a cellular
mechanism in bacteria that generates genetic changes in non-growing
population under stress. The difﬁculty to differentiate whether newly
emerged mutants are due to selection or induction by stress results in
controversies over its existence. This study aimed at determining whether
target-speciﬁc adaptive mutation played a role in conferring antibiotic
resistance to bacteria. Four major aspects of antibiotic resistance gene
mutations were studied – drug speciﬁcity in resistance induction,
mutation site speciﬁcity, rate of mutation formation and physiological
stages in which mutations preferentially developed.
Methods: The study approach involved phenotypic screening and
analysis of several categories of resistant mutants of a model organism
Escherichia coli, which were collected under different physiological
conditions with or without antibiotic stress, as well as subsequent
determination of drug susceptibility proﬁles and sequencing of speciﬁc
genes. Four antibiotics of different classes (ampicillin, ciproﬂoxacin,
rifampicin and gentamicin) were used in cross induction and screening
experiments. The number and phenotypes of resistant isolates that
emerged at various physiological stages, under short and long term
exposure to different levels of antibiotic stresses, were used to depict
the mutation induction characteristics of speciﬁc antibiotic stress.
Results: In an attempt to assess mutation induction speciﬁcity of
antibiotics, the cellular process governing the emergence of antibiotic
resistant cells was found insensitive to drug induction. Mutation
development was highly dependent on bacterial physiological stages.
Rifampicin and gentamicin resistant isolates existed before antibiotic
induction and selection, however, such mutants were not cross-resistant
to other antibiotics, indicating presence of site-speciﬁc mutant sub-
groups among the spontaneous mutants in various bacterial populations.
Analysis of mutation patterns of resistance genes in isolates collected
from various induction conditions provided further information on the
speciﬁcity of the mutations which emerged before or after the antibiotic
induction.
Conclusion: Our data suggest the presence of speciﬁc physiological
processes that regulate the production, nature and size of antibiotic-
resistant mutant populations. Such processes appear to be sensitive to
starvation rather than antibiotic stress.
P1320 Mycobacterium tuberculosis cpsA is a master regulator in
adaptation to the macrophage phagosome
M. Alzohairy °, J.E. Graham (Buraydah, SA)
Mycobacterium tuberculosis maintains a relatively large genetic reper-
toire for adaptation to a variety of different environments encountered
during typical respiratory infections. Adaptation to these in vivo niches
is critical in maintain and sustaining infection. An environment of
central relevance in all infections, and among the ﬁrst encountered, is
that within the phagosomes of human macrophages. Global analyses
of bacterial RNAs produced in response to phagocytosis produced a
list of candidates including that predicted to encode the transcriptional
regulator CpsA. We investigated the contribution of cpsA regulated
gene expression to M. tuberculosis pathogenesis and identiﬁed a large
regulaon consisting of about 30 genes whose transcript levels were
increased by increased cpsA expression. These included transcriptional
regulators sigE, sigB, Rv0195, and indicating a regulatory cascade
initiated by cpsA expression following phagocytosis. Bacterial mutants
unable to express cpsA were impaired in intracellular growth and
this defect was complemented by restoration of cpsA. We provide the
initial characterisation of a key transactional activator initiating a global
regulatory response allowing M. tuberculosis to colonise its normal
ecological niches in the macrophages phagosome.
P1321 Evaluation of MTB Q Alert kit for detection of
Mycobacterium tuberculosis directly on patient samples
A.C. Mendes °, S.J. Fernandes, L.C. Ferreira, M. Pereira, H. Ramos,
J.M. Cabeda (Porto, PT)
Objectives: Laboratory diagnosis of active tuberculosis is still very
time consuming, since culture takes weeks to months for positivity,
and the molecular biology assays generally used for this purpose are
very labour intensive. Thus the clinical need for a fast diagnosis of
tuberculosis would beneﬁt from the use of Real-time-PCR techniques
that are generally very fast, automated and extremely sensitive and
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speciﬁc. In the present study we evaluated such an assay, comparing its
output to the method currently in use in the Clinical molecular diagnostic
lab of our hospital.
Methods: Forty patient samples and 5 quality control samples were
used for the evaluation of the MTB Q Alert Real-Time-PCR kit
from Nanogen. All Patient samples had been routinely tested for
Mycobacterium tuberculosis by the Ampliﬁed MTD Assay (Genprobe).
Results: All Real-time-PCR results obtained with the MTB Q Alert
kit proved to be completely concordant with the Ampliﬁed MTD
results. Also, all quality control samples tested were found to generate
concordant results with the expected results provided by the external
control panel manufacturer. However, 33% of the patient samples studied
did not generate Real-time-PCR data due to PCR reaction inhibition
attributable to the sample.
The Real-time-PCR assay was found to have a 100% sensitivity,
speciﬁcity, Negative predictive value and positive predictive values, but
seems to be useless in a signiﬁcant number of patient samples due to
inability of the extraction procedure to remove PCR inhibitors from the
sample. Furthermore, the extremely labour intensive extraction procedure
counterbalances the Real-time-PCR speed, drastically reducing its
advantages in the clinical setting. In addition, the use of the relatively
slow ABI 7300 platform further reduces the advantage of the Real-time-
PCR in an assay that should be performed as soon as sample arrives to
the lab.
Conclusion: In conclusion, the ampliﬁcation assay proved to be very
sensitive and speciﬁc, but its usefulness was severely damaged by
the DNA extraction procedure. Future work on alternative preferably
automated extraction procedures should be done to obtain maximal
usefulness of the ampliﬁcation procedure.
P1322 Development and application of a multiplex polymerase
chain reaction assay for rapid differential diagnosis between
extrapulmonary tuberculosis and focal complications of
brucellosis
J.D. Colmenero °, M.I. Queipo-Ortun˜o, P. Bermudez, A. Plata,
P. Morata (Ma´laga, ES)
Objectives: The aim of this study was to develop a multiplex real-
time PCR (M RT-PCR) assay to simultaneously detect Brucella spp
and M. tuberculosis complex DNA and analyze its yield in the rapid
differential diagnosis between extrapulmonary tuberculosis and certain
focal complications of brucellosis.
Methods: A broad panel of Brucella and Mycobacterium strains and
forty-ﬁve consecutive non-blood clinical specimens from 25 patients
with different focal complications of brucellosis and 18 patients with
extrapulmonary tuberculosis were studied by M RT-PCR assay. Control
samples were obtained from 26 patients with other disorders initially
involving a differential diagnosis with extrapulmonary tuberculosis or
brucellosis. For the detection of Brucella spp, a 207 bp fragment from the
conserved region of the gene which encodes an immunogenic membrane
protein of 31 kDa of B. abortus (BCSP31) speciﬁc to the Brucella
genus and present in all its biovars was ampliﬁed using the primers
B1 and B2. Primers M1 and M3 amplifying a sequence of 164 bp
based on the intergenic region of the genes coding for a mycobacterial
two-component system SenX3-RegX3 were used for the identiﬁcation
of Mycobacterium tuberculosis complex. To conﬁrm the identities of
the ampliﬁed fragments, sequence analysis was carried out. Sensitivity,
speciﬁcity, positive and negative predictive values, accuracy, likelihood
ratios (LR) and 95% conﬁdence intervals (CI) of M RT-PCR were
calculated
Results: The detection limit of the M RT-PCR was 2 genomes per
reaction for both pathogens and the intra- and inter-assay coefﬁcients
of variation were 0.44% and 0.93% for Brucella and 0.58% and 1.12%
for Mycobacterium. M RT-PCR correctly identiﬁed 42 of the 45 samples
from patients with tuberculosis or brucellosis and was negative in all the
controls. Thus, the overall sensitivity, speciﬁcity, PPV and NPV values of
the M RT PCR assay were 93.3%, 100%, 100% and 89.7%, respectively,
with an accuracy of 95.8% (95%CI, 91.1%-100%).
Conclusions: Since M RT-PCR is highly reproducible and more rapid
and sensitive than conventional microbiological tests, this technique
could be a promising and practical approach for the differential
diagnosis between extrapulmonary tuberculosis and focal complications
of brucellosis.
P1323 Identiﬁcation of Nocardia from respiratory specimens
by using 16SrRNA gene sequencing in Zaragoza, Spain
between 1998 and 2003
M.C. Villuendas, A. Betran, A. Rezusta °, B. Moles, M.J. Revillo,
P. Boiron, A. Couble, V. Rodriguez Nava (Zaragoza, ES; Lyon, FR)
Objectives: To determine the incidence of Nocardia sp. from respiratory
specimens in the H.U. Miguel Servet between 1998 and 2003.
Identify Nocardia to the species level using 16SrRNA gene sequencing.
Methods: Respiratory samples were cultured in blood, chocolate,
Sabouraud and BCYE agar and were incubate for 7 days at 37ºC.
In this period of 5 years, 125 Nocardia strains were isolated from
bronchoalveolar lavage ﬂuids, bronchial secretion aspirates and sputa.
The identiﬁcation was performed on the basis of visualisation of
colony coloration and morphology, Gram and modiﬁed acid-fast staining,
adenine, casein, xanthine, hypoxanthine, tyrosine, Middlebrook and
antimicrobial susceptibility patterns. Complete molecular identiﬁcation
was performed in the French Observatoire for Nocardiosis based on 16S
rRNA gene sequencing.
Results: Between 1995 and 2003, were diagnosed 125 cases of
respiratory isolates being 48 females (38%) and 77 males (62%).
The following species were isolated: Nocardia abscessus (n = 45),
Nocardia farcinica (n = 24), Nocardia cyriacigeorgica (n = 14), Nocardia
transvalensis (n = 4), Nocardia veterana (n = 5), Nocardia nova (n = 3),
Nocardia pneumoniae (n = 5), Nocardia asteroides (n = 2), Nocardia
carnea (n = 8), Nocardia cerradoensis (n = 1), Nocardia ﬂavorosea
(n = 1), Nocardia ignorata (n = 1), Nocardia otitidiscaviarum (n = 1),
Nocardia testacea (n = 1) and Nocardia spp (n = 10).
Conclusions: The present study shows the ﬁrst results of nocardial
incidence in Zaragoza and exposes the predominance of Nocardia
abscessus (36%) and Nocardia farcinica (19%). The development of
methods like 16SrRNA gene sequencing will facilitate rapid diagnosis,
epidemiological studies and prompt the initiation of the appropriate
chemotherapy. The incidence of Nocardia spp. in our hospital is
remarkable so when physician have one suspicion about this infection in
patients with risk factors, should informed to microbiologists to include
speciﬁc media cultures and be incubated for a long period of time.
P1324 Genetic analysis of the cap locus of Haemophilus inﬂuenzae
serotype E
M. Giufre`, R. Cardines, M. Accogli, P. Mastrantonio, M. Cerquetti °
(Rome, IT)
Objectives: Although immunisation of infants with conjugate vaccines
against H. inﬂuenzae serotype b (Hib) has dramatically decreased the
incidence of invasive Hib disease in developed countries, the potential
for emergence of non-vaccine preventable strains has been suggested.
Invasive disease caused by H. inﬂuenzae serotype e (Hie) strains has
been recently observed in Italy, suggesting the importance of further
molecular investigations on Hie genetic locus for the capsule biosynthetic
genes (cap locus). The sequence of the entire Hie cap locus has not
been previously described. In the present study, the Hie cap locus was
characterised.
Methods: The location of the Hie cap locus within the chromosome
was investigated in 11 invasive Hie isolates by PCR ampliﬁcation and
sequencing of the DNA regions ﬂanking the ends of the locus. The cap
locus from the invasive strain Hie 274 was sequenced. To encompass the
entire cap locus, overlapping amplicons, ranging from 1500 bp to 9 kb,
were generated by PCR. Each amplicon was then subcloned into pCR4-
TOPO and the insert from each plasmid was sequenced. In all isolates,
the copy number of the Hie cap locus was determined by Southern blot
analysis.
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Results: In each isolate, the chromosomal location of the Hie cap locus
was identical to that previously described for H. inﬂuenzae serotype f
strain 7000222 and associated with the same ﬂanking genes (sodC at
the 5prime; end and HI1637 at the 3′ end). No sequences reminiscent
of the IS1016 element were found to ﬂank the locus. The Hie cap locus
included 14 ORFs organised in three distinct functional regions (I, II
and III). Both regions I and III showed high sequence identity to the
previously described corresponding regions from Hib and Hif. Eight new
ORFs (named ecs1 to ecs8) were identiﬁed in the Hie capsule-speciﬁc
region II. All isolates were found to contain only one copy of the Hie
cap locus.
Conclusion: Chromosomal location of the Hie cap locus is conserved
among our isolates. Although Hie strains belong to the major
phylogenetic division I (majority of serotypes a, b strains and all
serotypes c, d, and e strains), the Hie cap locus appeared to be located
in the same chromosomal site as that of serotype f strains. The Hie cap
locus is not ﬂanked by direct repeats of IS1016 and, accordingly, it is not
ampliﬁed. Genes within the locus are organised in three distinct regions
as other group II capsule biosynthetic clusters.
P1325 Global comparison of recA gene sequences from clinical
and environmental Vibrio cholerae strains isolated in Iran
A. Dashtbani °, B. Bakhshi, M. Pourshaﬁe (Tehran, IR)
Objectives: Vibrio cholerae is a natural inhabitant of the aquatic
environments. Pathogenic strains of V. cholerae can cause cholera
disease which is one of the major concerns in the health system.
Recently, it was hypothesized that some pathogenic strains evolved
from environmental nonpathogenic strains. We aimed to determine the
genetic relatedness and pattern of nucleotide sequence variation among
clinical and environmental V. cholerae strains in Iran based on recA
gene analysis. We also compared our sequences with that of strains
from different countries available online in the database.
Methods: We ampliﬁed internal fragment of recA gene of 10
environmental and 12 clinical strains of Vibrio cholera isolated from
surface waters and hospitalised patients from Iran during 2004–2008.
PCR products, sized 1100 bp, were subjected to sequencing. DNA
sequence data were analyzed with MEGA4 program. Sequences of recA
gene of 203 strains were obtained from NCBI database. Alignment of
all the mentioned sequences were performed. We found 530 nucleotide
in common. The gene tree was constructed by UPGMA method.
Results: From the 530 nucleotide (nt), 395 nt (74%) were conserved
among all the global strains. We found 135 variable sites. Of which, 25
nt (4.71%) and 110 nt (20.75%) were singleton and phylogenetically
informative, respectively. One of our environmental isolates was
identical to clinical ones based on recA sequence. We observed the
most variation among the environmental isolates (59 nt) whereas the
clinical isolates showed at most 5nt difference with each other. Three
of our environmental isolates had unique sequences but the others
were clustered with strains from some other countries. Most of the
clinical isolates grouped together forming the largest cluster containing
71 members which included 8 of our clinical isolates. The other two
Iranian clinical isolates formed a separate cluster.
Conclusion: DNA-based typing methods enables researchers to compare
their results with other countries online and draw conclusions about
the evolution of pathogenic bacteria. Our ﬁndings suggest that analysis
of recA gene sequences can be used as a reliable tool for global
investigations of V. cholerae population stucture. In future, we analyze
some other housekeeping genes for drawing more robust conclusion
about the genetic variation in Vibrio cholerae population.
P1326 Characterisation of diversity in wbeT region of the
O-antigen biosynthesis gene cluster in Ogawa and Inaba
serotypes of Vibrio cholerae
A. Sharifnia °, B. Bakhshi, M. Hashemi, M.R. Pourshaﬁe (Tehran, IR)
Objectives: Vibrio cholerae serotype O1 Inaba and Ogawa have been
associated with widespread cholera outbreaks which occur annually in
Iran. An approximately 22 kb gene cluster is responsible for O1 antigen
biosynthesis. Serotype switching occurs within this cluster in the genome
of V. cholerae O1. It has been identiﬁed that product of wbeT region in
the cluster is a transferase enzyme and is responsible for the expression
of the B determinant, which is Ogawa-speciﬁc.
We determined to investigate any deletion in the wbeT region of the O1
antigen biosynthesis gene cluster responsible for serogroup conversion
in the V. cholerae O1 strains.
Methods: Thirty two V. cholerae isolates of clinical origin, isolated
and subjected to analysis. Serogrouping of isolates performed using
O1 polyvalent Ogawa and Inaba monospeciﬁc antisera. PCR assay
performed to analyze any deletion in the wbeT region from the beginning
up to end. Restriction fragment length polymorphism (RFLP), done by
using EcoRI restriction enzyme to digest the products and determine
any deletion or point mutation within the restriction sites of the enzyme.
Complete sequence analysis of wbeT region performed to assess any
variation in this region responsible for serogroup conversion in Inaba
isolates.
Results: The results of serogrouping showed that 66% isolates were
Inaba and 34% were Ogawa. An approximately 800 bp product obtained
for all of the isolates under study. RFLP analysis revealed no diversity
in the restriction sites of the enzymes nor any deletion in the fragments
obtained from the assay. Sequence analysis of the ampliﬁed fragments
performed by Clustal software, determined substitution of C for T in 295
in all Inaba strains. In addition to the unique mutation which mentioned
above, the strain 62013 (V. cholerae O1, Classic, Ogawa) which used as
positive control in all PCR assays, showed another substitution which
was A for C in 310. The recent mutation only reported in the strain
62013.
Conclusion: Results of this study indicate that no obvious deletion has
occurred in the wbeT region of Inaba strains in comparison to Ogawa.
Complete sequence analysis determined a substitution of Pro for Ser.
Another mutation which occurred in the strain 62013, led to substitution
of Lys for Gln. Since all of the strains under study were El Tor biotype
and 62013 was the only strain which was Classic, it seems that the
nucleotide in 310 in Classic biotypes can be an appropriate place for
point mutations.
P1327 Improved detection of bacterial gastro-intestinal pathogens
using molecular screening
R.F. de Boer °, A. Ott, B.I. Kesztyu¨s, A.M.D. Kooistra-Smid (Groningen,
NL)
Objectives: Traditional methods to detect gastro-intestinal (GI)
pathogens are slow, and/or lack sensitivity. Molecular detection of GI
pathogens has proven to be rapid, sensitive and feasible in a routine
microbiology setting (Schuurman, T. et al., JCM (45):3692–3700). Since
December 2006 a molecular screening approach for detection of bacterial
GI pathogens has been implemented in our microbiology laboratory. This
study describes the improved detection frequency of bacterial enteric
pathogens using multiplex real-time PCR (mPCR) in 2007.
Methods: During 2007, 10189 stool samples were sent to our
laboratory, and analysed with conventional culture (39.9%) or screened
for the presence of bacterial enteric pathogens with mPCR (61.1%).
Using mPCR, samples were screened for Salmonella enterica (SE),
Campylobacter jejuni (CJ), Shiga toxin-producing Escherichia coli
(STEC), and Shigella spp./enteroinvasive E. coli (SH/EIEC). All PCR
positive stool samples as well as samples that demonstrated PCR
inhibition were additionally tested with conventional culture (mPCR
guided culture). Detection frequencies of the molecular approach
were compared with those found using conventional culture for SE,
Campylobacter spp., STEC O157, and SH.
Results: Using the molecular approach, the detection frequencies were
2.5% for SE, 9.2% for CJ, 2.0% for STEC, and 1.5% for SH/EIEC. A
total of 133 (84%), 435 (77%), 9 (7.5%) and 19 (20%) mPCR positive
samples could be conﬁrmed with culture for SE, CJ, STEC, and Shigella
spp. respectively. Detection frequencies using conventional culture were
3.0% for SE, 5.8% for Campylobacter spp., 0.6% for STEC O157, and
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0.2% for SH. In comparison with conventional culture, the detection
of bacterial enteric pathogens, increased from 9.6% to 15.2% using the
molecular approach.
Conclusion:
1. In comparison with conventional culture, using a molecular screening
approach improved the detection of bacterial enteric pathogens
signiﬁcantly.
2. Pre-screening with PCR increased the proportion of Campylobacter
culture positive stools (7.0% versus 5.8%) signiﬁcantly.
3. This new molecular strategy in screening stool specimens for gastro-
intestinal pathogens has a potential to expand the mPCR enteric panel
with viral, parasitic and other bacterial targets.
P1328 Development and evaluation of internal ampliﬁcation
controls for real-time duplex PCR to detect Campylobacter
coli and C. jejuni
L.P. Randall °, A. Vidal, J. Rodgers, F. Clifton-Hadley (New Haw, UK)
Objectives: A common problem of both conventional and real time
PCRs is failure of DNA ampliﬁcation due to the presence of inhibitory
substances in the samples, particularly when using DNA from faecal
samples. In view of this, our aim was to develop/evaluate Internal
Ampliﬁcation Controls (IACs) for use with an existing duplex real time
PCR for Campylobacter coli and C. jejuni.
Methods: The Campylobacter PCR detected the ceuE gene of C. coli
and the mapA gene in C. jejuni. Both competitive and non-competitive
IAC’s were developed/evaluated. The competitive approach involved a
DNA fragment (60 bp) of the coding region of the viral ﬁsh haemorrhagic
septicaemia virus, ﬂanked by the mapA PCR primers, whilst the non
competitive approach utilised an extra set of universal 16S primers. Both
IAC PCR types were evaluated using pure cultures of C. coli or C. jejuni
and suitable negative control cultures as well as with chicken caecal
DNA extracts and diluted faecal supernatants, to study inhibitory effect
of faeces on the PCR. Duplicate naturally-infected and artiﬁcially-spiked
chicken caecal samples were prepared with Campylobacter (coli and/or
jejuni) present at c. 108, 106, 104 and 102 cfu/g. DNA was extracted
from these samples and from a further 20 “ﬁeld” faecal samples using
the “ExtraMaster Fecal DNA extraction kit”.
Results: Both the competitive (ﬁsh virus) and non-competitive (16S)
IACs had the potential to reduce the sensitivity of the PCR, although
this was reversed by dilution of the competitive IAC to 10–7. The signal
from the 16S IAC was lost in the presence of strong positive signal for
either C. coli or C. jejuni, whereas the signal from the ﬁsh virus IAC was
rarely affected by positive signals from C. coli and C. jejuni (Figure 1).
Faecal supernatants inhibited PCR reactions down to dilutions of ~1/16
to 1/128 and both the competitive and non-competitive components of
the PCR reactions were more sensitive to inhibition than the C. coli or
C. jejuni components of the PCR reactions.
Figure 1. Fluorescence readings for a chicken faecal sample positive for
IAC and Campylobacter jejuni.
Conclusion: Both IACs were shown to work in the duplex real time
PCR, but the competitive IAC was chosen as the preferred option, as the
signal for this IAC was not compromised by positive signals for C. coli
or C. jejuni. Both of the IAC’s were more sensitive to faecal inhibitors
than the C. coli or C. jejuni components of the PCR, making them both
suitable to detect inhibition which could lead to false negatives.
P1329 Whole genome sequencing of pathogenic and non-
pathogenic treponemes: comparison of syphilis and yaws
strains with Treponema paraluiscuniculi
D. Smajs °, M. Zobanı´kova´, D. Cejkova´, P. Matejkova´, M. Strouhal,
G.M. Weinstock (Brno, CZ; St. Louis, US)
Objectives: Treponema pallidum subsp. pallidum (TPA) is the causative
agent of syphilis, T. pallidum ssp. pertenue (TPE) causes endemic
treponematosis yaws, and T. paraluiscuniculi is not infectious to humans
but causes venereal spirochetosis in rabbits. TPA and TPE treponemes
are morphologically indistinguishable and their genomes show nearly
99% identity to the genome of T. paraluiscuniculi. To identify these
subtle genetic differences, whole genome sequencing is required.
Methods: The genomes of TPE strain Samoa D and T. paraluiscuniculi
strain Cuniculi A were sequenced using several whole-genome sequenc-
ing methods including comparative genome sequencing, pyrosequencing,
Solexa sequencing, and dideoxyterminator sequencing. Obtained whole
genome sequences were compared to the published sequence of TPA
strain Nichols.
Results: The genome size of TPA Nichols (1,138,006 bp), TPE Samoa D
(1,139,299 bp) and T. paraluiscuniculi Cuniculi A (1,133,391 bp) and the
overall gene order is similar in all investigated genomes. More than 50%
of Nichols and Samoa D genes encode sequentially identical proteins
whereas only 15% of those genes were found in the Cuniculi A and
Samoa D genomes. Major sequence changes including frameshifts were
found in 30 genes of the Samoa D genome and in 88 genes of the
Cuniculi A genome when compared to the Nichols genome.
Conclusions: Our results showed that the TPE Samoa D sequence is
more closely related to the reference Nichols genome than the Cuniculi A
sequence. Observed genetic changes are responsible for different
pathogenicity and host speciﬁcity of syphilis and yaws treponemes
compared to T. paraluiscuniculi.
This work was supported by the grants from the Internal Grant Agency
of the Ministry of Health of the Czech Republic (NR/8967–4/2006) and
from the Grant Agency of the Czech Republic (310/07/0321).
P1330 Study on the prevalence of tick-borne pathogens in the
Lublin region (eastern Poland)
A. Wo´jcik-Fatla, E. Cisak °, J. Chmielewska-Badora, J. Zwolinski
(Lublin, PL)
Objectives: The aim of the study was to evaluate infection rates
of Borrelia burgdorferi, Anaplasma phagocytophilum and tick-borne
encephalitis virus in ticks collected in from different provinces of the
Lublin region.
Methods: One thousand eight hundred thirteen Ixodes ricinus ticks
(females, males and nymphs) collected from forest areas of six provinces
of the Lublin region were examined for the presence of Borrelia
burgdorferi sensu lato DNA and Anaplasma phagocytophilum DNA by
PCR method. Fifty seven I. ricinus ticks from three provinces of the
Lublin region were tested in pools for tick borne encephalitis virus
(TBEV) by mice inoculation and cell culture.
Dermacentor reticulatus ticks collected from the Poleski National Park,
situated in the eastern part of the Lublin upland (Wlodawa district) were
examined individually for TBEV by nested RT-PCR method according
to Schrader and Su¨ss after a total RNA extraction by RNeasy Mini kit
(Qiagen, USA).
Results: The infection rate of B. burgdorferi DNA in I. ricinus ﬂuctuated
from 1.7% to 10.9% and the mean infection rate amounted to 5.4%.
The percentage of I. ricinus ticks infected with A. phagocytophilum was
within the range of 0.8%-8.3% (mean 5.9%). The minimum infection
rate of TBEV in I. ricinus ticks collected from Radzyn Podlaski district
was estimated as 4.2% and in the total area of the Lublin region was
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estimated as 1.8%. The total infection rate of TBEV in Dermacentor
reticulatus ticks from the Poleski National Park localities (Wlodawa
district) amounted 1.4%.
Conclusions:
1. Borrelia burgdorferi, Anaplasma phagocytophilum and tick-borne
encephalitis virus circulate in forest environment of the Lublin region
and indicate a risk for residents as well as for visitors.
2. The obtained results indicated a necessity for further study on TBEV
in the whole Lublin region.
Acknowledgement: This study was partly supported by the Polish
Ministry of Science and Higher Education, Grant No. N N404 029435.
P1331 Towards a comprehensive proteome mapping of the
opportunistic pathogen Cronobacter turicensis 3032
P. Carranza, I. Hartmann, A. Lehner, R. Stephan, P. Gehrig,
J. Grossmann, S. Barkow-Oesterreicher, B. Roschitzki, L. Eberl,
K. Riedel ° (Zurich, CH)
Members of the genus Cronobacter are notorious opportunistic
pathogens associated with contaminated milk powder formulas for
neonates; however, our knowledge about virulence mechanisms or
natural reservoirs is still scarce. The proteome of Cronobacter
turicensis 3032, which has recently caused 2 deaths in the Children
Hospital of Zurich, was mapped aiming on a better understanding
of physiology and putative pathogenic traits of this clinical isolate.
Our analyses of extracellular, surface-associated and whole-cell proteins
by two complementary proteomics approaches, one-dimensional gel-
electrophoresis coupled to liquid chromatography and electrospray
ionisation tandem mass spectrometry and two-dimensional liquid
chromatography coupled to matrix-assisted laser desorption/ionisation
time-of-ﬂight tandem mass spectrometry, lead to the identiﬁcation of
853 proteins corresponding to a remarkably 20% of the theoretically
expressed protein complement of C. turicensis. The majority of
the identiﬁed proteins are involved in central metabolic pathways,
translation, protein folding and stability; moreover, we detected several
potential virulence factors, expression of which was conﬁrmed by
phenotypic assays: a macrophage infectivity potentiator involved in
C. turicensis persistence in host cells, a superoxide dismutase protecting
the pathogen against reactive oxygen species, and an enterobactin-
receptor protein for the uptake of siderophore bound iron. Most
interestingly, an insecticidal chitinase and metalloprotease but no casein
hydrolysing enzymes were found, suggesting that C. turicensis 3032
originates from an environmental habitat rather than a milk-processing
production site.
P1332 Extracellular metalloprotease complex of Proteus mirabilis:
a bio-informatic study
L. Michelim °, J. Fracasso, A.P. Delamare, S. Echeverrigaray (Caxias
do Sul, BR)
Objectives: Metalloproteases, particularly mirabilysin (ZapA), are
considered important virulence factors of Proteus mirabilis. Mirabilysin
is active against a broad range of proteins including IgA and IgG. In this
study we report a bioinformatic study of the metalloprotease complex
of P. mirabilis, as well as a structural analysis of mirabilysin.
Methods: The nucleotide and aminoacid sequences of ZapA gene
and Zap operon of P. mirabilis, as well as the orthologous sequences
present in other bacterial species were obtained from NCBI. Promoters
prediction was carried out using BPROM and PPP, and rho-independent
terminators and RNA secondary structure were analyzed using FindTerm
and RNAfolder. The comparison of mirabilysin sequence with other
proteins was carried out using BLASTp. Orthologous protein sequences
from different genera were aligned using Clustal X, and a dendrogram
was generated by the Mega 4.0.1 program using the Neighbour-joining
algorithm. ZapA conserved domains were identiﬁed by the Conserved
Domain Architecture Retrieval Tool (CDART) of NCBI. Sequence
alignment was carried out using the ClustalX program and the results
were edited in the BioEdit environment. The structural model of ZapA
protein of P. mirabilis was determined using the Swiss-model Workspace.
The 3-D protein model used to predict ZapA structure was the serralysin
of Serratia marcescens. The stereochemical quality of the ZapA protein
model was evaluated by Procheck and Ramachandran plot.
Results: The results showed the presence of: (1) ﬁve metalloprotease
genes located in a contiguous region within bacterial genome; (2) two
different structural and functional proteases in P. mirabilis, one
represented by four highly similar Zn-metalloproteases with a long
C-terminal Peptidase M10 calcium-binding domain, and a typical
serralysin Zn-metalloprotease represented by mirabilysin (ZapA); (3) a
sigma 28 promoter controlling the Zap operon transcription; and (4) a
precocious rho-independent terminator within Zap operon.
Conclusion: The structure of mirabilysin exhibited the typical
N-terminus ZnMc serralysin domain, characterised by an a-b structure
with a HExGHxxGLxH motif, and the C-terminus peptidase M10 do-
main formed by nine b-rolls with calcium binding G-rich nonapeptides.
P1333 Actinobaculum schaalii, a common cause of urine tract
infections?
S. Bank °, J. Prag (Viborg, DK)
Objectives: Actinobaculum schaalii is a slow growing, CO2 demanding,
trimethoprim and ciproﬂoxacin resistent Gram positive rod and has
been reported as a cause of urine tract infections, occasionally with
bacteraemia. Due to its slow growth, also under optimal conditions
A. schaalii is often overgrown with faster growing commensal and
patogen bacteria and is therefore only found in monocultures in large
quantities. Identiﬁcation by morphology and biochemistry often takes
weeks. Since most microbiological laboratories routinely culture urine
overnight at 37ºC in ambient air using Columbia blood agar and
MacConkey agar A. schaalii is generally overlooked.
We developed a TaqMan real-time quantitative PCR assay targeting the
gyrB gene to rapidly detect A. schaalii. The real-time PCR assay has been
used to determine the presence and to get a hint to a better understanding
of the clinical importance of A. schaalii.
Methods: A universal primer set was used to sequence the gyrB gene
from fourteen A. schaalii strains including a A. schaalii reference strain
CCUG 27420. The sequences were used to develop a TaqMan real-
time quantitative PCR assay targeting the gyrB gene of A. schaalii. The
assay was then tested against 37 A. schaalii isolates as well as several
genetically related and clinically relevant bacterial strains. Finally the
assay was used to screen 150 clinical, consecutive urine samples from
patients above 60 years of age.
Results: Of the 150 urine samples 22 were found to harbour a load of
more then 105 A. schaalii CFU/ml and 11 with less than 105. Of the
33 samples where A. schaalii was detected there were 27 with common
patogenic bacteria present in the sample.
Conclusion: Real-time PCR is a fast and reliable method to identify
A. schaalii. A. schaalii may be an important co-patogen in many
urine tract infections. Patients suffering from chronic UTI are often
blindly treated with ciproﬂoxacin to which some patient respond well
whereas others do not show improvements after prolonged treatment. If
A. schaalii is the cause of infection other antibiotics are needed to cure
the infection. The real-time PCR assay can be used for fast diagnosis
which will lead to better antibiotic treatment and thereby faster recovery
and lesser admission.
P1334 Comparison of alpha-amylase enzyme production between
immobilised and submerged cells by native Bacillus
licheniformis G
F. Mahmoudnia °, A. Pourbabaee, N. Ghaemi (Fars, IR)
Background: The possibilities of producing alpha-amylase with
immobilised Bacillus cells have been investigated This enzyme are
widely used industrially for starch liquefaction.
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The most frequently used immobilisation method is entrapment in gel
matrices.
The submerged productions of alpha-amylase using synthetic media have
been reported by many workers.
Objective:
– To choose optimal conditions for immobilisation of growing cells of
Bacillus licheniformis G in alginate.
– To evaluate alpha-amylase production by the immobilised cells in
Batch fermentations
Methods:
• To cultivation bacteria in preculture medium. (This biomass was used
both for immobilisation and in experiments with free cells)
• To immobilisation of bacteria cells in Ca-alginate gel. (microencap-
sulation method)
• To carry out Batch fermentations with immobilised cells and free
cells.
• alpha-amylase assay according to the method of Bernfeld by 3,5-
dinitro salicylic acid reagent.
Results: The optimal immobilisation parameters (gel concentration, ini-
tial cell quantity, biomass age, Bead size and solidiﬁcation prolongation)
were determined.
The immobilisation procedure was most effective at a gel concentration
of 3% using cells from a 12 h culture. The optimal initial cell quantity
was found to be 2.6% in Ca-alginate gel with bead size of 5.0mm and
solidiﬁed for 24 h in 2.5% Calcium Chloride solution.
An enzyme yield 20 U/ml culture medium was reached in Batch
fermentation with immobilised cells. In contrast with corresponding
enzyme yield obtained with free cells, signiﬁcant increases (2.2 fold)
in the enzyme yield with immobilised cells was observed.
Conclusion: Higher gel concentration the rate of substrate mass transfer
and the enzyme yield decreased.
Solidiﬁcation of alginate improved the enzyme yield, presumably owing
to decrease of the release from the beads. Amylase biosynthesis is also
dependent on bead size, but in the case of initial cell loading in alginate
beads, enzyme yield decreased at high initial cell density.
P1335 Bacterial DNA in Egyptian patients with cirrhosis and
culture-negative non-neutrocytic ascites: a marker of
bacterial translocation and a prognostic indicator
N. Fam °, A. Ghali, A. El-Sayed, M. Shemis, M. Saber (Cairo, EG)
Bacterial translocation (BT) from intestinal wall to blood and other
extra-intestinal sites is considered the key step in the pathogenesis
of spontaneous bacterial peritonitis (SBP) in liver cirrhosis. The
translocation of bacterial products as endotoxin and bacterial DNA, and
the consequences of such translocations are under investigation
Objectives: to study the presence of bacterial DNA and its possible
role as a marker of BT in patients with advanced cirrhosis and culture-
negative non-neutrocytic ascites (CNNA). The clinical signiﬁcance of
bacterial DNA as a possible prognostic marker in these patients was
also evaluated.
Methods: 69 patients with cirrhosis and CNNA were included in the
study. Bacterial DNA was detected in blood and ascitic ﬂuid (AF)
samples using polymerase chain reaction (PCR) for 16S ribosomal
RNA. The corresponding bacterial DNA was identiﬁed by nucleotide
sequencing of the puriﬁed PCR products by ABI 3130XL automated
genetic analyzer (Applied Biosystem, USA). Results showed that
bacterial DNA was detected in ascitic ﬂuid and/or blood samples
in 34.7% of patients (24/69). It was simultaneously found in both
blood and ascitic ﬂuid samples in 11 patients, in ascitic ﬂuid samples
only in another 11 patients and in blood samples only in 2 patients.
Nucleotide sequencing was performed for the DNA simultaneously
found in blood and AF sand the similarity between the sequences found
in both samples was >97% indicating single clonal origin. Nucleotide
sequencing identiﬁed Escherichia coli as the main bacterial species
detected in 70.8% of samples. Klebsiella pneumoniae was detected in
16.6% and Staphylococcus aereus in 12.5%. Follow-up of patients for
2 months showed a signiﬁcantly higher mortality rate and progression
to hepatorenal syndrome among patients with bacterial DNA in blood
and/or AF compared to those without (p< 0.01, < 0.001).
Conclusions: These data represent the ﬁrst detection of bacterial traces
(DNA) in Egyptian patients with CNNA. It also provides molecular
evidence of translocation of bacterial DNA that can serve as a prognostic
marker predicting unfavourable outcome, so primary prophylaxis might
be considered as a future perspective in such patients.
P1336 Direct detection of Bordetella pertussis and B. parapertussis
in clinical specimens by a rapid molecular dipstick assay
U. Eigner °, M. Holfelder, A. Mahlke, A.M. Fahr (Heidelberg, DE)
Objectives: The purpose of this study was to evaluate the new molecular
dipstick assay GenoQuick (GQ) Bordetella (Hain Lifescience, Nehren,
Germany) for the direct and speciﬁc detection of Bordetella pertussis
and B. parapertussis in clinical specimens. The PCR-dipstick contains
3 lines, one for wild type detection, ampliﬁcation control and run control,
and is evaluated after 10 min by eye.
Methods: The lower detection limit of the assay was determined by
serial dilutions of isolates of Bordetella pertussis and B. parapertussis.
Analytical speciﬁcity was calculated with 35 “non-Bordetella”-isolates
of different culture collections (ATTC, DSMZ and others). For the
evaluation of the direct detection in clinical swab specimens, the GQ
Bordetella assay was compared to a Real-Time-PCR assay speciﬁc for
B. pertussis. Two different extraction methods (Hain Q-Lys-Method
(Hain Lifescience) and EasyMAG (BioMe´rieux, Nu¨rtingen, Germany)
were used. 80 patient specimens (30 positive, 50 negative with the Real-
Time PCR) were collected from routine samples. Discrepant results were
retested with B. pertussis and B. parapertussis-speciﬁc PCR assays.
Results: With regard to analytical sensitivity a lower median detection
limit of 10CFU/ml was determined. All 35 “non-Bordetella” isolates
were tested negative with the assay.
For clinical specimens the GQ Bordetella assay showed a sensitivity,
speciﬁcity, positive predictive and a negative predictive value of 100%,
96%, 93.8%, and 100% with regard to the extraction method with
EasyMAG and 100%, 100%, 100%, 100% with the Q-Lys-method,
respectively. One B. parapertussis containing specimen was only tested
positive when DNA was isolated with the EasyMAG system.
Time-to-result for the direct detection of B. pertussis and B. parapertussis
from clinial specimens is 2.5 h with the molecular dipstick assay (2.25 h
for ampliﬁcation and 10 minutes for detection). Ca. 15 min have to be
added for the Q-Lys-DNA-isolation procedure.
Conclusions: The GenoQuick Bordetella dip stick assay is proved to be
a rapid, sensitive and speciﬁc tool for the direct detection of Bordetella
pertussis and B. parapertussis in clinical specimens within 2.5 h to 3 h.
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P1337 Limitations of tpi and bg sub-genotypings for
characterisation of human Giardia duodenalis isolates
J. Bonhomme, L. Le Goff, V. Lemee, G. Gargala, J.J. Ballet,
J.F. Rossignol, L. Favennec ° (Rouen, Caen, FR; Stanford, US)
The intestinal protozoan Giardia duodenalis is a cosmopolitan parasite
frequently involved in human parasite gastroenteritis with two genetically
different G. duodenalis assemblages A and B. Little is known so far on
the genotypes of G. duodenalis strains which are infectious to humans
in France.
Objectives: The present characterisation of 19 French clinical strains
was aimed at determining their genotype patterns and associations with
clinical symptoms, and in vivo metronidazole resistance, respectively.
Methods: Faecal human samples were puriﬁed and analysed using PCR
ampliﬁcation and direct sequencing of 2 fragment genes, i.e. triose
phosphate isomerase (TPI) and b-giardin (BG).
Results: Twelve isolates were identiﬁed as assemblage A, and 7 as
assemblage B for the 2 gene loci. High intra-assemblage genetic
variability determined many subgenotypes with uncomplete overlap
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at the 2 loci. Using TPI gene analysis, 10/12 isolates belonged to
subgenotype A2, and 2/12 genotype A and all B isolates could not
be subgenotyped. Using BG gene analysis, 6/12 isolates belonged to
genotype A2, 6/12 to genotype A3, 5/7 to genotype B3, and 2/7
genotype B isolates could not be subgenotyped. In addition, several
heterogeneous nucleotide positions (i.e., the presence of 2 nucleotides at
the same position) were highlighted in the two assemblages A and B and
for both gene sequences. No association was found between genotype
and clinical symptoms or metronidazole resistance, respectively.
Conclusion: Data support consensual improvements in multilocus
G. duodenalis sub-genotyping strategies to better understand molecular
epidemiology of giardiasis and the zoonotic potential of this parasite.
P1338 Multilocus sequence typing of Campylobacter jejuni isolated
from bovines, poultry and patients in Finland
A. de Haan °, R. Kivisto¨, M. Hakkinen, H. Rautelin, M.L. Ha¨nninen
(Helsinki, FI)
Objectives: Campylobacter is known to be the major cause of bacterial
gastroenteritis worldwide. It has been shown to be present in a variety of
animal sources, but chicken is thought to be the main source of human
Campylobacter infections. A clear peak of Campylobacter infections is
observed in the summer months.
Multilocus sequence typing (MLST) has previously been employed to
characterise Campylobacter and was used to identify sequence types
(STs) in our datasets.
The main aim of the present study was to map the distribution of MLST
types of Campylobacter across Finland, since data on this is scarce and
will help to better understand the epidemiology and source attribution
in Finland.
Methods: A total of 107 bovine strains were isolated in 2003. The study
included 71 chicken isolates from 2006 and 94 chicken isolates from
2007 (June-October included) as well. The bovine and poultry isolates
were representative of the distribution of Campylobacter in the whole
of Finland.
Eighty-nine isolates from patients with domestically acquired in-
fections were collected from the Helsinki-Uusimaa area in 2006
(July-December included). A total of 361 strains were typed by
MLST. Sequence types were assigned by using the pubmlst database
(http://pubmlst.org/campylobacter/). The population structure and source
attribution will be analyzed by the chi-square test, STRUCTURE and
BAPS.
Results: Up to date 75% of all isolates have been successfully
characterised by MLST. Of these, 13% of the strains were found to
have a novel ST. Less than 5% of the strains were either not typable
or Campylobacter was not recovered after primary isolation. According
to preliminary ﬁndings, ST-21 and ST-61 clonal complexes were most
prevalent in bovines, while ST-45 and ST-283 clonal complexes were
more common in poultry. In patients ST-22 clonal complex was more
frequently found compared to both bovine and poultry. The results of
comprehensive data analysis will be presented at the conference.
Conclusions: The number of novel sequence types found seems to be
slightly higher compared to published data. Nevertheless, the distribution
looks fairly the same compared to the rest of Europe while ST-677 seems
to be more prevalent in Finland.
P1339 Molecular characterisation of epidemic isolates of Vibrio
cholerae O1 recovered from an outbreak occurred in
different parts of Iran in 2005
R. Ranjbar °, M. Pourshaﬁe, N. Sadeghifard, M. Parzadeh, M. Izadi,
N. Jonaidi, M. Sedaghat (Tehran, Ilam, IR)
Objective: Aim of this study was to evaluate AP-PCR for investigation
of clonal relatedness among the strains of V. cholerae recovered from an
outbreak occurred in different parts of Iran in 2005.
Material and Methods: The study was conducted during the cholera
outbreak occurred in some of provinces in Iran in summer 2005.
Bacterial isolation and identiﬁcation was carried out according to the
standard bacteriological methods. Arbitrarily primed PCR (AP-PCR)
used to study the genetic relatedness between the V. cholerae isolates.
Results: Thirty-nine isolates of V. cholerae O1 were identiﬁed. All
isolates belonged to serotype Inaba. AP-PCR could differentiate the
isolates into ﬁve groups. AP-PCR cluster types 1 and 2 were the
most prevalent groups, accounting for 36% and 41%, respectively, of
V. cholerae isolates.
Conclusion: The most of V. cholerae O1 strains could be attributed
to two predominant clusters including AP-PCR cluster types 1 and 2
accounting for more than 77% of isolates. In conclusion, a few epidemic
clones were responsible for the apparently epidemic occurrence of
cholera in provinces studied.
P1340 Comparison of PFGE and MLVA in subtyping of Salmonella
Typhimurium strains
T. Kauko °, K. Haukka, A. Siitonen (Helsinki, FI)
Objectives: In Finland, microbiological laboratories send the Salmonella
strains isolated from humans to the Salmonella Reference Laboratory
of THL for further typing. All S. Typhimurium strains isolated from
the patients with domestically-acquired infection, were genotyped by
pulsed-ﬁeld gel electrophoresis (PFGE) and multiple-locus variable-
number tandem-repeat analysis (MLVA). The discriminatory power and
epidemiological concordance of MLVA and PFGE were compared and
the epidemiological relatedness of Finnish S. Typhimurium strains was
established.
Methods: Finnish S. Typhimurium isolates (N = 63) of human origin from
the year 2008 were analysed by PFGE and MLVA. The strains belonged
to the deﬁnitive phage types (DTs) 1, 104, 41, NST, U277, 104B,
U322, 99, 195 and 120. PFGE was performed according to international
standardised PulseNet Europe protocol using XbaI restriction enzyme.
MLVA was performed as described [1] with following differences:
forward primers of loci STTR3 and STTR5 were labeled with NED
ﬂuorescence colour, locus STTR10 was labeled with PET ﬂuorescence
marker, LIZ600 served as internal standard and sequencing was carried
out by capillary electrophoresis using the 3730xl DNA Analyzer
(Applied Biosystems).
Results: DT1 (N= 22) and DT104 (N= 11) were the most common
S. Typhimurium phage types. Salmonella isolates of DT1 were divided
into three MLVA and ﬁve PFGE proﬁles. 20 of the 22 DT1 isolates
belonged to the MLVA cluster 02−12–00−00−03 where only three loci
are present. The MLVA cluster 02−12–00−00−03 was divided by PFGE
into three XbaI macrorestriction proﬁles differing by one or more bands.
The most common PFGE proﬁle among the DT1 isolates, called STYM1
(N= 16), could not be divided further by MLVA.
MLVA analysis of the 11 DT104 isolates yielded ﬁve MLVA proﬁles
and three XbaI proﬁles. The most common MLVA cluster 2−12–12−7−3
(N= 4) was divided into two different PFGE proﬁles.
Conclusion: Concordance between PFGE and MLVA was generally
good. MLVA method is less discriminatory than PFGE, but in few cases,
especially in epidemiological surveillance of S. Typhimurium DT104 it
is a valuable tool. However, most of the isolates of S. Typhimurium DT1
which is the most frequent phage type in domestic human infections,
show limited discrimination by MLVA due to present of only three
polymorphic loci.
Reference(s)
[1] Lindstedt, B.-A., Vardund, T., Aas, L., Kapperud, G. 2004.
J Microbiol Methods 59, 163–172.
P1341 Search for surface-anchored and strain-variable
Streptococcus agalactiae proteins in clinical Streptococcus
pyogenes isolates
A.I. Kvam °, J.A. Mæland (Trondheim, NO)
Objectives: Group A streptococci; (GAS) are among the most frequent
causes of bacterial infections in humans. Group B streptococci: (GBS)
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are a less frequent cause of infections in humans but still are important
pathogens. Serotype determination of GBS is based on the capsular
polysaccarides and serosubtype determination on a varity of surface-
anchored an strain-variable proteins, including C beta (bca) C alpha
(bac), Alp1 (alp1), Alp2 (alp2), Alp3 (alp3), Alp4 (alp4), R4(Rib) (rib),
and the R3 protein. In this study we have tested a collection of clinical
GAS isolates for the presence of these GBS protein genes.
Methods: A total of 88 GAS strains isolated from infectious disease
cases during the period 2004 to 2006 were examined. GAS strain
R28 was used as alp3 positive reference strain. Multiplex PCR (J Clin
Microbiol 42: 1326, 2004) was used to detect the genes mentioned above
and antibody-based methods (APMIS 107: 869, 1999) to test for R3
protein expression.
Results: Of 88 clinical GAS strains examined, 23/88 (26.1%) were
alp3 PCR positive. Of these, 2/14 (14.2%) blood culture isolates, 15/34
(44.1%) skin and soft tissue strains, and 6/40 (15%) respiratory tract
strains possessed alp3. The frequency of possesion of alp3 by the skin
isolates was signiﬁcantly higher than by the blood or respiratory strains
(P< 0.05). All isolates were PCR negative for the genes bac (C beta
protein), bca (C alpha protein), alp1 (epsilon), alp2 (Alp2), alp4 (Alp4),
and rib (R4/Rib). R3 protein expression was not detected. Antibody-
based testing of several isolates showed results in agreement with PCR
results.
Conclusion: Our results show that the gene alp3 which encodes Alp3
in GBS and R28 in GAS, occurs with a high frequency in clinical GAS
strains from our geographical area, with particularly high frequency in
strains causing skin and soft tissue infections. It is a possibility that
Alp3, which probably is identical to the T28 antigen, plays an important
role in colonisation and pathogenesis of GAS-induced skin and soft
tissue infections. One possibility is that Alp3/R28 functions as an adhesin
which mediates attachment of GAS to receptor molecules in human skin.
The other GBS genes tested in this study may never occur in GAS
isolates.
P1342 Pili are a clonal property of Streptococcus agalactiae
E.R. Martins °, J. Melo-Cristino, M. Ramirez (Lisbon, PT)
Objectives: Streptococcus agalactiae (GBS) isolates express protective
antigens recognized as major components of pilus-like structures. Pili
were described in three distinct variants (PI-1, PI-2a and PI-2b) and
appear to play a key role in both adhesion and attachment of the bacteria
to the host cells, being currently seen as important candidates for vaccine
development. Our aim was to investigate the distribution of pilus islets
among clones deﬁned by pulsed-ﬁeld gel electrophoresis (PFGE) and
multilocus sequence typing (MLST).
Methods: Representatives of a large collection (n = 491) from colonisa-
tion and infection were further characterised. A multiplex PCR reaction
was set up to detect the presence of the pili-associated sortase genes
to discriminate pili variants and another for surface protein proﬁling
(bca, alp2, alp3, alp4, eps and rib genes). Simpson’s index of diversity
(SID) was calculated to evaluate the diversity found among the isolates
studied. Wallace coefﬁcient (W) was calculated to quantitatively measure
the clustering concordance between different typing methods.
Results: The SID for the classiﬁcation in PFGE clones was 90.04%
(CI 95% 86.53–93.54) for the isolates tested and 92.29% (CI 95%
91.24–93.35) for the whole collection, indicating that the set of isolates
chosen is representative of the overall diversity. The two most prevalent
genotypes were PI-1+PI-2a and PI-2a (53% and 37% of the isolates,
respectively). The Wallace coefﬁcient relating the PFGE clusters with the
presence of pili (W= 0.8627) was higher than for serotype (W=0.566),
indicating that pili are clonally distributed. Furthermore, MLST sequence
type (ST) showed an even higher correspondence with pili (W=0.9263)
and also surface protein proﬁle (W=0.9539), indicating that ST is a very
good predictor of pili and surface proteins and suggesting that it provides
a better identiﬁcation of GBS clones.
Conclusions: The high Wallace coefﬁcients relating PFGE and MLST
with pilus type indicate that pili are a clonal property of GBS.
P1343 The prevalence of pneumococcal pilus among invasive
isolates of Streptococcus pneumoniae serotypes covered by
7-valent pneumococcal conjugate vaccine
H. Zemlickova °, M. Fridrichova, V. Jakubu, J. Kasik, K. Tyllova,
M. Musilek, J. Motlova (Prague, CZ)
Objectives: The effective spread of certain invasive clones has not been
fully elucidated yet. Apart from the capsule a number of virulence
factors could have inﬂuenced the success of particular clones. One of
the lately identiﬁed virulence factor is pneumococcal pilus encoded by
rlrA pathogenicity islet. The pilus producing ability is implicated in
the bacterial adherence at the very beginning of the nasopharyngeal
colonisation and at the same time may also be the triggering factor for
the inﬂammation of the mucous membrane causing damage to it and
consequently facilitating pneumococcal penetration into the tissue and
the development of infection. The aim of the study was to determine the
prevalence of the pilus in a set of invasive strains covered by 7-valent
pneumococcal conjugate vaccine (PCV7).
Methods: A total of 135 pneumococcal invasive isolates of 7 serotypes
recovered from blood (n = 82) and cerebrospinal ﬂuid (n = 53), were
studied. The isolates were of the following serotypes: 4 (37), 6B (18), 9V
(27), 14 (4), 18C (11), 19F (6), and 23F (32). Serotyping was performed
by the Quellung reaction and all isolates were analyzed by MLST. The
presence of pilus was performed by PCR of the sortase B, C, and D genes
which are a structural part of the rlrA pathogenicity islet. Conﬁrmation of
pneumococcal pilus absence was done by ampliﬁcation of the entire pilus
islet with primers PFL-up and PFL-dn and comparison of the obtained
PCR product with R6 DNA as non-piliated control.
Results: The 7 serotypes were classiﬁed into 34 sequence types (ST),
range 2 to 12 ST’s per serotype. Except ST808 in serotype 4, all
remaining ST’s possesed at least 2 isolates. More than half of isolates
were positive for the presence of sortases genes (n = 71, 52%). The pilus
was found in serotypes 4, 6B, 9V, 14, and 19F. The presence of the pilus
was highly congruent with serotypes as well as clonal types. Only 3
out of 33 clonal groups were composed of isolates that differed in the
presence of the rlrA islet.
Conclusions: With the exception of serotypes 18C and 23F, all
paediatric serotypes covered by PCV7 were capable of formation of
the pneumococcal pilus. The high prevalence of the pilus in invasive
isolates indicates that the pilus play a role in human infections.
This work was supported by a research grant from the Internal Grant
Agency, Ministry of Health (CZ), IGA 9643−4.
P1344 Emergence of a clone of Streptococcus pneumoniae serotype
19A in children in Murcia, Spain
G. Yague °, C. Martinez-Toldos, A. Iborra, S. Alfayate, J. Ruiz,
M. Segovia (Murcia, ES)
Background: Serotype 19A is know to have risen as important cause
of invasive pneumococcal disease (IPD) after the introduction of the
heptavalent pneumococcal conjugate vaccine (PCV7). During routine
surveillance of serotype distribution of paediatric invasive S. pneumoniae
isolates in Murcia (Spain), we detected an increased of 19A serotype.
The objective of this study was to describe S. pneumoniae serotype
distribution in our geographic area in children <11 years with emphasis
on serotype 19A.
Methods: From March 2006 to April 2008 we studied 40 isolates of
S. pneumoniae obtained from a normally sterile site (IPD) from children
attending in Hospital Virgen Arrixaca, Murcia. Serotyping was made by
Quellung reaction. Susceptibility to penicillin (P), cefotaxime (CTX),
erythromycin (ER), levoﬂoxacin (LV), chloranphenicol (C), tetracycline
(TE) and vancomycin (VA) was determined by E-test and interpreted
according to CLSI guidelines. Molecular typing of 19A isolates was
performed by Pulsed Field Gel Electrophoresis (PFGE) using SmaI
endonuclease.
Results: The most common serotypes were the non-PCV7 serotype 19A
(8, 20%) and the PCV7 cover serotype14 (8, 20%). The distribution of
Molecular typing − part 2 S373
the rest were as follows: serotype 1, 12.5%; 3 and 7F, 10%;19F, 23B, and
9V, 5%;9N, 18C, 23F and 23A 2.5% respectively. Non-PCV7 serotypes
caused 67.5% of IPD. The ﬁrst isolate of serotype 19A was detected on
February 07 then, six 19A strains were isolated in a four month period
(October-2007/January-2008). Pulsed ﬁeld gel electrophoresis patterns
of these six 19A isolates were indistinguishable and different to the ﬁrst
isolate. Illnesses of the related 19A strains included empyema (67.6%),
pneumonia whit bacteraemia (16.7%) and bacteraemia (16.7%). Respect
antibiotic susceptibility, within the entire S. pneumoniae population
(n = 40), a 45% were non susceptible to P (deﬁned as a penicillin
MIC of 0.12). Among 19A strains 75% were considered as non
susceptible. The proportion of CTX susceptible S. pneumoniae was
80% all isolates/87.5% 19A strains. Resistant rates (%all/%19A strains)
among non-b-lactam agents were as follows: E 25/37.5; TE 25/62.5; C
5/0. No resistance to VA or LV was observed
Conclusion: In our area the recent increase in serotype 19A could be
explain by introduction of a speciﬁc clone responsible of an outbreak of
IPD. The proportion of 19A isolates that are nonsusceptible to commoly
used antimicrobial was greater than the proportion for other serotypes.
P1345 Modiﬁed sequential multiplex PCR for determining
capsular serotypes of invasive Streptococcus pneumoniae
clinical isolates
P. Iraurgui, M.J. Torres, E. Cabrera, J.A. Lepe, J. Garnacho, I. Obando,
J. Aznar ° (Seville, ES)
Objectives: The objective of this study was to evaluate a modiﬁed
scheme of the sequential multiplex PCRs that devised the CDC for
determining capsular serotypes of Streptococcus pneumoniae (J Clin
Microbiol. 2006 44:124–131). The modiﬁed method was that the primer
combinations used were adapted to the serotype distribution in Sevilla,
Andalucı´a (Spain).
Methods: Two hundred ﬁfty-seven invasive pneumococcal isolates
obtained during 2004 to 2008 were tested using the modiﬁed multiplex
PCR system, including 102 previously typed paediatric isolates by
serological determination of capsular type, and 155 adult isolates. The
primers were grouped into seven multiplex reactions, except for the
serotype 10 primer that was not included in none of these reactions.
Each reaction includes four primer pairs, and an internal positive control
targeting all known pneumococcal cps operons. The main modiﬁcation
was to include primer pairs for the 1 and 5 serotypes in the ﬁrst three
reactions.
Results: In the paediatric isolates group, the concordance of the PCR
results with conventional serotyping was 91%. Three of the 5 isolates for
which serotypes could not be deduced were serotypes not included in the
multiplex reaction scheme. The multiplex PCR typed 97.4% (151/155) of
adult’s isolates, and 93% (95/102) of paediatric isolates. In adult isolates,
the modiﬁed multiplex PCR scheme, allowed us to type 73% of them,
and with two additional PCRs 92%, while using the original scheme we
would type 63% and 74.8% of the isolates respectively. In the paediatric
isolates group, results obtained were the 73.5% versus 60%, with the ﬁrst
three reactions and 90% versus 72.5% with the two additional PCRs.
Conclusion: The modiﬁed sequential multiplex PCR is better adapted
to the serotype distribution of invasive Streptococcus pneumoniae from
our geographic area and this scheme, improve the efﬁciency of original
CDC seven multiplex PCR.
P1346 Insight into the genetic diversity of multidrug-resistant
Mycobacterium tuberculosis in southern Brazil
P.F. Perizzolo °, E.R. Dalla Costa, A. Ribeiro, M. Ribeiro,
M.L.R. Rossetti (Vancouver, CA; Porto Alegre, BR)
We present a picture of the biodiversity of Mycobacterium tuberculosis
in the Southern Brazilian state of Rio Grande do Sul. This state
harbours more than 10 million inhabitants with a tuberculosis prevalence
rate of 41/100,000 in 2007. The objective of this study was to
genotype the multidrug-resistant M. tuberculosis in order to improve
our understanding of tuberculosis (TB). Spoligotyping was chosen due
to its fast generation of genotyping results, high reproducibility and low
operating costs. SpolDB4 database was used to assign the isolates to
families, subfamilies and variants. The results of a study can thus be
analyzed in a more global context. All the strains of M. tuberculosis
genotyped were isolated from patients with pulmonary TB who had a
positive acid fast bacilli smear. Heat-killed samples were DNA extracted
as described by van Soolingen et al, and samples were spoligotyped
according to Kamerbeek et al. The samples from this population-based
molecular epidemiology study were obtained from 148 consecutive TB
cases in Rio Grande do Sul. Patients were 61.5% male and 38.5% female.
Of these, 71.8% were tested for HIVusing the ELISA method and 28.2%
were seropositive. The percentages of HIV cases between male and
female were 61.2% and 38.7% respectively. Rifampicin (R) and isoniazid
(H) resistance were detected in 114 (77%) strains. In 35 (23%) strains,
we detected other associated resistance, such as RH + Streptamicin (SM)
in 20 cases (13.6%) and RH + ethambutol (EMB) in 8 cases (5.3%).
There were 6 related MDR-TB cases (4.1%) that were resistant to R + H
+ SM + EMB. The molecular analysis gave 35 different spoligopatterns
that presented an overall diversity of 48%: 17 spoligopatterns occurred
only once and the remaining 18 patterns were associated with 131 of
the isolates (88.5%). Seven of the 35 patterns had not been described
previously. The prevalence of the MDR-TB lineages in this study was:
Latin-American & Mediterranean (LAM) family: 65%; T family: 17.9%;
U family: 12.1%; Haarlem family: 3.6%; X family: 1.4%. Spoligotyping
is very useful in gaining an overall understanding of the TB epidemic.
This study demonstrated that the MDR-TB situation in Rio Grande do
Sul, Brazil was caused by only a few M. tuberculosis families of which
the most prevalent was the RH-resistant LAM family commonly found
in Mediterranean region.
P1347 Molecular typing of Legionella pneumophila from a
hospital’s water system
S. Vourli °, E. Velonakis, A. Tarpatzi, M. Pantelaki, L. Zerva,
A. Vatopoulos (Athens, GR)
Objectives: Colonisation of water systems of large buildings, such as
hospitals, with L. pneumophila, happens frequently and its containment
is necessary in order to prevent nosocomial legionellosis. It has been
reported that colonisation of a water system for long time periods is
related to the persistence of a small number or one clone.
The aim of this work was to study the clonality of L. pneumophila
isolates that colonised the water distribution system of “Attikon”
University Hospital over a two-year period. Additionally, we searched
for the genetic loci lvh and rtxA, which have been related with highly
virulent L. pneumophila strains.
Methods: 149 water samples were collected from March 2006 to March
2008 and were cultured according to the guidelines of the European
Working Group for Legionella Infections (EWGLI). Identiﬁcation of
suspected colonies and serotyping were performed by appropriate latex
agglutination kits (Oxoid). Twenty-six isolates, representative of each site
and date of sampling, were typed with the Ampliﬁed Fragment Length
Polymorphism method (AFLP), as suggested by EWGLI. Electrophoretic
proﬁles were compared with the GelCompar software (Applied Maths).
The presence of the genetic loci lvh and rtxA was examined by PCR.
For the diagnosis of patient infection by Legionella, the urine antigen
test was applied (Binax).
Results: Cultures from 36 water samples (24.2%) were positive for
L. pneumophila serogroup 1. Colony counts ranged from 500 to
304,000CFU/lt. All 26 isolates that were typed were indistinguishable,
suggesting the domination of one clone over the two-year period of
the colonisation. Furthermore, the 26 isolates carried both lvh KAI
rtxA. During the study period, no nosocomial legionellosis occurred, and
with the implementation of appropriate control measures containment of
colonisation was succeeded.
Conclusion: Prolonged colonisation of the water system of our hospital
by L. pneumophila was probably due to the domination of a single clone.
Although this clone carried both lvh KAI rtxA genetic loci, associated
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by previous studies with high virulence, no patients were infected during
the two-year colonisation period.
P1348 Plasmid proﬁle of multiresistant enterobacteria other than
Escherichia coli in Cantabria, Spain
B. Ruiz del Castillo °, E. Roma´n, A. Carattoli, L. Martı´nez-Martı´nez
(Santander, ES; Rome, IT)
Objectives: The aim of this study was to characterise plasmid of
multiresistant enterobacteria other than E. coli isolated in our sanitary
area.
Methods: One hundred consecutive clinical isolates of enterobacteria
resistant to 3 of: expanded-spectrum b-lactams, quinolones, chlo-
ramphenicol, gentamicin/tobramycin, and cotrimoxazole isolated in our
centre (January 2004 to March 2006) were included. Susceptibility
testing and ESBL detection were determined by microdilution (CLSI
guidelines), and clonal relationship by Rep-PCR. Plasmids were
extracted (Kado-Liu method), analysed by agarose gel electrophoresis
and characterised by replicon typing (J Microbiol Methods 2005;
63:219–28), with conﬁrmation of positive results by sequencing.
Results: The following species and Rep-PCR patterns were observed:
Citrobacter freundii (n = 6; 6 clones), Enterobacter aerogenes (2/2),
E. cloacae (11/6), Klebsiella pneumoniae (21/7), K. oxytoca (n = 1/1),
Morganella morganii (27/3) and Proteus mirabilis (32/16). Plasmids
were studied in at least one isolate of every Rep-PCR patterns, and in up
to 3 isolates of the same pattern if MICs of at least 2 compounds differed
in at least two dilutions. All E. cloacae carried IncHI2 plasmids; three of
them also carried IncN plasmids. The 7 clonal groups of K. pneumoniae
produced ESBL and carried plasmids IncFII (positive for repFIIAs),
and plasmids of groups IncN (Kp1, Kp7), IncHI1 (Kp4), IncK (Kp5)
and IncI1 (Kp 6). The single K. oxytoca produced a plasmid-mediated
AmpC and carried an IncP plasmid. All P. mirabilis isolates carried
IncFI plasmids (carrying the repFIC only replicon). One E. aerogenes
(producing ESBL) carried IncF plasmids, positive for the repFIB and
repF replicons. The following incompatibility groups were identiﬁed in
C. freundii: IncF (positive for repFIC) and IncP (C1), IncHI2 (C2) and
IncHI1, repF and IncFIIAs (C3). No amplicons by the replicon typing
were detected in any of the clonal groups of M. morganii, in three clonal
groups of C. freundii and in one clonal group of E. aerogenes.
Conclusions: Most multiresistant enterobacteria other than E. coli
(except M. morganii) isolated in our area contains plasmids of different
incompatibility groups. Similar plasmids have been observed in isolates
of the same species but of different clonal groups.
P1349 Replicon typing of plasmids coding for b-lactamases of the
CTX-M-9 group or CMY-2 in multiresistant E. coli clinical
isolates from Cantabria, Spain
B. Ruiz del Castillo °, B. Guerra, A. Carattoli, L. Martı´nez-Martı´nez
(Santander, ES; Berlin, DE; Rome, IT)
Objectives: In an ongoing study on multiresistant E. coli producing
(n = 100) or not (n = 100) extended-spectrum b-lactamases (ESBL)
isolated in Santander, Spain, 21 clonally-unrelated (as determined by
Rep-PCR) isolates producing b-lactamases of the CTX-M-9 group
(CTX-M-14 or CTX-M-9; n = 16) or CMY-2 (n = 5), respectively, were
identiﬁed. The aim of this study was to characterise the plasmids of
these isolates.
Methods: BlaCTX-M-9-group and blaCMY-2 genes were detected
by PCR. Conjugation experiments were made using azide (Az)-
resistant E. coli J53 as recipient strain. Transconjugants were selected
with Az (100mg/l) and cefotaxime (2mg/l; blaCTX-M-9-group) or
ampicillin/gentamicin/sulfametoxazole (100mg/l, 8mg/l and 1000mg/l;
blaCMY-2), respectively. Plasmid from both parental strains and derived
transconjugants were extracted by the Kado-Liu method, analysed
by agarose gel electrophoresis and characterised by replicon typing
(J Microbiol Methods 2005; 63:219–28), with conﬁrmation of positive
results by sequencing. The relationship between replicon units and
b-lactamase genes in the same plasmid was assessed by Southern blot
hybridisation using speciﬁc DNA probes.
Results: Plasmids of several sizes (around 100–150 kb) were detected in
all 21 clinical isolates evaluated. Transconjugants were obtained from all
16 isolates with CTX-M-9 group and from 3 out of the 5 with CMY-2
plasmid analysis showed that in 13 of 16 cases the gene coding for the
blactx-m-9-group enzyme was located on conjugative IncK plasmids,
and in the remaining 3 cases on Inc I1 plasmids. In 2 and 1 out of
3 transconjugants with blaCMY-2, this gene was on IncA/C2 and IncI1
plasmids, respectively.
Conclusions: In our area, we have observed an association of certain
b-lactamase genes with speciﬁc large conjugative plasmid: those coding
for blactx-m-9-group are of IncK and Inc I1 incompatibility groups,
while blaCMY-2 is related to plasmids of IncA/C2 and Inc I1 groups.
P1350 Characterisation of extended-spectrum b-lactamase-
producing Klebsiella pneumoniae isolates causing an
outbreak in an intensive care unit
T. Halaby °, R. Muts, C. Blijdens, A. van der Zanden, R. Hendrix,
W. Goessens (Enschede, NL)
Objectives: The prevalence of ESBL-positive K. pneumoniae (ESBL-
Kp) as a cause of nosocomial outbreaks in intensive care units is high.
In this study the genetic relatedness and the characterisation of ESBL
genes of ESBL-Kp isolates involved in a large outbreak in an intensive
care unit (ICU) are described.
Methods: Isolates were obtained by surveillance cultures taken on
admission and during hospitalisation twice a week. For the present
analysis only one ESBL-Kp isolate per patient was included. VITEK 2
was used for identiﬁcation and susceptibility testing. Phenotypic ESBL
conﬁrmation was performed by the double disk method. ESBL and
integron characterisation was performed by PCR. Diversilab® and Multi
Locus Sequence Typing (MLST) were used as genotyping methods.
Results: Between August 2001 and January 2008, 191 ESBL-Kp positive
patients were identiﬁed. 130 stored strains were included for analysis.
118 were identiﬁed as K. pneumoniae. The majority of the 118 strains
were resistant to 3rd generation cephalosporins, gentamicin, tobramycin,
amikacine and ciproﬂoxacin. ESBL PCR was performed on 107 of the
118 strains. In 79 isolates the SHV-amplicon was digested with NheI
and was therefore regarded as ESBL-positive. 107 out of 118 showed
the presence of an integron with an amplicon size corresponding with
the aadB gene. By Diversilab® all 118 ESBL-Kp strains clustered in the
same group. Diversilab® furthermore revealed some other small groups,
consisting of ESBL-Kp strains found in the same ICU, but not related
to the large cluster. With MLST performed on a subset of 24 strains
identical results were obtained compared to the Diversilab® results.
Conclusions: The majority of the patients and isolates involved in the
outbreak at the ICU appeared to be closely related as demonstrated
by Diversilab® and conﬁrmed by MLST. Diversilab® is useful in
investigating genetic relatedness of suspected outbreak strains.
P1351 An outbreak of multidrug-resistant Acinetobacter baumannii
in an intensive care unit: the usefulness of Diversilab® in
studying clonal relatedness
T. Halaby °, W. Goessens, C. Blijdens, R. Hendrix, A. van der Zanden
(Enschede, NL)
Objectives: Genotyping is an essential epidemiological tool to aid
in outbreak investigations and to determine the genotypic relatedness
among isolates, which is important for establishing the sources and
modes of transmission of the outbreak strains. In this study the
usefulness of the Diversilab® was evaluated during an outbreak of
MDR-Acinetobacter baumannii in an intensive care unit (ICU), and was
compared to Random Ampliﬁcation Polymorphism Detection (RAPD)
and selective restriction fragment ampliﬁcation by ampliﬁed fragment
length polymorﬁsms (AFLP) as a reference method.
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Methods: The VITEK 2 system was used for identiﬁcation and
susceptibility testing. AFLP, RAPD and Diversilab® were used as
molecular genotyping methods.
Results: The outbreak occurred during the ﬁrst 4 weeks of 2008 and
was ended by temporarily closing the ward. Twenty one A. baumannii
isolates were included. Fingerprints obtained with AFLP, RAPD and
Diversilab® showed identical relatedness. On the basis of these data,
2 distinct groups were identiﬁed. Group 1 consisted of 13 identical strains
isolated from 5 patients during the outbreak, 7 positive environmental
screening cultures, and one patient isolate, known to harbour MDR
A. baumannii (MRD-AB). Group 2 consisted of 4 identical isolates,
all from one patient admitted to the temporary ICU. The remaining
4 isolates showed different patterns, 3 known non-related strains and
one (non-MDR) from a patient admitted to the ICU during the outbreak.
Conclusions: Diversilab® provides strain discrimination identical to that
obtained by RAPD and AFLP. All three methods demonstrated the
genetic relatedness between the strain from the suspected index patient,
the environmental contamination with the same strain and the strains
detected in the 5 patients involved in the outbreak. Furthermore, the data
indicated that group 2 included a non-related strain rather than spread
of the epidemic strain from the ICU to the temporary ICU. Diversilab®
makes molecular typing feasible in laboratories that lack equipment and
experience regarding different conventional typing methods.
P1352 Rapid and effective analysis of nosocomial outbreaks using
the DiversiLab semi-automated repetitive sequence-based
PCR test system
A.J. Grisold °, G. Zarfel, V. Strenger, G. Feierl, V. Dosch, E. Leitner,
L. Masoud, U. Wagner-Eibel, M. Hoenigl, E. Marth (Graz, AT)
Objectives: Rapid and sensitive methods are essential for typing
and monitoring of hospital associated infections. The new DiversiLab
system (BioMerieux) exhibits a semiautomated repetitive-sequence-
based polymerase chain reaction (rep-PCR) for typing. Aim of the study
was to evaluate the usefulness and accuracy of the DiversiLab system for
bacterial strain typing and determination of genetic relatedness of strains
associated with nosocomial outbreaks and integration of the system in
the workﬂow of a routine microbiological laboratory.
Methods: For evaluation 20 Methicillin-resistant Staphylococcus aureus
(MRSA), 26 multi-drug resistant (MDR)-Acinetobacter baumannii
strains and 43 extended-spectrum-b-lactamase producing Klebsiella spp.
strains (30 K. pneumoniae and 13 K. oxytoca strains) from well-deﬁned
nosocomial outbreaks were typed using rep-PCR on the DiversiLab
system. As reference method for bacterial strains-typing pulsed-ﬁeld gel
electrophoresis (PFGE) was performed.
Results: Concerning the 20 MRSA isolates, there was identical cluster
formation in both, the DiversiLab and the PFGE systems. The same
result could be observed in the 26 multi-resistant A. baumannii strains,
where strains showed identical cluster formation (into 3 separate clusters)
and very similar dendrograms. The 30 ESBL-positive K. pneumoniae
strains originated from two chronologically separated nosocomial
outbreaks: PFGE placed 28 of the ESBL-positive K. pneumoniae
strains into the same cluster, whereas PFGE deﬁned all strains as
indistinguishable. The DiversiLab-system also formed a cluster of these
28 strains, but the strains in this cluster were not deﬁned as identical, but
similar. Both systems identiﬁed 2 K. pneumoniae strains as non-outbreak
strains. Results from the K. oxytoca outbreak provide similar minor
differences between PFGE and results obtained with the DiversiLab-
system, whereas rep-PCR on the DiversiLab system exhibits slightly
more discriminatory power than PFGE.
Conclusion: The DiversiLab system is a rapid, semi-automated repetitive
sequence-based PCR test system for typing and analysing bacterial
strains, including fungi.
– Compared to PFGE, this study conﬁrms the good discriminatory
power of the DiversiLab system.
– Results on the DiversiLab system could be obtained in a short period
(8–24 h), which is an essential advantage in rapid analysis of hospital
associated infections.
P1353 Optical typing in bacterial epidemiology using Raman
spectroscopy
D. Willemse-Erix °, J. Jachtenberg, W. van Leeuwen, T. Bakker Schut,
G. Puppels, M. Vos, A. van Belkum, K. Maquelin (Rotterdam, NL)
Objectives: Raman spectroscopy is a non destructive optical technique
capable of providing detailed biochemical information on the molecular
composition of analyzed samples. Due to recent optimisation and
automation, this method has shown to be sufﬁciently powerful to
discriminate between strains within a species. This discriminatory power
combined with a very short processing time and high reproducibility
makes the technology ideally suited for microbial typing.
Methods: All isolates were cultured for 20 hr on Trypticase Soy agar
plates. Biomass was suspended in 10 microliter of sterile distilled
water, transferred onto a quartz slide and allowed to dry. Spectroscopic
ﬁngerprints were obtained using a dedicated Raman spectrometer,
requiring 10 to 80 seconds per sample. Cluster analysis on these
ﬁngerprints was performed using the pair wise correlations as a distance
measure in combination with Ward’s cluster algorithm.
Results: Technological proof-of-principle for efﬁcient, reproducible typ-
ing has been obtained for Staphylococcus species, Acinetobacter species,
Klebsiella pneumoniae, Escherichia coli and Enterococcus faecium.
The discriminatory power for these species matches that of established
genotyping techniques such as pulsed ﬁeld gel electrophoresis (D-values
>0.95). The Raman clustering of isolates was reproducible to the strain
level for independent cultures. The typing information gathered with this
technique is comparable to information obtained by genotyping methods,
but available in a fraction of the time.
Conclusion: Using Raman spectroscopy as a typing method, a signiﬁcant
decrease in turn-around time can be achieved. This allows infection
control professionals to act in a timely manner and thus prevent the
transmission of microorganisms in an early stage by the implementation
of adequate hygienic measures. Therefore we conclude that Raman
spectroscopy is an easy-to-use and rapid alternative in the battle against
hospital acquired infections.
P1354 Molecular and epidemiological plasmid proﬁle analysis of
Enterococcus faecalis isolates
E. Wardal °, E. Sadowy, W. Hryniewicz (Warsaw, PL)
Objective: The aim of the study was to analyze the correlation between
different types of plasmid proﬁles obtained from various investigation
approaches such as PCR-based replicon typing, PCR-based relaxase and
stabilisation/partition modules detection and PFGE-S1 visualisation of
plasmid molecules and to compare them with selected epidemiological
data of investigated isolates.
Methods: The heterogenous group of 152 E. faecalis isolates comprising
52 different STs has been chosen for the investigation. They were
representatives of the pool of isolates collected in the National Medicines
Institute in Warsaw from several Polish hospitals during 10 year
period (between 1996 and 2005). Among them invasive (n = 54), non-
invasive (n = 67) and carrier isolates (n = 28) were present. Replication,
stabilisation/partition and relaxase genes typical for different groups of
plasmids were detected by PCR. The allelic proﬁle of ampliﬁed genes
were determined by sequence analysis. Megaplasmids were visualised by
PFGE-S1 typing method. Pearson correlation coefﬁcient and chi-square
tests were used to calculate signiﬁcance of association of data.
Results: There were 11 different rep genes, 3 different relaxase genes
and 1 toxin gene detected by PCR among investigated isolates. Majority
of isolates showed the presence of >1rep gene and >1 relaxase gene.
33 rep proﬁle types were proposed based on the combination of rep genes
present in each isolate. Sequence analysis showed the greatest diversity
of alleles (n = 27) within group of rep genes typical for pheromone
responsive plasmids. The number of plasmid bands visualised by PFGE-
S1 were highly positively correlated with the number of different rep
genes per isolate as well as with the number of relaxase genes. The
number of rep genes as well as the number of plasmid bands detected
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by PFGE-S1 was the highest among carrier isolates. The results for
relaxase and stabilisation/partition modules detection showed statistically
signiﬁcant higher number of these genes among invasive and carrier
strains.
Conclusion: Variable analysis of plasmid proﬁle and content showed
important correlation between PCR-based replication genes detection
and the number of plasmids detected by PFGE-S1 typing. The highest
number of plasmids and rep genes present among carrier isolates may
reﬂect their role as important source of mobile genetic information.
P1355 Polymorphisms of the ﬁmbriae ﬁm2 and ﬁm3 genes in the
Finnish Bordetella pertussis population
T. Kallonen °, J. Mertsola, Q. He (Turku, FI)
Objectives: Bordetella pertussis, the causative agent of pertussis
produces three distinct serotypes: Fim2, Fim3 or Fim2,3. These ﬁmbriae
are coded by the ﬁm2 and ﬁm3 genes, level of ﬁmbrial expression
determines the serotypes of B. pertussis. The ﬁmbriae elicit type-speciﬁc
immunity. In Finland, B. pertussis Fim2 strains were found to be the most
common serotype when 1109 clinical isolates from 1974 to 2006 were
studied. Emergence of Fim3 strains started in 1999 and coincided with
nationwide epidemics. So far two ﬁm2 (ﬁm2−1 and ﬁm2−2) and four
ﬁm3 (ﬁm3−1 to ﬁm3−4) alleles have been found. The different alleles
are due to single nucleotide polymorphism(s) in ﬁm2 and ﬁm3 genes
which result in amino acid substitution(s). However, polymorphisms of
the ﬁm2 and ﬁm3 genes have been only reported in a few countries. In
this study we analyzed the ﬁmbrial gene alleles of Finnish B. pertussis
isolates collected since 1990 s.
Methods: PCR-based sequencing was performed for the previously
reported polymorphic regions of the ﬁm2 and ﬁm3 genes. For ﬁm2
gene 43 isolates from 1991 to 2005 were studied, and for ﬁm3 gene
128 isolates from 1992 to 2006 were studied. All the isolates were
randomly selected from the strain collection of Pertussis Reference
Laboratory of the National Public Health Institute, Turku, Finland. The
international reference strain Tohama I and the two Finnish vaccine
strains were also tested.
Results: For ﬁm2 gene, all Finnish isolates tested as well as the reference
strain Tohama I had ﬁm2−1. For ﬁm3 gene, two alleles ﬁm3−1 (23%) and
ﬁm3−2 (77%) were detected. Before 1999, all isolates had ﬁm3−1. The
allele ﬁm3−2 emerged in 1999 and became predominant since then. The
two Finnish vaccine strains with serotypes Fim2,3 and Fim3 represented
ﬁm2–1/ﬁm3−1 and ﬁm3−1.
Conclusion: Polymorphism was found in ﬁm3 gene, but not in ﬁm2
gene, of Finnish B. pertussis isolates. Emergence of ﬁm3−2 alleles
started in 1999 and coincided with nationwide epidemics. The possible
impact of different ﬁm alleles on protective immunity needs further
investigation.
P1356 Usefulness of automated ribotyping to type Corynebacterium
striatum isolates
E. Carretto °, D. Barbarini, A. Grosini, C. Farina on behalf of the
APSI Study Group
Objective: in the past 5 years, Corynebacterium striatum (CS) was
increasingly reported in different Italian hospitals as the cause of
severe diseases (pneumonia, wound infections) in immunocompromised
patients or admitted to ICUs. Recently, we performed molecular
characterisation of different multidrug-resistant strains of CS. Pulsed-
ﬁeld gel electrophoresis and automated ribotyping allowed us to conﬁrm
the presence of a single clone, possessing erm(X), tetA/B, cmxA/B, and
aphA1 genes, but few related subclones (Campanile et al., EID 2009, 15:
75−8). To further investigate the usefulness of the automated ribotyping
for typing CS strains, we analysed isolates collected in different Italian
hospitals belonging to the APSI (Associazione per la Prevenzione e lo
Studio delle Infezioni, Italy) study group.
Methods: the RiboPrinter Microbial Characterisation System® (Quali-
con, Wilmington, USA) was used to perform the strains’ ribotyping. Two
reference strains (DSM 20668T and DSM 7185) and a set of 16 clinical
isolates collected in different periods were analysed using EcoRI, BstEII
and PvuII as restriction enzymes. Among the clinical isolates, some
strains that we previously documented belonging to the same clone were
included as internal control. The reproducibility of the patterns obtained
was evaluated with repeat testing of 8 of isolates randomly chosen. All
strains were stored at −80ºC until use.
Results: among the restriction enzymes used, EcoRI allowed the best
discrimination. This enzyme generated more complex ﬁngerprints with
5−7 bands, whereas BstEII and PvuII generated 3−5 band proﬁles. As
expected, using EcoRI the fragment comprised in the range 6−15 kbp
allowed a good discrimination among the tested strains, whereas the
bands with lower molecular weight appeared to be more conserved.
EcoRI distinguished 7 different ribotypes with a good agreement with
the internal controls, whereas both BstEII and PvuII differentiated only
6 ribotypes.
Conclusions: the increasing reports of infections caused by multidrug-
resistant CS in our country is responsible for the awareness that led
to the subsequent in-depth examination of these strains. The APSI
study group allowed us to collect, to date, more than 150 CS isolates
from different Italian hospitals. This preliminary study points out that
automated ribotyping using EcoRI could be a good ﬁrst line typing
method to analyze the circulation of CS strains in different geographical
areas of our country.
P1357 cDNA-AFLP strategy applied in the search of drug
resistance markers in medically important fungi
V. Levterova °, N. Brankova, K. Tankova, S. Panaiotov (Soﬁa, BG)
AFLP (Ampliﬁed Fragment Length Polymorphism) is a whole genome
analysis technique applied for typing of strains. Both modiﬁcations of
the technique, DNA and cDNA-AFLP are highly reproducible typing
methods.
Objective: Development of cDNA-AFLP strategy applied in the search
of antimycotic drug resistance marker(s) in medically important fungi.
Methods: Clinical Candida isolate, susceptible to azole antimycotics
was subcultured on agar plates with increased concentrations of
tested antimycotics (ﬂuconazole, and ketoconazole). Six drug resistant
mutants were subject to DNA- and cDNA-AFLP typing. The six
mutants originated from plates with gradually increased concentration of
ﬂuconazole and ketoconazole. BamHI, PstI, MboI and HindIII restriction
enzymes, appropriate adaptors for the restriction sites, adaptor primers
and ampliﬁcation conditions have been tested with the aim to identify
the characteristic AFLP patterns. Mutant genotypes were compared with
the original drug sensitive strain.
Results: DNA-AFLP typing strategy was used with the aim to evaluate
possible microevolution in the original and mutant strains. AFLP
patterns demonstrate low level of microevolution of the strains after
subculturing on antimycotic containing plates. Only few bands showed
polymorphisms under this selective pressure. Differential expression of
several RNA products were observed by cDNA-AFLP typing.
Conclusions: cDNA-AFLP, is an AFLP-based transcript proﬁling
method. It was applied for genome-wide expression analysis in medically
important Candida species. The technique offers the possibility to
analyze organisms without the need for prior sequence knowledge.
In essence, the cDNA-AFLP method involves reverse transcription of
mRNA into double-stranded cDNA, followed by restriction digestion,
ligation of speciﬁc adapters and separation of this mixture of cDNA
fragments on an automated ﬂuorescently based system. The differential
RNA expression proﬁle is linked to drug resistance as showed by the
differential expression of few RNAs. Observed differences in band
intensities between samples provide a good measure of the relative gene
expression level. Identiﬁcation of differentially expressed genes can be
accomplished by purifying cDNA-AFLP fragments from sequence gels
and subsequent sequencing. This method has found to be an attractive
technique for gene discovery of genes involved in antimycotic resistance
in medically important fungi.
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P1358 Molecular epidemiology of invasive meningococcal disease
in the Czech Republic
J. Kalmusova, M. Musilek, P. Kriz ° (Prague, CZ)
Objectives: Enhanced surveillance of invasive meningococcal disease
(IMD) has been conducted in the Czech Republic since 1993, when a
new hyperinvasive clonal complex, cc11, emerged and caused increase
in IMD incidence and morbidity. Molecular methods for the character-
isation of Neisseria meningitidis which have been used continuously in
the National Reference Laboratory for Meningococcal Infections (NRL)
allow precise assessment of the epidemiological situation. The aims of
this study were to identify possible epidemiological links between IMD
cases across districts of the country, to detect secondary IMD cases, and
to assess possible epidemiological links between patients and healthy
contacts.
Methods: Epidemiological and microbiological data from the surveil-
lance database for 2007 were analysed. All meningococcal isolates from
IMD cases (43 isolates) and healthy contacts (38 isolates) referred to
the NRL were characterised by serogrouping, PorA and FetA sequencing
(http://neisseria.org/nm/typing/) and multilocus sequence typing (MLST)
(http://pubmlst.org/neisseria/).
Results: IMD in the Czech Republic in 2007was caused mainly
by serogroup B (67.4%), followed by serogroups C (20.9%) and Y
(9.3%). The following clonal complexes were most frequently associated
with IMD: cc11, cc18, cc41/44 and cc32 (18.6%, 13.9%, 9.3% and
9.3%, respectively). Most isolates from healthy contacts were either
serogroup B (63.1%) or non-groupable (31.6%). They showed high
heterogeneity in clonal complexes, with the prevalence of cc41/44
(18.4%) and a high proportion of strains not assigned to clonal complex
(39.9%). In 2007, invasive meningococcal disease occurred in 49 out
of 86 districts. A single case was reported in 30 districts, two or more
cases occurred in 19 districts. No secondary case of IMD was detected
by the analysis of epidemiological data and isolate genotypes. Genotypes
were identiﬁed for 8 clusters of pair case/contact isolates. The case and
contact isolates had identical genotypes in 3 clusters, the former differed
in genotype from the latter in other 3 clusters and mixed genotypes were
observed in 2 clusters. All pair case/close contact isolates had identical
genotypes in contrast to most pair case/non-close contact isolates that
differed in genotype.
Conclusion: No secondary case of IMD has been detected in the Czech
Republic. The measures taken in IMD foci are efﬁcacious and need to
be targeted at close contacts only.
P1359 Genotypes of Coxiella burnettii. Comparison between AFLP
and VNTR typing strategies
S. Panaiotov °, N. Brankova, V. Levterova, P. Butaye, W. Vanderhaegen,
R. Toman (Soﬁa, BG; Brussels, BE; Bratislava, SK)
The accurate typing is a difﬁcult part in the epidemiological research.
Selection of the typing strategy for bacteria has been one of the most
important practical questions to be solved within the bacteriological
laboratories.
Objective: To compare typeability of VNTR and AFLP techniques
applied for Coxiella burnettii.
Methods: We investigated the possibility to apply the AFLP technique
for typing of the C. burnettii isolates collected in Europe and North
America. BamHI, PstI, MboI and HindIII restriction enzymes, the
appropriate adaptors for the restriction sites, and both adaptor primers
and ampliﬁcation conditions have been tested with the aim to identify
the characteristic AFLP patterns. The BamHI/PstI combination showed
promising results. The PCR ampliﬁed Cy-5 ﬂuorescently labeled
restriction fragments were separated on an automated sequencer. The
obtained restriction patterns were elaborated with the GelComparII
software. Seven polymorphic VNTR markers were selected for typing.
The typing results demonstrated homogeneity in the genotypes from
Slovakia and a good distinction from the North American C. burnettii
genotypes. Only two VNTR markers demonstrated polymorphisms in
the Slovak isolates.
Results: The VNTR typing demonstrated that the C. burnettii isolates
from Slovakia form quite a homogeneous genotypic cluster. Both typing
methods, VNTR and AFLP, have demonstrated that the C. burnettii
genome is conservative and evolutionary stable. The generation of
polymorphisms is not dynamic. It appears that C. burnettii is not
rich in the BamHI and PstI recognition sequences. The AFLP pattern
demonstrates a relatively small number of ampliﬁed fragments in
comparison to Chlamydia trachomatis. HindIII/MboI gives signiﬁcantly
more fragments. A small number of them are polymorphic.
Conclusions: VNTR identiﬁes ﬁve clusters. All Slovak isolates belong
to cluster 5. The proposed AFLP methodology identiﬁes only three
clusters. In the same time, the AFLP has identiﬁed unique “Slovak”
AFLP patter not found in other isolates. Results of DNA digesting with
HindIII and MboI restriction enzymes repeat both results and conclusions
found for BamHI and PstI. Both AFLPs conﬁrm that two isolates, one
from Slovakia and one from the USA are different from others. Based
on the AFLP results of the investigated C. burnettii isolates a speciﬁc
PCR could be developed for unique marker(s).
P1360 Direct genotyping of Coxiella burnettii in human and
animal clinical samples
C. Klaassen °, M. Nabuurs-Franssen, J. Tilburg, M. Hamans,
H.J. Roest, R. Ruuls, P. Willemsen, A. Horrevorts (Nijmegen,
Eindhoven, Lelystad, NL)
Objectives: Studies towards the molecular epidemiology of Coxiella
burnettii are hampered by the availability of sufﬁcient material for
analysis. So far, molecular ﬁngerprinting of C. burnettii has relied on
cultivation/enrichment of the pathogen prior to analysis which requires
speciﬁc biosafety facilities. Molecular diagnosis of Q-fever has mainly
focussed on the use of serum/plasma for analysis. We explored the direct
genotyping of C. burnettii on various human and animal clinical samples
from the current and ongoing Q-fever outbreak in The Netherlands.
Methods: A 6-marker MLVA panel (selected from Arricau-Bouvery et
al., 2006) distributed over 2 multiplex PCR reactions was applied to
DNA extracted from serum/plasma, sputa, faeces, urine, throat-swabs
and genital swabs. PCR products were analyzed by multicolour capillary
electrophoresis. Repeat numbers were deduced from the fragment sizes
relative to those obtained using the well characterised and sequenced
Nine-Mile strain. The relative DNA load of C. burnettii in these samples
was determined using real-time PCR targeting the IS1111a element.
Results: Multiple different genotypes were obtained in those clinical
samples with the highest DNA loads (Ct value  35). These clinical
samples included all of the above mentioned sample materials. Partial
genotyping results were obtained in some of the samples with a lower
DNA load. Certain genotypes were found in both human and animal
samples. Despite several minor differences, all genotypes were very
similar indicating a possible clonal origin of the outbreak.
Conclusions: Direct genotyping may be a promising and welcome
addition to the current techniques used to study the molecular
epidemiology of C. burnettii and to identify the possible origin of human
Q-fever infections.
P1361 Molecular typing of Listeria monocytogenes virulent
serotypes
M.A. Ferrus °, Y. Moreno, L. Ballesteros, A. Rodrigo, G. Cuesta,
J. Herna´ndez (Valencia, ES)
Objectives: Listeria monocytogenes is the causal agent of one of
the most important foodborne diseases worldwide. Pregnant women,
newborns and immunocompromised persons are especially susceptible
to the infection, with a case-fatally rate until 75%. L. monocytogenes
presents a great strain virulence variation. Among the 14 known
serotypes, only three (1/2a, 1/2b and 4b) produce 95% of the infection
cases. So, molecular methods which can differentiate among strains
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belonging to the same serotype are greatly required for epidemiological
surveillance. The repetitive extragenic palindromic element-based PCR
(REP-PCR) is rapid, as discriminatory as PFGE and has a typing
potential similar to RADP method. In this study we have evaluated the
utility of an automated rep-PCR method for genomic ﬁngerprinting of
L. monocytogenes strains belonging to serotypes 1/2a, 1/2b and 4b.
Material and Methods: Ninety-ﬁve Listeria monocytogenes and ﬁve
non-monocytogenes Listeria strains isolated from different sources were
studied. Identiﬁcation was conﬁrmed by multiplex PCR using speciﬁc
primers to amplify a 938 pb fragment from 16S rDNA of Listeria spp.
and a 750 pb fragment from hlyA gene of L. monocytogenes. Biotype was
determined by API-Listeria system. Serotyping was performed by heat-
inactivated bacteria agglutination with the commercial system Listeria
antisera set (Denken Seiken.Co, Ltd., Tokio).
Results: All the isolates were analysed with an automated repetitive
element-based PCR (rep-PCR) system. Results of the similarity analysis
revealed four primary genetic groups among the isolates, separated at a
relative similarity of 85%. Listeria species other than L. monocytogenes
had similarity scores of less than 70%, and could be easily distinguished
from L. monocytogenes isolates. No relationship could be found between
the serotype and the rep-PCR pattern. However, distinct biotypes were
found in the different genetic groups, with a statistically signiﬁcant
distribution.
Conclusion: This study shows that the automated REP-PCR system
possesses a great discriminatory ability for subtyping L. monocytogenes.
This rapid method may be useful for species identiﬁcation and could
be considered as an alternative method for epidemiological tracking of
L. monocytogenes virulent serotypes.
Acknowledgments: This work was supported by AGL2005–07776-
C03−01 and AGL2008–05275-C03–02/ALI grants from Ministerio de
Ciencia y Tecnologı´a, Spain (National and FEDER funds)
P1362 Molecular typing of human isolates of Listeria
monocytogenes
D. De Vito °, M. Santantonio, C. Rizzo, M.F. Coscia, R. Monno,
G. Rizzo (Bari, IT)
Objectives: Listeria monocytogenes is a Gram-positive intracellular
bacterial pathogen responsible for serious infections in immunocompro-
mised individuals, pregnant women, and neonates. Current surveillance
schemes assume that all the isolates of L. monocytogenes are equally
pathogenic, but several observations have suggested that virulence varies
from one strain to another. Therefore, the ability to differentiate strains
of L. monocytogenes is particularly important for tracking transmission
of pathogenic strains within food-processing plants and developing more
effective intervention strategies to prevent recalls and human illness.
The present study was carried with the aim of analysing biochemically,
serologically and molecularly 15 human isolates strains of L. monocyto-
genes.
Methods: A total of 15 L. monocytogenes strains were isolated from
human sources at the Microbiology and Virology Department, Policlinico
di Bari, Italy. They were serotyped by commercially available listerial O
and H antisera and characterised by PFGE method with three different
restriction enzymes, ApaI, AscI, and SmaI.
Results: All the strains were conﬁrmed by conventional biochemical
tests as L. monocytogenes. The prevalent serovars were 4b (60%) and
1/2a (40%).
The genomic DNA restriction proﬁles of the 15 L. monocytogenes
isolates obtained after digestion with endonucleases resulted similar.
Only one strain presented a different electrophoretic pattern using all
three enzymes. This strain prfA gene, transcriptional activator of the
majority of virulence genes, was ampliﬁed and sequenced. This gene
presented multiple silent mutations and one not conservative mutation
that transforms Hys 181 in Leu.
This mutation could probably explain the different degree of
pathogenicity of this strain that caused a severe disease in a not
immunocompromised patient.
Conclusion: The results so obtained conﬁrm that these molecular
subtyping methods can usefully support the epidemiologic and laboratory
investigation of L. monocytogenes infections. They allow to establish
speciﬁc relationships between different isolated strains and their
pathogenic grade.
P1363 Chlamydia trachomatis genotypes in a group of male
patients coming from a sexually transmitted diseases clinic
in a city in northern Spain
P. Mejuto °, P. Suarez-Leiva, A. Palacio, M. Rodriguez, S. Melon,
D. Gonzalez, J.A. Boga (Oviedo, ES)
Objectives: Chlamydia trachomatis is one the most prevalent sexually
transmitted bacterial pathogen. Serovars D to K are commonly associated
with urogenital infections in males such as uretrithis and epididymitis.
Lymphogranuloman venereum (LGV), a sexually transmitted disease
(STD) caused by C. trachomatis serovars L1, L2 and L3, is endemic
in tropical countries but from the year 2004 there are reported cases in
Europe. We try to study the circulating genotypes in a group of male
patients coming from a STD clinic in our city.
Methods: We undertook a two years review, from January 2007 to
December 2008. We included 84 male patients coming from a STD
clinic (median age was 29.7 years). To detect bacterial DNA in clinical
specimens, the COBAS TaqMan CT Test (Roche) was used. To genotype
bacterial strains, a 990 pb-fragment of ompA gene was ampliﬁed by a
nested PCR. The amplicons were puriﬁed by using Montage DNA Gel
Extraction Kit (Millipore) and sequenced with BigDye Teminator Cycle
Sequencing Kit (Applied Biosystems). The individual sequences were
compared to those available in the GenBank databases with the BLASTN
program run on the NCBI Server.
Results: Twenty-two of 84 (26.2%) rectal swabs positive for C. tra-
chomatis were found. Sixteen of 22 (72.7%) C. trachomatis positive
samples were genotyped. The most prevalent genotype was E (50%)
followed by D (18.7%), G (12.5%) and J (12.5%). The median age was
31.62 years. HIV status was known for 2 patients (12.5%) and another
concomitant sexually transmitted disease was present in 6 cases (37.5%):
1 syphilis (6.25%), 3 human papillomavirus (HPV) type 6 (18.75%) and
2 HPV type 11 (12.5%).
Conclusions: Genotype E is the most frequent in this group of patients.
Genotypes distribution is similar to other reports. Any C. trachomatis
variant related with LGV was not found.
P1364 Genotyping of Chlamydia trachomatis in Bilbao, Spain
N. Ortiz °, G. Ezpeleta, M. Imaz, V. Esteban, R. Cisterna (Bilbao, ES)
Introduction: Chlamydia trachomatis is the most common cause of
bacterial sexually transmitted infections (STI) worldwide. Besides,
Chlamydia acts as a marker of increased risk for HIV infection. There
are 19 serovars of C. trachomatis, as deﬁned by serological responses to
the outer membrane protein (ompA) and can be conveniently deﬁned
by sequence analysis and genotyping of the ompA gene. There has
been signiﬁcant interest in whether these genotypes are differentially
associated with clinical manifestations, geographic locations or gender.
Objective: The aim of this study was to explore the distribution of these
genotypes in a group of patients referred from Bilbao health area located
in the North of Spain.
Material and Methods: One hundred clinical samples from different
anatomical sites sent to the Basurto Hospital STI Laboratory for
assessment between January 2007 and June 2007 were screened as
positive for C. trachomatis by polymerase chain reaction (PCR) using
and in-house real-time PCR assay targeting the cryptic plasmid.
Direct real-time PCR assay was used to produce two 480-bp amplicons
deﬁning the V1-V2 and V3-V4 regions of the ompA gene using the
primers previously described by Dean et al. The PCR reaction was
carried out in a volume of 20 uL and was performed in a LightCycler
480. The ﬁnal product was puriﬁed using UltraClean PCR puriﬁcation
system and sequenced using BigDye Terminator Version 3.1 chemistry
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according to the kit instructions. Sequencing reactions were puriﬁed with
AutoSeq G-50 (GE Healthcare) and sequenced on an ABI 3130 Genetic
Analyzer. DNA sequences obtained were aligned to obtain full-length
sequence information of each sample and queried against the BLAST
database.
Results: 82 (82%) of the specimens tested contained only one serovar
and 18 (18%) contained two or three serovars. In common with studies
from other countries, genotypes E and F were the dominant strains
found in our patient population. The other genotypes distribution was the
following: K (13.41%), D (12.19%), G (10.97%), Ja (9.75%), J (7.31%),
H (10.97%), Ia (4.87%), L2 (1.21%), and L2b (3.66%). Patients with
C. trachomatis type G were signiﬁcantly older than the mean of the other
groups. This result could suggest that the immune response to E drives a
population switch to the G genotype with repeated exposure as pointed
in other studies, but further research in this point is necessary.
P1365 Detection and genotyping of Chlamydia trachomatis in
clinical urogenital samples from north-eastern Croatia
Z. Bosnjak °, D. Vukovic, N. Ruzman, I. Roksandic-Krizan, M. Peric,
S. Dzijan (Osijek, HR)
Objectives: Due to the chronic and “silent” infection and variable
antigenic structure of the Chlamydia trachomatis we supplemented
Direct Immune Fluorescence with the molecular diagnostic method using
COBAS TaqMan 48 real time PCR instrument. The fast molecular
diagnostics of C. trachomatis infections and adequate therapy of the
infected individuals are the crucial step in the C. trachomatis spread
control. The epidemiological data obtained from the Osijek-Baranja
County Institute of Public Health archives revealed the true number of
chlamydia genital infections among other genital infections in the last
ﬁve years in our county.
The aim of the present study has been to reveal the most prevalent
serotype of the C. trachomatis detected in urine and gynaecological
samples in the population of the Osijek – Baranja County and to
monitor the infection and the therapy efﬁciency. The determined serotype
distribution has been compared with the C. trachomatis distribution
pattern in other regions of the World. All the samples were collected from
the Osijek-Baranja County Institute of Public Health and gynaecologist’s
ofﬁces.
Methods: COBAS TaqMan CT test is an in vitro nucleic acid
ampliﬁcation test which utilises real time PCR technology. The test has
been developed to conﬁrm analogous detection of all 15 C. trachomatis
serotypes and it produces results within 3 hours. Subsequently all the
positive samples have been analysed directly by sequencing of the
ampliﬁed omp1 fragments using Applied Biosystems 3130 Genetic
Analyser. Genotyping and sequence mutation analysis have been
performed by BLAST searching and compared with the reference
sequences of all known C. trachomatis serotypes.
Results: The most prevalent genotype in Osijek-baranja County was
serotype E (in agreement with Sweden and Taiwan data), followed by
F, G, D, K, J, H, B, and Ia (differs from Sweden and Taiwan data). The
sequence of omp1 gene showed limited variation.
Conclusion: The obtained omp1 gene genotyping results could be useful
tool for epidemiological characterisation of circulating C. trachomatis in
our community. Further analyses in this ongoing project might also reveal
the inﬂuence of certain serovar on clinical signs, intensity of infection,
duration of genitourinary infection considering age and sex and therapy
efﬁciency, as well as possible presence of chlamydial coinfection and
reinfection.
P1366 Molecular analysis of Pseudomonas aeruginosa and
Acinetobacter baumannii strains, isolated from intensive
care unit patients of with hospital-acquired pneumonia
A. Budak °, D. Wlodarczyk, P. Nowak, P. Mrowiec, M. Wegrzyn
(Cracow, PL)
Objective: The aim of study was genotypical analysis of Pseudomonas
aeruginosa (10) and Acinetobacter baumannii (14) strains, isolated from
tracheal aspirates, which were aetiologic agents of hospital acquired
pneumonia in patients of ICU.
Methods: Genetic material was isolated by using Genomic Mini AX
BACTERIA kit (A&A Biotechnology, Poland). In order to obtain
ampliﬁcation products, RAPD-PCR method with primers: 272, 208,
ERIC 2 and PAL 2 was used. With the help of agarose gel electrophoresis
with EtBr, reaction products were exposed. The result was analysed with
computer program BIO-PROFIL Bio1D++ (Vilber Lourmat, France).
Genetic similarity between strains was viewed by using dendrograms.
The dendrograms with UPGMA clusterisation method were received.
Result: As a result of bacteria genotyping, the genetic similarity
value of speciﬁed clonal groups, was equal for the following primers:
P. aeruginosa: 272−47%, 208−71%, ERIC 2−46%, PAL 2−49%,
A. baumannii: 272−63%, 208−59%, ERIC 2−52%. The homology value
between strains was also evaluated. Isolates were closely related if the
genetic similarity degree was in the range of 100−85%.
In the group of P. aeruginosa isolates, for primers 272 and 208, one
clonal group with the high level of homology between strains was
speciﬁed (appropriately isolates 5, 6 and 2, 3). For the primer ERIC 2
one clonal group (5, 6) and one pair of strains with the same genetic
proﬁle (7, 8) were observed. The primer PAL 2 viewed high similarity
degree for 3 pairs of isolates (1, 2; 4, 7; 6, 8).
In the group of A. baumannii strains, for the primer 272, three clonal
groups were speciﬁed: 1, 2; 8, 10, 11; 12, 14. The primer 208 let specify
four clonal groups: 5, 10; 8, 11; 2, 3, 6, 9; 12, 13, however ERIC 2 − two
groups with high homology value between strains.
Conclusion: P. aeruginosa: all analysed isolates probably derived
from several subpopulations of a hospital strain, which has undergone
evolutionary divergence phenomenon in time, as a result of medicine
application and changing conditions of the hospital environment.
A. baumannii: there was observed higher degree of homology between
isolates. All strains have hospital nature, except isolate number 7. A lack
of high similarity degree with the rest of strains, can indicate posthospital
origin.
P1367 Molecular typing of a new variant of Encephalitozoon
cuniculi responsible for disseminated microsporidiosis in a
renal transplant recipient
H. Talabani, C. Sarfati, E. Pillebout, T. van Gool, F. Derouin,
J. Menotti ° (Paris, FR; Amsterdam, NL)
Objectives: To identify and subtype a microsporidian strain responsible
for disseminated infection in a renal transplant recipient presenting fever
and abdominal pain.
Patient and Methods: A 38-year-old female renal transplant recipient
presented fever, cough, non speciﬁc abdominal pain and anorexia
4 months after transplantation. No bacterial aetiology was found. After
a 1-month hospitalisation, many spores of microsporidia were detected
in sputum, urines and kidney biopsy. For species diagnosis, speciﬁc
PCR amplifying Enterocytozoon bieneusi internal transcribed spacer
(ITS) and Encephalitozoon intestinalis, Encephalitozoon cuniculi and
Encephalitozoon hellem small subunit rRNA genes were performed.
Indirect immunoﬂuorescence technique (IFAT) was used to search
for antibody responses against the spore wall and the polar tube
of E. cuniculi. Subspeciﬁc molecular typing was made by PCR and
sequence analysis of a 403-bp DNA fragment containing E. cuniculi ITS.
Results: Speciﬁc PCR for E. bieneusi, E. intestinalis and E. hellem
were negative, but the presence of E. cuniculi DNA was evidenced in
urines, sputum and kidney biopsy specimens. An IgG antibody response
against the spore wall of E. cuniculi were evidenced by IFAT in a serum
specimen sampled early after infection. Additionally, an IgG antibody
response against the polar tube of E. cuniculi was evidenced in a
serum specimen sampled 3 months after. Sequence analysis of the DNA
fragment containing E. cuniculi ITS showed the presence of 5 repeats of
5′-GTTT-3′ in all tested specimens collected from our patient (1 sputum,
1 kidney biopsy and 4 urine samples), which does not correspond to the
number of repeats found in the 3 described strains of E. cuniculi in the
literature.
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Conclusion: Molecular typing showed that our patient was infected with
a previously undescribed variant of E. cuniculi, which we propose to
name type IV strain.
Epidemiology of MRSA in animals
P1368 Exposure related carriage of methicillin-resistant
Staphylococcus aureus in veal calf farmers in the Netherlands
H. Graveland °, J. Wagenaar, D. Heederik (Utrecht, NL)
Objectives: Recent studies showed that pig and cattle farming is a
risk factor for MRSA colonisation in humans. In depth analysis of
the speciﬁc risk factors associated with MRSA colonisation in veal
farmers is lacking. To study the prevalence of MRSA in veal farmers
and associated risk factors, we conducted a cross sectional study among
390 farmers and family members. To gain more insight in the dynamics
and persistence of MRSA colonisation in this population a longitudinal
study is ongoing in which repeated nasal- and throat swabs are being
taken, comprising MRSA colonisation in periods with and absence of or
reduced animal contact.
Methods: 102 veal calf farms were randomly selected and visited from
March 2007 – February 2008. Participating farmers were asked to ﬁll in a
questionnaire (n = 390) with questions about life style factors (smoking),
activities on the farm and contact with animals. A nasal swab was taken
from each participant. Swabs were analysed for MRSA by selective
enrichment, culturing and conﬁrmed by MecA pcr. Spa types of the
isolates were identiﬁed. Data were analyzed using multi-level logistic
regression analysis to adjust for potential clustering within farms.
Results: MRSA prevalence was 33% in calve farmers and 8% in
family members. Duration of animal contact was strongly and positively
associated with nasal human MRSA colonisation. Additionally, activities
with direct animal contact, such as feeding the calves and tasks involving
different forms of veterinary care were also positively associated with
MRSA colonisation. Furthermore the percentage of MRSA positive
calves on the farm is a risk factor. Initial results from the longitudinal
study indicates that the prevalence of MRSA colonisation is lower in
periods with reduced animal contact.
Conclusions: The association between duration of contact with animals
and MRSA colonisation indicates that especially intensive contact with
animals might put them at risk for MRSA colonisation. However, the
large differences in MRSA prevalence between farmers and family
members and the strong association with the percentage of positive
calves is suggestive of either transient colonisation of NT-MRSA in
humans or contamination of the sampled nasal cavities with MRSA
containing dust from the stable air instead of carrier ship. Full analysis
of the ongoing longitudinal study will gain more insight in the dynamics
and duration of MRSA colonisation.
P1369 Spread of methicillin-resistant Staphylococcus aureus
sequence type 398 in Europe
B. van Cleef °, D. Monnet, A. Voss, J. Kluytmans, H. Mittermayer,
F. Allerberger, M. Struelens, H. Zemlickova, R. Skov, J. Vuopio-Varkila,
W. Witte, A. Friedrich, I. Spiliopoulou, J. Paszti, H. Hardardottir,
A. Rossney, A. Pantosti, M. Borg, H. Grundmann, M. Mueller-Premru,
B. Olsson-Liljequist, A. Widmer, S. Harbarth, A. Schweiger, S. Unal,
A. Pan on behalf of the ST398-Study Group
Objective: To estimate the contribution of livestock associated
methicillin-resistant Staphylococcus aureus Sequence Type 398 (MRSA-
ST398) to the burden of MRSA from humans in Europe in 2007.
Methods: A cross sectional survey was performed. In September 2008, a
questionnaire was sent to 43 laboratories in 23 countries, with questions
on general laboratory information, number of MRSA isolates and
number of MRSA-ST398 isolates in 2007.
Preliminary results: As of December 2008, we have received the replies
from 24 (56%) laboratories from 17 (74%) countries. Only results from
the 20 laboratories that typed MRSA isolates are reported. This includes
data from the following 15 countries: Austria, Belgium, Czech Republic,
Denmark, Finland, Germany, Greece, Hungary, Iceland, Italy, Ireland, the
Netherlands, Sweden, Switzerland and Turkey.
In total 7,770 MRSA isolates with typing results were reported and 113
(1.5%) were MRSA-ST398. Eight of the 15 countries reported MRSA-
ST398. The proportion of MRSA-ST398 ranged from 0 to 11.9%.
The countries with the highest proportion of MRSA-ST398 were the
Netherlands (11.9%), Belgium (4.7%), Austria (2.7%) and Denmark
(1.6%).
Preliminary conclusions: MRSA-ST398 has spread across Europe,
but the proportion of such isolates generally remains low. The highest
proportions were reported by the Netherlands, Belgium, Austria and
Denmark. Three of these countries, i.e. the Netherlands, Belgium and
Denmark, have the highest pig density per square kilometre among
European countries.
P1370 Methicillin-resistant Staphylococcus aureus Clonal Complex
398 does not spread from farms into the community
B. van Cleef °, E. Verkade, M. Wulf, A. Buiting, A. Voss, X. Huijsdens,
M. Mulders, J. Kluytmans (Bilthoven, Breda, Veldhoven, Tilburg,
Nijmegen, Amsterdam, NL)
Objective: To determine whether methicillin-resistant Staphylococcus
aureus Clonal Complex 398 (MRSA-CC398) has spread from livestock
farms into the general community in the Netherlands.
Methods: A cross-sectional prevalence study was conducted in
3 urban municipalities with the highest densities of pigs in the
Netherlands (a). Adult persons (n = 2703) were randomly selected from
the national registry of inhabitants. A questionnaire was mailed asking
for participation and contact with livestock, working in healthcare,
past history of MRSA, contact with MRSA-positive persons and
hospitalisation abroad. Furthermore, a nasal swab was taken to determine
the presence of MRSA. To determine if spread from farms into the
community had occurred, a stratiﬁed analysis was done for persons with
and without contact with livestock. The sample size was calculated at
450 persons without livestock contact to exclude a prevalence of at least
2%, assuming a background prevalence of 0.5% (a=0.05 and b=0.10).
Results: As of December 2008, complete data were collected from 517
individuals (response 19%). All of the 478 persons without contact with
livestock tested negative for MRSA. Of the 39 persons who indicated
regular contact with livestock (either work at or live on a livestock
farm), 8 persons (8/39: 20.5%, 95% conﬁdence interval 10.8–35.5) tested
MRSA-positive. Seven of these 8 persons reported contact with pigs
and 1 with poultry, 3/8 had been tested MRSA-positive previously, and
5/8 reported recent contact with MRSA-positive persons. Spa-typing is
currently being performed.
Conclusions: MRSA-CC398 was not found in persons without contact
with livestock. Therefore there are presently no indications that this clone
is spreading into the community in the Netherlands.
(a) according to the annual count of farming 2005–2007 done by CBS
Statistics Netherlands (www.cbs.nl).
P1371 Detection of Staphylococcus aureus multi-locus sequence
type 398 (ST398) in blood cultures
E. Verkade °, A. Budding, V. Weterings, J. van Baal-Vissers, A. Bergmans,
P. Savelkoul, A. Buiting, J. Kluytmans (Breda, Amsterdam, Tilburg, NL)
Objectives: Recently a new clone of methicillin-resistant Staphylococcus
aureus (ST398 MRSA) has emerged which is related to animal
husbandry. The methicillin-susceptible ancestor of this strain is a
common S. aureus variant in pigs. A recent study showed that 2.1%
of MSSA strains that caused bacteraemia in humans were ST398. This
ﬁnding is worrying but the study did not use a well-deﬁned collection
of strains and thus the results may be biased. Therefore, we determined
the prevalence of ST398 MSSA in consecutive bacteraemic patients in
an area in The Netherlands with a high density of pigs.
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Methods: In two time periods all consecutive episodes of MSSA
bacteraemia were included. 251 MSSA strains were isolated between
1996 and 1998 in Tilburg and Breda, The Netherlands. Another
210 MSSA strains were isolated between 2002 and 2005 from patients
in Breda, The Netherlands. The cities of Tilburg and Breda are located
in the Southern part of The Netherlands, which is an area with a high
density of pigs.
In order to identify ST398 MSSA, the 16S-23S interspace (IS) region
lengths from all isolates were determined using speciﬁc primers in a
PCR. Every S. aureus strain has 5 or 6 IS regions in its chromosome.
The length of the individual regions vary within the chromosome, so
when ampliﬁed and sorted by length using gel electrophoresis, each
strain produces an unique pattern of bands.
All isolates were subcultured to obtain fresh growth. A 1 McFarland
suspension was made in 0.75% NaCl suspension. This suspension was
centrifuged at 14,000 rpm for 3 minutes in an eppendorf vial. The
supernatant was removed and the pellet was resuspended in AquaDest
water by vortexing. This suspension was then centrifuged at 14,000
rpm for 3 minutes. The supernatant was used for PCR without further
processing. For ampliﬁcation of the 16S-23S rRNA spacer regions, two
primers were constructed in conserved regions of 16S and 23S rDNA
respectively. PCR products were separated on a 2% agarose gel. All
banding patterns were then visualised using an UV Transilluminator and
were checked for the unique ST398 banding pattern.
Results: None of the 461 MSSA strains showed a banding pattern that
corresponded to that of ST398 (95% conﬁdence interval of 0.00–0.01).
Conclusion: In an area with a relative high density of pigs, ST398
MSSA was not found as a cause of bacteraemia in humans. This ﬁnding
indicates that ST398 MSSA is not a frequent cause of invasive disease
in humans.
P1372 Heterogeneity among porcine MRSA ST398 isolates
R. Ehricht °, K. Kadlec, S. Schwarz, U.S. Steinacker, H.K. Kaspar,
S. Monecke (Jena, Neustadt-Mariensee, Berlin, Dresden, DE)
Objectives: Within the last few years, methicillin-resistant Staphylo-
coccus aureus strains of sequence type ST398 which carried a type V
SCCmec cassette (ST398-MRSA-V) gained considerable attention as
they were found to colonise and cause infections in both, animals and
humans with exposure to animal husbandry, especially swine farming.
Strains of this type were ﬁrst detected in The Netherlands, but are now
also detected in other countries such as Germany, Belgium and Denmark.
Methods: Fifty-three independent strains obtained from pigs all over
Germany on the basis of one strain per farm as well as one canine
isolate were screened using diagnostic microarrays.
Results: Fifty-three strains harboured SCCmec type V elements while
the remaining one carried mecA and ugpQ, but no recombinase
genes. b-lactamase genes (blaZ, blaI, blaR) were found in ﬁfty-three
strains. Macrolide/lincosamide resistance genes ermA, ermB and ermC
were found in ﬁve, seven, and thirteen strains, respectively. The
streptogramin resistance gene vga(A) was detected in seven strains, the
aminoglycoside resistance genes aacA-aphD in eight and aadD in nine
strains. Tetracycline resistance genes were commonly found with tetK
in ﬁfty-one and tetM in ﬁfty-three strains. Usually, both tet genes were
simultaneously present in the ST398-MRSA-V strains. Chloramphenicol
resistance was rare (fexA in two strains). Some strains carried enterotoxin
genes which might be of relevance in the pathogenesis of diseases in
humans. One strain was positive for the enterotoxin B (seb) gene, another
three strains for the enterotoxin K and Q (sek, seq) genes. None of the
isolates harboured the Panton-Valentine leukocidin genes lukF-PV and
lukS-PV or the genes sak, chp, and scn indicative for haemolysin beta
converting phages. The carriage of haemolysin alpha and delta genes,
the protease genes sspA, sspB, and sspP, the ssl and set genes, as well
as MSCRAMM genes was uniform among all strains.
Conclusion: The microarray results revealed a high degree of diversity
regarding resistance genes and virulence determinants. These data might
point towards a tendency of the ST398-MRSA-V strains to readily
acquire resistance genes commonly associated with mobile genetic
elements such as plasmids or Transposons. Moreover, the presence of
enterotoxin genes seb, sek and seq could indicate an evolutionary trend
towards an increased pathogenicity for humans.
P1373 Longitudinal evaluation of methicillin-resistant
Staphylococcus aureus and Clostridium difﬁcile in pigs
J.S. Weese °, R. Friendship, T. Wakeford, A. Zwambag, J. Rousseau,
R. Reid-Smith (Guelph, CA)
Objectives: The potential public health concerns of MRSA and
Clostridium difﬁcile in food animals are receiving increasing attention,
yet little is known about the dynamics of colonisation in pigs. The
objectives of this study were to characterise the prevalence of MRSA
and C. difﬁcile colonisation in piglets over time on commercial swine
farms.
Methods: One farm was evaluated for each organism. For MRSA, nasal
swabs were collected from sows 2 weeks prior to farrowing, then from
piglets from 3 MRSA positive and 7 MRSA negative sows at 1, 3, 7, 14,
21, 28, 42, 56 and 70 days of life. Enrichment culture for MRSA was
performed. For C. difﬁcile, sows were sampled 30, 22 and 15 days prior
to farrowing and rectal swabs were collected from piglets from 5 positive
and 5 negative sows on days 2, 7, 30, 44 and 62 for enrichment culture
and typing.
Results: MRSA colonisation rates were low initially, but increased
over time, with 79% of piglets positive on at least one occasion. The
prevalence of MRSA colonisation on days 1, 3, 7, 14 and 21 was 1%,
6.2%, 8.5%, 4.4%, 20%, respectively, with 35% of piglets positive prior
to weaning. 34%, 64%, 50% and 41% of pigs were colonised on days
28, 42, 56 and 70, respectively. Of piglets surviving to weaning 84% of
piglets from negative sows and 100% of piglets from positive sows were
positive on at least 1 sample. A piglet from an MRSA positive sow was
1.4 times more likely to be colonised than a piglet from a negative sow
(P = 0.037). All MRSA isolates were PFGE non-typable and spa t034. In
contrast, C. difﬁcile colonisation rates were high initially and decreased
over time. C. difﬁcile was isolated on one or more occasions from 97%
(117/121) of piglets. The prevalence of colonisation on days 2, 7, 30,
44 and 62 was 74%, 56%, 40%, 23% and 3.7%, respectively. 133/143
(93%) tested isolates were ribotype 078/toxinotype V.
Discussion: Colonisation rates were high for both pathogens, but the
contrasts between them were interesting. The reasons for the changes in
prevalence over time are unclear and require investigation to determine
whether factors can be modiﬁed to reduce the risk of transmission. The
use of single farms limits making broad conclusion, but this study
provides insight into age-related effects on colonisation that should
be considered in future studies. While colonisation status of the sow
inﬂuences the piglets, there is not an absolute relationship and other
sources of infection need to be considered.
P1374 Evaluation of Clostridium difﬁcile and methicillin-resistant
Staphylococcus aureus contamination of retail chicken meat
J.S. Weese °, B. Avery, J. Rousseau, R. Reid-Smith (Guelph, CA)
Objectives: Concern has been raised about the potential for foodborne
transmission of MRSA and C. difﬁcile, yet there has been minimal
investigation of these pathogens in chickens or retail chicken meat. This
study evaluated the prevalence of C. difﬁcile contamination of retail
meat.
Methods: Chicken wings, legs and thighs were purchased from retail
outlets in Ontario, Canada as part of the Canadian Integrated Program
for Antimicrobial Resistance Surveillance. Samples rinsed in phosphate
buffered saline. 1ml of rinse was added to 9ml enrichment broth
(CDMN with sodium taurocholate), which was incubated for 24 h then
inoculated onto CDMN agar. Isolates were characterised by ribotyping,
PCR for detection of toxin A, B and CDT (binary toxin) genes and
sequencing of the regulatory gene tcdC.
Results: C. difﬁcile was isolated from 16/83 (19%) samples; 8/50 (16%)
thighs, 6/28 (21%) wings, 2/5 (40%) legs (P = 0.40). All 12 tested isolates
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were ribotype 078 (toxinotype V), possessed genes encoding toxins A,
B and CDT, and had a deletion and mutation in tcdC. MRSA was not
isolated from any sample.
Discussion: This study provides further evidence that C. difﬁcile
contamination of retail meat may be rather common. The ﬁnding
of the potentially food-animal-associated ribotype 078 was somewhat
surprising in light of a recent study reporting diversity of C. difﬁcile
types in chickens. The absence of MRSA is in contrast to recent studies
of retail beef and pork in Canada, but is perhaps not surprising since
MRSA has not yet been reported in poultry in North America. The
clinical relevance of C. difﬁcile contamination is unclear but further
investigation of food in the epidemiology of community-associated
C. difﬁcile infection, as well as evaluation of sources of contamination
and measures to reduce contamination, are indicated.
P1375 Virulence and resistance determinants in methicillin-
resistant Staphylococcus aureus ST398 isolates
M.A. Argudı´n, A. Fetsch, B.A. Tenhagen, J. Kowall, J. Hammerl,
U. Kaempe, S. Hertwig, A. Schroeter, J. Bra¨unig, A. Ka¨sbohrer,
B. Appel, K. No¨ckler, R. Helmuth, M.C. Mendoza, M.R. Rodicio,
B. Guerra ° (Oviedo, ES; Berlin, DE)
Objective: Detection of virulence and resistance genes in German
MRSA isolates of the MLST clone ST398.
Methods: A series of 106 S. aureus isolates were selected. They included
100 MRSA (2004–2007) of the ST398 clone, and six out-group/control
strains. The isolates originated from healthy and sick pigs, dust from
pig farms, milk, carcasses and meat from food-producing animals.
They displayed different resistance patterns (tetracycline, oxacillin,
erythromycin, and clindamycin being the most frequent resistances),
and carried different SCCmec types (III, IVa, V or non-typeable), and
spa types (mainly t011 and t034). The isolates were analyzed by SmaI-
PFGE, and screened for thirty seven genes involved in virulence and
eight involved in tetracycline or erythromycin resistance by PCR.
Results: The 100 ST398 isolates were non-typeable by SmaI-PFGE.
They were negative for leukotoxins, exfoliatins and superantigen toxins.
They carried only genes encoding haemolysins (hla, hlb, hld± hlg) and
were of the agr quorum sensing system type I. Out-group and control
isolates displayed different virulence proﬁles and were from other agr
groups. All the isolates of the clone were tetracycline resistant and
carried the gene tet(M) together with one or two plasmid associated genes
[tet(K) and tet(L) (18%), tet(K) (51%), tet(L) (22%)]. For erythromycin
and clindamycin resistance, eight patterns [ermA, ermB, ermC (8.2%),
ermA, ermB (19.2%), ermA, ermC (8.2%), ermB, ermC (1.4%), ermA
(11%), ermB (12.3%), ermC (35.6%), non-typeable (4.1%)] were found
among resistant isolates. A relationship between the presence of certain
resistance genes and the SCCmec type was detected. Most of the
SCCmec III isolates carried ermA, which is associated with the Tn554
transposon present in this cassette. The plasmid gene tet(K) was found
only in isolates with SCCmec V.
Conclusions: The ST398 isolates from swine, milk, carcasses and meat
lack several clinically important S. aureus associated virulence factors,
including PVL. Generally, only some haemolysin encoding genes and
the agr type I were present. Other virulence mechanisms related to the
adhesion or production of bioﬁlms may play an important role in the wide
spread of ST398 isolates. All MRSA ST398 were tetracycline resistant
and carried the tet(M) gene with additional resistance genes mediated by
plasmids (tet(K) and/or tet(L)). Most isolates (69%) were erythromycin-
clindamycin resistant and carried different combinations of erm genes.
P1376 Animal-associated ST398 MRSA strains lack
human-associated virulence and adhesion genes
M. Hallin °, R. De Mendonc¸a, O. Denis, A. Lefort, F. El Garch,
P. Butaye, M.J. Struelens (Brussels, BE)
Background: In Belgium, national epidemiological surveillance of
methicillin resistant S. aureus (MRSA) strains isolated from hospitalised
patients showed that nearly 90% belong to nine predominant PFGE types,
belonging to well known international pandemic MRSA lineages, MLST
Clonal Complex (CC) 45, CC8, CC5 and CC22. More recently, ST398
MRSA strains have been described as agent of infection or colonisation
in horses, pigs, poultry and humans.
Objective: The aim of the present study was to detect, by the DNA-
microarray technique, virulence and resistance genes possessed by
ST398 “animal-associated” MRSA strains compared to strains belonging
to well known hospital acquired (HA-) MRSA clones.
Methods: Representative strains of the most frequent Belgian HA-
MRSA epidemic clones (n = 9) and ST398 strains (n = 16) were selected
from the National Reference Laboratory for Staphylococci collection.
ST398 strains were selected from a wide range of host species
(horse, pig, poultry and human). These strains were characterised by
a microarray designed among 8 S. aureus sequenced genomes and
composed of 390 oligonucleotide probes targeting resistance (37%),
virulence (31%) and adhesion factors (32%).
Results: 196 genes (49%) displayed variable results among the 25 strains
tested. Each MLST lineage presented a speciﬁc gene proﬁle that was
highly conserved between strains belonging to a common MLST CCs.
ST398 strains displayed very homogenous gene proﬁles (>92% of
homology) despite their host diversity. This “ST398-speciﬁc” proﬁle
was characterised by the absence of several virulence-associated genes
harboured by most of the HA-MRSA strains tested, such as genes
encoding enterotoxins, proteases (spl operon, sak), haemolysins (hlgB,
hlY) or adhesion factors (embbp, ebpS, hlgB, mapW). The resistance
gene proﬁles were less conserved within lineages than virulence-
associated genes, except that possessing the tetM gene was a common
characteristic of all ST398 strains.
Conclusion: The ST398 MRSA strains were lacking several virulence
associated genes that were harboured by most of the HA-MRSA strains
tested. These ﬁndings may reﬂect that this lineage has emerged from a
peculiar ecological niche – possibly from another host than human – and
raise the issue of its colonising and infecting capacity for humans.
P1377 Methicillin-resistant Staphylococcus aureus CC398 in
humans and animals, Finland
S. Salmenlinna °, O. Lyytika¨inen, A. Vainio, A.L. Myllyniemi, S. Raulo,
M. Kanerva, J. Vuopio-Varkila (Helsinki, FI)
Objective: Animals may serve as a reservoir for methicillin-resistant
Staphylococcus aureus (MRSA). In Denmark and the Netherlands, the
MRSA lineage CC398 is common among pigs (10−40%). In Finland,
the occurrence of MRSA among pigs is under investigation, so far one
isolate has been found. In 2007, an epidemic of CC398 occurred in a
veterinary hospital involving 11 horses and one employee. During 2008,
CC398 was recognized in six other humans. To recognize the possible
connections among CC398 clusters, the background information from
persons with CC398 is enquired by a questionnaire, and all the CC398
isolates recovered from humans and animals are characterised in detail
by molecular methods.
Methods: The plausible CC398 isolates were initially recognized by
their non-typability in SmaI-pulsed ﬁeld gel electrophoresis (PFGE).
Further analysis was performed by spa typing, multilocus sequence
typing (MLST), Staphylococcal chromosome mec (SCCmec)-typing,
detection of Panton-Valentine leukocidin genes (PVL), ApaI-PFGE, and
antimicrobial resistance testing. The background data enquired included
presence of preceding animal contacts and known risk factors for
MRSA, and whether the specimen was obtained because of symptomatic
infection or screening.
Results: The seven human ﬁndings, with no apparent connections
between each other, were from three health care districts. All seven
isolates were resistant to tetracycline, but resistance to aminoglycosides,
macrolides and clindamycin was variable. All human and animal isolates
analyzed thus far, fell into three spa types: the horse isolates and
two human isolates from separate health care districts were spa type
t011, two human isolates from the same health care district were spa
type t034, and the pig isolate was spa type 108. The t034 isolates
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harboured PVL-genes. By ApaI-PFGE, three clusters, separated by 5−7
band differences, were found: 1) t034 human isolate, 2) t011 horse isolate
and the epidemiologically related human isolate, and 3) the other t011
human isolate and the t108 pig isolate. Other typing results and the
background information will be presented.
Conclusion: Subtyping of human and animal MRSA suggests non-
common source for recent emergence of CC398 MRSA in humans in
Finland. However, clustering of human and animal isolates was detected.
Further epidemiological background information is required to reveal the
transmission chains.
P1378 First infections by methicillin-resistant Staphylococcus
aureus sequence type 398 in Spain
C. Potel, M. A´lvarez-Ferna´ndez °, L. Constenla, V. Barbeito,
P. A´lvarez-garcı´a (Vigo, Pontevedra, ES)
Objectives: An emerging ST398 MRSA clone producing infections in
humans has been detected in France, Netherlands, and Denmark. Recent
Dutch studies indicate that it is widely distributed in farm animals
paticularly in pigs and may give rise to infection in humans.
In this study we present the three ﬁrst cases of MRSA infections in Spain,
which with all probability where acquired from contact with animals.
Methods: Three MRSA strains resistant to tetracycline were isolated
in the Northwest of Spain (Pontevedra Province) in 2006. The isolates
were studied by analysis of restriction fragment length polymorphism of
the coagulase gene patterns (RFLP). All the strains were analyzed by
multilocus sequence typing (MLST). The staphylococcal chromosome
cassette (SCC) mec and the accesory gene regulator (agr) types were
determined by multiplex and duplex PCR respectively. The presence of
Panton-Valentine leukocidin-encoding (PVL) genes were identiﬁed by
PCR.
Clinical and demographic data from the three patients were obtained.
Results: The three MRSA strains were identical by RFLP and different
from the known local epidemic clonal lineages (ST5, ST36, ST125).
The strains were ST398, SCCmec-V, agr-1 and PVL genes negative.
The prevalence of this clone was 1.8% (3 ST398 strains from a total of
168 MRSA isolated in 2006).
The average age of the three patients was 75 years old. Two patients
owned pigs and the other a cattle. They had had some admission to
the hospital in 12 months before the diagnosis. Two patients were
diabetic and developed skin and soft-tissue infections, the third one had
bronchitis.
Conclusion: Because of the rapid adaptability of the ST398 clone, we
must be aware about the increase of the prevalence of this clone in
Spanish hospitals as it has been reported in the Netherlands recently. To
limit further spread, strict isolation precautions should be taken in the
case of patients with MRSA isolates typically tetracycline resistant.
The Northwest of Spain is very rural and many families have their
own small farms, therefore veterinary studies are warranted to know
the prevalence of this emerging clone.
P1379 Comparison of methicillin-resistant and methicillin-
susceptible Staphylococcus aureus infections in dogs and cats
M. Faires, M. Traverse, K. Tater, D. Pearl, J.S. Weese ° (Guelph, CA;
Philadelphia, Boston, US)
Objective: Methicillin-resistant Staphylococcus aureus (MRSA) is
emerging as an important pathogen in companion animals, but there
has been minimal objective comparison of MRSA infections with
those caused by methicillin-susceptible Staphylococcus aureus (MSSA)
infections. The objectives of this study were to compare the infection
types, clinical outcomes, and determine the risk factors associated with
MRSA, compared to MSSA infections, in dogs and cats.
Methods: A retrospective case-control study was conducted at
3 veterinary referral hospitals. An MRSA infection was identiﬁed
and was matched by species, veterinary referral hospital, and date
of admission to 2 MSSA controls: the MSSA infection immediately
preceding and following the MRSA case. A questionnaire was used to
collect information from the medical record of all cases and controls.
Data were collected concerning signalment, medical and surgical history,
infection, and clinical outcome. Outcomes were deﬁned as animals
having an MRSA or MSSA infection. Analyses were performed using
exact logistic regression. Due to the sample size, a multivariable model
could not be constructed due to concerns of model stability and issues
associated with over-ﬁtting the model. Consequently, only univariable
models were constructed.
Results: A total of 46 MRSA cases and 92 MSSA controls were
enrolled consisting of 120 (86.9%) dogs and 18 (13.1%) cats. The largest
proportion of MRSA and MSSA infections were located on the skin
58.7% (27/46) and 64.4% (58/90), respectively. The majority of animals
with MRSA (93.3%, 42/45) and MSSA (91.1%, 81/89) infections were
discharged from the hospital. Antimicrobial administration (OR= 3.55;
95%CI: 1.22–11.94; P = 0.014) and ﬂuoroquinolone administration
(OR= 3.77; 95%CI: 1.03–17.03; P = 0.037) were signiﬁcantly associated
with the development of an MRSA infection.
Conclusion: This study is the ﬁrst to objectively compare MRSA
and MSSA infections in dogs and cats and identify risk factors
for the development of an MRSA infection. The identiﬁcation of
antimicrobials, speciﬁcally ﬂuoroquinolones, as risk factors for MRSA
infection supports the need for prudent use of antimicrobials in pets. The
high survival rate indicates that MRSA is largely a treatable infection,
likely because of the high frequency of non-invasive infections. While
no difference in outcome for MRSA and MSSA infections was observed,
further study of invasive infections is warranted.
P1380 Microbiological characterisation of Staphylococcus
pseudintermedius isolates from dogs
M. Faires, S. Gard, D. Aucoin, J.S. Weese ° (Guelph, CA; Irvine, Santa
Monica, US)
Objectives: In dogs, Staphylococcus intermedius has traditionally been
regarded as the predominant pathogenic Staphylococcus species and
a leading cause of skin and soft tissue infections. However, it has
been recently reported that most isolates identiﬁed conventionally
as S. intermedius are truly the related species S. pseudintermedius.
The objectives of this study were to determine the prevalence of
S. pseudintermedius among isolates from infections from dogs that
have been classiﬁed, phenotypically, as S. intermedius and determine
the prevalence of selected virulence factors and methicillin-resistance of
S. pseudintermedius isolates.
Methods: Isolates from various infections in dogs that were phe-
notypically identiﬁed as S. intermedius were collected. Isolates were
molecularly identiﬁed by sequence analysis of the sodA gene. For all
isolates identiﬁed as S. pseudintermedius, genes for exfoliative toxins A
(ETA) and B (ETB), S. intermedius exfoliative toxin (SIET), toxic
shock syndrome toxin – 1 (TSST-1), Panton-Valentine leukocidin (PVL)
toxin, and methicillin-resistance (mecA) were investigated. Each mecA
positive isolate was evaluated for susceptibility to oxacillin (1 mg) and
cefoxitin (30mg) using the disk diffusion method and the presence of
the penicillin-binding protein 2a (PBP2a) using a latex agglutination
test (LAT).
Results: 102 isolates phenotypically identiﬁed as S. intermedius, were
analyzed. 88/102 (86.3%) were molecularly identiﬁed as S. pseudinter-
medius. None were identiﬁed as S. intermedius. The SIET gene was
detected in 60.2% (53/88) of S. pseudintermedius isolates. Genes for
ETA, ETB, TSST-1, and PVL were not detected. The mecA gene was
identiﬁed in 15.9% (14/88) isolates. 11/14 (78.6%) methicillin-resistant
strains were phenotypically resistant to oxacillin and produced PBP2a.
However, none were identiﬁed as resistant to cefoxitin.
Conclusion: The re-classiﬁcation of a large proportion of S. intermedius
isolates as S. pseudintermedius provides additional support to the
hypothesis that S. pseudintermedius is the predominant pathogenic
Staphylococcus species in dogs. The SIET gene was common and its role
in disease requires further study. The low rate of cefoxitin-resistance but
high rate of oxacillin-resistance in methicillin-resistant strains is opposite
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to that reported for S. aureus and must be considered when developing
testing regimens for methicillin-resistant S. pseudintermedius.
P1381 An investigation of a methicillin-resistant Staphylococcus
aureus outbreak in marine mammals
M. Faires, J.S. Weese ° (Guelph, CA)
Objective: Methicillin-resistant Staphylococcus aureus (MRSA) is
emerging as an important cause of morbidity and mortality in animals
and has been found in an impressive range of species. In 2006, MRSA
was isolated from the blowhole of a captive dolphin suspected of having
pneumonia. To determine the extent of MRSA colonisation among the
marine mammals, an investigation was conducted.
Methods: Nasal swabs were collected from consenting personnel,
blowhole swabs were collected from dolphins and killer whales, and
nasal swabs were collected from walruses and seals. Selective culture
for MRSA was performed and isolates were typed via pulsed ﬁeld gel
electrophoresis (PFGE) and spa typing.
Results: On initial sampling, in January 2007, MRSA was not
isolated from personnel (0/22), killer whales (0/4), or seals (0/16)
but was isolated from dolphins (2/6, 33.3%) and a walrus (1/6,
16.7%). Colonised animals were isolated, contact with colonised animals
was restricted and all personnel were required to wear gloves and
masks when handling colonised animals. Routine hand hygiene was
emphasized. Antimicrobials were not used for decolonisation. Following
these recommendations, follow-up testing for MRSA colonisation was
performed on the dolphins and walruses throughout 2007 and 2008
(Table). Overall, MRSA was isolated on one or more occasions from
5 dolphins and 3 walruses. All isolates were indistinguishable on PFGE
and were consistent with the Canadian epidemic MRSA 2 (USA 100)
strain, spa type t002, clonal complex 5 human epidemic clone.
Date Number of MRSA positive animals/Total number
of animals tested (% MRSA positive animals)
Dolphins Walruses
February 2007 2/6 (33.3%) 2/5 (40%)
April 2007 2/5 (40%) 0/6 (0%)
May 2007 2/3 (66.7%) 0/6 (0%)
October 2007 1/5 (20%) 0/5 (0%)
May 2008 1/5 (20%) –
July 2008 0/5 (0%) –
October 2008 0/5 (0%) –
Conclusion: This is the ﬁrst report of MRSA colonisation in several
marine mammals with apparent transmission between species. A human
origin is suspected because of the clone that was isolated. Colonisation
was eliminated without antimicrobials, as has been reported in many
animal species, however long term (14 months) colonisation was present
in one dolphin. This study shows the impressive ability of MRSA to
infect diverse animal species and provides further evidence suggesting
that interspecies transmission of human epidemic clones can occur
between people and animals.
P1382 Methicillin-resistant Staphylococcus aureus colonisation of
veterinary personnel at a surgical conference
L. Burstiner, M. Faires, J.S. Weese ° (Tampa, US; Guelph, CA)
Objectives: Some studies of veterinary personnel and other individuals
with animal contact have reported high rates of MRSA colonisation, but
further information about colonisation of different groups and evaluation
of factors associated with colonisation is required to better understand
zoonotic MRSA transmission and develop control programs. This study
evaluated the prevalence of and risk factors for MRSA colonisation
among attendees of a veterinary surgeon specialty conference.
Methods: Nasal swabs were collected from volunteers at the 2008
conference of the American College of Veterinary Surgeons in San
Diego, USA. Enrichment culture was performed and isolates were
characterised using standard techniques.
Results: 341 individuals from 12 countries participated. MRSA was
isolated from 59/341 (17.3%, exact 95%CI 13.4–21.7%) individuals;
53/308 (17%) veterinarians and 6/33 (18%) technicians (P = 0.81). In
the multivariable model, contact with small ruminants in the preceding
30 days (OR 2.2, 95%CI 1.1−5.6, P = 0.032), having another person
in their residence diagnosed with MRSA in the preceding year (OR
19.8, 95%CI 1.9–203, P = 0.012) and working in a clinic where there
is a speciﬁc person in charge of the infection control program (OR 1.9,
95%CI 1.1−3.5, P = 0.035) were associated with colonisation. The most
common MRSA strain was spa type t002 or related types, which were
PVL negative and accounted for 32 (54%) isolates. 16 (27%) were spa
type t064 or related and PVL negative. 8 (14%) were t018 or related
and PVL negative. 2 (3.7%) were t379 and PVL negative. 1 (1.9%) was
t008 and contained PVL genes, consistent with the USA300 clone. Most
individuals carrying spa type t002 or related were from small animal
practices, while most people harbouring t064 were from equine practice.
ST398 strains were not isolated.
Discussion: The colonisation rate in this study was striking and provides
further support suggesting MRSA exposure is an occupational risk for
veterinary personnel. Unlike earlier studies, there were no differences
between small animal and large animal personnel. The association of
MRSA and small ruminant contact was unexpected and requires further
investigation. The association with a person in charge of infection control
presumably reﬂects the fact that facilities with infection control personnel
at inherently at higher risk as opposed to a negative impact of infection
control programs.
P1383 Emergence and differentiation of pig-associated methicillin-
resistant Staphylococcus aureus CC398 in Austria
G. Zarfel °, A.J. Grisold, G. Feierl, E. Leitner, L. Masoud,
U. Wagner-Eibel, A. Badura, E. Marth (Graz, AT)
Objectives: For many countries in Europe a new form of CA-MRSA is
reported, associated with animals, particularly pigs. This MRSA forms
the clonal complex (CC) 398. MRSA CC398 consists of 8 MLST types
and a range of closely related protein A (spa) gene types (e.g. t011, t034,
t108, t567, t1451).
In this study we report the ﬁrst occurrence and emergence of MRSA
CC398 in Austria. Because MRSA CC398 is not typeable with PFGE,
determination of genetic relatedness was performed using rep-PCR on
the new DiversiLab system (BioMerieux).
Methods: A total of 585 non-duplicated MRSA strains, isolated from
2002 to 2008 at the Institute of Hygiene, Medical University Graz,
Austria, were investigated. The isolates were characterised by standard
laboratory methods and resistance patterns were determined according
to the CLSI guidelines. MRSA isolates that were deﬁned as CA-MRSA,
following the CDC criteria, subsequently were spa-typed. Determination
of the genetic relatedness of strains belonging to MRSA CC398 spa
types was performed using rep-PCR on the new DiversiLab system.
Results: A total of 13 MRSA CC398 could be detected, with ﬁrst
detection of MRSA CC 398 in 2004. MRSA CC398 was then present in
every following year, with one MRSA CC398 strain in 2004 up to four
MRSA CC398 strains in 2008.
Spa-typing identiﬁed 11 isolates belonging spa-type t011, one to spa-
type t034 and one spa-type t1451.
Resistance patterns of all MRSA CC398 isolates showed, beside the
resistance to all b-lactam antibiotics, resistance to tetracycline only. Only
the spa-type t034 isolate showed additional resistances to clindamycin,
erythromycin and trimethoprim/sulfamethoxazole.
Determination of the genetic relatedness using rep-PCR on the Diversilab
System surprisingly resulted in one single cluster for all MRSA CC398
isolates from 2002–2007.
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All affected patients had had contact to animals, in 12 cases to pigs; one
person had contact to horses only.
Conclusion: In this retrospective analysis MRSA CC398 could for the
ﬁrst time be identiﬁed in patients in Austria and is present in Austrian
patients since 2004. MRSA CC398 could only be detected in patients
with close contact to animals, particularly pigs. Even if there was only
a small number of MRSA CC398 from 2002 to 2007 active surveillance
is once more needed to monitor the spread of this new MRSA subtype.
Using the semi-automated rep-PCR method on the DiversiLab system
may help to determine genetic relatedness of this new subtype of MRSA.
P1384 First methicillin-resistant Staphylococcus aureus of ST398
isolated in Poland from nasal carriers
N. Marszalek, J. Empel °, J. Zmudzki, A. Nowak, Z. Pejsak,
W. Hryniewicz (Warsaw, Pulawy, PL)
Objectives: Pig farming is a risk factor for carriage of S. aureus
sequence type 398 (ST398). This new lineage of S. aureus has
emerged in many countries. The aim of our study was the screening
of veterinarians in Poland for the occurrence of MRSA ST398.
Methods: Nasal swabs were taken from participants at a conference
concerning pig health and farming. All mecA-positive isolates of S. au-
reus were characterised by PFGE using SmaI restriction enzyme, MLST
analysis, spa-typing, agr-typing and SCCmec typing. Additionally, the
detection of genes encoding virulence factors, such as enterotoxins
(sea-see, seg-sei), exfoliative toxins (eta, etb), tsst, lukS-PV/lukF was
performed. Susceptibility testing according to CLSI and CA-FSM
criteria was determined for the following antimicrobials: tetracycline,
daptomycin, fusidic acid, erythromycin and clindamycin.
Results: Among 222 samples, 5 MRSA isolates (2.25%) were detected.
Four of them (1.8%) were PFGE nontypeable, had ST398, spa-type t034
(n = 1) or t108 (n = 3), SCCmec type V, agr-type I and were negative for
any toxins. All of these isolates were fully susceptible to daptomycin and
fusidic acid but resistant to tetracycline, the antibiotic most frequently
used in pig farming. All but one isolate presented the MLSB constitutive
phenotype.
Conclusion: This report ﬁrst described cases of nasal colonisation with
MRSA ST398 of a healthy veterinary staff in Poland. These strains were
genotypically similar to those MRSA ST398 observed in many countries
in Europe, Asia and America. It shows that MRSA ST398 has become
a more common, international problem.
P1385 Antibiotic resistance in the food chain: characterisation of
S. aureus isolated from milk and cheese in Italy
G. La Salandra °, E. Crisetti, C. Pedarra, D. Chiocco, A. Parisi,
G.V. Celano, G.L. Germinario, G. Mula, G. Normanno (Foggia, Bari,
Sassari, IT)
Objectives: Milk and dairy products are the foods most frequently
implicated in staphylococcal food poisoning, since Staphylococcus
aureus could be present in humans and in ruminants. The use of
antibiotics in human medicine and in veterinary practices, could
determine the selection of antibiotic-resistant clones of S. aureus,
including methicillin-resistant S. aureus (MRSA). In this note are
reported the results of the characterisation of 151 S. aureus isolates
from milk and cheeses produced in Italy.
Methods: 151 strains of S. aureus isolates from raw milk (37) and cheese
samples (114) during 2007 were studied. They were characterised in
order to determine the staphylococcal enterotoxin(s) (SEs) production
(SEA to SED) by reverse-passive latex agglutination, the antibiotic-
resistance proﬁle using the disc agar diffusion method on Mueller-
Hinton, and the detection of the mecA gene by PCR. Furthermore, the
ecological origin of the strains were determined by biotyping.
Results: Among the 37 milk isolates, 17 (45.9%) resulted resistant at
least to two antibiotics tested and, among these, 15 (88.2%) resulted
resistant to ampicillin and 7 (41.7%) showed multidrug resistance
proprieties (MDR). The main SEs detected were SEA (56.7%), followed
by SED (21.6%). The most frequent ecovars were the Non Host Speciﬁc
biotype (NHS) (48.6%) followed by the Bovine biotype (5.4%). Among
the 114 cheese isolates, 25 (21.9%) resulted resistant at least two
antibiotics tested and among these, 17 (68%) were resistant to ampicillin;
4 strains (16%) were MDR. The main SEs detected were SEA (17%)
followed by SEC (16.6%) and the most detected ecovars were the NHS
(26.3%) followed by the Ovine (11.4%). No MRSA strains were detected.
Conclusion: The presence of enterotoxigenic strains of S. aureus in milk
and cheeses produced in Italy represent a potential risk for consumers
especially in the absence of strict hygienic and preventive measures to
avoid SEs production in these foods. A remarkable level of resistance to
several antibiotics such as ampicillin, tetracycline and erythromycin was
found in the S. aureus strains analyzed in this survey: this ﬁnding may
constitute an additional risk of foodborne infection hard to be treated.
The ecological origin of the analyzed strains was primary NHS, but most
strains derived from human and animal reservoir. These ﬁndings calls
for improved hygiene in the primary production and handling of milk
and cheeses.
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P1386 Antibiotic susceptibilities of 90 isolates of Yersinia pestis to
14 antimicrobial agents
T. Meka-Mechenko °, L. Nekrassova, G. Temiraliyeva, B. Atshabar,
G. Kovaleva (Almaty, KZ)
Objectives: Ninety isolates of Yersinia pestis isolated in 1998–2008
were evaluated for their susceptibilities to 14 antibiotics by the agar
dilution method. Today, the majority of plague cases are sporadic. The
most Y. pestis are exquisitely susceptible to commonly administered
antimicrobial agents. But in 1995, a multidrug-resistant strain of Y. pestis
was isolated in Madagascar from a 16-year-old boy. Besides, Y. pestis
is one of several agents possibly to be used as biological means in
bioterrorism case. Therefore constant monitoring of sensitivity plague
strains to antibacterial preparations is very important.
Materials and Methods: Ninety strains of Y. pestis were tested in the
present investigation. These strains were isolated over 10-year period in
Republic of Kazakhstan (1998–2008). The sources of strains isolation
were: animal carcasses, humans, ﬂeas. The MICs of 14 antimicrobial
agents for Y. pestis were determined by disk-diffusion methods. The
antimicrobial agents tested included: amoxicillin, imipenem, cefalotin,
cefoxin, aztreonam, oﬂoxacin, peﬂoxacin, ciproﬂoxacin, streptomycin,
gentamicin, amikacin, tobramycin, doxycycline, chloramphenicol.
Results: Investigated strains were conﬁrmed as Y. pestis by standard
criteria and had typical properties. Determination of antibiotic suscepti-
bility is obligatory tests of study plague strains in laboratory practice
in Kazakhstan. All the isolates were susceptible to all investigated
antibiotics. There are no resistant strains. And there was no resistant or
intermediate strain to imipenem. Though in the literature are described
such Y. pestis strains. Y. pestis remains susceptible to most antibiotics
tested with a higher efﬁcacy for ﬂuoroquinolones, cephalosporins and
aminoglycosides. All the strains tested were susceptible to the antibiotics
recommended for post-exposure prophylaxis. However, further in vivo
studies are needed for determining alternative antibiotic treatments
in case of bioterrorist attack with strains resistant to recommended
antibiotics.
Conclusions: All Y. pestis strains were found susceptible to antimicrobial
agents traditionally recommended for the treatment of Y. pestis
infections. All the isolates were susceptible to b-lactam antibiotics
including imipenem, to ﬂuoroquinolones, aminoglycosides and to
doxycycline.
We have no detected resistant Y. pestis strains during 10-year of
investigation.
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P1387 Intraphagocytic activity of ciproﬂoxacine against
intracellular Brucella melitensis
A. Cubero, M.A. Bratos, S. Gonzalez Cabrero, F. Menegotto,
P. Gutie´rrez, A.I. Duen˜as, A. Orduna ° (Valladolid, ES)
Introduction: Brucella is a facultative intracellular pathogenic bacteria
which is able to multiply inside phagocytic cells. Human brucellosis is
characterised by its trend to chronicity and recurrence, even when the
antibiotic treatment was correct. The quinolones usually shown a very
good activity “in vitro” against Brucella and they are able to get a very
high concentration inside the phagocytic cells. However, the treatment
of human brucellosis using ciproﬂoxacin did not reach the expected
results. This study aims to determine the intraphagocytic activity of
ciproﬂoxacine and rifampin against Brucella.
Material and Methods: Polymorphonuclear leukocytes (PML) were
harvested from heparinised human blood by dextran sedimentation and
differential centrifugation on Ficoll-Hypaque gradient. Smooth Brucella
melitensis 16 M were opsonised with speciﬁc human IgG anti-Brucella.
Neutrophils were coincubated with smooth opsonised B. melitensis 16M
for 30 min at 37ºC in a ﬁnal volume of 1ml HBSS plus 10% HNS.
The extracellular bacteria were separated by differential centrifugation
and the rest of extracellular bacteria were killed with streptomycin.
The neutrophils were washed in antibiotic-free HBSS and then they
were suspended in the same media or in HBSS containing various
concentrations of antibiotics. The various systems were incubated for
30 and 60min at 37ºC after which the neutrophils were washed to
remove antimicrobial agents. Intraphagocytic bacteria were released by
the addition of 1ml of distilled water and diluted and 100ml of each
dilution transferred to isosensitest agar plates. The plates were incubated
and the bacterial colonies enumerated. The results of each series (n = 8)
of experiments are presented as the means values of the bactericidal
percent compared with a control without antimicrobial.
Results: Figure 1 shows the percentage of killing of intracellular
phagocytosed Brucella in the presence of various concentrations of
Ciproﬂoxacin. The bactericidal activity of Ciproﬂoxacin is dose-
dependent and the curves are very similar to the Rifampin. There
were not statistical differences between the bactericidal activity against
phagocytosed Brucella at 30 minutes and 60 minutes.
The activity of Rifampin and Ciproﬂoxacin against phagocytosed
Brucella is higher than the activity against the extracellular bacteria.
This suggest that the both antibiotics accumulates in the granulocytes,
increasing their bactericidal activity.
Figure 1. Effect of ciproﬂoxacin in the killing of phagocytosed Brucella.
P1388 In vitro activity of tigecycline, doxycycline, streptomycin,
rifampicin, and ciproﬂoxacin against 70 strains of Brucella
melitensis
F. Kibar, A. Yaman °, E. Zorluer, P. Etiz, B. Kurtaran, A. Candevir
(Adana, TR)
Objectives: Brucellosis is a common worldwide public health problem.
The aim of this study was the investigation of the antibiotic susceptibility
pattern of brucella isolates.
Methods: The susceptibilities of 70 Brucella melitensis isolates obtained
from clinical samples were tested in vitro. MIC values of tigecycline,
doxycycline, streptomycin, rifampicin, and ciproﬂoxacin detected by
E-test method. For antibiotic susceptibility test, Mueller Hilton agar
plates with 5% sheep blood agar, and the E-test strips were used. The
plates were incubated at 37ºC in a 5% CO2 atmosphere for 48 hour.
Results: According to the MIC50 and MIC90, doxycycline was found to
be the most active agent; followed by tigecycline, ciproﬂoxacin, strep-
tomycin, rifampicin. All the isolates were susceptible to doxycycline,
streptomycin and ciproﬂoxacin (except one strain). Rifampicin had the
highest MIC50 and MIC90 values. For rifampicin, 33 (%47) of brucella
strains had higher MICs than 1mg/I.
Conclusion: Brucella isolates remain susceptible in vitro to most antibi-
otics (doxycycline, streptomycin and ciproﬂoxacin, except rifampicin)
used for treatment of brucellosis. In vitro activity of a new antimicrobial
agent, tigecycline was slightly lower than doxycycline.
Table. In vitro susceptibilities of Brucella melitensis isolates to ﬁve
antibiotics
Antibiotic Range (mg/l) MIC50 (mg/l) MIC90 (mg/l)
Tigecycline 0.064–1 0.38 0.5
Doxycycline 0.047–1.5 0.19 0.25
Streptomycin 0.25–1 0.5 1
Rifampicin 0.5–32 1 2
Ciproﬂoxacin 0.125–32 0.38 0.5
P1389 Anti-Helicobacter pylori and anti-internalisation activities
of Thai folk remedies used to treat gastric ailments
N. Chaichanawongsaroj °, R. Vilaichone, S. Amornyingjarean,
Y. Poovorawan (Bangkok, TH)
Helicobacter pylori, an aetiological agent of active chronic gastritis and
peptic ulcer disease, is now considered to be as invasive enteropathogen.
Invasion of gastric epithelium cells contribute to persistence infection
and eradication failure due to the bacteria could escape from antibiotic
treatment and immune defence mechanism. The aims of this study
were to investigate the anti-Helicobacter pylori and anti-internalisation
activities of nine Thai plant extracts used for gastric ailments in
traditional medicine including Kaempferia parviﬂora, Allium sativum,
Musa sapientum, Curcuma longa, Cymbopogon citratus, Centella
asiatica, Andrographis paniculata, Aloe vera and Ocimum basilicum.
The minimum inhibitory concentrations against 11 clinical isolates
and 2 reference strains of H. pylori were examined using an agar
dilution method. The level of internalisation against HEp-2 cells
was determined by a conventional gentamicin internalisation assay.
Only the methanolic extracts of Curcuma longa and Kaempferia
parviﬂora exhibited signiﬁcant antibacterial activities at MIC of 32 ug/ml
and 64 ug/ml, respectively. Four common medicinal plants including
Curcuma longa, Kaempferia parviﬂora, Allium sativum and Musa
sapientum were further tested for their anti-internalisation activities
against H. pylori ATCC 43504 at 3, 6 and 12 h of incubation using
the concentration equal to their MIC. All four plant extracts showed
inhibitory effects on the invasion of H. pylori to HEp-2 cells except
Curcuma longa enhanced the invasion at 6 and 12 h. Although, Allium
sativum and Musa sapientum demonstrated marked anti-internalisation
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activities, the high concentrations of the extracts may have cytotoxic
effects. However, the use of medicinal plants still have potential beneﬁt in
H. pylori eradication and could be a useful choice to avoid the antibiotic
resistance. Moreover, the anti-internalisation activities may be a new
strategy to prevent H. pylori infection and improve the therapy.
P1390 In vitro activities of 22 antimicrobial agents against
macrolide-resistant Campylobacter jejuni and Campylobacter
coli isolates
M. Lehtopolku, U.M. Nakari, P. Kotilainen, U. Kaasalainen,
M. Haanpera¨, J. Jalava, P. Huovinen, A. Siitonen, A. Hakanen ° (Turku,
Helsinki, FI)
Objectives: The increasing emergence of macrolide resistance among
Campylobacter jejuni and Campylobacter coli will complicate the
treatment of bacterial gastroenteritis. The aim of this study was to
compare the activities of various ﬂuoroquinolones, macrolides and
additional antimicrobial agents towards C. jejuni and C. coli, focusing
special attention on macrolide-resistant strains. In addition, disk diffusion
method was compared to agar dilution method in susceptibility testing.
Methods: We analyzed the in vitro activities of 21 anti-microbial agents
by the standard agar plate dilution method against 232 C. jejuni and
C. coli strains collected from Finnish patients between the years 2002
and 2005. Tigecycline susceptibilities were determined by the E-test
method. Mutations causing macrolide resistance at Escherichia coli
equivalent bases 2058 and 2059 of the 23S rRNA gene were analyzed
from 19 erythromycin-resistant and 25 erythromycin-susceptible strains
by pyrosequencing.
Results: Of all 232 Campylobacter isolates, 19 were resistant
to erythromycin (MIC  16mg/L). Of the erythromycin-resistant
Campylobacter strains, 18 (95%) were also ciproﬂoxacin-resistant. None
of the resistant strains were resistant to imipenem or tigecyclin. Disk
diffusion results were not always in line with the MIC results. 17
of the 19 erythromycin-resistant Campylobacter strains had a point
mutation at the E. coli equivalent base 2059 of the rRNA gene. None
of the erythromycin-susceptible strains had point mutation at the E. coli
equivalent bases 2058 and 2059 of the 23S rRNA gene.
Conclusions:
1. Of the antimicrobials studied tigecycline and sitaﬂoxacin were in vitro
most effective towards C. jejuni and C. coli, with low MIC values
also for the macrolide-resistant strains. They might be good candidate
for clinical trials on campylobacteriosis.
2. Of the 19 erythromycin-resistant C. jejuni strains, 18 (95%) were
also ciproﬂoxacin-resistant and 15 (79%) had high MIC values for
telithromycin (MIC> 32mg/L). None of these strains were resistant
to imipenem or tigecyclin.
P1391 Antimicrobial susceptibility of genital Mycoplasma hominis
and Ureaplasma urealyticum
H. Turan °, E. Ozcimen, H. Arslan (Konya, Ankara, TR)
Objectives: Ureaplasma urealyticum and Mycoplasma hominis are
causally linked to urethritis, prostatitis, epididymitis, urethral syndrome,
cervicitis and urolithiasis. Susceptibility testing of U. urealyticum and
M. hominis is necessary, because it allows adequate antimicrobial
treatment. The aim of this study was to determine the susceptibility of
U. urealyticum and M. hominis to doxycycline, erythromycin, josamycin,
oﬂoxacin, tetracycline, ciproﬂoxacin, azithromycin, clarythromycin, and
pristinamycin.
Methods: This study included U. urealyticum and M. hominis strains
with 10,000 colony-forming units detected in female and male patients.
Clinical specimens examined were urethral and endocervical swabs.
Detection, quantiﬁcation and antimicrobial susceptibility testing of
U. urealyticum and M. hominis in clinical specimens were performed by
MYCOPLASMA IST 2 test (BioMerieux SA). In study period between
April 2008 and December 2008, susceptibility testing was performed in
80 U. urealyticum and 5 M. hominis strains.
Results: Antimicrobial susceptibility testing results of U. urealyticum
and M. hominis were shown on the Table 1 and Table 2. Both
U. urealyticum (100%) and M. hominis (100%) were the most sensitive
to josamycin, and the most resistant to ciproﬂoxacin (U. urealyticum
56.2%) and erythromycin, clarythromycin (M. hominis 80%).
Conclusion: Both U. urealyticum and M. hominis indicated high rates of
susceptibility to doxycycline (99% and 100% respectively). We conclude
that doxycycline may be used in empirical treatment of U. urealyticum
and M. hominis genital infections.
Table 1: Antimicrobial susceptibility testing of U. urealyticum (n: 80)
Antimicrobial agent S, n (%) I, n (%) R, n (%)
Doxycycline 79 (98.8) 0 1 (1.2)
Erythromycin 68 (85) 6 (7.5) 6 (7.5)
Josamycin 80 (100) 0 0
Oﬂoxacin 34 (42.5) 28 (35) 18 (22.5)
Tetracycline 77 (96.3) 0 3 (3.7)
Ciproﬂoxacin 19 (23.8) 16 (20) 45 (56.2)
Azithromycin 68 (85) 6 (7.5) 6 (7.5)
Clarithromycin 70 (87.5) 3(3.8) 7 (8.7)
Pristinamycin 79 (98.8) 1 (1.2) 0
S: susceptible, I: intermediate, R: resisant.
Table 2: Antimicrobial susceptibility testing of M. hominis (n: 5)
Antimicrobial agent S, n (%) I, n (%) R, n (%)
Doxycycline 5 (100) 0 0
Erythromycin 1 (20) 0 4 (80)
Josamycin 5 (100) 0 0
Oﬂoxacin 4 (80) 0 1 (20)
Tetracycline 4 (80) 0 1 (20)
Ciproﬂoxacin 3 (60) 1 (20) 1 (20)
Azithromycin 1 (20) 1 (20) 3 (60)
Clarithromycin 1 (20) 0 4 (80)
Pristinamycin 5 (100) 0 0
S: susceptible, l: intermediate, R: resistant.
P1392 Antibiotic susceptibilities of genital mycoplasmas in male
patients with urethritis
M. Hui °, N.M. Luk, W.H. Lam, M. Eastel, C. Fu, C.Y. Chan, K.K. Lo
(Shatin, Hong Kong, HK)
Objectives: To determine the antibiotic susceptibility proﬁle of
Mycoplasma hominis and Ureaplasma urealyticum in male patients with
urethritis.
Methods: During a nine-month period, male patients presented with
urethritis were recruited. First-void urine specimens were collected.
Microbial growth and susceptibilities results were determined by the
use of Mycoplasma IST2 kit.
Results: A total of 523 patients were recruited. Ureaplasma urealyticum
was isolated in 69 (13.2%) patients, Mycoplasma hominis was found
in 15 (2.9%) of them. No patient exhibited co-existence of these
two bacteria. For Ureaplasma urealyticum isolates, 62 (89.9%) and
42 (60.9%) of them were resistant to ciproﬂoxacin and oﬂoxacin
respectively. Resistance against azithromycin, clarithromycin, ery-
thromycin, josamycin and pristinamycin were 5.8%, 2.9%, 5.8%,
2.9% and 2.9% respectively. Resistance against doxycycline was
5.8%. For Mycoplasma hominis, 11 (73.3%) and 7 (46.7%) isolates
were resistant to ciproﬂoxacin and oﬂoxacin respectively. Resistance
against azithromycin, clarithromycin, erythromycin, josamycin and
pristinamycin were 66.7%, 100%, 100%, 0% and 0% respectively. No
resistance was observed against doxycycline.
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Conclusion: Fluoroquinolones resistance was very high among My-
coplasma hominis and Ureaplasma ureayticum isolates. Macrolides
resistance was low in Ureaplasma urealyticum. ForMycoplasma hominis,
which are intrinsically resistant to many macrolides, only josamycin and
the streptogramin pristinamycin were active. Doxycycline was active
against both organisms. These results highlighted the emergence of
antibiotic resistance in genital mycoplasmas. Thus, the treatment of
which should be guided by antibiotic susceptibility testing and local
antibiotic resistance pattern.
P1393 Activity of linopristin/ﬂopristin (NXL 103) against
Streptococcus pneumoniae, Haemophilus inﬂuenzae, and
Staphylococcus aureus
P. McGhee, G. Lin, G. Pankuch, A. Bryskier, P.C. Appelbaum °
(Hershey, US; Romainville, FR)
Background: Lower respiratory tract infections apart from being caused
principally by Streptococcus pneumoniae and Haemophilus inﬂuenzae,
are increasingly being caused by methicillin-resistant Staphylococcus
aureus (MRSA), and future empiric therapy for this infection must take
all resistance phenotypes of all 3 bacterial species into consideration.
Linopristin/ﬂopristin (NXL 103) is an experimental oral streptogramin,
being in a ratio of a 30:70 combination of linopristin and ﬂopristin. This
study examined the in vitro activity of linopristin/ﬂopristin compared to
a spectrum of other agents against 261 S. pneumoniae, 150 H. inﬂuenzae,
and 200 MRSA strains. The pneumococci comprised 86 penicillin
susceptible, 81 penicillin intermediate, and 94 penicillin resistant strains:
120 were erythromycin resistant (MICs >1mg/L)[(65 erm(B), 32
mef(A), 1 erm(B) and mef(A), 19 L4 and 3 23S rRNA)]. The 150
H. inﬂuenzae (146 untypeable, 4 serotype b), included 50 b-lactamase
negative, 79 b-lactamase positive, and 21 BLNAR organisms. Two
hundred MRSA included 128 community-acquired and isolated from
sites throughout the US, and 40 were hospital-acquired; strains also
comprised 2 hetero-vancomycin intermediate (hVISA), 25 VISA and
5 vancomycin-resistant (VRSA).
Methods: For pneumococci and MRSA, agar dilution using Mueller-
Hinton + 5% added sheep blood for pneumococci was used, and
microdilution using commercially prepared trays contaning freshly
prepared Haemophilus Test Medium was used for H. inﬂuenzae.
Results: Against pneumococci, both components of linopristin/ﬂopristin
were inactive, but synergy was observed when both components were
combined, with MIC50 and MIC90 values of 0.12–0.5mg/L and 0.25–
0.5mg/L in the various b-lactam and macrolide resistance phenotypic
groups. By contrast, against H. inﬂuenzae linopristin was inactive and
all activity resided in ﬂopristin, whose MICs were the same as those seen
with the combination: an MIC50 of 0.25mg/L and MIC90 s 0.5−1mg/L
for all resistance phenotypes. Against MRSA strains linopristin/ﬂopristin
yielded MICs of 0.125–0.5mg/L (MIC50 and MIC90 values both
0.25mg/L) amongst vancomycin susceptible strains and 0.06–2mg/L
(MIC50 0.5mg/L, MIC90 1mg/L) amongst vancomycin non-susceptible
strains.
Conclusion: Linopristin-ﬂopristin (NXL103) was very potent against all
strains of S. pneumoniae, H. inﬂuenzae, and MRSA tested, irrespective
of resistance phenotype.
P1394 A study on bacteria isolated from intra-abdominal
infections in Japan and their antimicrobial susceptibility
K. Tanaka °, H. Mikamo, T. Ichiishi, Y. Takesue, T. Yokoyama,
N. Shinagawa, K. Watanabe (Gifu, Aichi, Nishinomiya, Hiroshima,
Nagoya, JP)
Objectives: To obtain information for empiric therapy, deﬁne bacteria,
especially obligate bacteria isolated from relatively recent cases of intra-
abdominal infections in Japan and susceptibility patterns of those isolates
Methods: Seventy-eight specimens were collected into anaerobic
transporter during operation and subjected to bacterial culture within
24−48 hrs. Specimens were plated onto several aerobic and anaerobic
media (selective and non-selective) in an anaerobic chamber. Anaerobic
culture continued for 1 week. Identiﬁcation of isolates was done
principally using biochemical method. Molecular-biological method was
also used in some cases. The minimum inhibitory concentrations were
determined by agar dilution method according to the CLSI guideline.
Results: A total of 208 anaerobes and 138 aerobes were isolated
from 68 culture-positive specimens. Major anaerobes were Bacteroides
fragilis group, Gram-positive cocci, Fusobacterium spp., and spore (−)
Gram-positive rods. Dialister invisus, Desulfovibrio spp, Synergistes spp.
were included in minor Gram-negative anaerobes. Major aerobes were
Enterobacteriaceae, Enterococcus spp. and Staphylococcus spp.. Staphy-
lococcus spp. was signiﬁcant in post-operative infection. Carbapenems
and b-lactamase inhibitor (BLI)/b-lactam (BL) kept potent activity to
most of the isolated bacteria except for aerobic Gram-positive cocci.
Susceptibility (%) to clindamycin based on CLSI breakpoint were 67%
in B. fragilis, 25% in other species of B. fragilis group, and 78 to 100%
in other Gram-negative and spore (−) Gram-positive anaerobes.
Conclusion: Carbapenems and BLI/BL keep potent activity to most of
isolates from intra-abdominal infection. Decrease of susceptibility rate
in B. fragilis group species except B. fragilis is signiﬁcant.
P1395 Prevalence of quinolone susceptible Pseudomonas
aeruginosa and Staphylococcus aureus in delayed-healing
diabetic foot ulcers in Ekpoma, Nigeria
E. Agwu °, J. Ihongbe, N. Inyang (Ishaka, UG; Ekpoma, NG)
Aim: To investigate the prevalence and antibiogram of Pseudomonas
aeruginosa and Staphylococcus aureus from delayed-healing foot ulcers
of diabetic patients in Ekpoma.
Methods: Using standard aseptic microbiological methods, 220 delayed-
healing diabetic-foot ulcer samples were analyzed for bacteria isolation,
identiﬁcation and susceptibility test. Chi-square (a´=0.01) was used to
test the statistical signiﬁcance of data obtained.
Results: Out of 220 samples analyzed, 82.3% were infected (41.8%
P. aeruginosa, 30.0% S. aureus and 10.5% co-infection of P. aeruginosa
and S. aureus). There was statistically signiﬁcant (p< 0.01) association
between P. aeruginosa and S. aureus in the population studied. Among
the quinolones tested, S. aureus and P. aeruginosa showed the highest
(74.2% and 71.3%) and lowest (38.2% and 34.8%) susceptibilities to
Levoﬂoxacin and Sparﬂoxacin respectively. P. aeruginosa was also:
68.7% susceptible to rifampicin; 53.0% to erythromycin, 52.2% to
vancomycin; 38.3% to ceftriazone; 36.5% to cefuroxin; and 32.2% to
oxacillin. S. aureus was: 51.7% susceptible to rifampicin, 37.1% to
cefuroxin; 33.7% to ceftriazone; 28.1% to vancomycin and 25.8% to
oxacillin.
Conclusion: Delayed-healing diabetic foot ulcers in Ekpoma are
colonised by levoﬂoxacin and sparﬂoxacin susceptible Pseudomonas
aeruginosa and Staphylococcus aureus. Surveillance with improved
diagnostic facilities, surgical and biosurgical debridement of nonviable
tissue, to halt progression of infection is recommended.
P1396 Whether tablets for mouth disinfection possess antibacterial
activity required by European Standard EN 1040:2006
S. Tyski °, E. Mikiciuk, E. Bocian (Warsaw, PL)
Objectives: Several medicinal or cosmetic products present on the
market in Poland as well as in other countries, should act as oral
antiseptics. It is claimed, that these drugs or cosmetics in tablets
form possess antibacterial and sometimes anti-inﬂammatory activity.
Recently, several European Standards have been created by European
Standardisation Committee for establishing, whether an antiseptic or
disinfectant has or does not have an antimicrobial activity under the
laboratory conditions.
The aim of the study was to analyze bactericidal activity of selected
compressed lozenge (chewable tablets) or oral tablets for mouth
disinfection and eradication of oral infections
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Methods: Several products from market have been investigated:
Chlorchinaldin, Cholinex, Cholisept, Halset, Menthosept, Neo-angin,
Orofar, Propolki, Sebidin, Sebidim Plus, Septolete D, Septolete Plus,
Strepsils, Strepsils Intensive, and Tantum Verde.
Basic bactericidal activity of preparations was analyzed according
to European Standard EN 1040:2006, with additional test organisms
recommended by prEN 13727. Appropriate standard strains of S. aureus
ATCC 6538, E. hirae ATCC 1541, E. coli NCTC 10538 and
P. aeruginosa ATCC 15442 were used. Two contact times (15 min
and 1 h) and bacterial suspensions density of 1.5−5×108 cfu/ml, were
applied. Investigated tablets were suspended in water (1 tablet/5ml).
This method was validated and the suitability of neutraliser in the assay
was evaluated.
Results: Only 3 preparations: Neo-angin, Orofar and Strepsils fully
comply with EN 1040 criteria for antiseptics. Required reduction (5-
log) of cells count of four tested bacterial strains was achieved, not only
after 1 h but even after 15min of contact time. In case of Cholinex,
Cholisept, Propolki, Sebidin, Septolete D, Septolete Plus and Tantum
Verde, required reduction of cells count (1 to 3 strains) was achieved
but after 1 h contact. It was estimated that other investigated preparations
completely do not comply with EN 1040:2006.
Conclusion: The products for oral antiseptics should be evaluated
according to normalised criteria, e.g. EN and these recommendations
should ensure effective bacterial infection treatment. Preparations
without required antibacterial – antiseptic activity should be excluded
from the market.
P1397 Corynebacterium macginleyi: susceptibility to 7 usual
ophthalmic antibiotics
A´. Somodevilla °, D. Domingo, M.C. Martinez, T. Alarco´n,
M. Lope´z-Brea (Madrid, ES)
Objectives: Clinical importance of Corynebacterium macginleyi isolated
from conjunctival infections has been recently recognized.
The aim of this study was to evaluate the susceptibility of 23 Corynebac-
terium macginleyi isolates obtained from conjunctival samples (Novem-
ber 2006 to June 2008) to 7 usual ophthalmic antibiotics: penicillin,
gentamicin, ciproﬂoxacin, tetracycline, vancomicin, rifampicin and
linezolid.
Methods: Conjunctival swabs obtained from symptomatic patients were
cultured onto blood and chocolate agar and incubated in aerobic and
microaerophilic environment, respectively. Plates were incubated for two
days.
Identiﬁcation was performed using the API Coryne system (bioMe´rieux).
Susceptibility was determined by microdilution broth method according
to CLSI breakpoints and using its recomendations as well: Cation-
adjusted Mueller-Hinton broth with lysed horse blood (2.5 to 5% v/v),
35ºC, aerobic atmosphere and 24 to 48 hours of incubation.
Results: After 48 hours of incubation all the strains were susceptible
to penicillin (1mg/l), gentamicin (4mg/l), vancomicin (4mg/l),
rifampicin (1mg/l) and linezolid (2mg/l). Only one strain was
resistant to ciproﬂoxacin (16mg/l  4mg/l) and another to tetracycline
(64mg/l  16mg/l).
MIC50 and MIC90 obtained were as follows: 0.06mg/l and
0.06mg/l,  0.06mg/l and 0.25mg/l,  0.06mg/l and 0.25mg/l,
0.5mg/l and 1mg/l, 0.5mg/l and 1mg/l, 0.06mg/l and 0.06mg/l,
0.25mg/l and 1mg/l to penicillin, gentamicin, ciproﬂoxacin, tetracycline,
vancomicin, rifampicin and linezolid, respectively.
Conclusions: Corynebacterium macginleyi showed high susceptibility
to all the ophthalmic antibiotics tested.
Only two strains were found to be resistant to one of them: ciproﬂoxacin
or tetracyclin.
From these data we conclude that antimicrobial treatment of C. macgin-
leyi obtained from ophthalmic samples is not an important problem, at
least for the time being.
P1398 In vitro activity of co-trimoxazole and comparators against
Gram-positive and negative blood stream pathogens
K. Bowker °, A. Noel, S. Tomaselli, A.P. MacGowan (Bristol, UK)
Objectives: Co-trimoxazole (Co-t) has been reported to have a low risk
of Clostridium difﬁcile associated diarrhoea (CDAD). It is therefore of
potential value as a prophylactic and therapeutic agent as part of an
infection control strategy to reduce the incidence of CDAD. However,
there is little recent data on its in vitro activity against key bacterial
pathogens. In this study, we compared the in vitro activity of Co-t to
comparators against Gram negative and positive blood stream infection
(BSI) pathogens isolated in our hospital in 2006–07.
Methods: MICs were performed using CLSI methods against 725
BSI pathogens. Susceptibility was determined using EUCAST clinical
breakpoints. For Gram negatives, the comparators were ampicillin
(AMP), co-amoxiclav (CoA), cefuroxime (CXM), ceftriaxone (CTRI),
ciproﬂoxaxin (CIP), gentamicin (GEN) and ertapenem (ERT). For
Gram positives, the comparators were erythromycin (ERY), vancomycin
(VAN), ciproﬂoxacin (CIP), fusidic acid (FUS), penicillin (P), dapto-
mycin (DAP), linezolid (LIN).
Results: The number of strains tested and percent susceptible for Gram
negatives and Gram positives are shown (Table). The proportion of
Enterobacteriacae susceptible to Co-t is similar to CoA and CXM but
inferior to CRTI, GEN and ERT. Co-t is active against most Gram
positive pathogens excepting Enterococci.
Conclusion: Co-t demonstrated broad spectrum activity against Gram
negative and Gram positive pathogens, including MRSA. Co-t may rep-
resent a useful formulary alternative to ﬂuoroquinolones, cephalosporins
and CoA in hospitals with high rates of CDAD.
Species n % Susceptible
C
o-
t
A
M
P
C
oA
C
X
M
C
T
R
I
C
IP
G
E
N
E
R
T
E. coli 191 60 35 64 79 88 73 80 99
Ent. cloacae 30 83 0 0 53 50 83 90 90
K. pneumoniae 47 60 0 45 53 62 55 81 98
S. marcescens 16 75 0 6 6 50 69 100 94
Proteus 28 71 82 79 100 100 100 100 100
Other Enterobacteriaceae 23 87 0 48 65 83 78 91 96
All 335 66 27 56 69 80 74 84 98
Species n % Susceptible
C
o-
t
A
M
P
/P
V
A
N
D
A
P
L
IN
C
IP
F
U
S
E
RY
MRSA 98 95 − 100 100 100 9 89 31
MSSA 68 98 − 100 100 100 24 92 90
CNS 24 71 − 100 100 100 58 58 50
E. faecalis 52 7 81 98 100 100 − − −
E. faecium 28 4 10 85 100 100 − − −
BHS (ABCG) 32 100 100 − − − − − −
P1399 In vitro susceptibilities of Mycobacterium marinum isolates
in Taiwan
T.S. Wu °, P.C. Chiang, T.L. Wu, H.C. Lai (Taoyuan Hsien, TW)
Objectives: Mycobacterium marinum belongs to Runyon class I
mycobacterium. It causes soft tissue infection, bone and joints infections,
and even disseminated infection. We encountered a few of failed cases.
Susceptibility testing is important for the management of patients with
tuberculosis and those with disease caused by certain nontuberculous
mycobacteria. In this study, the minimal inhibitory concentrations of
these isolated strains will be analysed by microdilution method.
Methods: Bacterial strains: Twenty ﬁve consecutive isolates were
obtained from the Division of Bacteriology, Department of Clinical
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Pathology Laboratory, Chang Gung Memorial Hospital, Lin-Kuo
Medical Center from Oct 1, 1999 to Mar 31, 2008.
Susceptibility tests: We use 96 wells plates for microdilution methods
of susceptibility tests described by Wallace et al. We made bacterial
7H9 broth equal to 0.5 McFarland turbidity, then diluted to 1:1000,
and delivered 0.01ml into each well containing 0.1ml broth. Each
antimicrobial agent was added by twofold dilution by sequence.
Breakpoints: RIF  1mg per L; EMB  5mg per L; CLR  16mg per
L; DOX  4mg per L; SMX  32mg per L; AMK  32mg per L;
LZD  8mg per L
Results: Among 25 isolates, they are all susceptible to EMB, CLR,
AMK, and LZD. Most of them are susceptible to RIF, and SMX. The
least active agent is DOX.
Table. In vitro susceptibilities of 25 Mycobacterium marinum isolates.
Antibiotic MIC (mg/L) % Susceptible
50% 90% Range
RIF 1 4 0.5–4 84%
EMB 0.5 4 0.25–4 100%
CLR 4 8 2–8 100%
DOX 16 32 8–32 0%
SMX 4 64 0.5–64 92%
AMK 4 16 1–16 100%
LZD 2 4 0.5–4 100%
Conclusion: M. marinum is an important microorganism causing
aquatic animals-related infections in Taiwan. Doxycycline is not a
good antimicrobial agent for treating such infections. Both rifampin
and ethambutol remain the mainstay of regimens against M. marinum
infection. Clarithromycin, linezolid, and amikacin are the alternative
agents for treating M. marinum infections. For sulfamethoxazole,
although high susceptible percentage was observed, as high as 20%
(5/25) isolates (not shown in the table) are borderline susceptible
(MIC= 16mg/L); it may be not a good alternative agent for treating
such infections.
P1400 Comparative in vitro activities of moxiﬂoxacin and 6 other
antimicrobial agents against aerobic bacterial isolates
causing intraabdominal infection: results from the PRISMA
study
H. Seifert ° (Cologne, DE)
Objectives: Moxiﬂoxacin is a fourth generation ﬂuoroquinolone with
bactericidal activity against both Gram-positive and Gram-negative aer-
obic and anaerobic bacteria, including those involved in intraabdominal
infections (IAI). The Prospective In Vitro Study to Determine the
Activity of Moxiﬂoxacin against Isolates from Patients with Abdominal
Infection (PRISMA) compares the susceptibilities of common pathogens
causing serious IAI in hospitalised patients.
Methods: 3,240 aerobic bacterial isolates (including Citrobacter spp.,
n = 186; Enterobacter spp., 298; Enterococcus faecalis, 385; E. faecium,
291; E. coli, 731; Klebsiella spp., 400;Morganella morganii, 97; Proteus
mirabilis, 200; P. vulgaris, 96; Pseudomonas aeruginosa, 264; Serratia
spp., 57; and Staphylococcus aureus, 235) were collected from 32 centres
(including 24 university hospitals) in Germany in 2007. MICs were
determined at each centre using microbroth dilution for the following an-
timicrobials: ampicillin/sulbactam (AMP/SUL); piperacillin/tazobactam
(PIP/TAZ); ceftriaxone (CTX); ertapenem (ERT); meropenem (MER);
levoﬂoxacin (LEV); and moxiﬂoxacin (MOX). EUCAST guidelines were
used for interpretation.
Results expressed as MIC50 s and MIC90 s (mg/L) are listed in the Table.
Conclusions: Moxiﬂoxacin showed good activity against common
aerobic bacterial isolates causing serious IAI. Compared to levoﬂoxacin,
MICs for moxiﬂoxacin were one dilution higher/lower for Gram-negative
and Gram-positive isolates, respectively. Compared to AMP/SUL,
PIP/TAZ and CTX, the antimicrobial activity of the two ﬂuoroquinolones
was higher against all Gram-negative species with the exception of
E. coli. Ertapenem and meropenem showed the highest in vitro activity
against most bacterial species obtained from IAI.
MIC50/90
AMP/SUL PIP/TAZ CTX ERT MER LEV MOX
Citrobacter spp. 4/256 2/64 0.25/64 0.03/0.12 0.03/0.12 0.06/1 0.12/2
Enterobacter spp. 128/256 4/128 1/128 0.06/0.5 0.06/0.5 0.06/1 0.12/2
E. faecalis 1/2 2/8 128/128 4/8 4/16 1/32 0.5/16
E. faecium 128/256 256/256 128/128 128/128 128/128 64/64 16/64
Escherichia coli 4/256 1/16 0.06/2 0.03/0.03 0.03/0.06 0.06/16 0.12/16
Klebsiella spp. 4/256 2/64 0.06/16 0.03/0.06 0.03/0.06 0.06/1 0.12/2
M. morganii 32/128 0.25/16 0.25/16 0.03/0.06 0.12/0.5 0.06/1 0.25/4
Proteus mirabilis 1/8 1/8 0.03/0.5 0.03/0.12 0.06/0.25 0.06/1 0.25/2
Proteus vulgaris 4/64 4/64 0.5/16 0.03/0.25 0.12/0.25 0.06/0.25 0.25/2
P. aeruginosa 256/256 256/256 32/128 4/32 1/16 0.5/16 2/16
Serratia spp. 64/256 64/256 0.25/32 0.03/0.25 0.06/0.12 0.25/2 0.5/4
S. aureus 0.25/16 0.25/16 4/128 0.06/8 0.12/16 0.25/16 0.06/4
P1401 Antibacterial effects of marboﬂoxacin on bacteria isolated
from mastitis in cattle
R. Firouzi °, H. Rajaian, I. Mansourian Tabaee, A. Saeedzadeh (Shiraz,
IR)
Mastitis is the inﬂammation of mammary glands and various microor-
ganisms are known to cause the disease. Many antimicrobial agents
have been evaluated to combat the causative agents in order to cure
mastitis. As the rate of developing resistance in pathogens may be high
against conventional antibiotics, so the efﬁcacy of a new ﬂuoroquinolone
antibiotic against pathogens, isolated from clinical mastitis in Shiraz area,
was examined in this research.
Milk samples (73) were taken from 28 dairy farms around Shiraz,
Iran. Antibiotic sensitivity test (Kirby-Bauer method) was carried out
for marboﬂoxacin, enroﬂoxacin, gentamicin, penicillin and tetracycline.
Minimum inhibitory concentration (MIC) and minimum bactericidal
concentration (MBC) of marboﬂoxacin against the sensitive bacteria was
also determined.
Staphylococcus aureus (24.1%), Escherichia coli (18.1%), Streptococcus
dysgalactiae (9.3%), Corynebacterium bovis (9.3%), Staphylococcus
epidermidis (3.7%), and Pseudomonas aeruginosa (3.7%), were iden-
tiﬁed among 54 bacterial isolates. All of the isolated bacteria were
sensitive to marboﬂoxacin, whereas sensitivities against other antibiotics
varied from zero to 94.1%. The values obtained as MIC and MBC of
marboﬂoxacin against three bacterial isolates (Staphylococcus aureus,
Streptococcus agalactiae, and Staphylococcus epidermidis) were in the
range of 0.2 to 1.56 microgram/ml and 0.8 to 6.25 microgram/ml,
respectively.
Since the isolated bacteria have shown adequate sensitivities to
ﬂuroquinolones, especially marboﬂoxacin, it is concluded that its usage
could be beneﬁcial in the treatment of cows with clinical mastitis.
P1402 In vitro susceptibilities of toxigenic clostridium difﬁcile
strains to 10 antimicrobial agents
D. Velissari, M. Martsoukou, N. Skarmoutsou, V. Liapis, C. Sarkatzidi,
E. Papafrangas, M. Kanellopoulou ° (Athens, GR)
Objectives: Clostridium difﬁcile (CD) was identiﬁed as the major
cause of nosocomial diarrhoea and pseudomembranous colitis. Recently
an increased number of CD community associated diarrhoea have
been reported. The aim of this study was to determine the in vitro
susceptibilities of 10 antimicrobial agents against toxigenic C. difﬁcile
strains isolated from adult inpatients attending a tertiary hospital during
2007–2008.
Material-Methods: A total number of 52 clinical strains isolated
on Cycloserine Cefoxitin Fructose Agar, CCFA (Oxoid, Hampshire,
England) were tested. The detection of C. difﬁcile toxins was performed
by the Rapid Enzyme Immunoassay for Toxins A+B (Immunocard,
Meridian Bioscience Inc. Cincinatti Ohio). The susceptibilities to the
antimicrobial agents were investigated by E-test (AB Biodisk Solna,
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Sweden) according to the manufacturer’s recommendations. B. fragilis
ATCC 25285 was used as quality control strain.
Results: The MICs 50/MICs 90 as well the MIC range (mg/l) were as
follows: vancomycin 1/1.5 (0.5–3), metronidazole 0.125/0.25 (0.023–
0.5), imipenem >32/>32, meropenem1/8 (0.125−>32), levoﬂoxacin
>32/>32, moxiﬂoxacin 1/>32 (0.75–>32), oﬂoxacin >32/>32, rifampin
0.002/<0.002 (0.002–>32), tigecycline 0.064/0.25 (0.023–0.38),
daptomycin 0.25/0.75 (0.038−6).
Conclusions: Our C. difﬁcile strains were sensitive to vancomycin and
metronidazole which constitute the ﬁrst choice of treatment for the
CD associated disease (CDAD). High resistance rates to the quinolones
levoﬂoxacin and oﬂoxacin were observed. Imipenem was inactive against
the examined strains. Rifampin, daptomycin and tigecycline which
showed an excellent in vitro activity, will probably offer an alternative
therapeutic option for CDAD.
P1403 Comparative in vitro activities of moxiﬂoxacin and 6 other
antimicrobial agents against anaerobic bacterial isolates
causing intraabdominal infection: results from the PRISMA
study
H. Seifert ° (Cologne, DE)
Objectives: Moxiﬂoxacin is a fourth generation ﬂuoroquinolone with
bactericidal activity against both Gram-positive and Gram-negative aer-
obic and anaerobic bacteria, including those involved in intraabdominal
infections (IAI). The Prospective In Vitro Study to Determine the
Activity of Moxiﬂoxacin against Isolates from Patients with Abdominal
Infection (PRISMA) compares the susceptibilities of common pathogens
causing serious IAI in hospitalised patients.
Methods: 430 Gram-negative anaerobic bacterial isolates (including
Bacteroides distasonis, n = 16; B. fragilis, 238; B. ovatus, 10; B. thetaio-
taomicron, 79; B. uniformis, 33; B. vulgatus, 22; and Prevotella
spp., 21) were collected from 32 centres (including 24 university
hospitals) in Germany in 2007. MICs were determined centrally using
microbroth dilution for the following antimicrobials commonly used for
antianaerobic coverage: ampicillin/sulbactam (AMP/SUL); ertapenem
(ERT); meropenem (MER); levoﬂoxacin (LEV); moxiﬂoxacin (MOX);
clindamycin (CLI); and metronidazole (MET). EUCAST guidelines were
used for interpretation.
Results expressed as MIC50 s and MIC90 s (mg/L) are listed in the Table.
MIC50/90
AMP/SUL ERT MER LEV MOX CLI MET
B. distasonis 4/64 0.12/1 0.25/2 1/32 0.5/16 8/64 2/2
B. fragilis 0.5/4 0.06/1 0.125/2 2/32 0.5/8 1/64 2/4
B. ovatus 0.25/0.5 0.25/0.25 0.25/0.25 8/16 2/4 4/32 2/2
B. thetaiotaomicron 0.25/1 0.25/0.5 0.25/0.5 8/64 2/16 4/64 2/4
B. uniformis 0.25/0.5 0.25/0.25 0.25/0.25 8/32 2/8 4/64 2/4
B. vulgatus 0.25/1 0.06/0.5 0.25/0.25 32/64 16/32 0.12/2 2/2
Prevotella spp. 0.12/0.5 0.06/0.25 0.12/0.25 2/2 0.5/2 0.03/1 1/2
Conclusion: Moxiﬂoxacin showed good activity against most Bac-
teroides and Prevotella species involved in serious IAI. Resistance rates
ranged between 10 and 20% (with the exception of B. vulgatus with 59%
of isolates being resistant). Clindamycin had only poor activity with
20−50% of Bacteroides isolates being resistant. Ampicillin/sulbactam
and metronidazole were active against most isolates. Ertapenem and
meropenem showed the highest in vitro activity against Bacteroides
species obtained from IAI, however, 8% of B. fragilis isolates were
resistant to the carbapenems.
Tuberculosis diagnosis
P1404 Accuracy of QuantiFERON-TB Gold test versus Tuberculin
Skin test to detect latent tuberculosis infection in
HIV-positive individuals in Iran
M. Mardani °, P. Tabarsi, F. Hadavand, Z. Mohamadtaheri, E. Chitsaz,
B. Farokhzad, L. Gachkar, M.R. Masjedi (Tehran, IR)
Background: Despite it is widely used for Latent Tuberculosis Infection
(LTBI) detection and other TB clinical conditions, Tuberculin Skin Test
(TST) bears several limitations. Because of considerable rates of false
positive and false negative results obtained by TST, several methods have
been introduced to be used interchangeably for detecting LTBI instead of
TST. QuantiFERON-TB Gold Test (QFT) is a laboratory method which
has recently attracted much attention and is said to be more speciﬁc than
TST to identify LTBI. In this study we have attempted to identify QFT
accuracy in detecting LTBI in HIV infected patients.
Methods: This cross-sectional study is conducted in a HIV clinic in
Tehran in 2007. Totally, 50 HIV positive patients were recruited for
the study. All patients had neither history of previous tuberculosis nor
were currently affected by active TB. All cases had the history of BCG
vaccination. Positive PPD was deﬁned as indurations larger than 5mm. A
whole blood gamma interferon release assay to early secreted antigenic
target 6 (ESAT-6) and culture ﬁltrate protein 10 (CFP-10) antigens were
performed and g-IFN were measured via ELISA.
Results: Of total 50 HIV positive patients, 43 (86%) were males. Mean
age of the cases was 38.4±7.2 (range=21–53). 36 (72%) had negative
PPD test while 14 revealed positive PPDs. Of the positive PPD group,
12 had concomitant positive QFT, just one case was PPD positive but
QFT negative, and QFT was indeterminate in one PPD positive case.
Of 36 negative PPD tests 18 (50%) had negative QFTs, 8 (22%) had
positive tests and 10 (28%) yielded Indeterminate results.
Agreement between PPD and QFT was 76.9% (ú = 0.54, 95%CI =
38.4–69.6, P value <0.001). However, there was no association between
PPD results and CD4 counts.
Conclusion: Our study denotes that QuantiFERON-TB Gold Test
renders more accurate results for LTBI detection in HIV infected patients
compared to TST.
P1405 Comparison of an interferon-gamma release assay with
tuberculin skin test for the diagnosis of tuberculosis
infection in a contact investigation
E. Perez-Escolano °, J. Gutierrez, E. Menor, J.C. Alados Arboledas,
M.I. Lo´pez, S. de Tena, M.D. Lo´pez-Prieto (Jerez de la Frontera, ES)
Objectives: To evaluate the agreement of the QuantiFERON® TB Gold
In Tube test (QFT) and the tuberculin skin test (TST) for the diagnosis
of the tuberculosis infection (TBI) in a contact investigation (CI), and to
establish the utility of QFT as a tool for the indication of the treatment
of TBI.
Methods:We studied 337 immunocompetent persons with recent history
of contact with tuberculosis patients and a different degree of exposition
to the index case; average age was 39 years (SD: 18.6), 56.3% were
women and 46% were vaccinated with BCG. All were screened with
chest X-ray, TST, QFT (Cellestis, Australia) and risk factors were
registered in a questionnaire. TST was performed by Mantoux method
and a positive test was deﬁned as an induration 5mm. QTF was
made according to the manufacturer speciﬁcations. We considered
as vaccinated persons those presenting with a suggestive scar. CDC
recommendations were followed for the interpretation of the QFT and
the treatment of the TBI in contacts. Agreement between TST and QFT
was assessed by the Cohen kappa coefﬁcient.
Results: Agreement between the TST and the QFT was moderate among
non-vaccinated population (74%, ú0.48, CI (0.36–0.61)) and poor among
the vaccinated group (40%, ú0.09, CI (0.03–0.15)). Agreement was high
for people with greater degree of exposure to index case, mainly in
non-vaccinated group. TST(+)/QFT(−) was the most frequently detected
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discordant result, for vaccinated and non-vaccinated groups. A hundred
eight non-vaccinated persons showed TST (+), from these 38 were
negative for QTF. In the vaccinated group 132 showed TST (+), from
these 92 were negative for QFT. The indication of TBI treatment made
by TST and risk situation was modiﬁed in 52% of cases according to
QFT test. We prescribed treatment of TBI by QFT in 8% of the contacts
that did not have indication according to the TST.
Conclusions: Agreement between TST and QFT was moderate in non-
vaccinated people and was improved in the subgroup with more than
six hours/day of exposure to index case. Whereas, in vaccinated people
the agreement was poor. The use of QFT allows to a better selection of
infected individuals and to reduce the number of unnecessary treatments
of the TBI, particularly in vaccinated population.
P1406 Predictive value of puriﬁed protein derivative in pulmonary
tuberculosis in a high BCG-vaccinated population
M. Soﬁan, A. Ramezani °, M. Mohraz, H. Khalili, S. Farahani, L. Moeini,
A. Aghakhani, B. Eshrati, A. Eslamifar, M. Banifazl (Arak, Tehran, IR)
Objectives: Tuberculin skin testing (TST) is used for the identiﬁcation
of individuals with infection by Mycobacterium tuberculosis and other
non-tuberculous mycobacteria. However, its value for the evaluation of
household contacts and suspected cases of tuberculosis in populations
with high BCG vaccination coverage is controversial. We aimed to
determine the prevalence of tuberculosis infection and the predictive
value of TST in suspicious subjects to pulmonary tuberculosis in central
province of Iran.
Methods: A total of 344 suspicious subjects to tuberculosis infection
(>3 weeks productive cough or a chest-x-ray suggestive for tuberculosis)
with or without contact with TB cases enrolled in this study. Gold
standard for tuberculosis diagnosis was smear and culture. All subjects
were tested using 5 tuberculin units of puriﬁed protein derivative (PPD).
The predictive value of induration was examined 48−72 hours after PPD
administration.
Results: The prevalence of pulmonary tuberculosis was 20.05% in our
cohort of study. Indurations of PPD  5mm had a positive predictive
value (PPV) 33% and negative predictive value (NPV) 91%, indurations
10mm had 34% PPV and 85% NPV and indurations 15mm had
40% PPV and 83% NPV.
Conclusion: TST does not consider being a valuable tool for the
evaluation of household contacts and suspected cases of tuberculosis
in populations with high BCG vaccination coverage. The traditional
induration 10mm does not seem to be the best discriminating value
between TST reactions due to infection and those due to vaccination.
The frequencies of TST cut-off diameters will be calculated and
presented in the congress.
P1407 QuantiFERON-TB gold cut-off values signiﬁcance in the
diagnosis of active pulmonary M. tuberculosis infection
S. Karabela °, D. Papaventsis, S. Nikolaou, A. Sainti, E. Konstantinidou,
P. Ioannidis, S. Kanavaki (Athens, GR)
Objective: Quantiferon-TB Gold (QFT) In-Tube (Cellestis, Australia) is
an in vitro diagnostic assay of Interferon-gamma (IFN-g) detection for
the diagnosis of M. tuberculosis infection. The purpose of this study was
to evaluate QFT diagnostic accuracy by using different cut-off values.
Methods: A cross-sectional study involving 54 patients with culture-
conﬁrmed pulmonary tuberculosis and 175 healthy individuals was
carried out. The QFT assay was performed in blood samples according
to the manufacturer’s recommendations. The optimal cut-off level was
recalculated from Receiver Operator Characteristic (ROC) analysis.
Sensitivities and speciﬁcities of the QFT assay were calculated by using
cut-off values of IFN-g above 0.10, 0.20, 0.30, 0.35, 0.40, 0.50, 0.60 and
0.70 IU/ml.
Results: When the proposed by the manufacturer cut-off value of
>0.35 IU/ml was used, sensitivity, speciﬁcity, positive and negative
predictive value of the QFT assay was 83%, 67%, 44% and 93%,
respectively. By using lower cut-off values (>0.10–0.30 IU/ml) a slight
increase in sensitivity (2−8%) was associated with an even greater
decrease in speciﬁcity (4−10%). On the contrary, ROC analysis indicated
that by using higher cut-off values (>0.40–0.80 IU/ml), QFT speciﬁcity
slightly improved (1−5%), but important loss of assay sensitivity was
recorded (2−14%).
Conclusion: We evaluated the diagnostic accuracy of QFT assay with
different cut-off values for the diagnosis of active pulmonary tubeculosis.
The manufacturer’s recommended QFT cut-off value of 0.35 IU/ml
of IFN-g was found appropriate for the diagnosis of M. tuberculosis
infection. The determination of new cut-off values for interferon-gamma
(IFN-g) detection as proposed by previous studies, might improve the
assay’s sensitivity and speciﬁcity, but should be performed with caution
in different populations.
P1408 QuantiFERON TB Gold in tube assay for TB diagnosis:
a two-year experience
S. Karabela °, S. Nikolaou, A. Sainti, E. Konstantinidou, D. Papaventsis,
P. Ioannidis, K. Konstantinou, S. Kanavaki (Athens, GR)
Objective: To retrospectively evaluate Quantiferon TB Gold in Tube
(QFT) test for TB diagnosis in respect to: concordance with TST, as
well as, in relation to previous BCG vaccination, to immunnological
status, to TB exposure and to active TB.
Materials and Methods: Quantiferon TB Gold in Tube (Cellestis,
Australia) was performed according to manufacturers’ instructions, in
2000 whole blood samples from an equal number of patients.
Results: In total, QFT(+) results were 627 (31.4%), QFT(−)
1302 (65.1%) and indeterminated 71 (3.5%)
– TST data was available in 1715 cases: in 1087 (63.4%) TST(+),
QFT(+) were 461 (42.4%), QFT(−) 611 (56.2%) and indeterminated
15 (1.4%). However, in 628 (36.6%) TST(−), QFT(+) were
100 (15.9%) QFT(−) 487 (77.5%) and indeterminated 41 (6.6%).
– BCG vaccination-TST data was available in 763 cases: 436 (57.1%)
were TST(+) QFT(−), 167 (21.9%) were TST(+) QFT(+), 142 (18.6%)
TST(−) QFT(−) and 18 (2.4%) TST(−) QFT(+).
– Immunology status data was available in 1554 cases: 243 immuno-
suppressed and 1311 immunocompetent. Among the ﬁrst, TST(+)
were 70 (28.8%), QFT(+) 59 (24.3%) TST(−) 173 (71.2%) and
QFT(−) 156 (64.2%). In immunosuppressed, indeteminated results
were 28 (11.5%) in contrast to 27 (2.0%) in immunocompetent.
– M. tuberculosis (MTB) exposure-BCG vaccination-TST data was
available in 365 cases: in 234 BCG vaccinated, MTB exposed
individuals, QFT(+) were 44 (18.8%) while TST(+) 182 (77.8%)
– Data for sputum culture-QFT test was available in 280 cases:
in 74 positively cultured patients, 69 MTB and 5 NTM were
isolated. 63 (91.3%) MTB(+) cases were QFT(+) and 1 (20%) NTM
(M. malmoensae, but with an old MTB history) was QFT (+).
Conclusion: QFT is a very useful method in TB diagnosis because in
contrast to TST, it reduces over diagnosis of latent TB, distinguishing
truly TB affected among BCG vaccinated, being also, highly correlated
to active TB.
P1409 QuantiFERON-TB Gold assay for diagnosis of active
tuberculosis
S. Karabela °, D. Papaventsis, S. Nikolaou, E. Konstantinidou,
A. Sainti, P. Ioannidis, S. Kanavaki (Athens, GR)
Objective: The purpose of this study was to evaluate and compare
Quantiferon-TB Gold In-Tube (QFT, Cellestis, Australia) and the
tuberculine skin test (TST) in patients with active TB, with and without
previous BCG vaccination.
Methods: Patients with symptoms compatible with active TB were
included. The TST was performed according to the Mantoux method
and the QFT assay according to the manufacturer’s instructions. The
cut-off value for a positive result was 0.35 IU/ml interferon-gamma
(IFN-g). Sensitivity, speciﬁcity, positive and negative predictive values
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were calculated and compared for QFT and TST tests. Agreement
between QFT and TST was assessed by the kappa (ú) coefﬁcient.
Results: A total of 229 patients were enrolled in the study. One hundred
ﬁfty-eight had a record regarding BCG vaccination. Forty-one (26%)
of the 158 patients had been vaccinated. In total, the sensitivity and
speciﬁcity of QFT, excluding those with indeterminate results, was
83% (45/54; 95%CI: 70−92%) and 67% (117/175; 95%CI: 59−74%),
respectively. The sensitivity and speciﬁcity of TST was 74% (40/54;
95%CI: 60−85%) and 64% (112/175; 95%CI: 56−71%), respectively.
The overall concordance between the QFT and TST tests was 72.1%,
with a ú value of 0.435 (95%CI: 0.318–0.553). In the BCG-vaccinated
subgroup, agreement between the two assays was 66%, with a ú value
of 0.352 (95%CI: 0.105–0.599). The difference with the non-vaccinated
subgroup (ú=0.452; 95%CI: 0.292–0.612) was considered to be not
quite statistically signiﬁcant (p = 0.0576). Initial TST positive screening
followed by a QFT positive result was found to have greater sensitivity
and speciﬁcity in the non-vaccinated [sensitivity=22/28; 79% (95%CI:
59−92%); speciﬁcity=72/89; 81% (95%CI: 71−88%)] compared to the
BCC-vaccinated subgroup [sensitivity=6/9; 67% (95%CI: 30−92%);
speciﬁcity=24/32; 75% (95%CI: 57−89%)].
Conclusion: This study conﬁrmed previous reports that QFT assay has
higher sensitivity for detecting active TB compared to TST. An overall
moderate agreement between TST and QFT was found. The difference
in agreement between non-vaccinated and BCG-vaccinated subgroups
could be attributed to TST inﬂuence by vaccination. In patients with
active TB and no BCG-vaccination history, TST screening followed by
subsequent QFT testing proved to present the highest sensitivity and
speciﬁcity for TB diagnosis. Larger prospective studies are needed to
conﬁrm our results.
P1410 Evaluation of peripheral blood mycobacterium tuberculosis
PCR in tuberculosis patients
A.R. Davoodi °, M. Haji Abdolbaghi, M. Rasooli Nejad, A. Tayyebi
(Bandar Abbas, Tehran, IR)
Background: Tuberculosis is still one of the most important cause of
mortality and morbidity in many countries and is second only to human
Immunodeﬁciency virus as a cause of death worldwide resulting from
a single infectious agent, and in 1993 the World Health Organization
declared tuberculosis a global public health emergency. Conventional
methods for the diagnosis of Mycobacterium tuberculosis infections are
time consuming, for example culture needs 3−8 weeks to grow and
there is a need for new methods for accurate and rapid diagnosis of
tuberculosis. To determine the sensitivity of polymerase chain reaction
(PCR) in peripheral blood mononuclear cells (PBMC), we have evaluated
Mycobacterium tuberculosis DNA in peripheral blood samples with PCR
technique in adult patients with new cases of pulmonary and extra-
pulmonary tuberculosis.
Material and Methods: In a cross sectional study lasting 3 years (2004–
2007), 3cc Citrated Blood samples were obtained from 190 patients
with pulmonary and extra – pulmonary tuberculosis. DNA extraction by
QIAGEN (commercial kit) and PCR with IS1081 Primer was performed.
for prevention of cross contamination and reduction of false positive, all
steps were performed under laminar hood.
Findings: 134 cases of pulmonary and 56 with extra-pulmonary
tuberculosis were enrolled in this study. PCR was positive in 78 of 190
(41%) patients and negative in 112 of 190 (59%). The overall sensitivity
and accuracy of the PCR assay was 50% for pulmonary and 25% for
extra-pulmonary and 28.5% for disseminated tuberculosis.
Conclusion: The use of IS1081 primer MTB-PCR assay on PBMC may
pose problems for the rapid diagnosis of tuberculosis with regard to low
sensitivity. However, further studies are needed to conﬁrm this technique
as an alternative test for the diagnosis of tuberculosis.
P1411 Evaluation of an oligochromatographic test for identiﬁcation
of mycobacteria most frequently isolated in human from
liquid and solid culture media
M.J. Martı´nez-Lirola °, N. Montiel Quezel-Guerraz, M. Marı´n Arriaza,
J.A. Carrillo on behalf of the Indal TB Group
Objectives: To evaluate a novel assay (SpeedOligo mycobacteria®,
Vircell) for the identiﬁcation of cultured mycobacteria at the species
level.
Methods: A convenience sample of 182 positive cultures for my-
cobacteria from 121 patients: 22 MGIT® (Becton-Dickinson), 72
Bact/ALERT-MP® (BioMerieux), and 88 LJ. Mycobacteria identiﬁcation
was performed applying Genotype® Mycobacterium CM/AS (Hain) and
corresponded to 61 M. tuberculosis complex, 114 MOTT group-specie
identiﬁed, 7 Mycobacterium sp. identiﬁed only to the genus level. Nine
mycobacteria-related organisms: 3 Streptomyces spp., 4 Nocardia spp.,
1 R. equi, 1 P. acnes were included to test the speciﬁcity of the assay.
The sample was blindly assayed by the oligochromatographic test.
DNA was extracted by heating and centrifugation without requiring
a puriﬁcation step. The 16S rRNA and 16S-23S rRNA gene spacer
regions were used as targets for ampliﬁcation. The ampliﬁcation
products were hybridised on a dipstick using speciﬁc probes bound
to colloidal gold and to the membrane. The whole procedure took
120 minutes. The results were interpreted by identiﬁcation of 7 bands
speciﬁc for each of the following categories: (1) Mycobacterium sp.
(2) M. fortuitum, (3) M. avium–M. intracellulare, (4) M. tuberculosis
complex, (5) M. kansasii, (6) M. gordonae, (7) M. abscessus–
M. chelonae.
Results: All 182 positive cultures and 9 mycobacteria-related or-
ganisms were tested. No cross reactivity was observed with any
mycobacteria-related organisms. The agreement between both tests
was 94.5%. SpeedOligo mycobacteria® and reference method iden-
tiﬁed 61/61 (100%) C.M. tuberculosis and 111/121 (91.7%) MOTT:
39 M. avium, 15 M. intracellulare, 14 M. gordonae, 9 M. abscessus,
11 M. chelonae, 7 M. fortuitum, 6 M. kansasii, 2 M. avium +
M. gordonae, 1 M. chelonae + M. gordonae, 7 Mycobacterium sp. The
discrepancies were distributed in (i) minor: some MOTTs not included in
the test that were identiﬁed as Mycobacterium sp: 1 M. heckeshornense,
1 M. lentiﬂavum, 1 M. scrofulaceum, 3 M. simiae. And (ii) major:
2 M. marinum misidentiﬁed as M. kansasii and 1 M. scrofulaceum as
M. avium–M. intracellulare.
Conclusion: SpeedOligo Mycobacteria® is a fast and sensitive assay for
mycobacteria identiﬁcation. It showed high correlation when results were
compared with the standard method. The few discrepancies observed will
be resolved by sequenciation and PRA methods.
P1412 TB testing using T-SPOT.TB after overnight sample storage
I. Durrant °, J. Radcliffe, T. Day (Abingdon, UK)
Objectives: T-SPOT®.TB is a regulatory approved interferon gamma
release assay for the diagnosis of TB infection. The assay procedure
currently requires blood samples to be collected and processed within
eight hours. However, in some clinical settings it would be advantageous
to be able to process samples on the day following blood collection in
order to allow overnight shipment of blood samples, for example to
central testing laboratories. This study investigated a potential addition
to the sample preparation process of the assay that was proposed to allow
blood samples to be stored and processed greater than sixteen hours after
collection without affecting the clinical result of the T-SPOT.TB assay.
Methods: Blood samples were collected in duplicate from consenting
donors at three separate clinical sites; two in South Africa, one in the UK.
Anonymised samples were tested with the T-SPOT.TB assay according
to the manufacturer’s instructions both on the day of blood collection and
following overnight storage of the sample at room temperature using the
investigational procedure. The assay results were interpreted according
to the manufacturer’s guidelines and compared between the two assay
time points.
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Results: A total of 352 samples were processed successfully on both
days such that the T-SPOT.TB assay results could be compared between
fresh blood samples processed within 8 hours of collection and stored
blood samples processed between 16 and 32 hours after collection. The
overall agreement was 342/352 (97.2%; 95%CI = 95.1–98.7%) with a
kappa value of 0.94. In samples that were taken from culture conﬁrmed
TB cases 42/43 (97.7%) were T-SPOT.TB +ve for both the fresh and
the stored blood samples.
>16 hr +ve >16 hr −ve Total
<8 hr +ve 144 5 149
<8 hr −ve 5 198 203
Total 149 203 352
Conclusion: The study demonstrates that processing of blood samples,
with only a minor addition to the overall assay procedure, the day
following collection is practicable and yields substantially equivalent
performance in the T-SPOT.TB assay.
P1413 Test performance of the ampliﬁed Mycobacterium
tuberculosis Direct Test in early diagnosis of Chinese
pulmonary tuberculosis
J.S. Lin °, Y.Y. Yu, C.Y. Lin, C.H. Lin, L.F. Shih, M.S. Hseih, R.H. Hsiao
(Changhua, TW)
Objective: Mycobacterial culture of sputum (MCS) is time-consuming
but remains a gold standard for laboratory diagnosis of pulmonary
tuberculosis (PT). The use of the Ampliﬁed Mycobacterium tuberculosis
Direct Test (MTD, Gen-Probe; San Diego, CA) for direct identiﬁcation
of mycobacterium tuberculosis complex (MTBC) in sputa may aid to
early diagnosis of PT. The MTD in diagnosis of PT is less well studied
in Chinese.
Methods: An observational study was conducted to evaluate the test
performance of MTD in diagnosis of Chinese PT. All respiratory samples
submitted to MTD were tested together with acid-fast (AF) stain of sputa
and MCS. The sediment of each specimen was prepared after digestion,
decontamination and concentration by the NALC-NAOH method. The
sediment was tested by MTD according to the manufacturer’s protocol.
Smears of the sediments were stained by Truant ﬂuorochrom staining
method. MCS was done by inoculating sediments into Lowenstein
Jensen (LJ) slant and liquid culture medium (Bactec MGIT 960; Becton,
Dickinson and Company, Franklin Lakes, NJ). Positive growths of liquid
media were sub-cultured into LJ slants. Growth of mycobacteria on
LJ slants were subject to molecular detection of speciﬁc gene loci
(16S rRNA, IS6110, Rv0577) using a polymerase chain reaction-based
method to differentiate MTBC from other mycobacteria. The ﬁnal
diagnosis of PT was regarded as a gold standard. Area under Receiver
Operator Characteristic (ROC) curves of MTD and MCS were compared
for diagnostic accuracy of PT.
Results: A total of 218 respiratory specimens obtained from 208 Chinese
patients were analyzed. The ﬁnal diagnosis of PT was made in 118
(56.7%) patients. AF bacilli were found in 177 (81.2%) specimens.
MTBC-positive rates of specimens were 109 (50%) and 91 (41.7%)
detected by MTD and MCS, respectively. The sensitivity, speciﬁcity,
positive predictive value (PPV) and negative predictive value (NPV) of
MTD in diagnosis of PT were 83.1%, 93.6%, 94.5% and 80.7%, whereas
they were 65.3%, 100%, 100% and 68.6% for MCS. The area under ROC
curve (95% conﬁdence interval) was 0.88 (0.84–0.93) and 0.87 (0.82–
0.92) for MTD and MCS, respectively. Positive and negative likelihood
ratios of MTD were 13.0 and 0.18, respectively.
Conclusion: The MTD was demonstrated to have a comparable
diagnostic accuracy of PT as MCS, implicating its clinical usefulness
in direct detection of MTBC in respiratory samples and improvement of
early diagnosis of PT.
P1414 Laboratory diagnosis of Mycobacterium xenopi and its
clinical relevance
S. Davidson, A. Abed Yassin, M. Gruper, E. Braun, H. Sprecher °
(Haifa, IL)
Background: Accurate laboratory detection of mycobacterial infection
is of utmost importance. Unfortunately, very little is currently known
about the performance of automated systems widely used in clinical
laboratories.
Methods: Over a period of 3 years (2006–2008), 37 MGIT tubes
were scored as negative by the BACTEC™ MGIT 960™ system
(Becton-Dickinson). At the end of 6 weeks of incubation they were
visually inspected, as recommended by the manufacturer. If positive,
an acid-fast stain was performed. Acid fast isolates were then speciﬁed
using an Hsp65-based PCR assay. 35 of these isolates were identiﬁed
as Mycobacterium Xenopi. These isolates were assessed using Pulse
ﬁeld Gel Electrophoresis (PFGE) and the epidemiological and clinical
characteristics of patients with M. Xenopi positive cultures were
retrospectively analyzed.
Results: The yearly false-negative detection rate of the automated system
studied was 1% as opposed to the <0.5% false negative detection rate
mentioned by the manufacturer. During the study period, 35 samples
were erroneously diagnosed as negative by the automated system and
were ﬁnally identiﬁed as M. Xenopi positive cultures. Eight cultures out
of 17, 7 out 13 and 0 out 10 were isolated from patients hospitalised
in one internal medicine department during 2006, 2007 and 2008
respectively. During 2006−7, this department was temporarily re-located
due to local refurbishment work, and transferred back to its permanent
location in 2008, suggesting that M. Xenopi isolation in this department
was dependent upon collection site location. M. Xenopi-positive cultures
were mostly of respiratory origin (86%). Patient disease course and
clinical features were not consistent with atypical mycobacterial infection
in most of the cases.
Conclusions: The false-negative detection rate of the BACTEC MGIT
960 system is higher than previously reported and is mainly accounted
for by M. Xenopi cases. The pathogenic relevance of M. Xenopi isolation
is questionable.
P1415 Clarithromycin and amikacin versus clarithromycin
and moxiﬂoxacin as the treatment for post-acupuncture
cutaneous infection due to Mycobacterium abscessus:
prospective observation study
D.W. Park °, M.J. Kim, W.S. Choi, Y.S. Heo, S.W. Son, Y.K. Yoon,
J.Y. Kim, Y.S. Park, C.S. Lim, T. Song, S.M. Bae, J.W. Sohn,
H.J. Cheong, M.J. Kim (Ansan, Seoul, KR)
Objectives: Mycobacterium abscessus (M. abscessus) has been a well-
documented cause of cutaneous infections following inoculation, minor
trauma and surgery. The aim of this study is to compare clarithromycin
(CLR) and amikacin (AMK) with clarithromycin and moxiﬂoxacin
(MXF) as the treatment for cutaneous infection due to M. abscessus.
Methods: An outbreak of postacupuncture cutaneous infection occurred
in Ansan, Korea. From Dec 2007 to Mar 2008, about 100 patients
developed localised cutaneous infection. M. abscessus infection was
diagnosed microbiologically or epidemiologically. Patients were treated
by combination of CLR (500mg/day, oral) and AMK (250mg q
3 times/week, IM) (group I) or CLR and MXF (400mg/day, oral)
(group II). The clinical response of respective treatment groups were
evaluated at 8−12 weeks after treatment, completion of treatment,
and 2 months after completion of treatment. Treatment success was
deﬁned as the absence of symptoms and decrease of more than 50% in
subcutaneous nodules or full recovery of skin 2 months after completion
of treatment. The efﬁcacy of each treatment groups was assessed by
mean duration of medical treatment.
Results: Fifty-two patients were enrolled in this study. Of these, 16
(30.8%) were diagnosed microbiologically. In group I and II, 26 and
16 patients were enrolled, respectively. Other patients were treated
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with CLR (n = 7) or MXF (n = 3) alone. There were no signiﬁcant
differences in age (50.5±11.5 vs 51.9±14.7), sex (female) (n = 22 vs
13), co-morbidity, number of nodule (n = 1.9±1.4 vs 2.0±1.6), and pus
discharge from wound (n = 8 vs 3) except for initial surgical excision
(n = 23 vs 4, p< 0.001). In each groups, 21 (76.9%) and 13 (81.3%)
patients completed treatment. 5 (19.2%) and 6 (37.5%) patients required
subsequent surgical resection during medical treatment in each groups
(p = 0.281). The mean duration (weeks) of medical treatment in group I
was signiﬁcantly longer than that of group II (20.2±3.9 vs 16.4±4.6,
p = 0.013). The frequency of drug related adverse events between two
groups was not signiﬁcantly different (n = 14 vs 11, p = 0.518). The most
common adverse event was grastrointestinal discomfort.
Conclusion: Combination therapy with CLR and MXF was signiﬁcantly
short in duration of treatment. Our study suggests that combination
therapy with CLR and MXF is efﬁcacious for treating M. abscessus
cutaneous infection.
P1416 Experience with tigecycline in infections due to Mycobac-
terium abscessus complex and Mycobacterium chelonae
R.J. Wallace, G. Dukart °, B.A. Brown-Elliott, D.E. Grifﬁth, B. Marshall
(Tyler, Collegeville, US)
Objectives: Treatment of infection with rapidly growing mycobacteria
(RGM) including Mycobacterium abscessus complex (M. abscessus,
M. massiliense, M. bolletii) and M. chelonae is difﬁcult, particularly
among patients (pts) with M. abscessus complex lung disease, as RGM
are resistant to most antibiotics. Tigecycline, a ﬁrst-in-class expanded
broad-spectrum glycylcycline antibiotic, was examined for efﬁcacy in
the treatment of RGM infections in a combined analysis of data obtained
from three settings.
Methods: Clinical efﬁcacy and safety data from pts with RGM infection
were pooled and assessed from: (1) an open-label clinical trial of pts
with RGM infection with resistant isolates (7 pts); (2) a multicentre,
open-label trial of pts with multiple drug-resistant pathogens resistant
to standard therapies (7 pts); (3) a single-patient, compassionate-use
program for pts who had failed or were intolerant of other therapies
(38 pts). Target tigecycline dosage was 50 to 100mg daily, in single
or twice-daily doses, with treatment duration as clinically appropriate.
Other antibiotics could be administered concomitantly.
Results: Among the 52 pts, the median (range) age was 32 (12−81)
years. The lung was the site of infection in 36 (69.2%) pts; 38 (73.1%)
had M. abscessus complex infection, 9 (17.3%) had M. chelonae
infection, and 5 (9.6%) were infected with both organisms. Treatment
discontinuation occurred in 29 (55.8%) pts, 16 (30.8%) of these due to
adverse events (AEs), primarily vomiting and/or nausea (9/16). A total
of 25 pts (48.1%) were considered clinically improved, 16 (30.8%) were
considered clinical failures, and 11 (21.2%) were indeterminate. The
most common AEs were nausea in 33 (63.5%), vomiting in 18 (34.6%),
fever in 13 (25.0%), diarrhoea in 12 (23.1%), and asthenia and anorexia
in 11 pts each (21.2%).
Conclusions: Clinical experience in 52 pts with RGM infection treated
with tigecycline in combination with other antibiotics demonstrated
clinical improvement in nearly 50% of pts and an acceptable safety
proﬁle in pts treated for up to 3 years.
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P1417 Serologic response to inﬂuenza vaccine in coronary artery
disease patients: FLUVAC study
Maryam Keshtkar-Jahromi °, H. Vakili, S.M. Razavi, S. Gholamin,
A. Eskandari, M. Rahnavardi, Mitra Keshtkar-Jahromi, B. Haghighat,
L. Gachkar, S. Rahmati Roodsari, Marzieh Keshtkar-Jahromi,
T. Mokhtari-Azad (Tehran, IR)
Background: Recent studies suggested inﬂuenza vaccine may reduce
the risk of ischaemic events in coronary artery disease (CAD) patients
but no data was available on serologic response in this group. We
conducted a clinical trial to investigate the efﬁcacy of 2007−08
inﬂuenza vaccine (FluVacc) in inducing serologic response in CAD
patients (ClinicalTrials.gov #NCT00607217). We are now presenting the
serologic response to the FluVacc antigens.
Methods: A trial was conducted from January to August 2007
and enrolled 204 study subjects (137 CAD and 67 healthy controls
[HC]). Each enrolled participant received 0.5 cc intramuscular dose
of trivalent anti-inﬂuenza vaccine. The 2007–2008 inﬂuenza vaccine
consisted of three strains, nominated as Solmon Island/3/2006[H1N1],
Wisconsin/67/2005[H3N2], and Malaysia/2506/2004[B]. Antibody (Ab)
titers (haemagglutination inhibition) were measured just before and
1 month after vaccination. The proportion of protective Ab titers (i.e.
>1/40), the serological response (i.e. >4-fold rise in titers) rates, and the
magnitudes of change in titers were the main outcome measures. Angina
severity (Seattle angina questionnaire – SAQ), coronary artery stenosis
(modiﬁed Gensini), and cardiac ejection fraction (EF) were measured.
Results: Serologic response against H1N1 antigen was observed in 90
(65.7%) CAD patients and 39 (58.5%) HCs. CAD and HC groups were
similar in all outcome measures for all antigens (Figure). SAQ, Gensini
and EF score were not signiﬁcantly correlated with the magnitude
of change in any of the Ab titers in CAD patients. Valvular heart
disease and lower baseline titers were independently associated with
less magnitude of antibody titer increment against H1N1 antigen in
CAD group. Multivitamin supplement was independently associated with
better antibody response against H3N2 antigen. Multivariate analysis
failed to recognize any independent factor associated with the magnitude
of titer change against B antigen.
Conclusions: CAD and HC groups were not signiﬁcantly different in
serologic response and magnitude of change in antibody titers against
each of the vaccine antigens. Severity of CAD does not have any
signiﬁcant impact on the magnitude of serologic response.
Table. Response measures to the antigens of 2007–2008 trivalent inﬂuenza vaccine
CAD,
n= 137
HC,
n= 67
Solomon Islands/3/2006 (H1N1)
Magnitude of change, × fold, median (IQR) 4 (14) 4 (6)
Serologic response (4-fold HI titer rise), n (%) 90 (65.7) 39 (58.2)
Wisconsin/67/2005 (H3N2)
Magnitude of change, × fold, median (IQR) 4 (4) 8 (14)
Serologic response (4-fold HI titer rise), n (%) 100 (73.0) 50 (74.6)
Malaysia/2506/2004
Magnitude of change, × fold, median (IQR) 4 (6) 2 (3)
Serologic response (4-fold HI titer rise), n (%) 78 (56.9) 30 (44.8)
P1418 The efﬁcacy of inﬂuenza vaccination in reducing
cardiovascular events in patients with coronary artery
diseases: IVCAD study
Maryam Keshtkar-Jahromi °, H. Vakili, M. Rahnavardi,
S. Gholamin, S.M. Razavi, A. Eskandari, R. Sadeghi, O. Taziki,
Marzieh Keshtkar-Jahromi, T. Mokhtari-Azad (Tehran, IR)
Objectives: It is a matter of controversy whether inﬂuenza vaccine is
effective in reducing the risk of ischaemic events in coronary artery
disease (CAD) patients. Our clinical trial was conducted to investigate
the efﬁcacy of 2007–2008 inﬂuenza vaccine (Flu Vacc) in reducing
adverse cardiac events in CAD patients.
Methods: A trial was conducted from January to August 2008
(ClinicalTrials.gov NCT00607178) and enrolled 281 CAD patients. They
were randomised to receive either FluVacc (CAD-inﬂuvac, n = 141)
or placebo (CAD-Placebo, n = 140). Antibody titers against inﬂuenza
vaccine subgroups were measured before and 1 month after vaccination
and the results were reported separately. CAD patients were followed
for 6 months and angina severity (Seattle angina questionnaire – SAQ)
before and 6 months after vaccination, coronary artery stenosis score
(modiﬁed Gensini), cardiac ejection fraction (EF), number of ﬂu episodes
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and cardiac adverse event (acute coronary syndrome [ACS], coronary
revascularisation, or cardiovascular death) were recorded as outcome
measures.
Results: 135 CAD-Placebo and 131 CAD-Inﬂuvac subjects completed
the study. The CAD-Placebo group experienced inﬂuenza infection
signiﬁcantly more than the CAD-inﬂuvac group (P = 0.049). Two
cardiovascular deaths happened in CAD-Inﬂuvac group which was
comparable with one death in CAD-placebo group. None of the
secondary endpoint (6 months) outcome measures were markedly
different among the two groups when compared individually. However,
when occurrence of at least one of the outcome measures in each subject
was considered, CAD-placebo group had signiﬁcantly higher cardiac
adverse events (ACS, coronary revascularisation, or cardiovascular death)
than their CAD-Inﬂuenza counterparts. Angina severity scores (SAQ)
improved more in CAD-Inﬂuenza than in CAD-Placebo group.
Conclusion: Inﬂuenza vaccine reduces cardiac adverse events and
improves SAQ score in patients with coronary artery diseases in
6 months follow up. Timely inﬂuenza vaccination is highly recommended
in this group of patients.
P1419 Long-term immunogenicity of inﬂuenza vaccine among the
elderly adults
J.Y. Song, H.J. Cheong, J. Lee, D.W. Park, Y.M. Jo, W.S. Choi,
M.J. Kim, J.Y. Heo, J.Y. Noh, W.J. Kim ° (Seoul, KR)
Background: Concerning the high risk of serious complication from
inﬂuenza, the elderly have been considered as the priority group of
inﬂuenza vaccination. However, inﬂuenza vaccine-induced antibody had
been thought to decline more rapidly in the elderly.
Methods: During 2007–2008 inﬂuenza seasons, this study was
conducted to compare the long-term immunogenicity of inactivated
trivalent inﬂuenza vaccine among the elderly compared to the healthy
young adults. Study subjects were stratiﬁed into four groups: 18−49
aged healthy adults, 50−64 aged healthy adults, 50−64 aged adults with
co-morbidities and 65 aged adults. Serum haemagglutinin inhibition
(HI) antibody titers were determined against the recommended in-
ﬂuenza strains A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005
(H3N2) and B/Malaysia/2506/2004, at pre-vaccination and 1, 6 and
12 months after vaccination.
Results: Of the 1,018 enrolled subjects, 716 (70.3%) were followed
up during 12 month period. Seroprotection (titer 40) rate at 1 month
post-vaccination in 18−49 aged healthy adults, 50−64 aged healthy
adults, 50−64 aged adults with co-morbidities and 65 aged adults
were 89.4% vs. 90.3% vs. 87.4% vs. 79.8% for inﬂuenza A/H1N1
virus, 87.6% vs. 89.1% vs. 89.8% vs. 85.0% for A/H3N2 virus, and
89.4% vs. 74.3% vs. 70.1% vs. 73.1% for inﬂuenza B virus. At six
months later, compared to 1 month post-vaccination, seroprotection rates
for all three strains declined signiﬁcantly in ±65 aged adults (p< 0.001),
but still met the CHMP criteria: A/H1N1 (69.2%), A/H3N2 (77.9%) and
B (64.4%). At 12 month after vaccination, seroprotection rates for all
three strains declined far below the CHMP criteria irrespective of age and
co-morbidities. Intriguingly, seroprotection rates were not inﬂuenced by
pre-immunisation history, but good responders (pre-HI titer40) showed
superior long-term immunogenicity compared to the poor responders;
even in the elderly aged  65 years, seroprotection rates were maintained
>60% up to 12 month post-vaccination against all three strains.
Conclusion: Current inﬂuenza vaccine showed adequate immunogenic-
ity for Korean adults including ±65 year aged persons. However, in
the elderly, long-term immunogenicity of current conventional inﬂuenza
vaccination was marginally seroprotective. Strategy to improve the
immunogenicity of inﬂuenza vaccine may need to be considered in 65
aged adults such as adjuvanted vaccine, high-dose vaccine, intradermal
vaccine, etc.
P1420 Comparison of long-term immunogenicity of inﬂuenza
vaccine among healthy young adults: intradermal versus
intramuscular vaccination
J.Y. Song, H.J. Cheong, Y.M. Jo, W.S. Choi, M.J. Kim, J.Y. Heo,
J.Y. Noh, W.J. Kim ° (Seoul, KR)
Objectives: For fear of vaccine shortage during an inﬂuenza pandemic,
several antigen sparing strategies have been investigated. We are to eval-
uate the long-term immunogenicity of both one-half dose and one-ﬁfth
dose intradermal vaccination compared to the full-dose intramuscular
vaccination of a commercial inﬂuenza vaccine in healthy young adults.
Methods: During 2006–2007 inﬂuenza season, this study was conducted
to compare the long-term immunogenicity of intradermal inﬂuenza
vaccination (one ﬁfth and one half the conventional antigenic contents)
with that of intramuscular vaccination (conventional dose) in healthy
young adults. Ninety-six subjects were randomly assigned to each
group: 0.1ml dose intradermal vs. 0.25ml dose intradermal vs. 0.5ml
dose intramuscular vaccination. Serum haemagglutinin inhibition (HI)
antibody titers were determined against the recommended inﬂuenza
strains A/New Caledonia (H1N1), A/Wisconsin/67/2005 (H3N2) and
B/Malaysia/2506/2004, at pre-vaccination and 1 and 6 months after
vaccination.
Results: Seroprotection (titer±40) rate at 1 month post-vaccination
in 0.1ml dose intradermal, 0.25ml dose intradermal and 0.5ml dose
intramuscular groups were 76.7% vs. 90% vs. 87.5% for inﬂuenza
A/H1N1 virus, 70% vs. 93.3% vs. 84.4% for A/H3N2 virus, and
56.7% vs. 60.0% vs. 65.6% for inﬂuenza B virus without signiﬁcant
inter-group difference, which were maintained until 6 month post-
vaccination. Seroconversion rates were above 40%, while geometric
mean titer showed an increase by a factor of >2.5 throughout the 1−6
month periods in all 3 strains irrespective of injection routes and doses.
Geometric mean titers of A/H3N2 at 6 month were signiﬁcantly lower
in one-ﬁfth intradermal group compared to the others (p = 0.03).
Conclusion: Intradermal administration of one-ﬁfth dose inﬂuenza
vaccine showed the tendency to elicit lower antibody responses compared
to the one-half dose intradermal and conventional dose intramuscular
vaccination, but those were still sufﬁcient to meet the requirement
guidelines of European Committee for Proprietary Medicinal Products
(CPMP) until 6 month time after inﬂuenza vaccination.
P1421 Inﬂuenza A(H3N2) strains in North Greece: genetic
relations and vaccine strain match for the 2004−07 period
A. Melidou, M. Exindari, G. Gioula, D. Chatzidimitriou °,
Y. Pierroutsakos, E. Diza-Mataftsi (Thessaloniki, Athens, GR)
Purpose: The purpose of this study was to identify the A(H3N2)
inﬂuenza strains that circulated in North Greece during the three
inﬂuenza seasons 2004–05, 2005−06 and 2006–07, and compare them
with the respective vaccine strains.
Methods: A total of 34 A(H3N2) inﬂuenza strains from 83 infected
individuals of the periods 2004−07 were examined. Regions of the
neuraminidase (NA) and haemagglutinin (HA) genes were ampliﬁed
using one-step RT-PCR and then sequenced. Phylogenetic clades of
circulating strains were determined and the HA sequences were
compared with those of vaccine strains.
Results: During 2004–05, northern Greek circulating strains were
A/Lisbon/3/04-like and A/BW/38/05-like. Both clades had 97% HA
sequence homology with the vaccine strain, A/Fujian/411/02. Some of
the variations were observed on antigenic sites of the viruses.
During 2005–06, circulating strains were A/Wisconsin/67/05-like and
A/Berlin/2/06-like. The ﬁrst clade had 97%, whereas the second had
98% HA sequence homology with the vaccine strain, A/California/7/04.
During 2006–07, Greek strains belonged to three clades. A/Hiroshima/
52/05-like and A/Brisbane/10/07-like strains had 99%, whereas A/Nepal/
921/06-like strains had 96% HA sequence homology with this year’s
vaccine strain, A/Wisconsin/67/05. One of the strains that belonged to
the last phylogenetic clade, A/Serres/77/07, was chosen by WHO as a
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reference strain, because of unique HA sequence variations observed on
antigenic sites.
During 2005–06, none of the 11 positive for inﬂuenza A(H3N2) patients
were vaccinated, whereas during 2006–07, three out of 45 patients
were vaccinated. Interestingly, two of these patients were infected by
an A/Serres/77/07-like strain.
Conclusions: Results show that two or more clades of inﬂuenza
A(H3N2) viruses co-circulated during 2004−07 in North Greece. During
2004–05, a relatively low match with the vaccine strain and the altered
antigenicity of greek strains, possibly decreased protection offered by
the vaccine. During 2005–06, a low match with the vaccine strain was
also observed. During 2006−07 the majority of the isolated strains had a
high match with the vaccine strain. However, the vaccine did not protect
patients infected by A/Serres/77/08-like strains. Constant monitoring of
the circulating strains is essential in order to predict the severity of the in-
ﬂuenza epidemic and also contribute to the next year’s vaccine selection.
P1422 Polymorphism of pertactin gene in circulating Bordetella
pertussis strains in Serbia
G. Dakic °, T. Kallonen, A. Elomaa, T. Pljesa, M. Vignjevic-Krastavcevic,
M. Svabic-Vlahovic, Q. He (Belgrade, RS; Turku, FI)
Objectives: Despite the routine use of pertussis vaccines, pertussis
remains an important cause of disease among young infants, adolescents
and adults. Pertactin (Prn), a 69 kDa outer membrane protein of Borde-
tella pertussis, induces protective immunity and is included in the acel-
lular pertussis vaccines. Polymorphism in Prn gene of circulating B. per-
tussis strains has been found in many countries with long vaccination
tradition, and today 12 allelic variants (prn1–12) have been reported. The
allele prn1 or prn7 are present in most vaccine strains and predominated
in the pre-vaccine era, and the allele prn2 is by far the most prevalent
type in actual isolates in most of countries. However, little is known of
polymorphism of Prn gene in B. pertussis isolates in Serbia where vacci-
nation against pertussis has been used for 50 years (pertussis vaccination
was started in this country in 1957). The aim of this study was to analyse
and compare Prn types in the Serbian isolates collected since 1950 s.
Methods: The analysis included genotyping of prn by sequencing and
LightCycler PCR. A total of 56 clinical isolates together with four
vaccine strains were tested. The clinical isolates were from 1953 to 1958
(n = 16) and from 1981 to 2000 (n = 40).
Results: The allele prn1 was predominant among the Serbian isolates,
although the prn2 (5%), prn3 (10%) and prn11 (15%) occurred in some
isolates over the period from 1981 to 2000. The alleles prn3 and prn11
were detected in 1981 and 1984, respectively. However, the allele prn2
was only found in two strains isolated in 2000. The current Serbian
whole-cell vaccine has been used since 1985 and contains both prn1
(three strains: 1772/57, 2047/57 and 23/81) and prn2 (one strain: 8/84).
Interestingly, the vaccine strain 8/84 was isolated in 1984.
Conclusions: The frequency of modern B. pertussis isolates with prn2
was signiﬁcantly low in Serbia compared to that found in most of
countries with long vaccination histories. In contrast to other European
countries, the prevalence of strains with prn2 seemed to come late in
Serbia. The real impact of the inclusion of prn2 strains in vaccines
on the antigenic variation of Prn and occurrence of new Prn types in
B. pertussis population should be further investigated.
P1423 Is BCG vaccine scar necessary for conﬁrmation of
immunity against Mycobacterium tuberculosis infection?
S. Sayyahfar °, A. Karimi, S.A. Fahimzad (Tehran, IR)
Objective: Comparison of Gamma Interferon response to human PPD
in scar negative and scar positive BCG vaccinated children.
Methods: Between august 2006 and may 2007 a total of 236 children
aged 1 month to 168 months (mean 21 months) admitted to different
wards of Mofeed children hospital and met the inclusion criteria were
enrolled in a cross sectional study with sequential manner. Each patient
was examined for BCG vaccine scar and then tested with both Tuberculin
skin Test (TST) and human PPD based Interferon Gamma release assay
(IGRA).
Results: From total of 236 patients, 15 (40% female, 60% male, 1–
156 months, mean 42 months) who were scar negative, 100% were TST
negative. In scar negative patients the IGRA was positive in 10 (66.7%),
negative in 4 (26.7%) and indeterminate in 1 (6.7%) respectively.
221 cases (44% female, 56% male, 1–168 months, mean 21 months)
were scar positive. 5% and 95% of scar positive cases were TST positive
and negative respectively. In scar positive patients the IGRA result was
positive in 110 (49.8%) negative in 85 (38.5%) and indeterminate in
26 (11.8%) respectively.there was no signiﬁcant statistically distinction
between scar positive and negative groups in TST and IGRA results.
Conclusion: It seems that immunity against mycobacterium tuberculosis
in scar negative children does not relate to scar formation and may be
better evaluated with a more accurate tool such as IGRA than contenting
with scar formation alone.
P1424 Meningococcal disease in Italy in the era of conjugate
menC vaccination
P. Stefanelli °, C. Fazio, T. Soﬁa, A. Neri, P. Mastrantonio (Rome, IT)
Objectives: Invasive Meningococcal Disease (IMD) remains a life-
threatening disease. To determine the change in epidemiological
characteristics of IMD in Italy after the introduction of conjugate menC
vaccine in 2005, analysis of the microbiological features of isolates and
of the clinical characteristics of patients has been carried out.
Methods: MD cases from 2005 through 2008 were identiﬁed according
to the National Meningococcal Surveillance System. Serogrouping,
sero/subtype and susceptibility testing were performed on all the
meningococci received at the National Reference laboratory at the
Istituto Superiore di Sanita`.
Results: In 2005 and 2008, IMD showed an incidence of 0.5 and
0.2 x 100,000 inhabitants, respectively. While the incidence due to
serogroup B remained quite stable in the total population as well as
in the 0−4 and 15−24 age ranges, IMD incidence due to serogroup C
has decreased in the total population since 2005. In particular, the
decrease was markedly signiﬁcant among infants with an incidence of
0.46 and 0.5 per 100,000 inhabitants in 2006 and 2007 respectively,
vs. 1.69 and 1.29, in 2004 and 2005. A less signiﬁcant decrease, was
found among adolescents and young adults. Information on the clinical
presentation was registered for 88% of cases; outcome was known
for 82%. Clinical manifestations and outcome of infections underlined
more severe diseases associated with C:2a isolates, with an increase in
septicaemia from 28% in 2005 to 70% in 2007. Conversely septicaemia
cases due to C:2b remained quite stable: 45% and 33%, respectively. In
the same period, fatal cases due to C:2a meningococci increased, from
7% to 55%. All the examined strains were susceptible to rifampicin,
ceftriaxone, ciproﬂoxacin and penicillin. However, 82% of C:2b showed
a decreased susceptibility to penicillin.
Conclusions: The Italian setting, following the introduction of meningo-
coccal C conjugate vaccine recommended by the Ministry of Health but
applied according to different regional strategies, can provide insight on
possible effects of vaccination not only in the decreasing incidence of the
disease but also on the prevalent spreading of speciﬁc meningococcal
types. Data from ongoing surveillance of IMD to evaluate long-term
effects of vaccination and to monitor the disease burden, predominantly
caused by serogroup B meningococci, will be further evaluated.
P1425 Prospective study assessing the tetanus immunisation status
and its determinants among patients consulting for wound
care at the emergency department of a non-universitary
hospital
S. Fanello °, V. Delmas, J. Choukroun, Y. Lannehoa (Angers, Le Mans,
FR)
Tetanus is a severe acute toxi-infection, often lethal, caused by a
neurotoxin produced by Clostridium tetani; it can be prevented by
vaccination.
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Objective: To assess the tetanus vaccination status and deﬁne its main
causative factors; to compare the patient’s self-declared vaccination status
with his actual immunisation cover.
Methods: Prospective study assessing the tetanus immunisation status
based on reliable evidence (injection certiﬁcates or point of care quick
serodiagnostic test) and its determinants among patients consulting for
wound care at the Emergency Department of a non universitary Hospital.
Results: 1120 patients were included. 50% declared they had their
boosters in time, 31% didn’t know their vaccination status, and 16% had
some kind of vaccination certiﬁcate. As for actual coverage, it appeared
that only 61% were immunised and 8% not immunised against tetanus,
but for 30.5% it was unsoeciﬁed (no document, no test). The cover
decreased signiﬁcantly with age. It was better for men.
Conclusion: According to current data, our ﬁndings conﬁrm that only
61% of the population is immunised against tetanus, with a lack of
coverage in particular for women and elderly. Therefore we have to
change our practices to increase immunisation coverage and reduce the
use of speciﬁc human immunoglobulins for tetanus prophylaxis.
P1426 Diphtheria antitoxin levels among adults in Manisa, Turkey
S. Vural, C.B. Cetin °, T. Sanlidag, G. Dinc, E. Keskin, O. Tunger
(Manisa, TR)
Objective: Diphtheria is an infectious disease caused by Corynebac-
terium diphtheriae, which can be prevented by immunisation. In pre-
vaccination period, disease has engendered high death rates and serious
complications among children. In 1930 s, with the vaccination all over
the world, a decrease has been determined in morbidity and mortality.
In 1990 s, outbreak that occurred in neighbouring countries of Turkey
and mostly affecting the adults has attracted the attention to this disease
again. The aim of the study was to evaluate the rate of immunity to
diphtheria among adults and determining the affected factors.
Method: Blood samples were collected from 856 adults more than
18 years old living in Manisa, Turkey. For each participant, a
questionnaire was completed for socio-demographic characteristics
and diphtheria immunisation status. Anti diphtheria IgG levels were
determined by using enzyme immunoassay method (Genzyme Virotech
GmbH, Germany). The levels of 0.1 IU/ml and above were considered
to be immune and below the 0.1 IU/ml titers were accepted insufﬁcient
immunity.
Results: In the study, it was determined that 61.9% of the people
are being protected against the disease whereas 38.1% of them were
sensitive. There was a signiﬁcant relation between the protective
immunity and the age. The highest protection rate was existing among
people 20 years old and 71 years old. However, the most sensitive
age group against the disease was 30−50 ages. There was no signiﬁcant
relation between the sex, alcohol consumption and protective immunity.
But, a signiﬁcant relation between immunity and co-morbidity, living
place in childhood, socio-economic level and social status was found.
Conclusion: The high sensitivity rates in adults in our study emphasize
the importance of the booster immunisation in adulthood.
P1427 Immunity to pertussis 10 years after acellular booster
vaccine in adolescence and response to a second dTpa
booster in young adults
Q. He °, O. Van Der Meeren, L. Mannermaa, A. Linko-Parvinen,
J. Mertsola (Turku, FI; Rixensart, BE)
Background: We conducted a 10-year follow-up study on persistence of
pertussis speciﬁc antibody and cell-mediated immunity (CMI) following
booster immunisation of 11-year-old adolescents with a reduced-antigen-
content tri-component acellular pertussis vaccine (Boostrix™). The study
subjects were re-immunised with the same vaccine at 21 years of age.
This is the ﬁrst study to evaluate the decennial administration of a dTpa
vaccine.
Methods: CMI and antibodies to the three vaccine antigens pertussis
toxin (PT), ﬁlamentous haemagglutinin (FHA) and pertactin (PRN) were
measured in adults before and one-month after the second dTpa booster
immunisation.
Results: Ten years following the pertussis booster vaccination, the
geometric mean concentrations of IgG elicited by each of the three
vaccine antigens had decreased from the ﬁve-year post-vaccination
levels, but 100% of the adults still had detectable FHA-IgG, 96% had
PRN-IgG and 65% had PT-IgG. CMI to FHA, PRN and PT was positive
in 96%, 57% and 54% of the subjects, respectively. The geometric mean
antibody concentrations were back to the same level as 10 years ago
before the ﬁrst booster. A booster IgG response was found in 97% (FHA),
93% (PRN) and 85% (PT) of the subjects in 21 years of age after the
second dTpa. CMI levels to FHA, PRN and PT persisted above the pre-
booster levels 10 years before and showed signiﬁcant increase after the
second booster immunisation, being positive in 96%, 80% and 80% of
the subjects, respectively.
Conclusions: The results of the present study in young adults indicate
that the interval between acellular pertussis booster immunisations might
be extended to 10 years. This study supports the use of Boostrix™ as a
decennial booster.
P1428 Evaluation of anti-measles IgG antibody level in medical
students 4 years after mass vaccination
N. Jonaidi Jafari °, M. Izadi, M. Kakaei, R. Ranjbar, M. Mohammad
Jonaidi (Tehran, IR)
Objectives: Measles is a severe contagious disease that can be prevented
by vaccination. In addition to prevalence of measles in Iran, ministry
of health and medical education has done a national wide vaccination
against measles for all 5−25 years old population in 2004. Edmunston
Zogreb vaccine was used. This study was done to evaluate anti measles
IgG antibody in medical students 4 years after mass vaccination.
Methods: This is a cross-sectional study on 196 medical students of
Baqiyatallah University of medical science. The chart contain age,
history of vaccination in childhood, history of vaccination in 2004,
history of measles, history of measles in family history of contact with
measles case and history of fever in time of vaccination. IgG conﬁrmed
with ELISA test in 5 cc blood that taken from each cases. The IBL
German kit was used.
Results: In this study total of case was man. With mean age of
23/5±3/01. History of vaccination in childhood in 194 persons (99%),
history of vaccination in 1382 (2004) in 188 persons (95/9%), history of
measles infection in 14 persons (7/1%), history of measles in family in
17 persons (8/7%), history of contact with measles case in 19 persons
(9/7%) and history of fever in time of vaccination in 1 person (0/5%)
was positive. Anti measles IgG antibody in 174 persons (88/8%) was
positive, in 19 persons (9/7%) was negative and in 3 persons (1/5%)
was equivocal.
Conclusion: In our study IgG level is lower than to prevent small
epidemics. Because medical students are living in high risk area. We
suggest that evaluate anti measles IgG antibody then prescribe vaccine
for who is IgG negative on equivocal.
P1429 Hepatitis B vaccination efﬁcacy among school-age children
in south of Iran
M. Moghadami °, S. Hashemi, K. Bagheri lankarani (Shiraz, IR)
Objective: Hepatitis B infection is an important cause of morbidity and
mortality in the world wide due to causing cirrhosis and hepatocellular
carcinoma. Despite advances in antiviral therapy, only a minority of
patients with chronic hepatitis B will have a sustained response.
Thus, primary prevention by vaccination to increase herd immunity
remains the main thrust in the control of hepatitis B virus (HBV)
infection and many countries such as Islamic republic of Iran HBV
vaccination has been incorporated into the national expanded program
on immunisation.
Method:We have assessed the efﬁcacy of vaccine against HBV infection
and chronic carriage by examining 392 students (age 6−8 years old) who
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had received the vaccine in infancy and 314 students (age 9−10 years
old) who had not received it in Sepidan City, a south Iranian city. Also
we determined the titer of Anti HBs Ab in vaccinated students.
Results: Among 394 vaccinated students only 2 (0.5%) were HBV
infected (HBC Ab positive) and no one were chronic carrier 294 students
(63%) had Anti HBs titer of greater than 10 IU/ml 117 students (30%)
had Anti HBs titer between 1 to 10 IU/ml and only 28 children had Anti
HBs titer less than 1 IU/ml.
Among 314 unvaccinated students 5 person (1.6%) were HBV infected
(positive HBc Ab) and 2 students (0.6%) also was chronic carrier
(positive HBs Ag).
Conclusion: We found vaccination cannot reduce infection rate among
vaccinees but has signiﬁcant effect among reduction of chronic infection
and carrier state. our ﬁndings are as same as other studies and
emphasized on vaccine role in control of HBV infection control in
endemic area.
P1430 Immunogenicity of hepatitis A and B vaccines among liver
transplant candidates
L. Belarbi °, P. Loulergue, Y. Calmus, F. Conti, S. Grabar, J. Meritet,
A. Rosenberg, O. Launay (Paris, FR)
Objectives: Immunisation against hepatitis A (HAV) and B (HBV)
viruses is strongly recommended for liver transplant candidates. The
objective of this prospective study was to evaluate the immunogenicity
of HAV and HBV vaccines in patients waiting for a liver transplant.
Methods: Between March 2006 and March 2008, 100 liver transplant
candidates attending our transplant unit were studied for serological
markers for hepatitis viruses and received an update of HAV (2 doses
24 weeks apart of 1440 UI of HAV vaccine) and HBV (3 double doses
(40mg) of HBV vaccine at week 0, 4 and 24) immunisation.
Results: Their mean age was 51 years (range, 19−66), M/F ratio was
2.5; 97% had cirrhosis, mostly due to alcohol abuse (37%), chronic viral
hepatitis (35%) or autoimmune disease (14%); 20% had liver carcinoma
complicating the cirrhosis. On a declarative basis, only 18% and 11%
of them had received HBV and HAV vaccine, respectively. Prevalence
of anti-HAV and anti-HCV antibodies was 88%, and 37% respectively.
Prevalence of serologic markers of HBV infection was 52%, with isolated
anti-HBs in 21 patients. A total of 53 patients had an indication of
vaccination against viral hepatitis: 5 for HAV vaccination alone, 41 for
HBV vaccination alone, and 7 for both vaccines.
Among the 48 patients with no marker against HBV, 16 patients received
a liver transplant before vaccine schedule completion (2 before the 1st
injection, 4 before the 2nd and 10 before the 3rd). Seroprotection against
HBV occurred in only 42% of the vaccinated with the 3 doubles doses.
Seroconversion (anti-HAV antibody >20mIU/ml) occurred in 100% of
patients after 2 doses of HAV vaccine.
Conclusion: In liver transplant candidates, immunogenicity of HBV
vaccine, even using a double dose regimen, is poor. Furthermore, almost
one third of the patients have been transplanted before the vaccination
was over. Taking together, our results support the recommendations that
patients should be proposed HBV vaccine earlier in the course of the
liver diseases.
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P1431 Food-borne Salmonella enteritidis outbreak in a mental
health institution
B. Kotnik-Kevorkijan °, Z. Simonovic, K. Ekart-Koren, M. Rosker,
J. Rebersek-Gorisek (Maribor, Hrastovec, SI)
Objectives: In the state institution for the mentally impaired (IMI), an
acute outbreak of gastroenteritis occurred in over 100 people during
a single day. Over the next three days, 407 residents (out of 580) and
15 staff members (out of 350) suffered from vomiting and diarrhoea. All
of them ate a bean salad prepared the day before. A total of 39 residents
were hospitalised.
Methods: Microbiological: examination of stool samples, blood cultures
in hospitalised patients, PFGE genotyping.
Clinical: follow-up of signs and symptoms: body temperature, vomiting,
diarrhoea, secondary infection and outcome.
Results: Salmonella enteritidis was conﬁrmed from the stool samples
of IMI residents and staff members, as well as from the bean salad.
PFGE genotyping showed a 96% match between Salmonellae isolated
from the stool samples and bean salad. Two months after the outbreak,
50 residents (12.3%) were still Salmonella carriers, but only one was a
Salmonella carrier a year later.
In all, 369 residents had an acute enteric infectious gastrointestinal illness
with vomiting and diarrhoea, 306 of them also with fever. 38 residents
were only febrile without vomiting and diarrhoea but with positive stool
samples. They all needed rehydration: 208 residents needed intravenous
rehydration and the addition of other substances.
A total of 39 residents with serious morbidity and mortality risk were
hospitalised, 20 of whom (51.3%) were given antibiotics. There were
positive blood cultures in two hospitalised residents. Four residents with
severe underlying diseases died (mortality rate 0.8%), one from septic
shock and the others due to pneumonia.
Conclusion: The salmonellosis outbreak at the IMI was signiﬁcant
because of the more than 70% attack rate, probably due to high
antacid consumption and sedatives used in the institution. The residents
are mentally impaired and were not able to follow infection control
guidelines such as hand washing, hand rubbing and contact precautions
strictly. Personnel with acute diarrhoeal disease were promptly removed
from resident care activities and non-medical personnel were involved in
care activities helping the medical staff stop the spread of salmonellosis.
It is important to note that only a few secondary transmissions occurred.
P1432 Increased risk of postpartum infections after caserean
section compared with vaginal birth
R.A. Leth °, J.K. Møller, R.W. Thomsen, N. Uldbjerg, M. Nørgaard
(Aarhus, Aalborg, DK)
Objective: The prevalence of caesarean section (CS) in Denmark has
increased (from 13% of births in 1997 to 22% in 2007), and a substantial
part of the women has a CS without medical contraindications to vaginal
birth (VB). Infection is the most frequent complication after CS, and may
occur after hospital discharge. We compared the risk of urinary tract
infection (UTI), postoperative wound infection (PWI) and bloodstream
infection (BSI) within 30 days after VB, emergency CS and elective CS,
respectively.
Methods: We conducted a register-based cohort study including all
women giving birth in hospitals in the County of Aarhus, Denmark
between 2001–2005. We combined data from various hospital registries
to identify postpartum infections. We deﬁned UTI as presence of a
positive urine culture with 100, 000 colony forming units per mL
and/or treatment by a physician with a UTI-speciﬁc antibiotic. PWI
was deﬁned as either presence of a positive culture from the wound
or an associated abscess, treatment with dicloxacillin, readmission or
reoperation of the patient due to wound infection. BSI was identiﬁed
as presence of a positive blood-culture with a relevant pathogen and
concomitant antibiotic treatment.
Results: During the 5-year period we included 32,468 women. Of these,
26,288 (81%) women had a VB and 6,180 (19.0%) had undergone CS.
The prevalence proportion of postpartum UTI was 1.5% (403/26,288)
after VB and 2.8% (176/6,180) after CS, and the prevalence proportion
of PWI was 0.08% (20/26,288) after VB and 5.0% (308/6,180) after CS.
Only 0.06% (18/32,468) women had BSI. Women having undergone
emergency and elective CS did not differ concerning the risk of
postpartum UTI. In contrast emergency CS was associated with a ﬁfty
per cent higher risk of having postpartum PWI compared with elective
CS when adjusted for well-known risk factors (OR 1.52, 95%CI 1.15–
2.02). Seventy-nine per cent (258/328) of PWI and 76% (439/579) of
UTI were diagnosed post discharge.
Conclusions: The risk of acquiring a postpartum infection was
substantially increased after caesarean section compared with vaginal
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birth. Without post discharge surveillance the infection rate would be
underestimated.
P1433 Assessment of the treatment and outcomes associated with
severe and mild-to-moderate Clostridium difﬁcile infection
S. Wieczorkiewicz °, J. Jourjy, L. Danziger, D. McMahon (Chicago,
Lexington, US)
Objective: The incidence and severity of Clostridium difﬁcile infection
(CDI) have increased dramatically in recent years as a result of a more
virulent and resistant strain. Thus, it is essential for prompt diagnosis
and early treatment interventions to occur. The objectives of this study
were to determine the treatment approach for CDI at an urban, teaching
institution, identify the incidence of severe disease, and to describe
treatment outcomes.
Methods: This was a single-centre, retrospective study in hospitalised
patients (HP) greater than 18 years-old who received metronidazole
(MTR) or oral vancomycin (VAN) for the treatment of CDI over a ﬁve-
year period (2002–2007).
Results: 7,280 HP were identiﬁed. Of these, 106 were randomly selected
for further review (46% male). 236 treatment observations (TO) were
evaluated; 91% MTR use versus 9% VAN use. 64% of CDI cases were
considered severe (S) and 36% mild-to-moderate (MM). 84% of S CDI
cases were treated (tx) with MTR and 25% of MM CDI cases were tx
with VAN. Of S CDI cases, 53% tx deﬁnitively (DEF) with MTR, 16%
tx DEF with VAN, 31% tx empirically (EMP) with M, 0 tx EMP with
VAN. Of MM CDI cases, 61% tx DEF with MTR, 7% tx DEF with
VAN, 30% tx EMP with MTR, and 2% tx EMP with VAN. Only 31%
of the S cases were treated EMP. The percentage of TO that resulted
in a lack of symptom resolution, MTR failure, and recurrence is 41 in
both S and MM, 33 S and 20 MM, and 40 S and 41 MM respectively.
An overall MTR failure rate of 22% was observed. Recurrence rates
increased with each recurrent CDAD episode. By the third episode,
patients were 100% likely to experience a recurrence. In 203 (86%)
TO, the HP were continued on the offending antimicrobial despite the
CDI diagnosis.
Conclusions: In our institution, high rates of S disease were observed
overall. Most patients were treated with MTR regardless of disease
severity and no patients in the S CDI group were tx EMP with VAN. In
both the S and MM groups, many CDI cases did not result in symptom
resolution. A higher incidence of MTR failures was observed in the
S group. Similar rates of recurrence were observed in both groups and
recurrence rates dramatically increased with each recurrent CDI episode
comparable to that reported in the literature. Causative antimicrobials
were rarely discontinued. More attention is needed in identifying those
HP at high risk and ensuring these HP receive appropriate treatment to
improve outcomes.
P1434 First results of hospital-based surveillance of Clostridium
difﬁcile-associated infections in Finnish acute care hospitals
O. Lyytika¨inen °, T. Mo¨tto¨nen, S. Kotila, S. Ibrahem,
A. Virolainen-Julkunen (Helsinki, FI)
Objectives: In January 2008, a new surveillance module for CDI
started as a part of the Finnish Hospital Infection program (SIRO) in
collaboration with the national reference laboratory in order to estimate
the incidence of CDI in Finnish hospitals, to detect severe cases of CDI
and outbreaks.
Methods: From January through September 2008, prospective
laboratory-based surveillance was conducted using the interim case
deﬁnitions of the European Centre for Disease Prevention and Control
(ECDC) for CDI, origin and severe case of CDI. Clinical and
microbiological data were recorded on a standardised form. Patient-days
and admissions were obtained from the hospital’s information technology
department. We calculated the overall and nosocomial incidence rates
of CDI, and prevalence of CDI among admitted patients. All clinical
microbiology laboratories in participating hospitals were asked to send
C. difﬁcile isolates from severe cases of CDI and/or persistent outbreaks
for genotyping. PCR ribotyping of the toxin positive C. difﬁcile isolates
was performed according to the protocol of the Anaerobe Reference Unit
in Cardiff. When a local outbreak was suspected, also pulsed-ﬁeld gel
electrophoresis (PFGE) was performed.
Results: A total of 740 cases of CDI were reported from 12 hospitals;
514 (69.5%) were nosocomial. Of all CDI cases, 125 (16.9%; range
by hospital, 1.5−50.0%) were severe: 84 (11.4%; range, 1.5−50.0%)
were related to readmission, 32 (4.3%; range, 0−12.5%) death, 7 (0.9%;
range, 0−9.5%) intensive care and 2 (0.3%; range, 0−1.6%) colectomy.
The overall rate, nosocomial rate and prevalence at admission was 0.71
per 1000 patient-days (range, 0.10–1.92), 0.49 per 1000 patient-days
(range, 0.05–1.15) and 0.71 per 1000 admissions (range, 0.12–2.18),
respectively. Of the 12 hospitals having reported cases of CDI, 8 had
sent isolates for genotyping. The PCR ribotype 027 was detected in
three of the 8 hospitals: in one of them both the proportion of severe
cases and nosocomial rate was high and in the others low or moderate.
Conclusions: The surveillance provides the ﬁrst detailed information
on CDI epidemiology in Finnish hospitals, showing major differences
between hospitals. However, only minority of isolates from severe
cases of CDI were sent for genotyping. This may be due to lack
of communication between the infection control staff and clinical
microbiology laboratory.
P1435 Resource use and costs associated with Clostridium difﬁcile
diarrhoea in a university hospital
N. Agthe, E. Mattila, V.J. Anttila, M. Kanerva ° (Helsinki, FI)
Objectives: C. difﬁcile is one of the most common healthcare-associated
infections. It is also associated with increased resource use and costs.
We wanted to study the incidence and the economic burden caused by
C. difﬁcile in the Helsinki University Central hospital during Feb 2007-
May 2008.
Methods: We conducted laboratorio-based prospective surveillance of
healthcare-associated C. difﬁcile incidence at six acute care wards
during a 16 months’ study period, and reviewed the patient records
for symptoms, diagnostic tests and treatment. A case was deﬁned as
a symptomatic patient with positive stool sample for C. difﬁcile between
3 days after admission and 4 weeks after discharge, and symptoms
associated with infection. The data of the resource use was gathered
from the patient records. Prolongation of hospital stay was analyzed by
appropriateness evaluation protocol (AEP) method. Unit costs for bed
days, isolation, diagnostic tests and medication were obtained from the
literature, hospital administration, laboratory and pharmacy.
All incremental resource use and costs caused by C. difﬁcile infection
from hospital perspective were calculated for those patients who were in
the hospital at the time of symptoms.
Results: The monthly incidence of the C. difﬁcile infection varied
between the study wards throughout the study period from 0.7 to 3.8
cases/1000 patient days. Altogether 72 patients were included in the
cost analyses. The average incremental costs associated with C. difﬁcile
infection was 2300 €/patient, but the cost data was highly skewed.
Incremental cost for hospital were 165 000 € during study period
(approximately 1700 €/month/ward). C. difﬁcile infection prolonged the
stay by a mean of 2.7 days. Most of the recourse use came from
extra days (85%). Other cost drivers were incremental ICU days (6%),
laboratory (4.5%), medication (1.4%) costs and isolation (1.2%).
Conclusion: Healthcare-associated C. difﬁcile infection caused signiﬁ-
cant extra costs for the hospital mostly due to prolongation of hospital
stay.
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P1436 Epidemiology of healthcare-associated Stenotrophomonas
maltophilia infections in CF and in ICU patients: role of
bioﬁlm formation
R. Cipresso, M. Barchitta, R. Marzagalli, G. Di Bonaventura °,
A. Pompilio, G. Gherardi, A. Agodi (Catania, Chieti, Rome, IT)
Objectives: Stenotrophomonas maltophilia is an emerging bacterial
pathogen which is currently isolated with increasing frequency from the
airways of cystic ﬁbrosis (CF) patients as well as from different sites of
intensive care units (ICU) patients. In a previous study S. maltophilia
strains isolated from the airways of independent CF patients, have been
characterised for the expression of several virulence-associated factors.
The present study was designed in order to: (i) investigate the clonality,
the mode of transmission and the patients’ risk proﬁle for acquisition
of S. maltophilia in CF and ICU patients, and (ii) to evaluate the
epidemiological signiﬁcance of bioﬁlm formation both in CF-associated
and in ICU-associated strains.
Methods: Patterns of S. maltophilia acquisition in the ICU during
the period of the survey were carriage, colonisation and infection
(ventilator-associated pneumonia, urinary tract infection, bloodstream
infection, catheter related infection), characterised using well established
deﬁnitions. Clonality assessment was performed by PFGE of genomic
DNA digested with 25 U/ml of XbaI. Macrorestriction fragments were
separated using a CHEF-DR III apparatus and genomic relatedness
performed using Tenover criteria. Cross-transmission was assumed when
two patients had indistinguishable isolates. Bioﬁlm formation was
assessed by crystal violet staining in polystyrene 96-well microtiter plates
after 24 h of incubation at 37ºC.
Results: A total of 42 CF-associated isolates and of 38 ICU-associated
isolates were subjected to macrorestriction analysis. A total of 32
different PFGE proﬁles were observed among CF isolates. Twelve
distinct clones were identiﬁed among the ICU isolates, six associated
with cross-transmission of infection and/or colonisation; a major
clone (named clone A) was responsible for the epidemic spread of
S. maltophilia. Notably, the degree of bioﬁlm formation was shown to
be signiﬁcantly higher in ICU strains than in CF strains (p< 0.05).
Conclusion: Health care-related infections are associated with high
attributable mortality. S. maltophilia is an important alert organism
increasingly isolated both in CF and in ICU patients: increasing levels of
antibiotic resistance and the ability to form bioﬁlms surrounding invasive
devices pose special challenges to be addressed for appropriate control
strategies.
P1437 Creating a collaborative network for the study of
bacteraemia in Denmark: frequency of recurrence with the
same and different micro-organisms
U.S. Jensen °, C. Østergaard, H.C. Schønheyder, J.D. Knudsen
(Copenhagen, Aalborg, DK)
Objectives: In most countries bacteraemia is a reportable infection
only if the causative agent is subject to national surveillance. In a few
countries all cases of bacteraemia are reportable but only one episode
per microorganism is included per year. Therefore population-based
data are sparse especially with regard to the epidemiology of recurrent
bacteraemia. We present data from a newly established collaborative
network in Denmark with prospective registration of bacteraemia in a
population of approximately 1.7 mill. inhabitants.
Methods: Three departments of clinical microbiology (DCMs) partici-
pate in the network (Hvidovre Hospital and Herlev Hospital, The Capital
Region and Aalborg Hospital, North Denmark Region). Bacteraemia is
deﬁned as a clinical episode with one or more positive blood cultures
(BCs) given signiﬁcance by a clinical microbiologist and the attending
physicians. A recurrence was deﬁned as a positive BC with the same
microorganism/s as obtained 30 days or with another microorganism/s
>48 hours after the ﬁrst positive BC, respectively. We included all
patients with bacteraemia during 2006–2007 and follow-up extended for
6 months or until death.
Results: In total, recurrent Escherichia coli bacteraemia was the most
frequent with 23 to 31 episodes (table). A recurrent episode of either
Staphyloccus aureus or Streptococcus pneumoniae bacteraemia was
rare in the participating hospitals (2.0% to 3.9% and 0.6% to 1.0%,
respectively). For all major blood culture pathogens the frequency
range was 0% to 4.1% with the exception of Enterococcus faecalis
(range 0% to 9.4%; table). A recurrent episode with any microorganism
was most frequent following bacteraemia caused by E. faecalis (range
8.9% to 24.5%) and Klebsiella pneumoniae (range 6.7 to 11.3%). The
frequency of recurrent candidaemia ranged from 6.9% to 13.6% (table).
Table. Recurrence of bacteraemia within six months of follow-up
Microorganism of the ﬁrst
bacteraemia
Number of ﬁrst episodes,
2006−2007
Recurrence, same
microorganism: n (%)
Any recurrence:
n (%)
DCM
Herlev
DCM
Hvidovre
DCM
Aalborg
DCM
Herlev
DCM
Hvidovre
DCM
Aalborg
DCM
Herlev
DCM
Hvidovre
DCM
Aalborg
Escherichia coli 740 956 579 31 (4.2) 30 (3.1) 23 (4.0) 83 (11.2) 53 (5.5) 40 (6.9)
Staphylococcus aureus 358 247 234 14 (3.9) 5 (2.0) 7 (3.0) 39 (10.9) 19 (7.7) 23 (9.8)
Klebsiella pneumoniae 151 164 115 6 (4.0) 5 (3.0) 4 (3.5) 17 (11.3) 11 (6.7) 13 (11.3)
Streptococcus pneumoniae 173 191 200 1 (0.6) 2 (1.0) 2 (1.0) 5 (2.9) 11 (5.7) 7 (3.5)
Enterococcus faecalis 140 90 53 8 (5.7) 0 (0) 5 (9.4) 16 (11.4) 8 (8.9) 13 (24.5)
Pseudomonas aeruginosa 79 63 63 1 (1.2) 0 (0) 1 (1.6) 5 (6.3) 5 (7.9) 2 (3.2)
Candida spp. 59 96 58 0 (0) 1 (1.0) 0 (0) 8 (13.6) 7 (7.3) 4 (6.9)
Non-haemolytic
streptococci
134 134 61 0 (0) 1 (0.7) 0 (0) 13 (9.7) 5 (3.7) 4 (6.6)
DCM = Department of Clinical Microbiology.
Conclusion: The frequency of recurrent S. aureus and S. pneumoniae
bacteraemia was lower than reported in previous studies. We found only
small differences among major pathogens in the frequency of recurrence
with the same microorganism. However, recurrent bacteraemia with any
microorganism is common subsequent to K. pneumoniae and E. faecalis
bacteraemia and to a lesser extent candidaemia. This suggests that host
factors and therapeutic regimens in these patients should be targeted in
further studies in order to optimise bacteraemia management.
P1438 Predictors of mortality in patients with ventilator-associated
pneumonia: a meta-analysis
I. Siempos °, K. Vardakas, C. Kyriakopoulos, T. Ntaidou, M. Falagas
(Athens, GR)
Objective: Studies exploring predictors of mortality in patients with
ventilator-associated pneumonia (VAP) produced conﬂicting results.
Methods: Potentially eligible reports were searched in PubMed,
EMBASE, CINAHL and HEALTHSTAR with no language restrictions.
Eligible studies were studies that enrolled only patients with microbio-
logically conﬁrmed VAP and reported on mortality.
Results: Twenty-one reports were included. Factors associated with
mortality were malignancy (OR= 2.85; 95%CI 1.19 to 6.82) at intensive
care unit admission as well as inappropriate initial treatment (i.e.
treatment either in vitro inactive against the causative bacteria or
administered later than 24 hours after diagnosis of VAP) (OR= 2.77;
95%CI 1.95 to 3.94), shock (OR= 4.98; 95%CI 2.65 to 9.38), sepsis
(OR= 4.77; 95%CI 2.22 to 10.25), disease severity and sepsis-related
organ failure score at the day of diagnosis of VAP. Isolation of non-
fermenting Gram-negative bacteria in general (OR= 1.71; 95%CI 1.09 to
2.68) and Acinetobacter baumannii in speciﬁc (OR= 1.67; 95%CI
1.02 to 2.73) was also associated with higher fatality; whereas, isolation
of Streptococcus pneumoniae was linked to lower mortality.
Conclusion: These ﬁndings may explain the variability in mortality
across studies on VAP, may help investigators to formulate relevant
predicting scores, and may further motivate clinicians to provide
appropriate initial treatment.
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P1439 Epidemiology of candidaemia and antifungal susceptibility
patterns in an Italian medical-surgical intensive care unit
between July 2003 and June 2008
A.M. Azzini °, F. Boccafoglio, G. Lo Cascio, E. Concia (Verona, IT)
Objective: To evaluate epidemiological trends of candidaemia (CA) and
to identify risk factors for it in critically ill patients; to deﬁne antimycotic
susceptibility patterns inside our intensive care unit (ICU) in order to
optimise both chemotherapy and prevention of drug resistance of this
infection.
Methods: We retrospectively identiﬁed all cases of CA and collected
their demographic/clinical/laboratory data, in particular the presence of
medical devices and antibiotics/antimycotics administration within the
3 weeks before a CA episode. We also considered if CA was CVC-
related. Antifungal susceptibility patterns were collected and empirical
treatment’s adequacy was evaluated as well.
Results: 58 CA were identiﬁed but only 51 were evaluable (all
nosocomial, 80% ICU-acquired) The overall incidence of CA was
29.5/10000 patient-days, with a peak during 2004 (37.9/10000 patient-
days) and 2005 (32.8/10000 patient-days). C. parapsilosis was isolated
in 47% of CA, followed by C. albicans (29%), C. glabrata (12%),
C. tropicalis (7%), C. guilliermondii (3%) and C. sake (2%). Non-
albicans species remained the more frequent pathogens during 2004–
2005–2006, only in 2007 we observed a reversal of trend. 100% of
C. albicans and C. tropicalis were ﬂuconazole-sensible (S), on the
contrary C. parapsilosis resulted ﬂuconazole-S in only 33% of cases,
in 60% SDD and in 7% resistant (R). Most of R or SDD C. parapsilosis
were isolated during 2005–2006. C. glabrata was ﬂuconazole-S in 29%
of cases and SDD in 71%. Most of patients had a medical device
(i.e. 98% CVC), 96% of them was on antibiotic therapy within the 3
weeks before. 65% underwent surgery, particularly abdominal (79%).
CVC-related CA were 59%, mainly due to C. parapsilosis. 76% of CA
were treated. Fluconazole was employed in 54%, any amphotericin B
formulation in 41% and caspofungin in 5%. Treatment was adequate
in 74% of CA (inadequacy due to a delay in starting treatment or to
posology). 30-days crude mortality was 62.5%, and 61.5% in patients
adequately treated (p = 0.27). We didn’t ﬁnd risk factors statistically
signiﬁcant for mortality (table1).
Risk factors OR 95%CI P
Age (years) 0.7518
<60 1 –
60 1.300 0.256–6.610
Gender 0.5995
Female 1 –
Male 0.727 0.222–2.387
Underlying disease 0.7435
Other 1 –
Solid neoplasia 3.000 0.642–14.023
Acute pancreatitis 3.000 0.423–21.297
Haematological neoplasia 1.500 0.106–21.312
Neuropathy 3.000 0.150–59.890
Cardiopathy + Rheumatic disease + Polytrauma 1.200 0.164–8.799
Ward of origin 0.3723
Medical 1 –
Surgical 0.436 0.106–1.804
Haematology + Emergency + Other hospital 1.067 0.183–6.212
Diagnosis 0.7155
Post-surgical 1 –
Respiratory failure 1.143 0.250–5.224
Septic shock 2.357 0.485–11.452
Cardiogenic shock + Major trauma + Cardiac arrest 1.714 0.228–12.890
CVC removed 0.0516
No 1 –
Yes 0.118 0.014–1.015
Concomitant bacteraemia 0.1005
No 1 –
Yes 4.000 0.765–20.918
Corticosteroids 0.5947
No 1 –
Yes 1.889 0.181–19.670
Candida albicans 0.3003
No 1 –
Yes 2.026 0.532–7.711
Conclusions: We described an epidemic outbreak by C. parapsilosis
in 2004–05, as demonstrated by DNA-ﬁngerprinting. This epidemic
was faced by the implementation of more strict infection control
measures (hand-hygiene and CVC-management guide-lines) Because of
the frequence of ﬂuconazole-R or SDD C. parapsilosis we recommended
to start CA treatment with an amphotericin B formulation.
P1440 Epidemiology of candidaemia in non-neutropenic patients
in an Italian tertiary-care hospital between 2005 and 2008
A.M. Azzini °, C. Recchia, A. Tedesco, E. Concia (Verona, IT)
Objective: To evaluate epidemiological trends in candidaemia (CA)
between 2005 and 2008.
Methods: All cases of CA were identiﬁed retrospectively;demographic
and clinical data were collected, together with data about the use of
antifungal/antibacterial drugs, and others predisposing factors, within
the 3 weeks before its onset. The antifungal susceptibility patterns were
collected as well
Results: 100 episodes of CA were identiﬁed. The average incidence was
0.99/10000 patient-days/year, ranging from 1.2 in 2005 to 1.1 in 2007.
54% of CA occurred in ICUs, followed by surgical (30%) and medical
(16%) wards. Most common predisposing factors were antibiotics (96%),
CVC (94%), bladder catheter (93%), total parenteral nutrition (64%),
mechanical ventilation (62%) and surgery (58%); steroids accounted
for only 32% of cases, no-one was neutropenic or transplant recipient.
C. albicans was isolated in 53% of cases, followed by C. parapsilosis
(21%), C. glabrata (9%) and C. tropicalis (9%); non-albicans species
never exceeded C. albicans (Table 1).
Candida spp. 2005 (n = 37) 2006 (n = 32) 2007 (n = 22) 2008 (n = 9)* Total
M S UTI M S UTI M S UTI M S UTI
C. albicans 4 7 11 2 6 8 1 3 8 2 0 1 53%
C. parapsilosis 0 2 7 1 1 3 2 1 2 0 1 1 21%
C. glabrata 1 0 1 0 3 2 0 0 0 1 0 1 9%
C. tropicalis 0 0 2 0 1 2 1 2 1 0 0 0 9%
C. guilliermondii 0 0 0 1 0 1 0 0 0 0 0 0 2%
C. krusei 0 0 1 0 0 0 0 0 0 0 1 0 2%
Others 0 0 1 0 1 0 0 0 1 0 1 0 4%
Total 5, 9, 23, 4, 12, 16, 4, 6, 12, 3, 3, 3, 100%
13.5% 24.3% 62.2% 12.5% 37.5% 50% 18.2% 27.3% 54.5% 33.3% 33.3% 33.3%
C. albicans 22/37 (59.4%) 16/32 (50%) 12/22 (54.4%) 3/9 (33.3%)
C. non albicans 15/37 (40.6%) 16/32 (50%) 10/22 (45.6%) 6/9 (66.7%)
*First six months.
CVC related CA were 30% and in 9.6% of them CVC was not removed
87% of patients received antifungal therapy and in 92% of cases
it was adequate; ﬂuconazole was most frequently employed (74.7%),
followed by caspofungin and any amphotericin B formulation (10.3%
both), voriconazole (3.4%) and itraconazole (1.2%). No azole-resistant
C. albicans was isolated, instead of 9.5% of C. parapsilosis that was
ﬂuconazole-resistant (n 2).
The 30-day crude mortality rate was 26%, 19.7% in adequately treated
population.
Conclusions: The overall annual incidence of CA was high, but stable
during the study period. Compared with a similar study conducted
between 1992–2001, it showed an increased number of CA inside
medical wards (16% vs 8%), and a signiﬁcant reduction inside ICU
(54% vs 65%). Interestingly inside surgical wards remained quite
constant (30% vs 27%), in spite of the increasing number of surgical
patients. CVC related CA decreased (30% vs 43%) instead of the widest
use of CVC. If only 12% of patients with CA received an antifungal
prophylaxis, the quite constant number of cases could be attributable to
a sort of balance between the increasing patients’ critical-status and the
improved infection control policy, particularly inside ICU.
Although the consumption of ﬂuconazole was high, C. albicans remained
the predominant species (save for the ﬁrst half of 2008), but we observed
an increasing number of C. parapsilosis resistant to ﬂuconazole
Various aspects in nosocomial infections S403
P1441 Infections and mortality of obese patients in the intensive
care unit
G. Kallitsi, M. Kompoti °, M. Michalia, M. Charitidi,
P.M. Clouva-Molyvdas (Athens, GR)
Obesity is a well-recognized risk factor of morbidity and cardiovascular
mortality. Data concerning critically ill patients are often conﬂicting.
Objective: The aim of this study was to investigate the impact of obesity
on the occurrence of infections and mortality in the intensive care unit
(ICU).
Patients-methods: All patients admitted to our general ICU were
prospectively enrolled in the study. Information recorded included:
demographics, APACHE II score at admission in the ICU, body mass
index (BMI), number of infectious episodes during ICU LOS, ICU
LOS and ICU outcome. Patients with BMI< 20, 20−24.9, 25−29.9 and
>30 kg/m2 were classiﬁed as underweight, normal weight, overweight
and obese, respectively. Data analysis was performed with logistic
regression and a statistical signiﬁcance level at p< 0.05.
Results: One hundred two patients (64 males, 38 females) were
included in the study. Age (mean±SD) was 51.1±18.5 years, BMI
29.0±5.8 kg/m2, APACHE II score 19.5±6.7. There were 3 underweight,
17 normal weight, 46 overweight and 36 obese patients. Underweight
and normal weight patients were merged into a single category (non-
obese patients). One hundred forty infectious episodes were recorded
in 63 patients. Ventilator-associated pneumonia (VAP) and bloodstream
infection (BSI) were the most common types of infection (40% and 45%
of infectious episodes, respectively). There was no signiﬁcant difference
in VAP occurrence rate or in time to VAP resolution according to
BMI category. Obese patients developed marginally more BSI episodes
compared to non-obese (2.2±0.8 vs. 1.2±0.4 BSI episodes, respectively,
p = 0.043). Crude mortality rate was 35.3% in non-obese, 31.1% in
overweight and 10.0% in obese patients (p for linear trend=0.033). In
a logistic model adjusted for age, gender and APACHE II score at
admission in the ICU, obese patients had 82% lower probability of ICU
death compared with non-obese ones (p = 0.047).
Conclusions: In our patient sample, obese patients displayed an
increased occurrence rate of BSI and a lower mortality rate compared
with non-obese patients.
P1442 Molecular typing is a cornerstone for infection control in
neonatology: a case with extended-spectrum b-lactamase
Escherichia coli and Staphylococcus aureus
S. Melin °, M. Toepfer, S. Wetterbrandt, G. Rensfeldt, S. Lofgren
(Jonkoping, SE)
Objectives: Neonatology wards are extreme environments from the
infection control perspective. When an outbreak of extended-spectrum
b-lactamase (ESBL)-producing E. coli was suspected in our neonatology
unit, isolates were characterised and follow-up cultures were obtained.
Simultaneous recovery of S. aureus of a previously recognized spa type
in other samples further catalyzed our analysis. Were these infections
sporadic or was there a general breech in hygiene practice?
Methods: Weekly and discharge rectal screening was performed on all
in-patients after two cases of infection with ESBL-producing E. coli
were identiﬁed in June 2008. Thereafter, ESBL-positive children were
screened monthly. Parents and staff at the neonatal ward were screened
and environmental samples were collected. Concurrent identiﬁcation
of S. aureus infections in two neonates prompted epidemiological
characterisation. Pulsed-ﬁeld gel electrophoresis (PFGE) and spa typing
were used to discriminate isolates of ESBL-producing E. coli and
S. aureus, respectively.
Results: A total of 118 neonates (430 samples during 6 months) were
screened for ESBL-producing E. coli. Fourteen individuals had ESBL-
producing E. coli: two infected neonates, six intestinally colonised
neonates, both parents of two colonised children, and two staff. One
E. coli type caused infection in two children and colonised the intestine
of three children and one staff member. At least four of the children had
positive cultures at three months follow-up.
Two S. aureus isolates from infected neonates were of spa type t091. No
S. aureus were found in the environment at this time. Six months earlier,
isolates of this spa type infected two neonates and were found in six of
seven S. aureus positive environmental samples.
Conclusion: Several different ESBL-producing E. coli types were
recovered in the neonatal ward, one of which spread nosocomially.
Simultaneously, there was a S. aureus type spreading, indicative of a
nosocomial transmission. Molecular characterisation helped to quickly
identify the scope of the problem with these common pathogens in this
unit and became the baseline for further infection control efforts.
P1443 Bone biopsy in guiding appropriate antimicrobial usage
in chronic osteomyelitis and improving microbiological
surveillance of chronic bone infection in orthopaedic surgery
R. Ferretto °, A. Carlotto, F. Marranconi (Schio, IT)
Objective: Appropriate antimicrobial usage is a key issue of any
antibiotic policy. Antibiotics susceptibility testing of the causative
organism(s) are mandatory in treating chronic osteomyelitis for required
protracted therapy with valuable antimicrobials for hospital environment
and risk of antibiotics misuse. The aim of the present observational study
was to enforce appropriateness of antibiotic therapy selecting the best
specimen for chronic osteomyelitis bacterial diagnosis.
Methods: From January 2004 to October 2008, retrospective review of
cultures results of intraoperative bone biopsy from 21 patients admitted
to our 462-bed general hospital, were compared with cultures from swabs
of ﬁstulae and surgical wounds taken from the same patients, 4 weeks
before intraoperative bone biopsy for surgical debridment or devices
removal. Discontinuance of any antibiotic therapy 48 hours before bone
biopsy was required. Patients with bone infection secondary to diabetic
foot, decubitus ulcers or open fractures were excluded.
Results: Bacterial isolates obtained from overall specimens were 39. We
found only 33% bacterial concordance between swab and intraoperative
bone biopsy specimens. Antibiotic therapy guided by swab specimens
antibiogram was inappropriate in 67% of patients. After cultures
results from bone biopsy antibiotic streamlining was done in 14 of
21 patients. We found from bone biopsy 5 cases of polymicrobial
infection (23%): one included B. fragilis; another patient presented
polymicrobial infection including Enterobacter spp. and E. faecium
with Van B phenotype (teicoplanin susceptible). Gram-negative rods
were isolated in 22% of patients (all from bone biopsy): bone biopsy
culture from 1 patient yielded to growth of P. aeruginosa resistant
to carbapenems and ciproﬂoxacin whereas superﬁcial swabs cultures
were misleading showing monomicrobial growth of MRSA. From bone
biopsy MRSA were isolated in 6 cases whereas from 4 of same patients
superﬁcial swabs cultures yielded to growth of MSSA.
Conclusions: Precise identiﬁcation of pathogens using correct specimen
for bacterial diagnosis, is a cornerstone of antibiotic therapy. Prescribing
ineffective antibiotic or untreating bone infection due to unrecognized
P. aeruginosa carbapenems resistant or delayed identiﬁcation of
Van B phenotype E. faecium neglecting isolation precautions, have
serious epidemiological and clinical consequences regarding spreading
antibacterial resistance and hospital costs.
P1444 Evaluation of device-associated nosocomial infection rates
in intensive care units of a university hospital in Turkey
N. Erben °, S. Nayman Alpat, E. Doyuk Kartal, I. Ozgunes, G. Usluer
(Eskisehir, TR)
Objective: To describe the incidence of device-associated nosocomial
infections in intensive care units (ICUs) of a university hospital in Turkey.
Methods:We performed a prospective nosocomial infection surveillance
in nine ICUs of a university hospital between January and December
2008. Nosocomial infections were identiﬁed using the Centers for
Disease Control and Prevention National Nosocomial Infections
Surveillance (NNIS) system deﬁnitions. Device-associated nosocomial
infection rates were calculated.
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Results: During the study, we collected data from 5937 patients
hospitalised in ICUs for a total 26577 patient days, 7622 central vascular
catheter days, 4678 mechanical ventilator days, and 18083 urinary
catheter days. The overall nosocomial infection rates were 8.08%
(480/5937) and 18.1 per 1000 patient days (480/26577). Central venous
catheter-associated blood stream infection (CA-BSI) rate was 14.69 per
1000 device days (112/7622), ventilator-associated pneumonia (VAP)
rate was 27.79 per 1000 device-days (130/4678) and symptomatic
catheter-associated urinary tract infection (CA-UTI) rate was 7.63 per
1000 device-days (138/18083). Device use and incidence densities for
speciﬁc device-associated infections concerning the types of ICUs are
shown in Table I. The most frequent pathogen from patients with
BSI was Staphylococcus aureus (15.3%) followed by coagulase-negative
Staphylococcus (CoNS) (14.4%) and Klebsiella pneumoniae (8.5%). The
most frequent pathogen from patients with VIP was Acinetobacter spp
(26.3%), followed by Staphylococcus aureus (12.9%) and P. aeruginosa
(6.1%). The most frequent pathogen from patients with CA-UTI was
Candida albicans (17.6%), followed by Escherichia coli (17%) and
Enterococcus faecium (8.8%).
Of all Staphylococcus aureus infections, 87.3% were caused by
methicillin-resistant strains. Extended-spectrum b-lactamase rates were
25/40 (62%) for K. pneumoniae, 4/7 (%57) for Klebsiella oxytoca and
(21/49) 43% for E. coli.
Conclusions: Although we found that device utilisation rates in our ICUs
were lower than those reported by the NNIS system and International
Nosocomial Infection Control Consortium (INICC), VAP and CA-BSI
rates were similar to those reported by the INICC while higher than
NNIS rates. CA-UTI rates were within acceptable limits, considering
the NNIS and INICC rates.
Table 1. Device use and incidence densities for speciﬁc device-associated infections
according to the types of ICUS
Type of ICU No. of Patient- Device utilisation Rate per 1000 device days
patients days MV CVC UC VAP CA-BSI CA-UTI
Anaesthesia 465 2689 0.41 0.47 0.67 29.73 31.45 15.57
Coronary 1161 3430 0.08 0.05 0.40 30.53 0 7.25
Medical 756 3141 0.08 0.18 0.69 0 16.33 12.87
Surgical 1554 6194 0.07 0.44 0.79 28.37 11.78 5.11
Cardiothoracic 692 1801 0.09 0.26 0.65 41.1 1.7 7.51
Respiratory 239 1866 0.38 0.13 0.95 37.97 8.03 3.40
Neurology 187 1156 0.25 0.21 0.98 17.12 8.33 15.90
Neurosurgical 450 3128 0.22 0.39 0.91 37.15 11.45 3.88
Burn 71 1089 0 0.02 0.26 0 0 3.6
Paediatric 362 2083 0.38 0.31 0.31 16.52 13.78 13.82
Total 5937 26577 0.18 0.29 0.68 27.79 14.69 7.63
ICU, intensive care unit; MV, mechanical ventilator; CVC, central vascular catheter;
UC, urinary catheter; VAP, ventilator-associated pneumonia; CA-BSI, central
venous catheter-associated blood stream infection; CA-UTI, catheter-associated
urinary tract infection.
P1445 Evaluation of the risk factors, mortality and cost of nosoco-
mial infections in intensive care units of a university hospital
H. Meric, I. Ozgunes, N. Erben °, S. Nayman Alpat, E. Doyuk Kartal,
A. Musmul, G. Usluer (Eskisehir, TR)
Objective: The aim of this study is to determine the risk factors in
nosocomial infections (NIs) in intensive care units (ICUs) and effects of
NIs on mortality and cost.
Methods: This study was performed in ICUs of a university hospital
between January and June 2007. Nosocomial infections were identiﬁed
using the CDC National Nosocomial Infections Surveillance system
deﬁnitions.
Results: The study included 520 patients (7606 patient days). A
total of 285 infections were identiﬁed in 187 patients (35.9%). The
most commonly observed nosocomial infections were hospital acquired
pneumoniae (HAP) (35.3%) (including ventilator associated pneumoniae
(VAP), 14.7%), urinary tract infections (UTI) (23.1%), blood stream
infections (BSI) (15.7%), surgical site infections (15.7%) and the
others (10.8%). Frequently isolated microorganisms were S. aureus
(22.1%), Acinetobacter spp. (18.5%), Candida spp. (14%) and E. coli
(11%). Median lenght of stay of patients with NIs and those without
NIs in ICUs were 15.17±10.24 and 7.56±4.69 days, respectively.
Extra lenght of stay of patients with NIs was found 7.6 days. In
our study there was a signiﬁcant relation between NIs and mortality
rates (P< 0.05). Mortality rates concerning the infection sites were
66/95 (69.5%) for HAPs (VAPs, 37/42 (88.1%), 28/45 (62.3%) for
BSIs and 31/66 (49.2%) for UTIs. The result of univariate analysis
showed that high APACHE II score, coma, respiratory failure, entubation,
steroids, blood transfusion, parenteral nutrition, urinary catheter,
haemodialysis, mechanical ventilation, tracheoctomy, central venous
catheter, nasogastric tube and the longer stay in ICUs were signiﬁcantly
associated with NIs (P< 0.05). Multivariate logistic regression analysis
showed that longer stay in ICUs (OR= 5.046; 95%CI, 3.325–7.657;
P< 0.001), entubation (OR= 4.177; 95%CI, 2.595–6.724; P = 0.001),
use of urinary catheter (OR= 2.591; 95%CI, 1.133–5.929; P = 0.024)
and haemodialysis (OR= 2.390; 95%CI, 1.092–5.228; P = 0.029) were
the independent risk factors. Attributable total cost for patients with NIs
was 5460 Euros, whereas it was 2452 Euros for patients without NIs.
Thus, a patient’s acquiring a NI in ICUs costs an extra 3008 Euros.
Conclusions: Longer stay in ICUs, use of urinary catheter, haemodialysis
and entubation are the independent risk factors for patients with NIs. NI
development in ICUs increases the mortality signiﬁcantly. A patient’s
acquiring a NI in ICUs costs an extra 3008 Euros.
P1446 Management of infections associated with combat-related
extremity injuries in Iraqi patients
M. Rahbar °, N. Blackwell, D. Yadegarinia, M. Mohammad Zadeh
(Tehran, IR)
Background and Objectives: Osteomyelitis is a progressive infection of
bone, that results in inﬂammatory destruction of the bone, bone necrosis,
and new bone formation and may progress to a chronic and persistent
state. Orthopedic injuries suffered by casualties during combat constitute
approximately 65% of the total percentage of injuries and are evenly
distributed between upper and lower extremities. The aim of this study
was management of infections.
This study carried out by Doctors Without Borders (MSF group) in
Imam Hosein Hospital of Mehran. This city located in Ilam province,
near the border of Iran and Iraq. During our study from April
2008 to Novamber 2008 Sixty three Iraqui patients with compact
related ostemylitits hospitalised in Imam Hosein hospital. Management
strategies of combat-related injuries primarily focus on early Surgical
debridement and stabilisation, antibiotic administration, and delayed
primary closure. Herein, we provide evidence-based recommendations
from military and civilian data to the management of combat-related
injuries of the extremity. Specimens collected and sent to Milad Hospital
of Tehran for culture and susceptibility testing. Isolated microorganisms
identiﬁed by conventional bacteriological methods and susceptibility
testing performed by disk diffusion methods as recoomonded Clinical
Laboratory Standards Institute (CLSI).
Results: From April 2008 to November 2008 Ninety-six specimens
obtained from patients hospitalised in Imam Hosein hospital of Mehren
city in border of Iran and Iraq. All specimens were sent to Milad
Hospital of Tehran. The most important isolated bacteria included:
Staphylococcus aurues (10 isolates), E. coli (7 isolates), Klebsiella
pneumoniae (5 isolates), Pseudomonas aeruginosa (4 isolates), Proteus
mirabilis (4 isolates), Moganella morgani (3 isolates) and Acintobacter
baumannii (2 isolates). All isolates of S. aureus were susceptible to
vancomycin and 30% were methicillin resistant. All isolates of E. coli
were ESBLs positive. The most effective antibiotic against ESBLs
strains were imipenem. 80% isolates of K. pneumoniae also were
ESBLs positive. The most effective antibiotic against P. aeruginosa and
Acinetobacter baumannii was colisitin.
Conclusion: Our study showed that S. aureus and E. coli were the
predominant isolates from osteomylitis and all l isolates of E. coli and
80 of K. pneumoniae were ESBLs positive.
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P1447 Long-term trends in the occurrence of adult blood stream
infection
X. Ma °, Y. Lv, M. Zhang (Beijing, CN)
Objective: Blood stream infections (BSI) are a major cause of morbidity
and mortality in developing countries. Reports have suggested that the
epidemiological proﬁle of invasive bacteria infections is changing. We
sought to determine trends in the occurrence of adult blood stream
infection at Peking University ﬁrst Hospital in north China
Methods: The medical records of all cases of BSI were manually
reviewed by the experienced infectious diseases investigator to conﬁrm
the diagnosis. Data were collected including demographic features,
underlying diseases, presence of invasive devices (central venous
catheters, urinary catheters, endotracheal tubes), and all clinical and
laboratory data pertaining to infection during 2000–2007.
Results: There were 231 cases; the mean±SD age was 59±21.3 years,
and 59% were male. Primary bacteraemia was the most common source
(48.4%), followed by respiratory tract (19.9%), urinary tract (12.6%),
and skin sources (6.0%). The most common organisms identiﬁed were
Escherichia coli (in 89 patients with BSIs [38.5%]), Staphylococcus
aureus (in 36 patients with BSIs [15.6%]) and Klebsiella pneumoniae
(in 25 patients with BSIs [10.8%]). Fungi, mainly Candida species,
accounted for 9.1%, and Streptococcus. spp. for 4.8%. Signiﬁcant
increases occurred between 2000 and 2007 in community-acquired BSI
(from 1.6 to 8.3/10000 admissions, P< 0.01) and nosocomial BSI (from
6.3 to 10.7/10000 admissions, P = 0.01). The most frequent comorbid
medical conditions were diabetes mellitus (30.2%) in community-
acquired BSI patients.
Conclusions: The community-acquired blood stream infection rate in
the hospital has sharply risen in the past 7 years, possibly partly due to
increased diabetes mellitus.
P1448 Characteristics of infections associated with external
drainage devices of cerebrospinal ﬂuid: a retrospective
analysis over 12 years
L. Walti °, J. Coward, A. Conen, A. Trampuz (Basel, CH)
Objectives: External drainages devices (EDD) are used to treat
transitory hydrocephalus. EDD infections often resemble the underlying
neurosurgical condition, mainly intracranial bleeding, and data on EDD
infections are limited. We therefore retrospectively analyzed EDD
infections in adults at our institution.
Methods: Hospitalised patients aged 18 y presenting with an EDD
infection from 01/98 through 12/08 were included. EDD infection was
diagnosed by modiﬁed CDC criteria for nosocomial infections. Hospital
charts were reviewed to retrieve demographic, clinical, and laboratory
data.
Results: 52 patients (median age 55 y, range 20−76 y, 56% males)
with EDD infections were included (46 ventricular drainages, 3 lumbar
drainages, 2 Jackson-Pratt drains and 1 Liquor guard). Common
neurosurgical conditions were subarachnoidal (n = 34), intracerebral
(n = 10) and intraventricular bleeding (n = 2). The median EDD-
indwelling time was 7 d (range 1−17 d). The reasons for EDD
removal were no further indication for draining (n = 37), dysfunction
or dislocation (n = 7), patient death and suspicion of infection (each
n = 4). Most infections (62%) manifested 3−7 d (median 5 d) after EDD
insertion, less often >7 d (27%) or <3 d (12%). In 11 patients (21%),
the EDD has been removed up to 10 d before manifestation of infection.
The causing pathogens were coagulase-negative staphylococci (n = 20),
Propionibacterium acnes (n = 4) Staphylococcus aureus (n = 3), mixed
organisms (n = 10), G+ anaerobe cocci (n = 3) and culture-negative
(n = 12). Fever >38ºC was more often present at manifestation of
infection than during EDD insertion (77% vs. 12%, p< 0.001), whereas
other clinical signs and symptoms (headache, vomiting, neck stiffness)
were not discriminative for infection. In blood, C-reactive protein was
more often elevated (>10mg/l) at manifestation of infection (88% vs.
55%., p< 0.01). In cerebrospinal ﬂuid (CSF), median leukocyte count
was higher at manifestation of infection (182 vs. 46 G/l, p< 0.05),
granulocyte count was similar (46 vs. 15 G/l, p> 0.05) and total protein
concentration was lower (1060 vs. 2316mg/l, p< 0.05) than during EDD
insertion. 8 patients (15%) died because of severe neurological disease.
Conclusions: Most EDD infections manifested 5 days after insertion
(range 0−17 d) and in 21% the infection manifested after EDD removal.
EDD infections are difﬁcult to distinguish from underlying neurosurgical
condition warranting a high index of suspicion and CSF cultures.
P1449 Comparison between multi-locus variable number of
tandem repeats and pulse ﬁeld gel electrophoresis for
typing of nosocomial Pseudomonas aeruginosa isolates
R. Vatcheva-Dobrevski °, I. Ivanov, E. Dobreva, T. Kantardjiev (Soﬁa,
BG)
Objectives: To compare the performance (discriminatory power,
typeability and reproducibility) of traditional PFGE and MLVA6 for
molecular typing of hospital P. aeruginosa isolates.
Methods: A total of 81 non-repeat clinical P. aeruginosa isolates were
included in the study collected at two university and two regional hos-
pitals during 2004–2008. All isolates were identiﬁed by conventional as
well as automated (API or VITEK II, BioMerieux, France.) identiﬁcation
systems. PFGE molecular typing was performed with SpeI according to
a standardised protocol and thiourea was added in the electrophoresis
buffer for preventing DNA degradation. Six previously described VNTR
loci were combined in the MLVA assay and the fragment analysis
was performed on a capillary electrophoresis system. Data and cluster
analysis was carried out in Bionumerics v4.5 (Applied Maths, Belgium)
The reproducibility, typeability and discriminatory power (Simpson’s
Index of Diversity − D) were evaluated and compared for the methods.
Results: Both methods were 100% reproducible whereas typeability was
99% and 97.5% for PFGE and MLVA respectively. The clustering of the
strains with the two methods was surprisingly similar with approximately
85% concordance. A total of 21 (D= 0.95) types were distinguished
by the MLVA assay versus 18 (D= 0.93) by PFGE. The genotype
distribution appeared to be non-hospital dependent. As expected, most of
the genotypes were associated with different wards at the two university
hospitals but several types were located in all hospitals. In general the two
methods performed similarly although MLVA was more discriminative.
Conclusions: Although PFGE is technically demanding and costly
it is still the referent and most often applied method for typing of
nosocomial isolates. With this study we demonstrate that a simpliﬁed
MLVA alternative could be as equally effective as PFGE but far more
rapid and cost-effective for typing P. aeruginosa.
P1450 Risk factors for hospital infections with multidrug-resistant
bacteria in patients with cancer
E. Sahin, G. Ersoz °, M. Goksu, S. Karacorlu, A. Kaya (Mersin, TR)
Objectives: Infections with multidrug-resistant (MDR) bacteria have
been linked to increases in morbidity, length of hospitalisation, healthcare
cost, and mortality. We aimed to determine the prevalence, risk factors,
and outcomes of nosocomial infection due to MDR bacteria in patients
with cancer.
Methods: Design: Retrospective observational cohort study of prospec-
tively collected data. All patients who had nosocomial infection in
patients with cancer between January 2004 to December 2008 at
the University of Mersin through searching the microbiology and the
Infection Control Surveillance records were identiﬁed retrospectivelly.
All clinical specimens were performed following standard procedures.
Biological isolates were identiﬁed with the help of API (bioMe´rieux
sa Marcy l’Etoile, France). MDR bacteria were deﬁned as methicillin-
resistant Staphylococcus aureus (MRSA), ceftazidime- or imipenem-
resistant P. aeruginosa, A. baumannii, Stenotrophomonas maltophilia,
and extending spectrum b-lactamase producing Gram negative bacilli.
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SPPS 11.5 (Chicago, IL) package program was used for statistical
analysis. Univariate statistical analysis and Multivariate logistic regres-
sion analysis were performed to determine risk factors independently
associated with the development of MDR bacteria infections. P values
of <0.05 were considered to indicate statistical signiﬁcant.
Results: A total of 219 patients with cancer were analyzed; 61% were
male, 145 (66.2%) were solid malignancies, 74 (33.8%) haematologic
malignancies, 57 (26%) were in ICU wards and the mean age was
50.51±21.13 years. Of these patients, 82 (37.4%) had nosocomial
infections due to MDR bacteria. Overall mortality was higher in patients
with MDR bacteria infections (37.8%) than patients with non-MDR
infections (21.1%) (p = 0.008).
Multivariable logistik regression analysis revealed that duration of
hospital stay (p = 0.001, OR= 1.045, CI%95 1.018–1.072), solid mali-
nancy (p = 0.029, OR= 3.961, CI%95 1.151–13.631), mechanical venti-
ation (p = 0.008, OR= 54.804, CI%95 2.858–1050.911), tracheostomy
(p = 0.044, OR= 6.276, CI%95 1.055–37.333), and broad spectrum
antibiotic use (p = 0.000, OR= 4.089, CI%95 1.912–8.744) were
independently associated risk factors for infections with MDR bacteria.
Conclusion: Among cancer patients, hospital infection caused by MDR
bacteria ocurred more frequently in patients with solid malignancy,
invaziv procedures, receiving broad spectrum antibiotic and prolonged
lenght of hospital stay.
P1451 Dimension of nosocomial infections in a burn care centre:
analysis of 7-year active surveillance
O. Oncul, E. Ulkur, A. Acar °, F. Yuksel, S. Cavuslu, L. Gorenek
(Istanbul, TR)
Objectives: To determine the trends of nosocomial infection (NI),
aetiological agents and risk factors in burned patients.
Methods: Data were collected prospectively from 456 burned patients
admitted to a Turkish Burn Care Unit (BCU) between 2001 to 2008.
A researched assistant reviewed the medical record for each patients by
active surveillance according to CDC and NNIS criteria.
Results: Among 456 burned patients, 329 cases acquired 436 NI
(11.0% pneumonia, 52.0% burn wound infection (BWI), 5.5% urinary
tract infection and 31.5% bloodstream infection) for an overall NI
rate of 25.8 per 1,000 patient-days. The mean age (42.1±9.7), the
mean hospitalisation time (46.2±14) and the mean body surface area
burned (BSAB) (37.4±11) of the patients with NI were higher than
those with non-NI (22.3±9.3), (25.8±9.1) and (16.4±4.7) (P = 0.001,
P = 0.01, P = 0.001) respectively. Of all the patients, 81 (17.8%) died.
By multiple logistic regression analysis, BSAB (odds ratio (OR: 3.5),
comorbidities (OR: 1.8), transfer from another hospital (OR: 2.7), broad
spectrum antibiotic usage (OR:2.3) and invasive devices (OR: 1.9) were
signiﬁcantly related to acquisition of NI. No difference was seen in
mortality between years, whereas panresistant Acinetobacter baumannii
and Pseudomonas aeruginosa rates increased after 2004 (P = 0.001).
P. aeruginosa (44.7%), A. baumannii (35.9%) and Staphylococcus aureus
(11.4%) were most common bacteria identiﬁed in 396 strains. The most
effective antibacterial agents for P. aeruginosa was meropenem (75%)
and, that for A. baumannii was neutromycin (93%) respectively. Thirteen
(7.3%) strains of P. aeruginosa and 16 (11.3%) strains of A. baumannii
were panresistant to all antibiotics. In S. aureus strains, 38.6% were
methicillin resistant.
Conclusions: Considering the high incidence of BWI, high mortality
rate and panresistant strains in our BCU, more strictly infection control
policies and comprehensive education campaing are required.
P1452 Use of drotrecogin alpha in a surgical septic cohort of
patients
P. Mas-Serrano, J. Navarro-Martinez °, M. Aparicio Cueva,
J.P. Ordovas Baines, R. Company Teuler (Alicante, ES)
Objectives: Drotrecogin alpha is a drug used in high risk patients with
severe sepsis and septic shock, deﬁned by an Acute Physiology and
Chronic Health Evaluation (APACHE II) score in the United States
indication more than 25 and at least 2 acute organ dysfunctions in
the European Union indication (SOFA). Drotrecogin alpha is considered
to have a broad range of effects, not only on multiple stages of the
coagulation cascade, but also as a ﬁbrinolytic agent and as an anti-
inﬂammatory agent. The main side effect is the risk of bleeding due to
the inactivation of the V and VIII coagulation factors. In both clinical
trials and “real practice” registries the proportion of surgical patients is
always small. After surgery there is a 12 hour window for the initiation
of the therapy with drotrecogin alpha, even though the risk of bleeding
continues during all the treatment.
Methods: We analyzed retrospectively all the patients (78) admitted to
the Surgical Critical Care Unit with surgery in the previous 30 days
and that were treated with drotrecogin alpha between June 2003 and
November 2008.
Results: We included 78 patients. The age was 62.41±16.9 (69.2%
male). The severity score measured by the APACHE II was 20.2±5.0
and the SOFA was 3.3±1.0 (98.7% had 2 or more organ dysfunction).
The delay from the diagnosis of the sepsis until the initiation of the
therapy was 22.4±16.5 hours. The origin of the patient was in the
51.3% nosocomial, and the surgery was emergency in the 88.5% of
the cases. The type of surgery was in the 74.4% abdominal, 5.1%
cardiac, 6.4% vascular, 3.8% thoracic and 10.3% other. The infection
site was in the 46.2 peritonitis, 29.5% pneumonia, 3.8%, mediastinitis
and 20.8 other. During the sepsis episode other coadjutants used were:
Insulin perfusion (60.3%), corticoids (38.5%) and prophylactic low
weigh heparin (78.2%). The 88% of the patients didn’t received renal
replacement. The 28 day mortality was 42.3%. We found 4/78 serious
bleeding complications (5%), two of them fatal.
Conclusion: We need speciﬁc trials in the subgroup of surgical patients,
especially nosocomial ones, due to the high mortality. The use of
different therapies to lower the mortality is e encouraged. In our cohort
the survival rate of patients treated with drotrecogin alpha was 57.7%
with a low incidence of bleeding if we apply the measures related to the
selection of patients, control of abdominal drains and coagulation times.
P1453 External ventricular drain infections
J.D. Ruiz-Mesa °, L. Valiente De Santis, I. Portales, B. Sobrino, A. Plata
Ciezar, J.M. Reguera Iglesias, J.D. Colmenero Castillo (Malaga, ES)
Objectives: The aim of this study was to determinate the incidence,
clinical features, microbiologic ﬁndings and pronostic of cerebrospinal
ﬂuid (CSF) infection during external ventricular drainage (EVD).
Methods: We carried out a descriptive study of nosocomial EVD-
associated CSF infections from January 2005 to November 2008 in
Carlos Haya Hospital, Malaga, a tertiary hospital. In January 2008 we
achieved clinical intervention for the management of EVD between
Neurosurgery and Infectious Diseases Services with the objective to
decrease the risk of infection
Results: Nineteen patients had nosocomial EVD-associated CSF
infections, with twenty three events of EVD infection, in 16 patients
(1 event); two patients (2); and one patient (3). In 2005 were 7 cases;
in 2006 (8); in 2007 (7); and in 2008 only 1 case. The incidence
of infection in 2007 was 12.5% and 2008 was 2.27%. The mean
age at the time of admission was 53.6±11.7 years (R: 31−72) and
63.2% were male. The latency of symtoms was 9.53±6.6 days (R = 2–
26). Open craniotomy was achieved in 26.1% and 73.9% closed
craniotomy, with concomitant surgery in ﬁve cases. The drains were
placed while the patient was in the emergency department in 89.5%
of the cases. Prophylactic antibiotics were prescribed in 14 patients
(63.6%). Seventeen patients (73.9%) were charged in ICU a mean time
of 16±1 days (R = 1–90), with EVD infection during the stay in 12 cases.
Fourteen patients (61%) had tracheostomy. The most frequent presenting
symptoms and signs were fever (100%), headache (56.5%), altered
mental status (52.2%), nausea and vomiting (30.4%) and meningismus
(56.5%). The infecting organisms isolated were Coagulase negative
sthaphylococcus (11), Acinetobacter b. (6), Gram negative bacilli (5),
Candida parasilopsis (1), Staph. aureus (1). Eighteen cultures were
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monomicrobial and 4 polimicrobial. The mean duration of treatment
was 29.83±17.1 days (r = 11–30), and intrathecal treatment in 16 cases.
The removal of catheter was achieved in 91.3%, followed by placement
of a new EVD in 78.3% and in 43.5% (10 patients) needed a VP-shunt.
Seventeen patients (89.5%) had a excellent response to antimicrobial
therapy, 2 patients (10.5%) had relapse and 4 patients (21.1%) had re-
infections. The attributable mortality was 10.3% (2 cases).
Conclusion: The management of these patients should be standardised
in order to reach better results and to reduce the risk infections at the
Central Nervous System, especially after neurosurgery.
P1454 Seasonal variation in the incidence of Gram-negative
bacteria in intensive care units
F. Schwab, P. Gastmeier, B. Schroeren-Boersch, E. Meyer ° (Berlin, DE)
Objective: To look for an association of temperature changes and
incidence densities of pathogens in intensive care units participating in
SARI (Surveillance of Antimicrobial Use and Antimicrobial Resistance
in Intensive Care Units).
Methods: We conducted a prospective unit based surveillance in
49 German ICUs from July 2000 to June 2008. Time-series analyses
with autoregressive integrated moving average (ARIMA) models and
dynamic regressor was used to estimate the association of the incidence
densities of pathogens with seasons and temperature (winter: January to
March, spring: April to June, summer: July to September and autumn:
October to December).
Results: 49 ITS reported data on 1,292,600 patient days (pd) and
118,490 pathogens (63,293 Gram-positves and 55,198 Gram-negatives).
Incidence densities i.e. the number of pathogens per 1000 pd of Gram-
negative pathogens showed signiﬁcant seasonal variation. They were also
associated with the temperature 1 and/or 2 months before. Incidence
densities for P. aeruginosa, E. coli and A. baumannii were signiﬁcantly
higher in autumn than in winter. Gram-positve pathogens were not
associated with season.
Conclusion Signiﬁcant higher incidence densities of Gram-negative
pathogens were observed during summer and autumn. These ﬁndings
have implications for infection control and the choice of empiric
antibiotic therapy.
Pharmacokinetics and pharmacodynamics of
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P1455 An open-label pharmacokinetic, safety and tolerability
study of single-dose intravenous ceftaroline in subjects with
end-stage renal disease on intermittent haemodialysis
T. Riccobene °, A. Jakate, D. Rank, D. Thye (Jersey City, Alameda, US)
Objectives: Ceftaroline (CPT) is a novel, parenteral, broad-spectrum
cephalosporin exhibiting bactericidal activity against Gram-positive
organisms, including methicillin-resistant Staphylococcus aureus and
multidrug-resistant Streptococcus pneumoniae, as well as many Gram-
negative pathogens. This open-label study evaluated safety, tolerability,
and pharmacokinetics (PK) of an intravenous (IV) dose of CPT in
subjects with end-stage renal disease (ESRD) on haemodialysis (HD)
and in subjects with normal renal function.
Methods: 12 adult males (6 with ESRD and 6 with normal renal
function [age, weight, and gender-matched]) received 400mg CPT via a
1 hour IV infusion. ESRD subjects received 2 doses, one dose 4 hours
before HD and one dose after HD, with at least a 7-day washout
between doses. Blood, dialysate ﬂuid, and urine (if possible from ESRD
subjects), were obtained and analyzed for concentrations of CPT using
a validated LC-MS/MS method. Adverse events (AEs) were monitored,
and physical examination ﬁndings, vital signs, clinical laboratory tests,
and electrocardiograms (ECGs) were recorded at baseline and throughout
the study.
Results: Plasma PK results in subjects with ESRD and normal renal
function are summarised in Table 1.
Table 1. CPT PK parameters (mean±SD)
Parameter ESRD Normal renal
dosed before HD dosed after HD function
Cmax (mg/mL) 17.5±3.75 29.1±8.49 16.5±3.36
AUC0−∞ (mg·h/mL) 84.1±13.8 128.5±12.5 48.5±9.2
Tmax (h) 1.01±0.03 1.0±0.0 1.03±0.04
t1/2 (h) 6.12±0.81 6.16±0.81 2.75±0.22
CL (mL/h) 4870.71±853.11 3139.87±321.89 8493.66±1550.62
AUC0−t = area under the plasma concentration vs time curve from time 0 to t;
AUC0−∞ = area under the plasma concentration vs time curve from time 0 to
inﬁnity; CL = plasma clearance; Cmax = maximum plasma drug concentration;
Tmax = time of maximum plasma drug concentration; t1/2 = terminal elimination
half-life.
The AUC of CPT was greater in subjects with ESRD dosed before or
after HD (increased by 76% and 167%, respectively) relative to subjects
with normal function. Mean recovery of CPT in dialysate during the
4 hour HD session was 76.5mg (or 21.6% of the administered dose).
Four AEs occurred in 3 subjects during the study (2 ESRD subjects,
1 subject with normal function). All AEs were considered not related
to study drug, except for muscle spasms in a subject with normal
function which was considered possibly related and occurred 6 days
after drug administration. No serious AEs, discontinuations due to AEs,
or clinically meaningful changes in laboratory parameters, ECGs, or vital
signs were observed.
Conclusions: The PK parameters of CPT were altered in ESRD subjects
relative to subjects with normal renal function resulting in greater
systemic exposure. HD removed CPT to some extent. Study data will
be used in population PK analyses and simulations to explore target
attainment (% T>MIC) for different dose regimens for subjects receiving
HD.
P1456 A new semi-physiological absorption model to assess the
pharmacodynamic proﬁle of cefuroxime axetil using non-
parametric and parametric population pharmacokinetics
J. Bulitta, S. Hu¨ttner °, C. Landersdorfer, M. Kinzig, U. Holzgrabe,
F. So¨rgel (Nuremberg-Heroldsberg, Wurzburg, DE)
Objectives: Cefuroxime axetil is widely used to treat respiratory tract
infections. This study presents a new population pharmacokinetic (PK)
model for the oral absorption of cefuroxime axetil using nonparametric
and parametric population PK methodology. To develop a semi-
physiological population PK model and evaluate the pharmacodynamic
(PD) proﬁle for cefuroxime axetil.
Methods: Twenty-four healthy volunteers received 250mg oral cefurox-
ime after a standardised breakfast. LC-MS/MS was used for drug
analysis, NONMEM and S-ADAPT (results reported) for parametric
population PK, and NPAG for nonparametric population PK modeling.
Monte Carlo simulations were used to predict the time of non-protein
bound concentration above the MIC (fT>MIC).
Results: A model with one disposition compartment, a saturable and
time-dependent drug release from stomach and fast drug absorption
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from intestine yielded precise (r> 0.992) and unbiased curve ﬁts and
an excellent predictive performance. Apparent clearance was 21.7 L/h
(19.8% CV) and volume of distribution 38.7 L (17.6%). Robust
(90%) probabilities of target attainment (PTA) were achieved by
250mg Q12 h (Q8 h) cefuroxime for MICs 0.375mg/L (0.5mg/L) for
the bacteriostasis target fT>MIC 40% and for MICs 0.094mg/L
(0.375mg/L) for the near-maximal killing target fT>MIC 65%. For
the fT>MIC 40% target, PTAs for 250mg cefuroxime Q12 h were
97.8% against S. pyogenes and penicillin-susceptible S. pneumoniae.
Cefuroxime 250mg Q12 h (Q8 h) achieved PTAs below 73% (92%)
against H. inﬂuenzae, M. catarrhalis, and penicillin-intermediate
S. pneumoniae for susceptibility data from various countries.
Conclusion:
1. Depending on the MIC distribution, 250mg oral cefuroxime Q8 h
instead of Q12 h should be considered especially for more severe
infections that require near-maximal killing by cefuroxime.
2. The proposed semi-physiological population PK model was robust
and yielded excellent curve ﬁts for the variable oral absorption of
cefuroxime axetil.
P1457 Population pharmacokinetics and optimised dosage
regimens of ceftazidime in cystic ﬁbrosis patients and
healthy volunteers
S. Hu¨ttner °, J. Bulitta, M. Kinzig, U. Holzgrabe, U. Stephan, F. So¨rgel
(Nuremberg-Heroldsberg, Wurzburg, Duisburg-Essen, DE)
Objectives: Premature mortality in patients with cystic ﬁbrosis (CF)
is predominantly (90%) caused by respiratory tract infections. Early
efﬁcacious treatment against Pseudomonas aeruginosa can postpone
chronic lung infection by this pathogen in CF-patients. The pharma-
cokinetics of ceftazidime in CF-patients has rarely been compared
to healthy volunteers in the same study. To compare the population
pharmacokinetics and pharmacodynamics of ceftazidime between CF-
patients and healthy volunteers and to identify optimal dosage regimens.
Methods: We studied eight CF-patients (total body weight:
42.9±18.4 kg, average±SD) and seven healthy volunteers (66.2±4.9 kg).
Dose: 2 g ceftazidime as 5min intravenous infusion. Ceftazidime
was determined by HPLC and NONMEM was used for population
pharmacokinetics and Monte Carlo simulation. We used a target time of
non-protein bound concentration above MIC of 65% which represents
near-maximal kill.
Results: Unscaled total clearance was 19% lower and volume of
distribution was 36% lower in CF-patients. Allometric scaling by fat-free
mass reduced the between subject variability by 32% for clearance and
by 18−26% for volume of both peripheral compartments compared to
linear scaling by WT. The standard ceftazidime dosage regimen 2 g/70 kg
WT q8 h as 30 min infusion had robust (90%) PTAs for MICs 1mg/L
in CF-patients and 3mg/L in healthy volunteers. Alternative modes of
administration achieved robust PTAs up to markedly higher MICs of
8–12mg/L in CF-patients for 5 h-infusions of 2 g/70 kg WT q8 h and
12mg/L for continuous infusion of 6 g/70 kg WT daily.
Conclusion: Prolonged ceftazidime infusion had PTA expectation values
between 74% and 94% in CF-patients against P. aeruginosa based on
susceptibility data from ﬁve European CF-clinics.
P1458 Estimation of MIC breakpoints for various intravenous
dosage regimens of mecillinam
K.S. Jensen °, A.S. Henriksen, N. Frimodt-Møller (Copenhagen,
Ballerup, DK)
Objectives: Mecillinam (i.v.) is used in Denmark for treatment of
complicated, even bacteraemic, urinary tract infections (UTI). Apart
from being highly active against E. coli with MIC values of 0.125–
0.5mg/l, it also retains activity against b-lactamase producing, even
many ESBL-producing, E. coli, where the MIC has increased to
1−2mg/l. Recently, the dose vial has been changed to 1000mg. We
therefore wanted to analyze a number of dosage regimens related to the
new vial size with respect to relevant MIC levels including ESBL.
Methods: Data for mecillinam concentrations after intravenous bolus
injection of a 400, 800, and 1200mg dose, respectively, in healthy
volunteers were on ﬁle at LEO Pharma. 11 measurements of serum
concentration within 8 hours from the injection were recorded in
6 individuals for the 800mg as well as the 1200mg dose. For the 400mg
dose, 9 measurements within 6 hours were recorded in 9 individuals.
The NPAG program was used to ﬁt a linear two-compartment model to
each of the three data sets. Monte Carlo simulations of various dosage
regimens were then made with the compartment model, and results
were obtained on MIC breakpoints with respect to a Time>MIC of 40
and 50%, respectively, for several values of the probability of target
attainment (PTA = 50, 90, 95%). The free fraction of mecillinam in
serum was assumed to be 0.9.
Results: After the parameter estimation process, the compartment model
was able to reproduce the measured serum concentrations with good
precision. Using the population PK parameter distributions derived
from data on the 800 and 1200mg dose, we simulated the mecillinam
concentration in serum when receiving a 1000mg dose TID. For a target
Time>MIC of 40% (PTA=95%), the calculated MIC breakpoint was
2.0mg/l. Based on the PK parameter values obtained from the data on
a 400mg dose, another dosage regimen, 500mg QID, was simulated for
which a MIC breakpoint of 1.15mg/l was found (for a Time>MIC of
40%, PTA=95%).
Conclusion: According to the simulation results, a dose of 500mg
QID i.v. would sufﬁce for UTI caused by non-ESBL producing E. coli.
For ESBL-producing E. coli, if clinical data allow, the dose should be
increased to 1000mg TID. The high dose is still manageable since
mecillinam has low toxicity; a total dose of 60mg/kg is tolerated in
mature humans. The results suggest that a clinical breakpoint of 1mg/l
should be recommended for mecillinam.
P1459 Killing kinetics of cefditoren against recent isolates of
Streptococcus pneumoniae in Greece
D. Hatzaki °, G. Poulakou, M. Souli, J. Katsarolis, N. Lambri,
Z. Chryssouli, K. Kanellakopoulou, H. Giamarellou (Athens, GR)
Objectives: To evaluate the killing kinetic of cefditoren, an oral
3rd generation cephalosporin, against recently isolated Streptococcus
pneumoniae strains in Greece.
Methods: A total of 262 S. pneumoniae strains isolated from invasive
and non-invasive infections of adults and children, as well as from
nasopharyngeal swabs of preschool healthy children were tested against
cefditoren (CFD) by agar dilution. CLSI 2007 methodology was used.
Strains with CFD MIC  2mg/L were considered as non-susceptible,
according to recent literature. The killing kinetic proﬁle of CFD
was explored with killing curves for 20 isolates of S. pneumoniae
(19 susceptible, 1 non-susceptible, with MICs at 0.125, 0.25, 0.5, 1 and
4mg/L) using concentrations of 1×, 2× and 4× MIC and within 0 h,
2 h, 4 h, 6 h, 8 h, 10 h, 12 h and 24 h of incubation.
Results: Against the studied isolates, CFD MIC50/90 were 0.03/1mg/L
(range 0.008–4mg/L). Only 1/262 tested strains (0.4%) exhibited
resistance to CFD (MIC= 4mg/L). Killing curves showed that the
bactericidal end point (3 log10 reduction) was reached for 1×MIC
concentration within 8 h for 2 strains and within 10 h for 2 strains. For
2×MIC killing was observed within 6 h for 3 strains, within 8 h for
15 strains and within 10 h for 2 strains. For 4×MIC killing was observed
within 6 h for 11 strains and within 8 h for 9 strains. Taking into account
the average Cmax attained after a single dose of CFD 200mg in fasted
and after fat meal conditions (1.8±0.6 and 3.1±1mg/L, respectively)
and after a single 400mg dose following fat meal (4.4±0.9mg/L) a rapid
killing effect is anticipated against strains with MIC< 1mg/L in fasted
condition, whereas for strains with MIC 1mg/L, dosing of 400mg
following a fat meal might be required.
Conclusion: CFD displayed rapid killing (within 10 h) for 1×
and 2×MIC concentrations which represented clinically attainable
pharmacokinetic targets. CFD could be a useful addition in our
community, with favourable resistance proﬁle and killing kinetics.
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P1460 Cefuroxime prophylaxis for elective orthopaedic surgery
and limits for use of standard dosing
J.D. Knudsen °, U. Urionabarrenetxea, C. Jensen, B. Kristensen,
J. Mouton (Hvidovre, DK; Nijmegen, NL)
Background: Cefuroxime is widely used for orthopaedic surgery
prophylaxis, mainly with the aim of protecting against the methicillin
susceptible S. aureus, MSSA. A standard dose of 1.5 g is often given
together with the anaesthesia, app. 30 min before the surgical procedure
starts in-depended of patient age, gender, weight or body-mass index
(BMI).
With the aim of evaluating the effectiveness of this used prophylaxis, 2−4
serum samples from patients were taken during the surgical procedures.
Materials and Methods: Serum samples from 77 patients were
evaluated for cefuroxime level by HPLC. In total, 40 female and 37 male,
all admitted for elective orthopaedic procedures, and otherwise healthy.
All patients gave their written permission together with their data on
gender, age, height and weight. From the measured serum concentrations,
the values for max concentration, C(0), the volume of distribution, Vd,
and the serum half-life, t1/2, were calculated. From these actual values
for the groups of females and males, the pharmacodynamic parameter of
importance for cephalosporins, the T>MIC, were calculated for bacteria
as MSSA.
Results: The median (range) for female/male: Age in years: 66 (25–
86)/54 (22–76); weight in kg: 70 (45–131)/86 (60–120); and BMI in
kg/m2: 26 (17–44)/29 (21–35).
The calculated values (95% c.i.) for female/male were: Vd in L: 17 (14–
19)/19 (17–22); C(0) in mg/L: 114 (94–134)/102 (75–130)/; t1/2 in min:
88 (63–112)/81 (63–98).
Signiﬁcantly correlations were found between weight and Vd (p = 0.01),
and BMI and Vd (p< 0.01) and a tendency to an inverse correlation
between BMI and C(0) (p = 0.05), for the pooled population.
The parameter T>MIC for these patients, with a goal of being 240 min
above a MIC of 4mg/L (equal to MSSA and T>MIC for 50% of t.i.d.
dosing) was only achieved, if males were less than 110 kg, and with a
BMI< 33 kg/m2, but for all our female patients.
Conclusion: For patients with BMI above 33 kg/m2 and weighting more
than 110 kg the cefuroxime dose for orthopaedic prophylaxis may be
insufﬁcient.
P1461 Pharmacodynamically-linked variable for the combination
of ceftaroline plus Novexel104
G. Drusano °, M. Castanheira, W. Liu, B. van Scoy, G. Williams,
I. Critchley, T. Riccobene, D. Thye, R. Jones, A. Louie (Albany, North
Liberty, Alameda, US)
Objectives: To evaluate the optimal administration schedule of
the broad-spectrum b-lactamase inhibitor Novexel104 (NXL104) in
combination with the MRSA- and Gram-negative-active drug ceftaroline
(CPT) against a strain of K. pneumoniae carrying KPC-2 in high copy
number plus TEM-1 and SHV-27 enzymes.
Methods: We employed our hollow ﬁber infection model (HFIM). CPT
was administered as 600mg Q8 h in all experiments. We conducted 3
experiments. Two were dose ranging (DR) with NXL104 administered
at different dose levels in continuous infusion (CI). The third was a
fractionation experiment in which the same daily AUC of NXL104 was
administered as a CI, on Q24 h, Q12 h, and Q8 h schedules. Samples
were taken for pharmacokinetics and for total and resistant organism
counts. Resistant organisms were quantitated on plates containing 4mg/L
NXL104 plus 3×baseline MIC of CPT (MIC with 4mg/L of NXL104).
MIC values were determined by CLSI methods. CPT and NXL104 were
measured in Mueller-Hinton II broth (medium of HF experiments) by
LC/MS/MS. Target organism density was 3×107. All experiments were
carried out for  10 days.
Results: The MIC for CPT in the presence of 4mg/L of NXL 104
was 0.75/4mg/L. For CPT and NXL104 alone, MIC values were 1024
and >64mg/L, respectively. The ﬁrst DR experiment examined CI
concentrations of NXL104 from 2 through 8mg/L. NXL104 at 2 and
4mg/L allowed emergence of resistance after 1 and 6 days, respectively.
Six mg/L had resistance failure at the very end (day 10). Eight mg/L had
no resistance and provided multi-log cell kill for the whole 10 days. In
the second DR experiment, 6mg/L did not have resistance emergence,
along with higher concentrations (8, 10, 12mg/L). Microbiological effect
was optimal at 10−12mg/L. In the third experiment, we fractionated the
exposure for 8mg/L (8mg/L CI = AUC 192mg*h/L; AUC 192 once;
AUC 96 Q12 h; AUC 64 Q8 h). Q24 administration failed with resistance
at day 3. All others suppressed resistance. Microbiological effect was
optimal for 8 hourly and continuous infusion. In all experiments, CPT
alone demonstrated no microbiological activity against this strain.
Conclusion: Resistance suppression for NXL104 administration in the
background of CPT 600mg 8 hourly is linked to Time>Threshold. The
linkage for effect is, therefore, the same for both the b-lactam and the
b-lactamase inhibitor, implying that they can be administered together
on the same schedule.
P1462 A pharmacodynamic approach of the antibacterial effect of
different b-lactams against mixed inocula of Haemophilus
inﬂuenzae strains and selection of resistant populations
N. Gonzalez, L. Aguilar, L. Alou, M.J. Gimenez °, D. Sevillano,
M. Torrico, F. Caﬁni, P. Coronel, J. Prieto (Madrid, ES)
Objectives: To explore pharmacodynamic activities of cefditoren
(CDN), amoxicillin/clavulanic acid (AMC) and cefuroxime (CXM)
against an Haemophilus inﬂuenzae multibacterial niche, as an approach
to effects of antibiotics on multiple carriage of H. inﬂuenzae strains in
the nasopharynx.
Methods: Isolates (MICs – mg/l – of CDN, CXM and AMC) used
were: One b-lactamase negative (Bneg; 0.015, 1, and 1), one b-lactamase
positive (B+; 0.03, 4 and 8), and two strains exhibiting ftsI gene
mutations [one b-lactamase negative (BLNAR; 0.015, 8, and 4), one
positive (BLPACR; 0.03, 8 and 4)]. A computerised two-compartment
pharmacodynamic model (avoiding the dilution of the bacterial inoculum
together with the drug along time) was used. Serum free concentrations
of antibiotics (A) along 24 h, obtained with 400mg bid CDN, 500mg
bid CXM and 875/125mg tid AMC dosing regimens, were simulated
in HTM to explore antibacterial activity against initial mixed inocula
(4×106 cfu/ml) including 25% of each strain (106 cfu/ml per strain).
Antibiotic-free simulations were used as control (K). Samples for
measurement of antibiotic concentrations and colony counts (for the
Total population and for each strain) were taken at 0, 2, 4, 6, 8, 10,
12 and 24 h. Areas under killing curves 0−24 h (AUKC; log cfu·h/ml)
were calculated. The antibacterial effect over 24 h was measured as the
difference between AUKC values in antibiotic-free (AUKC-K) and in
antibiotic simulations (AUKC-A): AUKC-K−AUKC-A.
Results: In antibiotic-free simulations, mean AUKC-K (log10 cfu·h/ml)
was 150 for the total population, 148 for Bneg, 124 for B+, 108 for
BLNAR and 142 for BLPACR strains.
Conclusion: The antibacterial effect (AUKC-K−AUKC-A) was sig-
niﬁcantly higher (p< 0.01) for CDN than for CXM or AMC whether
considering Total population, B+, BLNAR or BLPACR strains. CDN at
least doubled the antibacterial effect of CXM and AMC against the Total
population and those subpopulations exhibiting mutations in the ftsI gene
(only CDN exhibited activity against the BLPACR subpopulation).
Antibacterial effect: AUKC-K−AUKC-A
Total Bneg Bpos BLNAR BLPACR
CDN 70.4±8.8 133.6±7.1 77.8±3.0 66.1±3.7 40.8±7.1
CXM 31.1±2.1a 120.3±2.2 53.2±1.3a 18.6±3.2a −2.8±2.0a
AMC 34.3±1.5a 84.4±1.3a,b 50.1±1.0a 30.4±2.5a,b 1.1±1.6a
aSigniﬁcant (p< 0.01) difference vs. CDN.
bSigniﬁcant (p< 0.01) difference AMC vs. CXM.
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P1463 Use of the hollow ﬁbre infection model in the pharmaco-
dynamic evaluation of the b-lactamase inhibitor NXL104
P. Levasseur °, A.M. Girard, L. Lavallade, H. Merdjan, M.H. Quernin,
G. Drusano (Romainville, FR; Albany, US)
Objective: NXL104 is a novel b-lactamase inhibitor undergoing Phase
II clinical evaluation in combination with ceftazidime (CAZ). CAZ
pharmacodynamics (PD) are Time>MIC dependent, but little is known
about the relationship of pharmacokinetics (PK)/PD for the combination.
The aim of the study was to determine the importance of NXL104 PK
on the PD of CAZ+NXL104 combinations.
Methods: Exponentially growing Enterobacter cloacae 293HT96 (Ecl)
(AmpC), Klebsiella pneumoniae (Kpn) Tunisie C4 (CTX-M-15), Kpn
181 and Kpn 236 (SHV-5, TEM-10) were exposed to various dosing
regimens of the combination in a hollow-ﬁber infection model:
(1) CAZ+NXL104 continuous infusion; and (2) CAZ+NXL104 human-
like proﬁle (mimicking a biexponential proﬁle following a single 30min
intravenous infusion in humans). CAZ was held constant at 16mg/L
throughout the assay. NXL104 was added so as to have the same total
exposure in both regimens, but with different concentration-time curves.
Samples were taken at different time points for determination of viable
bacterial count and CAZ and NXL104 concentrations.
Results: The combination CAZ+NXL104 was rapidly cidal against Ecl,
Kpn C4, Kpn 181 and Kpn 236, reducing the bacterial count by 3 log10
within 4 h. Growth of the four strains was fully suppressed throughout
the test period following the continuous infusion regimen while the anti-
bacterial effect of the combination was lost when the concentration of
NXL104 fell below a critical level as seen after exposure to the human-
like proﬁle. Neither CAZ nor NXL104, alone, suppressed the growth of
bacteria.
Conclusions: Findings qualitatively support maintenance of a critical
NXL104 concentration as one of the important PD factors for the
CAZ+NXL104 combination under these experimental conditions. This
critical concentration of inhibitor is necessary to sufﬁciently suppress
b-lactamase activity.
P1464 Activity of moxiﬂoxacin, ceftriaxone and
amoxicillin/clavulanic acid against methicillin-susceptible
Staphylococcus aureus in an in vitro hollow ﬁbre model
M. Glenschek-Sieberth °, I. Knezevic, G. Weskott, R. Endermann
(Wuppertal, DE)
Objective: Methicillin-susceptible Staphylococcus aureus (MSSA) is
frequently involved in skin and skin structure infections (SSSIs).
Moxiﬂoxacin (MXF), ceftriaxone (CRO) and amoxicillin/clavulanic
acid (AMX/CLA) have been approved for this indication. This study
compares the bactericidal activities of MXF, CRO and AMX/CLA
against a clinical MSSA isolate in a hollow ﬁbre (HF) pharmacoki-
netic/pharmacodynamic (PK/PD) model.
Methods: MICs were determined by the broth microdilution method
according to CLSI guidelines. A recent clinical isolate, MSSA strain HF
1012717, was exposed to MXF (400mg q.d.: Cmax 2.0mg/L, T1/2 12 h;
MIC= 0.03mg/L), CRO (2000mg q.d.: Cmax 25.7mg/L, T1/2 7.5 h;
MIC= 4mg/L) and AMX/CLA (1125mg b.i.d.: Cmax 13.5/1.7mg/L,
T1/2 1.3 h; MIC= 2mg/L) in the PK/PD model. These concentrations
are equivalent to human free drug serum pharmacokinetics. For the
PK/PD model, an initial inoculum of 108CFU/mL was applied and
all experiments were performed, in triplicate, over 24 h. Antimicrobial
concentrations were determined by bioassay. Antimicrobial effect was
measured as the time to achieve a 3-log10 unit reduction (bactericidal
kill) and the log10 unit reduction in viable counts per mL after 24 h.
Results: MXF achieved a 3-log10 unit kill at 1.5−2.5 h. When CRO
and AMX/CLA pharmacokinetics were simulated, a 3-log10 unit kill
was seen at 7.5−8.5 h. After 24 h, the MXF regimen led to a reduction
of about 5.2 log10 units whereas the CRO and AMX/CLA regimens
resulted in reductions of 3.4 log10 units and 3.0 log10 units, respectively.
After 24 h, neither signiﬁcant re-growth nor elevation in the MICs of the
isolated colonies had occurred under any regimen.
Conclusions: Simulated human pharmacokinetics of MXF, CRO and
AMX/CLA showed bactericidal activity against an MSSA isolate when
tested in an HF PK/PD model. MXF was signiﬁcantly more effective than
CRO and AMX/CLA with regard to time to a 3-log10 unit reduction in
bacterial counts and total bactericidal activity after 24 h.
P1465 Pharmacokinetics of ertapenem in critically ill patients
with acute renal failure undergoing extended daily dialysis
O. Burkhardt °, C. Hafer, V. Kaever, H. Haller, T. Welte, J.T. Kielstein
(Hanover, DE)
Objective: Extended daily dialysis (EDD) is an increasingly popular
mode of renal replacement therapy in the ICU (intensive care unit)
as it combines the advantages of intermittent haemodialysis (IHD)
and continuous renal replacement therapy (CRRT), i.e. excellent
detoxiﬁcation accompanied by cardiovascular tolerability. The aim of this
study was to evaluate pharmacokinetics (PK) of ertapenem, the newest
carbapenem with once-daily dosing, in critically ill patients with anuric
acute renal failure (ARF) undergoing EDD.
Methods: In a single-centre, prospective, open-label study six ICU
patients with ARF undergoing EDD were treated with 1 g ertapenem
given as a single intravenous dose. EDD was performed using a high-
ﬂux dialyzer (polysulphone, 1.3m2). Blood and dialysate ﬂow were
160mL/min, and the length of treatment was 480min. Plasma samples
were collected at different time-points up to 24 h after medication. Drug
concentrations were determined by a validated LC-MS method. Free drug
concentrations were estimated using a two-class binding site equation.
Results: After a single dose of 1000mg free ertapenem, protein-unbound
plasma concentrations exceeded a MIC90 value of 2mg/L for >20 h after
dosing. The clearance of the tested dialyzer was 38.5±14.2mL/min.
Conclusions: In contrast to patients undergoing regular IHD, in which
a dose reduction is required, our data suggest that in patients treated
with EDD a standard dose of ertapenem (1 g/day), i.e. dose for patients
without renal failure, is required to maintain adequate plasma drug levels.
P1466 Increased glomerular ﬁltration rate associated with low
imipenem blood concentrations in febrile neutropenic
cancer patients
F. Lamoth °, T. Buclin, A. Pascual, L.A. Decosterd, T. Calandra,
O. Marchetti (Lausanne, CH)
Objectives: Imipenem (IMP) is a standard therapy in febrile neutropenia.
For optimal efﬁcacy in this life-threatening condition, IMP blood con-
centrations are expected to exceed the minimal inhibitory concentration
(MIC) of the causal pathogen throughout the dosing interval. The
renal mode of elimination of IMP requires a dose adjustment to the
glomerular ﬁltration rate (GFR). Modiﬁed pharmacokinetic parameters
including GFR variations may inﬂuence IMP blood concentrations
in febrile neutropenic patients. This study aimed at evaluating the
relationship between GFR, IMP doses and blood concentrations in febrile
neutropenia.
Methods: IMP therapy courses in febrile neutropenic patients were
retrospectively studied. The renal function was evaluated by the
calculated GFR (Cockroft-Gault). Trough blood concentrations (HPLC)
were interpreted as low if <MIC or MIC90 of the most common bacteria
in febrile neutropenia (1mg/L, EUCAST data). The IMP dose adjustment
to the renal function was evaluated by the daily dose per 100mL/min
GFR (2 to 4 g/d per 100mL/min GFR are recommended in febrile
neutropenia).
Results: 50 febrile neutropenic episodes were studied (18 microbi-
ologically and 20 clinically documented infections, 12 FUO). The
median GFR was 82mL/min (range: 31–230). Median IMP blood
trough concentrations measured at a median of 2 days (1−9) after
start of therapy were 0.8mg/L (0.1–5). IMP daily dose adjusted
to GFR and trough concentrations displayed a linear correlation
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(Spearman’s coefﬁcient 0.76, p< 0.001). IMP trough concentrations were
interpreted as low in 24/50 (48%) patients. IMP daily doses and blood
concentrations according to the GFR are summarised in the Table. IMP
low concentrations were more frequent in patients receiving a daily
dose per 100ml/min GFR <2 g/day when compared with those receiving
2−2.9 or 3 g/day (83, 48 and 0%, respectively, p< 0.001).
Conclusion: Increased glomerular ﬁltration rate is frequently observed in
febrile neutropenic patients and is associated with insufﬁcient imipenem
doses resulting in low blood concentrations. Upfront imipenem dose
adjustment to renal function is crucial for optimising antibacterial drug
exposure.
Table
Renal function
GFR* <70ml/min
(n = 13)
GFR* 70−100ml/min
(n = 22)
GFR* >100ml/min
(n = 15)
Median IMP dose [g/d] 2 (0.75–2) 2 (2−4) 2 (2−3)
Median IMP dose [g/d] per 100ml/min GFR 3.3 (2.2–4.5) 2.6 (2.1–4.8) 1.7 (1−2.3)
Median IMP trough [mg/L] 1.5 (0.7–5) 0.6 (0.2–4) 0.3 (0.1–1.2)
Low IMP concentrations (trough<MIC/MIC90) 1 (8%) 9 (41%) 11 (73%)
*GFR = Calculated glomerular ﬁltration rate (Cockroft–Gault formula).
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P1467 Multiplex PCR for detection of plasmid-mediated quinolone
resistance genes in Enterobacteriaceae consecutively isolated
from blood cultures
M.E. Cano °, J. Calvo, J. Agu¨ero, L. Martı´nez-Martı´nez (Santander, ES)
Objectives: Plasmid-mediated quinolone resistance (PMQR) caused
by qnr, qepA and/or aac(6′)-Ib-cr genes have often been investigated
in enterobacteria with concrete resistance phenotypes or in particular
species. In this study, the presence of PMQR genes in enterobacteria
consecutively isolated from blood cultures was evaluated using a
multiplex PCR.
Methods: Three hundred and forty-two Enterobacteriaceae (1/patient)
consecutively isolated from blood cultures (January 2007-March 2008)
were studied. Identiﬁcation and susceptibility testing were performed
with the MicroScan WalkAway system (Dade Behring). Isolates
containing PMQR genes were typed by REP-PCR and the MICs of
nalidixic acid (NAL), ciproﬂoxacin (CIP) and levoﬂoxacin (LEV) against
them were determined by Etest. qnrA, qnrB, qnrS, qepA and aac(6′)-Ib
were detected by a multiplex PCR (degenerated primers for amplifying
20 qnrB variants were used). Positive reactions were conﬁrmed by
sequencing (both strands) of amplicons obtained with other primers
amplifying the entire, or almost entire, gene.
Results: We tested 180 E. coli, 44 K. pneumoniae, 31 E. cloacae,
24 S. marcescens, 17 P. mirabilis, 13 K. oxytoca, 10 C. freundii, 8
E. aerogenes and 15 other species. The multiplex PCR correctly detected
PMQR genes of positive controls, individually and in all possible
combinations. PMQR genes were overall detected in 24 (7%) isolates.
qnrB, qnrS and aac(6′)-Ib-cr were detected in ﬁve (1.5%), 13 (3.8%) and
seven (2%) isolates, respectively. One E. coli contained both qnrS1 and
aac(6′)-Ib-cr. No isolates carried qnrA or qepA. Four of 5 qnrB were new
alleles detected in 4 clonally unrelated C. freundii; the remaining case
corresponded to qnrB1 in an E. cloacae. qnrS genes corresponded to 12
qnrS1 (3 in 3 clones of E. coli, 8 in 3 clones of E. cloacae, 1 isolate
of K. pneumoniae) and 1 qnrS2 (in a K. pneumoniae strain clonally
unrelated to the qnrS1-positive strain). aac(6′)-Ib-cr was detected in 6
E. coli (4 clones) and 1 E. aerogenes. In the 24 isolates with PMQR
genes, resistance (CLSI breakpoints) to NAL, CIP and LEV were 75%,
46% and 42%, respectively.
Conclusion: PMQR genes were successfully detected with the multiplex
PCR developed in this study. qnrS variants were the more common
PMQR genes detected, followed by aac(6′)-Ib-cr and qnrB alleles. A
signiﬁcant proportion of strains with these genes are susceptible to both
nalidixic acid and ﬂuoroquinolones.
P1468 Novel plasmid mediated quinolone resistance determinant
(Qnr-B21) identiﬁed in E. coli isolated from hospital efﬂuent
S. Galvin °, F. Boyle, D. Morris, M. Cormican (Galway, IE)
Objectives: The quinolone group are an important class of broad-
spectrum antimicrobial agents. Plasmid mediated quinolone resistance
(PMQR) determinants have emerged as a signiﬁcant concern in recent
years. The role the environment plays in the dissemination, maintenance
and ampliﬁcation of antimicrobial resistance is an area of increased
interest. This study reports screening of E. coli isolates resistant to
multiple antimicrobial agents for PMQR determinants and detection of
a novel QnrB variant.
Methods: Multi-antimicrobial-resistant E. coli were isolated from
hospital efﬂuent between March 2006 to June 2007. Antimicrobial
susceptibility to 16 antimicrobial agents including nalidixic acid and
ciproﬂoxacin were determined by Clinical Laboratory Standards Institute
(CLSI) disk diffusion methods and ciproﬂoxacin MIC was determined
by Etest. Forty three isolates representative of different locations and
dates of sampling were screened for the presence of qnrA, qnrB and qnrS
using a multiplex PCR assay as previously described. Appropriate control
strains were used. Amplicons were sequenced using primers speciﬁc to
the full coding region of the gene.
Results: One (2%) isolate was positive for qnrB and sequencing
revealed it as a novel variant of QnrB differing from the derived
amino acid sequence of QnrB8 by a single substitution Asp198Ser and
has been provisionally designated QnrB21. This isolate was resistant
to ampicillin, nalidixic acid, cefoxitin, trimethoprim, cefpodoxime,
cefpodoxime/clavulanic acid, intermediate to tetracycline, cefotaxime.
Conclusion: We describe a novel QnrB variant in a nalidixic acid-
resistant but ciproﬂoxacin susceptible E. coli isolate from hospital
efﬂuent. Further studies to evaluate the association between the novel
QnrB variant and the observed phenotype are under way.
P1469 Plasmid-mediated quinolone resistance in Salmonella
isolates from different sources of Portugal
P. Antunes °, R. Matias, L. Peixe (Porto, PT)
Objectives: Plasmid-mediated quinolone resistance is emerging world-
wide in Enterobacteriaceae, including Salmonella. Given the importance
of ﬂuoroquinolones in therapeutics, we evaluated the incidence of qnr
genes and characterised their associated plasmids among a collection
of nontyphoidal Salmonella isolates with decreased susceptibility to
ciproﬂoxacin (CipR) obtained from different sources in Portugal.
Methods: We studied all CipR isolates (n = 300; MIC 0.25–1mg/L)
obtained from a collection of 1511 Portuguese Salmonella isolates
(2002–2004). They were identiﬁed in human clinical sources (n = 214),
food products (n = 82), predominantly poultry (n = 53), and environment
(n = 4). Antibiotic susceptibility was determined for streptomycin,
kanamycin, gentamicin, ampicillin, nalidixic acid, ciproﬂoxacin, chlo-
ramphenicol, tetracycline, sulfamethoxazole and trimethoprim, by the
agar dilution method (CLSI). Qnr resistance genes (qnrA, qnrB and qnrS)
were sought by PCR according to Cattoir’s method and conﬁrmed by
sequencing. Plasmid analysis included conjugation assays, determination
of size (S1-PFGE) and content (incompatibility groups by rep-PCR
typing method, hybridisation and sequencing). Location of qnr and intI1
genes was done by hybridisation of I-CeuI/S1-PFGE.
Results: Twenty per cent of the isolates of our collection exhibited
CipR, being the serotype Enteritidis, isolated from humans and poultry
products, the main contributor to this phenotype. None of the isolates
was found to be positive for qnrA or qnrB. The qnrS1 gene was detected
in a single clinical isolate of the serotype Enteritdis from 2003, which
was susceptible to all antimicrobial agents, except ciproﬂoxacin (1mg/L),
nalidixic acid (32mg/L) and trimethoprim (>16mg/L). We identiﬁed a
conjugative IncN plasmid of ca.30Kb carrying the qnrS1 gene and the
intI1 gene. Remarkably, this isolate also harboured a non-conjugative
plasmid (50Kb) of the FIIA type which is a common replicon found
among Salmonella virulence plasmids.
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Conclusion: We ﬁrstly describe the qnrS1 gene on an IncN plasmid of a
Salmonella Enteritidis strain, a serotype commonly implicated in human
infections. Despite the presence of this gene on a conjugative plasmid,
a low prevalence of qnr genes was observed in Portugal.
P1470 Dissemination of a small ColE1-like plasmid harbouring
qnrB19 among commensal Escherichia coli, Bolivia
L. Pallecchi °, E. Riccobono, A. Mantella, S. Sennati, F. Bartalesi,
G. Lentini, C. Trigoso, A. Bartoloni, G.M. Rossolini (Siena, Florence,
IT; La Paz, BO)
Background: In 2005, qnrB19 was detected in three clonally unrelated
Escherichia coli isolates from the commensal microbiota of healthy
children living in two urban areas of Bolivia. Here we investigated the
qnrB19-harbouring plasmids from those isolates.
Methods: Electroporation was used for plasmid transfer in E. coli
HB101. Susceptibility tests were performed by the microdilution method,
as recommended by CLSI. Plasmid analysis was carried out by RFLP
(Restriction Fragments Length Polymorphism), PCR replicon typing
(Carattoli et al.), and sequence analysis.
Results: The three qnrB19-harbouring plasmids were transferred in
E. coli HB101 using nalidixic acid 8mg/ml for selection of transformants.
All plasmids showed the same RFLP pattern after digestion with SacII
or HindIII or EcoRI, and an estimated size of 3.0 Kb. Replicon types
could not be identiﬁed using the PCR method. Sequence analysis of
the qnrB19-harbouring plasmids showed that qnrB19 was located on
ColE1-like plasmids. The genetic regions ﬂanking qnrB19 showed 100%
homology with those reported in the qnrB19-harbouring transposons
Tn5387 from USA (244 bp upstream and 225 bp downstream) and
Tn1721 from Colombia (155 bp upstream and 225 bp downstream).
However, neither ISEcp1 nor other putative transposases were identiﬁed
in the qnrB19-harbouring plasmids from Bolivia.
Conclusions: We observed the dissemination of a small qnrB19-
harbouring ColE1-like plasmid among commensal E. coli from healthy
children living in Bolivia. The genetic environment of qnrB19 was found
to be different from that of the previously described qnrB19 genes.
P1471 Prevalence of qnr genes in nalidixic acid resistant,
ciproﬂoxacin sensitive Escherichia coli and Klebsiella
pneumoniae clinical isolates from a university general
hospital, Athens, Greece
N. Mitchell, I. Galani, M. Souli, H. Giamarellou ° (Athens, GR)
Objectives: To determine the prevalence of plasmid-mediated quinolone
resistance (qnr) genes in nalidixic acid resistant (NR), ciproﬂoxacin
sensitive (CS) E. coli and K. pneumoniae clinical isolates.
Methods: During a ﬁve month period (Febuary to June 2008) 231 E. coli
and 231 K. pneumoniae isolates were collected from separate inpatients
and outpatients of the Attikon University General Hospital. Of these sam-
ples, 13 E. coli and 11 K. pneumoniae isolates had the above phenotype.
Ciproﬂoxacin MIC values ranged from  0.125 to 1mg/L for the E. coli
isolates and 0.125 to 0.5mg/L for the K. pneumoniae isolates. Isolates
were screened for the presence of genes qnrA, qnrB and qnrS by multi-
plex PCR, using universal primers for each gene amplifying all related
alleles. The qnr positive isolates were conﬁrmed by genomic sequencing.
The qnr positive isolates were additionally tested for extended-spectrum
b-lactamases (ESBL) and metallo-b-lactamases (MBL).
Results: One E. coli (1/13, 7.7%) was positive for qnrB and one
K. pneumoniae (1/11, 9.1%) was positive for qnrA. No isolates from
those collected were positive for qnrS. Both the qnrA positive and the
qnrB positive isolates were ESBL negative, MBL positive, carrying the
blaVIM-1 gene.
Conclusions: This is the ﬁrst report of a qnrA positive K. pneumoniae
and qnrB positive E. coli with concurrent blaVIM-1 genes. Among NR,
CS E. coli and K. pneumoniae clinical isolates collected during this ﬁve
month time period, the qnr gene prevalence rate detected was 7.7% and
9.1% respectively.
P1472 Association of DNA gyrase mutations and qnrS1 gene in
quinolone-resistant E. coli isolated from food animal, in Italy
C. Forcella °, A. Alessiani, E. Di Giannatale, K. Zilli, M. Perilli,
G. Celenza, G. Amicosante (L’Aquila, Teramo, IT)
Objectives: Quinolones recognize as targets both DNA gyrase and
topoisomerase IV, thus the most common mechanism of resistance is
originated by altered domains in these enzyme active sites that can
reduce or block the drug binding capacity. The aim of the study was
to investigate the quinolone resistance in E. coli collected from food
animal in an Italian region.
Methods: Fifty nine E. coli were isolated from food animal (chicken,
rabbit, ship, bovine) during 2000–2007 period in the Istituto Zoopro-
ﬁlattico Sperimentale Abruzzo e Molise (IZSA&M), Italy. Molecular
analysis was performed by colony hybridisation using speciﬁc probes
for integrase (IntI) genes, by PCR, sequencing and PFGE analysis. The
antibiotics susceptibility proﬁle was determined by Phoenix system.
Results: Among the screened isolates, 44/59 E. coli were found to be
resistant to nalidixic acid but susceptible to ciproﬂoxacin; 4/59 isolates
were resistant to ciproﬂoxacin and nalidixic acid susceptible; 11/59
isolates were resistant to ciproﬂoxacin and nalidixic acid. Quinolone
Resistant Determinant Region (QRDR) of gyrA and gyrB of 59 E. coli
were ampliﬁed and sequenced in order to verify the presence of
mutations. Twenty eight isolates showed a single mutation in gyrA at
position 83 where a residue of serine was changed in leucine (27/28
isolates) or alanine (one isolate). One isolates showed an additional
mutation Asp87Asn. Mutations in gyrB where found only in three
E. coli (3/59) The mutations were as follows: Gln434His, Lys447Arg
(in association with Ser83Leu) and Gly435Val (in association with
Ser83Leu). Large plasmids sized 100 Kb were detected in 16 out 59
isolates. All E. coli were also screened for the presence of qnr elements.
Only one isolate, with Ser83Leu mutation, showed the presence of qnrS1
element. The PFGE analysis of 59 E. coli showed no relatedness.
Conclusion: In this study we demonstrated that quinolone resistance
is mediated by chromosomal mutations in bacterial topoisomerase and
qnr genes responsible for plasmid-borne quinolone resistance in E. coli
isolated from food animal. Resistance to quinolones in zoonotically
transmitted enterobacteria is an almost inevitable consequence of the
use of these molecules in food animal production.
P1473 Decreased quinolone susceptibility in high percentage of
Enterobacter cloacae clinical isolates caused only by Qnr
determinants
X. Zhao, X. Xu, D. Zhu, X. Ye, M. Wang ° (Shanghai, CN)
Objectives: To investigate the prevalence of Qnr and other plasmid-
mediated quinolone resistance (PMQR) determinants in Enterobacter
cloacae clinical isolates, and to determine the role of Qnr and/or target
mutations in the development of quinolone resistance.
Methods: The presence of qnrA, qnrB, qnrS, aac(6’)-Ib-cr and qepA
genes was evaluated by PCR in 101 consecutive strains of E. cloacae,
including quinolone-resistant and -susceptible strains, isolated at a
university hospital in Shanghai from January to December 2005. ESBLs
and plasmid-mediated AmpC-b-lactamases were identiﬁed, and their
genotypes were determined. Mutations in the quinolone resistance-
determining region (QRDR) of gyrA and parC were determined by PCR
ampliﬁcation and DNA sequencing for PMQR positive strains.
Results: Of 101 E. cloacae strains, 33 (32.7%) and 4 (4%) were resistant
and intermediate to ciproﬂoxacin, respectively, and 52 (51.5%) produced
ESBL and/or acquired AmpC b-lactamases. PMQR determinants were
present in 42 (41.6%) isolates with qnr and aac(6’)-Ib-cr detected alone
or in combination in 39 (38.6%) and 7 (6.9%) strains, respectively.
qepA was not detected. qnr genes included 19 qnrA, 18 qnrB and
3 qnrS; one strain was positive for both qnrB and qnrS. qnr genes
were present in 48.4% (16/33) and 32.8% (21/64) of ciproﬂoxacin-
resistant and -susceptible strains, respectively (Pearson Chi-square test,
P = 0.22), indicating that the prevalence of qnr genes was similar in the
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ciproﬂoxacin-resistant and -susceptible groups. No amino acid change
in QRDRs was found in any of the 21 qnr positive, but ciproﬂoxacin-
susceptible strains of which 20 had ciproﬂoxacin MICs of 0.06 to
0.25mg/ml and one an MIC of 1 mg/ml, indicating that decreased
quinolone susceptibility in those clinical strains may be caused by Qnr,
but not by target mutations. Two or more amino acid substitutions in
GyrA and/or ParC were detected in 15 of 16 qnr positive strains with
ciproﬂoxacin MICs 8 to 32mg/ml.
Conclusion: The presence of qnr genes in ciproﬂoxacin-susceptible
strains was similar to that in ciproﬂoxacin-resistant strains. Qnr may be
present prior to target mutations in some clinical strains with decreased
quinolone susceptibility.
P1474 Mechanisms of ﬂuoroquinolone resistance in E. coli isolates
O. Vasilaki °, E. Ntokou, A. Kontodimou, F. Frantzidou, D. Soﬁanou,
S. Alexiou-Daniel, S. Pournaras (Thessaloniki, Larissa, GR)
Objective: Quinolone resistance is relatively common among Greek Es-
cherichia coli isolates. The underlying quinolone resistance mechanisms
were investigated in 114 ciproﬂoxacin (CIP) resistant E. coli isolates
from individual patients in 4 Greek tertiary care hospitals.
Materials and Methods: The study included 114 single E. coli
isolates from 4 Greek tertiary care hospitals. All strains were identiﬁed
and tested for antibiotic susceptibility with the VITEK 2 automated
system (bioMe´rieux, Marcy l’Etoile, France). All isolates were highly
CIP-resistant (MIC  4). Resistance by target modiﬁcation was
screened by PCR ampliﬁcation and sequencing of the quinolone
resistance determining regions (QRDRs) of gyrA and parC genes.
Synergy experiments were also performed using ciproﬂoxacin and the
proton-gradient dependent efﬂux pump inhibitor carbonyl-cyanide-m-
chlorophenylhydrazone (CCCP), to check the contribution of efﬂux
pumps. The presence of qnrA, qnrB and qnrS was also screened by PCR.
Results: All high-level CIP-resistant E. coli had two mutations in gyrA
in combination with mutations in parC genes. Mutations in parC were
only found in combination with gyrA mutations. The mutations found for
gyrA were S83L, D87N and D87Y and for parC were S80R, S80I, E84V,
E84K and E84G. 111 isolates had only the gyrA mutations. 17 isolates
had double mutations both in gyrA and parC. 84 had double mutation in
gyrA and a single mutation in parC. Contribution of efﬂux pump mech-
anisms was not detected in the isolates of the study. No qnrA or qnrB
gene was detected, whereas 11 qnrS-positive E. coli isolates were found
by sequencing of the amplicons to carry the qnrS1 allele. PFGE was per-
formed in qnrS1 isolates that were found to belong in distinct genotypes.
Conclusions: Target mutation in QRDRs was the most prevalent
mechanism of quinolone resistance in Greek CIP-resistant E. coli
isolates. Transferable resistance by target protection or enzymatic
modiﬁcation was less common (9.6%). qnr genes seem to be common
in ciproﬂoxacin-resistant clinical E. coli isolates and may contribute to
the alarming rates of quinolone resistance in Greece.
P1475 First description of a multidrug-resistant Citrobacter
freundii carrying both qnrA and qnrB in Aveiro, Portugal
S. Ferreira °, A. Paradela, J. Velez, E. Ramalheira, T. Walsh, S. Mendo
(Aveiro, PT; Cardiff, UK)
Objectives: Resistance to quinolone is classically chromosomally
mediated. However, plasmid mediated qnr genes emerged, and are now
described worldwide. The plasmid encoded nature of these genes may
play an important role in dissemination of these determinants in the
community and also in the hospital environment.
Methods: Citrobacter freundii was identiﬁed by the automatic VITEK
2 system and Advanced Expert System (VITEK 2 AES) (BioMe´rieux,
Marcy L’E´toile, France). Resistance proﬁle was also determined by
disc diffusion methods. Presence of ESBL was conﬁrmed by Etest™
(AB Biodisk) ESBL with Cefotaxime/Cefotaxime + Clavulanic acid,
Ceftazidime/Ceftazidime + Clavulanic acid and Cefepime/Cefepime +
Clavulanic acid strips, according to manufacturer’s instructions. PCR,
nucleotide sequencing and sequence analysis was employed to identify
qnr-encoding sequences.
Results: C. freundii, CIT1, was recovered from a 17-year-old boy
admitted in mid-August 2008, with the diagnosis of dorso-lumbar
spondylodiscitis caused by a MSSA. CIT1 was highly resistant
to b-lactams (ampicillin/sulbactam, cefotaxime ceftazidime, cefepime,
piperacillin and piperacillin/tazobactam), aminoglycosides (gentamicin
and tobramycin) and ﬂuoroquinolones (ciproﬂoxacin, levoﬂoxacin and
norﬂoxacin); susceptibility was shown only to carbapenems. qnrA and
qnrB were detected and were located on different plasmids. qnrA1
was associated with class 1 integron, In37 and a ISCR1. qnrB was
not associated either with ISCR1 or ISEcp1, as expected, its genetic
environment still being studied. The presence of qnrS and aac(6′)-Ib-cr
were not detected.
Conclusion: This is the ﬁrst report of a Citrobacter freundii carrying
both qnrA and qnrB. Results obtained also suggest that isolates, which
are not commonly linked to sepsis, can be a reservoir of antibiotic
resistance genes.
P1476 Serratia marcescens carries a chromosomally encoded
pentapeptide repeat protein, conferring reduced
susceptibility to quinolones in E. coli
C. Velasco °, J.M. Rodrı´guez-Martı´nez, A. Briales, P. Dı´az de Alba,
P. Alvaro (Seville, ES)
Objectives: Since the discovery of qnrA1 in 1998, related plasmid-
mediated genes and chromosomal homologues have been described. The
presence of peptapeptide repeat proteins (PRPs) with activity against
quinolones have been described in the chromosome of several Gram-
positive and Gram-negative species. A new pentapeptide repeat protein
from clinically relevant specie, Serratia marcescens, which confers
reduced susceptibility to quinolones when expressed in E. coli, is herein
reported.
Methods: A protein BLAST analysis revealed the presence of a gene
encoding for PRP in S. marcescens strain Db11with 80% of amino acid
identity with QnrB1. By using the information deposited in the databases,
primers suitable for PCR ampliﬁcation were designed. Fragments
carrying the coding region and upstream non coding sequences from
several clinical isolates were cloned in pCR-Blunt TOPO. MIC values of
quinolones were determined in E. coli DH10B and E. coli ATCC 25922
using the E test strips. Southern hybridisation was used to explore the
presence of this gene within the genus Serratia.
Results: Recombinant plasmids coding for PRPs reduced the suscepti-
bility to ciproﬂoxacin between 8−16 folds in E. coli ATCC 25922 and
between 3−11 folds in E. coli in DH10B, depending on the allele. MIC
against nalidixic acid also increases 3−4 folds in the later strain. The
sequence upstream from theses genes contains a LexA box involved in
SOS response. Results of Southern hybridisation analysis suggest the
presence of similar genes in several species within the genus Serratia.
Conclusion: The PRP analysed conferred a reduced susceptibility
phenotype against ﬂuoroquinolones in E. coli. These data provide
evidence of its possible role in quinolone resistance in S. marcescens.
This Gram-negative specie may constitute a reservoir for Qnr-like
quinolone resistance protein
P1477 In vivo acquisition of aac(6′)-Ib-cr and mutations in
gyrA gene after ciproﬂoxacin treatment of a clinical
qnrS1-positive Salmonella typhimurium strain
M. de Toro, B. Rojo-Bezares, L. Vinue´, E. Undabeitia, I. Olarte,
M. Zarazaga, C. Torres, Y. Sa´enz ° (Logrono, ES)
Objective: To characterise the phenotypes and genes implicated in the
in vivo selection of a clinical Salmonella typhimurium isolate with
quinolone and aminoglycoside resistance, recovered from a patient after
ﬂuoroquinolone treatment.
Methods: A 92-years-old woman was admitted at hospital with acute
gastroenteritis and was treated with ciproﬂoxacin, ampicillin and
S414 19th ECCMID, Posters
metronidazol during seven days. Two faecal S. typhimurium isolates
were obtained before (Se6) and after (Se20) treatment, showing Se20
resistance to quinolones and tobramycin. The clonal relationship among
both isolates was examined by PFGE. Antimicrobial susceptibility was
determined by disk diffusion and agar dilution methods. Presence of
the following genes was studied by PCR and sequencing: qnrA, qnrB,
qnrS, qepA; tet(A)-(E); aph(3′)-Ia, aph(3′)-IIa, aac(6′)-Ib, aadA, strA-
strB; sul1, sul2, sul3; class 1, 2 and 3 integrase genes, and qacDE1+sul1
region of class 1 integron. Mutations in gyrA and parC genes were
studied by PCR and sequencing. Mating experiments to Escherichia coli
recipient strain was assayed.
Results: Both S. typhimurium strains presented indistinguishable
PFGE patterns and were resistant to tetracycline, streptomycin and
sulphonamides, but susceptible to all b-lactams and gentamicin. The MIC
values (mg/L) for Se6/Se20 were as follows: nalidixic acid (16/>512),
ciproﬂoxacin (0.5/8), norﬂoxacin (4/>8), kanamycin (4/64), tobramycin
(1/32), amikacin (4/16) and trimethoprim (1/>128). S. typhimurium
Se6 and Se20 presented the sul2-strA-strB structure, tet(A) and qnrS1
genes, but quinolone and tobramycin resistance found in Se20 was due
to the presence of aac(6′)-Ib-cr gene and the Ser83Tyr substitution
in GyrA. This strain also presented one defective class 1 integron
lacking qacDE1+sul1, which included the trimethoprim resistance
dfrA17 gene cassette downstream of intI1 gene. The two types of E. coli
transconjugants obtained from Se20 (Se20A/Se20L) acquired qnrS1, sul2
and intI1-dfrA17 genes, but not strA-strB or tet(A). In addition, the
Se20A included the aac(6′)-Ib-cr gene, but not the Se20L, being their
different MICs (mg/L) as follows: ciproﬂoxacin (4/1), kanamycin (64/4),
tobramycin (32/1), and amikacin (8/4).
Conclusions: First report of in vivo selection of aac(6′)-Ib-cr gene and
Ser83Tyr change in GyrA in a qnrS1-positive S. typhimurium strain
after ciproﬂoxacin treatment; in vitro transfer of both plasmid-mediated
quinolone resistance genes is demonstrated.
P1478 Prevalence of plasmid-mediated quinolone resistance and
its association with extended-spectrum b-lactamase in
clinical isolates from Korea
J.H. Shin, H.S. Jeong, H.J. Jung, S.H. Kim, J.Y. Lee, S.H. Oh,
H.R. Kim, J.N. Lee, I.K. Bae, C.L. Chang ° (Busan, KR)
Objectives: The aims of this study were to investigate the prevalence of
plasmid-mediated quinolone resistance and its association with extended-
spectrum b-lactamase (ESBL) in clinical isolates from Korea.
Methods: A total of 347 non-duplicated isolates of Enterobacteriaceae
and 200 non-duplicated isolates of Pseudomonas aeruginosa in 2006
were collected from various clinical specimens in two hospitals. The
qnr determinant screening was carried out by PCR ampliﬁcation of
qnr genes, and all positive results were conﬁrmed by direct sequencing
of the PCR products. We determined the presence of ambler class A
b-lactamase and AmpC b-lactamase genes for qnr-positive strains to
investigate the association with ESBL.
Results: The qnr gene was detected in 47 of the 347 clinical Enter-
obacteriaceae isolates. No qnr gene was detected in 200 P. aeruginosa
strains. Among 47 qnr-positive strains, K. pneumoniae (N = 30) was the
most common, followed by E. coli (N = 7), E. cloacae (N = 5), and others
(N = 5). These were ﬁnally identiﬁed as new qnrA1 like (N= 6), eight
qnrB subtype (N= 40) including new qnrB4 like (N= 29) and qnrB12
like (N= 1), and qnrS1 (N= 1). The antimicrobial-resistance rates of
qnr-positive strains to ciproﬂoxacin, levoﬂoxacin, norﬂoacin, nalidixic
acid, and moxiﬂoxacin were 51.1%, 46.8%, 46.8%, 74.5%, and 53.2%,
respectively. The qnr-positive strains showed also high positive rates of
ESBL such as TEM (N= 16), SHV (N= 29), CTM-M (N= 15), and DHA
(N= 23).
Conclusion: The qnr genes were highly prevalent in various clinical
isolates, mainly the qnrB subtypes. The qnr-positive strains were closely
associated with diverse ambler class A and AmpC b-lactamases.
P1479 A high-level ﬂuoroquinolone-resistant Salmonella
Typhimurium strain shows decreased invasion ability. Is
there any regulatory link?
A. Fabrega °, L. du Merle, C. Le Bouguenec, J. Vila (Barcelona, ES;
Paris, FR)
Objective: The main objective was to determine a possible link
between ciproﬂoxacin-resistance in Salmonella Typhimurium and a loss
of expression of virulence genes, such as those encoding invasion
proteins. This link could justify why nalidixic acid resistance has steadily
been increasing during the last years, whereas ciproﬂoxacin resistance
has remained stable.
Methods: A high-level ciproﬂoxacin resistant mutant (strain 50−64)
was obtained in vitro from a susceptible clinical isolate. A reverted
phenotype of 50−64 could be obtained (strain 50-rev). Sequencing of
the genes encoding the target proteins as well as those encoding a
multiple antibiotic resistance (MAR) phenotype was performed. Analysis
of nalidixic acid, norﬂoxacin and ciproﬂoxacin resistance was checked in
the presence and absence of PAN (an efﬂux pump inhibitor). A Western
Blot methodology was carried out using antibodies against AcrB and
TolC. A full-genome microarray analysis was performed. The invasion
ability was determined using the gentamicin protection assay.
Results: The sequencing analysis showed that 50−64 acquired 3
mutations (2 in gyrA (G81C and D87G) and 1 in parE (E470K)).
No other mutation was found in any regulatory protein (AcrR, MarR,
SoxR, RamR). 50−64 achieved a MIC of ciproﬂoxacin of 64mg/L,
which reverted to 1.5 in 50-rev. In the presence of PAN, both strains
showed a similar MIC of ciproﬂoxacin (1mg/L). Western Blot analysis
showed overexpression of AcrB and TolC in 50−64 that decreased to
nearly the wild-type levels in 50-rev. The invasion results showed a
decrease in the percentage of invasion from 11.1 to 0.2% in 50−64,
whereas a signiﬁcant reversion could not be detected in 50-rev (0.7%).
The microarray results demonstrated a signiﬁcant decrease in 50−64 of
the whole SPI-1 (Salmonella Pathogenicity Island) and all the operons
that encode ﬂagellum assembly and function. However, only a partial
reversion could be detected in 50-rev.
Conclusion: High-level quinolone resistance not only depends on
mutations within the target genes but also on the overexpression of the
main efﬂux pump, AcrAB. This ciproﬂoxacin resistance can be reverted
to a decreased-susceptibility phenotype. As no mutation could be found
in AcrR, MarR, SoxR and RamR, another regulatory loci must be
implicated to justify the increased expression of AcrAB. This regulation
could be linked with the decreased expression of the SPI-1 and ﬂagellum
operons that may lead to decreased invasion ability.
P1480 Decreased cell invasion by a high-level ciproﬂoxacin-resistant
mutant of Yersinia enterocolitica
A. Fabrega °, L. du Merle, C. Le Bouguenec, J. Vila (Barcelona, ES;
Paris, FR)
Objective: The main objective of this study was to characterise a
ciproﬂoxacin-resistant Yersinia enterocolitica mutant to determine the
potential relationship between quinolone resistance acquisition and cell
invasion.
Methods: A quinolone-resistant Y. enterocolitica mutant (strain Y-64)
was selected in vitro by serial passages from a quinolone-susceptible
Y. enterocolitica (strain Y-wt) in subinhibitory concentracions of
ciproﬂoxacin. Y-64 was grown in the absence of the antibiotic to
obtain a reverted phenotype (strain Y-rev). Sequencing of the quinolone
resistance-determining regions (QRDRs) of the gyrA, gyrB, parC and
parE genes was performed. The MICs of ciproﬂoxacin, norﬂoxacin and
nalidixic acid were determined in the presence and absence of PAN (an
efﬂux pump inhibitor). An SDS-PAGE was run with a cell envelope
extract to know the outer membrane protein proﬁle. RT-PCR analysis
was used to check the mRNA levels of the yadA gene as well as of
a homolog of marA (YE1991). The invasion ability was tested with a
gentamicin protection assay.
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Results: Sequencing results showed that Y-64 had acquired four different
point mutations within the QRDRs: one in gyrA (D87Y), one in gyrB
(S464L), and two in parC (S84R and A85E). Y-rev did not show any
reversion of the resistance phenotype. In the presence of PAN, only the
MIC of nalidixic acid decreased 64-fold in Y-64, whereas the MICs of
ciproﬂoxacin and norﬂoxacin remained the same. SDS-PAGE analysis
showed overexpression of AcrA and AcrB in Y-64. The RT-PCR assays
showed a decreased expression of yadA whereas marA mRNA increased
signiﬁcantly. The gentamicin protection assay indicated a decrease in the
percentage of invasion, from 6.9% in Y-wt to 0.2 in Y-64.
Conclusion: This high-level ciproﬂoxacin resistance phenotype has been
generated from the acquisition of four mutations within the QRDRs. In
addition, the overexpression of AcrAB is also present in Y-64. However,
it does not seem to affect the ﬂuoroquinolone MICs. AcrAB may only be
important for nalidixic acid resistance. This is the ﬁrst report of a marA
homolog found in Y. enterocolitica which is, in addition, overexpressed
in a quinolone-resistant strain, which may explain the AcrAB
overexpression detected. Furthermore, the decrease in the percentage
of invasion, as well as the decrease in yadA expression, suggests a link
between the regulatory networks behind these two phenotypes.
P1481 Prevalence of hypermutability in clinical isolates of
Klebsiella pneumoniae and its role in ciproﬂoxacin resistance
S. Aathithan °, G.L. French (London, UK)
Objectives: To investigate the prevalence of hypermutability in clinical
isolates of Klebsiella pneumoniae, and its possible role in the
accumulation of mutations in the quinolone resistance-determining
region (QRDR) and hence in ciproﬂoxacin resistance.
Methods: Sixty-four distinct clinical isolates of K. pneumoniae with
widely differing ciproﬂoxacin MICs (range 0.016 to >512mg/L) and
known gyrA and parC QRDR sequences, were investigated for high
frequency of mutations to rifampicin resistance using selective media
containing 100mg/L rifampicin. Twelve selected isolates with multiple,
single or no QRDR mutations were also assessed for high frequency of
mutation (or further mutation) to ciproﬂoxacin resistance, using selective
media containing ciproﬂoxacin concentrations at 4× the MICs of the
respective isolates.
Results: The rifampicin study identiﬁed three hypermutable isolates
amongst the 64 tested (<5%); one was ciproﬂoxacin susceptible (1 of
12 such isolates), one ciproﬂoxacin resistant (1 of 28) and one high-
level ciproﬂoxacin resistant (1 of 24). There was no association between
ciproﬂoxacin MIC or gyrA and parC mutations and hypermutability.
The ciproﬂoxacin study identiﬁed only two of the hypermutant isolates
found by the rifampicin study (one was the ciproﬂoxacin susceptible
isolate with no mutations in the gyrA or parC QRDR; the other was the
highly ciproﬂoxacin resistant isolate with double mutations in gyrA and
a single mutation in parC QRDR). The ciproﬂoxacin study identiﬁed no
other hypermutable isolates.
Conclusions: Hypermutation is uncommon in clinical isolates of
K. pneumoniae and occurs randomly amongst ciproﬂoxacin resistant and
susceptible isolates and in those with both no and multiple mutations in
gyrA and parC. This suggests that hypermutation contributes to neither
the accumulation of mutations in the QRDR nor directly to ciproﬂoxacin
resistance.
P1482 Study of ﬂuoroquinolone resistance mechanisms among
extended-spectrum b-lactamase-producing E. coli urinary
isolates in Madrid, Spain
E. Rios °, I. Rodriguez-Avial, C. Rodriguez-Avial, E. Hernandez,
J. Picazo (Madrid, ES)
Objectives: During 2005 a total of 191 ESBL-producing E. coli strains
were isolated from urine in our hospital and a high percentage of
ciproﬂoxacin (Cip) resistance was observed (75%) corresponding to
141 strains. We studied the mechanism accounting for ﬂuoroquinolone
resistance in these isolates.
Methods: Of the 141 Cip-resistant strains 30 isolates were chosen
to represent the full range of Cip resistance and were classiﬁed in
three groups according to the Cip MIC; Group 1 MIC range 4−8mg/l,
Group 2 MIC range 16−64mg/l and Group 3 MIC 128mg/l. In the
selected isolates sequencing of the QRDR of the gyrA and parC genes
was performed. All 191 ESBL-producing strains were screened for the
presence of the qnrA, qnrB and qnrS genes by multiplex-PCR. Mating
assays with E. coli K-12 as recipient strain were attempted to determine
the transferability of qnr genes.
Results: Distribution of gyrA and parC sequences is displayed in the
Table.
Group No. of strains gyrA parC
(MIC range, mg/L) Ser83 Asp87 Ser80 Glu84
1 (4−8) 5 Leu Asn Ile WT
2 Leu Gly Ile WT
1 Leu Asn Trp WT
1 Leu Tyr Ile WT
1 Leu WT WT Arg
2 (16−64) 4 Leu Asn Ile WT
3 Leu Asn Ile Val
1 Leu Asn Ile Gly
1 Leu Asn Ile Ala
1 Leu Asn WT Lys
1 WT Asn Ile WT
3 (128) 5 Leu Asn Ile Val
2 Leu Asn Ile WT
1 Val Thr Ile Val
1 Leu Asn Arg WT
All of the 30 selected Cip-resistant strains studied had at least one muta-
tion in gyrA, most isolates showing Ser83Leu substitution, and 93% had
two gyrA QRDR mutations. All isolates harboured at least one QRDR
parC substitution, most isolates showing Ser80 Ile, and approximately
17% of the isolates had two parC substitutions. In general, isolates with
increased numbers of gyrA and parC mutations had higher Cip MICs.
qnrB gene was detected in one SHV producing isolate (Cip MIC 16mg/l,
gyrA Ser83Leu, Asp87Asn and parC Ser80Ile). The isolate was positive
for qnrB19 by DNA sequencing. qnrB19 and SHV were transferred to
E. coli K12 by conjugation. Susceptibility testing conﬁrmed the transfer
of resistance to ceftazidime, cefotaxime and aztreonam while the Cip
MIC of the transconjugant was as low as <0.03mg/l. None of 191 ESBL-
producing strains harboured qnrA or qnrS.
Conclusions: In general, strains with higher Cip MICs have increased
the number of gyrA and parC mutations. The prevalence of qnr genes
among our ESBL-producing E. coli isolates is low (0.5%).
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P1483 The differential effect of mutations in RamR, in mediating
antibiotic susceptibility in Klebsiella pneumoniae
J. Findlay, T. Schneiders ° (Edinburgh, UK)
Objectives: The transcriptional activator RamA confers an antibiotic
resistance phenotype in Klebsiella pneumoniae when overexpressed.
Recently a tetR-like gene that lies upstream of ramA, known as ramR,
has been identiﬁed as a repressor of ramA. Correspondingly clinical
isolates of K. pneumoniae with mutations within ramR have been shown
to overexpress ramA; however ramA overexpresssing clinical isolates
with no changes within the repressor ramR or within the associated
promoter regions have also been found. Thus the aims of this study were:
to ﬁrstly determine whether ramA overexpression mediated through
ramR-derepression was dependent on the selective agent and secondly
to determine which mutations within the ramR gene would impact on
resistance proﬁles upon complementation with wild-type ramR.
Methods: Laboratory mutants from K. pneumoniae Ecl8 were selected
for by the culturing of exponential growth phase bacterial cultures on
ciproﬂoxacin or chlorpromazine plates at four times the MIC. The ramR
gene was ampliﬁed from a selection of the mutants and was sequenced.
The subsequent MICs to chloramphenicol (Cm), norﬂoxacin (Nor) and
tetracycline (Tet) of the selected mutants with changes within the ramR
gene were then determined. ramR mutants were complemented with a
plasmid containing the wild-type ramR, pACramR, and their subsequent
MICs were determined to Cm, Nor and Tet as before.
Results: Four of the selected mutants were revealed to harbour mutations
resulting in amino acid changes within the ramR gene. The mutations
(G96D, S137Stop, E175K) found in the ramR gene appeared to favour
the C-terminus region. The mutants exhibited 32−4 fold increases in
MICs compared to the parental strain depending on which mutations
were sustained within ramR. Complementation with the wild-type ramR
resulted in 1−16 fold reductions in the MICs also dependent on the type
of ramR mutations.
Conclusion: All the mutants appeared to sustain ramR changes
regardless of the compound used in the selection, indicating that ramR
is a critical factor in mediating ramA overexpression. The partial
restoration of the parental phenotypes in the ramR-mutants indicates
the MDR phenotypes are attributable to mutations within the RamR
protein but another factor may be required to restore susceptibility
to parental levels. The mutations identiﬁed within RamR protein are
clustered around the C-terminus suggesting the relative importance of
this region in the derepression of ramA.
P1484 Emergence of AcrAB-mediated tigecycline resistance in a
clinical isolate of Enterobacter cloacae
M. Hornsey °, M.J. Ellington, M. Doumith, G. Scott, D.M. Livermore,
N. Woodford (London, UK)
Objectives: Tigecycline resistance in the Enterobacteriaceae remains
rare in the UK, as elsewhere, but has been associated with up-regulation
of the AcrAB efﬂux system. Using a susceptible and resistant pair of UK
clinical isolates, we investigated the role of this pump in the emergence
of tigecycline resistance in E. cloacae.
Methods: Two isolates of E. cloacae, identiﬁed by API20E, were
recovered from a spinal abscess complicating metal work inserted 2 years
previously for a fracture of L2 in an adult male. MICs were determined
by agar dilution on IsoSensitest agar according to BSAC guidelines.
Laboratory mutants were selected from the susceptible isolate in vitro
by exposure to increasing concentrations of tigecycline. PFGE was used
to determine relatedness. Expression of the acrAB operon was monitored
by real-time RT-PCR using primers for acrB and was quantiﬁed relative
to rpoB. Insertional inactivation of the acrB gene with a gentamicin
resistance cassette was mediated by the bacteriophage lambda Red
recombination system.
Results: The clinical isolates required tigecycline MICs of 0.5 and
4mg/L, respectively, whilst the most resistant laboratory-selected mutant
required a tigecycline MIC of 32mg/L. Real-time RT-PCR identiﬁed a
mean 5× and 12× increase in acrAB transcript in the resistant clinical
isolate and ﬁnal mutant, respectively, compared with the susceptible
clinical isolate. Although the PFGE proﬁles of the wild-type pair
were not identical, analysis of the ﬁnal and intermediate laboratory
mutants showed an analogous transition from the PFGE proﬁle of
the susceptible clinical isolate to that of the resistant clinical isolate.
Insertional inactivation of the acrB gene in the resistant clinical isolate
restored full susceptibility to tigecycline.
Conclusions: E. cloacae is a problematic nosocomial pathogen, but is
generally susceptible to tigecycline. We report the emergence of low-
level resistance to this agent in vivo, associated with up-regulation of
the AcrAB efﬂux pump. We also demonstrated in vitro the potential to
select highly tigecycline-resistant mutants in this species.
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P1485 BEL-2, an expanded-spectrum b-lactamase with increased
activity toward broad-spectrum cephalosporins in
Pseudomonas aeruginosa
L. Poirel °, J.D. Docquier, F. De Luca, A. Verlinde, L. Ide, G.M. Rossolini,
P. Nordmann (Le Kremlin-Biceˆtre, FR; Siena, IT; Roeselare, BE)
Objectives: Acquired extended-b-lactamases (ESBLs) are rarely iden-
tiﬁed in Pseudomonas aeruginosa, being of the TEM, SHV, CTX-M,
PER, GES, PER, and BEL types. In Belgium, the occurrence of
BEL-1 producers showing reduced susceptibility to expanded-spectrum
cephalosporins has been previously reported. Our study reports the
characterisation of a BEL-type variant identiﬁed in a P. aeruginosa
isolate highly resistant to expanded-spectrum cephalosporins.
Methods: ESBL production was assessed by disk synergy tests. PCR
experiments were performed using primers speciﬁc for ESBL genes.
Plasmid extraction was performed by the Kieser technique. Mating-
out assays were performed using P. aeruginosa PU21 as reference
strain. Cloning of the PCR amplicons was realised in vector pTOPO-
Blunt II. Genotyping was performed by using Pulsed-Field Gel
Electrophoresis (PFGE). b-lactamase puriﬁcation was performed by ion-
exchange chromatography, and kinetic measurements performed using
UV spectrophotometry.
Results: P. aeruginosa isolate 531 was recovered from a urine sample of
a patient hospitalised in Belgium in February 2007. It was highly resistant
to all b-lactams, except to carbapenems. ESBL test was positive, and
PCR revealed the presence of a blaBEL-like gene that was identiﬁed
as chromosomally-located. Sequencing identiﬁed b-lactamase BEL-2
differing from BEL-1 by a single substitution (Leu to Phe at position
Ambler 162). Susceptibility testing showed that the E. coli recombinant
strain expressing BEL-2 exhibited higher MICs of CAZ, CTX, CRO,
and FEP as compared to the isogenic construct expressing BEL-1.
Kinetic analysis of puriﬁed BEL-2 revealed much lower Km values
as compared to BEL-1. PFGE analysis showed that isolate 531 was
undistinguishable from the BEL-1-positive isolate 51170 previously
reported from Belgium.
Conclusion: This study identiﬁed a novel BEL-type enzyme which
possesses increased activity against most b-lactams. The Leu162Phe
substitution located in the omega-loop of the b-lactamase largely
improved apparent substrate afﬁnities, particularly with expanded-
spectrum cephalosporins. BEL-2 was identiﬁed in a strain that is
clonally-related to the original BEL-1 producer and recovered from the
same geographical area, although three years later. These data support
the hypothesis of the persistence and evolution of a BEL-type ESBL-
producing P. aeruginosa clone in Belgium.
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P1486 Molecular epidemiology and mechanisms of carbapenem
resistance in Pseudomonas aeruginosa isolates from a
French hospital
J.M. Rodriguez-Martinez, L. Poirel °, P. Nordmann (Le Kremlin Bicetre,
FR)
Objectives: The aim of the work was to evaluate the contribution of
different mechanisms of resistance to carbapenems in Pseudomonas
aeruginosa including the recently discovered expression of extended-
spectrum cephalosporinases (ESACs). Those enzymes correspond to
natural AmpCs of P. aeruginosa possessing a T105A substitution
conferring the ability to hydrolyse carbapenems at low level.
Methods: Thirty-two non-repetitive P. aeruginosa clinical isolates
recovered in 2007 being resistant or of intermediate susceptibility to
imipenem (IMP) were studied. MICs were determined by agar dilution
and E-test techniques. The level of expression of the AmpC b-lactamases
was determined by UV spectrophotometry. PCR and sequencing were
used to characterise the blaampC genes. Overexpression of AmpC was
evaluated by using Mueller-Hinton agar plates containing cloxacillin
(AmpC inhibitor). PCR, sequencing and SDS-PAGE were used to
characterise the outer-membrane protein OprD. The level of expression
of OprD, and of the efﬂux systems MexAB-OprM, MexXY-OprM and
MexCD-OprJ were determined by real time RT-PCR assays.
Results: 87% (n = 28) of the isolates were resistant to IMP. The main
mechanism involved in that resistance was loss of OprD. 78% of the
isolates contained modiﬁcations leading to the inactivation of OprD, and
a reduced expression of OprD compared to PAO1 was noticed in the
remaining isolates (Table).
Table. Number of carbapenem resistant/intermediate isolates and corresponding mechanisms involved
OprD AmpC ESAC Efﬂux pump overexpression
inactivation overproduction phenotype MexAB MexXY MexCD
IPM-R (n = 28) 28 24 20 7 2 10
IPM-I (n = 4) 4 1 1 1 0 1
IPM-R: Resistance to imipenem; IMP-I: intermediate susceptibility to imipenem.
78% overexpressed their AmpC b-lactamase. Among those AmpC
overproducers, 84% showed reduced MIC values of ceftazidime,
cefepime and carbapenems in presence of cloxacillin, suggesting
production of an ESAC. The additive presence of ESACs and loss of
OprD was observed in 65% of the total collection, those isolates being
all resistant to imipenem. Overexpressions of MexAB-OprM, MexXY-
OprM or MexCD-OprJ efﬂux systems were observed in 25%, 6.2% and
34% of the isolates, respectively, suggesting their major contribution in
resistance to meropenem observed in 78% of the isolates.
Conclusions: Resistance to imipenem and meropenem in P. aeruginosa
is multifactorial, combining loss of OprD porin, overexpression of
ESACs and efﬂux pumps overexpression.
P1487 Molecular epidemiology and b-lactamase resistance
mechanisms of ceftazidime-resistant Pseudomonas
aeruginosa causing blood infections in a Brazilian hospital
R. Picao, L. Poirel °, A. Gales, P. Nordmann (Le Kremlin Bicetre,
FR; Sao Paulo, BR)
Objective: To investigate the mechanisms responsible for b-lactam
resistance among a collection of ceftazidime-resistant P. aeruginosa
recovered from blood samples in a University Hospital in Sa˜o Paulo,
Brazil, during a one-year period. The spread of extended-spectrum
b-lactamase (ESBL) or metallo-b-lactamase (MBL) was evaluated.
Methods: 154 non-repetitive P. aeruginosa were recovered from blood
cultures of patients hospitalised in Sa˜o Paulo in 2005. 43 isolates (28%)
displayed ceftazidime resistance and were further studied. Susceptibility
testing and ESBL detection was performed by disk diffusion and synergy
tests. Molecular typing was performed by PFGE. PCR and sequencing
was used to identify b-lactamase genes and their genetic environment.
Studies of the genetic support of b-lactamase-encoding genes were
performed by plasmid hybridisation, transformation experiment and the
I-Ceu1 technique.
Results: Resistance rates for the 43 ceftazidime resistant isolates
were over 80% for carbapenems, aminoglycosides and quinolones.
Only colistin remained systematically active against all isolates. PFGE
analysis identiﬁed seven different genotypes. AmpC overproduction
was found to be the only mechanism responsible for ceftazidime
resistance in four isolates (9.3%). Nine isolates (20.9%) showed an
ESBL-positive phenotype, corresponding either to production of ESBL
GES-1 (n = 7, 16.3%), or ESBL CTX-M-2 (n = 2, 4.6%). The isolates
which were neither AmpC overproducers nor ESBL producers (n = 30,
70%) showed carbapenemase activity. Of those, two isolates (4.6%)
produced the ESBL GES-5 (possessing carbapenemase activity), one
isolate (2.3%) produced MBL IMP-1, and 27 isolates produced MBL
SPM-1 (62.8%). None of the isolates studied co-produced ESBL and
MBL determinants. Insertion sequence elements ISCR4 and ISCR1 were
associated with blaSPM-1 and blaCTX-M-2 genes, respectively. The
blaGES-1, blaGES-5 and blaIMP-1 genes were embedded into class 1
integron structures. All those b-lactamase genes identiﬁed here were
likely chromosomally-located.
Conclusion: This study underlines the spread of MBL-producing
P. aeruginosa as well as the emergence ESBL production in that species,
including ESBL with carbapenemase property (GES-5).
P1488 Metallo-b-lactamases detection among Pseudomonas
aeruginosa isolated from bloodstream infections at a
university hospital, Sa˜o Paulo, Brazil
M. Franco, H. Caiaffa Filho, M. Burattini, F. Rossi ° (Sao Paulo, BR)
Objectives: To determine MBL prevalence in Pseudomonas aeruginosa
(PA) resistant to imipenem; to compare phenotypic and molecular
methods to detect MBL; to evaluate the clonality of the MBL producers
strains and to determine the susceptibility proﬁle of all isolates included
in this study.
Methods: A retrospective study was carried analysing 69 PA strains
resistant to imipenem isolated from blood cultures of patients at HC-
FMUSP during 2005. They were submitted to the susceptibility proﬁle
test by microdilution method and Etest® to colistin. The isolates were
also tested for MBL production by phenotypic methods like Double
Disk Synergy (DDS), Etest™ MBL, Modiﬁed Hodge Test (MHT). The
Polimerase Chain Reaction (PCR) was used to detect the following
genes: (blaSPM-1, blaIMP-1, blaIMP-2, blaVIM-1 and blaVIM-2). The
clonality of the MBL producers was evaluated by Pulsed Field Gel
Electrophoresis (PFGE).
Results: Fifty-three isolates (76.8%) had positive results with DDS
and Etest® MBL, and 19 isolates (27.5%) were positive by MHT.
Twenty-one isolates (30.4%) had a blaMBL gene by PCR, being 17
(81%) positive for blaSPM-1 and 4 (19%) for blaVIM-2. The blaIMP-1,
blaIMP-2 and blaVIM-1 genes had not been detected. Mercaptoacetic
acid (MAA) inhibitor and MHT showed the best agreement with PCR,
with kappa value ranging from 0.81 to 0.86 and 0.79, respectively.
Etilenodiaminotetracetic acid (EDTA) inhibitor showed high sensibility
(100%), low speciﬁcity (33.3%), and poor agreement with PCR. Among
isolates producing blaSPM-1 gene, 5 were indistinguishable, 11 were
closely related and 1 was possibly related. Among isolates producing
blaVIM-2 gene, 2 were indistinguishable, 1 closely related and 1 was
different. Among MBL-producing strains, colistin and aztreonam were
the most active drugs with 90.5% and 85.7% of sensitivity, respectively.
Conclusions: The results reinforce the Brazilian epidemiology where
SPM-1 enzyme is the most prevalent among PA isolates. The DDS
method with MAA inhibitor and MHT had the best agreement with PCR,
showing themselves as good options for MBL phenotypical detection in
microbiology laboratories. The MBL producers had shown multiresistant
phenotype with a clonal standard, reinforcing the necessity of infection
control practices in our institution.
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P1489 Study of metallo-b-lactamase production in clinical isolates
of pan-resistant Pseudomonas aeruginosa
L. Fung, I. van der Heijden, A.K. Mostachio, A.S. Levin,
I. Boszczowski, F. Rossi, J. Paez, S.F. Costa ° (Sao Paulo, BR)
Metallo-b-lactamases (MBLs) are being reported with increasing
frequency and from several countries worldwide. Several phenotypic
tests have been developed for MBL detection, such as the MBL
Etest, double-disk synergy tests (DDST), combined disk assay, and
microdilution test. All of these tests are based upon the ability of
chelating agents, EDTA and thiol-based compounds, to inhibit the MBL
activity. However, an international consensus on appropriate phenotypic
test to detect MBL is lacking.
Objectives: Compare MBL phenotypic production and detection
of MBL genes by multiplex PCR in pan-resistant (susceptible to
polymyxins) clinical isolates of P. aeruginosa.
Material: 104 P. aeruginosa isolates pan-resistant from 02 Brazilian
hospitals were screened for MBL production by DDSTT assay
employing carbapenem and ceftazidime disk to which EDTA and
2-mercaptopropionic acid (MPA) were added, minimum inhibitory
concentration (MIC) reduction test with phenanthroline and Etest
containing Imipenem and EDTA. Disk Diffusion susceptibility to
Aztreonam and MIC microdilution of b-lactams, quinolones and
aminoglycosides were done according with the CLSI. Multiplex PCR
using speciﬁc primers for IMP, VIM, SPM, GIM and SIM was performed
to conﬁrm the presence of the MBL genes. PFGE was done to evaluate
the clonality of isolates.
Results: MIC50 and MIC90 for Imipenem and Meropenem were
respectively 64mg/ml, 256mg/ml, 32mg/ml and 256mg/ml. MBLs were
detected by multiplex PCR only in 18 isolates (17%). SPM was the
most frequent MBL being present in 14 isolates, followed by VIM in 3
and IMP in 1 isolate. PFGE showed that 50% of SPM positive strains
belong to a predominant clone. Two MBL positive isolates were resistant
to Aztreonam. DDSTT using Ceftazidime detected production of MBL
in 3 strains, and using Imipenem disk only in 1 strain. MIC reduction test
was positive in 55% of MBL positive strains. MBL Etest was positive
in all PCR MBL positive isolates, with sensibility of 100%, speciﬁcity
of 16% and positive predictive value (PPV) of 4%. The combination of
MIC reduction test and MBL Etest showed speciﬁcity of 98%, sensibility
of 55%, PPV of 90% and predictive negative value of 86%.
Conclusions: MBL presence was less frequent than expect. MBL Etest
was the most sensitive phenotypic method to detect MBL, however
showed low speciﬁcity. The combination of MIC reduction test and MBL
Etest increased the speciﬁcity of phenotypic detection of MBL.
P1490 Molecular epidemiology of metallo-b-lactamase-producing
Pseudomonas putida in a Spanish hospital
C. Juan °, L. Zamorano, S. Albertı´, J.L. Pe´rez, A. Oliver (Palma, ES)
Objective: To study the prevalence, nature, involved genetic elements,
and the molecular epidemiology of metallo-b-lactamase (MBL)-
producing P. putida strains isolated in a Spanish hospital between 2005
and 2008.
Methods: Etest and API 20NE were used, respectively, for the
susceptibility testing and identiﬁcation of P. putida clinical isolates.
The MBL Etest was used for screening, and was followed by the
ampliﬁcation of blaVIM genes by PCR. The clonal relatedness between
the isolates was evaluated by pulsed-ﬁeld-gel-electrophoresis (PFGE).
The plasmids harbouring the MBL genes were characterised and
compared through the analysis of the restriction (BamHI-HindIII)
fragments length polymorphisms (RFLP) followed by Southern blot
hybridisation using blaVIM probes. Additionally, electroporation of the
plasmids to P. aeruginosa PAO1 was attempted. The genetic composition
of the integrons harbouring the MBLs was investigated by PCR and
sequencing, following previously described protocols.
Results: MBL-producing P. putida was detected in clinical samples (1
urine, 1 sputum, 3 blood, 1 vascular catheter, and 2 peritoneal ﬂuid) from
8 patients, representing 14% of all the infections by P. putida/ﬂuorescens
group strains during the study period. In contrast, MBL production
was detected in only 0.32% of P. aeruginosa infections during the
same period. PFGE revealed that the 8 P. putida isolates belonged to
8 different clones, 2 of them harbouring blaVIM-1 and 6 blaVIM-2. All
the strains showed resistance or reduced susceptibility to gentamicin and
tobramycin, and half of them were additionally resistant to ciproﬂoxacin.
Southern blot revealed that all the MBLs, except 1 VIM-2, were plasmid-
located. An important plasmid diversity was also denoted, since RFLP
analysis yielded 6 different patterns among the 7 blaVIM-encoding
plasmids. On the other hand, all the MBLs were found to be encoded in
class 1 integrons, that showed conserved structures among the different
isolates for each MBL: intI1-aacA4-blaVIM-2 and intI1-blaVIM-1-
aacA4-aadA1, respectively.
Conclusion: The alarmingly high proportion and clonal diversity
of MBL-producing P. putida clinical isolates suggest an important
environmental reservoir of these highly relevant resistance determinants.
Therefore, considering the threat of potential horizontal transfer of
these plasmid-located MBL-encoding integrons to other species such
as P. aeruginosa, active surveillance is warranted.
P1491 Ability of Spanish clinical laboratories in detecting
MBL-producing strains of Pseudomonas: results from the
SEIMC QC programme
E. Ruiz de Gopegui, C. Juan Nicolau, N. Orta Mira, R. Guna Serrano,
M. Ovies, A. Oliver, C. Gimeno Cardona, J.L. Pe´rez ° (Madrid, Palma
de Mallorca, Gandia, Valencia, ES)
Background: Although rare, MBL-producing strains of Pseudomonas
are increasingly reported in Spain. Interpretation of resistance pattern to
b-lactams could be difﬁcult when several mechanisms coexist in a strain.
Genetic determinants for MBL are located in transposons codifying for
resistance to other drugs. Then, it is crucial that clinical laboratories
were able to recognize this infrequent, but dangerous, mechanism. The
Spanish Society of Clin Microbiol & Infect Dis (SEIMC) has launched
a QC Programme, being continuous education one of its most distinctive
features. We present results of a recent QC with a MBL-producing
P. putida strain.
Methods: A VIM-1 MBL-producing strains was sent to 281 participants
along with a brief clinical history (pneumonia in an oncology patient not
responding to imipenem). Participants were asked to identify the strain,
perform susceptibility tests, and make relevant comments related to the
case. Identiﬁcation of a speciﬁc resistance mechanism was not asked. The
strain was characterised by a reference laboratory that report resistance to
all b-lactams, including cefepime, aztreonam and carbapenems, as well
as gentamicin and tobramycin, remaining susceptible only to amikacin
and colistin. VIM1-type MBL was determined by sequencing.
Results: The 88.2% of participants answered this QC. Results of the
susceptibility studies to b-lactams were almost coincident with that of the
reference laboratory, including resistance to carbapenems. Only 67.8%
agreement was observed for tobramycin (8% major discrepancies). A
total of 29 (11.7%) reported the presence of a MBL, and 11 additional
participants suggested the possibility. Some of these also remark the
possible existence of an additional mechanism explaining this phenotype
(resistance to aztreonam). Four participants reported presence of several
resistance determinants (no particular one detected). Although there
was a place in the form for reporting “special features”, 167 (67.3%)
laboratories gave no information about it.
Conclusion: Only a modest percentage of participants detected
or suspected the MBL (16.1%). Most of these correctly reported
the susceptibility phenotype. Implementing tests for MBL detection
(imipenem+EDTA) is a need for the future. According with the
experience of the SEIMC QC Programme with other resistance determi-
nants (e.g. ESBL-producing enterobacteria), a notorious improvement is
expected when the strain were sent again in the future.
Resistance in Pseudomonas spp. S419
P1492 Relatedness of Pseudomonas aeruginosa isolates producers
of VIM-2 from two central hospitals in Portugal
T. Reis °, G. Ribeiro, C. Vital, A. Alves, O. Cardoso (Coimbra, PT)
Objective: Pseudomonas aeruginosa (PA) remains one of the most
important pathogens in nosocomial setting. Understanding the pathogen
distribution and relatedness is essential for determining the epidemiology
of hospital infections and aiding in the design of rational pathogen
control methods. In this work we proposed to characterise PA VIM-2
producers belonging to two central hospitals of Portugal by random
ampliﬁcation of polymorphic DNA (RAPD) to understand if isolates
are inter or intra related between hospitals.
Methods: Of the 27 VIM-2 producing isolates, 15 were from Hospitais
da Universidade de Coimbra (HUC) collected in ﬁrst semester of 2008
and were from Neurotraumatology (WNT), Surgery III (WS), Hepatic
Transplant Unit (HTU), Cardiology (WC), Medicine (WMI), Orthopedy
(WO), Infectious (WIC), and Emergency (ER). Twelve were collected
from Centro Hospitalar de Coimbra (CHC) during a year (2007–
2008), and were from wards of Pneumology (WP), Neurosurgery (WN),
Infectious (WI), Medicine (WM), Paediatric Hospital (PH), and Hospital
of Pombal (HP). The samples were from different products, namely,
urine, sputum, blood, and exudates. The minimal inhibitory concentration
(MICs) of the VIM-2 strains was determined by E-test method. DNA
was ampliﬁed using the primer 5′-AGCGGGCCAA-3′. We assigned a
letter for each different RAPD proﬁle.
Results: Among the 27 blaVIM-2 isolates the MICs revealed that
aztreonam inhibited 81.5%, followed by piperacillin 66.7%, ceftazidime
25.9%, and meropenem 22.2%. RAPD typing generated 14 different
patterns (A to O). Seven patterns were from HUC (A to G) and the
most prevalent was pattern A that appeared to be disseminated in 3
wards namely WNT, WS and HTU (seven strains), and other patterns
were represented by two or one strain. The patterns H to O belonged
to CHC where H pattern was predominant (ﬁve strains) and appeared
in different wards of PH, other proﬁles were constituted by one or two
strains. Identical RAPD patterns between the two hospitals were not
seen.
Conclusions: Fourteen genotypically different strains were identiﬁed,
indicating that prevalence of carbapenemases-encoding genes was mainly
due to a gene spread and in a lesser extent to clonal dissemination. The
possibility of spreading of VIM-2 in Gram negative pathogens could
emerge as a great problem in the clinical setting and underscores the
need for systematic surveillance of these resistant determinants.
P1493 Detection of VIM-2 metallo-b-lactamase in Pseudomonas
aeruginosa isolates from two central hospitals in Portugal
T. Reis °, G. Ribeiro, C. Vital, A. Alves, O. Cardoso (Coimbra, PT)
Objective: Pseudomonas aeruginosa (PA) is one of the leading causes
of nosocomial infections as it is an opportunistic human pathogen with
an amazing capacity to resist antibiotics either intrinsically or following
acquisition of resistance genes. The aim of this study was to identify
metallo-b-lactamases (MBLs) in imipenem resistant isolates obtained
from two central hospitals belonging to the centre region of Portugal.
Methods: Imipenem resistant bacterial isolates (n = 91) from Centro
Hospitalar de Coimbra (CHC) were collected from June 2007 to June
2008 (one year) and 31 from Hospitais da Universidade de Coimbra
(HUC) collected from January 2008 to June 2008 (half year). Double-
disk synergy test was used for screening MBLs. For research of blaVIM,
blaIMP, blaGIM, and blaSPM, PCR was done. PCR products obtained
were sequenced and analysed. The minimal inhibitory concentration
(MICs) of the VIM-2 isolates was determined by E-test method.
Results: The double disk synergy test was positive in 32 isolates from
CHC and in 18 of HUC. The presence of blaVIM was positive in 12
from CHC and 15 from HUC, and DNA sequencing showed the presence
of blaVIM-2 gene in all of the 27 isolates (54%). The other metallo-
b-lactamases tested were not observed. Among the strains that harboured
VIM-2, MICs were determined and the results revealed that aztreonam
inhibited 81.5% followed by piperacillin 66.7%, ceftazidime 25.9%, and
meropenem 22.2%.
Conclusions: Our ﬁndings are of concern since they demonstrate that
VIM-2 can emerge and turn into a major cause of broad spectrum
b lactam resistance among nosocomial pathogens. The monitoring of
these non-fermenting Gram negative bacilli for production of metallo-
b-lactamases should become a standard aspect of any local or global
surveillance systems.
P1494 Epidemic spread of carbapenem-resistant Pseudomonas
aeruginosa producing VIM-2 metallo-b-lactamase in a
Tunis teaching hospital
S. Hammami, R. Ghozzi °, S. Ben Redjeb (Tunis, TN)
Emergence of carbapenem-hydrolysing metallo-b-lactamase (MBL) in
Pseudomonas aeruginosa has been described worldwide causing a
therapeutic problem.
We report an epidemic spread of VIM-2 producing P. aeruginosa in a
teaching Tunisian hospital.
During the year 2007, 23 carbapenem-resistant P. aeruginosa with
moderate susceptibility to aztreonam recovered from different wards
were analysed for MBL production. MICs of carbapenems were
determined by Etest and all isolates were screened for metallo-
b-lactamase by EDTA double disc synergy test. Isolates with positive
screen test were submitted to PCR analysis with blaIMP, blaVIM and
blaVIM-2 primers. The genetic similarity of metallo-b-lactamase positive
strains was evaluated by pulsed-ﬁeld gel electrophoresis
The isolates were particularly recovered from urology (48%), collected
from urines (48%) and belonged to serotype O11 (61%). They
showed increased MICs of imipenem (MIC range 1−>32mg/ml;
MIC50 = 16mg/ml) and meropenem (MIC range 1.5−>32mg/ml;
MIC50 >32mg/ml). The EDTA double disc synergy test was positive
for 10 strains (43.5%). Using PCR assay, none of these ten strains was
positive for blaIMP gene whereas they were positive for blaVIM-2 gene,
Nine out of 10 MBL positive strains corresponded to a single clone (A).
The epidemic spread of MBL-producing P. aeruginosa isolates,
underlines the need of early detection of these resistant strains for the
strengthening of hygien measures.
P1495 First identiﬁcation of metallo-b-lactamase-producing
Pseudomonas aeruginosa in the Czech Republic
J. Hrabak, M. Fridrichova °, M. Stolbova, T. Bergerova, P. Urbaskova,
H. Zemlickova (Plzen, Prague, U´stı´ nad Labem, CZ)
Objectives: Since 2005, invasive isolates of Pseudomonas aeruginosa
are collected by National Reference Laboratory for Antibiotics of the
National Institute of Health in Prague within the European Antibiotic
Resistance Surveillance System (EARSS). During this time, metallo-b-
lactamase (MBL) production has been veriﬁed by double disk synergy
test with EDTA, imipenem and ceftazidime in the strains showing
resistance to meropenem (n = 424). First two MBL producing strains
of P. aeruginosa were identiﬁed in the blood cultures from patients
with a history of hospitalisation in the Department of Neurosurgery of
Masaryk’s Hospital (Usti nad Labem, Czech Republic).
Methods: MICs to 12 antibiotics were determined by microdilution
broth method according to CLSI recommendation. MICs to meropenem
and imipenem were veriﬁed by E-test. MBL production was conﬁrmed
by spectrophotometric assay. Further characterisation was based on a
multiplex PCR, ampliﬁcation and sequencing of a whole bla gene.
Localisation of the gene on class 1 integron was determined by PCR
using 5′ CS and 3′ CS and internal primers of bla gene followed by
sequencing of ampliﬁcation products. Strains were typed by PFGE and
MLST.
Results: PCR ampliﬁcation and sequencing revealed the MBL enzyme
to be IMP-7 in both isolates carried out on class 1 integron. According
to PFGE analysis, both isolates were of the same clone showed a high
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degree of the resistance to tested antibiotics. Strains were susceptible
only to amikacin (MIC= 8mg/l) and colistin (MIC= 1mg/l).
Conclusions: Despite all neighbouring countries, MBLs have never
been described and detected in the Czech Republic before this ﬁnding.
In this time, it is not possible to identify a geographical origin of
these isolates. However, the IMP-7 MBL, ﬁrstly described in Canada
recently in Malaysia and Japan, seems to be uncommon in the Europe.
Epidemiological data will be completed by MLST which is on going.
This work was supported by a research project grant MSM 2E08003.
P1496 Multiresistant epidemic clones of Pseudomonas aeruginosa
in the Czech Republic
A. Nemec °, M. Maixnerova, L. Krizova, M. Musilek (Prague, CZ)
Objective: To determine whether the high prevalence of antimicrobial
resistance among bloodstream isolates of Pseudomonas aeruginosa in
the Czech Republic is associated with the clonal spread of multidrug
resistant (MDR) strains.
Methods: The study set included 108 bloodstream isolates, which were
selected from 437 isolates of P. aeruginosa collected in the Czech
Republic within the European Antimicrobial Resistance Surveillance
System (EARSS) project in 2007. The 108 isolates originated from 49
hospitals in 36 cities. They were tested for susceptibility to piperacillin,
ceftazidime, cefepime, meropenem, imipenem, ciproﬂoxacin, gentam-
icin, tobramycin, amikacin and colistin by E-test. The genotypes of
the isolates were assessed by multilocus sequence typing (MLST),
macrorestriction analysis of genomic DNA and class 1 integron typing.
Results: Forty-six isolates were susceptible to all antimicrobial agents
while 16 and 46 isolates were resistant or intermediate to 1−3 and
4−9 agents, respectively. A total of 41 multilocus sequence types (ST)
were identiﬁed, which, except for four unique STs, differed from each
other in at least three alleles. ST235 and ST175 included 19 and 16
isolates, respectively. The isolates with either ST235 or ST175 originated
from 25 hospitals in 19 cities. Each of other eight STs included 3−7
isolates, seven STs were found in 2 isolates and the remaining 24 isolates
yielded each a unique ST. Isolates of the same ST had highly similar
macrorestriction proﬁles. ST235 and ST175 encompassed 34 (74%) of
46 isolates resistant to more than 3 agents. Class 1 integrons were found
in 47 MDR isolates, with at least 18 different integron variable regions.
Twelve isolates with ST235 harboured an integron with a 1.9 kb variable
region while 15 isolates with ST175 shared an integron with a 1.6 kb
variable region.
Conclusion: The high prevalence of antimicrobial resistance in
P. aeruginosa isolates in the Czech Republic is predominantly associated
with two MDR epidemic clones, one of which (ST235) belongs to
international clonal complex CC11.
Supported by grant NR/9428−3 of the Ministry of Health of the Czech
Republic.
P1497 Isolation and characterisation of an imported pan-resistant
Pseudomonas aeruginosa clinical isolate producing three
different ESBL enzymes, hyperproducing multidrug-efﬂux
pumps
C. Ratkai, S. Quinteira, F. Grosso, E. Nagy °, L. Peixe (Szeged, HU;
Porto, PT)
Objectives: Pseudomonas aeruginosa is one of the most frequently
isolated nosocomial pathogens, causing life-threatening infections,
such as pneumonia, bacteraemia, and wound infections. It exhibits
intrinsic resistance to several b-lactams and acquire easily additional
resistance mechanisms, including the production of extended spectrum
b-lactamases (ESBLs), down-regulation of porins, hyperproducing multi-
drug efﬂux-pumps, confer resistance to almost all antipseudomonas
antibiotics.
Methods: During the period of 2004 to 2008 we isolated 27 ceftazidime
resistant, non-mucoid P. aeruginosa isolates from different non-cystic
ﬁbrosis patients, hospitalised in nine different hospital wards of South-
Hungary. Identiﬁcation by VITEK 2 system and susceptibility test
by disk-diffusion method was performed, using CLSI breakpoints.
The genes of the extended spectrum b-lactamases (PER-1, PER-2,
TEM, SHV, GES, VEB-1, OXA groups) were looked for by PCR
methods. The iso-electric focusing of the b-lactamases was performed,
the enzymes were visualised with nitroceﬁn. To investigate the location
of the b-lactamase gene plasmid puriﬁcation, PCR detection of the
Tn1213 speciﬁc IS element were performed. The transcription of the
chromosomal genes encoding the OprD, ampC, and the efﬂux pumps
MexAB-OprM, MexXY-OprM, MexCD-OprJ was studied with real-time
PCR assays. The genetic relatedness of the strains was investigated by
PFGE and MLST analyses.
Results: PCR experiments revealed the presence of blaPER, blaOXA-I,
II group in one isolate. Sequencing of the coding region and the RFLP
analyses identiﬁed the PER-1, OXA-2 and OXA-74 genes. The real-time
PCR assays revealed, that this strain hyperproduces two different multi-
drug efﬂux-pumps, namely the MexAB-OprM and the MexXY-OprM.
According to the MLST typing analyses, this strain belongs to a clonal
complex, previously identiﬁed in VIM metallo-b-lactamase producers
in Hungary, namely CC11. Interestingly, the pan-resistant strain was
isolated from a polytraumatised Romanian citizen on admission to the
hospital of Szeged. This suggests the possibility, that this strain was
imported to Hungary from abroad.
P1498 Emergence and persistence of multidrug-resistant
Pseudomonas aeruginosa serogroups O11 and O12
J.-P. Pirnay °, F. Bilocq, J. Van Eldere, M. Vaneechoutte, P. Soentjens,
S. Jennes, P.T. Tassios, N.J. Legakis, A.J. Mifsud, T.L. Pitt, D. De
Vos (Brussels, Leuven, Ghent, BE; Athens, GR; London, UK)
Objectives: In 1989 Pitt et al. (Epidemiol Infect. Dec;103(3):565–
76) reported the emergence of a European multidrug resistant (MDR)
serotype O12 clone, and in 1998 Tassios et al. (J Clin Microbiol.
Apr;36(4):897–901) reported the emergence of MDR in the ubiquitous
and dominant serogroup O11. The objective of the present study was
to investigate the emergence, spread and actual status of these MDR
serogroups in the light of the global P. aeruginosa population structure.
Methods: 328 unrelated P. aeruginosa clinical CF (43) and non-
CF (142), environmental (63) and animal (55) strains, including 61
serotype O11 and 24 O12 strains, collected between 1882 and 2008
in 69 localities (30 countries, 5 continents) were characterised by
ﬁngerprinting (FAFLP), MLST (oprI, oprL and oprD genes), pyoverdine
receptor gene typing, prevalence of exoS and exoU genes and serotyping.
The prevalence of 23 ‘Antibiotic Resistance Genes’ (ARGs) (15 coding
for b-lactamases and 8 for aminoglycoside-modifying enzymes) was
determined by PCR. The MIC values for 21 antibiotics were determined
using the VITEK 2 Advanced Expert System (AES).
Results: In the minimum spanning tree, based on the combination
of the characteristics from the 328 strains, we identiﬁed 11 clonal
complexes (CCs). Fifty-nine strains (22.4%) were MDR, including 14
O11 (23.7%) and 17 O12 (28.8%) strains. Forty-eight of the 58 detected
ARGs were found in MDR O11 and O12 strains. Twenty MDR O12
strains, isolated in 9 countries, some of them separated by thousands of
miles, were shown to cluster into a very conserved clone. Only clinical
non-CF strains isolated post 1980 clustered into this clone. The MDR
serotype O11 strains showed, with the exception of some clonal strains,
an overall higher genetic divergence. They belonged to 2 distant CCs,
which also included environmental and animal strains, but no CF strains.
Most members of the O12 clone harboured the two original (1989)
ARGs (PSE-1 and AAC(6’)II), while others harboured recent ARGs
(e.g. VIM-8).
Conclusion: We suggest that MDR O11 P. aeruginosa epidemic strains
are members of two widespread and successful CCs that were selected
from the environment, in different locations and on several occasions,
adapted to the high care niche, and dispersed in hospitals. MDR O12
strains are probably the offspring of a minority clone, which was locally
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selected from the environment, adapted to the high care niche, and
rapidly spread across high care facilities all over the world.
P1499 Correlation between antibiotic resistance gene detection and
antibiotic resistance phenotype in Pseudomonas aeruginosa
strains
J.P. Pirnay °, F. Bilocq, J. Van Eldere, P. De Schacht, M. Vaneechoutte,
P. Soentjens, S. Jennes, D. De Vos (Brussels, Leuven, Ghent, BE)
Objectives: P. aeruginosa exhibits high inherent antibiotic resistance
(ABR) combined with acquired ABR mechanisms. Important acquired
ABR mechanisms in P. aeruginosa are b-lactamases (BL) and
aminoglycoside-modifying enzymes (AME). The objective of this study
was to analyze the relation between the presence of ‘Antibiotic
Resistance Genes’ (ARGs) and the ABR phenotype.
Methods: 328 unrelated P. aeruginosa clinical CF (43) and non-CF
(142), animal (63) and environmental (55) strains, collected between
1882 and 2008 in 69 localities (30 countries, 5 continents) and
characterised by, amongst others, FAFLP ﬁngerprinting, serotyping and
MLST were screened, by PCR, for the presence of 23 ARGs (15 coding
for BLs and 8 for AMEs). The MIC values for 21 antibiotics were
determined using the VITEK 2 Advanced Expert System (AES). An
arbitrary ABR index (the area of the region bounded by the graph and
the x-axis in ﬁgure 1) was determined. Additionally, the oprD gene was
screened for ‘defective oprD mutations’ (DOMs) that confer carbapenem
resistance.
Results: Fifty-eight ARGs were detected. Most of them (48) were found
in multidrug resistant (MDR) epidemic strains exhibiting serotypes O11
and O12. None of the 43 CF strains exhibited ARGs. We observed a
gradient in ABR phenotype (ABR index), from strains isolated in the pre-
antibiotic era (0.63) to the contemporary serotype O12 epidemic strains
(3.63), over environmental (1) and animal (1.31) strains. There was a
total absence of MDR among the 49 strains isolated before 1980. The
ABR index of the CF isolates (2.05) was comparable to that of clinical
non-CF isolates (2.25), but showed a broader distribution (Figure 1).
This is probably the result of differences in ABR mechanisms. Inherent
ABR mechanisms like efﬂux pumps and bioﬁlms cause broad spectrum
ABR and are more common in CF isolates. Most of the clinical non-
CF strains showed either a moderate or a very high ABR, depending on
whether they acquired ARGs or not. Twenty-one distinct DOMs mediated
resistance to MER in 22 clinical strains, including 7 CF strains. Overall,
there was a satisfactory correlation between the detected ARGs and the
ABR phenotype.
Conclusion: Since the introduction of antibiotics in clinical practice
ABR is spreading, also in the environment, and has reached dramatic
levels in some MDR P. aeruginosa clones. The detection of ARGs
through PCR has potential to generate partial, but rapid, information
regarding ABR in non-CF P. aeruginosa strains.
P1500 Resistance to carbapenems and ciproﬂoxacin of intensive
care unit Pseudomonas aeruginosa isolates in relationship to
the ICU antimicrobials use at a university hospital, Zagreb,
Croatia
V. Erdeljic °, I. Francetic, S. Kalenic, Z. Bosnjak, A. Budimir, K. Makar
Ausperger, R. Likic, L. Bielen, M. Radacic Aumiler (Zagreb, HR)
Objectives: The selection of resistant bacteria as a result of wide use of
antibiotics is predictable and cannot be avoided. However, non-adherence
to other infection control measures is an often underestimated problem
that deserves attendance. Despite the lack of a surveillance system,
the problem of multi-drug resistant P. aeruginosa strains has been well
established in our hospital, especially in the Intensive Care Units (ICUs).
We have evaluated trends in P. aeruginosa resistance to carbapenems and
ciproﬂoxacin in the ICU of the Department of Medicine during a period
of 9 months with regard to antibiotic consumption.
Methods: Data on antibiotic use were collected from the hospital’s
pharmacy. The numerator used was DDD (deﬁned daily dose); the
denominator used was per-100 admissions. Data on admissions were
collected from the administration ofﬁce. Microbiology data were
obtained from the Department of Clinical Microbiology. The evaluation
period was: November 2006-July 2007.
Results: During the evaluated period, the hospital’s microbiology
laboratory isolated 61 non-duplicate P. aeruginosa strains. The average
observed monthly percentages of ciproﬂoxacin, piperacillin/tazobactam,
imipenem/cilastatin and meropenem-resistant P. aeruginosa were 55.8%
(0–100%), 52.9% (0−83.3%), 51.9% (0−91.7%) and 44.5% (0−91.7%)
respectively. The observed results are higher than average hospital
resistance rates of P. aeruginosa to these antibiotics (36%, 22%, 32%
and 30% respectively). Out of 32 antibiotics, the most prescribed
in the evaluated ICU were amoxicillin/clavulanic acid (14.8%),
ciproﬂoxacin (9.4%), carbapenems (9.3%), azithromycin (7.4%) and
piperacillin/tazobactam (6.9%). Correlating the monthly resistance rates
with antibiotic consumption did not demonstrate signiﬁcant relationship
between ciproﬂoxacin, piperacillin/tazobactam, imipenem/cilastatin and
meropenem consumption and P. aeruginosa resistance rates to these
antibiotics.
Conclusion: The results show disturbingly high resistance of P. aerugi-
nosa to carbapenems and ciproﬂoxacin in the evaluated ICU, without
causative relationship to antibiotic usage. This indirectly points out
towards non-compliance with infection control measures and to bacterial
spread of resistant strains of P. aeruginosa in the evaluated ICU.
Surveillance systems aimed at monitoring not only antibiotic use,
but also other infection control measures are lacking and should be
implemented as soon as possible.
P1501 Pseudomonas aeruginosa clones disseminated among
patients in a tertiary care teaching hospital in Greece
during a two-year period
M. Koutsogiannou °, E. Drougka, E.D. Anastassiou, M. Christoﬁdou,
I. Spiliopoulou (Patras, GR)
Objective: Pseudomonas aeruginosa is a cause of a wide diversity
of infections in immunocompromised hosts. The high level of
antibiotic resistance combined with the frequent spread of epidemic
strains make P. aeruginosa one of the major nosocomial pathogens.
Antibiotic resistance patterns, serotypes and clones were determined
in P. aeruginosa isolates recovered from clinical samples of different
hospitalised patients during a two-year period.
Methods: A total of 220 P. aeruginosa isolates recovered from inpatients
during 2006–2007 were identiﬁed at species level by standard methods
(Oxiferm, BD, BBL). Antibiotic susceptibility testing was performed
by the agar disk diffusion method according to CLSI guidelines. MIC
of colistin (CL) was determined by the Etest (AB Biodisk) and the
production of metallo-b-lactamases (MBL) was tested by the double
strip Etest. Serotyping was performed by 17 monovalent antisera against
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the O antigen according to the International Antigenic Typing Scheme.
Clones were deﬁned by PFGE of chromosomal DNA SpeI digests.
Results: Eighty-four isolates were recovered from patients hospitalised
in the Intensive Care Unit (ICU), followed by the Departments of Internal
Medicine (74), Surgery (23), Paediatrics (20) and Outpatients (19).
Sixty-one P. aeruginosa were isolated from respiratory tract samples
from the ICU, followed by wounds’ infections (56), bacteraemias (37),
urinary tract (37), catheters (12) and stool specimens (17). Multi-resistant
isolates were 52% and 61% in 2006 and 2007 respectively; MBL-positive
isolates were 42 (19%), while no isolate was resistant to colistin. The
predominant serotype was O:11 (112 isolates), followed by O:1 (18).
Eighty clones were identiﬁed by PFGE, with ﬁve predominant: A (74
strains), B (9 strains), C (6 strains), D (28 strains) and S (5 strains). Four
out of ﬁve clone S strains were recovered from children. These clones
were dominant in the hospital during the two-year period. Serotype O:11
strains were classiﬁed into clones A and D, isolated mainly from the
ICU. Among MBL-positive strains 16 belonged to clone D and were
serotype O:11, six to clone A and four to clone B.
Conclusions: Multi-resistant P. aeruginosa strains are disseminated
in our hospital, mainly among ICU patients. Polyclonality combined
with the spread of certain dominant clones including multi-resistant
strains, indicate the need of appropriate antibiotic policy and continuous
infection control measures.
P1502 Prevalence and epidemiology of antibiotic resistance in
Pseudomonas aeruginosa isolated from low respiratory
tract of patients hospitalised in intensive care units from
5 Belgian hospitals, 2004–2008
M. Riou °, S. Carbonnelle, L. Avrain, Y. Glupczynski, D. De Vos,
J.-P. Pirnay, A. Simon, D. Pierard, F. Jacobs, A. Dediste, F. Van
Bambeke, P. Tulkens (Brussels, BE)
Objectives: Pseudomonas aeruginosa (PA) is a major cause of
nosocomial infections, with one of its preferential “niches” in respiratory
tract of patients in ICU. Our objective was to evaluate the level of
resistance of PA towards commonly used antibiotics in this setting.
Methods: 138 ﬁrst, non-duplicate isolates were collected from 5
hospitals over the last 4 years from ICU patients with a suspicion
of nosocomial pneumonia (conﬁrmed in most cases by retrospective
analysis of medical records). MICs of 5 commonly used antibiotics
plus ticarcillin and aztreonam (as efﬂux reporters) were determined
by geometric microdilution in cation-adjusted Muller-Hinton broth.
Susceptibility was assessed according to EUCAST Breakpoints (BP).
Results: Based on EUCAST breakpoints, and using a 20% resistance
cut-off, only amikacin could be considered effective globally as well
as in each individual hospital. Meropenem was globally effective, but
resistance exceeded the cut-off in 3/5 hospitals. Gentamicin, aztreonam,
ciproﬂoxacin and cefepime were globally ineffective, with resistance
exceeding 40% for cefepime in 2 hospitals (cefepime-resistant isolates
were also often resistant to other antibiotics [GEN, 24%; AMK; 8%;
ATM, 27%; MEM, 20%; and CIP, 20%]).
Global H1 (n = 12) H2 (n = 30) H3 (n = 18) H4 (n = 22) H5 (n = 56)
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GEN 2/64 0.0/25 2/64 0.0/25 2/64 0.0/30 4/64 0.0/33 2/32 0.0/27 2/8 0.0/20
AMK 4/16 9.4/8.0 4/8 0.0/8.3 4/32 13/13 8/16 11/5.6 4/32 18/14 8/8 3.6/5.4
MEM 1/16 0.0/10 1/4 25/8.3 2/16 6.7/37 1/4 17/5.6 1.0/16 4.5/27 1/16 16/27
FEP 8/64 0.0/46 4/32 0.0/33 16/64 0.0/70 12/64 0.0/44 6/64 0.0/36 8/64 0.0/37
CIP 0.25/8 7.2/22 0.25/8 8.3/25 0.4/16 6.7/37 0.25/16 11/33 0.19/8 0.0/14 0.19/16 8.9/16.1
TIC 64/512 0.0/87.0 32/256 0.0/78 128/256 0.0/83 64/256 0.0/80 48/512 0.0/91 64/512 0.0/90
ATM 12/32 67/30 6.0/32 67/33 16/32 67/33 16/32 56/33 16/128 64/36 8/32 75/23
aEUCAST breakpoints: gentamicin (GEN): S4, R>4; amikacin (AMK): S8, R>16; meropenem (MEM): S2,
R>8; cefepime (FEP): S8, R>8; ciproﬂoxacin (CIP): S0.5, R>1; ticarcillin (TIC): S16, R>16: aztreonam
[ATM]: S1, R>16.
Figures in bold indicate situations (global or per hospital) in which resistance to a clinically-used given antibiotic
exceeds 20% of isolates.
Conclusion: The level of antibiotic resistance in Pseudomonas
aeruginosa (including cross-resistance, as illustrated for cefepime) in the
ICU surveyed is critically limiting therapeutic options, but in variable
way that justiﬁes early and careful assessment of susceptibilities for
ensuring appropriate therapy. Efﬂux-mediated resistance seems also very
prevalent and will need appropriate diagnostic approaches.
P1503 Pseudomonas aeruginosa and the hospital: antimicrobial
susceptibility trends over a four-year observation period
R. Manfredi °, A. Nanetti (Bologna, IT)
Introduction: A prospective microbiological surveillance monitoring
including culture and systematic in vitro antimicrobial susceptibility
studies of all relevant pathogens, is ongoing at our Hospital. Particular
attention has been deserved to Pseudomonas aeruginosa, and a leading
Gram-negative, often multiresistant organisms in hospital settings.
Materials-Methods: The temporal variations of in vitro antimicrobial
sensitivity rates of all isolated Pseudomonas aeruginosa strains were
collected for all suitable isolates, during the four-year period ranging
from January 2004, up to December 2007. The same pathogen cultured
more than once from the same patient within one month, was considered
one time only (one episode).
Results: Among Pseudomonas aeruginosa isolates (2,083 evaluable
tested strains), the best performance was obtained by the old colistin
(colimycin), with a sustained 100% susceptibility rate, followed by
amikacin (72.8–81.2% of tested strains), imipenem (76.8–80.8%),
piperacillin-tazobactam (70.9–78.7%), ceftazidime (68.9–77.1%), and
tobramicin (64.6–70.9%). On the other hand, gentamicin (55.1–63.5%
of tested strains), aztreonam (57.5–66.8%), ciproﬂoxacin (55.7–65.0%),
ticarcillin-clavulanate (53.7–60.5%), and mezlocillin (48.4–55.2%),
proved less affordable. A signiﬁcant temporal trends towards a reduced
antibiotic sensitivity was found for the majority of tested molecules, but
it resulted signiﬁcant for aztreonam, ciproﬂoxacin (p< 0.001), ticarcillin-
clavulanate (p< 0.02), and mezlocillin and tobramicin (p< 0.04).
Conclusions: A prospective monitoring of antimicrobial susceptibility
rates of a major hospital-associated organism like Pseudomonas aerug-
inosa is relevant, to add to local and national guidelines of antibiotic
treatment and prophylaxis. Despite a signiﬁcant increase of resistance
rates against the majority of compounds which usually test active against
Pseudomonas aeruginosa, however amikacin, carbapanems, piperacillin-
tazobactam, amikacin, imipenem, and ceftazidime still maintain a
reliable role in eventual, empiric regimens to be added pending microbial
isolation and in vitro sensitivity assays, since they remained active in at
least 70% of hospital isolates of the last four years (2004–2007). Colistin,
which maintains full in vitro activity against all Pseudomonas strains,
remain as a possible component of combined antimimicrobial strategies,
when multiresistant pathogens are of concern.
P1504 Incidence of Pseudomonas aeruginosa resistant to colistin
in a tertiary care hospital
E. Gardun˜o °, M. Fajardo, R. Hidalgo, M. Sa´nchez-Gonza´lez, J. Rangel,
J. Blanco-Palenciano (Badajoz, ES)
Objective: Infections caused by multidrug-resistant Pseudomonas
aeruginosa pose a serious problem due to the limited number of
antimicrobials available for treatment, which sometimes requires the use
of old antibiotics, such as colistin. The widespread use of this antibiotic
in our hospital due to an outbreak of multidrug-resistant Acinetobacter
baumannii has led to the appearance of strains of P. aeruginosa resistant
to colistin (Pae-CR). The aim of this study is to analyze the incidence
of Pae-CR and describe its clinical and epidemiological characteristics.
Methods: A retrospective study of patients with Pae-CR isolates during
the years 2006–2008 was conducted. The sensitivity to colistin was
determined by the MicroScan Walkaway automated system (Siemens
Healthcare), and resistance was conﬁrmed using the Etest method
(Izasa). We related the annual consumption of colistin in our hospital
with the proportion of Pae-CR to that same year.
Results: 16 patients with one or more isolates of Pae-CR were retrieved:
6 patients in 2006, 8 in 2007 and 2 in 2008. The percentage of Pae-CR for
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total P. aeruginosa was 6.5% in 2006, 4.34% in 2007 and 3.84% in 2008.
Colistin consumption in our centre was 12,796 units in 2006, 6041 in
2007 and 160 in 2008. Analysing data by the chi-square method we found
no statistically signiﬁcant differences with respect to the consumption
of colistin with the number of isolations of Pae-CR between 2006 and
2007, but there is a statistically signiﬁcant relationship between the years
2007–2008 and 2006–2008 (p = 0.0139 and p = 0.03796, respectively).
The origin of the samples was: 6 respiratory samples, 6 wound exudates,
2 catheter tips, 1 blood and 1 skin. All the isolates, except the skin,
were considered causing infection. The age range of patients was
41−72 years (median = 50); 62.5% were men; 50% had been or were
in ICU. 4 patients were coinfected with A. baumannii, 2 with extended-
spectrum b-lactamase producing Escherichia coli and 2 with methicillin-
resistant Staphylococcus aureus. Only the four patients coinfected with
A. baumannii were treated with colistin.
Conclusions: In our hospital the incidence of Pae-CR is low, with a
tendency to decrease directly related to the decline in the use of colistin.
The emergence of resistance seems not to be associated with exposure
to colistin of the isolates of P. aeruginosa studied.
P1505 Resistance and epidemiology of Pseudomonas aeruginosa
isolated from cystic ﬁbrosis patients: a French multi-centre
study
A. Me´rens °, C. Llanes, C. Pourcel, M. Roussel-Delvallez, G. Vergnaud,
J.D. Cavallo, P. Ple´siat on behalf of the GERPA Study Group
Objectives: To describe the epidemiology and the resistance of
P. aeruginosa strains isolated from cystic ﬁbrosis (CF) patients in France.
Methods: 204 P. aeruginosa strains isolated from 153 CF patients (from
1 to 45 years old) were collected in 10 French University-afﬁliated
hospitals in 2007. Their susceptibility (MICs) to 14 antipseudomonal
antibiotics was determined by the standard broth microdilution method.
Resistance mechanisms to b-lactams were assessed phenotypically
(susceptibility proﬁles in the presence/absence of cloxacillin or EDTA),
by isoelectrofocusing, PCR, and gene sequencing. The enzymatic ac-
tivities of chromosomally-encoded b-lactamase AmpC were determined
spectrophotometrically. The expression levels of efﬂux pumps MexAB-
OprM and MexXY/OprM were quantiﬁed by real-time RT-PCR. The
strains were genotyped by MLVA (Multiple Loci Variable Number of
Tandem Repeat Analysis) using 15 Variable Number Tandem Repeat
(VNTR) markers. MLVA clustering analysis was performed using the
categorical coefﬁcient and the Unweight Pair Group Method with
Arithmetic mean (UPGMA).
Results: The resistance rates of P. aeruginosa (according to the
EUCAST breakpoints) were found to increase with patients’ age
for all the antibiotics tested except for colistin. 128/204 strains
(62.7%) displayed a wild-type susceptibility phenotype to b-lactams.
Susceptibility rates to ticarcillin, piperacillin, piperacillin-tazobactam,
ceftazidime and imipenem were 67%, 74%, 77%, 81%, and 80%,
respectively. Analysis of the resistance mechanisms to b-lactams in
67 isolates with ticarcillin MIC >16mg/L showed that 39/67 strains
overexpressed b-lactamase AmpC, 57/67 overproduced efﬂux pumps
MexAB-OprM and/or MexXY/OprM while 62/67 lacked carbapenem-
speciﬁc porin OprD. 11/67 strains were found to harbour acquired
b-lactamases including VIM (n = 1), TEM-2 (n = 1), PSE-1 (n = 1), as
well as OXA-1-like (n = 4) and OXA-2-like derivatives (n = 4). MLVA
analysis identiﬁed 111 different genotypes and 41 clusters among the
204 collected isolates, three of which correspond to previously identiﬁed
strains (clone C, sequenced strain Pa 14, sequenced strain 3719).
Conclusion: The resistance of CF strains of P. aeruginosa to b-lactams
is quite high in France but not really different from that reported for
nosocomial strains. It mainly results from intrinsic mechanims emerging
in individual strains submitted to repeated courses of chemotherapy.
P1506 RT-PCR to investigate the roles of efﬂux, porins and
b-lactamases in multi-resistance of Pseudomonas aeruginosa
from cystic ﬁbrosis
M. Tomas °, M. Doumith, A. Beceiro, M. Warner, G. Bou, D. Livermore,
N. Woodford (A Corunha, ES; London, UK)
Introduction: P. aeruginosa isolates from cystic ﬁbrosis (CF) patients
are often highly resistant to multiple antimicrobial classes, with
phenotypes that do not match those for single efﬂux, b-lactamase or
impermeability mechanisms. We investigated whether real-time reverse
transcriptase (RT)-PCR could be used to identify the combinations of
mechanisms present.
Methods: 25 P. aeruginosa isolates were studied, collected from UK CF
patients in 2007−8; 7 P. aeruginosa strains with characterised efﬂux and
AmpC served as controls. MICs were determined by agar dilution and in-
terpreted vs. EUCAST guidelines. Expression of mexAB-oprM, mexCD-
oprJ, mexEF-oprN and mexXY-oprM efﬂux, ampC b-lactamase and oprD
porin genes was analyzed by real-time RT-PCR and compared with strain
PAO1. One gene was assayed from each efﬂux system. Carbapenemase
activity was assessed by modiﬁed Hodge and EDTA synergy tests, with
carbapenemase genes sought by PCR. Transcription variations were used
as variables in a Student’s t test to evaluate associations with antibiotic
resistance; those signiﬁcantly associated with a resistance (P< 0.05) were
used as covariates in a logistic regression model.
Results: The 25 isolates included representatives resistant to carbapen-
ems (n = 20), ceftazidime (13), aztreonam (16), ciproﬂoxacin (21), and
aminoglycosides (20). In univariate analysis, overexpression of mexA
and mexC was signiﬁcantly associated with resistance to meropenem,
cephalosporins, aztreonam and carbenicillin;mexX overexpression corre-
lated with elevated amikacin MICs, and mexE overexpression with raised
cefotaxime MICs. Increased ampC transcription was associated with
resistance to cephalosporins and, surprisingly, meropenem, while reduced
oprD expression was associated with carbapenem resistance and presum-
ably owing to combination with other mechanisms, not causality with
raised MICs of aminoglycosides and ciproﬂoxacin. Logistic regression
identiﬁed reduced oprD expression (P = 0.048) and mexA overexpression
(P = 0.057) as the main mechanisms underlying meropenem resistance,
whilst mexA overexpression was also associated with resistance to
aztreonam (P = 0.023). EDTA synergy suggested carbapenemase activity
in 2 isolates, but blaMBL genes were not detected by PCR.
Conclusions: RT-PCR proved useful for investigating the multiplicity of
mechanisms present in these complex P. aeruginosa isolates from CF.
P1507 b-lactamase activity evolution of Aeromonas hydrophila
CphA metallo-b-lactamase by design of a chimeric
CphA-VIM-1 enzyme
M. Perilli °, C. Di Lisio, S. Rainaldi, G. Celenza, M. Galleni,
P.S. Mercuri, C. Pellegrini, C. Forcella, P. Bellio, G. Amicosante
(L’Aquila, IT; Lie`ge, BE)
Objectives: Metallo-b-lactamases are zinc enzymes belonging to molec-
ular class B. They are able to hydrolyze b-lactam antibiotics in particular
carbapenems. Among subclass B2 b-lactamases, Aeromonas hydrophila
CphA enzyme efﬁciently hydrolyses only carbapenems while VIM-1, be-
longing to subclass B1, hydrolyses a broad array of b-lactam antibiotics
including penicillins and cephalosporins. CphA (254 aa, 25kDa, pI 8.0)
and VIM-1 (266 aa, 26kDa, pI 5.2) contain a-b-b-a sandwich structure
with one and two zinc ions, respectively, essential to the hydrolysis
reaction. The goal of this study was to design and produce a new
chimeric enzyme from CphA and VIM-1 in order to improve the catalytic
efﬁciency of CphA against non-carbapenem b-lactam antibiotics.
Methods: The construction of chimeric enzyme was performed
by overlapping three different DNA segments obtained from PCR
ampliﬁcation of blaCphA and blaVIM-1 genes. Automatic DNA
sequencing was performed on PCR fragments and recombinant plasmid
using an automatic sequencer ABI-PRISM 310. blaCphA-VIM-1 gene
was generated by a PCR-overlap using blaCphA and blaVIM-1 genes
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as template. blaCphA-VIM-1 gene was cloned into pBC-SK vector
and the recombinant strain was inserted by transformation into E. coli
JM109. The determination of MICs was performed by the conventional
macrodilution broth procedure as recommended by CLSI.
Results: The CphA-VIM-1 chimera was made using CphA enzyme
as scaffold. A domain of 92 amino acid residues, including Asn116,
Asn118 and Asp120, was substituted in CphA metallo-b-lactamase by
the corresponded domain of 78 amino acid from VIM-1. In vitro
susceptibility was tested on E. coli pBC-CphA-VIM-1, E. coli pBC-
CphA and E. coli pBC-VIM-1 versus a large pattern of antibiotics.
E. coli pBC-CphA-VIM-1 recombinant strain showed an higher MIC
value for piperacillin (MIC value, 32mg/L) with respect to E. coli
pBC-CphA (8mg/L) and E. coli pBC-VIM-1 (8mg/L). Concerning
cephalosporins, MIC values for cefazolin was 64mg/L for E. coli
pBCCphA-VIM and 2mg/L for E. coli pBC-CphA and E. coli pBC-
VIM-1. The molecular weight and pI was evaluated on pure enzyme
by SDS-Page and isoelectrofocusing and seem to be 24 kDa and 6.2,
respectively.
Conclusion: Starting with CphA enzyme, that hydrolyzes only
carbapenems, we have obtained a new chimeric enzyme that evolves
versus a much broader spectrum activity.
Integron-related antibiotic resistance
P1508 Prevalence of class 1 and class 2 integrons among Escherichia
coli isolates of human and animal origin in Lithuania
J. Povilonis °, V. Seputiene, M. Ruzauskas, R. Siugzdiniene, A. Pavilonis,
E. Suziedeliene (Vilnius, Kaisiadorys, Kaunas, LT)
Objectives: Investigation of the prevalence and diversity of class 1 and
class 2 integrons in 232 Escherichia coli isolates of human and animal
origin obtained during period 2005–2008 in Lithuania.
Methods: Total 232 isolates of E. coli from various clinical specimens
collected in 5 hospitals in Lithuania (n = 98) and from various disease
condition and healthy animals (n = 134, poultry, swine, cattle) were tested
for their antimicrobial susceptibility by disk diffusion method. Isolates
resistant to at least two antimicrobials were selected for further studies.
PCR and RFLP based analysis were used for the detection of class 1
and class 2 integrons. Resistance gene cassette structure was determined
by DNA sequencing of variable parts of integrons. Plasmid location of
integrons was conﬁrmed by the conjugation experiments.
Results: One hundred out of 232 (43%) E. coli isolates harboured class
1 and/or class 2 integrons. Class 1/class 2 integrons were detected
in 45 E. coli isolates associated with human infections and in 55
E. coli isolates from animal origin. Single class 1 integrons were
detected in 78 (34%) E. coli isolates. Combination of class 1 and
class 2 integrons were detected in 4 (2%) isolates. Eighteen different
genes spread within 11 different gene cassette arrays were observed
in class 1 integrons. The most frequent cassette arrangements of
class 1 integron were as follows (number of isolates/%): dfrA1+aadA1
(30/37%), dfrA17+aadA5 (22/27%) and aadA1 (11/13%). dfrA1+aadA1,
dfrA17+aadA5 and dfrA12+orfF+aadA2 gene cassette arrays were found
in isolates either of human or animal origin. aadA1, estX+aadA1,
dfrA14+aadA6, aacA4+catB3+dfrA1+orfX, 330 bp+sat2+aadA2 gene
cassette arrays were exclusively associated with class 1 integrons in
isolates from animal origin, whereas dfrA5+ereA2, oxa30+aadA1 and
dfrA17+cmlA gene cassette arrays were found in isolates from human
origin only.
Single class 2 integrons were found in 18 (8%) of E. coli
isolates and were represented by four different gene cassette arrays.
The most frequent cassette arrangement of class 2 integrons was
dfrA1+sat1+aadA1 (15/68%) present in human and animal isolates.
The plasmid location was conﬁrmed for 8 out of 11 identiﬁed class 1
and for 2 out of 4 identiﬁed class 2 integrons.
Conclusions: This study is the ﬁrst report on the prevalence and
characteristics of class 1 and class 2 integrons in Lithuania indicating
their broad dissemination among human and animal E. coli isolates.
P1509 The genetic environment inﬂuencing selection and
persistence of sul2 in clinical isolates
T. Curiao °, R. Canto´n, Aˆ. Novais, F. Baquero, T.M. Coque (Madrid, ES)
Objectives: sul2 has been found as the most prevalent sulfonamide
resistance gene in isolates from distinct origins and species. Firstly
identiﬁed on plasmid RSF1010 in 1988, it has been frequently found
adjacent to strAB and ISCR2 sequences on different plasmids. In this
work, we determine sul2 genetic environment in human enterobacterial
clinical isolates.
Methods: A collection of 129 clinical enterobacterial isolates containing
sul2 from our institution (1988–2006) including extended spectrum-
(ESBL, n = 96)/metalo- (MBL, n = 3) b-lactamase producers and non-
producers (n = 30) was studied. Clonal relatedness was established
(PFGE, phylogenetic groups) and antibiotic susceptibility by disk
diffusion (CLSI). Genetic platforms were determined based on known
sequences by PCR, long-PCR, RFLP and sequencing. Twenty-four sul2-
positive strains were selected for conjugation assays. Plasmid analysis
included determination of size (S1 nuclease), incompatibility groups,
replicases and relaxases (PCR, hybridisation and sequencing) and rep
and mob genes of recent published low %CG sul2-plasmids from
environmental origin.
Results: sul2 was similarly distributed among E. coli (n = 124)
phylogroups (A+B1=49%, B2+D=43%) and it was identiﬁed in strains
with a variety of ESBLs (CTX-M-1, -3, -32, -15, -9, -14, SHV-5,
-12, TEM-4, -24, -27, -52) and MBL (VIM-1) and, similarly, in non-
producers. sul2 gene was transferable in 19/24 of cases, associated
with sulfonamide, streptomycin and/or tetracycline markers. Some
(n = 12) transconjugants presented more than one plasmid. No apparent
association between sul2 gene and speciﬁc plasmids was observed. Some
strains presented two different sul2-containing plasmids, conjugative
(50–380 kb) and non-conjugative (5−12Kb). Most conjugative plasmids
belonged to rep type Inc B/O. sul2 was found adjacent to ISCR2, entire
or truncated (n = 48) and to both repC (pRSF1010) and strAB (n = 31)
genes. Overall, 34% sul2-positive strains presented colicin genes. sul2
was also detected in 5 non-E. coli strains.
Conclusions: Despite scarce use of sulfonamides in humans, the sul2
gene is frequent in clinical isolates. Its presence is related to different
plasmids and genetic platforms containing ISCR2 and other resistance
genes affecting widely used antimicrobials. Co-selection processes might
have fuelled persistence of sul2 gene containing isolates.
P1510 Sul3-carrying class 1 integrons in clinical Enterobacteriaceae
isolates and their plasmid association
T. Curiao °, R. Canto´n, A. Valverde, F. Baquero, T.M. Coque (Madrid, ES)
Objectives: Sulfonamide resistance, caused by sul3 located in unusual
integrons, seems to be widespread among bacteria from animals and
humans in the community. The aim of this work was to determine
the frequency and genetic environment of sul3 gene from clinical
Enterobacteriaceae isolates recovered in the last years.
Methods: A collection of 344 Enterobacteriaceae clinical isolates
from our institution (1988–2006) which included extended-spectrum
or metallo-b-lactamases (ESBL or MBL) producers (n = 241) and non
producers (n = 103) was studied. Clonal relatedness was established
(PFGE, phylogenetic groups) and antibiotic susceptibility determined by
disk diffusion (CLSI). Characterisation of sul3-integrons was determined
by long-PCR, RFLP and sequencing. Plasmid analysis included size
determination (S1 nuclease), and incompatibility grouping (PCR of
replicases and relaxases, hybridisation, sequencing).
Results: We identiﬁed 22 sul3-positive Escherichia coli isolates
(6.4%) from 1997 to 2006. They mainly belonged to A and
B1 phylogroups (n = 14/22). sul3-positive isolates showed decreased
susceptibility to sulfonamides (86%), streptomycin (86%), trimethoprim
(77%), tetracycline (77%) and chloramphenicol (68%). Most of the
isolates also contained sul1 and sul2 and all were ESBLs (n = 22) or
MBL (n = 1) producers and mainly recovered from community patients.
sul3 was transferable in 86% of the cases. Five different integron arrays
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were found, three of them identical to those previously described. All of
them showed a common region qacH-IS440-sul3. Size of sul3-plasmids
varied from 55 to 220 Kb, although those of 100 Kb were the most
common and belonged to IncI1 complex (n = 13). Ten strains contained
plasmids carrying both sul3 and blaSHV-12. Three of them also produced
other ESBLs/MBL (CTX-M-type or VIM-1 together with SHV-12).
Conclusions: sul3 was relatively frequent and linked mainly, with
human isolates from the community expressing ESBLs and/or MBLs.
An association with an epidemic IncI1 plasmid carrying blaSHV-12 is
reported.
P1511 Diversity of Tn402 defective variants associated with class
1 integrons
Aˆ. Novais °, E. Machado, R. Canto´n, L. Peixe, F. Baquero, T.M. Coque
(Madrid, ES; Oporto, PT)
Objectives: Class 1 integrons are Tn402 derivatives frequently
associated with mercury transposons. Whole characterisation of class 1
integrons has scarcely been described. A comprehensive analysis of class
1 integrons was performed among representative Enterobacteriaceae
isolates recovered in our institution during the last 15 years.
Methods: Forty-ﬁve Enterobacteriaceae (n = 32 E. coli, n = 8 K. pneu-
moniae, 3 E. cloacae, 1 S. enterica and 1 K. oxytoca) of clinical
(n = 37, 82.2%) and non-clinical (n = 8, 17.5%) origin, producing and
non-producing different ESBL (TEM-4, -24, SHV-2, -2a, -5, -12,
-13, CTX-M-10, -14) were studied (1988–2003). Analysis of class 1
integrons included characterisation of intI1, 5′CS-3′CS variable region,
tniTn402, and screening of sequences orf5, IS1326, IS135 and, IS6100
(PCR simplex and overlapping, sequencing)., Association with mercury
tranposons was searched by screening the presence of merA, tniTn21,
tniTn1696 (hybridisation, PCR simplex and overlapping, sequencing).
Results: Isolates were classiﬁed in Group I (n = 38), showing variable
gene cassette content [XVI integron (In) types were identiﬁed]; and
Group II (n = 7), positive only for IntI1. Four subtypes were established
according to the presence of sequences truncating the tniTn402 module:
Subtype a) IS1326+ (n = 10; In types I, II and VII); subtype b) IS1326
plus IS1353 (n = 3; In types VI and XII); subtype c) IS6100 (n = 14; In
types I, III, V, VI, VIII, IX, XIII-XVI, IntI1+); and subtype d) absence
of ISs (n = 11; In types I, II, VII-XI). merA (n = 25/45; 55.6%) was
commonly detected among subtypes a, b (mostly associated with Tn21-
mer sequences and/or tnpTn21 transposition module), subtype c (linked
to tnpTn1696, tnpTn21 or none of them) and less frequently to subtype d
(eventually linked to tnpTn1696, tnpTn21). In2 promotor sequence (weak
version) was the most frequently identiﬁed (72%), although variants In1
(intermediate) and In4 (strong) were also detected. Group I subtypes
were mostly identiﬁed among ESBL producing isolates but those of
group II were absent among ESBL producers.
Conclusions: A high diversity of Tn402 variants located in different
mercury transposons platforms was associated with identical gene
cassette arrays (5CS-3CS). The high variability observed among the
genetic platforms suggests recombinatorial events between mobile
elements widely disseminated among human Enterobacteriaceae isolates.
P1512 Antimicrobial resistance of Salmonella strains implicated
in 38 community outbreaks in northern Spain
M. Bances, M.A. Gonza´lez Hevia °, R. Rodicio, C. Mendoza (Oviedo, ES)
Objective: To analyze the antimicrobial resistance of Salmonella strains
related with community outbreaks recorded in Asturias, Spain, between
2002–2005.
Methods: A total of 377 Salmonella isolates related with 38 outbreaks
that occurred in institutions (restaurants, hospitals, schools and others)
were analysed. Of these isolates, 349 were collected from patients
attended in hospitals and recorded in the Public Health Laboratory del
Principado de Asturias (PHLPA), the other 28 isolates were collected
from foods outbreak associated in the PHLPA. Serotyping and phage
typing were determined in the “Centro Nacional de Referencia de
Salmonella”, Madrid Susceptibility/resistance was assayed according to
CLSI, by the disk diffusion method, using Mueller Hinton agar plates,
and disks of ampicillin 10 (Ap), ciproﬂoxacin 5 (Cip), cloramphenicol
30 (Cm), gentamicin 10 (Gm), kanamycin 30 Km), streptomycin 10
(Sm), nalidixic acid 30 (Nal) tetracycline 30 (Te), sulfadiazine 300 (Su)
and trimethoprim-sulfamethoxazole 1.25/23.75 (Sxt). Plasmid analysis
was done by the Kado-procedure; presence of integrons of clase 1 by
PCR using primers of conserved 3′CS and 5′CS regions; and presence
of speciﬁc R-genes by PCR using described primers.
Results: Twenty nine outbreaks were caused by S. Enteritidis, six by
S. Typhimurium and one by S. Infantis, S. Panama and S. Hadar. More
than a half of S. Enteritidis were susceptible, whereas near of a quarter
part were resistant to ampicillin, encoded by the gene blaTEM-1 (24%),
and nalidixic acid (20.7%). Two of the six S. Typhimurium isolates were
susceptibles, other two resistant only to tetracycline, and the other two
were multirresistant, each with a R-proﬁle: Ap, Te, Su, Cm, S (carrying
a class 1 integron, InH) and Te, Su, S, K. Isolates belonging to S.
Infantis were susceptible, whereas isolates of S. Panama were nalidixic
acid resistant, and isolates of S. Hadar were resistant to Nal, Te, Ap, S.
Most of the isolates carried plasmids, some of these corresponding in
size to virulence (V) plasmids speciﬁc of serotypes Enteritidis (60 Kb),
Typhymurium (90 and 125 kb, this is an hybrid VR plasmid carrying the
integron H).
Conclusion: A majority of Salmonella outbreaks were caused by S.
Enteritidis, with an increase in the rate of isolates resistant to ampicillin
and nalidixic acid, that was also noticed in the last decade. Interestingly
one S. Typhimurium strain, causing a nursery outbreak, belonged to an
emergent clone carrying a hybrid VR-plasmid.
P1513 Occurrence and characterisation of class 1 integrons from
isolates collected in a hospital’s sanitary facility in Aveiro,
Portugal
C. Santos °, T. Caetano, E. Ramalheira, S. Ferreira, S. Mendo (Aveiro,
PT)
Objective: In a hospital environment, antibiotic resistant strains are not
only conﬁned to the patients but they can also “colonise” the surrounding
environment. We investigated the presence of antibiotic resistance mobile
elements, such as class 1 integrons, in bacterial strains collected in a
hospital’s female ward sanitary facility (SF).
Methods: Sterile swabs were rubbed over various SF surfaces and incu-
bated in rich medium at 37ºC. Serial dilutions were plated in MacConkey
agar for Gram negative isolates selection. Phenotypically different
colonies were selected and their clonal relationship was evaluated by
rep-PCR. Identiﬁcation to the species level and antibiotic susceptibilities
were determined using automatic VITEK2 system and Advanced Expert
System (VITEK2 AES) (BioMe´rieux, Marcy L’E´toile, France). Presence
and characterisation of Class 1 integrons was performed by PCR
followed by nucleotide sequencing. Nucleotide and deduced aminoacid
sequences were analyzed with Blast and ClustalW programs.
Results: Eighty-two genetically different strains were identiﬁed belong-
ing to the following genera: Acinetobacter, Alcaligenes, Citrobacter,
Escherichia, Enterobacter, Klebsiella, Morganella, Pseudomonas, Pro-
teus, Serratia and Stenotrophomonas. Class 1 integrons were ampliﬁed
from 24% of the isolates. 17 different gene arrays were identiﬁed: 35%
consisted of novel combinations of gene cassettes and 41% consisted
of a ﬁrst description in the species. aacA4 was the most abundant
gene, followed by aadA1 and aadA2. 67% (n = 18) of Pseudomonas spp.
integrons possessed a metallo-b-lactamase gene (blaIMP-8 or blaVIM-2)
which were found exclusively in this genus. dhfr, blaPSE-1, arr-3, catB3,
ORF and tnpA genes were also detected, but at lower rates. Ancestral
integrons possessing the tniC-gene instead of the traditionally 3′CS were
identiﬁed in 2 isolates (P. aeruginosa and P. putida).
Conclusions: The results showed that class 1 integrons are widely spread
among the isolates collected from SF, particularly among opportunistic
strains. Several new gene arrays were characterised. This is the ﬁrst
description of tniC-containing integron in Portugal. These results suggest
that strains harbouring class 1 integrons constitute part of the normal
human ﬂora, able to survive outside a host, constituting a vehicle to the
dissemination of bacterial strains between patients.
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P1514 Characterisation of class 1 and class 2 integrons among
bacteria isolated from an urban waste water treatment
plant in Italy
C. Pellegrini °, G. Celenza, C. Forcella, E. Sacchetti, B. Segatore,
P. Bellio, D. Setacci, C. Di Lisio, S. Rainaldi, G. Amicosante, M. Perilli
(L’Aquila, IT)
Objectives: The role of environmental bacteria as a reservoir for
antibiotic resistance determinants is still poorly established. The spread
of resistance genes is greatly enhanced when they form part of a mobile
gene cassette, associated with integrons. The aim of this study was to
investigate the presence and distribution of integron-carrying bacteria
from a urban waste water treatment plant of L’Aquila city (Italy).
Organisms Integrase
type
(location)*
Variable region
size (bp)
Variable region
content
Resistance phenotype Plasmid b-lactamase
Escherichia coli I (C) 1664 dfr17, aadA5 AMP, AMX, AMC,
STX
+ blaTEM
Escherichia coli II (P) 1227 dfr1, sat1 AMP, AMX, PIP,
CAZ, STX
+ −
Serratia liquefaciens I (C) – ND AMP, AMX, PIP,
CAZ
+ −
Enterobacter
agglomerans
I (C) – ND AMP, AMC, AMX,
CEF, CAZ
− −
Acinetobacter
baumannii
I (C) 1664 dfr17, aadA5 AMP, AMX, PIP,
CEF, CTX, CAZ,
IMP, STX
+ −
Serratia odorifera II (C) – ND AMP, AMX, PIP, CEF + −
Escherichia coli I (C) 880 aadA10 AMP, AMX, AMC,
PIP, LVF, STX
+ blaTEM
Acinetobacter
baumannii
I (C) – ND AMP, AMX, AMC,
PIP, CEF, CTX, CAZ,
LVF
− −
Escherichia coli II (C) 2158 dfr1, sat1,
aadA1
AMP, AMX, AMC,
PIP, CEF, CTX, STX,
LVF
+ blaTEM
Escherichia coli I (C) – ND AMP, AMX, AMC,
PIP, CEF, CAZ, LVF
− blaTEM
Escherichia coli I (C) – ND AMP, AMX, PIP,
CEF, CAZ, STX
− blaTEM
Klebsiella pneumoniae I (C) 1664 dfr17, aadA5 AMP, AMX, AMC,
CEF, STX, LVF
+ blaTEM
Klebsiella oxytoca II (C) 2158 dfr1, sat1,
aadA1
AMP, AMX, PIP,
TZP, CEF, STX
+ blaTEM
Aeromonas hydrophila I (C) – ND AMP, AMX, CEF − −
Escherichia coli I (C) – ND AMP, AMX, PIP,
CEF, CAZ
− blaTEM
Escherichia coli I (C) 1664 dfr17, aadA5 AMP, AMX, AMC,
PIP, CEF, STX
− blaTEM
Citrobacter freundii I (C) 880 aadA10 AMP, AMX, AMC,
PIP, CEF, STX
− −
Klebsiella oxytoca I (C) 1664 dfr17, aadA5 AMP, AMX, PIP,
CEF, CTX, CAZ,
LVF, STX
+ blaTEM
Acinetobacter
baumannii
I (C) 1664 dfr17, aadA5 AMP, AMX, PIP,
CEF, CTX, CAZ,
LVF, STX
+ blaTEM
Escherichia coli I (C) – ND AMP, AMX, PIP,
CEF, LVF
+ blaTEM
Klebsiella pneumoniae I (C) 1664 dfr17, aadA5 AMP, AMX, AMC,
PIP, CEF, STX, LVF
+ blaTEM
Citrobacter freundii II (P) 2158 dfr1, sat, aadA1 AMP, AMX, AMC,
PIP, TZP, CAZ, IMP,
STX
− −
Enterobacter
agglomerans
I (C) – ND AMP, AMX, CEF,
CAZ, STX
− −
Enterobacter
agglomerans
II (C) 2158 dfr1, sat, aadA1 AMP, AMX, AMC,
PIP, CEF, CAZ, IMP,
STX
− blaTEM
Pseudomonas putida I (C) 930 blaVIM-1 AMP, AMX, AMC,
PIP, CEF, CTX, CAZ,
IMP
− blaVM
Pseudomonas
ﬂuorescens
I (C) 1281 blaIMP-22,
ORFXX
AMP, AMX, AMC,
PIP, CEF, CTX, CAZ,
IMP
− blaIMP
Pseudomonas
ﬂuorescens
I (C) 1910 blaIMP-22,
ORFXX, aacA4
AMP, AMX, AMC,
PIP, CEF, CTX, CAZ,
IMP, STX
− blaIMP
Enterobacter
intermedius
I (C) 1664 dfr17, aadA5 AMP, AMX, PIP,
CEF, CAZ, STX
− blaAmpC
Escherichia coli I (C) 570 mobA AMP, AMX, AMC,
PIP, CEF, CTX, CAZ,
STX
+ blaTEM
Escherichia coli I (C) – ND AMP, AMX, PIP, CEF − blaTEM
Alcaligenes faecalis I (C) – ND CEF, CTX, CAZ + blaCTX -M
Escherichia coli I (C) 880 aadA10 AMP, AMX, PIP,
CEF, CAZ, STX
− blaAmpC
*C: chromosomal localisation; P: plasmidic localisation. ND: not detected.
Methods: During two years (may 2005-december 2007), 628 Gram-
negative bacteria were isolated at different stages of the waste water
treatment process, and selected on selective medium supplemented
with ceftazidime 6mg/L and imipenem 2mg/L. Resistant bacteria were
screened for the presence of integrase genes by colony blot hybridisation.
Genotyping of integrase-positive strains was carried out by RAPD
analysis. Variable region was investigated by PCR using primers designed
to conserved regions of the integron structure, and sequenced. Plasmid
proﬁle was performed on selected strains.
Results: Overall 40% (251/628) of strains harboured an integron.
The predominant organism (37.5%) was represented by Escherichia
coli. PCR analysis with speciﬁc primers for intI1and intI2 genes was
performed on 32 isolates that showed different genotype proﬁle. The
intI1 gene was detected in 26 out of 32 isolates screened and intI2 gene
in 6 out 32 isolates. Sequence analysis of variable regions showed ﬁve
cassette arrays in class 1 integrons and two arrays in class 2 integrons,
encoding for antibiotic resistance determinants, as shown in table 1.
Most of the integrons were located in chromosomal DNA, whereas only
two integrons were found to be into large plasmids. Several strains
contained b-lactamase genes, such as blaTEM-1 gene, blaCTX-M-1-
type gene (detected in Alcaligenes faecalis), blaIMP-22, blaVIM-1 and
blaAmpC gene.
Conclusion: Our results support the hypothesis that waste water
treatment might be an important antibiotic resistance reservoirs and
highlight the risk of spreading of harmful gene cassettes through
discharges in aquatic ecosystems.
P1515 Class 1 and 2 integrons determining multidrug resistance
to Acinetobacter spp. and Pseudomonas aeruginosa
E.C. Clı´maco, D.Y. Takata, M.G. Oliveira, A.L.C. Darini ° (Ribeirao
Preto, Juiz de Fora, BR)
Objective: The main objective of this study was to determinate the
importance of class 1, 2 and 3 integrons in multidrug resistance
phenotypes of Acinetobacter spp. and P. aeruginosa. In addition, the
presence of carbapenemases-encoding genes was investigated.
Methods: Firstly, 63 Acinetobacter spp. and 149 P. aeruginosa, isolated
from inpatients of University Hospital of Juiz de Fora, Brazil, from 2000
to 2007, were classiﬁed as multidrug resistant (MDR) or non-multidrug
resistant (n-MDR). Class 1, 2 and 3 integrons were investigated by
speciﬁc PCR ampliﬁcation of intI1, 2 and 3 genes fragments. The
prevalence of integrons were compared among MDR and n-MDR
groups, and statistical signiﬁcance was estimated applying Fisher’s
exact. Metallo-carbapenamase production was also investigated by PCR
ampliﬁcation and sequencing of blaIMP, blaVIM and blaSPM genes.
Results: 54 (36%) P. aeruginosa isolates and 45 (71.4%) Acinetobacter
spp. were considered MDR isolates. Class 1 integrons were detected in
68 (45.6%) P. aeruginosa isolates, 51 of them (75%) were MDR; and in
11 (17.5%) Acinetobacter spp. isolates, all of them were MDR. Class 1
integrons association with MDR P. aeruginosa and MDR Acinetobacter
spp. was statistically signiﬁcant. Class 2 integrons were found in only
one MDR P. aeruginosa and in 23 (36.5%) Acinetobacter spp. isolates.
Of them, 20 isolates (87%) were MDR. Class 2 integrons relationship
with MDR Acinetobacter spp. isolates was statistically signiﬁcant. Class
3 integrons were detected only in one MDR P. aeruginosa isolates. Table
1 shows the association of class 1 and 2 integrons with susceptibility
rates to each tested antibiotic. Carbapenemase production was detected
in 27 (18.1%) P. aeruginosa isolates by ampliﬁcation and sequencing
of blaSPM-1. Of them, 26 isolates were MDR and harboured class 1
integrons.
Conclusions: Class 1 integrons were more prevalent than other classes of
integron in P. aeruginosa isolates, and it shows statistical association with
MDR phenotypes, suggesting its importance to confer this resistance
proﬁle. SPM-encoding genes were found coexisting with these integrons
in P. aeruginosa. Class 2 integrons were more prevalent than class 1
ones in Acinetobacter spp. isolates, although both classes seem to be
determinant to MDR phenotypes in these isolates. Further studies about
cassette genes are going to be evaluated to better elucidation about real
role of integrons in MDR phenotypes. Supported by FAPESP and CNPq.
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Table 1. Comparison between antimicrobial susceptibility rates of P. aeruginosa with and without intl1 and of
Acinetobacter spp. with and without intl1 and intl2
Antimicrobiala Susceptibility (%)
P. aeruginosa (n = 149) Acinetobacter spp. (n = 63)
intl1+ intl1− P valueb intl1+ intl1− P valueb intl2+ intl2− P valueb
(n = 68) (n = 81) (n = 11) (n = 52) (n = 23) (n = 40)
AMI 191 96.3 <0.0001 0 28.9 0.0528 0 37.5 0.0004
GN 1.5 93.8 <0.0001 0 26.9 0.1034 0 35 0.0010
TOB 1.5 95.1 <0.0001 0 59.6 0.0003 21.7 65 0.0015
CIP 2.9 70.4 <0.0001 0 23.1 0.1044 0 30 0.0024
NOR 2.9 72.8 <0.0001 – – – – – –
LEV 2.9 66.7 <0.0001 0 23.1 0.1044 0 30 0.0024
CAZ 33.8 77.8 <0.0001 0 26.9 0.1034 0 35 0.0010
CTX – – – 0 0 ND 0 0 ND
CFP 4.4 71.6 <0.0001 – – – – – –
FEP 27.9 82.7 <0.0001 0 25 0.1005 0 32.5 0.0023
SAM – – – 100 90.4 0.5763 100 87.5 0.1488
AZT 19.1 64.2 <0.0001 – – – – – –
TZP 30.9 79 <0.0001 0 25 0.1005 0 32.5 0.0023
TIM 7.4 71.6 <0.0001 0 19.2 0.1868 0 25 0.0099
IMP 25 92.6 <0.0001 100 100 ND 100 100 ND
MER 20.6 92.6 <0.0001 72.7 92.3 0.1314 100 82.5 0.0414
PB 100 100 ND 100 100 ND 100 100 ND
CT – – – 100 100 ND 100 100 ND
DO – – – 100 100 ND 100 100 ND
MH – – – 100 100 ND 100 100 ND
TGC – – – 9.1 61.5 0.0020 73.9 40 0.0175
a AMI, amikacin; GN, gentamicin; TOB, tobramycin; CIP, ciproﬂoxacin; NOR, norﬂoxacin; LEV, levo-
ﬂoxacin; CAZ, ceftazidime; CTX, cefotaxime; CFP, cefoperazone; FEP, cefepime; SAM, ampicillin–sulbactam;
AZT, aztreonam; TZP, piperacillin–tazobactam; TIM, ticarcillin–clavulanate; IMP, imipenem; MER, meropenem;
PB, polymyxin B; CT, colistin; DO, doxycycline; MH, minocycline; TGC, tigecycline.
b Statistically signiﬁcant: P values 0.05; ND: not determinable.
P1516 Impact of genetic surroundings on the function of integrons
L. Sundstro¨m °, K. Hansson, E. Larsson, D. Bajka, S. Pollini,
G.M. Rossolini (Uppsala, SE; Siena, IT)
Horizontal gene transfer has produced a large part of the fastly increasing
antibiotic resistance among Gram-negative bacteria. Integrons and ISCR
elements have contributed to renewal of the mobile assortments of
resistance genes and also promoted exchange between clinically impor-
tant bacteria and microorganisms in the environment. It is increasingly
realised that this exchange may be regulated by stress response and
that integrons may be organised in larger networks of DNA-processive
elements called mobilomes. This study focuses on a few integrons
carrying aminoglycoside resistance and antifolate resistance genes and
the variable stability of the cassettes integrated. The observations support
that the level of integrase expression and the genetic surrounding both
have strong inﬂuence on the operation of integrons. The aadA2 cassette
of the small plasmids pMS126 and pMS128 is excised two orders of
magnitude more often in the latter than in the former. An assembly line
for these elements relate them also to similar elements in IncN-plasmids
N3 and pLMO20. The formation of a composite element of IS6100 in
pMS126 has allowed an integration bypass of a barrier that normally
excludes integrons in an IncQ plasmid. We assume that integrons are
normally excluded from this highly disseminated class of plasmids.
P1517 Role of natural transformation in integron dissemination
S. Domingues °, O.D. Wikmark, A. Utnes, G.J. da Silva, K.M. Nielsen
(Coimbra, PT; Tromsø, NO)
The rapid evolution of bacterial genomes associated with the widespread
use of antibiotics has resulted in emergence and dissemination of
antibiotic resistance genes, facilitated by horizontal transfer. Class 1
integrons are genetic units associated with multiple antibiotic resistance
genes and have been associated with the ongoing spread of such genes.
Identical integrons have been found in the chromosome of unrelated
bacteria, suggesting the presence of mechanisms facilitating horizontal
movement of integrons. Natural transformation is one of the mechanisms
that allow bacteria to acquire foreign DNA without plasmid or phage
involvement.
The aim of this study was to test the hypothesis that natural
transformation might be involved in integron transfer. The natural
competent Acinetobacter baylyi BD413 was used as recipient bacterium
and integron-carrying bacteria Acinetobacter baumannii 65FFC and 064,
Escherichia coli 12FFC, Morganella morganii 235HUC, Pseudomonas
aeruginosa, Salmonella rissen 486 and Salmonella typhimurium 490
were the donor used in natural transformation assays, performed by
an in vitro protocol where a ﬁlter was used as a physical support.
Transfer of class 1 integrons was screened by PCR with 5′CS and
3′CS primers. It was observed that integrons can be transferred in vitro
by natural transformation at a low frequency, especially when present
in plasmids. Presence of plasmids in donor bacteria and absence in
transformants where transfer of integrons occurred lead to the hypothesis
that plasmids may have an important role in integron transformation,
but, after transfer, plasmids might be incorporated in the chromosome
of the transformant or the integron may jump from the plasmid into the
chromosome and the plasmid is lost by the cell. Natural transformation
assays with transformants that previously acquired integrons as donor
bacteria were also performed and high transformation frequencies
were obtained. Sequencing of integron ﬂanking regions shown that all
integrons from both donor and transformant bacteria seem to be present
on transposons. These experiments allowed concluding that, though
natural transformation of integrons is rare, once a recipient bacterium
has integrated an integron, it can be quickly disseminated, which could
lead to its broad accumulation in the environment. Integrons that were
transferred by natural transformation are incorporated in a stable way,
even when the transformant is in an antibiotic-free environment.
P1518 Charecterisation of a complete DNA region surrounding
non-mosaic tet(32) gene. Evolutive relation with the element
carrying tet(W) gene
J.C. Galan °, M. Rodriguez-Alcayna, G. D’auria, M.R. Baquero,
R. Canto´n, F. Baquero (Madrid, Valencia, ES)
Objective: A recent work about the description of DNA regions
ﬂanking the tet(32) gene suggested a high similarity with TnB1230
element carrying the tet(W) gene (Warburton, 2009). This result
could have interesting implications because tet(W) has emerged as
a widespread determinant, but because also Tet(32) confers slight
increased tetracycline MIC. We wanted to know the real relationship
between both regions carrying these tet genes in the most extended
known region harbouring tet(32), to suggest the evolutive relationship
between them and the ecological implications.
Material and Methods: One clinical isolates of Acidaminococcus
intestini RYCMR95 were found carrying tet(32) gene as part of an
epidemiological study. The DNA regions surrounding was known and
an analysis of comparative genome with Genebank sequences allowed
to deﬁne the element carrying tet(32). When the DNA region was deﬁne
in Acidaminococcus, then was compared with the known genetic element
carrying tet(W).
Results: A total of 15Kb were sequenced in RYCMR95 strain. However
only 11.2Kb was identical in other species: Clostridium scindens
and Anaerotruncus colihominis. The homology was 99% throughout
11.2Kb among them including the distance between the different orfs,
suggesting a recent event of horizontal transfer. The homology of
the ﬂanking sequences to this region was below 50%. This 11.2Kb-
region was characterised by the presence of a site speciﬁc recombinase,
at 7Kb and a relaxase at 3.3Kb downstream of tet(32) respectively.
An orf located at 362 bp upstream of tet gene showed homology to
aminonucleoside antibiotic resistance. When this 11.2Kb-region was
compared to TnB1230 of Butyrivibrio and ATE-3 of Arcanobacterium
pyogenes which carry tet(W) gene, the homology was 78% between
tet genes, 86% in 853 bp upstream including the orf with homology to
aminonucleoside antibiotic resistance and 96% in 390 bp downstream.
In other A. intestini and A. fermentans strains the presence of tet(32)
and tet(W) was also detected.
Conclusion: These results suggest that the hypothetical element carrying
tet(32) is the 11.2Kb and has a common ancestral element with elements
carrying tet(W), although subsequently they diverged. This work suggest
that the recombination between modules belonging to tet(W) element or
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tet(32), could be easy and might contribute to the constant diversiﬁcation
observed in elements carrying tet(W) and probably similar a process
could be described in element carrying tet(32).
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P1519 Skin and soft-tissue infection in patients with solid tumours
D. Kofteridis, A. Valachis, M. Christofaki °, M. Rovithi, E. Koutsounaki,
S. Maraki, V. Georgoulias, G. Samonis (Heraklion Crete, GR)
Objective: To describe clinical, microbiological characteristics and
outcome of skin and soft tissue infections (SSTI) in patients with solid
tumours (ST) and to determine factors leading to treatment failure.
Methods: Records of patients with ST and SSTI, cared for at the
University Hospital of Heraklion, from 2002 to 2006 were retrospectively
studied. Infection’s reccurrence, need for repeated drainage, and sepsis
leading to death were considered as treatment failures.
Results: A total of 81 episodes of SSTIs, occurring in 71 patients
with ST, has been evaluated. Their median age was 65 years (34−82);
38 (53%) were males. The most common underlying malignancy was
breast cancer in 17 patients (24%), followed by colon in 14 (20%), lung
in 13 (18%), genital in 10 (14%), head & neck in 5 (7%), urinary
tract cancer in 4 (6%), and sarcoma in 3 (4%). The remaining 5
(7%) consisted of hepatobiliary, pancreatic and stomach cancer. Most
episodes (72; 89%) occurred in non-neutropenics. Cellulitis/erysipelas
was the most common clinical presentation (56; 69%), followed by
abscesses (18; 22%), wound infection 5 (6%), furunculosis 1 (1%)
and myositis 1 (1%). Bacterial cultures were possible in 29 (36%)
patients and 33 pathogens were isolated. In 5 episodes (17%) more than
one pathogens were isolated. Among the microbiologically documented
episodes, Gram negative bacteria were isolated in 18 (54.5%), with
E. coli (7 out of 18; 39%) and P. aeruginosa (6; 33%) being the most
frequent, followed by E. cloacae (2; 11%), K. pneumoniae (2; 11%)
and C. freundii.(1; 5.5%). Gram positive organisms were isolated in 14
cases (42%), with Enterococcus spp being the most common (6 cases
out of 14; 43%), followed by S. epidermidis (5; 36%) and S. aureus
(3; 21%). B. fragilis was isolated in 1 episode (3%). Three out of 20
successfully treated patients (15%) and 7 out of 9 who failed (78%)
received inappropriate empirical treatment (p = 0.001). Five (7%) patients
died due to sepsis. None was neutropenic. Multivariate analysis showed
that sepsis on admission (OR 21.921, 95%CI: 2.970–161.815; p = 0.002)
was associated with treatment failure.
Conclusion: SSTIs can be life-threatening among patients with ST, even
in the absence of neutropenia. Early diagnosis is of utmost importance,
since sepsis on admission was proven a signiﬁcant factor of unfavourable
outcome.
P1520 Factors affecting the duration of intravenous antibiotic
therapy for cellulitis in an outpatient setting
P. Lillie °, T. Darton, D. Andrews, K. Eaves, A. Chapman (Shefﬁeld, UK)
Objectives: Cellulitis is a common community acquired infection that
is increasingly treated with IV antibiotics in an outpatient setting. We
analysed patients under the care of our outpatient IV antibiotic service
for cellulitis to ascertain factors affecting duration of therapy.
Methods: A retrospective review of cases of cellulitis managed by the
outpatient IV antibiotic service at our institution between 1st October
2007 and 30th September 2008. Demographic, clinical, laboratory
and outcome data were collected. Cases were split into short course
therapy (3 days) or extended course (7 days). Factors associated
with increased duration on univariate analysis were then entered into
a multivariate regression analysis. P values <0.05 were considered
signiﬁcant.
Results: 98 cases were available for review. 61.2% were male, the mean
age was 54.6 years and the mean duration of therapy was 6 days. 28 cases
had 3 days therapy, 32 had 4−6 days and 38 had 7 days. On univariate
analysis (table 1) extended course treatment was associated with higher
baseline CRP, ESR, creatinine, longer duration of cellulitis pre outpatient
IV antibiotics, lower haemoglobin, increasing age, presence of diabetes
and male sex. In the multivariate model, male sex (P< 0.001), increasing
age (P = 0.038) haemoglobin (P< 0.001) and CRP (P = 0.001) remained
predictive of an extended course.
Conclusion: An extended course of IV therapy for cellulitis in an
outpatient setting is associated with male sex, increased age, low baseline
haemoglobin and high baseline CRP. These factors may be useful to
guide frequency of medical review of patients in this setting and may also
help with decisions about the nature of intravenous access for antibiotics.
Table 1. Univariate factors affecting duration of treatment
3 day,
n = 28 (%)
7 days,
n = 38 (%)
P value
Diabetes 0 (0) 8 (21.1) 0.0169
Male gender 13 (46.4) 31 (81.6) 0.0038
CRP (mg/L) 31.2 84.6 0.002
ESR (mm/hr) 20.4 46.8 <0.001
Creatinine (mmol/dl) 77.2 89.6 0.0423
Albumin (g/L) 37.4 32.2 <0.001
Haemoglobin (g/dl) 14.3 13.5 0.0423
Duration of symptoms pre treatment (days) 5.0 9.3 0.014
Age (years) 48.4 62.1 0.0013
P1521 Clinical and microbiological analysis of skin and soft tissue
infections over ﬁve-year periods
J.Y. Noh °, J.Y. Heo, Y.M. Jo, W.S. Choi, J.Y. Song, H.J. Cheong,
W.J. Kim (Seoul, KR)
Objective: The incidence of skin and soft tissue infections (SSTIs) is
uprising and community-acquired methicillin-resistant Staphylococcus
aureus (CA-MRSA) emerged as a signiﬁcant causative pathogen. Yield
of culture by needle aspiration or tissue biopsy is known to be not
productive in SSTIs. The objectives of this study are analysis of clinical
features and microbiological distributions of SSTIs at a tertiary hospital
in Korea and comparison of yield as each method collecting the specimen
for microbiological identiﬁcation.
Methods: We retrospectively reviewed medical records of 760 adult
cases of community-acquired SSTIs from September 2003 to August
2008 of Korea University Guro Hospital. Demographic ﬁndings, clinical
features and microbiological distributions were evaluated. We compared
the positive culture rate of each method: blind needle aspiration,
ultrasound (US)-guided needle aspiration and US-guided tissue gun
biopsy.
Results: The annual number of cases and admitted cases due to SSTIs
per total number of inpatients (case number/1000 persons) has been
increased for recent 3 years: 117, 1.93 from September 2005 to August
2006, 140, 2.12 from September 2006 to August 2007 and 213, 2.58
from September 2007 to August 2008. More than half of patients
(52%) did not have suspected precipitating factor and 76.1% of patients
did not have underlying disease. Repetitive cases were 10.0% and
they tend to occur at same site with previous infection (86.8%) at
an interval of 6 months to 2 years (52.6%). Mean height, weight and
BMI were higher and more patients had cirrhosis in repetitive infection
group (p< 0.05). Cirrhosis was an independent risk factor for repetitive
infection (OR 3.64, 95%CI 1.36–9.76). Most common pathogen was
methicillin-susceptible Staphylococcus aureus (MSSA) and CA-MRSA
was cultivated at 4 cases (2 in 2003–2004 and 2 in 2006–2007). US-
guided aspiration showed higher positive culture rate than blind needle
aspiration (73.9% vs. 48.3%, p< 0.05). US-guided gun biopsy was not
productive (positive culture rate, 17.5%).
Conclusions: Considering microbiological distribution of SSTIs in
Korea, penicillinase-stable penicillin or 1st generation cephalosporin
would be enough to use as initial antibiotic. In the cases with ﬂuctuating
lesion, US-guided needle aspiration was superior to blind needle
aspiration for the identiﬁcation of pathogens. Considering that there are
occult abscesses in many cases, US examination would be valuable.
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P1522 Common pathogens isolated in diabetic foot infection in a
rural hospital
T. Exiara °, L. Papazoglou, A. Kalpaka, A. Risggits, S. Bousios,
G. Metallidis, G. Hasan, S. Papanastasiou (Komotini, GR)
Objectives: Foot ulcers are a frequent complication of patients with
diabetes mellitus, accounting for up to 20% of diabetes-related hospital
admission in previous studies. Secondary infection of these ulcers
associated with high morbidity and risk of lower extremity amputation.
The aim of the present study was to determine the pathogens isolated
from soft-tissue in patients with diabetic foot infections in our hospital.
Methods: 78 patients (hospitalised and outpatients) with diabetic foot
infection, 51 (65.4%) male and 27 (34.6%) female with mean age
52±12.7 years, were enrolled in this study. All patients underwent
surgical debridement and tissue specimens were obtained by scarping the
base of the ulcer with a scalpel or by wound. Bacteriological diagnosis
and antibiotic sensitivity proﬁles were carried out and analyzed using
standard procedures. In patients with clinically suspected osteomyelitis,
magnetic resonance imaging or bone scintigraphy with white blood cell
scanning, were performed.
Results: 102 bacteria were documented microbiologically in this study.
The most frequent bacterial isolated were: Staphylococcus aureus
in 44 (42.3%) cases, Enterobacteriaceae in 13 (12.5%), coagulase-
negative Staphylococcus spp. in 11 (10.6%), Pseudomonas aeruginosa
in 11 (10.6%), Streptococcus spp. in 10 (9.6%) and Escherichia
Coli in 6 (5.8%) cases. No anaerobes were isolated from the ulcers.
Polymicrobial infection was found in 12 (15.5%) cases. 11 (14.1%)
patients had combined osteomyelitis and deep soft tissue infection. All
Staphylococci were sensitive to vancomycin and teicoplanin, 86.3% to
cotrimoxazole and 64.2% to clindamycin. The sensitivity of Gram-
negative microorganisms to antibiotics was: 96% to ciproﬂoxacin,
94% to piperacillin/tazobactam, 84.7% to cotrimoxazole, 69.4% to
amoxicillin/clavoulanic. MRSA was isolated in 4 samples. Bacteria were
obtained from patients with both osteomyelitis and deep soft tissue
infection had statistically high rate resistance to antibiotics than bacteria
were isolated from patients with soft tissue infection only, p< 0.001.
Conclusions: Gram-positive cocci were the most common causes
of diabetic foot infection in our area (up to 50%). Knowledge of
microorganism panel in patients with diabetic foot infection in our
hospital may help us for effective empirically treatment until culture
results and susceptibility data of ulcer lesions be known.
P1523 Diabetic foot ulcers: a bacteriologic study of 193 patients
S. Baka °, E. Panagiotopoulou, A. Spathi, A. Lykas, F. Petropoulou,
E. Logothetis, K. Gerolymatou, E. Kouskouni (Athens, GR)
Objectives: Diabetic foot ulceration and infection represent an important
cause for hospitalisation, enhancing the risk for subsequent amputation.
Usually these infections are polymicrobial in nature so correct and early
isolation and identiﬁcation, as well as prompt initiation of appropriate
antibiotic therapy are important steps toward a successful outcome. This
study was undertaken to identify the pathogens associated with diabetic
foot infections in our hospital.
Methods: A total of 193 consecutive patients were included in the study
during the period November 2006 to November 2008. Only diabetic
patients presenting with foot infection and who did not receive antibiotics
for the past 30 days were included in the study. Clinical specimens
collected from patients were inoculated onto appropriate plates for
standard aerobic and anaerobic cultures and incubated at 37ºC for 24 h
and 48 h, respectively. A Gram-stained smear from the specimen was
examined under microscope to obtain valuable information about the
types of microorganisms present. The isolated pathogens were identiﬁed
using the automated system Vitek 2 (BioMerieux, France).
Results: The mean age of the patients was 61.4 years (range 24−78)
with 109 (56.5%) of them being males and 84 (43.5%) females. A
total of 368 pathogens were isolated, resulting in an average of about
1.9 microorganisms per sample. We isolated 127 aerobic Gram-positive
cocci representing 34.5% of all pathogens, 179 (48.7%) aerobic Gram-
negative rods, 61 (16.7%) anaerobic bacteria and only 1 Candida sake
(0.01%) from our samples. Staphylococcus aureus was more frequently
isolated among the Gram-positive cocci (60.1%), Proteus mirabilis was
more frequently isolated among the Gram-negative rods (31.4%) and
Bacteroides species represented the 91.9% of all anaerobic bacteria
isolated. One hundred and four (53.9%) patients had one microorganism,
38 (19.7%) had 2 pathogens, 26 (13.5%) had 3, 20 (10.4%) patients had
4 pathogens and 5 (2.5%) patients had 5 pathogens isolated from their
foot ulcers.
Conclusion: In our study group diabetic foot infections were mostly
monomicrobial. The most frequently isolated microorganisms from the
ulcers were S. aureus, P. mirabilis and Bacteroides species. Constant
awareness of isolated pathogens in these infections is essential for the
optimal management and a successful outcome of diabetic foot ulcers.
P1524 Quinolone monotherapy in diabetic foot infections: rate of
failure and selection for resistant strains
C. Tascini °, S. Fondelli, A. Leonildi, S. Capolupo, A. Piaggesi,
F. Menichetti (Pisa, IT)
Background: Quinolones are different for capability to select resistant
strains during therapy. The in vitro measure for this characteristic is
deﬁned mutant prevention concentration. In vivo there are few data about
quinolone monotherapy and rate of failure and emergence of resistant
strains. For this purpose we review the ﬁles of patients with diabetic foot
infections (DFI) treated with quinolone monotherapy, at Pisa Hospital in
Italy from January 2006 and December 2008.
Methods: We compare the microbiological results of all patients with
DFI that were treated with quinolone monotherapy.
Results: In the period studied, 167 patients were treated with
ciproﬂoxacin monotherapy, 373 patients with levoﬂoxacin monotherapy
and 169 patients with moxiﬂoxacin monotherapy. From the microbio-
logical point of view levoﬂoxacin was able to eradicate all bacteria in
40% of patients, moxiﬂoxacin 32% and ciproﬂoxacin 22%. Selection of
resistant bacteria among Gram positive and Gram negative was higher for
levoﬂoxacin (56%) with respect to moxiﬂoxacin (43%) and ciproﬂoxacin
(40%) (p:0.03 for moxiﬂoxacin and p:0.02 for ciproﬂoxacin). Selection
of resistant Gram positive strains was higher for levoﬂoxacin (59%)
with respect to moxiﬂoxacin (41%) (p:0.03). Selection of resistant Gram
negative strains was higher for levoﬂoxacin (53%) with respect to
ciproﬂoxacin (39%) (p:0.01).
Levoﬂoxacin select S. aureus quinolone-resistant more easily than
moxiﬂoxacin (p:0.05). P. aeruginosa quinolone-resistant was selected
more easily by moxiﬂoxacin with respect to ciproﬂoxacin (p:0.01)
Conclusions: Quinolone monotherapy efﬁcacy in eradicating bacteria in
DFI is scarse. Levoﬂoxacin is the most effective molecule but in case of
persistance of bacteria in DFI, levoﬂoxacin has the higher capability to
select strains resistant to quinolone. In DFI, monotherapy with quinolone
has to be reconsidered in the light of selection of resistant strains.
P1525 Clinical, biological and radiological differences between
P. aeruginosa and other Gram-negative bacilli vertebral
osteomyelitis
J.D. Colmenero °, E. Garcı´a-Cabrera, J.M. Reguera, J.L. Haro,
M. Delgado, J. Marquez-Rivas, J.D. Ruiz-Mesa, M.E. Jimenez-Mejı´as
(Malaga, Seville, ES)
Objectives: To describe clinical, biological and radiological ﬁndings as
well as the prognosis of P. aeruginosa vertebral osteomyelitis (PAVO)
in comparison with vertebral osteomyelitis produced by other Gram
Negative Bacilli (OGNBVO).
Methods: Retrospective and descriptive study including 267 patients
older than 14 years old diagnosed with pyogenic vertebral osteomyelitis
(PVO) between January 1983 and November 2008 in two tertiary
hospitals. Data were collected prospectively according to a speciﬁcally
designed protocol. The diagnosis of VO was established by the presence
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of spinal pain unrelieved by rest or fever and spinal pain on physical
examination, together with one or more imaging techniques showing
data compatible with VO following the criteria of Dagirmanjian et al.
All patients received speciﬁc antibiotic treatment for two months, being
intravenous for at least four weeks. Patients with large soft tissue masses,
cord compression, highly destructive lesions or those who suffered a
therapeutic failure, were also treated surgically.
Results: Of 267 patients with PVO, 51 (19.1%) had GNBVO and of
them 12 (23.5%) were PAVO. Of the patients with PAVO, 7 (58.3%)
were male and 5 (41.7%) female (mean age, 59.1±13.6 years). Five
patients (41.7%) had previous spinal surgery, 4 (33.3%) had skin or soft
tissue infection and 3 (25%) were diabetic. The vertebral level involved
was lumbar in 7 cases (58.3%) and thoracic in 5 (41.7%). The median
time to diagnosis was 12 days (range; 4–120 days). Five patients (41.7%)
had neurological deﬁcits. Paravertebral or epidural masses were detected
in 6 cases (50%). Five patients (50%) required surgery. One case was
lost in follow-up. Of the 11 remaining cases, all cured, although two
(18.1%) had severe functional sequels.
Previous spinal surgery and skin or soft tissue infection were signiﬁcantly
more frequent in PAVO, whereas urinary or gastrointestinal infection was
more frequent in OBGNVO. The mean hospital stay was signiﬁcantly
higher in PAVO group, 72.7.1±33.19 days versus 42.8+25.2 days
respectively. We did not ﬁnd other clinical, biological or radiological
differences between both groups.
Conclusions: P. aeruginosa is a frequent cause of BGNVO. In patients
with VO, previous spinal surgery and skin or soft tissue infection should
make considering P. aeruginosa as as a possible aetiologic agent. With
an appropriate treatment, the prognosis of PAVO does not differ of others
VO caused by GNB.
P1526 Epidemiological trends of empirical or microbiologically
documented treatment of chronic osteomyelitis. Results
from a ten-year survey at a reference bone and joint
infectious diseases department
E. Giannitsioti °, A. Papadopoulos, S. Athanasia, E. Koratzanis,
A. Drakou, P. Papagelopoulos, P. Panagopoulos, D. Plachouras,
H. Giamarellou, K. Kanellakopoulou (Athens, GR)
Background: Chronic osteomyelitis (CO) is a treatment challenge for
ID specialists as the optimal regimen and treatment duration are still not
fully established.
Methods: We retrospectively analyzed 144 CO cases, documented upon
clinical, radiological, histology and available microbiological data. Cases
were retrieved from a data-base registry of all patients with bone and
joint infections followed in our Department during the last decade.
Only pathogens isolated either from intra-operative or bone aspiration
samples were included. CO cases treated either empirically (ET) or
upon microbiological documentation (MT) were comparatively assessed.
Duration of treatment was individualised. Predictors of treatment failure
were analyzed. Treatment failure was the absence of clinical, radiological
and microbiological resolution of the infection.
Results: From 144 CO eligible cases, 105 (73%) were male. Median
(IQR) age was 48 (31–63) years, and median (IQR) duration of treatment
was 6 (4–10) months. Surgical debridment was performed in 90/144
cases (65.3%). Distribution of aetiology in the MT group (117/144,
81.2%) was as follows: MRSA (21.3%), MSSA (22.2%), CoNS (12.8%),
P. aeruginosa (11.1%), other Gram negative (12.8%), Gram positive (6%)
and polymicrobial infection (9%). In the ET group ciproﬂoxacin – along
with either rifampicin or clindamycin – was administered in 17/27 cases
(63%), while glycopeptides only in 3/27 ones (11.1%). Patients in the
ET group were older (>60 years, p = 0.05), with more comorbidities
(p = 0.007) less often sinus tract (p = 0.003), more clindamycin use
(p = 0.01) and less surgical debridment (p = 0.01) compared to patients
in the MT group. No difference in treatment duration (p = 0.9), side
effects (p = 1.0) and rates of treatment failure (37/117, 31.6%, vs 6/2,
22.2%, p = 0.5) was assessed between MT and ET group. Overall,
side effects (n = 38/144, 26.3%) were mostly related to SMX-TMP
administration (n = 16). Regarding predictors of outcome, only fever
(OR 2.8, 95%CI 0.9−8.3, p = 0.03) and the relatively short (3months)
duration of treatment (OR 1.8, 95%CI 1.0−3.0, p = 0.05) were found to
predict treatment failure.
Conclusions: Treatment duration more than 3 months appears to be the
most important factor related to the remission of the infection regardless
of ET or MT antimicrobial treatment of CO. Cautious choice of an
empirical combined antimicrobial treatment in a selected population with
CO may lead to a favourable clinical outcome of the infection.
P1527 Vertebral osteomyelitis by Streptococcus spp.
E. Garcı´a-Cabrera °, J.D. Ruiz-Mesa, M.E. Jime´nez-Mejı´as, A. Plata,
J.L. Haro, J. Delgado, J. Marquez-Rivas, J.D. Colmenero (Seville,
Malaga, ES)
Objectives: To study the epidemiologic, clinical and diagnostic features,
biologic ﬁndings and outcome of all cases of vertebral osteomyelitis (VO)
caused by Streptococcus spp.
Methods: Multicentre, retrospective/prospective, transverse and descrip-
tive study of 514 patients diagnosed of VO. Inclusion criteria: 1) spinal
inﬂammatory pain or fever and spinal pain on physical examination, 2)
imaging techniques showing ﬁndings compatible with VO, 3) aetiologic
diagnosis. We analyse the epidemiology factors, clinical and radiologic
features, aetiological agents, and treatment and outcome. We followed
all patients since 12 months.
Results: Pyogenic vertebral osteomielytis was diagnosed in 267 patients
(52%) since January 1983 to November 2008. Of them, 17 cases (6.4%)
were caused by Streptococcus spp. The median age of the patients was
65 years±11 IQR (10 cases >65 years old). Thirteen patients (77%)
were male. Predisposing factors: (1) previous infection: 9 patients (53%);
(2) immunosupresion status: 4 cases (23.5%); (3) previous bacteraemia:
4 cases (23.5%); (4) previous vertebral surgery: 3 patients (18%); and
(5) diabetes mellitus: 2 patients (12%). Duration symptoms previous
diagnosis: 30 days (15–180 range). Vertebral level affected: 8 lumbar
(47%), 4 lumbosacral (24%), 3 thoracic (18%) and 2 cervical. Clinical
features: spinal pain on physical examination 17 patients (100%),
inﬂammatory pain 15 cases (88%), neurologic symptoms 11 patients
(65%), fever 8 (47%) chills/rigors 7 (41%), and constitutional symptoms
6 (36%). Blood cultures were positives in 6/10 cases (60%), bone biopsy
was positive in 10/11 (91%), and adjacent infectious foci cultures in
9/9 (100%). Causal agents isolated: Streptococcus spp. viridians group
7 (41%), S. agalactiae 4 (24%), S. pneumoniae 3 (18%), and others
Streptococcus spp. 3 (18%). Paravertebral masses were detected in 10
cases (59%), epidural masses in 7 (41%), and psoas abscesses 2 (12%).
Nine patients (53%) required surgical treatment. Of the 17 cases, 14
cases (82%) were cured, although 3 patients (18%) had severe functional
sequels.
Conclusions: 1) VO caused by Streptococcus spp. occurred more
frequent in elderly patients. 2) Previous infections at other site is
frequent. 3) Diagnostic yield of microbiological techniques is very
high. 4) Paravertebral and/or epidural masses are frequent. 5) Surgical
treatment is frequently necessary. 6) Severe function al sequels are
infrequent.
P1528 Osteoarthricular involvement in brucellosis: study of 155
cases
H. Turan °, K. Serefhanoglu, E. Karadeli, T. Togan, H. Arslan (Konya,
Ankara, TR)
Objectives: Despite the high morbidity rates of brucellosis in Turkey,
its mortality rate is relatively low. Osteoarthiculary complications has
been reported in 10−80% of all brucellosis cases. The aim of this study
was to determine the rates, types and clinical features osteoarthricular
involvement of 155 brucellosis cases.
Methods: 155 brucellosis cases admitted to our hospital between June
2003 and November 2008 were evaluated in terms of clinical and
laboratory ﬁndings. The diagnosis was established on the basis of
standard tube agglutination titre of 1/160 of antibodies for brucellosis
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and/or positive blood sample cultures. Osteoarthicular involvement was
deﬁned by inﬂammatory signs in peripheral joints with radiologic
alterations and/or lumbar and sacral vertebrate magnetic resonance
imagine in for patients who had lumbago of brucellosis.
Results: Sixty-ﬁve patients (42%) had osteoarthicular involvement
(55.4%male, 44.6% female). The mean age was 45.8 18 years.
Sacroiliitis was the most common involvement (n: 39, 60%), followed
by spondylodiskitis (n: 27, 41.5%), peripheral arthritis (n: 10, 15.4%),
bursitis (n: 1, 1.5%). In addition, there were 11 (17.5%) patients with
more than one site of involvement: nine had concomitant sacroiliitis and
spondylodiskitis, one had sacroiliitis and peripheral arthritis, and the
remainder sacroiliitis and bursitis. Spinal epidural abscess was found
seven cases. Sacroiliitis has been determined symmetrical 82% rate.
Lumbar spondylodiskitis was the most common involvement among the
spondylodiskitis (n:25, 92.5%). All of the cases were treated doxycycline
and rifampicin or streptomycin, rifampicin and doxycycline according to
their clinical progress at least 3 months.
Conclusion: Brucellosis should be included in the differential diagnosis
of any patient with arthralgia or symptoms of sacroiliitis and
spondylodiskitis especially where this infection is endemic countries
such as Turkey.
P1529 Clinical presentation and outcome of septic arthritis
diagnosed in a community hospital
A. Leach, C. Amador °, J. Rosas, M. Lopez, C. Martinez, M. Gil,
F. Pasquau (Villajoyosa. Alicante, ES)
Objective: To describe the aetiology, clinical presentation, treatment and
prognostic factors of septic arthritis (SA) in adult patients diagnosed in
our hospital.
Methods: Retrospective analysis of the records of patients diagnosed
of SA according the database of Admission Service and review of the
cultures of synovial ﬂuid in the Microbiology department from January
2002 to november 2008.
Results: 53 episodes of SA were included on the period of study
According to the modiﬁed criteria of Newman and Cooper Cawley
(1). 68% of these patients were male, the mean age was 53 years
(16−91 years) and 50% had underlying diseases, 20% joint disease.
Clinical manifestations were pain (95%), joint swelling (90%) and fever
(45%). Only 6.7% had general malaise. The knee was the most frecuent
joint affected (58%) followed by the hip (10%). Only one patient had
polyarticular involvement. The most common causative organisms were
S. aureus (37%) followed by Streptococcus sp. (8%) and Gram-negative
bacilli (7%). 8.3% of the cultures of synovial ﬂuid were Polimicrobial.
Bacteraemia was documented in 10% of patients but blood cultures
were draw just in one third of cases. Empiric antibiotic therapy was
considered correct in 46% of the cases. 39% of patients received NSAIDs
and 6.8% were treated with steroids. Surgical drainage and continuous
lavage were done in 33 (55%) patients and 17% had repeated punctures
joints. 38% of patients had functional sequelae and 4 patients died during
admission, two of them was related to the infection. Poor outcome was
signiﬁcative related with febrile presentation (p< 0.04). There were no
other predictors variables of morbi-mortality.
Conclusions: 1. Half of our patients had underlaying diseases. 2 Inﬂam-
matory symptoms were more prevalent that infectious manifestations.3.
There were not changes on bacterial aetiology according with the
literature 4. An optimal combined treatment is desirable to improve the
elevated mobility, specially in febrile patients.
1 Cooper C, Cawley MI. Bacterial arthritis in an English health district:
a 10 year review. Ann Rheum Dis 1986; 45:458−63
P1530 Septic arthritis caused by anaerobic bacteria
M.D. Rojo-Martin °, C. Miranda, E. Torres, T. Sabalete, P. Mazuelas
(Granada, ES)
Objectives: Anaerobic bacteria are uncommon pathogens in septic
arthritis. The objective of this study was to review acute arthritis due to
anaerobic bacteria in patients without prosthetic joint implants diagnosed
in the University Hospital Virgen de las Nieves (Granada, Spain) in the
last ten years.
Methods: From January 1999 to December 2008 we studied in our
service 1733 synovial ﬂuid samples, analyzed by Gram stain, aerobic and
anaerobic culture, and in addition, enrichment in broth culture. Cases
included were: patients without prosthetic joint implants from whom
anaerobic bacteria were detected in the synovial ﬂuid and whose clinical
data were compatible with septic arthritis.
Results: During the study period, we detected two cases of septic arthritis
by anaerobes. The ﬁrst case took place in December 2002 in a 23-
years-old woman, with a previous diagnosis of pharyngitis. The affected
joint was the left ankle, F. necrophorum was isolated in blood and
synovial ﬂuid cultures. The outcome was favourable after metronidazol
therapy. The second case took place in October 2008 in a 3-years-old
boy, with previous traumatism in the left knee. He had no wound nor
haematoma in the traumatism area. F. nucleatum was isolated from the
ﬁrst synovial ﬂuid sample, and in another one, it was detected only by
universal PCR and subsequent sequencing and phylogenetic analysis of
the PCR products. The patient needed arthrotomy and parenteral therapy
with imipenem and metronidazol; the patient was discharged with oral
clindamycin and the outcome was satisfactory.
Conclusions:
– The incidence of septic arthritis due to anaerobic bacteria was very
low; in our series, it was caused by Fusobacterium spp.
– Arthritis caused by anaerobic bacteria is very rare in childhood;
however, one of the two cases of anthritis by anaerobes in our series
was due to F. nucleatum, which took place in a boy.
– Some anaerobic bacteria are difﬁcult to recover by culture. In cases
with suspicion of septic arthritis and negative cultures, PCR could be
an important tool to reach a diagnosis.
P1531 Risk factors for lower extremity amputation among diabetic
patients hospitalised for a foot infection
B.A. Lipsky °, J.A. Weigelt, X. Sun, D. Johannes, V. Gupta, Y.P. Tabak
(Seattle, Madison, Chicago, US)
Objectives: Lower extremity amputation (LEA) is one of the most
feared complications of diabetes, and infection is the chief precipitating
cause. We investigated the demographic, clinical, and microbiological
characteristics of diabetic patients hospitalised for a foot infection, and
attempted to identify, and develop a model for, risk factors for LEA.
Methods: Using the Cardinal Research Database we identiﬁed diabetic
patients admitted to any of 97 hospitals from 2003 to 2007 for a culture-
proven lower extremity skin or soft tissue infection (SSTI). We compared
various characteristics of patients who underwent a LEA with patients
who did not.
Results: We identiﬁed 3018 eligible patients, 647 (21.4%) of whom
underwent LEA. The site of amputation was toe in 43.6%, foot in
20.9% and leg in 35.5%. Only 40 patients died (1.3%), 37.5% of whom
underwent LEA. Mortality was signiﬁcantly higher for patients with a leg
(major) amputation compared to a toe/foot (minor) amputation (3.9% vs
1.4%, p< 0.05). The illness severity was in the top 2 quartiles for 80.2%
of patients with LEA vs 41.6% for patients without LEA, and 91.3%
for patients with major vs 74.1% for patients with minor amputations.
The most frequent single pathogen was S. aureus, comprising 22.2% of
all cultures; 36.3% of these isolates were methicillin-resistant (MRSA).
Overall, 57.2% of infections were polymicrobial. LEA patients were
more likely to have polymicrobial infections than patients without LEA
(64.1% vs 55.3%, p< 0.0001). Patients with major amputations were
more likely to have polymicrobial infections that included MRSA (12.6%
vs 7.4%, p< 0.05) or Pseudomonas (14.8% vs 8.2%, p< 0.01) than
patients with a minor LEA. Signiﬁcant independent risk factors for
LEA are shown in the table. The resultant model showed very good
discrimination and ﬁt (c-statistic 0.76, Hosmer-Lemoshow p= 0.18).
Conclusions: Among diabetic patients hospitalised for a LE SSTI, over
20% underwent LEA and over a third were major. LEA was associated
with increased illness severity and mortality. S. aureus was the most
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frequent pathogen, but most infections were polymicrobial. Signiﬁcant
(p< 0.0001) covariates associated with LEA included surgical site
infection, vasculopathy, hypoalbuminaemia, leukocytosis, coagulopathy,
and polymicrobial infection. Using this large database we developed a
model that appears to accurately estimate LEA likelihood based on easily
available demographic, clinical and laboratory data.
Signiﬁcant independent variables associated with lower extremity amputation
Variable Multivariable Odds ratio
(95%CI)
p value
Male gender 1.37 (1.12, 1.68) 0.0024
Transfer from another acute care facility 3.44 (1.45, 8.19) 0.0053
Ulcer and “other” infection vs cellulitis 1.60 (1.26, 2.02) 0.0001
Surgical site infection vs cellulitis 3.32 (2.17, 5.10) <0.0001
Albumin <2.8 g/dL 1.76 (1.34, 2.32) <0.0001
PT/INR >1.2 or PT >14 seconds 1.89 (1.41, 2.52) <0.0001
White blood cell count 11,000/mm3 2.72 (2.22, 3.32) <0.0001
History of peripheral vascular disease 2.22 (1.80, 2.73) <0.0001
History of previous lower extremity amputation 1.40 (1.13, 1.73) 0.002
Streptococcus monomicrobial infection 1.82 (1.20, 2.75) 0.005
Enterococcus monomicrobial infection 2.56 (1.38, 4.75) 0.0028
Gram− (non-Pseudomonas) monomicrobial infection 2.60 (1.55, 4.34) 0.0003
Any type of polymicrobial infection 1.74 (1.38, 2.19) <0.0001
Epidemiology and clinical aspects of
infections
P1532 Actinobaculum spp.: clinical observation of 19 cases
C. Be´guelin °, L. Reto, M.L. Tritten, H. Siegrist, D. Genne´ (La
Chaux-de-Fonds, CH)
Objectives: Actinobaculum spp. are new species that have so far been
isolated from human blood, urine and pus. Their importance has probably
been underestimated and the different species underdiagnosed until
today, as the laboratory needs to search them actively. The aim of this
study is to examine their clinical relevance.
Methods: This retrospective study takes into consideration all known
cases of Actinobaculum spp. infections identiﬁed since 2004 in
the canton of Neuchaˆtel (169 000 inhabitants), Switzerland. Strains
were cultivated and isolated in the bacteriology laboratory in its
routine procedure. Identiﬁcation usually included a API 32 A gallery
(bioMerieux) and 16S RNA gene sequencing.
Results: Twenty positive samples could be found in 19 patients:
(11M/8F) of all ages (16−91), 10 urine (50%), 6 blood (30%), 1 blood
and urine (5%), and 3 pus (15%).
12/13 (92%) cases of urinary tract infection (UTI) had an underlying
pathology of the genitourinary tract. When urine cultures were positive
for Actinobaculum spp., leucocytes were found in all samples but
nitrite tests were mostly negative [6/7 (86%)]. All samples showed
Gram positive rods. Onset of concordant treatments were delayed by
an average of 2.7 days (range 0−13 days), due to the diminished
sensitivity of Actinobaculum spp. to the commonly used antibiotics
in UTI (ciproﬂoxacine and sulfamethoxazol/thrimetoprime) and to the
length of microbiological diagnosis. Fifty percent of the cases were
treated as outpatients and 18/19 (95%) had a favourable outcome.
Conclusion: To our knowledge, this is the largest series published to
date.
In case of leukocyturia with a negative nitrite test but presence of
Gram positive rods, in patients with an underlying genitourinary tract
pathology, Actinobaculum spp. should speciﬁcally be searched instead
of considering clinically irrelevant colonisation by Corynebacteria. This
infection is probably much more common than previously thought.
P1533 Community-acquired Stenotrophomonas maltophilia
infections: a systematic review
M. Falagas, A. Kastoris °, E. Vouloumanou, G. Dimopoulos (Athens, GR)
Objective: Stenotrophomonas maltophilia is a pathogen that causes in-
fections mainly in immunocompromised patients. However, community-
acquired S. maltophilia infections have been occasionally reported.
Objective: To collect and evaluate the available published data referring
to community-acquired S. maltophilia infections.
Methods: We searched PubMed, Cochrane Library, and Scopus
for articles providing data for patients with community-acquired
S. maltophilia infections.
Results: Eight case series and 23 case reports (involving 77 and 26
patients with community-acquired S. maltophilia infections, respectively)
were regarded as eligible for inclusion in our review. Regarding the
77 patients with community-acquired S. maltophilia infections included
in the identiﬁed case series, 45 had bacteraemia, 6 ocular infections,
5 respiratory tract infections, 4 wound/soft tissue infections, 2 urinary
tract infections, 1 conjunctivitis, 1 otitis, and 1 cellulitis; data were not
reported for the remaining 12 patients. Comorbidity (such as malignancy,
HIV infection, prior hospitalisation) was common. Data included in the
8 case series regarding the outcome of infection were limited. From the
26 patients with community-acquired S. maltophilia infections reported
in the case reports, 22 were cured from the infection, whereas 4 of 26
patients died; 1 death was attributed to septic shock due to S. maltophilia.
Conclusion: Several publications report patients with community-
acquired S. maltophilia infections; the majority of them refers to
patients with some kind of comorbidity. Physicians should be aware
that S. maltophilia infections are not restricted to hospitalised patients.
P1534 Seasonal patterns of invasive Streptococcus pyogenes disease
in the Northern hemisphere
T. Lamagni °, G. Tyrrell, M. Lovgren, T. Siljander, O. Lyytika¨inen,
J. Vuopio-Varkila, C. Van Beneden, D. Martin, A. Efstratiou (London,
UK; Edmonton, CA; Helsinki, FI; Atlanta, US; Porirua, NZ)
Objectives: To compare the seasonal patterns of invasive Streptococcus
pyogenes disease among four countries in two northern hemisphere
continents on order to evaluate the degree of congruence in timing and
magnitude of peaks and troughs in incidence.
Methods: National S. pyogenes surveillance data were extracted for
Canada, Finland, UK (England, Wales, Northern Ireland) and from ten
USA sites for the period 2004–07. For Canada, the UK and USA isolates
from all sterile sites were included whilst for Finland just blood and CSF
isolates were available. Weekly counts were analysed for each country,
with sub-analyses for Western and Eastern Canada. Data were smoothed
using six-week moving averages. Seasonal patterns were compared both
between countries and to published inﬂuenza surveillance data.
Results: Comparison of invasive S. pyogenes data between three of the
countries identiﬁed broadly similar patterns in Canada, the UK and USA
of winter/spring peaks and autumn troughs, although seasonal increases
started on average 8−10 weeks earlier in Canada (weeks 32−43) and the
USA (weeks 34−43) than in the UK (weeks 45−51). Seasonal patterns
in western Canada were typically several weeks earlier than in Eastern
Canada. Winter peaks in Finland were much less pronounced than those
in Canada, UK or USA and tended to start earlier. Unlike the other
countries, a distinct midsummer inﬂux could be identiﬁed in Finland;
21% of all cases in Finland occurred during June and July, compared
to 16% for the others (Chi sq. (1 df)=19.71; p< 0.001). Based on the
analysis of six-week moving averages, the magnitude of the seasonal
peaks were broadly similar in Canada, UK and USA, with the incidence
increasing by a magnitude of 2 to 3 on average compared to the autumnal
nadir. In all four countries, the start of the winter inﬂux in S. pyogenes
disease preceded the start of the inﬂuenza season in most years, although
the peak season for both infections overlapped.
Conclusion: Seasonal patterns of invasive S. pyogenes infection showed
a high degree of congruence between Canada, the UK and USA.
Epidemiology and clinical aspects of infections S433
Distinct midsummer peaks were evident in Finland, possibly related
to the widespread custom of retreating to summer cottages and the
accompanying outdoor activities which could increase skin trauma and
exposure to biting insects. Inﬂuenza appears to have a limited inﬂuence
on the initiation of winter increases in S. pyogenes disease but may
contribute to later winter peaks.
P1535 The epidemiology of botulism in Romania
D. Dobre, R. Moroti °, A. Hristea, V. Arama, D. Lemeni, M. Sisiroi,
A. Luka (Bucharest, RO)
Objectives: The aim of this study is to establish the incidence of
botulism and the dominant type of the botulinic toxin in Romania.
Methods: This is a retrospective analytical study based on information
provided by the Cantacuzino National Microbiology Institute (INCD-
MIC), The National Centre of Informatics of the Health Department
(CNOASIIDSB) and by the Bals National Infectious Diseases Institute
(INBI) − Bucharest.
Results: In a 7 years period (2000–2007) the total number of cases
according to the CNOASIIDSB was 181.
INCDMIC conﬁrmed the presence of the botulinic toxin in 92 biological
samples received in the same period. Of these 92, 55 tested positive for
type B toxin, in 36 cases the type of the toxin couldn’t be identiﬁed
because of insufﬁcient amount of serum for serotyping, and one sample
was positive for type E toxin (in 2007, related to ﬁsh products).
The disease had a sporadic evolution, most frequently appearing in
familial outbreaks, usually associated with the consumption of home
prepared meat products.
Most cases were reported from the western part of the country (116)
and the fewest cases were in southern Romania (26 cases).
The average number of cases was about 22/year.
The highest incidence was reported in 2007 (0.18/100000), with 38
cases, the most affected being the western areas, almost half of them
related to industrially prepared Romanian meat products (liver paste
and canned ﬁsh). The lowest incidence was recorded in 2002 and 2006
(0.06/100000).
INBI reported 10 cases in 2007. All patients presented diplopia, palpebral
ptosis, midriasis, xerosis and constipation. Nine patients presented
urinary retention (severe in 2 cases) and 5 out of 10 developed respiratory
failure, one patient requiering tracheostomy.
Conclusions: In Romania, type B botulinic infection was widely spread
between 2000–2007, the ratio being 55:1 – B:E which explains the less
severe forms of the disease due to the predominantly autonomic nervous
system involvement in type B botulism. From an average of 20 cases
per year during 2000–2006, the incidence increased rapidly (2 fold in
2007). The incidence is high in the western and central regions, sparing
the southern area. Most cases occur from small familial outbreaks due to
home prepared meat products, except in 2007, when industrially canned
products were involved.
P1536 Acute diffuse bacterial external otitis in primary care
St. Fokas °, F. Arapis, Sp. Fokas, D. Rebelou, M. Dionysopoulou
(Sparta, GR)
Objectives: Acute diffuse bacterial external otitis (AEO) is an infection
of the skin of the cartilaginous portion of the ear canal and is commonly
seen in all age groups in the primary care setting. We aimed to isolate,
characterise and obtain susceptibility proﬁles of bacteria and fungi from
the external auditory canals in adults patients with AEO and to deﬁne
correlation (if any) of pathogens with Senturia classiﬁcation.
Methods: Specimens were collected from the external canals of 93
patients who visited for the ﬁrst time the outpatient otolaryngologist
department of our hospital with symptoms of AEO, during a 3 years
period (2005–2007). AEO was clinically diagnosed and the Senturia
classiﬁcation was done by the otolaryngologist. Patients in the
Senturia class IIa and higher were eligible for the study. Conventional
methodology for culture and identiﬁcation to the species level was used
and susceptibility tests were performed by Vitek 2 system. Statistical
analysis was done by using Fisher’s exact test.
Results: A total of 85 (91%, 85/93) specimens were found positive
for pathogens. Single organism growth was occurred in 67 (79%)
samples and two organisms were isolated from 18 (21%) samples.
The most common isolates were P. aeruginosa (43%), S. aureus
(17%), Candida albicans (15%), Proteus spp. (7%), Streptococcus
pyogenes (6%), Haemophilus spp. (4%), Klebsiella oxytoca (3%), Vibrio
alginolyticus (2%), Streptococci Group C and G (2%) and E. coli
(1%). A total of 3 (17.5%, 3/17) MRSA strains were recovered and
P. aeruginosa ciproﬂoxacin and gentamycin resistance rates were 9%
and 13% respectively. No cases of malignant (necrotising) external otitis
were diagnosed. No statistical association between speciﬁc pathogen and
Senturia class was found.
Conclusions: P. aeruginosa was the most frequent bacterial species
isolated and did not present association with Candida spp. Polymicrobial
nature of AEO was established in one-ﬁfth of the patients and Candida
spp. was found more common than the other pathogens in these cases.
Clinical signs and symptoms as they were classiﬁed using Senturia
class were not associated with any speciﬁc pathogen. Although the
susceptibility tests are not used for topical use of antibiotics our data
suggest that local antibiotic resistance patterns should be considered
since MRSA strains and ciproﬂoxacin-resistant P. aeruginosa were
isolated.
P1537 Epidemiology and drug resistance pattern of cholera
outbreak in summer 2008 in Iran
M. Rahbar °, M. Zahraei, A. Omidvarnia, M.T. Afshani, M. Glami,
H. Gholami, P. Islami, M. Mohammad Zadeh (Tehran, IR)
Objective: Cholera is an endemic disease in Iran. The aim of this study
was to determine epidemiology and antimicrobial susceptibility patterns
of Vibrio cholerae O1 biotype EL Tor in summer of 2008 in Iran
Methods: Stool samples were collected from patients suspected to
have cholera admitted to hospitals and clinics. Specimens examined by
conventional bacteriological methods. All isolates were sent to cholera
reference laboratory for conﬁrmation, stereotyping and susceptibility
testing. Antimicrobial susceptibility testing was performed by disk
diffusion methods as recommended by Clinical laboratory standard
Institute (CLSI). Demographic data collected from questioner forms. The
antimicrobial drugs testes included Ampicillin (AM), Co-trimoxazole
(SXT), Ciproﬂoxacin (CI), Tetracycline (TC), Erythromycin (EM),
Choleramphenicol (C), cefexime (CFM) Furazolidone (F). Nalidixic acid
(NA). The E-test MIC method used for detection of minimal inhibitory
concentration (MIC) for erythromycin.
Results: In total 220 patients diagnosed clinically and laboratory
conﬁrmation to have cholera Of 220 cases 199 serotypes were inaba
and 21 cases were Ogawa. Disease reported from thirteen provinces.
The majority of cases were from Tehran, Qum and Zahedan with 56,
26 and 25 cases respectively. 24 (11%) of patients were under 15 years
old and 196 (89%) of patients were older than 15 years. 149 (68%) of
patients were male and 71 (32%) were female. 129 (59%) of patients
had Iranian nationality, 79 (36%) were from Afghanistan and 12 (5%)
from Pakistan. All isolates were resistant to co-trimoxazole, nalidixic
acid, furazolidone, and intermediate to chloramphenicol. All isolates
were susceptible to tetracycline, ciproﬂoxacin, and erythromycin. MIC
ranged1–1.5mg/ml for erythromycin. The antimicrobial results and pulse
ﬁeld gel electrophoresis (PFGE) showed that all isolates had the same
epidemiology and susceptibility patterns.
Conclusion: Our study reveals that in recent outbreak caused by
V. cholerae EL Tor serotype Inaba were the predominant serotype. All
isolates were resistant to co-trimoxazole, nalidix acid and furazolidon.
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P1538 Peritonitis in continuous ambulatory peritoneal dialysis:
ﬁve-year experience in our hospital
T. Exiara °, K. Tasiopoulou, L. Papazoglou, A. Kalpaka, G. Hasan,
S. Bousios, G. Metallidis, S. Saridou (Komotini, GR)
Objectives: Peritonitis is the most important and life-threatening
complication of continuous ambulatory peritoneal dialysis (CAPD). The
aim of this study was to evaluate epidemiological, clinical and laboratory
ﬁndings, microbiological aspects, treatment approach and outcome of
patients with CAPD-related peritonitis
Methods: A total of 89 patients, 51 (57.3%) female and 38 (42.7%)
male with mean age of 59±16 years, with CAPD-related peritonitis
were enrolled in this retrospective study. Demographical data, clinical,
laboratory and physical examination ﬁndings of patients were registered.
Peritonitis was diagnosed by standard clinical and laboratory criteria
(abdominal pain, cloudy dialysate ﬂuid, white blood cell count >100/ml
of efﬂuent). Gram stain and cultures were obtained from each patient.
Identiﬁcation and susceptibility testing were performed by Vitek 2
automated system (bioMercieux, France).
Results: 104 episodes of peritonitis were detected in a ﬁve-year
period.12 (13.8%) patients had more than one episode of peritonitis.
The most frequent clinical signs and symptoms were: cloudy efﬂuent
in 104 (100%) cases, abdominal pain in 92 (88.4%), rebound
tenderness in 87 (83.6%), fever in 74 (71.2%) and nausea/vomiting in
56 (53.8%) cases. Peripheral leukocytosis, elevated C-reactive protein
and erythrocyte sedimentation rate were detected in 60.6%, 82.7% and
87.5% cases, respectively. The WBC count of peritoneal efﬂuent ranging
from 187 to 6950/ml. Gram stain was positive in 28 (26.9%) efﬂuent.
The positivity of peritoneal ﬂuid culture was 77.9%. The microorganisms
isolated were: coagulase-negative staphylococcus in 51 (62.9%) cases
(S. epidermidis in 84.3% of cases and S. hominis and S. haemolyticus
in the rest of cases), Staphylococcus aureus in 7 (8.6%), Escheriscia
Coli in 6 (7.4%), Klebsiella spp. in 5 (6.2%), Pseudomonas spp. in
5 (6.2%), Streptococcus spp in 3 (3.7%), Enterobacter spp, in 2 (2.5%)
and Candida albicans in 2 (2.5%) cases. All patients took empirically
antibiotic therapy. In 36 (34.6%) cases the initial therapy was changed
according to antimicrobial susceptibility. The mortality rate was 2.2%.
Conclusions: CAPD-related peritonitis is still remaining a serious
complication of CAPD and coagulase-negative staphylococci are
the leading causes in our patients. Systematically registration of
migroorganisms related with peritonitis of CAPD and their antimicrobial
susceptibilities will be helpful for earlier and targeting treatment.
P1539 Epidemiological changes in the human brucellosis
E. Vamvaka, P. Sidira, A. Kaftantzi, A. Ifantidou, A. Kansouzidou °
(Thessaloniki, GR)
A signiﬁcant increase of brucellosis cases in animals and humans has
been observed in Greece over the last years. The purpose of this report
is the epidemiological study and the evaluation of the identiﬁcation and
typing of 189 Brucella strains isolated from blood cultures of patients
admitted to the Infectious Diseases Hospital during the years 2003–2008.
The BACTEC 9050 system and BACTEC PLUS+ Aerobic/F bottles
were used for the isolation of Brucella strains from blood cultures.
The identiﬁcation and typing of the strains were based on conventional
biochemical characteristics, lysis by the Tb phage and agglutination
reactions with the monospeciﬁc A and M antisera. Antimicrobial
susceptibility testing was performed by disk diffusion method and all
strains were found susceptible to all antibiotics. The appearance of
positive results in blood cultures with the BACTEC system ranged from
2.5 to 5 days. It was found that all Brucella strains were B. melitensis
(they were not lysed by the Tb phage) and out of them, 16 strains were
identiﬁed as B. melitensis biotype 1 (8.5%), 41 strains as B. melitensis
biotype 2 (21.7%) and 132 strains as B. melitensis biotype 3 (69.8%). A
correlation of these strains to the Brucella strains isolated from humans
in previous years (1970–2008) was attempted. The B. melitensis biotype
2 caused illness in the humans almost exclusively, but from 1996 a
remarkable increase of the biotype 3 was recorded. From 2001, the
proportion of isolation of B. melitensis biotype 3 strains was increased
considerably, but a simultaneous increase of biotype 1 and elimination of
the biotype 2 was observed. The study of the strains that were isolated
at time period 2003–2008 revealed further increase of the biotype 3
as opposed to the previous years. Results of this study showed that
B. melitensis continues to be the major agent of human brucellosis in
Northern Greece, with the biotype 3 as the most frequent. These ﬁndings
signal epidemiologic changes in the appearance of illness.
P1540 Are measles still a problem? Istanbul, Turkey data
G. Sengoz °, T. Colakoglu, T. Ersoy, N. Kuzgunkaya, E. Celikkol,
M. Bakar (Istanbul, TR)
Measles is an infectious disease documented since the early years of
20th century in Turkey. Measles was included to required to be reported
diseases list in 1930 and nine months old infants were began to get
vaccinated since 1970 as National Vaccination Programme requested.
As a conclusion of this strategy, an obvious decline of the disease
incidence was observed in last 20 years. Since 2006, measles vaccine
has being applied as MMR to 1 and 7 years old children.
Comparison of annual measles incidences between 1951–2005
Health Ministry of Turkey started a “Measles Elimination Programme”
in 2004, by this programme Ministry envisioned to eliminate measles by
2010 year and with this goal began to use probable and conﬁrmed case
deﬁnitions.
As an important branch of this programme Istanbul Health Directorate
provided a 96% vaccination rate in “School Vaccination Days” in the
meantime 1,485,125 primary school children vaccinated in 2003 in
Istanbul metropolis which has 13 millions of population and 210,000
infants under 1 year. In 2005 “Measles Vaccination Days”, 1,338,823
children in 0−6 age group and 6−14 age group not attending to school
have been vaccinated and 94% vaccination rate was reached. Besides
every year intense effort is spent to get vaccination rates 95% and over.
By carrying out measles vaccination campaigne 18,219,757 children
have been vaccinated and 94.6% immunisation rate was reached.
After the last case peak of 3,250 patients in 2001, measles elimination
programme rapidly concluded and since June 2006 only one measles
case was reported in Istanbul. The case reported in October 2008 is
a 27 years old woman who traveled to Thailand 3 weeks before and
accepted as a foreign sourced case.
Measles elimination in Istanbul can be declared as already provided
as a consequence of determined and effective realisation of measles
vaccination campaigne which was planned to get by 2010 at ﬁrst.
P1541 Epidemiological and clinical features regarding Rickettsia
conorii infection in Romania
A. Hristea °, R. Serban, M. Savastre, D. Badescu, M. Apostol,
A. Streinu Cercel, A. Raﬁla, V. Arama, R. Moroti (Bucharest, RO)
Objectives: presenting the epidemiological and clinical aspects of
Rickettsia conorii infection in Romania between 2000 and 2008
Methods: Epidemiological descriptive study of Mediterranean spotted
fever (MSF) cases reported in Romania during 2000–2008 presenting
the clinical features of cases admitted to INBI “Prof Dr Matei Bals”. The
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inclusion criteria were the presence of at least three of the following:
fever, maculopapular rash, eschar, history of tick bite/contact plus
positive serology (indirect immunoﬂuorescence reaction). The sources
of the data are the centralised reports from the National Center for
Surveillance and Control of Communicable Diseases Bucharest, case
enquiries and charts of the patients admitted between 2000 and 2008.
Results: The incidence for the whole country varied from 0.4/100,000
(2006) to 2/100,000 (2001). All the cases reported during 2000–2008
were from the southern part of Romania. The counties with the highest
incidence were Constanta (44.2/100,000 in 2001), Tulcea (39/100,000 in
2002), and Bucharest (3.15/100,000 in 2002). The patients were mainly
from urban areas (85.5%) the infection being related to recreational
activities. Most patients (83%) acquired the infection between June
and September. We have also collected clinical data from 270 patients
admitted to the National Institute of Infectious Diseases “Matei Bals”
of which 56.7% were women and 43.3% men, with a mean age of
47 years. The painless tick bite was often-unnoticed (46.6% of patients).
The clinical features consisted of: fever 96.6%, rash 97.4%, eschar
46.8%, myalgia 42.6%, arthralgia 15.9%, headache 39.3%, neurologic
manifestations 2.9%. Laboratory tests revealed: ALT>N in 103/244
(42.2%), of which >2N in 29/244 (11.9%); WBC >10,000/mm3 68/269
(25.3%), PLT <150,000/mm3 116/269 (43.2%), ﬁbrinogen >400mg/dl
in 140/194 (72.2%). There were two fatal cases during this period but
none among the patients admitted to our institute.
Conclusion: The sporadic nature of cases demonstrates the endemicity
of the disease in Romania. Present ecological and climatic changes
lead to the widening of previous endemic areas, thus contributing to
an increasing number of infections especially the subclinical ones. The
geographic distribution of MSF widened to areas that are not on the
shores of the Black Sea. MSF should be considered in the differential
diagnosis of any traveler returning with fever, history of tick bite, rash,
and/or eschar (tache noire) from endemic areas.
P1542 Lymphadenopathy due to uncommon infectious agents:
Coxiella burnettii, Rickettsia typhi/conorii, and Bartonella
henselae/quintana
M. Pape °, K. Mandraveli, S. Dionysopoulou, F. Kesidou, F. Frantzidou
(Thessaloniki, GR)
Objectives: Although the ﬁnding of lymphadenopathy sometimes raises
fears about serious illness such as lymphoma, acquired immunodeﬁ-
ciency syndrome, metastatic cancer, or mononucleosis syndrome it is,
usually a result of benign infectious causes. The aim of this study was to
investigate whether there is an association between lymphadenopathy and
infection with Coxiella burnettii, Rickettsia conorii/typhi, and Bartonella
henselae/quintana.
Methods: 280 patients who were diagnosed with lymphadenopathy (the
typical causes were excuded by clinical evaluation and conﬁrmatory
laboratory tests) in AHEPA University Hospital, from 2004 to 2008,
were prospectively studied. Characteristics of the patients were collected
including age, sex, underlying disease, occupation, contact with animals,
consumption of unpasteurised products and the histopathological results
in the cases where a lymph node biopsy had been performed.
Paired serum specimens were obtained from all patients and IgG/IgM
antibody titers against Coxiella burnettii, Rickettsia conorii/typhi and
Bartonella henselae/quintana were assessed by immunoﬂuorescence
assay (Focus, kit). A serological diagnosis was made on the basis of
either evaluated titers of IgM antibodies >1:20 or IgG antibodies >1:256,
or the presence of a fourfold rise in the serum IgG titer between acute
and convalescent phase.
Results: The patients tested negative for the presence of Rickettsia
conorii or typhi infection. In 70 patients (29 adults/41children) the
diagnosis of Bartonella henselae infection was conﬁrmed. In 15 out
of 29 adults and in 18 out of 41 children contact with cats was reported.
In two cases a contact with dogs was also reported. In ﬁve patients the
histological examination of lymph nodes pointed out histopathological
ﬁndings compatible with cat scratch disease. Acute Q fever was identiﬁed
in four cases. Two patients had a history of recent exposure to possible
sources of C. burnettii.
Conclusions: Bartonella henselae infection is a common cause of
lymphadenopathy. A deﬁnitive diagnosis should be made by laboratory
examination, while history and physical examination and clinical
evaluation may strongly suggest a particular cause.
P1543 Differences in clinical features between the Boryoung and
Karp genotypes of Orientia tsutsugamushi
D.M. Kim ° (Gwang-Joo, KR)
Background: Scrub typhus is an acute febrile illness caused by Orientia
tsutsugamushi (O. tsutsugamushi) and transmitted through the bites of
thrombiculid mites. The aim of this study was to investigate whether
there are any differences in clinical features and severity between the
Boryoung and Karp genotypes.
Methods: Nested polymerase chain reactions (PCR) were performed
with the blood buffy coats or eschars of patients with suspected scrub
typhus who visited Chosun University Hospital from September to
December in both 2005 and 2006. We compared the clinical features
and severity of the patients who were conﬁrmed by nested PCR to have
the Boryoung and Karp genotypes.
Results: Of 145 patients deﬁnitively diagnosed with scrub typhus, 132
were positive by nested PCR. Of these 132 patients, 120 were clustered
as having the Boryoung genotype and nine as having the Karp genotype.
Eschars were observed in 97.5% of the patients with the Boryoung
genotype and in 66.7% of patients with the Karp genotype, and the
difference was statistically signiﬁcant. However, there were no signiﬁcant
differences in complication rate, need for intensive care or mean length
of hospital stay.
Conclusions: We found that 97.5% of patients with the Boryoung
genotype had eschars, compared with only 66.7% of those with the
Karp genotype. To the best of our knowledge, this is the ﬁrst report of
suggestion that rate of eschar formation may depend on genotype.
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P1544 Molecular epidemiology of human papillomavirus in
Madrid, Spain
M.J. Uria °, J. Valverde, M. Martin, A. Sanchez, L. Molina,
A. Delgado-Iribarren (Alcorcon, Madrid, ES)
Objectives: Human papillomavirus (HPV) are the most common
sexually transmitted infections worldwide. Persistence of high-risk HPV
genotypes is a signiﬁcant risk factor for the development of cervical
cancer. The main goal of the present study was to investigate the
prevalence and genotype distribution of HPV in Madrid (Spain) during
2006–2008.
Methods: We present a retrospective study including samples obtained
from 7 different hospitals in Madrid in the last three years involving
women with an abnormal cervical cytology. To detect the HPV in the
different cervical cell specimens, we have used the Linear Array HPV
Genotyping Test (Roche Diagnostic). The test utilises ampliﬁcation of
target DNA by PCR and nucleic acid hybridisation detecting up to thirty
seven HPV DNA genotypes including high-risk (16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68) and low-risk genotypes (6, 11, 40, 42, 44, 53,
54, 55, 61, 62, 64, 66, 67, 69, 70, 71, 72, 73, 81, 82, 84, IS39, CP6108).
Results: In this study we have analysed a total number of 1551 samples.
The overall HPV prevalence was 77% from cervical samples collected.
HPV genotypes distribution was widely heterogeneous with up to 37
different genotypes identiﬁed. High-risk and low-risk genotypes were
found in 53% and 47% of all cases, respectively. Among these HPV
types, genotype 16 was detected in 14% of the patients whereas genotype
18 was only detected in 3% of the patients. Our data showed that up to
68% of the HPV high risk genotypes detected, belonged to genotypes
not included in the HPV vaccine. Co-infection with multiple HPV types
was detected in 38% of the women included in our study. The presence
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of two, three and four different HPV genotypes infecting the same
individual was detected in 56%, 25% and 12% of the co-infection cases
respectively. Furthermore, more than ﬁve different genotypes were found
in 8% of the cases.
Conclusions: According to this study, HPV prevalence was markedly
high in women presenting cervical cellular alterations. HPV genotypes
16 and 18 were detected in less than 20% of the patients although
we have found a large percentage of cases belonging to genotypes not
covered by the quadrivalent vaccine. Overall, co-infection with multiple
HPV types was a common ﬁnding.
P1545 Performance of the Gen-Probe APTIMA COMBO 2® assay
on the Panther analyser
C. Clark °, M. Vi, J. Pham, C. Nguyen, T. Trsic, L. Villegas, A. Worlock
(San Diego, US)
Objectives: The objective was to evaluate the analytical performance
of the Panther; a new fully automated molecular diagnostic analyzer
under development at Gen-Probe and compare it to the TIGRIS® DTS®
Automated Analyzer.
Methods: A six-member panel was made by spiking rRNA from
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) into
Specimen Transport Medium (STM). Positive panel members included
CT at 5 and 0.5 fg/reaction and NG at 250 and 50 fg/reaction. A dual-
positive panel member combined 5 fg/reaction of CT and 250 fg/reaction
of NG, and a negative panel member contained unspiked STM. Panels
were tested with the Gen-Probe APTIMA COMBO 2® Assay on 3
prototype Panther instruments weekly over a period of 2 months. The
positive and negative agreement with expected results and the inter-run
precision were calculated. In addition, panels containing serial dilutions
of CT and NG were tested with the APTIMA COMBO 2 Assay on one
Panther instrument and one Gen-Probe TIGRIS DTS instrument. Results
were compared by plotting the signal generated for each instrument in
a scatter plot and calculating the slope using linear regression.
Results: The positive agreement with the expected results was 99% to
100% for all Panther instruments and all runs. Negative agreement was
100%. For CT, within-run precision was 10% at 5 fg/reaction and
15% at 0.5 fg/reaction. Within-run precision was 5% for NG at 250
and 50 fg/reaction. The within-run precision for the dual-positive panel
member was 5%.
A scatter plot comparing dilution panel results for the Panther and
TIGRIS instruments gave a linear regression slope of approximately 0.9.
Reactivity rates were 100% for both the TIGRIS and Panther for CT at
0.25 fg/reaction and NG at 12.5 fg/reaction. The Panther processed 120
samples in approximately 5.5 hours.
Conclusion: The newly developed, fully automated Panther molecular
diagnostic analyzer provides precise results comparable to the TIGRIS
analyzer when running the APTIMA COMBO 2 Assay. In addition to
superior assay performance, the Panther offers the optimum throughput,
workﬂow and turn around time that is ideal for the low to mid volume
molecular testing laboratory.
P1546 An automated magnetic extraction system for Chlamydia
trachomatis DNA, tested with the Roche COBAS® TaqMan
detection system
A.M.E. Foster °, Z.F. Hall (Dumfries, UK)
Objective: Chlamydia trachomatis accounts for more cases of sexually
transmitted infection than any other bacterial pathogen. Methods of
detection include culture or antigen detection, both now superseded by
ampliﬁcation reactions. This method is advantageous offering superior
sensitivity and speciﬁcity and is much quicker to perform. The aim of
the study was to evaluate the performance of the automated NorDiag
BUGS’N BEADS™ STI-fast kit on the NorDiag Bullet instrument
using swabs collected and transported in M4RT® MicroTest Culture
Transport System (Remel, Inc) media with the aim to CE IVD the
process. The study was carried out at Dumfries and Galloway Royal
Inﬁrmary which serves a population of 146,000. In 2007–08, the total
number of Chlamydia tests performed in the region was 7202 with a
prevalence rate of 8.8%.
Methods: 704 swabs were tested in parallel using two different extraction
methods detailed below. The performance of the BUGS’N BEADS™
STI-fast kit on the Bullet system was compared to the nucleic acid
extraction using the Roche AMPLICOR® CT/NG specimen preparation
kit on the Tecan Freedom EVO75 instrument. The BUGS’N BEADS™
STI-fast method is based on nucleic acid extraction using magnetic beads
that bind to bacteria and are then magnetically removed from the sample
matrix allowing for concentration of the sample, as lysis occurs on the
captured cells only. This differs from the Roche specimen preparation
kit as it uses detergents to release Chlamydial DNA from Chlamydia
reticulate bodies in preparation for ampliﬁcation.
Detection of Chlamydial DNA for both extraction methods was
performed with the COBAS® TaqMan CT test v 2.0 on a COBAS®
TaqMan 48 analyser. Samples with discrepant results from the two
methods were reprocessed in duplicate for both methods. A true positive
result was then based on two out of three results.
Results: A total of 704 specimens were tested in parallel. The overall
prevalence rate based on true disease status was 5.7%. Table 1 shows
the overall results of the study including inhibition.
Conclusion: The results of this study demonstrate that the BUGS’N
BEADS™ STI-fast kit exhibits excellent sensitivity and speciﬁcity
values comparable with the Roche system. Inhibition is signiﬁcantly
reduced; therefore decreasing the number of repeat tests resulting in
quicker turn around times. Another beneﬁt of the NorDiag system is
the automated sample barcode reader which reduces the possibility of
transcription error.
Table 1. Overall results
Results True status
M4RT swab
samples
Roche COBAS® TaqMan® CT Test, v2.0
manual method
BUGS’n BEADS™ STI-fast on NorDiag
Bullet
+ − + −
Test + 39 3 (F+) 40 3 (F+)
Test − 2 (F−) 660 1 (F−) 660
Sensitivity 95% 97.5%
Speciﬁcity 99.5% 99.5%
PPV 92.8% 93%
NPV 99.6% 99.8%
Inhibition 39 10
P1547 External quality assessment for the detection of Chlamydia
trachomatis and Neisseria gonorrhoeae in clinical biology
labs using molecular techniques
B. China °, K. Vernelen, W. Mackay, J.C. Libeer (Brussels, BE;
Glasgow, UK)
Objective: Chlamydia trachomatis and Neisseria gonorrhoeae are two of
the most prevalent sexually transmitted pathogens. The detection of these
two bacteria using molecular techniques was recently included into the
nomenclature of the Belgian Health Care Insurance. Therefore, to respect
the Belgian legislation and to be reimbursed, the clinical biology labs
must participate to an external quality assessment organised by IPH.
The aim was to evaluate the proﬁciency of the labs and of the used
techniques.
Methods: External quality samples were provided by QCMD (Glasgow,
Scotland) for surveys in 2008. The results were encoded in the QCMD
database on their webpage (www.qcmd.org). The response form included
the qualitative result (positive, negative or not determined) and all
the information about the used technique. Samples were considered as
negative, weak positive, positive or strong positive regarding to the level
of contamination. A false positive result and a false negative result for
a strong positive sample were considered as clinically relevant error and
the labs with an incorrect answer received an ofﬁcial claim.
Results: For C. trachomatis, the matrixes (urine and swabs) were
considered separately. For urine, 96 labs participated with 66.7% of
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good results. The sensitivity and the speciﬁcity were 96% and 52%
respectively. The percentage of clinically relevant errors was 3.72%.
Thirteen different methods were used with a percentage of correct
results ranging from 14 to 100%. For swabs, 97 labs participated with a
percentage of good results of 89% with no false positive results and 13%
of false negative results. The percentage of clinically relevant errors was
1.03%. For N. gonorrhoeae, 24 labs participated. The percentage of good
results was 78.75%. The sensitivity and the speciﬁcity were 80.7%and
71%, respectively. The percentage of false positive results was 24%.
Three types of negative samples were used: a blank sample, a sample
containing N. cinerea and a sample containing N. lactamica. All false
positive results came from the two latter samples.
Conclusion: For the detection of C. trachomatis in urine, the survey
revealed a problem of sensitivity. For N. gonorrhoeae, a problem of
speciﬁcity occurred especially with some commercial kits. Therefore,
this kind a study allowed thus to detect proﬁciency problems either for
some of the labs or for some of the used kits.
P1548 Diagnosis of multiple respiratory pathogens with the
Multiplex ligation-dependent probe ampliﬁcation
R. Jansen °, B.M.W. Diederen, R.A. Guseinova, C.W. Koomen (Haarlem,
NL)
Objectives: Infections of the respiratory tract are very common in the
population and can be caused by a number of different viruses and
bacteria. A reliable diagnosis of the pathogen is often cumbersome
and time consuming but necessary to prevent superﬂuous antibiotic
treatments, to rationalise isolation of hospital patients and to get insight
into the prevalence of respiratory pathogens. The Multiplex ligation-
dependent probe ampliﬁcation (MLPA) of the RespiFinder Plus ® kit
is able to detect seven viral and four bacterial pathogenic species
simultaneously. In this report we evaluate the MLPA as a diagnostic
tool and its performance on QCMD proﬁciency panels.
Methods: We tested the performance of the MLPA on 420 clinical
respiratory samples and on the 2008 QCMD proﬁciency panels for
inﬂuenza A/B virus, rhino/corona virus, parainﬂuenza virus, adenovirus,
and respiratory syncytial virus (RSV)/human metapneumovirus (hMPV).
To mimic mixed infections, the QCMD panels were tested as mixtures.
The QCMD-MLPA samples consisted of a mixture of randomly chosen
samples of each of the ﬁve panels. In total twelve QCMD-MLPA
mixtures were analyzed.
Results: We analyzed the clinical samples with a maximum turnaround
time of three days. The MLPA detected no pathogens in 16% of the
samples, a single pathogen in 55% and multiple pathogens in 26% of
the samples. In 3% of the samples a non-conclusive result was obtained.
RSV was present in 40% of the positive samples, rhinovirus in 25%,
coronavirus in 17%, adenovirus in 10%, hMPV in 7%, inﬂuenza virus in
6%, and parainﬂuenza virus in 2%. The bacterial pathogens Mycoplasma
pneumoniae and Chlamydophila pneumoniae were found in 6 and 1
samples respectively. Bordetella pertussis and Legionella pneumophila
were not detected.
In the QCMD-MLPA samples all the virus species and subtypes were
identiﬁed correctly. The lowest titers of the parainﬂuenza and inﬂuenza
panels and a moderate titer of adenovirus type 3 were not detected by
MLPA.
A possible drawback of the MLPA is its proneness to cross-
contamination, because the test has no closed-tube procedure. No
evidence was found for cross-contamination, due to preventive measure-
ments, such as dedicated workspace and pipettes.
Conclusion: The MLPA of the RespiFinder Plus ® kit is a useful asset
for a diagnostic laboratory that combines a short turn-around time and
cost effectiveness with a good sensitivity and speciﬁcity.
P1549 Lower respiratory viral infections in hospitalised adults
V. Fuse °, J. Niubo`, J. Lin˜ares, R. Martin (Barcelona, ES)
Objective: Lower respiratory tract infections (LRTIs) are a leading cause
of hospitalisation, morbidity and mortality, particularly in patients with
immunosupression and/or underlying conditions. The aim of this study
was to evaluate the usefulness of molecular diagnostic methods and to
assess the prevalence of respiratory viruses (RVs) in hospitalised adults
who underwent a bronchoalveolar lavage (BAL) for an acute respiratory
event.
Methods: Over a 1 year period (2007–2008), 118 BAL samples were
prospectively collected from 95 patients (35 females; mean age: 57)
with community- (n: 72) or hospital-acquired (n: 46) severe pneumonia.
Viral isolation was routinely performed by conventional culture (MRC-5
cell line) and 48 h shell vial cultures (Vero, A549, HEp-2 and MDCK
cell lines). Molecular methods included two in house multiplex RT-
PCR nested assays for simultaneous detection of 14 RVs and a
single in house RT-PCR nested assay for human metapneumovirus
(hMPV) identiﬁcation. Conventional microbiological tests for bacteria,
micobacteria, fungi and parasite detection were routinely performed.
Results: Twenty three RVs were identiﬁed by molecular methods in 22
of 118 BAL specimens (18.6%). Rhinovirus was the most frequently
detected virus (n:11, 47.8%) followed by inﬂuenza virus A (n:2) and
hMPV (n:2). Respiratory syncytial virus (RSV) A, RSV B, parainﬂuenza
virus (PIV) 1, PIV 2, PIV 3, PIV 4, adenovirus (ADV) and enterovirus
were each identiﬁed in one case. In addition, 11 cytomegalovirus
and 5 herpes simplex virus type 1 (HSV 1) were isolated by viral
culture. Except for ADV, no other RV could be detected by culture.
Mixed infections were found in 13 of 22 (59.1%) RVs positive BAL
specimens. In other 2 cases viral co-infection was detected (PIV 3 +
rhinovirus, PIV 1 + HSV 1). RVs were mainly identiﬁed in patients
with community-acquired LRTIs (18/72, 25.0%). An immunosuppressive
and/or underlying condition was present in all except one of the patients
with viral infection.
Conclusions: RVs were frequently detected in BAL specimens from
hospitalised adults, particularly in those with LRTI of community
acquisition. Although these viruses were mainly found in mixed
infections, its presence in the lower respiratory tract suggests a
pathogenic role. Molecular assays enabled multiple, sensitive and rapid
identiﬁcation of RVs and should be included as routine diagnostic
procedures.
P1550 Application of an expanded gold standard and latent class
analysis to decide on the strategy for the diagnosis of
M. pneumoniae infections
K. Loens °, N. Hens, D. Ursi, H. Goossens, M. Aerts, M. Ieven
(Antwerp, Diepenbeek, BE)
Objectives: Serology and PCR are widely used for diagnosis of
M. pneumoniae (MP) in respiratory tract infections, but studies
comparing the different methods are rare. The aim of this study was
to evaluate PCR, NASBA, 2 IgA, and 4 different IgM and IgG EIA
assays and the combination of these for the detection of MP in patients
with lower respiratory tract infections (LRTI).
Methods: 205 paired sera from 224 patients with CAP and 10 paired
sera from 20 MP PCR positive patients with LRTI were available.
From 29 patients only an acute phase serum sample was available. Four
different EIA’s were evaluated: ImmunoWell IgG and IgM EIA (Genbio);
Medac IgM, IgA, and IgG EIA (Medac); AniLabsystems IgM and IgG
EIA (Biomedical Diagnostics); and Euroimmun IgM, IgA and IgG EIA
(Biognost). PCR and NASBA were applied to respiratory specimens.
(1) An expanded gold standard (EGS) and latent class analysis (LCA)
were used to calculate the sensitivities and speciﬁcities of all individual
tests and of the combination of 2 or 3 of these approaches.
Results: EGS: The sensitivities of the EIAs ranged from 11−30% for
IgM and from 14−22% for IgA in the acute phase serum and from
17−38% for IgM and from 52−62% for IgA in the convalescent serum.
IgG seroconversion or a signiﬁcant rise in titre ranged from 40−69%.
The speciﬁcities ranged from 80−99% for IgM and from 84−89% for
IgA both in the acute phase and in the convalescent phase serum, and
from 91%-98% for IgG. The MP IgM assay with the best combined
values for sensitivity and speciﬁcity was the AniLabsystems EIA. The
best MP IgG assay was the Medac EIA. (2) The results were validated
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by LCA. Sensitivities and speciﬁcities of PCR and NASBA alone were
79% and 76%, and 98% and 97%, respectively. In combination with a
second or a third test, sensitivity increases to 92% and 95%, respectively.
Results of LCA conﬁrmed the results obtained with the use of an EGS.
Conclusion: Evaluation of the 4 EIAs and 2 independent ampliﬁcation
tests for MP showed substantial differences between the performances
of the assays. Ampliﬁcation methods are the most sensitive tests to
diagnose an acute MP infection. IgM and IgA antibodies are of limited
value. IgG serology has usually a moderate sensitivity but results in late
diagnosis. The combination of different tests increases the speciﬁcity
and sensitivity.
P1551 Chlamydophila pneumoniae and Mycoplasma pneumoniae
EQA Pilot Study
K. Loens °, W.G. MacKay, C. Scott, H. Goossens, P. Wallace, M. Ieven
(Antwerp, BE; Glasgow, UK)
Objectives: To assess the proﬁciency of laboratories in the correct
detection of C. pneumoniae and M. pneumoniae by nucleic acid
ampliﬁcation techniques (NAATs).
Methods: This EQA panel consisted of a total of 13 samples in BAL
or transport medium: 6 samples containing various concentrations (4.9–
490 IFU/ml) of C. pneumoniae (ATCC VR-1355), 5 samples containing
various concentrations (20–5000 CCU/ml) of M. pneumoniae (ATCC
29085) and 2 samples negative for both.
Results: 79 laboratories from 18 countries participated in this EQA
study. 64 datasets were returned for C. pneumoniae (n = 5 conventional
commercial, n= 10 conventional in-house, n = 4 real-time commercial,
n= 43 real-time in-house, n = 2 SDA). 67 datasets were obtained for
M. pneumoniae (n = 5 conventional commercial, n= 10 conventional
in-house, n = 4 real-time commercial, n= 46 real-time in-house, n = 2
SDA). For the total panels, correct results per sample varied between
95.3% and 100% for C. pneumoniae and between 53.7% and 98.5% for
M. pneumoniae. Correct results for positive and strong positive samples
for both C. pneumoniae and M. pneumoniae ranged between 88.1%
and 100%. 95.3% and 98.4% correct results were obtained for samples
with the lowest C. pneumoniae input (4.9 IFU/ml). 53.7% and 55.2%
correct results were obtained for samples with the lowest M. pneumoniae
input (50 CCU/ml). In general, commercial conventional NAATs showed
sensitivity problems compared to conventional in-house NAATs for both
organisms. On the other hand, real-time commercial NAATs scored
better than real-time in-house assays in terms of sensitivity for both
organisms. For C. pneumoniae and M. pneumoniae, 2.0% and 2.4%
false-positive results, respectively, were reported.
Conclusion: Analysis of the data for C. pneumoniae showed that the
concentrations used were easily detectable by the vast majority of
participants with percentages of correct results ranging from 95.3–
100%. The percentage of correct qualitative results for M. pneumoniae
demonstrated that the range of concentrations included in this panel
proved challenging for a number of participants. False negative results
were the most important problem for M. pneumoniae positive samples.
The inclusion of low positive M. pneumoniae samples allows also to
evaluate the sensitivities of individual tests.
P1552 Evaluation of three commercial serological tests versus
real-time PCR for diagnosis of Mycoplasma pneumoniae
infection in children
K. Papavasileiou °, H. Papavasileiou, A. Voyatzi, S. Chatzipanagiotou
(Athens, GR)
Mycoplasma pneumoniae, (MP) is a common cause of community
acquired respiratory tract infections. Laboratory diagnosis of MP
infection is usually performed with serological methods. Direct isolation
by culture is time consuming, can be inﬂuenced by previously
administered empiric antimicrobial therapy and therefore not suitable for
clinical practice, while molecular detection methods, such as polymerase
chain reaction (PCR) are very sensitive and practical diagnostic tools.
Purpose: The aim of this study was to compare real-time PCR of
oropharyngeal swabs with serology, for diagnosis of MP infection,
performed by two commercial enzyme-linked immunosorbent assays
(ELISA) and one commercial indirect immunoﬂuorescence test (IFT).
Methods: From October 2007 to April 2008, 102 children with clinical
signs of lower respiratory tract infection were investigated for MP 1) by
real-time PCR (Real time Alert Q-PCR, Nanogen Advanced Diagnostics
S.r.L., Corso Torino, Italy), 2) by ELISA IgG-IgM (Hycor, Amsterdam
Zuidoost, The Netherlands), 3) by IFT IgG-IgM (Pneumoslide IgG-IgM,
Vircell, Granada, Spain) and 4) by a rapid ELISA-IgM (Immunocard
Mycoplasma, Meridian Bioscience Inc., Cincinnati, Ohio, USA).
Results: MP was detected in 30 children out of 102 (29.41%) with real-
time PCR. From these 30 children, 11 (36.66%) were found positive by
all three serological tests, 3 (10%) by ELISA IgG-IgM and IFT IgG-IgM,
4 (13.33%) by ELISA IgG-IgM and the rapid ELISA-IgM, 7 (23.33%)
only by ELISA IgG-IgM, 3 (10%) only by the rapid ELISA-IgM and 2
(6.66%) only by IFT IgG-IgM. The speciﬁcity of all three serological
tests as referred to real-time PCR was 100%, while the sensitivity was
as follows: 86.66% for ELISA IgG-IgM, 53.33% for IFT IgG-IgM and
60% for the rapid ELISA-IgM.
Conclusions: PCR was superior to serology for the diagnosis of MP
infection, while ELISA IgG-IgM proved to be the most sensitive
serological method. However, if PCR is practically or technically difﬁcult
to performed, the use of two serological tests is warranted.
P1553 Evaluation of a real-time PCR assay for the molecular
identiﬁcation of Pneumocystis jirovecii pneumonia
S. Zhang °, C. Seah, G. Tsui, B. Yu, A. Boggild, J. Thornback,
S. Richardson (Toronto, CA; Manchester, UK)
Objectives: Pneumocystis jirovecii an opportunistic fungal pathogen,
causes pneumonia in HIV and immunocompromised patients. We
evaluated the performance of a commercial real-time PCR assay
FXG®: RESP (Asp+), (Myconostica) by comparing it with two routine
microscopic tests for the detection of P. jirovecii from respiratory
specimens.
Methods: 363 respiratory specimens, 78% bronchial washing (BW)
or bronchoalveolar lavage (BAL) specimens, 17.6% sputum (SP), and
4.4% other respiratory samples. The microscopic tests were calcoﬂuor
white(FF) (Fungi-Fluor®, Polysciences, Inc) and immunoﬂuoroscence
(IFA) (MonoﬂuoTM, Bio-Rad). DNA was extracted using the MycXtra®
Fungal DNA Extraction Kit (Myconostica). PCR was set up using the
FXG®: RESP (Asp+) Kit (Myconostica). Ampliﬁcation, detection, and
interpretation were performed using the AB7500 Real-time PCR system.
Samples were considered positive if the P. jirovecii Ct value was 38.5
and negative if P. jirovecii Ct value was >38.5 with a valid IAC value.
Results: The positivity rate of PCR, FF and IFA was 15.7%, 7.2% and
8.3%, respectively. 80.7% of PCR positive results were from BW and
BAL, 14% were from SP specimens. Compared to either FF or IFA, the
PCR assay showed 91.9% sensitivity, 92.9% speciﬁcity, 59.6% PPV and
99.0% NPV. 3 samples were negative by PCR but positive by microscopic
tests, 23 samples were positive by PCR but negative by microscopic tests.
As all the specimens were from patients who had a clinical suspicion of
pneumocystis pneumonia as a prerequisite for testing, we consider that
these 23 samples most likely reﬂect increased detection of P. jirovecii
by a more sensitive assay, rather than false positives. Therefore, in our
patient population, the PCR assay is 118% more sensitive than FF and
89% more sensitive than IFA. When comparing test performance based
on the type of specimens we found the test performance was better using
BAL and BW specimens (93.8% sensitivity, 93.6% speciﬁcity, 65.2%
PPV and 99.1% NPV) than using SP specimens (66.7% sensitivity,
90.1% speciﬁcity, 25% PPV and 98.2% NPV).
Conclusions: Our ﬁndings demonstrated that the FXG®: RESP (Asp+)
assay was more sensitive than standard microscopy using calcoﬂuor
white (FF) or IFA for the detection of P. jirovecii from patients with
possible pneumocystis pneumonia. Although, the assay can be applied
to a variety of respiratory specimens, BW and BAL appear to be the
optimal specimens for this molecular testing.
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P1554 Use of optical mapping to identify prophages involved in
virulence in Pseudomonas aeruginosa
T.K. Wagner °, B. Stahl, C.W. Dykes (Madison, US)
Objectives: Pseudomonas aeruginosa is a Gram-negative bacterium that
can be found readily throughout the environment and is a cause of
numerous opportunistic infections in humans. Complete full genome
sequences have indicated that P. aeruginosa strains are highly similar
but can differ in genomic islands that can contain virulence genes and
genes important in conferring antibiotic resistance. Recent sequencing
and animal model data have identiﬁed and implicated prophage islands
as important factors in the ability of P. aeruginosa to cause disease.
However, whole genome sequencing to identify these important prophage
islands is impractical due to time and cost. In contrast, Optical Mapping
can rapidly yield a whole-genome ordered restriction map that can be
used to easily detect the prophages. The purpose of this study was to
determine whether Optical Mapping could identify prophages that have
been shown to be involved in the virulence of P. aeruginosa.
Methods: Whole-genome Optical Maps were generated from four
clinically relevant American Type Culture Collection (ATCC) isolates
of P. aeruginosa (ATCC 9027, ATCC 17649, ATCC 17651, and ATCC
27317). Optical maps were compared to the recently published Liverpool
Epidemic Strain whole-genome sequence that contained three prophages
(Prophage 2, Prophage 3, and Prophage 5) shown to increase survival
of P. aeruginosa during infection. Whole-genome comparative genomics
was performed with MapViewer software. MapViewer software was then
used to search the ATCC isolate Optical Maps for motifs similar to the
motifs of the identiﬁed prophages.
Results: None of the Optical Maps of the four ATCC isolates contained
motifs similar to the three prophages of the Liverpool Epidemic Strain,
indicating that the prophages were absent from the isolates. However,
sites of phage insertions were identiﬁed in all but one ATCC isolate
when compared to the prophage-containing reference. Motifs similar to
two additional known prophages not yet implicated in virulence were
identiﬁed in two of the Optical Maps.
Conclusions: These data conﬁrm the ability of Optical Mapping to
rapidly identify regions in the P. aeruginosa genome that contain
prophages and the sites of phage insertion. The ability to rapidly generate
a whole-genome ordered restriction map to identify prophages can be
used to identify more virulent strains and to identify novel genetic
elements involved in virulence.
P1555 Fast detection of the V176F mutation of multiresistant
Mycobacterium tuberculosis isolates using high-resolution
melting curve PCR analysis
A. Pietzka °, A. Sto¨ger, J. Zeinzinger, F. Allerberger, W. Ruppitsch
(Vienna, AT)
Objective: In tuberculosis (TB), drug resistance to rifampicin, one of
the two most potent ﬁrst-line drugs, is increasing globally. Resistance
to rifampicin is mainly associated with single point mutations in the
RNA polymerase gene (rpoB) gene. Several point mutations occur in
the 81-bp hot-spot region of cluster I (codons 432 to 458) of the
rpoB gene. A frequent mutation outside cluster I associated with high-
level resistance to rifampicin is the V176F (GTC176TTC) mutation. To
improve the detection of multidrugresistant (MDR)-TB isolates with wild
type cluster I rpoB sequence, we describe a fast and accurate detection
method for the V176F mutation based on high-resolution melting curve
PCR analysis.
Methods: Forty-nine rifampicin resistant and nineteen fully susceptible
Mycobacterium tuberculosis strains, as determined by conventional drug
susceptibility testing, were used to develop a PCR assay to detect
the V176F mutation. A 125 bp fragment of the rpoB gene containing
the amino acid exchange was ampliﬁed for HRM analysis on a
LightCycler480 instrument (Roche Diagnostics, Penzberg, Germany).
Results: Three of the forty-nine resistant isolates (6%) showed the single
nucleotide polymorphism (SNP) class 2 sequence alteration V176F. The
remaining forty-six resistant isolates didn’t have any mutation in the
125 bp amplicon as well as the susceptible isolates.
Conclusions: Rifampicin resistance is associated with MDR-TB and is
therefore a surrogate marker for genotypic drug susceptibility testing.
Molecular detection of mutations within cluster I of the rpoB gene
is already well known. In addition we describe the feasibility of a
new single-step closed-tube screening method for the occurrence of
the frequent V176F mutation in the rpoB gene which allows a broad
detection of multi drug resistance and which can easily be combined
with an assay for mutation testing in cluster I.
Figure: V176F mutation.
P1556 A prospective cross-over study demonstrating that rapid
MRSA screening leads to a reduction in the rate of MRSA
acquisition
K. Hardy °, C. Bean, A. Szczepura, S. Gossain, R. Davies, N. Stallard,
S. Shabir, C. McMurray, Y. Meng, A. Bradbury, P. Hawkey
(Birmingham, Coventry, UK)
Objectives: To determine the impact of rapid MRSA screening on the
transmission of MRSA whilst controlling for other variables.
Methods: A prospective, cluster, two period cross-over design on 7
surgical wards was used. For the ﬁrst 8 months, 4 wards used rapid
MRSA screening and three wards used a standard culture method. The
groups were reversed for the second 8 months. Regardless of the method
of detection all patients were screened on admission and then every
4 days. MRSA control measures remained constant.
Results: A total of 12,682/13,952 patient ward episodes were included
in the study, with characteristics of the patient groups across the
study periods being comparable. Admission screening identiﬁed 453
(3.6%) MRSA positive patient ward episodes, with a further 268 (2.2%)
acquiring MRSA. A log-linear Poisson regression model was used to
compare MRSA acquisition rates. Both length of stay on the ward and the
proportion of emergency procedures carried out on a ward signiﬁcantly
increased the likelihood of MRSA acquisition. After adjusting for
these and other variables, rapid screening was shown to reduce MRSA
acquisition with patients being 1.49 (95% conﬁdence interval 1.115–
2.003; p = 0.007) times more likely to acquire MRSA in wards where
they were screened using the slower culture method.
Conclusions: Screening of surgical patients using rapid testing resulted
in a statistically signiﬁcant reduction in MRSA acquisition. This result
was achieved in a routine surgical service with high bed occupancy and
low availability of isolation rooms, making it applicable to the majority
of health-care systems worldwide.
P1557 The impact of rapid PCR screening for methicillin-resistant
Staphylococcus aureus on patient isolation
A. Dolan °, E. Creamer, O. Sherlock, T. Thomas, J. Moore, E. O’Neill,
A. Shore, A.S. Rossney, D. Coleman, H. Humphreys (Dublin, IE)
Objectives: This study aimed to determine the diagnostic accuracy of the
GeneXpert Xpert MRSA™ real-time PCR assay (Cepheid) and whether
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availability of MRSA results within two hours of specimen reception
facilitates more rapid isolation of MRSA-positive patients.
Methods: The study was carried out in a 700-bed tertiary-referral
hospital over a 10-week period from October to December 2008.
Patients (n = 319) at risk for carriage of MRSA were investigated.
Specimens (n = 704) were collected from nasal and groin sites using
Copan double swabs in Stuart’s liquid transport medium. One swab was
processed by Xpert MRSA; the second was inoculated onto MRSA-
Select chromogenic agar (CA) (Bio-Rad) and retained to investigate
discrepancies between PCR and culture results. CA plates were incubated
for 24 h at 37ºC. Discrepancies were investigated by culturing the second
swab in salt enrichment with subculture onto blood agar and CA. Xpert
MRSA assay results were compared with results of direct and enrichment
culture and also on an amended basis where kit-positive culture-negative
specimens were considered true positive results if patients had previously
been MRSA-positive or had positive samples from another site.
All Xpert MRSA results were reported to the Infection Control Team
twice daily but positive results were communicated immediately. Data
were collected on the isolation parameters of patients.
Results: One-hundred and fourteen specimens were positive by the Xpert
MRSA assay and 59 were positive by culture. Sensitivity, speciﬁcity,
positive and negative predictive values of the Xpert MRSA assay were
95%, 97%, 82% and 99%, respectively, compared with amended results.
Five specimens were kit-negative and MRSA culture-positive while 21
specimens were kit-positive and MRSA culture-negative. Six of these
samples were conﬁrmed to be false-positives.
Seventy-six patients (24%; 76/319) were positive by PCR. On assessment
of the impact of these rapid results: six were discharged from hospital
and 19 were already isolated/cohorted before results were reported while
51 were isolated/cohorted following the positive result. Seventy percent
(36/51) were isolated within 8 hours of specimen result which is up to
48 hours earlier than occurs with routine culture results.
Conclusions: Rapid screening using the Xpert MRSA assay greatly
facilitated earlier isolation of MRSA-positive patients and combined with
good diagnostic accuracy can contribute to improved MRSA control.
P1558 Evaluation of commercially available molecular and culture-
based assays for rapid detection of methicillin-resistant
Staphylococcus aureus
W. Sabiiti °, J. Cortin˜as Abrahantes, C. Lammens, G. Molenberghs,
M. Aerts, H. Goossens, S. Malhotra-Kumar on behalf of the MOSAR
WP2 Study Group
Background: The need for rapid methods to accurately detect
methicillin-resistant Staphylococcus aureus (MRSA) is widely acknowl-
edged. We assessed 3 commercial assays − 2 molecular, GeneOhm
(BD Diagnostics) and GeneXpert (Cepheid) − and 1 culture-based,
Baclite (3M) − for their ability to correctly identify MRSA utilising
well-characterised isolates, either pure or in mixtures, at varying
concentrations.
Methods: Fifty-two isolates (27 MRSA of which 9 were animal strains;
25 non-MRSA of which 8 were MRCoNS, 5 MSSA, and 12 enterococci,
Enterobacteriaceae and Acinetobacter spp.), and 21 mixtures of these
isolates were tested on the three assays following manufacturer’s
recommendations. As pure strains, non-MRSA were tested at 1 dilution
(105 CFU/ml for GeneOhm and GeneXpert, and 108 CFU/ml for Baclite
according to manufacturer’s instructions), while serial dilutions (101 to
103 or 104 CFU/ml) of the 27 MRSA strains were tested to determine the
limit of detection (LoD) of each assay. Mixtures were made using isolates
at varying concentrations according to CLSI guidelines. Moreover, 10ml
of each sample was also simultaneously spiral-plated on blood agar with
6mg/ml cefoxitin and in case of MRSA positive samples, colony counts
were made after overnight incubation. Mean sensitivity and speciﬁcity
and conﬁdence intervals (CIs) were estimated for each assay by logistic
regression model using a penalised likelihood approach.
Results: GeneOhm showed the highest sensitivities for both isolates and
mixtures at lower (103 CFU/ml) concentrations (Table).
Table. Performance of three commercial assays for rapid detection of MRSA
Assay Mean sensitivity (95%CI)
at MRSA concentration
Mean speciﬁcity
(95%CI)
Minimum limit of
detection
103 CFU/ml 104 CFU/ml (CFU/ml)
Using isolates as samples
GEneOhm™ MRSA
(BD Diagnostics, BE)
93.7% (80.2–98.2) ND* 77.2% (60.0–88.5) 140
GeneXpert™ MRSA
(Cepheid, FR)
86.8% (75.2–93.5) 99.5% (97.9–99.9) 82.3% (55.2–94.6) 140
Baclite™ MRSA
(3M, USA)
40.1% (26.1–55.9) 93.8% (86.7–97.2) 98.2% (90.5–99.7) 410
Using mixtures as samples
GEneOhm™ MRSA
(BD Diagnostics, BE)
97.6% (90.6–99.4) ND** 55.6% (31.9–77.1) 44
GeneXpert™ MRSA
(Cepheid, FR)
94.8% (88.3–97.8) 99.8% (99.2–100) 63.2% (38.7–82.4) 27
Baclite™ MRSA
(3M, USA)
26.9% (14.8–43.8) 89.3% (77.7–95.2) 95.3% (81.7–98.9) 2400
∗ND, Not determined. Only samples negative at the lower concentration (n = 2) were tested at this concentration.
**Not determined as all MRSA-positive mixtures were detected at the lower concentration.
Of the 27 MRSA tested, 2 strains that could not be detected at
103 CFU/ml were positive at 104 CFU/ml, giving a 100% positivity for
GeneOhm at the latter concentration. Mean sensitivity for GeneXpert
was 100% at 104 CFU/ml with narrow CIs indicating high precision
of this parameter estimate. Baclite showed the highest mean speciﬁcities
for both mixtures and isolates. False-positive results with the 2 molecular
tests were primarily due to MRCoNS. Minimum LoD for both molecular
assays was similar for isolates, while GeneXpert could detect upto
27CFU/ml of MRSA in mixtures.
Conclusions: A general increase in mean sensitivities of all three assays
was observed with increasing MRSA concentrations. GeneOhm and
GeneXpert showed comparable performance in terms of sensitivity,
speciﬁcity and LoD.
P1559 Clinical evaluation of four molecular methicillin-resistant
Staphylococcus aureus tests: Becton Dickinson GeneOhm,
Hain GenoType MRSA Direct and two in-house assays
M. Broeren, L. Linssen, L. Roorda, M. Hermans, T. Trienekens ° (Venlo,
Rotterdam, NL)
Objective: Methicillin-resistant Staphylococcus aureus (MRSA) has
become an increasing problem in nosocomial infection. Rapid detection
of MRSA-colonised patients is a prerequisite to limit spread of the
organism in hospitals. Several molecular assays to quickly identify
MRSA are available. The performance of such assays depends on many
factors among which sensitivity and speciﬁcity of the assay. Besides, the
incidence and type of MRSA strains that are locally present (foreign
inﬂuence, presence of animal farms) inﬂuence positive and negative
predictive values.
Methods: We evaluated the performance of four molecular methods on
an ABI 7500 platform (BD GeneOhm MRSA real-time PCR assay, Hain
GenoType MRSA direct and two in house real time PCR assays), using
samples from 226 patients. In house PCR-1 was based on the detection
of a S. aureus speciﬁc gene together with the MecA gene, in house
PCR-2 was an MRSA direct PCR adapted from Huletsky. A minimum
of two samples (each containing swabs from nose, throat and perineum)
were analysed per patient. Before ampliﬁcation, samples were enriched
by overnight incubation in Tryptose Phosphate Broth with aztreonam.
After overnight incubation CHROMagar MRSA and blood agar plates
were inoculated. The outcome of the cultures after 2 days was considered
gold standard.
Results: Twenty-three of the 226 patients carried MRSA. The
sensitivities of the BD GeneOhm, Hain MRSA direct and in house
PCR-1 and -2 were 95.7%, 95.6%, 69.9% and 87% respectively. The
positive predictive values were 62.9%, 59.5%, 25%, and 33.3% and
the negative predictive values were 99.5%, 99.5%, 95.3% and 98.2%
respectively. The MRSA that were missed after overnight culture were
retested as pure cultures. One MRSA strain remained negative in both
the BD and Hain test, none were negative in PCR-1 and PCR-2.
Conclusions: We conclude that in our geographical region both the BD
GeneOhm MRSA test and the Hain MRSA direct test displayed excellent
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sensitivities and negative predictive values to detect MRSA in overnight
cultures. Considering the relative small turnaround time of the BD test,
after overnight incubation (3 hr BD versus 6 hr for the Hain test) and
the advantage of ampliﬁcation detection in a closed system, the BD test
offers us a welcome tool for quick MRSA screening.
P1560 Detection of methicillin-resistant Staphylococcus aureus in
skin/soft tissue samples using a commercial PCR method
B. Puche, A. Ubeda, J.L. Garcia-Lopez, M. Marin, C. Castro,
F. Lucena, E. Martin-Mazuelos ° (Seville, ES)
Objective: Prevalence of community-acquired methicillin resistant
S. aureus (MRSA) has increased in the last decade, becoming one of the
most frequent causes of skin/soft tissue infections (SSTI). In order to
avoid inadequate empiric antibiotherapy and to take isolation measures,
early detection of MRSA is of major importance. Our aim was to evaluate
a commercial PCR method for the detection of MSSA/MRSA on SSTI
samples compared to conventional culture methods.
Methods: A prospective analysis was carried out in patients with SSTI
attending the ER of our hospital and requiring hospitalisation during
2008. Three samples were tested per patient. One nasal and one SSTI
swab were processed following conventional culture on blood agar,
MacConkey agar, chocolate agar and chromogenic MRSA agar plates.
Another SSTI swab was used for PCR analysis using the XpertTM
MRSA/SA SSTI Assay (Cepheid Innovation) on the GeneXpert platform
following manufacturer’s instructions.
Results: 139 patients were included, with a mean age of 67.4 years
(±15.67). Within the risk factors for the presence of MRSA, the most
common were chronic wounds (47.5%), diabetes (44.6%), hospitalisa-
tion (43.2%), antibiotherapy (28.8%), institutionalisation(7.2%) and/or
previous detection of MRSA (4.3%). Cellulitis was observed in 47.5%
of the patients, diabetic foot ulcer in 29.5% and pressure ulcer in 20.1%.
In total 148 samples were analyzed. In 9 cases, PCR was invalidated and
in 7 conventional culture was not carried out, of which 6 were negative
and one was MSSA by PCR. Of the remaining samples, 72 were negative
and 32 positive either to MSSA (25 samples) or MRSA (7 samples) by
both methods. False negative results were observed in 25 samples (23
cultures and 2 PCRs), whereas discordances in methicillin resistance
was observed in 3 samples, all MSSA by PCR. Time employed for
conventional culture varies from 24 to 72 hours while PCR is performed
in 1 hour, aproximately. Compared to conventional culture, sensitivity of
PCR was 100%, speciﬁcity was 99%, precision rate was 0.90 and NPV
was 1.
Conclusions: 1. Community-acquired MRSA is present in 7.6% of SSTI
in our region. 2. This commercial PCR method is rapid, sensitive and
accurate in the detection of both MSSA and/or MRSA in SSTI samples,
with high precision rate and NPV. 3. The differences in the detection
of resistance to methicillin are probably due to the presence of other
mechanisms, rather than the mecA gene.
P1561 Performance of Becton Dickinson GeneOhm methicillin-
resistant Staphylococcus aureus PCR assay in different
spa- and PFGE-types of MRSA
J. van der Velden, A. Heumassej, M. Hermans, T. Trienekens ° (Venlo,
Den Bosch, NL)
Objective: Methicillin-resistant Staphylococcus aureus (MRSA) has
become an increasing problem in nosocomial infection. Rapid detection
of MRSA-colonised patients is a prerequisite to limit spread of the
organism in hospitals. Several molecular assays to quickly identify
MRSA are available. Beside assay design, the incidence and types of
MRSA strain that are locally present (foreign inﬂuence, presence of
animal farms) inﬂuence the performance of such assays.
We evaluated the ability to detect different Staphylococcal Protein A
(spa) and pulsed-ﬁeld gel electrophoresis (PFGE) types of MRSA with
BD GeneOhm MRSA real-time PCR assay on an ABI 7500 platform.
Methods: In total seventy-nine MRSA strains were tested. Thirty-one
strains were collected since autumn 2005 from the region of Venlo and
selected to include as many spa-types as possible in the evaluation.
To collect more different types, also strains from the region of Den
Bosch were included. From those strains mostly PFGE typing was
available (typing was done at the RIVM, Bilthoven, the Netherlands),
because before 2007 MRSA strains were not routinely spa-typed in
the Netherlands. A disadvantage of PFGE-typing is that data cannot
be compared between different laboratories. Spa-typing, in contrast,
is sequence based and its results are valid worldwide. Hence, if both
typing results were available only the spa type was considered in our
evaluation. From some spa-or PFGE-types more than one MRSA strain
was collected.
Results: Thirty-six different PFGE types were collected from which 4
strains with 4 different PFGE-types were not detected.
From the 29 different spa types 2 MRSA strains with 2 different spa-
types were not detected.
In the region of North-Limburg the predominating spa types were t011
and t108. These are animal farm related types. The other spa-types
obtained from this region were isolated only once or twice.
Conclusions: We conclude that the BD GeneOhm MRSA test missed
several MRSA strains. However in our region, with a speciﬁc selection of
MRSA types, the BD GeneOhm test performed well for MRSA screening
purposes.
P1562 Cost-efﬁcacy of rapid diagnostic testing of methicillin-
resistant Staphylococcus aureus with the GeneXpert® system
M. Wassenberg °, A. Box, A. Troelstra, J. Kluytmans, M. Bonten on
behalf of the Dutch Rapid MRSA Diagnostics Study Group
Objectives: Pre-emptive isolation of high risk patients is a cornerstone
of the Dutch MRSA control strategy. However, most high risk patients
are not colonised and remain in isolation for 3 to 5 days awaiting
conventional culture results. We determined cost-efﬁcacy of adding rapid
diagnostic testing (using the Xpert MRSA assay on the GeneXpert®
system) to the current MRSA control policy in a prospective multi-centre
study.
Methods: All patients with increased risk of MRSA colonisation and
fulﬁlling the criteria for pre-emptive isolation in 9 participating hospitals
between 04/07 and 06/08 were eligible. In addition to the standard set
of conventional microbiological cultures, MRSA PCR was performed
directly on patient material. Infection prevention measures were based
upon immediate PCR results, and, were thus withdrawn when negative.
Culture results were used as reference.
Results: 917 patients (mean 48 years and 56.9% male) were enrolled,
mainly because of previous hospitalisation abroad (64.4%), contact
screening related to MRSA positive index patients (18.5%) and
professional contact with pigs (14.7%). 2989 PCRs were performed
(3.3 per patient including nose, throat, perineum), of which 158 (5.3%)
yielded unresolved results. MRSA prevalence (based upon culture
results) was 3.7%. Compared to conventional culture results sensitivity,
speciﬁcity, positive predictive value and negative predictive value of
the MRSA PCR were 76.5%, 94.6%, 35.1% and 99.1% respectively.
In 779 (85.0%) patients pre-emptive isolation was discontinued upon
negative PCR results. Median turn around times (TOT) between start of
pre-emptive isolation and notiﬁcation of PCR and culture results were
13.7 hours (range between hospitals 6.3 to 27.0 hours) and 87.6 hours
(range 74.0 to 131.7 hours), respectively. Median TOT between start of
isolation and discontinuation of isolation was 15.4 hours. Costs of the
PCR were €67 per test (on average €221.10 per patient). We performed
an economic evaluation (abstract number 718) and estimated the costs
of an isolation day to be €27.30. Therefore adding MRSA PCR to the
current policy will not be cost saving.
Conclusion: In a low endemicity setting, guiding of pre-emptive
isolation upon the Xpert MRSA assay on the GeneXpert® system is
safe and reduces pre-emptive isolation time to 15.4 hours at the costs of
€221.10 per patient.
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P1563 Direct detection of methicillin-resistant Staphylococcus
aureus in broth-enriched clinical samples using a real-time
multiplex PCR
B. So¨derquist °, L. Stark, J. Zimmermann, M. Neander, C. Berglund,
S. Melin, A. Matussek, P. Mo¨lling (Orebro, Jonkoping, SE)
Objectives: A rapid, reliable, and sensitive method for methicillin-
resistant Staphylococcus aureus (MRSA) screening is warranted in a low-
endemic area such as Scandinavia. A method for excluding the presence
of MRSA in clinical samples using an MRSA-selective enrichment
broth incubated over night followed by PCR of the nuc gene is widely
used. However, a method for direct detect of MRSA in clinical samples
would further facilitate the infection control management of patients and
hospital staff.
Methods: A real-time multiplex PCR for direct detection of MRSA
using a S. aureus orfX-speciﬁc primer and a set of SCCmec-
speciﬁc primers was developed on a LightCycler PCR system (Roche
Diagnostics). The study included i) broth enriched clinical samples
pooled from patients; DNA prepared manually (n = 1328), manually
compared with an automated Tecan Miniprep 75 with BUGS’n
BEADS™ MRSA kit (NorDiag ASA) (n = 130), and the latter compared
with a fully automated (from primary tubes) Xiril with BUGS’n
BEADS™ STI-Fast (NorDiag ASA) (n = 308), ii) MRSA strains of
different spa types and SCCmec types (n = 171), iii) methicillin-
sensitive S. aureus (MSSA) isolates (n = 95) and iv) various coagulase-
negative staphylococcal (CoNS) isolates (n = 33). The multiplex PCR
was compared with the nuc screening PCR using the broth enriched
clinical samples.
Results: The multiplex PCR detected all MRSA strains as well as
all broth enriched clinical samples with MRSA (n = 64) and none of
the CoNS were positive. MSSA strains were positive in 4/95 (4%).
One to three percent of consecutive broth enriched clinical samples
were false positive in the multiplex PCR and subsequently subcultured
compared with 12−14% of samples analysed with nuc screening PCR.
The automated DNA preparation on the Tecan Miniprep 75 was better
compared with the manual preparation resulting in lower crossing point
values and the fully automated Xiril was even more efﬁcient.
Conclusion: The developed real-time multiplex PCR using a S. aureus
orfX-speciﬁc primer and a set of SCCmec-speciﬁc primers was sensitive
and detected all heterogenic and diverse MRSA strains present in our
low endemic area. Four percent of MSSA was false positive. However,
the percentage of clinical samples demanding further subculturing
decreased with about 10% using the multiplex PCR. The automated
DNA preparation facilitates handling of a large amount of samples such
is the case in MRSA outbreaks.
P1564 Multiple-locus variable-number tandem repeat analysis in
a setting of polyclonal endemicity of methicillin-resistant
Staphylococcus aureus
B. Rivero-Pe´rez °, E. Pe´rez-Roth, S. Me´ndez-A´varez (La Laguna, Santa
Cruz de Tenerife, ES)
Objectives: The mehicillin-resistant Staphylococcus aureus (MRSA)
population in the Hospital Universitario Nuestra Sen˜ora de Candelaria
(HUNSC) over a 5-year period was marked by shifts in the circulation
of pandemic clones. The aim of the study was to investigate if a
MLVA (Multi-Locus Variable number tandem repeat Analysis) assay
could predict MRSA clones previously identiﬁed by PFGE and supported
by MLST and SCCmec typing. Also to establish possible criteria of
clustering MLVA patterns and to check concordance levels between the
results produced by MLVA and other typing methods. This study expects
to validate the MLVA, thus allowing us to introduce MLVA as a routine
typing method in the HUNSC.
Methods: Over a ﬁve-year period, 296 well-characterised isolates
belonging mainly to 5 major pandemic lineages of MRSA were tested
by MLVA. MLVA was carried out by a multiplex PCR in which clfA,
clfB, sdrCDE, sspA, and spa locus were ampliﬁed. Banding patterns
were analyzed both visually and with InfoQuest software. We also
quantitatively assess the congruence between typing methods by using
Adjusted Rand index (AR) and Wallace’s coefﬁcient (W).
Results: All the isolates were typeable by MLVA, and the results were
repetitive. PFGE was able to divide the 296 isolates into 20 PFGE types
(>six bands different) and 41 subtypes (one to six bands different).
The 296 isolates were classiﬁed in 35 MLVA types (one different band
cut off), 17 types (80% cut off) and, 11 types (70% cut off). The
discrimination power of PFGE was higher (D= 75.14(70.28–79.99) than
for MLVA (D=71.33(66.14–76.52)). The higher congruence between
PFGE and MLVA was found applying the 80% cut off criteria for
MLVA, with a value of AR=0.86. Thus, two strains with the same
MLVA type have 83.63% chance of having the same PFGE type.
This value is improved to 84.46% with the one different band criteria.
When comparing partitions obtained by international nomenclature, ST-
SCCmec, the higher congruence was achieved with MLVA 80% cut off,
with AR=0.98. Applying this cut off, two strains with the same MLVA
type have 99.09% chance of having the same PFGE type. With the one
different band cut off criteria, this probability rises to 99.33%. MLVA
typing has a very good predictive power over the clonal relationships
deﬁned by PFGE and ST-SCCmec typing.
Conclusion: Our results suggest that MLVA may be reliable for the
identiﬁcation of endemic MRSA clones circulating in the HUNSC.
P1565 Comparisons of healthcare-associated and community-
associated MRSA strains using SCCmec EVIGENE and
routine susceptibility testing
A.K.I. Rasmussen, A. Mortensen, D. Houg °, H.K. Johansen (Vedbaek,
Copenhagen, DK)
Background: Healthcare-associated (HA) methicillin-resistant Staphy-
lococcus aureus (MRSA) possess multiple antimicrobial resistance
determinants and are typically multidrug resistant with a SCCmec type I,
II or III. In contrast, SCCmec IV community-associated CA-MRSA
strains are generally susceptible to non-b-lactam antibiotics including
clindamycin and glycopeptides.
Methods: In the current study we compared the antimicrobial patterns
between CA-MRSA and HA-MRSA in Danish strains. Identiﬁcation of
HA-MRSA and CA-MRSA strains were done with SCCmec EVIGENE
(AdvanDx) a signal-amplifying, sandwich hybridisation assay which
provides results within 3 hrs.
67 clinical MRSA isolates from Denmark (Rigshospitalet) were tested
by SCCmec EVIGENE for the presence of each of the ﬁve SCCmec
types, mecA (conferring resistance to methicillin), nuc (S. aureus-
speciﬁc nuclease gene) and PVL (virulence genes for Panton-Valentine
leukocidin). Antimicrobial susceptibility patterns were acquired by agar
disk diffusion using Neosensitabs (Rosco).
Results: Thirteen % (9/67) of the 67 MRSA positive isolates were
identiﬁed as HA-MRSA strains by the presence of SCCmec type I (1),
II (7) or III (1) and 81% (54/67) were identiﬁed as CA-MRSA strains
by the presence of SCCmec type IV without PVL 40% (27/67), type IV
with PVL 34% (23/67) and 6% (4/67) with multiple SCCmec types (1&4
or 1&4&5 or 4&5). All multi-types were identiﬁed as CA-MRSA as the
type I marker (pls) has in few cases been found in type IV. Six % (4/67)
were negative for all ﬁve SCCmec types and therefore unidentiﬁed.
All tested MRSA isolates were resistant to penicillin and cefuroxime.
When comparing antimicrobial resistance patterns between HA-MRSA
and CA-MRSA we found that HA-MRSA have a higher prevalence of
resistance to azithromycin & clindamycin than CA-MRSA (89% (8/9)
vs. 36% (19/53)), and to gentamicin (33% (3/9) for HA-MRSA vs.
2% (1/53)) for CA-MRSA). Furthermore, CA-MRSA negative for PVL
have a higher prevalence of resistance to azithromycin & clindamycin
compared to CA-MRSA positive for PVL (66% (19/29) vs.13% (3/24)).
Conclusions: SCCmec EVIGENE is an easy diagnostic tools to
differentiate HA-MRSA (type I, II, III) and CA-MRSA (IV, V) strains.
Comparisons of Danish HA-MRSA vs. CA-MRSA isolates showed
that HA-MRSA were more likely to be resistant to azithromycin,
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clindamycin, erythromycin and gentamicin than CA-MRSA, especially
PVL-positive CA-MRSA.
P1566 Molecular typing of enterotoxigenic strains of Staphylococcus
aureus isolated from different foods of animal origin
G. La Salandra °, G. Normanno, E. Crisetti, L. Serrecchia, T. Onni,
M. Fiori, V. Lorusso, S. Tola (Foggia, Bari, Sassari, IT)
Objectives: Staphylococcal food poisoning (SFP) remains one of the
most important cause of foodborne diseases in industrialised countries.
Because of the great genetic variability of Staphylococcus aureus, its
ability to synthesize an extensive number of staphylococcal enterotoxins
(SEs), and its large host spectrum, results from epidemiological
investigations and risk analyses were often difﬁcult to assess. The aim
of this work was to genetically characterise 159 enterotoxigenic strains
of S. aureus isolated from food of animal origin (milk, cheese, meat and
ﬁsh products) and pastry products, collected in Southern Italy during
2007–2008, in order to detect the SEs coding genes, and to obtain a
genetic ﬁngerprinting of the strains.
Methods: Genomic DNA extracted from strains of S. aureus was
analysed for the detection of 12 SEs genes (sea, seb, sec, sed,
see, seg, seh, sei, sej, sem, sen, seo) using three multiplex-PCR
assay. The enterotoxigenic strains were tested by pulsed ﬁeld gel
electrophoresis (PFGE) after SmaI restriction treatment. DNA restriction
bands were analysed using the Gel Compar II software (Applied Maths).
Dendrograms were obtained using the unweighted pair group method
with arithmetic mean (UPGMA) and Dice’s coefﬁcient.
Results: The results showed a prevalence of classical SEs encoding
genes (sea, seb, sec, sed and see) compared with the “new” SEs encoded
genes; the new SEs encoding genes are generally associated with the
classical ones. Overall out of 159 analysed strains, 59 (37.1%) S. aureus
isolates were found to be positive for only one se gene, 52 (32.7%) for
two, 30 (18.9%) for three, 5 (3.1%) for four, 10 (6.3%) for ﬁve and
3 (1.9%) for six se genes. All the strains were typable by PFGE and
showed a great genetic heterogeneity especially among the bovine food
isolates.
Conclusion: The present work might help to trace an epidemiological
map of different enterotoxigenic strains and to investigate the possible
correlations between genotype and presence of enterotoxin genes. The
results obtained conﬁrm the high frequency of the SEs encoded genes
among S. aureus and the potential risk for the consumer, if good hygienic
practices are not observed. In terms of risk analysis, it could be important
to better understand the source and the signiﬁcance of the presence in
foods of S. aureus strains carrying multiple ses genes and whether these
strains are more likely to synthesize SEs in foods than the strains carrying
only one se gene.
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P1567 Molecular detection of mecA and pvl genes in clinical setting
H. Moraitou °, M. Makarona, F. Havouti, D. Papaventsis, N. Souﬂa,
S. Mytas, V. Spyropoulos, A. Georgousi, A. Pefanis, S. Kanavaki
(Athens, GR)
Objectives: The aim of the study was to investigate the presence of pvl
and mecA genes of S. aureus strains isolated from clinical samples in
our laboratory.
Materials and Methods: From January to October 2008, 217 S. aureus
strains were isolated from different clinical samples, corresponding to
7.4% (217/2945) of positive cultures. In particular, 35 (8.3%) S. aureus
strains were isolated from blood cultures, 48 (18.9%) from pus or
wound infections, 84 (9.4%) from respiratory samples and 50 (3.6%)
from various other samples. All strains were identiﬁed using Vitek2
automated system (Biomerieux, France). Antibiotic susceptibility testing
was performed by Vitek2 and manual Kirby-Bauer method (EUCAST
guidelines). All oxacillin resistant strains were further tested by PCR for
the presence of mecA and pvl genes (Genotype Staphylococcus, Hain
Lifescience).
Results: From a total of 217 S. aureus strains, 129 were identiﬁed as
MRSA (59.4%) by Vitek2. All MRSA strains carried mecA gene.
18/35 (51.4%) of S. aureus strains isolated from blood cultures were
MRSA, whereas 2 of them (11.1%) carried the pvl gene.
In addition, 27/48 (56.3%) of S. aureus strains isolated from pus were
MRSA. The pvl gene was found in 9 out of 15 (60%) tested by PCR.
In respiratory samples, 51 MRSA strains were identiﬁed (51/84, 60.7%),
and among these, 4 (7.8%) carried the pvl gene.
Conclusions: In the present study, virulent, pvl positive MRSA strains
were isolated from various clinical specimens. In respiratory samples,
MRSA strains were frequently isolated indicating either a carrier’s status
or active infection. Conﬁrming previous reports, all strains carrying the
pvl gene, were also carrying the mecA gene. The highest rate of pvl (+)
MRSA strains was isolated from pus samples. Molecular methods have
revolutionised clinical practice in the medical microbiology laboratory by
providing a suitable tool for the rapid and sensitive detection of bacterial
virulence and resistance to antibiotics.
P1568 Vancomycin-intermediate Staphylococcus aureus from
bloodstream infections in Italy
M. Monaco °, A. Sanchini, F. D’Ambrosio, A. Pantosti (Rome, IT)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is one
of the leading causes of morbidity and mortality in hospital settings.
Vancomycin still represents the drug of choice for treating MRSA
infections, although reduced susceptibility or resistance to vancomycin
has emerged. The aim of this study was to examine invasive S. aureus
strains in order to investigate the presence of vancomycin-intermediate
Staphylococcus aureus (VISA) or hetero (h)/VISA and to characterise
them using molecular typing methods.
Methods: In the period 1 September 2006 − 28 February 2007 150
Staphylococcus aureus strains, mostly from bloodstream infections, were
obtained from 19 hospital laboratories distributed all over the country,
within the joint EARSS/SeqNet.org initiative. Eighty-four were MSSA
and 66 MRSA. Susceptibility to vancomycin was assayed by E-test using
CLSI breakpoints. VISA/hVISA screening was performed according
to E-test protocol. Vancomycin population analysis proﬁle (PAP) was
carried out on selected strains. The agr group and the staphylococcal
chromosomal cassette (SCCmec) were determined by PCR. The repeat
region of the S. aureus protein A (spa) gene was sequenced and analysed
by the Ridom Staph Type software. MLST was also performed.
Results: Vancomycin susceptibility for MSSA was: MIC50 = MIC90 =
1.5mg/L; for MRSA: MIC50 = 1.5mg/L, MIC90 = 2mg/L. Among
MSSA no strains were VISA or h/VISA. Among MRSA 3 strains
were VISA (MIC = 3mg/L) and 10 isolates h/VISA. PAP conﬁrmed
heteroresistant subpopulations in the presence of 4mg/L of vancomycin.
By spa typing, MSSA showed high heterogeneity while among MRSA
three main groups were identiﬁed: t041(23 isolates), t008(19 isolates)
and t001(9 isolates). Out of 3 VISA, 2 were assigned to spa type 041;
of 10 h/VISA, 9 were assigned to spa type 041. All the isolates assigned
to spa type 041 harboured SCCmec type I and agr 2 that is mostly
associated with reduced susceptibility to vancomycin. By MLST, all
VISA and h-VISA isolates belonged to clonal complex (CC)5.
Conclusions: VISA and h-VISA were detected only among MRSA. The
majority of VISA and h-VISA were assigned to spa type t041 which is
the most frequent spa type among MRSA from bloodstream infections
in Italy.
P1569 Skin lesion caused by ST398 and ST1 methicillin-resistant
Staphylococcus aureus in a young girl in Spain and MRSA
nasal colonisation study in their family members
C. Aspiroz, C. Lozano, A. Vindel, J.J. Lasarte, M. Zarazaga, C. Torres °
(Zaragoza, Logrono, Madrid, ES)
A 12 years old Ecuadorian girl, living close to a pig farm where her father
was working, presented an skin lesion on her chin (June 2008), ﬁrstly
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assumed as a case of Tinea but dermathopytes could not be recovered,
and this diagnosis was later discarded. Two types of MRSA were the
unique organisms that could be recovered from the lesion and they were
characterised by MLST, SCCmec and spa typing and were identiﬁed
as ST398-SCCmecV-t011 and ST1-SCCmecII-t127, being both isolates
negative for the Panton Valentine leukocidin. The ST398 strain showed
resistance to penicillin, oxacillin, tetracycline, erythromycin, clindamycin
and telithromycin and contained the mecA, tetK, ermA, and ermC genes.
The ST1 strain showed the above mentioned resistances and genes, and
in addition included gentamicin, tobramycin, kanamycin, ciproﬂoxacin,
levoﬂoxacin and trimethoprim-sulphamethoxazole resistances and msrA,
ermB, tetL, ant(4′)(4”), aph(2”)-aac(6′) genes, as well as a Ser84Leu
amino acid change in GyrA and a Ser80Phe change in ParC protein.
The skin lesion was resolved after topical treatment with mupirocin
during ten days. An epidemiological study was started in order to know
the nasal colonisation status of the family members, using nasal swabs
that were streaked in ORSAB medium (Oxoid) for MRSA recovery
and obtained isolates where characterised by MLST, SCCmec and spa
typing. The following family members turned out to be colonised by
MRSA: patient girl (ST398-SCCmecV-t108), father (ST398-SCCmecV-
t108), mother (ST398-SCCmecV-t108 and ST1-SCCmecII-t127), and
brother (ST398-SCCmecV-t011). Most of ST398 nasal isolates presented
the phenotype of resistance that included b-lactams, macrolides,
clindamycin, telithromycin and tetracycline. The nasal ST1-t127 isolate
recovered from the mother showed the same phenotype and genotype of
resistance that ST1-t127 strain recovered in the skin lesion of the girl.
All isolates were negative for TSST, ETA-a y ETA-b toxins.
Conclusion: The ﬁrst case of an skin lesion associated with ST398-t011
and ST1-t127 MRSA isolates is reported in Spain in the daughter of a pig
farmer. Of special interest is the multiresistant-phenotype showed by the
ST1-t127 MRSA clinical isolate. Nasal colonisation by different ST398
genetic lineages of MRSA seems to be frequent in persons that live close
to pig farms. Dissemination of ST398-MRSA in humans, associated with
animals, is an emerging problem that should be tracked in the future.
P1570 Epidemiology of methicillin-resistant Staphylococcus aureus
in the dermatology department of a university hospital,
Casablanca, Morocco
S. Bouhali Zriouil, K. Zerouali °, M. Timinouni, M. Bekkali,
J.D. Perrier-Gros-Claude, S. Breurec, B. Garin, H. Benchikhi, N. El
Mdaghri (Casablanca, MA; Dakar, SN)
Objectives: Methicillin resistance Staphylococcus aureus (MRSA) is
a common pathogen amongst nosocomial infections in Morocco. At
the University Hospital Ibn Rochd most of the isolated Staphylococcus
aureus strains came from samples of patients hospitalised in the Der-
matology Department.. In order to better understand the epidemiology
of MRSA in dermatology, we determined the antibiotic susceptibility of
the isolated strains and their genetic proﬁles.
Methods: A prospective study was undertaken between January and
March 2007: 13 MRSA were isolated during this period in Dermatology
Department. These strains were characterised by testing susceptibility
to 16 antibiotics using agar disk diffusion method according to CLSI
guidelines. The methicillino resistance was conﬁrmed by the presence
of gene mecA by PCR. Genetic typing of the agr system and the
staphylococcal cassette chromosome mecA (SCCmecA) were realised by
multiplex PCR, and the sequence type of these strains was determined
by MLST.
Results: The MRSA prevalence in Dermatology Department raised
30.3% while the general MRSA prevalence in the hospital is 19.1%. The
MRSA strains were resistant to Tetracyclin, Peﬂoxacin, Trimethoprim-
sulfamethoxazole, Fucidic acid and Erythromycin; 11 strains were also
resistant to Rifampin and 12 to Kanamycin, Gentamycin and Tobramycin
The genetic typing demonstrated that all strains are agr1, SCCmec III
and belong to the Sequence Type 241, (ST241) showing the same proﬁle
than Hungarian clone.
Conclusions: The high prevalence of MRSA in Dermatology Depart-
ment is related to the spread of the multidrug resistant Hungarian clone,
thus limiting the choice of effective antibiotherapy for MRSA infection
treatment.
P1571 Present prevalence of Panton-Valentine leukocidine-positive
methicillin-resistant and susceptible Staphylococcus aureus
in Spain
E. Cercenado °, M. Marin, R. Insa, O. Cuevas, A. Vindel, E. Bouza
(Madrid, Majadahonda, ES)
Objectives: At present, the prevalence of Panton-Valentine leukocidine-
positive (PVL+) community-acquired methicillin-resistant Staphylococ-
cus aureus (CA-MRSA) in Spain is low, however two nationwide surveys
have demonstrated that the prevalence of PVL is increasing among
methicillin-susceptible S. aureus (MSSA) (from 1.6% in 2002 to 18%
in 2006). In this study we determine the present prevalence of PVL+
MSSA and PVL+ MRSA in Madrid (Spain).
Methods: From November-2007 to January-2008 we investigated the
presence of the PVL in all S. aureus recovered in our laboratory; in
addition, from February to November 2008 the presence of PVL was
investigated in all MRSA isolates. The PVL genes were detected by
PCR. SCCmec types were determined using a multiplex PCR. PFGE
and MLST typing of the PVL+ MRSA was performed as described.
Results: Over the ﬁrst period of the study, a total of 454 S. aureus were
isolated in our laboratory (272 MSSA and 182 MRSA). Of the MSSA
5.5% (n = 15) were PVL+, and corresponded to 11 patients (6 children,
5 adults); of the MRSA 1.1% (n = 2) were PVL+. MSSA PVL+ isolates
were from skin and soft-tissue (SST) (n = 9), blood (n = 3), bone (n = 2),
and peritoneal ﬂuid (n = 1). Over the second period a total of 691 MRSA
isolates were recovered and 9 were PVL+ (1.3%). All PVL+ isolates were
community-acquired. Overall, PVL+ MRSA were from SST (n = 10; 8
adults, 2 children), and blood (n = 1; child; resistant to erythromycin and
clindamycin). Five PVL+ MRSA isolates were from Ecuadorian patients,
5 from Spanish patients and 1 from an African patient. All belonged to
ST8-SCCmecIV. None of the isolates belonged to the USA300 clone.
All patients recovered after adequate treatment.
Conclusions: At present, infections due to PVL+ MRSA are not a cause
for concern in our area. However surveillance of PVL+ MSSA should
be considered, since the higher prevalence of the PVL among our MSSA
isolates could establish a background for the emergence of PVL+ MRSA.
P1572 Prevalence of genes encoding pyrogenic toxin superantigens,
the Panton-Valentine leukocidin and exfoliative toxins
in Staphylococcus aureus isolated from furunculosis −
association with agr group
H. Masiuk °, S. Holtfreter, J. Kolata, B. Bro¨ker, S. Giedrys-Kalemba
(Szczecin, PL; Greifswald, DE)
Staphylococcus aureus is an important skin and soft tissues community-
acquired infections pathogen, that produces many extracellular virulence
factors. There are Panton-Valentine leukocidin (lukS-lukF genes),
exfoliative toxins (eta, etb, etd), pyrogenic toxin superantigens (SAg)
comprising TSST-1 (tst) and the staphylococcal enterotoxins (sea-r, seu).
The genes are located on mobile genetic elements. The gene expression
of some factors is controlled by a complex network of global regulators,
including agr (accessory gene regulator, groups I-IV).
The aim of this study was to investigate the relationship between toxin
gene proﬁle of S. aureus isolates from furunculosis and agr group.
Methods: 75 S. aureus strains were collected between 2002 and 2008
from West Pomeranian region (Poland) patients with furunculosis. For
agr typing and for the detection of 19 SAg genes (sea, seb, sec, sed,
see, seg, she, sei, sej, sek, sel, sem, sen, seo, sep, seq, ser, seu, tst) and
exfoliative genes (eta, etd) we performed a set of six multiplex-PCRs.
The prevalence of lukS-lukF and mecA gene was determined by PCR.
Results: Most of the isolates (56%) belonged to the agr IV group (all
carried the enterotoxin gene cluster: seg, sei, sem, sen, seo, seu and
most additionally seb), 28% − agr I (most carried seg, sei, sem, sen,
seo, single seg, sei, sem, sen, additionally seb, sel, seh, sek, seq or none
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SE gene), 14.7% − agr III (seg, sei, sem, sen, seo, seu or none, one
strain: tst and sea, one: eta), 2.6% − agr II (one: sec, one: sej, ser, sep).
84% strains (all from agr IV and most from the other groups) possessed
lukS-lukF genes. The one MRSA (mecA+) strain possessed agr I, seg,
sei, sem, sen, seo, seu and seb, sek, seq.
Conclusion: The great variety of virulence genes among S. aureus
isolated from furunculosis cases has been observed. More than half of
isolates were classiﬁed as agr IV, only single to agr II. Most strains
possessed lukS-lukF genes and gene cluster: seg, sei, sem, sen, seo, seu.
Only single strains carried tst and eta genes.
P1573 Characterisation of Panton-Valentine leukocidine positive
methicillin-resistant Staphylococcus aureus in Italy
S. Stefani °, M. Monaco, F. Campanile, V. Caﬁso, A. Sanchini,
P. Marone, A. Pantosti (Catania, Rome, Pavia, IT)
Objectives: Recent reports show a dramatic increase worldwide of
infections caused by community-acquired methicillin-resistant Staphylo-
coccus aureus (CA-MRSA). These strains, by deﬁnition, infect patients
with no risk factors for acquiring nosocomial MRSA strains, and are also
well characterised by genetic markers such as the presence of SCCmec
type IV, V or VII and the presence of the Panton-Valentine leukocidin
(PVL). The aim of this study was to characterise a collection of PVL-
positive CA-MRSA strains isolated in Italy.
Methods: 15 PVL-positive CA-MRSA strains were collected from
2005 to 2008 in Italy from severe infections: 6 from skin and soft
tissue infections, 1 from a brain abscess, 6 from necrotising pneumonia
and 2 from disseminated infections. The phenotypic and genotypic
characteristics of the strains were determined including antibiotic
susceptibility, SCCmec and agr types, protein A (spa) types, multilocus
sequence types (MLST) and toxin proﬁles.
Results:Most of the PVL-positive CA-MRSA strains were susceptible to
all non-lactam antibiotics with few exceptions: resistance to tetracyclines
(3 isolates), to gentamicin (1 isolate) and to ﬂuoroquinolones (1 isolate).
Thirteen isolates harboured SCCmec type IV and 1 isolate type V. The
agr types were: 1 (7 strains), 2 (3 strains) and 3 (4 strains). Six different
spa types were assigned: t008 (5), t44(1), t319(1), t755(1), t2453(1),
t2526(1). The strains belonged to 5 different STs, namely ST5, ST8,
ST30, ST80 and ST88. With the exception of a strain belonging to ST8
that carried superantigenic toxin genes, all other isolates encoded other
pore-forming leukotoxins, such as alpha, delta, gamma-haemolysins and
lukE; in addition they harboured the genes for a serin protease like-B,
and various adhesins such as ﬁbronectin A, sdrC and sdrE, adhesion
factors for ﬁbrinogen, and both polysaccharide intercellular accumulation
protein (icaA) and initial attachment adhesion (atl).
Conclusion: We documented the isolation of PVL-CA-MRSA clones
in Italy, belonging to different lineages. All these clones possessed
virulence determinants that are more common in invasive isolates, and
together with the ability of some strains to produce bioﬁlm, could
contribute independently to virulence.
P1574 Molecular epidemiology of methicillin-resistant
Staphylococcus aureus in a northern Italy hospital
C. Parlato °, P. Cavallerio, L. Fossati, T. Allice, R. Serra (Turin, IT)
Objectives: We conducted a one year-study on the epidemiology of
methicillin-resistant Staphylococcus aureus (MRSA) in our hospital, San
Giovanni Battista of Turin (Italy), from August 2007 to August 2008.
The aim was to identify one or more MRSA clones within circulating in
58 wards, including Intensive Care Units (ICUs), surgical and specialistic
surgical units, general and specialistic medicines, transplant organ units,
using molecular epidemiological methods.
Methods: 225 MRSA isolates were derived from clinical samples of
patients with active infections like surgical wound infections (22%),
urine (16%), blood (15%), bronchoaspirate (13%), endovasal catheter
(8%), wound infections (8%), bronchoalveolar lavage (5%), tracheal
aspirate (4%), cerebrospinal ﬂuid (3%), perithoneal ﬂuid (2%), drainage
(1%), biopsy (1%), bile (1%), pericardial ﬂuid (1%), transplant organ
preservation ﬂuid (0.5%) and perithoneal exhaust (0.5%). All isolates
were analysed by PFGE, rep-PCR, SCCmec typing, PVL-typing and
spa-typing.
Results: the isolates were classiﬁed into following SCCmec types: 48
SCCmec type I (21.3%), 106 SCCmec type II (47.1%), 2 SCCmec
type III (0.8%), 66 SCCmec type IV (29.3%) and 3 SCCmec type V
(1.3%). Of the SCCmec type IV, only 2 were positive for PVL (0.9%).
Overall, 20 spa types were detected, with t242, t008 and t001 being most
prevalent (44.9%, 23.5% and 21.3%, respectively). PFGE and rep-PCR
showed speciﬁc proﬁles that reﬂect the molecular features of strains.
Conclusion: using molecular typing and sequence-based methods we
were able to identify the presence of three MRSA clones within the
hospital. The most common strain is t242 with SCCmec type II.
In addition to the b-lactams resistance, the strain is resistant to
ciproﬂoxacin, levoﬂoxacina and erythromycin but is sensitive to
gentamicin, rifampicin and tetracyclines. The other two, less prevalent
MRSA clones (6.6% and 1.9% of all isolates, respectively), were t008
(SCCmec type IV) and t001 (SCCmec type I). Our hospital is the ﬁrst
in Italy, where t242 reached an endemic level.
P1575 Clonal study of methicillin-resistant Staphylococcus aureus
isolates of nosocomial origin in a Spanish hospital
E. Baos °, G. Morales, J. Picazo (Madrid, ES)
Objectives: Analysis of susceptibility to a wide panel of antibiotics of
MRSA strains obtained from hospitalised, infected patients. Restriction
proﬁle analysis by PFGE of the strains to assign them to clones.
Identiﬁcation of predominant circulating clones.
Methods: 1-Selection of MRSA strains obtained from different types of
clinical samples: Identiﬁcation of strains and antibiotic susceptibility
determination were made using WIDER panels and VITEK cards.
MIC90 was determined by E-test and dilution in agar following CLSI
indications. In the case of vancomycin MICs were read at 24 and
48 hours for detection of putative VISA strains.
2-Clonal analysis: Total DNA of each MRSA strain was digested with
SmaI and analyzed by PFGE. Macrorestriction proﬁles obtained were
analyzed and compared with FPQuest software (Bio-Rad) using the
Dice correlation coefﬁcient and the UPGMA with 1% band tolerance.
A similarity cut-off of 80% and the criterion of a difference 6 bands,
were used to deﬁne a cluster.
Results: All strains presented MIC90> 512 to oxacillin, cefoxitin,
cefotaxime, ceftazidime, cefepime, erytromicyn and clindamycyn.
MIC90 was 64 to gentamycin and 16 to amikacin and levoﬂoxacin. All
strains analyzed were sensitive to glycopeptides, linezolid, tigecycline
and rifampicin.
Comparative analysis of electrophoretic patterns showed high variability
among the strains although they could be clustered into three main
groups according to their band similarity. The predominant cluster
contained eight strains that were obtained in the ICU. Correlation
between clonal relationship and hospital ward origin in other cases was
also found.
Conclusion: MRSA strains analyzed presented high level of antibiotic
resistance as well as multiresistance as expected because of their
nosocomial origin.
There is association among clonal groups and hospital ward origin
what points to several and distinct reservoirs of MRSA in our hospital.
Determination of the circulating clones will facilitate the control and
prevention of nosocomial outbreaks.
P1576 The occurrence of Panton-Valentine leukocidin in MRSA
strains isolated from hospitalised patients in Slovakia
V. Kmet, D. Ohlasova, M. Niks ° (Kosice, Bratislava, SK)
Objectives: The occurrence of MRSA in Slovakia is increasing. In 2003
community and hospital MRSA represented 3% and 6%, respectively. In
2008 already 8% of community and 13% of hospital S. aureus isolates
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were MRSA. In ICUs reached MRSA proportion in 2008 22% (Slovak
National AMR Database www.snars.sk). To characterise hospital MRSA
and to detect a possible participation of community strains on hospital
invasive infections we have evaluated the Panton-Valentine leukocidin
(PVL) genes and identiﬁed staphylococcal chromosomal cassettes types
in current MRSA hospital isolates.
Methods: During year 2008 75 methicillin resistant S. aureus isolated
from soft tissue abscesses and chirurgical wounds in inpatients (1 per
patient) from 7 county hospitals around the country were obtained and
analyzed. PVL gene (lukF-PV, lukS-PV), mecA gene and SCCmec types
were determined by PCR. For phenotypic methicillin resistance detection
and antibiotic resistance determination, CLSI (2008) criteria were used.
Results: All of 75 strains phenotypically determined as MRSA possessed
the mecA gene. PVL positive strains represented 14.6% (11/75). Single
PVL positive MRSA strain possessed SCCmec type IV cassette and was
resistant only to erythromycin. In this case the MRSA was isolated from
surgically treated deep abscess in a patient on the second hospitalisation
day and the isolate should be considered a community acquired MRSA.
Another PVL positive MRSA had SCCmec type III, while in other 9
PVL+ strains SCCmec cassettes were not typable. Of 64 PVL negative
MRSA strains, in 22 SCCmec cassette could be determined. 18 of them
possessed type II SCCmec cassette and were phenotypically resistant
also to erythromycin, clindamycin and ciproﬂoxacin. Resistance to
chloramphenicol could be detected in only three strains. All of 75 tested
MRSA strains were phenotypically susceptible to linesolid.
Conclusions:
1. The occurrence of PVL genes in current invasive MRSA strains
isolated from hospitalised patients in Slovakia is around 14.6%.
2. In this study only one PVL+ MRSA strain possessed SCCmec type IV
cassette and most probably originated from community.
3. The predominating SCCmec type in PVL negative and SCCmec
typable invasive MRSA was II. All these strains were resistant also
to erythromycin, clindamycin and ciproﬂoxacin.
4. Of all 75 analyzed MRSA strains only three were resistant to
chloramphenicol. The linezolid resistance in MRSA strains from
Slovak hospitals was not recorded.
P1577 Clones and toxin genes’ carriage of coagulase-negative
staphylococci isolated from bacteraemic infants hospitalised
in an intensive care unit
N. Giormezis °, F. Kolonitsiou, A. Foka, V. Hondrou, K. Drosopoulou,
S. Mantagos, G. Dimitriou, E.D. Anastassiou, I. Spiliopoulou (Patras,
GR)
Objective: Coagulase-negative staphylococci (CNS), especially Staphy-
lococcus epidermidis and S. haemolyticus, are the leading causative
agents of neonatal nosocomial sepsis. High prevalence of resistance
to methicillin and other antistaphylococcal agents is observed among
CNS (MR-CNS), a key factor for persistence in neonatal intensive
care units (NICUs). An extracellular polysaccharide intercellular adhesin
(PIA) encoded by the ica operon has received much concern in bioﬁlm
formation. Of clinical importance is the production of TSST-1 and
enterotoxins acting as superantigens by CNS. The aim of the present
study was to investigate MR-CNS clonal dissemination in the NICU of
our University Hospital during a two-year period in correlation to toxin
genes’ carriage and the presence of ica operon with bioﬁlm formation.
Methods: A total of 180 CNS from 69 patients with bacteraemia
were identiﬁed at species level by the API Staph System (bioMe´rieux)
and by restriction fragment length polymorphism of the ampliﬁed tuf
gene. The MICs of oxacillin, linezolid, vancomycin and teicoplanin
were determined by the Etest (Ab Biodisk). Susceptibility against
antistaphylococcal agents was tested by the disk diffusion method.
Bioﬁlm production was tested by the qualitative method. The presence
of mecA gene, icaA and icaD (ica operon), tst (TSST-1) and the
enterotoxins’ genes sea, seb, sec and sed was tested by PCRs. Clones
were deﬁned by PFGE of chromosomal DNA SmaI digests.
Results: In total 177/180 CNS were mecA-positive (MR-CNS). Eighty-
nine strains produced bioﬁlm, 76 of them were ica-positive, while 63
additional CNS were ica-positive and bioﬁlm-negative. The majority of
isolates (>70%) were multi-resistant including 9 strains in vitro resistant
to vancomycin (MIC> 32mg/L). Table 1 summarises the results of
species and clones identiﬁcation in relation to toxin genes. Three clones
were dominant during the two-year period: a and b among S. epidermidis
and h in S. haemolyticus. Clone c emerged in 2007. tst gene carriage was
clonal related among S. epidermidis and S. haemolyticus, but enterotoxin
genes were more widely distributed.
Conclusions: Multi-resistant MR-CNS clones mainly S. epidermidis and
S. haemolyticus were distributed in the NICU of our University Hospital
during the two-year study period. Besides bioﬁlm formation, a factor
that might contribute to their clinical importance and virulence capacity
is the toxin gene carriage of the superantigens family.
Table 1. Species identiﬁcation of CNS, clones and toxin genes carriage
Species (no. of strains) Clones (no. of strains) Positive toxin genes (no. of strains)
tst sea seb sec sed tst/sea tst/sec
S. epidermidis (106) a (63) 11 4 – 6 1 1 2
b (14) – 2 – – – – –
c (10) 1 1 – 3 – – 1
Others (16 clones: 19 strains) 2 1 – 3 1 – 1
S. haemolyticus (59) h (44) 10 3 – 1 – 1 –
Others (9 clones: 15 strains) 1 3 – – – – –
S. hominis (9) Others (8 clones: 9 strains) – 1 – – 1 – –
S. saprophyticus (1) n – – – – – – –
S. warneri (3) 3 clones – – – – – – –
S. lugdunensis (2) 2 clones – 1 – – – – –
Total: 180 43 clones 25 16 0 13 3 2 4
P1578 Clones and toxin gene proﬁles of methicillin-resistant
Staphylococcus aureus causing infections among children
and adults
E. Drougka °, O. Koureli, E. Petinaki, O. Obasuyi, A. Foka, V. Chini,
N. Giormezis, A. Athanassiadou, E.D. Anastassiou, I. Spiliopoulou
(Patras, Larissa, GR)
Objective: Methicillin-resistant Staphylococcus aureus (MRSA) in-
fections and especially community-associated (CA-MRSA), including
superﬁcial, deep-seated infections and pneumonia, are widespread
among adults and children in Greece. CA-MRSA usually carry the genes
encoding Panton-Valentine leukocidin (PVL). We have investigated and
compared the distribution and clonal evolution of CA-MRSA during
2006–2008 among adults and children in Greece.
Methods: A total of 800 MRSA were isolated from clinical specimens
of infected patients from January 2006 till September 2008 in a
tertiary teaching and a paediatric hospital in South Greece. Isolates
were identiﬁed at species level by conventional tests, followed by the
determination of MIC of oxacillin by the Etest (AB Biodisk) and
their antibiotic resistance patterns to antistaphylococcal agents by the
disk diffusion method. PBP2a production was investigated by a Latex
agglutination test (bioMerieux). The genes: mecA (encoding PBP2a),
lukS and lukF (encoding PVL), tst (encoding toxic shock syndrome
toxin), sem/seg (of the enterotoxin gene cluster egc) and agr groups
were deﬁned by PCRs with speciﬁc primers. Clones were determined by
PFGE of chromosomal DNA SmaI digests and MLST. CA-MRSA were
isolated from patients without any predisposing risk factors.
Results: Four hundred and seventy-three MRSA were recovered from
adults, and 327 from children. The majority were CA-MRSA (80%
among adults and 99% from children). Genes encoding PVL were
detected in 408 strains (86%) from adults and 312 (95%) from children,
belonging to ST80 and ST377 clones. Genes of the superantigens’ family
(tst and/or egc) were identiﬁed among 11% and 7% of adults and
children, respectively. PVL-negative strains were classiﬁed into ST239,
ST30, ST22, ST225, ST585 clones. Multi-resistant strains were identiﬁed
among adults.
Conclusions: PVL-positive MRSA are widely distributed in Greece,
mainly among children and to less extend in the adults, causing soft skin
and tissue infections but also osteomyelitis and pneumonia. Most of the
cases are community-associated belonging to two clones, reinforcing
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the aspect of an epidemic that needs application of infection control
measures.
P1579 Belgian MRSA population: nursing homes versus hospital
isolates (2007)
C. Wildemauwe °, D. De Brouwer, P. Bifani, C. Godard, M. Dehem,
R. Joseph, D. Van Kerkhoven, R. Vanhoof (Brussels, BE; Lille, FR;
Ypres, Sint-Truiden, BE)
Objectives: Staphylococcus aureus is a long-standing subject of epi-
demiological investigation typically employing a variety of (molecular)
techniques: methicillin-resistant S. aureus (MRSA) receiving the most
attention. In Belgium, in 2006, the MRSA proportion at hospital level
was estimated 24% (EARSS). Considering the global and dynamic nature
of MRSA, continued surveillance is important to more clearly understand
the role of potential reservoirs, such as the in stream of elder patients
coming from nursing homes, in hospital MRSA population. Therefore,
we looked for a possible correlation between hospital and nursing home
MRSA.
Methods: We compared 179 MRSA isolates, collected in Belgium by
a medical laboratory (requests from 22 nursing homes; N=74) and by a
general hospital (N = 105) between June and December 2007. We used
phage- and spa-typing as well as PCR detection of the Panton-Valentine
leukocidin (PVL) gene.
Results: In 2007, in the nursing homes, 70% of the MRSA population
belonged to phage types group [O]* and 9% to [J]*. The remaining
isolates (19%) could not be assigned to a deﬁned group. Nineteen
different spa types (Ridom StaphType) were found: 55% belonged to
t038, 12% to t740 and 4% to t1359. Five spa types were only represented
in two isolates and eleven spa types were unique. Four (5.41%) isolates
were PVL positive, all of spa type t038. In the hospital, 35% of the
isolates belonged to the phage types group [J]*, 23% to [O]* and 39%
could not be put in a deﬁned group. Eighteen different spa types were
found: 30% belonged to t740, 29% to t121, 13% to t038 and 10% to
t002. Three spa types were only represented in two isolates and eleven
spa types were unique. Only one (0.95%) isolate was PVL positive.
In both MRSA populations, the dominant phage types groups were
[O]* and [J]*; spa types t038, t740 were frequent and only few PVL
positive isolates were found. Signiﬁcant differences between the MRSA
populations from the nursing homes and the hospital were found in the
percentages of phage types groups and dominant spa types.
Conclusion: The “super bug” MRSA has caused increasing problems in
nursing homes and hospitals. Some concordances were found between
the two Belgian MRSA populations, namely the same phage types
groups, some spa types and few PVL positive isolates. However, typing
by means of bacteriophages and spa sequences showed signiﬁcant
quantitative differences.
P1580 Evolution of the MRSA clones at a university hospital in
the Canary Islands
I. Montesinos, B. Castro °, Y. Barroso, T. Delgado, M.J. Ramos,
M. Lecuona, A. Sierra (La Laguna, ES)
Objectives: The aim of this study is to present the evolution of the
MRSA clones circulating in the University Hospital of Canary Islands
(HUC) between 1997 and 2008.
Methods: The HUC is a tertiary-care hospital of 650 beds with a high
MRSA endemicity. We have studied a total of 1192 MRSA isolates
between 1997 and 2008 by PFGE prepared in agarose blocks and
digested with SmaI. Other molecular typing methods were performed
(MLST; SCCmec typing method previously described by Oliveira et al.)
to a representative subset of MRSA isolates.
Results: From 1997 to 2000 only two clones were present in our
hospital, the Iberian clone (PFGEtype A, ST247-MRSA-I) with a clear
predominance (between 67 and 93% of the MRSA isolated in this
period), and the Paediatric clone (PFGEtype B, ST5-MRSA-IVA). In
2000, the Iberian clone was the predominant one (66%) but other two
MRSA clones were isolated the New York/Japan clone (PFGEtype D,
ST5-MRSA-II variant) and the EMRSA-16 clone (PFGEtype E, ST32-
MRSA-II). From 2001 to 2005, EMRSA-16 clone was the predominant
one (between 68 and 74% of the MRSA isolated in this period) replacing
the Iberian clone. In 2003, EMRSA-15 (PFGEtype F, ST22-MRSA-IV)
appears in our hospital for the ﬁrst time. In the last three years (2006–
2008) the EMRSA-15 and the Paediatric clone have increased little by
little replacing the EMRSA-16 clone. In 2008 these two clones were
the 82% of the MRSA isolated. A SCCmec type IIIA was observed in
one MRSA isolated in 2008 with a new PFGE proﬁle. We are trying to
conﬁrm by MLST that we have the ﬁrst Brazilian clone isolate in our
hospital.
Conclusions: The picture of the clones circulating in our hospital
has completely changed, starting with a predominance of the Iberian
clone practically eliminated in the last years, following with a
period of EMRSA-16 clone dominance and currently with a co-
dominance of EMRSA-15 and Paediatric clone. More microbiological
and epidemiological studies are necessary to explain these clonal
changes.
P1581 Community-onset methicillin-resistant Staphylococcus
aureus in Belgium: changing epidemiology and clone
diversiﬁcation
J. Brauner °, O. Denis, A. Deplano, C. Nonhoff, R. De Mendonc¸a,
R. De Ryck, S. Rottiers, M.J. Struelens (Brussels, BE)
Objectives: Panton-Valentine Leukocidin (+) community-onset methi-
cillin-resistant S. aureus (CO-MRSA) infections are reported in Belgium
since 2003. The objectives of this study were to update the demographic
characteristics and molecular epidemiology of cases of CO-MRSA
colonisation and infection in Belgium over the last 3 years.
Material and Methods: CO-MRSA was deﬁned as MRSA detected
in outpatients or in the ﬁrst 48 h after hospital admission. From 2005
to 2007, 120 CO-MRSA strains were referred for characterisation
together with epidemiologic data. MRSA were conﬁrmed by PCR for
16S rRNA, nuc and mecA genes. Strains were genotyped by SmaI
macrorestriction, SCCmec typing and MLST. Multiplex PCR was used to
detect genes encoding PVL, TSST-1, exfoliatin A, B and D, enterotoxin
A to R and resistance to tetracyclines, aminoglycosides and macrolides-
lincosamides-streptogramins.
Results: Among CO-MRSA strains, 77 (64%) isolates were PVL(+).
Patients with MRSA PVL(−) had a bimodal age distribution with
very young and old patients whereas patients with PVL(+) strains
had a unimodal age distribution. Compared with PVL(−) strains,
PVL(+) strains more frequently associated (p< 0.05) with skin and soft
tissue infections (79% vs 39%) and with recent travel abroad (26%
vs 9%). Compared with PVL(+) strains, PVL(−) strains were often
associated (p< 0.05) with asymptomatic carriage (28% vs 7%) and
previous hospitalisation (37% vs 17%). Cross infection was limited to
a small cluster of PVL(−) cases (n = 10) in a maternity ward. PVL(+)
strains belonged predominantly to genotypes: PFGE X-ST80-SCCmec
IV (n = 47), J-ST30-SCCmec IV (n = 6) and A-ST8-SCCmec IV (n = 7).
Five A-ST8-SCCmec IV strains carried the arcA gene of the ACME
gene cluster (USA300-marker) One of these was from a patient who
had travelled to the USA. PVL(−) strains showed a higher PFGE type
diversity and more frequently harboured enterotoxin genes than PVL(+)
strains. The distribution of enterotoxin and resistance genes was strongly
linked to PFGE type.
Conclusion: CO-MRSA strains from Belgium showed clonal diversiﬁca-
tion in 2005–2007. PVL(+) were strains associated with recent travel and
skin and soft tissue infections whereas PVL(−) strains were associated
with asymptomatic carriage and healthcare exposure. PVL(+) MRSA
strains predominantly belonged to the European ST80 clone. The spread
of the USA300 clone is of concern.
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P1582 Molecular epidemiology of methicillin-resistant
Staphylococcus aureus isolates from nursing homes (NH) of
western Switzerland suggests transmission within NH
L. Senn °, C. Petignat, C. Bellini, E. Masserey, L. Christin, A. Cometta,
G. Zanetti, D.S. Blanc (Lausanne, Nyon, Yverdon, CH)
Background: In Western Switzerland, an area of low MRSA prevalence,
more than two-third of the strains isolated in acute-care hospitals between
1997 and 2007 belong to 4 predominant genotypes. Few data exist on
the molecular epidemiology of MRSA in NH and its correlation to the
epidemiology of local hospitals. These data should help to determine
whether MRSA carriage in NH residents is mainly imported from
hospitals or originates from transmission within NH.
Objectives: To describe the molecular epidemiology of MRSA carriage
among residents of NH in Western Switzerland and to compare this
epidemiology with that of the local tertiary care hospital (TCH).
Methods: Study population: i) in NH: all MRSA-positive residents
identiﬁed through a point prevalence survey conducted in 130 NH of
Western Switzerland (Oct. 07-Mar. 08); ii) in TCH: all newly identiﬁed
MRSA-positive patients in 2007.
Molecular typing: double locus sequence typing (DLST) − a new typing
strategy for MRSA that uses the repeat sequences of clfB and spa genes −
was performed on 1 isolate per patient.
Results: In NH, we identiﬁed 44 genotypes in 273 residents, of which
i) 2 were predominant: DLST 2−2 and 3−3 found in 163 (60%) and
42 (15%) residents, respectively; ii) 11 (37 residents − 14%) belonged
to small clusters of 2 to 7 residents; and iii) 31 (11%) were unique. In
TCH, we identiﬁed 42 genotypes in 235 patients, of which i) 3 were
predominant: DLST 2−2, 3−3 and 4−4 found in 128 (54%), 24 (10%),
and 19 (8%) patients, respectively; ii) 17 (42 patients − 18%) belonged
to small clusters of 2 to 3 patients; and iii) 22 (9%) were unique.
Only 7 genotypes were recovered from NH residents and from TCH
patients, of which 2 were predominant (DLST 2−2 and 3−3). The third
predominant TCH genotype (DLST 4−4) was signiﬁcantly less frequent
in NH than in TCH, and all other genotypes were speciﬁc to either NH
or TCH. These results suggest that MRSA carriage in NH residents is
not only imported from TCH. Moreover, among 11 genotypes involved
in small clusters of NH residents, 10 were not recovered in TCH patients,
suggesting transmission within NH.
Conclusion: Molecular epidemiology of MRSA in NH of Western
Switzerland shows that MRSA carriage in NH residents is not only
imported from local hospitals, but also originates from transmission
within NH.
P1583 Temperature affects ccrAB-mediated excision of SCCmec
IV in USA300 and USA400 community-associated
Staphylococcus aureus strains
J. Black, R.V. Goering ° (Omaha, US)
Objectives: A variety of studies have suggested that the relatively small
size of SCCmec IV may facilitate its horizontal transfer contributing
to the emergence of community-associated MRSA. Encoded within
SCCmec, ccrAB recombinase activity is envisioned as important in
this process mediating site-speciﬁc cassette integration and excision.
However, with regard to S. aureus strain USA400 (MW2) the literature
is conﬂicted with reports of both normal and defective SCCmec
excision (Jansen et al., 2006; Antimicrob. Agents Chemother. 50:2072–
78; Noto and Archer, 2006; Antimicrob. Agents Chemother. 50:2782–
88, respectively) the latter attributed to an interfering downstream
enterotoxin H sequence. To clarify this issue we examined both CA-
MRSA 400 (MW2) and USA300 strains for site-speciﬁc excision of
SCCmec and, in the case of USA300, the arginine catabolic mobile
element (ACME).
Methods: Site-speciﬁc excision of SCCmec and ACME were assessed
by both conventional and real-time PCR employing primers designed
to detect and amplify chromosomal, SCCmec, and ACME junctions
generated due to excision. Experiments were conducted with DNA
templates prepared from cells grown at 25ºC, 37ºC, and 45ºC to examine
the potential inﬂuence of temperature on the excision process.
Results: In both USA300 and USA400 S. aureus strains, site-speciﬁc
SCCmec excision was readily detected at 25ºC but was markedly reduced
at increased temperatures. Similarly, in USA300, excision of the ACME
“cassette” either alone or in combination with SCCmec also occurred in
a temperature-dependent manner. ACME excision was not observed in
USA300 strains which had lost SCCmec conﬁrming the importance of
ccrAB recombinase activity in the process.
Conclusions: Site-speciﬁc excision of SCCmec IV appears to readily
occur in both USA300 and USA400 S. aureus strains but with reduced
efﬁciency at temperatures above 25ºC. The ability of ACME to excise
(alone or in combination with SCCmec) only in the presence of ccrAB
recombinase favours a model of CA-MRSA (e.g., USA300) evolution
where SCCmec is acquired ﬁrst, followed by ACME, rather than vice
versa.
P1584 Geographic dissemination of methicillin-resistant Staphy-
lococcus aureus spa-types in hospitals and rehabilitation
clinics in the Dutch-German EUREGIO MRSA-net
R. Ko¨ck °, A. Mellmann, K. Becker, B. Middendorf, I. Daniels-Haardt,
A. Jurke, R. Hendrix, A. Friedrich (Munster, DE; Enschede, NL)
Objectives: Hospitals and laboratories within the Dutch-German quality
network EUREGIO MRSA-net have agreed to use protein A (spa) typing
as a common area-wide standard for the molecular characterisation of
MRSA. A geographic information system (GIS) was developed for the
visualisation of differences in the regional spread of MRSA clones. Here
we describe changes in the regional distribution of MRSA spa types
obtained between 2006 and 2008.
Methods: Each ﬁrst MRSA isolated either from screening swabs or from
clinical specimens obtained from patients of 36 regional German and 4
regional Dutch hospitals (representing 94% and 100% of all regional
beds, respectively) between 2006 and 2008 was spa sequence-typed and
entered in the GIS database. Differences in the distribution of spa types
between different regional districts and facilities were calculated using
chi-square, ﬁsher exact or t-test where appropriate.
Results: The GIS database (data retrieval 06.01.2009) includes 1,780
German MRSA isolates from 2006 (including 31 blood cultures, BC),
2,539 from 2007 (including 50 BC) and 2,654 from 2008 (including 27
BC). Furthermore, the database contains 18, 57 and 71 Dutch MRSA
isolates (n = 0 BC) isolated 2006, 2007 and 2008, respectively. The
German isolates were assigned to a total of 105 different spa types
in 2006, 131 in 2007 and 169 in 2008. Among the Dutch isolates 9
spa types were found in 2006, 18 in 2007 and 15 in 2008. While the
predominating spa types among the German isolates (% of all isolates)
were represented by t003 (34%), t032 (27%), t011 (6%), t004 (4%) and
t034 (3%), the predominating Dutch spa types were t011 (40%), t458
(10%), t108 (9%), t026 (7%) and t008 (7%). Overall, the distribution of
the major spa types varied signiﬁcantly on a local level, between different
German districts and across the border. The GIS indicated geographic
and temporal clusters.
Conclusion: The EUREGIO MRSA-net GIS allows an area-wide and
crossborder molecular surveillance of MRSA. The genotypic background
of MRSA isolates distributed in 40 different hospitals in the Dutch and
the German part of the EUREGIO varies signiﬁcantly with respect to
spa types. The implementation of the newly established MRSA network-
associated GIS facilitates the detection of outbreaks and clusters for
local infection control staff and rapidly indicates emerging clones with
epidemic potential.
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P1585 Emergence of a methicillin-resistant Staphylococcus aureus
USA300 clone lacking arginine catabolic mobile element,
in Spain
S. Molinos, R. Ehricht, M. Gime´nez °, S. Monecke, C. Rodrigo, C. Prat,
N. Sopena, V. Ausina (Badalona, ES; Jena, Dresden, DE)
Objectives: Community-associated MRSA (CA-MRSA) disease usually
presents as pyogenic skin and soft tissue infections (SSTIs) in previously
healthy individuals. USA300, ST-8 is the most prevalent clone in this
country and contains a genomic island, known as arginine catabolic
mobile element (ACME), which encodes an arginine deaminase. This
enzyme may enhance the virulence of USA 300 by enabling it to colonise
and evade host defences.
In Spain, CA-MRSA isolates don’t belong to the main European clone
ST80, but to the ST8.
Here, we report the ﬁrst three Spanish isolates of the CA-MRSA USA
300 ST-8 clone without the ACME-associated arcA gene in their genetic
background.
Methods: DNA microarrays based on the Array-Tube platform
(CLONDIAG, Jena, Germany) were used for genotyping three isolates
from two children with superﬁcial skin infections and one adult with
septic arthritis and bacteraemia (Table 1).
Case Age Patient
location
Infection Treatment Risk factors Evolution
I 6 months Paediatrics Impetigo on the
lip
Clarithromycin 125/5ml, susp. q12 h
10 days
– Cure
II 4 years Paediatrics Breast abscess.
Symptoms
started twelve
days before
Amoxicillin/clavulanic 2.8ml
susp. q8 h 5 days
<5 cm/drainage
– Cure
III 47 years Emergency Septic arthritis
(ankle) and
bacteraemia
Vancomycin 1 g q12 and clindamycin
600mg q8 23 days
+ ciproﬂoxacin 750mg q12 8 weeks
Diabetes, obesity
and dilated
cardiomyopathy
Cure
Results: Hybridisation patterns for the agr-speciﬁc probes showed that
three isolates matched to agr type I, carried a type IV staphylococcal
cassette (SCC) and belonged to CA-MRSA of clonal group ST8.All
isolates contained the genes for both toxin Panton-Valentine leukocidin
(PVL) components (lukF-PV and lukS-PV). Moreover, the three isolates
also lack ACME-arcA gene. In addition, all isolates contained the chp
gene for chemotaxis inhibitory protein (CHIPS).
Conclusion: The three isolates of our patients lacked the ACME. To
date, these are the ﬁrst Spanish isolates of ACME-negative USA300.
Our study shows the emergence and spread of a clone that could
potentially change the clinical spectrum of S. aureus infections in our
community; thus, the comparison of the virulence gene content of well
characterised isolates causing different clinical syndromes is crucial in
predicting the clinical outcome and the most accurate treatment for CA-
MRSA infections.
P1586 ST22 methicillin-resistant Staphylococcus aureus is a major
epidemic clone circulating in hSR
R. Baldan °, M. Moro, P. Cichero, D. Cirillo (Milan, IT)
Objectives: In the late 1990s, highly virulent Methicillin-Resistant
Staphylococcus aureus (MRSA) clones, the major cause of nosocomial
infections, emerged in the community, causing infections in healthy
people, without predisposing risk factors. Community-acquired MRSA
(CA) differ from Hospital-acquired (HA) for the genetic background on
the staphylococcal cassette chromosome mec (SCCmec), susceptibility to
non-b-lactams and virulence. In order to investigate the presence of CA-
MRSA and to characterise MRSA major clones in a large nosocomial
setting, we investigated at the molecular level all clinically signiﬁcant
MRSA strains isolated at the hSR from 2006.
Methods: We tested 275 MRSA for SCCmec type, PVL and other
toxins genes and we performed cluster analysis by Pulsed-Field Gel
Electrophoresis after SmaI restriction, spa and multilocus sequence
typing.
Results: 48% of isolates collected carried SCCmec typical of hospital
strains, predominantly SCCmec I (44.7%), while 41.5% carried SCCmec
IV (V in one case) typical of CA-MRSA and was more susceptible to
non b-lactams than HA-MRSA; 10% was not or partially typeable but
had susceptibility pattern typical of CA-MRSA. Eight strains were PVL-
positive and 6 of them (5 SCCmec IV and 1 V), considering clinical data,
were identiﬁable as CA-MRSA: spa, MLST and PFGE of 5 of them
showed their relatedness to the epidemic CA-MRSA clone USA300.
Cluster analysis of SCCmec I MRSA showed 4 major clades with several
established pulsotypes. Cluster analysis of SCCmec IV MRSA showed 2
major clades: 1 of them represented the 29% of all isolates or >65% of
SCCmec IV MRSA. PFGE identiﬁed this clone as ST22 EMRSA15,
a major epidemic HA-MRSA clone circulating in the UK hospitals.
SCCmecIV MRSA isolated from blood cultures increased from 35%
in 2006 to 50% in 2008.
Conclusion: 41.5% of MRSA circulating at the hSR carried SCCmec IV
and >65% of them had characteristics of the epidemic UK EMRSA15
ST22; we report that 2.2% of the strains are CA-MRSA PVL positive,
according to European data. Considering isolates obtained from sepsis
in the last 3 years, we observed an increase of MRSA SCCmec IV from
35% to 50%.
P1587 Molecular characterisation of methicillin-resistant
Staphylococcus aureus in Cape Town hospitals
V.E. Madikane °, M.J. van Rensburg, M. Chachage, A. Whitelaw,
G. Elisha (Cape Town, ZA)
Objective: The objective of the study was to gain an understanding
of the molecular epidemiology and SCCmec content of clinical MRSA
strains in hospitals in Cape Town.
Methods: A total of 56 MRSA strains, isolated from patients in
any four hospitals in Cape Town, were characterised. Pulsed ﬁeld
gel electrophoresis (PFGE) was used to study the relatedness of the
MRSA and multiplex PCR assays were carried out to determine their
staphylococcal chromosomal cassette mec (SCCmec) content. Antibiotic
susceptibility proﬁles of the MRSA were analysed with respect to genetic
background and SCCmec type.
Results: Using a threshold of 80% similarity, 7 PFGE clusters were
identiﬁed; 30 MRSA were assigned to either cluster 3 or 5. When
clusters 1, 3, 5 and 7, containing 4 or more strains, were stratiﬁed by
hospital, clusters 1 and 3 were identiﬁed in Groote Schuur (GSH), Red
Cross War Memorial Children’s (RCCH) and Victoria (VH) hospitals.
Cluster 5 was observed in MRSA from Mowbray Maternity hospital
(MMH) as well as GSH and RCCH. MRSA strains belonging to cluster
7 were isolated from only GSH, and RCCH. SCCmec types I and
IV were identiﬁed in 24 and 26 strains, respectively. SCCmec types
II and III were observed in 4 and 2 strains, respectively. Grouping
the mec types in PFGE clusters showed that cluster 5 comprised only
SCCmec type I strains (17/24). Similarly, SCCmec type IV strains
were unique to cluster 3 (13/26) and 1 (6/26). The SCCmec type II
and III strains belonged to cluster 7 and 6, respectively. There were
striking differences between the antimicrobial susceptibility proﬁles of
SCCmec IV containing MRSA and the SCCmec I strains. Resistance
to gentamicin, co-trimoxazole, ciproﬂoxacin and rifampicin was nearly
universal in the 26 MRSA type IV strains. Only 10 of these isolates
were resistant to erythromycin and clindamycin. In contrast, almost all
of the MRSA SCCmec type I strains were resistant to erythromycin and
clindamycin (21/24) but susceptible to the other antibiotics.
Conclusions: Related MRSA strains were identiﬁed across hospitals in
Cape Town, suggesting a common epidemiology and transmission of
MRSA either by patients or by healthcare workers. Over half of the
MRSA segregated in two PFGE clusters, which also accommodated the
majority of the two most frequently detected SCCmec types, I and IV.
A majority of the SCCmec type IV strains were resistant to a spectrum
of antibiotics.
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P1588 The use of Raman spectroscopy in epidemiology of
methicillin-resistant Staphylococcus aureus
M.W.H. Wulf °, H.F.M. Willemse-Erix, C.M. Verduin, A. van Belkum,
K. Maquelin (Veldhoven, Rotterdam, NL)
Objective: The Netherlands has an active search and destroy policy
for methicillin resistant Staphylococcus aureus (MRSA). In order to
maintain this policy, a reliable and quick typing method for isolates is
essential. The objective of this study was to see if Raman spectroscopy
provides such a method for normal- and livestock-associated MRSA.
Methods: Between 2002 and 2007 a total of 433 MRSA positive subjects
were identiﬁed. Of these a total of 392 isolates were analysed using
Raman spectroscopy. Spectroscopic ﬁngerprints were obtained using a
dedicated Raman spectrometer, requiring approx. 40 seconds per sample.
Cluster analysis on these ﬁngerprints was performed using the pair wise
correlations as a distance measure in combination with Ward’s cluster
algorithm.
Results were compared with PFGE cluster typing results obtained from
the national reference library and with epidemiological data.
Results: Of the 403 isolates analysed, 157 were non-typable by PFGE.
The remaining 246 represented a total of 51 different PFGE types.
Raman typing resulted in a total of 86 Raman clusters. Of the subjects,
83 were unexpected MRSA cases, 150 came from targeted screening of
known risk groups, 11 were family members of MRSA positive patients
and 135 came from outbreak screening cultures. Further analyses of 20
clusters of epidemiologically linked isolates (n = 154) showed that 128
(82%) had identical PFGE clusters. Raman typing of the same isolates
showed that 126 (81%) had corresponding Raman clusters. Of the 28
mismatches, 13 (8.4%) isolates had both a different Raman and PFGE
of the outbreak strain.
Analyses of PFGE non-typable isolates showed that in one outbreak
with 10 cases, all had identical Raman types, in one case of possible
transmission, 2 Raman clusters were seen. An overall analyses of the
PFGE non-typable isolates in our collection (n = 157) resulted in 24
different Raman clusters.
Conclusions: Raman spectroscopy is a reproducible method for typing
of MRSA for epidemiological typing. The results obtained with this
technique are comparable to PFGE and in good concordance with the
epidemiological data
Antimicrobial susceptibility of tigecycline
P1589 Can tigecycline rescue the activity of imipenem against
highly resistant metallo-b-lactamase-nonproducing
Pseudomonas aeruginosa?
A. Burillo °, Y. Gil, F. Lo´pez-Fabal, J.L. Go´mez-Garce´s (Madrid, ES)
Objectives: To explore the possibility of restoring the activity of
currently available antimicrobials using different combinations of these
agents.
Methods: Time-kill curves of tigecycline plus imipenem were deter-
mined for one strain of
a multi-drug resistant P. aeruginosa in which resistance mechanisms
were characterised genetically: the strain overexpressed AmpC and the
efﬂux pump MexEF-OprN, had point mutations in oprD and was metallo-
b-lactamase-nonproducing (MBL−). The MIC of each antibiotic for this
strain was 64mg/L. Tests were conducted using: a) the corresponding
MICs of both antimicrobials; b) a 2mg/L concentration of each drug; and
c) a tigecycline concentration of 2mg/L (equivalent to the physiological
concentration reached in tissues) along with the MIC of imipenem.
Results: At antibiotic concentrations equal to 1×MIC of tigecycline
and imipenem, a synergistic and action-restoring effect was produced
from 24 hours onwards. At low antibiotic concentrations relative to the
MIC (0.03×MIC), the synergistic and action-restoring effects seen at
higher antibiotic concentrations persisted, although a lower decrease in
the number of microorganisms of 1−1.5 log10 was observed. Finally,
concentrations of tigecycline as low as 0.03×MIC (2mg/L) when
combined with imipenem were able to rescue the activity of imipenem
against this highly imipenem-resistant P. aeruginosa strain (Figure 1).
The effect observed was bactericidal with an inoculum reduction of
>3 log10 units.
Conclusions: Our results point to the potential use of tigecycline in
combination with carbapenems to combat multiresistance in MBL−
P. aeruginosa.
P1590 Activity of tigecycline against Acinetobacter spp. from
various specimen sources collected in Europe over the past
ﬁve years
D. Draghi °, N. Brown, M. Torres, C. Pillar, C. Thornsberry, D. Sahm,
M. Dowzicky (Chantilly, Collegeville, US)
Objective: In 2006, tigecycline (TIG) was approved in Europe (EU)
for treatment of complicated skin and skin structure infections and
complicated intra-abdominal infections, infections which can be caused
by Acinetobacter spp (AC). AC infections can be difﬁcult to treat due
to the multi-drug resistance commonly encountered with this pathogen.
Additionally, the activity of antimicrobials used to treat these infections
can vary based on the site of infection. The current study examined the
in vitro activity of TIG against AC isolated in Europe for the purpose of
detecting any differences in activity pre- and post-launch of this recently
approved agent and any variation in the activity proﬁle against isolates
from prevalent specimen sources for AC infection (respiratory, blood,
urine, and skin/wound).
Methods: In total, 272 AC isolates were obtained from 31 hospitals
in 11 countries across EU from 2003 to 2008. Isolates were tested
centrally by broth microdilution (CLSI M7-A7). There are currently no
EUCAST TIG interpretive breakpoints (BP) for AC; therefore, EUCAST
Enterobacteriaceae BPs was used to interpret TIG MIC results.
Results: See the table.
Year of isolation/ N TIG MIC (mg/L) %S
Specimen sourcea Range Mode MIC50 MIC90
2003 40 0.12–2 1 0.5 2 80.0
2005 47 0.06–2 0.25 0.25 2 89.4
2006 87 0.06–4 1 0.5 2 88.5
2007 78 0.06–4 0.5 0.5 2 87.2
2008 20 0.06–2 1 0.5 1 95.0
Respiratory 104 0.06–4 1 0.5 2 87.5
Blood 58 0.06–2 0.25 0.5 2 89.7
Urine 55 0.06–2 0.25 0.5 2 85.5
Skin/wound 50 0.06–4 0.5 0.5 2 86.0
aIsolates of unknown specimen source were excluded.
Conclusions: TIG maintained potent in vitro activity against AC.
The TIG MIC50 (0.25–0.5mg/L) and MIC90 (1 to 2mg/L) remained
consistent, regardless of the year isolated or the specimen source. Due
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to the capacity for resistance to multiple agents among AC, it is essential
to continue to monitor the susceptibility patterns of this organism against
new agents used to treat AC infection such as TIG.
P1591 In vitro activity of tigecycline against pathogens isolated
from most common body sites – Eastern European
Data – T.E.S.T. Program 2008
S. Bouchillon, B. Johnson, D. Hoban, M. Renteria, J. Johnson, R. Badal,
S. Hawser °, M. Hackel, M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), a new glycylcycline, has been shown to
have potent broad spectrum activity against most commonly encountered
species responsible for community and hospital acquired infections.
The T.E.S.T. program determined the in vitro activity of TIG and 10
comparators against respective Gram positive/negative species. For the
overall T.E.S.T. program isolates were collected from 205 hospital sites
in 30 countries from 2004 to 2008.
Methods: In this survey, clinically signiﬁcant isolates from East
European testing sites (Poland, Hungary, Greece, and Latvia) were
analyzed. The isolates were identiﬁed to the species level at the
participating sites and conﬁrmed by the central laboratory. MICs were
determined by each site using supplied broth microdilution panels and
interpreted according to CLSI guidelines.
Results: TIG activity against selected pathogens and body sites are
shown in the table.
Blood Respiratory Urinary tract
n %Sa MIC90a n %Sa MIC90a n %Sa MIC90a
EcKpKo 26 100 1 40 97.5 0.5 77 98.7 0.5
Enterobacter spp. 11 100 1 27 96.3 2 14 92.9 1
Acinetobacter spp. 9 na – 40 na 1 6 na –
S. aureus 17 100 0.12 25 100 0.12 7 100 –
Enterococcus spp. 12 100 0.12 5 100 – 20 100 0.12
S. pneumoniae 17 na 1 37 na 1 0
H. inﬂuenzae 1 na – 56 na 0.25 0
*na = breakpoints not available.
a No MIC90 calculated if n< 10; %S may not be statistically signiﬁcant when n’s
are small.
Conclusions: Tigecycline showed excellent inhibitory activity against
all groups of pathogens regardless of isolation site. Tigecycline MIC90
of 1mg/ml against Gram positive pathogens (including resistant
phenotypes) and MIC90 of 2mg/ml against Enterobacteriaceae and
Acinetobacter spp. validate the potent inhibitory activity of TIG against
Eastern European community/hospital pathogens.
P1592 In vitro activity of tigecycline against inpatient and
outpatient pathogens from centres in Paciﬁc Rim
countries − a multi-year update
D. Hoban, M. Renteria, J. Johnson, R. Badal °, S. Hawser, M. Hackel,
S. Bouchillon, B. Johnson, M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline, a member of a new class of antimicrobials
(glycylcyclines), has been shown to have potent broad spectrum activity
against most commonly encountered species responsible for community
and hospital acquired infections.
Methods: A total of 653 clinical isolates from ﬁve Paciﬁc Rim testing
sites during 2004 to 2008 were identiﬁed to the species level and
conﬁrmed by the central laboratory. Minimum Inhibitory Concentration
(MICs) were determined by each site using supplied broth microdilution
panels and interpreted according to CLSI guidelines.
Results: Selected results are listed in the tables.
Conclusion: Tigecycline’s in vitro activity was comparable to or
greater than most commonly prescribed broad spectrum antimicrobials
without any demonstrable change in susceptibility between in- and out-
patient bacterial study strains. Tigecycline’s inhibitory activity against
Enterobacteriaceae was comparable to imipenem; vs. Acinetobacter
spp. tigecycline’s MIC90 was 32-fold lower than imipenem’s. Against
S. aureus and Enterococcus spp., Tigecycline’s activity was similar to
linezolid and vancomycin.
Enterobacteriaceae Acinetobacter spp.a
In-patients
(n = 219)
Out-patients
(n = 83)
In-patients
(n = 37)
Out-patients
(n = 7)
%S MIC90 %S MIC90 %S MIC90 %S MIC90
Tigecycline 98.6 1 100 1 na 0.5 na –
Amikacin 95.2 8 96.5 4 91.9 16 100 –
Cefepime 88.2 16 95.6 2 73 >32 85.7 –
Ceftazidime 73.7 >32 92 8 70.3 >32 100 –
Imipenem 100 1 100 1 81.1 16 100 –
Levoﬂoxacin 79.4 8 92.9 0.5 70.3 >8 100 –
Minocycline 80.5 8 90.3 4 97.3 4 100 –
Pip-Tazo 87.1 32 92 16 75.7 >128 100 –
*na = breakpoints not available.
a No MIC90 calculated if n< 10.
S. aureus Enterococcus spp.
In-patients
(n = 61)
Out-patients
(n = 19)
In-patients
(n = 38)
Out-patients
(n = 12)
%S MIC90 %S MIC90 %S MIC90 %S MIC90
Tigecycline 100 0.5 100 0.12 100 0.12 100 0.12
Levoﬂoxacin 75.4 4 100 0.25 71.1 >32 66.7 16
Linezolid 100 4 100 4 100 2 100 2
Minocycline 85.2 8 100 0.25 34.2 >8 16.7 8
Vancomycin 100 1 100 1 100 2 100 2
P1593 A comprehensive analysis of European data from Tigecycline
Evaluation Surveillance Trials (TEST) Program, 2004–2008
R. Badal, S. Hawser °, M. Hackel, S. Bouchillon, B. Johnson, D. Hoban,
M. Renteria, J. Johnson, M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), a new glycylcycline, has been shown to
have potent broad spectrum activity against most commonly encountered
species responsible for community and hospital acquired infections.
The T.E.S.T. program determined the in vitro activity of TIG and 10
comparators against respective Gram positive/negative species. Isolates
were collected from 316 hospital sites in 24 countries from 2004 through
2008.
Methods: 34,401 clinically signiﬁcant isolates were identiﬁed to the
species level at participating sites and conﬁrmed by the central
laboratory. MICs were determined by each site using supplied broth
microdilution panels and interpreted according to CLSI guidelines.
Results: TIG in vitro activity on selected pathogens are shown in the
table. Data on resistant phenotypes will be presented.
Organism (n) Tigecycline % inhibited at MIC (mg/mL)
MIC50 MIC90 0.5 1 2 4 8
A. baumannii (2053) 0.5 1 68.9 91.9 98.1 99.8 100
E. faecalis/faecium (2458) 0.12 0.12 100 – – – –
Enterobacteriaceae (14311) 0.5 1 79.2 92.0 96.5 99.1 99.9
ESBLs (625) 0.5 2 63.2 83.7 93.4 98.7 100
P. aeruginosa (3394) 8 >16 1.4 2.7 6.1 19.1 56.1
S. aureus (4063) 0.12 0.25 100 – – – –
S. pneumoniae (1784) 0.03 0.5 99.2 100 – – –
H. inﬂuenzae (2066) 0.12 0.5 96.1 99.1 100 – –
Conclusions: TIG has been described an expanded broad spectrum
antimicrobial because of its consistent activity against Enterobacteriaceae
including extended spectrum b-lactamase producers, S. aureus including
methicillin-resistant strains, S. pneumoniae including penicillin-resistant
strains, both vancomycin-sensitive and -resistant Enterococcus spp., and
H. inﬂuenzae including b-lactamase producers. TIG wide spectrum of
activity promises to provide enhanced antimicrobial coverage of serious
nosocomial/community pathogens.
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P1594 Susceptibility of Gram-negative/positive pathogens isolated
in the United Kingdom and Ireland: a multi-year update
S. Hawser, M. Hackel, S. Bouchillon, B. Johnson, D. Hoban, M. Renteria,
J. Johnson °, R. Badal, M. Dowzicky (Schaumburg, Collegeville, US)
Background: The rapid emergence of multi-drug resistant pathogens
has undermined the efﬁcacy of many widely used broad spectrum
antibacterials and prompted the development of newer antimicrobials.
Tigecycline is a new glycylcycline shown to have broad spectrum
activity against many hospital pathogens. The purpose of this study was
to examine the activity of tigecycline and comparators to nosocomial
pathogens isolated in the UK and Ireland between 2004–2008.
Methods: A total of 1,321 nosocomial pathogens were identiﬁed at each
site and conﬁrmed at a reference laboratory. MICs were determined at
each site utilising supplied broth microdilution panels and interpreted
according to EUCAST guidelines.
Results: See the tables.
E. coli, K. oxytoca/
pneumoniae, n = 346
Acinetobacter spp.,
n = 101
P. aeruginosa,
n = 139
%S MIC90 %S MIC90 %S MIC90
Tigecycline 95.7 1 IE 1 – 16
Amikacin 99.4 4 86.1 64 94.2 8
Cefepime 87.6 2 – 32 82.0 32
Imipenem 100 0.5 89.1 16 88.5 8
Levoﬂoxacin 80.6 >8 75.2 >8 63.3 >8
S. aureus
n = 162
Enterococcus spp.
n = 94
S. pneumoniae
n = 90
%S MIC90 %S MIC90 %S MIC90
Tigecycline 100 0.25 100 0.12 IE 0.5
Levoﬂoxacin 77.2 8 – >32 100 1
Linezolid 100 4 100 2 100 1
Minocycline 99.4* 0.5 54.3* 8 12.2∗ 2
Vancomycin 100 1 91.5 2 100 0.5
IE = There is insufﬁcient evidence that the species in question is a good target for
therapy with the drug.
− = Susceptibility testing not recommended as the species is a poor target for
therapy with the drug.
*CLSI breakpoints used if no EUCAST breakpoints determined yet.
Conclusions: Tigecycline was the third most active agent against
Enterobacteriaceae spp. after imipenem and amikacin, displayed the
lowest MICs against Acinetobacter spp., but had minimal activity against
P. aeruginosa. Against Gram-positives, tigecycline was as active as
vancomycin and linezolid, and superior to levoﬂoxacin and minocycline.
P1595 In vitro activity of tigecycline and comparators against
nosocomial pathogens in Italy from 2004–2008
M. Hackel, S. Bouchillon, B. Johnson, D. Hoban, M. Renteria, J. Johnson,
R. Badal °, S. Hawser, M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline has demonstrated potent activity against a
range of pathogens encountered in hospitalised patients. The TEST
program was designed to determine the in vitro activity of tigecycline and
comparators to nosocomial pathogens isolated in Italy between 2004–
2008.
Methods: Over 1015 clinical isolates were collected/identiﬁed at each
site and conﬁrmed by the reference lab. Following CLSI guidelines,
MICs were determined/interpreted using supplied broth microdilution
panels.
Results: The spectrum and potency of Tigecycline against nosocomial
pathogens is shown in the table.
Conclusions: Italian isolates of both Gram positive/negative hospital
pathogens demonstrated excellent Tigecycline MIC90 s excluding
P. aeruginosa. For most resistant phenotypes TIG MIC90 s were
1mcg/mL or less and the majority of isolates inhibited at MICs of
2mcg/mL or less. All ESBLs isolated in Italy were inhibited by
Tigecycline at MICs of 2 or less. Tigecycline promises expanded broad
spectrum coverage against multiply resistant pathogens isolated in Italy.
Organism (n) Tigecycline % inhibited at MIC
%S MIC90 =0.25 0.5 1 2 4
Acinetobacter spp. (68) NA 1 53 85 99 100 –
Enterobacteriaceae (420) 94 1 40 70 91 94 99
ESBL producersa (45) 100 2 53 78 87 100 –
Enterobacter spp. (122) 90 2 20 56 83 90 99
E. faecalis (41) 95 0.25 100 – – – –
E. faecium (29) 100 0.25 100 – – – –
H. inﬂuenzae (72) NA 0.25 90 97 100 – –
P. aeruginosa (100) NA >16 – – – 4 14
S. aureus (MSSA) (69) 100 0.25 – 30 83 99 10
S. aureus (MRSA) (54) 96 0.5 – 7 56 93 100
S. pneumoniae (70) NA 1 40 71 100 – –
S. agalactiae (41) 100 0.06 100 – – – –
a ESBL producing E. coli, K. oxytoca, K. pneumoniae.
P1596 A multi-year update of in vitro activity of tigecycline and
commonly used antimicrobials against signiﬁcant clinical
isolates collected from 2004 to 2008 in Belgium
S. Bouchillon, B. Johnson, D. Hoban, M. Renteria, J. Johnson, R. Badal,
S. Hawser °, M. Hackel, M. Dowzicky (Schaumburg, Collegeville, US)
Background: Development of bacterial resistance continues to cause
concern world-wide, but availability of newer agents offers clinicians
options for therapy. Tigecycline (TIG) has a very broad spectrum
of activity, including strains resistant to other drugs. As part of the
global Tigecycline Evaluation Surveillance Trial, strains collected in
Belgium from 2004 to 2008 were evaluated for susceptibility to several
antimicrobials.
Methods: Strains were collected and identiﬁed at 4 sites in Belgium.
MICs were determined at each site using custom broth microdilution
panels following CLSI guidelines.
All Gram pos S. aureus Enterococci S. pneumoniae
n = 179 n = 76 n = 46 n = 42
Tigecycline 0.5 0.25 0.25 1
Amox/Clav 2 8 1 0.12
Ampicillin >16 >16 2 0.5
Ceftriaxone >64 32 >64 0.12
Imipenem 1 0.5 4 0.25
Levoﬂoxacin 8 16 >32 1
Linezolid 4 4 2 1
Minocycline >8 0.5 >8 4
Penicillin >8 >8 4 0.06
Pip/Tazo 8 16 8 0.5
Vancomycin 2 1 4 0.5
All Gram neg E. coli/Kleb Enterobacter spp. Acinetobacter
n = 369 n = 141 n = 66 n = 36
Tigecycline 8 1 2 1
Amikacin 8 8 8 >64
Amox/Clav >32 32 >32 >32
Ampicillin >32 >32 >32 >32
Cefepime 16 4 32 32
Ceftazidime >32 8 >32 >32
Ceftriaxone >64 16 >64 >64
Imipenem 2 0.5 2 2
Levoﬂoxacin >8 8 >8 >8
Minocycline >16 16 16 1
Pip/Tazo 64 64 64 >128
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Results: The tables summarise results for all isolates, and for speciﬁc
key pathogens.
Conclusions: Tigecycline’s consistently low MIC90 values and broad
spectrum of activity, including otherwise resistant strains, should make
it a useful option for difﬁcult-to-treat infections.
P1597 In vitro antibacterial activity of Tigecycline against
multidrug resistant Acinetobacter baumannii isolates
N. Iris, T. Yildirmak, M. Ersoz Arat °, F. Simsek (Istanbul, TR)
Objectives: Acinetobacter baumannii is known to be highly resistant in
hospital settings and has always been a challenge for clinicians and hospi-
tal infection control. We performed this study to investigate Tigecycline
susceptibility of multidrug resistant Acinetobacter baumannii isolates
which have been found in patients infected by these bacteria in our
hospital.
Methods: Between January and December 2008, 60 multidrug resistant
Acinetobacter baumannii isolates were recovered from inpatients of
Okmeydany´ Teaching and Research Hospital. Tigecycline susceptibility
was determined by disc-diffusion method and E test; other antibiotic
susceptibilities and identiﬁcation were performed by mini-API automated
identiﬁcation and susceptibility system.
Results: The isolates were recovered from 29 endotracheal aspirates
(48.4%), 11 wounds (18.3%), 11 haemocultures (18.3%), 3 urines
(5%), 3 sputums (5%) and 3 spinal ﬂuids (5%). The majority of the
samples were taken from inpatients of intensive care units. 59 isolates
(98.3%) were susceptible to Tigecycline, only one isolate was resistant
to Tigecycline by E test method (MIC= 16).
Conclusion: Tigecycline may be an effective and reliable therapeutic
option against strains of Acinetobacter baumannii, including multi-drug
resistant strains.
P1598 In vitro activity of tigecycline and other commonly used
antibiotics against Burkholderia cepacia complex and other
multi-resistant, difﬁcult-to-treat cystic ﬁbrosis-associated
Gram-negative non-fermentative bacteria
J. Kenning, M. Denton ° (Leeds, UK)
Objectives: To ascertain the in vitro activity of tigecycline and other
commonly used antibiotics against Burkholderia cepacia complex (Bcc)
and other multi-resistant, difﬁcult-to-treat cystic ﬁbrosis (CF)-associated
Gram negative non-fermentative bacteria.
Methods: The test panel contained 157 non-duplicate isolates collected
from respiratory samples of people with CF (143 isolates) or laboratory
controls (14), and comprised of Burkholderia multivorans (BM)
(37 isolates), B. cenocepacia (BC) (23), other Bcc members (12),
Stenotrophomonas maltophilia (SM) (49), Achromobacter xylosoxidans
(AX) (20) and other CF-associated species (16). MICs of tigecycline
and 10 other commonly used antibiotics were determined using Etest.
BSAC breakpoints (or CLSI if not available) were used to determine
susceptibility. Synergy testing with tigecycline in combination with one
of eight other antibiotics was performed using an Etest method. Synergy
was deﬁned as a summation fractional inhibitory concentration of <0.5.
Results: Tigecycline exhibited good activity against AX and SM, with
85% and 78% of isolates fully susceptible, respectively. All tested isolates
of Pandoraea spp and Ralstonia spp were fully susceptible. Activity
against different members of the Bcc was variable with only 13% of
BC, 3% of BM, and 33% of other members being fully susceptible.
By comparison, 91% of BC, 97% of BM and 92% of other Bcc
members were fully susceptible to minocycline. Antagonism between
tigecycline and other agents was rarely encountered, except when used
in combination with colistin. However, the occurrence of synergy was
variable. The most synergistic combination against members of the Bcc
was with ceftazidime, with enhancement of activity against 17% of
BC and 19% of BM. Synergy with meropenem was less common with
enhanced activity occurring against 0% of BC and 14% of BM.
Conclusions: These data suggest tigecycline has useful activity against
some multi-resistant, difﬁcult-to-treat pathogens in people with CF, and
could be used as an alternative to an aminoglycoside when combined
with a b-lactam. Clinical studies are needed to ascertain the correlation
between in vitro susceptibility, synergy testing and patient outcomes.
P1599 In vitro activity of tigecycline against methicillin-resistant
Staphylococcus aureus, including animal-related strains
E.J.M. Verkade °, C.J.M.M. Verhulst, X.W. Huijsdens, J.A.J.W. Kluytmans
(Breda, Bilthoven, NL)
Objective: To assess the in vitro activity of tigecycline of methicillin-
resistant Staphylococcus aureus, including the recently emerging animal-
related strains.
Methods: A well-deﬁned collection of 202 methicillin-resistant Staphy-
lococcus aureus (MRSA) isolates was tested. The collection consisted
of 3 subsets. The ﬁrst set of isolates used in this study contained
76 hospital-associated MRSA isolates that were collected between
1990 and 1998 in The Netherlands (old MRSA). The second were
93 hospital-associated MRSA isolates collected between 2003 and
2005 (recent MRSA). The third set of isolates tested consisted of 33
animal-related MRSA strains (AR-MRSA). The MIC of tigecycline was
determined by using the Etest system (AB Biodisk, Solna, Sweden).
Etest strips were applied to the surface of Mueller-Hinton (MH) agar
plates. The MICs of the following antimicrobial agents were determined
simultaneously: gentamicin, cotrimoxazole, ciproﬂoxacin, erythromycin,
clindamycin, rifampin, daptomycin, tetracycline, linezolid, vancomycin
and teicoplanin.
Results: The MIC50 and MIC90 of tigecycline and of the other
antimicrobial agents are provided in Table 1. No signiﬁcant differences
were found for the MIC50 of tigecycline between old MRSA, recent
MRSA and AR-MRSA. The MIC values of most other antimicrobial
agents decreased signiﬁcantly over time. Among the 202 MRSA strains
evaluated, three (1%) had a tigecycline MIC> 0.5mg/liter, which are
considered resistant. However, when Etest strips were applied on Iso-
Sensitest agar plates (Oxoid Ltd.), all three isolates were susceptible for
tigecycline.
Table 1. MIC50 and MIC90 of antimicrobial agents against 76 hospital-associated MRSA collected between 1990
and 1998, 93 hospital-associated MRSA collected between 2003 and 2005 and 33 animal-related MRSA strains
collected in The Netherlands between 2003 and 2005
Antibiotic Old MRSA Recent MRSA AR-MRSA P (MIC90)
MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 old vs
recent
old vs
AR
recent vs
AR
Tigecycline 0.19 0.42 0.19 0.38 0.25 0.38 0.618 0.230 0.296
Oxacillin 256 256 32.0 256 12 48 <0.001a <0.001a <0.001a
Gentamicin 12 256 0.75 48 0.38 12 <0.001a <0.001a <0.001a
Cotrimoxazole 0.13 32 0.025 0.5 0.02 0.13 <0.001a <0.001a 0.202
Ciproﬂoxacin 32 32 24 32 0.38 2 <0.001a <0.001a <0.001a
Erythromycin 256 256 0.38 256 0.25 256 <0.001a <0.001a 0.036a
Clindamycin 0.19 256 0.09 256 0.06 256 <0.001a <0.001a 0.179
Rifampin 0.012 32 0.006 0.60 0.004 0.006 <0.001a <0.001a <0.001a
Daptomycin 0.38 0.75 0.38 0.75 0.13 0.19 0.243 <0.001a <0.001a
Tetracycline 12 32 0.38 32 32 48 0.001a <0.001a <0.001a
Linezolid 1 1 1 1 0.75 1 0.032a <0.001a <0.001a
Vancomycinb 3 4 4 8 4 4 <0.001a 0.176 0.077
Teicoplaninb 3 12 4 12 3 4 0.385 0.05 <0.001a
aP-value of <0.05 is considered statistically signiﬁcant.
bThe Etest system with a large inoculum and 48 h of incubation was used.
Conclusion: The collection of MRSA showed a good susceptibility
against tigecyclin and there were no differences observed in the three
collections of strains. The three strains, which were resistant using MH
agar plates, were susceptible when Iso-Sensitest medium was used. This
discrepancy is currently under further evaluation. The other antimicrobial
agents tested showed variable results. Remarkable was the trend towards
a better susceptibility for non-b lactam antibiotics in more recently
obtained strains. This may be caused by the emergence of MRSA in
the community.
S454 19th ECCMID, Posters
P1600 The Tigecycline Evaluation Surveillance Trial (TEST) in
Canada from 2004–2008
B. Johnson, D. Hoban, M. Renteria, J. Johnson °, R. Badal, S. Hawser,
M. Hackel, S. Bouchillon, M. Dowzicky (Schaumburg, Collegeville, US)
Objectives: Tigecycline (TIG) is a new glycylcycline with enhanced
activity against many multidrug resistant (MDR) pathogens including
ESBL and AmpC producing Enterobacteriaceae, methicillin-resistant
S. aureus (MRSA), carbapenem resistant Acinetobacter and ﬂuoro-
quinolone resistant Gram-negative rods. The TEST study evaluated the
activity of TIG and comparators to pathogens in Canada 2004–2008.
Methods: A total of 1675 pathogens were collected from 8 participating
sites in Canada from 2004–2008. Isolates were identiﬁed to the species
level and CLSI speciﬁed MICs were performed at each site. CLSI
or FDA breakpoints were used, where applicable, to determine %
susceptibility.
Results: Tigecycline MICs are recorded in the table.
Organisms (n = 1675) Tigecycline MICs (mg/ml)
MIC50 MIC90 Range
Acinetobacter spp. (n = 123) 0.12 1 0.015−2
Enterobacter spp. (n = 215) 0.5 1 0.12−8
E. coli (n = 220) 0.12 0.25 0.008−2
Klebsiella spp. (n = 218) 0.5 2 0.12−8
ESBLs (n = 16) 0.12 0.5 0.06−2
Enterococcus spp. (n = 136) 0.06 0.12 0.03–0.25
VREs (n = 5) 0.03 0.06 0.03–0.06
Serratia spp. (n = 93) 0.5 1 0.25−8
H. inﬂuenzae (n = 132) 0.25 0.5 0.03−2
S. aureus (n = 214) 0.12 0.12 0.06–0.5
MRSA (n = 30) 0.12 0.12 0.06–0.5
S. agalactiae (n = 87) 0.03 0.06 0.008–0.12
S. pneumoniae (n = 130) 0.03 0.03 0.008–0.12
Conclusions: Tigecycline showed excellent in vitro activity against a
diverse collection of pathogens isolated in Canada between 2004–2008.
MIC90 values of <0.5mcg/ml against most Enterobacteriaceae including
ESBL and MIC90 of <0.12mcg/ml against Gram-positive pathogens
document the in vitro potency of tigecycline, a new glycylcycline.
P1601 Antimicrobial susceptibility of bacteraemia pathogens in
Europe (2004–2008): results of the Tigecycline Evaluation
Trial (TEST)
B. Johnson, D. Hoban, M. Renteria, J. Johnson, R. Badal °, S. Hawser,
M. Hackel, S. Bouchillon, M. Dowzicky (Schaumburg, Collegeville, US)
Objectives: Bacterial resistance patterns vary by time and country.
Surveillance studies help to identify those patterns to assist in therapeutic
decisions. The Tigecycline Evaluation Surveillance Trial (TEST) is
a multi-year global study that assists in the recognition of current
trends in resistance on many levels. This report evaluates differences
in susceptibility of bacteraemia pathogens isolated in Europe from 2004
to 2008.
Methods: 3762 bacteraemia pathogens were collected and identiﬁed
from 2004–2008 at 77 hospitals in 21 countries in Europe. MICs for
each strain were determined per EUCAST guidelines at each facility
using broth microdilution.
Results: Tigecycline MICs are recorded in the table.
Conclusions: Tigecycline showed excellent in vitro activity against all
causative bacteraemic pathogens with the exception of P. aeruginosa.
Tigecycline demonstrated MIC90 values of <0.5mcg/ml against Gram-
positive pathogens (including resistant phenotypes) and MIC90 values
of <2mcg/ml against the Enterobacteriaceae including ESBL producers
and Acinetobacter spp. Tigecycline possesses potent activity against
bacteraemic pathogens.
Organisms (n = 3762) Tigecycline MICs (mg/ml)
MIC50 MIC90 Range
Acinetobacter spp. (n = 255) 0.25 1 0.015−4
P. aeruginosa (n = 299) 8 16 0.5−>16
Enterobacter spp. (n = 481) 0.5 1 0.06−8
Enterococcus spp. (n = 356) 0.06 0.12 0.015–0.25
VREs (n = 31) 0.06 0.12 0.015–0.12
E. coli (n = 775) 0.12 0.25 0.03−2
Klebsiella spp. (n = 595) 0.5 1 0.12−8
ESBLs (n = 93) 0.5 2 0.06−8
Serratia spp. (n = 171) 0.5 1 0.12−8
H. inﬂuenzae (n = 27) 0.12 0.25 0.03−1
S. aureus (n = 432) 0.12 0.12 0.03–0.5
MRSA (n = 105) 0.12 0.25 0.03–0.5
S. agalactiae (n = 109) 0.03 0.12 0.015–0.25
S. pneumoniae (n = 289) 0.03 0.5 0.008–0.5
P1602 Changes in susceptibility of select nonfermentors in Europe:
2004–2008
R. Badal °, S. Hawser, M. Hackel, S. Bouchillon, B. Johnson, D. Hoban,
M. Renteria, J. Johnson, M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline was approved for use in Europe in 2006
for complicated skin and soft tissue infections and has demonstrated
promising activity against multiply-resistant species and phenotypes.
The Tigecycline Evaluation Surveillance Trial (T.E.S.T.) program is an
ongoing global surveillance with the ﬁrst post-marketing prospective
report of tigecycline and comparator in vitro activity for the years
2004 through 2008. This study evaluates trends in susceptibility of
Acinetobacter spp. and Pseudomonas aeruginosa isolated in Europe
during this time period.
Methods: More than 4,530 clinical isolates were collected from 78
investigative sites in 22 countries in Europe. Clinical isolates were
identiﬁed to the species level at each participating site and conﬁrmed by
the central laboratory. Minimum Inhibitory Concentrations (MICs) were
determined by the local laboratory using supplied broth microdilution
panels and interpreted according to EUCAST guidelines.
Results: Summary data for tigecycline and comparators by year are
presented in the table.
MIC90 (mg/mL)
Acinetobacter spp. Pseudomonas aeruginosa
2004 2005 2006 2007 2008 2004 2005 2006 2007 2008
n 455 232 572 602 575 609 364 810 890 575
Tigecycline 1 1 1 1 1 >16 >16 >16 >16 >16
Amikacin >64 64 >64 >64 >64 16 16 16 16 16
Cefepime 32 32 >32 >32 32 32 32 32 32 32
Ceftazidime >32 >32 >32 >32 >32 32 32 >32 32 >32
Ceftriaxone >64 >64 >64 >64 >64 >64 >64 >64 >64 >64
Meropenem na >16 16 16 16 >16 >16 >16 16 16
Levoﬂoxacin >8 >8 >8 >8 >8 >8 >8 >8 >8 >8
Minocycline 8 1 2 2 2 >16 >16 >16 >16 >16
Pip/tazo >128 >128 >128 >128 >128 128 64 128 128 128
Conclusions: Tigecycline demonstrated no shift in MIC values in Europe
over four years from its pre-marketing baseline values when tested
against non-fermentors. Consistent MIC90 values values (1mcg/mL)
against Acinetobacter spp., including strains resistant to other drugs, may
make it an option when treating infections caused by strains resistant to
treatment with other agents.
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P1603 Is the number of ESBLs increasing in Asia/Paciﬁc
Rim countries? A longitudinal evaluation of organisms
associated with ESBL production between 2004–2008
S. Hawser °, M. Hackel, S. Bouchillon, B. Johnson, D. Hoban,
M. Renteria, J. Johnson, R. Badal, M. Dowzicky (Schaumburg,
Collegeville, US)
Background: ESBL producing organisms continue to be a therapeutic
dilemma for physicians as many currently marketed antimicrobials are
ineffective against these strains. Carbapenems and newer antimicrobials
such as tigecycline have proven to effective against many of these strains.
Tigecycline, the ﬁrst member of the glycylcyclines, was marketed in mid
2005 and has demonstrated success against ESBL producing organisms.
Four years of data are now available on the incidence and activity of
tigecycline against these strains.
Methods: All clinical isolates identiﬁed as E. coli, K. pneumoniae and
K. oxytoca were conﬁrmed as ESBL producers or non-ESBL producers
using criteria established by CLSI. MICs were determined by broth
microdilution according to CLSI guidelines using identical panels.
Results: Results of trends in incidence and antimicrobial susceptibility
for tigecycline for ESBLs for each country between 2004 and 2008 are
listed in the table.
Country 2004 2005 2006 2007 2008
%
E
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90
Australia 0 NA 1.46 1 3.1 4 2.9 1 3.0 1
China 18 1 34.8 8 24.1 0.25 NA NA NA NA
Hong Kong NA NA 0 NA 0 NA 7.2 0.5 NA NA
India 65.3 1 NA NA 0 NA 12.6 1 10.5 1
Korea NA NA 26.5 1 6.2 2 18.5 1 24.1 1
Pakistan 69.2 4 17.6 2 0 NA NA NA NA NA
Philippines 2.1 0.5 NA NA 9.8 2 9.1 0.5 8.8 0.5
Singapore 18.4 1 0 NA 27.1 0.5 9.2 2 NA NA
Taiwan NA NA NA NA 18.3 2 24.1 1 22.2 2
Conclusions: With exception of Taiwan it would appear the rates of
ESBLs producing organisms are going down. High rates still exist in
India, Korea and Taiwan. Tigecycline in vitro activity varies by country.
P1604 Activity of tigecycline and ﬁve comparators against recent
Gram-positive anaerobes in Europe − the Tigecycline
European Surveillance Trial
M. Hackel, S. Bouchillon, B. Johnson, D. Hoban, M. Renteria,
J. Johnson °, R. Badal, S. Hawser, M. Dowzicky (Schaumburg,
Collegeville, US)
Objectives: Tigecycline is a novel antimicrobial with expanded broad-
spectrum activity from a new class of compounds, the glycylcyclines.
Tigecycline was developed to provide activity against tetracycline and
multi-drug-resistant Gram-positive pathogens and has demonstrated
signiﬁcant broad-spectrum activity against aerobic and anaerobic Gram-
positive and Gram-negative microorganisms. In this study we evaluated
tigecycline and ﬁve comparator compounds against European Gram-
positive anaerobic isolates.
Methods: 454 Gram-positive anaerobic pathogens were collected and
identiﬁed from 18 sites in 6 countries in Europe. MICs of tigecycline
and ﬁve comparators were determined per EUCAST guidelines using
agar dilution.
Results: European Gram-positive pathogens tested against tigecycline
and comparators are shown in the table.
Anaerococcus
spp. (n = 43)
Clostridium spp.
(n = 249)
Fingoldia magna
(n = 56)
Peptoniphilus
(n = 28)
PStrepa
(n = 78)
MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90
Tigecycline <0.06 0.12 <0.06 0.5 <0.06 0.12 <0.06 <0.06 <0.06 0.12
Clindamycin <0.25 >8 2 >8 0.5 >8 <0.25 >8 <0.25 <0.25
Metronidazole 0.25 1 0.5 1 0.25 0.5 0.5 1 0.25 0.5
Pip/Tazo <0.06 0.25 0.5 8 <0.06 0.12 <0.06 <0.06 <0.06 0.25
Meropenem <0.06 0.12 0.12 1 <0.06 0.12 <0.06 <0.06 <0.06 0.25
Penicillin <0.25 0.5 <0.25 2 <0.25 0.5 <0.25 <0.25 <0.25 0.5
aPStrep, Peptostreptococcus spp.
Conclusions: Tigecycline showed excellent in vitro activity against
Gram-positive anaerobic microorganisms isolated from European hos-
pitals. MIC50 values for tigecycline against all isolates tested were
<0.06mcg/mL, while MIC90 values were <0.5mcg/mL. Using the FDA
breakpoint of <4mcg/mL, 100% of the isolates were susceptible to
tigecycline, including difﬁcult to treat Clostridium difﬁcile.
P1605 Activity of tigecycline against recent European clinical
isolates of Clostridium difﬁcile
B. Johnson, D. Hoban, M. Renteria, J. Johnson °, R. Badal, S. Hawser,
M. Hackel, S. Bouchillon, M. Dowzicky (Schaumburg, Collegeville, US)
Background: The role of toxin-producing Clostridium difﬁcile in
antibiotic-associated diarrhoea is well established. The incidence of this
difﬁcult to treat disease has increased dramatically since the 1980s.
Tigecycline, a member of a new class of antimicrobials (glycylcyclines),
has been shown to have potent expanded broad spectrum activity against
most commonly encountered species responsible for community and
hospital acquired infections, including Gram-positive anaerobes. The
T.E.S.T. program determined the in vitro activity of tigecycline and
ﬁve comparators against Clostridium difﬁcile strains collected from 18
investigational sites in 6 countries in Europe throughout 2008.
Methods: A total of 88 clinical isolates of C. difﬁcile were identiﬁed to
the species level at each participating site and conﬁrmed by the central
laboratory. Minimum Inhibitory Concentrations (MICs) were determined
using agar dilution. Antimicrobial resistance was interpreted according to
EUCAST breakpoints or CLSI and FDA breakpoints where no EUCAST
breakpoints were available.
Results: Results are shown in the table.
Clostridium difﬁcile (n = 88)
MIC50 MIC90 %S Range
Tigecycline 0.06 0.25 100 0.06−2
Clindamycin 4 >8 31.8 <0.25−>8
Meropenem 1 2 100 0.06−4
Metronidazole 0.5 1 100 0.12−2
Penicillin 1 4 14.8 0.25−>32
Pip/tazo 4 16 98.9 <0.06−>64
Conclusions: Tigecycline showed excellent in vitro activity against
European clinical isolates of Clostridium difﬁcile, with MIC50/MIC90
values of <0.06 and 0.25mcg/mL. Tigecycline’s low MIC50/MIC90
values suggest that it may be an option against this difﬁcult to treat
pathogen.
P1606 In vitro susceptibility to tigecycline and to an extended
panel of antimicrobials of Gram-positive and Gram-negative
isolates in Portugal
C. Silva-Costa °, A. Fria˜es, M.D. Pinho, M. Ramirez, J. Melo-Cristino
(Lisbon, PT)
Objectives: Tigecycline is a new antibiotic active against a variety
of bacterial species, including strains resistant to other antibiotics. In
order to increase awareness of this antibiotic in Portuguese hospitals
we determined the susceptibility to tigecycline and to several other
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antimicrobials of a collection of clinical isolates isolated in Portugal
in 2007.
Methods: A total of 1485 clinically signiﬁcant isolates were collected
and identiﬁed at 16 hospitals in Portugal. Susceptibilities were
determined at the coordinating laboratory by disk diffusion. The
antimicrobials tested against Gram-positive bacteria were: tigecy-
cline, vancomycin, teicoplanin, linezolid, quinupristin-dalfopristin, lev-
oﬂoxacin, gentamicin, rifampicin, cefoxitine, erythromycin, clindamycin,
ampicillin, streptomycin, tetracycline, penicillin, cefotaxime (the latter
were also tested using E-test for S. pneumoniae). The antimicro-
bials tested against Gram-negative bacteria were: tigecycline, lev-
oﬂoxacin, gentamicin, imipenem, piperacillin-tazobactam, cefepime, cef-
tazidime, ampicillin-sulbactam, trimetoprim-sulfamethoxazole, minocy-
clin, amoxicillin-clavulanate, cefotaxime, gentamicin, amikacin, ampi-
cillin, ciproﬂoxacin and tetracycline.
Results: Among Gram positive isolates (n = 839), all Staphylococcus
spp. isolates (n = 388) were fully susceptible to tigecycline, including
methicillin-resistant strains. All Enterococcus spp. (n = 160) isolates,
including vancomycin-resistant strains were susceptible to tigecycline,
as well as all the Streptococcus spp. isolates tested (n = 291).
Among Gram negative isolates (n = 646), ESBL-producing or quinolone-
resistant Escherichia coli strains (n = 232) were susceptible to tige-
cycline, while approximately 90% of ESBL-producing or quinolone-
resistant Klebsiella spp. strains (n = 134) were susceptible to this
antibiotic. Among Haemophilus inﬂuenzae (n = 53), Enterobacter spp.
(n = 80), Stenotrophomonas maltophilia (n = 67), and Acinectobacter
baumannii (n = 80) we found susceptibilities to tigecycline of 100%,
96%, 87% and 31%, respectively.
Conclusion: Tigecycline showed a good activity against most of the
pathogens included in this study, including strains resistant to many
broad-spectrum antibiotics, showing that tigecycline could be a valid
choice for difﬁcult to treat infections.
P1607 Proﬁle of tigecycline and other agents against enteric bacilli
collected across Europe
N. Brown °, C. Pillar, D. Draghi, C. Thornsberry, D. Sahm, M. Torres,
M. Dowzicky (Chantilly, Collegeville, US)
Objective: Tigecycline (TIG), a derivative of minocycline, has a
broad spectrum of activity which includes Enterobacteriaceae (EN). EN
infections can be problematic to treat due to antibiotic resistance (R).
Monitoring the activity of TIG against EN with clinically relevant R and
for the continued emergence of R among EN is important. This study
examines the activity of TIG and comparators against EN across Europe
(EU).
Methods: In total, 1,307 EN (464 E. coli [EC], 397 K. pneumoniae
[KP], 146 Citrobacter spp. [CS], 189 Enterobacter spp. [ES], and
111 S. marcescens [SM]) isolates were obtained from Belgium, Czech
Republic, France, Germany, Hungary, Italy, Spain, and the United
Kingdom during ’06-’08. Isolates were tested centrally by broth
microdilution (CLSI M7-A7). EUCAST breakpoints (BP) were used
to interpret TIG MIC results and CLSI (M100-S18) BP were used to
interpret all other agents, where applicable.
Results: TIG MIC90 was 1mg/L against EN overall and % susceptibility
(S) was 96.4, comparable to imipenem (MIC90 of 1mg/L; 99.8%S)
and 4-fold more potent than cefepime (4; 93.2%S), ceftriaxone (64;
83.9%S), ciproﬂoxacin (>4; 80.5%S), and piperacillin-tazobactam (64;
85.2%S). Against EC, KP, CS, ES, and SM the TIG MIC90 s (mg/L)
were, 0.5, 1, 0.5, 2, and 1, respectively. Overall TIG %S ranged
89.9% (ES) to >99% (EC and CS). The TIG MIC50/MIC90 was not
notably affected by R to advanced generation cephalosporins, though
the %S for ES and SM was lower among resistant isolates relative to
susceptible isolates. Isolates non-susceptible to minocycline remained
largely susceptible to TIG regardless of species. TIG MIC proﬁles and
%S were similar across evaluated countries for EC (99–100%S), KP
(93−98.6%S), and CS (100%S). Among ES and SM decreased S was
noted for isolates from the UK (70.6% SM, 81.6% ES) and to a lesser
extent with Spain (92.3% SM, 84.6% ES) and Czech Republic (84.2%
SM, 90.6% ES), while isolates in other countries were more susceptible
(90–100%S).
Conclusions: Overall, EN in EU was 96.4% S to TIG. Isolates with
clinically relevant R remained susceptible to TIG, though for ES
and SM there was a drop in TIG %S among isolates resistant to
advanced generation cephalosporins. TIG activity was consistent across
the evaluated countries, though low %S for ES and SM was noted among
UK isolates. Increased use of TIG and the concern regarding R among
EN highlight the continued need for surveillance both on the regional
and local levels.
P1608 Update on the spectrum and potency of tigecycline tested
against 7,133 Gram-positive and -negative pathogens from
13 countries (2008)
D. Biedenbach, R. Jones, M. Janechek, H. Sader ° (North Liberty, US)
Objectives: To assess the contemporary potency and spectrum of
tigecycline against Gram-positive (GP) and -negative (GN) pathogens,
including strains with various resistant phenotypes. Tigecycline is
a glycylcycline antimicrobial recently approved by the European
Medicines Agency (EMEA) for the treatment of complicated skin and
skin structure as well as intra-abdominal infections.
Methods: A total of 7,133 GN and GP clinically-signiﬁcant non-
duplicate isolates from multiple types of infections were collected from
12 EU countries and Israel that participated in tigecycline surveillance
program during 2008. Susceptibility (S) testing was performed by a
central monitoring laboratory (JMI Laboratories) using CLSI methods
(M7-A7, 2006). All concurrent quality control tests were within
published ranges.
Results: Tigecycline inhibited all S. aureus and coagulase-negative
staphylococci (CoNS) isolates at 0.5mg/L, regardless of S to oxacillin,
with a MIC90 at 0.25mg/L. Tigecycline also had potent activity against
all enterococci (MIC90, 0.25mg/L), including vancomycin-resistant
(VRE) strains, and b-haemolytic streptococci (bHS, MIC90, 0.06mg/L).
The MIC90 for Enterobacteriaceae was 0.25, 0.5 and 1mg/L for E. coli,
Klebsiella spp. and Enterobacter spp., respectively. Tigecycline was
active against Acinetobacter spp. (MIC90, 2mg/L), but less active
against isolates of P. aeruginosa (MIC50/90, 4/>4mg/L). Tigecycline
activity is summarised in the Table against nine organism groups.
Organism (no. tested) TIGMIC (mg/L) Cum. % inhibited at Tigecycline MIC (mg/L):
50% 90% 0.03 0.06 0.12 0.25 0.5 1 2 4
S. aureus (2,505) 0.12 0.25 0.2 22.9 70.0 99.2 100.0 – – –
CoNS (648) 0.12 0.25 2.2 24.9 59.1 94.3 100.0 – – –
Enterococcus spp. (898) 0.12 0.25 9.4 39.0 74.3 100.0 – – – –
bHS (323) 0.03 0.06 77.1 96.9 99.7 100.0 – – – –
E. coli (1,262) 0.12 0.25 0.0 16.6 66.6 95.3 99.6 100.0 – –
Klebsiella spp. (529) 0.25 0.5 0.0 0.0 11.2 68.6 90.7 96.8 99.8 –
Enterobacter spp. (281) 0.25 1 0.0 0.0 4.6 53.7 87.2 96.4 99.3 100.0
P. aeruginosa (517) 4 >4 0.0 0.0 0.0 0.0 0.8 2.5 12.0 52.6
Acinetobacter spp. (170) 1 2 0.0 2.9 11.2 24.1 38.2 75.5 94.1 98.8
Conclusions: Tigecycline demonstrated broad antimicrobial activity
against common pathogens associate with numerous types of clinical
infections occurring in EU. Tigecycline was active against antimicrobial-
resistant strains including MRSA, VRE, multidrug-resistant iso-
lates of Enterobacteriacea, including those producing broad-spectrum
b-lactamases such as ESBLs. Based on the potency and spectrum of
tigecycline shown here for 2008 isolates, this agent has a role in empiric
therapy for treating bacterial pathogens in these EU nations.
P1609 Worldwide activity of tigecycline against community-
acquired respiratory tract infection pathogens collected
during 2006–2008
D. Biedenbach, R. Jones, P. Strabala, H. Sader ° (North Liberty, US)
Objectives: To assess the contemporary potency and spectrum of
tigecycline tested against Gram-positive and -negative CARTI pathogens,
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including strains with various resistant (R) phenotypes. Tigecycline is
a glycylcycline antimicrobial with proven activity against numerous
bacterial species, including staphylococci and streptococci. Based upon
in vitro activity and demonstrated clinical trial efﬁcacy, tigecycline has
received approval in the USA and Europe (EU) for treating complicated
skin and skin structure and intra-abdominal infections.
Methods: A total of 9,235 clinically-signiﬁcant non-duplicate isolates
from patients with CARTI were collected from North and Latin America
and EU medical centres participating in surveillance of tigecycline
(2006–2008). Susceptibility (S) testing was performed by a central
laboratory (JMI Laboratories) using CLSI methods (M7-A7, 2006) and
all quality control tests were within published ranges.
Results: Tigecycline was active against all (2mg/L) tested strains as
summarised in the Table.
Organism (no. tested) TIGMIC (mg/L) Cum. % inhibited at Tigecycline MIC (mg/L):
50% 90% 0.03 0.06 0.12 0.25 0.5 1 2
S. aureus (714) 0.12 0.25 0.6 27.6 80.1 99.4 100.0 – –
Oxacillin-S (450) 0.12 0.25 0.7 28.4 80.4 99.8 100.0 – –
Oxacillin-R (264) 0.12 0.25 0.4 26.1 79.6 98.9 100.0 – –
S. pneumoniae (5,375) 0.03 0.06 80.3 96.3 99.3 99.9 >99.9 100.0
Penicillin-S (3,519) 0.03 0.06 81.7 96.5 99.4 >99.9 – – –
Penicillin-I (881) 0.03 0.06 83.9 96.8 99.6 100.0 – – –
Penicillin-R (975) 0.03 0.06 72.1 95.1 98.7 99.8 99.9 100.0 –
H. inﬂuenzae (3,129) 0.5 1 0.1 0.1 0.2 11.7 73.7 99.6 100.0
b-lactamase-neg. (2,486) 0.5 1 0.1 0.1 0.2 12.4 74.1 99.6 100.0
b-lactamase-pos. (642) 0.5 1 0.3 0.3 0.5 9.0 72.0 99.7 100.0
M. catarrhalis (17) 0.12 0.12 23.5 47.1 100.0 – – – –
Tigecycline inhibited S. aureus at 0.5mg/L, with a MIC90 at
0.25mg/L, regardless of S or R to oxacillin. Tigecycline also had good
activity against S. pneumoniae isolates (MIC90, 0.06mg/L), including
penicillin-R strains. The MIC90 for fastidious Gram-negative pathogens
was 1mg/L for H. inﬂuenzae (HI) and 0.12mg/L for M. catarrhalis
(MCAT). There was no signiﬁcant difference in tigecycline activity
between the three monitored regions for any of CARTI pathogens.
Conclusions: Tigecycline demonstrated broad antimicrobial activity
against pathogens associated with CARTI. Tigecycline was active
against antimicrobial-R strains including oxacillin-R staphylococci and
penicillin-R S. pneumoniae, as well as HI and MCAT isolates, including
those producing b-lactamase enzymes. Tigecycline potency and spectrum
shown here for 2006–2008 conﬁrms that this agent may have a role in
treating CARTI.
P1610 Tigecycline in vitro activity against isolates of S. pneumoniae
and H. inﬂuenzae: a multi-year update from the TEST
Program in 2008
J. Johnson, R. Badal, S. Hawser °, M. Hackel, S. Bouchillon, B. Johnson,
D. Hoban, M. Renteria, M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), a new glycylcycline, has been shown to
have potent broad spectrum activity against most commonly encountered
species responsible for community and hospital acquired infections.
The T.E.S.T. program determined the in vitro activity of TIG and 10
comparators against Gram positive/negative species. Isolates for the
overall T.E.S.T program were collected from 1016 hospital sites in 53
countries from 2004 to 2008.
Methods: A total of 5,084 clinically signiﬁcant respiratory isolates
collected worldwide were analyzed in this survey. The isolates were
identiﬁed to the species level at the participating sites and conﬁrmed by
the central laboratory. MICs were determined by each site using supplied
broth microdilution panels and interpreted according to CLSI guidelines.
Results: Activities of tigecycline and comparator antimicrobials are
shown in the table.
Overall, 23.3% of H. inﬂuenzae were b-lactamase producers and 38.1%
of S. pneumoniae presented some degree of non-susceptibility to
penicillin. Tigecycline demonstrated potent inhibitory activity with an
MIC90 of 0.5mcg/ml against b-lactamase positive H. inﬂuenzae and
penicillin non-susceptible S. pneumoniae.
Conclusions: Tigecycline showed excellent inhibitory activity against
H. inﬂuenzae and S. pneumoniae regardless of the presence of
b-lactamase or penicillin-resistance mechanisms. The results of this study
suggest that tigecycline may be a reliable therapeutic option for the
treatment of respiratory infections due to these species.
H. inﬂuenzae (2,433) S. pneumoniae (2,651)
%SUS %INT %RES MIC90 %SUS %INT %RES MIC90
Tigecycline na na na 0.5 na na na 0.5
Ceftriaxone 99.8 – 0.2 =0.06 97.8 1.3 0.9 1
Levoﬂoxacin 100 – – 0.03 99.9 0.1 – 1
Minocycline na na na 1 na na na 4
Amox/Clav 99.8 – 0.2 1 94.8 3.2 2.0 2
Penicillin – – – – 61.0 26.8 11.3 2
PipTazo 99.8 – 0.2 =0.06 na na na 2
Linezolid – – – – 100 – – 1
Vancomycin – – – – 100 – – 0.5
*na = breakpoints not available.
P1611 Evaluation of in vitro activity of tigecycline and ten
comparators against methicillin-resistant Staphylococcus
aureus from Europe: TEST Program 2004–2008
M. Renteria, J. Johnson °, R. Badal, S. Hawser, M. Hackel, S. Bouchillon,
B. Johnson, D. Hoban, M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline (TIG), a member of a new class of
antimicrobials (glycylcyclines), has been shown to have potent expanded
broad spectrum activity against most commonly encountered species
responsible for community and hospital acquired infections. The
T.E.S.T. program determined the in vitro activity of TIG compared
to amoxicillin-clavulanic acid, piperacillin-tazobactam, levoﬂoxacin,
ceftriaxone, linezolid (LZD), minocycline (MIN), vancomycin (VAN),
ampicillin, penicillin, and imipenem (IMP) against methicillin-resistant
S. aureus (MRSA) isolates collected from 316 sites in 24 European
countries between 2004 and 2008.
Methods: A total of 1016 clinical isolates of MRSA were identiﬁed to
the species level at each participating site and conﬁrmed by the central
laboratory. Minimum Inhibitory Concentration (MICs) were determined
by the local laboratory using supplied broth microdilution panels and
interpreted according to EUCAST guidelines.
Results: The %S for the study drugs with MRSA activity–TIG, VAN,
LZD, and MIN–was 99.9, 100, 100, and 83.7, respectively. MIC50/90
(mcg/ml) for TIG, VAN, LZD, and MIN were 0.12/0.25, 1/1, 2/4, and
0.25/4, respectively.
Conclusions: European susceptibility patterns of MRSA remain fairly
consistent. TIG was as potent as VAN and LZD, inhibiting 1015/1016
(99.9%) of the MRSA isolates at their respective breakpoints. TIG’s
excellent expanded broad spectrum of activity against MRSA should
make it a very useful drug in treatment of difﬁcult staphylococcal
infections.
P1612 Comparative in vitro activity of tigecycline against
pathogens obtained from intensive care patients in Germany
R. Mutters, W.R. Heizmann, B. Ko¨rber-Irrgang, E. Leitner, M. Kresken °
(Marburg, Berlin, Rheinbach, Munster, DE)
Objectives: Tigecycline has been shown to be active against a wide range
of bacteria including multi-resistant pathogens. The German Tigecycline
Evaluation Trial (G-TEST) is an ongoing surveillance programme
comprising 15 German laboratories monitoring the susceptibility of
bacterial pathogens to tigecycline. The objective of this study was to
evaluate the in vitro activity of tigecycline against intensive care unit
isolates of four Gram-positive and three Gram-negative species.
Methods: A total of 996 isolates (152 S. aureus [of which 83
were MRSA], 126 S. epidermidis, 96 E. faecalis, 140 E. faecium,
182 E. cloacae, 179 E. coli, 121 K. pneumoniae) collected in
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2005 (n = 523) and 2007 (n = 473) were included. Agents tested were
tigecycline, ciproﬂoxacin, cefotaxime, gentamicin, imipenem, linezolid,
moxiﬂoxacin, oxacillin, piperacillin-tazobactam, and vancomycin. MICs
were determined by the broth microdilution method according to the
standard of the guideline EN ISO 20776−1 in a central laboratory and
interpreted by EUCAST criteria.
Results: The majority of isolates derived from respiratory tract
specimens (n = 363, 36%), followed by blood cultures (n = 245, 25%)
and wound specimens (n = 205, 21%). Of the S. epidermidis isolates,
84% were oxacillin-resistent. Rates of resistance to moxiﬂoxacin
and gentamicin were 14% and 9% for MSSA, 92% and 17% for
MRSA, and 44% and 63% for S. epidermidis. All staphylococci were
susceptible to vancomycin and linezolid. In contrast, 12% of the
E. faecium isolates were resistant to vancomycin. High-level resistance
to gentamicin was >40% in both enterococcal species. Tigecycline
inhibited all Gram-positive cocci at 0.5mg/l. MIC50/90 values of
tigecycline for E. cloacae, E. coli and K. pneumoniae were 0.5/1,
0.125/0.25 and 0.5/4mg/l, respectively. Rates of resistance (%)
to tigecycline, ciproﬂoxacin, cefotaxime, gentamicin, imipenem and
piperacillin-tazobactam were as follows: E. cloacae − 6, 5, 51, 5, 0,
25; E. coli − 0, 26, 11, 12, 0, 6; K. pneumoniae − 12, 18, 12, 7, 0, 12.
Of the E. coli and K. pneumoniae isolates, 22 (12%) and 16 (13%) were
ESBL+. Tigecycline inhibited 36/38 (95%) ESBL+ isolates at 2mg/l.
Conclusions: Tigecycline demonstrated excellent in vitro activity against
the tested Gram-positive and Gram-negative pathogens including MRSA,
VRE and ESBL producing bacteria. Therefore, tigecycline may be an
alternative for the treatment of infections caused by pathogens of the
tested species on intensive care units.
P1613 Proﬁle of tigecycline and comparator agents against
Gram-positive organisms collected across the United States
and Europe in 2007–2008
N. Brown, C. Pillar °, D. Draghi, C. Thornsberry, D. Sahm,
M. Dowzicky (Chantilly, Collegeville, US)
Objective: Tigecycline (TIG), a broad-spectrum glycylcycline, was ap-
proved in both the US and Europe (EU) for treatment of complicated skin
and intra-abdominal infections, and is currently undergoing development
for the treatment of community-acquired pneumonia. Gram-positive
cocci including Staphylococcus aureus (SA), Streptococcus pneumoniae
(SP), S. pyogenes (GAS), and enterococci are signiﬁcant pathogens
associated with these indications. It is important to understand the
activity proﬁle of new agents against target organisms and to monitor
for development of resistance. This study examines the activity proﬁle
of TIG and other select agents against recent isolates of Gram-positive
pathogens collected across the US and EU.
Organism Agent US EU
Total
n
MIC50
(mg/L)
MIC90
(mg/L)
%S Total
n
MIC50
(mg/L)
MIC90
(mg/L)
%S
SA Tigecycline 1807 0.12 0.25 100 428 0.12 0.25 100
Clindamycin 0.12 >2 80.3 0.12 >2 73.1
Daptomycin 0.5 1 99.9 0.5 1 99.8
Linezolid 1 2 100 l 2 100
Vancomycin 1 1 100 1 1 100
SP Tigecycline 250 0.015 0.03 –a 138 0.015 0.03 –
Clindamycin 0.06 >2 84.4 0.06 >2 81.2
Daptomycin 0.12 0.25 – 0.12 0.25 –
Linezolid 0.5 1 100 0.5 1 100
Vancomycin 0.25 0.5 100 0.25 0.5 100
GAS Tigecycline 250 0.03 0.06 100 100 0.03 0.03 100
Clindamycin 0.06 0.06 98.0 0.06 0.06 98.0
Daptomycin 0.06 0.06 100 0.06 0.06 100
Linezolid 1 1 100 1 1 100
Vancomycin 0.25 0.25 100 0.25 0.25 100
ES Tigecyclineb 100 0.12 0.5 80.0 25 0.12 0.25 96.0
Clindamycin >2 >2 – >2 >2 –
Daptomycin 1 2 99.0 2 4 96.0
Linezolid 0.5 1 100 1 2 100
Vancomycin 1 2 96.0 1 2 96.0
aCLSI and EUCAST breakpoints are unavailable for interpretation of susceptible (S).
bE. faecalis (vancomycin-susceptible isolates only) FDA breakpoints were applied to all US ES.
Methods: In 2007–2008 a total of 1,807 SA, 250 SP, 250 GAS, and 100
Enterococcus spp. (ES; 100 E. faecalis) clinical isolates from the US
and 428 SA, 138 SP, 100 GAS, and 25 ES (18 E. faecalis; 7 E. faecium)
from EU, were tested centrally by broth microdilution (CLSI M7-A7).
EUCAST and FDA breakpoints were used to interpret EU and US TIG
MIC results, respectively, and CLSI (M100-S18) breakpoints were used
to interpret all other agents.
Results: See the table.
Conclusions: TIG had potent in vitro activity against all evaluated Gram-
positive organisms, with identical or lower MIC90 s than comparator
agents. Isolates of SA and GAS were 100%S to TIG, while susceptibility
of ES varied from 80% in the US to 96%S in EU. The activity proﬁle
of TIG was consistent between EU and US isolates of the evaluated
organisms. Further surveillance is warranted both to support the ongoing
development of TIG and to monitor for the emergence of resistance.
P1614 In vitro activity of tigecycline against pathogens from
Crete, Greece − T.E.S.T Program 2006
S. Maraki °, M. Katrinaki, A. Valachis, D. Kofteridis, Y. Tselentis,
G. Samonis (Heraklion, GR)
Objective: Tigecycline (TIG), a member of glycycyclines, has been
shown to have broad spectrum of activity against most bacterial
pathogens. The T.E.S.T program determined the in vitro activity of
tigecycline and 10 comparators against aerobic Gram-positive and
negative bacterial species.
Methods: A total of 200 non-duplicate clinical isolates collected in
2006 were analyzed in this survey. Minimum inhibitory concentrations
(MICs) were determined using supplied broth microdilution panels
and interpreted according to CLSI guidelines. Breakpoints deﬁned by
EUCAST were used for tigecycline, where applicable.
Results: Tigecycline activity against aerobic Gram-positive and negative
bacteria is shown in the table.
Organism (n) MIC50 MIC90 Range % susceptibility
S. aureus (25) 0.12 0.12 0.06–0.25 100
Enterococcus spp. (15) 0.06 0.25 0.03–0.25 100
S. pneumoniae (15) 1 1 0.25–2 na*
S. agalactiae (10) 2 2 2–2 0
E. coli (25) 0.12 0.12 0.06–0.5 100
Klebsiella spp. (25) 0.5 2 0.12–16 88
Enterobacter spp. (25) 0.5 0.5 0.25–2 96
Serratia spp. (10) 1 2 0.25–4 80
H. inﬂuenzae (15) 0.12 0.25 0.06–0.25 na
Acinetobacter spp. (15) 0.5 2 0.06–4 na
P. aeruginosa (20) 8 16 4–16 na
*na: not applicable.
Conclusion: Tigecycline showed excellent inhibitory activity against
both Gram-positive and Gram-negative bacteria (except for Streptococ-
cus agalactiae and Pseudomonas aeruginosa), representing an effective
option for treatment of infections caused by these pathogens.
P1615 Survival predictors in patients treated with tygecicline in
clinical practice
D. Conde-Este´vez °, S. Grau, S. Luque, J.P. Horcajada, F. Alvarez-Lerma,
J. Mateu-de Antonio, O. Urbina, H. Knobel (Barcelona, ES)
Background:Most clinical experience with Tigecycline (TGC) proceeds
from clinical trials. The objective of the study was to determinate survival
predictor factors in patients treated with TGC.
Methods: Prospective observational study of all patients treated with
TGC from april 2007-april 2008 admitted in a 450-bed university
hospital.
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Measures: demographics, length of stay (LOS), ICU admission, SAPS-
II at admission (SAPSII-A) and at TGC beginning (SAPSII-TGC),
empirical TGC-therapy, TGC days, patients with previous (PA) and
concomitant antibiotics (CA), isolated microorganisms before TGC-
treatment (M-TGC), infection site, microbiological eradication (ME),
favourable clinical outcome (FCO) and mortality during or 28 days after
ﬁnishing TGC therapy (M). SAPS-II was transformed in a dichotomic
variable (cut-off point 40). Fischer exact test for dichotomic and “U”
Mann-Whitney test for continuous variables and a multiple logistic
regression for prediction survival were employed.
Results: Patients: 62; male: 32 (51.6%); mean age: 61.6 (SD+15.3);
mean LOS: 39.9 (SD+34.1); ICU patients: 24 (38.7%); SAPSII-A:
31.3 (SD+10.4); SAPSII-TGC: 31.2 (SD+11.7), empirical treatment
12 (19.4%); TGC days: 7.5 (SD+5.7); PA: 41 (66.1%); CA: 43
(69.4%); infection site: SSTI 21 (33.9%), intraabdominal 19 (30.6%),
low respiratory tract 11 (17.7%), CNS 5 (8.1%), others (9.7%); main
M-TGC: Stenotrophomonas maltophilia 9 (14.50%), Escherichia coli 8
(12.9%); FCO: 35 (58.3%), ME 29 (47.5%) and M: 11 (17.7%).
In multivariate analysis, only the lack of isolation of S. maltophilia
[OR: 23.1 (CI95%: 3.3–160.5) (p = 0.001)], and SAPS-II-TGC <40 [OR:
13.2 (CI95%:2.1–82.2) (p = 0.006)] were independently associated with
survival.
Conclusions:
– Survival predictor factors in patients treated with TGC were a SAPSII-
TGC score lower than 40 and lack of S. maltophilia isolation.
– TGC treatment was related to a low mortality considering the high
severity of patients.
P1616 Activity of tigecycline against multidrug-resistant anaerobic
isolates from Europe in 2008 − the T.E.S.T. Program
S. Bouchillon, B. Johnson, D. Hoban, M. Renteria, J. Johnson, R. Badal,
S. Hawser °, M. Hackel, M. Dowzicky (Schaumburg, Collegeville, US)
Background: Tigecycline, a member of a new class of antimicrobials
(glycylcyclines), has been shown to have potent expanded broad spec-
trum activity against most commonly encountered species responsible
for community and hospital acquired infections. The T.E.S.T. program
determined the in vitro activity of tigecycline compared to piperacillin-
tazobactam, clindamycin, metronidazole, meropenem, penicillin, and
cefoxitin against anaerobic multi-drug resistant (MDR) strains collected
from 18 investigational sites in 6 countries in Europe throughout 2008.
Methods: A total of 1090 clinical anaerobic pathogens were identiﬁed to
the species level at each participating site and conﬁrmed by the central
laboratory. Minimum Inhibitory Concentrations (MICs) were determined
using agar dilution. Antimicrobial resistance was interpreted according to
EUCAST breakpoints or CLSI and FDA breakpoints where no EUCAST
breakpoints were available. Strains were grouped by resistance to 0, 1,
or 2 drug classes.
Results: The MIC90 s of tigecycline to MDR groups 0−2 are shown in
the table.
MDR Group MIC90 (n)
Group 0 Group 1 Group 2
Aerococcus spp. 0.12 (33) 0.12 (10) –
Bacteroides spp. 1 (354) 4 (104) 2 (8)
Clostridium spp. 0.5 (167) 1 (60) 1 (22)
Finegoldia spp. 0.12 (44) 0.06 (12) –
Peptoniphilus spp. 0.06 (24) 0.06 (4) –
Peptostreptococcus spp. <0.06 (72) 0.12 (6) –
Prevotella spp. 0.5 (130) 0.5 (37) 0.12 (1)
*MDR Group is deﬁned as resistant to 0, 1, or 2 or more separate drug
classes.
Conclusions: Tigecycline retained activity against 100% of multi-drug
resistant anaerobes, with MIC90 values 4mcg/mL. Tigecycline’s in
vitro activity against multi-drug resistant anaerobic pathogens should
prove useful in the treatment of infections caused by such therapeutically
challenging strains.
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P1617 Comparative in vitro activity of moxiﬂoxacin, tigecycline
and 8 other antimicrobial agents against contemporary
clinical isolates of Streptococcus pyogenes
J. Blondeau °, S. Borsos (Saskatoon, CA)
Objectives: Streptococcus pyogenes is the predominant cause of
bacterial pharyngitis and is often associated with skin and skin structure
infections. We tested contemporary clinical isolates for susceptibility
resistance to 10 antimicrobial agents: azithromycin (AZ), ciproﬂoxacin
(CP), clarithromycin (CL), erythromycin (ER), gemiﬂoxacin (GM),
levoﬂoxacin (LVF), moxiﬂoxacin (MFX), penicilllin (P), telithromycin
(TEL) and tigecycline (TIG).
Methods: Minimum inhibitory concentration (MIC) testing was by
microbroth dilution according to the Clinical and Laboratory Standards
Institute recommended procedure. Brieﬂy, 105 cfu/ml of test organism
in Mueller-Hinton broth were exposed to doubling drug dilutions and
following incubation under ambient conditions (35−37 degree Celsius
in O2 for 18−24 hours) the lowest concentration preventing growth was
the MIC.
Results: A total of 177 clinical isolates were tested. MIC50, MIC90 and
MIC range values (mg/L) for AZ, CIP, CL, ER, GEM, LFX, MFX, P,
TEL and TIG respectively were as follows: 0.125, 0.125, 0.063−4;
0.5, 0.5, 0.125−4; 0.031, 0.031, 0.004−2; 0.031, 0.031, 0.008−2;
0.008, 0.016, 0.004–0.063; 0.5, 0.5, 0.5−2; 0.125, 0.125, 0.031–0.5;
0.008, 0.008, 0.002–0.016; 0.008, 0.016, 0.002–0.016; 0.016, 0.031,
0.004–0.063. Two percent of strains were macrolide resistant.
Conclusions: Macrolide resistance rates were low (2%) against
S. pyogenes strains. Of the quinolones, GEM and MFX were 4−32 more
active than CIP or LFX. TIG and TEL MIC90 values were equal to or
lower than those for AZ, CL, ER. No strains were resistant to penicillin
and the highest MIC was 0.016mg/L. CIP and LFX were the least active
agents based on MIC90 values (0.5mg/L). The rank order of potency
based on MIC90 values were P > TEL = GEM> TIG = CL, ER >
MFX = AZ > LFX = CFX.
P1618 A multi-centre evaluation of in vitro activity of oritavancin
and comparators against staphylococci, enterococci, and
streptococci − the ORION Study
R. Badal, S. Bouchillon, D. Hoban, S. Hawser, A. Johnson, M. Hackel,
J. Johnson °, G. Moeck, F. Arhin (Schaumburg, US; Saint-Laurent, CA)
Background: Oritavancin (ORI) is a bactericidal lipoglycopeptide with
multiple modes of action, and has superior pharmacodynamic properties
compared to vancomycin. The ORI Susceptibility Proﬁle Initiative
(ORION) study determined the activity of ORI against a variety of
Gram-positive pathogens collected in the USA and South Korea. This
analysis focuses on the in vitro activity of ORI and comparators against
common clinical staphylococcal, streptococcal, and enterococcal species
and resistant phenotypes.
Methods: 2,973 clinical isolates were collected from 35 labs in the USA
(21) and Korea (14) in 2007–2008. MICs were determined using broth
microdilution according to CLSI guidelines and interpretive criteria (M7-
A7 and M100-S18).
Results: ORI MIC90 (mg/L) and % Susceptible (%S) compared to
vancomycin (VAN), daptomycin (DAP) and linezolid (LIN) are presented
in the table.
Conclusions: ORI had the lowest MICs against most clinical isolates
compared to VAN, DAP, and LIN. Against all species and phenotypes,
ORI MIC90 s were 2- to >1024-fold lower than comparators, except for
DAP vs. S. pyogenes, where DAP and ORI MIC90 s were both 0.25mg/L.
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Notably, ORI demonstrated potent in vitro activity against both pan-
sensitive isolates and those resistant to VAN, DAP, or LIN.
Organism or phenotype ORI VAN DAP LIN
(n) MIC90 %S MIC90 %S MIC90 %S MIC90 %S
S. pneumoniae (125) 0.015 na* 0.5 100 0.5 na 2 100
Penicillin-RES (46) 0.008 na 0.5 100 0.5 na 2 100
Macrolide-RES (64) 0.008 na 0.5 100 0.5 na 2 100
S. agalactiae (127) 0.25 na 1 100 0.5 100 2 100
S. pyogenes (118) 0.25 na 0.5 100 0.25 100 2 100
Viridans group strep
(104)
0.06 na 1 99.0 1 96.2 2 100
S. aureus (1466) 0.25 na 1 99.9 1 99.9 4 100
MRSA (678) 0.25 na 2 99.9 1 99.7 4 100
MSSA (788) 0.25 na 1 100 0.5 100 4 100
Coag-neg Staph (160) 0.12 na 2 100 1 98.8 2 98.1
E. faecalis (455) 0.12 na 4 95.6 2 100 2 96.9
VAN-RES (18) 0.25 na >128 0 2 100 2 100
E. faecium (393) 0.12 na >128 46.1 4 99.0 4 89.6
VAN-RES (212) 0.12 na >128 0 4 99.1 4 85.8
*na = breakpoints not deﬁned.
P1619 Activity of telavancin against reference and recent clinical
isolates of hVISA and VISA assessed by population analysis
proﬁling
S. Difuntorum °, K. Krause, C. Lunde, J. Blais, B. Benton (San
Francisco, US)
Objectives: Infections caused by vancomycin-intermediate Staphylococ-
cus aureus (VISA) and heterogeneous VISA (hVISA) are associated with
high rates of vancomycin (VAN) treatment failure. Telavancin (TLV)
possesses potent activity against S. aureus, including methicillin-resistant
S. aureus (MRSA), hVISA and VISA isolates. We used population
analysis proﬁling (PAP) to evaluate the activity of TLV against hVISA
and VISA isolates.
Methods: A total of 16 recent clinical S. aureus isolates and 4 reference
strains including 1 vancomycin-susceptible S. aureus (VSSA), 1 hVISA
and 2 VISA were tested. Minimum inhibitory concentrations (MICs)
were determined by broth microdilution (CLSI). Screening methods to
identify hVISA included a modiﬁed VAN agar screen (Brain Heart
Infusion agar containing 3mg/L VAN [VAN-3]), VAN and teicoplanin
(TEI) Macro Etest and VAN PAP. VAN PAP-area under the plasma
concentration-time curve (AUC) ratios (AUC of test strain/AUC of
Mu3) were used to categorise VSSA (<0.9), hVISA (0.9–1.3) and VISA
(>1.3). TLV PAP assays were conducted on selected isolates.
Results: MICs for all 16 clinical isolates were 0.25–1mg/L for TLV
and 1−4mg/L for VAN. Three isolates with VAN MIC=4mg/L were
classiﬁed as VISA. The remaining 13 isolates were screened for the
hVISA phenotype; 6 grew on VAN-3 agar, 4 of these had VAN
MIC=2mg/L, and, of these, 3 isolates were identiﬁed by Macro Etest
as potential hVISA. VAN PAP analysis of the 4 isolates with VAN
MIC=2mg/L identiﬁed 2 as hVISA (VAN PAP AUC ratios of 0.9 and
1.0), 1 as VISA (ratio of 1.7) and 1 as VSSA (ratio of 0.8). TLV
PAP analysis of these 4 isolates and the 4 reference strains revealed no
TLV heteroresistant subpopulations. Against all tested strains, no colony
growth was observed in TLV PAP assays at concentrations >0.5mg/L.
Conclusions: This report summarises the ﬁrst attempt to identify
potential TLV heteroresistance in S. aureus. PAP studies demonstrated
that TLV was uniformly active against all VSSA, hVISA and VISA
isolates. These results are consistent with the improved targeting of Lipid
II by TLV relative to VAN. No evidence for telavancin heteroresistance
was detected.
P1620 Longitudinal analysis of the in vitro activity proﬁle
of oritavancin and comparator glycopeptides against
Gram-positive organisms from Europe: 2005–2008
D. Draghi °, C. Pillar, G. Moeck, F. Arhin, D. Sahm (Chantilly, US;
Saint-Laurent, CA)
Objective: Oritavancin (ORI), currently in clinical development for use
in the treatment of infections caused by Gram-positive (GP) bacteria,
is a potent bactericidal lipoglycopeptide. ORI has previously shown
potent activity against GP organisms, including resistant (R) strains. This
comparative analysis was undertaken to proﬁle the in vitro activity of
ORI in Europe (EU) across multiple years.
Methods: In total 2036, recent (2005–2008) clinical isolates of
S. aureus (SA; n = 757), coagulase-negative staphylococci (CoNS;
n = 340), Enterococcus spp. (EN; n = 492), S. pyogenes (GAS; n = 235),
and S. agalactiae (GBS; n = 212) from 49 hospital sites in EU (15
countries) were centrally tested by broth microdilution (CLSI; M7-A7)
against ORI, teicoplanin (TEI), and vancomycin (VAN). ORI assays
included 0.002% polysorbate-80 throughout.
Results: ORI MIC90 s ranged from 0.12–0.25mg/L for SA across all
years studied; MIC90 s for VAN (1mg/L) and TEI (0.5–2mg/L) were
4−16 fold higher, comparatively. For CoNS, ORI MIC90 s ranged from
0.12–0.25mg/L across all years studied; MIC90 s for VAN (2mg/L)
and TEI (2 to 8mg/L) were 16−64 fold higher, comparatively. ORI
modal MICs, MIC50 s, and MIC90 s by year were generally equivalent
(1 doubling dilution) against oxacillin (OX)-susceptible (S) and -R
staphylococci (STA). The ORI MIC90 for VAN-S EN was 0.06mg/L
from 2005 to 2008. For the VAN-S population MIC90 s for TEI (0.25–
0.5mg/L) and VAN (2mg/L) were consistently higher compared with
ORI each year. For VAN-non S EN (2005 only), ORI MIC90 was
0.5mg/L compared to 256mg/L and >256mg/L for TEI and VAN,
respectively. ORI MIC90 s ranged from 0.12 to 0.25mg/L against GAS
and 0.25–0.5 for GBS, including both erythromycin-S and -R isolates,
similar to the MIC90 s of VAN (GAS: 0.25mg/L; GBS: 0.5mg/L) and
slightly higher than those of TEI (GAS: 0.03mg/L; GBS: 0.12mg/L).
Conclusions: No trend towards decreased susceptibility or elevated
MICs was apparent for ORI or comparator agents over time against the
evaluated GP cocci. ORI was more potent than comparator glycopeptides
against both STA and EN, including resistant isolates, across the
evaluated years.
P1621 Susceptibility of coagulase-negative staphylococci to
telavancin, a new lipoglycopeptide antibiotic and
comparison with vancomycin
M. John, S. Milburn, D. Diagre, B. Wilson, R. Lannigan, Z. Hussain °
(London, CA)
Objectives: Coagulase negative staphylococci (CoNS) have become
recognized as important human pathogens. Many CoNS are resistant
to methicillin and require treatment with vancomycin. In recent
years reduced susceptibility to vancomycin has been noted amongst
Staphylococcus aureus and to a lesser extent among CoNS. Telavancin is
a new lipoglycopeptide which has shown increased activity against Gram
positive organisms compared to vancomycin. We undertook this study to
compare in vitro susceptibilities of a large series of speciated coagulase
negative staphylococci (CoNS) to telavancin and vancomycin, using agar
dilution. Further, the study assessed the reliability of the Vitek® 2 system
for determining vancomycin susceptibility.
Methods: Susceptibility was performed on 699 non duplicate CoNS
isolates, comprising 15 species and subspecies. Agar dilution was
performed using methodology described by the CLSI and was used to
determine MICs to telavancin and vancomycin. All strains were also
tested for their susceptibility to vancomycin by the Vitek® 2 system,
using the AST-GP66 card.
Results: Of 669 strains, eight strains of S. cohnii cohnii failed to grow in
the Vitek® 2 system. Overall telavacin was more active than vancomycin.
For most species and subspecies of CoNS the MIC’s of telavancin were
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1 to 2 dilutions lower than those of vancomycin, as measured by the
agar dilution method. The MIC 50 and MIC90 of telavancin for all
isolates were 0.25 (range, <0.125 to 0.5mg/L) and 0.5mg/L (range,
<0.125 to 1.0mg/L) respectively, whereas the overall MIC 50 and MIC
90 for vancomycin by the agar dilution method were 1.0 (range 0.5 to
1.0mg/L) and 2.0mg/L (range, 0.5 to 2.0mg/L). Not all MICs obtained
on the Vitek® 2 system could be compared as 375 strains had an MIC
to vancomycin of <1.0mg/L and 8 strains failed to grow, making exact
MIC values unavailable. For 286 strains exact MIC values of vancomycin
by agar dilution and Vitek® 2 were available. MIC of all but three
of 204/286 (71.3%) strains with non-concordant results was at least 1
dilution higher by the Vitek® 2 system.
Conclusion: Telavancin is more active against CoNS than vancomycin,
with MICs 1 to 2 dilutions lower. For evaluable isolates the Vitek® 2
system tended to report MICs of vancomycin one dilution higher than
agar dilution.
P1622 In vitro proﬁling of the activity of ceftaroline against
European clinical isolates collected in the CANVAS 1 and
2 trials of complicated skin and skin-structure infections
D. Biek °, I.A. Critchley, A. Jandourek, H.D. Friedland, D. Thye
(Alameda, US)
Objectives: Ceftaroline (CPT) is an investigational, parenteral,
cephalosporin exhibiting activity against Gram-positive organisms,
including methicillin resistant Staphylococcus aureus (MRSA) and
multi-drug resistant Streptococcus pneumoniae, as well as Gram-negative
organisms. CPT has recently been evaluated in patients with complicated
skin and skin structure infections (cSSSI) in two blinded multinational
Phase 3 trials (CANVAS 1 and 2). The aims of this paper were to
determine the national distribution of pathogens collected from European
subjects enrolled in CANVAS 1 and 2; to assess the prevalence of key
resistance phenotypes; and to determine the activity of CPT against
baseline pathogens.
Methods: From the CANVAS 1 and 2 trials, a total of 840 isolates from
subjects with cSSSI were collected at sites in Austria, Germany, Latvia,
Poland, Romania, Russia, United Kingdom and Ukraine. All isolates
were centrally tested for susceptibility to CPT and other agents using
broth microdilution in accordance with CLSI guidelines.
Results: In Europe (EU), the most commonly isolated skin pathogens
were Staphylococcus aureus (SA) and Streptococcus pyogenes (SP) with
prevalence rates of 49% and 12%, respectively. Among SA, the majority
of isolates were collected from Russia (51%), followed by Ukraine
(15%), Romania (10%) and Poland (10%). The prevalence of methicillin
resistance among SA isolates varied by country, and ranged from 0%
in Austria and Latvia to 20% in Russia and 35% in Romania. CPT
was active in vitro against SA, regardless of geographic origin, with
MIC90 values of 0.25 or 0.5mg/L for each country. CPT was active
against both methicillin-susceptible SA and MRSA (MIC90 s of 0.25
and 1mg/L, respectively). All SP and other b-haemolytic streptococci
(BHS) were inhibited by CPT at 0.015mg/L. CPT was also active
against Enterococcus faecalis and Escherichia coli with MIC90 s of
1 and 0.5mg/L, respectively. CPT was less active against Klebsiella
pneumoniae (MIC90, >16mg/L), with 11% of isolates resistant to
ceftazidime (CAZ).
Conclusions: A diverse collection of skin pathogens was collected
from European subjects during CANVAS 1 and 2. While MRSA rates
varied by country, CPT retained in vitro activity against all SA isolates
regardless of geographic origin. CPT was also active against BHS and
most CAZ-susceptible Gram-negative enteric bacilli. CPT exhibits potent
in vitro activity against isolates from subjects with cSSSI.
P1623 In vitro susceptibility proﬁles of teicoplanin, vancomycin,
linezolid and daptomycin among coagulase-negative
staphylococci in oncology patients with bacteraemia
C. Gregory °, U. Riley (London, UK)
Objectives: To determine the in vitro susceptibility proﬁles of
teicoplanin, vancomycin, linezolid and daptomycin among coagulase-
negative staphylococci (CNS) isolated from bacteraemic patients in a
specialist oncology hospital, and whether any signiﬁcant change in
minimum inhibitory concentration (MIC) over the study period had
occurred.
Methodology: 302 isolates of clinically signiﬁcant CNS from bacter-
aemic patients collected between the years 2001 and 2007 were examined
retrospectively and the MIC to teicoplanin, vancomycin, linezolid and
daptomycin determined by Etest methodology. Results were expressed as
geometric mean MICs and frequency distributions according to species,
source of infection and clinical unit. One-way analysis of variance was
used to determine whether any signiﬁcant change in the mean MIC had
occurred over the study period.
Results: The overall prevalence of decreased susceptibility to teicoplanin
was considered low, when compared to similar studies, at 5.3%; however,
there was a peak in 2006 at 19.1%. No decreased susceptibility to
vancomycin, linezolid or daptomycin was detected. Using one-way
analysis of variance, a signiﬁcant increasing linear trend was detected
in teicoplanin MICs over time (p< 0.05); conversely, vancomycin and
linezolid MICs decreased linearly (p< 0.05). No linear trend was
detected in daptomycin MICs. The percentage of isolates with a
teicoplanin MIC of greater than 2mg/L increased between 2001 and
2007, with nearly 50% of isolates having an MIC of greater than
2mg/L in 2006. Decreased susceptibility to teicoplanin was nearly three
times more prevalent in isolates of S. haemolyticus (16%) than in
S. epidermidis (5.5%); all other species were fully susceptible. Isolates
attributed to Hickman line-related bacteraemia had a higher rate of
decreased susceptibility than isolates believed to be attributed to febrile
neutropaenia (8.1% compared to 3.4%). Although cases of bacteraemia
caused by CNS were most common in patients admitted to the paediatric
unit (40.7%), patients admitted to the leukaemia unit had a higher rate of
bacteraemia with isolates showing decreased susceptibility to teicoplanin
(10.8% compared to 4.1% in paediatrics).
Conclusion: The activity of teicoplanin against CNS has decreased over
the last decade, and the use of an alternative antimicrobial may be
warranted in this patient population.
P1624 In vitro activity of daptomycin and other antimicrobial
agents against Staphylococcus coagulase-negative isolated
from catheter-related bloodstream infections in intensive
care unit patients
C. Seral, M.J. Gude´, A.K. Pereira, S. Algarate, E. Dura´n, S. Salvo,
P. Luque, C. Rubio, F.J. Castillo ° (Zaragoza, ES)
Objectives: The present study was designed to compare the in
vitro activity of daptomycin and other comparator antimicrobial
agents against Staphylococcus coagulase-negative (CoNS) isolated from
catheter related-bloodstream infections (BSI) in ICU-patients.
Methods: In vitro daptomycin activity was tested by E-test method
against 64 CoNS clinical strains (S. epidermidis (n = 49, 76.56%),
S. hominis (n = 11, 17.18%), S. haemolyticus (n = 2, 3.12%), S. capitis
(n = 1, 1.56%), S. warneri (n = 1, 1.56%) collected during 2008 from 54
patients and isolated from catheter-related infections (33 from blood and
31 from the catheter). MICs were also determined for 5 comparison drugs
by E-test: oxazillin, linezolid, tigecycline, vancomycin and teicoplanin
and interpreted according to CLSI M100-S18 guidelines.
Results: The prevalence of methicillin resistance was (79.68%).
Resistance to aminoglycosides (gentamycin), macrolides and quinolones
was strongly associated with methicillin resistance (74.50%, 54.90% and
76.47% of resistance, respectively). 4.68% CoNS were non-susceptible
to teicoplanin and 17.18% were non-susceptible to linezolid, but there
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was no-vancomycin non-susceptibility found. The newer antibiotics,
daptomycin and tigecycline, had excellent activity against CoNS.
The rank order of intrinsic activity (MIC90, mg/l) was daptomycin (1) =
tigecycline (1) < vancomycin (2) < teicoplanin (4) < linezolid (32).
The most active drugs on the basis of MICs were daptomycin
and tigecycline, showing MIC50 and MIC90 values of 0.25/1 and
0.125/1mg/l and a MIC range, 0.019 to 1.5 and 0.032 to 3mg/l,
respectively. Vancomycin, teicoplanin and linezolid showed a MIC50
and MIC90 values of 1.5/2, 1.5/4 and 0.5/32mg/l and a MIC range,
0.19 to 3, 0.125 to 24 and 0.019 to >256mg/l, respectively.
Conclusion: Daptomycin showed an excellent in vitro activity against
CoNS clinical strains isolated from catheter related-BSI, irrespective
of their resistance to methicillin, aminoglycosides, macrolides and
quinolones, making it a useful addition to the therapeutic armamentum
for the treatment of Gram-positive catheter related-BSI.
Susceptibility testing of new compounds, as daptomycin and tigecycline,
is required to establish those settings where these compounds offer real
advantages over established antibiotics as glycopeptides.
P1625 Daptomycin susceptibility of Gram-positive pathogens
collected from 61 centres in 9 European countries in 2007
I. Morrissey ° on behalf of the Dutch Rapid MRSA Diagnostics Study
Group
Objectives: Daptomycin (DAP) has been shown to be highly active
against contemporary Gram-positive bacteria (GPB) circulating in
several European countries (Daptomycin Susceptibility of Contemporary
Gram-positive pathogens circulating in Europe between 2004 and 2007.
Morrissey et al. Abstract submitted to ECCMID 2009). The objective
of this study was to determine the DAP susceptibility of selected Gram
positive pathogens circulating in 61 centres in 9 additional European
countries.
Methods: 2,305 GPB: Staphylococcus aureus (SA), coagulase-negative
staphylococci (CNS), Enterococcus faecalis & E. faecium, b-haemolytic
streptococci (BHS), ‘viridans’ streptococci (VS) and Corynebacterium
spp. (COR) were collected from the Czech Republic, Denmark, Greece,
Hungary, Norway, Poland, Russia, the Slovak Republic and Turkey during
2007. CLSI broth microdilution MIC was determined for DAP and
selected comparators. EUCAST and/or CLSI breakpoints were used
where available.
Results: All SA, 99.8% of CNS, 99.8% of BHS and all COR were
inhibited by 1mg/L DAP and 99.8% of enterococci were inhibited by
4mg/L DAP. VS were slightly less susceptible to DAP (90.5%) using
the break point of 1mg/L. Most of the isolates that were non-susceptible
to DAP had a DAP MIC generally only one dilution above the break
point for susceptibility. Linezolid, vancomycin and tigecylcine were also
very active with 99.8%, 99.5% and 95.4% of isolates being susceptible
to these agents. DAP susceptibility of isolates collected in the 9 countries
of this study were similar to that seen in other countries (1).
Conclusion: DAP was very active against contemporary GPB in the
9 European countries studied and susceptibility in these countries was
similar to that seen in other European countries. DAP remains an
excellent alternative therapeutic option for the treatment of infections
caused by GBP.
P1626 Daptomycin susceptibility of contemporary Gram-positive
pathogens circulating in Europe between 2004 and 2007
I. Morrissey ° on behalf of the European Daptomycin Study Group
Objectives: Daptomycin (DAP) is a novel cyclic lipopeptide antibiotic
active against Gram-positive bacteria (GPB) and has been available for
use in Europe since early 2006 for the treatment of Gram-positive
infections. Monitoring susceptibility of pathogens to new agents is
necessary to predict or detect possible development of resistance that
could ultimately undermine its utility. The objective of this study
was to compare the susceptibility of selected Gram positive pathogens
circulating in 12 European countries in 2004−5 with that of isolates
circulating in the same centres in 2007.
Methods: In late 2004 and early 2005, 2867 GPB [Staphylococcus
aureus (SA), coagulase-negative staphylococci (CNS), Enterococcus
faecalis & E. faecium, b-haemolytic streptococci, ‘viridans’ streptococci
(VS) and Corynebacterium spp. (COR)] were collected from Austria,
Belgium, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain,
Sweden, Switzerland and UK. In 2007, 2973 GPB were collected
from the same centres. CLSI broth microdilution MIC was determined
for DAP, vancomycin (VAN), linezolid (LZD) and other comparators.
EUCAST and/or CLSI breakpoints were used where available.
Results: DAP was highly active with 99.7% of the 5,840 isolates col-
lected being susceptible. Activity against staphylococci and enterococci
was unaffected by their susceptibility to methicillin and vancomycin
respectively. Susceptibility of isolates collected during 2007 was very
similar to that of isolates collected during 2004−5. Few (0.3%) of isolates
were non-susceptible to DAP and for most of these, the DAP MIC was
only one dilution above the break point for susceptibility. VAN and LZD
were also highly active with >99% of isolates being susceptible. LZD-
resistant enterococci increased from 0.2% in 2004−5 to 4.5% in 2007. No
differences in VAN susceptibility were seen between the two collection
periods.
Conclusion: DAP, VAN and LZD were very active against contemporary
GPB in Europe. There was no evidence for an increase in DAP or VAN
NS in currently circulating GPB but LZD resistant enterococci were more
prevalent in 2007 than in 2004−5. DAP remains an excellent alternative
therapeutic option for the treatment of infections caused by GPB.
P1627 In vitro activity of daptomycin combined with other
antimicrobial agents against Gram-positive cocci
B. Ko¨rber-Irrgang °, M. Kresken (Rheinbach, DE)
Objectives: Daptomycin (DAP), a cyclic lipopeptide, exerts rapid
bactericidal activity against clinically important Gram-positive bacteria
including multidrug resistant organisms such as methicillin-resistant
Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci
(VRE). Since DAP may be used in combination with other antibiotics,
we evaluated the in vitro activities of DAP in combination with 14 other
drugs against a panel of S. aureus (SA) and enterococcal isolates.
Methods: Thirty strains including VRE, MRSA, vancomycin-
intermediate SA and daptomycin-resistant isolates were studied. Synergy
testing was performed by using the checkerboard broth microdilution
method. DAP in combination with VAN, GEN, fosfomycin (FOS),
piperacillin-tazobactam (P/T), amikacin (AMK), rifampin (RIF), cef-
tazidime (CAZ), ceftriaxone (CRO), meropenem (MEM), imipenem
(IMP), ciproﬂoxacin (CIP), moxiﬂoxacin (MOX), doxycycline (DOX),
or clindamycin (CLI) were tested against 10 SA strains (in total 140
drug combination tests), while DAP in combination with VAN, GEN,
AMK, RIF, or ampicillin (AMP) was tested against 10 strains each of
Enterococcus faecalis (EFS) and E. faecium (EFM) isolates (in total
50 drug combination tests with each species). The fractional inhibitory
concentration indices (FICIs) were calculated to interpret the results.
Synergism was deﬁned as FICI 0.5, indifference as FICI >0.5 to 4,
and antagonism as FICI> 4.
Results: Of 140 drug combination tests performed with the 10 SA
strains, 125 showed no signiﬁcant effect. In contrast, synergism was
observed for 6, 3, 4, and 2 strains with CAZ, CRO, P/T and IMP,
respectively. Likewise, the vast majority of drug combination tests
performed with the 10 EFS strains revealed indifferent effects. However,
DAP plus RIF was synergistic against one strain. Of the 50 drug
combination tests performed with the 10 EFM, 31 showed no signiﬁcant
effect, while synergy was observed for 7, 6, 3, and 2 strains with RIF,
AMP, GEN, and VAN, and for one strain with AMK.
Conclusion: Generally, DAP combinations showed no signiﬁcant
synergistic effects, however with b-lactams (in particular CAZ) there may
be a synergistic effect against some SA strains, while DAP combined
with rifampin or ampicillin may be useful in the treatment of EFM
infections.
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P1628 Royal jelly’s effect on glucosyltransferase expression in
Streptococcus mutans
A. Shoae Hassani °, K. Hamdi (Fars, Tehran, IR)
Objectives: The bulk of dental plaque is composed of bacterial derived
extracellular polysaccharide known as glucan, which is synthesized
by streptococcal glucosyltransferase (Gtf) enzymes. The objective of
this study was to evaluate the speciﬁc efﬁcacy of Royal Jelly Extract
(RJE) on Glucosyltransferase (the bioﬁlm initiation involved enzyme
in Streptococcus mutans) that is responsible for dental caries and
bacteraemias following dental manipulations. Royal Jelly so called
because it is the exclusive food of the Queen bees, the creamy product
secreted by young nurse worker bees (Apis mellifera) to feed the queen
and queen larvae.
Methods: Royal jelly was supplied by a traditional Bee keeper in
Lahijan, a city situated in the south coast of Caspian Sea, north of
Persia. The sample was obtained in spring (April) and was transferred
to the Science and Research campus of IAU in Tehran, in the ice
ﬂask. Ether soluble and non soluble fractions of the Royal jelly
were extracted by means of Clevenger extractor. GC analyses were
performed with a Shimadzu 17A gas chromatograph (Shimadzu, Japan)
equipped with a ﬂame ionisation detector and a 60m× 0.25mm
(I.D.) DB-WAX (J&W Scientiﬁc, Folsom, CA) fused-silica capillary
column. Minimum inhibitory concentration (MIC) of the RJE was
assessed by broth dilution method. Examination of the cell adherence
(Bioﬁlm inhibitory concentration) was calculated by colony counts
from surface scratching of glass slides that were located in the media
cultures. Glucosyltransferase expression was detected on 15% SDS
poly acrylamide gel electrophoresis and was conﬁrmed by western blot
analysis. The ANOVA test (p 0.05) was used in this study as the
statistical method.
Results: Concentration of 1mg ml−1 of RJE was bioﬁlm inhibitor and it
was repressed the production of glucosyltransferase completely. Activity
of 6mg ml−1 of RJE was bacteriostatic and 30mg ml−1 of RJE was
bactericidal for S. mutans (p 0.05).
Conclusion: The results of the assays suggest that RJE was able to
block the major enzyme that contributes to S. mutans bioﬁlm formation
in low concentrations in vitro. The growth of S. mutans was prevented
completely in higher concentrations of RJE.
P1629 Antimicrobial resistance of Staphylococcus aureus in a
university hospital, Setif, Algeria, from 2002–2006
F. Sahli °, N. Radji, A. Touabti (Se´tif, DZ)
Objectives: to assess the antimicrobials resistance (R) of Staphylococcus
aureus (SA) in the university hospital of Setif, Algeria from 2002–2006
among inpatients (IN) and outpatients (OUT).
Methods: 1342 SA strains isolated between 2002 and 2006 were
studied for their susceptibility to oxacillin (OXa), gentamicin (GEN),
kanamicin (KA), amikacine (AK), erythromycin (E), pristinamicin (PRI),
oﬂoxacin (OFX), fucidic acid (FA), fosfomicin (FO), rifampicin (RIF),
and vancomycin (VA) according to CLSI guidelines.
Results: OXA R was observed for 29.7% among IN and 25.9% among
OUT. For the other antimicrobials, the higher rates of resistance were
mentioned for KA and FA: 42.5% for IN, 35.7% for OUT and 38.7%
for IN, 40.3% for OUT respectively. 7.3% and 4.2% of IN and OUT
strains respectively were resistant to OFX. None strain was resistant to
VA. Wounds and skin isolates were resistant in 30.1% to OXA while
bacteraemic strains were resistant in 20.2% to the same antimicrobial.
Conclusion: IN SA and OUT SA strains had nearly the same OXA R
rates. The OXA R strains had the higher resistance rates to KA and FA.
The higher resistance rates were observed in wounds and skin isolates.
P1630 Staphylococcus aureus from blood stream infections
B. Catry, E. Hendrickx °, R. Preal, R. Mertens (Brussels, BE)
Objectives: In blood stream infections mortality and treatment costs
in hospitals can considerably increase when antimicrobial resistance is
present and inappropriate empiric antimicrobial therapy is administered.
This study gives an overview of the susceptibility results of Staphy-
lococcus aureus isolated from septicaemias as reported by diagnostic
laboratories in Belgium.
Methods: Laboratory results of 397 cases of Staphylococcus aureus
blood stream infections (BSI) were obtained from 13 voluntary
diagnostic laboratories in Belgium during the year 2005 in collaboration
with the intermutualistic agency (IMA) coordinating the national health
insurance funds. Susceptibility proﬁles were predominantly based on
the Kirby Bauer disk diffusion test according to CLSI guidelines
and interpretation was often recorded by semi-automated systems.
All participating labs were certiﬁed by an external quality control
organisation.
Results: Only the ﬁrst isolate per patient during the observation period
was included (236 men, 161 women) and the mean age of the patients
was 67.5 years (range 0−96). The mean age of patients with methicillin
resistant S. aureus (MRSA) strains (n = 143) was 70.4 compared to 66.1
when the isolates were susceptible for methicillin (n = 248). The gender
distribution for MRSA was 83 men versus 60 women. Susceptibility
proﬁles of the S. aureus isolates are presented in the table (resistance
percentages include intermediary results).
Antimicrobial compound %R n tested (% tested of total S. aureus)
Penicillin 91.57 344 (86.65)
Ampicillin/amoxicillin 91.98 262 (65.99)
Amoxicillin-clavulanic acid 28.85 104 (26.20)
Cefalothin (group) 35.71 70 (17.63)
Cefazolin 25.42 59 (14.86)
Cefotaxim (ceftriaxone) 34.29 70 (17.63)
Cefoxitin 32.43 111 (27.96)
Cefuroxime 37.14 70 (17.63)
Oxacillin 37.08 391 (98.49)
Imipenem 27.36 106 (26.70)
Erythromycin 38.66 357 (89.92)
Azithromycin 30.00 70 (17.63)
Clarithromycin 22.73 22 (5.54)
Clindamycin 28.97 390 (98.24)
Tetracycline 15.00 160 (40.30)
Doxycycline 2.19 183 (46.10)
Minocycline 0.00 52 (13.10)
Trimethroprim-sulphonamides 1.23 324 (81.61)
Norﬂoxacin 33.91 115 (28.97)
Ciproﬂoxacin 47.11 225 (56.68)
Oﬂoxacin 27.55 98 (24.69)
Levoﬂoxacin 34.97 163 (41.06)
Moxiﬂoxacin 36.18 152 (38.29)
Gentamicin 1.33 376 (94.71)
Kanamycin 13.95 43 (10.83)
Tobramycin 12.50 144 (36.27)
Nitrofurantoin 16.91 136 (34.26)
Fosfomycin 9.57 94 (23.68)
Fusidic acid 7.42 283 (71.28)
Mupirocin 1.77 113 (28.46)
Novobiocin 0.00 39 (9.82)
Rifampicin 2.10 238 (59.95)
Teicoplanin 0.00 231 (58.19)
Vancomycin 0.00 379 (95.47)
Quinupristin-Dalfopristin 2.13 94 (23.68)
Linezolid 0.00 225 (56.68)
Conclusion: S. aureus isolates from blood stream infections were
highly susceptible for different compounds tested, whereas resistance
was abundantly present (>25%) for b-lactams (including methicillin),
ﬂuoroquinolones, macrolides, and lincosamides. These data can guide
empiric antimicrobial use in septicaemic patients.
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P1631 Comparison of the in vitro activity of linezolid with ery-
thromycin against coagulase-negative staphylococci isolates
A. Poiata, C. Tuchilus, L.S. Iancu °, I. Badicut, D. Buiuc (Iasi, RO)
Linezolid belong to a new class of synthetic antimicrobial agents called
the oxazolidinones.
The spectrum of activity embraces Gram-positive organisms, including
methicillin resistant staphylococci, vancomycin-resistant enterococci and
penicillin-resistant pneumococci.
The objective of the study was to determine the in vitro activity of
linezolid against coagulase-negative staphylococci (CNS) isolates and
compared it to that of erythromycin.
Methods: A total of 355 CNS strains were examined. All strains
were collected from healthy individuals (nasal swabs and ﬁnger-replica
platings) during 2007 year. The minimum inhibitory concentrations
(MICs) for linezolid and erythromycin were performed by agar dilution
method according to the National Committee for Clinical Laboratory
Standards (NCCLS) recommendations. Resistance rates are reported
using the NCCLS breakpoints for the fully susceptible category;
moderately susceptible isolates are classiﬁed as resistant. Also the MIC
of oxacillin was determined.
Results: Linezolid has the best activity when compared with ery-
thromycin. Of the 355 strains reported only 0.85% were resistant
to linezolid. The MICs for linezolid were consistently low 1mg/l
for majority of strains (51.2%). The rate of erythromycin-sensitive
strains resistant to linezolid was signiﬁcantly lower. Also the associated-
resistance trend is indicated by elevated MICs for erythromycin and
oxacillin-resistant CNS strains. Approximately 55% of the oxacillin-
resistant CNS were resistant to erythromycin. The MIC of erythromycin
against CNS strains ranges from 0.06mg/l to 8mg/l and the MIC 50
were two-fold higher than breakpoint for susceptibility.
Conclusion: Linezolid has excellent activity against CNS strains and
may be useful in the treatment of staphylococci infections. The
absence of associated-resistance with linezolid was clearly evident.
With regard to oxacillin-resistant CNS, linezolid resistance was absent
among these strains. The percentage of erythromycin resistance was
15.2% while oxacillin-resistant strains of CNS tend to be resistant
to erythromycin, majority of oxacillin-susceptible strains are also
susceptible to erythromycin.
P1632 Reversal of oxacillin resistance in MRSA with phenothiazines
M. Rahbar °, H. Mehragan, S. Hadji-Nezhad (Tehran, IR)
Background and Objectives: The antibiotic resistance is now common
place throughout the globe. One of the most highly problematic antibiotic
resistance is that caused by methicillin resistant Staphylococcus aureus
(MRSA) The aim of this study was to evaluate psychotropic therapeutics,
especially phenothiazines antimicrobial activity and reversal of antimi-
crobial activity.
Methods: This study investigated the anti-MRSA activity of phenoth-
iazines presence in Iranian market and the the interaction of theses
compounds with oxacillin. The minimum inhibitory concentration (MIC)
of each of phenothiazines and as well as oxacillin against MRSA isolates
was determined by the agar dilution method as recommended CLSI.
The possible synergy between test substrate and the antibiotic was also
investigated by this method employing combination of phenothizines at
their 1/2 MIC50 and oxacillin in the range of concentration 1/2MIC.
Degree of synergy is yet to be established by the checkerboard technique.
S. aureus ATCC 33591 (Mec A Positive) and S. aureus ATCC 29213
(MecA Negative) were used as standard strains.
Results: All MRSA isolates were inhibited by test phenotiazines at
MIC 50 ranging from 12–256mg/ml with order of thioridizine >
ﬂuphenazine > chlorpromazine > triﬂuoprazine > prometazine. Chlor-
promazine, thioridazine, promethazine and perphenazine decreasing
oxacillin MIC50 from 384mg/ml to 24mg/ml showed a signiﬁcant
synergy with these antibiotics. Triﬂuperazine and ﬂuphenazine however
had variable synergistic effect with oxacillin against 10 clinical MRSA
isolates. The study is still under way to determine degree of synergy for
drugs and antibiotics.
Conclusion: This study revealed the there is a signiﬁcant synergism
between oxacillin and phenothiazines against MRSA.
P1633 Comparative susceptibility of European Gram-positive
pathogens to ceftobiprole, vancomycin, teicoplanin and
linezolid
F.J. Schmitz, J. Perry, R. Zbinden, A. Quintana, J. Laeuffer,
M.L. Cassettari, I. Morrissey ° (Minden, DE; Newcastle-upon-Tyne,
UK; Zu¨rich, CH; Raritan, US; Baar, CH; Fordham, UK)
Objectives: Ceftobiprole (BPR) is a novel cephalosporin with
bactericidal activity against both Gram-positive and Gram-negative
bacteria, including activity against methicillin resistant S. aureus
(MRSA). The Ceftobiprole Local Antibiotic Susceptibility Surveillance
Study (CLASS) compares the susceptibility of common pathogens
causing serious infections in hospitalised patients. Here we report the
comparative activity of BPR, vancomycin (VAN), teicoplanin (TEI) and
linezolid (LIN) to Gram-positive pathogens (GPP).
Methods: 1,688 GPPs (including 281 MRSA, 302 MSSA, 250
methicillin-resistant CoNS [MRC], 174 methicillin-susceptible CoNS
[MSC], 198 Enterococcus spp. [ES], 103 Viridans Group streptococci
[VGS], 38 PRSP and 338 b-haemolytic streptrococci [BHS]) were
collected from 32 centres in Austria, Germany, Ireland, Poland,
Switzerland and UK during 2008. MICs were determined at each centre
using Etest methodology.
Results: Against all isolates combined, BPR had the lowest MIC50 at
0.25mg/L compared with 1mg/L for both TEI and LIN, and 2mg/L for
VAN. BPR and LIN were equal in activity in terms of MIC90 (2mg/L),
both being lower than VAN and TEI (4mg/L). Against MRSA, BPR had
similar activity to VAN, TEI and LIN (all MIC90 of 2mg/L). However,
against MSSA, BPR MIC90 was 0.5mg/L compared with 2mg/L for
the other three agents. Against CoNS, BPR was slightly less active than
LIN against MRC (MIC90 = 2 and 1mg/L respectively) but was similar
against MSC (MIC90 = 1 for both agents). Both VAN and TEI were less
active than both BPR and LIN against both groups of CoNS. Against
ES, BPR and TEI had an MIC50 of 0.25mg/L compared with 2mg/L
for both VAN and LIN but the MIC90 against ES for TEI was 1mg/L
compared with 2mg/L for LIN and 4mg/L for both BPR and VAN. BPR
had the lowest MIC90 of the four agents against both VGS and BHS
being at least 4 fold more active than VAN and LIN, and twice as active
as TEI. Against PRSP, BPR had similar activity to TEI, both of which
were more active than VAN and LIN.
Conclusion: BPR was highly active against a range of GPPs. Of note
was that all staphylococci, regardless of their susceptibility to methicillin,
were susceptible to CBP.
P1634 Activity proﬁle of empiric respiratory tract infection agents
against Streptococcus pneumoniae in Europe based on
patient population
N. Brown, D. Draghi °, C. Thornsberry, C. Pillar, D. Sahm (Chantilly,
US)
Objective: The activity of antibiotics can vary based on patient location,
as hospitalised patients are more likely to be infected by resistant (R)
or multi-drug resistant (MDR) bacteria. For respiratory tract infection
(RTI), patient location and disease severity are important criteria during
the selection of empiric therapy. This study proﬁles empiric RTI agents
against S. pneumoniae (SP) collected in Europe (EU) to determine
R trends across varied patient populations.
Methods: During the GLOBAL 2007 surveillance program, 257
intensive-care unit (ICU), 684 inpatient (IP), 168 long-term care (LTC),
and 623 outpatient (OP) isolates of SP were collected from 6 countries
across EU, and were centrally tested by broth microdilution (CLSI M7-
A7). Results were interpreted according to CLSI M100-S18 excluding
ciproﬂoxacin (CIP) where FDA breakpoints were applied. MDR was
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deﬁned as R to 2 of the following: penicillin (PEN), cefuroxime
(CFX), azithromycin (AZI), trimethoprim-sulfamethoxazole (SXT), and
tetracycline.
Results: PEN-R and MDR rates among SP varied by patient location
(PL): PEN-R= 7% LTC and OP, 12% IP, and 21% ICU; MDR = 22%
LTC, 25% OP, 30% IP, and 40% ICU. Levoﬂoxacin (LVX) MIC90 s
remained at 1mg/L against SP, regardless of PL and R phenotypes
with overall susceptibility (S) rates of >98% across PL. Similar trends
were noted for CIP, though isolates were less S to CIP (91%S) than
LVX (99%S) overall. MIC90 s of the b-lactams (PEN, CFX, ceftriaxone
[CRO], and amoxicillin-clavulanate [AMC]) were 2−4 fold higher
against IP and ICU populations relative to OP and LTC. For the
b-lactams, AZI, and SXT S was lowest for isolates from the ICU and IP
populations (PEN: ICU 61%, IP 68%, LTC 73%, OP 68%; CFX: ICU
67%, IP 82%, LTC 91%, OP 88%; AZI: ICU 61%, IP 68%, LTC 73%,
OP 68%; SXT: ICU 69%, IP 73%, LTC 82%, OP 77%).
Conclusions: The prevalence of MDR and PEN-R isolates was highest
in EU among the ICU and IP populations. A trend towards decreased S
when moving from OP to IP and ICU populations was apparent for all
evaluated agents excluding ﬂuoroquinolones (FQ). Regardless of PL, SP
isolates overall remained >97%S to LVX and LVX remained the most
potent agent tested against SP. Variation in S to b-lactams and macrolides
and the consistent activity of FQ against SP from the OP to IP and ICU
settings are factors which should be strongly considered when selecting
an empiric agent for the treatment of respiratory infections.
P1635 Activity of zaboﬂoxacin, a new ﬂuoroquinolone, against
common respiratory pathogens, compared with ﬁve other
ﬂuoroquinolones
Y.S. Kim, S.J. Park, C.H. Lim, J.M. Ryu, J. Rock, D.R. Choi ° (Seoul,
Anyang, KR; San Diego, US)
Objectives: Zaboﬂoxacin (DW-224a, PB-101), a new ﬂuoroquinolone,
has broad in vitro antibacterial activity against Gram-negative and Gram-
positive organisms, including levoﬂoxacin (Levo) resistant S. pneumo-
niae (QRSP). This study compared the in vitro activity of Zabo and
5 other quinolone antibiotics against clinical isolates of H. inﬂuenzae
(H.ﬂu), and S. pneumoniae (S.pn), including levoﬂoxacin resistant
strains.
Methods: MICs (CLSI methodology) were determined by agar dilution
method against clinical isolates of H.ﬂu (233) and S.pn (264) including
24 levoﬂoxacin resistant strains collected from 1997 to 2008 in South
Korea.
Results: The MIC50/MIC90 of Zabo against H.ﬂu are similar those of
other quinolones 0.016/0.03 ug/ml. Against S.pn, the MIC90 of Zabo
was 0.03 ug/ml and 0.5 ug/ml against the Levo susceptible and resistant
strains, respectively. MIC50 and MIC90 values for Zabo and comparators
are presented in the table.
Quinolone Levoﬂoxacin susceptible S.pn
(240)
Levoﬂoxacin resistant S.pn
(24)
MIC range MIC50 MIC90 MIC range MIC50 MIC90
Zaboﬂoxacin 0.08–1 0.015 0.03 0.03–0.5 0.25 0.5
Moxiﬂoxacin 0.06–1 0.25 0.25 1−>8 4 8
Levoﬂoxacin 0.25–4 1 1 8−>16 16 16
Gemiﬂoxacin 0.015–0.5 0.03 0.06 0.06–2 1 1
Gatiﬂoxacin 0.125–4 0.5 0.5 2−>8 8 8
Ciproﬂoxacin 0.25–16 2 4 8−>32 >32 >32
Conclusion: Zabo was the most active of all tested quinolones against
clinical isolates of S. pn including levoﬂoxacin resistant.
P1636 Report of linezolid resistance from the Zyvox® Annual
Appraisal of Potency and Spectrum Program (Europe,
Latin America, Asia Paciﬁc)
J. Ross °, P. Hogan, D. Sheehan, R. Jones (North Liberty, New York, US)
Objectives: To monitor Linezolid (LZD)-resistance (R) strains, the
Annual Appraisal of Potency and Spectrum (ZAAPS) Program (year 6;
2007) was initiated in various geographic areas of the world. LZD, the
ﬁrst oxazolidinone agent clinically applied, has become an important
therapeutic addition for infections caused by antimicrobial-R Gram-
positive (GP) pathogens. LZD-R has been observed particularly in
enterococci (ENT) and recently among coagulase-negative staphylococci
(CoNS), but occurrence rates are extremely low for indicated S. aureus
(SA) and streptococci.
Methods: 5,591 GP strains were collected from 64 sites in 23 countries
in 2007. Strains were received from the following organism groups: SA
(3000), CoNS (716), ENT (906), S. pneumoniae (SPN; 452), viridans
group (VGS; 155) and b-haemolytic streptococci (BHS; 362). At least
200 isolates from each country (expect China [800] and United Kingdom
[400]) were requested to be sent to a reference laboratory for CLSI broth
microdilution susceptibility (S) testing.
Results: The ZAAPS reports from 2006 and 2007 cited LZD-R
S. epidermidis from the same hospital in Rome (Table).
Table: Linezolid-R isolates found in the 2007 ZAAPS Program
Species City/Country LZD MIC
(mg/L)
R-mechanism
(23S mutation)
S. aureus Dublin/Ireland 8 G2576T
S. epidermidisa Rome/Italy 8 G2576T
S. epidermidisa Rome/Italy 8 G2576T
E. faecalis Brasilia/Brazil >8 G2576T
aClonal.
Further examination of other S. epidermidis isolates from the same
hospital showed ﬁve other strains with LZD MIC values of 4 or 8mg/L.
MRSA rates ranged from 1.7% (Sweden) to 68.0% (Japan). Among
vancomycin resistant enterococci, Korea had the highest rate of 38.6%.
SPN had overall penicillin and erythromicin resistance rates of 20.1%
and 33.6%, respectively. All streptococci had LZD MIC values of
2mg/L. Overall LZD-R was 0.07% (0.12% in 2006). LZD-R rates
among organism groups were: SA (0.03%), CoNS (0.28%), and ENT
(0.11%).
Conclusions: LZD remained highly active against contemporary
pathogens from indicated organism groups with an overall S rate of
99.83%. As LZD use continues to evolve, the need for close monitoring
of the LZD in vitro activity versus Gram-positive pathogens and for the
emergence of R is apparent.
P1637 A current look at the in vitro activity of oritavancin and
vancomycin against isolates of S. aureus from both Europe
and the US
D. Draghi °, C. Pillar, D. Sahm, G. Moeck, F. Arhin (Chantilly, US;
St. Laurent, CA)
Background: Reports have emerged regarding an upward shift in
vancomycin (VAN) MICs against S. aureus (SA) and the impact
of elevated VAN MICs on clinical outcome. Oritavancin (ORI), a
lipoglycopeptide, is currently under development for the treatment of
Gram-positive infections. It is important to understand ORI activity as
it relates to SA isolates with elevated VAN MICs (should these isolates
become more prevalent). This study evaluates the trend in VAN MICs
observed among recent surveillance (SURV) isolates (2005–2008) and
the activity of ORI activity against SURV isolates with deﬁned VAN
MICs (0.25/0.5/1/2mg/L).
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Methods: SA clinical isolates collected in 2005–2008 (n = 8,186) from
geographically diverse SURV studies in the US and Europe (EU) were
centrally tested by broth microdilution (CLSI; M7-A7) against ORI and
VAN in accordance with CLSI M100-S18.
Results: With the exception of an increasing trend in the amount
of isolates with VAN MICs of 1mg/L from 2005–2007 in the US,
no notable MIC creep for VAN was apparent among SURV isolates,
with a consistent mode, MIC50 and MIC90 of 1mg/L. Interestingly,
SURV isolates from EU and the US in 2008 had more isolates with
VAN MICs of 0.5mg/L than in prior years. Similarly, a lower overall
ORI MIC50/MIC90 (mg/L) in 2007 and 2008 was observed (0.03/0.06
US; 0.03/0.12 EU) relative to 2005 and 2006 (0.06/0.12 US; 0.06/0.25
EU). Against SA with VAN MICs of 0.5 and 1mg/L, ORI maintained
potent activity with MIC50 s from 0.03–0.06mg/L and MIC90 s 0.06–
0.25mg/L among evaluated SURV isolates from 2005–2008. However,
ORI MIC50 s and MIC90 s against SA with VAN MICs of 2mg/L
(MIC50 s of 0.12–0.25mg/L; MIC90 s of 0.25mg/L) were slightly higher
relative to isolates with VAN MICs 1mg/L over this period.
Conclusions: Apart from a slight upward shift in VAN MICs apparent
with US isolates from 2005–2007, little evidence for VAN MIC creep
was evident with isolates from large scale SURV studies. In fact, VAN
MICs in 2008 tended to be slightly lower than those from 2005–2007.
Regardless, ORI MIC50 s and MIC90 s were consistent and lower than
VAN against SA with deﬁned VAN MICs of 0.5, 1, or 2mg/L, though
ORI MICs were slightly elevated against the small subpopulation of
isolates with VANMICs of 2mg/L. Future SURV is warranted to monitor
for shift in VAN MICs and its effect, if any, on the activity of ORI.
P1638 Update on daptomycin activity and spectrum when tested
against Gram-positive strains collected in European medical
centres (2007–2008)
R. Jones, G. Moet, M. Castanheira, H. Sader ° (North Liberty, US)
Objective: To evaluate the in vitro activity and spectrum of daptomycin
(DAP) tested against recent clinical isolates collected in European
hospitals. DAP is a cyclic lipopeptide approved by European Medicines
Agency (EMEA) for the treatment of complicated skin and skin structure
infections (cSSSI) and S. aureus (SA) endocarditis.
Methods: 10,430 consecutive strains were collected in 28 medical
centres located in 11 European countries, Turkey and Israel. The
following pathogens were evaluated: SA (27.4% oxacillin [OXA]-
resistant [R]); coagulase-negative staphylococci (CoNS; 76.3% OXA-R),
E. faecalis (EF; 1.2% vancomycin [VAN]-R), E. faecium (EFM; 25.6%
VAN-R), b-haemolytic Streptococcus spp. (BHS; 807), and viridans
group Streptococcus spp. (VGS; 274). The organisms were isolated
mainly from bloodstream infections (49%) and cSSSI (20%). The strains
were susceptibility (S) tested against DAP and numerous comparators
by CLSI broth microdilution methods in cation-adjusted Mueller-Hinton
broth supplemented to 50mg/L of calcium for DAP tests.
Results: DAP was highly active against SA and CoNS (MIC50/90,
0.25/0.5mg/L for both organisms) and its activity was not adversely
inﬂuenced by resistance to OXA (see Table).
Organism (no. tested) Cumulative % inhibited at daptomycin MIC
(mg/L) of:
%S
0.12 0.25 0.5 1 2 4
SA
OXA-S (4,047) 5.7 86.5 99.7 100.0 – – 100.0
OXA-R (1,531) 4.0 76.5 99.1 100.0 – – 100.0
CoNS (1,665) 10.2 65.3 96.0 99.9 100.0 – 99.9
EF (1,306) 0.5 3.2 37.3 92.2 99.9 100.0 100.0
EFM
VAN-S (533) 0.9 2.1 7.1 32.7 94.0 100.0 100.0
VAN-R (210) 0.0 1.4 4.3 42.9 96.2 100.0 100.0
BHS (807) 83.9 99.4 100.0 – – – 100.0
VGS (274) 31.4 65.7 92.3 100.0 – – 100.0
MRSA varied from 1.4 in Sweden to 55.9% in Greece and showed
high R rates to levoﬂoxacin (87.7) and clindamycin (34.0%). DAP
(MIC50/90, 0.25/0.5mg/L) and VAN (MIC50/90, 1/1mg/L) were active
against all MRSA (100.0% S), and linezolid (99.9% S) and TMP/SMX
(98.6% S) was also very active against this pathogen. All EF were
S to DAP (MIC50/90, 1/1mg/L). VAN-R EFM was observed in 10 of
12 countries evaluated and was highest in Ireland (58.7%) and Greece
(46.0%). Among VAN-R EFM isolates, only 80% were S to quinupristin/
dalfopristin and 43.3% showed high-level R to gentamicin. DAP was
highly active against BHS (MIC90, 0.25mg/L) as were most comparison
agents tested. DAP was also very active against VGS (MIC90, 0.5mg/L).
Conclusions: DAP showed signiﬁcant potency and broad-spectrum
activity against recent clinical isolates of Gram-positive organisms
isolated in European medical centres, including R subsets. All organisms
tested except for 2 CoNS were S to DAP and R to other compounds
did not adversely inﬂuence the DAP potency against staphylococci,
enterococci or streptococci.
P1639 Potent antimicrobial activity of daptomycin tested against
Staphylococcus aureus with vancomycin MIC of 2mg/L
isolated in United States and European hospitals (2006–2008)
H. Sader °, G. Moet, H. Becker, R. Jones (North Liberty, US)
Objective: To evaluate daptomycin activity (MIC and MBC) against
S. aureus strains with elevated (2mg/L) vancomycin (VAN) MIC
values. Daptomycin is a cyclic lipopeptide approved by European
Health Authorities for the treatment of complicated skin and soft tissue
infections (cSSTI) and S. aureus bacteraemia, including right sided
infective endocarditis.
Methods: A total of 410 S. aureus isolates with VAN MIC of 2mg/L
were collected from 50 United States (USA, 282) and European (EU,
128) hospitals in the 2006–2008. MIC was assessed by reference CLSI
broth microdilution method in cation-adjusted Mueller-Hinton broth,
additionally supplemented to 50mg/L of calcium for daptomycin testing.
VAN MBC and the presence of VAN heteroresistant population (hVISA)
were evaluated in a randomly selected subset of 31 isolates. MBC was
assessed by plating the entire volume of the broth from each well above
the MIC for each organism. The lowest concentration of antimicrobial
agent that killed 99.9% of the initial inoculum was deﬁned as the MBC
endpoint. hVISA was evaluated using the GRD Etest strip (AB Biodisk,
Solna Sweden) according to manufacturer’s instructions.
Results: Daptomycin MIC distributions are presented in the Table. All
EU strains were susceptible (S) to daptomycin and only 3.9% of strains
from US exhibited elevated daptomycin MIC results (>1mg/L). Overall,
>90% of isolates had daptomycin MIC of 0.5mg/L. Daptomycin
exhibited potent bactericidal activity with MBC values at the MIC
concentration (74.2%) or one dilution above (25.8%). In contrast, VAN
MBC was 32mg/L in 12.9% of strains and 25.8% of strains tested for
hVISA were positive.
Table. MRSA with VAN MICs at 2mg/L
Region (no of isolates) Cumulative % inhibited at daptomycin MIC (mg/L) of: MIC50 MIC90
0.25 0.5 1 2 4
Europe (128) 31.3 93.0 100.0 – – 0.5 0.5
United States (282) 29.4 89.4 96.1 98.9 100.0 0.5 1
Conclusions: S. aureus strains with VAN MIC of 2mg/L showed high
rates of hVISA and VAN tolerance. The vast majority of S. aureus with
VAN MIC of 2mg/L were susceptible to daptomycin. Daptomycin also
retained potent bactericidal activity against S. aureus with VAN MIC of
2mg/ml.
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P1640 Susceptibility trends for methicillin-resistant Staphylococcus
aureus and methicillin-susceptible Staphylococcus aureus
bloodstream isolates over a 2.5 year period
M.B. Perri °, C. Moore, S. Donabedian, N. Haque, A. Naqvi, M. Zervos
(Detroit, US)
Objectives: To access changes in vancomycin (V) and daptomycin (D)
minimum inhibitory concentration (MIC) and minimum bactericidal
concentration (MBC) for methicillin-resistant Staphylococcus aureus
(MRSA) and methicillin-susceptible Staphylococcus aureus (MSSA)
bloodstream isolates, including USA300 strains over a 2.5 year period.
Methods: We evaluated 360 MRSA (170 USA100, 146 USA300, 44
other) and 97 MSSA consecutive bloodstream isolates from patients in
urban Detroit from January 2006 to June 2008 to determine susceptibility
trends using susceptibility methods for MIC by manual microbroth
dilution and Etest (bioMerieux, Inc.) to V, D and susceptibility to
linezolid (L) by Etest. MBC was determined for V and D. Tolerance
for V and D was determined by a >16 fold difference of MBC/MIC.
Pulsed-Field Gel Electrophoresis (PFGE) was performed on the MRSA
to determine the USA strain type as described by CDC. Trends through
10 quarters were analyzed for each of the methods. The geometric mean
was determined for each quarter and analyzed over time.
Results: Statistical analysis was performed using Spearman’s correlation,
and signiﬁcant statistical increases or decreases are described in table 1.
Table 1
Strain (Range, MIC or MBC mg/ml, or MBC/MIC ratio) Method Correlation coefﬁcient,
P-value
MRSA (0.19–3) D Etest −0.307, p 0.001
MRSA (1−4) V Etest −0.178, p 0.001
MRSA (0.5–2) L Etest −0.382, p 0.001
MRSA (MBC range 0.25–64) MBC V −0.186, p 0.001
MRSA (MBC/MIC range 1–128) MBC/MIC ratio V −0.221, p 0.001
MSSA (0.25–1) Manual MIC V +0.250, p = 0.014
MSSA (0.12–1) D Etest −0.227, p = 0.026
MSSA (MBC range 0.25–64) MBC V +0.251, p = 0.013
MRSA USA100/USA 300 (0.19–2/0.25−2) D Etest −0.267, p 0.001 /
−0.412, p 0.001
MRSA USA100/USA 300 (1−4/1–2) V Etest −0.209, p = 0.006 /
−0.182, p = 0.028
MRSA USA100/USA 300 (0.75–2/0.5−2) L Etest −0.426, p 0.001 /
−0.311, p 0.001
MRSA USA100/USA 300 (MBC range 0.25–64/0.25–64) MBC V −0.262, p 0.001 /
−0.168, p = 0.042
MRSA USA100/USA 300 (MBC/MIC range 1–128/1–128) MBC/MIC ratio V −0.250, p = 0.001 /
−0.192, p = 0.020
For MRSA, and speciﬁcally both USA100 and USA300 strains, a
signiﬁcant decrease across time was detected in MIC’s for D, V and
L using Etests, as well as MBC’s and tolerance for V. A signiﬁcant
decrease with the MSSA was seen in the D Etest, while a signiﬁcant
increase was noted across time in the MIC using manual microbroth
and MBC for V. Over the 2.5 year study period, 23% of MRSA and
13% of MSSA were tolerant to V, while 0% of the strains exhibited
tolerance to D. There were no signiﬁcant changes in MIC’s of MRSA to
V (range 0.25−2) or D (range 0.12−2) over the study period by manual
microbroth.
Conclusion: Over a 2.5 year period in urban Detroit, we found a
signiﬁcant decrease in MIC’s, MBC’s and in vitro tolerance of MRSA
bloodstream isolates to vancomycin, linezolid and daptomycin, however,
a signiﬁcant increase was seen in the MIC’s and MBC’s to MSSA.
P1641 Antibiotic susceptibility patterns of Staphylococcus aureus
in north-eastern Romania and comparison of phenotypic
methods for detection of oxacillin resistance
O. Dorneanu °, T. Vremera, E. Miftode, E. Nastase, O. Filip,
C. Dorobat (Iasi, RO)
Objectives: 1. To assess the antibiotic susceptibility patterns of
methicillin-susceptible (MSSA) versus methicillin-resistant Staphylococ-
cus aureus (MRSA) isolated from systemic or localised infections in
North-East Romania. 2. To compare the accuracy of phenotypic methods
for detection of oxacillin resistance in S. aureus.
Methods: We have tested by disk diffusion method (CLSI 2008)
and with ATB Staph5 (bioMerieux, France) 668 S. aureus strains
isolated from blood culture, cerebrospinal ﬂuid, pus, sputum or urine
from patients hospitalised in the Infectious Diseases Hospital, Iasi,
Romania, between 1.01.2005–31.12.2008. Susceptibility to oxacillin was
assessed by 5 methods: oxacillin disks, cefoxitin disks, ATB Staph5
(bioMerieux, France), oxacillin E-test strips (AB Biodisk, Sweden) and
a penicillin-binding protein (PBP) 2a latex agglutination test (Slidex
MRSA, bioMerieux, France).
Results: Oxacillin resistance rate was 46.9%. 17.6% strains showed
oxacillin heteroresistance. More than one third (34.2%) of the tested
strains had oxacillin minimum inhibitory concentration (MIC) over
256mg/L and 37.1% had vancomycin MIC=2mg/L. For oxacillin,
MIC90 was over 256mg/L and MIC 50 was 8mg/L. For vancomycin,
MIC90 was 2mg/L and MIC50 1.5mg/L. 17.1% of all strains present
inducible resistance to clindamycin.
MRSA strains showed multiple resistance to antibiotics (84.7% to
erythromycin, 58.8% to tetracycline, 55.3% resistance to gentamycin,
36.4% to ﬂuoroquinolones, but only 8.2% to cotrimoxazol). MSSA have
low resistance rates to other antibiotics. All strains were susceptible to
vancomycin, quinupristin-dalfopristin and linezolid.
Slidex MRSA, disk diffusion testing with cefoxitin disks and ATB
Staph5 correlated very well with E-test results, considered gold standard
(efﬁcacy 100%, 99.4%, and 98.8%, respectively). Disk diffusion testing
with oxacillin disks is a good, but less reliable method (efﬁcacy 97%).
Conclusions: Resistance to antibiotics, especially to oxacillin represents
a problem in the management of S. aureus infections. Vancomycin,
linezolid and quinupristin-dalfopristin remain excellent alternatives for
the therapy of severe infections produced by MRSA strains. Slidex
MRSA, ATB Staph5 and cefoxitin disk diffusion are accurate methods
for the assessment of oxacillin resistance.
P1642 In vitro activity of daptomycin against staphylococcal and
streptococcal isolates from orthopaedic patients
S. Tsiplakou, V. Papaioannou °, A. Stylianakis, F. Zoumpouloglou,
D. Paraskevopoulou, A. Koutsoukou (Athens, GR)
Objectives: This study examines the activity of daptomycin and focuses
on multi-trauma patients, who usually require prolonged hospitalisation
and suffer mainly from complicated soft tissue infections. The aim of
the present study is to determine the in vitro efﬁcacy of daptomycin
against staphylococci and streptococci, including multi-resistant strains
isolated from patients with septicaemia, skin and soft tissue and implant-
associated infections, and to provide a preliminary evaluation of the
efﬁcacy of the drug for infections in orthopedic patients.
Methods: A total of 110 non-duplicate clinical isolates were selected,
including 35 methicillin-resistant Staphylococcus aureus (MRSA),
30 methicillin-susceptible S. aureus (MSSA), 30 methicillin-resistant
Staphylococcus epidermidis (MSSE), and 15 group A Streptococci
(S. pyogenes). MICs of penicillin, oxacillin, erythromycin, clindamycin,
gentamicin, fucidic acid, ciproﬂoxacin, moxiﬂoxacin, linezolid, te-
icoplanin, vancomycin, and sulfamethoxazole/trimethoprim were deter-
mined by the automated VITEK II system (Biomerieux, France), and
MICs of daptomycin were determined by the E-test method (AB Biodisk,
Solna, Sweden) according to CLSI guidelines. The S. aureus ATCC
29213 reference strain was used for quality control.
Results: All staphylococcal isolates were susceptible to daptomycin,
linezolid, teicoplanin and vancomycin. The MRSA and MRSE isolates
were multi-drug resistant, resistance phenotypes including resistance
to b-lactams, erythromycin, clindamycin, gentamicin, fucidic acid,
ciproﬂoxacin, and sulfamethoxazole/trimethoprim. MIC values of MRSA
and MRSE for daptomycin ranged from 0.19 to 1mg/L, the majority
of isolates showing MICs of 0.25 to 0.5mg/L. MIC values of MSSA
for daptomycin ranged from 0.19 to 0.5mg/L, with the majority of
isolates showing MICs of 0.125 to 0.25mg/L. S. pyogenes isolates
were susceptible to all antimicrobials tested, with the exception of
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sulfamethoxazole/trimethoprim, and the MICs for daptomycin ranged
from 0.047 to 0.5mg/L, the majority of isolates showing MICs of
0.094mg/L.
Conclusion: All Gram-positive clinical isolates tested, including multi-
drug resistant isolates such as MRSA and MRSE, were susceptible to
daptomycin, which could be a new therapeutic option in the treatment
of infections in orthopaedic patients.
Clean(ing) hospitals
P1643 Does targeted and quantiﬁed control of the microbiological
environment within the intensive care unit reduce
colonisation and healthcare-acquired infection?
G. Moore °, D. Smyth, J. Singleton, R. Jackson, G. Bellingan, M. Singer,
S. Shaw, E. James, V. Gant, B. Cooper, B. Cookson, P. Wilson (London,
UK)
Objective: There is currently little evidence to link inadequate cleaning
with hospital-acquired infections. The aim of this study was to determine
if a reduction in environmental MRSA contamination rates by enhanced
cleaning led to a reduction in new colonisation of patients.
Methods: The study was conducted in the intensive care units of
two London hospitals over one year and was divided into six eight-
week phases randomised to ‘standard’ or ‘enhanced’ cleaning regimens.
Enhanced cleaning was carried out by trained hygiene technicians who
cleaned the high contact areas such as keyboards and bed rails in the
near-patient environment twice a day using ultramicroﬁbre cloths. This
cleaning regimen was in addition to the routine (standard) cleaning
performed by the nurses. Conventional microbiological methods were
used to sample 10 target sites three times a day. Samples were collected
on 12 bed-days at each ICU each week. All patients were screened on
admission and weekly during stay. Infections were deﬁned using HELICS
or CDC criteria.
Results: The proportion of patients who were MRSA-positive on
admission to the ICU was similar at both Hospital A (124/1662; 7.5%)
and Hospital B (88/921; 9.5%). However, the number of bed area
samples from which MRSA was isolated was signiﬁcantly higher in
Hospital A (159/10052; 1.6%) than in Hospital B (76/10157; 0.8%,
p< 0.001). Despite this, MRSA acquisition was 2.7 times more likely
to occur at Hospital B (95%CI 1.6−4.6, p< 0.001). The total viable
count recovered from target sites within both ICUs was signiﬁcantly
lower following enhanced cleaning than during the standard clean. The
aggregated number of sites from which MRSA was isolated also fell
signiﬁcantly during the enhanced clean (165/10141; 1.6% vs. 70/10068;
0.7%, p< 0.001). However, in comparison to the standard clean, there
was no evidence of reduced MRSA acquisition during enhanced cleaning
at either Hospital A (10 vs. 12, OR 0.56 [0.10, 3.22]) or Hospital B (24
vs. 18, OR 0.72 [0.22, 2.38]).
Conclusions: Intensive cleaning of high contact areas within the near-
patient environment reduced local bacterial load and potential risk to
which the patient was exposed. However, within the limitations of this
study, a lower level of environmental contamination was not associated
with reduced colonisation or infection of patients.
P1644 Measuring the effect of enhanced cleaning in a UK hospital:
a prospective cross-over study
S. Dancer °, L. White, J. Lamb, E. Girvan, C. Robertson (East Kilbride,
Glasgow, UK)
Objectives: There is some evidence for cleaning in the control of
hospital-acquired infections. This study aimed to evaluate the effect
of one extra cleaner using microbiological standards based on aerobic
colony counts and the presence of Staphylococcus aureus including
meticillin-resistant S. aureus (MRSA).
Methods: We introduced one extra cleaner into two matched wards
from Monday to Friday, with each ward receiving extra cleaning for
six months in a cross-over design. Ten hand-touch sites on both wards
were screened weekly using standardised methods and patients were
monitored for MRSA infection throughout the year-long study. Patient
and environmental MRSA isolates were characterised using molecular
methods in order to investigate temporal and clonal relationships.
Results: Enhanced cleaning was associated with a 32.5% reduction
in levels of microbial contamination at hand-touch sites when wards
received enhanced cleaning (p< 0.0001: 95%CI 20.2%, 42.9%). There
was little effect on environmental MRSA/S. aureus. Near-patient sites
(lockers, overbed tables and beds) were more frequently contaminated
with MRSA/S. aureus than sites further from the patient (p = 0.065).
Genotyping identiﬁed indistinguishable strains from both hand-touch
sites and patients. There was a 26.6% reduction in new MRSA infections
on the wards receiving extra cleaning, despite higher MRSA patient-days
and bed occupancy rates during enhanced cleaning periods (p = 0.032:
95%CI 7.7%, 92.3%). Adjusting for MRSA patient-days, and based
upon nine new MRSA infections seen during routine cleaning, we
expected thirteen new infections during enhanced cleaning periods rather
than the four that actually occurred. Clusters of new MRSA infections
were identiﬁed 2−4 weeks after the cleaner left both wards. Enhanced
cleaning potentially saved the hospital up to £70,000.
Conclusion: Introducing one extra cleaner working Monday to Friday
produced a measurable effect on the clinical environment, with apparent
beneﬁt to patients regarding MRSA infection. MRSA strains originally
identiﬁed from hand-touch sites were later found in patients. There
is scope for further research on hospital cleaning as a cost-effective
component in the control of hospital-acquired infection.
P1645 Results of a 6-month in-use efﬁcacy trial of AzoMaxActive™
cleaning products compared to hypochlorite
M. Muzslay, J. Cawthorne, M. Upton, C.G. Gemmell, A.R. Dodgson °
(Manchester, St. Andrews, UK)
Objectives: The hospital environment acts as a reservoir for transmission
of nosocomial pathogens, thus maintenance of a clean environment is
essential for patient safety. Hypochlorite is recommended for cleaning
areas at high risk for C. difﬁcile as it is sporicidal. However, it
poses health and safety concerns and may damage the hospital
environment. The AzoMaxActive™ range of cleaning products contain
Byotrol™ technology, a novel combination of biocides sequestered to a
nanopolymer backbone, which is sporicidal in-vitro and displays residual
antibacterial effect following use. The objective of the present study was
to compare the antibacterial efﬁcacy of AzoMaxActive to hypochlorite
(Chlorclean), and to measure their effect on nosocomial infection.
Methods: The study took place in four identical acute medical wards
each consisting of 5 four-bedded bays and 8 side rooms. Two control
wards were cleaned with a regime of 1,000ppm hypochlorite on
horizontal surfaces and neutral detergent on ﬂoors, two test wards were
cleaned using the study products. Side rooms were not included in
the study. Forty environmental sites per ward were sampled weekly.
Two adjacent 25 cm2 areas were swabbed per site. One swab was
plated directly on blood agar for a total viable count (TVC), and
then to Brazier’s medium after enrichment in Robertson’s cooked meat
medium to identify C. difﬁcile. The second swab was inoculated onto
chromogenic MRSA agar before and after enrichment in 7% salt broth.
Numbers of patients identiﬁed as MRSA or C. difﬁcile toxin (CDT)
positive were monitored.
Results: A total of 2080 sites were sampled in each area, the number
of sites with a TVC> 10 or >100 or positive for MRSA or C. difﬁcile
are shown in the table.
There was a highly signiﬁcant difference in the proportion of sites with
a TVC> 100 or >10 in favour of the test areas. The difference was
evident after 5 weeks and persisted thereafter. The number of MRSA or
C. difﬁcile positive sites was low and the differences not signiﬁcant. Ten
patients in the control area were C. difﬁcile +ve and 8 in the test, for
MRSA these numbers were 7 and 9.
Conclusion: These 6 month results show that in use, the AzoMaxActive
products have a signiﬁcantly greater antibacterial activity than hypochlo-
rite. The residual activity was also conﬁrmed. Although the numbers are
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small there appears to be no difference in C. difﬁcile cases between the
2 arms of the study. The trial continues with a crossover phase.
Sites +ve for Test Control p
TVC> 10 1211 (58.2%) 1575 (75.7%) <0.0001
TVC> 100 436 (21.0%) 627 (30.1%) <0.0001
MRSA Direct 31 (1.5%) 37 (1.8%) ns
MRSA Total 45 (2.2%) 46 (2.2%) ns
C. difﬁcile 12 (0.6%) 8 (0.4%) ns
P1646 High sporocidal activity using dissolved chlorine dioxide
(SanDes™) on different surface materials contaminated by
Clostridium difﬁcile spores
J. Andersson °, M. Sjo¨berg, L. Sjo¨berg, M. Unemo, T. Noren (Orebro, SE)
Objectives: To evaluate the sporocidal activity of dissolved chlorine
dioxide (ClO2) on spore-concentrates from clinical C. difﬁcile (CD)
strains contaminating different surfaces in hospital environment.
Methods: Pure colonies of two CD strains; PCR ribotype 029 and
027/NAP1, both comprising high morbidity and sporulation capacity,
were cultured anaerobically on Fastidious anaerobe agar (FAA). 8−10
colonies were then diluted in 1mL NaCl, seeded into 30mL prereduced
peptone-yeast broth deﬁcient of cystein, and cultured under anaerobe
conditions imitating the in vivo nutritional starvation and transition to
inactive spores. Maximum ratio of spores was seen after 5 days (60−80%
of spores), according to calculations in Bu¨rker-chamber using Phase-
contrast microscopy.
On harvest the broth was diluted 1/100 in NaCl and 0.1mL of this
suspension was dried on glass, chrome metal, plastic and carpet.
Subsequently, 0.1mL 70% ethanol, 70% ethanol+200 ppm ClO2, 200
ppm, 400 ppm, 800 ppm or 1500 ppm ClO2, all in duplicates, were
applied. The surface sample was then washed in 250mL NaCl on a
shaker for 20 minutes and ﬁltrated through a 0.45mm Millipore ﬁlter.
Finally, the ﬁlter was cultured anaerobically for 48 h on FAA and CFU
count was recorded.
Results: The mean concentration of inoculum was 25×109 cells/L
(12−31×109/L; 40−80% spores). The international epidemic strain
027/NAP1 showed the highest sporulation capacity (62−80%). In
comparison with untreated contaminated surface sample, 70% ethanol
gave a 30% mean reduction in CFU correlating with the proportion of
susceptible vegetative cells, while this ethanol shock + 200 ppm ClO2
reduced growth by 97%. 800 ppm and 1500 ppm of ClO2 inhibited
growth by 100%. Similar inhibition levels were seen for all surface
materials examined.
Conclusion: This in vitro study demonstrated unique chemical
disinfection of C. difﬁcile spores, which may prove to be of great
importance in hospital environmental cleaning from where infective CD
spores are a major source of epidemic CD infection (CDI). Both clinical
strains used, comprising high sporulating capacity, were effectively killed
(97–100%) on the four surfaces tested when using ClO2 (200–1500
ppm) and may thus be used to clean ﬂoors, bedrails (chrome-metal) or
plastic WC-seats. Additional organic contamination and in vivo bioﬁlm
on surfaces need to be investigated as well as the value as hand-rub using
ethanol 70%, which in this study did not show any sporocidal activity.
P1647 The efﬁcacy of dry-mist-generated hydrogen peroxide
system against methicillin-resistant Staphylococcus aureus
and Acinetobacter baumannii
N. Piskin, G. Celebi °, C. Kulah, Z. Mengeloglu, M. Yumusak
(Zonguldak, TR)
Objectives: The aim of this study was to evaluate the efﬁcacy of dry-
mist-generated hydrogen peroxide system (Sterinis®) against methicillin-
resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii
on the environmental surfaces in an intensive care unit room.
Methods: 0.5 McFarland suspensions of two test bacteria, either pure or
containing 5% sterile serum were prepared. Inoculums of 5 ml from each
suspension were inoculated on the sterile stainless steel disks separately.
Each disk in a sterile Petri plate, either the plate cover closed or opened,
was placed on the following locations: upper surface of the wardrobe,
on the bedside table, into the drawer of whatnot and on the ground
ﬂoor. Additionally, to test the efﬁcacy of the Sterinis® on the lateral and
underside surfaces of the equipments in the room, disks were placed in
horizontal and prone positions using suitable apparatus. Duplicate disks
for each location and for each position were placed. The system was
run with a dose of 6ml/mm3 for one cycle according to manufacturer
recommendations and quantitative cultures of each disk were performed
after the cycle.
Results: Except one disk containing serum, no growth occurred on the
disks with or without serum in the absence of a barrier, as a drawer or
a covered plate or both, that limited air circulation. The presence of a
barrier caused failure in the disinfection activity of the system: Cultures
were positive for 8.3% of the disks in the opened plates and in 56.3%
of the disks in closed plates. The difference was statistically signiﬁcant
(p< 0.001). Likewise, the rate of positive cultures inside the drawer was
higher than the rate of positive cultures outside the drawer (4.2% and
68.8% respectively, p< 0.001). When the disks were compared according
to serum content, disks with organic load had a higher rate of culture
positivity but the difference was not statistically signiﬁcant (Table 1).
The results were similar when the analyses were performed for each
bacteria separately.
Conclusion: Sterinis® was capable of killing MRSA and A. baumannii
on the open surfaces in the hospital room with one cycle, however,
presence of serum on the surfaces diminished the efﬁcacy of it. Sterinis®
was not effective in closed or semi-closed areas in the hospital room.
Table 1. Culture results of the disks according to variables
Growth No growth Total p
n* (%) n* (%) n* (%)
Disks in
opened plates 4 (8.3) 44 (91.7) 48 (100) <0.001
closed plates 9 (56.3) 7 (43.8) 16 (100)
Disks
outside the drawer 2 (4.2) 46 (95.8) 48 (100) <0.001
inside the drawer 11 (68.8) 5 (31.3) 16 (100)
Disks containing
pure suspension 4 (12.5) 28 (87.5) 32 (100) >0.05
serum + suspension 9 (28.1) 23 (71.9) 32 (100)
*n = The number of disks.
P1648 Efﬁcacy of selected weak organic acids against
multi-antibiotic-resistant planktonic and bioﬁlm bacteria
Z. Nack °, J. Stenos, H. Dunstan, S. Graves (Geelong, Newcastle, AU)
Objective: Determine the efﬁcacy of selected weak organic acids
(WOAs) and their combinations against planktonic and bioﬁlm Methi-
cillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant
Enterococcus faecium (VRE), Multiresistant Acinetobacter baumannii
(MRAB) and extended-spectrum b-lactamase (ESBL) positive Klebsiella
pneumoniae.
Four organic acids, ascorbic, citric, lactic and malic were tested alone
or in various combinations.
Methods: For planktonic bacteria, an in-house test was developed. A
time-concentration dependent study was carried out using individual
and combinations of WOAs. For bioﬁlm bacteria, bacterial suspensions
were added to RPMI-1640 media supplemented with 1%v/v ethanol and
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1%w/v NaCl. Microtiter plates were inoculated with bacterial suspension
to establish bioﬁlms.
Bioﬁlm formation was detected by staining wells with crystal violet and
then resolve the crystal violet in a mixture (2:8) of acetone and ethanol.
Bioﬁlm formation was conﬁrmed, if the reading at 570 nm of the positive
control was at least three times more than the reading of the negative
control. Wells were exposed to WOAs in different concentration, washed
with distilled water and RPMI-1640 growth media was added detecting
any bacterial growth at 570 nm.
Results: For planktonic Gram-positive bacteria (MRSA, VRE) at least
8%w/v concentrations of WOAs and their combinations were effective
after 6 to 10 minutes exposure. For planktonic Gram-negative bacteria
(MRAB, ESBL positive Klebsiella pneumoniae) at least 2.5%w/v
concentrations of WOAs and their combinations were effective after
2 minutes exposure. Lactic acid alone and in combination with malic acid
showed to be the most effective against both type of bacteria. Individual
and combination of WOAs in 10%w/v concentration after 60 minutes
exposure were capable to penetrate into bioﬁlms and eliminate bacteria.
Conclusion: Our results indicate that WOAs, especially lactic acid
and combinations thereof, are effective bactericidal agents against
planktonic Gram-negative and Gram-positive multiresistant bacteria.
Enhanced efﬁcacy with Gram-negative bacteria is probably due to their
lipopolysaccharide layer, which is more permeable to acids due to the
acid soluble lipid component. These WOAs alone or in combination are
also capable to penetrate into bioﬁlms, increasing their potential to be
used as sanitizer.
P1649 Efﬁcacy of selected weak organic acids against enveloped
and non-enveloped viruses and an intracellular bacterium
Z. Nack °, J. Stenos, H. Dunstan, S. Graves (Geelong, Newcastle, AU)
Objective: Determine the efﬁcacy of selected weak organic acids
(WOAs) and their combinations against enveloped Herpes simplex type
1 (HSV-1) and non-enveloped Human adenovirus type 4 and against
Rickettsia honei an intracellular, spotted fever group bacteria.
Four organic acids, ascorbic, citric, lactic and malic were tested alone
or in various combinations.
Methods: Organic acids were diluted in RPMI-1640. We used different
adherent cell lines, including Vero cells for HSV-1 and for Rickettsia
honei and A549/88 cell line for Human adenovirus type 4 in 96
wells microtitre plates. The initial concentration of the viruses and
the Rickettsia were determined by a ten-fold serial dilution method.
Uninfected cell lines and cell lines exposed to low concentration of
WOAs were used as negative control for all tests. Toxic effects of the
WOAs on adherent cells were determined prior to experiment. Cell
lines were grown up to form a monolayer and exposed to appropriate
virus or bacteria for 48 hours. Individual and variation of WOAs in
different concentrations were added to the cell lines for 60 minutes.
After exposure, wells were washed with growth media (RPMI-1640) to
remove any residuals of the WOAs and the same growth media was used
to detect any viral or bacterial growth up to 14 days.
Results: The effective concentration of the WOAs to eliminate HSV-1
or Human adenovirus type 4 after 60 minutes exposure were as low as
0.16 w/v%.
Our results showed no major difference in concentration to eliminate
enveloped or non-enveloped viruses, although it may be due to the
limited number of tests performed so far. Malic acid alone and in
combination with citric and lactic acid was very effective against
Rickettsia honei in 0.32 w/v% after 60 minutes exposure.
Conclusion: Our results indicate that WOAs alone or in combination
work effectively against some enveloped and non-enveloped viruses and
Rickettsia honei.
They penetrate into adherent cells maintaining their efﬁcacy without
damaging the eukaryotic cells. The hazards associated with using these
natural WOAs as sanitizer are probably signiﬁcantly lower than the use
of chemically based sanitizers because of their moderate or very low
toxicity for humans.
Pharmacokinetics and pharmacodynamics of
antibacterials and antifungals
P1650 Target controlled infusion as a mode of i.v. administration
for time-dependent antibiotics
J.B. Glen °, S. Ruton (Knutsford, UK; Brezins, FR)
Objective: In many countries, approved Target controlled infusion
(TCI) pumps are widely used for anaesthetic and analgesic drugs.
These devices could be easily adapted for selected antibiotics by the
incorporation of an appropriate pharmacokinetic (PK) model such that
the system will aim to achieve a desired target drug concentration in
blood and tissues. The aim of this ongoing study is to identify suitable
candidates to test the hypothesis that the TCI mode of administration
could provide clinical advantages.
Methods: Advantages of TCI over conventional continuous infusion
are (i) improved individualisation of dosage if a well characterised
population PK model is available (ii) target concentration proﬁles can
be determined to achieve effective drug concentrations in tissues more
quickly and (iii) proportional changes in the target concentration can be
made if drug monitoring reveals inadequate or excessive concentrations.
Computer simulation is being used to examine the PK of those antibiotic
agents that have been advocated for use by continuous infusion.
Cumulative drug delivery over time is used to compare the inﬂuence
of different published PK models for the same drug. Different target
concentration proﬁles are being explored to determine the rate of
equilibration between predicted blood and tissue concentrations.
Results: With vancomycin as an example, cumulative drug delivery
over 24 hr for a 70 kg patient, with a blood target concentration (CbT)
of 15mcg.ml1, ranged from 1803 to 2878mg with 7 different PK
models. With CbT of 20mcg.ml1 for 1 hr followed by 10mcg.ml1
and a population PK model described by Mulla (2005), 24 hr drug
delivery was 1415mg in an adult patient with serum creatinine (Cr)
80mmol.l1, 940mg in an adult with Cr 160mmol.l1 and 385mg
in a 5 yr, 18 kg child with Cr 80mmol.l1. This latter CbT proﬁle
achieves equilibration between predicted blood and tissue vancomycin
concentrations of 10mcg.ml1 within 2 h and predicted concentrations
remain stable thereafter.
Conclusions: In line with the plea that currently available drugs should
be administered in the optimum fashion, TCI may provide a new option
worthy of investigation. Once potential candidates are identiﬁed, it will
be desirable to achieve a consensus among PK experts on the most
appropriate PK models for particular drugs and populations.
P1651 New horizons to modern therapeutic drug monitoring −
use of tandem mass spectrometry to analyze the 40 most
important anti-infectives
M. Rodamer °, V. Jakob, R. Strauss, M. Ganslmayer, C. Gleich,
F. So¨rgel, M. Kinzig (Nuremberg-Heroldsberg, Erlangen, DE)
Objectives: Previously only very few anti-infectives could be measured
within a reasonable time to allow a physician to react to reported drug
levels. This is particularly regrettable since pharmacodynamic principles
have begun to be ready for clinical use, yet needing validation in the
“real world”. Modern tandem mass spectrometry has opened a new era
to measure anti-infectives with relatively short development time for the
assay and quick response to urgent needs for blood or tissue levels from
the clinic.
Methods: We developed tandem mass spectrometry for the most
important forty anti-infectives (antibiotics, anti-TB-agents, antivirals,
anti-fungals, anti-malarials), applied the strict FDA-Guidelines for
Bioanalytical Work and set up a quality assurance system. Precursor →
product ion transitions for representative anti-infectives such as: 548 →
539 caspofungin, 547 → 468 ceftazidime, 332 → 314 ciproﬂoxacin,
198 → 108 clavulanic acid, 811 → 159 daptomycin, 474 →
265 ertapenem, 735 → 158 erythromycin, 307 → 238 ﬂuconazole,
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137 → 79 fosfomycin, 300 → 98 imipenem, 338 → 296 linezolid,
384 → 68 meropenem, 172 → 128 metronidazole, 516 → 330
piperacillin, 245 → 113 ribavirin, 232 → 140 sulbactam, 254 → 156
sulfamethoxazole, 299 → 138 tazobactam, 586 → 569 tigecycline,
291 → 230 trimethoprim, 725 → 144 vancomycin, 350 → 127
voriconazole.
For very fast and emergency sample analysis we developed one point
calibration with high assay reliability.
Results: We successfully used this system for providing intensive care
units within a distance of up to 200 km from our laboratory drug levels
within 2−6 hours. Suggested dosage adjustments are delivered by us via
appropriate PK-software. For samples from countries in Europe where
a fast courier system is available, we were able to report drug levels
within less than 24 hours of sampling. We have used this in 30 patients
so far where the clinician considered drug concentration monitoring vital.
In many of these cases the drug monitoring deﬁnitely optimised drug
therapy leading to faster discharge. The effect on mortality cannot be
assessed at this time but with more patients to enter we will be able to
approach this most important question. Several cases will be presented
in detail.
Conclusion: Modern bioanalytical technology is here, but its use
in the everyday care of severely sick patients is still completely
underdeveloped.
P1652 Tigecycline by Lc-Ms/Ms in seven human intestinal tissues
and comparison with rat and porcine tissue
S.T. Mees, V. Jakob, M. Rodamer, M. Kinzig, J. Haier, W. Haupt,
V. Schellerer, F. So¨rgel ° (Munster, Nuremberg-Heroldsberg, Erlangen,
DE)
Objectives: Due to the high volume of distribution of tigecycline in
humans it is of great interest to study the distribution of tigecycline in
various tissues in the body. Very few assays used for the measurement
of antibiotics in tissue have been truly validated according the FDA-
guideline for bioanalytical work. This was done here.
Methods: Determination of tigecycline in human colon (whole wall,
mucosa), human duodenum (whole wall, mucosa), human ileum (whole
wall, mucosa), human jejunum (whole wall), human stomach (whole
wall, mucosa), human oesophagus (whole wall, mucosa), human liver,
rat liver and porcine liver was performed with tandem mass spectrometric
detection (LC-MS/MS) using TurboIonSpray® ionisation. Deuterated
tigecycline was used as the internal standard. The following singly
charged precursor → product ion transitions were monitored: 586 →
569 for tigecycline and 596 → 579 for d9-tigecycline. Sample
preparation was performed by homogenisation and extraction with
organic solvent. Chromatography was performed on a reversed-phase
column with a mobile phase consisting of ammonium formate and
acetonitrile.
Results: Linearity could be shown within 0.00763–1.54mg/mL and
correlation coefﬁcients were at least 0.998 on all validation days. Intra-
run CVs ranged from 1.3 to 7.6% in human colon, 1.7 to 6.7% in human
colon mucosa, 1.1 to 5.5% in human duodenum, 1.7 to 5.9% in human
jejunum, 4.6 to 5.6% in human ileum, 1.3 to 6.7% in human liver, 1.4 to
8.2% in human stomach, 1.8 to 2.3% in human stomach mucosa, 1.2 to
11.2% in human oesophagus, 1.8 to 8.8% in human oesophagus mucosa,
1.9 to 9.4% in human duodenum mucosa, 2.1 to 6.5% in human ileum
mucosa.
Conclusion: The inter-run precision (CV) ranged from 4.8 to 7.2%
for tigecycline. Mean recovery was 68.1%±7.8% SD for tigecycline
and 68.1%±2.3% SD for d9-tigecycline. There was no instability
observed for tigecycline during the validation procedure. Six different
human colon tissue samples showed no effect on the determination of
tigecycline. We developed and validated a method for the determination
of tigecycline in human tissues with high batch acceptance rate and
according to the demanding FDA-guideline.
P1653 Tigecycline and polymorphonuclear leukocyte function
A. Naess °, H. Andreeva, S. Sørnes (Bergen, NO)
Objectives: Tigecycline is an antibiotic which achieves high intracellular
concentrations in polymorphonuclear leukocytes (PMNs). To evaluate
the effects of tigecycline on the function of human PMNs, PMNs from
fresh whole blood were incubated with tigecycline dilutions (0.1 to
100mg/L).
Methods: Phagocytosis and oxidative burst induced by Staphylococcus
aureus, as well as PMN Fcgamma- and complement receptors, were
measured by ﬂow cytometry.
Results: Tigecycline had no effect on the phagocytosis or oxidative
burst induced by S. aureus. However, incubation with tigecycline was
associated with small but statistically signiﬁcant decreases in the density
of PMN complement receptors CD11b and CD35 (all concentrations)
and Fcgamma receptors CD16 (100mg/L) and CD32 (10 and 100mg/L),
but not in the percentages of receptor-bearing cells, except for small
reductions in the proportions of CD16 positive cells at 10 and 100mg/L
of tigecycline.
Conclusion: Tigecycline was thus associated with decreased density
of human PMN complement and (at high concentrations) Fcgamma
receptors. Although statistically signiﬁcant, these differences were small
and did not inﬂuence PMN function as measured by phagocytosis and
oxidative burst induced by S. aureus.
P1654 Epithelial lining ﬂuid concentrations of antibiotics −
methodological artifacts?
M. Rodamer °, F. So¨rgel, V. Jakob, M. Kinzig, B. Basel, W. Kru¨ger,
M. Peiffer, T. Lodise, J. Bulitta (Nuremberg-Heroldsberg, Tubingen, DE)
Objectives: In the desperate search for a better predictor of pharmaco-
dynamic and clinical response epithelial lining ﬂuid (ELF) has become
most popular. However, bioanalytical methodology for the antibiotics in
ELF has remained obscure because of hidden “proprietary issues” of
the assays. That is completely unacceptable, although accepted by many
journals. It virtually does not allow to assess the validity of the published
work on ELF and thus makes it worthless. Any bioanalytical work should
follow the FDA-guideline. Urea − a crucial factor when calculating
ELF − concentrations from bronchoalveolar lavage concentration (BAL)
was always measured by the clinical routine method that neither was
ever designed or validated for this work. Hence it is not surprising
that ELF-data are controversial with no meaningful relationship to
physicochemical properties of the agents.
Methods: We developed and validated (according to FDA-Guideline)
hyphenated chromatography/mass spectrometry methods for antibiotics
and urea that were uniformly applied to the compounds reported. Patients
were from an intensive care unit except for ceftidoren. That should allow
a long awaited valid comparison between agents.
Results: ELF to plasma ratio: Trovaﬂoxacin: 2.75±1.933, Ceftidoren:
0.32±0.19, Meropenem: 1.51±0.72, Piperacillin: 3.54±2.19, Tazobac-
tam: 5.60±5.38, Vancomycin: 0.92±0.85, Linezolid: 1.81±1.83.
Conclusion: This data helps to differentiate between agents and
reincarnate an agent like vancomycin which, due to inappropriate
bioanalytical technology, was considered poorly penetrating into ELF.
Based on our data b-lactams show differences that reﬂect their chemically
different properties. For the ﬁrst time it was shown by a speciﬁc chemical
method that an oral cephalosporin can penetrate into ELF.
P1655 Modelling the auto-inhibition of clarithromycin metabolism
during repeated oral administration
V. Jakob °, K. Abduljalil, M. Kinzig, J. Bulitta, S. Horkovics-Kovats,
U. Fuhr, F. So¨rgel (Nuremberg-Heroldsberg, Cologne, DE; Kundl, AT)
Objectives: Clarithromycin decreases CYP3A4 activity and thus
gradually inhibits its own metabolism as well as that of co-administered
S472 19th ECCMID, Posters
drugs. This study aimed at understanding the time course of these
changes.
Methods: Plasma concentration time proﬁles of clarithromycin and its
active metabolite, 14(R)-hydroxy-clarithromycin, from 12 young healthy
volunteers after oral administration of a clarithromycin suspension
(500mg bid for 7 doses) were modelled by population pharmacokinetic
analysis in NONMEM.
Results: Non-linearity of clarithromycin metabolism was considered
during model development and metabolite disposition kinetics was
assumed to be linear. The absorption kinetics of clarithromycin was
best described by a Weibull function model. Pharmacokinetics of
clarithromycin and its 14(R)-hydroxyl metabolite were adequately
described by a one-compartment model each for clarithromycin and
its metabolite as well as an inhibition compartment that reﬂects auto-
inhibition of clarithromycin metabolism. Up to 90% of the apparent
total clarithromycin clearance (60 L/h) was susceptible to reversible auto-
inhibition, depending on the concentration in the inhibition compartment.
The proposed semi-mechanistic population pharmacokinetic model
successfully described the auto-inhibition of clarithromycin metabolism
and may be used to adjust doses of other drugs metabolised by CYP3A4
that are co-administered with clarithromycin.
Conclusion: Simulations showed that for the 500mg bid standard dose
no further increase of exposure occurs after approximately 48 h of
treatment. For a 1000mg bid dose reaching steady state is expected
to take several days and to achieve a 3.6-fold higher clarithromycin
exposure compared to 500mg bid. This evaluation provides a rationale
for a safer and more effective therapy with clarithromycin.
P1656 Effects of azidothymidine on apoptotic cell death: role of
nuclear factor kB
C. Matteucci, A. Minutolo, E. Balestrieri, S. Grelli °, B. Macchi,
A. Mastino (Rome, Messina, IT)
Objectives: We have recently shown that azidothymidine (AZT) affects
caspase activation in peripheral blood mononuclear cells in absence
of remarkable apoptotic cell death (Pharmacol. Res., 2008, Epub). To
investigate mechanisms underlying this apparent paradox we investigated
the action of AZT on cell death in a monocytic tumour cell line. In
particular, we have focused our attention on the relationship between
nuclear factor kB (NF-kB) activation and apoptosis modulation by AZT.
Materials and Methods: U937 cells wt and U937 cells stable
transfected with a dominant negative murine IkBa (mIkBa) or a control
vector (pcDNA3.1), were treated with AZT or vehicle and, in some
experiments, with AZT in combination with different inhibitors of
NF-kB. Apoptosis was evaluated by ﬂow cytometry analysis. Gene
expression was evaluated by a SuperArray.
Results: U937 cells response to AZT raised a peak of apoptosis only
at 48 h after treatment. SuperArray results, at 18 h, showed the up-
regulation of both pro- and anti-apoptotic genes and also of some genes
associated to DNA repair and cell survival. U937-mIKB cells were
more susceptible than U937-pcDNA3 to AZT-induced apoptosis, thus
inhibition of the NF-kB system seemed to render target cells more
susceptible to AZT-induced cell death. This was further conﬁrmed by
the fact that treatment of U937 cells with AZT + a pharmacological
IkBa inhibitor increased their susceptibility to apoptosis.
Conclusions: Our data suggest that some of the paradoxical effects
of AZT on apoptosis could rely on various mechanisms driven by
modulation of NF-kB dependent genes belonging both to the apoptotic
and to the anti apoptotic downstream signalling. Combination of AZT
+ NF-kB inhibitor could be a new interesting pharmacological approach
to simultaneously control infection and dysfunction of cell growth.
P1657 Post-antibiotic effect of various antibiotics on Legionella
pneumophila strains isolated from water systems
S. Birtekso¨z Tan °, Z. Zeybek (Istanbul, TR)
Objectives: The aim of our study is to examine the PAE of azithromycin,
clarithromycin, ciproﬂoxacin and levoﬂoxacin against L. pneumophila
strains isolated from several water systems of different buildings in
Istanbul.
Methods: Azithromycin, clarithromycin, ciproﬂoxacin and levoﬂoxacin
MICs were determined by microbroth dilution technique as described
by CLSI. PAEs were determined by a standard viable method where
bacteria in the logarithmic phase of growth were exposed for 1 hour to
antibiotics and antibiotics were removed by centrifugation and repeated
washing. The PAE was deﬁned as PAE=T−C, where T is the time
(in hours) required for the count in the test culture to increase 1 log10
above the count observed immediately after centrifugation and C is the
corresponding time for the controls. Experiments were performed in
duplicate.
Results: The MICs were determined in a range of 0.0156–0.0312mg/ml
for azithromycin, 0.0078–0.0156mg/ml for clarithromycin, 0.0156mg/ml
for ciproﬂoxacin and 0.0078–0.0156mg/ml for levoﬂoxacin. The PAEs
of L. pneumophila strains exposed for 1 h to 1×MIC and 4×MIC of
azithromycin, ciproﬂoxacin, clarithromycin and levoﬂoxacin ranged from
0.70 to 2.75 h and from 2.95 to 4.5 h; from 1.45 to 5.75 h and from 1.7
to 7.20 h; from 1.85 to 3.55 h and from 2.95 to 4.8 h; from 1.25 to 2.65
and from 2.0 to 4.75 h, respectively.
Conclusion: All of the antibiotics have PAEs on L. pneumophila strains.
When the concentration of antibiotics were increased, the duration of
PAE was prolonged. The duration of PAE was prolonged related to the
increasing concentrations. The ﬁndings of this study may have important
information for the optimal timing of the doses during therapy with these
antibiotics.
P1658 Combination therapy for multidrug-resistant Acinetobacter
baumannii in a neutropenic murine pneumonia model
Z. Yuan, K. Ledesma, R. Singh, J.G. Hou, R. Prince, V. Tam °
(Chongqing, CN; Houston, US)
Objective: We have previously demonstrated the feasibility of using
combination therapy against a multidrug-resistant (MDR) A. baumannii
(AB) clinical isolate in an in-vitro infection model (Lim, AAC 08), but
the in-vivo relevance of the observations is not well established. In this
study, we examined the utility of combination therapy in a neutropenic
murine pneumonia model.
Methods: Female Swiss-Webster mice (20−25 g) were rendered neu-
tropenic by 2 doses of cyclophosphamide on days −4 and −1; transient
nephrotoxicity was induced by uranyl nitrate on day −2. Anaesthetized
animals were infected with approximately 107 CFU of MDR AB intra-
tracheally under laryngoscopic guidance. Serum TNF-a and IL-6 were
measured 24 hours after infection. Pharmacokinetics of amikacin,
cefepime and levoﬂoxacin in infected animals were determined by a
single dose study. Animals were treated with placebo and various 2-agent
combinations intra-peritoneally, 2 hours after infection for 96 hours.
Quantitative assessment of bacterial burden in animal lung tissues was
performed at baseline, after 24 h of therapy, and upon death or at the
end of experiment. Relative effectiveness of various agent combinations
was predicted previously by a novel mathematical model using a
3-dimensional response surface.
Results: Both serum TNF-a and IL-6 were found to be signiﬁcantly
elevated in infected animals, compared to controls (p< 0.01). Animals
were given combination humanised drug exposures (amikacin 20mg/kg
every 24 h, cefepime 180mg/kg every 8 h, and levoﬂoxacin 150mg/kg
every 24 h). All infected animals expired after 80 hours if untreated.
Different agent combinations were not equally efﬁcacious; cefepime +
amikacin was found to have the most favourable mortality rate (40%),
as predicted by the mathematical model. Tissue bacterial burden at 24 h
was consistent with the mortality data.
Conclusion: Our in-vivo results validated the utility combination therapy
for MDR AB. Optimal (mathematical model-guided) combination
therapy may be useful for MDR infections and deserves further
evaluation.
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P1659 Testing the antibacterial and antifungic activity of the
species Pelargonium roseum and Pelargonium graveolens
C. Gaˆlea °, C. Csedo (Targu Mures, RO)
Objectives: The objective of the present study is to test the antibacterial
and antifungic activity of essential oils yielded by Pelargonium roseum
and Pelargonium graveolens.
Methods: In order to test their antibacterial and antifungic activity, we
made use of the radial diffusimetric method, impregnating round ﬁltre
disks made of paper with essential oil yielded by the above-mentioned
plants.
Previously sterilised 6mm diameter round disks were used. Onto each we
dripped 0.01ml essential oil, using a sterile semi-automatic micropipette.
The paper disks were put in Petri plates, onto simple gelose cultures,
which were preserved at 37ºC in thermostat during 24 h. Reading was
done by measuring the diametres of inhibation of microbial development
around the round disks.
The microorganisms used for testing the antimicrobial activity of
essential oils were selected from the standardised microorganism
collection of Tg-Mures Public Health Centre. We used the following
bacterial stems:
1. Gram-negative bacteria: Escherichia coli, Proteus mirabilis and
Pseudomonas aeruginosa;
2. Gram-positive bacteria: Staphylococcus aureus, Enterococcus fae-
calis;
3. Fungi: Candida albicans.
The intensity of their antimicrobial effect was tested in comparison with
some referential antibiotics, in form of microcapsules for antibiogram
(cyproﬂoxacine, cotrimoxazole, gentamycine, amykacin, cephotaxim,
cephalotin).
Results: The results obtained are presented in the table.
Stem being tested Inhibition zone (mm)
Essential oils Antibiotics
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Sample 1 2 4 5 6 7 8
Pseudomonas aeruginosa
ATCC 27853
22 26 18 20 26 20 31 30 11 11 19 21 24 10
Proteus mirabilis
ATCC 29906
11 13 12 10 17 16 13 35 35 28 20 20 35 38
Staphylococcus aureus
ATCC 25923
21 28 22 21 25 25 31 25 29 28 22 19 35 38
Escherichia coli
ATCC 25922
14 15 10 11 11 11 15 28 23 25 17 16 36 16
Enterococcus faecalis
ATCC 19433
22 15 16 12 10 15 13 22 30 25 17 16 37 26
Candida albicans
ATCC 10231
compl compl compl compl compl compl compl – – – – – – –
Sample 1 − essential oil of Pelargonium graveolens (China)
Sample 2 − essential oil of Pelargonium roseum (Reunion)
Sample 4 − essential oil of Pelargonium roseum (Targu-Mures, 2004)
Sample 5 − essential oil of Pelargonium roseum (France)
Sample 6 − essential oil of Pelargonium roseum (Targu-Mures, 2005)
Sample 7 − essential oil of Pelargonium graveolens (Egypt)
Sample 8 − essential oil of Pelargonium roseum (Targu-Mures, 2003)
Conclusions: In case of Pseudomonas aeruginosa (Gram-negative)
and Staphylococcus aureus (Gram-positive) an inhibition comparable
with that of microcapsules containing antibiotics was discovered. No
signiﬁcant differences between the two types of essential oils being
studied in the present study were found. As to their bioactivity against
Candida albicans, a complete inhibition of the development of this
fungus was found.
Further studies, made on the basis of the dilution method, are needed in
order to determine the minimal concentration of the inhibitory effect of
geranium (Pelargonium) essential oils against Pseudomonas aeruginosa,
Staphylococcus aureus and respectively, Candida albicans.
P1660 Pharmacokinetics of colistin after intravenous
administration in critically ill patients receiving continuous
venovenous haemodiaﬁltration
M. Karvanen °, D. Plachouras, L.E. Friberg, E. Papadomichelakis,
B. Jansson, E. Paramythiotou, A. Armaganidis, O. Cars,
H. Giamarellou (Uppsala, SE; Athens, GR)
Objectives: Colistin is used in infections by multi-drug resistant Gram-
negative bacteria (MDR-GNB) but pharmacokinetic data are limited,
especially in patients receiving continuous renal replacement therapy
(CRRT). The pharmacokinetics of colistimethate sodium (CMS) and
colistin in a population of critically ill receiving CRRT was studied.
Methods: Critically ill patients on renal replacement therapy through
continuous venovenous haemodiaﬁltration (CVVHDF) receiving colistin
for infection by MDR-GNB were enrolled. CVVHDF was performed
using an AN 69 HF hollow ﬁbre haemoﬁlter/dialyser (Prisma M100 Pre
Set; Hospal Industrie, Meyzieu, France)with an effective surface area
of 0.90m2. CMS was administered at a dose of 2 MU (160mg) q8 h.
Venous, afferent and efferent blood was collected immediately before and
at multiple occasions after the fourth infusion. Plasma CMS and colistin
concentrations were determined with a novel LC-MS/MS method after a
rapid precipitation step that avoids signiﬁcant degradation of CMS and
colistin.
Results: Five patients (3 female, mean age 65.8 years) were included.
Mean (SD) blood ﬂow rate, substitution and dialysate ﬂow rates were
134 (15.2) ml/min, 1120 (779.9) ml/h and 1430 (383.4) ml/h respectively.
Selected pharmacokinetic parameters are shown in Table 1.
Table 1. Calculated PK parameters, mean (SD).
CMS Colistin
Cmax (mg/L) 4.93 (2.01) 0.92 (0.46)
Cmin (mg/L) 1.08 (0.40) –
T1/2 (terminal, h) 3.29 (0.62) –
Extraction (%) 30 (13) 68 (8)
CLHDF (L/h) 2.45 (1.26) 5.5 (1.10)
Conclusion: Both CMS and colistin are signiﬁcantly eliminated
by CVVHDF in these patients, resulting in insufﬁcient plasma
concentrations of colistin. This raises questions of the necessity and
magnitude of dosage adjustment in this population of patients.
P1661 Pharmacodynamic efﬁcacy of levoﬂoxacin against
multidrug-resistant Pseudomonas aeruginosa isolated from
patients with ventilator-associated pneumonia
A. Safarika, M. Raftogiannis, F. Baziaka, A. Antonopoulou,
P. Koutoukas, E. Giamarellos-Bourboulis ° (Athens, GR)
Objectives: Although levoﬂoxacin (LVF) has been proposed for the
treatment of ventilator-associated pneumonia (Benko R, et al. IJAA
2007; 30: 162), there is a lot of scepticism about the appropriateness
of its administration in settings with high-resistance rates. The in vitro
effect of LVF at concentrations close to those achieved in the epithelial
lining ﬂuid (ELF) against multidrug-resistant Pseudomonas aeruginosa
(MDRPA) pathogens from patients with ventilator-associated pneumonia
(VAP) was assessed.
Methods: Eleven MDRPA from patients with VAP enrolled in a
prospective trial (NCT00297674) were tested. Pathogens were grown
at a density greater than 1×106/ml from tracheobronchial secretions in
parallel with a clinical pulmonary infection score more than 6. A log-
phase inoculum of 1×106 cfu/ml of pathogens was exposed over time
to 5, 10 and 25 microg/ml of LVF that corresponds to its ELF levels.
They were also exposed to 18 microg/ml of meropenem (MER), to 5
microg/ml of colistin (COL) and to their interactions. The latter are
S474 19th ECCMID, Posters
concentrations equal to their mean serum levels. MER and COL were
applied because these were prescribed by the attending physicians.
Results: MIC50 and MIC90 of LVF was 64 and 128 microg/ml
respectively. A more than 3 log10 bactericidal effect of LVF was shown
by concentrations of 5, 10 and 25 microg/ml against ﬁve, ﬁve and ﬁve
isolates respectively at all times of growth. MER was bactericidal in nil
isolates and COL in two isolates. Synergy deﬁned as any more than
2 log10 decrease of bacterial growth compared with the most active
single agent was shown between 5 microg/ml of LVF and MER in four,
four, ﬁve and six isolates at 2, 4, 6 and 24 hours of growth respectively;
between 10 microg/ml of LVF and MER in ﬁve, ﬁve, ﬁve and eight
isolates respectively; and between 25 microg/ml of LVF and MER ﬁve,
ﬁve, six and eight isolates respectively. Respective synergy between
5 microg/ml of LVF and COL was found in four, four, four and two
isolates; between 10 microg/ml of LVF and COL in four, four, ﬁve and
three isolates; and between 25 microg/ml of LVF and COL in four, ﬁve,
ﬁve and three isolates.
Conclusions: Despite the great MIC values, LVF showed considerable in
vitro bactericidal effect against MDRPA pathogens of VAP when applied
at concentrations close to ELF. Single MER and COL were not that
effective but they acted in synergy with LFV. These ﬁndings reinforce
the application of LVF for VAP by MDRPA.
P1662 New insights into the most commonly studied drug
interaction with antibiotics: pharmacokinetic interaction
between ciproﬂoxacin, gemiﬂoxacin and probenecid at renal
and non-renal sites
C. Landersdorfer, V. Jakob °, C. Kirkpatrick, M. Kinzig, J. Bulitta,
U. Holzgrabe, F. So¨rgel (Nuremberg-Heroldsberg, Wurzburg, DE;
Brisbane, AU)
Objectives: Probenecid interacts with transport processes of drugs at
several sites in the body. Although frequently used in any new antibiotic
development program, there has been very little sophisticated modeling
to understand probenecid’s action. We modeled gemiﬂoxacin in plasma
and urine with and without probenecid simultaneously and compared
it to the simultaneous model of ciproﬂoxacin (CIP), its metabolite CIP-
M1, and probenecid. This allowed us to compare the extent, time course,
and mechanism of the quinolone-probenecid interaction at the renal and
non-renal sites between CIP and gemiﬂoxacin. Additionally, we studied
the effect of probenecid on the formation of CIP-M1.
Methods: We ran two randomised, two-way crossover studies in healthy
volunteers (CIP 6M/6F; gemiﬂoxacin 9M/8F). Study 1: 200mg CIP
as 30min iv infusion without and with 3 g probenecid divided in ﬁve
oral doses. Study 2: 320mg oral gemiﬂoxacin without and with 4.5 g
probenecid divided in eight oral doses. Drug analysis by LC-MS/MS
and HPLC. We used non-compartmental analysis and modeled the full
time course of gemiﬂoxacin and probenecid as well as of CIP, CIP-M1
and probenecid in plasma and urine simultaneously with WinNonlin(R).
We used ANOVA statistics.
Results: Data are ratio of geometric means [90% conﬁdence intervals]
(* p< 0.01). Addition of probenecid reduced the renal clearance to
35% [29−41%]* of baseline for CIP, to 34% [27−43%]* for CIP-
M1 (estimated by modeling) and to 49% [47−51%]* for gemiﬂoxacin.
Probenecid reduced the non-renal clearance to 81% [74−88%]* for
gemiﬂoxacin and to 92% [86−99%] (p< 0.08) for CIP. Pharmacokinetic
modeling showed a competitive inhibition of the renal tubular secretion
of CIP by probenecid. The afﬁnity for the renal transporter was 3.8 fold
higher (median) for CIP than for probenecid and 7.2 fold higher for
gemiﬂoxacin than for probenecid. Our models indicated that probenecid
inhibited the non-renal clearance of gemiﬂoxacin, but did not affect the
non-renal clearance of CIP or the formation of CIP-M1.
Conclusion: Simultaneous modeling of the full time course of
gemiﬂoxacin and probenecid as well as of CIP, CIP-M1 and probenecid
as expected was superior to non-compartmental analysis in providing
insight into the mechanisms of the interactions. Probenecid inhibited the
renal secretion of gemiﬂoxacin, CIP and CIP-M1 and slightly decreased
the non-renal clearance of gemiﬂoxacin.
P1663 Absorption, distribution, metabolism and excretion of
zaboﬂoxacin (DW-224a, PB-101) after a single oral
administration
J.A. Rock °, S. Johnson, M. Tasawar, B.A. John, C. Webber, J.M. Ryu
(San Diego, US; Cambridgeshire, UK; Anyang, KR)
Objectives: To examine the pharmacokinetics, tissue distribution,
metabolism and excretion of Zaboﬂoxacin (also known as DW-224a
and PB-101), a new broad-spectrum ﬂuoroquinolone-type antibiotic with
enhanced in vitro activity against Streptococcus pneumoniae.
Methods: [14C]Zaboﬂoxacin hydrochloride (100mg salt/kg), as a
solution in puriﬁed water, was dosed to fasted male Sprague-Dawley
rats and male Lister-Hooded rats.
Results: After oral administration of [14C]Zaboﬂoxacin 93.9% of
radiolabelled dose was recovered after seven days of which 79% dose
was eliminated in faeces and about 13% dose excreted in urine. In
bile duct-cannulated rats, 84% of the dose was recovered in faeces
with 3.7% and 3.4% dose excreted in urine and bile, respectively.
The total circulating drug-related material increased to a Cmax of
5.39mg equivalents free base/mL after 1 h, and then declined (to 1% of
Cmax at 12 h post-dose). Tissue concentrations of drug-related material
were generally maximal between 0.5−1 h post-dose, with a later Cmax
observed in gastrointestinal tract, testes and skin. In pigmented rats,
tissue concentrations were highest in the eyes and remained measurable
over 112-days. Essentially, all radioactivity excreted in faeces and urine
was unchanged Zaboﬂoxacin, as was the majority within the kidney and
liver. In bile, Zaboﬂoxacin was essentially absent but up to three major
metabolites were present. In circulating plasma, whilst Zaboﬂoxacin was
detectable, a conjugate of Zaboﬂoxacin was also prominent, and this
Phase II metabolite was also detectable in a number of tissue matrices
(lung, testes, thymus).
Conclusion: [14C]Zaboﬂoxacin hydrochloride orally administered
demonstrated good absorption and generally higher tissue concentrations
than plasma levels. The majority of dose was recovered in the faeces
followed by the urine and bile. Drug-related material was found to bind
to pigmented tissue particular ocular melanin. Minimal metabolism was
found in the faeces and urine but up to three major metabolites were
detected in bile with conjugates present in plasma and tissues.
P1664 Toxicodynamics of itraconazole
J.M. Lestner °, S.A. Roberts, D.W. Denning, W.W. Hope (Manchester, UK)
Objective: To identify the frequency of adverse events that occurred
during treatment with itraconazole (ITZ), and examine the relationship
between ITZ concentrations and the probability of toxicity.
Methods: Patients who received ITZ and underwent therapeutic
drug monitoring (TDM) were identiﬁed from the Regional Mycology
Laboratory database. The following information was obtained from
patients’ medical records: age, gender, diagnosis, ITZ dosages and
duration of treatment. All plasma ITZ concentrations were measured
by bioassay. Toxicity was deﬁned as any symptom, sign or biochemical
disturbance that occurred during treatment and resolved or improved with
ITZ withdrawal or dose-reduction. Observed features of toxicity were
sub-classiﬁed as gastro-intestinal (GI), cutaneous, metabolic disturbance,
and symptoms of ﬂuid retention. For patients with toxicity, the mean
ITZ concentration in the 3 months preceding an adverse event were
calculated. These were compared to ITZ concentrations in an equivalent
3-month-period for patients without adverse events. The relationship
between mean ITZ concentrations and the probability of an adverse event
was deﬁned using logistic regression.
Results: Data from 216 patients were available for analysis. The overall
rate of toxicity was 47%. The incidence of GI symptoms, ﬂuid retention,
cutaneous symptoms, and metabolic disturbance were 21, 18, 7 and 4%,
respectively. The mean±SD ITZ concentrations in patients experiencing
an adverse event versus patients not experiencing an adverse event were
7.0±5.9 and 16.0±8.7mg/L, respectively (p< 0.001). Logistic regression
demonstrated a progressive increase in the probability of an adverse
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event with higher drug concentrations (p< 0.001). Concentrations of
5mg/L and 15mg/L were associated with probabilities of toxicity of
26 and 63%, respectively. There was no ITZ concentration identiﬁed
that corresponded to a marked increase in the probability of an adverse
event, meaning the population could not be divided into discrete groups
with different probabilities of toxicity.
Conclusions: Adverse events are common with ITZ therapy, and show a
statistically signiﬁcant relationship with mean ITZ concentrations. These
analyses demonstrate that ITZ has a narrow therapeutic window and
TDM may therefore aid in the optimisation of treatment regimens, in
order to maximise the probability of success and minimise toxicity.
P1665 Oral pharmacokinetics of isavuconazole in liver impairment
due to cirrhosis
A.H. Schmitt-Hoffmann °, B. Roos, E. Peterfai, D. Edwards,
J. Spickermann, M. Heep (Basel, CH; Balatonfu¨red, HU; Detroit, US)
Background: Isavuconazole is an extended-spectrum azole administered
orally or intravenously as a water-soluble pro-drug (WSA). Isavucona-
zole is currently under investigation in phase 3 studies in patients with
systemic candidiasis, aspergillosis or invasive fungal infection with rare
moulds. Isavuconazole is slowly eliminated by CYP-mediated clearance.
Therefore, we investigated the oral PK of isavuconazole in subjects with
hepatic impairment due to alcohol consumption.
Methods: Healthy volunteers and subjects with mild and moderate liver
impairment received a single oral dose of WSA equivalent to 100mg
isavuconazole. Subjects were enrolled in three groups (n = 8) matched
for age, gender, body weight and BMI. Pharmacokinetic parameters were
derived using WinNonlin 5.1. The Tuckey test was used to assess the
statistical signiﬁcance of differences in isavuconazole pharmacokinetics.
Results: Average Child-Pugh scores of 5.2 and 7.6 were measured in
subjects with mild and moderate hepatic impairment, respectively.
Subjects with liver impairment had signiﬁcantly lower systemic clearance
(CL/F) of isavuconazole, compared with healthy subjects, accompanied
by almost a two-fold increase in the half-life and the AUC (p< 0.05).
Cmax was slightly decreased in patients corresponding to a modest
increase of V/F (p> 0.05). A similar effect was observed after
intravenous administration (ICAAC 2008, Poster A-007). The impact of
liver impairment was not statistically different to results after intravenous
administration shown previously or the gender.
Conclusion: Administration of isavuconazole to patients with mild or
moderate hepatic impairment will require a dose adjustment compared
to normal patients. The dose adjustment will be the same irrespective of
the route of administration and the gender.
Subjects/
parameters
Cmax
(mg/mL)
Tmax
(h)
AUC0−∞
(mg·h/mL)
CL/F (L/h) T1/2 (h) V/F (L)
Healthy 0.843±0.171 1.5–3.0 44.6±11.3 2.38±0.640 148±73.2 480±149
Impairment
Mild 0.729±0.165 1.0–4.0 97.8±52.8 1.26±0.550 292±117 485±212
Moderate 0.472±0.122 2.0–4.0 62.2±24.9 1.82±0.640 240±58.3 598±183
Arithmetic mean (±SD), except for Tmax presented as range.
P1666 Skin concentrations and pharmacokinetics of posaconazole
after oral administration
G. Krishna °, L. Ma, E. Beresford, A. Tavakkol, M. Martinho, X. Yu,
S. Komjathy (Kenilworth, Lenexa, US)
Objectives: The primary objective of this study was to determine the
concentration of posaconazole (POS) in 4-mm skin punch biopsy in
human subjects given POS 400mg twice daily (BID) orally (PO).
Secondary objectives were to compare skin concentration and plasma
levels of POS to the MIC90 of relevant pathogens.
Methods: This was a randomised, single-centre, open-label study of POS
in healthy adults. Subjects received 400mg POS BID for 8 days with a
high-fat meal. Blood samples for plasma POS level determination were
collected at prespeciﬁed times on Day 1 and Day 8. From each subject,
two skin samples were obtained, one immediately before or after both
the ﬁrst and last doses of POS. A MIC90 value of 250 ng/ml, which
encompasses the majority of common dermatophytes [1], was used to
calculate the PK/PD parameters AUC (0−24 hr)/MIC90 and time-above-
MIC90 in plasma and skin.
Results: A total of 30 adult subjects (18 to 60 yr) were dosed. On Days 1
and 8, POS attained peak plasma concentrations at a median Tmax of 8
and 5 hours, respectively. On Days 1 and 8, POS peak skin concentrations
were attained at 12 and 3 hours; peak skin concentrations were obtained
from a single composite proﬁle. On Day 1, the AUC/MIC90 ratio was 29
and 14 in plasma and skin, respectively. On Day 8, these AUC/MIC90
values increased to 149 and 187 in plasma and skin, respectively. On
Day 8, POS concentrations in skin and plasma were several-fold higher
than the MIC90 for the entire dosing interval. POS dosed at 400mg BID
PO was safe and well tolerated among healthy subjects.
Figure 1. Mean plasma ± 1 SD) and skin concentration-time proﬁles of
posaconazole on Day 8 after oral administration of posaconazole (400mg
BID) in healthy subjects.
Conclusions: AUC/MIC90 ratio in skin and plasma was similar. POS
skin concentration on Day 8 remained several-fold above the MIC90
value1 for dermatophytes commonly seen in cutaneous infections. These
ﬁndings demonstrate adequate skin penetration and have implications for
treatment of dermatophytic skin and nail infections.
Reference(s)
[1] A. K. Gupta, Y. Kohl, and R. Batra. In vitro activities of
posaconazole, ravuconazole, terbinaﬁne, itraconazole and ﬂucona-
zole against dermatophyte, yeast and non-dermatophyte species.
Medical Mycology March 2005, 43 (179–185).
P1667 Inhibition effects of four antifungal triazoles (itraconazole,
ﬂuconazole, voriconazole and posaconazole) on speciﬁc
activities of CYP3A4 in human liver microsomes
S. Baloul, Y. Nivoix °, P. Engel, D. Leveˆque, R. Herbrecht, G. Ubeaud
(Strasbourg, FR)
Triazoles are inhibitors of various cytochrome P450 (CYP) isoenzymes
such as CYP3A4, CYP2C9 and CYP2C19. Their inhibitory potencies
are vastly different and also differ for the various isoforms. Itraconazole
inhibits CYP3A4 stronger than ﬂuconazole and voriconazole, in human
liver microsomes. Few data exists in regards to the comparative inhibitory
effects of posaconazole on CYP3A4.
Objective: To compare in vitro the inhibition effects of 4 antifungal
triazoles (itraconazole, ﬂuconazole, voriconazole and posaconazole) on
speciﬁc activities of CYP3A4 via Ki values under identical experimental
conditions.
Methods: The inhibition effects of the four antifungal drugs were
assessed on cytochrome CYP3A4-mediated midazolam oxidation ac-
tivities in human liver microsomes. Ki values were estimated from
Dixon plots using the appropriate enzyme inhibition model by nonlinear
regression. These studies were performed by using midazolam, a speciﬁc
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substrate of CYP3A4 in presence and in absence of these antifungal
drugs after incubation of liver microsomes and regenerating system
after dosage of midazolam. The inhibition model was evaluated with
ketoconazole as a positive control of CYP3A4 inhibition.. At 25mM and
75mM ketoconazole, midazolam metabolism from 5mM midazolam was
inhibited by 46% and 87% respectively.
Results: The Ki values (±SD) of itraconazole, ﬂuconazole, voricona-
zole and posaconazole were 16±2mM, 221±2mM, 151±4mM and
215±14mM, respectively (Figure 1).
Figure 1. Ki values of antifungal triazoles against CYP3A4 activities. A
higher Ki indicates a lower inhibition of CY3A4.
The inhibitory effect on CYP3A4 is the strongest for itraconazole
(itraconazole >>> voriconazole > ﬂuconazole = posaconazole) (p value
= 0.024). Itraconazole was also determined to be a competitive inhibitor
whereas ﬂuconazole, posaconazole and voriconazole seem to induce a
non-competitive or mixed-type inhibition.
Our in vitro results show that posaconazole is a weak CYP3A4 inhibitor
comparable in intensity to ﬂuconazole as opposed to itraconazole or
voriconazole, which induce a much stronger inhibitory effect. When
compared with other extended-spectrum triazoles, this suggests that
posaconazole may have a decreased potential of drug-drug interactions
via CYP3A4 inhibition.
P1668 Development and validation of a liquid chromatography-
tandem mass spectrometry procedure for the quantiﬁcation
of tigecycline in human serum: application to drug
monitoring
M. Rodamer, V. Jakob, S.T. Mees, M. Kinzig, S. Hu¨ttner, F. So¨rgel °
(Nuremberg-Heroldsberg, Munster, DE)
Objectives: There is general agreement that following new drug approval
more work needs to be done to further understand an agents clinical
properties. Therapeutic drug monitoring is one way to help assess a new
agent in a broader range of patients.
For that purpose we developed and validated (according to FDA-
Guideline) an assay for the determination of tigecycline in human serum.
Methods: Determination of tigecyclin in human serum was per-
formed with tandem mass spectrometric detection (LC-MS/MS) using
TurboIonSpray® ionisation. Deuterated tigecycline was used as the
internal standard. The following singly charged precursor → product ion
transitions were monitored: 586 → 569 for tigecycline, 596 → 579 for
d9-tigecycline. The plasma samples were extracted with organic solvent
including internal standard and injected into the LC-MS/MS System.
Chromatography was performed on a reversed-phase analytical column
with a mobile phase consisting of ammonium formate and acetonitrile.
Results: Linearity could be shown within 0.0100–10.0mg/mL and
correlation coefﬁcients were at least 0.998 on all validation days. Intra-
run CVs ranged from 0.5 to 8.3%, inter-run precision (CV) ranged
from 1.6 to 4.8%. Mean recovery over the whole concentration range
was 90.2%±4.2% SD for tigecycline and 90.5%±2.3% SD for d9-
tigecycline. There was no instability observed for tigecycline during the
validation procedure. Prepared samples are stable for at least 48 hrs at
+4ºC. Serum samples are stable for at least 5 months at −70ºC and up to
three freeze and thaw cycles. Haemolytic, lipaemic and six different
plasmas showed no effect on the determination of tigecycline. Also
diluting samples has no inﬂuence on the measurement. Blinded sample
analysis precision ranged from 0.7 to 10.3%. Cross validation CVs to
heparine, EDTA and citrate plasma ranged from 0.8% to 11.3%.
Conclusion: We developed and validated a method for the determination
of tigecycline in human serum and plasma. Due to short analytical
runtime we can analyze over 300 samples per day per LC-MS/MS system
according to GLP guidelines. Analysing clinical drug monitoring serum
and plasma samples demonstrated the excellent performance of the assay.
P1669 Effect of protein binding in the activity of voriconazole
and anidulafungin alone or combined against Aspergillus
sp. using a time-kill methodology
F. Caﬁni, D. Sevillano, L. Alou °, N. Gonza´lez, M. Torrico, N. Mir,
J. Prieto (Madrid, ES)
Objectives: To study the effect of the presence of physiological
concentrations of human albumin and 75% human serum by con-
centrations similar to the Cmax obtained in serum after steady-state
doses of voriconazole (VOR) (400/200mg) and anidulafungin (ANF)
(200/100mg) against two Aspergillus fumigatus (MIC VOR=1 and
MEC ANF=0.015 and 0.12mg/L) and two Aspergillus ﬂavus (MIC
VOR=1mg/L and MIC ANF= 0.03 and 0.12mg/L) strains.
Methods: Killing curves were performed with a ﬁnal inoculum of
approximately 105 spore/ml, and a ﬁnal VOR and ANF concentration
of 2.08 and 8.6mg/l, respectively (Cmax) in different media: a) RPMI
broth (Cmax); b) RPMI broth with 75% human serum (Cmax-S), and
c) RPMI broth with 3.75 g/dL human albumin (Cmax-Alb). In parallel,
killing curves with VOR or ANF concentrations (0.87 and 0.086mg/L,
respectively) corresponding to free-drug (CmaxF) were performed in
RPMI broth considering 58%, and 99% protein binding for VOR for
ANF, respectively. Control growth curves were performed in all media
tested without antibiotics. Cultures were incubated at 35ºC. At each time
point (6, 10, 24 and 48 h) the metabolic activity was assessed using an
XTT assay. All experiments were performed in triplicate.
Strain/MEC (mg/L) Cmax Cmax-S Cmax-Alb CmaxF
A. fumigatus 5/0.015 42.44 50.55 45.57 100.00
A. fumigatus 8/0.12 40.00 35.00 70.49 100.00
A. ﬂavus 9/0.12 100.00 64.91 100.00 98.28
A. ﬂavus 10/0.03 87.06 59.8 77.32 92.78
Results: A rapid decrease in the cellular viability was observed for all
strains in VOR and VOR plus ANF curves independently of the presence
of human serum or albumin in the medium. In ANF curves, cellular
viability (%) at 48 h was:
Conclusions: Synergism could not be demonstrated due to the high
activity showed by VOR. Theoretical extrapolation of active drug from
total drug by using the protein binding rate seems a non accurate method
to study antifungal activity considering the implications of protein
binding.
Public health
P1670 UK infectious disease research network
M. Head ° (London, UK)
Objective: The Infectious Disease Research Network (IDRN) provides
an innovative infrastructure that promotes multi-disciplinary collabora-
tions, provides information on funding opportunities, organises training
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events, and acts as a forum for encouraging high quality translational
infectious disease research.
Methods: We achieve this by several methods. These include running
of research strategy workshops to identify priority research topics and
providing support to groups who are focussed on a speciﬁc research
question. Support may include arranging further meetings, identifying
extra collaborators and assisting with the ﬁnancial projections for
the project. We also run training events, and have various electronic
resources, such as current funding and training bulletins, and an online
researchers database.
Results: IDRN research outcomes include Flu-Watch (household cohort
study on transmission of inﬂuenza), National Intestinal Infectious
Disease Study (looking at diarrhoeal illness in the community) and a
Medical Research Council fellowship looking at community-acquired
MRSA. See the ’research’ page on the IDRN website for a complete
list.
Conclusions: The IDRN provides a model of how a small administrative
infrastructure, with academic input from Network members, can initiate
and support a wide range of collaborations, training events and
information resources, ultimately leading to better collaborative research.
Our website is www.idrn.org
P1671 Biological risk in a pharmaceutical dump: Brucella abortus
strain viable after 20 years of disposal
R. Koncan °, S. Bianchi, A. Amendola, M. Canuti, G. Tridente,
G. Cornaglia (Verona, Milan, IT)
Objective: To evaluate the viability of the Brucella abortus B19 vaccine
strain, recovered 20 years after storage in sealed vials
Methods: Material of potential biological risk have remained buried
for years in the soil of the 12,000 square metres wasteyard of
a pharmaceutical research institute in Milan (Istituto Sieroterapico
Milanese, ISM). During the ISM reclamation, huge quantities of live
vaccine against B. abortus were discovered in hermetically sealed vials.
The procedure of reclamation of the ISM waste pit was carried out under
strict safety conditions, using individual and environmental protection.
Two vaccine types of B. abortus (in liquid and in lyophilised form)
have been unearthed during the process of reclamation and subsequently
analyzed. A review of documentation revealed that all these vaccines
had been produced by the ISM prior to 1975.
To evaluate the viability of the bacterial strains, vial contents were ﬁrst
inoculated into Brain Heart Infusion (Oxoid). After visible growth the
colonies were subcultured onto Columbia and MacConkey agar plates
(Oxoid). Brucella species were conﬁrmed by PCR using speciﬁc primers
based on the AMOS test for Brucella melitensis and B. abortus (JCM,
Nov 1994).
Results: Both the liquid and the lyophilised vaccines demonstrated
growth on Brain Heart Infusion. After 24 hours of incubation in 5% CO2,
non-pigmented non-haemolytic colonies were observed on Columbia
agar plates. The lyophilised strain also grew in MacConkey agar on
the third day after seeding.
Conﬁrmatory identiﬁcation was carried out by molecular methods.
Fragments obtained with the AMOS test were sequenced and the BLAST
analysis performed revealed that both lyophilised and liquid samples
contained B. abortus biovar 1, i.e. the Buck 19 vaccinal strain.
Conclusion: Our results reveal the existence of a biological risk
associated with the uncontrolled burial of pharmaceutical industry waste,
such as live vaccines. Humans may inadvertently be exposed to products
derived from vaccine manufacture by means of unintentional inoculation
or other routes of exposure (aerosol, oral, injection).
It is noteworthy that Brucella is classiﬁed a class-3 organism and is a
potential agent for bioterrorism according to the WHO guidelines.
P1672 Phenotypic and genetic investigation of virulence and
antibioresistance hallmarks in Escherichia coli strains
isolated from Black Sea water on Romanian coast
E. Panus °, C. Bleotu, M.C. Chiﬁriuc, N. Rosoiu, V. Lazar, M. Mitache
(Constanta, Bucharest, RO)
Purpose: The aim of this study was to investigate by phenotypic and
molecular techniques the antibioresistance proﬁle and the virulence
markers of 100 environmental Escherichia coli aquatic isolated marine
water in Constanta, Romania.
Material and Methods: The antibiosusceptibility testings were
performed by disk diffusion method (CLSI, 2008) and phenotypic
screening of b-lactamases. The presence of different antibioresistance
markers was correlated with the plasmidial pattern of the analyzed
strains. Eleven (11) virulence factors were tested by using speciﬁc
culture media. PCR was performed for the following antibioresistance
and virulence genes: blaTEM-like, blaSHV-like, blaOXA-like, blaCTX-
M-like.
Results: The tested strains exhibited high susceptibility to imipenem,
ceftriaxone, cefoxitin and nitrofurantoin (99%), tobramycin (98%),
cephtazidime (97%), gentamycin and amikacin (96%), ciproﬂoxacin
(93%), nalidixic acid and chloramphenicole (92%) sulphametoxazole
(89%) and high resistance levels to ampicillin (94%). The tested strains
exhibited between 1 and 8 antibioresistance markers, the most frequent
associations being: AMP+SXT (10%), AMP+C (9%), AMP+CIP (8%)
and AMP+NA (7%). Morevoer, the tested strains exhibited resistance
to heavy metals, i.e. to Zn (72%), Mn (98%), Cu (98%), Co
(95%), and Ni (99%). 43.6% strains exhibiting resistance to b-lactam
antibiotics proved to be positive for the presence of b-lactamases when
tested by nitrocephine rapid test. The synergy test was negative for
all tested strains. 25% of the tested strains exhibited at least one
plasmid with variable molecular weights. Concerning the virulence
hallmarks harboured by the sea water strains, 44% exhibited capacity
of adherence to the cellular substrate (adherence indexes of 30% with
localised, aggregative and diffuse patterns) and inert substrata (60%).
Unexpectedely, an important number of strains (70.37%) also exhibited
invasion ability of HeLa cells demonstrating the potential of these strains
to colonise the animal and human tissues and to initiate an infectious
process. The tested strains produced also soluble virulence factors,
i.e. mucinase (100%), lysin-decarboxilase (93%), aesculin hydrolysis
(67%), b-haemolysins (6%). PCR analysis conﬁrmed the presence of
the resistance and virulence genes in the sea water E. coli genome,
demonstrating its contribution to the maintenance of the environmental
reservoir of pathogenicity.
P1673 Microbiological quality of air conditioning systems in cars
R.P. Vonberg °, P. Gastmeier, B. Kenneweg, H. Holdack-Janssen, D. Sohr,
I.F. Chaberny (Hanover, Berlin, Braunschweig/Wolfenbuttel, DE)
Objectives: Because of better comfort for the passengers, air condi-
tioning (AC) systems are a common feature in new built automobiles
these days. However, there is some concern about a potential risk for the
health for example for immune-compromised passengers that might be
deriving from AC systems, as its impact on the number of particles and
microorganisms in the air inside the vehicle remains yet unknown.
Methods: The study was performed between January 2004 and July 2006
(30 months) on the campus of the university of Wolfsburg and Hannover
Medical School. The following study cars were used: Volkswagen (VW)
Passat (station wagon, diesel, built 1998, 110,000 km), VW Polo FSI
(small car, gasoline, built 2003, 10,000 km), Seat Alhambra (small
van, gasoline, built 1997, 175,000 km). All cars were equipped with
an automatic air conditioning system. Operation modes (maximum
capacity) using fresh air from outside the car as well as circulating air
from inside the car were examined. The total number of microorganisms
and the number of mould spores were measured by impaction in a high
ﬂow air sampler. Particles of 0.5 to 5.0mm diameter were counted by
a laser particle counter device. Samples were taken within the vehicle
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before starting the AC system an after 20 minutes of use. Air outlets
other than the ones examined were taped during sampling. Outside air
samples were also taken to determine the bio-burden in the fresh air.
Results: Overall 32 occasions of sampling were performed. The
concentration of microorganisms outside the cars was always higher
than it was inside the cars. After starting the air conditioning system
the total number of microorganisms was reduced by 81.7%, the number
of mould spores was reduced by 83.3%, and the number of particles
was reduced by 87.8%. Tthere were no signiﬁcant differences neither
between the types of cars nor between the types of operation mode of
the air conditioning system (fresh air vs. circulating air; Figure 1).
Figure 1.
Conclusion: The airborne concentration of all parameters (total number
of pathogens, number of mould spores, and number of particles) that
were looked for in this study improved during utilisation of the car’s AC
system. Thus, we believe that there is no increased risk of infection for
immune-compromised persons when driving in cars with AC systems
in use. Most probably the risk for an allergic reaction will be reduced
during use also.
P1674 Characterisation of bacterial isolates in cheese production
surveillance in an organic farming site
R. Ehricht °, R. Labugger, S. Monecke, H. Hotzel (Jena, Dresden, DE)
Objectives: During the last decade, organic farming became popular in
Germany. Therefore, demand for surveillance in such facilities increased
accordingly. In cheese production from sheep milk it is not only
necessary to screen the ﬁnal product, but also to screen the milk and the
udders. Furthermore, transmission of pathogens from the farmers and
their families to live-stock and to raw milk have to be ruled out.
Methods: At an organic farm, milk and cheese samples as well as
swabs from sheep and farmers were collected. Subsequently, they were
subjected to analysis using standard microbiological screening as well
as molecular techniques, such as PCR, sequencing and diagnostic
microarrays to characterise the bacterial isolates.
Results: By growing the different samples from cheese, milk, humans
and sheep on Columbia blood agar plates and subsequent microbiological
and molecular analysis, 13 different bacterial species were identiﬁed
and conﬁrmed by sequencing, PCR and diagnostic microarrays. Most
of them belonged to the genus of Staphylococcus, representing the
species S. warneri, S. chromogenes, S. ﬂeuretti, S. xylosus, S. equorum,
S. epidermidis and S. aureus. But also other bacteria as Kocuria
spec., Acinetobacter spec., Moraxella spec., Corynebacterium spec.
and Streptococcus pyogenes were identiﬁed. All staphylococci were
analysed for 334 different sequences representing species, virulence
and antimicrobial resistance markers using the StaphyType-Kit. By this
method, a unique ﬁngerprint of a S. aureus isolate was generated
allowing to trace transmission of the agent. No MRSA or PVL positive
isolate was detected. Most interestingly, the isolates from a human wound
swab and from the cheese sample were completely identical. It was an
agrIV/CC121, capsule type 8 isolate that contained no antimicrobial
resistance genes but yielded signals for enterotoxins G, I, M, N and O
and U. PVL and mecA were not present. Another isolate cultured from
a human nasal swab was identiﬁed by 16S sequencing as S. ﬂeuretti.
It was mecA positive and additionally contained the genes mecI, mecR,
ugpQ and xylR. The isolates from sheep udders (partially suffering from
mastitis) were all identical. They were agrI/cc133 MSSA containing
enterotoxins C and L as well as leukocidin components lukM and lukF-
P83.
Conclusion: The surveillance of organic farming, e.g., cheese production
is necessary and can be done economically and fast with the described
techniques.
P1675 Carriage state of Neisseria meningitidis isolated from
healthy individuals in West Pomeranian region of Poland
M. Zienkiewicz °, M. Richter, M. Kadlubowski, W. Hryniewicz,
S. Giedrys-Kalemba (Szczecin, Warsaw, PL)
N. meningitidis are responsible for community-acquired invasive
infections (meningitis, sepsis) with a high degree of morbidity and
mortality. The source of infection is usually asymptomatic carrier.
Carriage state of menigococci in the nasopharynx is estimated at 5−30%
in the population, including pathogenic strains which are 1.4−1.6%.
Colonising and infecting serogroups differ in countries and regions.
The aim of this study was to determine meningococcal carriage state in
West Pomeranian region of Poland, the serogroup, susceptibility pattern
and genetic relatedness of isolates.
Methods: The representative group of 1354 healthy individuals of 1
month to 87 years was studied. Nasopharyngeal samples were collected
with cotton-tipped swab and subsequently cultured on chocolate
agar + PolyVitex VCAT3. Meningococci were identiﬁed by using
API NH (bioMerieux) and NEISSERIAtest (Pliva Lachema) and
serogrouped with latex agglutination tests: BD Directigen Meningitis
(Becton Dickinson), Pastorex Meningitidis (BioRad) and PCR method.
Susceptibility patterns to antibiotics: penicillin, ceftriaxone, rifampicin
and ciproﬂoxacin were determined using E-tests. Molecular character-
istic was performed by PFGE method with SpeI restriction enzyme
and computer analysis with Molecular Analyst (BioRad) software
application.
Results: The carriage rate of N. meningitidis in the region was estimated
at 3.03% (41individuals). 56.6% of carriers came from collectiveness,
78% were men and 86.49% smokers. Serogroup B was identiﬁed
in 13 isolates, C − 9, Y − 3, W135 − 1, 15 strains were non
groupable. Serogrouped strains were mainly isolated from the group
of age: 15−24 years (7) and >40 years (8). MIC ranges for all isolates
were: penicillin 0.047–0.25 (3 isolates: group B, C, Y possess reduced
susceptibility, MICs 0.094–0.25), ceftriaxone 0.002–0.004, rifampicin
0.006–0.094, ciproﬂoxacin 0.006–0.016mg/mL. Isolates showed a high
genetic diversity − 7 PFGE clusters consisted of 2 to 4 strains and 22
unique proﬁles have been described. Serogrouped isolates belonged to
genetic types and unique proﬁles also.
Conclusions: There are 3% carriers of N. meningitidis in the population
of West Pomeranian region. About 50% isolates belonged to group B
and C. All pathogenic isolates are sensitive to ceftriaxone, rifampicin and
ciproﬂoxacin, the most to penicillin. The high genetic diversity among
isolates is observed. Supported by Grant N404 033 31/1927.
P1676 How widespread are antibodies to Acinetobacter baumannii
and Haemophilus inﬂuenzae lipopolysaccharides in a
healthy population in Scotland?
R.F.S. Morgan °, I.R. Poxton (Edinburgh, UK)
Objectives: Nosocomial pneumonia is currently a major problem in
intensive care units worldwide. Little is known about how widespread
exposure is to two of the major bacterial causes of nosocomial
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pneumonia: Acinetobacter baumannii and Haemophilus inﬂuenzae,
in the healthy population. Our objective was to determine how
widespread antibody levels (as indicators of exposure) were to the
lipopolysaccharides (LPS) of these two species. These were compared
to antibody levels to the LPSs of E. coli, Klebsiella pneumoniae and
Pseudomonas aeruginosa of which we know more about antibody levels.
Methods: 475 serum samples from healthy donors were collected from
the Southeast Scotland Blood Transfusion Service. These were used in
ELISAs against LPS extracted by the aqueous phenol method from
8 strains of A. baumannii, 4 of H. inﬂuenzae, 2 of E. coli, 2 of
K. pneumoniae, and 2 of P. aeruginosa.. All bacteria were isolated
from patients with respiratory tract infections at the Royal Inﬁrmary
Edinburgh. The antibody levels to LPSs as determined by ELISAs were
then compared between donors and the different species.
Results: The results indicated that antibody levels to LPS could be
detected in all serum samples, ranging widely with the highest levels
up to 5 times the median level. By regression analysis of scattergrams,
comparing pairs of LPSs, antibodies to LPS from A. baumannii showed
similar levels to P. aeruginosa, while those to H. inﬂuenzae showed
antibody levels similar to those of E. coli and K. pneumoniae LPSs.
Conclusions: In the healthy population of SE Scotland it appears
that healthy people are exposed to strains of A. baumannii at similar
levels to their exposure to P. aeruginosa, and both species are found
commonly in the environment. Similarly, exposure to H. inﬂuenzae
was at similar levels to both E. coli and K. pneumoniae and all are
common commensals. Pre-existing antibody levels speciﬁc to the LPS
of these species could be directly related to susceptibility of patients to
nosocomial pneumonia caused by the particular opportunist pathogen.
P1677 Extended-spectrum b-lactamase producing
Enterobacteriaceae in the faecal ﬂora of Portuguese nursing
home residents
D. Gonc¸alves, H. Ferreira ° (Porto, PT)
Objectives: Our previous work in community clinical isolates alerted us
for the ﬁnding of extended-spectrum b-lactamase (ESBL) producers in
particular niches, as nursing homes. In that way, the aim of our study was
the detection and characterisation of ESBL producing Enterobacteriaceae
in the faecal ﬂora of nursing home residents, in Northern Portugal.
Methods: Faecal samples of nursing home residents from the North
of Portugal were collected from January to July 2008. Samples
were suspended in BHI. Isolates were selected in MacConkey
agar with ceftazidime (2mg/L), cefotaxima (2mg/L), and aztreonam
(2mg/L). Lactose fermenters were randomly selected and susceptibility
to antimicrobial agents was determined by agar diffusion methods
according to the CLSI guidelines. Screening of ESBL producers was
performed by the double disk synergy test and conﬁrmed according to
the CLSI. Identiﬁcation of the selected strains was achieved by API 20
E. b-lactamases were characterised by isoelectric focusing. Conjugation
assays were performed with Escherichia coli HB101.
Results: Of 184 faeces samples of residents in 6 nursing homes in the
North of Portugal we screened 48 ESBL producing Enterobacteriaceae
isolates: 39 Escherichia coli, 3 Klebsiella pneumoniae, 2 Citrobacter
freundii, 2 Enterobacter cloacae, 1 Enterobacter aerogenes and 1
Proteus mirabilis, showing an ESBL of pI> 8 alone or in association
with b-lactamases of pIs 5.4 and 7.4.
ESBL gene was successfully transferred coding a b-lactamase of pI> 8
alone or in combination with the other b-lactamases.
Conclusion: Our results showed that nursing homes are particular
niches of community, acting as reservoirs of ESBL producing
Enterobacteriaceae.
b-lactamase isoelectric points, alert for the hypothesis of one successful
track of community dispersion of CTX-M-15, in different combination
with other b-lactamases, as in the CTX-M-15 producing Portuguese
ST131 Escherichia coli epidemic clone, that needs further research.
This reality poses questions in terms of hospital admission of patients
originating from nursing homes, relating to prevention of hospital
dissemination of ESBL producers, colonising those patients. Also the
inverse, spreading to nursing homes and community in general, from
colonised elderly patients discharged from hospital when return to the
ancient care facility or even to family home, might create a cycle of
dissemination of ESBL producing Enterobacteriaceae and ESBL coding
genes.
P1678 The epidemiology of Staphylococcus aureus nasal and
throat carriage in a large community-based population in
northern Norway. The Tromsø Staph and Skin Study
K. Olsen °, G. Skov Simonsen, A. Sundsfjord, H. Husom Haukland,
J. Ericson Sollid, K. Danielsen, B. Haldorsen, A.E. Eggen,
A.S. Furberg (Tromsø, NO)
Objective: Staphylococcus aureus nasal carriage is associated with
increased risk of bacteraemia and skin/soft tissue infections as well
as atopic dermatitis. Studies suggest that the tonsils also may be
a signiﬁcant reservoir for the microbe. Our aim was to study the
epidemiology of S. aureus nasal and throat colonisation and carriage
in a large community-based population in North Norway.
Methods: A cross-sectional study was done as part of the sixth Tromsø
Study in 2007–2008. Random samples of adult birth cohorts were invited
to a health survey including clinical examinations, blood samples, and
questionnaires on socio-demographic factors, lifestyle, health, chronic
diseases and symptoms. The participation rate was about 66%. Nasal
and throat swab cultures were performed in 3,996 participants for the
assessment of S. aureus colonisation. A repeated set of cultures were
performed in 2,986 participants for the assessment of S. aureus carriage
(1,707 women and 1,279 men). Mean age was 54.5 years (range=30–
87 years). Median length of the time interval between cultures was
28 days. All specimens were cultured within 24 hours on chromID
S. aureus agar. Two carriage patterns for each site were distinguished:
non-or-intermittent and persistent carriage.
Results: The prevalence of persistent S. aureus nasal and throat carriage
were 25.1% and 6.0% respectively, and the results were almost constant
across quartiles of the time interval between cultures (cut-off values: 18,
28 and 40 days). Considering culture results from both sites, 11.9%
were deﬁned as consistently persistent carriers, a minor group was
single throat carriers (9.8%), and the majority was single nasal carriers
(78.3%). Male sex was related to higher risk of nasal carriage (odds
ratio, OR= 1.91; 95% conﬁdence interval, 95%CI=1.61–2.27; adjusted
for age). Age was negatively related to nasal carriage (OR= 0.91 per
10 years; 95%CI=0.85–0.98; adjusted for sex). S. aureus throat carriage
was strongly related to nasal carriage (OR= 3.98 for nasal persistent
carriage vs non-or-intermittent carriage; 95%CI=2.90–5.46; adjusted for
sex and age).
Conclusion: The nasal vestibulum is the major niche for S. aureus.
Age and sex are predictors for nasal S. aureus carriage. The role of
other potential risk factors in S. aureus nasal and throat carriage is
currently under investigation. This project brings prospects to studies of
the host-microbe-environment triad in S. aureus carriage, infection, and
skin disease.
Virtuals and E-bugs: teaching microbiology
P1679 e-Bug: evaluation of the e-Bug educational pack in England,
France and the Czech Republic
D.M. Lecky °, J. Weinberg, N. Verlander, J. Benes, P. Touboul,
C.A.M. McNulty for the European e-Bug Working Group
Objectives: To measure the effectiveness of the e-Bug pack in improving
children’s knowledge in 4 key areas − Introduction to Microbes, Transfer
of Infection, Treatment of Infection and the Prevention of Infection, when
used within the National Curriculum in England, France and the Czech
Republic.
Methods: Teaching, using the e-Bug pack, was given by junior and
senior school teachers.
S480 19th ECCMID, Posters
A minimum sample of 151 students from both age groups completed
each of the questionnaires in a range of schools.
Quantitative questionnaires were completed by all students, at three
different time points, to assess student baseline knowledge, knowledge
change and knowledge retention.
Qualitative data was obtained via teacher focus groups, teacher
questionnaires and student questionnaires.
All analyses will be performed in STATA version 10.
Results: Preliminary ﬁndings of the quantitative data shows a knowledge
change (P< 0.001) in all subject areas in the UK. At the time of writing
this abstract, data for France and the Czech Republic have not yet been
analysed.
Qualitative data demonstrated that students in both age groups preferred
the Transfer of Infection sections of the pack as these were more
interactive ‘hands on’ activities and group work activities were preferred
by the majority of schools. The Antibiotic Use and Vaccines sections
were the least liked by students as these followed a more class
discussion/comprehension format. The STI activity was the only activity
liked 100% by both students and teachers.
Photocopying student sheets in the pack was disliked due to high
costs, however teachers found the whiteboard presentations very useful.
Teachers also felt that the provision of more electron microscope
images of the microbes on the web would make this section of the
curriculum more realistic for the students. All teachers liked the inclusion
of background information for themselves although some would have
preferred more detail.
Conclusions: The e-Bug teaching pack was effective at improving
knowledge about micro-organisms, hygiene and antibiotic use however
a variety of changes based on both student and teacher feedback are
required.
The data from this evaluation will be used to modify the packs further,
ready for translation into a variety of European languages in January
2009.
P1680 Virtual microbiology laboratory − teaching and learning
experience in the modern era
M. Hui °, L.P.L. Low, L.W. Lam, C.Y. Chan (Shatin, HK)
Objectives: Acquisition of microbiological knowledge is both
intellectual- and skills-oriented. The traditional ‘wet-lab’ is an important
platform to achieve this goal. The heightened interest in microbiology
and infectious diseases, and the administrative clustering of many insti-
tutions, has lead to increased number of students from geographically
diversed locations. As a result, it is increasingly difﬁcult to organise
laboratory classes with limited resources such as laboratory space
and number of teachings staffs. To address the situation, a web-based
“Virtual Microbiology Laboratory” was developed and evaluated for its
effectiveness.
Methods: Starting 2007/2008, a web-based Virtual Microbiology
Laboratory was set up for nursing undergraduate microbiology studies.
Students’ performance and perception of the course were analysed for
three consecutive academic years (2006/07, 2007/08, 2008/09; class-size
ranged from 174 to 190). These web materials comprised of a series
of 58 web images, 19 videos, 9 on-line quizzes and an anonymous
forum. Access to this web was voluntary, but usage was logged. Students’
learning outcomes were assessed by course evaluation questionnaire (23
items on a 6-point Likert scale: 1 = strongly disagree, 6 = strongly agree)
and examination. The course evaluation was conducted at the end of the
course, but prior to the examination. The examination was paper-based
with long-answer-questions and a-type MCQ, which were marked by the
same panel of teachers.
Results: An improved perception on understanding of concepts and
interest in microbiology was observed with the launch of Virtual
Microbiology Laboratory. An improvement in scoring on the MCQ was
also observed (2008/09 vs 2006/07, p< 0.05) However, scoring with
long-answer-questions had declined (p< 0.05).
Conclusion: The development of Virtual Microbiology Laboratory has
stimulated interest among undergraduate students. Their knowledge,
however, when assessed by traditional examination method had yielded
divergent results. Ability to recall factual information, as tested by
a-type MCQ, is enhanced. Ability to assimilate information, and
to present them in a logical written manner (as tested by long-
answer-question) had declined. While web-based e-learning is a useful
shotgun approach to improve the breath of information, it may not
replace classroom or bench-side teaching where in-depth discussion
are generated, hypothesizing- and theorising-skills are developed and
practised.
Carbapenem resistance in Enterobacteriaceae
P1681 Emergence of multidrug-resistant Klebsiella pneumoniae
producing KPC-type carbapenemase, Italy
T. Giani, M.M. D’Andrea, P. Pecile, L. Borgianni, P. Nicoletti,
F. Tonelli, A. Bartoloni, G.M. Rossolini ° (Sienna, Florence, IT)
Background: KPC-type carbapenemases have recently undergone a
consistent dissemination in various geographic areas (e. g. New York,
Israel, Greece, Colombia), where they represent an important mechanism
of acquired resistance to carbapenems and other b-lactams in Klebsiella
pneumoniae and other Gram-negative pathogens. Here we report on the
emergence of KPC-producing K. pneumoniae in Italy.
Methods: Susceptibility testing was performed by broth microdilution
and Etest. Carbapenemase activity was determined by spectrophotom-
etry. b-lactamase genes were investigated by PCR and sequencing.
Outer membrane proteins (OMPs) were investigated by SDS-PAGE and
sequencing of the corresponding genes.
Results: K. pneumoniae FIPP1 was isolated in October 2008 from
a post-surgical intra-abdominal infection in an inpatient at Florence
University Hospital. The isolate showed a multiresistant phenotype
including carbapenems (imipenem, meropenem and ertapenem MICs,
>32mg/L) other b-lactams, ﬂuoroquinolones, amikacin, tobramycin and
trimethoprim-sulphamethoxazole. Susceptibility was retained only to
gentamicin, colistin and tigecycline. The patient had been empirically
treated with a carbapenem-based regimen. After isolation of FIPP1,
therapy was switched to tigecycline with a favourable outcome. A crude
extract of FIPP1 exhibited carbapenemase activity that was not inhibited
by EDTA. Molecular analysis revealed carriage of KPC-3- and SHV-11-
encoding genes. Analysis of the OMP proﬁle revealed the absence of
k36 porin, which was due to gene inactivation by insertion of IS5-like
sequence. This likely contributed to the high-level carbapenem resistance
of FIPP1. Epidemiological investigations are underway to trace possible
epidemiological links with settings where KPC-producing Klebsiellae
are known to be endemic.
Discussion: Carbapenem resistance in Enterobacteriaceae is still very
uncommon in Italy, where only metallo-b-lactamases have occasionally
been reported as acquired carbapenemases in enterobacterial species.
To our best knowledge this is the ﬁrst report on KPC-producing
K. pneumoniae in Italy, a ﬁnding of major concern due to the spreading
propensity that similar strains exhibited in other settings.
P1682 Emergence of KPC(+) K. pneumoniae strains in Greece:
evaluation of detection methods
H. Moraitou °, I. Galani, D. Papaventsis, M. Makarona, N. Souﬂa,
F. Havouti, S. Mytas, A. Georgousi, V. Spyropoulos, S. Kanavaki
(Athens, GR)
Objectives: Carbapenem resistance, as a result of the production
of Klebsiella pneumoniae carbapenemase (KPC)-type b-lactamases is
emerging worldwide. The purpose of the present study was to detect
KPC (+) strains of Klebsiella pneumoniae, in a tertiary Greek Hospital,
during 2008.
Materials and Methods: A total of 50 multidrug resistant clinical
isolates of Klebsiella pneumoniae strains with a resistance phenotype
compatible with KPC carbapenemase production were included in the
study. More than 50% of clinical specimens were collected from
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Intensive Care Units (ICUs) and were of respiratory system origin. Strain
identiﬁcation and antibiotic susceptibility testing were performed by the
automated Vitek2 system (Biomerieux, France). All strains were further
tested for the production of various b-lactamases, both phenotypically
(ESBL double disk test, VIM EDTA test, E-test imipenem, Hodge test,
boronic acid/imipenem disc test) and by PCR for the detection of blaKPC
gene.
Results: In 38 (72%) of isolates, the EDTA test was positive, the Hodge
and boronic acid/imipenem tests were negative and imipenem MIC was
>32mg/dl, a phenotype indicative of a VIM-carbapenemase production.
In the remaining 12 (24%) isolates, the EDTA test was negative; however,
the Hodge and Boronic acid/imipenem tests were positive and imipenem
MIC was 8−32mg/dl, thus indicating production of KPC b-lactamase.
Most KPC(+) strains were isolated after October 2008, both from ICU
and non-ICU patients, with or without history of previous hospitalisation.
In all cases, phenotypic identiﬁcation of KPC-carbapenemase production
was conﬁrmed by molecular techniques. Further genotype investigation
revealed that all KPC(+) isolates had the same rep-PCR patterns.
Conclusions: This is the ﬁrst report of isolation and identiﬁcation of
KPC(+) Klebsiella pneumoniae strains in our hospital. More than 50% of
these strains were collected from ICU patients, although infection control
measures should be taken to avoid further dissemination throughout the
Hospital setting. The microbiology laboratory could contribute to this
purpose, by including phenotypic investigation of all multidrug resistant
enterobacteriacae in routine practice. Boronic acid/imipenem disc test is
safe, quick and easy to perform, in order to detect KPC(+) strains.
P1683 Rapidly rising prevalence of KPC-2-producing Klebsiella
pneumoniae in a Greek tertiary-care hospital
O. Zarkotou, V. Mamali, E. Voulgari, S. Pournaras, P. Tselioti,
P. Giakkoupi, D. Voutsinas, A. Prekates, K. Digalaki °, A. Vatopoulos,
A. Tsakris (Athens, Larissa, GR)
Objectives: MBL-producing K. pneumoniae is a major public health
problem in several Greek hospitals. Recently KPC-possessing K. pneu-
moniae isolates have been described. We describe the recent widespread
of KPC producers among carbapenem non-susceptible K. pneumoniae
(CNSKP) clinical isolates in our hospital.
Methods: During May-December 2008 all K. pneumoniae isolates
exhibiting elevated imipenem and/or meropenem MICs (>1mg/L) were
screened with combined imipenem-EDTA disk test, cloverleaf test and
boronic acid disk tests. MICs were determined by Vitek 2 and Etest.
All isolates expressing a probable KPC phenotype were tested by PCR
and sequencing assays. Patient records were reviewed for demographic
characteristics, co-morbidities and antibiotic exposure prior to KPC
isolation.
Results: A total of 83 patients harbouring CNSKP isolates were
identiﬁed. In 31 of them (37%) the presence of KPC-2 was conﬁrmed
by phenotypic and molecular assays. Records of patients harbouring
KPC-producing isolates (18 males/13 females; mean age 66.4 y, range
17−88 y) showed that 25 were infected and 6 were colonised. KPC
producers caused bacteraemic episodes in 11 (35%) patients. The median
time from admission to KPC isolation was 17 days. KPC producers
were detected during or after ICU-hospitalisation in 20 patients (64.5%).
Prior hospitalisation (in other hospitals or private health care system)
or nursing home residency was noted for 9/11 non-ICU patients.
Among co-morbidities, cardiovascular and renal diseases (45% and 29%,
respectively) prevailed. Prior antibiotic exposure analysis revealed that
the majority of patients had received b-lactams/b-lactamase inhibitors
(71%) and quinolones (67%). Tigecycline and colistin were mostly
used as treatment regimens. The crude mortality was 40%. All but one
single patient KPC producers were susceptible to gentamicin. Notably,
meropenem MICs were within CLSI susceptibility range in 15 cases.
Colistin-resistant isolates were recovered from 8 patients (26%); 6 of
them had no prior administration of colistin. Elevated tigecycline MICs
(4mg/L) were detected in 2 cases. Long exposure to tigecycline was
noted in one of these patients.
Conclusion: KPC-producing CNSKP poses a new threat. Guidelines
regarding the successful detection of KPC producers, advice on antibiotic
policy and strict infection control measures are urgently needed in order
to restrain a new hyperendemic situation.
P1684 Emergence of Klebsiella pneumoniae isolates possessing KPC
b-lactamase in Israel, Puerto Rico, Colombia and Greece
D. Hoban, M. Renteria, J. Johnson, R. Badal °, S. Hawser, M. Hackel,
S. Bouchillon, B. Johnson, M. Dowzicky (Schaumburg, Collegeville, US)
Background: Klebsiella pneumoniae carbapenemases (KPCs), are
carbapenem-hydrolysing b-lactamases belonging to Bush group2f,
molecular class A. KPC enzymes confer resistance to all b-lactam
agents including penicillins, monobactams, and cephalosporins, as well
as carbapenems. KPC b-lactamases have great potential to spread due
to their location on plasmids. While initially limited to the eastern
United States, KPC enzymes have recently been reported in France (FR),
Colombia (CO), China (CN) and Israel (IL). In this report, we describe
the detection of KPC enzymes in Klebsiella pneumoniae (Kpn) isolates
collected in the 2004 to 2008 Tigecycline Evaluation Surveillance Trial
(T.E.S.T.) from IL, Puerto Rico (PR), CO and Greece (GR).
Methods: Kpn from GR, IL, PR, S. Africa (ZA), S. Korea (KR), Taiwan
(TW), Italy (IT), Argentina (AR), Brazil (BR) and CO with meropenem
(MER) or imipenem (IMI) MIC values of >4, or ertapenem (ERT) MIC
values of >2 were screened by PCR for the presence of blaKPC, the gene
responsible for the KPC enzyme. MICs were determined using manual
broth microdilution following CLSI guidelines.
Conclusions: Monitoring the world-wide dissemination of KPC outside
of the US via the T.E.S.T. global surveillance program revealed isolates
in four countries, including the ﬁrst cases reported from PR and GR.
KPC+ isolates from PR were collected in 2006, while all other KPC+
isolates were from 2007–2008. Since therapy of infections caused by
these multi-drug resistant organisms is difﬁcult, it is essential to monitor
their spread into new regions of the world.
Country Number
tested
Number
positive
Number of
sites
MIC range for KPC
positive isolates (mg/mL)
for KPC for KPC
(KPC+)
with KPC ERT IMI MER
GR 11 1 1 >16 16 32
IL 14 13 4 >16 8−>32 8−>32
PR 8 8 1 0.5−>16 2–16 1−32
ZA 5 0 0 – – –
KR 2 0 0 – – –
TW 1 0 0 – – –
IT 1 0 0 – – –
AR 3 0 0 – – –
BR 1 0 0 – – –
CO 4 4 2 4–16 2−32 1−>32
P1685 Presence of the KPC carbapapenemase in Klebsiella
pneumoniae and Pseudomonas aeruginosa isolated from 6
hospitals in Colombia
A.L. Leal, S.Y. Saavedra, C.H. Saavedra, N. Olarte, M.V. Ovalle,
J.A. Cortes °, G. Buitrago, J.S. Castillo, C.A. Alvarez (Bogota, CO)
Objective: To determine microbiological and molecular presence of the
carbapenemases from isolates carbapenem-resistant K. pneumoniae and
P. aeruginosa.
Methods: A total of thirty-six isolates resistant to carbapenems were
sent to the laboratory, 34 isolates of K. pneumoniae from 6 hospitals of
different cities (Bogota: 4 hospitals, Medellin: 1 hospital, Barranquilla:
1 hospital) and 2 isolates of P. aeruginosa from an institution the
city of Tunja. The isolates were re-identiﬁcated with MicroScan and
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meropenem, imipenem, and ertapenem susceptibilities were determined
by disk diffusion method. For detection of carbapenemases we used
the modiﬁed Hodge test (using disks imipenem and ertapenem) and for
detection of metallo-carbapenemases was performed double-disk synergy
tests (DDSTs) using an IPM disk and an EDTA + mercaptoacetic acid
(SMA) disk. The identiﬁcation of genes encoding of carbapenemases
KPC and metallo-carbapenemases was performed by PCR.
Results: We observed variability of resistant proﬁles to carbapenems.
Resistance to the three carbapenems tested (23 isolates of K. pneumoniae
and 1 isolate of P. aeruginosa), resistance to ertapenem and meropenem
and intermediate susceptibility to imipenem (3 isolates of K. pneumoniae
and 1 isolate of P. aeruginosa), resistance to ertapenem and imipenem
and susceptibility to meropenem (1 isolate of K. pneumoniae), resistance
to ertapenem and meropenem and susceptibility to imipenem (1 isolate of
K. pneumoniae), resistance to ertapenem, intermediate susceptibility to
meropenem and susceptibility to imipenem (1 isolate of K. pneumoniae)
and ﬁnally resistance to ertapenem and susceptibility to meropenem and
imipenem (5 isolates of K. pneumoniae). All isolates were positive for
the Hodge test and no difference was observed when using a disk of
imipenem and ertapenem. We founded that all isolates were negative
for metallo-b-lactamases by PCR and DDST and all isolates were
positive for carbapenemase KPC by PCR. Sequencing from ampliﬁcation
products conﬁrmed the presence from KPC-3 in the vast majority of
isolates.
Conclusions: Despite the variability in resistance proﬁles, all isolates
were resistant to carbapenems. Our results indicate spread of KPC in
isolates in different cities from Colombia. This is the ﬁst report of KPC-3
from Colombia.
P1686 Outbreak of KPC-2-producing Klebsiella pneumoniae in a
university hospital, Ribeira˜o Preto City, Brazil
L.N. Andrade, E.C. Clı´maco, J.C. Ferreira, R. Martinez, A.L.C. Darini °
(Ribeirao Preto, BR)
Objectives: The main objective of this study was to investigate the
resistance mechanism of carbapenem-resistant K. pneumoniae outbreak
in a university hospital in the Ribeira˜o Preto city − Brazil.
Methods: 43 carbapenem-resistant K. pneumoniae were isolated from
non-repeated patients in the Intensive Care Unit of “Hospital das
Clı´nicas de Ribeira˜o Preto (HCRP)”, from April of 2007 to June
of 2008. Identiﬁcation and antimicrobial susceptibility proﬁle of the
isolates were evaluated with Vitek®1 System. Genetic proﬁles of
carbapenem-resistant K. pneumoniae were determined by Pulsed Field
Gel Electrophoresis (PFGE). Minimum inhibitory concentration (MIC)
of imipenem, meropenem and ertapenem were determined using ETest.
Modiﬁed Hodge test was performed to detect carbapenemase production.
PCR and sequencing were used to investigate several carbapenemases
encoding genes (blaKPC, blaGES, blaSPM, blaIMP, blaVIM) and their
genetic environment. Conjugation experiment was utilised to investigate
carabepenem resistance transfer.
Results: The isolates demonstrated susceptibility only to polymyxin B
and tigecycline. PFGE revealed the spread of a unique clonal type.
Imipenem, meropenem and ertapenem MICs values were, respectively,
8mg/L, 8mg/L and 32mg/L. Modiﬁed Hodge test was positive,
indicating carbapenemase production. PCR ampliﬁcation and sequencing
identiﬁed blaKPC-2 gene, ﬂanked by insertion sequence ISKpn7 and
ISKpn6. This genetic environment suggests that blaKPC-2 gene may be
mobilised by transposon Tn4401, as published previously. Conjugation
experiment demonstrated that blaKPC-2 gene and carabapenem-resistant
phenotype was transferred to recipient strain.
Conclusion: An outbreak of KPC-2-producing K. pneumoniae took
place in the HCRP. The spread of blaKPC genes was related with a
unique clonal type of K. pneumoniae, however, this gene was associated
with mobile elements and can be transferred to other bacterial species.
The KPC-producing K. pneumoniae can be considered as the “select of
select” of multiresistant bacteria and it can become pandrug-resistant in
little time.
P1687 Detection of KPC enzymes in Klebsiella pneumoniae isolates
from NY/NJ sites in the TEST Program
M. Renteria, J. Johnson, R. Badal, S. Hawser °, M. Hackel, S. Bouchillon,
B. Johnson, D. Hoban, M. Dowzicky (Schaumburg, Collegeville, US)
Background: Carbapenem resistance in Klebsiella pneumoniae (KPN)
is mainly due to the presence of an acquired carbapenem-hydrolysing
b-lactamase known as Klebsiella pneumoniae carbapenemase (KPC).
The KPC enzyme confers resistance to all b-lactam agents including
penicillins, monobactams, and cephalosporins, as well as carbapenems.
Since the initial discovery in North Carolina in 2001, KPC enzymes have
been reported in several outbreaks in the eastern United States, as well as
sporatic cases in France, Colombia, China and Israel. We evaluated 173
ESBL+ KPN isolates from New York and New Jersey (NY/NJ) collected
in the 2004 to 2008 Tigecycline Evaluation Surveillance Trial (TEST)
for the presence of the KPC gene via PCR.
Methods: Imipenem (IMI), meropenem (MER) and ertapenem (ERT)
MICs were determined for 173 ESBL+ KPN from 25 sites in New York
and New Jersey. A subset of isolates was screened for the presence
of blaKPC by PCR. All MIC testing was done by manual broth
microdilution following CLSI protocols.
Results: 88 of 173 (47%) ESBL+ KPN had carbapenem MICs of >2.
Of these, 85 (96.6%) were positive for the KPC gene. 15 isolates with
carbapenem MICs of <1 were also screened and all were negative for
KPC.
MIC (mg/mL) ERT MER IMI
32 na 31/31 (100) na
16 66/66 (100) 31/31 (100) 18/18 (100)
8 12/13 (92.3) 9/9 (100) 53/54 (98.1)
4 6/8 (75) 11/12 (91.6) 12/13 (92.3)
Conclusions: The emergence and rapid spread of KPC is of concern, as
therapeutic options against these multi-resistant organisms are limited.
K. pneumoniae with blaKPC have been present in multiple sites in
the NY/NJ area since at least 2004. The prevalence of KPC may be
underreported due to the widespread use of commercial automated
testing systems. The TEST study isolates were identiﬁed through manual
microdilution testing, and may give a more accurate depiction of the
prevalence of these organisms.
P1688 Prevalence of extended-spectrum b-lactamases among
Enterobacteriaceae strains from the United States (USA;
2007) and correlation with KPC carbapenemases
M. Castanheira °, A. Waters, P. Strabala, L. Woosley, R. Mendes,
R. Jones (North Liberty, US)
Objective: To determine the types and prevalence of ESBL enzymes
among carbapenem-non-susceptible (CARB-NS) and carbapenem-
susceptible (CARB-S) Enterobacteriaceae isolates with the correlation
of ESBL-types with KPC production.
Methods: As part of the SENTRY Antimicrobial Surveillance Program,
Enterobacteriaceae collected in USA medical centres (2007) with ele-
vated cephalosporin MIC values (2mg/L) by CLSI broth microdilution
test were screened for the presence of ESBL-encoding genes. CTX-M,
VEB, PER, OXA-2-like, OXA-10-like, TEM and SHV encoding genes
were tested by PCR. Amplicons were sequenced on both strands.
Carbapenemase genes (encoding KPC, IMP, VIM, NMC-A/IMI, SMEs
and OXA-48) were screened in isolates showing MIC values at >2mg/L
for imipenem and/or meropenem. Statistical analyses were performed
using Epi-Info 3.4.1.
Results: Among 2,844 Enterobacteriaceae, 287 strains (10% of the
total) displayed elevated cephalosporins MIC values. Among those, 215
belonged to four species: E. coli, K. pneumoniae (KPN), K. oxytoca
and P. mirabilis. The 72 remaining isolates were AmpC-producing
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species (dominantly E. cloacae [72%]). Fifty-two isolates showed
elevated carbapenem MIC values associated with high MIC values for
cephalosporins and KPC-production was detected in 45 strains (86%).
At least 18 types of b-lactamases were detected: CTX-M (4 variants;
Table), SHV (9), TEM (2), OXA (2) and PER-like. Over 60% of the
CARB-S isolates carried ESBL genes, while 48% of the CARB-NS
strains carried these genes (P = 0.04). However, a more limited variety
of b-lactamases was found among CARB-NS isolates when compared
to CARB-S. TEM-1 and SHV-encoding genes were signiﬁcantly more
prevalent among KPC-producing isolates (77% for both; P< 0.01) than
in CARB-S strains (39% TEM-1 and 43% SHV). blaSHV-11 and
blaSHV-12 were detected in 17 (37%) and 12 (34%) of the KPC-
producers, respectively. All 35 KPN KPC-producing isolates detected in
New York state sites also harboured TEM-1 and SHV-encoding genes,
while 9 of the 12 KPN CARB-S carried both of these genes.
Conclusions: ESBL production was observed with the same frequency
among CARB-S and CARB-NS isolates. However, KPC-encoding genes
seemed to be more prevalent among SHV-producing isolates also
carrying blaTEM-1. Furthermore, these enzymes were found in the
majority of CARB-S isolates from the same medical sites, suggesting
that CARB-S strains carrying blaSHV and blaTEM have likely acquired
KPC genes.
Organism groups (no.) b-lactamase types (no. of isolates)
CTX-M- SHV- TEM- OXA- Other
(15) (14) (2) (3) 1 (5) (7) 11 (12) (27) (30) (31) (40) 1 (10) 2 10 b-lactam-
ases
Carbapenem-susceptible
(235)
34 22 1 1 19 10 10 20 26 2 10 4 1 93 1 16 6 (PER-
like)
Carbapenem
non-susceptible strains
(51)a
– 1 – – 4 1 – 18 12 – 3 – 1 45 – 2 2 –
KRC-producing isolates
(45)
– – – – 4 – – 17 11 – 2 – 1 40 – 1 1 –
1. Include KPC-producing isolates.
2. Enzyme variants with extended spectrum activity (ESBLs) were in parentheses.
P1689 Carbapenem-resistant Enterobacter cloacae harbouring
IMI-2 gene in Finland
S. Koskela °, J. Antikainen, M. Vaara, J. Kirveskari (Helsinki, FI)
Objectives: Biochemical methods have been considered insufﬁcient to
identify the carbapenem resistance mechanisms. To supplement these
gaps, a Real-Time multiplex PCR was developed for screening of clini-
cally signiﬁcant carbapenem resistance genes among Enterobacteriaceae,
Acinetobacter sp. and Pseudomonas sp.
Methods: The Real-Time PCR assay design was divided in two
multiplex reactions. The ﬁrst multiplex was designed to detect VIM
1−22, IMP 1−24, OXA-48, KPC 1−7, GES 1−10, SPM, NMC-A, IMI
1−2, SME 1−3, GIM-1, and SIM-1 genes. The other multiplex was
designed for OXA genes with carbapenemase properties only, including
OXA-24, -25, 26, -40, -72, OXA-23, -27, OXA-50, OXA-51, 64−71,
75−78, 83−89, -92, -94, -95, OXA-55, OXA-58, OXA-60, and OXA-
62. SYBR Green chemistry was chosen to allow numerous genes to be
detected within single reaction. A melting curve analysis was used to
preliminarily identify putative molecular mechanism of positive samples,
which were conﬁrmed with sequencing with reference primers. This
assay was used to screen putative ESBL strains systematically. Moreover,
the screening assay is part of routine diagnostics to screen putative
Enterobacteriaceae species with reduced susceptibility (meropenem disk
diameter <23mm), or reduced MIC (I/R) to either meropenem or
ertapenem.
Results: Over 250 putative ESBL strains were systemically screened to
evaluate prevalence of carbapenemase producing strains, but they were
not detected. In contrast, a highly carbapenem resistant Enterobacter
cloacae strain harbouring IMI-2 gene was isolated from a patient
in intensive care unit. The IMI-2 positive strain was highly resistant
to meropenem (MIC> 32), imipenem (MIC> 32) and ertapenem
(MIC> 256), but interestingly not, however, resistant to third generation
cephalosporins, or trimetoprim/sulfa.
Conclusion: Large reservoir of carbapenem resistance genes in
environmental species combined with increasing carbapenem use
provoke the risk of emergence of rare or new carbapenemase genes,
which may remain undetected even though broad combinations of
biochemical and molecular techniques are implemented. Using the new
high-throughput screening assay an E. cloacae harbouring IMI-2 gene
was identiﬁed. To our knowledge, an E. cloacae with IMI-2 gene
has previously been reported only once, in China. Furthermore, this
is the ﬁrst reported Finnish Enterobacteriaceae strain harbouring a
carbapenemase gene as well.
P1690 Molecular epidemiology of VIM-1-producing Klebsiella
pneumoniae in Italy
E. Nucleo, R. Migliavacca, M. Spalla, G. Fugazza, C. Matti, R. Daturi,
A. Navarra, M.T. Labonia, L. Pagani ° (Pavia, San Giovanni Rotondo, IT)
Objectives: metallo-b-lactamases (MBLs) are emerging resistance
determinants in Enterobacteriaceae nosocomial pathogens worldwide,
with an epidemiology of production following country speciﬁc patterns
of occurrence.
The aim of this study was to investigate the presence of MBL
determinants among MDR Klebsiella pneumoniae isolates from three
Italian hospitals.
Methods: 30 non replicate K. pneumoniae isolates showing reduced
susceptibility to carbapenems were collected during 2007–2008 from
three hospitals. Imipenem (IPM) MIC was determined by E-test
and broth macrodilution method (CLSI 2008 guidelines). MBL and
extended-spectrum b-lactamase (ESBL) production were screened by
the IPM-EDTA disc synergy test and the double disc synergy test,
respectively. The genes encoding the MBLs were characterised by PCR
and sequencing analysis. All strains were probed after isoelectricfocusing
(IEF) for ESBLs genes and genotyped by PFGE using XbaI. The
MBL and ESBL genes transferability was investigated by conjugation.
Plasmids were characterised by RFLP analysis.
Results: 14/30 strains, characterised by IPM MICs ranging from 2
to 128mg/L, resulted positive to the IPM-EDTA disc synergy test
and PCR experiments detected blaVIM-1 like genes. In all strains
blaVIM-1 gene was on a conjugative plasmid and blaSHV-5 and
blaCTX-M-1 genes were cotransferred in 11 and 3 cases respectively.
VIM-1 producers were isolated from the ICU of the S.Giovanni Rotondo
hospital, from a Pavia Rehabilitation facility and from 6 different wards
of the Pavia hospital. These latest strains clonally related by PFGE
harboured different conjugative plasmids 80−90 kb large, on the contrary
an apparent identical conjugative plasmid 85 kb large was characteristic
of the clone detected in S. Giovanni Rotondo hospital. Two of the clones
detected were responsible for outbreaks, but none for inter-hospitals
diffusion. The PFGE ﬁngerprint software analysis showed a notably
difference between K. pneumoniae VIM producers previously detected
in Bolzano and Genova Italian areas and the three clones of our study.
Conclusions: This is the ﬁrst report on the emergence of a MDR clone
of K. pneumoniae producing VIM and CTX-M transferable enzymes.
Control measures including screening by IPM-EDTA disc synergy tests
should be applied to detect the MBL producers and to contrast the
vertical and plasmidic diffusion of carbapenem-resistant K. pneumoniae
in acute care and rehabilitation facilities.
P1691 First blaVIM positive metallo-b-lactamase producing
Enterobacter cloacae isolate in Germany
R. Schaumann °, G.H. Genzel, D. Adler, C.S. Stingu, A.C. Rodloff
(Leipzig, DE)
Objectives: The frequency of metallo-b-lactamase (MBL) producing
strains of Pseudomonas spp. is increasing worldwide. Nowadays, also
MBL producing Enterobacteriaceae are detected in clinical specimens
creating signiﬁcant therapeutic problems, since these strains are not only
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resistant to all b-lactams but often posses further resistance mechanism.
Here we report about an Enterobacter cloacae strain with elevated
MIC values against carbapenems isolated from clinical specimens at
an University Hospital in Germany.
Methods: A Gram-negative rod isolated from multiple blood cultures of
a haematological patient of the University Hospital of Leipzig, Germany
was identiﬁed by the ID 32 E system. MICs against 23 antimicrobial
agents were determined by broth microdilution. Furthermore, MBL test
was carried out by Etest and PCRs were performed for blaVIM and
blaIMP genes.
Results: The isolate was identiﬁed as E. cloacae. MICs for imipenem,
meropenem and ertapenem were 4mg/L, 4mg/L, and 8mg/L, respec-
tively. MIC for imipenem determined by Etest for MBL detection was
>32mg/L and for imipenem plus EDTA 2mg/L. Thus, the strain was
identiﬁed as a MBL producer. The PCR was positive for the blaVIM but
negative for the blaIMP gene.
Conclusion: To our knowledge we report here the ﬁrst blaVIM positive
MBL producing E. cloacae isolated from clinical specimens in Germany.
P1692 Emergence of pan-resistant VIM-1 producing Klebsiella
pneumoniae in Belgian hospitals
Y. Glupczynski °, H. Rodrigues-Villalobos, P. Bogaerts, L. Blairon,
M. Ge´rard, M. Aoun, A. Deplano, M.J. Struelens, B. Jans (Yvoir,
Brussels, BE)
Objectives: The emergence of carbapenemases in Enterobacteriaceae
is becoming a matter of concern. We studied the microbiological
characteristics and epidemiological data of VIM-1 producing K. pneu-
moniae (VPKP) isolates recovered from clinical specimens of patients
hospitalised in Belgian hospitals.
Methods: Antibiotic susceptibilities were determined using standard
agar diffusion, VITEK2 and Etest MIC determination. The production
of metallo-b-lactamase (MBL) was examined by synergy testing with
imipenem and EDTA. Isolates were typed by PFGE. Detection of
blaVIM-1 and mapping of the VIM-1 encoding integrons were performed
by PCR-sequencing. b-lactamase activities were analyzed by IEF and
spectrophotometry.
Results: Between 06/08 and 08/08, 5 patients with VPKP isolates were
identiﬁed in 3 teaching hospitals in Brussels. At hospital A and B,
VPKP were detected from rectal swabs by screening upon admission in
2 patients transferred from a Greek hospital where they had been treated
in an ICU. At hospital C, VPKP were found in clinical specimens (post-
operative wounds [2], lower respiratory tract [1]) in 3 patients with severe
underlying diseases hospitalised in 3 units. All patients were colonised
and none of them developed an infection. No common epidemiological
transmission link could be established between any patients. By PFGE,
the 5 isolates clustered in 2 clones and 4 variants.
All VPKP isolates showed a positive synergy test with EDTA, had high
resistance level to meropenem and imipenem (MICs >32mg/L) detected
by disk diffusion and automated systems. They were pan-resistant but
susceptible to aztreonam and gentamicin only; 4/5 strains were also
resistant to colistin (MIC= 16mg/L). Tigecycline was active against
4/5 strains (one isolate with intermediate resistance, MIC= 4mg/L).
blaVIM-1 was part of a class 1 integron that also carried aacA7, dhfr1,
aadA1 and sul1. After implementing additional contact precautions and
a nationwide alert system, no new cases were observed after 4 months
of surveillance in the concerned hospital. Only one additional sporadic
case was detected at another hospital.
Conclusions: Emergence of VIM-1 MBL-producing, pan-resistant
K. pneumoniae is reported for the ﬁrst time in Belgium. This event
conﬁrms the potential risk of spread of multiresistant bacteria with
international transfer of patients between acute care hospitals and
highlights the value of early screening and control measures to contain
their spread.
P1693 Systemic infection by multiresistant Klebsiella pneumoniae,
VIM-1, TEM-1 and SHV-12 b-lactamase producer in a
kidney transplant recipient patient: study of 5 isolates
C. Rodrı´guez-Avial, I. Rodrı´guez-Avial °, P. Merino, J. Picazo (Madrid,
ES)
Objectives: Carbapenem-resistant Klebsiella pneumoniae (CRKP) is
an emerging nosocomial pathogen. Our aim was to evaluate the
antimicrobial susceptibility proﬁles, the genetic relatedness and the
mechanisms of b-lactam resistance among 5 clinical isolates of
K. pneumoniae that caused infections in a renal transplanted patient
throught a month.
Methods: The patient, a 74-year-old man, had a UTI after one week
of a kidney transplant and levoﬂoxacin treatment. It was changed to
imipenem (Ip) after K1 isolation. K2, K3 and K4 were isolated 4 days,
1 and 3 weeks later. As K4 is resistant to Ip treatment was changed
to tygecicline (Ty). One week later K5 is recovered. Susceptibility
to 13 b-lactamic (BL) and to 12 non-BL agents was determined
(CSLI). Extended-spectrum-BL (ESBL) and metallo-BL production were
detected using synergy test. PCR of bla TEM, -SHV, -CTX, DHA-1
and-VIM was performed and VIM, TEM and SHV products sequenced.
Clonal relatedness was determined by ERIC PCR and PFGE.
Results: The 5 isolates are of the same clonal group. Resistance to 10
or all of BL and to 8 of non-BL was found. Main results are shown in
the table.
KP isolates
K1 K2 K3 K4 K5
Origin Urine Urine Urine Urine Blood(2)
Ip treatment* No Yes Yes Yes No
Ty treatment No No No No Yes
Aztreonam MIC (mg/1) 128 128 128 8 128
Ip MIC (mg/1) 0.12 2 2 64 0.12
Ty MIC (mg/l) 1 1 1 0.5 8
ESBL test (CSLI) + − − − +
EDTA test − + + + −
VIM-1 − + + + −
TEM-1 + + + − +
SHV-12 + + + + +
*4 or more days prior to isolation.
Conclusions: For the CRKPs (VIM-1 producers) imipenem MIC can
be as low as 2mg/l. As the presence of VIM-1 mask the presence
of an ESBL when CSLI conﬁrmatory test is done with cefotaxime or
cetazidime, it should be done with aztreonam. Resistance to tygecicline
is of concern. There is a relation between previous antibiotic take
and resistance genes. The emergence of CRKP as a consequence of
circulation of blaVIM gene must be prevented by active laboratory
surveillance and carefully carbapenem use.
P1694 Detection of metallo-b-lactamases in Enterobacteriaceae
clinical isolates at a university hospital
V. Mirovic, B. Jovanovic °, S. Stepanovic, N. Mazic, Z. Lepsanovic,
V. Mioljevic (Belgrade, RS)
Objectives: The aim of our study was to determine the occurrence of
MBLs in isolates of the Enterobacteriaceae resistant to carbapenems that
had been isolated from the University Hospital, Clinical Center of Serbia,
Belgrade, during the ﬁrst nine months of 2008.
Material and Methods: A total of 195 non-replicate Enterobacteriaceae
isolates (47 Proteus mirabilis and 148 Klebsiella pneumoniae) were
obtained from specimens of patients with nosocomial infections. MIC
for imipenem and meropenem was determined by E-test (AB Biodisk,
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Solna Sweden). MBL production was determined by using the imipenem-
EDTA synergy test. For detection of ESBLs production, double disk
synergy test was used. Multiplex PCR assay was used to detect and
differentiate each of ﬁve families of MBL genes: IMP, VIM, SPM-1,
GIM-1, and SIM-1.
Results: In total, 12 carbapenem-resistant isolates, nine isolates of
P. mirabilis and three isolates of K. pneumoniae, were recovered. All
these isolates were MBL positive and expressed MICs for both imipenem
and meropenem of >32mg/L and simultaneously produced ESBLs. All
P. mirabilis MBL positive strains were isolated from clinical samples
of patients in one surgical ICU while 3 of MBL positive isolates
of K. pneumoniae were isolated from clinical samples of patients at
Clinic of Urology. Seven of nine MBL positive P. mirabilis strains
belong to IPM family, and two other MBL positive strains belong to
VIM family. Interestingly, three MBL positive strains of K. pneumoniae
belong to SPM family of MBL. All patients from whom MBL positive
Enterobacteriaceae were recovered had already had carbapenem therapy
and central venous catheter.
Conclusion: For the ﬁrst time we recovered MBL producing Enterobac-
teriaceae in our hospital. All these isolates expressed high MICs for both
imipenem and meropenem and produced ESBLs. They belong to IMP,
VIM and SPM family.
P1695 Recurrent urinary tract infections due to metallo-
b-lactamase-producing Klebsiella pneumoniae in the
community setting
A. Poulou °, F. Markou, G. Vrioni, S. Pournaras, P. Rozi, A. Tsakris
(Serres, Athens, Larissa, GR)
Objectives: Metallo-b-lactamases (MBLs) constitute a major public
health problem limiting the therapeutic options. Until now these enzymes
were considered to be conﬁned in the hospital setting. We present
the emergence of VIM-1-producing K. pneumoniae causing recurrent
community-onset urinary tract infections (UTIs).
Materials and Methods: During July 2007-February 2008, carbapenem-
resistant K. pneumoniae (CRKP) isolates were identiﬁed to cause UTIs
in 12 outpatients (mean age 73 y). All had a history of previous
hospitalisation due to genitourinary pathology or urologic surgical
intervention. In 2 of them CRKP isolates were ﬁrstly isolated during their
hospitalisation. Among the remaining outpatients, 8 had the ﬁrst CRKP
isolation within 30 days after hospital discharge and 2 within 3 months
after hospital discharge. Identiﬁcation and susceptibility testing was
performed with Microscan System (Dade Behring) and E-test. Double
disk synergy test using ipimenem-EDTA and E-test MBL were used for
phenotypic MBL detection. MBL genes were characterised by PCR and
sequencing analysis. Medical records were reviewed to access patient’s
characteristics.
Results: Imipenem and meropenm MICs ranged from 8 to >32mg/l.
All isolates were susceptible to aminoglycosides, aztreonam and colistin
but resistant to other b-lactams, trimethoprim and ﬂuoroquinolones. One
strain exhibited resistance to tigecycline. MBL phenotypic tests were
positive for all 12 single patient CRKP isolates and molecular testing
detected VIM-1 carbapenemase in all cases. Previous antibiotic exposure
included quinolones and/or ticarcillin/clavulate during hospitalisation
and oral quinolones after hospital discharge. Seven of the outpatients
were successfully treated with gentamicin or amikacin. The remaining
5 outpatients had recurrent UTIs due to VIM-1-producing CRKP for a
period of 3 to 8 months. Medical records revealed that 3 of them had a
history of bladder cancer and 2 of lithiasis.
Conclusions: The emergence of community-onset, MBL-positive
K. pneumoniae infections among outpatients with a previous hospitali-
sation is an awesome issue. Predisposing factors, such as malignancy
and lithiasis, were associated with failure of antimicrobial treatment
and prolonged carriage of VIM-1-producing CRKP. Infection control
measures and continuous surveillance are essential for the detection and
successful treatment of infections caused by such multidrug-resistant
pathogens in the community.
P1696 OXA-48 carbapenemase-producing Klebsiella pneumoniae
in the UK
J. Zhang ° (London, UK)
Objectives: OXA-48 carbapenemase has been found mainly in
K. pneumoniae and other Enterobacteriaceae in Turkey, rarely from
elsewhere. We characterised the ﬁrst 10 isolates of K. pneumoniae with
OXA-48 enzyme referred from UK hospitals.
Methods: Bacteria were identiﬁed by API20E. MICs were determined
by agar dilution according to EUCAST/BSAC protocols. Isolates were
compared by PFGE of XbaI genomic digests. b-lactamase genes and IS
elements were sought by PCR with sequencing of selected amplicons.
Plasmids were extracted by alkaline lysis.
Results: Ten isolates of K. pneumoniae with OXA-48 enzyme were
received from 6 patients hospitalised in four UK centres as follows:
Centre 1, 1 isolate from a patient transferred from Turkey; Centre 2, 5
isolates from 3 patients; Centre 3, 3 isolates from 2 patients; Centre 4, 1
isolate from a patient transferred from centre 2. Patients in centres 2, 3
and 4 had no links with Turkey. Isolates were from wounds (6), urine (3)
and blood (1). All patients had PFGE-distinct strains except in centre 3
where there was evidence of cross-infection. All isolates were resistant
to ertapenem (MIC 8−>16mg/L) and non-susceptible to imipenem
(MICs 4−>128mg/L), but 3 remained susceptible to meropenem (MICs
1−2mg/L). A blaOXA-48 gene was detected in all isolates, ﬂanked
on both sides by IS1999. Nine isolates had blaTEM and blaSHV
genes, 4 had both blaOXA-1 and blaCTX-M group 1 genes; none had
blaOXA-9. The 4 isolates with blaCTX-M were resistant to tobramycin
and Amikacin, but susceptible to gentamicin, consistent with AAC(6’)-I
activity, and were resistant to ciproﬂoxacin; 5 of 6 without blaCTX-M
were aminoglycoside-susceptible and 3 were ciproﬂoxacin-susceptible.
Sequencing the blaOXA-48-IS1999 links on both sides of blaOXA-48
in 2 isolates showed one to be identical to GenBank AY236073, the other
had its upstream IS1999 copy disrupted by IS1. PCR indicated that the
other 8 isolates had combinations of both structures, suggesting multiple
blaOXA-48 copies.
Conclusion: The association of OXA-48 with multiple other
b-lactamases, in diverse K. pneumoniae strains with different antibi-
ograms indicate that OXA-48-mediated carbapenem resistance in the
UK has varied origins. The potential for spread warrants high vigilance
to ensure prompt detection and adequate control measures.
P1697 In vivo selection of resistance to carbapenems in SHV-5
and DHA-1 producing strains of Klebsiella pneumoniae in
a university hospital, Plzen (Czech Republic)
E. Chudackova, T. Bergerova, J. Empel, P. Urbaskova, M. Gniadkowski,
J. Hrabak ° (Plzen, Prague, CZ; Warsaw, PL)
Objectives: Resistance to carbapenems in enterobacteria can be
mediated by a production of several carbapenemases or by a decreasing
permeability of outer membrane of the cell wall combined with a
production of some extended-spectrum (ESBL) or AmpC b-lactamase.
The objective of this analysis is to characterise carbapenem resistant
strains of Klebsiella pneumoniae in one of the biggest Czech hospitals,
the University Hospital in Plzen.
Methods: All non-repetitive isolates of K. pneumoniae resistant to
carbapenems were collected during the period of January 2007 and
June 2008. In these isolates, ESBL, AmpC and MBL production were
preliminary identiﬁed by DDST and carbapenemase production was
veriﬁed by a spectrophotometric assay. The isolates were typed by
PFGE and MLST. ESBLs and AmpCs were characterised by isoelectric
focusing, bioassay, and PCR and sequencing of bla genes. Plasmids
were typed by PBRT. Porin analysis was done by a selective isolation
of these proteins followed by SDS-PAGE and western-blotting with
speciﬁc antibodies against OmpK35 and OmpK36. OmpK35, OmpK36,
and OmpK37 genes were ampliﬁed and sequenced.
Results: During described period, six resistant strains were found.
Isolates with the same b-lactamase content, but susceptible to
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carbapenems were isolated from three patients with a later or subsequent
colonisation/infection by carbapenem-resistant strain after a long therapy
with a carbapenem (multiresistant strains are stored for at least one
week in the laboratory). Two isolates produced SHV-5 ESBL, three
DHA-1 AmpC, and one both enzymes − SHV-5 and DHA-1. bla genes
were carried out on the plasmids with FII and FIC replicons. Only two
carbapenem resistant isolates showed the same PFGE pattern, despite the
carbapenem susceptible and resistant strains isolated from three patients
that showed the same pattern. All resistant isolates did not express neither
OmpK35 or OmpK36 porins. The genes encoded these porins were not
detected. OmpK37 was identiﬁed in four isolates.
Conclusions: This work showed a possible in vivo selection of
carbapenem resistant subpopulation in SHV-5 and/or DHA-1 producing
K. pneumoniae due to a decreasing permeability of outer membrane.
Such studies are important for the veriﬁcation of possible treatment
failure of carbapenems in treatment of infections caused by ESBL/AmpC
producers. MLST analysis is on going.
This work was partially ﬁnanced by a research project MSM2E08003
and MSM0021620819.
P1698 In vivo selection of imipenem-resistant Klebsiella pneumo-
niae producing clavulanic acid inhibited extended-spectrum
b-lactamase and plasmid-encoded cephalosporinase
G. Cuzon °, T. Naas, M. Guibert, P. Nordmann (Le Kremlin-Biceˆtre,
Clamart, FR)
Objectives: Resistance to carbapenems, while uncommon in Enterobac-
teriaceae, can be mediated by two main mechanisms. The ﬁrst involves
production of a chromosomal or plasmid-mediated cephalosporinase
combined with decreased permeability due to loss or alteration of
porins. The second one is the production of a b-lactamase that is
capable of hydrolysing carbapenems (carbapenemases). This study was
aimed to characterise the genetic basis of carbapenem resistance in
a multidrug resistant clinical isolate of Klebsiella pneumoniae after
prolonged imipenem exposure.
Methods: Four Klebsiella pneumoniae (KP1−4) isolates were recovered
sequentially from rectal swabs and clinical samples in an elderly patient.
Laboratory investigations included pulsed-ﬁeld gel electrophoresis of
XbaI digested genomic DNA, isoelectric focusing, imipenem hydrolysis,
resistance gene analysis by PCR and sequencing, and outer membrane
protein analysis by SDS-PAGE. Plasmid analysis by DNA-DNA
hybridisation, electroporation and conjugation were also performed.
Results: KP1 to 3 were recovered from urine, blood culture and rectal
swab respectively. They showed resistance to all b-lactams, except
carbapenems. KP4 was recovered after 24 days of imipenem therapy
from colostomy. It had an identical PFGE pattern when compared with
those of KP1 to 3. However, resistance to all carbapenems was present
only for KP4. Molecular characterisation revealed that, KP4 expresses
the ESBL blaCTXM-15 gene, plasmid-mediated AmpC b-lactamase
gene (blaDHA-1) and blaTEM-1 gene (existing in KP1−3), and failed
to express OmpK36, because of a point mutation leading to a premature
stop of the protein. All four isolates carried two large plasmids (65
and 95 kb). DNA-DNA hybridisation revealed that the 95 kb plasmid
harboured blaCTXM-15 gene and could be transferred to Escherichia
coli by mating out assay. The plasmid-mediated blaDHA-1 b-lactamase
gene was harboured on the 65 kb plasmid but could be transferred
by conjugation. No carbapenem-hydrolysing enzymes nor carbapenem-
hydrolysis could be identiﬁed in that isolate.
Conclusion: The present study demonstrated the development of
carbapenem resistance in a KP isolate harbouring ESBL and plasmid-
mediated cephalosporinase, after prolonged imipenem exposure. Resis-
tance was related to the loss of OmpK36 expression
P1699 Failure of meropenem therapy for hospital-acquired
multiple-resistant Klebsiella pneumoniae urinary tract
infection
A. Hamouda, S. Dancer, S. Amyes ° (Edinburgh, Lanarkshire, UK)
Objectives: Carbapenem resistance among the Enterobacteriaceae is of
great concern as these compounds are considered the last resort for
treating infections caused by these bacteria. The purpose of this study
was to investigate meropenem-resistance mechanism in a Klebsiella
pneumoniae collected from urinary tract infections.
Methods: Two K. pneumoniae strains K1 and K2 were collected
from urine on 8th and 13th May 2008 respectively from a septic
and catheterised 71-year-old man from Hairmyres Hospital, Lanarkshire
treated with meropenem. MICs of antibiotics were performed according
to the BSAC guidelines. Isolates found resistant to cefotaxime and
ceftazidime were considered as potential ESBL producer and were
subsequently subjected to conﬁrmatory tests. ESBL production was
conﬁrmed by double and combination disk methods. The blaTEM,
blaSHV, blaCTX-M, blaOXA, and blaKPC and metallo-b-lactamses
genes were screened by PCR and multiplex PCR respectively and
conﬁrmed by sequencing. Pulsed-ﬁeld gel electrophoresis (PFGE) typing
was performed using XbaI restriction endonuclease.
Results: K. pneumoniae strain K2 was resistant to all antibiotics tested
except colistin. The MICs (mg/L) were: amikacin (32), gentamicin
(>32), tobramycin (>32), ampicillin (>64), aztreonam (>64), cefo-
taxime (>256), ceftazidime (>256), cefoxitin (>64), cefpirome (>64),
ertapenem (128), imipenem (4), meropenem (8), piperacillin (>64),
piperacillin/tazobactam (>64), sulbactam (>2), cefotaxime/cloxacillin
(>256), colistin (0.5), ciproﬂoxacin (>8), minocycline (32) and
tigecycline (2). K. pneumoniae strain K1 was resistant to ertapenem
(16) but susceptible to imipenem and meropenem with MICs of 1
and 0.25mg/L respectively. ESBL conﬁrmatory tests were positive for
both isolates and the presence of blaTEM-1, blaSHV-1, blaCTX-M-15,
blaOXA-1 was conﬁrmed by DNA sequencing analysis. No metallo-
b-lactamases nor KPC b-lactamases were found. The two K. pneumoniae
strains were considered to belong to the same PFGE type.
Conclusion: A case of failed meropenem treatment for hospital-
acquired multiply-resistant Klebsiella pneumoniae urinary tract infection
producing CTX-M-15 is reported. Resistance to all major antibiotics
including tigecycline is consistent with permeability changes including
porin loss and upregulated efﬂux. No carbapenemase could be detected.
P1700 Multifocal emergence of ESBL-producing Klebsiella
pneumoniae clone with differential non-carbapenemase-
mediated resistance to carbapenems in Italian hospitals
M.M. D’Andrea, T. Giani, F. Arena, L. Borgianni, G. Gesu, M. Li Bergoli,
E. Manso, M. Mussap, V. Sambri, M. Sarti, F. Luzzaro, G.M. Rossolini °
(Siena, Milan, Foggia, Ancona, Genoa, Bologna, Modena, Lecco, IT)
Background: Klebsiella pneumoniae is a major nosocomial pathogen.
Carbapenems are among the few active drugs against multidrug-
resistant (MDR) strains of K. pneumoniae producing extended-spectrum
b-lactamases (ESBLs). Carbapenem resistance is increasingly reported
in this species, being a matter of great clinical concern. In this work we
report on the recent multifocal emergence, in several Italian hospitals,
of an ESBL-producing K. pneumoniae clone with differential non-
carbapenemase-mediated resistance to carbapenems.
Methods: Antimicrobial susceptibility was determined by disk diffusion
and Etest. Clonal relatedness was investigated by PFGE of XbaI-digested
genomic DNA. Carbapenemase activity was assayed spectrophotomet-
rically. b-lactamase genes were investigated by PCR and sequencing.
Outer membrane proteins (OMPs) were investigated by SDS-PAGE and
by analysis of the corresponding genes.
Results: during 2007–08, ESBL-positive K. pneumoniae isolates
showing a differential carbapenem resistance phenotype (resistance to
ertapenem, reduced susceptibility to meropenem and susceptibility to
imipenem) started to be reported from several Italian hospitals. We have
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investigated 22 nonreplicate isolates showing this phenotype from 6
different hospitals located in various Italian regions. Isolates were from
bloodstream, lower respiratory tract, urinary tract and intra-abdominal
infections. Carbapenemase activity and known carbapenemase genes
were not detectable. All isolates produced the CTX-M-15 ESBL and
resident SHV enzyme. Decreased expression of the k36 OMP was
detected in all isolates. PAbN (40mg/L) did not affect carbapenem MICs.
PFGE analysis revealed a dominant clone (20 isolates) present in the 6
hospitals, plus one additional unrelated clone from a single hospital.
Conclusions: Although production of plasmid-encoded carbapenemases
is the most common mechanism of carbapenem resistance in K. pneu-
moniae, strains with non-carbapenemase-mediated resistance have occa-
sionally been described. To our best knowledge, this is the ﬁrst evidence
for multifocal clonal spread of ESBL-producing K. pneumoniae with a
similar resistance phenotype. Clinical impact, and implications for detec-
tion and reporting by the clinical microbiology laboratory are discussed.
P1701 Biological cost of resistance to carbapenems in a Klebsiella
pneumoniae isolate
A. Gonza´lez-Torralba °, A. Martı´n-Dı´az, J.I. Alo´s (Getafe, ES)
Carbapenems (imipenem, meropenem, ertapenem) are bactericidal
antibiotics that acts by inhibiting the bacterial cell wall, and which
are used mainly in the treatment of severe infections. Resistance to
carbapenems are exceedingly rare in Enterobacteriaceae despite its
frequent use since long time ago. The objective of this study was to
ascertain whether a strain of K. pneumoniae resistant to carbapenems
have less ﬁtness than those that are carbapenem-sensitive in competing,
and would therefore tend to disappear in their competition with
carbapenem-sensitive strains in the absence of antibiotics.
Methods: One carbapenem-resistant strain and six carbapenem-sensitive
strains of K. pneumoniae.
Thirty competition experiments by pairs of strains were conducted,
5 by each sensitive strain (carbapenem-R versus carbapenem-S). The
experiments were performed in nutrient broth (NB). Equal amounts of
the strains were challenged (approx. 50% and approx. 50%) for 5 days,
with a daily change to a new medium. Six differential counts were
performed (days 0, 1, 2, 3, 4 and 5). For the differential counts on
the ﬁfth day, MacConkey agar with and without ertapenem (2mg/L) and
a replica plater machine were used.
The mean of results for each pair of strains and the range, in parenthesis,
are presented below.
Results: In all the pair experiments there were a relative increase in
the carbapenem-sensitive strain that translated into a count of 76%
(63−90%), 94% (90−98%), 80% (71−95%), 93% (78−99%), 83%
(78−89%), and 95% (89−98%) on the ﬁfth day.
Conclusions:
• Resistance to carbapenem entails a biological cost (less ﬁtness) in all
the experiments by pairs for the K. pneumoniae strain assayed.
• This biological cost hinders their competition with carbapenem-
sensitive strains in the normal intestinal ﬂora, which would make them
less likely to cause infections.
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P1702 Proteomic analysis of the secretome of Acinetobacter
baumannii
P. Espinal °, S. Marti, J. Sanchez-Cespedes, J. Vila (Barcelona, ES)
Objectives: To identify extracellular proteins secreted by different strains
of Acinetobacter baumannii which could be potentially responsible for
the disease, using a proteomic approach.
Methods: The proteomic study was performed in nine A. baumannii
clinical isolates previously identiﬁed by ARDRA and classiﬁed into
different clones by PFGE. The isolates caused a nosocomial outbreak (3
strains), sporadic infectious diseases (4 strains) and community-acquired
diseases (2 strains). Antimicrobial susceptibility tests were performed
by E-test. To obtain the proteins, the isolates were grown in minimal
medium plus casaminoacids to an OD600 = 0.6. The cells were harvested
by centrifugation; the supernatant was ﬁltered with 0.22mm ﬁlters and
concentrated with Amicon Tubes (50ml). Protein analysis was performed
by 12 to 20% polyacrylamide gradient gel electrophoresis with SDS.
Characterisation of the proteins was done by MALDI-TOF/TOF mass
spectrometry analysis.
Results: Nine isolates of A. baumannii were studied. Seven were
resistant to all antimicrobial agents but colistin and the other two strains
were susceptible to meropenem, imipenem, ciproﬂoxacin, piperacillin
and aztreonam. Among the proteins characterised the following were
found: 1.The presence of a 45Kda protein OmpA, a 25Kda alkali-
inducible disulﬁde interchange protein, the putative toluene tolerance
protein, a putative outer membrane protein, a putative exported protein
and the chaperone GroEl in all the strains. 2. In the community-acquired
strains, which were susceptible to carbapenems, the protein CarO was
found and it is important to highlight a putative outer membrane
protein (circa 35 Kda), which was not found in the isolates causing
nosocomial infections, and 3. In the carbapenem resistant strains the
outer membrane protein HMP, three putative outer membrane proteins
and the b-lactamases class C and OXA-26.
Conclusion: The identiﬁcation of secreted proteins provides a target
for an anti-Acinetobacter vaccine and drug development as well as
for further investigation on the pathogenicity of the infections by
A. baumannii.
P1703 Multi-centre study of dissemination and diversity of
carbapenem-resistant Acinetobacter baumannii Spanish
clinical isolates
J. Head °, E. Culebras, R. Andrade, M. Go´mez, J. Picazo (Madrid, ES)
Objectives: To investigate the differences in antimicrobial susceptibility
and clonal relatedness against carbapenem-resistant Acinetobacter
baumannii collected in several Spanish Hospitals in two different time
period (from 15-April-1998 to 17-November-1998 and from January to
February 2006).
Methods: A total of 93 imipenem-resistant A. baumannii were collected
from 25 general hospitals in Spain in 1998 (44 isolates) and 2006
(49 isolates). Species identiﬁcation and antibiotic susceptibilities were
determined by Vitek-2. MICs were determined by microdilution, agar
dilution methods and E-test (tigecylcine and colistin). Clonal relatedness
was determined by RAPD-PCR and ERIC2-PCR. E-test with imipenem
(IMP) and imipenem plus EDTA was performed to check metallo-
b-lactamase (MBL) production. The isolates were screened by PCR
analysis with speciﬁc primers for carbapenemase genes.
Results: Epidemiologic relatedness of 44 imipenem-resistant isolates
from 1998, revealed only 4 different genetic backgrounds. In the isolates
from the second period, the four original clones are maintained and 4
new proﬁles, closely related with previous ones, were identiﬁed. Overall,
100% A. baumannii isolates were resistant to >3 antimicrobials classes.
All the isolates carried a gene encoding a b-lactamase belonging to
OXA-51-like group. 15 of the 44 isolates (34.1%) from 1998 and 13
of the 49 isolates (26.5%) from 2006 contained the insertion sequence
ISAba1 upstream the promoter region of the blaOXA-51-like gene. 66%
of the isolates from 1998 carried a gene encoding an OXA-40-like
enzyme, alone (21 isolates) or combined with an IMP carbapenemase (8
isolates). In 2006, OXA-40-like oxacillinase was the enzyme prevalent
(22 isolates; 18 isolates alone, 4 combined with another enzyme) but
OXA-58-like and OXA-23-like enzymes were detected in a signiﬁcant
percentage of isolates (28.6% and 18.4% respectively). Some degree
of heterogeneity was observed within each genetic background. This
heterogeneity was higher in groups from 2006 than in groups from 1998.
Conclusions: Several clones among A. baumannii multirresistant
isolates are maintained over the time in Spanish hospitals. The
predominant clones appeared in most than one hospital indicating
possible inter-hospital spread of carbapenem resistant A. baumannii
strains. OXA-40-like enzyme, is the enzyme prevalent at Spanish
hospitals.
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P1704 Spread of different STs of Acinetobacter baumannii carrying
speciﬁc acquired carbapenem-hydrolysing oxacillinases
F. Grosso °, S. Quinteira, L. Peixe (Porto, Famalicao, PT)
Objectives: OXA-40 was the only acquired carbapenem-hydrolysing
oxacillinase detected in Acinetobacter baumannii (AB) for several years
in our country, but since 2006 we observed an increase in the appearance
of OXA-23-producers, some of them associated to outbreaks. Recently,
some isolates carrying the blaOXA-58 were also identiﬁed. Together
they greatly contribute to the high rate of imipenem-resistance in this
species in our hospitals. The aim of this work was to investigate the
relationship between blaOXA-23, blaOXA-58 and blaOXA-40-carrying
isolates by PFGE and two different schemes of MLST, comparing their
capacity of discrimination.
Methods: We analysed the population structure of eight isolates
representative of blaOXA-23 (n = 2), blaOXA-40 (n = 4) and blaOXA-
58 (n = 1) strains, disseminated and persisting over years, that were
selected among well characterised 186 AB isolates recovered from 3
Portuguese hospitals. A carbapenem-susceptible isolate (CSAB) was
also included. Isolates were identiﬁed by API32GN and by 16S
rRNA sequencing. Susceptibility testing (CLSI) and PFGE (ApaI) were
performed. blaOXA-23, blaOXA-40, blaOXA-51-like and blaOXA-58
genes were identiﬁed by sequencing of respective amplicons. MLST
schemes were performed according to Bartual et al. (2005) (B) and
Brisse et al (www.pasteur.fr/mlst) (IP).
Results: A clonal relatedness was observed by PFGE for all isolates
except for the one carrying blaOXA-58. The sequence analysis of
blaOXA51-like revealed the presence of OXA-66 in all isolates, except
for the blaOXA-58-carrying isolate. MLST typing revelead that this
isolate belonged to a new ST by the B-scheme and to ST15 by IP-scheme.
Both blaOXA-23-carrying AB and CSAB belonged to the disseminated
ST22 (B-scheme) and to ST2 (IP-scheme). According to B-scheme, the
OXA-40-producing AB isolates corresponded to a new ST, which is a
DLV of ST22, whereas with MLST-IP scheme we observed that they
shared 6 of the 7 alleles of ST2.
Conclusions: In our country, carbapenem-resistant AB are mainly
related to the dissemination of three different STs, each one associated to
different acquired OXA-type. The rapid increase in the recently described
OXA-23 producers is associated with the spread of the internationally
disseminated ST22 AB clone. Remarkably, MLST data indicates a
common origin between ST22 and the persistent new ST OXA-40-
producing clone.
P1705 Characterisation of blaOXA-40-carrying plasmids among
Acinetobacter spp. isolates in Portuguese hospitals
F. Grosso °, S. Quinteira, L. Peixe (Porto, Famalicao, PT)
Objectives: OXA-40, an acquired carbapenemase initially conﬁned to
Iberian Peninsula and associated to a long term prevalent Acinetobacter
baumannii (Ab) strain, has been more recently observed in Ab outbreaks
in USA and in A. haemolyticus (Ah) in Portugal. The purpose of this
study was to characterise the genetic background of this carbapenemase.
Methods: Thirteen OXA-40-Ab-producers were selected from a
collection obtained during 2001–2007 in 2 Portuguese hospitals. An
OXA-40-producig Ah and one imipenem-susceptible Ab (ISAb) isolate
that did not present any acquired oxacillinase, were also included.
Chromossomal and/or plasmid location of blaOXA-40 was determined
by I-CeuI hybridisation with a speciﬁc probe for this oxacillinase and for
16S rDNA. Plasmid extraction followed by sequencing was performed
in order to assess the vicinity of the blaOXA-40 gene. PCR for repAc1
was also conducted. The amplicons obtained were used as a probe for
subsequent I-CeuI hybridisation.
Results: All OXA-40 producers revealed a plasmid location for blaOXA-
40. Plasmids sizes varied from 45 kb to 220 kb. In some isolates was also
observed a chromosomal hybridisation with blaOXA-40 probe.
All plasmids showed identical regions upstream the blaOXA-40
gene which presented homology with a plasmid previously described
(pAB02). The Ah plasmid also presented identity with the pAB02
plasmid in the downstream region of blaOXA-40 gene. However, the
Ab isolates displayed homology with other plasmids (pAB2, p2ABAYE,
pACICU1) in the regions following the 3′ end of the blaOXA-40 gene.
The ISAb revealed a plasmid with ca. 60 Kb, that presented the repAc1
gene, characteristic of the downstream regions of blaOXA-40 in Ab
plasmids. Duplicated motifs associated to insertion process were not
observed in ﬂanking regions of blaOXA-40.
Conclusions: The blaOXA-40 seems to have been acquired by particular
disseminated plasmids with repAC1 in Ab isolates persistently recovered
from our hospitals, and was co-located in the chromosome in most
of them. The persistence of these plasmids among isolates of the
Iberian clone might play a role in the maintenance of this successful
lineage. The Ah isolate carried other OXA-40 plasmid similar to the
pAB02 plasmid, which enable us to anticipate its dissemination among
Acinetobacter species. An insertional process does not seem the most
reliable explanation for the plasmidic acquisition of this carbapenemase
gene, as already described for other oxacillinases.
P1706 Clonal outbreak of multidrug-resistant ST22 Acinetobacter
baumannii in a university hospital, Plzen, Czech Republic
F. Grosso °, M. Pinheiro, S. Quinteira, T. Bergerova´, J. Hraba´k,
L. Peixe (Porto, Famalicao, PT; Plzen, CZ)
Objectives: Acinetobacter baumannii has recently emerged as a
pathogen of substantial concern namely due to the acquisition of
resistance to several antibiotics, being associated to a considerable
mortality. Since December 2007 a dramatic increase in infections caused
by MDR A. baumannii (MDR Ab) was observed in different units of
the University Hospital of Plzen. The objective of this study was to
investigate this outbreak using epidemiologic and molecular techniques
and to relate it to previous reports of MDR Ab.
Methods: In the beginning of 2008, 1-month survey of carbapenem
resistant strains of A. baumannii was performed. From a total of 97
isolates collected, nine non-repetitive isolates causing infection were
selected from different units involved in the outbreak − Cardiosurgery
(n = 5), Surgery (n = 3) and Pulmonary (n = 1). MICs to several antibiotics
were determined by standard microdilution broth method according to
EUCAST recommendation. Carbapenemase activity was determined by
a bioassay. The OXA-51 type was determined by PCR followed by
sequencing. ISAba1 upstream the blaOXA-51 and acquired OXA-type
b-lactamases (blaOXA-23-like, blaOXA-40 and blaOXA-58-like) were
searched by a multiplex PCR. The isolates were typed by PFGE with
digestion with Apa I endonuclease and by MLST scheme of Bartual et
al (2005).
Results: Isolates were resistant to ciproﬂoxacin and to b-lactams,
including meropenem, with the exception of one isolate susceptible to
imipenem. Most isolates were susceptible to aminoglycosides, with the
exception of gentamicin. Susceptibility to colistin was observed only in
three isolates. No carbapenemase activity was found as well as acquired
carbapenemases. ISAba1 was found upstream of OXA-66 in all isolates.
PFGE indicated a common pattern, identiﬁed as belonging to ST22 by
MLST.
Conclusions: Spread of ST22 A. baumannii strain, the main clone in
Czech Republic, and also globally disseminated, was responsible for the
emergence of MDR Ab in this hospital. Particular features of this lineage
might contribute for its success and prevalence.
P1707 Identiﬁcation and typing of multiresistant Acinetobacter
baumannii in Latvian hospitals
A. Balode °, M. Petrova, D. Berzina, J. Denisova, U. Dumpis,
J. Zestkova, E. Miklaievics (Riga, LV)
Objectives: Acinetobacter baumannii is an important nosocomial
pathogen which is often associated with multiple drug resistance.
First imepenem resistant Acinetobacter baumannii isolates in Latvian
hospitals were detected in fall of 2007 and afterwards rapidly spread
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throughout the country. The aim of this study was to characterise isolates
both by their phenotype and genotype.
Methods: 109 Acinetobacter baumannii isolates were collected from
three biggest Latvian hospitals in Riga. All isolates were identiﬁed by BD
Crystal E/EN. Antibiotic resistance was determined by disc susceptibility
tests according to CLSA standards. Presence of the OXA-51 like and
OXA-23 like elements was established by PCR (Turton et al., 2006). All
strains were typed by ERIC-PCR and using DiversiLab (Biomerieux).
MLST was done as described by Bartual et al., 2005.
Results: All Acinetobacter baumannii isolates showed resistance to
imepenem and with some minor differences were also resistant to other
antibiotics (amikacin, ampicillin-sulbactam, cefepime, ceftazidine, gen-
tamicin, piperacillin-tazobactam and trimethoprim-sulfamethoxazole).
All isolates were carrying OXA-51 like element and 103 isolates also
possessed OXA-23 like element. Both typing methods − ERIC-PCR
and DiversiLab did not reveal any differences in the chromosomal
background of the tested strains indicating that they belong to the same
strain. MLST of several arbitrary chosen isolates resulted in identical
sequences and revealed a new sequence type (compared to ones in
mlst.zoo.ox.ac.uk) as on December 2008.
Conclusion: A new sequence type imepenem resistant Acinetobacter
baumannii strain has become endemic in three hospitals in Riga, Latvia.
P1708 Detection of the OXA-58 carbapenemase in clinical isolates
of Acinetobacter baumannii from Cochabamba, Bolivia
E. Sevillano °, E. Fernandez, C. Valderrey, Z. Bustamante, S. Zabalaga,
J. Zamora, I. Rosales, A. Umaran, R. Cisterna, L. Gallego (Leioa,
ES; Cochabamba, BO)
Objectives: The aim of this work was to study the presence of
carbapenemases and their related genetic structures in clinical isolates
of A. baumannii from hospitals in Cochabamba, Bolivia.
Methods: The study included 10 A. baumannii isolates obtained in
a hospital from Cochabamba, Bolivia (Hospital Gastroenterolo´gico
Boliviano-Japone´s) during 2008. Susceptibility to antimicrobial agents
was determined by disk difussion method following the CLSI recommen-
dations. Antibiotics tested were amikacin, cotrimoxazole, cloranpheni-
col, amoxicillin/clavulanic acid, piperacilline, imipenem, meropenem,
ceftazidime, cefepime, cefotaxime, cefexime, ciproﬂoxacine, and lev-
oﬂoxacine. Clonal relatedness was performed by PCR-ﬁngertyping,
plasmids were determined by a commercial kit, and class 1 integrons
and insertion sequences (ISAba 1, ISAba 2 and ISAba 3) by PCR
experiments with the corresponding primers, (integrons were also
digested with HaeIII and EcoRI). OXA-type carbapenemases (-23, -40,
-51 and -58) were detected by Multiplex PCR. Sequencing experiments
were done with OXA-58 carbapenemase positive isolates.
Results: The resistance results showed that 7 isolates were resistant
to most of the antibiotics tested, mainly to imipenem and meropenem.
Typing experiments showed 5 different genotypes, one of them (named
Bol1) including 5 isolates. Class 1 integrons were detected in all
isolates belonging to clone Bol1, ranging in size between 540 to 780 bp.
Multiplex-PCR and sequencing analysis showed the presence of the
OXA-51 and OXA-58 carbapenemases in all isolates from clone Bol1.
All of them also contained IS Aba 3 and two were positive for ISAba
1. ISAba2 was present in an isolate from other clone. We found clear
relationship between OXA-58 gene and ISAba 3. Plasmid analysis
and hybridisation with an OXA-58 probe detected the relation of the
carbapenemase gene with different structures.
Conclusions: This is the ﬁrst description of the OXA-58 carbapenemase
in isolates of A. baumannii from Bolivia. The detection of the enzyme
in a multiresistant clone, named Bol1, and its relationship with plasmids
is of great concern as it means the possibility of spreading carbapenem
resistance amongst the hospitals of the country.
P1709 Development of resistance to tigecycline, co-trimoxazole
and tobramycin associated with increased expression
of the Acinetobacter baumannii efﬂux pump AdeB in a
hospitalised patient
P.G. Higgins °, H. Seifert (Cologne, DE)
Objectives: To investigate the mechanism of stepwise acquired multi-
drug resistance in Acinetobacter baumannii isolated from a hospitalised
patient.
Methods: 13 consecutive multi-drug resistant A. baumannii isolates were
recovered from the same patient during a 2-month period. Sensitivity
to antimicrobials was performed by VITEK2, broth microdilution and
E-test. Speciation was conﬁrmed by gyrB multiplex. Presence of
OXA-type enzymes were investigated by multiplex PCR. Strains were
molecularly typed by rep-PCR using the DiversiLab system. Plasmids
were isolated to determine if imipenem-resistance was transferable.
Expression of the adeB and adeJ efﬂux pump genes was performed
by semi-quantitative real-time RT-PCR.
Results: Molecular typing revealed that the patient was infected with
the same A. baumannii strain during the 2-month period. All isolates
were resistant to imipenem, meropenem, cephalosporins, fosfomycin,
gentamicin, ampicillin-sulbactam, ﬂuoroquinolones, piperacillin and
piperacillin-tazobactam and sensitive to colistin. Isolates were positive
for blaOXA-58-like gene. Imipenem-resistance was not transferable. The
patient was treated with a combination of amikacin, ciproﬂoxacin and
co-trimoxazole for an unrelated bacterial infection. After treatment, all
subsequent isolates were resistant to tigecycline and co-trimoxazole and
recorded higher levoﬂoxacin MICs simultaneously (see Table).
Strain MIC (mg/ml)
TGC IPM MPM SXT TOB LEV
A009703 4 32 32 40 1 8
A009747 4 32 32 40 1 8
A009808 4 32 8 40 1 8
A009974 4 32 32 40 1 8
A010018 4 32 32 40 1 8
A010068 4 32 16 40 1 8
Antimicrobial therapy of amikacin, ciproﬂoxacin and co-trimoxazole
A010324 16 >32 >32 320 1 >8
A010416 16 >32 >32 320 1 >8
A010482 16 >32 >32 320 1 >8
A011650 16 >32 >32 320 8 >8
A012428 16 >32 >32 320 1 >8
F015146 16 >32 32 320 8 >8
Two later isolates also showed resistance to tobramycin. Tigecycline-
resistant isolates showed a >100-fold increase in adeB mRNA transcripts
compared to tigecycline-sensitive isolates. There was no increase in adeJ
transcripts.
Conclusions: These data show the propensity of A. baumannii to develop
efﬂux-mediated resistance during antimicrobial therapy. This efﬂux-
mediated resistance was stable and had a broad speciﬁcity.
P1710 Tigecycline resistance of Acinetobacter bloodstream isolates
in a teaching hospital
S. Vamvacopoulou °, K. Michalacopoulou, C. Bartzavali,
I. Spiliopoulou, E.D. Anastassiou, M. Christoﬁdou (Patras, GR)
Objective: Acinetobacter calcoaceticus-A. baumannii complex, an
opportunistic pathogen frequently involved in infection outbreaks in
Intensive Care Units (ICU), constitutes a serious problem because of its
virulence and multidrug resistance. Tigecycline (TIG), is a glycylcycline
antibiotic with broad-spetrum activity that appears to be the only new
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therapeutic option for serious infections caused by multidrug resistant
(MDR) Gram negative bacteria. The aim of this study was to deﬁne the
susceptibility proﬁle of bloodstream Acinetobacter isolates to antibiotics,
including TIG, during the last three years in Patras University Hospital.
Methods: A total of 162 Acinetobacter bloodstream isolates were
collected between September 2005 to September 2008 from inpatients
hospitalised in ICU (82), in Internal Medicine units (52) and in
Surgical Wards (28). Identiﬁcation at species level was performed using
Gram negative BD BBL Crystal ID system. Antimicrobial susceptibility
was tested by disk diffusion method, according to CLSI criteria, for
cefepime (FEP), ceftazidime (CAZ), imipenem (IMP), aztreonam (AZT),
gentamicin (GM), netilmicin (NET), amikacin (AN) and ciproﬂoxacin
(CIP), and by E-test strips (AB Biodisk) for MIC of colistin (CL) and
TIG. MIC breakpoint of susceptibility for CL is equal or less than 1
microg/mL whereas for TIG is equal or less than 2 microg/mL. IMP-
resistant isolates were examined by double E-Test strips (IMP versus
IMP plus EDTA) (AB Biodisk) for detection of metallo-b-lactamases
(MBL).
Results: Forty ﬁve isolates were recovered during the ﬁrst year, 61 the
following year, whereas 56 isolates were identiﬁed the third year, one
isolate per patient. A total of 159 (98%) isolates were identiﬁed as
Acinetobacter bawmannii. Resistance rate was as high as 96%, 94%,
93% and 90% to AZT, IMP, FEP and CAZ, respectively, and 87%, 86%,
85% and 68% to AN, NET, CIP and GM. Among IMP-resistant isolates,
95% were MBL (+). No isolate was resistant to CL as MIC was 0.38−1
microg/mL. All isolates were susceptible to TIG as MIC ranged between
1−2 microg/mL.
Conclusions: A total of 148 (86%) Acinetobacter isolates were MDR
(resistant to four or more used antimicrobials) in our hospital. As MBL
was produced by many MDR isolates, imipenem seems not to be useful
in empiric therapy of critically ill, bacteraemic patients. Colistin and
tigecycline remain the only active agents towards such strains, according
to our results.
P1711 Genetic basis of resistance to aminoglycosides in
Acinetobacter species and spread of armA in Acinetobacter
baumannii sequence group 1 in Korean hospitals
Y.J. Cho, D.C. Moon, J.S. Jin, J. Kim, Y.C. Lee, S.Y. Seol, D.T. Cho,
J.C. Lee ° (Daegu, KR)
A total of 75 Acinetobacter isolates resistant to all available
aminoglycosides obtained from two Korean hospitals were studied for
the genetic basis of resistance to aminoglycosides. Minimal inhibitory
concentrations of aminoglycosides were higher in A. baumannii isolates
(n = 61) than Acinetobacter genomic species 13TU isolates (n = 14).
Genes encoding aminoglycoside-modifying enzymes, ant(3′′)-Ia, aac(6′)-
Ib, aph(3′)-1a, aac(3)-Ia and aph(3′)-VI and 16S rRNA methylase armA
were detected. ant(3′′)-Ia and aac(6′)-Ib were commonly detected in
both Acinetobacter species, but armA and aph(3′)-Ia were only detected
in A. baumannii. armA was located on the plasmids. A. baumannii
isolates carrying armA were classiﬁed into seven pulsotypes, but
belonged to sequence group 1. The combination of aminoglycoside-
modifying enzymes is responsible for the moderate-level resistance
to aminoglycosides in Acinetobacter genomic species 13TU, whereas
armA is responsible for the high-level resistance to aminoglycosides in
A. baumannii sequence group 1.
P1712 Antibiotic resistance pattern of Acinetobacter species in
Kuwait hospitals
N. Al-Sweih °, M. Al-Hubail, V. Rotimi (Kuwait, KW)
Objective: As high and increasing resistance of Acinetobacter spp to
many potential therapeutic agents limit the choice of appropriate therapy,
this study was carried out to determine the resistance pattern of strains
causing clinically proven infections and those associated with mere
colonisation.
Methods: A total of 250 consecutive isolates were collected from
infected and colonised patients in 8 major hospitals in Kuwait. They
were identiﬁed by VITEK-2 and their susceptibility to 18 antibiotics
determined by Etest method. Susceptibility and resistance were assessed
according to the recommended criteria of the CLSI and FDA for
tigecycline. Metallo-b-lactamase (MBL) production was detected by the
MBL Etest method.
Results: Resistance to many of the tested antibiotics were very high, in
particular to amikacin (82.8%), gentamicin (68.4%), cefepime (69.6%),
ciproﬂoxacin (73.2%) and piperacillin-tazobactam (71.2%). It is note-
worthy that, in this study, resistance to tigecycline was as high as 13.6%.
Similarly, of clinical importance were the resistance rates of 25.2, 37.3
and 12% to imipenem, meropenem and colistin, respectively. The overall
prevalence of MBL was 37.2%. Both MIC50 and MIC90 of amikacin,
cefotaxime, ceftazidime, cefepime and piperacillin-tazobactam were
each 256 ug/ml, while MIC50 and MIC90 of imipenem, meropenem,
tigecycline and colistin were 1.5 and 32, 3 and 32, 0.38 and 3, 1 and 3,
respectively. Interestingly, only 36% of MBL-positive strains were from
infected patients, with the highest rate (48.3%) from Mubarak hospital
followed by 44.9% from Al-Jahra hospital.
Conclusion: Multi-resistant Acinetobacter spp is highly prevalent in our
hospitals and has reached an alarming level which justiﬁes continuous
surveillance and stringent infection control measures to control its
spread.
P1713 Outbreak of pan aminoglycoside-resistant armA producing
Acinetobacter baumannii in a Korean hospital
M.W. Kang °, S.I. Kim, Y.J. Kim, S.H. Wie, Y.R. Kim, E.J. Oh, Y.J. Park
(Seoul, KR)
Background: Recently, 16S rRNA methylase-mediated highly amino-
glycoside-resistant isolates of Acinetobacter baumannii have been
reported worldwide. However, there has been only one case report of
outbreak by pan aminoglycoside resistant armA producing A. baumannii
so far. We prospectively investigate a nosocomial outbreak of infection
with pan aminoglycoside resistant A. baumannii in neonatal ICU and
respiratory ward of Korean hospital.
Methods: Prospective outbreak investigation was done in a tertiary
1,000-bed university hospital in Korea. Antibiograms determined by
the double-disk diffusion technique. All isolates were screened for the
presence of aminoglycoside modifying enzymes, class 1 integron, and
16S rRNA methylases (rmtA, rmtB, rmtC and armA) genes by PCR and
sequencing.
Results: Nine isolates from eight patients were investigated for three
months. All A. baumannii isolates shown resistant to piperacillin,
piperacillin/tazobactam and all aminoglycosides tested except neomycin.
Four strains were resistant to meropenem, 2 intermediate, and 3 sensitive
in disk diffusion test. PCR and sequencing showed that all isolates
were negative for aac(3)-1, aadB(ant2), aph3−3, aph3−6, ant4−1, ant4−2,
aac(3)-2, aac(3)-3, aac(3)-4, aac(6’)-2b, aph2, rmtA, rmtB, rmtC, and
rmtD. Positive for aac(6’)-1b, Int 1, orf513 and armA. Molecular typing
showed two types of closely related strains.
Conclusion: Outbreak of pan-aminoglycosie resistant A. baumannii
is becoming a great concern about nosocomial infection control in
Korean hospital. Appropriate antibiotics usage, management of active
surveillance system, and strict contact precaution should be kept to
prevent further occurring of outbreak.
P1714 Mechanisms of resistance to ciproﬂoxacin,
ampicillin/sulbactam and imipenem in Acinetobacter
baumannii in Taiwan
H.Y. Lee °, C.H. Chiu, S.Y. Liu, M.H. Tsai (Taoyuan, Changhua, TW)
Objectives: Nosocomial infections caused by multidrug-resistant Acine-
tobacter baumannii (MDRAB) have been increasing in recent years,
posing serious threat to public health worldwide.
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Methods: The susceptibility to 9 antimicrobial agents of 35 clinical
A. baumannii isolates from Chang Gung Memorial Hospital was tested.
Isolates were examined by PCR and sequencing for b-lactamase genes
and mutations of gyrA and parC genes. The expression of AdeB, an
efﬂux pump protein, was evaluated by real-time quantitative PCR.
Results: The level of adeB expression correlated with resistance
to ciproﬂoxacin and ampicillin/sulbactam in A. baumannii isolates.
Furthermore, mutation analyses of gyrA or parC showed that certain
mutations in these target genes, together with over-expression of Ade
transporter, conferred the resistance to ciproﬂoxacin. All 13 isolates
with full resistance to ciproﬂoxacin had both high adeB expression
and mutations in gyrA or parC, but 4 intermediately resistant isolates
had only high adeB expression without mutations in gyrA or parC,
in contrast to 18 susceptible isolates with low adeB expression and
without any mutations. Two ciproﬂoxacin-resistant isolates in our study
had mutations only at parC but not at gyrA, suggesting parC might not
only be a minor or secondary target for the action of quinolones in
A. baumannii. Sixteen isolates (45.7%) carrying type 1 integron were
multi-drug resistant (MDR) and more resistant to imipenem, amikacin,
gentamicin, ceftazidime, cefepime, or piperacillin than those without
the integron (all p< 0.002). The type 1 integron contained different
resistance gene cassettes, including 5’CS-blaIMP-1-aadA4–3’CS, 5’CS-
aacA4-aadA1–3’CS, and 5’CS-aacC1-aadA1–3’CS.
Conclusion: The expression of adeB gene was associated with resistance
to ciproﬂoxacin and ampicillin/sulbactam in A. baumannii. Multiple
mutations in gryA and parC also played a role in ciproﬂoxacin resistance.
The major metallo-b-lactamase contributing to imipenem resistance in
A. baumannii in Taiwan was blaIMP-1, which was carried by class
1 integron. Class 1 integron was associated with MDR phenotype to
A. baumannii.
P1715 Multiplex PCR for rapid detection of genes encoding Oxa
and metallo-b-lactamases in Acinetobacter spp.
A. Mostachio, I. van der Heijden, L. Miranda, I. Boszczowski,
L. Miranda, F. Rossi, E. Arau´jo, A. Levin, S. Costa ° (Sao Paulo, BR)
Acinetobacter spp, resistance to carbapenems, have become common
in hospitals worldwide. Carbapenem resistance mechanisms described
in A. baumannii include hydrolysis by b-lactamases, alterations in
outer membrane proteins and penicillin-binding proteins, and increased
activity of efﬂux pumps. However, carbapenemases, such as metallo-b-
lactamase (MBL) or oxacillinases, are the most concerning.
Objective: The present study aimed to develop a multiplex PCR assay
to detect and differentiate alleles coding oxacillinase and MBL in
nosocomial carbapenem resistant Acinetobacter spp.
Material: The study included a total of sixty-eight isolates of
A. baumannii, sixty four carbapenem-resistant and four carbapenem-
susceptible strains. These isolates were obtained from 4 different
hospitals of the state of Sa˜o Paulo, Brazil. The following reference strains
were used in this study: P. aeruginosa producing IMP-1, VIM-1, SIM-1
enzymes and A. baumannii producing Oxa-23 and Oxa-25 enzymes
as positive controls and A. baumannii ATCC 19606 was used as a
negative control. The isolates were identiﬁed by API (NE) (Biomerieux-
France). Minimum inhibitory concentrations (MICs) of carbapenem
were determined by broth microdilution and interpreted using Clinical
Laboratory Standards Institute (CLSI) breakpoints. MBL ETEST was
performed following the manufacturer’s recommendations (AB Biodisk
(North America Inc., N.J.) to conﬁrm the MBL expression phenotypically
in these strains.
Ampliﬁcation by polymerase chain reaction with oligonucleotide primers
speciﬁc for ISAba1 region was performed as described elsewhere
Results: Among, 64 carbapenem-resistant A. baumannii strains isolated
from 4 Brazilian hospitals, blaoxa-23-like was present in 22 and IMP-1
only in 4 isolates. ISAba1 was identiﬁed in all carbapenem resistant
strains except one. The imipenem MIC among blaoxa-23-like positive
strains ranged from 16 to 128 ug/ml and was lower compared with
IMP-1 positive strains (MIC> 128 ug/ml). Phenotypically expression of
metallo-b-lactamase was conﬁrmed by MBL-ETEST in all 4 IMP-1
positive strains.
Conclusion: The multiplex PCR results detected and distinguished
alleles coding oxacillinase and MBL carbapenemases in carbapenem
resistant A. baumannii and was consistent with the previous single PCR
assays and could be an useful tool to understanding the dissemination
of resistance of this microorganism in the hospital setting.
P1716 Multidrug-resistant Acinetobacter baumannii: clinical
impact at a university-afﬁliated hospital
A. Hernandez-Torres °, J. Go´mez-Go´mez, E. Garcia-Vazquez, G. Yagu¨e,
A.M. Garcia-Hernandez, M. Canteras, J.A. Herrero, M. Valdes
(Murcia, ES)
Objectives: To evaluate impact of multidrug resistant A. baumannii
(MRAB) on clinical outcome of patients admitted at a university
afﬁliated hospital.
Patients and Methods: Observational and prospective study of a cohort
of non-paediatric patients with MRAB isolates. Data collection from
clinical records was done according to a standard protocol. We analysed
epidemiological, clinical, microbiological and laboratory data from
January 2007 through June 2008. Patients with MRAB were identiﬁed by
review of results of microbiology cultures from the hospital microbiology
laboratory. A. baumannii isolation, identiﬁcation and sensitivity test
(VITEK-2; Biomerieux, France) were performed by standard criteria.
Mortality was assessed till 30 days. Colonisation was deﬁned as positive
culture but no clinical symptoms or signs of infection.
Results: 101 patients with MRAB isolates were studied (35 female); 24
(24%) were considered as colonisation; 25 developed bacteraemia and 57
non-bacteraemic infection. Mean age was 56 years (range 18−88); 16%
patients were located in Medical Wards and 84% in Surgical Wards; 33%
had a previous admission at surgical-ICU and 48% at general ICU (mean
stay of 27.5 days). Most frequent underline conditions were high blood
presure (42%), heart disease (32%), diabetes (30%), pulmonary disease
(22%), cancer (14%) and renal failure (14%). Most frequent predisposing
factors were previous surgery (83%), central venous catheter (88%),
urinary catheter (92%), mechanical ventilation (84%), tracheostomy
(54%), parenteral nutrition (54%) and blood transfusions (48%). 41%
patients had received previous carbapenem treatment; 42% piperacilin-
tazobactam and 17% another antibiotic. The source of MRAB was
respiratory (46%), abdominal (14%) and surgical wound in 20% (not
clariﬁed in 5%); 42 patients developed complications. All A. baumannii
isolates were carbapenem, cephalosporins, piperacillin-tazobactam and
quinolones resistant; 26% were ampicillin-sulbactam susceptible, 38%
aminoglycoside, colistin and tigecycline susceptible but ampicillin-
sulbactam resistant and 20% only colistin and tigecycline susceptible.
Empirical antibiotic treatment was wrong in 90% and mortality rate
was 38% in the global sample and 50% (38 out of 77) in patients who
developed MRAB infection.
Conclusions: Knowledge about risk factors and clinical aspects of
MRAB is necessary to improve empirical treatmets and dicreased
associated mortality and morbility.
P1717 Ten-year resistance trends of nosocomial Acinetobacter spp.
in Russia
A. Martinovich, N. Ivanchik, O. Kretchikova, G. Reshedko, E. Riabkova,
M. Edelstein °, R. Kozlov (Smolensk, RU)
Objectives: To assess the trends in antimicrobial resistance of
nosocomial Acinetobacter spp. in Russia over the period of 1997–2007.
Materials and Methods: A total of 997 consecutive non-duplicate
nosocomial isolates of Acinetobacter spp. were collected as part of the
national surveillance studies in Russia during the following periods:
1997–1999 (n = 203), 2002–2004 (n = 464), and 2006–2007 (n = 330).
The susceptibilities of isolates to various antimicrobial agents were
determined by agar dilution method and interpreted according to
EUCAST clinical breakpoints.
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Results: The antimicrobial susceptibility of Acinetobacter isolates is
summarised in the Table.
Antibiotic MIC, mg/ml % of isolates
Years 50% 90% S I R
Imipenem
1997–1999 0.5 1 97.0 0.5 2.5
2002–2004 1 2 93.9 3.9 2.2
2006–2007 1 2 95.5 2.4 2.1
Amikacin
1997–1999 2 16 88.6 2.0 9.4
2002–2004 128 256 33.6 1.3 65.1
2006–2007 256 512 20.6 0.3 79.1
Gentamicin
1997–1999 32 256 31.0 – 69.0
2002–2004 128 256 11.2 – 88.8
2006–2007 128 256 15.8 – 84.2
Netilmicin
1997–1999 ND ND ND ND ND
2002–2004 ND ND ND ND ND
2006–2007 4 16 78.2 13.9 7.9
Ciproﬂoxacin
1997–1999 1 32 69.0 – 31.0
2002–2004 64 128 26.3 – 73.7
2006–2007 128 128 8.5 – 91.5
Colistin
1997–1999 ND ND ND ND ND
2002–2004 ND ND ND ND ND
2006–2007 0.5 1 100.0 – 0.0
ND, Not Determined.
A constant increase in resistance rates to ciproﬂoxacin (from 31.0%
to 91.5%), gentamicin (from 69.0% to 84.2%), and amikacin (from
9.4% to 79.1%) was observed from 1997/99 to 2006/07. In the same
time, the percentage of isolates non-susceptible to imipenem remained
relatively low: 3.0% in 1997/99, 6.1% in 2002/04, and 4.5% in 2006/07.
Netilmicin was the most active in vitro among aminoglycosides (21.8%
non-susceptible isolates) and colistin was the most active among all
antibiotics tested (no resistant isolates) in 2006/07.
Conclusions: The rapid increase in antimicrobial resistance, particularly
to ciproﬂoxacin and amikacin, in nosocomial strains of Acinetobacter
spp. in Russia is noteworthy. Based on results of in vitro surveillance
studies imipenem, netilmicin and colistin may be recommended as
effective treatment for Acinetobacter infections.
P1718 Acinetobacter baumannii 2002–2007: mathematical model
insights on imipenem non-susceptibility and multi-class
resistance
R.M. Mera °, L.A. Miller, H. Amrine-Madsen, D.F. Sahm (Durham,
Upper Providence, Hendon, US)
Objectives: To use a hospital based mathematical model of A. baumannii
to provide insights for the statistical analysis of a surveillance study.
Methods: A compartmental mathematical model at the hospital level was
created to investigate the changes over time of A. baumannii imipenem
and multi-class resistance. The model was calibrated using 48,551
US isolates from the TSN Network® surveillance database (Euroﬁns
Medinet) for the period 2002–2007. A multivariate nonlinear model
was ﬁtted to the data using the insights from the mathematical model.
Covariates available for analysis were time, age, sex, state, location (Ward
or ICU) and source (blood, sputum, etc). Antimicrobial classes included
were carbapenems, cephalosporins, aminoglycosides, ﬂuoroquinolones
and b-lactamase inhibitors. Multi-class or multiple resistance was deﬁned
as non susceptibility to three or more classes.
Results: According to the analysis of the surveillance study, Imipenem
non susceptibility has had a 3.1 fold (2.8–3.4) increase from 12.6% in
2002 to 40.1% in 2007. Subjects <18 years old had signiﬁcantly lower
rates (8.8 and 31.1% for 2002 and 2007) than adults and the elderly
(p< 0.001), but with similar trends. There were signiﬁcant differences
by source, with blood isolates at 34.8%, and sputum at 43.2% in 2007.
The predictions for imipenem non-susceptibility for 2010 according to
the mathematical model are: overall rate 62.5% (60.6−64.3); <18 years
53.2% (50.9–55.5); 65 and older 68.5% (66.6–70.3); blood/CSF 57.4%
(55.1–59.7); sputum 65.7% (63.8–67.6). Multiple resistance was high
in 2002 (49.9%), and has increased slowly to 54.9% in 2007. The rate
of increase has been steeper in those less than 18 years old than in
the elderly (p< 0.001 for interaction), although the latter had the highest
rates in 2007 (64.3%). Predictions of multiple resistance according to the
mathematical model for 2010 are: overall 58% (56.4–59.6); 65 and older
67.5% (65.9–69); blood/CSF 47.1% (45.3–49); sputum 63.8% (62.2–
65.4).
Conclusion: In addition to the predictions of the nonlinear model, the
mathematical model showed that reducing the rate of carbapenem use
may not reduce resistance to imipenem at the hospital, that reducing
the use of quinolones may stop the growth of multiple resistance, but
not reduce it, and that reducing transmission at the hospital through
interventions may reduce imipenem and multiple resistance to a level
similar that strains outside the hospital have.
A. baumannii non-susceptibility.
P1719 Acinetobacter infection in adult critical care unit
N. Arora °, A. Gogia, P.K. Agarwal, C. Wattal, B.K. Rao (New Delhi, IN)
Objective: To study Acinetobacter infection in an adult critical care
unit, the sites of infections, predisposing factors/associated conditions
and antibiotic sensitivity patterns and to monitor the clinical progress
and outcome in these patients.
Methods: 40 patients admitted to the adult critical care units who
develop Acinetobacter infection were analyzed. All relevant clinical
specimens were evaluated including blood, endotracheal aspirate,
pus, wound swab, CSF and other body ﬂuids, etc. The following
variables were analyzed as patient’s age, sex, and the presence of
underlying diseases or conditions, number of days in the ICU/HDU,
antibiotic therapy and the outcome. Acinetobacter isolates were identiﬁed
phenotypically in the microbiology laboratory, using standard techniques
for identiﬁcation and susceptibility testing. The data was analyzed using
standard statistical methods.
Results: A total of 40 patients with culture positive Acinetobacter
baumannii were studied. There were 28 males and 12 females. Mean age
of the patients was 55.12 years. The mean duration of ICU stay prior to
culture positivity was 10.68 days. Out of 40 patients, all were colistin
sensitive while 5 were sensitive to Tigecycline and 15 were moderately
sensitive to Tigecycline, 4 were sensitive to Cefoperazone-sulbactum and
10 were moderately sensitive to Cefoperazone-sulbactum. All of them
were resistant to imipenem. In 31 cases, endotracheal aspirates were
positive, blood culture was positive in 3 patients, sputum was positive in
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4 patients and Urine culture was positive in 3 patients. Out of 40 patients,
24 patients died despite therapy with sensitive antibiotics. 16 patients
who grew Acinetobacter survived. Of the 24 patients who died 10 had
acute renal failure, 1 had malignancy, 3 had COPD, 4 had Diabetes
mellitus, hepatic failure was present in 3 patients and 1 patient was on
long term steroids.16 patients who survived had diabetes mellitus in 4
patients, 3 had hepatic failure and only 1 was on long term steroids.
Conclusion: Most of the patients of Acinetobacter baumannii isolates
were multi-drug resistant in our set up and infections due to them
were associated with signiﬁcant mortality. Infection with the resistant
strains were associated with prolonged ICU stay, use of indiscriminate
broad spectrum antibiotics prior to admission in ICU and multiple co-
morbidities like acute renal failure, diabetes mellitus, malignancy and
prolonged steroid use.
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P1720 Prevalence and antimicrobial susceptibility patterns of
methicillin-resistant S. aureus and vancomycin-resistant
E. faecium causing bloodstream infections in European
hospitals (2005–2008)
H. Sader °, R. Mendes, R. Jones (North Liberty, US)
Objective: To evaluate the prevalence and antimicrobial susceptibility
(S) of MRSA and vancomycin-resistant E. faecium (VREFM) in
European hospitals. These organisms are usually multidrug-resistant
(MDR) with very limited therapeutic options.
Methods: Non-duplicate consecutive strains causing BSI were collected
in the 2005–2008 period from 27 hospitals located in 11 European
countries, Turkey and Israel. A total of 22,712 organisms (9,299 Gram-
positives [GP]) were collected, including 3,962 S. aureus and 1,700
Enterococcus spp. (677 E. faecium), and tested for S by CLSI broth
microdilution methods in cation-adjusted Mueller-Hinton broth.
Results: Overall MRSA rates decreased from 31.5% in 2005 to 23.9%
in 2008. Marked decreases occurred in Turkey (from 41.0% in 2005
to 16.2% in 2008), Italy (51.1 to 29.6%), UK (52.3 to 30.9%) and
Poland (25.3 to 15.4%). MRSA rates varied widely among the countries
evaluated and, in 2008 were highest in Israel (50.0%) and Ireland
(44.6%), and lowest in Sweden (1.8%) and Poland (15.4%). Overall
VREFM increased from 6.1% (2005) to 10.0% (2008), but occurred
only in 5 countries in 2008, varying from 4.6% in Italy and 5.3% in UK
to as high as 26.2% in Germany and 22.2% in Ireland. The only country
with a consistent VREFM increase was Germany (from 7.7 to 26.2%).
VREFM was not observed in Spain, Sweden and Switzerland during
the study interval. Daptomycin (DAP) was the most active compound
against these organisms (see Table), followed by linezolid (LZD), and
the activity of these compounds was not negatively affected by resistant
(R) to oxacillin or vancomycin (VAN). All other compounds exhibited
limited activity against VREFM. Among E. faecalis (956 strains), only
0.6% were VAN-R, while 77.8% of coagulase-negative staphylococci
were oxacillin-R.
Organism (no. tested) MIC90 (mg/L) / % susceptible
Daptomycin Vancomycin Teicoplanin Q/Da Linezolid
MRSA (1,086) 0.5/100.0 1/100.0 2/100.0 1/99.8 2/99.9
VREFM (134) 2/99.3 >16/0.0 >16/41.8 >2/73.1 2/98.5
aQ/D = quinupristin/dalfopristin.
Conclusions: S. aureus and Enterococcus spp. represent important
causes of BSI in European hospitals and the prevalence of MRSA and
VREFM differs signiﬁcantly among countries and has varied in many
countries in recent years. DAP and LZD were the most active compounds
tested against these MDR organisms as well as other GP pathogens
isolated from episodes of BSI. Due to broad spectrum, potent bactericidal
activity and approved indications, DAP represents a valuable treatment
option for BSI caused by GP in European hospitals.
P1721 Antibiotic susceptibility pattern of Gram-positive cocci
cultured from patients in three university hospitals in
Tehran, Iran during 2001–2005
M. Emaneini °, M. Aligholi, F. Jabalameli, S. Shahsavan,
M. Taherikalani, S. Hossein, N. Jonaidi (Tehran, Ilam, IR)
Objective: The antimicrobial susceptibility patterns of 1897 Gram-
positive bacterial Isolates were evaluated.
Methods: The minimum inhibitory concentration (MIC) of isolates
which comprised Staphylococcus aureus (927 isolates), coagulase-
negative staphylococci (CNS; 425 isolates), Enterococcus faecalis (320
isolates), Enterococcus faecium (157 isolates), and pneumococci (50
isolates) collected from 3 teaching hospitals in Tehran were determined
by agar dilution method according to Clinical and Laboratory Standards
Institute (CLSI) guidelines. The presence of mecA gene was investigated
in methicillin-resistant staphylococci by PCR method and vanA and vanB
genes were targeted in enterococcal isolates by Multiplex PCR method.
Results: The resistance rate to methicillin among S. aureus and CNS
isolates were 33% and 49%, respectively. All S. aureus isolates were
susceptible to vancomycin. The lowest rate of resistance in all S. aureus
isolates was found for rifampicin (<4%). The vancomycin resistance
rate in enterococci isolates was 11% which was more frequent among
E. faecium (19%) than E. faecalis (4%), all resistant isolates carrying
vanA. High-level resistance to gentamicin and streptomycin, were
detected in 47% and 87% of enterococcal isolates respectively.
Discussion: The rate of penicillin resistance in pneumococci was 3%
and about 27% of isolates had reduced susceptibility to penicillin. The
prevalence of erythromycin resistant among pneumococci was 58%. All
pneumococcal isolates were susceptible to ceftriaxone, rifampicin and
vancomycin.
P1722 Invasive pneumococcal infection in Scottish paediatric
patients in the conjugate vaccine era
C. Lucas, C. Williams ° (Glasgow, UK)
Introduction: Community acquired invasive infection in children is
primarily mediated by capsulate bacteria, with infants at greatest risk
due to poor responsiveness to carbohydrate antigens. The spectrum of
infecting organisms has been dramatically altered by the Hib and MenC
polysaccharide-protein conjugate vaccines and, following introduction
of the heptavalent pneumococcal conjugate vaccine (PCV) into the
routine UK immunisation schedule in 2006, this study was undertaken
to examine pneumococcal strains associated with invasive disease in the
local paediatric community.
Methods: Retrospective data, collected between January 1996 and
December 2008, on invasive isolates of pneumococci cultured from
paediatric patients in the West of Scotland, were examined. Serotype
distribution and incidence of strains demonstrating reduced sensitivity
to penicillin and erythromycin were calculated.
Results: Over the 13 year period, pneumococci were cultured from
normally sterile sites in 216 patients. Of these, 127 patients were
infected with potentially PCV preventable strains. Serotype 14a was the
predominant strain, causing 25% of infections. MIC data, for penicillin
and eryrthromycin, were available on 212 isolates. Seven strains with
“intermediate” sensitivity to penicillin were cultured sporadically during
the study period. No fully penicillin resistant isolates were grown. Forty
erythromycin resistant strains were grown in total, 32 of which belonged
to serotype 14a. With limited data available post introduction of PCV, no
statistically signiﬁcant change in infection rate or antibiotic sensitivity
pattern is evident to date.
Conclusion: The majority of pneumococcal strains causing invasive
infection in paediatric patients in the West of Scotland are included in
PCV. A positive impact of this vaccine on infection rates and prevalence
of antibiotic resistant strains remains to be demonstrated. Some 40%
of infections in this study were caused by strains not included in PCV
and the relative importance these requires to be carefully monitored over
forthcoming years.
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P1723 Individual dose impact on resistance selection in the
community: a mathematical model of Streptococcus
pneumoniae dynamics and b-lactams
L. Opatowski, J. Mandel, P.Y. Boe¨lle, L. Temime, D. Guillemot ° (Paris,
FR)
Objectives: Streptococcus pneumoniae is a major pathogen in the
community. Controlling its resistance has become a public health priority.
Increasing the dose, particularly of b-lactams, has been suggested to
avoid failed treatments of infections caused by highly resistant bacteria.
Methods: To assess the impacts of antibiotic-exposure frequency
and doses on resistance emergence, a mathematical model was con-
structed, combining S. pneumoniae pharmaco- and population-dynamic
approaches in a community of individuals stratiﬁed according to their
colonisation and b-lactam-exposure status, and speciﬁcally including
prescribed-dose heterogeneity in the population. Decolonisation could
be either natural or induced by antibiotic exposure if the prescribed
dose exceeded the carried strain’s MIC. Simulations over a 50 years
period were run to test the impact of dose-distribution and antibiotic-
exposure frequency changes on community resistance patterns, and the
accuracy of deﬁned daily dose (DDD) as a predictor of resistance.
Results: After 50 years, nonsusceptible strain prevalence among carriers
strongly reﬂected antibiotic exposure. Nonsusceptible strain prevalence
increased with antibiotic-exposure frequency. The dose-distribution shift
to higher doses had 2 paradoxical effects: while the prevalence of
resistant strains dropped, these were comparatively more resistant as
evidenced by larger MICs. Keeping the volume of antibiotic constant in
the population, different patterns of use could lead to markedly different
resistance distribution and prevalence.
Conclusions: Our results suggest that pneumococcal resistance pattern
in the community is strongly linked to individual prescribed dose:
recommendations to increase them should magnify nonsusceptible strain
MIC in the community. Therefore, surveillance networks are encouraged
to collect both daily antibiotic-exposure frequencies and individual
prescribed doses.
P1724 Invasive infections caused by drug-resistant Streptococcus
pneumoniae at a Thai hospital
J. Visuthranukul °, G. Suwanpimolkul, T. Chatsuwan, S. Nilgate,
C. Suankratay (Bangkok, TH)
Objective: To determine the prevalence and clinical features of drug-
resistant Streptococcus pneumoniae (DRSP) isolated from adult patients
with invasive infections.
Methods: A retrospective study of all adult patients with S. pneu-
moniae bacteraemia and meningitis who were hospitalised at King
Chulalongkorn Memorial Hospital, Thailand, was carried out between
2004 and 2008.
Results: Of 65 pneumococcal isolates, there were 51 (78%) and 14
(22%) patients with bacteraemia and meningitis. Of 51 patients with
bacteraemia, the most common diagnosis was pneumonia (74.6%),
followed by primary bacteraemia (17.6%), skin and soft tissue infections
(5.9%), and peritonitis (1.9%). Of these, there were 96%, 4%, and 0%
of penicillin-susceptible S. pneumoniae (PSSP), penicillin-intermediately
resistant S. pneumoniae (PISP), and penicillin-resistant S. pneumoniae
(PRSP), respectively. All isolates were susceptible to cefotaxime. Of 14
patients with meningitis, there were 43% and 57% of PSSP and PRSP.
In contrast to the observation in patients with bacteraemia, cefotaxime-
susceptible, -intermediately resistant, and -resistant S. pneumoniae were
noted in 72%, 14%, and 14%, respectively. All isolates from patients
with bacteraemia and meningitis were susceptible to vancomycin. Of 4
patients with cephalosporin-nonsusceptible S. pneumoniae meningitis,
3 had community-acquired meningitis and 1 developed meningitis
after neurological operation. All of these patients survived with the
treatment of ceftriaxone (4 g/day) alone. In our institute, the prevalence of
penicillin- and cephalosporin-nonsusceptible S. pneumoniae in patients
with meningitis has been markedly increasing from 22.2% to 57% and
from 0% to 29%, respectively, during the periods of 1997–2003 and
2004–2008.
Conclusions: There has been an markedly increasing prevalence of
penicillin- and cephalosporin-nonsusceptible S. pneumoniae in adult
patients with meningitis in our institute. This emphasizes an urgent need
to strengthen both appropriate use of antimicrobials and strict infection
control measures to help reduce the transmission of DRSP.
P1725 Emergence of antimicrobial resistance among Viridans
group streptococci: a six-year surveillance in children
attending day care centres
H. Carsenti Dellamonica °, M. Roussel Delvallez, B. Dunais,
C. Pradier, M. Lelieur Pierard, C. Laurans, P. Touboul, P. Bruno,
G. Melica, M. Sabah, G. Mancini, H. Haas for the GEPIE Group
Resistance of Viridans Group Streptococci (VGS) is important to follow
since they are a reservoir of resistant bacteria in oral cavities.
Objectives: to determine colonisation and resistance rates to antibiotics
of VGS isolated from healthy children 3 months to 3 years old attending
DCC in Nice (AM) in 2002, 2004, 2006 and Nord (N) in 2006 and
2008 (AM). NP aspirates were obtained from a random sample. Trends
in resistance in pneumococcal strains (SP) and in VGS were compared.
An intervention program to promote judicious antibiotic use started in
AM in 2000, 2002 and a national campaign was launched in 2002.
Methods: Antibiotic susceptibility was determined by disk diffusion
method and E-test on blood agar plates
Results: See the table.
2002 2004 2006/06 2006/59 2008/06
Penicillin 55.56 56.45 37.25 57.58 51.56
Amoxicillin 22.22 53.23 29.41 57.58 53.13
Cefotaxime 50.00 25.49 48.48 40.63
Tetracycline 29.63 30.65 27.45 42.42 42.19
Chloramphenicol 11.11 12.90 5.88 24.24 50.00
Erythromycin 66.67 66.13 50.98 63.64 73.44
Clindamycin 22.22 27.42 21.57 33.33 18.75
Spiramycin 54.84 33.33 48.48 54.69
Lincomycin 22.22 17.74 11.76 24.24 42.19
Telithromycin 12.90 1.96 0.00 34.38
Ciproﬂoxacin 18.52 56.45 66.67 51.52 100.00
Levoﬂoxacin 3.70 6.56 9.80 12.12 38.10
Moxiﬂoxacin 8.20 7.84 12.12 49.21
A diminution of strains with decreased susceptibility to b-lactams was
observed in 2006 only in AM and increase in resistance is observed in
2008
The same evolution is observed for tetracycline, chloramphenicol and
macrolides
Resistance to ﬂuoroquinolones is increasing although these antibiotics
are not prescribed in this population of children
Conclusion: Penicillin resistance of VGS (37% in AM and 57% in N)
is equivalent to penicillin resistance of SP (34% in AM, 56% in N)
in this children population in 2006 and increased in 2008 to 52%
and Sp resistance to 42%. Erythromycin resistance in the SP isolates
(45% in AM, 68% in N) is in 2006 also similar to the resistance rate
in VGS isolates (51% in AM, 64% in N) and resistance increased in
2008 in VGS. For levoﬂoxacin and moxiﬂoxacin increased resistance was
observed from 3% in 2004 to 35% in 2008, not easily comprehensive in
this children population and which requires further evaluations.
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P1726 Diverse populations of ﬂuoroquinolone nonsusceptible
group A streptococci recovered from colonisation and
infections in Portugal (1999–2006)
R. Pires °, C. Ardanuy, V. Oliveira, D. Rolo, J.F. Almeida, A. Brito-Avoˆ,
A. Morais, J. Gonc¸alo-Marques, J. Lin˜ares, I. Santos-Sanches
(Caparica, Oeiras, Lisbon, PT; Barcelona, ES)
Objectives: To examine ciproﬂoxacin nonsusceptible (Cip-NS) Group A
streptococci (GAS) isolated from clinical origins and asymptomatic
colonisation, and to explore the associated clones and mechanisms of
resistance.
Methods: A total of 1,541 GAS collected from oropharyngeal
colonisation (n = 938), tonsillitis (n = 487), skin/soft tissue infections
(n = 72) and invasive disease (n = 44) were studied. Susceptibility to
ciproﬂoxacin was evaluated by disk diffusion and by microdilution
methods. Point mutations in the parC-quinolone resistance determining
region (QRDR) were identiﬁed by sequencing and by restriction of PCR
amplicons with HinfI and LweI. Cip-NS isolates were characterised
by emm-typing, pulsed-ﬁeld gel electrophoresis (PFGE) and multilocus
sequence typing (MLST) to assign sequence types (ST).
Results: Eighty-one (5%) isolates were Cip-NS showing a MIC
range between 2 and 8mg/L. This rate was higher among skin/soft
tissue infection isolates (15%, n = 11/72). All but three strains had
ParC changes: S79F (n = 73), D83N (n = 4) and D83Y (n = 1). Seven
ST or lineages, of diverse emm and PFGE types, were found
among 81 Cip-NS isolates. A major lineage ST382/emm6;others/
PFGE.AD;DX;DY;AM;DW (n = 73 isolates from different origins)
showed the ParC-S79F change. Other Cip-NS strains were (all
n = 1): ST52/emm28/PFGE.AC ParC-D83N, ST52/emm28/PFGE.BT
ParC-D83Y, ST46/emm22/PFGE.B ParC-D83N, ST99/emm5/PFGE.BB
ParC-D83N, ST-unassigned/emm5/PFGE.K ParC-D83N. The remain-
ing 3 strains with no ParC changes were: ST36/emm12/PFGE.AP,
ST39/emm4/PFGE.CH and ST39/emm89/PFGE.CZ. Lineages ST36 and
ST-unassigned were associated with oropharyngeal colonisation isolates,
ST39 and ST46 with tonsillitis and ST52 and ST99 with skin/soft tissue
infections.
Conclusions: Nonsusceptibility to Cip among GAS in Portugal was
similar to the one reported in European surveys. The majority of Cip-
NS isolates belonged to emm6 (ST382) with S79F mutation however
other different types emm28 (ST52), emm22 (ST46) or emm5 (ST99)
found among colonisation and/or clinical isolates showed different
ParC changes (D83N/Y). The absence of point mutations in the parC-
QRDR region of emm4/89 (ST39) and emm12 (ST36) isolates suggests
mechanism(s) of ﬂuoroquinolone resistance other than point mutations in
the parC-QRDR region (e.g., single parE mutations and/or efﬂux pumps).
P1727 Trends in invasive group A streptococci in adult patients
in Barcelona
C. Ardanuy °, D. Rolo, A. Domenech, F. Tubau, J. Ayats, I. Grau,
R. Pallares, R. Martin, J. Lin˜ares (L’Hospitalet de Llobregat, ES)
Objective: The aim of this study was to analyze the invasive disease
due to Streptococcus pyogenes (GAS) in adults patients during a ten-
year period (1998–2007) in Barcelona.
Methods: All invasive GAS episodes detected in our hospital were
collected. Antibiotic susceptibility was studied by microdilution.
Molecular typing was performed by PFGE (SmaI) and emm-typing and
selected strains were studied by MLST.
Results: A total of 127 episodes of invasive GAS disease were observed
during the study period. Of them, 76 occurred in men (60%). The
medium age was 57 (SD19.7, range 18−98). The overall incidence
of invasive GAS disease was 2.2 episodes per 100,000 inhabitants.
Among people older than 65 the invasive GAS disease (6.4/100,000)
was higher than those observed among adults aged 18−64 years
(1.4/100,000, p< 0.001). The sources of invasive GAS were blood 110
(87%), joint ﬂuid 9 (7%), pleural ﬂuid 7 (6%), and ascitic ﬂuid 1
(0.8%). Most of invasive diseases were related to soft-tissue infections.
The antibiotic resistance rates were as follows: erythromycin 20.5%,
clindamycin 12.6%, tetracycline 17% and ciproﬂoxacin 2%. All strains
were susceptible to penicillin. Ninety-ﬁve strains were available for
molecular typing. The six most frequent emm types and their related
sequence-types (STs) were emm1-ST28 (31%), emm59-ST172 (10%),
emm28-ST52 (6%), emm4-ST39 (5%) emm12-ST36 (5%) and emm25-
ST350 (5%).
Conclusion: The majority of invasive infections caused by Streptococcus
pyogenes in adult patients in our area were related to soft-tissue
infections and were associated with emm1-ST28 type, whereas the
emm59-ST172 and emm25-ST350 types were mainly associated with
injection drug users.
P1728 Phenotypes and genotypes of erythromycin-resistant
group A streptococci in Barcelona
A. Domenech, D. Rolo, L. Calatayud, F. Tubau, J. Ayats, R. Martı´n,
J. Lin˜ares, C. Ardanuy ° (L’Hospitalet de Llobregat, ES)
Objective: The aim of this study was to analyze the evolution of
phenotypes, genotypes and macrolide resistance genes of Streptococcus
pyogenes (GAS) isolated from invasive and non-invasive disease among
adults patients from 1998 to 2007.
Methods: A total of 445 GAS strains were isolated in our hospital during
the study period. Antibiotic susceptibility was studied by microdilution
and macrolide resistance phenotypes by disk diffusion. Molecular typing
was performed by PFGE (SmaI) and emm-typing, and selected strains
were studied by MLST. Macrolide resistant genes and those of Tn916-
family of transposons were detected by PCR.
Results: During the study period 95 (21%) erythromycin resistant
isolates were detected. Of them, 50 occurred in men (53%). The medium
age was 49 (SD19, range 18−90). The 59% of them were isolated from
soft-tissue infections, 15% from respiratory tract specimens and 6%
from pharyngitis. By two year period the rates of erythromycin-resistant
(EryR) were: 18.42% (1998–1999), 15.58% (2000–2001), 45.6% (2002–
2003), 25.49% (2004–2005) and 9.84% (2006–2007). Thirty-six (37.9%)
strains had M phenotype and 59 (62.1%) had MLSB phenotype (39
cMLSB and 20 iMLSB). The proportion of M decreased throughout the
study period (from 10/14 in 1998−99 to 4/12 in 2006–2007, p = 0.05).
All 26 M phenotype GAS studied had mefA gene. Of 21cMLSB studied
20 had ermB and 1 had ermTR genes. Five iMLSB GAS had ermTR
and 8 had ermB. No tetracycline resistance nor tetM gene was detected
among M phenotype GAS. All GAS harbouring ermB gene had tetM
gene and the majority of them (75%8) were related to Tn916-family
of transposons (Tn6002 and Tn1545). Three GAS with ermTR gene
were resistant to tetracycline related to tetM gene probably harboured
by Tn916 transposon. The predominant genotypes were emm11-ST403
(12%), emm4-ST39 (7%) and emm25-ST350 (n = 6%).
Conclusion: Macrolide resistance rates among GAS isolated from adults
ﬂuctuates throughout the study period. The peak observed in 2002–2003
period was associated with an outbreak due to emm25-ST350 among
injection drug users. The increased rates of MLSB phenotype were
associated with the spread of Tn916-family of transposons harbouring
ermB and tetM genes.
P1729 Oropharyngeal colonisation by group A streptococci in
Portugal: an eight-year surveillance study (2000–2007)
I. Santos-Sanches °, R. Pires, D. Rolo, F. Esteves, J.F. Almeida,
R. Mato, I. Valadares, T. Ramos, C. Gameiro, F. Andrade, A. Lopes,
J. Rosas, E. Ferreira, L. Romeiro, F. Vaz, A. Morais, A. Brito-Avoˆ,
J. Gonc¸alo-Marques (Caparica, Oeiras, Lisbon, PT)
Objectives: To evaluate trends of oropharyngeal colonisation (OC) by
Group A streptococci (GAS) and to assess the clonal structure of
sporadic and persistent strains.
Methods: During 16 periods in 2000–07, oropharyngeal samples were
taken from different populations: 6965 from children (0−6 yrs) in
day-care centres (DCC), 2337 from school-aged children (7−16 yrs)
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and 1276 from adults (1169 school staff and 107 family members).
Bacterial identiﬁcation was carried out by standard methods. Resistance
to erythromycin (E) and clindamycin (Da) was evaluated by disk
diffusion and minimal inhibitory concentrations using E-tests. Clones of
all resistant and a subset of susceptible isolates were deﬁned by pulsed-
ﬁeld gel electrophoresis (PFGE) and further characterised by serotyping
for T antigen (T-typing), and by sequencing for assignment of emm-types
and multilocus sequence types (ST).
Results: A total of 1026 GAS were isolated. OC in younger children
was higher (11.6%) than among older than 7 yrs (7.8%), and in adults
was higher among family members (8.4%) than among school staff
(2.6%). OC rates varied with DCC (min. 0%; max. 49%). Higher
OC rates (>10%) were usually detected during winter periods (17%
in 2001, 13% in 2002/03, 12% in 2007), and occasionally, during
autumn of 2003 (15%) and spring of 2001 and 2004 (15% and 18%,
respectively). E resistance was 10% in 2000–02, 28% in 2003, 20%
in 2004, 3% in 2005, 14% in 2006 and 10% in 2007. Da resistance
was lower than 10%, except in 2006 (14%). Six out of 98 PFGE
types accounted for 49% of isolates studied (n = 380/775) which were
included in ﬁve ST or lineages: ST36 (T12/emm12/PFGE.AB;PFGE.AP)
(n = 172, mainly E susceptible); ST28 (T1/emm1/PFGE.X) (n = 87, all
E susceptible); ST406 (T3.13.B3264/emm3/PFGE.BG) (n = 48, all E
susceptible); ST382 (T6/emm6/PFGE.AD) (n = 38, all E susceptible);
and ST39 (T4/emm4/PFGE.CZ) (n = 35, all E resistant). Three lineages
and four PFGE types prevailed during peaks of OC: ST406 (PFGE.BG)
in 2001 (winter and spring); ST36 (PFGE.AB) in 2002 (winter) and
2003 (autumn); ST36 (PFGE.AP) in 2003 (winter); and ST28 (PFGE.X)
in 2004 (spring).
Conclusions: The GAS carrier state was seasonal and variable with age
and DCC attendance. A very heterogeneous population of GAS colonised
healthy carriers during 2000–07. However, some lineages/clones either
resistant or susceptible to macrolides were identiﬁed as putative poor
colonisers and others as widely disseminated and persistent over time.
P1730 Nocardiosis over 20 years in a tertiary care hospital
J. Ambrosioni °, K. Bouchuiguir-Wafa, J. Garbino (Geneva, CH)
Objectives: The aim of the study was to review and characterise the
cases of nocardiosis identiﬁed in our institution between January 1989
and December 2008.
Methods: Retrospective analysis of all cases with emphasis on
clinical presentation, diagnosis, treatment and outcome. Analysis of the
antimicrobial susceptibility patterns of all the identiﬁed strains.
Results: During the study period 28 cases were identiﬁed; 25 were
considered infections and included for analysis and 3 cases were not
included because they were considered as colonisation in patients with
chronic obstructive pulmonary disease, cystic ﬁbrosis and bronchiectasis.
The highest number of cases (n = 4) was identiﬁed in 2008. The median
age was 54.3 years old and 60% were male. The most frequent underlying
diseases in patients with infection were cancer in 20%, solid organ
transplantation 20%, HIV infection 12% and diabetes mellitus 12%;
32% received steroid therapy within one month before the diagnosis
of Nocardia infection. Clinical presentations were pulmonary in 72%
followed by cutaneous 12%, cerebral 8%, disseminated 4% and articular
4%. The species isolated were N. asteroides in 52%, N. asteroides
complex in 16%, N. farcinica 8%, N. nova and N. brasiliensis 4% in
each and Nocardia spp. in 16% of cases. Clinical outcome was cure or
improvement in 80%, treatment failures in 4%, relapses in 4% and death
in 12%.
Sensitivity tests showed that amikacin was active in 20/20 of tested
strains, imipenem in 20/22, trimethoprim-sulphamethoxazole (TMS) in
19/22, minocycline in 7/7, ciproﬂoxacine in 8/13 and ceftriaxone in 6/9.
Two tested strains were sensitive to linezolide; one strain was sensitive
to imipenem but resistant to ertapenem. TMS was the initial antibiotic
treatment in 15 patients. In 6 cases (40%) it was switched to another
treatment due to intolerance or lack of efﬁcacy.
Conclusions: Nocardia infection is increasing in our centre. It must be
considered an opportunistic infection in our centre since most of the
patients presented immunosuppression as a predisposing factor. TMS
presented a good in vitro activity, but it was frequently switched to
another antibiotic due to intolerance or lack of efﬁcacy. Susceptibility
tests showed that amikacin plus imipenem cover Nocardia spp. isolated
in our institution. This combination could be considered the treatment of
choice for nocardiosis. Sensitivity to imipenem cannot be extrapolated
to other carbapenems.
P1731 Characterisation of clinical Clostridium difﬁcile isolates by
rep-PCR, PFGE and PCR ribotyping
S. Frye, C. Smith, K. Reece, M. Wise, N. Krishnaswami, A. Foussadier,
J. Embry, S. Abedi, T. Ross, M. Healy ° (Athens, US; Marcy l’Etoile, FR)
Objectives: Clostridium difﬁcile is a major cause of nosocomial
infections. In recent years, a highly virulent strain (NAP1/ribotype 027)
that causes more serious disease and increased mortality has emerged in
both Europe and North America. Tracking the source and spread of these
infections through strain-typing will help to contain hospital associated
infections. Several molecular typing methods are used as tools to strain-
type C. difﬁcile, including PFGE and PCR ribotyping. An automated
repetitive sequence-based PCR system, the DiversiLab System, has also
been used in strain typing of C. difﬁcile. This study compares rep-PCR,
PCR ribotyping and PFGE methods for strain typing.
Methods: A total of 84 C. difﬁcile consisting of clinical isolates from a
healthcare facility in the UK (17 isolates) and a healthcare facility in the
US (67 isolates) were previously characterised by PCR ribotyping. The
sample set consisted of 25 different PCR ribotypes including multiple
ribotype 027. Each isolate was cultured and genomic DNA was extracted
using the UltraCleanTM Microbial DNA Isolation Kit. For rep-PCR,
DNA was ampliﬁed using the Clostridium Kit for DNA Fingerprinting.
The ampliﬁed product fragments were separated using microﬂuidics
lab-on-a-chip technology and analyzed using web-based data analysis
software. PFGE was carried out using the CHEF-DRTMII (Bio-Rad
Laboratories) electrophoresis system following a previously described
method.
Results: Rep-PCR and PCR ribotyping ﬁngerprints were generated
for every sample. PFGE ﬁngerprints were generated for over 95% of
isolates. Rep-PCR, PFGE and PCR ribotyping clustering showed a high
concordance; however, rep-PCR and PFGE showed a higher level of
discrimination by divisions within some ribotype clusters. Additionally,
rep-PCR and PFGE provided multiple ﬁngerprints for ribotype 027.
Conclusions: Rep-PCR and PCR ribotyping had a more rapid turnaround
time and were more robust because DNA degradation was less of a
concern as compared to PFGE. However, both PFGE and rep-PCR
provided a higher level of discrimination than PCR ribotyping including
for isolates of ribotype 027.
P1732 A 20-month survey of molecular characterisation and
antimicrobial susceptibilities of Clostridium difﬁcile isolates
in a Chinese university hospital
H. Huang, S. Wu, M. Wang, Y. Zhang, H. Fang, A.C. Palmgren,
A. Weintraub, C.E. Nord ° (Stockholm, SE; Shanghai, CN)
Objectives: Clostridium difﬁcile infection (CDI) is the leading cause of
nosocomial diarrhoea and the number of outbreaks has risen markedly
since 2003. However, there is still a paucity of data on CDI in China.
A 20-month study of CDI was conducted at the University Hospital
Huashan in order to characterise the clinical isolates of C. difﬁcile.
Methods: 136 C. difﬁcile isolates recovered between 2007 and 2008
were analyzed. The presence of tcdA, tcdB, binary toxin genes and
tcdC deletion nt 117 was detected by polymerase chain reaction (PCR),
toxin B was reconﬁrmed by the cytotoxicity neutralisation assay. The
minimum inhibitory concentrations (MICs) of 12 antimicrobial agents
were determined using the agar dilution method according to Clinical
Laboratory Standard Institute (CLSI).
Results: Of 136 isolates, 104 were from the ﬁrst episode of CDI,
11 were from relapses, 3 were from reinfections, and 18 were toxin-
negative. Of the 107 nonrepeated and toxigenic isolates, 76 were A
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(+)B(+), 29 were A(−)B(+), and 2 were A (+)B(+)Binary toxin(+).
No TcdC nt 117 deletion was detected. Twenty-three different PCR
ribotypes were identiﬁed with a speciﬁc clone (SH II) accounting
for 18.5% of the isolates. None of them belonged to ribotype 027
or 078. All strains were susceptible to metronidazole, vancomycin
and piperacillin/tazobactam. Resistance to moxiﬂoxacin, ciproﬂoxacin,
levoﬂoxacin, erythromycin, clindamycin, tetracycline, rifampin, fusidic
acid and meropenem was found in 43.9%, 100%, 78.5%, 72.6%, 79.2%,
40.2%, 20.6%, 17.6% and 0.9% of the isolates, respectively. Thirty-
two strains exhibited multiresistance to erythromycin/clindamycin,
moxiﬂoxacin and tetracycline. The prevalence of resistance genes in the
isolates was as follows: ermB, 23; ermFS, 0; tetM, 32; gyrA mutation,
22; gyrB mutation, 2; gyrA and gyrB mutation, 8.
Conclusion: One special clone (SH II) dominated and ribotype 027
was not found. The prevalence of combined drug resistance is high and
the growing load of resistance mechanisms needs more investigations.
Further epidemiological surveillance of CDI is required to detect
clustering of cases and to monitor the emergence of speciﬁc highly
virulent clones in China.
P1733 An epidemiological study of detection rates of Clostridium
difﬁcile toxins A and B at a hospital in King’s Lynn,
England from 2000 to 2008
C. Micallef °, G. Rogerson, L. Liebowitz (King’s Lynn, UK)
Introduction: Clostridium difﬁcile associated diarrhoea (CDAD) is an
important cause of hospital-acquired infection. It has been estimated
that in the United Kingdom, this accounts for an additional cost
of £400,000/100 patients [1]. Predisposing factors include: antibiotic
therapy, age 65 years or more, chemotherapy, proton pump inhibitors,
and increased hospital stay [2,3]. Additional risk factors include gastric
acid suppression medications [3]. C. difﬁcile produces a number of
toxins, notably, Toxin A (TcdA), an enterotoxin and Toxin B (TcdB),
a cytotoxin4.
Objectives:
• Exploring the epidemiological pattern of toxin-producing C. difﬁcile
at The QEH during an eight-year period.
• Investigating impact of infection control interventions.
Methodology: The QEH is a district general hospital in the East
of England, with 480 beds, providing a service to 280,000 people.
Stool samples which were submitted for testing to the Microbiology
Department from 2000 to 2008 were screened for C. difﬁcile toxins
A and B. Use of cephalosporins and quinolones was discouraged from
July 2005. The infection control team was increased and an isolation
ward introduced in 2008.
Results: Highest rates occurred in 2005 with a total of 546 cases. From
2005 to 2008 there was a progressive decrease in rates of C. difﬁcile
toxin detection to 129.
Figure 1. No. of C. difﬁcile toxins A and B positive patients from 2000
to 2008.
Conclusions: This study suggests that enlargement of the infection
control team, introduction of isolation ward and antibiotic prescribing
guidelines, minimising the use of cephalosporins and quinolones has
had a direct impact on the C. difﬁcile infection rates at The QEH.
Reference(s)
[1] Spencer, RC. Clinical impact and associated costs of Clostridium
difﬁcile-associated disease, 1998. J Antimicrobial Chemotherapy, 41.
Suppl C, 5−12.
[2] Barbut, F, Petit, JC. Epidemiology of Clostridium difﬁcile-associated
infections, 2001. Clin Microbiol Infect, 7: 405–410.
[3] Monaghan, T, Boswell, T, Mahida, YR. Recent advances in
Clostridium difﬁcile disease, 2008. Gut, 57: 850–860.
[4] Voth, DE, Ballard, JD. Clostridium difﬁcile Toxins: Mechanism of
action and role in disease, 2005. Clinical Microbiology Reviews,
18(2): 247–263.
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P1734 European Surveillance of Antimicrobial Consumption
(ESAC): outpatient antimycotic use in Europe
N. Adriaenssens °, S. Coenen, A. Muller, V. Vankerckhoven,
E. Hendrickx, H. Goossens on behalf of the ESAC Project Group
Objectives: To assess the total outpatient systemic antimycotic use in
Europe and to identify the antimycotic substances most commonly used.
Methods: The European Surveillance of Antimicrobial Consumption
(ESAC; www.esac.ua.ac.be) project, now funded by the European
Center for Disease Control and Prevention (ECDC; agreement number
2007/001), continues to collect data on antimicrobial consumption
for all Member States, candidate countries and European Free Trade
Association-European Economic Area countries using the anatomic
chemical therapeutic (ATC) classiﬁcation and the deﬁned daily dose
(DDD) measurement unit. For 2007, data on outpatient use of all
antimycotics for systemic use (ATC J02 and D01B), aggregated at the
level of the active substance, was collected and use was expressed in
DDD (WHO ATC/DDD, version 2007) per 1000 inhabitants per day
(DID). Only countries for which data on both J02 and D01B use was
available were included in the analysis.
Results: Total outpatient antimycotic use in 2007 in 11 European
countries (data for Estonia include hospital use) varied by a factor of
11.65 between the country with the highest (3.03 DID in Belgium) and
the country with the lowest (0.26 DID in Slovakia) use. Terbinaﬁne,
itraconazole, and ﬂuconazole were the most prescribed substances, and
represented more than 96% of the total outpatient antimycotic use in all
countries except for Estonia, Slovakia and Latvia (83.8%, 78.5% and
74.6%, respectively). Terbinaﬁne use represented more than 50% of the
total outpatient antimycotic use in 8 out of 11 countries (not in Latvia,
Hungary and Italy).
Figure: Total outpatient systemic antimycotic use in 11 European
countries in 2007.
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Conclusion: Our study demonstrates a variation of outpatient systemic
antimycotic use in Europe as striking as that of outpatient systemic
antibiotic use. The ESAC data facilitate auditing of antimycotic
prescribing and evaluation of the implementation of guidelines and
public health policies to promote its judicious use.
P1735 Management of candiduria: an interview schedule
V. Avkan-Oguz °, N. Yapar, M. Avci, G. Mermut, H. Pullukcu, S. Sacar,
S. Sayin-Kutlu, B. Cetin, B. Ertugrul on behalf of the West Anatolian
Fungal Infection Study Group
Objectives: Management of candiduria remains controversial, mainly
due to uncertainties of clinicians how to diagnose and when to
start treatment. In this study we aimed to investigate diagnostic and
therapeutic approach of different specialists for candiduria.
Methods: An interview schedule composed of 10 questions on
candiduria was applied interactively to 393 clinicians during three
months in six different tertiary care hospitals. We separated the questions
into two parts. First part was about demographic features, following up
of Candida guidelines and the advice of participants for patients who
have Candida growth in the ﬁrst urine culture. Second part consisted of
six questions about diagnostic and therapeutic approach. These questions
were not asked to participants who did not suggest second urine culture
after ﬁrst positive one. We compared the answers of infectious diseases
(ID) specialists with the others (internist, surgeon, and intensivist). The
data of each participant were evaluated using the Statistical package for
Social Sciences version 11. For statistical analyses chi-square test was
used.
Results: Of 393 participants, 88 (22.4%) were ID and 305 (87.6%)
were other (199 internists, 79 surgeons, 27 intensivists) specialists. Of
the participants, 215 (54.7%) were male, 178 (45.3%) were female
and mean age was 34.27±8.4 (24−63). The number of participants
diagnosing candiduria more than 20 times in a year was 76 (19.4%). The
details of interview are presented in the table. The difference between the
compliance of ID and other specialist to the guidelines or literature about
diagnosis and starting therapy for candiduria was statistically signiﬁcant.
First choice of therapy was amphotericin B for neutropenic patients and
ﬂuconazole for nonneutropenic patients.
Conclusion: The ID specialists displayed a more proactive and consistent
approach to Candiduria treatment than the other specialists. This
approach was especially observed in the high-risk patient group and
also in utilising the second urinary culture. Accordingly, the above
mentioned results, point to a room for improvement in the management
of candiduria, aiming for a consensus.
Table: The approach of Infectious Diseases (ID) and other specialists to candiduria
ID specialists Other specialists Statistic
n = 88 (%) n = 305 (%) p
Mean age (year) 38.28±8.4
(24−60)
33.12±8.1
(24−63)
Mean time after specialisation training 7.72±7.85
(min 0 −
max 30)
3.58±6.37
(min 0 −
max 28)
Following related guidelines 65 (73.9) 59 (19.3)
Second urinary culture 74 (84) 130 (42.6) 0.0000*
Starting of therapy without second culture result 25 (33.7) 24 (18.4) 0.013*
Starting of therapy according to second culture result 49 (66.3) 106 (81.5)
Starting of therapy in high risk patient when second
urine culture is positive
66 (89.1) 87 (66.9) 0.0004*
Changing of the urinary catheter 55 (74.3) 95 (72.5) 0.849
Searching for another fungal infection focus 66 (89.1) 105 (80.7) 0.116
Choice of therapy for patients with neutropenia
Fluconazole 29 (39.2) 39 (29.7)
Other antifungal agent 45 (60.8) 91 (70.3)
Choice of therapy for patients without neutropenia
Fluconazole 72 (97.3) 116 (89.2)
Other antifungal agent 2 (2.7) 14 (10.8)
P1736 Empirical antifungal therapy in selected patients with
persistent febrile neutropenia
A. Martı´n-Pen˜a °, M. Aguilar-Guisado, J.M. Cisneros, E. Cordero,
I. Espigado, R. Parody, J. Pacho´n for the Spanish Network for
Research in Infectious Disease (REIPI)
Objectives: The aim of this study is to analyze the incidence and related
mortality of invasive fungal infection (IFI) in patients with persistent
febrile neutropenia, using empiric antifungal therapy (EAT) only in
selected patients by risk factors and clinical criteria.
Methods: Prospective observational study including every persistent
febrile neutropenia episodes in patients with haematological malig-
nancies or stem cell transplantation (SCT) recipients admitted in
the Haematology Service from October 2007 to November 2008. A
diagnostic and therapeutic protocol based in clinical criteria and risk
factors was applied in every episode in order to select patients for EAT
indication. Comparative analysis of incidence of proven or probable IFI
and IFI-related mortality in patients with persistent febrile neutropenia
according to the indication or not of EAT.
Results: Fifty three episodes PFN in forty six patients were included.
The 56.5% were male and the median age in years was 51 (15−71).
The most frequent haematological malignancies were acute leukaemia
(36.9%) and lymphoma (26.1%). Eighteen patients were SCT recipients,
50% allogeneic. The 21.7% were IFI-high risk patients. The mean of
duration of neutropenia and fever were 14 days (range: 6−63) and 11 days
(range: 4−33) respectively. A diagnostic of proven or probable infection
was established in 79.2% of the cases. The most frequent clinical
syndromes were: respiratory (35.8%) and non focused fever (35.8%).
EAT was indicated in thirty two episodes (60.4%) with a median of
duration of 10 days (range: 2–164); in the rest of episodes (n = 21) EAT
was no indicated. The overall IFI incidence was 17% (n = 9). In the group
that received EAT, nine patients developed IFI (28.1%), in comparison
with no-one patient in the group that did not receive EAT. The 30 days-
global mortality was 18.9%, 28.1% in the group that received EAT and
4.8% in the group that did not received it. The IFI-related mortality in
the group that received EAT was 6.2% and 0% in the group that did not
received EAT.
Conclusion: These data suggest that EAT in selected patients used in
the basis of clinical criteria and risk factors, may be effective and safe
in the management of PFN and avoid over-treatment.
P1737 Outcomes associated with antifungal treatment and
ﬂuconazole treatment failure for candidaemia or invasive
candidiasis in patients admitted into intensive care units
A. Escudero, J. Ferna´ndez, F.J. Be´cares, B. Sa´nchez, B. Ruı´z, S. Grau °,
E. Roma´ (Valencia, Barcelona, Madrid, Santander, ES)
Objectives: To compare the resource utilisation and outcomes within
patients with candidaemia or invasive candidiasis (IC) admitted in ICU.
Methods:We used data from 5-large Spanish hospitals by retrospectively
clinical charts reviews. Patients were selected from January07 to April08
on the following criteria: primary or secondary diagnosis using ICD-9
codes for candidaemia or IC receiving any IV antifungal drug (AF),
age 18, and admitted in ICU. Patients were classiﬁed in two groups:
those who started with ﬂuconazole (FLC) and those who started with any
other licensed AF therapy (OLAT). FLC success was considered when
no second-line AF was needed. Final clinical evolution was registered.
Hospital length of stay-LOS (pre-ICU, ICU, Post-ICU) and resource use
(ventilation assistance, central catheter, second-line AF) was calculated
from the start of AF until discharge from ICU or death.
Results: A total of 43-patients met inclusion criteria, 36 of whom started
on IV FLC, and 7 on OLAT (4 caspofungin, 1 AmB-L, 1 AmB-LC,
1 voriconazole). Mean age (SD) was 61.8 (14.7) years in the FLC
arm vs. 46.9 (16.5) in the OLAT (p> 0.05); 63.9% men vs. 57.1%
(p< 0.05), respectively. Sixty-four percent of patients had an average
of one underlying disease in the FLC arm, while 57.1% in the OLAT
(p< 0.05), where the severity disease was “rapidly fatal” 58.3% vs.
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57.1% (p< 0.05), respectively. Apache score (SD) was superior in the
OLAT, 16 (10) vs. 13.7 (7.1) in FLC, p< 0.01. IC was mostly diagnosed
(66.7%) in FLC arm while candidaemia were diagnosed (57.1%) in
OLAT arm. C. albicans was isolated in the 52.8% of FLC arm, while
C. parapsilosis was isolated in 42.9% of OLAT. Mean (SD) ﬁrst-line
AF treatment duration was 17.3 (23.6) days in the FLC arm vs. 9.4
(11.6) days in OLAT arm (p< 0.01). Mean LOS and resources use was
superior in the FLC arm (p< 0.01). When considering FLC arm alone,
it was considered success in 58.3% of patients, while failed in 41.7%.
Final clinical evolution were failure (36.1%) and unclassiﬁed (36.1%) in
FLC vs. failure (57.1%) in OLAT (p< 0.01). Mortality rates were 52.8%
in FLC arm vs. 85.7% in OLAT arm (p< 0.01), mostly due to invasive
fungal infections+other reason.
Conclusions: Over all 37% of patients required second-line AF therapy.
Mortality rates due to the fungal infection were higher in the OLAT
arm thereby resource use was slightly lower versus the FLC arm. No
adjustment was made due to being an interim analysis but further analysis
will be required.
P1738 The effect of an antimycotic restriction programme
on mortality rate and incidence of candidaemia at a
cardiothoracic intensive care unit
C. Kratzer °, S. Tobudic, A. Lassnigg, W. Graninger, E. Presterl
(Vienna, AT)
Objective: In recent years echinocandines are likely to replace
ﬂuconazole as empiric antifungal therapy among intensive care patients.
However to reduce costs, an antimycotic restriction program was initiated
at our institution. To compare the effect of antifungal restriction on the
mortality rate and incidence of candidaemia, a prospective study was
performed at the cardiothoracic intensive care unit (ICU).
Methods: All patients admitted at the cardiothoracic ICU between
December 2006 and 2008 for at least 4 days were enrolled. Before
the 25th of October 2007 the choice of any antifungal treatment was
left to the discretion of the treating physicians at the cardiothoracic ICU.
Thereafter the use of systemic antifungal treatment except for ﬂuconazole
was restricted to the guidance by a specialist for infectious diseases. The
outcome of the ICU patients and the incidence of candidaemia were
analyzed.
Results: In the ﬁrst study period 23 (27.7%) and 4 (4.8%) out
of 83 patients died or developed candidaemia caused by Candida
albicans in 2 patients and Candida parapsilosis in 3 patients during
admittance at the ICU. Caspofungin was administered as predominant
antimycotic treatment in 42 patients for a total time of 642 days, whereas
ﬂuconazole was only given in 5 patients for a total time of 83 days.
After implementation of the antifungal restriction policy, the overall
use of empiric antimycotic treatment was signiﬁcantly reduced in the
ICU population (p = 0.004), and ﬂuconazole was administered as initial
antifungal treatment in the majority of patients (29 out of 107 patients
for a total time of 424 days), followed by caspofungin in 8 patients
for a total time of 130 days. In the second study period candidaemia
due to Candida albicans in 4 patients, Candida lusitaniae and Candida
parapsilosis in 1 patient was detected in 4.6% of the ICU patients and
the overall mortality rate was 20.4%. Antimycotic costs could be reduced
from 28.9 Euros per patient and day of ICU stay to 14.9 Euros per patient
and day after implementation of the antimycotic restriction program.
Conclusion: Similar mortality rates were found in the cardiothoracic
ICU population before and after restriction of systemic antifungal
treatment. Fluconazole was still effective as early antifungal empiric and
preemptive treatment in the ICU population because Candida albicans
was the predominant candidaemia species.
P1739 Decreasing candidaemia rate in abdominal surgery patients
after introduction of prophylactic and early presumptive
therapy with ﬂuconazole
B.J. Holzknecht °, J.D. Knudsen (Hvidovre, DK)
Objectives: Candidaemia in intensive abdominal surgery patients has
been of increasing interest recently and antimycotic prophylaxis is
now widely recommended for these patients. In 2007 ﬂuconazole
was added to the prophylactic and early presumptive antibiotic
treatment recommendations in our hospitals in Copenhagen for patients
with documented or suspected gastrointestinal tract perforation and
necrotising pancreatitis.
The aim of this study was to examine the effectiveness of this
intervention.
Methods: All positive blood culture results in our department of
clinical microbiology serving 6 hospitals are registered prospectively
and supplemented by clinical information. This is part of a collaborative
network between 3 departments of clinical microbiology and a semina-
tional database of bacteraemia. The rates and clinical characteristics of
candidaemias and bacteraemias in the abdominal surgical departments
and surgical intensive care units of the 2 major hospitals were compared
in the years 2006 and 2008.
Results: The overall incidence of candidaemia in the 2 abdominal
surgical departments and intensive care units decreased signiﬁcantly
from 17 cases of 203 bacteraemia cases in 2006 to 5 cases of 205
bacteraemias in 2008 (p = 0.01).
The amount and nature of surgical procedures performed and the number
of discharges did not differ considerably in these 2 years and no
other changes in routine protocols were considered to have affected the
outcome.
The most frequently isolated organism was Candida albicans (13 cases,
57%), followed by C. glabrata (7 cases, 30%), 2 isolates were C. krusei
(9%) and 1 C. tropicalis (4%). One case was a mixed infection with
C. glabrata and C. krusei. All of the 5 cases in 2008 (4 C. albicans and
1 C. tropicalis) were ﬂuconazole-susceptible.
The clinical picture was predominated, as expected, by 14 cases (64%)
having an intraabdominal focus. Four cases (18%) were intravenous
catheter infections and in the remaining 4 cases (18%) there were more
than 1 possible focus. Thirty-day mortality was 55% for all 22 cases
taken together.
Conclusion: The incidence of candidaemia decreased signiﬁcantly from
2006 to 2008 in abdominal surgery patients in 2 Copenhagen hospitals.
The addition of ﬂuconazole to the prophylactic and early presumptive
antibiotic regimen is the most likely reason for that change.
The study’s main limitations are the small case numbers and the
descriptive nature of the study design.
P1740 Liposomal amphotericin B in intensive care unit patients
previously treated with ﬂuconazole: a retrospective, efﬁcacy
and safety multi-centre study
F. A´lvarez-Lerma, G. Rialp, M. Nieto, C. Arago´n, T. Puente, I. Ausı´n °
for the Study Group on Liposomal Amphotericin B, Madrid, ES
Objective: Efﬁcacy and safety of Liposomal amphotericin B (L-AmB)
in intensive care unit (ICU) patients previously treated with ﬂuconazole.
Methods: Retrospective, multicentre study of patients admitted to ICUs
and treated with L-AMB as second line treatment after ﬂuconazole.
Invasive fungal infections (IFIs) were classiﬁed as proven, probable or
possible
Results: 41 patients were included, 60% were male and median age was
62 years. Mean length in ICU was 31.8 (SD:22.6) days and mortality rate
in ICU 59%. Mean APACHE II score was 20.7 (SD:7.8) and at admission
34% of the patients had severe sepsis or septic shock. Most common
pathologies were surgery (49%) and medical pathology (39%). Invasive
fungal infections were proven, probable and possible in 42%, 19% and
32%, of patients, respectively, and not classiﬁed in 7%. Most common
fungi identiﬁed (it was possible several species) were C. glabrata (56%)
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C. albicans (54%) C. parapsilosis (15%) and Aspergillus spp (12%).
Most common reasons for choosing L-AmB were: severe sepsis or
septic shock (61%) L-AmB spectrum including suspicion of ﬁlamentous
fungi (56%) guidelines application (42%) and infection localisation
(24%). Median Candida score was 4.0 and median Sevilla score was
11.0. Mean duration of L-AmB treatment was 15.2 days and mean
dose was 4.2mg/kg/day. Satisfactory clinical response (complete and
partial response) was achieved in 49% (95%CI:34, 64) of patients
and microbiological response (negative culture) in 44% (95% CI:29,
59) of patients in the intention to treat analysis. Within evaluable
patients, satisfactory clinical and microbiological responses were: 61%
(95%CI:44, 77) and 82% (95%CI:66, 98), respectively. Eight treatment-
related AEs were reported, but only 1 was serious: a case of renal failure
requiring a change in antifungal treatment. There was no change in the
overall mean creatinine value at the end of treatment in the patients
treated with L-AMB, despite the fact that 51% of the patients were
receiving nephrotoxic drugs concomitantly.
Conclusion: L-AmB as second line treatment after ﬂuconazole showed
high clinical and microbiological response in evaluable patients. L-AmB
was well tolerated even in patients with concomitant nephrotoxic drugs.
L-AmB was mainly selected for patients with severe sepsis or septic
shock and also due to its broad spectrum activity. L-AmB can be
considered an effective and safe option both in empiric and conﬁrmed
IFIs in critically ill patients after ﬂuconazole treatment.
P1741 Continuous infusion of amphotericin B deoxycholate in the
treatment of cryptococcal meningoencephalitis: analysis of
safety and fungicidal activity
D.R. Falci °, L. Lunardi, C.G. Ramos, V.R. Aquino, L.Z. Goldani (Porto
Alegre, BR)
Objective: Cryptococcosis is a deep mycosis commonly seen in
immunocompromised hosts. The mainstay of treatment remains am-
photericin B deoxycholate, which is associated with nephrotoxicity and
other adverse events. New lipid formulations provide a good solution
to toxicity concerns. Reduction in nephrotoxicity and side effects can
be explained by slower drug distribution in tissues. However, costs of
these formulations are prohibitive. In this scenario, continuous infusion
of amphotericin B deoxycholate for the treatment of serious fungal
infections like cryptococcosis could reveal a promising strategy. Our
objective in this study is to evaluate safety, clinical and microbiological
efﬁcacy of continuous infusion of amphotericin B deoxycholate in
treatment of cryptococcal meningoencephalitis.
Methods: Non-comparative clinical trial, including patients with
disseminated cryptococcosis. All patients received continuous infusion
of amphotericin B deoxycholate (0.7mg/kg daily) and oral ﬂucytosine
(25mg/kg four times a day), during induction phase of 14 days.
We measured fungicidal activity using serial quantitative cultures of
cerebrospinal ﬂuid (CSF) obtained from lumbar punctures in days 0,
3, 7 and 14 of treatment. We monitored patients in hospital for 2 weeks.
At this time of study, 6 patients have been included.
Results: Analysis of data on 6 patients has shown that all patients
presented a progressive reduction in CSF cryptococcal colony-forming
units (CFU), and LCR was sterile at 2 weeks of treatment. An
exponential reduction of CFU counts was observed (ﬁgure 1). Although
two patients developed severe hypokalaemia, glomerular renal function
was well preserved in all patients with creatinine serum levels below
1.5mg/dl at end of 14 days of antifungal therapy. We observed the
occurrence of anaemia (decrease of haemoglobin at least of 3 g/dL) in 3
patients.
Conclusions: The preliminary data presented here are indicating that
continuous infusion of amphotericin B seems to be safe and well
tolerated, despite the development of anaemia and hypokalaemia in some
patients. Mycological efﬁcacy was comparable as standard of treatment,
with adequate reduction rate of CFU and sterilisation of CSF. These
results could suggest that continuous infusion reduces nephrotoxicity
while keeping fungicidal activity. Larger and comparative trials, against
new lipid formulations and even novel antifungal agents, are necessary
to further evaluate this treatment regimen.
Figure 1. Reduction in CFU (log).
P1742 Efﬁcacy and safety of liposomal amphotericin B in intensive
care unit patients with conﬁrmed invasive fungal infection:
a retrospective, multi-centre study
F. Alvarez-Lerma, J. Dı´az, F. Mariscal, M. Nieto, I. Ausı´n ° on behalf
of the Study Group for Liposomal Amphotericin B
Objective: Invasive fungal infections (IFI) are a frequent life-threatening
complication in high risk patients hospitalised in ICUs. The objective
of this study was to analyse the efﬁcacy and safety of liposomal
amphotericin B (L-AmB) administered to ICU patients with conﬁrmed
IFI.
Methods: Retrospective, multicentre and observational study of patients
admitted to ICUs with conﬁrmed fungal infection and treated with
L-AMB.
Results: Seventy-eight patients were included, 57.1% were male and
median age was 56 years. Mean time in ICU was 46.4 (SD: 50.4) days
and mortality rate in ICU was 42.7%. Mean APACHE II score was 21.3
(SD: 8.0) and severe sepsis or septic shock was 65.4%. Most common
pathologies were medical (4.3%) and surgery pathology (42.3%).
Most common proven IFIs were Candida albicans (56.4%), Candida
glabrata (14.1%), Candida parapsilosis (11.5%) and Aspergillus spp
(7.7%). Mean duration of treatment was 16.5 days and mean dose
was 3.7mg/kg/day. Previous antifungal treatment was administered to
56.4% of patients, mainly ﬂuconazole (29.5%) and Caspofungin (21.8%).
Most common reasons L-AmB was initiated were: non-stable disease
(48.7%), infection localisation (38.5%) and L-AmB spectrum (34.6%).
Satisfactory clinical response (Complete and partial response) was
achieved in 68% (95%CI: 57.6, 78.3) of the patients and microbiological
response (negative culture) in 61.5% (95%CI: 50.7, 72.3) of the patients.
Within evaluable patients these results were: 72.6% (95%CI: 62.4, 82.8)
and 76.2 (95%CI: 65.7, 86.7). 34 related AEs were reported, but only
2 were reported as serious: a case of hypokalaemia and a case of renal
failure requiring a change in the antifungal treatment. There was no
change in the global mean creatinine value at the end of treatment in the
patients treated with L-AMB, despite the fact that 52.6% were receiving
nephrotoxic drugs concomitantly.
Conclusion: L-AmB was used in critically ill patients (haemody-
namically unstable) with conﬁrmed IFI, including a high proportion
who had received previous therapy for IFI. Satisfactory clinical and
microbiological response in evaluable patients was high. L-AmB was
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well tolerated with little alteration of renal function even in patients
taking concomitant nephrotoxic drugs. L-Amb can be considered an
effective and safe option in conﬁrmed IFIs in critically patients.
P1743 Micafungin versus liposomal amphotericin B for the
treatment of serious Candida infections in intensive care
unit and non-ICU patients: results of post-hoc analyses
B. Dupont °, O. Lortholary, L. Ostrosky-Zeichner, F. Stucker, V. Yeldandi
(Paris, FR; Houston, US; Leiderdorp, NL; Melrose Park, US)
Objective: Assess efﬁcacy and safety of micafungin (MICA) versus
liposomal amphotericin B (L-AmB) for the treatment of invasive
candidiasis (IC) or candidaemia in ICU and non-ICU patients and
identify factors associated with outcomes.
Method: Post-hoc analyses of data from a phase 3 non-inferiority trial of
MICA (100mg/day for patients >40 kg; 2mg/kg/day for patients40 kg)
vs L-AmB (3mg/kg/day). Subgroups were deﬁned according to the type
of ward on the ﬁrst day of treatment: ICU or non-ICU. Multivariate
regression analyses were performed to identify factors associated with
treatment success at end of therapy and all-cause mortality at days 8 and
30 post-treatment initiation.
Results: In non-ICU patients, treatment success was signiﬁcantly higher
for MICA vs L-AmB (85% [n = 108/127] vs 72.1% [n = 98/136];
P = 0.0113). However, for ICU patients, treatment success rates for MICA
vs L-AmB were similar (62.5% [n = 75/120] vs 66.4% [n = 73/110];
not signiﬁcant). Overall, treatment success was signiﬁcantly lower in
ICU patients compared with non-ICU patients (64.3% [n = 148/230] vs
78.3% [n = 206/263]; P = 0.0006). Furthermore, multivariate regression
analysis revealed a lower likelihood of treatment success for: ICU vs
non-ICU patients; patients with persistent neutropenia during therapy;
and patients with high versus low APACHE II scores. However, when
interactions between potential explanatory factors were included in the
analysis model, ICU status no longer emerged as a signiﬁcant associated
variable but the association between APACHE II score and treatment
outcome remained. Further analyses indicated that the likelihood of
mortality at day 8 and day 30 was lower for patients with lower APACHE
II scores. Renal function was signiﬁcantly better in MICA versus L-AmB
patients: a difference (L-AmB-MICA) in mean peak change in estimated
glomerular ﬁltration rate (mL per min per 1.73m2) of −18.2 (P< 0.0001)
and −17.7 (P = 0.0124) in non-ICU and ICU patients, respectively.
Conclusion: Overall, ICU patients had lower treatment success rates
than non-ICU patients for both L-AmB and MICA. When controlling
for confounding factors, multivariate analysis revealed that APACHE
II score remained the only potential explanatory factor associated with
treatment success, mortality at day 8, and mortality at day 30. Further
characterisation of this ﬁnding and its implications is required.
P1744 High rate of breakthrough invasive aspergillosis among
patients with persistent fever and neutropenia receiving
empirical caspofungin therapy
M. Lafaurie °, J. Lapalu, S. Touratier, P. Ribaud, E. Raffoux,
C. Lacroix, B. Brethon, G. Thierry, J.M. Molina (Paris, FR)
Objectives: A number of agents are now available for empirical
antifungal treatment (EAFT) of patients with persistent fever and
neutropenia. We wished to study the antifungal drugs used in our
institution and their efﬁcacy to prevent breakthrough invasive fungal
infections.
Methods: A prospective study was carried out from November 2005
to February 2006 by reviewing the medical records of all consecutive
patients admitted in haematology, oncology, intensive care and infectious
diseases wards who received EAFT. Baselines patients characteristics at
the time of EAFT initiation were recorded as well as the type, dose and
duration of the antifungal agents used. Breakthrough invasive fungal
infections were documented according to the EORTC/MSG deﬁnition.
Patients were followed until they were discharged from the hospital or
died.
Results: Sixty-three episodes of persistent fever with neutropenia
requiring EAFT were recorded among 56 patients. All patients
received high dose chemotherapy for either acute myeloid leukaemia
(52%), acute lymphoid leukaemia (14%), lymphoma (13%) or other
haematologic conditions (21%). Fifteen (27%) and 5 (9%) patients
were allogeneic and autogenic haematopoietic stem cell transplant
recipients, respectively. Caspofungin was prescribed initially for 40
episodes (63.5%), amphotericin B (AmB) deoxycholate and liposomal
AmB for 12 (19%) and 11 (17.5%) episodes, respectively. Six patients
were switched from liposomal AmB to caspofungin because of adverse
events. Median duration of therapy was 9 days (1−42) for caspofungin,
9 days (1−31) for AmB and 4.5 days (1−22) for liposomal AmB. During
follow-up, 7 patients (11.1%) were diagnosed with invasive aspergillosis
(IA), after a median of 7 days (3−19) of EAFT. IA were probable in
4 cases and possible in 3. IA occurred in 6/46 (13%) of caspofungin
recipients and in 1/23 (4.3%) of AmB (dexoxycholate and liposomal)
recipients (OR: 3.3).
Conclusion: We documented in our study a high rate of breakthrough
invasive aspergillosis among high risk patients receiving preferentially
caspofungin for EAFT. The association between the use of caspofungin
and the risk of invasive aspergillosis requires further evaluation.
P1745 Cost-effectiveness of anidulafungin in conﬁrmed
candidaemia and other invasive Candida infections in Spain
S. Grau, M. Garcı´a-Vargas, B. Martı´ °, N. Mir (Barcelona, Alcobendas,
Madrid, ES)
Background: Candidaemia and other invasive Candida infections are
economically costly and can cause patient death. Anidulafungin, a newly
licensed candin, has shown to be effective in treating candidaemia. The
aim of the study is to evaluate the cost-effectiveness of anidulafungin
compared with current standard of care, ﬂuconazole, for the treatment
of invasive candidiasis and candidaemia in Spain.
Methods: A decision tree model from the hospital perspective was
constructed to examine the cost-effectiveness of anidulafungin compared
with ﬂuconazole in the treatment of conﬁrmed candidaemia. Treatment
success, patient treatment patterns, and patient survival were based on
the results from a randomised, double-blind multicentre trial (Reboli AC,
et al. N Engl J Med. 2007). Only in-hospital (€2007) direct costs per-
patient were considered. Costs were obtained from a Spanish national
database. Renal toxicity probabilities and costs were extracted from the
published literature. The incremental cost per successfully treated patient
was calculated. One-way sensitivity analyses were performed to test the
robustness of the model.
Results: The percentage of successfully treated patients at the end of all
therapy was higher for patients treated with anidulafungin than with
ﬂuconazole (74% vs. 57%). Treating with anidulafungin resulted in
a higher antifungal drug costs (5,780€ vs. 2,082€); however, overall
costs are lower for treatment with anidulafungin than for treatment with
ﬂuconazole (37,240€ vs. 37,327€) due to an offset in other medical costs.
Univariate sensitivity analyses showed that anidulafungin remained the
most cost-effective option.
Conclusions: Anidulafungin has demonstrated to improve the clinical
efﬁcacy versus standard of care in treating conﬁrmed candidaemia.
Despite an increase in drug costs, treating conﬁrmed candidaemia with
anidulafungin is a cost-effective strategy.
P1746 Economic evaluation of anidulafungin (Eraxis®) versus
intravenous ﬂuconazole in the treatment of hospital
inpatients diagnosed with candidaemia and other forms of
invasive candidiasis
A. Reboli, C. Rotstein, D. Kett, A. Shorr, R. Chambers, M. Hux,
M. Maschio, M. Tarallo ° (Camden, US; Toronto, Burlington, CA;
Miami, Washington, New York, US)
Objective: In clinical trial anidulafungin (ANI) achieved higher global
response rates at the end of therapy (EOT) and 2 weeks after EOT
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compared with intravenous ﬂuconazole (FLU) in the treatment of
candidaemia/invasive candidiasis (C/IC; P = 0.01). We assessed the
economic impact of this therapy in hospital inpatients with C/IC.
Methods: Clinical and resource use data for 234 hospital inpatients with
C/IC who received 1 dose of study drug from North American sites
participating in a Phase 3, randomised clinical trial comparing ANI with
FLU were retrospectively analyzed through chart review methodology.
Charts were available for 159 patients. To estimate missing intensive
ward (ICU) length of stay data for the remaining 75 patients, two
approaches were evaluated: a blinded adjudication process conducted by
4 clinicians; and a regression imputation method. Treatment efﬁcacy and
C/IC-related cost to a US hospital payer were evaluated over a 13-week
period from the initiation of treatment. One-way sensitivity analyses were
conducted to assess the robustness of the results.
Results: Patients treated with ANI achieved a higher global response
rate by EOT (ANI 72.7% vs. FLU, 57.5%; P = 0.02). Over a 13-week
period total hospital days and ICU days were similar for ANI and FLU
(total: 28.6 vs. 26.0, P = 0.20; ICU-adjudication: 7.8 vs. 9.1, P = 0.77;
and ICU-regression 9.8 vs.10.7, P = 0.72). Compared to FLU, patients
treated with ANI appeared to spend more days alive out of the hospital
(47.2 vs. 43.6, P =0.65), when assessed at 13 weeks. After adjusting
for baseline APACHE II and catheter status, total costs were similar in
the two treatment groups (total cost-adjudication: $44,781 vs. $42,558,
P = 0.70; total cost-regression: $47,658 vs. $44,977, P = 0.66).
Conclusions: In hospital inpatients with C/IC, treatment with ANI
was associated with superior clinical response with no increase in cost
compared to treatment with IV FLU.
P1747 Antifungal therapy with voriconazole improves outcome in
patients with invasive pulmonary aspergillosis and chronic
obstructive pulmonary disease
J. Guinea °, M. Torres-Narbona, P. Gijo´n, J. de Miguel, P. Mun˜oz,
T. Pela´ez, E. Bouza (Madrid, ES)
Objectives: Invasive pulmonary aspergillosis (IPA) in patients with
chronic obstructive pulmonary disease (COPD) is an emerging fungal
infection with a high mortality rate, despite antifungal therapy. However,
ﬁrst-line antifungal therapy for IPA in this population has not been
properly established. We determined risk factors that predict poor
outcome in patients with COPD and IPA, with emphasis on the role
of antifungal therapy.
Methods: From November 1999 to March 2008, we evaluated 57 cases
of probable IPA in patients with COPD. We reviewed their charts for
clinical features, bacterial co-infections, analytical data, previous use of
corticosteroids/antibacterial agents before the isolation of Aspergillus,
antifungal treatment, and outcome.
Results: The 57 patients with IPA showed an overall mortality of
71.9%. We detected 4 independent variables able to predict poor
outcome (P< 0.05) (OR, 95%CI): “chronic heart failure” (38.5; 2.7–
500), “broad-spectrum antibiotic use within the 3 months previous to
admission” (16.4; 1.63–166.7), “COPD exacerbation when Aspergillus
was isolated” (50, 2.7−1,000), and “antifungal therapy with a drug other
than voriconazole” (46.5, 3.2–668.1). A total of 27 (47.3%) patients
received voriconazole (alone [n = 13] or in combination [n = 14]), and
30 (52.7%) patients received other antifungal drugs. Both groups were
comparable, but survival was higher in patients treated with voriconazole
(n = 13) than in patients receiving other antifungals (n = 3) (48% vs. 10%;
P = 0.002). There were no differences between the number of days from
the isolation of Aspergillus to initiation of antifungal treatment in patients
with poor and good outcome (4.06 vs 3.56; P = 0.634).
Conclusions: Patients with COPD and IPA had a high mortality rate,
above 70%, particularly in patients with a worse clinical condition.
Although our series included a limited number of cases, antifungal
therapy with voriconazole in patients with COPD and IPA had a better
outcome. J. Guinea is contracted by FIS CM05/00171; M. Torres-
Narbona is contracted by FIS CM08/00277.
P1748 Voriconazole-impregnated beads in the treatment of
candidal prosthetic joint infection
D. Harvey °, J. Tomlinson, A. Cooper, S. Buckley, R. Townsend,
R. Kerry, D. Oliver (Shefﬁeld, Bristol, UK)
Objective: Below we report on the use of voriconazole-loaded bone
cement and its elution data in salvage therapy in 2 cases of candidal
prosthetic hip infection.
Methods: Candida tropicalis and C. albicans respectively were cultured
after aseptic aspiration under radiological guidance of two patients
with infected hip prostheses. As part of a 2-stage revision procedure,
voriconazole beads were inserted at the time of the ﬁrst stage. 1 gram
of voriconazole powder was mixed with the bone cement to make the
beads. Deep drains were left in situ for 48 hours. The drain volume and
voriconazole concentration as well as serum voriconazole concentration
were recorded at intervals for 48 hrs. The use of prolonged intravenous
antifungal therapy was avoided.
Results: The table shows high local voriconazole concentrations in the
drain and thus by inference at the operative site, which reduce over 48 hrs
but still remain relatively high. Furthermore there was no detectable
serum voriconazole in the ﬁrst patient and minimal levels in the second
patient.
Conclusions: Fungal prosthetic joint infections, whilst rare, provide
a difﬁcult treatment challenge. Excision arthroplasty and prolonged
intravenous antifungal agents appear to be the mainstay of therapy.
Previously our unit has reported the successful use of ﬂuconazole
impregnated cement beads to eradicate C. albicans and C. parapsilosis
joint infection. Fluconazole is no longer available in powdered form
thus this option is not available. Voriconazole is available in powdered
form and is thermostable which makes it suitable for incorporation in
polymethylmethacrylate beads. Using this method the data presented
show very high local concentrations of voriconazole are achieved which
would be expected to sterilise the operative site, whilst avoiding any
potential systemic side effects of voriconazole.
Long-term follow-up data is awaited. In conclusion we present a
potential therapeutic option for the treatment of candidal prosthetic joint
infections.
Location Voriconazole concentration (mg/L)
Time since operation (hrs) 6 12 18 24 30 36 42 48
Patient 1
Serum 0 0 0 0
Drain 306 251 179 169 92 46 43 51
Patient 2
Serum 0.6 0.6 0.7 0.4
Drain n/a 187 179 110 81 70 85 49
P1749 Voriconazole plasma levels monitoring in haemato-
oncological patients
M. Tosˇkova´ °, J. Winterova´, Z. Ra´cil, L. Mala´skova´, I. Kocmanova´,
M. Lengerova´, B. Weinbergerova´, J. Mayer, K. Hrncı´rova´ (Brno, CZ)
Objectives: Voriconazole plasma levels measurement enables to
optimise dosing and improves the efﬁcacy of antifungal treatment.
Methods: Retrospective analysis of documentation and laboratory results
of patients treated with voriconazole from August 2005 to November
2008 was performed. Steady-state plasma voriconazole levels were
obtained using a high-performance liquid chromatography assay.
Results: 618 plasma samples from 112 patients were analyzed; 1−29
samples per patient. 45.5% (n = 51) patients were after allogeneic
haematopoietic stem cell transplantation. Voriconazole was administered
in 43% as prophylaxis, in 11% as an empirical antifungal treatment and
in 46% as a preemptive treatment of invasive fungal infection. In 105
patients (93.7%) voriconazole was administrated orally, only in 7 cases
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intravenously. The total daily dose of voriconazole varied from 200 to
800mg. The mean trough voriconazole plasma concentration after the
standard daily dose 400mg orally was 1.46mg/ml (0.2–8.98mg/ml). In
10.8% (47) of plasma samples from 27 (18.9%) patients the voriconazole
plasma concentration was undetectable (<0.2mg/ml). In 43.5% (n = 189)
of samples from 70 (63%) patients after this standard dose (400mg/day)
the plasma concentration was under 1mg/ml − below the level associated
with a better response to therapy and better prognosis of invasive
aspergillosis. The increase in daily voriconazole dose from 400 to 600mg
in 16 patients led to elevation of voriconazole trough plasma level above
1.0mg/ml in 4 cases and above 0.5mg/ml in 5 cases. In 7 patients the
concentration did not changed or decreased.
Conclusion: Our results demonstrate that high percentage of patients
did not achieved sufﬁcient voriconazole plasma concentration after the
standard daily dose of voriconazole. Monitoring of plasma levels enables
an individual dosage adjustment and lead to improving response to
antifungal treatment in patients in high risk of invasive fungal infection.
Daily doses of voriconazole 200mg 400mg 600mg 800mg
Number of samples 64 434 81 16
Number of patiens 18 111 20 2
Plasma concentration, mg/ml 0.75 1.46 1.44 2.24
Plasma concentration <0.2mg/ml 8 (12.5%) 47 (10.8%) 6 (7.4%) 2 (12.5%)
Plasma concentration <1.0mg/ml 51 (79.6%) 189 (43.5%) 41 (50.6%) 5 (31.3%)
P1750 Therapeutic drug monitoring of posaconazole in 54 adult
patients
D. Lebeaux °, F. Lanternier, C. Elie, F. Suarez, A. Buzyn, J.P. Viard,
M. Lecuit, V. Jullien, O. Lortholary (Paris, FR)
Objective: To assess the prevalence of low posaconazole (PSZ) plasma
levels (PPL) in case of prophylactic or curative treatment, and host
factors associated with low PPL.
Methods: We retrospectively reviewed all adult patients who underwent
measurement of PPL after at least 5 days of treatment between 2006 and
2008 at Necker-Enfants malades university hospital. Therapeutic drug
monitoring (TDM) was performed by high-performance chromatography
and ultra-violet detection. Clinical and biological data were obtained at
the initiation of PSZ. Low PPL was deﬁned as a concentration lower
than 500 ng/ml (Andes et al., AAC January 2009).
Results: 54 patients were included: 36 receiving prophylactic (200mg
t.i.d.) [allogenic bone marrow transplantation (75%), haematological
malignancy with prolonged neutropenia (19%) or constitutive immun-
odeﬁciency (6%)] and 18 curative posaconazole therapy (400mg b.i.d.).
Prevalence of low PPL was 16/36 (44%) in the prophylactic group and
22% (4/18) in the curative treatment group.
In the prophylactic group, low PPL tended to be more frequent in case
of digestive disease (62% versus 30%, p = 0.051) and was signiﬁcantly
more frequent in patients with diarrhoea (71% versus 24%, p = 0.009)
or mucositis (100% versus 33%, p = 0.004).
In the prophylactic group, only 2 patients experienced IFI and both
exhibited a low PPL. The only adverse event was hepatotoxicity in 2/54
patients (3.7%).
Conclusions: Low PPL is common, signiﬁcantly more frequent in
case of diarrhoea or mucositis and potentially associated with the
subsequent occurrence of IFI. PSZ TDM is therefore mandatory in
immunosuppressed adults.
P1751 Posaconazole therapeutic drug monitoring in cystic ﬁbrosis
lung transplant patients
M. Berge, R. Guillemain, S. Lefeuvre, C. Amrein, V. Boussaud,
P. Chevalier, E. Dannaoui, E.M. Billaud ° (Paris, FR)
Invasive aspergillosis represents a major complication in lung transplan-
tation (LTx) particularly in case of cystic ﬁbrosis (CF). Posaconazole
(PSZ) is indicated for the curative and prophylactic treatment of invasive
fungal infections using respectively 400mgx2/day and 200mgx3/day
doses. PSZ absorption is saturable, therefore dose increase often needed
in CF patients is limited. PSZ half life is long (35 h), resulting in long
time to steady state (SS).
Objective: To show that PSZ therapeutic drug monitoring (TDM)
in CFLTx allows 1. the achievement of trough concentrations (C0)
levels consistent with efﬁciency (>0.5mg/L) or at least detectable
(>0.2mg/L); 2. the management of PSZ metabolic drug interactions
with immunosuppressants.
Methods: Retrospective and prospective cohort of CFLTx under PSZ
between 2006 and 2008 in our centre. Longitudinal collection of both
doses and C0 (at SS) data for PSZ and immunosuppressants. TDM by
determination of plasma PSZ by LC assay with ﬂuorimetric detection.
Results: 17 CFLTx, aged 26±8 years, received curative (n = 2),
preemptive (n = 14) or prophylactic (n = 1) PSZ treatment. Caspofungin
was combined to PSZ in 8 patients. The mean treatment duration was
228±197 days, [14–621]. PSZ introduction corresponded to immediate
(n = 4), ﬁrst year (n = 5) or beyond (n = 8) post Tx. 220 PSZ C0 were
analyzed. No post Tx time effect on PSZ exposure was observed. The
mean PSZ C0 was 0.7±0.5mg/L, [0.2;1.6] using an average PSZ dose
of 1084±310mg/day, [733;1889], resulting in more than +35% of the
recommended dose (p< 0001). In 65% of patients, a dose adjustment
was required on day 11 as an average. Such adjustment has been
successful in 86% of cases. PSZ was withdrawn (n = 8) because of 7
negative cultures and 1 intravenous route (voriconazole + caspofungin).
No particular adverse event (gastrointestinal disorders, headache) has
been recorded during PSZ courses. The immunosuppressant tacrolimus
dose was tapered by a factor 3 during the coprescription with PSZ.
Conclusion: PSZ TDM was useful to achieve PSZ therapeutic C0
in CFLTx. Despite increase and/or split dose, no C0> 3mg/L has
been observed. PSZ safety proﬁle was good. Indeed, PSZ acted as a
moderate CYP3A4 metabolic inhibitor, justifying a joint TDM of both
PSZ and immunosuppressants to manage the immunosuppressants dose
adjustment at the introduction or discontinuation of PSZ.
P1752 Salvage therapy with posaconazole and topical
amphotericin B: an unusual case of Aspergillus fumigatus
empyema and bronchopleural ﬁstulae after extrapleural
pneumonectomy and chemo-radiotherapy
A. Guleri, M. Purohit, J. Zacharias, J. Paterson ° (Blackpool, UK)
Background: Malignant mesothelioma, an aggressive malignancy, has a
median survival of 14-months after onset of symptoms. A combination
of chemo-radiotherapy and extrapleural pneumonectomy [CREPP],
recommended treatment, is still associated with 4−15% mortality and
a 62% complication rate.
Having found no similar report in literature, we believe this is ﬁrst case
of aspergillus fumigatus [AF] empyema and bronchopleural ﬁstulae after
CREPP, and treated successfully with systemic and topical antifungal
therapy and went on to have his deﬁnitive surgical procedure.
Case study: A 63-yr-male was hospitalised with chest symptoms
2-weeks post chemoradiotherpy following right extra-pleural pneu-
monectomy for malignant epitheloid mesothelioma in November 2006.
CT scan and bronchoscopy revealed bronchopleural ﬁstula in rt
pleural cavity. He underwent rib-resection to permit drainage of
empyema. He was treated with multiple broad spectrum antibiotics
matching positive bacterial cultures. Multiple cultures of AF and a
visible growth of gray-cottony growth lining mesh [dome diaphragm];
prosthetic patch/pericardium and chest cavity. Voriconazole followed
by caspofungin failed to clear fungus [ﬁgure 1]. His further surgical
management was held up in presence of fungus. A salvage therapy, after
exhausting all options and with patient consent − a paste-mixture of
Spongostan [a topical haemostat in surgery] and amphotericin B applied
to the whole of right pleural cavity;prosthetic sheaths replacing the
pericardium and diaphragm, under general anaesthesia and rib resection
refashioned. Oral posaconazole was given for 6-weeks. Following
multiple negative cultures, the patient went on to have planned surgery
and closure of his chest defect.
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He made good recovery from this complication but subsequently
succumbed to mesothelioma after 8-months.
Discussion: This case of AF empyema and bronchopleural ﬁstulae
following CREPP was complicated by local fungal colonisation/
infection. This fungal presence held up his further surgical management.
Systemic antifungals failed to clear the relatively avascular ﬁbrosed
chest cavity with extensive prosthetic material. Spongostan® mixed with
amphotericin B to allow sustained exposure at this complex anatomic
site and posaconazole as systemic therapy. Intra-pleural irrigation with
amphotericin B in Aspergillus Empyema is reported but would have not
provided sustained local exposure in this unusual case. Video/picture to
be presented.
Figure 1.
Infections in the immunocompromised host
P1753 Febrile neutropenia in patients with haematological
malignancies
A. Pouli, D. Sotiropoulos, A. Manaka, L.G. Petrikkos, A. Syrigou,
M. Kotsopoulou, M. Pagoni, A. Rekleiti, A. Sioni, A. Symeonidis,
E. Katodritou, L. Hatzihannas, N. Neokleous °, X. Mitsouli,
E. Nikiforakis, A. Anagnostopoulos, G.L. Daikos, G. Petrikkos (Athens,
Thessaloniki, Patra, GR)
Aim: The aim of this study was to evaluate the incidence of infection in
neutropenic patients with haematological malignancies in a prospective
study in 7 haematological centres.
Patients/methods: We enrolled neutropenic patients (neutrophil count,
ANC 500/mm3) due to chemotherapy. We recorded: fever >38ºC,
disease, chemotherapy, duration of neutropenia, growth factor (G-CSF),
chemoprophylaxis, antibiotics, conditions of hospitalisation, Central
Venus Catheter (CVC), isolated bacteria and resistance to antibiotics.
Results: We studied 892 cases of neutropenia in 581 patients. In
305 cases there was a CVC. G-CSF was administered in 725 cases.
Chemoprophylaxis was administered in 510 cases. The median duration
of neutropenia was 14 days. In 672 cases, one or more fever waves
have been observed. 51 patients died due to the infection (8.8%). The
existence of CVC was signiﬁcant for the incidence of fever (85% vs
70% p< 0.01) while the administration of G-CSF was not (74% vs
79%, p=ns). The nadir of the ANC was statistical signiﬁcant (84.4%
for ANC 100/mm3 vs 53.5% for ANC> 100/mm3, p< 0.01). Bacteria
were isolated in 559 of the febrile cases (62%). The ratio of Gram(+)
bacteraemia to Gram(−) was 10 to 6. 30% of Enterococci were resistant
to glycopeptides. The percentage of resistance of Pseudomonas sp. in
carbapenems was also high (50%). Resistance of Enterobacteriacae to
carbapemens is alarmingly increasing (8−12%).
Conclusions: Febrile neutropenia is the major complication in neu-
tropenic patients with haematological malignancies. Our data showed
a statistical signiﬁcant difference for patients with CVC and with
ANC 100/mm3. There was no statistical signiﬁcant difference for
patients receiving G-CSF, chemoprophylaxis and there was no correlation
to the duration of neutropenia and to HEPA ﬁlter rooms. The mortality
due to infection was low.
P1754 Updated epidemiology of severe infections as a cause
of admission in an intensive care unit in patients with
haematological malignances. Preliminary report of a
Spanish multicentre study
R. Zaragoza °, M. Borges, J. Bonastre, R. Granada, G. Mun˜iz,
P. Ugarte, F. Mariscal, P. Marcos, Y. Diaz, E. Quintana, S. Sancho
on behalf of Spanish GTEI-SEMICYUC-EMEHU Investigators Group
Background: The aim of this study were to asses the principal
“microbiological” features and clinical presentation of the patients with
a haematological malignance (HMP) admitted in an ICU due to a severe
infection and specially to analyse the main aetiologies of these infections
in order to avoid an excessive rate of inadequate empirical antibiotic
treatment in these patients
Methods: This prospective observational multicentre study was con-
ducted at 30 sites in Spain from June 2006 through October 2008. Any
patient with haematological admitted in ICU was potentially eligible.
Clinical and microbiological features were recorded. A preliminary
descriptive analysis was performed.
Results: Among 237 HMP admitted in an ICU, 154 of them (64.9%)
presented a severe infection as a cause of admission. Relation
men:women was 1.2.The age of patients was 54.17±16.65 years.
APACHE II score was 23.8±8.3. Septic shock was the most frequent
clinical presentation (58.5%). The principal origins of infections
were: respiratory (59.7%), abdominal (14%) and unknown (16.6%)
The majority of episodes were nosocomial acquired (63%). The
most frequent severe infections involved were; Nosocomial pneumonia
(28.6%), community acquired pneumonia (26.4%) primary bacteraemia
(10%) and peritonitis (5.7%). Associated bacteraemia was present in
49.3% of infected HMP.The most frequently microorganism isolated
were: Escherichia coli (17.9%), Streptococcus pneumoniae (10.3%),
Acinetobacter baumannii (6.6%), Klebsiella peumoniae (6.6%) and
Staphylococcus aureus (5.6%). The incidence of fungal infections was
also high; Candida spp. was isolated in 2.8% of the infected HMP
and proven or probable invasive Aspergillosis was considered in 5.1%
of infected HMP. Pseudomonas aeruginosa (13.2%) and Acinetobacter
baumannii (6.6%) were the most frequent microorganisms isolated in
respiratory samples.
Conclusions: Severe infection is the main cause of admissio´n in ICU
of HMP. The most common clinical presentation still is septic shock
secondary to pulmonary foci. Nowadays potential multidrug resistant
microorganism such as Pseudomonas aeruginosa, Acinetobacter bau-
mannii, Klebsiella peumoniae and Staphylococcus aureus as well as
invasive fungal infections should be keep in mind in order to avoid
inadequate empirical antibiotic therapy in HMP admitted in ICU due to
a severe infection.
P1755 Differences in development of catheter-related infections in
critically ill patients
E. Chinou °, E. Dalla, Z. Chiolou, A. Georgouli, P. Giannakakos,
E. Skouteli (Athens, GR)
Objectives: To study and compare some characteristics of infections
associated with central venous catheters in patients hospitalised in
Intensive Care Unit (ICU) and Oncology Units (OUs) of our hospital.
Methods: During one year period (2008) we studied 118 patients from
a seven bed ICU(60 patients) and two oncology units (58 patients) for
catheter related infections. The catheter tips were cultured using the
semi-quantitative Maki’s method and the quantitative Cleri’s method.
Blood culture samples were taken from a peripheral vein at the time
of removing the catheter and incubated using the BacT-Alert automated
system for 7 days.
Results: We cultured 150 central iv catheters, used for parenteral
nutrition and drug administration. The preferred vein in ICU and OUs
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was v. subclavia in 40/82–58/68 and v. femoralis in 42/82–10/68 cases
respectively. The main duration of catheterisation was 8 days in ICU
and 19 days in OUs. The most common microorganisms in ICU from
61/82 positive catheter tips were Gram negative rods: A. baumannii
(21/61), K. pneumoniae (7/61), P. aeruginosa (7/61), E. cloacae (3/61),
and E. coli (2/61) followed by Coagulase-negative staphylococci (18/61)
and Candida sp (3/61). From 68 catheter tips sent from OUs, 25 had
positive culture and in most of cases were isolated CNS (18/25) followed
by P. aeruginosa (4/25) and Candida sp (3/25). As catheter related
bacteraemias were considered in 25 cases, 20 in ICU and 5 in OUs,
the causative microorganisms in ICU were Gram negative rods (15/25)
while in oncology units were CNS (4/5).
Conclusion: The frequency of CRB in ICU (24.4%) is signiﬁcantly
higher than in oncology patients (7.3%). They developed earlier and were
caused by Gram negative rods. Because the probable way to development
of CRB is the skin of patients, the preventive measures should be focused
on better aseptic techniques and training of the medical staff.
P1756 Sepsis in the elderly: different?
J. Nikhilesh °, S. Ratan (Indore, IN)
Objective: To analyze outcomes in patients with sepsis in geriatric vis-
a`-vis non geriatric cohorts admitted in critical care unit(CCU) and the
epidemiological proﬁle for organisms leading to same
Methods: Patients presenting with sepsis were enrolled and divided into
a control group (<65 years) and test group (>65 years). Data collection
was done with a focus on demographics, SOFA scores, requirement of
mechanical ventilation (MV), requirement of renal replacement therapy
(RRT), co-morbidities (Diabetes mellitus [DM], Hypertension [HTN],
coronary artery disease [CAD]) and length of stay in CCU (LOS). A set
of paired blood cultures were collected at baseline from each patient.
Discharges from CCU/death were considered as end points.
Results: Sixty ﬁve patients (n = 65, M: F-44:21, Age-42.5+ 8.6 years)
in control group and seventy four patients in test group (n = 74,
M:F = 52:22, Age 72.7+6.3 years) were enrolled (Jan 2007–Dec 2008).
Variable Control Test
DM 32.3% (n = 21) 44.6% (n = 33)
HTN 38.5% (n = 25) 52.8% (n = 39)
CAD 27.7% (n = 18) 44.6% (n = 33)
MV 49.2% (n = 32) 43.2% (n = 32)
RRT 56.9% (n = 37) 37.9% (n = 28)
LOS (days) 8.7+3.9 7.8+3.8
SOFA scores 13.5+3.9 15.3+3.9
Culture positive 40% (52/130) 44.6% (66/148)
The organisms grown in cultures were MSSA (n = 10), MRSA(n = 14),
Klebsiella [ESBL] (n = 19), E. coli [ESBL] (n = 3) and Acinetobacter
(n = 6) for control group and MSSA (n = 6), MRSA (n = 12), Klebsiella
[ESBL] (n = 26), E. coli (n = 9), Pseudomonas (n = 7) and Acinetobacter
(n = 6) respectively for test group. Logistic regression revealed MV in
control group and MV, RRT in test group were independent predictors
of mortality.
Conclusion: Prevalence of ESBLs and Pseudomonas is more in geriatric
groups vis-a`-vis non-geriatric cohorts and requirement of MV and RRT
in geriatric groups confers an additional risk of mortality. However,
owing to small sized samples it would be difﬁcult to interpret the above
ﬁndings on a generalised basis and we would need bigger samples and
more epidemiological studies to conﬁrm the same.
P1757 The production of ESBLs does not affect the early and late
clinical outcome of E. coli or K. pneumoniae bacteraemia
in febrile neutropenia
S.H. Kim °, J.C. Kwon, S.M. Choi, D.G. Lee, S.H. Park, J.H. Choi,
J.H. Yoo, W.S. Shin (Seoul, KR)
Objectives: Gram-negative bacilli (GNB) such as E. coli and Klebsiella
species are main pathogen in febrile neutropenia even if the proportion
of Gram-positive cocci is increasing. GNB producing extended-
spectrum b-lactamases (ESBLs) are an emerging problems in nosocomial
infection. Nevertheless, information about risk factors and clinical
outcomes of ESBLs-producing GNB bacteraemia is limited in febrile
neutropenia.
Methods: We retrospectively reviewed medical records and analyzed
patients’ characteristics, risk factors and outcomes of ESBLs-producing
E. coli and K. pneumoniae bacteraemia compared with non-ESBLs-
producing strains in febrile neutropenia at the Catholic HSCT centre
from Jan 2005 to Dec 2006.
Results: In a total of 101 isolates of E. coli or K. pneumoniae
bacteraemia in febrile neutropenia, ESBLs and non-ESBLs were 25
and 76, respectively. Production of ESBLs were more common in
K. pneumoniae (10/14) than E. coli (15/87) (P< 0.001). Age, sex,
underlying disease, and type of co-morbidity of two groups were not
different. Mean hospital stay before bacteraemia were longer in ESBLs
group (27±14 vs 15±5 days, P< 0.001). Number and total duration of
admission during prior 12 months did not differ in two groups, but care
in intensive care unit (ICU) was more frequent in ESBLs group (20% vs
3%, P = 0.004). There was no difference in exposure to antibiotics and
total duration of antibiotics administration during prior 90 days between
the two groups. Duration of febrile neutropenia was longer in ESBLs
group (5±5 vs 2±2 days, P< 0.001). Intravenous antifungal therapy and
granulocyte transfusion were applied more frequently in ESBLs group
(76% vs 47%, P = 0.027, 28% vs 8%, P = 0.013, respectively). But there
was no difference in SAPS-II score, total duration of IV antibiotics,
length of hospitalisation, and mortality rate at 7-, 30-day, and last visit
between the two groups.
Conclusion: Prior care in ICU and duration of hospital stay were
risk factors for acquisition of ESBLs-producing GNB. Despite ESBLs-
producing GNB bacteraemia was associated with longer duration of
febrile neutropenia and so more frequent use of IV antifungals, clinical
outcomes showed no difference between ESBLs and non-ESBLs groups.
Decision of empirical antibiotics in febrile neutropenia should be made
carefully under consideration of presence of ICU care, recent hospital
stay, and prolonged febrile neutropenia.
P1758 Taxonomic structure of anaerobic bacteria in cancer
patients in a Russian cancer research centre
I. Shilnikova °, N. Dmitrieva (Moscow, RU)
Objective: To determine the frequency of isolation and spectrum of
anaerobic bacteria in cancer patients within the 6-year period (2003–
2008).
Methods: Anaerobic bacteria isolated from various clinical specimens
were analysed. They were obtained from surgical wounds after
orthopaedic operations, pleuropulmonary, abdominal, biliary tract and
genitourinary infections and bacteraemia. Pus, body ﬂuids, discharges
from drain pipes, bile and the pieces of tumour tissues were the most
common clinical material used. Clinical samples were transported within
2 h of collection and special anaerobic transport systems were not used.
Cultivation methods included enrichment media and GasPak jar. Isolates
were identiﬁned by the BBL Crystal anaerobes identiﬁcation system,
API System rapid ID 32 A, and routine methods.
Results: The total number of positive cultures including both aerobes
and anaerobes was 1303 out of 2384 (54.6%). Anaerobes were detected
in 186 samples, in 139 (74.7%) of them grew both aerobic and anaerobic
bacteria, and in 47 (25.3%) cultures only anaerobes were found. A
monocultures or mix of anaerobes, without facultative and aerobic
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bacteria, were isolated from aspirates from surgical wounds (38%),
abscesses (22%), blood (21%) and body ﬂuids (19%). A total of 259
strains of anaerobic bacteria were isolated: Lactobacillus − 59(22.8%),
Gram(+) cocci − 39(15.1%), Gram(−) rods − 39(15.1%), Veillonella −
27(10.4%), Propionibacterium acnes − 27(10.4%), Actinomyces −
16(10.0%), Clostridium − 25(9.7%), other anaerobes − 17(6.5%). The
majority of anaerobic bacteria were recovery from patients with stomach
cancer followed by pancreas cancer, liver and biliary tract cancer and
also bone cancer. Lactobacillus spp. are usually isolated from the pieces
of neoplastic tissues of oral cavity and oesophagus, collected at the
time of surgery, and very often from bile. Although Lactobacillus spp.,
Propionibacterium acnes and Veillonella spp. are considered to be of low
virulence, they may cause a serious infections in immunocompromised
patients with malignancies.
Conclusion: Taxonomic structure of anaerobic bacteria in cancer
patients have speciﬁc differences. Anaerobic infections arise from the en-
dogenous ﬂora, provided that appropriate host and environmental factors
are present. One of the underlying conditions to anaerobes proliferation is
malignancies, often associated with surgery, chemotherapy and radiation
therapy, when the host immune response is compromised.
P1759 Infections caused by Gram-positive anaerobic cocci in
cancer patients
I. Shilnikova °, N. Dmitrieva (Moscow, RU)
Objective: Gram-positive anaerobic cocci (GRAP) originally classiﬁed
in the genus Peptostreptococcus are clinically signiﬁcant organisms
often isolated from mixed infections. The aim of present study was
to determine the frequency of GRAP in cancer patients, their isolation
sites and the susceptibility to antibiotics in N.N.Blokhin Cancer Research
Center of Russia.
Methods: Data on GRAP isolated from various clinical specimens of
cancer patients were analysed. Aspirates from surgical wounds, pus of
abscesses, body ﬂuids and the pieces of tumour tissues were transported
within 2 h of collection without using special anaerobic transport systems
and cultivated in Schaedler’s agar and Thioglycolate broth enriched with
hemin and menadione. The cultures were incubated anaerobically using
the GasPak jars (Oxoid) at 37C for 48−96 h and identiﬁed biochemically
by using a combination of conventional tests and the commercial
kits Rapid ID 32A (BioMerieux) and Crystal Anaerobe ID (Becton
Dickinson).
Results: In total, 39 strains of GRAP were isolated from 34 patients:
Finegoldia magna − 17 (44%), Peptoniphilus asaccharolyticus − 10
(26%), Peptostreptococcus micros – 8 (20%) and Peptostreptococcus
anaerobius – 4 (10%). Sources of their isolation were head and
neck region (5 species), lungs (6), intra-abdominal area (6), women’s
reproductive system (7), soft tissue (9), bone and joint (prosthetic
infection, 6). All isolates showed high susceptibility to penicillins,
metronidazole, chloramphenicol and doxicycline. Over 50% F. magna
strains were resistant to clindamycin, cefotaxime and ceftriaxone;
30−40% − to ﬂuoroquinolones, including moxiﬂoxacin, and 60−70% −
to azithromycin and erytromycin. In P. anaerobius strains only
resistance to ﬂuoroquinolones (33%) was found. P. asaccharolyticus
strains demonstrated intermediate resistance to azithromycin (22%)
and erytromycin (56%) and resistance to ciproﬂoxacin (44%), but all
strains were susceptible to levoﬂoxacin and moxiﬂoxacin. In contrast
to F. magna, P. anaerobius and P. asaccharolyticus were susceptible to
clindamycin and cefalosporins.
Conclusion: Gram-positive anaerobic cocci are frequently isolated from
a wide range of body sites and associated with serious infections in
cancer patients.
P1760 Infectious complications in cancer patients treated with
dasatinib (BMS-354825)
S. Ahmed, G. Rodriguez, S. Ejaz, F. Al Akhrass, A. Safdar ° (Houston, US)
Background: Tyrosine kinase inhibitors (TKI) interrupt T-cell receptor
mediated T-cell proliferation, activation and selective inhibition of
memory CTL responses without affecting primary T or B cell responses.
Few cases of cytomegalovirus (CMV), varicella-zoster virus (VZV) and
Parvovirus B19 infections have been reported during dasatinib therapy.
However, the true spectrum of infections in patients receiving this TKI
remains unknown. To this effect, we evaluated all infections during
dasatinib therapy in patients at our tertiary care cancer centre.
Methods: This retrospective analysis of infections in 57 patients during
dasatinib therapy alone or in combination with other antineoplastic
regimens during May 2006 through December 2007 was performed
after obtaining IRB approval. The values are presented as median±s.d.
Categorical data was analyzed using Chi-square.
Results: Forty-two episodes of infection were identiﬁed in 28 patients
(49%) including 19 episodes (42%) during neutropenia; please refer to
the table below. Duration of chemotherapy was 135±191 days in patients
who developed infection vs. 228±347 days in who no infection occurred.
There were no signiﬁcant differences in age, race or prior haematopoietic
stem cell transplantation in patients who developed infection vs. patients
with no infection (n = 29; 51%). In patients who developed infections vs.
who did not, had more co-morbidities including diabetes (32% vs. 14%;
P =0.04); had Ph+ acute lymphocytic leukaemia (ALL; 39% vs. 10%;
P = 0.01); had received high-dose steroids (50% vs. 21%; P = 0.02), and
frequently received dasatinib with another antineoplastic agent(s) (54%
vs. 28%; P = 0.04). Dasatinib was discontinued due to adverse events
in 24% of patients with infection vs. 16% with no infection. Overall
mortality was higher in patients with infection (61%) compared with
24% in patients with no infection (P = 0.08). In only one patient infection
was considered as the cause of death.
Conclusions: Infections were common in patients receiving dasatinib
therapy and signiﬁcantly more frequently seen in patients with ALL
being treated with steroids and multiple antineoplastic agents.
Table. Type of infection episodes in 26 patients during dasatinib therapy
Infection episodes n (%)
Total infection episodes 42 (100)
Clinical documented infections 23 (55)
Clinical pneumonia (bacterial) 11 (26)
Possible fungal pneumonia 4 (10)
Soft tissue infection* 3 (7)
Gastroenteritis/mucositis** 3 (7)
Febrile neutropenia (cause not identiﬁed) 1 (2)
Urinary tract infection 1 (2)
Microbiological documented infections 19 (45)
Gram-positive bacterial infections 12 (29)
Clostridium difﬁcile colitis (14)
CoNS CrBSI 1 (2)
Enterococcus CrBSI 2 (5)
MRSA CrBSI 2 (5)
MRSA otitis extema 1 (2)
Gram-negative bacterial infections 4 (10)
Klebsiella spp. neutropenic enterocolitis 2 (5)
Pseudomonas spp. CrBSI 1 (2)
Pseudomonas spp.–Klebsiella spp. urinary tract infection 1 (2)
Viral infections
RSV pneumonia 1 (2)
HSV oral labial 1 (2)
Fungal infection
Candida krusei CrBSI 1 (2)
*2 cellulites/1 perirectal abscess; **1 neutropenic enterocolitis.
CrBSI: catheter-related bloodstream infection; CoNS: coagulase-negative
staphylococci; MRSA: methicillin resistant Staphylococcus aureus.
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P1761 Biomarkers of infection and septic shock in neutropenic
patients
R. Jeddi °, R. Ben Amor, L. Aissaoui, L. Thabet, K. Kacem,
W. Bouteraaˆ, H. Ben Abid, Z. Bel Hadjali, B. Meddeb (Tunis, TN)
Procalcitonin and C-reactive protein are the most markers of inﬂam-
mation used in the diagnosis of infection. We aimed at evaluating
the diagnostic and prognostic value for infection of semi-quantitative
PCT (>0.5, >2 and >10 ng/ml), CRP (N< 6mg/l), serum bicarbonate
(N: 24−26mmol/L), serum lactate (N< 2.2mmol/L) and phosphataemia
(N:0.8–1.4mmol/L).
50 neutropenic febrile episodes were noted among 27 patients with
acute leukaemia. All patients presented neutropenia (ANC< 0.5×109/L)
lasting for more than 7 days. They were on oral anti-bacterial (polymixin
B, gentamicin) and anti-fungal (fungizone) prophylaxis. The ﬁrst
neutropenic febrile episode was treated with Piperacillin-Tazobactam and
Polymixin B IV, if the patient remain febrile at 48 hour from the start of
this ﬁrst line the fungizone iv is added. Imipenem is introduced in case
of non response and ﬁnally glycopeptides are introduced according to the
IDSA criteria [1]. Severe sepsis and septic shock are deﬁned according
to the criteria of the consensus conference of the ACCP/SCCM [2].
Consecutive sample for PCT (semi-quantitative test, BRAHAMS), CRP,
Phosphataemia, Serum lactate, and serum bicarbonate were measured at
each neutropenic febrile episode.
Seven episodes (14%) were clinically documented: pneumonia (4),
neutropenic enterocolitis (1), mucositis (1) and skin infection (1). Mi-
crobiologically documented infection (30%) were due to 9 Gram− and 6
Gram+: Klebsiella (7), Acinetobacter (1), E. coli (1), Staphylococcus (6).
Fever of unknown origin accounted for the remaining 28 febrile episodes.
6 episodes (12%) were complicated with septic shock, with infection
related mortality of 18.5% (5/27 patients).
PCT< 0.5 ng/ml was noted in 18 (36%) febrile episodes, whearas high
level (>10 ng/ml) are noted in 11 episodes. Median level of each
biomarker was: CRP 88.8mg/L (range, 2.2–183mg/L), Serum lactate
2.3mmol/L (range, 0.8−3.3mmol/L), Serum bicarbonate 24.3mmol/L
(range, 9.4−32.1mmol/L), and phosphataemia 1.08mmol/L (range,
9.4−32.1mmol/L).
PCT> 0.5 ng/ml (p = 0.004; OR= 6.6) and CRP> 100mg/L (p = 0.008;
OR= 6.1) were correlated with microbiologically and/or clinically
documented infection. CRP> 100mg/L correlates with Gram− infection
(p = 0.045). PCT> 10 ng/ml (p = 0.017; OR 10.5) and serum lactate
>3mmol (p = 0.04; OR= 16) are associated with occurrence of septic
shock.
Several level of PCT correlated with infection and severity and is useful
to monitor in neutropenic setting.
Reference(s)
[1] Clin Infect Dis 2002;34:730–751.
[2] Crit Care Med 1992;20:864–874.
P1762 Can multiplex PCR (SeptiFast) detect DNAemia before
occurrence of sepsis in neutropenic patients?
C. Orasch °, M. Weiser, Y. Latiﬁ, U. Loeffel, P. Schuetz, H. Hermann,
N. Schmid, A. Steinhuber, R. Frei, A. Gratwohl, A. Trampuz (Basel, CH)
Objectives: Invasive infections are the leading cause of morbidity and
mortality in patients treated for haematological malignancies. Blood
cultures are often negative in neutropenic patients because of low-burden
of organisms, previous antibiotic therapy or non-infectious reason of
fever. More rapid, accurate and sensitive diagnostic tools are needed.
We assessed the multiplex real-time PCR SeptiFast (Roche Diagnostics)
to detect microbial DNA in neutropenic patients without fever.
Methods: We prospectively included all patients aged 18 years
hospitalised between 01/2007 and 12/2008 in the bone marrow transplant
unit at our institution for an autologous or allogeneic haematopoietic
stem cells transplantation or induction/consolidation chemotherapy.
1.5ml of EDTA-blood was routinely collected for SeptiFast at admission
and thereafter 3×/week (Mo, We, Fr) until discharge or recovery from
neutropenia (>0.5×109/l neutrophils over >3 days). In addition, blood
was collected for SeptiFast simultaneously with blood cultures at new
appearance or persistence of fever despite antibiotic treatment of >72 h.
Results: During the study period, 875 SeptiFast tests were performed
in 82 patients (median age, 47 y; range 18−80 y; 54% males). Overall,
102 episodes of neutropenia occurred in 82 patients with a median
duration 14 d (= 1428 neutropenic days). The haematological diseasesin-
cluded acute myeloic leukaemia (44%), acute lymphatic leukaemia
(16%), non-Hodkin lymphoma (8%), chronic myeloid leukaemia (7%),
myelodysplastic syndrome (6%) and other (19%). SeptiFast was positive
in 56/875 performed tests (6%) from 6/82 patients (7%). Tests were
repeatedly positive for the same organism in sequential samples from
each of the 6 patients, identifying coagulase-negative staphylococci
(n = 3), enterococci (n = 2) and P. aeruginosa (n = 1). 5 of 6 patients
developed infection (3 sepsis, 2 without focus) during hospitalisation.
DNA of the respective organism was detected in blood by SeptiFast
2−23 d (median 10 d) before the same organism was detected by blood
cultures collected during the febrile episode. In all 6 patients, DNAemia
sequentially increased until start of adequate antibiotic therapy.
Conclusions: In haematological patients, SeptiFast detected DNAemia
2−23 d before occurrence of the febrile episode and positive blood
cultures. An automated molecular diagnostic test may be useful for
screening blood of neutropenic patients, allowing an intervention before
occurrence of fever.
P1763 How diverse can be the management of this special group
of at-risk patients? A regional multidisciplinary audit on
febrile neutropenia in hospitals of northwestern England
A. Guleri, I. Thakur, R. Sharma ° (Blackpool, UK)
Background: Febrile neutropenia [FN] is a common emergency in
Haemato-oncology. Optimal management FN is crucial to improving
outcomes for patients with potentially curable malignancies. However,
currently there are no national guidelines on diagnosis and management
of FN. There is an apparent inter-hospital variation in FN policies and
in currently available international and regional guidance documents.
Blackpool Victoria Hospital is a large district hospital [DGH] offering
enhanced regional haematology services. A regional audit was carried
out jointly by Clinical Microbiology and haematology.
Methods: Completed questionnaires from 14 hospitals in the region were
analysed. Details of audit to be presented. Standards on FN included
guidance documents from IDSA, BCSH, Christie hospital [CH] and
www.uptodate.com
Figure: Deﬁnition of FEVER in the policy.
Results: Respondents included DGH [10/14]; Teaching hospitals [2/14]
and Specialist tertiary [2/14]. Microbiologist and haematologist jointly
co-author FN policies. Over 90% policies address initial clinical
assessment, investigations and ﬁrst line antibiotics; 50% mention risk
stratiﬁcation [without any reﬂection in the policy]; over 71% discuss
subsequent assessment and treatment modiﬁcation; 42% made reference
to any guidelance documents; Variations [14−28%] in deﬁnitions of
fever and neutropenia was noted. Antifungal use follows clinical
suspicion [85%]; BAL culture and HRCT [78%]; Galactomannan EIA
[<10%]. 85% consider antifungal on day 4/5 unresponsive fever while
15% at 72hs. Liposomal amphotericin and caspofungin were common
options. Itraconazole [prophylaxis] in leukaemia/lymphoma patients
[>90]. Piperacillin-tazobactam/gentamicin or carbapenem used 1st line
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in >85%. Teicoplanin [57% /single daily dosing] was preferred. Patient
information card [PIC] detailing chemo regimes/dates offered by 29%;
Contact number for direct admission to haematology offered 71%.
Variation in suggested use of antifungals noted between the standards.
Recommendations: There is an evident need for a national [UK]
guideline on diagnosis and management of FN. Appropriate and timely
specimen collection could be optimised. PIC should be provided by
all centres. Choice, appropriateness and timing of antifungal agents
requires deﬁnite clarity in hospital FN policies. Smaller units with
limited experience could avoid addressing risk stratiﬁcation in hospital
FN policy and a potential risk of under-treating a high-risk patient with
FN leaving this to specialist centres.
P1764 Empirical use of teicoplanin versus vancomycin in febrile
neutropenic patients at high risk for Gram-positive
bacteraemia: results of a multi-centre prospective
randomised clinical trial
H. Akan, V. Korten, Z. Bolaman, I. Aydogdu, G. Alanoglu, V. Hazar,
T. Fen, Z. Gulbas, M. Akova ° (Ankara, Istanbul, Aydin, Malatya,
Isparta, Antalya, Eskisehir, TR)
Objectives: To evaluate the efﬁcacy and safety of empirical use of
teicoplanin versus vancomycin in febrile neutropenic patients at high
risk of Gram positive bacteraemia.
Methods: A total of 190 febrile neutropenic patients from 21 centres
were randomised to receive teicoplanin (97 patients) or vancomycin
(93 patients) in addition to a standart empirical regimen of intravenous
ceftazidime and amikacin for duration of 5 to 21 days depending on
response to the treatment.
Results: There was no difference between teicoplanin and vancomycin
groups in terms of overall survival rates (92.5% vs. 92.6%, p> 0.05)
and response rates (55.7% vs. 53.3%, p> 0.05). Gram positive isolates
from peripheral blood cultures were more than Gram negative isolates
(62.2%). Similar adverse events without any statistical signiﬁcance
occurred in both groups; most common ones being hypokalaemia, rash,
diarrhoea, and hepatotoxicity. There was no difference between treatment
groups according to adverse events.
Conclusion: Teicoplanin is as effective as vancomycin in terms of
treatment response and overall survival rate in febrile neutropenic
patients. Both antibiotics have acceptable safety proﬁles.
P1765 Three-day treatment with imipenem for unexplained fever
during prolonged neutropenia. A prospective observational
study on the safety in haematology patients receiving
ﬂuoroquinolone and ﬂuconazole prophylaxis
L. Slobbe °, B. Rijnders (Rotterdam, NL)
Objectives: Guidelines advocate at least 7 days of broad-spectrum
antimicrobial therapy for unexplained fever during neutropenia. How-
ever, effective antimicrobial prophylaxis reduces the incidence of
Gram-negative infections, which may allow shorter treatment. This
study evaluates the safety of discontinuing empirical broad-spectrum
antibiotics if no microbial source is documented after 72 hours.
Methods: Prospective observational study at a tertiary care haematology
unit in patients suffering from haematologic malignancies, with treatment
induced prolonged neutropenia of 10 days. Oral ﬂuoroquinolone and
ﬂuconazole prophylaxis was given from day 1. A standardised diagnostic
protocol was followed and fever was empirically treated with imipenem,
which was discontinued after 72 hours if no infectious aetiology was
documented. Duration of fever, antimicrobial therapy and all-cause
mortality 30 days after neutrophil recovery were registered.
Results: 166 patients were evaluated during 276 neutropenic episodes.
29 patients (17.5%) did not develop fever during any episode.
137 patients (82.5%) experienced 1 febrile episodes. A total of
317 febrile episodes were observed, of which 177 (56%) were
diagnosed as unexplained fever (UF). In 135 febrile episodes (43%),
a probable/deﬁnite infectious origin was documented. Mean duration of
fever in neutropenic periods with 1 febrile episode was 5 days, with
imipenem given for 4.7 days. In patients with UF, imipenem was given
for 3.7 days. All-cause mortality 30 days after neutrophil recovery was
3.6% (6/166); in 4 of these patients, an infectious origin could not be
established.
Conclusion: Discontinuation of broad-spectrum antimicrobial therapy
given for unexplained fever during neutropenia in haematology patients
on ﬂuoroquinolone and ﬂuconazole prophylaxis is safe if no infectious
origin is found after 72 hours.
Cause of fever in 202 neutropenic episodes (137 patients). Febrile
episodes caused by the same aetiology during a single period of
neutropenia were counted only once, therefore adding up totals may
give slightly different numbers compared to results when multiplying
the number of neutropenic periods with the number of febrile episodes.
a FUO, fever of unknown origin. b DTTP, differential time to positivity.
c IPA, invasive pulmonary aspergillosis, classiﬁed according to updated
EORTC-MSG criteria.
P1766 Antiviral prophylaxis in haematological patients: systematic
review and meta-analysis
D. Yahav, A. Gafter-Gvili, E. Muchtar, K. Skalsky, G. Kariv,
M. Yeshurun, L. Leibovici, M. Paul ° (Petah Tikva, IL)
Objectives: Herpesviruses cause major morbidity among haematological
patients undergoing haematopoietic stem cell transplantation (HSCT) or
following chemotherapy. We conducted a systematic review and meta-
analysis to quantify overall patients’ gain with antiviral prophylaxis in
speciﬁc clinical scenarios.
Methods: Included were randomised controlled trials assessing antiviral
prophylaxis vs. placebo, no treatment, preemptive treatment or another
antiviral drug. Patients undergoing HSCT or intensive chemotherapy
for acute leukaemia or high-grade lymphoma were included. No
restrictions on language, year or publication status were applied. All-
cause mortality, herpes simplex (HSV) and cytomegalovirus (CMV)
disease were assessed as primary outcomes. Pooled relative risks (RR)
and numbers needed to treat (NNT) with 95% conﬁdence intervals are
reported.
Results: HSCT was the condition assessed in 22 trials and intensive
chemotherapy in 5 trials. In the pre-engraftment setting of autologous
or allogeneic HSCT, antiviral prophylaxis (mainly acyclovir for HSV
seropositive recipients or donors) signiﬁcantly reduced HSV (NNT 2,
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2−2) and CMV disease, with no effect on all-cause mortality. In the
allogeneic post-engraftment setting (mainly CMV-seropositive recipi-
ents/donors), antiviral prophylaxis resulted in a signiﬁcant reduction
in all-cause mortality, RR 0.79 (0.65–0.95), NNT 12 (7−50) and all
viral-related outcomes. The effect on CMV was more pronounced with
ganciclovir (5 trials) and maribavir (1 trial), but acyclovir alone (7 trials)
also signiﬁcantly lowered mortality. During chemotherapy, acyclovir
signiﬁcantly decreased HSV disease (NNT 3, 2−4) and infection rates,
with no effect on mortality. HSV disease represented mostly HSV-
positive oral mucositis. Overall mucositis and pneumonitis rates were not
reported. Small study’s effect was observed for viral-related outcomes.
Conclusions: Antiviral prophylaxis reduced mortality with a small
NNT in the post-engraftment setting of allogeneic HSCT and should
be administered to all CMV-seropositive HSCT recipients. Since
prophylaxis in this setting signiﬁcantly reduced VZV and HSV disease
rates, consideration should be given to the use of prophylaxis also for
VZV-seropositive or HSV-seropositive (CMV seronegative) recipients.
During the pre-engraftment period and for patients undergoing intensive
chemotherapy, antiviral prophylaxis does not reduce mortality and its
effect on overall patient morbidity is unknown.
P1767 Cytomegalovirus disease among immunocompromised
non-transplanted patients
M. Chitasombat, S. Watcharananan °, V. Chantratitaya,
S. Sungkanuparph (Bangkok, TH)
Objectives: To study clinical characteristics, outcome and predicting
factors of death among immunocompromised non-transplanted patients
who had Cytomegalovirus (CMV) disease
Methods: A retrospective study was conducted among non transplanted
patients who received immunosuppressive therapy and were diagnosed
with CMV disease between January 2005 and December 2008.
Results: CMV disease occurred in 34 patients, 21 (61.7%) and 13 (38%)
of whom had deﬁnite and probable diagnosis, respectively. Median (IQR)
age of patients was 49 (40−60) years. Systemic lupus erythematosus
(SLE) was the major underlying disease, noted in 21 (61%) patients.
Major immunosuppressive agents included prednisolone (34, 100%) and
oral endoxan (16, 47%). Pulse methyl prednisolone, pulse endoxan,
mycophenolate mofetil and rituximab was used in 21 (61.8%), 15
(44%), 2 (5.8%) and 2 (5.8%) patients, respectively. Among CMV
disease, pneumonitis was the most common (26, 76.5%), followed by
enterocolitis (10, 29.4%), and disseminated infection (6, 17.6%). Overall,
the median (IQR) blood CMV viral load (VL) was 12200 (1820–55125)
copies/mL. Among patients with disseminated CMV disease was 43,450
(1497–73,075) copies/mL. Other opportunistic infections were noted in
23 (67.7%). Of these, pulmonary aspergillosis was the most common
(16 patients, 47.1%), followed by candidiasis (11, 32.4%), and PCP
(10, 29.4%), respectively. Active tuberculosis was noted in 5 patients
(14.7%) The overall mortality rate was 67.6%. Major causes of death
were respiratory failure (26.6%) and sepsis (26.6%). From multivariate
analysis, predicting factors of death were recent use of intravenous
pulse endoxan (p = 0.001), use of mycofenolate mofetil or rituximab
(p = 0.031), blood CMV viral load (p = 0.029), co-infection with PCP
(p = 0.008), pulmonary aspergillosis (p = 0.02) and active tuberculosis
(p = 0.007).
Conclusion: CMV disease is a signiﬁcant complication resulting in a
high mortality among immunocompromised non-transplanted patients.
Our study reﬂected the advanced course of CMV disease among this
severely immunosuppressed population. Blood monitoring of CMV
viral load is suggested for early detection of CMV infection among
immunocompromised non-transplanted patients.
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P1768 Detection of cytomegalovirus resistance to antivirals in
paediatric haematopoietic stem cell transplant recipients:
study in a paediatric cohort in the Czech Republic
P. Hubacek °, D. Boutolleau, A. Hrdlickova, F. Conan, M. Zajac,
P. Keslova, R. Formankova, H. Agut, P. Sedlacek (Prague, CZ; Paris, FR)
Objectives: Despite the improvement of infection monitoring and
antiviral treatments, cytomegalovirus (CMV) infections remain a major
cause of morbidity and mortality in allogeneic haematopoietic stem cell
transplant (alloHSCT) recipients. CMV resistance to antivirals, which
is one reason for treatment failure, was investigated in a paediatric
population.
Methods: Between 2002 and 2008, 6339 whole blood samples (median:
30/patient) from 192 alloHSCT patients (median age at HSCT: 8.9 yrs)
were tested. After DNA extraction, CMV genome and albumin gene
were quantiﬁed using real-time quantitative PCR, and results were
expressed as normalised viral copies (NVCs) per 100000 human genome
equivalents. First-line antiviral treatment, usually ganciclovir (GCV),
was initiated when CMV load exceeded 1000 NVCs, and switched to
foscarnet or cidofovir in case of none response or clinical signs of CMV
infection. If clinical resistance was suspected, based on the absence
of viral response after 2 weeks of a well-conducted treatment, CMV
resistance was studied by restriction analysis and sequencing of UL97
phosphotransferase and UL54 DNA polymerase genes.
Results: CMV load was over 100 NVCs in 839 samples from 86 patients
(45%), over 1000 NVCs in 346 samples from 55 patients (29%) and
10000 NVCs in 87 samples from 20 patients (10%). Despite treatments,
mild signs of CMV infection developed in 22 patients (11%), and CMV
disease was observed in 8 patients (4%; 6 pneumonias, encephalitis and
colitis). Seven patients died in consequence of CMV infection.
Among the 22 patients (11%) with suspicion of resistance, genotypic
resistance of CMV was evidenced in 4 patients (7%), with median of
273 days post-alloHSCT and CMV load of 10277 NVCs. Resistance
to GCV was associated with mutations L595S and A591V in
UL97, del981–982, N408K, V715M and P522S in UL54. Natural
polymorphisms in UL54 were detected in 16 patients (8%). Four novel
changes of unknown phenotype in UL97 and 6 in UL54 were detected.
The detection of GCV resistance of CMV led to the switch of the
treatment in 4 patients, with success in 3.
Conclusions: CMV load normalisation is useful for the surveillance
and the treatment of CMV infection after alloHSCT. Genotypic testing
of CMV resistance proved to be important in case of clinical resistance.
Further studies are required to ascertain the true nature of the novel
mutations within UL97 and UL54 genes appearing after prolonged
antiviral treatments.
Supported by VZ FNM642003, MSTM0021620813, NR9418−3
P1769 Treatment failure and antiviral resistance in
cytomegalovirus infections in stem cell transplant recipients
M.T. van der Beek °, E. Marijt, A.C.T.M. Vossen, C.S. van der Blij-
de Brouwer, C.J.M. Halkes, E.C.J. Claas, A.C.M. Kroes (Leiden, NL)
Objectives: Treatment of cytomegalovirus infections after stem cell
transplantation does not always lead to a rapid and sustained viral
response. It is important to unravel possible causes of treatment failure
to improve therapeutic strategies. This study investigated the occurrence
and risk factors of treatment failure in CMV infections in SCT patients,
including the role of antiviral resistance.
Methods: Ninety-two consecutive adult recipients of allogeneic T-cell
depleted stem cell transplants who were at risk for CMV (donor
and/or recipient CMV seropositive) were studied retrospectively. CMV
infections had been treated with (val)ganciclovir according to a pre-
emptive strategy, based upon regular monitoring of the CMV-DNA load
in plasma. Patient charts were reviewed for patient and transplantation
characteristics and antiviral treatment data. Treatment failure was deﬁned
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as a CMV DNA load of at least 1000 copies/ml after at least 2 weeks
of treatment. Resistance was analyzed by nucleotide sequence analysis
of the UL97 and UL54 genes in the ﬁrst CMV DNA positive sample of
all patients and in follow-up samples during treatment failure.
Results: Pre-emptive treatment for CMV infections was administered
in 51 of 92 patients; 24% of seronegative recipients and 63% of
seropositive recipients, irrespective of donor serostatus (Pearson Chi-
Square, p< 0.05).
Treatment failure occurred in 49% of the treated patients (25 of 51).
A high maximum CMV DNA load correlated with treatment failure
(Spearman correlation coefﬁcient, p< 0.01); treatment failure was found
in 27%, 63% and 100% of patients with a maximum CMV load of
10 log 4, 10 log 5 and at least 10 log 6 copies/ml respectively. No clear
association was found between CMV serostatus of donor or recipient,
donor type (related/unrelated) or conditioning regimen (myeloablative/
non-myeloablative) and the risk of treatment failure.
In 1 patient, who developed CMV encephalitis during treatment failure,
ganciclovir-resistant viral isolates with the well-characterised A594V
mutation in the UL97 gene were found.
Conclusion: In stem cell transplant patients, CMV infections with a slow
response to antiviral treatment occur frequently. Antiviral resistance was
observed but apparently played a minor role in treatment failure.
P1770 Clinical applicability of a diagnostic DNA-microarray for
the simultaneous detection of herpesviruses and adenovirus
co-infections in patients undergoing allogeneic stem cell
transplantation
A.K. Ditzen °, A. Rutzka, M. Stichling, R. Mu¨ller, R. Ehricht, T. Illmer,
J. Rohayem (Kiel, Dresden, Jena, DE)
Introduction: Herpesviruses and adenovirus are an important cause
of end-organ disease (EOD) and are associated with graft versus
host disease (GVHD) in patients undergoing allogeneic stem cell
transplantation (SCT). Since more than one herpes- or adenovirus are
reported to be present shortly after transplantation, we validated a DNA-
microarray (VINAray) for the simultaneous detection and monitoring
of those viruses. Still, evaluations as to the best possible clinical and
diagnostic applicability of the array have not been performed.
Methods: We studied the (simultaneous) viral reactivation of herpes-
simplex-virus-1 and -2 (HSV-1/2), cytomegalovirus (CMV), varicella-
zoster-virus (VZV), Epstein-Barr-virus (EBV), human herpesvirus-6
(HHV-6) and adenovirus of 35 patients during the ﬁrst 100 days after
allogeneic SCT. Time post SCT was devided in phase 1 (pre-engraftment,
day 0−14), phase 2 (engraftment, day 15−30), phase 3 (post-engraftment,
day 31−60) and phase 4 (late phase, >day 60). We evaluated the
frequency and diversity of viral (co-)reactivation in the different phases
post SCT.
Results: In phase 1, samples of 34 patients (97.1%) were available, in
phase 2 and 3 of 32 patients (91.4%) and in phase 4 of 29 patients
(82.9%), respectively. In the different phases, 17 of 34 patients (50%)
had positive samples in phase 1, 19 of 32 patients (59%) in phase 2, 27
of 32 patients (84%) in phase 3 and 24 of 29 patients (72%) in phase 4.
Among the positive patients, CMV was detected most frequently (58%
in phase 1, 57% in phase 2, 88% in phase 3, 83% in phase 4), followed
by HHV-6 (35%, 57%, 41%, 33%), EBV (12%, 26%, 38%, 33%) and
adenovirus (12%, 22%, 19%, 20%), respectively. Simultaneous infections
with 2 viruses were diagnosed in 12% of positive patients in phase 1,
36% in phase 2, 19% in phase 3 and 33% in phase 4. Triple infections
were diagnosed in 0%, 5%, 14% and 8% of positive patients, respectively.
Conclusion: We conclude that monitoring of multiple viral infections
is necessary in patients undergoing SCT, since clinical symptoms of
viral reactivation of herpes- and adenovirus may be very similar. Best
diagnostic applicability seems to be in phases of engraftment and post-
engraftment. By screening and monitoring SCT-patients for viruses
known to be associated with EOD or GVHD we herewith introduce an
innovative molecular technique that can simultaneously detect multiple
viral infections on a large scale.
P1771 Incidence, timing and aetiology of bloodstream infections
following orthotopic liver transplantation or haematopoietic
stem cell transplantation − a single-centre experience
A. Mrzljak, Z. Peric, T. Filipec-Kanizaj, D. Gustin,
V. Kovacevic, J. Sedlacek, S. Bukovski-Simonoski, V. Colic-Cvrlje,
S. Naumovski-Mihalic, H. Minigo, A. Tambic-Andrasevic, B. Jaksic,
R. Vrhovac ° (Zagreb, HR)
Bloodstream infections (BSI) are major complications of orthotopic
liver transplantation (OLT) and haematopoeitic stem cell transplantation
(HSCT). Knowing characteristical timing of their occurrence enables
anticipation of these infections and their earlier detection, and knowing
the pattern of causative microorganisms is a prerequisite for determining
suitable empirical therapy.
Objective: to evaluate and compare incidence, timing and aetiology of
BSI post transplantation (TX) in two groups (OLT and HSCT) of patients
in a single institution.
Methods: 263 consecutive TXs performed from Jan 2005 to Oct 2008
have been evaluated. OLT patients: n = 136; mean age 49 (range 16−75,
SD 12); HSCT patients: n = 126; mean age 45 (range 19−70, SD 14);
autologous TX 80.2%, allogeneic 19.8%. Patients were followed up 1
year after TX; blood culture dates and isolates were recorded.
Results: 78 BSI were identiﬁed (OLT: n = 42, HSCT: n = 36) at a median
of 18 (range 1–256, SD 75) days post TX (OLT: median 42, range 1–
248 SD 65 days; HSCT: median 8, range 1–256, SD 85 days, Mann
Whitney p = 0.004). In both groups, the majority of BSI were observed
in the ﬁrst trimester following TX, in HSCT patients mostly (69.4% of all
BSI in HSCT) during the ﬁrst two weeks (Fig. 1). Gram-negative (GN)
organisms were the prevalent cause (52.6%) of BSI in both groups, with
Pseudomonas aeruginosa accounting for 16.7% of all BSI and 31.7% of
all GN BSI. Gram-positive (GP) pathogens were responsible for 37.2%
of BSI, with coagulase-negative staphylococci being the most prevalent
in this group (17.9% of all pathogens, 48.3% of all GP organisms).
Mixed BSI represented 3.8% and fungaemias (candidaemias) 6.4% of
all BSI. No statistically signiﬁcant differences in aetiology of BSI (GN,
GP, fungal) were found between OLT and HSCT patients, neither during
the whole period of observation (1 year), nor in any of the 4 trimesters.
A trend towards higher incidence of fungaemia in OLT and allogeneic
HSCT compared to autologous HSCT patients was revealed (Chi square,
p = 0.09).
Conclusions: BSI are frequent complications of both OLT and HSCT,
especially during the ﬁrst trimester post TX. In HSCT patients they
occur signiﬁcantly earlier than in OLT patients. Signiﬁcant differences in
aetiology of BSI between OLT and HSCT patients were not found, most
BSI were caused by GN organisms in both groups. Empirical therapy
in these immunosuppressed patients should include agents with strong
antipseudomonal activity.
Figure 1. Incidence of bloodstream infections in patients after
haematopoietic stem cell transplantation (HSCT) or orthotopic liver
transplantation (OLT).
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P1772 Outbreak of Ralstonia pickettii bacteraemia in patients with
haematological malignancies and haematopoietic stem cell
transplant recipients
M. Mikulska °, M. Alberti, P. Durando, M.P. Molinari, M.T. Van Lint,
S. Bregante, A. Dominietto, A.M. Raiola, V. Del Bono, G. Icardi,
G. Orengo, A. Bacigalupo, C. Viscoli (Genoa, IT)
Objectives: Ralstonia pickettii is a non-fermenting Gram-negative rod
commonly found in soil and moist environments. It is rarely isolated
from clinical specimens or associated with infections, although blood
stream infections (BSI) have been reported.
Methods: We describe a series of 11 R. pickettii BSI occurring
over a period of 3 months (3/06/08–19/08/08) in 10 patients with
haematological malignancies or after haematopoietic stem cell transplant
(HSCT). Of them, 9 were cared for in the HSCT Unit, both in inpatient
and outpatient facilities, and 1 was admitted for chemotherapy to another
haematology unit in the same hospital.
Results: Clinical and microbiological features of the patients are shown
in Table 1.
Table 1. Clinical and microbiological features of patients with Ralstonia pickettii bacteraemia
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1. PC F 55 NHL – 03/06/08 1 1 0 ND − − + 1 −
2. DO M 24 AML – 17/06/08 3 2 1 180 + + − 2 +
3. SL M 40 ALL – 26/06/08 2 0 2 51 + + + ND +
4. CL F 59 NHL 23/07/08 22/07/08 2 1 1 Neg − − − 1 +
5. CR M 54 AML 23/03/08 08/08/08 1 0 1 Neg − − − ND +
6. SG M 36 ALL 21/05/08 08/08/08 6 4 2 Neg − − + 18 +
7. TV M 63 MF 24/01/08 08/08/08 10 8 2 25 + + + 12 +
8. CV M 53 MDS 26/09/06 10/08/08 1 1 0 179 − − + 1 +
9. RD M 55 NHL – 13/08/08 1 1 0 Neg − − − ND +
10. CG* M 36 HD 15/06/07 19/08/08 6 5 1 58 + + + 9 +
*Two separate episodes of R. pickettii bacteraemia, the ﬁrst one occurred on 16th June 2008, and was treated in a
different hospital.
ALL, acute lymphatic leukaemia; AML, acute myeloid leukaemia; CRP, C-reactive protein; HD, Hodgkin disease;
MDS, myelodysplastic syndrome; MF, myeloﬁbrosis; ND, no data; Neg, negative, NHL, non-Hodgkin lymphoma.
32 isolates were recovered from blood and 1 from a catheter tip.
All patients had a central venous catheter at the time of BSI. The
isolates were susceptible to aminoglycosides, ﬂuoroquinolones, 3rd and
4th generation cephalosporins, piperacillin/tazobactam and carbapenems,
and resistant to aztreonam.
In 5/11 BSI, the patients had a full-blown sepsis syndrome, while the
other 6 episodes were free of symptoms, with no increase in C-reactive
protein. All the patients received intravenous antibiotic therapy with
cephalosporins or meropenem. The symptomatic patients improved and
blood cultures became negative after a median of 2 days (range: 1−18).
Six patients had the central venous catheter removed and 1 tip culture
was positive for R. pickettii, 1 for K. pneumoniae and 3 were negative.
No patient died due to R. pickettii BSI; 1 patient died of other causes
(cardiomyopathy).
Epidemiological and microbiological investigations were undertaken
and environmental samples, together with samples of several potential
contaminated substrates (chlorhexidine, sterile saline and water, glucose
and heparin solutions, hand-washing antiseptic soap) were cultured.
Additionally, all the existing hygiene and infection control procedures
were reviewed and actively monitored. All the cultures resulted negative
for R. pickettii.
Conclusion: We report successful treatment and control of an outbreak
of R. pickettii BSI in a HSCT Unit. Although R. pickettii is a pathogen
with low intrinsic virulence and it might be a contaminant of blood
cultures, it should not be overlooked when it is repeatedly recovered
from sterile body ﬂuids, especially in immunocompromised hosts who
lack both classical signs and symptoms of the sepsis and full capacity
to ﬁght infections.
P1773 Tailor-made therapy to prevent postoperative sepsis in
living donor liver transplantation
T. Kaido °, H. Egawa, S. Uemoto (Kyoto, JP)
Objectives: Recipients undergoing liver transplantation (LT) have an
extremely high risk of postoperative infection leading to lethal sepsis
from various aetiologies including preoperative impaired immunological
competence due to protein energy malnutrition, major surgery, and
postoperative immunosuppressive treatment. Therefore, the results of LT
can be improved by prevention of postoperative severe infection. We
describe our tailor-made preventive therapy against postoperative sepsis
in living donor LT (LDLT).
Methods and Results: 1) Cause of in-hospital death: We retrospectively
analyzed 1282 consecutive cases that underwent LDLT at a single
medical centre between June 1990 and December 2007. The most
frequent cause of in-hospital death was sepsis (34%) followed by
multiple organ failure (20%), and primary graft nonfunction or acute
cellular rejection (12%) in numerical order. This ﬁnding demonstrates
that postoperative sepsis is central to improvement in short-term outcome
of recipients.
2) Preoperative immunological status: We reported that in liver transplant
recipients undergoing LT, CD8+ T-cell subpopulation enriched with
cytotoxic T lymphocytes was associated with a signiﬁcantly higher rate
of infection and a lower survival rate after LT. Based on these results, we
have modiﬁed the immunosuppressive treatment for this subpopulation in
order to prevent postoperative infection since January 2007. We reduced
the daily dose of steroids in ABO-incompatible patients and stopped
postoperative steroid administration in ABO-identical or -compatible
patients. The incidence of sepsis as well as in-hospital mortality
was signiﬁcantly decreased, especially in ABO incompatible patients
(p< 0.001).
3) Preoperative nutritional assessment: In February 2008, we introduced
a new preoperative nutritional assessment using a body composition
analyzer on admission. Patients showing poor nutrition preoperatively
had a signiﬁcantly higher incidence of postoperative sepsis than well-
nourished patients. Therefore, we have started aggressive preoperative
nutritional intervention for poorly nourished patients including supple-
mentation of branched-chain amino acid-enriched nutrient mixture and
got good results.
Conclusion: Preoperative immunological status and nutritional assess-
ment could predict a high-risk group for postoperative sepsis. Tailor-
made therapy to prevent postoperative sepsis in high-risk patients would
be useful to improve the results of LDLT.
P1774 Widespread subcutaneous nodules as a manifestation of
breakthrough invasive aspergillosis in a bone marrow
transplant patient: assessment of disease extension by
positron emission tomography scan imaging
M. Abecasis °, P. Lapa, G. Teixeira, N. Miranda, J. Nascimento Costa,
Z. Saraiva (Lisbon, Coimbra, PT)
Invasive aspergillosis often presents as a respiratory tract infection in
transplant patients, but after haematogenous disssemination virtually
any other organ may be involved. Metastatic cutaneous aspergillosis
usually presents as necrotising cutaneous papules or ulcerating skin
lesions due to embolisation and skin infarcts. We report an unusual form
of disseminated aspergillosis and the usefulness of positron emission
tomography (PET) scan imaging in assessing its extension.
An acute leukaemia patient underwent an unrelated mismatched
non-myeloablative allogeneic stem cell transplantation after highly
immunosuppressive conditioning. Primary antifungal prophylaxis was
with itraconazol oral solution. An episode of acute gut graft vs
host disease was treated with high dose steroids plus extra-corporeal
photopheresis and itraconazol was replaced by oral voriconazol. He
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remained very prostrated and 1 month later painless subcutaneous
nodules were noted. An excised nodule revelead inﬁltration of the
subcutaneous tissue by hyphae and cultures grew Aspergillus fumigatus.
He was apyrexial, non-neutropenic and had no respiratory tract
symptoms but a computorised tomography scan showed conﬂuent lung
opacities and serum galactomannan was strongly positive. A PET
scan revealed numerous lesions involving the limbs, chest wall and
lungs. Voriconazol was replaced by Ambisome® and caspofungin in
combination, followed by posaconazol and high dose Ambisome® to no
avail since the patient died 4 months later.
Disseminated aspergillosis presenting with cutaneous nodules and intact
overlying skin is extremely unusual. The PET scan allowed an evaluation
of the metastatic infection supporting the interest of this technique
in assessing the extent of the disease. Profound immunosuppression
and steroid therapy allowed for invasive aspergillosis despite prolonged
theoretically protective prophylaxis and adequate neutrophils. The best
management of breakthrough invasive aspergillosis in the context of
mould-active azole prophylaxis is not known as there are no clinical
studies to support an adequate strategy. It should be individualised on
the basis of clinical criteria as well as consideration of other antifungal
drug classes. Treatment with several antifungal combinations proved
ineffective in controlling the infection, emphasizing the need for an
increased awareness of invasive fungal infections, even when mould-
active antifungal prophylaxis is given.
P1775 A decision support system for diagnosis and treatment of
gastrointestinal tract infections in solid-organ transplant
recipients
E. Goldberg °, G. Kariv, V. Shani, J. Bishara, L. Leibovici, M. Paul
for the TREAT Study Group
Objectives: To build a computerised decision support system for
diagnosis and treatment of suspected gastrointestinal tract infections in
solid organ transplant patients, as a part of a larger causal probabilistic
network (CPN) that will include other sites of infection (TREAT).
Methods: The information used to build the model was obtained
from existing local databases of infections and antimicrobial resistance
patterns, and systematic literature searches.
We used the HUGIN graphical interface to build a CPN model and
populated it with the incidences and probabilities obtained from the
search. We prospectively identiﬁed solid organ transplant patients,
hospitalised due to diarrhoeal disease (passage of three or more
abnormally liquid or unformed stools for at least two days) during
the years 2007–2008 in our hospital. We compared the model’s
prediction for each patient with the empirical diagnosis given by the
managing clinicians. The gold standard for comparison was the ﬁnal
microbiological diagnosis. This analysis was meant to determine the
safety of the model before it is joined with the larger network.
Results: The CPN model includes the different pathogens that may
cause diarrhoea in solid organ transplant patients, speciﬁc risk factors for
each pathogen, anti-rejection drugs that may induce diarrhoea, clinical
symptoms and laboratory tests.
Twenty solid organ transplant recipients presenting primarily with
gastrointestinal manifestations were included. Mean age was 53 years
(range 29−75). Most patients were men (17/20), and most underwent
kidney transplantation (15/20).
Our model predicted the correct diagnosis in 14/20 cases (70%),
compared with 4/20 (20%) correct initial diagnoses of the treating
physicians. The model predicted the presence of CMV infection in 8
cases, of which 5 were microbiologically documented. One case of
diagnosed CMV was not predicted by the model. ROC analysis for CMV
infection yielded an area under the ROC curve of 0.75 (95%CI 0.501–
0.999).
Conclusions:We were able to create a safe and reliable model to support
clinicians in diagnosis of infectious causes of diarrhoea in solid organ
transplant patients. Using this model may shorten the time to diagnosis,
prevent unnecessary antibiotic treatment and prevent future resistance.
This model will be incorporated into a larger network dealing with all
sites of infection in these patients.
P1776 Amphotericin B as antifungal prophylaxis in liver
transplantation
A. Talento °, S. McDermott, A. Gilleece, A. McCormick, L. Fenelon,
K. Schaffer (Dublin, IE)
Objective: The rate of fungal infections in orthotopic liver transplant
(OLT) patients ranges from 5 to 42%. Antifungal prophylaxis has been
shown to decrease the incidence of fungal infections. In this study, we
wanted to analyse the efﬁcacy of liposomal/lipid complex amphotericin B
as universal antifungal prophylaxis in OLT patients
Methods: We conducted a retrospective chart review of OLT patients
who were treated for fungal infections over a 15year time period from
January 1993 to December 2007. Two separate time periods were
analyzed: 1. From 1993 to 1999, 71% of patients received ﬂuconazole,
10% liposomal amphotericin B, 15% oral amphotericin B and 3%
received both ﬂuconazole and amphotericin B as antifungal prophylaxis;
2. From 2000 to 2007, liposomal or lipid complex amphotericin B
was given for universal antifungal prophylaxis due to building works
that commenced in the hospital early in 2000. Only patients who
did not tolerate liposomal amphotericin B were given lipid complex
amphotericin B as prophylaxis(10%).
Results: There were a total of 506 OLTs performed on 463 patients
during the 15year period. One hundred thirty six OLTs were performed in
117 patients during the ﬁrst period while there were 370 liver transplants
in 346 patients in the second period. During the ﬁrst period, 21 patients
out of 117(18%) were treated for fungal infections compared to 21
patients out of 346 (6.1%) during the second period. This is a signiﬁcant
decrease in fungal infections between the two time periods (chi square
15.03, p value <0.001).
Conclusion: In our centre, universal prophylaxis with liposomal/lipid
complex amphotericin B was found to be efﬁcient in preventing fungal
infections. Other factors that most likely contributed to the observed
decrease are improved surgical techniques and new, more speciﬁc
immunosuppressive agents.
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P1777 Long-term evaluation of pre-emptive treatment after
solid organ transplant in patients at high risk for
cytomegalovirus infection
O.J. Ben Marzouk-Hidalgo °, E. Cordero, A. Martı´n-Pen˜a,
E. Garcı´a-Prado, B. Sa´nchez, M.A. Go´mez-Bravo, M.A. Gentil,
J.M. Cisneros, P. Perez-Romero (Seville, ES)
Objectives: To determine if in solid organ transplant (SOT) recipients
at high risk for cytomegalovirus (CMV) infection, pre-emptive
valganciclovir (VGC) therapy guided by a sensitive diagnostic method
prevents CMV disease and allows early activation of a CMV speciﬁc
immune response.
Methods: SOT patients, seronegative for CMV receiving a seropositive
graft, were enrolled. Viral load (VL) was determined periodically, from
week 2 post-transplantation for a total of 18 months by real-time PCR
(rt-PCR), which was used to guide VGC administration when VL was
over 1,000 cop/ml. Twin samples were used to detect infection by
antigenaemia. The CMV-speciﬁc T-cell immune response was measured
by ﬂow cytometry using speciﬁc cell surface markers (CD69, CD3, CD4
and CD8) and cytokine production (IL-4 and IFN-g). In addition, the
emergence of resistance mutations in UL97 and UL54 was determined,
and treatment adherence was characterised by measuring plasma VGC
levels using HPLC.
Results: Ten patients fulﬁlled the study requirements and a total of 230
plasma samples were collected. In 42.6% of the samples the results
were discordant for CMV infection, with rt-PCR more sensitive than
antigenaemia. Moreover, within the same patients positive antigenaemia
was delayed by two to three weeks compared to positive rt-PCR.
The highest risk for infection after the transplant occurred between days
43 and 63. Treated episodes over 1,000 copies/ml occured between
days 28 and 119. No disease symptoms or graft rejection related to
CMV infection were detected. Nine patients acquired a speciﬁc immune
response against CMV between days 84 and 98 post-transplantation. One
patient acquired immunity at day 140, which correlated with a lower VL.
After acquisition of immunity, nine patients cleared new CMV episodes
without VGC administration. One patient did not control the infection,
which correlated with the emergence of the M460 mutation in UL97,
and suboptimal levels of VGC in plasma.
Conclusion: Pre-emptive therapy guided by rt-PCR can be used
successfully for SOT patient at high risk to prevent CMV disease. In
addition, pre-emptive therapy allows for an interaction between viral
antigens and host immune system, which results in a speciﬁc immune
response against CMV that further controls infection without treatment
administration. A lack of control of infection after the immunity was
associated with the emergence of viral resistance due to poor treatment
adherence.
P1778 Current status of CMV reactivations in adult liver transplant
patients monitored by frequent quantitative PCR testing
I. Lautenschlager °, R. Loginov, H. Ma¨kisalo, K. Ho¨ckerstedt (Helsinki,
FI)
Objectives: Cytomegalovirus (CMV) is a signiﬁcant infectious agent
causing morbidity in transplant patients. CMV-infection mostly appears
within 2−3 ﬁrst months after transplantation. To prevent CMV, most
liver centres use prophylaxis for high risk patients of CMV-seronegative
recipients receiving an organ from a seropositive donor (R−/D+) and
many centres even for all seroposive recipients (R+). Preemptive
treatment is mainly used for those at a moderate or low risk of CMV, with
a major advantage of reduced drug expose. Preemptive therapy is based
on the screening for early evidence of CMV by frequent monitoring
of viral load. The current status of CMV-reactivations demonstrated
by quantitative PCR-monitoring of adult CMV-seropositive (R+) liver
transplant patients was studied.
Patients and Methods: Altogether 211 adult patients were trans-
planted 2003–2007. The basic immunosuppression consisted of CNI
inhibitors, azathioprine/MMF plus steroids. High risk patients received
valganciclovir (or ganciclovir) prophylaxis, i.v. ganciclovir was used for
preemptive therapy for (R+) patients, and in the case of symptomatic
CMV. Most recipients, 176 (84%), were CMV-seropositive (R+). The
patients were frequently monitored for CMV by a TaqMan based real-
time quantitative plasma PCR, which correlates with the commercial
quantitative CMV-PCR Cobas Amplicor Monitor. Of those, 161 (R+)
patients with a follow-up over six months were studied.
Results: In most cases, 98/161 (61%) no evidence of CMV was seen, and
just 63/161 (39%) developed CMV-DNAemia during the post transplant
monitoring of six months. Only 25/63 reactivations exceeded 5000
copies/ml considered as cutoff level for preemptive treatment (median
21500, range 5100–813300 copies/ml), and most had self-limiting, low-
level CMV-DNAemia (median 850, range 234–4000 copies/ml). Thus,
low-level temporal CMV-reactivation occurred in 38/161 (R+) patients
(23.5%), and only 25/161 (15.5%) demonstrated signiﬁcant viral loads.
No correlation to immunosuppression regimen could be found. No
patient or graft was lost due to CMV.
Conclusions: These results demonstrate that most CMV-seropositive
adult liver recipients do not develop CMV-reactivation, and even if
reactivations occur, most of them are temporal, low-level DNAemias.
Thus, universal prophylaxis for all R+ patients would not seem to be
reasonable in this patient population.
P1779 Valganciclovir prophylaxis for CMV infection in thoracic
transplant patients
S. Lefeuvre, R. Guillemain, R. Zekkour, M. Berge, C. Amrein,
V. Boussaud, C. Charpentier, P. Chevalier, E.M. Billaud ° (Paris, FR)
Cytomegalovirus (CMV) infection is a very common opportunistic
infection after solid organ transplantation. Intravenous Valganciclovir
(vGCV), an haematotoxic drug with renal elimination pathway, remains
the ﬁrst-line treatment for CMV disease. Due to its poor bioavailability,
oral GCV was replaced by an oral prodrug valganciclovir (vGCV) for
prophylaxis.
Objectives: We analyzed In a retrospective study, the efﬁcacy and safety
of vGCV during and for 4 months after discontinuation of prophylaxis
in heart (HT) and lung transplant patients with (CFLT) cystic ﬁbrosis or
not (LT).
Methods: Selected patients were HT, LT and CFLT, with a stable renal
function (RF) receiving 900mg vGCV daily for preventing CMV disease
between 2005 and 2007. Prophylaxis was introduced in the early post
transplantation period during respectively 3 to 6 months in HT and to
12 months in CFLT and LT. Donor (D) and recipient (R) CMV serostatus
were collected. A GCV therapeutic drug monitoring (TDM) was realised
to document efﬁcient concentrations in the 0.5−1.5mg/L range. Plasma
GCV trough levels were measured by UV-LC assay. Moreover, efﬁcacy
was checked by pp65 antigenaemia (Ag) detection in peripheral blood
leukocytes.
Results: 32 thoracic transplants (11 HT, 7 LT, 14 CFLT) were included
into the study. CMV serostatus distribution was 53% D+/R-, 25% D−/R+
and 22% D+/R+. vGCV was maintained for 106±67 days in case
of HT versus 270±85 days for LT and CFLT. 300 determinations of
GCV through concentrations have been performed, representing 7 to
12 samples per patient. HT, LT and CFLT have received respectively
700±225, 915±60 and 820±150mg per day, resulting in mean GCV
trough level of 0.75±0.5mg/L. Lower doses registered in HT were
adapted to RF. The safety data indicated that 9 neutropenia were recorded
but only 2 were attributable to vGCV. Three D+/R− CFLT patients
presented a positive pp65 Ag, 1 during the vGCV prophylaxis and 2
within the 4 months after discontinuation. 2 patients developed CMV
disease, corresponding to an incidence of 6%.
Conclusion: 900mg vGCV daily, adapted to RF appeared effective and
safe for long CMV prophylaxis, related to efﬁcient exposure to GCV
in thoracic transplant patients. These ﬁrst results also conﬁrmed that a
regular TDM is not necessary in case of oral vGCV prophylaxis for
patients with stable RF.
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P1780 Clinical features and outcome of tuberculosis in solid-organ
transplant recipients
N. Ferna`ndez-Sabe´ °, L. Llado´, S. Gil-Vernet, F. Alcaide, M. Santı´n,
J. Carratala` (Barcelona, ES)
Objectives: The aim of this study was to analyze the frequency,
characteristics, treatment and outcome of tuberculosis in solid-organ
transplant (SOT) recipients.
Methods: We retrospectively reviewed medical charts of all cases of
tuberculosis occcurring in SOT recipients from 2000 to 2007. Data
regarding baseline and clinical features, treatment and outcome were
retrieved.
Results: A total of 13 of 1304 SOT recipients developed tuberculosis
(1%). The frequency of tuberculosis according to the type of allograft
was 1.3% (9 of 700) for kidney recipients, 0.8% (4 of 485) for liver
recipients, and 0% (0 of 119) for heart recipients. Eight patients were
males (61%) and the mean age was 55 years (range, 35−74 years).
Seven patients were receiving more than one immunosuppressive
drug by the time of diagnosis: corticosteroids (6), cyclosporine (5),
mycophenolate mofetil (7), sirolimus (2) and tacrolimus (4). The mean
time to the development of tuberculosis was 1726 days (range, 57–
4131 days). Four patients (31%) developed tuberculosis within the
ﬁrst year post-transplantation. The mean duration of symptoms until
diagnosis was 30 days (range, 1–180 days). Seven patients (54%)
had pulmonary tuberculosis, 4 (31%) had disseminated infection and
2 patients (15%) had lymph nodes involvement. One patient had
concomitant cytomegalovirus infection. No Mycobacterium tuberculosis
strain was resistant to ﬁrst-line antituberculous drugs. All patients were
given isoniazid, and most of them received a 3-drug regimen. Rifampin
was used in 9 cases. Six patients (4 liver and 2 renal recipients) developed
hepatotoxicity, leading to discontinuation of antituberculous treatment
in 4 cases. One patient developed rejection during treatment without
allograft lost. Overall mortality was 15% (2 of 13 patients).
Conclusions: In this study, 1% of SOT recipients developed tuber-
culosis, which frequently presented with extra-pulmonary involvement
and caused considerable mortality. Hepatotoxicity was a signiﬁcant
therapeutic drawback, mainly among liver transplant recipients.
P1781 Need for a screening with antitoxoplasma IgG and IgM in
transplantation
F. Genco, A. Di Matteo, E. Sarchi, L. Minoli, V. Meroni ° (Pavia, IT)
Objectives:Toxoplasmosis is an opportunistic parasitosis that could be
life-threatening in transplanted patients. The highest risk of infection
and disease occurs in recipients with primary infection transmitted by
a seropositive donor to a seronegative recipient (mismatch), but also
as a reactivation of a previous infection. Screening for toxoplasmosis
is mandatory and in mismatch recipients therapy is given immediately
after transplantation. We have previously described the effectiveness
of chemoprophylaxis and hygienic measures in in a cohort of donors
and recipients of solid organ transplantation referred to our Infectious
Diseases Department. On the other hand, we noticed that presence of
antitoxoplasma IgM in donors correlates with an higher seroconversion
rate. Therefore, we suggest to screen donors not only for speciﬁc
antitoxoplasma IgG but also for IgM.
Patients and Methods: We analyzed 1084 recipients and 540 donors
with the following serological tests: CLIA IgG IgM, Toxok IgA (Diasorin
Saluggia Italia), IgG ELFA (Biomerieux Marcy L’Etoile) Toxo IgM
ISAGA, Toxo IgG Avidity (Biomerieux Marcy L’Etoile France), IgG
IgM Western-Blot (LDBIO Lyon France). In all symptomatic cases
nested PCR(Clonit Milano Italia) was performed on peripheral blood
and cardiac biopsies.
Results: In our group of recipients seroprevalence was 56% and in the
donors group it was 53%. Among these patients 1.7% (9) were IgM
positive though IgG avidity test was low only in one case. The recipients
of hearts from IgM positive donors were seropositive in 5 cases and
seronegative in 4. Among these patients we recorded 2 seroconversions
and 1 reactivation with ending of the patient.
Conclusions:The overall percentage of seroconversions was 11.8%, in
mismatches it was 17.24%, but in transplanted patients with IgM positive
donors seroconversion reached 50%. Furthermore, we observed 1 case of
lethal reactivation. These preliminary data point out the different pattern
of Toxoplasma infection (more frequent, more severe) when donors are
IgM positive and therefore the need for testing for IgG and IgM.These
ﬁndings also call for a more accurate follow-up in recipients of organs
from an IgM positive donor even in presence of high avidity index.
Clinical trials of antibiotics
P1782 Safety and efﬁcacy of intravenous tigecycline in patients with
bacteraemia: pooled analysis from 8 phase 3 clinical trials
D. Gardiner °, G. Dukart, T. Babinchak, A. Cooper (Collegeville, US)
Background: Tigecycline (TGC), the ﬁrst approved glycylcycline
antibiotic, has a broad spectrum of in vitro activity against both
susceptible and multidrug-resistant bacteria. TGC has been studied
for the treatment of complicated skin/skin structure infection (cSSSI),
complicated intraabdominal infection (cIAI), and community-acquired
pneumonia (CAP), but data supporting its efﬁcacy in patients with
concomitant bacteraemia is limited.
Methods: Pooled data from patients with bacteraemia from 7
double-blind and 1 open-label trial of TGC compared with van-
comycin/aztreonam, imipenem/cilastatin, levoﬂoxacin, vancomycin, or
linezolid as standard therapies for cSSSI, cIAI, CAP, or serious
infections due to vancomycin-resistant enterococcus, methicillin-resistant
Staphylococcus aureus (MRSA), or resistant Gram-negative organisms
were analyzed. The primary efﬁcacy endpoint was the clinical cure rate
at the test-of-cure assessment.
Results: A total of 190 patients with bacteraemia were identiﬁed (TGC
n= 107; comparator n = 83). Mean Acute Physiology and Chronic Health
Evaluation (APACHE) II scores (8.48 vs.7.38; p< 0.05) and body mass
index (27.2 vs. 25.5; p< 0.045) were statistically signiﬁcantly greater in
the TGC than the comparator group; the groups were otherwise balanced
with respect to demographic and clinical characteristics. Clinical cure
rates were 76.6% and 77.1% for TGC and comparator, respectively
(p = 1.000). Analyses by sex, age, creatinine clearance, primary infection
site (cSSSI, cIAI, or CAP), APACHE score, and Fine score demonstrated
clinical cure rates of 69% to 86% with no signiﬁcant differences between
TGC and comparator. Cure rates for diabetic patients were 11/21 (52.4%)
and 12/15 (80.0%) for TGC and comparator, respectively (p = 0.1590).
Clinical cure rates for the most commonly represented pathogens,
S. aureus, Streptococcus pneumoniae, and Gram-negative species, were
also not signiﬁcantly different between treatment groups. No decrease
in rate of cure was found in organisms with increasing TGC minimal
inhibitory concentrations (MICs). The overall incidence of treatment-
emergent adverse events was similar between TGC and comparator, with
more gastrointestinal adverse events with TGC.
Conclusions: Tigecycline was effective and generally well tolerated
in the treatment of bacteraemia associated with cSSSI, cIAI, and
CAP, including MRSA infection. Cure rates were similar to those of
comparative standard therapies.
P1783 Comparison of the effects of ciproﬂoxacin, cotrimoxazole,
amoxicillin, and chloramphenicol in patients with typhoid
fever
I. Mahmood °, K. Abdullah (Mosul, IQ)
Objectives: To compare the effects of ciproﬂoxacin, chloramphenicol,
cotrimoxazole and amoxicillin in patients with typhoid fever.
Methods: Ninety three patients with symptoms and signs of typhoid
fever and positive Widal test participated initially in the study. Seven
patients were excluded from the study because of loss of follow-up and
the ﬁnal results were thus obtained from the remaining 86 patients.
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The main symptoms and signs reported at the start of the study were
fever, headache, malaise, anorexia, abdominal pain, dry cough and
splenomegaly. Widal test was positive in all patients which revealed 4
to 8 folds increase in the titer of antibodies against O and H antigens of
Salmonella typhi.
The response to therapy was evaluated by: time taken to defervescence
and the improvement of the patient’s condition. The later was deﬁned as
the improvement of the GIT symptoms, improvement or disappearance
of headache, improvement of general conditions of the patients, and the
patient’s survival without a major complications.
Results: Duration of illness before antimicrobial administration were
10.43, 10.48, 11.15, and 10.64 days for ciproﬂoxacin, cotrimoxazole,
amoxicillin and chloramphenicol groups, respectively. No statistical
differences in the duration of the illness were found before therapy
among the 4 treatment groups.
The mean time of defervescence for ciproﬂoxacin group was 3.74 days,
for amoxicillin group 5.9 days, for cotrimoxazole group 6 days and
5.2 days for chloramphenicol group. Time taken for defervescence was
signiﬁcantly shorter in those treated with ciproﬂoxacin as compared
with patients given cotrimoxazole, amoxicillin or chloramphenicol.
Time taken for clinical improvement was signiﬁcantly shorter in those
treated with ciproﬂoxacin (6.2 days) as compared with those taken
cotrimoxazole (10.05days), amoxicillin (9.8 days) or chloramphenicol
(8.32 days).
Conclusion: ciproﬂoxacin is a better drug for the treatment of patients
with typhoid fever as it signiﬁcantly reduces fever and other symptoms
within a shorter time as compared with cotrimoxazole, amoxicillin or
chloramphenicol.
P1784 Randomised clinical trial of short-course norﬂoxacin vs
single dose fosfomycin for uncomplicated UTI in region
with 10% resistance level of uropathogenic E. coli to
ﬂuoroquinolone
V. Rafalskiy °, L. Khodnevitch, I. Malev, A. Derevickiy (Smolensk,
Tula, Roslavl, RU)
Objectives: Cut-off level of uropathogens resistance in the region is
currently used in clinical guidelines (IDSA, 1999; EUA, 2006) as
a selection criterion for some antimicrobials (co-trimoxasole − CTZ,
ﬂuoroquinolones − FQ). Our previous epidemiological study (2008)
shows that in Smolensk region resistance of uropathogenic E. coli
(UPEC) in community exceed 10% level. The aim of this study was
to estimate of clinical outcomes after therapy by short course of FQ in
patients with uncomplicated UTI in the region with community UPEC
FQ-resistance >10%. As a comparator was selected antimicrobial with
level of UPEC resistance equal 0% − fosfomycin tromitamin.
Methods: A prospective controlled randomised study, including 108
women with uncomplicated UTI was carried out in primary health
care centre. Women 18−55 years with signs and symptoms of lower
UTI and signed informed consent were included in the study. We
do not include women with upper, complicated or nosocomial UTI;
duration of UTI> 7 days; with >2 relapses of UTI during last 6 months;
antimicrobials treatment during last 30 days; hypersensitivity to FQ or
fosfomycin; invasive urologic manipulation during last 30 days. Patients
of the Group 1 were treated by norﬂoxacin 400mg twice a day for a
3 days, patients of the Group 2 were treated by one dose of fosfomycin
tromitamine 3.0 g. The results of urine cultures and clinical investigations
were collected on the days 5−7 (V2), 9−11 (V3) and 26−29 (V4) after
ﬁrst dose of medication.
Results: There were no differences between recovered uropathogens,
age, and signs duration for patients of Groupe 1 and 2 (Table 1). Clinical
improvement, cure and failure rate at V2 were 98.2%, 68.5%, 1.9% for
Groupe 1 and 76%, 98%, 2.0% for Group 2. Eradication and persistence
rate at V2 were 100% and 0% for Groupe 1, 95.8% and 4.3% for Group 2
(Table 1). There were no signiﬁcant differences between efﬁcacy and
safety outcomes in Group 1 and 2.
Conclusions: Short course of FQ are effective for treatment of
uncomplicated UTI even in region with UPEC resistance level exceed
10%. The results of antimicrobial susceptibility testing were not always
related to the clinical outcome and bacterial resistance may overestimate
the risk of therapeutic failure in UTI. Probably it is necessary more
exactly to estimate and to use a resistance cut-off level for selection of
antimicrobial for UTI.
Table 1. Characteristic of patients before treatment and key parameters of efﬁcacy and safety
Group 1 Group 2 P value
Number of patients included 55 53
Age, M±m 35.0±11.0 31.4±8.4 >0.05
Duration of UTI, days, M±m 2.1±0.8 2.0±0.8 >0.05
Isolated recovered before treatment, n/N(%)
E. coli 45/53 (84.9%) 39/49 (79.6%) >0.05
E. faecalis 3/53 (5.7%) 3/49 (6.1%) >0.05
S. saprophyticus 2/53 (3.8%) 2/49 (6.1%) >0.05
Staphylococcus spp. 1/53 (1.9%) 1/49 (2.0%) >0.05
Other 2/53 (3.8%) 3/49 (6.0%) >0.05
Microbiological efﬁcacy, n/N(%)
Eradication rate (on V2) 54/54 (100%) 46/48 (95.8%) >0.05
Persistence (on V2) 0/54 (0%) 2/48 (4.3%) >0.05
Reinfection (on V3 or V4) 1/21 (4.8%) 0/15 (0%) >0.05
Relapse (on V3 or V4) 1/21 (4.8%) 0/15 (0%) >0.05
Clinical efﬁcacy, n/N(%)
Cure (on V2) 37/54 (68.5%) 38/50 (76%) >0.05
Improvement (on V2) 53/54 (98.2%) 49/50 (98.0%) >0.05
Failure (on V2) 1/54 (1.9%) 1/50 (2.0%) >0.05
Relapse (on V3 or V4) 1/37 (2.7%) 0/20 (0%) >0.05
Adverse events, n/N(%) 1/54 (1.9%) 0/53 (0%) >0.05
P1785 Efﬁcacy of IV/oral moxiﬂoxacin in the treatment of
complicated skin and skin-structure infections: results of
the RELIEF study
I.C. Gyssens °, M. Dryden, P. Kujath, D. Nathwani, N. Schaper, P. Arvis,
P. Reimnitz, J. Alder, B. Hampel (Nijmegen, Maastricht, NL; Winchester,
Dundee, UK; Lubeck, Berlin, Wuppertal, DE; Lille, FR; Montville, US)
Objectives: Selection of the optimal antimicrobial for treatment
of complicated skin and skin structure infections (cSSSIs) can be
difﬁcult. A number of IV antimicrobials have been investigated for the
management of cSSSIs. Amongst them, moxiﬂoxacin (MXF) has been
shown to have efﬁcacy similar to standard therapies. The RELIEF study
was conducted to provide additional data in well-characterised patients
with conﬁrmed cSSSIs.
Methods: RELIEF was a prospective, randomised, double-dummy,
double-blind, multinational, multicentre study enrolling patients with a
diagnosis of major abscess, diabetic foot infection, wound infection or
infected ischaemic ulcer. Patients were stratiﬁed according to infection
severity, requirement for surgery, and cSSSI diagnosis, and randomised
to IV/PO MXF 400mg qd or piperacillin/tazobactam 4.0/0.5 g tds
followed by PO amoxicillin-clavulanic acid (PIP/TAZ-AMC) 875/125mg
bd, for 7−21 days. The primary efﬁcacy variable was clinical response
14−28 days after completion of therapy. Non-inferiority of MXF was
demonstrated if the lower limit of the 95% conﬁdence interval (CI) was
above −10%.
Table: Clinical and bacteriological response in the different patient
populations of the RELIEF study
Populations MXF PIP/TAZ-AMC 95%CI
n/N (%) n/N (%)
Clinical response
Per-protocol 322/363 (88.7) 275/307 (89.6) −5.2, 4.0
MBV 235/270 (87.0) 215/243 (88.5) −7.4, 3.5
ITT 353/426 (82.9) 305/377 (80.9) −3.1, 7.0
ITT with organisms 256/313 (81.8) 234/290 (80.7) −5.2, 6.6
Bacteriological response
MBV 224/270 (83.0) 210/243 (86.4) −10.2, 1.7
ITT with organisms 244/313 (78.0) 227/290 (78.3) −7.5, 5.0
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Results: Of 813 patients randomised (MXF=432, PIP/TAZ-AMC=381),
803 were valid for ITT/safety analyses (MXF=426, PIP/TAZ-
AMC=377). In the PP population (MXF=363, PIP/TAZ-AMC=307), di-
agnoses were: abscess (n = 320, 47.8%), diabetic foot infection (n = 207,
30.9%), wound infection (n = 110, 16.4%), and infected ulcer (n = 33,
4.9%). The most frequent individual pathogens in the microbiologically
valid (MBV) population were: methicillin-susceptible Staphylococcus
aureus (n = 308), Escherichia coli (n = 113), Enterococcus faecalis
(n = 110), Streptococcus pyogenes (n = 60) and Bacteroides fragilis
(n = 44). For the primary efﬁcacy variable (clinical response at TOC),
MXF was non-inferior to PIP/TAZ-AMC (Table). Good bacteriological
efﬁcacy was also seen (Table).
In the ITT/safety population, incidences of treatment-emergent adverse
events, and treatment-emergent drug-related adverse events were similar
in the MXF and PIP/TAZ-AMC groups (23% vs 19%, P = 0.14, and 9%
vs 7%, P = 0.60, respectively).
Conclusion: In this large multicentre study, IV/PO MXF was clinically
non-inferior to IV PIP/TAZ-AMC in the treatment of patients with
cSSSIs. Both treatments were well tolerated. Safety proﬁles of study
regimens were similar. These data conﬁrm the efﬁcacy of IV/PO MXF
for the treatment of cSSSIs.
P1786 Efﬁcacy of IV/oral moxiﬂoxacin and IV
piperacillin/tazobactam followed by oral amoxicillin-
clavulanic acid in the treatment of major abscess: results
of the RELIEF study
I.C. Gyssens °, M. Dryden, P. Kujath, D. Nathwani, N. Schaper, P. Arvis,
P. Reimnitz, J. Alder, B. Hampel (Nijmegen, Maastricht, NL; Winchester,
Dundee, UK; Lubeck, Berlin, Wuppertal, DE; Lille, FR; Pine Brook, US)
Objectives: Major abscesses often need signiﬁcant surgical intervention
and antimicrobial therapy. Depending on their location, bacterial
aetiology is variable or polymicrobial. Fluoroquinolones − such as
moxiﬂoxacin (MXF) − may offer advantages over other antimicrobial
classes due to their broad spectrum and pharmacodynamic properties.
MXF is approved in some European countries for the treatment of
complicated skin and skin structure infections (cSSSIs) but due to limited
data the approval does not include major abscesses. The RELIEF study
was conducted to provide further data on the efﬁcacy of MXF in speciﬁc
cSSSI diagnoses. Data on major abscesses are presented.
Methods: This was a double-dummy, double-blind, randomised,
controlled trial. Patients with a major abscess associated with extensive
cellulitis and requiring antimicrobial therapy in addition to surgical
incision and drainage, were stratiﬁed according to infection severity and
randomised to IV/PO MXF 400mg qd or IV piperacillin/tazobactam
4.0/0.5 g tds followed by PO amoxicillin/clavulanic acid (PIP/TAZ-
AMC) 875/125mg bd, for 7−21 days. The diagnosis of major abscess
was documented by repeated pictures and conﬁrmed by an independent
data review committee. The primary efﬁcacy variable was clinical
response 14−28 days after completion of therapy (test-of-cure, TOC).
Non-inferiority of MXF to PIP/TAZ-AMC was demonstrated if the lower
limit of the 95%CI was >−10%.
Results: A total of 354 patients (MXF=184, PIP/TAZ-AMC=170) with
an abscess were randomised and 352 (MXF=183, PIP/TAZ-AMC=169)
were valid for ITT/safety analyses. In the PP population (MXF=167,
PIP/TAZ-AMC=153), 94 (56.3%) MXF- and 93 (60.8%) PIP/TAZ-
AMC-treated patients had involvement of fascia, muscle or deeper
tissues; fat was the deepest tissue involved in the remaining patients
(MXF: 73, 43.7%; PIP/TAZ-AMC: 60, 39.2%). Among PP patients,
111 (34.7%) required local or extensive debridement in addition to
surgical drainage. Mean (SD) lesion area was (MXF) 111 (141) cm2 and
(PIP/TAZ-AMC) 110 (161) cm2. Abscesses of the rectal area (64.2%)
and of the buttocks (36.1%) were most frequent. MXF was non-inferior
to PIP/TAZ-AMC with respect to clinical response at TOC (Table).
Bacteriological success rates were also comparable.
Conclusion: IV/PO MXF was non-inferior to IV PIP/TAZ-AMC in the
patients with major abscesses. Based on these results, MXF can be
considered a valuable option for the treatment of major abscesses.
Table: Clinical and bacteriological responses at TOC
MXF PIP/TAZ 95%CI
n/N (%) n/N (%)
Clinical response
Per-protocol 160/167 (95.8) 147/153 (96.1) −4.2, 4.5
MBV 119/125 (95.2) 113/117 (96.6) −5.5, 4.3
ITT 163/183 (89.1) 151/169 (89.3) −5.6, 7.2
ITT with organisms 122/135 (90.4) 114/125 (91.2) −5.6, 8.1
Bacteriological response
MBV 117/125 (93.6) 113/117 (96.6) −7.5, 3.1
ITT with organisms 119/135 (88.1) 114/125 (91.2) −8.0, 6.3
Bacteriological response by key organism
Staphylococcus aureus
Methicillin-susceptible 65/69 (94.2) 66/67 (98.5) 0.366†
Methicillin-resistant 4/4 (100) 2/2 (100) −
Escherichia coli
non-ESBL 28/31 (90.3) 22/23 (95.7) 0.628†
ESBL 3/3 (100) 0 −
Enterococcus faecalis 13/14 (92.9) 9/10 (90.0) 1.000†
Streptococcus pyogenes 23/23 (100) 15/17 (88.2) 0.174†
Bacteroides fragilis 16/20 (80.0) 9/11 (81.8) 1.000†
†Fisher’s exact test. MBV: microbiologically valid.
P1787 Single-dose antibiotic prophylaxis for urinary catheter
removal does not reduce the risk for urinary tract
infection in surgical patients: a randomised double-blind
placebo-controlled trial
B.C. van Hees °, P.L. Vijverberg, L.E. Hoorntje, E.H. Wiltink, P.M. Go,
M. Tersmette (Nieuwegein, NL)
Objectives: We conducted a double-blind, placebo-controlled trial to as-
sess the efﬁcacy of singledose therapy of trimethoprim-sulfamethoxazole
(co-trimoxazol) or ciproﬂoxacin versus placebo therapy in surgical
patients with scheduled bladder drainage for 3−14 days.
Methods: Patients were randomly assigned to receive either placebo, a
single-dose of co-trimoxazol (960mg) or a single-dose of ciproﬂoxacin
(500mg). Primary outcome measures were signiﬁcant bacteriuria and
UTI. Urine cultures were obtained directly after urinary catheter removal
and 12−14 days after urinary catheter removal, in combination with
a questionnaire for UTI symptoms. This trial was registered with
ClinicalTrials.gov, number NCT00126698.
Results: Thirty-ﬁve percent of analysed placebo patients (n = 44) had
signiﬁcant bacteriuria directly following catheter removal compared with
9% of patients receiving ciproﬂoxacin prophylaxis (n = 34) (p = 0.01)
and 27% patients receiving co-trimoxazol prophylaxis (n = 37) (p 0.43).
Two weeks after catheter removal there was no signiﬁcant difference
in bacteriuria between the placebo group and the two prophylaxis
groups. UTI was found in 2.9% of the placebo group, versus 3.2%
in the ciproﬂoxacin group (p = 0.93) and 0% in the cotrimoxazol group
(p = 0.40).
Conclusion: Ciproﬂoxacin prophylaxis is effective in resolving asymp-
tomatic bacteriuria directly following catheter removal; however, overall
there was no signiﬁcant beneﬁt of prophylaxis with respect to reduction
of bacteriuria or rate of UTI two weeks after catheter removal. Because of
the lack of evidence for short- or long-term adverse outcomes, treatment
of asymptomatic bacteriuria has not been recommended. We conclude
that surgical patients do not beneﬁt from antibiotic prophylaxis for
urinary catheter removal.
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P1788 Catheter exit site infections in patients undergoing
continuous ambulatory peritoneal dialysis
K. Tzanetou, G. Tsirpanlis, K. Ziva °, G. Tsoufakis, G. Moustakas,
E. Tzoumakidou, A. Virla, N. Afentakis, P. Ziroyiannis,
E. Malamou-Lada (Athens, GR)
Objectives: (a) To study the bacterial and fungal causes of catheter
exit site infections in CAPD patients, the frequency of isolations and
the susceptibility patterns to antimicrobial agents. (b) To evaluate the
frequency of catheter exit-site infection-related peritonitis and (c) to
determine the refractory cases to treatment and the frequency of catheter
loss.
Material-Methods: We reviewed all the cases of catheter exit-site
infections from January 2002 through December 2007. Smear or purulent
exit-site drainage of patients with symptoms and signs of exit site
inﬂammation were cultured for aerobic and anaerobic bacteria and fungi
with the standard laboratory methods. Antibiotic susceptibility testing
was performed by the disk diffusion technique, the Vitek-2 system and
the Etest.
Results: Ninety one episodes of culture-positive exit-site infection
occurred in 41 CAPD patients. Pseudomonas aeruginosa, Gram-negative
(A. baumannii, A. lwofﬁi, P. mirabilis, E. cloacae, S. marcescens,
K. pneumoniae, E. coli, Morganella morganii, Moraxella, P. putida, Sph-
ingomonas paucimobilis, Achromobacter xylosoxidans), mixed infections
caused by Gram-negative and Gram-positive bacteria (S. epidermidis,
Bacillus spp, Corynebacterium spp), coagulase-negative staphylococci
(CoNS), Staphylococcus aureus and Candida spp, were identiﬁed in 9
(9.9%), 18 (19.78%), 7 (7.7%), 34 (37.36%), 6 (6.6%), and 2 (2.19%)
cases respectively. The susceptibility testing showed a high resistance
rate of S. epidermidis to methicillin (60.5%) and a low resistance rate
of S. aureus (16.7%). A Corynebacterium group I was susceptible
only to glycopeptides and rifampicin. All Gram-negative bacteria were
multisusceptible except for A. baumannii and S. maltophilia.
Conclusions: (a) CoNS are the most common cause of exit-site infection
followed by P. aeruginosa and S. aureus. (b) P. aeruginosa and Candida
exit-site infections are refractory to treatment and may lead to catheter
loss. (c) Peritonitis associated with exit-site infections occurs in low
rate and is caused by Gram-negative bacteria and CoNS. (d) In case
of empirical treatment the high resistance rate of CoNS to methicillin
and the high frequency of P. aeruginosa as a cause of exit site infection
should be taken in to account. (e) The empiric therapy for severe catheter
exit site infections in CAPD patients should be adapted to the local
epidemiology (frequency of causative agents and their susceptibility
pattern).
P1789 Effect of intermittent moxiﬂoxacin therapy on the
microbiology of sputum cultures from patients with chronic
obstructive pulmonary disease (the PULSE study)
S. Sethi °, J. Alder for the PULSE Study Group
Objectives: The PULSE study has demonstrated the efﬁcacy and safety
of intermittent pulsed therapy of moxiﬂoxacin (MXF) (400mg PO q.d.
for 5 days every 8 weeks for 6 cycles) in the reduction in the number
of exacerbations of chronic obstructive pulmonary disease (COPD).
Intermittent therapy was used to reduce the potential for emergence of
resistant isolates associated with chronic, daily therapy. We now present
the results of sputum microbiological analysis [microbial identiﬁcation,
eradication, and changes in minimal inhibitory concentration (MIC)]
carried out during the 72-week study in patients treated with MXF or
placebo.
Methods: Sputum samples were collected from all 1149 patients in
the ITT population at all clinic visits. MXF susceptibility testing was
performed for Haemophilus spp., Streptococcus pneumoniae, Moraxella
catarrhalis, Klebsiella pneumoniae, Pseudomonas aeruginosa, and
Staphylococcus aureus from both treatment arms. MIC to a range of
antibacterial agents was determined by broth microdilution. Frequency
of isolation and changes in MIC distributions of speciﬁc pathogens were
compared for the MXF and placebo arms, among patients colonised with
these pathogens at randomisation.
Results: The most frequent isolates at randomisation were H. inﬂuenzae,
H. parainﬂuenzae, S. pneumoniae, S. aureus and P. aeruginosa. MXF
therapy achieved eradication in a majority of the patients colonised by
H. inﬂuenzae, H. parainﬂuenzae, and S. pneumoniae, but not in those
colonised by S. aureus or P. aeruginosa. Spontaneous eradication was
seen at a signiﬁcantly
lower frequency in the placebo group (Table).
Isolate Patients with isolate
N at EOT/N at randomisation (%)
Median net change in MIC value (mg/L)
(from randomisation to EOT)
MXF Placebo P valuea MXF Placebo
H. inﬂuenzae 4/24 (17) 28/36 (78) <0.001 None None (−0.06)
H. parainﬂuenzae 9/27 (33) 14/22 (64) 0.047 None None (−0.03)
S. pneumoniae 6/15 (40) 12/16 (75) 0.073 None None
S. aureus 5/8 (63) 2/11 (18) 0.074 None (−0.02) None (−0.02)
P. aeruginosa 7/9 (78) 11/8 (138) 1.000 None (−0.5) 1.625
aFisher’s exact test.
MIC values to MXF remained stable for most bacterial species isolated
from sputum during the study. For S. aureus and P. aeruginosa there were
transient increases in MIC in some isolates during the study, but these
appeared to be independent of treatment arm or timing of treatment.
Conclusion: The higher clinical efﬁcacy of intermittent MXF therapy
in the reduction of exacerbations in COPD correlates with a higher
eradication of primary pathogens compared to placebo treatment. There
was no consistent MXF-related increase in MIC during the 48-week
PULSE study or the 24-week follow-up period. Therefore chronic
intermittent therapy with MXF was effective in reducing bacterial burden
without an associated increase in the emergence of resistant bacteria
during the treatment period.
P1790 Safety and clinical outcomes of high-dose daptomycin
(>6mg/kg)
K. Lamp °, L. Friedrich (Lexington, US)
Objectives: Daptomycin, a bactericidal, concentration-dependent antibi-
otic, has been administered safely to healthy volunteers in doses as high
as 12mg/kg for 14 days and to patients (pts) with skin and soft-tissue
infections (SSTI) at 10mg/kg for 4 days. The objective of this study
was to describe the use of daptomycin at doses >6mg/kg for extended
durations.
Methods: Data were collected in CORE (2005 to 2007 program years),
a retrospective, observational registry of pt experience in the US. All pts
who received daptomycin >6mg/kg were evaluated for safety through
30 days after completing daptomycin and efﬁcacy at end of daptomycin
therapy. Clinical outcomes (cure, improved, failure, and nonevaluable)
were assessed using protocol-deﬁned criteria. Success was deﬁned as
cure or improved. Nonevaluable pts were excluded from the efﬁcacy
analysis.
Results: Two hundred thirty-one of 3617 (6%) received daptomycin
>6mg/kg; 94 of 231 (41%) patients received doses 8mg/kg. Overall,
the infection types with the highest use of doses >6mg/kg were infective
endocarditis (IE, 11%) and bacteraemia (BAC, 8%). The percentage
with BAC, SSTI and IE were: 75/231, 32%; 64/231, 28%; and 17/231,
7%, respectively. The most common causative pathogens were S. aureus
(83/231, 36%; methicillin-resistant 72%) and Enterococcus sp. (66/231,
29%; vancomycin-resistant 59%). Fifty percent were female, 39% were
66 yrs old, 24% initial creatinine clearance <30mL/min, 12% on
dialysis, and 27% received daptomycin in an intensive care unit. Diabetes
was present in 28% and 18% had a history of cancer. The median
(min, max) daptomycin duration of therapy was 10 days (1, 90; 71%
5 days). Twelve (5%) of the 231 pts experienced 1 or more adverse
events (AE) possibly related to daptomycin. Fifteen (6.5%) of the 231 pts
discontinued daptomycin due to AE; however, it was due to a possibly
related AE in only 6 (2.6%). An elevated creatine phosphokinase (CPK)
was reported in 4 (1.7%) patients. One hundred seventy-three (75%)
patients were considered evaluable for efﬁcacy. The overall clinical
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success rate was 91% (35% cured, 55% improved). The success rates
by infection type were: BAC (46/50; 92%), SSTI (46/51; 90%), and IE
(9/13; 69%); success was not different by dose (>6 to <8 vs. 8mg/kg).
Conclusion: Daptomycin was well tolerated and effective in BAC, SSTI
and IE at doses of >6mg/kg. Further studies of daptomycin at doses
above 6mg/kg are warranted.
P1791 Safety of daptomycin in the treatment of osteomyelitis:
results from a registry
J. Crompton, D. North, S. McConnell, K. Lamp ° (Lexington, US)
Objectives: Antibiotic safety is a major determinant in selecting
osteomyelitis therapy. Recent publications highlight the preliminary
experience with daptomycin in the treatment of osteomyelitis and
orthopedic-related infections. Additional data describing the long-term
safety of daptomycin treatment is valuable.
Methods: Data were collected as part of the Cubicin Outcomes Registry
and Experience (CORE) program, a retrospective, observational,
multicentre study, to describe the clinical use of daptomycin. Efﬁcacy
at the end of daptomycin therapy was determined by each centre’s
investigator as cure, improved, failure, or nonevaluable. Patients (pts)
who had a diagnosis of osteomyelitis were selected from the combined
2005 and 2006 CORE database as the safety population. Pts who had an
evaluable clinical outcome, received greater than 3 days of daptomycin
therapy, and had appropriate ﬁnal dose adjustment for renal function
were included in efﬁcacy population.
Results: Three hundred twenty-seven pts met study criteria for safety,
188 (57%) received 6mg/kg and 139 (43%) received <6mg/kg. Two
hundred and twenty-two (68%) pts received daptomycin for 21 days
or more. Thirty-one (10%) pts experienced adverse events classiﬁed as
possibly related to daptomycin. Serious adverse events were reported
less frequently in pts receiving 6mg/kg (4%, 8/188) than those
receiving <6mg/kg (9%, 13/139); P = 0.07. The incidence of adverse
events classiﬁed as possibly-related, whether serious or non-serious, were
similar regardless of daptomycin dose. No difference was observed in
the rate of CPK elevations by daptomycin dose 9/188 (5%) 6mg/kg);
6/139, (4%) <6mg/kg. Pts receiving ﬁnal doses of 6mg/kg or more
showed a trend of higher improved rates (96%, 137/143) than those
receiving lower doses (90%, 96/107), P = 0.08.
Conclusion: These data suggest that daptomycin is well-tolerated
at higher dosages and for the longer therapy durations needed for
osteomyelitis. Doses of daptomycin of 6mg per kg or greater may be
associated with greater clinical improvement. Ideally, these results should
be conﬁrmed via a prospective clinical trial.
P1792 CANVAS-2: randomised, double-blinded, phase 3 study
(p903–07) of the efﬁcacy and safety of ceftaroline versus
vancomycin plus aztreonam in complicated skin and
skin-structure infections
M. Wilcox, R. Corey, G.H. Talbot, T. Baculik °, D. Thye (Leeds, UK;
Durham, Alameda, US)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) has
emerged as a common cause of complicated skin and skin structure
infections (cSSSI). Increasing antibiotic resistance and signiﬁcant
morbidity in cSSSI have led to a need for new effective and
safe therapies. Ceftaroline (CPT), a novel parenteral cephalosporin
with excellent in vitro activity against MRSA, multi-drug resistant
Streptococcus pneumoniae, and many Gram-negative pathogens, was
evaluated as therapy of cSSSI. The primary objective was to determine
noninferiority (lower limit of 95%CI −10%) in clinical cure rate of CPT
to vancomycin plus aztreonam (V/A) in clinically evaluable (CE) and
modiﬁed intent-to-treat (MITT) populations.
Methods: Adult patients with cSSSI requiring IV therapy received CPT
600mg q12 h or V 1 g plus A 1 g q12 h for 5−14 days (randomised
1:1). Clinical and microbiological response, adverse events (AEs), and
laboratory tests were assessed.
Results: Of 694 enrolled patients, 348 received CPT and 346 V/A.
Baseline characteristics of treatment groups were comparable. Clinical
cure rates were similar for CPT and V/A in CE (92.2%, 271/294 vs.
92.1%, 269/292; 95%CI, −4.4 to 4.5) and MITT (85.1%, 291/342 vs.
85.5%, 289/338; 95%CI, −5.8 to 5.0) populations, respectively. Clinical
cure rate for MRSA cSSSI was 91.4% (64/70) for CPT and 93.3%
(56/60) for V/A. Microbiological success rate was also similar for CPT
and V/A overall and for MRSA. The rates of AEs, SAEs, deaths and
discontinuations due to AEs were similar for CPT and V/A. Most
common AEs for CPT and V/A were diarrhoea (6.5% vs. 4.4%), nausea
(6.2% vs. 5.6%), headache (5.3% vs. 5.3%), and pruritus (3.8% vs.
8.3%), respectively.
Conclusions: CPT had high clinical cure and microbiological success
rates, was efﬁcacious against MRSA and other common cSSSI
pathogens, and was well tolerated. CPT has the potential to provide
a monotherapy alternative for treatment of cSSSI.
P1793 Clinical cures with oral linezolid versus intravenous
vancomycin in propensity score-matched subjects with
complicated skin and soft-tissue infections proven to be due
to methicillin-resistant Staphylococcus aureus
K. Itani °, A. Reisman, P. Biswas, H. Bhattacharyya, A. Baruch,
C. Cassino (Boston, New York, US)
Objectives: Linezolid (LIN), an oxazolidinone antibiotic, is 100%
bioavailable in oral (PO) and intravenous (IV) formulations. Clinical
outcomes of treatment of methicillin-resistant Staphylococcus aureus
(MRSA) complicated skin and soft tissue infections (cSSTI) with PO
LIN vs IV vancomycin (VAN) have not been well described. Data from
a previously reported randomised, open-label study of LIN vs VAN in
proven MRSA cSSTI allow post hoc comparison of outcomes in PO LIN-
vs matched IV VAN-treated subjects.
Methods: Subjects 18 y were randomised to LIN (600mg IV or
PO q12 h) or VAN (15mg/kg IV q12 h, adjusted for CLcr) for
7−14 d. Subjects who met key protocol criteria were included.
Characteristics differentiating PO LIN (n = 95) from IV LIN (n = 134)
subjects were identiﬁed by logistic regression. PO LIN and IV VAN
subjects were retrospectively matched based on region, age, presence
of diabetes, hospitalisation, and signs/symptoms using propensity score
(PS) methodology. Clinical outcomes in PO LIN and IV VAN subgroups
were compared at end of study (7−10 d after last dose).
Results: Of 95 PO LIN and 210 IV VAN subjects evaluated, 82 per
group had comparable PS. Mean age was 50 vs 48 y; 82.9% vs 84.1%
of subjects were hospitalised, and 26.8% vs 25.6% had diabetes (PO
LIN vs IV VAN, respectively). Number of signs/symptoms was similar
in both groups. Clinical cure was achieved in 96.3% (78/81) of PO
LIN subjects vs 87.8% (72/82) of IV VAN subjects (Chi square test,
p = 0.045; Fisher exact test, p = 0.079). 1 PO LIN subject had unknown
response. Median length of hospital stay was similar for both groups
(3.5 d PO LIN; 4 d IV VAN). Overall adverse event (AE) rates were
similar in each group (58.5% PO LIN [48/82] and 59.8% VAN [49/82]),
with gastrointestinal symptoms more prevalent in PO LIN and allergic
symptoms more prevalent in IV VAN.
Conclusions: PO LIN showed comparable clinical cure rates to those
achieved with IV VAN in PS-matched subjects with proven MRSA
cSSTI. Overall AEs in both groups were similar, and consistent with
the known safety proﬁle of each drug.
P1794 Results of a phase 2 study comparing two doses of
delaﬂoxacin to tigecycline in adults with complicated skin
and skin-structure infections
W. O’Riordan, J. Surber, P. Manos, P. Mehra, S. Babazadeh, S. Hopkins,
E. Burak ° (San Diego, Columbus, Santa Ana, New Haven, US)
Objectives: Delaﬂoxacin (DFX) is an investigational ﬂuoroquinolone
active against a variety of Gram-positive bacteria, including methicillin-
and quinolone-resistant strains of Staphylococcus aureus (MRSA,
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QRSA). Two doses of DFX were compared to a standard dose of
tigecycline (TIG) in patients with complicated skin and skin structure
infections (cSSSI).
Methods: A multicentre, randomised, double-blind trial enrolled adults
with the following: wound infections following surgery, trauma, burns
or animal/insect bites; abscesses; or cellulitis. Patients were randomised
1:1:1 to receive either DFX 300mg IV BID, DFX 450mg IV BID,
or TIG, 100mg IV×1, followed by 50mg IV BID; randomisation was
stratiﬁed by infection type. Duration of therapy was 5 to 14 days. The
primary efﬁcacy analysis, performed on the clinically evaluable (CE)
population at the Test-of-Cure (TOC) visit (14 to 21 days after the ﬁnal
dose of study drug), compared the clinical response rates in the DFX
and TIG arms. Clinical response rates in the two DFX treatment arms
were also compared. The Fisher exact test was used for the comparisons.
Results: Of the 150 patients randomised, 68% were male; the mean age
was 40±14.5 yrs. Thirty-six percent had cellulitis, 33% had abscesses
and 31% had wound infections; 111 (74%) patients had pathogens
identiﬁed at baseline. S. aureus (95) was the most frequent isolate; 72%
(68/95) were MRSA (MIC90 values, in mcg/mL, were as follows: DFX
= 0.06, TIG = 0.12, ciproﬂoxacin = 16, levoﬂoxacin = 4, linezolid =
1). Overall, the most frequent adverse events were nausea, vomiting
and diarrhoea; the 300mg BID DFX arm was the best tolerated of the
regimens.
Conclusions: DFX, dosed at either 300mg BID or 450mg BID, was as
effective as TIG 50mg BID when used to treat adults with a variety of
cSSSIs, including those caused by MRSA and QRSA.
Percent Clinical Cure at TOC
Population DFX 300 BID DFX 450 BID TIG 50 BID
Clinically evaluable 97.2% 92.5% 91.20%
p= 0.3498* p = 1.0000*
p = 0.6170+
Modiﬁed Intent-to-Treat 89.8% 90.2% 82.00%
p= 0.3881* p = 0.2632*
p = 1.0000+
*p value for comparison between DFX and TIG group.
+p value for comparison between DFX groups.
P1795 Randomised, placebo-controlled phase III trial of docetaxel
plus carboplatin with or without levoﬂoxacin prophylaxis in
elderly patients with advanced non-small cell lung cancer:
The APRONTA Trial
N. Dickgreber °, S. Nagel, K. Roscher, W. Schuette (Hanover, Halle,
Berlin, DE)
Objectives: Elderly patients receiving chemotherapy are more likely than
younger patients to experience febrile neutropenia and infection. Prophy-
lactic ﬂuoroquinolone administration during chemotherapy reduces the
rate of febrile neutropenia, infection and hospitalisation vs placebo. The
aim of this study was to examine the effect of levoﬂoxacin prophylaxis
on infection rates during chemotherapy with docetaxel plus carboplatin
in elderly patients with advanced non-small cell lung cancer (NSCLC).
Methods: This was a randomised, double-blind, placebo-controlled
Phase III study. Patients aged 65 years with previously untreated,
histologically/cytologically proven stage IIIB/IV NSCLC and normal
cardiac, renal, hepatic and haematological function were included. Active
infection or antibiotics 72 hours before inclusion was not permitted.
Patients were randomised to receive docetaxel (75mg/m2 intravenous
[IV], Day 1) plus carboplatin (AUC 6 IV, Day 1) every 3 weeks, plus
either placebo or levoﬂoxacin (500mg oral [po], once daily) on Days
5−11. The primary endpoint was grade 3/4 infection rate or grade 1/2
infection rate with infection therapy.
Results: Overall, 192 patients (median age 70 years; 80% male; Eastern
Cooperative Oncology Group performance status 0/1/2 in 36%/55%/9%)
were randomised to docetaxel plus carboplatin and either levoﬂoxacin
(n = 99) or placebo (n = 93); 5 patients received no treatment and were
excluded from the ITT population. The rate of grade 3/4 infection was
27.5% (95%CI: 19.3–39.0%) with levoﬂoxacin vs 36.7% (95%CI: 27.1–
48.0%) with placebo. Median time to ﬁrst infection was 67 days for
levoﬂoxacin vs 46 days for placebo. The between-group difference in
median time to ﬁrst infection was greater for patients aged over 70 years
(69 vs 27 days for levoﬂoxacin and placebo, respectively). Grade 3/4
infection occurred in 8% of patients receiving levoﬂoxacin vs 26% of
patients receiving placebo; there was one grade 5 infection in each group.
Pneumonia and sepsis occurred in 12% and 1% of levoﬂoxacin patients,
respectively, vs 22% and 4% of the placebo group. Grade 3/4 mucositis,
nausea and vomiting occurred in 5%, 3% and 3% of levoﬂoxacin
patients, respectively, vs 0%, 1% and 0% of placebo patients. Efﬁcacy
was similar in both groups.
Conclusions: Levoﬂoxacin prophylaxis is well tolerated in elderly
patients receiving docetaxel plus carboplatin chemotherapy and reduces
the rate of infection compared with placebo.
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P1796 Comparative antimicrobial susceptibility of bioﬁlm versus
planktonic forms of Salmonella spp. from children with
gastroenteritis
K. Papavasileiou °, H. Papavasileiou, A. Voyatzi, S. Chatzipanagiotou
(Athens, GR)
Bioﬁlms are involved in a variety of bacterial and fungal infections.
Bioﬁlm bacteria produce an extracellular polymeric substance (ESP),
which protects them against antimicrobial agents, thus leading to a multi-
drug clinical resistance and therapeutic failure. Numerous studies have
shown that Salmonella is capable of adhering and forming bioﬁlms on
metal, glass, or rubber surfaces.
Objective: This study aimed to detect the production of bioﬁlms
by clinical strains of Salmonella spp. isolated from children with
gastroenteritis and to compare the antimicrobial susceptibility of
planktonic versus bioﬁlm forms.
Methods: During a three year period (2005–2007) 194 strains of
Salmonella were collected from hospitalised children with gastroenteritis
as well as from children presenting at the outpatient department, aging
from 1−14 years. The isolation and identiﬁcation of Salmonella spp.
was performed by conventional bacteriological methods. MIC was
determined by the Broth Dilution Method (macrodilution) according
to the guidelines of CLSI. Bioﬁlm formation was detected by using
silicone disks. The strains producing bioﬁlms were further tested for their
antimicrobial susceptibility by using a modiﬁed broth dilution method.
Results: Bioﬁlm formation was detected in 109 out of 194 Salmonella
strains (56%). Planktonic bacteria were signiﬁcantly more susceptible to
the antimicrobials as compared to the bioﬁlm bacteria. The resistance
rates respectively for the planktonic and the bioﬁlm forms were as
follows: gentamicin 0% and 89.9%, ampicilln 12.8% and 84.4%,
coamoxiclav 0% and 51.4%, cotrimoxazole 0.9% and 63.3%, cefuroxime
7.4% and 63.3%, cefotaxime 0.9% and 23.8%, imipenem 0% and 7.3%,
ciproﬂoxacin 0% and 2.8%, moxiﬂoxacin 0% and 2.8%.
Conclusions: The great majority of the bioﬁlm forms were susceptible
to the ﬂuoroquinolones, while they showed high level resistance
to ampicillin, coamoxiclav and cotrimoxazole. The present study
demonstrated a high rate of bioﬁlm production among the clinical
isolates of Salmonella spp., as well as a signiﬁcant association of the
bioﬁlm forms with increased antimicrobial resistance. This phenomenon
might be a cause of clinical therapeutic failure in Salmonella infections,
despite the in vitro antimicrobial susceptibility of the causative bacterial
strains.
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P1797 Evaluation of aggregative adherence and bioﬁlm formation
in b-lactamase producing Proteus mirabilis isolates from
different clinical settings in Italy
G. Fugazza, E. Nucleo, M. Debiaggi, R. Migliavacca, M. Spalla,
F. Luzzaro, L. Pagani ° (Pavia, Lecco, IT)
Objectives: P. mirabilis is the second most relevant uropathogen and
urinary tract infections (UTIs) caused by TEM-92 ESBL and CMY-
16 CBL producers are increasing in Italian settings. In catheterised
patients UTI may become chronic, with a microbial persistence maybe
due to both antibiotic resistance and adhesion. We investigated the
bioﬁlm formation and the aggregative adherence of TEM-92 and CMY-
16 producers.
Methods: 20 epidemiologically distinct clinical isolates of P. mirabilis
collected during 2003–2007 from Italian hospitals and nursing homes,
including CMY-16 and TEM-92 producers and b-lactamase (BL)
negative strains, were examined for bioﬁlm formation by crystal violet
assay in different culture conditions and in presence of imipenem
(IMP) or piperacillin/tazobactam (TZP) sub-MIC concentrations. All
strains were susceptible to IMP and TZP by conventional tests. The
presence of mrpA gene encoding for the major ﬁmbrial subunit of MR/P
ﬁmbriae was investigated by PCR. 4 selected strains were also tested for
adherence to LLC-MK2 epithelial cells grown on a coverslip.
Results: All strains resulted proﬁcient in bioﬁlm formation which
was favoured by nutrient-deﬁcient medium (urine). Bioﬁlm formation
was similar for CMY-16 and TEM-92 producers; on the contrary, a
fewer bioﬁlm formation was observed in BL negative strains. Sub-
MIC concentrations of IMP and TZP stimulated bioﬁlm increase in all
strains. mrpA gene was detected in all strains; the 4 strains studied
for adherence to LLC-MK, after 1 h of incubation, showed few bacteria
forming aggregates in intercellular spaces and 75% of bacteria adhered to
the coverslips, instead after 4 hrs great adherence in intercellular spaces
and few bacteria on cells, especially arranged in chains along the border
of the cytoplasm, were observed. We found differences in arrangement
on coverslips among the 4 strains tested.
Conclusions: All BL producers, regardless of the enzyme type, resulted
equally proﬁcient in bioﬁlm production that increased in presence of
sub-MIC concentrations of IMP and TZP, b-lactams to wich they
resulted susceptible; while the BL negative strains showed a low
ability to produce adhesion factors. Cellular adherence assays showed a
preferential adhesion trend to inert surfaces rather than to epithelial cells.
Altough the results didn’t fully support a direct correletion between BL
production, bioﬁlm and persistence, both these mechanisms contribuite
to UTIs chronicness
P1798 Bioelectric effect decreases alginate production in
Pseudomonas aeruginosa bioﬁlms
K. Hamdi, A. Shoae Hassani ° (Tehran, Fars, IR)
Objectives: Low electrical currents are able to increase biocides activity
against microorganisms especially in bioﬁlms. Here we report the
enhanced activity of effective antibiotics by bioelectric effect against
the more resistant bioﬁlm of Pseudomonas aeruginosa due to inhibiting
the extracellular alginate polymer production.
Methods: Pseudomonas aeruginosa bioﬁlm was designed on a
membrane suspended between two electrode plates in an electrical
colonisation cell. Amikacin (4mg l−1) and gentamicin (10mg l−1) were
attempted on bioﬁlms at ten times of their MIC for 24 h in the presence of
0 and 9mAcm−2 current density. The alginate production was measured
at these concentrations and in combination with bioelectric effect.
Cultures were stirred with a magnetic bar for 3 to 5 h, and bacterial
cells were removed by centrifugation for 1 h at 18,000×g at 4ºC. The
clear supernatant was heated for 30min at 80ºC to kill viable bacteria and
passed through a 0.45m ﬁlter. Crude alginate was precipitated from the
supernatant by addition of cold absolute ethanol to a ﬁnal concentration
of 80% (v/v). The results were compared in pairs using the SPSS method.
For signiﬁcant differences, P 0.05.
Results: The antibiotics alone reduced the bioﬁlm population and in the
presence of bioelectric effect the viable population was further reduced
by gentamicin and especially by amikacin due to 47% and 60% reduction
in alginate production, respectively.
Alginate production in P. aeruginosa strain 8821 after treatment with 0
and 9mA/cm2 electrical current in combination with antibiotics.
Electric current Antibiotics Time
8 16 24
9mA/mm2 Amikacin 1.44 1.11 0.63
DC Gentamicin 2.27 1.64 0.91
No antibiotic 2.54 2.86 3.13
0mA/mm2 Amikacin 2.15 1.92 1.10
DC Gentamicin 2.33 2.10 1.94
Control No antibiotic 2.79 3.22 3.48
Conclusion: The bioelectric effect reduced the alginate production in
P. aeruginosa and enhanced the penetration of effective antibiotics into
the bioﬁlms.
P1799 Lack of differences in mutation frequency rates between
cystic ﬁbrosis Pseudomonas aeruginosa isolates in
planktonic and bioﬁlm type of growth
M. Garcia-Castillo °, M.C. Turrientes, M.I. Morosini, F. Baquero,
R. Canton, R. del Campo (Madrid, ES)
Objective: To compare the mutation frequency of Pseudomonas
aeruginosa isolates from cystic ﬁbrosis (CF) patients using both
planktonic and bioﬁlm type of growth.
Methods: A total of 42 P. aeruginosa isolates recovered from sputum
samples of 10 CF patients attending our hospital during 2004–2008
were studied. Genetic relatedness was performed by PFGE-XbaI and
antibiotic susceptibility of planktonic cultures was determined by the
standard CLSI agar dilution method. Bioﬁlm formation was developed
along 3 days on the surface of nitrocellulose ﬁlter disks inoculated
with 100ml of an overnight LB broth culture. Mutants were detected
on rifampin-containing (300mg/ml) LB agar plates from both types
of cultures: 10ml LB broth of the planktonic culture obtained after
18-h incubation under shaking, and the whole nitrocellulose bioﬁlm-
culture eluted with 0.5ml of saline. To determine viable cells, different
dilutions of the two-types of original inocula were plated onto BHI agar.
Mutation frequencies were expressed as the ratio of no. mutants/no.
viable cells. All experiments were performed in triplicate and results
correspond to the mean value. The P. aeruginosa PAO1 (normomutator)
and PAO1deltamutS (hypermutator) strains were included as controls.
Results: Eighteen PFGE patterns were found among the 42 isolates,
being 3 pulsotypes present in two different patients. Antibiotic suscepti-
bility tests demonstrated that although being multi-resistant, all isolates
were susceptible to 100mg of rifampin per ml. In general, a similar
mutation frequency rate was detected when considering planktonic
cultures (5×10−6 to 6.2×10−10, mean: 4.8×10−7) or when using bioﬁlm
growing cultures (3.3×10−6 to 3.3×10−9, mean: 2.7×10−7). However, in
28 strains the mutation frequency rate decreased (mean value, 4.6 times)
in bioﬁlm-growing cultures while in the other 14 strains it increased
(mean value 4.5 times). For the PAO1deltamutS strain, mutation rate
values were 1×10−6 to 8×10−7 in planktonic and bioﬁlm type of growth,
respectively, being of 2.5×10−8 to 7.9×10−9 for the PAO1 strain.
Conclusion: The mutation frequency rate to rifampin of CF-P. aerug-
inosa isolates growing in planktonic conditions were similar to that
obtained in bioﬁlm-growing conditions. This result indicates that other
factors different that bacterial type of growth might inﬂuence in the
increase of mutation frequency of P. aeruginosa in CF patients.
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P1800 Mixed bioﬁlms formed by Haemophilus inﬂuenzae and
Streptococcus pneumoniae and expression of certain
bioﬁlm-related genes
E. Kulmuni, P. Asumaniemi, T. Kaijalainen, T. Tapiainen, M. Uhari,
M. Leinonen, A. Saukkoriipi ° (Oulu, FI)
Objectives: Nontypeable Haemophilus inﬂuenzae (NTHi) and Strepto-
coccus pneumoniae (Pnc) cause otitis media, which has been suggested
to be caused by bacteria residing in bioﬁlms. Both NTHi and Pnc have
been shown to be able to form bioﬁlms. We studied bioﬁlm formation
of mixed cultures of Hi and Pnc in vitro and the expression of certain
genes that have been associated to the bioﬁlm form of growth in these
bacteria.
Methods: Four H. inﬂuenzae (Hi; three NTHi and one type b) and 4 Pnc
isolates (two unencapsulated, two encapsulated) were grown separately
and combined on polystyrene microwell plates for 5, 18, and 22 h.
For each time point there was one plate for crystal violet staining and
another for RNA extraction. All strains and combinations were tested in
triplicate. The expression levels of peroxiredoxin-glutaredoxin (pdgX)
and outer membrane protein P6 genes of Hi and autolysin (lytA) and
penicillin-binding protein 2x (pbp2x) genes of Pnc were studied by
relative quantitative PCR where the 16 s rRNA genes of Hi and Pnc
were used as reference genes.
Results: At 18 h, the unencapsulated Pnc isolates formed bioﬁlms
detectable by crystal violet staining whereas the Hi isolates did not.
When an unencapsulated Pnc was grown together with an NTHi and Hib
isolate, the OD540 value of the bioﬁlm decreased from 0.31 to 0.07 and
0.09. However, when the unencapsulated Pnc was grown together with a
capsulated Pnc, no difference was seen. Differences in gene expression
were seen at 5 h. The mean expression levels of P6 were 3.79 and 3.32
in two of the nontypeable Hi isolates and 0.20 in the Hib isolate. When
an unencapsulated Pnc isolate was grown with the NTHi and Hib, the
mean expression level of P6 was 5.98 and 3.26, respectively. When the
NTHi and Hib isolates were grown together, no increase in the expression
levels were seen as compared to the NTHi alone (3.94 vs. 3.79). The
expression of lytA and pbp2x at 5 h in one of the unencapsulated Pnc
isolates were 1.38 and 0.59, respectively. When an NTHI or Hib was
grown together with this isolate, the expression of lytA decreased to
0.41 and 0.37, respectively, and pbp2x to 0.13 and 0.26, respectively.
Expression of these two genes in the other Pnc isolates was below 0.5
when grown separately and together with Hi.
Conclusion: Unencapsulated Pnc and Hi affect each other’s bioﬁlm
formation and gene expression in vitro. Mixed bioﬁlms may play a role
e.g. in the pathogenesis of otitis media.
P1801 In vitro interference of cefditoren on slime production by
Streptococcus pneumoniae
J.R. Maestre, M. Mateo, M.J. Gimenez, L. Aguilar °, M.L. Mendez,
J.J. Granizo, L. Alou, P. Coronel, J. Prieto (Madrid, ES)
Objectives: To explore the in vitro effect of cefditoren (CDN) on
slime production by slime-producing Streptococcus pneumoniae strains
belonging to different serotypes and with different CDN MICs.
Methods: Eleven S. pneumoniae isolates with the following CDN MICs
(mg/l) were used: 0.015 (serotypes 23A and 21), 0.03 (serotype 31), 0.06
(serotype 42), 0.25 (serotypes 6B and 35B) and 0.5 (serotypes 9V − 2
strains − 14, 19A and 23F). Slime production was assessed as previously
described (J Clin Microbiol 1985;22:996–1006), with modiﬁcations, in
microtiter plates with HTM in the absence of CDN (basal) and in
the presence of CDN 0.03mg/l, by measuring optical density (OD)
at 450 nm using an spectrophotometer. S. pneumoniae R6 was used as
positive control and non-inoculated HTM broth as negative control. All
experiments were performed 12 times and mean values were considered.
Results: The Figure shows mean OD corresponding to basal determi-
nations (triangles, continuous line) and determinations in the presence
of CDN (squares, dotted line) for the eleven strains distributed by CDN
MIC.
Conclusion: CDN at supra-inhibitory concentration (strains with MIC
of 0.015mg/l), inhibitory concentration (strain with MIC of 0.03mg/l)
or sub-inhibitory concentration (strains with MIC of 0.06–0.5mg/l),
reduced slime production in slime-producing S. pneumoniae strains,
regardless the serotype or the magnitude of basal slime production.
P1802 Macrophage interactions with bioﬁlm-producing
Staphylococcus epidermidis
A. Spiliopoulou, F. Kolonitsiou, M. Krevvata, I. Spiliopoulou,
G. Dimitracopoulos, E.D. Anastassiou ° (Patras, GR)
To compare immune responses of bioﬁlm-producing S. epidermidis
existing either in planktonic or in bioﬁlm phase in terms of IL-
12p40 production, bacterial adhesion on macrophages and resistance to
phagocytosis process.
ATCC35983 and two clinical bioﬁlm-positive, ica-positive S. epidermidis
stains were used. Planktonic phase bacteria were obtained after 2 h
incubation in Tryptic Soy Broth (TSB); whereas bioﬁlm phase bacteria
after 24 h incubation of bacterial suspensions and homogenisation of
bacterial cells embedded in bioﬁlm attached to the bottom of the tube.
Monocytes were separated from human peripheral blood mononuclear
cells by plastic adherence and differentiated in macrophages. Phagocy-
tosis experiments were performed by co-incubation of cells with bacteria
at 1:10 ratio for 20, 60, 90 and 120min; removal of extracellular bacteria
and further incubation in antibiotic supplemented medium. Intracellular
bacteria were counted by serial dilutions on blood agar plates. For
measuring bacterial adhesion to macrophages, a modiﬁed ELISA was
used where macrophages cultured on 96-well plates were incubated
with biotinylated bacterial suspensions. For cytokine determination,
macrophages cultured on 24-well plates were stimulated with bacteria at
1:10 and 1:25 ratio for 45min, extracellular bacteria were removed and
macrophages were further incubated for 12 h. IL-12p40 concentrations
were measured in supernatants by commercial ELISA kit.
Bioﬁlm phase bacteria showed increased adhesion on macrophages
compared to planktonic phase bacteria (7.6±0.02×106 for bioﬁlm phase
bacteria vs 3±0.06×106 CFU/macrophage monolayer for planktonic
phase bacteria). Bioﬁlm phase bacteria were internalised in greater
proportion (10-fold) than planktonic phase bacteria and showed higher
degree of intracellular survival (Table 1). Planktonic phase bacteria
elicited higher amounts of IL-12p40 than bioﬁlm phase bacteria
(planktonic phase 645±95 and 1,029±48 pg/ml vs bioﬁlm phase 231±72
and 396±26 pg/ml for 1:10 and 1:25 ratio respectively) (p< 0.05).
Phase % intracellular survival
Compared to initial inoculum Compared to 2 h intracellular survival
20min 60min 90min 120min 4 h 12 h 24 h 48 h 3 days 5 days
Bioﬁlm 39 31 27 15 66 40.2 24 1.5 0.8 0.05
Planktonic 3.64 2.3 1.3 0.4 11.4 2.05 1.8 0.4 0.11 0
Bioﬁlm phase bacteria are efﬁciently internalised but seem to be more
resistant to killing by macrophages than their planktonic counterparts.
Internalisation of bioﬁlm phase bacteria does not promote IL-12
production and macrophages can not manage an efﬁcient Th1 response.
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These ﬁndings could contribute to insight mechanism of resistance of
bioﬁlm-associated infections to immune system responses.
P1803 The effect of different proteases on staphylococcal bioﬁlm
V. Caﬁso °, T. Bertuccio, S. Stefani, R. Papa, G.L. Scoarughi, A. Cellini,
M. Artini, L. Selan (Catania, Rome, IT)
Objectives: The metalloprotease serratiopeptidase (SPEP) has been
proved to be effective in the treatment of bioﬁlm of different Gram-
positive bacterial species belonging to the Listeria and Staphylococcus
genera. Furthermore, SPEP has been used as an anti-inﬂammatory agent
for over 30 years. The analysis of surface protein proﬁles of treated
and untreated bacteria revealed that SPEP modulates speciﬁcally the
protein pattern acting on different adhesins and autolysins. In order to
highlight the mechanism of action of SPEP, different proteases, including
metalloproteases and serin-proteases, were tested and compared for their
capability to impair bioﬁlm formation and to modulate protein expression
of different staphylococcal strains.
Methods: Six Staphylococcus strains were studied, 3 S. epidermidis and
3 S. aureus. Bioﬁlm formation and surface protein pattern was evaluated
in the presence of the following proteases: SPEP, carboxypeptidase-A,
proteinase-K, trypsin, chymotrypsin. Bioﬁlm growth was assessed by
the Christensen method. Proteins were analyzed by SDS-PAGE and
zymography to evaluate modiﬁcations of the expression of autolytic
enzymes. The presence of ica locus and of genes involved in adhesion
and autolytic pattern was revealed by PCR. agr-typing was carried out
by RT-PCR.
Results: The effect of tested proteases was not related to the protease
category but was strain-dependent. SPEP, reducing the bioﬁlm growth
in 4 of 6 strains tested, is the more effective; in particular the effect
seemed to be proportional to bioﬁlm production. Moreover SPEP
treatment showed a limited modiﬁcation of surface protein patterns as
demonstrated by SDS-PAGE and zymogram analysis, while treatment
with serin-proteases induced a complete digestion of most of them. A
correlation between the action of SPEP and agr-type of different bacterial
strains is ongoing.
Conclusion: The degradation of staphylococcal surface proteins does not
necessarily result in bioﬁlm inhibition. Moreover, the action of proteases
is not related to the presence of icaADCB locus. In the strain more
sensitive to SPEP action, S. aureus 6538P, we investigated the agrD
expression, which markedly increases following SPEP treatment.
P1804 Sterilisation of staphylococcal bioﬁlms with delta-toxin plus
rifampin in a rat model
V. Pintens, R. Merckx, M. Shahrooei °, J. Van Eldere (Leuven, BE)
Objectives: Bioﬁlm-associated staphylococci are resistant to antibiotics,
making eradication difﬁcult. This may partly be due to low metabolic
activity of sessile bacteria. The agr (accessory gene regulator) operon
is a quorum-sensing system and may be involved in detachment of
staphylococci from bioﬁlm. We have previously shown that the agr-
encoded delta-toxin increases agr expression and metabolic activity in
bioﬁlm-bacteria. Here we investigated the effect of delta-toxin alone and
combined with rifampin on persistence of established S. epidermidis
bioﬁlms in vitro and in vivo.
Methods: In vitro bioﬁlms were grown in 96-well plates. Bioﬁlm
formation was quantiﬁed optometrically with 1% crystal violet. For
in vivo experiments we used a previously described rat model with
subcutaneously implanted catheters; the amount of bioﬁlm-bacteria was
determined by quantiﬁcation of gDNA copies of the housekeeping gene
guanylate monokinase via quantitative PCR. The effect of delta-toxin
was measured 24 hrs after administration unless otherwise speciﬁed.
Results: In vitro, treatment of 1-day old bioﬁlms with 10mg/ml delta-
toxin reduced the bioﬁlm cells with 2 log10 compared to controls. In
vivo, a single injection of 10mg delta-toxin at the place of catheter
implantation decreased cells in 1-day old bioﬁlms with 2 log10. The
level of reduction was smaller when bioﬁlms were older than 1 day
when treated and the effect of delta-toxin disappeared with time. No
signiﬁcant effect was observed in 7-days old bioﬁlms and the delta-
toxin effect had disappeared after 7 days. Incubation of 1-day old in
vitro bioﬁlms with delta-toxin plus rifampin (10mg/ml) had more effect
(2.50 log10) than each compound alone. This was also true in vivo;
delta-toxin plus rifampin (25mg/kg) gave a 3.81 log10 reduction. This
effect also diminished over time and had disappeared after 7 days. Three
consecutive doses of delta-toxin (24 hrs interval) reduced the number
of bioﬁlm-bacteria 3.5 log10 to 2.03 log10CFU/catheter at 24 hrs after
the 3rd injection. The effect again completely disappeared after 7 days.
Three consecutive doses of delta-toxin plus rifampin reduced the number
of bacteria 4.81 log10 to 0.69 log10CFU/catheter. However, no regrowth
was observed after 7 or 10 days.
Conclusion: We conclude that delta-toxin causes detachment and
increases susceptibility to antibiotics. Three consecutive treatments with
delta-toxin plus rifampin succeeded in sterilising the FBI.
P1805 Staphylococcus aureus bioﬁlm formation depends on the
S. aureus lineage
S. Croes °, R. Deurenberg, M.L. Boumans, P. Beisser, E. Stobberingh,
C. Neef (Maastricht, NL)
Objective: The aim of the present study was to examine the contribution
of the genetic background of both MRSA and MSSA to bioﬁlm
formation under physiologic glucose concentration (0.1%).
Methods: In vitro bioﬁlm formation of 228 clinical Staphylococcus
aureus commensal isolates of distinct clonal lineages was characterised
by the polystyrene crystal violet adherence assay. Additionally, 26 MSSA
isolates recovered from blood from individual patients and associated
with either MLST CC8 or CC7 (one of the main clonal lineages among
blood stream isolates in our hospital) were tested. These isolates were
considered as invasive strains. The genetic backgrounds were determined
by spa typing. The associated multilocus sequence typing (MLST) clonal
complexes (CCs) were allocated through the SpaServer, since it has been
shown that spa typing/ based upon repeat pattern (BURP) results are
in agreement with results obtained by MLST. Congo red agar (CRA)
screening was used as phenotypic detection of slime producing ability.
Furthermore, the accessory gene regulator (agr) types were determined
by a real-time multiplex PCR assay.
Results: Of all strains classiﬁed as strong bioﬁlm producers, MRSA and
MSSA associated with MLST CC8 produced markedly more biomass
under all tested glucose concentrations, i.e. 0%, 0.1%, 0.25% and 0.5%.
At 0.1% glucose, more than 60% of the S. aureus strains associated
with MLST CC8 produced thick bioﬁlms, compared to 0−7% for various
other clonal lineages. Strong bioﬁlm formation was not related with slime
formation, based on CRA screening. Additionally, S. aureus bloodstream
isolates associated with MLST CC8 and CC7 had similar bioﬁlm forming
capacities as their commensal counterparts.
Conclusions: Bioﬁlm formation of S. aureus on polystyrene surfaces
under physiologic glucose concentration (0.1%) was dependent on the
clonal lineage. The isolation site was not an (additional) predisposing
factor for strong bioﬁlm formation of S. aureus isolates associated with
MLST CC8 or CC7. CRA screening forms no alternative for crystal
violet staining to detect bioﬁlm formation. Furthermore, strong bioﬁlm
formation could not be attributed to a speciﬁc agr genotype. The agr
genotypes were strictly associated with the clonal lineages.
P1806 Agr-functionality and ability to form bioﬁlm in COL and
NRS149 Staphylococcus aureus
V. Caﬁso °, T. Bertuccio, S. Purrello, D. Spina, S. Chiarenza, G. Vizzari,
S. Stefani (Catania, IT)
Objectives: Sessile communities, known as bioﬁlm, represent the
microbial lifestyle responsible for the chronic-polymer-associated
infections caused by Staphylococcus aureus. The switch from planktonic
to sessile is due to the expression of genes involved in the initial
attachment and maturation of bioﬁlm. These events are modulated by
Bioﬁlms S523
a complex network of regulator-systems (agr-locus or master regulators
such as sarA) conditioned by environmental variables such as pH,
nutrient availability, O2-gradient and cellular-density.
We investigated the different levels of expression of four genes involved
in bioﬁlm formation (sarA, rnaIII, atl and icaA) in two isolates (COL,
NRS149 − kindly supplied by NARSA) of agr-I and II, showing different
abilities to form bioﬁlm, in particular, weak and strong.
Methods: Real time RT-PCR was performed using mRNA extracted us-
ing time-course experiments (exponential and post-exponential growth-
phases) to obtain a relative and comparative quantiﬁcation of sarA,
rnaIII, atl and icaA mRNA.
Results: Our results show that the expression of sarA and rnaIII
regulatory genes was higher during the exponential phase with respect
to the post-exponential one in both strains and, in particular, COL
presented a greater amount of mRNA transcripts than NRS149. In the
same strains the expression of atl (initial attachment gene) and icaD
(bioﬁlm accumulation genes) showed an opposite transcription proﬁle,
in fact, in COL it was higher in the post-exponential phase while in NRS
149 it was higher in the exponential-phase. Moreover, icaD mRNA was
more abundant in NRS149 than in COL.
Conclusions: Our data emphasize the hypothesis of a different
functionality of agr-II with respect to agr-I that could be correlated
to the diverse abilities to form bioﬁlm of the two agr-groups. agr-I, a
weak bioﬁlm producer, in fact, showed a poor expression of the initial
attachment and bioﬁlm maturation genes that increased only in the late
growth phase, while agr-II, a strong bioﬁlm producer, presented a high
expression of the same genes already in the early growth phase.
P1807 Bioﬁlm formation and combinations of virulence factors
among methicillin-resistant Staphylococcus aureus isolates
in a teaching hospital in Slovenia
V. Ursic °, V. Tomic (Golnik, SI)
Objectives: Staphylococci have been conﬁrmed to form bioﬁlms on
various biomaterials. The purpose of this study was to investigate
bioﬁlm formation among methicillin-resistant Staphylococcus aureus
(MRSA) in a teaching hospital in Slovenia and to assess the relationship
between bioﬁlm-forming capacities and virulence determinants/clinical
background.
Methods: A total of 105, randomly chosen, non-copy coagulase positive
staphylococcal strains, recovered from diverse clinical samples over an
8-year period from 1999 through 2007 were studied. We used the in vitro
microtiter plate assay to quantify bioﬁlm formation. We then investigated
the presence of several virulence determinants by polymerase chain.
Results: Six determinants (hla, hlb, fnbA, clfA, icaA, and agrII)
were found to be predominant among these isolates. Enhanced bioﬁlm
formation was conﬁrmed in hla-, hlb- and fnbA-positive MRSA isolates,
both individually and in combination.
Conclusion: Upon review of the associated medical record, we
concluded that the bioﬁlm-forming capacities of MRSA isolates from
catheter-related cases were signiﬁcantly greater than those from catheter-
unrelated cases. The percentage of hla-, hlb-, and fnbA-positive isolates
was higher among MRSA isolates from catheter-related cases than
those from catheter-unrelated cases. Our studies suggest that MRSA
colonisation and infection may be promoted by hla, hlb, and fnbA gene
products.
P1808 Association of accessory gene regulator locus with bioﬁlm
formation and methicillin-resistance in Staphylococcus
aureus
A. Ikonomidis °, A. Tsakris, A. Vasdeki, S. Xytsas, K. Malizos,
S. Pournaras, A. Maniatis (Larissa, Athens, GR)
Objectives: Pathogenicity of Staphylococcus aureus is coordinated by
the accessory gene regulator (agr) system. Previous studies indicate that
agr group II methicillin-resistant S. aureus (MRSA) may be related with
overproduction of bioﬁlm and reduced responsiveness to vancomycin.
The current study investigated the distribution of agr groups among
MRSA and methicillin-susceptible S. aureus (MSSA) as well as their
association with bioﬁlm formation, in a hospital environment that
experiences endemic occurrence of MRSA.
Methods: Forty-two MRSA and 32 MSSA non-repetitive isolates
recovered from clinical infections in a Greek university hospital were
tested. The presence and the type of the agr locus were determined
by PCR and restriction enzyme analysis. Quantitative determination of
bioﬁlm formation was performed using a reference microtitre assay.
Results were statistically compared to detect the association of agr
groups with methicillin resistance and bioﬁlm formation.
Results: agr groups I, II and IV were equally distributed among MRSA
and MSSA
populations, while agr group III was not detected in MRSA or MSSA.
agr group II MRSA isolates showed signiﬁcantly higher levels of bioﬁlm
production in comparison with MRSA isolates of the remaining agr
groups as well as with all three agr groups of MSSA isolates. Levels of
bioﬁlm production were independent of agr group in MSSA isolates.
Conclusion: The present ﬁndings suggest that in our S. aureus
population agr group II is simultaneously associated with both
bioﬁlm overproduction and methicillin resistance. This indicates another
infectious potential of isolates carrying this agr polymorphism.
P1809 Antibacterial activity of ozonised water and gaseous O3
against bioﬁlm
S. Tyski °, A. Kalicinska, A. Pietruczuk, E. Bocian, B. Bukowska,
M. Czajkowska, D. Bialoszewski (Warsaw, PL)
Objectives: Ozone antimicrobial activity is generally known, but its
activity against bioﬁlm remains not widely investigated. Specially
developed apparatus which allows ozone in statu nascendi production
from oxygen and preparation of ozonised water, has been applied in this
study.
The aim of this study was to analyse bactericidal activity of ozonised
water and gaseous O3 against selected clinical strains of Staphylococcus
aureus and Pseudomonas aeruginosa, grown in form of bioﬁlms on
microplates.
Methods: 18 bacterial strains were cultivated in Luria-Bertani (LB)
medium placed into microplate wells and incubated in 37ºC for up
to 72 h. Planctonic cells were removed and bacterial bioﬁlm layer
was treated with freshly obtained ozonised water or gaseous O3.
After various contact time of bacteria and ozone solution: from
30 sec to 4min, and gaseous O3: 20 and 40min, microplate wells
were washed to remove ozone. Alive bacterial cells were stained
with 3-(4,5-dimethyl-2-thiazolyl)-2,5 diphenyl-2H-tetrazolium bromide
(MTT). Parallely, appropriate bacterial bioﬁlms not treated with ozone
preparations were used as a control. After 2 h of staining, solution was
removed and bioﬁlm was solubilised by DMSO/glicyne buffer treatment.
Solution absorbance was measured at 554 nm.
The ozone concentration in ozonised water was determined by
iodometric titration using 0.02 mol/L solution of sodium thiosulphate.
Concentration of ozone determined chemically, which varied in the
range: 1.2−3.6 ug/mL, was compared with antibacterial activity of
ozonised water.
Results: Bioﬁlm of P. aeruginosa strains was formed earlier and more
intensively as compared with bioﬁlm of S. aureus. Different age bioﬁlms:
2 h (only P. aeruginosa strains) and 24 h, 48 h and 72 h (both groups
of strains), were treated by ozone preparations, in order to determine
sensitivity to this agent. Some variances between strains were noticed.
Ozonised water, produced by prototype apparatus, proved to be very
effective biocidal agent toward bacterial bioﬁlm, even after 30 sec of
contact. However, gaseous O3 was much less effective as biocidal agent.
Even after 40min of treatment, levels of alive S. aureus and P. aeruginosa
bioﬁlm cells were still considerable high.
Conclusion: Ozonised water as effective biocidal agent might be applied
for destruction of bacterial bioﬁlm.
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P1810 Antimicrobial activity of crude eucalyptus oil against
Staphylococcus aureus, MRSA, Escherichia coli,
Pseudomonas aeruginosa and Candida albicans grown in
planktonic and bioﬁlm cultures
E.R. Hendry °, T. Worthington, B.R. Conway, A.C. Hilton, P.A. Lambert
(Birmingham, UK)
Objectives: To investigate the antimicrobial efﬁcacy of crude eucalyptus
oil (EO) and determine the minimum inhibitory concentration (MIC)
and minimum bactericidal concentration (MBC) against a range of
microorganisms associated with healthcare associated infections (HAI),
when cultured in planktonic and bioﬁlm modes of growth.
Methods: Optimum bioﬁlms were established in sterile ﬂat bottom
microplates following 48 hour growth in Muller Hinton broth with
Sabouraud dextrose broth used for C. albicans. Bioﬁlm production
was veriﬁed for Staphylococcus aureus ATCC 6538, meticillin resistant
Staphylococcus aureus (MRSA) N315, Escherichia coli NCTC 10418,
Pseudomonas aeruginosa ATCC 15442 and Candida albicans ATCC
76615, using Congo red agar. Planktonic and 48 hour bioﬁlm cultures
of the ﬁve microorganisms were exposed to EO dissolved in Tween 80
(512–0.25mg/ml) in sterile round bottom and ﬂat bottom microplates
respectively. In line with CLSI (formerly NCCLS) guidelines, the MIC
and MBC/fungicidal concentrations of EO were determined for each
microorganism.
Results: Eucalyptus oil demonstrated a broad range of antimicrobial
activity, however it was signiﬁcantly more active against microorganisms
grown in planktonic culture, compared with bioﬁlm (P< 0.05). The
MIC/MBC (mg/ml) for EO against planktonic cultures were: S. aureus
4/8; MRSA 2/2; E. coli 8/8; P. aeruginosa 256/256; C. albicans 8/32.
MIC/MBC (mg/ml) for EO against bioﬁlms were: S. aureus 256/512;
MRSA 512/512; E. coli 16/256; P. aeruginosa >512/>512; C. albicans
8/32.
Conclusion: Crude EO possessed a broad spectrum of antimicrobial
activity against a range of microorganisms cultured in planktonic and
bioﬁlm modes of growth. EO may have a place in the clinical setting as
an adjunct to, or in combination with currently used disinfectants and
antiseptics in the prevention of HAI. Further studies are warranted.
P1811 Activity of oritavancin against a clinical isolate of
Staphylococcus aureus in in vitro bioﬁlm models
A. Belley °, E. Neesham-Grenon, G. James, E. Pulcini, L. Boegli,
T. Parr Jr., G. Moeck (Saint-Laurent, CA; Bozeman, US)
Objectives: Oritavancin (ORI) is a semi-synthetic lipoglycopeptide that
is currently in clinical development for serious Gram-positive infections.
The activity of ORI and comparator agents was determined against in
vitro bioﬁlms derived from a methicillin-resistant Staphylococcus aureus
(MRSA) clinical isolate in two bioﬁlm model systems.
Methods: A clinical isolate of MRSA isolated from an osteomyelitis
infection was used to form 72-hour bioﬁlms under low shear-forces
in a drip-ﬂow reactor (DFR) on hydroxyapatite-coated glass slides
or in MBEC™ Physiology & Genetics Assay plates (Innovotech,
Canada). Following exposure to ORI (32mg/L), vancomycin (VAN;
32mg/L) or minocycline (MIN; 150mg/L) for 48 hours, DFR bioﬁlm
cell viability was determined by serial dilution plating. The minimal
bioﬁlm eradication concentration (MBEC) for the antibacterial agents
was determined in the MBEC™ plates after 24 hours of exposure.
Results: DFR bioﬁlm cell densities after 48-hour exposure to VAN, ORI
and are shown in the ﬁgure (results from 3 independent experiments).
ORI and the positive control MIN reduced bioﬁlm cell density compared
to control bioﬁlms by 1.9±0.5 and 1.9±0.8 log, respectively (P< 0.05 vs.
control for both drugs), whereas the effect of VAN was negligible. In the
MBEC™ bioﬁlm model, ORI sterilised the MRSA bioﬁlms at MBEC
= 8−32mg/L whereas VAN and MIN did not and exhibited MBECs
>128mg/L.
Conclusion: These results demonstrate that ORI is active against in vitro
bioﬁlms of MRSA in different bioﬁlm model systems and show promise
for development of ORI as a therapy for bioﬁlm-type infections.
P1812 Effects of voriconazole on the shedding of Candida albicans
cells from mature bioﬁlms in an in vitro pharmacokinetic
model by using bioﬁlm sampling device
M. El-Azizi, N. Khardori ° (Cairo, EG; Springﬁeld, US)
Objectives: Shed cells from the bioﬁlm may enter the circulation causing
serious and very hard to treat bioﬁlm-associated infections. Voriconazole
(VOZ) was tested at exponentially decreasing concentrations against
mature bioﬁlms of Candida albicans on vascular catheter segments in
an in vitro pharmacokinetic model by using bioﬁlm sampling device
(BSD).
Methods: Brieﬂy, 24 h old culture of C. albicans on Sabouraud agar
was used to inoculate RPMI medium to give initial inoculum 1
to 5×106 CFU/ml. The bottle containing the culture suspension was
connected to the BSD through an automatic pump. The suspension was
delivered to the BSD at 30ml/h for 2 h and free cells were removed
by passing plain RPMI at the same rate for 2 h. The bioﬁlms on the
catheter segments were kept under continuous ﬂow of fresh RPMI
at 10ml/h. VOZ was tested against 2, 5 and 10 day-old bioﬁlms at
initial concentration of 3mg/ml (similar to its in vivo Cmax). The bottle
containing the drug in RPMI was connected to the BSD via a pump and
to another bottle containing plain RPMI via a second pump. The rate
of delivery of both the drug and the plain medium was kept at 10ml/h
and by this way the drug delivered to the bioﬁlms was exponentially
diluted at a rate that follows ﬁrst order kinetics. Four other doses of the
drugs were added to the bottle every 12 h (t1/2 of VOZ =6.5 h). Efﬂuent
samples from the BSD were taken for cell count (shed cells) at 12 h time
interval after each dose.
Results: Our data show that the log10 reductions in the shed cells
compared to drug-free control were 0.430, 0.942, 1.0, 1.22 and 1.1.22
for 2 days old, 0.50, 0.98, 0.99, 1.11, and 1.08 for 5 days old, and 0.166,
0.519, 0.0.91, 0.102, and 0.90 for the 10 days old bioﬁlms.
Conclusion: So it is obvious from our model that VOZ was able to
minimise but not to stop dispersion of CA cells from the bioﬁlms.
P1813 Interactions between triazoles and echinocandins against
Candida albicans planktonic cells and bioﬁlms
A. Chatzimoschou °, M. Simitsopoulou, C. Antachopoulos,
T. Stergiopoulou, E. Georgiadou, T.J. Walsh, E. Roilides (Thessaloniki,
GR; Bethesda, US)
Objectives: Candida albicans (CA) is an important cause of endovascu-
lar infections that are related to foreign bodies. As antifungal triazoles
are commonly administered concurrently with echinocandins, and as
triazoles have been previously shown to have antifungal activity against
Candida bioﬁlms (BF) only at very high concentrations (>256mg/L,
Katragkou et al, AAC 2008; 52: 357), we studied the antifungal
activity of voriconazole (VRC) against CA BF or planktonic cells
(PL) in combination with two echinocandins, caspofungin (CAS) or
anidulafungin (AND). Similarly, we studied the activity of posaconazole
(PSC) in combination with the same two echinocandins.
Bioﬁlms S525
Methods: CA-M61, a well-documented BF-producing CA strain, was
grown in RPMI at 5×105 blastoconidia/mL on silicone disks in 96-
well plates at 37ºC for 48 h in order to produce BF. PL were grown
in YNB at 37ºC for 24 h. PL and BF were then incubated for 24 h
with 2-fold dilutions of VRC or PSC (16–1024mg/L), and CAS or
AND (0−16mg/L) alone or concurrently, VRC/PSC with CAS/AND in
a checkerboard format. Fungal damage induced by antifungal agents
to PL and BF was assessed by XTT assay. The interactions between
VRC+AND, VRC+CAS, PSC+AND and PSC+CAS were analyzed using
the Bliss model (Meletiadis et al, Med. Mycol. 2005; 43: 133). Synergy,
antagonism or indifference was concluded when the observed fungal
damage was signiﬁcantly higher than, lower than or equal to the expected
damage, respectively.
Results: Against PL, a synergistic interaction was observed between 32–
128mg/L of PSC combined with 0.008–0.25mg/L of CAS. By contrast,
antagonism was observed when either of the two triazoles was combined
with AND at the following concentration ranges: 128–1024mg/L PSC
+ 0.03–0.5mg/L AND, 16–512mg/L VRC + 0.008–0.015mg/L AND
or 128–512mg/L VRC + 0.03–0.25mg/L AND. Against BF, all drug
combinations demonstrated indifferent interactions.
Conclusions: The differential interactions of synergy or antagonism
between triazoles and echinocandins observed against CA PL become
indifferent in the presence of CA BF.
P1814 Evaluation of triazole-echinocandin interactions against
Candida parapsilosis planktonic cells and bioﬁlms
A. Chatzimoschou °, M. Simitsopoulou, C. Antachopoulos, T.J. Walsh,
E. Roilides (Thessaloniki, GR; Bethesda, US)
Objectives: Candida parapsilosis (CP) frequently causes nosocomial
blood stream infections, especially in neonates and patients with central
venous catheters. Antifungal triazoles are commonly used in combination
with echinocandins in cases of serious fungal infections. While triazoles
have been previously shown to have antifungal activity against Candida
bioﬁlms (BF) only at very high concentrations (>256mg/L, Katragkou
et al, AAC 2008; 52: 357), little is known about the combined activity of
these antifungal drug classes against CP BF. Therefore, we investigated
the activities of two triazoles, voriconazole (VRC) and posaconazole
(PSC), against CP BF or planktonic cells (PL) in combination with each
of two echinocandins, caspofungin (CAS) and anidulafungin (AND).
Methods: CP-A71, a well documented BF-producing CP strain, was
grown in RPMI at 5×105 blastoconidia/mL on silicone disks in 96-
well plates at 37ºC for 48 h in order to produce BFs. PL of CP were
grown in yeast nitrogen base growth media at 37ºC for 24 h. PL and
BFs were then incubated for an additional 24 h with 2-fold dilutions of
VRC or PSC (16–1024mg/L) and CAS or AND (0−16mg/L), alone or
concurrently, PSC/VRC with AND/CAS in a checkerboard format. The
degree of fungal damage induced on BF and PL was assessed by the
XTT metabolic assay. The interactions between VRC+CAS, VRC+AND,
PSC+CAS and PSC+AND were analyzed using the Bliss model
(Meletiadis et al, Med. Mycol. 2005; 43: 133). Synergy, antagonism
or indifference was concluded when the observed BF damage was
signiﬁcantly higher than, lower than or equal to the expected theoretical
damage, respectively.
Results: The interaction between VRC at concentrations from 32
to 1024mg/L and CAS at concentrations from 1 to 16mg/L was
antagonistic against CP PL but indifferent against CP BF. The other drug
combinations (VRC+AND, PSC+CAS, PSC+AND) were indifferent
against CP PL or BFs.
Conclusions: The antagonistic or indifferent interactions between
triazoles and echinocandins, observed against C. parapsilosis PL or
BFs at the concentrations studied, do not support the concurrent
administration of these antifungal classes in cases of C. parapsilosis
infections of vascular catheters.
P1815 Combined activities of antifungal azoles with calcineurin
inhibitors against Candida albicans bioﬁlms
A. Katragkou °, E. Georgiadou, M. Kruhlak, M. Simitsopoulou,
T. Stergiopoulou, A. Chatzimoschou, I. Frantzis, T. Walsh, E. Roilides
(Thessaloniki, GR; Bethesda, US)
Objectives: Candida albicans (CA) bioﬁlms (BF) are frequent causes
of foreign body-related infections and are resistant to even high
concentrations of azoles (Katragkou et al, AAC 2008; 52: 357).
Calcineurin inhibitors, such as cyclosporine A (CsA) and tacrolimus
(TCR), are synergistic with ﬂuconazole (FLC) against CA planktonic
cells. We aimed to determine the efﬁcacy of FLC, voriconazole (VRC)
or posaconazole (PSC) combined with CsA or TCR against CA BF.
Methods: CA-M61, a clinical BF-producing strain was used. Confocal
laser scanning microscopy (CLSM) and XTT assays were performed.
For CLSM, BF were formed on silicone disks placed in 12-well plates
at 37ºC under continuous rocking for 48 h. BF were then incubated
with either no drugs, or with FLC (10 and 125mg/l), VRC (1 and
32mg/l), PSC (1 and 32mg/l), CsA (0.5mg/l), TCR (20mg/l) alone,
or with each of the azoles combined with CsA or TCR for 24 h.
Treated BF were stained with FUN-1 and concanavalin A-Alexa Fluor
488 conjugate. Stained BF were examined by CLSM. Drug interactions
were also assessed by checkerboard micromethod and XTT metabolic
assay. For these experiments, BF were grown in 96-well plates at
37ºC for 24 h and were then incubated with fourfold dilutions of
each azole (0.06–1000mg/l) combined with CsA or TCR (0.016–
64mg/l) for 24 h. CLSM and XTT assays were performed 2 and
5 times, respectively.
Results: CLSM showed that BF individually treated with an azole, CsA
or TCR were morphologically similar to untreated controls. Among the
combinations tested, FLC (10 or 125mg/l) + CsA (0.5mg/l) displayed
the most prominent effects, where shorter hyphae and looser matrix were
observed. Similar changes, but to a lesser extent, were evident with VRC
(1 or 32mg/l) + CsA (0.5mg/l) and PSC (1 or 32mg/l) + CsA (0.5mg/l).
TCR did not appear to cause any morphological changes, when combined
with each of the azoles. FLC (1 and 8mg/l) + CsA (0−32mg/l) showed
increasing BF damage (16−40%) with increasing CsA concentrations,
as compared to drugs alone (FLC 7−10% and CsA 9−14%; n = 4).
Conclusions: Among the combinations tested, FLC+CsA demonstrated
a collaborative effect against CA BF followed by VRC+CsA and
PSC+CsA. Combination antifungal treatment mediated via different
mechanisms may have utility against CA BF. Combination therapy may
prove a novel therapeutic intervention in difﬁcult to treat BF-related
infections.
P1816 Bacterial adhesion on antibiotic-loaded
polymethylmethacrylate bone cement
E. Bertazzoni Minelli °, A. Benini (Verona, IT)
Background: Polymethylmethacrylate (PMMA) bone cement, com-
monly used for the ﬁxation of joint prostheses and also for orthopaedic
devices, may be colonised by Gram positive cocci. The use of antibiotic-
loaded PMMA should prevent bacterial colonisation of cement surfaces.
Bioﬁlm formation on bone cement could be more effectively reduced by
incorporation of a second antibiotic The aim of our study was to evaluate
the in vitro effects of gentamicin (G)- and vancomycin (V)-loaded
PMMA cement specimens on the bacterial adhesion of multiresistant
clinical isolates staphylococci.
Materials: Different strains of clinical isolates staphylococci (Met-R
and Gent-R, and VRSA) and E. coli were studied. The PMMA
specimens (discs), loaded with G (1.9%) or V (1.9%) or with their
combination were placed singularly in Mueller-Hinton Broth inoculated
with bacterial strains. After incubation at 37ºC for 24−72 hours, bacterial
growth was determined by subcultures and optical density (OD540),
and bioﬁlm was stained with crystal violet. The bioﬁlm PMMA-
associated was measured spectrofotometrically. Antibiotic concentrations
were determined by FPIA.
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Results: Antibiotic-loaded specimens released high and inhibitory
concentrations of G and V. G and V alone in PMMA cement reduced
the bacterial adhesion of susceptible and intermediate-resistant Staphy-
lococci. Only VRSA strain and E. coli were able to grow and to adhere
to V-loaded specimens after 24 h. The combination exhibited synergistic
bactericidal activity against all different multiresistant Staphylococcus
strains (no bacterial growth); only low drug concentrations from the
combination determined delayed and poor bacterial colonisation. The
amount of antibiotic released exerts different inhibitory capacity on
bacterial growth and adhesion, being the effect strain-dependent. The
higher release of drug from PMMA resulted in a stronger and more
prolonged inhibition of bacterial growth.
Conclusions: (i) The presence of G in PMMA specimens reduces the
bacterial adhesion in susceptible and intermediate-resistant Staphylo-
cocci. (ii) The combination G-V exhibits synergistic activity against
all strains; moreover, inhibits the growth and adhesion of V-resistant
strains. (iii) The anti-adhesive effect of the antibiotic-loaded cement
depends on the characteristics of the microorganism and its capacity of
adhering to antibiotic-loaded surfaces. (iv) Bacterial adhesion is reduced
in specimens presenting a higher capacity of antibiotic elution.
P1817 A scanning electron microscopy based quantitative method
to evaluate plaque accumulation in patients undergoing
different oral home care protocols
F. Tessarolo °, E. Bressan, C. Tomasi, F. Piccoli, G. Nollo, I. Caola
(Trento, Padua, IT; Gothenburg, SE)
Objectives: The quantiﬁcation of plaque bioﬁlm (PB) in oral cavity
surfaces is an important indicator to test the efﬁcacy of oral home
care protocols. The study aimed at deﬁning a quantitative method for
evaluating PB formation by scanning electron microscopy (SEM) on
titanium surfaces in patients rehabilitated by osseointegrated implants.
The feasibility of the method was veriﬁed by running a pilot study to
evaluate the effect of antiseptic in preventing plaque accumulation on
healing abutments (HAs).
Figure 1. Plaque on healing abutment imaged by SEM in BSE mode:
(a) raw and (b) thresholded image. (c) Bacterial morphologies in plaque
bioﬁlms at higher magniﬁcation.
Methods: The study was designed as a single blind randomised cross-
over controlled experiment to reveal the inﬂuence of 0.12% CHX
mouthrinses in the formation of PB during a 7-days plaque accumulation
model. Ten new HAs were placed in 5 voluntary patients one week
after implant surgery and removed after 7 days. At removal, a new
set of HAs was placed and removed one week after. During the two
testing period, patients were instructed to apply the following protocols
in a randomised order: CHX mouthrinsing twice daily and no brushing
(Test); no CHX mouthrinsing and no brushing (Control). HAs were ﬁxed
immediately after removal in 2.5% glutaraldehyde phosphate-buffered
solution, washed in buffer, dehydrated by graded alcohol series, vacuum
dried, and gold sputtered. One low-magniﬁcation image per sample of
the coronal surface was acquired by SEM in backscattered mode and
then thresholded by an automated image analysis software. PB amount
was computed by considering dark pixels associated to PB and bright
pixels representing the clean surface of the HA. Mann-Whitney test was
used to compare groups.
Results: The protocol for preparing and observing PB by SEM provided
quantitative data with a wide variation among subjects and implant sites.
The mean values of the ratio of titanium surface covered from PB were
23%(S.E. 34) and 33%(S.E. 37) for test and control respectively, but no
statistically signiﬁcant difference was detected between the groups.
Conclusion: The quantiﬁcation of PB on HAs by SEM was feasible
and allowed to create a non-subjective indicator of PB amount. HA
is a valid substrata for oral microbiota adhesion and growth, easy to
remove and substitute without causing any trauma to peri-implant tissues.
The sensitivity of the presented quantiﬁcation method and the inter-
patients and inter-implant-sites variability demands for a larger number
of samples to have higher statistical conﬁdence on the results obtained
in this pilot study.
P1818 Evaluation of natural compounds derived from plants on
planktonic and sessile form of staphylococci
C. Avanzolini °, A. Cellini, R. Papa, G.L. Scoarughi, E. Bombardelli,
P. Morazzoni, M. Artini, L. Selan (Rome, Milan, IT)
Objective: In this study the activity of different compounds of
natural origin on planktonic and sessile cultures of S. aureus and
S. epidermidis was tested. We used: i) a synthetic derivative of
the dihydroxybenzofuran (DHBF), originally isolated from Krameria
lappacea; ii) two quaternary benzo[c]phenanthridine alkaloids (QBAs),
sanguinarine (SA) and chelerythrine (CH), extracted from Papaveraceae
and Fumariaceae; iii) proanthocyanidin (proAC) and a standardised
extract prepared from Vaccinium myrtillus L (BB).
Methods: S. aureus 6538P and S. epidermidis RP62A strains were used,
reference strains for the bioﬁlm formation. Determination of MIC and
MBC for all natural compounds used was carried out. The inﬂuence on
bioﬁlm formation was assessed by a modiﬁed Christensen technique. The
effect of the tested compounds on surface proteins and autolysins of the
studied strains was evaluated by SDS-PAGE and zymogram, respectively.
Surface proteins were extracted from bacteria cultured in the absence and
in the presence of sub-inhibiting concentration of each compound.
Results: In planktonic cultures, both proAC and BB do not show an
antibacterial activity in the range of used concentration, while DHBF
and both QBAs show a clear bacteriostatic and/or bactericidal activity
on the two tested strains. Interestingly, inhibition of bioﬁlm formation
was observed for all tested compounds, including proAC and BB.
Moreover, DHBF, proAC and SA reduced S. epidermidis preformed
bioﬁlm despite the active concentration required are quite high. SDS-
PAGE and zymogram analyses revealed diverse modiﬁcation of surface
protein pattern for treated bacteria in comparison with that of untreated
bacteria, depending on the speciﬁc molecule used. In particular, the
protein pattern of DHBF-treated samples is similar to the untreated
samples. Furthermore, the modiﬁcation proﬁle observed for each strain
is similar for both polyphenols (proAC and BB) and QBAs.
Conclusion: Our data suggest that some of the analyzed compounds
could be proposed as antibacterial drugs in infection sustained by
Staphylococcus spp. Their action on sessile phenotype renders them
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particularly interesting for a possible application in bioﬁlm infections
in synergic therapy.
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P1819 The role of CTX phage in the emergence of the Vibrio
cholerae variants with different genomic organisations
B. Bakhshi °, M.R. Pourshaﬁe (Tehran, IR)
Objectives: Cholera toxin is encoded by the ctxAB operon in the genome
of a ﬁlamentous bacteriophage (CTXtheta). The multiple copies of CTX
prophage are tandemly arranged in El Tor strains of V. cholerae but
the number and arrangement of the CTX elements and the repetitive
sequences are known to vary in different toxigenic strains and is a useful
basis for study of diversity and characterisation of isolates.
The objective was to investigate the genetic arrangement and copy
number of CTX elements in the V. cholerae strains isolated during
outbreaks in Iran.
Methods: Extracted DNA of 37 isolates was subjected to digestion with
PstI restriction enzyme which has only one cutting site inside the CTX
element. The fragments were separated with agarose gel electrophoresis
and then transferred to positively charged nylon membrane. Digoxigenin-
labeled ctxA and zot gene probes were used for hybridisation.
Results: The results showed 3 hybridisation proﬁles for each of the
probes used with the bands ranging from 4.2 to 8.3 kb in size. The
results showed that CTX element in 30% of isolates was residing on
the fragments of 5.6 kb (proﬁle A) when either ctx or zot probe was
used. The strains with hybridisation proﬁle C showed two fragments of
6.9 and 8.3 kb with either ctx or zot probes for %17of the isolates. In
the strains with hybridisation proﬁle B, fragments of 4.2, 5.6 and 6.9 kb
was displayed when zot probe was used. When the same strains were
hybridised with ctx probe, only one band of 6.9 kb was detected.
Conclusion: Southern blot hybridisation using ctx or zot probes showed
the presence of 1(30%), 2 (17%) and 3 (53%) copy numbers among the
isolates. The isolates with 1 or 2 copies were shown to carry the whole
CTX element with 6.9 kb. On the hand, 2 of the CTX elements (5.6 kb)
were found to be truncated in ctxAB for the isolates with 3 copies of
CTX element. These variations in the CTX phage acquisition results
in the emergence of new variants of V. cholerae with different toxicity
power.
P1820 The inﬂuence of enterocin B on the morphophysiology of
Escherichia coli
O. Rybalchenko, E. Yermolenko, A. Kolobov, A. Chernish, A. Suvorov °,
A. Totolian (St. Petersburg, RU)
Objectives: Bacteriocins are the novel target for the search of new
antimicrobibial agents different from antibiotics. Previously it was shown
that enterococcal bacteriocin (enterocin B) is highly effective against
Gram-positive bacteria (Moreno et al. 2006, Nilsen et al.1998, Casaus et
al. 1997). However, the activity of this enterocin against Gram-negative
bacteria never been described. The aim of this study was to reveal
peculiarities of action of enterocin B on the growth and morphology
of Escherichia coli.
Methods: Enterocin B (B5) and its analog (B2) without the several
amino acids at the N-terminus, were synthesized. The peptides in
concentrations (0, 02−0, 0002mg/ml) were added on the surface of
the solid medium (Tripticase agar) immediately after inoculation of
the culture of E. coli ML-35p at the exponential phase of growth
(6 lg CFU/ml). The lysozyme (50mcg/ml) was used as a control. After
incubation for 24 h the diameters of inhibition growth zones have been
measured. The thin sections taken from the marginal areas of inhibition
growth have been studied by electron microscopy.
Results: Both synthetic peptides and lysozyme showed inhibitory
activity against culture of E. coli. Diameters of inhibition of the growth
zones on the lawn of indicator bacteria were 12, 12 and 14mm,
consequently. The factors under study caused different damages of E. coli
cells. Peptides B5 and B2 used in concentration 0.002mg/ml caused
pathological changes approximately 20% of the cells of indicator culture.
Under electron microscopy we could determine rejection of the cell wall
from the cytoplasmic membrane of bacteria. Most likely the destruction
of the cell wall was caused by the pressure from the inside. One of the
possible mechanisms explaining this effect is the action on the membrane
of Gram-negative bacterial cell as it was earlier described regarding
Gram-positive bacteria.
Conclusion: Enterocin B can inhibit the growth of E. coli and cause a
damage of surface structures of these bacteria. This fact is important for
the possible application of enterocin B and it analogs for the therapy and
prophylactic of infections, caused by E. coli and other Gram-negative
bacteria. The work was supported by grant of RFFI 06−04-48949.
P1821 Complementation in hypermutable Escherichia coli strains
shows that mismatch repair and 8-oxoG pathway genes are
not always responsible for mutator phenotype
M.C. Turrientes °, A. Ripoll, M. Rodrı´guez-Domı´nguez, M.R. Baquero,
J.L. Martı´nez, R. Canto´n, F. Baquero, J.C. Gala´n (Madrid, ES)
Objective: Few published data have conﬁrmed the role of genes
belonging to mismatch repair system (MMR) or 8-oxoG pathway (GO)
in the mutator phenotype (MP) by complementation studies in bacteria.
The aim of our study was to characterise the genes involved in the MP
in four Escherichia coli isolates from different origins.
Methods: PCR-ampliﬁcation of the mismatch repair genes (mutS, mutL,
mutH, uvrD) and 8-oxoG pathways (mutT, mutY) from E. coli MG1655
was performed, and these genes were cloned in the multicopy plasmid
pGEMT-easy and transformed into four hypermutable strains: ECU24
and DA6879 urine isolates, ECC19 recovered from faeces from a healthy
volunteer and ECB23 from a surgical wound in an immunocompromised
patient. These wild-type genes were also transformed in a normomutator
laboratory strain, as control. Mutation frequency was calculated in wild-
type and transformed isolates.
Results: Mutation frequency decreased when wild-type mutS gene
was hyper-expressed in ECU24 (81x reduction), DA6879 (x152) and
ECB23 (x225) strains, suggesting that mutS gene was defective. It was
demonstrated by sequencing, so the ECU24 strain presented a deletion
of 8 bp in mutS altering the open reading frame; DA6879 strain carried
a deletion of 11,903 bp including mutS and rpoS genes; and in ECB23
strain a copy of IS10 in the position 2067 of the mutS gene (coding
for the ATP binding domain) was detected. The ECC19 strain showed
the highest mutation frequency value (500-fold higher than modal value
for E. coli). Unexpectedly, the ECC19 mutator phenotype was not
complemented with any of the mut genes studied, suggesting that this
strain was not defective in either MMR or GO pathways. Interestingly,
a partial restoration of mutation frequencies (5−10x reduction) was
obtained in ECU24 by hyper-expression of the mutH gene, or by mutT
gene in ECB23 and DA6879 strains, while this phenomenon was not
observed in the control strain.
Conclusions: A defective mutS gene was responsible of the MP in three
out of four strong hypermutable E. coli strains, similar to described
in Pseudomonas aeruginosa.In one strain, and as it has been shown
in Salmonella typhimurium (Yang B, 2008) the MMR or GO systems
do not appear involved in some cases of MP. In strains with defective
mutS gene, the hyper-expression of mutH or mutT genes could partially
revert the MP, suggesting that a second order of selection by hitchhiking
process can be possible.
P1822 Comparative distribution of phylogenetic groups, virulence
genes and antimicrobial resistance in Escherichia coli
isolated from blood, urine and faeces
S. Lee °, J.K. Yu, K. Park, E.J. Oh, S.Y. Kim, Y.J. Park (Seoul, KR)
Objectives: We compared the distribution of phyolgenetic groups and
virulence genes of Escherichia coli between pathogenic strains (from
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blood and urine) and commensal strains (from faeces), and antimicrobial
resistance of E. coli isolated from blood and urine.
Methods: A total of 550 non-duplicate E. coli isolates (145 from blood,
200 from urine, and 205 from faecal specimens of healthy humans)
were consecutively obtained. PCR experiments for phylogenetic groups
(A, B1, B2, D) and nine virulence genes (sfsS, fogG, hlyA, cnf1, iutA,
fyuA, iroN, traT, PAI) were performed by using published primers for
all isolates. Antimicrobial susceptibility tests for ampicillin, piperacillin,
amoxicillin/clavulanic acid, piperacillin/tazobactam, cefazolin, cefoxitin,
cefotaxim, ceftazidime, cefepime, amikacin, gentamicin, tobramycin,
tetracycline, ciproﬂoxacin, trimethoprim/sulfamethoxazole, imipenem
were determined by VITEK 2 automated system (bioM?ieux, VITEK)
and ESBL conﬁrmatory test was performed according to the CLSI
guideline for 345 E. coli isolates from blood and urine. Statistical
analyses were performed by using chi-square tests. A P value of <0.05
was considered statistically signiﬁcant.
Results: The phylogenetic distribution showed similar pattern between
E. coli from blood and urine (B2 (44.8%, 58.5%, respectively) > D
(29.0%, 23.0%, respectively) > A(18.6%, 9.5%, respectively) > B1
(7.6% and 9.0%, respectively). However, isolates from faeces revealed
different distribution (A (38.0%) > B2 (22.9%) > D (21.0%) > B1
(18.0%).
Out of the nine virulence genes, the prevalence of all but sfaS were
signiﬁcantly higher in pathogenic strains than in commensal strains, and
that of PAI, fyuA and traT were signiﬁcantly higher in E. coli from blood
than isolates from urine.
The antimicrobial resistance rate showed no signiﬁcant difference
between in E. coli from blood and E. coli from urine, but in phylogenetic
group B2, the prevalence of ESBL (18.5% vs 6.0%) was signiﬁcantly
higher in E. coli from blood than in E. coli from urine.
Conclusion: Most (78.3%) of pathogenic E. coli strains belonged to
the phylogenetic groups B2 or D. Unexpectedly, as many as 43.9% of
commensal strains belonged to group B2 and D.
The ﬁnding that the prevalence of PAI, fyuA and traT were signiﬁcantly
higher in E. coli from blood than E. coli from urine suggests the presence
of these virulence factors indicate higher risk of bacteraemia.
P1823 Enteric pathotypes of Escherichia coli involved in infectious
diarrhoeal syndrome
M. Nica °, T. Biolan, E. Mozes, A. Dascalu, D. Caliga, R. Rusu,
M. Homos, V. Melinte, S. Florescu, E. Ceausu, P. Calistru, M. Damian,
C.R. Usein, I. Apostol, A. Kosa (Bucharest, RO)
Objectives: 1.Assessment of incidence for enteric pathogenic strains of
E. coli in a samples of patients with acute diarrhoeal syndrome (ADS),
with or without concomitant HIV infection. 2.Assessment of the role
of classical diagnostic versus genotypical methods, in diagnosing ADS
caused by E. coli.
Methods: The study included 1830 patients, with ADS, hospitalised in
SVB, between 1st Jan 2006−31 June 2007. There were excluded other
cases of infectious diarrhoea, except E. coli: viruses, parasites, other
enteral bacterial pathogens. The classical methodology was based on
isolation, phenotypic identiﬁcation and serological testing. Isolation was
made on mild/moderate selective media (MacConkey, SMAC, CLED,
Hektoen/ADCL). Phenotypic identiﬁcation was based on growth culture
proprieties on multitests media: TSI, MIU, MILF, Citrate and conﬁrmated
by: API 20 E, ID 20 E, VITEK 2 C. Serology was based on antigenity
criteria: serotyping OB (Denka Seiken, Tokio, Japan). Microscopic
examination, macroscopic aspects and epidemiological data were used
for obtaining an oriented stool culture for E. coli. Internal quality control
was provided by using E. coli ATCC 25922. All strains of E. coli isolated
in pure culture were analyzed through multiplex PCR in INCDMIC.
Results: We identiﬁed 410 strains of E. coli: 369 HIV(−) and 41
HIV(+), the most ones at the age group 0−5 years: 74.3% cases. Enteric
pathogenic E. coli was identiﬁed by phenotypical methods in 12.29%
(46 strains) and by molecular methods in 13.12% (54 strains). We
identiﬁed 31.5% EPEC pathotype, 0.7% EIEC pathotype and 0.5%
EHEC pathotype by phenotypical tests. The molecular tests showed
5.12% atypical EPEC (eae gene), 0.7% typical EPEC (bfp and eae
genes), 2.7% atypical STEC/VTEC (with one gene or association of 2−3
genes: eae, stxI, stxII, mdh), 0.2% typical STEC/EHEC (all 4 genes),
4.4% EAEC (agg gene), 0% EIEC and ETEC (genetic unconﬁrmed).
There were no enteric pathogenic strains of E. coli isolated from HIV
(+) patients.
Conclusions: 1. Pathotyps of E. coli was conﬁrmed by genotypical
methods, only in HIV(−) patients; in HIV(+) patients, ADS occured
by other non-infectious pathophysiological mechanisms of SIDA. 2. In
diagnosing enteric pathotypes of E. coli, a comparative analyse of the
two techniques used, lead to superior results for genetic methods versus
phenotypical methods (13.12% versus 12.29%).
P1824 Development and validation of a real-time PCR assay for
detection of enteropathogenic Escherichia coli, as part of
a Dutch study on the epidemiology of gastro-enteritis
M.C. Scholts °, G.J. Wisselink, R.F. de Boer, A.M.D. Kooistra-Smid,
Y.T.H.P. van Duynhoven (Groningen, Bilthoven, NL)
Objectives: Enteropathogenic Escherichia coli (EPEC) is a major cause
of infantile diarrhoea predominantly in developing countries but are
also identiﬁed with increasing frequency in developed areas and in
adults. Typical and atypical EPEC strains harbour the pathogenic “locus
of enterocyte effacement” (LEE) region, which is responsible for the
phenotype of attaching-and-effacing lesions. On this region the escV
gene is located. Typical EPEC harbour an additional adherence factor
plasmid on which the bfpA gene is located. Identiﬁcation of EPEC strains
is currently based on adherence assays and serotyping with speciﬁc
antisera. Both assays are time-consuming and demand considerable
technical expertise.
In May 2008 a study in 6 Dutch hospitals has started to asses the
incidence, aetiology and course of patients hospitalised for gastro-
enteritis (GEops study). As part of this study, and to facilitate rapid
diagnosis, a real-time PCR assay was developed and validated for the
detection of typical and atypical EPEC.
Methods: A real-time PCR assay targeting the escV and bfpA genes was
developed. DNA isolation from stool samples was performed with the
easyMAG speciﬁc A stool protocol (bioMe´rieux). As internal control,
phocine herpes virus-1 was used. The selectivity of the assay was
validated using a panel of well-characterised EPEC isolates (n = 35),
a panel of E. coli spp. non-EPEC isolates (n = 52) and a panel of
non-E. coli strains (n = 30). Analytical sensitivity was assessed by
dilution series (n = 2), spiked in a pool of faecal matrices, with different
consistencies. Also, a clinical validation was performed on stool samples
routinely screened for bacterial and parasitic enteric pathogens (n = 101).
Results: The assay proved to be speciﬁc for EPEC, as no cross reaction
was observed. All thirty-ﬁve isolates of EPEC scored positive in the real-
time PCR for the escV target. Additionally, 9 isolates scored also positive
for the bfpA target. The assay is capable of detecting approximately 6600
CFU per gram of stool, for both targets. Typical and atypical EPEC DNA
was detected with this real-time PCR assay in respectively 1% and 16%
of the 101 clinical samples. PCR inhibition was not observed in these
clinical samples.
Conclusion: These data prove the assay to be a sensitive method for the
detection of typical and atypical EPEC in stool samples. The assay is
currently used as a rapid screening tool for the detection of EPEC in the
GEops study.
P1825 Development and validation of a rapid molecular screening
panel for detection of enteroaggregative Escherichia coli, as
part of a Dutch study on the epidemiology of gastro-enteritis
M.C. Scholts °, G.J. Wisselink, R.F. de Boer, A.M.D. Kooistra-Smid,
Y.T.H.P. van Duynhoven (Groningen, Bilthoven, NL)
Objectives: Enteroaggregative Escherichia coli (EAEC) is an in-
creasingly recognized enteric pathogen. It causes acute and persistent
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diarrhoea among children, adults and HIV-infected persons. The Hep2-
assay is considered to be the gold standard for the detection of EAEC.
However, the Hep2-assay is not suitable as a diagnostic tool, as it is
time-consuming and demands considerable technical expertise. In May
2008 a study in 6 Dutch hospitals has started to asses the incidence,
aetiology and course of patients hospitalised for gastro-enteritis (GEops
study). As part of this study, and to facilitate rapid diagnosis, a molecular
screening panel was developed and validated for the detection of EAEC.
Methods: Since EAEC strains are heterogeneous, real-time PCR assays
were developed targeting not only the aat and aggR genes, but also
the astA and pic genes. In this study results were considered EAEC
positive if aat, aggR or a combination of 2 or more targets were detected.
DNA isolation from stool samples was performed with the easyMAG
speciﬁc A stool protocol (bioMe´rieux). As internal control, phocine
herpes virus-1 was used. Selectivity of the assays was validated with a
panel of well characterised EAEC strains (n = 16), a panel of E. coli spp.
non-EAEC strains (n = 77) and non-E. coli strains (n = 30). Analytical
sensitivity was assessed by dilution series (n = 2), spiked in a pool of
faecal matrices, with different consistencies. A clinical validation was
performed on stool samples routinely screened for bacterial and parasitic
enteric pathogens (n = 101).
Results: Eleven (69%) of the 16 EAEC strains scored positive with the
real-time PCR, 5 strains remained negative or were only astA positive.
Of the 107 non-EAEC and non-E. coli strains 12 were astA positive.
The real-time PCR assays were capable of detecting approximately 3520
CFU per gram of stool for all targets. Totally 31% of the clinical samples
scored positive for one or more of the 4 targets. Fourteen (14%) of these
clinical samples were suspected for containing EAEC. The remaining
17% scored positive for astA only. PCR inhibition was observed in less
than 1% of these clinical samples.
Conclusion: These data prove the molecular screening panel to be a
useful tool for the detection of EAEC in stool samples. The assay is
currently used as a rapid screening tool for the detection of EAEC in
the GEops study.
P1826 Molecular characterisation of pUO-StVR2 variants
belonging to a family of virulence-resistance hybrid
plasmids of Salmonella enterica serovar Typhimurium
originated from pSLT
A. Herrero, R. Rodicio, P. Garcı´a, M.C. Mendoza, B. Guerra,
M.R. Rodicio ° (Oviedo, ES; Berlin, DE)
Objective: To investigate the genetic structure of ﬁve variants of pUO-
StVR2, a virulence-resistance hybrid plasmid originated from pSLT, the
virulence plasmid speciﬁc of Salmonella enterica serovar Typhimurium.
Methods: Analysis of the plasmid variants pUO-StVR4 to pUO-StVR8,
was performed by PCR ampliﬁcation, Southern hybridisation and DNA
sequencing.
Results: pUO-StVR2 differs from pSLT by a ca. 12 kb deletion and a
47.6 kb insertion of foreign DNA. The latter consists of a central resis-
tance island and two ﬂanking regions. The resistance island is respon-
sible for the ampicillin-cloramphenicol-streptomycin/spectinomycin-
sulphonamycin-tetracycline/blaOXA-1-catA1-aadA1-sul1-tet(B) pattern
conferred by the plasmid to S. Typhimurium. The left and right
ﬂaking regions provide genes for plasmid maintenance and iron
acquisition, respectively. pUO-StVR4 shared the tripartite structure of
pUO-StVR2, but contained additional DNA inserted within the left
region. All other variants lacked the right region, this being the only
difference found between pUO-StVR5 and pUO-StVR2. In the remaining
variants, the resistance clusters suffered deletions and/or insertions that
reduced or expanded the resistance proﬁle. pUO-StVR6 and pUO-
StVR7 (ampicillin-streptomycin-sulphonamycin) had different deletions
that removed the catA1 and tet(B) genes, which were shown to be
carried by Tn9- and Tn10-like transposons, respectively. In addition,
pUO-StVR7 has gained a second integron (1000 bp/aadA22), apart from
InH (2000 bp/blaOXA-1-aadA1) that, associated to a Tn21-like element,
is present in the six members of the pUO-StVR2 family. pUO-StVR8
has acquired a orf513-dfrA10–3′CS element, which converts InH into a
complex integron, and conferred additional resistance to trimethoprim.
The insertion site of the foreign DNA, between the ccdAB and pefI
genes of pSLT, coincide in all members of the group, but the deletion
affecting the resistance cluster in pUO-StVR6 has spanned into the pSLT
DNA downstream of pefI.
Conclusions: the study reports on new plasmid variants which can be
generated in nature through insertion and/or deletion of virulence and/or
resistance determinants. Such changes constitute an interesting example
of evolutive engineering, and may have important consequences for the
interaction of pathogenic bacteria with the human host, leading to more
virulent strains and of more difﬁcult treatment.
P1827 Rapid molecular diagnosis of severe sepsis in patients with
SIRS
J.C. Palomares °, B. Puche, A. Martos, F. Lucena, M. Marı´n,
E. Martı´n-Mazuelos (Seville, ES)
Objective: Blood culture (BC) is considered the gold standard for
detection of bacterial bloodstream infections, but the aetiology of sepsis
is identiﬁed only in a small number of patients and results are usually
unavailable until next day. We assesed the utility of an automatic
method to extract DNA for a multiplex real-time PCR Septifast (Sf,
Roche Molecular Systems) in rapid diagnosis of bacterial and fungal
bloodstream infections.
Methods: A total of 73 adult patients (76 samples) from the intensive
care unit (ICU) of the Valme University Hospital with suspected
blood-stream infection and at least two criteria of the systemic
inﬂammatory response syndrome (SIRS) were enrolled. Blood samples
for BC and SF (three milliliters of whole blood in EDTA bottles)
were simultaneously drawn. DNA extraction was performed by an
automatic method (MagNAPure Compact. Roche) and compared with
the manual method recommended by the manufacturer (Septifast Prep
kit). The ampliﬁcation was performed with the LightCycler® Septifast
kit (Roche Molecular Systems). The ﬁnal diagnosis was adjudicated by
2 independent infectious diseases specialist not aware of the SF results.
Results: Twenty-seven cases got concordant negative results by BC and
PCR. Seven cases were positive concordant by BC and PCR (4 S. aureus,
1 Streptococcus pneumoniae, 1 Staphylococcus epidermidis and 1
Pseudomonas aeruginosa + Candida albicans); median time to positivity
was 23 h (range 10−48 h). In 7 additional patients with sepsis, BC were
false-positive with coagulase-negative staphylococci (contamination). In
3 patients with positive BC (1 Salmonella enteritidis − not included in
SF master list, 1 P. aeruginosa and 1 Escherichia coli), SF was false-
negative. SF detected clinical signiﬁcative microorganisms in 10 cases,
not detected by BC (2 E. coli, 2 S. aureus, 2 Aspergillus fumigatus, 2
S. pneumoniae, 1 P. aeruginosa and 1 Klebsiella pneumoniae/oxytoca).
68 patients (93%) had received prior antibiotic therapy.
Conclusions: SF using an automatic DNA extraction method allows
the detection and identiﬁcation of potentially signiﬁcant bacteria and
fungi in 4 hours (2 h 30min less than the manual one), showing a better
sensitivity than BC for the diagnosis of SIRS (23% vs 18%); PCR could
serve as an adjunct to current culture methods to facilitate same-day
microbiological diagnosis of sepsis.
P1828 Diagnosis of periprosthetic joint infection using multiplex
PCR in sonication ﬂuid of removed implants
Y. Achermann °, M. Vogt, M. Leunig, H. Hermann, J. Wu¨st, A. Trampuz
(Baar, Basel, Zurich, CH)
Objectives: The microbiological diagnosis of periprosthetic joint
infection (PJI) is crucial for successful outcome. Cultures have
limited sensitivity, especially in patients receiving previous antimicrobial
treatment. We compared the multiplex real-time PCR test (SeptiFast,
Roche Diagnostics) for detection of microbial DNA with cultures of
sonication ﬂuid.
Methods: We prospectively included patients in whom an infected
prosthesis (or part of it) was removed from 8/08 through 12/08. PJI
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was deﬁned as visible purulence, acute inﬂammation on histopathology,
sinus tract or microbial growth in periprosthetic tissue (at least 2 positive
tissues were required for low-virulent organisms). The removed implant
was sonicated (described in NEJM 2007;357:654) and the resulting
sonication ﬂuid was cultured aerobically and anaerobically. In addition,
1ml of the ﬂuid was investigated using SeptiFast.
Results: In this ongoing study, 21 episodes of PJI in 18 patients were
included (median age 75 y; range 49−86 y), including hip (n = 9), knee
(n = 9), shoulder (n = 2) and ankle prosthesis (n = 1). The following
pathogens were cultured: Staphylococcus aureus (n = 3), coagulase-
negative staphylococci (n = 6), streptococcus agalactiae(n = 1), Propioni-
bacterium acnes (n = 2) and mixed infection (n = 3). In sonication culture,
the causative organism was identiﬁed in 14 (67%) cases and by SeptiFast
PCR in 18 (86%) cases. In 7 false-negative cultures, the pathogen
was identiﬁed only by SeptiFast (4 S. aureus, 1 coagulase-negative
staphylococcus, 1 streptococcus sp.) or an additional microorganism was
found with the SeptiFast (Klebsiella oxytoca/pneumoniae). In all 3 false-
negative cases by SeptiFast, P. acnes was missed. All patients with false-
negative cultures received previous antibiotic therapy. Among 11 cases
receiving antibiotics for a median of 16 d (range 3−60 d) before the
diagnostic procedure, SeptiFast was positive in all 11 (100%), whereas
sonication cultures grew the organism in only 4 (36%).
Conclusions: SeptiFast in sonication ﬂuid has a higher sensitivity
for diagnosis of PJI compared to sonication culture (86% vs 67%),
particularly among patients receiving previous antibiotic therapy (100%
vs 36%). All missed organisms by SeptiFast were P. acnes, which can not
be detected due to lack of speciﬁc primers in the PCR kit. With modiﬁed
primer sets, multiplex PCR has the potential for further improvement of
the diagnosis of PJI, particularly in patients receiving antibiotics.
P1829 Direct identiﬁcation of aerobic Gram-positive cocci and
Gram-negative rods from positive bioMerieux blood culture
bottles by GenoType blood culture assay (HAIN)
S. Jolkkonen °, P. Ka¨rpa¨noja, H. Sarkkinen (Lahti, FI)
Objectives: Reliable and rapid identiﬁcation of bacteria directly from
blood cultures is important for the clinicians to help them decide on
appropriate antibiotic therapy. The aim of this study was to evaluate a
DNA strip assay (GenoType blood culture, Hain Lifescience) for the
detection of the most important bacterial sepsis pathogens directly from
positive blood cultures (bioMerieux BacT/Alert FA, SN and PF-bottles).
Methods: The material consisted of 100 positive blood cultures (92
patients, one quality control sample) out of which 152 positive bottles
(FA and/or SN or PF and/or SN) were studied. Gram staining was carried
out to decide whether to use GenoType BC GP (Gram positive cocci)
or GN (Gram negative rods) test. The results were compared with the
routine identiﬁcation methods used in our laboratory. Aerobic bottles (FA
and PF) contain charcoal which in blood culture vials may inhibit PCR
reaction. To exclude the inhibitory effect of charcoal, blood samples were
heated in 95ºC for 5 minutes before DNA extraction. All the samples
regardless of the bottle type were heated and the test was performed
with both heated and unheated samples.
Results: The GenoType BC test was easy to perform and required only
a small amount of blood as starting material (15ml). The results were
available within 5 hours.
The heating of blood samples for 5 minutes in 95ºC before DNA
extraction yielded more results compared to unheated samples. This
was found, not only in FA and PF blood culture bottles which contain
charcoal, but also in SN bottles which do not contain charcoal. In total
we performed the Geno Type test from 152 heated and 152 unheated
specimens. We yielded a result from 122/152 (80.3%) heated bottles
and 107/152 (70.7%) from unheated bottles.
Four blood cultures (4/100) contained multiple pathogens. These were
excluded from the data. Based on Gram staining 62/96 of the samples
were Gram positive and 34/96 were Gram negative. Of the 96 positive
blood cultures, seven (7.3%) were not identiﬁed by GenoType because
the primers for these species are not included in the assay. The
identiﬁcation of the remaining 89 specimens (Table 1) was consistent
with our reference method in 51/56 (91.1%) of Gram positive cocci and
in 30/33 (90.9%) of Gram negative rods.
Conclusions: GenoType Blood culture kits provide fast and reliable
results for the identiﬁcation of the most important sepsis pathogens.
Our results indicate that heating improves tests efﬁciency.
Table 1. Comparison between conventional methods and GenoType assay with either heated or unheated samplesa
Isolate Identiﬁcation
by
conventional
methods (n)
Consistent
results by
GenoType
(n)
Contradictory results by GenoType (n)
Gram-positive cocci
S. aureus 16 16
S. epidermidis 9 9
S. hominis 6 6
S. warneri 2 1 1, No result by GenoType
Staphylococcus spp. 1 0 1, No result by GenoType
Str. pneumoniae 7 7
Str. pyogenes A 4 4
Str. G 2 2
Str. anginosus group 3 2 1, Strain identiﬁed as Str. mitis/oralis by GenoType
Str. mitis 1 0 1, No result by GenoType
E. faecium 2 1 1, No result by GenoType
E. faecalis 3 3
Total 56 51 5
Gram-negative rods
E. coli 21 21
K. pneumoniae 5 4 1, Strain identiﬁed as K. oxytoca by GenoType
P. mirabilis 1 1
Ps. aeruginosa 4 3 1, No result by GenoTtype
Enterobacter aerogenes 1 1
Salmonella Newport 1 0 1, Strain identiﬁed as S. enteritidis/typhimurium by GenoType
Total 33 30 3
a71/89 (79.8%) of the isolates were identiﬁed from heated and unheated bottles.
10/89 (11.2%) of the isolates were identiﬁed only from heated bottles.
3/89 (3.4%) of the isolates were identiﬁed only from unheated bottles.
5/89 (5.6%) of the isolates were not identiﬁed either from heated or unheated bottles.
P1830 Usefulness of PCR on normally sterile body ﬂuids for the
detection of fastidious bacteria
K. Jaton-Ogay °, G. Greub, C. Andre´, J. Bille (Lausanne, CH)
Objectives:Molecular techniques to detect difﬁcult to grow microorgan-
isms in the clinical microbiology laboratory have become routine. Their
contribution to patient care needs to be addressed. Thus, we assessed
here the performance of PCR done on various types of normally sterile
body ﬂuids (i.e articular, pericardic, peritoneal and pleural ﬂuids) for
the detection of fastidious bacteria. These bacteria frequently remain
undetected as they grow poorly or not at all on conventional culture
media.
Methods: A total of 1247 samples (249 articular, 73 pericardic, 161
peritoneal and 764 pleural ﬂuids) were investigated by PCR in our
molecular diagnostic laboratory between 2000 and 2008. The different
home-made molecular tests were 7 real-time TaqMan PCR detecting
Chlamydia trachomatis, Neisseria gonorrhoeae, Mycobacterium tuber-
culosis complex, Borrelia burgdorferi, Chlamydophila pneumoniae,
Mycoplasma pneumoniae, Legionella pneumophila, and 2 broad-range
PCR with classic ampliﬁcation of the 16S rDNA followed by sequencing
of the ampliﬁed product i.e. a bacterial broad-range and a Mycobacterial
spp. broad-range PCR.
Results: On the 1247 samples, 1370 PCR tests were performed. Eighty-
three samples were positive for one of the PCR corresponding to 7% of
the samples. Eleven samples (0.9%) contained inhibitors. In 4 to 14%
of the various types of samples a positive PCR result could document
the infection, with M. tuberculosis complex PCR (4%), bacterial broad-
range PCR (14%), and C. trachomatis (12%), being the most productive
tests (see Table).
For the other PCR results, 2/39 articular ﬂuids were positive for
B. burgdorferi, and 2/37 for N. gonorrhoeae; 1/38 peritoneal ﬂuid
was positive for N. gonorrhoeae; 1/13 pleural ﬂuid was positive for
L. pneumophila and 1/20 for M. pneumoniae. No speciﬁc samples
were positive for C. pneumoniae nor for Mycobacteria spp other then
M. tuberculosis complex.
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Conclusion: Carefully indicated molecular methods could bring a
positive added value over conventional testing especially for fastidious
organisms. Here for 7% (83 out of 1247 normally sterile body ﬂuids
tested by various PCR) a difﬁcult to grow bacteria has been detected
and identiﬁed by speciﬁc PCR or broad-range PCR. The economical
and clinical impact of such a diagnosis strategy need to be assessed.
Fluids Samplesa
All
(n = 1247)
All +
(n = 83)
%of + + for
M. tuberculosis/
total no. of
samples tested
%of + + for bacterial
broad-range
PCR/
total no. of
samples tested
%of + + for
C. trachomatis/
total no. of
samples tested
%of +
Articular 249 21 8% 5/91 5% 12/97 12% 0/20 0%
Pericardic 73 6 8% 5/67 7% 1/11 9% 0/0 –
Peritoneal 161 22 14% 0/21 0% 2/6 33% 19/134 14%
Pleural 764 34 4% 23/699 3% 9/62 15% 0/0 –
Total 1247 83 7% 33/878 4% 24/176 14% 19/154 12%
a+, positive.
P1831 Performance of PCR on adenopathies for the detection of
fastidious pathogens
K. Jaton-Ogay °, G. Greub, C. Andre´, J. Bille (Lausanne, CH)
Objectives: Molecular tools have proven to be extremely useful in
the clinical diagnostic laboratory, especially for detecting difﬁcult to
grow microorganisms. Although technical issues such as reproducibility,
sensitivity, and speciﬁcity of these tests are important, costs and potential
contribution to patient care are also of concern and need to be addressed.
Here, we assessed the performance of PCR on adenopathies, for the
detection of fastidious bacteria, which frequently remain undetected as
they grow poorly or not at all on conventional culture media.
Methods: A total of 377 samples (322 fresh biopsies and 55 parafﬁn-
embedded adenopathies) were investigated by 3 different PCR in our
molecular diagnostic laboratory between 2000 and 2008. These PCR
included 2 in house real-time TaqMan PCR speciﬁc for Bartonella
henselae and Mycobacterium tuberculosis.) and a bacterial broad-range
PCR with classic ampliﬁcation of the 16S rDNA followed by sequencing
of the ampliﬁed product.
Results: On the 377 samples, 483 PCR tests were performed. Ninety-two
samples (73 fresh biopsies and 19 parafﬁn-embedded) were positive for
one of the PCR corresponding to 24% (23% and 35% respectively) of
the samples. Only one sample contained inhibitors. As many as 34% of
the parafﬁn-embedded samples gave a positive result for M. tuberculosis
complex (see Table).
Adenopathies Samples
All
(n = 377)
All
positive
(n = 92)
%of + Positive for
B. henselae/total no.
of samples tested
%of + Positive for
M. tuberculosis/
total no. of samples
tested
%of +
Freshly biopsied 322 73 23% 11/108 10% 60/248 24%
Parafﬁn-embedded 55 19 35% 1/14 7% 18/53 34%
Total 377 92 24% 12/122 10% 78/301 26%
For the bacterial broad-range PCR, 2/23 (1 Rothia mucilaginosa, 1
Pseudomonas spp.) were positive both in freshly biopsied specimens.
Conclusion: Assessing the performance of molecular diagnosis on
clinical management will be the future challenge for molecular diagnosis.
These data will help to better focus the indications for molecular tests.
Here for 24% of the adenopathies tested, a fastidious pathogen has
been detected and identiﬁed by speciﬁc PCR or bacterial broad-range
PCR. Nevertheless more studies with economical and clinical impacts
are needed.
P1832 Is multiplex PCR (SeptiFast) useful for diagnosis of
infectious endocarditis?
A. Conen °, N. Schaub, Y. Achermann, M. Battegay, R. Frei, A. Trampuz
(Basel, CH)
Objectives: Blood cultures (BC) represent the main diagnostic tool in
patients with suspected infectious endocarditis (IE). However, BC can be
false-negative when difﬁcult-to-culture microorganisms are involved or
patients have received previous antibiotic treatment. The multiplex real-
time PCR SeptiFast (Roche Diagnostics) is a culture-independent method
that detects microbial DNA of 25 bacterial and fungal pathogens within
6 h. We assessed the diagnostic value of SeptiFast in comparison with
BC in patients with IE.
Methods:We prospectively included adult patients with suspected native
or prosthetic valve IE, deﬁned as at least 2 SIRS criteria plus 1
major Duke criterion (i.e. bacteraemia with a typical microorganism or
evidence of endocardial involvement by echocardiography), presenting
in the emergency room. Blood was simultaneously drawn for BC
(BacT/ALERT FA/FN, bioMe´rieux) and for SeptiFast (1.5ml EDTA-
blood). If the heart valve was removed, culture, histology and broad-
range PCR were performed. Patients were retrospectively classiﬁed
according to Duke criteria by 2 independent investigators, blinded to
the SeptiFast results, into conﬁrmed or rejected IE.
Results: In this ongoing study (07−12/2008), 23 patients were included,
of whom IE was conﬁrmed in 9 (39%) and rejected in 14 (61%). Among
9 patients with conﬁrmed IE (median age 50 y, range 34−80 y, 44%
males), BC grew the pathogen in 6 (67%) including Staphylococcus
aureus (n = 3), Streptococcus mitis (n = 2) and S. gallolyticus (n = 1);
SeptiFast detected pathogens in 8 of 9 IE-patients (89%), among whom
6 matched BC, 1 patient was positive in SeptiFast only (Escherichia coli)
and 1 in broad-range PCR of the valve (S. agalactiae). In 1 patient with
negative BC and negative SeptiFast, Haemophilus sp. was detected by
broad-range PCR of the valve. 2 of 3 patients with negative BC received
antibiotics before blood collection, among whom both were positive by
SeptiFast. IE involved 4 native, 3 prosthetic (all aortic) and 1 native +
prosthetic valve; in 1 patient the valve was not involved, but 3 minor
Duke criteria were fulﬁlled.
Conclusions: BC detected 6 of 9 (67%) organisms causing IE, whereas
SeptiFast 8 of 9 (89%). SeptiFast detected all 8 organisms for which
speciﬁc primers are included in the test kit and deserves further
investigation in the diagnosis of intravascular infections. A modiﬁed
primer set may further improve detection of organisms causing IE,
including culture-negative IE.
P1833 Multiplex PCR (SeptiFast®) for diagnosis of sepsis in
patients presenting to the emergency room
N. Schaub °, A. Steinhuber, T. Boldanova, M. Noveanu, C. Stelzig,
H. Hermann, R. Frei, M. Siegemund, R. Bingisser, A. Trampuz,
C. Mueller (Basel, CH)
Background: Blood cultures (BC) identify the aetiology of sepsis in
only a minority of patients and results are usually available 1 days
later. More rapid and sensitive tools are needed. We assessed the utility
of the multiplex real-time PCR SeptiFast® (SF) (Roche Diagnostics) to
detect microbial DNA of the 25 pathogens of sepsis within 6 h.
Methods: In this prospective ongoing study, we included unselected
adult patients presenting to the emergency room with suspected sepsis,
deﬁned as core temperature >38.3ºC or <36.0ºC and 1 additional
SIRS criterion. BC (BacT/ALERT, FA/FN, bioMe´rieux) and SF were
simultaneously drawn at presentation and 0.5−2 h thereafter. The ﬁnal
diagnosis of sepsis or non-infectious SIRS was adjudicated by 2
independent investigators unaware of the SF result.
Results: To date (06/07–12/08), 88 patients with suspected sepsis were
included (median age, 65 years; range 29−96 years; 48% males),
of whom 74 (84%) had a conﬁrmed sepsis and 14 (16%) were
diagnosed as non-infectious SIRS. The severity of sepsis was classiﬁed
as sepsis without organ dysfunction in 59 (80%), severe sepsis in 11
(15%) and septic shock in 4 (5%) patients. The infectious foci were
pulmonal (34%), urinary tract (23%), abdominal (12%), skin (9%),
ENT (7%), musculoskeletal (3%), other (4%) and not identiﬁable (8%).
The causative organism was identiﬁed in 40 (54%) sepsis patients by
conventional microbiology, including 21 (28%) with positive BC (14
E. coli, 3 K. pneumoniae, 3 S. aureus, 1 S. pyogenes). Median time to
positivity was 17 h (range 6−45 h). SF revealed the causative organism
in 17 (23%) patients with sepsis, of which 14 matched the BC result.
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3 samples were positive in SF only (E. coli – cholangitis, E. coli –
urosepsis, S. aureus – primary sepsis), whereas 7 samples were positive
in BC only (5 E. coli – urosepsis, 1 S. aureus – implant infection,
1 S. pyogenes – erysipelas). In patients with non-infectious SIRS, BC
were positive in 2 patients (both contamination with coagulase-negative
staphylococci), while SF remained negative. Table shows the overall test
performance (%) of BC and SF in diagnosis of sepsis.
Conclusion: In patients with conﬁrmed sepsis, BC detected the causative
organism in 21 (28%) and SF in 17 (23%). BC missed the causing
organism in 3 and SF in 7 sepsis patients, reﬂecting discontinuous
bacteraemia/DNAemia in these patients or limited sensitivity of the
respective assay. SF warrants further evaluation for the diagnosis of
sepsis.
Parameter Blood culture (BC) SeptiFast® (SF)
Sensitivity 28% 23%
Speciﬁcity 86% 100%
Positive predictive value 91% 100%
Negative predictive value 19% 20%
Accuracy 38% 35%
P1834 Contribution of the real-time polymerase chain reaction
from heart valve tissue for the diagnosis of infective
endocarditis
R. Boussier, F. Denis, M.C. Ploy, F. Garnier ° (Limoges, FR)
Objectives: We conducted a retrospective study to compare the results
of conventional microbiology with real-time PCR approach directly from
explanted heart valve tissues infective endocarditis (IE).
Method: We analyzed 82 valves obtained from patients with deﬁnite
IE using the modiﬁed Duke criteria. For each valve, we have performed
conventional cultivation method and real-time PCR assay using the Smart
Cycler® II (Cepheid, Instrumentation Laboratory) with the researches
of Bartonella, Tropheryma whipplei, Coxiella burnettii, Chlamydia
pneumoniae and Mycoplasma pneumoniae and universal gene encoding
16SrRNA (with primers 91E and 13BS). Ampliﬁcation products obtained
with the universal primers were sequenced and analyzed with the BIBI
GenBank.
Results: On the 82 valves, we isolated bacterial strains from 22 (26.8%)
by conventional culture and we obtained an ampliﬁcation product with
the universal RT-PCR for 18 (22%) valves with a concordance in 5
cases. The RT-PCR allowed to detect a bacterial origin of the IE in
13 new cases. When culture and universal RT-PCR were associated, a
bacterial identiﬁcation was obtained in 35 cases, corresponding to 42.7%
of patients (see Table).
Results of conventional culture and universal RT-PCR
Positive PCRs Negative PCRs Total
Positive cultures 5 17 22
Negative cultures 13 47 60
Total 18 64 82
In two supplementary cases, T. whipplei was identiﬁed by speciﬁc in-
house RT-PCR, whereas all other speciﬁc RT-PCRs were negative.
Conclusion: RT-PCRs appear as complementary methods of the
conventional culture for the diagnosis of IE from explanted heart valve
tissues notably for patients without blood cultures or with negative blood
cultures. It must be noted that the culture remains the reference method
since it allow to obtain the antimicrobial susceptibility of strains from
positive cultures.
P1835 The Mobidiag Prove-it sepsis PCR and microarray
platform: a 2-centre study designed to validate a system for
speciating blood culture bacterial isolates within 3 hours
P. Tissari, S. Mero, L. Savolainen, E. Tarkka, M. Vaara, A. Aittakorpi,
S. Laakso, M. Lindfors, H. Piiparinen, M. Ma¨ki, C. Carder, J. Huggett,
V. Gant ° (Helsinki, FI; London, UK)
Objective: Better, more efﬁcient clinical management would ﬂow from
quicker identiﬁcation of organisms in blood culture to taxon and/or
species level. The Mobidiag Prove-it Sepsis PCR and microarray
platform is designed to speciate the most common blood culture-
related organisms within 3 hours of positive blood culture ﬂagging by
conventional systems.
Methods: We compared this system’s diagnostic performance with
conventional identiﬁcation systems in two major teaching hospitals in
Helsinki and London.
Results: 3298 blood cultures were analysed, of which 2087 yielded a
pathogen by conventional techniques. Of these, 320 organisms were
not covered by appropriate probes, and 135 contained more than one
organism. Prove-it Sepsis sensitivity and speciﬁcity were 98% and 96%,
respectively, for blood cultures containing a single organism within the
detection panel. The system provided a result on average 18 hours earlier
than conventional systems. Of particular signiﬁcance was its faultless
ability to differentiate MRSA from MSSA and from coagulase negative
staphylococci. Investigation of discrepant results revealed 30 cases where
the system’s sensitivity limits were likely exceeded; other discrepant
cases related to human error, likely contamination during the extraction
stage, and the system’s limitations relating to blood cultures containing
more than one organism. Other issues relating to batch reagent variation
were also identiﬁed and corrected within the trial timeframe. The system
proved to be fast, reliable, robust, and rapid, with biochip analysis taking
less than 10 seconds per sample.
Conclusions: Both centres identiﬁed cases where timely information
which only this system could provide would have signiﬁcantly improved
patient management. Examples here include more rational antibiotic
choice both through rapid differentiation of MRSA from either S. aureus
or coagulase negative staphylococci, and speciation of Gram negative
organisms. Once primers and probes for additional targets (speciﬁcally
Candida spp.) are validated, we aim to perform a cost/beneﬁt trial where
decisions made with results provided by this simple, rapid, and robust
diagnostic platform will be analysed for their impact on better patient
outcome.
P1836 Comparison of molecular biology-based methods and
culture methods in diagnosing infectious endophthalmitis
S. Zimmermann °, F. Mackensen, U. Wiehler, M. Becker, A. Dalpke
(Heidelberg, DE)
Objective: Rapid detection of the infectious pathogen is crucial when
confronted with a patient with endophthalmitis. Conventional culture
methods used to be the standard. Developments in molecular biology
allow new approaches in the diagnostic of ocular ﬂuids such as PCR of
intraocular ﬂuids. Especially broad-range PCR testing for 16S ribosomal
genes have increased detection rates and help to decrease contamination.
18 months ago we changed our approach to endophthalmitis diagnostics
and want to report ﬁrst results.
Methods: Intraocular ﬂuids (anterior chamber and/or vitreous) of
patients presenting with acute or chronic endophthalmitis were obtained.
Culture medium was inoculated with the undiluted specimen directly in
the operating room. Remaining specimen was left in the sterile syringe
and used for eubacterial PCR. A positive result was sequenced with
speciﬁc primers.
Results: In 12 of 24 patients (50%) a speciﬁc pathogen could be detected
with PCR within 1−2 days. Later the results could be conﬁrmed by
culture. There were no discrepancies between both methods regarding
the detected pathogen. In 12 patients no pathogen could be identiﬁed
with either method.
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Conclusions: Compared to culture PCR allows a faster detection of
microbes in endophthalmitis patients. This is very important regarding
the therapeutical consequences. The number of cases with negative
results in both methods remains high in our study.
P1837 Molecular charecterisation of S. pneumoniae with reduced
susceptibility to macrolides
A. Martynova °, E. Sokurova, K. Smirnov (Vladivostok, RU)
Despite of the gained results in treatment and diagnostics, S. pneumoniae
is still remaining the actual pathogen of pneumonias, meningitids etc.
Macrolide resistance has been reported to be high among pneumococci
in Asian countries, but there is no information on macrolide resistance of
Streptococcus pneumoniae at the Far East of Russia. The main objective
of this study was to characterise isolates of S. pneumoniae with reduced
susceptibility to macrolides by different typing methods and to evaluate
possible ways of clonal dissemination.
Methods: Isolated 48 macrolide non-susceptible strains of pneumococ-
cus were serotyped, PCR with macrolide resistance primers, molecular
typed by pulsed-ﬁeld gel electrophoresis (PFGE) and automated
ribotyped. Antimicrobial agents resistance was studied by NCCLS
standards.
Results: A total of 35.82% (48 of 134 strains) of the S. pneumoniae
strains were resistant to erythromycin with a MIC of 1.0 g/ml. Of
these, 31.25% (15of 48) showed an MLSB phenotype with erythromycin
and clindamycin; 66.6% showed resistance to erythromycin alone
(M phenotype). One isolate was postive with both ermB and mefE
primers. Of the isolates expressing the MLSB phenotype, only the ermB
gene was detected in 86.63% (13 strains of 15) of the isolates by PCR.
Two isolates were repeatedly negative on testing for ermB but were
positive for ermA gene. Before 2000, it was recorded that among the
erythromycin-resistant S. pneumoniae isolates, the majority (78%) had
an ML phenotype and 22% had an M phenotype. The isolates were
distributed among four major serotypes: 23F (29.1%), 14 (35.4%), 18C
(25%), 6B (12.5%). However, distinct molecular patterns were detected
among isolates with a unique serotype. Six and eight PFGE patterns
were identiﬁed among isolates with serotype 23F and 18C, respectively.
When PFGE and automated ribotyping analyses were combined, ﬁve
clusters were identiﬁed. The largest cluster (14 isolates) was represented
by isolates heterogeneous but six were highly similar to the Spanish
multidrug-resistant 23F clone although possibly related to the Taiwan
multidrug-resistant 23F clone.
Conclusion: New techniques allowed us to evaluate the clonal
dissemination of S. pneumoniae strains and they should be more wide
included to the epidemiology surveillance schemes.
P1838 Invasive and pharyngeal emm-3 Streptococcus pyogenes
infections in Norway: a molecular genetic analysis
R. Meisal °, E.A. Høiby, J.M. Musser, D.A. Caugant (Oslo, NO;
Houston, US)
Group A streptococci (GAS) are important pathogens worldwide, mostly
causing mild forms of disease, such as impetigo and pharyngitis,
but invasive and life-threatening forms of disease, such as necrotising
fasciitis (NF) and streptococcal toxic shock syndrome may occur. After
the introduction of penicillin GAS disease almost disappeared, but since
the late 1980 s it has re-emerged, showing a marked increase both in
incidence and severity in Norway. Moreover, strains with the emm-3
variant of the gene coding for the M-protein, a major virulence factor,
are often associated with higher mortality rates and higher frequencies
of NF than are other strains.
Objectives: To better understand the role of emm-3 GAS in disease
production 128 emm-3 pharyngeal and invasive isolates from 1988–
2003 were analyzed with respect to their content of prophages which
harbours superantigens and other important virulence factors, and for
the Streptococcus collagen-like protein B (SclB) which is associated
with NF.
Methods: Analysis was performed using standard PCR, electrophoresis
using E-Gel, Sanger sequencing on a ABI 3730 DNA analyzer, and
principal component analysis (PCA) for motif pattern analysis.
Results: Both pharyngeal and invasive isolates were mainly emm-3.1 and
prophage proﬁle, phi-G3.01. In 1993 sclB harbouring 5-CAAAA tandem
repeats emerged and by 2003, this was the only number of in-frame
repeats observed. The variable collagen structural motif (CSM) region
of SclB was highly modular mainly consisting of two novel motifs;
M3CSMR-1 and -2, organised into unique motif-patterns for most of
the strains. A third motif M3CSMR-3 was also found for eleven strains,
nine of which originated from the same geographical location. It was
not possible to discern between motif patterns produced by invasive or
pharyngeal strains by PCA.
Conclusion: Taken together, the Norwegian emm-3 GAS are relatively
homogenous, dominated by the widespread subtype emm-3.1, and the
prophage proﬁle phi-G3.01. It also became clear that a successful strain
variant harbouring a sclB with 5 CAAAA repeats emerged in 1993 and
was associated with the increase in emm-3 cases of invasive disease.
Furthermore, the CSM region of sclB was found to be consisting of two
novel emm-3 speciﬁc conserved motif repeats, displaying highly variable
motif patterns.
P1839 Restoration of the wild-type phenotypes in Streptococcus
pyogenes rgg mutant strains depends on the expression
level of Rgg transcriptional regulator
A.V. Dmitriev °, E.J. McDowell, K.V. Kappeler, S. Anbalagan,
M.S. Chaussee (St. Petersburg, RU; Vermillion, US)
Objectives: The clinical outcomes of Streptococcus pyogenes infections
range from mild pharyngitis to severe toxic shock syndrome and
necrotising fasciitis. The expression of S. pyogenes virulence factors
is coordinately regulated transcriptionally, translationally and post-
translationally. Rgg is a global transcriptional regulatory protein
necessary for SpeB expression. In a strain-speciﬁc manner, Rgg
additionally affects numerous phenotypes such as virulence, tolerance
to thermal and oxidative stress, fermentation of amino acids during the
exponential phase of growth, and the ability to grow in enriched and
chemically deﬁned media, among others. Given the potential differences
in expression level of Rgg in S. pyogenes strains, it was of interest to
determine if a correlation existed between the Rgg-regulated phenotypes
and the level of Rgg expression.
Methods: The wild-type S. pyogenes strains NZ131, SF370, and
their rgg isogenic mutants were used. Rgg expressing plasmids were
constructed by methods of genetic engineering. Complementation of the
rgg mutants was done episomally and chromosomally under inducible
promoter and chromosomally under native rgg promoter. Chromosomal
complementation was done by the insertional mutagenesis. Phenotypes
of all the strains were analyzed by the methods of biochemistry and
microbiology. Gene expression levels were assessed by quantitative RT-
PCR.
Results: The rgg gene was cloned into pMSP3535 vector under control
of a nisin-inducible promoter and introduced into the rgg mutant strains
resulting in episomal complementation of the rgg gene. Alternatively, the
rgg gene was cloned into a suicide vector, which was unable to replicate
in streptococci. Subsequently, an intact rgg gene was chromosomally
restored either under inducible promoter or native rgg promoter.
Restoration of rgg in the chromosome under the control of native
promoter restored wild-type phenotypes, as determined by qRT-PCR
and biochemical assays. In contrast, both episomal complementation
and chromosomal complementation of rgg under control of an inducible
promoter, resulting in over-expression of rgg, did not restore any of
metabolic properties associated with the wild-type strain.
Conclusion: Rgg transcriptional activity depends on the rgg expression
level. Given the importance of the rgg level in controlling virulence
factor expression in S. pyogenes, further characterisation of the
mechanism of Rgg-mediated gene transcription is necessary.
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P1840 Inactivation of the transcriptional regulator mutR gene
affects virulent phenotype of Streptococcus pyogenes
A.A. Zutkis °, A.V. Dmitriev, M.S. Chaussee, A.A. Totolian (St.
Petersburg, RU; Vermillion, US)
Objectives: Streptococcus pyogenes (group A streptococcus) is Gram-
positive pathogen exclusively adapted to humans. It is able to colonise
numerous organs and tissues and cause a variety of diseases. In
order to adapt changing environmental conditions, S. pyogenes employs
different mechanisms of gene regulation, in particular, by the global
genome transcriptional regulators, such as Mga, Rgg, RofA-like proteins
and others. The MutR protein, which is encoded by the mutR gene
is a putative transcriptional regulator and belongs to Rgg-family of
regulators. The goal of this study is to analyze the potential role of
MutR protein in S. pyogenes virulence.
Methods: A total of 20 S. pyogenes strains of different serotypes were
used. The methods of molecular microbiology and genetic engineering
were employed for cloning of the mutR gene fragment. Inactivation of
the mutR gene in strain SF370 was done by insertional mutagenesis.
Growth of the strains was analyzed in Todd-Hewitt broth. Virulent
properties of the mutR mutant and parental SF370 strain were analyzed
using intraperitoneal model of streptococcal infection in laboratory mice.
Virulence was assessed by the lethal coefﬁcient.
Results: The mutR gene was revealed in all the strains under analysis.
The SacI-PstI internal fragment of the mutR gene was cloned in
the vector, which is unable to replicate in Gram-positive cocci. This
recombinant plasmid was used to inactivate the mutR gene in strain
SF370. Erythromycin resistant clones were screened and the insertion
of recombinant plasmid in the chromosomal DNA was conﬁrmed by
PCR and nucleotide sequencing. Growth curves of the mutR isogenic
mutant and parental SF370 strain were analyzed in Todd-Hewitt broth.
The strains demonstrated signiﬁcant difference in the growth rate; the
lag-phase of the mutant strain was 30 minutes, compared to 60 minutes
for the wild-type strain. The maximum OD600 values reached were
1.1 and 0.8 for the mutR mutant and wild-type strain, respectively.
Two infectious doses, 1×108 and 5×108 CFU/animal, were used for
intraperitoneal model of streptococcal infection. With these infectious
doses, the wild-type strain demonstrated the lethal coefﬁcients equal to
0.13 and 0.22, respectively. The virulence of mutR isogenic mutant was
dramatically decreased: neither 1×108 no 5×108 CFU/animal resulted
in the death of laboratory mice.
Conclusion: The MutR transcriptional regulator plays an important role
in the virulence of S. pyogenes.
P1841 Comparison of Gene Xpert real-time PCR and various
culture methods for the detection of group B Streptococcus
in rectovaginal samples from ante-natal women
A. Curry °, M. Walsh, M. Matheson, E. Collins, A. Donegan,
S. Knowles (Dublin, IE)
Group B Streptococci (GBS) is an important cause of maternal and
neonatal infection. The Gene Xpert real time polymerase chain reaction
(PCR) was evaluated for the detection of GBS and was compared with
various culture methods.
Four ATCC strains: GBS, Enterococcus faecalis, E. coli and Staphy-
lococcus aureus in pure and mixed cultures were initially trialled on
the Gene Xpert. Low vaginal/rectal GBS screening of 102 antenatal
women, using a double-swab, were compared using the Gene Xpert and
5 different culture methods. One swab was inoculated directly onto blood,
ChromID CPS, neomycin blood and Granada agars and then placed in
Todd Hewitt enrichment broth. The enrichment broth was subcultured
onto ChromID CPS following overnight incubation. All suspect colonies
underwent streptococcal grouping in order to conﬁrm the presence or
absence of GBS. The second swab was used for the Gene Xpert PCR.
All ATCC strains gave the expected results for the presence or absence
of GBS in both pure and mixed cultures using the PCR system. Among
patient samples, culture was used as the ‘Gold Standard’. The Gene
Xpert PCR and ChromID CPS agar following enrichment in Todd Hewitt
showed good sensitivity at 92% and 96% respectively. Direct culture
methods onto the various agars showed lower sensitivity for the detection
of GBS, with sensitivity of direct culture on ChromID CPS lowest at 61%
and highest on Granada agar at 83%. In two women the Gene Xpert
PCR was positive and the culture negative for GBS. The speciﬁcity of
ChromID CPS following enrichment in Todd Hewitt was 100%; Granada
agar 99%; Gene Xpert PCR 98% and direct culture of ChromID CPS
97%. All methods gave good negative predictive values ranging from
97−99%. Direct culture of ChromID CPS agar gave the lowest positive
predictive value at 82% but this increased to 100% following enrichment;
the Gene Xpert PCR was 92% and Granada agar 95%.
The Gene Xpert is a rapid method taking approximately 1.5 hours from
receipt of specimen to result, compared with culture methods, which
can take 24−48 hours. However it is more expensive and culture must
be retained in order to perform susceptibility testing if the patient is
penicillin allergic. In conclusion, the Gene Xpert is a sensitive and
speciﬁc method which provides rapid results for the presence of absence
of GBS in ante-natal women and may be useful for rapid intrapartum
testing.
P1842 Evaluation of two real-time PCR methods to direct
detection of group B streptococci against conventional
chromogenic cultures
I. Jesus de la Calle °, M. Roman-Enry, M.A. Rodrı´guez-Iglesias (Cadiz,
ES)
Objectives: Group B streptococcal disease remains a leading infectious
cause of morbidity and mortality among newborns. Asymptomatic
carriage of group B streptococci (GBS) in the maternal genitourinary
tract or gastrointestinal tract commonly leads to colonisation of the
neonate. Real-time PCR (PCR) methods that offer the ability to detect
GBS colonisation within 1 h of sample receipt have also been developed.
The aim of this study was to assess the use of these 2 new molecular
methods in comparison with conventional culture methods for the
isolation of GBS from vaginal-rectal swabs.
Methods: A total of 103 consecutive vaginal-rectal swabs from distinct
pregnant women were included in this study. Any red colonies on
Granada Agar agar were regarded as presumptive GBS. Such colonies
were conﬁrmed as GBS using latex agglutination for group B antigen.
Two commercial PCR was tested: i) BD GeneOhm StrepB Assay (Becton
Dickinson, USA) based in the ampliﬁcation of cfb gene sequence
of GBS and ﬂuorogenic target-speciﬁc hybridisation for the detection
of the ampliﬁed DNA; and ii) Speed-Oligo Group B Streptococcus
(Vircell, Spain), that use a real-time PCR method and detection of
DNA through hybridisation in a dipstick device based in reactive lines
with colloidal gold technology. All methods follow the manufacturing
recommendations.
Results: Twenty-one GBS strains could be isolated by culture from
103 samples. BD GeneOhm StrepB Assay detects DNA in 16 samples
with positive culture and one sample with negative culture. However,
Speed-Oligo Group B Streptococcus could detect DNA in 19 samples
with culture positive and 4 samples with negative culture. Sensitivity,
speciﬁcity, positive and negative predictive values was respectively 76.1,
98.7, 94.1, and 94.1 for GeneOhm versus 90.4, 95.1, 82.6, and 97.5 for
Speed-Oligo. Analysing the discrepancies there was a close correlation
between CFU in the culture and false negative in molecular test. In false-
positive we cannot exclude the further possibility that PCR was detecting
the presence of nonviable.
Conclusions: The PCR assay is rapid (<1 h) and is, therefore,
particularly useful if testing needs to be performed during labour. This is
an attractive option because colonisation with GBS may be transient, and
results achieved weeks before labour may no longer be relevant at time
of delivery. Although routine use of PCR during labour would require a
local availability of a 24-h service, and a greater expense per test.
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P1843 Inactivation of DNA-binding response regulator Sak189
abrogates b-antigen expression and affects virulence of
Streptococcus agalactiae
A. Rozhdestvenskaya °, Y. Il’yasov, I. Mikula, M. Bhide, A. Totolian,
A. Dmitriev (St. Petersburg, RU; Kosice, SK)
Objectives: Streptococcus agalactiae (group B streptococcus) is able to
colonise numerous tissues and to cause variety of diseases in human
and animals. This bacterium rapidly adapts to changing environmental
conditions employing different mechanisms of gene regulation. Recently,
putative two-component regulatory system genes encoding for sensor
histidine kinase (sak188) and DNA-binding response regulator (sak189)
were identiﬁed in S. agalactiae. They were located on pathogenicity
island downstream the bac gene encoding for b-antigen with IgA binding
capacity, which was supposed to be important virulence factor. Given
their adjacent location in the genome, we suggested that Sak188/Sak189
system inﬂuenced b-antigen expression and virulence properties in
S. agalactiae.
Methods: S. agalactiae strain 168/00 was used in the study. sak188 and
sak189 isogenic mutants were constructed by insertional mutagenesis.
Microbiological and biochemical properties of the mutant strains were
compared with those of 168/00. Cell lysates were analyzed by SDS-
PAGE and western blotting. Virulence properties of the strains were
assessed using intraperitoneal model of streptococcal infection in
laboratory mice.
Results: DNA fragments of sak188 and sak189 genes were cloned in the
vector unable to replicate in streptococci. These recombinant plasmids
were used to inactivate sak188 and sak189 genes in the strain 168/00,
respectively. Analysis of the growth in Todd-Hewitt broth revealed
slightly slower growth of the mutant strains compared to the parental
strain. SDS-PAGE demonstrated no difference among the mutant strains
and wild-type strain, with the exception of a single band of about 140
kDa, which was present in wild-type strain and sak188 mutant, but not
in sak189 mutant. Western blotting identiﬁed this protein as b-antigen.
Experimental streptococcal infection in vivo demonstrated an increase in
virulence properties of sak189 mutant compared to the wild-type strain
and sak188 mutant.
Conclusion: DNA-binding response regulator Sak189 is necessary
for b-antigen expression. Inactivation of the sak189 gene affects
S. agalactiae virulence.
P1844 Characterisation of group G streptococcal strains recovered
from humans
P. Lyskova °, M. Vydrzalova, T. Kroupa, J. Mazurova (Pardubice, CZ)
Background: Group G streptococci form a heterogeneous group
of microorganisms. In humans, they may colonise pharynx, skin,
gastrointestinal and female genital tract. However, they have been
reported with increasing frequency as a cause of variety of human
infections with clinical manifestations similar to infections caused by
S. pyogenes. Recently, group G streptococci have been associated with
severe invasive infections such as necrotising fasciitis and toxic shock
syndrome.
Method: In present study 200 strains of group G streptococci isolated
from ambulant and hospitalised patients in Pardubice were collected.
Strains were identiﬁed using PCR aimed at species-speciﬁc parts of
the 16S-23S rDNA intergenic spacer region. Isolated strains were
further searched for genes encoding streptococcal exotoxins including
those with superantigenic or mitogenic activities (sagA, spegg, smeZ).
Antimicrobial susceptibilities were determined by microdilution method
according to the CLSI recommendations.
Results: Out of 200 group G streptococcal strains, 185 were identiﬁed
as S. dysgalactiae ssp. equisimilis and 5 as S. canis. The sagA
gene was detected in 97% S. dysgalactiae ssp. equisimilis and
60% of S. canis strains. All group G streptococcal strains were
PCR-negative for the presence of spegg and smeZ using primers
that anneal to structural gene sequences. All strains were suscep-
tible to penicillin (MIC 0.063mg/l), ampicillin (MIC 0.125mg/l),
ampicillin/sulbactam (MIC 0.125mg/l), cefatotin (MIC 0.125mg/l),
nitrofurantoin (MIC 16mg/l), teicoplanin (MIC 0.5mg/l) and van-
comycin (MIC 0.5mg/l). The least effective antimicrobial agent was
found to be tetracycline (MIC> 16mg/l).
Conclusion: Although group G b-haemolytic streptococci don’t belong
among common streptococcal species, their importance should not be
underestimated. S. dysgalactiae ssp. equisimilis is associated with 5−8%
of human streptococcal infections, including serious, life-threatening
states. S. canis, important animal pathogen, may cause similar symptoms
when infecting human. This work was supported by MSM 0021627502.
P1845 Emm-types of group A and G streptococci: invasive and
noninvasive strains
S. Va¨ha¨kuopus °, R. Vuento, J. Syrja¨nen, J. Vuopio-Varkila (Helsinki,
Tampere, FI)
Objectives: This study aims to characterise molecular properties of
invasive and noninvasive group A (GAS) and group G streptococci
(GGS). We compare strains isolated from superﬁcial and invasive
infections to see if tissue speciﬁcity is found.
Methods: During a six month period, 122 GAS and 138 GGS strains
were collected in Pirkanmaa Health District from patients with various
streptococcal infections. Each month approximately ten ﬁrst clinical
throat and skin isolates were selected amongst GAS and GGS isolates for
analysis. In addition, all blood and deep tissue isolates were collected.
Altogether, we collected 124 throat (62 GAS, 62 GGS), 101 skin (45
GAS, 56 GGS), 11 abscess (6 GAS, 5 GGS) and 22 blood isolates (8
GAS, 14 GGS), one bursa isolate (GAS) and one deep tissue isolate
(GGS). All strains were characterised using emm typing.
Results: Among GAS 19 different emm types were found. Emm1 and
emm28 were the most prevalent types (23%, 21%, respectively). Other
common types among GAS were emm12 (12%), emm77 (12%) emm89.0
(12%). Emm77 was found more often on skin than other sites (p = 0.005)
whereas emm1 and emm12 were more often found on throat than other
sites (p = 0.017 and p = 0.025, respectively). Among GGS we found 18
different emm-types. Typing of seven GGS strains is still ongoing. The
most prevalent emm types among GGS were stG480 (25%), stG643
(20%) and stC6979 (10%).
Conclusions: Several emm types were found from GAS and GGS. Most
of the emm types are found from strains isolated from different infection
sites. In GGS no association between emm types and isolation site was
detected. In GAS emm77 associated with skin infections and emm1 and
emm12 with throat infections. Emm typing may not be the best method
to determine the tissue speciﬁcity of the streptococci strains.
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P1846 Telavancin activity against S. aureus and coagulase-negative
staphylococci collected from clinical infections in Europe
(2007–2008)
H. Sader, P. Rhomberg °, R. Jones (North Liberty, US)
Objectives: To assess the activity of telavancin, a potent investigational
lipoglycopeptide agent with a multifunctional mechanism of action, and
rapid bactericidal activity, against Gram-positive bacterial pathogens. We
compared the antimicrobial potency of telavancin to key comparator
agents by testing contemporary European (EU) clinical strains of
S. aureus and coagulase-negative staphylococci (CoNS).
Methods: A total of 7,534 non-duplicate staphylococci including 5,726
S. aureus (oxacillin-resistant [OX-R], 27.5%) and 1808 CoNS (OX-R,
76.8%) were submitted in 2007 and 2008 as part of a Telavancin
Surveillance Program from 28 medical centres in 11 EU countries,
Turkey (2 sites) and Israel (1 site). Susceptibility (S) testing was
performed on all strains using CLSI broth microdilution methods (CLSI,
M7-A7 2006).
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Results: All EU staphylococcal strains were inhibited by telavancin at
0.5mg/L. For both S. aureus (MIC50/90, 0.12/0.25mg/L) and CoNS
(MIC50/90, 0.12/0.25mg/L), telavancin MIC results were identical
when comparing OX-S and OX-R subsets. There was no variation in
MIC results for telavancin among S. aureus strains based on source
of infection or by the eight major CoNS species groups analyzed.
Highest vancomycin MIC values for CoNS species were observed for
S. haemolyticus strains. Highest teicoplanin MIC values among CoNS
were among S. haemolyticus and S. capitis strains. S. aureus strains from
Ireland/United Kingdom had the highest MRSA rate (39.5%) followed
by Italy (28.9%), France (26.5%), Spain (23.8%) and Germany (16.2%).
CoNS teicoplanin-R rates ranged from 1.7% (Italy), 0.7% (France),
and 0.3% (Ireland/United Kingdom) to 0.0% (Germany and Spain).
Telavancin activity against staphylococci is summarised in the Table.
Organism (no. tested) No. of strains (cumulative %) inhibited at telavancin MIC (mg/L) of:
0.015 0.03 0.06 0.12 0.25 0.5 1
SA (5726) – 16 (0.3) 382 (7.0) 3722 (72.0) 1574 (99.4) 32 (100.0) –
OX-S (4150) – 14 (0.3) 251 (6.4) 2765 (73.0) 1099 (99.5) 21 (100.0) –
OX-R (1576) – 2 (0.1) 131 (8.4) 957 (69.2) 475 (99.3) 11 (100.0) –
CoNS (1808) 12 (0.7) 13 (1.4) 176 (11.1) 1003 (66.6) 566 (97.9) 38 (100.0) –
OX-S (420) 2 (0.5) 9 (2.6) 56 (16.0) 236 (72.1) 113 (99.1) 4 (100.0) –
OX-R (1388) 10 (0.7) 4 (1.0) 120 (9.7) 767 (64.9) 453 (97.6) 34 (100.0) –
Conclusions: Telavancin was highly active (all MIC values at
0.5mg/L) against both S. aureus and CoNS isolates collected in
EU medical centres during 2007 and 2008. No variation in telavancin
MIC was observed for staphylococci when categorised by oxacillin
susceptibility, infection site, species or geographic origin. Continued
surveillance to detect emergence of resistance is warranted to monitor
this new lipoglycopeptide.
P1847 Antimicrobial activity of telavancin tested against
streptococcal species isolates collected from European
medical centres (2007–2008)
P. Rhomberg °, H. Sader, R. Jones (North Liberty, US)
Objectives: To determine the antimicrobial potency and spectrum of
activity of telavancin and key comparator agents against b-haemolytic
streptococci (BST), S. pneumoniae (SPN) and viridans group strep-
tococci (VGS) recovered from patient infections in European medical
centres. Telavancin is a potent investigational lipoglycopeptide agent
possessing a multifunctional mechanism of action and displaying
rapid bactericidal activity against aerobic and anaerobic Gram-positive
bacterial pathogens.
Methods: A total of 2,856 streptococcal clinical isolates including BST
(820), SPN (1714) and VGS (285) were collected in 2007–2008 from
28 medical centres in 11 European countries, Turkey (2 sites) and Israel
(1 site) as part of a Telavancin Surveillance Program. Susceptibility (S)
testing for all strains was performed using the CLSI broth microdilution
method (M7-A7; 2006) at a central processing laboratory.
Results: Against BST, telavancin was 16-fold more potent (MIC50;
0.03 vs. 0.5mg/L) than vancomycin (VAN). Telavancin was more active
against Group A BST (MIC90, 0.03mg/L) compared to Groups G and B
BST (0.06 and 0.12mg/L, respectively). All VGS and SPN strains were
inhibited by telavancin at 0.12mg/L. Telavancin (MIC90, 0.06mg/L)
was also 16-fold more active than VAN (MIC90, 1mg/L) against VGS
strains. Telavancin results for the 4 major species of VGS were analyzed
separately and no MIC variation was observed among these organisms.
SPN strains from Italy and Spain had telavancin MIC results (MIC50/90;
0.03/0.06mg/L) slightly higher compared to France, Germany and
Ireland/United Kingdom (MIC50/90; 0.015/0.03mg/L). Similarly, SPN
isolates from community-acquired respiratory tract infections exhibited
telavancin MIC values slightly higher (MIC50/90, 0.06/0.12mg/L) than
those from bloodstream infections (MIC50/90, 0.03/0.03mg/L). Overall,
15.3 and 1.4% of SPN were resistant to penicillin and levoﬂoxacin,
respectively. Telavancin activity is summarised in the Table.
Conclusions: Telavancin was highly active against BST, VGS and SPN
streptococcal strains isolated from European medical centres cultured
in the past two years (2007–2008); all streptococci were inhibited
at 0.25mg/L. Telavancin was four- to 16-fold more potent than
vancomycin overall, based on both MIC50 and MIC90 values. Continued
monitoring for resistance emergence among Gram-positive streptococcal
species is warranted to detect possible threats to this potent new
therapeutic agent.
Organism (no. tested) MIC
(mg/L)
Cumulative % inhibited at MIC
(mg/L):
50% 90% 0.015 0.03 0.06 0.12 0.25
BST (820) 0.03 0.12 13.5 57.2 87.9 99.4 100.0
Group A (341) 0.03 0.03 27.9 93.0 99.7 100.0 –
Group B (330) 0.06 0.12 0.0 11.8 72.4 98.5 100.0
SPN (1714) 0.03 0.03 49.5 95.3 99.8 100.0 –
VGS (285) 0.03 0.06 14.2 69.8 95.1 100.0 –
P1848 Telavancin antimicrobial activity when tested against
enterococci and uncommonly isolated Gram-positive species
(European sample for 2007–2008)
R. Jones, P. Rhomberg °, H. Sader (North Liberty, US)
Objectives: To determine the potency and spectrum of activity of
telavancin, an investigational lipoglycopeptide, against selected Gram-
positive organisms (Enterococcus spp. and rare species) isolated in
European (EU) medical centres in 2007–2008. Telavancin is under
FDA/regulatory review for skin and skin structure infections (SSSI) and
hospital-acquired pneumonia (HAP) indication.
Methods: A total of 13,565 EU isolates of Gram-positive cocci were
tested, of which 2,210 were enterococci (1,337 E. faecalis [EF]; 809
E. faecium [EFM] and four other species having samples of >10 isolates
(B. cereus [BC; 11], L. monocytogenes [LM; 14], M. luteus [ML;
17], Corynebacterium spp. [CS; 30]. All 2,282 isolates were processed
by reference broth microdilution method in a central laboratory
(JMI Laboratories) with validated identiﬁcations and concurrent QC
procedures per CLSI M100-S18 (2008).
Results: Activity of telavancin versus the most prevalent enterococci are
listed in the Table.
Table:
Organism (no. tested) MIC (mg/L) Cum. % inhibited at MIC (mg/L):
50% 90% 0.06 0.12 0.25 0.5 1 2
VSEF (1,320) 0.25 0.5 1.1 16.6 72.2 99.6 100.0 –
VREF (17) >2 >2 – – 5.9 17.7 17.7 23.6
VSEFM (543) 0.06 0.12 71.3 98.1 100.0 – – –
VREFM (216) 2 >2 17.1 23.1 26.3 27.7 35.1 81.5
E. avium (24) 0.06 0.12 70.8 91.6 91.6 91.6 100.0 –
E. gallinarum (16) 0.5 1 12.5 43.8 43.8 56.5 100.0 –
Telavancin was more active against EFM (four-fold) then EF.
Vancomycin (VAN) resistance (R) adversely affected telavancin MIC
results for both EF and EFM increasing MIC90 results to >2mg/L,
however, VAN-susceptible (S) EF (MIC90, 0.5mg/L) and EFM (MIC90,
0.25mg/L) were telavancin-S. The telavancin MIC90 (mg/L) for
E. avium, E. gallinarum, BC, LM, ML and CS were 0.12, 1, 0.12,
0.06, 0.06 and 0.06mg/L, respectively. Against all strains, site of
infection and geography had no inﬂuence on telavancin potency (MIC50,
0.25mg/L). VAN-R rates varied from 0.0−0.8% (Spain, France) to 22.9%
(UK) with VAN-A patterns ranging from 0.0 (France) to 98.7% (UK).
High-level R for gentamicin (35.9%) and streptomycin (43.2% was also
noted).
Conclusions: Among EU isolates, telavancin was more potent and
provided wider coverage of EFM than EF strains. Continued monitoring
of this new lipoglycopeptide would be prudent to detect any emerging R
and to establish the role of this novel, potent agent against Enterococcus
spp. infections in EU.
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P1849 Efﬁcacy of oritavancin at single or infrequent doses for the
treatment of complicated skin and skin-structure infections
L.M. Dunbar °, J. Milata, M. Fitzpatrick, A. Larrison, T. McClure,
M.M. Wasilewski (New Orleans, Indianapolis, US)
Objective: Oritavancin (Ori) is a semisynthetic lipoglycopeptide
with demonstrated efﬁcacy against Gram-positive complicated skin
and skin structure infections (cSSSI) including methicillin-resistant
Staphylococcus aureus (MRSA), when given 200mg IV daily for
3−7 days or in a daily-dose fashion. Animal and phase 2 and 3
pharmacokinetic data suggest potential for single dose or infrequent
doses of Ori as potentially efﬁcacious for cSSSI.
Methods: Phase 2, multi-centre, double blind, randomised, parallel,
active comparator study of patients with Gram-positive cSSSI. Patients
were randomised to comparator Ori daily-dose, Ori single dose (1200mg
on Day 1), or Ori infrequent dose (800mg on Day 1/optional 400mg on
Day 5). IV placebo was given to maintain blind. Signs and symptoms
of cSSSI, blood/cSSSI cultures, and safety measures were assessed at
predetermined times. Clinical efﬁcacy was assessed at end of therapy,
test of cure (TOC), & late follow-up (LFU).
Results: 302 patients received Ori (100 daily dose; 99 single dose; 103
infrequent dose). Efﬁcacy of single and infrequent dose was similar to
daily dose at TOC. The rate of treatment emergent adverse events was
similar between dosing groups and all were well tolerated.
Pop (N) TOC Cure Rate (%)
MD
Ori 200mg daily
for 3−7 days
SD
Ori 1200mg D1
(90%CI)*
ID
Ori 800mg D1/400mg D5
(90%CI)*
ITT (300) 72.4 81.8 (−1.7, 17.8) 78.2 (−5.8, 14.6)
CE (228) 72.4 81.5 (−2.5, 18.2) 77.5 (−6.8, 15.4)
MRSA CE (82) 73.9 74.3 (−18.8, 18.7) 83.3 (−5.7, 28.0)
ME (161) 69.1 79.3 (−5.2, 20.0) 81.3 (−2.9, 22.6)
LFU Relapse (%)
CE (160) 0 1.6 3.7
*CI is based on estimated difference in response rate between patients in MD vs. SD or ID using Mantel–Haenszel
method stratiﬁed by disease.
Conclusion: Single and infrequent doses of oritavancin were as
efﬁcacious as daily doses for cSSSI caused by Gram-positive pathogens,
including MRSA. Safety and tolerability were similar among dosing
groups.
P1850 Oritavancin in the treatment of immunocompromised
patients with complicated skin and skin-structure infections
C.S. Hartman °, M.M. Wasilewski, S.R. Moriarty, B.M. Bates
(Indianapolis, US)
Objectives: Oritavancin, a novel semisynthetic lipoglycopeptide with
activity against a wide range of Gram-positive bacteria, including
vancomycin-resistant staphylococci and enterococci, is presently under
regulatory review for the treatment of complicated skin and skin structure
infections (cSSSI). Immunocompromised patients are a vulnerable
population who run the risk of increased morbidity and lower cure rates
compared to immunocompetent patients.
Methods: Two randomised, double-blind, multicentre, phase 3 trials
were designed to test whether 3 to 7 days of oritavancin (ORI) was
noninferior to 10 to 14 days of vancomycin/cephalexin (VAN) in the
treatment of cSSSI. Test-of-cure (TOC) occurred between Days 21 to
35. Described here are results from the group of patients considered to
be immunocompromised at study entry. The immunocompromised group
includes patients with baseline HIV/AIDS, AIDS, neutropenia, adverse
events of neutropenia or those taking immunosuppressive concomitant
medications.
Results: 1763 patients received study medication, of which 85 were
immunocompromised. Clinical cure rates in non-immunocompromised
patients in the clinically evaluable (CE) population at TOC were 76.9%
(688/895) in ORI compared to 76.1% (337/443) for VAN. Similar
response rates were observed in the immunocompromised group of
patients and clinical cure rates in the CE population at TOC were
77.3% (34/44) in ORI compared to 66.7% (10/15) for VAN. Overall,
more immunocompromised patients had at least one AE (78.0% for
ORI and 76.9% for VAN) than patients who were immunocompetent
(52.2% for ORI and 61.7% for VAN). Laboratory changes were similar
between ORI and VAN treatment groups in patients with and without
immunocompromise.
Conclusions: Oritavancin is a novel lipoglycopeptide with demonstrated
efﬁcacy and a favourable safety proﬁle with short course therapy
(3−7 days) in immunocompromised patients in two phase 3 studies of
cSSSI.
P1851 Oritavancin in the treatment of diabetic patients with
complicated skin and skin-structure infections
C.S. Hartman °, M.M. Wasilewski, S.R. Moriarty, B.M. Bates
(Indianapolis, US)
Objective: Oritavancin is a novel semisynthetic lipoglycopeptide with
multiple mechanisms of action and rapid, bactericidal activity against
a wide range of Gram-positive bacteria, including those resistant to
currently existent therapies, and is presently under regulatory review for
the treatment of complicated skin and skin structure infections (cSSSI).
Patients with diabetes mellitus (DM) have increased risk and prevalence
of SSSI and frequently have co-morbidities contributing to increased
morbidity with lower cure rates. We compared the efﬁcacy and safety of
oritavancin to vancomycin for cSSSI in patients with DM.
Methods: Two randomised, double-blind, multicentre, phase 3 trials were
designed to test whether 3 to 7 days of oritavancin (ORI) was noninferior
to 10 to 14 days of vancomycin/cephalexin (VAN) in the treatment of
patients with cSSSI. Patients randomised to ORI received 3−7 days of
IV drug then 7−11 days of IV/oral placebo. Patients randomised to VAN
received 3−14 days of IV drug then 0−11 days of oral cephalexin.
ORI was dosed at 1.5mg/kg or 3.0mg/kg in 1 study and 200mg/d
(300mg for patients >110 kg) in the other. VAN was dosed at 15mg/kg
q 12 h, dose-adjusted based on creatinine clearance. Test-of-cure (TOC)
occurred from Days 21 to 35. Described here are results from the subset
of patients with DM.
Results: 1763 patients received study medication, of which 386 had DM.
In clinically evaluable (CE) patients, mean duration of total active dosing
was 5.2 days in the ORI group compared to 11.3 days in the VAN group.
Clinical cure rates in the non-DM patients in the CE population at TOC
were 80.9% (597/738) in ORI patients compared to 79.2% (286/361)
for VAN patients (95%CI: −3.4, 6.7). Consistent with reports of lower
response rates for infections in diabetics, clinical cure rates in DM
patients in the CE population at TOC were 62.2% (125/201) in ORI
patients compared to 62.9% (61/97) for VAN patients (95%CI: −12.4,
11.0). Overall, higher percentages of patients with DM had at least one
adverse event (61.5% for ORI and 69.0% for VAN) than those who
did not (51.3% for ORI and 60.6% for VAN), as is clinically expected.
Laboratory changes were comparable between the ORI and VAN groups
with and without DM.
Conclusions: Oritavancin is a novel lipoglycopeptide with demonstrated
efﬁcacy and a favourable safety proﬁle with short course therapy
(3−7 days) in the treatment of cSSSI in patients with diabetes.
P1852 Hepatic insufﬁciency and outcomes in patients with
complicated skin and skin-structure infections treated with
oritavancin
C.S. Hartman °, M.M. Wasilewski, S.R. Moriarty, B.M. Bates
(Indianapolis, US)
Objective: Oritavancin (ORI) is a novel semisynthetic lipoglycopeptide
with activity against a wide range of Gram-positive bacteria, including
those resistant to currently existent therapies. Pharmacokinetics of ORI
in mild or moderate hepatically impaired subjects do not indicate a need
for dose adjustment. Therefore, ORI outcomes are not expected to be
affected by liver disease.
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Methods: Two randomised, double-blind, multicentre, phase 3 trials were
designed to test whether 3 to 7 days of oritavancin (ORI) was noninferior
to 10 to 14 days of vancomycin/cephalexin (VAN) in the treatment
of complicated skin and skin structure infections (cSSSI). Test-of-cure
(TOC) occurred between Days 21 to 35. Outcomes were analyzed for
patients with hepatic insufﬁciency at baseline. Patients were identiﬁed
through the reporting of preexisting conditions or adverse events (AEs)
prior to baseline by searching for preferred terms related to hepatic
insufﬁciency.
Results: 1763 patients received study medication, 1173 ORI and 590
VAN. 38 ORI patients and 21 VAN patients had hepatic insufﬁciency.
Clinical cure rates in non-hepatically impaired patients in the clinically
evaluable (CE) population at TOC were 76.9% (698/908) in ORI
compared to 76.3% (338/443) for VAN. Similar response rates were
observed in hepatically impaired patients with clinical cure rates in the
CE population at TOC of 77.4% (24/31) in ORI compared to 60.0%
(9/15) for VAN. Overall, more patients with hepatic insufﬁciency had
at least one AE (71.1% for ORI and 76.2% for VAN) than patients
without insufﬁciency (53.0% for ORI and 61.9% for VAN) as is clinically
expected. Laboratory changes were similar between ORI and VAN
treatment groups in patients with and without hepatic insufﬁciency.
Conclusions: Oritavancin is a novel lipoglycopeptide with demonstrated
efﬁcacy and a favourable safety proﬁle with short course therapy
(3−7 days) in the treatment of cSSSI that is not affected by liver disease.
P1853 Safety of oritavancin versus vancomycin for treatment of
patients with complicated skin and skin-structure infections
S.R. Moriarty °, M.M. Wasilewski, A.S. Rosen, M. Perry (Indianapolis,
US)
Objective: Oritavancin (ORI) is a novel semisynthetic lipoglycopeptide
with activity against a wide range of Gram-positive bacteria. Two
randomised, double-blind, phase 3 studies compared the safety of
ORI/placebo to VAN/cephalexin in patients treated for complicated skin
and skin structure infections (cSSSI).
Methods: Patients randomised to ORI received 3−7 days of IV drug then
7−11days of IV/oral placebo. Patients randomised to vancomycin (VAN)
received 3−14days of IV drug then 0−11days of oral cephalexin. ORI
was dosed at 1.5mg/kg or 3.0mg/kg in 1 study and 200mg/d (300mg
for patients >110 kg) in the other. VAN was dosed at 15mg/kg q 12 h,
dose-adjusted based on creatinine clearance. We integrated safety data
for analyses of adverse event incidence, clinical laboratory and vital
signs changes.
Results: 1763 patients received study drug; 1173 ORI and 590 VAN.
Signiﬁcantly lower percentages of ORI versus VAN patients had 1
treatment-emergent adverse event and adverse events leading to study
drug discontinuation. Lower but not signiﬁcantly different percentages
of ORI versus VAN patients died or had serious adverse events. Also,
signiﬁcantly (p< 0.05) lower percentages of ORI versus VAN patients
had treatment emergent adverse events potentially related to histamine-
like infusion reactions (pruritus, erythema, pruritus generalised, ﬂushing,
red man syndrome, urticaria, infusion site pruritus). Comparable
percentages of ORI versus VAN patients had other treatment emergent
adverse events potentially related to glycopeptides (infusion site pain,
infusion site phlebitis, phlebitis, infusion site thrombosis, infusion site
erythema). Neither treatment showed clinically relevant laboratory or
vital signs changes.
Event type Number* (%) with event p-value
ORI (N= 1173) VAN (N= 590) ORI vs VAN
TEAE 628 (53.5) 368 (62.4) <0.001
SAE 107 (9.1) 67 (11.4) 0.150
AE Leading to SD DC 35 (3.0) 34 (5.8) 0.006
Death 19 (1.6) 12 (2.0) 0.566
*Except death includes pts with 1 event.
Conclusions: ORI as short-course therapy (3−7days) is safe and well
tolerated in patients with cSSSI and has a favourable beneﬁt-risk proﬁle
versus VAN.
P1854 Evaluation of oritavancin activity in vitro in the presence
of human and mouse serum
G.A. McKay, S. Beaulieu, D. Lehoux, T.R. Parr, Jr., G. Moeck °
(Saint-Laurent, CA)
Objectives: Oritavancin (ORI), a semisynthetic lipoglycopeptide, exerts
bactericidal activity against Gram-positive bacteria including drug-
resistant strains. ORI is highly bound to human plasma components,
principally serum albumin. It is generally held that the free fraction of
an antibiotic in plasma is predictive of its activity. We therefore sought
to compare the binding of ORI to human (hu) serum (SER) relative to
mouse (mo) SER in vitro to support pharmacodynamics studies.
Methods: Avid binding of ORI to ﬁltration and dialysis membranes
renders most protein binding methodologies unsuitable. We therefore
quantiﬁed MIC shifts (from arithmetic drug dilutions) and area under the
inhibitory curve (AUIC) shifts (from time-kill assays) in the presence
of SER compared to SER ultraﬁltrate (ULTRA; free of albumin) to
estimate ORI binding to serum. Pooled huSER and moSER were from
Equitech-Bio (Kerrville, TX). ULTRA from both species was prepared
using Amicon ﬁltration units (50k MW cutoff). ORI stock solutions were
prepared following CLSI M100-S18. Staphylcococcus aureus ATCC
29213 was used as the test isolate at a ﬁnal inoculum of ~5×105
CFU/mL in both MIC and AUIC studies.
Results: Mean ORI MICs in huSER and huULTRA were
0.78±0.32mg/mL and 0.13±0.04mg/L, respectively. Mean ORI MICs
in moSER and moULTRA were 0.54±0.05 and 0.08±0.004mg/L,
respectively. The resulting estimated mean serum protein binding value
for ORI to huSER (81.6%) is signiﬁcantly different from that observed
for moSER (85.3%) (Mann-Whitney U test; two-sided P = 0.017).
From time kill-based AUIC studies the mean binding of ORI to
huSER (64.3±2.9%) and to moSER (67.8±1.3%) is not signiﬁcantly
different (unpaired t-test assuming equal variances: P = 0.063 [one-
sided], P = 0.126 [two-sided]).
Conclusions: Binding estimates of ORI to huSER and moSER using
arithmetic MIC methodology demonstrates a small but signiﬁcant
difference between the species. Conversely, AUIC analysis of time kill
data suggested that ORI binding to huSER was similar to binding to
moSER. These two methods provide the ﬁrst cross-species examination
of ORI serum protein binding and serve as a benchmark in situations
where nonspeciﬁc drug binding precludes use of standard serum protein
binding methods.
P1855 In vitro time-kill studies of oritavancin against clinical
isolates of Streptococcus pyogenes
G.A. McKay, S. Beaulieu, I. Sarmiento, F.F. Arhin, T.R. Parr Jr.,
G. Moeck ° (Saint-Laurent, CA)
Objectives: Oritavancin (ORI), a semi synthetic lipoglycopeptide,
exerts bactericidal activity against drug-resistant Gram-positive bacteria.
To characterise ORI activity in vitro we performed time-kill (TK)
experiments against recent clinical isolates of S. pyogenes, including
erythromycin (ERY)-resistant isolates.
Methods: 11 strains of S. pyogenes were tested in TK assays based on
CLSI guidelines. To insure quantitative recovery of ORI, assays included
0.002% polysorbate-80 throughout. ORI and commonly recommended
antibiotics for the treatment of S. pyogenes complicated skin and skin
structure infections (penicillin G [PEN] and ERY) were tested alongside
comparators vancomycin (VAN), teicoplanin (TEI), linezolid (LIN) and
daptomycin (DAP) at ﬁxed concentrations approximating their free peak
(fCmax) and free trough levels in plasma when administered at standard
doses taking into account serum protein binding. Cell counts were
determined by serial dilution plating.
Results: ORI showed rapid concentration-dependent killing of all strains:
when tested at its fCmax, ORI displayed bactericidal activity (3 log kill
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relative to starting inoculum) against ERY-susceptible S. pyogenes (n = 8)
between 5min to 3 h while for ERY-resistant strains (n = 3) ORI was
bactericidal by between 30min and 3 h. When tested at its free trough
concentration, ORI demonstrated 3 log kill within 5 h, regardless of
ERY susceptibility status. Against all tested strains, ORI was signiﬁcantly
more rapidly bactericidal than VAN, ERY, PEN, TEI, LIN or DAP each
at physiologically-relevant concentration.
Conclusions: The concentration-dependent killing of S. pyogenes by
ORI in vitro was independent of ERY susceptibility status of the clinical
isolates. These data support the conclusion that ORI displays rapid,
concentration-dependent bactericidal activity against recent S. pyogenes
isolates and is effective against drug-resistant isolates of S. pyogenes.
P1856 Comparative activity of oritavancin against recent genetically
diverse methicillin-resistant Staphylococcus aureus isolates
F.F. Arhin °, N. Kurepina, B. Kreiswirth, I. Sarmiento, T.R. Parr Jr.,
G. Moeck (Saint-Laurent, CA; Newark, US)
Objectives: Oritavancin (ORI) is a lipoglycopeptide with bactericidal
activity against Gram-positive bacteria including drug-resistant S. aureus.
This study describes ORI activity against recent genetically diverse
MRSA isolates compared to vancomycin (VAN), teicoplanin (TEI),
oxacillin (OXA), erythromycin (ERY), daptomycin (DAP), ciproﬂoxacin
(CIP) and linezolid (LIN).
Methods: Strains (n = 58) were clinical isolates obtained between 2005
and 2006 from hospitals in the New York/New Jersey, USA area. Broth
microdilution MICs were determined according to CLSI guidelines.
Identiﬁcation of the Panton-Valentine leukocidin (pvl) genes was by
polymerase chain reaction (PCR). Multiplex PCR was used for staphylo-
coccal cassette chromosome (SCC) mec typing. Staphylococcal protein
A (spa) typing was by PCR followed by sequencing of the PCR products.
Results: The MRSA isolates were genetically diverse and included
classical community-associated USA300 isolates (n = 17), PVL+ strains
(n = 33) and PVL− strains (n = 25). Majority (95%) of the PVL+ isolates
were typed as SCCmec IV. Of the PVL− isolates, 60% were SCCmec II
and 40% were SCCmec IV.ORI MIC90 s were identical for the isolates
regardless of the PVL type, SCCmec type or spa type. Based on MIC90 s,
ORI was more potent than the comparators used in this study. ORI
MIC90 s against all MRSA were 16-, 8-, and 4-fold lower than those for
the LIN, DAP, and VAN, respectively.
Agent MIC range (MIC90), mg/L
Total
(n = 58)
PVL+
(n = 33)
PVL−
(n = 25)
SCCmecII
(n = 16)
SCCmecIV
(n = 42)
ORI 0.03–0.25 0.03–0.25 0.06–0.25 0.06–0.25 0.03–0.25
(0.25) (0.25) (0.25) (0.25) (0.25)
OXA 4−>64 4−64 8−>64 32−>64 4−>64
(64) (32) (>64) (>64) (32)
VAN 0.25–2 0.25−1 0.25–2 0.25−2 0.25−2
(1) (1) (2) (2) (1)
TEI 0.25–2 0.25−1 0.25–2 0.25−1 0.25−2
(1) (1) (2) (1) (1)
DAP 0.5–4 0.5−4 0.5–4 0.5−4 0.5−4
(2) (1) (2) (2) (1)
CIP 0.12−>64 0.12−>64 0.25−>64 32−>64 0.12−>64
(>64) (>64) (>64) (>64) (>64)
ERY 0.25−>64 0.25−>64 0.5−>64 2−>64 0.25−>64
(>64) (>64) (>64) (>64) (>64)
LIN 1–64 1−64 1–8 1−8 1−64
(4) (4) (4) (4) (4)
Conclusions: ORI MICs did not exceed 0.25mg/L for any MRSA strain
in this study. ORI activity was unaffected by presence of PVL, SCCmec
type or spa type. Finally, MRSA isolates were more susceptible to ORI
than to the comparators used in this study.
P1857 Telavancin disrupts bacterial membrane function by
targeted interaction with the cell wall precursor Lipid II
C. Lunde °, S. Hartouni, J. Janc, M. Mammen, B. Benton (San
Francisco, US)
Objectives: Telavancin (TLV) is an investigational, bactericidal lipo-
glycopeptide antibiotic with potent activity against a broad range of
Gram-positive bacteria, including methicillin-resistant Staphylococcus
aureus (MRSA). The antibacterial mode of action of TLV includes
inhibition of cell wall synthesis and disruption of essential membrane
barrier functions. The purpose of this study was to further elucidate the
mechanism by which TLV interacts with the bacterial membrane.
Methods: Bacterial membrane potential was assayed by ﬂow cytometry
using the ﬂuorescent dye, DiOC_2(3), and early log phase S. aureus
cells in cation-adjusted Mueller–Hinton broth. Cultures were incubated
for 10min in the pretreatment condition prior to exposure to TLV. Percent
depolarisation was calculated relative to TLV-treated cells without
pretreatment. Cultures that were suspended in nutrient-free medium (PBS
with cations) were incubated for 10min prior to TLV exposure.
Results: TLV (8mcg/mL) induced complete depolarisation of S. aureus
membranes. The role of Lipid II in TLV-induced depolarisation
was demonstrated in bacteria expressing reduced levels of Lipid
II. Pretreatment of S. aureus cells with inhibitors of Lipid II
synthesis, fosfomycin, D-cycloserine, or bacitracin, suppressed TLV-
induced depolarisation by 71%, 62%, and 73%, respectively. TLV-
induced depolarisation was suppressed by 98% when Lipid II production
was reduced by suspending cells in nutrient-free medium.
Conclusions: The membrane mechanism of TLV requires binding to
the cell wall precursor, Lipid II. Therefore, through interaction with the
membrane-embedded target Lipid II, TLV both inhibits peptidoglycan
synthesis and disrupts membrane barrier function.
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P1858 Prevalence of Panton-Valentine leukocidin genes in
methicillin-resistant Staphylococcus aureus strains and
susceptibility patterns
C. Pitart °, M. A´lvarez, M. Almela, J. Mensa, J.A. Martı´nez, A. Soriano,
J. Puig de la Bellacasa, J. Vila, M.T. Jime´nez de Anta, F. Marco
(Barcelona, ES)
Objectives: MRSA is an important cause of both nosocomial and
community-acquired infections. Severe MRSA infections, including
necrotising pneumonia, bacteraemia and skin and soft tissue infections
(SSTIs) have been associated with the virulence factor Panton-Valentine
leukocidin (PVL). The aim of this study was to investigate the presence
of PVL genes, clonality and their susceptibility patterns in MRSA
isolates collected from patients in our institution from October 2007
to December 2008.
Methods: All MRSA strains isolated during this period of time
were screened for PVL genes. Genotype characterisation of PVL was
made by co ampliﬁcation of the genes lukS-PV and lukF-PV by
PCR. Biochemical and antimicrobial susceptibility of isolates were
performed by Phoenix® (Becton Dickinson, Franklin Lakes, NJ, USA).
Glycopeptides, daptomycin and linezolid MICs were determined by
Etest® (AB Biodisk, Solna, Sweden). All MRSA PVL positive isolates
were genotyped by pulsed ﬁeld gel electrophoresis (PFGE)after digestion
with SmaI.
Results: 213 MRSA isolates were collected, 24 (11.3%) were PVL
positive. Strains were isolated from cutaneous abscesses (7), ulcer
infection (5), cellulitis (5), folliculitis (4), surgical site infection
(2) and nasal swab (1). Ten different susceptibility patterns were
found. Resistance only to penicillin and oxacillin was observed in
5 isolates. All isolates were susceptible to cotrimoxazole, rifampin,
vancomycin, teicoplanin, daptomycin, fusidic acid and linezolid. MIC90
for vancomycin, teicoplanin, daptomycin and linezolid were 2, 2, 0.75
and 0.5mcg/ml, respectively. Patients carrying PVL positive MRSA
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strains (24) were from Spain (16), USA (2), France (1), Italy (1), Cuba
(1), Brazil (1), Ecuador (1) and Argentina (1). Among these strains, nine
PFGE patterns were observed.
Conclusion: MRSA PVL strains are an increasing problem due to its
involvement in SSTIs. In our institution these isolates represent 11.3%
of MRSA strains. Recent marketed anti-staphylococci antibiotics such
as daptomycin and linezolid demonstrated good activity against these
particular MRSA isolates.
P1859 Comparison of clinical features and mortality risk associated
with pneumonia due to community-acquired methicillin-
resistant and methicillin-susceptible Staphylococcus aureus
producing the Panton-Valentine leukocidin
K. Vardakas °, D. Matthaiou, M. Falagas (Athens, GR)
Objective: Studies comparing patients with methicillin-resistant Staphy-
lococcus aureus (MRSA) and methicillin-sensitive S. aureus (MSSA)
community-acquired pneumonia (CAP) are not forthcoming. The present
review was undertaken to investigate the clinical features and prognosis
of patients with MRSA CAP as compared to those of patients with
MSSA CAP producing the Panton-Valentine leukocidin (PVL).
Methods: Pubmed and Scopus were searched to identify articles that
studied patients with MRSA CAP. Inclusion was stratiﬁed according
to S. aureus susceptibility, clinical, microbiological, and outcome data
regarding individual patients or group of patients with S. aureus CAP;
both primary and secondary cases of CAP (haematogenous spread from
other sites of infection) could be included.
Results: We identiﬁed 74 and 63 articles reporting data on MRSA and
MSSA CAP, respectively. 107 patients had S. aureus CAP due to PVL
positive strains (76 MRSA and 31 MSSA). There were no differences in
demographics and history among patients with MRSA and MSSA CAP.
The features associated with MRSA CAP were gastrointestinal tract
symptoms (p = 0.016) and unilobar inﬁltrates (p = 0.043). The features
associated with MSSA CAP were airway haemorrhage (p = 0.010),
multilobar inﬁltrates (p = 0.043) and acute respiratory distress syndrome
(ARDS, p = 0.023). ARDS was the only independently associated
variable with MSSA CAP in the multivariate analysis. Although MSSA
patients were more likely to receive initial appropriate antimicrobial
therapy (p< 0.001), there was no difference in mortality between the
two groups (p = 0.919). Univariate analysis showed that respiratory
disease (p = 0.027), inﬂuenza like symptoms (p< 0.001), rash (p = 0.024),
septic shock (p = 0.010), mechanical ventilation (p< 0.001), multi-organ
failure (p< 0.001), pleural effusion (p = 0.034), ARDS (p = 0.021), lung
abscess (p = 0.025), leucopenia (p< 0.001), use of macrolides after
microbiological cultures (p = 0.011), admission to the ICU (p< 0.001),
and necrotising characteristics of CAP (p = 0.026) were the factors
associated with mortality.
Conclusions: Patients with MRSA CAP did not have higher mortality
than did patients with MSSA CAP.
P1860 Do laboratory characteristics predict outcome in
methicillin-resistant Staphylococcus aureus bacteraemia?
S.M. Donabedian °, C.L. Moore, M.B. Perri, T. Chua, M.J. Zervos
(Detroit, US)
Objectives: To determine if laboratory characteristics, such as suscep-
tibility testing and molecular analysis, are associated with outcome in
methicillin-resistant Staphylococcus aureus bacteraemia (MRSA-B).
Methods: We identiﬁed consecutive subjects with MRSA-B empirically
treated with vancomycin(VAN) and lab characteristics of the index
strains were evaluated. Susceptibility testing for VAN and daptomycin
(DAP) and pulsed-ﬁeld gel electrophoresis (PFGE) for strain types
was conducted. Heteroresistance (GISA/hGISA) was assessed using the
macrodilution Etest. The objective was to correlate lab characteristics
to a composite outcome of failure, deﬁned by mortality 30 days from
index culture, microbiologic failure (10 days of bacteraemia), and/or
recurrence of MRSA-B within 30 days of end of therapy. Predictors
of failure were determined on univariate analysis and independent
predictors were determined using stepwise logistic regression analysis.
Results: Subjects with MRSA-B (n 189) were identiﬁed over a two year
period. VAN MIC by broth microdilution (n 185) was 0.25 (16.8%), 0.5
(69.2%), 1.0 (13.5%), 2.0 (0.5%). VAN MIC by Etest (n 189) was 1.0
(5.8%), 1.5 (75.7%), 2 (18.5%). VAN MIC by Vitek (n 189) was 1
(90.5%), 2 (9.5%). DAP MIC by Etest (n 187) was 0.25 (2.7%), 0.5
(56.7%), 1 (39.0%), 2 (1.6%). PFGE (n 189) were USA100 (49.2%),
USA300 (40.2%), USA600 (2.5%) and other (7.9%). GISA/hGISA (n
151) was found in 5.3%.
Failure occurred in 22.6% of subjects. Lab characteristics in the success
group were compared to the failure group, respectively. VAN MIC by
broth microdilution was 0.25 (19.4% vs 7.3%), 0.5 (69.4% vs 68.3%),
1.0 (11.1% vs 22%), 2.0 (0 vs 2.4%), p = 0.028. VAN MIC by Vitek was
1 (93.2% vs 81%) and 2 (6.8% vs 19%), p = 0.017. VAN and DAP MIC
by Etest were not associated with outcome. PFGE was similar between
groups except for USA600, where all 5 subjects failed. GISA/hGISA
was more common in the failure than success group (15.6% vs 2.5%),
p = 0.003. GISA/hGISA was the only independent predictor for failure
(OR 6.6; 95%CI 1.1−39.9, p = 0.04). VAN MIC by broth microdilution
trended towards an independent association with failure (OR 5.2, 95%CI
0.9−30.3, p = 0.06).
Conclusion: USA600 strain type and higher VAN MIC, still within the
susceptible range, by both broth microdilution and Vitek were associated
with poor outcome. VAN and DAP MIC by Etest were not associated
with outcome. GISA/hGISA was independently associated with failure.
P1861 A unique way to predict vancomycin failure in patients with
methicillin-resistant Staphylococcus aureus bacteraemia
early in therapy: a classiﬁcation and regression tree analysis
C. Moore °, F. Cheema, T. Chua, P. Osaki Kiyan, M. Perri, S. Davis,
S. Donabedian, N. Haque, M. Zervos (Detroit, US)
Objectives: To determine the effect of a combination of lab, patient,
and treatment (tx) factors on outcome of MRSA bacteraemia (MRSA-B)
treated with vancomycin (VAN).
Methods: We conducted medical records review and lab analysis of
consecutive subjects/strains with MRSA-B treated with VAN. Failure
was a composite of: 30-day mortality, microbiologic failure (positive
cultures 10 days from index culture) and/or recurrence of MRSA-B
within 30 days of end of tx. Logistic regression (LR) was conducted.
Classiﬁcation and Regression Tree (CART) analysis was performed with
a combination of baseline data and clinical/tx data on day 3 of VAN tx.
Results: Subjects with MRSA-B (n 190) had a median age of 55 y
with 57.4% male. Risk level for source of infection was low (28.9%),
intermediate (45.8%) and high (25.3%). Strains were USA100 (49.2%),
USA300 (40.2%) and other (10.6%). VAN MIC by broth microdilution
(n 185) was 0.25 (16.8%), 0.5 (69.2%), 1.0 (13.5%), 2.0 (0.5%). VAN
MIC by Etest (n 189) was 1.0 (5.8%), 1.5 (75.7%), 2 (18.5%).
Failure occurred in 22.6% of subjects. LR revealed high risk source
(OR 3.1, 95%CI 1.6−6.0), peptic ulcer disease (OR 12.7, 95%CI
2.1−75.3), cardiovascular disease (OR 3.4, 95%CI 1.3−9.1), cancer
(OR 3.8, 95%CI 1.3−11.6) were independently associated with failure.
Empiric synergy (OR 0.3, 95%CI 0.1−0.8) was associated with a positive
outcome. Trends were seen in VAN MIC by broth (OR 5.3, 95%CI
0.9−30.6), immunosuppression (OR 3.3, 95%CI 1.0−10.8) and ICU at
onset (OR 2.5, 95%CI 0.9−7.0).
CART analysis revealed in dialysis subjects, the strongest predictor of
failure was age with a cutoff of 73.5 y found by the analysis. In subjects
with age >73.5 failure rate was 54.5%, whereas in subjects with age
73.5 failure rate was 6.9%. In non-dialysis subjects, the strongest
predictor for failure was initial VAN trough, with a cutoff of 22 ug/ml
found. In subjects with trough >22, failure rate was 80%. In subjects with
trough 22, the next best predictor of failure was creatinine clearance
(CrCl). In subjects with CrCl> 32, failure rate was 13.3%. In subjects
with CrCl 32, failure rate was 55%.
Conclusion: Independent predictors of failure in MRSA-B are high risk
source, peptic ulcer disease, cardiovascular disease, and malignancy.
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Empiric synergy conveyed beneﬁt in outcome. The CART analysis
provides a useful clinical decision tree model to classify the likelihood
of failure in subjects with MRSA-B at day 3 of VAN therapy.
P1862 How does persistent bacteraemia affect outcome in
methicillin-resistant Staphylococcus aureus bacteraemia?
C. Moore °, T. Chua, F. Cheema, P. Osaki Kiyan, M. Perri,
S. Donabedian, N. Haque, M. Zervos (Detroit, US)
Objectives: The impact of persistent bacteraemia (P-B, 7 days)
on outcome of methicillin-resistant Staphylococcus aureus bacteraemia
(MRSA-B) remains controversial. The primary objective of this study
was to determine the effect of P-B on 30 day mortality. Secondarily,
we determined what association patient-speciﬁc, treatment, and lab data
have on P-B.
Methods: We conducted medical records review and lab analysis of
consecutive subjects with MRSA-B treated with vancomycin (VAN).
Subjects were classiﬁed by duration of bacteraemia (7d vs <7d).
Stepwise logistic regression analysis was conducted to determine
independent predictors of persistence.
Results: Subjects with MRSA-B (n 190) had a median age 55.0 and
57.4% male. Source of infection was low risk (28.9%), intermediate risk
(45.8%) and high risk (25.3%). Median duration of bacteraemia was
4.0d (1−20). 30-day mortality was 13.2% and 7.7% had a recurrence
of MRSA-B within 30 days of end of therapy. 20.5% had persistent
bacteraemia.
The group with bacteraemia <7 days (n 151) was compared to the P-B
group (n 39). 30-day mortality was 10.6% vs 23.1%, p = 0.04. Factors
signiﬁcantly (p< 0.05) associated with P-B were baseline creatinine
clearance 30ml/min, left-sided endocarditis, initial vancomycin trough
15, higher VAN MIC by broth microdilution and USA600 strain type.
Female sex and higher VAN AUC/MIC ratio (by broth microdilution)
were associated with successful outcome (p< 0.05). Several factors
demonstrated a trend (p< 0.1) towards association with P-B, including:
older age, CHF, DM, higher VAN MIC by Etest and VAN MBC 32.
Other factors were evaluated and showed no association with P-B,
including: APACHE II score, risk level of source, multiple comorbidities,
treatment characteristics such as synergy, heteroresistance and other
PFGE types. Logistic regression analysis revealed left-sided endocarditis
(OR 10.5; 95%CI 1.5−73.6, p = 0.02) and USA600 strain type (OR 18.5;
95%CI 1.2–274.8, p = 0.03) as independent predictors of P-B. Female
sex (OR 0.18; 95%CI 0.05–0.6, p< 0.01) and every 100 unit increase in
AUC/MIC (OR 0.83; 95%CI 0.7−0.96, p = 0.01) were associated with
bacteraemia <7 d.
Conclusion: This study demonstrates that P-B is associated with higher
30-day mortality in subjects with MRSA-B. Left-sided endocarditis and
USA600 strain type were independent predictors of P-B. Female sex
and every 100 unit increase in AUC/MIC ratio were associated with
clearance of bacteraemia within 7days.
P1863 Impact of mandatory surveillance on the measurement of
methicillin-resistant Staphylococcus aureus bacteraemia in
the English NHS: comparison of mandatory and voluntary
surveillance reporting systems
A. Pearson °, R. Guy, M. Murray (London, UK)
Background: The routine surveillance of bacteraemia in England is
based on voluntary reporting of laboratory diagnosed cases to a national
database (LabBase reporting system). In 2001 the Department of Health
(DH) mandated an additional reporting system for methicillin-resistant
Staphylococcus aureus (MRSA) bacteraemia.
Objective: To report the impact of introducing a parallel mandatory
reporting system for MRSA bacteraemia by comparison of reports made
to the mandatory and voluntary systems.
Methods: The analysis reported here covers MRSA bacteraemia cases
reported on the basis of specimens collected during the period 2002
to 2007. National data from the Healthcare Associated Infection data
capture system (HCAI DCS) was extracted on the basis of the total
annual reports received.
Case reports sent to the voluntary LabBase system were extracted in
August 2008. Reports in both systems are based on the specimen date,
excluding duplicates or repeat specimens taken within two weeks of the
ﬁrst or previous report from the same patient.
Results: The ﬁgure depicts the comparison of yearly MRSA bacteraemia
reports.
During the six year period 32,606 reports of MRSA bacteraemia were
made to the voluntary national surveillance system (LabBase). The
introduction of mandatory reporting to the web enabled HCAI DCS
increased this number to 41,133. The impact of mandatory reporting had
the greatest impact in the ﬁrst year when reporting increased by 31.5%
from 5529 to 7274 cases. Comparison of the reported numbers for the
next four years showed between 25 and 27% differences between the
mandatory and voluntary schemes. During the sixth year of mandatory
surveillance the reporting difference dropped to 17% (718 cases).
Conclusion: Comparison of voluntary and mandatory reporting systems
provides a tool for internal QC for mandatory surveillance. The marked
fall in the differential of reported cases requires investigation to discern
the extent to which this ﬁnding resulted from changes in ascertainment
or was a result of the complex programme of target driven interventions.
P1864 Fitness cost: a possible explanation for the disappearance
of multiresistant MRSA in Denmark during 1970–1975
K.L. Nielsen °, T.M. Pedersen, R.L. Skov, D. Hughes, L.H. Hansen,
N. Frimodt-Møller (Copenhagen, DK; Uppsala, SE)
Objectives: Denmark and other European countries experienced the ﬁrst
epidemic of methicillin resistant Staphylococcus aureus (MRSA) during
1965–75, which was caused by an increasingly multi-resistant clone of
the 83A phage com-plex. In Denmark it disappeared almost completely,
being replaced by other phage types, predominantly only penicillin
resistant. Albeit interventions including infection control measures and
reduced administration of broad spectrum antibiotics were instituted,
a solid explanation for the disappearance of the clone has not been
found. The objective of this study was to investigate the ﬁtness cost of
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Staphylococcus aureus (S. aureus) isolates from the period 1957–1980
in correlation to resistance patterns.
Methods: All bacteraemia isolates of S. aureus from Denmark have
been collected and stored since 1960. From this collection we chose 20
S. aureus strains, selected according to phagetype (83A complex), clonal
complex, time of isolation (a range from 1957 to 1980 represented)
and with varying antibiotic resistance proﬁles. The resistance genotypes
for macrolide- and tetracycline resistance were determined by multiplex
PCR. The ﬁtness cost of each of the selected isolates was determined
in a competition assay with a reference isolate. The relative ﬁtness was
calculated based on the growth of the isolate compared to the reference
iso-late.
Results: The mean ﬁtness cost of the 20 S. aureus isolates was
−3.4% (SE=1.05). A signiﬁcant negative correlation between number of
antibiotic resistances and ﬁtness of the bacteria was found (R2=0.65;
Pfts;< 0.0001); i.e. the growth rate was reduced with the more
resistance markers the isolates carried. Furthermore, a signiﬁcant
negative correlation between ﬁtness and time of isolation of PSTEM
(penicillin, streptomycin, tetracycline, erythromycin and methicillin)
resistant isolates in the period 1965–1975 was demonstrated (R2=0.70;
P = 0.038). These ﬁndings indicate that the isolates are burdened over
time as well as by the number of resistances they carry. All tetracycline
resistant isolates carried tet(M) and tet(K), while erm(A) was detected in
all erythromycin resistant strains, indicating that the observed difference
in ﬁtness is not caused by different resistance markers.
Conclusion: We suggest that increasing ﬁtness cost was an important
contribution to the disappearance of multiply resistant MRSA of phage
complex 83A during the epidemic in 1965–1975.
P1865 Prevalence of Staphylococcus aureus in health professionals
in a Brazilian teaching hospital
E. Gir °, M. Carvalho, M. Hayashida, A. Silva, C. Barbosa, S. Canini,
S. Santiago, F. Pimenta (Ribeirao Preto, Santo Andre, Goiania, BR)
Objective: To analyze the prevalence of Staphylococcus aureus in the
saliva of health professionals, in a Brazilian large sized teaching hospital.
Methods: This cross-sectional study was carried out in a large sized
public hospital, in Santo Andre´-SP, Brazil between 2006 and 2008,
by applying a questionnaire to the participants and collecting saliva in
three different moments. Among the 340 participants, 22 were medical
doctors, 42 nurses, 99 nursing technicians and 177 nursing auxiliaries.
Ethical aspects were considered. After the isolation and identiﬁcation
of the Staphylococcus aureus, the antimicrobial susceptibility tests were
carried out. Data were processed using the Statistical Package Social
Science (SPSS), version 15.0 for Windows.
Results: Among the 340 professionals who had three saliva samples
collected, 162 (47.6%) were colonised. Therefore, the prevalence of
Staphylococcus aureus was of 47.6% (162/340), being 43.5% of
methicillin sensible Staphylococcus aureus. Through the disk diffusion
test and Etest®, 14 Staphylococcus aureus methicillin resistant (MRSA)
were detected (prevalence = 4.1%), being 9 in nursing auxiliaries and 5 in
nursing technicians; 11 females and most (42.9%) aged between 19 and
29 years. Regarding the working area, the results were: surgical unit (4),
Obstetric centre and Delivery room (4), nursery and Neonatal Intensive
Care Unit (2), Intensive Care Unit (ICU) (2), Surgery centre and Post
anaesthesical Unit (1), Coronary and Paediatric ICU (1). The MRSA
prevalence was of 4.1% (14/340). The MRSA isolated presented 100%
resistance to oxacillin; 92.8% to erythromycin, 57.1% to clindamycin,
57.1% to cefoxitin, 42.8% to ciproﬂoxacin, 7.1% to gentamicin and
7.1% sulfamethoxazole-trimethoprim. All of them presented sensibility
to tetracycline, rifampicin, vancomycin, linezolid and mupirocin.
Conclusion: The prevalence of Staphylococcus aureus among health
professionals was of 47.6% (MSSA= 43.5%, MRSA = 4.1%). Evaluating
the prevalence of MRSA among health professionals is relevant and it
is also a preventive measure for hospital infection. It should be invested
in preventive and control measures, specially standard precautions and
contact precautions, to control the situation of prevalence rates.
P1866 Trends in the incidence of methicillin-resistant
Staphylococcus aureus nosocomial bloodstream infections
in a tertiary care hospital in Greece: a three-year study
M. Kimouli, P. Karle, I. Daniil, E.T. Piperaki, I. Petraki, A. Tsiabouris,
M. Karakatsanis, D. Petropoulou °, A. Tsakris (Athens, GR)
Objective: Greece is one of the European countries that experiences high
rates of methicillin-resistant Staphylococcus aureus (MRSA). However,
data regarding the incidence of MRSA infections are limited. We
describe the trends in the incidence of MRSA nosocomial bloodstream
infections (BSI) in a large tertiary care hospital in the broad region of
Piraeus, Greece.
Methods: Data from January 2006 to December 2008 were analyzed.
We focused in hospital departments of high risk for nosocomial
infections (ICU, medical and surgical departments). Only the ﬁrst BSI of
each patient was included in the incidence calculation. Staphylococcal
bacteraemia was detected by BacT/Alert 3D system (Biomerieux,
France); identiﬁcation and MICs were performed using Vitek 2
(Biomerieux, France) and API Staph systems. Disc diffusion and E-test
methods were used to conﬁrm MRSA detection according to CLSI
guidelines. The incidence rate of nosocomial BSI due to MRSA was
calculated as the number of cases/100 admissions and the number of
cases/1,000 patient-days.
Results: Data from 23,107 patients were evaluated. MRSA caused BSI
in a total of 44 patients. The incidence rate increased signiﬁcantly in
ICU (from 0.60 cases/100 ICU admissions in 2006 to 1.15 cases in
2007 and to 1.22 cases in 2008 and from 0.57 cases/1,000 patient-days
in 2006 to 0.93 in 2007 and to 1.13 cases in 2008; x2 test for trend;
Pfts;< 0.001, respectively). In medical departments the incidence rate
was not considerably changed (0.15 cases/100 admissions in 2006, 0.16
in 2007 and 0.21 in 2008), whereas in surgical departments a signiﬁcant
increase was detected (from 0.04 cases/100 admissions in 2006 to 0.13
in 2007 and to 0.17 in 2008). Overall, the total incidence of MRSA
increased signiﬁcantly (from 0.79 cases/100 admissions in 2006 to 1.44
cases in 2007 and to 1.60 cases in 2008 and from 0.89 cases/1,000
patient-days in 2006 to 1.34 in 2007 and to 1.71 in 2008).
Conclusions: In hospital departments with high risk of BSIs, MRSA is
a serious concern causing difﬁculties in treatment and infection control
measures. The incidence of nosocomial BSI due to MRSA should be an
indicator reﬂecting the capability of a hospital to control its bacterial
ecology using preventive measures against cross-transmission. These
preliminary ﬁndings suggest that although Gram-negative BSIs prevail
in Greece, there is also a raise in the incidence of MRSA bacteraemia.
Further analyses are needed to conﬁrm this trend.
P1867 The prevalence of carriers of methicillin-resistant
Staphylococcus aureus in Copenhagen
A. Kjerulf °, R.L. Skov, C. Forsberg, T. Larsen, N-E. Fiehn
(Copenhagen, DK)
Objectives: The aim of the study was to elucidate the frequency of
MRSA carriage in patients receiving treatment at the School of Dentistry
in order to achieve a greater knowledge of the carrier state of MRSA
in a population of children and adults in Copenhagen. Furthermore we
wanted to investigate whether dentists and dental students were at risk
of being carriers of MRSA.
Methods: During a period of two years from 01.10.06 to 01.10.08 2230
specimens from 1115 patients and 534 specimens from 267 dentists/
dental students were collected. A specimen from both nostrils and a
specimen from both tonsils were taken from each patient, i.e. two
specimens per patient. Each specimen was immediately plated on a
5% blood agar and inoculated into a nutrient selective broth. Both
were incubated overnight at 37ºC. At day two material from the broth
was plated on a chrome agar plate and incubated overnight at 37ºC.
Susceptibility testing was performed at day three using a 10 microgram
cefoxitin disk (Oxoid, Basingstoke, UK) and semi-conﬂuent growth
on Iso-sensitest agar and incubated overnight at 37ºC. Resistance was
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deﬁned as 21mm (SRGA). Cefoxitin resistant S. aureus were sent to
the Staphylococcus Laboratory at Statens Serum Institut to PCR for the
mecA gene, spa typing and susceptibility testing.
Results: 1025 adults 18 years with a mean age of 42.1 and a range of
18 to 91 years, 90 children 2 years with a mean age of 7.5 and a range
of 2 to16 years and 267 dentists and dental students with a mean age of
29 and a range of 18 to 71 years were included in the study. Two MRSA
positive patients were found, one child and one adult. The child was
positive for MRSA in the nose, the strain was a t022 spa type. It was a
healthy 13 year old boy born in Denmark of Danish parents. He had not
been hospitalised in Denmark or abroad and he had not been travelling
abroad for the last year. The adult was also positive for MRSA in the
nose, the strain was a t008 spa type. It was a healthy 27 year old Danish
man who had been travelling abroad for 11 months the last year visiting
South and Central America and was treated for a wound infection in a
private clinic. None of the dentists/dental students were MRSA positive.
Conclusion: The prevalence of carriers of MRSA in Copenhagen seems
to be very low and in this study only 0.2%. During the last two years
the number of patients with MRSA in Denmark has declined as a result
of the implementation of national guidelines.
P1868 Emergence of Panton-Valentine leukocidin-positive
community-acquired MRSA and MSSA infections in an
Italian hospital
G. Gattuso °, D. Tomasoni, L. Palvarini, F. Ferri, C. Chiarelli,
A. Scalzini (Mantua, IT)
Objectives: The worldwide emergence of CA-MRSA infections caused
by hypervirulent strains producing PV leukocidin (PVL, coded lukS-
lukF) is a problem of extreme interest. Molecular studies suggest a spread
of a limited number PVL-producing MRSA clones that are genetically
distinct from hospital-acquired strains. This emergence of PVL+ CA-
MRSA represents a public health threat, because these strains are
associated with severe soft tissue infection and necrotising pneumonia.
In this report the Authors describe 3 cases of PVL+CA-MRSA and 1
case of PVL+CA-MSSA infections observed in 2008.
Methods: Staphylococcus aureus (Sa) isolates in Mantova hospital (530
beds) were identiﬁed by conventional tests, followed by the determination
of MIC for Oxacillin by the agar dilution method. The presence of lukS
and lukF genes (encoding PVL) were deﬁned by PCRs at the National
Institute of Health (Istituto Superiore di Sanita`) in Rome.
Results: A total of 348 S. aureus isolates were collected from different
patients during 2008. Among them 97 (27.9%) were MRSA and 251
(72.1%) were MSSA. Three MRSA cases were PVL+ and also 1 MSSA
case was PVL+. 2/3 cases of CA-MRSA were associated with skin and
soft tissue infection and 1/3 case was sepsis complicated by meningitis
and brain abscess. The case of PVL+CA-MSSA was associated to the
cervical spondylodiscitis. Every patient was positive for Sa oro-nasal
carriage. In just one case of PVL+ CA-MRSA there was a recent history
of hospitalisation. No case of staphylococcal infection was reported
among the relatives or close social contacts. The cases were resolved
thanks to a treatment with glycopeptides, but one case required linezolid
therapy. Mupirocin was used to eliminate Sa nasal carriage.
Conclusions: Speciﬁc surveillance of MRSA and MSSA infections in
the community is required to monitor and prevent the spread of these
PVL+ strains. The alert system and the control of the local epidemiology
of PVL+ CA-MRSA/MSSA represents a priority even in small hospitals.
P1869 Surveillance of methicillin-resistant Staphylococcus aureus
within Irish intensive care units
M. Skally, F. Roche, S. Donlon, T. Farrell, M. Twohig, H. Humphreys,
F. Fitzpatrick ° (Dublin, Sligo, Drogheda, IE)
A voluntary national weekly prevalence survey of meticillin resistant
Staphylococcus aureus (MRSA) in general intensive care units (ICUs)
within acute Irish hospitals commenced in April 2008. This paper
reviews the ﬁrst six months of the project.
Methods: The Health Protection Surveillance Centre (HPSC) co-
ordinates data collation and produces quarterly reports for participants.
Participants complete an annual baseline form detailing bed capacity
and isolation room facilities and weekly MRSA surveillance data on the
same day each week.
Results: Thirty-two ICUs submitted data during the ﬁrst two quarters of
the project (22 general, 9 regional and one specialist hospital). Nineteen
ICUs contained a mixture of ICU and high dependency/coronary care
patients (mixed ICUs) and 13 contained ICU patients only (non-mixed
ICUs). The majority (20) contained between ﬁve and ten beds, with
nine containing less than four beds. Four have no rooms available for
isolation. Of the remainder, the average number of rooms is 2.2 rooms
per ICU, only eight ICUs have three or more isolation rooms, of which
39% have an anteroom and 76% a handsink. All ICUs screen patients
for MRSA on admission.
The median rate of ventilated patients was 44.2% (range 1.6−82.5%),
with a higher rate in non mixed (0−82%, median 54.7%) than mixed
ICUs (1.6–76%, median 25.6%). National MRSA ICU prevalence rates
ranged from 0% to 25% (median 8.7%) and were higher in non-mixed
(median 13.5%) than mixed ICUs (median 7.1%). MRSA acquisition
ranged from 0% to 3.7% (median 0.27%) and again was higher in non
mixed ICUs (median 0.6%).
Conclusions: Isolation room facilities are crucial for the prevention and
control of MRSA. There is a wide variation in isolation room facilities
across ICU’s. Many of the single rooms cannot be truly classiﬁed as
isolation rooms as they lack an isolation room such as a hand sink and
anteroom.
Since ICUs vary considerably in case mix, size and the provision of
isolation rooms, direct comparisons between ICUs is difﬁcult. However,
data can be used locally to monitor trends over time. A more detailed
study is required to more accurately identify the underlying issues within
each hospital.
P1870 Community-onset versus nosocomial bloodstream infections
due to methicillin-resistant Staphylococcus aureus in Spain
A.B. Milla´n, M.A. Domı´nguez, C. Borraz, M.P. Gonza´lez, B. Almirante,
E. Cercenado, B. Padilla, M. Pujol, J. Rodrı´guez-Ban˜o ° and
GEIH/GEMARA/REIPI
Objectives: Community strains of methicillin-resistant Staphylococcus
aureus (MRSA) are still rare in Spain, but a signiﬁcant proportion of
infections caused by MRSA are community-onset, healthcare-associated.
The aims of this study were to compare the epidemiology and clinical
features of community-onset and nosocomial bloodstream infections
(BSI) due to MRSA in Spain.
Methods: Prospective cohort of cases of BSI due to MRSA from
59 Spanish hospitals during June 2003. Episodes were considered
community-onset when diagnosed within 48 hours of hospital ad-
mission, and nosocomial when diagnosed subsequently. Community-
onset episodes were subclassiﬁed as healthcare-associated on the bases
of epidemiological data (Friedman’s criteria) and molecular typing of
isolates (e.g., clonal relation with typical nosocomial isolates), which
was performed using PFGE and MLST.
Results: We included 64 episodes; 21 (33%) were community-onset, all
of which were considered healthcare-associated. We found no signiﬁcant
differences between community-onset and nosocomial BSI regarding
demographic features or clinical and epidemiological characteristics,
except for the source of BSI: central venous catheter was more common
among nosocomial episodes (39% vs 5%, p = 0.005), while the urinary
tract was more common among community-onset episodes (25% vs 0%,
p = 0.001). Empirical treatment was inappropriate in 86% of community-
onset episodes and in 67% of nosocomial episodes (p = 0.1). Related
mortality and 30-day mortality were 19% vs 23% (p = 0.7), and 19% vs
28% (p = 0.4), respectively.
Conclusions: One third of BSI due to MRSA bacteraemia in our study
was considered community-onset, and all of them were healthcare-
associated. The epidemiological and clinical features of community-
onset and nosocomial episodes were similar, except for the sources of
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bacteraemia. Clinicians should be aware of the need to consider coverage
against MRSA more frequently, particularly for certain infectious
syndromes in patients with community sepsis and previous healthcare
association.
P1871 Regional variations of methicillin-resistant Staphylococcus
aureus incidence densities among 169 German hospitals
which participated in the MRSA-KISS module
I.F. Chaberny °, F. Schwab, P. Gastmeier (Hanover, Berlin, DE)
Background: A country-wide prospective multicentre hospital-based
surveillance of MRSA case-patients was established in the year
2003 with participating hospitals of the national German nosocomial
infections surveillances system (KISS). This is called the MRSA-KISS
module.
Objectives: To assess regional variations of MRSA incidence densities
in German hospitals.
Methods: The data were recorded during routine surveillance by the
infection control team of each hospital and send to the national reference
centre for analysing every year. The German Federal Counties were
grouped into ﬁve regions to create comparable regions according to
the number of inhabitants (North (N), West (W), East (E), South-West
(SW) and South-East (SE)). The summarised data from 2006 and 2007
were stratiﬁed to the ﬁve regions and a multiple logistic regression was
performed.
Results: A total of 36,162 MRSA case-patients and 36,797,125 patient
days from 169 hospitals were analyzed. MRSA identiﬁcation later than
48 h after admission was classiﬁed into nosocomial cases. Hence, 28.1%
(24.7% to 31.7%) were nosocomial and a total of 71.9% (68.3% to
75.3%) were imported MRSA case-patients. The total MRSA incidence
density was 0.98. The data show signiﬁcant differences of the regions
(see Table 1).
Table 1. MRSA incidence densities (ID) (MRSA case-patients per 1,000 patient days) of 169 hospitals grouped
into 5 regions
MRSA data East South-East South-West North West Total p-value
ID (pooled mean) 0.96 1.37 0.78 0.79 1.00 0.98
95%CI 0.94; 0.98 1.34; 1.40 0.78; 0.80 0.78; 0.81 0.98; 1.03 0.97; 0.99
ID (median) 0.69 1.11 0.77 0.63 0.96 0.83 0.009
Conclusion: This study demonstrated signiﬁcant regional variations
according to the MRSA incidence densities, which may be explained
by differences of the various dominating MRSA strains or variations of
the infection control habits among the regions.
P1872 Prevalence of MRSA and staphylococcal toxins among
cystic ﬁbrosis adult patients
O. Zaferiadou, N. Skarmoutsou, I. Iglezos, A. Damani, E. Petinaki,
E. Papafrangas, M. Kanellopoulou ° (Athens, Larissa, GR)
Objectives: Staphylococcus aureus which expresses numerous toxins to
evade host defence is recognized as a major pathogen in Cystic Fibrosis
(CF) patients. This study was designed to determine 1) the prevalence
of MRSA and 2) the presence of toxins genes among S. aureus isolated
from adult CF patients attending our CF unit.
Methods: Antibiotic susceptibilities were performed by the automated
Wider system and the Kirby Bauer method according to CLSI
recommendations. Methicillin resistance was conﬁrmed by the PB2a
detection (slidex BioMerieux). The mecA gene (encoding PBP2a), lukS
and lukF genes (encoding PVL), tst (encoding toxic shock syndrome
toxin), sem/seg (genes of the enterotoxin gene cluster egc) were deﬁned
by PCRs with speciﬁc primers.
Results: A total of 87 S. aureus strains were recovered out of 150 CF
patients. Most of them (74/87) were MSSA. Among the 13 MRSA
isolates (prevalence 8.6%) tested for the presence of genes encoding
toxins, one was found to be positive for PVL, one for TST-1 and two
for enterotoxins. On the other hand, among ten, randomly collected
MSSA isolates, none was found to carry the PVL genes, while one
strain was positive for TST-1 gene and ﬁve for the enterotoxin gene
cluster. All MRSA isolates were susceptible to Linezolid, Quinupristin/
dalfopristin, Cotrimoxazole but resistant to ciproﬂoxacin and 4/13
resistant to Rifampin.
Conclusions: 1. The prevalence of MRSA strains among CF adult
patients found to be 8.6%, in agreement with the European records.
2. Although PVL coding gene was present only in one strain, the
ﬁnding suggested an emergency for our CF population, because of
necrotising pneumonia fear. 3. The presence of TST-1 gene as well
as enterotoxin genes in both MRSA and MSSA isolates imposes the
systemic staphylococcal gene toxins determination for early treatment
of CF patients harbouring toxigenic strains in their respiratory system.
P1873 Epidemiology of MRSA bacteraemia and clinical relevance
of reduced susceptibility to vancomycin
T. Lewis, R. Chaudry, I. Das °, P. Lambert (Birmingham, UK)
Objectives: Recent reports suggest a reduced efﬁcacy of vancomycin
in the treatment of meticillin resistant Staphylococcus aureus (MRSA)
infection. This has been attributed to a reduced susceptibility of MRSA
to vancomycin. We analysed the epidemiology and outcome of MRSA
bacteraemia. We determined the minimum inhibitory concentrations
(MIC) of vancomycin and other antibiotics, and looked for the
presence of heteroresistant vancomycin intermediate Staphylococcus
aureus (hVISA). We looked for associations of raised vancomycin MIC
and hVISA with clinical outcome.
Methods: University Hospital Birmingham is a 1200 bed tertiary referral
centre. Episodes of MRSA bacteraemia over a 28 month period in
2005−7 were retrospectively analysed. hVISA were identiﬁed by the
presence of microcolonies at 6mg/l using the macro E-test method.
SCCmec typing and sub-typing was carried out by PCR.
Results: We identiﬁed 195 distinct episodes of MRSA bacteraemia from
179 patients, which included 16 relapses. 194 episodes were healthcare-
associated infections. Intravascular devices were the most common focus
of infection (39%). Overall mortality at 30 days was 28%. Mortality was
highest in those with no identiﬁable focus (52%), compared with all other
sites (17%; p< 0.01).
The modal vancomycin MIC was 0.5mg/l, and no isolates had a
vancomycin MIC above 1.5mg/l. All isolates were sensitive to linezolid,
daptomycin and tigecycline. 18% of isolates were hVISAs. hVISA was
associated with previous vancomycin usage (p = 0.02) and specialties
that use high volumes of vancomycin (p = 0.01). We did not observe
an association of hVISA with high burden sources. Compared to non-
hVISA episodes, hVISA was not associated with increased mortality
(p = 1), relapse rate (p = 0.48) or rate of other complications (p = 0.56).
SCCmec type IVh (EMRSA15) was the most common type in both
hVISA and non hVISA groups.
Conclusions: This is the ﬁrst report analysing the prevalence and clinical
relevance of hVISA from the UK. We identiﬁed a high prevalence
of vancomycin heteroresistance. This is associated with vancomycin
use, both in individual patients and in particular specialties, suggesting
antibiotic selection pressure is changing the ecology of MRSA. There
was no correlation between hVISA and adverse outcome. MRSA
bacteraemia remains a serious infection with a high mortality and high
rate of relapse. Further studies are required into the epidemiology and
continued evolution of hVISA.
P1874 Detection and characterisation of MRSA 6−12 months post
successful decolonisation: persistence or re-colonisation?
D. Gilpin °, S. Small, S. Bakkshi, P. Kearney, M. Tunney (Belfast,
Antrim, UK)
Objectives: Colonisation by Meticillin-resistant Staphylococcus aureus
(MRSA) is considered to be the pre-cursor to invasive infection. It
is widely accepted that decolonisation, using topical agents such as
chlorhexidine and mupirocin, is key to reducing the transmission and
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spread of MRSA within the hospital environment. This study aimed
to re-screen successfully decolonised patients at 6 and 12 months to
determine the extent of persistence, or re-colonisation, of MRSA among
these patients.
Methods: MRSA-colonised patients were identiﬁed by routine sample
submission to the diagnostic laboratory, at Antrim Area Hospital and
decolonised in accordance with standard hospital protocols (4% (w/v)
chlorhexidine wash once daily, and mupirocin applied nasally three times
daily, for seven days). Patients were described as “decolonised” after
submission of three negative screening swabs, each one-week apart.
At 6 and 12 months, the patients were re-screened. Pre- and post-
decolonisation isolates were analyzed by pulsed-ﬁeld gel electrophoresis
(PFGE) and similarities between banding patterns obtained compared
using GelCompar II.
Results: Of 92 successfully decolonised patients, 36 (39.1%) were
positive at either 6 or 12 months post decolonisation. Post-decolonisation
isolates were obtained for 25 patients. Of these, isolates from 21
patients were similar or identical to pre-decolonisation isolates (>70%
homology). Isolates from the remaining 4 patients shared <60%
homology pre- and post-decolonisation and were recorded as different.
Conclusion: This study suggests the need for 12 month follow up
screening for successfully decolonised patients. For the majority of
patients in this study, standard decolonisation protocols were found to
be effective for long-term (up to 12 months) decolonisation of MRSA.
In a small number of cases, patients were re-colonised with a different
strain of MRSA. However, in a signiﬁcant proportion of patients, despite
being apparently effectively decolonised, the same strain, as was initially
isolated, was detected up to 12 months post decolonisation. This may
be due to a range of factors including repeated exposure to the same
source of MRSA or a reduction in MRSA numbers to below detectable
level without complete eradication. Further phenotypic analysis of these
isolates is currently underway, together with more detailed examination
of patient characteristics.
P1875 Risk factors for methicillin-resistant Staphylococcus aureus
B. Catry, E. Hendrickx °, R. Preal, R. Mertens (Brussels, BE)
Objectives: The present study aimed to investigate the relationship be-
tween the prescriptions of antimicrobial agents and infection/colonisation
with MRSA in the ambulatory and in the in-patient setting.
Methods: The microbiological results retrieved from 16 voluntary
participating clinical laboratories during 2005 were coupled with the
individual antimicrobial consumption patterns (July 2004-December
2005) as provided by the pooled data of the seven Belgian health
insurance funds (intermutualistic agency, IMA). Herein, all S. aureus
positive patients (only ﬁrst isolate) and susceptibility testing result
for oxacillin were retained. Logistic regression was used to identify
risk factors for oxacilline resistance (MRSA) following antimicrobial
consumption and sociodemographic characteristics (e.g. age, admission
to healthcare setting, . . . ). Antimicrobial consumption was transformed
into deﬁned daily doses (DDD) and categorised using the ATC
classiﬁcation up to 4 digits (eg. JO1C) according to WHO terminology
(2007).
Results: A total of 6844 patients were included in the ﬁnal logistic
regression model, of which 1200 (17.5%) died in the year 2005. Within
the latter group, 51.2% (n = 614) were MRSA positive whereas in the
patients that survived 2005 only 28.1% (1568/5644) were found to
have MRSA (OR for death in case of MRSA=2.68; 95%CI 2.36–
3.05; p< 0.01). The multivariate model found following factors (95%CI)
to be signiﬁcant (p< 0.01) associated with MRSA: admission to a
long term care settings (3.22–5.11); aged 55–104 (3.76–6.35); aged
15−54 (1.36–2.37); consumption (per DDD) of chinolones (1.017–
1.026); cephalosporins, monobactams and carbapenems (1.004–1.012);
penicillins, aminopenicillins +/− clavulanic acid, b-lactamase stable
penicillins (1.0006–1.0039).
Conclusions: These data strongly support the existence of a risk
for acquired antimicrobial resistance in the major bacterial pathogen
S. aureus, directly related to the consumption of antimicrobial agents
at the individual patient level. In addition the study conﬁrmed an
association of MRSA with speciﬁc healthcare settings and age.
P1876 Resident- and institution-related factors associated with
methicillin-resistant Staphylococcus aureus carriage in
nursing homes in western Switzerland
C. Petignat, C. Bellini °, M. Bonard, L. Christin, A. Cometta,
E. Masserey, D.S. Blanc, L. Senn, G. Zanetti (Lausanne, Rolle,
Yverdon, CH)
Background: Nursing home (NH) environment is likely propitious to
circulation of MRSA among residents and between NHs and acute care
hospitals through transfers of residents. However, few data exist on the
prevalence of MRSA carriage in NHs residents although this should be
the basis for decisions on infection control measures.
Objectives: Assessment of the prevalence of MRSA carriage among
residents of NH in Canton of Vaud (Western Switzerland), an area of
presumably low MRSA prevalence (12% of S. aureus isolates in the
local tertiary hospital), and identiﬁcation of resident- and NH-related
risk factors for carriage.
Methods: Point prevalence survey in residents from 130 of 155 NHs
in Canton of Vaud. The proportion of residents randomly assigned to
screening of MRSA carriage was 25%, 33% or 50% in NH of >100,
50 to 99, and <50 beds, respectively. Nose, groin and wounds of
included residents were swabbed, and an urine culture was obtained in
the presence of a urinary catheter. A short questionnaire was completed
for each included resident and each NH.
Results: Residents: 273 of 2275 (12%) screened residents were MRSA
carriers. Independent risk factors for carriage were diabetes mellitus
(p = 0.015), wound (p = 0.041), urinary catheter (p< 0.001), hospital stay
within the previous 2 years (p = 0.013) and antibiotic therapy within the
previous 4 weeks (p = 0.001).
Nursing homes: MRSA-positive residents were identiﬁed in 81 of 130
(62%) NH, with a prevalence that ranged from 0 to 57% (median 7%).
NHs with MRSA carriers were larger (p = 0.002), had less individual
rooms (p = 0.013), and had a trend toward a lower nurses-to-residents
ratio (p = 0.069).
Conclusions: Prevalence of MRSA carriage in NH of Western
Switzerland varies from 0 to 57%. This is inﬂuenced by structural
characteristics of NH in addition to classical resident-related risk factors.
These results highlight the need to reassess control strategies in NH.
Further studies are needed to determine the potential health beneﬁts of
reducing MRSA colonisation rates in this setting.
P1877 5-year evolution of methicillin-resistant Staphylococcus
aureus carriage in nursing-home residents of western
Switzerland
C. Bellini °, C. Petignat, M. Bonard, L. Christin, A. Cometta,
E. Masserey, D.S. Blanc, L. Senn, G. Zanetti (Lausanne, Rolle,
Yverdon, CH)
Background: Nursing homes (NH) environment is probably favourable
to the acquisition and spread of MRSA. In addition, transfers of residents
to or from acute care hospitals are opportunities for circulation of MRSA.
It is therefore important to determine to what extend enforced infection
control measures in NHs appropriately control the spread of MRSA in
this setting.
Objectives: To measure the evolution of MRSA carriage over 5 years
among residents of NHs in Canton of Vaud (Western Switzerland), an
area of presumably low MRSA prevalence (12% of S. aureus isolates in
the local tertiary hospital).
Methods: Point-prevalence surveys within the 155 NHs in Canton of
Vaud in 2003 (17 NHs), 2005 (34 NHs), and 2008 (130 NHs). All
NH’s residents were screened for MRSA carriage during 2003’s and
2005’s surveys. In 2008 the proportion of residents randomly assigned to
screening of MRSA carriage was 25%, 33% or 50% in NHs of >100, 50
to 99, and <50 beds, respectively. Nose, groin, and wounds of included
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residents were swabbed, and a urine culture was obtained in the presence
of a urinary catheter.
Incidence of MRSA infection (deﬁned according to CDC criteria) in
carriers was evaluated with a questionnaire sent every 3 months to nurses
from 2005 to 2008.
Standard precautions were applied for all NH’s residents including
MRSA carriers (except transmission-based precautions for colonised or
infected wound or urine).
Results: The proportion of MRSA carriers was 4.5% (39/872 residents)
in 2003, 10.3% (179/1730) in 2005, and 12.0% (273/2275) in 2008
(p< 0.001). Among them, 34 (87%), 116 (65%), 112 (41%) respectively,
were newly identiﬁed.
A total of 413 residents participate in both the 2005 and 2008 surveys:
among the 60 of them who were MRSA carriers in 2005, 35 (58%) were
no longer screened positive in 2008.
355 MRSA-positive residents had a median 12-month (range: 3−24)
follow-up of MRSA infection. 57 infections occurred in 44 residents,
which represented an incidence rate of 0.1 episode per resident-year.
The most frequent sites of infection were wounds (43%) and the urinary
tract (32%).
Conclusions: We observed a 167% increase (up to 12%) in prevalence
of MRSA carriage over 5 years in NH’s residents of Western
Switzerland. Although the estimated risk of infection was moderate
(0.1 episode/resident-year), this trend should prompt reappraisal of the
infection control measures for MRSA carriers in this setting.
P1878 Staphylococcus aureus colonisation/infection in a neonatal
intensive care unit: a four-year study
M. Papadimitriou °, E. Koemtzidou, G. Antonaki, M. Matsas,
A. Alexaki, G. Kourakis, E. Lebessi (Athens, GR)
Objectives: To assess the colonisation/infection by Staphylococcus
aureus among neonates in a 30-bed, university-afﬁliated, level III-IV
Neonatal Intensive Care Unit (NICU) at a large paediatric hospital in
Athens.
Methods: All cases of S. aureus infection or colonisation in the
NICU were identiﬁed by using the data from laboratory and the
medical records. Routine surveillance cultures for the detection of
multidrug resistant pathogens was a standard practice in our NICU.
Surveillance consisted of swabbing the throat and rectum upon admission
and weekly until discharge. When infection is suspected, additional
cultures are taken (blood, urine, stool, skin lesions, umbilical and
eye swabs). Culture of samples and identiﬁcation was made by
standard methods. Susceptibility to penicillin (PN), oxacillin (OX),
cefoxitin (FOX), kanamycin (KN), tobramycin (TB), gentamicin (GN),
erythromycin (ER), clindamycin (CL), ciproﬂoxacin (CP), fusidic acid
(FA), trimethoprim-sulfamethoxazole (SXT), tetracycline (TE), rifampin
(RF), chloramphenicol (CHL), vancomycin (VAN) and teicoplanin
(TEC) was tested using the disk diffusion method, according to the
current CLSI guidelines.
Results: During the study period (2004–2007), 1822 neonates (59%
male and 41% female) were admitted in the NICU. Two hundred seventy
neonates (14.8%), ranging in age from 3 to 54days, were found colonised
with S. aureus upon admission (referred cases), whereas 69 neonates
(3.8%) were colonised during their NICU stay (NICU-acquired cases).
The median length of stay to the NICU before colonisation was 14days
(range 3–207d). The incidence of methicillin resistant S. aureus (MRSA)
was 21.8% (59/270) and 23.1% (16/69) among referred and NICU-
acquired cases, respectively. Yearly incidence of MRSA isolates from
2004 through 2007 was as follows: 17.1%, 21.2%, 28.0%, and 22.2%.
The following resistance phenotypes were identiﬁed: PN/OX (33.8%);
PN/OX/FA/KN/TE (14.9%); PN/OX/TB/KN (9.5%). Infection due to
MSSA was identiﬁed in 29 cases (bacteraemia, 3; UTI, 2; opthalmia, 18;
cutaneous infections, 3; umbilicitis, 3), and to MRSA in 17 cases
(ophthalmia, 8; cutaneous infections, 7; umbilicitis, 2). Epidemics were
not identiﬁed.
Conclusions: S. aureus appears endemic in maternity units and
NICUs. The rate of MRSA is very high. Systematic surveillance to
optimise detection of colonised newborns and aggressive infection-
control measures in maternity units and NICUs are necessary to prevent
the spread of MRSA.
P1879 Frequency of mecA gene and borderline oxacillin resistant
Staphylococcus aureus in nosocomial acquired methicillin
resistance Staphylococcus aureus infections
F. Khorvash, K. Mostafavizadeh, S. Mobasherizadeh, M. Jalali °
(Isfahan, IR)
Objectives: MRSA (methicillin resistant staphylococcus aureus), one of
the most important causes of nosocomial infections, is now endemic in
many hospitals. The aim of the study was to determine the frequency and
type of MRSA strains and antibiotic susceptibility in Al-Zahra Hospital,
Isfahan, Iran.
Methods: In an analytic descriptive survey in 2005 and early 2006,
patients admitted to the hospital who contracted S. aureus nosocomial
infections were enrolled in the study. All isolates were identiﬁed by the
conventional laboratory tests. MIC (Minimal Inhibitory Concentration)
of oxacillin on isolated bacteria was determined by E-Test method.
According to CLSI (Clinical and Laboratory Standard Institute) criteria
all strains with MIC of 4mg for oxacillin were identiﬁed as MRSA.
Intrinsic high level resistance (Mec A positive) and borderline oxacillin
resistant staphylococcus aureus (BORSA) were detected by amoxicillin-
clavulanate E-Test strips. Strains with MIC of 4mg for oxacillin and
8mg for amoxicillin-clavulanate were identiﬁed as mec A positive
MRSA. Other staphylococcus with MIC 4mg for oxacillin and 4
for amoxicillin-clavulanate were identiﬁed as mec A negative MRSA
(BORSA). MIC of vancomycin also was determined on isolated bacteria.
Data were analyzed by SPSS version 13 and Who net version 5.
Results: Out of 134 Staphylococcus aureus samples which were isolated
from nosocomial infections 90(67.2%) were MRSA. 67 out of 90(74.5%)
MRSA were Mec A positive and 23out of 90(25.5%) were mec A
negative (BORSA). Although most of the MRSA strains were isolated
from surgical site infections, there were no statistically signiﬁcant
difference between types of staphylococcus aureus growing from variant
sites of infections. Only one (1.49) of the Mec A positive MRSA
had reduced susceptibility to vancomycin but all of the mecA-negative
MRSA (BORSA) were sensitive to it.
Conclusion: Because one fourth of our staphylococcus strains are
mec A negative BORSA and there is no alternative for vancomycin
against mec A positive MRSA and Enterococcus spp. in our hospital,
vancomycin should be reserved only for life threatening infections due
to these organisms. Thus MRSA typing should be done to choose
appropriate antibiotic for optimal treatment of MRSA infections.
P1880 A four-year trend of in vitro sensitivity proﬁle of
Staphylococcus aureus strains cultured at a teaching
hospital, northern Italy
R. Manfredi °, A. Nanetti (Bologna, IT)
Introduction: The increased rate of drug resistance among Gram-
positive cocci is a general concern, especially in hospital settings. A
prospective bacteriological monitoring including a continued surveil-
lance of antimicrobial susceptibility rates, is ongoing at our General
Hospital, since the year 2004.
Materials and Methods The temporal variations of in vitro
antimicrobial sensitivity ﬁgures were examined quarterly for all suitable
Staphylococcus aureus strains, and followed from 2004 to 2007. The
same pathogen cultured more than once from the same patient within
one month, has been considered once.
Results: Among overall Staphylococcus aureus isolates (1,863 strains
tested on the whole), a complete (100%) sensitivity was shown
against vancomycin and teicoplanin, while some compounds retained
interesting activity (92.0–97.1% for cotrimoxazole, 76.1–88.7% for
chloramphenicol, 64.1–69.5% for rifampin). Oxacillin (methicillin)
resistance ranged from 46.2% of year 2007, to 53.3% of year
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2005. As a consequence, b-lactam derivatives proved an in vitro
activity of 46.7–54.1% for co-amoxiclav, 46.6–54.1% for cefotaxime,
and only 7.3−11.2% for penicillin. Among other tested molecules,
clindamycin reached a comprehensive 50% susceptibility rate (40.8–
54.3% of all tested strains), followed by erythromycin (40.3–54.7%), and
gentamicin (42.6–49−5%). No statistically signiﬁcant temporal variations
of antimicrobial susceptibility rates occurred during the four-year study
time
Conclusions: A long-term bacteriological surveillance of antimicrobial
susceptibility rates of relevant hospital-related microorganism like
Staphylococcus aureus is important, to found reliable guidelines of
antibiotic treatment and prophylaxis, in common clinical settings.
Despite a stable, signiﬁcant rate of methicillin resistance rates (mean
value around 47% of all Staphylococcus aureus isolates), we have to
underline that “older” compounds like cotrimoxazole, chloramphenicol,
and also rifampin, may still play some role in selected clinical situations,
while the activity of available glycopeptides is 100% maintained
presently.
P1881 Assessment of screening all patients and the environment
for MRSA in an acute hospital
E. Creamer, O. Sherlock, D. Fitzgerald-Hughes, D. Sullivan,
M. O’Donnell, A. Shore, P. Kinnevey, A. Rossney, P. O’Lorcain,
R. Cunney, D. Coleman, H. Humphreys ° (Dublin, IE)
Objectives: MRSA is endemic in Irish hospitals. A four-year research
grant was awarded to study the prevalence of MRSA in new patient
admissions to an acute tertiary referral hospital, prior to assessing the
value of enhanced decontamination, improved hand hygiene compliance
and molecular methods for the rapid detection of MRSA. We sought to
establish baseline MRSA prevalence data over a 12-month period prior
to the implementation of the interventions.
Methods: All consenting patients admitted to two medical and two
surgical wards of a 700-bed acute hospital were screened within
72 hours of admission (‘admission’ patients) and at weekly intervals
over a six-week period on each ward. In-patients hospitalised for
longer than 72 hours were also screened to establish the extent of
the MRSA reservoir in these wards (‘reservoir’ patients). Sampling
was also undertaken to investigate the MRSA burden in the inanimate
environment.
Results: MRSA was isolated from 10% (92/938) of all patients,
including, 8% (51/635) of ‘admission’ and 13% (41/303) of ‘reservoir’
patients. Of the 635 ‘admission’ patients, MRSA was recovered from 5%
of patients (32/635) on admission; 2% of MRSA-positive patients were
already known to be MRSA-positive and 2% (4/635) were considered
to be hospital-acquired. Of the 303 ‘reservoir’ patients, MRSA was
isolated from 7% of patients (22/303) who were hospitalised for longer
than 72 hours. Seven MRSA-positive patients (2%; 7/303) were known
to have had MRSA on admission but MRSA was recovered from 12
patients (4%; 12/303) with previous MRSA-negative screening results.
Six per cent (77/1361) of environmental screens including; mattresses
(8%; 36/462), bed frames (5%; 5/106), patient lockers (3%; 4/125), air
sampling (12%; 21/180) were MRSA-positive.
Conclusions: Screening revealed a high prevalence of MRSA among
patients hospitalised for over 72 hours, and to a lesser extent amongst
‘admission’ patients. These results indicate that additional efforts are
required to reduce patient and environmental contamination with MRSA.
P1882 An anonymous survey to determine the nasal colonisation
rates of methicillin-resistant Staphylococcus aureus in
patients attending the emergency department of a tertiary
referral hospital in Dublin, Ireland
R.J. Drew °, P. Gavin, G. McMahon, B. O’Connell (Dublin, IE)
Objectives: In recent years, in North America and continental Europe,
rates of nasal colonisation and severe infection caused by meticillin-
resistant Staphylococcus aureus (MRSA) have been increasing, in par-
ticular community-acquired strains (CA-MRSA). The aim of this study
was to determine the prevalence of methicillin-resistant Staphylococcus
aureus (MRSA) nasal colonisation among patients presenting to the
Emergency Department of a large urban tertiary referral hospital in
Dublin.
Methods: In June 2008, a nasal swab was obtained from patients
presenting to the Emergency Department, and it was cultured in nutrient
broth and tested for the presence of MRSA using standard laboratory
methods. Patients answered a standardised questionnaire regarding risk-
factors for MRSA colonisation. CDC epidemiological deﬁnitions for CA-
MRSA were used. Ethical permission was received from the Hospital’s
Ethics Committee.
Results: 538 patients were included in the study; two patients withdrew
from the study prior to obtaining the nasal swab. MRSA was recovered
from nasal swabs of ﬁfteen patients (2.8%). Five of the ﬁfteen patients
fulﬁlled the deﬁnition for CA-MRSA, hence the prevalence of CA-
MRSA was 0.93%. Only one isolate was ciproﬂoxacin susceptible and
6 isolates (40%) were fucidin resistant. No vancomycin intermediate
Staphylococcus aureus (VISA) was detected. The median age of patients
was 42 years (inter-quartile range 28−68 years) and 57.8% patients
were male. Almost half (45.4%) of patients were from the immediate
surrounding area of the hospital.
On bivariate analysis; living alone, age sixty years or over, living in long
term care, attending the General Practitioner in the last year, presenting
with a medical/surgical complaint (in comparison to a musculoskeletal
or psychiatric complaint) and having chronic obstructive pulmonary
disease (COPD) were all found to be statistically signiﬁcant (p 0.05).
A multivariate analysis was then performed to ensure that there was
no bias effect amongst the risk factors. Multivariate analysis indicated
that, aged sixty years or over (p = 0.01), having COPD (p 0.01) and
presenting with a medical/surgical complaint (p = 0.03) were independent
risk factors.
Conclusions: Prevalence of CA-MRSA in this region of Dublin, Ireland
is low (1%). At present, limiting MRSA screening to patients with
speciﬁc risk factors may represent a more efﬁcient use of resources
for our patient population.
P1883 Occurrence of methicillin-resistant Staphylococcus aureus
among clinical samples in Tehran and its correlation with
the site of infection
S. Hiradfar °, A. Azimian, S. Najar Peerayeh, M. Naderi,
M. Farshchian, Z. Salehipoor (Mashhad, Tehran, IR)
Introduction and Objectives: Methicillin-resistant Staphylococcus
aureus (MRSA) is responsible for an increasing number of serious
nosocomial and community acquired infections including superﬁcial
lesions and wound infections, osteomyelitis, endocardiris, pneumonia,
bacteraemia, Toxic shock syndrome and food poisoning. The purpose
of this study was to deﬁne the prevalence of of MRSA strains
among S. aureus strains isolated from selected Tehran hospitals with
conventional and molecular methods.
Material and Methods: A total 235 isolates were evaluated by disk
diffusion and MIC agar dilution tests according to the guidelines of the
National Committee for Clinical Laboratory Standards (NCCLS) and
PCR assay for mecA gene.
Table 1. Resistance against oxacillin in different specimens with various phenotypic
and genotypic tests
Sample Resistant
MIC* Disk diffusion mecA gene positive
Blood (n = 60) 29 (48%) 30 (50%) 30 (50%)
Urine (n = 37 16 (43%) 16 (43%) 17 (46%)
Cutaneous sample (n = 43) 18 (42%) 18 (42%) 19 (44%)
Respiratory tract (n = 55) 27 (49%) 27 (49%) 28 (51%)
Other (n = 9) 4 (45%) 5 (46%) 5 (46%)
Nasal swab (n = 31) 11 (35%) 12 (39%) 11 (35%)
*According to NCCLS guidelines isolates with MIC 4mg are resistant to
oxacillin.
S548 19th ECCMID, Posters
Results: from 2006 to 2007 a total of 235 strains from patients and
healthy persons (163(%69) men and 72(%31) women) were evaluated.
Our strains isolated from blood, urine, coetaneous samples, respiratory
tract samples, nasal swaps and miscellaneous samples. Prevalence of
MRSA strains in different samples is shown in table 1.
Conclusion: our results show good correlation between phenotypic and
genotypic methods for antibiotic susceptibility tests. Highest percent of
MRSA strains isolated from respiratory tract samples (%49), followed by
Blood(%48), other samples (for example Tissues or Exudates or Bone
marrow) (%45), Urine (%43), Coetaneous samples (%41) and ﬁnally
Nasal swabs (%34). These differences were not statistically signiﬁcant
(P> 0.05).
P1884 Antimicrobial susceptibility in PVL positives S. aureus
strains. 2005–2008 study
R. Blanco °, G. Ezpeleta, M.D. Suarez, J.A. Cardoso, A. Morla,
O. Herrero, R. Cisterna (Bilbao, ES)
Objectives: Panton-Valentine leukocidin (PVL)-producing Staphylococ-
cus aureus is emerging as a serious problem worldwide. It has been
described as usually causing skin and soft-tissue infections, but also
necrotising pneumonia affecting previously healthy young people and
associated with a very high mortality.
Therapeutical management in these infections has been long debated
without any treatment consensus. Clindamycin and Daptomycin have
been proposed as effective treatments in patients with soft tissue or skin
infections.
In the presented study we investigated the activity of Daptomycin and
others antistaphylococcal agents against such isolates.
Methods: A retrospective study was performed in order to detect
Staphylococcal strains harbouring PVL genes. 2014 S. aureus strains
from our hospital (January 2005 − June 2008) were analyzed by an in-
house Real-Time PCR assay, 45 isolates from 38 patients were positive.
Identiﬁcation and antimicrobial susceptibility testing were performed
against 24 antimicrobial agents using the BD Phoenix™. Macrolide
resistance was performed by using the disk induction test. Additional
E-test susceptibility testing in Muller Hinton II Agar was performed for
the new antimicrobial daptomycin.
Results: Samples origin was: 37 of the 45 (82.22%) from complicated
skin or soft tissue infections (cSSTI), 3 (6.66%) from blood culture, 3
(6.66%) from Infection Control procedures, 1 (2.22%) from a infected
surgical wound and 1 (2.22%) from a bronchial aspirate.
Number of strains and percentages of resistance against selected
antimicrobials (OXA = oxacillin, ERY = erythromycin, CLI =
clindamycin, GEN = gentamicin, CIP = ciproﬂoxacin, RIF = rifampicin,
SXT = trimethoprim/sulfamethoxazole, VAN = vancomycin, DAP =
daptomycin), are summarised in the table. No resistance to linezolid,
vancomycin and daptomycin was found.
MICs to Clindamycin were 0.5 in all the isolations but 7 of the strains
(15.55%) showed a MLSB phenotype conferring a inducible clindamicyn
resistance. Daptomycin MIC 50 was 0.24mg/l and MIC 90 0.38mg/l, 4
and 3 times higher respectively to the accepted susceptible breakpoint
of 1mg/l.
Conclusion: Clindamycin showed inducible resistance in more than 15%
of the PVL positive S. aureus strains tested, Daptomycin was shown to
be active against all of them. Daptomycin should be proposed to treat
PVL cSSTI.
Table. Number of strains and percentages of resistance
Resistance OXA ERY CLI GEN CIP RIF SXT VAN DAP
Number 29 18 7 0 9 1 1 0 0
Percentage 64.44 40 15.55 0 20 2.22 2.22 0 0
P1885 Staphylococcus aureus methicillin-resistant colonisation
among healthcare workers at a general hospital
M. A´lvarez-Ferna´ndez °, C. Potel-Alvarellos, L. Constenla, P. Prieto,
P. A´lvarez-Garcı´a, V. Barbeito, I. Alonso-Troncoso (Vigo, Pontevedra, ES)
Objectives: Studies of MRSA colonisation among health care workers
(HCW) are important in order to control the emergence and spread of
this organism in health-care institutions. The goal of the study was to
estimate the prevalence of MRSA colonisation in HCW.
Methods: A total of 67 HCW were studied from January-February 2007,
a nasal swab was obtained from each participant in the study. The nasal
swabs were cultured on MRSA ID media(bioMe´rieux). The cultures were
read at 24 and 48 hours. The MRSA phenotype was conﬁrmed by the
identiﬁcation of the mecA by PCR. The genetic relatedness of the isolates
was studied by RFLP (cfo I)-PCR of the coa gene. The spa, MLST,
SCCmec, and agr types were studied. The presence of the pvl genes
were studied by PCR.
Results: Six HCW were colonised by MRSA strains (8.9%). The strains
according to the RFLP (cfo I)-PCR, were identiﬁed as two clones. The
isolates belong to the t008-ST8-IV-agr 1 (CC8) (n = 2), and t018-ST36-
II-agr 3 (CC30) (n = 4). Both clones were PVL negative.
Conclusion: The colonisation of HCWs with the epidemic community
USA 300 related clone (t008-ST8-IV-agr1) is a matter of concern. The
other clone belongs to the international British EMRSA-16 (t018-ST36-
II-agr 3) that is endemic in the studied hospital. HCWs could be the
reservoir for the spread MRSA strains.
P1886 Methicillin-resistant S. aureus infections among patients in
an emergency department
V.R. Bollineni ° (Kharkov, UA)
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is
increasingly recognized in infections among persons in the community
without established risk factors for MRSA.
Methods: We enrolled adult patients with acute, purulent skin and
soft-tissue infections presenting to 11 university-afﬁliated emergency
departments during the month of August 2004. Cultures were obtained,
and clinical information was collected. Available S. aureus isolates
were characterised by antimicrobial-susceptibility testing, pulsed-ﬁeld
gel electrophoresis, and detection of toxin genes. On MRSA isolates,
we performed typing of the staphylococcal cassette chromosome mec
(SCCmec), the genetic element that carries the mecA gene encoding
methicillin resistance.
Results: S. aureus was isolated from 320 of 422 patients with skin
and soft-tissue infections (76 percent). The prevalence of MRSA was
59 percent overall and ranged from 15 to 74 percent. Pulsed-ﬁeld
type USA300 isolates accounted for 97 percent of MRSA isolates;
74 percent of these were a single strain (USA300–0114). SCCmec
type IV and the Panton-Valentine leukocidin toxin gene were detected
in 98 percent of MRSA isolates. Other toxin genes were detected
rarely. Among the MRSA isolates, 95 percent were susceptible to
clindamycin, 6 percent to erythromycin, 60 percent to ﬂuoroquinolones,
100 percent to rifampin and trimethoprim-sulfamethoxazole, and 92
percent to tetracycline. Antibiotic therapy was not concordant with the
results of susceptibility testing in 100 of 175 patients with MRSA
infection who received antibiotics (57 percent). Among methicillin-
susceptible S. aureus isolates, 31 percent were USA300 and 42 percent
contained pvl genes.
Conclusions: MRSA is the most common identiﬁable cause of skin
and soft-tissue infections among patients presenting to emergency
departments in 11 U.S. cities. When antimicrobial therapy is indicated
for the treatment of skin and soft-tissue infections, clinicians should
consider obtaining cultures and modifying empirical therapy to provide
MRSA coverage.
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P1887 Costs and beneﬁts of a peri-operative screen-and-treat
strategy in nasal carriers of S. aureus
M.M.L. van Rijen °, L.G.M. Bode, M.C. Vos, J.A.J.W. Kluytmans for
the STEP Study Group
Objectives: A multicentre double-blind randomised-controlled trial (M-
RCT), carried out in the Netherlands between October 2005 and June
2007, showed that hospitalised patients with S. aureus nasal carriage
who were treated with mupirocin nasal ointment and chlorhexidine
gluconate medicated soap (MUP-CHX), had a signiﬁcantly lower risk of
nosocomial S. aureus infections than patients receiving placebo (3.4%
vs. 7.7%, 95% CI 0.23–0.75). We determined the costs and beneﬁts of
MUP-CHX in patients undergoing elective surgery.
Methods: The costs consisted of the screening and the treatment costs.
To estimate the beneﬁts, the difference in length of stay (LOS) between
the two treatment groups was determined and the associated costs were
estimated.
Results: In total, 5736 patients were screened pre-operatively. 1062 of
these patients were found to be nasal carrier of S. aureus. Subsequently,
799 of them were included in the M-RCT: 436 in the MUP-CHX group
and 363 in the placebo group. To identify one carrier, 6 patients had to
be screened. The cost of one screening test was €25, resulting in €150
to identify one carrier. The costs of treatment with MUP-CHX were €13
per carrier. So, the total costs were €163 per treated carrier. Costs for
one patient day were €385. The mean LOS was 2.2 days shorter for
patients treated with MUP-CHX (11.8 vs. 14.0, p = 0.032), resulting in a
savings of €847. Taking into account the screening and treatment costs
and the savings for prevented LOS, €684 was saved per MUP-CHX
treated patient. Subgroup analysis revealed that the strategy was most
cost-effective in cardiothoracic surgery.
Conclusion: Screening for S. aureus carriage in elective surgical patients
and subsequently treating carriers with MUP-CHX is highly cost-
effective.
P1888 Carriage of Staphylococcus aureus and methicillin-resistant
Staphylococcus aureus in medical microbiology laboratory
personnel
M. Jager °, J. Kluytmans, C. Vandenbroucke-Grauls (Amsterdam, NL)
Objective: To determine whether personnel working in clinical
microbiology laboratories in The Netherlands is at increased risk for
colonisation with MRSA.
Methods: Anterior nares and throat swab samples were obtained from
266 employees of ﬁve different clinical microbiology laboratories.
Both swabs were placed in enrichment broth (Becton, Dickinson and
Company, France); these were incubated for 48 hours at 37ºC and then
subcultured by plating aliquots on a chromogenic selective medium
(bioMerieux, France) for 24 hours at 37ºC for the isolation of MRSA,
and on a mannitol salt agar for 48 hours at 37ºC for the isolation of
S. aureus. MRSA and S. aureus were identiﬁed according to standard
protocols. For each participating individual, the professional category
(technician, clinical microbiologist, trainee or other) was noted.
Results: S. aureus was detected in 45.1% (CI 95; 39−51) of the screened
individuals. Of these, 31.7% (CI 95; 20−50) carried S. aureus in the
throat only. MRSA was detected in the throat sample of one person
(0.38%, CI 95: 0.07–2.11). Further analyses of the MRSA strains isolated
in that laboratory revealed that the employee who carried the MRSA
worked with the same clinical strain months before. AFLP was used, to
conﬁrm that the strains were similar. There was no signiﬁcant difference
in carriage rate of S. aureus between the ﬁve laboratories nor between
employees of different professional categories.
Conclusions: To the best of our knowledge, this is the ﬁrst assessment
of carriage of S. aureus and MRSA in a microbiology laboratory. We
found a high carriage rate of S. aureus; a reason for this could be that
both nose and throat samples were used for carriage detection. One
employee carried a MRSA strain that had been recently manipulated
in the laboratory. Therefore, it may indicate occupational acquisition of
MRSA. The ﬁnding that 0.38% of lab personel is MRSA positive is not
signiﬁcantly different from a previous survey of patients on admission
to the hospital in The Netherlands. Therefore, we conclude that risk of
acquiring MRSA during work in a microbiology laboratory is limited.
Staphylococcus aureus carriers among employees of ﬁve hospitals.
P1889 Estimating the effect of methicillin-resistant Staphylococcus
aureus infection on length of stay in an intensive care unit
using a longitudinal model
A. Barnett, R. Batra, J. Edgeworth, N. Graves, J. Robotham °,
B. Cooper (Brisbane, AU; London, UK)
Objectives: To quantify increased length of stay in the intensive care
unit (ICU) and ICU mortality due to methicillin-resistant Staphylococcus
aureus (MRSA).
Methods: We use a multinomial longitudinal model for estimating the
daily probability of death and discharge applied to more than ﬁve years
of detailed longitudinal ICU data. We then extend the basic model
to estimate how the effect of MRSA infection on the probability of
discharge changes over time, and to quantify the number of excess ICU
days due to infection as a function of the day of the ICU stay on which
the infection was acquired.
Results: We ﬁnd that MRSA infection decreases the relative risk of
discharge (relative risk ratio 0.76, 95% credible interval: 0.62, 0.93) but
is only indirectly associated with increased mortality. An infection on
the ﬁrst day of admission resulted in a mean extra stay of 0.6 days for a
patient with an APACHE II score of 10, and 1.2 days for a patient with
an APACHE II score of 30. The decrease in the relative risk of discharge
remained fairly constant with day of MRSA infection, but was slightly
stronger closer to the infection time.
Conclusions: These results conﬁrm the importance of MRSA infection
in increasing ICU stay, but highlight the attributable length of stay due
to MRSA can be highly dependent on whether an infection is acquired
early or late in a patient’s stay. The results also suggest that previous
work may have systematically overestimated the effect size.
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P1890 Exploring the fourth dimension: the clinico-economic
impact of a distinct model of MRSA screening by PCR in
United Kingdom
A. Guleri, R. Palmer, C. Danson, B. Lunt, S. Ellershaw °, J. Lickiss,
J. Carter Lindsay, K. Woodrow, N. Harper (Blackpool, UK)
Background: Accurate and rapid identiﬁcation of methicillin-resistant
Staphylococcus aureus (MRSA)in hospital admissions is essential for
timely decisions on isolation/bio-burden reduction, effective antimicro-
bials[if infected], and reducing the potential for cross transmission and
self acquisition of HCAI.
Blackpool Victoria Hospital [BVH] is a large district hospital in
northwest England housing two speciality centres [cardiac surgery and
haematology]. Hospital charitable committee provided grant to pump
prime a 6-month pilot using MRSA PCR to screen all emergency
admissions [medical and surgical]; intensive care, high dependency and
surgical high care unit admissions.
S550 19th ECCMID, Posters
Method: The steering group [Microbiologists, Diagnostics Manager,
nursing leads – medicine/surgery, infection control and data analyst]
strategy included: clinico-economic modelling; revised MRSA guideline;
analysis of hospital admissions/24 hrs; comprehensive MRSA contain-
ment strategy [management-infection management team-clinical staff
liaison; advertisement & training/education drive; raise awareness; dress
code; management run infection prevention road shows; etc]. The project
[over 6-months] offered PCR runs 8am–midnight [TAT 3−8 h]. Snap shot
audits of TAT [swab to patient isolation], real time data analysis and
feeding back.
Results: Total reduction in MRSA infection episodes [bacteraemias 63%
and wound infections 38%]; 31% [2865/4145] reduction in estimated
glycopeptides unit-days over 6-months [2008 v 2007]and cost savings;
enhancing quality care and patient safety. Fourth dimension – MRSA
PCR is used in clinical decision making, early institution of optimal
therapy/alternate diagnosis and reduction in morbidity/mortality.
Cost saving: Estimated savings from [cost of total MRSA infection
episodes prevented + savings from reduced GP usage] minus [cost of test
+ stafﬁng]; First in region/country to use clinico-economic modelling to
run 8am–midnight service with demonstrable success.
Conclusions: Following success of the pilot, the trust has accepted a
business case for regular delivery of MRSA PCR service. A remarkable
reduction in total MRSA infection episodes including bacteraemias. A
lack of correlation between high risk and MRSA carriage noted. This
overall success is attributed to the comprehensive bundle of initiatives
including PCR. The clinical impact of MRSA PCR has been most
signiﬁcant in guiding decision making. A separate study is set to analyse
this impact.
Reduction in total MRSA infection episodes − PCR introduced mid
March.
P1891 Molecular assay for the rapid screening of methicillin-
resistant S. aureus colonised patients in an intensive care unit
P. Cavallerio °, C. Parlato, L. Fossati, R. Serra (Turin, IT)
Objectives: The prevalence of methicillin-resistant Staphylococcus
aureus (MRSA) is constantly increasing in hospitals and communities
in Europe.
The costs that MRSA cause on the healthcare system are often
underestimated, because of the signiﬁcant prevalence of asymptomatic
carriers colonised. To minimise the time needed for isolation of patients
a rapid identiﬁcation of MRSA colonisation is needed.
We used the GeneXpert™, an automated real-time-PCR system and the
diagnostic kit, Xpert MRSA (Cepheid, Inc., Sunnyvale, CA) to screen
nasal swabs from about 34 patients admitted to and outgoing of an
intensive care unit (ICU). The results were compared to culture-based
methods to assess sensitivity and speciﬁcity in detecting carriers of
MRSA. The aim is to propose a new rapid screening method for the
intensive care units of our hospital.
Methods: 65 Patients from an ICU unit at San Giovanni Battista Hospital
were included in the study. Double nasal swabs (Copan®, Italy) were
taken from patients. One was used for ampliﬁcation directly using
Xpert MRSA. The second was for the culture control, that included
the enrichment with Tryptic Soy Broth with NaCl 6.5% for 24 h and
then inoculated onto agar. Patients with positive tests results were put in
isolation and treated, for the decolonisation, with nasal mupirocin and
baths of 4% chlorhexidine for 5 days. After eight days a nasal swab
control was taken. Patients with negative results were reexamined after
seven days.
Results: A total of 122 nasal swabs were tested by using Xpert MRSA
assays and culture based-methods. Nine (7.4%) were unresolved. Nighty-
eight specimens (78.7%) were negative and six were positive (4.9%) for
MRSA by Xpert MRSA and culture-based methods. Eleven (9.0%)were
positive for MRSA by the PCR assay and, in contrast, were negative by
culture-based methods and classiﬁed as false-positive. However, ﬁve of
these, were positive by PCR-assay but negative by culture-based method,
because have been performed after decolonisation.
Conclusion: Xpert MRSA™ detects patients with MRSA nasal
colonisation in less than 2 hour and it’s easy to use. Compared to
culture-based methods, the Xpert MRSA assay provided signiﬁcantly
faster turnaround times and resulted in more prompt isolation of MRSA-
colonised patients. The relevance of samples false positives by the PCR
method is to take into account; however, it should be noted that there
were no false negative by PCR assay.
P1892 Cost analysis of rapid diagnostic testing of methicillin-
resistant Staphylococcus aureus using PCR or chromogenic
agar in a low endemic setting
M. Wassenberg °, A. de Wit, B. van der Zanden, M. Bonten (Utrecht,
Bilthoven, NL)
Objectives: To determine whether rapid diagnostic testing of methicillin-
resistant Staphylococcus aureus (MRSA) is cost saving when used for
screening of pre-emptively isolated patients.
Methods: Incremental direct costs caused by addition of PCR (BD
GeneOhmTM MRSA assay) or chromogenic agar (MRSA-ID by
bioMe´rieux) to conventional cultures were calculated applying a hospital
perspective. This included costs attributed to the rapid screening tests,
costs because of false negative test results and savings because of avoided
isolation days. The number of pre-emptive isolation days avoided with
rapid diagnostic testing was determined in a prospective multi-centre
experimental cohort study in 12 Dutch hospitals. This study included
853 patients.
Results: Costs of an isolation day, including supply costs and the
extra time needed by nurses, physicians and cleaning personnel were
estimated to be €27.30. The number of isolation days was reduced
by 60.4% with PCR-based screening and would haven been reduced
with 47.4% with chromogenic agar screening. Cost per test, when
added to standard culture procedures, was €52.70 for the PCR and
€2.05 for chromogenic agar. Four false negative test results during the
study resulted in additional costs of €10,077.41. The costs per isolation
day avoided were €92.25 and €8.28 for PCR and chromogenic testing,
respectively. Performing MRSA PCR added €143.73 per patient to the
overall costs, while chromogenic testing would have saved €29.88 per
patient.
Conclusion: Chromogenic screening, but not PCR-based screening, can
be considered a cost saving procedure to reduce unnecessary isolation
days in patients at high risk for MRSA colonisation.
P1893 Evaluation of the impact of screening and signalling
carriers of methicillin-resistant Staphylococcus aureus on
hand hygiene compliance and MRSA cross-transmission in
4 intensive care units
H. Hitoto, A. Kouatchet, L. Dube´, A. Mercat, M.L. Joly-Guillou,
M. Eveillard ° (Angers, FR)
Objective: Strategies combining systematic screening of methicillin-
resistant Staphylococcus aureus (MRSA) carriers and subsequent
implementation of barrier measures are usually recommended, but are
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money and time consuming. Our objective was to assess the impact of
screening and signalling MRSA carriers on hand hygiene compliance
(HHC) and MRSA cross-transmission in intensive care units (ICU).
Methods: We conducted an evaluative study with two 6-month periods
in 4 ICU. During the study, a systematic screening was performed
on patient admission and then weekly within hospitalisation. Screening
results were not transmitted to clinical staffs in the ﬁrst period (P1) but
were transmitted and carriers signalled during the second period (P2).
During P1, 200 contacts were observed without any awareness about
the carriage status of patients. During P2, the ﬁrst 200 contacts were
observed independently of the carriage status of the patient, whereas the
last 200 contacts observed were chosen in order to have the same number
of observations for MRSA carriers and non-carriers during P2. The ﬁrst
comparison (C1) of HHC represented our main objective and concerned
the contacts with MRSA carriers and the contacts with non-carriers in
P2. The second comparison (C2) of HHC was performed to evaluate the
overall impact of screening and signalling and concerned observations
in P1 and the ﬁrst 200 observations in P2. Lastly, a comparison of
MRSA cross-transmission (MRSACT) (C3) was performed between P1
and P2. Two indicators were used: the incidence of acquired MRSA/1000
patient-days (I1), and the incidence of acquired MRSA/1000 days of
hospitalisation of patients admitted with an MRSA.
Results: All categories of personnel were observed but 80% of the
observations concerned nurses and nurse assistants. Overall, HHC
was 43.5% (39.5% before contact vs. 43.1% after contact, P = 0.004).
Concerning C1, the HHC for contacts with MRSA carriers was 42.5% vs.
43.1% for contacts with non-carriers (not signiﬁcant). Concerning C2,
the HHC in P1 was 44.8% vs. 48.5% in P2 (not signiﬁcant). Concerning
C3, the 2 indicators were discordant. I1 was 3 fold higher in P2 than
in P1 (2.0 (CI95%= (1.97–2.03)) vs. 0.70 (CI95%=(0.68–0.72). I2 was
higher in P1 (16.0 (CI95%= (14.0–18.0)) than in P2 (11.4 (CI95%=(7.4–
15.4)).
Conclusion: We failed to identify any advantage by using screening and
signalling MRSA carriers in those 4 ICU.
P1894 Costs of nosocomial methicillin-resistant Staphylococcus
aureus pneumonia
E. Ott °, K. Graf, F. Schwab, C. Reichardt, I.F. Chaberny (Hanover,
Berlin, DE)
Background: Numerous studies demonstrated that nosocomial infec-
tions with methicillin-resistant Staphylococcus aureus (MRSA) are
attended by increased morbidity and mortality. Furthermore they present
a high ﬁnancial burden for hospitals and community.
Objective: The purpose of this study was to investigate attributable costs
for nosocomial MRSA-pneumonia inside the German DRG-System.
Methods: We conducted a case-control study including all patients
(pts.) with nosocomial pneumonia caused by MRSA and by meticillin-
susceptible S. aureus (MSSA) admitted between January 2005 and
December 2007. Pneumonia was deﬁned using CDC criteria.
Nosocomial cases with MRSA-pneumonia were matched to control
patients with MSSA-pneumonia in a ratio 1:1 using following
matching criteria: admission in the same year, minimum length of
stay corresponding to time at risk of the case, Charlson Comorbidity-
Index ±1, occurrence of pneumonia at intensive care unit (ICU).
Results: Our analysis includes 82 patients (41 cases, 41 controls). The
median overall costs for patients with nosocomial MRSA-pneumonia
were signiﬁcant higher than for control patients (60,684€ vs. 38,731€;
p = 0.011). Furthermore we detected a signiﬁcant difference in the
median ﬁnancial loss for cases and controls (11,704€ vs. 2,662€;
p = 0.002). The attributable costs for MRSA-pneumonia were 17,282€
in median (p< 0.001).
The acquisition of MRSA-pneumonia on ICU (ME=2.6; p< 0.001), ven-
tilation >500 h (ME=2.6; p< 0.001), liver disease (ME=1.5; p = 0,021)
and MRSA-pneumonia (ME=1.8; p = 0.01) were predictive for increased
costs in multivariate regression analysis.
Conclusion: This study pointed out that nosocomial MRSA-pneumonia
is associated with high costs for healthcare systems compared with
MSSA-Pneumonia. Appropriate infection control measures will be cost-
effective and therefore essential.
P1895 Eradication of an epidemic methicillin-resistance
Staphylococcus aureus from a geriatric university hospital.
Evidence from a >10-year follow-up
D. Mertz °, R. Frei, N. Periat, C. Scheidegger, M. Battegay, W. Seiler,
A.F. Widmer (Basel, CH)
Objectives: Published studies of successful eradication of methicillin-
resistant S. aureus (MRSA) in health care institutions are scarce. We
report the successful eradication of MRSA after an epidemic in the year
1992 involving 37 individuals in the geriatric hospital of the University
Hospital of Basel, Switzerland, an institution with 142 beds and about
50,000 patient days per year with less than one MRSA patient/year before
1992.
Methods: After detection of the outbreak, a multifaceted intervention
was performed including contact isolation precautions, optimising of
infection control activities with a focus on hand disinfection, screening of
all individuals at risk and decolonisation of all MRSA carriers. Identiﬁed
MRSA carriers were strictly kept on contact isolation or cohorted
until successful decolonisation. Decolonisation of MRSA carriers was
performed using mupirocin, chlorhexidine and systemic antibiotics if
indicated. All isolates from the epidemic as well as all MRSA isolates
ever cultured from a patient of our institutions between 1992–2005 were
typed by multiple molecular typing methods, at least by pulsed-ﬁeld gel
electrophoresis and the majority by spa typing.
Results: After identiﬁcation of MRSA in 7 patients, a MRSA screening
of all patients and staff members in the geriatric hospital was performed.
Overall, 32 patients and 5 staff members were found to be MRSA
carriers. 21/32 patients (66%) and all 5 staff members were successfully
decolonised. 7/32 patients (22%) died during the epidemic before
decolonisation. 2/32 patients (6%), a couple, were discharged with
persisting MRSA colonisation, and 2(6%) were lost to follow-up.
Systematic screening of 142 patients and all staff members after the
epidemic in 1995 and 1997 revealed no MRSA carriers. Since more than
10 years, the strain was not anymore identiﬁed, based on epidemiological
surveillance and molecular typing of all MRSA strains from any
specimen submitted to the microbiology laboratory.
Conclusion: This study provides strong evidence that long-term
eradication of an MRSA epidemic in a hospital is feasible, and
endemicity of MRSA after an outbreak can be avoided. The successful
bundle approach for eradication of MRSA during an epidemic is
expensive, but the long-term beneﬁts likely outweigh the initial heavy
use of resources.
P1896 Development and use of an on-line tool for completion of
MRSA bacteraemia root cause analysis
K. Hardy °, S. Gossain, A. Penny (Birmingham, UK)
Objectives: To develop an on-line tool that allows timely and targeted
completion of a root cause analysis investigation (RCA) for MRSA
bacteraemia cases within an acute hospital setting.
Methods: For all MRSA bacteraemia cases in England there is a
requirement to complete a RCA. The process in our Trust involved
completion of a paper form which was sent back to a central point
for analysis. This resulted in partially completed forms, with varied
data being provided. Completion and data entry for analysis were time
consuming and the missing data meant the analysis was not standardised
S552 19th ECCMID, Posters
and resulted in difﬁculties in trend analysis. Using web based technology
an on-line form was designed to overcome these pitfalls.
Results: Development of the on-line web based form allows the entire
RCA process to be completed electronically. Initially the electronic form
is populated with personal identiﬁable information and then links to other
hospital based systems to acquire information about ward movements.
The users are then taken through a series of targeted questions to
establish risk factors and focus of infection, identify lessons to be
learnt or where non-compliances with policies have occurred. All of
the questions either have drop down boxes with options, or are date
and time ﬁelds to enable meaningful analysis and comparison of cases.
On completion of the RCA, there are a series of veriﬁcation processes,
ﬁrstly by the user and then by the infection control team. If key questions
have not been completed the user will be asked to return to these. An
action plan must be developed to cover the key learning points, for all
actions the person responsible is nominated and the action plan link sent
to them. On completion a comment is placed on the system and once all
actions relating to a speciﬁc RCA are complete the case is considered
closed. All entries carried out on the on-line system are tracked with
date, time and user allowing audit of the process.
Conclusion: The on-line tool is easy to use, resulting in a reduced time
to completion and analysis of the ﬁndings. This has allowed us to analyse
and interpret the data enabling the introduction of targeted and effective
infection control measures.
Surgical site infections
P1897 Region-wide surveillance of surgical site infections after
orthopaedic surgery in Crete, Greece
M. Roumbelaki, E. Kritsotakis, A. Messaritaki, E. Bolikas, C. Tsioutis,
A. Gikas ° on behalf of the Cretan Coordination Center for Nosocomial
Infection Control
Objectives: In this ﬁrst attempt to implement an active surveillance
system of surgical site infections (SSI) in a network of hospitals
in Greece, our objective was to identify areas for improvement by
comparing SSI rates with international benchmarks and by specifying
main epidemiologic features of SSI after orthopedic surgery.
Methods: The US National Nosocomial Infections Surveillance (NNIS)
system protocols were employed to prospectively collect data for patients
who underwent orthopedic surgery during an 11-month period in 7
hospitals in the region of Crete in Greece. Operative procedures surveyed
included open reduction of fracture (FX), knee prosthesis (KPRO),
hip prosthesis (HPRO), and spinal fusion (FUSN). Comparisons of
procedure-speciﬁc SSI rates with international data were performed by
means of indirect standardisation after stratifying the rates by the NNIS
risk index, and were reported in terms of standardised infection ratios.
Risk factors for SSI were evaluated by multivariate logistic regression.
Results: A total of 68 SSIs were detected in 1478 operations (4.6 per
100 operations), of which 46% were detected post-discharge. Among the
recorded SSI, 44% were superﬁcial, 52% were deep and 4% were organ-
space infections. Antibiotic prophylaxis was administrated for 97% of
the procedures classiﬁed as clean and for 77% of clean-contaminated
procedures, for a median duration of 6 days. Procedure speciﬁc SSI rates
and risk-adjusted comparisons with international data are presented in
the Table. SSI rates were signiﬁcantly higher for 3 operation categories
compared with US data (FX, HPRO, KPRO), and for 2 operation
categories compared with Spanish data (FX, KPRO) and UK data (FX,
HPRO). Independent risk factors for SSI included: Charlson comorbidity
index 1 (odds ratio [OR]=1.8, p = 0.024), wound class not clean
(OR= 2.2, p = 0.035), and prolonged duration of operation (OR= 4.0,
p< 0.001). The mean postoperative hospital stay was signiﬁcantly longer
for patients who acquired a SSI than those without SSI (28.6 vs
10.6 days, p< 0.001). SSI was not associated with mortality.
Conclusion: This study demonstrated the feasibility of implementing
a standardised surveillance protocol of SSI after orthopedic surgery
in our region, created awareness of the magnitude of the problem of
SSI, and generated data useful for designing targeted infection control
interventions.
Procedure speciﬁc SSI rates and risk-adjusted comparisons with international data
NNIS Operative Category Study results US rates1 Spanish rates2 UK rates3
No. of SSI/
procedures
SSI rate
(%)
SIR p SIR p SIR p
Open reduction of fracture 26/456 5.7 5.0 <0.001 2.0 0.001 1.9 0.002
Hip prosthesis 19/506 3.8 3.0 <0.001 1.0 0.531 2.0 0.003
Knee prosthesis 14/268 5.2 4.7 <0.001 2.6 0.001 1.3 0.217
Spinal fusion 9/248 3.6 1.7 0.080 0.9 0.459 – –
NNIS, National Nosocomial Infection Surveillance system; SSI, surgical site infection; SIR, standardised infection
ratio.
1Am J Infect Control 2004;32:470−85. 2Am J Infect Control 2006;34:134−41. 3UK Health Protection Agency
2006.
P1898 Incidence and determinants of surgical site infections after
colorectal surgery
Y.J.A.M. Hendriks °, R.M.P.H. Crolla, J.A.J.W. Kluytmans (Breda, NL)
Objective: Surgical site infections (SSI) are well known complications
of colorectal surgery. We determined the incidence and determinants of
SSI after colorectal surgery.
Methods: Prospective follow-up from November 2007 until December
2008 of all patients undergoing colorectal surgery at our hospital.
Patients with dirty or infected procedures were excluded from the
analysis. SSI were deﬁned by the criteria of the Centers of Disease
Control. Follow-up included post-discharge surveillance until 42 days
after the initial operation.
The following variables were included in the analysis: Age, sex, Body
Mass Index (BMI), ASA score, removal of hair, the number of operations
performed by the individual surgeons, lowest body temperature during
surgery, duration of the surgical procedure, the use of prophylactic
antibiotics, and elective or acute procedure. Univariate and multivariate
analyses were performed and statistical signiﬁcance was accepted when
p< 0.05.
Results: 282 patients undergoing clean-contaminated or contaminated
colorectal surgery were included. The mean patient age was 66.5 years
and 40% were female. 64% had a diagnosis of cancer. SSI were found
in 56 patients (20%). 6.4% had a superﬁcial incisional SSI and 13.5%
had deep incisional SSI or organ/space infections. In univariate analysis
the following variables were associated with the occurrence of SSI
(p< 0.1): Surgeons with a low amount of procedures, acute procedures,
no removal of hair before surgery, a high BMI and a longer duration of
the surgical procedure. After multivariate analysis the following variables
were statistical signiﬁcant: BMI (p = 0.037) and duration of the surgical
procedure (p= 0.006).
Conclusions: The incidence of SSI in patients undergoing colorectal
surgery is high. The two variables that were associated with the
occurrence of SSI (BMI and duration of surgery) do not offer an easy
target for preventive interventions.
P1899 Consequences of surgical site infections after colorectal
surgery
Y.J.A.M. Hendriks °, R.M.P.H. Crolla, J.A.J.W. Kluytmans (Breda, NL)
Objective: Surgical site infections (SSI) were found in 20% of
patients undergoing colorectal surgery in our hospital. We estimated the
consequences of SSI by determining the length of hospital stay and
mortality.
Methods: Patients (n = 282) who had undergone colorectal surgery
between November 2007 and December 2008 were included in the
analysis. SSI were deﬁned by the criteria of the Centers of Disease
Control. The patients were followed for the development of SSI including
post-discharge surveillance for 42 days after the initial operation.
Mortality was followed for 6 months after the initial surgical procedure.
Results: Of the 282 patients, 56 suffered from SSI (20%). The average
age for the patients was 66.5 years. The operations were elective in 98%
of the cases and 2% were urgent. Patients with a SSI had a signiﬁcant
longer post-operative stay (Mean: 28.3 versus 8.9 days, p< 0.001) and
a longer post-operative stay on the Intensive Care Unit (Mean: 4.2
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versus 0.3 days, p< 0.001). Also, the mortality in infected patients was
signiﬁcantly higher (see ﬁgure, p< 0.001).
Conclusions: The incidence of SSI of patients undergoing colorectal
surgery is high (20%) and is associated with signiﬁcant mortality and
prolongation of stay on the ICU and in the hospital.
P1900 Surgical wound infection after median sternotomy:
incidence and risk factor analysis. Results of a large
multi-centre study in Italy
C. Santini ° on behalf of GIS-INCARD (Gruppo Italiano per lo Studio
delle Infezioni in Cardiochirurgia)
Objectives: Sternal wound infection(SWI) after cardiac surgery is
associated to high mortality and costs. The adherence to the
recommendations to prevent SWI is usually low, independently from
their ranking. Despite the weak control of several modiﬁable risk factors,
in 2007 the GIS-INCARD documented a rate of SWI acceptably low.
Aim of the present study was to verify the incidence of SWI and to
re-evaluate the adherence to standard recommandations in a large series
of patients.
Methods: Nineteen divisions of Cardiac Surgery participated in this
observational study.
From March to September 2008, all the patients undergoing median
sternotomy were followed for one month to detect SWI, deﬁned
according to the CDC diagnostic criteria.
In a single day every 2 months, all the inpatients with median
sternotomy had recorded several variables regarding patients and
operation characteristics, co-morbidity, pre, intra and post-operative
risk factors, Staph. aureus nasal colonisation, timing and modality of
depilation and perioperative prophylaxis.
All the data were inserted in a data base and analysed by a central
supervisor.
Results: Overall, 3381 patients underwent median sternotomy;out
of them 3043 (90.0%) were evaluated. Eighty SWI were observed
(2.62%). Clinical variables referred to 610 patients were analysed.
In table 1 we report the characteristics of patients and operations,
the incidence of several risk factors and the antibiotics used for
perioperative prophylaxis in the present and in the previous study.
Comparing to the previous study, almost all the modiﬁable risk
factors were slightly better controlled: preoperative hospitalisation was
shorter (−0.5 days), less patients had preoperative hyperglycaemia
(−5%), more patients were investigated for staphylococcal nasal
carriage (+8%), less patients had hair shaving (−4%) and more
patients had hair removal soon before surgery (+17%). According
to scientiﬁc recommendations, the use of antibiotic prophylaxis
regimens based on glycopeptides cut in half (−8%), while increased
the number of patients receiving a single dose of vancomycin as
adjuvant (+12%).
Conclusions: The present study conﬁrms an incidence of SWI
acceptably low, despite the increased mean age and the higher rate of
patient with emergent-urgent surgery in the present series.
Although the adherence to guidelines and recommendations for
preventing SWI remains quite low, comparing to the previous study all
the risk factor resulted slightly better controlled.
2005–2006 2008
Incidence of sternal wound infection 2.63 2.62
Mean age (years) 65.9 68.8
Mean preoperative hospitalisation (days) 5.54 5.09
Coronary artery bypass graft/valve replacement (%) 58.4/34.9 61.6/29.6
Elective procedures (%) 88.9 84.2
Cardiopulmonary bypass (%) 90.9 95.1
Length of surgery >5 hours (%) 22.3 24.4
Preoperative hyperglycaemia (%) 22.7 17.8
Cigarette smoking (%) 21.3 20.3
Patients with cultures for staphylococcal nasal colonisation (%) 52.2 60.5
Staphylococcal nasal carrier (% of cultured patients) 8.6 8.1
Shaving of operative site (%) 97.8 93.9
Shaving of operative site at day of surgery 40.6 57.2
Prohhylaxis with 1st−2nd generation cephalosporins (%) 75.4 78.8
Prophylaxis with glycopeptides – multiple doses (%) 16.4 8.4
Prophylaxis with glycopeptides – single doses (%) 8.1 20.9
Prophylaxis with not antistaphylococcal agents (%) 2.3 5.6
P1901 Risk factors for fungal surgical site infections in recipients
of ventricular-assist devices
A. Schweiger °, C. Ruef, M. Wilhelm (Zurich, CH)
Objectives: Ventricular-assist-devices (VAD) are mechanical support
systems to maintain blood-circulation in patients with terminal cardiac
failure. The aim of our study was to evaluate potential risk-factors for
fungal infections in VAD-recipients during the period between 2004 and
2008.
Methods: Retrospective comparison of 4 patients (3 male) with candida
surgical-site-infection (SSI) of the VAD (3 C. albicans, 1 C. parapsilosis)
to 8 consecutive patients under VAD-support during the same time
period without candida infection. Information from medical records was
retrieved on patient history, number of body sites colonised with Candida
sp., antibiotic treatment, days in ICU, and days on mechanical ventilation,
dialysis, gastrointestinal complications and/or abdominal surgery and
antibiotic treatment.
Results: Median age at time of VAD-implantation was 55 years (44−59)
in cases, and 33 years (16−61 years; p = 0.089, Mann-Whitney) in
controls. 2 involved mediastinum (both C. albicans), the other 2 only soft
tissue. Median time to development of SSI after admission was 38.5 days
(range 19–223) and 17 days (range 2–195) after VAD-implantation.
For detailed clinical information see table. Candida colonisation of 4
body sites prior to infection was found in 2 patients, compared to 1
in the control-group (p = 0.236, Chi-square). Mechanical ventilation for
14 days (3/4 in infection group, 3/8 in controls) was signiﬁcantly
associated with development of candidal infection (p< 0.05, univariate
logistic regression). Development of mesenteric ischaemia showed a
trend as risk-factor (p = 0.053). Exposure to broad-spectrum antibiotic
treatment (Mean 706 days/1000 observation days in infection group
vs. 463 days/1000 observation days in controls, P = 0.1763) was higher
in the infection group. No single antibiotic was associated with an
increased infection risk. Other analysed factors as mentioned above were
statistically not signiﬁcant.
Conclusion: The only signiﬁcant predictor for candida SSI in patients
with ventricular-assist devices was mechanical ventilation for 14 days.
Other analysed factors were not signiﬁcant, possibly due to low
number of cases. The optimum strategy for prevention of candida
SSI (e.g. rigorous evaluation of candidal colonisation, minimising
antibiotic pressure, pre-emptive antifungal treatment in patients suffering
of mesenteric ischaemia) in VAD-recipients should be investigated in
prospective studies.
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1 Candida
albicans
1
(dialysis
catheter)
1 Neg Media-
stinitis
(SSI-MED)
19 6 Caspofungin
Fluconazole
6 d
82 d
BSI-LCBI,
CVS-VASC,
SSI-VASC,
SSI-IAB
Transplantation
on day 94.
Exitus
day 1 post-
transplantation
(haemorrhage
and thrombosis
of left ventricle)
?
2 Candida
albicans
4
(urine,
respiratory,
abdominal
wound,
genital)
12 Pos Media-
stinitis
(SSI-MED)
21 2 Fluconazole
Caspofungin
10 d
61 d
SSI-IAB,
PNEU-PNU1,
UTI-ASB,
SSI-SKIN
Removal of
VAD after 49 d
of support.
Exitus due to
haemorrhage
on day 17 after
removal
No
3 Candida
para-
psilosis
1
(respira-
tory)
3 Neg Soft tissue
(SSI-ST)
52 28 Caspofungin
Fluconazole
16 d
40 d
SSI-MED,
CVS-VASC,
SSI-IAB
Death on
day 89 under
support due
to aspiration-
Pneumonia
No
4 Candida
albicans
4
(inguinal
wound,
urine,
respiratory,
VAD)
189 Neg Soft tissue
(SSI-ST)
223 195 Fluconazole 81 d BSI-LCBI,
LRI-BRON,
CVS-VASC,
UTI-ASB,
PNEU-PNU1
Transplantation.
Death
2 years after
transplantation
No
Neg, negative; Pos, positive.
BSI-LCBI: Laboratory-conﬁrmed bloodstream infection; CVS-VASC: Venous infection; LRI-BRON: Bronchitis
without evidence of pneumonia; PNEU-PNU1, Pneumonia; SSI-IAB: Surgical site infection of abdominal space;
SSI-MED: Surgical site infection of mediastinum; SSI-SKIN: Surgical site infection of superﬁcial incisional site;
SSI-VASC: Surgical site infection of blood vessels; UTI-ASB: Asymptomatic bacteriuria.
P1902 Associations between operative site microbial counts and
procedure classiﬁcation in neurosurgery
S. Maraki, D. Karabetsos, S. Tsiodras, I. Kourbeti °, A. Ioannou,
C. Neophytou, M. Filippou, A. Vakis (Heraklion, Athens, Chalkida, GR)
Objectives: Correlation between operative site skin bacterial counts in
neurosurgical procedures and the development of surgical site infections
(SSI) has not been proven. We evaluated the association of bacterial
Colony Forming Units(CFU), type of procedure and development of
SSI in a prospective pilot study
Methods: Skin swab cultures were obtained within 1 cm from the
incision; pre-, post-preparation and preclosure samples were obtained.
Bacterial counts were enumerated and the most prevalent organisms were
recorded. Procedures were classiﬁed as clean, clean with foreign body,
clean contaminated, contaminated and dirty
Results: 83 procedures (42.1% clean, 21.7% clean-contaminated, 18%
clean with foreign body, 14.5% contaminated and 4.8% dirty) in 70
patients(70% male) were evaluated prospectively. Trauma was the most
common reason for surgery (31.8%). 93 sample sets were cultured.
88.2% preprep, 28% postprep and 43.5% of the preclosure samples
tested positive. Coagulase-negative staphylococci (CoNS) were the most
frequently isolated organisms irrespectively of sampling time (62.4%,
18.3% and 29.3% for samples 1, 2 and 3 respectively) and independently
of procedure classiﬁcation. The median cfu count log for CoNS were
3 log(range 2−6.3), 2.6(range 2−3.7) and 2.4(range 2−4) respectively for
each sampling. P. acnes was the second most frequent pathogen isolated.
The median cfu count log for P. acnes were 3.9 log (range 2.2−6.6), 3.2
(range 2−3.8) and 4.3 (range 2−5.4) respectively for each sampling.
There was a signiﬁcant difference in the P. acnes counts isolated from
head versus other sites. Procedure classiﬁcation or prolonged surgery
duration were not associated with microbial counts irrespectively of
sampling time. SSI development was not associated with bacterial CFU
at any sampling, therefore there was a trend for association with CoNS
pre-preparation CFU.
Conclusion: CoNS was the most frequent bacterial pathogen cultured
irrespectively of sampling. The pathogen cfu log did not signiﬁcantly
differ among the samples. P. acnes was signiﬁcantly more isolated
from head specimens. Procedure classiﬁcation was not associated with
microbial skin counts at any sampling but CoNS prepreparation CFU
carried a trend for statistical association with SSI development in this
pilot study
P1903 Post-discharge surveillance of surgical site infections after
total hip and knee arthroplasty
P. Mitt °, K. Telling, V. Adamson, M. Ro˜o˜m, H. Kolk, A. Ma¨rtson,
M. Maimets (Tartu, EE)
Objective: The aim of the study was to investigate the surgical
site infection (SSI) rate after total hip (THA) and total knee (TKA)
arthroplasties using postdischarge surveillance.
Methods: From January to June 2007 a total of 553 patients were
evaluated after THA (n = 253) and TKA (n = 300) in Tartu University
Hospital. SSI was identiﬁed according to the National Nosocomial
Infection Surveillance system (NNIS) criteria during hospital stay and
for 12 months postdischarge using telephone calls, laboratory data and
medical record review. Potential prophylaxis-, patient-, and procedure-
related risk factors were also collected prospectively.
Results: A total of 8 SSIs were identiﬁed. SSI was recorded in 5 patients
after THA (cumulative incidence rate 2.4%): 3 deep or organ/space and 2
superﬁcial SSIs. After TKA 3 SSIs were identiﬁed (cumulative incidence
rate 1.0%): 1 organ/space and 2 superﬁcial SSIs. Most of the operations
were performed in patients with the NNIS risk index category 0 or
1 (47.0% or 51.4%, respectively). The incidence of SSI in THA and
TKA stratiﬁed according to the NNIS risk index was 2.26% and 1.57%
(NNIS = 0), and 1.72% and 0.59% (NNIS = 1), respectively. The total
response rate to the telephone questionnaire survey was 95.3% and 2
out of three SSIs detected by telephone questionnaire were superﬁcial.
All the other cases were detected on readmission. The median length of
hospital stay after operation was 5 days (range 3−24 days). Time between
operation and detection of SSI cases ranged from 14 to 356 days. 72.1%
of patients received antibiotic prophylaxis within 30−60min before
incision.
Conclusions: Although our numbers are small, all SSIs were identiﬁed
using postdischarge surveillance. In our centre the incidence of SSI in
risk index category 0 is higher than the notiﬁed incidence in the Hospitals
in Europe Link for Infection Control Through Surveillance or NNIS
system which needs further investigation.
P1904 Reducing surgical site infection rates in cardiac surgery:
results of 10-year infection control programme
R. Finkelstein °, G. Rabino, T. Mashiach, Y. Bar-El, Z. Adler,
V. Kerztman, O. Cohen, S. Milo (Haifa, IL)
Background: To report the results of an infection control program on
surgical site infections (SSIs) complicating cardiac operations.
Methods: Prospective cohort study of patients undergoing cardiac
operations. Interventions included prospective surveillance, povidone-
iodine scrub showers, depilation before surgery, administration of
preoperative antibiotic prophylaxis in the operating room and compre-
hensive postdischarge follow-up. Infections were evaluated using CDC’s
deﬁnitions. Logistic regression models were ﬁtted to assess infection
rates over time, adjusting for factors known to affect SSI rates (NNIS
risk index category, type of operation, sex, age, emergency operation,
administration of preoperative antibiotic prophylaxis, length of stay in
hospital before surgery).
Results: 3,249 consecutive procedures were evaluated from January 1st,
1997 to December 31, 2006. Rates of deep incisional SSIs remained
low, but unchanged over the study period (mean 1.8%). The rate
of superﬁcial incisional SSIs (SUP), all organ/space infections (OS),
and mediastinitis (MED) during the ﬁrst two years were 4.7%, 3.1%,
and 2.22, respectively and they decreased to 2.6%, 1.31%, and 0.19,
respectively by the end of 2002 (p = 0.04, 0.07, 0.02). The rate of SSIs
due to methicillin-resistant S. aureus (MRSA) decreased from 1.48% to
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0.75% (p = 0.25). The adjusted odds ratios (OR) for these infections at
the end of 2002 compared to December 31, 1998, were as follow: SUP
0.5 (95% conﬁdence interval [CI-95], 0.26–0.97, OS 0.44 (CI-95, 0.39–
2.08), MED 0.09 (CI-95, 0.012–0.73), and MRSA 0.49 (CI-95, 0.15–
1.64, respectively. The 1-year mortality rate among patients with SSIs
was 8.3% as compared with a mortality rate of 4.6% among non-infected
patients. By logistic regression analysis, SSI remained an independent
risk associated with an increased mortality (OR 1.8; CI-95, 1.12–2.93).
Conclusions: We observed signiﬁcant reductions in infection rates in
most types of infections, particularly in superﬁcial SSI and mediastinitis.
These differences remained signiﬁcant when adjusted for potential
confounding variables.
P1905 Evaluation of three preoperative preparation products
when used in a preoperative site-wash regimen
C. Beausoleil ° (Bozeman, US)
Objective: Many patients undergoing orthopedic, cardiovascular, and
general thoracic or abdominal surgeries experience post-surgical infec-
tions, prolonging their medical treatments, and imposing unnecessary
medical risk and expense. The standard of practice for preoperative
preparation (PreOp Prep) is to treat the intended surgical site with
an effective topical antimicrobial immediately prior to a surgery,
usually with prophylactic antibiotic therapy before and after the surgery.
However, some medical practitioners currently prescribe for their
presurgical patients, in addition, a preoperative site-wash (PreOp SW)
regimen with the intention of reducing microbial populations residing on
the skin prior to the routine site preparation at the time of the surgery.
The logical rationale has been that such a combination procedure would
reduce potentially contaminative microbial populations to levels far lower
than could the PreOp Prep alone.
The purpose of this study was to evaluate effectiveness of a PreOp
SW procedure by measuring reductions of normal and transient
microorganisms produced at a speciﬁc site, the knee, by applications
of a marketed PreOp Prep product over the course of 4 consecutive
days. Three different commercially available products were tested –
TRISEPTIN® Water-Aided, MaxiClens®, and ChloraPrep®.
Methods: Two products were evaluated on each human subject to
provide 10 data ﬁles per product (15 subjects, total). Technicians applied
the products per use-instructions to the skin of subjects’ knees once per
day for 4 consecutive days. Microbial populations were sampled each day
prior to and immediately following treatment. Performance of a product
was evaluated in terms of its ability to reduce microbial populations
progressively and in total over the 4-day period of testing.
Results: All products tested produced signiﬁcant reductions in the
populations of microbial ﬂora on the skin of the knee (see table).
Sample time log10 differences from day 1 pre-application population
(pre/post-
application)
TRISEPTIN®
Water-Aided
(70% EtOH v/v)
N= 10
Day 1 Pre-Application
(Baseline)
Baseline Mean = 2.56
(S.D. = 0.64)
CHLORAPREP®
(2.0% w/v CHG in 70% w/v
IPA)
N= 10
Day 1 Pre-Application
(Baseline)
Baseline Mean = 2.62
(S.D. = 0.60)
MAXICLENS™
Antiseptic Skin Cleanser
(4% w/v CHG)
N= 10
Day 1 Pre-Application
(Baseline)
Baseline Mean = 2.43
(S.D. = 0.52)
Mean Reduction
(SD)
95%CI Mean Reduction
(SD)
95%CI Mean Reduction
(SD)
95%CI
Post-Day 1 2.24 (0.72) 1.73, 2.75 2.45 (0.61) 2.01, 2.89 2.20 (0.47) 1.86, 2.54
Pre-Day 2 0.58 (0.92) −0.08, 1.24 0.21 (0.27) 0.02, 0.40 0.33 (0.57) −0.08, 0.73
Post-Day 2 2.52 (0.65) 2.05, 2.98 2.51 (0.55) 2.11, 2.90 1.80 (1.07) 1.03, 2.56
Pre-Day 3 0.81 (0.87) 0.19, 1.43 0.41 (0.49) 0.07, 0.76 0.61 (0.78) 0.05, 1.17
Post-Day 3 2.50 (0.71) 1.99, 3.01 2.47 (0.66) 2.00, 2.94 2.32 (0.48) 1.98, 2.67
Pre-Day 4 0.75 (0.86) 0.14, 1.36 0.54 (0.33) 0.31, 0.78 0.81 (0.66) 0.34, 1.28
Post-Day 4 2.56 (0.64) 2.11, 3.02 2.61 (0.60) 2.18, 3.04 2.43 (0.52) 2.05, 2.80
S.D. = Standard Deviation; CI = Student’s t Conﬁdence Interval, a = 0.05.
Conclusion: A PreOp SW regimen using any of the products tested –
TRISEPTIN® Water-Aided, MaxiClens®, or ChloraPrep® – plainly
would present a much reduced population of microbial ﬂora in challenge
to the site PreOp Prep procedure to be performed immediately prior to
surgery. The data indicate that the PreOp SW process should be initiated
at least 2 days prior to the scheduled surgery, and that 3 or 4 days prior
would be better yet.
P1906 Efﬁcacy of chlorhexidine gluconate against Staphylococcus
aureus in a respiratory epithelial infection model
M.J. Anderson, Y.C. Lin, P.J. Parks °, M.L. Peterson (Minneapolis,
St. Paul, US)
Background: Staphylococcus aureus, a signiﬁcant pathogen, can invade
via skin or mucosal epithelium. Chlorhexidine gluconate (CHG) is a
common antiseptic agent used at concentrations from 0.12% (oral rinses)
to 4% (surgical site preparations) to minimise the risk of nosocomial
infections. This study evaluated the efﬁcacy of CHG against a clinical
isolate of Staphylococcus aureus, MN8, using two in vitro respiratory
epithelial infection models.
Methods: S. aureus MN8 invasion of lung epithelial cells (A549) was
characterised using ﬂuorescently labeled bacteria (BacLight, Molecular
Probes), and ﬂow cytometry. Extracellular ﬂuorescence (bound but
not internalised bacteria) was quenched using trypan blue. Conﬂuent
nasal (RPMI 2650) and lung (A549) epithelial cells were infected with
S. aureus MN8 1×106 CFU/mL for 15min prior to treatment with
CHG (2.0–128 ug/mL; 0.0002 to 0.0128%) for 2 h. Antiseptic efﬁcacy
was evaluated by serial diluting and plating supernatants. Intracellular
bacteria were enumerated by washing the adherent cells with PBS,
resuspending in Triton X-100, serial dilution and plating. Cytotoxicity
was evaluated by Cell Titer Aqueous One (Promega).
Results: S. aureus were bound to A549 within 10min (16% of
ﬂuorescence) with approximately 50% being internal; therefore, we
determined the ability of CHG to kill intra and extra-cellular
S. aureus. At 2 h, complete S. aureus killing was observed in the
supernatant at CHG 64 ug/mL; and cell associated was achieved at
CHG 128 ug/mL.
Epithelial cell line Chlorhexidine gluconate
S. aureus
2 1og10 CFU/mL kill
supernatant
S. aureus
2 1og10 CFU/mL kill
epithelial cell-associated
Epithelial cytotoxicity
(LD50)
Nasal (RPMI 2650) 2 ug/mL (0.0002%) 16 ug/mL (0.0016%) 64 ug/mL (0.0064%)
Lung (A549) 4 ug/mL (0.0004%) 16 ug/mL (0.0016%) 128 ug/mL (0.0128%)
P1907 Economic aspects of deep sternal wound infections
K. Graf °, E. Ott, F. Helm, F. Schwab, A. Haverich, I.F. Chaberny
(Hanover, Berlin, DE)
Objectives: Surgical site infections (SSI) are a very expensive
complication in cardiac surgery. The total costs for coronary artery
bypass grafting (CABG) surgery followed by deep sternal wound
infection (DSWI) are estimated to be much higher than for normal,
caused by expanded length of stay, reoperations and special treatment
such as vacuum-assisted closure therapy and expensive antibiotic therapy.
This study compares the length of stay and the total costs of patients
undergoing CABG and developing a DSWI or not.
Methods: A case-control study was performed. The total costs were
analyzed and compared to patients undergoing CABG without DSWI.
Inclusion criterion for cases was the development of a deep sternal
wound infection according to CDC-criteria during the hospital stay with
CABG. Cases with a readmission were excluded. Controls were matched
by having the same type of surgery (DRG), age±ﬁve years, gender,
the same duration of preoperative stay±two days. The time until the
development of the infection was taken as the minimum length of stay
for the controls. Controls showing sings of infection during the hospital
stay were excluded.
Results: 17 CABG patients with DSWI, between January 2006 and
December 2007, were included in the study. The cases were matched
to 34 controls. The average cost of CABG procedure plus treatment
of DSWI was 34755.63 Euro per patient and almost two times higher
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than the mean cost of CABG alone (19258.39 Euro, p< 0.0001) The
average length of stay (LOS) in hospital was more than two times longer
(34.4 days vs. 16.5 days) although the average LOS on ICU was shorter
(2 days vs. 5.3 days).
Conclusion: DSWI is a devasting complication for surgeons and
patients. But it is also an important economic factor for the hospital.
Measures for the reduction of DSWI will be cost-effective. Therefore a
bundle of infection control measures will be essential.
Diagnosis of viral infections
P1908 The combination of antibody bridging and avidity index
methodology for reliable and simple determination of
infection phase
H.M. Smolander °, J.O. Koskinen, R. Vainionpa¨a¨, K. Hedman,
M. Lappalainen, E. Ja¨rvinen, N. Meltola, A.E. Soini (Turku, Helsinki, FI)
Objective: Measurement of serum antibodies is widely used for
diagnosing the state of viral infections. In order to improve the accuracy
and simplicity of serodiagnostic testing, and to speed up the diagnosis,
innovative approaches are needed. We propose a new methodology for
serological assessment of the infection phase.
Methods: Our approach combines the antibody bridging assay scheme
with the avidity index technique. Accordingly, serum antibodies bind
with one arm to an antigen on the solid phase and with the other arm to
a labeled antigen in solution. When the serum diluent is supplemented
with a chaotropic agent, the formation of low-avidity immunocomplexes
is prevented.
The aim of this study was to evaluate the suitability of the
antibody bridging avidity index (ABAI) methodology for rapid in vitro
serodiagnostic testing. We developed ABAI methods for two different
ﬂuorescence immunoassay platforms, the heterogeneous time-resolved
ﬂuoroimmunoassay (TR-FIA) and the separation-free (homogeneous)
two-photon excitation (TPX) assay technique. The new methods for
adenovirus speciﬁc antibodies were compared to the conventional class-
speciﬁc detection and to the validated IgG-avidity measurement principle
(N = 35).
Results: The results show that the ABAI methodology allows reliable
assessment of IgG avidity with considerably simpler assay protocols than
the conventional IgG-avidity tests. The measurement of antibody avidity
eliminates the need for paired serum sampling.
Conclusions: The new methodology allows simpler and quicker
serodiagnostic testing than possible before. Thus, the novel approach
could provide a competitive and cost-efﬁcient alternative for the
conventional methods; especially when using the one-step TPX assay
technique which enables high sensitivity analyses from a few microliter
reaction volumes.
P1909 Novel multianalyte point-of-care test for pathogen-speciﬁc
diagnosing of respiratory infections
J.O. Koskinen °, R. Vainionpa¨a¨, A.E. Soini (Turku, FI)
Objectives: Unfortunately, pathogen-speciﬁc diagnosis and treatment of
respiratory infections is seldom possible. This is due to overlapping
symptoms, long result-time of centralised laboratory testing, and the
lack of efﬁcient point-of-care diagnostic tests. Empirical treatment
of respiratory infection patients has lead to overuse of antibiotics
and inefﬁcient use of virus-speciﬁc drugs. We have developed
an immunoassay methodology which allows rapid and automated
multianalyte detection of respiratory pathogens at the point-of-care.
Methods: The one-step immunoassay test is based on a separation-
free ArcDia TPX ﬂuorescence detection technology and dried reagents.
This enables simple assay protocols; A swab sample from the nose or
the throat is dissolved in sample buffer and subjected to automated
quantitative multianalyte testing. The multianalyte test provides results
within 20 minutes. The pathogen portfolio of the test system covers a
signiﬁcant proportion of respiratory infection cases, currently including:
– Group A streptococci
– Streptococcus pneumoniae
– inﬂuenza A and B viruses
– respiratory syncytial virus
– metapneumovirus
– adenovirus
– parainﬂuenza 1, 2 and 3 viruses.
Results: Validation of the methods with clinical samples (n = 400)
and standard preparations showed similar analytical sensitivities (on
average 90−95%) and speciﬁcities (on average 99.6%) to the reference
laboratory methods. Cross-reactivities were not observed between
analyte pathogens or microbes frequently present in the samples. The
results demonstrate that the new methodology enables rapid multianalyte
testing of respiratory pathogens. The test reports positive results in
20 minutes while the results for low positive and negative samples are
reported in two hours.
Conclusion: Due to its simplicity and low cost structure, the
methodology is well suited for rapid point-of-care testing, allowing
accurate diagnosis and pathogen-speciﬁc medication. The test would
bring the performance of standard laboratory methods into point-of-care
testing. The use of such a rapid multianalyte test in clinical settings is
expected to reduce the unnecessary use of antibiotics and to enable more
efﬁcient virus-speciﬁc medication.
P1910 Evaluation of the performance of RSV Respi-Strip® in
comparison with cell culture and reverse transcriptase PCR
I. Wybo °, D. Pie´rard, D. Stevens, O. Soetens, S. Lauwers (Brussels, BE)
Objectives: Respiratory syncytial virus (RSV) infection is a common
respiratory infection in young children, occurring as a winter epidemic
in temperate climates. A rapid and reliable diagnosis is very important
for prompt institution of infection control measures. The purpose of
this study was to compare RSV Respi-Strip® (Coris-Bioconcept), an
immunochromatographic assay, with “in house” reverse transcriptase
(RT) PCR and viral culture. The need for incubation of the sample in
extraction buffer before insertion of the strip was also evaluated.
Methods: Hundred nasopharyngeal aspiration samples were submitted
by the emergency department or the paediatric wards from October 15
to November 21, 2008. For viral isolation 3 cell lines were inoculated to
optimise recovery: MRC5, Hep 2 and LLC-MK2. A multiplex RT-PCR
followed by hybridisation was performed for the detection of RSV and 8
other respiratory RNA-viruses. RSV Respi-Strip kit® was used according
to instructions from the manufacturer. Brieﬂy, 0.25ml of nasopharyngeal
aspirate was mixed with 0.25ml of extraction buffer and incubated at
room temperature for 0, 1 and 10min. Subsequently strips were inserted
into the buffer suspension and incubated for 15min prior to reading. To
calculate test performance samples were considered as true positive if
positive by cell culture or if positive by both PCR and RSV Respi-Strip®
in culture negative samples.
Results: 42% of samples were positive by RSV Respi-Strip®. No
discrepancies were detected between results obtained with the different
incubation times of the sample in extraction buffer. 25% were positive
by cell culture and 54% were positive by PCR. 45% were considered as
true positive – 25 positive by cell culture and 20 culture negative but
positive by both PCR and RSV Respi-Strip®. 55% were RSV negative.
Sensitivity and speciﬁcity of culture, PCR and RSV Respi-strip® were
respectively 25/45 (56%) and 55/55(100%); 45/45 (100%) and 46/55
(84%); 41/45 (91%) and 54/55 (98%).
Conclusion: With a sensitivity of 91% and a speciﬁcity of 98% this
rapid test method can be relied on to make infection control decisions
during RSV epidemics. By omitting the incubation step in extraction
buffer, the assay time can be reduced from 25 to 15 minutes.
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P1911 Evaluation of the Copan ﬂocked swab with UTM-
RT medium for antigen detection of HSV, direct
immunoﬂuorescence of RSV and viral culture of HSV
S. Vijgen, S. Nys °, R. Cartuyvels, K. Magerman (Hasselt, BE)
Objectives: Successful preservation of viral viability and antigens
depends on specimen collection, transport and preservation system used.
In this study, the newly developed nylon-ﬂocked swab with universal
transport medium (UTM), specially designed to optimise specimen
collection and to minimise entrapment of the microorganisms, was
compared with the Copan virus transport system for antigen detection of
HSV-1, direct immunoﬂuorescence of RSV and viral culture of HSV-1.
Methods: Viral culture of a PCR-conﬁrmed HSV-1 positive clinical
sample was harvested and serially diluted in MEM 2% culture medium
(CAMBREX).
The Copan ﬂocked swab with UTM-RT medium (UTM, Copan, 395C)
and the virus transport system (VTS, Copan 147C) were inoculated in
100mL of each dilution and preserved respectively at room temperature
or 4ºC for 2 hours. Each swab was inoculated on the cell lines A459,
MRC-5 and Hep2 and controlled daily for the cytopathogenic effect of
HSV-1. The serial dilutions of the positive clinical sample were used as
a positive control.
For the antigen detection and direct immunoﬂuorescence, 500mL of the
UTM cell suspension was pelleted, washed and resuspended in PBS.
Twenty microliters of this ﬁnal suspension was stained using standard
procedures.
Results: The MRC-5 and A549 cell lines inoculated with samples of
the UTM swab showed a cytopathogenic effect as soon as the positive
control wells. Also, dilutions of UTM were sooner positive as compared
to VTS. These differences were less clear in the Hep-2 cells.
There were no signiﬁcant differences in results of HSV-1 antigen
detection and direct immunoﬂuorescence of RSV with UTM compared
to VTS. However, the yield with UTM was higher as compared to VTS,
even at low viral loads.
Conclusion: The ﬂocked swab with UTM-RT medium showed an overall
better recovery of HSV-1 after culture. Furthermore, the ﬂocked swab
seems to have a greater diagnostic sensitivity in the HSV-1 antigen
detection and RSV direct immunoﬂuorescence.
P1912 Standardisation of cytomegalovirus antigenaemia assay by
in vitro generation of peripheral blood leukocytes positive
controls and comparison of two commercial monoclonal
antibody pools and immunostaining techniques
T. Baptista-Fernandes, A. Dias °, T. Marques (Carnaxide, PT)
Objectives: HCMV is responsible for high morbidity and mortality
rate in immunocompromised patients. The HCMV antigenaemia test,
which detects phosphoprotein pp 65 (ppUL83) in nuclei of peripheral
blood leukocytes (PBL), is a rapid and sensitive assay that allows the
detection of infection prior to the onset of clinical disease, and is useful
for monitoring response to therapy. We present a model for in vitro
preparation of HCMV positive controls and results from comparing two
monoclonal antibodies for HCMV antigenaemia testing: MAbs C10+C11
(Biotest) and MAbs 1C3+AYM-1(Argene). We also compared detection
by immunoﬂuorescence assay (IFA) and immunoperoxidase assay (IPA).
Methods: For positive controls, PBL from healthy donors were isolated
and co-cultivated with wild strains HCMV infected MRC5. PBL
recovered after infection, were ﬁxed and stained with speciﬁc MAbs,
followed by IFA and IPA. For leukocyte extraction, we followed the
protocol described by Gerna et al. 2×105 PBL were applied per slide,
ﬁxed in formaldehyde solution, permeabilised with nonidet (NP-40
solution), and immunostained by IFA, as well as IPA, with MAbs against
HCMV pp65 (Biotest and Argene).
Results: Our results showed that ﬁbroblasts infected with wild strains,
isolated from newborn urines with congenital infection, could efﬁciently
induce pp65 uptake by PBL. A total of 1292 blood specimens
from transplant recipients and human HIV+ patients were tested. 308
specimens were positive for HCMV with one or both MAbs. We found
a statistical signiﬁcant difference between two pools of MAbs. Argene
pool showed a signiﬁcant higher sensitivity (p = 0.000355 Chi-Squared
test) with 133 (86%) positive tests, than Biotest pool with 107 (69%)
positive tests. On applying Wilcoxon signed rank analysis to the positive
cell counts, Argene pool showed signiﬁcant higher levels of positivity,
and capacity of detecting low levels of viraemia (p = 0.0001). Concerning
immunostaining technique, results with IFA showed a lower rate of
artifacts, a shorter processing time and a higher sensitivity.
Conclusion: The availability of a proper positive control can lead to
development of standardisation protocols and quality programs. Data
suggests that a method with two slides per patient (PBL 2×105 per slide),
combined with formaldehyde ﬁxation and NP-40 permeabilisation,
Argene pool (MAb 1C3+AYM-1) and IFA immunostaining provides
optimal results, with a considerable improvement of antigenaemia
HCMV assay.
P1913 Analytical performance of the new Access CMV IgG assay
N. Groleau, B. Roussel, V. Potelle, M. Bullenger, J. Poropane,
R. Falcou-Briatte, F. Bouniort °, R. Theis, O. Flecheux
(Marnes-la-coquette, FR; Nyon, CH; Chaska, US)
Objectives: An automated CMV IgG assay has been developed by
Beckman Coulter. The purpose of this study was to evaluate the
analytical sensitivity: limit of Blank (LoB), limit of detection (LoD),
limit of quantiﬁcation (LoQ), as well as linearity, accuracy, imprecision
and analytical speciﬁcity of the Access® CMV IgG assay.
Methods: LoB and LoD were determined using ﬁve negative samples
and ﬁve unique samples below the assay cut-off, respectively: 20
replicates of each sample. LoB and LoD calculation were performed
according to CLSI EP17-A procedure. The LoQ was determined with
two samples tested in 40 replicates. Linearity was evaluated by testing
high positive samples diluted from 3/4 to 1/16. The actual v. expected
concentrations, as determined on Access and UniCel DxI 800 systems,
were analyzed by linear regression. Imprecision studies used negative,
low, medium and high positive samples and included intra-assay, inter-
assay and inter-lot determinations. Analytical speciﬁcity was determined
by testing 122 samples obtained from patients with speciﬁc disease
conditions.
Results: The Access CMV IgG assay displays LoB, LoD and LoQ
of 1.9AU/mL, 3.2AU/mL and 7.0AU/mL, respectively. The linear
regression slope for linearity was 1.09 with a total mean recovery
percentage of 97.9%. The mean percentage of recovery for accuracy was
equal to 100% on the Access system and 101% on the UniCel DxI 800
system. Imprecision studies demonstrated %CVs below 11% and 14%
for intra-assay and inter-assay, respectively, independent of the system
in use. Inter-lot studies exhibited a %CV lower than 10%. Among the
122 samples tested for the analytical speciﬁcity, 121 were found negative
with the Access CMV IgG assay.
Conclusion: The Access CMV IgG assay provides excellent analytical
performance, with the advantages of a rapid, automated, random-access
immunoassay system.
P1914 Comparative studies of the Access CMV IgG assay
N. Groleau, B. Roussel, V. Potelle, M. Bullenger, J. Poropane,
R. Falcou-Briatte, F. Bouniort °, R. Theis, O. Flecheux
(Marnes-la-coquette, FR; Nyon, CH; Chaska, US)
Objectives: A new quantitative Access CMV IgG assay, developed
by Beckman Coulter for use on the family of Access® immunoassay
systems, was evaluated to determine concordance (total, negative and
positive agreement) with the AxSYM CMV IgG assay.
Methods: The concordance studies were performed with samples
from negative blood donors (n = 400), non-selected hospitalised patients
(n = 1,212), non-selected pregnant women (n = 622), transplant patient
serum samples (n = 143) and HIV positive serum samples (n = 42). The
comparative device used for these studies was the Abbott AxSYM
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CMV IgG assay and a percentage agreement between both methods was
calculated. Discrepant results were further tested with the bioMe´rieux
VIDAS** CMV IgG assay.
Results:
• Blood donors: The agreement between the Access CMV IgG and the
AxSYM CMV IgG assays was 99.75% (397/398). Two samples with
equivocal results were excluded from the calculation. The discrepant
sample was negative with the VIDAS assay.
• Non-selected hospitalised patients: The agreement between both
assays was 98.76% (1194/1209). Three samples with equivocal results
were excluded from the calculation. The Access CMV IgG assay
displayed a negative and positive agreement of 98.69% (601/609)
and 98.83% (593/600), respectively. Among the 15 discrepant results,
9 Access CMV IgG assay results (5 positive and 4 negative) were
conﬁrmed with the VIDAS CMV IgG assay.
• Pregnant women: The agreement between both assays was 99.36%
(617/621). One sample with equivocal result was excluded from the
calculation. Among the four discrepant results, three Access CMV
IgG assay results (negative results) were conﬁrmed with the VIDAS
CMV IgG assay.
• Transplant patients: The agreement between both assays was 99.30%
(141/142). One sample with an equivocal result was excluded from
the calculation. The VIDAS assay result for the discrepant sample
conﬁrmed the AxSYM assay result.
• HIV patients: The agreement was 100% (42/42).
Conclusion: The Access CMV IgG assay provides good agreement with
the AxSYM CMV IgG assay. The Access CMV IgG assay displays
excellent results as conﬁrmed with the VIDAS CMV IgG assay. The
Access CMV IgG assay can be used on the Access systems, the high-
throughput UniCel® DxI 800 Immunoassay System and the integrated
UniCel DxCi systems.
P1915 MRSA on a closed psychiatric ward
W. Ebner °, J. Schlachetzki, M. Dettenkofer, J. Langosch (Freiburg, DE)
Objectives: Surveillance data regarding prevalence and spread of MRSA
among psychiatric patients are missing. Psychiatric patients do not
belong to the groups at risk for an infection with MRSA. Nevertheless
psychiatric patients may transmit MRSA into sensible medical areas.
Setting We report the case of an 85-year-old female index patient
suffering from alcohol and benzodiazepine dependency and senile
dementia, who was admitted on our closed ward (14 patients) in the
psychiatric university hospital of Freiburg, Germany. She was screened
for MRSA because her husband has been known to be a carrier
of MRSA. She was found to be MRSA-positive in the swabs of
the nostrils (further swabs not taken). Single room isolation was not
possible. Instructions of the patient to personal hygiene or adequate hand
disinfection or the body washing with chlorhexidine or octenidine were
not possible. Mupirocine nasal ointment was applied according to the
common standard. Infection control measures were limited and focused
on regular hand disinfection of the medical staff.
Methods: When the carrier state of the index patient was identiﬁed the
13 other patients of the ward were screened by taking swabs from nose
and throat (day 0). Swabs were taken in the same manner on day 3 and
day 7 from 11 patients (two patients had been meanwhile shifted to an
open ward and control swabs were not taken). Additionally, swabs from
the nose of the two ward physicians were taken on day 7.
Results: None of the 13 patients screened were found to be MRSA-
positive on day 0 and neither on day 3 and 7. In addition, the swabs of
the two physicians were tested negative. The nasal swabs of the index
patient were negative on day 3 after completion of mupirocin therapy.
The observed compliance of the personnel to hand hygiene was high.
Conclusion: Extended hygienic measures when handling with MRSA-
positive patients are usually not practicable on closed psychiatric wards.
Some measures like the single room isolation are generally not desirable
within the scope of psychiatric therapy. Our case report suggests that
transmission of MRSA can be averted by the strict observance of
standard hygienic measures, above all thorough regular hand disinfection
after physical contact with MRSA-patients. A direct transmission of
MRSA from patient to patient was not observed in our case. Reliable,
systematic data regarding prevalence and spread of MRSA on psychiatric
wards are still lacking.
P1916 Diagnosis of CMV infection by serology: comparison of
methods
K. Tsiveriotis, J. Meletiadis °, N. Siafakas, S. Damianidou, M. Bobola,
L. Zerva (Athens, GR)
Introduction: Accurate diagnosis of CMV infection is important, but
false positive IgM results occur even with established commercial assays.
The frequent observation of IgM-CMV positivity during our routine
testing with AxSYM (Abbott) necessitated the implementation of parallel
testing with another IgM assay as well as IgG avidity testing.
Material and Methods: In our setting (750-bed tertiary health care
centre) and during a 5-month period all serum samples submitted to the
laboratory for IgG and IgM CMV testing were examined by AxSYM.
Samples with IgM-positive or indeterminate results were additionally
tested for IgM antibodies and IgG avidity by VIDAS (Biomerieux);
obtained results were compared.
Results: Among 449 samples tested by IgM-AxSYM, 374 (83.3%) were
negative, 58 (12.9%) positive and 18 (4%) indeterminate. All 18 IgM-
AxSYM indeterminate samples were IgM-VIDAS negative (11 of high,
7 of moderate avidity). Out of 58 IgM-AxSYM positive samples, 8 were
IgM-VIDAS positive (6 of high, 2 of moderate avidity), 6 indeterminate
(4 of high, 2 of moderate avidity) and 44 negative (27 of high, 16 of
moderate, 1 of low avidity). Overall, among the 76 patients with positive
or indeterminate IgM-AxSYM results, high IgG-avidity was detected
in 48 (63.2%), moderate in 27 (35.5%) and low in 1 (1.3%) patient.
Concordant IgM positive or indeterminate results between AxSYM and
VIDAS were obtained only for 14 samples (18.4%) including 10 of high
and 4 of moderate avidity.
Agreement of positive results between IgM-AxSYM (positive or
indeterminate) and IgG avidity testing (medium or low) was detected
for 28 samples (36.8%). Among 14 samples positive or indeterminate
by IgM-VIDAS, 4 demonstrated medium and none low avidity (28.3%
agreement). Conversely, out of 27 samples exhibiting medium avidity
only 4 (14.8%) were positive or indeterminate by IgM-VIDAS; the single
sample demonstrating low avidity was IgM-VIDAS negative.
Conclusions: These results demonstrate that the serological diagnosis of
CMV infection is problematic even when using established assays. The
frequent detection of high IgG-avidity in IgM-AxSYM positive samples
and the high rates of CMV infection diagnosis by AxSYM in a low risk
population, point to a speciﬁcity problem of the assay. Results obtained
by IgM-VIDAS did not correlate with avidity testing. Finally, the clinical
signiﬁcance of medium IgG avidity results remains undeﬁned, while
more relevant cutoff values need to be set.
P1917 Performance evaluation of the Access CMV IgG assay
performed on the UniCel DXC 880i in a French hospital
A. Decoster °, S. Delplanque, C. Bazin (Lomme, FR)
Objective: The aim of the present study was to evaluate the performance
of Access CMV IgG assay performed on the UniCel DXC 880i
(Beckman, USA) in routine conditions in our laboratory.
Methods: A study was performed during 6 weeks on 181 sera from
the laboratory routine collected for cytomegalovirus IgG testing in 59
children (0−18 old, 30 women, 29 men) and 122 adults (18−93 old,
74 women, 48 men). We have evaluated the performance of the Access
CMV IgG (Beckman, USA) in comparison with the LIAISON CMV
IgG (Diasorin, Saluggia, Italy). Complementary testing was performed
in case of discrepancies using (BioMe´rieux, Marcy l’Etoile, France).
Results: Correlation coefﬁcient between Access and LIAISON CMV
IgG assays was found at 92.1% and the concordance between the
results of the two tests was 96.1% (IC 95%: 92.2–98.4). We obtained
0 equivocal result with Access CMV IgG assay but 2 equivocal results
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with LIAISON CMV IGG assay (1.1%). We obtained 98 positive
results (54%), 76 negative results (42%) and 7 discrepant (4%) results
with Access CMV IgG assay. All the discrepant sera was tested in
duplicate by VIDAS system: 3 were equivocal, 1 negative, 3 positive.
Relative sensitivity and speciﬁcity were calculated for the two tests:
speciﬁcity Access was 96.2% and sensitivity Access was 98%;
speciﬁcity LIAISON was 97.4% and sensitivity LIAISON was 97%.
Reproducibility and repetability were also evaluated for the Access CMV
IgG assay: variation coefﬁcient was between 4.6% and 10.5%.
The ergonomics of the automated system UniCel DXC 880i on which
Access is performed shows many advantages related to organisation
strategies in a laboratory.
Conclusion: The results obtained during this study demonstrate that
Access CMV IgG assay performed on UniCel DXC 880i could
adequately discriminate between IgG positive and negative samples and
that it is valuable for the diagnosis of CMV infection by testing speciﬁc
IgG in primary tube. Adapted to high throughput routine testing, Access
CMV IgG assay performed on UniCel DXC 880i can be easily integrated
and used in a laboratory.
P1918 Performance characteristics of an anti-Varicella zoster
glycoprotein IgG ELISA
J. Harley °, R. Budd, D.J. Taylor, S. Starling, P.A.C. Maple, K.E. Brown,
D.W.G. Brown, A.R. Bradwell (Birmingham, London, UK)
Objective: To evaluate the performance of the VaccZymeTM anti-
Varicella zoster glycoprotein IgG EIA by comparison to a reference time
resolved ﬂuorescence immunoassay (VZV TRFIA), and conﬁrmation of
the assay reproducibility and linearity.
Background: Sensitive laboratory tests are required to measure anti-
VZV antibodies as an aid in determining response to VZV vaccination
and establishing the immune status of pregnant women exposed to VZV
infection. ELISAs utilising glycoprotein antigen have been shown to
offer greater sensitivity and show better correlation to FAMA (ﬂuorescent
antibody-to-membrane antigen) “gold standard” method than traditional
assays utilising puriﬁed virus particles.
Method: Anti-VZV glycoprotein antibodies were measured using the
VaccZymeTM anti-VZV glycoprotein IgG EIA kit (The Binding Site,
UK) and a VZV TRFIA reference immunoassay (HPA, UK). The panel
of 336 sera included 139 antenatal patients and 79 post vaccination
sera. Based on TRFIA cut-off guidelines 63% had antibody levels
150mIU/ml, 26% had antibody levels <100mIU/ml and 11% were
within the range of 100–150mIU/ml. Intra-assay reproducibility was
determined on nine samples (20 replicates) and inter-assay precision
was tested on ten samples on six separate occasions. Linearity was
examined using three high titre sera including the international standard
code W1044 (NIBSC).
Results: See the table.
Performance characteristic Anti-VZVgp IgG
Intra-assay reproducibility (%CV) 2.3–3.6
Inter-assay reproducibility (%CV) 1.5–9.7
Linearity R2 >0.999
Linearity % recovery 97
Sensitivity relative to TRFIA (%) 98.5
Speciﬁcity relative to TRFIA (%) 97.7
Agreement relative to TRFIA (%) 98.3
Correlation coefﬁcient (R2) 0.81
Conclusion: The VaccZymeTM anti-VZV glycoprotein IgG assay
demonstrates excellent linearity and reproducibility as well as good
agreement compared to the reference TRFIA. The VaccZymeTM assay
is a useful addition to the available assays for detection of anti-VZV
antibody following vaccination or infection with VZV. In addition, the
assay is ideally suited to automation for high throughput screening.
P1919 Comparison of Siemens IMMULITE® 2000 versus DiaSorin
LIAISON® serology in case of Epstein-Barr virus
G.J. van Hooydonk-Elving °, M. Steemers-Hack, K. van Zundert,
P.J. Kabel (Tilburg, NL)
Objective: Two new chemiluminescent enzyme immunoassays for EBV
VCA IgM and EBNA IgG detection in serum on the IMMULITE® 2000
automated analyzer (Siemens Healthcare Diagnostics, Los Angeles, US)
have been evaluated versus the immunoassays of the LIAISON® system
(DiaSorin, Saluggia, Italy).
Methods: The IMMULITE® EBV performance and serological status
agreement were compared to the LIAISON® EBV VCA IgM and EBNA
IgG assays. For all samples with discordant results in interpretation
of the EBV serological status, the samples were retested using the
EUROLINE® EBV IgM and IgG blots (EUROIMMUN, Lu¨beck,
Germany) as the gold standard.
Results: In case of 957 human serum samples EBNA IgG determined by
IMMULITE® was compared to EBNA IgG determined by LIAISON®.
Results indicated an agreement of 93% between the two systems.
Comparison of IMMULITE® versus LIAISON® EBV VCA IgM
resulted in a 91% agreement.
811 of the 957 serum samples (85%) tested by IMMULITE® and
LIAISON® demonstrated concordant results for VCA IgM and/or EBNA
IgG, therewith showing 100% agreement for the interpretation of the
EBV serological status.
The 146 remaining serum samples tested by IMMULITE® and
LIAISON® showed discordant results for VCA IgM and/or EBNA
IgG. However, in case of 79 of these samples the interpretation of the
EBV serological status was similar (54% agreement). Of the remaining
67 discordant results, 66 samples were additionally tested using the
EUROLINE® EBV IgM and IgG blot. One of the 67 samples did not
have enough volume for follow-up.
Regarding the interpretation of the EBV serological status, the blot
characterised 50 of 66 samples similar to IMMULITE® and 14 of 66
samples similar to LIAISON®.
Concerning all 956 concordant and discordant results these data
demonstrated that as well the IMMULITE® EBV VCA IgM and EBNA
IgG assays as the LIAISON® EBV results demonstrated respectively
98% and 95% agreement for the interpretation of the EBV serological
status.
Conclusions: These data indicate that as well the IMMULITE®
EBV VCA IgM and EBNA IgG assays as the LIAISON® EBV
results demonstrated good agreement for the interpretation of the EBV
serological status.
The IMMULITE® 2000 EBV automated assays would be suitable for
EBV testing.
P1920 Performance of the Focus Diagnostics second-generation
Parvovirus IgG and IgM ELISA kits utilising parvovirus V9
viral protein 2 antigen
H. Prince °, C. Yeh, S. Vogeli, C. Gardner, X. Su, P. Lee (Cypress, US)
Objectives: Due to the high degree of homology (98%) between viral
protein 2 (VP2) from parvoviruses B19 and V9, assays utilising VP2
from V9 can detect antibodies induced by infection with either B19 or
V9 parvoviruses. Focus Diagnostics developed new Parvovirus IgG and
IgM ELISA kits that utilise V9 VP2 antigen. We sought to determine
the performance of these second generation kits in a reference laboratory
setting (the kits are not FDA approved).
Methods: Selected sera (N = 88) submitted for parvovirus serology were
evaluated using Biotrin’s B19-based Parvovirus IgG and IgM ELISA
kits and Focus’ new V9-based Parvovirus IgG and IgM ELISA kits.
To estimate the adult seroprevalence of parvovirus antibodies using the
Focus kits, 41 de-identiﬁed sera from healthy volunteers were evaluated.
To assess potential cross-reactivity, sera containing antibodies to other
infectious agents were tested.
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Results: Of 88 selected sera submitted for parvovirus serology, 56
were Biotrin IgG-positive, and 53 of these 56 (95%) were Focus IgG-
positive; 32 sera were Biotrin IgG-negative, and 31 of these 32 (97%)
were Focus IgG-negative. Similar ﬁndings were observed for the IgM
comparison: 27 of 27 (100%) Biotrin IgM-positive sera were Focus IgM-
positive, and 57 of 60 (95%) Biotrin IgM-negative sera were Focus
IgM-negative. One specimen was Biotrin IgM-equivocal and Focus IgM-
positive. Seroprevalence of parvovirus antibodies in healthy adults using
the Focus kits was 59% (24/41) IgG-positive and 5% (2/41) IgM-positive.
In cross-reactivity studies, 62% (15/24) of sera positive for IgG to other
infectious agents were Focus Parvovirus IgG-positive, and 10% (2/20) of
sera positive for IgM to other infectious agents were Focus Parvovirus
IgM-positive; these proportions did not signiﬁcantly differ from the
comparable percentages observed for the healthy adult serum panel.
Conclusion: Focus Diagnostics’ new V9-based Parvovirus IgG and IgM
ELISA kits performed similarly to Biotrin’s B19-based Parvovirus kits.
Parvovirus IgG and IgM prevalence rates, as assessed using the Focus
kits, did not signiﬁcantly differ when comparing a healthy adult serum
panel and a cross-reactivity serum panel.
P1921 Evaluation of the new versant HIV-1 RNA 1.0 Assay
(kPCR) for quantiﬁcation of human immunodeﬁciency
virus type 1 RNA
A. Amendola °, P. Zaccaro, R. Sabatini, A. Bibbo, M. Bloisi, E. Patella,
A. Natale, G. Rossi, M.R. Capobianchi (Rome, IT)
Objective: To compare performance of the new Versant HIV-1
RNA 1.0 (kPCR) assay (Siemens Healthcare Diagnostics) for quan-
tiﬁcation of HIV-1 RNA in clinical samples from HIV-1-infected
individuals with Versant HIV-1 RNA v3.0 (Siemens Healthcare
Diagnostics) and COBASAmpliprep/COBASTaqMan HIV-1 CAP-TCM
(Roche Diagnostics) procedures. Versant HIV-1 RNA 1.0 (kPCR) and
COBASAmpliprep/COBASTaqMan HIV-1 assays are both based on RT
real-time PCR technology; Versant HIV-1 RNA v3.0 is based on bDNA
technology and was considered as reference method.
Methods: The study was conducted on 256 retrospectively collected
plasma samples from HIV-1 infected individuals attending the out-
patient care facility of the “Lazzaro Spallanzani” Hospital in Rome.
Quantitative results were compared with correlation, linear regression,
Bland&Altman and k-statistic analyses of log10 transformed HIV-1
RNA copy numbers.
Results: Agreement between Versant HIV-1 RNA 1.0 (kPCR) and
other assays was elevated (>0.940) and high correlation coefﬁcients
were measured: r = 0.9662, p< 0.0001 between Versant HIV-1 RNA
1.0 (kPCR) and Versant HIV-1 RNA v3.0 (bDNA); r= 0.9597,
p< 0.0001 between Versant HIV-1 RNA 1.0 (kPCR) and COBAS
Ampliprep/COBAS TaqMan HIV-1. Analysis of mean differences of
measurement between assays, conducted according to Bland&Altman
method, showed no clinically signiﬁcant differences in quantiﬁcation of
viral load (lower than 0.2 log10 cp/ml) along all the overlapping range.
Conclusion: Versant HIV-1 RNA 1.0 (kPCR) assay for quantiﬁcation
of HIV-1 RNA in plasma samples from HIV-infected individuals is
based on RT real-time PCR technology. This new commercially available
diagnostic system produces viral load results that can be considered
equivalent to results given by the reference diagnostic system and a
similar RT-real-time PCR-based procedure.
P1922 Signiﬁcance of QuantiFeron®-TB Gold test for patients
infected with HIV-1
M. Dinu °, L. Gavrila, M. Iosipenco, C. Craciun, C. Baicus, D. Otelea
(Bucharest, RO)
Objective: Viral load testing, antiretroviral treatment resistance and other
immunological tests like CD4+/CD8+ counts are used to monitor patients
infected with HIV-1. Previous studies showed that when HIV-1 viral load
is higher CD4+ values are small, because lymphocytes TCD4+ are the
most affected from HIV. Some studies revealed the capacity of HIV-1 to
change the tropism in vivo and CD8+ lymphocytes could be transiently
infected by HIV-1.
Theoretically because of the decrease number of TCD4+ and TCD8+,
QuantiFeron is not recommended when the immunological status of
patients is affected. When the number of CD4+/CD8+ cells is low the
level of IFN-g released by lymphocyte stimulation, is too low to be
meaningfully evaluated by ELISA.
IFN-g is a lymphokine, a subset of cytokines family, secreted by Th1,
Tc, dendritic and NK cells. It has antiviral, immunoregulatory and anti-
tumour properties.
HIV pandemic inﬂuenced the tuberculosis epidemiology in many
countries. HIV is a risk factor for passage from latent tuberculosis to an
active form of the disease. In HIV seropositive patients after infection
with Mycobacterium tuberculosis, the number of TCD4+ decreases
drastically for a short period and, as previous studies reported, the HIV-1
viral loads increase.
The aim of our study was to determine if the test is useful for those
patients HIV-1 seropositive who are monitored on TARV.
Methods: We used for QuantiFeron testing a panel of 298 samples from
HIV-1 positive patients; in addition viral load levels and TCD4+/TCD8+
counts were determined.
Statistical analysis used are Spearman Rank correlation, Student’s test
and Mann-Whitney U.
Results and Conclusions: Correlation for QF-HIV VL: r = 0.066,
p = 0.272; for QF-CD4+ count: r = −0.032, p = 0.605; Mann-Whitney U
association of QF-HIV VL (p = 0.771) and QF-CD4 count (p = 0.06)
reveals no correlation between these results which indicates that the test
can be used even for those patients who have low CD4 counts.
We wanted to compare the results of QuantiFeron test within the
dynamical range of HIV viral loads and we noticed that the percent
of indeterminate results increased proportionally with increases of viral
load: for undetectable viral load we obtain 15% indeterminate results
for QuantiFeron test, the second category (1 log-4 log RNA HIV-1
copies/ml) 17%, the third category (4 log − 7 log RNA HIV-1 copies/ml)
28%. A possible explanation for these is that virus changes the tropism
for TCD8+and affects all susceptible cells.
Figure 1. QuantiFeron test–HIV viral load association p = 0.02 (QF:
1 = negative; 2 = positive, indeterminate was not considered).
Diagnosis of viral infections S561
P1923 Performance evaluation of VIDIA® HIV DUO, a
new automated immunoassay test for qualitative HIV
antigen/antibodies detection
V. Lemee °, R. Croise, F. Descamps, F. Barin, V. Barlet,
M. Maniez-Montreuil, G. Kreplak, H. Menan, J.C. Plantier (Rouen,
Metz-Tessy, Lille, Tours, Paris, FR; Abidjan, CI)
Objectives: We performed a study to evaluate the performances of the
qualitative 4th generation combined antigen/antibodies VIDIA® HIV
DUO (bioMe´rieux, France) test in terms of sensitivity and speciﬁcity.
Methods: The VIDIA HIV DUO assay principle combines a two-
step enzyme immunoassay sandwich method with chemiluminescence
detection. The raw materials selected enable to detect HIV1 groups
M and O, and HIV2 antibodies as well as Antigen from HIV1.
Speciﬁcity was studied using 5160 fresh blood donor samples, 203
fresh blood hospitalised patients samples, 98 risk behaviour individuals
samples and 124 potentially interfering samples.
Specimens for diagnostic sensitivity evaluation included 608 charac-
terised HIV positive samples and 17 primary HIV infection samples.
For analytical sensitivity evaluation, 30 commercial seroconversion
panels were included and P24 analytical sensitivity was established
from range dilution according to the International reference reagent
HIV-1 P24 antigen (NIBSC, United Kingdom) and French Society of
Blood Transfusion Antigen Standard from BIORAD (Paris, France).
The performance characteristics of this new product were established
during the veriﬁcation stage of the development of the product in various
geographic sites.
Results: Speciﬁcity determined on blood donors was 99.88%, hospi-
talised patients samples and risk behaviour individuals was 100%, 1
sample syphilis positive was reacted with VIDIA HIV DUO. Diagnostic
sensitivity was 100%. As regards the seroconversion and the performance
panels, the results with VIDIA HIV DUO were comparable to those
provided by the panel’s manufacturer and appear as sensitive as the
majority of antigen tests for detection of primary HIV infection.
HIV antigen sensitivity against the International reference, NIBSC HIV1
P24 antigen was evaluated to 0.5 IU/mL. The analytical sensitivity
against the BIORAD antigen was evaluated to 15.74 pg/mL.
Conclusion: This new HIV 4th generation assay shows excellent
performance in terms of sensitivity and speciﬁcity. Results on the
seroconversion panels are an added value for patients in terms of
diagnosis and prevention. The combination of automation and high
performance makes this product an excellent test for routine screening.
P1924 Assessment of the Siemens ADVIA Centaur® HIV Combo
assay for routine use in a virology laboratory
H.J. Fleury ° (Bordeaux, FR)
Objective: To compare the performance of the new Siemens ADVIA
Centaur HIV Combo assay (CHIV) with the Siemens ADVIA Centaur
Enhanced HIV 1/O/2 (EHIV) and the Bio-Rad Genscreen™ ULTRA
HIV Ag-Ab assays that are used in our virology laboratory for
routine HIV testing; In addition, further comparisons were made using
seroconversion panels and other commercially available known non-B
HIV-1 samples.
Methods: Clinical samples were collected from hospitalised patients
(1864), milk donors (7), individuals from an IST screening centre (212),
pregnant women (99) and dialysed patients (61). Seroconversion panels
samples (4), plasma samples with HIV-1 subtype B (60) and with
non-B subtypes (38) coming from our sample bank were also tested.
Both CHIV and EHIV assays were run on the ADVIA Centaur XP
Automated Immunoassay System. Discrepant samples were centrifuged
and duplicate tested with EHIV and Genscreen ULTRA HIV Ag-Ab
assays and, when available, western blot and molecular data (RNA viral
load). Seroconversion panels used were PRA801, PRB916, PRB944,
PRB945 and PRB952. In addition, 29 control plasma samples with non-B
HIV-1 subtype (A, B, C, D, F, H, CRF01-AE and CRF02-AG) were also
tested during this study. A total of 2345 samples were tested.
Results: Based on seroconversion panels, the sensitivity of CHIV for
detection of seroconversions was excellent with a positive result between
7 and 10 days after ﬁrst bleed; the p24 antigen sensitivity of the assay
was less than 125 HIV p24mIU/mL (WHO traceable via BBI panel)
(10 pg/mL DuPont Standard, 38 pg/mL Sanoﬁ Standard). After resolution
of initial discrepancies, 2176 samples were found negative while 169
were positive and 8 still discrepant. The resolved sensitivity of the CHIV
assay was 100% and the resolved speciﬁcity 99.64%. The CHIV assay
allowed the detection of antibodies and/or p24 antigen in all B and non-B
characterised samples.
Conclusion: Taking into account all data of this evaluation (sensitivity
for detection of primary infections and p24 antigen, detection of B and
non-B HIV infections, sensitivity and speciﬁcity evaluated on more than
2000 samples from a French university hospital) we consider that the
Siemens ADVIA Centaur HIV Combo assay is suitable for routine use.
P1925 Comparability of results obtained with ELECSYS
Anti-HCV and Beckman Coulter HCV-ab using routine
laboratory samples
T. Rieger ° (Oberhausen, DE)
Objectives: The objectives of the evaluation were to check the
comparability of results obtained with Elecsys® Anti-HCV (on
MODULAR Analytics E170) and Beckman Coulter HCV ab® (on DxC
880i) in the ﬁeld using routine laboratory samples
Methods: Left-over serum or plasma samples from the daily routine of
a general hospital laboratory were ﬁrst measured with Elecsys® Anti-
HCV on MODULAR Analytics E170 and than with Beckman Coulter
HCV ab® on DxC 880i. Discrepant results were veriﬁed with Abbott
AxSYM Anti-HCV® and/or immunoblot.
Results: The performance of Elecsys® Anti-HCV was compared to the
current Beckman Coulter HCV ab® on the DxC 880i analyzer in a
clinical environment. The evaluation has been performed at a clinical
laboratory in Oberhausen. The sample material were 603 anonymised
left over serum/plasma samples from daily routine.
The samples were measured with Elecsys® Anti-HCV and Beckman
Coulter HCV ab®. Discrepant results were veriﬁed with Abbott AxSYM
Anti-HCV® and/or immunoblot.
With a speciﬁcity of 99.66% compared to 99.16%, Elecsys® Anti-HCV
showed a superior performance compared to Beckman Coulter HCV
ab®.
Conclusion: In an experimental setting that represents the routine
workload of a common hospital laboratory Elecsys® Anti-HCV on
MODULAR Analytics E170 showed a superior speciﬁcity compared to
Beckman Coulter HCV ab® on Beckman Coulter DxC 880i analyzer.
With a speciﬁcity of 99.66% compared to 99.16% with Beckman Coulter
HCV ab® Elecsys® Anti-HCV was better by 0.5%.
P1926 Evaluation of fully automated assays for the detection
of anti-rubella IgM and IgG antibodies on the Elecsys®
immunoassays system
J. van Helden °, L. Grangeot-Keros, K. Vleminckx, F. Masset,
M.G. Revello, E. Pfaffenrot, W. van der Helm (Monchengladbach,
DE; Paris, Coquelles, FR; Pavia, IT; Rotkreuz, CH)
Objectives: Screening for acute rubella infection in pregnancy is
an important element of antenatal care due to the potential risk
of birth defects associated with congenital rubella syndrome (CRS)
arising from primary infection, particularly in the ﬁrst trimester.
Vaccination programmes have reduced the incidence of both acute
rubella infection and CRS but coverage of the population is incomplete.
This study compared the sensitivity, speciﬁcity and reproducibility of
fully automated Elecsys® Rubella IgM and IgG immunoassays designed
for the Elecsys 2010, Modular analytics E170, cobas e 411 and cobas e
601 analytical platforms, with current assays.
Methods: Elecsys Rubella IgG and Rubella IgM are electrochemilu-
minescence immunoassays which use recombinant rubella-like particles
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and monomeric E1 antigen, as a validated alternative to authentic rubella
virus. Comparisons with current methods were performed in clinical
laboratories in France, Germany and Italy. Studies of assay sensitivity
and speciﬁcity were done using frozen serum specimens. Fresh serum
samples from routine pregnancy screening were also used for method
comparison.
Results: Reproducibility of test results for the Elecsys Rubella IgM
and IgG assays showed good between-run and within-run precision. The
Elecsys Rubella IgM assay demonstrated a sensitivity of 80−96% in
primary, early (<30 days) acute infection, similar to existing assays. The
Elecsys Rubella IgG assay exhibited high seroconversion sensitivity in
specimen samples after Rubella vaccination. The average time interval
to the ﬁrst positive bleed was 14.1 days with the Elecsys Rubella IgG
assay and 19.7 days with the comparison assay. The Elecsys Rubella IgM
assay revealed high speciﬁcity (98.7–99.0%) in fresh samples obtained
from clinical routine antenatal screening (n = 1,556); and a statistically
lower reactivity towards persistent Rubella IgM when compared to
the reference assays. Resolved relative sensitivity of 99.9–100% and
resolved relative speciﬁcity of 97.4–100% was found for the Elecsys
Rubella IgG assay in pre-selected frozen samples and fresh samples
from routine antenatal screening.
Conclusion: The Elecsys Rubella IgM and IgG assays provide
convenient and reliable determination of anti-Rubella antibodies, with
speciﬁcity, sensitivity and reproducibility that is comparable with assay
systems in current use. Adoption of this new assay can help in the
monitoring of rubella status in pregnant patients.
P1927 Evaluation of fully automated assays for the detection of
Cytomegalovirus IgM and IgG antibodies on the Elecsys®
immunoassays system
J. van Helden °, L. Grangeot-Keros, T. Lazzarotto, M.G. Revello,
Y. Dickstein, A. Mu¨hlbacher, E. Pfaffenrot, W. van der Helm
(Monchengladbach, DE; Paris, FR; Bologna, Pavia, IT; Tel Aviv,
IL; Salzburg, AT; Rotkreuz, CH)
Objectives: Cytomegalovirus (CMV) infection is the leading cause of
congenital viral infection worldwide with an incidence of 0.15–3.0%.
Long-term consequences of foetal/neonatal CMV infection can be severe
and may include hearing loss, visual impairment and mental retardation.
Early detection of primary CMV infection in pregnant patients is
therefore important so that the patient can be correctly managed and
counselled. The Elecsys® CMV-IgM and CMV-IgG assays are new, rapid
and fully automated diagnostic tests designed for routine use on the
Roche Elecsys 2010, MODULAR Analytics E170 (Elecsys module),
cobas® e 411 and cobas e 601 analyzers.
Methods: Elecsys CMV IgG and CMV IgM are electrochemilumines-
cence immunoassays based on recombinant antigens. Comparisons of the
Elecsys CMV IgM and IgG tests with current methods were performed
in clinical laboratories in Italy, France, Israel, Austria and Germany
using a range of clinically predeﬁned samples. Frozen serum specimens
were used for sensitivity and speciﬁcity studies. In addition, fresh serum
samples from unselected routine clinical practice (pregnancy testing or
blood donors) were tested.
Results: Results of reproducibility testing for the Elecsys assays showed
typical values for the coefﬁcient of variation of ~2% for within-assay,
and ~3−5% for between-assay repeatability. Both IgM and IgG assays
showed similar speciﬁcity and sensitivity to comparator methods in
samples from primary CMV infection, past infection and samples with
conﬁrmed absence of CMV infection. Less reactivity towards samples
containing persistent CMV antibodies was found with Elecsys CMV
IgM as compared to reference assays. On samples from clinical routine
(blood donors and pregnancy testing; n = 1,668) Elecsys CMV IgG
showed excellent correlation with the comparator methods (96.8–99.4%).
The Elecsys CMV IgM assay revealed higher speciﬁcity (97.0–98.8%)
than the reference assays (92.9–96.6%) when testing routine samples
(n = 1,646).
Conclusion: The Elecsys CMV-IgM and IgG assays showed good
concordance with other test methods In addition, the Elecsys CMV IgM
assay revealed higher speciﬁcity compared to the comparison assays.
The performance evaluation data demonstrated that the high throughput
Elecsys CMV IgG and CMV IgM assays are reliable tools in routine
diagnosis of Cytomegalovirus infection.
P1928 A ten months’ results of a commercial enzyme immunoassay
for detection of norovirus in outbreak specimens
H. Tuokko ° (Oulu, FI)
Objectives: Norovirus is a major cause of nonbacterial gastroenteritis
especially in hospitals and nursing homes. The aim of this work was
retrospectively to study the ability of a commercial enzyme immunoassay
to detect norovirus antigen in specimens taken in outbreaks and sporadic
cases of gastroenteritis in the Northern part of Finland in 2008. A total
of 1064 diarrhoea specimens were collected for viral and bacterial tests
in ten months from patients in nursing homes, hospitals, health care
centres and departments of Oulu University Hospital.
Methods: Norovirus was detected by RIDASCREEN Norovirus enzyme
immunoassay (EIA) (R-Biopharm, Darmstadt, Germany). Noro RT-PCR
(Huslab, Helsinki, Finland) was used to identify 22 specimens.
Results: Altogether 188 (17.7%) specimens were noroviruspositive.
Concerning age groups of patients, the highest noropositivity was
detected in specimens from children around of one year of age (39.1%),
the lowest 11.9% from patients with age of from 10 to 65 years, 20.3%-
positivity in specimens from patients older than 65 years. The major
amount of the patients (732) were in age of from 75 to 95 years with
noropositivity of 22.3% in their samples. In faecal samples of the seven
largest outbreaks, taken during 2 to 3 weeks from the start, noropositivity
was (60.6±15.5)%, during 1 month (50±18)%, and during 3 months
(40.1±8.5)%. Those 22 specimens included 14 positive and 8 negative
NoroRT-PCR samples. The sensitivity of RIDASCREEN Norovirus EIA
was 71.4% compared to NoroRT-PCR. The other ﬁndings were one Rota
positive and 22 diarrhoea bacteria positive samples.
Conclusion: RIDASCREEN Norovirus EIA, rapid, easy to carry out
and economic, detected as noro positive (60.6±15.5)% of the outbreak
specimens taken during 2 to 3 weeks. Although the sensitivity of 71.4%
to NoroRT-PCR, the kit, like this with monoclonal antibodies against
different norovirusgroups, could be recommended (as screening test)
for noro diagnosis in outbreak samples, but not for single-specimen in
microbiological laboratories.
P1929 Automated Enzygnost Rubella portfolio (Siemens
Healthcare Diagnostics) as an important aid during 2008
rubella outbreak in Italy
A. Marangoni °, A. Moroni, S. Accardo, R. Cevenini (Bologna, IT)
Objectives: Rubella virus (RV) infection causes a benign disease in
immunocompetent individuals, but may lead to congenital infection with
serious sequelae for the newborn after primary infection in pregnant
women. Accurate IgM, IgG and avidity assays are critical to diagnose
RV infection and to clearly understand the serological status of patients.
Although vaccination has substantially reduced the incidence of RV
infection, Italy has faced an upsurge of RV cases since the end of
2007, with outbreaks reported in many regions. Here we report results
obtained from September 2007 to August 2008 for sera submitted to
the Microbiology Laboratory of S. Orsola Hospital, Bologna for RV
serological testing.
Methods: Sera were tested by Enzygnost Rubella IgG and Enzygnost
Rubella IgM, processed using BEPIII analyzers (Siemens Healthcare
Diagnostics Products GmbH, Marburg, Germany). In both the kits the
difference between OD values in the wells coated with antigen (Ag)
and in the wells coated with control antigen (CoAg) is a measure
of the concentration of RV antibodies detected in the samples. Sera
showing OD> 0.200 values in CoAg wells of IgM assay were considered
suspective and they were retested by Vidas Rub IgM (bioMerieux, Marcy
l’Etoile, France), as well as all the samples scored positive or Border-
line.
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Finally, IgG avidity test was performed by using Urea 3.6M in combi-
nation with Enzygnost Rubella IgG. The antigen/antibody dissociating
agent (Urea) was used in parallel with the usual IgG antibody assay, and
the OD obtained with Urea was compared with the OD obtained without
Urea, yielding an AI (Avidity Index), as follows: AI = OD with urea/OD
without Urea.
Results: During the study period we screened 3409 serum samples for
IgG and IgM anti-RV. IgM testing was repeated by Vidas Rub IgM,
because of screening positive (127), Border-Line (61) or suspective
results (112). Moreover, 245 samples were tested by IgG avidity test.
Low avidity results were obtained in 59 samples, whereas 12 sera showed
intermediate avidity: as expected, these 71 sera were scored positive by
both IgM methods.
Conclusion: The IgG avidity test can be used to rapidly distinguish
between acute RV infection and long lasting of IgM on the ﬁrst
sample from a patient. The implementation of the avidity test on the
automated BEPIII system has allowed us to perform this test in the daily
routine. Moreover, in this study we conﬁrmed the good performances of
Enzygnost Rubella IgM as screening test.
Table 1. IgM results obtained by Vidas Rub IgM when sera scored
positive, Border-Line or suspective by Enzygnost Rubella IgM were
tested.
ELISA ELFA
Negative Positive Border-line
Positive (127 sera) 9 (7.1%) 111 (87.4%) 7 (5.5%)
Border-line (61 sera) 22 (36.0%) 9 (14.8%) 30 (49.2%)
Suspective (112 sera) 112 (100.0%) 0 (0.0%) 0 (0.0%)
It is worthy to underline that no suspective sera (i.e. showing OD larger
than CoAg limit of IgM ELISA assay) were reactive by ELFA,
conﬁrming that all these sera had simply nonspeciﬁc reaction, correctly
identiﬁed by screening test.
P1930 Detection of antibodies to West Nile virus in people with
schizophrenia using recombinant prM and E proteins
produced by COS-1 cells
M. Aslan °, B. Kocazeybek, N. Turan, H. Yilmaz, A.R. Karakose,
P. Yuksel, S. Saribas, H. Cakan, M. Bunning, R. Caliskan, M. Torun
(Istanbul, TR; Colorado, US)
Aim: Antibodies to West Nile virus (WNV) have been found in many
warm blooded animals and people and cause fever and encephalitis.
As it is known, neurotropic viruses like WNV and Borna disease virus
with a predilection for latency are potential associates. However, the role
of WNV infection in schizophrenia is not well documented. Therefore,
we aimed to investigate the frequency of antibodies to WNV and its
association with neurological diseases like schizophrenia.
Method: 200 sera from patients with schizophrenia were collected from
Bakirkoy Mental Health Hospital.100 sera from healty controls (HC)
were collected from blood donors and 100 sera from the patients with
other anxiety and depressive disorders were collected from the Psychiatry
Department of the Cerrahpasa Medical Faculty. HC were blood donors
with no history of non-progressive and non-infectious neurological
disorders. The sera were analysed by ELISA using the recombinant
antigens (prM and E) of WNV produced by COS-1 transformed cells.
The home-made of ELISA showed the optimal concentration of antigen
as 6 ug/mL and the optimal dilution of serum as 1/40. Human sera were
therefore tested at this dilution. Each serum was tested in antigen coated,
non-coated and COS-1 cell-coated wells to measure the background
optical density. Sera that read at least 2-fold higher compared with
background were considered positive
Results: We detected higher WNV antibody titers only in one case
(no: 128). Borna virus IgG was also detected. No positivity was detected
in any other patients and HC.
Patient (no:128): She is 70 years old and born in Adana city (Cukurova
region of Turkey) which the endemic diseases transmitted with vectors
(especially mosquito) are most commonly found. She was hospitalised
in Bakirko¨y Mental Hospital for 40 years and still taking antipsychotic
therapy. WNV antibody titer was highly elevated in this patient
(Patient OD = 1.479, OD of control = 0.240).
Conclusion: In conclusion, the results of this preliminary study showed
that antibodies to WNV in people do not seem to be frequently associated
with schizophrenia and other psychatric disorders. In spite of that,
detecting high WNV antibody titres in one patient suggests us to
consider the possibility of relationship between WNV infections and
psychiatric diseases in endemic areas. However, a secondary test is
needed. Therefore, we have extracted RNA from the blood of those
patients and the presence of WNV will be analysed by real-time RT-
PCR.
Paediatric infections
P1931 Antibiotics versus placebo or watchful waiting for acute
otitis media: a meta-analysis of randomised controlled trials
E. Vouloumanou °, D. Karageorgopoulos, M. Kazantzi, A. Kapaskelis,
M. Falagas (Athens, GR)
Objective: Recommendations on withholding antibiotics in children
with acute otitis media (AOM) have been inadequately implemented
in clinical practice. We evaluated the role of prescribing antibiotics for
AOM.
Methods: We searched PubMed and Cochrane. We performed a meta-
analysis of randomised controlled trials (RCTs) that compared antibiotic
treatment to placebo or watchful waiting (delayed antibiotic treatment if
clinically indicated) for patients with AOM.
Results: We identiﬁed 7 trials comparing antibiotic treatment to placebo
(all double-blinded), and 4 trials comparing antibiotic treatment to
watchful waiting (2 investigator-blinded, 2 open-label) trials, all of which
involved children (6 months to 12 years). Clinical success was more
likely with antibiotics than comparator treatment, in placebo-controlled
trials [7 RCTs, 1405 patients, odds ratio (OR)=2.00, 95% conﬁdence
interval (CI)=1.34–2.99]; watchful waiting trials (4 RCTs, 915 patients,
OR= 2.22, 95%CI=1.20–4.13); and all trials (11 RCTs, 2320, OR= 2.06,
95%CI=1.49–2.84). Similarly, persistence of symptoms 2−4 days after
treatment initiation was less likely with antibiotics in placebo-controlled
trials (4 RCTs, 1014 patients, OR= 0.57, 95%CI=0.43–0.76); and all
trials (5 RCTs, 1299 patients, OR= 0.53, 95%CI=0.41–0.69). Diarrhoea
was more likely with antibiotics (7 RCTs, 1807 patients, OR= 1.59,
95%CI=1.18–2.16). No differences between the compared treatments
were found regarding other effectiveness and safety outcomes.
Conclusion: Antibiotic treatment is associated with a more favourable
clinical course in children with AOM, compared to placebo, and to
watchful waiting, as well. However, safety issues and the rather small
treatment effect difference render the consideration of additional factors
necessary in relevant clinical decision-making.
P1932 Nasopharyngeal microbiota of children with acute otitis
media (AOM) versus children with upper respiratory
infection without AOM
L. Lindholm °, A. Ruohola, P.A. Ta¨htinen, M. Keina¨nen, R. Vainionpa¨a¨,
P. Huovinen, J. Jalava (Turku, FI)
Objectives: Nasopharyngeal microbiota, which consists of both bacteria
and viruses, is a complex ecosystem which structure and function are
inadequately characterised. Nasopharynx is the gateway to microbes to
cause respiratory diseases. Thus, it is fundamental to know the microbial
species and to elucidate the interactions between bacteria and respiratory
viruses.
The aim of this study is to compare the nasopharyngeal microbiota
between children who have acute otitis media (AOM) and those who
have uncomplicated upper respiratory infection (URI).
Methods: Nasopharyngeal specimens were taken from total of 557
children (aged 6−35mo) in whom AOM was suspected by parents.
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Nasopharyngeal bacteriota was analysed by semi-quantitative culture-
based methods and respiratory viruses by PCR and antigen detection
methods. In 319 children AOM was diagnosed and URI group consisted
of 238 children with healthy ears. The nasopharyngeal microbiota of
these two groups was compared.
Results: The composition of bacteriota and viruses in both groups (AOM
vs. URI non-AOM) are shown in Figure 1.
Figure 1. Bacterial and viral ﬁndings in the nasopharynx of patients with
acute otitis media (AOM) vs patients with upper respiratory infection
without AOM.
Respiratory virus was detected in 82% of the samples in both groups
(AOM 81.5%, URI non-AOM 81.9%). Typical bacterial pathogens of
AOM (S. pneumoniae, H. inﬂuenzae, M. catarrhalis and also S. aureus)
were found in 309 (97%) AOM patients but only in 188 (79%) URI
cases. Pathogenic bacteria and viruses were concomitantly found in 252
(79%) of AOM patients and in 153 (64%) of URI non-AOM patients.
AOM patients had signiﬁcantly (P = 0.0002) less non-pneumococcal
streptococcal species in their nasopharynx than URI non-AOM patients.
Conclusion: Our comparative data further conﬁrms that in AOM
coinfection with bacteria and viruses occurs more often than in URI non-
AOM. There were no differences in the occurrence of viruses between
the groups. However, the AOM patients had more pathogenic bacteria
and less non-pathogenic streptococci.
P1933 Serotype distribution, antibiotic resistance of strains
causing acute otitis media and antibiotic comsuption in
children in Slovakia
H. Hupkova °, J. Trupl, J. Jakubikova, M. Gezo, E. Novakova
(Bratislava, Zilina, SK)
Objectives: To assess the distribution of serotype and antibiotics
resistance among strains S. pneumoniae and H. inﬂuenzae causing acute
otitis media among children <5 year old. To estimate the rates of acute
otitis media (AOM)-related ambulatory visits and antibiotic prescriptions
patients in Health Insurance.
Methods: The otitis media study followed children from 1 month to
5 years of age. Study was started in December 2006, data collected
until June 2007 were included. S. pneumoniae strains (n = 61) and
H. inﬂuenzae strains (n = 25)were isolated from 133 children.
If AOM was diagnosed, myringotomy was performed to verity of
diagnosis of AOM and middle ear ﬂuid was aspirated for culture of
bacterial pathogens. Clinical specimens cultured in laboratory following
standard procedures, susceptibility testing according CLSI guidelines.
Pneumococci were serotyped using the Quellung method using speciﬁc
antisera (Statens Serum Institut, Denmark). Paediatricians prescription
habits in AOM were analyzed retrospectively from the General health
insurance fund data.
Results: In 133 of patients, the tympanic membrane was perforated and
ear discharge observed. In 61 of these cases(45.9%)S. pneumoniae and
in 25 cases (18.8%) H. inﬂuenzae was cultured. The overall coverage
of serotypes contained in the 7-valent conjugate vaccine causing otitis
media in children under 5 years of age was 88.5%. High prevalence
of nonsusceptibility to penicillin (51.8%), erytromycin (47.5%) and
cotrimoxazole (75. 4%) was observed. In our collection of pneumococcal
strains serotype 23 F (29. 5%) and 14 (24.6%) are leading serotypes.
20 strains (80%) of H. inﬂuenzae strains were nontypable, 1 strain was
serotype 1, 3 strains serotype B and 1 strain serotype F. In total 2 strains
(8%) were resistant to ampicilin.
75,846 patients insured in General Health Insurance Fund were treated
by AOM in year 2007. 51% of them were children <5 year old. Total
costs for antibiotic prescriptions for children <5 year were 139,727 €. In
prescriptions were dominant cephalosporins (33.2%) and combinations
of penicillins (31.9%).
Conclusions: The present study reports a 88% coverage of the
7-valent pneumococcal conjugate vaccine of pneumococcal AOM strains.
Serotypes 23F and 14 were most common among S. pneumoniae AOM
isolates. Prospective surveillance for AOM among children, vaccination,
consumption of antibiotics and resistance is going on.
P1934 Clonality and pilus protein genes of pneumococcal isolates
causing acute otitis media in children
A. Vainio °, T. Kaijalainen, R. Sihvonen, L. Siira, A. Virolainen
(Helsinki, Oulu, FI)
Objectives: Acute otitis media (AOM) is one of the most common
infectious diseases among young children in the developed countries
and S. pneumoniae is still the major bacterial pathogen causing AOM
infections. Our aim was to characterise the molecular background of
pneumococcal isolates cultivated in the middle ear ﬂuid (MEF) and/or
nasopharyngeal aspirate (NPA) of the AOM cases.
Methods: The 56 children (age range from 9 months to 6 years
and 11 months) with clinically deﬁned AOM were divided into
three groups: those with MEF and NPA positive for pneumococci
(MEF+/NPA+, N= 19), those with only MEF positive for pneumococci
(MEF+/NPA−, N=3), and those with only NPA positive for pneumococci
(MEF−/NPA+, N= 34). All S. pneumoniae isolates (N = 75) were studied
for antibiotic susceptibility, serotyped by latex agglutination and/or
counterimmunoelectrophoresis, and pilus islet 1 (rlrA, rrgC) and 2
(pitA-sipA) genes were detected by PCR. In addition, 17 isolates were
selected for genotyping by multi locus sequence typing (MLST), based
on serotype and pilus islet gene results.
Results: All the 75 pneumococcal isolates were susceptible to penicillin.
Among all the isolates, 14 different serotypes were found: 19F (27%),
23F (25%), 6B, 14, 6A, 19A, 11A, 9V, 18C, 24, 33, 3, 15A, and 38, in
decreasing order of incidence. The serotype was the same in both MEF
and NPA isolates in the same child. Serotypes 9V, 19A, 24, and 33 were
found only in the MEF+/NPA+ group and serotypes 3 and 38 only in
the MEF−/NPA+ group. Fifteen (20%) of the 75 isolates were detected
positive for the pilus islet 1 genes, and they were of serotypes 6B, 6A,
9V, 23F, and 38, in decreasing order of incidence. In MEF+/NPA+ group
8/41 (20%) pneumococcal isolates from four children had pilus islet 1
genes and in MEF−/NPA+ group 7/34 (21%). The pilus islet 2 was not
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detected among any of the isolates. The MLST analysis of the selected
isolates is currently underway.
Conclusion: Pilus 1 gene positivity among pneumococcal MEF and
NPA isolates seemed to appear in certain serotypes as reported earlier
for invasive isolates. However, the MLST results will reveal the pilus
gene association with clonality in more detail.
P1935 Pneumonia cases in the paediatric intensive care unit of a
tertiary-care university hospital
E. Hajdu´ °, K. Ra´cz, G. Ta´losi, S. Tu´ri, E. Nagy (Szeged, HU)
Objectives: Children patients of pneumonia need ICU admission in
cases of respiratory or circulatory failure, pleural effusion, empyema or
abscess. Microbiological results can help the effective therapy, especially
in cases of nosocomial infections. We evaluate our data of pneumonia
patients treated in paediatric ICU from Jan. 01, 2005 to Dec. 31, 2007.
Methods: Pneumonia was diagnosed by physical examination, chest
X-ray, CT scan, MRI and laboratory examinations. We cultured blood
(BACTEC System, Becton Dickinson, Sparks Md), pleural punctions and
endotracheal aspirates. Bacteria were identiﬁed by conventional methods
and VITEK 2 system (bioMe´rieux, L’Etoile, France). The antibiotic
susceptibility tests of isolates were determined by using disk diffusion
method, E-test and the breakpoints recommended in the NCCLS/CLSI
guidelines. RSV antigen was detected by immunochromatography.
Results: Our results are summarised in the table.
Patients’ data
Number of patients
Male 31
Female 23
Age 1 month to 20 years
(mean 52.6 months)
Diagnosis
Pneumonia 23
Pleuropneumonia 31
Other chronic disease
Somatomental retardation 6
Congenital vitium cordis 5
Prematurity 4
Gastro-oesophageal reﬂux 4
Diabetes mellitus 2
Status post renal transplantation 2
Asthma bronchiale 2
Morbus Down 1
Admission
From home 19
From other hospital 30
From other ward of Department of Paediatrics 4
Antibiotic use before admission 46 (85%)
Length of stay in ICU 2–48 days (mean 7.4 days)
Antibiotic therapy
Cefalosporins 23
Penicillins 11
Macrolides 10
Aminoglycosides 5
Trimethoprim/sulfamethoxazole (suspected Pneumocystis carinii infection) 2
Glycopeptide 1
Carbapenem 1
Lethality rate 5.5%
Aetiology
Streptococcus pneumoniae 8
Haemophilus inﬂuenzae 4
Pseudomonas aeruginosa 4
Staphylococcus aureus 2
Klebsiella pneumoniae ESBL+ 1
Chlamydia pneumoniae 1
Candida krusei 1
Anaerobes 2
RSV 3
Pathogen not identiﬁed 28
Conclusions: Despite the high rate of pre-treated patients, in 48% of the
cases the pathogens could be identiﬁed. All three children lost at the ICU
had other severe chronic diseases. Our study indicates the importance of
microbiological diagnosis in ﬁnding efﬁcient treatments.
P1936 Clinical evaluation of a new commercial PCR-DNA microar-
ray system for simultaneous detection of 17 respiratory
viruses in French infants hospitalised for acute bronchiolitis
L. Andreoletti °, A. Huguenin, L. Moutte, M. Abely, K. Bessaci,
F. Renois, T. Nenninger, F. Carrat, N. Leveque (Reims, FR)
Background: Rapid testing for viral infection is recommended in infants
who require admission to hospital with acute bronchiolitis in order to
guide cohort arrangements or to improve therapeutic management in
case of respiratory distress. Clinical virology laboratories used traditional
methods as direct ﬂuorescent-antibody assay (DFA) and culture for the
detection of six or seven conventional respiratory viruses. In the present
study, a new commercially available assay using RT-PCR followed by
microarray detection assay designed for detection of 17 pathogenic
respiratory RNA viruses was evaluated by testing clinical samples of
infants hospitalised for bronchiolitis.
Methods: From October 2007 to December 2008 for we retrospectively
selected 65 infants (mean age: 3.5 months, SD: 3.2 months) admitted
to the paediatric department (University Hospital Center of Reims,
France) for acute bronchiolitis. Infants with congenital heart disease
or with a chronic genetic or acquired-immunodepression were excluded.
Nasopharyngeal aspirate samples of the selected patients were tested
by DFA and cell-culture detection assays and by microarray detection
assay (Clart Pneumovir Version 3.0, Genomica, Madrid, Spain) for the
presence of respiratory viruses.
Results: One or more potential causative viral agents were detected in
47, 51, 63 of 65 samples by viral culture, DFA and the microarray
detection assay, respectively (P< 10−3). The frequency of detection of
conventional respiratory viruses appeared to signiﬁcantly higher using
the microarray assay than using the classical techniques (P = 0.02).
The Pneumovir assay detected 43 mixed infections that the most
common associations were: adenovirus and RSV (26%), bocavirus and
RSV (23%) and metapneumovirus and RSV (23%). Mixed infections
appeared not to be statistically associated with the severity of the disease
or secondary hospitalisation events for acute bronchiolitis or asthma
within 6 months after the time of inclusion.
Conclusion: The use of this PCR-DNA microarray system in clinical
virology practice allows a rapid and accurate detection of conventional
and newly discovered viral respiratory pathogens in infants hospitalised
for acute bronchiolitis. Moreover this new assay would be of major
interest for the development of future therapeutic and preventive
strategies to ﬁght against the viral causes of bronchiolitis.
P1937 Detection of atypical bacterial and viral antibodies in
lower respiratory tract infections in children by use of an
immunoﬂuorescence method
K. Papavasileiou °, H. Papavasileiou, I. Varzakakos,
S. Chatzipanagiotou, A. Voyiatzi (Athens, GR)
Lower respiratory tract infections (LRTIs) are the leading cause of
morbidity and mortality among children. Most commonly leads to
hospitalisation due to the frequent relapses of the disease.
Objective: The aim of the study was the detection of antibodies (IgM,
IgG) of viruses and atypical bacteria in children with lower respiratory
tract infections during the period October 2007–April 2008.
Methods: Sera were collected from a total of 100 hospitalised children,
aged 2 months to 14 years, with LRTIs in acute and convalescent-
phase. We used the indirect immunoﬂuorescence method (pneumoslide
IgG, IgM − VIRCELL) in order to detect simultaneously speciﬁc
(IgM, IgG) antibodies against 4 atypical bacteria (L. pneumophila,
M. pneumoniae, C. burnettii, C. pneumoniae) and 4 viruses (Adenovirus,
RSV, Inﬂuenza A, Inﬂuenza B).
Results: Antibodies against viral or atypical bacteria were detected in 88
out of 100 children (88%) with LRTIs. A single pathogen was identiﬁed
in 38children (43%). Mixed infections were found in 50 children (57%):
RSV + Adenovirus (20), RSV + Adenovirus + M. pneumoniae (15),
M. pneumoniae + Adenovirus + Infuenza B (5), RSV + Inﬂuenza A
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(5) and M. pneumoniae + RSV (5). RSV was the most common virus
(33%) followed by Adenovirus (30%), Inﬂuenza A (9%) and Inﬂuenza
B (9%). M. pneumoniae was the most frequent atypical microorganism
detected (15%), followed by L. pneumophila (3%), C. burnettii (1%)
whereas C. pneumoniae was not detected. Only 24 children (27.3%)
had antibodies of acute-phase. RSV was more frequent in children aged
3 months to 1 year, while M. pneumoniae was detected in older patients
(4−6 years). Infection was more frequent in winter months, especially in
January and February.
Conclusions: RSV was the prevalent causative agent of bronchiolitis in
children <1 year, frequently associated with Adenovirus. M. pneumoniae
was very common in atypical pneumonia and usually associated with
Adenovirus or Inﬂuenza A and B. Due to the high prevalence of
co-infections, the empiric administration of antimicrobial (such as
macrolides) to children with LTRIs, might contribute to the treatment
and the prevention of relapses.
P1938 Colonisation of intravascular catheters in the intensive
care unit of a paediatric hospital during a ten-year period
(1999–2008)
K. Papavasileiou °, H. Papavasileiou, G. Oikonomopoulos, C. Iliadou,
A. Voyatzi (Athens, GR)
Intravascular catheters (IVC) are indispensable in modern-day medical
practice, particularly in intensive care units (ICUs). Although such
catheters provide necessary vascular access, their use puts patients at
risk for local and systemic infectious complications.
Objective: To study the rate of colonisation of intravascular catheters, the
frequency of appearance of the pathogens, as well as their susceptibility
pattern to various antimicrobial agents.
Methods: During a ten year period (1999–2008) we performed routine
examination of the tips of 413 IVC’s. The catheters were cultured by
the Maki semi quantitative method and all samples, after enrichment in
cooked meat broth, were subculture on selective media. All pathogens
were identiﬁed by classical microbiological methods and susceptibility
to antibiotics (MIC) was determined with the automated system VITEK
2 (BioMerieux, France), according to CLSI recommendations.
Results: Out of the 413 catheters examined, 247 (60%) were sterile,
while 166 (40%) were colonised. We found 198 pathogens. In 80.7% of
catheters one pathogen was isolated, in 14.5% two and in 4.8% three
or more. Gram(+) cocci (126, 63.6%) were most frequently isolated,
followed by Gram(−) bacteria (34, 17.2%), fungi (25, 12.6%) and ﬁnally
Gram(+) bacteria (13, 6.6%). Coagulase negative Staphylococci (CNS)
(105, 53%) were the dominant isolates, followed by fungi (25, 12.6%),
Enterococcus spp (12, 6%), Acinetobacter spp (11, 5.5%) and S. aureus
(7, 3.5%). From the 105 CNS, 54.2% were resistant to methicillin, 60%
to erythromycin, 45.7% to clindamycin, 38% to gentamicin, 25.7% to
ciproﬂoxacin, 10.5% to tetracycline and 35% to netilmicin. There was
no resistance to levoﬂoxacin, linezolid and vancomycin, whereas one
stain showed intermediate susceptibility to teicoplanin. Multiresistance
was detected in Acinetobacter baumannii strains. 52% of patients with
positive blood culture had catheter-associated bacteraemia.
Conclusions: The methicillin resistant CNS is the most frequent
cause of colonisation of intravascular catheters in ICU. Increased
resistance to antibiotics is observed. Physicians should observe the
international recommendations that are designed to reduce the infectious
complications associated with intravascular catheter use.
P1939 Epidemiology of Moraxella catarrhalis infections in children
and resistance phenotypes
A. Makri °, G. Oikonomopoulos, F. Vagia, K. Kalimeratzi, C. Iliadou,
E. Panagiotaki, A. Voyatzi (Penteli, GR)
Objectives: To investigate the incidence and the antibiotic resistance
phenotype patterns of Moraxella catarrhalis strains isolated from
respiratory tract infections and to evaluate the burden of disease in
childhood.
Material and Methods: A total of 200 M. catarrhalis strains
recovered from children aged 0 to 14 years during a four year
period (2005–2008). Identiﬁcation of M. catarrhalis strains was based
on the production of DNAse and the tributyrin hydrolysis reaction.
Antimicrobial susceptibility performed through the disk diffusion
method and conﬁrmed by E-test (AB Biodisk). b-lactamase production
determined by a chromogenic cephalosporin test.
Results: M. catarrhalis strains isolated in 32% clinically diagnosed
respiratory tract infections (RTIs). The origin of these 200 strains
was: sputum 38%, bronchoalveolar lavage (BAL) 30%, ear smears
15%, nasal secretions 11% and conjunctival smears 6%. It is notable
that a rise of incidence of otitis media and bronchiolitis, followed by
conjunctivitis, observed during autumn and winter concerning children
ages <3 years. All M. catarrhalis strains were sensitive to: amoxi-
cillin/CA (AMC) (MIC50 0.064mg/l-MIC90 0.50mg/l), ciproﬂoxacin
(MIC50 0.047mg/l-MIC90 0.125mg/l), cefuroxime (MIC50 0.25mg/l-
MIC90 1mg/l), and imipenem (MIC50 0.064mg/l-MIC90 0.19mg/l).
A low rate of resistance to chloramphenicol 3% (MIC50 0.25mg/l-
MIC90 1mg/l), tetracycline 6% (MIC50 0.25mg/l-MIC90 1mg/l)
and trimethoprim/sulfamethoxazole 8% (MIC50 0.125mg/l-MIC90
0.50mg/l) determined. Remarkable resistance exhibited to erythromycin
(23.3%, MIC50 0.094mg/l-MIC90 1.5mg/l) while resistance to newer
generation macrolides was: to clarithromycin 30.9% (MIC50 0.094mg/l-
MIC90 3mg/l) and to azithromycin 16.6% (MIC50 0.023mg/l–
MIC90 1mg/l). All M. catarrhalis strains resistant to ampicillin (90%),
were producing b-lactamase.
Conclusions: 1.A seasonal distribution of M. catarrhalis infections
incidence observed, according to sample origin. 2. In children with
severe respiratory consequences consecutive quantitative sputum cultures
obtained in order to clarify whether it was a simple colonisation or an
active infection. 3. M. catarrhalis strains were recovered from 30% of
children with chronic obstructive pulmonary disease as the predominant
pathogen. 4. b-lactamase producing strains presented a considerable MIC
increase to clarithromycin. 5. AMC remains the appropriate antibiotic of
choice due to the appearance of resistance to macrolides.
P1940 Prevalence and antimicrobial susceptibility among Pseudo-
monas aeruginosa strains isolated in a paediatric hospital
A. Makri °, K. Kalimeratzi, G. Oikonomopoulos, E. Nika, C. Iliadou,
A. Voyatzi (Penteli, GR)
Objectives: to evaluate the prevalence and to investigate the antimicro-
bial resistance patterns of Pseudomonas aeruginosa (P.a.) strains isolated
from hospitalised children with severe infection during a four year period
(2005–2008).
Material and Methods: Totally, 472 P.a. strains were isolated from
hospitalised children in Surgical clinics (60.8%), Paediatric clinics
(24.2%), Intensive Care Unit (ICU) (10.8%) and from outpatients
(4.2%). Identiﬁcation and susceptibility patterns were performed by the
automated system Vitek 2 (bio-Me`rieux). Metalo-b-lactamases (MBL)
production was screened by E-test MBL-strip (AB-Biodisk) and by
double disk synergy test IMP/EDTA.
Results: The origin of the 472 studied isolates was: ear smears 39.8%,
low respiratory tract secretions 25%, wound specimen 21.8%, urine
12.2% and blood specimen 2.1%. Resistance rates of P.a. strains to
12 antibiotics ranged: ticarcillin (TIC) 33%, netilmicin (NET)18.9%,
aztreonam(AZT) 14.1%, piperacillin (PIP) 14%, ceftazidime (CAZ)
13.5%, gentamicin (GM) 10.3%, ciproﬂoxacin (CIP) 10.3%, ticar-
cillin/CA (TIM) 10%, tobramycin (TOB) 9.9%, amikacin (AN) 8.5%,
imipenem (IMP) 6.5% and piperacillin-tazobactam (TZP) 4.7%. Most
of P.a. isolates from urine was susceptible to the majority of the
antibiotics, expressing a low rate resistance to AZT (4.7%) and TIM
(4.7%). P. aeruginosa isolates from bronchopulmonary infections showed
a signiﬁcant resistance to TIC (33%), PIP (10%), CAZ (10%) and AZT
(9%) due to chromosomal resistance and the production of extended
spectrum b-lactamases (ESBL) plasmid. Multiple antibiotics resistance
(>5 antibiotics) was observed to the majority of isolated P.a. strains from
ICU samples while resistance rate to carbapenems was 11.1% (MIC50
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2mg/l-MIC90 8mg/l) because a percentage of MBL producing strains
(7.8%) were found. Among the resistant to aminoglycosides P.a. strains,
AAC (6′-1) and ANT (2”-1) enzymes were predominant.
Conclusions: 1. The majority of P.a. strains was associated with surgical
wounds (60%) followed by low respiratory tract infections (25%).
2. The overall proportion of P.a. isolates from ICU patients presented
multiple resistant phenotypes including even resistance to carbapenems.
3. Different mechanisms of resistance are involved in the expression
of multiple antibiotic resistant phenotypes, especially in ICU patients.
4. Monitoring of antibiotic sensitivity among ICU P.a. strains may
prevent the spread of resistance in paediatric clinics.
P1941 Anaerobic bacteriology and antibiotic susceptibility of
intra-abdominal community-acquired infections in children
A. Makri °, C. Iliadou, K. Kalimeratzi, G. Oikonomopoulos,
A. Pantazatou, A. Avlami, A. Voyatzi (Penteli, Athens, GR)
Objectives: To investigate the incidence and the antibiotic susceptibility
of anaerobes isolated in complicated intra-abdominal (cIAIs) and
postoperative wound infections (PSWIs) in paediatric patients.
Material-Methods: Retrospective data for bacterial clinical specimen
from 432 hospitalised children with intraperitoneal and surgical wound
infections over a two years period were analysed. Cultures were
performed and conﬁrmed by the Greek National Centre of Gram negative
anaerobe bacteria.
Results: From 303 examined positives cultures (70%) were recovered
aerobes 64.5%, anaerobes 5.5% and mixed aerobes and anaerobes
30%. The anaerobes bacteria isolated were: Bacteroides fragilis group
(Bacteroidales-32%), Peptostreptococci (28%), Clostridium spp (14%),
Prevotella spp. (8%), Bacteroides capilosus (6%), Fusobacterium spp
(5%), Vellionella spp (4%) and Porphyromonas spp (3%). Bacteroides
fragilis group and Peptostreptococci predominated more often in
abdominal pus samples, while Clostridium spp. and Prevotella spp. were
associated with PSWIs. Out of Bacteroides fragilis group, Bacteroides
fragilis was the most recognised anaerobic pathogen in appendicitis-
related infections accounted for 15%. Clostridium perfringens (10%)
was specially found in cases with gangrenous appendicitis. All strains
of Clostridium spp were susceptible to the antibiotics tested while
Porphyromonas spp and Prevotella spp showed a resistance rate 33% and
25% to clindamycin respectively (high MIC >256mg/l). All Bacteroides
fragilis group isolates were susceptible to imipenem but a signiﬁcant
increase in resistance was observed to clindamycin (28.5%, high MIC
>256mg/l), piperacillin-tazobactam (14.2%, high MIC >256mg/l) and
cefoxitin (7.1%, MIC 96mg/l), while a total of 17.8% strains showed
intermediate susceptibility to cefoxitin (MIC 32mg/l) and 3.5% to
metronidazole (MIC 16mg/l) and tigecycline (2%).
Conclusions: 1. Polymicrobial mixed aerobes and anaerobes were
responsible for half of established peritonitis cases so the antibiotic
therapy should provide coverage for both types of pathogens. 2. B. fragilis
is the most frequently isolated anaerobic pathogen in IAIs. 3. Imipenem
is the most potent agent tested while the emergence of resistance to
metronidazole has important implications in the treatment of cIAIs and
PSWIs. 4. Multiple resistance phenotypes of anaerobes emerge the issue
of surveillance necessity for antimicrobial susceptibility.
P1942 Viral, bacterial and parasitic aetiology of acute gastroen-
teritis in hospitalised children in north-western Greece
S. Levidiotou °, C. Gartzonika, D. Papamichail, C. Pappa, E. Priavali,
N. Zotos, E. Kapsali, P. Bouranta, E. Papapetrou, C. Christaki,
G. Vrioni (Ioannina, Athens, GR)
The aim of this study was to determine the aetiology of acute diarrhoea
in hospitalised children under 5 years of age in Northwest Greece and
to improve knowledge of the aetiology of gastrointestinal pathogens
using traditional and molecular diagnostic techniques. From 2000 to
2006, faecal samples from 4604 children under 5 years old (median
age 14 months) were collected from ﬁve hospitals in NW Greece.
Various common bacteria and parasites associated with diarrhoea were
investigated by conventional techniques. Viral agents were investigated
by antigen detection [e.g. rotavirus (Group A), adenovirus, astrovirus and
norovirus] using an enzyme immunoassay (IDEIA; DAKO Cytomation,
Angel Drove, UK) and molecular methods [e.g Rotavirus using an “in
house” RT-PCR and Adenovirus using a PCR-microplate hybridisation
assay (PCR Adenovirus Consensus, Argene, Biosoft, France)]. From
4604 stool samples examined, aetiologic agents were detected in 1789
cases (38.9%). Monobacterial infections were detected in 389 (21.8%)
cases (Salmonella spp. in 258, Shigella spp. in 5, Campylobacter jejuni
in 118, Yersinia enterocolitica in 4, E. coli in 2, Aeromonas hydrophila in
2), while single viral infections were identiﬁed in 1338 children (74.8%).
Viral-bacterial coinfection was found in 26 (1.4%) cases and viral-viral
coinfection in 36 (2%) cases. No sample was positive for parasites.
Viral pathogens were identiﬁed in 1400 children (30.4%): Group A
rotavirus was detected in 983 (21.35%) cases (941 monoinfections, 32
virus-virus coinfections and 10 virus-bacteria coinfections), adenoviruses
in 162 (3.5%) cases (142 monoinfections, 16 virus-virus coinfections
and 4 virus-bacteria coinfections), astroviruses in 108 cases (2.35%)
(70 monoinfections, 26 virus-virus infections and 12 virus-bacteria)
and noroviruses in 185 cases (4.02%) (all monoinfections). Although
intensive efforts at laboratory conﬁrmation were attempted in our study,
an enteropathogen was found in approximately half of the cases. In
conclusion, eventhough Rotavirus group A was the leading cause of acute
gastroenteritis with the most signiﬁcant role in hospitalised children
with severe diarrhoea in Greece, further studies will be necessary to
augment our knowledge in the aetiology of enteric infections, which
will be helpful in the rational application of effective vaccines.
P1943 Infectious complications in paediatric acute liver failure,
a single-centre experience
G. Godbole °, A. Dhawan, N. Shanmugam, A. Verma (London, UK)
Objective: Acute liver failure (ALF) is rare in children but carries
high mortality. Infectious complications in adults are considered to
be an important cause of mortality, however there is lack of data
in paediatric population. The aim was to determine the incidence of
infectious complications (IC) and their effect on outcome in children
with ALF.
Methods: Retrospective review of the case records of children presenting
with ALF. All patients had surveillance of cultures from all sterile
body ﬂuids every week or more often if clinically indicated. All
received antimicrobial prophylaxis with amoxicillin, a cephalosporin, an
antifungal; ﬂuconazole or amphotericin B (if on assisted ventilation)
and high dose acyclovir in neonates. Biochemical parameters of liver
dysfunction, renal dysfunction, duration of hospital stay and patient
outcome were compared between patients with IC and non-infectious
groups.
Results: 145 children (69 male), median (range) age of 4.22 (1 day-
16 yrs) years were studied. The aetiology of ALF included paracetamol
overdose, viral infections, metabolic, indeterminate, autoimmune,
neonatal hemochromatosis and others. 47/145 patients had proven IC
(32%). 18 episodes of bacteraemia were observed in 13 patients, the most
common organism was Enterococci spp. Lower respiratory tract infection
was seen in 12 patients and most common organism was Pseudomonas
spp. Urinary tract infection (UTI) was also seen in 12; Candida albicans
contributed to more than half of the UTI cases. IC occurred in patients
after a median (range) duration of 14 days (0−54 days) of admission.
8 (5%) had IC at admission. Median (range) duration of hospital stay
in patients with IC 35(4–201) days was signiﬁcantly higher than those
without IC 11 (1−14) day, p< 0.0001. The duration of ventilation was
also signiﬁcantly higher in the group with IC (10 days) as compared to
non-infectious group (5 days); p< 0.01. 45% (21) in IC group had liver
transplantation while as compared to only 26% (26) in non-infectious
group (Pfts;< 0.03). Overall mortality was 16% (23) of which 5% (8)
were from IC group, 10% (15) from non infectious group, the difference
was not statistically signiﬁcant.
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Conclusions: Incidence of culture proven sepsis and mortality associated
with it is low in our experience. Breakthrough sepsis is more common
hence a more stringent surveillance should be employed in whom the
duration of hospital stay is more than two weeks.
P1944 Low-dose erythromycin in the treatment of gastro-
oesophageal reﬂux disease in infants. A pilot, randomised,
double-blind, placebo-controlled trial
A. Banaszkiewicz °, A. Gawron˜ska, P. Albrecht, A. Radzikowski
(Warsaw, PL)
Objectives: Gastro-oesophageal reﬂux disease (GERD) is deﬁned as
symptoms or complications of reﬂux of gastric content into the
oesophageus. Commonly used medications for the treatment of GERD
include acid-suppressant and prokinetic drugs. Based on systematic
review, the literature supports the use of erythromycin as a prokinetic
agent, however most reviewed trials were conducted in preterm infants.
The aim of this study was to assess the effectiveness of low-dose
erythromycin in the treatment of gastro-oesophageal reﬂux (GERD) in
full-term infants.
Methods: This was a double-blind, randomised, placebo-controlled clini-
cal trial. Subjects aged 1−11 months with symptoms of GERD conﬁrmed
both by 24-hours pH-monitoring and the Infant Gastroesophageal Reﬂux
Questionnaire Revised (I-GERQ-R) were randomly assigned to receive
either erythromycin at dose 1−3mg/kg/dose or a comparable placebo.
Both the active treatment and placebo were taken orally three times daily
(20 minutes before meals) for 2 weeks. Parents were asked to ﬁll out
the I-GERQ-R at the study entry and at 2 and 4 weeks after enrollment.
Results: 24 infants were enrolled in the study, 12 in erythromycin
group and 12 in placebo group; no signiﬁcant difference was found
between two groups. Difference in the I-GERQ-R score in erythromycin
group compared with placebo group was statistically signiﬁcant reduced
(p = 0.000003) between beginning therapy and 4 weeks but was not
between beginning therapy and 2 weeks (p = 0.07).
Conclusions: Erythromycin at dose 1−3mg/kg/dose given three times
daily was effective in treating GERD in full-term infants. Its effect
seemed to be time-dependent.
P1945 Vesicoureteral reﬂux in children with suspected and proven
urinary tract infection
A. Hannula °, M. Venhola, M. Renko, T. Pokka, N.P. Huttunen,
M. Uhari (Oulu, FI)
Objectives: The clinical signiﬁcance of vesicoureteral reﬂux (VUR)
has been challenged. We wanted to estimate the prevalence of VUR
and clinically signiﬁcant ultrasonography (US) abnormalities in a large
unselected group of children with proven and suspected UTI and even
without UTI.
Methods:We reviewed the reports of renal or abdominal US and voiding
cystouretrography (VCUG)during an 11 year period. Altogether 8567
patients were identiﬁed and 2145 patients had imaging studies performed
because of UTI and 2036 patients (1481 girls, 555 boys) under the age
of 15 years fulﬁlled the inclusion criteria. Based on the data of the urine
cultures we classiﬁed the reliability of UTI diagnoses into 5 classes
(proven, likely, unlikely, false and no data). The mean age of the children
was 3.2 years (SD 2.9). Renal US was performed on all children and
VCUG was performed on 1185 (58%) children.
Results: Vesicoureteral reﬂux was found in 405/1185 (34.2%) children
and in 181 (15.0%) VUR was grade III to V. The prevalence of VUR
was similar among those with proven and false UTI (37.4% vs. 34.8%,
relative risk (RR) 1.08, 95%CI 0.7 to 1.7, p = 0.75). There was a
signiﬁcant negative trend in occurrence of VUR with increasing age
(p = 0.001). Ultrasonography was abnormal in 424/2036 (20.8%) cases.
Clinically signiﬁcant US abnormalities occurred in 87/583 (14.9%) of
patients with proven UTI and signiﬁcantly more seldom in 11/145 (7.6%)
of patients with false UTI diagnosis (RR 1.96, 95%CI 1.1 to 3.5,
p = 0.02).
Conclusion: The prevalence of VUR was similar in all patient groups
irrespective of the diagnostic reliability of UTI and decreased with
increasing age. On the contrary, the frequency of signiﬁcant US
abnormalities increased as the reliability of UTI diagnosis improved.
This supports the claim that VUR is not signiﬁcantly related to UTI and
its occurrence even among healthy children is signiﬁcantly higher than
the traditional estimates. We suggest that routine search for VUR with
VCUG after UTI cannot be recommended.
P1946 Risk factors predicting recurrent urinary tract infection in
childhood
M. Mikelsaar °, I. Vainuma¨e, K. Truusalu, E. Sepp, S. Ko˜ljalg (Tartu, EE)
The urinary tract infection (UTI) is one of the most common recurrent
bacterial diseases in childhood. However, the role of clinical and
microbiological risk factors in the development of recurrent UTI has
not been evaluated applying novel molecular methods.
Aim: to assess if patient age, recurrent UTI causing microbiological
agent, clinical presentations and antimicrobials administered in the
treatment predict the recurrences of UTI in children.
Methods: Prospectively, 64 patients (1 month-15 years) with ﬁrst acute
pyelonephritis were conducted for evaluation of clinical and laboratory
data during a year. Urine cultures, antibiotic susceptibility of the agent,
genotyping by randomly ampliﬁed PCR (RAPD-PCR) and pulsed ﬁeld
gel electrophoresis (PFGE) of 78 consecutive Escherichia coli isolates
from 27 patients with recurrent UTI were performed.
Results: Half (32/64) of the patients experienced recurrences (79
episodes, 2.5±1.5 per patient) and the majority (62%) of recurrent
episodes were symptomatic. Vesicoureteral reﬂux was found in
22% (14/64) of patients. The majority (55/64, 86%) of ﬁrst acute
pyelonephritis and recurrent episodes (73/79, 92%) were caused by
Escherichia coli.
E. coli was initially resistant to ampicillin (33%), trimethoprim-
sulfamethoxazole (41%) and both (23%). There were no differences in
resistance to b-lactams between initial and consecutive E. coli isolates.
In more than half of the 21/27 patients (78%) the unique genotypically
identical E. coli strains caused the UTI relapses indicating the persistence
of the particular strain. Individual risk factors predicting a complicated
course of UTI were age over 2 years (OR 4.19, CI1.42–12.37, p = 0.01)
and initial b-lactam treatment (OR 5.9, CI 1.5−20, p = 0.01, adjusted for
gender and age).
Conclusion: Genotypically identical E. coli strains with stabile b-lactam
susceptibility in patients at the age over 2 years treated initially with
b-lactams predict the recurrent UTI in childhood as these antimicrobials
may not reach the intracellular clones of persisting E. coli.
P1947 Children’s urinary pathogens in a Greek hospital, 2007–2008
L. Zachariadou °, M. Kypraios, M. Zioga, M. Chondrogianni,
A. Pangalis (Athens, GR)
Objectives: To present the frequency of urinary tract infection pathogens
in children, as well as the differentiation in isolation rates of species,
among in and out patients.
Methods: 28,313 urine specimens were examined from January 2007
to December 2008. 20,814 samples derived from in and 7,499 from out
patients, either visiting the emergency unit or the special nephrology
department, on a monthly follow up program, due to urinary tract
congenital anatomic or functional abnormalities. Samples were mainly
collected by suprapubic aspiration, in and out catheterisation, or clean-
catch midstream or “bagged” specimen, depending on the age of the little
patients. The diagnosis of urinary tract infection was based on precise
clinical and laboratory criteria according to the European guidelines and
in case of doubt the culture was repeated.
Results: 2,476 (8.7%) cultures were positive with one causative pathogen
and only 45 (0.16%) with two and 2 with three pathogens. As
expected, the dominant pathogen in all isolates was E. coli (70.7%),
followed by P. mirabilis (8.4%), K. pneumoniae (6.6%), Enterococcus
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spp (4.2%) and P. aeruginosa (3.0%). The most frequent species of
the remaining 7.2% of isolates were E. cloacae, C. albicans, K. oxytoca,
A. baumannii, Citrobacter spp, Coagulase Negative Staphylococci (CNS)
and S. aureus. The incidence of E. coli in non hospitalised children
reached 77.8%, followed by P. mirabilis (13.4%) and K. pneumoniae
(4.7%). In hospitalised children, the most frequent isolate was E. coli
(66.1%), followed by K. pneumoniae (7.8%), Enterococcus spp (5.6%),
P. mirabilis (5.2%) and P. aeruginosa (4.3%). P. mirabilis was more
frequent in girls (54.1%) than in boys. 68/72 P. aeruginosa and
16/17 C. albicans strains were isolated from hospitalised patients.
The vast majority of these strains were isolated from children with
vesicoureteral reﬂux (3rd grade or more), surgery in the urinary tract,
immunosuppression, prematurity or prolonged hospitalisation.
Conclusions: E. coli was the predominant causative pathogen of
urinary tract infections in children, with an increased prevalence in non
hospitalised patients. The higher isolation rate of P. mirabilis in girls
in this study (54.1%) shows that boys are not the great preference of
this uropathogen. This ﬁnding indicates that positive urine cultures with
P. mirabilis in boys must be evaluated with particular prudence. There
is a low frequency of mixed urinary tract infections in children.
P1948 Outcome of acute childhood bacterial meningitis in Luanda,
Angola
T.I. Pelkonen °, M. Leite Cruzeiro, L. Monteiro, A. Pitka¨ranta, I. Roine,
H. Peltola (Luanda, AO; Lisbon, PT; Helsinki, FI; Santiago, CL)
Objectives: Little reliable information on the outcomes of bacterial
meningitis (BM) of childhood is available from sub-Saharan Africa,
although the incidence is highest there. We report data from a large
prospective study in Luanda, Angola.
Methods: The series comprised all children who presented at the Luanda
Children’s Hospital with suspected BM in the 36-month period of 2005–
08. Our three outcome measures were death, severe neurological sequelae
(SeNeSe) comprising blindness, quadriplegia, hydrocephalus, or severe
psychomotor retardation, and deafness (better ear’s threshold 80 dB).
Hearing was measured using brain stem auditory evoked response.
Results: The preset criteria of acute BM were met by 522/680 (77%)
patients with the median age of 11 months. The median length of illness
before admission was 4 days, and 68% had had convulsions. No less than
88% had received some medication, 41% antimicrobials. On admission,
consciousness was impaired in 71%, focal neurological signs were
observed in 25%, extrameningeal focus of infection in 26%, dyspnoea
in 51%, malnourishment in 28%, positive malaria test in 29% and blood
haemoglobin <8 g/dL in 55%. Of those tested, 7% were HIV-positive.
Of the 428 analyzed cases, 177 (41%) were caused by Haemophilus
inﬂuenzae type b (Hib), 171 (40%) by Streptococcus pneumoniae (Pnc),
49 (11%) by Neisseria meningitidis (Mnc) and 31 (7%) by other (mostly
Gram-negative) bacteria. The overall case fatality was 37%; 32% in
Hib, 45% in Pnc, and 16% in Mnc meningitis. Of survivors 13% were
left with SeNeSe; 13%, 17% and 2% in Hib, Pnc and Mnc meningitis,
respectively. Deafness at discharge was found in 18% (47/267); 21%,
21% and 9% in Hib, Pnc and Mnc meningitis, respectively. In the group
of “other bacteria” only 12 of 31 children (39%) survived, 10 of whom
without sequelae. When controlled 1 month later, 13% of children had
SeNeSe, 8% were deaf and 2 children had died.
Conclusions: BM of childhood continues to be a major problem in
Angola. Fatality was highest in meningitis caused by Pnc or Gram-
negative bacteria, and lowest in Mnc meningitis. Importantly, no recovery
from SeNeSe occurred during the ﬁrst month post-hospitalisation,
whereas deafness decreased from 18% to 8%. Since such improvement
in hearing has not been found previously, we are looking for explanations
to this positive ﬁnding.
P1949 Invasive meningococcal disease in children
R. Nemescu °, D. Mihalache, C. Luca, C. Dorobat (Iasi, RO)
Neisseria meningitidis is a well-known cause of acute meningitis and
fatal sepsis in healthy children worldwide.
Objectives: To describe the epidemiologic features, clinical presentation,
bacteriological and therapeutic ﬁndings, spectrum of complications
and outcome in children with invasive meningococcal disease (IMD)
admitted to the Hospital of Infectious Diseases of Iasi during ten years.
Methods: Retrospective review of medical records of all children aged
18 years with IMD hospitalised in our clinic from 1998 through 2007.
Results: From 1998 through 2007, 225 cases of IMD were admitted
to the Hospital of Infectious Diseases of Iasi; most of them, 191
(85%), occurred in children. Clinically, 79% of the cases presented
with meningitis predominantly and 21% had sepsis (+/−) meningitis.
We had an average of 19 patients for each year (range, 10−26 patients).
Most of the patients (70%) were from rural communities. The highest
incidence (60% of cases) was recorded in the late winter and early
spring months. The male to female ratio was 1:1. Half of patients
had less than 2 years old. The median age of patients was 24 months
(range, 3 weeks to 18 years). Clinical manifestations included meningitis
in 150 patients (79%), rash in 127 (67%), hypotension in 36 (19%),
seizures in 28 (15%), respiratory failure in 20 (10%), septic arthritis in
3 (1.6%). Microbiological conﬁrmation was based on direct microscopic
examination after Gram staining in 51.5% of the cases, culture in
36%, and detection of soluble antigens in cerebrospinal ﬂuid in 34.5%.
Serogrouping was available on 95 (50%) of the patients. Serogroup B
was isolated in 46 (48%) of 95 patients. The clinical form was severe in
40 cases (21%). Unfavourable outcomes occurred in 24 of 191 patients,
including a mortality rate of 11%. Among the survivors, three patients
had hearing loss. Only 77 (40.3%) of all cases was treated before
admission, 60 (77.9%) of them receiving preadmission b-lactamins. The
treatment was based upon penicillin G (49%). All isolates were sensitive
to penicillin. The average duration of antibiotic therapy was 8±4.3 days
(m±SD). In 97 cases (51%) we administrated cortisone therapy.
Conclusion: Due to variable clinical manifestations and preadmission
antibiotherapy, early diagnosis is sometimes difﬁcult; that’s why
laboratory conﬁrmation should be improved by the introduction of PCR-
based techniques.
P1950 Ampicillin or penicillin for empiric treatment of early-onset
neonatal sepsis: inﬂuence on bowel colonisation by aerobic
and facultative anaerobic bacteria
Y. Parm °, E. Sepp, T. Metsvaht, M.L. Ilmoja, H. Pisarev, M. Pauskar,
I. Lutsar (Tartu, EE)
Objective: Narrow spectrum penicillins have been shown to have
least impact on bowel colonisation in neonates. The most widely
recommended empiric regimens of penicillin or ampicillin combined
with gentamicin have never been compared in these terms.
We aimed to compare the ampicillin with penicillin in terms of inﬂuence
on bowel colonisation by opportunistic microorganisms including
ampicillin resistant Enterobacteriaceae in neonates with suspected early
onset neonatal sepsis and to identify risk factors interfering with
colonisation process.
Methods: A cluster-randomised two-centre switch-over study included
all neonates hospitalised from August 2, 2006 until November 30, 2007
and needing empiric therapy with ampicillin or penicillin and gentamicin.
Microbes were identiﬁed on the genus and species level using biweekly
collected rectal swabs. The ratio of colonising days to 100 PICU days
(total colonisation density – TCD) and number of patients colonised was
used to compare the two regimens.
Results: Each treatment group included 139 neonates. Compared to
penicillin the mean TCD of Klebsiella pneumoniae and Candida
spp. was higher but that of K. oxytoca, Acinetobacter baumannii,
Enterococcus spp, Streptococcus spp and S. aureus was lower in the
ampicillin group. The ratio of patient colonised by ampicillin resistant
Eneterobacteraciae in both treatment groups was similar. Multivariate
logistic regression analyses identiﬁed ampicillin as an independent factor
favouring colonisation with K. pneumoniae (OR 2.41; 95%CI 1.1−5.27)
and preventing that with S. aureus, enterococci and ampicillin resistant
A. baumannii (OR 0.24; 95%CI 0.09–0.68; OR 0.48; CI 95% 0.27–0.87
and OR= 0.11; 95%CI 0.002–0.78, respectively).
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Conclusion: Ampicillin and penicillin when combined with gentamicin
are associated with different bowel colonisation pattern by individual
microorganisms but neither regimen appears to have a clear disadvantage
of out-selecting ampicillin resistant Enterobacteriaceae.
P1951 Strategies for the sequence study of the exposure to
pulmonary tuberculosis in a neonatal unit
C. Molera °, A. Mirada, R. Font, M. Olmo, L. Canales, J.L. de Marco
(Terrassa, ES)
Objectives: Almost the 50% of newborns exposed to tuberculosis
disease develop lung disease and 20% can develop disseminated
disease/meningitis. On the other hand, tuberculin skin test (TST) has very
low sensitivity before 6 month age. The recommended strategy in this
population is to start an empirical treatment early. The aim of our study is
to assess the incidence of infection/latent disease in a cohort of newborns
exposed to a smear-negative nurse with tuberculosis lung disease (culture
positive in samples obtained by bronchoscopy) in a neonatal unit, as well
as to describe the diagnostic and therapeutic management.
Methods: All the newborns exposed at least 1 day to the index
case in the 3 previous months to her diagnosis (January–April 2008)
were investigated. The study strategy consisted in a TST, blood
analysis at inclusion and 1 month after to exclude adverse effects and
chest radiograph (Rx). Chest Tomography (CT) and Quantiferon were
performed in case of misdiagnosis. Once tuberculous disease was ruled
out, cases initiated prophylaxis with isoniazid orally (10mg/kg/d) up to
6 months of age, then a second TST was performed. TST was assessed
on all healthcare workers.
Results: In the study period, 60 newborns were exposed to the index
case. The patients were included and studied in a period of 3 weeks. The
TST was negative at the time of inclusion and at 6 months in all cases
(1 death for underlying pathology before the second TST). One case
had abnormal Rx, with subsequent CT and Quantiferon normal tests.
53 (88.6%) patients accepted to start prophylaxis; in 2 (3%) prophylaxis
was contraindicated for underlying pathology and in 5 (8%) there was
negative by parents. Blood analysis one month after inclusion was
performed in 47 out of 53 (88.6%) newborns in isoniazid treatment, and
in only one case (2%) prophylaxis was stopped for hypertransaminaemia.
78% of the contacts ﬁnished prophylaxis. 5 patients (9%) discontinued
prophylaxis by decision of the parents. After 9 months of follow up, no
cases of tuberculosis are reported regardless of having done prophylaxis.
Conclusions: Given the limited bibliography, the small size of our
sample and the potential severity of the disease we feel justiﬁed the
prophylaxis until 6 months age and close follow up of the exposed cases.
The realisation of TST at the time of inclusion and at 6 months age, as
well as chest radiograph, seems to be a valid strategy to exclude the
disease in this population.
P1952 Childhood brucellosis in northern Greece
D. Rallis °, O. Tsiatsiou, O. Karamitsiou, M. Spanidou, A. Kansouzidou,
J. Kavaliotis (Thessaloniki, GR)
Objectives: Human brucellosis is a common zoonotic infection
worldwide. Greece is one of the countries of the European Union with
high incidence of the disease. The aim of this study was to evaluate the
epidemiological, clinical and laboratory characteristics of brucellosis in
children hospitalised in our Department.
Methods: We evaluated the records of 164 children, up to 14 years
old, with brucellosis, who were hospitalised in our Department from
1980 to 2008. Inclusion criteria were: 1) clinical picture compatible with
brucellosis, 2) Wright seroagglutination test positive with titers 1:160 or
above 3) blood culture positive for brucella, 4) PCR positive for brucella.
Patients who fulﬁlled two or more of the above criteria were included in
the research.
Results: The 68% of the patients were males. The median age of children
was 8.5 years (2 months − 14 years). Consumption of unpasteurised
milk or dairy products was reported to 47% of patients, whereas 44%
of the cases were related to other intrafamiliar instances. Fever was
the most common symptom, (81%), with mean duration of 16 days.
Other manifestations included arthralgia (59%), night sweets (43%),
hepatomegaly (57%), splenomegaly (35%), lymphadenopathy (11%) and
limp (12%). Brucella spp. was isolated in 30% of the patients. The course
of the disease was good in the majority of patients. Complications were
observed only in 3%: meningitis (2), pneumonia (1) and osteochondri-
tis (2). The treatment schedule we used was doxycycline p.o. for 21 days
plus streptomycin IM for 14 days. Recurrences were noted in 7.5% of the
patients. In most cases the main symptom was fever of short duration.
Conclusion: Childhood brucellosis remains a common health problem in
Greece. The disease manifests itself mostly mildly in children, with a low
rate of complications. The treatment with doxycycline plus streptomycin
is very effective with a recurrence rate that is lower than that of other
therapeutic schedules, despite the shortness of the course. However,
because this duration is shorter than that of ofﬁcial guidelines, perhaps
it needs a more extended study for a full evaluation.
P1953 Study of bacterial conjunctivitis in neonates with special
reference to Chlamydia trachomatis
S. Tabatabaei °, A. Afjee, A. Karimi, F. Fallah, N. Tahami Zanjani
(Tehran, IR)
Background: Conjunctivitis is the most common eye disease of
newborns. Conjunctivitis during the neonatal period is usually acquired.
The most common bacterial infections can cause serious eye damage
are gonorrhoea (Neisseria gonorrhoeae) and Chlamydia (Chlamydia
trachomatis), which can be passed from mother to child during
birth. The incidence of gonococcal ophthalmia neonatorum decreased
in industrialised countries secondary to widespread use of silver
nitrate prophylaxis and prenatal screening and treatment of maternal
gonorrhoea. In comparison, chlamydia trachomatis is the most common
organism causing ophthalmia neonatorum in the USA.
This study is to identify the prevalence of the causative agents of
ophthalmia neonatorom, chieﬂy Chlamydia trachomatis in two hospitals
(moﬁd & mahdieh) on 2007–2008.
Methods and Materials:We will study 114 neonates with conjunctivitis
in ﬁrst 4 weeks of life. We obtain two swab specimens containing
epithelial cells of conjunctiva. Laboratory diagnosis was based on
bacterial culture and Gram staining. The isolated bacteria were identiﬁed
using standard procedures. For identifying Chlamydia trachomatis we
will use cell culture (gold standard) and Giemsa staining.
Results: Of 114 neonates with positive eye swab or conjunctival scraping
cultures, Chlamydia trachomatis was the second most common (n = 17,
14.9%) cause of acute neonatal conjunctivitis after coagulase-negative
staphylococci (n = 86, 51%). Bacterial cultures were negative in 23.1%
of neonates despite clinical signs of conjunctivitis. The median age of
positive Chlamydia trachomatis neonates was day 9 of life (range, day
1−30).
Conclusion: Based on previous studies, prevalence of Chlamydia
trachomatis in neonates was 6−21%. This prevalence is 14.9% in
our study. Chlamydia trachomatis was the second most common
causative organism in acute neonatal conjunctivitis. Gram Positive Cocci
were the most common cause of bacterial infections. Therefore we
recommend doing giemsa staining for the characteristic intracellular
plasmic inclusions and tissue culture techniques for the organism from
a conjunctival swab.
P1954 Epidemiology of bacterial hand infections in a paediatric
population
M. Matsas, N. Paleologou, M. Papadimitriou, A. Kallimani, E. Lebessi °
(Athens, GR)
Objectives: Hand infections pose difﬁcult diagnostic problems because
of the wide microbiology and anatomy involved. The aim of this study
was to evaluate the bacteriological spectrum and the antimicrobial
susceptibility patterns in infants and children with bacterial hand
infections, referred for care at “P. & A. Kyriakou” Children’s Hospital.
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Methods: All specimens from hand infections operated on in the
outpatient clinic and the department of orthopedics from January 1, 2007
to October 31, 2008, were reviewed retrospectively, using the laboratory
archives and the patient charts. Culture of specimens and identiﬁcation
of bacteria were performed by conventional methods. Antimicrobial
susceptibilities of isolates were determined by disk diffusion method
according to the CLSI guidelines.
Results: Totally, 142 specimens from an equal number of children
[82 boys (56%) and 60 girls (44%)] were recorded. The median age
of the patients was 5.5 years (range 9 months to 14 years). Most
of them were presented with paronychia. One to ﬁve bacteria were
isolated from 113 specimens (79.6%), while in 29 (20.4%) there was
no isolation of any bacterial pathogen. The majority of infections were
monomicrobial (69/113, 61%), with most frequently isolated bacteria
Staphylococcus aureus (49/69, 71%) and Streptococcus pyogenes (18/69,
26%). In mixed infections (44/113, 39%) the most frequently isolated
bacteria were also S. aureus (31/44, 70%) and S. pyogenes (21/44,
48%), followed by anaerobes (15/44, 34%) and Eikenella corrodens
(8/44, 18%). The majority of infections occured in spring and
summer, with higher incidence of S. aureus in summer months. Of
S. aureus isolates, 89% (71/80) were found resistant to penicillin and
35% (28/80) to methicillin (MRSA). Of MRSA strains there was a
high prevalence (85%) of the resistant phenotype penicillin/oxacillin/
fusidic acid/kanamycin/tetracycline, which commonly characterises the
community-acquired strains (CA-MRSA). The resistance to macrolides
among S. aureus isolates was 16.25% [I-phenotype 5% (4/80), MLSBi
(inducible resistance) 8.75% (7/80) and MLSBc (constitutive resistance)
2.5% (2/80)]. Of S. pyogenes isolates, 23% were resistant to macrolides
[MLSBi 18% (7/39) eae MLSBc 5% (2/39)].
Conclusions: Hand infections, especially at preschool age, are often
monomicrobial and are usually caused by common ﬂora of the skin and
mouth such as S. aureus and S. pyogenes.
P1955 Prevalence of coronavirus subtypes infection in paediatric
patients by real-time RT-PCR in Slovenia
M. Jevsˇnik °, T. Ursˇic, N. Zˇigon, M. Praprotnik, U. Krivec, A. Borinc
Beden, M. Petrovec (Ljubljana, SI)
Objectives: Acute respiratory viruses are a major cause of morbidity and
mortality in humans worldwide and most acute respiratory infections are
caused by viruses. It is estimated that 10% of all viral respiratory tract
infections of hospitalised children are caused by four genotypes of human
coronaviruses (HCoVs): HCoV-229E, HCoV-OC43, HCoV-HKU1 and
HCoV-NL63. Coronaviruses are enveloped, positive-strand RNA viruses
belonging to the order Nidovirales, family Coronaviridae and genera
Coronavirus. The aim of the present study was to estimate the prevalence
of HCoVs in a cohort of hospitalised infants and young children with
symptoms of respiratory tract disease from June 2007 to May 2008.
Methods: The samples (1076) from children (834) were sent to
laboratory for routine detection of respiratory viruses. From 1076
samples there were, 717 (66.6%) nasopharyngeal swabs, 228 (21.2%)
throat swabs, 92 (8.5%) tracheal aspirates and 39 (3.6%) others. Female
to male ratio was 1:1.35. All patients (834) were distributed in to
ﬁve age groups. Total nucleic acid was isolated from 200ml of each
respiratory specimen on MagNa Pure Compact (Roche Diagnostics,
Mannheim, Germany) according to manufacturers instructions. All four
human coronaviruses were detected by real-time RT-PCR assay using
eight primers and 3 MGB probes to amplify 85- to 100 bp fragments of
the polymerase 1b gene.
Results: Human coronavirus RNA was detected in 5.3% of samples. The
highest prevalence of infections (8.3%) was found in children between 2
and 3 years of age. Coronaviruses were detected in every month except
June, with a maximum number in February, 20 (35.1%) of 57 positive
specimens. Of the 57 specimens positive for a coronavirus, 9/1076
(0.8%) were HCoV-229E, 6/1076 (0.6%) were HCoVNL63, 29/1076
(2.7%) were HCoVHKU1 and 13/1076 (1.2%) were HCoVOC43.
Conclusion: All four genotypes of coronaviruses were detected
in samples from hospitalised children. These results conﬁrms that
coronaviruses are important human pathogens associated with acute
respiratory tract infections in Slovenian children.
P1956 Prevalence of human bocavirus in paediatric patients with
respiratory infection in Slovenia
T. Ursˇic °, M. Jevsˇnik, N. Zˇigon, M. Praprotnik, U. Krivec, A. Borinc
Beden, M. Petrovec (Ljubljana, SI)
Objectives: Human Bocavirus (HBoV), was discovered in 2005 in
children with lower respiratory tract infections (LRTI). Since then, the
respiratory infections with HBoV has been reported worldwide with
frequencies ranging from 1.5% to 19.3% in respiratory samples of
children. Aim of our study was to estimate incidence of HBoV infections
in Slovenian children.
Methods: We tested respiratory samples of paediatric patients hospi-
talised in University Children’s hospital in Ljubljana with respiratory
tract infection from July 2007 to June 2008. From total of 820 respiratory
samples collected from 688 patients, there was 76.3% nasopharyngeal
swabs, 19.5% throat swabs and 4.2% of other samples. For DNA
extraction 195ml of respiratory specimen and 5ml of Equine herpesvirus
1 (EHV1) as internal control was used. DNA was eluated in 100ml
eluation buffer. DNA isolation was performed on MagNa Pure Compact
automatic nucleic acid extraction platform. NS1 region (88 bp) of HBoV
DNA was ampliﬁed by real-time PCR using Taqman probe. The amount
of virus in each sample was assesed quantitatively using a part of cloned
HBoV genome as a standard.
Results: Overall, 175 of 820 samples (21.5%) were positive for HBoV
by real-time PCR. The highest percentage of positivity was found in
children in the age group between 13−24 months (33.3%). A seasonal
distribution was evident and number of positive samples rose from
October to March with the peak in December.
Conclusion: HBoV was frequently detected in respiratory samples from
Slovenian hospitalised paediatric patients with respiratory infection.
Although we found the highest percentage (21.5%) of HBoV DNA
in paediatric samples so far, 47.4% of those are in the group with
the lowest amount of HBoV DNA detected. The study showed that
infections with HBoV are more frequent during the late autumn and
winter time in children age group between 13−24 month. We conﬁrm that
HBoV is widespread respiratory tract infection in children. The clinical
signiﬁcance of the low level HBoV DNA in majority of respiratory
samples warrants further studies.
P1957 Clinical course and sequelae in tick-borne encephalitis in
children in southern Moravia (Czech Republic)
L. Krbkova °, H. Stroblova on behalf of EMESG
Objectives: The aim of the study was to characterise the clinical course
of the illness in children and laboratory ﬁndings including CSF, to
identify neurological sequlae and duration of IgM positivity.
Patients and Methods: We evaluated demographic and epidemiologic
data of 94 children, signs and symptoms at admission, clinical course
during hospital stay, laboratory ﬁndings and sequelae. Serology for
neurotropic viruses including TBEV and for antiborrelial antibodies was
performed looking for coinfections. CSF was analysed for cells, protein,
glucose and TBEV speciﬁc IgM antibodies. Children were followed up
for at least 12 months.
The data were analysed with StatSoft 7. Quantitative data were compared
by Mann-Whitney test and qualitative data by the Fisher’s exact test.
Two-tailed p-values of 0.05 were interpreted as statistically signiﬁcant.
Results: A total of 445 children were admitted for aseptic meningitis.
94 cases with TBE represent 21% of the viral neuroinfections among
children in the Southern Moravian region.
The clinical course of the illness was biphasic in 61% of cases. The
second phase was characterised by headache in 96%, high fever in 99%,
vomiting in 55% and meningeal signs in 90% of children. Meningitis
(74%) dominated over meningoencephalitis (14%).
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No difference in clinical parameters between children with meningitis
compared to meningoencephalitis was found. Disturbances of concious-
ness (p< 0.001), seizures (p = 0.03) and paretic involvement (p = 0.01)
were the only exceptions.
Inﬂammatory changes in CSF were found in 89% of children. 81%
of children had elevated cell count for polymorphonuclears and for
lymphocytes. Abnormal protein concentration in the CSF (>0.45 g/l)
was detected in 55/94 (59%) of children. IgM antibodies against TBEV
were found early in the second phase in 89% of children.
Conclusions: Severe sequelae persist in two children (2%) while in three
children (3%) the sequelae were classiﬁed as mild or moderate. Acquired
aphasia, lasting tremor of the upper extremities, language deterioration,
inversion of sleep and wakefulness, abnormal hyperkinetic movements
and vertigo were found as permanent, but not progressing sequelae.
There is no known relationship between the sequlae of TBE and the
length of serological positivity of IgM antibodies. Immunological status
in children with sequelae and those with prolonged duration of IgM
seropositivity did not show any deﬁciency or autoimmune antibodies.
P1958 Vertical transmission of CMV in HIV seropositive mothers
at a Bangkok, Thailand hospital
P. Bhattarakosol °, P. Prisuwanna (Bangkok, TH)
Objectives: Cytomegalovirus (CMV), one of the opportunistic infections
in HIV patients is known to cause a congenital infection. Vertical
transmission of CMV can happen via transplacenta or in utero or
perinatal transmission. The virus can infect several types of tissue and
organs therefore variety of diseases with different symptoms can occur,
varying from asymptomatic to severe leading to death. Transmission
rate of CMV may be high up to 20−40% in primary infected mothers
whereas only 0.2−2.2% has been reported in mothers with recurrent
infection. Increase vertical transmission rate was previously reported
in HIV infected mothers and it is believed that CMV may play role
in the outcome of the diseases developed in newborns. Therefore, the
prevalence of CMV infection of the HIV seropositive pregnant women
and vertical transmission of CMV in newborns were investigated.
Methods: 43 HIV seropositive mothers who delivered at King
Chulalongkorn Memorial Hospital, Bangkok, Thailand during January
2005 to June 2006 were recruited. EDTA blood and clotted blood were
obtained from mother and newborn on the day of birth or within 72 hours
after delivery. Urine from newborn was collected during the same period
of time. The sera were determined for the presence of anti-CMV IgM
and IgG by ELISA method. Plasma and white blood cells (WBC) were
separated from EDTA blood. All clinical samples were extracted for viral
DNA and detected for CMV-DNA by PCR.
Results: The prevalence of CMV infection in HIV infected mothers
was 97.67% (42/43). Neither mothers nor newborns had anti-CMV
IgM. CMV-DNA was detected in 17 (39.53%) newborn’s samples, i.e.,
53% (9/17) in WBC; 47% (8/17) in plasma and 59% (10/17) in urine.
Three cases (17.65%) were found CMV-DNA in all 3 samples, 4 cases
(23.52%) were found in WBC and urine and the rest (58.82%, 10/17)
was found in one of the 3 samples. Only 12 out of 17 mothers were able
to detect CMV-DNA, 2 in plasma, 2 in plasma and WBC and 8 in WBC.
Conclusion: Almost all Thai HIV seropositive mothers in this study had
already been infected with CMV. Urine is the best specimen for detection
of CMV-DNA in newborn. The vertical transmission of CMV was shown
at least 17.65% and possible up to 58.82%. No clinical symptoms was
observed in all 17 newborns suggesting that they were asymptomatic
CMV infection.
P1959 Epidemiological and clinical aspects of measles cases
hospitalised in a Bucharest infectious diseases clinic in
2005, during the measles outbreak in Romania (2005–2006)
R. Botgros °, S. Florescu, A.M. Nicolescu, C.P. Popescu, P.I. Calistru,
E. Ceausu (Bucharest, RO)
Introduction: Measles is a disease affecting mostly children and
possibly causing serious complications, mainly in the malnourished and
immune compromised. It is the deadliest childhood rash illnesses, despite
of being vaccine preventable. Starting with April 2005 an increase in
the number of probable measles cases presenting to our hospital ward
was observed. The hospitalisation of measles cases is mandatory in
Roumania, and all presented patients were admitted in the hospital.
Objectives: Description of the basic epidemiological and clinical
features of the measles patients admitted during 2005 in the “Dr. Victor
Babes” Hospital Bucharest.
Methods: Retrospective clinical study of 444 measles patients admitted
in our hospital between January and December 2005. Diagnosis of
measles was established according to the CDC measles case deﬁnition.
Laboratory conﬁrmation was made by measuring the IgM antibodies
against measles in the patient sera. Viral cultures were not performed.
Rubella antibodies were measured at the same time.
Results: A total of 444 measles cases were admitted (9.7% of all
4601 hospitalised in Roumania in 2005), both children and adults.
No imported case occurred. Fig.1 shows the case numbers by month
of onset. The hospitalisation period varied between 1 and 33 days
(mean 7.4 days). Almost 90% of cases were under 15 years old and
16.4% were under 1 year of age. Information on vaccination status
was provided in 39.6% of the cases, with only 9% of the cases
having been vaccinated with at least one dose. The most frequent
complications were measles pneumonia (57.9% over all, of which 22.6%
in the 0−1 years and 27.2% in the 1−2 years age group), followed by
rhinoadenoiditis and conjunctivitis (5.4% each).14.2% of all patients
were malnourished or immune deﬁcient. 50 cases were diagnosed as
nosocomial infections (epidemiological linkage proven) with additional
17 patients with possible nosocomial measles accounting for 15% of all
patients. No deaths were observed.
Figure 1. Measles occurrence by month of admission.
Conclusions:
1. Despite the isolation measures, 15% of our patients developed
nosocomial measles, probably due to the very high contagiosity index,
combined with the large number of receptive individuals.
2. Data from our patients suggest a possible too low coverage of
vaccination despite extensive vaccination campaigns in the last
15 years.
3. The most frequent complication was measles pneumonia which
affected mostly the 0−2 years age group.
4. Mortality in our patient group was 0%.
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P1960 Aetiology of fever in children from urban and rural Tanzania
V. D’Acremont °, M. Kilowoko, E. Kyungu, S. Philipina, W. Sangu,
J. Kahama-Maro, P. Kibatala, E. Kahigwa, C. Lengeler, B. Genton
(Basel, CH; Dar es Salaam, Ifakara, TZ)
Objectives: Several studies have looked at the proportion of either
malaria, pneumonia, diarrhoea or bacteraemia among fever cases in
Africa but none of them has looked at the overall spectrum of aetiologies.
We aimed at investigating the precise cause of fever episodes in children
attending an outpatient clinic in urban (Dar es Salaam) and rural settings
(Ifakara) in Tanzania.
Methods: All consenting children aged 2 months–10 years with an
axillary temperature >38ºC were recruited, except for those that required
immediate supportive treatment. A detailed medical history and clinical
examination were done to identify obvious foci of infection. A blood
sample was taken to perform rapid tests for malaria and typhoid, blood
culture as well as serological and molecular analyses. All had a throat and
nasal swab taken for molecular investigation of respiratory pathogens.
Urine was taken when no obvious cause of fever was found on clinical
examination and a stool sample when diarrhoea was present. A chest
X-ray was performed when IMCI criteria for clinical pneumonia were
met. Each diagnosis was assigned a probability level (high, moderate,
low) on the basis of pre-deﬁned criteria.
Results: 1010 children were recruited, 510 in DSM and 500 in Ifakara.
Preliminary results (prior to any molecular analysis or serologies) on the
causes of fever (of high probability only) were as follows: 43% had acute
respiratory infection (ARI) [30% URTI, 13% LRTI (6% clinical pneumo-
nia and 7% pneumonia conﬁrmed by X-ray)], 12% malaria, 9% diarrhoea
(3% rotavirus and 6% bacterial or unknown), 8% urine infection, 4% ty-
phoid, 2% skin infection, 1% occult bacteraemia and 21% still unknown
at this stage. 8% had more than one diagnosis (high probability).
Conclusion: These results provide for the ﬁrst time an accurate picture
of the respective causes of fever in African children. As expected, ARI
contribute to the largest burden of disease, most of them being URTI.
There was a sizeable proportion of fevers due to typhoid documented
by the rapid test for most of them. Malaria conﬁrmed to be lower than
generally thought. Results of molecular analyses and serologies will be
presented and will provide further insight on the respective contribution
of bacteria and viruses, a critical issue for appropriate management of
fever and rational use of antibiotics.
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P1961 Candidaemia in Finland, 1995–1999 versus 2004–2007
E. Poikonen °, O. Lyytika¨inen, P. Ruutu (Vantaa, Helsinki, FI)
Objectives: We studied the epidemiology of candidaemia in Finland
(population, 5.3 million) by assessing the incidence and outcome as well
as causative Candida sp. during 2004–2007 and compared the results to
our previous study from years 1995–1999.
Methods: Since 1995 all Finnish clinical microbiology laboratories have
notiﬁed all isolations positive for Candida sp. from blood to the National
Infectious Diseases Register. Data collected include date of isolation,
date of birth, sex, type of specimen, and place of treatment; since 2004,
dates of death have been available from the Population Information
System. A case of candidaemia was deﬁned as a patient with at least one
blood culture positive for Candida sp. Notiﬁcations of the same Candida
sp. within 3 months from the ﬁrst diagnostic sample in the same person
were deﬁned as one case.
Results: During 2004–2007, a total of 603 cases of candidaemia were
identiﬁed. Median age of case-patients was 64 years (range 0−94 years)
and 56% were male. The average annual incidence rate was 2.86 per
100,000 population (range by year, 2.59–3.09). The rate was higher in
males than in females (3.27 vs. 2.47), especially among patients aged
<1 and >65 years. The highest rate was observed in males >65 years
(12.23), and lowest in patients aged 1−15 years (0.25). The most
frequent causative species was C. albicans (67%); C. glabrata ranked
the second (19%), followed by C. parapsilosis (5%), C. krusei (3%) and
C. tropicalis. The one-month case fatality varied between 33−38%.
Compared to years 1995–1999, the average annual incidence rate
increased from 1.9 (range by year 1.7−2.2) to 2.86 during 2004–2007.
According to sex the rate was higher in males than in females during
both periods of observation. During 1995–1999, the highest rate were in
males aged <1 year (11.9) and >65 years (7.4), although the increase
in incidence occurred in males aged 16−65 years (from 1.0 to 2.4).
C. albicans remained the common causative species (70−67%), but the
proportion of C. glabrata increased from 9% during 1995–1999 to 19%
during 2004–2007, and the proportion of C. krusei diminished from 8%
to 5%, respectively. As a whole the proportion of non-albicans spp. was
stable.
Conclusions: The incidence of candidaemia increased in Finland
compared to 1990 s. The increase in incidence was associated with males
aged >65 years. The proportion of C. glabrata rose, in spite of no shift
towards non-albicans species. Crude mortality remained high.
P1962 The pattern of candidaemia in a tertiary referral hospital
in the United Kingdom
I. Das °, P. Jumaa, P. Nightingale, M. Patel (Birmingham, UK)
Objectives: Despite advances in diagnostic technology and antifungal
agents, candidaemia continues to be associated with a high mortality.
We analysed the epidemiology of candidaemia in our institution with an
aim to optimise the management of this infection.
Methods: A prospective observational study of candidaemia over
33 months: 1 October 2005 to 30 June 2008.
Results: 107 episodes of candidaemia were detected in 102 patients. The
incidence of candidaemia was 10.9 episodes/100,000 bed-days. 88% of
episodes were hospital acquired and 51% of episodes were from intensive
care units (ICU). Non-Candida albicans species comprised 57% of the
episodes. Overall, C. albicans was the commonest species accounting
for 43% of episodes. The next commonest species were C. glabrata and
C. parapsilosis accounting for 31% and 20% of episodes respectively.
C. tropicalis, C. krusei, C. norvegensis and C. lusitaniae together
comprised 7% episodes. During the ﬁrst 15 months of the study period in
2005–2006, C. glabrata was the commonest species isolated. No resis-
tance to amphotericin, ﬂuconazole, voriconazole or caspofungin was de-
tected in the C. albicans isolates. Resistance to amphotericin was not de-
tected in any of the Candida species. Reduced susceptibility to ﬂucona-
zole was detected in 30% of C. glabrata isolates. The most frequently
identiﬁed focus of infection was the intravascular device (IVD) followed
by a respiratory focus (35% and 21% of episodes respectively). A respi-
ratory focus of candidaemia was associated with a higher mortality com-
pared with IVD or an unidentiﬁable focus (53% vs 27% and 37% respec-
tively). Delay in the initiation of antifungal therapy for >24 hours after a
positive blood culture report occurred in 19% episodes. Four-week mor-
tality was 37%. Multivariable analysis revealed association of advanced
age and septic shock with mortality (P = 0.003 and 0.038 respectively).
Conclusion: Candidaemia remains an important cause of nosocomial
infection with a high mortality. We report a higher proportion of non-
C. albicans species, especially C. glabrata than that reported from other
UK studies. This study highlights that the pattern of Candida species
isolated from candidaemia is not always predictable from national studies
and emphasizes the need for local surveillance. Effective measures
against candidaemia should be considered in the empirical management
of hospital acquired sepsis especially in ICU patients and the elderly.
P1963 Prevalence of Candida metapsilosis and Candida orthopsilosis
isolates in a Spanish yeast stock collection
I. Miranda-Zapico, E. Eraso °, C. Marcos-Arias, J.L. Herna´ndez
Almaraz, A.J. Carrillo Mun˜oz, G. Quindo´s (Bilbao, Barakaldo,
Barcelona, ES)
Objectives: To study the prevalence and antifungal susceptibility of
Candida metapsilosis and Candida orthopsilosis among clinical isolates
previously identiﬁed as Candida parapsilosis.
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Methods: One hundred and twenty-one recent clinical isolates from
our stock collection yielded during the last years were studied. The
isolates included 72 from blood, 22 from genitalia, 19 from mouth
and 8 from different clinical specimens. C. parapsilosis ATCC 22019
and ATCC 90018, C. metapsilosis ATCC 96143 and ATCC 96144
and C. orthopsilosis ATCC 96139 and ATCC 96141, were included
as reference strains. Isolates were identiﬁed as C. parapsilosis by
conventional mycological methods. These isolates were differentiated
by a two-step DNA-based identiﬁcation test and AFLP described by
Tavanti et al. (Candida orthopsilosis and Candida metapsilosis spp. nov.
to replace Candida parapsilosis groups II and III. J Clin Microbiol
2005; 43: 284–292). Brieﬂy, a 716-bp fragment of the SADH (secondary
alcohol dehydrogenase) gene was ampliﬁed, puriﬁed, and digested with
BanI. C. parapsilosis, C. metapsilosis, and C. orthopsilosis SADH
amplicons contained, respectively, one, three, and zero BanI restriction
sites.
Results: One hundred and sixteen isolates were C. parapsilosis sensu
lato (95.9%), 3 C. metapsilosis (2.5%) and 2 C. orthopsilosis (1.6%).
One isolate each of C. metapsilosis were from blood, genitalia and
faeces. C. orthopsilosis was isolated from blood and genitalia. The
antifungal susceptibilities to amphotericin B, anidulafungin, ﬂuconazole,
micafungin, and voriconazole of both blood isolates of C. metapsilosis
and C. orthopsilosis and of 28 randomly-chosen C. parapsilosis blood
isolates were tested by the CLSI M27A3 method. These isolates showed
the same antifungal susceptibility patterns than C. parapsilosis blood
isolates with a non-signiﬁcant decrease of anidulafungin and micafungin
MICs and with a non-signiﬁcant increase of ﬂuconazole MICs.
Conclusion: C. metapsilosis and C. orthopsilosis were identiﬁed as
the cause of 2.8% of the invasive candidiasis previously attributed to
C. parapsilosis. C. metapsilosis and C. orthopsilosis were also implicated
in cases of superﬁcial candidiasis.
Funding: Projects GIC07 123-IT-222−07 (from the Departamento
de Educacio´n, Universidades e Investigacio´n, Gobierno Vasco) and
PI061895/2006 (from the Fondo de Investigacio´n Sanitaria del Ministerio
de Sanidad y Consumo de Espan˜a).
P1964 Do candiduria predict candidaemia in intensive care units
in a Danish tertiary-care hospital?
J.K. Møller ° (Aarhus, DK)
Objectives: Invasive mycoses are life-threatening opportunistic infec-
tions and have emerged as a major cause of morbidity and mortality in
critically ill patients. This study aimed to determine whether candiduria
is associated with the occurrence of nosocomial candidaemia and may
serve as an early marker of disseminated infection.
Methods: A retrospective observational study. Microbiological data on
patients in 4 ICUs at Aarhus University Hospital (AUH) during 1992–
2008 were compiled from the laboratory information system MADS.
AUH is a 1200 bed tertiary care hospital. All patients with at least one
blood and/or one urine culture positive for Candida sp. were included.
Results: During the study period from 1992 to 2008, 306 patients
had candidaemia and 892 had candiduria. The 30-days crude mortality
rate for candidaemia at the AUH ICUs was about 40% during the
period 2000–2005. Candida spp. became the most common cause of
bloodstream infections in the ICUs at the end of the study period,
less than 2% in 1992 and 21% in 2008. Candida albicans was by
far the predominant species, causing about two-thirds of all cases of
candidaemia (70%) and candiduria (68%). Other frequently isolated
candida species in blood were C. glabrata (15%) and C. krusei (2%).
Among the 306 patients with candidaemia, 124 (40%) had also
candiduria but 57 of the 124 patients were cultured after the candidaemia
was detected, 146 (48%) had their urine cultured but were culture-
negative with candida spp., and 36 (12%) had not been examined
for candiduria. Among the 892 patients with candiduria, 67 (8%) had
subsequently a candidaemia.
Thus on one hand, candiduria served as an early marker of candidaemia
in 25% (67/270) of the cases. On the other hand, 92% (825/892) of
patients with candiduria had not a candidaemia detected subsequently.
Conclusions: The data indicated that candiduria is not a reliable
predictor of candidaemia. Furthermore, the urinary tract was probably
the source for the candidaemia in less than half of the cases observed.
Continued efforts to ﬁnd better predictors of candidaemia are needed
in order to identify patients at risk and to develop empirical treatment
protocols to reduce the current high incidence and mortality of
candidaemia in ICUs.
P1965 A most unusual case of Candida parapsilosis endocarditis
in intravenous drug user
A. Guleri, M. Przybylo °, R. More, F. Sogliani, M. Walsh, R. Palmer
(Blackpool, UK)
Background: Candida endocarditis is one of the most serious
manifestations of candidiasis with mortality in excess of 50% without
surgery and 41% with combined therapy and surgery. We present here an
unusual case of Candida parapsilosis [CP] endocarditis in an intravenous
drug user [IVDU]who miraculously survived/improved over 9-months
with only intermittent antifungal treatment during three admissions/self
discharge cycles before receiving surgical treatment.
Case study: A 47-year-old IVDU male underwent treatment for
C. parapsilosis aortic and mitral valve endocarditis. He intermittently
admitted and self discharged on 4-occasions [stay 22d; 5d; 24d and
83 days] between Nov 06−07. He was ﬁrst admitted with a history
of headache, confusion and fever. CT brain revealed temporal lobe
infarct and echocardiogram was consistent with moderate to severe aortic
regurgitation [AR]; Mitral valve [MV] changes. His cerebrovascular
event delayed his surgery during 1st admission. C. parapsilosis [CP] was
isolated from total 10 sets of blood cultures [Nov 06–Sept 07] during
the 4 admissions. Patient was partially treated during these hospital
admissions with amphotericin, ﬂucytosine, ﬂuconazole and caspofungin.
He refused to accept any treatment post self discharge and continued
IVDU with amphetamines. After worsening of his ECHO ﬁndings during
ﬁrst 3 admissions; he presented in July 2007 [admission 4] with chest
pain; minor cardiac vegetation and improved ﬁndings on ECHO; white
cells 7; CRP 7 and then underwent a mitral and aortic valve replacement
in Sept 2007. He was precribed prolonged ﬂuconazole at discharge post
surgery.
Figure 1. TOE 21/11/06 conﬁrming vegetation affecting 2 leaﬂets of the
aortic valve associated with severe aortic regurgitation. Some oedema
of the aortic valve annulus was noted with suspicion of early abscess
formation. 1 cm vegetation noted.
Discussion: IVDUs are at an increased risk for infections through the
unsterilised injection technique. fungal endocarditis is often difﬁcult to
diagnose because the presentation may be nonspeciﬁc and the disease
typically occurs in otherwise critically ill patients with confusing clinical
Fungal epidemiology S575
pictures. The mortality rate remains 75−90% because of difﬁculty in
making the diagnosis, lack of effective antifungal antibiotics, the need
for surgical intervention in most cases. There is currently no consensus
on the treatment of invasive Candida parapsilosis endocarditisis. The
therapeutic approach typically includes heart valve replacement surgery
and administration of systemic anti fungal. Amphotericin B has been the
most frequently used anti fungal. Fluconazole is an alternative. Detailed
clinical ﬁndings and literature review to be presented.
Figure 2. 30/7/07 Vegetation hardly noticeable, possible prolapse of left
coronary cusp. Severe regurgitation.
P1966 Cryptococcal meningitis: 12-year experience in a single
tertiary-care centre
S.J. Jeong °, H.K. Choi, H.S. Lee, B.S. Chin, S.H. Han, C.O. Kim,
J.Y. Choi, J.M. Kim (Seoul, KR)
Objectives: Cryptococcal infections are frequent in HIV-infected
patients and are regulary looked after. This infection may occur in
others immunosuppressives situations and, in these cases, diagnosis is
often delayed. There are few reports on cryptococcal meningitis in non-
HIV-infected patients in Korea. We reviewed the clinical features and
efﬁcacy of antifungal therapy in 33 patients who treated in a single
tertiary care centre of Korea.
Methods: The medical records of 33 consecutive patients who had been
admitted to our institution for cryptococcal meningitis from 1995 to 2007
were reviewed retrospectively. Cryptococcal meningitis was conﬁrmed
by positive culture of cerebral spinal ﬂuid (CSF) or compatible clinical
features plus a positive cryptococcal antigen test of CSF.
Results: 33 patients were analyzed and 30 cases were non-HIV patients.
The outcomes were: complete cure in 23 cases, cure with sequelae
in 4 cases, and mortality by treatment failure in 6 cases. The main
initial manifestations were headache (84.8%), fever (54.5%) and seizure
(33.3%). There was no statistical difference between patients who
received amphotericin B treatment and those received ﬂuconazole
treatment mainly for long term, in terms of mortality rate. Factors
signiﬁcantly associated with unfavourable outcomes, including mortality
and cure with sequelae cases, were fever, mental change, hearing
impairment, initial high opening pressure of CSF (>250mmH20) and
low initial absolute neutrophil count. On multivariate analysis, fever was
independent predictors of unfavourable outcomes (odds ratio 17.3; 95%
conﬁdence interval, 1.0−28.3; P = 0.045)
Conclusions: On the basis of our ﬁndings, it seems mandatory to closely
observe cryptococcal meningitis patients with factors mentioned above.
P1967 Cryptococcal infections in non-HIV-infected patients: de-
scription of 9 cases collected in a tertiary hospital, 1989–2008
M. Torres-Narbona, J. Guinea °, P. Mun˜oz, E. Bouza (Madrid, ES)
Background: Cryptococcosis in the last 25 years has mainly affected
HIV-infected patients. Other debilitating conditions (e.g. haematological
cancer, solid organ transplantation, rheumatic disease) were much less
common among patients with cryptococcosis. We describe nine non-
HIV-infected patients with cryptococcosis, with emphasis on the clinical
manifestations, laboratory and radiological ﬁndings, microbiological
diagnosis, and outcome.
Methods: We reviewed the charts of nine patients with cryptococcosis
(isolation of Cryptococcus from ordinarily sterile sites or respiratory
samples) and non-HIV predisposing conditions (1989–2008).
Results: We collected data on 58 patients with CCS during the study
period, and 9 (15.5%) patients had no-HIV infection. A total of ﬁve
patients were male and their age ranged from 21 to 80 years. The
predisposing conditions were solid organ transplant (3, 33.3% [2 renal,
1 heart]), chronic lymphocytic leukaemia (1, 11.1%), cirrhosis by
HBV (1, 11.1%), biliary-tract carcinoma (1, 11.1%), and rheumatologic
disease (2, 22.2% [1 rheumatoid arthritis and 1 alveolar proteinosis])
and none (1, 11.1%). We only detected one case of infection in an
apparently immunocompetent subject caused by C. gattii. Six of the
patients were receiving corticosteroid therapy and ﬁve were receiving
immunosuppressive agents. The clinical forms were neurocryptococcosis
and meningitis (4, 44.4%), fungaemia + meningitis (1, 11.1%),
fungaemia + pulmonary disease (2, 22.2%), and fungaemia alone (2,
22.2%). Fever (n = 8) and headache (n = 4) were the most frequent
symptoms. The analytical CSF parameters were (in ranges) opening
pressure (18−30 cm H2O), leukocytes (0–313 cells/mm3), glucose level
(9−51mg/dl), and protein level (25–319mg/dl). Cryptococcal antigen
was detected in 6 patients (all patients with meningitis and two with
fungaemia). The distribution of aetiological agents was: C. neoformans
var. grubii (n = 6, 66.6%), C. neoformans var. neoformans, (n = 2, 22.2%),
and C. gattii (n = 1, 11.1%). All patients responded to antifungal
treatment (amphotericin B, ﬂucytosine, or oral ﬂuconazole).
Conclusions: Cryptococcosis in non-HIV-infected patients is a very
uncommon fungal infection, occurring mostly in patients receiving
corticosteroids. Patients with cryptococcosis and non-HIV infections had
meningitis in only half of the cases and presented a good outcome.
C. neoformans var. grubii was the most common causative agent.
P1968 Non-bacillary Mycobacterium tuberculosis pneumonia
preceding Cryptococcus neoformans co-infection in an
otherwise healthy young girl
R. Manfredi °, B. Piergentili, L. Calza (Bologna, IT)
Introduction: The concurrence of cerebral tuberculosis and crypto-
coccosis is an exceedingly rare event without a severe underlying
immunosuppression.
Case report: A 25-year-old student recently immigrated from China
was admitted due to a presumed meningoencephalitis. Epidemiological
features and clinical history were mute. Since cerebrospinal (CSF)
ﬂuid examination showed pleocytosis with lymphocyte predominance,
increased albumin content, and low glucose, and all microscopic, culture,
and antigen search for Cryptococcus neoformans tested positive, an an-
tifungal treatment was started with high dose ﬂuconazole. HIV serology
tested negative, but a moderate impairment of CD4+ lymphocyte count
was detected (299 cells/mL). Due to a persisting clinical-neurological-
CSF impairment, liposomal amphotericin B replaced ﬂuconazole. The
appearance of cranial nerve deﬁcits paralleled the culture isolation
of Mycobacterium tuberculosis from the ﬁrst CSF specimen, while
intradermal tuberculin testing remained negative, and cryptococcosis
was microbiologically cured. Serial contrast-enhanced brain CT scans
showed the appearance and the worsening of multiple ﬂogystic frontal,
hypothalamic, and ponto-cerebellar leptomeningeal lesions, conﬁrmed
my MRI scans. A 5-drug anti-tubercular therapy was immediately
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started and subsequently potentiated with quinolones and linezolid.
After 5 months of hospitalisation, thanks to an extensive rehabilitation
program, a slow ameliorement of clinical-neurological picture allowed
discharge, while all repeated testing for both cryptococcosis and
tuberculosis became negative, and CD4+ count rose to 399 cells/mL.
Discussion: One single case report of a concomitant cerebral
criptococcosis-tuberculosis was described in an AIDS patient from South
Africa [Silber E, Neurology 1998;51:1213]. The present report, which
exceptionally included an apparently concurrent, severe cryptococcal
and tubercular meningoencephalitis in absence of evident underlying
immunodeﬁciencies, represents a warning again underestimation of
combined, rare infectious illnesses. From a pathogenetic point of
view, an initial, slowly progressing meningeal tuberculosis (although
diagnosed later in the disease course), probably prompted some
grade of immunodeﬁciency, thus supporting the occurrence of brain
cryptococcosis.
P1969 12-year post-mortem analysis of invasive mould infections
in intensive care units in a tertiary care hospital
C. Glaeser °, M. Schneemann, C. Ruef, A. Imhof (Zurich, CH)
Background: Invasive mould infections (IMI) are an important and
increasing cause of morbidity and mortality in patients hospitalised on
intensive care units (ICU).
Methods: All autopsy protocols of our university hospital performed
during a 12-year period (1997–2008) were reviewed to investigate the
incidence of IMI in ICU patients.
Results: 4251 protocols were analysed. 63 cases of mould infections
were yielded in ICU patients. The median age was 63 years (range:
24−81) and there were 36 males and 27 females. The median ICU stay
was 10 days (1−53). 59 cases with IMI and 4 patients with aspergilloma
were diagnosed. The most frequent isolates were Aspergillus sp.
(94%) followed by Fusarium sp. (2%), Scedosporium sp. (2%) and
Zygomycetes (2%).
Fungal aetiology was diagnosed pre-mortem in only 28 (44%) of the
patients. All these patients were treated with mould-active antifungal
agents. However, in 40 (66%) patients, IMI was the primary cause
of death. The major underlying conditions were haemato-oncological
tumours (33%), followed by patients after solid organ transplantation
(18%), patients with prolonged ICU stays after surgery (15%), patients
with rheumatologic or immunological disorders receiving high dose
corticosteroids (15%), patients with sepsis or cardiogenic shock (11%),
and chronic lung diseases (4%), HIV patients (2%) and patients with
solid organ cancer (2%).
Conclusion: This post-mortem analysis found IMI to be a frequent cause
of death in ICU patients with a wide range of underlying conditions. The
high incidence of not clinically entertained IMI conﬁrms the importance
of autopsy as a tool for quality control in medical diagnostic and
therapeutic activity.
P1970 Fungiscope: a global database for rare fungal infections
M. Ru¨ping, J.J. Vehreschild, C. Beisel, G. Fischer, C. Mu¨ller,
A.J. Kindo, C. Lass-Flo¨rl, W.J. Heinz, O.A. Cornely ° (Cologne, Aachen,
Wurzburg, DE; Porur, IN; Innsbruck, AT)
Objectives: The incidence and clinical relevance of rare invasive
fungal infections is increasing worldwide, but reliable information on
their clinical course, diagnosis and treatment is scarce. To determine
the clinical pattern of disease, to describe and improve diagnostic
procedures, and therapeutic regimens, as well as to facilitate the
exchange of clinical isolates, we are coordinating a global registry for
rare invasive fungal infections.
Methods: Patients with cultural, histopathological, antigen, or molecular
biologic evidence of invasive fungal infection may be included into
the study. Those with infections due to Aspergillus spp., Candida spp.,
Cryptococcus neoformans, Pneumocystis jirovecii or any endemic fungal
infection, such as coccidioidomycosis or histoplasmosis, as well as
colonisation or other non-invasive infections are excluded. Data entry
is accomplished via a web-based electronic case report form.
Results: By now, 65 patients with rare invasive fungal infections from
a wide variety of pathogens have been included. The most common
underlying conditions were chemotherapy for a haematologic malignancy
(13%, n = 15), haematopoietic stem cell transplantation (11%, n = 13),
Diabetes mellitus (13%, n = 11) and/or stay at an intensive care unit
(11%, n = 13). The lungs were the most common site of infection (38%,
n = 26), followed by soft tissues (16%, n = 11) and the paranasal sinuses
(13%, n = 3). 20 patients displayed disseminated disease. At the latest
assessment, complete response to antifungal therapy was observed in
44% (n = 28). The crude mortality rate was 39% (n = 26). 5 patients
(8%) were lost to follow up and in 2 patients (3%), ﬁnal evaluation of
clinical evolution is still pending.
Conclusion: The clinical relevance of rare invasive fungal infections is
increasing steadily. In a short period of time, current cases from Europe,
Asia and South America could be documented. Further investigators and
coordinators are cordially invited to contribute to Fungiscope.
P1971 A retrospective, multi-centre study of 25 cases of proven
zygomycosis: risk factors associated with mortality
A. Llorente, I. Heras, V. Fraile, E. Garcı´a, P. Garcı´a, J. Lo´pez,
M. Salavert, I. Pe´rez, F. Bobillo, A. Cantalapiedra, J. Go´mez,
M.A. Andreu, J. Fortu´n, M.M. Antona, M. Heredia, P. Martı´n, P. Martı´nez
Garcı´a, Y. Sanduende, C. Sarria´, A. Bermu´dez, C. Bethancourt, I. Ausı´n °
for the Study Group on Liposomal Amphotericin B (Madrid, ES)
Objectives: Identify risk factors associated with zygomicosis mortality
Methods: A retrospective multicentre study was designed in order to
identify proven cases of zygomycosis diagnosed during 2006 and 1st
semester 2007 in 17 hospitals in Spain. Updated EORTC criteria were
applied
Results: Twenty ﬁve patients (20 males) median age 46 (range 21−76)
with proven zygomycosis were identiﬁed. Most important underlying
conditions were: haematological 13 (52%); diabetes 8 (32%); solid organ
transplant 3 (12%); trauma 2 (8%); solid tumour 2 (8%); rheumatologic
1 (4%); in one case no underlying condition was identiﬁed. From
the haematologic patients 11 (84.6%) had active disease and all were
neutropenic (<500mm3). Steroids were used during the month prior
to diagnosis by 13 patients (52%) and other immunosuppressants in
52%. Median days from hospital admission to diagnosis was 15 days.
Zygomycosis was diagnosed in 11 cases (44%) by histopathologic or
cytopathologic techniques in 7 cases (28%) by culture and in the
remaining cases (28%) using both techniques. The infection was only
rhinoorbitocerebral in 7 cases (28%) disseminated, affecting soft tissues
and skin in 5 patients (20%) each, gastro-intestinal in 3 cases (12%),
rhinoorbitocerebral+sinus in 2 cases (8.0%) and others in 3 (12%) cases.
Ten patients (40%) received prophylaxis (7 ﬂuconazole, 3 itraconazole).
Eleven (44%) received empiric or pre-emptive treatment. Only 4/11
received liposomal amphotericin B, one combined with caspofungin.
One received another lipid formulation and the remaining 6 patients
received different treatment strategies. One patient did not receive any
treatment, and the remaining 13 patients (52%) only started treatment
after diagnosis. Seventeen patients (68%) had surgery. Overall mortality
was 72% and attributable to zygomycosis in 13 cases (52%). 7/11
patients (53.8%) who received only anti-fungals after diagnosis died.
In a univariate analysis neutropenia and haemato-oncologic conditions
were signiﬁcantly associated with mortality; in multivariate analysis no
risk factors were identiﬁed
Conclusions: Zygomycosis is a difﬁcult fungal infection to diagnose
with high mortality rate. Effective treatment that covers zygomycetes
should be initiated early in order to reduce mortality. Neutropenia
and haemato-oncologic conditions are risk factors, although in the
multivariate analysis no risk factors associated with mortality were
identiﬁed; this may have been due to the small sample size.
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P1972 Filamentous fungi in cystic ﬁbrosis: occult Scedosporium
colonisation detected by selective media
C.C. Blyth °, P.G. Middleton, A. Harun, S. Sleiman, T.C. Sorrell,
W. Meyer, S.C.A. Chen (Sydney, AU)
Objectives: Scedosporium spp. are the second most frequent ﬁlamentous
fungi after Aspergillus spp. isolated in cystic ﬁbrosis (CF). Invasive
infection is rare in patients prior to transplantation but fungal
colonisation may be a risk factor for invasive disease, with its attendant
high mortality, post lung transplant. As colonisation with more than
one fungus is frequent, the prevalence of non-Aspergillus moulds may
be underestimated in patients with CF. Furthermore, following recent
taxonomic changes, contemporary epidemiological and microbiological
data for Scedosporium colonisation in CF are required.
Methods: Expectorated sputum samples were collected from outpatients
with CF from April to December 2008 and cultured on non-
selective (Sabouraud’s agar + chloramphenicol/gentamicin), Mycosel and
Scedosporium selective media (SceSel+) at 30ºC for up to 28 days.
Colonies suspicious for ﬁlamentous fungi were identiﬁed to species
level by routine laboratory methods. Scedosporium spp. were further
characterised by RFLP analysis of the ITS region.
Results: Samples (n = 152) were received from 56 patients (median age
24 years, IQ range 21−28years, 41.1% male). The median number of
samples per patient was 3 (range 1−6). Filamentous fungi were detected
in 38 patients (67.9%). The most frequent pathogen was Aspergillus
fumigatus (31 patients; 55.4%) followed by Scedosporium spp. (9
patients; 16.1%), Penicillium spp. (8 patients, 14.3%) and A. ﬂavus (5
patients, 8.9%). ITS_RFLP analysis demonstrated that S. aurantiacum
was the most frequent isolate (n = 4 patients) followed by S. proliﬁcans
(n = 3) and S. apiospermum (n = 1); one isolate was speciated as P. boydii
species complex. Scedosporium spp. and A. ﬂavus were more frequently
present in mixed cultures compared with A. fumigatus (p = 0.036 and
0.009 respectively). SceSel+ media was 44% more sensitive than non-
selective media (88.8% vs. 44.4%). Up to 14 days of incubation was
required to identify Scedosporium spp. in all samples.
Conclusions: The prevalence of Scedosporium colonisation in patients
with CF in Sydney is 16.1%. S. aurantiacum is the predominant
species. The use of selective media increases the rate of detection
of Scedosporium spp. More than 50% of cases are missed with non-
selective media due to overgrowth of other ﬁlamentous fungi.
P1973 Fungi from airway secretions of children with cystic ﬁbrosis
H. Alexandrou-Athanasoulis °, A. Stathi, S. Doudounakis, A. Pangalis
(Athens, GR)
Objectives: Last years there is an increasing trend of isolation of fungi
from airway secretions of patients with cystic ﬁbrosis (CF), which is
accompanied with the presence of new fungal species. The aim of our
study was to determine the prevalence as well as the species of fungi
from airway secretions of children with CF.
Material and Methods: During a 23 months period (February 2007–
December 2008) 2770 sputum or deep throat cultures from 393
children with CF (mean age 8.9±3.8 years) were performed. Sabouraud
dextrose agar (Conda Pronandisa, Spain), with Gentamicin, was used
for the culture of fungi, incubated at 35ºC for up to 5 days. The
identiﬁcation of ﬁlamentous fungi was based on the macroscopic
and microscopic morphological features in accordance with standard
descriptions. Identiﬁcation of yeasts was based on the carbohydrate’s
assimilation (API 20 AUX, Biomerieux).
Results: 426 cultures from 221 children were positive for fungi (15.4%).
Multiply isolates of the same fungus per patient were included only once.
The prevalence of potentially pathogenic fungi from patients with CF as
Candida albicans, Aspergillus fumigatus, Scedosporium apiospermum
and Exophialla (Wangiella) dermatitidis was 62.9, 11.8, 3.8, and 0.4%
respectively. All species of fungi isolated from the 221 children are
presented in the table.
Conclusions: Suitable culture methods for the isolation and identi-
ﬁcation of fungi to species level is essential for patients with CF.
The reason is that fungi participate in the inﬂammatory process and
allergic bronchopulmonary reactions of these patients as well as that
new pathogenic species are described, often resistant to many antifungal
agents as Scedosporium apiospermum and Exophialla (Wangiella)
dermatitidis.
Fungi from airway secretions of patients with CF
Species Number %
C. albicans 149 62.9
C. parapsilosis 17 7.2
C. lusitaniae 3 1.3
C. famata 3 1.3
C. kefyr 1 0.4
A. fumigatus 28 11.8
A. terreus 12 5.1
A. ﬂavus 9 3.8
A. versicolor 1 0.4
A. oryzae 1 0.4
Scedosporium apiospermum 9 3.8
Exophialla (Wangiella) dermatitidis 1 0.4
Geotruchon spp. 1 0.4
Cryptococcus laurentis 2 0.8
Total 237
P1974 Scedosporium apiospermum from airway secretions of
children with cystic ﬁbrosis
H. Alexandrou-Athanasoulis °, S. Doudounakis, A. Stathi, A. Katelari,
A. Pangalis (Athens, GR)
Objective: Scedosporium apiospermum has recently been included to the
fungal agents which may be of clinical importance in patients with cystic
ﬁbrosis. Aim of the study: The incidence of airway colonisation/infection
by Scedosporium apio-spermum in comparison with clinical data and the
MICs of 5 antifungal agents (itraconazole, ketoconazole, voriconazole,
posaconazole and gaspofungin) against the isolated species.
Material and Method: Over a twenty three months period
(February 2007 – C December 2008) 2770 sputum or deep throat
cultures were performed to 393 children (mean age 8.5±3.9 ys) with
cystic ﬁbrosis attending our department. For the detection of fungi the
Sabouraud dextrose agar (Conda Pronandisa, Spain) with gentamicin
was used, incubated at 35ºC and examined daily for fungal growth for
up to 5 days. The identiﬁcation of Scedosporium apiospermum was
based on the macroscopic and microscopic morphological features in
accordance with standard descriptions. The MICs of antifungal agents
were determined with the gradient MIC method using E-test strips (75%
reduction of growth). C. parapsilosis ATCC 22019 was used as quality
control.
Results: Positive for Scedosporium apiospermum were 57 cultures
(2.1%) from 9 children (2.3%) (mean age 12.5,±0.5 ys). Five children
are constantly colonised and four seem to have a transient colonisation.
Seven of them have a very good clinical status (with FEV1 and
spirometric ﬁndings within normal values) while one has allergic
bronchopulmonary disease. The cultures of the last patient have yielded
A. fumigatus, Exophialla dermatitidis, C. albicans A. terreus and
Cryptococcus laurentis as well. The MICs (mg/L) of 5 antifungal agents
were: itraconazole: 0.008–0.5, ketoconazole: 0.0012–0.9, voriconazole:
0.006–0.047, posaconazole: 0.008−32 and caspofungin: 0.003−32).
Conclusions: 1. The airways surveillance of CF patients should include
suitable culture methods for the isolation of Scedosporium apiospermum
from sputum cultures. 2. Although the numbers of isolates tested to
antifungal agents are low, it seems that voriconazole is the most active
antifungal agent against Scedosporium apiospermum.
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P1975 Clinico-mycological proﬁle of onychomycoses in patients
attending dermatology clinics at a tertiary care centre in
southern India
P. Yegneswaran Prakash °, I. Bairy, G. Shrijana (Manipal, IN)
Objectives: To study the pattern of clinical manifestation in ony-
chomycoses patients and to identify the various dermatophytic, non
dermatophytic mould and yeasts implicated in Onychomycoses.
Methods: The patient population involved those attending the dermatol-
ogy outpatient clinic during the time frame of January 2006 to August
2008. During this period a total of 520 patients representing both genders
who volunteered by their consent after being informed about the study
with clinical features of Onychomycoses were recruited. Patients on
prior anti fungal therapies for more than 4 weeks were excluded. Nail
clippings collected were portioned and used for direct microscopy and
recovery of the aetiological fungal agent by culture. Identiﬁcation of
the Filamentous/Yeast fungi was done based on the macroscopic and
microscopic features and by performing physiological tests as per the
standard mycological protocols.
Results: The most common type of clinical presentation was distal lateral
subungual Onychomycoses and the common organism isolated from this
type of presentation was Fusarium spp, followed by Total dystrophic
Onychomycoses caused by Dermatophytes. The common age group that
was affected by Onychomycoses was those in the 41 to 50 years age
group with a mean age of 41.47 years. The type of occupation with
the highest presentation of Onychomycoses were those involved with
work that required them to be in constant contact with water like the
housewives 26.2%, and the paddy ﬁeld workers 23.8%. Diabetes mellitus
was associated with Onychomycoses in 31.3% and with hypertension
in 18.8% of the patients. A prior trauma to the nails was associated
with Onychomycoses in 54.8% of the patients, and the p value of 0.04
proved this association to be signiﬁcant. In some instance exotic agents of
onychomycoses like Onychocola canadensis, Lasiodiploidia theobromae
were isolated.
Conclusion: The burden of Onychomycoses in the society, causing
morbidity cannot be ignored. Although in a developing country like
ours where there are more immediate and life threatening disease to
combat, it is important to note that a great majority of Onychomycoses
sufferers are unseen or hidden patients, and if they are to report
to a dermatologist the actual number would be much higher. It is
important to recognize, identify and conﬁrm Onychomycoses due to non
dermatophyte ﬁlamentous fungi as they may not be responsive to even
newer antifungal agents.
P1976 Onychomycosis in Tehran: mycological study of 504 patients
J. Hashemi ° (Tehran, IR)
Background: Onychomycosis, a common nail disorder results from
invasion of the nail plate by a dermatophytes, yeasts or mould species
that these fungi give rise to some diverse clinical presentations.
Objectives: The purpose of present study was to isolate and determine
the causative fungi of onychomycosis in the population in Tehran, Iran.
Methods: Totally nail materials of 504 patients with prediagnosis
of onychomycosis during 2005, were examined both with direct
microscopy observation of fungal elements in KOH preparations and
culture to identify the causative agent. All samples were inoculated
on (1) Sabouraud dextrose agar (SDA, Merk) (2) SDA with 5%
chloramphenicol and cycloheximide in dublicate for dermatophyte and
(3) SDA with 5% chloramphenicol triplicate for mould isolation.
Results: Out of a total of 504 cases examined, 216 (42.8%), were
mycologically proven cases of onychomycosis (144 ﬁnger nails, 72 toe
nails). Among the positive results, dermatophytes were diagnosed in
46 (21.3%), yeasts in 129 (59.7%) and non dermatophytic mould in
41(19%). Trichophyton mentagrophytes was the most common causative
agent (n = 22), followed by Trichophyton rubrum (n = 13), Candida
albicans (n = 42), C. spp. (n = 56) and Aspergillus spp. (n = 21).
Conclusions: near the half of clinical suspected fungal nail infections is
onychomycosis and yeast is responsible for most of the infections in Iran.
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P1977 In vitro pharmacodynamic properties of colistin
methanesulfonate and amikacin against Pseudomonas
aeruginosa isolates from patients with cystic ﬁbrosis
C. Bozkurt Gu¨zel °, A. Gerceker (Istanbul, TR)
Objectives: The in vitro pharmacodynamic properties of colistin
methanesulfonate and amikacin were investigated by studying time-kill
kinetics, and postantibiotic effect (PAE) against strains of Pseudomonas
aeruginosa isolated from patients with cystic ﬁbrosis.
Methods: Synergy was investigated at 0.5×, 1× and 5×MIC
concentrations of antibiotics using time-kill curve method. PAEs were
determined by the standard viable counting method where bacteria in the
logarithmic phase of growth were exposed for 1 hour to the antibiotics
at 1× or 20×MIC, alone and in combinations.
Results: Synergy and additive effects were detected with colistin
methanesulfonate and amikacin combination, at 1×MIC concentrations,
at 24 h. Some of the strains produced an earlier synergistic effect
at 12 h. No antagonism was observed with any combination. Colistin
methanesulfonate at 1× and 20×MIC concentrations produced PAEs 1
to 2,85 h, amikacin at the same concentrations produced 0.6 to 3.75 h.
When the antibiotics were used in combination at a concentration of 20
times of the MIC values the PAEs were prolonged to a value of 4.8 h.
Conclusion: Consequently, the ﬁndings of this study may play useful
role in selecting the appropriate combinations when a single agent is
inadequate, and may have important information for optimising the dose
intervals. Optimisation of antibiotic dosing intervals will allow us for
the design of rational dosage regimens, thereby reducing the costs and
development of resistance and toxicity during therapy.
P1978 Pharmacokinetics of amikacin at a Portuguese burn unit
M. Caetano, M. Joa˜o Rocha, L. Cabral °, C. Cruzeiro, G. Tribuna,
M.A. Cabral (Coimbra, PT)
Objectives: Burns can cause serious complications like electrolyte
imbalance and infection. Amikacin is an antibiotic available to treat
patients with suspected or documented severe Gram negative (−)
infections. The aim of this study is to evaluate the administration and
the response to amikacin in burn patients at a burn unit, and to analyse
their pharmacokinetic behaviour.
Methods: This is a retrospective study conducted between January
2005 and December 2008. The study population included patients on
amikacin treatment for Gram(−) infections. The pharmacokinetic study
was done assuming a monocompartment open model with zero-order
absortion (ev perfusion) and a ﬁrst-order elimination. The Sawchuk-
Zaske equation and the SPSS 11.5. statistical analysis program were
used for the pharmacokinetic calculations.
Results: This study involved 76 patients with an average age of
48±18 years and an average weight of 72±15 kg. The mean Total
Body Surface Area (TBSA) burned was 22±10% and the average
length of treatment was 14±9 days. 47% of the patients had a burned
TBSA 20%. The amikacin standard dose was 18±9mg/kg/day. 300
amikacin plasmatic levels were collected. Out of the through/peak
pairs, only nearly 15% were within the recommended range. The
average analytic values found were, serum creatinine: 0.8±0.7mg/dL,
albumin: 3.3±0.6mg/dL, potassium: 4.0±0.6mg/dL. The C-Reactive
Protein (PCR) values ranged from 1.8 to 39mg/dL. The average
pharmacokinetic parameters estimated were Volume of Distribution
(VD): 0.5±0.8 L/kg, serum half-life (t1/2): 3.1±3.6 h and Clearence
(CL):8.8±6.4 L/h for patients with TBSA< 20%, and VD: 0.5±0.6
L/kg, t1/2:4.40±3.70 h and CL:8.50±13.90 L/h for patients with
TBSA 20%. After the pharmacokinetic adjustment, amikacin doses
had rised to 34.0±20.0mg/kg/day.
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Conclusions: As expected, these results show a great interindivid-
ual variation in amikacin pharmacokinetic parameters. Taking the
trough/peak values into account, the standart dose used is not adequate
for this group of patients. So, the routine pharmacokinetic adjustment
of this antibiotic would be useful. Further studies would be important
to ﬁnd an ideal standard dose for these patients as well as the better
frequency of administration of amikacin.
P1979 Quantitative comparison of aminoglycoside nephrotoxicity
in rats for effective screening and evaluation of new
derivatives, and dosing rationales that minimise toxicity
C.F. Kostrub °, R. Diokno, J. Aggen, G. Miller, K. Judice, P. Tulkens
(South San Francisco, US; Brussels, BE)
Objectives: Aminoglycosides (AG) are a well-known class of antibiotics
with an established record of efﬁcacy, but limited in their use because
of the risks of oto- and nephrotoxicity. To support the development of
the next generation of AGs with an improved antibacterial spectrum and
clinical safety (neoglycosides), we have reﬁned a rat toxicity model to
effectively quantitate AG nephrotoxic potential. The model was based
on integration of extensive past research on AG nephrotoxicity and
allows for effective screening of novel AGs with potentially reduced
nephrotoxicity.
Methods: Our standard rat nephrotoxicity study design used 14 days
of once-daily dosing. We also monitored changes in serum markers of
glomerular ﬁltration rate (GFR) and microscopic examination of kidney
slices using H&E staining, as well as scoring of cellular necrosis, tubular
dilation, and basophilia. This rat model provided a consistent measure
of AG nephrotoxicity, as evidenced by the reliable dose-response of
serum creatinine changes for gentamicin across a number of independent
studies (no change at 10mg/kg, mild elevation at 30mg/kg, and >2x
elevation/mortality at 100mg/kg).
Results: Neomycin, sisomicin, gentamicin, apramycin, tobramycin,
paromomycin, and amikacin were evaluated. Their nephrotoxic ranking
in this rat model (minimum dose that affects GFR) correlates well with
their relative clinical nephrotoxicity, where clinical data are available. AG
induced kidney changes were detected by H&E at doses many multiples
below those that cause a GFR functional deﬁcit (30x for gentamicin).
Consistent with prior work and the model that kidney uptake of AGs
is a saturable process, once-daily dosing of gentamicin was signiﬁcantly
less toxic than twice- or three-times daily dosing of the same total daily
dose. Also, supporting the model that AG nephrotoxicity is correlated
to the total duration of treatment, we found that limiting the duration of
dosing to 5 days allows for doubling the dose of gentamicin without a
signiﬁcant increase in toxicity compared with 14 days of dosing.
Conclusions: Our rat model allows for a consistent evaluation of the
nephrotoxic potential of AGs, and also points to conditions that minimise
toxicity. This model should allow for the reliable evaluation of the
nephrotoxic potential of new AG derivatives, and guide their selection
for further clinical development. This work also provides a rationale for
shorter course dosing of AGs to minimise toxicity.
P1980 Assessment of amikacin plasma level in a referral hospital
in southern Iran
S. Namazi °, M. Sagheb, G. Vessal, M. Hashempoor (Shiraz, IR)
Objective: Amikacin exhibits concentration-dependent effects, therefore
plasma level monitoring of amikacin to improve treatment efﬁcacy and
safety is an important factor. In our hospital amikacin plasma level
monitoring is not performed routinely. This study was designed to
determine the appropriate use of amikacin in Namazi hospital in Iran.
Methods: All patients who received amikacin in internal wards of
Namazi hospital were selected during a 1-year period. Trough and
peak plasma levels were drawn from patients at steady state condition.
Samples were assayed by a turbidometer autoanalyzer (Cobas-Mira,
Roche, Germany). A log sheet that included 12 items regards indication,
dosing, administration, and monitoring of amikacin was provided. This
log sheet was completed for each patient and compared to a standard
guideline designed by a clinical pharmacist. A score of 1 or 0 was given
to each variable depending on the fact that each variable was evaluated
appropriate or inappropriate, respectively. A total score was given to each
patient by adding the scores for each variable. Statistical analysis was
performed using SPSS version 11.5.
Results: 63 patients were enrolled into the study. The age range was
18−92 (55±22.5) years. The most common cause of admission was
fever (63.49%). Pyelonephritis was the primary indication for amikacin
therapy. 76% of patients had a creatinin clearance 50ml/min based
on Cockroft-Gualt formula. Only in 25% of patients amikacin dose was
adjusted based on creatinin clearance. The averages trough and peak
levels of amikacin were 15.67±7.79mcg/ml and 15.67±7.79mcg/ml,
respectively. 45% and 38% of trough and peak levels respectively were
in therapeutic range. Data analysis of log sheets indicated that the average
total score for appropriateness of amikacin usage was 5.8±0.3 (4−10)
out of 12.
Conclusion: Amikacin use and serum levels were inappropriate in most
of our patients. Standard treatment guideline should be provided and
implemented in order to improve amikacin use.
P1981 Aminoglycosides: acoustic toxicity screening
R. Moroti °, M. Georgescu, A. Pascu, A. Hristea, V. Arama, E. Kovacs,
M. Rufa (Bucharest, Cluj-Napoca, RO)
Objectives: Aminoglycosides (AG) are widely prescribed despite their
notorious toxicity. The aim of this study was to monitor and to
characterise the acoustic toxicity of the AG using an otoacoustic emission
(OAE) analyser.
AG cause irreversible hearing loss, starting with high frequencies and
progressing toward
conversational frequencies (0.5−2 kHz), by destroying the cochlear cells.
The integrity of these cells could be analyzed by recording the faint
sounds that they produce − otoacoustic emissions.
Methods: We performed a prospective study of 49 patients receiving
gentamicin (G) during 2007–2008.
We used serial OAE recordings with an ILO 92 analyser (1−8kH) on at
least 3 occasions: at the start, during the course and after the cessation of
G therapy (1−6 months). The recordings were performed at the patients’
bedside, independently of their status of consciousness. The method is
fast, non-invasive, accurate and doesn’t require an ENT specialist.
We included patients presenting OAEs. The exclusion criteria were acute
middle ear affection or OAE absence on the initial test. Ototoxicity was
deﬁned (related to the highest previously recorded frequencies) as a
decrease of at least 20dB at one frequency, a 10 dB decrease at 2 adjacent
frequencies or a loss of 3 adjacent frequencies.
Results: We studied 49 patients, 24/25 female/male, mean age 37.24
(3−70 years old), who received G for 4 to 42 days: 24 patients were
treated for less than 10 days and 25 patients had longer courses of
treatment.
Hearing impairment was observed in 10 patients (20.4%) and appeared
during the therapy or in the next 3 months, with the loss of one or 2 high
frequencies that occurred unilaterally in 9 out of 10 cases. The acoustic
damage correlates with the length of AG treatment (50% for long versus
8.3% for short courses).
We didn’t ﬁnd a statistical correlation between the degree of impairment
and the age, doses or association of another ototoxic drug, although the
hearing loss was slightly higher in those with concomitant exposure: 4
out of 10 versus 13 out of 39 non-exposed.
Conclusions: OAE monitoring of AG treatment is a very useful way
for detecting and preventing acoustic toxicity, because it could warn
about hearing loss before damage of the conversational frequencies. The
accuracy is similar to the classical methods, but it is easier to perform
and faster.
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P1982 Validation of a high-trough vancomycin nomogram to
achieve trough concentrations of 15 to 20mg/L
R. Kullar °, S. Leonard, S. Davis, G. Delgado, K. Wahby, J. Pogue,
A. Sheth, P. Shah, B. Falcione, M. Rybak (Detroit, Royal Oak,
Pittsburgh, US)
Objective: We previously validated a vancomycin (VAN) nomogram
at Detroit Receiving Hospital to achieve targeted trough concentrations
of 5−20mg/L (Karam et al, Pharmacotherapy 1999). Recent guidelines
(Rybak et al, AJHP 2009; 82−98) proposed by the American
Society of Health-System Pharmacists, the Infectious Diseases Society
of America, and the Society of Infectious Diseases Pharmacists
recommend increasing the targeted trough serum concentration of VAN
to 15−20mg/L. The objective was to evaluate and validate the ability of
a revised VAN dosing nomogram to achieve the targeted trough serum
concentrations of 15−20mg/L.
Methods: This was a prospective multi-centre validation study from
4 U.S. academic centres. The construction of the revised nomogram
utilised actual body weight, estimated creatinine clearance (CrCl),
standard VAN equations and population pharmacokinetics to determine
VAN dose and interval (Karam et al, Pharmacotherapy 1999; Ducharme
et al, Ther Drug Monit 1994). Exclusion criteria consisted of patients
with weight> 110 kg, CrCl< 30ml/min or >110ml/min, and rapidly
changing or unstable renal function or volume of distribution. All
patients with empiric VAN dosage determined by the nomogram had
serum concentrations measured between the 3rd and 5th doses according
to standard pharmacy procedures.
Results: 109 eligible patients were identiﬁed. Baseline characteristics:
Median age 56 yrs (range 18−86), median weight 69.0 kg (47–110),
and median CrCl 63.0ml/min (37–105). 37.6% patients were in the
intensive care unit at time of initial VAN. 79.8% were placed on
VAN for empiric therapy. 75.2% received concomitant antimicrobial
therapy. Most common dosage and interval for VAN was 1000mg every
12 hours (20.2%), followed by 1250mg every 12 hours (17.4%). 54.1%
achieved target attainment (TA) of 15−20mg/L, 66.4% achieved TA of
14−21mg/L, while 73.4% patients achieved TA of 13−22mg/L. 13.8%
of patients had TA> 20mg/L and 12.8% <15mg/L. Safety: 11/109
patients developed nephrotoxicity; however, 72.3% of these patients that
experienced nephrotoxicity were on concomitant nephrotoxic agents (i.e.
aminoglycosides, colistin, acyclovir).
Conclusion: This revised high-trough VAN nomogram reveals that
the ability to achieve a small increment of 5mg/L (15−20mg/L) was
somewhat variable. However, allowing for a range of 13−22mg/L
achieved approximately 75% of TA and would appear to be clinically
acceptable for empiric dosage adjustment.
P1983 Pharmacokinetics analysis of vancomycin initial dose in
critically ill patients
P. Mas-Serrano °, M. Aparicio-Cueva, I. Gascon-Ros,
J. Navarro-Martinez, E. Asensi-Vilar, J.P. Ordovas-Baines (Alicante, ES)
Objectives: Pharmacokinetics analysis of vancomycin initial dose in
critically ill patients.
Methods: Design: observational prospective study. Duration: six months
(January 2008–July 2008). Inclusion criteria: all patients in a critical care
unit and treated with vancomycin. Vancomycin initial dose: 1000mg
bid i.v. From the pharmacokinetic registry of pharmacy department
were collected the following variables: demographics, infectious disease,
clinical situation at the beginning of treatment (mechanical ventilation,
vasoactive drugs and renal function) and through serum concentration
(corresponding to sample just before the next dose) estimated in
stationary state (Cpss).
The Cpss target was deﬁned 4−8×MIC; in pneumonia AUC/MIC> 350;
and in absence of antibiogram the target was 10−20mg/L. Vancomycin
serum concentration was determined by Axym® (Abbott®) autoanalyzer.
Pharmacokinetics analysis was performed through the package PKS®
(Abbott®). The results are expressed as mean (standard deviation).
Results: 34 patients were included (M:W 27:7). The mean age was 51.3
(17.0) years, with a mean weight of 82.8 (25.5) kg and a mean height
of 171 (9) cm. The indication of treatment with vancomycin was 35.5%
bacteraemia, 18% CNS, 15% pneumonia, intraabdominal infection 6%,
26% others. The mean Cockroft-Wault clearance creatinin was 153 (92)
mL/min.
73.5% of patients (n = 25) treated with vancomycin required adjustment
of the initial dosing. Patient distribution: 19 had Cpss below target
concentration (mean dose: 12.2 (2.7) mg/kg; mean Cpss: 5.0 (2.7) mg/L)
and 6 patients had Cpss above target concentration (mean dose: 12.8 (1.7)
mg/kg; mean Cpss: 25.3 (4.5) mg/L). 26.5% of patients (n = 9) did not
required dose adjustment (mean dose: 13.7 (1.2) mg/kg; mean Cpss: 9.2
(3.1) mg/L).
Conclusion: The high percentage of patients who need a change in
dosing suggests a protocol amending the initial dose of vancomycin.
Given the wide variability pharmacokinetics observed in these patients
and the severity of infections in critical care units, is necessary an
extensive monitoring and early pharmacokinetics in order to achieve
plasma concentrations effective as soon as possible.
P1984 High-dose daptomycin for complicated Gram-positive
infections
R. Kullar °, S.L. Davis, D. Levine, J. Zhao, C.W. Crank, S.E. Cosgrove,
J. Segreti, M.J. Rybak (Detroit, Chicago, Baltimore, US)
Objective:We evaluated the safety and efﬁcacy of high-dose daptomycin
(HD DAP) therapy, deﬁned as 8mg/kg/day.
Methods: A retrospective case series from 4 academic medical centres.
Consecutive patients (pts) treated with HD DAP for 72 h inpt or
continued as outpt therapy, excluding dialysis pts, were collected from
2005–2008. Charts were reviewed for demographics, comorbidities,
antimicrobial therapy, microbiologic cultures, clinical outcomes, and
adverse events.
Results: 105 eligible pts were identiﬁed. Baseline characteristics:
Median age 54 yrs (range 19−89), 79.0% prior hospitalisation 1 yr,
32.4% renal disease, 30.5% diabetes, 27.6% IDU, 23.8% prior MRSA
infection 1 yr. Primary infections: 26.7% complicated bacteraemia,
25.7% bone/joint, 23.8% endocarditis (by Duke criteria), 22.9%
skin/wound. 68.6% received HD DAP following non-response to
vancomycin (VAN) therapy. Median dose of DAP was 8.2mg/kg/day
(range 8.0−12.1). Median duration of total antibiotic therapy was
17.0 days (range 1−98) and duration of HD DAP was 9.0 days (range
1−49). Median length of hospital stay (LOS) was 18.0 days (range
3–111), duration of bacteraemia 4.0 days (range 1−36). 81.9% had a
favourable clinical outcome, deﬁned as clinically improved or cured,
and 71.4% (of 96 patients) microbiological eradication. Safety: 80.0%
of pts had maximum creatine phosphokinase (CPK) levels 150 IU/L
(range 8–1758), and 90.6% had end-of-therapy CPK levels 150 IU/L
(range 11–412). Of note, 16.2% pts were on concomitant HMG-CoA
reductase inhibitors. No pts required discontinuation of HD DAP because
of myopathy. Non-susceptibility to DAP (NSD) developed in 4 pts with
MRSA as primary organism, IDU, and non-response to VAN in common.
Median total LOS in NSD was 21 days (range 8−30). 3 out of 4 pts were
initially treated with VAN for organisms with VAN MIC 2mg/L for at
least 2 days prior to HD DAP therapy. Primary infections for these pts:
2 bone/joint + skin/wound, 1 right-sided endocarditis, and 1 right- and
left-sided endocarditis. 3 pts improved on alternative therapy while 1 pt
was considered clinical cure + eradication despite DAP MIC 2mg/L.
Table 1. Initial susceptibility of pathogens
Organism VAN (mg/L) DAP (mg/L)
MIC50 MIC90 MIC50 MIC90
Enterococci (N = 36) 32 64 2 2
MRSA (N= 54) 2 2 0.75 1
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Conclusions: HD DAP is a viable treatment option in pts with
complicated Gram-positive infections, and is associated with favourable
clinical response and safety proﬁle.
P1985 Vancomycin and daptomycin susceptibility related to the
accessory gene regulator locus in MRSA using in vitro
pharmacokinetic/pharmacodynamic models
C. Vidaillac °, G.W. Kaatz, S.M. Seo, M.J. Rybak (Detroit, US)
Objectives: The agr locus is a quorum-sensing gene cluster involved in
the pathogenesis of Staphylococcus aureus (SA) that has been associated
with vancomycin (VAN) treatment failure with a higher propensity for
agr group II. This study evaluated the relationship between VAN and
daptomycin (DAP) reduced susceptibility and agr group and function
in methicillin-resistant SA (MRSA) after exposure to VAN using two
different in-vitro PK/PD models.
Methods: Two isogenic pairs of agr+/agr− group I and II MRSA
were exposed to VAN for 72 or 192 h. Selected VAN dosing regimens
simulating fAUC/MIC ratios from 7 to 224 (31–1000mg q 12 h) were
evaluated in duplicate in a one-compartment PK/PD model and 112
(500mg q 12 h) in a two-compartment PK/PD model with simulated
endocardial vegetations (SEV). agr function as well as resistance and
tolerance to VAN and DAP were evaluated over 72 or 192 h. MICs were
determined according to CLSI guidelines.
Results: Pre-exposure MICs were 0.5 and 1 for VAN and 0.25mg/L
for DAP for all test strains. In the one-compartment model, fAUC/MIC
of 7 and 56 resulted in an increase in MIC of 6 and 3× for VAN and
4 and 2× for DAP for the agr I and II null strains versus 3 and 1×
for VAN and 4 and 1× DAP for the agr positive strains, respectively.
A VAN fAUC/MIC of 224 was needed to suppress VAN and DAP
resistance in the agr I and II null strains versus 112 and 56 in the
agr I and II functional strains, respectively. In the SEV model, a VAN
fAUC/MIC of 112 led to the emergence of VAN resistance at 144 h for
the agr II null strain versus 192 h for the isogenic agr+ strain. Mutants
of the agr null strain recovered from plates containing 3× the baseline
VAN MIC at 192 h exhibited increases in both VAN and DAP MICs of
4−6× and 6−8×, respectively. In contrast, mutants of the agr positive
strain demonstrated increases in the VAN and DAP MIC of only 2×.
No change in agr function was observed with any VAN regimen.
Conclusions: We have demonstrated a more rapid rate of emergence of
VAN resistance in isogenic MRSA agr null compared to agr functional
strains at human simulated VAN concentrations. The emergence of VAN
resistance was also associated with an elevation in the DAP MIC. Further
research is warranted to understand the relationship of agr function and
SA susceptibility to VAN and DAP.
P1986 The anti-staphylococcal activity of telavancin in comparison
to teicoplanin studied in an in vitro pharmacokinetic model
of infection
K. Bowker °, A. Noel, S. Tomaselli, A.P. MacGowan (Bristol, UK)
Objectives: Telavancin (tela) is a lipoglycopeptide antimicrobial with a
double mechanism of action, acting on both the bacterial cell wall and
membrane. It has a broad spectrum of in vitro activity against Gram
positive pathogens. Clinical trials have shown tela to be non-inferior in
effectiveness to vancomycin in treatment of skin infection and hospital
acquired pneumonia. However, there is little pre clinical and no clinical
data on the comparative activity of tela and teicoplanin (teico). In this
study, we used an in vitro pharmacokinetic (pK) model to compare the
antibacterial effects of tela and teico against 2 strains of MRSA and a
single VISA strain.
Methods: A single chamber dilutional pK model was used to simulate
free drug serum concentrations: tela Cmax 10mg/L, 12 hr concentration
3.3mg/L, 24 hr concentration 1.1mg/L; teico Cmax 4.5mg/L, 12 hr
concentration 2mg/L, 24 hr concentration 0.75mg/L. Two strains of
MRSA were used, tela MICs 0.19 and 0.25mg/L, teico MICs 0.19 and
0.12mg/L. The VISA strain tela MIC was 0.75mg/L, teic MIC 16mg/L.
Experiments were performed in at least triplicate at an initial inoculum
of 106 CFU/ml. Antibacterial effect was measured by log change in
viable count at 12 h (d12), 24 h (d24), 36 h (d36) and 48 h (d48). The
area-under-the-bacterial-kill curve was between 0−24 h (AUBKC24) and
0−48 h (AUBKC48).
Results: As the killing kinetics of both agents were the same for both
MRSA strains, the data was combined and compared (table).
MRSA (2 strains) VISA (1 strain)
tela teico P tela teico P
d12 −3.4±0.5 −2.8±0.2 p = 0.02 −2.0±0.4 0±0.4 p< 0.01
d24 −3.1±0.6 −2.9±0.2 p = 0.41 −2.7±0.2 1.0±0.4 p< 0.01
d36 −2.8±0.3 −2.6±0.3 p = 0.28 −3.1±0.6 1.2±0.3 p< 0.01
d48 −2.7±0.5 −1.3±1.4 p< 0.01 −2.8±0.9 1.0±0.3 p< 0.01
AUBKC24 22.7±10.1 42.0±2.9 p< 0.01 55.1±4.7 92.7±5.0 p< 0.01
AUBKC48 46.7±17.0 80.4±10.7 p< 0.01 79.9±10.5 216.2±13.9 p< 0.01
Conclusion: Tela produced a greater anti staphylococcal effect on the
MRSA strains than teico, showing more rapid early killing and lack of
grow back. Tela was also signiﬁcantly more effective against the VISA
strain than teico. This data helps support the clinical use of tela as an
alternative therapy to teico.
P1987 Pharmacodynamic comparison of daptomycin and
vancomycin against clinical isolates of methicillin-resistant
Staphylococcus aureus in three European countries
A. Canut °, A. Rodrı´guez-Gasco´n, E. Cercenado, C. Betriu´, A. Labora,
J.L. Pedraz (Vitoria, Madrid, ES)
Objective: A reduction in the efﬁcacy of vancomycin against
methicillin-resistant Staphylococcus aureus (MRSA) strains with high
vancomycin MIC values (1−2mg/L) has been described in recent studies.
Accordingly, the objective of the current study was to calculate the
probability of attaining targeted pharmacodynamic exposure for various
regimens of vancomycin and daptomycin against clinical isolates of
S. aureus collected in Belgium, United Kingdom and Spain.
Methods: Susceptibility data to vancomycin and daptomycin of clinical
MRSA isolates from Belgium (n = 511), United Kingdom (n = 97) and
Spain (n = 298) were analyzed. Steady-state exposure was assessed
for the following antibiotic regimens: vancomycin (1000mg/12 h,
1000mg/8 h, 2000mg/12 h, 1500mg/8 h and 1500mg/6 h) and dapto-
mycin (4, 6, 8mg/Kg every 24 h). Mean pharmacokinetic parameters and
their distribution were extrapolated from published patients’ studies for
each antibiotic. The area under the concentration-time curve divided by
the MIC (AUC/MIC) was utilised as the pharmacodynamic parameter to
predict vancomycin and daptomycin efﬁcacy (pharmacodynamic targets
of >400 and >438, respectively). For vancomycin, Cmin,free/MIC
was also calculated (values of >4). A 10000-patient Monte-Carlo
simulation was performed to calculate the AUC/MIC for vancomycin and
daptomycin and Cmin,free/MIC for vancomycin. Cumulative fraction of
response (CFR) for the requisite pharmacodynamic target was calculated
weighing the probability of target attainment at each MIC by the
percentage of organism with that MIC.
Results: In Belgium, CFR higher than 90% was achieved with
vancomycin doses higher than 1000mg/8 h. However, in United
Kingdom and in Spain, CFR> 90% is only achieved with the highest
dose: 1500mg/6 h. The differences are due to differences in susceptibility
of the isolates; whereas in Belgium 100% of the isolates presented
MIC values 1mg/L, only 64% and 69% of the isolates reached these
MIC values in United Kingdom and in Spain, respectively. Concerning
daptomycin, CFR values higher than 90% are achieved with the lowest
dose (4mg/Kg) for isolates from Belgium, United Kingdom and Spain.
CFR values of 100% were achieved with 6mg/Kg and 8mg/Kg in the
isolates of the three countries.
Conclusion: Daptomycin had a greater likelihood of obtaining its
requisite pharmacodynamic exposure against MARSA due to the
excellent activity against all strains recovered in Belgium, United
Kingdom and Spain.
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P1988 In vitro bactericidal activity of daptomycin versus
vancomycin Cmax concentrations in the presence of
human albumin physiological concentrations against
vancomycin-susceptible but tolerant methicillin-resistant
Staphylococcus aureus
M. Torrico, L. Aguilar, N. Gonzalez, M.J. Gimenez, F. Caﬁni, L. Alou,
D. Sevillano °, R. Cleeland, J. Prieto (Madrid, ES; East Hanover, US)
Objective: To study the antibacterial activity (log10 reduction) and
time to obtain bactericidal activity (time to obtain 3 log10 − 99.9% −
initial inocula reduction, T99.9%) in the presence of physiological
concentrations of human albumin by concentrations similar to Cmax
obtained in serum with 6mg/kg od daptomycin and 1g bid vancomycin
regimens, against vancomycin-susceptible but tolerant methicillin-
resistant Staphylococcus aureus (MRSA).
Methods: Killing curves were performed with ﬁnal inocula of approx.
107 cfu/ml, and a ﬁnal concentration of 98.6mg/l daptomycin or
65.7mg/l vancomycin, using as media Mueller-Hinton broth (Cmax-MH)
and MH broth with 4 g/dl human albumin (Cmax-HAlb). In the case of
daptomycin, media were supplemented with Ca2+ (by adding 100mg/l
of Ca2+ in media containing albumin and 50mg/l in media without
albumin) in order to obtain a physiological free Ca2+ concentration.
Results: MIC/MBC (mg/l) of daptomycin and vancomycin, T99.9% (h)
and log10 initial inocula reduction at 12 h/24 h are shown in the Tables.
Daptomycin
MIC/MBC 1/1
Strain 1
1/2
Strain 2
2/2
Strain 3
2/4
Strain 4
T99.9% 12 h/24 h T99.9% 12 h/24 h T99.9% 12 h/24 h T99.9% 12 h/24 h
Cmax-MH 2 5.8/5.9 1 6.0/6.0 1 6.0/6.0 2 6.0/6.0
Cmax-HAlb 3 5.5/5.6 2 6.0/6.0 2 6.0/6.0 3 5.2/5.9
Vancomycin
MIC/MBC 0.5/16
Strain 1
1/32
Strain 2
2/32
Strain 3
1/32
Strain 4
T99.9% 12 h/24 h T99.9% 12 h/24 h T99.9% 12 h/24 h T99.9% 12 h/24 h
Cmax-MH >24 0.1/0.4 >24 0.1/1.3 >24 0.1/1.0 >24 0.1/1.5
Cmax-HAlb >24 0.1/0.9 >24 0.3/1.8 >24 0.2/1.3 >24 0.2/1.1
Conclusions: Daptomycin Cmax exhibited rapid (3 h) bactericidal
activity while vancomycin did not achieve bactericidal activity along
24 h against vancomycin-susceptible but tolerant MRSA. The presence
of human albumin physiological concentrations slightly delayed T99.9%
for daptomycin.
P1989 Vancomycin protein binding in a general hospital
population with S. aureus sepsis
A. Lovering °, M. Darville, A.P. MacGowan (Bristol, UK)
Objectives: Pharmacodynamic assessment of antibacterials is now most
often conducted using free drug concentrations. This means that protein
binding (PB) is a vital pharmacokinetic measure and the distribution of
PB values in patients needs to be known for Monte Carlo modelling. In
man, vancomycin outcome has been predicted by total drug AUC:MIC
ratio with little reference to PB. Although there are published PB data
for vancomycin (VAN), patient-based data are limited (<50 patients)
and appear to differ from data for healthy volunteers; as a result, it is
not clear which free drug values should be used in pharmacodynamic
analysis. The purpose of this study was to determine the PB of VAN
and its variance in patient population with S. aureus infection.
Methods: Over a 3m period (2008), pre dose VAN samples from 81
patients with conﬁrmed staphylococcal sepsis were collected. PB was
evaluated by ultraﬁltration and concentrations of VAN were determined
by ﬂuorescence polarisation assay. Multivariate analysis was undertaken
to investigate associations between the degree of PB and individual
patient factors.
Results: The mean patient age was 66 y (range 24−98) and the mean
total VAN concentration 9.8mg/L (range 3.6−18.4mg/L). The mean
PB was 31.5% (95%CI 29.9–33.0%) with a range from 12.6–55.7%.
In multivariate linear regression, no relationship was found between
age (P = 0.857), total VAN concentration (P = 0.866), serum albumin
(P = 0.981) but a weak association (0.046% increase in PB per mL/min
increase in eGFR) was seen between PB and eGFR (P = 0.016).
Conclusion: In patients with S. aureus sepsis VAN PB is more consistent
with healthy volunteer data (PB≈ 30%) than to the limited patient
data (PB≈ 50%). Unlike earlier studies, we did not ﬁnd a relationship
between albumin and PB, perhaps related to differences in patient
populations studied and/or severity of sepsis. We conclude that in a
general hospital population, VAN PB may be lower than often believed.
In pharmacodynamic calculations, PB values derived from infected
patients relevant to the population being studied should be employed.
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P1990 Clinical features of acute hepatitis A outbreak in Korea
H. Choi °, S.J. Jeong, H.S. Lee, B.S. Chin, S.H. Han, D.Y. Kim,
J.Y. Park, C.O. Kim, J.Y. Choi, Y.G. Song, J.M. Kim (Seoul, KR)
Objectives: From April 2008 to August 2008, many cases of hepatitis A
were notiﬁed in Korea. The aim of the present study was investigate the
clinical features of recent hepatitis A outbreak.
Methods: We retrospectively reviewed the medical records of 245
patients with acute hepatitis A from January 2006 to November 2008.
Patients who 1) were positive to the other markers of acute hepatitis,
2) had underlying liver disease, 3) had a history of recent exposure of
hepatotoxic drugs, and 4) had biliary obstruction on imaging studies
were excluded. A total of 221 cases of hepatitis A were analyzed in this
study. We compared clinical manifestations of hepatitis A between this
outbreak (April 2008 to August 2008, Period 1) and before the outbreak
(January 2006 to March 2008 and September 2008 to November 2008,
Period 2).
Results: 113 cases of hepatitis A were detected during Period 1 (160.0
cases per 10,000 hospital admissions). The mean age was 32 and
the proportion of adult patients older than 30 yr was increased from
62.7% during period 1, to 46.5% during period 2 (p = 0.024). The most
frequently reported symptoms include fever, myalgia, nausea, abdominal
pain and dark urine. The proportions of severe hepatitis A were 11.8%
during period 1 and 6.1% during period 2, respectively. Eleven patients
experienced acute renal failure and all of them completed recovered
from renal failure (5 patients during period 1 and 6 patients during
period 2). The laboratory tests (WBC count, Hemoglobin, platelet count,
AST, ALT, total bilirubin, albumin and prothrombin time) at admission
day were not signiﬁcantly different. One patient developed fulminant
hepatitis with hepatic encephalopathy and expired due to liver failure
(Period 2). Others completely recovered without sequelae.
Conclusion: The majority of hepatitis A cases were completely
recovered without sequelae although severe cases were slightly increased
during outbreak period. The proportion of adult patients older than 30 yr
has increased recently and this result is concordant with previously
reported data.
P1991 Cholestasis syndrome in viral hepatitis A
A. Petrov ° (Plovdiv, BG)
Objectives: Cholestasis forms in viral hepatitis A (VHA) occurs rarely
and is more correct to note the presence of cholestasis component
in the jaundice cyclical form of the disease. Despite the marked
patomorfological changes showing reliable intrahepatic cholestasis in
VHA, clinical manifested cases are single and found mostly in adult
patients.
Material and Methods: The study includs 820 patients with VHA,
of which 400 cases of sporadic icteric form of the disease for ﬁve
years period, 2002–2006 included as well as 220 children and 200 adult
patients from outbreak in gipsy residential districts of Plovdiv − 2006 y.
Analyzed are eight parameters characterising cholestasis syndrome: max
Hepatitis from A − E S583
T BIL, max ALT, ALP, GGT, lack of urobilinogen in urine, liver
sonography control, stay in the clinic and age.
Results: In 14 patients VHA evinces cholestasis component and 3 cases
are with cholestasis form of the disease. These are 2.07 percent of the
surveyed contingent. Of them − a young man of 17 years, eight women
and eight men aged between 27 and 62 years, with an average hospital
stay − 49.1±11.5 days, as the longest stay − 75 days, is of a 27 years old
man. Hyperbilirubinaemia is higher in the heat of the disease, average −
356.6mkmol/l, and detained more than 150mkmol/l over a month. The
values of T BIL in the discharge of the patients are at 2.5 times above
normal. Ten patients show transaminase activity over 1400U/l, average −
2011U/l, while one patient reached level of 4923U/l that lessened after
hospital stay of 51 days. In 14 patients the investigated acute icteric
form of the disease run expressed with distinct cytolysis. Against this
background are the symptoms of cholestasis syndrome: itching, acholic
stools, the disappearance of urobilinogen in urine, increased ALP and
GGT.
Conclusion: VHAmay manifest with cholestasis syndrome as 25 percent
of these cases are severe form of disease and 75 percent − medium. This
is conﬁrmed by raised transaminase activity, higher T BIL, expressed
adinamiya, intoxication, vomiting, headache, dizziness, objectiﬁed by
the score system, we have created.
P1992 Contemporary epidemiological characteristics of viral
hepatitis A in Plovdiv region, Bulgaria
N. Vatev °, M. Stoycheva, I. Batashki, M. Troyancheva, E. Kuncheva
(Plovdiv, BG)
Objectives: The aim of the work is: To examine whether during
the preceding several years there have been any alterations in the
epidemiology of VHA and whether there are substantial differences
in the epidemiology of the disease regarding different groups of the
population, living under different sanitary–hygienic conditions.
Methods: All clinical cases of VHA in 2005–2007 have been examined.
The comprehensive method for epidemiological research and analysis has
been used. A random group of 180 people has been examined to evaluate
the seroprevalence of anti-HAVt. The persons belong to 2 groups –
living under bad and good sanitary–hygienic conditions. The serological
research has been done with the ELISA method.
Results: The patients with VHA were 3 881. The morbidity rate varied
from 52.74% to 69.4%. 68.24% of the patients are from Roman origin,
living under bad sanitary–hygienic conditions and with low personal
hygiene. In this group the highest morbidity was established in the
childhood − above 60% in the age between 2 and 14 years. 31.76% are
persons living under good sanitary–hygienic conditions. The majority
of them (above 65%) are young people (20−30 years old), or older.
The results from the seroepidemiological research (such research not
having been performed in the country for more than 20 years) for the
seroprevalence of anti-HAVt are as follows: in the group of people
living under bad sanitary–hygienic conditions, the examined persons
are positive of anti-HAVt in 90.32%. The persons living under good
sanitary–hygienic conditions are positive in 44.83%.
Conclusion: Improvement in the sanitary–hygienic does not comprise all
groups of the population in a particular region or country. Therefore it is
necessary to conduct differentiated monitoring for control and prevention
of the disease for the separate groups. We identify considerable
differences in the epidemiology of VHA among the persons living under
different sanitary–hygienic conditions. Reduction of the morbidity from
VHA among people living under good sanitary–hygienic conditions
results in increase in the risk of becoming infected as adults. Therefore,
for them it is appropriately to conduct immunoprevention if they are in
contact with infected from VHA, or if they are traveling to a country
endemic of the disease. This is a new recommendation, additional to
the measures for prevention of the disease, which have thus far been
supplied for the population of the country as a whole.
P1993 Seroprevalence of and occupational risk for hepatitis A
among healthcare workers in Korean hospitals
E.S. Kim °, K.H. Park, C.S. Lee, A. Huh, M.S. Kim, S.I. Jung (Goyang,
Gwangju, Jeonju, KR)
Objectives: The cases of hepatitis A have been increasingly reported in
Korea due to socioeconomic growth and a relatively low immunisation
rate for hepatitis A in the general population. An outbreak of hepatitis A
in Korean healthcare workers (HCWs) was recently reported. This study
was performed to evaluate the serological epidemiology of hepatitis A
among HCWs in Korean hospitals.
Methods: A total of 3,696 HCWs in 4 hospitals were tested for IgG
antibodies against hepatitis A virus (HAV) using commercially available
kits in 2008. Data including demographic characteristics, occupations,
and departments were collected. Seroprevalence and risk factors were
evaluated.
Results: Among 3,696 participants, 2,742 (74%) were women and the
majority (96%) were in their twenties or thirties. The median age was
28 years (range, 19−68). Eighteen percent were medical doctors, 46%
nurses, 10% nursing assistants, 11% technicians, and 15% workers in
administration. Seropositivity for HAV signiﬁcantly increased with age
(p< 0.01); 2% for the age group <25 years, 15% for 25−29, 42% for
30−34, 76% for 35−39, and >90% for >40. Among the participants
under the age of 40, anti-HAV seroprevalence was signiﬁcantly lower
in HCWs working in the metropolitan area and in the group of medical
doctors. Statistically signiﬁcant difference was not seen according to the
departments.
Conclusion: Younger age, living in the metropolitan area, and working
as a medical doctor were associated with lower anti-HAV seroprevalence
in Korean HCWs. Immunisation for this group should be considered.
P1994 Modiﬁed epidemiology of hepatitis A in Italy. Prophylactic
measures targeted on potential sexual transmission
R. Manfredi °, L. Calza (Bologna, IT)
Introduction: Outbreaks of hepatitis A have been recently observed
worldwide, with special attention focused on homosexual men, i.v. drug
users, and also heterosexual partners.
Methods: An observational survey of all hospitalisations due to
hepatitis A occurred in the Bologna metropolitan area, performed from
1999 to mid-2007, was carried out.
Results: One hundred and 76 consecutive patients (p) with acute
HAV hepatitis were hospitalised. From October 2002 to September
2004, hepatitis A largely prevailed over acute HBV-HCV-HEV hepatitis.
Adult female p and children represented only 15.9% of overall cases.
Among the 176 p with ascertained acute hepatitis A, the prevalence of
immigrants increased over time, from 1−3 cases/year from year 1999
to year 2001, up to 14 cases in the 21 months elapsed from 2003
to September 2004 (p< 0.02). Even 121 out of 176 p (68.7%) were
represented by male adults, aged 22−56 y, who recognised unprotected
homo-bisexuals contacts in the two months preceding hepatitis A onset
in 83.5% of cases. Nobody was aware and/or underwent prior anti-
HAV vaccination. Among the 121 adult males with acute HAV hepatitis,
concurrent infections were found in 44 p (p< 0.003 versus other p with
HAV disease): chronic hepatitis B in 8 cases, hepatitis C in 19, syphilis
in 11, and HIV in 11 p. The temporal trend of male adults admitted for
hepatitis A showed a signiﬁcant increase from 1999 to the ﬁrst 9 months
of 2004: a ~300% increase versus the year 1999, leading to a crude rate
of 7.7/100,000 residents/year.
Conclusions: Despite the availability of anti-HAV vaccination, and
information campaigns against the spread of STD and HIV, the
epidemic of HAV recognizes an increased prevalence of homo-
bisexual transmission. Epidemiological monitoring, targeted educational
campaigns, and public health measures (such as an recommendation of
immunoprophylaxis), may help contain the outbreak of hepatitis A by
sexual route, and reduce the spread of other concurrent STDs.
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P1995 Medical nursing students’ knowledge and attitudes toward
viral hepatitis in Turkey: a multi-centre cross-sectional study
T. Yamazhan, R. Durusoy, M. Tasbakan, Y. Tokem, H. Pullukcu,
O. Sipahi °, S. Ulusoy (Izmir, TR)
Objectives: Medical nurses can potentially be exposed to the hepatitis
B (HBV) or C virus (HCV) during their daily nursing tasks. Transmission
can typically occur following a needle stick injury or mucosal exposure.
It is necessary to inform them about viral hepatitis and to complete
a full course of HBV immunisation regarding their prevention. The
objectives of this study were to identify medical nursing students’ levels
of knowledge on viral hepatitis and to ascertain their immunisation status
of hepatitis A virus (HAV) and HBV infection in Turkey.
Methods: This cross-sectional study was conducted on third and fourth-
year nursing students in 14 nursing schools located on all geographical
regions of Turkey. A questionnaire comprising of 47 questions was
applied (including 12 questions on sociodemographic factors, 22 about
level of knowledge on HAV, HBV, HCV, 5 about immunisation status,
4 about risky behaviour history and attitudes in these situations). The
knowledge score of participants was calculated by assuming that every
correct answer=1 point, with maximum possible score 33.
Results: 1491 third and fourth-year nursing students were enrolled in the
study. The mean age of the students was 21.4±1.3. The mean knowledge
score of students was 23.7±4.6. The mean knowledge score of fourth-
year students was signiﬁcantly higher than third-year students (p:0.000).
Students graduated from medical high school and who have a family
member with chronic HBV infection had higher knowledge score than
others (p:0.000 and p:0.01). 56.8% of the students rated their own
knowledge level of viral hepatitis as intermediate and 29.9% of them
rated as good. Knowledge sources of students were university education
93%, web pages 49.1%, high school education 41.4%, printed media
35% and TV/radio 27.2%. 85.3% of the participants had received HBV
vaccine and 9.1% had received HAV vaccine. The percentage of students
who signify themselves at increased risk of acquiring viral hepatitis
was 97.3%. 28.1% of the students had needle stick injury and 5.4%
had conjunctival exposure to blood. 98.2% % of participants stated that
they would take different precautions before performing routine tasks to
patients with known infection.
Conclusion: Medical nursing students are at risk of acquiring blood-
borne infections during their daily practice. This should be considered
before management of education programmes about transmission of
blood-borne infections and protection strategies.
P1996 Chronic hepatitis E in human immunodeﬁciency
virus-infected patients living in south-eastern France
M. Kaba, P. Brouqui, H. Richet, I. Ravaux, J. Moreau, C. Tamalet,
J.M. Rolain, D. Raoult, P. Colson ° (Marseille, FR)
Objectives: Autochthonous hepatitis E is an emerging disease in
industrialised countries. Chronic hepatitis E and even hepatitis E-
associated cirrhosis have been recently described in organ-transplant
recipients. This deserves increased awareness for HEV infection in
immunosuppressed individuals. Limited information is available about
HEV infection in HIV-infected patients (pts). We aimed at assessing the
prevalence of anti-HEV antibodies (Ab) and HEV RNA in HIV-infected
pts in Marseilles, south-eastern France.
Methods: Serum samples from 190 HIV-infected pts were tested for
IgG/IgM anti-HEV Ab, and HEV RNA using in house real-time PCR
and sequencing assays. HIV-1-infected pts were divided into 4 groups:
73 pts had a CD4-cells count (CD4cc) <50/mm3 (mean, 27/mm3), 69
were recently diagnosed (in 2006) for their HIV infection (mean CD4cc,
386/mm3), 31 had liver cirrhosis (mean CD4cc, 375/mm3), and 17 were
infected with HIV-2 (mean CD4cc, 481/mm3).
Results: IgG anti-HEV Ab were detected from 15 pts (8%); 5 of them
were concurrently IgM anti-HEV Ab+. In addition, 2 other pts only
harboured IgM anti-HEV Ab. IgG anti-HEV prevalence was 8%, 3%,
14%, and 13% in groups 1, 2, 3, and 4, respectively, without signiﬁcant
differences between groups. HEV RNA was detected from one HIV-1-
infected pt. Retrospective analysis of sequential serum samples showed
HEV RNA and IgM anti-HEV Ab detection from June 2006 until March
2007 (10 months), indicating chronic HEV infection. Further follow-up
was not possible since the pt died due to cardiovascular disease. IgM anti-
HEV Ab could be detected from June 2006 until March 2007, whereas
testing for IgG anti-HEV was negative on all serum samples. The pt was
a 44-year-old male who acquired HIV through intravenous drug use and
was diagnosed in 1986 in the setting of Hodgkin lymphoma. In June
2006, the CD4cc was 157/mm3, virological markers indicated past HBV
and HCV infections, and ALT level peaked at 219 IU/l. The pt underwent
several courses of chemotherapy for non-Hodgkin lymphoma from the
end of 2006. The CD4cc progressively decreased to reach 27/mm3 in
March 2007. ALT were within normal range from September 2006. The
patient did not recently travel abroad. HEV genotype was 3f.
Conclusion: HEV should be considered as an aetiologic agent of
hepatitis in HIV-infected individuals and might cause chronic infection
in this population. HEV RNA and IgM anti-HEV Ab testings should be
performed for reliable diagnosis of HEV infection.
P1997 Acute liver failure due to HEV in a long-term oral
contraceptive treated patient
M. Rodrı´guez-Domı´nguez °, J. Graus, S. Ferna´ndez-Barredo, M.T. Pe´rez-
Garcı´a, F. Garcı´a de la Hoz, M.L. Mateos (Madrid, Valencia, ES)
Introduction: HEV causes epidemics in developing countries but in
industrialised there are autochthonous cases with different clinical and
epidemiological features. In pregnant women the mortality rate is very
high (up to 20%) mainly in the third quarter of pregnancy. Recently
we have had a case of sudden hepatitis E in a patient treated with oral
contraceptives. The sudden course may have been caused by a hormonal
situation similar to pregnancy.
Case report: A 37 years old woman, was attended in our Hospital
with an important increase in transaminases (AST 4522 U/L and ALT
3751 U/L), jaundice and coagulation changes (INR 1.5 rising to 3.7 at
48 hours despite of K vitamin treatment). Serological markers against
HAV, HBV, HCV, HIV, EBV CMV and HHV were negative. IgG and IgM
against HEV were positive by inmuno-enzymatic assay and conﬁrmed
by inmunoblot, also RNA-HEV from two samples was detected by
RT-nested-PCR. Genotype was 3f. A partial sequence of the strain
isolated was obtained and compared to other human and swine strains.
Phylogenetic analysis of a 260 bp long fragment belonging to the ORF2
revealed that this isolate showed a high homology (91.9–97.3%) with
some Spanish human strains followed by other Spanish swine strains
(86.9–94.2%). Compared to other human European strains, the closest
homology was with some British strains (83.4–91.9%), and compared to
other European swine strains, the highest homology was for Dutch strains
(81.9–93%) followed by British (85.7–86.5%). Most of the mutations
were found to be silent and did not result in signiﬁcant differences at
the amino acid level. The only previous data about toxics or drugs was
oral contraceptives during last 20 years. Patient got better after admission
taking routine antiencephalopathy treatment, K vitamin, acetil-cistein and
antimicrobial prophylaxis. Liver transplant was not necessary because of
the improvement of the patient.
Discussion: We think this is the ﬁrst case of acute liver failure in a
non pregnant women taking oral contraceptive, caused by HEV. An
exhaustive interview was made in our patient in order to investigate
risk factors that could justify the sudden course of hepatitis E. Only
contraceptive oral treatment during 20 years could be found as risk factor.
It has been suggested that estrogens and progestagens can simulate a
pregnancy situation. Contraceptive treatment may be considered a risk
factor for sudden course of hepatitis E.
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P1998 Prevalence of HBV, HCV and HIV infections among
obstetrics/gynaecology patients
K. Tsiveriotis, N. Siafakas, J. Meletiadis °, S. Damianidou, D. Fioretou,
L. Zerva (Athens, GR)
Introduction: Hepatitis B and C and the acquired immunodeﬁciency
syndrome are major problems of public health worldwide. Infection of
woman of childbearing age by these viruses is especially important
due to the risk of vertical transmission in the perinatal period. The
purpose of this study was to analyze results of routine serology screening
for hepatitis B virus (HBV), hepatitis C virus (HCV) and human
immunodeﬁciency virus (HIV) among patients of the Department of
Obstetrics/Gynaecology of our hospital.
Materials and Methods: The study included all patients admitted to the
Department of Obstetrics/Gynaecology during a 17 months period (from
7/2007 until 11/2008) and tested for markers of HBV, HCV and HIV
infection. All data were retrospectively retrieved from laboratory records.
Testing for HBsAg, anti-HBc, IgM anti-HBc, anti-HBs, HBeAg, anti-
HBe, anti-HCV and anti-HIV was performed by a Microparticle Enzyme
Immunoassay (AxSYM, Abbott), whereas the Inno-Lia (Innogenetics)
and NewLavBlot (BioRad) Western Blot assays were used for the
conﬁrmation of HCV and HIV positivity.
Results: Among 1,403 women that were examined for HBV infection,
197 (14%) had been exposed to the virus (anti-HBc positive). Past
infection (HBsAg negative) was detected in 171 (12.2%), while
26 (1.8%) suffered from chronic infection (HBsAg positive). No
woman exhibited signs of acute disease (IgM anti-HBc negative),
whereas 282 (20%) were either vaccinated or had a past infection
with undetectable anti-HBc titers (anti-HBc negative/anti-HBs positive).
Chronically infected patients were all HBeAg negative and anti-HCV
negative; at least 38% of them were immigrants from other countries.
Among 1,648 women examined for anti-HCV, only 9 (0.5%) were
conﬁrmed as positive. Finally, all 1,549 women that were tested for
anti-HIV were negative.
Conclusions: The prevalence of HCV infection is low between women
hospitalised in the Department of Obstetrics/Gynaecology of our
hospital. However, the higher prevalence of chronic HBV infection
and the low frequency of anti-HBs positivity imply that intensiﬁcation
of vaccination programs is required. Finally, the predominance of the
HBeAg negative/anti-HBe positive pattern among chronically infected
patients indicates a low risk of vertical perinatal transmission in this
population.
P1999 Molecular epidemiology of hepatitis B virus infection
among chronic carriers in Greece, 2000–2007
A. Fylaktou, D. Papaventsis, L. Skoura °, M. Daoudaki, N. Malisiovas
(Thessaloniki, GR)
Objectives: Hepatitis B virus (HBV) infection is a global health problem
affecting >1/3 of the world’s population. Greece is considered an
intermediate endemicity area, where genotypes A and D predominate.
The purpose of this study was to investigate HBV genotypes and HBsAg
subtypes among HBV chronically infected patients, as no previous
genotype data were available from Greece.
Methods: Serum samples from 136 HBsAg (+) patients were tested
(Jan 2000-Dec 2007). Virologic and biochemical markers (serum ALT)
used in HBV monitoring were analyzed. HBsAg, anti-HBs, HBeAg
and anti-HBe were measured by commercial immunoassay (AxSYM
or ARCHITECT, Abbott Diagnostics, France). Serum HBV DNA
was analyzed quantitatively with Cobas Amplicor (Roche Diagnostics,
Basel, Switzerland). HBV genotypes were studied by partial sequencing
of the S gene, containing the HBsAg “a” antigenic determinant.
Genotyping was performed by using the NCBI online Genotyping tool
and phylogenetic analysis. Nucleotide sequences were aligned pair wise
with ClustalW and phylogenetic trees were constructed by the neighbour-
joining method. Statistical signiﬁcance was estimated by bootstrap
analysis. The sequences were also used to predict the HBV HBsAg
subtype.
Results: In 6/136 (4%) patients, coexisting HBsAg and antiHBs were
found. Forty-six of 136 (34%) were HBeAg(+), 86/136 (63%) were
anti-HBe(+), and 4/136 (3%) were HBeAg(+)/antiHBe(+). Mean ALT
was 238 IU/L, and HBV-DNA levels ranged from 8.2×105–11.51×107
copies/ml. Agreement between the two genotyping methods was found in
all cases and a HBV genotype was assigned to all samples. Genotype D
was almost exclusively prevalent (133/136=98%). Viral groups D/ayw2
(73%) and D/ayw3 (25%) were predominant. Group A/adw accounted for
the 1% of cases. Strains from genotypes B and C were exclusively found
among Chinese immigrants (1%). Single or multiple point mutations
were found in 35 cases (26%). Some of the most common mutations
occurred in amino acid positions 129, 133, 134, 144, and 145, including
the ‘vaccine escape’ mutation G145R.
Conclusion: This was the ﬁrst study presenting data regarding HBV
genotypes in chronic HBV carriers in Greece. Our data conﬁrmed that
genotype D predominates in the Mediterranean basin. HBsAg escape
mutants were found highly prevalent. Epidemiological monitoring of
occult HBV is essential for HBV vaccine designing and for diagnostic,
transplantation, blood banking, and haematological health services.
P2000 Prevalence of sexually transmitted diseases among female pa-
tients presenting with hepatitis B virus and human immun-
odeﬁciency virus infections in a Nigerian teaching hospital
O. Onigbogi °, O. Ojo (Ibadan, Lagos, NG)
Objectives: The prevalence of HIV infection has been on the increase in
Nigeria in recent times. HIV-positive patients in our setting sometimes
have hepatitis B virus (HBV) infection co-existing in them. Female
patients are sometimes at particular risk because of the co-existence
of other sexually transmitted infections (STIs) with these two viral
infections. The aim of the study was to determine prevalence of sexually
transmitted infections among female patients attending the clinic in a
Nigerian teaching hospital. The clinic also serves as the reference centre
for STIs in our region of the country.
Methods: A retrospective review of 221 case notes of human
immunodeﬁciency (HIV)-positive female patients who had been found
to also have HBV infection from January 2001 to December 2007 were
analyzed by utilising an on-going observational database at the STI
clinic. Records of sexually transmitted diseases were based on clinical
assessment and laboratory diagnosis as recorded in the case notes. Rate
ratios, comparing prevalence rates (number of infections among the
women surveyed) were calculated.
Results: The age of the women surveyed ranged from 18 to 54 years.
Twenty-two (10%) of the patients were found to have clinical and
laboratory evidence of several other STIs co-existing. Fifty patients
(38%) had clinical and laboratory evidence of single-occuring STIs.
Sixteen respondents (31%) had gonorrhoea infection, 14 (29%) had
chlamydiasis, 13 (25%) had candida infection while 7 respondents (13%)
had trichomoniasis.
The survival rate among women with STIs with HIV and HBV co-
infection rose from 2.28 to 3.12 in the last 2 years of the review (Rate
ratio = 3.15; 95% conﬁdence interval (CI) =1.31–7.44; p = 0.0002).
Conclusion: There was been a signiﬁcant rise in the incidence of co-
existing multiple STIs in the years 2005 and 2006. This coincides
with the introduction anti-retroviral drugs in the hospital with greater
survival rates and increased attendance and testing. Care providers should
therefore be more vigilant for co-existing STIs and more aggressive in
their management especially among HIV-positive women because of the
peculiar nature of such infections when they also co-exist with HBV.
P2001 Occult hepatitis B infection in Tunisian pregnant women
N. Hannachi, O. Bahri, S. Mhalla, H. Triki, J. Boukadida ° (Sousse,
Tunis, TN)
Objective: In Tunisia, the national screening programme for identi-
ﬁcation of hepatitis B virus (HBV) infection in pregnant women is
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based on HBs antigen (HBsAg) test. HBV-DNA in the serum can be
detected in the absence of HBsAg in case of occult hepatitis B infection.
The objective of this study is to evaluate the prevalence rate of occult
hepatitis B in healthy pregnant Tunisian women.
Methods: During one year period (September 2007 to September
2008), a total of 2709 pregnant women were prospectively screened
for HBsAg and anti-HBc antibody (anti-HBc). Negative HBsAg sera
were systematically tested for anti-HBs antibody (anti-HBs). Detection
of HBV-DNA was performed for “anti-HBc isolated” sera. The presence
of HBV genome was tested by a single-step PCR in Pre-S gene and a
nested PCR in X region. The sensitivity of the PCR assays was evaluated
using samples with known viral load.
Results: Seroprevalence of positive HBsAg was 4%. Vaccinal immunity
was detected in 3% of HBsAg negative women. Anti-HBc was detected
in 22% of pregnant women (including HBsAg positive women). Anti-
HBc was associated with anti-HBs in 13.5% and isolated in 4.5% of total
pregnant women. Among 123 women with anti-HBc isolated marker,
anti-HBs concentration varied between 5 and 10mUI/ml in 19 women.
Detection of HBV-DNA was performed in 98 cases (with anti-HBs lower
than 5mUI/ml) and was positive in three cases (3%) by the two PCR
assays. Sensitivity of HBV-DNA detection was 103 copies/ml.
Conclusion: occult hepatitis B can be misdiagnosed by selective HBsAg
screening in pregnancy. This can lead to a lack of appropriate prophylaxis
in newborns. Anti-HBc antibody should be tested routinely on pregnant
women especially in a country of intermediate endemicity for HBV
infection. More effort is needed for HBV vaccination strategies in
Tunisian women.
P2002 Prevalence of hepatitis B genotypes and resistance
mutations in patients with chronic hepatitis B infection
A. Gutierrez °, I. Viciana, L. Mora, A. Infante, E. Clavijo, V. Garcia,
A. Pinedo (Malaga, ES)
Introduction: Nearly 400 million people worldwide suffer from chronic
hepatitis B virus (CHB) infection. HBV strains can be classiﬁed into
eight genotypes, designed A-H with distinct geographical distribution.
Seven drugs have been approved for the treatment of CHB and others
already used as antiretroviral agents show anti HBV activity and most
likely will soon be approved as therapy for hepatitis B. However, the
emergence of HBV resistance mutations can reduce or annul the activity
of the drugs.
Objective: The aim of this study was to estimate the distribution of
genotypes of HBV and the prevalence of drug resistance mutations
in patients with chronic hepatitis B attending in several centres across
Malaga (Andalucia).
Methods: Genotype and drug resistance mutations were determined by
population sequencing using TruGene HBV genotyping kit (Siemens
Healthcare). For nucleic acid isolation we used the automatic system
MagnaPure (Roche) in patients with detectable viral load of HBV.
Results: A total of 143 patients with chronic hepatitis B infection were
recruited at 3 care centres during years 2005–2008. Of these, 70.6%
were male and 29.4% female with the following characteristics: median
age 46 years, median baseline viral load 1.7 107 copies/mL and unknown
factors for HBV infection in 66.1% following for vertical transmission
in 25.2%. Genotype distribution was: Genotype A: 36 (25.4%): A2 90%,
A1 10%, Genotype D: 86 (60.6%), Genotype E: 5 (3.5%), Genotype F:
3 (2.1%). Genotype G: 1 (0.7%). Coinfection with several genotypes
were not detected. 80 patients (56%) were under antiviral treatment and
in 32(40%) resistance mutations were selected. The changes in the HBV
polymerase were L180M and M204 I/V in 30 cases(21.1%) with cross
resistance to Lamivudine, Emtricitabine and Telvibudine and N236T
and A181V/T which confer resistance to Adefovir in 5(3.5%) of cases.
Mutations associated with Entecavir or Tenofovir were not selectioned
and transmission of drug resistant strains were not detected.
Conclusions: The genotype predominant in our area is genotype D
following for genotype A. The rate of emergence of HBV resistance
mutations is signiﬁcant in patients on going treatment, mainly those
associated with Lamivudine. The availability of antiretrovirals with
potent antiHBV activity, in particular Entecavir and Tenofovir, appears
to modify this poor outcome in recent years.
P2003 Delta hepatitis infection in patients with chronic hepatitis B
infection in Isfahan, Iran
B. Ataei °, H. Kalantari, S. Soleimani, A. Javadi, P. Adibi, M. Yaran,
Z. Nokhodian, M. Ataie (Isfahan, IR)
Introduction: Hepatitis D virus is a defective RNA virus dependent on
hepatitis B virus infection for its replication and expression. Infection
with HDV can occur simultaneously with acute HBV infection or
may be superimposed on chronic HBV infection. It is known that
coexistent infection with HBV infection with HDV tend to accelerate
the progress of chronic HBV infection to chronic hepatitis, cirrhosis and
hepatocellular carcinoma. This study was carried out to determine the
seroprevalence of HDV among chronic hepatitis B patient in Isfahan in
year 2008.
Materials and Methods: This study was done at ﬁrst 7 month of year
2008 and was cross-sectional and done among 347 chronic hepatitis B
patients that got along more than six months from their diagnosis and
had medical ﬁle at infectious disease and tropical medical research
centre. All Case were evaluated for the presence of total HDV Ab using
Elisa (Diapro-Italy). Chi-square and Fisher test and T-student was used
to determine the relationship between independent variables and HDV
seropositivity.
Results: Of 347 cases 246 were male (70.9%) and 101 were female
(29.1%). 232 were Anti HBe positive (66.9%) with mean age 41.2±11.8
and 88 were HBe Ag positive (25.4%) with mean age 34.6±12.8. Anti-
HDV Anti body was positive in 6 male (2.4%) and in 4 female (4%)
(P = 0.48). Anti HDV Ab was positive in 8 Anti HBe positive (3.4%)
and in 2 HBe Ag positive (P= 0.5). The mean age in HDV Ab positive
patients was 43.9±12.4 years. Mean long duration disease in HDV Ab
positive patients was3.5±2.7 years. The total seroprevalence of HDV Ab
in hole patients was 2.9%.
Conclusion: This Findings show that HDV infection is endemic in
Isfahan province and its prevalence is high in HBe Ab positive patients
than HBe Ag positive patients. We found no relationship between HDV
seropositivity and age, sex, long duration of disease and kind of diagnosis
and transmission. The seroprevalance of hepatitis D in this study at
compare previous study in Iran is nearly equal.
P2004 Prevelance of blood-borne viruses amongst antenatal clinic
patients and blood donors in a tertiary referral hospital in
Oman
H. Schuster °, E. Serebour, J. Nograles, I. Al-Belushi, K. Hassan
(Muscat, OM)
Objective: Recent data published for the Gulf region on chronic
hepatitis B infection in pregnancy suggested a prevalence of 7.1% for
Omani woman. The sample population in this report was small and
we intended to re-evaluate the prevalence of Hepatitis B infection for
pregnant woman attending antenatal care at Sultan Qaboos University
Hospital. We compared the data for Hepatitis B and HIV infection and
also assessed the Hepatitis C infection rate amongst of a blood donor
population at the same institution.
Methods: The laboratory information for HIV, HBV and HCV infection
data was obtained from the laboratory information system for the period
from 01/07/2006 to 31/12/2008. The data was analysed with MSExcel
and Minitab.
Results: Amongst 3142 pregnant woman a prevalence rate of 7.07%
was found for chronic HBV infection. 0.12% of chronic infections
in pregnancy were of high infectivity. For 0.34% neither Hepatitis B
e antigen nor anti-Hepatitis B e antigen antibody could be detected.
There was a signiﬁcant difference between the HBV infection rate
amongst blood donors (n = 6726) and pregnant women 2.81% vs. 7.07
respectively. The HIV rate was found to be 0.17% for pregnant women
and amongst blood donors 0.01%. Only blood donors were tested for
HCV infection and a rate of 0.45% was seen.
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Amongst blood donors anti-Hepatitis core antibody was detected in
18.8% of 745 donors without Hepatitis B surface antigenaemia. Hepatitis
core antibody testing had only been introduced into blood bank screening
in November 2008.
Conclusions: The rate of hepatitis B infection in Omani pregnant women
remains at an intermediate endemicity level. The lower blood donor
prevalence may be explained by a pool of stable donors although ad
hoc blood donations by relatives are common. The HIV rate amongst
pregnant women is very low and even lower in the blood donor
population. The HCV infection rate amongst blood donors is very low
in the Sultanate.
A high rate of anti-Hepatitis B core antibody presence was found for
blood donors without Hepatitis B surface antigenaemia. Because of the
danger of occult HBV infection in such cases strategies for effective
testing have to be found in order to maintain sufﬁcient quantities of
blood products.
Prevalence of blood borne viruses amongst antenatal clinic patients and blood
donors in a tertiary referral hospital in Oman from 01/07/2006 to 31/12/2008
Antenatal
clinic
Blood
donors
HBV
Total patients 3142 6762
Total tests 7002 10100
Age range at ﬁrst visit (yrs) 12–55 17−65
Mean age at ﬁrst visit (yrs) 28.8 28.1
HBsAg positive patients 222 190
Prevalence rate (%) 7.07 2.81
Hepatitis B carriers, n (%)
high infectivity 4 (0.12) 14 (0.21)
low infectivity 208 (6.61) 169 (2.5)
HBeAg and anti-BeAg antibody negative, n (%) 10 (0.34) 7 (0.1)
HIV
Total patients 3015 6690
Total tests 7006 10272
Age range at ﬁrst visit (yrs) 13–53 17−65
Mean age at ﬁrst visit (yrs) 28.9 28
HIV positive (conﬁrmed by Western Blot), n 5 1
Prevalence rate (%) 0.17 0.01
HCV
Total patients 6725
Total tests 10272
Age range at ﬁrst visit (yrs) 17−65
Mean age at ﬁrst visit (yrs) 28
HCV positive (conﬁrmed by HCV RIBA), n 30
Prevalence rate (%) 0.45
P2005 Atypical serological pattern in chronic hepatitis B virus
infection: a real problem or a sensitivity default of the
analytical kit?
L.S. Iancu °, C. Durnea, A. Nastase, E. Enache, C. Manciuc,
G.I. Pandele (Iasi, RO)
Chronic carriage of hepatitis B virus (HBV) is sometimes associated
with an atypical serological pattern characterised by the presence of
hepatitis B surface antigen (HBsAg) without antibodies to the HB core
antigen (HBcAb).
The objective of our work was to study the reasons of the lack of HBcAb
in HBsAg positive chronic HBV infected patients.
Methods: From 320 cases of chronic hepatitis and cirrhosis, 44 patients
(13.7%) were selected as reaching our criteria. The sera were provided by
2 hospitals in 2007 in order to select samples for DNA/HBV genotyping
analysis.
Measurements of HBsAg, anti-HBcAb, in paralel with HBeAg, anti-
HBeAb were done using commercially available ELISA kit from
DiaSorin (ETI-AB-COREK-PLUS – producer A). The discordant results
for HBcAb obtained after ﬁrst set of determination imposed the new tests
using ELISA kits from Biome´rieux (Hepanostika anti-HBc Uni-Form –
producer B) and Orgenics (ImmunoLISA HBc Ab – producer C).
Results: From 44 cases, 7 sera (2.1%) remained negative for HBcAb
using B kit and 9 sera (2.8% respectively) with C test. For 2 discordant
results the samples absorbances from B producer were around to
cutt-off values and we can consider the results as “low postive”
and “echivocal” respectively. The lack of HBeAg and/or HBeAb in
5 HBsAg positive patients suggested a false positive result for this
marker; we certiﬁed this possibility by conﬁrmatory test from the same
producer, A respectively. Because of these discordant results and in the
lack of another conformatory test we cannot calculate the sensitivity and
speciﬁcity of the tests. A further determination by biological molecular
techniques for these cases will be neccesary. The low performance of
A producer kit for HBcAb indicates this kit as being inappropriate and
it strongly recommends B and C producers kits for HBcAb. The test
results obtained using A test cannot be explained by the existance of
immunosuppression or by mutant variants of HBV in this high percent
(13.7%); this can be a consequence mainly due to a sensitivity default
of analytical assay.
Conclusion: The low sensitivity of A producer kit for HBcAb strongly
recommends to test this marker using more sensitive kits such as those
from B or C producer. The true negative HBcAb cases can be explained
by mutants strains and/or by associated pathology that induces a low
immunsupression; a future testing using sequence analysis for pre-
core/core region of DNA/HBV is recommended.
P2006 Are isolated anti-Hbc blood donors in a high-risk
group? The detection of HBV DNA in isolated anti-HBc
cases with NAT nucleic acid ampliﬁcation test based on
transcription-mediated ampliﬁcation
B. Kocazeybek °, E. Kosan, H. Altunay, M. Aslan, O. Yenen, S. Saribas,
P. Yuksel, I. Birinci, K. Kirali, A. Aksoy (Istanbul, Ankara, TR)
Aim: Hepatitis B virus (HBV) can be transmitted by blood transfusions
even so using serological tests having high sensitivity and speciﬁcity.
We aimed to detect HBV DNA in isolated anti-HBc donors and show if
they have transfusion risk or not.
Method: We investigated Anti-Hbc and Anti-HBs in serum samples
of 12858 HBsAg negative blood donors who were applied to the
Turkish Redcrescent between June 2007-October 2008 by the Micro
ELISA kit (Hepanostica ultra HBsAg, Bio Meriux, France). Anti-
HBc and Anti-Hbs positive cases were omitted. We used Procleix
ultrio (Chiro, USA) test kit (Chiron Tigris automated instrument was
used) based TMA (Transcription Mediated Ampliﬁcation) for NAT
study in Anti-HBc positive and Anti-HBs negative serum samples. The
discrimination of HBV in NAT positive samples were performed by
Procleix Discrimination (Chiro, USA) test.
Results: 2748 (21.4%) Anti-HBc seropositivity were detected in 12852
HBsAg(−) serum samples. 23.5% Anti-HBs negativity was detected
in 2748 Anti-HBc positive serum samples. On the other hand, 5.1%
isolated Anti-Hbc positivity [HBsAg(−), Anti HBc(+), Anti-HBs(−)]
were detected in 12852 HBsAg(−) serum samples. 0.091% and 0.047%
HBV DNA positivity were detected in isolated Anti-HBc positive serum
samples and HBsAg(−) serum samples, respectively.
Conclusion: As a result, even we have detected one (1) HBV
transmission in every 2142 blood transfusion by HBsAg screening tests;
we suggest that it is not necessary to add additional tests to detect
isolated Anti-HBc for routine purposes in Blood Banking. The reasons
are higher negativity rates (99%) of isolated Anti-HBc serum samples
and the rejection of blood donors with Anti-HBc positivity and also
additional tests (anti-HBc) are not being cost-effective.
P2007 Twenty-year follow-up of vaccination against hepatitis B in
patients with chronic renal failure
L. Roznovsky, L. Kabieszova, L. Hozakova °, A. Kloudova, J. Mrazek,
I. Lochman (Ostrava, CZ)
Objectives: The vaccination against hepatitis B can considerably
decrease number of hepatitis B virus infection among patients with
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chronic renal failure. Breakthrough infections and anti-HBs antibodies
response after immunisation were investigated in patients from 4 dialysis
units in the north-eastern part of the Czech Republic.
Methods: Active immunisation against hepatitis B was commenced in
1988. The number of immunised patients with renal failure gradually
increased and the group included 1163 patients in January 2009. Of these
patients, 522 died during investigation. The vaccination schedule was 0,
1, 6 moths for pre-dialysis patients and 0, 1, 2 months for dialysis patients
and patients with renal transplantation. Plasma-derived or recombinant
vaccines (since 1990) were administered intramuscularly. Each vaccine
contained 40 microgram of HBsAg, but for pre-dialysis patients only
20 microgram till 1998. The immunisation schedules were completed in
806 patients.
Blood samples were obtained 6 weeks after third or next dose of vaccine
and biannual thereafter. Samples were tested by ELISA methods for
HBsAg, anti-HBs and anti-HBc. The patients without protective anti-
HBs level after basic vaccination were once or twice re-vaccinated. The
patients with vanishing of anti-HBs antibodies were also re-vaccinated.
Results: The new HBsAg positive status was proved in 28 dialysis
patients, most of them suffered from acute hepatitis B. Breakthrough
infections were more frequent after initiation of vaccination programme,
27 of them were in period 1988–1994, the latest breakthrough infection
was proved in 2000. Asymptomatic infections with new appearance of
anti-HBc antibodies (two or more consecutive positive results) were
detected only in 8 patients. The anamnestic response (double increase
of anti-HBs without revaccination) was observed in 91 patients. Two or
more anamnestic responses were recorded in 15 of them.
Anti-HBs antibodies after vaccination were investigated in 728 patients.
Protective anti-HBs levels were proved in 350 of 728 patients (48%)
after 3 doses of vaccine and in 451 (62%) or 504 (69%) patients after
fourth or ﬁfth dose of vaccine.
Conclusion: Long-term vaccination considerably reduced hepatitis B
incidence in 1163 patients with chronic renal failure, but only 69%
immunised patients developed protective anti-HBs level after 5 doses
of vaccine.
Grant support: IGA Ministry of Health, Czech Republic, NR/9257–
3/2007.
P2008 Hepatitis B nucleic acid testing of healthy blood donors in
Finland
S. Pastila °, S. Wessberg, S. Ekblom-Kullberg, M. Naukkarinen,
M. Lappalainen (Helsinki, FI)
Objectives: Finnish Red Cross Blood Service (FRC-BS) started
hepatitis B nucleic acid testing (HBV NAT) of all blood donations in
2008. Earlier, only hepatitis B surface antigen (HBsAg) was tested in
FRC-BS blood donations. Annual detection of 1−2 cases of low grade
HBV DNAemia without HBsAg (occult HBV infection) was anticipated,
based on published European blood donor surveys.
Methods: Each blood donation was tested with the Ultrio Kit for the
detection of HIV-1 RNA, HCV RNA and HBV DNA (Gen-Probe,
Chiron), with a sensitivity of 13.48 IU/ml for HBV-DNA. Reactive
samples were conﬁrmed with the HBV Discriminatory Probe Reagent
(Gen-Probe, Chiron). All samples were tested for HBsAg (Bio-Rad
Monolisa HBsAg Ultra). Samples with positive HBV DNA or HBsAg
result were additionally tested for hepatitis B core antibody (HBcAb,
Abbott AxSYM CORE).
Results: During 2008, altogether around 270,000 donations and roughly
160,000 individuals were tested for HBV DNA. One donor with HBV
DNA positivity without HBsAg was detected, the donor was positive for
HBcAb and had a very low level of antibodies against hepatitis B surface
antigen (HBsAb, 2 IU/L). Two previously HBsAg negative donors were
found positive for HBsAg and HBV DNA. One donor cleared both HBV
DNA and HBsAg within few weeks, with introduction of HBcAb. The
other showed clearance of HBsAg and HBV DNA but no introduction
of HBcAb.
Conclusion: With HBV NAT testing, one occult HBV case was detected
during one year, as expected. The number of HBV positive blood
donors was higher than in previous years, but there was no statistical
change in the prevalence of HBV markers (HBsAg, HBV DNA). The
prevalence rate of HBV carrier status in new donors was 0.22 per 100
000, only 1/20 of the rate reported by the National Infectious Diseases
Register for the whole population. The incidence of HBV in blood
donors was exceptionally high in 2008, 1.57 per 100,000, over twice
as high as reported in the National Infectious Diseases Register. Since
1990 the incidence of HBV in blood donors has varied from zero to
over 3/100,000. As there has been seven years since the latest HBV
seroconversion in a blood donor, the high incidence rate in 2008 might
suggest that HBV is reemerging in the Finnish population.
P2009 Evaluation of anti-HBs titre in surgeons vaccinated for HBV
I. Karimi °, R. Sherkat, M. Rostami (Isfahan, IR)
Objectives: Health care workers including surgeons are frequent subjects
of exposure to blood and infected tissues of HBsAg positive patients.
A complete course of vaccine usually gives protection in majority of
time but it may cause a false sense of security which in case of vaccine
failure infection is inevitable. So it is essential to measure the level of
antibody after vaccination. We designed this study to estimate the rate
of people who has protective response to vaccine.
Methods: This descriptive and prospective study designed to know
the response rate in surgeons after vaccination against Hepatitis B.
99 Medical surgeons who had history of vaccination were chosen
conveniently. They ﬁlled a questionnaire regarding demographic and
individual data.5ml of venous blood was taken and after separation
of 2ml of serum, anti HBsAg measured by ELISA method using
Hepanostica Anti-HBs kits from the Organon series.
Results: According to the kits instruction titers <10 Iu/l are negative
and >10 Iu/L positive. Strongly positive is >100 Iu/l.
Group 1: included 36 people who had received vaccine during recent
3 years. In This group 17 people had complete course of vaccination
that 7 had titers less than 10 Iu/L and another 10 were in range of
positive titers.
Group 2: included 32 people who had received vaccine during recent
3 to 5 years. 24 people had complete course of vaccination that among
them 8 had titers less than 10 Iu/L and 14 were in range of positive titers
and 2 were negative.
Group 3: included 41who had received vaccine more than 5 years ago.
32 people had complete course of vaccination that among them 24 had
positive titers and 5 had titers less than 10 Iu/L and 3 were negative.
Among 9 who had incomplete course of vaccination 2 were positive, 1
weakly positive and 6 were negative.
Conclusion:We had no case of non responder in those who had complete
course of vaccination during 3 years from study. We had more negative
titers in people who had completed the course between 3 to 5 years
or more. This may be due to type of vaccines used in that period of
time. Because of higher risk of infection in health care workers and
primary and secondary failure to make antibody against virus in 40%
we recommend strict adhesion to standard precautions even in everybody
including vaccinated people. We need to say that, if all the subjects had
received the same generation of vaccine we were able to make better
and more precise comments.
P2010 Decline in HBsAg level during treatment with PEGASYS®
is signiﬁcantly associated with post-treatment response in
patients with HBeAg-negative disease
P. Marcellin °, M. Brunetto, F. Bonino, S. Hadziyannis, H.P. Kapprell,
D. Messinger, R. Batrla (Clichy, FR; Pisa, Milan, IT; Athens, GR;
Wiesbaden, Mannheim, DE; Basel, CH)
Objectives: A 48-week course of treatment with PEGASYS® (pegylated
interferon alfa-2a with dual immunomodulatory and antiviral properties),
is able to induce a sustained virological response 6 months post-
treatment in around one third of patients with HBeAg-negative
disease. Such patients have an increasing chance of developing HBsAg
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clearance during longer term follow-up − the closest outcome to
cure in patients with this chronic condition. In a phase 3 study
comparing PEGASYS® with lamivudine, PEGASYS®±lamivudine but
not lamivudine monotherapy resulted in signiﬁcant decline in HBsAg
levels by end of 48 weeks treatment in chronic hepatitis B patients. Thus,
it was hypothesised that monitoring HBsAg levels during the course of
treatment may be a useful marker to identify the patients most likely to
beneﬁt from this treatment approach.
Methods: This was a retrospective subanalysis of patients treated
with PEGASYS®±lamivudine in the phase 3 study. A total of
230 patients treated with PEGASYS®±lamivudine entered a roll-over
observational follow-up study to determine long-term response: HBV
DNA suppression (<400 copies/mL) or HBsAg clearance 4 years post-
treatment. HBsAg levels were measured (Abbott Architect HBsAg
Assay) in all available sera pretreatment, and at weeks 12, 24, 48 and
72. We compared the HBsAg decline during therapy in patients with and
without an HBV DNA response 6 months post-treatment to determine
if HBsAg levels during therapy may be indicative of response.
Results: A high proportion of patients with an HBV DNA response <400
copies/mL 4 years post-treatment had cleared HBsAg at this time (66%,
25/38). Mean baseline HBsAg levels in patients treated with PEGASYS®
were signiﬁcantly lower in patients with a sustained virological response
(HBV DNA 10,000 copies/mL) 6 months post-treatment than in
those without (Table). HBsAg levels declined throughout treatment with
PEGASYS®. By treatment week 24 HBsAg decline was signiﬁcantly
greater in patients with a sustained response vs those without (Table).
Table 1. Analysis of HBsAg decline in patients with and without
virological response (HBVDNA 10,000 copies/ml 6 months post-
treatment): PEGASYS monotherapy
HBsAg (log10 IU/mL), mean±SD (N)
Respondera Non-responder P-valueb
Baseline 4.20±0.70 (61) 4.45±0.48 (71) 0.0204
Decline from baseline to
week 12 0.19±0.52 (36) 0.08±0.43 (49) 0.2854
week 24 0.69±1.14 (52) 0.12±0.66 (60) 0.0052
week 48 1.01±1.27 (61) 0.28±0.64 (68) 0.0005
week 72 0.83±1.23 (58) 0.23±0.52 (67) 0.0020
aResponse: HBVDNA 10,000 copies/mL 6 months post-trt.
bWald chi-square test for association between response and change in
HBsAg from baseline.
Conclusion: Patients who achieve a sustained virological response
following PEGASYS treatment have a high chance of clearing
HBsAg during longer term follow-up. Monitoring HBsAg levels during
PEGASYS® therapy can help identify the patients most likely to achieve
a virological response 6 month post-treatment and clear HBsAg and
could help optimise the management of PEGASYS® therapy in patients
with HBeAg-negative chronic hepatitis B.
P2011 Lamivudine treatment for acute severe hepatitis B
A. Verhaz ° (Banja Luka, BA)
Objectives: Lamivudin has been approved for the treatment of chronic
hepatitis B but experience with lamivudin treatment for acute severe
hepatitis B is still limited. Fulminant hepatitis develops in 1% of patients
with acute hepatitis B. Severe acute hepatitis B in immunocompetent
patients may progress to fulminant hepatitis and death.
Aim: To evaluate the efﬁcasy of lamivudine for the treatment of acute
severe hepatitis B virus infection in imunocompetent adults in Clinic for
infectious diseases Banja Luka.
Patients and Methods: In the period of 2006–2008 years, 9
immunocompetent patients (3 women, 6 men, age 30−77 years) with
severe acute hepatitis B were treated with lamivudin. All 9 patients
fulﬁl at least two of the criteria for severe acute hepatitis B infection:
1. hepatic encephalopathy; 2. total bilirubin 210 micromole per litre; and
severe coagulopathy (international normalised ratio-INR was 4.5±6.4
or prothrombin time – PT< 40%). All patients had evidence of severe
hepatocyte lysis. Nine patients had rapid increase of total bilirubin and
contemporary decrease of alanine aminotransferase level, which escalate
risk of development of fulminant hepatitis B. All patients received
lamivudin at a dose 100mg per day.
Results: Eight patients responded well to the treatment and their
biochemical parameters improved rapidly. Within 1−6 months, the
HBsAg was undetectable in 8 out of 9 investigated patients. Protective
anti-HBs antibodies developed in 8 of them in 2−14 months. The
corticosteroid therapy was short-term in 2 of 9 patients. One patient
developed fulminant hepatitis B and died 4 days after the lamivudine
therapy was initiated. Lamivudine treatment was well tolerated in all
patients.
Conclusion: Lamivudin induces a prompt clinical, biochemical and
serological response in immunocompetent patients with severe acute
hepatitis B. Early treatment with lamivudine probably decreases the
risk of progression to fulminant hepatitis in patients with severe acute
hepatitis B.
P2012 Patterns of resistance mutations in patients with chronic
infection by hepatitis B virus treated with lamivudine
and/or adefovir-dipivoxil
B. Puche, J.C. Palomares °, M.C. Nogales, B. Figueruela, E. Suarez,
E. Martı´n-Mazuelos (Seville, ES)
Objectives: Treating chronic hepatitis and liver cirrhosis caused by
hepatitis B virus (HBV) infection with nucleos(t)ide analogues (NA) is
very challenging due to the appearance of resistance mutations. Our aim
was to study the prevalence of these mutations after viral breakthrough
in patients treated with lamivudine (LMV) or adefovir-dipivoxil (ADV)
in Occidental Andalusia.
Methods: 37 patients were studied, 89% were HBeAg negative, 70.3%
were diagnosed of chronic hepatitis and 29.7% of liver cirrhosis. General
follow-up was carried out measuring viral load (COBAS Ampliprep-
Taqman, Roche Diagnostics) and serum ALT levels before treatment and
every 3 months and genotype and resistance mutations were determined
before treatment and in cases where viral breakthrough was observed.
The latter were determined by direct sequencing of the surface and
polymerase gene, respectively, using the Trugene HBV Genotyping kit
(Siemens Medical Solutions).
Results: Genotype D was observed in 75.7% of our patients, 18.9% A,
2.7% B and 2.7% F. All were wild-type (WT) strains before treatment.
Twenty-two patients were initially treated with LMV. After a mean of
2.5 years, 20 (91%) presented viral breakthrough. LMV was substituted
for ADV in 15 cases, entecavir (ETV) in one and ADV was added in 4.
Resistance mutations to LMV were developed in an 80% of the cases,
L180M+M204V in 10 (one accompanied by V207I) and M204I in 6
(accompanied by L180M and V173L in one case each). Five patients
(33.4%) treated with ADV presented viral breakthrough after a mean
of 2 years. ADV was substituted for tenofovir (TDF) or LMV+TDF
in 2 cases each and ETV in one. Resistance mutations to ADV were
developed in 3 cases, one A181V and 2 A181V+N236T. On the other
hand, 15 patients were initially treated with ADV. After a mean of 2 years,
4 (26.7%) presented viral breakthrough. ADV was changed to TDF in
2 cases and LMV was added in 2. Resistance mutations to ADV were
observed in 1 patient (A181V). All studied patients are currently treated
with the last cited antivirals and no viral breakthrough has been observed
in a mean of 10 months.
Conclusions: 1. Resistance mutation development is the major cause
of viral breakthrough during treatment with NA, specially in LMV
monotherapy and in non-naive patients treated with ADV. 2. The most
frequent mutations involved in LMV treatment failure are L180M and
M204V/I. 3. The most frequent mutations involved in ADV treatment
failure are A181V and N236T.
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P2013 Failure to treat HBV with adefovir due to early selection
of rtA181T mutation
M. Rodrı´guez-Domı´nguez °, J.M. Sanchez-Calvo, V. Moreira, G. Arranz,
M.L. Mateos (Madrid, ES)
Introduction: The main goal of antiviral treatment against HBV is to
abolish viral replication. Lamivudine is widely used but a high number
of patients have no response to treatment due to the selection of HVB
mutants, resistant to lamivudine during treatment. Therefore, adefovir-
dipivoxil is the main alternative because it is less frequent to found
resistant mutants of HBV. Recently we have had a patient with chronic
HBV, HBeAg negative, in which treatment with adefovir get failed due
to an early selection of a resistant mutant rt A181T.
Case report: A 47 years old female, asymptomatic, in a routine
laboratory test was found to have a light increase in transaminases levels.
Serological markers against hepatotropic viruses were studied founding a
positive surface antigen for HBV (HBsAg) and a viral load (DNA-HBV)
of 25×106 UI/mL, HBeAg was negative and anti-HBe was positive. No
antibodies against HCV and HDV were found. Treatment with adefovir
was started (10mg/24 h). During a one year period, viral load decreased
but always remaining about 8−9×104 UI/mL. A year and a half later viral
load increased to 7.4×105 UI/mL. Suspecting a failure due to resistant
HBV, adefovir was changed to tenofovir (300mg/24 h). In a retrospective
study of resistant mutations against lamivudine, adefovir, tenofovir and
entecavir by a reverse-hybridation technique (INNO-Lipa DR v2 and v3,
Innogenetics, Belgium) we found that the mutation rtA181T appears two
months after the beginning of adefovir treatment. Also, we tested serum
samples previous to adefovir treatment, and we did not found any other
resistant mutation.
Discussion: rtA181T mutation is mainly associated with lamivudine
resistant HBV from which susceptibility is reduced about three times.
Against adefovir, this mutation can be considered secondary because it
confers a low level of resistance in vitro. In our case, low levels of viral
load were maintained during one year but never under 104 UI/mL. The
retrospective study of banked serum samples allowed us to conﬁrm that
the treatment failure was due to the early selection of rtA181T mutant
of HBV.
P2014 Molecular analysis of “a” determinant region of the S gene
of HBV from healthy subjects with occult HBV infection
in Istanbul
K. Midilli °, M. Aslan, S. Ergin, P. Yuksel, S. Saribas, E. Kosan,
H. Altunay, O. Kucukbasmaci, A. Kaygusuz, M. Torun, R. Caliskan,
B. Kocazeybek (Istanbul, TR)
Objective: HBV DNA and AntiHBc antibody positivity without HbsAg
is deﬁned as occult HBV infection, which has been detected at varying
rates according to the local prevalence of HBV infection. Although in
subjects with occult HBV infection “a” determinant region containing a
dominant B cell epitope for anti-HBs response shows higher amino acid
substitutions compared to HbsAg positive carriers, the exact mechanism
of occult HBV infection is not fully elucidated. In this study we aimed
to determine the mutations in the “a” region of S gene in subjects with
occult HBV infection.
Methods: Eighty three blood donors positive for anti-HBc antibody
alone were screened for HBV DNA by PCR targeting S gene. Following
the sequencing of the PCR amplicons, mutations with a potantial of
antigenic change in the “a” determinant region of the S gene were sought.
Results: Eight of 83 subjects (9.63%) were positive for HBV DNA.
Based on the amino acid sequences between 101–180 all of them were
ayw2 subtype and had no mutations in the “a” determinant region which
might be related with antigenic change in the major B cell epitope.
Conclusion: Other mechanisms then the mutations in S gene of HBV
may be involved in the occult HBV infections in our region with the
exclusive predominance of the HBV genotype D.
P2015 Genotype characterisation of hepatitis G virus isolates from
Iranian patients infected with human immunodeﬁciency
virus
A. Ramezani °, M. Mohraz, A. Aghakhani, M. Banifazl, A. Eslamifar,
A.A. Velayati (Tehran, IR)
Objectives: Hepatitis G virus (HGV) infection is frequent in patients
infected with the HIV due to similar transmission routes of these viruses.
The aim of this study was to determine the rate of infection and genotypic
characteristics of HGV in this population.
Methods: The presence of HGV RNA was determined in serum
samples of 106 patients infected with HIV by reverse transcriptase-nested
polymerase chain reaction. HGV genotypes were determined by direct
sequencing. HBsAg, anti-HBs, anti-HCV, ALT, HIV viral load and CD4+
cells count were also tested in all subjects.
Results: The overall prevalence of HGV infection was 11.3% in
HIV positive patients. There was no signiﬁcant difference between
patients with and without HGV infection regarding age, sex, route of
transmission, viral load, ALT levels, HBV and HCV co-infection and
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treatment with antiretroviral drugs. 66.7% of patients with HGV had
a CD4+ cells count 200 and 33.3% had a CD4+ cells count <200
cells/mm3. Phylogenetic analysis revealed that all HGV isolates were
genotype 2, and classiﬁed as subtype 2a.
Conclusion: HGV infection is relatively common in patients infected
with HIV. The prevailing HGV genotype 2a in this study group concurred
with reports from other parts of the Middle East.
P2016 Accidental blood exposures among medical residents in
Paris, France
J. Adam, O. Mir, P. Berveiller, Y. Yordanov, P. Loulergue ° (Paris, FR)
Accidental blood exposure (ABE) exposes health care workers (HCW)
including medical residents (MRs) to the risk of occupational infection.
We aimed to determine the characteristics of ABEs in MRs in Paris,
France.
An anonymous self-reporting questionnaire was administered electroni-
cally. A total of 350 MRs (33% from surgical disciplines) entered this
survey. Median age was 27 years (range: 23−35), 32% were males.
One hundred and eighty ﬁve MRs (52%) reported at least one ABE
during their residency (median: 2, range 1−25), 53% of which occurred
in operatory rooms.
Sixty-nine percent of MRs followed the current procedures for local
disinfection. ABEs were notiﬁed to the hospital administration by 62%
of MRs, but only 51% of MRs referred to occupational medicine
department. However, in 74% of cases, the serologic status of the
index patient was investigated. Eight MRs received HAART, the most
frequently prescribed combination being zidovudine, lamivudine and
boosted lopinavir. None discontinued this treatment.
The most frequently reported concerns following ABEs were HIV
infection (52%) and HCV infection (39%). HBV was not a major concern
in this population with 54% of MRs being aware of their HBs antibody
titres.
ABE is a major issue in HCW. Medical residents, although aware of
the potential risks of blood-borne infections, behaved inappropriately in
up to 33% of cases in this survey. Further educational programs should
include MRs and not only senior HCW in order to improve individual
behaviour when facing ABEs.
P2017 Healthcare personnels’ experiences with sharps/needle-stick
injuries and preventive measures
M. Altiok, F. Kuyurtar, S. Karacorlu, G. Ersoz °, S. Erdogan, H. Gokce
(Mersin, TR)
Objective: In today’s work environment health care personnel are at
risk for infectious diseases from sharp instruments and needle sticks
contaminated with patients’ body ﬂuids.
This study was planned for the purpose of determining hospital
and public health clinic health care personnels’ experiences with
sharps/needle stick injuries and the preventive measures they take when
injured.
Methods: The population of this descriptive and cross-sectional study
was all 2532 health care personnel who worked at one university
hospital, two state hospitals, and 54 public primary health care clinics in
Mersin province. Using a random sampling method stratiﬁed by health
care professions the goal was to reach all professional groups (357
physicians, 578 nurses/midwives, and 78 laboratory technicians). Data
were collected by having the participants personally complete a data
collection form. The forms were collected and Chi square test was used
in the statistical analysis.
Results: A total of 956 (%37.7) of the health care personnel in hospitals
and public health care clinics were interviewed. In our study the
injury rate was %79.1; %60.9 of those were injured by instruments
contaminated by blood and the most (%89.2) had experienced needle
sticks. The majority of the injuries occurred at the patient’s bedside;
a signiﬁcant percentage had been injured using incorrect practices
of recapping a needle and removing a needle from a syringe and
while disposing of sharps/needles in the sharps container. Injuries
occurring while disposing in the sharps container happened the most
often in public health clinics. In our study the most injuries occurred
in nurses/midwives; the percentage of personnel having received the
hepatitis B vaccination was similar in physicians and nurses/midwives
and was low in laboratory technicians (P = 0.006, c2 = 10.378). Only
%12.7 of the health care personnel had reported their injury.
Conclusion: In this research a high percentage of blood contaminated
sharps/needle stick injuries was found, a low percentage of injuries were
reported, and a high percentage of personnel had received the Hepatitis B
vaccination. Although the level of vaccination was encouraging the
injuries from incorrect practices and low level of injury reporting shows
the need for regular continuing education on this subject.
P2018 Evaluation of the Roche Cobas HCV immunoassay
J.L.A.N. Murk °, A.M. Simoons-Smit, P.H.M. Savelkoul,
M. Bosschieter-Lust, C.W. Ang (Amsterdam, Almere, NL)
Objectives: The low prevalence of Hepatitis C virus (HCV) in developed
countries places large demands on the speciﬁcity of immunoassays
detecting antibodies to the HCV. Frequent false-positive test results
have necessitated costly and time consuming conﬁrmatory tests. We
have evaluated the performance of the new HCV immunoassay for
the Roche Cobas e411 automated analyzer and compared it with the
HCV immunoassay version 3.0 from Abbott for the AxSYM automated
analyzer.
Methods: 917 human sera, submitted to our laboratory as part of the
routine diagnostic process for HCV testing, were analyzed with the
immunoassays for the Cobas and AxSYM. 437 of these sera were tested
in parallel between September and December 2008.
480 sera had been submitted previously (retrospective samples) and
already been tested in the AxSYM. Anti-HCV reactivity was conﬁrmed
by immunublot or additional testing for HCV RNA.
Results: Of the 917 sera 68 tested positive in the AxSYM; 33 of
these were immunoblot or HCV-PCR positive and 7 sera had equivocal
immunoblots. The remaining 27/68 (40%) of initially reactive samples
were regarded as false-positive. The speciﬁcity of the AxSYM HCV
assay was therefore (848/876=) 96.8%. Out of 917 sera, the Cobas tested
46 sera positive. 33 were conﬁrmed and 7 had equivocal immunoblots.
Hence, 5/45 (11%) of the initially reactive samples could not be
conﬁrmed and were regarded as false-positive. The speciﬁcity of the
Roche assay was (871/876=) 99.3%. Both AsXYM and Cobas HCV
immunoassay detected all 33 conﬁrmed cases of HCV infection.
Conclusion: The speciﬁcity of the new Roche HCV assay was higher
than the Abbott HCV immunoassay and reduced the amount of
conﬁrmatory tests with about one third, although the difference may have
been caused by selection of samples initially reactive on the AxSYM.
Further parallel studies with larger numbers of samples from patients
who are HCV positive are required to solve this issue.
P2019 Hepatitis C − an opportunistic HIV coinfection: inhibitors
of NTPase/helicase activity as potential antivirals
A. Baier °, R.S. Hosmane (Lublin, PL; Baltimore, US)
Objectives: The end-stage liver diseases caused by hepatitis viral
infection is one of the major causes of death (>50%) in HIV patients.
HCV has lately taken the centre stage, and is ringing alarm bells in the
AIDS research community for many reasons, including less effective
HAART therapy. The protease inhibitors used in the HAART therapy
exert a signiﬁcant degree of extra strain on the liver that is already
stressed by HCV. The HCV infection is in turn believed to stimulate the
HIV activity. The approved anti-HCV therapy was shown to decrease the
potency of anti-HIV therapy. For all these reasons, mutually compatible
anti-HCV and anti-HIV drugs are urgently needed to combat HCV co-
infection in HIV patients.
Between the structural and non-structural (NS) proteins encoded by
the viral genome of HCV the NS3 protein appears to be one of the
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most promising targets for antiviral agents because of the multiple
enzymatic activities (serine protease and nucleoside triphosphatase
(NTPase)/helicase) associated with this protein. Our experience with
some inhibitors of the helicase activity reported previously shows that
the inhibition of the enzyme may lead to reduction of the replication of
the virus.
Methods: Recombinant HCV NTPase/helicase was puriﬁed to ho-
mogeneity from E. coli. Inhibition studies were performed with
radioactively labelled DNA or RNA substrate.
Results: Previous studies performed by us indicated that the extension
of the side-chain attached at the 6-position of the heterocyclic ring of
the ring-expanded nucleoside (REN) analog results in inhibitory activity
of NTPase/helicase. Here we present new nucleoside analogs as potent
HCV NTPase/helicase inhibitors with IC50 values in low micromolar
range. The nucleoside analogs that we screened may act through binding
to NTPase/helicase and cause inhibition (and in some cases activation)
of unwinding activity.
Conclusions: Since there is a close correlation between the inhibition of
the helicase activity in vitro and reduction of the virus replication in vivo
the compounds based on the structure of nucleosides may represent a
therapeutic concept against HCV. The aim of successful therapy against
HCV/HIV coinfection should be the design of compounds which exhibite
dual anti-HCV and anti-HIV activities in vitro with little toxicity to the
host cell lines.
Acknowledgement: This work is supported by NIH grant # 1-R01-GM-
087738–01A1.
P2020 Evaluation of the results of the SEIMC External Quality
Control Programme for HCV viral load
N. Orta Mira, R. Guna Serrano, M. Ovies, J.L. Pe´rez °, C. Gimeno
Cardona (Gandı´a, Valencia, Madrid, Palma de Mallorca, ES)
Objective: To analyze the results obtained in two consecutive QC
controls (years 2006 and 2007) for HCV viral load (VL) launched by
the Spanish Society of Clinical Microbiology and Infectious Diseases
(SEIMC) External QC Programme.
Methods: In 2006, two plasma standards (HCV-1/06 and HCV-2/06)
for the HCV VL determination by the method currently used in each
laboratory were sent to 65 participants. In 2007, two different standards
(HCV 1/07 and HCV 2/07) were sent to 77 participants. Standards were
made after diluting plasma drawn from unique HCV-infected patients
with HCV plasma from seronegative donors. Standards HCV-1/06 and
HCV-1/07 had a high HCV RNA content, in opposite to HCV-2/06
and HCV-2/07. Reference VL values for each standard (mean of 3
determinations) were determined by laboratories selected by the QC
Programme for each method. A conﬁdence interval of mean±1.96 SD
for the log10VL was acceptable.
Figure 1.
Results: Effective participation rate was similar in both years (90.8%).
Real time PCR was the method used for the majority of the participants
(Fig.1). Reported results from participants were compared with those of
the reference laboratories(same method. Acceptable results range from
87.2% (HCV-1/06) to 98.2% (HCV-2/07) for laboratories using TaqMan
Roche®. These ﬁgures were 66.7% (HCV-2/07) and 88.9% (HCV-2/06)
for Cobas Amplicor Roche®, and 83.3% for Abbott real time method;
although these percentages should be taken prudently because of the
limited number of participants by the former techniques. The same seems
to apply for the bDNA Versant Siemens® methodology, but the number
of participants made analysis unfeasible.
Conclusions: a) there is an increasing number of participants in the QC
Programme, being similar the effective participation rate within years;
b) real time PCR was the most frequent technique used; c) although
the majority of the participants obtained acceptable results, the Taqman
Roche® method seemed to perform better; d) external intercomparative
surveys are a useful tool for quality improvement in the microbiology
laboratories.
P2021 Routine twenty-four mini-pool HCV RNA screening
for the diagnosis of early hepatitis C virus infection in
non-transfusion setting
T. Mocilnik °, K. Seme, M. Poljak (Ljubljana, SI)
Objectives: Because of the period of up to 3 months between hepatitis C
virus (HCV) infection and seroconversion, serological assays are not
very efﬁcient for diagnosis of the early stages of HCV infection. Since
HCV RNA appears in blood as early as 2 weeks after infection, the
detection of HCV RNA can substantially shorten the diagnostic window,
which is particularly important in blood donors and in different high risk
populations. We have prospectively evaluated the usefulness of 24 mini-
pool HCV RNA screening in a routine diagnostic laboratory for viral
hepatitis, where more than half of newly diagnosed hepatitis C patients
are intravenous drug users (IVDU).
Methods: A total of 15,048 anti-HCV negative samples collected
between 1 June 2004 and 31 December 2008 were included in the study.
A total of 627 mini-pools were tested using an automated commercial
PCR assay for qualitative detection of HCV RNA, with lower limit of
detection of 50 IU/ml. HCV RNA positive pools were split for further
testing by the same assay. Immediately after recognition of an anti-HCV
negative/HCV RNA positive sample responsible physician was informed
and asked for follow-up samples.
Results: 30 (0.2%) anti-HCV negative/HCV RNA positive samples
obtained from 23 patients (14 male, 9 female, all IVDU) were detected.
21 patients responded to invitation for follow-up testing. 15, 5 and 1
patient seroconverted in the ﬁrst, second and third follow-up sample,
respectively. The interval between the ﬁrst HCV RNA positive/anti-
HCV negative sample and the ﬁrst anti-HCV positive sample was
between 19 and 154 days. Considering viral loads measured in anti-
HCV negative/HCV RNA positive samples, even 48 mini-pool strategy
could be used without reducing the sensitivity. The costs of detecting
a single anti-HCV negative/HCV RNA positive sample and a single
viraemic seronegative patient using this strategy were estimated to be
around €903 and €1178, respectively.
Conclusion: Combined screening using anti-HCV and 24 mini-pool
HCV RNA testing can be useful and cost effective outside a blood
transfusion setting, at least in laboratories at which signiﬁcant proportion
of tested patients belongs to high-risk populations.
P2022 Expression of interferon-induced microRNAs in patients
with chronic hepatitis C virus treated with pegylated
interferon alpha
C. Scagnolari °, P. Zingariello, C. Selvaggi, A. Zoccoli, J. Vecchiet,
S. Cicetti, E. Pizzigallo, G. Antonelli (Rome, Chieti, IT)
Objectives: In order to further elucidate the determinants of response
to interferon (IFN) therapy in patients with chronic hepatitis C, a gene
expression analysis of cellular microRNAs (miRNAs), which has been
previously reported to be involved in IFN-mediated antiviral activity
against hepatitis C virus (HCV), has been performed.
Methods: The expression of several miRNAs (mir-1, mir-30, mir-128,
mir-196, mir-296) was retrospectively measured in peripheral blood of
mononuclear cells (PBMC) derived from 12 patients with HCV before
and after 12 hours from the ﬁrst injection of IFN. Gene expression
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analysis of MxA, a well-characterised IFN type I-induced gene, was
also performed as positive control.
Results: PBMC from patients with HCV express all examined miRNAs
but their levels showed high variability (coefﬁcient of variation >100%).
In addition we observed that the overall expression of miRNAs was
signiﬁcantly different between patients with HCV and healthy subjects.
When levels of the above miRNAs were measured 12 hours after the
ﬁrst injection of IFN, increases in expression levels of these miRNAs
were observed in a percentage of patients ranging from 33.3% to 66.6%
depending on the type of miRNA examined.
Conclusion: These ﬁndings suggest that miRNAs can be differentially
induced by IFN treatment in HCV positive patients. Given the important
role of miRNAs in defending the host against virus infection it is possible
that such miRNAs may represent an important determinant of the clinical
outcome of IFN therapy in HCV infection.
P2023 Acute hepatitis C and nosocomial transmission of
hepatitis C virus: an emergent threat in the hospital setting?
G. Corti °, F. Baragli, A. Cavallo, D. Bartolozzi, S. Ambu, F. Leoncini,
A. Bartoloni (Florence, IT)
Objective: Symptomatic acute hepatitis C (AHC) is rarely identiﬁed
in the clinical practice, it is frequently followed by the spontaneous
resolution (SR) of hepatitis C virus (HCV) infection without evolution
into chronicity, and it generally responds to standard antiviral therapy
better than chronic hepatitis C does. We prospectively followed all
consecutive AHC cases we observed in the inpatient/outpatient services
of our hospital units during the last three-year period, in particular as
regards: 1) risk factors; 2) clinical outcome; 3) efﬁcacy of treatment, if
any.
Methods: Between 1st January 2005 and 31st December 2007, we
diagnosed symptomatic AHC in 13 males, median age 54 years; main
demographic characteristics are shown in the table. At the 12-week
follow-up, we began pegylated interferon (PegIFN) + ribavirin in patients
who had detectable plasma HCV RNA as measured by PCR (Cobas
Amplicor Monitor®, Roche, in copies/mL up to October 2005; TaqMan®
RT-PCR, Roche, in IU/mL from November 2005), whereas the PCR-
negative patients were followed up at least for 24 weeks, after which
they were considered as having SR of their AHC if still PCR-negative.
Results: Seven patients had one or more nosocomial risk factors that
were associated with several diagnostic and/or therapeutic procedures;
three patients were iv drug abusers, one had recent dental surgery, one
had a HCV-positive wife, the remaining one having no known risk
factors. Seven patients had SR of AHC, three responded to PegIFN
alpha 2b + ribavirin, and two relapsed to PegIFN alpha 2a + ribavirin,
as shown in the table; the 13th patient had spontaneous biochemical
normalisation with viral persistence.
Age Risk factors Genotype Peak PCR Peak ALT Therapy Outcome
23 IV drug abuse 1b 3.53×104 1,841 PegIFN alpha-2b SVR
54 Colonoscopy,
Herniorrhaphy
1b 1.8×106 1,615 No SR
73 Coronary
angiography/plasty,
Blood transfusion
2a/2c 1.26×105 969 PegIFN alpha-2b + Riba SVR
58 Gastroscopy,
Colonoscopy
2a/2c 7×105 1,108 PegIFN alpha-2b + Riba SVR
46 Dental surgery 1b 1.17×105 749 No SR
48 Blood transfusion,
Haemodialysis
1a 1.49×104 138 No SR
61 Coronariography 2a/2c 4.18×106 1,175 PegIFN alpha-2a + Riba Relapse
69 IV injection 1b 1.99×106 733 No Viral
persistence
67 ERCP,
Cholecystectomy
1b 8.14×104 1,356 PegIFN alpha-2a + Riba Relapse
66 HCV+ wife 1b 1.54×104 2,514 No SR
30 IV drug abuse 1b 8.72×103 3,118 No SR
35 None 3a 1.45×107 2,639 No SR
30 IV drug abuse 1b >6.9×107 3,894 No SR
ERCP, endoscopic retrograde cholangiopancreatography; ALT, alanine aminotransferase; SVR, sustained virological
response.
Conclusions: Our study, albeit carried out on a small number of patients,
conﬁrms the results of recently published papers on some features
of AHC, in particular: 1) the increasing impact of nosocomial HCV
acquisition resulting from unsafe hospital practices and contaminated
equipment; 2) the frequent SR of symptomatic AHC. We stress the need
of: 1) strict adherence to universal precautions in order to minimise the
risk of nosocomial HCV transmission; 2) wait for the ﬁrst 12 weeks after
acute infection in order to observe the possible SR of AHC.
P2024 Transversal study in a group of Spanish HIV/HCV co-
infected patients with non-treated chronic hepatitis C: epi-
demiological study, prevalence and grade of hepatic ﬁbrosis
E. Valencia °, V. Moreno, L. Martı´n-Carbonero, J. Gonza´lez Lahoz
(Madrid, ES)
Objectives: 1)To analyse hepatic ﬁbrosis using non invasive methods in a
group of HIV and non treated HCV infected patients and 2)To determine
the factors that inﬂuence on ﬁbrosis development: sex, alcohol and illegal
drugs abuse, hepatitis C genotype, co infection with HBV and HDV, HIV
and HCV viral load, CD4+ cells and HAART use. It was also analysed
why patients were not receiving treatment for HCV infection.
Methods: This is an observational and transversal study. Patients are a
subgroup of the multicentric study GRAPHICO and all had active HCV
infection without treatment. Hepatic ﬁbrosis was measured by Fibroscan
and APRI/Forns index. Statistical analysis was done by SPSS 13.0.
Results: 102 patients were included and most of them were male (71%).
93 (91%) had been IVDA (only 4 active drug users), 22.5% had been
heavy alcohol drinkers, 81% were smokers and 7% consumed cannabis.
Genotype 1 was the most frequent (61%), 7 were co infected with HBV
and 3 with HDV. Causes for no treatment were: patient rejection (52%),
previous fracases (22%) and contraindicated therapy and/or toxicity
(25.5%). Mean HCV viral load was 1.23×107 copies/ml and only 28
(27.5%) had detectable HIV viral load. Most subjects were receiving
HAART (89%) and mean CD4 cells was 479mm3. The CD4+ nadir
was 220 per mm3. Mean time of HCV infection was 12 years. Fibrosis
was detected by APRI/Forns in 21 patients (20.6%) and Fibroscan was
realised in 78 (76.5%) showing F0-F1 (7 kPa) in 33%, F2 (7.1–9.4 kPa)
in 20%, F3 (9.5–12 kPa) in 11% and F4 (>12 kPa) in 35%. As compared
with those without signiﬁcant ﬁbrosis, absolute, percentage and nadir of
CD4+ cells, platelets count, cholesterol level and protrombine activity
were lower in patients with signiﬁcant ﬁbrosis (p< 0.05). Similarly,
genotype 1, male sex, alcohol intake, tobacco and cannabis consumption
and HbsAg+ were more frequent in subjects with signiﬁcant ﬁbrosis
(p< 0.05). There was a direct correlation of ﬁbrosis grade by transient
elastography and APRI/Forns index.
Conclusions:1)Patients co infected with HCV and HIV who are not
receiving treatment for HCV have more hepatic ﬁbrosis if they are men,
if are co infected with HBV, if have genotype 1 and if are smokers, heavy
alcohol drinkers and cannabis consumer. 2)Fibrosis is more signiﬁcant
in those with lower absolute, percentage and nadir of CD4+ cells.
3)Fibroscan and APRI/Forns index are similarly for determining hepatic
ﬁbrosis using non invasive methods.
P2025 Genetic diversity of hepatitis C virus among Bulgarian
injecting drug users with hepatitis C
P. Teoharov °, I. Pavlov (Soﬁa, BG)
Objective: To assess the genotype diversity of hepatitis C virus (HCV)
among bulgarian injecting drug users with hepatitis C.
Methods: Serum samples from 147 anti-HCV positive injecting drug
users were tested by qualitative RT-PCR assay AMPLICOR Hepatitis C
virus (HCV) Test, version 2.0 (Roche Molecular Systems, Inc,
Branchburg, MJ, USA). Commercially available enzyme immunoassay
ETI−AB-HCVK-4 (Dia Sorin, S.p.A. Italy) was used to detect anti-
HCV antibody. Genotyping of HCV RNA obtained from serum samples
was performed using Versant HCV Genotype Assay (LiPa) – Bayer
HealthCare LLC, Belgium.
Results: Since January till November 2008 a total of 147 anti-HCV
positive serum samples from Bulgarian injecting drug users, were tested
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by RT-PCR for the presence of HCV RNA. One hundred and ﬁfteen
(78.2%) from the anti-HCV positive samples were positive for HCV
RNA. The genotype was determined in 113 samples and 2 sera positive
for HCV RNA couldn’t be genotyped.
Genotype 1a was detected in 2 (1.7%) and genotype 1b in 72 (63.7%)
of the samples. In only two cases with samples from genotype 1, the
subgenotype couldn’t be determined. Genotype 3a was present in 37
(32.7%) of the samples. No other genotypes were available in tested
samples.
Conclusions: These results demonstrate that the genotype 1b of HCV is
the most prevalent in Bulgarian drug users, but 3a genotype can be often
detected also. These two genotypes (1b, 3a) of HCV are predominant in
this high risk group.
P2026 Development of a low-cost approach for quantitation and
genotyping of hepatitis C virus
K. Shahzamani °, F. Sabahi, S. Merat, H. Rezvan, S. Mirab-Samiee,
R. Naghizadeh, H. Khademi, R. Malekzadeh (Tehran, IR)
Objectives: Concentration of HCV RNA in plasma and its genotype
determines the chance of therapeutic response and duration of treatment.
Our goal was to develop a low-cost method for simultaneous quantitation
and genotyping of HCV RNA.
Methods: A Real-time RT-PCR assay for quantitation of HCV RNA was
developed. A pair of primers and hybridisation probes was selected that
were speciﬁc for recognition of 5′UTR in HCV genome. Calculation of
HCV viral load was based on an external standard curve using standard
RNA calibrated with NIBSC standard panel. A genotyping method was
developed using ampliﬁcation products obtained from the HCV RNA
quantitation. Determination of HCV genotype was performed by melting
curve analysis using a pair of hybridisation probes.
Results: Our assay had a sensitivity of 50 IU/ml, with a dynamic range
of detection between 103 and 106 IU/ml. The coefﬁcient of variation
(CV) of the standard curve was, on average 0.99. The CV of threshold
cycle values in intra- and inter-assay were less than 1.77% and 3.40%
respectively. Parallel analysis by this new assay and Real-time RT-PCR
commercial kit on 56 clinical samples in different times of treatment
with IFN-alpha 2a and ribavirin, showed a good correlation (Before
treatment, R2 = 0.934 p< 0.05), (1 month after treatment, R2 = 0.992
p< 0.05), (3 months after treatment, R2 = 0.992 p< 0.05). Genotypes
were determined by melting curve analysis and compared to the results
of PCR-RFLP with good correlation (Kappa = 0.875 P< 0.001).
Conclusion: Our method has a good sensitivity and speciﬁcity
for detection, quantitation and genotyping of HCV RNA within
approximately 2 hours. They can be a good replacement for commercial
kits especially for clinical evaluation of therapy.
P2027 Oxidative stress and antioxidant defence in patients with
chronic hepatitis B and C
N. Tasdelen Fisgin °, B. Kilicoglu Aydin, H. Sarikaya, E. Tanyel,
S. Esen, M. Sunbul, H. Leblebicioglu (Samsun, Amasya, TR)
Objectives: Oxidative stress is deﬁned as a disturbance of balance
between free oxidative radicals and antioxidant substances. This study
investigated the in patients oxidative stress with chronic hepatitis B and
C.
Methods: Ninety eight patients with chronic viral hepatitis admitted
to Department of the Infectious Diseases and Clinical Microbiology
of Medical Faculty of Ondokuz Mayis University were enrolled into
study. Twenty healthy persons were included as control group. Study
group were divided into four groups as healthy controls (group 1),
chronic hepatitis B (group 2), chronic hepatitis C (group 3) and inactive
hepatitis B carriers (group 4). Antioxidant status of plasma, including
glutathione, glutathione peroxidase, vitamin E and vitamin C levels,
were measured. Carbonyl and lipid peroxidation levels were measured
as parameters of oxidative stress.
Results: Glutathione, glutathione peroxidase, vitamin E and vitamin C
levels were found to be signiﬁcantly decreased in chronic hepatitis B
group when compared with control group (9.5 vs 13.8, p< 0.05; 22.98
vs 32.4, p< 0.05; 15.1 vs 16.4, p< 0.05; 12.9 vs 18.4, p< 0.05). Carbonyl
and lipid peroxidation levels were signiﬁcantly increased in chronic
hepatitis B group than those of controls (0.7 vs 0.5, p< 0.05; 2 vs 0.7,
p< 0.05). Similarly, glutathione, glutathione peroxidase, vitamin E and
vitamin C levels were found to be signiﬁcantly decreased in chronic
hepatitis C group when compared with control group (9.2 vs 13.8,
p< 0.05; 17.7 vs 32.4, p< 0.05; 14.7 vs 16.4, p< 0.05; 11.1 vs 18.4,
p< 0.05), and carbonyl and lipid peroxidation levels were signiﬁcantly
increased in chronic hepatitis C group as compared with controls (0.8
vs 0.5, p< 0.05; 1.8 vs 0.7, p< 0.05). However, whereas glutathione
and carbonyl level correlation with HBV DNA levels were mild to
moderate (glutathione vs HBV DNA, r:-0.288, p< 0.05; carbonyl vs
HBV DNA, r:0.317, p< 0.05), lipid peroxidation level were strongly
related with HBV DNA levels in chronic hepatitis B (r:0.545, p< 0.05).
It was not determined any correlation between HCV RNA and oxidative
or antioxidative parameters.
Conclusion: In conclusion, there was decrease at the level of protective
antioxidative parameters, where as there was increase at the level
oxidative parameters in hepatitis B and C patients.
P2028 APRI Index, HCV genotype and HCV RNA as predictors
of early viral response in hepatitis C patients
J. Mata-Marin °, J. Fuentes-Allen, J. Gaytan-Martinez, A. Chaparro-
Sa´nchez, C. Arroyo-Anduiza, B. Manjarrez-Tellez (Mexico City, MX)
Background: Absence of therapeutic response in hepatitis C patients
is multifactorial; genotype 1, viral load major than 800,000UI/ml, and
APRI index of hepatic ﬁbrosis major than 1.2 are associated to an
unfavourable response.
Methods: We prospectively checked patients with diagnosis of
hepatitis C since July 2006 to February 2008, who were evaluated to
start therapy with interferon a-2b pegylated and ribavirin and reviewed
retrospectively clinical charts of patients with the same diagnosis from
January 2004 to June 2006. The treatment with Interferon a-2b pegylated
1.5mg/kg/weeks and ribavirin was adjusted (>75 kg; 1200 and <75 kg;
1000mg). Patients were allocated in one of two groups: Group 1 included
patients with hepatitis C with early viral response (EVR) and group
2 patients without EVR. We identify any clinical and/or biochemical
variable potentially predictive of the response.
Results: During the study, 80 patients were analyzed, 45 in retrospective
way and 25 in prospective way. The mean (±SD) age of these patients
was 42.9±12 years. 55 (68.8%) were genotype 1 and 25 (31.3%)
were genotype 2 or 3. Variables associated with absence of EVR
were genotype 1 (OR 0.28 IC 95% 0.08–0.94; p = 0.034) and the
combination of the factors genotype 1, APRI index >1.2 and HVC
RNA >800,000UI/ml (OR 0.162 IC 95% 0.02–0.89; p = 0.021). After
adjustment in a logistic regression model, only the factor genotype 1
remains signiﬁcant.
P2029 The efﬁcacy and adverse events of standard interferon
(alpha 2a or 2b) plus ribavirin versus pegylated interferon
(alpha 2a or 2b) plus ribavirin
H. Gedik °, M. Yahyaoglu, M. Fincanci (Istanbul, TR)
Objectives: In this study the efﬁcacy and adverse events of standard
interferon alpha 2a (or 2b) plus ribavirin versus peginterferon alpha 2a
(or 2b) plus ribavirin was evaluated in patients with chronic hepatitis C.
Methods: A total of 98 naive patients with biopsy proven chronic
hepatitis, elevated ALT levels, and positive HCV-RNA were enrolled.
Fifty-six patients received standard interferon a-2a or 2b (3 MIU tiw)
plus ribavirin (1000–1200mg qd) for 52 weeks (Group A) and 42
patients received peginterferon a-2b (1.5mg/kg subcutaneously weekly)
or Pegylated interferon a-2a (140mg or 180mg subcutaneously weekly)
plus ribavirin (1000–1200mg qd) for 52 weeks (Group B).
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Results: Baseline ALT levels were 79.05±53.82 in group A;
106.5±79.55 in group B, and ﬁbrosis scores were 1.75±1.16 in group A;
2±1.31 in group B. In Group A genotype 1 was 91%; genotype 3a was
9% and in group B genotype 1 was 82%; genotype 3a was 10% and
genotype 1+4 was 8%. End of treatment biochemical response was 89%
in Group A and 78% in group B, sustained virologic response 63%
in group A and 73% in group B, and similar relapse rates of 17% in
both groups. The percentages of adverse events were 92% and 97%,
respectively.
The most common adverse event was asthenia. Standard interferon plus
ribavirin was discontinued in 4 of 56; peginterferon plus ribavirin was
discontinued in 5 of 42.
Conclusion: In conclusion, no signiﬁcant difference on efﬁcacy and
adverse events between the two treatment schedules was observed in this
study. Both combination therapeutic regimens are effective in inducing
a sustained virologic response.
Emerging or re-emerging infections
P2030 Evaluation of the anthrax cases who were admitted to our
hospital in 2008
K. Ozden °, Z. Ozkurt, A. Kadanali, S. Erol, M. Parlak (Erzurum, TR)
Objectives: The study was conducted to evaluate characteristics of the
cases with anthrax, which is an endemic zoonosis in northeastern region
of Turkey.
Methods: The cases who were admitted to our hospital with the
suspicion of anthrax in 2008 were included in the study. After
ﬁrst evaluation, the cases with conﬁrmed diagnosis of anthrax
were subsequently evaluated with a standard questionnaire inquiring
demographic characteristics, risk factors and clinical data of the cases.
Results: A total of 27 cases, including 18 male (66.7%) and 9 female
(33.3%), were diagnosed as anthrax in 2008. All cases had a history
of exposure to sick animals, and were living rural areas. Exposure
types were skinning, butchering a sick animal and handling and eating
contaminated meat. The animals which were exposed to were sheep
(n = 4, 15%) and cattle (n = 23, 85%). All the cases were cutaneous
anthrax. Lesions were mostly located in wrist and arms (n = 12, 44.4%)
followed by hands and ﬁngers (n = 11, 40.7%) and eyelid and faces (n = 4,
14.8%). Twenty six cases were diagnosed between August and October.
Conclusions: This study shows that anthrax still remains as an important
health-problem in Turkey. It was common in males, mostly resulted
from cattle exposure, had seasonal characteristic and mostly was seen
in cutaneous form. Good surveillance, decontamination and disinfection
procedures, and education are mandatory to reduce the incidence of
anthrax and also employees should be educated about the disease to
reduce the risk for disease. Controlling the disease in humans ultimately
depends on controlling it in animals by effective surveillance and
immunisation.
P2031 Clinical features and epidemiology of leptospirosis in Spain
F. Puchades °, M. Montero, M. Salavert, M.D. Gomez, G. Silla,
J. Cordoba, P. Lopez Aldeguer, I. Mayo (Valencia, ES)
Leptospirosis is a worldwide distributed zoonosis, caused by infection
with pathogenic Leptospira species. We analyzed the cases between
January 1994 and September 2008. Clinical presentation, laboratory data,
treatment, evolution and complications were evaluated.
34 patients (25 males and 9 females) were diagnosed of leptospirosis.
The median age was 41 years. Conﬁrmation of the diagnosis was made
in 32 cases by ELISA and in two cases by detection of Leptospiral
DNA in urine (IgM initially negative with posterior sero-conversion). The
risks factors of exposure were assessed:10 patients were rice farmers, 6
patients have been contact with irrigation ditches, 2 were bricklayers and
in two cases an international travel was associated. The more frequent
symptoms were: fever (100%), artromyalgia (56%), dispnea (32%),
Shock (20%), Abdominal pain(36%), neurologic involvement(15%)
and jaundice(24%). The laboratory data showed: 16 patients renal
impairment(43% precised dialysis), 70% rises in transaminase levels
and 11% elevated levels of alkaline phospatase. 24% presented with
a total bilirrubin count more than 10mg/dL. Elevation of CPK occurred
in 25 patients and the levels of rabdomiolisis were correlated with
renal insufﬁciency and worse evolution.48% of the cases presented with
thrombopenia (17% the thrombopenia less than 20,000 platelets) that
was associated with low Quick index in 16%. 55% of the patients
presented with non signiﬁcative alterations of the urine sediment.
Lumbar puncture was performed in 5 patients being suggestive in all
cases of lymphocytic meningitis and the culture of the cerebrospinal
ﬂuid in Fletcher medium was negative. Two patients suffered pulmonary
involvement: One suffered pleural effusion and one patient presented
with alveolar haemorrhage. Ten patients suffered severe complications,
with intensive care hospitalisation. The mortality rate was 20%. The
more common antibiotic used was Doxicycline (11 cases), Penicillin
(5 cases), cephalosporines (8 cases), quinolones (4 cases) and other
combinations that included carbapenems.
Our area is endemic in Leptospira due to farmers and rice-workers.
Renal deterioration and alveolar haemorrhage were severe complications
correlated with intensive care hospitalisation and death. Due to the
fastidious growing of Leptospira spp., diagnosis has traditionally
established in our hospital by serology; this study emphasizes the pivotal
role that molecular biology can play now in order to get an early
diagnosis.
P2032 In vitro activity of antimicrobials in combination against
clinical strains of extreme drug-resistant Acinetobacter
baumannii resistant to all antibiotics including polymyxin B
in Singapore
T.P. Lim °, W. Lee, T.Y. Tan, S. Sasikala, T.T. Tan, L.Y. Hsu, A. Kwa
(Singapore, SG)
Objectives: We have used polymyxins since 1990 s in Singapore. Emer-
gence of extreme-drug resistant (XDR) Acinetobacter baumannii (AB)
infection resistant to all available antibiotics including polymyxins have
ﬁnally occurred in an immunocompromised patient with haematological
malignancy after weeks of polymyxin B(PB) therapy. Combination
therapy may be the only viable option until new antibiotics become
available. We assess the in vitro activity of various antimicrobials and
elucidate the most effective combination therapy against these XDR AB.
Methods: 2 isolates (AB 1 and AB 2) from the patient was collected
from blood samples on different days. MICs were determined according
to a modiﬁed CLSI broth-dilution method. Time-kill studies (TKS)
were performed with approximately 105 CFU/ml at baseline with the
maximum, clinically achievable, unbound concentration (mg/L) of PB
(2), (R)rifampicin (2), (M)meropenem (64), (C)cefepime (200) and
(T)tigecycline (2) alone and in combination against the 2 isolates.
Table 1: MIC (mg/L) panel of XDR AB1 and XDR AB2
Antibiotic XDR AB1 XDR AB2
Ampicillin/Sulbactam 32 32
Ciproﬂoxacin 16 16
Gentamicin 64 64
Imipenem 64 32
Meropenem 128 64
Aztreonam 128 64
Piperacillin/Tazobactam 256 256
Polymyxin B 64 32
Tigecycline 4 4
Ceftazidime 128 128
Amikacin 2048 2048
Cefepime 128 128
Rifampicin 2 4
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Results: MICs to various antibiotics are shown in Table 1. Both isolates
were resistant to all antibiotics including PB (MICs 32−64mg/L). In
single drug TKS, all drugs were bacteriostatic at 24 h except for PB and T
where the reduction in bacterial burden could hardly be seen against AB
1. Against AB 2, all drugs were bacteriostatic at 24 h except for PB where
the reduction in bacterial burden could hardly be seen. In combination
TKS, no combination was synergistic against AB 1 whereas RP, MP and
CP were synergistic against AB 2. They were bactericidal at 8 h and
exhibited sustained kill till 24 h.
Conclusions: Clinical isolates of AB resistant to PB is also resistant to
all major antibiotic classes with no compromise in bioﬁtness; in contrary
to previous reports that illustrate PB resistant AB with a substantial
deﬁcit in bioﬁtness in vitro. We had shown that RP, MP and CP may be
potential antibiotic combinations as pre-emptive therapy for XDR AB
infections and warrants further investigations.
P2033 Effective antimicrobials in combination against extreme
drug-resistant Pseudomonas aeruginosa with decreasing
susceptibilities to polymyxin B in Singapore
T.P. Lim, W. Lee, T.Y. Tan, S. Sasikala, T.T. Tan, L.Y. Hsu, A. Kwa °
(Singapore, SG)
Objective: Emergence of extreme drug-resistant (XDR) Pseudomonas
aeruginosa (PA) infections in immunocompromised hosts with de-
creasing susceptibilities (DS) to Polymyxin B (PB) have occurred in
Singapore. Combination therapy may be the only viable option until new
antibiotics become available. The objective of this study is to assess the
in vitro activity of various antimicrobials against XDR PA isolated from
our local hospitals.
Methods: Three clinical XDR PA isolates with MIC 4−8 to
polymyxin B collected from each public hospital (SGH, NUH, TTSH)
in Singapore were studied. Time-kill studies (TKS) were performed with
approximately 1×105 to 5×105 CFU/ml at baseline in clinically achiev-
able unbound concentrations of PB(2mg/L), levoﬂoxacin (24mg/L),
rifampicin(R)(2mg/L), amikacin (A) (80mg/L) and meropenem (M)
(64mg/L) alone and in combination. TKS screening were performed
with the above combinations elucidated against additional 12 clinical
XDR PA isolates from the same hospitals.
Results: In TKS, a sustained killing effect of >99% (>2 log kill)
from baseline inoculum at 24 h was only seen with at least a 3-drug
combination AMP (SGH), LRP(NUH), ALRP(TTSH), ALMP(TTSH)
and AMRP(TTSH). No regrowth was observed at 24 h. A sustained
killing effect of >99% by AMP was observed against 7 out of 12
screening isolates. A sustained killing effect of >99% by LRP was
observed against 7/12 isolates. Of these 7/12 isolates (sustained killing
seen with LRP), 3/12 isolates did not achieve sustained killing with AMP.
ALRP, ALMP, and AMRP when used in TKS screening for 2 isolates
(did not achieve >99% killing effect with AMP or LRP), achieved >99%
killing effect with 0/2, 0/2, and 1/2 isolates respectively.
Conclusion: AMP, LRP and AMRP achieved sustained killing effect
of >99% in 11/12 screening isolates. Sustained killing effect of
>99% is important in eradicating XDR PA infection, especially in
immunocompromised hosts. These ﬁndings demonstrate that in vitro
synergy of at least 3-antibiotic combinations in XDR PA were required to
eradicate this XDR PA which may be strain dependant. It may guide us
in making useful predictions on choosing a pre-emptive therapy for XDR
PA infections with decreasing susceptibility to Polymyxins, however, it
warrants further investigations
P2034 Investigation of N. cyriacigeorgica and N. abscessus
infections: a recent experience of 6 cases in Greece
H. Moraitou °, D. Papaventsis, C. Pantzartzi, M. Makarona, F. Havouti,
N. Souﬂa, M. Yiangou, Z. Skouras, S. Kanavaki (Athens, Thessaloniki,
GR)
Objectives: Nocardia infections are of great importance, especially
in immunocompromised patients. However, identiﬁcation of strains in
species level is difﬁcult in routine microbiology. The aim of this study
was to further investigate the cases of Nocardia infection occurred in our
Hospital, within 2008, in the terms of isolate identiﬁcation and antibiotic
susceptibility patterns.
Materials and Methods: In 2008, 6 cases of Nocardia infection
occurred in our Hospital. Five patients were immunocompromised: 4
of them presented with pulmonary infection and one with pulmonary
inﬁltrates and disseminated cutaneous nodular disease. A sixth patient
presented with respiratory infection and no sign of immune deﬁciency.
Five Nocardia strains were isolated from respiratory samples (BAL
and sputum) and one from pus taken by FNA. All specimens were
examined by Gram stain, inoculated onto blood agar and incubated for
at least 7 days at 35ºC. Phenotype-based identiﬁcation followed standard
routine laboratory protocols. The susceptibility proﬁle of all strains to 12
antibiotics was determined using Etest (AB Biodisk, Sweden), according
to the CLSI standard method. All isolates were subjected to further
identiﬁcation by16 s rRNA sequencing and phylogenetic analysis.
Results: Based on a similarity of >99% to the closest relative 16S
rRNA sequences, 5 strains were identiﬁed as N. cyriacigeorgica. The
sixth isolate, a slow growing and phenotypically different strain, was
N. abscessus derived from an immunocompetent patient with lung
inﬁltrates. The 16S rRNA sequences were clearly distinct from sequences
available in GenBank for N. asteroides, supported by high bootstrap
values.
N. cyriacigeorgica strains were resistant to b-lactams, ciproﬂoxacin,
piperacillin/tazobactam and clarithromycin but susceptible to imipenem,
linezolide, moxiﬂoxacin and amikacin. The N. abscessus isolate was
resistant only to ciproﬂoxacin and piperacillin/tazobactam.
Conclusions: This study indicates the high incidence of Nocardia
cyriacigeorgica in the clinical setting, showing major association with
lung infections. Molecular methods have improved accurate diagnosis,
resulting to the emergence of novel species. To our knowledge, these are
one of the few reports of disseminated N. cyriacigeorgica infections in
Europe.
P2035 Pertussis remains a health problem
D. Karabaxoglou, E. Bakali, P. Siasios, A. Kaftantzi, E. Dima,
A. Kansouzidou ° (Thessaloniki, GR)
Introduction: Pertussis is a highly contagious disease of childhood.
Clinical diagnosis is conﬁrmed by laboratory tests, especially by the
detection of IgM, IgG and IgA speciﬁc antibodies in the serum of
patients. The immunity from infection or vaccination lasts only a few
years. Therefore, an increase on adults vulnerable to the infection is
observed.
Aim: The aim of this report is the study of pertussis cases that
were recorded during the decade of 1999–2008, the estimation of the
laboratory ﬁndings and the frequency of the disease according to age.
Material and Methods: A total of 373 subjects (173 males and 200
females) aged 17 days to 65 years old were studied and serum samples
collected from them were analyzed. These subjects were divided into
three groups. First group: 283 children who were hospitalised with the
clinical diagnosis of pertussis. Second group: 57 house-hold contacts of
57 children with laboratory conﬁrmed pertussis. Third group: 33 adults
who suffered from chronic cough.
All serum samples were tested for B. pertussis speciﬁc IgM, IgA and
IgG antibodies using ELISA. The diagnosis of pertussis was based on
positive titers of IgM or/and IgG and IgA speciﬁc antibodies. Also, a
signiﬁcant increase in IgG speciﬁc antibodies between paired samples
and an epidemiological linkage with a conﬁrmed case were estimated.
Results: In 245 subjects the disease was conﬁrmed by laboratory
ﬁndings. In 166 children of the ﬁrst group a positive titer of IgM or/and
IgG and IgA antibodies was detected in single serum or paired serum
samples. A close contact with pertussis was found in 35 children of the
ﬁrst group. The diagnosis of the disease in 11 children was established by
epidemiological linkage with a conﬁrmed pertussis case from the family
environment. The prevalence of the disease was higher in children older
than eight years old (85%) than in children younger than four years old
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(54%). In addition antibodies were detected in the serum of 45 (78.9%)
adults of the second group and in 23 (69.7%) adults of the third group.
Conclusions: Despite the obligatory vaccination, pertussis continues to
be an infectious disease of all ages. Increased prevalence of the disease
was observed with increasing age. Pertussis is often responsible for the
infections of the close contacts (family environment) of the patient. The
chronic cough of the patients is often due to pertussis. Pertussis diagnosis
remains difﬁcult in case of neonates and small children.
P2036 Pigs as a source for toxigenic Corynebacterium ulcerans in
diphtheria-like disease
R. Schuhegger, C. Scho¨rner, J. Dlugaiczyk, I. Lichtenfeld, A. Trouillier,
V. Zeller-Peronnet, U. Busch, R. Kugler, S. Ho¨rmansdorfer, A. Sing °
(Oberschleissheim, Erlangen, Coburg, DE)
Objectives: Toxigenic Corynebacterium ulcerans may cause a zoonotic
infection similar to C. diphtheriae-caused diphtheria. Previously, mainly
dairy cattle were described as C. ulcerans reservoirs, while recent
publications suggest pet dogs and pet cats as carriers, the latter often
afﬂicted by binasal discharge. Here, we report the ﬁrst case of severe
C. ulcerans diphtheria-like disease after pig contact in a previously
healthy farmer presenting with severe diphtheria-like illness including
polyneuropathy and cardiomyopathia.
Methods:Species identiﬁcation of C. ulcerans was achieved by biochem-
ical differentiation (API Coryne), rpoB sequencing and MALDI-TOF
analysis Toxigenicity of the strain was veriﬁed using a C. diphtheriae
tox-PCR, a C. ulcerans tox-speciﬁc PCR and the Elek test as described
previously. An outbreak investigation involving both the patient’s family
and their farm animals (19 pigs and one dog) was started.
Results: Pharyngeal swabs of 3 family members, 19 pigs and the
farm dog were obtained and analysed for C. ulcerans. While all
family members and the dog were C. ulcerans-negative, one of the 19
asymptomatic pigs harboured a toxigenic C. ulcerans strain. Sequencing
of rpoB and tox revealed 100% homology between the human and the
pig strain. Ribotyping conﬁrmed this result suggesting the identity of
both strains.
Conclusion: To our knowledge, this is the ﬁrst case of proven
transmission of a toxigenic C. ulcerans strain between a livestock
animal and a human. Moreover, harbouring of toxigenic C. ulcerans has
previously not been reported in pigs. As the handling of C. ulcerans-
infected pigs might lead to diphtheria-like illnesses, studies on toxigenic
C. ulcerans carriage among pigs are certainly neeeded.
Toxigenic Corynebacterium ulcerans may cause a zoonotic infection
similar to C. diphtheriae-caused diphtheria. Previously, mainly dairy
cattle were described as C. ulcerans reservoirs, while recent publications
suggest pet dogs and pet cats as carriers, the latter often afﬂicted by
binasal discharge. Here, we report the ﬁrst case of severe C. ulcerans
diphtheria-like disease after pig contact.
P2037 Detection and enumeration of Clostridium difﬁcile in retail
meat
J.S. Weese °, B. Avery, J. Rousseau, R. Reid-Smith (Guelph, CA)
Objectives: Community-associated C. difﬁcile infection appears to be
an increasing problem and concern has been expressed about food as
a source of infection. While studies have identiﬁed C. difﬁcile in retail
meat, the level of contamination has not been reported. The objectives
of this study were to determine the prevalence and concentration of
C. difﬁcile spores in retail meat and to characterise recovered isolates.
Methods: Ground beef and ground pork were purchased from retail
outlets in 4 Canadian provinces. Broth enrichment using a rinse
of ground meat into CDMN broth with 0.1% sodium taurocholate
and inoculation onto CDMN agar was used for qualitative analysis.
Quantitative testing was performed using serial 10-fold dilutions of the
rinses and inoculation onto CDMN agar. Ribotyping, toxinotyping and
toxin gene PCR were performed on isolates.
Results: C. difﬁcile was isolated from 27/230 (12%) samples overall;
14/115 (12%) ground beef and 14/115 (12%) ground pork (P = 1.0) For
ground beef, 10/14 (69%) were positive on enrichment culture only while
2/14 (14%) were positive on both enrichment and direct culture and 2/14
(14%) were positive on direct culture only. Of the 4 ground beef samples
that were positive on direct culture, 20 spores/g were present in two while
120 and 240 spores/g were present in one each. For ground pork, 10/14
(71%) were positive on enrichment culture only while 2/14 (14%) were
positive on both enrichment and direct culture and 2/14 (14%) were
positive on direct culture only. Of the 4 ground pork samples that were
positive on direct culture, 20 spores/g were present in three while 60
spores/g were present in one. All samples that were positive on direct
but not enrichment culture only contained 20 spores/g. Typing data are
presented in the table.
Source Ribotype Toxinotype Toxin genes n (%)
Ground beef 078 V A+, B+, CDT+ 10 (71)
027 III A+, B+, CDT+ 1 (7.1)
C IX A+, B+, CDT+ 1 (7.1)
Not tested 2 (15)
Ground pork 078 V A+, B+, CDT+ 9 (64)
027 III A+, B+, CDT+ 1 (7.1)
C IX A+, B+, CDT+ 1 (7.1)
Y III A+, B+, CDT+ 1 (7.1)
Discussion: This is the ﬁrst study to quantify C. difﬁcile contamination
in retail meat and the ﬁnding of low levels may be important. While the
infectious dose for C. difﬁcile is not known and may be variable between
individuals, it is plausible that low numbers of spores are less relevant
than larger numbers. Yet, this low level contamination should not be
dismissed. The predominance of toxin variant strains in not surprising,
and the ﬁnding on ribotype 078 which has been associated with CA-CDI
and ribotype 027, an important epidemic strain, raise concerns. Further
study of food as a source of infection in warranted.
P2038 Clinical characteristics of infections with Clostridium
difﬁcile ribotype 027 versus other ribotypes: data from
prospective surveillance in Belgium
M-L. Lambert °, J. Van Broeck, C. Fontaine, C. Pulincks, V. Avesani,
M. Delme´e (Brussels, BE)
Objectives: to compare clinical characteristics of patients infected with
C. difﬁcile ribotype 027, and those with other ribotypes.
Methods: we linked patient data from the prospective surveillance of
C. difﬁcile in Belgian hospitals, with typing data from the Belgian
C. difﬁcile reference laboratory. We compared CDI with, and without,
ribotype 027, in terms of patient characteristics, type of infection
(hospital-associated, or not), length of stay in hospital post infection,
and outcome.
Table: Comparison of C. difﬁcile infections caused by C. difﬁcile ribotype 027, and other ribotypes
Ribotype 027
(N= 211)
Other ribotypes
(N= 769)
Ratio of
proportions
P
(c2)
n % n %
Female gender 136 64% 409 53% 1.2 0.00
Age 80 121 57% 323 42% 1.4 0.00
Hospital-associated CDI (2 days after admission) 130 62% 486 63% 1.0 0.8
Underlying condition fulminant or rapidly fatal 27 13% 95 12% 1.0 0.7
Death 48 23% 150 20% 1.2 0.3
CDI-related death 33 16% 85 11% 1.4 0.06
Median time from infection (or hospital admission
for imported cases) to discharge, days
20 19 ns*
Median time from infection to CDI-related death,
days (N= 114 CDI-related deaths)
14 15 ns*
*Mann-Whitney test − comparison of medians.
Results: Laboratory data were available for 980 episodes of C. difﬁcile
infections (CDI) which occurred between July 1, 2006, and June 30,
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2008 across 80 Belgian hospitals; 211/980 (21.5%) strains belonged to
the ribotype 027. Simple univariate comparisons can be found in the
table.
Using logistic regression, and taking into account the clustering effect
of hospitals, we modelled the probability of CDI-related death (CDI as
direct or indirect cause of death, dependant variable) using as covariate
age (<80 vs 80), sex, severity of underlying condition (not fatal,
ultimately fatal, fulminant or rapidly fatal), and the ribotype (ribo 027
vs other). We also added the time from infection to discharge (1−7 days,
8−14 days, 14 days) in the model to account for the time-dependant
nature of the observations.
Age over 80 (odds ratio, OR 1.6, p =0.01) and the severity of underlying
condition, but not sex, were independent predictors of CDI-related death.
Infection with ribotype 027 was associated with an OR of 1.9 (p = 0.041).
Conclusions: In this large prospective study, patient data and laboratory
data were collected independently and are therefore free from any
differential bias. CDI with ribotype 027 were no more frequent in
hospital-associated cases than in imported cases, and resulted only in
slightly higher length of stay after infection, but the odds to die from a
ribotype 027 CDI were almost double than the odds of dying from CDI
with another ribotype.
P2039 Clostridium difﬁcile in dogs and the home environment:
prevalence and risk factors
J.S. Weese °, R. Finley, R. Reid-Smith, N. Janecko, J. Rousseau
(Guelph, CA)
Objectives: A cross-sectional survey was conducted to determine the
prevalence of C. difﬁcile shedding in dogs and the home environment,
compare ribotypes, and identify risk factors for C. difﬁcile shedding.
Methods: Households containing dogs were recruited in southern
Ontario. Canine faecal samples were collected for 5 consecutive days.
Enrichment culture for C. difﬁcile was performed and isolates were
characterised by ribotyping, toxinotyping and toxin gene PCR. Nine
household sites were also tested (table) and a questionnaire was
administered.
Results: 84 households and 137 dogs were enrolled. C. difﬁcile was
isolated from 14/137 (10%) dogs, but 13 (93%) dogs were only positive
on 1/5 samples. Dogs living with an immunocompromised person were
8× as likely (p = 0.02) to shed C. difﬁcile than other dogs while dogs
allowed to run freely in a park were 3× less likely (p = 0.04) to shed
C. difﬁcile. 10 (71%) canine isolates were toxigenic. 5 different ribotypes
were present among toxigenic strains, all of which have been found in
people in Ontario. The most common was a toxinotype (TT) 0 strain
that is the most common strain in hospitalised humans in the province.
Two other TT0 strains were identiﬁed, plus a TT XII strain and a binary
toxin-positive TT IX strain. 77 C. difﬁcile isolates, 62 (81%) toxigenic,
were found in 26 (31%) households, with 1 to 4 positive samples per
household (table). Ribotype 027 was most common (13%), followed by
ribotype 078 and a TT0 ribotype (8% each). C. difﬁcile was isolated
concurrently from dogs and the environment in 4 households, but in all
cases canine and environmental ribotypes were different.
Site Prevalence Site Prevalence
Toilet 9/83 (11%) Dog eating area 4/84 (4.8%)
Dog food bowl 6/84 (7.1%) Kitchen sink taps 4/84 (4.8%)
Refrigerator 6/84 (7.1%) Main entryway 2/84 (2.4%)
Kitchen sink 6/84 (7.1%) Vacuum bag contents 1/81 (1.2%)
Kitchen counter 4/84 (4.8%)
Conclusions: Although the prevalence of C. difﬁcile in dogs is low,
the fact that all toxigenic strains are recognized human pathogens
raises concern about interspecies transmission. The relationship between
the presence of an immunocompromised individual in the home
and C. difﬁcile shedding by their dog supports this concern. The
sporadic nature of isolation of C. difﬁcile from dogs could represent
intermittent shedding, test sensitivity or transient passage (as opposed to
colonisation). The high prevalence of household contamination suggests
that exposure to low levels of C. difﬁcile may be a common event and the
commonness of positive kitchen sites raises questions about food as the
source of contamination. This study does not provide evidence that dogs
are an important source of environmental C. difﬁcile contamination.
P2040 Prevalence of Clostridium difﬁcile in retail pork
D.S. Metcalf °, R.J. Reid-Smith, B.P. Avery, J.S. Weese (Guelph, CA)
Objective: Clostridium difﬁcile has been isolated from varying
percentages of healthy animals, and some strains found in food animals
are those implicated in infections in humans. To date, only a few
studies assessing C. difﬁcile contamination of food products have been
performed and few have used systematic sampling methods over broad
geographic regions. The objective of this research was to determine
the prevalence of C. difﬁcile in Canadian retail pork products and to
characterise these isolates.
Methods: Retail pork was collected from 4 Canadian provinces between
November 2007 and May 2008. Five grams of each sample were
incubated anaerobically in a C. difﬁcile selective medium for 7 days
and plated onto blood agar plates. The colony identities were conﬁrmed
using biochemical tests and isolates were characterised using standard
typing techniques including ribotyping and toxinotyping, in addition to
being screened for the presence of tcdA, tcdB, binary toxin gene (cdtB),
and tcdC sequence analysis.
Results: C. difﬁcile was isolated from 1.8% (7/393) retail pork samples;
4/296 (1.4%) ground pork samples, and 3/97 (3.1%) pork chops. Five
different ribotypes and 3 different toxinotypes were identiﬁed. Three
isolates were ribotype 027 and toxinotype III, with genes encoding toxins
A, B and binary toxin, an 18 bp tcdC deletion and a truncating mutation
in tcdC. One strain had a different ribotype from 027 but was toxinotype
III, positive for all 3 toxin genes and had the same tcdC deletion and
mutation as 027. One isolate was toxinotype XXVI and possessed genes
for toxins A and B and an unaltered tcdC gene, while another was
a toxinotype 0 strain possessing the same toxin gene characteristics.
One isolate was non toxigenic. All toxigenic strains have been found
in people in Canada. There were no statistically signiﬁcant associations
between prevalence of C. difﬁcile and province (p = 0.28) or sample type
(p = 0.37).
Conclusions: Although the implications for food safety practices remain
elusive, the frequency of toxigenic isolates and isolates indistinguishable
from known human pathogenic strains suggests contaminated pork
may be a source of C. difﬁcile in humans. While the prevalence
of contamination was lower here than in some other reports, further
investigation of sources of contamination and clinical relevance are
needed.
P2041 Clostridium difﬁcile colonisation in veal calves
M. Costa, L. Arroyo, H. Staempﬂi, J.S. Weese ° (Guelph, CA)
Objectives: There is increasing concern that C. difﬁcile may be
a zoonotic pathogen, and that food may be a source of infection.
While C. difﬁcile can be found in retail beef and veal, there is very
little information available about C. difﬁcile colonisation in cattle.
The objective of this study was to longitudinally monitor C. difﬁcile
colonisation in veal calves.
Methods: 163 male Holstein-Friesen calves on one farm were enrolled.
Calves were approximately 2 weeks of age at arrival, came from several
different farms and were housed either individually or in groups in two
separate pens. Calves are managed in an all-in/all-out system and treated
with oral oxytetracycline after arrival. Faecal samples were obtained
on day 1 or 2 after arrival and 6 days later. Further sampling is
ongoing. Selective culture for C. difﬁcile was performed, and isolates
were characterised using standard methods.
Results: C. difﬁcile was isolated from 22/70 (34%) individually housed
calves at the ﬁrst sampling period and 42/69 (61%) 6 days later
(Pfts;< 0.001). Similarly, C. difﬁcile was isolated from 31/93 (33%)
Emerging or re-emerging infections S599
group housed calves initially and 46/93 (49%) later (P = 0.037). Overall,
C. difﬁcile was isolated from 53/193 (33%) calves initially and
88/162 (54%) 6 days later. There was no difference in the prevalence
of colonisation between management types at either sampling point
(P = 0.87 and 0.16 respectively). 14 of the 31 (45%) group housed calves
that were positive initially were negative on the 2nd sample, as were 7
(32%) of the initially-positive individually housed calves. Virtually all
calves had some degree of diarrhoea at the time of the second sampling,
which is typical for this farm. The role of C. difﬁcile in diarrhoea was
not evaluated because of the high overall prevalence of diarrhoea.
Conclusions: The colonisation rate of veal calves in this study was high,
even at the ﬁrst sampling time and increased signiﬁcantly shortly after
arrival. The signiﬁcant increase was not surprising and various factors,
including stress of transportation, diet change, environmental exposure
and antimicrobial administration, could be involved. Homogenous
management of calves, including antimicrobial therapy, precludes
evaluation of factors associated with colonisation. Further study of these
calves through their lifetime on the farm and evaluation of typing data
will provide additional insight into the epidemiology of C. difﬁcile in
veal calves.
P2042 First detection of Clostridium difﬁcile ribotype 027 in
Bochum, Germany, conﬁrmed by slpA sequencing
M. Kaase °, F. Szabados, A. Anders, T. Sakinc, S. Gatermann (Bochum,
DE)
Objectives: Due to its increased virulence reliable detection of
C. difﬁcile Type 027 is necessary. In Germany C. difﬁcile ribotype 027
has been described only in the south-west.
Methods: C. difﬁcile was cultured from stool samples of hospitalised
patients using selective media. C. difﬁcile isolates were tested for the
presence of tcdB by PCR. Susceptibility testing for erythromycin and
moxiﬂoxacin was used to screen for ribotype 027 and all isolates resistant
to erythromycin or moxiﬂoxacin were further characterised. A duplex
PCR for cdtA and cdtB was performed. Isolates with positive results were
typed by PCR ribotyping according to Stubbs et al. If results suggested
ribotype 027 we performed slpA and tcdC sequencing to conﬁrm the
results.
Results: Of 130 tcdB positive C. difﬁcile isolates resistant to
erythromycin and moxiﬂoxacin collected between April and December
2008 we could demonstrate the genes for the binary toxins cdtA and
cdtB in 47 (36.2%) isolates. PCR ribotyping gave the same banding
patterns as in a ribotype 027 reference strain in 9 isolates. All those
isolates showed slpA sequences typical of ribotype 027 and deletions at
position 117 and 330 to 347 of the tcdC gene.
Three cases of C. difﬁcile ribotype 027 occured in the same hospital
ward. The remaining cases were found in different hospitals. The mean
age of cases was 68.6 years (range 12 to 90).
Conclusion: For the ﬁrst time cases of C. difﬁcile ribotype 027 could be
demonstrated in our area. All isolates carried the genes for the binary
toxins cdtA and cdtB and deletions in the gene for the negative regulator
of toxin production tcdC.
P2043 Leptospirosis: an emerging disease in rural areas in Greece
E. Papathimitriou °, A. Masgala, D. Sﬁrass, G. Kiriazopoulos,
S. Pournaras, T. Douros (Lamia, Athens, Larissa, GR)
Objectives: To evaluate the incidence, clinical course and outcome of
leptospirosis in a tertiary care hospital in Greece.
Methods: All cases of leptospirosis were recorded during one year
period in our hospital.
Results: A total of 7 cases of leptospirosis were recorded. Of these, 6
were males and 1 was female. The mean age was 54.6 years. All patients
were farmers. Five of these (71.4%) presented with severe leptospirosis
(Weil’s syndrome) having jaundice, renal failure, and haemorrhage.
Two of the patients with severe leptospirosis experienced ARDS and
intrapulmonary haemorrhage during the course of the disease, whereas
the others three required renal dialysis for a time period of 1 month
to one year. The rest of the patients with leptospirosis presented only
with fever and thrombocytopenia while the course of the disease was
uneventful. Of note, thrombocytopenia (PLT< 70,000) was present in
all cases. Diagnosis was conﬁrmed by the fourfold rise of antibodies
against leptospira interrogans. The patients were treated successfully with
ceftriaxone, but 3 of them experienced the Jerich Herxheimer reaction.
The outcome was good in all patients
Conclusion: Leptospirosis is still emerging in rural areas in Greece.
Although in the literature Weil’s syndrome develops in 5−10% of
infected individuals, in our study concerns the 71.4% of the patients.
Thrombocytopenia, although it is usually associated with renal failutre,
it was present in all cases examined.
P2044 Clinical spectrum and microbiological features of nocardial
infection in Crete, Greece: a seven-year experience
S. Maraki °, E. Scoulica, A. Christidou, E. Nioti, Y. Tselentis
(Heraklion, Crete, GR)
Objective: To assess the incidence, species distribution, antimicrobial
susceptibility, predisposing factors, treatment and outcome of nocardial
infection over a 7-year period in a tertiary care hospital.
Methods: We reviewed the clinical and laboratory records of 20
patients with nocardial infection diagnosed at the University Hospital
of Heraklion, Crete, Greece, between 1996 and 2002.
Results: All patients were adults. The male to female ratio was 3:1. The
mean age was 57 years (range 32−83 years). Thirteen patients (65%)
had one or more underlying conditions predisposing to nocardiosis.
The skin was involved in 14 cases, followed by the lung (ﬁve); one
patient had disseminated disease and one bacteraemia. Four different
species were identiﬁed: N. brasiliensis (n = 11), N. otitidiscaviarum
(n = 4), N. abscessus (n = 3), and N. farcinica (n = 2). All isolates
were sensitive to linezolid, moxiﬂoxacin, and tigecycline, and 85% of
them to trimethoprim-sulfamethoxazole. Treatment with trimethoprim-
sulfamethoxazole (SXT), minocycline, imipenem with amikacin, line-
zolid alone or in combination with quinolones was given to all 20
patients. A cure was observed in 18 of them, while two died of
nocardiosis.
Conclusion: Nocardiosis is a rare but sometimes lifethreatening oppor-
tunistic infection, complicating immunosuppression. Molecular methods
can contribute to rapid and accurate diagnosis. Early identiﬁcation and
antibiotic susceptibility testing of Nocardia isolates are necessary for
prescribing the appropriate treatment. Nocardia brasiliensis was the most
common species found in our study and SXT was the most frequently
administered treatment.
P2045 Hepatitis E virus detection in wild boar liver samples from
south-eastern France
M. Kaba, B. Davoust, J.L. Marie´, J.M. Rolain, D. Raoult, P. Colson °
(Marseille, Toulon, FR)
Objectives: Autochthonous hepatitis E is currently considered as an
emerging disease in industrialised countries. To date, the routes of
transmission of hepatitis E virus (HEV) in these countries remain largely
unknown. However, a growing body of data suggests that animals,
especially pigs, might be reservoirs for HEV and a source for its
transmission to humans. In contrast, only few data are available about
the circulation of the HEV in wild boars, and, to our knowledge, no
study is available from France. We aimed at assessing the HEV RNA
prevalence in wild boar livers from south-eastern France.
Methods: Between September 2007 and January 2008, liver samples
were collected from 285 wild boars hunted in the Bouches-du-
Rhoˆne (n = 278) and the Var departments (n = 7). Total viral RNA
was extracted from 200 ml of each wild boar liver sample following
homogenisation in sterile phosphate-buffered saline, then clariﬁcation,
using the MagNA Pure LC RNA Isolation Kit. HEV RNA detection
and sequencing were performed using in house real-time PCR and
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ampliﬁcation/sequencing assays targeting the 5′ORF2 region of the HEV
genome. Genotype/subtype was determined using phylogenetic analysis.
Results: HEV RNA was detected using real-time PCR from liver of
seven (2.5%) of the 285 wild boars. HEV sequences were obtained in
ﬁve cases, and belong to genotype 3f. They showed 89–100% nucleotide
identity with each others, and 80−98% identity with genotype 3 HEV
sequences obtained from human hepatitis E cases diagnosed in the
Microbiology laboratory of Marseilles public hospitals. Phylogenetic
analysis showed that they clustered together with human and pig HEV
sequences from France and Spain. Moreover, a strong phylogenetic link
could be found between three wild boar HEV sequences from the present
study and sequences obtained from a French patient and from swine
manure in Spain.
Conclusion: Our results indicate that wild boars, together with domestic
pigs, might represent an HEV reservoir in southern France, and suggest
that wild boars should be a potential source of HEV transmission for
humans in this geographical area.
P2046 Investigation on the presence of WU and KI polyomaviruses
in central nervous system samples
L. Squarzon, M. Pacenti, V. Militello, M. Trevisan, P.G. Scotton,
L. Barzon, G. Palu` ° (Padua, Treviso, IT)
Objectives: WU and KI polyomaviruses have been recently discovered
in respiratory secretions from patients with acute respiratory tract
infections, where they are generally detected in 4% and 2% of cases,
respectively, often as coinfection with other respiratory viruses. However,
their association with human diseases remains still unclear.
Aim of this study was to investigate whether WUV and KIV are
detectable in central nervous system (CNS) samples and, in case of
positive results, to understand their possible association with neurological
diseases.
Methods: The presence of WUV, KIV, and JCV DNA was retrospectively
investigated by real-time PCR in cerebrospinal ﬂuid (CSF) samples from
60 consecutive patients (26 females and 34 males; median age 44 years;
range 0−88) with neurological signs and symptoms suggestive of acute
or chronic viral encephalitis and in 25 parafﬁn-embedded CNS samples
from 16 HIV-positive asymptomatic subjects (median age 31 years;
range 25−40) who died of acute opiate intoxication. CSF samples
were selected among those submitted to routine PCR screening for the
presence of neurotropic viruses in the period from January 2008 to April
2008, but without clear identiﬁcation of causative viral agents.
Results: CSF samples from 2 patients (F 5 yr and M 63 yr), both with
B-cell lymphoma, were positive for JCV DNA besides EBV DNA. All
CSF samples were negative for KIV DNA, whereas a CSF samples
from a 42 yr-old male tested positive for WUV DNA. The patient
was HIV-positive and had clinical and radiological signs of progressive
multifocal leukoencephalopathy (PML). All autoptic CNS samples were
negative for KIV and WUV DNA but positive for other common
neurotropic viruses.
Conclusion: While extending our study to further CSF samples and to
brain biopsies, these preliminary results raise the possibility that WUV
may be associated with PML.
P2047 A surveillance study of parvoviruses from animals in Hong
Kong discovered two novel parvoviruses closely related to
human parvovirus 4
J.S.Y. Chan °, S. Lau, P. Woo, H. Tse, C. Fu, H.W. Tsoi, K. Li,
B.J. Zheng, K.Y. Yuen (Hong Kong, HK)
Background: Parvoviruses are a family of viral pathogens with a
wide animal tropism. However, within the vertebrate speciﬁc sub-family
Parvovirinae, only a few members were known to be associated with
human disease, these are parvovirus B19, adeno-associated viruses, and
more recently, the human bocaviruses and human parvovirus 4 (PARV4).
PARV4 is an interesting novel human parvovirus since it is found to
have less than 30% amino acid similarity to other parvoviruses forming
a distinct branch in the phylogeny of the Parvovirinae sub-family. Since
zoonosis is a common theme in many emerging infectious diseases, we
sought to identify PARV4-like viruses in animal samples. Identifying
possible animal origins of PARV4 is important to the understanding of
its epidemiology and evolution, both of which are still poorly understood
for this novel human parvovirus.
Methods: Animal specimens were collected directly from slaughter
houses or pig farms and from wet markets in Hong Kong. A variety
of specimens were collected from the animals where possible, these
include lymph nodes, faecal, nasopharyngeal, and serum samples from
303 pigs. Additionally, 30 liver and spleen samples, from pigs and cattle
respectively, were also collected for the study. DNA extraction followed
by PCR was performed to identify PARV4-like viruses. Of the samples
positive for PARV-4 like viruses, ten samples (7 from pigs and 3 from
cattle) were chosen for partial genome sequencing.
Results: Of the porcine samples, a positive rate of 10% to 71% was
found among the different specimens with lymph nodes and faecal
samples having the highest and lowest positives respectively. Of the
bovine spleen samples, 13% were found to be positive for PARV-4 like
viruses. Partial genome sequencing of the porcine and bovine strains
showed a 62% and 63% nucleotide identity to PARV4 respectively.
Analysis of the genome organisation and phylogenetic analysis of
the genome sequences suggest the presence of two distinct novel
parvoviruses that are closely related to PARV4 where the three formed
a distinct cluster among other parvoviruses.
Conclusion: Two novel animal parvoviruses closely related to PARV4
were found. From the genomic organisation and phylogenetic analysis,
we propose that these two novel parvoviruses, together with PARV4, to
form a separate genus.
P2048 Crimean-Congo haemorrhagic fever among healthcare
workers in Turkey
B. Dokuzoguz °, N. Baykam, A. Celikbas, S. Eren, M. Eroglu,
S. Yaprakci, H. Esener, O. Ergonul (Ankara, Istanbul, TR)
Objectives: Crimean-Congo Haemorrhagic Virus (CCHFV) infection
causes a fatal haemorrhagic syndrome, which is a leading threat to
public.health in endemic countries. Since 2002, 3128 CCHF cases were
reported to the Ministry of Health of Turkey. Health care workers (HCW)
are under occupational risk of CCHF infection.
Methods: Occupationally infected 7 HCWs with CCHF during the
2002–2009 epidemic in Turkey were investigated. All of these HCWs
did not have exposure to the CCHFV via other routes such as tick bite.
The transmission routes, clinical course, laboratory ﬁndings, and the
management of the cases were described.
Results: Between 2002 and 2009, 272 CCHF cases were admitted to our
department. Seven of these cases were HCWs, and they were exposed
to virus during care of CCHF patients. Four of 7 HCWs were working
in our hospital and the other 3 were infected in other healthcare settings
located at the CCHF epidemic region of Turkey. The routes of infection
were described as; exposure of infected blood to skin and mucosa,
injury with needle stick contaminated with CCHFV, entubation of the
infected patient, placement of nasal tamponade for prevention of bleeding
of a patient. The lack of compliance to the standard precautions was
considered as the main factor for the acquisition of the CCHFV infection.
Ribavirin treatment was given to all the cases and one of them died.
Conclusion: Standard precautions and contact and droplet precautions
are known to be sufﬁcient for the protection from CCHFV infection
during routine care of CCHF patients. However, these precautions should
be strictly applied by the all HCWs.
P2049 Crimean-Congo haemorrhagic fever in Turkey
D. Ozturk Engin, A. Sengoz Inan °, P. Goktas, N. Ceran, J. Altintas,
S. Karli, E. Karagul (Istanbul, TR)
Objective: Crimean-Congo haemorrhagic fever(C-CHF) is severe viral
disease afﬂecting multiple organ systems. It is caused by infection with
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a member of the genus Nairovirus in the family Bunyaviridiae. C-CHF
has been found Eastern Europe, Central Asia, the Middle East, China
and Indian subcontinent. Many cases have been reported from Turkey.
We herein reported 8 cases with Crimean-Congo haemorrhagic fever.
Methods: The study was performed as retrospectively in adults patients
diagnosed with C-CHF in Haydarpasa Numune Training and Research
Hospital between 2006 and 2008.
Results: The mean age of patients (male 2, female 6) was 52.7 years.
The mean incubation period of the disease (from the bite of an
infected tick to onset of symptoms) was 5.6 days. The patients admitted
to our hospital from the other provinces of eastern Turkey. 3 of
8 patients were from Giresun, and the other 2 were from Ordu,
Kastamonu (1 patiens), Gu¨mu¨s¸hane(1 patients), and Sivas (1 patient).
All these patients had high fever. Other clinical features were as follows:
weakness (75%), myalgia (75%), headache (38%), petechial rash(38%),
nausea (25%), loss of appetite (25%), vomiting (13%), abdominal pain
(13%), gingival bleeding (13%), epistaxis (13%). The laboratory results
showed leukopenia in all patients, trombocytopenia in 7 of 8 patients.
Serum aspartate aminotransferase (AST) (median 107U/L, <37), alanine
aminotransferase (ALT) (median 117 U/L, <42), were elevated in all
patients. Lactate dehydrogenase (LDH) (median 636 U/L, >530) were
elevated in six patients. Creatine phosphokinase (CPK) levels were
elevated in 4 of 8 patients. Methods of diagnosis included antibody
detection by enzyme-linked immunassay (ELISA) in four patients.
Serum sample of one patient was positive by RT-PCR. Three serum
samples were positive for both ELISA and viral genom detection by RT-
PCR. All patients were treated with oral ribavirin and supportive therapy.
All the patients were cured.
Conclusion: C-CHF is characterised by haemorrhage, myalgia and fever,
with case-fatality rate of up to 50%. The lowest case-fatality rate was
reported from Turkey. There were no deaths among these patients. Tick
bite have been the major transmission routes in this report.
P2050 Crimean-Congo haemorrhagic fever in Kosova, 1989–2008
S.A. Ahmeti ° (Pristina, AL)
Crimean-Congo Haemorrhagic Fever (CCHF) is acute viral zoonossis
that appears after tick bit in endemic areas during months April-July.
Objectives: The aim of this study was to represent special clinical,
epidemiological and laboratory characteristics of CCHF in our cases
caused by native Hoti-Kosova virus.
Methods: There are studied 207 patients with Crimean-Congo
haemorrhagic fever serologically conﬁrmed (from totally 564 cases with
clinical manifestations) which are treated at the Infectious Diseases
Clinic of the University Clinical Center of Kosova during period 1989–
2008. Diagnosis of the disease is set based on epidemiological, clinical
and laboratory data and is conﬁrmed by serological-viral tests (ELISA,
RT-PCR).
Results: With viral examinations, in cooperation with Microbiological
Institute of Ljubljana, is isolated a new virus, causer of CCHF in Kosova
and is nominated Hoti-Kosova virus, which is different in phylogenesis
from other regional types of CCHF viruses. Infection is caused after
tick bit. Human transmission is found in 21.2% cases inside family, and
in 2.42% of cases between health personnel. Infection is more frequent
in males (57.9%) than in females. Diseases has shown severe course
with intensive haemorrhagic manifestations: petechie (69.3%), bloody
eyeball (49.2%), epistaxis (62.4%), haematemesis (70.5%), melena
(78.2%), haematuria (29.2%), metrorrhagia (34.5%), liver disorders like
hepatitis and mild renal disorders. Speciﬁc manifestations in our cases
are: otorrhagia (2.03%), Herpes Febrilis (6.6%), haematoperitoneum
(13.2%), pleuritis haemorrhagica (5.6%), pericarditis haemorrhagica
(8.6%) and thrombocitosis during period of convalescence (1.5%). There
has been high rate of Fatality (23.83%).
Conclusion: Republic of Kosova is endemic zone for CCHF. Disease is
caused from native type of virus Hoti-Kosova, closely related to a CCHF
virus strain Drosdov. Course of the disease has been severe with speciﬁc
clinical manifestations and with high Fatality Rate.
P2051 Evaluation of risk factors for fatality in patients with
Crimean-Congo haemorrhagic fever
C. Ataman Hatipoglu °, C. Bulut, M.A. Yetkin, G. Tuncer Ertem,
F.S. Erdinc, E. Kaya Kilic, T. Sari, S. Kinikli, B. Oral, A.P. Demiroz
(Ankara, TR)
Objectives: Crimean-Congo Haemorrhagic Fever (CCHF) is a fatal viral
infection caused by the CCHF virus. Fatality rate of the disease has been
reported as 5−50%. In this study we aimed to evaluate the risk factors
for fatality in patients with CCHF hospitalised in Ankara Training and
Research Hospital, between 2006 and 2008.
Methods: All CCHF patients admitted to our clinic between 2006 and
2008 were evaluated. Serum samples were analysed with immunological
(speciﬁc ELISA IgM and IgG) and molecular (RT-PCR) assays for the
conﬁrmation of the disease. All patients with positive IgM antibodies
and/or PCR for CCHF virus in blood were included to the study. To
determine the predictors of fatality among patients with CCHF, we
compared epidemiological, clinical and laboratory ﬁndings of the fatal
cases with survivors.
Results: Ninety-three conﬁrmed CCHF patients were included in
the study. Fifty-six (60.2%) of them were female, mean age was
48.4±17.7 years (14−83 years) and mean hospital stay was 7.9±3.0 days
(1−18 days). Five patients were died (5.4%). The age, gender, the rate of
tick bite, time from tick bite to admission to the hospital, hospital stay,
initial complaints (fever, fatigue, nausea, vomiting, myalgia, abdominal
pain, headache and skin eruption) were not signiﬁcantly different
between fatal and non-fatal cases (p> 0.05). The rates of haemorrhage,
diarrhoea and confusion were higher in fatal cases compared with
non-fatal cases (p< 0.05). Mean aspartate aminotransferase (AST),
alanin aminotransferase (ALT), alkaline phosphatase (ALP), lactate
dehydrogenase (LDH), creatin phosphokinase (CK), and C-reactive
protein (CRP) levels were higher in fatal cases than the non-fatal
ones, activated partial thromboplastin time (aPTT) was longer and mean
platelet counts were lower (p< 0.05). There was no differences between
ribavirin and steroid therapies, and fresh frozen plasma, platelet and
erythrocyte infusions between the two groups (p> 0.05). By multivariate
analysis only elevated serum ALT, AST, LDH levels and prolongation
of aPTT were independently risk factors associated with fatality.
Conclusions: In this study we found serum AST, ALT, LDH and aPTT
values as predictors for fatality among patients with CCHF. We suggest
that for patients who had these abnormal laboratory ﬁndings, physicians
should be aware of high fatality risk.
P2052 Clinical ﬁndings and laboratory data in Crimean-Congo
haemorrhagic fever as a re-emerging diseases
H. Salehi °, M. Rostami, F. Khorvash (Isfahan, IR)
Introduction: CCHF (Crimean Congo Haemorrhagic Fever) is a
zoonotic disease which arises from animals such as sheep, goat and
cow as sources and the main vector is tick (Hialoma). This disease as
a reemerging one appeared in Asia, middle east (especially in Iran) and
since 2001 is going to become a major health problem in these area.
Being aware of epidemiological and clinical features about it may be
essential.
Precise description of clinical signs may help to pick up patients in
prodromal phase especially in sporadic situation. We are going to
analyses the gathered data of our 8 years cases, according to their answer
sheets.
Material and Methods: We had 75 suspect cases during Nov 2001–
Oct 2008 who referred to our hospital (Alzahra) as referral centre.
For each patient 2 separate blood samples were sent to Institute pastur
of IRAN. Each sample was examined for speciﬁc IgG, IgM & RT PCR.
Of 75 cases simultaneously an answer sheet ﬁlled for every patient
includes: Data of Epidemiological, clinical manifestation and course of
disease. Study only includes conﬁrmed cases.
Results: 30 cases (75%) had speciﬁc IgM antibody and positive PCR
and they were conﬁrmed cases.
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The most important signs and symptoms in order of frequency in
conﬁrmed cases were: Fever in 30 cases (100%), petechia & purpura in
26 cases (83%), myalgia in 25 cases (83%), Malaise in 25 cases (83%),
Heamaturia in 20 cases (62%), Echymosis in 10 cases (32%), Icter in 5
cases (12%), dry cough in 3 cases (8%), Abdominal pain in 2 cases (5%).
Nearly all patients had one of the below Epidemiological factor: Close
contact with slaughtered animals, close contact with animal wastage or
Tick Bite.
All the contacts happen during last 7−10 days.
Lab data in order of frequency in conﬁrmed cases were: Thrombocy-
topenia 30 cases (100%), AST & ALT elevation in 23 cases (75%),
CPK rising in 18 cases (60%), leukopenia in 14 cases (45%) Anaemia
in 11 cases (35%), PT & PTT disorder in 6 cases (20%), Proteinuria in
6 cases (20%), Leukocytosis in 5 cases (15%), BUN & creatinin rise in
3 cases (10%), chest X Ray abnormalities were seen in 2 cases (5%).
23 patients (75%) cured with Ribavirin & supportive care, but 7 (22%)
died because of massive Haemorrhage.
Conclusion: CCHF as a viral haemorrhagic fever is scheduled as a re-
emerging and urgent disease which is prevalent in Asia and specially
middle east. Health care workers and hospitals have to be aware and
stand by for managing patients with this disease.
P2053 Preliminary study on immunological reactivity in people
occupationally exposed to tick-transmitted pathogens
J. Chmielewska-Badora °, V. Zajac, E. Cisak, J. Zwolinski (Lublin, PL)
Objectives: Our past research on prevalence of Borrelia burgdorferi,
Anaplasma phagocytophilum, Bartonella spp. and Babesia microti in
ticks in the Lublin region proved that the people attending forest are
exposed to these pathogens. The aim of the study was to evaluate the
infection rate with these pathogens in people inhabitating this region and
occupationally exposed.
Methods: Sera collected from 49 forestry workers, 39 farmers and 32
blood donors were examined with ELISA IgM and IgG for antibodies to
B. burgdorferi. A. phagocytophilum, Bartonella sp. and B. microti were
detected with IgG immunoﬂuorescence assay kits.
Results: Antibodies to B. burgdorferi were found frequently in forestry
workers and in farmers 21/49 (42.9%) and 15/39 (38.5%). Bartonella
was also frequent in forestry workers and less in farmers 20/49 (40.8%)
and 9/39 (23.1%), respectively. Rarely, but also more frequently in
forestry workers were found antibodies to Babesia and Anaplasma
equally in 6/49 (12.2%) whereas in farmers only in 1/39 (2.6%) and
2/39 (5.1%), respectively. In the control group (blood donors) antibodies
to Bartonella were the most freqent antibody found 12/32 (37.5%) with
antibodies to Borrelia found in 4/32 (12.5%) and in 3 cases Anaplasma
was detected (9.4%). In total, antibodies to one or more examined factors
were found in 35 forestry workers (74.4%), 19 farmers (48.7%) and in 18
persons belonging to the control group 56.3%. Analysing the frequency
of co-seroprevalence of examined factors with chi-squared test showed
statistically signiﬁcant differences between group of forestry workers
and the control group (16/49 vs. 1/32, p< 0.01) and forestry workers
and farmers (16/49 vs. 4/39, p< 0.05).
Conclusion: The results show frequent coinfections with tick-transmitted
pathogens in occupationally exposed people.
Acknowledgement: The study was supported by the Polish Ministry of
Science and Higher Education, Grant No. N N404 029135.
P2054 Prevalence of Pneumocystis jirovecii colonisation in the
general population of southern Spain: a preliminary study
R. Morilla °, N. Respaldiza, A. Medrano, R. Yang, L. Rivero,
J.R. Garcı´a Favero, M.A. Montes-Cano, C. de la Horra, J.M. Varela,
E. Caldero´n, F.J. Medrano (Seville, Cadiz, ES)
Objectives: The epidemiology of Pneumocystis in human populations
is largely unknown. A previous study conducted in our country has
shown that P. jirovecii DNA can be detected in the respiratory tract of
immunocompetent healthy adults. The objective of this preliminary study
was to know the prevalence of Pneumocystis colonisation in the general
population of Southern Spain.
Methods: This prospective community-based study included non-
selected 132 children and adults from a rural area of Seville (El
Coronil), evaluated at the local outpatients clinic for routine checkup
or minor symptoms. Each participant underwent a clinical-epidemiologic
examination. Identiﬁcation of P. jirovecii colonisation was done analysing
gargled oropharyngeal wash samples by nested-PCR assay that ampliﬁes
the mitochondrial large-subunit rRNA.
Results: The mean age of persons was 52.9±21.6 years (range: 3−88)
and 95 (72%) were male. Pneumocystis colonisation deﬁned by detecting
P. jirovecii DNA in a person without signs or symptoms of pneumonia
was found in 10.6% of cases (14/132). All carriers were adults and
had normal total lymphocyte and leukocyte cell counts. Twelve of them
were asymptomatic at the time of their enrolment in the study. One of
the carriers had been diagnosed with neoplasm and had taken steroids
before the study and the remaining 13 had not underlying lung disease
or immunosuppression. Mean age of Pneumocystis carriers was higher
than mean age of noncarriers (66.6±17.3 vs. 51.2±21.5, p = 0.01). No
differences were detected due to sex and smoking habit between carriers
and noncarriers.
Conclusions: This study conﬁrms that P. jirovecii DNA can be frequently
detected in the respiratory tract of immunocompetent persons, which
agrees with the hypothesis that the general population could be a
reservoir and source of this infection. Inmunocompetent carriers in
community ecosystems may present a public health issue that merits
further research.
Supported by CIBER de Epidemiologı´a y Salud Pu´blica and ERA-NET
Pneumocystis-PathoGenoMics.
P2055 Giardia and Cryptosporidium in Finland − who gets reported?
R. Rimhanen-Finne °, M. Kuusi (Helsinki, FI)
Objectives: The ﬁrst water and food-borne outbreaks of giardiasis
and cryptosporidiosis were detected in Finland, 2007 and 2008. In
order to ﬁnd out who gets reported with Giardia and Cryptosporidium
infection during peacetime, we describe the characteristics of giardiasis
and cryptosporidiosis cases notiﬁed to the Finnish Infectious Disease
Registry (FIDR).
Materials: Notiﬁcation of laboratory conﬁrmed Giardia and Cryp-
tosporidium infections to FIDR is mandatory in Finland since 1995.
The characteristics of persons with notiﬁcations between 1 January
1995 and 31 December 2006 were analyzed according to age, gender,
place of residence, seasonality and travel history. Data on country of
birth was available for notiﬁcations between 1 January 2004 and 31
December 2006. The deﬁnition ‘Finn’ included persons who were born
in Finland.
Results: During 1995–2006, 3390 Giardia and 130 Cryptosporidium
infections were notiﬁed. The average yearly incidence was 54 giardiasis
and 2 cryptosporidiosis cases/million inhabitants. No clear seasonality
was observed. Both genders were equally present; the median age was
22 years for giardiasis and 26 years for cryptosporidiosis cases. In
Helsinki metropolitan area, the incidence of giardiasis was 3-fold and
that of cryptosporidiosis 12-fold compared to other parts of Finland.
Data on travel history was limited, but most cases, in which data on
travel history was available, reported travelling abroad.
Majority of the giardiasis and all cryptosporidiosis cases were Finns.
Among Finns, the incidence of giardiasis was highest in the age group
of 20−29 years, whereas in non-Finns the infections were most common
in <5 year olds.
Conclusions: Giardiasis and cryptosporidiosis are mainly reported in
young adults living in the metropolitan area. These persons possibly
travel more, but this could not be veriﬁed due to the limited data
on travel history. The high incidence of giardiasis in young non-Finns
probably reﬂects the frequency of immigration examinations. Compared
to the reported incidences of giardiasis and cryptosporidiosis in the
neighbouring countries, the base line incidences in Finland appear low.
Traditionally, Giardia and Cryptosporidium have been considered as
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traveller’s diseases which might have led to underdetection of these
parasites in Finland.
P2056 Infectious diseases of immigrants − present screening
systems in Finland
A. Pulakka °, H. Nohynek, P. Ashorn (Tampere, Helsinki, FI)
Objectives: The aim of this master’s thesis study is to acquire detailed
information on the current practices, applicability and acceptability
of infectious disease (ID) screening of immigrants in different health
service facilities in Finland. Suggestions on how to improve the
prevailing screening practises is also asked.
Methods: The study is a cross-sectional survey utilising mixed-
mode data collection method. Data is primarily collected with an
electronic semi-structured questionnaire but a paper-and-pen version
of the questionnaire is also available. Participants are health care
professionals who work with immigrants in different settings: primary
health care facilities, services for refugees, reception centres for asylum
seekers, student health care facilities and occupational health clinics.
Health care providers from 20 different municipalities are included,
representing municipalities that received 64% of all immigrants and 76%
of all refugees who came to Finland during 2007. Data collection will
be done from October 2008 until the end of January 2009.
Preliminary results: Preliminary results are derived from answers of
73 respondents of whom 8 are medical doctors and 65 other health
professionals: public health nurses, nurses and midwives. Over half of
respondents consider ID screening very useful both for the immigrants
and the society. ID testing is done to all immigrant groups and in all
health care facilities. Most commonly screened IDs are hepatitis B and
HIV (Table 1). Testing has identiﬁed cases of hepatitis B, tuberculosis,
HIV and syphilis. 52% of the respondents are satisﬁed with existing
instructions to conduct screening although 69% of the respondents would
want to have new instructions and 86% state that more education is
needed.
Conclusion: In Finland, ID screening is done to different immigrant
groups and in different health care setting. Health care professionals
consider screening to be useful but new instructions and education is
requested.
Table 1: Testing of different infectious diseases from immigrants
Disease Tests % of respondents who
had tested this from
immigrants
Tuberculosis Chest radiograph 60
Tuberculin skin test 30
Hepatitis B Surface antigen (HBsAg) 82
Core antibody (HBcAb) 56
Hepatitis C Hepatitis C Antibody (HCV-Ab) 66
HIV HIV antibody 75
Syphilis Cardiolipin 63
Treponema Pallidum Haemagglutination Assay (TPHA) 33
Treponema Pallidum antibody (Trpa-Ab) 22
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P2057 Rapid detection of extended-spectrum b-lactamase-
producing Enterobacteriaceae: a randomised,
investigator-blinded evaluation of culture-based approaches
S. Malhotra-Kumar °, J. Cortin˜as Abrahantes, C. Lammens,
G. Molenberghs, M. Aerts, H. Goossens on behalf of the MOSAR
WP2 Study Group
Background: Rapid and accurate detection of extended-spectrum
b-lactamase-producing Enterobacteriaceae (ESBL-En) is crucial for
effective infection control. We assessed 4 chromogenic media-ChromID,
(bioMe´rieux), CHROMagar (CHROMagar Microbiology), Amber (AES
Chemunex), and a yet to be introduced formulation, Chromogenic-ESBL
(Oxoid) − and 1 selective medium − EbSA (Alpha-Omega) − for their
ability to correctly identify ESBL-En using well-characterised isolates
and spiked stool samples.
Methods: Eighty-four samples consisting of 16 ESBL-En (E. coli,
K. pneumoniae, Enterobacter spp., P. mirabilis, P. aeruginosa harbouring
CTX-M, SHV, TEM or PER), and 5 non-ESBL-En (E. coli, K. pneumo-
niae, Enterobacter spp., P. mirabilis) at concentrations of 101 CFU/ml
and 106 CFU/ml, respectively, and each of the 21 isolates spiked into
stools at 3 concentrations (106, 103, 101 CFU/ml) were randomised
and spiral plated on the 5 media. Media were read by 5 blinded
investigators for characteristic colonies after 24 and 48 hrs incubation.
One putative ESBL-En colony from the selective medium and 1 colony
of each colour/type from the chromogenic media for each plated sample
was conﬁrmed for species identiﬁcation on biochemical tests and for
presence of ESBL by double-disk synergy test. Mean sensitivity (SEN)
and speciﬁcity (SPEC), and conﬁdence intervals (CIs) were estimated
for each medium by logistic regression model based on reader response
for both incubation times, and both at the aggregated (any ESBL-En
detected) and penalised level (correct species-colony colour correlation),
using the penalised likelihood approach.
Results: Chromogenic-ESBL showed almost equal to 100% mean SEN
and SPEC at both 24 and 48 hrs with the aggregated reader response
and narrow CIs indicating a high precision of these parameter estimates
(Table). Although, Chromogenic-ESBL also showed the highest SEN
and a high SPEC with the penalised reader response for both incubation
times, these values were lower than the aggregated response primarily
due to misclassiﬁcations of E. aerogenes (TEM) and P. aeruginosa (PER)
based on colony colour. Mean SENs for the other 4 media increased on
average by 6.5% from 24 to 48 hrs. EbSA and ChromID showed almost
equal to 100% mean SPECs at both incubation times, and the latter also
with both reader responses.
Conclusions: Chromogenic-ESBL showed the best performance overall
irrespective of sample concentration, reader or incubation time.
Table. Mean sensitivities and speciﬁcities of media for ESBL-En detection
Media for ESBL-En detection 24 hours 48 hours
Sensitivity Speciﬁcity Sensitivity Speciﬁcity
Mean 95%CI Mean 95%CI Mean 95%CI Mean 95%CI
Reader response aggregated
EbSA* (Alpha-omega, BE) 79.6% 75.3, 83.3 99.6% 94.6, 100.0 86.0% 82.6, 88.8 99.4% 91.8, 100.0
ChromID (bioMe´rieux, FR) 84.1% 80.2, 87.4 99.6% 94.7, 100.0 89.3% 86.3, 91.7 99.4% 91.9, 100.0
CHROMagar
(CHROMagar Microbiology, FR)
77.5% 73.0, 81.4 96.2% 91.4, 98.4 84.4% 80.8, 87.5 94.1% 87.1, 97.4
Amber (AES Chemunex, FR) 54.4% 47.6, 61.0 74.0% 62.5, 83.0 65.3% 58.8, 71.2 64.4% 51.4, 75.6
Chromogenic ESBL (Oxoid, UK) 99.4% 97.6, 99.8 99.2% 95.0, 99.9 99.6% 98.5, 99.9 98.7% 92.3, 99.8
Reader response penalised
ChromID (bioMe´rieux, FR) 75.9% 71.5, 79.7 99.6% 94.4, 100.0 81.8% 78.1, 85.0 99.5% 92.1, 100.0
CHROMagar
(CHROMagar Microbiology, FR)
49.7% 44.8, 54.6 96.3% 91.5, 98.4 58.6% 53.7, 63.3 94.7% 88.3, 97.7
Amber (AES Chemunex, FR) 26.4% 22.2, 31.1 67.6% 57.2, 76.5 33.9% 29.0, 39.1 59.3% 48.4, 69.4
Chromogenic ESBL (Oxoid, UK) 82.2% 78.3, 85.6 98.1% 93.7, 99.4 86.9% 83.6, 89.5 97.3% 91.2, 99.2
*EbSA is a selective medium that does not differentiate the ESBL-En and thus the aggregated and penalised
responses are the same.
P2058 A laboratory evaluation of chromogenic screening media for
the detection of extended-spectrum b-lactamase producing
bacteria
A.J. Brown °, S. O’Brien, S. Cocks, J. Beaves, S. Dimmer (Basingstoke,
UK)
Objectives: Since the 1980 s, the increasing incidence of plasmid-
encoded extended-spectrum b-lactamases (ESBLs) has been of major
concern. The prevalence of ESBL-producing bacteria across Europe is
not well understood and is currently being studied by an EU project;
Mastering hOSpital Antimicrobial Resistance (MOSAR). Treatment
options for infections caused by bacteria possessing such plasmids
are limited due to their resistance to b-lactams, monobactams and
cephalosporins. In vivo resistance to aminoglycosides, ﬂuoroquinolones
and trimethoprim-sulfamethoxazole has also been widely reported,
leaving carbapenems as the currently preferred therapeutic option.
Routine screening for ESBL-producing Enterobacteriaceae is becoming
more widely adopted. Traditional culture-based screening is labour
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intensive and time consuming. The aim of this study was to examine
the performance of two chromogenic screening media for the detection
of ESBL-producing bacteria, ChromID™ ESBL (bioMe´rieux) and
Brilliance™ ESBL Agar (Oxoid).
Methods: A total of 80 pure culture isolates, comprising ESBLs (n = 23),
non-ESBL chromosomal AmpC (n = 13) and other non-ESBL producing
organisms (n = 44) were prepared as suspensions equivalent to 0.5
McFarland turbidity standard. Each ESBL isolate was serially diluted to
provide an inoculum of 10 to 100 cfu from a 50 microlitre volume, which
was spread over the surface of each medium. The negative organisms
were inoculated directly from the 0.5 McFarland suspension using a 10
microlitre loop and the diminishing sweep technique. All plates were
incubated aerobically at 37ºC for 24 hours.
Results: Both media obtained sensitivity and speciﬁcity of >90% in this
study. ChromID ESBL correctly identiﬁed 21 of 23 ESBLs and 52 of 57
non-ESBLs. Brilliance ESBL Agar correctly identiﬁed 22 of 23 ESBLs
and 53 of 57 non-ESBLs. Each medium also enabled differentiation of
E. coli and coliforms from other Gram-negative bacteria due to enzymic
cleavage of speciﬁc chromogenic substrates.
Conclusion: Chromogenic screening media can provide earlier presump-
tive identiﬁcation than traditional culture-based methods. Both media
examined in this study achieved high sensitivity and speciﬁcity within
24 hours.
P2059 Comparison of the chromID™ ESBL medium and
MacConkey agar supplemented with ceftazidime (5mg/l) for
the detection of extended-spectrum b-lactamase producing
Enterobacteriaceae from rectal swabs in hospitalised patients
C. Nonhoff °, H. Rodriguez-Villalobos, M.J. Struelens (Brussels, BE)
Objective: Rapid identiﬁcation of patients colonised with extended-
spectrum b-lactamase (ESBL)-producing Enterobacteriaceae is useful
for the early detection and control of nosocomial outbreaks. The aim
of this study was to evaluate the clinical diagnostic performance of
the selective chromogenic agar medium chromID™ ESBL (bioMe´rieux,
Marcy-l’Etoile, France), compared with our in-house medium CTAZ
(MacConkey agar + ceftazidime 5mg/l) for the detection of ESBL-
producing Enterobacteriaceae from rectal swabs in ICU hospitalised
patients.
Methods: Hospitalised patients (n = 299) were screened for ESBL
carriage by sampling rectal swabs (n = 436) from 5/11 to 17/12/2007.
After homogenisation by vortexing for 15 s, 100ml of eSwab were
inoculated onto chromID™ ESBL and CTAZ. Plates were incubated
at 35ºC for 18 and 48 h. Identiﬁcation and susceptibility testing were
performed by using the Vitek 2 system. The presence of ESBL was
conﬁrmed by combined double disks according to CLSI guidelines.
Genotypic characterisation was determined by PCR assays targeting
blaTEM, blaSHV and blaCTX-M genes. Isolates harbouring blaTEM
and/ blaSHV were further analyzed by sequencing to identify the ESBL.
Results: Of 95 Enterobacteriaceae strains isolated from 48 patients
(16.1%), 69 ESBL-positive strains were found in 32 patients. These
included Escherichia coli (n = 38), Enterobacter cloacae (n = 20),
Klebsiella pneumoniae (n = 8) and other (n = 3). CTX-M derived
enzymes (n = 53) were frequently encountered in E. coli and E. cloacae.
TEM (n = 10) and SHV (n = 6) were found in E. coli, K. pneumoniae
and Enterobacter spp. The sensitivities/speciﬁcities were 89.9/96.7%
and 84.1/94.3% for chromID™ ESBL and CTAZ, respectively. CTX-M
positive isolates were signiﬁcantly more frequently recovered on
chromID™ ESBL while TEM and SHV-producing strains were more
frequently isolated from CTAZ (p< 0.001). chromID™ ESBL was
more selective against non-ESBL-producing Enterobacteriaceae isolates
whereas CTAZ was more selective against other Gram-negative bacilli.
Conclusions: chromID™ ESBL and CTAZ media demonstrated
equivalent performance in terms of sensitivity and speciﬁcity for the
detection of ESBL-producing Enterobacteriaceae. The main advantages
of chromID™ ESBL over CTAZ were the direct identiﬁcation of E. coli
and the cost-saving due to reduced work-up of identiﬁcation of non-
Enterobacteriaceae strains.
P2060 Evaluation of a chromogenic bioMe´rieux chromID™
ESBL medium for screening and presumptive
identiﬁcation of extended-spectrum b-lactamase-producing
Enterobacteriaceae from surveillance cultures
T. Vicente, C. Sanchez-Carrillo °, M. Rivera, E. Cercenado, E. Bouza
(Madrid, ES)
Objectives: We evaluate a selective and differential chromogenic
medium, chromID™ ESBL (bioMe´rieux, Marcy l’Etoile, France)
which enables selective isolation and presumptive identiﬁcation of
extended spectrum b-lactamase-producing Enterobacteriaceae (ESBL)
from clinical samples.
Methods: A total of 293 surveillance rectal swab samples were in
parallel inoculated to chromID™ ESBL and MacConkey agar (MCK,
Tec-Laim. Madrid. Spain) and incubated for 24−48 h. Pink-burgundy,
green-blue and brown colonies on chromID™ ESBL were presumptively
identiﬁed as ESBL-producing Escherichia coli, Klebsiella/Enterobacter/
Serratia/Citrobacter group or Proteeae respectively. Any coloured
colonies (pink-burgundy, green-blue or brown) and all oxidase-negative
colonies on MCK were performed combined double disc method for
ESBL conﬁrmation and were also identiﬁed and tested susceptibility by
the MicroScan system (Dade Behring).
Results: Overall, 95 Enterobacteriaceae isolates were recovered on
91 specimens (31.1% of the total specimens studied) by at least
one of the two media. Eighty-four specimens were positive by both
media and eight specimens were positive only by chromID™ ESBL
(7.7% of all positive samples). The distribution of ESBL-producing
microorganisms was as follows: 64 E. coli, 21 Klebsiella pneumoniae,
7 Klebsiella oxytoca, 1 Citrobacter amalonaticus, 1 Enterobacter
cloacae and 1 Enterobacter aerogenes. The overall sensitivity, speciﬁcity,
positive predictive value and negative predictive value of chromID™
ESBL were: 100.0%, 92.6%, 85.8%, and 100.0%. On chromID™
ESBL, a total of 18 non-ESBL-producing organisms presented the
chromogenic appearance of ESBL-producers: E. cloacae (7), E. coli (4),
Klebsiella spp. (2), Pseudomonas aeruginosa (2), Serratia marcescens
(1), Citrobacter freundii (1), Stenotrophomonas maltophilia (1). Most of
these false positive results were due to Enterobacteriaceae overproducing
chromosomical cephalosporinase.
Conclusions: Our results showed that chromID™ ESBL is an appropri-
ate medium for the screening and presumptive identiﬁcation of ESBL-
producing Enterobacteriaceae directly from surveillance specimens.
The enhanced recovery and the easier detection of ESBL-producing
Enterobacteriaceae using this medium would beneﬁt the patients and
would decrease costs associated to infections caused by ESBL-producing
microorganisms.
P2061 Evaluation of ESBL producing E. coli and Klebsiella
pneumoniae strains with EUCAST and CLSI breakpoints
B. Grabein, M. Hoeck, H.M. Just, I. Schwede, B. Wiedemann ° (Munich,
Berlin, Nuremberg, Frankfurt-Oder, Schaalby, DE)
Objectives: The detection of E. coli and Klebsiella ESBL producing
strains is of great epidemiological importance for hospitals. Usually
ESBLs are suspected after the ﬁrst susceptibility test with various 3rd gen
cephalosporins, before a speciﬁc ESBL-test is performed. We analysed
6,318 E. coli and 1,513 Klebsiella pneumoniae strains including ESBL
producing strains to see whether CLSI or EUCAST breakpoints give
hints for ESBL production.
Methods: At present 4 laboratories participate in the network using
the automated BD PHOENIX system. The BD EPICENTER Data
Management System is used for the evaluation of the data in the
laboratory and for the transfer of the data to the concentrator for
evaluation. Copy strains are excluded. Quality control is mandatory. The
BD PHOENIX system detects ESBL producing strains based on results
fo a speciﬁc ESBL test and other 3rd gen cephaspoins present in the
panel.
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Results: Among the E. coli strains we found 503 (8%) strains producing
ESBLs. Comparing the MIC distributions for cefotaxime of ESBL and
non ESBL strains (ﬁg.) the differences were striking: No strains with
MICs >8mg/L in the non ESBL group, few with MICs between 4 and
16mg/L in both groups (mutation of chromosomal b-lactamase in non
ESBL group). High number of strains above 16 in the ESBL group.
Strains with an MIC of 2 were about 15 times higher in the ESBL
group, indicating a high number of ESBLs with low MICs. Although
EUCAST and CLSI breakpoints for amoxicillin/clavulanate differ for
only one MIC step marked differences in the % of resistant strains were
seen applying the respective brekpoints (75 vs. 28%). The difference
with Piperacillin/Tazobactam was not as pronounced (about 20 to 30%
resistance CLSI and EUCAST) Among the Klebsiella pneumoniae 137
strains (9.1%) were ESBL producers. The MIC distributions showed
similar phenomena.
Conclusion: To detect ESBL producing strains of E. coli and Klebsiella
with the ﬁrst susceptibility test laboratories should test very low
concentrations of 3rd gen cephalosporins (as low as the epidemiological
cut off point) since even the EUCAST breakpoints may fail to detect
ESBL producing strains with low MICs. Another help is the use of a
range of different b-lactams because of the different speciﬁcity of the
b-lactamases.
Figure: MIC distribution for ESBL and no-nESBL producing E. coli.
P2062 Clinical and molecular characteristics of phenotypically
false-positive extended spectrum b-lactamases in
Enterobacteriaceae in a low-endemicity setting
M. Buehlmann °, T. Bruderer, R. Frei, A. Widmer (Basel, CH)
Background: Detection of ESBL producing Enterobacteriaceae is
difﬁcult and requires testing with several screening antibiotics to
optimise diagnostic sensitivity. False-positive ESBL reports from the
microbiology laboratory (low speciﬁcity) result in overuse of broad-
spectrum antibiotics and unnecessary infection control measures. The
aim of our study was 1) to determine the rate of false-positive ESBL in
a low-endemicity setting (<4% of strains) and 2) to identify clinical and
phenotypic predictors for false-positive ESBL.
Methods: All consecutive single-patient isolates from 2003 through
2007 that fulﬁlled criteria of the Clinical Laboratory Standards Institute
(CLSI) and/or European Committee on Antimicrobial Susceptibility
Testing (EUCAST) for an ESBL phenotype were included. Cefpodoxime,
ceftriaxone, ceftazidime and aztreonam as well as cefepime were used
for screening. Molecular characterisation of all isolates was performed
by PCR and by DNA sequencing for the most common ESBL types
including CTX-M, TEM; and SHV as well as the non-ESBL types such
as SHV hyperproducer (SHV HP) and OXA-1. Epidemiological data
were prospectively collected in standardised case report forms.
Results: A total of 110 strains met the phenotypic study criteria
for ESBL. Only 70% (77/110) of phenotypic ESBL strains were
conﬁrmed by molecular analysis, whereof 68.8% (53/77) were expressing
a CTX-M-gene. Among the phenotypically 30% false-positive ESBL
strains, 45.4% (15/33) were SHV-1 HP and 30.3% (10/33) OXA-1.
In SHV-HP, only ceftazidime was positive in the ESBL screening
and conﬁrmation tests, and these strains were resistant to b-lactamase-
inhibitor combinations (BLIC). OXA-1 strains had an elevated cefepime
MIC, a positive ESBL conﬁrmation test with cefepime, but were negative
for all other screening compounds and also resistant to BLIC. E. coli
strains were more likely to represent true ESBL than other species (OR
5, CI95 1.25–20). False-positive ESBL were more prevalent in patients
with fatal comorbidities (p = 0.014) and cultures sites other sites than the
urine (p = 0.016).
Conclusions: Use of tests in addition to the recommendations of CLSI
may improve the sensitivity for detection of ESBL, but go along with
a lower positive predictive value in a low-endemicity setting. The most
important group of false-positive ESBL were SVH-1 HP and OXA-1.
The most common false positive ESBL results could be detected by
applying additional phenotypic criteria.
P2063 Detection of extended-spectrum b-lactamase among
Enterobacteriaceae using automated microbiology systems
X. Schleicher °, H. Wisplinghoff, I. Wiegand, H. Geiss, E. Sturenburg,
D. Mack, H. Seifert (Cologne, DE)
Objectives: The prevalence of extended-spectrum b-lactamase (ESBL)
producing Enterobacteriaceae has increased considerably in recent years.
Detection of the ESBL-phenotype is necessary to allow an accurate
interpretation of susceptility results and to guide antimicrobial therapy.
Therefore conﬁrmatory tests and corresponding software algorithms
have been added or improved in commercially available semiautomated
microbiology identiﬁcation and susceptibility testing systems.
Methods: To evaluate their ability to detect ESBL production in
Enterobacteriaceae, two of these systems, i.e. the VITEK2 System
(bioMe´rieux, Marcy l’Etoile, France), and the MicroScan WalkAway-96
System (Siemens Healthcare Diagnostics, West Sacramento, CA), using
the current routine testing panels which include ESBL detection and
conﬁrmation tests, were compared. A total of 147 isolates of Escherichia
coli (n = 61), Klebsiella pneumoniae (29), K. oxytoca (16), Enterobacter
cloacae (17), E. aerogenes (6), Citrobacter freundii (5), Serratia
marcescens (1), and Proteus spp. (12) were distributed blindly to two
participating laboratories. All of these had been previously characterised
by disk approximation method, the CLSI double-disk synergy test,
the Etest ESBL and a biochemical and molecular characterisation
of b-lactamases at an independent laboratory. Isolates included 95
ESBL producers and 52 non-ESBL produces such as hyperproducers
of chromosomal AmpC, Koxy, or SHV enzymes, and wildtype strains.
Results: The sensitivity, speciﬁcity, negative (NPV) and positive (PPV)
predictive values were determined (see Table).
Conclusion: These results indicate that both systems are highly reliable
for the detection of ESBLs in E. coli. The test performance was also
good for K. pneumoniae isolates but not reliable for ESBL detection in
K. oxytoca and the Citrobacter–Enterobacter–Serratia isolates.
E. coli K. oxytoca K. pneumoniae Enterobacter, Citrobacter
Vitek 2 Walkaway Vitek 2 Walkaway Vitek 2 Walkaway Vitek 2 Walkaway
Sensitivity 100.0 100.0 35.7 64.3 91.3 91.3 100.0 Nd
Speciﬁcity 100.0 100.0 100.0 0.0 100.0 83.3 44.4 Nd
NPV 100.0 100.0 18.2 50.0 75.0 71.4 100.0 Nd
PPV 100.0 100.0 100.0 81.8 100.0 95.5 52.4 Nd
P2064 Detection of AmpC enzymes and the prevalence of
plasmid-mediated AmpC resistance genes
C. Nic Fhogartaigh °, G. Vanstone, I. Balakrishnan (London, UK)
Background: b-lactamase resistance due to chromosomal AmpC
enzyme production has been described in several members of the
Enterobacteriaceae family and is a growing problem in hospital settings.
Of greater concern, increasing numbers of plasmid-mediated AmpC
(pmAmpC) genes have been discovered in nosocomial isolates of E. coli
and Klebsiella pneumoniae. Detection of AmpC production is critical
in order to optimise antibiotic therapy and clinical outcomes. There
are no recommended CLSI guidelines for detection of this resistance
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mechanism. The detection of pmAmpC genes has further implications
for infection control.
Objectives: To investigate local prevalence of AmpC producing
Enterobacteriaceae, compare phenotypic methods of detection, and
determine the extent of pmAmpC production.
Method: 226 consecutive Enterobacteriaceae isolates were included.
Identiﬁcation and sensitivity testing was performed using Phoenix
method. Phenotypic testing for extended spectrum b-lactamase(ESBL)
and AmpC production (including inducibility) was performed on all
isolates using, respectively, 4th generation cephalosporin +/− clavulanate
agar disc-diffusion synergy, and indicator cephalosporins cefoxitin, with
ceftazidime to detect inducible AmpC (current laboratory practice). In
addition, a novel synergy-based method using cefotaxime +/− boronic
acid as an AmpC inhibitor 1 (an increase in zone size of 4mm or more
deﬁning a positive result) was carried out, with the addition of cefoxitin
to detect inducibility. All isolates were then tested using multiplex PCR
for pmAmpC genes 2.
Results: The majority of isolates were urinary; 185 E. coli, 18 Klebsiella
sp., 7 Citrobacter sp., 7 Proteus sp., 6 Enterobacter sp., 2 Serratia sp.,
and 1 Providencia sp. By the standard ESBL/AmpC detection method,
there were 11 derepressed AmpC only (4.9%), 6 AmpC and ESBL
(2.7%), 5 inducible AmpC (2.2%), and 14 ESBL only (6.7%). The 17
AmpC isolates consisted of 12 E. coli, and 1 each of K. pneumoniae,
E. cloacae, E. aerogenes, C. freundii, and P. mirabilis. A comparison
with the boronic acid synergy-based method is shown in the table.
Table: Comparison of standard ESBL/AmpC detection with a boronic
acid synergy-based AmpC detection method.
Standard detection method Boronic acid synergy-based method
AmpC+ Inducible AmpC Neg Total
AmpC+ 7 1 3 11
ESBL and AmpC+ 4 0 2 6
Inducible AmpC 0 2 3 5
ESBL only 7 0 7 14
Neg 0 1 0 1
Isolates with discrepant results have been sent to the Antibiotic
Resistance Monitoring Reference Laboratory for further characterisation
of resistance genes. Multiplex PCR for pmAmpC yielded 2 positives:
C. freundii, with only inducible AmpC on phenotypic testing, and a
negative boronic acid synergy test, carried a CIT plasmid; and an E. coli
identiﬁed as derepressed AmpC by both phenotypic methods carried a
DHA plasmid. This suggests a presence of pmAmpC genes in 11.8% of
AmpC producing organisms, though this will vary with genus.
Conclusions: This provides useful data on laboratory detection of
AmpC, although we cannot make ﬁrm conclusions until reference
laboratory data is available. Surveillance of pmAmpC resistance is
necessary to monitor this emerging problem as infection control practices
may need to be reviewed.
P2065 Detection of plasmid-mediated AmpC b-lactamases in
Enterobacteriaceae lacking chromosomal ampC genes using
the Rosco double disc synergy test and the E-test
H. Adler °, D. Hohler, T. Bruderer, R. Frei (Basel, CH)
Objectives: to evaluate 2 commercial tests namely the Rosco double
disc synergy test (Rosco Diagnostica, Taastrup, Denmark) and the Etest
(AB bioMerieux, Solna, Sweden) to detect plasmid-mediated AmpC
b-lactamases in Enterobacteriaceae lacking chromosomal ampC genes.
Methods: A total of 48 isolates of Enterobacteriaceae (41 Klebsiella
pneumoniae, 4 Klebsiella oxytoca, 2 Salmonella Newport, 1 Proteus
mirabilis) were studied. They comprised 12 isolates with plasmid-
mediated AmpC b-lactamases of the CIT-, DHA-, and FOX-type, and
12 isolates producing extended-spectrum b-lactamases (ESBLs) of the
CTX-M and SHV-type. Except for ESBL-producers only cefoxitin-
resistant isolates were included in the study. All isolates were tested
for AmpC b-lactamase production with the following tests: 1) the
Rosco double disc synergy test which is based on the synergy between
ceftazidime or cefoxitin and cloxacillin, and ceftazidime+clavulanic acid
or cefotaxime+clavulanic acid and boronic acid, 2) a new Etest for AmpC
detection containing cefotetan/cefotetan + cloxacillin (a MIC ratio of 8
or a deformation of the ellipse was interpreted as positive, a MIC ratio
of <8 or a cefotetan MIC of 0.5mg/l was interpreted as negative).
Results: The Rosco synergy test detected 11 of 12 AmpC producers. In
these isolates, at least 3 combinations of antibiotics showed a synergy
phenomenon. One isolate harbouring an ampC gene produced double
inhibition zones that were not interpretable and was thus omitted from
the statistical evaluation. Of 36 isolates without AmpC, 34 (94%) showed
no synergy phenomenon with any combination of antibiotics, while
2 showed a synergy phenomenon with only one combination. When
interpreting only 2 or more positive synergy tests as indicative of an
AmpC b-lactamase, sensitivity and speciﬁcity of the test was 100%. The
Etest detected 10 of 12 AmpC producers. The MIC ratios of 3 isolates (2
isolates harbouring ampC and one without ampC) were not interpretable
and thus omitted from the statistical evaluation. One AmpC-negative
isolate gave a false positive result with a MIC ratio of >64. Sensitivity
and speciﬁcity of the Etest were 100% and 97%, respectively.
Conclusions: Both the Rosco double disc synergy test and the Etest
proved to be useful tools to detect plasmid-mediated AmpC b-lactamases
P2066 Routine susceptibility testing methods may fail to detect
plasmid-mediated AmpC enzymes in Enterobacteriaceae
T.Y. Tan °, L.S.Y. Ng, J. He, D.M.M. Chen (Singapore, SG)
Objectives: Plasmid-mediated AmpC enzymes in E. coli, Klebsiella spp.
and Proteus spp. confer resistance to third-generation cephalosporins.
This study determined the accuracy of cephalosporin susceptibility
testing against Enterobacteriaceae carrying plasmid-mediated ampC
genes using three methods: disk diffusion, Vitek 2 and microbroth
dilution.
Methods: 72 isolates of E. coli (n = 53), Klebsiella spp. (n = 15)
and P. mirabilis (n = 4) were tested by a multiplex PCR assay
detecting 6 families of plasmid-borne ampC. Susceptibility testing was
performed for cefotaxime, ceftriaxone and ceftazidime by disc diffusion
following CLSI guidelines and microbroth dilution (Microscan, Siemens
Diagnostics, USA). Automated susceptibility testing to ceftazidime
and ceftriaxone was performed using the N019 card, on the Vitek 2
Compact (bioMe´rieux, France) running system software version 02.01n.
All susceptibility breakpoints were interpreted according to 2008 CLSI
guidelines with the exception of the Vitek 2, which used the latest
available installed 2005 CLSI guidelines, with expert interpretation and
modiﬁcation of susceptibility test results via the proprietary Automated
Expert System (AES, version 1.9).
Results: CIT-like genes (n = 59) were predominantly found in E. coli
and P. mirabilis, and DHA-like genes in Klebsiella spp. (n = 13). 20
(28%) isolates were susceptible to all three cephalosporins by microbroth
dilution, as compared to only 13 (18%) by disc diffusion. Phenotypic
resistance was highest in ceftazidime, with only 21 (29%) and 17
(24%) susceptible by microbroth dilution and disc diffusion respectively.
Cephalosporin susceptibility interpretation was different for the Vitek
system, as susceptibilities to ceftazidime and ceftriaxone are inferred
using the AES. When the AES was disabled, 30 (42%) and 46 (64%) of
isolates tested by Vitek 2 were susceptible to ceftazidime and ceftriaxone,
respectively. When interpretation by the Vitek AES was subsequently
applied to the testing results, 12 (17%) isolates were reported as
susceptible to both cephalosporins.
Conclusions: Conventional susceptibility testing using existing CLSI
breakpoints to third-generation cephalosporins fails to accurately detect
some Enterobacteriaceae carrying plasmid-mediated ampC genes. The
development of accurate screening methods will improve detection and
reporting of this emerging resistance mechanism.
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P2067 Cefditoren versus ceftazidime in inducer-substrate
combinations for the evaluation of AmpC production in a
disk approximation test
F. Caﬁni, L. Aguilar, L. Alou, M.J. Gimenez, D. Sevillano, M. Torrico,
N. Gonzalez, P. Coronel °, J. Prieto (Madrid, ES)
Objective: To evaluate cefditoren (CDN) in inducer-substrate combina-
tions to screen for AmpC induction.
Methods: 100 clinical isolates (25 Pseudomonas aeruginosa, 25
Enterobacter cloacae, 14 Morganella morganii, 13 Serratia marcescens,
12 Citrobacter freundii, 7 Providencia rettgeri, and 4 Enterobacter
aerogenes) were tested by the Kirby-Bauer disc approximation method
using CDN and ceftazidime (CAZ) discs as substrates, and CDN and
imipenem discs as inducers. Photographs of the incubated plates were
taken using visualisation Gel Doc and inhibition zones were measured
using the ImageJ program. A positive induction was considered when
the inhibition zone of the substrate disc was reduced by 2mm.
Comparisons of percentages of AmpC isolates detected with the different
substrates were performed with the Fisher’s exact test, and reductions
in diameters were compared by the Student’s t-test. A p< 0.05 was
considered signiﬁcant.
Results: None of the strains showed induction of AmpC with CDN-CAZ
as inducer-substrate combination. Imipenem-CDN as inducer-substrate
combination was not useful for evaluating strains of P. aeruginosa since
no inhibition zones surrounding the cefditoren disc were found. Number
(%) strains showing reduction when using CDN and CAZ as substrate,
and mean±SD reduction in the inhibitory zone for valuable strains (those
showing inhibitory zone) among the enteric bacteria tested, are shown
in the Table.
Conclusion: CDN showed no induction capability, and when used as
substrate (with imipenem as inducer) it offered detection rates of AmpC
inducible enterobacteria higher than the imipenem-CAZ combination,
mainly for Enterobacter spp. and Serratia spp., with higher diameter
reductions for indol-positive proteae.
CDN 10mg CAZ 30mg
n No. (%) of strains
with reduction
Reduction
(mm)
n No. (%) of strains
with reduction
Reduction
(mm)
C. freundii 7 6 (85.7) 5.16±2.37 10 7 (70.0) 4.94±2.98
M. morganii 13 10 (76.9) 5.32±1.11a 13 11 (84.6) 3.92±1.59
P. rettgeri 7 3 (42.9) 3.47±0.25a 7 2 (28.6) 2.64±0.02
S. marcescens 11 11 (100.0)b 3.50±0.93 11 6 (54.5) 2.78±0.95
E. cloacae 22 16 (72.8)b 4.19±1.00 23 5 (21.7) 3.88±2.39
E. aerogenes 3 2 (66.6) 3.45±0.97 4 2 (50.0) 2.76±0.03
Total 63 48 (76.2)b 4.17±1.41 68 33 (48.5) 3.79±2.02
aSigniﬁcantly (p< 0.05) higher reduction than CAZ.
bSigniﬁcantly (p< 0.05) higher percentage of AmpC strains detected with CDN vs. CAZ.
P2068 Comparison of phenotypic techniques for the detection
of metallo-b-lactamases in Pseudomonas aeruginosa from
respiratory isolates
M. Galicia °, K. Bermejo, A. Limansky, C. Cero´n, F. Quinones (Mexico
City, MX; Rosario, AR)
Objective: The aim of this study was to compare different phenotype
techniques for metallo-b-lactamases (MBLs) production in P. aeruginosa.
Methods: from January 2004 to December 2005, 86 consecutive,
non duplicate carbapenems-resistance Pseudomonas aeruginosa isolates
were collected from patients attending the National Institute of
Respiratory Diseases in Mexico City. All isolates were processed to
carbapenems susceptibility (imipenem and meropenem) by standard
broth microdilution following CLSI guidelines. The EDTA disk synergy
test (EDS), synergy test with double disc of imipenem (DD), EDTA-
imipenem microbiological assay (EIM) and E-test was carried out by
the screening of MBLs production. The presence of genes encoding
blaVIM-like, blaIMP-like, or blaSPM-1 was conﬁrmed by PCR primers
and DNA sequence analysis.
Results: Among the 86 isolates of P. aeruginosa resistant to
carbapenems, 3 were positive by EIM assay, 5 by E-test, 38 by EDS
and 68 by DD. The table describes the estimated sensitivity, speciﬁcity,
positive predictive value and negative predictive value.
Conclusion: The EDTA disk synergy test (EDS) and synergy test with
double disc of imipenem (DD) are rapid and sensitive methods for MBL
production screening in P. aeruginosa but lacks speciﬁcity. The EDTA-
imipenem microbiological assay (EIM) displayed excellent speciﬁcity
but showed the lowest sensitivity among the analyzed procedures. E-test
had a performance comparable to the gold standard.
Test Result No. of specimens Sensitivity Speciﬁcity PPV NPV
Positive Negative (%) (%) (%) (%)
EDS assay Positive 5 33 100 59 13 100
Negative 0 48
DD assay Positive 5 63 100 22 7.3 100
Negative 0 18
EIM assay Positive 3 0 60 100 100 97.5
Negative 2 81
E-test Positive 5 0 100 100 100 100
Negative 0 81
P2069 Heteroresistance contributes to variable carbapenem
susceptibility levels in VIM-1 producing Klebsiella
pneumoniae strains belonging to the same clone:
consequences for routine susceptibility testing
M. Tato °, M.I. Morosini, L. Garcı´a, S. Albertı´, R. Canto´n (Madrid,
Palma de Mallorca, ES)
Introduction: Resistance to carbapenems due to MBL production
in Enterobacteriaceae is increasingly recognized. Different levels of
resistance to carbapenems have been observed in these isolates and
reproducible susceptibility testing results within the same or among
different methods is not always obtained. We studied the carbapenems
susceptibility proﬁles of VIM-1 producing K. pneumoniae isolates
belonging to the same clone which was involved in an epidemic in our
hospital (2005–2008) affecting 18 patients.
Methods: Eighteen VIM-1 producing K. pneumoniae isolates belonging
to an epidemic clone (XbaI-PFGE) were studied. Carbapenems MICs
obtained by microdilution (CLSI), WIDER semiautomatic system, and
Etest were compared. Errors in the clinical interpretive categories were
determined considering microdilution as reference. Other mechanisms
contributing to carbapenem resistance, such as porin expression, were
also studied. Heteroresistance was determined by population analysis
proﬁle (PAP) in 4 selected strains displaying different imipenem MICs.
Results: Imipenem MICs were in the range of 8−>128mg/L by
microdilution, 1−>8mg/L by WIDER and 0.75−>32mg/L by Etest.
Ranges for meropenem and ertapenem with Etest were 0.38−>32 and
0.75−>32mg/L, respectively. Only one isolate with high level imipenem
resistance (MIC> 128mg/L) did not express porins OmpK36. High
error rates were observed with WIDER and Etest when compared
with microdilution. The category agreement was 28% for WIDER and
11% for Etest with 28% of very mayor errors in both cases. Low
reproducibility of MICs was observed with Etest, even when the same
inoculum was used (up to 4-fold dilutions of diference). Heteroresistance
for imipenem was initially suspected due to the presence of colonies
in the inhibition zone of Etest strips. This was conﬁrmed by PAP
results obtained in all selected strains with the exception of the
porin deﬁcient K. pneumoniae isolate that homogeneously expressed
carbapenem resistance.
Conclusions: Low reproducibility of MIC results to carbapenems
obtained by different susceptibility testing methods could be due to
the presence of resistant subpopulations in carbapenemase producing
enterobacterial isolates. Variable expression of resistance mechanisms
affecting carbapenems might also contribute to this effect. Carbapenem
MICs are not good markers of MBL production and reliable phenotypic
methods are needed to conﬁrm the presence of this mechanism.
S608 19th ECCMID, Posters
P2070 Rising carbapenem resistance in Pseudomonas and
Enterobacteriaceae at a large district hospital in northwest
England − how relevant is antimicrobial disc susceptibility
testing?
A. Guleri, E. Trautt, B. Lunt °, R. Palmer (Blackpool, UK)
Objectives: Since Jan 2008, use of ﬂuroquinolones [FQ] and 3rd
generation cephalosporins [ESC] has been restricted as part of
hospital strategy to reduce rates of MRSA, ESBL and Clostridium
difﬁcile infections [CDI]. An increase in infections with carbapenem
resistant [CR] pseudomonas and Enterobacteriaceae has been observed.
Limitations of disc susceptibility testing [DST] has been reported. This
study was undertaken to compare DST with MIC determined by Etests
[AB bioMerieux]in CR Enterobacteriaceae and Pseudomonas; MBL
production and Doripenem MICs.
Methods: BSAC standard methodology [DST] was comapred with
MICs by E-test [AB bioMerieux] for Ceftazidime, Piperacillin-
tazobactam, Meropenem, Imipenem, Ciproﬂoxacin, Gentamicin. Also
Metallo-blactamase [MBL] production and Doripenem MIC was tested
by E-tests.
Results: Results of 28 of total 100 isolates [to be presented] are included
here: Of the 14 CR Pseudomonas isolates, disc-testing correlated with
MIC results in 58 of 70 total tests (83% of all tests). 13 isolates were
resistant to meropenem(93%) and only 1 was identiﬁed as an MBL
producer using MBL strips(7%). 12 of the 13 meropenem resistant
isolates were sensitive to ceftazidime(92%).
Of the 14 enterobacteriaceae isolates, disc-testing correlated with MIC
interpretation in 59 of 70 total tests(84% of tests).7 isolates intermediate
on Ertapenem disc testing were sensitive based on MIC (50% of
ertapenem tests), 3 isolates ertapenem intermediate on disc testing were
resistant based on MIC (21% of Ertapenem tests).
Doripenem Etest results ranged 0.023–0.38 for Enterobacteriaceae
studied.
Conclusion: Disc-susceptibility testing correlates well with MIC testing
by Etest for Enterobacteriaceae and Pseudomonas.The majority of
Pseudomonas sp in this study were not MBL-producers and this suggests
a different mechanism of resistance. This has implications for therapy
with other agents such as ceftazidime, which would otherwise not have
been deemed effective.
Ertapenem disc-interpretation differed from MIC in the majority of
isolates. This would suggest the MIC interpretation of Ertepenem is
more reliable than disc susceptibility testing.
Isolates appeared 100% susceptible to Doripenem despite lack of
deﬁning BSAC cutoff points. Doripenem MICs [to be presented] are
lower than Meropenem and Imipenem.
Community-acquired respiratory tract
infections
P2071 A prospective serological and virological prevalence
study of inﬂuenza infection and immunisation at a
metropolitan centre, northern Italy. A basis to re-evaluate
immunoprophylaxis strategies for inﬂuenza in the childhood
R. Manfredi °, E. Ubaldini, F. Bernardi, A. Moroni, M. Donati,
F. Chiodo (Bologna, IT)
Introduction: Anti-Inﬂuenza vaccination is presently considered a
relevant public health issue also in children aged less than 2 years
[MMWR 2006; 55:1062].
Patients and Methods: Starting from November 2005, a prospective
serological-virological monitoring of all children hospitalised due to
inﬂammatory/infectious diseases after Emergency Room access, is
ongoing.
Results: During the ﬁrst 18 months of observation, 265 patients aged
6 months to 17 years were evaluated, out of 1,774 overall hospitalised
children. Only 22 children (aged 2−11 years) (8.3%) had a positive
IgA serology for Inﬂuenza A (4 of them had a concurrent positive IgA
serology for Inﬂuenza B). IgG antibodies assays (prior immunity) were
positive in only 9 c (Inﬂuenza A) (3.4%), while all direct viral search
on respiratory secretions tested negative in all cases, save one. From
October 2006 to December 2006, we recognized 14 out of 22 cases of
IgA seropositivity, while in the remaining 15 months only 0−2 cases
per months were found. Of 22 children with positive IgA serology, 18
(77.3%) attended a community or a school.
Conclusions: Although actively searched through systematic serologic
and virologic assays, Inﬂuenza infection seems a proportionally rare
events among children. Further studies which compare different
laboratory techniques are needed to conﬁrm our preliminary data, which
however show an unexpected, reduced prevalence of Inﬂuenza infection
in a broad paediatric population hospitalised for inﬂammatory/infectious
diseases. A reappraisal of the phenomenon, sustained by strong
microbiological date (and not limited to clinical evidences, as currently
performed in common clinical practice) could lead to a revision of
current vaccination strategies.
P2072 The effect of psychological and psychosocial factors on
the outcome of or susceptibility to acute respiratory tract
infections
M. Falagas, C. Karamanidou, G. Karlis, A. Kastoris °, P. Rafailidis
(Athens, GR)
Objective: The association between psychological and psychosocial
factors and the onset and progression of acute respiratory tract infection,
is unclear. We aimed to perform a systematic review of the available
literature in order to assess the possible effect that, psychological or
psychosocial variables may have on the susceptibility and/or the outcome
of acute respiratory tract infections.
Methods: We performed searches on PubMed, Scopus, and PsychInfo.
Articles eligible for inclusion contained quantitative data regarding the
association between psychological or psychosocial variables and the
onset or progression of acute respiratory tract infections.
Results: We identiﬁed 46 studies, published between 1986 and 2008,
examining the role of psychological or psychosocial variables and the
onset or progression of acute respiratory tract infection. Ten studies
included the same study population although they assessed different
psychological or psychosocial variables. Of the 46 studies included in our
review, 41 showed at least one statistically signiﬁcant association between
psychological, psychosocial, or behavioural variables and susceptibility
to acute respiratory tract infection. Eighteen out of 46 studies revealed
at least one statistically signiﬁcant association between psychological,
psychosocial, or behavioural variables and outcome of acute respiratory
tract infection. Variables associated with a higher risk of infection but
also a less favourable outcome were depression, anxiety, negative affect,
higher levels of perceived stress, more negative life events, anxious
or angry mood states, and the personality trait neuroticism. Positive
personality traits on the other hand, decreased the risk of infection,
showing a more favourable effect on the outcome of infection.
Conclusion: Most of the studies included show a signiﬁcant relationship
between psychological, psychosocial, or behavioural variables and onset
or progression of acute respiratory tract illness. The psychological or
psychosocial variables measured are not consistently measured across
the included studies, and different methodological approaches were used
to examine the association between psychological or psychosocial factors
and acute respiratory tract illness. Thus, more research is necessary in
order to contribute to a better understanding of the association between
psychological or psychosocial factors and susceptibility and outcome of
acute respiratory infections
P2073 Distribution of Legionella in hot water systems of hospitals
and health resorts in Poland
A. Sikora, M. Wo´jtowicz °, A. Magrys, M. Koziol-Montewka (Lublin, PL)
Objective: Poland introduced the legal regulation of controlling water
systems for the presence of Legionella bacteria only in 2008. This project
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was undertaken to evaluate occurrence of Legionella spp. in hot water
systems in Polish hospitals and health resorts.
Methods: Forty eight hot water samples (1000ml each) were collected
from 3 hospitals and 2 health resorts. The water samples were collected
from hot tap outlets, selected intermediate sites − depending on the
length of the water system and distal sites. The samples were analyzed
using the International Standard Method, accepted in Poland as a
standard based on ﬁltration procedure and culture of bacteria on selective
media. The ﬁltration method was performed with subsequent volumes
of water samples: 10, 100 and 500ml for accurate determination of
Legionella number. In cases of samples with high contaminant ﬂora, the
smaller water volumes were ﬁltered: 1ml, 10ml and 100ml. The ﬁlters
were then placed on the selective GVPC agar plate and incubated at 37ºC
in a humid atmosphere for 7 days. Suspected Legionella colonies were
subcultured onto BCYE agar for veriﬁcation. The species serogroups
were determined by a commercially available latex agglutination test
kit.
Results: L. pneumophila SGs 2−14 were predominant and were detected
in 72.9% of all analyzed hot water samples. L. pneumophila SG 1 was
not detected in any of the tested sample. The numbers of legionellae
detected exceeded 102 cfu/100ml in 65.3% of the samples. Legionellae
contamination of water distribution system was higher in examined
hospitals comparing to health resorts (56.7% and 38.8% respectively).
Conclusions: A large public buildings with complex water distribution
systems represent ideal locations for Legionnaires’ disease transmission.
To reduce the likelihood of Legionnaires’ disease transmission in health
care facilities, a strategy focusing on proper maintenance of water
systems and investigation of situations in which transmission has been
shown to occur is strictly recommended. The higher consumption of
hot water used for treated bathing waters as well as speciﬁc quality of
natural waters might be the reason of lesser Legionella colonisation of
water system in health resorts comparing to hospitals.
P2074 The effectiveness of different methods eradicating
Legionella spp. from water distribution systems in selected
hospitals of Lublin region
M. Wo´jtowicz °, A. Sikora, A. Magrys, M. Koziol-Montewka (Lublin, PL)
Objective: Poland introduced the legal regulation of controlling water
systems for the presence of Legionella bacteria only in 2008. The
results presented have unique values indicating the level of Legionella
contamination in hot water distribution systems in cases of lack of
inspection. The aim of the work was to study occurrence of Legionella
pneumophila in water distribution systems of three hospitals in Lublin
region as well as eradication efﬁcacy by using different decontamination
methods.
Methods: Forty hot water samples (1000ml each) were collected from
examined hospitals. The samples were analyzed using the International
Standard Method (PN-ISO11731–2), accepted in Poland as a standard
based on ﬁltration procedure and culture of bacteria on selective media.
Results: All water samples tested for the presence of Legionella spp.
gave positive results. The numbers of legionellae detected exceeded
102−103 colony forming units per 100 milliliters in 70% of the samples.
All of the positive samples contained L. pneumophila SGs 2−14, as
detected by latex agglutination method. The major interventions included
performing thermal eradication by permanent increase in the hot water
temperature (>55ºC) and temporal increase in the temperature up to
70ºC for 2 hours. All shower heads and sink taps in the hospitals were
scalded out. Hot water temperature was monitored in selected points of
water sampling. As a result, thermal disinfection was not satisfactory.
Elimination of “dead ends” and application of sodium hypochlorite
allowed to reduce the number of Legionella in hospitals’ water systems.
However total elimination of bacteria by single action was not possible.
Conclusions: It was found that: Legionella pneumophila SGs 2−14
colonise hospital hot water distribution systems in the amounts exceeding
acceptable norms, thermal disinfection is not satisfactory, it is required to
perform chemical disinfection by using chemical preparation of chlorine
(chlorine dioxide, sodium hypochlorite), there is a need to eliminate
“dead ends” in water systems.
P2075 Invasive pneumococal disease after systematic use of
7-valent pneumococcal conjugated vaccine. Multi-centre
study with seven hospitals in Madrid, Spain
A. Sa´nchez Garcı´a °, C. Campelo Gutie´rrez, M.D. Martı´n Rodrigo,
J. Valverde Ca´novas, L. Molina Esteban, M.J. Uria Gonza´lez,
A. Delgado-Iribarren Garcı´a-Campero (Alcorco´n, ES)
Objectives: 7-valent pneumococcal conjugated vaccine (PCV7) was
licensed in 2001 in Spain, however, in the Automous Region of
Madrid, it was not included in the paediatric vaccination schedule until
2006. The objetive of this study was to determine the predominant
serotypes and antimicrobial susceptibility of Streptococcus pneumoniae
causing pneumococcal invasive disease (IPD) in the 7-valent pneumoccal
conjugate vaccine (PCV7) era.
Methods: Multicentre retrospective study involving patients with IPD
in seven hospitals in Madrid in 2008, attending 1,400,000 inhabitants.
Antimicrobial susceptibility was tested using E-test®, following the
Clinical Laboratory Standars Institute criteria. All the strains were
serotyped using the Pneumotest latex and Quellung reaction at the
Regional Public Health Laboratory. Urinary antigen detection was
performed by Binax Now®.
Results: A total of 79 episodes were observed, 52 in adults and 27 in
children, 23(29%) of the individuals were younger than 4 years, and
17(21.5%) were older than 65 years. S. pneumoniae was isolated from
specimens of blood (73), pleural ﬂuid (2), ascitic ﬂuid (1), and CSF
(3, two of them were also isolated in blood). 13.9% of IPD cases were
caused by serotypes included in PCV7, 9 adults and 2 children. One of
these children, 4 months aged, with a primary bacteraemia caused by
S. pneumoniae serotype 9V, had received two vaccine doses. The most
prevalent serotype was 19A (22.8%), followed by 1 (17.7%). Neither
of them were included in PCV7. The MIC90 for penicillin was 2
ug/ml (range; 0.016−4) and for cefotaxime 2 ug/ml (range: 0.016–4).
The susceptibilities to levoﬂoxacin, erythromycin and clindamycin were
96.2%, 81% and 86% respectively. One S. pneumoniae strain isolated
from CSF had reduced susceptibility to penicillin (MIC: 0.75 ug/ml) and
cefotaxime (MIC: 1 ug/ml). In 27 of the 52 adult patients S. pneumoniae
urinary antigen was required. Antigen detection was positive in 18 cases
(sensibility: 66.6%).
Conclusions: A worrying emergence of serotypes not contained in
vaccine such us 1 or 19A is observed. This could in future decrease
the effectiveness of the vaccine or lead to changes in the epidemiology
of pneumococcal disease. We expect PCV13 to be available in the near
future. 62% of the isolates in our study belong to one of the serotypes
included in this new vaccine. Additional surveillance studies focused on
the clinical and molecular epidemiology of IPD are needed to understand
the impact of PCV7 and the upcoming PCV13.
P2076 Comparison of invasive pneumococcal disease rates in
Alaska and northern Canada following PCV7 introduction
M. Bruce °, T. Zulz, M. Garner, D. Bruden, M. Lovgren, L. Jette,
K. Rudolph, D. Hurlburt, J. Wenger, A. Parkinson (Anchorage, US;
Ottawa, CA; Alberta, Sainte-Anne-de-Bellevue, CA)
Background: The International Circumpolar Surveillance Project is
a population-based surveillance network for invasive bacterial disease
among the following Arctic countries: Norway, Sweden, Finland, Iceland,
Greenland, Canada and the US (Alaska). The 7-valent pneumococcal
conjugate vaccine (PCV7) has been used for routine infant immunisation
in Norway since 2006, Alaska since 2001, and in northern Canada since
2003; however, the start date varied by region in the latter.
Methods: Invasive pneumococcal disease (IPD) data from the North
American Arctic (1999–2007, Alaska and Northern Canada, total
population 783,500) were analyzed to determine predominant clinical
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ﬁndings, disease rates, serotype distribution and antimicrobial suscepti-
bility.
Results: 1,386 cases of laboratory-conﬁrmed IPD were reported.
Bacteraemic pneumonia, the most common clinical ﬁnding, was
diagnosed in 63% of IPD cases. Annualised incidence rates of IPD in
Alaska and northern Canada were 18 and 27 cases per 100,000 persons,
respectively (rates among indigenous persons: 47 in Alaska and 35 cases
per 100,000 persons in northern Canada). Rates in children <2 years of
age were 109 and 156 cases per 100,000 persons in Alaska and northern
Canada, respectively (rates in indigenous children: 251 in Alaska; 170
in northern Canada). IPD rates in children <2 due to PCV7 serotypes
declined by >80% after routine vaccination with PCV7 (Alaska: 130
to 11 cases per 100,000 persons, p< 0.001; northern Canada: 129 to
37 cases per 100,000 persons, p< 0.001). Rates of disease with non-
PCV7 serotypes in children <2 increased in Alaska (25 to 76 cases per
100,000 persons, p< 0.001), and in northern Canada (41 to 74 cases per
100,000 persons, p = 0.17). Rates of IPD with penicillin-nonsusceptible
isolates decreased from 63 to 27 cases per 100,000 children in Alaska
(p = 0.001), and from 10 to 8 cases per 100,000 persons (p = 1.00) in
northern Canada.
Conclusions: The high IPD rates among Arctic Indigenous people have
declined in Alaska and northern Canada following PCV7 introduction.
An increase in non-vaccine type disease of the magnitude seen in Alaska
was not observed in northern Canada. Continued surveillance is needed
to determine the impact of PCV7 and future higher valency conjugate
vaccines when they come into use.
P2077 Usefulness of C-reactive protein and procalcitonin determi-
nation for the differential diagnosis and guidance of the clini-
cal management in pneumococcal and Legionella pneumonia
R. Bellmann-Weiler, M. Ausserwinkler, K. Schroecksnadel,
C. Lass-Floerl, G. Weiss ° (Innsbruck, AT)
Objectives: Community acquired pneumonia is a frequent and poten-
tially life threatening infection, Patients’ outcome greatly depends on
the timely initiation of adequate empirical therapy which is challenging
in patients suffering from pneumonia caused either by Streptococcus
pneumoniae or Legionella pneumophila since these pathogens have
different antibiotic susceptibility patterns. We thus investigated the
potential of widely used tests for serum markers of inﬂammation
to differentiate between those pathogens and to guide the clinical
management of these infections.
Methods: We retrospectively analysed the records of 60 patients with
severe S. pneumoniae (37) or L. pneumophila (23) pneumonia. Diagnosis
was conﬁrmed by urinary antigen tests, blood culture and/or serology.
The results of C-reactive protein (CRP), procalcitonin (PCT), blood
counts, liver and kidney function tests were available on day 1 and day
5 of admission.
Results: While we found no signiﬁcant differences between patients
suffering from S. pneumoniae and L. pneumophila infection at admission
in terms of CRP levels, leucocyte counts, haemoglobin concentration
or creatinine levels, PCT (p< 0.03), serum sodium (p< 0.02) and
chloride levels (p = 0.005) were signﬁcantly lower, and ferritin levels
signiﬁcantly higher (p< 0.01) in pneumonia patients suffering from
L. pneumophila than from S. pneumoniae infection. Moreover, patients
with L. pneumophila pneumonia more frequently suffered from an
underlying chronic obstructive pulmonary disease (p< 0.02), and were
more frequently admitted to the intensive care unit (p< 0.05). In
both groups, increased PCT levels on days 1 and 5 and high CRP
concentrations on day 5 predicted a poor clinical outcome concerning
the need of mechanical ventilation or death.
Conclusions: PCT may harbour diagnostic beneﬁts in the early
differential diagnosis between S. pneumoniae and L. pneumophila
pneumonia. In addition, high PCT levels at admission and follow up
are associated with an increased risk for an adverse clinical course and
may prompt physicians to consider early intensive care admission.
P2078 Genetic polymorphisms of innate immunity and
susceptibility to pneumococcal infection
E. Garcı´a-Cabrera °, J. Garnacho-Montero, R. Jime´nez-Alvarez,
J. Revuleto-Rey, A. Diaz-Martin, A. Garcı´a-Curiel, S. Barroso,
J. Aznar-Martin, C. Ortiz-Leyba (Seville, ES)
Objective: To investigate whether diverse genetic variants of innate
immunity (MBL, TLR2, TLR4, and FcgRIIa) that cause hyporespon-
siveness to S. pneumoniae might be associated with a higher risk of
invasive pneumococcal disease in adults.
Methods: All adult patients with community-acquired Streptococcus
pneumoniae disease admitted to the hospital from January 2005 to
November 2007 were enrolled in this prospective study. Patients with
congenital immunodeﬁciencies, HIV infections and severe neutropenia
(<500 cells/mm3) were excluded from this protocol. Controls were
patients of the same hospitalisation area and similar age range with
negative blood culture and without previous history of pneumonia or
meningitis. After obtaining written consent, we performed genotype
analysis with 5ml of peripheral blood and extract the DNA with
(High Pure PCR Template Preparation Kit, Roche). By PCR-RFLP
were detected MBL allelic variant B (ID:rs1800450), C (rs1800451)
and TLR2 Arg753Gln (rs5743708). The MBL D variant (rs5030737),
and Arg131His FcgRIIa, were performed by PCR. TLR4 Asp299Gly
(rs4986790) was determined by sequencing the speciﬁc region. For
statistical analysis, categorical variables were analysed using the chi-
square test and Fisher’s test when appropriate. Continuous variables
were compared using the Mann-Whitney U. Signiﬁcant differences were
deﬁned as p< 0.05.
Results: One hundred and eighteen patients were included; of them, 75
patients (63.5%) were bacteraemic. The source of the pneumococcal
disease were pneumonia 98 (83.1%), meningitis 18 (15.3%) and
abdominal focus 2 (1.7%). Of them, 74 patients (62.7%) were admitted
to the ICU, and 40 patients (34.2%) developed septic shock. The
mortality rate was 18.8% (22 patients). The median age of the patients
was 60 years±23 IQR and the median age of the controls (n = 52)
was 55 years±28 IQR (p = 0.213). TLR4 Asp299Gly polymorphism
was present in 25.4% of patients with pneumococcal disease and in
0% of control subjects (p< 0.001). In addiction, TLR2 Arg753Gln
polymorphism was present in 5.6% of patients with pneumococcal
disease and in 0% of control subjects (p = 0.156). Frequency of the other
variant alleles was similar in infected patients and controls.
Conclusions: Among the assessed genetic variants of innate immunity,
only TLR4 Asp299Gly polymorphism is associated with a higher risk
of invasive pneumococcal infection in adults.
P2079 Bacteraemic pneumococcal pneumonia in adults: infecting
serotypes and mortality
V. Pascual Granolle´s °, E. Calbo, M. Xercavins, M. Riera,
M. Rodrı´guez-Carballeira, J. Garau (Terrassa, ES)
Introduction: A secular trend in the epidemiology of infecting serotypes
in bacteraemic pneumococcal pneumonia (BPP) has been reported.
Heptavalent pneumococcal conjugate vaccine (HPCV) was licensed in
Spain in the second semester of 2001. The aim of our study was to
describe the evolution of serotypes distribution and its potential impact
on mortality in adults with BPP over a 15 years period in our institution.
Methods: From 1993–2007, all adult patients with BPP identiﬁed
through the records of the Microbiology Laboratory were included. Data
recorded were: demographics, co morbidities, serotypes, antimicrobial
susceptibility and in hospital mortality. Serotypes were analyzed
individually and classiﬁed as vaccine serotypes (VS), vaccine related
serotypes (VRS) and non-vaccine related serotypes (NVR) in relation
to HPCV. Serotypes were also classiﬁed as of high invasive potential
(HIP: 1, 5, 7) and low invasive potential (LIP: 3, 6A, 6B, 8, 19F and
23) and analysed accordingly. Three periods were distinguished: 1993–
1997 (P1), 1998–2002 (P2) and 2003–2007 (P3). Patients were divided
in three age groups 18−65 (A1), 66−79 (A2), and >80 years (A3).
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Results: A total of 419 patients with BPP were included, 96 (23%) in
P1, 136 (32%) in P2 and 187 (45%) in P3; 60%, 51% and 70% were
males in P1, P2 and P3, respectively (p< 0.05). Median age was 71 y in
P1, 71 y P2 and 63 y in P3 (p< 0.05). One or more co morbidities were
present in 50% of patients in P1, 52% in P2, and 56% in P3 (NS). In
P1, 10% of BPP were due to VS and 90% to NVR; in P2, 23%, 4%
and 73% were due to VS, VRS, and NVR, respectively, and in P3, 13%,
9% and 78% were due to VS, VRS and NVR, respectively (p< 0.05). In
P2, S1 was present in 22% in A1, 6.1% in A2 and 3% in A3 (p< 0.05)
and HIP represented 29%, 10%, and 5% in A1, A2 and A3, respectively
(p< 0.05). In P3, 17% in A1, 8% in A2 and 3% in A3 were due to S1
(p< 0.05) and HIP were responsible for 30%, 17% and 5% in A1, A2
and A3, respectively (p< 0.05). Mortality rates were 15%, 15% and 13%
in P1, P2 and P3, respectively (NS).
Conclusion: NVR serotypes have been the predominant infecting
serotypes causing adult BPP in our area throughout all the studied
periods. Among all studied serotypes, only S1 and HIP were more
frequently isolated in young patients in the two last periods. Despite of
the changing epidemiology, in-hospital mortality of BPP has remained
unchanged during the last 15 years.
P2080 Unexpectedly high prevalence of Chlamydophila psittaci in
patients with CAP
S.C.A. Meijvis °, H. Hardeman, B.J. Vlaminckx, P. Voorn, J.C. Grutters,
H. van Velzen-Bladt, W.J.W. Bos, D.H. Biesma (Nieuwegein, Utrecht, NL)
Background: Community-acquired pneumonia (CAP) is caused by
many different pathogens; most identiﬁed micro-organisms are Strepto-
coccus pneumoniae and Haemophilus inﬂuenzae. Previous studies have
shown that in approximately one third of patients with CAP no causative
agent is found. As part of a prospective trial to evaluate the additional
value of corticosteroids in the treatment of CAP, an extensive diagnostic
algorithm for the identiﬁcation of causative agents in CAP is currently
used in our hospital. Here, we report on the relative contribution of
respiratory pathogens identiﬁed in this study.
Material and Methods: Pathogen identiﬁcation was performed by
culture of sputum and blood. Urine samples were taken for antigen
testing of Legionella pneumophila serogroup 1 and S. pneumoniae
cell wall antigen. Polymerase chain reactions (PCRs) were performed
on sputum to detect Legionella species, Mycoplasma pneumoniae,
Chlamydophila psittaci and Chlamydophila pneumoniae. Serological
testing was performed for antibodies against M. pneumoniae, Coxiella
burnettii, C. psittaci or respiratory viruses (inﬂuenza A and B,
parainﬂuenza viruses 1, 2 and 3, adenovirus and respiratory syncytial
virus). IgG and IgM antibodies to Legionella were determined on day
1 and 30 by ELISA. For viral cultures, pharyngeal and nasal samples
were taken.
Results: So far, 70 patients with CAP have been included in our study.
S. pneumoniae (n = 19; 27%) and H. inﬂuenzae (n = 6; 9%) are the most
frequently found causative agents of CAP. Remarkably, 5 of 70 (7%)
patients had a C. psittaci pneumonia. All ﬁve patients demonstrated
a four-fold rise in antibody titre; two patients had a positive PCR for
C. psittaci. After diagnosing psittacosis, all ﬁve patients were − again −
asked for bird contacts. Two patients remember contact with dead birds
(a blackbird and a budgie) in the week before admission. The other
three patients did not recall any bird contact. One patient needed ICU
admission because of respiratory insufﬁciency, but responded well to
erytromycin. Three patients recovered before serology testing became
positive and one patient recovered after antibiotic switch to claritromycin.
Conclusion: C. psittaci has a remarkably high prevalence in our ongoing
study in patients with CAP. C. psittaci may result in severe pneumonia
and requires speciﬁc treatment. Bird contact known to the patient is not
a conditio-sine-qua-non for a C. psittaci pneumonia.
P2081 Prevalence of Chlamydia pneumoniae, Mycoplasma
pneumoniae, and Legionella pneumophila among patients
with atypical pneumonia in central Greece
C. Neocleous °, D. Klapsa, A. Liakopoulos, I. Gerogianni,
K. Gourgoulianis, E. Petinaki (Larissa, GR)
Objective: To evaluate the prevalence of the most common atypical pul-
monary pathogens, Mycoplasma pneumoniae, Chlamydia pneumoniae
and Legionella pneumophila, among patients with community acquired
pneumonia (CAP) in Central Greece.
Methods: One hundred and forty four patients (104 males and 40
females) mean age 67 years (17−92), hospitalised during 2008 in
the University Hospital of Larissa with CAP, were included. On the
admission, sputum, urine and serum from each patient were collected
and sent to the Microbiological Laboratory for further analysis All sera
were tested for the presence of antibodies against the above described
microorganisms by an enzyme-linked immunosorbent assay (Alphadia).
DNA extracted directly from the purulent portion of the sputa was
used for PCR with primers targeting genes speciﬁc for M. pneumoniae,
C. pneumoniae and L. pneumophila. Urine samples were tested for the
presence of L. pneumophila antigen (Binax).
Results: Among 144 serum samples, 17 (11.8%) were positive for
antibody titres of acute infection against atypical pulmonary pathogens:
13 (9%) of them against M. pneumoniae (11 IgA, one IgM and one
IgM and IgA), two (1.4%) were positive for IgM and IgA against
C. pneumoniae, one (0.7%) was positive for IgM against L. pneumophila,
while one more (0.7%) patient had serological data of dual acute
infection (IgM and IgA against M. pneumoniae and IgM against
C. pneumoniae). Sputum PCR results showed that, only one out 17
samples with positive serological tests carried DNA of L. pneumophila;
the urine test of this patient was also positive for the detection of
L. pneumophila antigen. On the other hand, two out 127 patients with
negative serological proﬁles for atypical pulmonary pathogens, gave
positive PCR results for M. pneumoniae. Repetition of M. pneumoniae
antibodies two weeks latter showed that these two patients remained
negative.
Conclusions: In Central Greece, during 2008, the prevalence of atypical
pulmonary pathogens in adult population was 13.2%. Combination
of serological and molecular tests is recommended for the accurate
diagnosis of atypical pneumonia.
P2082 Community-acquired pneumonia in elderly patients with
and without type 2 diabetes mellitus
D. Kofteridis °, C. Mattheou, J. Papadakis, A. Valachis, M. Tzanakakis,
D. Dimopoulou, S. Maraki, G. Samonis (Heraklion Crete, GR)
Introduction: It remains uncertain whether community acquired
pneumonia (CAP) is more severe and carries worse outcome in diabetic
patients. The aim of the present study was to investigate and to compare
clinical features and outcome in diabetic and non-diabetic elderly patients
with CAP.
Materials and Methods: All records of patients aged 65 years, with
and without type 2 diabetes mellitus (DM) and CAP, cared for at the
department of Medicine of the University Hospital of Heraklion from
January 2004 to December 2007 were retrospectively reviewed. The
severity of CAP was assessed using the CURB65 score.
Results: Eighty patients with type 2 DM and CAP (33 females; 41%),
with median age 77 (range:65–91) years, and 95 non-diabetics suffering
of CAP, age- and sex-matched serving as controls, were evaluated. Fever
upon presentation was more common among diabetics than controls
(88.8% vs 72.6%; p< 0.01). One hundred eight out of 175 patients (62%)
had a single lung opaciﬁcation, while 67 (38%) presented with multi-
lobar or multi-segmental opaciﬁcations. No differences in opaciﬁcation
types were observed between the two groups. Diabetics had signiﬁcantly
lower CURB65 score on admission (2.08±0.84 vs 2.37±0.95; p< 0.05).
No difference in the median time to defervencence was observed between
the two groups [3 (1−8) vs 3 (1−6) days]. However, DM patients had
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more prolonged hospitalisation [7 (2−35) vs 6 (1−24) days; p< 0.05].
Seven out of the 80 diabetics (9%) died due to pneumonia, while all non
diabetics survived (p< 0.01). In DM patients low serum albumin level
upon presentation was associated with unfavourable outcome (p< 0.05).
Conclusion: Elderly diabetics with CAP require prolonged hospital-
isation. Furthermore, in diabetics, despite the initial lower CURB65
score, mortality is higher, while low serum albumin upon presentation
is predictor of unfavourable outcome.
P2083 Bacterial respiratory tract infections as the sequelae of
tuberculosis
A. Martynova °, A. Prushinskyi, J. Skurichina, E. Sokurova, K. Smirnov
(Vladivostok, RU)
Despite of the results in treatment of tuberculosis, bacterial infections are
the most often complications in the patients with pulmonary tuberculosis.
We reported the causative microorganisms in children with remission of
clinically conﬁrmed tubersulosis.
Aim: Was to characterise the aetiology of bacterial respiratory tract
infections in children with tuberculosis in anamnesis and also to compare
the isolates gained from children with tuberculosis with isolates gained
from healthy carriers.
Methods: The isolates of H. inﬂuenzae (n = 32), S. pneumoniae (n = 25),
etc (n = 23)were isolated from lab material of 80 patients by the
quantitative sputum culture method (greater than or equal to 10(7)/ml) in
Far Eastern Pediatrics National Tuberculosis Center (control group (11
strains of H. inﬂuenzae and 17 strains of S. pneumoniae) was isolated
from 40 healthy carrier children). Antimicrobial resistance was checked
by disk-diffusion method and MIC.
Results: H. inﬂuenzae was the most frequent microorganism caus-
ing the bacterial infections in children with clinically conﬁrmed
tuberculosis. Antimicrobial resistance was a major problem only in
children hospitalised with tuberculosis (rifampicin 21.8%, penicillin
40%, erythromycin 84.37%, co-trimoxazole 59.37%). The antimicrobial
resistance pattern in healthy children was characterised as having less
resistance to penicillin (1 strain), and there were no resistant strains to
rifampicine. S. pneumoniae isolated in children with tuberculosis was
resistant to rifampicin in 2 cases from 25 strains (8%), and in 36% to
macrolides. The antimicrobial resistance pattern in healthy carriers had
also no rifamicine resistant strains.
Conclusions: Presumed bacterial respiratory infections sequelae of
tuberculosis should be diagnosed according standard criteria before
starting antibiotic therapy, and treatment modiﬁed depending on culture
results. Also it could help to prevent then with rational methods of
vaccination.
